PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Antommaria, AHM; Gibb, TS; McGuire, AL; Wolpe, PR; Wynia, MK; Applewhite, MK; Caplan, A; Diekema, DS; Hester, DM; Lehmann, LS; McLeod-Sordjan, R; Schiff, T; Tabor, HK; Wieten, SE; Eberl, JT				Antommaria, Armand H. Matheny; Gibb, Tyler S.; McGuire, Amy L.; Wolpe, Paul Root; Wynia, Matthew K.; Applewhite, Megan K.; Caplan, Arthur; Diekema, Douglas S.; Hester, D. Micah; Lehmann, Lisa Soleymani; McLeod-Sordjan, Renee; Schiff, Tamar; Tabor, Holly K.; Wieten, Sarah E.; Eberl, Jason T.		Task Force Assoc Bioethics Program	Ventilator Triage Policies During the COVID-19 Pandemic at US Hospitals Associated With Members of the Association of Bioethics Program Directors	ANNALS OF INTERNAL MEDICINE			English	Article							ALLOCATION	Background: The coronavirus disease 2019 pandemic has or threatens to overwhelm health care systems. Many institutions are developing ventilator triage policies. Objective: To characterize the development of ventilator triage policies and compare policy content. Design: Survey and mixed-methods content analysis. Setting: North American hospitals associated with members of the Association of Bioethics Program Directors. Participants: Program directors. Measurements: Characteristics of institutions and policies, including triage criteria and triage committee membership. Results: Sixty-seven program directors responded (response rate, 91.8%); 36 (53.7%) hospitals did not yet have a policy, and 7 (10.4%) hospitals' policies could not be shared. The 29 institutions providing policies were relatively evenly distributed among the 4 U.S. geographic regions (range, 5 to 9 policies per region). Among the 26 unique policies analyzed, 3 (11.3%) were produced by state health departments. The most frequently cited triage criteria were benefit (25 policies [96.2%]), need (14 [53.8%]), age (13 [50.0%]), conservation of resources (10 [38.5%]), and lottery (9 [34.6%]). Twenty-one (80.8%) policies use scoring systems, and 20 of these (95.2%) use a version of the Sequential Organ Failure Assessment score. Among the policies that specify the triage team's composition (23 [88.5%]), all require or recommend a physician member, 20 (87.0%) a nurse, 16 (69.6%) an ethicist, 8 (34.8%) a chaplain, and 8 (34.8%) a respiratory therapist. Thirteen (50.0% of all policies) require or recommend that those making triage decisions not be involved in direct patient care, but only 2 (7.7%) require that their decisions be blinded to ethically irrelevant considerations. Limitation: The results may not be generalizable to institutions without academic bioethics programs. Conclusion: Over one half of respondents did not have ventilator triage policies. Policies have substantial heterogeneity, and many omit guidance on fair implementation.	[Antommaria, Armand H. Matheny] Cincinnati Childrens Hosp Med Ctr, Eth Ctr, 3333 Burnet Ave,ML 15006, Cincinnati, OH 45229 USA; [Antommaria, Armand H. Matheny] Univ Cincinnati, Sch Med, Cincinnati, OH USA; [Gibb, Tyler S.] Western Michigan Univ Homer Stryker MD, Program Med Eth Humanities & Law, Sch Med, 1000 Oakland Dr, Kalamazoo, MI 49008 USA; [McGuire, Amy L.] Baylor Coll Med, Ctr Med Eth & Hlth Policy, 1 Baylor Plaza, Houston, TX 77030 USA; [Wolpe, Paul Root] Emory Univ, Ctr Eth, 1531 Dickey Dr, Atlanta, GA 30322 USA; [Wolpe, Paul Root] Emory Univ, Sch Med, Atlanta, GA USA; [Wynia, Matthew K.] Univ Colorado, Ctr Bioeth & Humanities, Sch Med, Aurora, CO USA; [Wynia, Matthew K.] Univ Colorado, Ctr Bioeth & Humanities, Sch Publ Hlth, Aurora, CO USA; [Wynia, Matthew K.] UC Hlth Syst, Aurora, CO USA; [Applewhite, Megan K.] Albany Med Coll, Alden March Bioeth Inst, Albany, NY 12208 USA; [Applewhite, Megan K.] Albany Med Coll, Dept Surg, Albany, NY 12208 USA; [Caplan, Arthur; Schiff, Tamar] NYU, Div Med Eth, Grossman Sch Med, New York, NY USA; [Diekema, Douglas S.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Diekema, Douglas S.] Univ Washington, Sch Med, Dept Bioeth & Humanities, Seattle, WA USA; [Diekema, Douglas S.] Seattle Childrens Res Inst, Treuman Katz Ctr Pediat Bioeth, 1900 Ninth Ave,JMB-6, Seattle, WA 98101 USA; [Hester, D. Micah] Univ Arkansas Med Sci, Dept Med Humanities & Bioeth, Coll Med, Little Rock, AR 72205 USA; [Lehmann, Lisa Soleymani] VA New England Healthcare Syst, 200 Springs Rd, Bedford, MA 01730 USA; [Lehmann, Lisa Soleymani] Harvard Med Sch, Boston, MA 02115 USA; [Lehmann, Lisa Soleymani] Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [McLeod-Sordjan, Renee] Northwell Hlth Syst, Div Med Eth, Dept Med, New Hyde Pk, NY USA; [McLeod-Sordjan, Renee] Hofstra Univ, Hofstra Northwell Sch Grad Nursing & Phys Assista, Hempstead, NY 11550 USA; [Tabor, Holly K.; Wieten, Sarah E.] Stanford Univ, Stanford Ctr Biomed Eth, Sch Med, Stanford, CA 94305 USA; [Eberl, Jason T.] St Louis Univ, Albert Gnaegi Ctr Hlth Care Eth, 3545 Lafayette Ave,Salus Ctr 501, St Louis, MO 63104 USA; [Wynia, Matthew K.] Univ Colorado Anschutz Med Campus, Ctr Bioeth & Humanities, 13080 East 19th Ave,Room 201E,Mail Stop B137, Aurora, CO 80045 USA; [Applewhite, Megan K.] Albany Med Coll, Ctr Med Eth Educ & Res, 50 New Scotland Ave,MC 193, Albany, NY 12211 USA; [Caplan, Arthur; Schiff, Tamar] NYU, Sch Med, Div Med Eth, 227 East 30th St,7th Floor, New York, NY 10016 USA; [Hester, D. Micah] UAMS Coll Med, Dept Med Humanities & Bioeth, 4301 West Markham St,646, Little Rock, AR 72205 USA; [Tabor, Holly K.; Wieten, Sarah E.] Stanford Univ, Ctr Biomed Eth, Sch Med, 1215 Welch Rd,Modular A, Stanford, CA 94305 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Baylor College of Medicine; Emory University; Emory University; University of Colorado System; University of Colorado Anschutz Medical Campus; Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; Albany Medical College; Albany Medical College; New York University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Northwell Health; Hofstra University; Stanford University; Saint Louis University; University of Colorado System; University of Colorado Anschutz Medical Campus; Albany Medical College; New York University; Stanford University	Antommaria, AHM (corresponding author), Cincinnati Childrens Hosp Med Ctr, Eth Ctr, 3333 Burnet Ave,ML 15006, Cincinnati, OH 45229 USA.	armand.antommaria@cchmc.org; tyler.gibb@med.wmich.edu	McLeod-Sordjan, Renee/AAI-9164-2021	McLeod-Sordjan, Renee/0000-0003-1952-2792; Caplan, Art/0000-0002-4061-8011; Diekema, Douglas/0000-0002-1703-5176				[Anonymous], 2015, VENTILATOR ALLOCATIO; [Anonymous], 2020, CORONAVIRUS CAUTIONA; Antommaria AHM, 2011, PEDIATR CRIT CARE ME, V12, pS163, DOI 10.1097/PCC.0b013e318234a88b; Babble E., 2004, PRACTICE SOCIAL RES; Biddison LD, 2014, CHEST, V146, pE145S, DOI 10.1378/chest.14-0742; Daniels N., 2007, JUST HLTH M HLTH NEE; Disability Rights Education Defense Fund, 2020, PREV DISCR TREATM CO; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Health Resources & Services Administration, 2018, FED OFF RUR HLTH POL; Hick John L, 2020, NAM Perspect, V2020, DOI 10.31478/202003b; Hick JL, 2009, DISASTER MED PUBLIC, V3, pS59, DOI 10.1097/DMP.0b013e31819f1ae2; Institute of Medicine, 2013, CRIS STAND CAR TOOLK, DOI [10.17226/18338, DOI 10.17226/18338]; Institute of Medicine, 2009, GUIDANCE ESTABLISHIN, DOI [10.17226/12749, DOI 10.17226/12749]; McCoy K, 2020, US TODAY; Neeman A., 2020, NEW YORK TIMES; Pandemic Influenza Ethics Initiative Work Group of the Veterans Health Administration's National Center for Ethics in Health Care, 2010, M CHALL PAND INFL ET; Parshley L, 2020, VOX             0406; Powell T, 2008, DISASTER MED PUBLIC, V2, P20, DOI 10.1097/DMP.0b013e3181620794; Rosen R., 2020, FORWARD; Rothstein MA, 2010, J LAW MED ETHICS, V38, P412, DOI 10.1111/j.1748-720X.2010.00499.x; Savin K, 2020, CONFRONTING DISABILI; Thomas James C, 2007, Am J Public Health, V97 Suppl 1, pS26, DOI 10.2105/AJPH.2006.093443; Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689; U.S. Census Bureau, 2020, CENS REG DIV US; Washington State Department of Health Northwest Healthcare Response Network, 2019, SCARC RES MAN CRIS S; White DB, 2020, JAMA-J AM MED ASSOC, V323, P1773, DOI 10.1001/jama.2020.5046; White DB, 2009, ANN INTERN MED, V150, P132, DOI 10.7326/0003-4819-150-2-200901200-00011; Winslow G. R., 1982, TRIAGE JUSTICE ETHIC	30	99	100	1	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 4	2020	173	3					188	+		10.7326/M20-1738	http://dx.doi.org/10.7326/M20-1738			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW7BG	32330224	Green Published			2023-01-03	WOS:000557186700006
J	Oehler, RL; Gompf, SG				Oehler, Richard L.; Gompf, Sandra G.			Shortcomings in the US Pharmaceutical Supply Chain Potential Risks Associated With International Manufacturing and Trade-Related Tariffs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint discusses vulnerabilities in the US drug supply chain given a shift in manufacturing of pharmaceutical ingredients to other countries and calls for a system to identify high-value medications, forecast supplies and shortages, and incentivize domestic production.	[Oehler, Richard L.; Gompf, Sandra G.] Univ S Florida, James A Haley Vet Hosp, Div Infect Dis & Int Med, Morsani Coll Med, Mailstop 111J,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	Oehler, RL (corresponding author), Univ S Florida, James A Haley Vet Hosp, Div Infect Dis & Int Med, Morsani Coll Med, Mailstop 111J,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	richard.oehler@va.gov	Gompf, Sandra/A-8882-2013	Gompf, Sandra/0000-0001-6533-7577				[Anonymous], CHINA DAILY; Cogan D., 2018, SHORTAGES STOCKOUTS; CY, 2018, CY 2018 ANN REP INSP; Denigan-Macauley M., 2019, DRUG SAFETY PRELIMIN; Eschoo AF, 2019, WASHINGTON POST; Gibson R., 2018, CHINA RX EXPOSING RI; Gross AE, 2017, CLIN INFECT DIS, V65, P613, DOI 10.1093/cid/cix379; Hunag Y, 2019, US DEPENDENCE PHARM; Stephan LS, 2017, JMIR MHEALTH UHEALTH, V5, DOI 10.2196/mhealth.6510; U.S. Food and Drug Administration, 2020, CURR RES DRUG SHORT	10	5	5	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2020	324	2					143	144		10.1001/jama.2020.1634	http://dx.doi.org/10.1001/jama.2020.1634			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ8RW	32176256				2023-01-03	WOS:000553161000014
J	Wadhera, RK; Wadhera, P; Gaba, P; Figueroa, JF; Maddox, KEJ; Yeh, RW; Shen, CY				Wadhera, Rishi K.; Wadhera, Priya; Gaba, Prakriti; Figueroa, Jose F.; Maddox, Karen E. Joynt; Yeh, Robert W.; Shen, Changyu			Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter								This study describes demographic characteristics and hospital bed capacities of the 5 New York City boroughs, and evaluates whether differences in testing for coronavirus disease 2019 (COVID-19), hospitalizations, and deaths have emerged as a signal of racial, ethnic, and financial disparities.	[Wadhera, Rishi K.; Yeh, Robert W.; Shen, Changyu] Beth Israel Deaconess Med Ctr, Richard A & Susan F Smith Ctr Outcomes Res Cardio, Boston, MA 02215 USA; [Wadhera, Priya] NYU Langone Med Ctr, Dept Med, New York, NY USA; [Gaba, Prakriti] New York Presbyterian Columbia Univ Med Ctr, Dept Med, New York, NY USA; [Figueroa, Jose F.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Maddox, Karen E. Joynt] Washington Univ, Sch Med, Cardiovasc Div, St Louis, MO USA	Harvard University; Beth Israel Deaconess Medical Center; NYU Langone Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; Washington University (WUSTL)	Wadhera, RK (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Richard A & Susan F Smith Ctr Outcomes Res Cardio, 375 Longwood Ave, Boston, MA 02215 USA.	rwadhera@bidmc.harvard.edu			Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology	Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology	This work was supported by the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology.	John Hopkins University Coronavirus Resource Center, COR COVID 19 GLOB CA; New York City Department of Health and Mental Hygiene, COVID 19 DAT; New York City Health Department of Health and Mental Hygiene, SUMM VIT STAT 2017 C; Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757; Wadhera RK, 2020, JAMA-J AM MED ASSOC, V323, P961, DOI 10.1001/jama.2020.1021; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548	6	392	399	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2020	323	21					2192	2195		10.1001/jama.2020.7197	http://dx.doi.org/10.1001/jama.2020.7197			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY8YS	32347898	Green Published, Bronze			2023-01-03	WOS:000540816000026
J	Chang, YL; Wang, JS; Yeh, HC; Ting, IW; Huang, HC; Chiang, HY; Hsiao, CT; Chu, PL; Kuo, CC				Chang, Yun-Lun; Wang, Jie-Sian; Yeh, Hung-Chieh; Ting, I-Wen; Huang, Han-Chun; Chiang, Hsiu-Yin; Hsiao, Chiung-Tzu; Chu, Pei-Lun; Kuo, Chin-Chi			Dialysis timing may be deferred toward very late initiation: An observational study	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CLINICAL-PRACTICE GUIDELINE; ANTIINFLAMMATORY DRUG-USE; CARDIOVASCULAR EVENTS; EARLY START; HEMODIALYSIS; OUTCOMES; RISK; EPIDEMIOLOGY; INFECTION	The optimal timing to initiate dialysis among patients with an estimated glomerular filtration rate (eGFR) of < 5 mL/min/1.73 m2 is unknown. We hypothesized that dialysis initiation time can be deferred in this population even with high uremic burden. A case-crossover study with case (0-30 days before dialysis initiation [DI]) and control (90-120 days before DI) periods was conducted in 1,079 hemodialysis patients aged 18-90 years at China Medical University Hospital between 2006 and 2015. The uremic burden was quantified based on 7 uremic indicators that reached the predefined threshold in case period, namely hemoglobin, serum albumin, blood urea nitrogen, serum creatinine, potassium, phosphorus, and bicarbonate. Dialysis timing was classified as standard (met 0-2 uremic indicators), late (3-5 indicators), and very late (6-7 indicators). Median eGFR-DI of the 1,079 patients was 3.4 mL/min/1.73 m(2) and was 2.7 mL/min/1.73 m(2) in patients with very late initiation. The median follow-up duration was 2.42 years. Antibiotics, diuretics, antihypertensive medications, and non-steroidal anti-inflammatory drugs (NSAIDs) were more prevalently used during the case period. The fully adjusted hazards ratios of all-cause mortality for the late and very late groups were 0.97 (95% confidence interval 0.76-1.24) and 0.83 (0.61-1.15) compared with the standard group. It is safe to defer dialysis initiation among patients with chronic kidney disease (CKD) having an eGFR of < 5 mL/min/1.73 m(2) even when patients having multiple biochemical uremic burdens. Coordinated efforts in acute infection prevention, optimal fluid management, and prevention of accidental exposure to NSAIDs are crucial to prolong the dialysis-free survival.	[Chang, Yun-Lun; Wang, Jie-Sian; Yeh, Hung-Chieh; Ting, I-Wen; Kuo, Chin-Chi] China Med Univ, China Med Univ Hosp, Dept Internal Med, Div Nephrol, Taichung, Taiwan; [Chang, Yun-Lun; Wang, Jie-Sian; Yeh, Hung-Chieh; Ting, I-Wen; Huang, Han-Chun; Chiang, Hsiu-Yin; Kuo, Chin-Chi] China Med Univ, Coll Med, Taichung, Taiwan; [Yeh, Hung-Chieh; Huang, Han-Chun; Chiang, Hsiu-Yin; Kuo, Chin-Chi] China Med Univ, Big Data Ctr, China Med Univ Hosp, Taichung, Taiwan; [Hsiao, Chiung-Tzu] China Med Univ Hosp, Dept Lab Med, Taichung, Taiwan; [Hsiao, Chiung-Tzu] China Med Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan; [Chu, Pei-Lun] Fu Jen Catholic Univ Hosp, Div Nephrol, Dept Internal Med, New Taipei, Taiwan; [Chu, Pei-Lun] Fu Jen Catholic Univ Hosp, Sch Med, New Taipei, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Fu Jen Catholic University; Fu Jen Catholic University Hospital; Fu Jen Catholic University; Fu Jen Catholic University Hospital	Kuo, CC (corresponding author), China Med Univ, China Med Univ Hosp, Dept Internal Med, Div Nephrol, Taichung, Taiwan.; Kuo, CC (corresponding author), China Med Univ, Coll Med, Taichung, Taiwan.; Kuo, CC (corresponding author), China Med Univ, Big Data Ctr, China Med Univ Hosp, Taichung, Taiwan.	chinchik@gmail.com	Wang, Jie-Sian/L-4452-2017	Wang, Jie-Sian/0000-0002-1943-3709	Ministry of Science and Technology of Taiwan [106-2314-B-039-041-MY3, 108-2314-B-039 -038 -MY3]; China Medical University Hospital, Taichung, Taiwan [CRS-106-018]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); China Medical University Hospital, Taichung, Taiwan	This study (Chin-Chi Kuo) was supported by the Ministry of Science and Technology of Taiwan (grant number: 106-2314-B-039-041-MY3 and 108-2314-B-039 -038 -MY3) and China Medical University Hospital, Taichung, Taiwan (grant number: CRS-106-018). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Centor RM., 1990, CLIN METHODS HIST PH; Cooper BA, 2010, NEW ENGL J MED, V363, P609, DOI 10.1056/NEJMoa1000552; Crews DC, 2014, AM J KIDNEY DIS, V63, P806, DOI 10.1053/j.ajkd.2013.12.010; Crews DC, 2014, J AM SOC NEPHROL, V25, P370, DOI 10.1681/ASN.2013050567; Dalrymple LS, 2008, CLIN J AM SOC NEPHRO, V3, P1487, DOI 10.2215/CJN.01290308; Dalrymple LS, 2011, CLIN J AM SOC NEPHRO, V6, P1708, DOI 10.2215/CJN.10151110; Daugirdas JT, 2015, AM J KIDNEY DIS, V66, P884, DOI 10.1053/j.ajkd.2015.07.015; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; Hassan HIC, 2016, KIDNEY INT, V90, P897, DOI 10.1016/j.kint.2016.07.013; Heleniak Z, 2017, J NEPHROL, V30, P781, DOI 10.1007/s40620-016-0352-z; Hwang SJ, 2010, NEPHROL DIAL TRANSPL, V25, P2616, DOI 10.1093/ndt/gfq308; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Khan YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159335; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013, KIDNEY INT S, V3, P1, DOI DOI 10.1038/KISUP.2012.64; Kim SY, 2012, BIOMOL THER, V20, P268, DOI 10.4062/biomolther.2012.20.3.268; Kraut JA, 2018, CLIN J AM SOC NEPHRO, V13, P343, DOI 10.2215/CJN.11941017; Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004; Liberek T, 2011, NEPHROL DIAL TRANSPL, V26, P2087, DOI 10.1093/ndt/gfr181; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; McDonald HI, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004100; Mehrotra R, 2018, NEPHROL DIAL TRANSPL, V33, P904, DOI 10.1093/ndt/gfy068; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; Nagin DS, 1999, PSYCHOL METHODS, V4, P139, DOI 10.1037/1082-989X.4.2.139; Naughton CA, 2008, AM FAM PHYSICIAN, V78, P743; Nesrallah GE, 2014, CAN MED ASSOC J, V186, P112, DOI 10.1503/cmaj.130363; O'Hare AM, 2011, ARCH INTERN MED, V171, P1663, DOI 10.1001/archinternmed.2011.436; Pacilio M, 2016, J NEPHROL, V29, P153, DOI 10.1007/s40620-015-0243-8; Plantinga L, 2011, ANN FAM MED, V9, P423, DOI 10.1370/afm.1302; Rosansky SJ, 2014, CLIN J AM SOC NEPHRO, V9, P222, DOI 10.2215/CJN.12231213; Rosansky SJ, 2011, ARCH INTERN MED, V171, P396, DOI 10.1001/archinternmed.2010.415; Scialla JJ, 2014, KIDNEY INT, V86, P798, DOI 10.1038/ki.2014.110; Sjolander A, 2011, AM J EPIDEMIOL, V174, P1204, DOI 10.1093/aje/kwr249; States. CfDCaPCKDSSU, 2010, IND DET PREV NSAID U; Stevens LA, 2011, KIDNEY INT, V79, P555, DOI 10.1038/ki.2010.462; Tattersall J, 2011, NEPHROL DIAL TRANSPL, V26, P2082, DOI 10.1093/ndt/gfr168; Teo BW, 2018, ADV CHRONIC KIDNEY D, V25, P41, DOI 10.1053/j.ackd.2017.10.005; Tsai CW, 2019, NEPHROL DIAL TRANSPL, V34, P2066, DOI 10.1093/ndt/gfy200; Tsai CW, 2018, NEPHROL DIAL TRANSPL, V33, P231, DOI 10.1093/ndt/gfx297; Viasus D, 2011, NEPHROL DIAL TRANSPL, V26, P2899, DOI 10.1093/ndt/gfq798; Wright S, 2010, CLIN J AM SOC NEPHRO, V5, P1828, DOI 10.2215/CJN.06230909; Yeh HC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54227-6; Yeh HC, 2019, CLIN CHIM ACTA, V497, P163, DOI 10.1016/j.cca.2019.07.035; Zhan M, 2017, CLIN J AM SOC NEPHRO, V12, P1778, DOI 10.2215/CJN.12311216; Zhao YY, 2018, THER APHER DIAL, V22, P600, DOI 10.1111/1744-9987.12721	44	1	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2020	15	5							e0233124	10.1371/journal.pone.0233124	http://dx.doi.org/10.1371/journal.pone.0233124			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU0VG	32401817	Green Published, gold			2023-01-03	WOS:000537481000054
J	Sachs, RE; Bagley, N				Sachs, Rachel E.; Bagley, Nicholas			Importing Prescription Drugs from Canada - Legal and Practical Problems with the Trump Administration's Proposal	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Sachs, Rachel E.] Washington Univ, Sch Law, St Louis, MO 63110 USA; [Bagley, Nicholas] Univ Michigan, Sch Law, Ann Arbor, MI 48109 USA	Washington University (WUSTL); University of Michigan System; University of Michigan	Sachs, RE (corresponding author), Washington Univ, Sch Law, St Louis, MO 63110 USA.							Food and Drug Administration, 2019, IMP PRESCR DRUGS PRE, DOI [10.1056/NEJMp2000464, DOI 10.1056/NEJMP2000464]; Food and Drug Administration, 2019, FED REGISTER, V84, P70796; Fralick M, 2019, NEW ENGL J MED, V381, P1793, DOI 10.1056/NEJMp1909402	3	2	2	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 7	2020	382	19					1777	1779		10.1056/NEJMp2000464	http://dx.doi.org/10.1056/NEJMp2000464			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LO1TS	32374960	Green Published			2023-01-03	WOS:000533411000006
J	Manjili, MH				Manjili, Masoud H.			The premise of personalized immunotherapy for cancer dormancy	ONCOGENE			English	Review							CIRCULATING TUMOR-CELLS; BREAST-CANCER; BONE-MARROW; NEOANTIGENS; EQUILIBRIUM; CARCINOMA; REVEALS; ENDOTHELIN-1; CHEMOTHERAPY; TRASTUZUMAB	Progress in cancer therapies has resulted in improved survival of patients with early stage breast cancer. However, mortality remains high in patients with distant recurrence of the disease after initially successful treatment of early stage breast cancer. To this end, tumor recurrences have been attributed to the presence of dormant tumor cells in breast cancer patients and cancer survivors. Current clinical practice guidelines recommend a "wait-and-watch" approach for tumor recurrence. This is because of our limited understanding of tumor dormancy. Dormant tumor cells are quiescent, and thus, do not respond to chemotherapies or radiation therapies, and they are not operable. Therefore, immunotherapy is the only option for the treatment of tumor dormancy. However, gaps in our knowledge as to dormancy-specific antigens prevent a relapse preventing vaccine design. Here, I provide a critical review of cancer immunotherapy, and discuss empirical evidence related to naturally occurring tumor dormancy and treatment-induced tumor dormancy at the site of primary tumor and in distant organs before and after cancer therapies. Finally, I suggest that personalized vaccines targeting dormancy-associated neoantigens, which can be given to patients with early stage disease after the completion of neoadjuvant therapies and tumor resection as well as to cancer survivors could eliminate relapse causing dormant cells and offer a cure for cancer.	[Manjili, Masoud H.] Massey Canc Ctr, VCU Sch Med, VCU Inst Mol Med, Dept Microbiol & Immunol, Richmond, VA 23298 USA	Virginia Commonwealth University	Manjili, MH (corresponding author), Massey Canc Ctr, VCU Sch Med, VCU Inst Mol Med, Dept Microbiol & Immunol, Richmond, VA 23298 USA.	masoud.manjili@vcuhealth.org			Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program [W81XWH-14-1-0087]; VCU Massey Cancer Center; NIH-NCI Cancer Center Support Grant [P30 CA016059]	Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program; VCU Massey Cancer Center; NIH-NCI Cancer Center Support Grant	This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program under Award No. W81XWH-14-1-0087 (MHM), pilot funding from the VCU Massey Cancer Center supported, in part, with funding from NIH-NCI Cancer Center Support Grant P30 CA016059.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alspach E, 2019, NATURE, V574, P696, DOI 10.1038/s41586-019-1671-8; American Cancer Society, 2016, CANC TREATM SURV FAC; Aqbi Hussein F, 2018, Oncotarget, V9, P22113, DOI 10.18632/oncotarget.25197; Ascierto PA, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0798-3; Bai Y, 2018, METHODS MOL BIOL, V1802, P193, DOI 10.1007/978-1-4939-8546-3_13; Bartkowiak K, 2015, CANCER RES, V75, P5367, DOI 10.1158/0008-5472.CAN-14-3728; Bartkowiak K, 2010, J PROTEOME RES, V9, P3158, DOI 10.1021/pr100039d; Baxevanis CN, 2015, VACCINES-BASEL, V3, P597, DOI 10.3390/vaccines3030597; Bidard FC, 2018, JNCI-J NATL CANCER I, V110, P560, DOI 10.1093/jnci/djy018; Boegel S, 2012, GENOME MED, V4, DOI 10.1186/gm403; Butturini E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174305; Cackowski FC, 2017, J CELL BIOCHEM, V118, P891, DOI 10.1002/jcb.25768; Cameron D, 2017, LANCET, V389, P1195, DOI 10.1016/S0140-6736(16)32616-2; Chen WY, 2018, J MATER CHEM B, V6, P327, DOI 10.1039/c7tb02608k; Clements ME, 2019, CURR OSTEOPOROS REP, V17, P353, DOI 10.1007/s11914-019-00532-y; Demicheli R, 2019, BREAST, V45, P61, DOI 10.1016/j.breast.2019.03.001; Dimco G, 2010, CELL CYCLE, V9, P4638, DOI 10.4161/cc.9.23.13955; Ebinger S, 2016, CANCER CELL, V30, P849, DOI 10.1016/j.ccell.2016.11.002; Eide N, 2019, PATHOL ONCOL RES, V25, P255, DOI 10.1007/s12253-017-0355-7; Emens LA, 2019, JAMA ONCOL, V5, P74, DOI 10.1001/jamaoncol.2018.4224; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a; Francescangeli F, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-019-1505-4; Gil M, 2013, P NATL ACAD SCI USA, V110, pE1291, DOI 10.1073/pnas.1220580110; Gubin MM, 2015, J CLIN INVEST, V125, P3413, DOI 10.1172/JCI80008; HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3; Hellmann MD, 2017, IMMUNITY, V47, P221, DOI 10.1016/j.immuni.2017.08.001; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Iyengar NM, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.16211; Jahanban-Esfahlan R, 2019, CANCERS, V11, DOI 10.3390/cancers11081207; Jiang T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0787-5; Johanns TM, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1561106; Kaplan MA, 2016, BREAST CARE, V11, P248, DOI 10.1159/000448186; Karagiannis GS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0026; Khazali AS, 2018, BRIT J CANCER, V118, P566, DOI 10.1038/bjc.2017.414; Kimura W, 1998, CANCER, V82, P1839, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1839::AID-CNCR5>3.0.CO;2-I; Kiyotani K, 2017, J HUM GENET, V62, P397, DOI 10.1038/jhg.2016.141; Kodumudi KN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01939; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Kortylewski M, 2004, J INVEST DERMATOL, V122, P414, DOI 10.1046/j.0022-202X.2004.22237.x; Krall JA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan3464; Kurppa KJ, 2020, CANCER CELL, V37, P104, DOI 10.1016/j.ccell.2019.12.006; Liang H, 2013, J IMMUNOL, V190, P5874, DOI 10.4049/jimmunol.1202612; Linette GP, 2017, TRENDS MOL MED, V23, P869, DOI 10.1016/j.molmed.2017.08.007; Linnemann C, 2015, NAT MED, V21, P81, DOI 10.1038/nm.3773; Liu YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15207; Loi S, 2019, LANCET ONCOL, V20, P371, DOI 10.1016/S1470-2045(18)30812-X; Loi S, 2016, JAMA ONCOL, V2, P1040, DOI 10.1001/jamaoncol.2016.0339; Luo XL, 2018, CANCER RES, V78, P3532, DOI 10.1158/0008-5472.CAN-18-0134; Ma KY, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.121387; Magbanua MJM, 2019, CLIN CANCER RES, V25, P5388, DOI 10.1158/1078-0432.CCR-18-3888; Manjili MH, 2018, ADV CANCER RES, V137, P17, DOI 10.1016/bs.acr.2017.11.005; Manjili MH, 2017, CANCER RES, V77, P2564, DOI 10.1158/0008-5472.CAN-17-0068; Manser RL, 2005, RESP MED, V99, P501, DOI 10.1016/j.rmed.2004.08.017; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Meng SD, 2004, CLIN CANCER RES, V10, P8152, DOI 10.1158/1078-0432.CCR-04-1110; Merlino G, 2016, PIGM CELL MELANOMA R, V29, P404, DOI 10.1111/pcmr.12475; Montagner M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00037; Namjoshi P, 2016, ONCOTARGET, V10, P6006; Nariai N, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S2-S7; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Nelson JB, 2005, NEOPLASIA, V7, P631, DOI 10.1593/neo.04787; Nichols Erin E, 2017, Int Ophthalmol Clin, V57, P1; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; Ogba N, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0489-4; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pan RY, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/4325874; Payne KK, 2016, J LEUKOCYTE BIOL, V100, P625, DOI 10.1189/jlb.5A1215-580R; Perez EA, 2019, CANCER-AM CANCER SOC, V125, P3974, DOI 10.1002/cncr.32392; Planes-Laine G, 2019, CANCERS, V11, DOI 10.3390/cancers11071033; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Ren D, 2019, J EXP MED, V216, P428, DOI 10.1084/jem.20180661; Sanger N, 2011, INT J CANCER, V129, P2522, DOI 10.1002/ijc.25895; Satelli A, 2015, CLIN CHEM, V61, P259, DOI 10.1373/clinchem.2014.228122; Schardt JA, 2005, CANCER CELL, V8, P227, DOI 10.1016/j.ccr.2005.08.003; Schmitt MJ, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-41; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shah SA, 2017, IMMUNOTHERAPY-UK, V9, P943, DOI 10.2217/imt-2017-0044; Sinha G, 2012, J NATL CANCER I, V104, P1693, DOI 10.1093/jnci/djs478; Spirig R, 2009, MOL IMMUNOL, V46, P3178, DOI 10.1016/j.molimm.2009.05.179; Szikriszt B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0963-7; Tan SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142466; Teng MWL, 2008, J LEUKOCYTE BIOL, V84, P988, DOI 10.1189/jlb.1107774; Thery L, 2019, JNCI CANCER SPECT, V3, DOI 10.1093/jncics/pkz026; Tjensvoll K, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6268-y; Tonnessen-Murray CA, 2019, J CELL BIOL, V218, P3827, DOI 10.1083/jcb.201904051; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tran E, 2017, NAT IMMUNOL, V18, P255, DOI 10.1038/ni.3682; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Triana-Martinez F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020346; Trujillo JA, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0780-0; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; van Buuren MM, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28836; van Maaren MC, 2019, INT J CANCER, V144, P263, DOI 10.1002/ijc.31914; Ward JP, 2016, ADV IMMUNOL, V130, P25, DOI 10.1016/bs.ai.2016.01.001; Zhang XN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4295; Zhu GZ, 2017, ACS NANO, V11, P2387, DOI 10.1021/acsnano.7b00978; Zolkind P, 2017, ORAL ONCOL, V71, P169, DOI 10.1016/j.oraloncology.2016.09.010	102	9	9	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4323	4330		10.1038/s41388-020-1295-3	http://dx.doi.org/10.1038/s41388-020-1295-3		APR 2020	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32322001	Green Accepted			2023-01-03	WOS:000528504800001
J	Hoffman, A; Sloan, CE; Maciejewski, ML; Wang, VG				Hoffman, Abby; Sloan, Caroline E.; Maciejewski, Matthew L.; Wang, Virginia			Medicare Enrollment Among Patients With End-Stage Kidney Disease Receiving Dialysis in Outpatient Facilities Between 2005 and 2016	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter								This study characterizes annual changes in enrollment of Medicare and non-Medicare patients treated at dialysis facilities before and after 2011 payment reforms and 2014 Affordable Care Act changes that influenced reimbursements.	[Hoffman, Abby; Wang, Virginia] Duke Univ, Sch Med, Dept Populat Hlth Sci, Campus Box 104023, Durham, NC 27701 USA; [Sloan, Caroline E.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA; [Maciejewski, Matthew L.] Durham Vet Affairs Hlth Care Syst, Durham Ctr Innovat Accelerate Discovery & Practic, Durham, NC USA	Duke University; Duke University	Wang, VG (corresponding author), Duke Univ, Sch Med, Dept Populat Hlth Sci, Campus Box 104023, Durham, NC 27701 USA.	virginia.wang@duke.edu		Hoffman, Abby/0000-0002-0972-9223; Sloan, Caroline/0000-0003-1611-3846	Duke University Department of Population Health Sciences predoctoral fellowship; Department of Veterans Affairs Office of Academic Affiliation postdoctoral fellowship; National Institute of Diabetes and Digestive and Kidney Diseases [R01DK097165]	Duke University Department of Population Health Sciences predoctoral fellowship; Department of Veterans Affairs Office of Academic Affiliation postdoctoral fellowship(US Department of Veterans Affairs); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Ms Hoffman was supported by a Duke University Department of Population Health Sciences predoctoral fellowship. Dr Sloan was supported by a Department of Veterans Affairs Office of Academic Affiliation postdoctoral fellowship. Drs Maciejewski andWang were supported by grant R01DK097165 from the National Institute of Diabetes and Digestive and Kidney Diseases.	[Anonymous], 2016, FED REGISTER, V81, P90211; [Anonymous], 2016, HLTH AFFAIRS BLOG; Sloan CE, 2019, CLIN J AM SOC NEPHRO, V14, P1763, DOI 10.2215/CJN.05910519; US Renal Data System, 2018, USRDS 2010 ANN DAT R	4	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2020	323	13					1314	1316		10.1001/jama.2020.0704	http://dx.doi.org/10.1001/jama.2020.0704			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE3DZ	32259222	Green Published, Bronze			2023-01-03	WOS:000526602700022
J	Gupta, V; Guleri, R; Gupta, M; Kaur, N; Kaur, K; Kumar, P; Anand, M; Kaur, G; Pati, PK				Gupta, Vasudha; Guleri, Rupam; Gupta, Muskan; Kaur, Navdeep; Kaur, Kuldeep; Kumar, Paramdeep; Anand, Manju; Kaur, Gurcharan; Pati, Pratap Kumar			Anti-neuroinflammatory potential of Tylophora indica (Burm. f) Merrill and development of an efficient in vitro propagation system for its clinical use	PLOS ONE			English	Article							NF-KAPPA-B; GENETIC STABILITY; MICROGLIA; CALLUS; MICROPROPAGATION; ESTABLISHMENT; REGENERATION; ACTIVATION; MECHANISMS; EXPRESSION	Neuroinflammation is a major risk factor associated with the pathogenesis of neurodegenerative diseases. Conventional non-steroidal anti-inflammatory drugs are prescribed but their long term use is associated with adverse effects. Thus, herbal based medicines are attracting major attraction worldwide as potential therapeutic candidates. Tylophora indica (Burm. f) Merrill is a valuable medicinal plant well known in Ayurvedic practices for its immunomodulatory, anti-oxidant, anti-asthmatic and antirheumatic activities. The present study aimed to elucidate the anti-neuroinflammatory potential of water and hydroalcoholic leaf extracts of micropropagated plants of T. indica using BV-2 microglia activated with lipopolysaccharide as an in vitro model system and development of an efficient reproducible protocol for its in vitro cloning. Non cytotoxic doses of the water and hydroalcoholic extracts (0.2 mu g/ml and 20 mu g/ml, respectively) were selected using MTT assay. alpha-Tubulin, Iba-1 and inflammatory cascade proteins like NF kappa B, AP1 expression was studied using immunostaining to ascertain the anti-neuroinflammatory potential of these extracts. Further, anti-migratory activity was also analyzed by Wound Scratch Assay. Both extracts effectively attenuated lipopolysaccharide induced microglial activation, migration and the production of nitrite via regulation of the expression of NF kappa B and AP1 as the possible underlying target molecules. An efficient and reproducible protocol for in vitro cloning of T. indica through multiple shoot proliferation from nodal segments was established on both solid and liquid Murashige and Skoog's (MS) media supplemented with 15 mu M and 10 mu M of Benzyl Amino Purine respectively. Regenerated shoots were rooted on both solid and liquid MS media supplemented with Indole-3-butyric acid (5-15 mu M) and the rooted plantlets were successfully acclimatized and transferred to open field conditions showing 90% survivability. The present study suggests that T. indica may prove to be a potential anti-neuroinflammatory agent and may be further explored as a potential therapeutic candidate for the management of neurodegenerative diseases. Further, the current study will expedite the conservation of T. indica ensuring ample supply of this threatened medicinal plant to fulfill its increasing demand in herbal industry.	[Gupta, Vasudha; Guleri, Rupam; Gupta, Muskan; Kaur, Navdeep; Kaur, Kuldeep; Kumar, Paramdeep; Kaur, Gurcharan; Pati, Pratap Kumar] Guru Nanak Dev Univ, Dept Biotechnol, Amritsar, Punjab, India; [Anand, Manju] Amity Univ, Amity Inst Biotechnol, Gurgaon, Haryana, India	Guru Nanak Dev University	Kaur, G; Pati, PK (corresponding author), Guru Nanak Dev Univ, Dept Biotechnol, Amritsar, Punjab, India.	kgurcharan.neuro@yahoo.com; pkpati@yahoo.com	; KAUR, NAVDEEP/GPK-0563-2022	pati, pratap/0000-0001-9017-7608; KAUR, NAVDEEP/0000-0002-4399-2797				Aid S, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-17; Ajmone-Cat MA, 2010, PHARMACEUTICALS, V3, P1949, DOI 10.3390/ph3061949; Anand M, 2012, MICROPROPAGATION SYS, V41; Aruna Bhatia, 2013, Journal of Natural Product and Plant Resources, V3, P1; Bach DH, 2019, CURR MED CHEM, V26, P4709, DOI [10.2174/10929867325666180726123339, 10.2174/0929867325666180726123339]; BERA TK, 1993, BOT BULL ACAD SINICA, V34, P83; Bhardwaj AK, 2018, PLANT CELL TISS ORG, V135, P499, DOI 10.1007/s11240-018-1482-x; Bhatia A, 2015, INT J CHEM PHARM ANA, V2, P88; BHUTANI KK, 1984, PHYTOCHEMISTRY, V23, P1765, DOI 10.1016/S0031-9422(00)83487-1; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Butiuc-Keul A, GENETIC STABILITY AS, V1, P61; Chaudhuri KN, 2004, PLANT CELL REP, V22, P731, DOI 10.1007/s00299-003-0753-z; Choi DK, 2011, MOLECULES, V16, P1021, DOI 10.3390/molecules16021021; Faisal M, 2005, IN VITRO CELL DEV-PL, V41, P511, DOI 10.1079/IVP2005674; Faisal M, 2003, PLANT CELL TISS ORG, V75, P125, DOI 10.1023/A:1025084203958; Faisal M, 2007, PLANT BIOTECHNOL REP, V1, P155, DOI 10.1007/s11816-007-0025-4; Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806-7819.2004; Ganguly T, 2001, PHYTOMEDICINE, V8, P348, DOI 10.1078/0944-7113-00055; Gantait S, 2017, 3 BIOTECH, V7, DOI 10.1007/s13205-017-0865-8; GOPALAKRISHNAN C, 1980, INDIAN J MED RES, V71, P940; Gottschalk RA, 2016, CELL SYST, V2, P378, DOI 10.1016/j.cels.2016.04.016; Gupta M, 2010, J PHARM SCI RES, V2, P401; Gupta M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0650-3; Harmanjit Kaur, 2011, International Journal of Medicinal and Aromatic Plants, V1, P83; JOSHI SG, 2000, MED PLANTS; Kang G, 2004, J PHARMACOL SCI, V94, P325, DOI 10.1254/jphs.94.325; Karlstetter M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-125; Kaur H, 2011, INT J BIOTECHNOLOGY, V2, P297; Kaur H, 2011, AFR J BIOTECHNOL, V10, P6928; Kaur H, 2011, J MED PLANTS RES, V5, P729; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kharrazi M., 2011, Journal of Biological & Environmental Sciences, V4, P1; Krishna H, 2016, 3 BIOTECH, V6, DOI 10.1007/s13205-016-0389-7; Kunene EN, 2018, ADV MED PLANT RES, V6, P26; Lakshmanan V, 2007, ELECTRON J BIOTECHN, V10, P106, DOI 10.2225/vol10-issue1-fulltext-12; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Lively S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-75; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Maroon Joseph C, 2010, Surg Neurol Int, V1, P80, DOI 10.4103/2152-7806.73804; Martins M, 2004, PLANT CELL REP, V23, P492, DOI 10.1007/s00299-004-0870-3; Minano HS, 2009, SCI HORTIC-AMSTERDAM, V122, P238, DOI 10.1016/j.scienta.2009.05.001; MULCHANDANI N B, 1971, Chemistry and Industry, V19, P505; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Oh JH, 2008, EUR J PHARMACOL, V599, P11, DOI 10.1016/j.ejphar.2008.09.017; Ohsawa K, 2000, J CELL SCI, V113, P3073; Overvoorde P, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001537; Palhares RM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127866; Raj C. D., 2006, Journal of Pharmacology and Toxicology, V1, P490; RAO KV, 1971, J PHARM SCI, V60, P1725, DOI 10.1002/jps.2600601133; Rao SN, 2013, J AM SCI, V4, P127; Renaud J, 2014, CURR PHARM BIOTECHNO, V15, P318, DOI 10.2174/1389201015666140617101332; Rock RB, 2006, J NEUROIMMUNE PHARM, V1, P117, DOI 10.1007/s11481-006-9012-8; Ruzic DV, 2008, HORTIC SCI, V35, P12, DOI 10.17221/646-HORTSCI; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Shehu U. I., 2016, African Journal of Agricultural Research, V11, P898; Sidhu Y., 2011, PLYMOUTH STUD SCI, V4, P432; Takayama S., 2005, LIQUID CULTURE SYSTE, P61; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Thomas TD, 2005, IN VITRO CELL DEV-PL, V41, P124, DOI 10.1079/IVP2004575; Waldie T, 2018, PLANT PHYSIOL, V177, P803, DOI 10.1104/pp.17.01691; Wang CC, 2014, KAOHSIUNG J MED SCI, V30, P73, DOI 10.1016/j.kjms.2013.09.012; Yang CW, 2006, MOL PHARMACOL, V69, P749, DOI 10.1124/mol.105.017764	62	5	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2020	15	3							e0230142	10.1371/journal.pone.0230142	http://dx.doi.org/10.1371/journal.pone.0230142			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ9HN	32210464	gold, Green Published			2023-01-03	WOS:000535307600017
J	Tadros, AR; Romanyuk, A; Miller, IC; Santiago, A; Noel, RK; O'Farrell, L; Kwong, GA; Prausnitz, MR				Tadros, Andrew R.; Romanyuk, Andrey; Miller, Ian C.; Santiago, Andrea; Noel, Richard K.; O'Farrell, Laura; Kwong, Gabriel A.; Prausnitz, Mark R.			STAR particles for enhanced topical drug and vaccine delivery	NATURE MEDICINE			English	Article							MICRONEEDLE PATCHES; SKIN-DISEASE; METHOTREXATE; PSORIASIS; EFFICACY; DESIGN; BURDEN; IMPACT	Drug delivery to the skin is highly constrained by the stratum corneum barrier layer(1). Here, we developed star-shaped particles, termed STAR particles, to dramatically increase skin permeability. STAR particles are millimeter-scale particles made of aluminum oxide or stainless steel with micron-scale projections designed to create microscopic pores across the stratum corneum. After gentle topical application for 10 s to porcine skin ex vivo, delivery of dermatological drugs and macromolecules, including those that cannot be given topically, was increased by 1 to 2 orders of magnitude. In mice treated with topical 5-fluorouracil, use of STAR particles increased the efficacy of the drug in suppressing the growth of subcutaneous melanoma tumors and prolonging survival. Moreover, topical delivery of tetanus toxoid vaccine to mice using STAR particles generated immune responses that were at least as strong as delivery of the vaccine by intramuscular injection, albeit at a higher dose for topical than intramuscular vaccine administration. STAR particles were well tolerated and effective at creating micropores when applied to the skin of human participants. Use of STAR particles provides a simple, low-cost and well-tolerated method for increasing drug and vaccine delivery to the skin and could widen the range of compounds that can be topically administered. Star-shaped, approximately 1-mm-wide ceramic particles, termed STAR particles, create micropores in the skin and, when added to topical formulations, enhance drug and vaccine delivery through the skin in mice.	[Tadros, Andrew R.; Romanyuk, Andrey; Prausnitz, Mark R.] Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA; [Miller, Ian C.; Santiago, Andrea; Kwong, Gabriel A.; Prausnitz, Mark R.] Georgia Tech, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; [Miller, Ian C.; Santiago, Andrea; Kwong, Gabriel A.; Prausnitz, Mark R.] Emory Univ, Georgia Inst Technol, Atlanta, GA 30322 USA; [Noel, Richard K.; O'Farrell, Laura] Georgia Inst Technol, Physiol Res Lab, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; Emory University; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	Prausnitz, MR (corresponding author), Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA.; Prausnitz, MR (corresponding author), Georgia Tech, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.	prausnitz@gatech.edu	Kwong, Gabriel A/M-5376-2013; Kwong, Gabriel/AAO-8266-2021	Kwong, Gabriel A/0000-0002-6255-6755; Kwong, Gabriel/0000-0002-6255-6755; Prausnitz, Mark/0000-0002-9076-8448	Georgia Research Alliance [GRA.VL17.B18]; CDC Foundation; UNICEF [969-17SC.GTRC]; National Institutes of Health Director's New Innovator Award [DP2HD091793]; Burroughs Wellcome Fund	Georgia Research Alliance; CDC Foundation(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); UNICEF; National Institutes of Health Director's New Innovator Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund)	The authors thank D. McAllister, S. Henry and W. Pewin for helpful discussions; R. Schafer for his expertise and assistance with laser micromachining; and D. Bondy for administrative support. This work was supported financially by the Georgia Research Alliance (no. GRA.VL17.B18, M.R.P.), the CDC Foundation with funding that originated from UNICEF (no. 969-17SC.GTRC, M.R.P.), the National Institutes of Health Director's New Innovator Award (no. DP2HD091793, G.A.K.) and a Career Award at the Scientific Interface from the Burroughs Wellcome Fund (G.A.K.).	Alster TS, 2018, DERMATOL SURG, V44, P397, DOI 10.1097/DSS.0000000000001248; [Anonymous], 2012, STAND SPEC HIGH PUR; Arora A, 2008, INT J PHARMACEUT, V364, P227, DOI 10.1016/j.ijpharm.2008.08.032; Becker LC, 2016, INT J TOXICOL, V35, p16S, DOI 10.1177/1091581816677948; Beyer V, 2010, ARCH DERMATOL, V146, P46, DOI 10.1001/archdermatol.2009.319; Bolognia JL, 2018, DERMATOLOGY, V4th; Cary JH, 2019, BIOMED MICRODEVICES, V21, DOI 10.1007/s10544-019-0371-3; Cazzaniga S, 2016, J EUR ACAD DERMATOL, V30, P628, DOI 10.1111/jdv.13479; Choy YB, 2011, PHARM RES-DORDR, V28, P943, DOI 10.1007/s11095-010-0292-6; Edens C, 2015, VACCINE, V33, P4683, DOI 10.1016/j.vaccine.2015.01.089; Eskicirak B, 2006, INT J DERMATOL, V45, P965, DOI 10.1111/j.1365-4632.2006.02911.x; Gill HS, 2008, CLIN J PAIN, V24, P585, DOI 10.1097/AJP.0b013e31816778f9; Gomaa YA, 2010, TOXICOL IN VITRO, V24, P1971, DOI 10.1016/j.tiv.2010.08.012; Good LM, 2011, J AM ACAD DERMATOL, V64, P413, DOI 10.1016/j.jaad.2009.12.013; Gross K, 2007, DERMATOL SURG, V33, P433, DOI 10.1111/j.1524-4725.2007.33090.x; Gupta PN, 2005, J PHARM PHARMACOL, V57, P295, DOI 10.1211/0022357055515; Hay RJ, 2014, J INVEST DERMATOL, V134, P1527, DOI 10.1038/jid.2013.446; Horn TD, 2005, ARCH DERMATOL, V141, P589, DOI 10.1001/archderm.141.5.589; Hutin YJF, 2003, BMJ-BRIT MED J, V327, P1075, DOI 10.1136/bmj.327.7423.1075; Karande P, 2005, P NATL ACAD SCI USA, V102, P4688, DOI 10.1073/pnas.0501176102; Kirby JS, 2010, J AM ACAD DERMATOL, V63, P689, DOI 10.1016/j.jaad.2009.09.048; Lee HS, 2017, PHARM RES-DORDR, V34, P101, DOI 10.1007/s11095-016-2042-x; Lim HW, 2017, J AM ACAD DERMATOL, V76, P958, DOI 10.1016/j.jaad.2016.12.043; McKay KM, 2013, BRIT J DERMATOL, V169, P549, DOI 10.1111/bjd.12402; Moustafa F, 2014, J AM ACAD DERMATOL, V71, P973, DOI 10.1016/j.jaad.2014.05.036; OECD, 2004, TEST NO 28 GUID DOC; Pastore MN, 2015, BRIT J PHARMACOL, V172, P2179, DOI 10.1111/bph.13059; Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504; Prausnitz MR, 2017, ANNU REV CHEM BIOMOL, V8, P177, DOI 10.1146/annurev-chembioeng-060816-101514; PRAUSNITZ MR, 1993, P NATL ACAD SCI USA, V90, P10504, DOI 10.1073/pnas.90.22.10504; Rademaker M, 2010, AUSTRALAS J DERMATOL, V51, P248, DOI 10.1111/j.1440-0960.2010.00657.x; Riedel R, 2008, CERAMICS SCI TECHNOL; Ripolin A, 2017, INT J PHARMACEUT, V521, P92, DOI 10.1016/j.ijpharm.2017.02.011; Siddhapura K, 2016, NANOMED-NANOTECHNOL, V12, P213, DOI 10.1016/j.nano.2015.10.009; Taudorff EH, 2015, EXPERT OPIN DRUG DEL, V12, P1059, DOI 10.1517/17425247.2015.1031216; Nguyen TT, 2018, EXPERT OPIN DRUG DEL, V15, P235, DOI 10.1080/17425247.2018.1410138; Upadhyaya A., 2011, POWDER METALLURGY SC, Vfirst; Watkinson AC, 2016, EXPERT OPIN DRUG DEL, V13, P523, DOI 10.1517/17425247.2016.1130034; Wollina U, 2001, CLIN RHEUMATOL, V20, P406, DOI 10.1007/s100670170004; Ye YQ, 2018, ADV DRUG DELIVER REV, V127, P106, DOI 10.1016/j.addr.2018.01.015	40	20	20	6	75	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2020	26	3					341	+		10.1038/s41591-020-0787-6	http://dx.doi.org/10.1038/s41591-020-0787-6		MAR 2020	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	KU0MC	32152581				2023-01-03	WOS:000518737200001
J	Tukue, D; Gebremeskel, TG; Gebremariam, L; Aregawi, B; Hagos, MG; Gebremichael, T; Tesfay, HN; Arefaine, ZG				Tukue, Desta; Gebremeskel, Teferi Gebru; Gebremariam, Lemlem; Aregawi, Bereket; Hagos, Merhawit Gebremeskel; Gebremichael, Tsega; Tesfay, Haben Nuguse; Arefaine, Zekarias Gessesse			Prevalence and determinants of modern contraceptive utilization among women in the reproductive age group in Edaga-hamus Town, Eastern zone, Tigray region, Ethiopia, June 2017	PLOS ONE			English	Article							HIV-POSITIVE WOMEN	Introduction All individuals and couples have a basic human right to decide freely and responsibly the number, spacing, and timing of their child. However, In Ethiopia, the prevalence of contraceptive utilization remains low and it varies in different regions. Therefore, this study was aimed to determine prevalence and determinant factors affecting the utilization of modern contraception in the reproductive age group (15-49 years) in Edaga-Hamus Town. Methodology A community based Cross-Sectional study was carried out on April 23 to May 10, 2017. A systemic random sampling method was used to select study participants. Information was collected using a structured, pre-tested questionnaire. The data were entered into EPI-info version 7.1 and imported to SPSS version 20. Summary statistics and logistic regression analysis were performed using SPSS version 20. Those variables having a P-value of less than 0.2 in the bivariable analysis were fitted in multivariable analysis. AOR with 95% CI and P-value< 0.05 were used during multivariable analysis to identify the factors associated with the utilization of modern in reproductive. Result In this study the overall prevalence of modern contraceptive utilization was 58.5%. Age (AOR = 0.406,95%,Cl: (0.000,0.398)), Educational status (AOR = 0.901,95% Cl (0.340,4.107)), Feeling of husband towards Modern contraceptive (AOR = 0.186, 95% CI (0.056,0.617) had protective effect of utilization of modern contraceptive. But Number of children 1-3 and 4-5 wanted(AOR = 10.802,95%(4.027,28.975)), AOR = 2.624,95% CI (1.437,4.791), was a risk for utilization of modern contraceptive. Conclusion and recommendation The prevalence of Modern contraceptive utilization was still to be low (far below the national target). Therefore, providing educational opportunities, creating awareness about contraception and effective counseling would increase modern contraceptive methods utilization.	[Tukue, Desta] Adigrat Gen Hosp, Adigrat, Ethiopia; [Gebremeskel, Teferi Gebru] Aksum Univ, Coll Hlth Sci, Dept Reprod Hlth, Aksum, Ethiopia; [Gebremariam, Lemlem] Adigrat Univ, Coll Med & Hlth Sci, Dept Publ Hlth, Adigrat, Ethiopia; [Aregawi, Bereket] Aksum Univ, Dept Internal Med Dept, Collage Med & Hlth Sci, Aksum, Ethiopia; [Hagos, Merhawit Gebremeskel] Aksum Univ, Coll Med & Hlth Sci, Dept Midwifery, Aksum, Ethiopia; [Gebremichael, Tsega] Aksum Univ, Coll Med & Hlth Sci, Dept Epidemiol & Bioststist, Aksum, Ethiopia; [Tesfay, Haben Nuguse] Aksum Univ, Coll Med & Hlth Sci, Dept Pedatr, Aksum, Ethiopia; [Arefaine, Zekarias Gessesse] Mekelle Univ, Coll Med & Hlth Sci, Dept Internal Med, Mekelle, Ethiopia	Mekelle University	Gebremeskel, TG (corresponding author), Aksum Univ, Coll Hlth Sci, Dept Reprod Hlth, Aksum, Ethiopia.	teferigebru12@gmail.com	Gebremeskel, Teferi Gebru/AAV-8340-2020	Gebremeskel, Teferi Gebru/0000-0002-8276-5685				Adair T, 2009, J BIOSOC SCI, V41, P269, DOI 10.1017/S0021932008003076; Adal TG, 2017, ANN MED HLTH SCI RES; Adera A., 2015, AM J HLTH RES, V3, P239, DOI [10.11648/j.ajhr.20150304.16, DOI 10.11648/J.AJHR.20150304.16]; Agyei-Baffour P, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0022-y; Alemayehu GA, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0611-3; Alemayehu M, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0321-7; Andia I, 2009, AM J PUBLIC HEALTH, V99, P340, DOI 10.2105/AJPH.2007.129528; Ashagrie A, 2017, KNOWLEDGE SCREENING; Ayele W, 2011, FURTHER ANAL 2000, V2005; Belete N, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0663-4; Ejembi CL., 2015, DHS WORKING PAPERS; Eko Jimmy E, 2013, INT J HUMANITIES SOC, V2; Eliason S, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-34; Ethiopia CSA, ETH MIN HLTH SURV 20; Gebremedhin M, 2015, INT J HEALTHCARE, V2, P82; Georgis FH, 2006, ASSESSMENT FACTORS I; Girma T, 2016, J PREG CHILD HLTH, V3, P2; Hoffman IF, 2008, JAIDS-J ACQ IMM DEF, V47, P477, DOI 10.1097/QAI.0b013e318165dc52; Ifeanyichukwu O., 2015, J ADV MED MED RES, V9, P1; Kassa TB., 2014, J PUBLIC HLTH, V2, P507, DOI DOI 10.11648/j.sjph.20140206.11; Lakew Y, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-52; Medhanyie AA, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0281-x; Mohammed A, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-13; Nations U, 2015, TRENDS CONTR US WORL; Tekelab T, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0208-z; Tobe A, 2015, J PREGNANCY CHILD HL, V2, P128; Tsehaye W. T., 2014, Journal of Bio Innovation, V3, P144; Uprety S., 2016, J CHITWAN MED COLL, V6, P48; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; Yitayal M, 2014, J MULTIDISCIP HEALTH, V7, P201, DOI 10.2147/JMDH.S62294	30	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2020	15	3							e0227795	10.1371/journal.pone.0227795	http://dx.doi.org/10.1371/journal.pone.0227795			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8TR	32142517	gold, Green Published			2023-01-03	WOS:000535271600002
J	Liu, CW; Liao, KH; Tseng, H; Wu, CM; Chen, HY; Lai, TW				Liu, Che-Wei; Liao, Kate Hsiurong; Tseng, Hsin; Wu, Ching Mei; Chen, Hsiao-Yun; Lai, Ted Weita			Hypothermia but not NMDA receptor antagonism protects against stroke induced by distal middle cerebral arterial occlusion in mice	PLOS ONE			English	Article							ISCHEMIC BRAIN-DAMAGE; D-ASPARTATE ANTAGONIST; N-TERMINAL KINASE; DIZOCILPINE MK-801; GLUTAMATE ANTAGONIST; NEURONAL DAMAGE; SPONTANEOUS HYPERTHERMIA; THERAPEUTIC WINDOW; PEPTIDE INHIBITOR; TRANSIENT	Excitotoxicity mediated by the N-methyl-D-aspartate receptor (NMDAR) is believed to be a primary mechanism of neuronal injury following stroke. Thus, many drugs and therapeutic peptides were developed to inhibit either the NMDAR at the cell surface or its downstream intracellular death-signaling cascades. Nevertheless, the majority of focal ischemia studies concerning NMDAR antagonism were performed using the intraluminal suture-induced middle cerebral arterial occlusion (MCAO) model, which produces a large cortical and subcortical infarct leading to hypothalamic damage and fever in experimental animals. Here, we investigated whether NMDAR antagonism by drugs and therapeutic peptides was neuroprotective in a mouse model of distal MCAO (dMCAO), which produces a small cortical infarct sparing the hypothalamus and other subcortical structures. For establishment of this model, mice were subjected to dMCAO under normothermic conditions or body-temperature manipulations, and in the former case, their brains were collected at 3-72 h post-ischemia to follow the infarct development. These mice developed cortical infarction 6 h post-ischemia, which matured by 24-48 h post-ischemia. Consistent with the hypothesis that the delayed infarction in this model can be alleviated by neuroprotective interventions, hypothermia strongly protected the mouse brain against cerebral infarction in this model. To evaluate the therapeutic efficacy of NMDAR antagonism in this model, we treated the mice with MK801, Tat-NR2B9c, and L-JNKI-1 at doses that were neuroprotective in the MCAO model, and 30 min later, they were subjected to 120 min of dMCAO either in the awake state or under anesthesia with normothermic controls. Nevertheless, NMDAR antagonism, despite exerting pharmacological effects on mouse behavior, repeatedly failed to show neuroprotection against cerebral infarction in this model. The lack of efficacy of these treatments is reminiscent of the recurrent failure of NMDAR antagonism in clinical trials. While our data do not exclude the possibility that these treatments could be effective at a different dose or treatment regimen, they emphasize the need to test drug efficacy in different stroke models before optimal doses and treatment regimens can be selected for clinical trials.	[Liu, Che-Wei; Wu, Ching Mei; Lai, Ted Weita] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan; [Liu, Che-Wei; Tseng, Hsin; Lai, Ted Weita] China Med Univ, Sch Med, Taichung, Taiwan; [Liao, Kate Hsiurong; Chen, Hsiao-Yun; Lai, Ted Weita] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Liao, Kate Hsiurong] China Med Univ Hosp, Dept Anesthesiol, Taichung, Taiwan; [Lai, Ted Weita] China Med Univ, Drug Dev Ctr, Taichung, Taiwan; [Lai, Ted Weita] China Med Univ Hosp, Translat Med Res Ctr, Taichung, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Lai, TW (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.; Lai, TW (corresponding author), China Med Univ, Sch Med, Taichung, Taiwan.; Lai, TW (corresponding author), China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan.; Lai, TW (corresponding author), China Med Univ, Drug Dev Ctr, Taichung, Taiwan.; Lai, TW (corresponding author), China Med Univ Hosp, Translat Med Res Ctr, Taichung, Taiwan.	ted.weita@me.com	Lai, Ted Weita/E-9392-2016	Lai, Ted Weita/0000-0002-6229-4134; Liu, Che-Wei/0000-0002-5050-5029; Tseng, Hsin/0000-0001-5077-7916	China Medical University [CMU105-S-14]; Ministry of Science and Technology [MOST108-2320-B-039-016, MOST105-2815-C-039-046-B, MOST106-2813-C-039-066-B, MOST108-2813-C039-125-B, MOST106-2813-C-039067-B]; National Health Research Institutes [NHRI-EX10910803NI]; 'Drug Development Center, China Medical University' from The Featured Areas Research Center Program within Ministry of Education (MOE) in Taiwan	China Medical University(China Medical University); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Health Research Institutes(National Health Research Institutes, Japan); 'Drug Development Center, China Medical University' from The Featured Areas Research Center Program within Ministry of Education (MOE) in Taiwan	This study was supported by research grants from the China Medical University (CMU105-S-14), Ministry of Science and Technology (MOST108-2320-B-039-016), the National Health Research Institutes (NHRI-EX10910803NI) and the `Drug Development Center, China Medical University' from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. C.W.L. and H.T. were supported by undergraduate student research awards from the Ministry of Science and Technology (MOST105-2815-C-039-046-B; MOST106-2813-C-039-066-B; MOST108-2813-C039-125-B to C.W.L. and MOST106-2813-C-039067-B to H.T.). The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Alkan T., 2001, Archives of Physiology and Biochemistry, V109, P135, DOI 10.1076/apab.109.2.135.4271; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; BUCHAN A, 1991, J NEUROSCI, V11, P1049; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUCHAN AM, 1992, BRAIN RES, V574, P171, DOI 10.1016/0006-8993(92)90814-P; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; Esneault E, 2008, NEUROSCIENCE, V152, P308, DOI 10.1016/j.neuroscience.2007.12.036; Gerriets T, 2003, STROKE, V34, P2234, DOI 10.1161/01.STR.0000087171.34637.A9; GILL R, 1987, J NEUROSCI, V7, P3343; GILL R, 1991, BRIT J PHARMACOL, V103, P2030, DOI 10.1111/j.1476-5381.1991.tb12371.x; HATFIELD RH, 1992, EUR J PHARMACOL, V216, P1, DOI 10.1016/0014-2999(92)90201-E; Hill MD, 2012, LANCET NEUROL, V11, P942, DOI 10.1016/S1474-4422(12)70225-9; IKONOMIDOU C, 1989, BRAIN RES, V487, P184, DOI 10.1016/0006-8993(89)90956-6; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Lai TW, 2011, TRENDS MOL MED, V17, P266, DOI 10.1016/j.molmed.2010.12.008; Lai TW, 2010, NAT MED, V16, P1376, DOI 10.1038/nm1210-1376; LEBLANC MH, 1991, STROKE, V22, P1270, DOI 10.1161/01.STR.22.10.1270; Li FH, 1999, STROKE, V30, P2464, DOI 10.1161/01.STR.30.11.2464; Liao KH, 2019, BRAIN RES, V1720, DOI 10.1016/j.brainres.2019.146320; Liu F, 2009, J NEUROSCI METH, V179, P1, DOI 10.1016/j.jneumeth.2008.12.028; Liu Y., 2017, SHOCK VIB, V2017, P1; LO EH, 1994, J CEREBR BLOOD F MET, V14, P597, DOI 10.1038/jcbfm.1994.74; Ma JY, 1998, BRIT J PHARMACOL, V124, P756, DOI 10.1038/sj.bjp.0701871; Margaill I, 1996, J CEREBR BLOOD F MET, V16, P107, DOI 10.1097/00004647-199601000-00013; MCDONALD JW, 1987, EUR J PHARMACOL, V140, P359, DOI 10.1016/0014-2999(87)90295-0; MEMEZAWA H, 1995, BRAIN RES, V670, P48, DOI 10.1016/0006-8993(94)01251-C; NELLGARD B, 1991, ANESTHESIOLOGY, V75, P279, DOI 10.1097/00000542-199108000-00016; NELLGARD B, 1992, J CEREBR BLOOD F MET, V12, P2, DOI 10.1038/jcbfm.1992.2; OLNEY JW, 1989, J NEUROSCI, V9, P1701; OZYURT E, 1988, J CEREBR BLOOD F MET, V8, P138, DOI 10.1038/jcbfm.1988.18; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; PARK CK, 1988, J CEREBR BLOOD F MET, V8, P757, DOI 10.1038/jcbfm.1988.124; Reglodi D, 2000, EXP NEUROL, V163, P399, DOI 10.1006/exnr.2000.7367; ROD MR, 1990, CAN J PSYCHOL, V44, P196, DOI 10.1037/h0084242; ROD MR, 1989, CAN J NEUROL SCI, V16, P340, DOI 10.1017/S031716710002919X; SWAN JH, 1990, J CEREBR BLOOD F MET, V10, P343, DOI 10.1038/jcbfm.1990.63; Taghibiglou C, 2009, NAT MED, V15, P1399, DOI 10.1038/nm.2064; WARNER MA, 1991, J CEREBR BLOOD F MET, V11, P600, DOI 10.1038/jcbfm.1991.110	41	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2020	15	3							e0229499	10.1371/journal.pone.0229499	http://dx.doi.org/10.1371/journal.pone.0229499			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8MS	32126102	Green Published, Green Submitted, gold			2023-01-03	WOS:000535253100027
J	Lusnig, L; Radach, R; Mueller, CJ; Hofmann, MJ				Lusnig, Larissa; Radach, Ralph; Mueller, Christina J.; Hofmann, Markus J.			Zen meditation neutralizes emotional evaluation, but not implicit affective processing of words	PLOS ONE			English	Article							FREQUENCY; ATTENTION; INTERFERENCE; DEPENDENCE; RESPONSES; AROUSAL	There is ample evidence that meditation can regulate emotions. It is questionable, however, whether meditation can down-regulate sensitivity to emotional experience in high-level cognitive representations such as words. The present study shows that adept Zen meditators rated the emotional valence of (low-arousal) positive and (high- and low-arousal) negative nouns significantly more neutral after a meditation session, while there was no change of valence ratings after a comparison intervention in the comparison group. Because the Zen group provided greater "openness to experience" and lower,need for achievement and performance" in the "Big Five" personality assessment, we used these scores as covariates for all analyses. We found no differential emotion effects of Zen meditation during lexical decision, but we replicated the slow-down of low-arousal negative words during lexical decision in both groups. Interestingly, Zen meditation elicited a global facilitation of all response times, which we discuss in terms of increased attentional resources after meditation.	[Lusnig, Larissa; Radach, Ralph; Hofmann, Markus J.] Univ Wuppertal, Dept Psychol, Wuppertal, Germany; [Mueller, Christina J.] Int Psychoanalyt Univ, Methods & Evaluat, Berlin, Germany	University of Wuppertal	Lusnig, L (corresponding author), Univ Wuppertal, Dept Psychol, Wuppertal, Germany.	larissa.lusnig@uni-wuppertal.de			Deutsche Forschungsgemeinschaft [HO 5139/2-2]; Evangelisches Studienwerk e.V.	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Evangelisches Studienwerk e.V.	This work was partly supported by a grant of the Deutsche Forschungsgemeinschaft to MH (HO 5139/2-2) and by a doctoral studies grant of the Evangelisches Studienwerk e.V. to LL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Baayen RH, 2008, J MEM LANG, V59, P390, DOI 10.1016/j.jml.2007.12.005; BALDWIN MW, 1993, PERS SOC PSYCHOL B, V19, P746, DOI 10.1177/0146167293196010; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bielefeldt C., 1988, DOGENS MANUALS ZEN M; Brefczynski-Lewis JA, 2007, P NATL ACAD SCI USA, V104, P11483, DOI 10.1073/pnas.0606552104; Brickenkamp R., 2015, D2 R TEST ATTENTION; Brysbaert M, 2011, EXP PSYCHOL, V58, P412, DOI 10.1027/1618-3169/a000123; Carter OL, 2005, CURR BIOL, V15, pR412, DOI 10.1016/j.cub.2005.05.043; Chan D, 2007, J ALTERN COMPLEM MED, V13, P651, DOI 10.1089/acm.2007.7022; Chau Bolton K H, 2018, Brain Neurosci Adv, V2, p2398212818771822, DOI 10.1177/2398212818771822; Chiesa A, 2011, J CLIN PSYCHOL, V67, P404, DOI 10.1002/jclp.20776; Citron FMM, 2012, BRAIN LANG, V122, P211, DOI 10.1016/j.bandl.2011.12.007; Corcoran KA, 2005, J NEUROSCI, V25, P8978, DOI 10.1523/JNEUROSCI.2246-05.2005; Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812; Desbordes G, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00292; Fox KCR, 2014, NEUROSCI BIOBEHAV R, V43, P48, DOI 10.1016/j.neubiorev.2014.03.016; Goyal M, 2014, JAMA INTERN MED, V174, P357, DOI 10.1001/jamainternmed.2013.13018; Grecucci A, 2015, BIO MED RES; Holzel BK, 2011, PSYCHIAT RES-NEUROIM, V191, P36, DOI 10.1016/j.pscychresns.2010.08.006; Hofmann MJ, 2007, BEHAV RES METHODS, V39, P620, DOI 10.3758/BF03193034; Hofmann MJ, 2009, COGN AFFECT BEHAV NE, V9, P389, DOI 10.3758/9.4.389; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555; Jacobs AM, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00714; Kanske P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030086; Kapleau P, 1965, 3 PILLARS ZEN TEACHI; Kissler J, 2007, PSYCHOL SCI, V18, P475, DOI 10.1111/j.1467-9280.2007.01924.x; Kok BE, 2017, MINDFULNESS, V8, P218, DOI 10.1007/s12671-016-0594-9; Kuchinke L, 2007, INT J PSYCHOPHYSIOL, V65, P132, DOI 10.1016/j.ijpsycho.2007.04.004; Kuperman V, 2014, J EXP PSYCHOL GEN, V143, P1065, DOI 10.1037/a0035669; Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13; Lehrl S., 2005, MANUAL ZUM MWT B; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; MEYER DE, 1971, J EXP PSYCHOL, V90, P227, DOI 10.1037/h0031564; Mueller CJ, 2016, COGN AFFECT BEHAV NE, V16, P489, DOI 10.3758/s13415-016-0408-5; New B, 2006, PSYCHON B REV, V13, P45, DOI 10.3758/BF03193811; Ortner CNM, 2007, MOTIV EMOTION, V31, P271, DOI 10.1007/s11031-007-9076-7; Pagnoni G, 2007, NEUROBIOL AGING, V28, P1623, DOI 10.1016/j.neurobiolaging.2007.06.008; Pagnoni G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003083; Peirce JW, 2007, J NEUROSCI METH, V162, P8, DOI 10.1016/j.jneumeth.2006.11.017; RUBENSTEIN H, 1970, J VERB LEARN VERB BE, V9, P487, DOI 10.1016/S0022-5371(70)80091-3; Satow L., 2011, ZENTRUM PSYCHOL INFO; Schacht A, 2009, BRAIN COGNITION, V69, P538, DOI 10.1016/j.bandc.2008.11.005; Schacht A, 2009, COGN AFFECT BEHAV NE, V9, P28, DOI 10.3758/CABN.9.1.28; Siegle GJ, 2002, COGNITIVE THER RES, V26, P73, DOI 10.1023/A:1013893705009; Slagter HA, 2007, PLOS BIOL, V5, P1228, DOI 10.1371/journal.pbio.0050138; Sobolewski A, 2011, NEUROSCI RES, V71, P44, DOI 10.1016/j.neures.2011.06.002; Suzuki S., 1970, ZEN MIND BEGINNERS M; Tang YY, 2007, P NATL ACAD SCI USA, V104, P17152, DOI 10.1073/pnas.0707678104; Tang YY, 2015, NAT REV NEUROSCI, V16, P213, DOI 10.1038/nrn3916; Tasioulis S, 2007, UNSERE ERDE FILM; Vo MLH, 2009, BEHAV RES METHODS, V41, P534, DOI 10.3758/BRM.41.2.534; Waddell N., 1996, ZEN WORDS HEART HAKU	52	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2020	15	2							e0229310	10.1371/journal.pone.0229310	http://dx.doi.org/10.1371/journal.pone.0229310			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8AS	32074130	gold, Green Published			2023-01-03	WOS:000535220600039
J	Jones, SR; Sliva, DD				Jones, Stephanie R.; Sliva, Danielle D.			Is Alpha Asymmetry a Byproduct or Cause of Spatial Attention? New Evidence Alpha Neurofeedback Controls Measures of Spatial Attention	NEURON			English	Editorial Material								Cued spatial attention differentially modulates alpha power in attended relative to non-attended brain representations, termed the alpha asymmetry. Yet a causal role for alpha in attention is debated. In this issue of Neuron, Bagherzadeh et al., (2019) utilize neurofeedback to train alpha asymmetry and causally impact measures of spatial attention.	[Jones, Stephanie R.; Sliva, Danielle D.] Brown Univ, Dept Neurosci, Providence, RI 02912 USA; [Jones, Stephanie R.] Providence VA Med Ctr, Ctr Neurorestorat & Neurotechnol, Providence, RI 02908 USA	Brown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center	Jones, SR; Sliva, DD (corresponding author), Brown Univ, Dept Neurosci, Providence, RI 02912 USA.; Jones, SR (corresponding author), Providence VA Med Ctr, Ctr Neurorestorat & Neurotechnol, Providence, RI 02908 USA.	stephanie_jones@brown.edu; danielle_sliva@brown.edu			NIGMS NIH HHS [P20 GM103645] Funding Source: Medline; NIMH NIH HHS [R01 MH106174] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bagherzadeh Y., 2019, NEURON, V105, P577; Jensen O, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00186; Jones SR, 2010, J NEUROSCI, V30, P13760, DOI 10.1523/JNEUROSCI.2969-10.2010; Kajal DS, 2017, HUM BRAIN MAPP, V38, P4353, DOI 10.1002/hbm.23663; Lakatos P, 2019, CURR BIOL, V29, pR890, DOI 10.1016/j.cub.2019.07.075; Muller N, 2012, CEREB CORTEX, V22, P1604, DOI 10.1093/cercor/bhr232; Okazaki YO, 2015, NEUROIMAGE, V107, P323, DOI 10.1016/j.neuroimage.2014.12.014; Ossadtchi A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04012-0; Shin H, 2017, ELIFE, V6, DOI 10.7554/eLife.29086	9	3	3	4	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	FEB 5	2020	105	3					404	406		10.1016/j.neuron.2019.12.033	http://dx.doi.org/10.1016/j.neuron.2019.12.033			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KK6WT	32027830	Green Accepted, Bronze			2023-01-03	WOS:000512880900005
J	Lubman, DI; Matthews, S; Heilbronn, C; Killian, JJ; Ogeil, RP; Lloyd, B; Witt, K; Crossin, R; Smith, K; Bosley, E; Carney, R; Wilson, A; Eastham, M; Keene, T; Shipp, C; Scott, D				Lubman, Dan, I; Matthews, Sharon; Heilbronn, Cherie; Killian, Jessica J.; Ogeil, Rowan P.; Lloyd, Belinda; Witt, Katrina; Crossin, Rose; Smith, Karen; Bosley, Emma; Carney, Rosemary; Wilson, Alex; Eastham, Matthew; Keene, Toby; Shipp, Carol; Scott, Debbie			The National Ambulance Surveillance System: A novel method for monitoring acute alcohol, illicit and pharmaceutical drug related-harms using coded Australian ambulance clinical records	PLOS ONE			English	Article							OPIOID OVERDOSE; GLOBAL BURDEN; MELBOURNE; DISEASE; TRENDS; DEPENDENCE	Although harmful consumption of alcohol and other drugs (both illicit and pharmaceutical) significantly contribute to global burden of disease, not all harms are captured within existing morbidity data sources. Indeed, harms occurring in the community may be missed or underreported. This paper describes the National Ambulance Surveillance System, a unique Australian system for monitoring and mapping acute harms related to alcohol and other drug consumption. Data are sourced from paramedic electronic patient care records provided by ambulance services from across Australia. Coding occurs in a purpose-built system, by a team of specialised research assistants. Alcohol, and specific illicit and pharmaceutical drugs, rather than broad drug classes, are manually coded and the dataset is reviewed and cleaned prior to analysis. The National Ambulance Surveillance System is an ongoing, dynamic surveillance system of alcohol and other drug-related harms across Australia. The data includes more than 140 output variables per attendance, including individual substances, demographics, temporal, geospatial, and clinical data (e.g., Glasgow Coma Scale score, naloxone provision and response, outcome of attendance). The National Ambulance Surveillance System is an internationally unique population-level surveillance system of acute harms arising from alcohol and other drug consumption. Dissemination of National Ambulance Surveillance System data has been used to inform and evaluate policy approaches and potential points of intervention, as well as guide workforce development needs and clinical practice at the local and national level. This methodology could be replicated in other countries.	[Lubman, Dan, I; Matthews, Sharon; Heilbronn, Cherie; Killian, Jessica J.; Ogeil, Rowan P.; Lloyd, Belinda; Witt, Katrina; Crossin, Rose; Scott, Debbie] Eastern Hlth, Turning Point, Richmond, Vic, Australia; [Lubman, Dan, I; Matthews, Sharon; Heilbronn, Cherie; Killian, Jessica J.; Ogeil, Rowan P.; Lloyd, Belinda; Witt, Katrina; Crossin, Rose; Scott, Debbie] Monash Univ, Eastern Hlth Clin Sch, Box Hill, Vic, Australia; [Lubman, Dan, I; Ogeil, Rowan P.; Witt, Katrina; Crossin, Rose; Scott, Debbie] Monash Univ, Monash Addict Res Ctr, Frankston, Vic, Australia; [Smith, Karen] Ambulance Victoria, Doncaster, Vic, Australia; [Smith, Karen] Monash Univ, Dept Community Emergency Hlth & Paramed Practice, Frankston, Vic, Australia; [Smith, Karen] Monash Univ, Dept Epidemiol & Preventat Med, Melbourne, Vic, Australia; [Bosley, Emma] Queensland Ambulance Serv, Brisbane, Qld, Australia; [Carney, Rosemary] New South Wales Ambulance, Rozelle, NSW, Australia; [Wilson, Alex] Ambulance Tasmania, Hobart, Tas, Australia; [Eastham, Matthew] St John Ambulance Australia NT Inc, Casuarina, NT, Australia; [Keene, Toby; Shipp, Carol] Australian Capital Terr Ambulance Serv, Fairbairn, ACT, Australia	Turning Point Alcohol & Drug Centre - Australia; Monash University; Monash University; Monash University; Monash University	Lubman, DI (corresponding author), Eastern Hlth, Turning Point, Richmond, Vic, Australia.; Lubman, DI (corresponding author), Monash Univ, Eastern Hlth Clin Sch, Box Hill, Vic, Australia.; Lubman, DI (corresponding author), Monash Univ, Monash Addict Res Ctr, Frankston, Vic, Australia.	dan.lubman@monash.edu	Killian, Jessica/AAV-3752-2021; Keene, Toby/HGC-3447-2022; Scott, Deborah/ABB-9055-2020; Witt, Katrina/AAN-4554-2020	Witt, Katrina/0000-0002-1489-4573; Scott, Deborah/0000-0002-4530-584X; Smith, Karen/0000-0002-9057-0685; Crossin, Rose/0000-0003-1814-1330; Matthews, Sharon/0000-0003-3105-7029; Lubman, Dan/0000-0002-6747-1937	Victorian Department of Health and Human Services; Commonwealth Department of Health (Australia)	Victorian Department of Health and Human Services; Commonwealth Department of Health (Australia)	NAP is funded by the Victorian Department of Health and Human Services and the Commonwealth Department of Health (Australia). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2017, DUBL DRUG POL SUMM R; [Anonymous], 2014, GLOB STAT REP ALC HL; Arunogiri S, 2020, ADDICTION, V115, P473, DOI 10.1111/add.14848; Arunogiri S, 2015, AUST NZ J PSYCHIAT, V49, P939, DOI 10.1177/0004867415585323; Australian Institute of Health and Welfare (AIHW), 2017, NAT DRUG STRAT HOUS; Camenga DR, 2015, DRUG ALCOHOL DEPEN, V146, pe237; Centre for Program Evaluation, 2016, EV SYDN CBD ENT PREC; Chou R, 2017, ANN INTERN MED, V167, P867, DOI 10.7326/M17-2224; Coomber K, 2019, DRUG ALCOHOL DEPEN, V205, DOI 10.1016/j.drugalcdep.2019.107685; Cox S, 2013, AUST HEALTH REV, V37, P54, DOI 10.1071/AH11161; Crossin R, 2019, MED J AUSTRALIA, V210, P75, DOI 10.5694/mja2.12036; Crossin R, 2018, DRUG ALCOHOL DEPEN, V190, P46, DOI 10.1016/j.drugalcdep.2018.05.026; Curtis A, 2019, J STUD ALCOHOL DRUGS, V80, P314, DOI 10.15288/jsad.2019.80.314; Degenhardt L, 2014, DRUG ALCOHOL REV, V33, P4, DOI 10.1111/dar.12088; Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0; Dietze PM, 2000, DRUG ALCOHOL REV, V19, P27; Gomes T, 2014, ADDICTION, V109, P1482, DOI 10.1111/add.12598; Heilbronn C, 2013, DRUG ALCOHOL REV, V32, P405, DOI 10.1111/dar.12028; Kaar SJ, 2015, DRUG ALCOHOL DEPEN, V155, P24, DOI 10.1016/j.drugalcdep.2015.08.021; Liew D., 2017, EVIDENCE INFORM INCL; Magura S, 1996, SUBST USE MISUSE, V31, P1131, DOI 10.3109/10826089609063969; Nambiar D, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014854; Nielsen S, 2019, ADDICTION, DOI [10.1136/bmjopen-2019-029170, DOI 10.1136/BMJ0PEN-2019-029170]; Ogeil RP, 2016, ADDICTION, V111, P626, DOI 10.1111/add.13213; Ogeil RP, 2015, AUST NZ J PUBL HEAL, V39, P121, DOI 10.1111/1753-6405.12308; Ogeil RP, 2016, AUST EPIDEMIOL, V23, P49; Patel V, 2007, LANCET, V369, P1302, DOI 10.1016/S0140-6736(07)60368-7; Rehm J, 2017, ADDICTION, V112, P968, DOI 10.1111/add.13757; Room R, 2005, LANCET, V365, P519, DOI 10.1016/S0140-6736(05)70276-2; Saunders JB, 2012, ALCOHOL ALCOHOLISM, V47, P216, DOI 10.1093/alcalc/ags024; Schmidt LA, 2010, EQUITY, SOCIAL DETERMINANTS AND PUBLIC HEALTH PROGRAMMES, P11; Scott D, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071385; Seth P, 2018, AM J PUBLIC HEALTH, V108, P500, DOI 10.2105/AJPH.2017.304265; Stockwell T, 2016, ADDICTION, V111, P1203, DOI 10.1111/add.13373; Studdert DM, 2016, INJURY PREV, V22, P314, DOI 10.1136/injuryprev-2015-041933; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; White V., 2016, AUSTR SECONDARY SCH; World Health Organization, 2018, MAN SUBST AB FACTS F	38	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2020	15	1							e0228316	10.1371/journal.pone.0228316	http://dx.doi.org/10.1371/journal.pone.0228316			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP9CX	32004349	Green Published, gold, Green Submitted			2023-01-03	WOS:000534614600032
J	O'Connor, AM; Cousins, G; Durand, L; Barry, J; Boland, F				O'Connor, Aisling Maire; Cousins, Grainne; Durand, Louise; Barry, Joe; Boland, Fiona			Retention of patients in opioid substitution treatment: A systematic review	PLOS ONE			English	Review							METHADONE-MAINTENANCE TREATMENT; MEDICATION-ASSISTED TREATMENT; LONG-TERM RETENTION; BUPRENORPHINE TREATMENT; TREATMENT MMT; FOLLOW-UP; BENZODIAZEPINE USE; TREATMENT CLIENTS; 3-YEAR RETENTION; POOR ADHERENCE	Background Retention in opioid substitution (OST) treatment is associated with substantial reductions in all cause and overdose mortality. This systematic review aims to identify both protective factors supporting retention in OST, and risk factors for treatment dropout. Methods A systematic search was performed using MEDLINE, Embase, PsycInfo, CINAHL and Web of Science (January 2001 to October 2019). Randomised controlled trials (RCTs) and observational cohort studies reporting on retention rates and factors associated with retention in OST were included. Factors associated with treatment retention and dropout were explored according to the Maudsley Addiction Profile. A narrative synthesis is provided. Results 67 studies were included in this review (4 RCTs and 63 observational cohort studies; N = 294,592), all assessing factors associated with retention in OST or treatment dropout. The median retention rate across observational studies was approximately 57% at 12 months, which fell to 38.4% at three years. Studies included were heterogeneous in nature with respect to treatment setting, type of OST, risk factor assessment, ascertainment of outcome and duration of follow-up. While the presence of such methodological heterogeneity makes it difficult to synthesise results, there is limited evidence to support the influence of a number of factors on retention, including age, substance use, OST drug dose, legal issues, and attitudes to OST. Conclusions Younger age, substance use particularly cocaine and heroin use, lower doses of methadone, criminal activity/incarceration, and negative attitudes to MMT appear to be associated with reduced retention in OST. A consensus definition of retention is required to allow for comparability across future studies.	[O'Connor, Aisling Maire; Cousins, Grainne; Durand, Louise] Royal Coll Surgeons Ireland, Sch Pharm & Biomol Sci, Dublin, Ireland; [Barry, Joe] Trinity Coll Dublin, Populat Hlth Med Publ Hlth & Primary Care, Dublin, Ireland; [Boland, Fiona] Royal Coll Surgeons Ireland, Data Sci Ctr, Dublin, Ireland	Royal College of Surgeons - Ireland; Trinity College Dublin; Royal College of Surgeons - Ireland	Cousins, G (corresponding author), Royal Coll Surgeons Ireland, Sch Pharm & Biomol Sci, Dublin, Ireland.	gcousins@rcsi.ie		O'Connor, Aisling/0000-0002-1574-6732; Boland, Fiona/0000-0003-3228-0046	Royal College of Surgeons in Ireland (RCSI) through their Strategic Academic Recruitment Programme [2037E]; Health Research Board [HRA-PHR-2015-1088]	Royal College of Surgeons in Ireland (RCSI) through their Strategic Academic Recruitment Programme; Health Research Board	This study was funded as part of author AMO's PhD scholarship awarded by the Royal College of Surgeons in Ireland (RCSI) through their Strategic Academic Recruitment Programme (2037E). Authors LD and GC (PI) are funded by the Health Research Board (HRA-PHR-2015-1088). The funders had no role in the design and conduct of the study.	Abramsohn Y, 2009, J PSYCHOACTIVE DRUGS, V41, P249, DOI 10.1080/02791072.2009.10400535; Adelson M, 2013, J PSYCHOACTIVE DRUGS, V45, P313, DOI 10.1080/02791072.2013.825032; Amato L, 2005, J SUBST ABUSE TREAT, V28, P321, DOI 10.1016/j.jsat.2005.02.007; Amiri S, 2018, DRUG ALCOHOL DEPEN, V193, P63, DOI 10.1016/j.drugalcdep.2018.08.024; Astals M, 2009, INT J ENV RES PUB HE, V6, P2822, DOI 10.3390/ijerph6112822; Banta-Green CJ, 2009, ADDICTION, V104, P775, DOI 10.1111/j.1360-0443.2009.02538.x; Bawor Monica, 2015, CMAJ Open, V3, pE344, DOI 10.9778/cmajo.20140089; Bell J, 2006, DRUG ALCOHOL DEPEN, V81, P55, DOI 10.1016/j.drugalcdep.2005.05.010; Bell J, 2019, BIOL PSYCHIAT; Bhatraju EP, 2017, ADDICT SCI CLIN PRAC, V12, DOI 10.1186/s13722-017-0072-2; Blanken P, 2010, ADDICTION, V105, P300, DOI 10.1111/j.1360-0443.2009.02754.x; BOUNES V, 2013, PAIN PHYSICIAN, V16, pE73; Brands B, 2008, J ADDICT DIS, V27, P37, DOI 10.1080/10550880802122620; Brorson HH, 2013, CLIN PSYCHOL REV, V33, P1010, DOI 10.1016/j.cpr.2013.07.007; Bukten A, 2014, ADDICT BEHAV, V39, P1504, DOI 10.1016/j.addbeh.2014.05.007; Burns L, 2009, ADDICTION, V104, P1363, DOI 10.1111/j.1360-0443.2009.02633.x; Cao XB, 2014, DRUG ALCOHOL DEPEN, V145, P87, DOI 10.1016/j.drugalcdep.2014.09.776; Chawarski MC, 2011, DRUG ALCOHOL DEPEN, V115, P237, DOI 10.1016/j.drugalcdep.2010.09.024; Cornish R, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5475; Cousins G, 2017, DRUG ALCOHOL DEPEN, V173, P126, DOI 10.1016/j.drugalcdep.2016.12.009; Cousins G, 2016, ADDICTION, V111, P73, DOI 10.1111/add.13087; Cousins G, 2011, J SUBST ABUSE TREAT, V41, P252, DOI 10.1016/j.jsat.2011.05.001; Cox J, 2013, J SUBST ABUSE TREAT, V44, P52, DOI 10.1016/j.jsat.2012.03.002; Cunningham CO, 2013, J ADDICT MED, V7, P287, DOI 10.1097/ADM.0b013e31829727b2; Davstad Ingrid, 2007, J Opioid Manag, V3, P27; Dayal P, 2017, J SUBST ABUSE TREAT, V80, P1, DOI 10.1016/j.jsat.2017.06.004; Deck D, 2005, J BEHAV HEALTH SER R, V32, P43, DOI 10.1007/BF02287327; Degenhardt L, 2018, LANCET PSYCHIAT, V5, P987, DOI 10.1016/S2215-0366(18)30337-7; Degenhardt L, 2011, ADDICTION, V106, P32, DOI 10.1111/j.1360-0443.2010.03140.x; Degenhardt L, 2009, DRUG ALCOHOL DEPEN, V105, P9, DOI 10.1016/j.drugalcdep.2009.05.021; Drew L, 2019, NATURE, V573, pS2, DOI 10.1038/d41586-019-02682-6; Dumchev K, 2017, INT J DRUG POLICY, V48, P44, DOI 10.1016/j.drugpo.2017.05.014; Eibl JK, 2015, J ADDICT MED, V9, P440, DOI 10.1097/ADM.0000000000000156; Evans E, 2015, ADDICTION, V110, P996, DOI 10.1111/add.12863; Franklyn AM, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0134-5; Friedmann PD, 2001, J SUBST ABUSE TREAT, V21, P97, DOI 10.1016/S0740-5472(01)00185-4; Gerra G, 2011, PROG NEURO-PSYCHOPH, V35, P483, DOI 10.1016/j.pnpbp.2010.12.002; Gryczynski J, 2014, J SUBST ABUSE TREAT, V46, P356, DOI 10.1016/j.jsat.2013.10.004; Gu J, 2012, ADDICTION, V107, P1641, DOI 10.1111/j.1360-0443.2012.03859.x; Haddad MS, 2013, DRUG ALCOHOL DEPEN, V131, P127, DOI 10.1016/j.drugalcdep.2012.12.008; Hickman M, 2018, ADDICTION, V113, P1461, DOI 10.1111/add.14188; Holton AE, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017453; Huissoud T, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-238; Jaffray Mariesha, 2014, Int J Pharm Pract, V22, P4, DOI 10.1111/ijpp.12049; Johns B, 2018, HEALTH SYST REFORM, V4, P101, DOI 10.1080/23288604.2018.1440347; Jordan CJ, 2019, NEUROPHARMACOLOGY, V158, DOI 10.1016/j.neuropharm.2019.04.015; Kayman DJ, 2006, J PSYCHOACTIVE DRUGS, V38, P93, DOI 10.1080/02791072.2006.10399832; Kelly SM, 2011, DRUG ALCOHOL DEPEN, V117, P170, DOI 10.1016/j.drugalcdep.2011.01.008; Kimber J, 2015, LANCET PSYCHIAT, V2, P901, DOI 10.1016/S2215-0366(15)00366-1; Kimber J, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3172; Kress HG, 2009, EUR J PAIN, V13, P219, DOI 10.1016/j.ejpain.2008.04.011; Lambdin BH, 2014, CLIN INFECT DIS, V59, P735, DOI 10.1093/cid/ciu382; Lawrinson P, 2008, ADDICTION, V103, P1484, DOI 10.1111/j.1360-0443.2008.02249.x; Ledgerwood DM, 2019, ADDICT BEHAV, V90, P191, DOI 10.1016/j.addbeh.2018.10.046; Lin CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117602; Lin HC, 2013, SUBST USE MISUSE, V48, P181, DOI 10.3109/10826084.2012.749411; Liu D, 2017, AIDS CARE, V29, P458, DOI 10.1080/09540121.2016.1259452; MacArthur GJ, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5945; Manhapra A, 2018, PSYCHIAT SERV, V69, P768, DOI 10.1176/appi.ps.201700363; Manhapra A, 2017, AM J ADDICTION, V26, P572, DOI 10.1111/ajad.12553; Marsch LA, 2014, J SUBST ABUSE TREAT, V46, P43, DOI 10.1016/j.jsat.2013.08.012; Mathers BM, 2010, LANCET, V375, P1014, DOI 10.1016/S0140-6736(10)60232-2; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; Meshberg-Cohen S, 2019, ADDICT BEHAV, V89, P29, DOI 10.1016/j.addbeh.2018.09.010; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Monico LB, 2015, J SUBST ABUSE TREAT, V57, P57, DOI 10.1016/j.jsat.2015.04.010; Montalvo C, 2019, AM J ADDICTION, V28, P339, DOI 10.1111/ajad.12896; Mullen L, 2012, AM J DRUG ALCOHOL AB, V38, P551, DOI 10.3109/00952990.2012.694516; Nielsen S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011117.pub2; Nosyk B, 2015, CLIN INFECT DIS, V61, P1157, DOI 10.1093/cid/civ476; Nosyk B, 2009, AM J EPIDEMIOL, V170, P783, DOI 10.1093/aje/kwp186; Panlilio LV, 2019, DRUG ALCOHOL DEPEN, V202, P200, DOI 10.1016/j.drugalcdep.2019.05.026; Peles E, 2008, J ADDICT DIS, V27, P11, DOI 10.1080/10550880802324382; Peles E, 2018, DRUG ALCOHOL DEPEN, V185, P112, DOI 10.1016/j.drugalcdep.2017.11.034; Perreault M R M., 2005, J MAINTENANCE ADDICT, V3, P37; Perreault M, 2015, SUBST USE MISUSE, V50, P24, DOI 10.3109/10826084.2014.957769; Platt L, 2018, ADDICTION, V113, P545, DOI 10.1111/add.14012; Popay J, 2006, GUIDANCE CONDUCT NAR, DOI DOI 10.13140/2.1.1018.4643; Proctor SL, 2015, PSYCHOL ADDICT BEHAV, V29, P906, DOI 10.1037/adb0000090; Rahimi-Movaghar A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007775.pub2; Ren JM, 2013, CURR MED RES OPIN, V29, P731, DOI 10.1185/03007995.2013.796284; Ruadze E, 2016, HARM REDUCT J, V13, DOI 10.1186/s12954-016-0124-z; Saloner B, 2017, MED CARE, V55, P669, DOI 10.1097/MLR.0000000000000727; Sarasvita R, 2012, J SUBST ABUSE TREAT, V42, P239, DOI 10.1016/j.jsat.2011.07.009; Schuman-Olivier Z, 2013, DRUG ALCOHOL DEPEN, V132, P580, DOI 10.1016/j.drugalcdep.2013.04.006; Schwartz RP, 2012, ADDICTION, V107, P943, DOI 10.1111/j.1360-0443.2011.03700.x; Shakira RHW, 2017, ADDICT DISORD TREAT, V16, P64, DOI 10.1097/ADT.0000000000000099; Shcherbakova N, 2018, ANN PHARMACOTHER, V52, P405, DOI 10.1177/1060028017751913; Socias ME, 2018, ADDICTION, V113, P2250, DOI 10.1111/add.14398; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Stein MD, 2005, J GEN INTERN MED, V20, P1038, DOI 10.1111/j.1525-1497.2005.0228.x; Stotts AL, 2009, EXPERT OPIN PHARMACO, V10, P1727, DOI 10.1517/14656560903037168; Strike CJ, 2005, ADDICT BEHAV, V30, P1025, DOI 10.1016/j.addbeh.2004.09.004; Sullivan SG, 2013, DRUG ALCOHOL DEPEN, V133, P427, DOI 10.1016/j.drugalcdep.2013.06.021; Sung SJ, 2006, ANN PHARMACOTHER, V40, P501, DOI 10.1345/aph.1G276; Teoh J Y A., 2017, HEROIN ADDICT REL CL, V20, P19; Timko C, 2016, J ADDICT DIS, V35, P22, DOI 10.1080/10550887.2016.1100960; Ward J, 1999, LANCET, V353, P221, DOI 10.1016/S0140-6736(98)05356-2; Wei XL, 2013, J ADDICT MED, V7, P342, DOI 10.1097/ADM.0b013e31829da05b; Weinstein ZM, 2017, J SUBST ABUSE TREAT, V74, P65, DOI 10.1016/j.jsat.2016.12.010; Wiessing L, 2018, DRUG ALCOHOL REV, V37, pS323, DOI 10.1111/dar.12608; Yang F, 2013, HARM REDUCT J, V10, DOI 10.1186/1477-7517-10-3; Zhang L, 2013, PLOS ONE, V8, P68906, DOI DOI 10.1371/J0URNAL.P0NE.0068906; Zhang L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139942; Zhou KN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179009; Zhou KN, 2017, J ADDICT MED, V11, P28, DOI 10.1097/ADM.0000000000000263; Zhou KN, 2014, ADDICT BEHAV, V39, P22, DOI 10.1016/j.addbeh.2013.09.001	108	84	85	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2020	15	5							e0232086	10.1371/journal.pone.0232086	http://dx.doi.org/10.1371/journal.pone.0232086			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU0YZ	32407321	Green Published, gold			2023-01-03	WOS:000537490700012
J	Luo, SQ; Lenon, GB; Gill, H; Hung, A; Dias, DA; Li, MD; Nguyen, LT				Luo, Shiqi; Lenon, George Binh; Gill, Harsharn; Hung, Andrew; Dias, Daniel A.; Li, Mingdi; Linh Toan Nguyen			Inhibitory effect of a weight-loss Chinese herbal formula RCM-107 on pancreatic alpha-amylase activity: Enzymatic and in silico approaches	PLOS ONE			English	Article							GREEN TEA; OBESITY; PHARMACOLOGY; INGREDIENTS	Reducing carbohydrates digestion by having a low glycaemic index (GI) foods has been linked to weight loss. Inhibiting related enzymes is an alternative way to decrease carbohydrate digestion. RCM-107 (Slimming Plus), an eight-herb formula that is modified from RCM-104, indicated significant weight-loss action in clinical trials. However, no published research has studied its mechanism of action on reducing carbohydrate absorption via suppressing the activities of porcine pancreatic alpha-amylase (PPA). In this paper, we used fluorescence PPA inhibition assay to investigate the inhibitory effects of RCM-107 and the individual herbs present in this herbal mixture on amylase activity. Subsequently, molecular docking predicted the key active compounds that may be responsible for the enzyme inhibition. According to our results, both the RCM-107 formula and several individual herbs displayed alpha-amylase inhibitory effects. Also, marginal synergistic effects of RCM-107 were detected. In addition, alisol B, (-)-epigallocatechin-3-gallate (EGCG) and plantagoside have been predicted as the key active compounds that may be responsible for the alpha-amylase inhibition effect of RCM-107 according to inter-residue contact analysis. Finally, Glu233, Gln63, His305, Asp300 and Tyr151 are predicted to be markers of important areas with which potential amylase inhibitors would interact. Therefore, our data has provided new knowledge on the mechanisms of action of the RCM-107 formula and its individual herbal ingredients for weight loss, in terms of decreasing carbohydrate digestion via the inhibition of pancreatic alpha-amylase.	[Luo, Shiqi; Lenon, George Binh; Dias, Daniel A.; Li, Mingdi] RMIT Univ, Sch Hlth & Biomed Sci, Melbourne, Vic, Australia; [Gill, Harsharn; Hung, Andrew] RMIT Univ, Sch Sci, Melbourne, Vic, Australia; [Linh Toan Nguyen] Vietnam Mil Med Univ, Dept Endocrine, Hanoi, Vietnam	Royal Melbourne Institute of Technology (RMIT); Royal Melbourne Institute of Technology (RMIT)	Lenon, GB (corresponding author), RMIT Univ, Sch Hlth & Biomed Sci, Melbourne, Vic, Australia.	george.lenon@rmit.edu.au		Hung, Andrew/0000-0003-3569-2951; Li, Mingdi/0000-0002-5329-4562	RMIT University, School of Health and Biomedical Sciences Seeding grant [341333]; Tong Lee Pty Ltd [RE-0256]	RMIT University, School of Health and Biomedical Sciences Seeding grant; Tong Lee Pty Ltd	This research project is supported by RMIT University, School of Health and Biomedical Sciences Seeding grant (341333) & Tong Lee Pty Ltd (RE-0256). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barrett ML, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-24; Bensky D, 2004, CHINESE HERBAL MED M, V3rd; Dong X, 2017, MOL MED REP, V16, P2331, DOI 10.3892/mmr.2017.6880; Geng F, 2009, PHYTOTHER RES, P1088; Gilles C, 1996, EUR J BIOCHEM, V238, P561, DOI 10.1111/j.1432-1033.1996.0561z.x; Han Y, 2015, FOOD CHEM, V188, P648, DOI 10.1016/j.foodchem.2015.05.039; Huang C, 2014, BRIEF BIOINFORM, V15, P710, DOI 10.1093/bib/bbt035; Jastreboff AM, 2019, OBESITY, V27, P7, DOI 10.1002/oby.22378; Lenon GB, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/435702; Li XX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043918; Luo SQ, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02453; Luo SQ, 2019, CURR DRUG TARGETS, V20, P399, DOI 10.2174/1389450119666180830125958; Manoj K, 2014, MED CHEM RES, V23, P810, DOI [10.1007/s00044-013-0654-9, DOI 10.1007/S00044-013-0654-9]; Marrelli M, 2013, PLANT FOOD HUM NUTR, V68, P340, DOI 10.1007/s11130-013-0390-9; Moyers SB, 2005, J AM DIET ASSOC, V105, P948, DOI 10.1016/j.jada.2005.03.010; Park J, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/732126; Paudel KR, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/789124; Perva-Uzunalic A, 2006, FOOD CHEM, V96, P597, DOI 10.1016/j.foodchem.2005.03.015; Piche ME, 2018, PROG CARDIOVASC DIS, V61, P103, DOI 10.1016/j.pcad.2018.06.004; Qian MX, 2002, BIOCHEMISTRY-US, V33, P6284, DOI [10.1021/bi00186a031, DOI 10.1021/BI00186A031]; Rios JL, 2011, PLANTA MED, V77, P681, DOI 10.1055/s-0030-1270823; Sharma BR, 2017, PHYTOTHER RES, V31, P3, DOI 10.1002/ptr.5732; Sun GL, 2009, J TRADIT CHIN VET ME, V28, P24; Tao WY, 2013, J ETHNOPHARMACOL, V145, P1, DOI 10.1016/j.jep.2012.09.051; Tucci SA, 2010, DIABET METAB SYND OB, V3, P125, DOI 10.2147/DMSO.S7005; Turkozu D, 2017, CRIT REV FOOD SCI, V57, P254, DOI 10.1080/10408398.2014.986672; Udani J, 2007, ALTERN THER HEALTH M, V13, P32; Wagner H, 2011, CHROMATOGRAPHIC FINGERPRINT ANALYSIS OF HERBAL MEDICINES: THIN-LAYER AND HIGH PERFORMANCE LIQUID CHROMATOGRAPHY OF CHINESE DRUGS, VOLS 1 AND 2, 2ND EDITION, pXXI; Wang F, 2017, J PHARMACEUT BIOMED, V132, P7, DOI 10.1016/j.jpba.2016.09.042; Wang X, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/519031; World Health Organization (WHO), 2016, 10 FACTS OB; Wu LF, 2016, MOLECULES, V21, DOI 10.3390/molecules21020227; Xiao WP, 2017, J FOOD DRUG ANAL, V25, P43, DOI 10.1016/j.jfda.2016.11.005; Xu XY, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0096780, 10.1371/journal.pone.0109950]; Xu Y, 2015, FOOD FUNCT, V6, P297, DOI 10.1039/c4fo00970c; Yang WJ, 2009, BIOL PHARM BULL, V32, P1021, DOI 10.1248/bpb.32.1021; Yilmazer-Musa M, 2012, J AGR FOOD CHEM, V60, P8924, DOI 10.1021/jf301147n; Yue GF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065164; Zhou X, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00201	39	4	4	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2020	15	4							e0231815	10.1371/journal.pone.0231815	http://dx.doi.org/10.1371/journal.pone.0231815			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LS8ZG	32348327	Green Published, gold			2023-01-03	WOS:000536668200027
J	Brannstrom, L; Forsman, H; Vinnerljung, B; Almquist, YB				Brannstrom, Lars; Forsman, Hilma; Vinnerljung, Bo; Almquist, Ylva B.			Inequalities in educational outcomes in individuals with childhood experience of out-of-home care: What are driving the differences?	PLOS ONE			English	Article							STOCKHOLM BIRTH COHORT; FOSTER-CARE; PSYCHOSOCIAL PROBLEMS; SCHOOL ACHIEVEMENTS; YOUNG-PEOPLE; CHILDREN; YOUTH; INTERVENTIONS; MALTREATMENT; PERFORMANCE	Background Prior research has shown that individuals with experience of out-of-home care (foster family care or residential care) in childhood are educationally disadvantaged compared to their peers. In order to be better equipped to design interventions aimed at improving the educational outcomes of children for whom society has assumed responsibility, this study seeks to further our understanding about which factors that contribute to the educational disparities throughout the life course. Methods Using longitudinal data from a cohort of more than 13,000 Swedes, of which around 7% have childhood experience of out-of-home care, Peters-Belson decomposition is utilized to quantify the extent to which the gap in educational achievement in school (age 16) and midlife educational attainment (age 50) captures differences in the prevalence of factors influencing educational outcomes, and differences in the impacts between these factors. Results We find that the achievement and the attainment gap was around 13% and 9% respectively. These gaps were to a large extent explained by differences in the distribution of predictors. The major explanatory factor for placed children's lower achievement was a lower average cognitive ability. Yet there were some evidence that the rewards of cognitive ability in these children differed across the life course. While the lower returns of cognitive ability suggest that they were underperforming in compulsory school, the higher returns of cognitive ability on midlife attainment indicate that-given previous underperformance-their attainment at age 50 reflects their cognitive capacity more accurately than their achievement at age 16 do. Conclusion The large influence of the unequal distribution of predictors suggests that policy efforts are needed to promote equity in the distribution of factors contributing to educational achievement and attainment. Since cognitive ability was found to be an important contributory factor, such efforts may include promoting cognitive and intellectual development among children in out-of-home care, preferably starting at a young age.	[Brannstrom, Lars; Forsman, Hilma; Vinnerljung, Bo] Stockholm Univ, Dept Social Work, Stockholm, Sweden; [Almquist, Ylva B.] Stockholm Univ, Dept Publ Hlth Sci, Stockholm, Sweden	Stockholm University; Stockholm University	Brannstrom, L (corresponding author), Stockholm Univ, Dept Social Work, Stockholm, Sweden.	lars.brannstrom@socarb.su.se		Brannstrom, Lars/0000-0002-8526-9396	Swedish Research Council [2017-01746]	Swedish Research Council(Swedish Research CouncilEuropean Commission)	This study was financially supported by the Swedish Research Council (grant no 2017-01746). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almquist YB, 2018, J EPIDEMIOL COMMUN H, V72, P997, DOI 10.1136/jech-2018-210487; BELSON WA, 1956, ROY STAT SOC C-APP, V5, P195; Berlin M, 2011, CHILD YOUTH SERV REV, V33, P2489, DOI 10.1016/j.childyouth.2011.08.024; BLINDER AS, 1973, J HUM RESOUR, V8, P436, DOI 10.2307/144855; Daehlen M., 2014, NORDIC SOCIAL WORK R, V4, P22, DOI [10.1080/2156857X.2013.779933, DOI 10.1080/2156857X.2013.779933]; Dill K, 2012, CHILD YOUTH SERV REV, V34, P1081, DOI 10.1016/j.childyouth.2012.01.031; Duyme M, 1999, P NATL ACAD SCI USA, V96, P8790, DOI 10.1073/pnas.96.15.8790; Evans R, 2017, BRIT EDUC RES J, V43, P68, DOI 10.1002/berj.3252; Forsman H, 2016, CHILD ABUSE NEGLECT, V57, P61, DOI 10.1016/j.chiabu.2016.06.006; Forsman H, 2012, CHILD YOUTH SERV REV, V34, P1084, DOI 10.1016/j.childyouth.2012.01.037; Foster EM, 2011, CHILD YOUTH SERV REV, V33, P118, DOI 10.1016/j.childyouth.2010.08.021; Frones I, 2016, CHILD INDIC RES, V9, P247, DOI 10.1007/s12187-015-9309-3; Jann B, 2008, STATA J, V8, P453, DOI 10.1177/1536867X0800800401; Janson C.-G., 1980, REGISTER DATA 2 CODE; Kaariala A, 2017, CHILD YOUTH SERV REV, V79, P107, DOI 10.1016/j.childyouth.2017.05.030; Liu Yang, 2015, Int J Stat Med Res, V4, P287; Naccarato T, 2010, CHILD YOUTH SERV REV, V32, P551, DOI 10.1016/j.childyouth.2009.11.009; O'Higgins A, 2017, CHILD YOUTH SERV REV, V79, P198, DOI 10.1016/j.childyouth.2017.06.004; Oaxaca R., 1973, INT ECON REV, V14, P693, DOI 10.2307/2525981; Pears KC, 2013, EARLY EDUC DEV, V24, P771, DOI 10.1080/10409289.2013.736037; Pecora PJ, 2012, CHILD YOUTH SERV REV, V34, P1121, DOI 10.1016/j.childyouth.2012.01.044; Peters CC, 1941, J EDUC RES, V34, P606, DOI 10.1080/00220671.1941.10881036; Romano E, 2015, TRAUMA VIOLENCE ABUS, V16, P418, DOI 10.1177/1524838014537908; Scherr TG, 2007, SCHOOL PSYCHOL INT, V28, P419, DOI 10.1177/0143034307084133; SCHIFF M, 1982, COGNITION, V12, P165, DOI 10.1016/0010-0277(82)90011-7; Sebba J., 2015, ED PROGR LOOKED CHIL; StataCorp, 2017, STATA 15 BAS REF MAN; Stenberg S.-A., 2018, BORN 1953; Stenberg SA, 2006, INT J EPIDEMIOL, V35, P546, DOI 10.1093/ije/dyi310; Stenberg SA, 2007, SCAND J PUBLIC HEALT, V35, P104, DOI 10.1080/14034940600777385; Stone S, 2007, CHILD YOUTH SERV REV, V29, P139, DOI 10.1016/j.childyouth.2006.05.001; Tideman E, 2011, ADOPT FOSTER, V35, P44, DOI 10.1177/030857591103500106; Trout AL, 2008, CHILD YOUTH SERV REV, V30, P979, DOI 10.1016/j.childyouth.2007.11.019; Vinnerljung B, 2014, ADOPT FOSTER, V38, P361, DOI 10.1177/0308575914553543	34	1	1	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2020	15	4							e0232061	10.1371/journal.pone.0232061	http://dx.doi.org/10.1371/journal.pone.0232061			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR9MR	32311003	gold, Green Published			2023-01-03	WOS:000536019800046
J	Rimoldi, S; Torrecillas, S; Montero, D; Gini, E; Makol, A; Valdenegro, VV; Izquierdo, M; Terova, G				Rimoldi, Simona; Torrecillas, Silvia; Montero, Daniel; Gini, Elisabetta; Makol, Alex; Valdenegro, Victoria V.; Izquierdo, Marisol; Terova, Genciana			Assessment of dietary supplementation with galactomannan oligosaccharides and phytogenics on gut microbiota of European sea bass (Dicentrarchus Labrax) fed low fishmeal and fish oil based diet	PLOS ONE			English	Article							PLANT ESSENTIAL OILS; GROWTH-PERFORMANCE; MANNAN-OLIGOSACCHARIDES; FEED-UTILIZATION; INTESTINAL MICROBIOTA; IMMUNE-SYSTEM; HEALTH; PREBIOTICS; L.; AQUACULTURE	There is an increasing interest from the aquafeed industry in functional feeds containing selected additives that improve fish growth performance and health status. Functional feed additives include probiotics, prebiotics, organic acids, and phytogenics (substances derived from plants and their extracts). This study evaluated the effects of dietary inclusion of a mucilage extract rich in galactomannan oligosaccharides (GMOS), a mixture of garlic and labiatae-plants oils (PHYTO), and a combination of them (GMOSPHYTO), on gut microbiota composition of European sea bass (Dicentrarchus labrax) fed with a low fishmeal (FM) and fish oil (FO) diet. Three experimental diets and a control diet (plant-based formulation with 10% FM and 6% FO) were tested in a 63-days feeding trial. To analyze the microbiota associated to feeds and the intestinal autochthonous (mucosa-adhered) and allochthonous (transient) microbial communities, the Illumina MiSeq platform for sequencing of 16S rRNA gene and QIIME2 pipeline were used. Metabarcoding analysis of feed-associated bacteria showed that the microbial communities of control (CTRL) feed deeply differed from those of experimental diets. The number of reads was significantly lower in CTRL feed than in other feeds. The OTU (operational taxonomic unit) number was instead similar between the feeds, ranging from 42 to 50 OTUs. The variation of resident gut microbiota induced by diet was lower than the variation of transient intestinal microbiota, because feedstuffs are a major source of allochthonous bacteria, which can temporarily integrate into the gut transient microbiome. However, the composition of transient bacterial communities was not simply a mirror of feed-borne bacteria. Indeed, the microbial profile of feeds was different from both faecal and mucosa profiles. Our findings suggest that the dietary inclusion of GMOS (0.5%) and PHYTO (0.02%) in a low FM and FO diet induces changes in gut microbiota composition of European sea bass. However, if on allochthonous microbiota the combined inclusion of GMOS and PHYTO showed an antagonistic effect on bactericidal activity against Vibrionales, at mucosa level, only GMOSPHYTO diet increased the relative abundance of Bacteroidales, Lactobacillales, and Clostridiales resident bacterial orders. The main beneficial effects of GMOS and PHYTO on gut microbiota are the reduction of coliforms and Vibrionales bacteria, which include several potentially pathogenic species for fish, and the enrichment of gut microbiota composition with butyrate producer taxa. Therefore, these functional ingredients have a great potential to be used as health-promoting agents in the farming of European sea bass and other marine fish.	[Rimoldi, Simona; Gini, Elisabetta; Terova, Genciana] Univ Insubria, Dept Biotechnol & Life Sci, Varese, Italy; [Torrecillas, Silvia; Montero, Daniel; Izquierdo, Marisol] Univ Las Palmas Gran Canaria, IU ECOAQUA, GIA, Las Palmas Gran Canaria, Canary Islands, Spain; [Makol, Alex] Delacon Biotech GmbH, Steyregg, Austria; [Valdenegro, Victoria V.] BioMar AS, Trondheim, Norway	University of Insubria; Universidad de Las Palmas de Gran Canaria	Terova, G (corresponding author), Univ Insubria, Dept Biotechnol & Life Sci, Varese, Italy.	genciana.terova@uninsubria.it	montero, daniel/ABE-3894-2020; Terova, Genciana/AAL-6412-2021; montero, daniel/O-7108-2015; Torrecillas, Silvia/F-5378-2016	Terova, Genciana/0000-0002-7532-7951; montero, daniel/0000-0002-4358-2157; Marisol, Izquierdo/0000-0003-4297-210X; Rimoldi, Simona/0000-0002-1995-263X; Izquierdo, Marisol/0000-0003-3583-6660; Torrecillas, Silvia/0000-0003-2823-9999	Italian AGER project Fine Feed for Fish (4F) [2016-01-01]; Spanish Government [AGL2016-79725-P]; Spanish Ministry of Economy, Industry and Competitiveness [IJCI-2015-25748]	Italian AGER project Fine Feed for Fish (4F); Spanish Government(Spanish GovernmentEuropean Commission); Spanish Ministry of Economy, Industry and Competitiveness	GT received an award from the Italian AGER project Fine Feed for Fish (4F), Rif. No. 2016-01-01 (https://acquacoltura.progettoager.it) DM, and ST received an award by Spanish Government through the specific program "Subprograma Estatal de Generacion de Conocimiento, en el marco del Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion 2013-2016" by the PROINMUNOIL PLUS (AGL2016-79725-P) project: "Functional diets for marine raw materials replacement: boosting the fish disease resistance through epithelial barriers reinforcement and immunization tools". ST received complementary funding from the Spanish Ministry of Economy, Industry and Competitiveness, though the "Subprogama Juan de la Cierva-Incoproracion. Convocatoria 2015. IJCI-2015-25748. The funders had no role in study design, data collection and analysis, decision to publish, and preparation of the the manuscript. Special thanks to Delacon Biotechnik GmbH and to BioMar A/S, which provided the functional products and diets, and support in the form of salaries for authors Alex Makol and Victoria Valdenegro, respectively, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Al-Sagheer AA, 2018, AQUACULT NUTR, V24, P1006, DOI 10.1111/anu.12637; Ankri S, 1999, MICROBES INFECT, V1, P125, DOI 10.1016/S1286-4579(99)80003-3; Apper E, 2016, AQUACULTURE, V453, P40, DOI 10.1016/j.aquaculture.2015.11.018; Awad E, 2015, FISH SHELLFISH IMMUN, V45, P454, DOI 10.1016/j.fsi.2015.04.035; Benedito-Palos L, 2008, BRIT J NUTR, V100, P992, DOI 10.1017/S0007114508966071; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Bonder MJ, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0295-y; Burt S, 2004, INT J FOOD MICROBIOL, V94, P223, DOI 10.1016/j.ijfoodmicro.2004.03.022; Butt RL, 2019, FRONT ENDOCRINOL, P10, DOI [10.3389/fendo.2019.0000930733706, DOI 10.3389/FEND0.2019.00009]; Buyukdeveci ME, 2018, AQUACULTURE, V486, P170, DOI 10.1016/j.aquaculture.2017.12.022; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Carda-Dieguez M, 2014, FEMS MICROBIOL ECOL, V87, P451, DOI 10.1111/1574-6941.12236; Chakraborty SB, 2014, REV AQUACULT, V6, P1, DOI 10.1111/raq.12021; Cho JH, 2014, LIVEST SCI, V160, P82, DOI 10.1016/j.livsci.2013.11.006; da Cunha JA, 2018, J APPL MICROBIOL, V125, P328, DOI 10.1111/jam.13911; Dawood MAO, 2018, REV AQUACULT, V10, P950, DOI 10.1111/raq.12209; Dimitroglou A, 2009, J ANIM SCI, V87, P3226, DOI 10.2527/jas.2008-1428; Dimitroglou A, 2011, FISH SHELLFISH IMMUN, V30, P1, DOI 10.1016/j.fsi.2010.08.009; Dimitroglou A, 2010, AQUACULTURE, V300, P182, DOI 10.1016/j.aquaculture.2010.01.015; Encarnacao P, 2016, AQUAFEED FORMULATION, P217, DOI 10.1016/B978-0-12-800873-7.00005-1; Esquivel-Elizondo S, 2017, MSYSTEMS, V2, DOI 10.1128/mSystems.00051-17; FAO, 2018, WORLD FISH AQ; Ferreira-Halder CV, 2017, BEST PRACT RES CL GA, V31, P643, DOI 10.1016/j.bpg.2017.09.011; Franciosini MP, 2016, J APPL ANIM RES, V44, P474, DOI 10.1080/09712119.2015.1091322; Francis G, 2001, AQUACULTURE, V199, P197, DOI 10.1016/S0044-8486(01)00526-9; Gatesoupe FJ, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0885-2; Giannenas I, 2012, AQUACULTURE, V350, P26, DOI 10.1016/j.aquaculture.2012.04.027; Giannenas I., 2013, MED AROMAT PLANTS, V2, P2167, DOI DOI 10.4172/2167-0412.1000140; GIBSON GR, 1995, J NUTR, V125, P1401, DOI 10.1093/jn/125.6.1401; Goncalves AT, 2017, J APPL MICROBIOL, V122, P1333, DOI 10.1111/jam.13437; Grisdale-Helland B, 2008, AQUACULTURE, V283, P163, DOI 10.1016/j.aquaculture.2008.07.012; Guardiola FA, 2017, FISH SHELLFISH IMMUN, V65, P169, DOI 10.1016/j.fsi.2017.04.014; Guerreiro I, 2018, AQUACULT NUTR, V24, P153, DOI 10.1111/anu.12543; Guerreiro I, 2018, REV AQUACULT, V10, P800, DOI 10.1111/raq.12201; Hammer Oyvind, 2001, Palaeontologia Electronica, V4, pUnpaginated; Harikrishnan R, 2011, AQUACULTURE, V317, P1, DOI 10.1016/j.aquaculture.2011.03.039; Helander IM, 1998, J AGR FOOD CHEM, V46, P3590, DOI 10.1021/jf980154m; Husnu K., 2007, FLAVOURS FRAGRANCES, P43, DOI [10.1007/978-3-540-49339-6_4, DOI 10.1007/9783-54049339-6_, 10.1007/978-3-540-49339-6_4/COVER, DOI 10.1007/978-3-540-49339-6_4/COVER]; Kim DH, 2007, J APPL MICROBIOL, V102, P1654, DOI 10.1111/j.1365-2672.2006.03185.x; Kim SK, 2012, ADV FOOD NUTR RES, V65, P353, DOI 10.1016/B978-0-12-416003-3.00023-8; Krogdahl A, 2010, AQUAC RES, V41, P333, DOI 10.1111/j.1365-2109.2009.02426.x; Kyu-Song S, 2014, FISH SHELLFISH IMMUN, V40, P40, DOI 10.1016/j.fsi.2014.06.016; Larsen JM, 2017, IMMUNOLOGY, V151, P363, DOI 10.1111/imm.12760; Levy-Pereira N, 2018, REV BRAS ZOOTECN, V47, DOI [10.1590/rbz4720170006, 10.1590/rbz472010006]; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Lozupone CA, 2007, APPL ENVIRON MICROB, V73, P1576, DOI 10.1128/AEM.01996-06; Mountzouris KC, 2011, ANIM FEED SCI TECH, V168, P223, DOI 10.1016/j.anifeedsci.2011.03.020; Nazzaro F, 2013, PHARMACEUTICALS, V6, P1451, DOI 10.3390/ph6121451; Overland M, 2009, AQUACULTURE, V288, P305, DOI 10.1016/j.aquaculture.2008.12.012; Pryde SE, 2002, FEMS MICROBIOL LETT, V217, P133, DOI 10.1111/j.1574-6968.2002.tb11467.x; Ran C, 2016, J NUTR, V146, P1132, DOI 10.3945/jn.115.229377; Reverter M, 2014, AQUACULTURE, V433, P50, DOI 10.1016/j.aquaculture.2014.05.048; Rimoldi S, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9040143; Rimoldi S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193652; Rimoldi Simona, 2016, Fisheries and Aquatic Sciences, V19, P40, DOI 10.1186/s41240-016-0041-9; Ringo E, 1998, AQUACULTURE, V160, P177, DOI 10.1016/S0044-8486(97)00299-8; Ringo E., 1995, Aquaculture Research, V26, P773, DOI 10.1111/j.1365-2109.1995.tb00870.x; Ringo E, 2010, AQUACULT NUTR, V16, P117, DOI 10.1111/j.1365-2095.2009.00731.x; Ringo E, 2007, AQUACULTURE, V268, P251, DOI 10.1016/j.aquaculture.2007.04.047; Roberfroid M, 2010, BRIT J NUTR, V104, pS1, DOI 10.1017/S0007114510003363; Sekirov I, 2010, PHYSIOL REV, V90, P859, DOI 10.1152/physrev.00045.2009; Shepherd CJ, 2013, J FISH BIOL, V83, P1046, DOI 10.1111/jfb.12224; Shtriker MG, 2018, NUTRITION, V46, P134, DOI 10.1016/j.nut.2017.07.012; Spring P, 2000, POULTRY SCI, V79, P205, DOI 10.1093/ps/79.2.205; Stevanovic ZD, 2018, MOLECULES, V23, DOI 10.3390/molecules23071717; Sutili FJ, 2015, J APPL MICROBIOL, V119, P47, DOI 10.1111/jam.12812; Sutili FJ, 2018, REV AQUACULT, V10, P716, DOI 10.1111/raq.12197; Takahashi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105592; Terova G, 2019, REV FISH BIOL FISHER, V29, P465, DOI 10.1007/s11160-019-09558-y; Terova G, 2009, COMP BIOCHEM PHYS B, V153, P372, DOI 10.1016/j.cbpb.2009.04.008; Torrecillas S, 2007, FISH SHELLFISH IMMUN, V23, P969, DOI 10.1016/j.fsi.2007.03.007; Torrecillas S, 2018, FISH SHELLFISH IMMUN, V81, P10, DOI 10.1016/j.fsi.2018.07.007; Torrecillas S, 2017, AQUACULTURE, V468, P386, DOI 10.1016/j.aquaculture.2016.11.005; Torrecillas S, 2016, AQUACULT NUTR, V22, P1079, DOI 10.1111/anu.12322; Torrecillas S, 2012, J FISH DIS, V35, P591, DOI 10.1111/j.1365-2761.2012.01384.x; Torrecillas S, 2011, AQUACULT NUTR, V17, P223, DOI 10.1111/j.1365-2095.2009.00730.x; Torrecillas S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222063; Torrecillas S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00397; Torrecillas S, 2015, FISH SHELLFISH IMMUN, V42, P508, DOI 10.1016/j.fsi.2014.11.033; Torrecillas S, 2014, FISH SHELLFISH IMMUN, V36, P525, DOI 10.1016/j.fsi.2013.12.029; Torrecillas S, 2013, FISH SHELLFISH IMMUN, V34, P1485, DOI 10.1016/j.fsi.2013.03.351; Walker AW, 2011, ISME J, V5, P220, DOI 10.1038/ISMEJ.2010.118; Wong JMW, 2006, J CLIN GASTROENTEROL, V40, P235, DOI 10.1097/00004836-200603000-00015; Wu SG, 2010, AQUACULTURE, V303, P1, DOI 10.1016/j.aquaculture.2009.12.025; Zaki MA, 2012, APCBEE PROC, V4, P220, DOI 10.1016/j.apcbee.2012.11.037; Ze XL, 2012, ISME J, V6, P1535, DOI 10.1038/ismej.2012.4; Zeng ZK, 2015, J ANIM SCI BIOTECHNO, V6, DOI 10.1186/s40104-015-0004-5; Zhou QC, 2010, AQUACULTURE, V309, P253, DOI 10.1016/j.aquaculture.2010.09.003	88	36	37	2	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2020	15	4							e0231494	10.1371/journal.pone.0231494	http://dx.doi.org/10.1371/journal.pone.0231494			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9JM	32298317	Green Published, gold			2023-01-03	WOS:000536011400053
J	Ahn, J; Ha, TY; Ahn, J; Jung, CH; Seo, HD; Kim, MJ; Kim, YS; Jang, YJ				Ahn, Jisong; Ha, Tae Youl; Ahn, Jiyun; Jung, Chang Hwa; Seo, Hyo Deok; Kim, Min Jung; Kim, Young-Soo; Jang, Young Jin			Undaria pinnatifida extract feeding increases exercise endurance and skeletal muscle mass by promoting oxidative muscle remodeling in mice	FASEB JOURNAL			English	Article						fucoxanthin; mitochondria biogenesis; oxidative muscle remodeling; running endurance; Undaria pinnatifida	FIBER-TYPE; TRANSCRIPTIONAL COACTIVATOR; MITOCHONDRIAL BIOGENESIS; RECEPTOR-GAMMA; NUTRITIONAL-VALUE; MESSENGER-RNA; ERR-ALPHA; PGC-1-ALPHA; ANGIOGENESIS; FUCOXANTHIN	Dietary habits can alter the skeletal muscle performance and mass, and Undaria pinnatifida extracts are considered a potent candidate for improving the muscle mass and function. Therefore, in this study, we aimed to assess the effect of U pinnatifida extracts on exercise endurance and skeletal muscle mass. C57BL/6 mice were fed a 0.25% U pinnatifida extract-containing diet for 8 weeks. U pinnatifida extract-fed mice showed increased running distance, total running time, and extensor digitorum longus and gastrocnemius muscle weights. U pinnatifida extract supplementation upregulated the expression of myocyte enhancer factor 2C, oxidative muscle fiber markers such as myosin heavy chain 1 (MHC1), and oxidative biomarkers in the gastrocnemius muscles. Compared to the controls, U pinnatifida extract-fed mice showed larger mitochondria and increased gene and protein expression of molecules involved in mitochondrial biogenesis and oxidative phosphorylation, including nuclear respiratory factor 2 and mitochondrial transcription factor A. U pinnatifida extract supplementation also increased the mRNA expression of angiogenesis markers, including VEGFa, VEGFb, FGF1, angiopoietin 1, and angiopoietin 2, in the gastrocnemius muscles. Importantly, U pinnatifida extracts upregulated the estrogen-related receptor gamma and peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC-1 alpha)/AMP-activated protein kinase (AMPK)/sirtuin 1 (SIRT1) networks, which are partially increased by fucoxanthin, hesperetin, and caffeic acid treatments. Collectively, U pinnatifida extracts enhance mitochondrial biogenesis, increase oxidative muscle fiber, and promote angiogenesis in skeletal muscles, resulting in improved exercise capacity and skeletal muscle mass. These effects are attributable to fucoxanthin, hesperetin, and caffeic acid, bioactive components of U pinnatifida extracts.	[Ahn, Jisong; Ha, Tae Youl; Ahn, Jiyun; Jung, Chang Hwa; Seo, Hyo Deok; Jang, Young Jin] Korea Food Res Inst, Nat Mat & Metab Res Grp, Wanju Gun 55365, South Korea; [Ahn, Jisong; Kim, Young-Soo] Chonbuk Natl Univ, Dept Food Sci & Technol, Jeonju Si, South Korea; [Ha, Tae Youl; Ahn, Jiyun; Jung, Chang Hwa] Univ Sci & Technol, Div Food Biotechnol, Daejeon, South Korea; [Kim, Min Jung] Korea Food Res Inst, Healthcare Res Grp, Wanju Gun, South Korea	Korea Food Research Institute (KFRI); Jeonbuk National University; University of Science & Technology (UST); Korea Food Research Institute (KFRI)	Jang, YJ (corresponding author), Korea Food Res Inst, Nat Mat & Metab Res Grp, Wanju Gun 55365, South Korea.	jyj616@kfri.re.kr	Jang, Young Jin/GLU-3087-2022; Jang, Young Jin/AAT-1192-2020		ISTK \ Korea Food Research Institute (KFRI)	ISTK \ Korea Food Research Institute (KFRI)	ISTK vertical bar Korea Food Research Institute (KFRI)	Amat R, 2009, J BIOL CHEM, V284, P21872, DOI 10.1074/jbc.M109.022749; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; Bezaire V, 2005, FASEB J, V19, P977, DOI 10.1096/fj.04-2765fje; Biesemann N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27614-8; Bocanegra A, 2009, J MED FOOD, V12, P236, DOI 10.1089/jmf.2008.0151; Bogdanis GC, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00142; Brown EM, 2014, NUTR REV, V72, P205, DOI 10.1111/nure.12091; Canto C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006; Chang YH, 2018, BIOCHEM BIOPH RES CO, V495, P197, DOI 10.1016/j.bbrc.2017.11.022; Chen YM, 2015, NUTRIENTS, V7, P239, DOI 10.3390/nu7010239; Chinsomboon J, 2009, P NATL ACAD SCI USA, V106, P21401, DOI 10.1073/pnas.0909131106; Cohen S, 2015, NAT REV DRUG DISCOV, V14, P58, DOI 10.1038/nrd4467; Craig DM, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00296; DeLisser HM, 1997, AM J PATHOL, V151, P671; Dufour CR, 2007, CELL METAB, V5, P345, DOI 10.1016/j.cmet.2007.03.007; Fan WW, 2018, CELL REP, V22, P2521, DOI 10.1016/j.celrep.2018.02.047; Fung A, 2013, FOOD CHEM, V136, P1055, DOI 10.1016/j.foodchem.2012.09.024; Granic A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040745; Grasa-Lopez A, 2016, MAR DRUGS, V14, DOI 10.3390/md14080148; Gray SR, 2018, CURR OPIN CLIN NUTR, V21, P104, DOI 10.1097/MCO.0000000000000441; Guridi M, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab3715; Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hashemi R, 2015, NUTRITION, V31, P97, DOI 10.1016/j.nut.2014.05.003; Horowitz JF, 2000, AM J CLIN NUTR, V72, p558S, DOI 10.1093/ajcn/72.2.558S; HOWALD H, 1985, PFLUG ARCH EUR J PHY, V403, P369, DOI 10.1007/BF00589248; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Jang YJ, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801149; Jang YJ, 2018, FOOD FUNCT, V9, P1102, DOI [10.1039/c7fo01683b, 10.1039/C7FO01683B]; Jeon SM, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.81; Jiang QY, 2019, FOOD FUNCT, V10, P3334, DOI [10.1039/c8fo02518e, 10.1039/C8FO02518E]; Jones TE, 2003, AM J PHYSIOL-ENDOC M, V284, pE96, DOI 10.1152/ajpendo.00316.2002; Jornayvaz FR, 2010, ESSAYS BIOCHEM, V47, P69, DOI [10.1042/BSE0470069, 10.1042/bse0470069]; Kadar L, 2000, ANN NY ACAD SCI, V904, P584; Khan MNA, 2008, J ENVIRON BIOL, V29, P465; Kissane RWP, 2019, CURR OPIN PHYSIOL, V10, P193, DOI 10.1016/j.cophys.2019.06.005; Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200; Lange K. W., 2015, Food Science and Human Wellness, V4, P87, DOI 10.1016/j.fshw.2015.08.001; Lee MK, 2018, MAR DRUGS, V16, DOI 10.3390/md16090328; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Liu J, 2015, SCI CHINA LIFE SCI, V58, P321, DOI 10.1007/s11427-015-4833-4; MacArtain P, 2007, NUTR REV, V65, P535, DOI 10.1111/j.1753-4887.2007.tb00278.x; McGee SL, 2009, J PHYSIOL-LONDON, V587, P5951, DOI 10.1113/jphysiol.2009.181065; Medeiros DM, 2002, J BIOENERG BIOMEMBR, V34, P389, DOI 10.1023/A:1021206220851; Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051; Narkar VA, 2011, CELL METAB, V13, P283, DOI 10.1016/j.cmet.2011.01.019; Park HJ, 2011, FOOD CHEM TOXICOL, V49, P727, DOI 10.1016/j.fct.2010.11.032; Pette D, 2000, MICROSC RES TECHNIQ, V50, P500, DOI 10.1002/1097-0029(20000915)50:6<500::AID-JEMT7>3.3.CO;2-Z; Potthoff MJ, 2007, J CLIN INVEST, V117, P2459, DOI 10.1172/JCI31960; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Rangwala SM, 2010, J BIOL CHEM, V285, P22619, DOI 10.1074/jbc.M110.125401; REN JM, 1994, J BIOL CHEM, V269, P14396; ROMANUL FCA, 1965, ARCH NEUROL-CHICAGO, V12, P497, DOI 10.1001/archneur.1965.00460290053007; Schiaffino S, 2011, PHYSIOL REV, V91, P1447, DOI 10.1152/physrev.00031.2010; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Suetsuna K, 2004, J NUTR BIOCHEM, V15, P267, DOI 10.1016/j.jnutbio.2003.11.004; Taboada C, 2013, J SCI FOOD AGR, V93, P1863, DOI 10.1002/jsfa.5981; Thompson KD, 2004, PHYTOTHER RES, V18, P551, DOI 10.1002/ptr.1487; Tong T, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201800173; Trovato FM, 2018, NUTRIENTS, V10, DOI 10.3390/nu10020231; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V258, P187, DOI 10.1006/bbrc.1999.0617; Wang SK, 2014, J FUNCT BIOMATER, V5, P29, DOI 10.3390/jfb5020029; Wilson JM, 2012, J STRENGTH COND RES, V26, P1724, DOI 10.1519/JSC.0b013e318234eb6f; Wolfe RR, 2006, AM J CLIN NUTR, V84, P475, DOI 10.1093/ajcn/84.3.475; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Wu MT, 2014, MAR DRUGS, V12, P964, DOI 10.3390/md12020964; Xu SY, 2017, MAR DRUGS, V15, DOI 10.3390/md15120388; Yan Z, 2011, J APPL PHYSIOL, V110, P264, DOI 10.1152/japplphysiol.00993.2010; Zhao Y, 2018, MAR DRUGS, V16, DOI 10.3390/md16090321; Zierath JR, 2004, PLOS BIOL, V2, P1523, DOI 10.1371/journal.pbio.0020348	71	8	8	2	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2020	34	6					8068	8081		10.1096/fj.201902399RR	http://dx.doi.org/10.1096/fj.201902399RR		APR 2020	14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MR4QG	32293073				2023-01-03	WOS:000526104500001
J	Humphries, C; Jaganathan, S; Panniyammaka, J; Singh, S; Dorairaj, P; Price, M; Gill, P; Greenfield, S; Lilford, R; Manaseki-Holland, S				Humphries, Claire; Jaganathan, Suganthi; Panniyammaka, Jeemon; Singh, Sanjeev; Dorairaj, Prabhakaran; Price, Malcolm; Gill, Paramjit; Greenfield, Sheila; Lilford, Richard; Manaseki-Holland, Semira			Investigating discharge communication for chronic disease patients in three hospitals in India	PLOS ONE			English	Article							HEART-FAILURE; HEALTH-CARE; TRANSITIONAL CARE; QUALITY; SUMMARIES; SAFETY; ISSUES; LEVEL	Objectives Poor discharge communication is associated with negative health outcomes in high-income countries. However, quality of discharge communication has received little attention in India and many other low and middle-income countries. Primary objective To investigate verbal and documented discharge communication for chronic non-communicable disease (NCD) patients. Secondary objective To explore the relationship between quality of discharge communication and health outcomes. Methods Design Prospective study. Setting Three public hospitals in Himachal Pradesh and Kerala states, India. Participants 546 chronic NCD (chronic respiratory disease, cardiovascular disease or diabetes) patients. Piloted questionnaires were completed at admission, discharge and five and eighteen-week follow-up covering health status, discharge communication practices and health-seeking behaviour. Logistic regression was used to explore the relationship between quality of discharge communication and health outcomes. Outcome measures Primary Patient recall and experiences of verbal and documented discharge communication. Secondary Death, hospital readmission and self-reported deterioration of NCD/s. Results All patients received discharge notes, predominantly on sheets of paper with basic preprinted headings (71%) or no structure (19%); 31% of notes contained all the following information required for facilitating continuity of care: diagnosis, medication information, lifestyle advice, and follow-up instructions. Patient reports indicated notable variations in verbal information provided during discharge consultations; 50% received ongoing treatment/management information and 23% received lifestyle advice. Within 18 weeks of follow-up, 25 (5%) patients had died, 69 (13%) had been readmitted and 62 (11%) reported that their chronic NCD/s had deteriorated. Significant associations were found between low-quality documented discharge communication and death (AOR = 3.00; 95% CI 1.27,7.06) and low-quality verbal discharge communication and self-reported deterioration of chronic NCD/s (AOR = 0.46; 95% CI 0.25,0.83) within 18-weeks of follow-up. Conclusions Sub-optimal discharge practices may be compromising continuity and safety of chronic NCD patient care. Structured protocols, documents and training are required to improve discharge communication, healthcare integration and NCD management.	[Humphries, Claire; Price, Malcolm; Greenfield, Sheila; Manaseki-Holland, Semira] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England; [Jaganathan, Suganthi; Panniyammaka, Jeemon; Dorairaj, Prabhakaran] Publ Hlth Fdn India, Delhi, India; [Jaganathan, Suganthi; Panniyammaka, Jeemon; Dorairaj, Prabhakaran] Ctr Chron Dis Control, Delhi, India; [Panniyammaka, Jeemon] Sree Chitra Tirunal Inst Med Sci & Technol, Trivandrum, Kerala, India; [Singh, Sanjeev] Amrita Inst Med Sci, Hosp Adm, Kochi, Kerala, India; [Price, Malcolm] Univ Hosp Birmingham NHS Fdn Trust, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England; [Price, Malcolm] Univ Birmingham, Birmingham, W Midlands, England; [Price, Malcolm] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Gill, Paramjit] Univ Warwick, Acad Unit Primary Care, Coventry, W Midlands, England; [Lilford, Richard] Univ Warwick, Ctr Appl Hlth Res & Delivery, Coventry, W Midlands, England	University of Birmingham; Public Health Foundation of India; Department of Science & Technology (India); Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST); Amrita Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Kochi; University of Birmingham; University of Birmingham; University of Birmingham; University of Warwick; University of Warwick	Manaseki-Holland, S (corresponding author), Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England.	s.manasekiholland@bham.ac.uk	JAGANATHAN, SUGANTHI/AAU-7807-2020; Manaseki-Holland, Semira/AFX-1728-2022	JAGANATHAN, SUGANTHI/0000-0001-6422-1329; Manaseki-Holland, Semira/0000-0001-5827-8855; Price, Malcolm/0000-0002-7352-3027; Jeemon, Panniyammakal/0000-0003-4172-4307; Humphries, Claire/0000-0001-9784-5218; Lilford, Richard/0000-0002-0634-984X	Department For International Development [MR/M00287X/1]; Economic and Social Research Council [MR/M00287X/1]; Medical Research Council [MR/M00287X/1]; Wellcome Trust [MR/M00287X/1]; National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands (NIHR CLAHRC WM); NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham National Health Service (NHS) Foundation Trust and the University of Birmingham; MRC [MR/M00287X/1] Funding Source: UKRI	Department For International Development; Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands (NIHR CLAHRC WM)(National Institute for Health Research (NIHR)); NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham National Health Service (NHS) Foundation Trust and the University of Birmingham; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This research was funded by a jointfunded grant (Ref No: MR/M00287X/1) from the following organisations: The Department For International Development, The Economic and Social Research Council, The Medical Research Council, and the Wellcome Trust. These funders had no role in study design, data collection, analysis, decision to publish, or reporting of this manuscript. This research was also supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands (NIHR CLAHRC WM) and by the NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham National Health Service (NHS) Foundation Trust and the University of Birmingham. The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.	Agarwal A, 2011, INDIAN J SURG, V73, P184, DOI 10.1007/s12262-010-0208-z; Akkuzu G, 2009, J WOUND OSTOMY CONT, V36, P610, DOI 10.1097/WON.0b013e3181bd7f53; Al-Damluji MS, 2015, CIRC-CARDIOVASC QUAL, V8, P77, DOI 10.1161/CIRCOUTCOMES.114.001227; Allison P. D., 2012, LOGISTIC REGRESSION; [Anonymous], INF RES INF DEC MAK; [Anonymous], 2011, HUMAN RESOURCES HLTH; Australian Council for Safety Quality in Health Care, 2005, CLIN HAND PAT SAF LI; British Medical Association, 2004, SAF HAND SAF PAT GUI, V7, P141; Cajanding RJ, 2017, J CARDIOVASC NURS, V32, P67, DOI 10.1097/JCN.0000000000000303; Campanella P, 2016, EUR J PUBLIC HEALTH, V26, P60, DOI 10.1093/eurpub/ckv122; Carvalho ARS, 2008, REV ELETRONICA ENFER, V96, DOI [10.1111/j.1440-172X.2010.01856.x, DOI 10.1111/J.1440-172X.2010.01856.X]; Chugh Amita, 2009, Front Health Serv Manage, V25, P11; Coleman EA, 2003, J AM GERIATR SOC, V51, P549, DOI 10.1046/j.1532-5415.2003.51185.x; DAVIES J, 2001, GUIDELINES PRACTICE, V4; Directorate of Health Services Government of Kerala, 2017, LIST MOD MED I; Doyle MA, 2015, CAN J DIABETES, V39, P457, DOI 10.1016/j.jcjd.2015.06.009; Dreyer R, 2019, SAMJ S AFR MED J, V109, P164, DOI [10.7196/samj.2019.v109i3.13367, 10.7196/SAMJ.2019.v109i3.13367]; Eshah NF, 2013, NURS HEALTH SCI, V15, P273, DOI 10.1111/nhs.12018; FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.2307/2336755; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Garg T, 2015, JT COMM J QUAL PATIE, V41, P126, DOI 10.1016/S1553-7250(15)41017-7; Ghooi R, 2012, INDIAN J MED ETHICS, V9, pe8; Giordani AT, 2016, ONLINE BRAZILIAN J N, V15, P124; Government of India, 2011, SOL POP CENS DAT 201; Government of India, 2011, HIM PRAD POP CENS DA; Government of India, 2011, ERN POP CENS DAT 201; Government of Kerala, EHEALTH PROJ; Government of Kerala, 2011, KER POP CENS DAT 201; Greenwald JL., 2007, J PATIENT SAF, V3, P97, DOI 10.1097/01.jps.0000236916.94696.12; Gulliford Martin, 2006, J Health Serv Res Policy, V11, P248, DOI 10.1258/135581906778476490; Heinze G, 2002, STAT MED, V21, P2409, DOI 10.1002/sim.1047; Hekmatpou D, 2010, INT J NURS PRACT, V16, P389, DOI 10.1111/j.1440-172X.2010.01856.x; Hesselink G, 2012, BMJ QUAL SAF; Hesselink G, 2013, INT J QUAL HEALTH C, V25, P66, DOI 10.1093/intqhc/mzs066; Horwitz LI, 2013, JAMA INTERN MED, V173, P1715, DOI 10.1001/jamainternmed.2013.9318; Humphries C, PLOS ONE; Humphries C MS, 2019, PROSPERO INT PROSPEC; Humphries C, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028199; Humphries C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207511; Hussain SF, 2005, INT J CLIN PRACT, V59, P912, DOI 10.1111/j.1742-1241.2005.00516.x; Kessels RPC, 2003, J ROY SOC MED, V96, P219, DOI 10.1258/jrsm.96.5.219; Koelling TM, 2005, CIRCULATION, V111, P179, DOI 10.1161/01.CIR.0000151811.53450.B8; Kripalani S, 2007, J HOSP MED, V2, P314, DOI 10.1002/jhm.228; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Kumar S., 2004, ASSESSMENT QUALITY H; Langelaan M, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2149-8; Lenert LA, 2014, ACAD MED, V89, P393, DOI 10.1097/ACM.0000000000000145; Li JYZ, 2013, J EVAL CLIN PRACT, V19, P76, DOI 10.1111/j.1365-2753.2011.01772.x; MacMillan TE, 2015, AM J MED QUAL, V30, P602, DOI 10.1177/1062860615586617; Merten H, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4328; Mittal A., 2015, INT J RES FDN HOSP H, V3, P71; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; Mutsch KS, 2010, QUAL MANAG J, V17, P25, DOI DOI 10.1080/10686967.2010.11918290; Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; Naidu DVN, 2008, INT J EMERG MED, V1, P321, DOI 10.1007/s12245-008-0077-4; Newnham H, 2017, INT J QUAL HEALTH C, V29, P752, DOI 10.1093/intqhc/mzx121; Ozcan H, 2010, INT J NURS PRACT, V16, P289, DOI 10.1111/j.1440-172X.2010.01843.x; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Pichitpornchai W, 1999, INT J NURS STUD, V36, P355, DOI 10.1016/S0020-7489(99)00043-7; Pun JKH, 2018, PATIENT EDUC COUNS, V101, P1193, DOI 10.1016/j.pec.2018.01.018; Regalbuto R, 2014, J CARD FAIL, V20, P641, DOI 10.1016/j.cardfail.2014.06.358; Rochon PA, 1996, MED CARE, V34, P1093, DOI 10.1097/00005650-199611000-00004; Saxena M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204607; Schwarz CM, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-3989-1; Shepperd SL, 2004, DISCHARGE PLANNING H, V31, P1; Smith S., 2013, DETERMINING SAMPLE S; Staveski SL, 2016, CARDIOL YOUNG, V26, P1213, DOI 10.1017/S1047951115002462; Suman, 2017, INT J ADV RES DEV, V2, P231; van Walraven C, 2002, J GEN INTERN MED, V17, P186, DOI 10.1046/j.1525-1497.2002.10741.x; van Walraven C, 1999, AM J MED QUAL, V14, P160, DOI 10.1177/106286069901400403; Vermeir P, 2015, INT J CLIN PRACT, V69, P1257, DOI 10.1111/ijcp.12686; World Health Organization, 2007, PROM SAF MED CHILDR, P1; Ziaeian B, 2012, J GEN INTERN MED, V27, P1513, DOI 10.1007/s11606-012-2168-4	73	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2020	15	4							e0230438	10.1371/journal.pone.0230438	http://dx.doi.org/10.1371/journal.pone.0230438			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR9GL	32294091	gold, Green Published, Green Submitted			2023-01-03	WOS:000536003500010
J	Padmakar, A; de Wit, EE; Mary, S; Regeer, E; Bunders-Aelen, J; Regeer, B				Padmakar, Archana; de Wit, Emma Emily; Mary, Sagaya; Regeer, Eline; Bunders-Aelen, Joske; Regeer, Barbara			Supported Housing as a recovery option for long-stay patients with severe mental illness in a psychiatric hospital in South India: Learning from an innovative dehospitalization process	PLOS ONE			English	Article							ASSERTIVE COMMUNITY TREATMENT; HOMELESS INDIVIDUALS; HEALTH-CARE; 1ST; PEOPLE; INTERVENTION; SERVICES; OUTCOMES; QUALITY	Individuals with severe mental illness have long been segregated from living in communities and participating in socio-cultural life. In recent years, owing to progressive legislations and declarations (in India and globally), there has been a growing movement towards promoting social inclusion and community participation, with emphasis on the need to develop alternative and inclusive care paradigms for persons with severe mental illness. However, transitions from inpatient care to community settings is a complex process involving implications at multiple levels involving diverse stakeholders such as mental health service users, care providers, local communities and policy makers. This article studies how the transition from a hospital setting to a community-based recovery model for personals with severe mental illness can be facilitated. It reflects on the innovative process of creating a Supported Housing model in South India, where 11 MH Service users transitioned from a psychiatric ECRC to independent living facilities. Experiences in various phases of the project development, including care provider- and community level responses and feedback were scrutinised to understand the strategies that were employed in enabling the transition. Qualitative methods (including in-depth interviews and naturalistic observations) were used with residents and staff members to explore the challenges they encountered in stabilizing the model, as well as the psychosocial benefits experienced by residents in the last phase. These were complemented with a Brief Psychiatric Rating Scale (BPRS) and WHO Quality of Life scale to compare baseline and post-assessment results and an increase of quality of life. Results display a significant reduction of psychiatric symptoms in patients (p<0.5). It also describes the challenges encountered in the current context, and strategies that were used to respond and adapt the model to address these concerns effectively. Positive behavioural and psycho-emotional changes were observed amongst the residents, significant amongst those being enhanced in their mobility and participation. The article concludes by discussing the implications of this study for the development of innovative community-based models in wider contexts.	[Padmakar, Archana; Mary, Sagaya] Banyan Acad Leadership Mental Hlth BALM, Chennai, Tamil Nadu, India; [de Wit, Emma Emily; Bunders-Aelen, Joske; Regeer, Barbara] Vrije Univ, Athena Inst, Fac Sci, Amsterdam, Netherlands; [Regeer, Eline] Altrecht, Mental Hlth Care, Utrecht, Netherlands	Vrije Universiteit Amsterdam	de Wit, EE (corresponding author), Vrije Univ, Athena Inst, Fac Sci, Amsterdam, Netherlands.	e.e.de.wit@vu.nl	; Regeer, Barbara/M-1207-2018	de wit, emmy/0000-0002-4047-0555; Regeer, Barbara/0000-0002-9044-9367				Acharya B, 2017, GLOBALIZATION HEALTH, V13, DOI 10.1186/s12992-016-0226-0; Adair CE, 2016, J URBAN HEALTH, V93, P682, DOI 10.1007/s11524-016-0062-9; Adriansen H.K., 2012, QUALITATIVE STUDIES, V3, P40, DOI [https://doi.org/10.7146/qs.v3i1.6272, DOI 10.7146/QS.V3I1.6272]; Aveling EL, 2017, SOC SCI MED, V173, P96, DOI 10.1016/j.socscimed.2016.11.026; Bond GR, 2001, DIS MANAG HEALTH OUT, V9, P141, DOI 10.2165/00115677-200109030-00003; BRAUN P, 1981, AM J PSYCHIAT, V138, P736; Bridges W, 1991, MANAGING CHANGE MAKI; Brown CH, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0134-8; CARLING PJ, 1993, HOSP COMMUNITY PSYCH, V44, P439; Chen FP, 2019, HEALTH SOC CARE COMM, V27, P788, DOI 10.1111/hsc.12697; Chow WS, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-169; Conway M, 1994, OXFORD COMPANION PUR; Crabtree BF., 1999, DOING QUALITATIVE RE, V2nd ed; Culhane DP, 2002, HOUS POLICY DEBATE, V13, P107, DOI 10.1080/10511482.2002.9521437; Daund M, 2018, INDIAN J PSYCHIAT, V60, P239, DOI 10.4103/psychiatry.IndianJPsychiatry_434_17; Gibbons Michael T., 2013, RE THINKING SCI KNOW; Gilmoor AR, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00439; Goel DS, 1946, MENTAL HLTH INDIAN P, V2003, P3; Gopikumar V., 2014, UNDERSTANDING MENTAL; Hannigan T., 2003, DEV SUPPORT SUPPORTI; Harcourt Bernard E., 2011, OHIO STATE J CRIMINA, V9, P53; Harkness J, 2004, HEALTH SERV RES, V39, P1341, DOI 10.1111/j.1475-6773.2004.00293.x; Israilov Sigal, 2017, AMA J Ethics, V19, P1139, DOI 10.1001/journalofethics.2017.19.11.mhst1-1711; Johnson G, 2011, AUST J SOC ISSUES, V46, P29, DOI 10.1002/j.1839-4655.2011.tb00204.x; Killaspy H, 2007, BRIT MED J, V335, P311, DOI 10.1136/bmj.39293.687674.AD; Killaspy H, 2016, LANCET PSYCHIAT, V3, P1129, DOI 10.1016/S2215-0366(16)30327-3; Kliewer SP, 2009, ALABAMA COUNSELING A, V35, P40; Kloos B., 2005, S 10 BIENN M SOC COM; Kotter J.P., 2002, LEADING CHANGE; Lewin SB, 1996, J ECON LIT, V34, P1293; Lipton FR, 2000, PSYCHIATR SERV, V51, P479, DOI 10.1176/appi.ps.51.4.479; Malhotra S, 2015, INDIAN J PSYCHIAT, V57, pS205, DOI 10.4103/0019-5545.161479; Narasimhan L., 2019, INT J MENTAL HLTH SY, V13; Nelson G, 1998, COMMUNITY MENT HLT J, V34, P57, DOI 10.1023/A:1018764229147; Nelson G, 2014, EVAL PROGRAM PLANN, V43, P16, DOI 10.1016/j.evalprogplan.2013.10.004; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Padgett DK, 2011, COMMUNITY MENT HLT J, V47, P227, DOI 10.1007/s10597-009-9283-7; Padgett DK, 2006, RES SOCIAL WORK PRAC, V16, P74, DOI 10.1177/1049731505282593; Patel V, 2007, BRIT MED BULL, V81-82, P81, DOI 10.1093/bmb/ldm010; Patel V, 2015, LANCET, V386, P2422, DOI 10.1016/S0140-6736(15)00955-1; Patrick V, 2006, PSYCHIATR REHABIL J, V29, P183, DOI 10.2975/29.2006.183.188; Pearson C, 2009, J COMMUNITY PSYCHOL, V37, P404, DOI 10.1002/jcop.20303; Pleace N, 2011, DEMONSTRATING EFFECT; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Rudkin J. K., 2003, COMMUNITY PSYCHOL GU; Sharma Shridhar, 2006, Indian J Psychiatry, V48, P109, DOI 10.4103/0019-5545.31600; Shen GC, 2014, INT J MENT HEALTH SY, V8, DOI 10.1186/1752-4458-8-47; Shields L, 2013, ANN AUSTRALASIAN COL; Tabol C, 2010, EVAL PROGRAM PLANN, V33, P446, DOI 10.1016/j.evalprogplan.2009.12.002; Thornicroft G., 2003, WHAT ARE ARGUMENTS C; Thornicroft G, 2016, WORLD PSYCHIATRY, V15, P276, DOI 10.1002/wps.20349; Tsai J, 2012, PSYCHIAT SERV, V63, P427, DOI 10.1176/appi.ps.201100047; Tsemberis S, 2000, PSYCHIATR SERV, V51, P487, DOI 10.1176/appi.ps.51.4.487; van Ginneken N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178954; Won Yin-Ling Irene, 2002, Ment Health Serv Res, V4, P13, DOI 10.1023/A:1014093008857; Wright PA, 2007, J ENVIRON PSYCHOL, V27, P79, DOI 10.1016/j.jenvp.2006.12.001	56	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2020	15	4							e0230074	10.1371/journal.pone.0230074	http://dx.doi.org/10.1371/journal.pone.0230074			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR8WI	32271784	Green Published, gold			2023-01-03	WOS:000535977000012
J	Barrot, L; Asfar, P; Mauny, F; Winiszewski, H; Montini, F; Badie, J; Quenot, JP; Pili-Floury, S; Bouhemad, B; Louis, G; Souweine, B; Collange, O; Pottecher, J; Levy, B; Puyraveau, M; Vettoretti, L; Constantin, JM; Capellier, G				Barrot, Loic; Asfar, Pierre; Mauny, Frederic; Winiszewski, Hadrien; Montini, Florent; Badie, Julio; Quenot, Jean-Pierre; Pili-Floury, Sebastien; Bouhemad, Belaid; Louis, Guillaume; Souweine, Bertrand; Collange, Olivier; Pottecher, Julien; Levy, Bruno; Puyraveau, Marc; Vettoretti, Lucie; Constantin, Jean-Michel; Capellier, Gilles		LOCO2 Investigators; REVA Res Network	Liberal or Conservative Oxygen Therapy for Acute Respiratory Distress Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRITICALLY-ILL PATIENTS; CLINICAL-OUTCOMES; LUNG INJURY; MORTALITY; CARE; TARGETS; ADULTS	Background In patients with acute respiratory distress syndrome (ARDS), the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network recommends a target partial pressure of arterial oxygen (Pao(2)) between 55 and 80 mm Hg. Prospective validation of this range in patients with ARDS is lacking. We hypothesized that targeting the lower limit of this range would improve outcomes in patients with ARDS. Methods In this multicenter, randomized trial, we assigned patients with ARDS to receive either conservative oxygen therapy (target Pao(2), 55 to 70 mm Hg; oxygen saturation as measured by pulse oximetry [Spo(2)], 88 to 92%) or liberal oxygen therapy (target Pao(2), 90 to 105 mm Hg; Spo(2), >= 96%) for 7 days. The same mechanical-ventilation strategies were used in both groups. The primary outcome was death from any cause at 28 days. Results After the enrollment of 205 patients, the trial was prematurely stopped by the data and safety monitoring board because of safety concerns and a low likelihood of a significant difference between the two groups in the primary outcome. Four patients who did not meet the eligibility criteria were excluded. At day 28, a total of 34 of 99 patients (34.3%) in the conservative-oxygen group and 27 of 102 patients (26.5%) in the liberal-oxygen group had died (difference, 7.8 percentage points; 95% confidence interval [CI], -4.8 to 20.6). At day 90, 44.4% of the patients in the conservative-oxygen group and 30.4% of the patients in the liberal-oxygen group had died (difference, 14.0 percentage points; 95% CI, 0.7 to 27.2). Five mesenteric ischemic events occurred in the conservative-oxygen group. Conclusions Among patients with ARDS, early exposure to a conservative-oxygenation strategy with a Pao(2) between 55 and 70 mm Hg did not increase survival at 28 days. (Funded by the French Ministry of Health; LOCO2 ClinicalTrials.gov number, NCT02713451.)	[Barrot, Loic; Winiszewski, Hadrien; Vettoretti, Lucie; Capellier, Gilles] Univ Hosp, Med Intens Care Unit, Besancon, France; [Barrot, Loic; Pili-Floury, Sebastien] Univ Hosp, Anesthesia & Intens Care Unit, Besancon, France; [Mauny, Frederic; Puyraveau, Marc] Univ Hosp, INSERM Clin Invest Ctr 1431, Unite Methodol, Besancon, France; [Barrot, Loic; Winiszewski, Hadrien; Pili-Floury, Sebastien; Capellier, Gilles] Univ Franche Comte, Res Unit EA3920, Besancon, France; [Asfar, Pierre] Univ Hosp Angers, Med Intens Care Unit, Angers, France; [Montini, Florent] Gen Hosp Avignon, Intens Care Unit, Avignon, France; [Badie, Julio] Gen Hosp Nord Franche Comte, Intens Care Unit, Trevenans, France; [Quenot, Jean-Pierre] Univ Hosp Dijon, Med Intens Care Unit, Dijon, France; [Bouhemad, Belaid] Univ Hosp Dijon, Anesthesia & Intens Care Unit, Dijon, France; [Louis, Guillaume] Gen Hosp Metz Thionville, Intens Care Unit, Metz, France; [Souweine, Bertrand] Univ Hosp Clermont Ferrand, Med Intens Care Unit, Clermont Ferrand, France; [Constantin, Jean-Michel] Univ Hosp Clermont Ferrand, Anesthesia & Intens Care Unit, Clermont Ferrand, France; [Collange, Olivier; Pottecher, Julien] Univ Hosp Strasbourg, Anesthesia & Intens Care Unit, Strasbourg, France; [Levy, Bruno] Univ Hosp Nancy, Med Intens Care Unit, Nancy, France; [Capellier, Gilles] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia	Universite de Franche-Comte; CHU Besancon; Universite de Franche-Comte; CHU Besancon; Universite de Franche-Comte; CHU Besancon; Universite de Franche-Comte; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Dijon Bourgogne; CHU Dijon Bourgogne; CHU Clermont Ferrand; CHU Clermont Ferrand; CHU Strasbourg; CHU de Nancy; Universite de Lorraine; Monash University	Capellier, G (corresponding author), Ctr Hosp Reg Univ Besancon, Reanimat Med, Blvd Fleming, F-25000 Besancon, France.	gilles.capellier@univ-fcomte.fr	Louis, Guillaume/AAF-4340-2021; souweine, bertrand/HHR-8972-2022	Louis, Guillaume/0000-0002-4208-8122; Koszutski, Matthieu/0000-0002-4382-972X; QUENOT, Jean-Pierre/0000-0003-2351-682X	French Ministry of Health Programme Hospitalier de Recherche Clinique Interregional 2015 [B09]	French Ministry of Health Programme Hospitalier de Recherche Clinique Interregional 2015	Supported by a grant (B09) from the French Ministry of Health Programme Hospitalier de Recherche Clinique Interregional 2015.	Aboab J, 2006, INTENS CARE MED, V32, P1979, DOI 10.1007/s00134-006-0382-4; Aggarwal NR, 2018, CRIT CARE MED, V46, P517, DOI 10.1097/CCM.0000000000002886; ARDSnet, NIH NHLBI ARDS CLIN; Bein T, 2016, INTENS CARE MED, V42, P699, DOI 10.1007/s00134-016-4325-4; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Calfee CS, 2018, LANCET RESP MED, V6, P691, DOI 10.1016/S2213-2600(18)30177-2; Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3; de Jonge E, 2008, CRIT CARE, V12, DOI 10.1186/cc7150; Ferguson ND, 2016, JAMA-J AM MED ASSOC, V316, P1553, DOI 10.1001/jama.2016.13800; Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Helmerhorst HJF, 2016, CRIT CARE MED, V44, P554, DOI 10.1097/CCM.0000000000001461; LUNDGREN O, 1974, GUT, V15, P1005, DOI 10.1136/gut.15.12.1005; Mackle D, 2020, NEW ENGL J MED, V382, P989, DOI 10.1056/NEJMoa1903297; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Mikkelsen Mark E, 2014, Ann Am Thorac Soc, V11, P613, DOI 10.1513/AnnalsATS.201401-001PS; Panwar R, 2016, AM J RESP CRIT CARE, V193, P43, DOI 10.1164/rccm.201505-1019OC; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Radermacher P, 2017, AM J RESP CRIT CARE, V196, P964, DOI 10.1164/rccm.201610-2156SO; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Richard JC, 2005, REANIMATION, V14, P313; Sander O, 2005, CRIT CARE MED, V33, P81, DOI 10.1097/01.CCM.0000150028.64264.14; Siemieniuk RAC, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4169; Sinclair SE, 2004, CRIT CARE MED, V32, P2496, DOI 10.1097/01.CCM.0000148231.04642.8D; Young P, 2020, INTENS CARE MED, V46, P17, DOI 10.1007/s00134-019-05857-x	25	168	177	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 12	2020	382	11					999	1008		10.1056/NEJMoa1916431	http://dx.doi.org/10.1056/NEJMoa1916431			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU7TA	32160661	Bronze			2023-01-03	WOS:000519914300006
J	Watanabe, R; Marcoux, J; Evangelista, MC; Dumais, Y; Steagall, PV				Watanabe, Ryota; Marcoux, Josee; Evangelista, Marina C.; Dumais, Yvan; Steagall, Paulo, V			The analgesic effects of buprenorphine (Vetergesic or Simbadol) in cats undergoing dental extractions: A randomized, blinded, clinical trial	PLOS ONE			English	Article								This study aimed to evaluate the analgesic efficacy of two dosage regimens using two different concentrations of buprenorphine in cats undergoing dental extractions. Twenty-three cats with oral disease (8.2 +/- 2.2 years old; 4.9 +/- 0.9 kg) were included in a prospective, blinded, randomized clinical trial. Cats randomly received either Simbadol (1.8 mg/mL; 0.24 mg/kg, subcutaneously, every 24h: SG, n = 11) or Vetergesic (0.3 mg/mL; 0.02 mg/kg, intramuscularly, every 8h: VG, n = 12) throughout the study. They were admitted at day 0, underwent oral examination/radiographs/treatment under general anesthesia (buprenorphinepropofol-isoflurane-meloxicam-local anesthetic blocks) at day 1 and discharged at day 4. Sedation and pain were scored using the dynamic interactive visual analog scale (day 1) and the Glasgow Composite Measure Pain Scale-Feline (CMPS-F; up to postoperative 8 hours at day 1, 8 am, 4 pm and midnight at days 2 and 3, and 8 am at day 4), respectively. Rescue analgesia was administered with hydromorphone (0.05 mg/kg intravenously on day 1 or 0.1 mg/kg intramuscularly after day 2) when CMPS-F >= 5. Resentment defined as any type of escape behavior associated with aversion to drug administration was recorded. Sedation and pain scores, the prevalence of rescue analgesia and resentment during drug administration were analyzed using linear mixed models and Fisher's exact test, respectively (p < 0.05). Pain and sedation scores were not significantly different between groups. Sedation scores were significantly higher up to postoperative 2 hours in both groups. Pain scores in SG and VG were significantly higher up to postoperative 8 hours and 8 am of day 2, respectively, than baseline. Prevalence of rescue analgesia and resentment were not significantly different between groups (SG: 27.3%, VG: 33.3% and SG: 0%, VG: 25%, respectively). Simbadol produced similar analgesic effects to Vetergesic without resentment during drug administration.	[Watanabe, Ryota; Evangelista, Marina C.; Steagall, Paulo, V] Univ Montreal, Fac Med Vet, Dept Sci Clin, St Hyacinthe, PQ, Canada; [Marcoux, Josee; Dumais, Yvan] Univ Montreal, CHUV, Fac Med Vet, St Hyacinthe, PQ, Canada	Universite de Montreal; Universite de Montreal	Steagall, PV (corresponding author), Univ Montreal, Fac Med Vet, Dept Sci Clin, St Hyacinthe, PQ, Canada.	paulo.steagall@umontreal.ca	Steagall, Paulo/W-6043-2019	Steagall, Paulo/0000-0003-4150-6043	Zoetis	Zoetis	This study was funded by Zoetis (RW, PS) (https://www.zoetisus.com).Zoetis read and accepted the study proposal and publication of the manuscript, but it had no role in the study design, data collection and analysis, or preparation of the manuscript.	Acs George, 1992, Pediatric Dentistry, V14, P302; Bellows J, 2019, J AM ANIM HOSP ASSOC, V55, P49, DOI 10.5326/JAAHA-MS-6933; Benito J, 2016, J FELINE MED SURG, V18, P906, DOI 10.1177/1098612X15610162; Doodnaught GM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176443; Epstein M.E., 2015, HDB VET PAIN MANAGEM, V3th ed., P161, DOI DOI 10.1016/B978-0-323-08935-7.00009-0; Evangelista M, 2019, AUT M ASS VET AN BEL; Giordano T, 2010, VET ANAESTH ANALG, V37, P357, DOI 10.1111/j.1467-2995.2010.00541.x; Gurney M, 2009, J SMALL ANIM PRACT, V50, P474, DOI 10.1111/j.1748-5827.2009.00786.x; Kukanich B, VET ANESTHESIA ANALG; Niemiec BA, WORLD SMALL ANIMAL V; Reid J, 2017, VET REC, V180, P449, DOI 10.1136/vr.104208; Simon BT, 2017, J VET PHARMACOL THER, V40, P315, DOI 10.1111/jvp.12377; Slingsby LS, 2012, VET J, V192, P523, DOI 10.1016/j.tvjl.2011.09.008; Steagall PVM, 2014, J VET INTERN MED, V28, P762, DOI 10.1111/jvim.12346; Steagall PVM, 2009, VET REC, V164, P359, DOI 10.1136/vr.164.12.359; Steagall PV, 2019, J FELINE MED SURG, V21, P25, DOI 10.1177/1098612X18808103; Steagall PV, 2018, J FELINE MED SURG, V20, P741, DOI [10.1177/1098612X17730173, 10.1177/1098612x17730173]; Steagall PVM, 2013, VET ANAESTH ANALG, V40, P83, DOI 10.1111/j.1467-2995.2012.00779.x; Taylor PM, 2016, J FELINE MED SURG, V18, P290, DOI 10.1177/1098612X15581206; Watanabe R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213195	20	5	5	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2020	15	3							e0230079	10.1371/journal.pone.0230079	http://dx.doi.org/10.1371/journal.pone.0230079			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8TR	32142538	Green Published, gold			2023-01-03	WOS:000535271600037
J	Rosenberg, LB				Rosenberg, Leah B.			What Are Two Days Worth? Facing Dilemmas Together at the End of Life	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Rosenberg, Leah B.] Massachusetts Gen Hosp, Dept Palliat Care & Geriatr Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Rosenberg, LB (corresponding author), Massachusetts Gen Hosp, Dept Palliat Care & Geriatr Med, Boston, MA 02114 USA.							[Anonymous], 2015, TRANSPLANTATION DIRE, V1, pe2, DOI 10.1097/TXD.0000000000000509; Kawashima H, 2019, J PALLIAT MED, V22, P908, DOI 10.1089/jpm.2018.0415; Maiser S, 2017, J PALLIAT MED, V20, P915, DOI 10.1089/jpm.2016.0464	3	3	3	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	2020	382	10					890	891		10.1056/NEJMp1913106	http://dx.doi.org/10.1056/NEJMp1913106			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KT7TC	32130812				2023-01-03	WOS:000519214900004
J	Wynne, SJ; Duarte, R; de Wildt, G; Meza, G; Merriel, A				Wynne, Sara Jabeen; Duarte, Rui; de Wildt, Gilles; Meza, Graciela; Merriel, Abi			The timing and quality of antenatal care received by women attending a primary care centre in Iquitos, Peru: A facility exit survey	PLOS ONE			English	Article							EARLY-PREGNANCY; PRENATAL-CARE; FOLIC-ACID; SERVICES; HEALTH; SATISFACTION; MALARIA	Background Maternal mortality is high in Loreto, Peru, but can be reduced by high quality antenatal care. Indicators for the quality of antenatal care received include the timing (with respect to gestational age) and number of antenatal appointments attended, the delivery of antenatal services and health information, and women's perceptions about their care. This study investigated these indicators amongst women receiving antenatal care in predominantly the San Juan Bautista district of Iquitos, Loreto. This was to identify areas for improvement through comparison with antenatal guidelines published by the Ministry of Health, Peru, and the World Health Organization. Methods A total of 134 women were recruited at the Centro de Salud, San Juan-a primary care centre in Iquitos. Information about the delivery of antenatal services and the number of and gestational ages at appointments attended was collected from 121/134 women's hand-held antenatal cards. The delivery of health information and women's perceptions about their antenatal care were investigated through questionnaires (133/134 completed). Descriptive statistics, such as frequencies and valid percentages, were determined. Results Hand-held antenatal cards revealed that 52.9% of participants began their antenatal care in the first trimester. Compared to national guidelines, 42.1% attended appointments at recommended gestational ages and no women received all recommended antenatal services. Most women received information about identifying complications in pregnancy and health and lifestyle topics. Over 85% of women reported satisfaction with their antenatal care. Conclusions Timely antenatal attendance and delivery of services should be encouraged to meet national and global standards. Although all services were not delivered in a combined manner according to national guidelines, individual services were mostly delivered to a high standard and therefore a high proportion of women were satisfied with their antenatal care.	[Wynne, Sara Jabeen] Univ Birmingham, Coll Med & Dent Sci, Med Sch, Birmingham, W Midlands, England; [Duarte, Rui] Univ Liverpool, Liverpool Reviews & Implementat Grp, Liverpool, Merseyside, England; [de Wildt, Gilles] Univ Birmingham, Coll Med & Dent Sci, Inst Clin Sci, Birmingham, W Midlands, England; [Meza, Graciela] Natl Univ Peruvian Amazon, Fac Med, Punchana, Peru; [Merriel, Abi] Univ Bristol, Southmead Hosp, Bristol Med Sch, Bristol, Avon, England	University of Birmingham; University of Liverpool; University of Birmingham; Universidad Nacional de la Amazonia Peruana; Southmead Hospital; University of Bristol	Wynne, SJ (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Med Sch, Birmingham, W Midlands, England.	sarajwynne@gmail.com	Meza, Graciela/AAK-8386-2021; Duarte, Rui/C-9635-2012	Duarte, Rui/0000-0001-6485-7415; Meza sanchez, Graciela Rocio/0000-0001-5752-8824	Population Sciences and Humanities department [FIN 7N]; Sir Arthur Thomson Trust [FIN 42]	Population Sciences and Humanities department; Sir Arthur Thomson Trust	The corresponding author received awards from the Population Sciences and Humanities department (grant number FIN 7N, https://www.birmingham.ac.uk/undergraduate/courses/med/InternationalHealthBMedScIntercalatedDegree.aspx) and the Sir Arthur Thomson Trust (grant number FIN 42, https://www.birmingham.ac.uk/research/activity/mds/icat/undergraduate/index.aspx), both at the University of Birmingham (United Kingdom). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Airoldi J, 2007, OBSTET GYNECOL SURV, V62, P117, DOI 10.1097/01.ogx.0000253301.55009.ac; Allen DR, 2009, MANAGING MOTHERHOOD; Alwan NA, 2011, HUM REPROD, V26, P911, DOI 10.1093/humrep/der005; American Diabetes Association, 2004, DIABETES CARE, V27, pS88, DOI [DOI 10.2337/DIACARE.27.2007.S88, 10.2337/diacare.27.2007.S88]; Amooti-Kaguna B, 2000, SOC SCI MED, V50, P203, DOI 10.1016/S0277-9536(99)00275-0; Arispe Claudia, 2011, Rev Med Hered, V22, P159; Arsenault C, 2018, LANCET GLOB HEALTH, V6, pE1186, DOI 10.1016/S2214-109X(18)30389-9; Ayala LSH, 2013, MATERN CHILD HLTH J, V17, P1112, DOI 10.1007/s10995-012-1113-9; Bassani DG, 2009, INT PERSPECT SEX R H, V35, P15, DOI [10.1363/3501509, 10.1363/ifpp.35.015.09]; Bleich SN, 2009, B WORLD HEALTH ORGAN, V87, P271, DOI 10.2471/BLT.07.050401; Blencowe H, 2010, INT J EPIDEMIOL, V39, P102, DOI 10.1093/ije/dyq027; Brown HC, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002856.pub3; del Carpio Ancaya Lucy, 2013, Rev. perú. med. exp. salud publica, V30, P461; Department of Making Pregnancy Safer, 2002, MAT IMM TET; Diaz JJ, 2019, HEALTH ECON, V28, P1099, DOI 10.1002/hec.3919; Doskoch P, 2014, INT PERSPECT SEX R H, V40, P102; Doubova SV, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-168; Edie GEHE, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.45.4858; Eggleston E, 2000, SOC SCI MED, V51, P1011, DOI 10.1016/S0277-9536(00)00010-1; Fagbamigbe AF, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0081-0; Fawole AO, 2008, J NATL MED ASSOC, V100, P1052, DOI 10.1016/S0027-9684(15)31443-7; Galle A, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0266-2; Gross K, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-16; Gross K, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-36; Gudayu TW, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-287; Hildingsson I, 2013, WOMEN BIRTH, V26, pE9, DOI 10.1016/j.wombi.2012.06.002; INEI UNFPA PNUD, 2009, PERF SOC DEP LOR; Instituto Nacional de Estadistica e Informatic, 2016, PER ENC DEM SAL FAM; Jallow IK, 2012, INT J QUAL HEALTH C, V24, P595, DOI 10.1093/intqhc/mzs033; Kruk ME, 2018, LANCET GLOB HEALTH, V6, pE1196, DOI 10.1016/S2214-109X(18)30386-3; Kyei NNA, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-151; Langer Ana, 2002, BMC Womens Health, V2, P7, DOI 10.1186/1472-6874-2-7; Launiala A, 2007, T ROY SOC TROP MED H, V101, P980, DOI 10.1016/j.trstmh.2007.04.005; Leeman L, 2008, AM FAM PHYSICIAN, V78, P93; Marsland H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209736; Mera KC, 2014, IDENTIFICACION PRIOR; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; Ministerio de Salud del Peru, 2013, NORM TECN SAL AT INT; Ministerio de Salud del Peru United Nations Population Fund Peru: Progresso Para Todos, 2013, PER PROGR TOD MORT M; Montasser N, 2014, INT J TROP DIS HLTH, V2, P145; Moore N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171136; Mrisho M, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-10; Myer L, 2003, J MIDWIFERY WOM HEAL, V48, P268, DOI 10.1016/S1526-9523(02)00421-X; Ndyomugyenyi R, 1998, HEALTH POLICY PLANN, V13, P94, DOI 10.1093/heapol/13.1.94; Nwaeze I L, 2013, Ann Ib Postgrad Med, V11, P22; Obican SG, 2010, FASEB J, V24, P4167, DOI 10.1096/fj.10-165084; Oladapo Olufemi T, 2008, Afr J Reprod Health, V12, P71; Osungbade KO, 2011, HEALTH CARE WOMEN IN, V32, P441, DOI 10.1080/07399332.2010.517878; Pan American Health Organization/World Health Organization The Partnership for Maternal Newborn & Child Health World Bank Group Alliance for Health Policy and Systems Research, 2015, SUCC FACTS WOM CHILD; Paredes I, 2005, INT J GYNECOL OBSTET, V88, P168, DOI 10.1016/j.ijgo.2004.09.024; Ryan JA, 2009, INT J GYNECOL OBSTET, V107, P162, DOI 10.1016/j.ijgo.2009.06.014; SCHOLL TO, 1994, AM J CLIN NUTR, V59, p492S, DOI 10.1093/ajcn/59.2.492S; Scholl TO, 2005, AM J CLIN NUTR, V81, p1218S; Schwarzler P, 1999, ULTRASOUND OBST GYN, V14, P92, DOI 10.1046/j.1469-0705.1999.14020092.x; Sholeye O. O., 2013, World Journal of Medical Sciences, V8, P359; Sibai BM, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.07.048; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701; Soliman FE, 2015, IJSRP, V5, P3; Tann Carolyn J, 2007, BMC Pregnancy Childbirth, V7, P23, DOI 10.1186/1471-2393-7-23; van Eijk Anna M, 2006, Reprod Health, V3, P2, DOI 10.1186/1742-4755-3-2; Victora CG, 2016, LANCET, V387, P2049, DOI 10.1016/S0140-6736(15)00519-X; WHO, 2022, WHO RECOMMENDATIONS; Williamson J, 2015, AM J TROP MED HYG, V92, P857, DOI 10.4269/ajtmh.14-0536; World Health Organization, 2011, WHO REC PREV TREATM; World Health Organization UNICEF UNFPA Wolrd Bank Group United Nations Population Division Maternal Mortality Estimation Inter-Agency Group, 2016, MAT MORT 1990 2015	65	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2020	15	3							e0229852	10.1371/journal.pone.0229852	http://dx.doi.org/10.1371/journal.pone.0229852			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8RK	32134987	Green Published, gold			2023-01-03	WOS:000535265600051
J	Rufiange, M; Leung, VSY; Simpson, K; Pang, DSJ				Rufiange, Maxime; Leung, Vivian S. Y.; Simpson, Keith; Pang, Daniel S. J.			Pre-warming before general anesthesia with isoflurane delays the onset of hypothermia in rats	PLOS ONE			English	Article							CORE-TEMPERATURE; POSTANESTHETIC HYPOTHERMIA; PREVENTION; RECOVERY; SURGERY; VASOCONSTRICTION; COMPLICATIONS; NORMOTHERMIA; PREVALENCE; EVOLUTION	General anesthesia causes hypothermia by impairing normal thermoregulatory mechanisms. When using inhalational anesthetic agents, Redistribution of warm blood from the core to the periphery is the primary mechanism in the development of hypothermia and begins following induction of anesthesia. Raising skin temperature before anesthesia reduces the temperature gradient between core and periphery, decreasing the transfer of heat. This prospective, crossover study (n = 17 adult male and female SD rats) compared three treatment groups: PW1% (pre-warming to increase core temperature 1% over baseline), PW40 (pre-warming to increase core temperature to 40 degrees C) and NW (no warming). The PW1% group was completed first to ensure tolerance of pre-warming. Treatment order was then randomized and alternated after a washout period. Once target temperature was achieved, anesthesia was induced and maintained with isoflurane in oxygen without further external temperature support. Pre-warming was effective at delaying the onset of hypothermia, with a significant difference between PW1% (12.4 minutes) and PW40 (19.3 minutes, p = 0.0044 (95%CI -12 to -2.2), PW40 and NW (7.1 minutes, p < 0.0001 (95%CI 8.1 to 16.0) and PW1% and NW (p = 0.003, 95%CI 1.8 to 8.7). The rate of heat loss in the pre-warmed groups exceed that of the NW group: PW1% versus NW (p = 0.005, 95%CI 0.004 to 0.027), PW40 versus NW (p < 0.0001, 95%CI 0.014 to 0.036) and PW1% versus PW40 (p = 0.07, 95%CI -0.021 to 0.00066). Pre-warming alone confers a protective effect against hypothermia during volatile anesthesia; however, longer duration procedures would require additional heating support.	[Rufiange, Maxime; Leung, Vivian S. Y.; Pang, Daniel S. J.] Univ Montreal, Dept Clin Sci, Fac Vet Med, St Hyacinthe, PQ, Canada; [Rufiange, Maxime; Leung, Vivian S. Y.; Pang, Daniel S. J.] Univ Montreal, Grp Rech Pharmacol Anim Que GREPAQ, Fac Vet Med, St Hyacinthe, PQ, Canada; [Simpson, Keith] Vetron Serv Ltd, Abbotskerswell, England	Universite de Montreal; Universite de Montreal	Pang, DSJ (corresponding author), Univ Montreal, Dept Clin Sci, Fac Vet Med, St Hyacinthe, PQ, Canada.; Pang, DSJ (corresponding author), Univ Montreal, Grp Rech Pharmacol Anim Que GREPAQ, Fac Vet Med, St Hyacinthe, PQ, Canada.	danielpang17@hotmail.com		Pang, Daniel/0000-0002-6420-477X	Natural Sciences and Engineering Research Council (NSERC) [424022-2013]; Fondation Levesque; Vetronic Services Ltd.	Natural Sciences and Engineering Research Council (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Fondation Levesque; Vetronic Services Ltd.	This work was supported by Natural Sciences and Engineering Research Council (NSERC) Discovery Grant (ID: 424022-2013; DSJP), Fondation Levesque (DSJP), and Vetronic Services Ltd. Author KS received support in the form of a salary from Vetronic Services Ltd. The specific role of this author is articulated in the `author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albrecht M, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0198-3; Andrzejowski J, 2008, BRIT J ANAESTH, V101, P627, DOI 10.1093/bja/aen272; [Anonymous], 2015, GUIDELINES PAIN DIST; [Anonymous], 2011, CCAC TRAINING MODULE; Armstrong T, 2018, J FELINE MED SURG, V20, P73, DOI 10.1177/1098612X17693517; Bindu Barkha, 2017, J Anaesthesiol Clin Pharmacol, V33, P306, DOI 10.4103/joacp.JOACP_334_16; Buisman M, 2017, VET ANAESTH ANALG, V44, P646, DOI 10.1016/j.vaa.2016.09.001; Caro AC, 2013, J AM ASSOC LAB ANIM, V52, P577; Clark-Price S, 2015, VET CLIN N AM-SMALL, V45, P983, DOI 10.1016/j.cvsm.2015.04.005; DILSAVER SC, 1992, PHARMACOL BIOCHEM BE, V42, P549, DOI 10.1016/0091-3057(92)90154-8; GLOSTEN B, 1993, ANESTH ANALG, V77, P488; Hasiuk MMM, 2015, JAVMA-J AM VET MED A, V246, P645, DOI 10.2460/javma.246.6.645; Hershey J., 2016, LAB ANIM SCI PROF, V4, P40; Hildebrand F, 2004, AM J SURG, V187, P363, DOI 10.1016/j.amjsurg.2003.12.016; Horn EP, 2012, ANAESTHESIA, V67, P612, DOI 10.1111/j.1365-2044.2012.07073.x; Hynson J M, 1992, J Clin Anesth, V4, P194, DOI 10.1016/0952-8180(92)90064-8; HYNSON JM, 1993, ANESTHESIOLOGY, V79, P219, DOI 10.1097/00000542-199308000-00005; JUST B, 1993, ANESTHESIOLOGY, V79, P214, DOI 10.1097/00000542-199308000-00004; Kehlet H, 1997, BRIT J ANAESTH, V78, P606, DOI 10.1093/bja/78.5.606; Kehlet H, 2008, ANN SURG, V248, P189, DOI 10.1097/SLA.0b013e31817f2c1a; Kleimeyer JP, 2018, J AM ACAD ORTHOP SUR, V26, pE497, DOI 10.5435/JAAOS-D-16-00742; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; KURZ A, 1995, J CLIN ANESTH, V7, P359, DOI 10.1016/0952-8180(95)00028-G; KURZ A, 1995, ANESTHESIOLOGY, V83, P491, DOI 10.1097/00000542-199509000-00007; Kurz A, 2008, BEST PRACT RES-CLIN, V22, P627, DOI 10.1016/j.bpa.2008.06.004; LOMAX P, 1966, NATURE, V210, P854, DOI 10.1038/210854a0; Marschner JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149489; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P662, DOI 10.1097/00000542-199503000-00008; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P1169, DOI 10.1097/00000542-199505000-00012; Monzon CG, 2013, REV COLOMB ANESTESIO, V41, P97, DOI [10.1016/j.rca.2013.03.002, DOI 10.1016/J.RCA.2013.03.002, 10.1016/j.rcae.2013.03.002, DOI 10.1016/J.RCAE.2013.03.002]; Pottie RG, 2007, AUST VET J, V85, P158, DOI 10.1111/j.1751-0813.2007.00128.x; Redondo JI, 2012, VET REC, V171, P374, DOI 10.1136/vr.100476; Redondo JI, 2012, VET REC, V170, P206, DOI 10.1136/vr.100184; Reynolds L, 2008, BEST PRACT RES-CLIN, V22, P645, DOI 10.1016/j.bpa.2008.07.005; Roehl AB, 2011, LAB ANIM-UK, V45, P45, DOI 10.1258/la.2010.010076; Rose N, 2016, J SMALL ANIM PRACT, V57, P447, DOI 10.1111/jsap.12547; SAKAGUCHI Y, 1995, CANCER RES, V55, P5459; SATINOFF E, 1978, SCIENCE, V201, P16, DOI 10.1126/science.351802; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; Schuster CJ, 2018, LAB ANIM-UK, V52, P142, DOI 10.1177/0023677217712539; Scott Eileen M, 2006, AORN J, V83, P1090, DOI 10.1016/S0001-2092(06)60120-8; Sessler DI, 2001, ANESTHESIOLOGY, V95, P531, DOI 10.1097/00000542-200108000-00040; SESSLER DI, 1995, ANESTHESIOLOGY, V82, P674, DOI 10.1097/00000542-199503000-00009; Sessler DI, 2000, ANESTHESIOLOGY, V92, P578, DOI 10.1097/00000542-200002000-00042; Sun Z, 2015, ANESTHESIOLOGY, V122, P276, DOI 10.1097/ALN.0000000000000551; Taylor DK, 2007, J AM ASSOC LAB ANIM, V46, P37; Torossian A, 2008, BEST PRACT RES-CLIN, V22, P659, DOI 10.1016/j.bpa.2008.07.006; Xiong JY, 1996, ANESTHESIOLOGY, V85, P240, DOI 10.1097/00000542-199608000-00003; Zhang EQ, 2017, J AM ASSOC LAB ANIM, V56, P786	49	14	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2020	15	3							e0219722	10.1371/journal.pone.0219722	http://dx.doi.org/10.1371/journal.pone.0219722			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8MS	32126085	Green Published, gold, Green Submitted			2023-01-03	WOS:000535253100001
J	Hyde, R				Hyde, Rob			Europe faces worsening medicine shortages	LANCET			English	Editorial Material																			0	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	2020	395	10223					481	482						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KN1CG	32061283				2023-01-03	WOS:000514576900014
J	Satia, I; Cusack, R; Greene, JM; O'Byrne, PM; Killian, KJ; Johnston, N				Satia, Imran; Cusack, Ruth; Greene, Justina M.; O'Byrne, Paul M.; Killian, Kieran J.; Johnston, Neil			Prevalence and contribution of respiratory viruses in the community to rates of emergency department visits and hospitalizations with respiratory tract infections, chronic obstructive pulmonary disease and asthma	PLOS ONE			English	Article							VIRAL-INFECTIONS; SYNCYTIAL VIRUS; EXACERBATIONS; MORTALITY; PRECIPITANTS; INFLUENZA; SYMPTOMS; CHILDREN; SEASON; AGE	Background The individual and combined contribution of viral prevalence in the community to Emergency Department (ED) visits and hospitalizations with respiratory tract infections (RTIs), chronic obstructive pulmonary disease (COPD) and asthma is unclear. Methods A retrospective analysis on daily viral positive tests and daily ED visits and hospitalizations between 01/01/2003 to 31/12/2013 in Ontario, Canada. Viral data was collected from the Centre for Immunization and Respiratory Infectious Diseases (CIRID). The Canadian Institute for Health Information reports daily ED visits and hospitalizations for RTIs, COPD and asthma as a primary diagnosis. Results There were 4,365,578 ED visits with RTIs of which 321,719 (7.4%) were admitted to hospital; 817,141 ED visits for COPD of which 260,665 (31.9%) were admitted and 649,666 ED visits with asthma of which 68,626 (10.6%) were admitted. The percentage of positive tests to influenza A and B, respiratory syncytial virus (RSV), parainfluenza and adenovirus prevalence explained 57.4% of ED visits and 63.8% of hospitalizations for RTI, 41.4% of ED visits and 39.2% of hospitalizations with COPD but only 1.5% of ED visits and 2.7% of hospitalizations for asthma. The further addition of human metapneumovirus, rhinovirus and coronavirus over the final 3 years accounted for 66.7% of ED visits and 74.4% of hospitalizations for RTI, 52.5% of visits and 48.2% of hospitalizations for COPD, and only 13.3% of visits and 10.4% of hospitalizations for asthma. Conclusions Community respiratory viral epidemics are major drivers of ED visits and hospitalizations with RTIs and COPD but only a modest contributor to asthma.	[Satia, Imran; Cusack, Ruth; O'Byrne, Paul M.; Johnston, Neil] St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON, Canada; [Satia, Imran] Univ Manchester, Div Infect Immun & Resp Med, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Cusack, Ruth; Greene, Justina M.; O'Byrne, Paul M.; Killian, Kieran J.] McMaster Univ, Dept Med, Hamilton, ON, Canada	McMaster University; University of Manchester; McMaster University	Satia, I (corresponding author), St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON, Canada.; Satia, I (corresponding author), Univ Manchester, Div Infect Immun & Resp Med, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.	satiai@mcmaster.ca	Satia, Imran/ABA-2872-2020	Satia, Imran/0000-0003-4206-6000; Cusack, Ruth/0000-0003-1204-648X; O'Byrne, Paul/0000-0003-0979-281X	AstraZeneca Canada	AstraZeneca Canada(AstraZeneca)	The research reported in this article was funded by an unrestricted grant from AstraZeneca Canada to PMO. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2018, REP CAN CHRON DIS SU; Beckham JD, 2005, J INFECTION, V50, P322, DOI 10.1016/j.jinf.2004.07.011; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Byington CL, 2015, PEDIATRICS, V135, pE24, DOI 10.1542/peds.2014-2151; Campbell MJ, 1997, BRIT MED J, V315, P1012, DOI 10.1136/bmj.315.7114.1012; Hardelid P, 2013, INFLUENZA OTHER RESP, V7, P35, DOI 10.1111/j.1750-2659.2012.00345.x; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; Hewitt R, 2016, THER ADV RESPIR DIS, V10, P158, DOI 10.1177/1753465815618113; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hung IFN, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020259; Johnston N, 2001, AM J RESP CRIT CARE, V163, ps359; Johnston NW, 2013, CHEST, V144, P507, DOI 10.1378/chest.12-2308; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Lee WM, 2012, AM J RESP CRIT CARE, V186, P886, DOI 10.1164/rccm.201202-0330OC; Mallia Patrick, 2005, Proc Am Thorac Soc, V2, P361, DOI 10.1513/pats.200504-025SR; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Nicholson KG, 1996, BMJ-BRIT MED J, V313, P1119, DOI 10.1136/bmj.313.7065.1119; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; Ritchie AI, 2015, ANN AM THORAC SOC, V12, pS115, DOI 10.1513/AnnalsATS.201503-151AW; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; van Asten L, 2012, J INFECT DIS, V206, P628, DOI 10.1093/infdis/jis415; Zheng XY, 2018, ARCH VIROL, V163, P845, DOI 10.1007/s00705-017-3700-y; Zwaans WAR, 2014, J CLIN VIROL, V61, P181, DOI 10.1016/j.jcv.2014.06.025	28	35	39	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2020	15	2							e0228544	10.1371/journal.pone.0228544	http://dx.doi.org/10.1371/journal.pone.0228544			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9GK	32027687	Green Published, gold			2023-01-03	WOS:000534623800045
J	Rebollido-Rios, R; Venton, G; Sanchez-Redondo, S; Felip, CII; Fournet, G; Gonzalez, E; Fernandez, WR; Escuela, DOB; Di Stefano, B; Penarroche-Diaz, R; Martin, G; Ceylan, I; Costello, R; Perez-Alea, M				Rebollido-Rios, Rocio; Venton, Geoffroy; Sanchez-Redondo, Sara; Iglesias i Felip, Carmela; Fournet, Guy; Gonzalez, Elena; Fernandez, Wilber Romero; Escuela, Dasiel Oscar Borroto; Di Stefano, Barbara; Penarroche-Diaz, Reinier; Martin, Guillaume; Ceylan, Ismail; Costello, Regis; Perez-Alea, Mileidys			Dual disruption of aldehyde dehydrogenases 1 and 3 promotes functional changes in the glutathione redox system and enhances chemosensitivity in nonsmall cell lung cancer	ONCOGENE			English	Article							STEM-CELLS; EXPRESSION; MECHANISM; 1A1; INHIBITORS; MARKER; APOPTOSIS; SUBSTRATE; REDUCTASE; ALDH1A3	Aldehyde dehydrogenases (ALDHs) are multifunctional enzymes that oxidize diverse endogenous and exogenous aldehydes. We conducted a meta-analysis based on The Cancer Genome Atlas and Gene Expression Omnibus data and detected genetic alterations in ALDH1A1, ALDH1A3, or ALDH3A1, 86% of which were gene amplification or mRNA upregulation, in 31% of nonsmall cell lung cancers (NSCLCs). The expression of these isoenzymes impacted chemoresistance and shortened survival times in patients. We hypothesized that these enzymes provide an oxidative advantage for the persistence of NSCLC. To test this hypothesis, we used genetic and pharmacological approaches with DIMATE, an irreversible inhibitor of ALDH1/3. DIMATE showed cytotoxicity in 73% of NSCLC cell lines tested and demonstrated antitumor activity in orthotopic xenografts via hydroxynonenal-protein adduct accumulation, GSTO1-mediated depletion of glutathione and increased H2O2. Consistent with this result, ALDH1/3 disruption synergized with ROS-inducing agents or glutathione synthesis inhibitors to trigger cell death. In lung cancer xenografts with high to moderate cisplatin resistance, combination treatment with DIMATE promoted strong synergistic responses with tumor regression. These results indicate that NSCLCs with increased expression of ALDH1A1, ALDH1A3, or ALDH3A1 may be targeted by strategies involving inhibitors of these isoenzymes as monotherapy or in combination with chemotherapy to overcome patient-specific drug resistance.	[Rebollido-Rios, Rocio] Univ Cologne, Fac Med, Dept Internal Med 1, Cologne, Germany; [Rebollido-Rios, Rocio] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany; [Venton, Geoffroy; Costello, Regis] Ctr Hosp Univ La Conception, Serv Haematol & Cellular Therapy, Marseille, France; [Sanchez-Redondo, Sara] Spanish Natl Canc Res Ctr CNIO, Microenvironm & Metastasis Lab, Mol Oncol Programme, Madrid, Spain; [Iglesias i Felip, Carmela] Barcelona UAB, Dept Anat Pathol, Vall dHebron Hosp, Barcelona, Spain; [Fournet, Guy] Univ Claude Bernard Lyon1, Inst Chim & Biochim Mol & Supramol, CNRS, UMR 5246,Univ Lyon, Villeurbanne, France; [Gonzalez, Elena; Perez-Alea, Mileidys] Vall dHebron Res Inst, Oncol Res Program, Barcelona, Spain; [Fernandez, Wilber Romero; Escuela, Dasiel Oscar Borroto] Uppsala Univ, Dept Cell & Mol Biol, Computat Biol & Bioinformat, Uppsala, Sweden; [Di Stefano, Barbara] Univ Palermo, Dichirons Dept Surg, Lab Biol & Regenerat Med Plast Surg BIOPLAST, Oncol & Stomatol Sci, Palermo, Italy; [Penarroche-Diaz, Reinier] Reixmor, Barcelona, Spain; [Martin, Guillaume; Ceylan, Ismail; Perez-Alea, Mileidys] Adv Biodesign ABD, Unit Res Cellular & Mol Biol, St Priest, France	University of Cologne; University of Cologne; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitari Vall d'Hebron; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Uppsala University; University of Palermo	Perez-Alea, M (corresponding author), Vall dHebron Res Inst, Oncol Res Program, Barcelona, Spain.; Perez-Alea, M (corresponding author), Adv Biodesign ABD, Unit Res Cellular & Mol Biol, St Priest, France.	mileidys.perez@gmail.com	Borroto-Escuela, Dasiel Oscar/F-3627-2014; Rebollido-Rios, Rocio/ABD-5458-2020; di stefano, anna barbara/K-1447-2016	Borroto-Escuela, Dasiel Oscar/0000-0002-5736-373X; Rebollido-Rios, Rocio/0000-0002-8910-867X; di stefano, anna barbara/0000-0003-4323-8564; fournet, guy/0000-0002-2478-4810; Romero-Fernandez, Wilber/0000-0001-9868-8074; PEREZ, Mileidys/0000-0002-8739-8087	La Marato TV3 Foundation program of Catalonia, Spain; Prometheus program of SENESCYT	La Marato TV3 Foundation program of Catalonia, Spain; Prometheus program of SENESCYT	The authors are grateful to Dr Gerard Quash, who has been a motivation and inspiration for this work. The authors also thank Alessandro Ventura for imaging support, Dr Alberto Indacochea for his advice and support in database analysis and Dr Yokota Jun for kindly providing the H441, H23, H2122, Hop62, and H829 cell lines. This work was partially funded by the La Marato TV3 Foundation program of Catalonia, Spain and the Prometheus program of SENESCYT.	AHMAD T, 1985, J LAB CLIN MED, V105, P464; Alamgeer M, 2013, THORAX, V68, P1095, DOI 10.1136/thoraxjnl-2012-203021; Alison MR, 2010, J PATHOL, V222, P335, DOI 10.1002/path.2772; [Anonymous], R LANG ENV STAT COMP; Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Barta JA, 2019, ANN GLOB HEALTH, V85, DOI 10.5334/aogh.2419; Canino C, 2015, ONCOTARGET, V6, P12637, DOI 10.18632/oncotarget.3703; Castro JP, 2017, FREE RADICAL BIO MED, V111, P309, DOI 10.1016/j.freeradbiomed.2016.10.497; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cvek B, 2011, CURR CANCER DRUG TAR, V11, P332, DOI 10.2174/156800911794519806; Eramo A, 2010, ONCOGENE, V29, P4625, DOI 10.1038/onc.2010.207; Fournet G, 2013, CURR MED CHEM, V20, P527; Franco R, 2009, CELL DEATH DIFFER, V16, P1303, DOI 10.1038/cdd.2009.107; Franklin CC, 2002, AM J PATHOL, V160, P1887, DOI 10.1016/S0002-9440(10)61135-2; Gene Expression Omnibus (GEO), GEN EXPR OMN GEO; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; Gyorff B, 2019, KAPLAN MEIER PLOTTER; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Jackson Brian, 2011, Human Genomics, V5, P283; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; JONES P, 1968, BIOCHEM J, V110, P621, DOI 10.1042/bj1100621; Koppaka V, 2012, PHARMACOL REV, V64, P520, DOI 10.1124/pr.111.005538; Levi BP, 2009, BLOOD, V113, P1670, DOI 10.1182/blood-2008-05-156752; Li X, 2012, J THORAC ONCOL, V7, P1235, DOI 10.1097/JTO.0b013e318257cc6d; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Mahmood T, 2012, N AM J MED SCI, V4, P429, DOI 10.4103/1947-2714.100998; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Marchitti SA, 2008, EXPERT OPIN DRUG MET, V4, P697, DOI 10.1517/17425255.4.6.697 ; Marullo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081162; MCKENNA R, 1983, J LAB CLIN MED, V102, P102; Mordant P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026073; Morgan CA, 2015, CHEM-BIOL INTERACT, V234, P18, DOI 10.1016/j.cbi.2014.12.008; Muller M, 2002, FREE RADICAL BIO MED, V33, P1527, DOI 10.1016/S0891-5849(02)01087-0; Oncomine Platform, 2015, ONCOMINE PLATFORM; Patel M, 2008, LUNG CANCER, V59, P340, DOI 10.1016/j.lungcan.2007.08.033; Perez-Alea M, 2017, ONCOGENE, V36, P5695, DOI 10.1038/onc.2017.160; Ponten F, 2011, J INTERN MED, V270, P428, DOI 10.1111/j.1365-2796.2011.02427.x; Pors K, 2014, DRUG DISCOV TODAY, V19, P1953, DOI 10.1016/j.drudis.2014.09.009; Postmus PE, 2017, ANN ONCOL, V28, P1, DOI 10.1093/annonc/mdx222; Quash G, 1999, ADV EXP MED BIOL, V463, P97; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rodriguez-Torres M, 2016, CLIN EXP METASTAS, V33, P97, DOI 10.1007/s10585-015-9755-9; Shao CL, 2014, CLIN CANCER RES, V20, P4154, DOI 10.1158/1078-0432.CCR-13-3292; Shien K, 2012, LUNG CANCER, V77, P162, DOI 10.1016/j.lungcan.2012.02.006; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Singh S, 2013, FREE RADICAL BIO MED, V56, P89, DOI 10.1016/j.freeradbiomed.2012.11.010; Sullivan JP, 2010, CANCER RES, V70, P9937, DOI 10.1158/0008-5472.CAN-10-0881; Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920; Vasiliou V, 2013, CHEM-BIOL INTERACT, V202, P2, DOI 10.1016/j.cbi.2012.10.026; Vassalli G, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/3904645; Wei D, 2015, HEART LUNG CIRC, V24, P780, DOI 10.1016/j.hlc.2015.03.021; Yang HT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0909-x; Zhou L, 2019, CELL BIOL TOXICOL, V35, P161, DOI 10.1007/s10565-018-9444-y	56	20	20	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2756	2771		10.1038/s41388-020-1184-9	http://dx.doi.org/10.1038/s41388-020-1184-9		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32015486	Green Published, hybrid			2023-01-03	WOS:000510820900001
J	Watson, J; Cumming, O; Aunger, R; Deola, C; Chase, RP; Dreibelbis, R				Watson, Julie; Cumming, Oliver; Aunger, Robert; Deola, Claudio; Chase, Rachel P.; Dreibelbis, Robert			Child handwashing in an internally displaced persons camp in Northern Iraq: A qualitative multi-method exploration of motivational drivers and other handwashing determinants	PLOS ONE			English	Article							HYGIENE BEHAVIOR; HAND HYGIENE; INTERVIEWS; EMERGENCIES; DISEASES; IMPACT	Background Children in humanitarian situations are particularly vulnerable to diseases such as diarrhoea. Handwashing with soap can greatly reduce transmission but handwashing rates are often low and traditional interventions ineffective. To aid future intervention design, this study aims to understand the determinants of child handwashing and the key motivational drivers of children's behaviour within a specific humanitarian setting. Methods In an internally displaced persons camp in Northern Iraq we conducted a series of 36 friendship-paired interviews with children aged 7-12 years, six semi-structured caregiver interviews, and three semi-structured hygiene promoter interviews. Perceived determinants of child handwashing were explored qualitatively, and motivational drivers were explored quantitatively with children in a rating exercise. Qualitative data were analysed thematically, using an inductive approach, and logistic regression analyses of motive rating data were performed to determine the predicted probabilities of motives being rated as important. Results Access to soap and water was perceived to be high across all participant groups. Children, caregivers and hygiene promoters all perceive the determinants of child handwashing to be associated with familial role, environmental factors pertaining to location and quality of handwashing materials and facilities, and level of exposure to hygiene promotion, and children also attribute their handwashing to social norms. We find that children in this context are motived most by play and nurture. Conclusions Provision of soap and water alone is not sufficient to encourage children to practice hand-washing with soap in a humanitarian context. Our findings suggest that equal consideration should be given to the quality and location of handwashing materials and facilities and social norms could be leveraged to promote and enhance child handwashing. Motive-based interventions targeting play or nurture may be a promising approach and are likely most effective when used in conjunction, along with other motivational drivers such as affiliation and love.	[Watson, Julie; Cumming, Oliver; Aunger, Robert; Dreibelbis, Robert] London Sch Hyg & Trop Med, Dept Dis Control, London, England; [Deola, Claudio] Save Children, Humanitarian Dept, London, England	University of London; London School of Hygiene & Tropical Medicine; Save the Children	Watson, J (corresponding author), London Sch Hyg & Trop Med, Dept Dis Control, London, England.	julie.watson@lshtm.ac.uk		Watson, Julie/0000-0003-1487-2443; Chase, Rachel/0000-0002-1503-4954; Cumming, Oliver/0000-0002-5074-8709	Humanitarian Innovation Fund [82603245]	Humanitarian Innovation Fund	JW, OC and CD received financial support from the Humanitarian Innovation Fund, under Grant No. 82603245. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiello AE, 2008, AM J PUBLIC HEALTH, V98, P1372, DOI 10.2105/AJPH.2007.124610; [Anonymous], 2018, DETAILS OMITTED DOUB; Aunger R., 2014, APPL EVOLUTIONARY AN, P271; Aunger R, 2016, HEALTH PSYCHOL REV, V10, P425, DOI 10.1080/17437199.2016.1219673; Aunger R, 2010, SOC SCI MED, V70, P383, DOI 10.1016/j.socscimed.2009.10.038; Behailu Besha, 2016, Epidemiology: Open Access, V6, P247; Biran A, 2014, LANCET GLOB HEALTH, V2, pE145, DOI 10.1016/S2214-109X(13)70160-8; Biran A, 2012, TROP MED INT HEALTH, V17, P1133, DOI 10.1111/j.1365-3156.2012.03045.x; Biran A, 2009, TROP MED INT HEALTH, V14, P1303, DOI 10.1111/j.1365-3156.2009.02373.x; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Chittleborough CR, 2012, HEALTH EDUC RES, V27, P1055, DOI 10.1093/her/cys061; Connolly MA, 2004, LANCET, V364, P1974, DOI 10.1016/S0140-6736(04)17481-3; Curtis V, 2001, J INFECTION, V43, P75, DOI 10.1016/S0163-4453(01)90862-X; Curtis V, 2011, LANCET INFECT DIS, V11, P312, DOI 10.1016/S1473-3099(10)70224-3; Curtis VA, 2009, HEALTH EDUC RES, V24, P655, DOI 10.1093/her/cyp002; De Buck E., 2017, CAMPBELL SYST REV, V13, P1, DOI DOI 10.4073/CSR.2017.7; Dickie R, 2018, PSYCHOL HEALTH MED, V23, P154, DOI 10.1080/13548506.2017.1338736; Ejemot-Nwadiaro RI, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004265.pub3; Freeman MC, 2014, TROP MED INT HEALTH, V19, P906, DOI 10.1111/tmi.12339; Greenland K, 2016, LANCET GLOB HEALTH, V4, pE966, DOI 10.1016/s2214-109x(16)30262-5; Grimes JET, 2016, PLOS NEGLECT TROP D, V10, DOI [10.1371/journal.pntd.0004515, 10.1371/journal.pntd.0005236]; Grover E, 2018, AM J TROP MED HYG, V99, P934, DOI 10.4269/ajtmh.17-0903; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Hirai M, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13090868; Houssart J, 2011, INT J RES METHOD EDU, V34, P63, DOI 10.1080/1743727X.2011.552337; Hulland KRS, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-877; Karabakh, 2020, REF IDPS AZ BRIEF IN; Kouadio IK, 2012, EXPERT REV ANTI-INFE, V10, P95, DOI [10.1586/eri.11.155, 10.1586/ERI.11.155]; Mariwah S, 2012, TROP MED INT HEALTH, V17, P447, DOI 10.1111/j.1365-3156.2011.02950.x; McMichael C, 2016, SOC SCI MED, V163, P28, DOI 10.1016/j.socscimed.2016.06.051; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10; Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; Nandrup-Bus I, 2009, AM J INFECT CONTROL, V37, P820, DOI 10.1016/j.ajic.2009.06.012; Phillips RM, 2015, CONFL HEALTH, V9, DOI 10.1186/s13031-015-0065-2; QSR International Pty Ltd, 2017, DW1000 DAT SHEET; Schmidt WP, 2009, TROP MED INT HEALTH, V14, P1534, DOI 10.1111/j.1365-3156.2009.02404.x; Seimetz Elisabeth, 2017, BMC Res Notes, V10, P280, DOI 10.1186/s13104-017-2599-4; Sphere Association, 2018, SPHER HDB HUM CHART, VFourth; StataCorp, 2015, STAT STAT SOFTW REL; Stocks ME, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001605; Strunz EC, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001620; Talaat M, 2011, EMERG INFECT DIS, V17, P619, DOI 10.3201/eid1704.101353; Vujcic J, 2015, J WATER SANIT HYG DE, V5, P574, DOI 10.2166/washdev.2015.009; Watson J, 2019, INT J HYG ENVIR HEAL, V222, P177, DOI 10.1016/j.ijheh.2018.09.002; Willmott M, 2016, ARCH DIS CHILD, V101, P42, DOI 10.1136/archdischild-2015-308875; Wilson AD, 2016, QUAL REP, V21, P1549	46	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2020	15	2							e0228482	10.1371/journal.pone.0228482	http://dx.doi.org/10.1371/journal.pone.0228482			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP9DJ	32012206	gold, Green Published, Green Submitted			2023-01-03	WOS:000534615800037
J	Lee, CH; Chen, PH; Lin, C; Wang, CY; Ho, CL				Lee, Cho-Hao; Chen, Po-Huang; Lin, Chin; Wang, Chieh-Yung; Ho, Ching-Liang			A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia	PLOS ONE			English	Article							PROGRESSION-FREE SURVIVAL; PHASE-III TRIAL; LENALIDOMIDE MAINTENANCE; RITUXIMAB MAINTENANCE; DOUBLE-BLIND; OPEN-LABEL; CLL; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; FLUDARABINE	Background Chronic lymphocytic leukemia (CLL) is incurable through conventional chemoimmunotherapy regimens. Despite durable responses to front-line therapy and sustained remission rates in patients with CLL, a majority of patients eventually relapse in 5 years of initial treatment. The depth of the response may affect the length of response. Maintenance therapies were aimed to deep remissions and extend the period of disease quiescence. Lenalidomide, rituximab and ofatumumab had demonstrated some efficacy as a maintenance therapy compared to no intervention for CLL patients. The relative effect on disease control and safety between different maintenance therapies were unclear. Methods We performed a systematic literature review and network meta-analysis to evaluate relative effect on disease control and safety of current available maintenance therapies. We searched PubMed, Embase and Cochrane database up to March 6, 2019. Relevant reference of review article and conference abstract including European Hematology Association Annual Meeting (EHA 2018), American Society of Hematology Annual Meeting (ASH 2018) and American Society of Clinical Oncology Annual Meeting (ASCO 2018) were searched. Randomized controlled trials (RCT) involving current available maintenance therapy including "Lenalidomide", "Rituximab", "Ofatumumab", "Ibrutinib", "Idelalisib", "Venetoclax"and "Obinutuzumab"were eligible. Outcomes of interest included progression-free survival (PFS), overall survival (OS) and serious adverse events (SAE) in CLL patients received subsequent maintenance therapy. Two authors CHL and CL) independently assessed eligibility for all identified citations and extracted data from the original trial reports. The selected studies' risk of bias was assessed following the guidelines of Cochrane Collaboration Handbook. Results In total, six phase III RCTs with total 1,615 CLL patients were identified. Maintenance therapy using lenalidomide, rituximab, and ofatumumab demonstrated a statistically significant effect in prolongation of progression-free survival (HR:0.37, 95% CI: 0.27-0.50 of lenalidomide; HR:0.50, 95% CI: 0.38-0.66 of rituximab; HR:0.52, 95% Cl:0.41-0.66 of ofatumumab, separately) compared with no intervention; however, for overall survival, the effect of maintenance therapy showed no significant difference versus no intervention (HR: 0.89, 95% CI: 0.70-1.14). Lenalidomide showed the best efficacy for PFS (HR: 0.37, 95% CI: 0.27-0.50, Probability of being best treatment: 96%). Conclusions Our network meta-analysis provided an integrated overview of relative efficacy and safety of different maintenance therapies in CLL. All maintenance therapies were effective in reducing the risk of disease progression versus no intervention. Based on current best evidence, maintenance therapy with lenalidomide is the most efficacious option.	[Lee, Cho-Hao; Chen, Po-Huang; Ho, Ching-Liang] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Hematol & Oncol Med, Taipei, Taiwan; [Lin, Chin] Natl Def Med Ctr, Sch Publ Hlth, Taipei, Taiwan; [Lin, Chin] Natl Def Med Ctr, Dept Res & Dev, Taipei, Taiwan; [Wang, Chieh-Yung] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, Taipei, Taiwan	National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital	Ho, CL (corresponding author), Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Hematol & Oncol Med, Taipei, Taiwan.	charileho22623@gmail.com	Lee, Cho-Hao/AAT-1548-2021; Chen, Po-Huang/AAX-2927-2021; Lin, Chin/M-2832-2015	Lee, Cho-Hao/0000-0002-6061-5168; Chen, Po-Huang/0000-0002-0280-6417; Lin, Chin/0000-0003-2337-2096	Fund of Tri-Service General Hospital/National Defense Medical Center [TSGH-C108200]	Fund of Tri-Service General Hospital/National Defense Medical Center	Fund of Tri-Service General Hospital/National Defense Medical Center (No. TSGH-C108200)	[Anonymous], 2013, BLOOD, V122, P3951, DOI 10.1182/blood-2013-05-502773; [Anonymous], 2014, REV MAN REVMAN; Badoux XC, 2011, BLOOD, V117, P3016, DOI 10.1182/blood-2010-08-304683; Beauchemin C, 2015, CURR ONCOL, V22, pE148, DOI 10.3747/co.22.2119; Byrd JC, 2014, NEW ENGL J MED, V371, P213, DOI 10.1056/NEJMoa1400376; Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654; Chanan-Khan AA, 2017, LANCET HAEMATOL, V4, pE534, DOI 10.1016/S2352-3026(17)30168-0; Cramer P, 2013, LEUKEMIA LYMPHOMA, V54, P1821, DOI 10.3109/10428194.2013.796050; Dartigeas C, 2018, LANCET HAEMATOL, V5, pE82, DOI 10.1016/S2352-3026(17)30235-1; Ding W, 2017, BLOOD, V129, P3419, DOI 10.1182/blood-2017-02-765685; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eichhorst B, 2015, ANN ONCOL, V26, pV78, DOI 10.1093/annonc/mdv303; Fink AM, 2017, LANCET HAEMATOL, V4, pE475, DOI 10.1016/S2352-3026(17)30171-0; Foa R, 2014, AM J HEMATOL, V89, P480, DOI 10.1002/ajh.23668; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Greil R, 2016, LANCET HAEMATOL, V3, pE317, DOI 10.1016/S2352-3026(16)30045-X; Grever MR, 2007, J CLIN ONCOL, V25, P799, DOI 10.1200/JCO.2006.08.3089; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hallek M, 2017, AM J HEMATOL, V92, P946, DOI 10.1002/ajh.24826; Hallek M, 2016, LANCET ONCOL, V17, P779, DOI 10.1016/S1470-2045(16)30029-8; Howlader N, 2015, SEER CANC STAT REV 1; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Jackson D, 2012, STAT MED, V31, P3805, DOI 10.1002/sim.5453; Jansen JP, 2014, VALUE HEALTH, V17, P157, DOI 10.1016/j.jval.2014.01.004; Kim C, 2016, MAYO CLIN PROC, V91, P713, DOI 10.1016/j.mayocp.2016.02.012; Krahn U, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-35; Leyva F, 2015, EUROPACE, V17, P339, DOI 10.1093/europace/euu384; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; (NCCN) NCCN, 2016, NCCN CLIN PRACT GUID; Oughton JB, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2107-0; Palumbo A, 2012, NEW ENGL J MED, V366, P1759, DOI 10.1056/NEJMoa1112704; Prasad V, 2015, JAMA INTERN MED, V175, P1389, DOI 10.1001/jamainternmed.2015.2829; Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549; Robak T, 2018, EUR J HAEMATOL, V100, P465, DOI 10.1111/ejh.13042; Robak T, 2010, J CLIN ONCOL, V28, P1756, DOI 10.1200/JCO.2009.26.4556; Roberts C, 1999, BRIT MED J, V319, P185, DOI 10.1136/bmj.319.7203.185; Rucker G, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0060-8; Salanti G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099682; Salanti G, 2012, RES SYNTH METHODS, V3, P80, DOI 10.1002/jrsm.1037; Shi Q, 2018, J CLIN ONCOL, V36, P2593, DOI 10.1200/JCO.2018.77.9124; Shindiapina P, 2016, AM J HEMATOL-ONCOL, V12, P25; Siddon AJ, 2013, AM J CLIN PATHOL, V139, P708, DOI 10.1309/AJCPLIR4GZWX3XKA; Statistics Canada, 2016, TABL 1030553 NEW CAS; Stilgenbauer S, 2010, HEMATOL-AM SOC HEMAT, P481, DOI 10.1182/asheducation-2010.1.481; Strati P, 2017, HAEMATOLOGICA, V102, P494, DOI 10.3324/haematol.2017.171561; Thieblemont C T H, 2016, AM SOC HEMATOLOGY; Thompson PA, 2016, BLOOD, V127, P279, DOI 10.1182/blood-2015-08-634816; van Oers MHJ, 2015, LANCET ONCOL, V16, P1370, DOI 10.1016/S1470-2045(15)00143-6; Wendtner CM, 2004, LEUKEMIA, V18, P1093, DOI 10.1038/sj.leu.2403354; Wierda W, 2005, J CLIN ONCOL, V23, P4070, DOI 10.1200/JCO.2005.12.516; Wierda WG, 2017, J NATL COMPR CANC NE, V15, P293, DOI 10.6004/jnccn.2017.0030; Zelenetz AD, 2010, J NATL COMPR CANC NE, V8, P288, DOI 10.6004/jnccn.2010.0021	53	4	4	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2020	15	1							e0226879	10.1371/journal.pone.0226879	http://dx.doi.org/10.1371/journal.pone.0226879			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9AX	31995577	Green Published, gold			2023-01-03	WOS:000534609400018
J	Hamad, Y; Maddox, KEJ; Powderly, WG				Hamad, Yasir; Maddox, Karen E. Joynt; Powderly, William G.			COVID-19 and Outpatient Parenteral Antimicrobial Therapy: The Need to Protect Vulnerable Medicare Beneficiaries	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Hamad, Yasir; Maddox, Karen E. Joynt; Powderly, William G.] Washington Univ, Sch Med, St Louis, MO USA; [Maddox, Karen E. Joynt; Powderly, William G.] Washington Univ, Inst Publ Hlth, St Louis, MO 63110 USA; [Hamad, Yasir; Powderly, William G.] Campus Box 8051,4523 Clayton Ave, St Louis, MO 63110 USA; [Maddox, Karen E. Joynt] Campus Box 8217,660 South Euclid Ave, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Hamad, Y (corresponding author), Campus Box 8051,4523 Clayton Ave, St Louis, MO 63110 USA.	yhamad@wustl.edu		Powderly, William/0000-0001-7808-3086	National Heart, Lung, and Blood Institute [R01HL143421]; National Institute on Aging [R01AG060935]; Washington University Institute of Clinical and Translational Sciences [UL1TR002345]; National Center for Advancing Translational Sciences of the National Institutes of Health	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Washington University Institute of Clinical and Translational Sciences; National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Dr. Joynt Maddox receives research support from the National Heart, Lung, and Blood Institute (R01HL143421) and National Institute on Aging (R01AG060935). Dr. Powderly was supported by the Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 from the National Center for Advancing Translational Sciences of the National Institutes of Health.	Centers for Disease Control and Prevention, PROV DEATH COUNTS CO; Centers for Disease Control and Prevention, 2020, INT CLIN GUID MAN PA; Cubanski J, 2019, 10 THINGS KNOW MED D; Hamad Y, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz363; Keller S, 2015, CLIN INFECT DIS, V61, P1890, DOI 10.1093/cid/civ750; Keller SC, 2018, PHARMACOTHERAPY, V38, P476, DOI 10.1002/phar.2099; Paladino JA, 2010, CLIN INFECT DIS, V51, pS198, DOI 10.1086/653520; RUCKER RW, 1974, PEDIATRICS, V54, P358; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994	9	5	5	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	2020	173	5					383	+		10.7326/M20-1774	http://dx.doi.org/10.7326/M20-1774			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK9XI	32422072	Green Published			2023-01-03	WOS:000567080900014
J	Areri, HA; Marshall, A; Harvey, G				Areri, Habtamu Abera; Marshall, Amy; Harvey, Gillian			Interventions to improve self-management of adults living with HIV on Antiretroviral Therapy: A systematic review	PLOS ONE			English	Review							SYMPTOM MANAGEMENT; WOMEN; ADHERENCE; OUTCOMES; PROGRAM; CARE; PERSPECTIVES; EDUCATION; BEHAVIOR; CONTEXT	Introduction Since its initial recognition, HIV has been responsible for around 35 million deaths globally. The introduction of Antiretroviral Therapy has helped to reduce mortality from HIV. However, the resulting increased longevity has influenced the experience of people living with HIV, which now manifests as a chronic condition requiring effective self-management. This review aimed to identify and evaluate the effectiveness of interventions to improve self-management of adults living with HIV on Antiretroviral therapy. Methods The review included published experimental studies addressing interventions to improve self-management of adults living with HIV on Antiretroviral Therapy. Studies were included if they addressed two or more outcomes of self-management, as defined by the Theory of Individual and Family Self-Management. The search covered four databases and was limited to papers published in the English language from 2001 to March 30, 2019. The reference lists of included studies were further searched for additional studies. Two independent reviewers using the Joanna Briggs Institute Meta-Analysis of Statistics Assessment and Review Instrument (JBI SUMARI) assessed the methodological quality of the reviewed papers. Data extraction was undertaken using the JBI SUMARI standardized data extraction tool. As the included papers were not homogeneous, it was not possible to conduct a meta-analysis. A narrative synthesis was undertaken to synthesize the findings of the included studies. Results The search identified 337 articles from which 10 experimental and 2 quasi-experimental studies were included. The total participant sample in the included studies was 1661 adults living with HIV. The overall evidence quality of the findings was considered moderate. Many of the studies included in this review comprised multi-component interventions to improve self-management. Skills training, in conjunction with other forms of interventions, particularly phone counseling, was commonly employed and generally effective in improving self-management outcomes. Counseling with a symptom management manual was another employed and effective intervention, followed by technology-assisted self-management interventions. The most common outcomes measured were maintaining medication adherence and quality of life, followed by symptom management, self-efficacy, coping, and social support. Conclusions Interventions to improve self-management varied across studies. However, promising outcomes achieved in the majority of studies through interventions comprising a combination of skills training, phone counseling, counseling with symptom management manuals, and technology-assisted interventions.	[Areri, Habtamu Abera; Marshall, Amy; Harvey, Gillian] Univ Adelaide, Adelaide Nursing Sch, Fac Hlth & Med Sci, Adelaide, SA, Australia; [Areri, Habtamu Abera] Addis Ababa Univ, Sch Nursing & Midwifery, Coll Hlth Sci, Addis Ababa, Ethiopia	University of Adelaide; Addis Ababa University	Areri, HA (corresponding author), Univ Adelaide, Adelaide Nursing Sch, Fac Hlth & Med Sci, Adelaide, SA, Australia.; Areri, HA (corresponding author), Addis Ababa Univ, Sch Nursing & Midwifery, Coll Hlth Sci, Addis Ababa, Ethiopia.	habtamu.areri@adelaide.edu	Marshall, Amy/AAO-5982-2020; Harvey, Gillian/J-9646-2014	Marshall, Amy/0000-0002-7084-3690; Harvey, Gillian/0000-0003-0937-7819	University of Adelaide Nursing School	University of Adelaide Nursing School	We want to thank The University of Adelaide Nursing School for librarian support.	Aantjes CJ, 2014, PATIENT EDUC COUNS, V95, P185, DOI 10.1016/j.pec.2014.01.007; [Anonymous], 2017, FACT SHEET LATEST ST; Apostolo Joao, 2018, JBI Database System Rev Implement Rep, V16, P140, DOI 10.11124/JBISRIR-2017-003382; Areri H., 2018, SYSTEMATIC REV PROTO; Aromataris E, 2017, J BRIGGS I REV MANUA; Bourbeau J, 2004, PATIENT EDUC COUNS, V52, P271, DOI 10.1016/S0738-3991(03)00102-2; Chiou PY, 2006, J ADV NURS, V55, P169, DOI 10.1111/j.1365-2648.2006.03902.x; Chiou PY, 2004, AIDS PATIENT CARE ST, V18, P539, DOI 10.1089/1087291042222992; Cote J, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.3264; EMOH, 2014, NAT GUID COMPR HIV P; Giordano TP, 2016, CLIN INFECT DIS, V63, P678, DOI 10.1093/cid/ciw322; Grady PA, 2014, AM J PUBLIC HEALTH, V104, pE25, DOI 10.2105/AJPH.2014.302041; Grainge M, 2015, EXCLUDING SMALL STUD; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Inouye J, 2001, J Assoc Nurses AIDS Care, V12, P71, DOI 10.1016/S1055-3290(06)60264-1; Johnson MO, 2011, ANN BEHAV MED, V41, P83, DOI 10.1007/s12160-010-9230-4; Kalichman SC, 2011, AIDS PATIENT CARE ST, V25, P303, DOI 10.1089/apc.2010.0367; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Martin F, 2013, AIDS PATIENT CARE ST, V27, P697, DOI 10.1089/apc.2013.0254; Merolli M, 2013, J BIOMED INFORM, V46, P957, DOI 10.1016/j.jbi.2013.04.010; Miles MS, 2003, NURS RES, V52, P350, DOI 10.1097/00006199-200311000-00002; Millard T, 2016, AIDS BEHAV, V20, P1907, DOI 10.1007/s10461-016-1301-5; Millard T, 2013, AIDS PATIENT CARE ST, V27, P103, DOI 10.1089/apc.2012.0294; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Richard AA, 2011, J NURS SCHOLARSHIP, V43, P255, DOI 10.1111/j.1547-5069.2011.01404.x; Russell S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147896; Ryan P, 2009, NURS OUTLOOK, V57, P217, DOI 10.1016/j.outlook.2008.10.004; Schulman-Green D, 2012, J NURS SCHOLARSHIP, V44, P136, DOI 10.1111/j.1547-5069.2012.01444.x; Smith SR, 2003, PATIENT EDUC COUNS, V50, P187; Swendeman D, 2009, AIDS CARE, V21, P1321, DOI 10.1080/09540120902803158; Wang KR, 2016, APPL NURS RES, V32, P91, DOI 10.1016/j.apnr.2016.06.004; Webel AR, 2019, AIDS BEHAV, V23, P627, DOI 10.1007/s10461-018-2319-7; Webel AR, 2013, SOC SCI MED, V87, P147, DOI 10.1016/j.socscimed.2013.03.037; Webel AR, 2012, WOMEN HEALTH ISS, V22, pE27, DOI 10.1016/j.whi.2011.05.010; Webel AR, 2010, AIDS CARE, V22, P1029, DOI 10.1080/09540120903214389	35	15	15	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2020	15	5							e0232709	10.1371/journal.pone.0232709	http://dx.doi.org/10.1371/journal.pone.0232709			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU0RD	32392245	gold, Green Published			2023-01-03	WOS:000537470300020
J	Hall, W; Degenhardt, L; Hickman, M				Hall, Wayne; Degenhardt, Louisa; Hickman, Matthew			Generational trends in US opioid-overdose deaths	NATURE MEDICINE			English	Editorial Material							DRUG		[Hall, Wayne] Univ Queensland, Ctr Youth Subst Abuse Res, Brisbane, Qld, Australia; [Hall, Wayne] Univ Queensland, Queensland Alliance Environm Hlth, Brisbane, Qld, Australia; [Degenhardt, Louisa] Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia; [Hickman, Matthew] Univ Bristol Sch Med, Populat Hlth Sci, Bristol, Avon, England	University of Queensland; University of Queensland; University of New South Wales Sydney; University of Bristol	Hall, W (corresponding author), Univ Queensland, Ctr Youth Subst Abuse Res, Brisbane, Qld, Australia.; Hall, W (corresponding author), Univ Queensland, Queensland Alliance Environm Hlth, Brisbane, Qld, Australia.	w.hall@uq.edu.au	Hickman, Matthew/Y-2400-2019; Hall, Wayne D/A-3283-2008	Hickman, Matthew/0000-0001-9864-459X; Hall, Wayne D/0000-0003-1984-0096	MRC [MR/N00616X/1] Funding Source: UKRI; Medical Research Council [MR/N00616X/1] Funding Source: Medline; Department of Health [RP-DG-0610-10055, RP-PG-0616-20008] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health		Boslett AJ, 2020, ADDICTION, V115, P1308, DOI 10.1111/add.14943; Case A, 2015, P NATL ACAD SCI USA, V112, P15078, DOI 10.1073/pnas.1518393112; Degenhardt L, 2019, LANCET, V394, P1560, DOI 10.1016/S0140-6736(19)32229-9; Hall WD, 1999, MED J AUSTRALIA, V171, P34, DOI 10.5694/j.1326-5377.1999.tb123495.x; Jalal H, 2020, NAT MED, V26, P699, DOI 10.1038/s41591-020-0855-y; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; Saloner B, 2018, PUBLIC HEALTH REP, V133, p24S, DOI 10.1177/0033354918793627; Strang J, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-019-0137-5; Strang J, 2019, DRUGS, V79, P1395, DOI 10.1007/s40265-019-01154-5; Wakeman SE, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.20622; Wilson N, 2020, MMWR-MORBID MORTAL W, V69, P290, DOI 10.15585/mmwr.mm6911a4	12	4	4	0	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2020	26	5					651	652		10.1038/s41591-020-0875-7	http://dx.doi.org/10.1038/s41591-020-0875-7		MAY 2020	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ML1JP	32367061				2023-01-03	WOS:000530244500003
J	Xiao, WJ; Yan, L; Chen, LP; Fu, GF; Yang, HT; Yang, C; Yan, HJ; Wei, CY				Xiao, Wenjing; Yan, Li; Chen, Liping; Fu, Gengfeng; Yang, Haitao; Yang, Cui; Yan, Hongjing; Wei, Chongyi			Sexual network distribution of HIV self-testing kits: Findings from the process evaluation of an intervention for men who have sex with men in China	PLOS ONE			English	Article							ACCEPTABILITY; FREQUENCY; GAY	Background The World Health Organization has recommended HIV self-testing (HIVST) as an alternative testing strategy given the limitations of facility-based testing. While the benefits of HIV self-testing have been demonstrated at the individual level among men who have sex with men (MSM), limited data exist on if this testing approach can be effectively diffused through individuals' social or sexual networks. The objectives of this study were to examine patterns and correlates of HIVST distribution within Chinese MSM's sexual networks. Methods Data used for this analysis was a part of the process evaluation of an HIVST intervention trial among MSM in Nanjing, China. Between May and October 2017, we enrolled 400 men into the trial. Participants assigned to the intervention group (N = 200) were given three HIVST kits at baseline and could request more during the follow-up periods. We incorporated measures for process evaluation in the self-administered online follow-up surveys. This analysis reported findings from the three-month follow-up survey in the intervention group. Frequencies and percentages were used to describe characteristics of participants who distributed kits to their sexual partners as well as patterns of distribution. Multivariable logistic regression was conducted to identify independent correlates of participants who distributed the kits. Results Of the 177 participants retained (88.5%) at the three-month follow-up, 72 (40.7%) distributed one or more kits to either primary or casual partners. About half of distributors (51.4%) gave one HIVST kit to their sexual partners while 15.3% distributed 3 or more. Over half gave these kits (58.3%) to primary sexual partners while 27.8% reported giving the kits to both primary and casual partners. About half (54.2%) of distributors used the kits together with their partners. Compared to participants who had an HIV test in the past six months, those who tested over six months ago or never tested had significantly lower odds of distributing the kits (AOR = 0.484, 95% CI: 0.250-0.983, p = 0.032). Compared to those who had not used the kits themselves, participants who did had significantly higher odds of distributing the kits (AOR = 3.345, 95% CI: 1.488-7.517, p = 0.003). Participants who reported higher HIV testing efficacy had 2.051 fold greater odds (95% CI: 1.062-3.961, p = 0.033) of distributing the kits compared to those who had lower efficacy. Conclusion Our study demonstrated that a sexual network-based approach to distributing HIVST among Chinese MSM is feasible and can be a promising strategy to improve the effectiveness of HIVST programs including its reach to untested men. Such approach should be complimented by intervention components that enhance HIV testing efficacy and improve experiences of HIVST.	[Xiao, Wenjing] Nanjing Med Univ, Nanjing, Jiangsu, Peoples R China; [Yan, Li] Xuzhou Cent Hosp, Xuzhou, Jiangsu, Peoples R China; [Chen, Liping; Fu, Gengfeng; Yan, Hongjing] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Jiangsu, Peoples R China; [Yang, Haitao] Jiangsu Inst Parasit Dis, Wuxi, Jiangsu, Peoples R China; [Yang, Cui] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA; [Wei, Chongyi] Rutgers Sch Publ Hlth, Dept Hlth Behav Soc & Policy, Piscataway, NJ 08854 USA	Nanjing Medical University; Jiangsu Provincial Center for Disease Control & Prevention; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Yan, HJ (corresponding author), Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Jiangsu, Peoples R China.; Wei, CY (corresponding author), Rutgers Sch Publ Hlth, Dept Hlth Behav Soc & Policy, Piscataway, NJ 08854 USA.	yanhongjing@hotmail.com; Chongyi.Wei@rutgers.edu			US National Institute of Mental Health [R34MH109359]	US National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	CW received funding from the US National Institute of Mental Health (grant number: R34MH109359; https://www.nimh.nih.gov/index.shtml).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339; Campbell CK, 2018, AIDS BEHAV, V22, P2387, DOI 10.1007/s10461-018-2083-8; Chen Q, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201953; Choko AT, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001873; Fan L., 2017, CHIN J PREV MED, V51, P970; Figueroa C, 2018, LANCET HIV, V5, pE277, DOI 10.1016/S2352-3018(18)30044-4; Figueroa C, 2015, AIDS BEHAV, V19, P1949, DOI 10.1007/s10461-015-1097-8; Gu J, 2011, PUBLIC HEALTH, V125, P275, DOI 10.1016/j.puhe.2011.01.010; Jamil MS, 2017, LANCET HIV, V4, pE241, DOI 10.1016/S2352-3018(17)30023-1; Krause J, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-735; Li RH, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3806-2; Lightfoot MA, 2018, JAIDS-J ACQ IMM DEF, V79, P38, DOI [10.1097/qai.0000000000001726, 10.1097/QAI.0000000000001726]; Lippman SA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206849; Lippman SA, 2018, JAIDS-J ACQ IMM DEF, V77, P279, DOI [10.1097/QAI.0000000000001601, 10.1097/qai.0000000000001601]; Lippman SA, 2016, AIDS BEHAV, V20, P928, DOI 10.1007/s10461-015-1236-2; Pai NP, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001414; Ren XL, 2017, BIOMED ENVIRON SCI, V30, P407, DOI 10.3967/bes2017.054; Starks TJ, 2013, AIDS BEHAV, V17, P2732, DOI 10.1007/s10461-013-0425-0; Tang WM, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002645; Tao J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102812; UNAIDS, GLOB HIV AIDS STAT 2; Wei CY, 2018, SEX TRANSM DIS, V45, P818, DOI 10.1097/OLQ.0000000000000885; WHO, 2016, GUID HIV SELF TEST P; Wu Z Y, 2018, Zhonghua Liu Xing Bing Xue Za Zhi, V39, P707, DOI 10.3760/cma.j.issn.0254-6450.2018.06.002; [吴尊友 Wu Zunyou], 2016, [中华疾病控制杂志, Chinese Journal of Disease Control & Prevention], V20, P1187; Yan HJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154466; Zhang L, 2013, LANCET INFECT DIS, V13, P955, DOI 10.1016/S1473-3099(13)70245-7; Zhu Z, 2018, BMJ OPEN, V9; Zou HC, 2012, AIDS BEHAV, V16, P1717, DOI 10.1007/s10461-012-0225-y	29	12	12	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2020	15	4							e0232094	10.1371/journal.pone.0232094	http://dx.doi.org/10.1371/journal.pone.0232094			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9QD	32320457	gold, Green Published			2023-01-03	WOS:000536028800055
J	Liu, WS; Stansbury, C; Singh, K; Ryan, AM; Sukul, D; Mahmoudi, E; Waljee, A; Zhu, J; Nallamothu, BK				Liu, Wenshuo; Stansbury, Cooper; Singh, Karandeep; Ryan, Andrew M.; Sukul, Devraj; Mahmoudi, Elham; Waljee, Akbar; Zhu, Ji; Nallamothu, Brahmajee K.			Predicting 30-day hospital readmissions using artificial neural networks with medical code embedding	PLOS ONE			English	Article							RISK; ADJUSTMENT; COVARIANCE; MODELS; RATES	Reducing unplanned readmissions is a major focus of current hospital quality efforts. In order to avoid unfair penalization, administrators and policymakers use prediction models to adjust for the performance of hospitals from healthcare claims data. Regression-based models are a commonly utilized method for such risk-standardization across hospitals; however, these models often suffer in accuracy. In this study we, compare four prediction models for unplanned patient readmission for patients hospitalized with acute myocardial infarction (AMI), congestive health failure (HF), and pneumonia (PNA) within the Nationwide Readmissions Database in 2014. We evaluated hierarchical logistic regression and compared its performance with gradient boosting and two models that utilize artificial neural networks. We show that unsupervised Global Vector for Word Representations embedding representations of administrative claims data combined with artificial neural network classification models improves prediction of 30-day readmission. Our best models increased the AUC for prediction of 30-day readmissions from 0.68 to 0.72 for AMI, 0.60 to 0.64 for HF, and 0.63 to 0.68 for PNA compared to hierarchical logistic regression. Furthermore, risk-standardized hospital readmission rates calculated from our artificial neural network model that employed embeddings led to reclassification of approximately 10% of hospitals across categories of hospital performance. This finding suggests that prediction models that incorporate new methods classify hospitals differently than traditional regression-based approaches and that their role in assessing hospital performance warrants further investigation.	[Liu, Wenshuo; Singh, Karandeep; Mahmoudi, Elham; Waljee, Akbar; Zhu, Ji; Nallamothu, Brahmajee K.] Univ Michigan, Michigan Integrated Ctr Hlth Analyt & Med Predict, Ann Arbor, MI 48109 USA; [Stansbury, Cooper] Univ Michigan, Sch Med, Dept Computat Biol & Bioinformat, Ann Arbor, MI USA; [Stansbury, Cooper] Univ Michigan, Sch Nursing, Dept Syst Populat & Leadership, Ann Arbor, MI 48109 USA; [Singh, Karandeep] Univ Michigan, Sch Med, Div Learning & Knowledge Syst, Dept Learning Hlth Sci, Ann Arbor, MI USA; [Singh, Karandeep] Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, Ann Arbor, MI USA; [Ryan, Andrew M.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA; [Sukul, Devraj; Nallamothu, Brahmajee K.] Univ Michigan, Sch Med, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48109 USA; [Mahmoudi, Elham] Univ Michigan, Sch Med, Dept Family Med, Ann Arbor, MI USA; [Waljee, Akbar] Univ Michigan, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Ann Arbor, MI USA; [Waljee, Akbar; Nallamothu, Brahmajee K.] VA Ann Arbor Hlth Care Syst, VA Ctr Clin Management Res, Ann Arbor, MI 48105 USA; [Zhu, Ji] Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan	Nallamothu, BK (corresponding author), Univ Michigan, Michigan Integrated Ctr Hlth Analyt & Med Predict, Ann Arbor, MI 48109 USA.; Nallamothu, BK (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48109 USA.; Nallamothu, BK (corresponding author), VA Ann Arbor Hlth Care Syst, VA Ctr Clin Management Res, Ann Arbor, MI 48105 USA.	bnallamo@med.umich.edu	Sukul, Devraj/ABE-2544-2020; Waljee, Akbar K/G-2067-2010	Waljee, Akbar K/0000-0003-1964-8790; Mahmoudi, Elham/0000-0002-9746-8165	MIDAS Challenge award Michigan Institute for Data Science	MIDAS Challenge award Michigan Institute for Data Science	MIDAS Challenge award Michigan Institute for Data Science https://midas.umich.edu/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, P C EUR CHAPT ASS CO; [Anonymous], 2016, 2016 CONDITION SPECI, P112; [Anonymous], 2019, SCALABLE PORTABLE DI; Beam A.L., 2018, CLIN CONCEPT EMBEDDI; Bengio Y, 2009, FOUND TRENDS MACH LE, V2, P1, DOI 10.1561/2200000006; Chakraborty H, 2017, HEALTH SERV RES, V52, P1040, DOI 10.1111/1475-6773.12579; CHANG IM, 1982, J CHRON DIS, V35, P669, DOI 10.1016/0021-9681(82)90019-4; Chen C, 2014, J HOSP MED, V9, P681, DOI 10.1002/jhm.2213; Chen TQ, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P785, DOI 10.1145/2939672.2939785; Choi E, 2017, KDD'17: PROCEEDINGS OF THE 23RD ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P787, DOI 10.1145/3097983.3098126; Choi Youngduck, 2016, AMIA Jt Summits Transl Sci Proc, V2016, P41; Deng L., 2014, FOND T SIGN PROC, V7, P197, DOI [10.1561/2000000039, DOI 10.1561/2000000039]; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Finlayson SG, 2014, SCI DATA, V1, DOI 10.1038/sdata.2014.32; Frizzell JD, 2017, JAMA CARDIOL, V2, P204, DOI 10.1001/jamacardio.2016.3956; Futoma J, 2015, J BIOMED INFORM, V56, P229, DOI 10.1016/j.jbi.2015.05.016; Goodfellow I, 2016, ADAPT COMPUT MACH LE, P1; Healthcare Cost and Utilization Project (HCUP, 2015, NRD OV; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Krompass D, 2014, EXPLOITING LATENT EM, V29, DOI [10.1007/s13218-014-0344-x, DOI 10.1007/S13218-014-0344-X]; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; LANE PW, 1982, BIOMETRICS, V38, P613, DOI 10.2307/2530043; LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539; LEE J, 1981, J CHRON DIS, V34, P415, DOI 10.1016/0021-9681(81)90040-0; Mortazavi BJ, 2016, CIRC-CARDIOVASC QUAL, V9, P629, DOI 10.1161/CIRCOUTCOMES.116.003039; Pennington J., 2014, PROC 2014 C EMPIRICA, P1532, DOI 10.3115/v1/D14-1162; Pope GC, 2004, HEALTH CARE FINANC R, V25, P119; Rajkomar A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0029-1; Rosenbaum S, 2011, PUBLIC HEALTH REP, V126, P130, DOI 10.1177/003335491112600118; Shickel B, 2017, DEEP EHR SURVEY RECE, DOI [10.1109/JBHI.2017.2767063, DOI 10.1109/JBHI.2017.2767063]; Sukul D, 2017, AM J MED, V130, DOI 10.1016/j.amjmed.2017.05.025; Voulodimos A, 2018, COMPUT INTEL NEUROSC, V2018, DOI 10.1155/2018/7068349; Young T, 2018, IEEE COMPUT INTELL M, V13, P55, DOI 10.1109/MCI.2018.2840738; Zaheer M., 2017, ADV NEURAL INFORM PR, P3391	35	11	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2020	15	4							e0221606	10.1371/journal.pone.0221606	http://dx.doi.org/10.1371/journal.pone.0221606			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9GL	32294087	gold, Green Published, Green Submitted			2023-01-03	WOS:000536003500002
J	Malleshappa, SKS; Valecha, GK; Mehta, T; Patel, S; Giri, S; Smith, RE; Parikh, RA; Mehta, K				Malleshappa, Sudeep K. Siddappa; Valecha, Gautam K.; Mehta, Tapan; Patel, Smit; Giri, Smith; Smith, Roy E.; Parikh, Rahul A.; Mehta, Kathan			Thirty-day readmissions due to Venous thromboembolism in patients discharged with syncope	PLOS ONE			English	Article							PULMONARY-EMBOLISM; PREVALENCE; MANAGEMENT; DIAGNOSIS; EMERGENCY	A recent study found that approximately 1 in every 6 patients hospitalized for the 1st episode of syncope had an underlying pulmonary embolism (PE). As current guidelines do not strongly emphasize evaluation for PE in the workup of syncope, we hypothesize that there might be a higher rate of 30-day readmission due to untreated venous thromboembolism (VTE). The objective of this study is to measure the 30-day readmission rate due to VTE and identify predictors of 30-day readmission with VTE among syncope patients. We identified patients admitted with syncope with ICD9 diagnoses code 780.2 in the Nationwide Readmission Database (NRD-2013), Healthcare Cost and Utilization Project (HCUP). The 30-day readmission rate was calculated using methods described by HCUP. Logistic-regression was used to identify predictors of 30-day readmission with VTE. Discharge weights provided by HCUP were used to generate national estimates. In 2013, NRD included 207,339 eligible patients admitted with syncope. The prevalence rates of PE and DVT were 1.1% and 1.4%, respectively. At least one syncope associated condition was present in 60.9% of the patients. Among the patients who were not diagnosed with VTE during index admission for syncope (N = 188,015), 30-day readmission rate with VTE was 0.5% (0.2% with PE and 0.4% with DVT). In conclusion, low prevalence of VTE in patients with syncope and extremely low 30-day readmission rate with VTE argues against missed diagnoses of VTE in index admission for syncope. These results warrant further studies to determine clinical impact of work up for PE in syncope patients without risk factors.	[Malleshappa, Sudeep K. Siddappa] Baystate Med Ctr, Div Hematol Oncol, Springfield, MA USA; [Valecha, Gautam K.] Staten Isl Univ Hosp, Dept Med, Staten Isl, NY USA; [Mehta, Tapan] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; [Patel, Smit] Univ Connecticut, Div Neurol, Hartford, CT 06112 USA; [Giri, Smith] Yale New Haven Med Ctr, Div Hematol Oncol, 20 York St, New Haven, CT 06504 USA; [Smith, Roy E.] Univ Pittsburgh, Med Ctr, Div Hematol Oncol, Pittsburgh, PA 15219 USA; [Parikh, Rahul A.; Mehta, Kathan] Univ Kansas, Med Ctr, Div Hematol Oncol, Kansas City, KS 66103 USA	Baystate Medical Center; Northwell Health; University of Minnesota System; University of Minnesota Twin Cities; University of Connecticut; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Kansas; University of Kansas Medical Center	Mehta, K (corresponding author), Univ Kansas, Med Ctr, Div Hematol Oncol, Kansas City, KS 66103 USA.	kmehta2@kumc.edu		Mehta, Tapan/0000-0003-0199-3967				Altinsoy B, 2016, THER CLIN RISK MANAG, V12, P1023, DOI 10.2147/TCRM.S105722; [Anonymous], 2013, HCUP NAT READM DAT H; Badertscher P, 2019, J AM COLL CARDIOL, V74, P744, DOI 10.1016/j.jacc.2019.06.020; Barco S, 2018, EUR HEART J, V39, P4186, DOI 10.1093/eurheartj/ehy631; Barrett MRS, 2012, 201204 US AG HEALTHC; Costantino G, 2018, JAMA INTERN MED, V178, P356, DOI 10.1001/jamainternmed.2017.8175; Epstein D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193725; Frizell A, 2018, AM J EMERG MED, V36, P253, DOI 10.1016/j.ajem.2017.07.090; Jenab Y, 2015, CLIN APPL THROMB-HEM, V21, P772, DOI 10.1177/1076029614540037; Kearon C, 2019, NEW ENGL J MED, V381, P2125, DOI 10.1056/NEJMoa1909159; Kelly C, 2020, RES PRACT THROMB HAE, V4, P263, DOI 10.1002/rth2.12294; Kline JA, 2004, J THROMB HAEMOST, V2, P1247, DOI 10.1111/j.1538-7836.2004.00790.x; Konstantinides SV, 2019, EUR HEART J, V40, P3453, DOI 10.1093/eurheartj/ehz726; Mehta KD, 2019, AM J CARDIOL, V124, P960, DOI 10.1016/j.amjcard.2019.06.015; Morpurgo Mario, 2004, Ital Heart J, V5, P3; Moya A, 2009, TURK KARDIYOL DERN A, V37, P135, DOI 10.1093/eurheartj/ehp298; Pop C, 2019, AM J THER, V26, pE301, DOI 10.1097/MJT.0000000000000825; Prandoni P, 2016, NEW ENGL J MED, V375, P1524, DOI 10.1056/NEJMoa1602172; Shen WK, 2017, HEART RHYTHM, V14, pE155, DOI 10.1016/j.hrthm.2017.03.004; THAMES MD, 1977, JAMA-J AM MED ASSOC, V238, P2509, DOI 10.1001/jama.238.23.2509; Wells PS, 2001, ANN INTERN MED, V135, P98, DOI 10.7326/0003-4819-135-2-200107170-00010; 2016, J PHYSIOTHER, V62, P171	22	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2020	15	4							e0230859	10.1371/journal.pone.0230859	http://dx.doi.org/10.1371/journal.pone.0230859			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9BE	32282801	Green Published, gold			2023-01-03	WOS:000535989800009
J	Song, A				Song, Anne			The Other Side	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								In this narrative medical essay, a medicine resident describes her father's vegetative state following a cardiac arrest and finds herself identifying with families who don't want limitations on medical care for their loved ones in conflict with her identity as an internist.	[Song, Anne] Hosp Univ Penn, Dept Med, 3400 Spruce St, Philadelphia, PA 19104 USA	University of Pennsylvania	Song, A (corresponding author), Hosp Univ Penn, Dept Med, Internal Med Residency Program, 3400 Spruce St,100 Centrex, Philadelphia, PA 19104 USA.	anne.song@pennmedicine.upenn.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	2020	323	12					1135	1136		10.1001/jama.2020.2054	http://dx.doi.org/10.1001/jama.2020.2054			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK4BZ	32207802				2023-01-03	WOS:000530807000014
J	Schitter, AM; Fleckenstein, J; Frei, P; Taeymans, J; Kurpiers, N; Radlinger, L				Schitter, Agnes M.; Fleckenstein, Johannes; Frei, Peter; Taeymans, Jan; Kurpiers, Nico; Radlinger, Lorenz			Applications, indications, and effects of passive hydrotherapy WATSU (WaterShiatsu)-A systematic review and meta-analysis	PLOS ONE			English	Review							HUMAN PHYSIOLOGY; AQUATIC THERAPY; ALTERED STATES; PAIN; CARE; REHABILITATION; CONSCIOUSNESS; TEMPERATURE; IMPROVE; QUALITY	Background WATSU (portmanteau word: water and shiatsu) is a form of passive hydrotherapy in chestdeep thermoneutral water (35 degrees C = 95 degrees F = 308.15 K). It combines elements of myofascial stretching, joint mobilization, massage, and shiatsu and is reported to be used to address physical and mental issues. The objective of this systematic review (PROSPERO Registration No. CRD42016029347) and the meta-analyses was to assess the applications, indications, and the effects of WATSU to form a basis for further studies. Methods A search for "WATSU OR watershiatsu OR (water AND shiatsu)" was conducted without any restrictions in 32 databases. Peer reviewed original articles addressing WATSU as a stand-alone hydrotherapy were assessed for risk of bias. Quantitative data of effects on pain, physical function, and mental issues were processed in random model meta-analyses with subgroup analyses by study design. Effect sizes were expressed as Hedges's g (+/- 95% confidence intervals). Results Of 1,906 unique citations, 27 articles regardless of study design were assessed for risk of bias. WATSU has been applied to individuals of all ages. Indications covered acute (e.g. pregnancy related low back pain) and chronic conditions (e.g. cerebral palsy) with beneficial effects of WATSU regarding e.g. relaxation or sleep quality. Meta-analyses suggest beneficial effect sizes of WATSU on pain (overall Hedges's g = -0.71, 95% CI = -0.91 to -0.51), physical function (overall Hedges's g = -0.76, 95% CI = -1.08 to -0.44), and mental issues (overall Hedges's g = -0.68, 95% CI = -1.02 to -0.35). Conclusion Various applications, indications and beneficial effects of WATSU were identified. The grade of this evidence is estimated to be low to moderate at the best. To strengthen the findings of this study, high-quality RCTs are needed.	[Schitter, Agnes M.; Fleckenstein, Johannes] Univ Bern, Inst Complementary Med, Bern, Switzerland; [Schitter, Agnes M.; Frei, Peter; Kurpiers, Nico] Univ Hildesheim, Inst Sport Sci, Hildesheim, Germany; [Fleckenstein, Johannes] Goethe Univ Frankfurt, Inst Sports Sci, Dept Sports Med, Frankfurt, Germany; [Taeymans, Jan] Vrije Univ Brussel, Fac Sports & Rehabil Sci, Lab Biometry, Brussels, Belgium; [Taeymans, Jan; Radlinger, Lorenz] Bern Univ Appl Sci, Dept Hlth Profess, Bern, Switzerland	University of Bern; University of Hildesheim; Goethe University Frankfurt; Vrije Universiteit Brussel	Schitter, AM (corresponding author), Univ Bern, Inst Complementary Med, Bern, Switzerland.; Schitter, AM (corresponding author), Univ Hildesheim, Inst Sport Sci, Hildesheim, Germany.	agnes.schitter@bluewin.ch	Kurpiers, Nico/AAT-2066-2021; Fleckenstein, Johannes/AAL-1315-2021; Schitter, Agnes/AAF-4415-2020	Kurpiers, Nico/0000-0002-3622-5282; Schitter, Agnes/0000-0002-0181-4650				Abaraogu UO, 2015, J ACUPUNCT MERIDIAN, V8, P220, DOI 10.1016/j.jams.2015.06.010; Ackerley R, 2014, J NEUROSCI, V34, P2879, DOI 10.1523/JNEUROSCI.2847-13.2014; [Anonymous], 2014, REV MAN REVMAN; [Anonymous], 2004, WATSU FREEING BODY W; Antunes MD, 2016, CONSCIENTIAE SAUDE, V15, P636, DOI [10.5585/conssaude.v15n4.6756, DOI 10.5585/CONSSAUDE.V15N4.6756]; Arias DIA, 2013, BENEFITS WATSU RELAX; BARBOSA Gustavo Augusto Seabra, 2014, RGO, Rev. Gaúch. Odontol., V62, P309, DOI 10.1590/1981-86372014000300000122409; Barker AL, 2014, ARCH PHYS MED REHAB, V95, P1776, DOI 10.1016/j.apmr.2014.04.005; Becker BE, 2009, INT J AQUAT RES ED, V3, P24, DOI [DOI 10.25035/IJARE.03.01.04, 10.25035/ijare.03.01.04]; Becker BE, 2018, PM&R, V10, P437, DOI 10.1016/j.pmrj.2017.09.001; Becker BE, 2009, PM&R, V1, P859, DOI 10.1016/j.pmrj.2009.05.017; BENSON H, 1975, INT J PSYCHIAT MED, V6, P87, DOI 10.2190/376W-E4MT-QM6Q-H0UM; Boeker M, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-131; Borenstein M, 2009, STAT PRACTICE; Borges RM, 2001, FISIOTERAPIA BRASIL, V2, P33; Brummelman E, 2019, DEV COGN NEUROS-NETH, V35, P87, DOI 10.1016/j.dcn.2018.05.002; Bystrova K, 2009, MED HYPOTHESES, V72, P143, DOI 10.1016/j.mehy.2008.09.033; Campos NSd, 2018, REV CIENTIFICA JOPEF; Carter AC, 1999, J BODYWORK MOVEMENT, V3, P19; Chaillet N, 2014, BIRTH-ISS PERINAT C, V41, P122, DOI 10.1111/birt.12103; Chen O, 2018, JIPTS, V20, P14; Chon SC, 2009, PHYSIOTHER RES INT, V14, P128, DOI 10.1002/pri.421; Cochrane Effective Practice and Organisation of Care (EPOC), 2017, EPOC RES REV AUTH 20; CRAIG AB, 1966, J APPL PHYSIOL, V21, P1577, DOI 10.1152/jappl.1966.21.5.1577; Cranmer LA, 1997, DPS COLONIAL CABARET; Cunha MGd, 2010, THESIS; Dornelas LdF, 2011, REV NEUROCIENC, V19, P85; Eggart M, 2019, MED HYPOTHESES, V128, P28, DOI 10.1016/j.mehy.2019.05.004; Faull K, 2005, J BODYW MOV THER, V9, P202, DOI 10.1016/j.jbmt.2004.12.001; Filingeri D, 2018, HAND CLINIC, V156, P83, DOI 10.1016/B978-0-444-63912-7.00005-9; Freitas GSdS, 2016, REV UNIABEU, V9, P182; Frishman L., WAIRUA SELF PATH LOV; Frishman L., 2011, WAIRUA SELF PATH LOV; Gabbai AA, 1998, REV NEUROCIENC, V6, P126; Gimenes Rafaela Okano, 2006, Rev. Bras. Reumatol., V46, P75, DOI 10.1590/S0482-50042006000100015; Gimenez MdF, 2018, UNISANTA HLTH SCI, V2, P42; Gliga T, 2019, DEV COGN NEUROS-NETH, V35, P1, DOI 10.1016/j.dcn.2018.05.006; Goncalves VP, 2007, BRAZ J PHYS THER; Grant MJ, 2009, HEALTH INFO LIBR J, V26, P91, DOI 10.1111/j.1471-1842.2009.00848.x; Guerra AMZ, 2015, APPL WATSU METHOD ME; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Habig K, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0963-6; Hancock PA, 2019, ACTA PSYCHOL, V198, DOI 10.1016/j.actpsy.2019.04.007; Herrington CJ, 2014, PAIN MANAG NURS, V15, P107, DOI 10.1016/j.pmn.2012.06.007; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hora CRB, 2017, BIOL SAUDE UNIT, V4, P31; Israel VL, 2006, 35 C INT SOC MED HYD; Jakaitis F, 2005, REV NEUROCIENC, V13, P215; Jithin TA, 2019, INT J SCI RES, V8, P35; Jonsson K, 2014, SOC BEHAV PERSONAL, V42, P1495, DOI 10.2224/sbp.2014.42.9.1495; Kjellgren A., 2009, IMAGIN COGNIT PERS, V29, P135, DOI DOI 10.2190/IC.29.2.D; Kjellgren A, 2008, QUAL REP, V13, P636; Krahe C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32865-6; Krahe C, 2016, PHILOS T R SOC B, V371, DOI 10.1098/rstb.2016.0009; Kramer RSS, 2013, CONSCIOUS COGN, V22, P846, DOI 10.1016/j.concog.2013.05.008; Kuehn E, 2018, NEUROSCI BIOBEHAV R, V86, P207, DOI 10.1016/j.neubiorev.2017.11.016; Leite JRS, 2013, 5 WORLD C SLEEP MED; Lima AARd, 2009, REV NEUROCIENC, V17, P283; LUDWIG AM, 1966, ARCH GEN PSYCHIAT, V15, P225; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Machado M., 2007, WATSU SENIORS; Maczkowiak S, 2007, BEWEGUNGSTHERAPIE GE, V23, P58, DOI 10.1055/s-2007-960607; Marcucci FCI, 2005, REV BRAS CANCEROL, V51, P67; Melo FR, 2012, REV NEUROCIENC, V20, P415; Mendes CPD, 2008, EFFECTS WATSU METHOD; Michel-Berling HU, 2007, AQUATIC BODYWORK ACC; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Molina TIT, 2015, WATSU AQUATIC TECHNI; Morgan PM, 2013, J STRENGTH COND RES, V27, P3467, DOI 10.1519/JSC.0b013e31828f277e; Morhenn VB, 2008, EVOL HUM BEHAV, V29, P375, DOI 10.1016/j.evolhumbehav.2008.04.004; Morris D M, 1994, J Back Musculoskelet Rehabil, V4, P297, DOI 10.3233/BMR-1994-4409; Morris DM, 1995, JNPT, V19, P22; Mota NM, 2007, REV UNIVAP, V14, P18; Naumann J, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4603; Neill SA, 1997, THESIS; NGUYEN VM, 2015, PLOS ONE, V10, DOI DOI 10.1371/JOURNAL.PONE.0138237; Nicol JF, 2002, ENERG BUILDINGS, V34, P563, DOI 10.1016/S0378-7788(02)00006-3; Niggemeier-Groben A., 2016, PREVENTIVE CURES FOR; Nourbakhsh E, 2012, HEALTH INFO LIBR J, V29, P214, DOI 10.1111/j.1471-1842.2012.00992.x; Oh S. J., 2015, J YOGA PHYS THER, V5, P212; Paiao RCN, 2012, ENS CIENC, V16, P153; Pastrello Fernando Henrique Honda, 2009, FISIOTER MOV, V22, P95; Pendergast DR, 2015, COMPR PHYSIOL, V5, P1705, DOI 10.1002/cphy.c140018; Peralta-Pizza F, 2019, COCHRANE DB SYST REV; Ramirez NP, 2019, REV CHIL PEDIATR-CHI, V90, P283, DOI 10.32641/rchped.v90i3.886; Pinkalsky A, 2011, FISIOTER BRAS, V12, P4; Rambo DC, 2019, 6 C INT SAUD IJ RIO; Ribeiro I, 2019, ARCH BIOSCIENCES HLT, V1, P113, DOI DOI 10.18593/ABH.19211; Rodrigues DC, 2009, QUALITY LIFE ASSESSM; Rosenberg JL, 1985, BODY SELF SOUL SUSTA; Santana JMd, 2005, REV HISPECI LEMA, V8, P77; Scaer R., 2014, BODY BEARS BURDEN TR; Schitter AM, 2018, COMPLEMENT MED RES, V25, P263, DOI 10.1159/000487768; Schitter AM, 2015, EVID-BASED COMPL ALT, V2015, P1; Schoedinger P., 1997, WATSU FREEING BODY W; Schoedinger P., 2011, COMPREHENSIVE AQUATI, P137; Smeeding SJW, 2011, CLIN J PAIN, V27, P146, DOI 10.1097/AJP.0b013e3181f158e8; Souza JPMd, 2001, THESIS; STEADMAN RG, 1979, J APPL METEOROL, V18, P861, DOI 10.1175/1520-0450(1979)018<0861:TAOSPI>2.0.CO;2; Sterne JAC, 2011, COCHRANE HDB SYSTEMA; Tegtmeier D, 2010, US ASS BOD PSYCH 6 A; Thomson B., 1990, MASSAGE TAKES WATER, P60; Tufekcioglu E, 2018, J ED TRAIN STUD, V6, P166, DOI DOI 10.11114/JETS.V6I2.2963; Useros-Olmo AI, 2018, PHYSIOTHERAPY THEORY, P1; Veith Ilza., 2015, YELLOW EMPERORS CLAS; Viswanathan M., 2017, METHODS GUIDE EFFECT; Vogel WA, 2005, SELF PERCEIVED BENEF, V19, P1; Vogtle L., 1998, PHYS THER CASE REP, V1, P250; von Mohr M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13355-7; Wieser A., 2007, AQUATIC THERAPY J, V9, P9; Wong JD, 2012, J NEUROPHYSIOL, V108, P3313, DOI 10.1152/jn.00122.2012; Yavelow A., 1999, FINDING YOURSELF WAR; Zimmerman F., 2018, THESIS	114	8	8	5	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2020	15	3							e0229705	10.1371/journal.pone.0229705	http://dx.doi.org/10.1371/journal.pone.0229705			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ9AU	32168328	Green Published, Green Submitted, gold			2023-01-03	WOS:000535290100011
J	Hsieh, HY; Lin, WY; Lee, AL; Li, YC; Chen, YJ; Chen, KC; Young, TH				Hsieh, Hao-Ying; Lin, Wei-Yang; Lee, An Li; Li, Yi-Chen; Chen, Yi-Jane; Chen, Ke-Cheng; Young, Tai-Horng			Hyaluronic acid on the urokinase sustained release with a hydrogel system composed of poloxamer 407: HA/P407 hydrogel system for drug delivery	PLOS ONE			English	Article							PEO TRIBLOCK COPOLYMERS; IN-VITRO; PHYSICOCHEMICAL CHARACTERIZATION; THERMOSENSITIVE HYDROGELS; AQUEOUS-SOLUTIONS; MICELLIZATION; THERMODYNAMICS; MANAGEMENT; GELATION; INSULIN	Pleural empyema is an inflammatory condition characterized by accumulation of pus inside the pleural cavity, which is usually followed by bacterial pneumonia. During the disease process, the pro-inflammatory and pro-fibrotic cytokines in the purulent pleural effusion cause proliferation of fibroblasts and deposition of extracellular matrix, which lead to fibrin deposition and fibrothorax. Urokinase instillation therapy through a chest drainage tube is frequently used for fibrinolysis in patients with empyema. However, urokinase treatment requires multiple instillation (2-3 times per day, for 4-8 days) and easily flows out from the chest drainage tube due to its high water solubility. In this in vitro study, we developed a thermo-responsive hydrogel based on poloxamer 407 (P407) combined with hyaluronic acid (HA) for optimal loading and release of urokinase. Our results show that the addition of HA to poloxamer gels provides a significantly more compact microstructure, with smaller pore sizes (**p < 0.001). The differential scanning calorimetry (DSC) profile revealed no influence on the micellization intensity of poloxamer gel by HA. The 25% poloxamer-based gel was significantly superior to the 23% poloxamer-based gel, with slower gel erosion when comparing the 16th hour residual gel weight of both gels (*p < 0.05; **p < 0.001). The 25% poloxamer-HA gel also exhibited a superior urokinase release profile and longer release time. A Fourier-transform infrared spectroscopy (FT-IR) study of the P407/HA hydrogel showed no chemical interactions between P407 and HA in the hydrogel system. The thermoresponsive P407/HA hydrogel may have a promising potential in the loading and delivery of hydrophilic drugs. On top of that, in vitro toxicity test of this combination demonstrates a lower toxicity.	[Hsieh, Hao-Ying; Lin, Wei-Yang; Lee, An Li; Chen, Ke-Cheng; Young, Tai-Horng] Natl Taiwan Univ, Dept Biomed Engn, Taipei, Taiwan; [Lin, Wei-Yang] Lotung Poh Ai Hosp, Lo Hsu Med Fdn, Dept Thorac Surg, Lotung, Taiwan; [Lee, An Li] Mackay Mem Hosp, Dept Surg, Div Plast Surg, Taipei, Taiwan; [Li, Yi-Chen] Feng Chia Univ, Dept Chem Engn, Taichung, Taiwan; [Chen, Yi-Jane] Natl Taiwan Univ Hosp, Dept Dent, Taipei, Taiwan; [Chen, Ke-Cheng] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan	National Taiwan University; Mackay Memorial Hospital; Feng Chia University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Chen, KC; Young, TH (corresponding author), Natl Taiwan Univ, Dept Biomed Engn, Taipei, Taiwan.; Chen, KC (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan.	cskchen@gmail.com; thyoung@ntu.edu.tw		CHEN, YI-JANE/0000-0002-9178-8379; Hsieh, Haoying/0000-0002-2517-837X	Ministry of Science and Technology (MOST), Taiwan [108-2314-B-002-117-MY3]	Ministry of Science and Technology (MOST), Taiwan(Ministry of Science and Technology, Taiwan)	This work was funded by the Ministry of Science and Technology (MOST), Taiwan with grant number 108-2314-B-002-117-MY3. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed AEH, 2010, CLIN MED INSIGHTS-CI, V4, P1; Akkari ACS, 2016, MAT SCI ENG C-MATER, V68, P299, DOI 10.1016/j.msec.2016.05.088; Alexandridis P, 1997, LANGMUIR, V13, P6074, DOI 10.1021/la9703712; ALEXANDRIDIS P, 1994, MACROMOLECULES, V27, P2414, DOI 10.1021/ma00087a009; ALEXANDRIDIS P, 1995, COLLOID SURFACE A, V96, P1, DOI 10.1016/0927-7757(94)03028-X; Amiji MM, 2002, PHARM DEV TECHNOL, V7, P195, DOI 10.1081/PDT-120003487; Barichello JM, 1999, INT J PHARM, V184, P189, DOI 10.1016/S0378-5173(99)00119-2; Bhardwaj R, 1996, J PHARM SCI-US, V85, P915, DOI 10.1021/js960097g; Brandani P, 2003, MACROMOLECULES, V36, P9492, DOI 10.1021/ma0342675; Chan PWK, 2000, J PAEDIATR CHILD H, V36, P375, DOI 10.1046/j.1440-1754.2000.00525.x; Choong PFM, 2003, CLIN ORTHOP RELAT R, pS46, DOI 10.1097/01.blo.0000093845.72468.bd; DENG Y, 1992, J CHEM SOC FARADAY T, V88, P1441, DOI 10.1039/ft9928801441; Ding SY, 2016, NAT REV MATER, V1, DOI [10.1038/natrevmats.2016.21, 10.1038/natrevmats.2016.71]; El-Kamel AH, 2002, INT J PHARMACEUT, V241, P47, DOI 10.1016/S0378-5173(02)00234-X; Fasoli E, 2015, ANAL CHEM, V87, P1509, DOI 10.1021/ac5037796; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Gou ML, 2008, INT J PHARMACEUT, V359, P228, DOI 10.1016/j.ijpharm.2008.03.023; Gratieri T, 2010, EUR J PHARM BIOPHARM, V75, P186, DOI 10.1016/j.ejpb.2010.02.011; Hsu SH, 2009, CHEM PHARM BULL, V57, P453, DOI 10.1248/cpb.57.453; Huh HW, 2015, CARBOHYD POLYM, V126, P130, DOI 10.1016/j.carbpol.2015.03.033; Jansen MMPM, 2013, INT J PHARMACEUT, V452, P266, DOI 10.1016/j.ijpharm.2013.05.032; Krishnan S, 1997, CHEST, V112, P1579, DOI 10.1378/chest.112.6.1579; Lee JW, 2010, J BIOMED MATER RES A, V92A, P378, DOI 10.1002/jbm.a.32377; Li CX, 2014, INT J PHARMACEUT, V474, P123, DOI 10.1016/j.ijpharm.2014.08.023; Liu Y, 2009, EUR J PHARM SCI, V37, P306, DOI 10.1016/j.ejps.2009.02.022; Mayo L, 2008, EUR J PHARM BIOPHARM, V70, P199, DOI 10.1016/j.ejpb.2008.04.025; Pillai O, 2003, J CONTROL RELEASE, V89, P127, DOI 10.1016/S0168-3659(03)00094-4; Sharma N, 2019, BIO-PROTOCOL, V9, DOI 10.21769/BioProtoc.3131; Singh-Joy SD, 2008, INT J TOXICOL, V27, P93, DOI 10.1080/10915810802244595; Stefanutti G, 2010, SURGERY, V148, P589, DOI 10.1016/j.surg.2010.01.010; Stief TW, 2006, CLIN APPL THROMB-HEM, V12, P21, DOI 10.1177/107602960601200105; Tanriverdi ST, 2018, PHARM DEV TECHNOL, V23, P815, DOI 10.1080/10837450.2016.1268158; Trong LCP, 2008, J COLLOID INTERF SCI, V328, P278, DOI 10.1016/j.jcis.2008.09.029; Ur-Rehman T, 2011, INT J PHARMACEUT, V409, P19, DOI 10.1016/j.ijpharm.2011.02.017; Ur-Rehman T, 2010, INT J PHARMACEUT, V394, P92, DOI 10.1016/j.ijpharm.2010.05.012; WATKINS E, 1961, SURG CLIN N AM, V41, P681; Yadav AK, 2008, J DRUG TARGET, V16, P91, DOI [10.1080/10611860701794296, 10.1080/10611860802095494 ]; Zhang K, 2015, DRUG DELIV, V22, P375, DOI 10.3109/10717544.2014.891272; Zhang L, 2002, J CONTROL RELEASE, V85, P73, DOI 10.1016/S0168-3659(02)00273-0	39	16	17	11	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2020	15	3							e0227784	10.1371/journal.pone.0227784	http://dx.doi.org/10.1371/journal.pone.0227784			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8YS	32160196	gold, Green Published			2023-01-03	WOS:000535284700005
J	Lee, RY; Brumback, LC; Sathitratanacheewin, S; Lober, WB; Modes, ME; Lynch, YT; Ambrose, CI; Sibley, J; Vranas, KC; Sullivan, DR; Engelberg, RA; Curtis, JR; Kross, EK				Lee, Robert Y.; Brumback, Lyndia C.; Sathitratanacheewin, Seelwan; Lober, William B.; Modes, Matthew E.; Lynch, Ylinne T.; Ambrose, Corey I.; Sibley, James; Vranas, Kelly C.; Sullivan, Donald R.; Engelberg, Ruth A.; Curtis, J. Randall; Kross, Erin K.			Association of Physician Orders for Life-Sustaining Treatment With ICU Admission Among Patients Hospitalized Near the End of Life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; OF-LIFE; ADVANCE DIRECTIVES; QUALITY; OUTCOMES; FAMILY; DEATH; POLST; PREFERENCES; COMPLETION	Importance Patients with chronic illness frequently use Physician Orders for Life-Sustaining Treatment (POLST) to document treatment limitations. Objectives To evaluate the association between POLST order for medical interventions and intensive care unit (ICU) admission for patients hospitalized near the end of life. Design, Setting, and Participants Retrospective cohort study of patients with POLSTs and with chronic illness who died between January 1, 2010, and December 31, 2017, and were hospitalized 6 months or less before death in a 2-hospital academic health care system. Exposures POLST order for medical interventions ("comfort measures only" vs "limited additional interventions" vs "full treatment"), age, race/ethnicity, education, days from POLST completion to admission, histories of cancer or dementia, and admission for traumatic injury. Main Outcomes and Measures The primary outcome was the association between POLST order and ICU admission during the last hospitalization of life; the secondary outcome was receipt of a composite of 4 life-sustaining treatments: mechanical ventilation, vasopressors, dialysis, and cardiopulmonary resuscitation. For evaluating factors associated with POLST-discordant care, the outcome was ICU admission contrary to POLST order for medical interventions during the last hospitalization of life. Results Among 1818 decedents (mean age, 70.8 [SD, 14.7] years; 41% women), 401 (22%) had POLST orders for comfort measures only, 761 (42%) had orders for limited additional interventions, and 656 (36%) had orders for full treatment. ICU admissions occurred in 31% (95% CI, 26%-35%) of patients with comfort-only orders, 46% (95% CI, 42%-49%) with limited-interventions orders, and 62% (95% CI, 58%-66%) with full-treatment orders. One or more life-sustaining treatments were delivered to 14% (95% CI, 11%-17%) of patients with comfort-only orders and to 20% (95% CI, 17%-23%) of patients with limited-interventions orders. Compared with patients with full-treatment POLSTs, those with comfort-only and limited-interventions orders were significantly less likely to receive ICU admission (comfort only: 123/401 [31%] vs 406/656 [62%], aRR, 0.53 [95% CI, 0.45-0.62]; limited interventions: 349/761 [46%] vs 406/656 [62%], aRR, 0.79 [95% CI, 0.71-0.87]). Across patients with comfort-only and limited-interventions POLSTs, 38% (95% CI, 35%-40%) received POLST-discordant care. Patients with cancer were significantly less likely to receive POLST-discordant care than those without cancer (comfort only: 41/181 [23%] vs 80/220 [36%], aRR, 0.60 [95% CI, 0.43-0.85]; limited interventions: 100/321 [31%] vs 215/440 [49%], aRR, 0.63 [95% CI, 0.51-0.78]). Patients with dementia and comfort-only orders were significantly less likely to receive POLST-discordant care than those without dementia (23/111 [21%] vs 98/290 [34%], aRR, 0.44 [95% CI, 0.29-0.67]). Patients admitted for traumatic injury were significantly more likely to receive POLST-discordant care (comfort only: 29/64 [45%] vs 92/337 [27%], aRR, 1.52 [95% CI, 1.08-2.14]; limited interventions: 51/91 [56%] vs 264/670 [39%], aRR, 1.36 [95% CI, 1.09-1.68]). In patients with limited-interventions orders, older age was significantly associated with less POLST-discordant care (aRR, 0.93 per 10 years [95% CI, 0.88-1.00]). Conclusions and Relevance Among patients with POLSTs and with chronic life-limiting illness who were hospitalized within 6 months of death, treatment-limiting POLSTs were significantly associated with lower rates of ICU admission compared with full-treatment POLSTs. However, 38% of patients with treatment-limiting POLSTs received intensive care that was potentially discordant with their POLST. This cohort study uses electronic health record (EHR) data to evaluate the association between Physician Orders for Life-Sustaining Treatment (POLST) and intensive care unit (ICU) admission and the incidence of and risk factors for POLST-discordant intensive care among adult patients hospitalized 6 months or less before death. Question For patients with treatment-limiting Physician Orders for Life-Sustaining Treatment (POLST) hospitalized near the end of life, how often is their inpatient care consistent with POLST-ordered limitations? Findings In this retrospective cohort study of 1818 decedents with POLSTs who were hospitalized within 6 months of death, rates of intensive care unit (ICU) admission differed significantly by POLST order for medical interventions (31% for those who indicated "comfort measures only," 46% for those who indicated "limited additional interventions," and 62% for those who indicated "full treatment"). Meaning For patients hospitalized near the end of life, treatment-limiting POLSTs were associated with significantly lower rates of ICU admission compared with full-treatment POLSTs, although many patients with treatment-limiting POLSTs received care that was potentially discordant with their POLST.	[Lee, Robert Y.; Brumback, Lyndia C.; Sathitratanacheewin, Seelwan; Lober, William B.; Modes, Matthew E.; Sibley, James; Engelberg, Ruth A.; Curtis, J. Randall; Kross, Erin K.] Univ Washington, Cambia Palliat Care Ctr Excellence, Seattle, WA 98195 USA; [Lee, Robert Y.; Modes, Matthew E.; Lynch, Ylinne T.; Engelberg, Ruth A.; Curtis, J. Randall; Kross, Erin K.] Univ Washington, Harborview Med Ctr, Dept Med, Div Pulm Crit Care & Sleep Med, 325 9Th Ave, Seattle, WA 98104 USA; [Brumback, Lyndia C.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Sathitratanacheewin, Seelwan] Chulalongkorn Univ, Fac Med, Bangkok, Thailand; [Lober, William B.; Sibley, James; Curtis, J. Randall] Univ Washington, Dept Biobehav Nursing & Hlth Informat, Seattle, WA 98195 USA; [Lober, William B.; Sibley, James] Univ Washington, Dept Bioinformat & Med Educ, Seattle, WA 98195 USA; [Ambrose, Corey I.] Univ Washington, Sch Med, Seattle, WA USA; [Vranas, Kelly C.; Sullivan, Donald R.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA; [Vranas, Kelly C.; Sullivan, Donald R.] Vet Affairs Portland Hlth Care Syst, Hlth Serv Res & Dev, Portland, OR USA; [Curtis, J. Randall] Univ Washington, Dept Bioeth, Seattle, WA USA	University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Chulalongkorn University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; University of Washington; University of Washington Seattle	Lee, RY (corresponding author), Univ Washington, Div Pulm Crit Care & Sleep Med, Cambia Palliat Care Ctr Excellence, Harborview Med Ctr, 325 9th Ave,Campus Box 359762, Seattle, WA 98104 USA.	rlee06@uw.edu	Lee, Robert Y./AAK-2305-2020	Lee, Robert Y./0000-0001-5535-287X; Curtis, J. Randall/0000-0001-9529-845X	National Institutes of Health; Cambia Health Foundation; UW Medicine; F32 award from the National Heart, Lung, and Blood Institute (NHLBI) [HL142211]; K12 award in implementation science from the National Heart, Lung, and Blood Institute (NHLBI) [HL137940]; palliative care T32 training fellowship from the National Heart, Lung, and Blood Institute (NHLBI) [HL125195]; pulmonary/critical care T32 training fellowship from the National Heart, Lung, and Blood Institute (NHLBI) [HL007287]; Prince Mahidol Youth Program Award, Bangkok, Thailand; K12 award - NHLBI [HL133115]; National Institute of Mental Health; National Center for Advancing Translational Sciences through the Clinical and Translational Science Awards (CTSA) Program [UL1 TR002319]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cambia Health Foundation; UW Medicine; F32 award from the National Heart, Lung, and Blood Institute (NHLBI); K12 award in implementation science from the National Heart, Lung, and Blood Institute (NHLBI); palliative care T32 training fellowship from the National Heart, Lung, and Blood Institute (NHLBI); pulmonary/critical care T32 training fellowship from the National Heart, Lung, and Blood Institute (NHLBI); Prince Mahidol Youth Program Award, Bangkok, Thailand; K12 award - NHLBI; National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Center for Advancing Translational Sciences through the Clinical and Translational Science Awards (CTSA) Program	This study was supported by the National Institutes of Health, Cambia Health Foundation, and UW Medicine. Dr Lee was supported by an F32 award (HL142211) and a K12 award in implementation science (HL137940); Drs Lee and Modes, by a palliative care T32 training fellowship (HL125195); and Drs Modes and Lynch, by a pulmonary/critical care T32 training fellowship (HL007287), all from the National Heart, Lung, and Blood Institute (NHLBI). Dr Sathitratanacheewin was supported by the Prince Mahidol Youth Program Award, Bangkok, Thailand. Dr Vranas was supported by a K12 award (HL133115) jointly funded by the NHLBI and the National Institute of Mental Health. Infrastructure and chart abstraction support was provided by the University of Washington Institute of Translational Health Sciences (ITHS), which is funded by the National Center for Advancing Translational Sciences through the Clinical and Translational Science Awards (CTSA) Program (UL1 TR002319).	Angus DC, 2004, CRIT CARE MED, V32, P638, DOI 10.1097/01.CCM.0000114816.62331.08; Ballou JH, 2019, J TRAUMA ACUTE CARE, V87, P153, DOI 10.1097/TA.0000000000002321; Byhoff E, 2016, J AM GERIATR SOC, V64, P1789, DOI 10.1111/jgs.14263; CHELLURI L, 1993, JAMA-J AM MED ASSOC, V269, P3119, DOI 10.1001/jama.269.24.3119; Curtis JR, 2012, AM J RESP CRIT CARE, V186, P587, DOI 10.1164/rccm.201206-1020CP; Davydow DS, 2008, GEN HOSP PSYCHIAT, V30, P421, DOI 10.1016/j.genhosppsych.2008.05.006; Feder SL, 2018, WESTERN J NURS RES, V40, P753, DOI 10.1177/0193945916689084; GLASSER JH, 1981, AM J PUBLIC HEALTH, V71, P231, DOI 10.2105/AJPH.71.3.231; Hammes BJ, 2012, J PALLIAT MED, V15, P77, DOI 10.1089/jpm.2011.0178; Hart JL, 2018, J GEN INTERN MED, V33, P145, DOI 10.1007/s11606-017-4223-7; Hickman SE, 2015, J AM GERIATR SOC, V63, P341, DOI 10.1111/jgs.13248; Hickman SE, 2011, J AM GERIATR SOC, V59, P2091, DOI 10.1111/j.1532-5415.2011.03656.x; Hickman SE, 2010, J AM GERIATR SOC, V58, P1241, DOI 10.1111/j.1532-5415.2010.02955.x; Hopping-Winn J, 2018, J PALLIAT MED, V21, P541, DOI 10.1089/jpm.2017.0317; Kim J, 2019, J PAIN SYMPTOM MANAG, V58, P857, DOI 10.1016/j.jpainsymman.2019.07.015; Lee MA, 2000, J AM GERIATR SOC, V48, P1219, DOI 10.1111/j.1532-5415.2000.tb02594.x; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lunney JR, 2018, J AM GERIATR SOC, V66, P503, DOI 10.1111/jgs.15224; Mack JW, 2010, J CLIN ONCOL, V28, P1203, DOI 10.1200/JCO.2009.25.4672; Mendelsohn AB, 2003, CRIT CARE MED, V31, pS400, DOI 10.1097/01.CCM.0000065278.90460.F0; Nicholas LH, 2014, HEALTH AFFAIR, V33, P667, DOI 10.1377/hlthaff.2013.1258; Parr JD, 2010, J PALLIAT MED, V13, P719, DOI 10.1089/jpm.2009.0337; Perkins HS, 2007, ANN INTERN MED, V147, P51, DOI 10.7326/0003-4819-147-1-200707030-00008; Puchalski CM, 2000, J AM GERIATR SOC, V48, pS84, DOI 10.1111/j.1532-5415.2000.tb03146.x; Puntillo KA, 2010, CRIT CARE MED, V38, P2155, DOI 10.1097/CCM.0b013e3181f267ee; Scarlet S., 2018, AMA J ETHICS, V20, P421, DOI DOI 10.1001/JOURNALOFETHICS.2018.20.5.FRED1-1805; Sudore RL, 2010, ANN INTERN MED, V153, P256, DOI 10.7326/0003-4819-153-4-201008170-00008; Teno JM, 2005, J AM GERIATR SOC, V53, P1905, DOI 10.1111/j.1532-5415.2005.53563.x; Teno JM, 2002, J AM GERIATR SOC, V50, P496, DOI 10.1046/j.1532-5415.2002.50116.x; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Tolle SW, 1998, J AM GERIATR SOC, V46, P1097, DOI 10.1111/j.1532-5415.1998.tb06647.x; Tschirhart EC, 2014, J AM GERIATR SOC, V62, P2088, DOI 10.1111/jgs.13104; Turnbull AE, 2014, CRIT CARE, V18, DOI 10.1186/cc13890; Visser M, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0604-z; Wright AA, 2016, JAMA-J AM MED ASSOC, V315, P284, DOI 10.1001/jama.2015.18604; Wunsch H, 2010, CRIT CARE MED, V38, P1947, DOI 10.1097/CCM.0b013e3181ef4460; Zive DM, 2015, J PAIN SYMPTOM MANAG, V50, P650, DOI 10.1016/j.jpainsymman.2015.06.004; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	38	51	52	2	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	2020	323	10					950	960		10.1001/jama.2019.22523	http://dx.doi.org/10.1001/jama.2019.22523			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KW1LV	32062674	Bronze, Green Published			2023-01-03	WOS:000520933900012
J	Schmidbauer, C; Schubert, R; Schutz, A; Schwanke, C; Luhn, J; Gutic, E; Pirker, R; Lang, T; Reiberger, T; Haltmayer, H; Gschwantler, M				Schmidbauer, Caroline; Schubert, Raphael; Schuetz, Angelika; Schwanke, Cornelia; Luhn, Julian; Gutic, Enisa; Pirker, Roxana; Lang, Tobias; Reiberger, Thomas; Haltmayer, Hans; Gschwantler, Michael			Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria	PLOS ONE			English	Article							CHRONIC HEPATITIS-C; GENOTYPE 1; PIBRENTASVIR; PREVALENCE; INITIATION; INFECTION; FIBROSIS	Background Directly acting antivirals (DAA) against hepatitis C virus (HCV) infection have facilitated sustained virologic response (SVR) rates > 90% in clinical studies. Yet, real life data regarding DAA treatment in people who inject drugs (PWIDs) are scarce. We evaluated the effectiveness of glecaprevir/pibrentasvir (G/P) in difficult-to-treat PWIDs with presumed high risk of non-adherence to DAA therapy using the concept of directly observed therapy involving their opioid substitution therapy (OST) facility. Methods N = 145 patients (m/f: 91/54; median age: 41.1 (IQR 19.5) years; HCV-genotype (GT) 1/2/3/ 4: 82/1/56/5, GT3: 38.6%; cirrhosis: n = 6; 4.1%) treated with G/P were included. PWIDs at high risk for non-adherence to DAA therapy received HCV treatment together with their OST under the supervision of medical staff ("directly observed therapy", DOT). The effectiveness of G/P given as DOT in PWIDs with presumed high risk of non-adherence to DAA therapy was compared to patients with suspected "excellent compliance" in the "standard setting" (SS) of G/P prescription at a tertiary care center and self-managed G/P intake at home. Treatment duration was 8-16 weeks according to the G/P drug label. Results DOT-patients (n = 74/145; 51.0%) were younger than SS-patients (median 38.7, IQR 12.5 vs. median 50.6, IQR 20.3 years), all had psychiatric co-morbidities and most had a poor socioeconomic status. 50/74 (67.6%) reported ongoing intravenous drug use (IDU). SVR was achieved in n = 70/74 (94.6%) patients with n = 3 being lost to follow-up (FU) and n = 1 showing nonresponse to therapy. SS-patients achieved SVR in 97.2% (69/71) with n = 1 patient being lost to FU and n = 1 patient with GT3 showing HCV relapse. Conclusion G/P given as DOT along with OST in PWIDs with high risk of non-adherence to DAA therapy resulted in similarly high SVR rates (94.6%) as in patients with presumed "excellent compliance" under standard drug intake.	[Schmidbauer, Caroline; Gutic, Enisa; Pirker, Roxana; Lang, Tobias; Gschwantler, Michael] Wilhelminenspital Stadt Wien, Dept Internal Med 4, Vienna, Austria; [Schmidbauer, Caroline; Reiberger, Thomas] Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, Vienna, Austria; [Schmidbauer, Caroline; Reiberger, Thomas] Vienna HIV & Liver Study Grp, Vienna, Austria; [Schubert, Raphael; Schuetz, Angelika; Schwanke, Cornelia; Luhn, Julian; Haltmayer, Hans] Suchthilfe Wien gGmbH, Ambulatorium Suchthilfe Wien, Vienna, Austria; [Gschwantler, Michael] Sigmund Freud Univ, Vienna, Austria	Wilhelminenspital; Medical University of Vienna	Gschwantler, M (corresponding author), Wilhelminenspital Stadt Wien, Dept Internal Med 4, Vienna, Austria.; Gschwantler, M (corresponding author), Sigmund Freud Univ, Vienna, Austria.	michael.gschwantler@wienkav.at	Reiberger, Thomas/H-7613-2019	Reiberger, Thomas/0000-0002-4590-3583; Schwarz, Caroline/0000-0001-7762-7483	City of Vienna; Austrian Ministry of Health	City of Vienna; Austrian Ministry of Health	There was no specific funding for this study. However, the following authors are employed by Suchthilfe Wien gGmbH: . Raphael Schubert , Angelika Schutz . Cornelia Schwanke . Julian Luhn . Hans Haltmayer Suchthilfe Wien gGmbH represents a governmental non-profit organization financed by the City of Vienna and the Austrian Ministry of Health. Suchthilfe Wien gGmbH did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Suchthilfe Wien gGmbH provided support in the form of salaries for authors [Raphael Schubert, Angelika Schutz, Cornelia Schwanke, Julian Luhn, Hans Haltmayer], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Asselah T, 2019, LANCET GASTROENTEROL, V4, P45, DOI 10.1016/S2468-1253(18)30341-8; Baumert TF, 2019, GASTROENTEROLOGY, V156, P431, DOI 10.1053/j.gastro.2018.10.024; Belli LS, 2018, J HEPATOL, V69, P810, DOI 10.1016/j.jhep.2018.06.010; Berenguer J, 2018, HEPATOLOGY, V68, P32, DOI 10.1002/hep.29814; Blach S, 2017, LANCET GASTROENTEROL, V2, P161, DOI 10.1016/S2468-1253(16)30181-9; Carrat F., 2019, LANCET, V393, P1453, DOI DOI 10.1016/S0140-6736(18)32111-1; Castera L, 2005, GASTROENTEROLOGY, V128, P343, DOI 10.1053/j.gastro.2004.11.018; Chromy D, 2019, AIDS PATIENT CARE ST, V33, P197, DOI 10.1089/apc.2018.0333; Chromy D, 2018, WIEN KLIN WOCHENSCHR, V130, P105, DOI 10.1007/s00508-017-1231-x; Cornberg M, 2019, ILC 2019 APR VIENN A; D'Ambrosio R, 2019, J HEPATOL, V70, P379, DOI 10.1016/j.jhep.2018.11.011; Eckman MH, 2018, CLIN GASTROENTEROL H; European Assoc Study Liver, 2018, J HEPATOL, V69, P461, DOI 10.1016/j.jhep.2018.03.026; Forns X, 2017, LANCET INFECT DIS, V17, P1062, DOI 10.1016/S1473-3099(17)30496-6; Foster GR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0208506; Foster GR, 2019, DRUG ALCOHOL DEPEN, V194, P487, DOI 10.1016/j.drugalcdep.2018.11.007; Graf C, 2019, CLIN INFECT DIS PUBL; Grebely J, 2019, INT J DRUG POLICY, V66, P73, DOI 10.1016/j.drugpo.2019.01.011; Hajarizadeh B, 2018, LANCET GASTROENTEROL, V3, P754, DOI 10.1016/S2468-1253(18)30304-2; Hepatitis C, 2017, LANCET GASTROENTEROL, V2, P325; Ioannou GN, 2019, GASTROENTEROLOGY, V156, P446, DOI 10.1053/j.gastro.2018.10.033; Mandorfer M, 2016, HEPATOL INT, V10, P424, DOI 10.1007/s12072-015-9691-4; Mandorfer M, 2016, AIDS, V30, P1039, DOI 10.1097/QAD.0000000000001020; Marshall AD, 2018, J HEPATOL, V69, P1188, DOI 10.1016/j.jhep.2018.06.016; Moser S, 2018, EUR J GASTROEN HEPAT, V30, P291, DOI 10.1097/MEG.0000000000001027; Moser S, 2016, DIGEST LIVER DIS, V48, P970, DOI 10.1016/j.dld.2016.05.004; Ogawa E, 2019, HEPATOL RES OFF J JP; Poordad F, 2018, HEPATOLOGY, V67, P1253, DOI 10.1002/hep.29671; Reiberger T, 2015, MINERVA GASTROENTERO, V61, P11; Schutz A, 2018, J VIRAL HEPATITIS, V25, P870, DOI 10.1111/jvh.12857; Schutz A, 2016, AM J GASTROENTEROL, V111, P903, DOI 10.1038/ajg.2016.119; Tampaki M, 2018, ANN GASTROENTEROL, V31, P670, DOI 10.20524/aog.2018.0306; Thomas DL, 2019, NEW ENGL J MED, V380, P2041, DOI 10.1056/NEJMra1810477; United Nations, 2015, TRANSF OUR WORLD 203; World Health Organization, 2016, COMB HEP B C REACH E; World Health Organization, 2017, VIRAL HEPATITIS; Wyles D, 2017, HEPATOL BALTIM MD; Zeuzem S, 2018, NEW ENGL J MED, V378, P354, DOI 10.1056/NEJMoa1702417	38	17	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2020	15	3							e0229239	10.1371/journal.pone.0229239	http://dx.doi.org/10.1371/journal.pone.0229239			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8WI	32155165	Green Published, gold			2023-01-03	WOS:000535278500012
J	Mitchell, C; Dolan, N; Dursteler, KM				Mitchell, Caroline; Dolan, Neil; Dursteler, Kenneth M.			Management of dependent use of illicit opioids	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							INJECT DRUGS; INTERVENTIONS; DISORDERS; METHADONE; DEATHS; PEOPLE; HEALTH		[Mitchell, Caroline] Univ Sheffield, Fac Med Dent & Hlth, Acad Unit Primary Med Care, Sheffield, S Yorkshire, England; [Dolan, Neil] Univ Sheffield, Sheffield, S Yorkshire, England; [Dursteler, Kenneth M.] Univ Basel, Psychiat Hosp, Ctr Addict Disorders, Basel, Switzerland; [Dursteler, Kenneth M.] Univ Hosp Psychiat Zurich, Dept Psychiat Psychotherapy & Psychosomat, Ctr Addict Disorders, Zurich, Switzerland	University of Sheffield; University of Sheffield; University of Basel	Mitchell, C (corresponding author), Univ Sheffield, Fac Med Dent & Hlth, Acad Unit Primary Med Care, Sheffield, S Yorkshire, England.	c.mitchell@sheffield.ac.uk	Dürsteler, Kenneth Michael/AAJ-2374-2021	Dürsteler, Kenneth Michael/0000-0003-1552-5822; Mitchell, Caroline/0000-0002-4790-0095				Advisory Council on the Misuse of Drugs, 2011, HIDD HARM REP CHILDR; Advisory Council on the Misuse of Drugs, 2010, CONS US FOIL INT RED; Amato L, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003409.pub4; [Anonymous], OP DEP CLIN KNOWL SU; [Anonymous], 2018, AD SUBST MIS STAT NA; [Anonymous], 2019, EUROPEAN DRUG REPORT; Banerjee G, 2016, ADDICTION, V111, P2021, DOI 10.1111/add.13491; Bawor M, 2015, DRUG ALCOHOL DEPEN, V149, P1, DOI 10.1016/j.drugalcdep.2015.01.038; Beletsky L, 2012, JAMA-J AM MED ASSOC, V308, P1863, DOI 10.1001/jama.2012.14205; Blanco C, 2019, LANCET, V393, P1760, DOI 10.1016/S0140-6736(18)33078-2; Clinical Guidelines on Drug Misuse and Dependence Update, 2017, CLIN GUID DRUG MIS D; Collins FS, 2018, JAMA-J AM MED ASSOC, V320, P129, DOI 10.1001/jama.2018.8826; Cornish R, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5475; Degenhardt L, 2017, LANCET GLOB HEALTH, V5, pE1192, DOI 10.1016/S2214-109X(17)30375-3; Drake RE, 1998, SCHIZOPHRENIA BULL, V24, P589, DOI 10.1093/oxfordjournals.schbul.a033351; Dunn C, 2001, ADDICTION, V96, P1725, DOI 10.1046/j.1360-0443.2001.961217253.x; European Monitoring Centre for Drugs and Drug Addiction, 2017, EUR DRUG REP 2017 TR; Grischott T, 2019, ADDICTION, V114, P868, DOI 10.1111/add.14559; Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence, GUID PSYCH ASS PHARM; Hallinan R, 2008, J SEX MED, V5, P684, DOI 10.1111/j.1743-6109.2007.00702.x; Hulin J, 2020, ADDICTION, V115, P832, DOI 10.1111/add.14870; Livingston JD, 2012, ADDICTION, V107, P39, DOI 10.1111/j.1360-0443.2011.03601.x; Mathers BM, 2013, B WORLD HEALTH ORGAN, V91, P102, DOI 10.2471/BLT.12.108282; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; McConnaughy E, 1983, HLTH BEHAV THEORY RE, V20, P3; McDonald R, 2016, ADDICTION, V111, P1177, DOI 10.1111/add.13326; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; Mitchell CA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012823; National Institute for Health and Care Excellence, 2007, NALTR MAN OP DEP TEC; National Institute for Health and Care Excellence, 2007, DRUG MIS 16S OP DET; National Institute for Health and Care Excellence, 2007, METH BUPR MAN OP DEP; National Institute for Health and Care Excellence, 2007, DRUG MIS 16S PSYCH I; Nordt C, 2019, ADDICTION, V114, P103, DOI 10.1111/add.14442; Oliver P, 2007, BENZODIAZEPINES COCA; Parmenter J, 2013, BRIT J GEN PRACT, V63, pE499, DOI 10.3399/bjgp13X669220; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; Public Health Agency of Canada, 2016, NAT REP APP OP REL D; Public Health England, 2018, DRUGS COMM SUPP PACK; Rollnick S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1900; Rosic T, 2017, NEUROPSYCH DIS TREAT, V13, P1399, DOI 10.2147/NDT.S129480; Roxburgh A., 2018, OPIOID AMPHETAMINE C; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Sohal H, 2007, BMC FAM PRACT, V8, DOI 10.1186/1471-2296-8-49; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Strang J, ANN REPORT CHIEF MED; STRANG J, 2010, BMJ-BRIT MED J, V341, DOI DOI 10.1136/BMJ.C4851; Substance abuse and mental health services administration, 2016, HHS PUBL; Taft A, 2013, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD007007.PUB2; World Health Organization, ICD 10 CLASS MENT BE; World Health Organization, 2009, GUID PSYCH ASS PHARM	50	0	0	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 9	2020	368								m710	10.1136/bmj.m710	http://dx.doi.org/10.1136/bmj.m710			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KU9AK	32152035	Green Accepted			2023-01-03	WOS:000520012000001
J	Huang, LP; Trieu, K; Yoshimura, S; Neal, B; Woodward, M; Campbell, NRC; Li, Q; Lackland, DT; Leung, AA; Anderson, CAM; MacGregor, GA; He, FJ				Huang, Liping; Trieu, Kathy; Yoshimura, Sohei; Neal, Bruce; Woodward, Mark; Campbell, Norm R. C.; Li, Qiang; Lackland, Daniel T.; Leung, Alexander A.; Anderson, Cheryl A. M.; MacGregor, Graham A.; He, Feng J.			Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MODERATE SALT RESTRICTION; CONVERTING-ENZYME-INHIBITOR; DOUBLE-BLIND; HYPERTENSIVE PATIENTS; INSULIN SENSITIVITY; POTASSIUM SUPPLEMENTATION; CARDIOVASCULAR-DISEASE; GLUCOSE-TOLERANCE; URINARY SODIUM; WEIGHT-LOSS	OBJECTIVE To examine the dose-response relation between reduction in dietary sodium and blood pressure change and to explore the impact of intervention duration. DESIGN Systematic review and meta-analysis following PRISMA guidelines. DATA SOURCES Ovid MEDLINE(R), EMBASE, and Cochrane Central Register of Controlled Trials (Wiley) and reference lists of relevant articles up to 21 January 2019. INCLUSION CRITERIA Randomised trials comparing different levels of sodium intake undertaken among adult populations with estimates of intake made using 24 hour urinary sodium excretion. DATA EXTRACTION AND ANALYSIS Two of three reviewers screened the records independently for eligibility. One reviewer extracted all data and the other two reviewed the data for accuracy. Reviewers performed random effects meta-analyses, subgroup analyses, and meta-regression. RESULTS 133 studies with 12 197 participants were included. The mean reductions (reduced sodium v usual sodium) of 24 hour urinary sodium, systolic blood pressure (SBP), and diastolic blood pressure (DBP) were 130 mmol (95% confidence interval 115 to 145, P<0.001), 4.26 mm Hg (3.62 to 4.89, P<0.001), and 2.07 mm Hg (1.67 to 2.48, P<0.001), respectively. Each 50 mmol reduction in 24 hour sodium excretion was associated with a 1.10 mm Hg (0.66 to 1.54; P<0.001) reduction in SBP and a 0.33 mm Hg (0.04 to 0.63; P=0.03) reduction in DBP. Reductions in blood pressure were observed in diverse population subsets examined, including hypertensive and non-hypertensive individuals. For the same reduction in 24 hour urinary sodium there was greater SBP reduction in older people, non-white populations, and those with higher baseline SBP levels. In trials of less than 15 days' duration, each 50 mmol reduction in 24 hour urinary sodium excretion was associated with a 1.05 mm Hg (0.40 to 1.70; P=0.002) SBP fall, less than half the effect observed in studies of longer duration (2.13 mm Hg; 0.85 to 3.40; P=0.002). Otherwise, there was no association between trial duration and SBP reduction. CONCLUSIONS The magnitude of blood pressure lowering achieved with sodium reduction showed a dose-response relation and was greater for older populations, non-white populations, and those with higher blood pressure. Short term studies underestimate the effect of sodium reduction on blood pressure.	[Huang, Liping] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia; [Huang, Liping; Trieu, Kathy; Yoshimura, Sohei; Neal, Bruce; Woodward, Mark; Li, Qiang] UNSW Sydney, George Inst Global Hlth, Sydney, NSW, Australia; [Yoshimura, Sohei] Natl Cerebral & Cardiovasc Ctr, Osaka, Japan; [Neal, Bruce] Imperial Coll London, Dept Epidemiol & Biostat, London, England; [Woodward, Mark] Univ Oxford, George Inst Global Hlth, Oxford, England; [Campbell, Norm R. C.; Leung, Alexander A.] Univ Calgary, Dept Med, Calgary, AB, Canada; [Campbell, Norm R. C.; Leung, Alexander A.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Lackland, Daniel T.] Med Univ South Carolina, Charleston, SC 29425 USA; [Anderson, Cheryl A. M.] Univ Calif San Diego, San Diego, CA 92103 USA; [MacGregor, Graham A.; He, Feng J.] Queen Mary Univ London, Wolfson Inst Prevent Med, Barts & London Sch Med & Dent, London E1 4NS, England	University of Sydney; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; National Cerebral & Cardiovascular Center - Japan; Imperial College London; University of Oxford; University of Calgary; University of Calgary; Medical University of South Carolina; University of California System; University of California San Diego; University of London; Queen Mary University London	He, FJ (corresponding author), Queen Mary Univ London, Wolfson Inst Prevent Med, Barts & London Sch Med & Dent, London E1 4NS, England.	f.he@qmul.ac.uk	Jayaraj, Rama/A-6526-2012; Leung, Alexander/L-9856-2018; He, Feng/HHS-6457-2022	Jayaraj, Rama/0000-0002-2179-0510; Leung, Alexander/0000-0002-7536-8497; He, Feng/0000-0002-1996-0744; MacGregor, Graham/0000-0001-9206-4500; Huang, Liping/0000-0002-0945-8988; He, Feng/0000-0003-2807-4119; Woodward, Mark/0000-0001-9800-5296; Neal, Bruce/0000-0002-0490-7465	MRC [MR/J015903/1] Funding Source: UKRI; Medical Research Council [MR/J015903/1] Funding Source: Medline; Department of Health [16/136/77] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health		Akita S, 2003, HYPERTENSION, V42, P8, DOI 10.1161/01.HYP.0000074668.08704.6E; Allen AR, 2014, J HYPERTENS, V32, P374, DOI 10.1097/HJH.0000000000000045; ALLI C, 1992, J HUM HYPERTENS, V6, P281; Ames RP, 2001, AM J HYPERTENS, V14, P653, DOI 10.1016/S0895-7061(01)01310-3; [Anonymous], 2017, J CLIN HYPERTENS, V19, P108, DOI DOI 10.1111/jch.12948; Appel LJ, 2001, ARCH INTERN MED, V161, P685, DOI 10.1001/archinte.161.5.685; Arroll B, 1992, MED HLTH SCI; Babcock MC, 2018, AM J PHYSIOL-REG I, V315, pR688, DOI 10.1152/ajpregu.00002.2018; Beeks E, 2004, HYPERTENSION, V44, P419, DOI 10.1161/01.HYP.0000141410.72537.fd; Bellini C, 1996, J AM SOC NEPHROL, V7, P2565; BENETOS A, 1992, J HYPERTENS, V10, P355, DOI 10.1097/00004872-199204000-00006; Boero R, 2000, Minerva Urol Nefrol, V52, P13; Bonfils PK, 2013, J HYPERTENS, V31, P2220, DOI 10.1097/HJH.0b013e328363c769; Brian MS, 2017, J HUM HYPERTENS, V31, P145, DOI 10.1038/jhh.2016.53; BRUUN NE, 1990, J HYPERTENS, V8, P219; Cappuccio FP, 2019, NUTR METAB CARDIOVAS, V29, P107, DOI 10.1016/j.numecd.2018.11.010; Cappuccio FP, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-13; Cappuccio FP, 1997, LANCET, V350, P850, DOI 10.1016/S0140-6736(97)02264-2; Carey RM, 2012, HYPERTENSION, V60, P1359, DOI 10.1161/HYPERTENSIONAHA.112.196071; CARNEY SL, 1991, CLIN EXP HYPERTENS A, V13, P401, DOI 10.3109/10641969109045059; Cavka A, 2015, J PHYSIOL-LONDON, V593, P5313, DOI 10.1113/JP271631; CHALMERS JP, 1989, CLIN EXP HYPERTENS A, V11, pR11, DOI 10.3109/10641968909035370; CHALMERS JP, 1989, LANCET, V1, P399; COBIAC L, 1992, J HYPERTENS, V10, P87, DOI 10.1097/00004872-199201000-00014; Cogswell ME, 2016, NEW ENGL J MED, V375, P580, DOI 10.1056/NEJMsb1607161; CREAGER MA, 1991, HYPERTENSION, V17, P989, DOI 10.1161/01.HYP.17.6.989; Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S; Davrath LR, 1999, AVIAT SPACE ENVIR MD, V70, P577; DELRIO A, 1993, J INTERN MED, V233, P409; DELRIO A, 1990, REV CLIN ESP, V186, P5; DENTON D, 1995, NAT MED, V1, P1009, DOI 10.1038/nm1095-1009; Dickinson KM, 2009, AM J CLIN NUTR, V89, P485, DOI 10.3945/ajcn.2008.26856; Dishy V, 2003, J HYPERTENS, V21, P153, DOI 10.1097/00004872-200301000-00025; DODSON PM, 1989, BMJ-BRIT MED J, V298, P227, DOI 10.1136/bmj.298.6668.227; DOIG JK, 1995, J CARDIOVASC PHARM, V25, P511, DOI 10.1097/00005344-199504000-00001; DRAAIJER P, 1995, J HUM HYPERTENS, V9, P263; Ebrahim S, 1998, J PUBLIC HEALTH MED, V20, P441, DOI 10.1093/oxfordjournals.pubmed.a024800; ELASHRY A, 1987, J HUM HYPERTENS, V1, P105; ELLIOTT P, 1988, BRIT MED J, V297, P319; ERWTEMAN TM, 1984, BMJ-BRIT MED J, V289, P406, DOI 10.1136/bmj.289.6442.406; Ferri C, 1996, J AM SOC NEPHROL, V7, P443; Foo M, 1998, CLIN SCI, V95, P157, DOI 10.1042/CS19980065; Forrester T, 2005, J HUM HYPERTENS, V19, P55, DOI 10.1038/sj.jhh.1001782; FOTHERBY MD, 1993, J HYPERTENS, V11, P657, DOI 10.1097/00004872-199306000-00010; Gates PE, 2004, HYPERTENSION, V44, P35, DOI 10.1161/01.HYP.0000132767.74476.64; Gefke M, 2017, CLIN PHYSIOL FUNCT I, V37, P688, DOI 10.1111/cpf.12360; Gijsbers L, 2015, BRIT J NUTR, V114, P1419, DOI 10.1017/S0007114515002986; GILLIES AHB, 1984, CLIN EXP PHARMACOL P, V11, P395, DOI 10.1111/j.1440-1681.1984.tb00286.x; Gomi T, 1998, AM J HYPERTENS, V11, P1048, DOI 10.1016/S0895-7061(98)00126-5; GOW IF, 1992, EUR J CLIN PHARMACOL, V43, P635, DOI 10.1007/BF02284963; Graffe CC, 2012, AM J PHYSIOL-RENAL, V302, pF264, DOI 10.1152/ajprenal.00442.2010; Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383; Graudal N, 2019, AM J CLIN NUTR, V109, P1273, DOI 10.1093/ajcn/nqy384; Graudal N, 2015, ADV NUTR, V6, P169, DOI 10.3945/an.114.007708; Graudal N, 2014, AM J HYPERTENS, V27, P1129, DOI 10.1093/ajh/hpu028; Graudal NA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004022.pub4; Grey A, 1996, AM J HYPERTENS, V9, P317, DOI 10.1016/0895-7061(95)00390-8; GROBBEE DE, 1987, J HYPERTENS, V5, P115, DOI 10.1097/00004872-198702000-00016; HARGREAVES M, 1989, CLIN SCI, V76, P553, DOI 10.1042/cs0760553; He F. J., 2013, BMJ, V346; He FJ, 2018, INT J EPIDEMIOL, V47, P1784, DOI 10.1093/ije/dyy114; He FJ, 2018, NAT REV CARDIOL, V15, P371, DOI 10.1038/s41569-018-0004-1; He FJ, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h770; He FJ, 2009, HYPERTENSION, V54, P482, DOI 10.1161/HYPERTENSIONAHA.109.133223; He FJ, 1998, HYPERTENSION, V32, P820, DOI 10.1161/01.HYP.32.5.820; Herlitz Hans, 1998, Blood Pressure, V7, P47; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Ho JT, 2007, HORM METAB RES, V39, P694, DOI 10.1055/s-2007-985354; HOWE PRC, 1994, J HUM HYPERTENS, V8, P43; Huang LP, 2016, INT J EPIDEMIOL, V45, P239, DOI 10.1093/ije/dyv313; HUGGINS RL, 1992, APPETITE, V18, P111, DOI 10.1016/0195-6663(92)90188-C; Inoue J, 1996, J HUM HYPERTENS, V10, P523; Ishimitsu T, 1996, CLIN SCI, V91, P293, DOI 10.1042/cs0910293; IWAOKA T, 1994, AM J HYPERTENS, V7, P460, DOI 10.1093/ajh/7.5.460; Jessani S, 2008, AM J HYPERTENS, V21, P1238, DOI 10.1038/ajh.2008.256; Johnson AG, 2001, J HYPERTENS, V19, P1053, DOI 10.1097/00004872-200106000-00009; Juraschek SP, 2017, HYPERTENSION, V70, P923, DOI 10.1161/HYPERTENSIONAHA.117.10017; Jurgens G, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004022.pub2, DOI 10.1002/14651858.CD004022.PUB2]; Koolen M I, 1984, J Hypertens, V2, P55, DOI 10.1097/00004872-198402000-00010; KOOLEN MI, 1984, HYPERTENSION, V6, P820, DOI 10.1161/01.HYP.6.6.820; LAWTON WJ, 1988, HYPERTENSION, V11, P529, DOI 10.1161/01.HYP.11.6.529; MACFADYEN RJ, 1994, BRIT J CLIN PHARMACO, V38, P329, DOI 10.1111/j.1365-2125.1994.tb04362.x; MACGREGOR GA, 1987, BMJ-BRIT MED J, V294, P531, DOI 10.1136/bmj.294.6571.531; MACGREGOR GA, 1982, LANCET, V1, P351, DOI 10.1016/S0140-6736(82)91389-7; MACGREGOR GA, 1989, LANCET, V2, P1244, DOI 10.1016/S0140-6736(89)91852-7; Mallamaci F, 2013, J HYPERTENS, V31, P1424, DOI 10.1097/HJH.0b013e328360ddd5; MARK AL, 1975, CIRC RES, V36, P194, DOI 10.1161/01.RES.36.6.194; Markota NP, 2015, J AM SOC HYPERTENS, V9, P214, DOI 10.1016/j.jash.2014.12.022; Matthews EL, 2015, J APPL PHYSIOL, V118, P1510, DOI 10.1152/japplphysiol.00023.2015; MAXWELL MH, 1984, ARCH INTERN MED, V144, P1581, DOI 10.1001/archinte.144.8.1581; McCarron DA, 1997, AM J HYPERTENS, V10, P68, DOI 10.1016/S0895-7061(96)00295-6; McCarron DA, 2013, AM J HYPERTENS, V26, P1218, DOI 10.1093/ajh/hpt139; Meland E, 1997, SCAND J CLIN LAB INV, V57, P501, DOI 10.3109/00365519709084600; Meland E, 2009, SCAND J PRIM HEALTH, V27, P97, DOI 10.1080/02813430802661795; Melander O, 2007, J HYPERTENS, V25, P619, DOI 10.1097/HJH.0b013e328013cd50; Mente A, 2018, LANCET, V392, P496, DOI 10.1016/s0140-6736(18)31376-x; Michell A R, 1989, Nutr Res Rev, V2, P149, DOI 10.1079/NRR19890012; Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590; MORGAN T, 1988, J HYPERTENS, V6, pS652, DOI 10.1097/00004872-198812040-00205; MORGAN T, 1988, J HUM HYPERTENS, V1, P311; MORGAN T, 1987, CAN J PHYSIOL PHARM, V65, P1752, DOI 10.1139/y87-274; MORGAN TO, 1981, MED J AUSTRALIA, V2, P396, DOI 10.5694/j.1326-5377.1981.tb101026.x; Mozaffarian D, 2014, NEW ENGL J MED, V371, P624, DOI 10.1056/NEJMoa1304127; MYERS JB, 1984, J CARDIOVASC PHARM, V6, pS204, DOI 10.1097/00005344-198400061-00032; NESTEL PJ, 1993, J HYPERTENS, V11, P1387, DOI 10.1097/00004872-199312000-00011; Newberry S., 2018, COMP EFFECTIVENESS R; NOWSON CA, 1988, CLIN EXP PHARMACOL P, V15, P225, DOI 10.1111/j.1440-1681.1988.tb01065.x; Nowson CA, 2003, J NUTR, V133, P4118, DOI 10.1093/jn/133.12.4118; PARIJS J, 1973, AM HEART J, V85, P22, DOI 10.1016/0002-8703(73)90522-X; PARKER M, 1990, HYPERTENSION, V16, P398, DOI 10.1161/01.HYP.16.4.398; Parvanova A, 2018, LANCET DIABETES ENDO, V6, P27, DOI [10.1016/S2213-8587(17)30359-5, 10.1016/s2213-8587(17)30359-5]; Paulsen L, 2009, SCAND J CLIN LAB INV, V69, P323, DOI 10.1080/00365510802571007; Pechere-Bertschi A, 2003, KIDNEY INT, V64, P1374, DOI 10.1046/j.1523-1755.2003.00239.x; Perry CG, 2003, CLIN SCI, V105, P187, DOI 10.1042/CS20020320; Peters R M, 2000, Prog Cardiovasc Nurs, V15, P138, DOI 10.1111/j.0889-7204.2000.080404.x; Pimenta E, 2009, HYPERTENSION, V54, P475, DOI 10.1161/HYPERTENSIONAHA.109.131235; Powles J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003733; PUSKA P, 1983, LANCET, V1, P1; REDONMAS J, 1993, J HYPERTENS, V11, P665, DOI 10.1097/00004872-199306000-00011; Resnick L M, 1985, Trans Assoc Am Physicians, V98, P313; Rhee OJ, 2016, INT J CARDIOL, V215, P120, DOI 10.1016/j.ijcard.2016.04.109; RICHARDS AM, 1984, LANCET, V1, P757, DOI 10.1016/S0140-6736(84)91276-5; Riphagen IJ, 2016, J HYPERTENS, V34, P215, DOI 10.1097/HJH.0000000000000786; Rorije NMG, 2018, ANESTHESIOLOGY, V128, P352, DOI 10.1097/ALN.0000000000001989; Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]; RUILOPE LM, 1993, J HYPERTENS, V11, pS17; RUPPERT M, 1993, J HYPERTENS, V11, P743, DOI 10.1097/00004872-199307000-00010; Schorr U, 1997, J HYPERTENS, V15, P845, DOI 10.1097/00004872-199715080-00007; Schorr U, 1999, J HYPERTENS, V17, P475, DOI 10.1097/00004872-199917040-00004; Schorr U, 1996, J HYPERTENS, V14, P131; Scientific Advisory Committee on Nutrition, 2003, SALT HLTH; SHARMA AM, 1990, HYPERTENSION, V16, P407, DOI 10.1161/01.HYP.16.4.407; SHARMA AM, 1991, J HYPERTENS, V9, P329, DOI 10.1097/00004872-199104000-00004; SHARMA AM, 1993, HYPERTENSION, V21, P273, DOI 10.1161/01.HYP.21.3.273; SHARMA AM, 1990, KLIN WOCHENSCHR, V68, P664, DOI 10.1007/BF01667013; SHARMA AM, 1993, AM J HYPERTENS, V6, P780, DOI 10.1093/ajh/6.9.780; SHARMA AM, 1993, J HYPERTENS, V11, P1381, DOI 10.1097/00004872-199312000-00010; SILMAN AJ, 1983, LANCET, V1, P1179; SINGER DRJ, 1991, HYPERTENSION, V17, P798, DOI 10.1161/01.HYP.17.6.798; SKRABAL F, 1981, LANCET, V2, P895; SKRABAL F, 1984, HYPERTENSION, V6, P152, DOI 10.1161/01.HYP.6.2_Pt_1.152; SKRABAL F, 1985, SCAND J CLIN LAB INV, V45, P47; STAESSEN J, 1988, J HYPERTENS, V6, P965, DOI 10.1097/00004872-198812000-00003; Starmans-Kool MJ, 2011, J APPL PHYSIOL, V110, P468, DOI 10.1152/japplphysiol.00917.2010; STEIN CM, 1995, CLIN PHARMACOL THER, V58, P425, DOI 10.1016/0009-9236(95)90056-X; Suckling RJ, 2016, HYPERTENSION, V67, P1189, DOI 10.1161/HYPERTENSIONAHA.115.06637; Swift PA, 2005, HYPERTENSION, V46, P308, DOI 10.1161/01.HYP.0000172662.12480.7f; Townsend RR, 2007, CLIN SCI, V113, P141, DOI 10.1042/CS20060361; Tzemos N, 2008, HYPERTENSION, V51, P1525, DOI 10.1161/HYPERTENSIONAHA.108.109868; U. S. Department of Health and Human Services, 2015 2020 DIET GUID; Uzu T, 1999, AM J HYPERTENS, V12, P35, DOI 10.1016/S0895-7061(98)00182-4; van Berge-Landry H, 2004, ANN HUM BIOL, V31, P477, DOI 10.1080/03014460412331281746; Visser FW, 2008, AM J HYPERTENS, V21, P323, DOI 10.1038/ajh.2007.63; Walkowska A, 2015, KIDNEY BLOOD PRESS R, V40, P323, DOI 10.1159/000368508; Wang M, 2015, GLOB HEART, V10, P291, DOI 10.1016/j.gheart.2014.10.009; Wang Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20048-2; WATT GCM, 1983, BMJ-BRIT MED J, V286, P432, DOI 10.1136/bmj.286.6363.432; Weir MR, 2010, J CARDIOVASC PHARM T, V15, P356, DOI 10.1177/1074248410377173; WEIR MR, 1995, HYPERTENSION, V25, P1339, DOI 10.1161/01.HYP.25.6.1339; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657; WHO, 2012, GUID SOD INT AD CHIL; Wing Lindon M.H., 1998, Blood Pressure, V7, P299; World Health Organization Rotary International Centers for Disease Control and Prevention and UNICEF, 2013, GLOB ACT PLAN PREV C; Yamamoto Hiroshi, 1997, Journal of the Osaka City Medical Center, V46, P255; Zanchi A, 2010, DIABETOLOGIA, V53, P1568, DOI 10.1007/s00125-010-1756-2; Zhu YB, 2018, BMC CARDIOVASC DISOR, V18, DOI 10.1186/s12872-018-0927-9; ZOCCALI C, 1994, J HYPERTENS, V12, P1249; Zoccali C, 1996, J HYPERTENS, V14, P1455, DOI 10.1097/00004872-199612000-00011; ZOCCALI C, 1993, J HYPERTENS, V11, pS326	170	125	126	8	29	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2020	368								m315	10.1136/bmj.m315	http://dx.doi.org/10.1136/bmj.m315			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU2IV	32094151	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000519533000001
J	Blum, MR; Oien, H; Carmichael, HL; Heidenreich, P; Owens, DK; Goldhaber-Fiebert, JD				Blum, Manuel R.; Oien, Henning; Carmichael, Harris L.; Heidenreich, Paul; Owens, Douglas K.; Goldhaber-Fiebert, Jeremy D.			Cost-Effectiveness of Transitional Care Services After Hospitalization With Heart Failure	ANNALS OF INTERNAL MEDICINE			English	Article							MANAGEMENT PROGRAMS; DISEASE; STROKE; ASSOCIATION; STATEMENT; MORTALITY; UPDATE; TRENDS; IMPACT; STAY	Background: Patients with heart failure (HF) discharged from the hospital are at high risk for death and rehospitalization. Transitional care service interventions attempt to mitigate these risks. Objective: To assess the cost-effectiveness of 3 types of post-discharge HF transitional care services and standard care. Design: Decision analytic microsimulation model. Data Sources: Randomized controlled trials, clinical registries, cohort studies, Centers for Disease Control and Prevention life tables, Centers for Medicare & Medicaid Services data, and National Inpatient Sample (Healthcare Cost and Utilization Project) data. Target Population: Patients with HF who were aged 75 years at hospital discharge. Time Horizon: Lifetime. Perspective: Health care sector. Intervention: Disease management clinics, nurse home visits (NHVs), and nurse case management. Outcome Measures: Quality-adjusted life-years (QALYs), costs, net monetary benefits, and incremental cost-effectiveness ratios (ICERs). Results of Base-Case Analysis: All 3 transitional care interventions examined were more costly and effective than standard care, with NHVs dominating the other 2 interventions. Compared with standard care, NHVs increased QALYs (2.49 vs. 2.25) and costs ($81 327 vs. $76 705), resulting in an ICER of $19 570 per QALY gained. Results of Sensitivity Analysis: Results were largely insensitive to variations in in-hospital mortality, age at baseline, or costs of rehospitalization. Probabilistic sensitivity analysis confirmed that transitional care services were preferred over standard care in nearly all 10 000 samples, at willingness-to-pay thresholds of $50 000 or more per QALY gained. Limitation: Transitional care service designs and implementations are heterogeneous, leading to uncertainty about intervention effectiveness and costs when applied in particular settings. Conclusion: In older patients with HF, transitional care services are economically attractive, with NHVs being the most cost-effective strategy in many situations. Transitional care services should become the standard of care for post-discharge management of patients with HF.	[Blum, Manuel R.] Univ Bern, Bern Univ Hosp, Inselspital, Dept Gen Internal Med, CH-3010 Bern, Switzerland; [Oien, Henning] Norwegian Inst Publ Hlth, POB 222, N-0213 Oslo, Norway; [Carmichael, Harris L.] Intermt Healthcare Delivery Inst, 5026 South State St,3rd Floor, Murray, UT 84107 USA; [Heidenreich, Paul] Palo Alto VA Hlth Care Syst, Cardiol 111C, 3801 Miranda Ave, Palo Alto, CA 94304 USA; [Owens, Douglas K.; Goldhaber-Fiebert, Jeremy D.] Stanford Univ, 615 Crothers Way,Encina Commons,MC6019, Stanford, CA 94305 USA	University of Bern; University Hospital of Bern; Norwegian Institute of Public Health (NIPH); Stanford University	Goldhaber-Fiebert, JD (corresponding author), Stanford Univ, Ctr Primary Care, 615 Crothers Way,Encina Commons,MC6019, Stanford, CA 94305 USA.; Goldhaber-Fiebert, JD (corresponding author), Stanford Univ, Ctr Outcomes Res, 615 Crothers Way,Encina Commons,MC6019, Stanford, CA 94305 USA.; Goldhaber-Fiebert, JD (corresponding author), Stanford Univ, Ctr Hlth Policy, 615 Crothers Way,Encina Commons,MC6019, Stanford, CA 94305 USA.	jeremygf@stanford.edu	Heidenreich, Paul/AAU-6864-2021; Carmichael, Harris/HGE-5171-2022; Blum, Manuel/P-9840-2016	Heidenreich, Paul/0000-0001-7730-8490; Blum, Manuel/0000-0003-4638-775X; Goldhaber-Fiebert, Jeremy/0000-0002-4007-5192	Research Council of Norway [256644]; Swiss National Science Foundation [P2BEP3_175289]; Intermountain-Stanford Collaboration Fellowship in Population Health and Care Delivery Science; U.S. Department of Veterans Affairs	Research Council of Norway(Research Council of Norway); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Intermountain-Stanford Collaboration Fellowship in Population Health and Care Delivery Science; U.S. Department of Veterans Affairs(US Department of Veterans Affairs)	Dr. Oien's work was supported by the Research Council of Norway: Project 256644, "A cross-sectoral approach to high quality health care transitions for older people." Dr. Blum's work was supported by a grant from the Swiss National Science Foundation (P2BEP3_175289). Dr. Carmichael's work was supported by the Intermountain-Stanford Collaboration Fellowship in Population Health and Care Delivery Science. Drs. Heidenreich and Owens were supported by the U.S. Department of Veterans Affairs.	Akintoye E, 2017, AM J CARDIOL, V120, P817, DOI 10.1016/j.amjcard.2017.05.058; Al-Omary MS, 2018, HEART LUNG CIRC, V27, P917, DOI 10.1016/j.hlc.2018.01.009; Albert NM, 2015, CIRC-HEART FAIL, V8, P384, DOI 10.1161/HHF.0000000000000006; [Anonymous], 2017, Circulation, V136, pe196, DOI 10.1161/CIR.0000000000000530; Arias Elizabeth, 2012, Natl Vital Stat Rep, V61, P1; Banka G, 2013, J AM COLL CARDIOL, V61, P1440, DOI 10.1016/j.jacc.2012.12.022; Bindman AB, 2018, JAMA INTERN MED, V178, P1165, DOI 10.1001/jamainternmed.2018.2572; Chen J, 2013, J AM COLL CARDIOL, V61, P1078, DOI 10.1016/j.jacc.2012.11.057; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Dharmarajan K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h411; Drummond MF, 2015, METHODS EC EVALUATIO; Federal Reserve Bank of St. Louis, CONS PRIC IND ALL UR; Glasgow RE, 2001, PATIENT EDUC COUNS, V44, P119, DOI 10.1016/S0738-3991(00)00186-5; Gohler A, 2008, EUR J HEART FAIL, V10, P1026, DOI 10.1016/j.ejheart.2008.07.018; Gohler A, 2009, VALUE HEALTH, V12, P185, DOI 10.1111/j.1524-4733.2008.00425.x; Hartman M, 2008, HEALTH AFFAIR, V27, pW1, DOI 10.1377/hlthaff.27.1.w1; Healthcare Cost and Utilization Project, 2018, HCUP FAST STATS MOST; Heidenreich PA, 2013, CIRC-HEART FAIL, V6, P606, DOI 10.1161/HHF.0b013e318291329a; Huckfeldt P, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0634; Husereau D, 2013, VALUE HEALTH, V16, pE1, DOI 10.1016/j.jval.2013.02.010; Krumholz HM, 2014, CIRCULATION, V130, P966, DOI 10.1161/CIRCULATIONAHA.113.007787; Maru S, 2016, EUR J CARDIOVASC NUR, V15, P82, DOI 10.1177/1474515114556031; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Organisation for Economic Co-operation and Development, 2019, 2014 PPP BENCHM RES; Savarese Gianluigi, 2017, Card Fail Rev, V3, P7, DOI 10.15420/cfr.2016:25:2; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Tuppin P, 2014, ARCH CARDIOVASC DIS, V107, P158, DOI 10.1016/j.acvd.2014.01.012; Van Spall HGC, 2017, EUR J HEART FAIL, V19, P1427, DOI 10.1002/ejhf.765; Voigt J, 2014, CLIN CARDIOL, V37, P312, DOI 10.1002/clc.22260; Wadhera RK, 2018, JAMA-J AM MED ASSOC, V320, P2542, DOI 10.1001/jama.2018.19232; Woo CY, 2015, ANN INTERN MED, V163, P417, DOI 10.7326/M14-1804	31	20	21	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 18	2020	172	4					248	+		10.7326/M19-1980	http://dx.doi.org/10.7326/M19-1980			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ2FN	31986526				2023-01-03	WOS:000516744600025
J	[Anonymous]				[Anonymous]			Effect of Acupuncture for Postprandial Distress Syndrome	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	5	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 16	2020	172	12								10.7326/P20-0006	http://dx.doi.org/10.7326/P20-0006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU7TW	32422080				2023-01-03	WOS:000573843400001
J	Bojkova, D; Klann, K; Koch, B; Widera, M; Krause, D; Ciesek, S; Cinatl, J; Munch, C				Bojkova, Denisa; Klann, Kevin; Koch, Benjamin; Widera, Marek; Krause, David; Ciesek, Sandra; Cinatl, Jindrich; Muench, Christian			Proteomics of SARS-CoV-2-infected host cells reveals therapy targets	NATURE			English	Article							NUCLEOCAPSID PROTEIN; RIBAVIRIN; INTERACTOME; SARS; REPLICATION; CYTOSCAPE	A new coronavirus was recently discovered and named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection with SARS-CoV-2 in humans causes coronavirus disease 2019 (COVID-19) and has been rapidly spreading around the globe(1,2). SARS-CoV-2 shows some similarities to other coronaviruses; however, treatment options and an understanding of how SARS-CoV-2 infects cells are lacking. Here we identify the host cell pathways that are modulated by SARS-CoV-2 and show that inhibition of these pathways prevents viral replication in human cells. We established a human cell-culture model for infection with a clinical isolate of SARS-CoV-2. Using this cell-culture system, we determined the infection profile of SARS-CoV-2 by translatome(3)and proteome proteomics at different times after infection. These analyses revealed that SARS-CoV-2 reshapes central cellular pathways such as translation, splicing, carbon metabolism, protein homeostasis (proteostasis) and nucleic acid metabolism. Small-molecule inhibitors that target these pathways prevented viral replication in cells. Our results reveal the cellular infection profile of SARS-CoV-2 and have enabled the identification of drugs that inhibit viral replication. We anticipate that our results will guide efforts to understand the molecular mechanisms that underlie the modulation of host cells after infection with SARS-CoV-2. Furthermore, our findings provide insights for the development of therapies for the treatment of COVID-19. SARS-CoV-2 modulates central cellular pathways, such as translation, splicing, carbon metabolism, proteostasis and nucleic acid metabolism, in human cells; these pathways can be inhibited by small-molecule inhibitors to prevent viral replication in the cells.	[Bojkova, Denisa; Widera, Marek; Ciesek, Sandra; Cinatl, Jindrich] Goethe Univ, Univ Hosp Frankfurt, Inst Med Virol, Frankfurt, Germany; [Klann, Kevin; Krause, David; Muench, Christian] Goethe Univ, Fac Med, Inst Biochem 2, Frankfurt, Germany; [Koch, Benjamin] Univ Hosp Frankfurt, Med Clin 3, Nephrol, Frankfurt, Germany; [Ciesek, Sandra] German Ctr Infect Res DZIF, External Partner Site Frankfurt, Frankfurt, Germany; [Muench, Christian] Frankfurt Canc Inst, Frankfurt, Germany; [Muench, Christian] Cardiopulm Inst, Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt Hospital; German Center for Infection Research	Cinatl, J (corresponding author), Goethe Univ, Univ Hosp Frankfurt, Inst Med Virol, Frankfurt, Germany.; Munch, C (corresponding author), Goethe Univ, Fac Med, Inst Biochem 2, Frankfurt, Germany.; Munch, C (corresponding author), Frankfurt Canc Inst, Frankfurt, Germany.; Munch, C (corresponding author), Cardiopulm Inst, Frankfurt, Germany.	cinatl@em.uni-frankfurt.de; ch.muench@em.uni-frankfurt.de	Widera, Marek/AAF-3691-2020; Munch, Christian/AAW-7256-2020	Widera, Marek/0000-0001-5417-9307; Klann, Kevin/0000-0003-2276-8128; Koch, Benjamin/0000-0002-3253-8396; Munch, Christian/0000-0003-3832-090X	Hilfe fur krebskranke Kinder Frankfurt; Frankfurter Stiftung fur krebskranke Kinder; European Research Council under the European Union [ERC StG 803565, CRC 1177]; Emmy Noether Programme of the Deutsche Forschungsgemeinschaft (DFG) [MU 4216/1-1]; Johanna Quandt Young Academy at Goethe; Aventis Foundation Bridge Award	Hilfe fur krebskranke Kinder Frankfurt; Frankfurter Stiftung fur krebskranke Kinder; European Research Council under the European Union(European Research Council (ERC)); Emmy Noether Programme of the Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Johanna Quandt Young Academy at Goethe; Aventis Foundation Bridge Award	We thank C. Pallas and L. Stegmann for experimental support and G. Tascher and M. Adrian-Allgood for proteomics support. J.C. acknowledges funding by the Hilfe fur krebskranke Kinder Frankfurt and the Frankfurter Stiftung fur krebskranke Kinder. C.M. was supported by the European Research Council under the European Union's Seventh Framework Programme (ERC StG 803565), CRC 1177 and the Emmy Noether Programme of the Deutsche Forschungsgemeinschaft (DFG, MU 4216/1-1), the Johanna Quandt Young Academy at Goethe and an Aventis Foundation Bridge Award.	Chen JY, 2009, ARCH VIROL, V154, P507, DOI 10.1007/s00705-009-0323-y; Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6; Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Cretu C, 2018, MOL CELL, V70, P265, DOI 10.1016/j.molcel.2018.03.011; Emmott E, 2013, J VIROL, V87, P9486, DOI 10.1128/JVI.00321-13; Gualdoni GA, 2018, P NATL ACAD SCI USA, V115, pE7158, DOI 10.1073/pnas.1800525115; Hoehl S, 2020, NEW ENGL J MED, V382, P1278, DOI 10.1056/NEJMc2001899; Jia HP, 2009, AM J PHYSIOL-LUNG C, V297, pL84, DOI 10.1152/ajplung.00071.2009; Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6; Jourdan SS, 2012, PROTEOMICS, V12, P1015, DOI 10.1002/pmic.201100469; Kamitani W, 2009, NAT STRUCT MOL BIOL, V16, P1134, DOI 10.1038/nsmb.1680; Klann K, 2020, MOL CELL, V77, P913, DOI 10.1016/j.molcel.2019.11.010; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Marcelin JR, 2014, TRANSPL INFECT DIS, V16, P242, DOI 10.1111/tid.12194; Martin P, 2008, J GASTROEN HEPATOL, V23, P844, DOI 10.1111/j.1440-1746.2008.05398.x; McKinney W, 2010, P 9 PYTH SCI C SCIPY, P56, DOI [10.25080/Majora-92bf1922-00a, DOI 10.25080/MAJORA-92BF1922-00A]; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07; Neuman BW, 2008, J VIROL, V82, P5279, DOI 10.1128/JVI.02631-07; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015; Plubell DL, 2017, MOL CELL PROTEOMICS, V16, P873, DOI 10.1074/mcp.M116.065524; Pruijssers AJ, 2019, CURR OPIN VIROL, V35, P57, DOI 10.1016/j.coviro.2019.04.002; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Saijo M, 2005, ANTIVIR RES, V66, P159, DOI 10.1016/j.antiviral.2005.01.003; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; She J, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169-020-00271-z; Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19; Song T, 2016, J PROTEOMICS, V142, P70, DOI 10.1016/j.jprot.2016.05.009; Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]; van der Walt S, 2011, COMPUT SCI ENG, V13, P22, DOI 10.1109/MCSE.2011.37; Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0; Wong HH, 2015, J VIROL, V89, P11116, DOI 10.1128/JVI.01360-15; Wu GM, 2017, METHODS MOL BIOL, V1558, P235, DOI 10.1007/978-1-4939-6783-4_11; Wu LS, 2015, ANTIMICROB AGENTS CH, V59, P2179, DOI 10.1128/AAC.04618-14; Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055; Yan BP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010073; Ye YH, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00039; Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204; Zhang JT, 2019, EUR J PHARM SCI, V133, P86, DOI 10.1016/j.ejps.2019.03.020; Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	43	491	493	18	156	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 16	2020	583	7816					469	+		10.1038/s41586-020-2332-7	http://dx.doi.org/10.1038/s41586-020-2332-7		MAY 2020	16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK4AA	32408336	Green Submitted, Bronze			2023-01-03	WOS:000546554300001
J	Silverman, JG; Fonseka, RW; Dehingia, N; Boyce, SC; Chandurkar, D; Singh, K; Hay, K; Atmavilas, Y; Raj, A				Silverman, Jay G.; Fonseka, Ruvani W.; Dehingia, Nabamallika; Boyce, Sabrina C.; Chandurkar, Dharmendra; Singh, Kultar; Hay, Katherine; Atmavilas, Yamini; Raj, Anita			Associations between recent intimate partner violence and receipt and quality of perinatal health services in Uttar Pradesh	PLOS ONE			English	Article							DOMESTIC VIOLENCE; PREGNANCY; CARE; MORTALITY; IMPACT; ABUSE; WOMEN; CHILD	Background India suffers some of the highest maternal and neonatal mortality rates in the world. Intimate partner violence (IPV) can be a barrier to utilization of perinatal care, and has been associated with poor maternal and neonatal health outcomes. However, studies that assess the relationship between IPV and perinatal health care often focus solely on receipt of services, and not the quality of the services received. Methods and findings Data were collected in 2016-2017 from a representative sample of women (15-49yrs) in Uttar Pradesh, India who had given birth within the previous 12 months (N = 5020), including use of perinatal health services and past 12 months experiences of physical and sexual IPV. Multivariate logistic regression models assessed whether physical or sexual IPV were associated with perinatal health service utilization and quality. Reports of IPV were not associated with odds of receiving antenatal care or a health worker home visit during the third trimester, but physical IPV was associated with fewer diagnostic tests during antenatal visits (beta = -0.30), and fewer health topics covered during home visits (beta = -0.44). Recent physical and recent sexual IPV were both associated with decreased odds of institutional delivery (physical IPV AOR 0.65; sexual IPV AOR 0.61), and recent sexual IPV was associated with leaving a delivery facility earlier than recommended (AOR = 1.87). Neither form of IPV was associated with receipt of a postnatal home visit, but recent physical IPV was associated with fewer health topics discussed during such visits (beta = -0.26). Conclusions In this study, reduced quantity and quality of perinatal health care were associated with recent IPV experiences. In cases where IPV was not related to care receipt, IPV remained associated with diminished care quality. Additional study to understand the mechanisms underlying associations between IPV and care qualities is required to inform health services.	[Silverman, Jay G.; Fonseka, Ruvani W.; Dehingia, Nabamallika; Boyce, Sabrina C.; Raj, Anita] Univ Calif San Diego, Ctr Gender Equ & Hlth GEH, La Jolla, CA 92093 USA; [Chandurkar, Dharmendra; Singh, Kultar] Sambodhi Res & Commun Pvt Ltd, Noida, Uttar Pradesh, India; [Hay, Katherine] Bill & Melinda Gates Fdn Seattle Off, Seattle, WA USA; [Atmavilas, Yamini] Bill & Melinda Gates Fdn India Country Off, Delhi, Uttar Pradesh, India	University of California System; University of California San Diego	Silverman, JG (corresponding author), Univ Calif San Diego, Ctr Gender Equ & Hlth GEH, La Jolla, CA 92093 USA.	jgsilverman@ucsd.edu	Hay, Katherine/ABB-7795-2021; Dehingia, Nabamallika/AAY-5588-2021; Dehingia, Nabamallika/AAF-1639-2021	Dehingia, Nabamallika/0000-0003-1787-9050; Fonseka, Ruvani W./0000-0002-2809-3574	Bill and Melinda Gates Foundation (BMGF); BMGF via Sambodhi Research and Communications Private Limited; BMGF [OPP1083531]; Sambodhi Research and Communications Private Limited	Bill and Melinda Gates Foundation (BMGF)(Bill & Melinda Gates Foundation); BMGF via Sambodhi Research and Communications Private Limited; BMGF; Sambodhi Research and Communications Private Limited	This manuscript and the survey used for data collection were supported by the Bill and Melinda Gates Foundation (BMGF www.gatesfoundation.org). JGS, RWF, ND, SCB and AR received funding from BMGF via Sambodhi Research and Communications Private Limited, where DC and KS are staff and received BMGF funding directly [all funded through #OPP1083531]. DC and KS received support in the form of a salary from Sambodhi Research and Communications Private Limited. KH and YA are BMGF staff who participated in the development of this study and the generation of this manuscript, and are recognized as coauthors. In their roles with BMGF, they were involved with the design and conduct of the TSU survey from which data for this study were obtained. They provided some oversight of data collection and management, and gave input into analyses included in this manuscript. They assisted with the interpretation of this paper and reviewed and approved this final manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Acharya A, 2015, AM J PUBLIC HEALTH, V105, P144, DOI 10.2105/AJPH.2014.302092; Ackerson LK, 2009, PEDIATRICS, V124, pE878, DOI 10.1542/peds.2009-0524; Afulani PA, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0925-9; Ahmed S, 2006, AM J PUBLIC HEALTH, V96, P1423, DOI 10.2105/AJPH.2005.066316; Alhusen JL, 2014, J WOMENS HEALTH, V23, P920, DOI 10.1089/jwh.2014.4862; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; Beydoun HA, 2011, SOC SCI MED, V72, P867, DOI 10.1016/j.socscimed.2011.01.006; Boyce SC, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1577-0; Campbell J, 2004, VIOLENCE AGAINST WOM, V10, P770, DOI 10.1177/1077801204265551; Chalmers B, 2001, BIRTH-ISS PERINAT C, V28, P202, DOI 10.1046/j.1523-536x.2001.00202.x; Chatterjee A, 2011, BJOG-INT J OBSTET GY, V118, P47, DOI 10.1111/j.1471-0528.2011.03112.x; Desa U.N., 2016, TRANSF OUR WORLD 203; Dhar D, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0551-2; Gilmore B, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-847; International Institute for Population Sciences, 2005, NAT FAM HLTH SURV NF; Kuhlmann AKS, 2017, REV PANAM SALUD PUBL, V41; Leserman J, 1996, PSYCHOSOM MED, V58, P4, DOI 10.1097/00006842-199601000-00002; Mahapatro M, 2011, J INTERPERS VIOLENCE, V26, P2973, DOI 10.1177/0886260510390948; Montgomery MR, 2000, DEMOGRAPHY, V37, P155, DOI 10.2307/2648118; Office of the Registrar General & Census Commissioner India, 2012, ANN HLTH SURV B VIT; Ononokpono DN, 2014, HEALTH CARE WOMEN IN, V35, P973, DOI 10.1080/07399332.2014.924939; Rahman M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-913; Raj A, 2010, ARCH DIS CHILD, V95, P931, DOI 10.1136/adc.2009.178707; Raj A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b4258; Sankar MJ, 2016, J PERINATOL, V36, pS3, DOI 10.1038/jp.2016.183; Seth A, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0538-6; Silverman JG, 2006, AM J OBSTET GYNECOL, V195, P140, DOI 10.1016/j.ajog.2005.12.052; Silverman JG, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0223-z; Silverman JG, 2016, MATERN CHILD HLTH J, V20, P149, DOI 10.1007/s10995-015-1814-y; StataCorp, 2009, STAT STAT SOFTW REL; Sudha S, 2011, WOMEN HEALTH ISS, V21, P214, DOI 10.1016/j.whi.2011.01.004; Tuncalp O, 2015, BJOG-INT J OBSTET GY, V122, P1045, DOI 10.1111/1471-0528.13451; Wardlaw T, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-82; WHO, 2022, WHO RECOMMENDATIONS; WHO, 2014, TRENDS MAT MORT 1990	35	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2020	15	5							e0232079	10.1371/journal.pone.0232079	http://dx.doi.org/10.1371/journal.pone.0232079			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU0YZ	32407320	Green Published, gold			2023-01-03	WOS:000537490700011
J	Li, SN; Peng, LB; Tan, CQ; Zeng, XH; Wan, XM; Luo, X; Yi, LD; Li, JH				Li, Sini; Peng, Liubao; Tan, Chongqing; Zeng, Xiaohui; Wan, Xiaomin; Luo, Xia; Yi, Lidan; Li, Jianhe			Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China	PLOS ONE			English	Article							ECONOMIC-EVALUATION; DOUBLE-BLIND; CHEMOTHERAPY; BEVACIZUMAB; COMBINATION; PERSPECTIVE; RAINBOW; PHASE	Aim That clinical trial (RAINBOW) showed that a 7.4 months overall survival benefit with the combination therapy with ramucirumab (RAM) and paclitaxel (PAC) as second-line therapy for patients with recurrent or metastatic gastric or gastro-oesophageal junction adenocarcinoma, compared with placebo (PLA) plus paclitaxel. We performed an analysis to assess the cost-effectiveness of RAM from a Chinese perspective and recognized the range of drug costs. Methods By building a Markov model to estimate quality-adjusted life-years (QALYs), life-years (LYs) and lifetime costs. Transition probabilities, costs and utilities were estimated for the published literature, Chinese health care system and local price setting. We performed threshold analyses and probabilistic sensitivity analyses to evaluate the uncertainty of the model. Results Compared with PLA strategy, RAM strategy provided an incremental survival benefit of 1.22 LYs and 0.64 QALYs. The probabilistic sensitivity analysis showed that when RAM costs less than $151 or $753 per 4 weeks, the incremental cost-effectiveness ratio (ICER) approximated the willingness-to-pay threshold (WTP), suggesting that there was 50% likelihood that the ICER for RAM + PAC would be less than $44528.4 per QALY or $48121 per QALY, respectively. Conclusions For patients with advanced gastric or gastro-oesophageal junction adenocarcinoma who fail first-line chemotherapy, our results are conducive to the multilateral drug price guidance negotiations of RAM in China.	[Li, Sini] Cent South Univ, Xiangya Nursing Sch, Changsha, Hunan, Peoples R China; [Peng, Liubao; Tan, Chongqing; Wan, Xiaomin; Luo, Xia; Yi, Lidan; Li, Jianhe] Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha, Hunan, Peoples R China; [Zeng, Xiaohui] Cent South Univ, Xiangya Hosp 2, PET CT Ctr, Changsha, Hunan, Peoples R China	Central South University; Central South University; Central South University	Li, JH (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha, Hunan, Peoples R China.	lijianhexy@126.com	Wan, Xiaomin/GPX-4388-2022	Li, Sini/0000-0002-1347-4024; /0000-0001-5315-8141				Boku N, 2014, GASTRIC CANCER, V17, P1, DOI 10.1007/s10120-013-0252-z; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buyukkaramikli NC, 2017, PHARMACOECONOMICS, V35, P1211, DOI 10.1007/s40273-017-0528-y; Choi YY, 2015, YONSEI MED J, V56, P1177, DOI 10.3349/ymj.2015.56.5.1177; Durkee BY, 2016, J CLIN ONCOL, V34, P902, DOI 10.1200/JCO.2015.62.9105; Goldstein DA, 2015, J CLIN ONCOL, V33, P3727, DOI 10.1200/JCO.2015.61.9569; Goldstein DA, 2015, J CLIN ONCOL, V33, P1112, DOI 10.1200/JCO.2014.58.4904; Greig SL, 2015, BIODRUGS, V29, P341, DOI 10.1007/s40259-015-0138-1; Gridelli C, 2014, J CANCER RES CLIN, V140, P1783, DOI 10.1007/s00432-014-1715-2; Juttner S, 2006, J CLIN ONCOL, V24, P228, DOI 10.1200/JCO.2004.00.3467; Lam SW, 2017, PHARMACOTHERAPY, V37, P94, DOI 10.1002/phar.1870; National Comprehensive Cancer Network, NCCN CLIN PRACT GUID; Ohtsu A, 2011, J CLIN ONCOL, V29, P3968, DOI 10.1200/JCO.2011.36.2236; Peng JY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199553; Peng LB, 2009, PHARMACOECONOMICS, V27, P873, DOI 10.2165/11314750-000000000-00000; Shitara K, 2016, GASTRIC CANCER, V19, P927, DOI 10.1007/s10120-015-0559-z; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Suzuki S, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-659; Tan CQ, 2014, PHARMACOECONOMICS, V32, P235, DOI 10.1007/s40273-013-0065-2; Tan CQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083396; Tao C, 2017, INT J CARDIOL, V240, P403, DOI 10.1016/j.ijcard.2017.05.003; The People's Bank of China, EXCH RAT; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wagner AD, 2006, J CLIN ONCOL, V24, P2903, DOI 10.1200/JCO.2005.05.0245; Wan XM, 2017, CANCER-AM CANCER SOC, V123, P2634, DOI 10.1002/cncr.30666; Wan XM, 2019, BREAST, V43, P1, DOI 10.1016/j.breast.2018.10.004; WHO, GLOB 2012 EST STOM C; Wilke H, 2014, LANCET ONCOL, V15, P1224, DOI 10.1016/S1470-2045(14)70420-6; Wu B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032530; Wu B, 2012, CLIN THER, V34, P468, DOI 10.1016/j.clinthera.2012.01.012; Zeng XH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088881	31	11	11	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2020	15	5							e0232240	10.1371/journal.pone.0232240	http://dx.doi.org/10.1371/journal.pone.0232240			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT7ZX	32379763	Green Published, gold			2023-01-03	WOS:000537285700028
J	De Natale, A; Mele, BH; Cennamo, P; Del Mondo, A; Petraretti, M; Pollio, A				De Natale, Antonino; Mele, Bruno Hay; Cennamo, Paola; Del Mondo, Angelo; Petraretti, Mariagioia; Pollio, Antonino			Microbial biofilm community structure and composition on the lithic substrates of Herculaneum Suburban Baths	PLOS ONE			English	Article							HETEROTROPHIC MICROORGANISMS; PHOTOTROPHIC BIOFILMS; COLONIZATION; DIVERSITY; CAVE; MORTARS; NAPLES; MONUMENTS; SAMPLES; FUNGI	In this work, we want to investigate the impact of different substrates and different environmental condition on the biofilm communities growing on plaster, marble, and mortar substrates inside the Herculaneum Suburban Baths. To do so, we measured environmental conditions and sampled biofilm communities along the walls of the baths and used culturedependent and -independent molecular techniques (DGGE) to identify the species at each sampling sites. We used the species pool to infer structure and richness of communities within each site in each substrate, and confocal light scanning microscopy to assess the three-dimensional structure of the sampled biofilms. To gather further insights, we built a meta-community network and used its local realizations to analyze co-occurrence patterns of species. We found that light is a limiting factor in the baths environment, that moving along sites equals moving along an irradiation gradient, and that such gradient shapes the community structure, de facto separating a dark community, rich in Bacteria, Fungi and cyanobacteria, from two dim communities, rich in Chlorophyta. Almost all sites are dominated by photoautotrophs, with Fungi and Bacteria relegated to the role of rare species., and structural properties of biofilms are not consistent within the same substrate. We conclude that the Herculaneum suburban baths are an environment-shaped community, where one dark community (plaster) and one dim community (mortar) provides species to a "midway" community (marble).	[De Natale, Antonino; Del Mondo, Angelo; Petraretti, Mariagioia; Pollio, Antonino] Univ Naples Federico II, Complesso Univ Monte St Angelo, Dipartimento Biol, Naples, Italy; [Mele, Bruno Hay] Stn Zool Anton Dohrn, Dept Integrat Marine Ecol, Naples, Italy; [Cennamo, Paola] Univ Suor Orsola Benincasa Naples, Fac Lettere, Naples, Italy; [Pollio, Antonino] Complesso Univ Monte St Angelo, Task Force Ateneo Federico II Napoli, Metodol Analit Salvaguardia Beni Culturali Masbc, Naples, Italy	University of Naples Federico II; Stazione Zoologica Anton Dohrn di Napoli; Suor Orsola Benincasa University Naples	Del Mondo, A (corresponding author), Univ Naples Federico II, Complesso Univ Monte St Angelo, Dipartimento Biol, Naples, Italy.	angelo.delmondo@unina.it	Del Mondo, Angelo/AAO-7634-2020; De Natale, Antonino/AAV-2128-2020; Hay Mele, Bruno/U-5841-2019; Del Mondo, Angelo/AAC-4737-2022	De Natale, Antonino/0000-0002-1481-449X; Hay Mele, Bruno/0000-0001-5579-183X; Del Mondo, Angelo/0000-0002-7983-0861	Herculaneum Archaeological Park	Herculaneum Archaeological Park	The authors thank the Herculaneum Archaeological Park, and particularly Giuseppe Zolfo for the kind guidance and support, the Societa dei Naturalisti in Napoli (Naples, Italy) for the assistance in research.	Albertano P, 1999, MICROB ECOL, V38, P244, DOI 10.1007/s002489900174; Albertano P, 2012, ECOLOGY CYANOBACTERI, VII, P317, DOI DOI 10.1007/978-94-007-3855-3_11; Amadori ML, 2015, MICROCHEM J, V118, P183, DOI 10.1016/j.microc.2014.08.016; [Anonymous], 2021, TIDYVERSE EASILY INS; [Anonymous], 2018, R LANG ENV STAT COMP; Barberousse H, 2007, BUILD ENVIRON, V42, P2555, DOI 10.1016/j.buildenv.2006.07.031; Cennamo P, 2016, SCI TOTAL ENVIRON, V543, P727, DOI 10.1016/j.scitotenv.2015.11.048; Cennamo P, 2012, J CAVE KARST STUD, V74, P243, DOI 10.4311/2011JCKS0194; Chen SL, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0008613, 10.1371/journal.pone.0015633]; Curtis TP, 2004, CURR OPIN MICROBIOL, V7, P221, DOI 10.1016/j.mib.2004.04.010; Cutler NA, 2015, FEMS MICROBIOL ECOL, V91, DOI 10.1093/femsec/fiu027; Deiss J.J., 1989, HERCULANEUM ITALYS B; Del Mondo A, 2017, INT J CONSERV SCI, V8, P651; Diez B, 2001, APPL ENVIRON MICROB, V67, P2942, DOI 10.1128/AEM.67.7.2942-2951.2001; Doyle J. L. ., 1987, FOCUS, V19, P11, DOI DOI 10.2307/2419362; FRUCHTERMAN TMJ, 1991, SOFTWARE PRACT EXPER, V21, P1129, DOI 10.1002/spe.4380211102; Gorbushina AA, 2007, ENVIRON MICROBIOL, V9, P1613, DOI 10.1111/j.1462-2920.2007.01301.x; Groth I, 1999, GEOMICROBIOL J, V16, P1, DOI 10.1080/014904599270703; Guidobaldi M.P, 2008, ERCOLANO TRE SECOLI; Hartig SM, 2013, CURRENT PROTOCOLS MO, V14; Haussler S, 2013, J BACTERIOL, V195, P2947, DOI 10.1128/JB.00239-13; Heydorn A, 2000, MICROBIOL-UK, V146, P2409, DOI 10.1099/00221287-146-10-2409; Izzo F, 2016, CONSTR BUILD MATER, V117, P129, DOI 10.1016/j.conbuildmat.2016.04.101; Laiz L, 2003, ENVIRON MICROBIOL, V5, P72, DOI 10.1046/j.1462-2920.2003.00381.x; Leone G, 2017, ARCHAEOMETRY, V59, P747, DOI 10.1111/arcm.12275; Leone G, 2016, THERMOCHIM ACTA, V624, P86, DOI 10.1016/j.tca.2015.12.003; Maciejewska M, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01181; McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401; Nubel U, 1997, APPL ENVIRON MICROB, V63, P3327; Paerl HW, 1992, ALGAE SYMBIOSES PLAN, P537; Pesaresi P, 2008, CONSERVATION MANAGEM, V8, P215; Pusz W, 2015, GEOMICROBIOL J, V32, P59, DOI 10.1080/01490451.2014.925010; Rawat S, 2017, DEV FUNGAL BIOL APPL; Roldan M, 2009, INT J SPELEOL, V38, P41, DOI 10.5038/1827-806X.38.1.5; Saarela M, 2004, INT BIODETER BIODEGR, V54, P27, DOI 10.1016/j.ibiod.2003.12.003; Saez-Nieto J. A., 2017, New Microbes and New Infections, V19, P19, DOI 10.1016/j.nmni.2017.05.006; Scheerer S, 2009, ADV APPL MICROBIOL, V66, P97, DOI 10.1016/S0065-2164(08)00805-8; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Thiel, 2011, ENCY GEOBIOLOGY ENCY, DOI DOI 10.1007/978-1-4020-9212-1_102; Tran TH, 2012, INT BIODETER BIODEGR, V70, P31, DOI 10.1016/j.ibiod.2011.10.017; Tomaselli L, 2000, INT BIODETER BIODEGR, V46, P251, DOI 10.1016/S0964-8305(00)00078-0; Tomczyk-Zak K, 2016, GEOMICROBIOL J, V33, P20, DOI 10.1080/01490451.2014.1003341; Urzi C, 2001, J MICROBIOL METH, V44, P1, DOI 10.1016/S0167-7012(00)00227-X; Urzi C, 2010, MICROB ECOL, V60, P116, DOI 10.1007/s00248-010-9710-x; VandeLiefvoort S, 2012, BABESCH, V87, P187; Vanderwolf KJ, 2013, INT J SPELEOL, V42, P77, DOI 10.5038/1827-806X.42.1.9; Vaughan DJ, 2002, MINERAL MAG, V66, P653, DOI 10.1180/0026461026650054; VILES H, 1995, GEOMORPHOLOGY, V13, P21, DOI 10.1016/0169-555X(95)00024-Y; WHITE JF, 1993, AM J BOT, V80, P1465, DOI 10.2307/2445676; White TJ, 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1; Yasir M, 2018, BRAZ J MICROBIOL, V49, P248, DOI 10.1016/j.bjm.2017.08.005; Zammit G, 2008, ISAS INT SEM LTD JER, P1; Zhang F., 2015, PLOS ONE, V10, P7, DOI DOI 10.1371/	53	5	5	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2020	15	5							e0232512	10.1371/journal.pone.0232512	http://dx.doi.org/10.1371/journal.pone.0232512			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT3GS	32365130	Green Published, gold			2023-01-03	WOS:000536959700036
J	Davidov, T; Efraim, Y; Dahan, N; Baruch, L; Machluf, M				Davidov, Tzila; Efraim, Yael; Dahan, Nitsan; Baruch, Limor; Machluf, Marcelle			Porcine arterial ECM hydrogel: Designing an in vitro angiogenesis model for long-term high-throughput research	FASEB JOURNAL			English	Article						angiogenesis; arterial ECM; ECM hydrogel; in vitro model	EXTRACELLULAR-MATRIX; GROWTH-FACTOR; SUNITINIB; VIVO; DECELLULARIZATION; ENCAPSULATION; CULTURE; ASSAYS	The field of angiogenesis research provides deep understanding regarding this important process, which plays fundamental roles in tissue development and different abnormalities. In vitro models offer the advantages of low-cost high-throughput research of angiogenesis while sparing animal lives, and enabling the use of human cells. Nevertheless, prevailing in vitro models lack stability and are limited to a few days' assays. This study, therefore, examines the hypothesis that closely mimicking the vascular microenvironment can more reliably support longer angiogenesis processes in vitro. To this end, porcine arterial extracellular matrix (paECM)- a key component of blood vessels-was isolated and processed into a thermally induced hydrogel and characterized in terms of composition, structure, and mechanical properties, thus confirming the preservation of important characteristics of arterial extracellular matrix. This unique hydrogel was further tailored into a three-dimensional model of angiogenesis using endothelial cells and supporting cells, in a configuration that allows high-throughput quantitative analysis of cell viability and proliferation, cell migration, and apoptosis, thus revealing the advantages of paECM over frequently used biomaterials. Markedly, when applied with well-known effectors of angiogenesis, the model measures reflected the expected response, hence validating its efficacy and establishing its potential as a promising tool for the research of angiogenesis.	[Davidov, Tzila; Efraim, Yael; Baruch, Limor; Machluf, Marcelle] Technion Israel Inst Technol, Fac Biotechnol & Food Engn, Haifa, Israel; [Dahan, Nitsan] Technion Israel Inst Technol, Life Sci & Engn Ctr, Infrastruct Unit, Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology	Machluf, M (corresponding author), Technion Israel Inst Technol, Life Sci & Engn Ctr, Haifa, Israel.	machlufm@bfe.technion.ac.il	Baruch, Limor/AAC-7019-2022		Technion-Israel Institute of Technology (Technion)	Technion-Israel Institute of Technology (Technion)	Technion-Israel Institute of Technology (Technion)	Abdel-Aziz AK, 2016, EXP NEUROL, V283, P129, DOI 10.1016/j.expneurol.2016.06.004; Aguirre A, 2010, BIOCHEM BIOPH RES CO, V400, P284, DOI 10.1016/j.bbrc.2010.08.073; Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; Cebe-Suarez S, 2006, CELL MOL LIFE SCI, V63, P601, DOI 10.1007/s00018-005-5426-3; Chaimov D, 2017, J CONTROL RELEASE, V257, P91, DOI 10.1016/j.jconrel.2016.07.045; Chwalek K, 2014, SCI REP-UK, V4, DOI 10.1038/srep04414; Clause KC, 2013, CURR OPIN BIOTECH, V24, P830, DOI 10.1016/j.copbio.2013.04.011; Coronado RE, 2017, CELL TRANSPLANT, V26, P1840, DOI 10.1177/0963689717742157; Dahan N, 2017, TISSUE ENG PT A, V23, P69, DOI [10.1089/ten.tea.2016.0126, 10.1089/ten.TEA.2016.0126]; Dahan N, 2012, TISSUE ENG PT A, V18, P411, DOI [10.1089/ten.tea.2011.0173, 10.1089/ten.TEA.2011.0173]; de Bouard S, 2007, NEURO-ONCOLOGY, V9, P412, DOI 10.1215/15228517-2007-024; Deng L, 2003, J INVEST DERMATOL, V121, P1060, DOI 10.1046/j.1523-1747.2003.12565.x; DeQuach JA, 2011, TISSUE ENG PT A, V17, P2583, DOI [10.1089/ten.tea.2010.0724, 10.1089/ten.TEA.2010.0724]; Efraim Y, 2017, ACTA BIOMATER, V50, P220, DOI 10.1016/j.actbio.2016.12.015; Eitan Y, 2010, TISSUE ENG PART C-ME, V16, P671, DOI [10.1089/ten.tec.2009.0111, 10.1089/ten.TEC.2009.0111]; Faibish M, 2011, JOVE-J VIS EXP, V55, P2; Feng XL, 2013, J ANAL METHODS CHEM, V2013, DOI 10.1155/2013/246986; Gilbert TW, 2006, BIOMATERIALS, V27, P3675, DOI 10.1016/j.biomaterials.2006.02.014; Grant CA, 2011, J MECH BEHAV BIOMED, V4, P535, DOI 10.1016/j.jmbbm.2010.12.011; Hao ZL, 2016, ONCOTARGETS THER, V9, P5495, DOI 10.2147/OTT.S112242; Heiss M, 2015, FASEB J, V29, P3076, DOI 10.1096/fj.14-267633; Hinderer S, 2016, ADV DRUG DELIVER REV, V97, P260, DOI 10.1016/j.addr.2015.11.019; Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3; Karamanos NK, 2019, MATRIX BIOL, V75-76, P1, DOI 10.1016/j.matbio.2018.08.007; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Keshaw H, 2005, BIOMATERIALS, V26, P4171, DOI 10.1016/j.biomaterials.2004.10.021; Khoo CP, 2011, TISSUE ENG PART C-ME, V17, P895, DOI [10.1089/ten.tec.2011.0150, 10.1089/ten.TEC.2011.0150]; Kim SH, 2011, J ENDOCRINOL, V209, P139, DOI 10.1530/JOE-10-0377; Maj E, 2016, INT J ONCOL, V49, P1773, DOI 10.3892/ijo.2016.3709; Martin S., 2009, ANGIOGENESIS PROTOCO; Massensini AR, 2015, ACTA BIOMATER, V27, P116, DOI 10.1016/j.actbio.2015.08.040; Moon JJ, 2010, BIOMATERIALS, V31, P3840, DOI 10.1016/j.biomaterials.2010.01.104; Morin KT, 2013, EXP CELL RES, V319, P2409, DOI 10.1016/j.yexcr.2013.06.006; Nakatsu Martin N, 2007, J Vis Exp, P186, DOI 10.3791/186; Nemati S, 2017, BIOTECHNOL BIOENG, V114, P2920, DOI 10.1002/bit.26395; Rosalina I, 2002, CARBOHYD POLYM, V48, P191, DOI 10.1016/S0144-8617(01)00235-1; Sarig U, 2016, ACTA BIOMATER, V44, P209, DOI 10.1016/j.actbio.2016.08.031; Sarig U, 2015, TISSUE ENG PT A, V21, P1507, DOI [10.1089/ten.tea.2014.0477, 10.1089/ten.TEA.2014.0477]; Sarkanen JR, 2011, FRONT PHARMACOL, V1, DOI 10.3389/fphar.2010.00147; Schor AM, 2001, METH MOLEC MED, V46, P145, DOI 10.1385/1-59259-143-4:145; Taylor DA, 2018, ACTA BIOMATER, V74, P74, DOI 10.1016/j.actbio.2018.04.044; Ucuzian AA, 2014, MICROVASC RES, V14, P220; Ucuzian AA, 2007, WORLD J SURG, V31, P654, DOI 10.1007/s00268-006-0763-4; West DC, 2001, METH MOLEC MED, V46, P107, DOI 10.1385/1-59259-143-4:107; Wolf MT, 2012, BIOMATERIALS, V33, P7028, DOI 10.1016/j.biomaterials.2012.06.051; Wood DJ, 2014, J R SOC INTERFACE, V12, P20141079	47	4	5	3	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2020	34	6					7745	7758		10.1096/fj.202000264	http://dx.doi.org/10.1096/fj.202000264		APR 2020	14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MR4QG	32337805	Bronze			2023-01-03	WOS:000529407300001
J	Lai, XL; Hao, WR; Friedman, A				Lai, Xiulan; Hao, Wenrui; Friedman, Avner			TNF-alpha inhibitor reduces drug-resistance to anti-PD-1: A mathematical model	PLOS ONE			English	Article							ACQUIRED-RESISTANCE; DENDRITIC CELLS; BREAST-CANCER; PD-1 BLOCKADE; T-CELLS; CHEMOTHERAPY; IPILIMUMAB; NIVOLUMAB; THERAPY; SENSITIVITY	Drug resistance is a primary obstacle in cancer treatment. In many patients who at first respond well to treatment, relapse occurs later on. Various mechanisms have been explored to explain drug resistance in specific cancers and for specific drugs. In this paper, we consider resistance to anti-PD-1, a drug that enhances the activity of anti-cancer T cells. Based on results in experimental melanoma, it is shown, by a mathematical model, that resistances to anti-PD-1 can be significantly reduced by combining it with anti-TNF-alpha. The model is used to simulate the efficacy of the combined therapy with different range of doses, different initial tumor volume, and different schedules. In particular, it is shown that under a course of treatment with 3-week cycles where each drug is injected in the first day of either week 1 or week 2, injecting anti-TNF-alpha one week after anti-PD-1 is the most effective schedule in reducing tumor volume.	[Lai, Xiulan] Renmin Univ China, Inst Math Sci, Beijing, Peoples R China; [Hao, Wenrui] Penn State Univ, Dept Math, State Coll, PA USA; [Friedman, Avner] Ohio State Univ, Math Biosci Inst, Columbus, OH 43210 USA; [Friedman, Avner] Ohio State Univ, Dept Math, 231 W 18th Ave, Columbus, OH 43210 USA	Renmin University of China; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Friedman, A (corresponding author), Ohio State Univ, Math Biosci Inst, Columbus, OH 43210 USA.; Friedman, A (corresponding author), Ohio State Univ, Dept Math, 231 W 18th Ave, Columbus, OH 43210 USA.	afriedman@math.osu.edu	Lai, Xiula/GMX-1854-2022	HAO, WENRUI/0000-0002-6925-7424	Fundamental Research Funds for the Central Universities [19XNLG14]; Renmin University of China; National Natural Science Foundation of China [11571364]; National Science Foundation [DMS-1818769]; Mathematical Biosciences Institute	Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Renmin University of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Foundation(National Science Foundation (NSF)); Mathematical Biosciences Institute	XL was partially supported by the Fundamental Research Funds for the Central Universities (19XNLG14), and the Research Funds of Renmin University of China, and National Natural Science Foundation of China (11571364). WH was partially supported by the National Science Foundation (Grant DMS-1818769).; The authors thank Mathematical Biosciences Institute for the support of this collaboration. WHwas partially supported by the National Science Foundation (Grant DMS-1818769). XL was partially supported by the Fundamental Research Funds for the Central Universities (19XNLG14), and the Research Funds of Renmin University of China, and the National Natural Science Foundation of China (No.11571364).	Anagnostou V, 2017, CANCER DISCOV, V7, P264, DOI 10.1158/2159-8290.CD-16-0828; Bertrand F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02358-7; Chen LH, 2014, INT J MOL SCI, V15, P817, DOI 10.3390/ijms15010817; Chen Y, 2017, J AM HEART ASSOC, V6, P1; Cheng X., HUMAN PD L1 B7 H1 CD; Cho H, 2018, J THEOR BIOL, V436, P120, DOI 10.1016/j.jtbi.2017.10.005; Cho H, 2018, APPL MATH MODEL, V64, P733, DOI 10.1016/j.apm.2018.07.025; Chou FC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020430; Cree IA, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-2999-1; DAcunto B., 2004, SERIES ADV MATH APPL, V67; Donia M, 2015, CANCER RES, V75, P3747, DOI 10.1158/0008-5472.CAN-14-2956; Feizabadi MS, 2017, THEOR BIOL MED MODEL, V14, DOI 10.1186/s12976-017-0052-y; Friedman A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192449; Friedman A, 2018, B MATH BIOL, V80, P1111, DOI 10.1007/s11538-017-0254-9; G T Zanudo Jorge, 2018, Curr Opin Syst Biol, V9, P1, DOI 10.1016/j.coisb.2018.02.002; Gaffney EA, 2004, J MATH BIOL, V48, P375, DOI 10.1007/s00285-003-0246-2; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Gillet JP, 2010, METHODS MOL BIOL, V596, P47, DOI 10.1007/978-1-60761-416-6_4; Hadjiandreou MM, 2014, IEEE T BIO-MED ENG, V61, P415, DOI 10.1109/TBME.2013.2280189; Hao WR, 2017, P NATL ACAD SCI USA, V114, P5011, DOI 10.1073/pnas.1620264114; He XB, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004176; Janco JMT, 2015, J IMMUNOL, V194, P2985, DOI 10.4049/jimmunol.1403134; Jenkins RW, 2018, BRIT J CANCER, V118, P9, DOI 10.1038/bjc.2017.434; Khunweeraphong N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11794-w; Komarova NL, 2005, P NATL ACAD SCI USA, V102, P9714, DOI 10.1073/pnas.0501870102; Lai XL, 2018, P NATL ACAD SCI USA, V115, P5534, DOI 10.1073/pnas.1721559115; Lai XL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178479; Lavi O, 2012, DRUG RESIST UPDATE, V15, P90, DOI 10.1016/j.drup.2012.01.003; Lee SM, 1998, LEUKEMIA LYMPHOMA, V29, P427, DOI 10.3109/10428199809050903; Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411; Li J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1200778; Liao KL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091844; Lim SO, 2016, CANCER CELL, V30, P925, DOI 10.1016/j.ccell.2016.10.010; Lisiero DN, 2011, J IMMUNOL, V186, P5068, DOI 10.4049/jimmunol.1003317; Ma Y, 2013, J CANCER, V4, P36, DOI 10.7150/jca.5046; Marino S, 2008, J THEOR BIOL, V254, P178, DOI 10.1016/j.jtbi.2008.04.011; Martincich L, 2004, BREAST CANCER RES TR, V83, P67, DOI 10.1023/B:BREA.0000010700.11092.f4; Maute RL, 2015, P NATL ACAD SCI USA, V112, pE6506, DOI 10.1073/pnas.1519623112; Muppidi M.R., 2015, J TARGET THER CANC, V4, P47; Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258; PhosphoSitePlus, 2014, NUCL AC RES PHOSPHOS, P43; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Rockne RC, 2019, PHYS BIOL, V16, DOI 10.1088/1478-3975/ab1a09; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Saenz R, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-211; Seidel JA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00086; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Shi L, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-74; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Simo R, 2012, DIABETES, V61, P372, DOI 10.2337/db11-0727; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Sucker A, 2014, CLIN CANCER RES, V20, P6593, DOI 10.1158/1078-0432.CCR-14-0567; Sun XQ, 2018, BRIEF BIOINFORM, V19, P1382, DOI 10.1093/bib/bbx065; Tomasetti C, 2010, P NATL ACAD SCI USA, V107, P16766, DOI 10.1073/pnas.1007726107; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Vescovi R, 2019, CANCER IMMUNOL RES, V7, P12, DOI 10.1158/2326-6066.CIR-18-0141; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Wooten DJ, 2017, BBA-REV CANCER, V1867, P167, DOI 10.1016/j.bbcan.2017.04.001; Xiao J, 2015, J CANCER, V6, P636, DOI 10.7150/jca.11738; YOUNG ME, 1980, BIOTECHNOL BIOENG, V22, P947, DOI 10.1002/bit.260220504; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271	62	5	5	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2020	15	4							e0231499	10.1371/journal.pone.0231499	http://dx.doi.org/10.1371/journal.pone.0231499			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9MR	32310956	gold, Green Published			2023-01-03	WOS:000536019800017
J	Assaf, E; Caricola, I; Gopher, A; Rosell, J; Blasco, R; Bar, O; Zilberman, E; Lemorini, C; Baena, J; Barkai, R; Cristiani, E				Assaf, Ella; Caricola, Isabella; Gopher, Avi; Rosell, Jordi; Blasco, Ruth; Bar, Oded; Zilberman, Ezra; Lemorini, Cristina; Baena, Javier; Barkai, Ran; Cristiani, Emanuela			Shaped stone balls were used for bone marrow extraction at Lower Paleolithic Qesem Cave, Israel	PLOS ONE			English	Article							MIDDLE PLEISTOCENE; OLDUVAI GORGE; USE-WEAR; MICRO-RESIDUES; AMUDIAN LAYERS; CENTRAL HEARTH; ESR/U-SERIES; BLIND TESTS; BED-II; TOOLS	The presence of shaped stone balls at early Paleolithic sites has attracted scholarly attention since the pioneering work of the Leakeys in Olduvai, Tanzania. Despite the persistent presence of these items in the archaeological record over a period of two million years, their function is still debated. We present new results from Middle Pleistocene Qesem Cave on the use of these implements as percussion tools. Use-wear and abundant bone and fat residues found on ten shaped stone balls indicate crushing of fresh bones by thrusting percussion and provide direct evidence for the use of these items to access bone marrow of animal prey at this site. Two experiments conducted to investigate and verify functional aspects proved Qesem Cave shaped stone balls are efficient for bone processing and provide a comfortable grip and useful active areas for repeated use. Notably, the patina observed on the analyzed items precedes their use at the cave, indicating that they were collected by Qesem inhabitants, most probably from older Lower Paleolithic Acheulian sites. Thus, our results refer only to the final phases of the life of the items, and we cannot attest to their original function. As bone marrow played a central role in human nutrition in the Lower Paleolithic, and our experimental results show that the morphology and characteristics of shaped stone ball replicas are well-suited for the extraction of bone marrow, we suggest that these features might have been the reason for their collection and use at Qesem Cave. These results shed light on the function of shaped stone balls and are consistent with the significance of animal fat in the caloric intake of Middle Pleistocene humans as shown by the archeozoological evidence at Qesem Cave and possibly beyond.	[Assaf, Ella; Gopher, Avi; Barkai, Ran] Tel Aviv Univ, Inst Archaeol, Tel Aviv, Israel; [Caricola, Isabella; Cristiani, Emanuela] Sapienza Univ Rome IT, Dept Oral & Maxillofacial Sci, DANTE Diet & Ancient Technol Lab, Rome, Italy; [Caricola, Isabella] Newcastle Univ, Sch Hist Class & Archaeol, Newcastle Upon Tyne, Tyne & Wear, England; [Rosell, Jordi] IPHES Inst Catala Palaeoecol Humana & Evolucio S, Tarragona, Spain; [Rosell, Jordi] Univ Rovira Virgili URV, Area Prehist, Tarragona, Spain; [Blasco, Ruth] Ctr Nacl Invest Evoluc Humana CENIEH, Burgos, Spain; [Bar, Oded; Zilberman, Ezra] Geol Survey Israel, Jerusalem, Israel; [Lemorini, Cristina] Sapienza Univ Rome IT, Dept Class, LTFAPA Lab, Rome, Italy; [Baena, Javier] Univ Autonoma, Dept Prehist & Archaeol, Madrid, Spain	Tel Aviv University; Sapienza University Rome; Newcastle University - UK; Universitat Rovira i Virgili; Centro Nacional de Investigacion de La Evolucion Humana (CENIEH); Geological Survey Israel; Sapienza University Rome; Autonomous University of Madrid	Assaf, E (corresponding author), Tel Aviv Univ, Inst Archaeol, Tel Aviv, Israel.; Cristiani, E (corresponding author), Sapienza Univ Rome IT, Dept Oral & Maxillofacial Sci, DANTE Diet & Ancient Technol Lab, Rome, Italy.	ellaassa@gmail.com; emanuela.cristiani@uniroma1.it	Blasco, Ruth/AAG-8200-2019; lemorini, cristina/ABD-5327-2020; Rosell, Jordi/G-8705-2015	Blasco, Ruth/0000-0001-9804-739X; lemorini, cristina/0000-0002-6998-1615; Caricola, Isabella/0000-0001-7808-3748; Rosell, Jordi/0000-0002-6758-6291	European Research Council (ERC Starting Grant Project HIDDEN FOODS) [639286]; MAECI (Italian Ministry for the Foreign Affairs); Azrieli Foundation; Deutsche Forschungsgemeinschaft (DFG) [UT 41/4-1]; Israel Science Foundation; CARE Archaeological Foundation; Leakey Foundation; Wenner-Gren Foundation; Dan David Foundation; German Research Foundation	European Research Council (ERC Starting Grant Project HIDDEN FOODS); MAECI (Italian Ministry for the Foreign Affairs); Azrieli Foundation; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Israel Science Foundation(Israel Science Foundation); CARE Archaeological Foundation; Leakey Foundation; Wenner-Gren Foundation; Dan David Foundation; German Research Foundation(German Research Foundation (DFG))	We acknowledge funding received for this project through the European Research Council (ERC Starting Grant Project HIDDEN FOODS, G.A. no. 639286 to EC). CL is grateful to MAECI (Italian Ministry for the Foreign Affairs) for its funding support to this project. EA is grateful to the Azrieli Foundation for the award of an Azrieli Fellowship. This study was funded by the grant UT 41/4-1 "Cultural and biological transformations in the Late Middle Pleistocene (420-200 ka ago) at Qesem Cave, Israel: In search for a post-Homo erectus lineage in the Levantine corridor" (A. Gopher, R. Barkai, Th. Uthmeier) of the Deutsche Forschungsgemeinschaft (DFG). The Qesem Cave excavation project was previously supported by the Israel Science Foundation, the CARE Archaeological Foundation, the Leakey Foundation, the Wenner-Gren Foundation, the Dan David Foundation, and the German Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams J.L, 1993, PACIFIC COAST ARCHAE, V29, P62; Agam A., 2019, J PALEOLITHIC ARCHAE, P1, DOI DOI 10.1007/S41982-019-00038-0; [Anonymous], 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-018-0474-7; Assaf E, 2018, LANCET HAEMATOL, V5; Assaf E, 2015, QUATERN INT, V361, P88, DOI 10.1016/j.quaint.2014.07.071; Bar-Yosef O, 1993, GUT, V34; Barkai R, 2017, CURR ANTHROPOL, V58, pS314, DOI 10.1086/691211; Barkai R, 2016, QUATERN INT, V398, P118, DOI 10.1016/j.quaint.2015.08.005; Barkal R, 2003, NATURE, V423, P977, DOI 10.1038/nature01718; Barsky D, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0352; Barton H, 1998, J ARCHAEOL SCI, V25, P1231, DOI 10.1006/jasc.1998.0300; Benito-Calvo A, 2018, ARCHAEOMETRY, V60, P419, DOI 10.1111/arcm.12325; Blasco R, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav9822; Blasco R, 2016, QUATERN INT, V398, P190, DOI 10.1016/j.quaint.2015.04.031; Blasco R, 2014, J ANTHROPOL ARCHAEOL, V35, P248, DOI 10.1016/j.jaa.2014.06.005; Bofill M., 2012, BROADENING HORIZONS, P63; Boschian G, 2019, QUATERNARY SCI REV, V215, P86, DOI 10.1016/j.quascirev.2019.05.010; Caceres I., 2002, CURRENT TOPICS TAPHO, P471; Caricola I, 2017, THESIS; Clark J. D., 1982, CAMBRIDGE HIST AFRIC, P248; Conte IC, 2015, MAN ARCHAEOL METH, P59, DOI 10.1007/978-3-319-08257-8_5; de Beaune SA, 2004, CURR ANTHROPOL, V45, P139, DOI 10.1086/381045; de la Torre I, 2013, J ARCHAEOL SCI, V40, P313, DOI 10.1016/j.jas.2012.08.007; Diez-Martin F, 2009, J ANTHROPOL ARCHAEOL, V28, P274, DOI 10.1016/j.jaa.2009.03.001; Dubreuil L, 2015, MAN ARCHAEOL METH, P105, DOI 10.1007/978-3-319-08257-8_7; Efrati B, 2019, MITEKUFAT HAEVEN J I; Falgueres C, 2016, QUATERN INT, V398, P6, DOI 10.1016/j.quaint.2015.02.006; Fullagar R, 2015, ARCHAEOL OCEAN, V50, P3, DOI 10.1002/arco.5053; Garcia del Cura M, 1994, B GEOLOGICO MINERO, V105, P574; Gopher A, 2010, QUAT GEOCHRONOL, V5, P644, DOI 10.1016/j.quageo.2010.03.003; Gopher A., 2005, MITEKUFAT HAEVEN J I, V35, P69; Hamon C, 2006, INT SERIES, V1551; Hayes E, 2018, J ARCHAEOL SCI-REP, V20, P97, DOI 10.1016/j.jasrep.2018.04.021; Isaac B, 1987, AFR ARCHAEOL REV, V5, P3, DOI [10.1007/BF01117078, DOI 10.1007/BF01117078]; Jones P.R., 1994, OLDUVAI GORGE, V5; Karkanas P, 2007, J HUM EVOL, V53, P197, DOI 10.1016/j.jhevol.2007.04.002; Kealhofer L, 1999, J ARCHAEOL SCI, V26, P527, DOI 10.1006/jasc.1998.0332; Keeley L.H., 1980, EXPT DETERMINATION S; Key AJM, 2017, J ANTHROPOL SCI, V95, P67, DOI [10.4436/jass.95017, 10.4436/JASS.95017]; Kleindienst MR, 1962, ACT 4 C PAN PREH ET; Langejans GHJ, 2010, J ARCHAEOL SCI, V37, P971, DOI 10.1016/j.jas.2009.11.030; Leakey LSB., 1931, STONE AGE CULTURES K; Leakey M.D., 1971, OLDUVAI GORGE; Lemorini C, 2016, QUATERN INT, V398, P86, DOI 10.1016/j.quaint.2015.05.013; Lemorini C, 2015, QUATERN INT, V361, P103, DOI 10.1016/j.quaint.2014.07.032; Lombard M, 2005, J HUM EVOL, V48, P279, DOI 10.1016/j.jhevol.2004.11.006; Lombard M, 2004, S AFRICAN ARCHAEOLOG, P37; Lombard M, 2007, J ARCHAEOL SCI, V34, P155, DOI 10.1016/j.jas.2006.04.008; Mercier N, 2013, J ARCHAEOL SCI, V40, P3011, DOI 10.1016/j.jas.2013.03.002; Mora R, 2005, J ANTHROPOL ARCHAEOL, V24, P179, DOI 10.1016/j.jaa.2004.12.001; Oliver JS, 1993, BONES BEHAV ETHNOARC, V21; Outram A, 1998, J ARCHAEOL SCI, V25, P839, DOI 10.1006/jasc.1997.0229; Parush Y, 2015, QUATERN INT, V361, P61, DOI 10.1016/j.quaint.2014.07.057; Pedergnana A, 2018, J ARCHAEOL METHOD TH, V25, P117, DOI 10.1007/s10816-017-9337-z; Ronen A., 1997, NEOLITHICS, V3, P7; Rosell J, 2015, QUATERN INT, V361, P297, DOI 10.1016/j.quaint.2014.08.009; Rots V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150437; Roussel M, 2011, INVESTIGACION EXPT A; Sahnouni M, 1997, J ARCHAEOL SCI, V24, P701, DOI 10.1006/jasc.1996.0152; Sahnouni M, 2018, SCIENCE, V362, P1297, DOI 10.1126/science.aau0008; Yustos PS, 2015, J ARCHAEOL SCI-REP, V2, P367, DOI 10.1016/j.jasrep.2015.03.005; Santonja M, 2014, QUATERN INT, V322, P181, DOI 10.1016/j.quaint.2013.10.069; Schick KD, 1994, INTEGRATIVE PATHS PA; Shahack-Gross R, 2014, J ARCHAEOL SCI, V44, P12, DOI 10.1016/j.jas.2013.11.015; Sharon G., 2010, PALEOANTHROPOLOGY, V2010, P79, DOI DOI 10.4207/PA.2010.ART35; Shimelmitz R, 2016, QUATERN INT, V398, P37, DOI 10.1016/j.quaint.2015.02.037; Shimelmitz R, 2011, J HUM EVOL, V61, P458, DOI 10.1016/j.jhevol.2011.06.003; Speth JD, 2012, QUATERN INT, V247, P85, DOI 10.1016/j.quaint.2011.03.001; Stiner MC, 2011, J HUM EVOL, V60, P213, DOI 10.1016/j.jhevol.2010.10.006; Stiner MC, 2009, P NATL ACAD SCI USA, V106, P13207, DOI 10.1073/pnas.0900564106; Texier P., 1995, CAHIER NOIR, V7, P31; Thiry M, 2014, EARTH-SCI REV, V136, P141, DOI 10.1016/j.earscirev.2014.05.008; Titton S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228290; van Gijn A., 1990, INTERPRETATIVE POSSI, P77; Venditti F, 2019, J HUM EVOL, V131, P109, DOI 10.1016/j.jhevol.2019.03.016; Wadley L, 2004, J ARCHAEOL SCI, V31, P1491, DOI 10.1016/j.jas.2004.03.010; Wadley L, 2007, J ARCHAEOL SCI, V34, P1001, DOI 10.1016/j.jas.2006.09.016; Walker N, 2008, S AFR ARCHAEOL BULL, V63, P12, DOI 10.2307/20474987; WILLOUGHBY PR, 1985, WORLD ARCHAEOL, V17, P44, DOI 10.1080/00438243.1985.9979949; Wilson L, 2016, QUATERN INT, V398, P61, DOI 10.1016/j.quaint.2015.02.015; Yang SX, 2014, QUATERN INT, V321, P3, DOI 10.1016/j.quaint.2013.05.012; Zupancich A, 2016, SCI REP-UK, V6, DOI 10.1038/srep37686; Zupancich A, 2016, QUATERN INT, V398, P94, DOI 10.1016/j.quaint.2015.10.101	83	20	20	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2020	15	4							e0230972	10.1371/journal.pone.0230972	http://dx.doi.org/10.1371/journal.pone.0230972			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LI0PQ	32271815	gold, Green Published			2023-01-03	WOS:000529188500001
J	Koval, KW; Lindquist, B; Gennosa, C; Mahadevan, A; Niknam, K; Patil, S; Rao, GVR; Strehlow, MC; Newberry, JA				Koval, Kathryn W.; Lindquist, Benjamin; Gennosa, Christine; Mahadevan, Aditya; Niknam, Kian; Patil, Sanket; Rao, G. V. Ramana; Strehlow, Matthew C.; Newberry, Jennifer A.			First look at emergency medical technician wellness in India: Application of the Maslach Burnout Inventory in an unstudied population	PLOS ONE			English	Article							HEALTH-CARE; PHYSICIAN BURNOUT; HUMAN-RESOURCES; SATISFACTION; ASSOCIATION; OUTCOMES; PREVALENCE; PREDICTORS; ENGAGEMENT; PARAMEDICS	Introduction Professional wellness is critical to developing and maintaining a health care workforce. Previous work has identified burnout as a significant challenge to professional wellness facing emergency medical technicians (EMTs) in many countries worldwide. Our study fills a critical gap by assessing the prevalence of burnout among emergency medical technicians (EMTs) in India. Methods This was a cross-sectional survey of EMTs within the largest prehospital care organization in India. We used the Maslach Burnout Inventory (MBI) to measure wellness. All EMTs presenting for continuing medical education between July-November 2017 from the states of Gujarat, Karnataka, and Telangana were eligible. Trained, independent staff administered anonymous MBI-Medical Personnel Surveys in local languages. Results Of the 327 EMTs eligible, 314 (96%) consented to participate, and 296 (94%) surveys were scorable. The prevalence of burnout was 28.7%. Compared to EMTs in other countries, Indian EMTs had higher levels of personal accomplishment but also higher levels of emotional exhaustion and moderate levels of depersonalization. In multivariate regression, determinants of burnout included younger age, perceived lack of respect from colleagues and administrators, and a sense of physical risk. EMTs who experienced burnout were four times as likely to plan to quit their jobs within one year. Conclusion This is the first assessment of burnout in EMTs in India and adds to the limited body of literature among low- and middle-income country (LMIC) prehospital providers worldwide. Burnout was strongly associated with an EMT's intention to quit within a year, with potential implications for employee turnover and healthcare workforce shortages. Burnout should be a key focus of further study and possible intervention to achieve internationally recognized targets, including Sustainable Development Goal 3C and WHO's 2030 Milestone for Human Resources.	[Koval, Kathryn W.] Med Univ South Carolina, Dept Emergency Med, Charleston, SC 29425 USA; [Lindquist, Benjamin; Niknam, Kian; Strehlow, Matthew C.; Newberry, Jennifer A.] Stanford Univ, Sch Med, Dept Emergency Med, Palo Alto, CA 94304 USA; [Gennosa, Christine] Med Univ South Carolina, Coll Med, Anderson, SC USA; [Mahadevan, Aditya] Univ San Diego, San Diego, CA 92110 USA; [Patil, Sanket] SGT Univ, Natl Reference Simulat Ctr, Budhera, Gurugram Haryan, India; [Rao, G. V. Ramana] GVK Emergency Management & Res Inst, Secunderabad, Telangana, India	Medical University of South Carolina; Stanford University; Medical University of South Carolina; University of San Diego	Koval, KW (corresponding author), Med Univ South Carolina, Dept Emergency Med, Charleston, SC 29425 USA.	kwk@musc.edu		Strehlow, Matthew Charles/0000-0002-0049-9716; Patil, Sanket/0000-0003-2708-1739; Koval, Kathryn/0000-0002-2865-0027				Alexander DA, 2011, BRIT J PSYCHIAT, V178, P76; Anand S, 2004, LANCET, V364, P1603, DOI 10.1016/S0140-6736(04)17313-3; [Anonymous], 2016, LANCET, V387, P1591, DOI 10.1016/S0140-6736(16)30246-X; Baier N, 2018, BMC EMERG MED, V18, DOI 10.1186/s12873-018-0177-2; Bennett P, 2005, BRIT J CLIN PSYCHOL, V44, P215, DOI 10.1348/014466505X29639; Berger E, 2013, ANN EMERG MED, V61, p17A, DOI 10.1016/j.annemergmed.2013.01.001; Boland LL, 2018, WEST J EMERG MED, V19, P987, DOI 10.5811/westjem.8.39034; Borritz M, 2006, OCCUP ENVIRON MED, V63, P98, DOI 10.1136/oem.2004.019364; Chen L, 2004, LANCET, V364, P1984, DOI 10.1016/S0140-6736(04)17482-5; Crisp N, 2008, LANCET, V371, P689, DOI 10.1016/S0140-6736(08)60309-8; Crowe RP, 2018, PREHOSP EMERG CARE, V22, P229, DOI 10.1080/10903127.2017.1356411; Deniz T, 2016, TURK J MED SCI, V46, P296, DOI 10.3906/sag-1406-53; Dewa CS, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-325; Dewa CS, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-254; Dunn PM, 2007, J GEN INTERN MED, V22, P1544, DOI 10.1007/s11606-007-0363-5; FIRTH H, 1989, J OCCUP PSYCHOL, V62, P55, DOI 10.1111/j.2044-8325.1989.tb00477.x; Fragoso ZL, 2016, WORKPLACE HEALTH SAF, V64, P479, DOI 10.1177/2165079916653414; Gallagher Sharon, 2009, Int J Emerg Ment Health, V11, P235; GRIGSBY DW, 1988, PSYCHOL REP, V63, P55, DOI 10.2466/pr0.1988.63.1.55; Haik J, 2017, NEUROPSYCH DIS TREAT, V13, P1533, DOI 10.2147/NDT.S133181; Hall LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159015; Hann M, 2011, EUR J PUBLIC HEALTH, V21, P499, DOI 10.1093/eurpub/ckq005; Healthcare Sector Skill Council, 2013, EM MED TECHN BAS; Heinemann L V, BURNOUT RES EMERGENC; Hulley SB., 2013, DESIGNING CLIN RES, V4th, P81; Italia S, 2008, PSYCHO-ONCOLOGY, V17, P676, DOI 10.1002/pon.1293; Jacobsen D., 2014, RECOGNIZING CULTUTES; Jones C., 2007, ONLINE J ISSUES NURS, V12, P4, DOI DOI 10.3912/OJIN.VOL12NO03MAN04; JONES JW, 1981, NURS RES, V30, P349; Khashaba Eman Omar, 2014, Indian J Community Med, V39, P103, DOI 10.4103/0970-0218.132733; Khatiban Mahnaz, 2015, Acta Med Iran, V53, P711; Krasner MS, 2009, JAMA-J AM MED ASSOC, V302, P1284, DOI 10.1001/jama.2009.1384; Langade D, 2016, CUREUS, V8, DOI 10.7759/cureus.771; Le Blanc PM, 2007, J APPL PSYCHOL, V92, P213, DOI 10.1037/0021-9010.92.1.213; Lindquist B, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-033404; Maslach C, 2012, MASLACH BURNOUT INVE; Moya PN, 2017, SCAND J TRAUMA RESUS, V25, DOI 10.1186/s13049-017-0433-6; Nirel N, 2008, PREHOSP DISASTER MED, V23, P537, DOI 10.1017/S1049023X00006385; Ospina-Kammerer Veronika, 2003, Int J Emerg Ment Health, V5, P29; Paller D, 2004, GALLUP BUSINESS J; Patterson PD, 2012, PREHOSP EMERG CARE, V16, P86, DOI 10.3109/10903127.2011.616261; Perlo J., 2017, IHI FRAMEWORK IMPROV; Peterson U, 2008, J ADV NURS, V62, P84, DOI 10.1111/j.1365-2648.2007.04580.x; Poghosyan L, 2009, INT J NURS STUD, V46, P894, DOI 10.1016/j.ijnurstu.2009.03.004; Popa Florian, 2010, J Med Life, V3, P207; Ramarajan L., 2006, WHAT MAKES JOB TOUGH; Rao M, 2011, LANCET, V377, P587, DOI 10.1016/S0140-6736(10)61888-0; Ratnakaran B, 2016, J POSTGRAD MED, V62, P157, DOI 10.4103/0022-3859.184274; Salyers MP, 2017, J GEN INTERN MED, V32, P475, DOI 10.1007/s11606-016-3886-9; Schooley B, COMP BURNOUT EMERGEN; Shanafelt TD, 2012, ARCH INTERN MED, V172, P1377, DOI 10.1001/archinternmed.2012.3199; Shapiro S. L., 2005, INT J STRESS MANAGE, V12, P164, DOI [10.1037/1072-5245.12.2.164, DOI 10.1037/1072-5245.12.2.164]; Stassen W, 2013, EMERG MED J, V30, P331, DOI 10.1136/emermed-2011-200920; Sterud T, 2011, J OCCUP MED TOXICOL, V6, DOI 10.1186/1745-6673-6-10; Suner-Soler R., 2014, BURNOUT RES, V1, P82, DOI [10.1016/j.burn.2014.07.004, DOI 10.1016/J.BURN.2014.07.004]; Swensen S, 2016, J HEALTHC MANAG, V61, P105, DOI 10.1097/00115514-201603000-00008; van der Ploeg E, 2003, OCCUP ENVIRON MED, V60, P40; Weiss SJ, 1996, AM J EMERG MED, V14, P640, DOI 10.1016/S0735-6757(96)90078-9; West CP, 2012, J GEN INTERN MED, V27, P1445, DOI 10.1007/s11606-012-2015-7; Wilson William, 2017, J Emerg Trauma Shock, V10, P199, DOI 10.4103/JETS.JETS_36_17; World Health Organisation, 2016, GLOB STRAT HUM RES H; Wurm W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149913; Zhang YM, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-235	63	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2020	15	3							e0229954	10.1371/journal.pone.0229954	http://dx.doi.org/10.1371/journal.pone.0229954			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8WI	32155192	Green Published, gold			2023-01-03	WOS:000535278500043
J	Baruch, J				Baruch, Jay			When Sensitivity Is a Liability	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								By the time the young man, having overdosed fresh out of rehab, arrives in the ED, EMS has been working on him for half an hour with no success. After further futile efforts, the ED physician can only wait with the father and aunt for the man to die a second time.	[Baruch, Jay] Brown Univ, Dept Emergency Med, Warren Alpert Med Sch, Providence, RI 02912 USA	Brown University	Baruch, J (corresponding author), Brown Univ, Dept Emergency Med, Warren Alpert Med Sch, Providence, RI 02912 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 20	2020	382	8					694	695		10.1056/NEJMp1911401	http://dx.doi.org/10.1056/NEJMp1911401			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ7SF	32074417				2023-01-03	WOS:000517119800004
J	Pro, G; Zaller, N				Pro, George; Zaller, Nick			Interaction effects in the association between methadone maintenance therapy and experiences of racial discrimination in US healthcare settings	PLOS ONE			English	Article							OPIOID USE DISORDER; MEDICATION-ASSISTED TREATMENT; ETHNIC-DIFFERENCES; PERCEIVED DISCRIMINATION; POSITIVE OUTCOMES; MENTAL-HEALTH; DRUG-USERS; GENDER; ABUSE; STIGMA	Background Disparities in methadone maintenance therapy (MMT) outcomes have received limited attention, but there are important negative outcomes associated with MMT that warrant investigation. Racial discrimination is common in healthcare settings and affects opioid use disorder (OUD) treatment and comorbidities. However, race/ethnicity alone may not fully explain experiences of discrimination. MMT remains highly stigmatized and may compound the effect of race/ethnicity on discrimination in healthcare settings. We sought to quantify differential associations between MMT and experiences of racial discrimination between racial/ethnic groups in a U.S. national sample. Methods We used the National Epidemiologic Survey on Alcohol and Related Conditions-III (2012-2013) to identify a subset of individuals with a lifetime OUD who had ever used MMT (survey n = 766; weighted population n = 5,276,507). We used multivariable logistic regression to model past-year experience of racial discrimination in a healthcare setting. We included an interaction term between race/ethnicity and MMT status to identify the odds of discrimination (MMT vs. no MMT [referent]) within racial/ethnic groups. We used survey procedures with weights to account for the parent study's complex survey design. Findings Twenty-two percent of our sample experienced racial discrimination in a healthcare setting in the past year. Discrimination was more common among those who had ever used MMT (x(2) = 10.00, p = 0.001) and racial/ethnic minorities (x(2) = 23.15, p<0.001). The interaction effect was much stronger than the main effects of race/ethnicity and MMT status. MMT status (versus no MMT) was positively associated with discrimination among Blacks (aOR = 3.93, 95% CI = 3.87-3.98, p<0.001), Whites (aOR = 2.25, 95% CI = 2.23-2.27, p<0.001), and Latino/Latinas (aOR = 1.59, 95% CI = 1.55-1.62, p<0.001). Among American Indian/Alaska Natives (AI/AN), those who had used MMT had over thirty times the odds of racial discrimination, compared to their non-MMT counterparts (aOR = 32.78, 95% CI = 31.16-34.48, p<0.001). Conclusion Race/ethnicity alone did not sufficiently account for racial discrimination in healthcare settings among those with a lifetime OUD. MMT status was strongly associated with racial discrimination among AI/AN. Our strong interaction effect is indicative of an additional barrier to health services utilization among AI/AN, which has important implications for OUD treatment outcomes and comorbidities. Health promotion programs aimed at increased adoption of MMT are promising, but should be considered in the context of racial/ethnic disparities, drug use and MMT stigma, and implicit biases in clinical settings.	[Pro, George] No Arizona Univ, Ctr Hlth Equ Res, Flagstaff, AZ 86011 USA; [Zaller, Nick] Univ Arkansas Med Sci, Coll Publ Hlth, Little Rock, AR 72205 USA	Northern Arizona University; University of Arkansas System; University of Arkansas Medical Sciences	Pro, G (corresponding author), No Arizona Univ, Ctr Hlth Equ Res, Flagstaff, AZ 86011 USA.	george.pro@nau.edu						Abraham AJ, 2017, AM J PUBLIC HEALTH, V107, P31, DOI 10.2105/AJPH.2016.303558; Alderks C.E., 2017, TRENDS USE METHADONE; Anstice S, 2009, SUBST USE MISUSE, V44, P794, DOI 10.1080/10826080802483936; Bailey ZD, 2017, LANCET, V389, P1453, DOI 10.1016/S0140-6736(17)30569-X; Becker WC, 2008, DRUG ALCOHOL DEPEN, V94, P38, DOI 10.1016/j.drugalcdep.2007.09.018; Boutwell Amy E, 2007, J Opioid Manag, V3, P328; Burgess DJ, 2008, J HEALTH CARE POOR U, V19, P894, DOI 10.1353/hpu.0.0063; Chou R, 2016, TECHNICAL BRIEFS AGE, V28; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Conner KO, 2008, J SOC WORK PRACT ADD, V8, P244, DOI 10.1080/15332560802157065; Connery HS, 2015, HARVARD REV PSYCHIAT, V23, P63, DOI 10.1097/HRP.0000000000000075; Conway KP, 2006, J CLIN PSYCHIAT, V67, P247, DOI 10.4088/JCP.v67n0211; Corsi KF, 2009, J SUBST ABUSE TREAT, V37, P120, DOI 10.1016/j.jsat.2008.11.004; Corsi KF, 2002, J DRUG ISSUES, V32, P999, DOI 10.1177/002204260203200316; D'Aunno T, 2002, JAMA-J AM MED ASSOC, V288, P850, DOI 10.1001/jama.288.7.850; Darke S, 2009, DRUG ALCOHOL REV, V28, P243, DOI 10.1111/j.1465-3362.2008.00024.x; Duvivier H, 2017, J AM PHARM ASSOC, V57, pS135, DOI 10.1016/j.japh.2017.01.005; Earnshaw V, 2013, INT J MENT HEALTH AD, V11, P110, DOI 10.1007/s11469-012-9402-5; Evans E, 2015, DRUG ALCOHOL DEPEN, V155, P228, DOI 10.1016/j.drugalcdep.2015.07.010; FitzGerald C, 2017, BMC MED ETHICS, V18, DOI 10.1186/s12910-017-0179-8; Friedman J, 2019, JAMA INTERNAL MED; Grant B.F., 2014, SOURCE ACCURACY STAT; Hansen H., 2012, CRIT PERSPECT, P79, DOI [10.1108/S1057-6290(2012)0000014008, DOI 10.1108/S1057-6290(2012)0000014008]; Hansen H, 2016, DRUG ALCOHOL DEPEN, V164, P14, DOI 10.1016/j.drugalcdep.2016.03.028; Henry J. Kaiser Family Foundation, 2017, OP OV DEATHS RAC ETH; Hosmer D. J., 2013, APPL LOGISTIC REGRES, DOI DOI 10.1002/9781118548387; HSER YI, 1991, INT J ADDICT, V25, P1295, DOI 10.3109/10826089009068465; Jernigan VBB, 2015, AM J PUBLIC HEALTH, V105, pS376, DOI 10.2105/AJPH.2014.302447; Jimenez-Trevino L, 2011, ADDICT BEHAV, V36, P1184, DOI 10.1016/j.addbeh.2011.07.019; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Kelly SM, 2011, DRUG ALCOHOL DEPEN, V117, P170, DOI 10.1016/j.drugalcdep.2011.01.008; Keyes KM, 2014, AM J PUBLIC HEALTH, V104, pE52, DOI 10.2105/AJPH.2013.301709; Krawczyk N, 2017, DRUG ALCOHOL DEPEN, V178, P512, DOI 10.1016/j.drugalcdep.2017.06.009; Lagisetty P, 2019, JAMA PSYCHIAT, DOI [10.1016/j.drugalcdep.2011.01.008, DOI 10.1016/J.DRUGALCDEP.2011.01.008]; Lee C, 2009, ETHNIC DIS, V19, P330; Lundgren LM, 2001, J SUBST ABUSE TREAT, V21, P145, DOI 10.1016/S0740-5472(01)00197-0; Maglione MA, 2018, J SUBST ABUSE TREAT, V89, P28, DOI 10.1016/j.jsat.2018.03.001; Martinez-Luna N, 2018, ADICCIONES, V30, P197, DOI 10.20882/adicciones.897; Martins SS, 2015, DRUG ALCOHOL DEPEN, V151, P278, DOI 10.1016/j.drugalcdep.2015.03.020; McKnight C, 2017, J ETHN SUBST ABUSE, V16, P404, DOI 10.1080/15332640.2017.1292418; Minnesota Department of Health, 2019, RAC RAT DISP DRUG OV; Ngo H, 2011, J PSYCHOPHARMACOLOGY, V25; Novins DK, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-63; Olsen Y, 2014, JAMA-J AM MED ASSOC, V311, P1393, DOI 10.1001/jama.2014.2147; Pollack HA, 2008, HEALTH SERV RES, V43, P2143, DOI 10.1111/j.1475-6773.2008.00870.x; Redden SM, 2013, QUAL HEALTH RES, V23, P951, DOI 10.1177/1049732313487802; Rieckmann T, 2011, SUBST ABUS, V32, P180, DOI 10.1080/08897077.2011.600122; Rigg KK, 2015, INT J DRUG POLICY, V26, P484, DOI 10.1016/j.drugpo.2014.10.001; Roncero C, 2016, PSYCHIAT RES, V243, P174, DOI 10.1016/j.psychres.2016.06.024; Rowan-Szal GA, 2000, J SUBST ABUSE TREAT, V19, P7, DOI 10.1016/S0740-5472(99)00091-4; Rudd RA, 2014, MMWR-MORBID MORTAL W, V63, P849; Serdarevic M, 2017, CURR OPIN PSYCHIATR, V30, P238, DOI 10.1097/YCO.0000000000000337; Smye V, 2011, HARM REDUCT J, V8, DOI 10.1186/1477-7517-8-17; Tipps RT, 2018, J LAW MED ETHICS, V46, P422, DOI 10.1177/1073110518782950; Venner KL, 2018, ADDICT BEHAV, V86, P111, DOI 10.1016/j.addbeh.2018.05.017; Volkow ND, 2019, JAMA PSYCHIAT, V76, P208, DOI 10.1001/jamapsychiatry.2018.3126; Wakeman Sarah E, 2017, AMA J Ethics, V19, P922, DOI 10.1001/journalofethics.2017.19.9.stas1-1709; Walls ML, 2006, COMMUNITY MENT HLT J, V42, P521, DOI 10.1007/s10597-006-9054-7; Walls ML, 2015, J AM BOARD FAM MED, V28, P231, DOI 10.3122/jabfm.2015.02.140194; Williams DR, 2015, JAMA-J AM MED ASSOC, V314, P555, DOI 10.1001/jama.2015.9260	60	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2020	15	2							e0228755	10.1371/journal.pone.0228755	http://dx.doi.org/10.1371/journal.pone.0228755			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP9GK	32027723	gold, Green Published			2023-01-03	WOS:000534623800072
J	Mcbride-Henry, K; Miller, C; Trenholm, A; Officer, TN				Mcbride-Henry, Karen; Miller, Charissa; Trenholm, Adrian; Officer, Tara N.			Occupying 'in-hospitable' spaces: Parental/primary-caregiver perceptions of the impact of repeated hospitalisation in children under two years of age	PLOS ONE			English	Article							CRITICALLY-ILL CHILDREN; PARENTS; FAMILIES; HEALTH; NEEDS; EXPERIENCES; MODELS	The experience of having a child hospitalised is stressful and disrupts families in myriad ways; however, the experiences of parents/caregivers who encounter repeated admissions of a child with acute lower respiratory infections are under-researched. This project aims to explore these experiences, from a qualitative perspective, using the philosophical tenets of reflective lifeworld research. The research included 14 face-to-face interviews with parents, grandparents, or primary caregivers, of children who, whilst under two years of age, were admitted to hospital multiple times with a lower respiratory infection diagnosis. Many of the participants were from Maori or Samoan ethnic backgrounds. The findings of this single site study revealed that these parents/caregivers' experiences were characterised by feelings of powerlessness, offering descriptions of hospitals as harsh and difficult places to reside, they are 'in-hospitable'. The findings suggest that repeated hospitalisations created a cycle of stressful experiences that impacted both familial relationships and interactions with society. This study draws attention to this previously obscured population group, and calls health care practitioners and policy advisors to engage differently over issues involving families in similar positions.	[Mcbride-Henry, Karen; Miller, Charissa] Victoria Univ Wellington, Fac Hlth, Sch Nursing Midwifery & Hlth Practice, Wellington, New Zealand; [Mcbride-Henry, Karen; Officer, Tara N.] Victoria Univ Wellington, Fac Hlth, Hlth Serv Res Ctr, Wellington, New Zealand; [Miller, Charissa; Trenholm, Adrian] Counties Manukau Dist Hlth Board, Kidz First Hosp, Auckland, New Zealand	Victoria University Wellington; Victoria University Wellington	Mcbride-Henry, K (corresponding author), Victoria Univ Wellington, Fac Hlth, Sch Nursing Midwifery & Hlth Practice, Wellington, New Zealand.; Mcbride-Henry, K (corresponding author), Victoria Univ Wellington, Fac Hlth, Hlth Serv Res Ctr, Wellington, New Zealand.	karen.mcbride-henry@vuw.ac.nz	McBride-Henry, Karen/F-5429-2018	McBride-Henry, Karen/0000-0003-4426-2574	Victoria University of Wellington [101514]	Victoria University of Wellington	KMH. Grant number: 101514. Funder name: Victoria University of Wellington, https://www.victoria.ac.nz/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Benner P, 1994, INTERPRETIVE PHENOME; Benner P., 2000, NURS PHILOS, V1, P5, DOI DOI 10.1046/J.1466-769X.2000.00014.X; Burke S O, 1991, Image J Nurs Sch, V23, P39; Byrnes C, 2019, THORAX; Case RJL, 2015, J PAEDIATR CHILD H, V51, P1097, DOI 10.1111/jpc.12949; Chisholm E, 2020, HEALTH PROMOT J AUST, V31, P7, DOI 10.1002/hpja.247; Colville Gillian, 2009, Intensive Crit Care Nurs, V25, P72, DOI 10.1016/j.iccn.2008.10.002; Crowley C., 2002, INT J SOC RES METHOD, V5, P193, DOI DOI 10.1080/13645570210146258; Curtis K, 2016, J PEDIATR NURS, V31, P330, DOI 10.1016/j.pedn.2015.11.009; Dahlberg K, 1997, J Holist Nurs, V15, P303; Dahlberg K., 2001, REFLECTIVE LIFEWORLD; Dahlberg K., 2007, REFLECTIVE LIFEWORLD; Foley D, 2019, J PAEDIATR CHILD H, V55, P528, DOI 10.1111/jpc.14234; Foster K, 2017, INJURY, V48, P114, DOI 10.1016/j.injury.2016.09.034; Freshwater Dawn, 2004, Nurs Philos, V5, P4, DOI 10.1111/j.1466-769X.2004.00151.x; Gadamer HG, 1989, TRUTH METHOD; Greenwood ML, 2012, PAED CHILD HEALT-CAN, V17, P381, DOI 10.1093/pch/17.7.381; Health Quality & Safety Commission New Zealand, 2019, HE MAT KI KOUNG HAU; Heidegger Martin, 1962, BEING TIME; Hopia H, 2005, J CLIN NURS, V14, P212, DOI 10.1111/j.1365-2702.2004.01041.x; Hudson SM, 2014, COMPR CHILD ADOLES N, V37, P61, DOI 10.3109/01460862.2013.855844; Inwood Michael, 1999, HEIDEGGER DICT; Ironside PM, 1997, PRESERVING READING W; Jackson, 2008, HLTH STATUS CHILDREN; JOHNSTON IDA, 1985, BRIT MED J, V290, P1636, DOI 10.1136/bmj.290.6482.1636; Kai J, 1996, BRIT MED J, V313, P983; Karron RA, 1999, J INFECT DIS, V180, P41, DOI 10.1086/314841; Landolt MA, 2012, J CHILD PSYCHOL PSYC, V53, P767, DOI 10.1111/j.1469-7610.2011.02520.x; Manguy AM, 2018, J PEDIATR NURS, V38, P46, DOI 10.1016/j.pedn.2017.10.014; Mast TC, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-11; Merleau-Ponty M, 1981, PHENOMENOLOGY PERCEP; Mumford V, 2018, J PAEDIATR CHILD H, V54, P987, DOI 10.1111/jpc.13923; Noyes J, 1999, J ADV NURS, V29, P427, DOI 10.1046/j.1365-2648.1999.00906.x; Palmer Richard E., 1969, HERMENEUTICS INTERPR; Price J, 2016, J PEDIATR PSYCHOL, V41, P86, DOI 10.1093/jpepsy/jsv074; SANDELOWSKI M, 1995, RES NURS HEALTH, V18, P371, DOI 10.1002/nur.4770180411; Seguin L, 2005, J EPIDEMIOL COMMUN H, V59, P42, DOI 10.1136/jech.2004.020438; Shudy M, 2006, PEDIATRICS, V118, pS203, DOI 10.1542/peds.2006-0951B; Simpson J, 2014, DETERMINANTS HLTH CH; Singleton RJ, 2003, PEDIATRICS, V112, P285, DOI 10.1542/peds.112.2.285; Smythe E., 1998, BEING SAFE CHILDBIRT; Trenholme A, 2012, NZ MED J, V125; Trenholme AA, 2013, PEDIATR PULM, V48, P772, DOI 10.1002/ppul.22661; Valery PC, 2004, PEDIATR INFECT DIS J, V23, P902, DOI 10.1097/01.inf.0000142508.33623.2f	44	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2020	15	1							e0228354	10.1371/journal.pone.0228354	http://dx.doi.org/10.1371/journal.pone.0228354			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP9CB	31999770	Green Published, gold			2023-01-03	WOS:000534612400071
J	Huang, LP; Heuer, OD; Janssen, S; Hackl, D; Schmedt, N				Huang, Liping; Heuer, Olivia Denise; Janssen, Sabrina; Haeckl, Dennis; Schmedt, Niklas			Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database	PLOS ONE			English	Article							COMPLEMENT DEFICIENCY; HEALTH BURDEN; UNITED-STATES; COST; COMPLICATIONS; SEQUELAE; IMPACT	Background Limited data is available to describe clinical characteristics, long-term outcomes, healthcare resource use and the attributable costs of invasive meningococcal disease (IMD) in Germany. We aimed to examine demographic and clinical characteristics as well as healthcare resource use and related costs. Methods We conducted a retrospective cohort study based on the InGef database in patients with IMD between 2009 and 2015. Cases were identified based on hospital main discharge diagnoses of IMD. Demographics, clinical characteristics, 30-day and 1-year mortality as well as IMD-related complications and sequelae in IMD cases were examined. In addition, short and long-term costs and healthcare resource use in IMD cases were analyzed and compared to an age- and sex-matched control group without IMD. Results The study population comprised 164 IMD cases between 2009 and 2015. The mean length of the IMD-related hospitalization was 13 days and 38% of all cases presented with meningitis only, 35% with sepsis only, 16% with both and 11% with other IMD. The 30-day and oneyear mortality were 4.3% and 5.5%, respectively. Approximately 13% of IMD cases had documented IMD-related complications at hospital discharge and 24% suffered from sequelae during follow-up. The IMD-related hospitalization was associated with mean costs of _ 9,620 (standard deviation: _ 22,197). The difference of mean costs between IMD cases and matched non-IMD controls were _ 267 in the first month and _ 1,161 from one month to one year after discharged from IMD-related hospitalization. During the later follow-up period, the mean overall costs and costs associated with individual healthcare sectors were also higher for IMD cases without reaching statistical significance. Conclusions IMD resulted in severe complications and sequelae and was associated with extensive costs and increased healthcare resource use in Germany, especially in the first year after IMD diagnosis and due the IMD-related hospitalization.	[Huang, Liping] Pfizer Inc, Collegeville, PA USA; [Heuer, Olivia Denise; Schmedt, Niklas] Inst Appl Hlth Res Berlin, Berlin, Germany; [Janssen, Sabrina] Pfizer Deutschland GmbH, Berlin, Germany; [Haeckl, Dennis] WIG2 GmbH, Leipzig, Germany	Pfizer; Pfizer	Schmedt, N (corresponding author), Inst Appl Hlth Res Berlin, Berlin, Germany.	niklas.schmedt@ingef.de			Pfizer Inc.	Pfizer Inc.(Pfizer)	This work was supported by Pfizer Inc. The funder provided support in the form of salaries for authors (LH, SJ), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersohn F, 2016, PHARMACOEPIDEM DR S, V25, P106, DOI 10.1002/pds.3895; Anonychuk A, 2013, PHARMACOECONOMICS, V31, P563, DOI 10.1007/s40273-013-0057-2; Benard S, 2016, J INFECT PUBLIC HEAL, V9, P339, DOI 10.1016/j.jiph.2015.10.016; Borg J, 2009, PEDIATRICS, V123, pe502, DOI 10.1542/peds.2008-0581; Christensen H, 2016, VACCINE, V34, P3412, DOI 10.1016/j.vaccine.2016.04.004; Davis KL, 2011, HUM VACCINES, V7, P458, DOI 10.4161/hv.7.4.14434; Dell'Agnello G, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019684; Erickson L, 1998, CLIN INFECT DIS, V26, P1159, DOI 10.1086/520303; Erickson LJ, 2001, CLIN INFECT DIS, V33, P737, DOI 10.1086/322587; European Centre for Disease Prevention and Control, 2018, SURV ATL INF DIS; Federal Ministry of Justice and Consumer Protection, 2019, SOC COD BOOK 5; Federal Ministry of Justice and Consumer Protection, 2019, SOC COD BOOK 10; FIGUEROA J, 1993, IMMUNOL RES, V12, P295, DOI 10.1007/BF02918259; Fijen CAP, 1999, CLIN INFECT DIS, V28, P98, DOI 10.1086/515075; German Institute of Medical Documentation and Information, 2018, GERM MOD 10 REV INT; Gustafsson N, 2018, CLINICOECONOMIC OUTC, V10, P563, DOI 10.2147/CEOR.S175835; Jafri RZ, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-17; Kaplan SL, 2006, PEDIATRICS, V118, pE979, DOI 10.1542/peds.2006-0281; Karve S., 2011, HLTH OUTCOMES RES ME, V2, pe215, DOI DOI 10.1016/J.EHRM.2011.08.001; O'Brien JA, 2006, VALUE HEALTH, V9, P236, DOI 10.1111/j.1524-4733.2006.00113.x; Pelton SI, 2016, J ADOLESCENT HEALTH, V59, pS3, DOI 10.1016/j.jadohealth.2016.04.012; Rober Koch-Institut (RKI), 2016, SIT AUSG INF DEUTSCH; Robert Koch-Institut, 2017, EMPF STA SPAC DIAER; Robert Koch-Institut, 2015, FALLD R KOCH I ZURU; Robert Koch-Institute, 2017, INF JB MELD KRANKH 2; Scholz S, 2019, VACCINE, V37, P1692, DOI 10.1016/j.vaccine.2019.01.013; Stein-Zamir C, 2014, PEDIATR INFECT DIS J, V33, P777, DOI 10.1097/INF.0000000000000282; Stoof SP, 2015, CLIN INFECT DIS, V61, P1281, DOI 10.1093/cid/civ506; Strifler L, 2016, J PEDIAT INF DIS SOC, V5, P417, DOI 10.1093/jpids/piv065; Vazquez JA, 2016, EPIDEMIOL INFECT, V144, P3052, DOI 10.1017/S0950268816001308; Wang B, 2018, PHARMACOECONOMICS; Wang B, 2014, VACCINE, V32, P4791, DOI 10.1016/j.vaccine.2014.05.069	32	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2020	15	1							e0228020	10.1371/journal.pone.0228020	http://dx.doi.org/10.1371/journal.pone.0228020			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP8ZJ	31990941	gold, Green Published			2023-01-03	WOS:000534605400036
J	Geng, XH; Shi, EM; Wang, SW; Song, YZ				Geng, Xinghua; Shi, Ermin; Wang, Shiwei; Song, Yuzhi			A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials	PLOS ONE			English	Review							CHRONIC KIDNEY-DISEASE; SECONDARY HYPERPARATHYROIDISM; MINERAL METABOLISM; DIALYSIS PATIENTS; ORAL PARICALCITOL; BONE-DISEASE; CALCITRIOL; SURVIVAL; MORTALITY; THERAPY	Paricalcitol, a new vitamin D receptor activator (VDRA), is reported to be more effective than other VDRAs in reducing calcium and phosphorus levels in patients undergoing hemodialysis. However, the efficacy and safety of paricalcitol remain controversial. This analysis compares paricalcitol with other VDRAs in patients undergoing hemodialysis. We searched the Cochrane Library, PubMed, EMBASE, Web of Science, and CNKI up to April 22, 2019. Standardized mean difference (SMD), risk ratio (RR) and 95% confidence interval (CI) values were estimated to compare the outcomes of the groups. Two reviewers extracted data and assessed trial quality independently. All statistical analyses were performed using the standard statistical procedures of RevMan 5.2 and Stata 12.0. Fifteen studies (N = 110,544) were included in this meta -analysis. Of these studies, 11 were randomized controlled trials (RCTs) and 4 were non -randomized studies of interventions (NRSIs). Patients receiving paricalcitol experienced better overall survival (OS) than patients receiving other VDRAs, with a pooled hazard ratio of 0.86 (95% CI 0.80-0.91; P < 0.00001). Intact parathyroid hormone (iPTH) levels were significantly reduced in the paricalcitol group compared to the group receiving other VDRAs, with a pooled SMD of -0.53 (95% CI -0.89 -0.16; P = 0.004). There was a significant increase in serum calcium levels from baseline in the paricalcitol group compared to the other VDRAs group when limiting the analysis to RCTs, with a pooled SMD of 2.14 (95% CI 0.903.38; P = 0.0007). Changes in serum calcium levels were significantly lower in the paricalcitol group when the analysis was limited to NRSIs, with a pooled SMD of -0.85 (95% CI -1.34-0.35; P = 0.0008). The NSRI analysis also showed a significant reduction in serum phosphorus levels in the paricalcitol group, with a pooled SMD of -0.57 (95% CI -1.00-0.13; P = 0.01). No significant differences were observed in the incidence of hypercalcemia, hyperphosphatemia, or adverse events. Generally, paricalcitol seems superior to other VDRAs in reducing mortality and iPTH levels in patients undergoing hemodialysis. However, the comparative effectiveness of paricalcitol in reducing serum calcium and phosphorus levels needs further exploration. No significant difference was found in the rate of adverse events.	[Geng, Xinghua; Wang, Shiwei; Song, Yuzhi] Fourth Cent Hosp Baoding City, Hemodialysis Room, Baoding, Hebei, Peoples R China; [Shi, Ermin] Fourth Cent Hosp Baoding City, Adm Dept, Baoding, Peoples R China		Song, YZ (corresponding author), Fourth Cent Hosp Baoding City, Hemodialysis Room, Baoding, Hebei, Peoples R China.	zhangzm1026@163.com						Adams JS, 2003, J CELL BIOCHEM, V88, P308, DOI 10.1002/jcb.10333; Adorini L, 2004, J STEROID BIOCHEM, V89-90, P437, DOI 10.1016/j.jsbmb.2004.03.013; Akizawa T, 2015, THER APHER DIAL, V19, P225, DOI 10.1111/1744-9987.12242; Andress DL, 2006, KIDNEY INT, V69, P33, DOI 10.1038/sj.ki.5000045; [Anonymous], 2012, REV MAN REVMAN COMP; Bikle DD, 2004, J STEROID BIOCHEM, V89-90, P355, DOI 10.1016/j.jsbmb.2004.03.020; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Cheng J, 2012, CLIN J AM SOC NEPHRO, V7, P391, DOI 10.2215/CJN.03000311; Clark HD, 1999, CONTROL CLIN TRIALS, V20, P448, DOI 10.1016/S0197-2456(99)00026-4; Collins Allan J, 2012, Am J Kidney Dis, V59, pe1, DOI 10.1053/j.ajkd.2011.11.015; Cozzolino M, 2012, NEPHROL DIAL TRANSPL, V27, P3588, DOI 10.1093/ndt/gfs108; Cozzolino M, 2010, EUR J HEART FAIL, V12, P1031, DOI 10.1093/eurjhf/hfq112; DerSimonian R, 2015, CONTEMP CLIN TRIALS, V45, P139, DOI 10.1016/j.cct.2015.09.002; Dusso AS, 2005, AM J PHYSIOL-RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004; Farhat K, 2018, PERITON DIALYSIS INT, V38, P220, DOI 10.3747/pdi.2017.00150; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Gafor AHA, 2009, NEPHROLOGY, V14, P488, DOI 10.1111/j.1440-1797.2008.01058.x; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Han TZ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/320560; Hansen D, 2011, KIDNEY INT, V80, P841, DOI 10.1038/ki.2011.226; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Ifudu O, 1998, NEW ENGL J MED, V339, P1054, DOI 10.1056/NEJM199810083391507; Jamaluddin EJ, 2014, CLIN EXP NEPHROL, V18, P507, DOI 10.1007/s10157-013-0844-2; Jean G, 2008, NEPHROL DIAL TRANSPL, V23, P3670, DOI 10.1093/ndt/gfn339; Kalantar-Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514; Ketteler M, 2012, NEPHROL DIAL TRANSPL, V27, P3270, DOI 10.1093/ndt/gfs018; LaClair RE, 2005, AM J KIDNEY DIS, V45, P1026, DOI 10.1053/j.ajkd.2005.02.029; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Li XH, 2015, NEPHROLOGY, V20, P706, DOI 10.1111/nep.12505; Liu Y, 2019, DRUG DES DEV THER, V13, P999, DOI 10.2147/DDDT.S176257; Lund RJ, 2010, AM J NEPHROL, V31, P165, DOI 10.1159/000266204; MANTEL N, 1959, J NATL CANCER I, V22, P719; Martin KJ, 2007, J AM SOC NEPHROL, V18, P875, DOI 10.1681/ASN.2006070771; Matias PJ, 2010, CLIN J AM SOC NEPHRO, V5, P905, DOI 10.2215/CJN.06510909; MILLINER DS, 1990, KIDNEY INT, V38, P931, DOI 10.1038/ki.1990.293; Moe SM, 2007, ADV CHRONIC KIDNEY D, V14, P3, DOI 10.1053/j.ackd.2006.10.005; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Ong LM, 2013, NEPHROLOGY, V18, P194, DOI 10.1111/nep.12029; PALMER SC, 2009, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD008175]; Rodriguez M, 2005, AM J PHYSIOL-RENAL, V288, pF253, DOI 10.1152/ajprenal.00302.2004; Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008; Shinaberger CS, 2008, CLIN J AM SOC NEPHRO, V3, P1769, DOI 10.2215/CJN.01760408; Sprague SM, 2003, KIDNEY INT, V63, P1483, DOI 10.1046/j.1523-1755.2003.00878.x; Sprague SM, 2001, AM J KIDNEY DIS, V38, pS51, DOI 10.1053/ajkd.2001.28110; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573; Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536; Tentori F, 2006, KIDNEY INT, V70, P1858, DOI 10.1038/sj.ki.5001868; University of York Centre for Reviews and Dissemination, 2009, SYSTEMATIC REV CRDS; Veceric-Haler Z, 2016, THER APHER DIAL, V20, P261, DOI 10.1111/1744-9987.12434; Wolf M, 2007, KIDNEY INT, V72, P1004, DOI 10.1038/sj.ki.5002451; Xie YF, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0691-6	52	4	5	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2020	15	5							e0233705	10.1371/journal.pone.0233705	http://dx.doi.org/10.1371/journal.pone.0233705			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1WS	32470067	Green Published, gold			2023-01-03	WOS:000537552800144
J	Ju, C; Park, E; Kim, T; Kim, T; Kang, M; Lee, KS; Park, SM				Ju, Chanyang; Park, Eunkyoung; Kim, Taewoo; Kim, Taekyung; Kang, Minhee; Lee, Kyu-Sung; Park, Sung-Min			Effectiveness of electrical stimulation on nerve regeneration after crush injury: Comparison between invasive and non-invasive stimulation	PLOS ONE			English	Article							FUNCTIONAL RECOVERY; RAT; BRAIN; FIELD	Several studies have investigated the use of invasive and non-invasive stimulation methods to enhance nerve regeneration, and varying degrees of effectiveness have been reported. However, due to the use of different parameters in these studies, a fair comparison between the effectiveness of invasive and non-invasive stimulation methods is not possible. The present study compared the effectiveness of invasive and non-invasive stimulation using similar parameters. Eighteen Sprague Dawley rats were classified into three groups: the iES group stimulated with fully implantable device, the tES group stimulated with transcutaneous electrical nerve stimulation (TENS), and the injury group (no stimulation). The iES and tES groups received stimulation for 6 weeks starting immediately after the injury. Motor function was evaluated using the sciatic functional index (SFI) every week. The SFI values increased over time in all groups; faster and superior functional recovery was observed in the iES group than in the tES group. Histological evaluation of the nerve sections and gastrocnemius muscle sections were performed every other week. The axon diameter and muscle fiber area in the iES group were larger, and the g-ratio in the iES group was closer to 0.6 than those in the tES group. To assess the cause of the difference in efficiency, a 3D rat anatomical model was used to simulate the induced electric fields in each group. A significantly higher concentration and intensity around the sciatic nerve was observed in the iES group than in the tES group. Vector field distribution showed that the field was orthogonal to the sciatic nerve spread in the tES group, whereas it was parallel in the iES group; this suggested that the tES group was less effective in nerve stimulation. The results indicated that even though rats in the TENS group showed better recovery than those in the injury group, it cannot replace direct stimulation yet because rats stimulated with the invasive method showed faster recovery and superior outcomes. This was likely attributable to the greater concentration and parallel distribution of electric field with respect to target nerve.	[Ju, Chanyang; Park, Sung-Min] Pohang Univ Sci & Technol, Dept Creat IT Engn, Pohang, South Korea; [Park, Eunkyoung; Kim, Taewoo; Kim, Taekyung; Kang, Minhee; Lee, Kyu-Sung] Sungkyunkwan Univ, Smart Healthcare Res Inst, Biomed Engn Res Ctr, Samsung Med Ctr,Sch Med, Seoul, South Korea; [Park, Eunkyoung; Kim, Taekyung; Kang, Minhee; Lee, Kyu-Sung] Sungkyunkwan Univ, Dept Med Device Management & Res, SAIHST, Seoul, South Korea; [Lee, Kyu-Sung] Sungkyunkwan Univ, Dept Urol, Samsung Med Ctr, Sch Med, Seoul, South Korea	Pohang University of Science & Technology (POSTECH); Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Samsung Medical Center	Park, SM (corresponding author), Pohang Univ Sci & Technol, Dept Creat IT Engn, Pohang, South Korea.; Lee, KS (corresponding author), Sungkyunkwan Univ, Smart Healthcare Res Inst, Biomed Engn Res Ctr, Samsung Med Ctr,Sch Med, Seoul, South Korea.; Lee, KS (corresponding author), Sungkyunkwan Univ, Dept Med Device Management & Res, SAIHST, Seoul, South Korea.; Lee, KS (corresponding author), Sungkyunkwan Univ, Dept Urol, Samsung Med Ctr, Sch Med, Seoul, South Korea.	ksleedr@skku.edu; sungminpark@postech.ac.kr		Ju, Chanyang/0000-0002-1658-3680; Kim, Taekyung/0000-0002-4233-8574; Park, Sung-Min/0000-0002-8359-8110; Park, Eunkyoung/0000-0001-7700-0250	National Research Foundation of Korea (NRF) - Korean government (MSIT) [2019R1A2C4070590, 2020R1A2C2005385, 2017R1A5A1015596]	National Research Foundation of Korea (NRF) - Korean government (MSIT)	This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (2019R1A2C4070590, 2020R1A2C2005385, 2017R1A5A1015596).	Al-Majed AA, 2000, EUR J NEUROSCI, V12, P4381, DOI 10.1046/j.1460-9568.2000.01341.x; Alrashdan MS, 2010, ACTA NEUROL BELG, V110, P168; Asensio-Pinilla E, 2009, EXP NEUROL, V219, P258, DOI 10.1016/j.expneurol.2009.05.034; Bervar M, 2005, BIOELECTROMAGNETICS, V26, P351, DOI 10.1002/bem.20108; Chang F, 2014, ANNU REV CELL DEV BI, V30, P317, DOI 10.1146/annurev-cellbio-100913-013357; Frostick SP, 1998, MICROSURG, V18, P397, DOI 10.1002/(SICI)1098-2752(1998)18:7<397::AID-MICR2>3.0.CO;2-F; Gabriel C, 1996, AIR FORCE MATERIEL C; Geremia NM, 2007, EXP NEUROL, V205, P347, DOI 10.1016/j.expneurol.2007.01.040; Gigo-Benato D, 2010, MUSCLE NERVE, V41, P685, DOI 10.1002/mus.21549; Gordon T, 2016, NEUROTHERAPEUTICS, V13, P295, DOI 10.1007/s13311-015-0415-1; Gordon T, 2011, J NEUROSCI, V31, P5325, DOI 10.1523/JNEUROSCI.6156-10.2011; Gordon T, 2009, INT REV NEUROBIOL, V87, P433, DOI 10.1016/S0074-7742(09)87024-4; Grossman N, 2017, CELL, V169, P1029, DOI 10.1016/j.cell.2017.05.024; Haastert-Talini K, 2013, INT REV NEUROBIOL, V109, P111, DOI 10.1016/B978-0-12-420045-6.00005-5; Huard J, 2002, J BONE JOINT SURG AM, V84A, P822, DOI 10.2106/00004623-200205000-00022; Kainz W, 2006, PHYS MED BIOL, V51, P5211, DOI 10.1088/0031-9155/51/20/009; Kanaya F, 1996, PLAST RECONSTR SURG, V98, P1264, DOI 10.1097/00006534-199612000-00023; Koo J, 2018, NAT MED, V24, P1830, DOI 10.1038/s41591-018-0196-2; Lu MC, 2008, NEUROREHAB NEURAL RE, V22, P367, DOI 10.1177/1545968307313507; McCaig CD, 2000, DEV DYNAM, V217, P299, DOI 10.1002/(SICI)1097-0177(200003)217:3<299::AID-DVDY8>3.0.CO;2-G; Mendonca AC, 2003, J NEUROSCI METH, V129, P183, DOI 10.1016/S0165-0270(03)00207-3; Menorca RMG, 2013, HAND CLIN, V29, P317, DOI 10.1016/j.hcl.2013.04.002; Millard RE, 2007, J NEUROSCI METH, V166, P168, DOI 10.1016/j.jneumeth.2007.07.009; de Assis DCM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/572949; Montgomery KL, 2015, NAT METHODS, V12, P969, DOI [10.1038/NMETH.3536, 10.1038/nmeth.3536]; Patterson M., 2013, ELECT STIMULATION RE; ROTH BJ, 1990, IEEE T BIO-MED ENG, V37, P588, DOI 10.1109/10.55662; Rui BY, 2013, EXP THER MED, V6, P22, DOI 10.3892/etm.2013.1110; RUSHTON WAH, 1951, J PHYSIOL-LONDON, V115, P101, DOI 10.1113/jphysiol.1951.sp004655; Varejao ASP, 2001, J NEUROSCI METH, V108, P1, DOI 10.1016/S0165-0270(01)00378-8; Vivo M, 2008, EXP NEUROL, V211, P180, DOI 10.1016/j.expneurol.2008.01.020; Zhang X, 2013, MOL MED REP, V7, P1523, DOI 10.3892/mmr.2013.1395	32	13	13	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2020	15	5							e0233531	10.1371/journal.pone.0233531	http://dx.doi.org/10.1371/journal.pone.0233531			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1NT	32453807	Green Published, gold			2023-01-03	WOS:000537529500030
J	Chang, PH; Lin, CR; Lee, YH; Liu, YL; Chang, GC; Hoogland, AI; Lai, YH				Chang, Pi-Hua; Lin, Ching-Rong; Lee, Yun-Hsiang; Liu, Yi-Lin; Chang, Gee-Chen; Hoogland, Aasha, I; Lai, Yeur-Hur			Exercise experiences in patients with metastatic lung cancer: A qualitative approach	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; OF-LIFE; FUNCTIONAL-CAPACITY; NARRATIVE INQUIRY; SYMPTOM BURDEN; STAGE CANCER; REHABILITATION; METHODOLOGY; INTERVENTION; PREFERENCES	Background Patients with metastatic lung cancer can have severe cancer-related symptoms and treatment-induced side effects. Exercise is beneficial for patients with metastatic lung cancer; however, little information is available on guiding patients how to perform exercise during hospitalization. The purpose of this qualitative study was to understand exercise experiences in patients with metastatic lung cancer. Methods Patients with metastatic lung cancer (n = 24) participated in face-to-face in-depth interviews at an inpatient ward of a medical center in central Taiwan. Interview transcripts were evaluated using narrative analysis to extract and validate themes. Results Three primary themes were identified: (1) modifying exercise to maximize physical functions; (2) living with symptoms and frustration, but still exercising; and (3) doing exercise to sustain hopes, inner power, and life. Secondary findings included: (1) adopting walking as their main form of exercise because of its convenience; and (2) among patients with severe symptoms, adjusting exercise towards shorter time durations and shorter distances, slower speeds, and higher frequencies. Conclusions The study found physically active lung cancer patients, although with metastatic condition, adjusted their exercise activities to balance disease and treatment-induced deteriorations and boost themselves to feel hope and fight for cancer. However, the results may not be applicable to physically inactive patients. Future research to explore experiences from those with even worse physical conditions and further helping them to take some mild exercise to enhance the positive side of cancer experiences are suggested.	[Chang, Pi-Hua; Liu, Yi-Lin] Taichung Vet Gen Hosp, Dept Nursing, Taichung, Taiwan; [Chang, Pi-Hua; Lee, Yun-Hsiang; Lai, Yeur-Hur] Natl Taiwan Univ, Coll Med, Sch Nursing, Taipei, Taiwan; [Lin, Ching-Rong] Chang Gung Univ, Coll Med, Sch Nursing, Taoyuan, Taiwan; [Lin, Ching-Rong] Chang Gung Mem Hosp, Proton & Radiat Therapy Ctr, Dept Radiat Oncol, Taoyuan, Taiwan; [Chang, Gee-Chen] Taichung Vet Gen Hosp, Div Chest Med, Taichung, Taiwan; [Chang, Gee-Chen] Taichung Vet Gen Hosp, Comprehens Canc Ctr, Dept Internal Med, Taichung, Taiwan; [Chang, Gee-Chen] Natl Yang Ming Univ, Fac Med, Sch Med, Taipei, Taiwan; [Hoogland, Aasha, I] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA; [Lai, Yeur-Hur] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan	Taichung Veterans General Hospital; National Taiwan University; Chang Gung University; Chang Gung Memorial Hospital; Taichung Veterans General Hospital; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University; H Lee Moffitt Cancer Center & Research Institute; National Taiwan University	Lai, YH (corresponding author), Natl Taiwan Univ, Coll Med, Sch Nursing, Taipei, Taiwan.; Lai, YH (corresponding author), Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan.	laiyhwk@ntu.edu.tw		LAI, YEUR-HUR/0000-0003-0313-2634; Hoogland, Aasha/0000-0002-8691-8132	Taichung Veterans General Hospital Research Program in Taiwan [TCVGH-997415B]	Taichung Veterans General Hospital Research Program in Taiwan	This study was funded by the Taichung Veterans General Hospital Research Program (TCVGH-997415B) in Taiwan. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	Aarts H, 1997, HEALTH EDUC RES, V12, P363, DOI 10.1093/her/12.3.363; Aboagye E, 2017, PAIN THER, V6, P85, DOI 10.1007/s40122-017-0067-4; Adamsen L, 2012, SCAND J MED SCI SPOR, V22, P804, DOI 10.1111/j.1600-0838.2011.01323.x; Albrecht TA, 2012, CLIN J ONCOL NURS, V16, P293, DOI 10.1188/12.CJON.293-300; Ament W, 2009, SPORTS MED, V39, P389, DOI 10.2165/00007256-200939050-00005; Bade BC, 2018, INTEGR CANCER THER, V17, P921, DOI 10.1177/1534735418781739; Bade BC, 2015, J THORAC ONCOL, V10, P861, DOI 10.1097/JTO.0000000000000536; Betof AS, 2013, BRAIN BEHAV IMMUN, V30, pS75, DOI 10.1016/j.bbi.2012.05.001; Booth S, 2014, MANAGING BREATHLESSN, P143; Buccheri G, 1996, EUR J CANCER, V32A, P1135, DOI 10.1016/0959-8049(95)00664-8; Buchan D. S., 2012, Journal of Obesity, V2012, P546459; Buman MP, 2010, PSYCHOL SPORT EXERC, V11, P223, DOI 10.1016/j.psychsport.2010.02.002; Chasen M, 2014, CAN MED ASSOC J, V186, P1071, DOI 10.1503/cmaj.131402; Cheng TYD, 2016, J THORAC ONCOL, V11, P1653, DOI 10.1016/j.jtho.2016.05.021; Cheville AL, 2013, J PAIN SYMPTOM MANAG, V45, P811, DOI 10.1016/j.jpainsymman.2012.05.006; Cheville AL, 2012, J PAIN SYMPTOM MANAG, V44, P84, DOI 10.1016/j.jpainsymman.2011.08.009; Clifford BK, 2018, SUPPORT CARE CANCER, V26, P685, DOI 10.1007/s00520-017-3964-5; Delaney LJ, 2018, COLLEGIAN, V25, P119, DOI 10.1016/j.colegn.2017.02.005; Denehy L, 2013, J THORAC ONCOL, V8, P1545, DOI 10.1097/JTO.0000000000000032; Dhillon HM, 2017, ANN ONCOL, V28, P1889, DOI 10.1093/annonc/mdx205; Edbrooke L, 2019, SUPPORT CARE CANCER; Edbrooke L, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091288; Edbrooke L, 2019, THORAX, V74, P787, DOI 10.1136/thoraxjnl-2018-212996; Edbrooke L, 2020, SUPPORT CARE CANCER, V28, P99, DOI 10.1007/s00520-019-04783-4; Eliott JA, 2007, SOC SCI MED, V64, P138, DOI 10.1016/j.socscimed.2006.08.029; Floersch J., 2010, QUAL SOC WORK, V9, P407, DOI [10.1177/1473325010362330, DOI 10.1177/1473325010362330]; Giovannucci EL, 2012, JNCI-J NATL CANCER I, V104, P797, DOI 10.1093/jnci/djs229; Granger CL, 2011, LUNG CANCER, V72, P139, DOI 10.1016/j.lungcan.2011.01.006; Granger CL, 2019, EUR J CANCER CARE, V28, DOI 10.1111/ecc.12946; Granger CL, 2017, SUPPORT CARE CANCER, V25, P983, DOI 10.1007/s00520-016-3484-8; Gysels M, 2008, J PAIN SYMPTOM MANAG, V35, P347, DOI 10.1016/j.jpainsymman.2007.05.012; Hannum SM, 2016, J AGING STUD, V36, P17, DOI 10.1016/j.jaging.2015.12.006; Haydon G, 2018, COLLEGIAN, V25, P125, DOI 10.1016/j.colegn.2017.03.001; Hayes SC, 2019, J SCI MED SPORT, V22, P1175, DOI 10.1016/j.jsams.2019.05.003; Health Promotion Administration, 2018, TAIW CANC REG ANN RE; Henke CC, 2014, SUPPORT CARE CANCER, V22, P95, DOI 10.1007/s00520-013-1925-1; Hwang CL, 2012, SUPPORT CARE CANCER, V20, P3169, DOI 10.1007/s00520-012-1452-5; Iyer S, 2013, LUNG CANCER, V81, P288, DOI 10.1016/j.lungcan.2013.03.008; Jones LW, 2012, LUNG CANCER, V76, P248, DOI 10.1016/j.lungcan.2011.10.009; Kartolo A, 2016, SUPPORT CARE CANCER, V24, P129, DOI 10.1007/s00520-015-2767-9; Kim KHC, 2004, PUBLIC HEALTH NUTR, V7, P773, DOI 10.1079/PHN2004601; Lakoski SG, 2012, NAT REV CLIN ONCOL, V9, P288, DOI 10.1038/nrclinonc.2012.27; Liao YC, 2014, ONCOL NURS FORUM, V41, pE44, DOI 10.1188/14.ONF.E44-E55; Marshall B, 2013, J COMPUT INFORM SYST, V54, P11, DOI 10.1080/08874417.2013.11645667; McClement SE, 2008, EUR J CANCER, V44, P1169, DOI 10.1016/j.ejca.2008.02.031; McTiernan A, 2004, CANCER INVEST, V22, P68, DOI 10.1081/CNV-120027581; Midtgaard J, 2015, ACTA ONCOL, V54, P609, DOI 10.3109/0284186X.2014.995777; Mikkelsen MK, 2019, EUR J ONCOL NURS, V41, P16, DOI 10.1016/j.ejon.2019.04.005; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Moen T., 2006, INT J QUALITATIVE ME, V5, P56, DOI [10.1177/160940690600500405, DOI 10.1177/160940690600500405]; Olivier C, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4102-6; Overcash JA, 2003, CRIT REV ONCOL HEMAT, V48, P179, DOI 10.1016/j.critrevonc.2003.04.006; OWEN WF, 1984, Q J SPEECH, V70, P274, DOI 10.1080/00335638409383697; Palinkas LA, 2015, ADM POLICY MENT HLTH, V42, P533, DOI 10.1007/s10488-013-0528-y; Quist M, 2015, INTEGR CANCER THER, V14, P341, DOI 10.1177/1534735415572887; Quist M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-477; Riley T, 2005, HEALTH EDUC RES, V20, P226, DOI 10.1093/her/cyg122; Sheilds L, 2015, INT J NURS STUD, V52, P207, DOI 10.1016/j.ijnurstu.2014.10.008; Sheill G, 2018, PM&R, V10, P843, DOI 10.1016/j.pmrj.2018.02.006; Silver JK, 2013, CA-CANCER J CLIN, V63, P295, DOI 10.3322/caac.21186; Sung MR, 2017, CLIN LUNG CANCER, V18, P274, DOI 10.1016/j.cllc.2016.12.010; Tanaka K, 2002, J PAIN SYMPTOM MANAG, V23, P417, DOI 10.1016/S0885-3924(02)00376-7; Temel JS, 2009, J THORAC ONCOL, V4, P595, DOI 10.1097/JTO.0b013e31819d18e5; Tsai E, 2018, PSYCHO-ONCOLOGY, V27, P563, DOI 10.1002/pon.4519; Tucker R, 2009, BRIT J SPORT MED, V43, P392, DOI 10.1136/bjsm.2008.050799; Turner RR, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010192.pub3; Walters S, 2013, THORAX, V68, P551, DOI 10.1136/thoraxjnl-2012-202297; Wang CC, 2015, Int J Nurs Sci, V2, P195, DOI 10.1016/j.ijnss.2015.04.014; Wang JW, 2015, SUPPORT CARE CANCER, V23, P1383, DOI 10.1007/s00520-014-2494-7; Woike BA, 2008, SOC PERSONAL PSYCHOL, V2, P434, DOI 10.1111/j.1751-9004.2007.00070.x	70	2	2	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2020	15	4							e0230188	10.1371/journal.pone.0230188	http://dx.doi.org/10.1371/journal.pone.0230188			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR8KJ	32240205	Green Published, gold			2023-01-03	WOS:000535945000019
J	Goecks, J; Jalili, V; Heiser, LM; Gray, JW				Goecks, Jeremy; Jalili, Vahid; Heiser, Laura M.; Gray, Joe W.			How Machine Learning Will Transform Biomedicine	CELL			English	Review							CANCER; HEALTH; PREDICTION; MUTATIONS; ALGORITHM; MEDICINE; SEQUENCE; BIOLOGY	This Perspective explores the application of machine learning toward improved diagnosis and treatment. We outline a vision for how machine learning can transform three broad areas of biomedicine: clinical diagnostics, precision treatments, and health monitoring, where the goal is to maintain health through a range of diseases and the normal aging process. For each area, early instances of successful machine learning applications are discussed, as well as opportunities and challenges for machine learning. When these challenges are met, machine learning promises a future of rigorous, outcomes-based medicine with detection, diagnosis, and treatment strategies that are continuously adapted to individual and environmental differences.	[Goecks, Jeremy; Jalili, Vahid; Heiser, Laura M.; Gray, Joe W.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA	Oregon Health & Science University	Goecks, J (corresponding author), Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA.	goecksj@ohsu.edu	Gray, Joe/AAX-9549-2020	Jalili, Vahid/0000-0003-4986-2157; Goecks, Jeremy/0000-0002-4583-5226	National Cancer Institute [U2C CA233280, U24 CA231877, U54 CA209988]; National Institutes of Health [U54 HG008100]; Prospect Creek Foundation; Susan G. Komen Foundation; Breast Cancer Research Foundation; Jayne Koskinas Ted Giovanis Foundation	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prospect Creek Foundation; Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; Jayne Koskinas Ted Giovanis Foundation	J.G. and J.W.G. are supported by National Cancer Institute (U2C CA233280). J.G. is supported by National Cancer Institute (U24 CA231877). L.M.H. and J.W.G. are supported by the National Institutes of Health (U54 HG008100) and National Cancer Institute (U54 CA209988). J.G., L.M.H., and J.W.G. are supported by the Prospect Creek Foundation. J.W.G. is supported by the Susan G. Komen Foundation. L.M.H. is supported by the Breast Cancer Research Foundation and The Jayne Koskinas Ted Giovanis Foundation.	Ahuja AS, 2019, PEERJ, V7, DOI 10.7717/peerj.7702; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Andreoletti G, 2019, HUM MUTAT, V40, P1197, DOI 10.1002/humu.23876; Ardila D, 2019, NAT MED, V25, P954, DOI 10.1038/s41591-019-0447-x; Arora S, 2015, PARKINSONISM RELAT D, V21, P650, DOI 10.1016/j.parkreldis.2015.02.026; Artzi NS, 2020, NAT MED, V26, P71, DOI 10.1038/s41591-019-0724-8; Batmaz Z, 2019, ARTIF INTELL REV, V52, P1, DOI 10.1007/s10462-018-9654-y; Bjornsson B, 2019, GENOME MED, V12, DOI 10.1186/s13073-019-0701-3; Bojarski M., 2016, ARXIV160407316; Brown BP, 2019, CLIN CANCER RES, V25, P3341, DOI 10.1158/1078-0432.CCR-18-3829; Bumgarner JM, 2018, J AM COLL CARDIOL, V71, P2381, DOI 10.1016/j.jacc.2018.03.003; Cai C.J., 2019, P ACM HUM COMPUT INT, V3, P104; Camacho DM, 2018, CELL, V173, P1581, DOI 10.1016/j.cell.2018.05.015; Car J, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0838-0; Chan J, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0128-7; Chang P, 2018, AM J NEURORADIOL, V39, P1201, DOI 10.3174/ajnr.A5667; Chang SH, 2016, IT PROF, V18, P14, DOI 10.1109/MITP.2016.48; Chang Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27214-6; Chaudharyl K, 2018, CLIN CANCER RES, V24, P1248, DOI 10.1158/1078-0432.CCR-17-0853; Chen KM, 2019, NAT METHODS, V16, P315, DOI 10.1038/s41592-019-0360-8; Chen PHC, 2019, NAT MATER, V18, P410, DOI 10.1038/s41563-019-0345-0; Ching T, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2017.0387; Chiu YC, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-018-0460-9; Costello JC, 2014, NAT BIOTECHNOL, V32, P1202, DOI 10.1038/nbt.2877; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Deng J, 2009, PROC CVPR IEEE, P248, DOI 10.1109/CVPRW.2009.5206848; Ellis MJ, 2013, CANCER DISCOV, V3, P1108, DOI 10.1158/2159-8290.CD-13-0219; Espay AJ, 2016, MOVEMENT DISORD, V31, P1272, DOI 10.1002/mds.26642; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Fu YS, 2018, IEEE T BIOMED CIRC S, V12, P784, DOI 10.1109/TBCAS.2018.2845856; Gao F, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0157-8; Gerstung M, 2017, NAT GENET, V49, P332, DOI 10.1038/ng.3756; Ginis P, 2016, PARKINSONISM RELAT D, V22, P28, DOI 10.1016/j.parkreldis.2015.11.004; Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216; Heitzer E, 2019, NAT REV GENET, V20, P71, DOI 10.1038/s41576-018-0071-5; Huang C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34753-5; Kang SL, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1191-5; Kobayashi Y, 2016, CANCER SCI, V107, P1179, DOI 10.1111/cas.12996; Konecny J., 2016, ARXIV161005492; Kreimeyer K, 2017, J BIOMED INFORM, V73, P14, DOI 10.1016/j.jbi.2017.07.012; Kurnit KC, 2018, CLIN CANCER RES, V24, P2719, DOI 10.1158/1078-0432.CCR-17-2494; Laing EE, 2019, SLEEP, V42, DOI 10.1093/sleep/zsy186; Lasso G, 2019, CELL, V178, P1526, DOI 10.1016/j.cell.2019.08.005; Lee J, 2018, JMIR MED INF, V6, P4, DOI 10.2196/medinform.7744; Litjens G, 2016, SCI REP-UK, V6, DOI 10.1038/srep26286; Liu XX, 2019, LANCET DIGIT HEALTH, V1, pE271, DOI 10.1016/S2589-7500(19)30123-2; Lonini L, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0071-z; McKinney SM, 2020, NATURE, V577, P89, DOI 10.1038/s41586-019-1799-6; Metzcar J, 2019, JCO CLIN CANCER INFO, V3, DOI 10.1200/CCI.18.00069; Micheletti J Morgan, 2016, J Diabetes Sci Technol, V10, P295, DOI 10.1177/1932296816629158; Mobadersany P, 2018, P NATL ACAD SCI USA, V115, pE2970, DOI 10.1073/pnas.1717139115; Paparrizos J, 2016, J ONCOL PRACT, V12, P735, DOI 10.1200/JOP.2015.010504; Pereira CR, 2016, SIBGRAPI, P340, DOI [10.1109/SIBGRAPI.2016.51, 10.1109/SIBGRAPI.2016.054]; Pons E, 2016, RADIOLOGY, V279, P329, DOI 10.1148/radiol.16142770; Rahman MM, 2017, COMPUT METHOD APPL M, V320, P261, DOI 10.1016/j.cma.2017.03.021; Rajkomar A, 2019, NEW ENGL J MED, V380, P1347, DOI 10.1056/NEJMra1814259; Rotow J, 2017, NAT REV CANCER, V17, P637, DOI 10.1038/nrc.2017.84; Saez-Rodriguez J, 2016, NAT REV GENET, V17, P470, DOI 10.1038/nrg.2016.69; Sage Bionetworks, 2020, DREAM CHALL; Sahoo PK, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17040711; Sakamoto M, 2018, MICROBIOL RESOUR ANN, V7, DOI 10.1128/MRA.01091-18; Shickel B, 2018, IEEE J BIOMED HEALTH, V22, P1589, DOI 10.1109/JBHI.2017.2767063; Shilo S, 2020, NAT MED, V26, P29, DOI 10.1038/s41591-019-0727-5; Silver D, 2018, SCIENCE, V362, P1140, DOI 10.1126/science.aar6404; Stokes JM, 2020, CELL, V180, P688, DOI 10.1016/j.cell.2020.01.021; Toh X., 2016, P IEEE INT C PERV CO, P1; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vermeulen R, 2020, SCIENCE, V367, P392, DOI 10.1126/science.aay3164; Wang YF, 2019, HINDU KUSH HIMALAYA ASSESSMENT: MOUNTAINS, CLIMATE CHANGE, SUSTAINABILITY AND PEOPLE, P17, DOI 10.1007/978-3-319-92288-1_2; Way GP, 2019, ANNU REV BIOMED DA S, V2, P1, DOI 10.1146/annurev-biodatasci-072018-021348; Way GP, 2018, CELL REP, V23, P172, DOI 10.1016/j.celrep.2018.03.046; White RW, 2017, JAMA ONCOL, V3, P398, DOI 10.1001/jamaoncol.2016.4911; Xiong HY, 2015, SCIENCE, V347, DOI 10.1126/science.1254806; Yang Q, 2019, ACM T INTEL SYST TEC, V10, DOI 10.1145/3298981; Zhang JJ, 2019, NAT BIOTECHNOL, V37, P367, DOI 10.1038/s41587-019-0055-9; Zitnik M, 2019, INFORM FUSION, V50, P71, DOI 10.1016/j.inffus.2018.09.012	78	122	126	17	70	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2020	181	1					92	101		10.1016/j.cell.2020.03.022	http://dx.doi.org/10.1016/j.cell.2020.03.022			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KZ5RI	32243801	Green Accepted, Bronze			2023-01-03	WOS:000523319000015
J	Wallar, LE; Rosella, LC				Wallar, Lauren E.; Rosella, Laura C.			Risk factors for avoidable hospitalizations in Canada using national linked data: A retrospective cohort study	PLOS ONE			English	Article							CARE-SENSITIVE CONDITIONS; OBSTRUCTIVE PULMONARY-DISEASE; ALCOHOL-CONSUMPTION; PREVENTABLE HOSPITALIZATIONS; HEART-FAILURE; HEALTH-CARE; UNCOMPLICATED HYPERTENSION; SOCIOECONOMIC-STATUS; GEOGRAPHIC-VARIATION; PHYSICIAN VISITS	Hospitalizations for certain chronic conditions are considered avoidable for adult Canadians given effective and timely primary care management. Individual-level risk factors such as income and health behaviours are not routinely collected in most hospital databases and as a result, are largely uncharacterized for avoidable hospitalization at the national level. The aim of this study was to identify and describe demographic, socioeconomic, and health behavioural risk factors for avoidable hospitalizations in Canada using linked data. A national retrospective cohort study was conducted by pooling eight cycles of the Canadian Community Health Survey (2000/2001-2011) and linking to hospitalization records in the Discharge Abstract Database (1999/2000-2012/2013). Respondents who were younger than 18 years and older than 74 years of age, residing in Quebec, or pregnant at baseline were excluded yielding a final cohort of 389,065 individuals. The primary outcome measure was time-to index avoidable hospitalization. Sex-stratified Cox proportional hazard models were constructed to determine effect sizes adjusted for various factors and their associated 95% confidence intervals. Demographics, socioeconomic status, and health behaviours are associated with risk of avoidable hospitalizations in males and females. In fully adjusted models, health behavioural variables had the largest effect sizes including heavy smoking (Male HR 2.65 (95% CI 2.17-3.23); Female HR 3.41 (2.81-4.13)) and being underweight (Male HR 1.98 (1.14-3.43); Female HR 2.78 (1.61-4.81)). Immigrant status was protective in both sexes (Male HR 0.83 (0.69-0.98); (Female HR 0.69 (0.57-0.84)). Adjustment for behavioural and clinical variables attenuated the effect of individual-level socioeconomic status. This study identified several risk factors for time-to-avoidable hospitalizations by sex, using the largest national database of linked health survey and hospitalization records. The larger effect sizes of several modifiable risk factors highlights the importance of prevention in addressing avoidable hospitalizations in Canada.	[Wallar, Lauren E.; Rosella, Laura C.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Rosella, Laura C.] Publ Hlth Ontario, Toronto, ON, Canada; [Rosella, Laura C.] Inst Clin Evaluat Sci, Toronto, ON, Canada	University of Toronto; University of Toronto	Rosella, LC (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.; Rosella, LC (corresponding author), Publ Hlth Ontario, Toronto, ON, Canada.; Rosella, LC (corresponding author), Inst Clin Evaluat Sci, Toronto, ON, Canada.	laura.rosella@utoronto.ca			Canada Research Chair [950 -230702]; Social Sciences and Humanities Research Council; Canadian Institutes of Health Research; Canada Foundation for Innovation, Statistics Canada	Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); Social Sciences and Humanities Research Council(Social Sciences and Humanities Research Council of Canada (SSHRC)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Foundation for Innovation, Statistics Canada	This study was funded by a Canada Research Chair held by LCR (950 -230702); The analysis presented in this paper was conducted at the University of Guelph Branch Research Data Centre and the University of Toronto Research Data Centre which is part of the Canadian Research Data Centre Network (CRDCN). The services and activities provided by Research Data Centres are made possible by the financial or in-kind support of the Social Sciences and Humanities Research Council, the Canadian Institutes of Health Research, the Canada Foundation for Innovation, Statistics Canada, and host universities. The views expressed in this paper do not necessarily represent the CRDCN's or that of its partners.	Agabiti N, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-457; Agha MM, 2007, AMBUL PEDIATR, V7, P258, DOI 10.1016/j.ambp.2007.02.005; Al-Sahab B, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-24; Ansari Z, 2006, MED CARE RES REV, V63, P719, DOI 10.1177/1077558706293637; Avoidable Hospitalization Advisory Panel, 2011, ENH CONT CAR REP AV; Baker J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183653; Bardsley M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002007; Bell S, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j909; Bewick V, 2004, CRIT CARE, V8, P389, DOI 10.1186/cc2955; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Bocour A, 2016, J URBAN HEALTH, V93, P974, DOI 10.1007/s11524-016-0090-5; Borda-Olivas A, 2013, EUR J PUBLIC HEALTH, V23, P946, DOI 10.1093/eurpub/cks163; Briasoulis A, 2012, J CLIN HYPERTENS, V14, P792, DOI 10.1111/jch.12008; Brown AD, 2001, CAN J PUBLIC HEALTH, V92, P155, DOI 10.1007/BF03404951; Busby J, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0638-9; Caminal J, 2004, EUR J PUBLIC HEALTH, V14, P246, DOI 10.1093/eurpub/14.3.246; Canadian Institute for Health Informatics, 2012, DISP PRIM HLTH CAR E; Canadian Institute for Health Information, 2018, AMB CAR SENS COND; Canadian Institute for Health Information, 2012, DAT QUAL DOC DISCH A; Canadian Institute for Health Information, IND LIB DIAGN TYP DE; Canadian Institute for Health Information, 2010, HOSP DISP SOC STAT M; Carriere GM, 2017, HEALTH REP, V28, P3; Chen CC, 2017, PUBLIC HEALTH, V151, P13, DOI 10.1016/j.puhe.2017.06.009; Chew RB, 2011, J BEHAV HEALTH SER R, V38, P3, DOI 10.1007/s11414-010-9215-x; Cloutier-Fisher D, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-104; Daniels LM, 2018, J GEN INTERN MED, V33, P737, DOI 10.1007/s11606-017-4285-6; Dantas I, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1584-2; Dorans KS, 2015, CIRC-HEART FAIL, V8, P422, DOI 10.1161/CIRCHEARTFAILURE.114.001787; Doshi RP, 2017, J RACIAL ETHN HEALTH, V4, P1100, DOI 10.1007/s40615-016-0315-z; Falster MO, 2015, MED CARE, V53, P436, DOI 10.1097/MLR.0000000000000342; Finegan MS, 2010, HEALTH SERV MANAG RE, V23, P66, DOI 10.1258/hsmr.2009.009023; Gibson OR, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-336; Gilotra NA, 2017, J CARD FAIL, V23, P252, DOI 10.1016/j.cardfail.2016.09.024; Goncalves A, 2015, EUR HEART J, V36, P939, DOI 10.1093/eurheartj/ehu514; Government of Canada, 2018, MED IN; Guttmann A, 2010, PEDIATRICS, V125, P1119, DOI 10.1542/peds.2009-2821; Hale N, 2016, J COMMUN HEALTH, V41, P451, DOI 10.1007/s10900-015-0113-2; Hossain M, 2009, INT J HEALTH GEOGR, V8, DOI 10.1186/1476-072X-8-51; Johnson PJ, 2012, MED CARE, V50, P1020, DOI 10.1097/MLR.0b013e318270bad4; Khan AM, 2017, J EPIDEMIOL COMMUN H, V71, P625, DOI 10.1136/jech-2016-208525; Knol MJ, 2012, CAN MED ASSOC J, V184, P895, DOI 10.1503/cmaj.101715; Laberge M, 2019, SSM-POPUL HLTH, V7, DOI 10.1016/j.ssmph.2018.100336; Laberge M, 2017, SOC SCI MED, V181, P24, DOI 10.1016/j.socscimed.2017.03.040; Laditka JN, 2006, ETHNIC HEALTH, V11, P247, DOI 10.1080/13557850600565640; Laditka JN, 2009, HEALTH PLACE, V15, P761, DOI 10.1016/j.healthplace.2008.12.007; Larsson SC, 2018, CLIN NUTR, V37, P1247, DOI 10.1016/j.clnu.2017.05.007; Li XH, 2016, AM J CLIN NUTR, V103, P818, DOI 10.3945/ajcn.115.114389; Lin IP, 2015, J AM BOARD FAM MED, V28, P222, DOI 10.3122/jabfm.2015.02.140141; Lu CH, 2019, HEALTH REP, V30, P3, DOI 10.25318/82-003-x201900400001-eng; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Murty S, 2016, J AMBUL CARE MANAG, V39, P253, DOI 10.1097/JAC.0000000000000115; Ng E, 2016, VACCINE, V34, P4437, DOI 10.1016/j.vaccine.2016.06.079; Ng R, 2019, INT J EPIDEMIOLOGY; Niti M, 2003, J EPIDEMIOL COMMUN H, V57, P17, DOI 10.1136/jech.57.1.17; O'Neil SS, 2010, AM J PREV MED, V38, P381, DOI 10.1016/j.amepre.2009.12.026; Pappas G, 1997, AM J PUBLIC HEALTH, V87, P811, DOI 10.2105/AJPH.87.5.811; Porter Joan, 2007, Healthc Q, V10, P26; Purdy S, 2009, PUBLIC HEALTH, V123, P169, DOI 10.1016/j.puhe.2008.11.001; Rehm J, 2006, ADDICTION, V101, P373, DOI 10.1111/j.1360-0443.2005.01338.x; Rizza P, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-134; Roos LL, 2017, CAN J PUBLIC HEALTH, V108, pE257, DOI [10.17269/CJPH.108.5935, 10.17269/cjph.108.5935]; Roos LL, 2005, HEALTH SERV RES, V40, P1167, DOI 10.1111/j.1475-6773.2005.00407.x; Rosano A, 2013, EUR J PUBLIC HEALTH, V23, P356, DOI 10.1093/eurpub/cks053; Rosella LC, 2019, AM J EPIDEMIOL, V188, P323, DOI 10.1093/aje/kwy245; Rotermann M, 2017, HEALTH REP, V28, P3; Saha S, 2007, MED CARE, V45, P712, DOI 10.1097/MLR.0b013e318053717c; Sanchez Maria, 2008, Healthc Q, V11, P20; Sanmartin C, 2011, HOSPITALIZATIONS AMB; Shields M, 2011, HEALTH REP, V22; Statistics Canada, 2018, CAN COMM HLTH SURV A; Statistics Canada, 2017, EV HLTH STAT PROGR 2; Statistics Canada, 2018, CAN COMM HLTH SURV D; Thomas Steven, 2009, Health Rep, V20, P53; Tran B, 2015, DRUG ALCOHOL DEPEN, V150, P85, DOI 10.1016/j.drugalcdep.2015.02.028; van Loenen T, 2014, FAM PRACT, V31, P502, DOI 10.1093/fampra/cmu053; Vuik SI, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015704; Walker MJ, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-52; Walker RL, 2014, CAN J CARDIOL, V30, P1640, DOI 10.1016/j.cjca.2014.09.035; Walker RL, 2013, CAN J CARDIOL, V29, P1462, DOI 10.1016/j.cjca.2013.05.002; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; Wetherbee EE, 2015, INT J CHRONIC OBSTR, V10, P1363, DOI 10.2147/COPD.S86572; Wood AM, 2018, LANCET, V391, P1513, DOI 10.1016/S0140-6736(18)30134-X; Yim B, 2019, AM J PREV MED, V56, P187, DOI 10.1016/j.amepre.2018.08.019	84	6	6	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2020	15	3							e0229465	10.1371/journal.pone.0229465	http://dx.doi.org/10.1371/journal.pone.0229465			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ9DF	32182242	Green Submitted, gold, Green Published			2023-01-03	WOS:000535296400009
J	Strike, C; Robinson, S; Guta, A; Tan, DH; O'Leary, B; Cooper, C; Upshur, R; Carusone, SC				Strike, Carol; Robinson, Samantha; Guta, Adrian; Tan, Darrell H.; O'Leary, Bill; Cooper, Curtis; Upshur, Ross; Carusone, Soo Chan			Illicit drug use while admitted to hospital: Patient and health care provider perspectives	PLOS ONE			English	Article							SUBSTANCE USE; CENTERED CARE; ADDICTION; PEOPLE; INTERVENTIONS; CONSULTATION; PERCEPTIONS; MANAGEMENT; MEDICINE; SERVICE	Background Across North America, the opioid overdose epidemic is leading to increasing hospitalizations of people who use drugs (PWUD). However, hospitals are ill-prepared to meet the needs of PWUD. We focus on illicit drug use while admitted to hospital and how PWUD and health care providers describe, respond, and attempt to manage its use. Methods and findings Using varied purposive methods in Toronto and Ottawa, we recruited n = 24 PWUD (who self-reported that they were living with HIV and/or HCV infection; currently or had previously used drugs or alcohol in ways that were harmful; had a hospital admission in the past five years) and n = 26 health care providers (who were: currently working in an academic hospital as a physician, nurse, social worker or other allied health professional; and 2) providing care to this patient group). All n = 50 participants completed a short, socio-demographic questionnaire and an audio-recorded semi-structured interview about receiving or providing acute care in a hospital between 04/2014 and 05/2015. Patient participants received $25 CAD and return transit fare; provider participants received a $50 CAD gift card for a bookseller. All participants provided informed consent. Audio-recordings were transcribed verbatim, corrected, and uploaded to NVivo 10. Using the seven-step framework method, transcripts were coded line-by-line and managed using NVvivo. An analytic framework was created by grouping and mapping the codes. Preliminary analyses were presented to advisory group members for comment and used to refine the interpretation. Questionnaire data were managed using SPSS version 22.0 and descriptive statistics were used to describe the participants. Many but not all patient participants spoke about using psycho-active substances not prescribed to them during a hospital admission. Attempts to avoid negative experiences (e.g., withdrawal, boredom, sadness, loneliness and/or untreated pain) were cited as reasons for illicit drug use. Most tried to conceal their illicit drug use from health care providers. Patients described how their self-reported level of pain was not always believed, tolerance to opioids was ignored, and requests for higher doses of pain medications denied. Some health care providers were unaware of on-site illicit drug use; others acknowledged it occurred. Few could identify a hospital policy specific to illicit drug use and most used their personal beliefs to guide their responses to it (e.g., ignore it, increase surveillance of patients, reprimands, loss of privileges/medications, threats of immediate discharge should it continue, and substitution dosing of medication). Conclusions Providers highlighted gaps in institutional guidance for how they ought to appropriately respond to in-hospital substance use. Patients attempted to conceal illicit drug use in environments with no institutional policies about such use, leading to varied responses that were inconsistent with the principles of patient centred care and reflected personal beliefs about illicit drug use. There are increasing calls for implementation of harm reduction approaches and interventions in hospitals but uptake has been slow. Our study contributes to this emerging body of literature and highlights areas for future research, the development of interventions, and changes to policy and practice.	[Strike, Carol; Robinson, Samantha; Tan, Darrell H.; Upshur, Ross] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Guta, Adrian] Univ Windsor, Sch Social Work, Windsor, ON, Canada; [Tan, Darrell H.] St Michaels Hosp, Toronto, ON, Canada; [O'Leary, Bill; Carusone, Soo Chan] Casey House, Toronto, ON, Canada; [Cooper, Curtis] Univ Ottawa, Div Infect Dis, Ottawa, ON, Canada; [Carusone, Soo Chan] McMaster Univ, Hamilton, ON, Canada	University of Toronto; University of Windsor; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Ottawa; McMaster University	Strike, C (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.	carol.strike@utoronto.ca	Strike, Carol/U-8317-2018	Strike, Carol/0000-0002-2716-3681; Chan Carusone, Soo/0000-0003-3977-0523; Upshur, Ross/0000-0003-1128-0557; Guta, Adrian/0000-0002-1380-2016; Robinson, Samantha/0000-0002-9410-6900; O'Leary, William/0000-0001-9999-2318	Ontario HIV Treatment Network, Community Based Research Grant [1035]; Canadian Institutes of Health Research [129926]	Ontario HIV Treatment Network, Community Based Research Grant; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We received funding for this project from two sources: the Ontario HIV Treatment Network, Community Based Research Grant #1035 and the Canadian Institutes of Health Research, Grant #129926. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript'	[Anonymous], 2002, INT J DRUG POLICY, DOI [DOI 10.1016/S0955-3959(02)00075-0, DOI 10.1016/S0955-3959]; [Anonymous], 2019, NAT REP APP OP REL D; Australian Bureau of Statistics, 2018, 33030 ABS; Baldacchino A, 2010, ADDICT BEHAV, V35, P270, DOI 10.1016/j.addbeh.2009.10.008; Berg KM, 2009, J GEN INTERN MED, V24, P482, DOI 10.1007/s11606-009-0908-x; Bowen EA, 2016, AM J PUBLIC HEALTH, V106, P223, DOI 10.2105/AJPH.2015.302970; Canadian Institutes for Health Information (CIHI), 2018, OP REL HARMS CAN; Carusone SC, 2019, HARM REDUCT J, V16, DOI 10.1186/s12954-019-0285-7; Day C, 2003, DRUG ALCOHOL REV, V22, P317, DOI 10.1080/0959523031000154463; Duff C., 2014, ASSEMBLAGES HLTH DEL; Englander H, 2017, J HOSP MED, V12, P339, DOI 10.12788/jhm.2736; European Monitoring Centre For Drugs And Drug Addiction, 2019, DRUG REL DEATHS MORT; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Grewal HK, 2015, DRUG ALCOHOL REV, V34, P499, DOI 10.1111/dar.12270; Haber PS, 2009, LANCET, V374, P1284, DOI 10.1016/S0140-6736(09)61036-9; Kalkman GA, 2019, LANCET PUBLIC HEALTH, V4, pE498, DOI 10.1016/S2468-2667(19)30128-8; Kirst M, 2017, INT J MENT HEALTH AD, V15, P514, DOI 10.1007/s11469-016-9693-z; Kitson A, 2013, J ADV NURS, V69, P4, DOI 10.1111/j.1365-2648.2012.06064.x; Kolind T, 2017, ADDICTION, V112, P465, DOI 10.1111/add.13673; McCall J., 2019, J MENT HLTH ADDICT N, V3, pe1, DOI [10.22374/jmhan.v3i1.33, DOI 10.22374/JMHAN.V3I1.33]; McNeil R, 2016, ADDICTION, V111, P685, DOI 10.1111/add.13214; McNeil R, 2014, SOC SCI MED, V105, P59, DOI 10.1016/j.socscimed.2014.01.010; Merrill J, 2002, J GEN INTERN MED, V17, P327, DOI 10.1046/j.1525-1497.2002.10625.x; Miller NS, 2001, ACAD MED, V76, P410, DOI 10.1097/00001888-200105000-00007; Miskovic M, 2018, AM J PUBLIC HEALTH, V108, P1363, DOI 10.2105/AJPH.2018.304600; Monks R, 2013, J ADV NURS, V69, P935, DOI 10.1111/j.1365-2648.2012.06088.x; Murphy MK, 2009, J CLIN PSYCHOL MED S, V16, P77, DOI 10.1007/s10880-009-9149-8; Orpana HM, 2019, HEALTH PROMOT CHRON, V39, P56, DOI 10.24095/hpcdp.39.2.03; Pauly B, 2015, ADV NURS SCI, V38, P121, DOI 10.1097/ANS.0000000000000070; Pecoraro A, 2013, AIDS CARE, V25, P1399, DOI 10.1080/09540121.2013.772273; Priest KC, 2019, J ADDICT MED, V13, P104, DOI 10.1097/ADM.0000000000000496; Raja S, 2015, FAM COMMUNITY HEALTH, V38, P216, DOI 10.1097/FCH.0000000000000071; Reeves E, 2015, ISSUES MENT HEALTH N, V36, P698, DOI 10.3109/01612840.2015.1025319; Rhodes T., 2002, INT J DRUG POLICY, V13, P85, DOI [10.1016/S0955-3959(02)00007-5, DOI 10.1016/S0955-3959(02)00007-5]; Rosenthal ES, 2016, AM J MED, V129, P481, DOI 10.1016/j.amjmed.2015.09.024; Roxburgh A, 2017, DRUG ALCOHOL DEPEN, V179, P291, DOI 10.1016/j.drugalcdep.2017.07.018; Rudasill SE, 2019, J AM COLL CARDIOL, V73, P559, DOI 10.1016/j.jacc.2018.10.082; Sharma M, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0163-0; Stewart M., 2001, GLOBAL DEFINITION PA; Strike C, 2014, INT J DRUG POLICY, V25, P640, DOI 10.1016/j.drugpo.2014.02.012; Switzer S, 2015, SOC SCI MED, V133, P77, DOI 10.1016/j.socscimed.2015.03.040; Ti LP, 2015, J HOSP MED, V10, P301, DOI 10.1002/jhm.2344; Velez CM, 2017, J GEN INTERN MED, V32, P296, DOI 10.1007/s11606-016-3919-4; Wakeman SE, 2017, J GEN INTERN MED, V32, P909, DOI 10.1007/s11606-017-4077-z; Wakeman SE, 2016, SUBST ABUS, V37, P635, DOI 10.1080/08897077.2016.1187240; Weinstein ZM, 2018, MED CLIN N AM, V102, P587, DOI 10.1016/j.mcna.2018.03.001; Werb D, 2008, INT J DRUG POLICY, V19, P332, DOI 10.1016/j.drugpo.2007.08.004; Wood E, 2004, CAN MED ASSOC J, V170, P1551, DOI 10.1503/cmaj.1031928	48	22	22	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2020	15	3							e0229713	10.1371/journal.pone.0229713	http://dx.doi.org/10.1371/journal.pone.0229713			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8RK	32134973	Green Published, gold			2023-01-03	WOS:000535265600039
J	Luo, ZJ; Han, SL; Sun, W; Wang, Y; Liu, SJ; Yang, L; Pang, BS; Jin, JW; Chen, H; Cao, ZX; Ma, YM				Luo, Zujin; Han, Silu; Sun, Wei; Wang, Yan; Liu, Sijie; Yang, Liu; Pang, Baosen; Jin, Jiawei; Chen, Hong; Cao, Zhixin; Ma, Yingmin			Maintenance of spontaneous breathing at an intensity of 60%-80% may effectively prevent mechanical ventilation-induced diaphragmatic dysfunction	PLOS ONE			English	Article							PHRENIC-NERVE STIMULATION; CONTRACTILE PROPERTIES; OXIDATIVE STRESS; SUPPORT VENTILATION; CROSS-TALK; ACTIVATION; CALPAIN; CASPASE-3; WEAKNESS; ATROPHY	Controlled mechanical ventilation (CMV) can cause diaphragmatic motionlessness to induce diaphragmatic dysfunction. Partial maintenance of spontaneous breathing (SB) can reduce ventilation-induced diaphragmatic dysfunction (VIDD). However, to what extent SB is maintained in CMV can attenuate or even prevent VIDD has been rarely reported. The current study aimed to investigate the relationship between SB intensity and VIDD and to identify what intensity of SB maintained in CMV can effectively avoid VIDD. Adult rats were randomly divided according to different SB intensities: SB (0% pressure controlled ventilation (PCV)), high-intensity SB (20% PCV), medium-intensity SB (40% PCV), medium-low intensity SB (60% PCV), low-intensity SB (80% PCV), and PCV (100% PCV). The animals underwent 24-h controlled mechanical ventilation (CMV). The transdiaphragmatic pressure (Pdi), the maximal Pdi (Pdi max) when phrenic nerves were stimulated, Pdi/Pdi max, and the diaphragmatic tonus under different frequencies of electric stimulations were determined. Calpain and caspase-3 were detected using ELISA and the cross-section areas (CSAs) of different types of muscle fibers were measured. The Pdi showed a significant decrease from 20% PCV and the Pdi max showed a significant decrease from 40% PCV (P<0.05). In vivo and vitro diaphragmatic tonus exhibited a significant decrease from 40% PCV and 20% PCV, respectively (P<0.05). From 20% PCV, the CSAs of types I, IIa, and IIb/x muscle fibers showed significant differences, which reached the lowest levels at 100% PCV. SB intensity is negatively associated with the development of VIDD. Maintenance of SB at an intensity of 60%-80% may effectively prevent the occurrence of VIDD.	[Luo, Zujin; Han, Silu; Sun, Wei; Wang, Yan; Liu, Sijie; Yang, Liu; Pang, Baosen; Jin, Jiawei; Cao, Zhixin; Ma, Yingmin] Capital Med Univ, Dept Resp & Crit Care Med, Beijing Engn Res Ctr Resp & Crit Care Med, Beijing Inst Resp Med,Beijing Chao Yang Hosp, Beijing, Peoples R China; [Chen, Hong] Capital Med Univ, Beijing Chao Yang Hosp, Dept Pathol, Beijing, Peoples R China	Capital Medical University; Capital Medical University	Cao, ZX; Ma, YM (corresponding author), Capital Med Univ, Dept Resp & Crit Care Med, Beijing Engn Res Ctr Resp & Crit Care Med, Beijing Inst Resp Med,Beijing Chao Yang Hosp, Beijing, Peoples R China.	caozhixinicu@126.com	jin, jiawei/AAJ-7378-2021	, Jiawei Jin/0000-0001-5598-6039	Beijing Natural Science Foundation [7173259]; Beijing Hospital Authority Youth Programme [QML20180303]	Beijing Natural Science Foundation(Beijing Natural Science Foundation); Beijing Hospital Authority Youth Programme	This study was supported by Beijing Natural Science Foundation (7173259) and Beijing Hospital Authority Youth Programme (QML20180303). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler D, 2014, AM J RESP CRIT CARE, V190, P347, DOI 10.1164/rccm.201404-0655LE; Ahn B, 2014, AM J RESP CRIT CARE, V190, P837, DOI 10.1164/rccm.201405-0993LE; Anzueto A, 1997, CRIT CARE MED, V25, P1187, DOI 10.1097/00003246-199707000-00021; Capdevila X, 2003, INTENS CARE MED, V29, P103, DOI 10.1007/s00134-002-1548-3; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Futier E, 2008, CRIT CARE, V12, DOI 10.1186/cc7010; Gayan-Ramirez G, 2005, CRIT CARE MED, V33, P2804, DOI 10.1097/01.CCM.0000191250.32988.A3; Goligher EC, 2018, AM J RESP CRIT CARE, V197, P204, DOI 10.1164/rccm.201703-0536OC; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Grosu HB, 2017, RESP CARE, V62, P904, DOI 10.4187/respcare.05370; Hooijman PE, 2015, AM J RESP CRIT CARE, V191, P1126, DOI 10.1164/rccm.201412-2214OC; Hudson MB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137693; Hudson MB, 2012, CRIT CARE MED, V40, P1254, DOI 10.1097/CCM.0b013e31823c8cc9; Hussain SNA, 2016, THORAX, V71, P436, DOI 10.1136/thoraxjnl-2015-207559; Jaber S, 2011, CRIT CARE, V15, DOI 10.1186/cc10023; Jaber S, 2011, AM J RESP CRIT CARE, V183, P364, DOI 10.1164/rccm.201004-0670OC; Jung B, 2010, ANESTHESIOLOGY, V112, P1435, DOI 10.1097/ALN.0b013e3181d7b036; Kim WY, 2011, CRIT CARE MED, V39, P2627, DOI 10.1097/CCM.0b013e3182266408; LEBOURDELLES G, 1994, AM J RESP CRIT CARE, V149, P1539, DOI 10.1164/ajrccm.149.6.8004310; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Maes K, 2007, AM J RESP CRIT CARE, V175, P1134, DOI 10.1164/rccm.200609-1342OC; Mankowski RT, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1060-0; Martin AD, 2014, CRIT CARE MED, V42, pE152, DOI 10.1097/CCM.0b013e3182a63fdf; McClung JM, 2007, AM J RESP CRIT CARE, V175, P150, DOI 10.1164/rccm.200601-142OC; Medrinal C, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1418-y; Mrozek S, 2012, ANESTHESIOLOGY, V117, P560, DOI 10.1097/ALN.0b013e318261e7f8; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nelson WB, 2012, CRIT CARE MED, V40, P1857, DOI 10.1097/CCM.0b013e318246bb5d; Powers SK, 2013, J PHYSIOL-LONDON, V591, P5255, DOI 10.1113/jphysiol.2013.254680; Radel P, 2004, ACTA ANAESTH SCAND, V48, P430, DOI 10.1111/j.1399-6576.2004.00352.x; Sassoon CSH, 2002, J APPL PHYSIOL, V92, P2585, DOI 10.1152/japplphysiol.01213.2001; Sassoon CSH, 2004, AM J RESP CRIT CARE, V170, P626, DOI 10.1164/rccm.200401-042OC; Shanely RA, 2004, AM J RESP CRIT CARE, V170, P994, DOI 10.1164/rccm.200304-575OC; Shanely RA, 2003, CHEST, V123, P195, DOI 10.1378/chest.123.1.195; Smuder AJ, 2018, FREE RADICAL BIO MED, V115, P179, DOI 10.1016/j.freeradbiomed.2017.11.025; Smuder AJ, 2010, FREE RADICAL BIO MED, V49, P1152, DOI 10.1016/j.freeradbiomed.2010.06.025; Tan YF, 2006, J BIOL CHEM, V281, P16016, DOI 10.1074/jbc.M601299200; Tidball JG, 2002, J PHYSIOL-LONDON, V545, P819, DOI 10.1113/jphysiol.2002.024935; Whidden MA, 2010, J APPL PHYSIOL, V108, P1376, DOI 10.1152/japplphysiol.00098.2010	39	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2020	15	3							e0229944	10.1371/journal.pone.0229944	http://dx.doi.org/10.1371/journal.pone.0229944			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8QU	32131083	Green Published, gold			2023-01-03	WOS:000535264000057
J	Rubin, R				Rubin, Rita			Rebates-The Little-Known Factor Behind Increasing Drug List Prices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item								This Medical News story examines the role of rebates in drug pricing.											0	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2020	323	9			SI		812	813		10.1001/jama.2020.1208	http://dx.doi.org/10.1001/jama.2020.1208			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU3SD	32125400				2023-01-03	WOS:000519630600001
J	Munshi, L; Ferguson, ND				Munshi, Laveena; Ferguson, Niall D.			Evolving Issues in Oxygen Therapy in Acute Care Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ARTERIAL HYPEROXIA		[Munshi, Laveena] Univ Toronto, Mt Sinai Hosp, Inst Hlth Policy Management & Evaluat, Interdept Div Crit Care Med,Dept Med, Toronto, ON, Canada; [Ferguson, Niall D.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Interdept Div Crit Care Med, Dept Med, Toronto, ON, Canada; [Ferguson, Niall D.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Interdept Div Crit Care Med, Dept Physiol, Toronto, ON, Canada; [Ferguson, Niall D.] Univ Hlth Network, Toronto, ON, Canada; [Ferguson, Niall D.] Mt Sinai Hosp, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Ferguson, ND (corresponding author), Toronto Gen Hosp, 585 Univ Ave,11-PMB-120, Toronto, ON M5G 2N2, Canada.	n.ferguson@utoronto.ca	Ferguson, Niall/D-7619-2019	Ferguson, Niall/0000-0002-6213-5264				Asfar P, 2017, LANCET RESP MED, V5, P180, DOI 10.1016/S2213-2600(17)30046-2; Aside LM, 2018, JAMA-J AM MED ASSOC, V319, P2190, DOI 10.1001/jama.2018.5725; de Jonge S, 2019, BRIT J ANAESTH, V122, P325, DOI 10.1016/j.bja.2018.11.024; Deane A, 2019, N ENGL J MED, DOI 10.1056/NEJMoa1903297; Fontes MT, 2014, J CARDIOTHOR VASC AN, V28, P462, DOI 10.1053/j.jvca.2013.03.034; Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; McHugh A, 2019, AM J OBSTET GYNECOL, V220, DOI 10.1016/j.ajog.2019.02.059; Stub D, 2015, CIRCULATION, V131, P2143, DOI 10.1161/CIRCULATIONAHA.114.014494; Young P, 2020, INTENS CARE MED, V46, P17, DOI 10.1007/s00134-019-05857-x	10	7	7	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	2020	323	7					607	608		10.1001/jama.2019.22029	http://dx.doi.org/10.1001/jama.2019.22029			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR0OF	31977030				2023-01-03	WOS:000517319500012
J	Sen, S; Karaca-Mandic, P; Georgiou, A				Sen, Soumya; Karaca-Mandic, Pinar; Georgiou, Archelle			Association of Stay-at-Home Orders With COVID-19 Hospitalizations in 4 States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Sen, Soumya] Univ Minnesota, Carlson Sch Management, Dept Informat & Decis Sci, Minneapolis, MN 55455 USA; [Karaca-Mandic, Pinar] Univ Minnesota, Carlson Sch Management, Dept Finance, Minneapolis, MN 55455 USA; [Georgiou, Archelle] Starkey Hearing Technol, Eden Prairie, MN USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Karaca-Mandic, P (corresponding author), Univ Minnesota, Carlson Sch Management, 321 19th Ave S, Minneapolis, MN 55455 USA.	pkmandic@umn.edu		Georgiou, Archelle/0000-0001-5832-8998	University of Minnesota Office of Academic Clinical Affairs; United Health Foundation	University of Minnesota Office of Academic Clinical Affairs; United Health Foundation	This research uses publicly available data from the University of Minnesota COVID-19 Hospitalization Project, which is partially funded by the University of Minnesota Office of Academic Clinical Affairs and United Health Foundation.	Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Karaca-Mandic P, 2020, HLTH AFFAIRS BLOG, DOI 10.1377/hblog20200406.532030/full/?cookieSet=1; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585	4	45	46	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2020	323	24					2522	2524		10.1001/jama.2020.9176	http://dx.doi.org/10.1001/jama.2020.9176			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OS4QL	32459287	Green Published, Bronze			2023-01-03	WOS:000590149400027
J	Sheppard, JP; Burt, J; Lown, M; Temple, E; Lowe, R; Fraser, R; Allen, J; Ford, GA; Heneghan, C; Hobbs, FDR; Jowett, S; Kodabuckus, S; Little, P; Mant, J; Mollison, J; Payne, RA; Williams, M; Yu, LM; McManus, RJ				Sheppard, James P.; Burt, Jenni; Lown, Mark; Temple, Eleanor; Lowe, Rebecca; Fraser, Rosalyn; Allen, Julie; Ford, Gary A.; Heneghan, Carl; Hobbs, F. D. Richard; Jowett, Sue; Kodabuckus, Shahela; Little, Paul; Mant, Jonathan; Mollison, Jill; Payne, Rupert A.; Williams, Marney; Yu, Ly-Mee; McManus, Richard J.		OPTIMISE Investigators	Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older The OPTIMISE Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMERICAN-COLLEGE; MANAGEMENT; ADULTS; DISCONTINUATION; WITHDRAWAL; GUIDELINE	IMPORTANCE Deprescribing of antihypertensive medications is recommended for some older patients with polypharmacy and multimorbidity when the benefits of continued treatment may not outweigh the harms. OBJECTIVE This study aimed to establish whether antihypertensive medication reduction is possible without significant changes in systolic blood pressure control or adverse events during 12-week follow-up. DESIGN, SETTING, AND PARTICIPANTS The Optimising Treatment for Mild Systolic Hypertension in the Elderly (OPTIMISE) study was a randomized, unblinded, noninferiority trial conducted in 69 primary care sites in England. Participants, whose primary care physician considered them appropriate for medication reduction, were aged 80 years and older, had systolic blood pressure lower than 150 mm Hg, and were receiving at least 2 antihypertensive medications were included. Participants enrolled between April 2017 and September 2018 and underwent follow-up until January 2019. INTERVENTIONS Participants were randomized (1:1 ratio) to a strategy of antihypertensive medication reduction (removal of 1 drug [intervention], n = 282) or usual care (control, n = 287), in which no medication changes were mandated. MAIN OUTCOMES AND MEASURES The primary outcome was systolic blood pressure lower than 150 mm Hg at 12-week follow-up. The prespecified noninferiority margin was a relative risk (RR) of 0.90. Secondary outcomes included the proportion of participants maintaining medication reduction and differences in blood pressure, frailty, quality of life, adverse effects, and serious adverse events. RESULTS Among 569 patients randomized (mean age, 84.8 years; 276 [48.5%] women; median of 2 antihypertensive medications prescribed at baseline), 534 (93.8%) completed the trial. Overall, 229 (86.4%) patients in the intervention group and 236 (87.7%) patients in the control group had a systolic blood pressure lower than 150 mm Hg at 12 weeks (adjusted RR, 0.98 [97.5% 1-sided CI, 0.92 to infinity]). Of 7 prespecified secondary end points, 5 showed no significant difference. Medication reduction was sustained in 187 (66.3%) participants at 12 weeks. Mean change in systolic blood pressure was 3.4 mm Hg (95% CI, 1.1 to 5.8 mm Hg) higher in the intervention group compared with the control group. Twelve (4.3%) participants in the intervention group and 7 (2.4%) in the control group reported at least 1 serious adverse event (adjusted RR, 1.72 [95% CI, 0.7 to 4.3]). CONCLUSIONS AND RELEVANCE Among older patients treated with multiple antihypertensive medications, a strategy of medication reduction, compared with usual care, was noninferior with regard to systolic blood pressure control at 12 weeks. The findings suggest antihypertensive medication reduction in some older patients with hypertension is not associated with substantial change in blood pressure control, although further research is needed to understand long-term clinical outcomes.	[Sheppard, James P.; Temple, Eleanor; Lowe, Rebecca; Fraser, Rosalyn; Allen, Julie; Heneghan, Carl; Hobbs, F. D. Richard; Mollison, Jill; Yu, Ly-Mee; McManus, Richard J.] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England; [Burt, Jenni] Univ Cambridge, Healthcare Improvement Studies Inst, Cambridge, England; [Lown, Mark] Univ Southampton, Primary Care Res Grp, Southampton, Hants, England; [Ford, Gary A.] Oxford Univ Hosp NHS Fdn Trust, Radcliffe Dept Med, Oxford, England; [Jowett, Sue; Kodabuckus, Shahela] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England; [Little, Paul] Univ Southampton, Primary Care Populat Sci & Med Educ Unit, Southampton, Hants, England; [Mant, Jonathan] Univ Cambridge, Primary Care Unit, Dept Publ Hlth & Primary Care, Cambridge, England; [Payne, Rupert A.] Univ Bristol, Ctr Acad Primary Care Populat Hlth Sci, Bristol, Avon, England	University of Oxford; University of Cambridge; University of Southampton; Oxford University Hospitals NHS Foundation Trust; University of Birmingham; University of Southampton; University of Cambridge; University of Bristol	Sheppard, JP (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Radcliffe Observ Quarter, Radcliffe Primary Care Bldg, Oxford OX2 6GG, England.	james.sheppard@phc.ox.ac.uk	Jowett, Sue/AAO-4198-2021; Ford, Gary/AAY-6405-2020; Sheppard, James/AAR-6793-2021; Burt, Jenni/L-2951-2013	Jowett, Sue/0000-0001-8936-3745; Ford, Gary/0000-0001-8719-4968; Sheppard, James/0000-0002-4461-8756; Yu, Ly-Mee/0000-0003-0331-7364; Lown, Mark/0000-0001-8309-568X; Little, Paul/0000-0003-3664-1873; Mant, Jonathan/0000-0002-9531-0268; Burt, Jenni/0000-0002-0037-274X; Mollison, Jill/0000-0002-5539-5615	NIHR CLAHRC at Oxford Health NHS Foundation Trust [P2-501]; NIHR School for Primary Care Research [335]; NIHR professorship [NIHR-RP-R2-12-015]; Wellcome Trust/Royal Society via a Sir Henry Dale Fellowship [211182/Z/18/Z]; NIHR Oxford Biomedical Research Centre; NIHR; NIHR School for Primary Care Research; NIHR CLAHRC Oxford	NIHR CLAHRC at Oxford Health NHS Foundation Trust; NIHR School for Primary Care Research; NIHR professorship; Wellcome Trust/Royal Society via a Sir Henry Dale Fellowship; NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); NIHR(National Institute for Health Research (NIHR)); NIHR School for Primary Care Research; NIHR CLAHRC Oxford	This work received joint funding from NIHR CLAHRC at Oxford Health NHS Foundation Trust (P2-501) and the NIHR School for Primary Care Research (335). Drs Sheppard and McManus were funded by an NIHR professorship (NIHR-RP-R2-12-015). Dr Sheppard reports receipt of funding from the Wellcome Trust/Royal Society via a Sir Henry Dale Fellowship (211182/Z/18/Z) and an NIHR Oxford Biomedical Research Centre senior fellowship. Drs McManus, Heneghan, and Ford are supported by NIHR senior investigator awards. Dr Heneghan reports receipt of support from the NIHR School for Primary Care Research and NIHR Oxford Biomedical Research Centre. Dr Hobbs reports receipt of partial support from NIHR School for Primary Care Research, NIHR CLAHRC Oxford, and the NIHR Oxford Biomedical Research Centre. Dr Payne reports receipt of funding from NIHR for polypharmacy and medicines optimization research.	[Anonymous], 1986, Br Med J (Clin Res Ed), V293, P988; Beckett NS, 2008, NEW ENGL J MED, V358, P1887, DOI 10.1056/NEJMoa0801369; Benetos A, 2016, HYPERTENSION, V67, P820, DOI 10.1161/HYPERTENSIONAHA.115.07020; Benetos A, 2015, JAMA INTERN MED, V175, P989, DOI 10.1001/jamainternmed.2014.8012; Bress AP, 2016, J AM COLL CARDIOL, V67, P463, DOI 10.1016/j.jacc.2015.10.037; Clegg A, 2016, AGE AGEING, V45, P353, DOI 10.1093/ageing/afw039; Dennis M, 2012, STROKE, V43, P851, DOI 10.1161/STROKEAHA.111.639708; FREIS ED, 1989, AM J CARDIOL, V63, P702, DOI 10.1016/0002-9149(89)90255-5; Gulla C, 2018, J GERIATR CARDIOL, V15, P275, DOI 10.11909/j.issn.1671-5411.2018.04.011; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Joint Comission, SPEC MAN JOINT COMM; Kostis JB, 1998, AM J CARDIOL, V82, P1501, DOI 10.1016/S0002-9149(98)00694-8; Krishnaswami A, 2019, J AM COLL CARDIOL, V73, P2584, DOI 10.1016/j.jacc.2019.03.467; Lahrmann H, 2006, EUR J NEUROL, V13, P930, DOI 10.1111/j.1468-1331.2006.01512.x; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Luymes CH, 2018, BMC MED, V16, DOI 10.1186/s12916-017-0988-0; Mansfield KE, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012690; Mattu GS, 2004, BLOOD PRESS MONIT, V9, P47, DOI 10.1097/00126097-200402000-00009; Moonen JEF, 2015, JAMA INTERN MED, V175, P1622, DOI 10.1001/jamainternmed.2015.4103; Morley JE, 2012, J NUTR HEALTH AGING, V16, P601, DOI 10.1007/s12603-012-0084-2; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; National Institute for Health and Care Excellence, 2019, HYP AD DIAGN MAN; National Institute for Health and Care Excellence, 2016, MULT ASS PRIOR MAN C, V56; Office for National Statistics, MEAS EQ GUID COLL CL; Palagyi A, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0181-x; Qaseem A, 2017, ANN INTERN MED, V166, P430, DOI 10.7326/M16-1785; Schuling J, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-56; Searle Samuel D, 2008, BMC Geriatr, V8, P24, DOI 10.1186/1471-2318-8-24; Sheppard JP, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4535; Sheppard JP, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022930; Sieg-Dobrescu D, 2001, J HYPERTENS, V19, P1387, DOI 10.1097/00004872-200108000-00006; SPRINT Research Group, 2015, N Engl J Med, V373, P2103, DOI 10.1056/NEJMoa1511939; Tinetti ME, 2014, JAMA INTERN MED, V174, P588, DOI 10.1001/jamainternmed.2013.14764; van der Wardt V, 2017, J HYPERTENS, V35, P1742, DOI 10.1097/HJH.0000000000001405; van Deudekom FJ, 2017, PLOS ONE, V12, DOI [10.1371/.journal.pone.0174053, 10.1371/journal.pone.0174053]; van Hout B, 2012, VALUE HEALTH, V15, P708, DOI 10.1016/j.jval.2012.02.008; Violan C, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-530; Whelton PK, 2018, J AM COLL CARDIOL, V71, pE127, DOI 10.1016/j.jacc.2017.11.006; Williams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339; Williamson JD, 2016, JAMA-J AM MED ASSOC, V315, P2673, DOI 10.1001/jama.2016.7050	41	50	51	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2020	323	20					2039	2051		10.1001/jama.2020.4871	http://dx.doi.org/10.1001/jama.2020.4871			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LU8UM	32453368	Green Published, Bronze			2023-01-03	WOS:000538023900035
J	Jalal, H; Buchanich, JM; Sinclair, DR; Roberts, MS; Burke, DS				Jalal, Hawre; Buchanich, Jeanine M.; Sinclair, David R.; Roberts, Mark S.; Burke, Donald S.			Age and generational patterns of overdose death risk from opioids and other drugs	NATURE MEDICINE			English	Article							UNITED-STATES; MONITORING PROGRAMS; HEROIN; REDUCTIONS; FENTANYL; SIBLINGS; ABUSE	The ongoing substance misuse epidemic in the United States is complex and dynamic and should be approached as such in the development and evaluation of policy(1). Drug overdose deaths (largely attributable to opioid misuse) in the United States have grown exponentially for almost four decades, but the mechanisms of this growth are poorly understood(2). From analysis of 661,565 overdose deaths from 1999 to 2017, we show that the age-specific drug overdose mortality curve for each birth-year cohort rises and falls according to a Gaussian-shaped curve. The ascending portion of each successive birth-year cohort mortality curve is accelerated compared with that of all preceding birth-year cohorts. This acceleration can be attributed to either of two distinct processes: a stable peak age, with an increasing amplitude of mortality rate curves from one birth-year cohort to the next; or a youthward shift in the peak age of the mortality rate curves. The overdose epidemic emerged and increased in amplitude among the 1945-1964 cohort (Baby Boomers), shifted youthward among the 1965-1980 cohort (Generation X), and then resumed the pattern of increasing amplitude in the 1981-1990 Millennials. These shifting age and generational patterns are likely to be driven by socioeconomic factors and drug availability, the understanding of which is important for the development of effective overdose prevention measures. A new age-period-cohort analysis reveals distinct generational patterns in deaths from opioid overdose in the United States, suggesting increased risks for Baby Boomers and Millennials.	[Jalal, Hawre; Sinclair, David R.; Roberts, Mark S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA; [Buchanich, Jeanine M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Sinclair, David R.] Newcastle Univ, Fac Med Sci, Populat Hlth Sci Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Burke, Donald S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Newcastle University - UK; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jalal, H (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA.; Burke, DS (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.	hjalal@pitt.edu; donburke@pitt.edu		Jalal, Hawre/0000-0002-8224-6834; Sinclair, David/0000-0002-3468-7475; /0000-0002-5704-8094	National Institutes of Health/National Center for Advancing Translational Sciences [1KL2TR0001856]; Robert Wood Johnson Foundation [72858]	National Institutes of Health/National Center for Advancing Translational Sciences; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF))	This study was in part supported by National Institutes of Health/National Center for Advancing Translational Sciences grant no. 1KL2TR0001856 (H.J.), and Robert Wood Johnson Foundation grant no. 72858 (J.B. and D.S.B.).	Ahmad FB, 2019, PROVISIONAL DRUG OVE; Bao YH, 2016, HEALTH AFFAIR, V35, P1045, DOI 10.1377/hlthaff.2015.1673; Best AF, 2018, LANCET PUBLIC HEALTH, V3, pE374, DOI 10.1016/S2468-2667(18)30114-2; Bjork JM, 2015, DEV COGN NEUROS-NETH, V11, P56, DOI 10.1016/j.dcn.2014.07.008; Blanco C, 2019, LANCET, V393, P1760, DOI 10.1016/S0140-6736(18)33078-2; Bluthenthal R N, 1997, Med Anthropol, V18, P61, DOI 10.1080/01459740.1997.9966150; Burke DS, 2016, SCIENCE, V354, P529, DOI 10.1126/science.aal2943; Chernyavskiy P, 2019, STAT METHODS MED RES, V28, P20, DOI 10.1177/0962280217713033; Ciccarone D, 2019, INT J DRUG POLICY, V71, P183, DOI 10.1016/j.drugpo.2019.01.010; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Coffin PO, 2019, J URBAN HEALTH, V96, P1, DOI 10.1007/s11524-018-00344-y; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Des Jarlais D, 2009, ADDICTION, V104, P1452, DOI 10.1111/j.1360-0443.2009.02607.x; Duncan DF, 2010, J AGING SOC POLICY, V22, P237, DOI 10.1080/08959420.2010.485511; Jalal H.J., 2019, HEXAMAPS VISUALIZING, DOI [10.1101/19011700, DOI 10.1101/19011700]; Jalal H, 2018, SCIENCE, V361, P1218, DOI 10.1126/science.aau1184; Keyes KM., 2012, INJURY RES, P409; Lambdin BH, 2018, DRUG ALCOHOL DEPEN, V188, P370, DOI 10.1016/j.drugalcdep.2018.04.004; LUTHAR SS, 1992, COMPR PSYCHIAT, V33, P190, DOI 10.1016/0010-440X(92)90029-P; MAGURA S, 1989, AM J PUBLIC HEALTH, V79, P459, DOI 10.2105/AJPH.79.4.459; Mars SG, 2015, SOC SCI MED, V140, P44, DOI 10.1016/j.socscimed.2015.06.032; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; McGinty EE, 2018, PREV MED, V111, P73, DOI 10.1016/j.ypmed.2018.02.026; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; NEEDLE R, 1986, INT J ADDICT, V21, P739, DOI 10.3109/10826088609027390; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P897, DOI 10.15585/mmwr.mm6634a2; Oldfield BJ, 2019, J GEN INTERN MED, V34, P1854, DOI 10.1007/s11606-019-05016-4; Patrick SW, 2016, HEALTH AFFAIR, V35, P1324, DOI 10.1377/hlthaff.2015.1496; Pew Research Center, 2015, WHYS HOWS GEN RES; Rosenberg PS, 2019, STAT METHODS MED RES, V28, P3363, DOI 10.1177/0962280218801121; Rosenberg PS, 2014, CANCER EPIDEM BIOMAR, V23, P2296, DOI 10.1158/1055-9965.EPI-14-0300; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Ruhm CJ, 2019, J HEALTH ECON, V64, P25, DOI 10.1016/j.jhealeco.2019.01.001; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Smith MK, 2018, EPIDEMIOL INFECT, V146, DOI 10.1017/S0950268818002042; Viboud C, 2016, EPIDEMICS-NETH, V15, P27, DOI 10.1016/j.epidem.2016.01.002; Weatherburn D, 2003, ADDICTION, V98, P83, DOI 10.1046/j.1360-0443.2003.00248.x; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631; Windle M., 2000, APPL DEV SCI, V4, P98, DOI DOI 10.1207/S1532480XADS0402_5; Yim N., 2019, CONVENTIONAL INNOVAT, P1	42	19	19	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2020	26	5					699	+		10.1038/s41591-020-0855-y	http://dx.doi.org/10.1038/s41591-020-0855-y		MAY 2020	11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ML1LF	32367060	Green Accepted			2023-01-03	WOS:000530244500001
J	Gilan, O; Rioja, I; Knezevic, K; Bell, MJ; Yeung, MM; Harker, NR; Lam, EYN; Chung, CW; Bamborough, P; Petretich, M; Urh, M; Atkinson, SJ; Bassil, AK; Roberts, EJ; Vassiliadis, D; Burr, ML; Preston, AGS; Wellaway, C; Werner, T; Gray, JR; Michon, AM; Gobbetti, T; Kumar, V; Soden, PE; Haynes, A; Vappiani, J; Tough, DF; Taylor, S; Dawson, SJ; Bantscheff, M; Lindon, M; Drewes, G; Demont, EH; Daniels, DL; Grandi, P; Prinjha, RK; Dawson, MA				Gilan, Omer; Rioja, Inmaculada; Knezevic, Kathy; Bell, Matthew J.; Yeung, Miriam M.; Harker, Nicola R.; Lam, Enid Y. N.; Chung, Chun-wa; Bamborough, Paul; Petretich, Massimo; Urh, Marjeta; Atkinson, Stephen J.; Bassil, Anna K.; Roberts, Emma J.; Vassiliadis, Dane; Burr, Marian L.; Preston, Alex G. S.; Wellaway, Christopher; Werner, Thilo; Gray, James R.; Michon, Anne-Marie; Gobbetti, Thomas; Kumar, Vinod; Soden, Peter E.; Haynes, Andrea; Vappiani, Johanna; Tough, David F.; Taylor, Simon; Dawson, Sarah-Jane; Bantscheff, Marcus; Lindon, Matthew; Drewes, Gerard; Demont, Emmanuel H.; Daniels, Danette L.; Grandi, Paola; Prinjha, Rab K.; Dawson, Mark A.			Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation	SCIENCE			English	Article							BROMODOMAIN INHIBITOR OTX015; SKIN INFLAMMATION; DOSE-ESCALATION; ACUTE-LEUKEMIA; RECOGNITION; RESISTANCE; CHROMATIN; BINDING; PROFILE; BRD4	The two tandem bromodomains of the BET (bromodomain and extraterminal domain) proteins enable chromatin binding to facilitate transcription. Drugs that inhibit both bromodomains equally have shown efficacy in certain malignant and inflammatory conditions. To explore the individual functional contributions of the first (BD1) and second (BD2) bromodomains in biology and therapy, we developed selective BD1 and BD2 inhibitors. We found that steady- state gene expression primarily requires BD1, whereas the rapid increase of gene expression induced by inflammatory stimuli requires both BD1 and BD2 of all BET proteins. BD1 inhibitors phenocopied the effects of pan-BET inhibitors in cancer models, whereas BD2 inhibitors were predominantly effective in models of inflammatory and autoimmune disease. These insights into the differential requirement of BD1 and BD2 for the maintenance and induction of gene expression may guide future BET-targeted therapies.	[Gilan, Omer; Knezevic, Kathy; Yeung, Miriam M.; Lam, Enid Y. N.; Vassiliadis, Dane; Burr, Marian L.; Dawson, Sarah-Jane; Dawson, Mark A.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Gilan, Omer; Lam, Enid Y. N.; Vassiliadis, Dane; Burr, Marian L.; Dawson, Sarah-Jane; Dawson, Mark A.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Rioja, Inmaculada; Bell, Matthew J.; Harker, Nicola R.; Chung, Chun-wa; Bamborough, Paul; Atkinson, Stephen J.; Bassil, Anna K.; Roberts, Emma J.; Preston, Alex G. S.; Wellaway, Christopher; Gray, James R.; Gobbetti, Thomas; Soden, Peter E.; Haynes, Andrea; Tough, David F.; Taylor, Simon; Lindon, Matthew; Demont, Emmanuel H.; Prinjha, Rab K.] GlaxoSmithKline Med Res Ctr, Epigenet RU, Stevenage, Herts, England; [Petretich, Massimo; Werner, Thilo; Michon, Anne-Marie; Vappiani, Johanna; Bantscheff, Marcus; Drewes, Gerard; Grandi, Paola] GlaxoSmithKline, Funct Genom R&D, Cellzome GmbH, Heidelberg, Germany; [Urh, Marjeta; Daniels, Danette L.] Promega Corp, Madison, WI USA; [Kumar, Vinod] GlaxoSmithKline, Computat Biol, Collegeville, PA USA; [Dawson, Sarah-Jane; Dawson, Mark A.] Univ Melbourne, Ctr Canc Res, Melbourne, Vic, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; GlaxoSmithKline; GlaxoSmithKline; Cellzome GmbH; Promega Corporation; GlaxoSmithKline; University of Melbourne	Dawson, MA (corresponding author), Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.; Dawson, MA (corresponding author), Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia.; Prinjha, RK (corresponding author), GlaxoSmithKline Med Res Ctr, Epigenet RU, Stevenage, Herts, England.; Dawson, MA (corresponding author), Univ Melbourne, Ctr Canc Res, Melbourne, Vic, Australia.	rabinder.prinjha@gsk.com; mark.dawson@petermac.org	Bantscheff, Marcus/AAQ-2903-2021; Dawson, Mark A/B-9317-2017	Bantscheff, Marcus/0000-0002-8343-8977; Dawson, Mark A/0000-0002-5464-5029; Gilan, Omer/0000-0003-4156-2619; Yeung, Miriam/0000-0002-9455-1887; Lam, Enid Yi Ni/0000-0001-5843-7836; Vassiliadis, Dane/0000-0002-7814-4851; Harker, Nicola/0000-0003-3612-4366; Knezevic, Kathy/0000-0002-3940-3363; Petretich, Massimo/0000-0001-7486-8222; Burr, Marian/0000-0002-8995-3398	CCV Dunlop fellowship; HHMI international research scholarship; Victoria Cancer Agency fellowship; CRUK; NHMRC [1106444, 1144649, 1146192]; University of Melbourne; Peter MacCallum Foundation; CSL Centenary fellowship	CCV Dunlop fellowship(Canadian Institutes of Health Research (CIHR)); HHMI international research scholarship; Victoria Cancer Agency fellowship; CRUK(Cancer Research UK); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); University of Melbourne(University of Melbourne); Peter MacCallum Foundation; CSL Centenary fellowship	We thank the following funders for fellowship and grant support: a CCV Dunlop fellowship and an HHMI international research scholarship to M.A.D.; a Victoria Cancer Agency fellowship to O.G. and E.Y. N.L.; CRUK to M.L.B.; and a CSL Centenary fellowship to S.J.D. Work from the Dawson laboratory is supported by grant funding from the NHMRC (1106444, 1144649, 1146192), the University of Melbourne, and the Peter MacCallum Foundation.	Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Baud MGJ, 2014, SCIENCE, V346, P638, DOI 10.1126/science.1249830; Becher I, 2016, NAT CHEM BIOL, V12, P908, DOI [10.1038/NCHEMBIO.2185, 10.1038/nchembio.2185]; Belkina AC, 2013, J IMMUNOL, V190, P3670, DOI 10.4049/jimmunol.1202838; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Burr ML, 2019, CANCER CELL, V36, P385, DOI 10.1016/j.ccell.2019.08.008; Daigneault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008668; Dawson M, 2017, BLOOD, V130; Dawson MA, 2017, SCIENCE, V355, P1147, DOI 10.1126/science.aam7304; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Duan QM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5084; Faivre EJ, 2020, NATURE, V578, P306, DOI 10.1038/s41586-020-1930-8; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; Gamsjaeger R, 2011, MOL CELL BIOL, V31, P2632, DOI 10.1128/MCB.05413-11; Hatemi G, 2015, NEW ENGL J MED, V372, P1510, DOI 10.1056/NEJMoa1408684; KELSO A, 1994, INT IMMUNOL, V6, P1515, DOI 10.1093/intimm/6.10.1515; Klein K, 2016, ANN RHEUM DIS, V75, P422, DOI 10.1136/annrheumdis-2014-205809; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Matzuk MM, 2012, CELL, V150, P673, DOI 10.1016/j.cell.2012.06.045; McLure KG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083190; Middleton SA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35653-4; Miller TCR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13855; Moriniere J, 2009, NATURE, V461, P664, DOI 10.1038/nature08397; Muhar M, 2018, SCIENCE, V360, P800, DOI 10.1126/science.aao2793; Nadeem A, 2015, PHARMACOL RES, V99, P248, DOI 10.1016/j.phrs.2015.06.001; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Riching KM, 2018, ACS CHEM BIOL, V13, P2758, DOI 10.1021/acschembio.8b00692; Seal J, 2012, BIOORG MED CHEM LETT, V22, P2968, DOI 10.1016/j.bmcl.2012.02.041; Shang EY, 2007, DEVELOPMENT, V134, P3507, DOI 10.1242/dev.004481; Shi J, 2013, GENE DEV, V27, P2648, DOI 10.1101/gad.232710.113; Sun LP, 2018, AM J PHYSIOL-RENAL, V315, pF469, DOI 10.1152/ajprenal.00527.2017; Tough DF, 2016, NAT REV DRUG DISCOV, V15, P835, DOI 10.1038/nrd.2016.185; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Tyler DS, 2017, SCIENCE, V356, P1397, DOI 10.1126/science.aal2066; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Vonrhein C, 2011, ACTA CRYSTALLOGR D, V67, P293, DOI 10.1107/S0907444911007773; Wang FN, 2010, BIOCHEM J, V425, P71, DOI 10.1042/BJ20090928; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	44	171	174	12	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	2020	368	6489					387	+		10.1126/science.aaz8455	http://dx.doi.org/10.1126/science.aaz8455			128	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH0XH	32193360	Green Accepted			2023-01-03	WOS:000528513300037
J	Murthy, S; Gomersall, CD; Fowler, RA				Murthy, Srinivas; Gomersall, Charles D.; Fowler, Robert A.			Care for Critically Ill Patients With COVID-19	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This JAMA Insights article reviews care for the most severely ill patients with coronavirus disease 2019 (COVID-19), including standards of management of ARDS, preventing SARS-CoV-2 spread in health care settings, and surge preparation.	[Murthy, Srinivas] Univ British Columbia, 4500 Oak St, Vancouver, BC V6H 3V4, Canada; [Gomersall, Charles D.] Chinese Univ Hong Kong, Hong Kong, Peoples R China; [Fowler, Robert A.] Univ Toronto, Sunnybrook Hosp, Toronto, ON, Canada	University of British Columbia; Chinese University of Hong Kong; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Murthy, S (corresponding author), Univ British Columbia, 4500 Oak St, Vancouver, BC V6H 3V4, Canada.	srinivas.murthy@cw.bc.ca	Murthy, Srinivas/AAS-7243-2020	Murthy, Srinivas/0000-0002-9476-839X				Alraddadi BM, 2019, INFLUENZA OTHER RESP, V13, P382, DOI 10.1111/irv.12635; Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3; De Backer D, 2017, JAMA-J AM MED ASSOC, V317, P807, DOI 10.1001/jama.2017.0059; Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST; Han SW, 2020, CANCER MED-US, V9, P6667, DOI 10.1002/cam4.3289; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; World Health Organization, 2020, MAST PROT MULT AD RA; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648	8	379	398	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	2020	323	15					1499	1500		10.1001/jama.2020.3633	http://dx.doi.org/10.1001/jama.2020.3633			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ1ZH	32159735	Bronze			2023-01-03	WOS:000529969700022
J	Si, H; Genna, B; Zhuang, XJ; Wang, J; Burenbatu, B; Feng, QY; Wang, HY				Si, Ha; Genna, Ba; Zhuang, Xiangjin; Wang, Jing; Burenbatu, B.; Feng, Qiyu; Wang, Hongyang			DaHuangWan targets EGF signaling to inhibit the proliferation of hepatoma cells	PLOS ONE			English	Article							COSTUNOLIDE INDUCES APOPTOSIS; CANCER CELLS; PATHWAY; ENDOCYTOSIS; ACTIVATION; LINE; ROS	DaHuangWan (DHW) is a traditional herbal medicine used by Mongolian to treat liver cancer for many years. Clinical application of the drug has been shown to help control tumor progression, prolong survival and improve quality of life. However, the underlying mechanisms and side effects of this drug remain unclear, which greatly limits the clinical application and further optimization of DHW. In this study, we found that DHW inhibits the proliferation of hepatoma cells by modulating the epithelial growth factor (EGF) signaling pathway. Berberine and Costunolide are the main active ingredients in DHW. Interestingly, the combination of Berberine and Costunolide has a dramatic synergistic effect on inhibiting the proliferation of hepatoma cells. Neither Berberine nor Costunolide directly block EGFR phosphorylation. Berberine promotes endocytosis of activated EGFR, while as Costunolide increases ubiquitination of EGFR and reduces EGFR recycling to cell membrane distribution, thereby inhibiting EGF signaling. Berberine and Costunolide target two different steps in regulating the EGF signaling, which explains the synergistic anti-cancer effect of DHW. Since Berberine and Costunolide do not directly target EGFR phosphorylation, DHW could be a supplementary medicine to tyrosine kinase inhibitors in cancer therapy.	[Si, Ha; Burenbatu, B.] Inner Mongolia Univ Nationalities, Affiliated Hosp, Tongliao, Inner Mongolia, Peoples R China; [Si, Ha; Genna, Ba] Inner Mongolia Univ Nationalities, Tongliao, Inner Mongolia, Peoples R China; [Si, Ha; Zhuang, Xiangjin; Wang, Jing; Feng, Qiyu; Wang, Hongyang] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp Inst, Natl Ctr Liver Canc, Shanghai, Peoples R China; [Wang, Jing] USTC, Affiliated Hosp 1, Canc Res Ctr, Div Life Sci & Med, Hefei, Anhui, Peoples R China	Inner Mongolia University for Nationalities; Inner Mongolia University for Nationalities; Naval Medical University; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Burenbatu, B (corresponding author), Inner Mongolia Univ Nationalities, Affiliated Hosp, Tongliao, Inner Mongolia, Peoples R China.; Feng, QY; Wang, HY (corresponding author), Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp Inst, Natl Ctr Liver Canc, Shanghai, Peoples R China.	brbt2013@163.com; qiyu@icloud.com; hywangk@vip.sina.com		Feng, qiyu/0000-0003-2715-0087; xiang jin, zhuang/0000-0002-9371-3143	Natural Science Foundation of Inner Mongolia [2018MS08038]; National Natural Science foundation of China (NSFC) [81773112]	Natural Science Foundation of Inner Mongolia; National Natural Science foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by grants from Natural Science Foundation of Inner Mongolia (NO. 2018MS08038, to HS) and National Natural Science foundation of China (NSFC, 81773112, to QF).	[Anonymous], 2015, PHARMACOPOEIAPEOPLES, P64; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Choi JY, 2009, MOLECULES, V14, P266, DOI 10.3390/molecules14010266; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Conte A, 2016, PROG MOL BIOL TRANSL, V141, P225, DOI 10.1016/bs.pmbts.2016.03.002; Conte A, 2017, METHODS MOL BIOL, V1652, P81, DOI 10.1007/978-1-4939-7219-7_5; Dong GZ, 2015, PHYTOTHER RES, V29, P680, DOI 10.1002/ptr.5299; HanZhiqiang HS, 2017, STUDY OPTIMUM EXTRAC, V24, P46; Hasson S S, 2018, Asian Pac J Cancer Prev, V19, P1917; Hou Q, 2011, CANCER SCI, V102, P1287, DOI 10.1111/j.1349-7006.2011.01933.x; Hou YL, 2017, BREAST CANCER-TARGET, V9, P429, DOI 10.2147/BCTT.S135665; Hua PY, 2016, J BIOCHEM MOL TOXIC, V30, P462, DOI 10.1002/jbt.21810; Hua PY, 2016, ONCOL LETT, V11, P2780, DOI 10.3892/ol.2016.4295; Jie SH, 2011, J GASTROEN HEPATOL, V26, P179, DOI 10.1111/j.1440-1746.2010.06389.x; Kim JH, 2011, BIOL PHARM BULL, V34, P580, DOI 10.1248/bpb.34.580; Lei CT, 2017, CELL PHYSIOL BIOCHEM, V42, P281, DOI 10.1159/000477329; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]; Miyamoto Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040752; Moon SM, 2013, PHARM BIOL, V51, P1372, DOI 10.3109/13880209.2013.792847; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Pinilla-Macua I, 2015, METHOD CELL BIOL, V130, P347, DOI 10.1016/bs.mcb.2015.05.008; Seo CS, 2015, MOL MED REP, V12, P7789, DOI 10.3892/mmr.2015.4342; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617; Singireesu SSNR, 2018, CELL BIOL TOXICOL, V34, P125, DOI 10.1007/s10565-017-9411-z; Tang J, 2009, J ETHNOPHARMACOL, V126, P5, DOI 10.1016/j.jep.2009.08.009; Tian X, 2017, MEDICINE, V96, P30; Wang N, 2010, INTEGR CANCER THER, V9, P354, DOI 10.1177/1534735410379121; Wang Z, 2016, CELL BIOL INT, V40, P289, DOI 10.1002/cbin.10564; Yang WJ, 2009, BIOL PHARM BULL, V32, P1021, DOI 10.1248/bpb.32.1021; Yang YI, 2011, GYNECOL ONCOL, V123, P588, DOI 10.1016/j.ygyno.2011.08.031; YOSHIKAWA M, 1993, CHEM PHARM BULL, V41, P214, DOI 10.1248/cpb.41.214	32	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2020	15	4							e0231466	10.1371/journal.pone.0231466	http://dx.doi.org/10.1371/journal.pone.0231466			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9JM	32298294	Green Submitted, gold, Green Published			2023-01-03	WOS:000536011400051
J	Leigh, E; Chiu, K; Clark, DM				Leigh, Eleanor; Chiu, Kenny; Clark, David M.			The effects of modifying mental imagery in adolescent social anxiety	PLOS ONE			English	Article							NEGATIVE SELF-IMAGERY; COGNITIVE THERAPY; VIDEO FEEDBACK; PHOBIA; MODEL; DISORDER; CHILDREN; PLACEBO; CLARK	Background The identification of negative self-imagery as a maintenance factor in adult social anxiety has led to enhanced treatments for this population. Whilst intrusive negative imagery is commonly reported by socially anxious adolescents, no studies have demonstrated that it plays a causal role in maintaining symptoms. To assess this possibility, we undertook an experimental study manipulating social self-imagery in high socially anxious adolescents. Methods High socially anxious adolescents undertook two conversations under different conditions. During one conversation they held a negative social self-image in mind, and in the other they held a benign social self-image in mind. Self-report, conversation partner report and independent assessor ratings were taken. Results When participants held a negative self-image in mind, they reported feeling more anxious, and believed they looked more anxious and performed more poorly. Furthermore, they overestimated how anxious they looked compared to conversation partner ratings. As well as distorting participants' perception of their anxious appearance, holding a negative image in mind also had observable effects on the interaction. Participants were rated as looking more anxious and performing less well by their conversation partner when they held such images in mind, and the conversation was rated more critically by conversation partners and independent observers. Finally, a preliminary mediation analysis suggested that the detrimental effect of negative imagery on the social interaction may be partly due to the spontaneous use of avoidant safety behaviours. Conclusions The findings provide support for a causal role of negative self-imagery in adolescent social anxiety and point to the potential clinical value of techniques targeting imagery to treat the disorder.	[Leigh, Eleanor; Clark, David M.] Univ Oxford, Dept Expt Psychol, Oxford, England; [Chiu, Kenny] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol, Oxford, England	University of Oxford; University of London; King's College London	Leigh, E (corresponding author), Univ Oxford, Dept Expt Psychol, Oxford, England.	eleanor.leigh@psy.ox.ac.uk		Leigh, Eleanor/0000-0003-2756-3770; Charakopoulou-Travlou, Mariana/0000-0002-7658-7771; Chiu, Kenny/0000-0001-8776-9864; Clark, David/0000-0002-8173-6022	Wellcome Trust [102176/Z/13/Z, WT069777]; NIHR [NF-SI-0512-10132]; King's College London-Hong Kong scholarship	Wellcome Trust(Wellcome TrustEuropean Commission); NIHR(National Institute for Health Research (NIHR)); King's College London-Hong Kong scholarship	Eleanor Leigh is funded by a Wellcome Trust clinical research fellowship (102176/Z/13/Z). David M. Clark is a Wellcome Trust (WT069777) and NIHR (NF-SI-0512-10132) senior investigator. Kenny Chiu was funded by the King's College London-Hong Kong scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alfano CA, 2008, J CLIN CHILD ADOLESC, V37, P327, DOI 10.1080/15374410801955870; Angold A, 1995, INT J METHOD PSYCH, V5, P237; Beesdo-Baum K, 2012, ACTA PSYCHIAT SCAND, V126, P411, DOI 10.1111/j.1600-0447.2012.01886.x; Clark D. M, 2005, 3 QUESTIONNAIRES MEA; Clark D.M., 1995, SOCIAL PHOBIA DIAGNO, P69; Clark DM, 2003, J CONSULT CLIN PSYCH, V71, P1058, DOI 10.1037/0022-006X.71.6.1058; Ganis G., 2006, CASE MENTAL IMAGERY; Hackmann A, 2000, BEHAV RES THER, V38, P601, DOI 10.1016/S0005-7967(99)00161-8; Hirsch C, 2004, MEMORY, V12, P496, DOI 10.1080/09658210444000106; Hirsch CR, 2003, BEHAV RES THER, V41, P909, DOI 10.1016/S0005-7967(02)00103-1; Ingul JM, 2014, PSYCHOTHER PSYCHOSOM, V83, P54, DOI 10.1159/000354672; Leigh E, 2018, CLIN CHILD FAMILY PS; Leigh E, 2018, CLIN CHILD FAM PSYCH, V21, P388, DOI 10.1007/s10567-018-0258-5; Leigh E, 2016, BEHAV COGN PSYCHOTH, V44, P1, DOI 10.1017/S1352465815000715; Mansell W, 1999, BEHAV RES THER, V37, P419, DOI 10.1016/S0005-7967(98)00148-X; Masia-Warner C, 2003, J AM ACAD CHILD PSY, V42, P1076, DOI 10.1097/01.CHI.0000070249.24125.89; Masia-Warner C., 1999, LIEBOWITZ SOCIAL ANX; Montoya AK, 2017, PSYCHOL METHODS, V22, P6, DOI 10.1037/met0000086; Parr CJ, 2009, CLIN PSYCHOL PSYCHOT, V16, P46, DOI 10.1002/cpp.599; Plasencia ML, 2011, BEHAV RES THER, V49, P665, DOI 10.1016/j.brat.2011.07.005; Ranta K, 2014, CLIN PSYCHOL PSYCHOT, V21, P252, DOI 10.1002/cpp.1833; Schreiber F, 2013, J BEHAV THER EXP PSY, V44, P158, DOI 10.1016/j.jbtep.2012.10.003; Schreiber F, 2012, INT J COGN THER, V5, P341, DOI 10.1521/ijct.2012.5.3.341; Thoemmes F, 2010, STRUCT EQU MODELING, V17, P510, DOI 10.1080/10705511.2010.489379; Warnock-Parkes E, 2017, COGN BEHAV PRACT, V24, P245, DOI 10.1016/j.cbpra.2016.03.007; Weems CF, 2005, J AM ACAD CHILD PSY, V44, P656, DOI 10.1097/01.chi.0000162583.25829.4b	27	8	8	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2020	15	4							e0230826	10.1371/journal.pone.0230826	http://dx.doi.org/10.1371/journal.pone.0230826			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR8OD	32251465	Green Accepted, Green Published, gold			2023-01-03	WOS:000535955000022
J	Pahapill, PA; Chen, G; Arocho-Quinones, EV; Nencka, AS; Li, SJ				Pahapill, Peter A.; Chen, Guangyu; Arocho-Quinones, Elsa V.; Nencka, Andrew S.; Li, Shi-Jiang			Functional connectivity and structural analysis of trial spinal cord stimulation responders in failed back surgery syndrome	PLOS ONE			English	Article							CHRONIC PAIN; PERIAQUEDUCTAL GRAY; STATE; REPRESENTATION; MULTICENTER; ANATOMY; PATIENT; FMRI	Background Chronic pain has been associated with alterations in brain structure and function that appear dependent on pain phenotype. Functional connectivity (FC) data on chronic back pain (CBP) is limited and based on heterogeneous pain populations. We hypothesize that failed back surgery syndrome (FBSS) patients being considered for spinal cord stimulation (SCS) therapy have altered resting state (RS) FC cross-network patterns that 1) specifically involve emotion and reward/aversion functions and 2) are related to pain scores. Methods RS functional MRI (fMRI) scans were obtained for 10 FBSS patients who are being considered for but who have not yet undergone implantation of a permanent SCS device and 12 healthy age-matched controls. Seven RS networks were analyzed including the striatum (STM). The Wilcoxon signed-rank test evaluated differences in cross-network FC strength (FCS). Differences in periaqueductal grey (PAG) FC were assessed with seed-based analysis. Results Cross-network FCS was decreased (p<0.05) between the STM and all other networks in these FBSS patients. There was a negative linear relationship (R-2 = 0.76, p<0.0022) between STMFCS index and pain scores. The PAG showed decreased FC with network elements and amygdala but increased FC with the sensorimotor cortex and cingulate gyrus. Conclusions Decreased FC between STM and other RS networks in FBSS has not been previously reported. This STMFCS index may represent a more objective measure of chronic pain specific to FBSS which may help guide patient selection for SCS and subsequent management.	[Pahapill, Peter A.; Arocho-Quinones, Elsa V.] US Dept Vet Affairs, Med Ctr, Dept Neurosurg, Milwaukee, WI USA; [Pahapill, Peter A.; Arocho-Quinones, Elsa V.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Chen, Guangyu; Li, Shi-Jiang] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; [Nencka, Andrew S.] Med Coll Wisconsin, Ctr Imaging Res, Milwaukee, WI 53226 USA	US Department of Veterans Affairs; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Arocho-Quinones, EV (corresponding author), US Dept Vet Affairs, Med Ctr, Dept Neurosurg, Milwaukee, WI USA.; Arocho-Quinones, EV (corresponding author), Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.	elsa.arocho@outlook.com		Arocho-Quinones, Elsa/0000-0002-6000-5503	Daniel M. Soref Charitable Trust	Daniel M. Soref Charitable Trust	Funding Source: The Daniel M. Soref Charitable Trust The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baliki MN, 2015, SCI REP-UK, V5, DOI 10.1038/srep07603; Baliki MN, 2015, NEURON, V87, P474, DOI 10.1016/j.neuron.2015.06.005; Baliki MN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106133; Baliki MN, 2012, NAT NEUROSCI, V15, P1117, DOI 10.1038/nn.3153; Brier MR, 2012, J NEUROSCI, V32, P8890, DOI 10.1523/JNEUROSCI.5698-11.2012; Brier MR, 2014, NEUROLOGY, V83, P1613, DOI 10.1212/WNL.0000000000000939; Cauda F, 2014, NEUROIMAGE-CLIN, V4, P676, DOI 10.1016/j.nicl.2014.04.007; Chen GY, 2016, J ALZHEIMERS DIS, V54, P983, DOI 10.3233/JAD-160537; Chen GY, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00456; Chou R, 2010, JAMA-J AM MED ASSOC, V303, P1295, DOI 10.1001/jama.2010.344; De Ridder D, 2016, NEUROMODULATION, V19, P47, DOI 10.1111/ner.12368; Deer TR, 2014, NEUROMODULATION, V17, P515, DOI 10.1111/ner.12208; Deogaonkar M, 2016, NEUROMODULATION, V19, P142, DOI 10.1111/ner.12346; Faria AV, 2012, NEUROIMAGE, V61, P613, DOI 10.1016/j.neuroimage.2012.03.078; Glover GH, 2012, J MAGN RESON IMAGING, V36, P39, DOI 10.1002/jmri.23572; Glover GH, 2000, MAGNET RESON MED, V44, P162, DOI 10.1002/1522-2594(200007)44:1<162::AID-MRM23>3.0.CO;2-E; Harper Daniel E, 2018, J Pain, V19, DOI 10.1016/j.jpain.2018.01.001; Hashmi JA, 2013, BRAIN, V136, P2751, DOI 10.1093/brain/awt211; Hemington KS, 2016, BRAIN STRUCT FUNCT, V221, P4203, DOI 10.1007/s00429-015-1161-1; Kapural L, 2016, NEUROSURGERY, V79, P667, DOI 10.1227/NEU.0000000000001418; Khan SA, 2014, PAIN, V155, P1472, DOI 10.1016/j.pain.2014.04.022; Kong J, 2019, BRAIN IMAGING BEHAV, V13, P482, DOI 10.1007/s11682-018-9875-3; Kucyi A, 2015, TRENDS NEUROSCI, V38, P86, DOI 10.1016/j.tins.2014.11.006; Levy RM, 2013, NEUROMODULATION, V16, P495, DOI 10.1111/ner.12148; Linnman C, 2012, NEUROIMAGE, V60, P505, DOI 10.1016/j.neuroimage.2011.11.095; Loggia ML, 2013, PAIN, V154, P24, DOI 10.1016/j.pain.2012.07.029; Maihofner C, 2004, NEUROLOGY, V63, P693, DOI 10.1212/01.WNL.0000134661.46658.B0; Mainero C, 2011, ANN NEUROL, V70, P838, DOI 10.1002/ana.22537; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Mohan A, 2016, SCI REP-UK, V6, DOI 10.1038/srep19683; Murray CJL, 2013, NEW ENGL J MED, V369, P448, DOI 10.1056/NEJMra1201534; Napadow V, 2010, ARTHRITIS RHEUM-US, V62, P2545, DOI 10.1002/art.27497; Pahapill PA, 2015, NEUROMODULATION, V18, P367, DOI 10.1111/ner.12239; Pahapill PA, 2014, NEUROMODULATION, V17, P22, DOI 10.1111/ner.12033; Seminowicz DA, 2011, J NEUROSCI, V31, P7540, DOI 10.1523/JNEUROSCI.5280-10.2011; Tass PA, 2012, ANN NEUROL, V72, P816, DOI 10.1002/ana.23663; Thomas JB, 2014, JAMA NEUROL, V71, P1111, DOI 10.1001/jamaneurol.2014.1654; Wang L, 2012, ANN NEUROL, V72, P571, DOI 10.1002/ana.23643; Woolf CJ, 2010, NAT MED, V16, P1241, DOI 10.1038/nm.2230; Yu RJ, 2014, NEUROIMAGE-CLIN, V6, P100, DOI 10.1016/j.nicl.2014.08.019	40	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2020	15	2							e0228306	10.1371/journal.pone.0228306	http://dx.doi.org/10.1371/journal.pone.0228306			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8AS	32074111	Green Published, gold			2023-01-03	WOS:000535220600011
J	Ferrando, L; Cirmena, G; Garuti, A; Scabini, S; Grillo, F; Mastracci, L; Isnaldi, E; Marrone, C; Gonella, R; Murialdo, R; Fiocca, R; Romairone, E; Ballestrero, A; Zoppoli, G				Ferrando, Lorenzo; Cirmena, Gabriella; Garuti, Anna; Scabini, Stefano; Grillo, Federica; Mastracci, Luca; Isnaldi, Edoardo; Marrone, Ciro; Gonella, Roberta; Murialdo, Roberto; Fiocca, Roberto; Romairone, Emanuele; Ballestrero, Alberto; Zoppoli, Gabriele			Development of a long non-coding RNA signature for prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma	PLOS ONE			English	Article							CANCER; EXPRESSION; BIOMARKERS; LINC00261; MODELS; TRIAL	Standard treatment for locally advanced rectal adenocarcinoma (LARC) includes a combination of chemotherapy with pyrimidine analogues, such as capecitabine, and radiation therapy, followed by surgery. Currently no clinically useful genomic predictors of benefit from neoadjuvant chemoradiotherapy (nCRT) exist for LARC. In this study we assessed the expression of 8,127 long noncoding RNAs (lncRNAs), poorly studied in LARC, to infer their ability in classifying patients' pathological complete response (pCR). We collected and analyzed, using lncRNA-specific Agilent microarrays a consecutive series of 61 LARC cases undergoing nCRT. Potential lncRNA predictors in responders and non-responders to nCRT were identified with LASSO regression, and a model was optimized using k-fold cross-validation after selection of the three most informative lncRNA. 11 lncRNAs were differentially expressed with false discovery rate < 0.01 between responders and non-responders to NACT. We identified lnc-KLF7-1, lnc-MAB21L2-1, and LINC00324 as the most promising variable subset for classification building. Overall sensitivity and specificity were 0.91 and 0.94 respectively, with an AUC of our ROC curve = 0.93. Our study shows for the first time that lncRNAs can accurately predict response in LARC undergoing nCRT. Our threelncRNA based signature must be independently validated and further analyses must be conducted to fully understand the biological role of the identified signature, but our results suggest lncRNAs may be an ideal biomarker for response prediction in the studied setting.	[Ferrando, Lorenzo; Cirmena, Gabriella; Garuti, Anna; Isnaldi, Edoardo; Gonella, Roberta; Ballestrero, Alberto; Zoppoli, Gabriele] Univ Genoa, Dept Internal Med, Genoa, Italy; [Scabini, Stefano; Grillo, Federica; Mastracci, Luca; Marrone, Ciro; Gonella, Roberta; Murialdo, Roberto; Fiocca, Roberto; Romairone, Emanuele; Ballestrero, Alberto; Zoppoli, Gabriele] IRCSS Osped Policlin San Martino, Genoa, Italy; [Grillo, Federica; Mastracci, Luca; Fiocca, Roberto] Univ Genoa, Dept Integrated Surg & Diagnost Sci, Genoa, Italy	University of Genoa; University of Genoa	Ballestrero, A; Zoppoli, G (corresponding author), Univ Genoa, Dept Internal Med, Genoa, Italy.; Ballestrero, A; Zoppoli, G (corresponding author), IRCSS Osped Policlin San Martino, Genoa, Italy.	aballestrero@unige.it; gabriele.zoppoli@unige.it	scabini, stefano/AAB-2292-2021; Ferrando, Lorenzo/AAA-9281-2022; Gonella, Roberta/AAA-7517-2021; Fiocca, Roberto/K-9705-2016; Ballestrero, Alberto/K-7546-2016	scabini, stefano/0000-0001-8011-0928; Ferrando, Lorenzo/0000-0002-4025-7930; Gonella, Roberta/0000-0001-7897-4102; Fiocca, Roberto/0000-0002-8856-6185; Ballestrero, Alberto/0000-0002-2601-7711; romairone, emanuele/0000-0002-0370-1481; Isnaldi, Edoardo/0000-0002-1055-7254; Cirmena, Gabriella/0000-0002-5794-2766	Associazione Italiana per la Ricerca sul Cancro (AIRC) AB Liberal donations; Associazione Italiana contro la Leucemia, il Linfoma e il Mieloma Multiplo (AIL);  [GZ MFAG 10570]	Associazione Italiana per la Ricerca sul Cancro (AIRC) AB Liberal donations(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana contro la Leucemia, il Linfoma e il Mieloma Multiplo (AIL); 	This work was supported by GZ MFAG 10570, Associazione Italiana per la Ricerca sul Cancro (AIRC) AB Liberal donations, Associazione Italiana contro la Leucemia, il Linfoma e il Mieloma Multiplo (AIL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Brown DN, 2016, SCI REP-UK, V6, DOI 10.1038/srep19435; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Dworak O, 1997, INT J COLORECTAL DIS, V12, P19, DOI 10.1007/s003840050072; Fang QJ, 2018, CELL BIOCHEM FUNCT, V36, P323, DOI 10.1002/cbf.3352; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Ghadimi BM, 2005, J CLIN ONCOL, V23, P1826, DOI 10.1200/JCO.2005.00.406; Horisberger K, 2008, INT J COLORECTAL DIS, V23, P257, DOI 10.1007/s00384-007-0408-6; Kauffmann Audrey, 2009, Bioinformatics, V25, P415, DOI 10.1093/bioinformatics/btn647; Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05; Li N, 2018, J CELL BIOCH; Li Y, 2016, INT J BIOL SCI, V12, P1022, DOI 10.7150/ijbs.15438; Liu Y, 2017, EUR REV MED PHARMACO, V21, P5691, DOI 10.26355/eurrev_201712_14014; Lopes-Ramos CM, 2014, BMC MED GENOMICS, V7, DOI 10.1186/s12920-014-0068-7; Nakao T, 2015, ONCOL REP, V34, P1961, DOI 10.3892/or.2015.4196; Pettit C, 2017, INT J ONCOL, V51, P393, DOI 10.3892/ijo.2017.4045; Pucciarelli S, 2011, ANN SURG, V253, P71, DOI 10.1097/SLA.0b013e3181fcb856; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sanz-Pamplona R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048877; Sauer R, 2012, J CLIN ONCOL, V30, P1926, DOI 10.1200/JCO.2011.40.1836; Scabini S, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-292; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sha LX, 2017, J OBSTET GYNAECOL RE, V43, P1563, DOI 10.1111/jog.13427; Shi T, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/9085195; Shi W, 2010, NUCLEIC ACIDS RES, V38, P2168, DOI 10.1093/nar/gkp1204; Simon R, 2007, CANCER INFORM, V3, P11; Simon R, 2010, PERS MED, V7, P33, DOI 10.2217/PME.09.49; Sun CC, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.94; Swellengrebel HAM, 2011, BRIT J SURG, V98, P418, DOI 10.1002/bjs.7315; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Wang ZH, 2017, TRANSPORT RES REC, P11, DOI 10.3141/2612-02; Watanabe T, 2006, CANCER RES, V66, P3370, DOI 10.1158/0008-5472.CAN-05-3834; Wei MM, 2016, GENOM PROTEOM BIOINF, V14, P280, DOI 10.1016/j.gpb.2016.03.007; Wibe A, 2013, COLORECTAL DIS, V15, P1333, DOI 10.1111/codi.12317; Zahurak M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-142; Zhang HY, 2018, COGN AFFECT BEHAV NE, V18, P964, DOI 10.3758/s13415-018-0616-2; Zoppoli G, 2012, WORLD J GASTRO SURG, V4, P275, DOI 10.4240/wjgs.v4.i12.275	38	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2020	15	2							e0226595	10.1371/journal.pone.0226595	http://dx.doi.org/10.1371/journal.pone.0226595			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9FN	32023246	Green Published, gold			2023-01-03	WOS:000534621500008
J	Wilson, ME; Dobler, CC; Morrow, AS; Beuschel, B; Alsawas, M; Benkhadra, R; Seisa, M; Mittal, A; Sanchez, M; Daraz, L; Holets, S; Murad, MH; Wang, Z				Wilson, Michael E.; Dobler, Claudia C.; Morrow, Allison S.; Beuschel, Bradley; Alsawas, Mouaz; Benkhadra, Raed; Seisa, Mohamed; Mittal, Aniket; Sanchez, Manuel; Daraz, Lubna; Holets, Steven; Murad, M. Hassan; Wang, Zhen			Association of Home Noninvasive Positive Pressure Ventilation With Clinical Outcomes in Chronic Obstructive Pulmonary Disease A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							STABLE HYPERCAPNIC COPD; MECHANICAL VENTILATION; RESPIRATORY-FAILURE; NASAL VENTILATION; CONTROLLED-TRIAL; MULTICENTER	Question In patients with chronic obstructive pulmonary disease (COPD) and hypercapnia, is the use of home noninvasive positive pressure ventilation (NIPPV) associated with better outcomes? Findings In this meta-analysis that included 51085 patients with COPD and hypercapnia, home use of bilevel positive airway pressure, compared with no device, was significantly associated with lower risk of mortality (odds ratio [OR], 0.66), fewer patients with hospital admissions (OR, 0.22), and lower need for intubation (OR, 0.34), but no significant difference in quality of life. Noninvasive home mechanical ventilator, compared with no device, was significantly associated with lower risk of hospital admission (rate ratio, 0.50), but there was no significant difference in mortality risk. However, the evidence was low to moderate in quality. Meaning Among patients with COPD and hypercapnia, home NIPPV, compared with no device use, was significantly associated with better clinical outcomes and no significant difference in quality of life. However, the evidence was low to moderate in quality, the evidence on quality of life was insufficient, and the analyses for some outcomes were based on small numbers of studies. This meta-analysis of trials and observational studies evaluates the association of the use of home noninvasive positive pressure ventilation (NIPPV) via home mechanical ventilator (HMV) and bilevel positive airway pressure (BPAP) devices with clinical outcomes and adverse events in patients with chronic obstructive pulmonary disease (COPD) and hypercapnia. Importance The association of home noninvasive positive pressure ventilation (NIPPV) with outcomes in chronic obstructive pulmonary disease (COPD) and hypercapnia is uncertain. Objective To evaluate the association of home NIPPV via bilevel positive airway pressure (BPAP) devices and noninvasive home mechanical ventilator (HMV) devices with clinical outcomes and adverse events in patients with COPD and hypercapnia. Data Sources Search of MEDLINE, EMBASE, SCOPUS, Cochrane Central Registrar of Controlled Trials, Cochrane Database of Systematic Reviews, National Guideline Clearinghouse, and Scopus for English-language articles published from January 1, 1995, to November 6, 2019. Study Selection Randomized clinical trials (RCTs) and comparative observational studies that enrolled adults with COPD with hypercapnia who used home NIPPV for more than 1 month were included. Data Extraction and Synthesis Data extraction was completed by independent pairs of reviewers. Risk of bias was evaluated using the Cochrane Collaboration risk of bias tool for RCTs and select items from the Newcastle-Ottawa Scale for nonrandomized studies. Main Outcomes and Measures Primary outcomes were mortality, all-cause hospital admissions, need for intubation, and quality of life at the longest follow-up. Results A total of 21 RCTs and 12 observational studies evaluating 51085 patients (mean [SD] age, 65.7 [2.1] years; 43% women) were included, among whom there were 434 deaths and 27 patients who underwent intubation. BPAP compared with no device was significantly associated with lower risk of mortality (22.31% vs 28.57%; risk difference [RD], -5.53% [95% CI, -10.29% to -0.76%]; odds ratio [OR], 0.66 [95% CI, 0.51-0.87]; P = .003; 13 studies; 1423 patients; strength of evidence [SOE], moderate), fewer patients with all-cause hospital admissions (39.74% vs 75.00%; RD, -35.26% [95% CI, -49.39% to -21.12%]; OR, 0.22 [95% CI, 0.11-0.43]; P < .001; 1 study; 166 patients; SOE, low), and lower need for intubation (5.34% vs 14.71%; RD, -8.02% [95% CI, -14.77% to -1.28%]; OR, 0.34 [95% CI, 0.14-0.83]; P = .02; 3 studies; 267 patients; SOE, moderate). There was no significant difference in the total number of all-cause hospital admissions (rate ratio, 0.91 [95% CI, 0.71-1.17]; P = .47; 5 studies; 326 patients; SOE, low) or quality of life (standardized mean difference, 0.16 [95% CI, -0.06 to 0.39]; P = .15; 9 studies; 833 patients; SOE, insufficient). Noninvasive HMV use compared with no device was significantly associated with fewer all-cause hospital admissions (rate ratio, 0.50 [95% CI, 0.35-0.71]; P < .001; 1 study; 93 patients; SOE, low), but not mortality (21.84% vs 34.09%; RD, -11.99% [95% CI, -24.77% to 0.79%]; OR, 0.56 [95% CI, 0.29-1.08]; P = .49; 2 studies; 175 patients; SOE, insufficient). There was no statistically significant difference in the total number of adverse events in patients using NIPPV compared with no device (0.18 vs 0.17 per patient; P = .84; 6 studies; 414 patients). Conclusions and Relevance In this meta-analysis of patients with COPD and hypercapnia, home BPAP, compared with no device, was associated with lower risk of mortality, all-cause hospital admission, and intubation, but no significant difference in quality of life. Noninvasive HMV, compared with no device, was significantly associated with lower risk of hospital admission, but there was no significant difference in mortality risk. However, the evidence was low to moderate in quality, the evidence on quality of life was insufficient, and the analyses for some outcomes were based on small numbers of studies.	[Wilson, Michael E.; Dobler, Claudia C.; Morrow, Allison S.; Beuschel, Bradley; Alsawas, Mouaz; Benkhadra, Raed; Seisa, Mohamed; Mittal, Aniket; Sanchez, Manuel; Daraz, Lubna; Murad, M. Hassan; Wang, Zhen] Mayo Clin, Evidence Based Practice Ctr, Rochester, MN USA; [Wilson, Michael E.] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA; [Wilson, Michael E.; Dobler, Claudia C.; Morrow, Allison S.; Beuschel, Bradley; Alsawas, Mouaz; Benkhadra, Raed; Seisa, Mohamed; Mittal, Aniket; Sanchez, Manuel; Daraz, Lubna; Murad, M. Hassan; Wang, Zhen] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN USA; [Wilson, Michael E.] Mayo Clin, Knowledge & Evaluat Res Unit, Rochester, MN USA; [Holets, Steven] Mayo Clin, Div Resp Care Educ, Rochester, MN USA; [Wang, Zhen] Mayo Clin, Dept Hlth Sci Res, Div Hlth Care Policy & Res, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Wilson, ME (corresponding author), Mayo Clin, Pulm & Crit Care Med, 200 First St SW, Rochester, MN 55905 USA.	wilson.michael1@mayo.edu	Murad, M. Hassan/AAW-4367-2020; Daraz, Ph.D, Lubna/GRS-6972-2022	Daraz, Ph.D, Lubna/0000-0003-4502-835X; Dobler, Claudia/0000-0002-5460-0189; Alsawas, Mouaz/0000-0002-0814-4098; Murad, Mohammad Hassan/0000-0001-5502-5975	Agency for Healthcare Research and Quality/US Department of Health and Human Services [HHSA290201500013I/Task Order 4]	Agency for Healthcare Research and Quality/US Department of Health and Human Services(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This project was funded under Contract No. HHSA290201500013I/Task Order 4 from the Agency for Healthcare Research and Quality/US Department of Health and Human Services.	Adeloye D, 2015, J GLOB HEALTH, V5, P186, DOI 10.7189/jogh.05.020415; Ambrosino N, 2015, MULTIDISCIP RESP MED, V10, DOI 10.1186/s40248-015-0028-x; [Anonymous], 2014, METHODS GUIDE EFFECT; Bhatt SP, 2013, INT J CHRONIC OBSTR, V8, P581, DOI 10.2147/COPD.S53619; Budweiser S, 2007, INT J CLIN PRACT, V61, P1516, DOI 10.1111/j.1742-1241.2007.01427.x; Casanova C, 2000, CHEST, V118, P1582, DOI 10.1378/chest.118.6.1582; Cheung APS, 2010, INT J TUBERC LUNG D, V14, P642; Clini E, 1998, RESP MED, V92, P1215, DOI 10.1016/S0954-6111(98)90424-3; Clini E, 2002, EUR RESPIR J, V20, P529, DOI 10.1183/09031936.02.02162001; Clini E, 1996, EUR RESPIR J, V9, P1605, DOI 10.1183/09031936.96.09081605; Coleman JM, 2019, ANN AM THORAC SOC, V16, P1091, DOI 10.1513/AnnalsATS.201810-657CME; De Backer L, 2011, INT J CHRONIC OBSTR, V6, P615, DOI 10.2147/COPD.S22823; Dreher M, 2010, THORAX, V65, P303, DOI 10.1136/thx.2009.124263; Dretzke J, 2016, INT J CHRONIC OBSTR, V11, P1, DOI 10.2147/COPD.S104238; Duiverman ML, 2008, THORAX, V63, P1052, DOI 10.1136/thx.2008.099044; Duiverman ML, 2020, THORAX, V75, P244, DOI 10.1136/thoraxjnl-2019-213303; Duiverman ML, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-112; Duiverman ML, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0542-9; Durao V, 2018, PULMONOLOGY, V24, P280, DOI 10.1016/j.pulmoe.2018.02.007; Funk GC, 2011, RESP MED, V105, P427, DOI 10.1016/j.rmed.2010.09.005; Gad DM, 2015, EGYPT J CHEST DIS TU, V64, P51, DOI 10.1016/j.ejcdt.2014.12.007; Galli JA, 2014, RESP MED, V108, P722, DOI 10.1016/j.rmed.2014.03.006; Garrod R, 2000, AM J RESP CRIT CARE, V162, P1335, DOI 10.1164/ajrccm.162.4.9912029; Gay PC, 1996, MAYO CLIN PROC, V71, P533, DOI 10.4065/71.6.533; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2019, GLOBAL STRATEGY DIAG; Guarascio AJ, 2013, CLINICOECONOMIC OUTC, V5, P235, DOI 10.2147/CEOR.S34321; Guyatt G., 2015, CUREUS J MED SCIENCE, V3rd ed., DOI DOI 10.7759/CUR; Heinemann F, 2011, RESPIROLOGY, V16, P1273, DOI 10.1111/j.1440-1843.2011.02054.x; Hill NS, 2017, JAMA-J AM MED ASSOC, V317, P2167, DOI 10.1001/jama.2017.5226; Ioannidis JPA, 2007, CAN MED ASSOC J, V176, P1091, DOI 10.1503/cmaj.060410; Kohnlein T, 2014, LANCET RESP MED, V2, P698, DOI 10.1016/S2213-2600(14)70153-5; Lewarski JS, 2007, CHEST, V132, P671, DOI 10.1378/chest.07-0558; Lloyd-Owen SJ, 2005, EUR RESPIR J, V25, P1025, DOI 10.1183/09031936.05.00066704; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Marquez-Martin E, 2014, RESP MED, V108, P1741, DOI 10.1016/j.rmed.2014.10.005; McEvoy RD, 2009, THORAX, V64, P561, DOI 10.1136/thx.2008.108274; McKim DA, 2011, CAN RESPIR J, V18, P197, DOI 10.1155/2011/139769; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Murphy PB, 2017, JAMA-J AM MED ASSOC, V317, P2177, DOI 10.1001/jama.2017.4451; National Clinical Guideline Centre, 2010, CHRON HEART FAIL NAT; Oscroft NS, 2014, RESP MED, V108, P1508, DOI 10.1016/j.rmed.2014.07.010; Oscroft NS, 2010, RESPIROLOGY, V15, P818, DOI 10.1111/j.1440-1843.2010.01787.x; Oscroft NS, 2010, COPD, V7, P111, DOI 10.3109/15412551003631725; Paone G, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/503145; Picot J, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004104.PUB3; Respiratory Network Domiciliary Non-Invasive Ventilation Working Group, 2012, DOM NON VENT AD PAT; Satici C, 2018, COPD, V15, P303, DOI 10.1080/15412555.2018.1500532; Simonds AK, 2016, ANN AM THORAC SOC, V13, P2035, DOI 10.1513/AnnalsATS.201606-454FR; Sin DD, 2007, CHEST, V131, P156, DOI 10.1378/chest.06-1423; Struik FM, 2014, THORAX, V69, P826, DOI 10.1136/thoraxjnl-2014-205126; Struik FM, 2014, RESP MED, V108, P329, DOI 10.1016/j.rmed.2013.10.007; Struik FM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002878.pub2; The Management of Chronic Obstructive Pulmonary Disease Working Group, 2014, VA DOD CLIN PRACT GU; Tsolaki V, 2008, RESP MED, V102, P904, DOI 10.1016/j.rmed.2008.01.003; Vasquez MM, 2017, AM J MED, V130, P809, DOI 10.1016/j.amjmed.2016.11.045; Windisch W, 2010, Pneumologie, V64, P640, DOI 10.1055/s-0030-1255558; Zhou LQ, 2017, INT J CHRONIC OBSTR, V12, P1279, DOI 10.2147/COPD.S127540	57	41	42	3	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2020	323	5					455	465		10.1001/jama.2019.22343	http://dx.doi.org/10.1001/jama.2019.22343			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL0PK	32016309	Green Published, Bronze			2023-01-03	WOS:000513134700015
J	Sartini, C; Tresoldi, M; Scarpellini, P; Tettamanti, A; Carco, F; Landoni, G; Zangrillo, A				Sartini, Chiara; Tresoldi, Moreno; Scarpellini, Paolo; Tettamanti, Andrea; Carco, Francesco; Landoni, Giovanni; Zangrillo, Alberto			Respiratory Parameters in Patients With COVID-19 After Using Noninvasive Ventilation in the Prone Position Outside the Intensive Care Unit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Sartini, Chiara; Carco, Francesco; Landoni, Giovanni; Zangrillo, Alberto] IRCCS San Raffaele Sci Inst, Dept Anesthesia & Intens Care, Milan, Italy; [Tresoldi, Moreno] IRCCS San Raffaele Hosp, Unit Gen Med & Adv Care, Milan, Italy; [Scarpellini, Paolo] IRCCS San Raffaele Sci Inst, Clin Infect Dis, Milan, Italy; [Tettamanti, Andrea] IRCCS San Raffaele Hosp, Dept Rehabil & Funct Recovery, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Landoni, G (corresponding author), Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Dept Anesthesia & Intens Care, Via Olgettina 60, I-20132 Milan, Italy.	landoni.giovanni@hsr.it	Sartini, Chiara/HGU-3723-2022	LANDONI, Giovanni/0000-0002-8594-5980; ZANGRILLO, Alberto/0000-0002-7687-7648; Tettamanti, Andrea/0000-0001-9183-274X; Tresoldi, Moreno/0000-0003-1541-6650				Cabrini L, 2016, CRIT CARE MED, V44, P2139, DOI 10.1097/CCM.0000000000001866; Ding L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2738-5; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Rice TW, 2007, CHEST, V132, P410, DOI 10.1378/chest.07-0617	4	172	175	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	2020	323	22					2338	2340		10.1001/jama.2020.7861	http://dx.doi.org/10.1001/jama.2020.7861			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA5KO	32412606	Green Published, Bronze			2023-01-03	WOS:000541952100031
J	Kanda, E; Epureanu, BI; Adachi, T; Tsuruta, Y; Kikuchi, K; Kashihara, N; Abe, M; Masakane, I; Nitta, K				Kanda, Eiichiro; Epureanu, Bogdan I.; Adachi, Taiji; Tsuruta, Yuki; Kikuchi, Kan; Kashihara, Naoki; Abe, Masanori; Masakane, Ikuto; Nitta, Kosaku			Application of explainable ensemble artificial intelligence model to categorization of hemodialysis-patient and treatment using nationwide-real-world data in Japan	PLOS ONE			English	Article							MORTALITY; OUTCOMES	Background Although dialysis patients are at a high risk of death, it is difficult for medical practitioners to simultaneously evaluate many inter-related risk factors. In this study, we evaluated the characteristics of hemodialysis patients using machine learning model, and its usefulness for screening hemodialysis patients at a high risk of one-year death using the nation-wide database of the Japanese Society for Dialysis Therapy. Materials and methods The patients were separated into two datasets (n = 39,930, 39,930, respectively). We categorized hemodialysis patients in Japan into new clusters generated by the K-means clustering method using the development dataset. The association between a cluster and the risk of death was evaluated using multivariate Cox proportional hazards models. Then, we developed an ensemble model composed of the clusters and support vector machine models in the model development phase, and compared the accuracy of the prediction of mortality between the machine learning models in the model validation phase. Results Average age of the subjects was 65.7 +/- 12.2 years; 32.7% had diabetes mellitus. The five clusters clearly distinguished the groups on the basis of their characteristics: Cluster 1, young male, and chronic glomerulonephritis; Cluster 2, female, and chronic glomerulonephritis; Cluster 3, diabetes mellitus; Cluster 4, elderly and nephrosclerosis; Cluster 5, elderly and protein energy wasting. These clusters were associated with the risk of death; Cluster 5 compared with Cluster 1, hazard ratio 8.86 (95% Cl 7.68, 10.21). The accuracy of the ensemble model for the prediction of 1-year death was 0.948 and higher than those of logistic regression model (0.938), support vector machine model (0.937), and deep learning model (0.936). Conclusions The clusters clearly categorized patient on their characteristics, and reflected their prognosis. Our real-world-data-based machine learning system is applicable to identifying high-risk hemodialysis patients in clinical settings, and has a strong potential to guide treatments and improve their prognosis.	[Kanda, Eiichiro] Kawasaki Med Sch, Med Sci, Kurashiki, Okayama, Japan; [Epureanu, Bogdan I.] Univ Michigan, Coll Engn, Ann Arbor, MI 48109 USA; [Adachi, Taiji] Kyoto Univ, Inst Frontier Life & Med Sci, Sakyo Ku, Kyoto, Japan; [Tsuruta, Yuki] Tsuruta Itabashi Clin, Itabashi Ku, Tokyo, Japan; [Kikuchi, Kan] Shimoochiai Clin, Shinjuku Ku, Tokyo, Japan; [Kashihara, Naoki] Kawasaki Med Sch, Dept Nephrol & Hypertens, Kurashiki, Okayama, Japan; [Abe, Masanori] Nihon Univ, Sch Med, Dept Internal Med, Div Nephrol Hypertens & Endocrinol, Tokyo, Japan; [Masakane, Ikuto] Yabuki Hosp, Dept Nephrol, Yamagata, Yamagata, Japan; [Nitta, Kosaku] Tokyo Womens Med Univ, Dept Nephrol, Shinjuku Ku, Tokyo, Japan	Kawasaki Medical School; University of Michigan System; University of Michigan; Kyoto University; Kawasaki Medical School; Nihon University; Tokyo Women's Medical University	Kanda, E (corresponding author), Kawasaki Med Sch, Med Sci, Kurashiki, Okayama, Japan.	kms.cds.kanda@gmail.com	Adachi, Taiji/P-8981-2016	Adachi, Taiji/0000-0001-5280-4156; Kanda, Eiichiro/0000-0003-0676-096X	Japan Society for the Promotion of Science (KAKENHI Grant) [JP 19K08740]	Japan Society for the Promotion of Science (KAKENHI Grant)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Japan Society for the Promotion of Science (KAKENHI Grant Number JP 19K08740) to EK. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akbilgic O, 2019, KIDNEY INT REP, V4, P1219, DOI 10.1016/j.ekir.2019.06.009; Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905; Castelvecchi D, 2016, NATURE, V537, P20, DOI 10.1038/538020a; Cozzolino M, 2018, NEPHROL DIAL TRANSPL, V33, P28, DOI 10.1093/ndt/gfy174; Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585; He JX, 2019, NAT MED, V25, P30, DOI 10.1038/s41591-018-0307-0; Ikizler TA, 2013, KIDNEY INT, V84, P1096, DOI 10.1038/ki.2013.147; Jacob AN, 2010, NEPHRON CLIN PRACT, V116, pC148, DOI 10.1159/000315884; Kanda E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214524; Kanda E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39908-6; Kanda E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128652; Low LL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195243; Ma LJ, 2017, INT J CARDIOL, V238, P151, DOI 10.1016/j.ijcard.2017.02.095; Masakane I., 2018, RENAL REPLACEMENT TH, V4, P1, DOI DOI 10.1186/s41100-018-0183-6; Masakane I, 2017, REN REPLACE THER, V3, P1; Mezzatesta S, 2019, COMPUT METH PROG BIO, V177, P9, DOI 10.1016/j.cmpb.2019.05.005; Nordio M, 2012, AM J KIDNEY DIS, V59, P819, DOI 10.1053/j.ajkd.2011.12.023; Obermeyer Z, 2016, NEW ENGL J MED, V375, P1216, DOI 10.1056/NEJMp1606181; Robinson BM, 2016, LANCET, V388, P294, DOI 10.1016/S0140-6736(16)30448-2; Saran R, 2019, AM J KIDNEY DIS, V73, pSVII; Topol EJ, 2019, NAT MED, V25, P44, DOI 10.1038/s41591-018-0300-7; Yan S, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0584-9	22	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2020	15	5							e0233491	10.1371/journal.pone.0233491	http://dx.doi.org/10.1371/journal.pone.0233491			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1WS	32469924	Green Published, gold			2023-01-03	WOS:000537552800082
J	Roglio, VS; Borges, EN; Rabelo-da-Ponte, FD; Scherer, JN; Schuch, JB; Passos, IC; Sanvicente-Vieira, B; Grassi-Oliveira, R; von Diemen, L; Pechansky, F; Kessler, FHP; Ornell, F				Roglio, Vinicius Serafini; Borges, Eduardo Nunes; Rabelo-da-Ponte, Francisco Diego; Scherer, Juliana Nichterwitz; Schuch, Jaqueline Bohrer; Passos, Ives Cavalcante; Sanvicente-Vieira, Breno; Grassi-Oliveira, Rodrigo; von Diemen, Lisia; Pechansky, Flavio; Paim Kessler, Felix Henrique; Ornell, Felipe			Prediction of attempted suicide in men and women with crack-cocaine use disorder in Brazil	PLOS ONE			English	Article							BIPOLAR DISORDER; SUBSTANCE-USE; GENDER-DIFFERENCES; CHILDHOOD-TRAUMA; COMMUNITY SAMPLE; SEXUAL-ABUSE; RISK-FACTORS; LIFE-SPAN; DIAGNOSIS; IDEATION	Background Suicide is a severe health problem, with high rates in individuals with addiction. Considering the lack of studies exploring suicide predictors in this population, we aimed to investigate factors associated with attempted suicide in inpatients diagnosed with cocaine use disorder using two analytical approaches. Methods This is a cross-sectional study using a secondary database with 247 men and 442 women hospitalized for cocaine use disorder. Clinical assessment included the Addiction Severity Index, the Childhood Trauma Questionnaire, and the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, totalling 58 variables. Descriptive Poisson regression and predictive Random Forest algorithm were used complementarily to estimate prevalence ratios and to build prediction models, respectively. All analyses were stratified by gender. Results The prevalence of attempted suicide was 34% for men and 50% for women. In both genders, depression (PRM = 1.56, PRW = 1.27) and hallucinations (PRM = 1.80, PRW = 1.39) were factors associated with attempted suicide. Other specific factors were found for men and women, such as childhood trauma, aggression, and drug use severity. The men's predictive model had prediction statistics of AUC = 0.68, Acc. = 0.66, Sens. = 0.82, Spec. = 0.50, PPV = 0.47 and NPV = 0.84. This model identified several variables as important predictors, mainly related to drug use severity. The women's model had higher predictive power (AUC = 0.73 and all other statistics were equal to 0.71) and was parsimonious. Conclusions Our findings indicate that attempted suicide is associated with depression, hallucinations and childhood trauma in both genders. Also, it suggests that severity of drug use may be a moderator between predictors and suicide among men, while psychiatric issues shown to be more important for women.	[Roglio, Vinicius Serafini; Borges, Eduardo Nunes; Rabelo-da-Ponte, Francisco Diego; Scherer, Juliana Nichterwitz; Schuch, Jaqueline Bohrer; von Diemen, Lisia; Pechansky, Flavio; Paim Kessler, Felix Henrique; Ornell, Felipe] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Ctr Drug & Alcohol Res, Porto Alegre, RS, Brazil; [Roglio, Vinicius Serafini; Rabelo-da-Ponte, Francisco Diego; Schuch, Jaqueline Bohrer; von Diemen, Lisia; Pechansky, Flavio; Paim Kessler, Felix Henrique; Ornell, Felipe] Univ Fed Rio Grande do Sul, Grad Program Psychiat & Behav Sci, Porto Alegre, RS, Brazil; [Borges, Eduardo Nunes] Univ Fed do Rio Grande, Ctr Computat Sci, Porto Alegre, RS, Brazil; [Rabelo-da-Ponte, Francisco Diego; Passos, Ives Cavalcante] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Mol Psychiat Lab, Porto Alegre, RS, Brazil; [Sanvicente-Vieira, Breno; Grassi-Oliveira, Rodrigo] Pontificia Univ Catolica Rio Grande do Sul, Dev Cognit Neurosci Lab, Porto Alegre, RS, Brazil	Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Pontificia Universidade Catolica Do Rio Grande Do Sul	Borges, EN (corresponding author), Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Ctr Drug & Alcohol Res, Porto Alegre, RS, Brazil.; Borges, EN (corresponding author), Univ Fed do Rio Grande, Ctr Computat Sci, Porto Alegre, RS, Brazil.	eduardoborges@furg.br	von Diemen, Lisia/D-5452-2015; Scherer, Juliana N/M-6344-2016; ornell, felipe/AAC-8207-2019; von Diemen, Lisia/GSE-1795-2022; KESSLER, FELIX HENRIQUE P/C-3798-2018; Borges, Eduardo N/N-5544-2017; Passos, Ives Cavalcante/U-7366-2019; Grassi-Oliveira, R/G-2623-2012; Schuch, Jaqueline Bohrer/L-1249-2015; Sanvicente-Vieira, Breno/H-5530-2013	von Diemen, Lisia/0000-0001-9228-7114; Scherer, Juliana N/0000-0002-9235-0416; ornell, felipe/0000-0002-3881-4283; KESSLER, FELIX HENRIQUE P/0000-0001-7059-2564; Borges, Eduardo N/0000-0003-1595-7676; Passos, Ives Cavalcante/0000-0001-6407-8219; Grassi-Oliveira, R/0000-0001-9911-5921; Schuch, Jaqueline Bohrer/0000-0002-2195-4407; Rabelo-da-Ponte, Francisco Diego/0000-0001-9016-2414; Sanvicente-Vieira, Breno/0000-0002-9922-966X	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [466802/20145, 478492/2013-8]; Secretaria Nacional de Politicas sobre Drogas (SENAD)/Ministerio da Justica e Seguranca Publica [822647/2015, 08129.015636/2017-78]; Research Support Fund at Hospital de Clinicas de Porto Alegre (FIPE-HCPA) [20150234]; Fundacao de Amparo a pesquisa do Estado do RS (FAPERGS) [TO 17/2551-0000872-3]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brazil (CAPES) [001]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Secretaria Nacional de Politicas sobre Drogas (SENAD)/Ministerio da Justica e Seguranca Publica; Research Support Fund at Hospital de Clinicas de Porto Alegre (FIPE-HCPA); Fundacao de Amparo a pesquisa do Estado do RS (FAPERGS)(Fundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brazil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This study was supported by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [grant numbers 466802/20145 and 478492/2013-8] to RG-O and LVD, Secretaria Nacional de Politicas sobre Drogas (SENAD)/Ministerio da Justica e Seguranca Publica [grant numbers 822647/2015 and 08129.015636/2017-78] to RG-O and FHPK, Research Support Fund at Hospital de Clinicas de Porto Alegre (FIPE-HCPA) [grant number 20150234] to LVD, Fundacao de Amparo a pesquisa do Estado do RS (FAPERGS) [grant number TO 17/2551-0000872-3] to ENB and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brazil (CAPES) - [finance code 001] to VSR and JBS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdalla RR, 2019, BRAZ J PSYCHIAT, V41, P437, DOI 10.1590/1516-4446-2018-0054; Acion L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175383; Adiguzel V, 2019, NORD J PSYCHIAT, V73, P490, DOI 10.1080/08039488.2019.1655589; Angelakis I, 2020, PSYCHOL MED, V50, P1, DOI 10.1017/S0033291719002848; Arias F, 2016, ADICCIONES, V29, P186, DOI [10.20882/adicciones.782, DOI 10.20882/ADICCIONES.782]; Arsenault-Lapierre G, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-37; Bachmann S, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071425; Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21; Bastos FI., 2017, 3 NATL SURVEY DRUG U, P528; Bastos FI, 2014, PESQUISA NACL USO CR; BERNSTEIN DP, 1994, AM J PSYCHIAT, V151, P1132, DOI 10.1176/ajp.151.8.1132; Beyer JL, 2016, PSYCHIAT CLIN N AM, V39, P111, DOI 10.1016/j.psc.2015.09.002; Bilsen J, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00540; Borges G, 2000, AM J EPIDEMIOL, V151, P781; Bradvik L, 2003, SUICIDE LIFE-THREAT, V33, P186, DOI 10.1521/suli.33.2.186.22773; Breiman L., 2001, RANDOM FORESTS, V45, P5, DOI DOI 10.1023/A:1010933404324; Brown GK, 2005, JAMA-J AM MED ASSOC, V294, P563, DOI 10.1001/jama.294.5.563; Campos RC, 2017, J MENT HEALTH, V26, P66, DOI 10.1080/09638237.2016.1222066; Cardoso TD, 2015, J AFFECT DISORDERS, V187, P179, DOI 10.1016/j.jad.2015.08.046; Chandrashekar G, 2014, COMPUT ELECTR ENG, V40, P16, DOI 10.1016/j.compeleceng.2013.11.024; Chartoff EH, 2014, BEHAV PHARMACOL, V25, P473, DOI 10.1097/FBP.0000000000000080; Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953; Chen LP, 2010, MAYO CLIN PROC, V85, P618, DOI 10.4065/mcp.2009.0583; Cibis A, 2012, J AFFECT DISORDERS, V136, P9, DOI 10.1016/j.jad.2011.08.032; Cipriani A, 2005, AM J PSYCHIAT, V162, P1805, DOI 10.1176/appi.ajp.162.10.1805; Daigre C, 2017, QUAL LIFE RES, V26, P3201, DOI 10.1007/s11136-017-1668-4; DeCou CR, 2016, PSYCHOL SERV, V13, P254, DOI 10.1037/ser0000096; Del-Ben Cristina Marta, 2001, Revista Brasileira de Psiquiatria, V23, P156, DOI 10.1590/S1516-44462001000300008; Duailibi Lígia Bonacim, 2008, Cad. Saúde Pública, V24, ps545, DOI 10.1590/S0102-311X2008001600007; Dube SR, 2001, JAMA-J AM MED ASSOC, V286, P3089, DOI 10.1001/jama.286.24.3089; Fayyad U, 1996, COMMUN ACM, V39, P27, DOI 10.1145/240455.240464; Forty L, 2014, BRIT J PSYCHIAT, V205, P465, DOI 10.1192/bjp.bp.114.152249; Franklin JC, 2017, PSYCHOL BULL, V143, P187, DOI 10.1037/bul0000084; Freeman A, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1398-8; Fujita J, 2015, SCHIZOPHR RES, V168, P209, DOI 10.1016/j.schres.2015.07.028; Fusar-Poli P, 2016, ACTA PSYCHIAT SCAND, V133, P76, DOI 10.1111/acps.12480; Garami J, 2019, PSYCHOL REP, V122, P433, DOI 10.1177/0033294118764918; Gradus JL, 2020, JAMA PSYCHIAT, V77, P25, DOI 10.1001/jamapsychiatry.2019.2905; Grassi-Oliveira R, 2006, REV SAUDE PUBL, V40, P249, DOI 10.1590/S0034-89102006000200010; Greenwald MK, 2014, DRUG ALCOHOL DEPEN, V141, P27, DOI 10.1016/j.drugalcdep.2014.04.028; Halpern SC, 2018, CHILD ABUSE REV, V27, P344, DOI 10.1002/car.2534; Halpern SC, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311X00037517, 10.1590/0102-311x00037517]; Harford TC, 2014, CHILD ABUSE NEGLECT, V38, P1389, DOI 10.1016/j.chiabu.2014.02.011; Harkness KL, 2015, J ABNORM PSYCHOL, V124, P1, DOI 10.1037/abn0000041; Hauser M, 2013, BIPOLAR DISORD, V15, P507, DOI 10.1111/bdi.12094; Hoertel N, 2015, MOL PSYCHIATR, V20, P718, DOI 10.1038/mp.2015.19; Huang J, 2005, IEEE T KNOWL DATA EN, V17, P299, DOI 10.1109/TKDE.2005.50; Ibrahim N, 2017, PSYCHOL RES BEHAV MA, V10, P129, DOI 10.2147/PRBM.S125176; Iemmi V, 2016, LANCET PSYCHIAT, V3, P774, DOI 10.1016/S2215-0366(16)30066-9; Ilgen MA, 2007, ALCOHOL CLIN EXP RES, V31, P635, DOI 10.1111/j.1530-0277.2007.00348.x; Ishii T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096272; Japkowicz N., 2000, P 2000 INT C ART INT; Karila L, 2012, CURR MED CHEM, V19, P5612, DOI 10.2174/092986712803988839; Kessler S, 2010, INC, V32, P48; Kim JH, 2009, COMPUT STAT DATA AN, V53, P3735, DOI 10.1016/j.csda.2009.04.009; Laranjeira R., 2013, 2 LEVANTAMENTO NACL; Lejuez CW, 2007, EXP CLIN PSYCHOPHARM, V15, P165, DOI 10.1037/1064-1297.15.2.165; Maki N, 2012, J EPIDEMIOL COMMUN H, V66, P302, DOI 10.1136/jech.2009.105908; Mann JJ, 2003, NAT REV NEUROSCI, V4, P819, DOI 10.1038/nrn1220; Maser JD, 2002, SUICIDE LIFE-THREAT, V32, P10, DOI 10.1521/suli.32.1.10.22183; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; McMahon K, 2018, PSYCHIAT RES, V269, P386, DOI 10.1016/j.psychres.2018.08.059; Mergl R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129062; Min KB, 2015, PREV MED, V71, P72, DOI 10.1016/j.ypmed.2014.12.017; Miranda-Mendizabal A, 2019, INT J PUBLIC HEALTH, V64, P265, DOI 10.1007/s00038-018-1196-1; Mohammadzadeh A, 2019, PSYCHIAT RES, V275, P100, DOI 10.1016/j.psychres.2019.03.023; MOSCICKI EK, 1995, SUICIDE LIFE-THREAT, V25, P22; Narvaez JCM, 2014, COMPR PSYCHIAT, V55, P1369, DOI 10.1016/j.comppsych.2014.04.021; Norman RE, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001349; North CS, 2017, BEHAV SCI-BASEL, V7, DOI 10.3390/bs7040074; Kessler FHP, 2012, AM J ADDICTION, V21, P370, DOI 10.1111/j.1521-0391.2012.00245.x; Pope SK, 2011, AM J DRUG ALCOHOL AB, V37, P491, DOI 10.3109/00952990.2011.600380; Post RM, 2013, BRIT J PSYCHIAT, V202, P172, DOI 10.1192/bjp.bp.112.116855; Runeson B, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3222; Sanvicente-Vieira B, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218334; Scherer JN, 2019, ACCIDENT ANAL PREV, V123, P256, DOI 10.1016/j.aap.2018.12.003; Shmueli G, 2010, STAT SCI, V25, P289, DOI 10.1214/10-STS330; Siliquini R, 2005, EUR J PUBLIC HEALTH, V15, P580, DOI 10.1093/eurpub/cki031; Silva Dhiordan Cardoso da, 2017, J. bras. psiquiatr., V66, P89, DOI 10.1590/0047-2085000000155; Stefanello S, 2008, REV BRAS PSIQUIATR, V30, P139, DOI 10.1590/S1516-44462006005000063; Tsujii N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175249; Turecki G, 2016, LANCET, V387, P1227, DOI 10.1016/S0140-6736(15)00234-2; van Buuren S, 2011, J STAT SOFTW, V45, P1; Watkins HB, 2013, BIPOLAR DISORD, V15, P542, DOI 10.1111/bdi.12090; Wilens TE, 2013, DRUG ALCOHOL DEPEN, V132, P114, DOI 10.1016/j.drugalcdep.2013.01.015; World Health Organization, PREV SUIC BEH TASK A; Yang JC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199741; Yuodelis-Flores C, 2015, AM J ADDICTION, V24, P98, DOI 10.1111/ajad.12185	88	5	5	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2020	15	5							e0232242	10.1371/journal.pone.0232242	http://dx.doi.org/10.1371/journal.pone.0232242			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LT3GS	32365094	gold, Green Published			2023-01-03	WOS:000536959700021
J	Teasdale, CA; Abrams, EJ; Yuengling, KA; Lamb, MR; Wang, CH; Vitale, M; Hawken, M; Melaku, Z; Nuwagaba-Biribonwoha, H; El-Sadr, WM				Teasdale, Chloe A.; Abrams, Elaine J.; Yuengling, Katharine A.; Lamb, Matthew R.; Wang, Chunhui; Vitale, Mirriah; Hawken, Mark; Melaku, Zenebe; Nuwagaba-Biribonwoha, Harriet; El-Sadr, Wafaa M.			Expansion and scale-up of HIV care and treatment services in four countries over ten years	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; FOLLOW-UP; RETENTION; METAANALYSIS; PREGNANCY; OUTCOMES; HEALTH; WOMEN	Background Scale-up and expansion of antiretroviral therapy (ART) for people living with HIV (PLHIV) have been a global priority for more than 15 years. Methods We describe PLHIV at enrollment in care and ART initiation in Ethiopia, Kenya, Mozambique and Tanzania from 2005-2014 and report on enrollment location, CD4 count and loss to follow-up (LTF), death, and combined attrition (LTF and death) pre- and post-ART initiation over time. Pre-ART outcomes were estimated using competing risk and post-ART using Kaplan-Meier estimators; LTF defined as no visit within six months pre-ART and 12 months after ART start. Results From 2005-2014, 884,328 PLHIV enrolled in care at 350 health facilities, median age was 32.0 years (interquartile range [IQR] 26.0-42.0), and majority were female (66.5%). The proportion of PLHIV enrolled at primary and rural facilities increased from 12.9% and 15.3% in 2005-2006 to 43.5% and 41.7% in 2013-2014 (p<0.0001). Median CD4+ cell count at enrollment increased from 171 cell/mm(3) in 2005-2006 (IQR 71-339) to 289 cell/mm(3) in 2013-2014 (IQR 133-485) (p<0.0001). A total of 460,758 (57.4%) PLHIV initiated treatment. Cumulative risk of LTF for PLHIV prior to ART initiation 12 months after enrollment was 33.5% (95%CI 33.36-33.58) and 21.98% (95%CI 21.9-22.1) after ART initiation. Pregnant women and the youngest PLHIV group had the highest attrition after ART initiation, at 24 months 40.8% (95%CI 40.1-41.6) of pregnant women and 47.4% (95%CI 46.4-48.4) of PLHIV 15-19 years were not retained. Attrition at 12 months after enrollment among PLHIV regardless of ART status was 38.5% (95%CI 38.4-38.6). Conclusion Over 10 years of HIV scale-up in four sub-Saharan African countries, close to a million PLHIV were enrolled in care increasingly at rural and primary facilities with increasing CD4 count. Loss to follow-up from HIV care remains alarmingly high, particularly among pregnant women and younger PLHIV.	[Teasdale, Chloe A.] CUNY, Dept Epidemiol & Biostat, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10021 USA; [Teasdale, Chloe A.; Abrams, Elaine J.; Yuengling, Katharine A.; Lamb, Matthew R.; Wang, Chunhui; El-Sadr, Wafaa M.] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY 10027 USA; [Teasdale, Chloe A.; Abrams, Elaine J.; Lamb, Matthew R.; Nuwagaba-Biribonwoha, Harriet; El-Sadr, Wafaa M.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10027 USA; [Abrams, Elaine J.] Columbia Univ, Dept Pediat, Irving Med Ctr, Vagelos Coll Phys & Surg, New York, NY 10027 USA; [Vitale, Mirriah] Columbia Univ, ICAP, Maputo, Mozambique; [Hawken, Mark] Columbia Univ, ICAP, Nairobi, Kenya; [Melaku, Zenebe] Columbia Univ, ICAP, Addis Ababa, Ethiopia; [Nuwagaba-Biribonwoha, Harriet] Columbia Univ, ICAP, Mbabane, Eswatini; [El-Sadr, Wafaa M.] Columbia Univ, Irving Med Ctr, Vagelos Coll Phys & Surg, New York, NY USA	City University of New York (CUNY) System; Columbia University; Columbia University; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	Teasdale, CA (corresponding author), CUNY, Dept Epidemiol & Biostat, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10021 USA.; Teasdale, CA (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY 10027 USA.; Teasdale, CA (corresponding author), Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10027 USA.	chloe.teasdale@sph.cuny.edu			President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention [5U62PS223540, 5U2GPS001537]	President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This work was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention under the terms of Cooperative Agreement Number 5U62PS223540 and 5U2GPS001537. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of PEPFAR or the Centers for Disease Control and Prevention. The authors were not paid by any outside entity to write this paper.	Abrams EJ, 2019, AIDS, V33, P45, DOI 10.1097/QAD.0000000000002027; [Anonymous], 2004, 2004 REP GLOB AIDS E; [Anonymous], 2018, TANZANIA HIV IMPACT; Auld AF, 2017, MMWR-MORBID MORTAL W, V66, P558, DOI 10.15585/mmwr.mm6621a3; Bedelu M, 2007, J INFECT DIS, V196, pS464, DOI 10.1086/521114; Bilinski A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185699; Brennan AT, 2011, AIDS, V25, P2027, DOI 10.1097/QAD.0b013e32834b6480; Bygrave H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052856; Chammartin F, 2018, CLIN INFECT DIS, V67, P1643, DOI 10.1093/cid/ciy347; Chan AK, 2010, TROP MED INT HEALTH, V15, P90, DOI 10.1111/j.1365-3156.2010.02503.x; El-Sadr WM, 2016, AIDS, V30, P2145, DOI 10.1097/QAD.0000000000001192; El-Sadr WM, 2012, JAIDS-J ACQ IMM DEF, V60, pS96, DOI 10.1097/QAI.0b013e31825eb27b; Eswatini Go (CDC) CfDCaP University IaC, 2016, SWAZILAND HIV INCIDE; Fox MP, 2015, JAIDS-J ACQ IMM DEF, V69, P98, DOI 10.1097/QAI.0000000000000553; Grimsrud A, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21484; Haas AD, 2016, LANCET HIV, V3, pE175, DOI 10.1016/S2352-3018(16)00008-4; Kaplan R, 2008, AIDS, V22, P1679, DOI 10.1097/QAD.0b013e32830ebcee; Knettel BA, 2018, JAIDS-J ACQ IMM DEF, V77, P427, DOI 10.1097/QAI.0000000000001616; Lamb MR, 2014, AIDS, V28, P559, DOI 10.1097/QAD.0000000000000054; Radin E, 2018, 22 INT AIDS C AMST N; Reidy W, 2016, CLIN INFECT DIS, V63, P426, DOI 10.1093/cid/ciw302; Teasdale CA, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25210; Thin K, 2019, AIDS, V33, P2393, DOI 10.1097/QAD.0000000000002351; UNAIDS, 2019, GLOBAL HIV AIDS STAT; Wang BX, 2011, SAMJ S AFR MED J, V101, P253, DOI 10.7196/SAMJ.4078; World Health Organization (WHO), 2013, 2013 CONS GUID US AN; Zurcher K, 2017, TROP MED INT HEALTH, V22, P375, DOI 10.1111/tmi.12843	27	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2020	15	4							e0231667	10.1371/journal.pone.0231667	http://dx.doi.org/10.1371/journal.pone.0231667			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9JM	32298331	gold, Green Published			2023-01-03	WOS:000536011400085
J	Georgi, TW; Kurch, L; Hasenclever, D; Warbey, VS; Pike, L; Radford, J; Sabri, O; Kluge, R; Barrington, SF				Georgi, Thomas W.; Kurch, Lars; Hasenclever, Dirk; Warbey, Victoria S.; Pike, Lucy; Radford, John; Sabri, Osama; Kluge, Regine; Barrington, Sally F.			Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial	PLOS ONE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; RESPONSE-ADAPTED THERAPY; FDG-PET/CT; INTERPRETATION CRITERIA; INTERNATIONAL WORKSHOP; MULTICENTER TRIALS; CHEMOTHERAPY; RADIOTHERAPY; CONCORDANCE; VALIDATION	Aim qPET is a quantitative method used to assess FDG-PET response in lymphoma. qPET was developed using 898 scans from children with Hodgkin Lymphoma (HL) in the EuroNet-PHL-C1 (C1) trial. The aim of this study was to determine if qPET could be applied as an alternative response method in adults in the RAPID trial. Methods PET-CT scans performed after 3 cycles of ABVD in RAPID were re-evaluated by an independent reader, blinded to PET results and outcome in RAPID. All initially involved regions were assessed visually and by qPET. The distribution of qPET measurements was compared for RAPID and C1 patients. Previously published qPET thresholds corresponding to visual DS (vDS) of 1-5 in C1 were used to derive quantitative DS (qDS) for RAPID patients. Results PET-CT scans were available for 450 patients from RAPID. vDS were 1 (171 scans), 2 (153 scans), 3 (72 scans), 4 (31 scans) and 5 (23 scans) respectively. The distribution of qPET values was similar to C1 patients, with a unimodal 'normal' distribution and a long tail to the right, suggestive of favorable response in the majority and less favorable response in the minority with outlying values. qPET thresholds from C1 applied in RAPID patients gave 86% concordance for vDS and qDS. There was 97% concordance for complete metabolic response (CMR; DS 1-3) vs. no-CMR using the Lugano classification. Conclusion qPET which was developed in pediatric patients receiving more intensive OEPA chemotherapy, was a suitable quantitative method for assessing response in adult patients treated with ABVD in a response-adapted setting in the RAPID trial.	[Georgi, Thomas W.; Kurch, Lars; Sabri, Osama; Kluge, Regine] Univ Leipzig, Dept Nucl Med, Leipzig, Germany; [Hasenclever, Dirk] Univ Leipzig, Inst Med Informat, Stat & Epidemiol, Leipzig, Germany; [Warbey, Victoria S.; Pike, Lucy; Barrington, Sally F.] Kings Coll London, London, England; [Warbey, Victoria S.; Pike, Lucy; Barrington, Sally F.] Kings Coll London, Guys & St Thomas PET Ctr, Sch Biomed Engn & Imaging Sci, London, England; [Radford, John] Univ Manchester, Manchester, Lancs, England; [Radford, John] Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England	Leipzig University; Leipzig University; University of London; King's College London; University of London; King's College London; University of Manchester; Christie NHS Foundation Trust	Georgi, TW (corresponding author), Univ Leipzig, Dept Nucl Med, Leipzig, Germany.	Thomas.Georgi@medizin.uni-leipzig.de	Radford, John/N-1331-2015	Radford, John/0000-0001-7898-2786; Barrington, Sally/0000-0002-2516-5288; Sabri, Osama/0000-0002-6425-3504	National Institute of Health Research (NIHR) [RP-2-16-07-001]; CRUK; EPSRC; Department of Health (England); MRC (England); Hermes Medical Solutions	National Institute of Health Research (NIHR)(National Institute for Health Research (NIHR)); CRUK(Cancer Research UK); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Department of Health (England); MRC (England)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Hermes Medical Solutions	SFB acknowledges support from the National Institute of Health Research (NIHR) [RP-2-16-07-001]. https://www.nihr.ac.uk/King's College London and UCL Comprehensive Cancer Imaging Centre is funded by the CRUK and EPSRC in association with the MRC and Department of Health (England). https://www.kcl.ac.uk/lsm/research/divisions/cancer/research/centres/ccic The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. The authors acknowledge support from Hermes Medical Solutions to apply and test the qPET method. https://www.hermesmedical.com/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barrington SF, 2017, EUR J NUCL MED MOL I, V44, pS97, DOI 10.1007/s00259-017-3690-8; Barrington SF, 2016, BLOOD, V127, P1531, DOI 10.1182/blood-2015-11-679407; Barrington SF, 2014, J CLIN ONCOL, V32, P3048, DOI 10.1200/JCO.2013.53.5229; Barrington SF, 2010, EUR J NUCL MED MOL I, V37, P1824, DOI 10.1007/s00259-010-1490-5; Barrington SF, 2014, BRIT J HAEMATOL, V164, P315, DOI 10.1111/bjh.12601; Biggi A, 2013, J NUCL MED, V54, P683, DOI 10.2967/jnumed.112.110890; Boellaard R, 2015, EUR J NUCL MED MOL I, V42, P328, DOI 10.1007/s00259-014-2961-x; BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Engert A, 2012, LANCET, V379, P1791, DOI 10.1016/S0140-6736(11)61940-5; Friedberg JW, 2010, BLOOD, V115, P752, DOI 10.1182/blood-2009-09-244947; Gallamini A, 2007, J CLIN ONCOL, V25, P3746, DOI 10.1200/JCO.2007.11.6525; Gallamini A, 2014, HAEMATOLOGICA, V99, P1107, DOI 10.3324/haematol.2013.103218; Hasenclever D, 2014, EUR J NUCL MED MOL I, V41, P1301, DOI 10.1007/s00259-014-2715-9; Horning SJ, 2010, BLOOD, V115, P775, DOI 10.1182/blood-2009-08-234351; Hoskin PJ, 2009, J CLIN ONCOL, V27, P5390, DOI 10.1200/JCO.2009.23.3239; Hutchings M, 2012, HEMATOL-AM SOC HEMAT, P322, DOI 10.1182/asheducation-2012.1.322; Johnson P, 2016, NEW ENGL J MED, V374, P2419, DOI 10.1056/NEJMoa1510093; Kaalep A, 2018, EUR J NUCL MED MOL I, V45, P1344, DOI 10.1007/s00259-018-3977-4; Kaalep A, 2018, EUR J NUCL MED MOL I, V45, P412, DOI 10.1007/s00259-017-3853-7; Kluge R, 2017, SEMIN NUCL MED, V47, P242, DOI 10.1053/j.semnuclmed.2017.01.001; Kluge R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149072; Kluge R, 2013, PEDIATR RADIOL, V43, P406, DOI 10.1007/s00247-012-2559-z; Lasnon C, 2013, EUR J NUCL MED MOL I, V40, P985, DOI 10.1007/s00259-013-2391-1; Mauz-Korholz C, 2015, J CLIN ONCOL, V33, P2975, DOI 10.1200/JCO.2014.59.4853; Mauz-Korholz C, 2010, J CLIN ONCOL, V28, P3680, DOI 10.1200/JCO.2009.26.9381; Meignan M, 2010, EUR J NUCL MED MOL I, V37, P1821, DOI 10.1007/s00259-010-1546-6; Meignan M, 2009, LEUKEMIA LYMPHOMA, V50, P1257, DOI 10.1080/10428190903040048; Nanni C, 2017, LEUKEMIA LYMPHOMA, V58, P2298, DOI 10.1080/10428194.2017.1298752; Radford J, 2015, NEW ENGL J MED, V372, P1598, DOI 10.1056/NEJMoa1408648; Raemaekers JMM, 2014, J CLIN ONCOL, V32, P1188, DOI 10.1200/JCO.2013.51.9298; Schaapveld M, 2015, NEW ENGL J MED, V373, P2499, DOI 10.1056/NEJMoa1505949; Schellong G, 1999, J CLIN ONCOL, V17, P3736, DOI 10.1200/JCO.1999.17.12.3736; Wolden SL, 2012, J CLIN ONCOL, V30, P3174, DOI 10.1200/JCO.2011.41.1819; Zinzani PL, 2016, J CLIN ONCOL, V34, P1376, DOI 10.1200/JCO.2015.63.0699	35	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2020	15	4							e0231027	10.1371/journal.pone.0231027	http://dx.doi.org/10.1371/journal.pone.0231027			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8KJ	32240248	gold, Green Published			2023-01-03	WOS:000535945000082
J	Farhana, L; Sarkar, S; Nangia-Makker, P; Yu, YJ; Khosla, P; Levi, E; Azmi, A; Majumdar, APN				Farhana, Lulu; Sarkar, Sarah; Nangia-Makker, Pratima; Yu, Yingjie; Khosla, Pramod; Levi, Edi; Azmi, Asfar; Majumdar, Adhip P. N.			Natural agents inhibit colon cancer cell proliferation and alter microbial diversity in mice	PLOS ONE			English	Article							GAMMA-TOCOTRIENOL; GUT MICROBIOTA; VITAMIN-E; SIGNALING PATHWAY; GOLDEN SPICE; CURCUMIN; BIOAVAILABILITY; POLYPHENOLS; METABOLITES; APOPTOSIS	The current study was undertaken to investigate the effect of differentially formulated polyphenolic compound Essential Turmeric Oil-Curcumin (ETO-Cur), and Tocotrienol-rich fraction (TRF) of vitamin E isomers on colorectal cancer (CRC) cells that produce aggressive tumors. Combinations of ETO-Cur and TRF were used to determine the combinatorial effects of ETO-Cur and TRF-mediated inhibition of growth of CRC cells in vitro and HCT116 cells xenograft in SCID mice. 16S rRNA gene sequence profiling was performed to determine the outcome of gut microbial communities in mice feces between control and ETO-Cur-TRF groups. Bacterial identifications were validated by performing SYBR-based Real Time (RT) PCR. For metagenomics analysis to characterize the microbial communities, multiple software/tools were used, including Quantitative Insights into Microbial Ecology (QIIME) processing tool. We found ETO-Cur and TRF to synergize and that the combination of ETO-Cur-TRF significantly inhibited growth of HCT-116 xenografts in SCID mice. This was associated with a marked alteration in microbial communities and increased microbial OTU (operation taxonomic unit) number. The relative abundance of taxa was increased and the level of microbial diversity after 34 days of combinatorial treatment was found to be 44% higher over the control. Shifting of microbial family composition was observed in ETO-Cur-TRF treated mice as evidenced by marked reductions in Bacteroidaceae, Ruminococcaceae, Clostridiales, Firmicutes and Parabacteroids families, compared to controls. Interestingly, during the inhibition of tumor growth in ETO-Cur treated mice, probiotic Lactobacillaceae and Bifidobacteriaceae were increased by 20-fold and 6-fold, respectively. The relative abundance of anti-inflammatory Clostridium XIVa was also increased in ETO-Cur-TRF treated mice when compared with the control. Our data suggest that ETO-Cur-TRF show synergistic effects in inhibiting colorectal cancer cell proliferation in vitro and in mouse xenografts in vivo, and might induce changes in microbial diversity in mice.	[Farhana, Lulu; Sarkar, Sarah; Nangia-Makker, Pratima; Yu, Yingjie; Levi, Edi; Majumdar, Adhip P. N.] John Dingell Vet Affairs Med Ctr, Detroit, MI 48201 USA; [Farhana, Lulu; Nangia-Makker, Pratima; Yu, Yingjie; Azmi, Asfar; Majumdar, Adhip P. N.] Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA; [Nangia-Makker, Pratima; Azmi, Asfar; Majumdar, Adhip P. N.] Karmanos Canc Inst, Detroit, MI 48201 USA; [Khosla, Pramod] Wayne State Univ, Dept Nutr & Food Sci, Detroit, MI USA; [Levi, Edi] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Majumdar, APN (corresponding author), John Dingell Vet Affairs Med Ctr, Detroit, MI 48201 USA.; Majumdar, APN (corresponding author), Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA.; Majumdar, APN (corresponding author), Karmanos Canc Inst, Detroit, MI 48201 USA.	majumdar@med.wayne.edu		Majumdar, Adhip/0000-0002-6413-5102	National Institute of Health, USA (NIH) [1R21CA175916]; Department of Veteran Affairs, USA [I101BX001927]; Metropolitan Detroit Research and Education Fund, Detroit, Michigan, USA (MDREF)	National Institute of Health, USA (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veteran Affairs, USA(US Department of Veterans Affairs); Metropolitan Detroit Research and Education Fund, Detroit, Michigan, USA (MDREF)	This study was funded by grants to Dr. Adhip Majumdar from the National Institute of Health, USA (NIH) (1R21CA175916), the Department of Veteran Affairs, USA (I101BX001927) and the Metropolitan Detroit Research and Education Fund, Detroit, Michigan, USA (MDREF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abubakar IB, 2015, NAT PROD RES, V29, P2137, DOI 10.1080/14786419.2014.991927; Aggarwal BB, 2010, BIOCHEM PHARMACOL, V80, P1613, DOI 10.1016/j.bcp.2010.07.043; Ahn KS, 2007, J BIOL CHEM, V282, P809, DOI 10.1074/jbc.M610028200; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Antony B, 2008, INDIAN J PHARM SCI, V70, P445, DOI 10.4103/0250-474X.44591; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Bachawal SV, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-84; Baxter NT, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-20; Cardona F, 2013, J NUTR BIOCHEM, V24, P1415, DOI 10.1016/j.jnutbio.2013.05.001; Espin JC, 2017, BIOCHEM PHARMACOL, V139, P82, DOI 10.1016/j.bcp.2017.04.033; Cerda B, 2005, J AGR FOOD CHEM, V53, P227, DOI 10.1021/jf049144d; Dethlefsen L, 2006, TRENDS ECOL EVOL, V21, P517, DOI 10.1016/j.tree.2006.06.013; Duineveld LAM, 2016, ANN FAM MED, V14, P215, DOI 10.1370/afm.1919; Dulal S, 2014, CANCER J, V20, P225, DOI 10.1097/PPO.0000000000000050; Evans HM, 1922, SCIENCE, V56, P650, DOI 10.1126/science.56.1458.650; Farhana Lulu, 2018, World J Gastrointest Pathophysiol, V9, P47, DOI 10.4291/wjgp.v9.i2.47; Farhana L, 2012, J ONCOL, V2012, DOI 10.1155/2012/796729; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gross G, 2010, J AGR FOOD CHEM, V58, P10236, DOI 10.1021/jf101475m; Gupta SC, 2012, CLIN EXP PHARMACOL P, V39, P283, DOI 10.1111/j.1440-1681.2011.05648.x; Jeffery M, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002200.pub2; Kaileh M, 2010, J AM COLL NUTR, V29, p334S, DOI 10.1080/07315724.2010.10719848; Keku TO, 2013, TRENDS MICROBIOL, V21, P506, DOI 10.1016/j.tim.2013.08.004; Li H, 2019, BIOTECHNOLOGY ADV; Lim SW, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-469; Lim SW, 2014, BIOMED PHARMACOTHER, V68, P1105, DOI 10.1016/j.biopha.2014.10.006; Majumdar APN, 2009, NUTR CANCER, V61, P544, DOI 10.1080/01635580902752262; Mantzorou M, 2018, PHYTOTHER RES, V32, P957, DOI 10.1002/ptr.6037; McGarr SE, 2005, J CLIN GASTROENTEROL, V39, P98; Mocchegiani E, 2014, AGEING RES REV, V14, P81, DOI 10.1016/j.arr.2014.01.001; Nangia-Makker P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084369; Nautiyal Jyoti, 2011, J Mol Signal, V6, P7, DOI 10.1186/1750-2187-6-7; Ohno M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185999; Prasad S, 2014, BIOTECHNOL ADV, V32, P1053, DOI 10.1016/j.biotechadv.2014.04.004; Rajendran P, 2011, BRIT J PHARMACOL, V163, P283, DOI 10.1111/j.1476-5381.2010.01187.x; Ridlon JM, 2014, CURR OPIN GASTROEN, V30, P332, DOI 10.1097/MOG.0000000000000057; Sargent DJ, 2005, J CLIN ONCOL, V23, P2020, DOI 10.1200/JCO.2005.01.112; Sen CK, 2004, ANN NY ACAD SCI, V1031, P127, DOI 10.1196/annals.1331.013; Sharma S, 2006, CLIN EXP PHARMACOL P, V33, P940, DOI 10.1111/j.1440-1681.2006.04468.x; Shishu, 2008, AAPS PHARMSCITECH, V9, P810, DOI 10.1208/s12249-008-9096-y; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Toden S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00812-6; van Gestel YRBM, 2014, CANCER EPIDEMIOL, V38, P448, DOI 10.1016/j.canep.2014.04.004; Wang LL, 2018, EUR REV MED PHARMACO, V22, P7257, DOI 10.26355/eurrev_201811_16260; Yan QL, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00381; Yang ZH, 2010, INT J CANCER, V126, P852, DOI 10.1002/ijc.24766; Yu YJ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0372-7; Yu YJ, 2009, TRANSL ONCOL, V2, P321, DOI 10.1593/tlo.09193; Zackular JP, 2013, MBIO, V4, DOI 10.1128/mBio.00692-13; Zam W, 2018, J NUTR METAB, V2018, DOI 10.1155/2018/1367984	50	7	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2020	15	3							e0229823	10.1371/journal.pone.0229823	http://dx.doi.org/10.1371/journal.pone.0229823			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ9FU	32196510	Green Published, gold			2023-01-03	WOS:000535303100014
J	Jodoin, M; Rouleau, DM; Bellemare, A; Provost, C; Larson-Dupuis, C; Sandman, E; Laflamme, GY; Benoit, B; Leduc, S; Levesque, M; Gosselin, N; De Beaumont, L				Jodoin, Marianne; Rouleau, Dominique M.; Bellemare, Audrey; Provost, Catherine; Larson-Dupuis, Camille; Sandman, Emilie; Laflamme, Georges-Yves; Benoit, Benoit; Leduc, Stephane; Levesque, Martine; Gosselin, Nadia; De Beaumont, Louis			Moderate to severe acute pain disturbs motor cortex intracortical inhibition and facilitation in orthopedic trauma patients: A TMS study	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; CORTICAL EXCITABILITY; POSTOPERATIVE PAIN; HEAT STIMULATION; AREA; MODULATION; CRPS; IMMOBILIZATION; REPRESENTATION; MECHANISMS	Objective Primary motor (M1) cortical excitability alterations are involved in the development and maintenance of chronic pain. Less is known about M1-cortical excitability implications in the acute phase of an orthopedic trauma. This study aims to assess acute M1-cortical excitability in patients with an isolated upper limb fracture (IULF) in relation to pain intensity. Methods Eighty-four (56 IULF patients < 14 days post-trauma and 28 healthy controls). IULF patients were divided into two subgroups according to pain intensity (mild versus moderate to severe pain). A single transcranial magnetic stimulation (TMS) session was performed over M1 to compare groups on resting motor threshold (rMT), short-intracortical inhibition (SICI), intracortical facilitation (ICF), and long-interval cortical inhibition (LICI). Results Reduced SICI and ICF were found in IULF patients with moderate to severe pain, whereas mild pain was not associated with M1 alterations. Age, sex, and time since the accident had no influence on TMS measures. Discussion These findings show altered M1 in the context of acute moderate to severe pain, suggesting early signs of altered GABAergic inhibitory and glutamatergic facilitatory activities.	[Jodoin, Marianne; Rouleau, Dominique M.; Bellemare, Audrey; Provost, Catherine; Larson-Dupuis, Camille; Sandman, Emilie; Laflamme, Georges-Yves; Benoit, Benoit; Leduc, Stephane; Levesque, Martine; Gosselin, Nadia; De Beaumont, Louis] HSCM, Montreal, PQ, Canada; [Jodoin, Marianne; Bellemare, Audrey; Larson-Dupuis, Camille; Gosselin, Nadia] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Rouleau, Dominique M.; Sandman, Emilie; Laflamme, Georges-Yves; Benoit, Benoit; Leduc, Stephane; De Beaumont, Louis] Univ Montreal, Dept Chirurg, Montreal, PQ, Canada; [Levesque, Martine] Hop Fleury, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	De Beaumont, L (corresponding author), HSCM, Montreal, PQ, Canada.; De Beaumont, L (corresponding author), Univ Montreal, Dept Chirurg, Montreal, PQ, Canada.	louis.de.beaumont@umontreal.ca			Fonds de Recherche du Que PRIME [35117]	Fonds de Recherche du Que PRIME	LDB received funding from the Fonds de Recherche du Que ' bec en Sante ' for this work Grant number: 35117 Website: http://www.frqs.gouv.qc.ca The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	Albrecht E, 2013, BRIT J ANAESTH, V110, P96, DOI 10.1093/bja/aes355; Alves CJ, 2016, BONE, V85, P107, DOI 10.1016/j.bone.2016.01.026; Angst F, 2011, ARTHRIT CARE RES, V63, pS174, DOI 10.1002/acr.20630; Archer KR, 2012, J TRAUMA ACUTE CARE, V72, P1068, DOI 10.1097/TA.0b013e3182452df5; Babiloni AH, 2018, J PAIN RES, V11, P1445, DOI 10.2147/JPR.S168705; Baliki MN, 2012, NAT NEUROSCI, V15, P1117, DOI 10.1038/nn.3153; Calabrese F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00430; Castillo RC, 2017, J ORTHOP TRAUMA, V31, pS71, DOI 10.1097/BOT.0000000000000793; Caumo W, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00357; Chang WJ, 2018, J PAIN, V19, P341, DOI 10.1016/j.jpain.2017.10.007; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Civardi C, 2000, CLIN NEUROPHYSIOL, V111, P624, DOI 10.1016/S1388-2457(99)00301-6; Clark BC, 2010, MUSCLE NERVE, V42, P363, DOI 10.1002/mus.21694; Cooper MS, 2011, PAIN RES TREAT, V2011, DOI 10.1155/2011/738645; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Dube JA, 2011, CLIN NEUROPHYSIOL, V122, P2318, DOI 10.1016/j.clinph.2011.03.026; Eisenberg E, 2005, PAIN, V113, P99, DOI 10.1016/j.pain.2004.09.030; Enna SJ, 1998, LIFE SCI, V62, P1525, DOI 10.1016/S0024-3205(98)00101-5; Frot M, 2013, HUM BRAIN MAPP, V34, P2655, DOI 10.1002/hbm.22097; Gaertner M, 2018, NEUROMODULATION, V21, P409, DOI 10.1111/ner.12760; Galic MA, 2012, FRONT NEUROENDOCRIN, V33, P116, DOI 10.1016/j.yfrne.2011.12.002; Garry MI, 2009, EXP BRAIN RES, V193, P267, DOI 10.1007/s00221-008-1620-5; Gerbershagen HJ, 2011, BRIT J ANAESTH, V107, P619, DOI 10.1093/bja/aer195; Gummesson C, 2003, BMC MUSCULOSKELET DI, V4, DOI 10.1186/1471-2474-4-11; Hammond G, 2004, EXP BRAIN RES, V155, P19, DOI 10.1007/s00221-003-1696-x; Hashmi JA, 2013, BRAIN, V136, P2751, DOI 10.1093/brain/awt211; Jasmin L, 2004, CNS NEUROL DISORD-DR, V3, P487, DOI 10.2174/1568007043336716; Kennedy DL, 2016, PAIN, V157, P2410, DOI 10.1097/j.pain.0000000000000689; Knabl J, 2008, NATURE, V451, P330, DOI 10.1038/nature06493; Koleva D, 2005, EUR J PUBLIC HEALTH, V15, P475, DOI 10.1093/eurpub/cki033; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Langer N, 2012, NEUROLOGY, V78, P182, DOI 10.1212/WNL.0b013e31823fcd9c; Lavigne G, 2015, PAIN, V156, pS75, DOI 10.1097/j.pain.0000000000000111; Le Pera D, 2001, CLIN NEUROPHYSIOL, V112, P1633, DOI 10.1016/S1388-2457(01)00631-9; Lefaucheur JP, 2006, NEUROLOGY, V67, P1568, DOI 10.1212/01.wnl.0000242731.10074.3c; Leo RJ, 2007, J PAIN, V8, P453, DOI 10.1016/j.jpain.2007.01.009; Liepert J, 1995, ELECTROMYOGR MOTOR C, V97, P382, DOI 10.1016/0924-980X(95)00194-P; Lima MC, 2008, NEUROLOGY, V70, P2329, DOI 10.1212/01.wnl.0000314649.38527.93; Lynch ME, 2011, PAIN RES MANAG, V16, P77, DOI 10.1155/2011/654651; Mansour AR, 2014, RESTOR NEUROL NEUROS, V32, P129, DOI 10.3233/RNN-139003; Mantyselka P, 2001, PAIN, V89, P175, DOI 10.1016/S0304-3959(00)00361-4; Martucci KT, 2018, ANESTHESIOLOGY, V128, P1241, DOI 10.1097/ALN.0000000000002137; Mauger AR, 2013, CAN J PHYSIOL PHARM, V91, P187, DOI 10.1139/cjpp-2012-0213; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; Mehta SP, 2015, J ORTHOP SPORT PHYS, V45, P119, DOI 10.2519/jospt.2015.5129; Meissner W, 2018, CURR MED RES OPIN, V34, P187, DOI 10.1080/03007995.2017.1391081; Mhalla A, 2010, PAIN, V149, P495, DOI 10.1016/j.pain.2010.03.009; Mori F, 2011, J NEUROPHYSIOL, V106, P1637, DOI 10.1152/jn.00318.2011; Moseley GL, 2014, J PAIN, V15, P16, DOI 10.1016/j.jpain.2013.08.009; O'Connell NE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009416.pub2; Parker RS, 2016, BRAIN STIMUL, V9, P488, DOI 10.1016/j.brs.2016.03.020; Paulus W, 2008, BRAIN STIMUL, V1, P151, DOI 10.1016/j.brs.2008.06.002; Pelletier R, 2017, J ELECTROMYOGR KINES, V34, P65, DOI 10.1016/j.jelekin.2017.04.002; Peurala SH, 2008, CLIN NEUROPHYSIOL, V119, P2291, DOI 10.1016/j.clinph.2008.05.031; Pfannmoller J, 2019, RESTOR NEUROL NEUROS, V37, P143, DOI 10.3233/RNN-180886; Picarelli H, 2010, J PAIN, V11, P1203, DOI 10.1016/j.jpain.2010.02.006; Pogatzki-Zahn EM, 2017, PAIN REP, V2, DOI 10.1097/PR9.0000000000000588; Reis J, 2008, J PHYSIOL-LONDON, V586, P325, DOI 10.1113/jphysiol.2007.144824; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; Salo KST, 2019, EXP BRAIN RES, V237, P1503, DOI 10.1007/s00221-019-05502-5; Schwenkreis P, 2000, NEUROSCI LETT, V293, P143, DOI 10.1016/S0304-3940(00)01517-2; Schwenkreis P, 2003, NEUROLOGY, V61, P515, DOI 10.1212/WNL.61.4.515; Schwenkreis P, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-73; Svensson P, 2003, EUR J PAIN-LONDON, V7, P55, DOI 10.1016/S1090-3801(02)00050-2; Tamura Y, 2004, NEUROLOGY, V62, P2176, DOI 10.1212/01.WNL.0000130081.96533.85; Turco CV, 2018, BRAIN STIMUL, V11, P59, DOI 10.1016/j.brs.2017.09.009; Valeriani M, 1999, CLIN NEUROPHYSIOL, V110, P1475, DOI 10.1016/S1388-2457(99)00075-9; Valeriani M, 2001, EXP BRAIN RES, V139, P168, DOI 10.1007/s002210100753; Velmahos CS, 2019, AM J SURG, V218, P864, DOI 10.1016/j.amjsurg.2019.03.022; Vezzani A, 2014, EPILEPSY CURR, V14, P3, DOI 10.5698/1535-7511-14.s2.3; Voscopoulos C, 2010, BRIT J ANAESTH, V105, pI69, DOI 10.1093/bja/aeq323; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030; Yarkoni T, 2011, NAT METHODS, V8, P665, DOI [10.1038/NMETH.1635, 10.1038/nmeth.1635]; Yarnitsky D, 2010, CURR OPIN ANESTHESIO, V23, P611, DOI 10.1097/ACO.0b013e32833c348b; Zanette G, 2004, CLIN NEUROPHYSIOL, V115, P1264, DOI 10.1016/j.clinph.2003.12.033; Zelman DC, 2005, J PAIN SYMPTOM MANAG, V29, P401, DOI 10.1016/j.jpainsymman.2004.06.018; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006; Ziemann U, 2003, SUPPL CLIN NEUROPHYS, V56, P226	83	5	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2020	15	3							e0226452	10.1371/journal.pone.0226452	http://dx.doi.org/10.1371/journal.pone.0226452			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ9FU	32196498	gold, Green Published, Green Submitted			2023-01-03	WOS:000535303100004
J	Obeng-Amoako, GAO; Wamani, H; Conkle, J; Aryeetey, R; Nangendo, J; Mupere, E; Kalyango, JN; Myatt, M; Briend, A; Karamagi, CAS				Obeng-Amoako, Gloria A. Odei; Wamani, Henry; Conkle, Joel; Aryeetey, Richmond; Nangendo, Joanita; Mupere, Ezekiel; Kalyango, Joan N.; Myatt, Mark; Briend, Andre; Karamagi, Charles A. S.			Concurrently wasted and stunted 6-59 months children admitted to the outpatient therapeutic feeding programme in Karamoja, Uganda: Prevalence, characteristics, treatment outcomes and response	PLOS ONE			English	Article							SEVERE ACUTE MALNUTRITION; MANAGEMENT; COMMUNITY; ADMISSION	This study assessed the prevalence of concurrently wasted and stunted (WaSt) children, their characteristics, treatment outcomes and response; and factors associated with time to recovery among children aged 6-59 months admitted to Outpatient Therapeutic Care (OTC) in Karamoja, Uganda. We conducted a retrospective cohort study with data from January 2016 to October 2017 for children admitted to nine OTCs in Karamoja. We defined wasted, stunted and underweight as 2.0 Z-scores below the median per WHO growth standards and < 12.5 cm for low Mid-Upper Arm Circumference (MUAC). WaSt was defined as concurrently wasted and stunted. Out of 788 eligible children included in the analysis; 48.7% (95% CI; 45.2-52.2) had WaSt. WaSt was common among males; 56.3% (95% CI; 51.3-61.3). Median age was 18 months in WaSt versus 12 months in non-WaSt children (p < 0.001). All WaSt children were underweight; and more severely wasted than non-WaSt children. During recovery, WaSt children gained weight more rapidly than non-WaSt children (2.2g/kg/day vs. 1.7g/kg/day). WaSt children had lower recovery rate (58.0% vs. 65.4%; p = 0.037). The difference in median time of recovery between WaSt and non-WaSt children (63 days vs. 56 days; p = 0.465) was not significant. Factors associated with time to recovery were children aged 24-59 months (aHR = 1.30; 95% CI;1.07-1.57;), children with MUAC 10.5-11.4 cm (aHR = 2.03; 95% CI; 1.55-2.66), MUAC. 11.5 cm at admission (aHR = 3.31; 95% CI; 2.17-5.02) and living in Moroto (aHR = 3.34; 95% CI; 2.60-4.30) and Nakapiripirit (aHR = 1.95; 95% CI; 1.51-2.53) districts. The magnitude of children with WaSt in OTC shows that existing therapeutic feeding protocols could be used to detect and treat WaSt children. Further research is needed to identify and address the factors associated with sub-optimal recovery in WaSt children for effective OTC programming in Karamoja.	[Obeng-Amoako, Gloria A. Odei; Nangendo, Joanita; Kalyango, Joan N.; Karamagi, Charles A. S.] Makerere Univ, Coll Hlth Sci, Sch Med, Clin Epidemiol Unit, Kampala, Uganda; [Wamani, Henry] Makerere Univ, Coll Hlth Sci, Sch Publ Hlth, Dept Community Hlth & Behav Sci, Kampala, Uganda; [Conkle, Joel] UNICEF Namibia, Hlth & Nutr Sect, Windhoek, Namibia; [Aryeetey, Richmond; Karamagi, Charles A. S.] Univ Ghana, Sch Publ Hlth, Legon, Ghana; [Mupere, Ezekiel] Makerere Univ, Coll Hlth Sci, Dept Paediat & Child Hlth, Kampala, Uganda; [Kalyango, Joan N.] Makerere Univ, Coll Hlth Sci, Dept Pharm, Kampala, Uganda; [Myatt, Mark] Brixton Hlth, Llwngwril, Wales; [Briend, Andre] Univ Tampere, Ctr Child Hlth Res, Sch Med, Tampere, Finland; [Briend, Andre] Univ Copenhagen, Dept Nutr Exercise & Sports, Copenhagen, Denmark	Makerere University; Makerere University; University of Ghana; Makerere University; Makerere University; Tampere University; University of Copenhagen	Obeng-Amoako, GAO (corresponding author), Makerere Univ, Coll Hlth Sci, Sch Med, Clin Epidemiol Unit, Kampala, Uganda.	agodei@yahoo.com	Aryeetey, Richmond/C-5836-2016	Aryeetey, Richmond/0000-0003-4667-592X; Mupere, Ezekiel/0000-0002-8746-9009; Odei Obeng-Amoako, Gloria/0000-0001-5004-3701; Nangendo, Joanita/0000-0002-0458-2111	Carnegie Corporation of New York through the Regional Universities Forum for Capacity Building in Agriculture (RUFORUM), Makerere University, Kampala Uganda	Carnegie Corporation of New York through the Regional Universities Forum for Capacity Building in Agriculture (RUFORUM), Makerere University, Kampala Uganda	Support for this research was made possible through the competitive grant for training the next generation of scientists by Carnegie Corporation of New York through the Regional Universities Forum for Capacity Building in Agriculture (RUFORUM), Makerere University, Kampala Uganda. The OTC dataset used in this study was part of SAM incidence and posttreatment relapse feasibility study in Karamoja supported by UNICEF Uganda. The content is solely the responsibility of the authors and does not necessarily reflect the views of Carnegie Corporation of New York or UNICEF Uganda. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript	[Anonymous], 2014, RELATIONSHIP WASTING; Bhutta ZA, 2013, LANCET, V382, P452, DOI 10.1016/S0140-6736(13)60996-4; Briend A, 2015, FOOD NUTR BULL, V36, pS15, DOI 10.1177/15648265150361S103; Chitekwe S, 2018, ARCH PUBLIC HEALTH, V76, DOI 10.1186/s13690-018-0266-4; Collins S, 2006, LANCET, V368, P1992, DOI 10.1016/S0140-6736(06)69443-9; Department of Maternal and Child Health and Community Health Ministry of Health PRC, 2009, CHILD GROWTH STAND I; Federal Minstry of Health, 2016, GUIDELINES MANAGEMEN; Garenne M, 2018, SENEGAL MATERNAL CHI; Khara T, 2018, MATERN CHILD NUTR, V14, DOI 10.1111/mcn.12516; Kish L., SURVEY SAMPLING; Martorell R, 2012, ADV NUTR, V3, P227, DOI 10.3945/an.111.001107; McDonald CM, 2013, AM J CLIN NUTR, V97, P896, DOI 10.3945/ajcn.112.047639; Mekuria Getnet, 2017, BMC Nutr, V3, P42, DOI 10.1186/s40795-017-0161-3; Mengesha MM, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.30704; Myatt M, 2006, FOOD NUTR BULL, V27, pS7, DOI 10.1177/15648265060273S302; Myatt M, 2019, PUBLIC HEALTH NUTR, V22, P862, DOI 10.1017/S136898001800318X; Myatt M, 2018, ARCH PUBLIC HEALTH, V76, DOI 10.1186/s13690-018-0277-1; Olofin I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064636; Saaka M, 2016, J NUTR METAB, V2016, DOI 10.1155/2016/4654920; Schoenbuchner SM, 2019, AM J CLIN NUTR; Shanka N., 2015, J NUTR DISORD THER, V5, P155, DOI [10.4172/2161-0509.1000155, DOI 10.4172/2161-0509.1000155]; Uganda Bureau of Statistics (UBOS) ICF, 2017, UG DEM HLTH SURV 201; Uganda IPC Technical Working Group, 2014, REP INT FOOD SEC PHA; UNICEF, 2017, FOOD SEC NUTR ASS KA; UNICEF/ WHO/ World Bank Group, 2016, JOINT CHILD MALN EST; United Nations High Commissioner for Refugees World Food Programme, 2011, GUID SEL FEED MAN MA; Venn J, 1880, LONDON EDINBURGH DUB, V10, P1, DOI [DOI 10.1080/14786448008626877, 10.1080/14786448008626877]; WHO, 2009, WHO ANTHROPLUS PERS; WHO, 2013, GUID UPD MAN SEV AC; WHO Multicentre Growth Reference Study Group, 2006, WHO CHILD GROWTH STA; World Health Organization, 2014, GLOB NUTR TARG 2025, DOI [10.1057/9781137477699_6, DOI 10.1057/9781137477699_6]	31	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2020	15	3							e0230480	10.1371/journal.pone.0230480	http://dx.doi.org/10.1371/journal.pone.0230480			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ9FU	32196526	Green Published, gold			2023-01-03	WOS:000535303100032
J	Neves, J				Neves, Joana			Aging eyes and the immune system	SCIENCE			English	Editorial Material									[Neves, Joana] Univ Lisbon, IMM, Fac Med, Lisbon, Portugal	Universidade de Lisboa	Neves, J (corresponding author), Univ Lisbon, IMM, Fac Med, Lisbon, Portugal.	joana.neves@medicina.ulisboa.pt		Mendes Neves, Joana/0000-0002-1027-3489				Kennedy BK, 2014, CELL, V159, P708, DOI 10.1016/j.cell.2014.10.039; Lindahl M, 2017, NEUROBIOL DIS, V97, P90, DOI 10.1016/j.nbd.2016.07.009; Neves J., 2017, U.S. Patent, Patent No. [US20170274048A1, 20170274048A1]; Neves J, 2020, FEBS J, V287, P43, DOI 10.1111/febs.15061; Neves J, 2017, CELL STEM CELL, V20, P161, DOI 10.1016/j.stem.2017.01.008; Neves J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf3646; Neves J, 2015, DEV CELL, V32, P9, DOI 10.1016/j.devcel.2014.11.028; Okabe Y, 2016, NAT IMMUNOL, V17, P9, DOI 10.1038/ni.3320; Sousa-Victor P, 2019, NAT METAB, V1, P276, DOI 10.1038/s42255-018-0023-6	9	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 13	2020	367	6483					1205	1206		10.1126/science.aba6114	http://dx.doi.org/10.1126/science.aba6114			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KU9DP	32165578				2023-01-03	WOS:000520023800028
J	Pinato, DJ; Guerra, N; Fessas, P; Murphy, R; Mineo, T; Mauri, FA; Mukherjee, SK; Thursz, M; Wong, CN; Sharma, R; Rimassa, L				Pinato, David J.; Guerra, Nadia; Fessas, Petros; Murphy, Ravindhi; Mineo, Takashi; Mauri, Francesco A.; Mukherjee, Sujit K.; Thursz, Mark; Wong, Ching Ngar; Sharma, Rohini; Rimassa, Lorenza			Immune-based therapies for hepatocellular carcinoma	ONCOGENE			English	Review							REGULATORY T-CELLS; GROWTH-FACTOR-BETA; CHRONIC HEPATITIS-B; SUPPRESSOR-CELLS; DENDRITIC CELLS; TUMOR MICROENVIRONMENT; DOUBLE-BLIND; TGF-BETA; ADOPTIVE IMMUNOTHERAPY; LIVER-CANCER	Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.	[Pinato, David J.; Fessas, Petros; Murphy, Ravindhi; Mauri, Francesco A.; Wong, Ching Ngar; Sharma, Rohini] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London W12 0HS, England; [Guerra, Nadia] Imperial Coll London, Dept Life Sci, South Kensington Campus,Exhibit Rd, London SW7 2AZ, England; [Mineo, Takashi] Tokyo Med & Dent Univ, Tokyo, Japan; [Mukherjee, Sujit K.; Thursz, Mark] Imperial Coll London, Dept Metab Digest & Reprod, St Marys Hosp, Praed St, London, England; [Rimassa, Lorenza] Humanitas Clin & Res Ctr IRCCS, Med Oncol & Haematol Unit, Humanitas Canc Ctr, Via Manzoni 56, I-20089 Milan, Italy; [Rimassa, Lorenza] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini, I-20090 Milan, Italy	Imperial College London; Imperial College London; Tokyo Medical & Dental University (TMDU); Imperial College London; Humanitas University	Pinato, DJ (corresponding author), Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London W12 0HS, England.	david.pinato@imperial.ac.uk	Rimassa, Lorenza/N-4884-2016; Pinato, David James/ABB-3719-2020	Rimassa, Lorenza/0000-0001-9957-3615; Thursz, Mark/0000-0002-8218-192X; Mauri, Francesco/0000-0003-4818-8500; Pinato, David James/0000-0002-3529-0103	Wellcome Trust Strategic Fund [PS3416]; Cancer Research UK [C57701/A26137]; Wellcome Trust	Wellcome Trust Strategic Fund; Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)	The authors would like to acknowledge the infrastructure support provided by Imperial Experimental Cancer Medicine Centre, Cancer Research UK Imperial Centre. DJP is supported by grant funding from the Wellcome Trust Strategic Fund (PS3416) and Cancer Research UK for the immune phenotyping of HCC (Postdoctoral Bursary Grant Ref. C57701/A26137). SJM is funded by a Wellcome Trust Clinical Research Training Fellowship.	Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alissafi T, 2019, J AUTOIMMUN, V104, DOI 10.1016/j.jaut.2019.102310; An Y, 2018, WORLD J GASTROENTERO, V24, P2733, DOI 10.3748/wjg.v24.i25.2733; Anderson AC, 2014, CANCER IMMUNOL RES, V2, P393, DOI 10.1158/2326-6066.CIR-14-0039; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Ang Celina, 2019, Oncotarget, V10, P4018, DOI 10.18632/oncotarget.26998; Anguille S, 2015, PHARMACOL REV, V67, P731, DOI 10.1124/pr.114.009456; Arihara F, 2013, CANCER IMMUNOL IMMUN, V62, P1421, DOI 10.1007/s00262-013-1447-1; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Bertuccio P, 2017, J HEPATOL, V67, P302, DOI 10.1016/j.jhep.2017.03.011; Bilate AM, 2012, ANNU REV IMMUNOL, V30, P733, DOI 10.1146/annurev-immunol-020711-075043; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Buttner R, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2018-000442; Bunt SK, 2007, CANCER RES, V67, P10019, DOI 10.1158/0008-5472.CAN-07-2354; Butterfield LH, 2006, CLIN CANCER RES, V12, P2817, DOI 10.1158/1078-0432.CCR-05-2856; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; Chang H, 2017, APMIS, V125, P690, DOI 10.1111/apm.12703; Chen J, 2016, ANN ONCOL, V27, P409, DOI 10.1093/annonc/mdv615; Chen KJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024671; Chen YC, 2015, HEPATOLOGY, V61, P1591, DOI 10.1002/hep.27665; Chen YC, 2014, HEPATOLOGY, V59, P1435, DOI 10.1002/hep.26790; Cheng A.L., 2019, ANN ONCOL, V30, pix195, DOI 10.1093/annonc/mdz446; Chiou SH, 2005, J REPROD IMMUNOL, V67, P35, DOI 10.1016/j.jri.2005.06.002; Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007; Ding W, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013301; Dougall WC, 2017, IMMUNOL REV, V276, P112, DOI 10.1111/imr.12518; Duffy AG, 2017, J HEPATOL, V66, P545, DOI 10.1016/j.jhep.2016.10.029; Dunham RM, 2013, J IMMUNOL, V190, P2009, DOI 10.4049/jimmunol.1201937; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Fabregat I, 2016, FEBS J, V283, P2219, DOI 10.1111/febs.13665; Fang L, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0076-7; Finn RS, 2020, J CLIN ONCOL, V38, P193, DOI 10.1200/JCO.19.01307; Finn RS, 2018, J HEPATOL, V69, P353, DOI 10.1016/j.jhep.2018.04.010; Flynn MJ, 2019, HEPATOLOGY, V69, P2258, DOI 10.1002/hep.30337; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Gao XH, 2017, HEPATOL RES, V47, P1061, DOI 10.1111/hepr.12831; George B, 2016, J THORAC ONCOL, V11, pS211, DOI 10.1016/j.jtho.2016.08.068; Ghadially H, 2017, BRIT J CANCER, V116, P1208, DOI 10.1038/bjc.2017.79; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Greten TF, 2019, J HEPATOL, V70, P999, DOI 10.1016/j.jhep.2019.01.027; Greten TF, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-209; Grosso JF, 2007, J CLIN INVEST, V117, P3383, DOI 10.1172/JCI31184; Guerra N, 1999, EUR CYTOKINE NETW, V10, P357; Guillot A, 2019, HEPATOL COMMUN, V3, P730, DOI 10.1002/hep4.1356; Hammers HJ, 2017, J CLIN ONCOL, V35, P3851, DOI 10.1200/JCO.2016.72.1985; Harmon C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01502; Harmon C, 2016, EUR J IMMUNOL, V46, P2111, DOI 10.1002/eji.201646559; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Heymann F, 2016, NAT REV GASTRO HEPAT, V13, P88, DOI 10.1038/nrgastro.2015.200; Heymann F, 2015, HEPATOLOGY, V62, P279, DOI 10.1002/hep.27793; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; Hochst B, 2013, J HEPATOL, V59, P528, DOI 10.1016/j.jhep.2013.04.033; Hokuto D, 2015, EUR J CANCER, V51, P157, DOI 10.1016/j.ejca.2014.11.004; Hudspeth K, 2016, J AUTOIMMUN, V66, P40, DOI 10.1016/j.jaut.2015.08.011; Jiang JW, 2019, HEPATOB PANCREAT DIS, V18, P19, DOI 10.1016/j.hbpd.2018.11.002; Jiang ZW, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00690; Jiaqiang, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0814-7; Jinushi M, 2003, INT J CANCER, V104, P354, DOI 10.1002/ijc.10966; Jung HI, 2017, CANCER RES TREAT, V49, P246, DOI 10.4143/crt.2016.066; Kahraman A, 2010, HEPATOLOGY, V51, P92, DOI 10.1002/hep.23253; Kamimura H, 2012, J HEPATOL, V56, P381, DOI 10.1016/j.jhep.2011.06.017; Karkampouna S, 2012, CURR PHARM DESIGN, V18, P4103, DOI 10.2174/138161212802430521; Kelley RK, 2019, J CLIN ONCOL S15, V35, P4072; Kelly AM, 2006, CYTOKINE, V35, P171, DOI 10.1016/j.cyto.2006.07.019; Kennedy PTF, 2008, J VIRAL HEPATITIS, V15, P901, DOI 10.1111/j.1365-2893.2008.01049.x; Kim D, 2019, HEPATOLOGY, V69, P1064, DOI 10.1002/hep.30161; KNOLLE P, 1995, J HEPATOL, V22, P226, DOI 10.1016/0168-8278(95)80433-1; Knolle PA, 1998, CLIN EXP IMMUNOL, V114, P427; Knolle PA, 1999, J IMMUNOL, V162, P1401; Kuang DM, 2009, J EXP MED, V206, P1327, DOI 10.1084/jem.20082173; Kudo M, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4072; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Kudo M, 2017, LIVER CANCER, V6, P16, DOI 10.1159/000449343; Langhans B, 2019, CANCER IMMUNOL IMMUN, V68, P2055, DOI 10.1007/s00262-019-02427-4; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Larmonier N, 2007, CANCER IMMUNOL IMMUN, V56, P48, DOI 10.1007/s00262-006-0160-8; Lee JH, 2015, GASTROENTEROLOGY, V148, P1383, DOI 10.1053/j.gastro.2015.02.055; Lee WC, 2005, J IMMUNOTHER, V28, P496, DOI 10.1097/01.cji.0000171291.72039.e2; Li F, 2018, CANCER MANAG RES, V10, P941, DOI 10.2147/CMAR.S162478; Liao HT, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00883; Liao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060444; Liu XD, 2015, CANCER IMMUNOL RES, V3, P1017, DOI 10.1158/2326-6066.CIR-14-0244; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS4152; Lohitesh K, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0538-7; Lu LC, 2019, LIVER CANCER, V8, P110, DOI 10.1159/000489021; Ma J, 2016, ONCOTARGETS THER, V9, P183, DOI 10.2147/OTT.S96999; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Mazzaferro V, 2018, GASTROENTEROLOGY, V154, P128, DOI 10.1053/j.gastro.2017.09.025; Mehrfeld C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00635; Meyer T, 2017, LANCET GASTROENTEROL, V2, P565, DOI 10.1016/S2468-1253(17)30156-5; Michelet X, 2018, NAT IMMUNOL, V19, P1330, DOI 10.1038/s41590-018-0251-7; Mittal D, 2014, CURR OPIN IMMUNOL, V27, P16, DOI 10.1016/j.coi.2014.01.004; Mizukoshi E, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0742-5; Norris S, 1998, J HEPATOL, V28, P84, DOI 10.1016/S0168-8278(98)80206-7; Oliviero B, 2009, GASTROENTEROLOGY, V137, P1151, DOI 10.1053/j.gastro.2009.05.047; Palmer DH, 2009, HEPATOLOGY, V49, P124, DOI 10.1002/hep.22626; Pan ZY, 2018, CANCER IMMUNOL IMMUN, V67, P1621, DOI 10.1007/s00262-018-2221-1; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Patsoukis N, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002796; Pedroza-Gonzalez A, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008355; Pinato DJ, 2019, ANN ONCOL, V30, P288; Pinato DJ, 2019, BRIT J CANCER, V120, P1033, DOI 10.1038/s41416-019-0466-x; Pinato DJ, 2017, J HEPATOL, V66, P338, DOI 10.1016/j.jhep.2016.09.008; PISHVAIAN MJ, 2018, ANN ONCOL S8, V29, P718, DOI DOI 10.1093/ANNONC/MDY424.028; PISHVAIAN MJ, 2018, ANN ONCOL S8, V29; Prieto J, 2015, NAT REV GASTRO HEPAT, V12, P681, DOI 10.1038/nrgastro.2015.173; Qin SK, 2019, FUTURE ONCOL, V15, P1811, DOI 10.2217/fon-2019-0097; Qin SK., 2018, ANN ONCOL, V29, pVIII719, DOI [DOI 10.1093/ANNONC/MDY424.029, 10.1093/annonc/mdy424.029]; Ramjiawan RR, 2017, ANGIOGENESIS, V20, P185, DOI 10.1007/s10456-017-9552-y; Raulet DH, 2009, NAT REV IMMUNOL, V9, P568, DOI 10.1038/nri2604; Ren L, 2016, ONCOTARGET, V7, P75763, DOI 10.18632/oncotarget.12409; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sabado RL, 2017, CELL RES, V27, P74, DOI 10.1038/cr.2016.157; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Sanchez-Correa B, 2019, CANCERS, V11, DOI 10.3390/cancers11060877; Sangro B, 2013, J HEPATOL, V59, P81, DOI 10.1016/j.jhep.2013.02.022; Schaaf MB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0061-0; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Schildberg FA, 2011, HEPATOLOGY, V54, P1108, DOI 10.1002/hep.24565; Schildberg FA, 2011, HEPATOLOGY, V54, P262, DOI 10.1002/hep.24352; Schmidt N, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.954919; Shen H, 1998, CELL, V92, P535, DOI 10.1016/S0092-8674(00)80946-0; Sheppard S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01808; Shetty S, 2018, NAT REV GASTRO HEPAT, V15, P555, DOI 10.1038/s41575-018-0020-y; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Shi FD, 2011, NAT REV IMMUNOL, V11, P658, DOI 10.1038/nri3065; Shimizu K, 2014, HUM VACC IMMUNOTHER, V10, P970, DOI 10.4161/hv.27678; Sia D, 2017, GASTROENTEROLOGY, V153, P812, DOI 10.1053/j.gastro.2017.06.007; Stegmann KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep26157; Sun HY, 2019, HEPATOLOGY, V70, P168, DOI 10.1002/hep.30347; Tacke F, 2017, J HEPATOL, V66, P1300, DOI 10.1016/j.jhep.2017.02.026; Takayama T, 2000, LANCET, V356, P802, DOI 10.1016/S0140-6736(00)02654-4; Tauber Catrin, 2019, Oncotarget, V10, P5194, DOI 10.18632/oncotarget.27146; Thomas M, 2009, J GASTROENTEROL, V44, P136, DOI 10.1007/s00535-008-2252-z; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Tray N, 2018, CANCER IMMUNOL RES, V6, P1122, DOI 10.1158/2326-6066.CIR-18-0214; Ugel S, 2015, J CLIN INVEST, V125, P3365, DOI 10.1172/JCI80006; Unitt E, 2005, HEPATOLOGY, V41, P722, DOI 10.1002/hep.20644; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; van Montfoort N, 2018, CELL, V175, P1744, DOI 10.1016/j.cell.2018.10.028; Varchetta S, 2012, HEPATOLOGY, V56, P841, DOI 10.1002/hep.25723; Varol C, 2015, ANNU REV IMMUNOL, V33, P643, DOI 10.1146/annurev-immunol-032414-112220; Vey Norbert, 2018, Oncotarget, V9, P17675, DOI 10.18632/oncotarget.24832; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wada Y, 1998, HEPATOLOGY, V27, P407, DOI 10.1002/hep.510270214; Wainberg ZA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4071; Wang XC, 2019, J HEPATOL, V71, P731, DOI 10.1016/j.jhep.2019.05.015; Yamamoto H, 2000, INT J ONCOL, V16, P543; Yan J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058006; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Yau T, 2019, ANN ONCOL, V30, DOI DOI 10.1093/ANNONC/MDZ394.029; Yau T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4012; Yegin EG, 2016, HEPATOB PANCREAT DIS, V15, P234, DOI 10.1016/S1499-3872(16)60097-8; Yen C-J, 2017, ANN ONCOL, V28, piii54, DOI [DOI 10.1093/ANNONC/MDX261.139, 10.1093/annonc/mdx261.139]; Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347; Zhang C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09212-y; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033; Zhao F, 2012, J IMMUNOL, V188, P6055, DOI 10.4049/jimmunol.1102918; Zhao QY, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1254855; Zhao WX, 2011, INT J CANCER, V129, P2651, DOI 10.1002/ijc.25920; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035; Zheng Y, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0650-9; Zhou GY, 2017, GASTROENTEROLOGY, V153, P1107, DOI 10.1053/j.gastro.2017.06.017; Zhou YL, 2002, J IMMUNOTHER, V25, P289, DOI 10.1097/00002371-200207000-00001; Zhu AX, 2018, LANCET ONCOL, V19, P940, DOI 10.1016/S1470-2045(18)30351-6; Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061	171	99	105	6	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3620	3637		10.1038/s41388-020-1249-9	http://dx.doi.org/10.1038/s41388-020-1249-9		MAR 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157213	Green Published, hybrid			2023-01-03	WOS:000518886000005
J	Ikari, S; Lu, SL; Hao, FK; Imai, K; Araki, Y; Yamamoto, YH; Tsai, CY; Nishiyama, Y; Shitan, N; Yoshimori, T; Otomo, T; Noda, T				Ikari, Sumiko; Lu, Shiou-Ling; Hao, Feike; Imai, Kenta; Araki, Yasuhiro; Yamamoto, Yo-hei; Tsai, Chao-Yuan; Nishiyama, Yumi; Shitan, Nobukazu; Yoshimori, Tamotsu; Otomo, Takanobu; Noda, Takeshi			Starvation-induced autophagy via calcium-dependent TFEB dephosphorylation is suppressed by Shigyakusan	PLOS ONE			English	Article							TRADITIONAL CHINESE MEDICINE; CA2+; PROGRESSION; PROTEIN; RECRUITMENT; CALCINEURIN; DISSECTION; MATURATION; EFFECTORS; RECEPTOR	Kampo, a system of traditional Japanese therapy utilizing mixtures of herbal medicine, is widely accepted in the Japanese medical system. Kampo originated from traditional Chinese medicine, and was gradually adopted into a Japanese style. Although its effects on a variety of diseases are appreciated, the underlying mechanisms remain mostly unclear. Using a quantitative tf-LC3 system, we conducted a high-throughput screen of 128 kinds of Kampo to evaluate the effects on autophagy. The results revealed a suppressive effect of Shigyakusan/TJ-35 on autophagic activity. TJ-35 specifically suppressed dephosphorylation of ULK1 and TFEB, among several TORC1 substrates, in response to nutrient deprivation. TFEB was dephosphorylated by calcineurin in a Ca2+ dependent manner. Cytosolic Ca2+ concentration was increased in response to nutrient starvation, and TJ-35 suppressed this increase. Thus, TJ-35 prevents the starvation-induced Ca2+ increase, thereby suppressing induction of autophagy.	[Ikari, Sumiko; Noda, Takeshi] Osaka Univ, Ctr Frontier Oral Sci, Grad Sch Frontier Biosci, Suita, Osaka, Japan; [Lu, Shiou-Ling; Hao, Feike; Araki, Yasuhiro; Yamamoto, Yo-hei; Noda, Takeshi] Osaka Univ, Ctr Frontier Oral Sci, Grad Sch Dent, Suita, Osaka, Japan; [Hao, Feike] China Natl Res Inst Food & Fermentat Ind, Beijing, Peoples R China; [Imai, Kenta; Yoshimori, Tamotsu] Osaka Univ, Grad Sch Frontier Biosci, Dept Intracellular Membrane Dynam, Suita, Osaka, Japan; [Tsai, Chao-Yuan] Osaka Univ, Immunol Frontier Res Ctr, Lab Immune Regulat, Suita, Osaka, Japan; [Nishiyama, Yumi] Kobe Pharmaceut Univ, Med Bot Garden, Kobe, Hyogo, Japan; [Shitan, Nobukazu] Kobe Pharmaceut Univ, Lab Med Cell Biol, Kobe, Hyogo, Japan; [Otomo, Takanobu] Kawasaki Med Sch, Dept Mol & Genet Med, Ku Rashiki, Kurashiki, Okayama, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Kobe Pharmaceutical University; Kobe Pharmaceutical University; Kawasaki Medical School	Noda, T (corresponding author), Osaka Univ, Ctr Frontier Oral Sci, Grad Sch Frontier Biosci, Suita, Osaka, Japan.; Noda, T (corresponding author), Osaka Univ, Ctr Frontier Oral Sci, Grad Sch Dent, Suita, Osaka, Japan.	takenoda@dent.osaka-u.ac.jp	Noda, Takeshi/B-7240-2008	Noda, Takeshi/0000-0003-3581-7961	Tsumura CO. LTD.; Tsumura CO LTD	Tsumura CO. LTD.; Tsumura CO LTD(Tsumura & Company)	Takeshi NODA has received research grant from Tsumura CO. LTD. Tsumura CO LTD has no role in the study design; collection, analysis, and interpretation of data; writing of the paper; and decision to submit for publication.	Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Bloor S, 2010, P NATL ACAD SCI USA, V107, P6970, DOI 10.1073/pnas.0908536107; Chan EY, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.284pe51; Chang CM, 2019, MOL CELL, V73, P339, DOI 10.1016/j.molcel.2018.10.035; Decuypere JP, 2011, AUTOPHAGY, V7, P1472, DOI 10.4161/auto.7.12.17909; Decuypere JP, 2011, CELL CALCIUM, V50, P242, DOI 10.1016/j.ceca.2011.04.001; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Hagen BM, 2012, CELL CALCIUM, V52, P170, DOI 10.1016/j.ceca.2012.05.010; Hansen M, 2007, MOL CELL, V25, P193, DOI [10.1016/j.molcel.2006.12.009, DOI 10.1016/J.MOLCEL.2006.12.009]; Hao FK, 2018, J CELL SCI, V131, DOI 10.1242/jcs.208017; Hara T, 2007, J CELL BIOL, V9, P497; Hashimoto D, 2008, J CELL BIOL, V181, P1065, DOI 10.1083/jcb.200712156; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Kageyama S, 2011, MOL BIOL CELL, V22, P2290, DOI 10.1091/mbc.E10-11-0893; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Kimura S, 2009, METHOD ENZYMOL, V452, P1, DOI 10.1016/S0076-6879(08)03601-X; Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9; Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652; Lamark Trond, 2012, Int J Cell Biol, V2012, P736905, DOI 10.1155/2012/736905; Lippai M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/832704; Liu MJ, 2018, CANCER SCI, V109, P3055, DOI 10.1111/cas.13746; Luo T, 2016, AUTOPHAGY, V12, P1355, DOI 10.1080/15548627.2015.1034405; Martina JA, 2013, J CELL BIOL, V200, P475, DOI 10.1083/jcb.201209135; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; Medina DL, 2015, NAT CELL BIOL, V17, P288, DOI 10.1038/ncb3114; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2018, NAT CELL BIOL, V20, P521, DOI 10.1038/s41556-018-0092-5; Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004; Nakai J, 2001, NAT BIOTECHNOL, V19, P137, DOI 10.1038/84397; Noda T, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7030052; Ohta Y, 2006, PHYTOTHER RES, V20, P256, DOI 10.1002/ptr.1832; Oka T, 2002, BRIT J PHARMACOL, V135, P1959, DOI 10.1038/sj.bjp.0704662; Okubo Shinya, 2019, Medicines (Basel), V6, DOI 10.3390/medicines6020063; Pena-Llopis S, 2011, EMBO J, V30, P3242, DOI 10.1038/emboj.2011.257; Proikas-Cezanne T, 2015, J CELL SCI, V128, P207, DOI 10.1242/jcs.146258; Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; Takanashi K, 2019, PHAMACOLOGY, V99, P2017; Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Wang SF, 2016, J ETHNOPHARMACOL, V194, P861, DOI 10.1016/j.jep.2016.10.069; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; YOSHIKAWA T, 1991, J CLIN BIOCHEM NUTR, V10, P189; Yu R, 2006, J INT MED RES, V34, P231, DOI 10.1177/147323000603400301; Yusuf IH, 2017, EYE, V31, P828, DOI 10.1038/eye.2016.298; Zatloukal B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096690; Zhao YG, 2019, CURR OPIN CELL BIOL, V61, P117, DOI 10.1016/j.ceb.2019.08.003	51	7	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2020	15	3							e0230156	10.1371/journal.pone.0230156	http://dx.doi.org/10.1371/journal.pone.0230156			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8RK	32134989	gold, Green Published, Green Submitted			2023-01-03	WOS:000535265600069
J	Matthews, I; Duong, M; Parsons, VL; Nozad, B; Qizilbash, N; Patel, Y; Guimicheva, B				Matthews, Ian; Duong, Mai; Parsons, Victoria L.; Nozad, Bayad; Qizilbash, Nawab; Patel, Yash; Guimicheva, Boriana			Burden of disease from shingles and post-herpetic neuralgia in the over 80 year olds in the UK	PLOS ONE			English	Article							HERPES-ZOSTER; LONG-TERM; VACCINE; COST	Background The current UK vaccination programme for herpes zoster (HZ) excludes people aged >= 80 years. This study aimed to quantify the number of individuals >= 80 years who missed HZ vaccination and the consequent epidemiological and economic burden of HZ and post-herpetic neuralgia (PHN). Methods Immunocompetent individuals aged >= 80 years between 1st September 2013 and 31st December 2017 in the Clinical Practice Research Datalink were selected and linked to Hospital Episodes Statistics, where available. Rates of HZ and PHN and healthcare resource utilisation were investigated for the overall study population and by age group (80-84, 85-89, >= 90 years old) and the burden of HZ and PHN was projected to the UK population. Results 4,858 HZ episodes and 464 PHN cases were identified in 255,165 individuals over 576,421 person-years (PY). Rates of HZ and PHN were 8.43 (95% confidence interval [CI] 8.19-8.66) and 0.80 (0.73-0.87) per 1,000 PY respectively and lowest in those aged.90 (HZ rate 7.37/1,000 PY; PHN rate 0.56/1,000 PY). Within HZ episodes, 10.27% of GP visits, 5.82% of prescribed medications and 21.65% of hospitalisations were related to HZ/PHN. Median length of hospitalisation increased from 7.0 days for all-cause to 10.5 days for HZ/PHN related hospitalisations. Individuals >= 90 stayed in hospital a median of 3-4 days longer than younger groups. Approximately 2.23 million individuals in the UK missed HZ vaccination since 2013 (1.86 million had never been eligible and 365,000 lost eligibility for HZ vaccination), resulting in an estimated 43,149 HZ episodes. Conclusion This study highlights the impact of the 80-year upper age limit policy on the health system. Our study estimates that 2.23 million individuals in the UK may have lost the opportunity to be vaccinated and that their burden of HZ and PHN remains high, especially among the very elderly.	[Matthews, Ian; Patel, Yash; Guimicheva, Boriana] Merck Sharp & Dohme Ltd, Hoddesdon, Herts, England; [Duong, Mai; Parsons, Victoria L.; Qizilbash, Nawab] OXON Epidemiol, London, England; [Nozad, Bayad] Imperial Coll London, Dept Primary Care & Publ Hlth, London, England; [Qizilbash, Nawab] London Sch Hyg & Trop Med, London, England	Merck & Company; Imperial College London; University of London; London School of Hygiene & Tropical Medicine	Matthews, I (corresponding author), Merck Sharp & Dohme Ltd, Hoddesdon, Herts, England.	ian.matthews@merck.com		Matthews, Ian/0000-0001-6175-6512	Merck Sharp Dohme Ltd, UK	Merck Sharp Dohme Ltd, UK	This work was sponsored and funded by Merck Sharp & Dohme Ltd, UK. IM, BG and YP were employees of Merck Sharp & Dohme Ltd. BN received consultancy fees from Merck Sharp & Dohme Ltd, UK. MD, NQ and VP were employed by OXON Epidemiology Ltd which received funds from Merck Sharp & Dohme Ltd, UK to conduct the study. The funder provided support in the form of salaries for authors IM, BQ and YP and approved the study design for scientific integrity but did not have any additional role in the data collection and analysis, decision to publish or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Amirthalingam G, 2018, LANCET PUBLIC HEALTH, V3, pE82, DOI 10.1016/S2468-2667(17)30234-7; [Anonymous], 2010, STAT VAR HERP ZOST V; [Anonymous], 2017, GREAT BRIT MID POP E; Baxter R, 2018, AM J EPIDEMIOL, V187, P161, DOI 10.1093/aje/kwx245; Delgado-Rodriguez M, 2004, J EPIDEMIOL COMMUN H, V58, P635, DOI 10.1136/jech.2003.008466; Dworkin RH, 2007, CLIN INFECT DIS, V44, pS1, DOI 10.1086/510206; Gauthier A, 2009, EPIDEMIOL INFECT, V137, P38, DOI 10.1017/S0950268808000678; Harding DM., 2018, SHINGLES HERPES ZOST; Herrett E, 2015, INT J EPIDEMIOL, V44, P827, DOI 10.1093/ije/dyv098; HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106; Kawai K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004833; Lukas K, 2012, J PUBLIC HEALTH-HEID, V20, P441, DOI 10.1007/s10389-011-0481-8; Matthews I, 2018, VACCINE, V36, P7105, DOI 10.1016/j.vaccine.2018.08.037; National Institute for Health and Care Excellence (NICE), 2018, SHINGL; National Institute for Health and Care Excellence (NICE), 2017, POST NEUR; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Public Health England, 2018, HLTH PROTECTION REPO, V12; Sanah Y, 2017, UK TOWNSEND DEPRIVAT; Schmader K, 2007, CLIN GERIATR MED, V23, P615, DOI 10.1016/j.cger.2007.03.003; Schmidt-Ott R, 2018, J INFECTION, V76, P475, DOI 10.1016/j.jinf.2018.02.001; Serpell M, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-92; Tseng HF, 2016, J INFECT DIS, V213, P1872, DOI 10.1093/infdis/jiw047; van Hoek AJ, 2009, VACCINE, V27, P1454, DOI 10.1016/j.vaccine.2008.12.024; Walker JL, 2018, VACCINE, V36, P2371, DOI 10.1016/j.vaccine.2018.02.021; WELLER TH, 1983, NEW ENGL J MED, V309, P1362, DOI 10.1056/NEJM198312013092205; Zorzoli E, 2018, AGING CLIN EXP RES, V30, P693, DOI 10.1007/s40520-018-0956-3	26	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2020	15	2							e0229224	10.1371/journal.pone.0229224	http://dx.doi.org/10.1371/journal.pone.0229224			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8EV	32097441	Green Submitted, gold, Green Published			2023-01-03	WOS:000535232000023
J	Runge, M; Snow, RW; Molteni, F; Thawer, S; Mohamed, A; Mandike, R; Giorgi, E; Macharia, PM; Smith, TA; Lengeler, C; Pothin, E				Runge, Manuela; Snow, Robert W.; Molteni, Fabrizio; Thawer, Sumaiyya; Mohamed, Ally; Mandike, Renata; Giorgi, Emanuele; Macharia, Peter M.; Smith, Thomas A.; Lengeler, Christian; Pothin, Emilie			Simulating the council-specific impact of anti-malaria interventions: A tool to support malaria strategic planning in Tanzania	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; COST-EFFECTIVENESS ANALYSIS; ENTOMOLOGIC INOCULATION RATES; LASTING INSECTICIDAL NETS; CARE RESOURCE-ALLOCATION; VECTOR CONTROL; PREVENT MALARIA; TRANSMISSION; MODEL; ELIMINATION	Introduction The decision-making process for malaria control and elimination strategies has become more challenging. Interventions need to be targeted at council level to allow for changing malaria epidemiology and an increase in the number of possible interventions. Models of malaria dynamics can support this process by simulating potential impacts of multiple interventions in different settings and determining appropriate packages of interventions for meeting specific expected targets. Methods The OpenMalaria model of malaria dynamics was calibrated for all 184 councils in mainland Tanzania using data from malaria indicator surveys, school parasitaemia surveys, entomological surveillance, and vector control deployment data. The simulations were run for different transmission intensities per region and five interventions, currently or potentially included in the National Malaria Strategic Plan, individually and in combination. The simulated prevalences were fitted to council specific prevalences derived from geostatistical models to obtain council specific predictions of the prevalence and number of cases between 2017 and 2020. The predictions were used to evaluate in silico the feasibility of the national target of reaching a prevalence of below 1% by 2020, and to suggest alternative intervention stratifications for the country. Results The historical prevalence trend was fitted for each council with an agreement of 87% in 2016 (95%CI: 0.84-0.90) and an agreement of 90% for the historical trend (2003-2016) (95%CI: 0.87-0.93) The current national malaria strategy was expected to reduce the malaria prevalence between 2016 and 2020 on average by 23.8% (95% CI: 19.7%-27.9%) if current case management levels were maintained, and by 52.1% (95% CI: 48.8%-55.3%) if the case management were improved. Insecticide treated nets and case management were the most cost-effective interventions, expected to reduce the prevalence by 25.0% (95% CI: 19.7%-30.2) and to avert 37 million cases between 2017 and 2020. Mass drug administration was included in most councils in the stratification selected for meeting the national target at minimal costs, expected to reduce the prevalence by 77.5% (95%CI: 70.5%-84.5%) and to avert 102 million cases, with almost twice higher costs than those of the current national strategy. In summary, the model suggested that current interventions are not sufficient to reach the national aim of a prevalence of less than 1% by 2020 and a revised strategic plan needs to consider additional, more effective interventions, especially in high transmission areas and that the targets need to be revisited. Conclusion The methodology reported here is based on intensive interactions with the NMCP and provides a helpful tool for assessing the feasibility of country specific targets and for determining which intervention stratifications at sub-national level will have most impact. This country-led application could support strategic planning of malaria control in many other malaria endemic countries.	[Runge, Manuela; Molteni, Fabrizio; Thawer, Sumaiyya; Smith, Thomas A.; Lengeler, Christian; Pothin, Emilie] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Runge, Manuela; Smith, Thomas A.; Lengeler, Christian; Pothin, Emilie] Univ Basel, Basel, Switzerland; [Snow, Robert W.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England; [Snow, Robert W.; Macharia, Peter M.] Kenya Govt Med Res Ctr, Populat Hlth Unit, Wellcome Trust Res Programme, Nairobi, Kenya; [Molteni, Fabrizio; Thawer, Sumaiyya; Mohamed, Ally; Mandike, Renata] Natl Malaria Control Programme NMCP, Dar Es Salaam, Tanzania; [Giorgi, Emanuele] Univ Lancaster, Lancaster Med Sch, CHICAS, Lancaster, England; [Pothin, Emilie] Clinton Hlth Access Initiat, Boston, MA USA	University of Basel; Swiss Tropical & Public Health Institute; University of Basel; University of Oxford; Kenya Medical Research Institute; Lancaster University	Runge, M (corresponding author), Swiss Trop & Publ Hlth Inst, Basel, Switzerland.; Runge, M (corresponding author), Univ Basel, Basel, Switzerland.	manuela.runge@swisstph.ch	Macharia, Peter M/E-2255-2015; Runge, Manuela/AAV-5429-2021; Snow, Robert William/AFR-1436-2022; Macharia, Peter/I-3496-2019; Macharia, Peter M/GSJ-0206-2022; Smith, Thomas A./B-5569-2015	Macharia, Peter M/0000-0003-3410-1881; Runge, Manuela/0000-0001-9918-760X; Snow, Robert William/0000-0003-3725-6088; Macharia, Peter/0000-0003-3410-1881; Macharia, Peter M/0000-0003-3410-1881; Smith, Thomas A./0000-0002-3650-9381; Giorgi, Emanuele/0000-0003-0640-181X	Global Fund to Fight Aids, Tuberculosis and Malaria; Swiss Agency for Development and Cooperation; Swiss Tropical and Public Health Institute; Bill and Melinda Gates Foundation [OPP1032350]; Wellcome Trust [079080, 103602, 212176]; Medical Research Council [MR/M015297/1]; UK's Department for International Development [203155]; Initiative to Develop African Research Leaders Project [107769]; MRC [MR/M015297/1] Funding Source: UKRI	Global Fund to Fight Aids, Tuberculosis and Malaria; Swiss Agency for Development and Cooperation; Swiss Tropical and Public Health Institute; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK's Department for International Development; Initiative to Develop African Research Leaders Project; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funding was received for EP and MR from the Global Fund to Fight Aids, Tuberculosis and Malaria URL: https://www.theglobalfund.org/en/, the NETCELL Project funded by the Swiss Agency for Development and Cooperation URL: https://www.eda.admin.ch/sdc, and the Swiss Tropical and Public Health Institute URL https://www.swisstph.ch.TAS received funding from the Bill and Melinda Gates Foundation, project OPP1032350. RWS is supported as a Wellcome Trust Principal Fellow (#079080, 103602 and 212176) URL: https://wellcome.ac.uk/.EG was supported by an Medical Research Council Strategic Skills Fellowship in Biostatistics (MR/M015297/1) URL: https://mrc.ukri.org/.RWS also acknowledges support from the UK's Department for International Development under a project entitled Strengthening the Use of Data for Malaria Decision Making in Africa (Department for International Development Programme Code #203155) URL: https://www.gov.uk/government/organisations/department-for-internationaldevelopment.PMM acknowledges support for his PhD under the Initiative to Develop African Research Leaders Project (#107769) URL: https://ideal.kemri-wellcome.org/.	Ali AS, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1982-x; Alonso PL, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000403; [Anonymous], 2011, MAL RAP DIAGN TEST P; [Anonymous], 2016, TANZ DEM HLTH SURV M; [Anonymous], 2013, 2012 POPULATION HOUS; [Anonymous], 2011, TANZ DEM HLTH SURV 2; [Anonymous], 2014, MAL CONTR MAL EL MAN; Arifin SMN, 2016, SPATIAL AGENT BASED; Baidjoe AY, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1362-y; Beier JC, 1999, AM J TROP MED HYG, V61, P109, DOI 10.4269/ajtmh.1999.61.109; Bhatt S, 2015, ELIFE, V4, DOI 10.7554/eLife.09672; Brady OJ, 2017, LANCET GLOB HEALTH, V5, pE680, DOI [10.1016/s2214-109x(17)30220-6, 10.1016/S2214-109X(17)30220-6]; Brady OJ, 2016, T ROY SOC TROP MED H, V110, P107, DOI 10.1093/trstmh/trv113; Briet OJT, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-401; Briet OJT, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-77; Brooks A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032587; Celhay Olivier J, 2019, Wellcome Open Res, V4, P61, DOI 10.12688/wellcomeopenres.14770.2; Chaki PP, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-311; Chipeta M. G., 2019, Wellcome Open Research, V4, DOI 10.12688/wellcomeopenres.15193.2; Chitnis N, 2008, B MATH BIOL, V70, P1272, DOI 10.1007/s11538-008-9299-0; Chitnis N, 2012, B MATH BIOL, V74, P1098, DOI 10.1007/s11538-011-9710-0; Cibulskis RE, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0151-8; Cohen JM, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2106-3; Cohen JM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-122; Cotter C, 2013, LANCET, V382, P900, DOI 10.1016/S0140-6736(13)60310-4; Crowell V, 2012, EPIDEMICS-NETH, V4, P1, DOI 10.1016/j.epidem.2011.10.003; DIETZ K, 1974, B WORLD HEALTH ORGAN, V50, P347; Drakeley C, 2003, TROP MED INT HEALTH, V8, P767, DOI 10.1046/j.1365-3156.2003.01100.x; Elbasha EH, 2004, HEALTH ECON, V13, P21, DOI 10.1002/hec.793; Fillinger U, 2009, B WORLD HEALTH ORGAN, V87, P655, DOI 10.2471/BLT.08.055632; Galactionova K, 2017, VACCINE, V35, P53, DOI 10.1016/j.vaccine.2016.11.042; Galactionova K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127818; Gerardin J, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1903-z; Giorgi E, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2238-0; Goodman CA, 1999, LANCET, V354, P378, DOI 10.1016/S0140-6736(99)02141-8; Govella NJ, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-124; Griffin JT, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000324; Gu WD, 2003, T ROY SOC TROP MED H, V97, P43, DOI 10.1016/S0035-9203(03)90018-6; Haara FO, 2012, MATH ENTHUS, V9; Hamilton M, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1705-3; Hansen KS, 2012, INT HEALTH, V4, P38, DOI 10.1016/j.inhe.2011.10.001; Hay SI, 2008, LANCET INFECT DIS, V8, P369, DOI 10.1016/S1473-3099(08)70069-0; Jones AE, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-162; Kabula B, 2014, MED VET ENTOMOL, V28, P244, DOI 10.1111/mve.12036; Kabula Bilali, 2011, Tanzan J Health Res, V13, P319; Killeen GF, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000211; Killeen GF, 2000, AM J TROP MED HYG, V62, P535, DOI 10.4269/ajtmh.2000.62.535; Kim D, 2017, RISK ANAL, V37, P231, DOI 10.1111/risa.12606; Kisinza WN, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2087-2; Korenromp E, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1461-9; KRAMER K, 2017, MALARIA J, V16, DOI DOI 10.1186/S12936-017-192-0; Kramer K, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1902-0; Kramer RA, 2009, HEALTH POLICY, V92, P133, DOI 10.1016/j.healthpol.2009.02.011; Lalji S, 2016, GLOB HEALTH-SCI PRAC, V4, P251, DOI 10.9745/GHSP-D-16-00040; Laska EM, 1999, HEALTH ECON, V8, P171, DOI 10.1002/(SICI)1099-1050(199903)8:2<171::AID-HEC424>3.0.CO;2-E; Le Menach A, 2011, SCI REP-UK, V1, DOI 10.1038/srep00093; Lee BY, 2017, AM J TROP MED HYG, V96, P1430, DOI 10.4269/ajtmh.16-0744; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; Lindblade KA, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0554-1; Lwetoijera DW, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-331; Macharia PM, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2489-9; Mandal S, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-202; Maude RJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037166; Ministry of Health Community Development Gender Elderly and Children (MoHCDGEC) [Tanzania Mainland] Ministry of Health (MoH) [Zanzibar] National Bureau of Statistics (NBS) Office of the Chief Government Statistician (OCGS) ICF, 2017, TANZ MAL IND SURV 20; MoHCDGEC (Tanzania), 2017, REP MIDT REV NAT MAL; MOLINEAUX L, 1978, B WORLD HEALTH ORGAN, V56, P565; Moonen B, 2010, LANCET, V376, P1592, DOI 10.1016/S0140-6736(10)61269-X; Msellemu D, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1340-4; Mwangangi JM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-228; National Malaria Control Programme (NMCP), 2014, NAT MAL STRAT PLAN 2; National Malaria Control Programme (Tanzania) WHO Ifakara Health Institute KEMRI-Wellcome Trust (Kenya), 2013, EP PROF MAL ITS CONT, P152; Newby G, 2015, AM J TROP MED HYG, V93, P125, DOI 10.4269/ajtmh.14-0254; Nikolov M, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005192; Nkumama IN, 2017, TRENDS PARASITOL, V33, P128, DOI 10.1016/j.pt.2016.11.006; Ochomo EO, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-368; Oduro F, 2012, J MATH RES, V4, P22, DOI DOI 10.5539/JMR.V4N6P22; Oduro FT, 2015, INT J SCI TECHNOLEDG, V3; Okell LC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020179; Okosun KO, 2011, BIOSYSTEMS, V106, P136, DOI 10.1016/j.biosystems.2011.07.006; Okosun KO, 2013, BIOSYSTEMS, V111, P83, DOI 10.1016/j.biosystems.2012.09.008; Otieno G, 2016, MATHEMATICS-BASEL, V4, DOI 10.3390/math4010014; Patouillard E, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000176; Pemberton-Ross P, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2010-x; Penny MA, 2016, LANCET, V387, P367, DOI 10.1016/S0140-6736(15)00725-4; Penny MA, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0864-3; Plummer M., 2003, JAGS PROGRAM ANAL BA; PMI, 2018, MAL OP PLAN FY 2018; Poirot E, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008846.pub2; Protopopoff N, 2018, LANCET, V391, P1577, DOI [10.1016/S0140-6736(18)30427-6, 10.1016/s0140-6736(18)30427-6]; QGIS Development Team, 2016, QGIS GEOGR INF SYST; R-Core-Team, 2016, LANG ENV STAT COMP; RBM, 2010, MATH MOD SUPP MAL CO; Renggli S, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-85; Reynolds R, 2017, WEATHER, V72, P206, DOI 10.1002/wea.3022; Scott N, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2019-1; Silal SP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144990; Silal SP, 2019, WELLCOME OPEN RES, V4, P62, DOI DOI 10.12688/WELLC0ME0PENRES.14771.1; Smith NR, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2442-y; Smith T, 2008, PARASITOLOGY, V135, P1507, DOI 10.1017/S0031182008000371; Smith T, 2006, AM J TROP MED HYG, V75, P56, DOI 10.4269/ajtmh.2006.75.56; Snow RW, 2017, NATURE, V550, P515, DOI 10.1038/nature24059; Snow RW, 1996, PARASITOL TODAY, V12, P455, DOI 10.1016/S0169-4758(96)30032-X; Stelmach R, 2018, AM J TROP MED HYG, V99, P627, DOI 10.4269/ajtmh.17-0537; Stelmach Rachel, 2016, TANZANIA VECTOR CONT; Stuckey EM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107700; Stuckey EM, 2013, TRENDS PARASITOL, V29, P477, DOI 10.1016/j.pt.2013.08.001; Stuckey EM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-357; TACAIDS Zanzibar AIDS Commission (ZAC) National Bureau of Statistics (NBS) [Tanzania] MEA- SURE DHS Macro International Inc, 2008, TANZ HIV AIDS MAL IN; TACAIDS Zanzibar AIDS Commission (ZAC) National Bureau of Statistics (NBS) [Tanzania] Office of the Chief Government Statistician (OCGS) ICF International, 2013, TANZ HIV AIDS MAL IN; Tanzania National Bureau of Statistics, TANZ TOT POP DISTR R; Tatem AJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-287; Theiss-Nyland K, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1184-y; Tusting LS, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008923.pub2; Walker PGT, 2016, LANCET GLOB HEALTH, V4, pE474, DOI 10.1016/S2214-109X(16)30073-0; WHO, 2019, GUID MAL VECT CONTR, P171; WHO, 2018, WORLD MALARIA REPORT; WHO, 2015, GLOB TECHN STRAT MAL; WHO, 2017, COND US LONG LAST IN; WHO World Health Organization, 2019, HIGH BURDEN HIGH IMP; Winskill P, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2755-5; Winskill P, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000090; World Health Organization (WHO), 2011, FOC MAINL TANZ; Yukich JO, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2051-1; Yukich JO, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-258	124	14	14	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2020	15	2							e0228469	10.1371/journal.pone.0228469	http://dx.doi.org/10.1371/journal.pone.0228469			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8AS	32074112	Green Accepted, gold, Green Published			2023-01-03	WOS:000535220600014
J	Nyondo-Mipando, AL; Kinshella, MLW; Bohne, C; Suwedi-Kapesa, LC; Salimu, S; Banda, M; Newberry, L; Njirammadzi, J; Hiwa, T; Chiwaya, B; Chikoti, F; Vidler, M; Dube, Q; Molyneux, E; Mfutso-Bengo, J; Goldfarb, DM; Kawaza, K; Mijovic, H				Nyondo-Mipando, Alinane Linda; Kinshella, Mai-Lei Woo; Bohne, Christine; Suwedi-Kapesa, Leticia Chimwemwe; Salimu, Sangwani; Banda, Mwai; Newberry, Laura; Njirammadzi, Jenala; Hiwa, Tamanda; Chiwaya, Brandina; Chikoti, Felix; Vidler, Marianne; Dube, Queen; Molyneux, Elizabeth; Mfutso-Bengo, Joseph; Goldfarb, David M.; Kawaza, Kondwani; Mijovic, Hana			Barriers and enablers of implementing bubble Continuous Positive Airway Pressure (CPAP): Perspectives of health professionals in Malawi	PLOS ONE			English	Article							RESPIRATORY-DISTRESS; NURSES; COLLABORATION; PHYSICIANS; COUNTRIES; INFANTS	Background Preterm birth complications are the leading cause of neonatal deaths. Malawi has high rates of preterm birth, with 18.1 preterm births per 100 live births. More than 50% of preterm neonates develop respiratory distress which if left untreated, can lead to respiratory failure and death. Term and preterm neonates with respiratory distress can often be effectively managed with Continuous Positive Airway Pressure (CPAP) and this is considered an essential intervention for the management of preterm neonates by the World Health Organization. Bubble CPAP may represent a safe and cost-effective method for delivering CPAP in low-income settings. Objective The study explored the factors that influence the implementation of bubble CPAP among health care professionals in secondary and tertiary hospitals in Malawi. Methods This was a qualitative study conducted in three district hospitals and a tertiary hospital in southern Malawi. We conducted 46 in-depth interviews with nurses, clinicians and clinical supervisors, from June to August 2018. All data were digitally recorded, transcribed verbatim and thematically analyzed. Results Factors that influenced implementation of bubble CPAP occurred in an interconnected manner and included: inadequate healthcare provider training in preparation for use, rigid division of roles and responsibilities among providers, lack of effective communication among providers and between providers and newborn's caregivers, human resource constraints, and inadequate equipment and infrastructure. Conclusion There are provider, caregiver and health system level factors that influence the implementation of bubble CPAP among neonates in Malawian health facilities. Ensuring adequate staffing in the nurseries, combined with ongoing training for providers, team cohesion, improved communication with caregivers, and improved hospital infrastructure would ensure optimal utilization of bubble CPAP and avoid inadvertent harm from inappropriate use.	[Nyondo-Mipando, Alinane Linda; Mfutso-Bengo, Joseph] Univ Malawi, Coll Med, Sch Publ Hlth & Family Med, Dept Hlth Syst & Policy, Blantyre, Malawi; [Nyondo-Mipando, Alinane Linda; Newberry, Laura; Njirammadzi, Jenala; Hiwa, Tamanda; Chiwaya, Brandina; Chikoti, Felix; Dube, Queen; Molyneux, Elizabeth; Mfutso-Bengo, Joseph; Kawaza, Kondwani] Coll Med, IMCHA Project, Blantyre, Malawi; [Kinshella, Mai-Lei Woo; Vidler, Marianne] BC Childrens & Womens Hosp, Dept Obstet & Gynaecol, Vancouver, BC, Canada; [Kinshella, Mai-Lei Woo; Vidler, Marianne; Goldfarb, David M.; Mijovic, Hana] Univ British Columbia, Vancouver, BC, Canada; [Bohne, Christine] Rice Univ, Inst Global Hlth, NEST 360, Houston, TX USA; [Suwedi-Kapesa, Leticia Chimwemwe; Salimu, Sangwani; Banda, Mwai; Newberry, Laura; Njirammadzi, Jenala; Hiwa, Tamanda; Kawaza, Kondwani] Univ Malawi, Coll Med, Dept Pediat & Child Hlth, Blantyre, Malawi; [Dube, Queen; Molyneux, Elizabeth; Kawaza, Kondwani] Queen Elizabeth Cent Hosp, Pediat, Blantyre, Malawi; [Mfutso-Bengo, Joseph] Ctr Bioeth Eastern & Southern Africa CEBESA, Blantyre, Malawi; [Goldfarb, David M.] BC Childrens & Womens Hosp, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Mijovic, Hana] BC Childrens Hosp, Dept Pediat, Vancouver, BC, Canada	University of Malawi; University of Malawi; University of British Columbia; University of British Columbia; Rice University; University of Malawi; University of Malawi; University of British Columbia; BC Childrens Hospital; University of British Columbia	Nyondo-Mipando, AL (corresponding author), Univ Malawi, Coll Med, Sch Publ Hlth & Family Med, Dept Hlth Syst & Policy, Blantyre, Malawi.; Nyondo-Mipando, AL (corresponding author), Coll Med, IMCHA Project, Blantyre, Malawi.	lmipando@medcol.mw	Nyondo, Alinane/AFN-8844-2022; Kinshella, Mai-Lei Woo/AAA-8117-2022; Goldfarb, David/ABD-4623-2021	Nyondo, Alinane/0000-0002-3572-3810; Kinshella, Mai-Lei Woo/0000-0001-5846-3014; Mitchell, Hana/0000-0002-6324-0779; Bohne, Christine/0000-0001-8541-1324; Goldfarb, David/0000-0003-0835-9504; Vidler, Marianne/0000-0002-7633-8812	Canadian International Development Research Centre (IDRC); Global Affairs Canada (GAC); Canadian Institutes for Health Research (CIHR) [108030]	Canadian International Development Research Centre (IDRC); Global Affairs Canada (GAC)(CGIAR); Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	ALNM, KK, QD and DG were funded by the Canadian International Development Research Centre (IDRC), Global Affairs Canada (GAC) and the Canadian Institutes for Health Research (CIHR). Project ID is 108030. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal S., 2016, MOBILE TECHNOLOGY SU; Ajuwon A, 2018, MALAWI MED J, V30, P120, DOI 10.4314/mmj.v30i2.12; Amudha P., 2018, J NURSING CARE, V7, P1, DOI [10.4172/2167-1168.1000455, DOI 10.4172/2167-1168.1000455]; [Anonymous], 2018, LEVELS TRENDS CHILD; Asibon A, 2020, ACTA PAEDIATR, V109, P705, DOI 10.1111/apa.15025; Atreya MR, 2018, ADV NEONAT CARE, V18, P500, DOI 10.1097/ANC.0000000000000510; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Brown J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053622; Charmaz K., 2008, HDB CONSTRUCTIONIST, DOI DOI 10.1016/J.DESTUD.2004.08.003; Crehan C, 2018, ARCH DIS CHILD, V103, P732, DOI 10.1136/archdischild-2017-313867; Dewez JE, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1311-8; Dewez JE, 2017, TROP DOCT, V47, P19, DOI 10.1177/0049475516630210; Earns J, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-0668; Edwards MO, 2013, PAEDIATR RESPIR REV, V14, P29, DOI 10.1016/j.prrv.2012.02.002; Ekhaguere OA, 2019, PAEDIATR RESPIR REV, V29, P31, DOI 10.1016/j.prrv.2018.04.004; Fulton C, 2013, BMJ OPEN QUAL, V2; Gondwe MJ, 2017, MALAWI MED J, V29, P5, DOI 10.4314/mmj.v29i1.2; Hagbaghery Mohsen Adib, 2004, BMC Nurs, V3, P2, DOI 10.1186/1472-6955-3-2; Kallander K, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2130; Kawaza K, 2014, PLOS ONE JAN MALAWI, V299; Lancaster G, 2015, J NURS SCHOLARSHIP, V47, P275, DOI 10.1111/jnu.12130; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6; Martin S, 2014, ARCH DIS CHILD-FETAL, V99, pF495, DOI 10.1136/archdischild-2013-305519; McAdams RM, 2015, RESP CARE, V60, P437, DOI 10.4187/respcare.03438; McCallin A, 2009, WHAT IS GROUNDED THE; Ministry of Health and Population, 2017, HLTH SECT STRAT PLAN; Myhre J, 2016, J TROP PEDIATRICS, V62, P385, DOI 10.1093/tropej/fmw023; Nahimana E, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0449-x; Ntigurirwa P, 2017, GLOBALIZATION HEALTH, V13, DOI 10.1186/s12992-017-0252-6; O'Regan Stephanie, 2016, Adv Simul (Lond), V1, P4, DOI 10.1186/s41077-015-0004-8; Olayo B, 2019, PAEDIATR INT CHILD H, V39, P193, DOI 10.1080/20469047.2019.1624007; Patton M. Q, 2015, QUALITATIVE RES EVAL, V4th; Pfadenhauer LM, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0552-5; Schmalenberg C, 2009, CRIT CARE NURSE, V29, P74, DOI 10.4037/ccn2009436; Tang CJ, 2013, INT NURS REV, V60, P291, DOI 10.1111/inr.12034; Thukral A, 2016, J PERINATOL, V36, pS21, DOI 10.1038/jp.2016.29; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Van den Heuvel M, 2011, ANN TROP PAEDIATR, V31, P59, DOI 10.1179/1465328110Y.0000000001; Willemse Juliana J., 2015, Curationis, V38, P1, DOI [10.4102/CURATIONIS.v38i2.1512, 10.4102/curationis.v38i2.1512]	40	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2020	15	2							e0228915	10.1371/journal.pone.0228915	http://dx.doi.org/10.1371/journal.pone.0228915			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ7SH	32053649	Green Published, gold			2023-01-03	WOS:000535198700068
J	Zhou, QL; Potluri, M				Zhou, Qiaoling; Potluri, Madhu			A woman with acute dyspnoea	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HYDROTHORAX; MANAGEMENT		[Zhou, Qiaoling; Potluri, Madhu] Gloucestershire Royal Hosp NHS Fdn Trust, Gloucester, Glos, England	Gloucestershire Hospitals NHS Foundation Trust; Gloucestershire Royal Hospital	Zhou, QL (corresponding author), Gloucestershire Royal Hosp NHS Fdn Trust, Gloucester, Glos, England.	qz8028@bristol.ac.uk						Chow KM, 2003, SEMIN DIALYSIS, V16, P389, DOI 10.1046/j.1525-139X.2003.16080.x; Chow KM, 2002, PERITON DIALYSIS INT, V22, P525; Dube BP, 2016, J CLIN MED, V5, DOI 10.3390/jcm5120113; Leblanc M, 2001, SEMIN DIALYSIS, V14, P50, DOI 10.1046/j.1525-139x.2001.00014.x; Lew SQ, 2010, PERITON DIALYSIS INT, V30, P13, DOI 10.3747/pdi.2008.00168; Szeto CC, 2004, CURR OPIN PULM MED, V10, P315, DOI 10.1097/01.mcp.0000127901.60693.d0	6	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 30	2020	368								l6970	10.1136/bmj.l6970	http://dx.doi.org/10.1136/bmj.l6970			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH1EV	32001487				2023-01-03	WOS:000510390600001
J	Fretheim, H; Chung, BK; Didriksen, H; Baekkevold, ES; Midtvedt, O; Brunborg, C; Holm, K; Valeur, J; Tennoe, AH; Garen, T; Midtvedt, T; Troseid, M; Zare, H; Lund, MB; Hov, JR; Lundin, KEA; Molberg, O; Hoffmann-Vold, AM				Fretheim, Havard; Chung, Brian K.; Didriksen, Henriette; Baekkevold, Espen S.; Midtvedt, Oyvind; Brunborg, Cathrine; Holm, Kristian; Valeur, Jorgen; Tennoe, Anders Heiervang; Garen, Torhild; Midtvedt, Tore; Troseid, Marius; Zare, Hasse; Lund, May Brit; Hov, Johannes R.; Lundin, Knut E. A.; Molberg, Oyvind; Hoffmann-Vold, Anna-Maria			Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial	PLOS ONE			English	Article							DIARRHEA; DISEASE; DONOR	Objectives Systemic sclerosis (SSc) is an auto-immune, multi organ disease marked by severe gastrointestinal (GI) involvement and gut dysbiosis. Here, we aimed to determine the safety and efficacy of fecal microbiota transplantation (FMT) using commercially-available anaerobic cultivated human intestinal microbiota (ACHIM) in SSc. Methods Ten patients with SSc were randomized to ACHIM (n = 5) or placebo (n = 5) in a double-blind, placebo-controlled 16-week pilot. All patients had mild to severe upper and lower GI symptoms including diarrhea, distention/bloating and/or fecal incontinence at baseline. Gastroduodenoscopy transfer of ACHIM or placebo was performed at weeks 0 and 2. Primary endpoints were safety and clinical efficacy on GI symptoms assessed at weeks 4 and 16. Secondary endpoints included changes in relative abundance of total, immunoglobulin (Ig) A- and IgM-coated fecal bacteria measured by 16s rRNA sequencing. Results ACHIM side effects were mild and transient. Two placebo controls experienced procedure-related serious adverse events; one developed laryngospasms at week 0 gastroduodenoscopy necessitating study exclusion whilst one encountered duodenal perforation during gastroduodenoscopy at the last study visit (week 16). Decreased bloating, diarrhea and/or fecal incontinence was observed in four of five patients in the FMT group (week 4 or/and 16) and in two of four in the placebo group (week 4 or 16). Relative abundance, richness and diversity of total and IgA-coated and IgM-coated bacteria fluctuated more after FMT, than after placebo. Conclusions FMT of commercially-available ACHIM is associated with gastroduodenoscopy complications but reduces lower GI symptoms by possibly altering the gut microbiota in patients with SSc.	[Fretheim, Havard; Didriksen, Henriette; Midtvedt, Oyvind; Tennoe, Anders Heiervang; Garen, Torhild; Molberg, Oyvind; Hoffmann-Vold, Anna-Maria] Oslo Univ Hosp, Rikshosp, Dept Rheumatol, Oslo, Norway; [Fretheim, Havard; Chung, Brian K.; Didriksen, Henriette; Holm, Kristian; Tennoe, Anders Heiervang; Troseid, Marius; Lund, May Brit; Hov, Johannes R.; Molberg, Oyvind; Hoffmann-Vold, Anna-Maria] Univ Oslo, Rikshosp, Inst Clin Med, Oslo, Norway; [Didriksen, Henriette; Holm, Kristian; Hov, Johannes R.] Oslo Univ Hosp, Norwegian PSC Res Ctr, Dept Transplantat Med, Oslo, Norway; [Chung, Brian K.; Troseid, Marius; Hov, Johannes R.] Oslo Univ Hosp, Rikshosp, Res Inst Internal Med, Oslo, Norway; [Baekkevold, Espen S.] Oslo Univ Hosp, Dept Pathol, Oslo, Norway; [Baekkevold, Espen S.] Oslo Univ Hosp, Ctr Immune Regulat, Oslo, Norway; [Brunborg, Cathrine] Oslo Univ Hosp, Res Support Serv, Oslo Ctr Biostat & Epidemiol, Oslo, Norway; [Valeur, Jorgen] Lovisenberg Diaconal Hosp, Unger Vetlesen Inst, Oslo, Norway; [Valeur, Jorgen; Hov, Johannes R.; Lundin, Knut E. A.] Oslo Univ Hosp, Dept Gastroenterol, Oslo, Norway; [Midtvedt, Tore] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Troseid, Marius] Oslo Univ Hosp, Rikshosp, Sect Clin Immunol & Infect Dis, Oslo, Norway; [Zare, Hasse] Oslo Univ Hosp, Rikshosp, Clin Trial Unit, Oslo, Norway; [Lund, May Brit] Oslo Univ Hosp, Dept Resp Med, Oslo, Norway; [Lundin, Knut E. A.] Univ Oslo, KG Jebsen Ctr Coeliac Dis Res, Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; University of Oslo; University of Oslo; Karolinska Institutet; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo; University of Oslo	Hoffmann-Vold, AM (corresponding author), Oslo Univ Hosp, Rikshosp, Dept Rheumatol, Oslo, Norway.; Hoffmann-Vold, AM (corresponding author), Univ Oslo, Rikshosp, Inst Clin Med, Oslo, Norway.	a.m.hoffmann-vold@medisin.uio.no	Valeur, Jørgen/AGF-5332-2022; Lundin, Knut E. A./AAW-9519-2021; Valeur, Jørgen/AFU-6716-2022; Valeur, Jorgen/AEO-0359-2022	Valeur, Jørgen/0000-0001-7193-7069; Lundin, Knut E. A./0000-0003-1713-5545; Valeur, Jørgen/0000-0001-7193-7069; Fretheim, Havard/0000-0002-0350-172X	Norwegian Women's Public Health Association; South-Eastern Norway Regional Health Authority; "Functional Genomics" program of the Research Council of Norway; "Infrastructure" program of the Research Council of Norway; South Eastern Regional Health Authorities	Norwegian Women's Public Health Association; South-Eastern Norway Regional Health Authority; "Functional Genomics" program of the Research Council of Norway; "Infrastructure" program of the Research Council of Norway; South Eastern Regional Health Authorities	This work was supported by grants from the Norwegian Women's Public Health Association and the South-Eastern Norway Regional Health Authority. The funding sources were not involved in any part of the study design, collection of data, analysis, interpretation or writing of the report.; The sequencing service was provided by the Norwegian Sequencing Centre, a national technology platform hosted by the University of Oslo and supported by the "Functional Genomics" and "Infrastructure" programs of the Research Council of Norway and the South Eastern Regional Health Authorities. Analyses of fecal SCFA levels were performed at Unger-Vetlesen Institute by bioengineers Gunn Helen Malmstrom and Jennifer T. Fiennes.	Burrello C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07359-8; Denton CP, 2017, LANCET, V390, P1685, DOI 10.1016/S0140-6736(17)30933-9; Ebert EC, 2006, J CLIN GASTROENTEROL, V40, P769, DOI 10.1097/01.mcg.0000225549.19127.90; Emmanuel A, 2016, NAT REV GASTRO HEPAT, V13, P461, DOI 10.1038/nrgastro.2016.99; Goldblatt F, 2002, GASTROENTEROLOGY, V123, P1144, DOI 10.1053/gast.2002.36057; Gustafsson A, 1998, SCAND J GASTROENTERO, V33, P721; Haro C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154090; HENDEL L, 1992, ALIMENT PHARM THERAP, V6, P565; Jorup-Ronstrom C, 2012, SCAND J GASTROENTERO, V47, P548, DOI 10.3109/00365521.2012.672587; Juul FE, 2018, NEW ENGL J MED, V378, P2535, DOI 10.1056/NEJMc1803103; Kao D, 2017, JAMA-J AM MED ASSOC, V318, P1985, DOI 10.1001/jama.2017.17077; Kelly BJ, 2018, CHEST, V153, P266, DOI 10.1016/j.chest.2017.09.002; Khanna D, 2011, J RHEUMATOL, V38, P1920, DOI 10.3899/jrheum.110225; Khanna D, 2009, ARTHRIT RHEUM-ARTHR, V61, P1257, DOI 10.1002/art.24730; Kootte RS, 2017, CELL METAB, V26, P611, DOI 10.1016/j.cmet.2017.09.008; Leffler DA, 2015, NEW ENGL J MED, V372, P1539, DOI 10.1056/NEJMra1403772; Li SS, 2016, SCIENCE, V352, P586, DOI 10.1126/science.aad8852; Paramsothy S, 2017, LANCET, V389, P1218, DOI 10.1016/S0140-6736(17)30182-4; Thoua N. M., 2011, AM J GASTROENTEROL, V107, P597, DOI DOI 10.1038/AJG.2011.399; Thoua NM, 2010, RHEUMATOLOGY, V49, P1770, DOI 10.1093/rheumatology/keq147; van den Hoogen F, 2013, ARTHRITIS RHEUM-US, V65, P2737, DOI 10.1002/art.38098; VERNE GN, 1995, DIGEST DIS SCI, V40, P1892, DOI 10.1007/BF02208652; Volkmann ER, 2017, BMJ OPEN GASTROENTER, V4, DOI 10.1136/bmjgast-2017-000134; Volkmann ER, 2016, ARTHRITIS RHEUMATOL, V68, P1483, DOI 10.1002/art.39572; Wang SA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161174	25	27	28	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2020	15	5							e0232739	10.1371/journal.pone.0232739	http://dx.doi.org/10.1371/journal.pone.0232739			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1JI	32437393	gold, Green Published			2023-01-03	WOS:000537517800024
J	Santulli, G				Santulli, Gaetano			In acute HF, intensive and sustained vasodilation did not reduce a composite of death or HF readmission at 180 days	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Santulli, Gaetano] Montefiore Univ Hosp, Albert Einstein Coll Med, New York, NY USA; [Santulli, Gaetano] Univ Naples Federico II, Naples, Italy; [Santulli, Gaetano] ITME, Naples, Italy	Yeshiva University; University of Naples Federico II	Santulli, G (corresponding author), Montefiore Univ Hosp, Albert Einstein Coll Med, New York, NY USA.; Santulli, G (corresponding author), Univ Naples Federico II, Naples, Italy.; Santulli, G (corresponding author), ITME, Naples, Italy.		Santulli, Gaetano/I-9203-2016	Santulli, Gaetano/0000-0001-7231-375X				Chan NYK, 2012, CIRCULATION, V125, P298, DOI 10.1161/CIRCULATIONAHA.111.059097; Packer M, 2019, NEW ENGL J MED, V381, P776, DOI 10.1056/NEJMe1904713; Shiraishi Y, 2020, EUR HEART J-ACUTE CA, V9, P448, DOI 10.1177/2048872619891075	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 19	2020	172	10					JC54	JC54		10.7326/ACPJ202005190-054	http://dx.doi.org/10.7326/ACPJ202005190-054			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP8XQ	32422099				2023-01-03	WOS:000534600900006
J	Lenzo, V; Bordino, V; Bonanno, GA; Quattropani, MC				Lenzo, Vittorio; Bordino, Valentina; Bonanno, George A.; Quattropani, Maria C.			Understanding the role of regulatory flexibility and context sensitivity in preventing burnout in a palliative home care team	PLOS ONE			English	Article							SUPPRESS EMOTIONAL EXPRESSION; PSYCHOLOGICAL MORBIDITY; PERSONALITY-FACTORS; RESILIENCE; NURSES; CLINICIAN; HOSPICE; PREVALENCE; PROFESSIONALS; PREDICTORS	Although burnout syndrome has been investigated in depth, studies specifically focused on palliative home care are still limited. Moreover, there is still a lack of evidence regarding the interplay between emotional flexibility and sensitivity to context in preventing burnout in home care settings. For these reasons, the aims of this study were to examine burnout symptoms among practitioners specializing in palliative home care and to investigate the role of regulatory flexibility and sensitivity to context in understanding burnout. An exploratory cross-sectional design was adopted. A convenience sample (n = 65) of Italian specialist palliative care practitioners participated in this study. Participants were recruited between February and April 2019 from two palliative home care services that predominantly cared for end-of-life cancer patients. The Italian version of the Maslach Burnout Inventory (MBI), the Flexible Regulation of Emotional Expression (FREE) scale (a measure of emotional flexibility), and the Context Sensitivity Index (CSI) (a measure of sensitivity to context) were administered. Analyses of variance were conducted using the three MBI factors as dependent variables and profession as an independent variable. Subsequently, three identical analyses of covariance were conducted with age, work experience, flexibility and sensitivity to context as covariates. The results showed a low burnout risk for all three of the MBI factors, and there were no gender differences. An ANOVA revealed a significant effect of profession type and age on the emotional exhaustion factor of the MBI, and an ANCOVA indicated that these effects persisted after covariates were accounted for. The results also showed a significant effect of the FREE score on emotional exhaustion. These findings can help explain the differential contributions of profession type and age to the burnout symptoms investigated. In addition, the emotional flexibility component, as an aspect of resilience, represents a significant and specific factor of emotional exhaustion. Interventions to prevent burnout must consider these relationships.	[Lenzo, Vittorio; Quattropani, Maria C.] Univ Messina, Dept Clin & Expt Med, Messina, Italy; [Bordino, Valentina] Sisifo Consortium Social Cooperat, Palliat Home Care Serv, Catania, Italy; [Bonanno, George A.] Columbia Univ, Teachers Coll, New York, NY 10027 USA	University of Messina; Columbia University; Columbia University Teachers College	Lenzo, V (corresponding author), Univ Messina, Dept Clin & Expt Med, Messina, Italy.	vittorio.lenzo@unime.it	Quattropani, Maria C./G-3504-2015; Lenzo, Vittorio/C-9425-2017	Quattropani, Maria C./0000-0003-0711-6412; Lenzo, Vittorio/0000-0001-8391-5123				Ablett JR, 2007, PSYCHO-ONCOL, V16, P733, DOI 10.1002/pon.1130; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Ang SY, 2018, APPL NURS RES, V43, P105, DOI 10.1016/j.apnr.2018.07.007; Armon G, 2014, PERS INDIV DIFFER, V58, P112, DOI 10.1016/j.paid.2013.10.020; Armon G, 2012, J PERS, V80, P403, DOI 10.1111/j.1467-6494.2011.00731.x; Back AL, 2016, J PAIN SYMPTOM MANAG, V52, P284, DOI 10.1016/j.jpainsymman.2016.02.002; Birk JL, 2016, EMOTION, V16, P657, DOI 10.1037/emo0000157; Bonanno GA, 2004, PSYCHOL SCI, V15, P482, DOI 10.1111/j.0956-7976.2004.00705.x; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Bonanno GA, 2014, REGULATORY FLEXIBILI, DOI [10.1037/e530972014-001, DOI 10.1037/E530972014-001]; Bonanno GA, CONTEXT SENSITIVITY; Bonanno GA, 2020, ASSESSMENT, V27, P261, DOI 10.1177/1073191118820131; Bonanno GA, 2013, PERSPECT PSYCHOL SCI, V8, P591, DOI 10.1177/1745691613504116; Brewer E., 2004, HUMAN RESOURCE DEV R, V3, P102, DOI [10.1177/1534484304263335, DOI 10.1177/1534484304263335]; Bujang A.M, 2017, EPIDEMIOL BIOSTAT PU, V14, P1, DOI [10.2427/12117, 10.2427/12267]; Burns KEA, 2019, CAN J ANESTH, V66, P503, DOI 10.1007/s12630-019-01321-y; Burton CL, 2016, PSYCHOL ASSESSMENT, V28, P929, DOI 10.1037/pas0000231; Cherny N., 2015, OXFORD TXB PALLIATIV, Vfifth, DOI [10.1093/med/9780199656097.001.0001, DOI 10.1093/MED/9780199656097.001.0001]; Cohen J., 2013, STAT POWER ANAL BEHA; De la Fuente-Solana EI, 2017, EUR J ONCOL NURS, V30, P91, DOI 10.1016/j.ejon.2017.08.004; Dreano-Hartz S, 2016, PALLIAT SUPPORT CARE, V14, P402, DOI 10.1017/S1478951515000991; Dunwoodie DA, 2007, INTERN MED J, V37, P693, DOI 10.1111/j.1445-5994.2007.01384.x; Dyrbye LN, 2010, MED EDUC, V44, P1016, DOI 10.1111/j.1365-2923.2010.03754.x; Faul F., 1992, GPOWER PRIORI POSTHO; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Gama G, 2014, EUR J ONCOL NURS, V18, P527, DOI 10.1016/j.ejon.2014.04.005; Gerhart J, 2016, J CONTEXT BEHAV SCI, V5, P89, DOI 10.1016/j.jcbs.2016.04.003; Gupta S, 2011, J ABNORM PSYCHOL, V120, P635, DOI 10.1037/a0023541; Harrison KL, 2017, J PAIN SYMPTOM MANAG, V53, P1091, DOI 10.1016/j.jpainsymman.2017.01.007; Kamal AH, 2016, J PAIN SYMPTOM MANAG, V51, P690, DOI 10.1016/j.jpainsymman.2015.10.020; Kavalieratos D, 2016, J PAIN SYMPTOM MANAG, V51, P404, DOI 10.1016/j.jpainsymman.2015.12.299; Kelly EP, 2019, EUR J CANCER CARE, V28, DOI 10.1111/ecc.12981; Koh MYH, 2015, PALLIATIVE MED, V29, P633, DOI 10.1177/0269216315575850; Lapa TA, 2017, EUR J ANAESTH, V34, P41, DOI 10.1097/EJA.0000000000000500; Lenzo V, 2020, MINERVA PSICH, V61, P10, DOI 10.23736/S0391-1772.19.02033-8; Lenzo V, 2016, EUR PROC SOC BEHAV, V9, P1, DOI 10.15405/epsbs.2016.05.02.1; Levy-Gigi E, 2016, STRESS, V19, P1, DOI 10.3109/10253890.2015.1113523; Garcia GM, 2012, INT NURS REV, V59, P101, DOI 10.1111/j.1466-7657.2011.00927.x; Marchalik D, 2019, ANN PALLIAT MED, V8, P428, DOI 10.21037/apm.2019.05.02; Masel EK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158830; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; MASLACH C, 1981, J OCCUP BEHAV, V2, P99, DOI 10.1002/job.4030020205; Maslach C., 1981, MASLACH BURNOUT INVE; McGreevy CA, 2015, PERS INDIV DIFFER, V85, P93, DOI 10.1016/j.paid.2015.04.033; O'Connor K, 2018, EUR PSYCHIAT, V53, P74, DOI 10.1016/j.eurpsy.2018.06.003; Ostacoli L, 2010, PALLIAT SUPPORT CARE, V8, P427, DOI 10.1017/S1478951510000295; Parola Vitor, 2016, JBI Database System Rev Implement Rep, V14, P45, DOI 10.11124/JBISRIR-2016-2633; Picione RD, 2017, J CONSTR PSYCHOL, V30, P339, DOI 10.1080/10720537.2016.1227738; Purvanova RK, 2010, J VOCAT BEHAV, V77, P168, DOI 10.1016/j.jvb.2010.04.006; Quattropani MC, 2017, PSICOLOGIA SALUTE, P121, DOI [10.3280/pds2017-002006, DOI 10.3280/PDS2017-002006]; Rizo-Baeza M, 2018, J NURS MANAGE, V26, P19, DOI 10.1111/jonm.12506; Rotenstein LS, 2018, JAMA-J AM MED ASSOC, V320, P1131, DOI 10.1001/jama.2018.12777; Rugnone L, 2017, WORLD FUTURES, V73, P353, DOI DOI 10.1080/02604027.2017.1333872; Rushton CH, 2015, AM J CRIT CARE, V24, P412, DOI 10.4037/ajcc2015291; Shanafelt TD, 2009, ANN SURG, V250, P463, DOI 10.1097/SLA.0b013e3181ac4dfd; Sirigatti S., 1993, ADAPTATION ADJUSTMEN; Southwick SM, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.25338; Steven B, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210325; Swider BW, 2010, J VOCAT BEHAV, V76, P487, DOI 10.1016/j.jvb.2010.01.003; Tabachnick B. G., 2007, USING MULTIVARIATE S, Vfifth; Wallace JE, 2009, LANCET, V374, P1714, DOI 10.1016/S0140-6736(09)61424-0; West CP, 2016, LANCET, V388, P2272, DOI 10.1016/S0140-6736(16)31279-X; World Health Organization, 2004, PALL CAR SOL FACTS	64	12	12	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2020	15	5							e0233173	10.1371/journal.pone.0233173	http://dx.doi.org/10.1371/journal.pone.0233173			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU1CK	32421730	Green Published, gold			2023-01-03	WOS:000537499600032
J	Sauini, T; da Fonseca-Kruel, VS; Yazbek, PB; Matta, P; Cassas, F; da Cruz, C; Barretto, EHP; dos Santos, MA; Gomes, MAS; Garcia, RJF; Honda, S; Passero, LFD; Conde, BE; Rodrigues, E				Sauini, Thamara; da Fonseca-Kruel, Viviane Stern; Yazbek, Priscila Baptistela; Matta, Priscila; Cassas, Fernando; da Cruz, Crenilda; Pereira Barretto, Eduardo Hortal; dos Santos, Maria Alice; Silva Gomes, Maria Angelica; Francischetti Garcia, Ricardo Jose; Honda, Sumiko; Domingues Passero, Luiz Felipe; Conde, Bruno Esteves; Rodrigues, Eliana			Participatory methods on the recording of traditional knowledge about medicinal plants in Atlantic forest, Ubatuba, Sao Paulo, Brazil	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; COMMUNITY; CONSERVATION; ETHNOBIOLOGY; ETHNOBOTANY; REGION; RIVER	Introduction Ethnobotanical studies that include participatory methods aim to engage residents in different steps to promote the strengthening and perpetuation of local culture, and empowerment in making decisions about the use of available environmental resources. Thus, the aim of this project was to perform an ethnobotanical survey based on traditional knowledge of medicinal plants with the active participation of residents living in Bairro do Cambury, Ubatuba, Sao Paulo State, Brazil. Materials and methods During meetings held between the researchers and community members, locally used plants were regarded as an important means for preserving local knowledge for future generations. Some residents showed interest in participating as local partners, and training courses for collecting ethnobotanical data were offered. Local partners and researchers from Sao Paulo Federal University (Universidade Federal de Sao Paulo) utilized ethnobotanical methods to select and interview the specialists in medicinal plants for 80 days between 2016 and 2018. Data on plant use were recorded, and plants were collected and deposited in two herbaria. Furthermore, participant observation and fieldwork diaries were used by the researchers, aiding the data analysis. Results Three local partners participated in objective definitions, data collection, analysis and publication. Nine local specialists were interviewed by the local partners and indicated the use of 82 plant species in 90 recipes for 55 therapeutic uses. These uses were grouped into 12 categories. In addition, a video and booklet were created. Conclusions Data obtained during participatory research show that training local communities in the registration of their own knowledge is feasible and necessary since they register knowledge based on local perceptions, as well as valuing knowledge and approaching the current discussion about intellectual property is a global concern.	[Sauini, Thamara; Yazbek, Priscila Baptistela; Cassas, Fernando; Conde, Bruno Esteves; Rodrigues, Eliana] Univ Fed Sao Paulo, UNIFESP, Ctr Ethnobot & Ethnopharmacol Studies CEE, Dept Environm Sci, Sao Paulo, Brazil; [da Fonseca-Kruel, Viviane Stern] Inst Pesquisas Jardim Bot Rio de Janeiro, Rio De Janeiro, Brazil; [Matta, Priscila] Univ Sao Paulo CEstA USP, Amerindian Studies Ctr, Sao Paulo, Brazil; [da Cruz, Crenilda; dos Santos, Maria Alice; Silva Gomes, Maria Angelica] Assoc Remanescentes Quilombo Cambury, Ubatuba, SP, Brazil; [Pereira Barretto, Eduardo Hortal; Francischetti Garcia, Ricardo Jose; Honda, Sumiko] Secretaria Municipal Verde Meio Ambiente Prefeitu, Herbario Municipal PMSP, Sao Paulo, Brazil; [Domingues Passero, Luiz Felipe] Sao Paulo State Univ, UNESP, Inst Biosci, Sao Vicente, SP, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Jardim Botanico do Rio de Janeiro; Universidade Estadual Paulista	Sauini, T (corresponding author), Univ Fed Sao Paulo, UNIFESP, Ctr Ethnobot & Ethnopharmacol Studies CEE, Dept Environm Sci, Sao Paulo, Brazil.	tha.sauini@gamil.com	Cassas, Fernando/AAM-5743-2020; Rodrigues, Eliana/B-5839-2013; Passero, Luiz Felipe D/B-9549-2012	Cassas, Fernando/0000-0002-5923-9919; Rodrigues, Eliana/0000-0001-8847-6676; Passero, Luiz Felipe D/0000-0002-5986-6381; Reis, AlessanRSS/0000-0001-8486-7469	FAPESP BIOTA PROGRAM [2015/120460]; CNPq -Universal 2016 [400802/2016-3]	FAPESP BIOTA PROGRAM(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq -Universal 2016	The research was funded by FAPESP BIOTA PROGRAM (process number 2015/120460) and CNPq -Universal 2016 (process number 400802/2016-3) to ER.	Alexiades MN., 1996, SELECTED GUIDELINES; AMOROZO M C D M, 1988, Boletim do Museu Paraense Emilio Goeldi Serie Botanica, V4, P47; [Anonymous], 2013, LIVRO VERMELHO FLORA; Barroso RM, 2010, ACTA BOT BRAS, V24, P518, DOI 10.1590/S0102-33062010000200022; Begossi A, 2002, HUM ECOL, V30, P281, DOI 10.1023/A:1016564217719; Beltreschi L, 2019, ENVIRON DEV SUSTAIN, V21, P1185, DOI 10.1007/s10668-017-0079-6; Bernard H.R., 1988, RES METHODS CULTURAL; CFCBR Almeida, 2002, INTERCIENCIA, V27, P276; Cunninghan AB, 2001, CONSERVATION MANUAL; Albuquerque UP, 2009, BIODIVERS CONSERV, V18, P127, DOI 10.1007/s10531-008-9463-8; de Santana BF, 2016, J ETHNOPHARMACOL, V181, P37, DOI 10.1016/j.jep.2016.01.014; Ericson JA, 2006, LANDSCAPE URBAN PLAN, V74, P242, DOI 10.1016/j.landurbplan.2004.09.006; Etkin NL, 2005, INTEGRATING ETHNOGRA, P1; Garcia D, 2010, J ETHNOBIOL ETHNOMED, V6, DOI 10.1186/1746-4269-6-29; GARLET T. M. B., 2001, REV BRAS PLANTAS MED, V4, P9; Gilmore MP, 2012, J ETHNOBIOL, V32, P6, DOI 10.2993/0278-0771-32.1.6; Goebel A, 1998, DEV CHANGE, V29, P277, DOI 10.1111/1467-7660.00079; Gomes TB, 2012, ACTA BOT BRAS, V26, P796, DOI 10.1590/S0102-33062012000400009; Grasser S, 2016, J ETHNOBIOL ETHNOMED, V12, DOI 10.1186/s13002-016-0119-6; Hitziger M, 2016, J ETHNOPHARMACOL, V186, P61, DOI 10.1016/j.jep.2016.03.040; Hunn Eugene, 2007, Journal of Ethnobiology, V27, P1, DOI 10.2993/0278-0771(2007)27[1:EIFP]2.0.CO;2; INPE, 2018, ATL REM FLOR MAT ATL; Johnson N, 2004, NAT RESOUR FORUM, V28, P189, DOI 10.1111/j.1477-8947.2004.00088.x; Jovchelevich P, 2008, REV BRAS AGROECOL, V3, P1; Kalibo HW, 2007, LANDSCAPE URBAN PLAN, V82, P145, DOI 10.1016/j.landurbplan.2007.02.005; Kawa NC, 2016, CULT AGRIC FOOD ENVI, V38, P84, DOI 10.1111/cuag.12073; Santos JDL, 2012, J ETHNOPHARMACOL, V142, P503, DOI 10.1016/j.jep.2012.05.027; Malinowski B, 1990, DESVENDANDO MASCARAS, P39; Medley KE, 2005, FIELD METHOD, V17, P302, DOI [10.1177/1525822X05277462, DOI 10.1177/1525822X05277462]; Merzouki A, 2000, FITOTERAPIA, V71, P278, DOI 10.1016/S0367-326X(00)00139-8; Moreira FR, 2017, REV BRAS CIENC, V5, P5; Mosse D., 2001, Participation: the new tyranny?, P16; Neto F.R.G, 2014, Rev. bras. plantas med., V16, P856, DOI 10.1590/1983-084X/11_207; O PAULO, 2002, REL TECN CIENT REM C; Oliveira L.R., 2015, REV VERDE AGROECOLOG, V10, P25, DOI [10.18378/rvads.v10i3.3408, DOI 10.18378/RVADS.V10I3.3408]; Paniagua-Zambrana NY, 2018, J ETHNOBIOL ETHNOMED, V9, P14; Pinto Erika de Paula Pedro, 2006, Acta Bot. Bras., V20, P751, DOI 10.1590/S0102-33062006000400001; Rego C.A.R.M., 2016, ACTA AGRON, V65, P284, DOI [10.15446/acag.v65n3.50240, DOI 10.15446/ACAG.V65N3.50240]; Rodrigues E, 2005, PHYTOTHER RES, V19, P129, DOI 10.1002/ptr.1636; Rodrigues E, 2004, PHYTOTHER RES, V18, P748, DOI 10.1002/ptr.1535; Rodrigues E, 2006, PHYTOTHER RES, V20, P378, DOI 10.1002/ptr.1866; Gazzaneo LRS, 2005, J ETHNOBIOL ETHNOMED, V1, DOI 10.1186/1746-4269-1-9; Schultes R.E, 2008, ETHNOBOTANY EVOLUTIO; Crepaldi MOS, 2010, BIODIVERS CONSERV, V19, P37, DOI 10.1007/s10531-009-9700-9; Silva N.C.B., 2012, B LATINOAM CARIBE PL, V11, P435; Stepp J.R., 2005, FIELD METHOD, V17, P211, DOI [10.1177/1525822X05277459, DOI 10.1177/1525822X05277459]; Tribess B, 2015, J ETHNOPHARMACOL, V164, P136, DOI 10.1016/j.jep.2015.02.005; Tuler AC, 2011, LEVANTAMENTO ETNOBOT; Voeks RA, 1996, ECON BOT, V50, P381, DOI 10.1007/BF02866520; Wolverton S, 2013, ETHNOBIOL LETT, V4, P21; Yazbek PB, 2019, J ETHNOPHARMACOL, V244, DOI 10.1016/j.jep.2019.112123; Zank S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174731	52	3	3	4	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2020	15	5							e0232288	10.1371/journal.pone.0232288	http://dx.doi.org/10.1371/journal.pone.0232288			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LT7ZX	32379779	Green Published, gold			2023-01-03	WOS:000537285700029
J	Gruber, MT; Witte, OW; Grosskreutz, J; Prell, T				Gruber, Maria Theresa; Witte, Otto W.; Grosskreutz, Julian; Prell, Tino			Association between malnutrition, clinical parameters and health-related quality of life in elderly hospitalized patients with Parkinson's disease: A cross-sectional study	PLOS ONE			English	Article							MINI-NUTRITIONAL ASSESSMENT; NONMOTOR SYMPTOMS; CHINESE PATIENTS; THE-LITERATURE; PREVALENCE; COGNITION; WEIGHT; IMPACT; RISK; TOOL	Objective This study aimed to explore the association between malnutrition, clinical parameters, and health-related quality of life in elderly hospitalized patients with Parkinson's disease (PD). Methods Cross-sectional study of 92 hospitalized elderly patients with PD (mean age 73.6 +/- 6.7 years) without dementia. The Mini Nutritional Assessment (MNA) was used to evaluate nutritional status. Motor impairment and non-motor symptoms burden (Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale [MDSUPDRS], Non-Motor Symptoms Questionnaire, and Hoehn & Yahr staging), depression (Becks Depression Inventory-II), and health-related quality of life (PD quality of life Questionnaire-39) were assessed. Results Every second patient was malnourished or at risk of malnutrition. In the multivariable analysis, male gender, longer disease duration, higher Hoehn & Yahr and depression were associated with total MNA score. Besides non-motor symptoms and motor impairment, malnutrition was an independent predictor of poor health-related quality of life. In the multivariate analysis, malnutrition had a statistically significant effect on emotional well-being, mobility, social support, stigmatization, and cognition. The strongest association was found between malnutrition and emotional well-being. Conclusion Elderly male persons with longer PD duration and higher disease stages are more likely to be malnourished or at risk for malnutrition. Malnutrition was mainly associated with poor emotional well-being, suggesting that treatment of depression and anxiety beside diet and physical activity can help improving nutrition status in these subjects. The MNA should not be used independent of other measures of cognition and depression in people with advanced PD.	[Gruber, Maria Theresa; Witte, Otto W.; Grosskreutz, Julian; Prell, Tino] Jena Univ Hosp, Dept Neurol, Jena, Germany; [Witte, Otto W.; Grosskreutz, Julian; Prell, Tino] Jena Univ Hosp, Ctr Hlth Ageing, Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Prell, T (corresponding author), Jena Univ Hosp, Dept Neurol, Jena, Germany.; Prell, T (corresponding author), Jena Univ Hosp, Ctr Hlth Ageing, Jena, Germany.	Tino.prell@med.uni-jena.de	Prell, Tino/AAE-5492-2020; Grosskreutz, Julian/G-2293-2010	Prell, Tino/0000-0002-6423-3108; Grosskreutz, Julian/0000-0001-9525-1424				Abd Aziz NAS, 2017, CLIN INTERV AGING, V12, P1615, DOI 10.2147/CIA.S140859; Ayers E, 2014, P NUTR SOC, V73, P302, DOI 10.1017/S0029665113003716; Cereda E, 2012, CURR OPIN CLIN NUTR, V15, P29, DOI 10.1097/MCO.0b013e32834d7647; Chen HL, 2003, ANN NEUROL, V53, P676, DOI 10.1002/ana.10577; Christner S, 2016, J HUM NUTR DIET, V29, P704, DOI 10.1111/jhn.12376; Fereshtehnejad SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091153; Ghimire S, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0881-5; Guigoz Y, 2006, J NUTR HEALTH AGING, V10, P466; Harris D, 2005, J ROY SOC MED, V98, P411, DOI 10.1258/jrsm.98.9.411; Jensen G, 2006, J NUTR HEALTH AGING, V10, P485; Johansson Y, 2009, J CLIN NURS, V18, P1354, DOI 10.1111/j.1365-2702.2008.02552.x; Jones JD, 2014, PARKINSONISM RELAT D, V20, P1236, DOI 10.1016/j.parkreldis.2014.09.014; Kaiser MJ, 2009, J NUTR HEALTH AGING, V13, P782, DOI 10.1007/s12603-009-0214-7; Kim SR, 2016, INT J NURS PRACT, V22, P129, DOI 10.1111/ijn.12377; Li HJ, 2010, MOVEMENT DISORD, V25, P2740, DOI 10.1002/mds.23368; Ma K, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00001; Malkki Hemi, 2013, Nat Rev Neurol, V9, P544, DOI 10.1038/nrneurol.2013.176; Martinez-Garcia PM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136101; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Ongun N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205100; Palhagen S, 2005, ACTA NEUROL SCAND, V111, P12, DOI 10.1111/j.1600-0404.2004.00364.x; Pilhatsch M, 2013, J NERV MENT DIS, V201, P76, DOI 10.1097/NMD.0b013e31827ab2cc; Pourhassan M, 2018, CLIN NUTR ESPEN, V27, P100, DOI 10.1016/j.clnesp.2018.05.013; Prell T, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00080; Richter D, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020151; Santos-Garcia D, 2013, J NEUROL SCI, V332, P136, DOI 10.1016/j.jns.2013.07.005; Sheard JM, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0212-1; Sheard JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057986; Sheard JM, 2011, NUTR REV, V69, P520, DOI 10.1111/j.1753-4887.2011.00413.x; Tomic S, 2017, J NEUROL SCI, V375, P235, DOI 10.1016/j.jns.2017.01.070; Tomic S, 2017, ACTA NEUROL BELG, V117, P207, DOI 10.1007/s13760-016-0739-6; van Bokhorst-de van der Schueren MAE, 2014, CLIN NUTR, V33, P39, DOI 10.1016/j.clnu.2013.04.008; Wang G, 2010, PARKINSONISM RELAT D, V16, P119, DOI 10.1016/j.parkreldis.2009.08.009; Wiesli D, 2017, DEMENT GER COGN D EX, V7, P297, DOI 10.1159/000478849	34	11	11	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2020	15	5							e0232764	10.1371/journal.pone.0232764	http://dx.doi.org/10.1371/journal.pone.0232764			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LT3GS	32365092	Green Published, gold			2023-01-03	WOS:000536959700058
J	Murakami, Y; Magome, T; Matsumoto, K; Sato, T; Yoshioka, Y; Oguchi, M				Murakami, Yu; Magome, Taiki; Matsumoto, Kazuki; Sato, Tomoharu; Yoshioka, Yasuo; Oguchi, Masahiko			Fully automated dose prediction using generative adversarial networks in prostate cancer patients	PLOS ONE			English	Article							ARC THERAPY VMAT; HEAD; RADIOTHERAPY	Purpose Although dose prediction for intensity modulated radiation therapy (IMRT) has been accomplished by a deep learning approach, delineation of some structures is needed for the prediction. We sought to develop a fully automated dose-generation framework for IMRT of prostate cancer by entering the patient CT datasets without the contour information into a generative adversarial network (GAN) and to compare its prediction performance to a conventional prediction model trained from patient contours. Methods We propose a synthetic approach to translate patient CT datasets into a dose distribution for IMRT. The framework requires only paired-images, i.e., patient CT images and corresponding RT-doses. The model was trained from 81 IMRT plans of prostate cancer patients, and then produced the dose distribution for 9 test cases. To compare its prediction performance to that of another trained model, we created a model trained from structure images. Dosimetric parameters for the planning target volume (PTV) and organs at risk (OARs) were calculated from the generated and original dose distributions, and mean differences of dosimetric parameters were compared between the CT-based model and the structurebased model. Results The mean differences of all dosimetric parameters except for D98% and D95% for PTV were within approximately 2% and 3% of the prescription dose for OARs in the CT-based model, while the differences in the structure-based model were within approximately 1% for PTV and approximately 2% for OARs, with a mean prediction time of 5 seconds per patient. Conclusions Accurate and rapid dose prediction was achieved by the learning of patient CT datasets by a GAN-based framework. The CT-based dose prediction could reduce the time required for both the iterative optimization process and the structure contouring, allowing physicians and dosimetrists to focus their expertise on more challenging cases.	[Murakami, Yu; Magome, Taiki; Matsumoto, Kazuki] Komazawa Univ, Grad Div Hlth Sci, Setagaya Ku, Tokyo, Japan; [Murakami, Yu; Sato, Tomoharu; Yoshioka, Yasuo; Oguchi, Masahiko] Japanese Fdn Canc Res, Canc Inst Hosp, Radiat Oncol Dept, Koto Ku, Tokyo, Japan	Japanese Foundation for Cancer Research	Magome, T (corresponding author), Komazawa Univ, Grad Div Hlth Sci, Setagaya Ku, Tokyo, Japan.	magome@komazawa-u.ac.jp	Murakami, Yu/HHN-7987-2022	Murakami, Yu/0000-0001-7716-9427; Magome, Taiki/0000-0002-0133-5932	JSPS KAKENHI [18K15604]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part to TM by JSPS KAKENHI Grant Number 18K15604. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Babier A, 2018, ARXIV181209309V1; Barragan-Montero AM, 2019, MED PHYS, V46, P3679, DOI 10.1002/mp.13597; Ben-Cohen A, 2019, ENG APPL ARTIF INTEL, V78, P186, DOI 10.1016/j.engappai.2018.11.013; Castriconi R, 2019, PHYS MEDICA, V57, P231, DOI 10.1016/j.ejmp.2018.12.002; Chang ATY, 2016, INT J RADIAT ONCOL, V95, P981, DOI 10.1016/j.ijrobp.2016.02.017; Nguyen D, 2019, PHYS MED BIOL, V64, DOI 10.1088/1361-6560/ab039b; Nguyen D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37741-x; Das Indra J, 2009, J Am Coll Radiol, V6, P514, DOI 10.1016/j.jacr.2008.12.013; Fan JW, 2019, MED PHYS, V46, P370, DOI 10.1002/mp.13271; Fogliata A, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0530-5; Isola P., 2017, ARXIV161107004V2; Jensen AR, 2007, RADIOTHER ONCOL, V84, P5, DOI 10.1016/j.radonc.2007.04.001; Jin CB, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19102361; Kamima T, 2019, PHYS MEDICA, V64, P174, DOI 10.1016/j.ejmp.2019.07.004; Kearney V, 2018, PHYS MED BIOL, V63, DOI 10.1088/1361-6560/aaef74; Khalvati F, 2018, BMC MED IMAGING, V18, DOI 10.1186/s12880-018-0258-4; Khalvati F, 2015, BMC MED IMAGING, V15, DOI 10.1186/s12880-015-0069-9; Kida S, 2019, ARXIV190105773V1; Kozuka T, 2017, JPN J RADIOL, V35, P269, DOI 10.1007/s11604-017-0630-2; Krayenbuehl J, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-1113-z; Mahapatra D, 2019, COMPUT MED IMAG GRAP, V71, P30, DOI 10.1016/j.compmedimag.2018.10.005; Mahmood R, 2018, ARXIV180706489V1; Murakami Y, 2018, J RADIAT RES, V59, P327, DOI 10.1093/jrr/rry012; Nguyen D, 2019, ARXIV190604778; Nguyen D, 2019, ARXIV190805874; Stoyanova R, 2016, TRANSL CANCER RES, V5, P432, DOI 10.21037/tcr.2016.06.20; Tol JP, 2015, INT J RADIAT ONCOL, V91, P612, DOI 10.1016/j.ijrobp.2014.11.014; Ueda Y, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-0994-1; vantRiet A, 1997, INT J RADIAT ONCOL, V37, P731, DOI 10.1016/S0360-3016(96)00601-3; Wu H, 2016, J APPL CLIN MED PHYS, V17, P78, DOI 10.1120/jacmp.v17i6.6410; Zhang PP, 2010, INT J RADIAT ONCOL, V76, P1456, DOI 10.1016/j.ijrobp.2009.03.033	32	21	21	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2020	15	5							e0232697	10.1371/journal.pone.0232697	http://dx.doi.org/10.1371/journal.pone.0232697			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT3GS	32365088	Green Published, gold			2023-01-03	WOS:000536959700054
J	Waldbaum, AS; Schwebke, JR; Paull, JRA; Price, CF; Edmondson, SR; Castellarnau, A; McCloud, P; Kinghorn, GR				Waldbaum, Arthur S.; Schwebke, Jane R.; Paull, Jeremy R. A.; Price, Clare F.; Edmondson, Stephanie R.; Castellarnau, Alex; McCloud, Philip; Kinghorn, George R.			A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose-ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis	PLOS ONE			English	Article							METRONIDAZOLE VAGINAL GEL; ORAL METRONIDAZOLE; ACCEPTABILITY; 1.3-PERCENT; RECURRENCE; BIOFILMS; THERAPY; TRIAL; RATES	Background Astodrimer Gel contains a novel dendrimer intended to treat and prevent bacterial vaginosis. We assessed the efficacy and safety of Astodrimer Gel for treatment of bacterial vaginosis. Methods 132 women with bacterial vaginosis were randomized 1:1:1:1 to Astodrimer 0.5% (N = 34), 1% (N = 33), or 3% (N = 32) Gel or hydroxyethyl cellulose placebo gel (N = 33) at a dose of 5 g vaginally once daily for 7 days at 6 centers in the United States. The primary endpoint was clinical cure (no bacterial vaginosis vaginal discharge and no more than one of 1) vaginal pH >= 4.5; 2)>= 20% clue cells; or 3) positive whiff test) at study days 21-30. Secondary analyses included clinical cure at study days 9-12, patient-reported symptoms, acceptability and adverse events. Results The Astodrimer 1% Gel dose was superior to placebo for the primary and selected secondary efficacy measures in the modified intent-to-treat population. Clinical cure rates at day 9-12 were superior to placebo for the Astodrimer 3%, 1% and 0.5% Gel groups (62.5% [15/24; P =.002], 74.1% [20/27; P <.001], and 55.2% [16/29; P =.001], respectively, vs. 22.2% [6/27]). At day 21-30, clinical cure rates were 46.2% (12/26) for the 1% dose vs. 11.5% for placebo (3/26; P =.006). A greater proportion of patients reported absence of vaginal discharge and vaginal odor at day 9-12 and day 21-30 for Astodrimer Gel groups compared with placebo. Adverse events considered potentially treatment-related occurred in only 25% of Astodrimer Gel-treated patients vs. 22% of placebo patients. Conclusion Astodrimer Gel once daily for 7 days was superior to placebo for treatment of bacterial vaginosis and was well-tolerated. The 1% dose consistently showed the strongest efficacy across endpoints. These results support a role for Astodrimer Gel, 1%, as an effective treatment for bacterial vaginosis.	[Waldbaum, Arthur S.] Downtown Womens Hlth Care, Denver, CO USA; [Schwebke, Jane R.] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA; [Paull, Jeremy R. A.; Price, Clare F.; Edmondson, Stephanie R.; Castellarnau, Alex] Starpharma Pty Ltd, Melbourne, Vic, Australia; [McCloud, Philip] McCloud Consulting Grp, Sydney, NSW, Australia; [Kinghorn, George R.] Royal Hallamshire & Sheffield Teaching Hosp, Sheffield, S Yorkshire, England	University of Alabama System; University of Alabama Birmingham	Paull, JRA (corresponding author), Starpharma Pty Ltd, Melbourne, Vic, Australia.	jeremy.paull@starpharma.com	Kinghorn, George/AAO-1425-2021	Kinghorn, George/0000-0001-6608-5076; Paull, Jeremy/0000-0002-9981-421X	Starpharma Pty Ltd.	Starpharma Pty Ltd.	The study was funded by Starpharma Pty Ltd. Starpharma Pty Ltd was responsible for the design, data collection and analysis, decision to publish, and preparation of the manuscript. The funder provided support in the form of research funding for this study to ASW. The funder provided support in the form of salaries for JRAP, SRE, CFP and AC, and consulting fees for JRS, PMcC and GRK. The specific roles of these authors are articulated in the `author contributions' section.	AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9; BARBONE F, 1990, AM J OBSTET GYNECOL, V163, P510, DOI 10.1016/0002-9378(90)91186-G; Bradshaw CS, 2016, J INFECT DIS, V214, pS14, DOI 10.1093/infdis/jiw159; Bradshaw CS, 2006, J INFECT DIS, V193, P1478, DOI 10.1086/503780; Chavoustie SE, 2020, EUR J OBSTET GYN R B, V245, P13, DOI 10.1016/j.ejogrb.2019.11.032; Chavoustie SE, 2015, J LOW GENIT TRACT DI, V19, P129, DOI 10.1097/LGT.0000000000000062; Donders GGG, 2013, INT J GYNECOL OBSTET, V120, P131, DOI 10.1016/j.ijgo.2012.08.022; FERRIS DG, 1995, J FAM PRACTICE, V41, P443; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; Machado D, 2016, FRONT MICROBIOL, V6, DOI [10.3389/fmicb.2015.00330, 10.3389/fmicb.2015.01528]; Marrazzo JM, 2019, CLIN INFECT DIS, V68, P803, DOI 10.1093/cid/ciy554; Marrazzo JM, 2010, SEX TRANSM DIS, V37, P732, DOI 10.1097/OLQ.0b013e3181fbbc95; McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q; McGowan I, 2011, AIDS, V25, P1057, DOI 10.1097/QAD.0b013e328346bd3e; Money Deborah, 2005, Can J Infect Dis Med Microbiol, V16, P77; Muzny CA, 2015, CLIN INFECT DIS, V61, P601, DOI 10.1093/cid/civ353; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac; Schwartz JL, 2007, CONTRACEPTION, V75, P136, DOI 10.1016/j.contraception.2006.09.003; Schwebke J, 2019, AM J OBSTET GYNECOL, V221, P672; Schwebke JR, 2007, CLIN INFECT DIS, V44, P213, DOI 10.1086/509577; Schwebke JR, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.08.017; Schwebke JR, 2015, SEX TRANSM DIS, V42, P376, DOI 10.1097/OLQ.0000000000000300; Schwebke Jane R, 2009, Curr Infect Dis Rep, V11, P143, DOI 10.1007/s11908-009-0021-7; Swidsinski A, 2005, OBSTET GYNECOL, V106, P1013, DOI 10.1097/01.AOG.0000183594.45524.d2; Tien D, 2005, AIDS RES HUM RETROV, V21, P845, DOI 10.1089/aid.2005.21.845; Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309; Workowski KA, 2015, MMWR RECOMM REP, V64, P1, DOI 10.15585/mmwr.rr7004a1	28	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2020	15	5							e0232394	10.1371/journal.pone.0232394	http://dx.doi.org/10.1371/journal.pone.0232394			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT3GS	32365097	Green Published, Green Accepted, gold			2023-01-03	WOS:000536959700027
J	Hollander, JE; Carr, BG				Hollander, Judd E.; Carr, Brendan G.			Virtually Perfect? Telemedicine for Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Telemedicine's payment and regulatory structures, licensing, credentialing, and implementation take time to work through, but health systems that have already invested in telemedicine are well positioned to ensure that patients with Covid-19 receive the care they need.	[Hollander, Judd E.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA; [Carr, Brendan G.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA	Jefferson University; Icahn School of Medicine at Mount Sinai	Hollander, JE (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.							Duffy S, 2018, NEW ENGL J MED, V378, P104, DOI 10.1056/NEJMp1710735; Joshi AU, 2020, ACAD EMERG MED, V27, P139, DOI 10.1111/acem.13890; Lacktman NM, 2021, 50 STATE SURVEY TELE; Langabeer JR, 2016, WEST J EMERG MED, V17, P713, DOI 10.5811/westjem.2016.8.30660; Lurie N, 2018, JAMA INTERN MED, V178, P745, DOI 10.1001/jamainternmed.2018.1314	5	1533	1566	23	102	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 30	2020	382	18					1679	1681		10.1056/NEJMp2003539	http://dx.doi.org/10.1056/NEJMp2003539			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL1YQ	32160451	Bronze			2023-01-03	WOS:000531351300009
J	Lennaerts-Kats, H; van der Steen, JT; Vijftigschild, Z; Steppe, M; Meinders, MJ; Munneke, M; Bloem, BR; Vissers, KCP; Groot, MM				Lennaerts-Kats, Herma; van der Steen, Jenny T.; Vijftigschild, Zefanja; Steppe, Maxime; Meinders, Marjan J.; Munneke, Marten; Bloem, Bastiaan R.; Vissers, Kris C. P.; Groot, Marieke M.			RADPAC-PD: A tool to support healthcare professionals in timely identifying palliative care needs of people with Parkinson's disease	PLOS ONE			English	Article							QUALITY-OF-LIFE; ADVANCE CARE; EUROPEAN ASSOCIATION; SURPRISE QUESTION; OLDER-PEOPLE; EXPERIENCES; END; RECOMMENDATIONS; CAREGIVERS; DEMENTIA	Background Parkinson's disease (PD) is a progressive degenerative disease without curative treatment perspectives. Even when palliative care for people with PD seems to be beneficial, the need for palliative care is often not timely recognized. Aim Our aim was to develop a tool that can help healthcare professionals in timely identifying palliative care needs in people with PD. Design We used a mixed-methods design, including individual and focus group interviews and a three-round modified Delphi study with healthcare professionals from a multidisciplinary field. Results Data from the interviews suggested two distinct moments in the progressive PD trajectory: 1) an ultimate moment to initiate Advance Care Planning (ACP); and 2) the actual start of the palliative phase. During the Delphi process, six indicators for ACP were identified, such as presence of frequent falls and first unplanned hospital admission. The start of the palliative phase involved four indicators: 1) personal goals have started to focus on maximization of comfort; 2) care needs have changed; 3) PD drug treatment has become less effective or an increasingly complex regime of drug treatments is needed; and 4) specific PD-symptoms or complications have appeared, such as significant weight loss, recurrent infections, or progressive dysphagia. Indicators for both moments are included in the RADboud indicators for PAlliative Care Needs in Parkinson's Disease (RADPAC-PD) tool. Conclusion The RADPAC-PD may support healthcare professionals in timely initiating palliative care for persons with PD. Identification of one or more indicators can mark the need for ACP or the palliative phase. We expect that applying the RADPAC-PD, for example on an annual basis throughout the PD trajectory, can facilitate identification of the palliative phase in PD patients in daily practice. However, further prospective research is needed on the implementation of the RADPAC-PD.	[Lennaerts-Kats, Herma; Steppe, Maxime; Munneke, Marten; Bloem, Bastiaan R.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Neurol, Med Ctr, Nijmegen, Netherlands; [Lennaerts-Kats, Herma; Vijftigschild, Zefanja; Vissers, Kris C. P.; Groot, Marieke M.] Radboud Univ Nijmegen, Dept Anesthesiol Pain & Palliat Care, Med Ctr, Nijmegen, Netherlands; [van der Steen, Jenny T.] Radboud Univ Nijmegen, Dept Primary & Community Care, Med Ctr, Nijmegen, Netherlands; [van der Steen, Jenny T.] Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands; [Meinders, Marjan J.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Sci Ctr Qual Healthcare, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen	Lennaerts-Kats, H (corresponding author), Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Neurol, Med Ctr, Nijmegen, Netherlands.; Lennaerts-Kats, H (corresponding author), Radboud Univ Nijmegen, Dept Anesthesiol Pain & Palliat Care, Med Ctr, Nijmegen, Netherlands.	Herma.lennaerts@radboudumc.nl	Bloem, Bastiaan/H-8013-2014; Groot, Marieke/L-4338-2015; van der Steen, Jenny T./E-5118-2016; Vissers, Kris/H-8110-2014	Bloem, Bastiaan/0000-0002-6371-3337; Groot, Marieke/0000-0002-5740-3607; van der Steen, Jenny T./0000-0002-9063-7501; Vissers, Kris/0000-0002-2919-6356; Lennaerts, Herma/0000-0002-1182-8300	Netherlands Organization for Health Research and Development (ZonMw) [80-84400-98-086]; Parkinson's Foundation	Netherlands Organization for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development); Parkinson's Foundation	This study is funded by The Netherlands Organization for Health Research and Development (ZonMw). (Grant reference number 80-84400-98-086). www.zonmw.nl Prof. Bastiaan R. Bloem was supported by a research grant of the Parkinson's Foundation. The funding party had no role in the design of the study, or in data collection, analysis or in writing the manuscript.	Aarsland D, 2005, MOVEMENT DISORD, V20, P1255, DOI 10.1002/mds.20527; [Anonymous], 2010, WHO DEF PALL CAR; Bloem BR, 2017, HEALTH AFFAIR, V36, P1987, DOI 10.1377/hlthaff.2017.0832; Bloem BR, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1838; Bouca-Machado R, 2018, MOVEMENT DISORD, V33, P750, DOI 10.1002/mds.27309; Darweesh SKL, 2018, J PARKINSON DIS, V8, P495, DOI 10.3233/JPD-181374; Downar J, 2017, CAN MED ASSOC J, V189, pE484, DOI 10.1503/cmaj.160775; Edmonds P, 2001, PALLIATIVE MED, V15, P287, DOI 10.1191/026921601678320278; EPDA, 2017, PARK LAT LIF; Fox S, 2015, MOV DISORD CLIN PRAC, V2, P142, DOI 10.1002/mdc3.12133; Fox S, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0087-6; Giles S, 2009, PALLIATIVE MED, V23, P120, DOI 10.1177/0269216308100773; Gomez-Batiste X, 2017, PALLIATIVE MED, V31, P754, DOI 10.1177/0269216316676647; Goy ER, 2008, J PALLIAT CARE, V24, P69, DOI 10.1177/082585970802400202; Goy ER, 2007, NEUROLOGY, V69, P611, DOI 10.1212/01.wnl.0000266665.82754.61; Hall K, 2017, NPJ PARKINSONS DIS, V3, DOI 10.1038/s41531-017-0016-2; Hasson F, 2010, PALLIATIVE MED, V24, P731, DOI 10.1177/0269216310371414; Highet G, 2014, BMJ SUPPORT PALLIAT, V4, P285, DOI 10.1136/bmjspcare-2013-000488; Hoare S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142723; Hudson PL, 2006, PALLIATIVE MED, V20, P87, DOI 10.1191/0269216306pm1108oa; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; Kalia LV, 2015, LANCET, V386, P896, DOI 10.1016/S0140-6736(14)61393-3; Kempster PA, 2010, BRAIN, V133, P1755, DOI 10.1093/brain/awq059; Keus SHJ, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/543426; Keus SHJ, 2009, MOVEMENT DISORD, V24, P1, DOI 10.1002/mds.22141; KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299; Kluger BM, 2017, PARKINSONISM RELAT D, V37, P19, DOI 10.1016/j.parkreldis.2017.01.008; Lennaerts H, 2019, BMC PALLIAT CARE, V18, DOI 10.1186/s12904-019-0441-6; Lennaerts H, 2017, BMC PALLIAT CARE, V16, DOI 10.1186/s12904-017-0248-2; Linstone H., 1975, DELPHI METHOD; Lum HD, 2019, NEUROLOGY, V92, pE2571, DOI 10.1212/WNL.0000000000007552; Martinez-Martin P, 2012, EXPERT REV PHARM OUT, V12, P221, DOI [10.1586/ERP.11.106, 10.1586/erp.11.106]; McKinley RK, 2004, BRIT J GEN PRACT, V54, P909; Meireles Joana, 2012, Front Neurol, V3, P88, DOI 10.3389/fneur.2012.00088; Miyasaki Janis M, 2012, Parkinsonism Relat Disord, V18 Suppl 3, pS6, DOI 10.1016/j.parkreldis.2012.06.013; Murray SA, 2011, PALLIATIVE MED, V25, P382, DOI 10.1177/0269216311401949; Nijkrake MJ, 2010, MOVEMENT DISORD, V25, P823, DOI 10.1002/mds.22813; Pennington S, 2010, PARKINSONISM RELAT D, V16, P434, DOI 10.1016/j.parkreldis.2010.04.010; Powell RA, 1996, INT J QUAL HEALTH C, V8, P499, DOI 10.1093/intqhc/8.5.499; Richfield EW, 2013, PALLIATIVE MED, V27, P805, DOI 10.1177/0269216313495287; Rietjens JAC, 2017, LANCET ONCOL, V18, pE543, DOI 10.1016/S1470-2045(17)30582-X; Rudkins H., 2006, BRIT J NEUROSCIENCE, V2, P10, DOI DOI 10.12968/BJNN.2006.2.1.20497; Schrag A, 2000, MOVEMENT DISORD, V15, P1112, DOI 10.1002/1531-8257(200011)15:6<1112::AID-MDS1008>3.0.CO;2-A; Seymour J, 2004, SOC SCI MED, V59, P57, DOI 10.1016/j.socscimed.2003.10.005; Simon J, 2015, BMJ SUPPORT PALLIAT, V5, P54, DOI 10.1136/bmjspcare-2013-000487; Sofaer S, 2002, INT J QUAL HEALTH C, V14, P329, DOI 10.1093/intqhc/14.4.329; Thomas K.T., 2016, GOLD STANDARDS FRAME; Thoonsen B, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X654597; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; van der Steen JT, 2014, PALLIATIVE MED, V28, P197, DOI 10.1177/0269216313493685; Waldron M, 2011, INT J THER REHABIL, V18, P48, DOI 10.12968/ijtr.2011.18.1.48; Waldron M, 2013, BRIT J SOC WORK, V43, P81, DOI 10.1093/bjsw/bcr157; Walker RW, 2014, BMJ SUPPORT PALLIAT, V4, P64, DOI 10.1136/bmjspcare-2012-000412; Wolf-Klein Gisele, 2007, Am J Hosp Palliat Care, V24, P77, DOI 10.1177/1049909106295297; Zwakman M, 2018, PALLIATIVE MED, V32, P1305, DOI 10.1177/0269216318784474	55	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2020	15	4							e0230611	10.1371/journal.pone.0230611	http://dx.doi.org/10.1371/journal.pone.0230611			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR9OP	32315302	Green Published, gold			2023-01-03	WOS:000536024800007
J	Fugger, L; Jensen, LT; Rossjohn, J				Fugger, Lars; Jensen, Lise Torp; Rossjohn, Jamie			Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases	CELL			English	Review							INFLAMMATORY-BOWEL-DISEASE; REGULATORY B-CELLS; ANTI-TNF THERAPY; T-CELLS; CROSS-REACTIVITY; TARGETED THERAPY; GUT MICROBIOTA; GENETIC RISK; DOUBLE-BLIND; METABOLITES	Autoimmune diseases are a result of the immune system being misdirected toward its host and have major and increasing unmet clinical needs. In general, present therapies are broadly acting and non-disease specific; consequently, they are associated with numerous side effects. Precise and early intervention strategies are urgently needed. We highlight the challenges, progress, and prospects in achieving these goals.	[Fugger, Lars; Jensen, Lise Torp] Univ Oxford, John Radcliffe Hosp, Div Clin Neurol, Nuffield Dept Clin Neurosci,Oxford Ctr Neuroinfla, Oxford OX3 9DS, England; [Fugger, Lars] Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, MRC Human Immunol Unit, Oxford OX3 9DS, England; [Fugger, Lars; Jensen, Lise Torp] Aarhus Univ Hosp, Dept Clin Med, DK-8200 Aarhus N, Denmark; [Rossjohn, Jamie] Monash Univ, Infect & Immun Program, Biomed Discovery Inst, Clayton, Vic 3800, Australia; [Rossjohn, Jamie] Monash Univ, Dept Biochem & Mol Biol, Biomed Discovery Inst, Clayton, Vic 3800, Australia; [Rossjohn, Jamie] Monash Univ, Australian Res Council Ctr Excellence Adv Mol Ima, Clayton, Vic 3800, Australia; [Rossjohn, Jamie] Cardiff Univ, Sch Med, Inst Infect & Immun, Heath Pk, Cardiff CF14 4XN, Wales	University of Oxford; University of Oxford; Aarhus University; Monash University; Monash University; Monash University; Cardiff University	Fugger, L (corresponding author), Univ Oxford, John Radcliffe Hosp, Div Clin Neurol, Nuffield Dept Clin Neurosci,Oxford Ctr Neuroinfla, Oxford OX3 9DS, England.; Fugger, L (corresponding author), Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, MRC Human Immunol Unit, Oxford OX3 9DS, England.; Fugger, L (corresponding author), Aarhus Univ Hosp, Dept Clin Med, DK-8200 Aarhus N, Denmark.; Rossjohn, J (corresponding author), Monash Univ, Infect & Immun Program, Biomed Discovery Inst, Clayton, Vic 3800, Australia.; Rossjohn, J (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Biomed Discovery Inst, Clayton, Vic 3800, Australia.; Rossjohn, J (corresponding author), Monash Univ, Australian Res Council Ctr Excellence Adv Mol Ima, Clayton, Vic 3800, Australia.; Rossjohn, J (corresponding author), Cardiff Univ, Sch Med, Inst Infect & Immun, Heath Pk, Cardiff CF14 4XN, Wales.	lars.fugger@imm.ox.ac.uk; jamie.rossjohn@monash.edu	Rossjohn, Jamie/F-9032-2013	Rossjohn, Jamie/0000-0002-2020-7522	Wellcome Trust [100308/Z/12/Z]; Oak Foundation [OCAY-15-520]; NIHR Oxford BRC; MRC UK; Australian Research Council [FL160100049]	Wellcome Trust(Wellcome TrustEuropean Commission); Oak Foundation; NIHR Oxford BRC; MRC UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Australian Research Council(Australian Research Council)	The authors wish to thank Dr. Kathrine Attfield for helpful discussions. L.F. is supported by the Wellcome Trust (100308/Z/12/Z), the Oak Foundation (OCAY-15-520), the NIHR Oxford BRC, and the MRC UK. J.R. is supported by an Australian Research Council laureate fellowship (FL160100049).	Angus DC, 2019, NAT REV DRUG DISCOV, V18, P797, DOI 10.1038/s41573-019-0034-3; Anzalone AV, 2019, NATURE, V576, P149, DOI 10.1038/s41586-019-1711-4; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Bachelez H, 2019, NEW ENGL J MED, V380, P981, DOI 10.1056/NEJMc1811317; Bachem A, 2019, IMMUNITY, V51, P285, DOI 10.1016/j.immuni.2019.06.002; Belarif L, 2019, J CLIN INVEST, V129, P1910, DOI 10.1172/JCI121668; Berer K, 2017, P NATL ACAD SCI USA, V114, P10719, DOI 10.1073/pnas.1711233114; Blanchard B, 2013, J NEUROSCI, V33, P11633, DOI 10.1523/JNEUROSCI.0774-13.2013; Bluestone JA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad4134; Britton GJ, 2019, IMMUNITY, V50, P212, DOI 10.1016/j.immuni.2018.12.015; Cekanaviciute E, 2017, P NATL ACAD SCI USA, V114, P10713, DOI 10.1073/pnas.1711235114; Charbonnier LM, 2019, NAT IMMUNOL, V20, P1208, DOI 10.1038/s41590-019-0442-x; Choi IY, 2016, CELL REP, V15, P2136, DOI 10.1016/j.celrep.2016.05.009; Choi SC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06686-0; Cignarella F, 2018, CELL METAB, V27, P1222, DOI 10.1016/j.cmet.2018.05.006; Collins N, 2019, CELL, V178, P1088, DOI 10.1016/j.cell.2019.07.049; Cortes A, 2020, NAT GENET, V52, P126, DOI 10.1038/s41588-019-0550-4; Danese S, 2019, GUT, V68, P40, DOI 10.1136/gutjnl-2017-314562; Dendrou CA, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1974; Dombrowski Y, 2017, NAT NEUROSCI, V20, P674, DOI 10.1038/nn.4528; Eftychi C, 2019, IMMUNITY, V51, P367, DOI 10.1016/j.immuni.2019.06.008; Ellebrecht CT, 2016, SCIENCE, V353, P179, DOI 10.1126/science.aaf6756; Feagan BG, 2017, LANCET, V389, P1699, DOI 10.1016/S0140-6736(17)30570-6; Fritz Y, 2017, J INVEST DERMATOL, V137, P696, DOI 10.1016/j.jid.2016.10.021; Geisler S, 2019, J EXP MED, V216, P294, DOI 10.1084/jem.20181040; Gianchecchi E, 2018, AUTOIMMUN REV, V17, P142, DOI 10.1016/j.autrev.2017.11.018; Godfrey DI, 2015, NAT IMMUNOL, V16, P1114, DOI 10.1038/ni.3298; Gopalakrishnan S, 2012, PEPTIDES, V35, P95, DOI 10.1016/j.peptides.2012.02.016; Graham WV, 2019, NAT MED, V25, P690, DOI 10.1038/s41591-019-0393-7; Gregory AP, 2012, NATURE, V488, P508, DOI 10.1038/nature11307; Hang SY, 2019, NATURE, V576, P143, DOI 10.1038/s41586-019-1785-z; Harkiolaki M, 2009, IMMUNITY, V30, P348, DOI 10.1016/j.immuni.2009.01.009; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Herold KC, 2019, NEW ENGL J MED, V381, P603, DOI 10.1056/NEJMoa1902226; Holt DQ, 2017, J HUM NUTR DIET, V30, P66, DOI 10.1111/jhn.12400; Jackson SW, 2019, IMMUNOL REV, V292, P102, DOI 10.1111/imr.12810; Jordan S, 2019, CELL, V178, P1102, DOI 10.1016/j.cell.2019.07.050; Kang SJ, 2019, IMMUNITY, V50, P1007, DOI 10.1016/j.immuni.2019.03.026; Kappos L, 2014, LANCET NEUROL, V13, P353, DOI 10.1016/S1474-4422(14)70028-6; Karnell JL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aar6584; Kim BS, 2020, J ALLERGY CLIN IMMUN, V145, P572, DOI 10.1016/j.jaci.2019.08.042; Knepper TC, 2018, NATURE, V557, P157, DOI 10.1038/d41586-018-05049-5; Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Kornberg MD, 2018, SCIENCE, V360, P449, DOI 10.1126/science.aan4665; Lai ZW, 2018, LANCET, V391, P1186, DOI 10.1016/S0140-6736(18)30485-9; Ley K, 2016, NAT REV DRUG DISCOV, V15, P173, DOI 10.1038/nrd.2015.10; Li W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00833; Lloyd-Price J, 2019, NATURE, V569, P655, DOI 10.1038/s41586-019-1237-9; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Mantovani A, 2019, IMMUNITY, V50, P778, DOI 10.1016/j.immuni.2019.03.012; Martin JC, 2019, CELL, V178, P1493, DOI 10.1016/j.cell.2019.08.008; Matusiewicz A, 2019, INT J RHEUM DIS, V22, P386, DOI 10.1111/1756-185X.13454; Meffre D, 2015, NEUROSCIENCE, V284, P962, DOI 10.1016/j.neuroscience.2014.10.064; Meng HM, 2018, CLIN IMMUNOL, V192, P40, DOI 10.1016/j.clim.2018.04.006; Monaco C, 2015, INT IMMUNOL, V27, P55, DOI 10.1093/intimm/dxu102; Myles IA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120608; Nagai M, 2019, CELL, V178, P1072, DOI 10.1016/j.cell.2019.07.047; Najm FJ, 2015, NATURE, V522, P216, DOI 10.1038/nature14335; Nakatsuji T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4680; Neumann B, 2019, CELL STEM CELL, V25, P473, DOI 10.1016/j.stem.2019.08.015; Neurath MF, 2019, NAT IMMUNOL, V20, P970, DOI 10.1038/s41590-019-0415-0; Olsson T, 2017, NAT REV NEUROL, V13, P25, DOI 10.1038/nrneurol.2016.187; Papp K, 2018, NEW ENGL J MED, V379, P1313, DOI 10.1056/NEJMoa1806382; Paramsothy S, 2017, LANCET, V389, P1218, DOI 10.1016/S0140-6736(17)30182-4; Petersen J, 2020, NAT STRUCT MOL BIOL, V27, P49, DOI 10.1038/s41594-019-0353-4; Raffin C, 2020, NAT REV IMMUNOL, V20, P158, DOI 10.1038/s41577-019-0232-6; Reich K, 2019, LANCET, V394, P831, DOI 10.1016/S0140-6736(19)31773-8; Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214; Rojas OL, 2019, CELL, V177, P492, DOI 10.1016/j.cell.2019.03.037; Rosser EC, 2014, NAT MED, V20, P1334, DOI 10.1038/nm.3680; Roth TL, 2018, NATURE, V559, P405, DOI 10.1038/s41586-018-0326-5; Sandborn WJ, 2013, NEW ENGL J MED, V369, P711, DOI 10.1056/NEJMoa1215739; Sberro H, 2019, CELL, V178, P1245, DOI 10.1016/j.cell.2019.07.016; Scally SW, 2013, J EXP MED, V210, P2569, DOI 10.1084/jem.20131241; Schmitt H, 2019, GUT, V68, P814, DOI 10.1136/gutjnl-2017-315671; Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201; Schwarz C, 2018, EXPERT REV CLIN IMMU, V14, P583, DOI 10.1080/1744666X.2018.1485489; Serra P, 2019, NAT BIOTECHNOL, V37, P238, DOI 10.1038/s41587-019-0015-4; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Sockolosky JT, 2018, SCIENCE, V359, P1037, DOI 10.1126/science.aar3246; Sollid LM, 2013, NAT REV IMMUNOL, V13, P294, DOI 10.1038/nri3407; Song XY, 2020, NATURE, V577, P410, DOI 10.1038/s41586-019-1865-0; Sonner JK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12776-4; Spangler JB, 2015, ANNU REV IMMUNOL, V33, P139, DOI 10.1146/annurev-immunol-032713-120211; Taylor PC, 2019, LANCET RHEUMATOL, V1, pE8, DOI 10.1016/S2665-9913(19)30016-5; Toubal A, 2019, NAT REV IMMUNOL, V19, P643, DOI 10.1038/s41577-019-0191-y; Tran JQ, 2014, NEUROL-NEUROIMMUNOL, V1, DOI 10.1212/NXI.0000000000000018; Trotta E, 2018, NAT MED, V24, P1005, DOI 10.1038/s41591-018-0070-2; Vieira SM, 2018, SCIENCE, V359, P1156, DOI 10.1126/science.aar7201; Wilck N, 2017, NATURE, V551, P585, DOI 10.1038/nature24628; Yang Z, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7151; Yilmaz B, 2019, NAT MED, V25, P323, DOI 10.1038/s41591-018-0308-z; Yin YM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0835; Yoshizaki A, 2012, NATURE, V491, P264, DOI 10.1038/nature11501; Zegarra-Ruiz DF, 2019, CELL HOST MICROBE, V25, P113, DOI 10.1016/j.chom.2018.11.009; Zeggini E, 2019, SCIENCE, V365, P1409, DOI 10.1126/science.aax4588; Zwicky P., 2020, J EXP MED, V217, P217	99	64	65	11	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2020	181	1					63	80		10.1016/j.cell.2020.03.007	http://dx.doi.org/10.1016/j.cell.2020.03.007			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KZ5RI	32243797	Bronze			2023-01-03	WOS:000523319000013
J	Yang, G; Xu, Y; Qu, GY; Zhang, YL				Yang, Guang; Xu, Yong; Qu, Genyi; Zhang, Yulong			Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis	PLOS ONE			English	Review							URGE URINARY-INCONTINENCE; DETRUSOR OVERACTIVITY; TOXIN-A; EFFICACY; SYMPTOMS	Objective To systematically review outcomes in patients with refractory overactive bladder (OAB) patients who underwent sacral neuromodulation therapy (SNM) therapy after unsuccessful onabotulinumtoxinA (BTX) therapy, and to compare outcomes with those who SNM as initial therapy. Methods A systematic search of Cochrane Library, Pubmed and Embase databases from July 2002 to November 2019, to analyze randomized controlled trials and retrospective studies of SNM therapy after failed initial BTX therapy. Two reviewers independently screened the studies and extracted data. A quality assessment of the included literature was conducted using Newcastle-Ottawa Scale (NOS), and Stata 12.0 software was used to conduct a meta-analysis of the collected data. Results A total of seven studies involving 319 patients were finally included. The success rate in refractory OAB patients who used SNM therapy after failed BTX therapy was 58.5%, 95% CI (0.47-0.70). There was no significant difference between refractory OAB patients who chose SNM as replacement therapy after failed BTX therapy and those who used SNM therapy as first choice [RR = 0.96, 95%CI (0.72-1.26), P = 0.735]. Conclusion OAB patients for whom an initial choice of BTX therapy ends in failure or dissatisfaction may consider switching to SNM therapy. There is no difference in outcomes between these patients and those whose first choice was SNM therapy.	[Yang, Guang; Xu, Yong; Qu, Genyi; Zhang, Yulong] Xiangya Med Coll CSU, Affiliated Zhuzhou Hosp, Urol, Zhuzhou, Peoples R China		Xu, Y (corresponding author), Xiangya Med Coll CSU, Affiliated Zhuzhou Hosp, Urol, Zhuzhou, Peoples R China.	tigerhnll@126.com		Xu, Yong/0000-0001-5889-1094; Xu, Yong/0000-0001-6787-1618	Science and Technology Innovation Project of Hunan Province [2017SK51003]	Science and Technology Innovation Project of Hunan Province	Yulong Zhang has received the Science and Technology Innovation Project of Hunan Province, 2017SK51003. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams P, 2002, AM J OBSTET GYNECOL, V187, P116, DOI 10.1067/mob.2002.125704; Abtahi B, 2013, INT UROGYNECOL J, V24, pS123; Agarwal S, 2018, NEUROUROL URODYNAM, V37, pS646; Amundsen CL, 2016, JAMA-J AM MED ASSOC, V316, P1366, DOI 10.1001/jama.2016.14617; Baron M, 2018, EUROPEAN UROLOGY S, V17, pe1356; Brubaker L, 2008, J UROLOGY, V180, P217, DOI 10.1016/j.juro.2008.03.028; Dowson C, 2012, EUR UROL, V61, P834, DOI 10.1016/j.eururo.2011.12.011; Forrest A, 2011, INT UROGYNECOL J, V22, pS1771; Gormley EA, 2015, J UROLOGY, V193, P1572, DOI 10.1016/j.juro.2015.01.087; Hassouna MM, 2000, J UROLOGY, V163, P1849, DOI 10.1016/S0022-5347(05)67558-1; Henriet B, 2015, Rev Med Brux, V36, P29; Hijaz A, 2006, UROLOGY, V68, P533, DOI 10.1016/j.urology.2006.03.020; Hoag N, 2017, NEUROUROL URODYNAM, V36, P1377, DOI 10.1002/nau.23117; Kirkpatrick G, 2015, NEUROUROL URODYNAM, V34, pS22; Lau J, 2006, BMJ-BRIT MED J, V333, P597, DOI 10.1136/bmj.333.7568.597; Milsom I, 2001, BJU INT, V87, P760, DOI 10.1046/j.1464-410x.2001.02228.x; Morton H, 2015, NEUROUROL URODYNAM, V34, pS236; Sahai A, 2007, J UROLOGY, V177, P2231, DOI 10.1016/j.juro.2007.01.130; Singh R, 2014, FEMALE PELVIC MED RE, V20, pS351; Smits MAC, 2013, J UROLOGY, V190, P2148, DOI 10.1016/j.juro.2013.07.017; Trinh H, 2018, NEUROUROL URODYNAM, V37, pS652; Wang YL, 2011, NEUROUROL URODYNAM, V30, P1448, DOI 10.1002/nau.21072	22	6	7	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2020	15	3							e0230355	10.1371/journal.pone.0230355	http://dx.doi.org/10.1371/journal.pone.0230355			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8HE	32226049	Green Published, gold			2023-01-03	WOS:000535936400005
J	Piggott, KL; Mehta, N; Wong, CL; Shing, LK; Rochon, PA				Piggott, Katrina L.; Mehta, Nishila; Wong, Camilla L.; Shing, Li Ka; Rochon, Paula A.			Using a clinical process map to identify prescribing cascades in your patient	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CHOLINESTERASE-INHIBITORS; MEDICATION; PEOPLE		[Piggott, Katrina L.; Rochon, Paula A.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Piggott, Katrina L.; Rochon, Paula A.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Mehta, Nishila] Univ Toronto, Fac Med, Undergrad Med, Toronto, ON, Canada; [Shing, Li Ka] Univ Toronto, St Michaels Hosp, Div Geriatr Med, Toronto, ON, Canada; [Piggott, Katrina L.; Mehta, Nishila; Rochon, Paula A.] Univ Toronto, Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital	Rochon, PA (corresponding author), Univ Toronto, Dept Med, Toronto, ON, Canada.; Rochon, PA (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.	paula.rochon@wchospital.ca	; Rochon, Paula/J-2918-2016	Mehta, Nishila/0000-0002-6804-5075; Rochon, Paula/0000-0002-5973-4151				Beijer HJM, 2002, PHARM WORLD SCI, V24, P46, DOI 10.1023/A:1015570104121; Brath H, 2018, J AM GERIATR SOC, V66, P2079, DOI 10.1111/jgs.15543; Daley BJ, 1999, J NURS EDUC, V38, P42; Donaldson LJ, 2017, LANCET, V389, P1680, DOI 10.1016/S0140-6736(17)31047-4; Farrell B., 2014, CANADIAN GERIATRICS, V4, P21; Ferner RE, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4051; Fick DM, 2019, J AM GERIATR SOC, V67, P674, DOI 10.1111/jgs.15767; Gill SS, 2005, ARCH INTERN MED, V165, P808, DOI 10.1001/archinte.165.7.808; Gill SS, 2009, ARCH INTERN MED, V169, P867, DOI 10.1001/archinternmed.2009.43; Graham-Rowe E, 2018, DIABETIC MED, V35, P1308, DOI 10.1111/dme.13686; Institute for Safe Medication Practices Canada, 2009, BEST POSS MED HIST I; Kalisch LM, 2011, AUST PRESCR, V34, P162; LENZER J, 2014, BMJ-BRIT MED J, V349, DOI DOI 10.1136/bmj.g7677; Lewis T, 2004, BRIT MED J, V329, P434, DOI 10.1136/bmj.329.7463.434; Liu Gordon G, 2002, J Am Pharm Assoc (Wash), V42, P847; NHS Digital, 2012, PRESCR DISP COMM ENG; NHS Scotland, POL GUID MED REV; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Reeder TA, 2008, AM J HEALTH-SYST PH, V65, P857, DOI 10.2146/ajhp070292; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; Rochon PA, 2017, LANCET, V389, P1778, DOI 10.1016/S0140-6736(17)31188-1; Rosenberg J, 2014, J AM GERIATR SOC, V62, P580, DOI 10.1111/jgs.12714; Sadasivaiah Shobha, 2017, BMJ Open Qual, V6, pe000102, DOI 10.1136/bmjoq-2017-000102; Scott IA, 2015, JAMA INTERN MED, V175, P827, DOI 10.1001/jamainternmed.2015.0324; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; Torre DM, 2013, MED TEACH, V35, P201, DOI 10.3109/0142159X.2013.759644; Trebble TM, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4078; Velo GP, 2009, BRIT J CLIN PHARMACO, V67, P624, DOI 10.1111/j.1365-2125.2009.03425.x; Weng MC, 2013, QJM-INT J MED, V106, P1009, DOI 10.1093/qjmed/hct141; World Health Organization, 2014, ASS MED ACC TRANS CA	30	14	14	4	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	2020	368								m261	10.1136/bmj.m261	http://dx.doi.org/10.1136/bmj.m261			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KO0KS	32075785				2023-01-03	WOS:000515235300003
J	Walek, P; Sielski, J; Gorczyca, I; Roskal-Walek, J; Starzyk, K; Jaskulska-Niedziela, E; Bartkowiak, R; Wozakowska-Kaplon, B				Walek, Pawel; Sielski, Janusz; Gorczyca, Iwona; Roskal-Walek, Joanna; Starzyk, Katarzyna; Jaskulska-Niedziela, Elzbieta; Bartkowiak, Radoslaw; Wozakowska-Kaplon, Beata			Left atrial mechanical remodelling assessed as the velocity of left atrium appendage wall motion during atrial fibrillation is associated with maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation	PLOS ONE			English	Article							TRANSTHORACIC TISSUE DOPPLER; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; EUROPEAN ASSOCIATION; PREDICT MAINTENANCE; AMERICAN SOCIETY; RECOMMENDATIONS; RECURRENCE; SUCCESS; UPDATE; FLOW	The velocity of left atrium appendage (LAA) wall motion during atrial fibrillation (AF) is a potential marker of mechanical remodelling. In this study, we investigated whether the velocity of LAA wall motion during AF predicted the success of electrical cardioversion and long-term sinus rhythm maintenance. Standard echocardiographic data were obtained by transthoracic echocardiography, and LAA wall motion velocities were measured by transoesophageal echocardiography. With logistic regression and receiver operating characteristic curve analyses, we related echocardiographic and clinical data to cardioversion outcomes and sinus rhythm maintenance at 12 months. Of 121 patients prospectively included in the study, electrical cardioversion restored sinus rhythm in 97 (81.2%), and 51 (42%) patients maintained sinus rhythm at 12 months. Patients in whom cardioversion restored sinus rhythm had higher LAA wall motion velocities than did the patients with failed cardioversions (p < 0.001). Compared to patients with AF at 12 months, patients who maintained sinus rhythm had lower maximum and end-diastolic left atrial volumes (p <= 0.01), lower E/e' ratios (p = 0.005), higher s' values (p = 0.013), and higher LAA motion velocities (p < 0.001). On multivariate logistic regression, only LAA wall motion velocity and E/e' ratios remained significant predictors of sinus rhythm maintenance at 12 months (p <= 0.04). LAA wall motion velocity was also a significant predictor of sinus rhythm maintenance when corrected for clinical variables (p = 0.039). Conclusion: LAA wall motion velocity, as a marker of mechanical remodelling, can predict short-term and long-term sinus rhythm maintenance after electrical cardioversion in AF.	[Walek, Pawel; Sielski, Janusz] Swietokrzyskie Cardiol Ctr, Intens Cardiac Care Unit, Kielce, Poland; [Sielski, Janusz; Roskal-Walek, Joanna; Wozakowska-Kaplon, Beata] Jan Kochanowski Univ Humanities & Sci, Fac Med & Hlth Sci, Kielce, Poland; [Gorczyca, Iwona; Starzyk, Katarzyna; Jaskulska-Niedziela, Elzbieta; Bartkowiak, Radoslaw; Wozakowska-Kaplon, Beata] Swietokrzyskie Cardiol Ctr, Dept Cardiol & Electrotherapy, Kielce, Poland	Jan Kochanowski University	Walek, P (corresponding author), Swietokrzyskie Cardiol Ctr, Intens Cardiac Care Unit, Kielce, Poland.	pawel.walek@o2.pl	Gorczyca-Głowacka, Iwona/M-9664-2013	Gorczyca-Głowacka, Iwona/0000-0002-7619-8426; Walek, Pawel/0000-0003-0632-6573; Sielski, Janusz/0000-0003-2414-0035; Starzyk, Katarzyna/0000-0002-0121-4487	program of the Minister of Science and Higher Education called "Regional Initiative of Excellence" [024/RID/2018/19]	program of the Minister of Science and Higher Education called "Regional Initiative of Excellence"	This project was financed under the program of the Minister of Science and Higher Education called "Regional Initiative of Excellence". Project no, 024/RID/2018/19; amount of financing, 11,999,000 PLN.	Agmon Y, 2000, AM J CARDIOL, V86, P769, DOI 10.1016/S0002-9149(00)01078-X; Allessie M, 2002, CARDIOVASC RES, V54, P230, DOI 10.1016/S0008-6363(02)00258-4; Arslan S, 2012, CARDIOLOGY, V121, P255, DOI 10.1159/000337291; Bartkowiak R, 2010, KARDIOL POL, V68, P48; Bauer F, 2005, J AM SOC ECHOCARDIOG, V18, P934, DOI 10.1016/j.echo.2005.05.014; De Vos CB, 2014, HEART RHYTHM, V11, P1514, DOI 10.1016/j.hrthm.2014.04.029; De Vos CB, 2009, J CARDIOVASC ELECTR, V20, P1374, DOI 10.1111/j.1540-8167.2009.01628.x; de Vos CB, 2009, HEART RHYTHM, V6, P1247, DOI 10.1016/j.hrthm.2008.11.003; Di Salvo G, 2005, CIRCULATION, V112, P387, DOI 10.1161/CIRCULATIONAHA.104.463125; Farese GE, 2019, J AM SOC ECHOCARDIOG, V32, P755, DOI 10.1016/j.echo.2019.01.016; Flachskampf FA, 2010, EUR J ECHOCARDIOGR, V11, P557, DOI 10.1093/ejechocard/jeq057; Goette A, 2016, EUROPACE, V18, P1455, DOI 10.1093/europace/euw161; Kim H, 2014, J AM SOC ECHOCARDIOG, V27, P1107, DOI 10.1016/j.echo.2014.05.013; Kirchhof P, 2016, EUR J CARDIO-THORAC, V50, pE1, DOI 10.1093/ejcts/ezw313; KORTZ RAM, 1993, AM J CARDIOL, V71, P976, DOI 10.1016/0002-9149(93)90917-2; Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014; Limantoro I, 2014, EUROPACE, V16, P1546, DOI 10.1093/europace/euu047; Luong CL, 2016, AM J CARDIOL, V118, P1345, DOI 10.1016/j.amjcard.2016.07.066; Machino-Ohtsuka T, 2013, CIRC J, V77, P1695, DOI 10.1253/circj.CJ-12-1518; Magnani JW, 2011, CIRCULATION, V124, P1982, DOI 10.1161/CIRCULATIONAHA.111.039677; Melduni RM, 2015, AM HEART J, V170, P914, DOI 10.1016/j.ahj.2015.07.027; Nagueh SF, 2016, J AM SOC ECHOCARDIOG, V29, P277, DOI 10.1016/j.echo.2016.01.011; Pisters R, 2012, EUROPACE, V14, P666, DOI 10.1093/europace/eur406; Quintana Miguel, 2005, Cardiovasc Ultrasound, V3, P4, DOI 10.1186/1476-7120-3-4; Takahashi N, 2008, ECHOCARDIOGR-J CARD, V25, P64, DOI 10.1111/j.1540-8175.2007.00565.x; Uretsky S, 2009, EUR J ECHOCARDIOGR, V10, P363, DOI 10.1093/ejechocard/jen339; Vizzardi E, 2014, J CARDIOVASC MED, V15, P235, DOI 10.2459/JCM.0b013e328358554b; Wang T, 2007, INT J CARDIOL, V114, P202, DOI 10.1016/j.ijcard.2006.01.051; Wozakowska-Kaplon B, 2015, POL ARCH MED WEWN, V125, P400, DOI 10.20452/pamw.2876; Wozakowska-Kaplon B, 2010, PACE, V33, P561, DOI 10.1111/j.1540-8159.2009.02673.x	30	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2020	15	1							e0228239	10.1371/journal.pone.0228239	http://dx.doi.org/10.1371/journal.pone.0228239			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9AX	31995607	Green Published, gold			2023-01-03	WOS:000534609400054
J	Minikel, EV; Karczewski, KJ; Martin, HC; Cummings, BB; Whiffin, N; Rhodes, D; Alfoldi, J; Trembath, RC; van Heel, DA; Daly, MJ; Schreiber, SL; MacArthur, DG				Minikel, Eric Vallabh; Karczewski, Konrad J.; Martin, Hilary C.; Cummings, Beryl B.; Whiffin, Nicola; Rhodes, Daniel; Alfoldi, Jessica; Trembath, Richard C.; van Heel, David A.; Daly, Mark J.; Schreiber, Stuart L.; MacArthur, Daniel G.		Genome Aggregation Database Prod T; Genome Aggregation Database Consor	Evaluating drug targets through human loss-of-function genetic variation	NATURE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; HUNTINGTONS-DISEASE GENE; FAMILIAL PRION DISEASE; PARKINSONS-DISEASE; MUTATIONS; PROTEIN; PREVALENCE; PENETRANCE; VARIANTS; EPIDEMIOLOGY	Naturally occurring human genetic variants that are predicted to inactivate protein-coding genes provide an in vivo model of human gene inactivation that complements knockout studies in cells and model organisms. Here we report three key findings regarding the assessment of candidate drug targets using human loss-of-function variants. First, even essential genes, in which loss-of-function variants are not tolerated, can be highly successful as targets of inhibitory drugs. Second, in most genes, loss-of-function variants are sufficiently rare that genotype-based ascertainment of homozygous or compound heterozygous 'knockout' humans will await sample sizes that are approximately 1,000 times those presently available, unless recruitment focuses on consanguineous individuals. Third, automated variant annotation and filtering are powerful, but manual curation remains crucial for removing artefacts, and is a prerequisite for recall-by-genotype efforts. Our results provide a roadmap for human knockout studies and should guide the interpretation of loss-of-function variants in drug development.	[Minikel, Eric Vallabh; Karczewski, Konrad J.; Cummings, Beryl B.; Whiffin, Nicola; Alfoldi, Jessica; Daly, Mark J.; MacArthur, Daniel G.] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA; [Minikel, Eric Vallabh] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA; [Minikel, Eric Vallabh; Schreiber, Stuart L.] Broad Inst MIT & Harvard, Chem Biol & Therapeut Sci Program, Cambridge, MA 02142 USA; [Minikel, Eric Vallabh; Karczewski, Konrad J.; Cummings, Beryl B.; Alfoldi, Jessica; Daly, Mark J.; MacArthur, Daniel G.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA; [Minikel, Eric Vallabh; Cummings, Beryl B.] Harvard Med Sch, Program Biol & Biomed Sci, Boston, MA 02115 USA; [Minikel, Eric Vallabh] Massachusetts Gen Hosp, Henry & Allison McCance Ctr Brain Hlth, Boston, MA 02114 USA; [Minikel, Eric Vallabh] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Minikel, Eric Vallabh] Prion Alliance, Cambridge, MA 02139 USA; [Martin, Hilary C.] Wellcome Sanger Inst, Hinxton, Cambs, England; [Whiffin, Nicola] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Whiffin, Nicola] Imperial Coll London, MRC London Inst Med Sci, London, England; [Rhodes, Daniel] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Ctr Translat Bioinformat, London, England; [Rhodes, Daniel] Barts Hearth NHS Trust, London, England; [Trembath, Richard C.] Kings Coll London, Fac Life Sci & Med, Sch Basic & Med Biosci, London, England; [van Heel, David A.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England; [Schreiber, Stuart L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; [MacArthur, Daniel G.] Garvan Inst Med Res, Ctr Populat Genom, Sydney, NSW, Australia; [MacArthur, Daniel G.] UNSW Sydney, Sydney, NSW, Australia; [MacArthur, Daniel G.] Murdoch Childrens Res Inst, Ctr Populat Genom, Melbourne, Vic, Australia	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Wellcome Trust Sanger Institute; Imperial College London; Imperial College London; University of London; Queen Mary University London; University of London; King's College London; University of London; Queen Mary University London; Harvard University; Garvan Institute of Medical Research; University of New South Wales Sydney; Murdoch Children's Research Institute	Minikel, EV; MacArthur, DG (corresponding author), Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA.; Minikel, EV (corresponding author), Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA.; Minikel, EV (corresponding author), Broad Inst MIT & Harvard, Chem Biol & Therapeut Sci Program, Cambridge, MA 02142 USA.; Minikel, EV; MacArthur, DG (corresponding author), Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.; Minikel, EV (corresponding author), Harvard Med Sch, Program Biol & Biomed Sci, Boston, MA 02115 USA.; Minikel, EV (corresponding author), Massachusetts Gen Hosp, Henry & Allison McCance Ctr Brain Hlth, Boston, MA 02114 USA.; Minikel, EV (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.; Minikel, EV (corresponding author), Prion Alliance, Cambridge, MA 02139 USA.; MacArthur, DG (corresponding author), Garvan Inst Med Res, Ctr Populat Genom, Sydney, NSW, Australia.; MacArthur, DG (corresponding author), UNSW Sydney, Sydney, NSW, Australia.; MacArthur, DG (corresponding author), Murdoch Childrens Res Inst, Ctr Populat Genom, Melbourne, Vic, Australia.	eminikel@broadinstitute.org; d.macarthur@garvan.org.au	Färkkilä, Martti/AAG-6970-2021; Cohen, Bruce M./AAZ-4986-2020; Ware, James S/G-5139-2012; Kaprio, Jaakko/A-1820-2008; Ma, Ronald/C-2788-2009; Rioux, John D/A-9599-2015; Daly, Mark/B-2453-2017; Glaser, Benjamin/F-8411-2017; sokol, harry/E-2290-2019; Loos, Ruth/Q-2862-2016; Erdmann, Jeanette/P-7513-2014; Bown, Matthew/P-1957-2016	Färkkilä, Martti/0000-0002-0250-8559; Ware, James S/0000-0002-6110-5880; Kaprio, Jaakko/0000-0002-3716-2455; Ma, Ronald/0000-0002-1227-803X; Rioux, John D/0000-0001-7560-8326; Daly, Mark/0000-0002-0949-8752; Rhodes, Daniel/0000-0002-2021-4773; Cibulskis, Kristian/0000-0003-1343-1582; Solomonson, Matthew/0000-0002-5344-9026; Glaser, Benjamin/0000-0003-4711-5000; ELOSUA, ROBERTO/0000-0001-8235-0095; sokol, harry/0000-0002-2914-1822; solinas, emilia/0000-0003-3532-1317; Loos, Ruth/0000-0002-8532-5087; Tai, E Shyong/0000-0003-2929-8966; Palotie, Aarno/0000-0002-2527-5874; Erdmann, Jeanette/0000-0002-4486-6231; Melander, Olle/0000-0002-2581-484X; Armean, Irina/0000-0002-1043-4756; Tuomi, Tiinamaija/0000-0002-8306-6202; Bown, Matthew/0000-0002-6180-3611; MacArthur, Daniel/0000-0002-5771-2290; van Heel, David/0000-0002-0637-2265	National Institutes of Health (NIH) [F31 AI122592]; NIDDK [U54 DK105566]; NIGMS [R01 GM104371]; Wellcome Trust [102627, 210561]; Medical Research Council [M009017]; Higher Education Funding Council for England Catalyst; Barts Charity [845/1796]; Health Data Research UK; Rosetrees and Stoneygate Imperial College Research Fellowship; Academy of Finland [312073]; Broad Institute; MRC [MC_UP_1102/20, MR/M009017/1] Funding Source: UKRI	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Higher Education Funding Council for England Catalyst(UK Research & Innovation (UKRI)Higher Education Funding Council for England (HEFCE)); Barts Charity; Health Data Research UK; Rosetrees and Stoneygate Imperial College Research Fellowship; Academy of Finland(Academy of Finland); Broad Institute; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was performed under ethical approval from the Partners Healthcare Institutional Research Board (2013P001339/MGH) and the Broad Institute Office of Research Subjects Protection (ORSP-3862) in compliance with all relevant ethical regulations; written informed consent was obtained from all research participants. We thank all of the research participants for contributing their data. E.V.M. acknowledges support from the National Institutes of Health (NIH) (F31 AI122592) and an anonymous organization. gnomAD data aggregation was supported primarily by the Broad Institute, gnomAD analysis was supported in part by NIDDK U54 DK105566, and development of LOFTEE by NIGMS R01 GM104371. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. E.L.G.H. is funded by the Wellcome Trust (102627, 210561), the Medical Research Council (M009017), Higher Education Funding Council for England Catalyst, Barts Charity (845/1796), Health Data Research UK (for London substantive site), and research delivery support from the NHS National Institute for Health Research Clinical Research Network (North Thames). N.W. is supported by a Rosetrees and Stoneygate Imperial College Research Fellowship. The results published here are in part based upon data: (1) generated by The Cancer Genome Atlas managed by the NCI and NHGRI (accession: phs000178.v10.p8). Information about TCGA can be found at http://cancergenome.nih.gov; (2) generated by the Genotype-Tissue Expression Project (GTEx) managed by the NIH Common Fund and NHGRI (accession: phs000424.v7.p2); (3) generated by the Exome Sequencing Project, managed by NHLBI; (4) generated by the Alzheimer's Disease Sequencing Project (ADSP), managed by the NIA and NHGRI (accession: phs000572.v7.p4). We thank J. Kaprio and M. Kurki (Finnish Twins AD cohort) and Academy of Finland grant 312073, and Ruth McPherson (Ottawa Genomics Heart Study) for providing information on individuals with PRNP-truncating variants. We thank J. B. Carroll, K. Heilbron, J. Fah Sathirapongsasuti, and L. C. Francioli for comments and suggestions. A subset of the analyses reported here originally appeared as a blog post on CureFFI.org (http://www.cureffi.org/2018/09/12/lof-and-drug-safety/).	Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277; AMBROSE CM, 1994, SOMAT CELL MOLEC GEN, V20, P27, DOI 10.1007/BF02257483; Andreadis A, 2012, J CELL PHYSIOL, V227, P1220, DOI 10.1002/jcp.22842; Bang J, 2015, LANCET, V386, P1672, DOI 10.1016/S0140-6736(15)00461-4; Bittles AH, 2010, P NATL ACAD SCI USA, V107, P1779, DOI 10.1073/pnas.0906079106; Blekhman R, 2008, CURR BIOL, V18, P883, DOI 10.1016/j.cub.2008.04.074; Bommarito G, 2018, EUR J NEUROL, V25, pE91, DOI 10.1111/ene.13665; Byrne S, 2011, J NEUROL NEUROSUR PS, V82, P623, DOI 10.1136/jnnp.2010.224501; Capellari S, 2018, ANN CLIN TRANSL NEUR, V5, P777, DOI 10.1002/acn3.568; Chen JH, 2018, EUR NEUROL, V79, P256, DOI 10.1159/000488938; Chio A, 2008, NEUROLOGY, V70, P533, DOI 10.1212/01.wnl.0000299187.90432.3f; Cole TA, 2019, BIORXIV, DOI 10.1101/830554; Collins RL, 2020, NATURE, V581, P444, DOI 10.1038/s41586-020-2287-8; Cudkowicz ME, 1997, ANN NEUROL, V41, P210, DOI 10.1002/ana.410410212; Cummings BB, 2020, NATURE, V581, P452, DOI 10.1038/s41586-020-2329-2; DeBoever C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03910-9; DeVos SL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag0481; DiMasi JA, 2016, J HEALTH ECON, V47, P20, DOI 10.1016/j.jhealeco.2016.01.012; Do CB, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002141; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Finckh U, 2000, AM J HUM GENET, V66, P110, DOI 10.1086/302702; Findlay GM, 2018, NATURE, V562, P217, DOI 10.1038/s41586-018-0461-z; Finer S, 2019, INT J EPIDEMIOL, V49, P20; Fisher ER, 2014, MOVEMENT DISORD, V29, P105, DOI 10.1002/mds.25717; Fong JC, 2017, J ALZHEIMERS DIS, V55, P249, DOI 10.3233/JAD-160300; Fuller ZL, 2019, NAT GENET, V51, P772, DOI 10.1038/s41588-019-0383-1; Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113; Goldwurm S, 2007, NEUROLOGY, V68, P1141, DOI 10.1212/01.wnl.0000254483.19854.ef; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514; Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121; Hart T, 2017, G3-GENES GENOM GENET, V7, P2719, DOI 10.1534/g3.117.041277; Hay M, 2014, NAT BIOTECHNOL, V32, P40, DOI 10.1038/nbt.2786; Healy DG, 2008, LANCET NEUROL, V7, P583, DOI 10.1016/S1474-4422(08)70117-0; Hernandez DG, 2016, J NEUROCHEM, V139, P59, DOI 10.1111/jnc.13593; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Hoshi N, 2010, MOL CELL, V37, P541, DOI 10.1016/j.molcel.2010.01.014; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jansen C, 2010, ACTA NEUROPATHOL, V119, P189, DOI 10.1007/s00401-009-0609-x; Jayadev S, 2011, ANN NEUROL, V69, P712, DOI 10.1002/ana.22264; Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7; Kay C, 2016, NEUROLOGY, V87, P282, DOI 10.1212/WNL.0000000000002858; Keum JW, 2016, AM J HUM GENET, V98, P287, DOI 10.1016/j.ajhg.2015.12.018; King EA, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008489; Kinoshita T, 2016, J LIPID RES, V57, P6, DOI 10.1194/jlr.R063313; KITAMOTO T, 1993, BIOCHEM BIOPH RES CO, V192, P525, DOI 10.1006/bbrc.1993.1447; Kosmicki JA, 2017, NAT GENET, V49, P504, DOI 10.1038/ng.3789; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lim ET, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004494; Logroscino G, 2010, J NEUROL NEUROSUR PS, V81, P385, DOI 10.1136/jnnp.2009.183525; Lv WH, 2016, ONCOTARGET, V7, P4961, DOI 10.18632/oncotarget.6755; MacArthur DG, 2012, SCIENCE, V335, P823, DOI 10.1126/science.1215040; MacArthur J, 2017, NUCLEIC ACIDS RES, V45, pD896, DOI 10.1093/nar/gkw1133; Maddox RA, 2020, NEUROLOGY, V94, pE153, DOI 10.1212/WNL.0000000000008680; Mainland JD, 2015, SCI DATA, V2, DOI 10.1038/sdata.2015.2; Matsuzono K, 2013, EUR J NEUROL, V20, pe67, DOI 10.1111/ene.12089; McCampbell A, 2018, J CLIN INVEST, V128, P3558, DOI 10.1172/JCI99081; Mead S, 2013, NEW ENGL J MED, V369, P1904, DOI 10.1056/NEJMoa1214747; Minikel EV, 2019, NEUROLOGY, V93, pE125, DOI 10.1212/WNL.0000000000007745; Minikel EV, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad5169; Minikel EV, 2020, NEUROSCIENCE, DOI [10.1101/2020.03.27.011940, DOI 10.1101/2020.03.27.011940]; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Motenko H, 2015, MAMM GENOME, V26, P325, DOI 10.1007/s00335-015-9573-z; Musunuru K, 2019, CELL, V177, P132, DOI 10.1016/j.cell.2019.02.015; Nagashima S, 2012, ARTERIOSCL THROM VAS, V32, P1824, DOI 10.1161/ATVBAHA.111.240754; Narasimhan VM, 2016, SCIENCE, V352, P474, DOI 10.1126/science.aac8624; Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314; Ohashi K, 2003, J BIOL CHEM, V278, P42936, DOI 10.1074/jbc.M307228200; Onyike CU, 2013, INT REV PSYCHIATR, V25, P130, DOI 10.3109/09540261.2013.776523; Petrovski S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003709; Plenge RM, 2013, NAT REV DRUG DISCOV, V12, P581, DOI 10.1038/nrd4051; Pringsheim T, 2014, MOVEMENT DISORD, V29, P1583, DOI 10.1002/mds.25945; Pringsheim T, 2012, MOVEMENT DISORD, V27, P1083, DOI 10.1002/mds.25075; Rehm HL, 2015, NEW ENGL J MED, V372, P2235, DOI 10.1056/NEJMsr1406261; Renton AE, 2014, NAT NEUROSCI, V17, P17, DOI 10.1038/nn.3584; Rodan LH, 2016, EUR J HUM GENET, V24, P1826, DOI 10.1038/ejhg.2016.74; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Saleheen D, 2017, NATURE, V544, P235, DOI 10.1038/nature22034; Samocha KE, 2014, NAT GENET, V46, P944, DOI 10.1038/ng.3050; Sulem P, 2015, NAT GENET, V47, P448, DOI 10.1038/ng.3243; Tabrizi SJ, 2019, NEW ENGL J MED, V380, P2307, DOI 10.1056/NEJMoa1900907; Trinh J, 2014, JAMA NEUROL, V71, P1535, DOI 10.1001/jamaneurol.2014.1909; Uhl K, 2002, DRUG SAFETY, V25, P885, DOI 10.2165/00002018-200225120-00006; Whiffin N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-10717-9; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037; Yates B, 2017, NUCLEIC ACIDS RES, V45, pD619, DOI 10.1093/nar/gkw1033; Zambrowicz BP, 2003, NAT REV DRUG DISCOV, V2, P38, DOI 10.1038/nrd987; Zhang W, 1996, J EXP MED, V183, P413, DOI 10.1084/jem.183.2.413; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005	89	55	55	1	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 28	2020	581	7809					459	+		10.1038/s41586-020-2267-z	http://dx.doi.org/10.1038/s41586-020-2267-z			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX9ZL	32461653	Green Submitted, Green Accepted, Green Published, hybrid			2023-01-03	WOS:000576060200006
J	Rauh, AL; Linder, JA				Rauh, Alicia L.; Linder, Jeffrey A.			Covid-19 care before, during, and beyond the hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Rauh, Alicia L.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hosp Med, Chicago, IL 60611 USA; [Linder, Jeffrey A.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Gen Internal Med & Geriatr, 750 North Lake Shore Dr,10th Floor, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Linder, JA (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Gen Internal Med & Geriatr, 750 North Lake Shore Dr,10th Floor, Chicago, IL 60611 USA.	jlinder@northwestern.edu	Linder, Jeffrey/AAF-3424-2021	Linder, Jeffrey/0000-0003-2217-184X				Arons MM, 2020, N ENGL J MED; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Johns Hopkins University, 2022, COVID 19 DASHB CTR S; Lewnard JA, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1923; National Institute for Health and Care Excellence, 2020, COVID 19 POSITIVE OU; Onder G, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.4683, DOI 10.1001/JAMA.2020.468]; Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9; Richardson S., 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI [10.1001/jama.2020.6775, DOI 10.1001/JAMA.2020.6775, 10.1001/jama.2020.7681]; Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468; Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272; Williamson E, 2020, OPENSAFELY FACTORS A, DOI [10.1101/2020.05.06.20092999v1, DOI 10.1101/2020.05.06.20092999V1]; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	15	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	2020	369								m2035	10.1136/bmj.m2035	http://dx.doi.org/10.1136/bmj.m2035			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV3JU	32444351	Bronze			2023-01-03	WOS:000538336800005
J	Streefkerk, N; Tissing, WJE; Korevaar, JC; van Dulmen-den Broeder, E; Bresters, D; van der Heiden-van der Loos, M; van de Heuvel-Eibrink, MM; Van Leeuwen, FE; Loonen, J; van der Pal, HHJ; Ronckers, CM; Versluys, AB; de Vries, ACH; Feijen, EAM; Kremer, LCM				Streefkerk, Nina; Tissing, Wim J. E.; Korevaar, Joke C.; van Dulmen-den Broeder, Eline; Bresters, Dorine; van der Heiden-van der Loos, Margriet; van de Heuvel-Eibrink, Marry M.; Van Leeuwen, Flora E.; Loonen, Jacqueline; van der Pal, Helena H. J.; Ronckers, Cecile M.; Versluys, A. Brigitte; de Vries, Andrica C. H.; Feijen, Elizabeth A. M.; Kremer, Leontine C. M.		Dutch LATER Study Grp	A detailed insight in the high risks of hospitalizations in long-term childhood cancer survivors-A Dutch LATER linkage study	PLOS ONE			English	Article							QUALITY-OF-LIFE; SECONDARY LEUKEMIA; HEALTH OUTCOMES; GROWTH-HORMONE; ADULT CANCER; POPULATION; COHORT; ADOLESCENT; RADIATION; SERVICE	Background Insight in hospitalizations in long-term childhood cancer survivors (CCS) is useful to understand the impact of long-term morbidity. We aimed to investigate hospitalization rates and underlying types of diagnoses in CCS compared to matched controls, and to investigate the determinants. Methods We linked 5,650 five-year CCS from the Dutch nationwide Dutch LATER cohort and 109,605 age- and sex-matched controls to the Dutch Hospital Discharge register, which contained detailed information on inpatient hospitalizations from 1995-2016. Relative hospitalization rates (RHRs) were calculated using a Poisson regression model. Adjusting for multiple hospitalizations per person via a Poisson model for generalized estimated equations, we investigated determinants for hospitalizations for all types of underlying diagnoses among CCS. Results CCS were twice as likely to be hospitalized as reference persons (hospitalization rate 178 and 78 per 1,000 person-years respectively; RHR 2.0, 95% confidence interval (CI) 1.9-2.2). Although CCS had more hospitalizations for 17 types of underlying diagnoses, they were especially more likely to be hospitalized for endocrine conditions (RHR: 6.0, 95% CI 4.6-7.7), subsequent neoplasms (RHR: 5.6, 95% CI 4.6-6.7) and symptoms without underlying diagnoses (RHR: 5.2, 95% CI 4.6-5.8). For those types of underlying diagnoses, female sex and radiotherapy were determinants. Conclusion This study provides new insights in the high risk of hospitalizations for many types of underlying diagnoses in CCS and treatment related determinants. CCS are especially at high risk for hospitalizations for endocrine conditions, subsequent neoplasms and symptoms without an underlying diagnosis. This new knowledge is important for survivorship care and to identify possible preventable hospitalizations among CCS.	[Streefkerk, Nina; Tissing, Wim J. E.; van Dulmen-den Broeder, Eline; Bresters, Dorine; van de Heuvel-Eibrink, Marry M.; van der Pal, Helena H. J.; Ronckers, Cecile M.; Versluys, A. Brigitte; de Vries, Andrica C. H.; Feijen, Elizabeth A. M.; Kremer, Leontine C. M.] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands; [Streefkerk, Nina; Ronckers, Cecile M.; Feijen, Elizabeth A. M.; Kremer, Leontine C. M.] Univ Amsterdam, Emma Childrens Hosp, Dept Pediat Oncol, Amsterdam UMC, Amsterdam, Netherlands; [Tissing, Wim J. E.] Univ Groningen, Beatrix Childrens Hosp, Univ Med Ctr Groningen, Dept Pediat Oncol Hematol, Groningen, Netherlands; [Korevaar, Joke C.] Netherlands Inst Hlth Serv Res, Utrecht, Netherlands; [van Dulmen-den Broeder, Eline] Vrije Univ Amsterdam, Amsterdam UMC, Dept Pediat Oncol Hematol, Amsterdam, Netherlands; [van der Heiden-van der Loos, Margriet] Dutch Childhood Oncol Grp, Utrecht, Netherlands; [van de Heuvel-Eibrink, Marry M.; de Vries, Andrica C. H.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Van Leeuwen, Flora E.] Netherlands Canc Inst, Dept Epidemiol & Biostat, Amsterdam, Netherlands; [Loonen, Jacqueline] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, Nijmegen, Netherlands; [Versluys, A. Brigitte] Wilhelmina Childrens Hosp, Univ Med Ctr Utrecht, Dept Pediat Oncol & Hematol, Utrecht, Netherlands	Emma Children's Hospital; University of Amsterdam; University of Groningen; Netherlands Institute for Health Services Research; University of Amsterdam; Vrije Universiteit Amsterdam; Dutch Childhood Oncology Group; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Netherlands Cancer Institute; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Kremer, LCM (corresponding author), Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands.; Kremer, LCM (corresponding author), Univ Amsterdam, Emma Childrens Hosp, Dept Pediat Oncol, Amsterdam UMC, Amsterdam, Netherlands.	e.a.feijen@amc.uva.nl	Ronckers, Cecile/GWN-0737-2022; Loonen, J.J./L-4495-2015	Loonen, J.J./0000-0002-9963-8367; Kremer, Leontien/0000-0001-7422-3248; kremer, leontien/0000-0002-7619-7845; Ronckers, Cecile M./0000-0003-3524-4657	Dutch Cancer Society [UVA2012-5517]	Dutch Cancer Society(KWF Kankerbestrijding)	NS is supported by the Dutch Cancer Society (Grant No. UVA2014-6805) and CMR is supported by the Dutch Cancer Society (Grant No. UVA2012-5517).	Bhakta N, 2017, LANCET, V390, P2569, DOI 10.1016/S0140-6736(17)31610-0; Bradley NME, 2010, EUR J CANCER, V46, P2441, DOI 10.1016/j.ejca.2010.05.001; Brewster DH, 2014, BRIT J CANCER, V110, P1342, DOI 10.1038/bjc.2013.788; Cohen JW, 2003, HEALTH AFFAIR, V22, P129, DOI 10.1377/hlthaff.22.2.129; Colao A, 2001, CLIN ENDOCRINOL, V54, P137, DOI 10.1046/j.1365-2265.2001.01218.x; Dutch Hospital Data, DUTCH HOSP DAT; Font-Gonzalez A, 2017, CANCER MED-US, V6, P1123, DOI 10.1002/cam4.1057; Gatta G, 2014, LANCET ONCOL, V15, P35, DOI 10.1016/S1470-2045(13)70548-5; Geenen MM, 2007, JAMA-J AM MED ASSOC, V297, P2705, DOI 10.1001/jama.297.24.2705; HAWKINS MM, 1991, LANCET, V338, P1408, DOI 10.1016/0140-6736(91)92294-C; Hudson MM, 2013, JAMA-J AM MED ASSOC, V309, P2371, DOI 10.1001/jama.2013.6296; Keene DL, 2006, CHILD NERV SYST, V22, P547, DOI 10.1007/s00381-006-0097-4; Kilian R, 2001, CLIN PSYCHOL PSYCHOT, V8, P206, DOI 10.1002/cpp.277; Kirchhoff AC, 2014, CANCER EPIDEM BIOMAR, V23, P1280, DOI 10.1158/1055-9965.EPI-13-1090; Kurt BA, 2012, PEDIATR BLOOD CANCER, V59, P126, DOI 10.1002/pbc.24017; Le Deley MC, 2003, J CLIN ONCOL, V21, P1074, DOI 10.1200/JCO.2003.04.100; Licht SD, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002296; Link K, 2004, J CLIN ENDOCR METAB, V89, P5003, DOI 10.1210/jc.2004-0126; Lorenzi MF, 2011, INT J CANCER, V128, P1624, DOI 10.1002/ijc.25751; Mueller BA, 2018, CANC CAUSES CONTROL; Mueller S, 2013, INT J RADIAT ONCOL, V86, P649, DOI 10.1016/j.ijrobp.2013.03.034; Murphy ES, 2015, J NEURO-ONCOL, V122, P421, DOI 10.1007/s11060-015-1732-2; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Rebholz CE, 2011, J CLIN ONCOL, V29, P4181, DOI 10.1200/JCO.2011.36.5619; Reynolds MR, 2010, AM HEART J, V160, P752, DOI 10.1016/j.ahj.2010.06.034; Rugbjerg K, 2016, JAMA ONCOL, V2, P193, DOI 10.1001/jamaoncol.2015.4393; Sieswerda E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159518; Statstics Netherlands (Centraal Bureau voor de Statistiek), DOC ZIEK LAND BAS ZI; Statstics Netherlands (Centraal Bureau voor de Statistiek), 2012, DOC LAND MED REG LMR; Steliarova-Foucher E, 2005, CANCER-AM CANCER SOC, V103, P1457, DOI 10.1002/cncr.20910; Stewart S, 2002, EUR J HEART FAIL, V4, P361, DOI 10.1016/S1388-9842(01)00198-2; Talvensaari KK, 1996, J CLIN ENDOCR METAB, V81, P3051, DOI 10.1210/jc.81.8.3051; Teepen JC, 2017, J CLIN ONCOL, V35, P2288, DOI 10.1200/JCO.2016.71.6902; van Dijk IWEM, 2016, INT J RADIAT ONCOL, V96, P597, DOI 10.1016/j.ijrobp.2016.03.049; Vatner RE, 2018, J CLIN ONCOL, V36, P2854, DOI 10.1200/JCO.2018.78.1492; WHO. World Health Organization, 1992, INT STAT CLASS DIS R	36	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2020	15	5							e0232708	10.1371/journal.pone.0232708	http://dx.doi.org/10.1371/journal.pone.0232708			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1DW	32427994	Green Published, gold			2023-01-03	WOS:000537503400010
J	van Dijk, B; Allen, KJH; Helal, M; Vogely, HC; Lam, MGEH; de Klerk, JMH; Weinans, H; van der Wal, BCH; Dadachova, E				van Dijk, B.; Allen, K. J. H.; Helal, M.; Vogely, H. C.; Lam, M. G. E. H.; de Klerk, J. M. H.; Weinans, H.; van der Wal, B. C. H.; Dadachova, E.			Radioimmunotherapy of methicillin-resistant Staphylococcus aureus in planktonic state and biofilms	PLOS ONE			English	Article							INFECTION	Background Implant associated infections such as periprosthetic joint infections are difficult to treat as the bacteria form a biofilm on the prosthetic material. This biofilm complicates surgical and antibiotic treatment. With rising antibiotic resistance, alternative treatment options are needed to treat these infections in the future. The aim of this article is to provide proof-of-principle data required for further development of radioimmunotherapy for non-invasive treatment of implant associated infections. Methods Planktonic cells and biofilms of Methicillin-resistant staphylococcus aureus are grown and treated with radioimmunotherapy. The monoclonal antibodies used, target wall teichoic acids that are cell and biofilm specific. Three different radionuclides in different doses were used. Viability and metabolic activity of the bacterial cells and biofilms were measured by CFU dilution and XTT reduction. Results Alpha-RIT with Bismuth-213 showed significant and dose dependent killing in both planktonic MRSA and biofilm. When planktonic bacteria were treated with 370 kBq of Bi-213-RIT 99% of the bacteria were killed. Complete killing of the bacteria in the biofilm was seen at 185 kBq. Beta-RIT with Lutetium-177 and Actinium-225 showed little to no significant killing. Conclusion Our results demonstrate the ability of specific antibodies loaded with an alpha-emitter Bismuth-213 to selectively kill staphylococcus aureus cells in vitro in both planktonic and biofilm state. RIT could therefore be a potentially alternative treatment modality against planktonic and biofilm-related microbial infections.	[van Dijk, B.; Vogely, H. C.; Weinans, H.; van der Wal, B. C. H.] Univ Med Ctr Utrecht, Dept Orthoped, Utrecht, Netherlands; [Allen, K. J. H.; Helal, M.; Dadachova, E.] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK, Canada; [Lam, M. G. E. H.] Univ Med Ctr Utrecht, Dept Radiol & Nucl Med, Utrecht, Netherlands; [de Klerk, J. M. H.] Meander Med Ctr Amersfoort, Dept Nucl Med, Amersfoort, Netherlands; [Weinans, H.] Delft Univ Technol, Dept Biomech Engn, Delft, Netherlands	Utrecht University; Utrecht University Medical Center; University of Saskatchewan; Utrecht University; Utrecht University Medical Center; Meander Medisch Centrum; Delft University of Technology	Dadachova, E (corresponding author), Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK, Canada.	ekaterina.dadachova@usask.ca			Health Holland; Netherlands Organization for Scientific Research (NWO) [LSHM17026]	Health Holland; Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	This research was funded by Health Holland, which is non for profit organization, financed by the Netherlands Organization for Scientific Research (NWO), Grant number LSHM17026. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen KJH, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040262; Boles BR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010146; Bryan RA, 2013, FUTURE MICROBIOL, V8, P1081, DOI 10.2217/fmb.13.79; Bryan RA, 2010, J INFECT DIS, V202, P633, DOI 10.1086/654813; Dadachova E, 2004, ANTIMICROB AGENTS CH, V48, P1624, DOI 10.1128/AAC.48.5.1624-1629.2004; Dadachova E, 2004, ANTIMICROB AGENTS CH, V48, P1004, DOI 10.1128/AAC.48.3.1004-1006.2004; Dadachova E, 2003, P NATL ACAD SCI USA, V100, P10942, DOI 10.1073/pnas.1731272100; Helal M, 2018, RADIOIMMUNOTHERAPY N, V33, P1; Larson SM, 2015, NAT REV CANCER, V15, P347, DOI 10.1038/nrc3925; Parvizi J, 2011, CLIN ORTHOP RELAT R, V469, P3022, DOI 10.1007/s11999-011-1971-2; Pulido L, 2008, CLIN ORTHOP RELAT R, V466, P1710, DOI 10.1007/s11999-008-0209-4; Quirk EK, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu016; Sadovskaya I, 2006, FEMS IMMUNOL MED MIC, V47, P75, DOI 10.1111/j.1574-695X.2006.00068.x; Stepanovic S, 2007, APMIS; Zimmerli W, 2012, FEMS IMMUNOL MED MIC, V65, P158, DOI 10.1111/j.1574-695X.2012.00938.x	15	5	5	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2020	15	5							e0233086	10.1371/journal.pone.0233086	http://dx.doi.org/10.1371/journal.pone.0233086			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU0YZ	32407350	Green Published, gold			2023-01-03	WOS:000537490700068
J	Curtis, JR; Kross, EK; Stapleton, RD				Curtis, J. Randall; Kross, Erin K.; Stapleton, Renee D.			The Importance of Addressing Advance Care Planning and Decisions About Do-Not-Resuscitate Orders During Novel Coronavirus 2019 (COVID-19)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint emphasizes the importance of advanced care planning and goals-of-care discussions with older patients and those with chronic disease during the spread of coronavirus disease (COVID-19), given the likelihood these patients could become critically ill and require resuscitation and advanced life support if they became infected with SARS-CoV-2.	[Curtis, J. Randall; Kross, Erin K.] Univ Washington, Div Pulm Crit Care & Sleep Med, Seattle, WA 98195 USA; [Curtis, J. Randall; Kross, Erin K.] Univ Washington, Cambia Palliat Care Ctr Excellence, 325 Ninth Ave,POB 359762, Seattle, WA 98104 USA; [Stapleton, Renee D.] Univ Vermont, Larner Coll Med, Div Pulm & Crit Care Med, Burlington, VT USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Vermont	Curtis, JR (corresponding author), Univ Washington, Cambia Palliat Care Ctr Excellence, 325 Ninth Ave,POB 359762, Seattle, WA 98104 USA.	jrc@u.washington.edu		Curtis, J. Randall/0000-0001-9529-845X				Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Back AL., 2020, COVID READY COMMUNIC; Bosslet GT, 2016, INTENS CARE MED, V42, P422, DOI 10.1007/s00134-015-4192-4; Cwrtis JR, 2007, CHEST, V132, P748, DOI 10.1378/chest.07-0745; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Goodman E, 2020, CONVERSATION PROJECT; Ornstein KA, 2017, J PAIN SYMPTOM MANAG, V53, P178, DOI 10.1016/j.jpainsymman.2016.08.023; Rubenfeld G., 2020, GLOBE MAIL; Sudore RL, 2018, JAMA INTERN MED, V178, P1616, DOI 10.1001/jamainternmed.2018.4657; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994	10	221	223	2	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2020	323	18					1771	1772		10.1001/jama.2020.4894	http://dx.doi.org/10.1001/jama.2020.4894			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LS2LS	32219360	Bronze			2023-01-03	WOS:000536221500009
J	Hong, JY; Kim, JH				Hong, Joo Young; Kim, Ju Han			PG-path: Modeling and personalizing pharmacogenomics-based pathways	PLOS ONE			English	Article							DRUG; PHARMACODYNAMICS; PHARMACOKINETICS; SMPDB; SIFT	A pharmacogenomics-based pathway represents a series of reactions that occur between drugs and genes in the human body after drug administration. PG-path is a pharmacogenomics-based pathway that standardizes and visualizes the components (nodes) and actions (edges) involved in pharmacokinetic and pharmacodynamic processes. It provides an intuitive understanding of the drug response in the human body. A pharmacokinetic pathway visualizes the absorption, distribution, metabolism, and excretion (ADME) at the systemic level, and a pharmacodynamic pathway shows the action of the drug in the target cell at the cellular-molecular level. The genes in the pathway are displayed in locations similar to those inside the body. PG-path allows personalized pathways to be created by annotating each gene with the overall impact degree of deleterious variants in the gene. These personalized pathways play a role in assisting tailored individual prescriptions by predicting changes in the drug concentration in the plasma. PG-path also supports counseling for personalized drug therapy by providing visualization and documentation.	[Hong, Joo Young; Kim, Ju Han] Seoul Natl Univ, Div Biomed Informat, Coll Med, Seoul, South Korea; [Hong, Joo Young] Cipherome Inc, Seoul, South Korea; [Kim, Ju Han] Seoul Natl Univ, Seoul Natl Univ Biomed Informat SNUBI, Div Biomed Informat, Coll Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Kim, JH (corresponding author), Seoul Natl Univ, Div Biomed Informat, Coll Med, Seoul, South Korea.; Kim, JH (corresponding author), Seoul Natl Univ, Seoul Natl Univ Biomed Informat SNUBI, Div Biomed Informat, Coll Med, Seoul, South Korea.	juhan@snu.ac.kr		Kim, Ju Han/0000-0003-1522-9038; Hong, Joo Young/0000-0003-1583-7164				Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Barbarino JM, 2018, WIRES SYST BIOL MED, V10, DOI 10.1002/wsbm.1417; Behjati S, 2013, ARCH DIS CHILDHOOD-E, V98, P236, DOI 10.1136/archdischild-2013-304340; Breitling R, 2010, FRONT PHYSIOL, V1, DOI 10.3389/fphys.2010.00009; Caraballo PJ, 2017, GENET MED, V19, P421, DOI 10.1038/gim.2016.120; Devuyst O, 2015, PERITON DIALYSIS INT, V35, P676, DOI 10.3747/pdi.2015.00261; Drozda K, 2018, JACC-BASIC TRANSL SC, V3, P545, DOI 10.1016/j.jacbts.2018.06.001; Franconi F, 2014, BRIT J PHARMACOL, V171, P580, DOI 10.1111/bph.12362; Frolkis A, 2010, NUCLEIC ACIDS RES, V38, pD480, DOI 10.1093/nar/gkp1002; Garcia-Campos MA, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00383; Ge SX, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2486-6; Goldstein David B, 2012, PRINCIPLES PHARMACOG; Jewison T, 2014, NUCLEIC ACIDS RES, V42, pD478, DOI 10.1093/nar/gkt1067; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Kutmon M, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004085; Luna A, 2011, BIOINFORMATICS, V27, P2165, DOI 10.1093/bioinformatics/btr336; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802; Park Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00654; Rajasethupathy P, 2005, CURR OPIN CHEM BIOL, V9, P400, DOI 10.1016/j.cbpa.2005.06.008; Relling MV, 2011, CLIN PHARMACOL THER, V89, P464, DOI 10.1038/clpt.2010.279; Schultink AHMD, 2015, CLIN PHARMACOKINET, V54, P797, DOI 10.1007/s40262-015-0273-3; Seo H, 2018, BMC MED GENOMICS, V11, DOI 10.1186/s12920-018-0323-4; Soukup T, 2018, J MULTIDISCIP HEALTH, V11, P49, DOI 10.2147/JMDH.S117945; Sousa M, 2008, J ANTIMICROB CHEMOTH, V62, P872, DOI 10.1093/jac/dkn330; Tannenbaum C, 2014, EXPERT REV CLIN PHAR, V7, P533, DOI 10.1586/17512433.2014.910111; Thorn C. F., 2007, Current Pharmacogenomics, V5, P79, DOI 10.2174/157016007780077167; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037; Zheng-Bradley X., 2016, BRIEF FUNCT GENOMICS	29	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2020	15	5							e0230950	10.1371/journal.pone.0230950	http://dx.doi.org/10.1371/journal.pone.0230950			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT3GS	32365122	Green Published, gold			2023-01-03	WOS:000536959700006
J	Zhang, X; Zegar, T; Lucas, A; Morrison-Smith, C; Knox, T; French, CA; Knapp, S; Muller, S; Siveke, JT				Zhang, Xin; Zegar, Tim; Lucas, Anais; Morrison-Smith, Chevaun; Knox, Tatiana; French, Christopher A.; Knapp, Stefan; Muller, Susanne; Siveke, Jens T.			Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma	ONCOGENE			English	Article							BROMODOMAIN INHIBITOR; CBP/P300 BROMODOMAIN; THYMIC CARCINOMA; BET; REARRANGEMENT	Nuclear protein of the testis (NUT) midline carcinoma (NMC), is a rare and highly aggressive form of undifferentiated squamous cell carcinoma. NMC is molecularly characterized by chromosomal rearrangement of the NUT gene to another gene, most commonly the bromodomain and extraterminal domain (BET) gene BRD4, forming the BRD4-NUT fusion oncogene. Therefore, inhibiting BRD4-NUT oncogenic function directly by BET inhibitors represents an attractive therapeutic approach but toxicity may limit the use of pan-BET inhibitors treating this cancer. We thus performed a drug screening approach using a library consisting of epigenetic compounds and 'Donated Chemical Probes' collated by the Structural Genomics Consortium (SGC) and identified the p300/CBP HAT inhibitor A-485, in addition to the well-known BET inhibitor JQ1, to be the most active candidate for NMC treatment. In contrast to JQ1, A-485 was selectively potent in NMC compared to other cell lines tested. Mechanistically, A-485 inhibited p300-mediated histone acetylation, leading to disruption of BRD4-NUT binding to hyperacetylated megadomains. Consistently, BRD4-NUT megadomain-associated genes MYC, CCAT1 and TP63 were downregulated by A-485. A-485 strongly induced squamous differentiation, cell cycle arrest and apoptosis. Combined inhibition of p300/CBP and BET showed synergistic effects. In summary, we identified the p300/CBP HAT domain as a putative therapeutic target in highly therapy-resistant NMC.	[Zhang, Xin; Zegar, Tim; Siveke, Jens T.] Univ Hosp Essen, West German Canc Ctr, Inst Dev Canc Therapeut, Essen, Germany; [Zhang, Xin; Zegar, Tim; Siveke, Jens T.] German Canc Consortium DKTK, Partner Site Essen, Div Solid Tumor Translat Oncol, Heidelberg, Germany; [Zhang, Xin; Zegar, Tim; Siveke, Jens T.] DKFZ, German Canc Res Ctr, Heidelberg, Germany; [Lucas, Anais; Knapp, Stefan; Muller, Susanne] Goethe Univ Frankfurt, Buchmann Inst Life Sci, Struct Genom Consortium, D-60438 Frankfurt, Germany; [Lucas, Anais; Knapp, Stefan; Muller, Susanne] Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60438 Frankfurt, Germany; [Lucas, Anais; Knapp, Stefan] German Canc Consortium DKTK, Partner Site Frankfurt Mainz, D-60438 Frankfurt, Germany; [Lucas, Anais; Knapp, Stefan] Frankfurt Canc Inst FCI, D-60438 Frankfurt, Germany; [Morrison-Smith, Chevaun; Knox, Tatiana; French, Christopher A.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA	University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt; Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Siveke, JT (corresponding author), Univ Hosp Essen, West German Canc Ctr, Inst Dev Canc Therapeut, Essen, Germany.; Siveke, JT (corresponding author), German Canc Consortium DKTK, Partner Site Essen, Div Solid Tumor Translat Oncol, Heidelberg, Germany.; Siveke, JT (corresponding author), DKFZ, German Canc Res Ctr, Heidelberg, Germany.	jens.siveke@uk-essen.de	Knapp, Stefan/AAG-2347-2019; Siveke, Jens/AAQ-6170-2021	Knapp, Stefan/0000-0001-5995-6494; Muller-Knapp, Susanne/0000-0003-2402-4157; Siveke, Jens/0000-0002-8772-4778	AbbVie; Bayer Pharma AG; SGC [1097737]; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genome Canada through Ontario Genomics Institute [OGI-055]; Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant] [115766]; Janssen; Merck KGaA; MSD; Novartis Pharma AG; Ontario Ministry of Research, Innovation and Science (MRIS); Pfizer; Sao Paulo Research Foundation-FAPESP; Takeda; Wellcome Trust; German Cancer Aid (PIPAC consortium) [70112505]; German Cancer Consortium (DKTK); Deutsche Forschungsgemeinschaft (DFG) [SI1549/3-1]; Deutsche Forschungsgemeinschaft (DFG) through Collaborative Research Center SFB824; Projekt DEAL	AbbVie(AbbVie); Bayer Pharma AG; SGC; Boehringer Ingelheim(Boehringer Ingelheim); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Eshelman Institute for Innovation; Genome Canada through Ontario Genomics Institute(Genome Canada); Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant]; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck KGaA; MSD; Novartis Pharma AG; Ontario Ministry of Research, Innovation and Science (MRIS); Pfizer(Pfizer); Sao Paulo Research Foundation-FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Takeda(Takeda Pharmaceutical Company Ltd); Wellcome Trust(Wellcome TrustEuropean Commission); German Cancer Aid (PIPAC consortium); German Cancer Consortium (DKTK); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (DFG) through Collaborative Research Center SFB824(German Research Foundation (DFG)); Projekt DEAL	We are grateful for support by the SGC, a registered charity (no. 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, Sao Paulo Research Foundation-FAPESP, Takeda, and the Wellcome Trust. JTS and SK are supported by the German Cancer Aid (grant no. 70112505; PIPAC consortium). JTS is supported by the German Cancer Consortium (DKTK) and the Deutsche Forschungsgemeinschaft (DFG) through grant SI1549/3-1 (Clinical Research Unit KFO337) and Collaborative Research Center SFB824 (project C4). Open access funding provided by Projekt DEAL.	Alekseyenko AA, 2015, GENE DEV, V29, P1507, DOI 10.1101/gad.267583.115; Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Brooks N, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-3826; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; French CA, 2003, CANCER RES, V63, P304; French CA, 2001, AM J PATHOL, V159, P1987, DOI 10.1016/S0002-9440(10)63049-0; GILES F, 2018, ANN ONCOL S8, V29, P279, DOI DOI 10.1093/annonc/mdy279.416; Hammitzsch A, 2015, P NATL ACAD SCI USA, V112, P10768, DOI 10.1073/pnas.1501956112; Haruki N, 2005, J MED GENET, V42, P558, DOI 10.1136/jmg.2004.029686; Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162; IGUCHI H, 1990, CANCER RES, V50, P3691; KEES UR, 1991, AM J PEDIAT HEMATOL, V13, P459; Kimura H, 2010, CHEM BIOL, V17, P1282, DOI 10.1016/j.chembiol.2010.10.011; KUZUME T, 1992, INT J CANCER, V50, P259, DOI 10.1002/ijc.2910500216; Lasko LM, 2017, NATURE, V550, P128, DOI 10.1038/nature24028; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Matzuk MM, 2012, CELL, V150, P673, DOI 10.1016/j.cell.2012.06.045; Muller S, 2018, ELIFE, V7, DOI 10.7554/eLife.34311; O'Dwyer PJ, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-CT014; Picaud S, 2015, CANCER RES, V75, P5106, DOI 10.1158/0008-5472.CAN-15-0236; Reynoird N, 2010, EMBO J, V29, P2943, DOI 10.1038/emboj.2010.176; Scheer S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07905-4; Stathis A, 2018, CANCER DISCOV, V8, P24, DOI 10.1158/2159-8290.CD-17-0605; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Toretsky JA, 2003, AM J CLIN ONCOL-CANC, V26, P300, DOI 10.1097/00000421-200306000-00019; Wu Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09672-2; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Yan JP, 2011, J BIOL CHEM, V286, P27663, DOI 10.1074/jbc.M111.246975; Yan YQ, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.62	32	17	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4770	4779		10.1038/s41388-020-1301-9	http://dx.doi.org/10.1038/s41388-020-1301-9		MAY 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32366905	hybrid, Green Published			2023-01-03	WOS:000530271400001
J	Grasselli, G; Pesenti, A; Cecconi, M				Grasselli, Giacomo; Pesenti, Antonio; Cecconi, Maurizio			Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy Early Experience and Forecast During an Emergency Response	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint describes the organization of a regional ICU network in Lombardy, Italy, to handle the surge in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who require intensive care and uses demand experience in the first 2 weeks of the outbreak to estimate resources required in coming weeks.	[Grasselli, Giacomo; Pesenti, Antonio] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy; [Grasselli, Giacomo; Pesenti, Antonio] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dipartimento Anestesia Rianimaz & Emergenza Urgen, Milan, Italy; [Cecconi, Maurizio] Humanitas Rozzano, Dipartimento Anestesia & Terapie Intens, Milan, Italy	University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico	Pesenti, A (corresponding author), Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Via F Sforza 35, I-20122 Milan, Italy.	antonio.pesenti@unimi.it	Pesenti, Antonio/H-7483-2012; Cecconi, Maurizio/HDN-8785-2022; Cecconi, Maurizio/A-6241-2012; basal, iskandar monem iskandar/F-7488-2013	Pesenti, Antonio/0000-0003-2593-729X; Cecconi, Maurizio/0000-0002-4376-6538; Cecconi, Maurizio/0000-0002-4376-6538; basal, iskandar monem iskandar/0000-0003-2837-1199				Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI [10.1056/NEJMoa2001316, 10.1001/jama.2020.2565]; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Patroniti N, 2011, INTENS CARE MED, V37, P1447, DOI 10.1007/s00134-011-2301-6; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204	5	2485	2527	4	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	2020	323	16					1545	1546		10.1001/jama.2020.4031	http://dx.doi.org/10.1001/jama.2020.4031			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL2GR	32167538	Bronze, Green Published			2023-01-03	WOS:000531373700012
J	Vilpert, S; Borrat-Besson, C; Borasio, GD; Maurer, J				Vilpert, Sarah; Borrat-Besson, Carmen; Borasio, Gian Domenico; Maurer, Jurgen			Associations of end-of-life preferences and trust in institutions with public support for assisted suicide evidence from nationally representative survey data of older adults in Switzerland	PLOS ONE			English	Article							RIGHT-TO-DIE; EUROPEAN COUNTRIES; GOOD DEATH; EUTHANASIA; PHYSICIAN; ATTITUDES; STATES; CARE; MEDICALIZATION; NETHERLANDS	The legality of euthanasia and assisted suicide (AS) and nature of regulations of these practices remain controversial and the subject of lively debate among experts and the general public. Our study investigates attitudes and behaviours towards AS among older adults in Switzerland where the practice of AS has a relatively long history and remains rather unregulated. We aim to explore how individuals' preferences regarding their end of life, as well as individuals' trust in institutions involved in the practice or control of AS are associated with attitudes and behaviours towards AS. We analyse nationally representative data of adults aged 55 and over from wave 6 (2015) of the Survey of Health, Ageing and Retirement in Europe (SHARE) in Switzerland (n = 2,145). While large majorities supported current legal arrangements around AS in Switzerland (81.7%) and stated that they could consider AS for themselves under certain circumstances (61.0%), only a minority either was a member of a right-to-die organisation already (4.9%) or stated they were likely to become a member of such an organisation (28.2%). Stated preferences for control over the end of life and for maintaining essential capabilities at the end of life showed a positive association with AS-related attitudes and behaviours, whereas preferences for feeling socially and spiritually connected, as well as for not being a burden displayed a negative association with our outcomes. Higher levels of trust in one's relative were positively associated with both support for the legality of AS and potential use of AS. A positive association was also found between trust in the Swiss legal system and support for the legality of AS. By contrast, trust in religious institutions displayed a negative association with all five AS-related attitudes and behaviours. Similarly, trust in healthcare insurance companies was negatively associated with potential use of AS. Taken together, older adults were generally supportive towards current practices regarding AS. This approval appears to be closely related to individuals' preferences and, at different extends, to trust in social and public institutions with regard to end-of-life issues, which is relatively high in Switzerland.	[Vilpert, Sarah] Univ Lausanne, Fac Biol & Med, Lausanne, Switzerland; [Vilpert, Sarah; Borrat-Besson, Carmen] Univ Lausanne, Swiss Ctr Expertise Social Sci FORS, Lausanne, Switzerland; [Borasio, Gian Domenico] Univ Lausanne, Med Ctr, Palliat & Support Care Serv, Lausanne, Switzerland; [Maurer, Jurgen] Univ Lausanne, Fac Business & Econ, Lausanne, Switzerland	University of Lausanne; University of Lausanne; University of Lausanne; University of Lausanne	Vilpert, S (corresponding author), Univ Lausanne, Fac Biol & Med, Lausanne, Switzerland.; Vilpert, S (corresponding author), Univ Lausanne, Swiss Ctr Expertise Social Sci FORS, Lausanne, Switzerland.	sarah.vilpert@unil.ch		/0000-0002-3923-677X; Vilpert Aeberhard, Sarah/0000-0001-8194-0421				Abrams S, 2011, PREDICTORS ATTITUDES; Al Rabadi L, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.8648; al-Awamer A, 2015, CAN FAM PHYSICIAN, V61, P1045; Andorno R, 2013, CAMB Q HEALTHC ETHIC, V22, P246, DOI 10.1017/S0963180113000054; Baranzke H, 2012, ETHICAL THEORY MORAL, V15, P295, DOI 10.1007/s10677-012-9369-0; Beauchamp TL, 2006, J MED PHILOS, V31, P643, DOI 10.1080/03605310601096619; Borasio GD, 2019, LANCET, V393, P982, DOI 10.1016/S0140-6736(18)32554-6; Borrat-Besson C, 2018, 10 WORLD RES C EUR A, P3; Borsch-Supan A., 2018, SURVEY HLTH AGEING R; Bosshard G, 2002, SWISS MED WKLY, V132, P527; Braun KL, 2001, GERONTOLOGIST, V41, P51, DOI 10.1093/geront/41.1.51; Broom A, 2017, SOC SCI MED, V173, P104, DOI 10.1016/j.socscimed.2016.12.001; Buiting HM, 2012, J MED ETHICS, V38, P267, DOI 10.1136/medethics-2011-100066; Bunker JP, 2001, INT J EPIDEMIOL, V30, P1260, DOI 10.1093/ije/30.6.1260; Cardona-Morrell M, 2016, INT J QUAL HEALTH C, V28, P456, DOI 10.1093/intqhc/mzw060; Carr D, 2009, SOCIOL FORUM, V24, P754, DOI 10.1111/j.1573-7861.2009.01135.x; Cavalli S, 2017, 21 IAGG WORLD C GER; Center PR, 2013, REL GROUPS VIEWS END; Cholbi M., 2015, J ETHICS; Cohen J, 2006, SOC SCI MED, V63, P743, DOI 10.1016/j.socscimed.2006.01.026; Cohen J, 2014, INT J PUBLIC HEALTH, V59, P143, DOI 10.1007/s00038-013-0461-6; Cohen J, 2013, EUR J PUBLIC HEALTH, V23, P378, DOI 10.1093/eurpub/cks186; Cohen-Mansfield J, 2018, J GERONTOL B-PSYCHOL, V73, P564, DOI 10.1093/geronb/gbx093; Danyliv A, 2015, SOC SCI MED, V128, P52, DOI 10.1016/j.socscimed.2014.12.030; Economist T., 2018, EC T; Emanuel EJ, 2016, JAMA-J AM MED ASSOC, V316, P79, DOI 10.1001/jama.2016.8499; federal C, 2011, SOINS PALL PREV SUIC; Fischer S, 2009, SWISS MED WKLY, V139, P333, DOI smw-12614; Flury R., 2018, NEU ZURCHER ZEITUNG; Francey O., 2016, TEMPS; Gamondi C, 2013, ANN ONCOL, V24, P1639, DOI 10.1093/annonc/mdt033; Gamondi C, 2015, BMJ SUPPORT PALLIAT, V5, P146, DOI 10.1136/bmjspcare-2013-000483; Ganzini L, 2008, J GEN INTERN MED, V23, P154, DOI 10.1007/s11606-007-0476-x; gfs.bern, 2018, VOLK ERW LOS POL VER; Givens JL, 2009, J PAIN SYMPTOM MANAG, V38, P167, DOI 10.1016/j.jpainsymman.2008.08.012; Groenewoud JH, 2000, NEW ENGL J MED, V342, P551, DOI 10.1056/NEJM200002243420805; Guay F, 2015, J EXP EDUC, V83, P51, DOI 10.1080/00220973.2013.876231; Hardwig J., 2014, JUSTICE LUCK RESPONS, P109; Hendry M, 2013, PALLIATIVE MED, V27, P13, DOI 10.1177/0269216312463623; Janisch W., 2019, SUDDEUTSCHE ZEITUNG; Jansen LA, 2019, J MED ETHICS, V45, P190, DOI 10.1136/medethics-2018-105003; Karsoho H, 2016, SOC SCI MED, V170, P188, DOI 10.1016/j.socscimed.2016.10.010; Koneke V, 2014, BMC MED ETHICS, V15, DOI 10.1186/1472-6939-15-86; Kriesi H., 2008, POLITICSWITZERLAND; Lapierre S, 2018, RELIGIONS, V9, DOI 10.3390/rel9030066; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; Loggers ET, 2013, NEW ENGL J MED, V368, P1417, DOI 10.1056/NEJMsa1213398; Marsh HW, 2009, STRUCT EQU MODELING, V16, P439, DOI 10.1080/10705510903008220; Materstvedt LJ, 2003, PALLIATIVE MED, V17, P97, DOI 10.1191/0269216303pm673oa; McCormick AJ, 2011, SOC WORK, V56, P119, DOI 10.1093/sw/56.2.119; Medicale ASdS, 2004, DIR MED ETH PRIS CHA; Meier EA, 2016, AM J GERIAT PSYCHIAT, V24, P261, DOI 10.1016/j.jagp.2016.01.135; Monforte-Royo C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037117; Muthen L. K., 2010, MPLUS USERS GUIDE, V6th; Myers ND, 2011, J SPORT EXERCISE PSY, V33, P779, DOI 10.1123/jsep.33.6.779; NEWS SW, 2018, NEWS SW; O'Neill C, 2003, SOC SCI MED, V57, P721, DOI 10.1016/S0277-9536(02)00421-5; OECD, 2013, TRUST GOV POL EFF GO; Office FS, 2016, SUIC ASS SEL SEX AG; Pacary C., 2019, MONDE; Pereira J, 2011, CURR ONCOL, V18, pE38; Pott M, 2018, ANGEW GERONTOLOGIE A, V14; Puttick H., 2019, TIMES; Rietjens JAC, 2005, SOC SCI MED, V61, P1723, DOI 10.1016/j.socscimed.2005.03.024; Rietjens JAC, 2006, PALLIATIVE MED, V20, P685, DOI 10.1177/0269216306070241; Rodriguez-Prat A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151435; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Rubin EB, 2016, JAMA INTERN MED, V176, P1557, DOI 10.1001/jamainternmed.2016.4362; Sarah V, 2018, SWISS MED WKLY, V148, DOI 10.4414/smw.2018.14642; Scherrens AL, 2018, DEATH STUD, V42, P491, DOI 10.1080/07481187.2017.1386734; Seay G, 2005, J MED PHILOS, V30, P517, DOI 10.1080/03605310500253071; SHARE, 2015, END OF LIF QUEST MUN; Sheeran P, 2016, SOC PERSONAL PSYCHOL, V10, P503, DOI 10.1111/spc3.12265; Simmons KM, 2018, J LAW BIOSCI, V5, P436, DOI 10.1093/jlb/lsy008; Steck N, 2013, MED CARE, V51, P938, DOI 10.1097/MLR.0b013e3182a0f427; Stettler P., 2018, BEVOLKERUNGSBEFRAGUN; Stevens KR, 2006, ISSUES LAW MED, V21, P187; Stolz E, 2017, BMC MED ETHICS, V18, DOI 10.1186/s12910-017-0233-6; Stolz E, 2017, J MED ETHICS, V43, P413, DOI 10.1136/medethics-2016-103731; Sulmasy DP, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.8628; UNESCO Institute for Statistics, 2011, INT STAND CLASS ED; Verbakel E, 2010, PUBLIC OPIN QUART, V74, P109, DOI 10.1093/poq/nfp074; von Hippel PT, 2007, SOCIOL METHODOL, V37, P83, DOI 10.1111/j.1467-9531.2007.00180.x; Wagner B, 2012, EUR PSYCHIAT, V27, P542, DOI 10.1016/j.eurpsy.2010.12.003	84	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2020	15	4							e0232109	10.1371/journal.pone.0232109	http://dx.doi.org/10.1371/journal.pone.0232109			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR9SA	32324815	Green Published, gold			2023-01-03	WOS:000536033700076
J	Hsu, PC; Kadlubar, SA; Siegel, ER; Rogers, LJ; Todorova, VK; Su, LJ; Makhoul, I				Hsu, Ping-Ching; Kadlubar, Susan A.; Siegel, Eric R.; Rogers, Lora J.; Todorova, Valentina K.; Su, L. Joseph; Makhoul, Issam			Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer	PLOS ONE			English	Article							RACIAL-DIFFERENCES; CELLS; TRANSCRIPTION; MICROARRAY; SITES; HYPOMETHYLATION; EXPRESSION; GENERATION; RESISTANCE; RECEPTOR	Neoadjuvant chemotherapy is given before surgery to patients with primarily unresectable, advanced-stage cancers to render the tumor resectable, and to facilitate breast conservation. Previously, we have reported a prospective phase II trial for women with stage IIA-B/IIIA-B-C breast cancer with improved pathologic complete response (pCR) when using bevacizumab in the neoadjuvant setting. Chemotherapy agents are given intravenously during multiple cycles of systemic treatments. However, the effect of the treatment is only evaluated upon the completion of therapy. Here, data from a clinical trial of 40 breast cancer patients with very aggressive disease and poor prognosis were studied aiming to identify epigenetic signatures in blood-derived DNA at baseline as potential non-invasive markers to predict pCR and to determine if treatment-related changes in-epigenetic profiles reflect responsiveness to therapy. We performed genome-wide DNA methylation profiling using blood-derived DNA, and found that pre-treatment methylation status of BRD9 was predictive of responsiveness to therapy. Post-treatment global methylation differences were also observed between responders and non-responders. Most differentially methylated (DM) CpGs were located in promoter CpG-island regions for responders and in the open-sea region for non-responders. In responders, DNMT3B was hypomethylated while most of the other genes were hypermethylated after 4 cycles of treatment. Hypomethylation of DNMT3B could potentially lead to the increased methylation of oncogenes and genes responsible for cell growth and proliferation, facilitating responsiveness to the therapy. These results support the possible development of BRD9 as a biomarker for treatment selection before neoadjuvant therapy with chemotherapy and bevacizumab, and indicate DNMT3B as a potential target to improve clinical response. Further prospective validation of these findings is warranted.	[Hsu, Ping-Ching; Kadlubar, Susan A.] Univ Arkansas Med Sci, Dept Environm & Occupat Hlth, Coll Publ Hlth, Little Rock, AR 72205 USA; [Siegel, Eric R.] Univ Arkansas Med Sci, Dept Biostat, Coll Med, Little Rock, AR 72205 USA; [Siegel, Eric R.] Univ Arkansas Med Sci, Dept Biostat, Coll Publ Hlth, Little Rock, AR 72205 USA; [Rogers, Lora J.; Su, L. Joseph] Univ Arkansas Med Sci, Dept Epidemiol, Coll Publ Hlth, Little Rock, AR 72205 USA; [Todorova, Valentina K.; Makhoul, Issam] Univ Arkansas Med Sci, Dept Internal Med, Coll Med, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Makhoul, I (corresponding author), Univ Arkansas Med Sci, Dept Internal Med, Coll Med, Little Rock, AR 72205 USA.	MakhoulIssam@uams.edu	Hsu, Ping-Ching/ABA-2876-2020; Hsu, Ping-Ching/D-6907-2014	Siegel, Eric/0000-0001-9824-6612; Hsu, Ping-Ching/0000-0002-1749-0662	Laura F. Hutchins, M.D. Distinguished Chair for Hematology and Oncology	Laura F. Hutchins, M.D. Distinguished Chair for Hematology and Oncology	This study was supported by funds from the Laura F. Hutchins, M.D. Distinguished Chair for Hematology and Oncology (IM).	Absmaier M, 2018, INT J ONCOL, V52, P755, DOI 10.3892/ijo.2018.4241; Akinyemiju T, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3557-1; Aubele M, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/4934608; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Crawford TD, 2017, BIOORG MED CHEM LETT, V27, P3534, DOI 10.1016/j.bmcl.2017.05.063; De Smet Charles, 2010, Epigenetics, V5, P206; Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587; Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI 10.2217/EPI.09.33; Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Flanagan JM, 2017, CLIN CANCER RES, V23, P2213, DOI 10.1158/1078-0432.CCR-16-1754; Fujii S, 2017, ONCOTARGET, V8, P19039, DOI 10.18632/oncotarget.15118; Gampenrieder SP, 2018, THERANOSTICS, V8, P2278, DOI 10.7150/thno.23544; Girault I, 2003, CLIN CANCER RES, V9, P4415; Hahn MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018844; Hervouet E, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0450-y; Hohmann AF, 2016, NAT CHEM BIOL, V12, P672, DOI 10.1038/nchembio.2115; Hu Y, 2013, LEUKEMIA, V27, P1580, DOI 10.1038/leu.2012.345; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Jung M, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0118-4; Jung SH, 2005, BIOSTATISTICS, V6, P157, DOI 10.1093/biostatistics/kxh026; Kang JU, 2008, CANCER GENET CYTOGEN, V182, P1, DOI 10.1016/j.cancergencyto.2007.12.004; Katz LS, 2013, STEM CELLS DEV, V22, P2551, DOI 10.1089/scd.2013.0134; Karmer KF, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071537; LI LH, 1970, CANCER RES, V30, P2760; Liu Y, 2018, J THORAC ONCOL; Lu LG, 2012, BREAST CANCER RES TR, V136, P875, DOI 10.1007/s10549-012-2314-z; Lund RJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01624-4; Makhoul I, 2016, AM J CLIN ONCOL-CANC, V39, P248, DOI 10.1097/COC.0000000000000046; Makhoul I, 2015, AM J CLIN ONCOL-CANC, V38, P74, DOI 10.1097/COC.0b013e31828940c3; Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44; McCartney DL, 2016, GENOM DATA, V9, P22, DOI 10.1016/j.gdata.2016.05.012; Moran S, 2016, EPIGENOMICS-UK, V8, P389, DOI 10.2217/epi.15.114; Ozdemir BC, 2017, TRENDS CANCER, V3, P181, DOI 10.1016/j.trecan.2017.02.002; Pidsley R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1066-1; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Risom T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05729-w; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Schlesinger F, 2013, GENOME RES, V23, P1601, DOI 10.1101/gr.157271.113; Scotto L, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-58; Song MA, 2015, EPIGENETICS-US, V10, P1177, DOI 10.1080/15592294.2015.1121362; Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607; Thomas RM, 2012, J BIOL CHEM, V287, P25049, DOI 10.1074/jbc.M112.351916; White MC, 2014, AM J PREV MED, V46, pS7, DOI 10.1016/j.amepre.2013.10.029; Xu JN, 2018, ONCOL LETT, V15, P2855, DOI 10.3892/ol.2017.7637; Yang XJ, 2010, TRENDS PHARMACOL SCI, V31, P536, DOI 10.1016/j.tips.2010.08.001; Yao S, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0641-1; Zhang ZH, 2013, STEM CELLS DEV, V22, P2268, DOI 10.1089/scd.2012.0650	49	8	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2020	15	4							e0230248	10.1371/journal.pone.0230248	http://dx.doi.org/10.1371/journal.pone.0230248			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9JM	32298288	gold, Green Published			2023-01-03	WOS:000536011400012
J	Kirby, AV; Diener, ML; Adkins, DE; Wright, C				Kirby, Anne V.; Diener, Marissa L.; Adkins, Daniel E.; Wright, Cheryl			Transition preparation activities among families of youth on the autism spectrum: Preliminary study using repeated assessments across a school year	PLOS ONE			English	Article							YOUNG-ADULTS; EMPLOYMENT OUTCOMES; DISORDERS; ADOLESCENTS; DISABILITIES; PERSPECTIVES; STUDENTS; CHILDREN; PARENTS	Much is still unknown about the transition to adulthood for youth with autism spectrum disorder (ASD), including what preparation activities best support positive adult outcomes. Parents play a crucial role in the transition planning and preparation process, yet the existing literature lacks detailed information about parent perceptions about transition preparation activities. To examine family transition preparation activities, we conducted a ten-month study of the transition preparation process of 15 families of youth with ASD across an academic year. Youth were ages 14-17 and 93% male. We collected data on transition preparation activity time spent and parent satisfaction over twenty data collection points. We used multi-level modeling to determine longitudinal trajectories of parent-reported preparation for the transition to adulthood based on endorsed transition preparation activities. Findings from this preliminary study revealed that discussions about the future were the most commonly endorsed activities, while social activities were most associated with increased parental perception of transition preparation over time. This study expands understanding of various transition preparation activities engaged in by families of youth with ASD during high school, though research with a larger and more diverse sample is needed to extend findings.	[Kirby, Anne V.] Univ Utah, Dept Occupat & Recreat Therapies, Coll Hlth, Salt Lake City, UT 84112 USA; [Diener, Marissa L.; Wright, Cheryl] Univ Utah, Dept Family & Consumer Studies, Coll Social & Behav Sci, Salt Lake City, UT 84112 USA; [Adkins, Daniel E.] Univ Utah, Dept Sociol, Coll Social & Behav Sci, Salt Lake City, UT USA; [Adkins, Daniel E.] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kirby, AV (corresponding author), Univ Utah, Dept Occupat & Recreat Therapies, Coll Hlth, Salt Lake City, UT 84112 USA.	avkirby@gmail.com		Kirby, Anne/0000-0003-0395-6684	University of Utah College of Health	University of Utah College of Health	This project was financially supported by a grant from the University of Utah College of Health (https://health.utah.edu/) [AK]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Ankeny EM, 2009, TEACH EXCEPT CHILD, V41, P28; Autism Speaks, 2012, MOUNT EV CRIT NEED A; Brown BW, 1997, STAT MED, V16, P2511, DOI 10.1002/(SICI)1097-0258(19971130)16:22<2511::AID-SIM693>3.0.CO;2-4; Camarena PM, 2009, FOCUS AUTISM DEV DIS, V24, P115, DOI 10.1177/1088357609332675; Carter EW, 2012, J DISABIL POLICY STU, V23, P50, DOI 10.1177/1044207311414680; Chen J, 2019, AUTISM, V23, P1363, DOI 10.1177/1362361318812141; Christensen Deborah L, 2018, MMWR Surveill Summ, V65, P1, DOI [10.15585/mmwr.ss6503a1, 10.15585/mmwr.ss6513a1]; Cimera RE, 2009, AUTISM, V13, P285, DOI 10.1177/1362361309103791; Constantino J. N., 2005, SOCIAL RESPONSIVENES; Eaves LC, 2008, J AUTISM DEV DISORD, V38, P739, DOI 10.1007/s10803-007-0441-x; Farley MA, 2009, AUTISM RES, V2, P109, DOI 10.1002/aur.69; Gelman A., 2007, DATA ANAL USING REGR, DOI 10.1017/CBO9780511790942; Griffin MM, 2014, J SPEC EDUC, V47, P256, DOI 10.1177/0022466913475668; Hatfield M, 2018, J RES SPEC EDUC NEED, V18, P3, DOI 10.1111/1471-3802.12388; Hatfield M, 2017, J RES SPEC EDUC NEED, V17, P187, DOI 10.1111/1471-3802.12377; Hedges SH., 2014, HIGH SCH J, V98, P64, DOI DOI 10.1353/HSJ.2014.0014; Hendricks DR, 2009, FOCUS AUTISM DEV DIS, V24, P77, DOI 10.1177/1088357608329827; Hoffman J, SUPPORTS BARRIERS YO; Holmes LG, 2018, J AUTISM DEV DISORD, V48, P2925, DOI 10.1007/s10803-018-3545-6; Howlin P, 2017, CURR OPIN PSYCHIATR, V30, P69, DOI 10.1097/YCO.0000000000000308; Kirby AV, 2019, AUTISM ADULTHOOD, V1, P37, DOI 10.1089/aut.2018.0008; Kirby AV, 2016, J AUTISM DEV DISORD, V46, P1643, DOI 10.1007/s10803-015-2691-3; Levy A, 2011, RES AUTISM SPECT DIS, V5, P1271, DOI 10.1016/j.rasd.2011.01.023; Newman L, 2007, FACTS NLTS2 SECONDAR; Newman L, 2011, POSTHIGH SCH OUTCOME; Poon KK, 2013, RES AUTISM SPECT DIS, V7, P382, DOI 10.1016/j.rasd.2012.10.006; Seltzer MM, 2004, MENT RETARD DEV D R, V10, P234, DOI 10.1002/mrdd.20038; Shattuck PT, 2012, PEDIATRICS, V129, P1042, DOI 10.1542/peds.2011-2864; Shogren KA, 2012, INTELLECT DEV DISAB, V50, P16, DOI 10.1352/1934-9556-50.1.16; Smith LE, 2014, REM SPEC EDUC, V35, P114, DOI 10.1177/0741932513514616; Sosnowy C, 2018, AUTISM, V22, P29, DOI 10.1177/1362361317699585; Steinhausen HC, 2016, ACTA PSYCHIAT SCAND, V133, P445, DOI 10.1111/acps.12559; Taylor JL, 2011, J AUTISM DEV DISORD, V41, P566, DOI 10.1007/s10803-010-1070-3; Wechsler D., 1999, WECHSLER ABBREVIATED; Wei X, 2016, REM SPEC EDUC, V37, P3, DOI 10.1177/0741932515581495	36	8	8	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2020	15	4							e0231551	10.1371/journal.pone.0231551	http://dx.doi.org/10.1371/journal.pone.0231551			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR9JM	32298327	Green Published, gold			2023-01-03	WOS:000536011400066
J	Pongking, T; Haonon, O; Dangtakot, R; Onsurathum, S; Jusakul, A; Intuyod, K; Sangka, A; Anutrakulchai, S; Cha'on, U; Pinlaor, S; Pinlaor, P				Pongking, Thatsanapong; Haonon, Ornuma; Dangtakot, Rungtiwa; Onsurathum, Sudarat; Jusakul, Apinya; Intuyod, Kitti; Sangka, Arunnee; Anutrakulchai, Sirirat; Cha'on, Ubon; Pinlaor, Somchai; Pinlaor, Porntip			A combination of monosodium glutamate and high-fat and high-fructose diets increases the risk of kidney injury, gut dysbiosis and host-microbial co-metabolism	PLOS ONE			English	Article							P-CRESOL SULFATE; OXIDATIVE STRESS; INTESTINAL MICROBIOTA; INDOXYL SULFATE; DISEASE; SPECTROSCOPY; CONTRIBUTES; SEQUENCES; OBESITY; DAMAGE	Consumption of either monosodium glutamate (MSG) or high-fat and high-fructose (HFF) diets changes the gut microbiome and hence contributes to development of several diseases. In this study, with an emphasis on kidney injury, hamsters were divided into 4 groups as follows: (1) hamsters fed with standard diet (control); (2) hamsters fed with standard diet and MSG in drinking water (MSG); (3) hamsters fed with high-fat and high-fructose diets (HFF), and (4) animals fed MSG+HFF. After 8 months, the animals were used for the study. Despite showing normal kidney function, hamsters fed with MSG+HFF exhibited signs of kidney damage as demonstrated by the highest expression levels of high-mobility group box-1 and kidney injury molecule-1 in kidney tissues, while slight changes of histopathological features in H&E-stained sections and normal levels of creatinine were observed, indicating possible early stages of kidney injury. Sequencing of the microbial 16S rRNA gene revealed that animals fed with the MSG+HFF diet had a higher ratio of gut Firmicutes/Bacteroidetes along with marked changes in abundance and diversity of gut microbiome compared to hamsters fed with MSG or HFF alone. In addition, H-1 Nuclear magnetic resonance spectroscopy showed an elevation of urine p-cresol sulfate levels in the MSG+HFF group. These results indicate that consumption of both MSG and HFF increases the risk of kidney injury, induces gut dysbiosis and an increase in the amount of p-cresol sulfate in hamsters.	[Pongking, Thatsanapong; Dangtakot, Rungtiwa] Khon Kaen Univ, Grad Sch, Biomed Sci Program, Khon Kaen, Thailand; [Pongking, Thatsanapong; Jusakul, Apinya; Sangka, Arunnee; Pinlaor, Porntip] Khon Kaen Univ, Fac Associated Med Sci, Ctr Res & Dev, Med Diagnost Labs, Khon Kaen, Thailand; [Haonon, Ornuma; Onsurathum, Sudarat; Intuyod, Kitti; Pinlaor, Somchai] Khon Kaen Univ, Fac Med, Dept Parasitol, Khon Kaen, Thailand; [Anutrakulchai, Sirirat] Khon Kaen Univ, Fac Med, Dept Med, Khon Kaen, Thailand; [Cha'on, Ubon] Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen, Thailand; [Pongking, Thatsanapong; Haonon, Ornuma; Dangtakot, Rungtiwa; Onsurathum, Sudarat; Jusakul, Apinya; Intuyod, Kitti; Sangka, Arunnee; Anutrakulchai, Sirirat; Cha'on, Ubon; Pinlaor, Somchai; Pinlaor, Porntip] Khon Kaen Univ, Fac Med, Chron Kidney Dis Prevent Northeast Thailand, Khon Kaen, Thailand; [Onsurathum, Sudarat] Naresuan Univ, Fac Med Sci, Dept Microbiol & Parasitol, Phitsanulok, Thailand	Khon Kaen University; Khon Kaen University; Khon Kaen University; Khon Kaen University; Khon Kaen University; Khon Kaen University; Naresuan University	Pinlaor, P (corresponding author), Khon Kaen Univ, Fac Associated Med Sci, Ctr Res & Dev, Med Diagnost Labs, Khon Kaen, Thailand.; Pinlaor, P (corresponding author), Khon Kaen Univ, Fac Med, Chron Kidney Dis Prevent Northeast Thailand, Khon Kaen, Thailand.	porawa@kk.ac.th	Saengwannakool, Walailak/C-5287-2009	Intuyod, Kitti/0000-0002-1096-9371; Jusakul, Apinya/0000-0001-7652-7771; Pinlaor, Somchai/0000-0002-8187-7247	Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University; CKDNET; Post-Doctoral Training Program from Research Affairs and Graduate School, Khon Kaen University,Thailand [60163]	Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University; CKDNET; Post-Doctoral Training Program from Research Affairs and Graduate School, Khon Kaen University,Thailand	Thatsanapong Pongking thanks the scholarship under the Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University. This study was supported by CKDNET. KI thanks the scholarship under the Post-Doctoral Training Program from Research Affairs and Graduate School, Khon Kaen University,Thailand. (Grant no. 60163). The authors would like to thank all of people whom voluntarily participated in this study.	Altunkaynak ME, 2008, J ANAT, V212, P845, DOI 10.1111/j.1469-7580.2008.00902.x; Aron-Wisnewsky J, 2016, NAT REV NEPHROL, V12, P169, DOI 10.1038/nrneph.2015.191; Asghari G, 2018, NUTR METAB, V15, DOI 10.1186/s12986-018-0322-7; Barrios C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134311; Beckonert O, 2010, NAT PROTOC, V5, P1019, DOI 10.1038/nprot.2010.45; Bokulich NA, 2013, NAT METHODS, V10, P57, DOI [10.1038/nmeth.2276, 10.1038/NMETH.2276]; Bratoeva K, 2017, CUREUS, V9, DOI 10.7759/cureus.1826; BUCKEL W, 1974, J BACTERIOL, V117, P1248, DOI 10.1128/JB.117.3.1248-1260.1974; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cerda B, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00051; Chaidee A, 2019, AM J TROP MED HYG, V101, P1161, DOI 10.4269/ajtmh.19-0442; Chen QJ, 2016, ACTA PHARM SIN B, V6, P183, DOI 10.1016/j.apsb.2016.02.004; Chowdhury SS, 2016, NUTRIENTS, V8, DOI 10.3390/nu8090521; Do MH, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060761; DuPont AW, 2011, NAT REV GASTRO HEPAT, V8, P523, DOI 10.1038/nrgastro.2011.133; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Eidi F, 2018, CLIN NUTR ESPEN, V28, P158, DOI 10.1016/j.clnesp.2018.08.010; Evenepoel P, 2017, KIDNEY INT, V92, P1323, DOI 10.1016/j.kint.2017.06.029; Feng ZM, 2015, OBESITY FACTS, V8, P87, DOI 10.1159/000380889; Franklin CL, 2017, LAB ANIMAL, V46, P114, DOI 10.1038/laban.1222; Gentile CL, 2018, SCIENCE, V362, P776, DOI 10.1126/science.aau5812; Gryp T, 2017, TOXINS, V9, DOI 10.3390/toxins9020052; Guo W, 2016, J PROTEOME RES, V15, P3500, DOI 10.1021/acs.jproteome.6b00179; Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110; Hawrelak Jason A, 2004, Altern Med Rev, V9, P180; Hill NR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158765; Hsu CN, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123699; Ingsathit A, 2010, NEPHROL DIAL TRANSPL, V25, P1567, DOI 10.1093/ndt/gfp669; Insawang T, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-50; Itthitaetrakool U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165798; Jakobsson HE, 2015, EMBO REP, V16, P164, DOI 10.15252/embr.201439263; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Jiang CY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066786; Jiang SH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02989-2; Jiang SH, 2016, ANTON LEEUW INT J G, V109, P1389, DOI 10.1007/s10482-016-0737-y; Khan TJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19013-2; Kikuchi K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09735-4; Kong C, 2019, NUTRITION, V60, P175, DOI 10.1016/j.nut.2018.10.002; KOVESDY CP, 2017, CAN J KIDNEY HLTH DI, V9, DOI DOI 10.4102/PHCFM.V9I1.1435; Li D, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-015-0634-1; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Mathur R, 2013, OBESITY, V21, P748, DOI 10.1002/oby.20277; Mbakwa CA, 2015, OBESITY, V23, P2508, DOI 10.1002/oby.21266; Murphy EA, 2015, CURR OPIN CLIN NUTR, V18, P515, DOI 10.1097/MCO.0000000000000209; MURPHY JC, 1984, J AM VET MED ASSOC, V185, P1359; Patra A., 2018, CLIN NUTR EXP, V19, P12, DOI [10.1016/j.yclnex.2018.02.002, DOI 10.1016/J.YCLNEX.2018.02.002]; Paul MVS, 2012, TOXICOL MECH METHOD, V22, P625, DOI 10.3109/15376516.2012.714008; Peng QN, 2018, J FUNCT FOODS, V49, P493, DOI 10.1016/j.jff.2018.09.015; Pokharel JN, 2013, NEPAL HEART J, V10, P6; Popkin BM, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-015-0631-4; Popkin BM, 2012, NUTR REV, V70, P3, DOI 10.1111/j.1753-4887.2011.00456.x; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Ramezani A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33018-5; Ramezani A, 2014, J AM SOC NEPHROL, V25, P657, DOI 10.1681/ASN.2013080905; Rangan GK, 2007, NEPHROLOGY, V12, P553, DOI 10.1111/j.1440-1797.2007.00855.x; Rosas-Villegas A, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040393; Seeba Z., 2019, CLIN PHARM ED PRACTI, P91, DOI [10.1016/B978-0-12-814276-9.00007-6, DOI 10.1016/B978-0-12-814276-9.00007-6]; Sekirov I, 2010, PHYSIOL REV, V90, P859, DOI 10.1152/physrev.00045.2009; Shafi T, 2017, KIDNEY INT, V92, P1484, DOI 10.1016/j.kint.2017.05.012; Sharma A, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0192-5; Sun GP, 2017, BIOCHEM BIOPH RES CO, V493, P964, DOI 10.1016/j.bbrc.2017.09.108; Sun J, 2016, NUTRITION, V32, P265, DOI 10.1016/j.nut.2015.08.020; Tang WHW, 2015, CIRC RES, V116, P448, DOI 10.1161/CIRCRESAHA.116.305360; Turner PV, 2018, ANIM MODEL EXP MED, V1, P109, DOI 10.1002/ame2.12022; van Timmeren MM, 2007, J PATHOL, V212, P209, DOI 10.1002/path.2175; Veselkov KA, 2009, ANAL CHEM, V81, P56, DOI 10.1021/ac8011544; Visconti A, 2019, BIORXIV, DOI [10.1101/561787, DOI 10.1101/561787]; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Watanabe H, 2013, KIDNEY INT, V83, P582, DOI 10.1038/ki.2012.448; Weerawatanakorn M., 2013, SONGKLANAKARIN J SCI, V35; White JR, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000352; Xu KY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01387-y; [No title captured], DOI DOI 10.3390/MOLECULES24061139	74	9	9	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2020	15	4							e0231237	10.1371/journal.pone.0231237	http://dx.doi.org/10.1371/journal.pone.0231237			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8SU	32267892	Green Published, gold			2023-01-03	WOS:000535967600037
J	El-Harakeh, A; Lotfi, T; Ahmad, A; Morsi, RZ; Fadlallah, R; Bou-Karroum, L; Akl, EA				El-Harakeh, Amena; Lotfi, Tamara; Ahmad, Ali; Morsi, Rami Z.; Fadlallah, Racha; Bou-Karroum, Lama; Akl, Elie A.			The implementation of prioritization exercises in the development and update of health practice guidelines: A scoping review	PLOS ONE			English	Review							CLINICAL-PRACTICE GUIDELINES; STAKEHOLDER ENGAGEMENT; PATIENT; TOPICS; MANAGEMENT; FRAMEWORK; DISEASE; CARE	Background The development of trustworthy guidelines requires substantial investment of resources and time. This highlights the need to prioritize topics for guideline development and update. Objective To systematically identify and describe prioritization exercises that have been conducted for the purpose of the de novo development, update or adaptation of health practice guidelines. Methods We searched Medline and CINAHL electronic databases from inception to July 2019, supplemented by hand-searching Google Scholar and the reference lists of relevant studies. We included studies describing prioritization exercises that have been conducted during the de novo development, update or adaptation of guidelines addressing clinical, public health or health systems topics. Two reviewers worked independently and in duplicate to complete study selection and data extraction. We consolidated findings in a semi-quantitative and narrative way. Results Out of 33,339 identified citations, twelve studies met the eligibility criteria. All included studies focused on prioritizing topics; none on questions or outcomes. While three exercises focused on updating guidelines, nine were on de novo development. All included studies addressed clinical topics. We adopted a framework that categorizes prioritization into 11 steps clustered in three phases (pre-prioritization, prioritization and post-prioritization). Four studies covered more than half of the 11 prioritization steps across the three phases. The most frequently reported steps for generating initial list of topics were stakeholders' input (n = 8) and literature review (n = 7). The application of criteria to determine research priorities was used in eight studies. We used and updated a common framework of 22 prioritization criteria, clustered in 6 domains. The most frequently reported criteria related to the health burden of disease (n = 9) and potential impact of the intervention on health outcomes (n = 5). All the studies involved health care providers in the prioritization exercises. Only one study involved patients. There was a variation in the number and type of the prioritization exercises' outputs. Conclusions This review included 12 prioritization exercises that addressed different aspects of priority setting for guideline development and update that can guide the work of researchers, funders, and other stakeholders seeking to prioritize guideline topics.	[El-Harakeh, Amena; Fadlallah, Racha; Bou-Karroum, Lama; Akl, Elie A.] Amer Univ Beirut, Ctr Systemat Reviews Hlth Policy & Syst Res SPARK, Beirut, Lebanon; [El-Harakeh, Amena; Akl, Elie A.] Amer Univ Beirut, Med Ctr, Clin Res Inst CRI, Beirut, Lebanon; [Lotfi, Tamara] Amer Univ Beirut, Global Evidence Synth Initiat GESI Secretariat, Beirut, Lebanon; [Lotfi, Tamara; Ahmad, Ali; Morsi, Rami Z.] Amer Univ Beirut, Fac Med, Beirut, Lebanon; [Fadlallah, Racha; Bou-Karroum, Lama] Amer Univ Beirut, Dept Hlth Management & Policy, Fac Hlth Sci, Beirut, Lebanon; [Akl, Elie A.] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon; [Akl, Elie A.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact HEI, Hamilton, ON, Canada	American University of Beirut; American University of Beirut; American University of Beirut; American University of Beirut; American University of Beirut; American University of Beirut; McMaster University	Akl, EA (corresponding author), Amer Univ Beirut, Ctr Systemat Reviews Hlth Policy & Syst Res SPARK, Beirut, Lebanon.; Akl, EA (corresponding author), Amer Univ Beirut, Med Ctr, Clin Res Inst CRI, Beirut, Lebanon.; Akl, EA (corresponding author), Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon.; Akl, EA (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact HEI, Hamilton, ON, Canada.	ea32@aub.edu.lb	Akl, Elie/K-5269-2019; Morsi, Rami/GLV-1948-2022; Akl, Elie A./R-2079-2016	Morsi, Rami/0000-0003-2131-3711; Akl, Elie A./0000-0002-3444-8618; Lotfi, Tamara/0000-0001-6101-3946; Ahmad, Ali/0000-0001-9669-8009; El Harakeh, Amena/0000-0003-4554-5875	Alliance for Health Policy and Systems Research, World Health Organization (WHO), Geneva	Alliance for Health Policy and Systems Research, World Health Organization (WHO), Geneva	This study was supported by the Alliance for Health Policy and Systems Research, World Health Organization (WHO), Geneva. The funder was not involved in the design of the study, in the collection, analysis, and interpretation of data or in the writing of the manuscript.	Agbassi C, 2014, J CLIN EPIDEMIOL, V67, P1335, DOI 10.1016/j.jclinepi.2014.06.013; Armstrong MJ, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0745-6; Armstrong Melissa J, 2017, Res Involv Engagem, V3, P19, DOI 10.1186/s40900-017-0070-2; Armstrong MJ, 2017, HEALTH EXPECT, V20, P3, DOI 10.1111/hex.12467; Atkins David, 2012, Proc Am Thorac Soc, V9, P225, DOI 10.1513/pats.201208-055ST; Banno M, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024942; Becker M, 2018, J CLIN EPIDEMIOL, V96, P101, DOI 10.1016/j.jclinepi.2017.12.011; Boivin A, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2009.034835; Borgonjen RJ, 2015, J EUR ACAD DERMATOL, V29, P1636, DOI 10.1111/jdv.12686; Brouwers MC, 2003, BMC HEALTH SERV RES, V3, DOI 10.1186/1472-6963-3-23; Bryant J, 2014, COST EFFECT RESOUR A, V12, DOI 10.1186/1478-7547-12-23; Concannon TW, 2012, J GEN INTERN MED, V27, P985, DOI 10.1007/s11606-012-2037-1; El-Harakeh A, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4567-2; El-Jardali F, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-2; Fadlallah R, 2019, J CLIN EPIDEMIOLOGY; Farrell B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122246; Field MJ, 1990, CLIN PRACTICE GUIDEL; Forsythe LP, 2016, J GEN INTERN MED, V31, P13, DOI 10.1007/s11606-015-3450-z; Glenton C, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-34; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Institute of Medicine, 2011, CLIN PRACTICE GUIDEL; Jaeschke R, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a744; Jo HS, 2015, J KOREAN MED SCI, V30, P1733, DOI 10.3346/jkms.2015.30.12.1733; Kaplan W., 2004, 3 PRIOR MED EUR WORL; Kastner M, 2015, J CLIN EPIDEMIOL, V68, P498, DOI 10.1016/j.jclinepi.2014.12.013; Kerr M, 2009, J INTELL DISABIL RES, V53, P687, DOI 10.1111/j.1365-2788.2009.01182.x; Khodyakov D, 2016, HEALTH EXPECT, V19, P868, DOI 10.1111/hex.12383; Kredo T, 2016, INT J QUAL HEALTH C, V28, P122, DOI 10.1093/intqhc/mzv115; Loeffen EAH, 2015, SUPPORT CARE CANCER, V23, P1987, DOI 10.1007/s00520-014-2559-7; Madden M, 2016, RES INVOLV ENGAGEM, V2, P12, DOI 10.1186/s40900-016-0026-y; Majeed-Ariss R, 2018, BRIT J DERMATOL, V178, P1383, DOI 10.1111/bjd.15992; Manafo E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193579; Garcia LM, 2017, J CLIN EPIDEMIOL, V86, P11, DOI 10.1016/j.jclinepi.2017.05.008; McGregor S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108787; McMillan SS, 2016, INT J CLIN PHARM-NET, V38, P655, DOI 10.1007/s11096-016-0257-x; Morgan RL, 2018, HEALTH RES POLICY SY, V16, DOI 10.1186/s12961-018-0330-0; Nasser M, 2013, J CLIN EPIDEMIOL, V66, P511, DOI 10.1016/j.jclinepi.2012.11.013; Nast A, 2019, J EUR ACAD DERMATOL, V33, P227, DOI 10.1111/jdv.15282; National Health and Medical Research Council, 2018, GUID GUID ENG STAK; Norris SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037413; O'Haire C., 2011, ENGAGING STAKEHOLDER; Rashid A, 2017, PATIENT, V10, P277, DOI 10.1007/s40271-016-0206-8; Reveiz L, 2010, HEALTH RES POLICY SY, V8, DOI 10.1186/1478-4505-8-7; Rosenfeld RM, 2013, OTOLARYNG HEAD NECK, V148, pS1, DOI 10.1177/0194599812467004; Schunemann HJ, 2014, CAN MED ASSOC J, V186, pE123, DOI 10.1503/cmaj.131237; Schunemann HJ, 2017, J CLIN EPIDEMIOL, V81, P101, DOI 10.1016/j.jclinepi.2016.09.009; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; Tomlinson M, 2011, HEALTH RES POLICY SY, V9, DOI 10.1186/1478-4505-9-19; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; van der Sanden WJM, 2002, COMMUNITY DENT ORAL, V30, P313, DOI 10.1034/j.1600-0528.2002.00060.x; van der Veer SN, 2016, INT UROL NEPHROL, V48, P859, DOI 10.1007/s11255-016-1257-4; van der Veer SN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128228; Viergever RF, 2010, HEALTH RES POLICY SY, V8, DOI 10.1186/1478-4505-8-36; Woolf SH, 2016, HEALTH AFFAIR, V35, P590, DOI 10.1377/hlthaff.2015.1512; World Health Organization, 2014, WHO HDB GUID DEV, Vsecond; Yoshida S., 2016, J GLOBAL HLTH, V6; Zhao G, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029693; 2019, LANCET LONDON ENGLAN, V394, P710	58	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2020	15	3							e0229249	10.1371/journal.pone.0229249	http://dx.doi.org/10.1371/journal.pone.0229249			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ9FU	32196520	gold, Green Published			2023-01-03	WOS:000535303100010
J	Yen, YH; Cheng, YF; Wang, JH; Lin, CC; Chen, YY; Yong, CC; Liu, YW; Cheng, JY; Chen, CH; Hu, TH				Yen, Yi-Hao; Cheng, Yu-Fan; Wang, Jing-Houng; Lin, Chih-Che; Chen, Yen-Yang; Yong, Chee-Chien; Liu, Yueh-Wei; Cheng, Jen-Yu; Chen, Chien-Hung; Hu, Tsung-Hui			Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West	PLOS ONE			English	Article							LIVER-CANCER; PRACTICE GUIDELINES; MANAGEMENT; CONSENSUS; RECOMMENDATIONS; ASSOCIATION; TOXICITY	Background and aims The Barcelona Clinic Liver Cancer (BCLC) stage C (BCLC C) of hepatocellular carcinoma (HCC) includes a heterogeneous population for which sorafeninb is one of the recommended therapies. We aim to evaluate the real world clinical treatment and survival of BCLC stage C patients in an Asian cohort. Methods This is a retrospective cohort study that enrolled 427 consecutive BCLC stage C patients diagnosed between 2011 and 2017 by using the HCC registry data for our hospital. All patients were managed via a multidisciplinary team (MDT) approach. Results Hepatitis B surface antigen positive was noted in 50.6% of the patients. The patients were classified as performance status (PS)1 alone (n = 83; 19.4%), PS2 alone (n = 23; 5.4%), or macrovascular invasion (MVI) or extrahepatic spread (EHS) (n = 321; 75.2%). The median overall survival (OS) was 11.0 months in the whole cohort. The most frequent treatments were transcatheter arterial embolization (TAE) in the PS1 (45.8%) and PS2 patients (52.2%) and sorafenib (32.4%) in the MVI or EHS patients. The independent prognostic factors were the PS, Child-Pugh class, MVI or EHS, alpha fetoprotein levels, and treatment type. Conclusions We reported the real world management in BCLC stage C patients in an Asian cohort through the use of personalized management via a MDT approach.	[Yen, Yi-Hao; Wang, Jing-Houng; Chen, Chien-Hung; Hu, Tsung-Hui] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan; [Yen, Yi-Hao; Wang, Jing-Houng; Chen, Chien-Hung; Hu, Tsung-Hui] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Cheng, Yu-Fan] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Diagnost Radiol,Liver Transplantat Ctr, Kaohsiung, Taiwan; [Lin, Chih-Che; Yong, Chee-Chien; Liu, Yueh-Wei] Kaohsiung Chang Gung Mem Hosp, Liver Transplantat Ctr, Kaohsiung, Taiwan; [Lin, Chih-Che; Yong, Chee-Chien; Liu, Yueh-Wei] Kaohsiung Chang Gung Mem Hosp, Dept Surg, Kaohsiung, Taiwan; [Chen, Yen-Yang] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, Kaohsiung, Taiwan; [Cheng, Jen-Yu] Kaohsiung Chang Gung Mem Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital	Hu, TH (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan.; Hu, TH (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.	dr.hu@msa.hinet.net	Cheng, Jen-Yu/V-5728-2019	Cheng, Jen-Yu/0000-0002-5080-0394	Kaohsiung Chang Gung Memorial Hospital, Taiwan [CMRPG8J1281]	Kaohsiung Chang Gung Memorial Hospital, Taiwan	This study was supported by Grant CMRPG8J1281 from the Kaohsiung Chang Gung Memorial Hospital, Taiwan. Grant Recipient is Yi-Hao Yen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Chiang CJ, 2015, HEPATOLOGY, V61, P1154, DOI 10.1002/hep.27630; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, 2019, J Hepatol, V70, P817, DOI 10.1016/j.jhep.2019.01.020; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Giannini EG, 2018, HEPATOLOGY, V67, P1784, DOI 10.1002/hep.29668; Guarino M, 2018, J GASTROEN HEPATOL, V33, P1123, DOI 10.1111/jgh.14013; Ikai Iwao, 2003, Surg Oncol Clin N Am, V12, P65, DOI 10.1016/S1055-3207(02)00082-0; Kudo M, 2015, LIVER CANCER, V4, P39, DOI 10.1159/000367727; Kudo M, 2013, ONCOLOGY-BASEL, V84, P21, DOI 10.1159/000345885; Kudo M, 2011, DIGEST DIS, V29, P339, DOI 10.1159/000327577; Lee LT, 2009, ANN EPIDEMIOL, V19, P323, DOI 10.1016/j.annepidem.2008.12.013; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Marrero JA, 2018, HEPATOLOGY, V68, P723, DOI 10.1002/hep.29913; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Omata M, 2017, HEPATOL INT, V11, P317, DOI 10.1007/s12072-017-9799-9; Omata M, 2010, HEPATOL INT, V4, P439, DOI 10.1007/s12072-010-9165-7; Park HC, 2016, LIVER CANCER, V5, P162, DOI 10.1159/000367766; Sangiovanni A, 2018, LIVER INT, V38, P1624, DOI 10.1111/liv.13888; Sangiovanni A, 2016, LIVER INT, V36, P124, DOI 10.1111/liv.13028; Schnadig ID, 2008, CANCER-AM CANCER SOC, V113, P2205, DOI 10.1002/cncr.23856; Serper M, 2017, GASTROENTEROLOGY, V152, P1954, DOI 10.1053/j.gastro.2017.02.040; Torzilli G, 2013, ANN SURG, V257, P929, DOI 10.1097/SLA.0b013e31828329b8; Ueda H, 2012, ONCOL LETT, V3, P259, DOI 10.3892/ol.2011.469; Wang CK, 2018, J FORMOS MED ASSOC, V117, P381, DOI 10.1016/j.jfma.2017.09.007; Yao FY, 2001, HEPATOLOGY, V33, P1394, DOI 10.1053/jhep.2001.24563; Yau T, 2014, GASTROENTEROLOGY, V146, P1691, DOI 10.1053/j.gastro.2014.02.032	28	7	9	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2020	15	3							e0230005	10.1371/journal.pone.0230005	http://dx.doi.org/10.1371/journal.pone.0230005			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ9AF	32163475	Green Published, gold			2023-01-03	WOS:000535288600047
J	Liff, I; Zash, R; Mingochi, D; Gaonakala, FT; Diseko, M; Mayondi, G; Johnson, K; James, K; Makhema, J; Shapiro, R; Wylie, BJ				Liff, Ingrid; Zash, Rebecca; Mingochi, Denis; Gaonakala, Findo Tsaone; Diseko, Modiegi; Mayondi, Gloria; Johnson, Katherine; James, Kaitlyn; Makhema, Joseph; Shapiro, Roger; Wylie, Blair J.			Mid-trimester cervical length not associated with HIV status among pregnant women in Botswana	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; PROTEASE INHIBITOR USE; PRETERM BIRTH; INFECTED WOMEN; DOUBLE-BLIND; VAGINAL PROGESTERONE; TH2-TYPE CYTOKINES; PREMATURE DELIVERY; INCREASED RISK; TRANSMISSION	Objective HIV-infected women on antiretroviral therapy have a higher risk of preterm birth than HIV-uninfected women in Botswana. To better understand the mechanism for preterm birth among HIV-infected women, we evaluated whether mid-trimester cervical length differed by HIV status as cervical shortening is associated with an increased risk for preterm birth. Methods We conducted a prospective cohort study among pregnant women receiving care at the Scottish Livingstone Hospital in Molepolole, Botswana. Consecutive women referred for routine obstetrical ultrasound were consented and enrolled if between 22w0d and 24w6d by ultrasound biometry. Blinded to maternal HIV status, an obstetrician measured transvaginal cervical length using standardized criteria. Cervical length, as well as the proportion of women with a short cervix (< 25mm), were compared among HIV-infected and HIV-uninfected women. The acceptability of transvaginal ultrasound was also evaluated. Results Between April 2016 and April 2017, 853 women presenting for obstetric ultrasound were screened, 187 (22%) met eligibility criteria, and 179 (96%) were enrolled. Of those enrolled, 50 (28%) were HIV-infected (86% on antiretroviral therapy), 127 (71%) were HIV-uninfected, and 2 (1%) had unknown HIV status. There was no significant difference in mean cervical length between HIV-infected and HIV-uninfected women (32mm vs 31mm, p = 0.21), or in the proportion with a short cervix (10% vs 14%, p = 0.44). Acceptability data was available for 115 women who underwent a transvaginal ultrasound exam. Of these, 112 of 115 (97%) women deemed the transvaginal scan acceptable. Conclusions The increased risk of preterm birth observed among HIV-infected women receiving antiretroviral therapy in Botswana is unlikely associated with mid-trimester cervical shortening. Further research is needed to understand the underlying mechanism for preterm birth among HIV-infected women.	[Liff, Ingrid; James, Kaitlyn; Wylie, Blair J.] Massachusetts Gen Hosp, Div Maternal Fetal Med, Dept Obstet & Gynecol, Boston, MA 02114 USA; [Zash, Rebecca; Shapiro, Roger] Beth Israel Deaconess Med Ctr, Dept Infect Dis, Boston, MA 02215 USA; [Zash, Rebecca; Gaonakala, Findo Tsaone; Diseko, Modiegi; Mayondi, Gloria; Makhema, Joseph; Shapiro, Roger] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; [Mingochi, Denis] Scottish Livingstone Hosp, Molepolole, Botswana; [Johnson, Katherine] Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Div Maternal Fetal Med, Boston, MA 02215 USA; [Liff, Ingrid] Tufts Med Ctr, Div Maternal Fetal Med, Boston, MA 02111 USA; [Wylie, Blair J.] Beth Israel Deaconess Med Ctr, Div Maternal Fetal Med, Boston, MA 02215 USA	Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Botswana-Harvard AIDS Institute Partnership; Harvard University; Beth Israel Deaconess Medical Center; Tufts Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Liff, I (corresponding author), Massachusetts Gen Hosp, Div Maternal Fetal Med, Dept Obstet & Gynecol, Boston, MA 02114 USA.	iliff@tuftsmedicalcenter.org		Liff, Ingrid/0000-0001-9572-5888	Queenan Fellowships for Global Health - Foundation for SMFM	Queenan Fellowships for Global Health - Foundation for SMFM	This work was supported by a grant from the Queenan Fellowships for Global Health sponsored by the Foundation for SMFM (IL). https://foundationforsmfm.org.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alimohamadi S, 2013, J REPROD IMMUNOL, V98, P52, DOI 10.1016/j.jri.2013.01.004; Bello FA, 2015, ANN AFR MED, V14, P52, DOI 10.4103/1596-3519.148740; Boelig RC, 2017, OBSTET GYNECOL, V129, P536, DOI 10.1097/AOG.0000000000001820; Chen JY, 2012, J INFECT DIS, V206, P1695, DOI 10.1093/infdis/jis553; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cotter AM, 2006, J INFECT DIS, V193, P1195, DOI 10.1086/503045; DeFranco EA, 2007, ULTRASOUND OBST GYN, V30, P697, DOI 10.1002/uog.5159; Erasmus I, 2005, SAMJ S AFR MED J, V95, P691; Fiore S, 2006, J REPROD IMMUNOL, V70, P143, DOI 10.1016/j.jri.2005.12.001; Fonseca EB, 2007, NEW ENGL J MED, V357, P462, DOI 10.1056/NEJMoa067815; Fowler M., 2015, PROMISE EFFICACY SAF; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; HADLOCK FP, 1984, RADIOLOGY, V152, P497, DOI 10.1148/radiology.152.2.6739822; Hassan SS, 2011, ULTRASOUND OBST GYN, V38, P18, DOI 10.1002/uog.9017; Iams JD, 1996, NEW ENGL J MED, V334, P567, DOI 10.1056/NEJM199602293340904; Lopez M, 2012, AIDS, V26, P37, DOI 10.1097/QAD.0b013e32834db300; Martin F, 2009, J ANTIMICROB CHEMOTH, V64, P895, DOI 10.1093/jac/dkp303; Minkoff H, 1997, AM J OBSTET GYNECOL, V176, P478, DOI 10.1016/S0002-9378(97)70519-2; Nold C, 2013, AM J OBSTET GYNECOL, V208, pS9, DOI 10.1016/j.ajog.2013.01.020; O'Brien JM, 2007, ULTRASOUND OBST GYN, V30, P687, DOI 10.1002/uog.5158; Okeji MC, 2017, BMC WOMENS HEALTH, V17, DOI 10.1186/s12905-017-0413-z; Parekh N, 2011, INT J GYNECOL OBSTET, V115, P20, DOI 10.1016/j.ijgo.2011.04.008; Patel K, 2010, J INFECT DIS, V201, P1035, DOI 10.1086/651232; PICCINNI MP, 1995, J IMMUNOL, V155, P128; Piccinni MP, 2000, J NEUROIMMUNOL, V109, P30, DOI 10.1016/S0165-5728(00)00299-X; Powis KM, 2011, J INFECT DIS, V204, P506, DOI 10.1093/infdis/jir307; Price JT, 2019, INT J GYNECOL OBSTET, V146, P206, DOI 10.1002/ijgo.12823; Reinhard G, 1998, BIOCHEM BIOPH RES CO, V245, P933, DOI 10.1006/bbrc.1998.8549; Shapiro RL, 2010, NEW ENGL J MED, V362, P2282, DOI 10.1056/NEJMoa0907736; Sibiude J, 2012, CLIN INFECT DIS, V54, P1348, DOI 10.1093/cid/cis198; Stiehm ER, 1999, J INFECT DIS, V179, P567, DOI 10.1086/314637; Townsend CL, 2010, BJOG-INT J OBSTET GY, V117, P1399, DOI 10.1111/j.1471-0528.2010.02689.x; Townsend CL, 2007, AIDS, V21, P1019, DOI 10.1097/QAD.0b013e328133884b; Tuomala RE, 2006, J INFECT DIS, V193, P1191, DOI 10.1086/503049; Tuomala RE, 2002, NEW ENGL J MED, V346, P1863, DOI 10.1056/NEJMoa991159; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Zash R, 2017, JAMA PEDIATR, V171, DOI 10.1001/jamapediatrics.2017.2222; Zash Rebecca, 2015, IMPACT MATERNAL ANTI	39	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2020	15	3							e0229500	10.1371/journal.pone.0229500	http://dx.doi.org/10.1371/journal.pone.0229500			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8YS	32160214	Green Published, gold			2023-01-03	WOS:000535284700027
J	Soboksa, NE; Gari, SR; Hailu, AB; Alemu, BM				Soboksa, Negasa Eshete; Gari, Sirak Robele; Hailu, Abebe Beyene; Alemu, Bezatu Mengistie			Association between microbial water quality, sanitation and hygiene practices and childhood diarrhea in Kersa and Omo Nada districts of Jimma Zone, Ethiopia	PLOS ONE			English	Article							HOUSEHOLD DRINKING-WATER; MIDDLE-INCOME SETTINGS; MICROBIOLOGICAL CONTAMINATION; SAFE STORAGE; CHILDREN; DISEASE; COMMUNITY; COUNTRIES; IMPACT	Introduction Diarrhea is one of the leading causes of child morbidity and mortality in low- and middle-income countries like Ethiopia. The use of safe drinking water and improved sanitation are important practices to prevent diarrhea. However, limited research has been done to link water supply, sanitation and hygiene practices and childhood diarrhea. Therefore, this study aimed at assessing the association between microbial quality of drinking water, sanitation and hygiene practices and childhood diarrhea. Methods Community-based matched case-control study design was applied on 198 paired children from June to July 2019 in Kersa and Omo Nada districts of Jimma Zone, Ethiopia. Cases are children < 5 years of age with diarrhea during the two weeks before the survey. The controls are children without diarrhea during the two weeks before the survey. Twenty-five percent matched pair samples of water were taken from households of cases and controls. Data were collected using structured questionnaire by interviewing mothers/caregivers. A sample of water was collected in nonreactive borosilicate glass bottles and analyzed by the membrane filtration method to count fecal indicator bacteria. A conditional logistic regression model was used; variables with p-value less than 0.05 were considered as significantly associated with childhood diarrhea. Results A total of 396 (each case matched with control) under-five children with their mothers/caregivers were included in this study. In the analysis, variables like presence of under-five child in their home (AOR = 2.76; 95% CI: 1.33-5.71), wealth status (AOR = 5.39; 95% CI: 1.99-14.55), main sources of drinking water (AOR = 4.01; 95% CI: 1.40-11.44), hand washing practice before water collection (AOR = 4.28; 95% CI: 1.46-12.56), treating water at household level (AOR = 1.22; 95% CI: 0.48-3.09), latrine use all the times of the day and night (AOR = 0.22; 95% CI: 0.06-0.78), using pit as method of waste disposal (AOR = 4.91; 95% CI: 1.39-13.29) and use of soap for hand washing (AOR = 2.89; 95% CI: 1.35-6.15) were significantly associated with childhood diarrhea. Moreover, 30% of sampled water from cases and 26% of sampled water from controls families were free from Escherichia coli whereas all sampled water analyzed for Total coliforms were positive. Conclusions We conclude that the main sources of drinking water, hand washing before water drawing from a storage container, domestic waste disposal place and use of soap for hand washing were the most important factors for the prevention of childhood diarrhea.	[Soboksa, Negasa Eshete; Gari, Sirak Robele] Addis Ababa Univ, Ethiopian Inst Water Resources, Addis Ababa, Ethiopia; [Hailu, Abebe Beyene] Jimma Univ, Dept Environm Hlth Sci, Jimma, Ethiopia; [Alemu, Bezatu Mengistie] Haramaya Univ, Coll Hlth & Med Sci, Harar, Ethiopia	Addis Ababa University; Jimma University; Haramaya University	Soboksa, NE (corresponding author), Addis Ababa Univ, Ethiopian Inst Water Resources, Addis Ababa, Ethiopia.	yeroosaa@gmail.com	Soboksa, Negasa Eshete/AAS-8611-2021; Gari, Sirak/AAG-6260-2021	Soboksa, Negasa Eshete/0000-0003-3451-175X; 	Addis Ababa University, Ethiopian Institute of Water Resources	Addis Ababa University, Ethiopian Institute of Water Resources	This work was supported by Addis Ababa University, Ethiopian Institute of Water Resources. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acharya D, 2018, J INFECT PUBLIC HEAL, V11, P69, DOI 10.1016/j.jiph.2017.04.007; Adane M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181516; Akoachere JTK, 2013, BMC PUBLIC HEALTH, V13, P1; Alebel A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199684; APHA, 2017, STANDARD METHODS EXA; Azage M, 2016, J HEALTH POPUL NUTR, V35, DOI 10.1186/s41043-016-0052-2; Azry F, 2018, BMC PUBLIC HEALTH, V18, P1; Brown JM, 2008, WATER SCI TECHNOL, V58, P757, DOI 10.2166/wst.2008.439; Centers for Disease Control and Prevention (CDC), 2014, WAT REL DIS CONT PUB; Central Statistical Agency [Ethiopia], 2014, ETH MIN DEM HLTH SUR; Chiller TM, 2006, B WORLD HEALTH ORGAN, V84, P28, DOI 10.2471/BLT.04.016980; Clasen T, 2007, BMJ-BRIT MED J, V334, P782, DOI 10.1136/bmj.39118.489931.BE; Dagnew AB, 2019, BMC INFECT DIS, P3; Degebasa MZ, 2018, PEDIATR HEALTH MED T, V9, P109, DOI 10.2147/PHMT.S159366; Diouf K, 2014, GLOBAL HEALTH ACTION, V7, P1, DOI 10.3402/gha.v7.24895; Ejemot-Nwadiaro RI, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004265.pub3; Emina JBO, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001930; Federal Democratic Republic of Ethiopia Ministry of Health, 2012, IMPL PROGR GUID CLTS; Fewtrell L, 2005, LANCET INFECT DIS, V5, P42, DOI 10.1016/S1473-3099(04)01253-8; Asfaha KF, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1098-7; Getachew B., 2018, E AFRICAN J HLTH BIO, V2, P26; Godana W., 2013, SC J PUBLIC HLTH, V1, P119, DOI DOI 10.11648/J.SJPH.20130103.12; Graham N., 1998, GUIDELINES DRINKING, V2nd, DOI [10.1016/S1462-0758(00)00006-6, DOI 10.1016/S1462-0758(00)00006-6]; Hashi Abdiwahab, 2017, Prev Med Rep, V6, P361, DOI 10.1016/j.pmedr.2017.04.011; Heitzinger K, 2015, AM J TROP MED HYG, V93, P501, DOI 10.4269/ajtmh.14-0802; Id SY, 2018, TROP MED INFECT DIS, V3, P1; Jimma Zonal Health Office, 2019, DIS PREV CONTR DEP A; Kampf G, 2004, CLIN MICROBIOL REV, V17, P863, DOI 10.1128/CMR.17.4.863-893.2004; Kapwata T, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081665; Kumi-Kyereme A, 2016, J EPIDEMIOL GLOB HEA, V6, P131, DOI 10.1016/j.jegh.2015.05.001; Luby SP, 2015, AM J TROP MED HYG, V93, P904, DOI 10.4269/ajtmh.15-0274; Luby SP, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001052; Lule JR, 2005, AM J TROP MED HYG, V73, P926, DOI 10.4269/ajtmh.2005.73.926; Majorin F, 2019, T ROY SOC TROP MED H, V113, P263, DOI 10.1093/trstmh/try142; Mengistie B, 2013, HOUSEHOLD WATER CHLO, V8, P1; Ayalew AM, 2018, J ENVIRON PUBLIC HEA, V2018, DOI 10.1155/2018/4271915; Mohammed A, 2016, SOUTH AFR J INFECT D, V31, P122, DOI 10.1080/23120053.2016.1156876; Oloruntoba EO, 2014, AFR HEALTH SCI, V14, DOI 10.4314/ahs.v14i4.32; Osumanu IK, 2007, GEOGR TIDSSKR-DEN, V107, P59, DOI 10.1080/00167223.2007.10801375; Pruss-Ustun A, 2014, TROP MED INT HEALTH, V19, P894, DOI 10.1111/tmi.12329; Quick RE, 2002, AM J TROP MED HYG, V66, P584, DOI 10.4269/ajtmh.2002.66.584; Soboksa NE, 2019, J HEALTH POPUL NUTR, V38, DOI 10.1186/s41043-019-0205-1; Tambe AB., 2015, CHALLENGES, V6, P229, DOI [DOI 10.3390/CHALLE6020229, 10.3390/challe6020229]; Thiam S, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/s40249-017-0323-1; UNICEF Ethiopia, 2018, WAT SAN HYG WASH; Usman MA, 2019, J DEV STUD, V55, P2193, DOI 10.1080/00220388.2018.1493193; WHO, 2014, PREV DIARRH BETT WAT, P1; WHO, 2016, WAT REL DIS; WHO, 2006, GUID DRINK QUAL 1 AD; Wolf J, 2014, TROP MED INT HEALTH, V19, P928, DOI 10.1111/tmi.12331; Wright J, 2004, TROP MED INT HEALTH, V9, P106, DOI 10.1046/j.1365-3156.2003.01160.x; Yongsi HBN, 2010, J HEALTH POPUL NUTR, V28, P424; Zedie FB., 2018, HLTH ED CARE, V3, P1, DOI DOI 10.15761/HEC.1000144	53	9	9	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2020	15	2							e0229303	10.1371/journal.pone.0229303	http://dx.doi.org/10.1371/journal.pone.0229303			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8AS	32074128	Green Submitted, Green Published, gold			2023-01-03	WOS:000535220600038
J	Ray, A; Song, Y; Du, T; Chauhan, D; Anderson, KC				Ray, Arghya; Song, Yan; Du, Ting; Chauhan, Dharminder; Anderson, Kenneth C.			Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma	ONCOGENE			English	Article							DRUG-RESISTANCE; IMMUNE; INHIBITOR; THERAPIES; HYPOXIA; CELLS; CYTOTOXICITY; GROWTH; OXYGEN; MODEL	Bone marrow plasmacytoid dendritic cells (pDCs) in patients with multiple myeloma (MM) promote tumor growth, survival, drug resistance, and immune suppression. Understanding the molecular signaling crosstalk among the tumor cells, pDCs and immune cells will identify novel therapeutic approaches to enhance anti-MM immunity. Using oligonucleotide arrays, we found that pDC-MM interactions induce metabolic enzyme Alpha-Enolase (ENO1) in both pDCs and MM cells. Analysis of MM patient gene expression profiling database showed that ENO1 expression inversely correlates with overall survival. Protein expression analysis showed that ENO1 is expressed in pDC and MM cells; and importantly, that pDC-MM coculture further increases ENO1 expression in both MM cells and pDCs. Using our coculture models of patient autologous pDC-T-NK-MM cells, we examined whether targeting ENO1 can enhance anti-MM immunity. Biochemical inhibition of ENO1 with ENO1 inhibitor (ENO1i) activates pDCs, as well as increases pDC-induced MM-specific CD8(+) CTL and NK cell activity against autologous tumor cells. Combination of ENO1i and anti-PD-L1 Ab or HDAC6i ACY-241 enhances autologous MM-specific CD8(+) CTL activity. Our preclinical data therefore provide the basis for novel immune-based therapeutic approaches targeting ENO1, alone or in combination with anti-PD-L1 Ab or ACY241, to restore anti-MM immunity, enhance MM cytotoxicity, and improve patient outcome.	[Ray, Arghya; Song, Yan; Du, Ting; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Med Sch, Dept Med Oncol, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA; [Ray, Arghya; Song, Yan; Du, Ting; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Med Sch, Jerome Lipper Myeloma Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Chauhan, D; Anderson, KC (corresponding author), Harvard Med Sch, Dept Med Oncol, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.; Chauhan, D; Anderson, KC (corresponding author), Harvard Med Sch, Jerome Lipper Myeloma Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA.	Dharminder_Chauhan@dfci.harvard.edu; Kenneth_Anderson@dfci.harvard.edu			Dr. Miriam and Sheldon Adelson Medical Research Foundation; National Institutes of Health Specialized Programs of Research Excellence (SPORE) grant [P50100707, R01CA207237, R01 CA050947]	Dr. Miriam and Sheldon Adelson Medical Research Foundation; National Institutes of Health Specialized Programs of Research Excellence (SPORE) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The grant supports for this investigation were provided by "Dr. Miriam and Sheldon Adelson Medical Research Foundation", and by the National Institutes of Health Specialized Programs of Research Excellence (SPORE) grant P50100707, R01CA207237, and R01 CA050947. KCA is an American Cancer Society Clinical Research Professor.	Ader I, 2008, CANCER RES, V68, P8635, DOI 10.1158/0008-5472.CAN-08-0917; Anderson KC, 2018, J ONCOL PRACT, V14, P411, DOI 10.1200/JOP.18.00311; Anderson KC, 2013, J NATL COMPR CANC NE, V11, P676, DOI 10.6004/jnccn.2013.0199; Anderson KC, 2012, J CLIN ONCOL, V30, P445, DOI 10.1200/JCO.2011.37.8919; Bae J, 2018, LEUKEMIA, V32, P1932, DOI 10.1038/s41375-018-0062-8; Barlogie B, 2006, NEW ENGL J MED, V354, P1021, DOI 10.1056/NEJMoa053583; Bi EG, 2018, J CLIN INVEST, V128, P4821, DOI 10.1172/JCI121421; Cappello P, 2017, FRONT BIOSCI-LANDMRK, V22, P944, DOI 10.2741/4526; Cappello P, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1112940; Chauhan D, 2003, BLOOD, V101, P3606, DOI 10.1182/blood-2002-10-3146; Chauhan D, 2009, CANCER CELL, V16, P309, DOI 10.1016/j.ccr.2009.08.019; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; de Broek IV, 2006, HAEMATOL-HEMATOL J, V91, P200; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Granchi C, 2014, BIOORG MED CHEM LETT, V24, P4915, DOI 10.1016/j.bmcl.2014.09.041; Gu ZM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0392-4; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heuck CJ, 2014, LEUKEMIA, V28, P2410, DOI 10.1038/leu.2014.232; Ikeda S, 2018, BLOOD ADV, V2, P323, DOI 10.1182/bloodadvances.2017008847; Jung DW, 2013, ACS CHEM BIOL, V8, P1271, DOI 10.1021/cb300687k; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Li WB, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071616; Liberti MV, 2016, NAT CHEM BIOL, V12, P577, DOI 10.1038/nchembio.2133; Lu CC, 2014, J CHROMATOGR A, V1372, P34, DOI 10.1016/j.chroma.2014.10.098; Maiso P, 2015, CANCER RES, V75, P2071, DOI 10.1158/0008-5472.CAN-14-3400; Manasanch EE, 2019, BLOOD ADV, V3, P2400, DOI 10.1182/bloodadvances.2019000300; Milosevic A, 2004, SEMIN RADIAT ONCOL, V14, P249, DOI 10.1016/j.semradonc.2004.04.006; Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331; Pacella I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01889; Qorraj M, 2017, LEUKEMIA, V31, P470, DOI 10.1038/leu.2016.214; Ray A, 2018, LEUKEMIA, V32, P843, DOI 10.1038/leu.2017.322; Ray A, 2015, LEUKEMIA, V29, P1441, DOI 10.1038/leu.2015.11; Ray A, 2014, LEUKEMIA, V28, P1716, DOI 10.1038/leu.2014.46; Ray A, 2020, LEUKEMIA, V34, P567, DOI 10.1038/s41375-019-0558-x; Ryans K, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0212-1; Shaughnessy JD, 2007, BLOOD, V109, P2276, DOI 10.1182/blood-2006-07-038430; Shin YC, 2008, CANCER RES, V68, P1751, DOI 10.1158/0008-5472.CAN-07-2766; Stessman HAF, 2013, MOL CANCER THER, V12, P1140, DOI 10.1158/1535-7163.MCT-12-1151; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Zhao MY, 2015, ONCOTARGET, V6, P15610, DOI 10.18632/oncotarget.3639; Zhu XH, 2015, EXP CELL RES, V335, P216, DOI 10.1016/j.yexcr.2015.05.020	41	17	19	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2786	2796		10.1038/s41388-020-1172-0	http://dx.doi.org/10.1038/s41388-020-1172-0		FEB 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32024967	Green Accepted			2023-01-03	WOS:000511273600001
J	Topalian, SL; Taube, JM; Pardoll, DM				Topalian, Suzanne L.; Taube, Janis M.; Pardoll, Drew M.			Neoadjuvant checkpoint blockade for cancer immunotherapy	SCIENCE			English	Review							PATHOLOGICAL COMPLETE RESPONSE; PD-1 BLOCKADE; PREDICT SURVIVAL; LUNG-CANCER; CTLA-4; CHEMOTHERAPY; RECEPTOR; THERAPY; B7-H1; CELLS	Cancer immunotherapies that target the programmed cell death 1 (PD-L1):programmed death-ligand 1 (PD-L1) immune checkpoint pathway have ushered in the modern oncology era. Drugs that block PD-1 or PD-U facilitate endogenous antitumor immunity and, because of their broad activity spectrum, have been regarded as a common denominator for cancer therapy. Nevertheless, many advanced tumors demonstrate de novo or acquired treatment resistance, and ongoing research efforts are focused on improving patient outcomes. Using anti-PD-1 or anti-PD-U treatment against earlier stages of cancer is hypothesized to be one such solution. This Review focuses on the development of neoadjuvant (presurgical) immunotherapy in the era of PD-1 pathway blockade, highlighting particular considerations for biological mechanisms, clinical trial design, and pathologic response assessments. Findings from neoadjuvant immunotherapy studies may reveal pathways, mechanisms, and molecules that can be cotargeted in new treatment combinations to increase anti-PD-1 and anti-PD-L1 efficacy.	[Topalian, Suzanne L.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21287 USA; [Topalian, Suzanne L.; Taube, Janis M.; Pardoll, Drew M.] Sidney Kimmel Comprehens Canc Ctr, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD 21287 USA; [Taube, Janis M.] Johns Hopkins Univ, Dept Dermatol, Sch Med, Baltimore, MD 21287 USA; [Pardoll, Drew M.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University	Topalian, SL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21287 USA.; Topalian, SL (corresponding author), Sidney Kimmel Comprehens Canc Ctr, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD 21287 USA.	stopali1@jhmi.edu			NCI [R01 CA142779]; Cancer Research Institute/Stand Up To Cancer-Immunology Translational Cancer Research Grant [AACR-DT1012]; Bristol-Myers Squibb; Barney Family Foundation; Moving for Melanoma of Delaware; Laverna Hahn Charitable Trust; Melanoma Research Alliance; Harry J. Lloyd Charitable Trust; Emerson Collective Foundation; Mark Foundation for Cancer Research; Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research Institute/Stand Up To Cancer-Immunology Translational Cancer Research Grant; Bristol-Myers Squibb(Bristol-Myers Squibb); Barney Family Foundation; Moving for Melanoma of Delaware; Laverna Hahn Charitable Trust; Melanoma Research Alliance; Harry J. Lloyd Charitable Trust; Emerson Collective Foundation; Mark Foundation for Cancer Research; Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy	We gratefully acknowledge research support from NCI R01 CA142779 (to S.L.T., J.M.T., and D.M.P.), the Cancer Research Institute/Stand Up To Cancer-Immunology Translational Cancer Research Grant AACR-DT1012 (to D.M.P.), Bristol-Myers Squibb (S.L.T., J.M.T., and D.M.P.), the Barney Family Foundation (S.L.T.), Moving for Melanoma of Delaware (S.L.T.), the Laverna Hahn Charitable Trust (S.L.T.), the Melanoma Research Alliance (J.M.T.), the Harry J. Lloyd Charitable Trust (J.M.T.), the Emerson Collective Foundation (J.M.T.), the Mark Foundation for Cancer Research (J.M.T. and D.M.P.), and the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy (S.L.T., J.M.T., and D.M.P.).	Amaria RN, 2019, LANCET ONCOL, V20, pE378, DOI 10.1016/S1470-2045(19)30332-8; Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Barry KC, 2018, NAT MED, V24, P1178, DOI 10.1038/s41591-018-0085-8; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007; Carthon BC, 2010, CLIN CANCER RES, V16, P2861, DOI 10.1158/1078-0432.CCR-10-0569; Cloughesy TF, 2019, NAT MED, V25, P477, DOI 10.1038/s41591-018-0337-7; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Cottrell TR, 2018, ANN ONCOL, V29, P1853, DOI 10.1093/annonc/mdy218; Damsky W, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0613-1; Dong HD, 2004, IMMUNITY, V20, P327, DOI 10.1016/S1074-7613(04)00050-0; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fife BT, 2009, NAT IMMUNOL, V10, P1185, DOI 10.1038/ni.1790; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Fransen MF, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.124507; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; Garris CS, 2018, IMMUNITY, V49, P1148, DOI 10.1016/j.immuni.2018.09.024; Gershenwald JE, 2017, CA-CANCER J CLIN, V67, P472, DOI 10.3322/caac.21409; Goldberg MV, 2007, BLOOD, V110, P186, DOI 10.1182/blood-2006-12-062422; Griss J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12160-2; Hellmann MD, 2014, LANCET ONCOL, V15, pE42, DOI 10.1016/S1470-2045(13)70334-6; Huang AC, 2019, NAT MED, V25, P454, DOI 10.1038/s41591-019-0357-y; Jacoberger-Foissac C, 2019, J IMMUNOTHER CANCER, V7; Kamphorst AO, 2017, SCIENCE, V355, P1423, DOI 10.1126/science.aaf0683; Keung EZ, 2018, ANN SURG ONCOL, V25, P1814, DOI 10.1245/s10434-018-6379-8; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Li ZY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189294; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; Liu JK, 2018, APPL ANAL, V97, P2122, DOI 10.1080/00036811.2017.1359556; Liu J, 2016, CANCER DISCOV, V6, P1382, DOI 10.1158/2159-8290.CD-16-0577; Lutz ER, 2014, CANCER IMMUNOL RES, V2, P616, DOI 10.1158/2326-6066.CIR-14-0027; McCracken MN, 2016, ADV IMMUNOL, V131, P187, DOI 10.1016/bs.ai.2016.02.004; Memarnejadian A, 2017, J IMMUNOL, V199, P3348, DOI 10.4049/jimmunol.1700643; Mouillet G, 2012, J THORAC ONCOL, V7, P841, DOI 10.1097/JTO.0b013e31824c7d92; Nanda R, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.506; Necchi A, 2018, J CLIN ONCOL, V36, P3353, DOI 10.1200/JCO.18.01148; Nghiem PT, 2016, NEW ENGL J MED, V374, P2542, DOI 10.1056/NEJMoa1603702; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; O'Donnell JS, 2019, CLIN CANCER RES, V25, P5743, DOI 10.1158/1078-0432.CCR-18-2641; Okazaki T, 2001, P NATL ACAD SCI USA, V98, P13866, DOI 10.1073/pnas.231486598; Pataer A, 2012, J THORAC ONCOL, V7, P825, DOI 10.1097/JTO.0b013e318247504a; Petrelli F, 2014, EUR UROL, V65, P350, DOI 10.1016/j.eururo.2013.06.049; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Provencio-Pulla M, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.7550; Prowell TM, 2019, NEW ENGL J MED, V380, P612, DOI 10.1056/NEJMp1900079; Qu Y, 2019, J THORAC ONCOL, V14, P482, DOI 10.1016/j.jtho.2018.11.017; Robert C, 2019, LANCET ONCOL, V20, P1239, DOI 10.1016/S1470-2045(19)30388-2; Roberts EW, 2016, CANCER CELL, V30, P324, DOI 10.1016/j.ccell.2016.06.003; Rozeman EA, 2019, LANCET ONCOL, V20, P948, DOI 10.1016/S1470-2045(19)30151-2; Rudd CE, 2009, IMMUNOL REV, V229, P12, DOI 10.1111/j.1600-065X.2009.00770.x; Salmon H, 2016, IMMUNITY, V44, P924, DOI 10.1016/j.immuni.2016.03.012; Sautes-Fridman C, 2019, NAT REV CANCER, V19, P307, DOI 10.1038/s41568-019-0144-6; Schalper KA, 2019, NAT MED, V25, P470, DOI 10.1038/s41591-018-0339-5; Schmid P, 2019, ANN ONCOL, V30, P853; Siddiqui I, 2019, IMMUNITY, V50, P195, DOI 10.1016/j.immuni.2018.12.021; Simoni Y, 2018, NATURE, V557, P575, DOI 10.1038/s41586-018-0130-2; Spring L, 2017, J NATL COMPR CANC NE, V15, P1216, DOI 10.6004/jnccn.2017.0158; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; Stein JE, 2019, ANN ONCOL, V30, P589, DOI 10.1093/annonc/mdz019; Stein JE, 2020, CLIN CANCER RES, V26, P545, DOI 10.1158/1078-0432.CCR-19-2379; Sun R, 2018, LANCET ONCOL, V19, P1180, DOI 10.1016/S1470-2045(18)30413-3; Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823; Tarhini AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087705; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Tetzlaff MT, 2018, ANN ONCOL, V29, P1861, DOI 10.1093/annonc/mdy226; Thangada S, 2010, J EXP MED, V207, P1475, DOI 10.1084/jem.20091343; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Topalian SL, 2019, JAMA ONCOL, V5, P1411, DOI 10.1001/jamaoncol.2019.2187; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Topalian SL, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9505; Trebeschi S, 2019, ANN ONCOL, V30, P998, DOI 10.1093/annonc/mdz108; Tsushima F, 2007, BLOOD, V110, P180, DOI 10.1182/blood-2006-11-060087; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Zhang JJ, 2020, CLIN CANCER RES, V26, P1327, DOI 10.1158/1078-0432.CCR-19-2931	84	303	308	21	193	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 31	2020	367	6477					525	+	eaax0182	10.1126/science.aax0182	http://dx.doi.org/10.1126/science.aax0182			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ9MD	32001626	Green Accepted			2023-01-03	WOS:000512377600030
J	Verveer, I; Remmerswaal, D; Jongerling, J; van der Veen, FM; Franken, IHA				Verveer, Ilse; Remmerswaal, Danielle; Jongerling, Joran; van der Veen, Frederik M.; Franken, Ingmar H. A.			No effect of repetitive tDCS on daily smoking behaviour in light smokers: A placebo controlled EMA study	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; PREFRONTAL CORTEX; DOUBLE-BLIND; CORTICAL STIMULATION; ALCOHOL-CONSUMPTION; MODULATION	Introduction The effectiveness of repetitive transcranial Direct Current Stimulation (tDCS) on reducing smoking behaviour has been studied with mixed results. Smoking behaviour is influenced by affect and context, therefore we choose to use mobile ecological momentary assessments (EMA) to measure changes in smoking behaviour after tDCS. Methods In a randomized, placebo-controlled, between subject study, we applied tDCS bilaterally with the anodal electrode targeting the right DLPFC (https://clinicaltrials.gov/ct2/show/ NCT03027687). Smokers were allocated to six sessions of either active tDCS (n = 35) or sham tDCS (n = 36) and received two sessions on three different days in one week. They were asked to keep track of their daily cigarette consumption, craving and affect in an application on their mobile phones for three months starting one week before the first tDCS session. Results Number of smoked cigarettes a day progressively decreased up to one week after the last tDCS session in both conditions. Active treatment had no additional effect on cigarette consumption, craving and affect. Conclusions In this exploratory study, repetitive bilateral tDCS over the DLPFC had no effect on daily smoking behaviour. Future research needs to investigate how motivation to quit smoking and the number of tDCS sessions affect the efficacy of repetitive tDCS.	[Verveer, Ilse; Remmerswaal, Danielle; Jongerling, Joran; van der Veen, Frederik M.; Franken, Ingmar H. A.] Erasmus Univ, Erasmus Sch Social & Behav Sci, Dept Psychol Educ & Child Studies, Rotterdam, Netherlands	Erasmus University Rotterdam	Verveer, I (corresponding author), Erasmus Univ, Erasmus Sch Social & Behav Sci, Dept Psychol Educ & Child Studies, Rotterdam, Netherlands.	verveer@essb.eur.nl	Franken, Ingmar/AAB-7562-2019	Franken, Ingmar/0000-0002-7853-2694; Verveer, Ilse/0000-0002-0593-6225; , Joran/0000-0001-5697-1381				Batista EK, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyv066; Behnam SG, 2019, EUR PSYCHIAT, V60, P41, DOI 10.1016/j.eurpsy.2019.04.010; Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004; Boggio PS, 2008, DRUG ALCOHOL DEPEN, V92, P55, DOI 10.1016/j.drugalcdep.2007.06.011; Boggio PS, 2010, DRUG ALCOHOL DEPEN, V112, P220, DOI 10.1016/j.drugalcdep.2010.06.019; Boggio PS, 2009, NEUROSCI LETT, V463, P82, DOI 10.1016/j.neulet.2009.07.041; Boniface S, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1297; Brevet-Aeby C, 2016, NEUROSCI BIOBEHAV R, V71, P112, DOI 10.1016/j.neubiorev.2016.08.028; Dunbar MS, 2018, ADDICT BEHAV, V80, P53, DOI 10.1016/j.addbeh.2018.01.006; Dvorak RD, 2018, PSYCHOL ADDICT BEHAV, V32, P583, DOI 10.1037/adb0000392; Falcone M, 2016, BRAIN STIMUL, V9, P191, DOI 10.1016/j.brs.2015.10.004; Fecteau S, 2014, DRUG ALCOHOL DEPEN, V140, P78, DOI 10.1016/j.drugalcdep.2014.03.036; Fregni F, 2008, J CLIN PSYCHIAT, V69, P32, DOI 10.4088/JCP.v69n0105; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Hox J.J., 2010, MULTILEVEL ANAL TECH, Vsecond, DOI DOI 10.4324/9781315650982; Jansen JM, 2013, NEUROSCI BIOBEHAV R, V37, P2472, DOI 10.1016/j.neubiorev.2013.07.009; Jones A, 2019, ADDICTION, V114, P609, DOI 10.1111/add.14503; Kang N, 2019, ADDICT BEHAV, V96, P133, DOI 10.1016/j.addbeh.2019.05.006; Lapenta OM, 2018, J ECT, V34, P182, DOI 10.1097/YCT.0000000000000541; Monk RL, 2018, ALCOHOL ALCOHOLISM, V53, P228, DOI 10.1093/alcalc/agx084; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Russo R, 2013, BRAIN STIMUL, V6, P946, DOI 10.1016/j.brs.2013.05.009; Stockwell T, 2014, ADDICTION, V109, P1657, DOI 10.1111/add.12609; Vance DE, 2016, NURSING-RES REV, V6, P23, DOI 10.2147/NRR.S115627; Brangioni MCVD, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00014; Volkow ND, 2010, BIOESSAYS, V32, P748, DOI 10.1002/bies.201000042; Wall AM, 2000, PSYCHOL ADDICT BEHAV, V14, P367, DOI 10.1037/0893-164X.14.4.367; Wang YJ, 2016, J PSYCHIATR RES, V79, P1, DOI 10.1016/j.jpsychires.2016.04.001; Woods AJ, 2016, CLIN NEUROPHYSIOL, V127, P1031, DOI 10.1016/j.clinph.2015.11.012; World Health Organization, 2019, WHO REP GLOB TOB EP; Yucel M, 2019, ADDICTION, V114, P1095, DOI 10.1111/add.14424	33	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2020	15	5							e0233414	10.1371/journal.pone.0233414	http://dx.doi.org/10.1371/journal.pone.0233414			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU1MJ	32442205	Green Published, gold			2023-01-03	WOS:000537525900040
J	Wang, SJ; Zhang, ZG; Yao, L; Ding, NN; Jiang, LJ; Wu, YC				Wang, Shengjun; Zhang, Zhigang; Yao, Li; Ding, Nannan; Jiang, Lingjie; Wu, Yuchen			Bright light therapy in the treatment of patients with bipolar disorder: A systematic review and meta-analysis	PLOS ONE			English	Review							SEASONAL AFFECTIVE-DISORDER; SLEEP-DEPRIVATION; DEPRESSIVE SYMPTOMS; CONTROLLED-TRIAL; EFFICACY; MOOD; SAFETY; ONSET; CHRONOTHERAPEUTICS; EPIDEMIOLOGY	The treatment of depressive symptoms of bipolar disorder (BD) has received increasing attention. Recently, some studies have shown that bright light therapy (BLT) seems to be useful for BD depression. This meta-analysis is intended to further elucidate the role of BLT in depressive symptoms in patients with BD. Register of Systematic Reviews PROSPERO: CRD 420191 33642.Randomized controlled trials and cohort studies were retrieved in PubMed, Cochrane Library, EMbase, Web of Science, CINHAL, CBM, CNKI, VIP, and Wanfang from their foundation to March 2020, and other sources as supplement was also retrieved. Data were extracted after strict evaluation of literature quality by two researchers, and Meta-analysis was conducted on literatures that met the inclusion criteria. Meta-analysis was performed using Revman 5.3 software. In total, 12 studies including 847 patients with BD depression were included in our meta-analysis. A meta-analysis found significant differences between BLT and placebo for the following outcomes: (1) depression severity before and after BLT [SMD = -0.43, 95% CI (-0.73,-0.13), P<0.05] in RCT and [SMD = -2.12, 95% CI (-2.3,-1.94), P<0.05] in cohort studies.; (2) the efficacy of duration/timing of light therapy for depressive symptoms in BD [I-2 = 85%, SMD = -1.88, 95% CI (-2.04, -1.71), P< 0.05] and [I-2 = 71%, SMD = -2.1,95% CI(-2.24, -1.96), P< 0.05]; (3) the efficacy of different color/color temperatures for depressive symptoms in BD [I-2 = 0%, SMD = -0.56, 95% CI (-0.92, -0.19), P< 0.05] and [I-2 = 97%, SMD = -1.74, 95% CI (-1.99, -1.49), P<0.05].We performed a subgroup meta-analysis of studies that used different light intensities. The results showed that light intensity.5000 lux significantly reduced the severity of depression. And patients without psychotropic drugs revealed significantly decreased disease severity [I-2 = 0%, SMD = -0.6, 95% CI (-1.06,-0.13), P<0.05]. Limitations of the study include studies only assessed short-term effects, and insufficient duration may underestimate adverse reactions and efficacy. Our results highlight the significant efficiency of BLT in the treatment of bipolar depression. Prospective studies with more rigorous design and consistent follow-up.	[Wang, Shengjun; Zhang, Zhigang; Yao, Li; Ding, Nannan; Jiang, Lingjie; Wu, Yuchen] Lanzhou Univ, Hosp 1, Intens Care Unit, Lanzhou, Peoples R China; [Wang, Shengjun; Zhang, Zhigang; Yao, Li; Ding, Nannan; Jiang, Lingjie] Lanzhou Univ, Sch Nursing, Lanzhou, Peoples R China	Lanzhou University; Lanzhou University	Zhang, ZG (corresponding author), Lanzhou Univ, Hosp 1, Intens Care Unit, Lanzhou, Peoples R China.; Zhang, ZG (corresponding author), Lanzhou Univ, Sch Nursing, Lanzhou, Peoples R China.	zzg3444@163.com						Bauer M, 2005, EPILEPSIA, V46, P8, DOI 10.1111/j.1528-1167.2005.463003.x; Benedetti F, 2005, J CLIN PSYCHIAT, V66, P1535, DOI 10.4088/JCP.v66n1207; Benedetti F, 2003, J CLIN PSYCHIAT, V64, P648, DOI 10.4088/JCP.v64n0605; Benedetti F, 2007, CHRONOBIOL INT, V24, P921, DOI 10.1080/07420520701649455; Benedetti F, 2018, AM J PSYCHIAT, V175, P905, DOI 10.1176/appi.ajp.2018.18020231; Benedetti F, 2014, J CLIN PSYCHIAT, V75, P133, DOI 10.4088/JCP.13m08455; Benedetti F, 2009, PSYCHIAT RES-NEUROIM, V173, P238, DOI 10.1016/j.pscychresns.2008.08.004; Calabrese J, 2005, ACTA PSYCHIAT SCAND, V112, P85, DOI 10.1111/j.1600-0447.2005.00534.x; Castellani A, 2015, J AFFECT DISORDERS, V174, P45, DOI 10.1016/j.jad.2014.11.032; Chandrasekaran V, 2019, J AFFECT DISORDERS, V249, P262, DOI 10.1016/j.jad.2019.02.013; Cipriani A, 2009, LANCET, V373, P746, DOI 10.1016/S0140-6736(09)60046-5; Colom F, 2009, BRIT J PSYCHIAT, V194, P260, DOI 10.1192/bjp.bp.107.040485; Dauphinais DR, 2012, PSYCHIAT RES, V196, P57, DOI 10.1016/j.psychres.2012.01.015; Deeks, 2008, ANAL DATA UNDERTAKIN; Desan PH, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-38; Evans M, 2013, COGNITIVE THER RES, V37, P1201, DOI 10.1007/s10608-013-9561-0; Frank E, 2005, ARCH GEN PSYCHIAT, V62, P996, DOI 10.1001/archpsyc.62.9.996; Frye MA, 2011, J CLIN PSYCHIAT, V72, P1295, DOI [10.4088/JCP.10123colc, 10.4088/JCP.10123co1c]; Garbazza C, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00481; Geddes JR, 2013, LANCET, V381, P1672, DOI 10.1016/S0140-6736(13)60857-0; Geoffroy PA, 2019, SLEEP MED REV, V48, DOI 10.1016/j.smrv.2019.101213; Geoffroy PA, 2018, SLEEP MED REV, V40, P218, DOI 10.1016/j.smrv.2018.03.002; Gottlieb JF, 2019, BIPOLAR DISORD, V21, P741, DOI 10.1111/bdi.12847; Grande I, 2016, LANCET, V387, P1561, DOI 10.1016/S0140-6736(15)00241-X; Grande I, 2015, CNS DRUGS, V29, P221, DOI 10.1007/s40263-015-0235-1; Grunze H, 2010, WORLD J BIOL PSYCHIA, V11, P81, DOI 10.3109/15622970903555881; Hooley JM, 2007, ANNU REV CLIN PSYCHO, V3, P329, DOI 10.1146/annurev.clinpsy.2.022305.095236; Jick H, 2004, JAMA-J AM MED ASSOC, V292, P2833, DOI 10.1001/jama.292.23.2833-c; Kaplan KA, 2013, AM J PSYCHIAT, V170, P716, DOI 10.1176/appi.ajp.2013.12050708; Kendall T, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5673; Kessler RC, 2004, INT J METH PSYCH RES, V13, P122, DOI 10.1002/mpr.169; Knapen SE, 2014, J AFFECT DISORDERS, V166, P343, DOI 10.1016/j.jad.2014.05.034; Krane-Gartiser K, 2016, J AFFECT DISORDERS, V202, P23, DOI 10.1016/j.jad.2016.05.012; Kreutzmann JC, 2015, NEUROSCIENCE, V309, P173, DOI 10.1016/j.neuroscience.2015.04.053; Kupeli NY, 2018, PSYCHIAT RES, V260, P432, DOI 10.1016/j.psychres.2017.12.020; Lam DH, 2005, AM J PSYCHIAT, V162, P324, DOI 10.1176/appi.ajp.162.2.324; Lam RW, 2020, CAN J PSYCHIAT, V65, P290, DOI 10.1177/0706743719892471; Leverich GS, 2003, J CLIN PSYCHIAT, V64, P506, DOI 10.4088/JCP.v64n0503; Levitan RD, 2005, J PSYCHIATR NEUROSCI, V30, P72; LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030; Machado-Vieira R, 2008, J CLIN PSYCHIAT, V69, P946, DOI 10.4088/JCP.v69n0610; Martiny K, 2005, ACTA PSYCHIAT SCAND, V111, P453, DOI 10.1111/j.1600-0447.2005.00532.x; Martiny K, 2014, ACTA PSYCHIAT SCAND, V129, P160, DOI 10.1111/acps.12219; Maruani J, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00085; Miura T, 2014, LANCET PSYCHIAT, V1, P351, DOI 10.1016/S2215-0366(14)70314-1; Nasr S.J., 2018, CURR PSYCHIAT, V17, P28; Okasha T, 2013, J AFFECT DISORDERS, V147, P217, DOI 10.1016/j.jad.2012.11.007; PAPATHEODOROU G, 1995, J PSYCHIATR NEUROSCI, V20, P226; Phillips ML, 2013, LANCET, V381, P1663, DOI 10.1016/S0140-6736(13)60989-7; Price AL, 2012, AM FAM PHYSICIAN, V85, P483; Sherazi R, 2006, HARVARD REV PSYCHIAT, V14, P273, DOI 10.1080/10673220601070047; Shuster J.J, 2011, RES SYNTH METHODS, V2, P126, DOI [DOI 10.1002/JRSM.38, 10.1002/jrsm.38]; Sidor MM, 2012, CURR PSYCHIAT REP, V14, P696, DOI 10.1007/s11920-012-0323-6; Sikkens D, 2018, J AFFECTIVE DISORDER; Sit D, 2015, BIOL PSYCHIAT, V77, p66S; Sit DK, 2018, AM J PSYCHIAT, V175, P131, DOI 10.1176/appi.ajp.2017.16101200; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Stephenson KM, 2012, SLEEP MED REV, V16, P445, DOI 10.1016/j.smrv.2011.09.002; Suzuki M, 2018, J AFFECT DISORDERS, V229, P371, DOI 10.1016/j.jad.2017.12.066; Suzuki M, 2016, J AFFECT DISORDERS, V204, P48, DOI 10.1016/j.jad.2016.06.044; Takeshima M, 2020, PSYCHIAT CLIN NEUROS, V74, P247, DOI 10.1111/pcn.12976; Takeshima N, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-30; Thompson C, 2002, J AFFECT DISORDERS, V68, P89; Tseng PT, 2016, EUR NEUROPSYCHOPHARM, V26, P1037, DOI 10.1016/j.euroneuro.2016.03.001; Tuunainen A, 2004, Cochrane Database Syst Rev, pCD004050, DOI 10.1002/14651858.CD004050.pub2; Vai B, 2014, EXPERT REV NEUROTHER, V14, P631, DOI 10.1586/14737175.2014.915744; Vieta E, 2008, BIPOLAR DISORD, V10, P163, DOI 10.1111/j.1399-5618.2007.00561.x; Vieta E, 2007, SCHIZOPHRENIA BULL, V33, P886, DOI 10.1093/schbul/sbm057; Vieta E, 2013, J AFFECT DISORDERS, V148, P28, DOI 10.1016/j.jad.2013.03.007; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Wang XH, 2019, J MED SYST, V43, DOI 10.1007/s10916-019-1212-x; Waraich P, 2004, CAN J PSYCHIAT, V49, P124, DOI 10.1177/070674370404900208; Wirz-Justice A, 2020, EUR J NEUROSCI, V51, P346, DOI 10.1111/ejn.14362; Wu JC, 2011, SLEEP BIOL RHYTHMS, V9, P209, DOI [10.1111/j.1479-8425.2011.00521.x, DOI 10.1111/J.1479-8425.2011.00521.X]; Wulsin LR, 1999, PSYCHOSOM MED, V61, P6, DOI 10.1097/00006842-199901000-00003; Yatham LN, 2013, BIPOLAR DISORD, V15, P1, DOI 10.1111/bdi.12025; Zhou TH, 2018, J AFFECT DISORDERS, V227, P90, DOI 10.1016/j.jad.2017.09.038	77	8	8	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2020	15	5							e0232798	10.1371/journal.pone.0232798	http://dx.doi.org/10.1371/journal.pone.0232798			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU1JI	32437356	Green Published, gold			2023-01-03	WOS:000537517800026
J	Silva, FF; Bonfante, GMD; Reis, IA; da Rocha, HA; Lana, AP; Cherchiglia, ML				Silva, Flavia Feliciana; da Silva Bonfante, Gisele Macedo; Reis, Ilka Afonso; da Rocha, Hugo Andre; Lana, Agner Pereira; Cherchiglia, Mariangela Leal			Hospitalizations and length of stay of cancer patients: A cohort study in the Brazilian Public Health System	PLOS ONE			English	Article							UNPLANNED PRESENTATIONS; PREDICTORS; CARE; COMPLICATIONS; ADMISSIONS; ADULTS; TRENDS	The hospitalizations are part of cancer care and has been studied by researchers worldwide. A better understanding about their associated factors may help to achieve improvements on this area. The aims of this study were to investigate the association between demographic and clinical characteristics and hospitalizations, as well as between these characteristics and the length of stay (LOS), within the first year of outpatient treatment, for the most incident cancers in the Brazilian population. In this cohort study, we investigated 417,477 patients aged 19 years or more, who started outpatient cancer treatment, from 2010-2014, for breast, prostate, colorectal, cervix, lung and stomach cancers. The outcomes evaluated were: i) Hospitalizations within the first year of outpatient cancer treatment; and ii) LOS of the hospitalized patients. It was performed a binary logistic regression to evaluate the association between the explanatory variables and the hospitalizations and a negative binomial regression to evaluate their influence on the length of hospital stay. The hospitalizations occurred for 34% of patients, with a median of LOS of 6 days (IQR: 2-15). Female patients were 16% less likely to be hospitalized (OR: 0.84; 95% CI: 0.82-0.86), with lower average of LOS (AR: 0.98; 95% CI: 0.97-0.99), each additional year of age reduced in 2% the hospitalization odds (OR: 0.98; 95% CI: 0.98-0.99) and in 1% the average of LOS (AR: 0.99; 95% CI: 0.98-0.99), patients from South region had twice more chances of hospitalization than from North region (OR: 2.01; 95% CI: 1.93-2.10) and patients with colorectal cancer had greater probability of hospitalization (OR: 4.42; 95% CI: 4.27-4.48), with the highest average of LOS (AR: 1.37; 95% CI: 1.35-1.40). In view of our results, we consider that the government must expand the policies with potential to reduce the number of hospitalizations.	[Silva, Flavia Feliciana; da Rocha, Hugo Andre; Lana, Agner Pereira] Univ Fed Minas Gerais, Postgrad Program Publ Hlth, Med Sch, Belo Horizonte, MG, Brazil; [da Silva Bonfante, Gisele Macedo] Pontificia Univ Catolica Minas Gerais, Dept Odontol, Belo Horizonte, MG, Brazil; [Reis, Ilka Afonso] Univ Fed Minas Gerais, Inst Exact Sci, Dept Stat, Belo Horizonte, MG, Brazil; [Cherchiglia, Mariangela Leal] Univ Fed Minas Gerais, Med Sch, Postgrad Program Publ Hlth, Dept Social & Prevent Med, Belo Horizonte, MG, Brazil	Universidade Federal de Minas Gerais; Pontificia Universidade Catolica de Minas Gerais; Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais	Silva, FF (corresponding author), Univ Fed Minas Gerais, Postgrad Program Publ Hlth, Med Sch, Belo Horizonte, MG, Brazil.	flaviafelisil@yahoo.com.br	Reis, Ilka Afonso/AAO-5375-2021; Cherchiglia, Mariangela/Z-3216-2019	Reis, Ilka Afonso/0000-0001-7199-8590; Cherchiglia, Mariangela/0000-0001-5622-567X; Rocha, Hugo/0000-0001-6433-0568; SILVA, FLAVIA FELICIANA/0000-0002-6878-6519	National Council of Technological and Scientific Development (CNPq), Brazil [3060/2018-7]; Research Support Foundation of the State of Minas Gerais (FAPEMIG), Brazil [PPM-00369-17]; Coordination for the Improvement of Higher Education Personnel (CAPES) [001]; Research Support Foundation of the State of Minas Gerais (FAPEMIG) [APQ-03475-13]	National Council of Technological and Scientific Development (CNPq), Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Research Support Foundation of the State of Minas Gerais (FAPEMIG), Brazil(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); Coordination for the Improvement of Higher Education Personnel (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Research Support Foundation of the State of Minas Gerais (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG))	MLC received research sponsorship from National Council of Technological and Scientific Development (CNPq), Brazil (3060/2018-7) and the Research Support Foundation of the State of Minas Gerais (FAPEMIG), Brazil (PPM-00369-17). This study was part financed by the Coordination for the Improvement of Higher Education Personnel (CAPES) (Financial Code 001) and the Research Support Foundation of the State of Minas Gerais (FAPEMIG) grant number: APQ-03475-13 (MLC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2019, ESTIMATE 2020 CANC I; Aprile G, 2013, SUPPORT CARE CANCER, V21, P397, DOI 10.1007/s00520-012-1524-6; Bekelman JE, 2016, JAMA-J AM MED ASSOC, V315, P272, DOI 10.1001/jama.2015.18603; Boccolini CS, 2016, DISCUSSION TEXTS; Brazil. Brazilian Institute of Geography and Statistics IBGE, 2008, HLTH PAN BRAZ ACC US; Brazil. Ministry of Health, INF TECHN DEP BRAZ P; Castro MC, 2019, LANCET, V394, P345, DOI 10.1016/S0140-6736(19)31243-7; Oliveira Max Moura de, 2015, Rev. bras. epidemiol., V18, P146, DOI 10.1590/1980-5497201500060013; Scolari GAD, 2018, REV BRAS ENFERM, V71, P811, DOI 10.1590/0034-7167-2017-0440; Dufton PH, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4509-z; Elias PE, 2008, CIENC SAUDE COLETIVA, V13, P2023, DOI 10.1590/S1413-81232008000900005; Farjah F, 2012, ANN THORAC SURG, V94, P881, DOI 10.1016/j.athoracsur.2012.04.082; Guerra Junior Augusto Afonso, 2018, Int J Popul Data Sci, V3, P446, DOI 10.23889/ijpds.v3i1.446; Hassett MJ, 2011, ONCOLOGIST, V16, P378, DOI 10.1634/theoncologist.2010-0354; Kelly M, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-77; Kunisawa S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166269; Livingston PM, 2011, AUSTRALAS EMERG NURS, V14, P62, DOI 10.1016/j.aenj.2011.03.005; Maciel MGS, 2012, MANUAL CUIDADOS PALI, P94; Manzano JGM, 2014, J CLIN ONCOL, V32, P3527, DOI 10.1200/JCO.2014.55.3131; May P, 2017, J HOSP MED, V12, P407, DOI 10.12788/jhm.2745; Numico G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120827; O'Connor NR, 2014, J CLIN ONCOL, V32, P3184, DOI 10.1200/JCO.2014.55.8817; O'Dwyer G, 2017, REV SAUDE PUBL, V51, DOI [10.11606/S1518-8787.2017051000072, 10.11606/s1518-8787.2017051000072]; O'Neill CB, 2016, J ONCOL PRACT, V12, P151, DOI 10.1200/JOP.2015.004812; Park M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197891; Perng DS, 2014, WORLD J GASTROENTERO, V20, P532, DOI 10.3748/wjg.v20.i2.532; Pugh Alison, 2015, Br J Nurs, V24, pS18, DOI 10.12968/bjon.2015.24.Sup16.S18; Seow Hsien, 2019, CMAJ Open, V7, pE73, DOI 10.9778/cmajo.20180113; Santos MAS, 2015, EPIDEMIOL SERV SAUDE, V24, P389, DOI 10.5123/S1679-49742015000300005; da Silva MJS, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6190-3; Strasser-Weippl K, 2015, LANCET ONCOL, V16, P1405, DOI 10.1016/S1470-2045(15)00218-1; Tamang S, 2015, J ONCOL PRACT, V11, pE313, DOI 10.1200/JOP.2014.002741; UICC, WHAT IS TNM; Waddle MR, 2015, PRACT RADIAT ONCOL, V5, pE245, DOI 10.1016/j.prro.2014.08.004; Whitney RL, 2019, J ONCOL PRACT, V15, P37, DOI 10.1200/JOP.18.00254; Whitney RL, 2017, J CLIN ONCOL, V35, P3610, DOI 10.1200/JCO.2017.72.4963	36	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2020	15	5							e0233293	10.1371/journal.pone.0233293	http://dx.doi.org/10.1371/journal.pone.0233293			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1GK	32433706	Green Published, gold			2023-01-03	WOS:000537510100045
J	Yahia, Y; Benabderrahim, MA; Tlili, N; Bagues, M; Nagaz, K				Yahia, Yassine; Benabderrahim, Mohamed Ali; Tlili, Nizar; Bagues, Mohamed; Nagaz, Kameleddine			Bioactive compounds, antioxidant and antimicrobial activities of extracts from different plant parts of two Ziziphus Mill. species	PLOS ONE			English	Article							PHENOLIC-COMPOUNDS; JUJUBA; ACID; FRUIT; PERFORMANCE; DIVERSITY; POLYSACCHARIDES; CONSTITUENTS; POPULATIONS; METABOLISM	Ziziphus lotus L. (Lam.) and Z. mauritiana Lam., as a widespread species in Tunisia, are well known for their medicinal and food uses. The aim of the present study was to screen the content of total polyphenols, flavonoids, and condensed tannins together with the radical scavenging capacity and the antimicrobial activity of leaves, fruits and seeds extracts of Z. lotus and Z. mauritiana from different localities. Results showed that leaves extracts presented the highest phenolic compounds content for both species. Furthermore, LC-ESI-MS analysis allowed the identification of 28 bioactive compounds regardless of species and organs, with the predominance of quinic acid and rutin. Leaves extract of Z. mauritiana possessed the highest total antioxidant capacity. The antimicrobial tests showed that leaves extracts of Z. mauritiana and Z. lotus from Oued Esseder exhibited the highest activity against four bacterial strains (Staphylococcus aureus, Listeria monocytogenes, Salmonella typhimurium and Escherichia coli). The main results showed that the studied species of Ziziphus genus are an excellent source of natural bioactive molecules that could be an interesting material for industrial and food purposes.	[Yahia, Yassine; Benabderrahim, Mohamed Ali; Bagues, Mohamed; Nagaz, Kameleddine] Inst Reg Arides, Lab Aridoculture & Cultures Oasiennes, Medenine, Tunisia; [Tlili, Nizar] Univ Tunis El Manar, Fac Sci Tunis, Dept Biol, Tunis, Tunisia; [Tlili, Nizar] Univ Carthage, Inst Super Sci & Technol Environm, Carthage, Tunisia	Institut des Regions Arides; Universite de Tunis-El-Manar; Faculte des Sciences de Tunis (FST); Universite de Carthage	Yahia, Y (corresponding author), Inst Reg Arides, Lab Aridoculture & Cultures Oasiennes, Medenine, Tunisia.	yahia.yassine@gmail.com		yahia, yassine/0000-0002-1088-3287				Abdoul-Azize S, 2016, J NUTR METAB, V2016, DOI 10.1155/2016/2867470; Abozed S. S., 2014, Annals of Agricultural Science (Cairo), V59, P63, DOI 10.1016/j.aoas.2014.06.009; Avello MA, 2013, REV BRAS FARMACOGN, V23, P44, DOI 10.1590/S0102-695X2012005000122; Baghazadeh-Daryaii L, 2017, J APPL RES MED AROMA, V7, P99, DOI 10.1016/j.jarmap.2017.06.006; Ben Yakoub AR, 2018, IND CROP PROD, V118, P206, DOI 10.1016/j.indcrop.2018.03.047; Bernard FX, 1997, ANTIMICROB AGENTS CH, V41, P992, DOI 10.1128/AAC.41.5.992; Bersuder P, 1998, J AM OIL CHEM SOC, V75, P181, DOI 10.1007/s11746-998-0030-y; Bin Kang K, 2016, MASS SPECTROM LETT, V7, P45, DOI 10.5478/MSL.2016.7.2.45; Boussaid M, 2018, ARID LAND RES MANAG, V32, P184, DOI 10.1080/15324982.2018.1424742; Buta JG, 1997, J PLANT GROWTH REGUL, V16, P43, DOI 10.1007/PL00006973; Chang SC, 2010, INT J BIOL MACROMOL, V47, P445, DOI 10.1016/j.ijbiomac.2010.06.010; Chen C, 1999, BIOCHEM MOL BIOL INT, V47, P397; Chen JP, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/3019568; Chevalier A., 1947, J AGR TRAD BOT APPL, V301-302, P470, DOI [10.3406/jatba.1947.6125, DOI 10.3406/JATBA.1947.6125]; Chirinos R, 2013, IND CROP PROD, V47, P145, DOI 10.1016/j.indcrop.2013.02.025; D'Angiolillo F, 2018, NOT BOT HORTI AGROBO, V46, P402, DOI 10.15835/nbha46211061; Daayf F, 2008, RECENT ADV POLYPHENO, V1, DOI [10.1002/9781444302400, DOI 10.1002/9781444302400]; Elaloui M, 2014, EMIR J FOOD AGR, V26, P602, DOI 10.9755/ejfa.v26i7.17513; Elaloui M., 2017, INT J SECOND MET, V4, P18, DOI [10.21448/ijsm.275886, DOI 10.21448/IJSM.275886]; Elfalleh W, 2019, IND CROP PROD, V127, P212, DOI 10.1016/j.indcrop.2018.10.078; Freney J, 2002, PRECIS BACTERIOLOGIE, P565; Gao QH, 2012, J FOOD SCI, V77, pC1218, DOI 10.1111/j.1750-3841.2012.02946.x; Gornas P, 2016, EUR FOOD RES TECHNOL, V242, P641, DOI 10.1007/s00217-015-2572-1; Guo S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00609; Guo S, 2015, FOOD CHEM, V167, P468, DOI 10.1016/j.foodchem.2014.07.013; Hossain A, 2016, PACIFIC SCI REV, V18, P78, DOI [10.1016/j.psra.2016.09.001, DOI 10.1016/J.PSRA.2016.09.001]; Islam MS, 2002, J AGR FOOD CHEM, V50, P3718, DOI 10.1021/jf020120l; Kanazawa K, 2000, J AGR FOOD CHEM, V48, P844, DOI 10.1021/jf9909860; Khaleel S.M., 2016, BRIT J MED MED RES, V14, DOI [https://doi.org/10.9734/BJMMR/2016/24935, DOI 10.9734/BJMMR/2016/24935, 10.9734/BJMMR/2016/24935]; Khanbabaee K, 2001, NAT PROD REP, V18, P641, DOI 10.1039/b101061l; Kolb CA, 2001, PLANT PHYSIOL, V127, P863, DOI 10.1104/pp.010373; Koley TK, 2016, ARAB J CHEM, V9, pS1044, DOI 10.1016/j.arabjc.2011.11.005; Kulkarni M, 2016, REPRODUCTIVE BIOL 3, DOI [10.1101/077289, DOI 10.1101/077289]; Lardeau A, 2013, J PHARMACEUT BIOMED, V76, P134, DOI 10.1016/j.jpba.2012.12.016; Li JW, 2007, FOOD CHEM, V103, P454, DOI 10.1016/j.foodchem.2006.08.016; Li M, 2014, FITOTERAPIA, V99, P48, DOI 10.1016/j.fitote.2014.09.001; Liu JS, 2012, J ETHNOPHARMACOL, V141, P257, DOI 10.1016/j.jep.2012.02.026; Liu MJ, 1995, ACTA HORTIC, P161, DOI 10.17660/ActaHortic.1995.390.23; Makris DP, 2001, J AGR FOOD CHEM, V49, P3216, DOI 10.1021/jf001497z; Marsh KB, 2009, FUNCT PLANT BIOL, V36, P463, DOI 10.1071/FP08240; Medan D, 2004, FA GE VAS P, V6, P320; Mondini L., 2009, Diversity, V1, P19; Moore J, 2006, J AGR FOOD CHEM, V54, P5313, DOI 10.1021/jf060381l; Naili MB, 2010, ARAB J CHEM, V3, P79, DOI 10.1016/j.arabjc.2010.02.002; Nasri-Ayachi MB, 2009, ACTA HORTIC, V840, P337, DOI 10.17660/ActaHortic.2009.840.46; Norouzi E, 2017, SCI HORTIC-AMSTERDAM, V222, P180, DOI 10.1016/j.scienta.2017.05.016; Orwa C., 2009, AGROFORESTRY TREE DA; Oueslati S, 2012, FOOD CHEM TOXICOL, V50, P2376, DOI 10.1016/j.fct.2012.04.036; Pietra F, 2002, TETRA OR G, V21, P205, DOI [10.1016/S1460-1567(02)80023-X, DOI 10.1016/S1460-1567(02)80023-X]; POMILIO AB, 1992, J ETHNOPHARMACOL, V36, P155, DOI 10.1016/0378-8741(92)90016-K; Pradhan KJ, 1999, FOOD SCI TECHNOL-LEB, V32, P121, DOI 10.1006/fstl.1998.0508; Razi MFUD, 2013, PAK J AGR SCI, V50, P211; Richardson JE, 2000, AM J BOT, V87, P1309, DOI 10.2307/2656724; Saran P. L., 2006, Journal of Food Agriculture & Environment, V4, P172; Sarikurkcu C, 2019, IND CROP PROD, V140, DOI 10.1016/j.indcrop.2019.111666; Seo EJ, 2013, PHYTOTHER RES, V27, P829, DOI 10.1002/ptr.4809; Serce S., 2016, CHIN DATES TRADIT FU, V14, P199; Shi QQ, 2018, MOLECULES, V23, DOI 10.3390/molecules23081917; Shukla AK, 2004, FRUIT BREEDING APPRO, P217; Simpson MG., 2006, ANT SYSTEM; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Stewart AJ, 2000, J AGR FOOD CHEM, V48, P2663, DOI 10.1021/jf000070p; Tahergorabi Zoya, 2015, Pharmacogn Rev, V9, P99, DOI 10.4103/0973-7847.162108; Taraneh Esteki, 2012, Journal of Pharmacy Research, V5, P2705; Tlili N, 2018, J FUNCT FOODS, V48, P234, DOI 10.1016/j.jff.2018.06.028; Tlili N, 2015, IND CROP PROD, V76, P930, DOI 10.1016/j.indcrop.2015.07.040; Tlili N, 2014, IND CROP PROD, V59, P197, DOI 10.1016/j.indcrop.2014.05.020; Tlili N, 2014, FOOD CHEM, V160, P98, DOI 10.1016/j.foodchem.2014.03.030; Tlili N, 2010, PLANT FOOD HUM NUTR, V65, P260, DOI 10.1007/s11130-010-0180-6; Vermerris W, 2006, PHENOLIC COMPOUND BI; Wang BN, 2011, J AGR FOOD CHEM, V59, P1288, DOI 10.1021/jf103982q; Wink M, 2010, ANN PLANT REV, V40; Wink M, 1992, INSECT PLANT INTERAC, P133; Wink M, 2008, NAT PROD COMMUN, V3, P1205; Wu Y, 2015, CHEM NAT COMPD+, V51, P247, DOI 10.1007/s10600-015-1254-3; Wu Y, 2013, CHEM NAT COMPD+, V49, P677, DOI 10.1007/s10600-013-0705-y; Xie JB, 2012, NAT PROD RES, V26, P479, DOI 10.1080/14786419.2010.516433; Zhang YQ, 2014, PHARMACOGN MAG, V10, P509, DOI 10.4103/0973-1296.141777; Zhao J, 2006, J CHROMATOGR A, V1108, P188, DOI 10.1016/j.chroma.2005.12.104; Zhao ZH, 2008, EUR FOOD RES TECHNOL, V226, P985, DOI 10.1007/s00217-007-0620-1	80	25	25	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2020	15	5							e0232599	10.1371/journal.pone.0232599	http://dx.doi.org/10.1371/journal.pone.0232599			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1DW	32428000	Green Published, gold			2023-01-03	WOS:000537503400008
J	Kim, DK; Shin, SD; Ro, YS; Song, KJ; Hong, KJ; Kong, SYJ				Kim, Dae Kon; Shin, Sang Do; Ro, Young Sun; Song, Kyoung Jun; Hong, Ki Jeong; Kong, So Yeon Joyce			Place-provider-matrix of bystander cardiopulmonary resuscitation and outcomes of out-of-hospital cardiac arrest: A nationwide observational cross-sectional analysis	PLOS ONE			English	Article							SURVIVAL; PROGRAM; EDUCATION; LOCATION; TIME	Aims This study aims to test the association between the place-provider-matrix (PPM) of bystander cardiopulmonary resuscitation (CPR) and outcomes of out-of-hospital cardiac arrest (OHCA). Methods Adult patients with OHCA with a cardiac etiology from 2012 to 2017 in Korea were analyzed, excluding patients who had unknown information on place, type of bystander, or outcome. The PPM was categorized into six groups by two types of places (public versus home) and three types of providers (trained responder (TR), family bystander, and layperson bystander). Outcomes were survival to discharge and good cerebral performance category (CPC) of 1 or 2. Multivariable logistic regression analysis was performed to test the association between PPM group and outcomes with adjustment for potential confounders to calculate adjusted odds ratios (AORs) and 95% confidence intervals (CIs) (reference = Public-TR). Results A total of 73,057 patients were analyzed and were categorized into Public-TR (0.6%), Home-TR (0.3%), Public-Family (1.8%), Home-Family (79.8%), Public-Layperson (9.9%), and Home-Layperson (7.6%) groups. Compared with the Public-TR group, the AORs (95% CIs) for survival to discharge were 0.61 (0.35-1.05) in the Home-TR group, 0.85 (0.62-1.17) in the Public-Family group, 0.38 (0.29-0.50) in the Home-Family group, 1.12 (0.85-1.49) in the Public-Layperson group, and 0.42 (0.31-0.57) in the Home-Layperson group. The AORs (95% CIs) for good CPC were 0.58 (0.27-1.25) in the Home-TR group, 0.88 (0.61-1.27) in the Public-Family group, 0.38 (0.28-0.52) in the Home-Family group, 1.20 (0.87-1.65) in the Public-Layperson group, and 0.42 (0.30-0.59) in the Home-Layperson group. Conclusion The OHCA outcomes of the Home-Family and Home-Layperson groups were worse than those of the Public-TR group. This finding suggests that OHCA occurring in private places with family or layperson bystanders requires a new strategy, such as dispatching trained responders to the scene to improve CPR outcomes.	[Kim, Dae Kon] Seoul Natl Univ, Bundang Hosp, Dept Emergency Med, Seoul, South Korea; [Shin, Sang Do] Seoul Natl Univ, Coll Med, Dept Emergency Med, Seoul, South Korea; [Ro, Young Sun; Kong, So Yeon Joyce] Seoul Natl Univ, Coll Med, Lab Emergency Med Serv, Seoul, South Korea; [Song, Kyoung Jun; Hong, Ki Jeong] Seoul Natl Univ, Boramae Med Ctr, Dept Emergency Med, Seoul, South Korea; [Song, Kyoung Jun] Seoul Natl Univ Hosp, Biomed Res Inst, Lab Emergency Med Serv, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital	Shin, SD (corresponding author), Seoul Natl Univ, Coll Med, Dept Emergency Med, Seoul, South Korea.	shinsangdo@gmail.com		KIM, DAE KON/0000-0002-3101-2413; Song, Kyoung Jun/0000-0002-0027-6352	National Emergency Management Agency of Korea; Korea CDC [2012-E33010-00, 2013-E33015-00, 2014-E33011-00, 2016-E33012-00]; Korea Centers for Disease Control and Prevention (CDC)	National Emergency Management Agency of Korea; Korea CDC; Korea Centers for Disease Control and Prevention (CDC)	This study was supported by the National Emergency Management Agency of Korea and the Korea Centers for Disease Control and Prevention (CDC). The study was funded by the Korea CDC (2012-2016) (Grant No: 2012-E33010-00; 2013-E33015-00; 2014-E33011-00, 2016-E33012-00, and 2017-Private Support Grant).	Bagai A, 2013, CIRCULATION, V128, P2595, DOI 10.1161/CIRCULATIONAHA.113.004164; Blewer AL, 2011, J HOSP MED, V6, P428, DOI 10.1002/jhm.847; Bradley SM, 2011, RESUSCITATION, V82, P680, DOI 10.1016/j.resuscitation.2011.02.006; Cartledge S, 2018, EUR J CARDIOVASC NUR, V17, P148, DOI 10.1177/1474515117721010; Daya MR, 2015, RESUSCITATION, V91, P108, DOI 10.1016/j.resuscitation.2015.02.003; Descatha A, 2015, RESUSCITATION, V96, P30, DOI 10.1016/j.resuscitation.2015.07.004; Fake AL, 2013, NEW ZEAL MED J, V126, P28; Fosbol EL, 2014, RESUSCITATION, V85, P1512, DOI 10.1016/j.resuscitation.2014.08.013; Grasner JT, 2016, RESUSCITATION, V105, P188, DOI 10.1016/j.resuscitation.2016.06.004; Gratton M, 1999, Prehosp Emerg Care, V3, P303, DOI 10.1080/10903129908958958; Hasselqvist-Ax I, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005873; Iwami T, 2006, RESUSCITATION, V69, P221, DOI 10.1016/j.resuscitation.2005.08.018; Jallow T, 2018, SCAND CARDIOVASC J, V52, P149, DOI 10.1080/14017431.2018.1453080; Kim TH, 2018, SIMUL HEALTHC, V13, P27, DOI 10.1097/SIH.0000000000000286; Kim YT, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016925; Kiyohara K, 2019, AM J CARDIOL, V123, P1060, DOI 10.1016/j.amjcard.2018.12.038; Lee MJ, 2016, CLIN EXP EMERG MED, V3, pS17, DOI 10.15441/ceem.16.134; Murakami Y, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000533; Nakanishi N, 2011, AM J EMERG MED, V29, P1037, DOI 10.1016/j.ajem.2010.06.018; Park YM, 2017, RESUSCITATION, V118, P55, DOI 10.1016/j.resuscitation.2017.06.024; Ro YS, 2017, ANN EMERG MED, V69, P52, DOI 10.1016/j.annemergmed.2016.07.028; Ro YS, 2016, RESUSCITATION, V102, P17, DOI 10.1016/j.resuscitation.2016.02.004; Ro YS, 2015, RESUSCITATION, V90, P35, DOI 10.1016/j.resuscitation.2015.02.006; Ro YS, 2013, RESUSCITATION, V84, P547, DOI 10.1016/j.resuscitation.2012.12.020; Schriefl C, 2019, RESUSCITATION, V142, P61, DOI 10.1016/j.resuscitation.2019.07.009; Shinozaki K, 2016, ACUTE MED SURG, V3, P61, DOI 10.1002/ams2.192; Smith CM, 2017, RESUSCITATION, V121, P123, DOI 10.1016/j.resuscitation.2017.10.020; Smith Richard M, 2013, EMS World, V42, P45; Stein P, 2017, RESUSCITATION, V118, P27, DOI 10.1016/j.resuscitation.2017.06.017; Waalewijn RA, 2001, RESUSCITATION, V50, P273, DOI 10.1016/S0300-9572(01)00354-9	30	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2020	15	5							e0232999	10.1371/journal.pone.0232999	http://dx.doi.org/10.1371/journal.pone.0232999			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1BA	32413089	Green Published, gold			2023-01-03	WOS:000537496000034
J	Sjollin, I; Back, M; Nilsson, L; Schiopu, A; Leosdottir, M				Sjollin, Ingela; Back, Maria; Nilsson, Lennart; Schiopu, Alexandru; Leosdottir, Margret			Association between attending exercise-based cardiac rehabilitation and cardiovascular risk factors at one-year post myocardial infarction	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; METAANALYSIS; SEX; PREVENTION; ENROLLMENT; PROGRAMS; EFFICACY; THERAPY; WOMEN; MEN	Background Randomized trials confirm the benefits of exercise-based cardiac rehabilitation on cardiovascular risk factors. Whether exercise-based cardiac rehabilitation provides the same favourable effects in real-life cardiac rehabilitation settings, in the modern era of myocardial infarction treatment, is less well known. We examined the association between attending exercise-based cardiac rehabilitation and improvements in cardiovascular risk factors at one-year post myocardial infarction in patients included in the Swedish heart disease registry, SWEDEHEART. Methods In this retrospective registry-based cohort study, we included 19 136 patients post myocardial infarction (75% men, 62.8 +/- 8.7 years) who were registered in SWEDEHEART between 2011 and 2013. The association between attending exercise-based cardiac rehabilitation (43% participation rate) and changes in cardiovascular risk profile between baseline and one-year follow-up was assessed using multivariable regression analysis adjusting for age, comorbidities and medication. Results Attenders more often reported to have stopped smoking (men 64% vs 50%; women 64% vs 53%, p< 0.001 for both, only smokers at baseline considered), be more physically active (men 3.9 +/- 2.5 vs 3.4 +/- 2.7 days/week; women 3.8 +/- 2.6 vs 3.0 +/- 2.8 days/week, p< 0.001 for both) and achieved a slightly larger reduction in triglycerides (men -0.2 +/- 0.8 vs -0.1 +/- 0.9 mmol/L, p = 0.001; women -0.1 +/- 0.6 vs 0.0 +/- 0.8 mmol/L, p = 0.01) at one-year compared to non-attenders. Male attenders gained less weight (+0.0 +/- 5.7 vs +0.3 +/- 5.7 kg, p = 0.01) while female attenders achieved better lipid control (total cholesterol -1.2 +/- 1.4 vs -0.9 +/- 1.4 mmol/L, p< 0.001; low-density lipoprotein -1.2 +/- 1.2 vs -0.9 +/- 1.2 mmol/L, p< 0.001) compared to nonattenders. Conclusions In an unselected registry cohort of patients post myocardial infarction, compared to nonattenders those attending exercise-based cardiac rehabilitation achieved significantly larger improvements in cardiovascular risk factors at one-year after the acute event.	[Sjollin, Ingela; Schiopu, Alexandru; Leosdottir, Margret] Lund Univ, Fac Med, Dept Clin Sci Malmo, Malmo, Sweden; [Sjollin, Ingela; Schiopu, Alexandru; Leosdottir, Margret] Skane Univ Hosp, Dept Cardiol, Malmo, Sweden; [Back, Maria] Linkoping Univ, Div Physiotherapy, Dept Med & Hlth Sci, Linkoping, Sweden; [Back, Maria] Sahlgrens Univ Hosp, Dept Occupat Therapy & Physiotherapy, Gothenburg, Sweden; [Nilsson, Lennart] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden	Lund University; Lund University; Skane University Hospital; Linkoping University; Sahlgrenska University Hospital; Linkoping University	Leosdottir, M (corresponding author), Lund Univ, Fac Med, Dept Clin Sci Malmo, Malmo, Sweden.; Leosdottir, M (corresponding author), Skane Univ Hosp, Dept Cardiol, Malmo, Sweden.	margret.leosdottir@med.lu.se	Schiopu, Alexandru/AAY-7229-2021	Leosdottir, Margret/0000-0003-1677-1566; Back, Maria/0000-0002-6031-7478; Schiopu, Alexandru/0000-0002-7587-5050				Anderson L, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001800.pub3, 10.1016/j.jacc.2015.10.044]; Back M, 2017, BMC CARDIOVASC DISOR, V17, DOI 10.1186/s12872-017-0512-7; Back M, 2008, EUR J CARDIOVASC NUR, V7, P307, DOI 10.1016/j.ejcnurse.2008.02.001; Balady GJ, 2011, CIRCULATION, V124, P2951, DOI 10.1161/CIR.0b013e31823b21e2; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; Borg S, 2019, BMC SPORTS SCI MED R, V11, DOI 10.1186/s13102-019-0125-9; Canto JG, 2012, JAMA-J AM MED ASSOC, V307, P813, DOI 10.1001/jama.2012.199; Caru M, 2018, WORLD J CARDIOL, V10, P26, DOI 10.4330/wjc.v10.i4.26; Colella TJF, 2015, EUR J PREV CARDIOL, V22, P423, DOI 10.1177/2047487314520783; Cooper AF, 2007, HEART, V93, P53, DOI 10.1136/hrt.2005.081299; Critchley JA, 2003, JAMA-J AM MED ASSOC, V290, P86, DOI 10.1001/jama.290.1.86; Dowd KP, 2018, INT J BEHAV NUTR PHY, V15, DOI 10.1186/s12966-017-0636-2; Ekblom O, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.010108; FRIEDEWA WT, 1972, CLIN CHEM, V18, P499, DOI [10.1093/clinchem/18.6.499, DOI 10.1093/clinchem/18.6.499]; Fulcher J, 2015, LANCET, V385, P1397, DOI 10.1016/S0140-6736(14)61368-4; Gerber Y, 2011, EUR J EPIDEMIOL, V26, P109, DOI 10.1007/s10654-010-9523-8; Giallauria Francesco, 2005, Monaldi Arch Chest Dis, V64, P110; Gibbons Larry W., 2001, Cardiology Clinics, V19, P347, DOI 10.1016/S0733-8651(05)70221-6; Goldfarb AH, 1997, SPORTS MED, V24, P8, DOI 10.2165/00007256-199724010-00002; Gorczyca AM, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005354; Harrison AS, 2018, EUR J PREV CARDIOL, V25, P1925, DOI 10.1177/2047487318798923; Jernberg T, 2012, SWEDEHEART ANN REPOR; Jernberg T, 2014, SWEDEHEART ANN REPOR; Jernberg T, 2010, HEART, V96, P1617, DOI 10.1136/hrt.2010.198804; Kavanagh T, 2002, CIRCULATION, V106, P666, DOI 10.1161/01.CIR.0000024413.15949.ED; Kotseva K, 2018, EUR J PREV CARDIOL, V25, P1242, DOI 10.1177/2047487318781359; Lawler PR, 2011, AM HEART J, V162, P571, DOI 10.1016/j.ahj.2011.07.017; Lemes IR, 2018, J AM SOC HYPERTENS, V12, P580, DOI 10.1016/j.jash.2018.06.007; Mandsager K, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3605; McKee G, 2014, EUR J CARDIOVASC NUR, V13, P329, DOI 10.1177/1474515113496686; Mikkelsen Tatsiana, 2014, Dan Med J, V61, pA4919; Neubeck L, 2012, EUR J PREV CARDIOL, V19, P494, DOI 10.1177/1741826711409326; Ostman C, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933-017-0590-y; Pan B, 2018, INT J BEHAV NUTR PHY, V15, DOI 10.1186/s12966-018-0703-3; Pattyn N, 2013, SPORTS MED, V43, P121, DOI 10.1007/s40279-012-0003-z; Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI 10.1093/eurheartj/ehw106; Piepoli MF, 2014, EUR J PREV CARDIOL, V21, P664, DOI 10.1177/2047487312449597; Prince SA, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-56; Rauch B, 2016, EUR J PREV CARDIOL, V23, P1914, DOI 10.1177/2047487316671181; Resurreccion DM, 2017, J WOMENS HEALTH, V26, P849, DOI 10.1089/jwh.2016.6249; Samayoa L, 2014, CAN J CARDIOL, V30, P793, DOI 10.1016/j.cjca.2013.11.007; Sandercock GRH, 2007, J SPORT SCI MED, V6, P471; Sumner J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177658; Taylor RS, 2006, EUR J CARDIOV PREV R, V13, P369, DOI 10.1097/00149831-200606000-00012; Taylor RS, 2004, AM J MED, V116, P682, DOI 10.1016/j.amjmed.2004.01.009; Wallert J, 2020, EUR J PREV CARDIOL, V27, P145, DOI 10.1177/2047487319871714; Well RP, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019656; Whelton SP, 2002, ANN INTERN MED, V136, P493, DOI 10.7326/0003-4819-136-7-200204020-00006; Witvrouwen I, 2021, EUR J PREV CARDIOL, V28, P779, DOI 10.1177/2047487319838221; Wyke S, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002736	50	5	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2020	15	5							e0232772	10.1371/journal.pone.0232772	http://dx.doi.org/10.1371/journal.pone.0232772			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU0RD	32392231	Green Published, gold			2023-01-03	WOS:000537470300024
J	Radbruch, L; Knaul, FM; de Lima, L; de Joncheere, C; Bhadelia, A				Radbruch, Lukas; Marie Knaul, Felicia; de Lima, Liliana; de Joncheere, Cornelis; Bhadelia, Afsan			The key role of palliative care in response to the COVID-19 tsunami of suffering	LANCET			English	Editorial Material									[Radbruch, Lukas] Univ Hosp Bonn, Dept Palliat Med, Bonn, Germany; [Marie Knaul, Felicia; Bhadelia, Afsan] Univ Miami, Inst Adv Study Amer, Miami, FL 33146 USA; [Marie Knaul, Felicia] Univ Miami, Leonard M Miller Sch Med, Coral Gables, FL 33124 USA; [Marie Knaul, Felicia] Fdn Mexicana Salud AC, Mexico City, DF, Mexico; [Marie Knaul, Felicia] Tomatelo Pecho AC, Mexico City, DF, Mexico; [de Lima, Liliana] Int Assoc Hosp & Palliat Care, Houston, TX USA; [de Joncheere, Cornelis] Int Narcot Control Board, Vienna, Austria; [Bhadelia, Afsan] Harvard TH Chan Sch Publ Hlth, Boston, MA USA	University of Bonn; University of Miami; University of Miami; Harvard University; Harvard T.H. Chan School of Public Health	Knaul, FM (corresponding author), Univ Miami, Inst Adv Study Amer, Miami, FL 33146 USA.; Knaul, FM (corresponding author), Univ Miami, Leonard M Miller Sch Med, Coral Gables, FL 33124 USA.; Knaul, FM (corresponding author), Fdn Mexicana Salud AC, Mexico City, DF, Mexico.; Knaul, FM (corresponding author), Tomatelo Pecho AC, Mexico City, DF, Mexico.	fknaul@miami.edu		Knaul, Felicia/0000-0002-0512-4788	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 2020, LANCET, V395, P1168, DOI 10.1016/S0140-6736(20)30822-9; Arya A, 2020, CAN MED ASSOC J, V192, pE400, DOI 10.1503/cmaj.200465; Bajwah S, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00815-2020; Berterame S, 2016, LANCET, V387, P1644, DOI 10.1016/S0140-6736(16)00161-6; Center to Advance Palliative Care, SYMPT MAN COURS; Costantini M, 2020, RESPONSE ROLE PALLIA, DOI [10.1101/2020.03.18.20038448, DOI 10.1101/2020.03.18.20038448]; De Lima L, 2018, J PALLIAT MED, V21, P1458, DOI 10.1089/jpm.2018.0149; Downar J, 2010, J PAIN SYMPTOM MANAG, V39, P291, DOI 10.1016/j.jpainsymman.2009.11.241; Horton R, 2020, LANCET, V395, P1100, DOI 10.1016/S0140-6736(20)30787-X; Indian Association of Pallative Care, PALLIKARE MOB APP PA; International Association for Hospice and Palliative Care, 2020, PALL CAR COVID 19; Knaul FM, 2018, LANCET, V391, P1391, DOI 10.1016/S0140-6736(17)32513-8; Nehls W, 2020, RECOMMENDATIONS TREA; Powell VD, 2020, J PAIN SYMPTOM MANAG, V60, pE1, DOI 10.1016/j.jpainsymman.2020.03.013; Rosenbaum L, 2020, NEW ENGL J MED, V382, P1873, DOI 10.1056/NEJMp2005492; Swiss Soc Intens Care Med, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20227; University of Toronto Joint Center for Bioethics, 2005, STAND GUARD THEE ETH; Wakam GK, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2007781; Wallace CL, 2020, J PAIN SYMPTOM MANAG, V60, pE70, DOI 10.1016/j.jpainsymman.2020.04.012; Weaver MS, 2020, J PAIN SYMPTOM MANAG, V60, pE8, DOI 10.1016/j.jpainsymman.2020.03.020; World Health Organization, 2018, INT PALL CAR SYMPT R; World Hospice and Palliative Care Association, 2020, TIM TALK VIRT HUB PE	22	124	129	5	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	2020	395	10235					1467	1469		10.1016/S0140-6736(20)30964-8	http://dx.doi.org/10.1016/S0140-6736(20)30964-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LO3QU	32333842	Green Published, Bronze			2023-01-03	WOS:000533544900005
J	Chiou, YA; Cheng, LK; Lin, SF				Chiou, Yu-An; Cheng, Li-Kuan; Lin, Shien-Fong			Effects of high-frequency biphasic shocks on ventricular vulnerability and defibrillation outcomes through synchronized virtual electrode responses	PLOS ONE			English	Article							TRIPHASIC WAVE-FORMS; TRANSTHORACIC DEFIBRILLATION; CARDIAC TISSUE; UPPER LIMIT; INTRACELLULAR CALCIUM; ALTERNATING-CURRENT; FIBRILLATION; STIMULATION; THRESHOLD; MODEL	Electrical defibrillation is a well-established treatment for cardiac dysrhythmias. Studies have suggested that shock-induced spatial sawtooth patterns and virtual electrodes are responsible for defibrillation efficacy. We hypothesize that high-frequency shocks enhance defibrillation efficacy by generating temporal sawtooth patterns and using rapid virtual electrodes synchronized with shock frequency. High-speed optical mapping was performed on isolated rat hearts at 2000 frames/s. Two defibrillation electrodes were placed on opposite sides of the ventricles. An S1-S2 pacing protocol was used to induce ventricular tachyarrhythmia (VTA). High-frequency shocks of equal energy but varying frequencies of 1251000 Hz were used to evaluate VTA vulnerability and defibrillation success rate. The 1000Hz shock had the highest VTA induction rate in the shorter S1-S2 intervals (50 and 100 ms) and the highest VTA defibrillation rate (70%) among all frequencies. Temporal sawtooth patterns and synchronous shock-induced virtual electrode responses could be observed with frequencies of up to 1000 Hz. The improved defibrillation outcome with high-frequency shocks suggests a lower energy requirement than that of low-frequency shocks for successful ventricular defibrillation.	[Chiou, Yu-An; Lin, Shien-Fong] Natl Chiao Tung Univ, Coll Elect & Comp Engn, Dept Elect & Comp Engn, Hsinchu, Taiwan; [Cheng, Li-Kuan; Lin, Shien-Fong] Natl Chiao Tung Univ, Coll Elect & Comp Engn, Inst Biomed Engn, Hsinchu, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Lin, SF (corresponding author), Natl Chiao Tung Univ, Coll Elect & Comp Engn, Dept Elect & Comp Engn, Hsinchu, Taiwan.; Lin, SF (corresponding author), Natl Chiao Tung Univ, Coll Elect & Comp Engn, Inst Biomed Engn, Hsinchu, Taiwan.	linsf5402@nctu.edu.tw			Ministry of Science and Technology, Taipei, Taiwan [103-2221-E-009 -036]	Ministry of Science and Technology, Taipei, Taiwan	This study was supported by Ministry of Science and Technology (103-2221-E-009 -036), Taipei, Taiwan, to SFL. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akar FG, 2001, AM J PHYSIOL-HEART C, V281, pH533, DOI 10.1152/ajpheart.2001.281.2.H533; Anderson C, 2000, J CARDIOVASC ELECTR, V11, P1386, DOI 10.1046/j.1540-8167.2000.01386.x; Boukens BJ, 2015, ADV EXP MED BIOL, V859, P343, DOI 10.1007/978-3-319-17641-3_14; Bray MA, 2000, IEEE T BIO-MED ENG, V47, P1382, DOI 10.1109/10.871412; CHEN PS, 1991, J AM COLL CARDIOL, V18, P1555, DOI 10.1016/0735-1097(91)90690-B; CHEN PS, 1988, CIRC RES, V62, P1191, DOI 10.1161/01.RES.62.6.1191; CHEN PS, 1986, CIRCULATION, V73, P1022, DOI 10.1161/01.CIR.73.5.1022; Dor-Haim H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066658; Dosdall DJ, 2010, ANNU REV BIOMED ENG, V12, P233, DOI [10.1146/annurev-bioeng-070909-105305, 10.1146/armurev-bioeng-070909-105305]; Dosdall DJ, 2008, BIOMED ENG ONLINE, V7, DOI 10.1186/1475-925X-7-22; Dura B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036217; Efimov IR, 2000, J CARDIOVASC ELECTR, V11, P339, DOI 10.1111/j.1540-8167.2000.tb01805.x; Fedorov VV, 2007, HEART RHYTHM, V4, P619, DOI 10.1016/j.hrthm.2006.12.047; FURMAN S, 1975, J SURG RES, V19, P149, DOI 10.1016/0022-4804(75)90074-8; GLINER BE, 1995, CIRCULATION, V92, P1634, DOI 10.1161/01.CIR.92.6.1634; Gotoh M, 1997, CIRCULATION, V95, P2141, DOI 10.1161/01.CIR.95.8.2141; Hayashi H, 2008, AM J PHYSIOL-HEART C, V295, pH1422, DOI 10.1152/ajpheart.00001.2008; HOLLEY LK, 1991, CARDIOVASC RES, V25, P979, DOI 10.1093/cvr/25.12.979; Hwang GS, 2008, J AM COLL CARDIOL, V52, P828, DOI 10.1016/j.jacc.2008.05.040; Hwang GS, 2006, CIRCULATION, V114, P2595, DOI 10.1161/CIRCULATIONAHA.106.630509; Jones JL, 1995, J ELECTROCARDIOL, V28, P25, DOI 10.1016/S0022-0736(95)80005-0; Keener JP, 1996, J THEOR BIOL, V178, P313, DOI 10.1006/jtbi.1996.0027; Kong CY, 2011, CANCER EPIDEM BIOMAR, V20, P2450, DOI 10.1158/1055-9965.EPI-11-0547; KRASSOWSKA W, 1987, IEEE T BIO-MED ENG, V34, P555, DOI 10.1109/TBME.1987.325986; Krinsky V, 1998, CHAOS, V8, P188, DOI 10.1063/1.166297; KROLL MW, 1994, PACE, V17, P1782, DOI 10.1111/j.1540-8159.1994.tb03746.x; Li YQ, 2010, RESUSCITATION, V81, P724, DOI 10.1016/j.resuscitation.2010.02.022; METZGER P, 1985, J PHYSIOL-LONDON, V366, P177, DOI 10.1113/jphysiol.1985.sp015791; Newton JC, 1999, J CARDIOVASC ELECTR, V10, P234, DOI 10.1111/j.1540-8167.1999.tb00666.x; Nikolski VP, 2002, AM J PHYSIOL-HEART C, V282, pH565, DOI 10.1152/ajpheart.00544.2001; PLONSEY R, 1986, MED BIOL ENG COMPUT, V24, P137, DOI 10.1007/BF02443926; Roberts SJ, 2003, PACE, V26, P599, DOI 10.1046/j.1460-9592.2003.00100.x; Sambelashvili AT, 2004, AM J PHYSIOL-HEART C, V286, pH2183, DOI 10.1152/ajpheart.00637.2003; SEPULVEDA NG, 1989, BIOPHYS J, V55, P987, DOI 10.1016/S0006-3495(89)82897-8; SEPULVEDA NG, 1994, J CARDIOVASC ELECTR, V5, P258, DOI 10.1111/j.1540-8167.1994.tb01162.x; Sung YL, 2018, COMPUT BIOL MED, V102, P390, DOI 10.1016/j.compbiomed.2018.08.016; Sweeney RJ, 1996, J CARDIOVASC ELECTR, V7, P134, DOI 10.1111/j.1540-8167.1996.tb00508.x; Swerdlow CD, 2007, PACE, V30, P258, DOI 10.1111/j.1540-8159.2007.00659.x; Swift LM, 2012, PFLUG ARCH EUR J PHY, V464, P503, DOI 10.1007/s00424-012-1147-2; Tandri H, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002445; Tang C, 2016, RESUSCITATION, V102, P57, DOI 10.1016/j.resuscitation.2016.02.018; Tang WC, 2001, CHEST, V120, P948, DOI 10.1378/chest.120.3.948; Trayanova Natalia, 2011, IEEE Rev Biomed Eng, V4, P89, DOI 10.1109/RBME.2011.2173761; Varghese F, 2017, CARDIOVASC RES, V113, P1789, DOI 10.1093/cvr/cvx172; Viana MA, 2014, J THORAC CARDIOV SUR, V148, P3213, DOI 10.1016/j.jtcvs.2014.07.035; Weinberg SH, 2013, HEART RHYTHM, V10, P740, DOI 10.1016/j.hrthm.2013.01.016; WEIRICH J, 1983, BASIC RES CARDIOL, V78, P604, DOI 10.1007/BF01907207; Weiss JN, 2005, CIRCULATION, V112, P1232, DOI 10.1161/CIRCULATIONAHA.104.529545; Wikswo JP, 1995, BIOPHYS J, V69, P2195, DOI 10.1016/S0006-3495(95)80115-3; Zhang Y, 2006, RESUSCITATION, V68, P251, DOI 10.1016/j.resuscitation.2005.05.025; Zhang Y, 2003, J AM COLL CARDIOL, V42, P568, DOI 10.1016/S0735-1097(03)00656-9	51	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2020	15	5							e0232529	10.1371/journal.pone.0232529	http://dx.doi.org/10.1371/journal.pone.0232529			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT3FY	32357163	gold, Green Published			2023-01-03	WOS:000536957700037
J	Angelucci, E; Li, JM; Greenberg, P; Wu, DP; Hou, M; Figueroa, EHM; Rodriguez, MG; Dong, XW; Ghosh, J; Izquierdo, M; Garcia-Manero, G				Angelucci, Emanuele; Li, Junmin; Greenberg, Peter; Wu, Depei; Hou, Ming; Montano Figueroa, Efreen Horacio; Guadalupe Rodriguez, Maria; Dong, Xunwei; Ghosh, Jagannath; Izquierdo, Miguel; Garcia-Manero, Guillermo		TELESTO Study	Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							PROGNOSTIC-FACTORS; SCORING SYSTEM; MDS PATIENTS; RISK MDS; THERAPY; OVERLOAD; SURVIVAL; DEFERASIROX; CRITERIA; ANEMIA	Background: Iron chelation therapy (ICT) in patients with lower-risk myelodysplastic syndromes (MDS) has not been evaluated in randomized studies. Objective: To evaluate event-free survival (EFS) and safety of ICT in iron-overloaded patients with low- or intermediate-1-risk MDS. Design: Multicenter, randomized, double-blind, placebo-controlled trial (TELESTO). (ClinicalTrials.gov: NCT00940602) Setting: 60 centers in 16 countries. Participants: 225 patients with serum ferritin levels greater than 2247 pmol/L; prior receipt of 15 to 75 packed red blood cell units; and no severe cardiac, liver, or renal abnormalities. Intervention: Deferasirox dispersible tablets (10 to 40 mg/kg per day) (n = 149) or matching placebo (n = 76). Measurements: The primary end point was EFS, defined as time from date of randomization to first documented nonfatal event (related to cardiac or liver dysfunction and transformation to acute myeloid leukemia) or death, whichever occurred first. Results: Median time on treatment was 1.6 years (interquartile range [IQR], 0.5 to 3.1 years) in the deferasirox group and 1.0 year (IQR, 0.6 to 2.0 years) in the placebo group. Median EFS was prolonged by approximately 1 year with deferasirox versus placebo (3.9 years [95% CI, 3.2 to 4.3 years] vs. 3.0 years [CI, 2.2 to 3.7 years], respectively; hazard ratio, 0.64 [CI, 0.42 to 0.96]). Adverse events occurred in 97.3% of deferasirox recipients and 90.8% of placebo recipients. Exposure-adjusted incidence rates of adverse events (>= 15 events per 100 patient treatment-years) in deferasirox versus placebo recipients, respectively, were 24.7 versus 23.9 for diarrhea, 21.8 versus 18.7 for pyrexia, 16.7 versus 22.7 for upper respiratory tract infection, and 15.9 versus 0.9 for increased serum creatinine concentration. Limitations: The protocol was amended from a phase 3 to a phase 2 study, with a reduced target sample size from 630 to 210 participants. There was differential follow-up between treatment groups. Conclusion: The findings support ICT in iron-overloaded patients with low- to intermediate-1-risk MDS, with longer EFS compared with placebo and a clinically manageable safety profile. Therefore, ICT may be considered in these patients. Primary Funding Source: Novartis Pharma AG.	[Angelucci, Emanuele] IRCCS Osped Policlin San Martino, Hematol & Transplant Ctr, Largo Rosanna Benzi 10, I-16132 Genoa, Italy; [Li, Junmin] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China; [Greenberg, Peter] Stanford Univ, Med Ctr, 875 Blake Wilbur Dr,Room 2335, Stanford, CA 94305 USA; [Wu, Depei] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Shizi St 188, Suzhou 215006, Peoples R China; [Hou, Ming] Shandong Univ, Qilu Hosp, Dept Hematol, 107 Wenhua West Rd, Jinan, Peoples R China; [Montano Figueroa, Efreen Horacio] Hosp Gen Mexico City, Dept Hematol, Dr Balmis 148, Mexico City 06720, DF, Mexico; [Guadalupe Rodriguez, Maria] Hosp Especialidades Ctr Med La Raza, Dept Hematol, Ctr Med Nacl Raza, IMSS, Seris & Zaachila S-N, Mexico City 02990, DF, Mexico; [Dong, Xunwei; Ghosh, Jagannath] Novartis Pharmaceut, One Hlth Plaza, E Hanover, NJ 07936 USA; [Izquierdo, Miguel] Novartis Pharma AG, Novartis Campus, CH-4056 Basel, Switzerland; [Garcia-Manero, Guillermo] Univ Texas Houston, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Garcia-Manero, Guillermo] Univ Texas Houston, MD Anderson Canc Ctr, Div Canc Med, Dept Leukemia,Sect Myelodysplast Syndromes, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA	Shanghai Jiao Tong University; Stanford University; Soochow University - China; Shandong University; Hospital General de Mexico; Instituto Mexicano del Seguro Social; Novartis; Novartis; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Angelucci, E (corresponding author), IRCCS Osped Policlin San Martino, Hematol & Transplant Ctr, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.	emanuele.angelucci@hsanmartino.it	Angelucci, Emanuele/AAC-1855-2021; Symeonidis, Argiris/K-2287-2019	Symeonidis, Argiris/0000-0002-3685-3473; Li, Junmin/0000-0003-1338-8764; KAPSALI, ELENI/0000-0002-5304-7553; Cascavilla, Nicola/0000-0002-8901-2379; Colita, Andrei/0000-0002-6531-7717; SANTINI, VALERIA/0000-0002-5439-2172	Novartis Pharma AG; Novartis Pharmaceuticals Corporation	Novartis Pharma AG; Novartis Pharmaceuticals Corporation(Novartis)	By Novartis Pharma AG. Financial support for medical writing assistance was provided by Novartis Pharmaceuticals Corporation.	Bollig C, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007476.pub3; Castelli R, 2018, MED ONCOL, V35, DOI 10.1007/s12032-018-1135-2; Cheson BD, 2006, BLOOD, V108, P419, DOI 10.1182/blood-2005-10-4149; De Swart L, 2011, BLOOD, V118, P1195; Delforge M, 2014, LEUKEMIA RES, V38, P557, DOI 10.1016/j.leukres.2014.02.003; Gattermann N, 2018, INT J HEMATOL, V107, P55, DOI 10.1007/s12185-017-2367-1; Gattermann N, 2010, LEUKEMIA RES, V34, P1143, DOI 10.1016/j.leukres.2010.03.009; Germing U, 2004, HAEMATOLOGICA, V89, P905; Germing U, 2012, LEUKEMIA, V26, P1286, DOI 10.1038/leu.2011.391; Goldberg SL, 2010, J CLIN ONCOL, V28, P2847, DOI 10.1200/JCO.2009.25.2395; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Greenberg Peter L, 2002, Hematology Am Soc Hematol Educ Program, P136; Imran F, 2017, EXPERT REV HEMATOL, V10, P53, DOI 10.1080/17474086.2017.1268910; Killick SB, 2017, BRIT J HAEMATOL, V177, P375, DOI 10.1111/bjh.14602; Langemeijer S, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.3186.3186; Leitch HA, 2018, LEUKEMIA RES, V74, P21, DOI 10.1016/j.leukres.2018.09.005; Leitch HA, 2017, BRIT J HAEMATOL, V179, P83, DOI 10.1111/bjh.14825; Lyons RM, 2017, LEUKEMIA RES, V56, P88, DOI 10.1016/j.leukres.2017.01.033; Mainous AG, 2014, BRIT J HAEMATOL, V167, P720, DOI 10.1111/bjh.13053; Malcovati L, 2005, J CLIN ONCOL, V23, P7594, DOI 10.1200/JCO.2005.01.7038; Malcovati L, 2011, HAEMATOL-HEMATOL J, V96, P1433, DOI 10.3324/haematol.2011.044602; Meerpohl JJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007461.pub3; Montalban-Bravo G, 2018, AM J HEMATOL, V93, P129, DOI 10.1002/ajh.24930; National Comprehensive Cancer Network, NCCN CLIN PRACT GUID; Neukirchen J, 2012, LEUKEMIA RES, V36, P1067, DOI 10.1016/j.leukres.2012.04.006; Nolte F, 2015, LEUKEMIA RES, V39, P1028, DOI 10.1016/j.leukres.2015.06.008; Novartis Pharmaceuticals, EXJADE DEF US PRESCR; Platzbecker U, 2017, LEUKEMIA, V31, P1944, DOI 10.1038/leu.2017.192; Remacha AF, 2015, ANN HEMATOL, V94, P779, DOI 10.1007/s00277-014-2274-y; Rose C, 2010, LEUKEMIA RES, V34, P864, DOI 10.1016/j.leukres.2009.12.004; SCHAFER AI, 1981, NEW ENGL J MED, V304, P319, DOI 10.1056/NEJM198102053040603; Steensma DP, 2013, BEST PRACT RES CL HA, V26, P431, DOI 10.1016/j.beha.2013.09.009; Taher AT, 2012, BLOOD, V120, P970, DOI 10.1182/blood-2012-02-412692; Tefferi A, 2009, NEW ENGL J MED, V361, P1872, DOI 10.1056/NEJMra0902908; Zeidan AM, 2019, ANN HEMATOL, V98, P339, DOI 10.1007/s00277-018-3539-7; Zeidan AM, 2018, BLOOD REV, V32, P368, DOI 10.1016/j.blre.2018.03.002; Zeidan AM, 2015, J COMP EFFECT RES, V4, P327, DOI [10.2217/CER.15.20, 10.2217/cer.15.20]	37	50	51	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 21	2020	172	8					513	+		10.7326/M19-0916	http://dx.doi.org/10.7326/M19-0916			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF9LH	32203980				2023-01-03	WOS:000527733800012
J	Piel, S; Chamkha, I; Dehlin, AK; Ehinger, JK; Sjovall, F; Elmer, E; Hansson, MJ				Piel, Sarah; Chamkha, Imen; Dehlin, Adam Kozak; Ehinger, Johannes K.; Sjovall, Fredrik; Elmer, Eskil; Hansson, Magnus J.			Cell-permeable succinate prodrugs rescue mitochondrial respiration in cellular models of acute acetaminophen overdose	PLOS ONE			English	Article							INDUCED HEPATOTOXICITY; COMPLEX-I; METABOLISM; PLATELETS; MICE; RESPIROMETRY; MECHANISMS; PROTECTS; SIGNAL	Acetaminophen is one of the most common over-the-counter pain medications used worldwide and is considered safe at therapeutic dose. However, intentional and unintentional overdose accounts for up to 70% of acute liver failure cases in the western world. Extensive research has demonstrated that the induction of oxidative stress and mitochondrial dysfunction are central to the development of acetaminophen-induced liver injury. Despite the insight gained on the mechanism of acetaminophen toxicity, there still is only one clinically approved pharmacological treatment option, N-acetylcysteine. N-acetylcysteine increases the cell's antioxidant defense and protects liver cells from further acetaminophen-induced oxidative damage. Because it primarily protects healthy liver cells rather than rescuing the already injured cells alternative treatment strategies that target the latter cell population are warranted. In this study, we investigated mitochondria as therapeutic target for the development of novel treatment strategies for acetaminophen-induced liver injury. Characterization of the mitochondrial toxicity due to acute acetaminophen overdose in vitro in human cells using detailed respirometric analysis revealed that complex I-linked (NADH-dependent) but not complex II-linked (succinate-dependent) mitochondrial respiration is inhibited by acetaminophen. Treatment with a novel cell-permeable succinate prodrug rescues acetaminophen-induced impaired mitochondrial respiration. This suggests cell-permeable succinate prodrugs as a potential alternative treatment strategy to counteract acetaminophen-induced liver injury.	[Piel, Sarah; Chamkha, Imen; Dehlin, Adam Kozak; Ehinger, Johannes K.; Sjovall, Fredrik; Elmer, Eskil; Hansson, Magnus J.] Lund Univ, Dept Clin Sci Lund, Mitochondrial Med, Lund, Sweden; [Piel, Sarah; Chamkha, Imen; Ehinger, Johannes K.; Elmer, Eskil; Hansson, Magnus J.] NeuroVive Pharmaceut AB, Lund, Sweden; [Piel, Sarah] Childrens Hosp Philadelphia, Ctr Mitochondria & Epigen Med, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Sjovall, Fredrik] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Intens Care & Perioperat Med, Malmo, Sweden; [Elmer, Eskil] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Clin Neurophysiol, Lund, Sweden	Lund University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Lund University; Skane University Hospital; Lund University; Skane University Hospital	Piel, S (corresponding author), Lund Univ, Dept Clin Sci Lund, Mitochondrial Med, Lund, Sweden.; Piel, S (corresponding author), NeuroVive Pharmaceut AB, Lund, Sweden.; Piel, S (corresponding author), Childrens Hosp Philadelphia, Ctr Mitochondria & Epigen Med, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA.	sarah.piel@med.lu.se	Ehinger, Johannes/D-7120-2013	Ehinger, Johannes/0000-0002-2417-5767; Piel, Sarah/0000-0002-1779-3532; Sjovall, Fredrik/0000-0001-5612-0325	Swedish government [F 2014/354]; Regional research and development grants (Southern healthcare region, Sweden) [170083]; Regional research and development grants (Crafoord Foundation) [2017-0776]; Regional research and development grants (Royal Physiographic Society in Lund) [20141112]; NeuroVive Pharmaceutical AB (Lund, Sweden)	Swedish government; Regional research and development grants (Southern healthcare region, Sweden); Regional research and development grants (Crafoord Foundation); Regional research and development grants (Royal Physiographic Society in Lund); NeuroVive Pharmaceutical AB (Lund, Sweden)	This work was funded by Swedish government project and salary funding for clinically oriented medical research ALF-grant F 2014/354 to E.E., Regional research and development grants (Southern healthcare region, Sweden grant 170083 to E.E.;, The Crafoord Foundation grant 2017-0776 to E.E., and The Royal Physiographic Society in Lund grant 20141112 to M.J.H.). Additionally, this study was partially funded by NeuroVive Pharmaceutical AB (Lund, Sweden). NeuroVive Pharmaceutical provided support in the form of salaries for authors [S.P., J.K.E., I.C., E.E., and M.J. H.]. The specific roles of these authors are articulated in the `author contributions' section. The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cho EH, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00455; Chrois KM, BASIC CLIN PHARM TOX; Correa PRAV, 2007, J HEPATOL, V47, P262, DOI 10.1016/j.jhep.2007.03.016; Du K, 2019, ARCH TOXICOL, V93, P163, DOI 10.1007/s00204-018-2331-8; Du K, 2017, ARCH TOXICOL, V91, P761, DOI 10.1007/s00204-016-1692-0; Ehinger JK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12317; Giorgi-Coll S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01149-w; Hakak Y, 2009, J LEUKOCYTE BIOL, V85, P837, DOI 10.1189/jlb.1008618; Heard KJ, 2008, NEW ENGL J MED, V359, P285, DOI 10.1056/NEJMct0708278; Hinke SA, 2007, BRIT J PHARMACOL, V150, P1031, DOI 10.1038/sj.bjp.0707189; Hinson Jack A, 2010, Handb Exp Pharmacol, P369, DOI 10.1007/978-3-642-00663-0_12; HUGHEY CC, 2011, JOVE J VIS EXP FEB, DOI DOI 10.3791/2431; Janowska JI, 2020, TOXICOL IN VITRO, V65, DOI 10.1016/j.tiv.2020.104794; Kramer PA, 2014, JOVE-J VIS EXP, DOI 10.3791/51301; Kramer PA, 2014, REDOX BIOL, V2, P206, DOI 10.1016/j.redox.2013.12.026; Lee KK, 2015, HEPATOLOGY, V61, P326, DOI 10.1002/hep.27385; Lin CS, 2012, P NATL ACAD SCI USA, V109, P20065, DOI 10.1073/pnas.1217113109; McGill MR, 2014, EXPERT OPIN DRUG MET, V10, P1005, DOI 10.1517/17425255.2014.920823; McGill MR, 2012, J CLIN INVEST, V122, P1574, DOI 10.1172/JCI59755; Nowak G, 2008, J PHARMACOL EXP THER, V324, P1155, DOI 10.1124/jpet.107.130872; Pesta D, 2012, METHODS MOL BIOL, V810, P25, DOI 10.1007/978-1-61779-382-0_3; Piel S, 2015, ACTA PHYSIOL, V213, P171, DOI 10.1111/apha.12311; Piel S, 2018, THESIS, P77; Piel S, MITOCHONDRIAL TARGET; Piel S, 2018, INTENS CARE MED EXP, V6, DOI 10.1186/s40635-018-0186-1; Porporato PE, 2018, CELL RES, V28, P265, DOI 10.1038/cr.2017.155; Prill S, 2016, ARCH TOXICOL, V90, P1181, DOI 10.1007/s00204-015-1537-2; Ramachandran A, 2017, GENE EXPRESSION; Ramachandran A, 2019, SEMINARS LIVER DIS; Ramachandran Anup, 2018, Gene Expression, V18, P19, DOI 10.3727/105221617X15084371374138; Saito C, 2010, HEPATOLOGY, V51, P246, DOI 10.1002/hep.23267; Shah AD, 2011, BRIT J CLIN PHARMACO, V71, P20, DOI 10.1111/j.1365-2125.2010.03765.x; Shiratori R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55296-3; Sjovall F, 2013, MITOCHONDRION, V13, P7, DOI 10.1016/j.mito.2012.11.001; Tretter L, 2016, BBA-BIOENERGETICS, V1857, P1086, DOI 10.1016/j.bbabio.2016.03.012; Tyrrell DJ, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/7317251; Tyrrell DJ, 2016, REDOX BIOL, V10, P65, DOI 10.1016/j.redox.2016.09.009; Wang FG, 2014, EXP THER MED, V8, P1939, DOI 10.3892/etm.2014.2019; Yoon E, 2016, J CLIN TRANSL HEPATO, V4, P131, DOI 10.14218/JCTH.2015.00052; Zielinski LP, 2016, MITOCHONDRION, V31, P45, DOI 10.1016/j.mito.2016.09.003	40	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2020	15	4							e0231173	10.1371/journal.pone.0231173	http://dx.doi.org/10.1371/journal.pone.0231173			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8OD	32251487	gold, Green Published			2023-01-03	WOS:000535955000040
J	Buresh, M; Gicquelais, RE; Astemborski, J; Kirk, GD; Mehta, SH; Genberg, BL				Buresh, Megan; Gicquelais, Rachel E.; Astemborski, Jacquie; Kirk, Gregory D.; Mehta, Shruti H.; Genberg, Becky L.			Fatal overdose prevention and experience with naloxone: A cross-sectional study from a community-based cohort of people who inject drugs in Baltimore, Maryland	PLOS ONE			English	Article							TAKE-HOME NALOXONE; OPIOID OVERDOSE; HEROIN OVERDOSE; USERS; EDUCATION; PROGRAMS; SUFFICIENT; DEPENDENCE; KNOWLEDGE; AWARENESS	Introduction Overdose is a leading cause of death in the United States, especially among people who inject drugs (PWID). Improving naloxone access and carrying among PWID may offset recent increases in overdose mortality associated with the influx of synthetic opioids in the drug market. This study characterized prevalence and correlates of several naloxone outcomes among PWID. Methods During 2018, a survey to assess experience with naloxone was administered to 915 participants in the AIDS Linked to the IntraVenous Experience (ALIVE) study, an ongoing community-based observational cohort of people who currently inject or formerly injected drugs in Baltimore, Maryland. We examined the associations of naloxone outcomes (training, supply, use, and regular possession) with socio-demographic, substance use and healthcare utilization factors among PWID in order to characterize gaps in naloxone implementation among this high-risk population. Results Median age was 56 years, 34% were female, 85% were African American, and 31% recently injected. In the past six months, 46% (n = 421) reported receiving training in overdose prevention, 38% (n = 346) had received a supply of naloxone, 9% (n = 85) had administered naloxone, and 9% (n = 82) reported usually carrying a supply of naloxone. Recent non-fatal overdose was not associated with any naloxone outcomes in adjusted analysis. Active opioid use (aOR = 2.10, 95% CI: 1.03, 4.28) and recent treatment of alcohol or substance use disorder (aOR = 2.01, 95% CI: 1.13, 3.56) were associated with regularly carrying naloxone. Conclusion Further work is needed to encourage PWID to carry and effectively use naloxone to decrease rates of fatal opioid overdose. While accessing treatment for substance use disorder was positively associated with carrying naloxone, EMS response to 911 calls for overdose, the emergency department, and syringe services programs may be settings in which naloxone access and carrying could be encouraged among PWID.	[Buresh, Megan] Johns Hopkins Sch Med, Div Addict Med, Baltimore, MD USA; [Buresh, Megan; Gicquelais, Rachel E.; Astemborski, Jacquie; Kirk, Gregory D.; Mehta, Shruti H.; Genberg, Becky L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Kirk, Gregory D.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Genberg, BL (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.	bgenberg@jhu.edu		Gicquelais, Rachel/0000-0002-7022-6385	National Institutes of Health (NIH); National Institute on Drug Abuse; National Institute of Allergy and Infectious Diseases [U01DA-036297, R01-DA-12568, T32-AI102623]; NIH [P30AI094189]; NIH: NICHD; NIH: NCI; NIH: NHLBI; NIH: NIDA; NIH: NIMH; NIH: NIA; NIH: FIC; NIH: NIGMS; NIH: NIDDK; NIH: OAR; NIH: NIAID	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH: NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH: NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH: NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH: NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIH: NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIH: NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH: FIC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIH: NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH: NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH: OAR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH: NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Grant support was provided by the National Institutes of Health (NIH) including the National Institute on Drug Abuse and the National Institute of Allergy and Infectious Diseases (U01DA-036297 [GDK, SHM], R01-DA-12568 [SHM], and T32-AI102623 [SHM]). This research was facilitated by the infrastructure and resources provided by the Johns Hopkins University Center for AIDS Research, an NIH funded program (P30AI094189), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2019, OV DEATH RAT; Baltimore City Health Department, 2018, SUBST US DIS; Banta-Green CJ, 2019, INJURY PREV, V25, P191, DOI 10.1136/injuryprev-2017-042676; Behar E, 2015, DRUG ALCOHOL DEPEN, V148, P209, DOI 10.1016/j.drugalcdep.2014.12.009; Clark AK, 2014, J ADDICT MED, V8, P153, DOI 10.1097/ADM.0000000000000034; D'Onofrio G, 2017, J GEN INTERN MED, V32, P660, DOI 10.1007/s11606-017-3993-2; Degenhardt L, 2013, LANCET, V382, P1564, DOI 10.1016/S0140-6736(13)61530-5; Donovan E, 2019, J URBAN HEALTH, V96, P367, DOI 10.1007/s11524-019-00349-1; Doyon S, 2016, AM J ADDICTION, V25, P301, DOI 10.1111/ajad.12384; Eggleston W, 2018, ADDICTION, V113, P2300, DOI 10.1111/add.14416; Enteen L, 2010, J URBAN HEALTH, V87, P931, DOI 10.1007/s11524-010-9495-8; Galea S, 2006, ADDICT BEHAV, V31, P907, DOI 10.1016/j.addbeh.2005.07.020; Green TC, 2008, ADDICTION, V103, P979, DOI 10.1111/j.1360-0443.2008.02182.x; Heavey SC, 2018, INT J DRUG POLICY, V51, P27, DOI 10.1016/j.drugpo.2017.09.015; Hedegaard Holly, 2020, NCHS Data Brief, P1; Hernandez-Delgado, 2018, LEG INT RED OV MORT; Katzman JG, 2019, J ADDICT MED, V13, P131, DOI 10.1097/ADM.0000000000000461; Kestler A, 2019, CAN J EMERG MED, V21, P226, DOI 10.1017/cem.2018.368; Kestler A, 2017, ANN EMERG MED, V69, P340, DOI 10.1016/j.annemergmed.2016.07.027; Koester S, 2017, INT J DRUG POLICY, V48, P115, DOI 10.1016/j.drugpo.2017.06.008; Lambdin BH, 2018, DRUG ALCOHOL DEPEN, V188, P370, DOI 10.1016/j.drugalcdep.2018.04.004; Lankenau SE, 2013, J COMMUN HEALTH, V38, P133, DOI 10.1007/s10900-012-9591-7; Mars Sarah G, 2018, J Psychoactive Drugs, V50, P167, DOI 10.1080/02791072.2017.1394508; Maryland Government, 2019, USE MARYLAND COMPOSI; McClellan C, 2018, ADDICT BEHAV, V86, P90, DOI 10.1016/j.addbeh.2018.03.014; Neale J, 2019, ADDICTION, V114, P708, DOI 10.1111/add.14510; Nolan S, 2017, PUBLIC HEALTH REP, V132, P563, DOI 10.1177/0033354917717230; Seal KH, 2005, J URBAN HEALTH, V82, P303, DOI 10.1093/jurban/jti053; Simmons J, 2018, SUBST USE MISUSE, V53, P1997, DOI 10.1080/10826084.2018.1451891; Strang J, 2008, ADDICTION, V103, P1648, DOI 10.1111/j.1360-0443.2008.02314.x; Tobin K, 2018, INT J DRUG POLICY, V59, P94, DOI 10.1016/j.drugpo.2018.07.003; VLAHOV D, 1991, J DRUG ISSUES, V21, P759, DOI 10.1177/002204269102100406; Wagner KD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223823; Wagner KD, 2010, INT J DRUG POLICY, V21, P186, DOI 10.1016/j.drugpo.2009.01.003; Walley Alexander Y, 2013, BMJ, V346, pf174, DOI 10.1136/bmj.f174; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631; Wildeman C, 2017, LANCET, V389, P1464, DOI 10.1016/S0140-6736(17)30259-3; Williams AV, 2014, ADDICTION, V109, P250, DOI 10.1111/add.12360; Wonder C., 2019, BALTIMORE 2018 OVERD	39	13	13	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2020	15	3							e0230127	10.1371/journal.pone.0230127	http://dx.doi.org/10.1371/journal.pone.0230127			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8YS	32160244	Green Published, gold			2023-01-03	WOS:000535284700061
J	Keller, LM; Eighmy, S; Li, C; Winter, L; Kerecman, J; Goodman, Z; Mittal, N; Blanco, CL				Keller, Laura M.; Eighmy, Stephanie; Li, Cun; Winter, Lauryn; Kerecman, Jay; Goodman, Zachary; Mittal, Naveen; Blanco, Cynthia L.			Association of novel markers of liver disease with neonatal liver disease in premature baboons, Papio sp.	PLOS ONE			English	Article							INTRAVENOUS LIPID EMULSIONS; SERUM HYALURONIC-ACID; PARENTERAL-NUTRITION; HEPATIC-FIBROSIS; DIAGNOSIS; CIRRHOSIS; CHILDREN; FAILURE; RISK	Parenteral Nutrition (PN) Associated Liver Disease (PNALD) affects up to 60% of neonates; however, techniques for diagnosing and monitoring disease progression remain limited. The neonatal baboon model may provide a unique opportunity to identify serologic markers associated with this disease. The purpose of this study was to investigate if Hyaluronic Acid (HA), TIMP metallopeptidase inhibitor 1 (TIMP1), Amino-terminal Propeptide of Type-III Collagen (PIIINP) and Enhanced Liver Fibrosis (ELF) score associate with histological liver disease in neonatal baboons exposed to PN. Preterm baboons delivered via c-section at 67% gestation received PN for 14 days with or without Intralipid (PRT+IL, PRT-IL, respectively) or were sacrificed after birth (PRTCTR). Term baboons were sacrificed after birth (TERMCTR) or survived 14 days (TERM+14d). Serum HA, TIMP1, and PIIINP concentrations were measured by ELISA. A blinded pathologist assigned liver histological scores following necropsy. HA increased 9.1-fold, TIMP1 increased 2.2-fold, and ELF score increased 1.4-fold in PRT-IL compared to PRTCTR. ALT, AST, and GGT were within normal limits and did not vary between groups. A trend towards increased fibrosis was found in PRT-IL baboons. Microvesicular hepatocyte steatosis and Kupffer cell hypertrophy were elevated in PRT-IL vs PRTCTR. HA and TIMP1 were significantly elevated in preterm baboons with early histological findings of liver disease evidenced by hepatic steatosis, Kupffer cell hypertrophy and a trend towards fibrosis whereas traditional markers of liver disease remained normal. These novel markers could potentially be utilized for monitoring early hepatic injury in neonates.	[Keller, Laura M.] San Antonio Mil Med Ctr, Dept Neonatol, San Antonio, TX USA; [Eighmy, Stephanie] Brooke Army Med Ctr, Dept Pediat, San Antonio, TX USA; [Li, Cun] Texas Biomed Res Inst, San Antonio, TX USA; [Li, Cun] Univ Wyoming, Texas Pregnancy & Life Course Hlth Res Ctr, Dept Anim Sci, Laramie, WY 82071 USA; [Winter, Lauryn; Mittal, Naveen; Blanco, Cynthia L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA; [Kerecman, Jay] Eastern Maine Hlth Syst, Dept Pediat, Div Neonatol, Bangor, ME USA; [Goodman, Zachary] Nova Fairfax Hosp, Ctr Liver Dis, Dept Pathol, Falls Church, VA USA; [Blanco, Cynthia L.] Univ Hlth Syst, Dept Pediat, Div Neonatol, San Antonio, TX 78229 USA	San Antonio Military Medical Center; San Antonio Military Medical Center; United States Department of Defense; United States Army; Texas Biomedical Research Institute; University of Wyoming; University of Texas System; University of Texas Health San Antonio	Blanco, CL (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA.; Blanco, CL (corresponding author), Univ Hlth Syst, Dept Pediat, Div Neonatol, San Antonio, TX 78229 USA.	blanco@uthscsa.edu			United States Army Department of Clinical Investigation; University of Texas Health Science Center at San Antonio CTSA [UL1RR025767]; Robert Wood Johnson Foundation; American Diabetes Association; University Health System Research Fund	United States Army Department of Clinical Investigation; University of Texas Health Science Center at San Antonio CTSA; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); American Diabetes Association(American Diabetes Association); University Health System Research Fund	Support for this project was provided by the United States Army Department of Clinical Investigation (https://www.bamc.health.mil/) (L. K.), The University of Texas Health Science Center at San Antonio CTSA (https://iims.uthscsa.edu/; UL1RR025767) (C.B.), Robert Wood Johnson Foundation (https://www.rwjf.org/) (C.B.), American Diabetes Association (http://www.diabetes.org/) (C.B.), and University Health System Research Fund (https://www.universityhealthsystem.com/).No individuals contracted or employed by the funders, other than the named authors, played any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alisi A, 2011, BEST PRACT RES CL GA, V25, P259, DOI 10.1016/j.bpg.2011.02.008; Alkhouri N, 2011, CLIN GASTROENTEROL H, V9, P150, DOI 10.1016/j.cgh.2010.09.015; Bai FC, 2017, CELL PHYSIOL BIOCHEM, V44, P436, DOI 10.1159/000485009; Baranova A, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-91; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Belkind-Gerson J, 2008, J PEDIATR GASTR NUTR, V47, pS7, DOI 10.1097/MPG.0b013e3181818e3f; Blanco CL, 2018, PLOS ONE, P1; Blanco CL, 2015, DIET NUTR CRITIAL CA, P1957; Blanco CL, 2015, ENDOCRINOLOGY, V156, P813, DOI 10.1210/en.2014-1757; Blanco CL, 2013, PEDIATR RES, V73, P337, DOI 10.1038/pr.2012.184; Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706; Carlson JJ, 2009, J GASTROEN HEPATOL, V24, P786, DOI 10.1111/j.1440-1746.2009.05778.x; Castera L, 2011, BEST PRACT RES CL GA, V25, P291, DOI 10.1016/j.bpg.2011.02.003; Castera L, 2011, HEPATOL INT, V5, P625, DOI 10.1007/s12072-010-9240-0; Cober MP, 2010, CURR OPIN ORGAN TRAN, V15, P330, DOI 10.1097/MOT.0b013e328338c2da; Dechene A, 2010, HEPATOLOGY, V52, P1008, DOI 10.1002/hep.23754; Dhawan A, 2001, J PEDIATR SURG, V36, P443, DOI 10.1053/jpsu.2001.21622; Eleazar JA, 2004, J HEPATOL, V41, P983, DOI 10.1016/j.jhep.2004.08.017; Fabre V, 2011, J INFECT DIS, V203, P707, DOI 10.1093/infdis/jiq099; Feldstein AE, 2010, J PEDIATR GASTR NUTR, V51, P378, DOI 10.1097/MPG.0b013e3181ecf3d4; French METAVIR Cooperative Study Group, 1994, HEPATOLOGY, V20; Hartley JL, 2006, J PEDIAT GASTROENTER, V43; Hasegawa T, 2000, J PEDIATR SURG, V35, P1643, DOI 10.1053/jpsu.2000.18342; Kaneda H, 2006, J GASTROEN HEPATOL, V21, P1459, DOI 10.1111/j.1440-1746.2006.04447.x; Kelly DA, 1998, NUTRITION, V14, P153, DOI 10.1016/S0899-9007(97)00232-3; Kerecman J, 2013, J PEDIATR GASTR NUTR, V57, P172, DOI 10.1097/MPG.0b013e318293e404; Kobayashi H, 1999, J PEDIATR SURG, V34, P1791, DOI 10.1016/S0022-3468(99)90314-7; Kossakowska AE, 1998, AM J PATHOL, V153, P1895, DOI 10.1016/S0002-9440(10)65703-3; Lebensztejn DM, 2005, WORLD J GASTROENTERO, V11, P7192, DOI 10.3748/wjg.v11.i45.7192; Lichtinghagen R, 2013, J HEPATOL, V59, P236, DOI 10.1016/j.jhep.2013.03.016; Matsumoto M, 2013, INT J EXP PATHOL, V94, P93, DOI 10.1111/iep.12008; Mayo MJ, 2008, HEPATOLOGY, V48, P1549, DOI 10.1002/hep.22517; Miranda RN, 2006, ARCH PATHOL LAB MED, V130, P1786; MUTIMER DJ, 1989, J HEPATOL, V9, P184, DOI 10.1016/0168-8278(89)90049-4; Nehra D, 2014, JPEN-PARENTER ENTER, V38, P693, DOI 10.1177/0148607113492549; Nie QH, 2006, WORLD J GASTROENTERO, V12, P3044, DOI 10.3748/wjg.v12.i19.3044; Nobili V, 2010, TRANSL RES, V156, P229, DOI 10.1016/j.trsl.2010.05.008; Nobili V, 2009, GASTROENTEROLOGY, V136, P160, DOI 10.1053/j.gastro.2008.09.013; Ovchinsky N, 2012, ADV ANAT PATHOL, V19, P250, DOI 10.1097/PAP.0b013e31825c6a20; Papastergiou V, 2012, ANN GASTROENTEROL, V25, P218; Parkes J, 2011, J VIRAL HEPATITIS, V18, P23, DOI 10.1111/j.1365-2893.2009.01263.x; Parkes J, 2012, COMP HEPATOL, V11, P1, DOI DOI 10.1186/1476-5926-11-1; Pereira TN, 2004, J HEPATOL, V41, P576, DOI 10.1016/j.jhep.2004.06.032; Poynard Thierry, 2011, Gastroenterol Hepatol (N Y), V7, P445; Premji SS, 2007, DIETARY PROTEIN RES, P63; Rath T, 2012, DIGEST LIVER DIS, V44, P780, DOI 10.1016/j.dld.2012.04.008; Rossi Enrico, 2007, Clin Biochem Rev, V28, P3; Rostami S, 2013, HEPAT MON, V13, DOI [10.5812/hepatmon.9611, 10.5812/hepatmon.13787]; Roy CC, 2013, PAED CHILD HEALT-CAN, V18, P357, DOI 10.1093/pch/18.7.357; Savini S, 2013, AM J CLIN NUTR, V98, P312, DOI 10.3945/ajcn.112.056556; Shah AG, 2009, CLIN GASTROENTEROL H, V7, P1104, DOI 10.1016/j.cgh.2009.05.033; Soden JS, 2010, J PEDIATR-US, V156, P327, DOI 10.1016/j.jpeds.2009.08.033; Suzuki A, 2005, LIVER INT, V25, P779, DOI 10.1111/j.1478-3231.2005.01064.x; Weiskirchen R, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010016; Xie Q, 2014, PLOS ONE, V9; Yang HR, 2012, WORLD J GASTROENTERO, V18, P1525, DOI 10.3748/wjg.v18.i13.1525	56	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2020	15	3							e0228985	10.1371/journal.pone.0228985	http://dx.doi.org/10.1371/journal.pone.0228985			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8UT	32150543	gold, Green Published			2023-01-03	WOS:000535274400006
J	Oliva, EM; Bowe, T; Manhapra, A; Kertesz, S; Hah, JM; Henderson, P; Robinson, A; Paik, M; Sandbrink, F; Gordon, AJ; Trafton, JA				Oliva, Elizabeth M.; Bowe, Thomas; Manhapra, Ajay; Kertesz, Stefan; Hah, Jennifer M.; Henderson, Patricia; Robinson, Amy; Paik, Meenah; Sandbrink, Friedhelm; Gordon, Adam J.; Trafton, Jodie A.			Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; CHRONIC PAIN; USE DISORDER; DRUG; DISCONTINUATION; THERAPY; RISK; EPIDEMIC; SAFETY	OBJECTIVE To examine the associations between stopping treatment with opioids, length of treatment, and death from overdose or suicide in the Veterans Health Administration. DESIGN Observational evaluation. SETTING Veterans Health Administration. PARTICIPANTS 1 394 102 patients in the Veterans Health Administration with an outpatient prescription for an opioid analgesic from fiscal year 2013 to the end of fiscal year 2014 (1 October 2012 to 30 September 2014). MAIN OUTCOME MEASURES A multivariable Cox non-proportional hazards regression model examined death from overdose or suicide, with the interaction of time varying opioid cessation by length of treatment (<= 30, 31-90, 91-400, and >400 days) as the main covariates. Stopping treatment with opioids was measured as the time when a patient was estimated to have no prescription for opioids, up to the end of the next fiscal year (2014) or the patient's death. RESULTS 2887 deaths from overdose or suicide were found. The incidence of stopping opioid treatment was 57.4% (n=799 668) overall, and based on length of opioid treatment was 32.0% (<= 30 days), 8.7% (31-90 days), 22.7% (91-400 days), and 36.6% (>400 days). The interaction between stopping treatment with opioids and length of treatment was significant (P<0.001); stopping treatment was associated with an increased risk of death from overdose or suicide regardless of the length of treatment, with the risk increasing the longer patients were treated. Hazard ratios for patients who stopped opioid treatment (with reference values for all other covariates) were 1.67 (<= 30 days), 2.80 (31-90 days), 3.95 (91-400 days), and 6.77 (>400 days). Descriptive life table data suggested that death rates for overdose or suicide increased immediately after starting or stopping treatment with opioids, with the incidence decreasing over about three to 12 months. CONCLUSIONS Patients were at greater risk of death from overdose or suicide after stopping opioid treatment, with an increase in the risk the longer patients had been treated before stopping. Descriptive data suggested that starting treatment with opioids was also a risk period. Strategies to mitigate the risk in these periods are not currently a focus of guidelines for long term use of opioids. The associations observed cannot be assumed to be causal; the context in which opioid prescriptions were started and stopped might contribute to risk and was not investigated. Safer prescribing of opioids should take a broader view on patient safety and mitigate the risk from the patient's perspective. Factors to address are those that place patients at risk for overdose or suicide after beginning and stopping opioid treatment, especially in the first three months.	[Oliva, Elizabeth M.; Bowe, Thomas; Henderson, Patricia; Paik, Meenah; Trafton, Jodie A.] Vet Affairs Off Mental Hlth & Suicide Prevent, Vet Affairs Program, Evaluat & Resource Ctr, Menlo Pk, CA 94025 USA; [Oliva, Elizabeth M.; Bowe, Thomas; Trafton, Jodie A.] Vet Affairs Palo Alto Hlth Care Syst, Vet Affairs Ctr Innovat Implementat, 795 Willow Rd,Bldg 324, Menlo Pk, CA 94025 USA; [Manhapra, Ajay] Vet Affairs Hampton Med Ctr, Adv PACT Pain Clin, Hampton, VA USA; [Manhapra, Ajay] Yale Sch Med, Dept Psychiat, New Haven, CT USA; [Manhapra, Ajay] New England MIRECC, West Haven, CT USA; [Manhapra, Ajay] Eastern Virginia Med Sch, Dept Phys Med, Norfolk, VA 23501 USA; [Manhapra, Ajay] Eastern Virginia Med Sch, Dept Rehabil & Psychiat, Norfolk, VA 23501 USA; [Kertesz, Stefan] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA; [Kertesz, Stefan] Univ Alabama Birmingham, Med Sch Birmingham, Birmingham, AL USA; [Hah, Jennifer M.] Stanford Univ, Dept Anesthesiol Perioperat & Pain Med, Div Pain Med, Stanford, CA 94305 USA; [Robinson, Amy] Vet Affairs Sierra Pacific Network, Pharm Serv, Palo Alto, CA USA; [Sandbrink, Friedhelm] Vet Hlth Adm, Natl Pain Management Program, Washington, DC USA; [Sandbrink, Friedhelm] Washington DC Vet Affairs Med Ctr, Dept Neurol, Washington, DC USA; [Sandbrink, Friedhelm] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; [Sandbrink, Friedhelm] George Washington Univ, Washington, DC USA; [Gordon, Adam J.] Program Addict Res Clin Care Knowledge & Advocacy, Salt Lake City, UT USA; [Gordon, Adam J.] Univ Utah, Sch Med, Dept Internal Med, Div Epidemiol, Salt Lake City, UT USA; [Gordon, Adam J.] Vet Affairs Salt Lake City Hlth Care Syst, Informat Decis Enhancement & Analyt Sci Ctr IDEAS, Salt Lake City, UT USA; [Trafton, Jodie A.] Stanford Univ, Dept Psychiat, Sch Med, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Yale University; Eastern Virginia Medical School; Eastern Virginia Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham; University of Alabama System; University of Alabama Birmingham; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Uniformed Services University of the Health Sciences - USA; George Washington University; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Stanford University	Oliva, EM (corresponding author), Vet Affairs Off Mental Hlth & Suicide Prevent, Vet Affairs Program, Evaluat & Resource Ctr, Menlo Pk, CA 94025 USA.; Oliva, EM (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, Vet Affairs Ctr Innovat Implementat, 795 Willow Rd,Bldg 324, Menlo Pk, CA 94025 USA.	elizabeth.oliva@va.gov	Gordon, Adam Joseph/AAX-9001-2020	Gordon, Adam Joseph/0000-0002-2453-8871; Hah, Jennifer/0000-0002-9739-3968	Veterans Affairs Office of Mental Health and Suicide Prevention	Veterans Affairs Office of Mental Health and Suicide Prevention	This project was supported by the Veterans Affairs Office of Mental Health and Suicide Prevention but the contents of this work do not represent the views of the Veterans Affairs or the US government.	Amour M., 2017, CENTRAL MAINE PATIEN; Bohnert ASB, 2019, NEW ENGL J MED, V380, P71, DOI 10.1056/NEJMra1802148; Bohnert ASB, 2018, ANN INTERN MED, V169, P367, DOI 10.7326/M18-1243; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Borucka J., 2014, EKONOMETRIA, V45, P85, DOI DOI 10.15611/EKT.2014.3.07; Breckenridge J, 2003, J PAIN, V4, P344, DOI 10.1016/S1526-5900(03)00638-2; Centers for Disease Control and Prevention, 2019, CALC TOT DAIL DOS OP; Centers for Medicare and Medicaid Services, 2017, CTR MED MED SERV CMS; Davis C., 2017, STATE STATE SUMMARY; de Heer EW, 2020, GEN HOSP PSYCHIAT, V63, P54, DOI 10.1016/j.genhosppsych.2018.11.005; Demidenko MI, 2017, GEN HOSP PSYCHIAT, V47, P29, DOI 10.1016/j.genhosppsych.2017.04.011; Dowell D, 2019, JAMA-J AM MED ASSOC, V322, P1855, DOI 10.1001/jama.2019.16409; Dowell D, 2019, NEW ENGL J MED, V380, P2285, DOI 10.1056/NEJMp1904190; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Frank JW, 2017, ANN INTERN MED, V167, P181, DOI 10.7326/M17-0598; Fulton-Kehoe D, 2015, MED CARE, V53, P679, DOI 10.1097/MLR.0000000000000384; Garcia MC, 2016, MMWR-MORBID MORTAL W, V65, P1125, DOI 10.15585/mmwr.mm6541a1; Gellad WF, 2017, JAMA INTERN MED, V177, P611, DOI 10.1001/jamainternmed.2017.0147; Glanz JM, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2613; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Hadlandsmyth K, 2018, J GEN INTERN MED, V33, P818, DOI 10.1007/s11606-017-4283-8; Ilgen MA, 2008, GEN HOSP PSYCHIAT, V30, P521, DOI 10.1016/j.genhosppsych.2008.09.003; James JR, 2019, J GEN INTERN MED, V34, P2749, DOI 10.1007/s11606-019-05301-2; Jawad I, 2018, THER ADV PSYCHOPHARM, V8, P349, DOI 10.1177/2045125318804364; Kertesz SG, 2017, SUBST ABUS, V38, P3, DOI 10.1080/08897077.2016.1261070; Lin LWA, 2017, PAIN, V158, P833, DOI 10.1097/j.pain.0000000000000837; Lovejoy TI, 2017, PAIN, V158, P526, DOI 10.1097/j.pain.0000000000000796; Mark TL, 2019, J SUBST ABUSE TREAT, V103, P58, DOI 10.1016/j.jsat.2019.05.001; Martins SS, 2017, JAMA PSYCHIAT, V74, P445, DOI 10.1001/jamapsychiatry.2017.0113; Meara E, 2016, NEW ENGL J MED, V375, P44, DOI 10.1056/NEJMsa1514387; Midboe AM, 2012, TRANSL BEHAV MED, V2, P57, DOI 10.1007/s13142-011-0104-5; Mokdad AH, 2018, JAMA-J AM MED ASSOC, V319, P1444, DOI 10.1001/jama.2018.0158; Murthy VH, 2016, NEW ENGL J MED, V375, P2413, DOI 10.1056/NEJMp1612578; Oliva EM, 2017, PSYCHOL SERV, V14, P34, DOI 10.1037/ser0000099; Racine M, 2018, PROG NEURO-PSYCHOPH, V87, P269, DOI 10.1016/j.pnpbp.2017.08.020; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Saha TD, 2016, J CLIN PSYCHIAT, V77, P772, DOI 10.4088/JCP.15m10386; Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324; Sullivan MD, 2006, ARCH INTERN MED, V166, P2087, DOI 10.1001/archinte.166.19.2087; The Opioid Therapy for Chronic Pain Work Group, 2017, VA DOD CLIN PRACT GU; US Department of Health and Human Services, 2019, HHS GUID CLIN APPR D; Wilson M., P MIDW SAS US GROUP; Zedler B, 2014, PAIN MED, V15, P1911, DOI 10.1111/pme.12480	45	87	87	1	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	2020	368								m283	10.1136/bmj.m283	http://dx.doi.org/10.1136/bmj.m283			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KU2KE	32131996	Green Published, hybrid			2023-01-03	WOS:000519536600001
J	Goto, K; Kojima, C; Kasai, N; Sumi, D; Hayashi, N; Hwang, H				Goto, Kazushige; Kojima, Chihiro; Kasai, Nobukazu; Sumi, Daichi; Hayashi, Nanako; Hwang, Hyejung			Resistance exercise causes greater serum hepcidin elevation than endurance (cycling) exercise	PLOS ONE			English	Article							IRON-METABOLISM; GROWTH-HORMONE; INFLAMMATION; ERYTHROPOIESIS; INTENSITY; RESPONSES; HEMOLYSIS; INCREASE; BALANCE	Background Hepcidin is an iron regulating hormone, and exercise-induced hepcidin elevation is suggested to increase the risk of iron deficiency among athletes. Objective We compared serum hepcidin responses to resistance exercise and endurance (cycling) exercise. Methods Ten males [mean +/- standard error: 172 +/- 2 cm, body weight: 70 +/- 2 kg] performed three trials: a resistance exercise trial (RE), an endurance exercise trial (END), and a rest trial (REST). The RE consisted of 60 min of resistance exercise (3-5 sets x 12 repetitions, 8 exercises) at 65% of one repetition maximum, while 60 min of cycling exercise at 65% of VO2max was performed in the END. Blood samples were collected before exercise and during a 6-h post-exercise (0h, 1h, 2h, 3h, 6h after exercise). Results Both RE and END significantly increased blood lactate levels, with significantly higher in the RE (P < 0.001). Serum iron levels were significantly elevated immediately after exercise (P < 0.001), with no significant difference between RE and END. Both the RE and END significantly increased serum growth hormone (GH), cortisol, and myoglobin levels (P < 0.01). However, exercise-induced elevations of GH and cortisol were significantly greater in the RE (trial x time: P < 0.001). Plasma interleukin-6 (IL-6) levels were significantly elevated after exercise (P = 0.003), with no significant difference between the trials. Plasma hepcidin levels were elevated after exercise (P < 0.001), with significantly greater in the RE (463 +/- 125%) than in the END (137 +/- 27%, P = 0.03). During the REST, serum hepcidin and plasma IL-6 levels did not change significantly. Conclusion Resistance exercise caused a greater exercise-induced elevation in hepcidin than did endurance (cycling) exercise. The present findings indicate that caution will be required to avoid iron deficiency even among athletes in strength (power) types of events who are regularly involved in resistance exercise.	[Goto, Kazushige; Sumi, Daichi; Hayashi, Nanako] Ritsumeikan Univ, Grad Sch Sports & Hlth Sci, Kusatsu, Shiga, Japan; [Kojima, Chihiro; Kasai, Nobukazu] Japan Inst Sports Sci, Tokyo, Japan; [Hwang, Hyejung] Konkuk Univ, Phys Act & Performance Inst, Seoul, South Korea	Ritsumeikan University; Konkuk University	Goto, K (corresponding author), Ritsumeikan Univ, Grad Sch Sports & Hlth Sci, Kusatsu, Shiga, Japan.	kagoto@fc.ritsumei.ac.jp	Sumi, Daichi/AAV-7107-2021		Japan Society for the Promotion of Science [23680063]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	Grant name: Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science. Grant number: 23680063 Recipient: Goto K URL:https://www.jsps.go.jp/english/index.html The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antosiewicz J, 2013, CELL IMMUNOL, V283, P12, DOI 10.1016/j.cellimm.2013.06.006; Badenhorst CE, 2015, EUR J APPL PHYSIOL, V115, P2521, DOI 10.1007/s00421-015-3252-3; Beard J, 2000, AM J CLIN NUTR, V72, p594S, DOI 10.1093/ajcn/72.2.594S; Diaz V, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12475; Fujii T, 2014, BIOL TRACE ELEM RES, V161, P101, DOI 10.1007/s12011-014-0075-8; Gassmann M, 2015, J APPL PHYSIOL, V119, P1432, DOI 10.1152/japplphysiol.00248.2015; GOLDE DW, 1977, SCIENCE, V196, P1112, DOI 10.1126/science.870971; Goto K, 2018, APPL PHYSIOL NUTR ME, V43, P221, DOI 10.1139/apnm-2017-0418; Govus AD, 2014, EUR J APPL PHYSIOL, V114, P2183, DOI 10.1007/s00421-014-2938-2; Hinton PS, 2014, APPL PHYSIOL NUTR ME, V39, P1012, DOI 10.1139/apnm-2014-0147; Ishibashi A, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080820; Ishibashi A, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030277; KURTZ A, 1988, P NATL ACAD SCI USA, V85, P7825, DOI 10.1073/pnas.85.20.7825; Ma XY, 2013, INT J SPORT NUTR EXE, V23, P513, DOI 10.1123/ijsnem.23.5.513; McClung JP, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-141; McKay AKA, 2019, J SCI MED SPORT, V22, P635, DOI 10.1016/j.jsams.2018.12.015; Milic R, 2011, EUR J APPL PHYSIOL, V111, P449, DOI 10.1007/s00421-010-1656-7; MILLER BJ, 1988, INT J SPORTS MED, V9, P56, DOI 10.1055/s-2007-1024979; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; Nicolas G, 2002, BLOOD CELL MOL DIS, V29, P327, DOI 10.1006/bcmd.2002.0573; Pasiakos SM, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12820; Peake JM, 2017, J PHYSIOL-LONDON, V595, P695, DOI 10.1113/JP272881; Peeling P, 2017, EUR J APPL PHYSIOL, V117, P1233, DOI 10.1007/s00421-017-3611-3; Peeling P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093002; Peeling P, 2010, EUR J APPL PHYSIOL, V110, P877, DOI 10.1007/s00421-010-1594-4; Peeling P, 2009, INT J SPORT NUTR EXE, V19, P583, DOI 10.1123/ijsnem.19.6.583; Peeling P, 2009, MED SCI SPORT EXER, V41, P1138, DOI 10.1249/MSS.0b013e318192ce58; Sim M, 2014, J INT SOC SPORT NUTR, V11, DOI 10.1186/1550-2783-11-14; Sim M, 2013, INT J SPORT NUTR EXE, V23, P178, DOI 10.1123/ijsnem.23.2.178; Steinberg GR, 2006, APPL PHYSIOL NUTR ME, V31, P302, DOI 10.1139/H06-003; Steinbicker AU, 2013, NUTRIENTS, V5, P3034, DOI 10.3390/nu5083034; Troutt JS, 2012, CLIN CHEM, V58, P1225, DOI 10.1373/clinchem.2012.186866; Zoller H, 2004, NUTRITION, V20, P615, DOI 10.1016/j.nut.2004.04.006	34	5	5	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2020	15	2							e0228766	10.1371/journal.pone.0228766	http://dx.doi.org/10.1371/journal.pone.0228766			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8GQ	32106271	gold, Green Published			2023-01-03	WOS:000535237000013
J	Sathyapalan, DT; Padmanabhan, A; Moni, M; P-Prabhu, B; Prasanna, P; Balachandran, S; Trikkur, SP; Jose, S; Edathadathil, F; Anilkumar, JO; Jayaprasad, R; Koramparambil, G; Kamath, RC; Menon, V; Menon, V				Sathyapalan, Dipu T.; Padmanabhan, Athira; Moni, Merlin; P-Prabhu, Binny; Prasanna, Preetha; Balachandran, Sabarish; Trikkur, Sreekrishnan P.; Jose, Soumya; Edathadathil, Fabia; Anilkumar, Jagan O.; Jayaprasad, Rekha; Koramparambil, Gireeshkumar; Kamath, Ravindra C.; Menon, Veena; Menon, Vidya			Efficacy & safety of Carica papaya leaf extract (CPLE) in severe thrombocytopenia (<= 30,000/mu l) in adult dengue - Results of a pilot study	PLOS ONE			English	Article							PLATELET TRANSFUSION; INHIBITION; FEVER	Severe thrombocytopenia in dengue often prompts platelet transfusion primarily to reduce bleeding risk. In India, about 11-43% of dengue patients report receiving platelet transfusions which is considered scarce and expensive especially in resource limited settings. Herein, we evaluated the efficacy and safety of Carica papaya leaf extract (CPLE) in the management of severe thrombocytopenia (<= 30,000/mu L) in dengue infection. 51 laboratory confirmed adult dengue patients with platelet counts <= 30,000/mu L were randomly assigned to either treatment (n = 26) or placebo (n = 24) group. By day 3, CPLE treated patients reported significantly (p = 0.007) increased platelet counts (482%+/- 284) compared to placebo (331%+/- 370) group. In the treatment group, fewer patients received platelet transfusions (1/26 v/s 2/24) and their median time for platelets to recover to >= 50,000/mu L was 2 days (IQR 2-3) compared to 3 days (IQR 2-4) in placebo. Overall, CPLE was safe and well tolerated with no significant decrease in mean hospitalization days. Plasma cytokine profiling revealed that by day 3, mean percent increase in TNF alpha and IFN gamma levels in treatment group was less compared to that observed in placebos; (TNF alpha: 58.6% v/s 127.5%; p = 0.25 and IFN gamma: 1.93% v/s 62.6% for; p = 0.12). While a mean percent increase in IL-6 levels occurred in placebos (15.92%+/- 29.93%) by day 3, a decrease was noted in CPLE group (12.95%+/- 21.75%; p = 0.0232). Inversely, CPLE treated patients reported a mean percent increase compared to placebo by day 3 (143% +/- 115.7% v/s 12.03%+/- 48.4%; p = 0.006). Further, by day 3, a faster clearance kinetics of viral NS1 antigenemia occurred-mean NS1 titers in treatment group decreased to 97.3% compared to 88% in placebos (p = 0.023). This study demonstrates safety and efficacy of CPLE in increasing platelet counts in severe thrombocytopenia in dengue infections. A possible immunomodulatory and antiviral activity may be attributed to CPLE treatment. These findings merit validation in larger prospective studies.	[Sathyapalan, Dipu T.; Moni, Merlin; P-Prabhu, Binny; Menon, Vidya] Amrita Inst Med Sci, Dept Gen Med, Kochi, Kerala, India; [Padmanabhan, Athira; Jose, Soumya; Anilkumar, Jagan O.; Menon, Veena] Amrita Inst Med Sci, Clin Virol Lab, Kochi, Kerala, India; [Prasanna, Preetha; Jayaprasad, Rekha] Amrita Inst Med Sci, Dept Med Adm, Kochi, Kerala, India; [Balachandran, Sabarish; Trikkur, Sreekrishnan P.; Koramparambil, Gireeshkumar] Amrita Inst Med Sci, Dept Emergency Med, Kochi, Kerala, India; [Edathadathil, Fabia] Amrita Inst Med Sci, Dept Allied Hlth Sci, Kochi, Kerala, India; [Kamath, Ravindra C.] Amrita Inst Med Sci, Dept Integrated Holist Med, Kochi, Kerala, India	Amrita Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Kochi; Amrita Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Kochi; Amrita Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Kochi; Amrita Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Kochi; Amrita Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Kochi; Amrita Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Kochi	Menon, V (corresponding author), Amrita Inst Med Sci, Dept Gen Med, Kochi, Kerala, India.	vidyapmenon@gmail.com	Balachandran, Sabarish/ABE-1732-2020	BALACHANDRAN, SABARISH/0000-0001-6333-4479	Micro Labs Ltd., Bangalore, India	Micro Labs Ltd., Bangalore, India	Funding by Micro Labs Ltd., Bangalore, India. Fund awarded to VM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad Nisar, 2011, Asian Pacific Journal of Tropical Biomedicine, V1, P330, DOI 10.1016/S2221-1691(11)60055-5; Assir MZK, 2013, TRANSFUS MED HEMOTH, V40, P362, DOI 10.1159/000354837; Azeredo EL, 2001, IMMUNOBIOLOGY, V204, P494, DOI 10.1078/0171-2985-00058; Charan Jaykaran, 2016, Int J Appl Basic Med Res, V6, P249; Chinnappan S, 2016, VIRAL IMMUNOL, V29, P164, DOI 10.1089/vim.2015.0083; de Azeredo EL, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/313842; Eapen CE, 2015, CURR SCI INDIA, V108, P168; Gadhwal Ajeet Kumar, 2016, J Assoc Physicians India, V64, P22; Government of India, 2015, NAT GUID CLIN MAN DE; Hetttige, 2008, SRI LANKAN FAMILY PH, V29, P17; Jayashree K, 2011, INDIAN J HEMATOL BLO, V27, P127, DOI 10.1007/s12288-011-0075-1; Kasture Prabhu Nagnathappa, 2016, J Assoc Physicians India, V64, P15; Kumar N D, 2000, Indian J Pathol Microbiol, V43, P55; LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992; Lee TH, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004576; Lum LCS, 2003, J PEDIATR-US, V143, P682, DOI 10.1067/S0022-3476(03)00503-1; Lye DC, 2017, LANCET, V389, P1611, DOI 10.1016/S0140-6736(17)30269-6; Makroo R N, 2007, Asian J Transfus Sci, V1, P4, DOI 10.4103/0973-6247.28065; Michels M, 2014, THROMB HAEMOSTASIS, V112, P352, DOI 10.1160/TH14-01-0056; Murgue B, 1997, J INFECT DIS, V175, P1497, DOI 10.1086/516486; Okoko Tebekeme, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P449, DOI 10.1016/S2221-1691(12)60074-4; PUTINTSEVA E, 1986, NOUV REV FR HEMATOL, V28, P269; Ranasinghe P, 2012, PHARMACOGN RES, V4, P196, DOI 10.4103/0974-8490.102261; Senthilvel P, 2013, BIOINFORMATION, V9, P889, DOI 10.6026/97320630009889; Sharma N, 2019, ARCH VIROL, V164, P1095, DOI 10.1007/s00705-019-04179-z; Sridharan A, 2013, J VIROL, V87, P11648, DOI 10.1128/JVI.01156-13; Subenthiran S., 2013, EVID-BASED COMPL ALT, V2013, P1, DOI [10.1155/2013/616737, DOI 10.1155/2013/616737]; Weaver SC, 2009, INFECT GENET EVOL, V9, P523, DOI 10.1016/j.meegid.2009.02.003; Whitehorn J, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001716; WHO, 2012, ACC WORK OV GLOB IMP, P13; WHO, 2009, DENG GUID DIAGN TREA; Wong JGX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148579; World Health Organization, 2012, HDB CLIN MAN DENG; World Health Organization, 2009, DENGUE GUIDELINES DI	34	14	14	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2020	15	2							e0228699	10.1371/journal.pone.0228699	http://dx.doi.org/10.1371/journal.pone.0228699			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8AS	32074143	Green Published, gold			2023-01-03	WOS:000535220600025
J	Matias, AM; Coelho, PM; Marques, VB; dos Santos, L; de Assis, ALEM; Nogueira, BV; Lima-Leopoldo, AP; Leopoldo, AS				Matias, Amanda Martins; Coelho, Priscila Murucci; Marques, Vinicius Bermond; dos Santos, Leonardo; Evangelista Monteiro de Assis, Aricia Leone; Nogueira, Breno Valentim; Lima-Leopoldo, Ana Paula; Leopoldo, Andre Soares			Hypercaloric diet models do not develop heart failure, but the excess sucrose promotes contractility dysfunction	PLOS ONE			English	Article							HIGH-FAT; CARDIOMYOCYTE DYSFUNCTION; MYOCARDIAL-INFARCTION; BRAZILIAN GUIDELINES; INSULIN-RESISTANCE; DIASTOLIC FUNCTION; BLOOD-PRESSURE; RAT MODEL; OBESITY; CARBOHYDRATE	Several diseases are associated with excess of adipose tissue, and obesity is considered an independent risk factor for the development of cardiac remodeling and heart failure. Dietary aspects have been studied to elucidate the mechanisms involved in these processes. Thus, the purpose was the development and characterization of an obesity experimental model from hypercaloric diets, which resulted in cardiac remodeling and predisposition to heart failure. Thirty-day-old male Wistar rats (n = 52) were randomized into four groups: control (C), high sucrose (HS), high-fat (HF) and high-fat and sucrose (HFHS) for 20 weeks. General characteristics, comorbidities, weights of the heart, left (LV) and right ventricles, atrium, and relationships with the tibia length were evaluated. The LV myocyte cross sectional area and fraction of interstitial collagen were assayed. Cardiac function was determined by hemodynamic analysis and the contractility by cardiomyocyte contractile function. Heart failure was analyzed by pulmonary congestion, right ventricular hypertrophy, and hemodynamic parameters. HF and HFHS models led to obesity by increase in adiposity index (C = 8.3 +/- 0.2% vs. HF = 10.9 +/- 0.5%, HFHS = 10.2 +/- 0.3%). There was no change in the morphological parameters and heart failure signals. HF and HFHS caused a reduction in times to 50% relaxation without cardiomyocyte contractile damage. The HS model presented cardiomyocyte contractile dysfunction visualized by lower shortening (C: 8.34 +/- 0.32% vs. HS: 6.91 +/- 0.28), as well as the Ca2+ transient amplitude was also increased when compared to HFHS. In conclusion, the experimental diets based on high amounts of sugar, lard or a combination of both did not promote cardiac remodeling with predisposition to heart failure under conditions of obesity or excess sucrose. Nevertheless, excess sucrose causes cardiomyocyte contractility dysfunction associated with alterations in the myocyte sensitivity to intracellular Ca2+.	[Matias, Amanda Martins; Coelho, Priscila Murucci; Lima-Leopoldo, Ana Paula; Leopoldo, Andre Soares] Univ Fed Espirito Santo, Ctr Hlth Sci, Postgrad Program Nutr & Hlth, Vitoria, ES, Brazil; [Marques, Vinicius Bermond; dos Santos, Leonardo] Univ Fed Espirito Santo, Ctr Hlth Sci, Dept Physiol Sci, Vitoria, ES, Brazil; [Evangelista Monteiro de Assis, Aricia Leone; Nogueira, Breno Valentim] Univ Fed Espirito Santo, Ctr Hlth Sci, Dept Morphol, Vitoria, ES, Brazil; [Lima-Leopoldo, Ana Paula; Leopoldo, Andre Soares] Univ Fed Espirito Santo, Ctr Phys Educ & Sports, Dept Sports, Vitoria, ES, Brazil	Universidade Federal do Espirito Santo; Universidade Federal do Espirito Santo; Universidade Federal do Espirito Santo; Universidade Federal do Espirito Santo	Leopoldo, AS (corresponding author), Univ Fed Espirito Santo, Ctr Hlth Sci, Postgrad Program Nutr & Hlth, Vitoria, ES, Brazil.; Leopoldo, AS (corresponding author), Univ Fed Espirito Santo, Ctr Phys Educ & Sports, Dept Sports, Vitoria, ES, Brazil.	andre.leopoldo@ufes.br	dos Santos, Leonardo/B-6509-2013; Leopoldo, André Soares/F-9924-2012; Coelho, Paulo Marcos Zech/ABE-6169-2021	dos Santos, Leonardo/0000-0002-4340-6364; Coelho, Paulo Marcos Zech/0000-0002-2443-8897; Bermond Marques, Vinicius/0000-0002-3522-3867; Leopoldo, Andre Soares/0000-0001-5999-2671	Brazilian National Council for Scientific and Technological Development - CNPq [402090/2016-0]; FAPES [590/2019]	Brazilian National Council for Scientific and Technological Development - CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPES(Fundacao de Amparo a Pesquisa do Estado de Espiritu Santo (FAPES))	This study was supported by the Brazilian National Council for Scientific and Technological Development - CNPq (grant number: 402090/2016-0) to ASL and FAPES (grant number: 590/2019). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abel ED, 2008, PHYSIOL REV, V88, P389, DOI 10.1152/physrev.00017.2007; Alfarano C, 2015, INT J OBESITY, V39, P312, DOI 10.1038/ijo.2014.122; Alpert MA, 2016, CURR OBES REP, V5, P424, DOI 10.1007/s13679-016-0235-6; Alpert MA, 2014, TRANSL RES, V164, P345, DOI 10.1016/j.trsl.2014.04.010; Balderas-Villalobos J, 2013, AM J PHYSIOL-HEART C, V305, pH1344, DOI 10.1152/ajpheart.00211.2013; Barnes MJ, 2003, BRAIN RES BULL, V61, P511, DOI 10.1016/S0361-9230(03)00188-6; Bastien M, 2014, PROG CARDIOVASC DIS, V56, P369, DOI 10.1016/j.pcad.2013.10.016; Bocchi EA, 2009, ARQ BRAS CARDIOL, V93, P1, DOI 10.1590/S0066-782X2009002000001; Carbone S, 2015, INT J CARDIOL, V198, P66, DOI 10.1016/j.ijcard.2015.06.136; Carvajal K, 2014, CELL CALCIUM, V56, P408, DOI 10.1016/j.ceca.2014.08.003; Chess DJ, 2008, CARDIOVASC RES, V79, P269, DOI 10.1093/cvr/cvn074; Clark AL, 2014, PROG CARDIOVASC DIS, V56, P409, DOI 10.1016/j.pcad.2013.10.004; Davidoff AJ, 2004, AM J PHYSIOL-ENDOC M, V286, pE718, DOI 10.1152/ajpendo.00358.2003; De Schutter A, 2014, PROG CARDIOVASC DIS, V56, P401, DOI 10.1016/j.pcad.2013.08.003; Doenst T, 2013, CIRC RES, V113, P709, DOI 10.1161/CIRCRESAHA.113.300376; Fauconnier J, 2007, DIABETES, V56, P1136, DOI 10.2337/db06-0739; Francis J, 2001, AM J PHYSIOL-REG I, V281, pR1734, DOI 10.1152/ajpregu.2001.281.5.R1734; Gonsolin D, 2007, MOL CELL BIOCHEM, V295, P217, DOI 10.1007/s11010-006-9291-7; HILL DJ, 1985, PEDIATR RES, V19, P879, DOI 10.1203/00006450-198509000-00001; Leopoldo AS, 2011, J CELL PHYSIOL, V226, P2934, DOI 10.1002/jcp.22643; Leopoldo AS, 2010, CAN J CARDIOL, V26, P423, DOI 10.1016/S0828-282X(10)70440-2; Lima-Leopoldo AP, 2014, J APPL PHYSIOL, V117, P669, DOI 10.1152/japplphysiol.00088.2014; Liu J, 2013, NUTR RES, V33, P311, DOI 10.1016/j.nutres.2013.02.005; Louch WE, 2011, J MOL CELL CARDIOL, V51, P288, DOI 10.1016/j.yjmcc.2011.06.012; Martins F, 2015, ARQ BRAS CARDIOL, V105, P479, DOI 10.5935/abc.20150095; Matias AM, 2018, NUTRIENTS, V10, DOI 10.3390/nu10081071; Pang XF, 2008, J ETHNOPHARMACOL, V117, P325, DOI 10.1016/j.jep.2008.02.002; Pereira RB, 2005, J PHARMACOL EXP THER, V312, P1321, DOI 10.1124/jpet.104.077701; Phillips RA, 1998, J CLIN ENDOCR METAB, V83, P4284, DOI 10.1210/jc.83.12.4284; Polegato BF, 2016, ARQ BRAS CARDIOL, V106, P105, DOI 10.5935/abc.20160015; Poudyal H, 2012, AM J PHYSIOL-ENDOC M, V302, pE1472, DOI 10.1152/ajpendo.00102.2012; Relling DP, 2006, J HYPERTENS, V24, P549, DOI 10.1097/01.hjh.0000203846.34314.94; Rosini TC, 2012, REV ASSOC MED BRAS, V58, P383; Salie R, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/s12933-014-0109-8; Santos RD, 2012, ARQ BRAS CARDIOL, V99, P1, DOI 10.1590/S0066-782X2013000900001; Sharma N, 2007, CARDIOVASC RES, V73, P257, DOI 10.1016/j.cardiores.2006.11.007; Shiojima I, 2002, J BIOL CHEM, V277, P37670, DOI 10.1074/jbc.M204572200; STRAUS DS, 1984, ENDOCR REV, V5, P356, DOI 10.1210/edrv-5-2-356; Teerlink JR, 1993, J AM COLL CARDIOL, V22, P615, DOI 10.1016/0735-1097(93)90073-A; Tucci PJF, 2011, ARQ BRAS CARDIOL, V96, P420, DOI 10.1590/S0066-782X2011005000049; Vasanji Z, 2006, AM J PHYSIOL-CELL PH, V291, pC772, DOI 10.1152/ajpcell.00086.2005	41	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2020	15	2							e0228860	10.1371/journal.pone.0228860	http://dx.doi.org/10.1371/journal.pone.0228860			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9HH	32032383	Green Published, gold			2023-01-03	WOS:000534626100031
J	Kiang, MV; Humphreys, K; Cullen, MR; Basu, S				Kiang, Mathew V.; Humphreys, Keith; Cullen, Mark R.; Basu, Sanjay			Opioid prescribing patterns among medical providers in the United States, 2003-17: retrospective, observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PILL MILL LAWS; CONTROLLED SUBSTANCES; PRESCRIPTION; RISK; THERAPY; CRISIS; IMPACT; ABUSE; RATES; US	OBJECTIVE To examine the distribution and patterns of opioid prescribing in the United States. DESIGN Retrospective, observational study. SETTING National private insurer covering all 50 US states and Washington DC. PARTICIPANTS An annual average of 669 495 providers prescribing 8.9 million opioid prescriptions to 3.9 million patients from 2003 through 2017. MAIN OUTCOME MEASURES Standardized doses of opioids in morphine milligram equivalents (MMEs) and number of opioid prescriptions. RESULTS In 2017, the top 1% of providers accounted for 49% of all opioid doses and 27% of all opioid prescriptions. In absolute terms, the top 1% of providers prescribed an average of 748 000 MMEs-nearly 1000 times more than the middle 1%. At least half of all providers in the top 1% in one year were also in the top 1% in adjacent years. More than two fifths of all prescriptions written by the top 1% of providers were for more than 50 MMEs a day and over four fifths were for longer than seven days. In contrast, prescriptions written by the bottom 99% of providers were below these thresholds, with 86% of prescriptions for less than 50 MMEs a day and 71% for fewer than seven days. Providers prescribing high amounts of opioids and patients receiving high amounts of opioids persisted over time, with over half of both appearing in adjacent years. CONCLUSIONS Most prescriptions written by the majority of providers are under the recommended thresholds, suggesting that most US providers are careful in their prescribing. Interventions focusing on this group of providers are unlikely to effect beneficial change and could induce unnecessary burden. A large proportion of providers have established relationships with their patients over multiple years. Interventions to reduce inappropriate opioid prescribing should be focused on improving patient care, management of patients with complex pain, and reducing comorbidities rather than seeking to enforce a threshold for prescribing.	[Kiang, Mathew V.; Cullen, Mark R.] Stanford Univ, Sch Med, Ctr Populat Hlth Sci, 1701 Page Mill Rd, Palo Alto, CA 94304 USA; [Kiang, Mathew V.; Humphreys, Keith] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA; [Humphreys, Keith] Palo Alto VA Hlth Care Syst, Palo Alto, CA USA; [Basu, Sanjay] Harvard Med Sch, Ctr Primary Care, Boston, MA 02115 USA; [Basu, Sanjay] Collect Hlth, Res & Analyt, San Francisco, CA USA; [Basu, Sanjay] Imperial Coll, Sch Publ Hlth, London, England	Stanford University; Stanford University; Harvard University; Harvard Medical School; Imperial College London	Kiang, MV (corresponding author), Stanford Univ, Sch Med, Ctr Populat Hlth Sci, 1701 Page Mill Rd, Palo Alto, CA 94304 USA.; Kiang, MV (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA.	mkiang@stanford.edu	Kiang, Mathew/J-5390-2019	Kiang, Mathew/0000-0001-9198-150X	National Institute on Drug Abuse of the National Institutes of Health (NIH) [T32 DA035165]; National Institute on Minority Health and Health Disparities of the NIH [DP2 MD010478]; Veterans Affairs Health Services Research and Development Service; Stanford Neurosciences Institute; NIH national center for advancing translational science clinical and translational science award [UL1 TR001085]	National Institute on Drug Abuse of the National Institutes of Health (NIH); National Institute on Minority Health and Health Disparities of the NIH; Veterans Affairs Health Services Research and Development Service(US Department of Veterans Affairs); Stanford Neurosciences Institute; NIH national center for advancing translational science clinical and translational science award	This study did not receive specific funding. MVK is supported in part by the National Institute on Drug Abuse of the National Institutes of Health (NIH) (T32 DA035165). MVK and SB were supported in part by the National Institute on Minority Health and Health Disparities of the NIH (DP2 MD010478). KH was supported by a senior research career scientist award from the Veterans Affairs Health Services Research and Development Service and a grant from Stanford Neurosciences Institute. Data access was provided by the Stanford Center for Population Health Sciences Data Core. The Population Health Sciences Data Core is supported by an NIH national center for advancing translational science clinical and translational science award (UL1 TR001085) and internal Stanford funding. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders, federal government, or any current or former employers of the authors. Data and analyses were conducted at Stanford University under a data use agreement between Stanford and Optum.	AHRQ, HCUP US TOOLS SOFTW; Barnett ML, 2017, NEW ENGL J MED, V376, P663, DOI 10.1056/NEJMsa1610524; Betses M, 2013, NEW ENGL J MED, V369, P989, DOI 10.1056/NEJMp1308222; Blutinger EJ, 2019, AM J EMERG MED, V37, P1963, DOI 10.1016/j.ajem.2019.03.023; Bohnert ASB, 2018, ANN INTERN MED, V169, P367, DOI 10.7326/M18-1243; CDC Injury Center, 2019, OPIOID OVERDOSE CDC; Chang HY, 2018, PHARMACOEPIDEM DR S, V27, P422, DOI 10.1002/pds.4404; Chang HY, 2016, DRUG ALCOHOL DEPEN, V165, P1, DOI 10.1016/j.drugalcdep.2016.04.033; Chen JH, 2016, JAMA INTERN MED, V176, P259, DOI 10.1001/jamainternmed.2015.6662; Chiu AS, 2018, JAMA SURG, V153, P1012, DOI 10.1001/jamasurg.2018.2083; Chou Roger, 2014, Evid Rep Technol Assess (Full Rep), P1, DOI 10.23970/AHRQEPCERTA218; Compton WA, 2006, DRUG ALCOHOL DEPEN, V83, pS4, DOI 10.1016/j.drugalcdep.2005.10.020; Cowell FA, 2011, OXFORD SCHOLARSHIP O, P1, DOI [10.1093/acprof:osobl/9780199594030.003.0001, DOI 10.1093/ACPROF:OSOBL/9780199594030.003.0001]; Darnall BD, 2012, PAIN MED, V13, P1181, DOI 10.1111/j.1526-4637.2012.01467.x; DeCarolis DD, 2007, PHARMACOTHERAPY, V27, P510, DOI 10.1592/phco.27.4.510; Delgado MK, 2018, J GEN INTERN MED, V33, P409, DOI 10.1007/s11606-017-4286-5; Doctor JN, 2018, SCIENCE, V361, P588, DOI 10.1126/science.aat4595; Dowell D, 2019, NEW ENGL J MED, V380, P2285, DOI 10.1056/NEJMp1904190; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Edlund MJ, 2007, PAIN MED, V8, P647, DOI 10.1111/j.1526-4637.2006.00200.x; Edlund MJ, 2014, CLIN J PAIN, V30, P557, DOI 10.1097/AJP.0000000000000021; Gelenberg AJ, 1998, THE PRACTITIONERS GU, P153, DOI [10.1007/978-1-4615-5877-4_4, DOI 10.1007/978-1-4615-5877-4_4]; Gini C., 1921, EC J; Guy GP, 2018, AM J PREV MED, V55, pE153, DOI 10.1016/j.amepre.2018.06.008; Hoffman KM, 2016, P NATL ACAD SCI USA, V113, P4296, DOI 10.1073/pnas.1516047113; Humphreys K, 2017, LANCET, V390, P437, DOI 10.1016/S0140-6736(17)31918-9; Jalal H, 2018, SCIENCE, V361, P1218, DOI 10.1126/science.aau1184; Kennedy-Hendricks A, 2016, AM J PUBLIC HEALTH, V106, P291, DOI 10.2105/AJPH.2015.302953; Kiang MV, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0040; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Latt N, 2009, ADDICTION MED, DOI [10.1093/med/9780199539338.003.0003, DOI 10.1093/MED/9780199539338.003.0003]; Levy B, 2015, AM J PREV MED, V49, P409, DOI 10.1016/j.amepre.2015.02.020; Lin LWA, 2017, PAIN, V158, P833, DOI 10.1097/j.pain.0000000000000837; Lyapustina T, 2016, DRUG ALCOHOL DEPEN, V159, P190, DOI 10.1016/j.drugalcdep.2015.12.025; Martin J, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2270; MDCalc, BENZ DIAZ CONV CALC; Mills JA, 1997, J APPL EC, DOI [10.1002/(SICI)1099-1255(199703)12:2<133::AID-JAE433>3.0.CO;2-H, DOI 10.1002/(SICI)1099-1255(199703)12:2<133::AID-JAE433>3.0.CO;2-H, DOI 10.1002/(SICI)1099-1255(199703)12:2&LT;133::AID-JAE433&GT;3.0.CO;2-H]; National Academies of Sciences Engineering and Medicine, 2017, PAIN MAN OP EP BAL S, DOI [10.17226/24781, DOI 10.17226/24781]; National Center for Injury Prevention and Control, 2017, CDC COMP BENZ MUSCL; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Reed WJ, 2001, ECON LETT, V74, P15, DOI 10.1016/S0165-1765(01)00524-9; Rutkow L, 2015, JAMA INTERN MED, V175, P1642, DOI 10.1001/jamainternmed.2015.3931; Sacarny A, 2016, HEALTH AFFAIR, V35, P471, DOI 10.1377/hlthaff.2015.1025; Schieber LZ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0665; Soelberg CD, 2017, ANESTH ANALG, V125, P1675, DOI 10.1213/ANE.0000000000002403; Swedlow A, 2011, PRESCRIBING PATTERNS; Tyrer P, 2008, CAMBRIDGE TEXTBOOK OF EFFECTIVE TREATMENTS IN PSYCHIATRY, P1, DOI 10.1017/CBO9780511544392; United Nation's International Narcotics Control Board, PROGR ENS AD ACC INT, DOI [10.18356/9b973caa-en, DOI 10.18356/9B973CAA-EN]; Von Korff M, 2011, ANN INTERN MED, V155, P325, DOI 10.7326/0003-4819-155-5-201109060-00011; Zivin K, 2019, PAIN MED, V20, P103, DOI 10.1093/pm/pnx304	50	31	31	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2020	368								l6968	10.1136/bmj.l6968	http://dx.doi.org/10.1136/bmj.l6968			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KH1ET	31996352	Green Published, hybrid			2023-01-03	WOS:000510390400001
J	Yang, JW; Wang, LQ; Zou, X; Yan, SY; Wang, Y; Zhao, JJ; Tu, JF; Wang, J; Shi, GX; Hu, H; Zhou, W; Du, Y; Liu, CZ				Yang, Jing-Wen; Wang, Li-Qiong; Zou, Xuan; Yan, Shi-Yan; Wang, Yu; Zhao, Jing-Jie; Tu, Jian-Feng; Wang, Jun; Shi, Guang-Xia; Hu, Hui; Zhou, Wei; Du, Yi; Liu, Cun-Zhi			Effect of Acupuncture for Postprandial Distress Syndrome A Randomized Clinical Trial	ANNALS OF INTERNAL MEDICINE			English	Article							FUNCTIONAL DYSPEPSIA PATIENTS; QUALITY-OF-LIFE	Background: Postprandial distress syndrome (PDS) is the most common subtype of functional dyspepsia. Acupuncture is commonly used to treat PDS, but its effect is uncertain because of the poor quality of prior studies. Objective: To assess the efficacy of acupuncture versus sham acupuncture in patients with PDS. Design: Multicenter, 2-group, randomized clinical trial. (ISRCTN registry number: ISRCTN12511434) Setting: 5 tertiary hospitals in China. Participants: Chinese patients aged 18 to 65 years meeting Rome IV criteria for PDS. Intervention: 12 sessions of acupuncture or sham acupuncture over 4 weeks. Measurements: The 2 primary outcomes were the response rate based on overall treatment effect and the elimination rate of all 3 cardinal symptoms: postprandial fullness, upper abdominal bloating, and early satiation after 4 weeks of treatment. Participants were followed until week 16. Results: Among the 278 randomly assigned participants, 228 (82%) completed outcome measurements at week 16. The esti-mated response rate from generalized linear mixed models at week 4 was 83.0% in the acupuncture group versus 51.6% in the sham acupuncture group (difference, 31.4 percentage points [95% CI, 20.3 to 42.5 percentage points]; P < 0.001). The estimated elimination rate of all 3 cardinal symptoms was 27.8% in the acupuncture group versus 17.3% in the sham acupuncture group (difference, 10.5 percentage points [CI, 0.08 to 20.9 percentage points]; P = 0.034). The efficacy of acupuncture was maintained during the 12-week posttreatment follow-up. There were no serious adverse events. Limitation: Lack of objective outcomes and daily measurement, high dropout rate, and inability to blind acupuncturists. Conclusion: Among patients with PDS, acupuncture resulted in increased response rate and elimination rate of all 3 cardinal symptoms compared with sham acupuncture, with sustained efficacy over 12 weeks in patients who received thrice-weekly acupuncture for 4 weeks.	[Yang, Jing-Wen; Wang, Li-Qiong; Zou, Xuan; Shi, Guang-Xia; Liu, Cun-Zhi] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, 11 Bei San Huan Dong Lu, Beijing 100029, Peoples R China; [Yan, Shi-Yan] China Acad Chinese Med Sci, Inst Basic Res Clin Med, 16 Dongzhimen Inside South St Dongchen Dist, Beijing 100700, Peoples R China; [Wang, Yu; Tu, Jian-Feng; Liu, Cun-Zhi] Capital Med Univ, Beijing Hosp Tradit Chinese Med, 23 Meishuguanhou St, Beijing 100010, Peoples R China; [Zhao, Jing-Jie; Du, Yi] Capital Med Univ, Beijing Friendship Hosp, Rd 95 Yongan, Beijing 100069, Peoples R China; [Wang, Jun] Beijing Univ Chinese Med, Dongzhimen Hosp, Hai Yun Cang 5th, Beijing 100700, Peoples R China; [Hu, Hui] Beijing Univ Chinese Med, Dongfang Hosp, 6 Fangxingyuan 1st Block, Beijing 100078, Peoples R China; [Zhou, Wei] Beijing Univ Chinese Med, Huguosi Hosp Chinese Med, 83 Mian Hua Hu Tong, Beijing 100035, Peoples R China	Beijing University of Chinese Medicine; China Academy of Chinese Medical Sciences; Institute of Basic Research In Clinical Medicine, CACMS; Capital Medical University; Capital Medical University; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine	Liu, CZ (corresponding author), Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, 11 Bei San Huan Dong Lu, Beijing 100029, Peoples R China.	lcz623780@126.com	; Tu, Jianfeng/J-7768-2017	Wang, Yu/0000-0002-0278-0405; Tu, Jianfeng/0000-0003-2887-3383	Beijing Municipal Science and Technology Commission [Z161100000516007]	Beijing Municipal Science and Technology Commission(Beijing Municipal Science & Technology Commission)	By grant Z161100000516007 from the Beijing Municipal Science and Technology Commission.	Aziz I, 2018, LANCET GASTROENTEROL, V3, P252, DOI 10.1016/S2468-1253(18)30003-7; Corazziari E, 2003, ALIMENT PHARM THER, V18, P569, DOI 10.1046/j.1365-2036.2003.01709.x; Creed F, 2001, ANN INTERN MED, V134, P860, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00010; Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4; Enck P, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.81; Ho RST, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09856-0; Hou YQ, 2019, TRIALS, V20, DOI 10.1186/s13063-018-3051-3; Irvine EJ, 2006, GASTROENTEROLOGY, V130, P1538, DOI 10.1053/j.gastro.2005.11.058; Lackner JM, 2018, GASTROENTEROLOGY, V155, P47, DOI 10.1053/j.gastro.2018.03.063; Lahner E, 2013, UNITED EUR GASTROENT, V1, P385, DOI 10.1177/2050640613499567; Lan L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008487.pub2; Lee IS, 2016, NEUROGASTROENT MOTIL, V28, P793, DOI 10.1111/nmo.12793; Ma TT, 2012, ALIMENT PHARM THER, V35, P552, DOI 10.1111/j.1365-2036.2011.04979.x; Ma TT, 2015, FORSCH KOMPLEMENTMED, V22, P94, DOI 10.1159/000380983; MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747; Mahadeva S, 2016, NEUROGASTROENT MOTIL, V28, P167, DOI 10.1111/nmo.12657; Matsueda K, 2012, GUT, V61, P821, DOI 10.1136/gutjnl-2011-301454; Pang B, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/3862916; Stanghellini V, 2016, GASTROENTEROLOGY, V150, P1380, DOI 10.1053/j.gastro.2016.02.011; Sun JQ, 2010, J CLIN ACUPUNCTURE M, V26, P9; Suzuki H, 2017, J NEUROGASTROENTEROL, V23, P325, DOI 10.5056/jnm17018; Talley NJ, 1999, AM J GASTROENTEROL, V94, P2390; Vakil N, 2008, AM J GASTROENTEROL, V103, P1906, DOI 10.1111/j.1572-0241.2008.01953.x; Van Den Houte K, 2019, EXPERT REV GASTROENT, V13, P37, DOI 10.1080/17474124.2019.1543586; van Zanten SV, 2006, AM J GASTROENTEROL, V101, P2096, DOI 10.1111/j.1572-0241.2006.00751.x; Vanheel H, 2017, AM J GASTROENTEROL, V112, P132, DOI 10.1038/ajg.2016.499; Zeng F, 2012, AM J GASTROENTEROL, V107, P1236, DOI 10.1038/ajg.2012.53; Zheng H, 2018, NEUROGASTROENT MOTIL, V30, DOI 10.1111/nmo.13316; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	29	35	44	10	32	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 16	2020	172	12					777	+		10.7326/M19-2880	http://dx.doi.org/10.7326/M19-2880			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MI6BB	32422066				2023-01-03	WOS:000547489700012
J	Elharrar, X; Trigui, Y; Dols, AM; Touchon, F; Martinez, S; Prud'homme, E; Papazian, L				Elharrar, Xavier; Trigui, Youssef; Dols, Anne-Marie; Touchon, Francois; Martinez, Stephanie; Prud'homme, Eloi; Papazian, Laurent			Use of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Elharrar, Xavier; Trigui, Youssef; Touchon, Francois; Martinez, Stephanie] Ctr Hosp Aix En Provence, Serv Malad Resp, Ave Tamaris, F-13100 Aix En Provence, France; [Dols, Anne-Marie] Univ Grenoble Alpes, Fac Med, Grenoble, France; [Prud'homme, Eloi] Assistance Publ Hop Marseille, Med Intens Reanimat, Marseille, France; [Papazian, Laurent] Aix Marseille Univ, Ctr Etud & Rech Serv Sante & Qual Vie EA 3279, Marseille, France	Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite	Elharrar, X (corresponding author), Ctr Hosp Aix En Provence, Serv Malad Resp, Ave Tamaris, F-13100 Aix En Provence, France.	xavierelharrar@hotmail.com						Ding L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2738-5; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Munshi L, 2017, ANN AM THORAC SOC, V14, pS280, DOI 10.1513/AnnalsATS.201704-343OT; Scaravilli V, 2015, J CRIT CARE, V30, P1390, DOI 10.1016/j.jcrc.2015.07.008; Sun Q, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00650-2	6	219	235	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	2020	323	22					2336	2338		10.1001/jama.2020.8255	http://dx.doi.org/10.1001/jama.2020.8255			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA5KO	32412581	Green Published, Bronze			2023-01-03	WOS:000541952100030
J	Marini, JJ; Gattinoni, L				Marini, John J.; Gattinoni, Luciano			Management of COVID-19 Respiratory Distress	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Marini, John J.] Univ Minnesota, Reg Hosp, Minneapolis, MN USA; [Gattinoni, Luciano] Med Univ Gottingen, Dept Anesthesiol Intens Care & Emergency Med, Gottingen, Germany	University of Minnesota System; University of Minnesota Twin Cities; University of Gottingen	Marini, JJ (corresponding author), Univ Minnesota, Reg Hosp, 640 Jackson St, St Paul, MN 55101 USA.	marin002@umn.edu	Mittal, Akriti/AAD-8632-2021					Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP; Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2; Gattinoni L, 2016, INTENS CARE MED, V42, P663, DOI 10.1007/s00134-015-4200-8; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Marini JJ, 2003, CRIT CARE, V7, P435, DOI 10.1186/cc2392; Marini JJ, 2020, AM J RESP CRIT CARE, V201, P767, DOI 10.1164/rccm.201908-1545CI; Vieillard-Baron A, 2016, INTENS CARE MED, V42, P739, DOI 10.1007/s00134-016-4326-3; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	10	581	596	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	2020	323	22					2329	2330		10.1001/jama.2020.6825	http://dx.doi.org/10.1001/jama.2020.6825			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA5KO	32329799	Bronze			2023-01-03	WOS:000541952100027
J	Grabowski, DC; Maddox, KEJ				Grabowski, David C.; Joynt Maddox, Karen E.			Postacute Care Preparedness for COVID-19 Thinking Ahead	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint discusses the second surge of COVID-19 patients on postacute care facilities and offers suggestions on how the medical community and policy makers should prepare by ensuring adequate infrastructure, staff training, and protective equipment.	[Grabowski, David C.] Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA; [Joynt Maddox, Karen E.] Washington Univ, Sch Med, Dept Med, Cardiovasc Div, St Louis, MO 63110 USA; [Joynt Maddox, Karen E.] Washington Univ, Inst Publ Hlth, Ctr Hlth Econ & Policy, St Louis, MO 63110 USA	Harvard University; Harvard Medical School; Washington University (WUSTL); Washington University (WUSTL)	Grabowski, DC (corresponding author), Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	grabowski@hcp.med.harvard.edu		Grabowski, David/0000-0003-2915-5770	NHLBI NIH HHS [R01 HL143421] Funding Source: Medline; NIA NIH HHS [R01 AG054656, P01 AG032952, R01 AG060935, R01 AG060935, R56 AG062544] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Buchman TG, 2020, CRIT CARE MED, V48, P289, DOI 10.1097/CCM.0000000000004226; Centers for Medicare & Medicaid Services, 2020, MED TEL HLTH CAR PRO; Geng FL, 2019, HEALTH AFFAIR, V38, P1095, DOI 10.1377/hlthaff.2018.05322; Grabowski DC, 2014, HEALTH AFFAIR, V33, P244, DOI 10.1377/hlthaff.2013.0922; Levine DM, 2019, ANN INTERN MED; Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633; Smith M, 2020, NY TIMES	7	85	86	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2020	323	20					2007	2008		10.1001/jama.2020.4686	http://dx.doi.org/10.1001/jama.2020.4686			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU8UM	32211831	Bronze			2023-01-03	WOS:000538023900023
J	Pathirana, CK; Ranaweera, LT; Madhujith, T; Ketipearachchi, KW; Gamlath, KL; Eeswara, JP; Sooriyapathirana, SS				Pathirana, Chamila Kumari; Ranaweera, Lahiru Thilanka; Madhujith, Terrence; Ketipearachchi, Kalyani Weerasinghe; Gamlath, Kumar Lakshman; Eeswara, Janakie Prasanthika; Sooriyapathirana, Suneth Sithumini			Assessment of the elite accessions of bael [Aegle marmelos (L.) Corr.] in Sri Lanka based on morphometric, organoleptic, and elemental properties of the fruits and phylogenetic relationships	PLOS ONE			English	Article							SUBFAMILY RUTACEAE AURANTIOIDEAE; MODEL; WEIGHT; PLANTS; AGE	Aegle marmelos L. (Bael) is a native tree fruit species in the Indian subcontinent and Southeast Asia. Bael is a popular fruit because of its significant nutritional and medicinal properties. However, bael is an underutilized fruit species in Sri Lanka. Thus, Fruit Crop Research and Development Station of the Department of Agriculture of Sri Lanka has selected five elite bael accessions (Beheth Beli, Paragammana, Mawanella, Rambukkana, and Polonnaruwa-Supun). We assessed these five accessions for the variation of the fruit size, pulp, organoleptic preference, elemental properties, genetic diversity, and evolutionary history. The fruits at the golden-ripe stage were collected during the peak fruiting seasons in 2015, 2016, and 2017. The fruit size, pulp, shell thickness, and seed size were measured and subjected to the General Linear Model (GLM) and Principal Component (PC) Analyses. The fruit pulp was distributed among a group of 30 taste-panelists to rank for the parameters: external appearance, flesh color, aroma, texture, sweetness, and overall preference. The rank data were subjected to association and PC analyses. The elemental contents of the fruit pulp samples were measured using Inductively coupled plasma mass spectrometry and subjected to GLM and PC analyses. We observed a significant diversity in fruit size, organoleptic preference, and elemental contents among bael accessions. Rambukkana and Polonnaruwa-Supun yield the biggest and most preferred fruits. We used trnH-psbA, atpB-rbcL spacer, matk-trnT spacer, and trnL markers to construct phylogenies. Sri Lankan bael split from an Indian counterpart, approximately 8.52 MYA in the Pliocene epoch. However, broader germplasm of Indian bael must be assessed to see the presence of any independent evolution within Sri Lanka.	[Pathirana, Chamila Kumari; Eeswara, Janakie Prasanthika] Univ Peradeniya, Fac Agr, Dept Crop Sci, Peradeniya, Sri Lanka; [Pathirana, Chamila Kumari; Madhujith, Terrence; Eeswara, Janakie Prasanthika] Univ Peradeniya, Postgrad Inst Agr, Peradeniya, Sri Lanka; [Ranaweera, Lahiru Thilanka; Sooriyapathirana, Suneth Sithumini] Univ Peradeniya, Fac Sci, Dept Mol Biol & Biotechnol, Peradeniya, Sri Lanka; [Madhujith, Terrence] Univ Peradeniya, Fac Agr, Dept Food Sci & Technol, Peradeniya, Sri Lanka; [Ketipearachchi, Kalyani Weerasinghe; Gamlath, Kumar Lakshman] Fruit Crop Res & Dev Stn, Peradeniya, Sri Lanka	University of Peradeniya; University of Peradeniya; University of Peradeniya; University of Peradeniya	Sooriyapathirana, SS (corresponding author), Univ Peradeniya, Fac Sci, Dept Mol Biol & Biotechnol, Peradeniya, Sri Lanka.	sunethuop@gmail.com	PATHIRANA, CHAMILA/AAS-8609-2020; Madhujith, Terrence/ABA-6101-2020; Eeswara, Janakie Prasanthika/AAT-8121-2021	PATHIRANA, CHAMILA/0000-0002-6560-8442; Eeswara, Janakie Prasanthika/0000-0002-8877-331X; Sooriyapathirana, Suneth/0000-0002-5592-1742				AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Asghar N, 2016, J FOOD PROCESS PRES, V40, P770, DOI 10.1111/jfpp.12658; Baliga MS, 2011, FOOD RES INT, V44, P1768, DOI 10.1016/j.foodres.2011.02.008; Bayer RJ, 2009, AM J BOT, V96, P668, DOI 10.3732/ajb.0800341; Bertin N, 2003, ANN BOT-LONDON, V92, P415, DOI 10.1093/aob/mcg146; Cavanaugh JE, 1997, STAT PROBABIL LETT, V33, P201, DOI 10.1016/S0167-7152(96)00128-9; Crepet WL, 2004, AM J BOT, V91, P1666, DOI 10.3732/ajb.91.10.1666; Deokar TG, 2018, INT J INNOV KNOWL CO, V6, P216; Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214; Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088; Dutta A., 2014, AM J ETHNOMED, V1, P290; Fen LumTsui, 2007, Journal of Tropical Medicinal Plants, V8, P93; GREGOR HJ, 1989, PLANT SYST EVOL, V162, P251, DOI 10.1007/BF00936920; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Kamalakkannan N, 2003, J ETHNOPHARMACOL, V87, P207, DOI 10.1016/S0378-8741(03)00148-X; Kenghe R. N., 2009, Journal of Maharashtra Agricultural Universities, V34, P65; Kintzios SE, 2006, CRIT REV PLANT SCI, V25, P79, DOI 10.1080/07352680500348824; Kumar D, 2010, INDIAN J PLANT GENET, V23, P303; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]; Manickavelu A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169416; Miller M. A., 2010, GAT COMP ENV WORKSH, P1; Morton F, 1987, FRUITS WARM CLIMATES; Mukherjee PK, 2007, EXPERT OPIN DRUG DIS, V2, P633, DOI 10.1517/17460441.2.5.633; Narendhirakannan RT, 2005, BIOL TRACE ELEM RES, V103, P109, DOI 10.1385/BTER:103:2:109; Parmar C, 1982, WILD FRUITS SUB HIMA; Pfeil BE, 2008, AM J BOT, V95, P1621, DOI 10.3732/ajb.0800214; Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083; Pushpakumara DKNG, 2007, UNDERUTILIZED FRUIT, V1, P249; Raja SB, 2008, DIAGN MICR INFEC DIS, V61, P321, DOI 10.1016/j.diagmicrobio.2008.02.006; Rambaut A, 2014, TRACER V1 6 COMPUTER; Rambaut A, 2014, FIGTREE V1 4 3 SOFTW; Robson A. D., 1983, Encyclopedia of plant physiology. New Series. Volume 15A. Inorganic plant nutrition, P147; RODRIGUEZ F, 1990, J THEOR BIOL, V142, P485, DOI 10.1016/S0022-5193(05)80104-3; Rosati A, 2009, SCI HORTIC-AMSTERDAM, V122, P399, DOI 10.1016/j.scienta.2009.05.034; ROY SK, 1979, ECON BOT, V33, P203, DOI 10.1007/BF02858290; Seth MK, 2003, BOT REV, V69, P321, DOI 10.1663/0006-8101(2004)069[0321:TATEI]2.0.CO;2; Sharma K., 2016, J CHEM PHARM RES, V10, P809; Singhal VK, 2011, NEW FOREST, V42, P85, DOI 10.1007/s11056-010-9239-3; Stadler T, 2009, J THEOR BIOL, V261, P58, DOI 10.1016/j.jtbi.2009.07.018; Stamatakis A, 2008, SYST BIOL, V57, P758, DOI 10.1080/10635150802429642; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Swofford DL, 2009, PHYLOGENETIC HANDBOOK: A PRACTICAL APPROACH TO PHYLOGENETIC ANALYSIS AND HYPOTHESIS TESTING, 2ND EDITION, P267; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van de Wiel H. J., 2003, DETERMINATION ELEMEN; Wan CY, 1993, SPERMIDINE FACILITAT; Zhang GR, 2010, TREE GENET GENOMES, V6, P25, DOI 10.1007/s11295-009-0225-x	46	3	3	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2020	15	5							e0233609	10.1371/journal.pone.0233609	http://dx.doi.org/10.1371/journal.pone.0233609			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1MJ	32442219	gold, Green Published			2023-01-03	WOS:000537525900059
J	Kalloch, B; Bazin, PL; Villringer, A; Sehm, B; Hlawitschka, M				Kalloch, Benjamin; Bazin, Pierre-Louis; Villringer, Arno; Sehm, Bernhard; Hlawitschka, Mario			A flexible workflow for simulating transcranial electric stimulation in healthy and lesioned brains	PLOS ONE			English	Article							FIELD; VISUALIZATION; OPTIMIZATION; REGISTRATION; CORTEX; ROBUST; HEAD; EEG	Simulating transcranial electric stimulation is actively researched as knowledge about the distribution of the electrical field is decisive for understanding the variability in the elicited stimulation effect. Several software pipelines comprehensively solve this task in an automated manner for standard use-cases. However, simulations for non-standard applications such as uncommon electrode shapes or the creation of head models from non-optimized T1-weighted imaging data and the inclusion of irregular structures are more difficult to accomplish. We address these limitations and suggest a comprehensive workflow to simulate transcranial electric stimulation based on open-source tools. The workflow covers the head model creation from MRI data, the electrode modeling, the modeling of anisotropic conductivity behavior of the white matter, the numerical simulation and visualization. Skin, skull, air cavities, cerebrospinal fluid, white matter, and gray matter are segmented semi-automatically from T1-weighted MR images. Electrodes of arbitrary number and shape can be modeled. The meshing of the head model is implemented in a way to preserve the feature edges of the electrodes and is free of topological restrictions of the considered structures of the head model. White matter anisotropy can be computed from diffusion-tensor imaging data. Our solver application was verified analytically and by contrasting the tDCS simulation results with that of other simulation pipelines (SimNIBS 3.0, ROAST 3.0). An agreement in both cases underlines the validity of our workflow. Our suggested solutions facilitate investigations of irregular structures in patients (e.g. lesions, implants) or new electrode types. For a coupled use of the described workflow, we provide documentation and disclose the full source code of the developed tools.	[Kalloch, Benjamin; Bazin, Pierre-Louis; Villringer, Arno; Sehm, Bernhard; Hlawitschka, Mario] Max Planck Inst Human Cognit & Brain Sci, Dept Neurol, Leipzig, Saxony, Germany; [Kalloch, Benjamin; Hlawitschka, Mario] Leipzig Univ Appl Sci, Fac Comp Sci & Media, Leipzig, Saxony, Germany; [Bazin, Pierre-Louis] Univ Amsterdam, Fac Social & Behav Sci, Amsterdam, North Holland, Netherlands	Max Planck Society; University of Amsterdam	Kalloch, B (corresponding author), Max Planck Inst Human Cognit & Brain Sci, Dept Neurol, Leipzig, Saxony, Germany.; Kalloch, B (corresponding author), Leipzig Univ Appl Sci, Fac Comp Sci & Media, Leipzig, Saxony, Germany.	kalloch@cbs.mpg.de	Hlawitschka, Mario/AAU-8942-2020	Bazin, Pierre-Louis/0000-0002-0141-5510; Kalloch, Benjamin/0000-0002-9856-1230; Villringer, Arno/0000-0003-2604-2404	FAZITSTIFTUNG; International Max Planck Research School on the Neuroscience of Communication (IMPRS NeuroCom)	FAZITSTIFTUNG; International Max Planck Research School on the Neuroscience of Communication (IMPRS NeuroCom)	Benjamin Kalloch was funded by FAZITSTIFTUNG and the International Max Planck Research School on the Neuroscience of Communication (IMPRS NeuroCom).	Ackermann M, 2005, PHYS REV D, V71, DOI 10.1103/PhysRevD.71.077102; Alam M, 2016, PHYS MED BIOL, V61, P4506, DOI 10.1088/0031-9155/61/12/4506; Anderson JW, 2007, CONTEMP MATH, V432, P1; Andersson JLR, 2016, NEUROIMAGE, V125, P1063, DOI 10.1016/j.neuroimage.2015.10.019; Antonenko D, 2019, BRAIN STIMULATION; Attene M, 2010, VISUAL COMPUT, V26, P1393, DOI 10.1007/s00371-010-0416-3; Ayachit U., 2007, THE PARAVIEW GUIDE; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Ben Naceur M, 2018, COMPUT METH PROG BIO, V166, P39, DOI 10.1016/j.cmpb.2018.09.007; Bikson M, 2015, PROG BRAIN RES, V222, P1, DOI 10.1016/bs.pbr.2015.08.005; Bogovic JA, 2013, COMPUT VIS IMAGE UND, V117, P145, DOI 10.1016/j.cviu.2012.10.006; Cignoni P., 2008, 6 EUR IT CHAPT C 200, DOI 10.2312/LocalChapterEvents/ItalChap/ItalianChapConf2008/129-136; Dannhauer M, 2017, BRAIN STIMUL, V10, pe12; Datta A, 2011, BRAIN STIMUL, V4, P169, DOI 10.1016/j.brs.2010.11.001; Dhollander T. R., 2016, P ISMRM WORKSH BREAK; Geuzaine C, 2009, INT J NUMER METH ENG, V79, P1309, DOI 10.1002/nme.2579; Guerrero R, 2018, NEUROIMAGE-CLIN, V17, P918, DOI 10.1016/j.nicl.2017.12.022; Han X, 2004, NEUROIMAGE, V23, P997, DOI 10.1016/j.neuroimage.2004.06.043; Htet AT, 2019, J NEURAL ENG, V16, DOI 10.1088/1741-2552/aafbb9; Huang Y, 2019, J NEURAL ENG, V16, DOI 10.1088/1741-2552/ab208d; Huang Y, 2017, ELIFE, V6, DOI 10.7554/eLife.18834; Huang Y, 2012, IEEE ENG MED BIO, P5376, DOI 10.1109/EMBC.2012.6347209; Huntenburg JM, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy082; Indahlastari A, 2016, J NEURAL ENG, V13, DOI 10.1088/1741-2560/13/6/066006; Jasak H., 1996, ERROR ANAL ESTIMATIO; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Kalloch B, 2018, MAGNETIC RESONANCE M; Kamnitsas K, 2017, MED IMAGE ANAL, V36, P61, DOI 10.1016/j.media.2016.10.004; Kasinadhuni AK, 2017, BRAIN STIMUL, V10, P764, DOI 10.1016/j.brs.2017.04.125; Kim JH, 2014, NEUROSCI LETT, V564, P6, DOI 10.1016/j.neulet.2014.01.054; Laakso I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37226-x; Lampe L, 2019, J CEREBR BLOOD F MET, V39, P36, DOI 10.1177/0271678X17740501; Lee C, 2017, J NEUROSCI METH, V277, P56, DOI 10.1016/j.jneumeth.2016.12.008; Loeffler M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1983-z; Lorensen C.H.E., 1987, ACM SIGGRAPH COMPUTE, V21, DOI 10.1145/37401.37422; Lucas BC, 2010, NEUROINFORMATICS, V8, P5, DOI 10.1007/s12021-009-9061-2; McAuliffe MJ, 2001, COMP MED SY, P381; McCann H, 2019, BRAIN TOPOGR, V32, P825, DOI 10.1007/s10548-019-00710-2; Minjoli S, 2017, NEUROIMAGE-CLIN, V15, P106, DOI 10.1016/j.nicl.2017.04.014; Nielsen JD, 2018, NEUROIMAGE, V174, P587, DOI 10.1016/j.neuroimage.2018.03.001; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Opitz A, 2016, SCI REP-UK, V6, DOI 10.1038/srep31236; Pion S., 2009, P 17 ACM SIGSPATIAL, P538, DOI [DOI 10.1145/1653771.1653865, 10.1145/1653771.1653865]; Quarteroni A., 2010, NUMERICAL MATH, V37; Riedel P, 2015, CORTEX, V68, P86, DOI 10.1016/j.cortex.2014.11.016; Rorden C, 2012, NEUROIMAGE, V61, P957, DOI 10.1016/j.neuroimage.2012.03.020; Ruffini G, 2013, IEEE T NEUR SYS REH, V21, P333, DOI 10.1109/TNSRE.2012.2200046; RUSH S, 1968, ANESTH ANAL CURR RES, V47, P717; RUSH S, 1969, IEEE T BIO-MED ENG, VBM16, P15, DOI 10.1109/TBME.1969.4502598; Sehm B, 2013, J NEUROSCI METH, V212, P234, DOI 10.1016/j.jneumeth.2012.10.006; SHAVADIA JS, 2019, BRAIN STIMUL, V12, DOI DOI 10.1161/CIRCOUTCOMES.118.005103; Shiee N, 2010, NEUROIMAGE, V49, P1524, DOI 10.1016/j.neuroimage.2009.09.005; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Taubin G., 1995, Computer Graphics Proceedings. SIGGRAPH 95, P351, DOI 10.1145/218380.218473; Thielscher A, 2015, IEEE ENG MED BIO, P222, DOI 10.1109/EMBC.2015.7318340; Tournier JD, 2012, INT J IMAG SYST TECH, V22, P53, DOI 10.1002/ima.22005; Veraart J, 2016, NEUROIMAGE, V142, P384, DOI 10.1016/j.neuroimage.2016.08.016; Veraart J, 2016, MAGN RESON MED, V76, P1582, DOI 10.1002/mrm.26059; Veraart J, 2013, NEUROIMAGE, V81, P335, DOI 10.1016/j.neuroimage.2013.05.028; Wagner S, 2016, NEUROIMAGE, V140, P163, DOI 10.1016/j.neuroimage.2016.04.005; Wang H, 2019, NEUROSCI LETT, V694, P46, DOI 10.1016/j.neulet.2018.10.041; Westin C.F., 1997, GEOMETRICAL DIFFUSIO, P1742; Wolters, 2013, INT C BAS CLIN MULT; Wolters CH, 2006, NEUROIMAGE, V30, P813, DOI 10.1016/j.neuroimage.2005.10.014	66	4	4	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2020	15	5							e0228119	10.1371/journal.pone.0228119	http://dx.doi.org/10.1371/journal.pone.0228119			36	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU0YZ	32407389	Green Published, Green Submitted, gold			2023-01-03	WOS:000537490700003
J	Margolis, DM; Archin, NM; Cohen, MS; Eron, JJ; Ferrari, G; Garcia, V; Gay, CL; Goonetilleke, N; Joseph, SB; Swanstrom, R; Turner, AMW; Wahl, A				Margolis, David M.; Archin, Nancie M.; Cohen, Myron S.; Eron, Joseph J.; Ferrari, Guido; Garcia, Victor; Gay, Cynthia L.; Goonetilleke, Nilu; Joseph, Sarah B.; Swanstrom, Ronald; Turner, Anne-Marie W.; Wahl, Angela			Curing HIV: Seeking to Target and Clear Persistent Infection	CELL			English	Review							CD4(+) T-CELLS; REPLICATION-COMPETENT HIV-1; ANTIRETROVIRAL THERAPY; LATENT RESERVOIR; TISSUE RESERVOIRS; VIRUS; VIREMIA; VIVO; INDIVIDUALS; RESPONSES	y Human immunodeficiency virus type 1 (HIV-1) infection persists despite years of antiretroviral therapy (ART). To remove the stigma and burden of chronic infection, approaches to eradicate or cure HIV infection are desired. Attempts to augment ART with therapies that reverse viral latency, paired with immunotherapies to clear infection, have advanced into the clinic, but the field is still in its infancy. We review foundational studies and highlight new insights in HIV cure research. Together with advances in ART delivery and HIV prevention strategies, future therapies that clear HIV infection may relieve society of the affliction of the HIV pandemic.	[Margolis, David M.; Archin, Nancie M.; Eron, Joseph J.; Gay, Cynthia L.; Goonetilleke, Nilu; Joseph, Sarah B.; Turner, Anne-Marie W.] Univ N Carolina, Sch Med, UNC HIV Cure Ctr, Chapel Hill, NC 27599 USA; [Margolis, David M.; Archin, Nancie M.; Cohen, Myron S.; Eron, Joseph J.; Gay, Cynthia L.; Turner, Anne-Marie W.] Univ N Carolina, Sch Med, Dept Med, Div Infect Dis, Chapel Hill, NC 27599 USA; [Margolis, David M.; Goonetilleke, Nilu; Joseph, Sarah B.] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Margolis, David M.] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Cohen, Myron S.] Univ N Carolina, Inst Global Hlth & Infect Dis, Chapel Hill, NC 27599 USA; [Ferrari, Guido] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Ferrari, Guido] Duke Univ, Med Ctr, Duke Human Vaccine Inst, Durham, NC 27710 USA; [Garcia, Victor; Wahl, Angela] Univ N Carolina, Sch Med, Int Ctr Adv Translat Sci, Div Infect Dis,Dept Med, Chapel Hill, NC 27599 USA; [Garcia, Victor; Joseph, Sarah B.; Swanstrom, Ronald; Wahl, Angela] Univ N Carolina, Sch Med, Ctr AIDS Res, Chapel Hill, NC 27599 USA; [Joseph, Sarah B.; Swanstrom, Ronald] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Swanstrom, Ronald] Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Margolis, DM (corresponding author), Univ N Carolina, Sch Med, UNC HIV Cure Ctr, Chapel Hill, NC 27599 USA.; Margolis, DM (corresponding author), Univ N Carolina, Sch Med, Dept Med, Div Infect Dis, Chapel Hill, NC 27599 USA.; Margolis, DM (corresponding author), Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.; Margolis, DM (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA.	dmargo@med.unc.edu	Ferrari, Guido/Z-2137-2019	Gay, Cynthia/0000-0002-3620-3059; Margolis, David/0000-0001-5714-0002; Turner, Anne-Marie/0000-0002-7312-4616	National Institutes of Health [UM1-AI126619, UL1TR002489, AI064518, AI50410]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are grateful to Luisa Ferrari for editorial support and especially for the dedication of the people living with HIV (PLWH) who participate in research towards an HIV cure. This study was supported by National Institutes of Health grants UM1-AI126619 (to D.M.M.), UL1TR002489 (to the UNC TRaCS Institute), AI064518 (to G.F.), and AI50410 (to the UNC Center for AIDS Research).	Abrahams MR, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw5589; Abreu CM, 2019, MBIO, V10, DOI 10.1128/mBio.01659-19; Anderson JL, 2020, J INFECT DIS, V221, P744, DOI 10.1093/infdis/jiz509; Archin NM, 2012, NATURE, V487, P482, DOI 10.1038/nature11286; Archin NM, 2017, J CLIN INVEST, V127, P3126, DOI [10.1172/JCI92684, 10.1172/jci92684]; Avalos CR, 2017, MBIO, V8, DOI 10.1128/mBio.01186-17; Badamchi-Zadeh A., 2018, J VIROL; Bailey JR, 2006, J VIROL, V80, P6441, DOI 10.1128/JVI.00591-06; Bale MJ, 2019, CURR OPIN HIV AIDS, V14, P188, DOI 10.1097/COH.0000000000000535; Banga R, 2016, NAT MED, V22, P754, DOI 10.1038/nm.4113; Bar KJ, 2016, NEW ENGL J MED, V375, P2037, DOI 10.1056/NEJMoa1608243; Boehm D, 2017, AIDS RES HUM RETROV, V33, pS8, DOI 10.1089/aid.2017.0180; Boehm D, 2013, VIRUSES-BASEL, V5, P1571, DOI 10.3390/v5061571; Borducchi EN, 2018, NATURE, V563, P360, DOI 10.1038/s41586-018-0600-6; Bradley T, 2018, CELL REP, V25, P107, DOI 10.1016/j.celrep.2018.09.020; Brodin J, 2016, ELIFE, V5, DOI 10.7554/eLife.18889; Bronnimann MP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00020; Bruner KM, 2019, NATURE, V566, P120, DOI 10.1038/s41586-019-0898-8; Bruner KM, 2016, NAT MED, V22, P1043, DOI 10.1038/nm.4156; Bui JK, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006283; Buzon MJ, 2014, NAT MED, V20, P139, DOI 10.1038/nm.3445; Cabrera C, 2015, CLIN CHEM, V61, P1372, DOI 10.1373/clinchem.2015.243287; Caskey M, 2017, NAT MED, V23, P185, DOI 10.1038/nm.4268; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Chapuis AG, 2011, BLOOD, V117, P5391, DOI 10.1182/blood-2010-11-320226; Cheng L, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94366; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Clutton GT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01452; Conrad RJ, 2017, MOL CELL, V67, P1001, DOI 10.1016/j.molcel.2017.07.025; Crooks AM, 2015, J INFECT DIS, V212, P1361, DOI 10.1093/infdis/jiv218; Dash PK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10366-y; Del Prete GQ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127717; Deng K, 2015, NATURE, V517, P381, DOI 10.1038/nature14053; Denton PW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003872; Denton PW, 2012, J VIROL, V86, P630, DOI 10.1128/JVI.06120-11; Denton PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008829; Denton PW, 2008, PLOS MED, V5, P79, DOI 10.1371/journal.pmed.0050016; Eisinger RW, 2018, EMERG INFECT DIS, V24, P413, DOI 10.3201/eid2403.171797; Estes JD, 2017, NAT MED, V23, P1271, DOI 10.1038/nm.4411; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Ferrari G, 2016, NAT REV DRUG DISCOV, V15, P823, DOI 10.1038/nrd.2016.173; Fidler S, 2020, LANCET, V395, P888, DOI 10.1016/S0140-6736(19)32990-3; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fisher L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02741; Fromentin R, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005761; Ganor Y, 2019, NAT MICROBIOL, V4, P633, DOI 10.1038/s41564-018-0335-z; Garcia JV, 2016, J CLIN INVEST, V126, P424, DOI 10.1172/JCI80562; Garrido C, 2018, J VIROL, V92, DOI 10.1128/JVI.00235-18; Gay CL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61878-3; Gay CL, 2017, J INFECT DIS, V215, P1725, DOI 10.1093/infdis/jix191; Goonetilleke N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01966; Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365; Gosselin A, 2017, AIDS, V31, P35, DOI 10.1097/QAD.0000000000001309; Gulick RM, 2019, ANNU REV MED, V70, P137, DOI 10.1146/annurev-med-041217-013717; Gutierrez C, 2016, AIDS, V30, P1385, DOI 10.1097/QAD.0000000000001064; Hamer DH, 2004, CURR HIV RES, V2, P99, DOI 10.2174/1570162043484915; Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003; Haynes BF, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaz2686; Henrich TJ, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002417; Hiener B, 2017, CELL REP, V21, P813, DOI 10.1016/j.celrep.2017.09.081; Ho YC, 2013, CELL, V155, P540, DOI 10.1016/j.cell.2013.09.020; Honeycutt JB, 2017, NAT MED, V23, P638, DOI 10.1038/nm.4319; Hosmane NN, 2017, J EXP MED, V214, P959, DOI 10.1084/jem.20170193; Houzet L, 2014, J INFECT DIS, V210, pS622, DOI 10.1093/infdis/jiu328; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang G, 2019, JCI INSIGHT, V4; Jiang GC, 2018, J CLIN INVEST, V128, P1190, DOI 10.1172/JCI98071; Jiang GC, 2015, AIDS RES HUM RETROV, V31, P4, DOI [10.1089/AID.2014.0199, 10.1089/aid.2014.0199]; Joseph SB, 2018, J LEUKOCYTE BIOL, V103, P421, DOI 10.1002/JLB.2RI0517-200R; JOSEPH SB, 2019, AIDS S2, V33, pS17, DOI DOI 10.1097/QAD.0000000000002253; Katlama C, 2016, AIDS, V30, P221, DOI 10.1097/QAD.0000000000000894; Kim JH, 2015, ANNU REV MED, V66, P423, DOI 10.1146/annurev-med-052912-123749; Lam S, 2013, IMMUNOTHERAPY-UK, V5, P407, DOI [10.2217/IMT.13.23, 10.2217/imt.13.23]; Lamers SL, 2016, J VIROL, V90, P8968, DOI 10.1128/JVI.00674-16; Lehrman G, 2004, JAIDS-J ACQ IMM DEF, V36, P1103, DOI 10.1097/00126334-200408150-00015; Leth S, 2016, LANCET HIV, V3, pE463, DOI 10.1016/S2352-3018(16)30055-8; Lim SY, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4521; Luzuriaga K, 2015, NEW ENGL J MED, V372, P786, DOI 10.1056/NEJMc1413931; Lynch RM, 2015, SCI TRANSL MED, V7; Macedo AB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02450; Maldarelli F, 2014, SCIENCE, V345, P179, DOI 10.1126/science.1254194; Marsden MD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006575; Mbonye U, 2014, VIROLOGY, V454, P328, DOI 10.1016/j.virol.2014.02.008; McBrien JB, 2020, NATURE, V578, P154, DOI 10.1038/s41586-020-1946-0; MEIER UC, 1995, SCIENCE, V270, P1360, DOI 10.1126/science.270.5240.1360; Melkus MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Moog C, 2014, MUCOSAL IMMUNOL, V7, P46, DOI 10.1038/mi.2013.23; Nixon CC, 2020, NATURE, V578, P160, DOI 10.1038/s41586-020-1951-3; Pache L, 2015, CELL HOST MICROBE, V18, P345, DOI 10.1016/j.chom.2015.08.009; Pallikkuth S, 2016, J VIROL, V90, P2718, DOI 10.1128/JVI.02883-15; Pankau MD, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008286; Pardons M, 2019, CELL REP, V29, P2783, DOI 10.1016/j.celrep.2019.10.101; Pegu A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9447; Peterson CW, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006956; Pollara J, 2013, CURR HIV RES, V11, P378, DOI 10.2174/1570162X113116660059; Prins JM, 1999, AIDS, V13, P2405, DOI 10.1097/00002030-199912030-00012; Rasmussen TA, 2014, LANCET HIV, V1, pE13, DOI 10.1016/S2352-3018(14)70014-1; Rasmussen TA, 2018, ADV EXP MED BIOL, V1075, P285, DOI 10.1007/978-981-13-0484-2_12; Razooky BS, 2015, CELL, V160, P990, DOI 10.1016/j.cell.2015.02.009; Rhode PR, 2016, CANCER IMMUNOL RES, V4, P49, DOI 10.1158/2326-6066.CIR-15-0093-T; Riddler SA, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy242; Robinson HL, 2018, CLIN PHARMACOL THER, V104, P1062, DOI 10.1002/cpt.1208; Ruelas DS, 2013, CELL, V155, P519, DOI 10.1016/j.cell.2013.09.044; Sampey GC, 2018, SMAC MIMETIC AZD5582, P312447, DOI [10.1101/312447, DOI 10.1101/312447]; Santra S, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005042; Scheid JF, 2016, NATURE, V535, P556, DOI 10.1038/nature18929; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Simonetti FR, 2016, P NATL ACAD SCI USA, V113, P1883, DOI 10.1073/pnas.1522675113; Sneller MC, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax3447; Sneller MC, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan8848; Sogaard OS, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005142; Soriano-Sarabia N, 2014, J VIROL, V88, P14070, DOI 10.1128/JVI.01900-14; Stacey AR, 2009, J VIROL, V83, P3719, DOI 10.1128/JVI.01844-08; Sun ZF, 2007, J EXP MED, V204, P705, DOI 10.1084/jem.20062411; Sung JA, 2018, MOL THER, V26, P2496, DOI 10.1016/j.ymthe.2018.08.015; Sung JA, 2015, J INFECT DIS, V212, P258, DOI 10.1093/infdis/jiv022; Sung JAM, 2015, J CLIN INVEST, V125, P4077, DOI 10.1172/JCI82314; Tebas P, 2014, NEW ENGL J MED, V370, P901, DOI 10.1056/NEJMoa1300662; Thaysen-Andersen M, 2016, GLYCOCONJUGATE J, V33, P417, DOI 10.1007/s10719-015-9627-1; Tobin NH, 2005, J VIROL, V79, P9625, DOI 10.1128/JVI.79.15.9625-9634.2005; Tran TA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003305; Nguyen TV, 2017, IEEE INT ENTERP, P8, DOI 10.1109/EDOCW.2017.11; Turner AMW, 2017, YALE J BIOL MED, V90, P229; Van Praag RME, 2001, J CLIN IMMUNOL, V21, P218, DOI 10.1023/A:1011091300321; Varela-Rohena A, 2008, NAT MED, V14, P1390, DOI 10.1038/nm.1779; Vibholm LK, 2019, AIDS, V33, P1315, DOI 10.1097/QAD.0000000000002213; Wagner TA, 2014, SCIENCE, V345, P570, DOI 10.1126/science.1256304; Wahl A, 2019, NAT BIOTECHNOL, V37, P1163, DOI 10.1038/s41587-019-0225-9; Wahl A, 2015, J VIROL, V89, P10868, DOI 10.1128/JVI.01702-15; Wahl A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002732; Wang FX, 2005, J CLIN INVEST, V115, P128, DOI 10.1172/JCI200522574; Warren JA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00291; Watson DC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006902; Webb GM, 2018, BLOOD ADV, V2, P76, DOI 10.1182/bloodadvances.2017012971; Whitney JB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07881-9; Wightman F, 2015, AIDS, V29, P504, DOI 10.1097/QAD.0000000000000562; Williams SA, 2004, J BIOL CHEM, V279, P42008, DOI 10.1074/jbc.M402124200; Winckelmann A, 2017, AIDS, V31, P771, DOI 10.1097/QAD.0000000000001400; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Wong JK, 2016, CURR OPIN HIV AIDS, V11, P362, DOI 10.1097/COH.0000000000000293; Xu YY, 2019, MOL THER-METH CLIN D, V15, P9, DOI 10.1016/j.omtm.2019.07.008; Yukl SA, 2013, J INFECT DIS, V208, P1212, DOI 10.1093/infdis/jit308; Zerbato JM, 2019, CLIN INFECT DIS, V69, P1919, DOI 10.1093/cid/ciz108; Zhen A, 2017, J CLIN INVEST, V127, P260, DOI 10.1172/JCI89488; Zhen AJ, 2015, MOL THER, V23, P1358, DOI 10.1038/mt.2015.102	149	61	63	6	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2020	181	1					189	206		10.1016/j.cell.2020.03.005	http://dx.doi.org/10.1016/j.cell.2020.03.005			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KZ5RI	32220311	Green Accepted, Green Published, Bronze			2023-01-03	WOS:000523319000021
J	Eisenberg, MJ; Habib, B; Alcaraz, M; Thombs, BD; Filion, KB				Eisenberg, Mark J.; Habib, Bettina; Alcaraz, Maria; Thombs, Brett D.; Filion, Kristian B.			Bright light therapy for depressive symptoms in hospitalized cardiac patients: A randomized controlled pilot trial	PLOS ONE			English	Article							SEASONAL AFFECTIVE-DISORDER; ARTERY-BYPASS-SURGERY; DOUBLE-BLIND; OUTCOMES; METAANALYSIS; MORTALITY; EFFICACY; ANXIETY; CARE	Depression is common among cardiac patients and associated with adverse cardiovascular outcomes. Bright light therapy has emerged as a promising treatment for depressive symptoms, however it has not yet been investigated in this population. We conducted a double-blind, randomized, placebo-controlled pilot trial to assess the feasibility of a larger-scale trial testing bright light therapy for depressive symptoms in cardiac patients. Patients hospitalized for an acute coronary syndrome or undergoing cardiac surgery were randomized to either bright light (10,000 lux) or dim light placebo (500 lux) lamps for 30 minutes each day over 4 weeks, beginning in-hospital. Depression was quantified using the Patient Health Questionnaire 9 (PHQ-9) and Depression Anxiety and Stress Scales (DASS-21). The Short-Form Health Survey 36 (SF-36) was used to measure quality of life. A total of 175 patients were screened and 15 were randomized (8 treatment, 7 placebo) (8.6%) over 10 months. Despite protocol amendments which broadened the inclusion criteria, the trial was terminated early for infeasibility based on the rate of enrollment (1-2 participants/month), with 39.5% of the target sample (38 participants) enrolled. Future trials should take into account the timing of the onset of depressive symptoms in these patients, and consider a less conservative approach to eligibility as well as ways to increase the acceptability of bright light therapy in hospitalized cardiac patients. Once enrolled, our findings suggest that most participants will adhere to the assigned treatment and complete follow-up.	[Eisenberg, Mark J.; Habib, Bettina; Alcaraz, Maria; Thombs, Brett D.; Filion, Kristian B.] Jewish Gen Hosp, Ctr Clin Epidemiol, Lady Davis Inst, Montreal, PQ, Canada; [Eisenberg, Mark J.; Thombs, Brett D.; Filion, Kristian B.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Eisenberg, Mark J.; Thombs, Brett D.; Filion, Kristian B.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Eisenberg, Mark J.] McGill Univ, Div Cardiol, Jewish Gen Hosp, Montreal, PQ, Canada; [Thombs, Brett D.] McGill Univ, Dept Psychiat, Montreal, PQ, Canada; [Thombs, Brett D.] McGill Univ, Dept Psychol, Montreal, PQ, Canada; [Thombs, Brett D.] McGill Univ, Dept Educ & Counselling Psychol, Montreal, PQ, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University	Eisenberg, MJ (corresponding author), Jewish Gen Hosp, Ctr Clin Epidemiol, Lady Davis Inst, Montreal, PQ, Canada.; Eisenberg, MJ (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.; Eisenberg, MJ (corresponding author), McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.; Eisenberg, MJ (corresponding author), McGill Univ, Div Cardiol, Jewish Gen Hosp, Montreal, PQ, Canada.	mark.eisenberg@ladydavis.ca			Lady Davis Institute Clinical Research Pilot Project (CliPP) in 2015; McGill University	Lady Davis Institute Clinical Research Pilot Project (CliPP) in 2015; McGill University	BEAM-P received funding from the Lady Davis Institute Clinical Research Pilot Project (CliPP) in 2015. Lamps were donated by Northern Light Inc., Montreal, Quebec (https://northernlighttechnologies.ca/).KBF holds a salary support award from the Fonds de recherche du Quebec -sante (FRQS; Quebec Foundation for Health Research) and a William Dawson Scholar award from McGill University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Karawi D, 2016, J AFFECT DISORDERS, V198, P64, DOI 10.1016/j.jad.2016.03.016; Blumenthal JA, 2003, LANCET, V362, P604, DOI 10.1016/S0140-6736(03)14190-6; Bullough J, 2000, BLUE LIGHT HAZARD RE; Connerney I, 2001, LANCET, V358, P1766, DOI 10.1016/S0140-6736(01)06803-9; Connerney I, 2010, PSYCHOSOM MED, V72, P874, DOI 10.1097/PSY.0b013e3181f65fc1; Cowan MJ, 2008, PSYCHOTHER PSYCHOSOM, V77, P27, DOI 10.1159/000110057; GALLIN PF, 1995, AM J OPHTHALMOL, V119, P202, DOI 10.1016/S0002-9394(14)73874-7; Golden RN, 2005, AM J PSYCHIAT, V162, P656, DOI 10.1176/appi.ajp.162.4.656; Huffman Jeff C, 2013, Cardiovasc Psychiatry Neurol, V2013, P695925, DOI 10.1155/2013/695925; Jiang W, 2008, AM HEART J, V156, P437, DOI 10.1016/j.ahj.2008.05.003; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lichtman JH, 2008, CIRCULATION, V118, P1768, DOI 10.1161/CIRCULATIONAHA.108.190769; Lovibond S.H., 1995, MANUAL DEPRESSION AN, V2; Pignay-Demaria V, 2003, ANN THORAC SURG, V75, P314, DOI 10.1016/S0003-4975(02)04391-6; Privitera MR, 2010, J PSYCHIATR PRACT, V16, P387, DOI 10.1097/01.pra.0000390757.19828.e0; Ravven S, 2013, HARVARD REV PSYCHIAT, V21, P59, DOI 10.1097/HRP.0b013e31828a3612; REME CE, 1992, AM J PSYCHIAT, V149, P1762; Spezzano MA, 2007, THESIS, V67, P5423; Stafford L, 2007, J PSYCHOSOM RES, V62, P401, DOI 10.1016/j.jpsychores.2006.12.009; Swedo SE, 1997, J AM ACAD CHILD PSY, V36, P816, DOI 10.1097/00004583-199706000-00019; Thombs BD, 2006, J GEN INTERN MED, V21, P30, DOI 10.1111/j.1525-1497.2005.00269.x; Thombs BD, 2008, JAMA-J AM MED ASSOC, V300, P2161, DOI 10.1001/jama.2008.667; Tsai YF, 2004, INT J GERIATR PSYCH, V19, P545, DOI 10.1002/gps.1125; Tseng PT, 2016, EUR NEUROPSYCHOPHARM, V26, P1037, DOI 10.1016/j.euroneuro.2016.03.001; Tully PJ, 2012, J GERIATR CARDIOL, V9, P197, DOI 10.3724/SP.J.1263.2011.12221; Tuunainen A, 2004, Cochrane Database Syst Rev, pCD004050, DOI 10.1002/14651858.CD004050.pub2; Wirz-Justice A, 2011, J CLIN PSYCHIAT, V72, P986, DOI 10.4088/JCP.10m06188blu	27	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2020	15	3							e0230839	10.1371/journal.pone.0230839	http://dx.doi.org/10.1371/journal.pone.0230839			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR8HE	32226019	Green Published, gold			2023-01-03	WOS:000535936400020
J	Bullock, JL				Bullock, Justin L.			Suicide - Rewriting My Story	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								As an intern with a mental illness, I approached the starting line knowing that at some point my vulnerabilities would be exposed and that hitting the wall was inevitable. I didn't know when, but if my history of mental illness was any indicator, my crash would be bad.	[Bullock, Justin L.] Univ Calif San Francisco, Sch Med, Dept Internal Med, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	Bullock, JL (corresponding author), Univ Calif San Francisco, Sch Med, Dept Internal Med, San Francisco, CA 94115 USA.		Bullock, Justin/AAJ-6017-2021	Bullock, Justin/0000-0003-4240-9798					0	2	2	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 26	2020	382	13					1196	1197		10.1056/NEJMp1917203	http://dx.doi.org/10.1056/NEJMp1917203			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KY1UO	32212517				2023-01-03	WOS:000522357300006
J	Sievert, A				Sievert, Alex			Against Medical Advice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Sievert, Alex] Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Oregon Health & Science University	Sievert, A (corresponding author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 12	2020	382	11					985	987		10.1056/NEJMp1914671	http://dx.doi.org/10.1056/NEJMp1914671			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KU7TA	32160660				2023-01-03	WOS:000519914300004
J	Gil, S; Solano, E; Martinez-Trucharte, F; Martinez-Esain, J; Perez-Bern, AJ; Conesa, JJ; Kamma-Lorger, C; Alsina, M; Sabes, M				Gil, Silvia; Solano, Eduardo; Martinez-Trucharte, Francesc; Martinez-Esain, Jordi; Perez-Bern, Ana J.; Javier Conesa, Jose; Kamma-Lorger, Christina; Alsina, Merce; Sabes, Manel			Multiparametric analysis of the effectiveness of cisplatin on cutaneous squamous carcinoma cells using two different types of adjuvants	PLOS ONE			English	Article							VISUALIZATION; RECOGNITION; TOMOGRAPHY; TRICINE; COMPLEX; DEATH	The objective of this study was to regulate the cytotoxicity of cisplatin (cisPt) minimizing its adverse effects. For this purpose, the lowest cisPt concentration needed to obtain a significant positive response in cutaneous squamous cell carcinoma (cSCC) was explored. Two adjuvant agents as gold nanoparticles (AuNP) and chelating tricine were tested as enhancers in cisPt treatment. Effectiveness of all treatments was assessed by means of biochemical techniques, which offer quantitative data, as well as two microscopy-based techniques that provided qualitative cell imaging. The present work confirms the effectiveness of free cisplatin at very low concentrations. In order to enhance its effectiveness while the side effects were probably diminished, cisPt 3.5 mu M was administered with AuNP 2.5 mM, showing an effectiveness practically equal to that observed with free cisPt. However, the second treatment investigated, based on cisPt 3.5 mu M combined with tricine 50 mM, enhanced drug effectiveness, increasing the percentage of cells dying by apoptosis. This treatment was even better in terms of cell damage than free cisPt at 15 mu M. Images obtained by TEM and cryo-SXT confirmed these results, since a notable number of apoptotic bodies were detected when cisPt was combined with tricine. Thus, tricine was clearly a better adjuvant for cisPt treatments.	[Gil, Silvia; Alsina, Merce] Hosp Clin Barcelona, Barcelona, Spain; [Gil, Silvia; Martinez-Trucharte, Francesc] Hosp Parc Tauli, Barcelona, Spain; [Solano, Eduardo; Perez-Bern, Ana J.; Javier Conesa, Jose; Sabes, Manel] ALBA Synchrotron Light Source, Barcelona, Spain; [Martinez-Esain, Jordi] Univ Autonoma Barcelona, Dept Quim, Bellaterra, Spain; [Kamma-Lorger, Christina] Australian Nucl Sci & Technol Org, Australian Synchrotron, Clayton, Vic, Australia; [Sabes, Manel] Univ Autonoma Barcelona, Fac Med, Unitat Biofis, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Autonomous University of Barcelona; Australian Nuclear Science & Technology Organisation; Autonomous University of Barcelona; University of Barcelona	Gil, S (corresponding author), Hosp Clin Barcelona, Barcelona, Spain.; Gil, S (corresponding author), Hosp Parc Tauli, Barcelona, Spain.	sgil@tauli.cat	Solano, Eduardo/M-6655-2015; Gil, Silvia/AAB-4008-2020	Solano, Eduardo/0000-0002-2348-2271; Gil, Silvia/0000-0002-2599-3016; Perez-Berna, Ana/0000-0003-4145-532X	Asociacion Espanola Contra el Cancer (Federacio de Barcelona); Institut d'Investigacio i Innovacio Parc Tauli (I3PT); synchrotron ALBA	Asociacion Espanola Contra el Cancer (Federacio de Barcelona); Institut d'Investigacio i Innovacio Parc Tauli (I3PT); synchrotron ALBA	1) S.G., M.A., M.S. received the funding of the Asociacion Espanola Contra el Cancer (Federacio de Barcelona), and the Institut d'Investigacio i Innovacio Parc Tauli (I3PT). https://www.aecc.es/es/sobre-nosotros/donde-estamos/sede-barcelona http://www.tauli.cat/i3pt/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 2) S.G., E.S., F.M.-T., J.M.-E., A.J. P.-B., J.J.C., C.K.-L., M.A., M.S. received the funding of synchrotron ALBA to perform part of this work in the Mistral beamline of this light source. Members of the Mistral beamline at ALBA synchrotron helped in the data collection and analysis, as well as in the preparation of the manuscript.	Agulleiro JI, 2011, BIOINFORMATICS, V27, P582, DOI 10.1093/bioinformatics/btq692; Carrascosa JL, 2009, J STRUCT BIOL, V168, P234, DOI 10.1016/j.jsb.2009.07.009; Comenge J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047562; Comenge J, 2010, J CONTROL RELEASE, V148, pE31, DOI 10.1016/j.jconrel.2010.07.041; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; Fernandez JJ, 2003, J STRUCT BIOL, V144, P152, DOI 10.1016/j.jsb.2003.09.010; Gil S, 2016, DERMATOL THER, V29, P341, DOI 10.1111/dth.12373; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; Hartmann JT, 2003, EXPERT OPIN PHARMACO, V4, P889, DOI 10.1517/eoph.4.6.889.22200; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Perez-Berna AJ, 2016, ACS NANO, V10, P6597, DOI 10.1021/acsnano.6b01374; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Keminer O, 1999, BIOPHYS J, V77, P217, DOI 10.1016/S0006-3495(99)76883-9; Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013; LARSEN SK, 1995, BIOCONJUGATE CHEM, V6, P635, DOI 10.1021/bc00035a020; Lenaz G, 2004, METHOD ENZYMOL, V382, P3; Liang ZD, 2012, MOL CANCER THER, V11, P2483, DOI 10.1158/1535-7163.MCT-12-0580; Neumaier F, 2017, ACTA PHYSL; Pandey A, 2019, AM J CASE REP, V20, P294, DOI 10.12659/AJCR.913488; Pereiro E, 2009, J SYNCHROTRON RADIAT, P16505; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rodriguez-Carino C, 2011, J COMP PATHOL, V144, P91, DOI 10.1016/j.jcpa.2010.07.001; Silva MR, 2001, ACTA CRYSTALLOGR C, V57, P9, DOI 10.1107/S0108270100014281; Sorrentino A, 2015, J SYNCHROTRON RADIAT, V22, P1112, DOI 10.1107/S1600577515008632; Tribius S, 2009, STRAHLENTHER ONKOL, V185, P675, DOI 10.1007/s00066-009-1992-x; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Zayed ME, 2014, J SAUDI CHEM SOC, V18, P774, DOI 10.1016/j.jscs.2011.08.006; Zong WX, 2006, GENE DEV, V20, P1, DOI 10.1101/gad.1376506	29	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2020	15	3							e0230022	10.1371/journal.pone.0230022	http://dx.doi.org/10.1371/journal.pone.0230022			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8TR	32143211	gold, Green Published			2023-01-03	WOS:000535271600031
J	Ganz, DA; Latham, NK				Ganz, David A.; Latham, Nancy K.			Prevention of Falls in Community-Dwelling Older Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; VISUAL IMPAIRMENT; RISK-FACTORS; DEMENTIA; TRENDS; METAANALYSIS; PREVALENCE; CARE; FEAR	A 79-year-old woman presents for her annual wellness visit. She reports having fallen 9 months ago and again a few weeks ago. She does not remember the details of the first fall, but for the second fall, she notes having tripped over uneven pavement while walking outside of her home. Despite some difficulty, she was able to get up unassisted and did not seek medical attention; she recalls having taken an over-the-counter "sleep aid" the night before. She said she has no fear of falling, dizziness, or loss of consciousness. Office staff perform a Timed Up and Go test, and it takes her 15 seconds to complete the test (>= 12 seconds indicates an increased risk of falls). How would you evaluate this patient and manage the risk of future falls?	[Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA; [Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA 90073 USA; [Ganz, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA; [Latham, Nancy K.] Brigham & Womens Hosp, Boston Claude D Pepper Older Amer Independence Ct, Res Program Mens Hlth Aging & Metab, 75 Francis St, Boston, MA 02115 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Brigham & Women's Hospital	Ganz, DA (corresponding author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,11G, Los Angeles, CA 90073 USA.	dganz@mednet.ucla.edu						[Anonymous], 2014, DIABETOL KLIN SA, V3, pA1; [Anonymous], 2019, BMJ-BRIT MED J, V364, pl320; Bergen G, 2016, MMWR-MORBID MORTAL W, V65, P993, DOI 10.15585/mmwr.mm6537a2; Bhasin S, 2018, J GERONTOL A-BIOL, V73, P1053, DOI 10.1093/gerona/glx190; Borson S, 2000, INT J GERIATR PSYCH, V15, P1021, DOI 10.1002/1099-1166(200011)15:11<1021::AID-GPS234>3.0.CO;2-6; Campbell AJ, 2005, BMJ-BRIT MED J, V331, P817, DOI 10.1136/bmj.38601.447731.55; Campbell AJ, 1999, J AM GERIATR SOC, V47, P850, DOI 10.1111/j.1532-5415.1999.tb03843.x; Cummings SR, 2014, JAMA-J AM MED ASSOC, V311, P2061, DOI 10.1001/jama.2014.3033; de Vries M, 2018, J AM MED DIR ASSOC, V19, DOI 10.1016/j.jamda.2017.12.013; Deandrea S, 2010, EPIDEMIOLOGY, V21, P658, DOI 10.1097/EDE.0b013e3181e89905; Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010; Ettinger B, 2010, OSTEOPOROSIS INT, V21, P25, DOI 10.1007/s00198-009-1032-9; Fick DM, 2019, J AM GERIATR SOC, V67, P674, DOI 10.1111/jgs.15767; Florence CS, 2018, J AM GERIATR SOC, V66, P693, DOI 10.1111/jgs.15304; Freedman VA, 2013, DEMOGRAPHY, V50, P661, DOI 10.1007/s13524-012-0167-z; Freeman R, 2011, AUTON NEUROSCI-BASIC, V161, P46, DOI 10.1016/j.autneu.2011.02.004; Ganz DA, 2007, JAMA-J AM MED ASSOC, V297, P77, DOI 10.1001/jama.297.1.77; Ganz DA, 2007, MED CARE, V45, P8, DOI 10.1097/01.mlr.0000241115.31531.15; Gill TM, 1999, AM J PUBLIC HEALTH, V89, P553, DOI 10.2105/AJPH.89.4.553; Grossman DC, 2018, JAMA-J AM MED ASSOC, V319, P1696, DOI 10.1001/jama.2018.3097; Guirguis-Blake JM, 2018, INTERVENTIONS PREVEN; Haran Mark J, 2010, BMJ, V340, pc2265, DOI 10.1136/bmj.c2265; Harwood RH, 2005, BRIT J OPHTHALMOL, V89, P53, DOI 10.1136/bjo.2004.049478; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Kelsey JL, 2012, AM J PUBLIC HEALTH, V102, P2149, DOI 10.2105/AJPH.2012.300677; Kenny RAM, 2011, J AM GERIATR SOC, V59, P148, DOI 10.1111/j.1532-5415.2010.03234.x; Kim DH, 2011, J AM GERIATR SOC, V59, P1019, DOI 10.1111/j.1532-5415.2011.03450.x; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kvelde T, 2013, J AM GERIATR SOC, V61, P694, DOI 10.1111/jgs.12209; Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532-5415.2005.53455.x; Langa KM, 2017, JAMA INTERN MED, V177, P51, DOI 10.1001/jamainternmed.2016.6807; Letts L, 2010, AUST OCCUP THER J, V57, P51, DOI 10.1111/j.1440-1630.2009.00787.x; Lord SR, 2007, FALLS IN OLDER PEOPLE: RISK FACTORS AND STRATEGIES FOR PREVENTION, 2ND EDITION, P1, DOI 10.1017/CBO9780511722233; Luppa M, 2012, J AFFECT DISORDERS, V136, P212, DOI 10.1016/j.jad.2010.11.033; Lusardi MM, 2017, J GERIATR PHYS THER, V40, P1, DOI 10.1519/JPT.0000000000000099; Man-Son-Hing M, 1999, ARCH INTERN MED, V159, P677, DOI 10.1001/archinte.159.7.677; Mol A, 2019, J AM MED DIR ASSOC, V20, P589, DOI 10.1016/j.jamda.2018.11.003; Muir SW, 2012, AGE AGEING, V41, P299, DOI 10.1093/ageing/afs012; Muir SW, 2010, J CLIN EPIDEMIOL, V63, P389, DOI 10.1016/j.jclinepi.2009.06.010; Nelson J Craig, 2013, Prim Care Companion CNS Disord, V15, DOI 10.4088/PCC.12m01419; Saedon NI, 2020, J GERONTOL A-BIOL, V75, P117, DOI 10.1093/gerona/gly188; Sarbjit G, 2018, WILEY INTERDISCIPL R, V7, pe286, DOI 10.1002/WENE.286; Scheffer AC, 2008, AGE AGEING, V37, P19, DOI 10.1093/ageing/afm169; Semenov YR, 2016, J GERONTOL A-BIOL, V71, P243, DOI 10.1093/gerona/glv069; Seppala LJ, 2018, J AM MED DIR ASSOC, V19, DOI 10.1016/j.jamda.2017.12.099; Shen WK, 2017, HEART RHYTHM, V14, pE155, DOI 10.1016/j.hrthm.2017.03.004; Sherrington C, 2017, BRIT J SPORT MED, V51, P1749, DOI 10.1136/bjsports-2016-096547; Stevens JA, 2012, AM J PREV MED, V43, P59, DOI 10.1016/j.amepre.2012.03.008; Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923; Szanton SL, 2019, JAMA INTERN MED, V179, P204, DOI 10.1001/jamainternmed.2018.6026; Tanna AP, 2012, OPHTHALMOLOGY, V119, P2028, DOI 10.1016/j.ophtha.2012.04.018; Zijlstra GAR, 2009, J AM GERIATR SOC, V57, P2020, DOI 10.1111/j.1532-5415.2009.02489.x; 2016, CANC DISCOV, V6, pE0093; 2019, LANCET DIGITAL HLTH, V1, pCD012	54	89	91	9	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 20	2020	382	8					734	743		10.1056/NEJMcp1903252	http://dx.doi.org/10.1056/NEJMcp1903252			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ7SF	32074420	Green Published			2023-01-03	WOS:000517119800009
J	Angoa-Perez, M; Zagorac, B; Winters, AD; Greenberg, JM; Ahmad, M; Theis, KR; Kuhn, DM				Angoa-Perez, Mariana; Zagorac, Branislava; Winters, Andrew D.; Greenberg, Jonathan M.; Ahmad, Madison; Theis, Kevin R.; Kuhn, Donald M.			Differential effects of synthetic psychoactive cathinones and amphetamine stimulants on the gut microbiome in mice	PLOS ONE			English	Review							DOPAMINE NERVE-ENDINGS; 3,4-METHYLENEDIOXYPYROVALERONE MDPV; BATH SALTS; METHYLENEDIOXYPYROVALERONE MDPV; METHAMPHETAMINE-SEEKING; GLUTAMATE TRANSPORTER; PLACE PREFERENCE; MEPHEDRONE; NEUROTOXICITY; METHYLONE	The list of pharmacological agents that can modify the gut microbiome or be modified by it continues to grow at a high rate. The greatest amount of attention on drug-gut microbiome interactions has been directed primarily at pharmaceuticals used to treat infection, diabetes, cardiovascular conditions and cancer. By comparison, drugs of abuse and addiction, which can powerfully and chronically worsen human health, have received relatively little attention in this regard. Therefore, the main objective of this study was to characterize how selected synthetic psychoactive cathinones (aka "Bath Salts") and amphetamine stimulants modify the gut microbiome. Mice were treated with mephedrone (40 mg/kg), methcathinone (80 mg/kg), methamphetamine (5 mg/kg) or 4-methyl-methamphetamine (40 mg/kg), following a binge regimen consisting of 4 injections at 2h intervals. These drugs were selected for study because they are structural analogs that contain a beta- keto substituent (methcathinone), a 4-methyl group (4-methyl-methamphetamine), both substituents (mephedrone) or neither (methamphetamine). Mice were sacrificed 1, 2 or 7 days after treatment and DNA from caecum contents was subjected to 16S rRNA sequencing. We found that all drugs caused significant time- and structure-dependent alterations in the diversity and taxonomic structure of the gut microbiome. The two phyla most changed by drug treatments were Firmicutes (methcathinone, 4-methyl-methamphetamine) and Bacteriodetes (methcathinone, 4-methyl-methamphetamine, methamphetamine, mephedrone). Across time, broad microbiome changes from the phylum to genus levels were characteristic of all drugs. The present results signify that these selected psychoactive drugs, which are thought to exert their primary effects within the CNS, can have profound effects on the gut microbiome. They also suggest new avenues of investigation into the possibility that gut-derived signals could modulate drug abuse and addiction via altered communication along the gut-brain axis.	[Angoa-Perez, Mariana; Zagorac, Branislava; Kuhn, Donald M.] John D Dingell VA Med Ctr, Res & Dev Serv, Detroit, MI 48201 USA; [Angoa-Perez, Mariana; Zagorac, Branislava; Kuhn, Donald M.] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48202 USA; [Winters, Andrew D.; Greenberg, Jonathan M.; Ahmad, Madison; Theis, Kevin R.] Wayne State Univ, Sch Med, Dept Biochem Microbiol & Immunol, Detroit, MI USA; [Theis, Kevin R.] Wayne State Univ, Sch Med, Perinatal Res Initiat Maternal Perinatal & Child, Detroit, MI USA	Wayne State University; Wayne State University; Wayne State University	Kuhn, DM (corresponding author), John D Dingell VA Med Ctr, Res & Dev Serv, Detroit, MI 48201 USA.; Kuhn, DM (corresponding author), Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48202 USA.	donald.kuhn@wayne.edu		Kuhn, Donald/0000-0002-8546-9507	Department of Veterans Affairs	Department of Veterans Affairs(US Department of Veterans Affairs)	This work was supported by the Department of Veterans Affairs. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abulseoud OA, 2012, BRAIN RES, V1456, P14, DOI 10.1016/j.brainres.2012.03.045; Albers DS, 1995, J PHARMACOL EXP THER, V275, P1104; Althobaiti YS, 2016, NEUROSCI LETT, V634, P25, DOI 10.1016/j.neulet.2016.09.058; Angoa-Perez M, 2013, J NEUROCHEM, V125, P102, DOI 10.1111/jnc.12114; Angoa-Perez M, 2012, J NEUROCHEM, V120, P1097, DOI 10.1111/j.1471-4159.2011.07632.x; Anneken JH, 2017, J PHARMACOL EXP THER, V360, P417, DOI 10.1124/jpet.116.237768; Anneken JH, 2015, J NEUROCHEM, V133, P211, DOI 10.1111/jnc.13048; Attarzadeh-Yazdi G, 2014, PROG NEURO-PSYCHOPH, V53, P142, DOI 10.1016/j.pnpbp.2014.04.008; Baker JH, 2010, INT J EAT DISORDER, V43, P648, DOI 10.1002/eat.20856; Barr T, 2018, GUT MICROBES, V9, P338, DOI 10.1080/19490976.2018.1441663; Baumann MH, 2016, NEUROPSYCHOPHARMACOL, V41, P663, DOI 10.1038/npp.2015.260; Baumann MH, 2012, NEUROPSYCHOPHARMACOL, V37, P1192, DOI 10.1038/npp.2011.304; Bonano JS, 2014, PSYCHOPHARMACOLOGY, V231, P199, DOI 10.1007/s00213-013-3223-5; Brannan Temple A, 2004, MedGenMed, V6, P6; CALDWELL J, 1973, J PHARM PHARMACOL, V25, P422, DOI 10.1111/j.2042-7158.1973.tb10043.x; Cameron K, 2013, PSYCHOPHARMACOLOGY, V227, P493, DOI 10.1007/s00213-013-2967-2; Carlson Terri L, 2012, Hawaii J Med Public Health, V71, P44; Chi L, 2017, CHEM RES TOXICOL, V30, P2110, DOI 10.1021/acs.chemrestox.7b00162; Choi JG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217194; Choi JG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19646-x; Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310; Dinan TG, 2017, GASTROENTEROL CLIN N, V46, P77, DOI 10.1016/j.gtc.2016.09.007; El Aidy S, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00222; Eshleman AJ, 2017, J PHARMACOL EXP THER, V360, P33, DOI 10.1124/jpet.116.236349; Eshleman AJ, 2013, BIOCHEM PHARMACOL, V85, P1803, DOI 10.1016/j.bcp.2013.04.004; Fantegrossi WE, 2013, NEUROPSYCHOPHARMACOL, V38, P563, DOI 10.1038/npp.2012.233; Flack A, 2017, EUR J NEUROSCI, V46, P1918, DOI 10.1111/ejn.13630; Foster JA, 2013, TRENDS NEUROSCI, V36, P305, DOI 10.1016/j.tins.2013.01.005; Gatch MB, 2017, PSYCHOPHARMACOLOGY, V234, P1237, DOI 10.1007/s00213-017-4562-4; German CL, 2014, LIFE SCI, V97, P2, DOI 10.1016/j.lfs.2013.07.023; Gregg RA, 2016, NEUROPHARMACOLOGY, V108, P111, DOI 10.1016/j.neuropharm.2016.04.014; Gregorowski C, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-289; Greig CJ, 2016, J SURG RES, V206, P151, DOI 10.1016/j.jss.2016.07.021; Gygi MP, 1997, J PHARMACOL EXP THER, V283, P1350; Gygi MP, 1996, J PHARMACOL EXP THER, V276, P1066; Gygi MP, 1996, NEUROPHARMACOLOGY, V35, P751, DOI 10.1016/0028-3908(96)84647-8; Hagiwara H, 2009, BRAIN RES, V1301, P189, DOI 10.1016/j.brainres.2009.09.010; Halpin LE, 2014, NEUROPSYCHOPHARMACOL, V39, P1031, DOI 10.1038/npp.2013.306; Halpin LE, 2012, J NEUROSCI, V32, P13155, DOI 10.1523/JNEUROSCI.2530-12.2012; Hamady M, 2009, GENOME RES, V19, P1141, DOI 10.1101/gr.085464.108; Hammer Oyvind, 2001, Palaeontologia Electronica, V4, pUnpaginated; Harvey EL, 2016, PSYCHOPHARMACOLOGY, V233, P673, DOI 10.1007/s00213-015-4142-4; Hashimoto K, 2007, BIOL PSYCHIAT, V61, P577, DOI 10.1016/j.biopsych.2006.03.019; HERR RD, 1991, AM J EMERG MED, V9, P406, DOI 10.1016/0735-6757(91)90073-S; JONES BD, 1988, J BACTERIOL, V170, P3342, DOI 10.1128/jb.170.8.3342-3349.1988; Karila L, 2018, NEUROPHARMACOLOGY, V134, P65, DOI 10.1016/j.neuropharm.2017.10.007; Karila L, 2016, BRAIN RES BULL, V126, P61, DOI 10.1016/j.brainresbull.2016.03.005; Karlsson L, 2014, BASIC CLIN PHARMACOL, V115, P411, DOI 10.1111/bcpt.12253; Kiraly DD, 2016, SCI REP-UK, V6, DOI 10.1038/srep35455; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; Lai F, 2018, NEUROCHEM RES, V43, P1986, DOI 10.1007/s11064-018-2620-x; Lee K, 2018, NEUROPSYCHOPHARMACOL, V43, P2606, DOI 10.1038/s41386-018-0211-9; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Li BG, 2019, CELL REP, V26, P2720, DOI 10.1016/j.celrep.2019.02.015; Li HK, 2016, EXPERT OPIN DRUG MET, V12, P31, DOI 10.1517/17425255.2016.1121234; Li ZS, 2010, J NEUROSCI, V30, P16730, DOI 10.1523/JNEUROSCI.2276-10.2010; Li ZS, 2004, J NEUROSCI, V24, P1330, DOI 10.1523/JNEUROSCI.3982-03.2004; Marusich JA, 2012, NEUROTOXICOLOGY, V33, P1305, DOI 10.1016/j.neuro.2012.08.003; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; Motbey CP, 2013, J PSYCHOPHARMACOL, V27, P823, DOI 10.1177/0269881113490325; Ning TT, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01620; Persons AL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190078; Pflughoeft KJ, 2012, ANNU REV PATHOL-MECH, V7, P99, DOI 10.1146/annurev-pathol-011811-132421; Rawson R, 2000, J PSYCHOACTIVE DRUGS, V32, P233, DOI 10.1080/02791072.2000.10400234; Ridge EA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40803-3; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Scorza C, 2019, NEUROTOX RES, V35, P111, DOI 10.1007/s12640-018-9936-9; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533; Shortall SE, 2016, ADDICT BIOL, V21, P1127, DOI 10.1111/adb.12283; Shreiner AB, 2015, CURR OPIN GASTROEN, V31, P69, DOI 10.1097/MOG.0000000000000139; Simon SL, 2002, J ADDICT DIS, V21, P35; Sparago M, 1996, J PHARMACOL EXP THER, V279, P1043; STEPHANS SE, 1995, BRAIN RES, V700, P99, DOI 10.1016/0006-8993(95)00938-M; Tackett JJ, 2017, J SURG RES, V208, P198, DOI 10.1016/j.jss.2016.09.036; Thomas DM, 2004, J PHARMACOL EXP THER, V311, P1, DOI 10.1124/jpet.104.070961; Tremlett H, 2017, ANN NEUROL, V81, P369, DOI 10.1002/ana.24901; Wade PR, 1996, J NEUROSCI, V16, P2352; White CM, 2016, J CLIN PHARMACOL, V56, P1319, DOI 10.1002/jcph.742; Winstock AR, 2011, ADDICTION, V106, P154, DOI 10.1111/j.1360-0443.2010.03130.x; Xiao HW, 2018, TOXICOL LETT, V287, P23, DOI 10.1016/j.toxlet.2018.01.021; Xu YC, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43453; Zhang L, 2019, P NATL ACAD SCI USA, V116, P13523, DOI 10.1073/pnas.1901182116	84	15	15	3	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2020	15	1							e0227774	10.1371/journal.pone.0227774	http://dx.doi.org/10.1371/journal.pone.0227774			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP8WY	31978078	gold, Green Published			2023-01-03	WOS:000534599100059
J	Rhodes, S; Banning, EB; Chazan, M				Rhodes, Stephen; Banning, E. B.; Chazan, Michael			Mugharat an-Nachcharini: A specialized sheep-hunting camp reveals high-altitude habitats in the earliest Neolithic of the Central Levant	PLOS ONE			English	Article							MORPHOLOGICAL DISTINCTIONS; MANDIBULAR TEETH; TOOTH ERUPTION; WEAR; MANDIBLES; CYPRUS; GOATS; OVIS; AGE	The earliest Neolithic of southwest Asia is generally perceived and portrayed as a period of emerging economic practices that anticipated full-fledged food-producing economies. This first Neolithic, however, can also be seen as the last gasp of an earlier way of life that remained fundamentally Epipaleolithic in character. While people at this time had begun to cultivate some of the plant foods gathered in preceding periods, and to live for lengthy periods in sites with substantial architecture, they also relied on hunting for a significant portion of their diet and logistical movement across landscapes to exploit diverse environments. The objective of our research on Nachcharini Cave, the only excavated early Neolithic site in the high mountains of northeastern Lebanon, is to evaluate its role in a form of logistical organization not well attested at other sites in the Levant during this period. On the basis of material that Bruce Schroeder excavated in the 1970s, we present here for the first time analyses of faunal and lithic evidence from Nachcharini Cave, along with new radiocarbon dates that place the major occupation layer of the site firmly in the earliest Neolithic. We conclude that Nachcharini was a short-term hunting camp that was periodically used over some two centuries.	[Rhodes, Stephen; Banning, E. B.; Chazan, Michael] Univ Toronto, Dept Anthropol, Toronto, ON, Canada	University of Toronto	Rhodes, S (corresponding author), Univ Toronto, Dept Anthropol, Toronto, ON, Canada.	stephen.rhodes@mail.utoronto.ca		Rhodes, Stephen/0000-0001-8416-7243	The Archaeology Centre at the University of Toronto; Ontario Graduate Scholarship program	The Archaeology Centre at the University of Toronto; Ontario Graduate Scholarship program(Ontario Graduate Scholarship)	Funding for radiocarbon dating was provided by The Archaeology Centre at the University of Toronto (MC and SR). Additional support for research was provided by the Ontario Graduate Scholarship program (SR).	Banning EB, 2011, CURR ANTHROPOL, V52, P619, DOI 10.1086/661207; BAR-YOSEF O., 1989, PALEORIENT, V15, P57; Bar-Yosef O, 1987, MITEKUFAT HAEVEN, V20, P151; Bar-Yosef O., 1997, EARLY NEOLITHIC VI 1; Belfer-Cohen A., 2010, J ISRAEL PREHISTORIC, V40, P1; Bieniek A., 2007, ORIGINS SPREAD DOMES, P327; Binford L.R., 1982, J ANTHROPOL ARCHAEOL, V1, P5, DOI [10.1016/0278-4165(82)90006-X, DOI 10.1016/0278-4165(82)90006-X]; BINFORD LR, 1980, AM ANTIQUITY, V45, P4, DOI 10.2307/279653; Boessneck J., 1964, KUHN ARCHIV, V78, P1; Boessneck J., 1969, SCI ARCHAEOLOGY SURV, P331; Buck C.E., 1999, INTERNET ARCHAEOLOGY, V7, DOI [10.11141/IA.7.1, DOI 10.11141/IA.7.1]; Chaboo CS, 2019, HIST TOXICOL ENVIR, P11, DOI 10.1016/B978-0-12-815339-0.00002-0; Conard NJ, 2013, INT MONOGRAPHS PREHI, P1; Copeland L, 1966, INVENTORY STONE AG 2, V42, P2; Copeland L., 1991, NATUFIAN CULTURE LEV, P27; Coppe J, 2017, J ARCHAEOL SCI-REP, V12, P109, DOI 10.1016/j.jasrep.2017.01.010; Crassard R, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0069665, 10.1371/journal.pone.0068061, 10.1371/journal.pone.0069221]; DAVIS SJM, 1980, ISRAEL J ZOOL, V29, P129; Ducos P, 1993, PALEORIENT, V19, P153; Edwards Y.H., 2007, Paleorient, V33, P143, DOI 10.3406/paleo.2007.5212; Fauvelle-Aymar F.-X., 2008, PALETHNOLOGIE, V1, P341; Garrard A.N., 2003, BAAL, V7, P15; Ghattas S, 2007, SYSTEMES TECHNIQUES, P87; Gillis R, 2011, J ARCHAEOL SCI, V38, P2324, DOI 10.1016/j.jas.2011.04.012; Grant A., 1982, BAR BRIT SERIES, P91; Greenfield HJ, 2008, J ARCHAEOL SCI, V35, P836, DOI 10.1016/j.jas.2007.06.003; Haidarboustani M., 2007, NEOLITHICS, V1, P3; Halstead P, 2002, J ARCHAEOL SCI, V29, P545, DOI 10.1006/jasc.2001.0777; Hecker Howard, 1982, J FIELD ARCHAEOL, V9, P217; Helmer D, 2008, ARCHAEOZOOLOGY NEAR, V49, P119; Horwitz L.K., 2003, Paleorient, V29, P19, DOI 10.3406/paleo.2003.4753; Hutchings K., 1991, THESIS; Hutchings WK, 2011, J ARCHAEOL SCI, V38, P1737, DOI 10.1016/j.jas.2011.03.005; Kaufman D, 2007, SYSTEMES TECHNIQUES, P103; Kuijt I., 2004, J FIELD ARCHAEOL, V29, P291; Manning S. W., 2014, EURASIAN PREHISTORY, V11, P9; Manning SW, 2010, ANTIQUITY, V84, P693, DOI 10.1017/S0003598X00100171; Mithen SJ, 2011, ANTIQUITY, V85, P350, DOI 10.1017/S0003598X00067806; Munro ND, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27647-z; Munro ND, 2009, J ARCHAEOL SCI, V36, P752, DOI 10.1016/j.jas.2008.10.020; Munro ND, 2018, SOCIAL ARCHAEOLOGY L, P47; Nadel D., 1991, PALEORIENT, V17, P109, DOI DOI 10.3406/PALEO.1991.4544; Napierala H., 2012, THESIS; PAYNE S, 1987, J ARCHAEOL SCI, V14, P609, DOI 10.1016/0305-4403(87)90079-3; PAYNE S, 1985, J ARCHAEOL SCI, V12, P139, DOI 10.1016/0305-4403(85)90058-5; PRUMMEL W, 1986, J ARCHAEOL SCI, V13, P567, DOI 10.1016/0305-4403(86)90041-5; Reimer PJ, 2013, RADIOCARBON, V55, P1869, DOI 10.2458/azu_js_rc.55.16947; Schimdt K, GOBEKLI TEPE STONE A; Schmid E., 1972, ATLAS ANIMAL BONES; Schmidt K., 2001, PALEORIENT, V26, P45, DOI DOI 10.3406/PALE0.2000.4697; Smith S, 2007, SYSTEMES TECHNIQUES, P75; TCHERNOV E, 1994, EARLY NEOLITHIC VI 2; Twiss KC, 2007, EVOL ANTHROPOL, V16, P24, DOI 10.1002/evan.20113; Vigne JD, 2012, P NATL ACAD SCI USA, V109, P8445, DOI 10.1073/pnas.1201693109; Weiss E, 2006, SCIENCE, V312, P1608, DOI 10.1126/science.1127235; Wright K.I., 1993, LEVANT, V25, P93, DOI DOI 10.1179/LEV.1993.25.1.93; Yeomans L, 2017, ROY SOC OPEN SCI, V4, DOI 10.1098/rsos.170409; Yerkes RW, 2003, J ARCHAEOL SCI, V30, P1051, DOI 10.1016/S0305-4403(03)00007-4; Zeder MA, 2010, J ARCHAEOL SCI, V37, P2887, DOI 10.1016/j.jas.2010.06.032	59	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2020	15	1							e0227276	10.1371/journal.pone.0227276	http://dx.doi.org/10.1371/journal.pone.0227276			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP5QT	31968012	Green Published, gold			2023-01-03	WOS:000534373000014
J	Zhu, DW; Shi, XF; Nicholas, S; He, P				Zhu, Dawei; Shi, Xuefeng; Nicholas, Stephen; He, Ping			Regional disparities in health care resources in traditional Chinese medicine county hospitals in China	PLOS ONE			English	Article							PERFORMANCE; MORTALITY	Objective We aimed to analyze regional disparities of health care resources in traditional Chinese medicine (TCM) county hospitals and their time trends, and to assess the changes of regional disparities before and after 2009 health care reforms. Methods We used hospital-based, longitudinal data from all TCM county hospitals in China between 2004 and 2016. To measure the key development features of TCM county hospitals, data were collected on government hospital investment, hospital numbers (the average number of TCM hospitals per county), hospital scale (the number of medical staff and hospital beds) and doctors' workload (the daily visits and inpatient stays per doctor). We used segmented linear regression to test the time trend for outcome variables. We set a breakpoint at 2011, dividing the pre-reform (2004-2011) and post-reform (2012-2016) periods. Results After the 2009 health reforms, TCM hospitals continued to display large disparities in the number, scale, and doctors' workload across the three regions. In the pre-reform period, yearly government subsidies for TCM hospitals in western area were roughly RMB0.6 million (US$89 thousand) more than those in central and eastern region, which increased under the 2009 reforms to roughly RMB2 million (US$298 thousand) more per yer in post-reform period. These increased subsidies saw an increase in the number of TCM hospitals in the western area, partly addressing regional disparities. But there was no improvement in the regional disparities in terms of scale (number of beds) and the doctors' workload (daily outpatient visits and inpatients per doctor) increased or remained unchanged between the western and other regions. Conclusion Although TCM hospital number, scale, and doctors' workload increased over the past 13 years, substantial regional disparities remained. The 2009 health reforms did not significantly change the regional disparities in health care resources, especially between the eastern and western regions.	[Zhu, Dawei; He, Ping] Peking Univ, China Ctr Hlth Dev Studies, Beijing, Peoples R China; [Shi, Xuefeng] Beijing Univ Chinese Med, Sch Management, Beijing, Peoples R China; [Shi, Xuefeng] Beijing Univ Chinese Med, Natl Inst Chinese Med Dev & Strategy, Beijing, Peoples R China; [Nicholas, Stephen] Guangdong Univ Foreign Studies, Res Inst Int Strategies, Guangzhou, Guangdong, Peoples R China; [Nicholas, Stephen] Tianjin Normal Univ, Sch Econ & Sch Management, Tianjin, Peoples R China; [Nicholas, Stephen] TOP Educ Inst, Sydney, NSW, Australia; [Nicholas, Stephen] Univ Newcastle, Newcastle Business Sch, Newcastle, NSW, Australia	Peking University; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Guangdong University of Foreign Studies; Tianjin Normal University; University of Newcastle	He, P (corresponding author), Peking Univ, China Ctr Hlth Dev Studies, Beijing, Peoples R China.	phe@pku.edu.cn	NICHOLAS, STEPHEN/ABE-4726-2021	Nicholas, Stephen/0000-0001-6770-7105; Zhu, Dawei/0000-0003-0167-6603	Peking University's Start-up Fund [BMU2018YJ004]	Peking University's Start-up Fund	This paper was supported by Peking University's Start-up Fund (No. BMU2018YJ004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barr B, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3310; Chen L, 2016, CHIN HOSP MANAG, V36, P1; Chen TX, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0827-8; China's state council, 2016, OUTL STRAT PLANN DEV; China's state council, 2009, IMPLEMENTATION PLAN; China's state council, 2016, WHIT PAP DEV TRAD CH; Division of the Eastern Central and Western China, 2000, CHINA POPUL TODAY, V3; Fan SG, 2011, REV DEV FINANC, V1, P47, DOI 10.1016/j.rdf.2010.10.001; Fang PQ, 2010, HEALTH POLICY, V94, P14, DOI 10.1016/j.healthpol.2009.08.002; GUO S, 2015, MODERN EC, V6, P871, DOI DOI 10.4236/ME.2015.68082; Han B.T., 2013, THESIS; He CH, 2017, LANCET GLOB HEALTH, V5, pE186, DOI [10.1016/S2214-109X(16)30334-5, 10.1016/s2214-109x(16)30334-5]; Horev T, 2004, HEALTH POLICY, V68, P223, DOI 10.1016/j.healthpol.2003.09.011; Jiang S, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2780-4; Jin J, 2015, IRAN J PUBLIC HEALTH, V44, P13; Kanbur SR, 1999, WHY IS INEQUALITY BA; Keppel K, 2013, VITAL HLTH STAT, V34; Li HB, 2005, J PUBLIC ECON, V89, P1743, DOI 10.1016/j.jpubeco.2004.06.009; Liang D, 2016, INQUIRY-J HEALTH CAR, V53, DOI 10.1177/0046958016631699; Liu D, 2015, INT J HEALTH ECON MA, V15, P407, DOI 10.1007/s10754-015-9175-z; Lu LM, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0882-1; Murray CJL, 2000, B WHO, V15; National Health and Family Planning Commission, 2016, CHIN HLTH FAM PLANN; Pan J, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0467-9; Wagstaff A, 2009, DIR DEV, P1, DOI 10.1596/978-0-8213-7982-0; Wang L, 2017, INT J HEALTH POLICY, V6, P19, DOI 10.15171/ijhpm.2016.72; Wang SP, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0896-8; World Bank, 2016, 1 WORLD BANK, p1e12; WPRO, 2011, HLTH SECT REF CHIN; Wu Q, 2016, CHIN HOSP MANAG, V36, P11; Yip WCM, 2012, LANCET, V379, P833, DOI 10.1016/S0140-6736(11)61880-1; Zhang T, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0543-9; Zhou KY, 2015, HUM RESOUR HEALTH, V13, DOI 10.1186/s12960-015-0089-0; Zhou MG, 2016, LANCET, V387, P251, DOI 10.1016/S0140-6736(15)00551-6	34	9	9	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2020	15	1							e0227956	10.1371/journal.pone.0227956	http://dx.doi.org/10.1371/journal.pone.0227956			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP5QJ	31961912	Green Published, gold			2023-01-03	WOS:000534372000020
J	Tsou, PS; Sawalha, AH				Tsou, Pei-Suen; Sawalha, Amr H.			Glycoprotein nonmetastatic melanoma protein B: A key mediator and an emerging therapeutic target in autoimmune diseases	FASEB JOURNAL			English	Review						autoimmunity; GPNMB; lupus; osteoactivin; vasculitis	WIDE DNA METHYLATION; FORMATION IN-VIVO; DC-HIL; ADIPOSE-TISSUE; OSTEOBLAST DIFFERENTIATION; OSTEOCLAST DIFFERENTIATION; TRANSGENIC EXPRESSION; TRANSCRIPTION FACTORS; PROGNOSTIC INDICATOR; MMP-3 EXPRESSION	The glycoprotein nonmetastatic melanoma protein B (GPNMB, also known as osteoactivin) is highly expressed in many cell types and regulates the homeostasis in various tissues. In different physiological contexts, it functions as a melanosome-associated protein, membrane-bound surface receptor, soluble ligand, or adhesion molecule. Therefore, GPNMB is involved in cell differentiation, migration, inflammation, metabolism, and neuroprotection. Because of its various involvement in different physiological conditions, GPNMB has been implicated in many diseases, including cancer, neurological disorders, and more recently immune-mediated diseases. This review summarizes the regulation and function of GPNMB in normal physiology, and discusses the involvement of GPNMB in disease conditions with a particular focus on its potential role and therapeutic implications in autoimmunity.	[Tsou, Pei-Suen] Univ Michigan, Dept Internal Med, Div Rheumatol, Ann Arbor, MI 48109 USA; [Sawalha, Amr H.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Rheumatol,UPMC Childrens Hosp Pittsburgh, Pittsburgh, PA 15261 USA; [Sawalha, Amr H.] Univ Pittsburgh, Sch Med, Dept Med, Div Rheumatol & Clin Immunol, Pittsburgh, PA 15213 USA; [Sawalha, Amr H.] Univ Pittsburgh, Sch Med, Lupus Ctr Excellence, Pittsburgh, PA USA	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sawalha, AH (corresponding author), Univ Pittsburgh, Sch Med, Div Pediat Rheumatol, UPMC Childrens Hosp Pittsburgh, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	asawalha@pitt.edu			National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [R01 AR070148]	National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health grant number R01 AR070148.	Abdelmagid SM, 2008, EXP CELL RES, V314, P2334, DOI 10.1016/j.yexcr.2008.02.006; Abdelmagid SM, 2007, J CELL PHYSIOL, V210, P26, DOI 10.1002/jcp.20841; Abdelmagid SM, 2015, J BIOL CHEM, V290, P20128, DOI 10.1074/jbc.M114.624270; Abdelmagid SM, 2014, AM J PATHOL, V184, P697, DOI 10.1016/j.ajpath.2013.11.031; Abe H, 2007, BIOCHEM BIOPH RES CO, V356, P610, DOI 10.1016/j.bbrc.2007.03.035; Akiyoshi H, 2010, J IMMUNOL, V184, P3554, DOI 10.4049/jimmunol.0903250; Altorok N, 2015, ANN RHEUM DIS, V74, P1612, DOI 10.1136/annrheumdis-2014-205303; Anderson MG, 2008, BMC GENET, V9, DOI 10.1186/1471-2156-9-30; [Anonymous], 2020, HUMAN PROTEIN ATLAS; Arazi A, 2019, NAT IMMUNOL, V20, P902, DOI 10.1038/s41590-019-0398-x; Arosarena OA, 2018, J CELL PHYSIOL, V233, P409, DOI 10.1002/jcp.25900; Ashktorab H, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4903-7; Athwal VS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36037-4; Baba M, 2019, MOL CANCER RES, V17, P1613, DOI 10.1158/1541-7786.MCR-18-1235; Bachner Dietmar, 2002, Brain Res Gene Expr Patterns, V1, P159; Bao G, 2016, EXP BIOL MED, V241, P1968, DOI 10.1177/1535370216654224; Bethunaickan R, 2011, J IMMUNOL, V186, P4994, DOI 10.4049/jimmunol.1003010; Bhaskaran M, 2012, PHYSIOL GENOMICS, V44, P970, DOI 10.1152/physiolgenomics.00145.2011; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Chen C, 2018, CANCER RES, V78, P6424, DOI 10.1158/0008-5472.CAN-18-0599; Choi MS, 2015, BRIT J NUTR, V113, P867, DOI 10.1017/S0007114515000100; Chung JS, 2007, J IMMUNOL, V179, P5778, DOI 10.4049/jimmunol.179.9.5778; Chung JS, 2014, J INVEST DERMATOL, V134, P2784, DOI 10.1038/jid.2014.254; Chung JS, 2014, J IMMUNOL, V192, P2576, DOI 10.4049/jimmunol.1301857; Chung JS, 2013, IMMUNOLOGY, V138, P173, DOI 10.1111/imm.12027; Chung JS, 2011, BLOOD, V117, P3382, DOI 10.1182/blood-2010-08-302034; Chung JS, 2009, J IMMUNOL, V183, P5190, DOI 10.4049/jimmunol.0901319; Chung JS, 2009, EUR J IMMUNOL, V39, P965, DOI 10.1002/eji.200838990; Coit P, 2013, J AUTOIMMUN, V43, P78, DOI 10.1016/j.jaut.2013.04.003; Dolcino M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128262; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; Frara N, 2016, J CELL PHYSIOL, V231, P72, DOI 10.1002/jcp.25020; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Furochi H, 2007, FEBS LETT, V581, P5743, DOI 10.1016/j.febslet.2007.11.036; Gabriel TL, 2014, DIABETES, V63, P3310, DOI 10.2337/db13-1720; Gong XM, 2019, NAT METAB, V1, P570, DOI 10.1038/s42255-019-0065-4; Gutknecht M, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0099-5; Hoashi T, 2010, FASEB J, V24, P1616, DOI 10.1096/fj.09-151019; Hong SB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015793; Hu XF, 2013, J CELL BIOCHEM, V114, P2729, DOI 10.1002/jcb.24621; Huang JJ, 2012, BRAIN BEHAV, V2, P85, DOI 10.1002/brb3.39; Huttenrauch M, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0612-3; Jing H, 2002, STRUCTURE, V10, P1453, DOI 10.1016/S0969-2126(02)00840-7; Katayama A, 2015, SCI REP-UK, V5, DOI 10.1038/srep16920; Kobayashi M, 2019, CLIN CANCER RES, V25, P828, DOI 10.1158/1078-0432.CCR-18-0330; Kong XF, 2019, ANN RHEUM DIS, V78, P1388, DOI 10.1136/annrheumdis-2019-215567; Kramer G, 2016, FEBS OPEN BIO, V6, P902, DOI 10.1002/2211-5463.12078; Kuan CT, 2006, CLIN CANCER RES, V12, P1970, DOI 10.1158/1078-0432.CCR-05-2797; Kumagai K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143413; Kumari K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39122-4; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Li B, 2010, FASEB J, V24, P4767, DOI 10.1096/fj.10-154757; Li H, 2019, HISTOL HISTOPATHOL, V34, P803, DOI 10.14670/HH-18-084; Li YJ, 2020, J CELL PHYSIOL, V235, P2071, DOI 10.1002/jcp.29107; Li YN, 2014, APMIS, V122, P140, DOI 10.1111/apm.12107; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Liu FX, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1146-8; Loftus SK, 2009, PIGM CELL MELANOMA R, V22, P99, DOI 10.1111/j.1755-148X.2008.00518.x; Maric G, 2015, ONCOGENE, V34, P5494, DOI 10.1038/onc.2015.8; Maric G, 2019, ONCOGENE, V38, P5294, DOI 10.1038/s41388-019-0793-7; Metz RL, 2005, CELL CYCLE, V4, P315; Mo JS, 2003, J EXP MED, V197, P1335, DOI 10.1084/jem.20022041; Mokarram P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007012; Moloney EB, 2018, NEUROBIOL DIS, V120, P1, DOI 10.1016/j.nbd.2018.08.013; Moussa FM, 2014, J CELL BIOCHEM, V115, P1243, DOI 10.1002/jcb.24760; Murata K, 2015, J NEUROCHEM, V132, P583, DOI 10.1111/jnc.13010; Murugesan V, 2018, BLOOD CELL MOL DIS, V68, P47, DOI 10.1016/j.bcmd.2016.12.002; Nakano Y, 2014, NEUROSCIENCE, V277, P123, DOI 10.1016/j.neuroscience.2014.06.065; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Narasaraju T, 2015, AM J RESP CELL MOL, V52, P253, DOI 10.1165/rcmb.2013-0021OC; Neal ML, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1100-1; Okita Y, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9397; Ono Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep23241; Oyewumi MO, 2016, ONCOTARGET, V7, P13932, DOI 10.18632/oncotarget.7323; Pahl MV, 2010, CLIN J AM SOC NEPHRO, V5, P56, DOI 10.2215/CJN.03390509; Patel-Chamberlin M, 2011, KIDNEY INT, V79, P1138, DOI 10.1038/ki.2011.28; Ramachandran P, 2012, P NATL ACAD SCI USA, V109, pE3186, DOI 10.1073/pnas.1119964109; Ren FF, 2020, J CELL PHYSIOL, V235, P2738, DOI 10.1002/jcp.29177; Ripoll VM, 2008, GENE, V413, P32, DOI 10.1016/j.gene.2008.01.014; Ripoll VM, 2007, J IMMUNOL, V178, P6557, DOI 10.4049/jimmunol.178.10.6557; Rose A, 2008, CANCER RES, V68, P3681; Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093; Rose AAN, 2010, CLIN CANCER RES, V16, P2147, DOI 10.1158/1078-0432.CCR-09-1611; Ruan WM, 2014, INT J CLIN EXP MED, V7, P4857; Safadi FF, 2002, J CELL BIOCHEM, V84, P12, DOI 10.1002/jcb.1259; Sasaki F, 2015, MOL MED REP, V12, P7503, DOI 10.3892/mmr.2015.4408; Sayed M, 2014, STEM CELL RES, V13, P12, DOI 10.1016/j.scr.2014.04.002; Scholer J, 2015, J BIOL CHEM, V290, P8154, DOI 10.1074/jbc.M114.615922; Sheng MHC, 2008, FEBS LETT, V582, P1451, DOI 10.1016/j.febslet.2008.03.030; Sheng MHC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035280; Shi FY, 2014, J MOL NEUROSCI, V54, P234, DOI 10.1007/s12031-014-0280-0; Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200; Singh M, 2012, J CELL PHYSIOL, V227, P390, DOI 10.1002/jcp.22791; Smuczek B, 2017, EXP CELL RES, V358, P323, DOI 10.1016/j.yexcr.2017.07.005; Sondag GR, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.78; Tanaka H, 2012, SCI REP-UK, V2, DOI 10.1038/srep00573; Terasawa K, 2016, BIOCHEM BIOPH RES CO, V479, P489, DOI 10.1016/j.bbrc.2016.09.093; Theos AC, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12084; Tian F, 2012, ONCOL RES, V20, P341, DOI 10.3727/096504013X13657689382851; Tomihari M, 2010, CANCER RES, V70, P5778, DOI 10.1158/0008-5472.CAN-09-2538; Tomihari M, 2009, EXP DERMATOL, V18, P586, DOI 10.1111/j.1600-0625.2008.00830.x; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Wang YL, 2015, INT J CLIN EXP PATHO, V8, P6498; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; Xie R, 2019, CANCER SCI, V110, P2237, DOI 10.1111/cas.14076; Yang CF, 2018, AM J HUM GENET, V102, P219, DOI 10.1016/j.ajhg.2017.12.012; Yang M, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0242-1; Yu B, 2018, J INVEST DERMATOL, V138, P219, DOI 10.1016/j.jid.2017.08.034; Yu B, 2016, J CELL BIOCHEM, V117, P1511, DOI 10.1002/jcb.25394; Zambonelli P, 2016, ANIM GENET, V47, P306, DOI 10.1111/age.12413; Zhang F, 2019, NAT IMMUNOL, V20, P928, DOI 10.1038/s41590-019-0378-1; Zhang P, 2013, BMB REP, V46, P364, DOI 10.5483/BMBRep.2013.46.7.250; Zhang P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042955; Zhang YX, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317699119; Zhou LT, 2017, CELL IMMUNOL, V316, P53, DOI 10.1016/j.cellimm.2017.03.006; Zhu SC, 2019, J MOL NEUROSCI, V69, P643, DOI 10.1007/s12031-019-01411-y	116	9	9	3	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2020	34	7					8810	8823		10.1096/fj.202000651	http://dx.doi.org/10.1096/fj.202000651		MAY 2020	14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MG8UN	32445534	Green Published, Green Accepted			2023-01-03	WOS:000535460100001
J	Reichenbach, S; Felson, DT; Hincapie, CA; Heldner, S; Butikofer, L; Lenz, A; da Costa, BR; Bonel, HM; Jones, RK; Hawker, GA; Juni, P				Reichenbach, Stephan; Felson, David T.; Hincapie, Cesar A.; Heldner, Sarah; Butikofer, Lukas; Lenz, Armando; da Costa, Bruno R.; Bonel, Harald M.; Jones, Richard K.; Hawker, Gillian A.; Juni, Peter			Effect of Biomechanical Footwear on Knee Pain in People With Knee Osteoarthritis The BIOTOK Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PRESSURE; OUTCOMES; THERAPY; MOMENT; CARE; HIP	Importance Individually calibrated biomechanical footwear therapy may improve pain and physical function in people with symptomatic knee osteoarthritis, but the benefits of this therapy are unclear. Objective To assess the effect of a biomechanical footwear therapy vs control footwear over 24 weeks of follow-up. Design, Setting, and Participants Randomized clinical trial conducted at a Swiss university hospital. Participants (N = 220) with symptomatic, radiologically confirmed knee osteoarthritis were recruited between April 20, 2015, and January 10, 2017. The last participant visit occurred on August 15, 2017. Interventions Participants were randomized to biomechanical footwear involving shoes with individually adjustable external convex pods attached to the outsole (n = 111) or to control footwear (n = 109) that had visible outsole pods that were not adjustable and did not create a convex walking surface. Main Outcomes and Measures The primary outcome was knee pain at 24 weeks of follow-up assessed with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore standardized to range from 0 (no symptoms) to 10 (extreme symptoms). The secondary outcomes included WOMAC physical function and stiffness subscores and the WOMAC global score, all ranging from 0 (no symptoms) to 10 (extreme symptoms) at 24 weeks of follow-up, and serious adverse events. Results Among the 220 randomized participants (mean age, 65.2 years [SD, 9.3 years]; 104 women [47.3%]), 219 received the allocated treatment and 213 (96.8%) completed follow-up. At 24 weeks of follow-up, the mean standardized WOMAC pain subscore improved from 4.3 to 1.3 in the biomechanical footwear group and from 4.0 to 2.6 in the control footwear group (between-group difference in scores at 24 weeks of follow-up, -1.3 [95% CI, -1.8 to -0.9]; P < .001). The results were consistent for WOMAC physical function subscore (between-group difference, -1.1 [95% CI, -1.5 to -0.7]), WOMAC stiffness subscore (between-group difference, -1.4 [95% CI, -1.9 to -0.9]), and WOMAC global score (between-group difference, -1.2 [95% CI, -1.6 to -0.8]) at 24 weeks of follow-up. Three serious adverse events occurred in the biomechanical footwear group compared with 9 in the control footwear group (2.7% vs 8.3%, respectively); none were related to treatment. Conclusions and Relevance Among participants with knee pain from osteoarthritis, use of biomechanical footwear compared with control footwear resulted in an improvement in pain at 24 weeks of follow-up that was statistically significant but of uncertain clinical importance. Further research would be needed to assess long-term efficacy and safety, as well as replication, before reaching conclusions about the clinical value of this device.	[Reichenbach, Stephan; Heldner, Sarah] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland; [Reichenbach, Stephan] Bern Univ Hosp, Dept Rheumatol Immunol & Allergol, Bern, Switzerland; [Felson, David T.] Univ Manchester, Arthrit Res UK Ctr Epidemiol, Ctr Musculoskeletal Res, Fac Biol Med & Hlth, Manchester, Lancs, England; [Felson, David T.] Manchester Univ Hosp NHS Fdn Trust, NIHR Manchester Musculoskeletal Biomed Res Ctr, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Felson, David T.] Boston Univ, Clin Epidemiol Unit, Boston, MA 02215 USA; [Hincapie, Cesar A.; da Costa, Bruno R.; Juni, Peter] St Michaels Hosp, Appl Hlth Res Ctr, Li Ka Shing Knowledge Inst, 250 Yonge St, Toronto, ON M5B 2L7, Canada; [Hincapie, Cesar A.] Univ Zurich, Fac Med, Dept Chiropract Med, Zurich, Switzerland; [Hincapie, Cesar A.] Balgrist Univ Hosp, Zurich, Switzerland; [Butikofer, Lukas; Lenz, Armando] Univ Bern, Clin Trials Unit, Bern, Switzerland; [da Costa, Bruno R.; Hawker, Gillian A.; Juni, Peter] Univ Toronto, Dept Med, Toronto, ON, Canada; [da Costa, Bruno R.; Hawker, Gillian A.; Juni, Peter] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Bonel, Harald M.] Bern Univ Hosp, Dept Diagnost Intervent & Pediat Radiol, Bern, Switzerland; [Jones, Richard K.] Univ Salford Manchester, Ctr Hlth Sci Res, Sch Hlth Sci, Manchester, Lancs, England	University of Bern; University of Bern; University Hospital of Bern; University of Manchester; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Boston University; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Geneva; University of Zurich; University of Zurich; University of Bern; University of Toronto; University of Toronto; University of Bern; University Hospital of Bern; University of Salford	Juni, P (corresponding author), St Michaels Hosp, Appl Hlth Res Ctr, Li Ka Shing Knowledge Inst, 250 Yonge St, Toronto, ON M5B 2L7, Canada.	peter.juni@utoronto.ca	Hincapié, Cesar A/AAH-7887-2021; Juni, Peter/Q-8700-2016	Hincapié, Cesar A/0000-0002-7257-8122; Juni, Peter/0000-0002-5985-0670; Jones, Richard/0000-0001-5242-185X; Reichenbach, Stephan/0000-0001-8098-6567; Butikofer, Lukas/0000-0002-0801-746X; Felson, David/0000-0002-2668-2447	Bern University Hospital; Canada Research Chairs Programme; Maxi Foundation	Bern University Hospital; Canada Research Chairs Programme(Canada Research Chairs); Maxi Foundation	The trial was sponsored by Bern University Hospital and coordinated by CTU Bern, the University of Bern's clinical trials unit. The trial was funded by the Maxi Foundation. Dr Juni is a tier 1 Canadian research chair in clinical epidemiology of chronic diseases; this research was completed, in part, with funding from the Canada Research Chairs Programme. Apos Medical Assets provided the biomechanical footwear system and the control footwear, and provided the technicians trained to install and calibrate the external pods on the biomechanical footwear without charge.	ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Bar-Ziv Y, 2013, ARTHRITIS, DOI 10.1155/2013/689236; Bar-Ziv Y, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-179; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140-6736(13)60900-9; CIOMS, 2016, INT ETH GUID HLTH RE; da Costa BR, 2017, LANCET, V390, pE21, DOI 10.1016/S0140-6736(17)31744-0; da Costa BR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003115.pub4; Drexler M., 2012, Annals of Physical and Rehabilitation Medicine, V55, P213, DOI 10.1016/j.rehab.2012.01.002; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Elbaz A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749-799X-9-1; Elbaz A, 2010, CLIN BIOMECH, V25, P920, DOI 10.1016/j.clinbiomech.2010.06.017; Gore M, 2012, PAIN PRACT, V12, P550, DOI 10.1111/j.1533-2500.2012.00532.x; Haim A, 2008, J BIOMECH, V41, P3010, DOI 10.1016/j.jbiomech.2008.07.029; Haim A, 2012, J BIOMECH, V45, P41, DOI 10.1016/j.jbiomech.2011.10.017; Haim A, 2011, J ORTHOP RES, V29, P1668, DOI 10.1002/jor.21422; Haim A, 2010, J BIOMECH, V43, P969, DOI 10.1016/j.jbiomech.2009.10.045; Hinman RS, 2016, ANN INTERN MED, V165, P381, DOI 10.7326/M16-0453; James KE, 1996, STAT MED, V15, P1421; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kapstad H, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-55; Khoury M, 2015, J FOOT ANKLE RES, V8, DOI 10.1186/s13047-015-0124-3; Khoury M, 2013, FOOT ANKLE INT, V34, P593, DOI 10.1177/1071100713477613; Klingenberg B, 2014, STAT MED, V33, P2968, DOI 10.1002/sim.6122; Laucis NC, 2015, J BONE JOINT SURG AM, V97A, P1628, DOI 10.2106/JBJS.O.00030; Lubovsky O, 2017, INT J RHEUM DIS, V20, P818, DOI 10.1111/1756-185X.12694; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; Nuesch E, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3244; Parkes MJ, 2013, JAMA-J AM MED ASSOC, V310, P722, DOI 10.1001/jama.2013.243229; R Core Team, R LANG ENV STAT COMP; Swiss Federal Council, ORD CLIN TRIALS HUM; Swiss Federal Council, FED ACT RES INV HUM; Trelle S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7086	34	16	16	2	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2020	323	18					1802	1812		10.1001/jama.2020.3565	http://dx.doi.org/10.1001/jama.2020.3565			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LS2LS	32396180	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000536221500020
J	Thiel, B; Godfried, MB; van Huizen, EC; Mooijer, BC; de Boer, BA; van Mierlo, RAAM; van Os, J; Geerts, BF; Kalkman, CJ				Thiel, Bram; Godfried, Marc B.; van Huizen, Elise C.; Mooijer, Bart C.; de Boer, Bouke A.; van Mierlo, Rover A. A. M.; van Os, Johan; Geerts, Bart F.; Kalkman, Cor J.			Patient reported postoperative pain with a smartphone application: A proof of concept	PLOS ONE			English	Article							QUALITY; MANAGEMENT; SATURATION; INTERVIEWS; TOOL	Postoperative pain management and pain assessment are still lacking the perspective of the patient. We have developed and studied a prototype smartphone application for patients to self-record postoperative pain. The main objective was to collect patient and stakeholder critique of improvements on the usability in order to develop a definitive version. The secondary objective was to investigate if patient self-recording compared to nurse-led assessment is a suitable method for postoperative pain management. Fifty patients and a stakeholder group consisting of ten healthcare- and ICT professionals and two members of the patient council participated in this study. Main outcome Thirty patients (60%) found it satisfying or very satisfying to communicate their pain with the app. Pain experienced after surgery was scored by patients as 'no': 3 (6%), 'little': 5 (10%), 'bearable': 25 (50%), 'considerable': 13 (26%) and 'severe': 1 (2%). Forty-five patients (90%) were positive about the ease of recording. Forty-five patients (90%) could correctly record their pain with the app. Thirty-eight patients (76%) agreed that in-app notifications to record pain were useful. Two patients (4%) were too ill to use the application. Based on usability feedback, we will redesign the pain intensity wheel and the in-app pain chart to improve clarity for patients to understand the course of their pain. Secondary outcomes The median patient recorded pain app score 4.0 (range 0 to 10) and nurse recorded numerical rating scale (NRS) for pain NRS 4.0 (range 0 to 9) were not statistically different (p = 0.06). Forty-two percent from a total of 307 patient pain app scores were. 5 (on a scale from 0 no pain at all to 10 worst imaginable pain). Of these, 83% were recorded as 'bearable' while only in 18% of the recordings patients asked for additional analgesia. The results suggest that self-recording the severity of postoperative pain by patients with a smartphone application could be useful for postoperative pain management. The application was perceived as user-friendly and had high satisfaction rates from both patients and stakeholders. Further research is needed to validate the 11-point numeric and faces pain scale with the current gold standards visual analogue scale (VAS) and NRS for pain.	[Thiel, Bram; Godfried, Marc B.] OLVG Hosp, Dept Anesthesiol, Amsterdam, Netherlands; [Thiel, Bram] Univ Med Ctr Utrecht, Utrecht, Netherlands; [van Huizen, Elise C.; Mooijer, Bart C.] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [de Boer, Bouke A.] OLVG Hosp, Dept Informat Technol, Amsterdam, Netherlands; [van Mierlo, Rover A. A. M.] Logicapps Inc, Amsterdam, Netherlands; [van Os, Johan] OLVG Hosp, Dept Business Intelligence, Amsterdam, Netherlands; [Geerts, Bart F.] Univ Amsterdam, Med Ctr, Dept Anesthesiol, Amsterdam, Netherlands; [Kalkman, Cor J.] Univ Med Ctr Utrecht, Dept Anesthesiol, Utrecht, Netherlands; [Kalkman, Cor J.] Univ Med Ctr Utrecht, Dept Intens Care, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; University of Amsterdam; University of Amsterdam; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Thiel, B (corresponding author), OLVG Hosp, Dept Anesthesiol, Amsterdam, Netherlands.; Thiel, B (corresponding author), Univ Med Ctr Utrecht, Utrecht, Netherlands.	b.thiel@olvg.nl		van Os, Jim/0000-0002-7245-1586	SIDN fund	SIDN fund	SIDN fund, public benefit organization for Dutch internet domain registration (Url: www.SIDNfonds.nl), partially funded the development of the smartphone application. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	Bech RD, 2015, PAIN RES TREAT, V2015, DOI 10.1155/2015/676212; Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Ekker A., 2013, MEDISCHE APPS IS CER; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Hennink MM, 2017, QUAL HEALTH RES, V27, P591, DOI 10.1177/1049732316665344; Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016; Kim EB, 2012, J PALLIAT MED, V15, P1222, DOI 10.1089/jpm.2012.0183; Krejcie RV, 1970, EDUC PSYCHOL MEAS, V30, P3; Lalloo C, 2017, JMIR MHEALTH UHEALTH, V5, DOI 10.2196/mhealth.8230; Malterud K, 2016, QUAL HEALTH RES, V26, P1753, DOI 10.1177/1049732315617444; Manias E, 2002, J CLIN NURS, V11, P724, DOI 10.1046/j.1365-2702.2002.00691.x; Meissner W, 2006, EUR J ANAESTH, V23, P142, DOI 10.1017/S026502150500205X; Giang NV, 2015, PAIN MANAG NURS, V16, P678, DOI 10.1016/j.pmn.2015.02.002; O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388; Pellino TA, 1998, J PAIN SYMPTOM MANAG, V15, P110, DOI 10.1016/S0885-3924(97)00255-8; Portelli P, 2016, BRIT J PAIN, V10, P135, DOI 10.1177/2049463716638700; Reynoldson C, 2014, PAIN MED, V15, P898, DOI 10.1111/pme.12327; Santo K, 2016, JMIR MHEALTH UHEALTH, V4, DOI 10.2196/mhealth.6742; Shipton EA, 2018, PAIN THER, V7, P23, DOI 10.1007/s40122-018-0096-7; Stinson JN, 2013, J MED INTERNET RES, V15, P137, DOI 10.2196/jmir.2350; Stone AA, 2007, PAIN MED, V8, P85, DOI 10.1111/j.1526-4637.2007.00372.x; van Andel J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121446; van Boekel Rianne L M, 2014, Ned Tijdschr Geneeskd, V158, pA7723; van Dijk JFM, 2016, INT J NURS STUD, V53, P260, DOI 10.1016/j.ijnurstu.2015.08.007; van Dijk JFM, 2012, INT J NURS STUD, V49, P65, DOI 10.1016/j.ijnurstu.2011.07.009; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; World Medical Association Declaration of Helsinki, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [10.1001/jama.2013.281053, DOI 10.1001/JAMA.2013.281053]	29	4	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2020	15	5							e0232082	10.1371/journal.pone.0232082	http://dx.doi.org/10.1371/journal.pone.0232082			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU0QJ	32384103	gold, Green Published			2023-01-03	WOS:000537468300008
J	Silva, T; Fragoso, YD; Rodrigues, MFSD; Gomes, AO; da Silva, FC; Andreo, L; Viana, A; da Silva, DDT; Chavantes, MC; Horliana, ACRT; De Angelis, K; Deana, AM; Branco, LP; Fernandes, KPS; Motta, LJ; Mesquita-Ferrari, RA; Bussadori, SK				Silva, Tamiris; Fragoso, Yara Dadalti; Setubal Destro Rodrigues, Maria Fernanda; Gomes, Andrea Oliver; da Silva, Fernanda Cordeiro; Andreo, Lucas; Viana, Ariane; Teixeira da Silva, Daniela de Fatima; Chavantes, Maria Cristina; Ratto Tempestini Horliana, Anna Carolina; De Angelis, Katia; Deana, Alessandro Melo; Branco, Luciana Prats; Santos Fernandes, Kristianne Porta; Motta, Lara Jansiski; Mesquita-Ferrari, Raquel Agnelli; Bussadori, Sandra Kalil			Effects of photobiomodulation on interleukin-10 and nitrites in individuals with relapsing-remitting multiple sclerosis - Randomized clinical trial	PLOS ONE			English	Article							T-CELLS; FATIGUE; BALANCE; OXIDE; CYTOKINES; EXERCISE	Objective Investigate the effects of photobiomodulation (PBM) on the expression of IL-10 and nitrites in individuals with Relapsing-Remitting multiple sclerosis (MS), as these biomarkers play a fundamental role in the physiopathology of the disease. The modulation of IL-10 and nitrites through treatment with PBM may be a novel treatment modality for MS. Methods A randomized, uncontrolled, clinical trial was conducted involving 14 individuals with a diagnosis of Relapsing-Remitting MS and a score of up to 6.0 on the Expanded Disability Status Scale (EDSS). The participants were randomized to two groups Group 1-PBM in the sublingual region; Group 2-PBM over the radial artery. Irradiation was administered with a wavelength of 808 nm and output power of 100 mW for 360 seconds twice a week, totaling 24 sessions. Peripheral blood was analyzed for the determination of serum levels of IL-10 and nitrites. Results After treatment with PBM, the expression of IL-10 increased in both the sublingual group (pre-treatment: 2.8 +/- 1.4 pg/ml; post-treatment: 8.3 +/- 2.4 pg/ml) and the radial artery group (pre-treatment: 2.7 pg/ml +/- 1.4; post-treatment: 11.7 +/- 3.8 pg/ml). In contrast, nitrite levels were not modulated in the sublingual group (pre-treatment: 65 +/- 50 nmol/mg protein; post-treatment: 51 +/- 42 nmol/mg protein) or the radial artery group (pre-treatment: 51 +/- 16 nmol/mg protein; post-treatment: 42 +/- 7 nmol/mg protein). Conclusion Treatment with PBM positively modulated the expression of IL-10 but had no effect on nitrite levels. Further studies should be conducted with a larger sample and a control group, as PBM may be a promising complementary treatment for the management of MS.	[Silva, Tamiris; Setubal Destro Rodrigues, Maria Fernanda; Gomes, Andrea Oliver; da Silva, Fernanda Cordeiro; Andreo, Lucas; Viana, Ariane; Teixeira da Silva, Daniela de Fatima; Chavantes, Maria Cristina; Ratto Tempestini Horliana, Anna Carolina; De Angelis, Katia; Deana, Alessandro Melo; Santos Fernandes, Kristianne Porta; Motta, Lara Jansiski; Mesquita-Ferrari, Raquel Agnelli; Bussadori, Sandra Kalil] Univ Nove Julho, UNINOVE, Sao Paulo, SP, Brazil; [Fragoso, Yara Dadalti; Branco, Luciana Prats] Univ Metropolitana Santos, UNIMES, Santos, SP, Brazil; [De Angelis, Katia] Univ Fed Sao Paulo UNIFESP, Escola Paulista Med, Sao Paulo, SP, Brazil; [Silva, Tamiris; Gomes, Andrea Oliver; da Silva, Fernanda Cordeiro; Mesquita-Ferrari, Raquel Agnelli; Bussadori, Sandra Kalil] Univ Nove Julho, Dept Postgrad Program Rehabil Sci, UNINOVE, Sao Paulo, SP, Brazil; [Setubal Destro Rodrigues, Maria Fernanda; Andreo, Lucas; Teixeira da Silva, Daniela de Fatima; Ratto Tempestini Horliana, Anna Carolina; Deana, Alessandro Melo; Santos Fernandes, Kristianne Porta; Motta, Lara Jansiski; Mesquita-Ferrari, Raquel Agnelli; Bussadori, Sandra Kalil] Univ Nove Julho UNINOVE, Dept Postgrad Program Biophoton Appl Hlth Sci, Sao Paulo, SP, Brazil; [Viana, Ariane; Chavantes, Maria Cristina] Univ Nove Julho UNINOVE, Dept Postgrad Program Med, Sao Paulo, SP, Brazil; [De Angelis, Katia] Univ Fed Sao Paulo UNIFESP, Dept Fisiol, Escola Paulista Med, Sao Paulo, SP, Brazil	Universidade Nove de Julho; Universidade Federal de Sao Paulo (UNIFESP); Universidade Nove de Julho; Universidade Nove de Julho; Universidade Nove de Julho; Universidade Federal de Sao Paulo (UNIFESP)	Bussadori, SK (corresponding author), Univ Nove Julho, UNINOVE, Sao Paulo, SP, Brazil.; Bussadori, SK (corresponding author), Univ Nove Julho, Dept Postgrad Program Rehabil Sci, UNINOVE, Sao Paulo, SP, Brazil.; Bussadori, SK (corresponding author), Univ Nove Julho UNINOVE, Dept Postgrad Program Biophoton Appl Hlth Sci, Sao Paulo, SP, Brazil.	sandra.skb@gmail.com	Fernandes, Kristianne Porta Santos/I-4417-2016; Motta, Lara/M-1966-2014; Horliana, Anna Carolina Ratto Tempestini/J-3257-2015; Andreo, Lucas/AAL-6265-2021; Horliana, Anna/ABH-9640-2020; Rodrigues, Maria Fernanda SD/E-7820-2018; Viana, Ariane/AAQ-2291-2021; Bussadori, Sandra/J-5458-2014; Motta, Lara/AAQ-9643-2020; Andreo, Lucas/GQB-0944-2022; Silva, Tamiris/AFO-4827-2022; Ferrari, Raquel/I-4419-2016; Deana, Alessandro M/K-4787-2012; Silva, Tamiris/AAS-5538-2021	Fernandes, Kristianne Porta Santos/0000-0001-7156-9286; Motta, Lara/0000-0002-7774-4345; Horliana, Anna Carolina Ratto Tempestini/0000-0003-3476-9064; Andreo, Lucas/0000-0001-8313-4300; Viana, Ariane/0000-0003-3866-5000; Bussadori, Sandra/0000-0002-9853-1138; Motta, Lara/0000-0002-7774-4345; Silva, Tamiris/0000-0003-2023-4798; Ferrari, Raquel/0000-0001-5142-9526; Silva, Tamiris/0000-0003-2023-4798; Deana, Alessandro Melo/0000-0002-0014-6953				Alvarenga H, 2016, J NEUROIMMUNOL, V293, P91, DOI 10.1016/j.jneuroim.2016.02.014; Berkowitz S, 2019, MULT SCLER RELAT DIS, V31, P82, DOI 10.1016/j.msard.2019.03.025; Callesen J, 2018, NEUROREHABILITATION, V42, P131, DOI 10.3233/NRE-172238; Chalah MA, 2018, J INFLAMM RES, V11, P253, DOI 10.2147/JIR.S167199; Chitnis T, 2007, INT REV NEUROBIOL, V79, P43, DOI 10.1016/S0074-7742(07)79003-7; da Silva T, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010627; Ghasemi M, 2014, NEUROSCI BIOBEHAV R, V45, P168, DOI 10.1016/j.neubiorev.2014.06.002; Giovannoni G, 1997, J NEUROL SCI, V145, P77, DOI 10.1016/S0022-510X(96)00246-8; Goncalves ED, 2015, AUTOIMMUNITY, V6934; Hamblin MR, 2017, AIMS BIOPHYS, V4, P337, DOI 10.3934/biophy.2017.3.337; Kallaur AP, 2013, MOL MED REP, V7, P1010, DOI 10.3892/mmr.2013.1256; Kjolhede T, 2016, SCAND J MED SCI SPOR, V26, P824, DOI 10.1111/sms.12504; Kozin MS, 2018, BIOCHEMISTRY, V83; Kubsik A, 2016, NEUROREHABILITATION, V38, P183, DOI 10.3233/NRE-161309; Kwilasz AJ, 2015, NEUROPHARMACOLOGY, V96, P55, DOI 10.1016/j.neuropharm.2014.10.020; Mercan F, 2016, MULT SCLER RELAT DIS, V7, P85, DOI 10.1016/j.msard.2016.03.015; Molina-Holgado E, 2002, J NEUROCHEM, V81, P1242, DOI 10.1046/j.1471-4159.2002.00925.x; Monjezi S, 2017, CLIN REHABIL, V31, P234, DOI 10.1177/0269215516639735; Muili KA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067358; Muili KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030655; SONG S, 2012, J NEUROINFLAMM, V9, P1; Stepien A, 2013, NEUROIMMUNOMODULAT, V20, P213, DOI 10.1159/000348701; Tang XY, 2017, NITRIC OXIDE-BIOL CH, V67, P75, DOI 10.1016/j.niox.2017.04.004; von Leden RE, 2013, LASER SURG MED, V45, P253, DOI 10.1002/lsm.22133; Wang KX, 2018, AM J MED SCI, V356, P552, DOI 10.1016/j.amjms.2018.08.018; Wong VL, 2019, BEHAV PHARMACOL, V30, P652, DOI 10.1097/FBP.0000000000000514; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Zhevago NA, 2006, PHOTOMED LASER SURG, V24, P129, DOI 10.1089/pho.2006.24.129	28	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2020	15	4							e0230551	10.1371/journal.pone.0230551	http://dx.doi.org/10.1371/journal.pone.0230551			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8PU	32255785	Green Submitted, Green Published, gold			2023-01-03	WOS:000535959400009
J	Chan, KK; Bass, AR				Chan, Karmela K.; Bass, Anne R.			Autoimmune complications of immunotherapy: pathophysiology and management	BMJ-BRITISH MEDICAL JOURNAL			English	Review							IMMUNE CHECKPOINT INHIBITORS; CELL LUNG-CANCER; ADVERSE EVENTS; PREEXISTING AUTOIMMUNE; COMBINED NIVOLUMAB; TUMOR RESPONSE; PD-1 BLOCKADE; STAGE-III; IPILIMUMAB; HYPOPHYSITIS	Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target inhibitory molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its ligand, programmed cell death protein ligand 1 (PD-L1), and lead to immune activation in the tumor micro-environment. ICIs can induce durable treatment responses in patients with advanced cancers, but they are commonly associated with immune related adverse events (irAEs) such as rash, colitis, hepatitis, pneumonitis, and endocrine and musculoskeletal disorders. Almost all patients experience some form of irAE, but high grade irAEs occur in approximately half of those on combination therapy (eg, anti-CTLA-4 plus anti-PD-1), and up to one quarter receiving ICI monotherapy. Fatal irAEs occur in approximately 1.2% of patients on CTLA-4 blockade and 0.4% of patients receiving PD-1 or PD-L1 blockade, and case fatality rates are highest for myocarditis and myositis. IrAEs typically occur in the first three months after ICI initiation, but can occur as early as one day after the first dose to years after ICI initiation. The mainstay of treatment is with corticosteroids, but tumor necrosis factor inhibitors are commonly used for refractory irAEs. Although ICIs are generally discontinued when high grade irAEs occur, ICI discontinuation alone is rarely adequate to resolve irAEs. Consensus guidelines have been published to help guide management, but will likely be modified as our understanding of irAEs grows.	[Chan, Karmela K.; Bass, Anne R.] Hosp Special Surg, Weill Cornell Med, 535 E 70th St, New York, NY 10021 USA	Cornell University	Bass, AR (corresponding author), Hosp Special Surg, Weill Cornell Med, 535 E 70th St, New York, NY 10021 USA.	bassa@hss.edu						Abdel-Wahab N, 2018, ANN INTERN MED, V168, P121, DOI 10.7326/M17-2073; Abu-Sbeih H, 2020, J CLIN ONCOL, V38, P576, DOI 10.1200/JCO.19.01674; Abu-Sbeih H, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0577-1; Abu-Sbeih H, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0502-7; Adler BL, 2018, J INTERN MED, V283, P568, DOI 10.1111/joim.12744; Aggarwal P, 2019, EXPERT OPIN DRUG SAF, V18, P623, DOI 10.1080/14740338.2019.1619693; Akturk HK, 2019, DIABETIC MED, V36, P1075, DOI 10.1111/dme.14050; Albarel F, 2015, EUR J ENDOCRINOL, V172, DOI 10.1530/EJE-14-0845; Ali OH, 2019, EUR J CANCER, V107, P8, DOI 10.1016/j.ejca.2018.11.009; Anquetil C, 2018, CIRCULATION, V138, P743, DOI 10.1161/CIRCULATIONAHA.118.035898; Arbour KC, 2018, J CLIN ONCOL, V36, P2872, DOI 10.1200/JCO.2018.79.0006; Arnaud-Coffin P, 2019, INT J CANCER, V145, P639, DOI 10.1002/ijc.32132; Beck KE, 2006, J CLIN ONCOL, V24, P2283, DOI 10.1200/JCO.2005.04.5716; Bergqvist V, 2017, CANCER IMMUNOL IMMUN, V66, P581, DOI 10.1007/s00262-017-1962-6; Berner F, 2019, JAMA ONCOL, V5, P1043, DOI 10.1001/jamaoncol.2019.0402; Bertrand A, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0455-8; Bertrand F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02358-7; Bitton K, 2019, AM J OPHTHALMOL, V202, P109, DOI 10.1016/j.ajo.2019.02.012; Braaten TJ, 2020, ANN RHEUM DIS, V79, P332, DOI 10.1136/annrheumdis-2019-216109; Brahmer JR, 2018, J ONCOL PRACT, V14, P247, DOI 10.1200/JOP.18.00005; Calabrese C, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-000906; Cappelli LC, 2019, RHEUMATOLOGY, V58, P476, DOI 10.1093/rheumatology/key358; Cappelli LC, 2018, SEMIN ARTHRITIS RHEU, V48, P553, DOI 10.1016/j.semarthrit.2018.02.011; Cappelli LC, 2017, ARTHRIT CARE RES, V69, P1751, DOI 10.1002/acr.23177; Caturegli P, 2016, AM J PATHOL, V186, P3225, DOI 10.1016/j.ajpath.2016.08.020; Chaput N, 2017, ANN ONCOL, V28, P1368, DOI 10.1093/annonc/mdx108; Coleman E, 2019, J AM ACAD DERMATOL, V80, P990, DOI 10.1016/j.jaad.2018.10.062; Cortazar FB, 2016, KIDNEY INT, V90, P638, DOI 10.1016/j.kint.2016.04.008; Cortellini A, 2019, ONCOLOGIST, V24, pE327, DOI 10.1634/theoncologist.2018-0618; Cui PF, 2018, CANCER MED-US, V7, P4115, DOI 10.1002/cam4.1579; Cuzzubbo S, 2017, EUR J CANCER, V73, P1, DOI [10.1016/j.ejca.2016.12.001, 10.1016/j.ejca.2016.12:001]; Danlos FX, 2018, EUR J CANCER, V91, P21, DOI 10.1016/j.ejca.2017.12.008; Das R, 2018, J CLIN INVEST, V128, P715, DOI 10.1172/JCI96798; de Filette J, 2019, HORM METAB RES, V51, P145, DOI 10.1055/a-0843-3366; De Martin E, 2018, J HEPATOL, V68, P1181, DOI 10.1016/j.jhep.2018.01.033; Delaney N, 2019, LANCET HAEMATOL, V6, pE48, DOI [10.1016/52352-3026(18)30175-3, 10.1016/S2352-3026(18)30175-3]; Draghi A, 2019, INT J CANCER, V145, P1408, DOI 10.1002/ijc.32080; Dubin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10391; Esfahani K, 2019, NEW ENGL J MED, V380, P2375, DOI 10.1056/NEJMc1903064; Esfahani K, 2017, NEW ENGL J MED, V376, P1989, DOI 10.1056/NEJMc1703047; Faje AT, 2018, CANCER-AM CANCER SOC, V124, P3706, DOI 10.1002/cncr.31629; Faje AT, 2014, J CLIN ENDOCR METAB, V99, P4078, DOI 10.1210/jc.2014-2306; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gowen MF, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1452-4; Gu LH, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5785-z; Hall ET, 2019, J PAIN SYMPTOM MANAG, V58, P137, DOI 10.1016/j.jpainsymman.2019.03.015; Hughes MS, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0756-0; Iwama S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008002; Iyer PC, 2018, THYROID, V28, P1243, DOI 10.1089/thy.2018.0116; Johansen A, 2019, NEUROLOGY, V92, P663, DOI 10.1212/WNL.0000000000007235; Johnson D, 2019, CANCER IMMUNOL RES, V7, P860, DOI 10.1158/2326-6066.CIR-18-0682; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Johnson DH, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0412-0; JOHNSON DB, 2019, J IMMUNOTHER CANCER, V7, DOI DOI 10.1186/S40425-; Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214; Kartolo A, 2018, CURR ONCOL, V25, pE403, DOI 10.3747/co.25.4047; Khan SA, 2016, JAMA ONCOL, V2, P1507, DOI 10.1001/jamaoncol.2016.2238; Khan S, 2019, BRIT J CANCER, V120, P63, DOI 10.1038/s41416-018-0155-1; Kimbara S, 2018, CANCER SCI, V109, P3583, DOI 10.1111/cas.13800; Kobayashi T, 2018, J ENDOCR SOC, V2, P241, DOI 10.1210/js.2017-00432; Kostine M, 2018, ANN RHEUM DIS, V77, P393, DOI 10.1136/annrheumdis-2017-212257; Larsabal M, 2017, J AM ACAD DERMATOL, V76, P863, DOI 10.1016/j.jaad.2016.10.044; Larsen BT, 2019, AM J SURG PATHOL, V43, P1331, DOI 10.1097/PAS.0000000000001298; Leaf RK, 2019, AM J HEMATOL, V94, P563, DOI 10.1002/ajh.25448; Lebbe C, 2014, ANN ONCOL, V25, P2277, DOI 10.1093/annonc/mdu441; Liewluck T, 2018, J IMMUNOTHER, V41, P208, DOI 10.1097/CJI.0000000000000196; Lim SY, 2019, CLIN CANCER RES, V25, P1557, DOI 10.1158/1078-0432.CCR-18-2795; Ma CJ, 2019, CANCER IMMUNOL RES, V7, P1214, DOI 10.1158/2326-6066.CIR-18-0613; Maher VE, 2019, J CLIN ONCOL, V37, P2730, DOI 10.1200/JCO.19.00318; Mahmood SS, 2018, J AM COLL CARDIOL, V71, P1755, DOI 10.1016/j.jacc.2018.02.037; Mamlouk O, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-018-0478-8; Marthey L, 2016, J CROHNS COLITIS, V10, P395, DOI 10.1093/ecco-jcc/jjv227; Min L, 2015, CLIN CANCER RES, V21, P749, DOI 10.1158/1078-0432.CCR-14-2353; Mir H, 2018, CAN J CARDIOL, V34, P1059, DOI 10.1016/j.cjca.2018.03.012; Moreira A, 2019, EUR J CANCER, V106, P12, DOI 10.1016/j.ejca.2018.09.033; Murakami N, 2017, CURR PROB CANCER, V41, P100, DOI 10.1016/j.currproblcancer.2016.12.004; Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005; Noble CW, 2020, OCUL IMMUNOL INFLAMM, V28, P854, DOI 10.1080/09273948.2019.1583347; O'Reilly A, 2020, SUPPORT CARE CANCER, V28, P561, DOI 10.1007/s00520-019-04818-w; Pavana A, 2019, ONCOLOGIST, V24, P1128, DOI 10.1634/theoncologist.2018-0563; Perez-Ruiz E, 2019, NATURE, V569, P428, DOI 10.1038/s41586-019-1162-y; Phillips GS, 2019, J CLIN ONCOL, V37, P2746, DOI 10.1200/JCO.18.02141; Pollack MH, 2018, ANN ONCOL, V29, P250, DOI 10.1093/annonc/mdx642; Puzanov I, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0300-z; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sakata Y, 2019, LUNG CANCER, V130, P159, DOI 10.1016/j.lungcan.2019.02.011; Salem JE, 2019, NEW ENGL J MED, V380, P2377, DOI 10.1056/NEJMc1901677; Santini FC, 2018, CANCER IMMUNOL RES, V6, P1093, DOI 10.1158/2326-6066.CIR-17-0755; Schadendorf D, 2017, J CLIN ONCOL, V35, P3807, DOI 10.1200/JCO.2017.73.2289; Shah M, 2019, SEMIN ARTHRITIS RHEU, V48, P736, DOI 10.1016/j.semarthrit.2018.05.006; Shahabi V, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-75; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Siegel J, 2018, J AM ACAD DERMATOL, V79, P1081, DOI 10.1016/j.jaad.2018.07.008; Simonaggio A, 2019, JAMA ONCOL, V5, P1310, DOI 10.1001/jamaoncol.2019.1022; Smith MH, 2019, ARTHRIT CARE RES, V71, P362, DOI 10.1002/acr.23467; Stroud CRG, 2019, J ONCOL PHARM PRACT, V25, P551, DOI 10.1177/1078155217745144; Sun MHM, 2020, OCUL IMMUNOL INFLAMM, V28, P217, DOI 10.1080/09273948.2019.1577978; Sznol M, 2017, J CLIN ONCOL, V35, P3815, DOI 10.1200/JCO.2016.72.1167; Tarhini AA, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0081-1; Teulings HE, 2015, J CLIN ONCOL, V33, P773, DOI 10.1200/JCO.2014.57.4756; Thompson JA, 2019, J NATL COMPR CANC NE, V17, P255, DOI 10.6004/jnccn.2019.0013; Toi Y, 2019, JAMA ONCOL, V5, P376, DOI 10.1001/jamaoncol.2018.5860; Topalian SL, 2019, JAMA ONCOL, V5, P1411, DOI 10.1001/jamaoncol.2019.2187; Touat M, 2018, NEUROLOGY, V91, pE985, DOI 10.1212/WNL.0000000000006124; Valpione S, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1467-x; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Verschuren EC, 2016, CLIN GASTROENTEROL H, V14, P836, DOI 10.1016/j.cgh.2015.12.028; Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923; Wang DY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1344805; Wang YH, 2018, NAT MED, V24, P1804, DOI 10.1038/s41591-018-0238-9; Wang YH, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0346-6; Wang YH, 2018, INFLAMM BOWEL DIS, V24, P1695, DOI 10.1093/ibd/izy104; Wang YC, 2019, JAMA ONCOL, V5, P1008, DOI 10.1001/jamaoncol.2019.0393; Warner BM, 2019, ONCOLOGIST, V24, P1259, DOI 10.1634/theoncologist.2018-0823; Weber J, 2009, CLIN CANCER RES, V15, P5591, DOI 10.1158/1078-0432.CCR-09-1024; Weber JS, 2012, J CLIN ONCOL, V30, P2691, DOI 10.1200/JCO.2012.41.6750; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Yamaguchi T, 2018, LUNG CANCER, V125, P212, DOI 10.1016/j.lungcan.2018.10.001; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	120	45	47	3	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	2020	369								m736	10.1136/bmj.m736	http://dx.doi.org/10.1136/bmj.m736			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF8XT	32253223				2023-01-03	WOS:000527698300001
J	Hotchkiss, RS; Opal, SM				Hotchkiss, Richard S.; Opal, Steven M.			Activating Immunity to Fight a Foe - A New Path	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Could the immunomodulatory drugs that have produced impressive outcomes in cancer be used to boost immunity to counter infection in the context of sepsis? Recent findings in animal models provide some support for this strategy.	[Hotchkiss, Richard S.] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Hotchkiss, Richard S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Hotchkiss, Richard S.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; [Opal, Steven M.] Brown Univ, Dept Med, Alpert Med Sch, Providence, RI 02912 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Brown University	Hotchkiss, RS (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA.; Hotchkiss, RS (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Hotchkiss, RS (corresponding author), Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.				NIGMS NIH HHS [R35 GM126928] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Francois B, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98960; Hotchkiss RS, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.45; Opal SM, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1549-1; Vesely MCA, 2019, CELL, V178, P1176, DOI 10.1016/j.cell.2019.07.032; Zander R, 2019, IMMUNITY, V51, P1028, DOI 10.1016/j.immuni.2019.10.009	5	28	29	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 26	2020	382	13					1270	1272		10.1056/NEJMcibr1917242	http://dx.doi.org/10.1056/NEJMcibr1917242			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KY1UO	32212525	Green Published, Green Accepted			2023-01-03	WOS:000522357300015
J	Xu, SB; Yu, LL; Luo, X; Wang, MH; Chen, GH; Zhang, Q; Liu, WH; Zhou, ZY; Song, JH; Jing, HT; Huang, GY; Liang, FX; Wang, H; Wang, W				Xu, Shabei; Yu, Lingling; Luo, Xiang; Wang, Minghuan; Chen, Guohua; Zhang, Qing; Liu, Wenhua; Zhou, Zhongyu; Song, Jinhui; Jing, Huitao; Huang, Guangying; Liang, Fengxia; Wang, Hua; Wang, Wei			Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLACEBO; ELECTROACUPUNCTURE; HEADACHE; PAIN; VALIDATION; DEPRESSION; INVENTORY; MECHANISM; EFFICACY; DISEASE	Objective - To assess the efficacy of manual acupuncture as prophylactic treatment for acupuncture naive patients with episodic migraine without aura. Design - Multicentre, randomised, controlled clinical trial with blinded participants, outcome assessment, and statistician. Setting - Seven hospitals in China, 5 June 2016 to 15 November 2018. Participants - 150 acupuncture naive patients with episodic migraine without aura. Interventions - 20 sessions of manual acupuncture at true acupuncture points plus usual care, 20 sessions of non-penetrating sham acupuncture at heterosegmental non-acupuncture points plus usual care, or usual care alone over 8 weeks. Main outcome measures - Change in migraine days and migraine attacks per four weeks during weeks 1-20 after randomisation compared with baseline (four weeks before randomisation). Results - Among 150 randomised patients (mean age 36.5 (SD 11.4) years; 123 (82%) women), 147 were included in the full analysis set. Compared with sham acupuncture, manual acupuncture resulted in a significantly greater reduction in migraine days at weeks 13 to 20 and a significantly greater reduction in migraine attacks at weeks 17 to 20. The reduction in mean number of migraine days was 3.5 (SD 2.5) for manual versus 2.4 (3.4) for sham (adjusted difference -1.4, 95% confidence interval -2.4 to -0.3; P=0.005) at weeks 13 to 16 and 3.9 (3.0) for manual versus 2.2 (3.2) for sham (adjusted difference -2.1, -2.9 to -1.2; P<0.001) at weeks 17 to 20. At weeks 17 to 20, the reduction in mean number of attacks was 2.3 (1.7) for manual versus 1.6 (2.5) for sham (adjusted difference -1.0, -1.5 to -0.5; P<0.001). No severe adverse events were reported. No significant difference was seen in the proportion of patients perceiving needle penetration between manual acupuncture and sham acupuncture (79% v 75%; P=0.891). Conclusions - Twenty sessions of manual acupuncture was superior to sham acupuncture and usual care for the prophylaxis of episodic migraine without aura. These results support the use of manual acupuncture in patients who are reluctant to use prophylactic drugs or when prophylactic drugs are ineffective, and it should be considered in future guidelines.	[Xu, Shabei; Yu, Lingling; Luo, Xiang; Wang, Minghuan; Wang, Wei] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurol, Wuhan 430030, Hubei, Peoples R China; [Chen, Guohua] Wuhan Hosp Tradit Chinese & Western Med, Wuhan Hosp 1, Dept Neurol, Wuhan, Hubei, Peoples R China; [Zhang, Qing; Huang, Guangying] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Inst Integrated Tradit Chinese & Western Me, Wuhan, Hubei, Peoples R China; [Liu, Wenhua] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Sci Res Management, Wuhan, Hubei, Peoples R China; [Zhou, Zhongyu] Hubei Prov Hosp Tradit Chinese Med, Dept Acupuncture, Wuhan, Hubei, Peoples R China; [Song, Jinhui] Hubei Univ Med, Xiangyang Peoples Hosp 1, Dept Neurol, Xiangyang, Hubei, Peoples R China; [Jing, Huitao] Second Hosp Huangshi, Dept Rehabil Med, Huangshi, Hubei, Peoples R China; [Liang, Fengxia; Wang, Hua] Hubei Univ Chinese Med, Coll Acupuncture & Orthoped, Hubei Prov Collaborat Innovat Ctr Prevent Treatme, Wuhan 430065, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Hubei University of Medicine; Hubei University of Chinese Medicine	Wang, W (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurol, Wuhan 430030, Hubei, Peoples R China.	wwang@vip.126.com	Liang, Fenghua/HHM-3798-2022; Liang, Feng/GZK-4305-2022		National Natural Science Foundation of China [61327902]; Hubei University of Chinese Medicine/Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibustion	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hubei University of Chinese Medicine/Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibustion	This study was supported by a grant from the National Natural Science Foundation of China (61327902), and a project grant from Hubei University of Chinese Medicine/Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibustion. Study sponsors were not involved in study design, data interpretation, writing the article, or the decision to submit the article for publication.	Allais G, 2002, HEADACHE, V42, P855, DOI 10.1046/j.1526-4610.2002.02203.x; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; Birch S, 2006, J ALTERN COMPLEM MED, V12, P303, DOI 10.1089/acm.2006.12.303; Buysse D J, 1989, Psychiatry Res, V28, P193; CADDEN SW, 1983, BRAIN RES, V275, P1, DOI 10.1016/0006-8993(83)90412-2; Cole JC, 2007, QUAL LIFE RES, V16, P1231, DOI 10.1007/s11136-007-9217-1; Diener HC, 2006, LANCET NEUROL, V5, P310, DOI 10.1016/S1474-4422(06)70382-9; Dodick DW, 2018, JAMA-J AM MED ASSOC, V319, P1999, DOI 10.1001/jama.2018.4853; Facco E, 2008, HEADACHE, V48, P398, DOI 10.1111/j.1526-4610.2007.00916.x; Geisser ME, 1997, CLIN J PAIN, V13, P163, DOI 10.1097/00002508-199706000-00011; Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562; Han JS, 2011, PAIN, V152, pS41, DOI 10.1016/j.pain.2010.10.012; Hay SI, 2017, LANCET, V389, pE1; He W, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1580-z; Hocum JD, 2016, SCI REP-UK, V6, DOI 10.1038/srep36610; Kaptchuk TJ, 2011, PHILOS T R SOC B, V366, P1849, DOI 10.1098/rstb.2010.0385; Kim BH, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1589-3; Kim SK, 2006, J PHYSIOL SCI, V56, P259, DOI 10.2170/physiolsci.SC002706; Le Bars D, 1992, Patol Fiziol Eksp Ter, P55; Leyfer OT, 2006, J ANXIETY DISORD, V20, P444, DOI 10.1016/j.janxdis.2005.05.004; Li Y, 2012, CAN MED ASSOC J, V184, P401, DOI 10.1503/cmaj.110551; Linde K, 2005, JAMA-J AM MED ASSOC, V293, P2118, DOI 10.1001/jama.293.17.2118; Linde K, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-75; Lipton RB, 2007, NEUROLOGY, V68, P343, DOI 10.1212/01.wnl.0000252808.97649.21; LIU X, 1986, PAIN, V24, P383, DOI 10.1016/0304-3959(86)90124-7; Lund Irene, 2006, Acupunct Med, V24, P13; Lundeberg Thomas, 2007, Acupunct Med, V25, P100; MacPherson H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093739; Makary MM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18870-1; Mao JJ, 2007, EXPLORE-NY, V3, P372, DOI 10.1016/j.explore.2006.12.003; Massiou H, 2005, REV NEUROL-FRANCE, V161, P681; Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356; Napadow V, 2005, HUM BRAIN MAPP, V24, P193, DOI 10.1002/hbm.20081; Plaster R, 2014, ACUPUNCT MED, V32, P236, DOI 10.1136/acupmed-2013-010489; Pringsheim T, 2012, CAN J NEUROL SCI, V39, pS1; Puledda F, 2018, NEUROTHERAPEUTICS, V15, P336, DOI 10.1007/s13311-018-0623-6; Santoro A, 2017, NEUROL SCI, V38, P1779, DOI 10.1007/s10072-017-3054-y; Schliessbach J, 2011, PAIN MED, V12, P268, DOI 10.1111/j.1526-4637.2010.01051.x; Schulte LH, 2015, LANCET NEUROL, V14, P6, DOI 10.1016/S1474-4422(14)70295-9; Skljarevski V, 2018, JAMA NEUROL, V75, P187, DOI 10.1001/jamaneurol.2017.3859; Spaeth RB, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/204259; Steiner TJ, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0846-2; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Thiese MS, 2016, J THORAC DIS, V8, pE928, DOI 10.21037/jtd.2016.08.16; Tsui P, 2002, ACUPUNCTURE ELECTRO, V27, P107, DOI 10.3727/036012902816026040; Wallasch TM, 2012, J ALTERN COMPLEM MED, V18, P777, DOI 10.1089/acm.2011.0308; Wang KL, 2010, COMPLEMENT THER MED, V18, P249, DOI 10.1016/j.ctim.2010.09.005; Wang LP, 2011, PAIN, V152, P1864, DOI 10.1016/j.pain.2011.04.006; Wang YY, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/920353; Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378; Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004	52	52	61	14	56	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	2020	368								m697	10.1136/bmj.m697	http://dx.doi.org/10.1136/bmj.m697			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA2DX	32213509	Green Published, hybrid			2023-01-03	WOS:000523764500003
J	Moreira, AG; Siddiqui, SK; Macias, R; Johnson-Pais, TL; Wilson, D; Gelfond, JAL; Vasquez, MM; Seidner, SR; Mustafa, SB				Moreira, Alvaro G.; Siddiqui, Sartaj K.; Macias, Rolando; Johnson-Pais, Teresa L.; Wilson, Desiree; Gelfond, Jonathon A. L.; Vasquez, Margarita M.; Seidner, Steven R.; Mustafa, Shamimunisa B.			Oxygen and mechanical ventilation impede the functional properties of resident lung mesenchymal stromal cells	PLOS ONE			English	Article							GENE-EXPRESSION; STEM-CELLS; GROWTH-FACTOR; DISEASE; PROTECTS; ALVEOLAR; PRETERM	Resident/endogenous mesenchymal stromal cells function to promote the normal development, growth, and repair of tissues. Following premature birth, the effects of routine neonatal care (e.g. oxygen support and mechanical ventilation) on the biological properties of lung endogenous mesenchymal stromal cells is (L-MSCs) is poorly understood. New Zealand white preterm rabbits were randomized into the following groups: (i) sacrificed at birth (Fetal), (ii) spontaneously breathing with 50% O-2 for 4 hours (SB), or (iii) mechanical ventilation with 50% O-2 for 4h (MV). At time of necropsy, L-MSCs were isolated, characterized, and compared. L-MSCs isolated from the MV group had decreased differentiation capacity, ability to form stem cell colonies, and expressed less vascular endothelial growth factor mRNA. Compared to Fetal L-MSCs, 98 and 458 genes were differentially expressed in the L-MSCs derived from the SB and MV groups, respectively. Gene ontology analysis revealed these genes were involved in key regulatory processes including cell cycle, cell division, and angiogenesis. Furthermore, the L-MSCs from the SB and MV groups had smaller mitochondria, nuclear changes, and distended endoplasmic reticula. Short-term hyperoxia/mechanical ventilation after birth alters the biological properties of L-MSCs and stimulates genomic changes that may impact their reparative potential.	[Moreira, Alvaro G.; Siddiqui, Sartaj K.; Macias, Rolando; Vasquez, Margarita M.; Seidner, Steven R.; Mustafa, Shamimunisa B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, Div Neonatol, San Antonio, TX 78229 USA; [Johnson-Pais, Teresa L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA; [Wilson, Desiree] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA; [Gelfond, Jonathon A. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Mustafa, SB (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, Div Neonatol, San Antonio, TX 78229 USA.	mustafa@uthscsa.edu			National Institutes of Health (NIH) [8UL1TR001120]; NIH (NCI) [P30 CA054174]; National Institutes of Health, National Center for Advancing Translational Sciences [KL2 TR001118]; Parker B. Francis Foundation	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health, National Center for Advancing Translational Sciences; Parker B. Francis Foundation	1. SM: National Institutes of Health (NIH) 8UL1TR001120, www.nih.gov, sponsor did not play a role in the study design, data collection, analysis, decision to publication, or preparation of the manuscript. Flow Cytometry Facility at UT Health San Antonio with funding from University and the NIH (NCI P30 CA054174), sponsor did not play a role in the study design, data collection, analysis, decision to publication, or preparation of the manuscript. 2. AM: National Institutes of Health, National Center for Advancing Translational Sciences KL2 TR001118, www.nih.gov, sponsor did not play a role in the study design, data collection, analysis, decision to publication, or preparation of the manuscript; Parker B. Francis Foundation, www.francisfellowships.org, sponsor did not play a role in the study design, data collection, analysis, decision to publication, or preparation of the manuscript.	Ahmad A, 2002, AM J PHYSIOL-LUNG C, V283, pL573, DOI 10.1152/ajplung.00410.2001; Ahmad T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.213; Ahn SY, 2017, J PEDIATR-US, V185, P49, DOI 10.1016/j.jpeds.2017.02.061; Asikainen TM, 2005, PEDIATR PULM, V40, P538, DOI 10.1002/ppul.20321; Aslam M, 2009, AM J RESP CRIT CARE, V180, P1122, DOI 10.1164/rccm.200902-0242OC; Balgi-Agarwal S, 2018, CELLS TISSUES ORGANS, V205, P137, DOI 10.1159/000489256; Baraldi E, 2007, NEW ENGL J MED, V357, P1946, DOI 10.1056/NEJMra067279; Collins JJP, 2018, STEM CELLS DEV, V27, P1109, DOI 10.1089/scd.2017.0145; Collins JJP, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00061; Collins JJP, 2014, ANTIOXID REDOX SIGN, V21, P1849, DOI 10.1089/ars.2013.5781; Collins JJP, 2014, BIRTH DEFECTS RES A, V100, P217, DOI 10.1002/bdra.23227; D'Angio CT, 2014, AM J PHYSIOL-LUNG C, V307, pL959, DOI 10.1152/ajplung.00228.2014; Digeronimo RJ, 2007, PEDIATR RES, V62, P277, DOI 10.1203/PDR.0b013e3181256aeb; Duggan N, 2010, NAT ED, V3, P5; Fung ME, 2014, PEDIATR RES, V75, P2, DOI 10.1038/pr.2013.176; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; Hou A, 2015, AM J PHYSIOL-LUNG C, V308, pL861, DOI 10.1152/ajplung.00099.2014; Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736; Jobe AH, 2011, CURR OPIN PEDIATR, V23, P167, DOI 10.1097/MOP.0b013e3283423e6b; Martinez-Lorenzo MJ, 2009, J ORTHOP RES, V27, P1499, DOI 10.1002/jor.20898; Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116; Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113; Lapi Simone, 2008, BMC Res Notes, V1, P53, DOI 10.1186/1756-0500-1-53; Lee TC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111390; Lee Tsung-Han, 2013, BMC Res Notes, V6, P528, DOI 10.1186/1756-0500-6-528; Mobius Marius A, 2016, Mol Cell Pediatr, V3, P18, DOI 10.1186/s40348-016-0046-6; Mobius MA, 2019, AM J RESP CELL MOL, V60, P592, DOI 10.1165/rcmb.2018-0358OC; O'Reilly M, 2017, CELL TISSUE RES, V367, P737, DOI 10.1007/s00441-016-2517-4; Ota C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31214-x; Pang JJ, 1998, GRAEF ARCH CLIN EXP, V236, P696, DOI 10.1007/s004170050143; Pierro M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011932.pub2; Pittenger MF, 1999, SCIENCE, P284; Popova AP, 2010, PEDIATRICS, V126, pE1127, DOI 10.1542/peds.2009-3445; Popova AP, 2010, AM J PHYSIOL-LUNG C, V298, pL735, DOI 10.1152/ajplung.00347.2009; PRINGLE KC, 1986, CLIN OBSTET GYNECOL, V29, P502, DOI 10.1097/00003081-198609000-00006; Schmalisch G, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-37; Shivanna B, 2016, TOXICOL SCI, V152, P155, DOI 10.1093/toxsci/kfw071; Stocks J, 2013, LANCET RESP MED, V1, P728, DOI 10.1016/S2213-2600(13)70118-8; Tan HL, 2013, THORAX, V68, P788, DOI 10.1136/thoraxjnl-2013-203307; Ten VS, 2017, PEDIATR RES, V81, P286, DOI 10.1038/pr.2016.216; Teng RJ, 2017, AM J PHYSIOL-LUNG C, V312, P1586, DOI 10.1152/ajplung.00405.2016; Teti G, 2012, MICROSC RES TECHNIQ, V75, P596, DOI 10.1002/jemt.21096; Thebaud B, 2007, AM J RESP CRIT CARE, V175, P978, DOI 10.1164/rccm.200611-1660PP; van Haaften T, 2009, AM J RESP CRIT CARE, V180, P1131, DOI 10.1164/rccm.200902-0179OC; Willis GR, 2018, PEDIATR RES, V83, P298, DOI 10.1038/pr.2017.256; Yick CY, 2013, AM J RESP CRIT CARE, V187, P1076, DOI 10.1164/rccm.201210-1886OC; Zaganescu R, 2015, MICROSC RES TECHNIQ, V78, P792, DOI 10.1002/jemt.22542	47	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2020	15	3							e0229521	10.1371/journal.pone.0229521	http://dx.doi.org/10.1371/journal.pone.0229521			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8TR	32142526	gold, Green Published			2023-01-03	WOS:000535271600015
J	Keers, RN; Hann, M; Alshehri, GH; Bennett, K; Miller, J; Prescott, L; Brown, P; Ashcroft, DM				Keers, Richard N.; Hann, Mark; Alshehri, Ghadah H.; Bennett, Karen; Miller, Joan; Prescott, Lorraine; Brown, Petra; Ashcroft, Darren M.			Prevalence, nature and predictors of omitted medication doses in mental health hospitals: A multi-centre study	PLOS ONE			English	Article							ADMINISTRATION ERRORS; SAFETY; CARE; OMISSIONS; NURSES; IMPACT; TIME; HARM	Objective Limited evidence concerning the burden and predictors of omitted medication doses within mental health hospitals could severely limit improvement efforts in this specialist setting. This study aimed to determine the prevalence, nature and predictors of omitted medication doses affecting hospital inpatients in two English National Health Service (NHS) mental health trusts. Methods Over 6 data collection days trained pharmacy teams screened inpatient prescription charts for scheduled and omitted medication doses within 27 adult and elderly wards across 9 psychiatric hospitals. Data were collected for inpatients admitted up to two weeks prior to each data collection day. Omitted doses were classified as 'time critical' and 'preventable' based on established criteria. Omitted dose frequencies were presented with 95% confidence intervals (CI). Multilevel logistic regression analyses determined the predictors of omitted dose occurrence, with omission risks presented as adjusted odds ratios (OR) with 95% CI. Results 18,664 scheduled medication doses were screened for 444 inpatients and 2,717 omissions were identified, resulting in a rate of 14.6% (95% CI 14.1-15.1). The rate of 'time critical' omitted doses was 19.3% (95% CI 16.3-22.6%). 'Preventable' omitted doses comprised one third of all omissions (34.5%, 930/2694). Logistic regression analysis revealed that medicines affecting the central nervous system were 55% less likely to be omitted compared to all other medication classes (9.9% vs. 18.8%, OR 0.45 (0.40-0.52)) and that scheduled doses administered using non-oral routes were more likely to be omitted compared the oral route (inhaled OR 3.47 (2.64-4.57), topical 2.71 (2.11-3.46), 'other' 2.15 (1.19-3.90)). 'Preventable' dose omissions were more than twice as likely to occur for 'time critical' medications than non-time critical medications (50.4% vs. 33.8%, OR 2.24 (1.22-4.11)). Conclusions Omitted medication doses occur commonly in mental health hospitals with 'preventable' omissions a key contributor to this burden. Important targets for remedial intervention have been identified.	[Keers, Richard N.; Alshehri, Ghadah H.; Brown, Petra; Ashcroft, Darren M.] Univ Manchester, Ctr Pharmacoepidemiol & Drug Safety, Div Pharm & Optometry, Sch Hlth Sci,Fac Biol Med & Hlth, Manchester, Lancs, England; [Keers, Richard N.; Ashcroft, Darren M.] Univ Manchester, Manchester Acad Hlth Sci Ctr MAHSC, NIHR Greater Manchester Patient Safety Translat R, Manchester, Lancs, England; [Keers, Richard N.; Miller, Joan] Greater Manchester Mental Hlth NHS Fdn Trust, Manchester, Lancs, England; [Hann, Mark] Univ Manchester, Sch Community Based Med, Primary Care Res Grp, Manchester, Lancs, England; [Bennett, Karen] Univ Bolton, Sch Hlth & Human Sci, Bolton, England; [Prescott, Lorraine] North West Boroughs Hlth Care NHS Fdn Trust, Warrington, Cheshire, England; [Brown, Petra] Pennine Care NHS Fdn Trust, Ashton Under Lyne, England	University of Manchester; University of Manchester; University of Manchester; University of Bolton	Keers, RN (corresponding author), Univ Manchester, Ctr Pharmacoepidemiol & Drug Safety, Div Pharm & Optometry, Sch Hlth Sci,Fac Biol Med & Hlth, Manchester, Lancs, England.; Keers, RN (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr MAHSC, NIHR Greater Manchester Patient Safety Translat R, Manchester, Lancs, England.; Keers, RN (corresponding author), Greater Manchester Mental Hlth NHS Fdn Trust, Manchester, Lancs, England.	richard.keers@manchester.ac.uk	Ashcroft, Darren/G-3244-2015; Keers, Richard/D-9136-2012	Ashcroft, Darren/0000-0002-2958-915X; Keers, Richard/0000-0001-7854-8154	University of Manchester	University of Manchester	The author(s) received no specific funding for this work. This work was supported internally by The University of Manchester and participating NHS trusts; no specific funding stream was used. These organisations had no role in the design, implementation or evaluation of this work, nor did they have a role in the decision to write and submit this manuscript for publication.	Abduldaeem HMK., 2016, IJPP, V24, P4; Alshehri GH, 2017, DRUG SAFETY, V40, P871, DOI 10.1007/s40264-017-0557-7; [Anonymous], 1982, AM J HOSP PHARM, V39, P321; Baqir W, 2015, INT J PHARM PRACT, V23, P327, DOI 10.1111/ijpp.12172; Barnes TRE, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007633; Barnes TRE, 2011, CNS DRUGS, V25, P383, DOI 10.2165/11587810-000000000-00000; Bressington D, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15020343; Carter S, 2010, PRIORY MED J; Coleman JJ, 2012, DRUG SAFETY, V35, P677, DOI 10.2165/11630750-000000000-00000; Cottney A, 2014, BMJ QUAL IMPROV REP, V3; Cottney A, 2015, BMJ QUAL IMPROV REP, V4; Cottney A, 2015, INT J MENT HEALTH NU, V24, P65, DOI 10.1111/inm.12096; Dickens Geoff, 2008, Nurs Stand, V22, P35; Donaldson LJ, 2017, LANCET, V389, P1680, DOI 10.1016/S0140-6736(17)31047-4; Duxbury JA, 2010, INT J MENT HEALTH NU, V19, P53, DOI 10.1111/j.1447-0349.2009.00638.x; Franklin BD, 2007, QUAL SAF HEALTH CARE, V16, P279, DOI 10.1136/qshc.2006.019497; Graudins LV, 2015, INT J QUAL HEALTH C, V27, P67, DOI 10.1093/intqhc/mzu099; Haw C, 2011, J PSYCHIATR MENT HLT, V18, P308, DOI 10.1111/j.1365-2850.2010.01664.x; Haw C, 2007, INT J QUAL HEALTH C, V19, P210, DOI 10.1093/intqhc/mzm019; Haw CM, 2005, PSYCHIAT SERV, V56, P1610, DOI 10.1176/appi.ps.56.12.1610; Howard L, 2011, J PSYCHIATR MENT HLT, V18, P105, DOI 10.1111/j.1365-2850.2010.01642.x; Janssen EM, 2015, GEN HOSP PSYCHIAT, V37, P199, DOI 10.1016/j.genhosppsych.2015.03.004; Jheeta S, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2462-2; Joint Formulary Committee, 2015, BRIT NATL FORMULARY; Keers RN, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206233; Keers RN, 2013, DRUG SAFETY, V36, P1045, DOI 10.1007/s40264-013-0090-2; Kothari M, 2016, INT J CLIN PHARM-NET, V38, P289, DOI 10.1007/s11096-015-0236-7; Latimer Sharon L., 2011, Journal of Pharmacy Practice and Research, V41, P188; Lewis PJ, 2019, EUR J HOSP PHARM, V26, P253, DOI 10.1136/ejhpharm-2017-001401; Maidment ID, 2005, PSYCHIATR BULL, V29, P298, DOI 10.1192/pb.29.8.298; Maidment Ian D, 2009, Ment Health Fam Med, V6, P203; Morley C, 2016, DRUGS THER PERSPECT, V32, P203, DOI DOI 10.1007/S40267-016-0289-2; Mutsatsa S., 2017, MED MANAGEMENT MENTA; National Patient Safety Agency, 2010, NPSA2010RRR009; Owiti JA, 2011, J PSYCHIATR MENT HLT, V18, P637, DOI 10.1111/j.1365-2850.2011.01713.x; Panagioti M, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4185; Paton C, 2013, BIPOLAR DISORD, V15, P865, DOI 10.1111/bdi.12128; Rostami P, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028170; Seston EM, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4146-6; Vincent C, 2014, BMJ QUAL SAF, V23, P670, DOI 10.1136/bmjqs-2013-002757	40	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2020	15	2							e0228868	10.1371/journal.pone.0228868	http://dx.doi.org/10.1371/journal.pone.0228868			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP9GK	32027720	Green Published, gold			2023-01-03	WOS:000534623800077
J	Costantino, G; Solbiati, M				Costantino, Giorgio; Solbiati, Monica			Atrial fibrillation cardioversion in the emergency department	LANCET			English	Editorial Material							STROKE PREVENTION; MANAGEMENT; ANTICOAGULATION; PREVALENCE; CONVERSION; GUIDELINES; RISK		[Costantino, Giorgio] Osped Maggiore Policlin, Fdn Ist Ricovero & Cura Carattere Sci Ca Granda, Unita Operat Complessa Pronto Soccorso & Med Urge, I-20122 Milan, Italy; [Solbiati, Monica] Univ Milan, Dipartimento Sci Clin & Comunita, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Costantino, G (corresponding author), Osped Maggiore Policlin, Fdn Ist Ricovero & Cura Carattere Sci Ca Granda, Unita Operat Complessa Pronto Soccorso & Med Urge, I-20122 Milan, Italy.	giorgio.costantino@unimi.it	Solbiati, Monica/K-4755-2016; costantino, giorgio/AAC-6441-2022	Solbiati, Monica/0000-0003-1964-3770; costantino, giorgio/0000-0002-6391-3849				Andrade JG, 2018, CAN J CARDIOL, V34, P1371, DOI 10.1016/j.cjca.2018.08.026; [Anonymous], 2018, J AM HEART ASSOC; Costantino G, 2017, INTERN EMERG MED, V12, P693, DOI 10.1007/s11739-016-1580-x; Go AS, 2003, JAMA-J AM MED ASSOC, V290, P2685, DOI 10.1001/jama.290.20.2685; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Heeringa J, 2006, EUR HEART J, V27, P949, DOI 10.1093/eurheartj/ehi825; January CT, 2019, J AM COLL CARDIOL, V74, P104, DOI 10.1016/j.jacc.2019.01.011; Kochiadakis GE, 2007, AM J CARDIOL, V99, P1721, DOI 10.1016/j.amjcard.2007.01.059; Pluymaekers NAHA, 2019, NEW ENGL J MED, V380, P1499, DOI 10.1056/NEJMoa1900353; RODMAN T, 1966, AM J MED, V41, P249, DOI 10.1016/0002-9343(66)90020-9; Stiell IG, 2020, LANCET, V395, P339, DOI 10.1016/S0140-6736(19)32994-0; Truchanwicz E, 2016, EUR HEART J, V37, P583	12	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 1	2020	395	10221					313	314						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KH7WI	32007148				2023-01-03	WOS:000510860200007
J	Bhowmik, KR; Das, S; Islam, MA				Bhowmik, Kakoli Rani; Das, Sumonkanti; Islam, Md. Atiqul			Modelling the number of antenatal care visits in Bangladesh to determine the risk factors for reduced antenatal care attendance	PLOS ONE			English	Article							MATERNAL HEALTH-SERVICES; ZERO-INFLATED POISSON; REGRESSION; TRENDS	The existence of excess zeros in the distribution of antenatal care (ANC) visits in Bangladesh raises the research question of whether there are two separate generating processes in taking ANC and the frequency of ANC. Thus the main objective of this study is to identify a proper count regression model for the number of ANC visits by pregnant women in Bangladesh covering the issues of overdispersion, zero-inflation, and intra-cluster correlation with an additional objective of determining risk factors for ANC use and its frequency. The data have been extracted from the nationally representative 2014 Bangladesh Demographic and Health Survey, where 22% of the total 4493 women did not take any ANC during pregnancy. Since these zero ANC visits can be either structural or sampling zeros, two-part zero-inflated and hurdle regression models are investigated along with the standard one-part count regression models. Correlation among response values has been accounted for by incorporating cluster-specific random effects in the models. The hurdle negative binomial regression model with cluster-specific random intercepts in both the zero and the count part is found to be the best model according to various diagnostic tools including likelihood ratio and uniformity tests. The results show that women who have poor education, live in poor households, have less access to mass media, or belong to the Sylhet and Chittagong regions are less likely to use ANC and also have fewer ANC visits. Additionally, women who live in rural areas, depend on family members' decisions to take health care, and have unintended pregnancies had fewer ANC visits. The findings recommend taking both cluster-specific random effects and overdispersion and zero-inflation into account in modelling the ANC data of Bangladesh. Moreover, safe motherhood programmes still need to pay particular attention to disadvantaged and vulnerable subgroups of women.	[Bhowmik, Kakoli Rani] Leiden Univ, Med Ctr, Dept Med Decis Making, Leiden, Netherlands; [Das, Sumonkanti] Maastricht Univ, Dept Quantitat Econ, Maastricht, Netherlands; [Das, Sumonkanti; Islam, Md. Atiqul] Shahjalal Univ Sci & Technol, Dept Stat, Sylhet, Bangladesh; [Das, Sumonkanti] Univ Wollongong, Fac Engn & Informat Sci, Wollongong, NSW, Australia	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Maastricht University; Shahjalal University of Science & Technology (SUST); University of Wollongong	Islam, MA (corresponding author), Shahjalal Univ Sci & Technol, Dept Stat, Sylhet, Bangladesh.	atique-sta@sust.edu	Das, Sumonkanti/AAY-3810-2020	Das, Sumonkanti/0000-0003-1560-2349; ISLAM, MD ATIQUL/0000-0003-2683-0945				Ali MM, 2012, INDIAN ECON J, V60, P91; Ali N, 2018, HEALTH SERV RES MANA, V5, DOI 10.1177/2333392818781729; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; Amrin A, 2016, INT J SCI RES METHOD, V5, P49; [Anonymous], [No title captured]; Anwar I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120309; Babalola S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-43; Bangladesh Bureau of Statistics, 2017, PREL REP HOUS INC EX; Beeckman K, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-527; Bolker BM, 2009, TRENDS ECOL EVOL, V24, P127, DOI 10.1016/j.tree.2008.10.008; Cameron A. Colin, 2013, ECONOMETRIC SOC MONO, V53; CAMERON AC, 2001, COMPANION THEORETICA, P331; Das S, 2019, J STAT COMPUT SIM, V89, P1090, DOI 10.1080/00949655.2018.1553242; Das S, 2017, J R STAT SOC A STAT, V180, P1137, DOI 10.1111/rssa.12311; Guliani H, 2014, HEALTH POLICY PLANN, V29, P589, DOI 10.1093/heapol/czt045; Hall DB, 2000, BIOMETRICS, V56, P1030, DOI 10.1111/j.0006-341X.2000.01030.x; Haque M., 2009, INTERNET J HLTH, V8, P1; He Hua, 2014, Shanghai Arch Psychiatry, V26, P236, DOI 10.3969/j.issn.1002-0829.2014.04.008; Hinde J, 1998, COMPUT STAT DATA AN, V27, P151, DOI 10.1016/S0167-9473(98)00007-3; Hossain B., 2015, J DEV AREAS, V49, P109, DOI [10.1353/jda.2015.0045, DOI 10.1353/JDA.2015.0045]; Islam MM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204752; Islam MR, 2011, RURAL REMOTE HEALTH, V11; Jahan M, 2017, INT J COMMUNITY MED, V3, P925; Kabir R, 2013, IOSR J NURSING HLTH, V2; Kamal S. M. M., 2009, Asian Population Studies, V5, P153, DOI 10.1080/17441730902992075; Mamun MAA, 2014, THESIS; Min YY, 2005, STAT MODEL, V5, P1, DOI 10.1191/1471082X05st084oa; Ministry of Health and Family Welfare, 2017, HLTH POPULATION NUTR; National Institute of Population Research and Training (NIPORT) Mitra and Associates and ICF International, 2016, BANGL DEM HLTH SURV; NIPORT International Centre for Diarrhoeal Disease Research Bangladesh MEASURE Evaluation, 2017, BANGL MAT MORT HLTH; Pinheiro JC., 1995, J COMPUTATIONAL GRAP, V4, P12, DOI DOI 10.2307/1390625; Rahman A, 2017, J HEALTH POPUL NUTR, V36, DOI 10.1186/s41043-016-0078-5; Rahman M., 2008, HLTH POLICY DEV, V6, P117; Rahman MM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157760; Sepehri A, 2008, SOC SCI MED, V67, P1009, DOI 10.1016/j.socscimed.2008.06.005; Shahabuddin ASM, 2015, TROP MED INT HEALTH, V20, P822, DOI 10.1111/tmi.12503; Shahjahan M, 2017, MIDWIFERY, V52, P42, DOI 10.1016/j.midw.2017.05.011; Staub KE, 2013, HEALTH ECON, V22, P673, DOI 10.1002/hec.2844; VUONG QH, 1989, ECONOMETRICA, V57, P307, DOI 10.2307/1912557; World Health Organization, 2007, INT MAN PREGN CHILD; Yau KKW, 2001, STAT MED, V20, P2907, DOI 10.1002/sim.860	41	12	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2020	15	1							e0228215	10.1371/journal.pone.0228215	http://dx.doi.org/10.1371/journal.pone.0228215			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP8WY	31978200	Green Published, gold			2023-01-03	WOS:000534599100128
J	Giummarra, MJ; Tardif, H; Blanchard, M; Tonkin, A; Arnold, CA				Giummarra, Melita J.; Tardif, Hilarie; Blanchard, Megan; Tonkin, Andrew; Arnold, Carolyn A.			Hypertension prevalence in patients attending tertiary pain management services, a registry-based Australian cohort study	PLOS ONE			English	Article							CARDIOVASCULAR RISK-FACTORS; REPORTING CHRONIC PAIN; HEART-RATE-VARIABILITY; STRESS SCALES DASS-21; BODY-MASS INDEX; LOW-BACK-PAIN; BLOOD-PRESSURE; GENERAL-POPULATION; SELF-REPORTS; DEPRESSION	Persistent pain and hypertension often co-occur, and share several biological and lifestyle risk factors. The present study aimed to provide insight into the prevalence of, and factors associated with, hypertension in the largest cohort of patients seeking treatment in 43 tertiary pain clinics in Australia. Adults aged > = 18 years registered to the electronic Persistent Pain Outcomes Collaboration registry between 2013 and 2018 were included if they had persistent non-cancer pain (N = 43,789). Risk Ratios (RRs) compared prevalence of self-reported hypertension with the general and primary care Australian populations, and logistic regression examined factors associated with hypertension. One in four (23.9%) patients had hypertension, which was higher than the Australian adult population (2014-15: RR = 5.86, 95%CI: 5.66, 6.06; 2017-18: RR = 9.40, 95%CI: 9.01, 9.80), and in primary care patients (2011-13: RR = 1.17, 95%CI: 1.15, 1.20). Adjusting for covariates, patients with higher odds of hypertension were older, lived in regions with higher socioeconomic disadvantage, had higher levels of BMI, were born outside the Oceania/Australasia region, and had comorbid arthritis, diabetes, or severe-extremely severe anxiety symptoms. Female patients and those with depression symptoms had lower adjusted odds. Unadjusted analyses showed an association between widespread pain, pain duration, pain severity and interference, and lower pain self-efficacy with hypertension; however, only pain severity remained significant in adjusted analyses. Hypertension was more prevalent in people with persistent pain than in the general community, was associated with more severe pain, and commonly co-occurred with pain-related impairments. Routine hypertension screening and treatment targeting shared mechanisms of hypertension and pain may improve treatment outcomes in the pain clinic setting.	[Giummarra, Melita J.; Tonkin, Andrew] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Giummarra, Melita J.; Arnold, Carolyn A.] Caulfield Hosp, Caulfield Pain Management & Res Ctr, Caulfield, Vic, Australia; [Tardif, Hilarie; Blanchard, Megan] Univ Wollongong, Australian Hlth Serv Res Inst, Wollongong, NSW, Australia; [Arnold, Carolyn A.] Monash Univ, Sch Med Nursing & Hlth Sci, Acad Board Anaesthesia & Perioperat Med, Clayton, Vic, Australia	Monash University; University of Wollongong; Monash University	Giummarra, MJ (corresponding author), Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia.; Giummarra, MJ (corresponding author), Caulfield Hosp, Caulfield Pain Management & Res Ctr, Caulfield, Vic, Australia.	melita.giummarra@monash.edu	Arnold, Carolyn Anne/AAP-8961-2021; Giummarra, Melita/H-8387-2012	Giummarra, Melita/0000-0001-7839-6058; Blanchard, Megan/0000-0002-8423-0203	ARC DECRA fellowship [DE170100726]	ARC DECRA fellowship(Australian Research Council)	This work was supported by an ARC DECRA fellowship (DE170100726) to MJG. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson HI, 2009, DISABIL REHABIL, V31, P1980, DOI 10.3109/09638280902874154; [Anonymous], 2013, SOC IND AR SEIFA; Atkinson TM, 2010, PAIN MED, V11, P337, DOI 10.1111/j.1526-4637.2009.00774.x; Australia Bureau of Statistics, 2016, STAND AUSTR CLASS CO; Australian Bureau of Statistics, 2016, NAT HLTH SURV 1 RES; Australian Bureau of Statistics, 2018, 4364055001D0003 AUST; Babu AS, 2016, HEART LUNG CIRC, V25, P333, DOI 10.1016/j.hlc.2015.10.015; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; Bertisch SM, 2009, J PSYCHOSOM RES, V66, P511, DOI 10.1016/j.jpsychores.2008.12.003; Bhat SK, 2017, J HYPERTENS, V35, P1983, DOI [10.1097/HJH.0000000000001410, 10.1097/hjh.0000000000001410]; Birk JL, 2019, HEALTH PSYCHOL, V38, P802, DOI 10.1037/hea0000737; Bramlage P, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-18; Britt HC, 2008, MED J AUSTRALIA, V189, P72, DOI 10.5694/j.1326-5377.2008.tb01919.x; Bruehl S, 2005, CLIN J PAIN, V21, P147, DOI 10.1097/00002508-200503000-00006; Bruehl S, 2018, PAIN, V159, P119, DOI 10.1097/j.pain.0000000000001070; Burns JW, 2015, J BEHAV MED, V38, P372, DOI 10.1007/s10865-014-9608-z; Bursac Z, 2008, SOURCE CODE BIOL MED, V3, DOI 10.1186/1751-0473-3-17; Buse DC, 2010, J NEUROL NEUROSUR PS, V81, P428, DOI 10.1136/jnnp.2009.192492; Chung OY, 2008, ANESTH ANALG, V107, P1018, DOI 10.1213/ane.0b013e31817f8dfe; Cleeland C, 1991, PAIN RES GR, P143; Cleeland CS, 1989, ADV PAIN RES THER, P391, DOI DOI 10.1093/BRAIN/113.5.1589; Deloitte Access Economics, 2019, COST PAIN AUSTR; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Edwards RR, 2016, J PAIN, V17, pT70, DOI 10.1016/j.jpain.2016.01.001; Fine PG, 2011, PAIN MED, V12, P996, DOI 10.1111/j.1526-4637.2011.01187.x; Garg N., 2012, J MUSCULOSKELET MED, V29, P13; Gerbershagen HJ, 2011, BRIT J ANAESTH, V107, P619, DOI 10.1093/bja/aer195; Ghosh A, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-557; Goldman N, 2003, J CLIN EPIDEMIOL, V56, P148, DOI 10.1016/S0895-4356(02)00580-2; Goncalves VSS, 2018, J HYPERTENS, V36, P970, DOI 10.1097/HJH.0000000000001648; Goodson NJ, 2013, PAIN, V154, P1595, DOI 10.1016/j.pain.2013.04.043; Hansson P, 2014, PAIN, V155, P1932, DOI 10.1016/j.pain.2014.07.016; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hoeper MM, 2005, EUR RESPIR J, V26, P858, DOI 10.1183/09031936.05.00075305; Kerkhoff AC, 2012, J HYPERTENS, V30, P2112, DOI 10.1097/HJH.0b013e3283588268; Khattar RS, 1999, CIRCULATION, V100, P1071, DOI 10.1161/01.CIR.100.10.1071; Kurita GP, 2012, PAIN, V153, P2332, DOI 10.1016/j.pain.2012.07.023; Leino-Arjas P, 2006, SCAND J WORK ENV HEA, V32, P12, DOI 10.5271/sjweh.971; Licht CMM, 2009, HYPERTENSION, V53, P631, DOI 10.1161/HYPERTENSIONAHA.108.126698; Lovibond SH, 1995, MANUAL DEPRESSION AN; MBF Foundation, 2007, HIGH PRIC PAIN EC IM; McLean SA, 2011, SPINE, V36, pS226, DOI 10.1097/BRS.0b013e3182387fb4; Meeus M, 2013, SEMIN ARTHRITIS RHEU, V43, P279, DOI 10.1016/j.semarthrit.2013.03.004; Mentz G, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-312; Mundal I, 2016, J PAIN, V17, P1246, DOI 10.1016/j.jpain.2016.08.006; Nicholas N, ANN C BRIT PSYCH SOC; Nolet PS, 2012, J MANIP PHYSIOL THER, V35, P176, DOI 10.1016/j.jmpt.2012.01.006; Nuttall Frank Q, 2015, Nutr Today, V50, P117; O'Connor SR, 2015, ARCH PHYS MED REHAB, V96, P724, DOI 10.1016/j.apmr.2014.12.003; Okura Y, 2004, J CLIN EPIDEMIOL, V57, P1096, DOI 10.1016/j.jclinepi.2004.04.005; Olsen RB, 2013, PAIN, V154, P257, DOI 10.1016/j.pain.2012.10.020; Pandey A, 2015, CIRC-HEART FAIL, V8, P1032, DOI 10.1161/CIRCHEARTFAILURE.115.002130; Park C, 2013, J CLIN PSYCHOL, V69, P45, DOI 10.1002/jclp.21910; Parkitny L, 2012, J CLIN EPIDEMIOL, V65, P189, DOI 10.1016/j.jclinepi.2011.05.010; Parsons S, 2015, EUR J PAIN, V19, P167, DOI 10.1002/ejp.533; Paterniti S, 2000, BRIT J PSYCHIAT, V176, P464, DOI 10.1192/bjp.176.5.464; Rubin Donald B., 1987, MULTIPLE IMPUTATION, DOI 10.1002/9780470316696; Sarink D, 2016, EUR J PREV CARDIOL, V23, P23, DOI 10.1177/2047487314554865; Searle A, 2015, CLIN REHABIL, V29, P1155, DOI 10.1177/0269215515570379; Semlitsch T, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008274.pub3; Shrestha PL, 2016, CURR OPIN CARDIOL, V31, P376, DOI 10.1097/HCO.0000000000000298; Smith N, 2016, PAIN MED, V17, P278, DOI 10.1093/pm/pnv048; Strine TW, 2008, PSYCHIAT SERV, V59, P1383, DOI 10.1176/appi.ps.59.12.1383; Sullivan M.J., 2009, PAIN CATASTROPHIZING; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524; Tardif H, 2016, PAIN MED MALDEN MASS; Tracy LM, 2016, PAIN, V157, P7, DOI 10.1097/j.pain.0000000000000360; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; van den Akker M, 2015, EUR J GEN PRACT, V21, P45, DOI 10.3109/13814788.2014.907266; Vernooij RWM, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0419-1; von Baeyer CL, 2011, PAIN MANAG, V1, P61, DOI 10.2217/PMT.10.2; Wolfe F, 2010, ARTHRIT CARE RES, V62, P600, DOI 10.1002/acr.20140; Wood BM, 2010, PAIN MED, V11, P1780, DOI 10.1111/j.1526-4637.2010.01005.x; Wooden M., 2008, HILDA PROJECT TECHNI; World Health Organization, 2013, BOD MASS IND BMI CLA; Xue J., 2014, INTEGRATIVE MED INT, V1, P162	76	7	7	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2020	15	1							e0228173	10.1371/journal.pone.0228173	http://dx.doi.org/10.1371/journal.pone.0228173			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP8WY	31978196	Green Published, gold			2023-01-03	WOS:000534599100123
J	Kaiser, HA; Saied, NN; Kokoefer, AS; Saffour, L; Zoller, JK; Helwani, MA				Kaiser, Heiko A.; Saied, Nahel N.; Kokoefer, Andreas S.; Saffour, Lina; Zoller, Jonathan K.; Helwani, Mohammad A.			Incidence and prediction of intraoperative and postoperative cardiac arrest requiring cardiopulmonary resuscitation and 30-day mortality in non-cardiac surgical patients	PLOS ONE			English	Article							RISK-FACTORS; ANESTHESIA; OUTCOMES; SURVIVAL	Background The incidence, prediction and mortality outcomes of intraoperative and postoperative cardiac arrest requiring cardiopulmonary resuscitation (CPR) in surgical patients are under investigated and have not been studied concurrently in a single study. Methods A retrospective cohort study was conducted using the American College of Surgeons National Surgical Quality Improvement Program data between 2008 and 2012. Firth's penalized logistic regression was used to study the incidence and identify risk factors for intraand postoperative CPR and 30-day mortality. simplified prediction model was constructed and internally validated to predict the studied outcomes. Results Among about 1.86 million non-cardiac operations, the incidence rate of intraoperative CPR was 0.03%, and for postoperative CPR was 0.33%. The 30-day mortality incidence rate was 1.25%. The incidence rate of events decreased overtime between 2008-2012. Of the 29 potential predictors, 14 were significant for intraoperative CPR, 23 for postoperative CPR, and 25 for 30-day mortality. The five strongest predictors (highest odd ratios) of intraoperative CPR were the American Society of Anesthesiologists (ASA) physical status, Systemic Inflammatory Response Syndrome (SIRS)/sepsis, surgery type, urgent/emergency case and anesthesia technique. Intraoperative CPR, ASA, age, functional status and end stage renal disease were the most significant predictors for postoperative CPR. The most significant predictors of 30-day mortality were ASA, age, functional status, SIRS/sepsis, and disseminated cancer. The predictions with the simplified five-factor model performed well and was comparable to the full prediction model. Postoperative cardiac arrest requiring CPR, compared to intraoperative, was associated with much higher mortality. Conclusions The incidence of cardiac arrest requiring CPR in surgical patients decreased overtime. Risk factors for intraoperative CPR, postoperative CPR and perioperative mortality are overlapped. We proposed a simplified approach compromised of five-factor model to identify patients at high risk. Postoperative, compare to intraoperative, cardiac arrest requiring CPR was associated with much higher mortality.	[Kaiser, Heiko A.; Kokoefer, Andreas S.; Saffour, Lina; Zoller, Jonathan K.; Helwani, Mohammad A.] Washington Univ, Dept Anesthesiol, St Louis, MO 63110 USA; [Kaiser, Heiko A.] Univ Bern, Dept Anesthesiol & Pain Med, Inselspital, Bern Univ Hosp, Freiburgstr, Bern, Switzerland; [Saied, Nahel N.] Univ Arkansas Med Sci, Dept Anesthesiol & Crit Care, Little Rock, AR 72205 USA; [Kokoefer, Andreas S.] Paracelsus Med Univ Salzburg, Dept Anesthesiol Perioperat Care & Intens Care Me, Strubergasse, Salzburg, Austria	Washington University (WUSTL); University of Bern; University Hospital of Bern; University of Arkansas System; University of Arkansas Medical Sciences; Paracelsus Private Medical University	Helwani, MA (corresponding author), Washington Univ, Dept Anesthesiol, St Louis, MO 63110 USA.	helwanim@wustl.edu	Kaiser, Heiko/AAB-1198-2021	Saied, Nahel/0000-0001-9242-4764; Zoller, Jonathan/0000-0002-3827-6163; Kaiser, Heiko/0000-0002-6082-9510				[Anonymous], 2013, APPL LOGISTIC REGRES; [Anonymous], 1993, BIOMETRIKA; Bainbridge D, 2012, LANCET, V380, P1075, DOI 10.1016/S0140-6736(12)60990-8; Ellis SJ, 2014, ANESTHESIOLOGY, V120, P829, DOI 10.1097/ALN.0000000000000153; Fleisher LA, 2014, CIRCULATION, V130, P2215, DOI 10.1161/CIR.0000000000000105; Harrell FE Jr, 2016, PACKAGE HMISC; Heinze G PM, 2013, FIRTHS BIAS REDUCED; Helwani MA, 2015, J BONE JOINT SURG AM, V97A, P186, DOI 10.2106/JBJS.N.00612; Hohn A, 2018, EUR J ANAESTH, V35, P266, DOI 10.1097/EJA.0000000000000685; Kazaure HS, 2013, JAMA SURG, V148, P14, DOI 10.1001/jamasurg.2013.671; King GZL, 2001, POLITICAL ANAL, V9; Merchant RM, 2011, CRIT CARE MED, V39, P2401, DOI 10.1097/CCM.0b013e3182257459; Nunnally ME, 2015, ANESTH ANALG, V120, P364, DOI 10.1213/ANE.0000000000000527; Ofoma UR, 2018, J AM COLL CARDIOL, V71, P402, DOI 10.1016/j.jacc.2017.11.043; Ramachandran SK, 2013, ANESTHESIOLOGY, V119, P1322, DOI 10.1097/ALN.0b013e318289bafe; Saied NN, 2017, BRIT J ANAESTH, V118, P105, DOI 10.1093/bja/aew383; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X	17	12	14	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2020	15	1							e0225939	10.1371/journal.pone.0225939	http://dx.doi.org/10.1371/journal.pone.0225939			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5QT	31967987	Green Published, gold			2023-01-03	WOS:000534373000003
J	Gostin, LO; Wood, AJ; Cuff, PA				Gostin, Lawrence O.; Wood, Alastair J.; Cuff, Patricia A.			Regulating Medicines in a Globalized World With Increased Recognition and Reliance Among Regulators A National Academies Report	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint summarizes recommendations from a 2020 National Academies of Sciences, Engineering, and Medicine (NASEM) committee report on ways to improve regulatory oversight of drugs in an era of global pharmaceutical research and development.	[Gostin, Lawrence O.] Georgetown Univ, ONeill Inst Natl & Global Hlth Law, Washington, DC USA; [Wood, Alastair J.] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA; [Cuff, Patricia A.] Natl Acad Sci, 2101 Constitut Ave Nw, Washington, DC 20418 USA; [Cuff, Patricia A.] Natl Acad Engn, Washington, DC 20418 USA; [Cuff, Patricia A.] Natl Acad Med, Washington, DC USA	Georgetown University; Vanderbilt University; National Academies of Sciences, Engineering & Medicine; National Academies of Sciences, Engineering & Medicine; National Academies of Sciences, Engineering & Medicine	Gostin, LO (corresponding author), Georgetown Univ, ONeill Inst Natl & Global Hlth Law, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu						European Medicines Agency, 2011, FIN REP INT API INSP; National Academies of Sciences Engineering and Medicine, 2019, REG MED GLOB WORLD N, DOI [10.17226/25594, DOI 10.17226/25594]; O'Brien J., 2019, THER INNOV REGUL SCI, V17, p216847901983452, DOI [10.1177/2168479019834529, DOI 10.1177/2168479019834529]; US Food and Drug Administration, 2018, FDA ANN VOL REC SEV; Valverde Jose Luis, 2016, Pharmaceuticals Policy and Law, V18, P19, DOI 10.3233/PPL-160429	5	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2020	324	2					145	146		10.1001/jama.2019.21793	http://dx.doi.org/10.1001/jama.2019.21793			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ8RW	32134427				2023-01-03	WOS:000553161000015
J	Ding, YQ; Ding, KJ; Yang, HJ; He, XM; Mo, WJ; Ding, XW				Ding, Yuqin; Ding, Kaijing; Yang, Hongjian; He, Xiangming; Mo, Wenju; Ding, Xiaowen			Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients	PLOS ONE			English	Article							PHASE-III TRIAL; SURGICAL ADJUVANT BREAST; PREOPERATIVE CHEMOTHERAPY; INTENSIFIED CHEMOTHERAPY; DARBEPOETIN ALPHA; PREPARE TRIAL; CYCLOPHOSPHAMIDE; EPIRUBICIN; DOCETAXEL; THERAPY	Purpose Neoadjuvant chemotherapy (NCT) is typically the initial treatment for non-early breast cancer patients. We thereby conducted a meta-analysis to explore whether dose-dense neoadjuvant chemotherapy (ddNCT) improved the long-term prognosis of patients compared to the standard NCT regimen. Methods We compared the differences in efficacy and prognosis between patients receiving standard NCT and ddNCT. We also calculated the pooled odds ratio (OR) of pathological complete response (pCR) and the pooled hazard ratio (HR) of overall survival (OS) and disease-free survival (DFS). Results Nine randomized controlled trials involving 3,724 patients from 10 published studies were included in the meta-analysis. The pooled OR for ddNCT was 1.18 (95% confidence interval (CI): 0.83-1.67, P = 0.356). A subgroup analysis in the cases with low hormone receptor expression levels showed the pCR in patients undergoing ddNCT was significantly higher than the pCR in patients undergoing standard NCT (OR = 1.36, 95% CI: 1.09-1.69, P = 0.007). There was no significant difference in DFS and OS between ddNCT and standard NCT (DFS: HR = 0.90, 95% CI: 0.79-1.02, P = 0.095; OS; HR = 0.91, 95% CI: 0.81-1.04, P = 0.160), regardless of hormone receptor expression levels. These data suggested the higher pCR rate in patients receiving ddNCT did not result in a survival benefit. Conclusions The meta-analysis demonstrated that ddNCT can significantly improve the pCR rate in patients with low hormone receptor expression levels, although patient survival was not significantly improved. The ddNCT can increase the breast-conserving rate and reduced preoperative waiting time without increasing adverse reactions. This regimen can be considered when developing an NCT plan.	[Ding, Yuqin; Yang, Hongjian; He, Xiangming; Mo, Wenju; Ding, Xiaowen] Chinese Acad Sci, Univ Chinese Acad Sci, Inst Canc Res & Basic Med Sci, Dept Breast Surg,Canc Hosp,Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China; [Ding, Kaijing] Zhejiang Univ, Affiliated Mental Hlth Ctr, Hangzhou Peoples Hosp 7, Dept Child Psychol, Hangzhou, Zhejiang, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Zhejiang Cancer Hospital; Zhejiang University	Ding, XW (corresponding author), Chinese Acad Sci, Univ Chinese Acad Sci, Inst Canc Res & Basic Med Sci, Dept Breast Surg,Canc Hosp,Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China.	dingxw@zjcc.org.cn		yuqin, ding/0000-0002-9562-7943	Natural Science Foundation of Zhejiang Province [LY18H160033]	Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	This study is supported by the Natural Science Foundation of Zhejiang Province (Grant number: LY18H160033), Hongjian Yang.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; [Anonymous], 2019, BREAST CANC VERS 3 2; [Anonymous], 2003, CANC LEUKEMIA GROUP, V21, P1431; Arun BK, 2011, ONCOLOGIST, V16, P1527, DOI 10.1634/theoncologist.2011-0134; Baldini E, 2003, ANN ONCOL, V14, P227, DOI 10.1093/annonc/mdg069; Bear HD, 2006, J CLIN ONCOL, V24, P2019, DOI 10.1200/JCO.2005.04.1665; Berruti A, 2014, J CLIN ONCOL, V32, P3883, DOI 10.1200/JCO.2014.55.2836; Boddington C, 2019, LANCET, V393, P1440, DOI 10.1016/S0140-6736(18)33137-4; Burnell M, 2010, J CLIN ONCOL, V28, P77, DOI 10.1200/JCO.2009.22.1077; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Curigliano G, 2017, ANN ONCOL, V28, P1700, DOI 10.1093/annonc/mdx308; Ellis GK, 2011, J CLIN ONCOL, V29, P1014, DOI 10.1200/JCO.2009.27.6543; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Miller KD, 1999, J CLIN ONCOL, V17, P3033, DOI 10.1200/JCO.1999.17.10.3033; Petrelli F, 2014, BREAST CANCER RES TR, V144, P223, DOI 10.1007/s10549-014-2876-z; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Therasse P, 2003, J CLIN ONCOL, V21, P843, DOI 10.1200/JCO.2003.05.135; Traina TA, 2016, ENCY CANC, P1; Untch M, 2011, ANN ONCOL, V22, P1988, DOI 10.1093/annonc/mdq709; Untch M, 2011, ANN ONCOL, V22, P1999, DOI 10.1093/annonc/mdq713; Untch M, 2009, J CLIN ONCOL, V27, P2938, DOI 10.1200/JCO.2008.20.3133; von Minckwitz G, 2005, J CLIN ONCOL, V23, P2676, DOI 10.1200/JCO.2005.05.078; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; Vriens BEPJ, 2013, EUR J CANCER, V49, P3102, DOI 10.1016/j.ejca.2013.06.012; Zardavas D, 2015, ANNU REV MED, V66, P31, DOI 10.1146/annurev-med-051413-024741	26	7	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2020	15	5							e0234058	10.1371/journal.pone.0234058	http://dx.doi.org/10.1371/journal.pone.0234058			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1WS	32470093	Green Published, gold			2023-01-03	WOS:000537552800226
J	Bockorny, B; Semenisty, V; Macarulla, T; Borazanci, E; Wolpin, BM; Stemmer, SM; Golan, T; Geva, R; Borad, MJ; Pedersen, KS; Park, JO; Ramirez, RA; Abad, DG; Feliu, J; Munoz, A; Ponz-Sarvise, M; Peled, A; Lustig, TM; Bohana-Kashtan, O; Shaw, SM; Sorani, E; Chaney, M; Kadosh, S; Haras, AV; Von Hoff, DD; Hidalgo, M				Bockorny, Bruno; Semenisty, Valerya; Macarulla, Teresa; Borazanci, Erkut; Wolpin, Brian M.; Stemmer, Salomon M.; Golan, Talia; Geva, Ravit; Borad, Mitesh J.; Pedersen, Katrina S.; Park, Joon Oh; Ramirez, Robert A.; Abad, David G.; Feliu, Jaime; Munoz, Andres; Ponz-Sarvise, Mariano; Peled, Amnon; Lustig, Tzipora M.; Bohana-Kashtan, Osnat; Shaw, Stephen M.; Sorani, Ella; Chaney, Marya; Kadosh, Shaul; Haras, Abi Vainstein; Von Hoff, Daniel D.; Hidalgo, Manuel			BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial	NATURE MEDICINE			English	Article							HUMAN CD34(+) CELLS; MOBILIZATION; IMMUNOTHERAPY; INHIBITORS; EFFICACY; ANTIBODY; GROWTH; BKT140	Results from the phase IIa COMBAT trial combining CXCR4 and PD-1 inhibition in patients with metastatic cancer show encouraging clinical responses in association with enhanced antitumor immune activation. Programmed cell death 1 (PD-1) inhibitors have limited effect in pancreatic ductal adenocarcinoma (PDAC), underscoring the need to co-target alternative pathways. CXC chemokine receptor 4 (CXCR4) blockade promotes T cell tumor infiltration and is synergistic with anti-PD-1 therapy in PDAC mouse models. We conducted a phase IIa, open-label, two-cohort study to assess the safety, efficacy and immunobiological effects of the CXCR4 antagonist BL-8040 (motixafortide) with pembrolizumab and chemotherapy in metastatic PDAC (). The primary outcome was objective response rate (ORR). Secondary outcomes were overall survival (OS), disease control rate (DCR) and safety. In cohort 1, 37 patients with chemotherapy-resistant disease received BL-8040 and pembrolizumab. The DCR was 34.5% in the evaluable population (modified intention to treat, mITT; N = 29), including nine patients (31%) with stable disease and one patient (3.4%) with partial response. Median OS (mOS) was 3.3 months in the ITT population. Notably, in patients receiving study drugs as second-line therapy, the mOS was 7.5 months. BL-8040 increased CD8(+) effector T cell tumor infiltration, decreased myeloid-derived suppressor cells (MDSCs) and further decreased circulating regulatory T cells. In cohort 2, 22 patients received BL-8040 and pembrolizumab with chemotherapy, with an ORR, DCR and median duration of response of 32%, 77% and 7.8 months, respectively. These data suggest that combined CXCR4 and PD-1 blockade may expand the benefit of chemotherapy in PDAC and warrants confirmation in subsequent randomized trials.	[Bockorny, Bruno] Beth Israel Deaconess Med Ctr, Div Med Oncol, Boston, MA 02215 USA; [Bockorny, Bruno; Wolpin, Brian M.] Harvard Med Sch, Boston, MA 02115 USA; [Semenisty, Valerya] Rambam Hlth Care Campus, Oncol, Haifa, Israel; [Macarulla, Teresa] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, IOB Quiron, Barcelona, Spain; [Borazanci, Erkut; Von Hoff, Daniel D.] HonorHlth Res Inst, Scottsdale, AZ USA; [Borazanci, Erkut; Von Hoff, Daniel D.] Translat Genom Res Inst, Phoenix, AZ USA; [Wolpin, Brian M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Stemmer, Salomon M.] Rabin Med Ctr, Davidoff Ctr, Inst Oncol, Petah Tiqwa, Israel; [Stemmer, Salomon M.; Golan, Talia] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Golan, Talia] Chaim Sheba Med Ctr, Oncol, Tel Hashomer, Israel; [Geva, Ravit] Tel Aviv Sourasky Med Ctr, Oncol, Tel Aviv, Israel; [Geva, Ravit] Tel Aviv Univ, Tel Aviv, Israel; [Borad, Mitesh J.] Mayo Clin Canc Ctr, Oncol, Scottsdale, AZ USA; [Pedersen, Katrina S.] Washington Univ, Sch Med, Oncol, St Louis, MO USA; [Park, Joon Oh] Sungkyunkwan Univ, Samsung Med Ctr, Hematol Oncol, Sch Med, Seoul, South Korea; [Ramirez, Robert A.] Ochsner Med Ctr, Oncol, New Orleans, LA USA; [Abad, David G.] Grp Oncol Fuenlabrada, Madrid, Spain; [Feliu, Jaime] Inst Invest Hosp Univ La Paz IdIPAZ, CIBERONC, Catedra UAM AMGEN, Madrid, Spain; [Munoz, Andres] Univ Complutense, Inst Invest Sanitaria Hosp Gregorio Maranon, Med Oncol Serv, Madrid, Spain; [Ponz-Sarvise, Mariano] Univ Navarra, Clin Univ Navarra, IDISNA, Pamplona, Spain; [Ponz-Sarvise, Mariano] Univ Navarra, Program Solid Tumors CIMA, IDISNA, Pamplona, Spain; [Peled, Amnon] Hebrew Univ Jerusalem, Goldyne Savad Inst Gene Therapy, Jerusalem, Israel; [Lustig, Tzipora M.; Bohana-Kashtan, Osnat; Shaw, Stephen M.; Sorani, Ella; Haras, Abi Vainstein] BioLineRx Ltd, Modiin, Israel; [Chaney, Marya] Merck & Co Inc, Early Oncol Dev, Kenilworth, NJ USA; [Kadosh, Shaul] StatExcellence Ltd, Nesher, Israel; [Hidalgo, Manuel] Weill Cornell Med, Joan & Sanford I Weill Dept Med, New York, NY 10065 USA; [Hidalgo, Manuel] New York Presbyterian Hosp, New York, NY 10038 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Rambam Health Care Campus; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Translational Genomics Research Institute; Harvard University; Dana-Farber Cancer Institute; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Mayo Clinic; Mayo Clinic Phoenix; Washington University (WUSTL); Sungkyunkwan University (SKKU); Samsung Medical Center; Ochsner Health System; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Hospital Universitario La Paz; Complutense University of Madrid; University of Navarra; University of Navarra; Hebrew University of Jerusalem; Merck & Company; Cornell University; NewYork-Presbyterian Hospital	Hidalgo, M (corresponding author), Weill Cornell Med, Joan & Sanford I Weill Dept Med, New York, NY 10065 USA.; Hidalgo, M (corresponding author), New York Presbyterian Hosp, New York, NY 10038 USA.	mah4006@med.cornell.edu	Ponz-Sarvise, Mariano/H-4104-2017; Ramirez, Robert A/G-4443-2015	Ponz-Sarvise, Mariano/0000-0002-3240-729X; Ramirez, Robert/0000-0001-8762-5852; Borazanci, Erkut/0000-0001-5136-5462; Pedersen, Katrina/0000-0003-2793-6901; Macarulla, Teresa/0000-0002-5856-4082	BioLineRx; Merck Sharp Dohme Corp.	BioLineRx; Merck Sharp Dohme Corp.(Merck & Company)	We thank the patients and their families for their participation in this study. This work was supported by BioLineRx and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA). Flow cytometry acquisition was performed at Sheba Medical Center (Tel HaShomer, Ramat Gan, Israel). MultiOmyx tests and analysis were performed at Neogenomics Laboratories (Aliso Viejo, CA, USA). The sponsor BioLineRx participated in the conception of this study. Data were analyzed and interpreted by BioLineRx in collaboration with the academic authors. The sponsor staff, M.H. and B.B., had access to all of the data. All authors vouch for the accuracy and completeness of the data and analyses reported and for the fidelity of the study to the protocol.	Abraham M, 2009, LEUKEMIA, V23, P1378, DOI 10.1038/leu.2009.56; Abraham M, 2007, STEM CELLS, V25, P2158, DOI 10.1634/stemcells.2007-0161; Abraham M, 2017, CLIN CANCER RES, V23, P6790, DOI 10.1158/1078-0432.CCR-16-2919; Benedicto A, 2018, ONCOL REP, V39, P2022, DOI 10.3892/or.2018.6254; Blando J, 2019, P NATL ACAD SCI USA, V116, P1692, DOI 10.1073/pnas.1811067116; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brown JS, 2018, BRIT J CANCER, V118, P312, DOI 10.1038/bjc.2017.376; Cubas R, 2018, J IMMUNOL, V201, P2273, DOI 10.4049/jimmunol.1800275; Deng Y, 2017, ONCOGENE, V36, P1090, DOI 10.1038/onc.2016.273; Fahham D, 2012, J THORAC CARDIOV SUR, V144, P1167, DOI 10.1016/j.jtcvs.2012.07.031; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Gaur P, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.5_suppl.73; Gerdes MJ, 2013, P NATL ACAD SCI USA, V110, P11982, DOI 10.1073/pnas.1300136110; Hu ZSI, 2018, CLIN CANCER RES, V24, P1326, DOI 10.1158/1078-0432.CCR-17-3099; Klein S, 2018, CANCER RES, V78, P1471, DOI 10.1158/0008-5472.CAN-17-0454; Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105; McKenzie JA, 2018, JNCI-J NATL CANCER I, V110, P777, DOI 10.1093/jnci/djx257; O'Reilly EM, 2019, JAMA ONCOL, V5, P1431, DOI 10.1001/jamaoncol.2019.1588; Peled A, 2019, J IMMUNOTHER CANCER, V7; Peled A, 2014, CLIN CANCER RES, V20, P469, DOI 10.1158/1078-0432.CCR-13-1302; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Schwickart M, 2016, CYTOM PART B-CLIN CY, V90, P209, DOI 10.1002/cyto.b.21327; Seo YD, 2019, CLIN CANCER RES, V25, P3934, DOI 10.1158/1078-0432.CCR-19-0081; Tamamura H, 2003, ORG BIOMOL CHEM, V1, P3656, DOI 10.1039/b306473p; Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X; Wang-Gillam A, 2019, EUR J CANCER, V108, P78, DOI 10.1016/j.ejca.2018.12.007; Wang-Gillam A, 2016, LANCET, V387, P545, DOI 10.1016/S0140-6736(15)00986-1; Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216	28	178	184	11	74	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2020	26	6					878	+		10.1038/s41591-020-0880-x	http://dx.doi.org/10.1038/s41591-020-0880-x		MAY 2020	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	LZ3ZG	32451495				2023-01-03	WOS:000535406400001
J	Rintoul, A; Colbert, A; Garner, S; Kotwani, A; Vogler, S; Bouvy, J; Hill, A				Rintoul, Andrew; Colbert, Allison; Garner, Sarah; Kotwani, Anita; Vogler, Sabine; Bouvy, Jacoline; Hill, Andrew			Medicines with one seller and many buyers: strategies to increase the power of the payer	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Rintoul, Andrew; Colbert, Allison; Garner, Sarah] World Hlth Org, Geneva, Switzerland; [Kotwani, Anita] Univ Delhi, VP Chest Inst, Delhi, India; [Vogler, Sabine] Gesundheit Osterreich, Vienna, Austria; [Bouvy, Jacoline] Natl Inst Hlth & Care Excellence, London, England; [Hill, Andrew] Univ Liverpool, Liverpool, Merseyside, England	World Health Organization; University of Delhi; National Institute for Health & Care Excellence; University of Liverpool	Colbert, A (corresponding author), World Hlth Org, Geneva, Switzerland.	colberta@who.int	Kotwani, Anita/ABF-6201-2021	Kotwani, Anita/0000-0003-3182-5155				Bouvy JC, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00280; Danzon PM, 2015, HEALTH ECON, V24, P238, DOI 10.1002/hec.3013; Department of Health and Human Services, 2019, FED REGISTER, V84, P2340; European Union, 2018, INN PAYM MOD HIGH CO; Flume Mathias, 2016, J Mark Access Health Policy, V4, DOI 10.3402/jmahp.v4.30970; Garner S, 2018, PHARMACOECONOMICS, V36, P5, DOI 10.1007/s40273-017-0567-4; Kotwani A., 2013, EC POLIT WKLY, P104; Kotwani A, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-285; Mackintosh M, 2018, SOC SCI MED, V200, P182, DOI 10.1016/j.socscimed.2018.01.008; Morgan SG, 2017, HEALTH POLICY, V121, P354, DOI 10.1016/j.healthpol.2017.02.002; OECD, 2018, PHARM INN ACC MED; OECD, 2017, NEW HLTH TECHN MAN A, DOI [10.1787/9789264266438, DOI 10.1787/9789264266438]; Organisation of Eastern Caribbean States, 2016, PHARM PROC SERV REP; Pan American Health Organization, WHAT IS PAHO REV FUN; Pacheco-Unguetti AP, 2014, SPAN J PSYCHOL, V17, DOI 10.1017/sjp.2014.32; Schneider P, 2019, MED PRICE SURVEYS AN; Thomson S, 2019, CAN PEOPLE AFFORD PA; Towse A, 2013, INT J TECHNOL ASSESS, V29, P360, DOI 10.1017/S0266462313000524; Vogler S, 2015, STUDY ENHANCED CROSS; Vogler S, 2018, POLICY BRIEF; Williams OD, 2015, AM J PUBLIC HEALTH, V105, P1290, DOI 10.2105/AJPH.2015.302554; Wirtz VJ, 2017, LANCET, V389, P403, DOI 10.1016/S0140-6736(16)31599-9; World Bank, 2017, WORK TOG BETT PROC O; World Health Organization, 2016, CHALL OPP IMPR ACC M; World Health Organization, 2007, WHOTCMMPM20071; World Health Organization, 2015, WHO GUID COUNTR PHAR	26	7	7	3	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2020	369								m1705	10.1136/bmj.m1705	http://dx.doi.org/10.1136/bmj.m1705			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LV3JK	32434753	hybrid, Green Published			2023-01-03	WOS:000538335800003
J	Armstrong, AW; Read, C				Armstrong, April W.; Read, Charlotte			Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SEVERE PLAQUE PSORIASIS; DOUBLE-BLIND; PHASE-III; CONTROLLED-TRIAL; MONOCLONAL-ANTIBODY; VS. METHOTREXATE; EFFICACY; SAFETY; MODERATE; RISK	This narrative review summarizes current evidence regarding the pathogenesis, clinical presentation, diagnosis, and treatments of plaque psoriasis. Importance Approximately 125 million people worldwide have psoriasis. Patients with psoriasis experience substantial morbidity and increased rates of inflammatory arthritis, cardiometabolic diseases, and mental health disorders. Observations Plaque psoriasis is the most common variant of psoriasis. The most rapid advancements addressing plaque psoriasis have been in its pathogenesis, genetics, comorbidities, and biologic treatments. Plaque psoriasis is associated with a number of comorbidities including psoriatic arthritis, cardiometabolic diseases, and depression. For patients with mild psoriasis, topical agents remain the mainstay of treatment, and they include topical corticosteroids, vitamin D analogues, calcineurin inhibitors, and keratolytics. The American Academy of Dermatology-National Psoriasis Foundation guidelines recommend biologics as an option for first-line treatment of moderate to severe plaque psoriasis because of their efficacy in treating it and acceptable safety profiles. Specifically, inhibitors to tumor necrosis factor alpha (TNF-alpha) include etanercept, adalimumab, certolizumab, and infliximab. Other biologics inhibit cytokines such as the p40 subunit of the cytokines IL-12 and IL-13 (ustekinumab), IL-17 (secukinumab, ixekizumab, bimekizumab, and brodalumab), and the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab, and mirikizumab). Biologics that inhibit TNF-alpha, p40IL-12/23, and IL-17 are also approved for the treatment of psoriatic arthritis. Oral treatments include traditional agents such as methotrexate, acitretin, cyclosporine, and the advanced small molecule apremilast, which is a phosphodiesterase 4 inhibitor. The most commonly prescribed light therapy used to treat plaque psoriasis is narrowband UV-B phototherapy. Conclusions and Relevance Psoriasis is an inflammatory skin disease that is associated with multiple comorbidities and substantially diminishes patients' quality of life. Topical therapies remain the cornerstone for treating mild psoriasis. Therapeutic advancements for moderate to severe plaque psoriasis include biologics that inhibit TNF-alpha, p40IL-12/23, IL-17, and p19IL-23, as well as an oral phosphodiesterase 4 inhibitor.	[Armstrong, April W.; Read, Charlotte] Univ Southern Calif Los Angeles, Dept Dermatol, Keck Sch Med, Los Angeles, CA USA; [Read, Charlotte] Imperial Coll London, Dept Med, London, England	Imperial College London	Armstrong, AW (corresponding author), Univ Southern Calif, 1975 Zonal Ave,KAM 510,MC 9034, Los Angeles, CA 90089 USA.	aprilarmstrong@post.harvard.edu						Abuabara K, 2010, BRIT J DERMATOL, V163, P586, DOI 10.1111/j.1365-2133.2010.09941.x; Ahlehoff O, 2011, J INTERN MED, V270, P147, DOI 10.1111/j.1365-2796.2010.02310.x; Ahlehoff O, 2012, EUR HEART J, V33, P2054, DOI 10.1093/eurheartj/ehr285; Alwan W, 2015, CLIN EXP RHEUMATOL, V33, pS2; ANDRESSEN C, 1982, HAUTARZT, V33, P214; Armstrong AW, 2020, JAMA DERMATOL, V156, P258, DOI 10.1001/jamadermatol.2019.4029; Armstrong AW, 2015, J AM ACAD DERMATOL, V72, P968, DOI 10.1016/j.jaad.2015.02.1095; Armstrong AW, 2014, JAMA DERMATOL, V150, P963, DOI 10.1001/jamadermatol.2014.1019; Armstrong AW, 2013, J AM ACAD DERMATOL, V68, P654, DOI 10.1016/j.jaad.2012.08.015; Armstrong AW, 2013, JAMA DERMATOL, V149, P84, DOI 10.1001/2013.jamadermatol.406; Armstrong AW, 2012, AM J CARDIOL, V109, P976, DOI 10.1016/j.amjcard.2011.11.025; Armstrong EJ, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000062; Bagel J, 2017, J AM ACAD DERMATOL, V77, P667, DOI 10.1016/j.jaad.2017.05.033; Barker J, 2011, BRIT J DERMATOL, V165, P1109, DOI 10.1111/j.1365-2133.2011.10615.x; Blauvelt A, 2017, J AM ACAD DERMATOL, V76, P405, DOI 10.1016/j.jaad.2016.11.041; Blauvelt A, 2017, J AM ACAD DERMATOL, V76, P60, DOI 10.1016/j.jaad.2016.08.008; Bruner Christine R, 2003, Dermatol Online J, V9, P2; Coates LC, 2013, BRIT J DERMATOL, V168, P802, DOI 10.1111/bjd.12190; Dalgard FJ, 2015, J INVEST DERMATOL, V135, P984, DOI 10.1038/jid.2014.530; Darley CR, 1996, BRIT J DERMATOL, V135, P390, DOI 10.1046/j.1365-2133.1996.d01-1010.x; Dey AK, 2017, JAMA CARDIOL, V2, P1013, DOI 10.1001/jamacardio.2017.1213; Dogra S, 2013, J EUR ACAD DERMATOL, V27, pe305, DOI 10.1111/j.1468-3083.2012.04644.x; Dowlatshahi EA, 2014, J INVEST DERMATOL, V134, P1542, DOI 10.1038/jid.2013.508; ELLIS CN, 1991, NEW ENGL J MED, V324, P277, DOI 10.1056/NEJM199101313240501; Elmets CA, 2019, J AM ACAD DERMATOL, V81, P775, DOI 10.1016/j.jaad.2019.04.042; Elmets CA, 2019, J AM ACAD DERMATOL, V80, P1073, DOI 10.1016/j.jaad.2018.11.058; Eppinga H, 2017, INFLAMM BOWEL DIS, V23, P1783, DOI 10.1097/MIB.0000000000001169; Gelfand JM, 2006, JAMA-J AM MED ASSOC, V296, P1735, DOI 10.1001/jama.296.14.1735; Gelfand JM, 2009, J INVEST DERMATOL, V129, P2411, DOI 10.1038/jid.2009.112; Gold LS, 2018, J AM ACAD DERMATOL, V79, P287, DOI 10.1016/j.jaad.2018.03.040; Gordon KB, 2018, LANCET, V392, P650, DOI 10.1016/S0140-6736(18)31713-6; Gottlieb A, 2017, J AM ACAD DERMATOL, V76, P70, DOI 10.1016/j.jaad.2016.07.058; Gottlieb AB, 2018, J AM ACAD DERMATOL, V79, P302, DOI 10.1016/j.jaad.2018.04.012; Gribetz C, 2004, J AM ACAD DERMATOL, V51, P731, DOI 10.1016/j.jaad.2004.06.010; Griffiths CEM, 2015, LANCET, V386, P541, DOI 10.1016/S0140-6736(15)60125-8; Griffiths CEM, 2010, NEW ENGL J MED, V362, P118, DOI 10.1056/NEJMoa0810652; Husni ME, 2007, J AM ACAD DERMATOL, V57, P581, DOI 10.1016/j.jaad.2007.04.001; Ito K, 2016, J DERMATOL, V43, P402, DOI 10.1111/1346-8138.13158; Kalb RE, 2015, JAMA DERMATOL, V151, P961, DOI 10.1001/jamadermatol.2015.0718; Karason A, 2003, AM J HUM GENET, V72, P125, DOI 10.1086/345646; Kimball AB, 2015, J AM ACAD DERMATOL, V72, P115, DOI 10.1016/j.jaad.2014.08.050; Koo JYM, 2000, J AM ACAD DERMATOL, V43, P821, DOI 10.1067/mjd.2000.107940; Landells I, 2015, J AM ACAD DERMATOL, V73, P594, DOI 10.1016/j.jaad.2015.07.002; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Lebwohl M, 2015, NEW ENGL J MED, V373, P1318, DOI 10.1056/NEJMoa1503824; Lebwohl Mark, 2007, J Drugs Dermatol, V6, P428; Lebwohl MG, 2019, J AM ACAD DERMATOL, V80, P282, DOI 10.1016/j.jaad.2018.09.002; Leonardi C, 2015, J DRUGS DERMATOL, V14, P1468; Lerman JB, 2017, CIRCULATION, V136, P263, DOI 10.1161/CIRCULATIONAHA.116.026859; Liao YH, 2007, BRIT J DERMATOL, V157, P1005, DOI 10.1111/j.1365-2133.2007.08201.x; Lin HW, 2011, J AM ACAD DERMATOL, V64, P495, DOI 10.1016/j.jaad.2010.01.050; Liu Y, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000041; Mansouri B, 2016, JAMA DERMATOL, V152, P1244, DOI 10.1001/jamadermatol.2016.2907; Mariette X, 2011, ANN RHEUM DIS, V70, P1895, DOI 10.1136/ard.2010.149419; Mease P, 2005, J AM ACAD DERMATOL, V52, P1, DOI 10.1016/j.jaad.2004.06.013; Mease PJ, 2020, ANN RHEUM DIS, V79, P123, DOI 10.1136/annrheumdis-2019-215386; Mehta NN, 2010, EUR HEART J, V31, P1000, DOI 10.1093/eurheartj/ehp567; Menter A, 2008, J AM ACAD DERMATOL, V58, P106, DOI 10.1016/j.jaad.2007.09.010; Menter A, 2019, J AM ACAD DERMATOL, V80, P1029, DOI 10.1016/j.jaad.2018.11.057; Menter A, 2017, DERMATOLOGY THER, V7, P365, DOI 10.1007/s13555-017-0198-x; Menter A, 2009, J AM ACAD DERMATOL, V61, P451, DOI 10.1016/j.jaad.2009.03.027; Menter A, 2009, J AM ACAD DERMATOL, V60, P643, DOI 10.1016/j.jaad.2008.12.032; Michalek IM, 2017, J EUR ACAD DERMATOL, V31, P205, DOI 10.1111/jdv.13854; Mody E, 2007, BRIT J DERMATOL, V157, P1050, DOI 10.1111/j.1365-2133.2007.08139.x; Nair RP, 2006, AM J HUM GENET, V78, P827, DOI 10.1086/503821; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Oranje AP, 1997, J AM ACAD DERMATOL, V36, P203, DOI 10.1016/S0190-9622(97)70281-0; Paller AS, 2008, NEW ENGL J MED, V358, P241, DOI 10.1056/NEJMoa066886; Paller AS, 2018, J DRUGS DERMATOL, V17, P187; Papp KA, 2005, BRIT J DERMATOL, V152, P1304, DOI 10.1111/j.1365-2133.2005.06688.x; Papp K, 2015, J AM ACAD DERMATOL, V73, P37, DOI 10.1016/j.jaad.2015.03.049; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; Parisi R, 2013, J INVEST DERMATOL, V133, P377, DOI 10.1038/jid.2012.339; Paul C, 2019, J AM ACAD DERMATOL, V80, P70, DOI 10.1016/j.jaad.2018.06.039; Rachakonda TD, 2014, J AM ACAD DERMATOL, V70, P512, DOI 10.1016/j.jaad.2013.11.013; Reich K, 2005, LANCET, V366, P1367, DOI 10.1016/S0140-6736(05)67566-6; Reich K, 2019, BRIT J DERMATOL, V181, P954, DOI 10.1111/bjd.17351; Reich K, 2019, LANCET, V394, P831, DOI 10.1016/S0140-6736(19)31773-8; Reich K, 2019, LANCET, V394, P576, DOI 10.1016/S0140-6736(19)30952-3; Reich K, 2017, LANCET, V390, P276, DOI 10.1016/S0140-6736(17)31279-5; Saurat JH, 2008, BRIT J DERMATOL, V158, P558, DOI 10.1111/j.1365-2133.2007.08315.x; Singh JA, 2019, ARTHRITIS RHEUMATOL, V71, P5, DOI 10.1002/art.40726; Singh S, 2017, J AM ACAD DERMATOL, V77, P425, DOI 10.1016/j.jaad.2017.05.019; Soleymani T, 2015, INT J DERMATOL, V54, P383, DOI 10.1111/ijd.12790; Stern RS, 2012, J AM ACAD DERMATOL, V66, P553, DOI 10.1016/j.jaad.2011.04.004; Stern RS, 2011, J INVEST DERMATOL, V131, P1159, DOI 10.1038/jid.2010.399; Tillett W, 2012, J RHEUMATOL, V39, P154, DOI 10.3899/jrheum.110845; Tom BDM, 2015, J RHEUMATOL, V42, P841, DOI 10.3899/jrheum.140857; Tsai TF, 2011, J DERMATOL SCI, V63, P40, DOI 10.1016/j.jdermsci.2011.03.002; Tsoi LC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15382; Warren RB, 2017, LANCET, V389, P528, DOI 10.1016/S0140-6736(16)32127-4; Weinstein GD, 1997, J AM ACAD DERMATOL, V37, P85, DOI 10.1016/S0190-9622(97)70216-0; World Health Organization, GLOB REP PSOR; Yeung H, 2013, JAMA DERMATOL, V149, P1173, DOI 10.1001/jamadermatol.2013.5015	94	395	417	48	185	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	2020	323	19					1945	1960		10.1001/jama.2020.4006	http://dx.doi.org/10.1001/jama.2020.4006			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT2XF	32427307				2023-01-03	WOS:000536934300021
J	Strumann, C; Steinhaeuser, J; Emcke, T; Sonnichsen, A; Goetz, K				Strumann, Christoph; Steinhaeuser, Jost; Emcke, Timo; Soennichsen, Andreas; Goetz, Katja			Communication training and the prescribing pattern of antibiotic prescription in primary health care	PLOS ONE			English	Article							RESPIRATORY-TRACT INFECTIONS; GENERAL-PRACTITIONERS; ACUTE COUGH; RESISTANCE; GPS; EXPECTATIONS; ASSOCIATION; DIFFERENCE; ATTITUDES; CLUSTER	Background The treatment of upper respiratory tract infections (URTIs) accounts for the majority of antibiotic prescriptions in primary care, although an antibiotic therapy is rarely indicated. Nonclinical factors, such as time pressure and the perceived patient expectations are considered to be reasons for prescribing antibiotics in cases where they are not indicated. The improper use of antibiotics, however, can promote resistance and cause serious side effects. The aim of the study was to clarify whether the antibiotic prescription rate for infections of the upper respiratory tract can be lowered by means of a short (2 x 2.25h) communication training based on the MAAS-Global-D for primary care physicians. Methods In total, 1554 primary care physicians were invited to participate in the study. The control group was formed from observational data. To estimate intervention effects we applied a combination of difference-in-difference (DiD) and statistical matching based on entropy balancing. We estimated a corresponding multi-level logistic regression model for the antibiotic prescribing decision of German primary care physicians for URTIs. Results Univariate estimates detected an 11-percentage-point reduction of prescriptions for the intervention group after the training. For the control group, a reduction of 4.7% was detected. The difference between both groups in the difference between the periods was -6.5% and statistically significant. The estimated effects were nearly identical to the effects estimated for the multi-level logistic regression model with applied matching. Furthermore, for the treatment of young women, the impact of the training on the reduction of antibiotic prescription was significantly stronger. Conclusions Our results suggest that communication skills, implemented through a short communication training with the MAAS-Global-D-training, lead to a more prudent prescribing behavior of antibiotics for URTIs. Thereby, the MAAS-Global-D-training could not only avoid unnecessary side effects but could also help reducing the emergence of drug resistant bacteria. As a consequence of our study we suggest that communication training based on the MAASGlobal-D should be applied in the postgraduate training scheme of primary care physicians.	[Strumann, Christoph; Steinhaeuser, Jost; Goetz, Katja] Univ Hosp Schleswig Holstein, Inst Family Med, Lubeck, Germany; [Emcke, Timo] Assoc Statutory Hlth Insurance Phys Fed State Sch, Bad Segeberg, Germany; [Soennichsen, Andreas] Med Univ Vienna, Ctr Publ Hlth, Dept Gen Practice & Family Med, Vienna, Austria	University of Kiel; Schleswig Holstein University Hospital; Medical University of Vienna	Strumann, C (corresponding author), Univ Hosp Schleswig Holstein, Inst Family Med, Lubeck, Germany.	c.strumann@uni-luebeck.de		Strumann, Christoph/0000-0003-2725-6543	German Federal Ministry of Health [ZMVI1-2515NIK002]	German Federal Ministry of Health	The study was funded by the German Federal Ministry of Health (grant-number: ZMVI1-2515NIK002). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.	Abadie A, 2005, REV ECON STUD, V72, P1, DOI 10.1111/0034-6527.00321; Ackerman SL, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-462; Akkerman AE, 2005, J ANTIMICROB CHEMOTH, V56, P930, DOI 10.1093/jac/dki283; Altiner A, 2004, FAM PRACT, V21, P500, DOI 10.1093/fampra/cmh505; Altiner A, 2007, J ANTIMICROB CHEMOTH, V60, P638, DOI 10.1093/jac/dkm254; Angrist JD, 2009, MOSTLY HARMLESS ECONOMETRICS: AN EMPIRICISTS COMPANION, P1; [Anonymous], 2017, SWEDRES SVARM REPORT; Baier N, 2019, HEALTH POLICY, V123, P1, DOI 10.1016/j.healthpol.2018.11.001; Barlam TF, 2015, INFECT CONT HOSP EP, V36, P153, DOI 10.1017/ice.2014.21; Bergman M, 2004, CLIN INFECT DIS, V38, P1251, DOI 10.1086/383309; Bjornsdottir I, 2002, J CLIN PHARM THER, V27, P431, DOI 10.1046/j.1365-2710.2002.00442.x; Bjornsdottir I, 2010, PHARM WORLD SCI, V32, P805, DOI 10.1007/s11096-010-9441-6; Brieler JA, 2015, J AFFECT DISORDERS, V172, P153, DOI 10.1016/j.jad.2014.09.056; Bundesministerium fur Gesundheit, DART 2020 DTSCH ANT; Cals JWL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1374; Chabe-Ferret S, 2015, J ECONOMETRICS, V185, P110, DOI 10.1016/j.jeconom.2014.09.013; Corallo AN, 2014, HEALTH POLICY, V114, P5, DOI 10.1016/j.healthpol.2013.08.002; Coxeter P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010907.pub2; Curtis HJ, 2019, J ANTIMICROB CHEMOTH, V74, P242, DOI 10.1093/jac/dky377; Deaton A, 2018, SOC SCI MED, V210, P2, DOI 10.1016/j.socscimed.2017.12.005; Deutsche Gesellschaft fur Allgemeinmedizin und Familienmedizin, HUST LEITL NR 11; Deutsche Gesellschaft fur Allgemeinmedizin und Familienmedizin, HALSSCHM LEITL NR 14; Deutsche Gesellschaft fur Allgemeinmedizin und Familienmedizin, S2K LEITL RHIN; Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; Francis NA, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2885; Fritz Z, 2019, J MED ETHICS, V45, P31, DOI 10.1136/medethics-2018-104866; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Gulliford MC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006245; Hainmueller J, 2012, POLIT ANAL, V20, P25, DOI 10.1093/pan/mpr025; Hammersen F, 2016, Z ALLGEMEINMEDIZIN, V92, P13; Hammersen F, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1293-5; Heckman JJ, 1997, REV ECON STUD, V64, P605, DOI 10.2307/2971733; Hummers-Pradier E, 2008, FAM PRACT, V25, P105, DOI 10.1093/fampra/cmn015; Kassenarztliche Bundesvereinigung, REG VERT DERA RZTE V; Kenealy T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000247.pub3; Kim AM, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875-018-0875-6; Kollef MH, 2008, CLIN INFECT DIS, V47, pS3, DOI 10.1086/590061; KUMAR S, 2003, BRIT MED J, V326, P138; Laxminarayan R, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001974; Le Corvoisier P, 2013, BRIT J GEN PRACT, V63, pE455, DOI 10.3399/bjgp13X669176; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; Lindner S, 2018, HLTH SERVICES OUTCOM; Little P, 2004, BMJ-BRIT MED J, V328, P444, DOI 10.1136/bmj.38013.644086.7C; Little P, 2013, LANCET, V382, P1175, DOI 10.1016/S0140-6736(13)60994-0; Livermore DM, 2012, KOREAN J INTERN MED, V27, P128, DOI 10.3904/kjim.2012.27.2.128; Lundkvist J, 2002, FAM PRACT, V19, P638, DOI 10.1093/fampra/19.6.638; Macfarlane J, 1997, BMJ-BRIT MED J, V315, P1211, DOI 10.1136/bmj.315.7117.1211; Magira EE, 2018, MED INTENSIVA, V42, P225, DOI 10.1016/j.medin.2017.07.006; Mangione-Smith R, 2002, HEALTH SERV RES, V37, P1603, DOI 10.1111/1475-6773.10482; McKay R, 2016, ANTIMICROB AGENTS CH, V60, P4106, DOI 10.1128/AAC.00209-16; MEYERSON D, 1996, TRUST ORG FRONTIERS, V166, P195; Mousques J, 2010, SOC SCI MED, V70, P1176, DOI 10.1016/j.socscimed.2009.12.016; Noordman J, 2014, J ADV NURS, V70, P2272, DOI 10.1111/jan.12376; O'Connor R, 2018, IRISH J MED SCI, V187, P969, DOI 10.1007/s11845-018-1774-5; O'Neill S, 2016, HEALTH SERV OUTCOME, V16, P1, DOI 10.1007/s10742-016-0146-8; Ong S, 2007, ANN EMERG MED, V50, P213, DOI 10.1016/j.annemergmed.2007.03.026; Oxford J, 2013, INT J CLIN PRACT, V67, P1, DOI 10.1111/ijcp.12334; Peters-Klimm F, 2013, GESUNDHEITSWESEN, V75, P321, DOI 10.1055/s-0032-1321742; Petursson P, 2005, SCAND J PRIM HEALTH, V23, P120, DOI 10.1080/02813430510018491; Ranji SR, 2008, MED CARE, V46, P847, DOI 10.1097/MLR.0b013e318178eabd; Rice LB, 2009, CURR OPIN MICROBIOL, V12, P476, DOI 10.1016/j.mib.2009.08.001; Riva S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090941; Robert A, 2017, MED MALADIES INFECT, V47, P142, DOI 10.1016/j.medmal.2016.10.003; Roca I., 2015, New Microbes and New Infections, V6, P22, DOI 10.1016/j.nmni.2015.02.007; Sabuncu E, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000084; Salm F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193336; Schroder W, 2016, J ANTIMICROB CHEMOTH, V71, P1800, DOI 10.1093/jac/dkw054; Sirota M, 2017, HEALTH PSYCHOL, V36, P402, DOI 10.1037/hea0000456; SMITH R, 2013, BMJ BRIT MED J, V346; Smith SM, 2017, COCHRANE DATABASE SY; Steinhauser J, 2015, MAAS GLOBAL HDB LEIT; Tarrant C, 2010, ANN FAM MED, V8, P440, DOI 10.1370/afm.1160; van der Velden A, 2013, ANTIBIOTICS-BASEL, V2, P316, DOI 10.3390/antibiotics2020316; van der Velden AW, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X659268; van Thiel J., 2000, MAAS GLOBAL MANUAL, P4; vanderMeer JWM, 2008, ARMY CHAPLAINCY  SPR, P17; Ventola C Lee, 2015, P T, V40, P277; Vervloet M, 2016, NPJ PRIM CARE RESP M, V26, DOI 10.1038/npjpcrm.2015.83; Wei XL, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002733; WHO, 2018, ANT RES FACT SHEET; World Health Organization, 2016, ICD 10 VERS, DOI DOI 10/2016/EN; Wu JY, 2018, J INT MED RES, V46, P1326, DOI 10.1177/0300060517740813; Yates TD, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875-018-0788-4; Zentralinstitut fur die kassenarztliche Versorgung in Deutschland (ZI), ZAHL VERS GKV GEM KM; Zoorob R, 2012, AM FAM PHYSICIAN, V86, P817	85	11	11	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2020	15	5							e0233345	10.1371/journal.pone.0233345	http://dx.doi.org/10.1371/journal.pone.0233345			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU1DW	32428012	Green Published, gold			2023-01-03	WOS:000537503400040
J	Talley, NJ; Irani, M				Talley, Nicholas J.; Irani, Mudar			In irritable bowel syndrome, fecal microbiota transplantation improved symptoms at 3 months	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Talley, Nicholas J.; Irani, Mudar] Univ Newcastle, Newcastle, NSW, Australia	University of Newcastle	Talley, NJ (corresponding author), Univ Newcastle, Newcastle, NSW, Australia.							Ford AC, 2018, ALIMENT PHARM THER, V48, P1044, DOI 10.1111/apt.15001; Hugerth LW, 2019, GUT; Ianiro G, 2019, ALIMENT PHARM THER, V50, P240, DOI 10.1111/apt.15330; Narula N, 2017, INFLAMM BOWEL DIS, V23, P1702, DOI 10.1097/MIB.0000000000001228	4	1	1	3	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 19	2020	172	10					JC52	JC52		10.7326/ACPJ202005190-052	http://dx.doi.org/10.7326/ACPJ202005190-052			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP8XQ	32422097				2023-01-03	WOS:000534600900004
J	Kim, JW; Im, I; Kim, H; Jeon, JS; Kang, EH; Jo, S; Chun, HS; Yoon, S; Kim, JH; Kim, SK; Park, HJ				Kim, Ji-Woo; Im, Ilkyun; Kim, Hyemin; Jeon, Jang Su; Kang, Eun-Hye; Jo, Seongyea; Chun, Hang-Suk; Yoon, Seokjoo; Kim, Jong-Hoon; Kim, Sang Kyum; Park, Han-Jin			Live-cell screening platform using human-induced pluripotent stem cells expressing fluorescence-tagged cytochrome P450 1A1	FASEB JOURNAL			English	Article						AHR; CRISPR-Cas9; high-content screening; toxicology	ARYL-HYDROCARBON RECEPTOR; KNOCKOUT MOUSE LINES; AH RECEPTOR; GENE; CANCER; CYP1A1; POLYMORPHISMS; INDUCTION; PROTEINS; LIGAND	Human-induced pluripotent stem cells (hiPSCs) are invaluable sources for drug screening and toxicity tests because of their differentiation potential and proliferative capacity. Recently, the CRISPR-Cas9-mediated homologous recombination system has enabled reporter knock-ins at desired loci in hiPSCs, and here, we generated a hiPSC reporter line expressing mCherry-tagged cytochrome P450 1A1 (CYP1A1), which can be utilized to screen for the modulators of aryl hydrocarbon receptor (AHR) in live cells. CYP1A1-mCherry hiPSCs exhibited typical characteristics of pluripotent stem cells such as marker expression, differentiation potential, and normal karyotype. After differentiation into hepatocyte-like cells (HLCs), CYP1A1-mCherry fusion protein was expressed and localized at the endoplasmic reticulum, and induced by AHR agonists. We obtained 23 hits modulating CYP1A1 expression from high-content screening with 241 hepatotoxicity chemicals and nuclear receptor ligands, and identified three upregulating chemicals and two downregulating compounds. Responses of hiPSC-HLCs against an AHR agonist were more similar to human primary hepatocytes than of HepG2 hepatocellular carcinoma cells. This platform has the advantages of live-cell screening without sacrificing cells (unlike previously available CYP1A1 reporter cell lines), as well as an indefinite supply of cells, and can be utilized in a wide range of screening related to AHR- and CYP1A1-associated diseases in desired cell types.	[Kim, Ji-Woo; Im, Ilkyun; Kim, Hyemin; Kang, Eun-Hye; Jo, Seongyea; Chun, Hang-Suk; Yoon, Seokjoo; Park, Han-Jin] Korea Inst Toxicol, Dept Predict Toxicol, Daejeon 34114, South Korea; [Jeon, Jang Su; Kim, Sang Kyum] Chungnam Natl Univ, Coll Pharm, Daejeon, South Korea; [Kang, Eun-Hye; Yoon, Seokjoo] Univ Sci & Technol, Sch Engn, Human & Environm Toxicol, Daejeon, South Korea; [Jo, Seongyea; Kim, Jong-Hoon] Korea Univ, Dept Biotechnol, Coll Life Sci & Biotechnol, Seoul, South Korea	Korea Institute of Toxicology; Chungnam National University; University of Science & Technology (UST); Korea University	Park, HJ (corresponding author), Korea Inst Toxicol, Dept Predict Toxicol, Daejeon 34114, South Korea.	hjpark@kitox.re.kr	Kim, Jong-Hoon/F-2504-2013	Kim, Jong-Hoon/0000-0003-3419-0538	National Research Foundation of Korea (NRF) [NRF-2017R1C1B2010444, NRF-2018M3A9H1021384]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea)	National Research Foundation of Korea (NRF), Grant/Award Number: NRF-2017R1C1B2010444 and NRF-2018M3A9H1021384	Barouki R, 2007, FEBS LETT, V581, P3608, DOI 10.1016/j.febslet.2007.03.046; Bersten DC, 2013, NAT REV CANCER, V13, P827, DOI 10.1038/nrc3621; Brignac-Huber LM, 2016, DRUG METAB DISPOS, V44, P1859, DOI 10.1124/dmd.115.068981; Byrne SM, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1246; Cauchi S, 2001, CARCINOGENESIS, V22, P1819, DOI 10.1093/carcin/22.11.1819; Chang JC, 2007, CLIN CANCER RES, V13, P1, DOI 10.1158/1078-0432.CCR-06-2405; Chen I, 1996, BIOCHEM PHARMACOL, V51, P1069, DOI 10.1016/0006-2952(96)00060-3; Ciolino HP, 2008, INT J CANCER, V122, P990, DOI 10.1002/ijc.23218; Corbett JL, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00265; Denison MS, 2011, TOXICOL SCI, V124, P1, DOI 10.1093/toxsci/kfr218; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Elliott DA, 2011, NAT METHODS, V8, P1037, DOI [10.1038/NMETH.1740, 10.1038/nmeth.1740]; Frotschl R, 1998, CHEM RES TOXICOL, V11, P1447, DOI 10.1021/tx980164h; Fu YF, 2013, NAT BIOTECHNOL, V31, P822, DOI 10.1038/nbt.2623; Gargaro M, 2016, AM J TRANSPLANT, V16, P2270, DOI 10.1111/ajt.13716; Garneau JE, 2010, NATURE, V468, P67, DOI 10.1038/nature09523; Go RE, 2015, J STEROID BIOCHEM, V147, P24, DOI 10.1016/j.jsbmb.2014.11.003; Goldring C, 2017, HEPATOLOGY, V65, P710, DOI 10.1002/hep.28886; Goulburn AL, 2011, STEM CELLS, V29, P462, DOI 10.1002/stem.587; Gregersen N, 2010, METHODS MOL BIOL, V648, P3, DOI 10.1007/978-1-60761-756-3_1; Grskovic M, 2011, NAT REV DRUG DISCOV, V10, P915, DOI 10.1038/nrd3577; HANKINSON O, 1991, BIOCHIMIE, V73, P61, DOI 10.1016/0300-9084(91)90075-C; Hao N, 2013, BIOCHEM PHARMACOL, V86, P561, DOI 10.1016/j.bcp.2013.07.004; He GC, 2011, TOXICOL SCI, V123, P511, DOI 10.1093/toxsci/kfr189; Hosaka T, 2010, CANCER SCI, V101, P652, DOI 10.1111/j.1349-7006.2009.01454.x; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang S, 2015, SCI REP-UK, V5, DOI 10.1038/srep08022; Irion S, 2007, NAT BIOTECHNOL, V25, P1477, DOI 10.1038/nbt1362; Jackson MP, 2016, ESSAYS BIOCHEM, V60, P173, DOI 10.1042/EBC20160005; Kakarougkas A, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130685; Kim HM, 2016, SCI REP-UK, V6, DOI 10.1038/srep21684; Kiss EA, 2011, SCIENCE, V334, P1561, DOI 10.1126/science.1214914; Kolluri SK, 2017, ARCH TOXICOL, V91, P2497, DOI 10.1007/s00204-017-1981-2; Li Y, 2011, TOXICOL SCI, V124, P388, DOI 10.1093/toxsci/kfr235; Liu C, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.156166; McIntosh BE, 2010, ANNU REV PHYSIOL, V72, P625, DOI 10.1146/annurev-physiol-021909-135922; Mojica FJM, 2009, MICROBIOL-SGM, V155, P733, DOI 10.1099/mic.0.023960-0; Murray IA, 2014, NAT REV CANCER, V14, P801, DOI 10.1038/nrc3846; Nagy SR, 2002, TOXICOL SCI, V65, P200, DOI 10.1093/toxsci/65.2.200; Navas JM, 2004, LIFE SCI, V76, P699, DOI 10.1016/j.lfs.2004.09.015; Nebert D W, 1994, Prog Liver Dis, V12, P63; Nebert DW, 2013, MOL PHARMACOL, V84, P304, DOI 10.1124/mol.113.086637; NEBERT DW, 1991, PHARMACOGENETICS, V1, P68, DOI 10.1097/00008571-199111000-00003; Nebert DW, 1996, DNA CELL BIOL, V15, P273, DOI 10.1089/dna.1996.15.273; Nguyen LP, 2008, CHEM RES TOXICOL, V21, P102, DOI 10.1021/tx7001965; Nie YZ, 2018, EBIOMEDICINE, V35, P114, DOI 10.1016/j.ebiom.2018.08.014; O'Donnell EF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013128; Oesch-Bartlomowicz B, 2009, BIOCHEM PHARMACOL, V77, P627, DOI 10.1016/j.bcp.2008.10.017; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Oyama T, 2007, FRONT BIOSCI, V12, P4497, DOI 10.2741/2404; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Ramadoss P, 2004, MOL PHARMACOL, V66, P129, DOI 10.1124/mol.66.1.129; Ramme AP, 2019, FUTUR SCI OA, V5, DOI 10.2144/fsoa-2019-0065; Safe S, 2013, TOXICOL SCI, V135, P1, DOI 10.1093/toxsci/kft128; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Sirenko O, 2016, ASSAY DRUG DEV TECHN, V14, P381, DOI 10.1089/adt.2016.729; Smith BW, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2574152; Sogawa K, 1997, J BIOCHEM, V122, P1075; Stockinger B, 2014, ANNU REV IMMUNOL, V32, P403, DOI 10.1146/annurev-immunol-032713-120245; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Uno S, 2006, MOL PHARMACOL, V69, P1103, DOI 10.1124/mol.105.021501; Uno S, 2008, FREE RADICAL BIO MED, V44, P570, DOI 10.1016/j.freeradbiomed.2007.10.044; Werck-Reichhart D., 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-6-REVIEWS3003; Wiedenheft B, 2012, NATURE, V482, P331, DOI 10.1038/nature10886; Wincent E, 2009, J BIOL CHEM, V284, P2690, DOI 10.1074/jbc.M808321200; Wong JMY, 2001, BIOCHEM BIOPH RES CO, V288, P990, DOI 10.1006/bbrc.2001.5861; Wourms MJ, 2015, CELL IMMUNOL, V295, P60, DOI 10.1016/j.cellimm.2015.02.012; Xie F, 2014, GENOME RES, V24, P1526, DOI 10.1101/gr.173427.114; Xue P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00286; Zhao B, 2010, SCI CHINA CHEM, V53, P1010, DOI 10.1007/s11426-010-0142-8; Zwaka TP, 2003, NAT BIOTECHNOL, V21, P319, DOI 10.1038/nbt788	74	2	3	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2020	34	7					9141	9155		10.1096/fj.201903110R	http://dx.doi.org/10.1096/fj.201903110R		MAY 2020	15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MG8UN	32421247				2023-01-03	WOS:000533521800001
J	Williams, JR; Cole, V; Girdler, S; Cromeens, MG				Williams, Jessica Roberts; Cole, Veronica; Girdler, Susan; Cromeens, Martha Grace			Exploring stress, cognitive, and affective mechanisms of the relationship between interpersonal trauma and opioid misuse	PLOS ONE			English	Article							ADVERSE CHILDHOOD EXPERIENCES; SUBSTANCE USE DISORDERS; INTIMATE PARTNER VIOLENCE; MAJOR DEPRESSIVE DISORDER; PAIN INTERFERENCE LEVELS; SEXUAL VIOLENCE; WOMEN SURVIVORS; PHYSICAL ABUSE; RISK-FACTORS; ASSOCIATION	Background People with a history of interpersonal trauma, including intimate partner violence, sexual assault, and adverse childhood experiences, are disproportionately affected by the current opioid epidemic. Interpersonal trauma has been shown to increase risk for chronic pain conditions, prescription opioid use, and opioid misuse. Stress, cognition, and affective function have been examined as potential mechanisms that may influence opioid misuse among individuals with a history of interpersonal trauma. However, no studies have examined these factors simultaneously, despite their interrelatedness. Objective The purpose of this study was to 1) examine perceived stress, perceived cognitive function, depressive symptoms, and PTSD symptoms as potential mechanisms of opioid misuse among individuals with a history of interpersonal trauma, 2) examine the types of interpersonal trauma that are associated with opioid misuse, and 3) assess the mediating role of pain and opioid prescription. Methods A cross-sectional, observational study design was conducted. Data were collected through a confidential self-report online survey using validated instruments (n = 230). A series of regression analyses were conducted to identify mechanistic factors and interpersonal trauma types associated with opioid misuse, opioid prescription, and pain intensity. Structural equation modeling was used to examine mediating effects of pain intensity and opioid prescription. Results Opioid prescription, depressive symptoms, and intimate partner violence increased the odds of reporting opioid misuse. Pain intensity and adverse childhood experiences increased the odds of opioid prescription. Higher levels of perceived stress and depressive symptoms were associated with increased pain intensity. Pain intensity emerged as a mediator of the relationship between depressive symptoms and opioid misuse. Conclusions Our work shows that there are likely several pathways through which interpersonal trauma can lead to opioid misuse. Interventions aimed at improving depressive symptoms and coping with traumatizing events should be included as part of comprehensive trauma-informed pain management practices.	[Williams, Jessica Roberts; Cromeens, Martha Grace] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27515 USA; [Cole, Veronica] Wake Forest Univ, Dept Psychol, Wake Forest, NC USA; [Girdler, Susan] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; Wake Forest University; University of North Carolina; University of North Carolina Chapel Hill	Williams, JR (corresponding author), Univ N Carolina, Sch Nursing, Chapel Hill, NC 27515 USA.	jrober65@email.unc.edu	Williams, Jessica/AAP-1744-2021	Williams, Jessica/0000-0001-6105-0296; Cromeens, Martha Grace/0000-0002-0551-5172	University of North Carolina at Chapel Hill School of Nursing	University of North Carolina at Chapel Hill School of Nursing	This study was supported though internal funding provided by the University of North Carolina at Chapel Hill School of Nursing. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdallah CG, 2017, CHRONIC STRESS, V1; Afari N, 2014, PSYCHOSOM MED, V76, P2, DOI 10.1097/PSY.0000000000000010; Afifi TO, 2012, CAN J PSYCHIAT, V57, P677, DOI 10.1177/070674371205701105; Anderson RE, 2018, PSYCHOL MEN MASCULIN, V19, P25, DOI 10.1037/men0000073; Austin AE, 2018, CHILD YOUTH SERV REV, V86, P84, DOI 10.1016/j.childyouth.2018.01.023; Austin AE, 2018, ADDICT BEHAV, V76, P265, DOI 10.1016/j.addbeh.2017.08.033; Bali A, 2015, NEUROSCI BIOBEHAV R, V51, P138, DOI 10.1016/j.neubiorev.2014.12.018; Balousek S, 2007, J GEN INTERN MED, V22, P1268, DOI 10.1007/s11606-007-0257-6; Bartlett SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138543; Baumeister D, 2016, MOL PSYCHIATR, V21, P642, DOI 10.1038/mp.2015.67; Becker Heather, 2014, Int J MS Care, V16, P1, DOI 10.7224/1537-2073.2012-047; Bershad AK, 2018, HORM BEHAV, V102, P41, DOI 10.1016/j.yhbeh.2018.04.009; Beydoun HA, 2012, SOC SCI MED, V75, P959, DOI 10.1016/j.socscimed.2012.04.025; Blevins CA, 2015, J TRAUMA STRESS, V28, P489, DOI 10.1002/jts.22059; Block C, 2013, NEUROREHABILITATION, V33, P343, DOI 10.3233/NRE-130965; Bonnie RJ, 2017, PAIN MANAGEMENT OPIO, Vxxv; Bourne S, 2014, NEUROSURG CLIN N AM, V25, P629, DOI 10.1016/j.nec.2014.06.001; Bovin MJ, 2016, PSYCHOL ASSESSMENT, V28, P1379, DOI 10.1037/pas0000254; Breiding MJ, 2014, MMWR SURVEILL SUMM, V63, P1; Brenner DR, 2014, CANCER EPIDEM BIOMAR, V23, P1729, DOI 10.1158/1055-9965.EPI-14-0064; Buscemi V, 2019, J PAIN, V20, P1127, DOI 10.1016/j.jpain.2019.02.008; Cadet JL, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00189; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Centers for Disease Control and Prevention, 2010, BEH RISK FACT SURV S; Centers for Disease Control and Prevention National Center for Health Statistics, 2018, MORT CDC WOND; Coelho R, 2014, ACTA PSYCHIAT SCAND, V129, P180, DOI 10.1111/acps.12217; COHEN Y, 1988, J CHEM SOC PERK T 2, P31, DOI 10.1039/p29880000031; Crofford LJ, 2007, TRAUMA VIOLENCE ABUS, V8, P299, DOI 10.1177/1524838007303196; Danese A, 2017, NEUROPSYCHOPHARMACOL, V42, P99, DOI 10.1038/npp.2016.198; Davis KC, 2014, PSYCHOL VIOLENCE, V4, P445, DOI 10.1037/a0037494; Douglas KR, 2010, ADDICT BEHAV, V35, P7, DOI 10.1016/j.addbeh.2009.07.004; Dube SR, 2004, CHILD ABUSE NEGLECT, V28, P729, DOI 10.1016/j.chiabu.2003.08.009; Edalati H, 2016, TRAUMA VIOLENCE ABUS, V17, P454, DOI 10.1177/1524838015584370; Fay D, 2017, J OCCUP HEALTH PSYCH, V22, P429, DOI 10.1037/ocp0000042; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Field M, 2008, DRUG ALCOHOL DEPEN, V97, P1, DOI 10.1016/j.drugalcdep.2008.03.030; Garami J, 2019, PSYCHOL REP, V122, P433, DOI 10.1177/0033294118764918; Goodman LA, 1998, J TRAUMA STRESS, V11, P521, DOI 10.1023/A:1024456713321; Gould Thomas J, 2010, Addict Sci Clin Pract, V5, P4; Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI 10.1080/03637750903310360; Herman JP, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00061; Hojsted J, 2012, CURR PHARM DESIGN, V18, P6116, DOI 10.2174/138161212803582522; Johnson SM, 2017, VIOLENCE VICTIMS, V32, P78, DOI 10.1891/0886-6708.VV-D-15-00110; Juster RP, 2010, NEUROSCI BIOBEHAV R, V35, P2, DOI 10.1016/j.neubiorev.2009.10.002; Kalmakis KA, 2015, J AM ASSOC NURSE PRA, V27, P457, DOI 10.1002/2327-6924.12215; Kaye AD, 2017, PAIN PHYSICIAN, V20, pS93; Kendall SE, 2010, PAIN, V150, P225, DOI 10.1016/j.pain.2010.05.012; Khantzian EJ, 1997, HARVARD REV PSYCHIAT, V4, P231, DOI 10.3109/10673229709030550; Koss MP, 2007, PSYCHOL WOMEN QUART, V31, P357, DOI 10.1111/j.1471-6402.2007.00385.x; Kupst MJ, 2015, ANXIETY STRESS COPIN, V28, P531, DOI 10.1080/10615806.2014.994204; Lagdon S, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.24794; Lai JS, 2014, PSYCHO-ONCOLOGY, V23, P1133, DOI 10.1002/pon.3522; Landro NI, 2013, PAIN, V154, P972, DOI 10.1016/j.pain.2013.01.013; Lindert J, 2014, INT J PUBLIC HEALTH, V59, P359, DOI 10.1007/s00038-013-0519-5; Lutz PE, 2013, TRENDS NEUROSCI, V36, P195, DOI 10.1016/j.tins.2012.11.002; MacKinnon DP, 2007, ANNU REV PSYCHOL, V58, P593, DOI 10.1146/annurev.psych.58.110405.085542; MacKinnon DP, 2004, MULTIVAR BEHAV RES, V39, P99, DOI 10.1207/s15327906mbr3901_4; Matsuda M, 2019, J ANESTH, V33, P131, DOI 10.1007/s00540-018-2579-4; McCall-Hosenfeld JS, 2014, J PSYCHOSOM RES, V77, P196, DOI 10.1016/j.jpsychores.2014.07.011; Miller GE, 2007, PSYCHOL BULL, V133, P25, DOI 10.1037/0033-2909.133.1.25; Moeller SJ, 2016, PROG BRAIN RES, V223, P165, DOI 10.1016/bs.pbr.2015.07.007; Moran LM, 2018, AM J DRUG ALCOHOL AB, V44, P512, DOI 10.1080/00952990.2018.1454934; Murphy A, 2014, CHILD ABUSE NEGLECT, V38, P224, DOI 10.1016/j.chiabu.2013.09.004; Muthen L. K., 2017, MPLUS USERS GUIDE, VEighth; Pechtel P, 2011, PSYCHOPHARMACOLOGY, V214, P55, DOI 10.1007/s00213-010-2009-2; Pergolizzi JV, 2012, J PSYCHOSOM RES, V72, P443, DOI 10.1016/j.jpsychores.2012.02.009; Pilkonis PA, 2017, PAIN MED, V18, P1516, DOI 10.1093/pm/pnw233; Pilkonis PA, 2011, ASSESSMENT, V18, P263, DOI 10.1177/1073191111411667; Powers A, 2014, PSYCHOSOMATICS, V55, P491, DOI 10.1016/j.psym.2013.10.004; Preston KL, 2018, PSYCHOPHARMACOLOGY, V235, P2713, DOI 10.1007/s00213-018-4966-9; PROMIS Health Organization, 2017, PROMIS ITEM BANK V1; PROMIS Health Organization and PROMIS Cooperative Group, 2017, PROMIS NUM RAT SCAL; PROMIS Health Organization and PROMIS Cooperative Group, 2016, PROMIS SHORT FORM V2; PROMIS Health Organization and PROMIS Cooperative Group, 2016, PROMIS IT BANK V1 0; Quinn K, 2016, DRUG ALCOHOL DEPEN, V169, P190, DOI 10.1016/j.drugalcdep.2016.09.021; R Core Team, 2017, R LANG ENV STAT COMP; Reddy MK, 2014, ADDICT BEHAV, V39, P965, DOI 10.1016/j.addbeh.2014.01.012; Renn CL, 2005, AACN ADV CRIT CARE, V16, P277, DOI 10.1097/00044067-200507000-00002; Rytwinski NK, 2013, J TRAUMA STRESS, V26, P299, DOI 10.1002/jts.21814; Salsman JM, 2013, NEUROLOGY, V80, pS76, DOI 10.1212/WNL.0b013e3182872e11; Schafer I, 2014, ADDICT BEHAV, V39, P1691, DOI 10.1016/j.addbeh.2014.07.008; Sherman AL, 2015, ANN BEHAV MED, V49, P785, DOI 10.1007/s12160-015-9712-5; Stene LE, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000614; Sterling P., 1988, HDB LIFE STRESS COGN, P629; Straus MA, 1996, J FAM ISSUES, V17, P283, DOI 10.1177/019251396017003001; Straus Murray A, 2004, Violence Vict, V19, P507; Substance Abuse and Mental Health Services Administration, 2019, 2018 NAT SURV DRUG U; Symes L, 2013, ISSUES MENT HEALTH N, V34, P2, DOI 10.3109/01612840.2012.709916; Tesarz J, 2016, PAIN, V157, P1799, DOI 10.1097/j.pain.0000000000000586; Vachon-Presseau E, 2013, BRAIN, V136, P815, DOI 10.1093/brain/aws371; Valentine TR, 2019, HEALTH PSYCHOL, V38, P351, DOI 10.1037/hea0000693; Walsh CA, 2007, J INTERPERS VIOLENCE, V22, P1536, DOI 10.1177/0886260507306484; Walsh K, 2015, J PSYCHIATR RES, V62, P7, DOI 10.1016/j.jpsychires.2015.01.002; Warshaw C., 2014, MENTAL HLTH SUBSTANC; Weathers F. W., 2013, THEPTSDCHECKLISTFORD, V10; White RS, 2014, J AM GERIATR SOC, V62, P2350, DOI 10.1111/jgs.13135; Woods SJ, 2011, FAMILY VIOLENCE NURS, P29; Wortmann JH, 2016, PSYCHOL ASSESSMENT, V28, P1392, DOI 10.1037/pas0000260; Wuest J, 2008, J PAIN, V9, P1049, DOI 10.1016/j.jpain.2008.06.009; Wuest J, 2007, CAN J PUBLIC HEALTH, V98, P460, DOI 10.1007/BF03405439; Wuest J, 2010, J WOMENS HEALTH, V19, P1665, DOI 10.1089/jwh.2009.1856; Wuest J, 2009, PAIN MED, V10, P739, DOI 10.1111/j.1526-4637.2009.00624.x; You DS, 2019, PAIN MED	103	20	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2020	15	5							e0233185	10.1371/journal.pone.0233185	http://dx.doi.org/10.1371/journal.pone.0233185			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU1BA	32413081	gold, Green Published			2023-01-03	WOS:000537496000056
J	Williams, LM; Hack, LM				Williams, Leanne M.; Hack, Laura M.			A precision medicine-based, 'fast-fail' approach for psychiatry	NATURE MEDICINE			English	Editorial Material							DISORDERS; ANHEDONIA		[Williams, Leanne M.; Hack, Laura M.] Stanford Univ, Psychiat & Behav Sci, Stanford, CA 94305 USA; [Williams, Leanne M.; Hack, Laura M.] VA Palo Alto Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Williams, LM (corresponding author), Stanford Univ, Psychiat & Behav Sci, Stanford, CA 94305 USA.; Williams, LM (corresponding author), VA Palo Alto Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Palo Alto, CA 94304 USA.	leawilliams@stanford.edu	Williams, Leanne/GLU-4975-2022	Williams, Leanne/0000-0001-9987-7360				Carlezon WA, 2016, DEPRESS ANXIETY, V33, P895, DOI 10.1002/da.22500; Epstein J, 2006, AM J PSYCHIAT, V163, P1784, DOI 10.1176/appi.ajp.163.10.1784; Friedrich M J, 2017, JAMA, V317, P1517, DOI 10.1001/jama.2017.3826; Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379; Keedwell PA, 2005, BIOL PSYCHIAT, V58, P843, DOI 10.1016/j.biopsych.2005.05.019; Krystal AD, 2020, NAT MED, V26, P760, DOI 10.1038/s41591-020-0806-7; Rizvi SJ, 2016, NEUROSCI BIOBEHAV R, V65, P21, DOI 10.1016/j.neubiorev.2016.03.004; Roehrig C, 2016, HEALTH AFFAIR, V35, P1130, DOI 10.1377/hlthaff.2015.1659; Rush AJ, 2006, AM J PSYCHIAT, V163, P1905, DOI 10.1176/appi.ajp.163.11.1905; Uher R, 2012, PSYCHOL MED, V42, P967, DOI 10.1017/S0033291711001905; World Health Organization, 2020, MENT HLTH SUIC DAT	11	2	2	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2020	26	5					653	654		10.1038/s41591-020-0854-z	http://dx.doi.org/10.1038/s41591-020-0854-z			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	ML1JP	32405056				2023-01-03	WOS:000549231500017
J	Li, C; Chen, L; Huo, N; Mishuk, AU; Hansen, RA; Harris, I; Kiptanui, Z; Wang, Z; Qian, JJ				Li, Chao; Chen, Li; Huo, Nan; Mishuk, Ahmed Ullah; Hansen, Richard A.; Harris, Ilene; Kiptanui, Zippora; Wang, Zhong; Qian, Jingjing			Generic escitalopram initiation and substitution among Medicare beneficiaries: A new user cohort study	PLOS ONE			English	Article							MAJOR DEPRESSIVE DISORDER; BRAND-NAME; ANTIDEPRESSANT TREATMENT; COMPETING RISKS; INHIBITORS; EFFICACY; ANXIETY; DRUGS	Objectives To examine patterns of generic escitalopram initiation and substitution among Medicare beneficiaries. Methods This retrospective new user cohort used a 5% random sample of 2013-2015 Medicare administrative claims data. Fee-for-service Medicare beneficiaries continuously enrolled in Parts A, B, and D during a 6-month washout period prior to their initial generic or brand oral escitalopram prescriptions were included (n = 12,351). The primary outcomes were generic escitalopram treatment initiation, and among brand escitalopram initiators, generic substitution within 12 months. Patient demographics, health service utilization, and prescription level factors were measured and assessed. Results Among all escitalopram initiators, about 88.2% Medicare beneficiaries initiated generic escitalopram. Beneficiaries who were younger age, male, residing in non-Northeast regions or urban area, in the Part D plan deductible benefit phase, and filling prescriptions at community/retail pharmacies were more likely to initiate generic treatment. Among brand escitalopram initiators (n = 1,464), about 20.7% switched to generic escitalopram, 31.2% switched to another alternative antidepressant, 25.1% discontinued treatment, and 8.7% were lost to follow up or passed away within 12 months after brand initiation. Factors associated with generic escitalopram substitution included region (Midwest vs. Northeast, adjusted hazard ratio (HR) = 1.46, 95% CI = 1.04-2.05), pre-index hospitalization (HR = 1.31; 95% CI = 1.16-1.48) and lower escitalopram average daily dosage (HR = 0.97; 95% CI = 0.95-0.99). Conclusions In 2013-2015, almost 90% Medicare beneficiaries initiated generic escitalopram treatment. Among brand escitalopram initiators, about 1 in 5 patients switched to generic escitalopram within 1 year, as compared to 1 in 4 or 1 in 3 who discontinued current or switched to alternative treatment, respectively. Medicare beneficiary's geographic region was independently associated with generic escitalopram initiation and substitution. Findings from this study not only provide up-to-date evidence in generic escitalopram use patterns among Medicare population, but also can guide educational and practice interventions to further increase generic escitalopram use.	[Li, Chao; Mishuk, Ahmed Ullah; Hansen, Richard A.; Qian, Jingjing] Auburn Univ, Harrison Sch Pharm, Auburn, AL USA; [Chen, Li] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Huo, Nan] Mayo Clin, Rochester, MN USA; [Harris, Ilene; Kiptanui, Zippora] IMPAQ Int LLC, Columbia, MD USA; [Wang, Zhong] US FDA, Ctr Drug Evaluat & Res, Off Res & Stand, Off Gener Drugs, Silver Spring, MD USA	Auburn University System; Auburn University; Indiana University System; Indiana University Bloomington; Mayo Clinic; American Institutes for Research; US Food & Drug Administration (FDA)	Qian, JJ (corresponding author), Auburn Univ, Harrison Sch Pharm, Auburn, AL USA.	jzq0004@auburn.edu	Huo, Nan/AAO-3467-2021; Mishuk, Ahmed Ullah/GUF-6551-2022; Huo, Nan/AAD-9300-2022	Huo, Nan/0000-0002-4980-2421; Kiptanui, Zippora/0000-0003-1212-7642	U.S. Food and Drug Administration (FDA) [U01FD005875]	U.S. Food and Drug Administration (FDA)	Funding for this manuscript was made possible, in part, by the U.S. Food and Drug Administration (FDA, https://www.fda.gov/) grant #U01FD005875. Views expressed in written materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government. The funder provided support for the conduct of the study but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2000, Am J Psychiatry, V157, P1; [Anonymous], GEN DRUGS OV BAS; [Anonymous], GEN DRUGS PAT ED PRE; [Anonymous], GEN DRUG ACC SAV REP; Austin PC, 2016, CIRCULATION, V133, P601, DOI 10.1161/CIRCULATIONAHA.115.017719; Baldwin DS, 2016, EUR NEUROPSYCHOPHARM, V26, P1062, DOI 10.1016/j.euroneuro.2016.02.013; Bech P, 2006, PHARMACOPSYCHIATRY, V39, P128, DOI 10.1055/s-2006-946702; Beland SG, 2011, VALUE HEALTH, V14, P492, DOI 10.1016/j.jval.2010.11.015; Bosak M, 2017, DRUG DES DEV THER, V11, P2287, DOI 10.2147/DDDT.S138270; Buffery D, 2009, AM HEALTH DRUG BENEF, V2, P120; Bull SA, 2002, ANN PHARMACOTHER, V36, P578, DOI 10.1345/aph.1A254; Bull SA, 2002, JAMA-J AM MED ASSOC, V288, P1403, DOI 10.1001/jama.288.11.1403; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cipriani A, 2016, LANCET, V388, P881, DOI 10.1016/S0140-6736(16)30385-3; Cipriani A, 2009, LANCET, V373, P746, DOI 10.1016/S0140-6736(09)60046-5; DeWitt EM, 2006, ARCH INTERN MED, V166, P57, DOI 10.1001/archinte.166.1.57; Dignam JJ, 2008, J CLIN ONCOL, V26, P4027, DOI 10.1200/JCO.2007.12.9866; Drugs@FDA: FDA Approved Drug Products, SEARCH RES ESC; Einarson TR, 2004, INT CLIN PSYCHOPHARM, V19, P305, DOI 10.1097/01.yic.0000139342.22133.77; Ereshefsky Larry, 2010, J Med Econ, V13, P527, DOI 10.3111/13696998.2010.511050; Fava M, 2000, J CLIN PSYCHIAT, V61, P10; Ferguson JM, 2001, J CLIN PSYCHIAT, V62, P22; Fischer MA, 2004, JAMA-J AM MED ASSOC, V291, P1850, DOI 10.1001/jama.291.15.1850; Fortney JC, 2011, J CLIN PSYCHIAT, V72, P827, DOI 10.4088/JCP.09m05528blu; Haas JS, 2005, ANN INTERN MED, V142, P891, DOI 10.7326/0003-4819-142-11-200506070-00006; Hansen RA, 2018, CLIN PHARMACOL THER, V103, P310, DOI 10.1002/cpt.591; Hansen RA, 2017, PHARMACOTHERAPY, V37, P429, DOI 10.1002/phar.1908; Hassali Mohamed A A, 2009, Int J Pharm Pract, V17, P79; Himmel W, 2005, INT J CLIN PHARM TH, V43, P472; Iosifescu A, 2008, PATIENT EDUC COUNS, V73, P377, DOI 10.1016/j.pec.2008.07.012; Kaplan C, 2012, J MENT HEALTH POLICY, V15, P171; Keenum AJ, 2012, RES SOC ADMIN PHARM, V8, P574, DOI 10.1016/j.sapharm.2011.12.004; Keks N, 2019, AUST PRESCR, V42, P152, DOI 10.18773/austprescr.2019.052; Kennedy SH, 2006, J PSYCHIATR NEUROSCI, V31, P122; Lau B, 2009, AM J EPIDEMIOL, V170, P244, DOI 10.1093/aje/kwp107; Limited Data Set (LDS), 2020, FIL CMS; MacQueen G, 2017, CAN J PSYCHIAT, V62, P11, DOI 10.1177/0706743716664885; MAP, EXPR SCRIPTS; Mark TL, 2011, AM J GERIAT PSYCHIAT, V19, P211, DOI 10.1097/JGP.0b013e3181f1803d; Middleton H, 2005, BMJ-BRIT MED J, V330, P267, DOI 10.1136/bmj.330.7486.267; National Center for Health Statistics, 2016, HLTH US 2015 SPEC FE; Noordzij M, 2013, NEPHROL DIAL TRANSPL, V28, P2670, DOI 10.1093/ndt/gft355; Pechlivanoglou P, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-89; Qian JJ, 2017, PHARMACOEPIDEM DR S, V26, P819, DOI 10.1002/pds.4224; Raina Parminder S, 2007, Healthc Policy, V3, pe128; Ruhe HG, 2006, J CLIN PSYCHIAT, V67, P1836, DOI 10.4088/JCP.v67n1203; Sansone Randy A, 2012, Innov Clin Neurosci, V9, P41; Schondelmeyer SW, TRENDS RETAIL PRICES, P29; Sewell K, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.120010; Shrank WH, 2009, HEALTH AFFAIR, V28, P546, DOI 10.1377/hlthaff.28.2.546; US Census Bureau, 2010, GEOGRAPHY; US Department of Health &Human Services, 2015, EXP US GEN DRUGS; Vasiliadis HM, 2013, CAN J PSYCHIAT, V58, P201, DOI 10.1177/070674371305800405; Wouters OJ, 2017, MILBANK Q, V95, P554, DOI 10.1111/1468-0009.12279; Zhang Mei-Jie, 2008, Expert Rev Clin Pharmacol, V1, P391, DOI 10.1586/17512433.1.3.391	55	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2020	15	4							e0232226	10.1371/journal.pone.0232226	http://dx.doi.org/10.1371/journal.pone.0232226			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LS9BE	32353006	Green Published, gold			2023-01-03	WOS:000536673200055
J	Chanda, SK; Ahammed, B; Howlader, MH; Ashikuzzaman, M; Shovo, TEA; Hossain, MT				Chanda, Sanjoy Kumar; Ahammed, Benojir; Howlader, Md. Hasan; Ashikuzzaman, Md; Shovo, Taufiq-E-Ahmed; Hossain, Md. Tanvir			Factors associating different antenatal care contacts of women: A cross-sectional analysis of Bangladesh demographic and health survey 2014 data	PLOS ONE			English	Article							SERVICES; QUALITY; ACCESS; INDIA	Antenatal care (ANC) contacts have long been considered a critical component of the continuum of care for a pregnant mother along with the newborn baby. The latest maternal mortality survey in Bangladesh suggests that progress in reducing maternal mortality has stalled as only 37% of pregnant women have attended at least four ANC contacts. This paper aims to determine what factors are associated with ANC contacts for women in Bangladesh. We analysed the data, provided by Bangladesh demographic and health survey 2014, covering a nationally representative sample of 17,863 ever married women aged 1549 years. A two-stage stratified cluster sampling was used to collect the data. Data derived from 4,475 mothers who gave birth in the three years preceding the survey. Descriptive, inferential, and multivariate statistical techniques were used to analyse the data. An overall 78.4% of women had ANC contacts, but the WHO recommended >= 8 ANC contacts and ANC contacts by qualified doctors were only 8% for each. The logistic regression analysis revealed that division, maternal age, women's education, husband's education, wealth index and media exposure were associated with the ANC contacts. Likewise, place of residence, women's education, religion, and wealth index were also found to be associated with the WHO recommended ANC contacts. Furthermore, the husband's education, division, religion and husband's employment showed significant associations with ANC contacts by qualified doctors. However, Bangladeshi women in general revealed an unsatisfactory level of ANC contacts, the WHO recommended as well as ANC contacts by qualified doctors. In order to improve the situation, it is necessary to follow the most recent ANC contacts recommended by the WHO and to contact the qualified doctors. Moreover, an improvement in education as well as access to information along with an increase of transports, care centres and reduction of service costs would see an improvement of ANC contacts in Bangladesh.	[Chanda, Sanjoy Kumar] Univ Leeds, Sch Healthcare, Fac Med & Hlth, Leeds, W Yorkshire, England; [Chanda, Sanjoy Kumar; Shovo, Taufiq-E-Ahmed; Hossain, Md. Tanvir] Khulna Univ, Social Sci Sch, Sociol Discipline, Khulna, Bangladesh; [Ahammed, Benojir] Khulna Univ, Sci Engn & Technol Sch, Stat Discipline, Khulna, Bangladesh; [Howlader, Md. Hasan; Ashikuzzaman, Md] Khulna Univ, Social Sci Sch, Dev Studies Discipline, Khulna, Bangladesh; [Shovo, Taufiq-E-Ahmed] Univ Newcastle, Fac Educ & Arts, Sch Humanities & Social Sci, Callaghan, NSW, Australia	University of Leeds; Khulna University; Khulna University; Khulna University; University of Newcastle	Chanda, SK (corresponding author), Univ Leeds, Sch Healthcare, Fac Med & Hlth, Leeds, W Yorkshire, England.; Chanda, SK (corresponding author), Khulna Univ, Social Sci Sch, Sociol Discipline, Khulna, Bangladesh.	hcskch@leeds.ac.uk	Hossain, Md. Tanvir/AAS-3339-2021; Howlader, Md. Hasan/AFR-1027-2022	Hossain, Md. Tanvir/0000-0003-0315-6900; Howlader, Md. Hasan/0000-0001-6603-7189; Chanda, Sanjoy Kumar/0000-0001-5950-5511; Ashikuzzaman, MD/0000-0002-4109-9321				Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; Amin R, 2010, INT J EQUITY HEALTH, V9, DOI 10.1186/1475-9276-9-9; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], 2016, BANGL DEM HLTH SURV; [Anonymous], 2017, BANGL MAT MORT HLTH; Arokiasamy P, 2013, PRIM HEALTH CARE RES, V14, P373, DOI 10.1017/S1463423612000552; Bin Nisar Y, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0829-8; Chakraborty N, 2003, HEALTH PROMOT INT, V18, P327, DOI 10.1093/heapro/dag414; Ciceklioglu M, 2005, INT J QUAL HEALTH C, V17, P533, DOI 10.1093/intqhc/mzi076; Defar A, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-1079-y; Desta M, 2019, J NUTR METABOLISM, P1; Fatmi Z, 2002, J Pak Med Assoc, V52, P138; FOSU GB, 1994, SOC SCI MED, V38, P1209, DOI 10.1016/0277-9536(94)90186-4; Hajizadeh M, 2014, INT J EQUITY HEALTH, V13, DOI [10.1186/1475-9276-13-18, 10.1186/s12939-014-0120-4]; Haruna-Ogun OA, 2018, HEALTH CARE WOMEN IN, V39, P34, DOI 10.1080/07399332.2017.1388804; Hodgins S, 2014, GLOB HEALTH-SCI PRAC, V2, P173, DOI 10.9745/GHSP-D-13-00176; Huda TM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211113; Huda TM, 2018, J GLOB HEALTH, V8, DOI 10.7189/jogh.08.010416; Islam MM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204752; Iyaniwura C A, 2009, Afr J Reprod Health, V13, P111; Joshi C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-94; Kamal SMM, 2013, ASIA PACIFIC J PUBLI, V27, DOI [10.1177/org/10.1093/heapro/dag414, DOI 10.1177/ORG/10.1093/HEAPRO/DAG414]; Kuhnt J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017122; Kumar G, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2473-6; Ministry of Health and Family Welfare, 2018, MIN HLTH FAM WELF HL; Mumtaz Z, 2007, SOCIOL HEALTH ILL, V29, P1, DOI 10.1111/j.1467-9566.2007.00519.x; Navaneetham K, 2002, SOC SCI MED, V55, P1849, DOI 10.1016/S0277-9536(01)00313-6; Nsibu CN, 2016, OBSTET GYNECOL INT, V2016, DOI 10.1155/2016/5423413; Okedo-Alex IN, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031890; Ousman SK, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00161; Pan American Health Organization (PAHO)/World Health Organization (WHO), 2018, EV INT ACT HLTH HLTH; Ponna Satyendra Nath, 2017, J Family Med Prim Care, V6, P231, DOI 10.4103/2249-4863.220024; Prual A, 2000, HEALTH POLICY PLANN, V15, P11, DOI 10.1093/heapol/15.1.11; Rahman MM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157760; Rahman MM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202879; Rai RK, 2015, J PUBLIC HEALTH-HEID, V23, P37, DOI 10.1007/s10389-014-0651-6; Saha S, 2017, HEALTH CARE WOMEN IN, V38, P2, DOI 10.1080/07399332.2016.1217864; Sarker Mohammad Abul Bashar, 2015, BMC Res Notes, V8, P590, DOI 10.1186/s13104-015-1374-7; Shahjahan M, 2017, MIDWIFERY, V52, P42, DOI 10.1016/j.midw.2017.05.011; Siddique AB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205149; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Souza JP, 2014, BJOG-INT J OBSTET GY, V121, P1, DOI 10.1111/1471-0528.12735; Tariku A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179056; Tegegne TK, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2550-x; Tekelab T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214848; Tey NP, 2013, SCI WORLD J, DOI 10.1155/2013/423403; Titaley CR, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-485; WHO, 2007, MAT MORT 2005 EST DE; WHO, 2022, WHO RECOMMENDATIONS; WHO, 2015, BANGLADESH HLTH SYST; World Bank, 2021, SUMM UN SUST DEV 201; World Health Organization, 2009, WHO REC INT IMPR MAT	52	15	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2020	15	4							e0232257	10.1371/journal.pone.0232257	http://dx.doi.org/10.1371/journal.pone.0232257			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LS8ZG	32348364	Green Published, gold			2023-01-03	WOS:000536668200051
J	Bouguellid, G; Russo, C; Lavorgna, M; Piscitelli, C; Ayouni, K; Wilson, E; Kim, HK; Verpoorte, R; Choi, YH; Kilani-Atmani, D; Atmani, D; Isidori, M				Bouguellid, Ghania; Russo, Chiara; Lavorgna, Margherita; Piscitelli, Concetta; Ayouni, Karima; Wilson, Erica; Kim, Hye Kyonn; Verpoorte, Rob; Choi, Young Hae; Kilani-Atmani, Dina; Atmani, Djebbar; Isidori, Marina			Antimutagenic, antigenotoxic and antiproliferative activities of Fraxinus angustifolia Vahl. leaves and stem bark extracts and their phytochemical composition	PLOS ONE			English	Article							IN-VITRO; UMU-TEST; 4-NITROQUINOLINE 1-OXIDE; ANTIOXIDANT ACTIVITY; XANTHINE-OXIDASE; MUTAGENICITY; CANCER; VERBASCOSIDE; MUTATION; PLANTS	In recent years, chronic degenerative diseases such as certain types of cancers, are becoming an evident issue. DNA damage has been for long recognized as a causal factor for cancer development because mutations or chromosomal aberrations affect oncogenes and tumor suppressor genes leading cells to malignant transformation and to the subsequent cancerous growth. Medicinal plants are often used for the prevention or treatment of various diseases with great scientific interest. Among the medicinal plants distributed in the Mediterranean region, Fraxinus angustifolia Vahl. has been used in traditional medicine for its remarkable curative properties. However, in spite of this popularity, little works have been performed on the activity so that further studies should be performed to investigate in depth the antimutagenic, antigenotoxic and antiproliferative activities of the plant. Thus, the present study was aimed to the evaluation of the potential antimutagenic, antigenotoxic and antiproliferative properties of leaves and stem bark extracts of this well-known tree. Antimutagenic activity was evaluated by Salmonella mutagenicity assay in Salmonella typhimurium TA98 and TA100 strains. The antigenotoxic potential was assessed by umu test in the strain of S. typhimurium TA1535/pSK1002. Antiproliferative activity was studied on human hepatoblastoma (HepG-2) and on breast adenocarcinoma (MCF-7) cell lines by MTT assay. Furthermore, the antiproliferative activity observed on cancer cells was compared with that on the human normal-like fibroblasts (TelCOFS02MA) and the selectivity index was calculated to understand if extracts were able to exert selective toxicity towards cancer cells. Moreover, phenolic compounds are plant substances with a large spectrum of biochemical activities with antioxidant, antimutagenic and anticarcinogenic effects. Based on the strong evidence of biological activities of phenolic compounds, the study was focused on the determination of total phenolics and flavonoids contents, and the phytochemical composition of the extracts assessed by LC/MS. The ethanol extracts of both leaves and stem barks showed significant from moderate to strong antimutagenic and antigenotoxic effects. In addition, selective cytotoxicity towards cancer cells was shown by ethanolic leaves extract and aqueous/chloroform leaves and stem bark extracts. The latter showed high levels of total phenolic contents among all the other extracts. Identified phenylethanoids (calceolariosides, verbascoside) and secoiridoids (oleuropein and ligstroside) could be responsible for the demonstrated broad spectrum of healthy properties.	[Bouguellid, Ghania; Ayouni, Karima; Kilani-Atmani, Dina; Atmani, Djebbar] Univ Bejaia, Lab Biochim Appl, Fac Sci Nat & Vie, Bejaia, Algeria; [Russo, Chiara; Lavorgna, Margherita; Piscitelli, Concetta; Isidori, Marina] Univ Campania Luigi Vanvitelli, Dipartimento Sci & Tecnol Ambientali Biol & Farma, Caserta, Italy; [Wilson, Erica; Kim, Hye Kyonn; Verpoorte, Rob; Choi, Young Hae] Leiden Univ, Nat Prod Lab, Inst Biol, Leiden, Netherlands	Universite de Bejaia; Universita della Campania Vanvitelli; Leiden University; Leiden University - Excl LUMC	Russo, C (corresponding author), Univ Campania Luigi Vanvitelli, Dipartimento Sci & Tecnol Ambientali Biol & Farma, Caserta, Italy.	chiara.russo@unicampania.it	Russo, Chiara/AAP-3102-2021; Choi, Young Hae/O-7886-2016	Choi, Young Hae/0000-0003-1484-1700; Isidori, Marina/0000-0002-0484-2796	University of Campania "Luigi Vanvitelli" through the VALERE program	University of Campania "Luigi Vanvitelli" through the VALERE program	This work was supported by the University of Campania "Luigi Vanvitelli" through the VALERE program. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abudayyak M, 2015, TURK J MED SCI, V45, P496, DOI 10.3906/sag-1401-153; Ahmane N, 2019, TURK J BIOL, V43, P133, DOI 10.3906/biy-1810-26; [Anonymous], 2000, 13829 ISO DIS; Anter J, 2014, MUTAT RES-GEN TOX EN, V772, P25, DOI 10.1016/j.mrgentox.2014.07.002; Atanasov AG, 2015, BIOTECHNOL ADV, V33, P1582, DOI 10.1016/j.biotechadv.2015.08.001; Atmani D, 2009, FOOD CHEM, V112, P303, DOI 10.1016/j.foodchem.2008.05.077; Ayouni K, 2016, IND CROP PROD, V88, P65, DOI 10.1016/j.indcrop.2016.01.001; BabaAissa F., 1999, ENCY PLANTES UTILES; Baharum Z, 2014, MOLECULES, V19, P18317, DOI 10.3390/molecules191118317; BAILLEUL B, 1989, JPN J CANCER RES, V80, P691, DOI 10.1111/j.1349-7006.1989.tb01698.x; Beloued A., 1998, PLANTES MED ALGERIA; Berboucha M, 2010, J MED FOOD, V13, P896, DOI 10.1089/jmf.2009.0164; Caillet S, 2011, FOOD CHEM, V124, P1699, DOI 10.1016/j.foodchem.2010.07.082; Camarda L, 2011, NATURAL RESINS CHEM; Cardinali A, 2013, FOOD RES INT, V54, P132, DOI 10.1016/j.foodres.2013.06.017; Casaburi I, 2013, MOL NUTR FOOD RES, V57, P71, DOI 10.1002/mnfr.201200503; Chatterjee S, 2005, CLIN CHIM ACTA, V352, P155, DOI 10.1016/j.cccn.2004.09.012; CHIANG HC, 1994, J ENZYM INHIB, V8, P61, DOI 10.3109/14756369409040777; Collins AR, 2012, EUR J NUTR, V51, P261, DOI 10.1007/s00394-012-0318-4; Coxam V, 2014, HUILE OLIVE SANTEPRI, V21, P7; de Carvalho MCRD, 2003, ENVIRON MOL MUTAGEN, V42, P185, DOI 10.1002/em.10183; Demirgan R, 2016, AFR J TRADIT COMPLEM, V13, P22, DOI 10.4314/ajtcam.v13i3.3; Duke J.A., 2008, DUKES HDB MED PLANTS; Elamin MH, 2013, FOOD CHEM TOXICOL, V53, P310, DOI 10.1016/j.fct.2012.12.009; Elgorashi EE, 2002, S AFR J BOT, V68, P408, DOI 10.1016/S0254-6299(15)30409-9; EMA (European medicine agency), 2012, ASS REP FRAX EXC FRA, P5; Fale P. L., 2013, Journal of Medicinal Plants Research, V7, P1370; Farooqi A, 2017, MOLECULES, V22, P1; Santos-Cruz LF, 2012, FOOD CHEM TOXICOL, V50, P1082, DOI 10.1016/j.fct.2011.12.006; Ferguson LR, 2001, MUTAT RES-FUND MOL M, V475, P89, DOI 10.1016/S0027-5107(01)00073-2; Ferguson LR, 2004, TOXICOLOGY, V198, P147, DOI 10.1016/j.tox.2004.01.035; Gallagher JEG, 2014, GENE DEV, V28, P409, DOI 10.1101/gad.228940.113; Galvez M, 2006, STUD NAT PROD CHEM, V33, P675; Goldsmith CD, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071937; Henn JG, 2019, J ETHNOPHARMACOL, V229, P145, DOI 10.1016/j.jep.2018.10.003; IKENAGA M, 1975, J MOL BIOL, V92, P341, DOI 10.1016/0022-2836(75)90233-8; Kahkonen MP, 1999, J AGR FOOD CHEM, V47, P3954, DOI 10.1021/jf990146l; Khan MS, 2018, TOXICOL RES-UK, V7, P156, DOI 10.1039/c7tx00269f; Kostova I, 2007, FITOTERAPIA, V78, P85, DOI 10.1016/j.fitote.2006.08.002; Lazzarini E, 1984, MANNA SALUTE NATURA; Lunenfeld B, 2013, BEST PRACT RES CL OB, V27, P643, DOI 10.1016/j.bpobgyn.2013.02.005; Macaluso AM, 1921, FRASSINO MANNA SICIL; Maksimovic Z, 2005, BIORESOURCE TECHNOL, V96, P873, DOI 10.1016/j.biortech.2004.09.006; MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9; Medjahed Z, 2016, TURK J MED SCI, V46, P910, DOI 10.3906/sag-1502-13; Mortelmans K, 2000, MUTAT RES-FUND MOL M, V455, P29, DOI 10.1016/S0027-5107(00)00064-6; Moulaoui K, 2015, EUR J MED CHEM, V89, P179, DOI 10.1016/j.ejmech.2014.10.047; Nagarathna K.M., 2013, INT J PHARM SCI REV, V22, P236; Nsimba RY, 2008, FOOD CHEM, V106, P760, DOI 10.1016/j.foodchem.2007.06.004; NUNOSHIBA T, 1993, CANCER RES, V53, P3250; ODA Y, 1985, MUTAT RES, V147, P219, DOI 10.1016/0165-1161(85)90062-7; Oda Y, 2016, GENES ENVIRON, V38, DOI 10.1186/s41021-016-0054-8; Oddo E, 2002, PLANT BIOSYST, V136, P29, DOI 10.1080/11263500212331358501; Orhan F, 2013, FOOD CHEM, V141, P366, DOI 10.1016/j.foodchem.2013.02.089; Ota M, 2005, SUMITOMO KAGAKU, V2, P1; Owen RW, 2000, CLIN CHEM, V46, P976; Papanikolaou C., 2019, FUNCTIONAL FOODS, P9, DOI [10.5772/intechopen.81394, DOI 10.5772/INTECH0PEN.81394]; Perucatti A, 2018, FOOD CHEM TOXICOL, V114, P311, DOI 10.1016/j.fct.2018.02.053; Resende FA, 2015, REGUL TOXICOL PHARM, V72, P506, DOI 10.1016/j.yrtph.2015.05.014; Resende FA, 2012, MOLECULES, V17, P2335, DOI 10.3390/molecules17032335; Santoro A, 2008, TOXICOL LETT, V178, P71, DOI 10.1016/j.toxlet.2008.02.006; Schicchi R, 2006, QUAD BOT AMBIENT APP, V17, P139; Sherif IO, 2018, LIFE SCI, V198, P87, DOI 10.1016/j.lfs.2018.02.027; Skrzypczak A, 2015, TOXICOL IN VITRO, V30, P364, DOI 10.1016/j.tiv.2015.09.029; Sloczynska K, 2014, J APPL GENET, V55, P273, DOI 10.1007/s13353-014-0198-9; Sofowora A, 2013, AFR J TRADIT COMPLEM, V10, P210, DOI 10.4314/ajtcam.v10i5.2; Torgovnick A, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00157; Visioli F, 1998, BIOCHEM BIOPH RES CO, V247, P60, DOI 10.1006/bbrc.1998.8735; Zahin M, 2010, MUTAT RES-GEN TOX EN, V703, P99, DOI 10.1016/j.mrgentox.2010.08.001	69	6	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2020	15	4							e0230690	10.1371/journal.pone.0230690	http://dx.doi.org/10.1371/journal.pone.0230690			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9JM	32298276	Green Published, gold			2023-01-03	WOS:000536011400019
J	Ge, L; Sadeghirad, B; Ball, GDC; da Costa, BR; Hitchcock, CL; Svendrovski, A; Kiflen, R; Quadri, K; Kwon, HY; Karamouzian, M; Adams-Webber, T; Ahmed, W; Damanhoury, S; Zeraatkar, D; Nikolakopoulou, A; Tsuyuki, RT; Tian, JH; Yang, KH; Guyatt, GH; Johnston, BC				Ge, Long; Sadeghirad, Behnam; Ball, Geoff D. C.; da Costa, Bruno R.; Hitchcock, Christine L.; Svendrovski, Anton; Kiflen, Ruhi; Quadri, Kalimullah; Kwon, Henry Y.; Karamouzian, Mohammad; Adams-Webber, Thomasin; Ahmed, Waleed; Damanhoury, Samah; Zeraatkar, Dena; Nikolakopoulou, Adriani; Tsuyuki, Ross T.; Tian, Jinhui; Yang, Kehu; Guyatt, Gordon H.; Johnston, Bradley C.			Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LOW-FAT DIETS; LOW-CARBOHYDRATE; OBESE ADULTS; HETEROGENEITY; OVERWEIGHT; QUALITY; EXTENT	OBJECTIVE To determine the relative effectiveness of dietary macronutrient patterns and popular named diet programmes for weight loss and cardiovascular risk factor improvement among adults who are overweight or obese. DESIGN Systematic review and network meta-analysis of randomised trials. DATA SOURCES Medline, Embase, CINAHL, AMED, and CENTRAL from database inception until September 2018, reference lists of eligible trials, and related reviews. STUDY SELECTION Randomised trials that enrolled adults (>= 18 years) who were overweight (body mass index 25-29) or obese (>= 30) to a popular named diet or an alternative diet. OUTCOMES AND MEASURES Change in body weight, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, systolic blood pressure, diastolic blood pressure, and C reactive protein at the six and 12 month follow-up. REVIEW METHODS Two reviewers independently extracted data on study participants, interventions, and outcomes and assessed risk of bias, and the certainty of evidence using the GRADE (grading of recommendations, assessment, development, and evaluation) approach. A bayesian framework informed a series of random effects network meta-analyses to estimate the relative effectiveness of the diets. RESULTS 121 eligible trials with 21 942 patients were included and reported on 14 named diets and three control diets. Compared with usual diet, low carbohydrate and low fat diets had a similar effect at six months on weight loss (4.63 v 4.37 kg, both moderate certainty) and reduction in systolic blood pressure (5.14 mm Hg, moderate certainty v 5.05 mm Hg, low certainty) and diastolic blood pressure ( 3.21 v 2.85 mm Hg, both low certainty). Moderate macronutrient diets resulted in slightly less weight loss and blood pressure reductions. Low carbohydrate diets had less effect than low fat diets and moderate macronutrient diets on reduction in LDL cholesterol (1.01 mg/dL, low certainty v 7.08 mg/dL, moderate certainty v 5.22 mg/dL, moderate certainty, respectively) but an increase in HDL cholesterol (2.31 mg/ dL, low certainty), whereas low fat (-1.88 mg/dL, moderate certainty) and moderate macronutrient (-0.89 mg/dL, moderate certainty) did not. Among popular named diets, those with the largest effect on weight reduction and blood pressure in comparison with usual diet were Atkins (weight 5.5 kg, systolic blood pressure 5.1 mm Hg, diastolic blood pressure 3.3 mm Hg), DASH (3.6 kg, 4.7 mm Hg, 2.9 mm Hg, respectively), and Zone (4.1 kg, 3.5 mm Hg, 2.3 mm Hg, respectively) at six months (all moderate certainty). No diets significantly improved levels of HDL cholesterol or C reactive protein at six months. Overall, weight loss diminished at 12 months among all macronutrient patterns and popular named diets, while the benefits for cardiovascular risk factors of all interventions, except the Mediterranean diet, essentially disappeared. CONCLUSIONS Moderate certainty evidence shows that most macronutrient diets, over six months, result in modest weight loss and substantial improvements in cardiovascular risk factors, particularly blood pressure. At 12 months the effects on weight reduction and improvements in cardiovascular risk factors largely disappear.	[Ge, Long; Yang, Kehu] Lanzhou Univ, Evidence Based Social Sci Res Ctr, Sch Publ Hlth, Lanzhou, Peoples R China; [Ge, Long] Lanzhou Univ, Sch Publ Hlth, Dept Social Med & Hlth Management, Lanzhou, Peoples R China; [Ge, Long; Sadeghirad, Behnam; Kiflen, Ruhi; Zeraatkar, Dena; Guyatt, Gordon H.; Johnston, Bradley C.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Sadeghirad, Behnam] McMaster Univ, Michael G DeGroote Inst Pain Res & Care, Hamilton, ON, Canada; [Ball, Geoff D. C.; Hitchcock, Christine L.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [da Costa, Bruno R.] Univ Bern, Inst Primary Hlth Care BIHAM, Bern, Switzerland; [da Costa, Bruno R.] Univ Toronto, St Michaels Hosp, Appl Hlth Res Ctr, Toronto, ON, Canada; [da Costa, Bruno R.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Hitchcock, Christine L.; Svendrovski, Anton; Johnston, Bradley C.] Dalhousie Univ, Fac Med, Dept Community Hlth & Epidemiol, Halifax, NS, Canada; [Quadri, Kalimullah] HOFSTRA Northwell Mather Hosp, Zucker Sch Med, Port Jefferson, NY USA; [Kwon, Henry Y.] Wayne State Univ, Sch Med, Detroit, MI USA; [Karamouzian, Mohammad] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Karamouzian, Mohammad] Kerman Univ Med Sci, HIV STI Surveillance Res Ctr, Kerman, Iran; [Karamouzian, Mohammad] Kerman Univ Med Sci, WHO Collaborating Ctr HIV Surveillance, Inst Futures Studies Hlth, Kerman, Iran; [Adams-Webber, Thomasin] Hosp Sick Children, Lib & Archives Serv, Toronto, ON, Canada; [Ahmed, Waleed] Univ Toronto, Dept Med, Toronto, ON, Canada; [Damanhoury, Samah] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB, Canada; [Nikolakopoulou, Adriani] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland; [Tsuyuki, Ross T.] Univ Alberta, Fac Med & Dent, Dept Pharmacol, Edmonton, AB, Canada; [Tian, Jinhui; Yang, Kehu] Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Peoples R China; [Johnston, Bradley C.] Texas A&M Univ, Dept Nutr, College Stn, TX 77845 USA	Lanzhou University; Lanzhou University; McMaster University; McMaster University; University of Alberta; University of Bern; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Dalhousie University; Wayne State University; University of British Columbia; Kerman University of Medical Sciences; Kerman University of Medical Sciences; World Health Organization; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Alberta; University of Bern; University of Alberta; Lanzhou University; Texas A&M University System; Texas A&M University College Station	Johnston, BC (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.; Johnston, BC (corresponding author), Dalhousie Univ, Fac Med, Dept Community Hlth & Epidemiol, Halifax, NS, Canada.; Johnston, BC (corresponding author), Texas A&M Univ, Dept Nutr, College Stn, TX 77845 USA.	bradley.johnston@tamu.edu	Sadeghirad, Behnam/A-1772-2009; Karamouzian, Mohammad/C-9277-2018; Zeraatkar, Dena/GNM-9600-2022; Hitchcock, Chris/AAW-7607-2020	Sadeghirad, Behnam/0000-0001-9422-5232; Karamouzian, Mohammad/0000-0002-5631-4469; Svendrovski, Anton/0000-0002-8235-312X	Dalhousie University; University of Alberta; Umm AlQura University, Makkah, Kingdom of Saudi Arabia; Alberta Health Services Chair in Obesity Research	Dalhousie University; University of Alberta(University of Alberta); Umm AlQura University, Makkah, Kingdom of Saudi Arabia; Alberta Health Services Chair in Obesity Research	This research was not funded by a specific grant from any funding agency in the public, commercial, or not-for-profit sectors. It was funded, in part, by internal investigator funds from Dalhousie University (awarded to BCJ) and the University of Alberta (awarded to GDCB). SD was supported by a scholarship from Umm AlQura University, Makkah, Kingdom of Saudi Arabia. GDCB was supported by an Alberta Health Services Chair in Obesity Research.	Ades AE, 2006, PHARMACOECONOMICS, V24, P1, DOI 10.2165/00019053-200624010-00001; Anton SD, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080822; Barnard ND, 2017, JAMA-J AM MED ASSOC, V318, P1435, DOI 10.1001/jama.2017.12083; Bazzano LA, 2014, ANN INTERN MED, V161, P309, DOI 10.7326/M14-0180; Berg AO, 2003, ANN INTERN MED, V139, P930, DOI 10.7326/0003-4819-139-11-200312020-00012; Bloomfield HE, 2016, ANN INTERN MED, V165, P491, DOI 10.7326/M16-0361; Brignardello-Petersen R, 2018, J CLIN EPIDEMIOL, V93, P36, DOI 10.1016/j.jclinepi.2017.10.005; Canada's Food Guide, 2019, EAT WELL LIV WELL; Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654; Chaimani A, 2012, RES SYNTH METHODS, V3, P161, DOI 10.1002/jrsm.57; Dias S, 2013, MED DECIS MAKING, V33, P618, DOI 10.1177/0272989X13485157; Dietary Guidelines Advisory Committee, 2015, RAPP ACT 2015 REP PE; Florez ID, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207701; Freedhoff Y, 2016, LANCET, V388, P849, DOI 10.1016/S0140-6736(16)31338-1; Furukawa TA, 2006, J CLIN EPIDEMIOL, V59, P7, DOI 10.1016/j.jclinepi.2005.06.006; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Huedo-Medina TB, 2016, AM J CLIN NUTR, V103, P841, DOI 10.3945/ajcn.115.112771; Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee; Johnston BC, 2014, JAMA-J AM MED ASSOC, V312, P923, DOI 10.1001/jama.2014.10397; Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201; Mansoor N, 2016, BRIT J NUTR, V115, P466, DOI 10.1017/S0007114515004699; Naude CE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200284; Organization WH, 2018, OBESITY OVERWEIGHT D; Puhan MA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5630; Rhodes KM, 2015, J CLIN EPIDEMIOL, V68, P52, DOI 10.1016/j.jclinepi.2014.08.012; Sackner-Bernstein J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139817; Salanti G, 2008, STAT METHODS MED RES, V17, P279, DOI 10.1177/0962280207080643; Schwingshackl L, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-48; Siervo M, 2015, BRIT J NUTR, V113, P1, DOI 10.1017/S0007114514003341; Soltani S, 2018, CLIN NUTR, V37, P542, DOI 10.1016/j.clnu.2017.02.018; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; Turner RM, 2012, INT J EPIDEMIOL, V41, P818, DOI 10.1093/ije/dys041; van Valkenhoef G, 2016, RES SYNTH METHODS, V7, P80, DOI 10.1002/jrsm.1167; Veroniki AA, 2016, J CLIN EPIDEMIOL, V76, P193, DOI 10.1016/j.jclinepi.2016.02.016; Volek JS, 2009, METABOLISM, V58, P1769, DOI 10.1016/j.metabol.2009.06.005; Willett W, 2019, LANCET, V393, P447, DOI 10.1016/S0140-6736(18)31788-4; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006; Zhong XM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06455-x	39	113	114	9	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2020	369								m696	10.1136/bmj.m696	http://dx.doi.org/10.1136/bmj.m696			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA2EU	32238384	Green Published, hybrid			2023-01-03	WOS:000523766800001
J	Olsen, HT; Nedergaard, HK; Strom, T; Oxlund, J; Wian, KA; Ytrebo, LM; Kroken, BA; Chew, M; Korkmaz, S; Lauridsen, JT; Toft, P				Olsen, Hanne T.; Nedergaard, Helene K.; Strom, Thomas; Oxlund, Jakob; Wian, Karl-Andre; Ytrebo, Lars M.; Kroken, Bjorn A.; Chew, Michelle; Korkmaz, Serkan; Lauridsen, Jorgen T.; Toft, Palle			Nonsedation or Light Sedation in Critically Ill, Mechanically Ventilated Patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARE; PROTOCOL; DELIRIUM; INTERRUPTION; TRIAL	Background In critically ill, mechanically ventilated patients, daily interruption of sedation has been shown to reduce the time on ventilation and the length of stay in the intensive care unit (ICU). Data on whether a plan of no sedation, as compared with a plan of light sedation, has an effect on mortality are lacking. Methods In a multicenter, randomized, controlled trial, we assigned, in a 1:1 ratio, mechanically ventilated ICU patients to a plan of no sedation (nonsedation group) or to a plan of light sedation (i.e., to a level at which the patient was arousable, defined as a score of -2 to -3 on the Richmond Agitation and Sedation Scale [RASS], on which scores range from -5 [unresponsive] to +4 [combative]) (sedation group) with daily interruption. The primary outcome was mortality at 90 days. Secondary outcomes were the number of major thromboembolic events, the number of days free from coma or delirium, acute kidney injury according to severity, the number of ICU-free days, and the number of ventilator-free days. Between-group differences were calculated as the value in the nonsedation group minus the value in the sedation group. Results A total of 710 patients underwent randomization, and 700 were included in the modified intention-to-treat analysis. The characteristics of the patients at baseline were similar in the two trial groups, except for the score on the Acute Physiology and Chronic Health Evaluation (APACHE) II, which was 1 point higher in the nonsedation group than in the sedation group, indicating a greater chance of in-hospital death. The mean RASS score in the nonsedation group increased from -1.3 on day 1 to -0.8 on day 7 and, in the sedation group, from -2.3 on day 1 to -1.8 on day 7. Mortality at 90 days was 42.4% in the nonsedation group and 37.0% in the sedated group (difference, 5.4 percentage points; 95% confidence interval [CI], -2.2 to 12.2; P=0.65). The number of ICU-free days and of ventilator-free days did not differ significantly between the trial groups. The patients in the nonsedation group had a median of 27 days free from coma or delirium, and those in the sedation group had a median of 26 days free from coma or delirium. A major thromboembolic event occurred in 1 patient (0.3%) in the nonsedation group and in 10 patients (2.8%) in the sedation group (difference, -2.5 percentage points; 95% CI, -4.8 to -0.7 [unadjusted for multiple comparisons]). Conclusions Among mechanically ventilated ICU patients, mortality at 90 days did not differ significantly between those assigned to a plan of no sedation and those assigned to a plan of light sedation with daily interruption. (Funded by the Danish Medical Research Council and others; NONSEDA ClinicalTrials.gov number, NCT01967680.)	[Olsen, Hanne T.] Svendborg Hosp, Odense Univ Hosp, Dept Anesthesiol, Svendborg, Denmark; [Olsen, Hanne T.] Svendborg Hosp, Odense Univ Hosp, Dept Intens Care, Svendborg, Denmark; [Olsen, Hanne T.; Nedergaard, Helene K.; Strom, Thomas; Oxlund, Jakob; Toft, Palle] Univ Southern Denmark, Dept Clin Res, Odense, Denmark; [Korkmaz, Serkan; Lauridsen, Jorgen T.] Univ Southern Denmark, Dept Econ & Business, Odense, Denmark; [Strom, Thomas; Toft, Palle] Odense Univ Hosp, Dept Anesthesiol & Intens Care, DK-5000 Odense C, Denmark; [Nedergaard, Helene K.] Hosp Lillebaelt, Dept Anesthesiol & Intens Care, Kolding, Denmark; [Oxlund, Jakob] Esbjerg Cent Hosp, Dept Anesthesiol & Intens Care, Esbjerg, Denmark; [Wian, Karl-Andre] Vestfold Hosp, Dept Anesthesiol & Intens Care, Tonsberg, Norway; [Ytrebo, Lars M.; Kroken, Bjorn A.] Univ Hosp North Norway, Dept Anesthesiol & Intens Care, Tromso, Norway; [Chew, Michelle] Linkoping Univ Hosp, Dept Anesthesiol & Intens Care, Linkoping, Sweden	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; University of Southern Denmark; University of Southern Denmark; Odense University Hospital; UiT The Arctic University of Tromso; University Hospital of North Norway; Linkoping University	Toft, P (corresponding author), Odense Univ Hosp, Dept Anesthesiol & Intens Care, DK-5000 Odense C, Denmark.	palle.toft@rsyd.dk	Nedergaard, Helene Korvenius/AAZ-8655-2021	Nedergaard, Helene Korvenius/0000-0002-5988-4563; Strom, Thomas/0000-0002-1868-0978; Toft, Palle/0000-0002-3188-449X; Lauridsen, Jorgen T./0000-0001-9889-6236	Danish Medical Research Council; Danielsens Foundation; Scandinavian Society of Anesthesiology and Intensive Care Medicine	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danielsens Foundation; Scandinavian Society of Anesthesiology and Intensive Care Medicine	Supported by the Danish Medical Research Council, the Danielsens Foundation, and the Scandinavian Society of Anesthesiology and Intensive Care Medicine.	Afshari A, 2007, BMJ-BRIT MED J, V335, P1248, DOI 10.1136/bmj.39398.682500.25; [Anonymous], 2015, J HEPATOL, V62, pS674; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Chanques G, 2017, LANCET RESP MED, V5, P795, DOI 10.1016/S2213-2600(17)30304-1; Colantuoni E, 2016, LANCET RESP MED, V4, P534, DOI 10.1016/S2213-2600(16)30138-2; Devlin JW, 2018, CRIT CARE MED, V46, pE825, DOI 10.1097/CCM.0000000000003299; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Laerkner E, 2015, NURS CRIT CARE; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Petty TL, 1998, CHEST, V114, P360, DOI 10.1378/chest.114.2.360; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shehabi Y, 2019, NEW ENGL J MED, V380, P2506, DOI 10.1056/NEJMoa1904710; Strom T, 2011, CRIT CARE, V15, DOI 10.1186/cc10218; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Toft P, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-499	19	63	66	4	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 19	2020	382	12					1103	1111		10.1056/NEJMoa1906759	http://dx.doi.org/10.1056/NEJMoa1906759			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW7AJ	32068366	Green Published, Bronze			2023-01-03	WOS:000521333700010
J	Welsh, C; Celis-Morales, CA; Ho, F; Lyall, DM; Mackay, D; Ferguson, L; Sattar, N; Gray, SR; Gill, JMR; Pell, JP; Welsh, P				Welsh, Claire; Celis-Morales, Carlos A.; Ho, Frederick; Lyall, Donald M.; Mackay, Daniel; Ferguson, Lyn; Sattar, Naveed; Gray, Stuart R.; Gill, Jason M. R.; Pell, Jill P.; Welsh, Paul			Association of injury related hospital admissions with commuting by bicycle in the UK: prospective population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TIME PHYSICAL-ACTIVITY; AGED FINNISH MEN; CYCLE TRACKS; RISK; WALKING; DISEASE; SAFETY; HEALTH; RATES	OBJECTIVE To determine whether bicycle commuting is associated with risk of injury. DESIGN Prospective population based study. SETTING UK Biobank. PARTICIPANTS 230390 commuters (52.1% women; mean age 52.4 years) recruited from 22 sites across the UK compared by mode of transport used (walking, cycling, mixed mode versus non-active (car or public transport)) to commute to and from work on a typical day. MAIN OUTCOME MEASURE First incident admission to hospital for injury. RESULTS 5704 (2.5%) participants reported cycling as their main form of commuter transport. Median follow-up was 8.9 years (interquartile range 8,29.5 years), and overall 10241 (4.4%) participants experienced an injury. Injuries occurred in 397 (7.0%) of the commuters who cycled and 7698 (4.3%) of the commuters who used a non-active mode of transport. After adjustment for major confounding sociodemographic, health, and lifestyle factors, cycling to work was associated with a higher risk of injury compared with commuting by a non-active mode (hazard ratio 1.45, 95% confidence interval 1.30 to 1.61). Similar trends were observed for commuters who used mixed mode cycling. Walking to work was not associated with a higher risk of injury. Longer cycling distances during commuting were associated with a higher risk of injury, but commute distance was not associated with injury in non-active commuters. Cycle commuting was also associated with a higher number of injuries when the external cause was a transport related incident (incident rate ratio 3.42, 95% confidence interval 3.00 to 3.90). Commuters who cycled to work had a lower risk of cardiovascular disease, cancer, and death than those who did not. If the associations are causal, an estimated 1000 participants changing their mode of commuting to include cycling for 10 years would result in 26 additional admissions to hospital for a first injury (of which three would require a hospital stay of a week or longer), 15 fewer first cancer diagnoses, four fewer cardiovascular disease events, and three fewer deaths. CONCLUSION Compared with non-active commuting to work, commuting by cycling was associated with a higher risk of hospital admission for a first injury and higher risk of transport related incidents specifically. These risks should be viewed in context of the health benefits of active commuting and underscore the need for a safer infrastructure for cycling in the UK.	[Welsh, Claire; Celis-Morales, Carlos A.; Ho, Frederick; Ferguson, Lyn; Sattar, Naveed; Gray, Stuart R.; Gill, Jason M. R.; Welsh, Paul] Univ Glasgow, Inst Cardiovasc & Med Sci, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland; [Celis-Morales, Carlos A.] Univ Mayor, Ctr Exercise Physiol Res CIFE, Santiago, San Pio, Chile; [Celis-Morales, Carlos A.; Lyall, Donald M.; Pell, Jill P.] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland; [Mackay, Daniel] Univ Glasgow, Sch Med Dent & Nursing, Glasgow, Lanark, Scotland	University of Glasgow; Universidad Mayor; University of Glasgow; University of Glasgow	Welsh, P (corresponding author), Univ Glasgow, Inst Cardiovasc & Med Sci, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland.	paul.welsh@glasgow.ac.uk	Welsh, Paul/H-5249-2019; Ho, Frederick/AAS-2647-2021; Welsh, Claire E/AAB-3743-2019; Gray, Stuart/L-2489-2017	Welsh, Paul/0000-0002-7970-3643; Ho, Frederick/0000-0001-7190-9025; Welsh, Claire E/0000-0001-9477-0775; Lyall, Donald/0000-0003-3850-1487; Celis-Morales, Carlos/0000-0003-2612-3917; Sattar, Naveed/0000-0002-1604-2593; Ferguson, Lyn/0000-0002-6136-8349; Gill, Jason/0000-0003-3615-0986; Gray, Stuart/0000-0001-8969-9636; mackay, daniel/0000-0001-5381-7098	Chest, Heart, and Stroke Association Scotland [Res16/A165]	Chest, Heart, and Stroke Association Scotland	This study was supported by a grant from Chest, Heart, and Stroke Association Scotland (Res16/A165]) The research was designed, conducted, analysed, and interpreted by the authors entirely independently of the funding sources.	Aldred R, 2018, ACCIDENT ANAL PREV, V117, P75, DOI 10.1016/j.aap.2018.03.003; [Anonymous], 2017, BRIT SOC ATT SURV 20; [Anonymous], 2010, CYCL DES; [Anonymous], 2017, PHYS IN SED BEH REP; [Anonymous], 2012, WALK CYCL LOC MEAS P; Audrey S, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/1479-5868-11-37; Baker BS, 2019, ECANCERMEDICALSCIENC, V13, DOI 10.3332/ecancer.2019.991; Bassett DR, 2008, J PHYS ACT HEALTH, V5, P795, DOI 10.1123/jpah.5.6.795; Blond MB, 2019, BRIT J SPORT MED, V53, P1183, DOI 10.1136/bjsports-2018-100036; Celis-Morales CA, 2019, MED SCI SPORT EXER, V51, P472, DOI 10.1249/MSS.0000000000001795; Celis-Morales CA, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1063-1; Celis-Morales CA, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1456; Department for Transport, 2016, CYCL WALK INV STRAT; Ding D, 2016, LANCET, V388, P1311, DOI 10.1016/S0140-6736(16)30383-X; Fraser SDS, 2011, EUR J PUBLIC HEALTH, V21, P738, DOI 10.1093/eurpub/ckq145; Gill J, 2019, CONFIDENCE RIDE CONF; Golbuff L., 2011, CYCLING POLICY UK HI; Grundy C, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4469; Hilbe JM, 2014, MODELING COUNT DATA, P1, DOI 10.1017/CBO9781139236065; Hou L, 2004, AM J EPIDEMIOL, V160, P860, DOI 10.1093/aje/kwh301; Hu G, 2003, DIABETOLOGIA, V46, P322, DOI 10.1007/s00125-003-1031-x; Hu G, 2007, ATHEROSCLEROSIS, V194, P490, DOI 10.1016/j.atherosclerosis.2006.08.051; Hu G, 2007, EUR HEART J, V28, P492, DOI 10.1093/eurheartj/ehl475; Iwinska K, 2018, TRANSPORT RES A-POL, V113, P291, DOI 10.1016/j.tra.2018.04.014; Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9; Lusk AC, 2013, AM J PUBLIC HEALTH, V103, P1240, DOI 10.2105/AJPH.2012.301043; Lusk AC, 2011, INJURY PREV, V17, P131, DOI 10.1136/ip.2010.028696; Mindell JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050606; Morrison CN, 2019, ACCIDENT ANAL PREV, V123, P123, DOI 10.1016/j.aap.2018.11.017; Pucher J, 2008, TRANSPORT REV, V28, P495, DOI 10.1080/01441640701806612; Pucher J, 2010, AM J PUBLIC HEALTH, V100, P1986, DOI 10.2105/AJPH.2009.189324; Reynolds CCO, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-47; ROJASRUEDA D, 2011, BMJ-BRIT MED J, V343, DOI DOI 10.1136/BMJ.D4521; Teschke K, 2012, AM J PUBLIC HEALTH, V102, P2336, DOI 10.2105/AJPH.2012.300762; Thomas B, 2013, ACCIDENT ANAL PREV, V52, P219, DOI 10.1016/j.aap.2012.12.017; Woodcock J, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g425; World Health Organization, 2018, GLOB ACT PLAN PHYS A; Zangenehpour S, 2016, ACCIDENT ANAL PREV, V86, P161, DOI 10.1016/j.aap.2015.10.025	38	14	14	2	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 11	2020	368								m336	10.1136/bmj.m336	http://dx.doi.org/10.1136/bmj.m336			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KU9AR	32161038	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000520012800001
J	Purohit, M; Diwan, V; Parashar, V; Tamhankar, AJ; Lundborg, CS				Purohit, Manju; Diwan, Vishal; Parashar, Vivek; Tamhankar, Ashok J.; Lundborg, Cecilia Stalsby			Mass bathing events in River Kshipra, Central India- influence on the water quality and the antibiotic susceptibility pattern of commensal E.coli	PLOS ONE			English	Article							ESCHERICHIA-COLI	Background Antibiotic resistance is one of the major global health emergencies. One potential source of dissemination of resistant bacteria is mass gatherings, e.g. mass bathing events. We evaluated the physicochemical parameters of water quality and the antibiotic resistance pattern in commensal Escherichia coli from river-water and river-sediment in pre-, during- and postmass bathing events in river Kshipra, Central India. Method/Design Water and sediment samples were collected from three selected points during eight mass bathing events during 2014-2016. Water quality parameters (physical, chemical and microbiological) were analyzed using standard methods. In river water and sediment samples, antibiotic susceptibility patterns of isolated E. coli to 17 antibiotics were tested. Results pH, turbidity and dissolved oxygen were significantly lower and total dissolved solid, free carbon dioxide were higher during mass bathing, whilst TSS, BOD and COD were lowest in pre-bathing and highest in post-bathing period. E.coli with multi drug resistance (MDR) or extended spectrum beta-lactamase (ESBL) production were between 9-44% and 6-24%, respectively in river-water as well as river-sediment. Total coliform count/ml and E. coli count were higher during-and post-bathing in river water than in pre-bathing period. Thus, the percentage of resistance was significantly higher during and post-bathing period (p<. 05) than in pre-bathing. Colony forming unit (CFU)/ml in river-sediment was much higher than in river-water. Percentage of resistance was significantly higher in river-water (p<.05) than in river-sediment. Conclusions Antibiotic resistance in E.coli isolated from the Kshipra River showed significant variation during mass bathing events. Guidelines and regulatory standards are needed to control environmental dissemination of resistant bacteria.	[Purohit, Manju; Diwan, Vishal; Tamhankar, Ashok J.; Lundborg, Cecilia Stalsby] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; [Purohit, Manju] RD Gardi Med Coll, Dept Pathol, Ujjain, Madhya Pradesh, India; [Diwan, Vishal; Parashar, Vivek] ICMR Natl Inst Res Environm Hlth, Bhopal, Madhya Pradesh, India; [Diwan, Vishal] RD Gardi Med Coll, Dept Publ Hlth & Environm, Ujjain, Madhya Pradesh, India; [Tamhankar, Ashok J.] RD Gardi Med Coll, Indian Initiat Management Antibiot Resistance, Dept Environm Med, Ujjain, Madhya Pradesh, India	Karolinska Institutet; Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Environmental Health (NIREH)	Purohit, M (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.; Purohit, M (corresponding author), RD Gardi Med Coll, Dept Pathol, Ujjain, Madhya Pradesh, India.	manjuraj.purohit@ki.se		purohit, manju/0000-0001-5385-7305; Stalsby Lundborg, Cecilia/0000-0001-6525-1861	Swedish Research Council [521-2012-2889, 2017-01237]	Swedish Research Council(Swedish Research CouncilEuropean Commission)	The project was funded by Swedish Research Council (grant no 521-2012-2889) and 2017-01237. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahammad ZS, 2014, ENVIRON SCI TECHNOL, V48, P3014, DOI 10.1021/es405348h; Akiba M, 2016, ANTIMICROB AGENTS CH, V60, P2972, DOI 10.1128/AAC.01950-15; [Anonymous], 1998, INTEGRATED COASTEL A; [Anonymous], 1990, WORLD HLTH STAT, V43, P118; [Anonymous], 1993, J ANTIMICROB CHEMOTH, P31; [Anonymous], 2010, ORIGINS EVOLUTION AN, V74, P417; [Anonymous], 2014, PERF STAND ANT SUS S; Arora NK, 2013, J ENVIRON BIOL, V34, P799; Asma Akhter, 2013, AFRICAN J MICROBIOLO, V8, P619; Azam M, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00176; Bisht A., 2015, INT J INNOVATIVE RES, V1, P107; Cabral JPS, 2010, INT J ENV RES PUB HE, V7, P3657, DOI 10.3390/ijerph7103657; Chitanand MP, 2010, INDIAN J MICROBIOL, V50, P216, DOI 10.1007/s12088-010-0042-9; Clermont O, 2000, APPL ENVIRON MICROB, V66, P4555, DOI 10.1128/AEM.66.10.4555-4558.2000; Daphne L.H.X., 2011, J WATER SUSTAINABILI, V1, P313, DOI DOI 10.11912/JWS.1.3.313-322; Diwan V, 2018, INT J ENV RES PUBLIC, V15; Diwan V, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14060574; Gonzales L, 2013, J MED MICROBIOL, V62, P1697, DOI 10.1099/jmm.0.060798-0; Gowd SS, 2008, ENVIRON MONIT ASSESS, V136, P197, DOI 10.1007/s10661-007-9675-5; Janzon A., 2012, ANTIMICROBIAL RESIST, P483; Khanna D. R, 2012, ENV CONSER JR, V13, P165; Liu YY, 2016, LANCET INFECT DIS, V16, P161, DOI 10.1016/S1473-3099(15)00424-7; Lundborg CS, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2632-2; MATSON EA, 1978, J WATER POLLUT CON F, V50, P13; Poonia Shubra, 2014, Indian J Community Med, V39, P156, DOI 10.4103/0970-0218.137152; Purohit MR, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14040386; Shukla S, 2013, J RES ENG TECHNOLOGY, V4; Taylor NGH, 2011, TRENDS ECOL EVOL, V26, P278, DOI 10.1016/j.tree.2011.03.004; Tyagi Aditya, 2003, Indian J Environ Health, V45, P15; Zhang XX, 2009, APPL MICROBIOL BIOT, V82, P1169, DOI 10.1007/s00253-009-1886-y	30	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2020	15	3							e0229664	10.1371/journal.pone.0229664	http://dx.doi.org/10.1371/journal.pone.0229664			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8QU	32130236	Green Published, gold			2023-01-03	WOS:000535264000040
J	Fernandes, M; Mendes, R; Vieira, SM; Leite, F; Palos, C; Johnson, A; Finkelstein, S; Horng, S; Celi, LA				Fernandes, Marta; Mendes, Ruben; Vieira, Susana M.; Leite, Francisca; Palos, Carlos; Johnson, Alistair; Finkelstein, Stan; Horng, Steven; Celi, Leo Anthony			Predicting Intensive Care Unit admission among patients presenting to the emergency department using machine learning and natural language processing	PLOS ONE			English	Article							HOSPITAL ADMISSIONS; ELECTRONIC TRIAGE; AGREEMENT; MODEL; TOOL	The risk stratification of patients in the emergency department begins at triage. It is vital to stratify patients early based on their severity, since undertriage can lead to increased morbidity, mortality and costs. Our aim was to present a new approach to assist healthcare professionals at triage in the stratification of patients and in identifying those with higher risk of ICU admission. Adult patients assigned Manchester Triage System (MTS) or Emergency Severity Index (ESI) 1 to 3 from a Portuguese and a United States Emergency Departments were analyzed. Variables routinely collected at triage were used and natural language processing was applied to the patient chief complaint. Stratified random sampling was applied to split the data in train (70%) and test (30%) sets and 10-fold cross validation was performed for model training. Logistic regression, random forests, and a random undersampling boosting algorithm were used. We compared the performance obtained with the reference model-using only triage priorities-with the models using additional variables. For both hospitals, a logistic regression model achieved higher overall performance, yielding areas under the receiver operating characteristic and precision-recall curves of 0.91 (95% CI 0.90-0.92) and 0.30 (95% CI 0.27-0.33) for the United States hospital and of 0.85 (95% CI 0.83-0.86) and 0.06 (95% CI 0.05-0.07) for the Portuguese hospital. Heart rate, pulse oximetry, respiratory rate and systolic blood pressure were the most important predictors of ICU admission. Compared to the reference models, the models using clinical variables and the chief complaint presented higher recall for patients assigned MTS/ESI 3 and can identify patients assigned MTS/ESI 3 who are at risk for ICU admission.	[Fernandes, Marta; Mendes, Ruben; Vieira, Susana M.] Univ Lisbon, Inst Super Tecn, IDMEC, Lisbon, Portugal; [Leite, Francisca] Hosp Luz Learning Hlth, Lisbon, Portugal; [Palos, Carlos] Hosp Beatriz Angelo, Lisbon, Portugal; [Johnson, Alistair; Celi, Leo Anthony] MIT, Harvard MIT Hlth Sci & Technol, Lab Computat Physiol, MIT Crit Data, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Finkelstein, Stan] MIT, Inst Data Syst & Soc, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Horng, Steven] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Ctr Healthcare Delivery Sci, Div Clin Informat, Boston, MA 02215 USA; [Celi, Leo Anthony] Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA	Universidade de Lisboa; Instituto Superior Tecnico; Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Fernandes, M (corresponding author), Univ Lisbon, Inst Super Tecn, IDMEC, Lisbon, Portugal.	marta.fernandes@tecnico.ulisboa.pt	Fernandes, Marta/AAE-2849-2022; Vieira, Susana/H-5688-2019; Vieira, Susana/D-1072-2009	Fernandes, Marta/0000-0002-7203-2832; Vieira, Susana/0000-0001-7961-1004; Vieira, Susana/0000-0001-7961-1004	Portuguese Foundation for Science & Technology (FCT) through IDMEC, under LAETA [UIDB/50022/2020]; Programa Operacional Regional de Lisboa by FEDER [LISBOA-01-0145FEDER-031474]; FCT [PD/BD/114150/2016]	Portuguese Foundation for Science & Technology (FCT) through IDMEC, under LAETA; Programa Operacional Regional de Lisboa by FEDER; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	This work was supported by the Portuguese Foundation for Science & Technology (FCT) (URL 1), through IDMEC, under LAETA, project UIDB/50022/2020 and LISBOA-01-0145FEDER-031474 supported by Programa Operacional Regional de Lisboa by FEDER (URL 2) and FCT. The work of Marta Fernandes was supported by the PhD Scholarship PD/BD/114150/2016 from FCT. URL 1: https://www.fct.pt/URL 2: https://www.europarl.europa.eu/factsheets/pt/sheet/95/el-fondo-europeo-de-desarrollo-regionalfeder-The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Araz OM, 2019, INT J PROD ECON, V208, P199, DOI 10.1016/j.ijpe.2018.11.024; Azari A, 2015, IEEE INT C BIOINFORM, P807, DOI 10.1109/BIBM.2015.7359790; Azeez D, 2015, TECHNOL HEALTH CARE, V23, P419, DOI 10.3233/THC-150907; Azeez D, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-416; Aziz D, 2012, 2012 4TH INTERNATIONAL CONFERENCE ON INTELLIGENT AND ADVANCED SYSTEMS (ICIAS), VOLS 1-2, P170, DOI 10.1109/ICIAS.2012.6306181; Barfod C, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-28; Berchet C, 2015, EMERGENCY CARE SERVI; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Cameron A, 2015, EMERG MED J, V32, P174, DOI 10.1136/emermed-2013-203200; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Coslovsky M, 2015, INTENS CARE MED, V41, P1029, DOI 10.1007/s00134-015-3737-x; Cramer Jan Salomon, 2002, ORIGINS LOGISTIC REG, P4; Dong Sandy L, 2007, CJEM, V9, P260; Erraguntla M, 2019, HEALTH INFORM J, V25, P1170, DOI 10.1177/1460458217747112; Fernandes MPB, 2014, IEEE INT FUZZY SYST, P1837, DOI 10.1109/FUZZ-IEEE.2014.6891779; Graham B, 2018, IEEE ACCESS, V6, P10458, DOI 10.1109/ACCESS.2018.2808843; Hong WS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201016; Horng S, 2019, APPL CLIN INFORM, V10, P409, DOI 10.1055/s-0039-1691842; Horta AB, 2018, INT J MED INFORM, V113, P56, DOI 10.1016/j.ijmedinf.2018.02.014; Ju C, 2018, J APPL STAT, V45, P2800, DOI 10.1080/02664763.2018.1441383; Levin S, 2018, ANN EMERG MED, V71, P565, DOI 10.1016/j.annemergmed.2017.08.005; LUHN HP, 1957, IBM J RES DEV, V1, P309, DOI 10.1147/rd.14.0309; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Moore BJ., TRENDS EMERGENCY DEP; Parker CA, 2019, AM J EMERG MED, V37, P1498, DOI 10.1016/j.ajem.2018.10.060; Raita Y, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2351-7; Salgado Catia M, 2015, 2015 IEEE INT C FUZZ, P1; Salgado M, 2017, CLASE O PUEBLO?: UNA CRITICA CIENTIFICA DESDE EL MARXISMO, P1, DOI 10.26448/9789568416539.2; Seiffert C, 2010, IEEE T SYST MAN CY A, V40, P185, DOI 10.1109/TSMCA.2009.2029559; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Sun Y, 2011, ACAD EMERG MED, V18, P844, DOI 10.1111/j.1553-2712.2011.01125.x; Teubner DJO, 2015, EMERG MED AUSTRALAS, V27, P300, DOI 10.1111/1742-6723.12425; Wang ST, 2013, J MED SYST, V37, DOI 10.1007/s10916-013-9968-x; Xiao YW, 2018, COMPUT METH PROG BIO, V153, P1, DOI 10.1016/j.cmpb.2017.09.005; Zlotnik A, 2016, CIN-COMPUT INFORM NU, V34, P224, DOI 10.1097/CIN.0000000000000230; Zmiri D, 2012, J EVAL CLIN PRACT, V18, P378, DOI 10.1111/j.1365-2753.2010.01592.x	37	16	16	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2020	15	3							e0229331	10.1371/journal.pone.0229331	http://dx.doi.org/10.1371/journal.pone.0229331			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8MS	32126097	Green Published, Green Submitted, gold			2023-01-03	WOS:000535253100021
J	Hernandez, V; Suzuki, T; Venture, G				Hernandez, Vincent; Suzuki, Tomoya; Venture, Gentiane			Convolutional and recurrent neural network for human activity recognition: Application on American sign language	PLOS ONE			English	Article							MOTION	Human activity recognition is an important and difficult topic to study because of the important variability between tasks repeated several times by a subject and between subjects. This work is motivated by providing time-series signal classification and a robust validation and test approaches. This study proposes to classify 60 signs from the American Sign Language based on data provided by the LeapMotion sensor by using different conventional machine learning and deep learning models including a model called DeepConvLSTM that integrates convolutional and recurrent layers with Long-Short Term Memory cells. A kinematic model of the right and left forearm/hand/fingers/thumb is proposed as well as the use of a simple data augmentation technique to improve the generalization of neural networks. DeepConvLSTM and convolutional neural network demonstrated the highest accuracy compared to other models with 91.1 (3.8) and 89.3 (4.0) % respectively compared to the recurrent neural network or multi-layer perceptron. Integrating convolutional layers in a deep learning model seems to be an appropriate solution for sign language recognition with depth sensors data.	[Hernandez, Vincent; Suzuki, Tomoya; Venture, Gentiane] Univ Agr & Technol Tokyo, GVLAB, Tokyo, Japan		Hernandez, V (corresponding author), Univ Agr & Technol Tokyo, GVLAB, Tokyo, Japan.	vincent.hernandez1985@gmail.com	Venture, Gentiane/E-7060-2013	Venture, Gentiane/0000-0001-7767-4765	Institute of Global Innovation Research, Tokyo University of Agriculture and Technology	Institute of Global Innovation Research, Tokyo University of Agriculture and Technology	This study was funded by the Institute of Global Innovation Research, Tokyo University of Agriculture and Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abadi M., 2016, TENSORFLOW LARGE SCA; ALTMAN NS, 1992, AM STAT, V46, P175, DOI 10.2307/2685209; [Anonymous], 2008, 2008 IEEE Hot Chips 20 Symposium (HCS), DOI 10.1109/HOTCHIPS.2008.7476516; Carpinella I, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-19; Chuan CH, 2014, 2014 13TH INTERNATIONAL CONFERENCE ON MACHINE LEARNING AND APPLICATIONS (ICMLA), P541, DOI 10.1109/ICMLA.2014.110; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; Dong C, 2015, AM SIGN LANGUAGE ALP, P44; Fok KY, 2015, 2015 INTERNATIONAL CONFERENCE ON CYBER-ENABLED DISTRIBUTED COMPUTING AND KNOWLEDGE DISCOVERY, P411, DOI 10.1109/CyberC.2015.81; Gers FA, 2000, NEURAL COMPUT, V12, P2451, DOI 10.1162/089976600300015015; Hochreiter S, 1997, NEURAL COMPUT, V9, P1735, DOI [10.1162/neco.1997.9.1.1, 10.1007/978-3-642-24797-2]; Kingma D.P., 2014, P 2 INT C LEARN REPR; Koller O, 2016, DEEP SIGN HYBRID CNN; Kumar P, 2017, PATTERN RECOGN LETT, V86, P1, DOI 10.1016/j.patrec.2016.12.004; Lee R.R. H., 2009, PROC 26 ANN INT C MA, P609, DOI 10.1145/1553374.1553453; Lipton Z.C., 2015, COMPUT SCI, DOI DOI 10.1093/eurheartj/ehw128; Marin G, 2014, IEEE IMAGE PROC, P1565, DOI 10.1109/ICIP.2014.7025313; Naidu C, 2016, INT J SCI RES RAIPUR, P2319; Ordonez FJ, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16010115; Ravi S, 2019, J COMPUT LANG, V52, P88, DOI 10.1016/j.cola.2019.04.002; Redmon J., 2015, IEEE C COMP VIS PATT, DOI 10.1109/CVPR.2016.91; Sainath TN, 2015, INT CONF ACOUST SPEE, P4580, DOI 10.1109/ICASSP.2015.7178838; Sarawate N, 2015, TURKISH J ELECT ENG, V23, P2017; Savur C, 2016, IEEE SYS MAN CYBERN, P2872, DOI 10.1109/SMC.2016.7844675; Shin H, 2019, ICIGP 2019: PROCEEDINGS OF THE 2ND INTERNATIONAL CONFERENCE ON IMAGE AND GRAPHICS PROCESSING / 2019 5TH INTERNATIONAL CONFERENCE ON VIRTUAL REALITY, P52, DOI 10.1145/3313950.3313967; Tin Kam Ho, 1995, Proceedings of the Third International Conference on Document Analysis and Recognition, P278, DOI 10.1109/ICDAR.1995.598994; Umet T. T., 2017, PROC 19 ACM INT C MU, P216; Weerasekera C, 2013, ROBUST ASL FINGERSPE, P1; Weichert F, 2013, SENSORS-BASEL, V13, P6380, DOI 10.3390/s130506380; Wu G, 2005, J BIOMECH, V38, P981, DOI 10.1016/j.jbiomech.2004.05.042; Yang S, 2017, CONTINUOUS CHINESE S, P7; Zafrulla Z., 2011, P 13 INT C MULT INT, P279, DOI DOI 10.1145/2070481.2070532; Zaremba W., 2014, ARXIV14092329; Zimmermann T, 2018, IMU TO SEGMENT ASSIG, V18	33	12	12	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2020	15	2							e0228869	10.1371/journal.pone.0228869	http://dx.doi.org/10.1371/journal.pone.0228869			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8AS	32074124	Green Published, gold			2023-01-03	WOS:000535220600028
J	Mambetsariev, I; Wang, YY; Chen, C; Nadaf, S; Pharaon, R; Fricke, J; Amanam, I; Amini, A; Bild, A; Chu, PG; Erhunmwunsee, L; Kim, J; Munu, J; Pillai, R; Raz, D; Sampath, S; Vora, L; Qiu, F; Smith, L; Batra, SK; Massarelli, E; Koczywas, M; Reckamp, K; Salgia, R				Mambetsariev, Ise; Wang, Yingyu; Chen, Chen; Nadaf, Sorena; Pharaon, Rebecca; Fricke, Jeremy; Amanam, Idoroenyi; Amini, Arya; Bild, Andrea; Chu, Peiguo; Erhunmwunsee, Loretta; Kim, Jae; Munu, Janet; Pillai, Raju; Raz, Dan; Sampath, Sagus; Vora, Lalit; Qiu, Fang; Smith, Lynette; Batra, Surinder K.; Massarelli, Erminia; Koczywas, Marianna; Reckamp, Karen; Salgia, Ravi			Precision medicine and actionable alterations in lung cancer: A single institution experience	PLOS ONE			English	Article							MOLECULAR TESTING GUIDELINE; OPEN-LABEL; TARGETED THERAPIES; COST-EFFECTIVENESS; CLINICAL ONCOLOGY; AMERICAN SOCIETY; POLICY STATEMENT; PHASE-III; RESISTANCE; ARID1A	Objectives Oncology has become more reliant on new testing methods and a greater use of electronic medical records, which provide a plethora of information available to physicians and researchers. However, to take advantage of vital clinical and research data for precision medicine, we must initially make an effort to create an infrastructure for the collection, storage, and utilization of this information with uniquely designed disease-specific registries that could support the collection of a large number of patients. Materials and methods In this study, we perform an in-depth analysis of a series of lung adenocarcinoma patients (n = 415) with genomic and clinical data in a recently created thoracic patient registry. Results Of the 415 patients with lung adenocarcinoma, 59% (n = 245) were female; the median age was 64 (range, 22-92) years with a median OS of 33.29 months (95% CI, 29.77-39.48). The most common actionable alterations were identified in EGFR (n = 177/415 [42.7%]), ALK (n = 28/377 [7.4%]), and BRAF V600E (n = 7/288 [2.4%]). There was also a discernible difference in survival for 222 patients, who had an actionable alteration, with a median OS of 39.8 months as compared to 193 wild-type patients with a median OS of 26.0 months (P< 0.001). We identified an unprecedented number of actionable alterations [53.5% (222/ 415)], including distinct individual alteration rates, as compared with 15.0% and 22.3% in TCGA and GENIE respectively. Conclusion The use of patient registries, focused genomic panels and the appropriate use of clinical guidelines in community and academic settings may influence cohort selection for clinical trials and improve survival outcomes.	[Mambetsariev, Ise; Pharaon, Rebecca; Fricke, Jeremy; Amanam, Idoroenyi; Bild, Andrea; Massarelli, Erminia; Koczywas, Marianna; Reckamp, Karen; Salgia, Ravi] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA; [Wang, Yingyu; Chen, Chen; Nadaf, Sorena; Munu, Janet] City Hope Natl Med Ctr, Ctr Informat, Duarte, CA USA; [Amini, Arya; Sampath, Sagus] City Hope Natl Med Ctr, Dept Radiat Oncol, Duarte, CA USA; [Chu, Peiguo; Pillai, Raju] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA USA; [Erhunmwunsee, Loretta; Kim, Jae; Raz, Dan] City Hope Natl Med Ctr, Dept Thorac Surg, Duarte, CA USA; [Vora, Lalit] City Hope Natl Med Ctr, Dept Diagnost Radiol, Duarte, CA USA; [Qiu, Fang; Smith, Lynette] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE USA; [Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA	City of Hope; City of Hope; City of Hope; City of Hope; City of Hope; City of Hope; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Salgia, R (corresponding author), City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA.	rsalgia@coh.org	Pillai, Raju/AAB-7230-2022	Pillai, Raju/0000-0001-8553-4252; Pharaon, Rebecca/0000-0003-0618-590X	National Cancer Institute of the National Institutes of Health [P30CA033572, R01CA218545, U54CA209978]; American Association for Cancer Research	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Association for Cancer Research	Research reported in this publication included work performed in the Core facilities, Biostatistics Core and Center for Informatics Core, supported by the National Cancer Institute of the National Institutes of Health under award number P30CA033572. Pilot Projects and Early Phase Clinical Research Support reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers R01CA218545 and U54CA209978. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The American Association for Cancer Research provided its financial and material support in the development of the AACR Project GENIE registry. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal A, 2016, J THORAC ONCOL, V11, P1040, DOI 10.1016/j.jtho.2016.03.010; Agrawal N, 2012, CANCER DISCOV, V2, P899, DOI 10.1158/2159-8290.CD-12-0189; Aisner D, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.11510; Ali SM, 2016, ONCOLOGIST, V21, P762, DOI 10.1634/theoncologist.2015-0497; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Andrews Audrey, 2015, Am Health Drug Benefits, V8, P37; Aso T, 2015, ANTICANCER RES, V35, P6819; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Carey LA, 2016, NEW ENGL J MED, V375, P83, DOI 10.1056/NEJMe1603691; Chuang JC, 2017, J THORAC ONCOL, V12, P833, DOI 10.1016/j.jtho.2017.01.023; Cornen S, 2012, ONCOGENE, V31, P4255, DOI 10.1038/onc.2011.598; Coyne GO, 2017, CURR PROB CANCER, V41, P182, DOI 10.1016/j.currproblcancer.2017.02.001; Daniel DC, 2002, MICROSC RES TECHNIQ, V59, P68, DOI 10.1002/jemt.10178; Drilon A.R., 2016, J CLIN ONCOL S, V34, DOI DOI 10.1200/JC0.2016.34.15_SUPPL.108; Drilon A, 2016, LANCET ONCOL, V17, P1653, DOI 10.1016/S1470-2045(16)30562-9; Jardim DLF, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv253; Gallego CJ, 2015, J CLIN ONCOL, V33, P2084, DOI 10.1200/JCO.2014.59.3665; Gerber DE, 2015, CLIN PHARMACOL THER, V97, P447, DOI 10.1002/cpt.91; Gong Jun, 2018, Oncotarget, V9, P15792, DOI 10.18632/oncotarget.24353; Gutierrez ME, 2017, CLIN LUNG CANCER, V18, P651, DOI 10.1016/j.cllc.2017.04.004; Haslem DS, 2017, J ONCOL PRACT, V13, pE108, DOI 10.1200/JOP.2016.011486; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Herbst RS, 2015, CLIN CANCER RES, V21, P1514, DOI 10.1158/1078-0432.CCR-13-3473; Hida T, 2017, LANCET, V390, P29, DOI 10.1016/S0140-6736(17)30565-2; Huang HT, 2015, ONCOL REP, V33, P283, DOI 10.3892/or.2014.3584; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Itchins M, 2017, ASIA-PAC J CLIN ONCO, V13, P3, DOI 10.1111/ajco.12754; Janku F, 2012, CLIN CANCER RES, V18, P6356, DOI 10.1158/1078-0432.CCR-12-0178; Joyner MJ, 2016, JAMA-J AM MED ASSOC, V316, P1355, DOI 10.1001/jama.2016.11076; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kim H, 2018, EUR RADIOL, V28, P861, DOI 10.1007/s00330-017-5006-6; Kirkwood MK, 2017, J ONCOL PRACT, V13, pE353, DOI 10.1200/JOP.2016.020743; Kirkwood MK, 2016, J ONCOL PRACT, V12, P339, DOI 10.1200/JOP.2015.010462; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6; Li CG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028204; Li SYD, 2017, GENOME MED, V9, DOI [10.1186/S13073-017-0478-1, 10.1186/s13073-017-0478-1]; Li YH, 2015, MOL DIAGN THER, V19, P169, DOI 10.1007/s40291-015-0140-9; Lim C, 2015, ANN ONCOL, V26, P1415, DOI 10.1093/annonc/mdv208; Lindeman NI, 2013, ARCH PATHOL LAB MED, V137, P828, DOI [10.5858/arpa.2012-0720-OA, 10.1097/JTO.0b013e318290868f]; Lindeman NI, 2018, J MOL DIAGN, V20, P129, DOI 10.1016/j.jmoldx.2017.11.004; Marignani P, 2018, J THORAC ONCOL, V13, pS989, DOI 10.1016/j.jtho.2018.08.1872; Mason C, J CLIN PATHWAYS, V4, P49; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Natarajan TG, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-13; National Comprehensive Cancer Network, 2020, CLIN PRACT GUID ONC; Paik PK, 2015, CANCER DISCOV, V5, P842, DOI 10.1158/2159-8290.CD-14-1467; Planchard D, 2017, LANCET ONCOL, V18, P1307, DOI 10.1016/S1470-2045(17)30679-4; Prasad V, 2016, NATURE, V537, pS63, DOI 10.1038/537S63a; Presley CJ, 2018, JAMA-J AM MED ASSOC, V320, P469, DOI 10.1001/jama.2018.9824; Ramalingam SS, 2018, J CLIN ONCOL, V36, P841, DOI 10.1200/JCO.2017.74.7576; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Sabari JK, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0587-4; Schwaederle M, 2016, JAMA ONCOL, V2, P1452, DOI 10.1001/jamaoncol.2016.2129; Schwaederle M, 2015, J CLIN ONCOL, V33, P3817, DOI 10.1200/JCO.2015.61.5997; Seibel NL, 2017, CURR PROB CANCER, V41, P194, DOI 10.1016/j.currproblcancer.2017.01.002; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Shaw AT, 2017, LANCET ONCOL, V18, P1590, DOI 10.1016/S1470-2045(17)30680-0; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7; Soria JC, 2015, LANCET ONCOL, V16, P990, DOI 10.1016/S1470-2045(15)00121-7; Spicer J, 2015, ANN ONCOL         S1, V26, pi57, DOI [DOI 10.1093/ANNONC/MDV128.04, 10.1093/annonc/mdv128.04]; Streppel MM, 2014, ONCOGENE, V33, P347, DOI 10.1038/onc.2012.586; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P132, DOI 10.1038/nrclinonc.2015.19; Tannock IF, 2016, NEW ENGL J MED, V375, P1289, DOI 10.1056/NEJMsb1607705; Wang Z, 2018, J THORAC ONCOL, V13, pS704, DOI 10.1016/j.jtho.2018.08.1157; Watanabe R, 2014, CANCER RES, V74, P2465, DOI 10.1158/0008-5472.CAN-13-3608; Yoshimoto T, 2015, PATHOL INT, V65, P595, DOI 10.1111/pin.12350; Yuan Y, 2017, ONCOTARGET, V8, P26414, DOI 10.18632/oncotarget.14476; Zhao HY, 2015, J THORAC ONCOL, V10, P655, DOI 10.1097/JTO.0000000000000445; Zon RT, 2016, J ONCOL PRACT, V12, P261, DOI 10.1200/JOP.2015.009134; Zon RT, 2009, J CLIN ONCOL, V27, P986, DOI 10.1200/JCO.2008.16.3691	71	3	3	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2020	15	2							e0228188	10.1371/journal.pone.0228188	http://dx.doi.org/10.1371/journal.pone.0228188			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9KA	32045431	Green Published, gold			2023-01-03	WOS:000534633200007
J	Adepoju, P				Adepoju, Paul			African nations to criminalise falsified medicine trafficking	LANCET			English	Editorial Material														Adepoju, Paul/0000-0003-1323-3017					0	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 1	2020	395	10221					324	324						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KH7WI	32007154				2023-01-03	WOS:000510860200014
J	Heidkamp, RA; Wilson, E; Menon, P; Kuo, H; Walton, S; Gatica-Dominguez, G; da Silva, IC; Aung, T; Hajeebhoy, N; Piwoz, E				Heidkamp, Rebecca A.; Wilson, Emily; Menon, Purnima; Kuo, Helen; Walton, Shelley; Gatica-Dominguez, Giovanna; da Silva, Inacio Crochemore; Aung, Tricia; Hajeebhoy, Nemat; Piwoz, Ellen			How can we realise the full potential of health systems for nutrition?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							OUTCOMES		[Heidkamp, Rebecca A.; Wilson, Emily; Kuo, Helen; Walton, Shelley; Aung, Tricia] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; [Menon, Purnima] Int Food Policy Res Inst, Poverty Hlth & Nutr Div, Washington, DC 20036 USA; [Gatica-Dominguez, Giovanna; da Silva, Inacio Crochemore] Univ Fed Pelotas, Int Ctr Equ Hlth, Postgrad Program Epidemiol, Pelotas, RS, Brazil; [Hajeebhoy, Nemat; Piwoz, Ellen] Bill & Melinda Gates Fdn, Nutr Div, Global Dev Program, Seattle, WA USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; CGIAR; International Food Policy Research Institute (IFPRI); Universidade Federal de Pelotas; Bill & Melinda Gates Foundation	Heidkamp, RA (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	rheidka1@jhu.edu	Silva, Inacio C M/L-9896-2017	Silva, Inacio C M/0000-0001-5390-8360; Walton, Shelley/0000-0003-3635-4567; Aung, Tricia/0000-0002-0567-0519				[Anonymous], 2013, FOLL UP POL DECL HIG; Bhutta ZA, 2013, LANCET, V382, P452, DOI 10.1016/S0140-6736(13)60996-4; Black RE, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010101; Boerma T, 2018, LANCET, V392, P1341, DOI 10.1016/S0140-6736(18)31928-7; Fanzo J, 2018, 2018 GLOBAL NUTR REP; G20 Research Group, 2019, OK DECL G20 HLTH MIN; Gillespie S, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001290; Gillespie S, 2018, FOOD NUTR BULL, V39, P335, DOI 10.1177/0379572118788155; Gillespie S, 2013, LANCET, V382, P552, DOI 10.1016/S0140-6736(13)60842-9; Hogan DR, 2018, LANCET GLOB HEALTH, V6, pE152, DOI 10.1016/S2214-109X(17)30472-2; Hunger AA, 2016, TERRE HOMMES MAKING; Kohli N, 2017, GLOB FOOD SECUR-AGR, V12, P38, DOI 10.1016/j.gfs.2017.01.007; Organization WH, 2018, GLOB NUTR POL REV 20; Perez-Escamilla R, 2016, MATERN CHILD NUTR, V12, P402, DOI 10.1111/mcn.12294; Unicef, 2018, COV CROSSR NEW DIR V; Unicef World Health Organization, 2018, CAPTURE THE MOMENT E; WHO, 2017, GLOB NUTR MON FRAM O; Wirth JP, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030190	18	15	15	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	2020	368								l6911	10.1136/bmj.l6911	http://dx.doi.org/10.1136/bmj.l6911			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH1EI	31983682	Green Published, hybrid			2023-01-03	WOS:000510389300001
J	Mezes, M; Havu, R; Tolmacheva, A; Lioumis, P; Makela, JP; Shulga, A				Mezes, Magdolna; Havu, Roope; Tolmacheva, Aleksandra; Lioumis, Pantelis; Makela, Jyrki P.; Shulga, Anastasia			The impact of TMS and PNS frequencies on MEP potentiation in PAS with high-frequency peripheral component	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; PAIRED ASSOCIATIVE STIMULATION; LONG-TERM-POTENTIATION; LTP-LIKE PLASTICITY; SPINAL-CORD-INJURY; HIPPOCAMPAL-NEURONS; NEUROTROPHIC FACTOR; BRAIN; INDUCTION; RECEPTORS	Paired associative stimulation (PAS) combines transcranial magnetic stimulation (TMS) and peripheral nerve stimulation (PNS) to induce plastic changes in the corticospinal tract. PAS employing single 0.2-Hz TMS pulses synchronized with the first pulse of 50-100 Hz PNS trains potentiates motor-evoked potentials (MEPs) in a stable manner in healthy participants and enhances voluntary motor output in spinal cord injury (SCI) patients. We further investigated the impact of settings of this PAS variant on MEP potentiation in healthy subjects. In experiment 1, we compared 0.2-Hz vs 0.4-Hz PAS. In experiment 2, PNS frequencies of 100 Hz, 200 Hz, and 400 Hz were compared. In experiment 3, we added a second TMS pulse. When compared with 0.4-Hz PAS, 0.2-Hz PAS was significantly more effective after 30 minutes (p = 0.05) and 60 minutes (p = 0.014). MEP potentiation by PAS with 100-Hz and 200-Hz PNS did not differ. PAS with 400-Hz PNS was less effective than 100-Hz (p = 0.023) and 200-Hz (p = 0.013) PNS. Adding an extra TMS pulse rendered PAS strongly inhibitory. These negative findings demonstrate that the 0.2-Hz PAS with 100-Hz PNS previously used in clinical studies is optimal and the modifications employed here do not enhance its efficacy.	[Mezes, Magdolna] Paracelsus Med Univ, Christian Doppler Med Ctr, Dept Neurol, Salzburg, Austria; [Mezes, Magdolna] Ctr Cognit Neurosci, Salzburg, Austria; [Havu, Roope; Tolmacheva, Aleksandra; Lioumis, Pantelis; Makela, Jyrki P.; Shulga, Anastasia] Univ Helsinki, HUS Med Imaging Ctr, BioMag Lab, Helsinki, Finland; [Havu, Roope; Tolmacheva, Aleksandra; Lioumis, Pantelis; Makela, Jyrki P.; Shulga, Anastasia] Helsinki Univ Hosp, Helsinki, Finland; [Lioumis, Pantelis] Aalto Univ, Sch Sci, Dept Neurosci & Biomed Engn, Helsinki, Finland; [Shulga, Anastasia] Univ Helsinki, Clin Neurosci Neurol, Helsinki, Finland	Paracelsus Private Medical University; Hyvinkaan Sairaala; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Aalto University; University of Helsinki	Shulga, A (corresponding author), Univ Helsinki, HUS Med Imaging Ctr, BioMag Lab, Helsinki, Finland.; Shulga, A (corresponding author), Helsinki Univ Hosp, Helsinki, Finland.; Shulga, A (corresponding author), Univ Helsinki, Clin Neurosci Neurol, Helsinki, Finland.	anastasia.shulga@helsinki.fi		Shulga, Anastasia/0000-0003-0262-3570; Makela, Jyrki/0000-0003-1252-4728	Academy of Finland [307951, 324160]; Christian Doppler Medical Centre Department of Neurology, Salzburg, Austria	Academy of Finland(Academy of Finland); Christian Doppler Medical Centre Department of Neurology, Salzburg, Austria	This work was funded by Academy of Finland (AS, grant numbers 307951 and 324160, www.aka.fi) and Christian Doppler Medical Centre Department of Neurology, Salzburg, Austria (MM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alder G, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00895; Balkowiec A, 2000, J NEUROSCI, V20, P7417, DOI 10.1523/jneurosci.20-19-07417.2000; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Borland MS, 2018, NEUROSCIENCE, V369, P76, DOI 10.1016/j.neuroscience.2017.11.004; Bunday KL, 2012, CURR BIOL, V22, P2355, DOI 10.1016/j.cub.2012.10.046; Carson RG, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00823; Christiansen L, 2018, NEUROTHERAPEUTICS, V15, P618, DOI 10.1007/s13311-018-0639-y; Cortes M, 2011, CLIN NEUROPHYSIOL, V122, P2254, DOI 10.1016/j.clinph.2011.02.038; Forster MT, 2011, NEUROSURGERY, V68, P1317, DOI 10.1227/NEU.0b013e31820b528c; GAJRAJ NM, 1994, ANESTH ANALG, V78, P574; Gartner AG, 2002, P NATL ACAD SCI USA, V99, P6386, DOI 10.1073/pnas.092129699; Hebb D.O., 1949, ORG BEHAV; Krieg SM, 2012, J NEUROSURG, V116, P994, DOI 10.3171/2011.12.JNS111524; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Leukel C, 2012, EUR J NEUROSCI, V35, P1622, DOI 10.1111/j.1460-9568.2012.08067.x; Lever IJ, 2001, J NEUROSCI, V21, P4469, DOI 10.1523/JNEUROSCI.21-12-04469.2001; McDonnell MN, 2007, EXP BRAIN RES, V180, P181, DOI 10.1007/s00221-006-0849-0; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; Muller-Dahlhaus F, 2015, NEUROSCIENTIST, V21, P185, DOI 10.1177/1073858414526645; Nicoll RA, 2017, NEURON, V93, P281, DOI 10.1016/j.neuron.2016.12.015; Picht T, 2011, NEUROSURGERY, V69, P581, DOI 10.1227/NEU.0b013e3182181b89; Quartarone A, 2014, ARCH ITAL BIOL, V152, P239, DOI 10.12871/00039829201444; RISON RA, 1995, NEUROSCI BIOBEHAV R, V19, P533, DOI 10.1016/0149-7634(95)00017-8; Rodionov A, 2019, SPINAL CORD SER CASE, V5; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; ROTHWELL JC, 1991, EXP PHYSIOL, V76, P159, DOI 10.1113/expphysiol.1991.sp003485; Shulga Anastasia, 2016, Spinal Cord Ser Cases, V2, P16016, DOI 10.1038/scsandc.2016.16; Shulga A, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00470; Shulga A, 2015, J NEUROSCI METH, V242, P112, DOI 10.1016/j.jneumeth.2015.01.012; Sjostrom PJ, 2001, NEURON, V32, P1149, DOI 10.1016/s0896-6273(01)00542-6; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; Stinear JW, 2005, J PHYSIOL-LONDON, V567, P701, DOI 10.1113/jphysiol.2005.090654; Suppa A, 2017, CLIN NEUROPHYSIOL, V128, P2140, DOI 10.1016/j.clinph.2017.08.003; Taylor JL, 2009, J NEUROSCI, V29, P11708, DOI 10.1523/JNEUROSCI.2217-09.2009; Tolmacheva A, 2019, CLIN NEUROPHYS PRACT, V4, P178, DOI 10.1016/j.cnp.2019.07.002; Tolmacheva A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40474-0; Tolmacheva A, 2017, J NEUROTRAUM, V34, P2668, DOI 10.1089/neu.2017.4996; Uy J, 2003, NEUROLOGY, V61, P982, DOI 10.1212/01.WNL.0000078809.33581.1F; Vitikainen AM, 2013, ACTA NEUROCHIR, V155, P507, DOI 10.1007/s00701-012-1609-5; Wolters A, 2003, J NEUROPHYSIOL, V89, P2339, DOI 10.1152/jn.00900.2002	42	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2020	15	5							e0233999	10.1371/journal.pone.0233999	http://dx.doi.org/10.1371/journal.pone.0233999			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1WS	32470028	Green Published, gold			2023-01-03	WOS:000537552800219
J	Hargreaves, SM; Araujo, WMC; Nakano, EY; Zandonadi, RP				Hargreaves, Shila Minari; Coelho Araujo, Wilma Maria; Nakano, Eduardo Yoshio; Zandonadi, Renata Puppin			Brazilian vegetarians diet quality markers and comparison with the general population: A nationwide cross-sectional study	PLOS ONE			English	Article							MEAT-EATERS; EPIC-OXFORD; HEALTH; CONSUMPTION; NUTRITION; NUTRIENT; VEGAN; FOOD	Background Vegetarianism is an increasingly common practice worldwide. Despite good evidence from other countries regarding vegetarians' diet quality, data from the Brazilian population is still scarce. Objective To characterize the vegetarian Brazilian population and evaluate their diet quality compared to the general Brazilian population. Methods We performed a nationwide cross-sectional study using an online self-administered questionnaire, previously validated for the Brazilian population, to evaluate diet quality markers of vegetarians. The invitation to participate in the survey was spread nationwide, aimed at vegetarian communities. Individuals who considered themselves vegetarians and were at least 18 years old were eligible to participate. The results on regular intake and intake adequacy were compared among vegetarians and between genders using the Pearson's chi-square test. The body mass index (BMI) were analyzed by the Analysis of Variance (ANOVA) followed by Tukey post-hoc test. The Kolmogorov-Smirnov test verified normality. All analyses considered bilateral hypotheses and a significance level of 5% (p < 0.05). Results Brazilian vegetarians presented better diet quality markers, such as higher regular weekly intake and adequate daily intake of fruits and vegetables, and lower regular intake of soft drinks when compared to the general Brazilian population. Vegetarians also presented a proportionally higher consumption of natural foods and lower consumption of processed foods. Among vegetarians, a higher proportion of vegans showed positive results regarding diet markers analysis, when compared to vegetarians, pesco-vegetarians, and semi-vegetarians. Conclusions Vegetarians showed better results of diet adequacy when compared to the general population in Brazil, and vegans fared better when compared with other vegetarians. Despite the good results found, a large proportion of the participants still did not achieve the fruits and vegetables daily intake, according to the World Health Organization recommendations.	[Hargreaves, Shila Minari; Coelho Araujo, Wilma Maria; Zandonadi, Renata Puppin] Univ Brasilia UnB, Fac Hlth Sci, Dept Nutr, Brasilia, DF, Brazil; [Nakano, Eduardo Yoshio] Univ Brasilia, Dept Stat, Brasilia, DF, Brazil	Universidade de Brasilia; Universidade de Brasilia	Hargreaves, SM (corresponding author), Univ Brasilia UnB, Fac Hlth Sci, Dept Nutr, Brasilia, DF, Brazil.	shilaminari@gmail.com	Zandonadi, Renata Puppin/O-7908-2017; Nakano, Eduardo Y/G-1660-2011	Zandonadi, Renata Puppin/0000-0003-0370-3089; Nakano, Eduardo Y/0000-0002-9071-8512	Universidade de Brasilia DPI/DPG [02/2020]	Universidade de Brasilia DPI/DPG	This study was supported by Universidade de Brasi ' lia DPI/DPG grant number Edital 02/2020. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkerwi A, 2014, NUTRITION, V30, P613, DOI 10.1016/j.nut.2013.10.001; [Anonymous], PESQ NAC AM DOM CONT; [Anonymous], WHO MEAN BOD MASS IN; Arvaniti F, 2008, CRIT REV FOOD SCI, V48, P317, DOI 10.1080/10408390701326268; Bedford JL, 2005, INT J BEHAV NUTR PHY, V2, P1; Beezhold B, 2015, NUTR NEUROSCI, V18, P289, DOI 10.1179/1476830514Y.0000000164; Beezhold BL, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-26; Brasil Ministerio da Saude, 2014, GUIA ALIMENTAR POPUL; Clarys P, 2014, NUTRIENTS, V6, P1318, DOI 10.3390/nu6031318; Coqueiro R da S, 2009, MEDIDAS AUTOREFERIDA, V11, P113, DOI [10.5007/1980-0037.2009v11n1p112, DOI 10.5007/1980-0037.2009V11N1P112]; Coulston AM, 2001, AM J CLIN NUTR, V74, P417; Craig WJ, 2009, J AM DIET ASSOC, V109, P1266, DOI 10.1016/j.jada.2009.05.027; Craig WJ, 2010, NUTR CLIN PRACT, V25, P613, DOI 10.1177/0884533610385707; Crozier SR, 2010, EUR J CLIN NUTR, V64, P99, DOI 10.1038/ejcn.2009.114; Davey GK, 2003, PUBLIC HEALTH NUTR, V6, P259, DOI 10.1079/PHN2002430; Davidson DJ, 1996, ENVIRON BEHAV, V28, P302, DOI 10.1177/0013916596283003; Davis C, 2015, NUTRIENTS, V7, P9139, DOI 10.3390/nu7115459; De Souza E.C.G., 2017, ALIMENTACAO VEGETARI, V1st ed.; Dinu M, 2017, CRIT REV FOOD SCI, V57, P3640, DOI 10.1080/10408398.2016.1138447; Dyett PA, 2013, APPETITE, V67, P119, DOI 10.1016/j.appet.2013.03.015; Evans JR, 2005, INTERNET RES, V15, P195, DOI 10.1108/10662240510590360; Fraser GE, 2009, AM J CLIN NUTR, V89, pS1607, DOI 10.3945/ajcn.2009.26736K; Gomes AA, 2015, CADERNOS SAUDE COLET, V23, P368, DOI [10.1590/1414-462X201500040055, DOI 10.1590/1414-462X201500040055]; Gossard M.H., 2003, HUM ECOL REV, V10, P1, DOI DOI 10.2307/24707082; Group TVR, 2016, MAN AD US VEG VEG MA; Hair J.F., 2009, AN LISE MULTIVARIADA; Holanda L. B., 2006, REV PAUL PEDIATR, V24, P62; Huang T, 2012, ANN NUTR METAB, V60, P233, DOI 10.1159/000337301; Instituto Brasileiro de Geografia e Estatistica, 2018, PNAD CONT TIC 2017 I; Kahleova H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030615; Kahleova H, 2015, J AM COLL NUTR, V34, P448, DOI 10.1080/07315724.2014.976890; Kant AK, 2004, DIETARY PATTERNS HLT, DOI [10.1016/j.jada.2004.01.010, DOI 10.1016/J.JADA.2004.01.010]; Kim MS, 2013, ENV MICROBIOL REP, V5, P765, DOI 10.1111/1758-2229.12079; Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145; Lea E, 2001, APPETITE, V36, P127, DOI 10.1006/appe.2000.0386; Lea EJ, 2006, EUR J CLIN NUTR, V60, P828, DOI 10.1038/sj.ejcn.1602387; Leitzmann C, 2014, AM J CLIN NUTR, V100, p496S, DOI 10.3945/ajcn.113.071365; Lyon MR, 2012, CURR OBES REP, V1, P59, DOI 10.1007/s13679-012-0016-9; Marsh K, 2012, AM J LIFESTYLE MED, V6, P250, DOI 10.1177/1559827611425762; McEvoy CT, 2015, WORLD REV NUTR DIET, V113, P134, DOI 10.1159/000367873; McEvoy CT, 2012, PUBLIC HEALTH NUTR, V15, P2287, DOI 10.1017/S1368980012000936; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Melina V, 2016, J ACAD NUTR DIET, V116, P1970, DOI 10.1016/j.jand.2016.09.025; Ministerio da Saude, 2018, VIGITEL BRASIL 2017; Ministerio da Saude, 2016, VIG BRAS 2016 HAB BR; Ministerio da Saude, 2019, VIG BRAS 2018 VIG FA, DOI [10.3390/nu11030615, DOI 10.3390/NU11030615]; Miranda D., 2013, DEMETRA ALIMENTACAO, V8, P163, DOI [10.12957/demetra.2013.4773, DOI 10.12957/DEMETRA.2013.4773]; Monteiro CA, 2005, REV SAUDE PUBL, V39, P47, DOI 10.1590/S0034-89102005000100007; Monteiro CA, 2008, REV SAUDE PUBL, V42, P582, DOI 10.1590/S0034-89102008000400002; ORLICH MJ, 2014, AM J CLIN NUTR, V100, P2, DOI DOI 10.3945/AJCN.113.071233.AM; Papier K, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040824; Parker HW, 2019, NUTR REV, V77, P144, DOI 10.1093/nutrit/nuy067; Patterson RE, 1989, J AM DIET ASSOC, V94, P57; Pratesi CB, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091167; RIOSCOVIAN D, 2016, FRONT MICROBIOL, V7, DOI DOI 10.3389/FMICB.2016.00001; Rizzo NS, 2013, J ACAD NUTR DIET, V113, P1610, DOI 10.1016/j.jand.2013.06.349; Rosenfeld DL, 2017, APPETITE, V116, P456, DOI 10.1016/j.appet.2017.05.039; Ruby MB, 2012, APPETITE, V58, P141, DOI 10.1016/j.appet.2011.09.019; Slywitch E., GUIA ALIMENTAR DIETA; Souza Amanda de Moura, 2011, Rev Bras Epidemiol, V14 Suppl 1, P44, DOI 10.1590/S1415-790X2011000500005; Spencer EA, 2003, INT J OBESITY, V27, P728, DOI 10.1038/sj.ijo.0802300; Teixeira Rita de Cássia Moreira de Almeida, 2006, Rev. bras. epidemiol., V9, P131, DOI 10.1590/S1415-790X2006000100016; Tharrey M, 2018, INT J EPIDEMIOL, V47, P1603, DOI 10.1093/ije/dyy030; Vartanian LR, 2007, AM J PUBLIC HEALTH, V97, P667, DOI 10.2105/AJPH.2005.083782; Wang FL, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002408; Weder S, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040832; WHO, 2003, WHO TECHN REP SER, V797, P149; Widmer RJ, 2015, AM J MED, V128, P229, DOI 10.1016/j.amjmed.2014.10.014; Williams EP, 2015, CURR OBES REP, V4, P363, DOI 10.1007/s13679-015-0169-4; Zimmer J, 2012, EUR J CLIN NUTR, V66, P53, DOI 10.1038/ejcn.2011.141	70	12	12	4	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2020	15	5							e0232954	10.1371/journal.pone.0232954	http://dx.doi.org/10.1371/journal.pone.0232954			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU0SY	32396556	Green Published, gold			2023-01-03	WOS:000537475000028
J	Bornstein, SS; Cooney, TG				Bornstein, Sue S.; Cooney, Thomas G.			Stemming the Escalating Costs of Prescription Drugs RESPONSE	ANNALS OF INTERNAL MEDICINE			English	Letter									[Bornstein, Sue S.] Texas Med Home Initiat, Dallas, TX 75205 USA; [Cooney, Thomas G.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Oregon Health & Science University	Bornstein, SS (corresponding author), Texas Med Home Initiat, Dallas, TX 75205 USA.							Bell D, 2018, IMPACT POTENTIAL CHA; CMS Office of the Actuary, 2018, PROP SAF HARB REG; Daniel H, 2019, ANN INTERN MED, V171, P825, DOI 10.7326/M19-0013; Daniel H, 2016, ANN INTERN MED, V165, P50, DOI 10.7326/M15-2768; Fincher JW, 2019, LETT OFFICE INSPECTO	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 21	2020	172	8					574	575		10.7326/L20-0111	http://dx.doi.org/10.7326/L20-0111			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF9LH	32311710				2023-01-03	WOS:000527733800026
J	Park, HJ; Kim, JT; Chung, JE; Yang, JA; Bae, HJ; Sung, YW; Park, JE; Kim, SH; Cho, JY; Jung, KM; Bae, HK				Park, Hyo Jung; Kim, Jung Tae; Chung, Jee Eun; Yang, Jin A.; Bae, Hye Jung; Sung, Ye Won; Park, Ji Eun; Kim, Sun Hwa; Cho, Ji Yoon; Jung, Kyung Mi; Bae, Hee Kyung			Practice of parenteral nutrition in hospitalized adult patients in Korea: A retrospective multicenter cross-sectional study	PLOS ONE			English	Article							MALNUTRITION; STAY	There have been no studies on the characteristics of parenteral nutrition (PN) supply for adult inpatients in South Korea. The aim of this retrospective multicenter cross sectional study was to investigate the current practice and characteristics of PN support in hospitalized adult patients in South Korea for the first time. This study was conducted retrospectively for the adult patients who were hospitalized and received PN in nine hospitals on August 1st, 2017 to October 30th, 2017. We evaluated the type of PN formulation, PN administration period, administration route, calories supplied, amount of protein supplied, and laboratory results. Among the 11,580 inpatient admissions on that day, 1,439 patients received PN (12.4%). The majority of enrolled patients (96.5%) used the commercial PN, of which 86.2% were multi-chamber. 71.2% of them received PN peripherally. The average in hospital PN duration was 17.8 +/- 52.6 days. Patients received only 65.4 +/- 25.4% calories of their target calories. The in-hospital mortality of enrolled patients was 22%. In South Korea, commercial PN was usually administered to hospitalized adult patients and in-hospital mortality in adult patients using PN was higher in South Korea compared to other countries. This study provides the characteristics and the PN support status of hospitalized adult patients receiving PN in South Korea.	[Park, Hyo Jung] Samsung Med Ctr, Dept Pharmaceut Serv, Seoul, South Korea; [Kim, Jung Tae; Bae, Hee Kyung] Kyung Hee Univ Hosp Kangdong, Dept Pharm, Seoul, South Korea; [Chung, Jee Eun] Hanyang Univ, Coll Pharm, Ansan, Gyeonggi Do, South Korea; [Yang, Jin A.] Asan Med Ctr, Dept Pharm, Seoul, South Korea; [Bae, Hye Jung] Seoul Natl Univ Hosp, Dept Pharm, Seoul, South Korea; [Sung, Ye Won] Chungnam Natl Univ Hosp, Dept Pharm, Daejeon, South Korea; [Park, Ji Eun] Severance Hosp, Dept Pharm, Seoul, South Korea; [Kim, Sun Hwa] Chung Ang Univ Hosp, Dept Pharm, Seoul, South Korea; [Cho, Ji Yoon] Daegu Fatima Hosp, Dept Pharm, Daegu, South Korea; [Jung, Kyung Mi] Ulsan Univ Hosp, Dept Pharm, Ulsan, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Kyung Hee University; Hanyang University; University of Ulsan; Asan Medical Center; Seoul National University (SNU); Seoul National University Hospital; Chungnam National University; Chungnam National University Hospital; Yonsei University; Yonsei University Health System; Chung Ang University; Chung Ang University Hospital; Daegu Fatima Hospital; University of Ulsan; Ulsan University Hospital	Park, HJ (corresponding author), Samsung Med Ctr, Dept Pharmaceut Serv, Seoul, South Korea.	hyoj.park@samsung.com	Kim, Sun/GSN-4867-2022	Park, Hyo Jung/0000-0002-3875-0224; Kim, Jung Tae/0000-0003-0661-4735	Korean Society of Parenteral and Enteral Nutrition (KSPEN)	Korean Society of Parenteral and Enteral Nutrition (KSPEN)	Scientific grant support for this report is provided by Korean Society of Parenteral and Enteral Nutrition (KSPEN, www.kspen.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal E, 2013, CLIN NUTR, V32, P737, DOI 10.1016/j.clnu.2012.11.021; Arends J, 2017, CLIN NUTR, V36, P1187, DOI 10.1016/j.clnu.2017.06.017; Duncan A, 2012, AM J CLIN NUTR, V95, P64, DOI 10.3945/ajcn.111.023812; Dyson JK, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012663; Kang MC, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e10; Kim So Young, 2015, Asian Pac J Cancer Prev, V16, P1295; Lee JS, 2018, NUTR CLIN PRACT, V33, P633, DOI 10.1002/ncp.10093; Lim B, 2013, INTEGR MED RES, V2, P81, DOI 10.1016/j.imr.2013.06.004; Lim SL, 2012, CLIN NUTR, V31, P345, DOI 10.1016/j.clnu.2011.11.001; McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI [10.1177/0148607115621863, 10.1097/CCM.0000000000001525]; Mogensen KM, 2019, NUTR CLIN PRACT; Petroff Barbara, 2016, Am J Health Syst Pharm, V73, P922, DOI 10.2146/ajhp151013; Petroff Barbara J, 2014, Am J Health Syst Pharm, V71, P325, DOI 10.2146/sp140004; Plauth M, 2019, CLIN NUTR, V38, P485, DOI 10.1016/j.clnu.2018.12.022; Ponta ML, 2018, CLIN NUTR ESPEN, V25, P87, DOI 10.1016/j.clnesp.2018.01.072; Saleh WA, 2018, CLIN NUTR, V37, P1976, DOI 10.1016/j.clnu.2017.09.001; Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037; Tuuminen T, 2019, CLIN NUTR ESPEN, V33, P283, DOI 10.1016/j.clnesp.2019.06.011; Volkert D, 2019, CLIN NUTR, V38, P10, DOI 10.1016/j.clnu.2018.05.024; Weimann A, 2017, CLIN NUTR, V36, P623, DOI 10.1016/j.clnu.2017.02.013; Wie GA, 2010, NUTRITION, V26, P263, DOI 10.1016/j.nut.2009.04.013; Wischmeyer PE, 2013, JPEN-PARENTER ENTER, V37, P56, DOI 10.1177/0148607112444448	22	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2020	15	4							e0230922	10.1371/journal.pone.0230922	http://dx.doi.org/10.1371/journal.pone.0230922			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8IA	32236124	Green Published, gold			2023-01-03	WOS:000535938700041
J	Cruz, EB; Canhao, H; Fernandes, R; Caeiro, C; Branco, JC; Rodrigues, AM; Pimentel-Santos, F; Gomesl, LA; Paiva, S; Pinto, I; Moniz, R; Nunes, C				Cruz, Eduardo B.; Canhao, Helena; Fernandes, Rita; Caeiro, Carmen; Branco, Jaime C.; Rodrigues, Ana M.; Pimentel-Santos, Fernando; Gomesl, Luis A.; Paiva, Sofia; Pinto, Isabel; Moniz, Rubina; Nunes, Carla			Prognostic indicators for poor outcomes in low back pain patients consulted in primary care	PLOS ONE			English	Article							MORRIS DISABILITY QUESTIONNAIRE; GLOBAL BURDEN; UNITED-STATES; EPIDEMIOLOGY; ADAPTATION; VALIDATION; GUIDELINES; MANAGEMENT; CONSENSUS; ILLNESS	Background Non-specific low back pain (NSLBP) is the most prevalent musculoskeletal condition in western countries and is associated with persistent disability and high consumption of health care resources. NSLBP patients first seek primary health care services but the outcomes are often uncertain. This study aimed to examine the clinical course of the outcomes and to identify prognostic indicators for poor outcomes in NSLBP patients who consulted primary care. Methods A prospective cohort study of 115 patients seeking treatment for NSLBP in primary care was conducted. Participants were consecutively recruited by their General Practitioners (GPs) and then assessed at baseline and 2 and 6 months later. Baseline assessment included socio-demographic and clinical data, psychosocial factors, pain, disability, and health related quality of life (HRQoL). Pain, disability, HRQoL and global perception of change were also assessed at 2 and 6-months' follow-up. In addition, information regarding the GP' practice was collected. Poor outcomes were determined according to the cut-off point used to define a persistent disabling condition and the minimal important change established for disability, pain and for global perception of change. The relationship between variables on baseline and poor outcomes was modulated through binary logistic regression analysis. The significance of associations was evaluated at. 0.05 p-value with 95% confidence intervals (CI) and adjusted odds ratios (AOR). Results 110 (94.8%) and 104 (89.7%) participants completed the follow-up assessment at 2 and 6 months, respectively. The mean age (+/- SD) was 48.06 +/- 11.41, with 53.9%, (N = 62) reporting an acute presentation of NSLBP. Six months after GP consultation, 53.8% (N = 56) of the participants reported a persistent disabling condition. An "LBP episode of less than 12 weeks" [AOR: 0.26; 95% CI (0.10, 0.65); AOR: 0.34; 95% CI (0.14, 0.81); AOR: 0.21; 95% CI (0.09, 0.53)],"maladaptive psychosocial factors" [AOR: 2.06; 95% CI (1.40, 3.04); AOR: 1.82; 95% CI (1.27, 2.59); AOR: 1.72; 95% CI (1.20, 2.47)] were significantly associated with poor outcomes on disability, pain and global perception of change, respectively. Besides these factors, being employed reduces the chances of poor outcomes on disability [AOR 0.31; 95% CI (0.11, 0.92)]. Conclusions A large proportion of LBP patients seeking primary health care reported poor outcomes 6 months after GP consultation. Patients who report chronic LBP, maladaptive psychosocial factors and are unemployed have a significant increase in the risk of poor outcome. These findings suggest the need of implementing effective models of care able to provide early screening and appropriate treatment to those at greatest risk of a poor outcome.	[Cruz, Eduardo B.; Fernandes, Rita; Caeiro, Carmen; Gomesl, Luis A.; Paiva, Sofia] Setubal Polytech Inst, Physiotherapy Dept, Setubal, Portugal; [Cruz, Eduardo B.; Canhao, Helena; Fernandes, Rita; Rodrigues, Ana M.; Nunes, Carla] CHRC, Lisbon, Portugal; [Canhao, Helena; Branco, Jaime C.; Rodrigues, Ana M.; Pimentel-Santos, Fernando] NOVA Med Sch, CEDOC, EpiDoC Unit, Lisbon, Portugal; [Pinto, Isabel; Moniz, Rubina] Reg Hlth Adm Lisbon & Tagus Valley, ACES Arrabida, Lisbon, Portugal; [Pinto, Isabel; Moniz, Rubina] Reg Hlth Adm Lisbon & Tagus Valley, ACES Arrabida, Tagus Valley, Portugal; [Nunes, Carla] Natl Sch Publ Hlth, Res Ctr Publ Hlth, Lisbon, Portugal		Cruz, EB (corresponding author), Setubal Polytech Inst, Physiotherapy Dept, Setubal, Portugal.; Cruz, EB (corresponding author), CHRC, Lisbon, Portugal.	eduardo.cruz@ess.ips.pt	Cruz, Eduardo B/L-5577-2017; Rodrigues, Ana/GYQ-6273-2022; Cruz, Eduardo/AAA-3907-2019; Canhao, Helena/C-9611-2018	Cruz, Eduardo B/0000-0003-1812-1815; Cruz, Eduardo/0000-0003-1812-1815; Gomes, Luis Antunes/0000-0002-4359-0122; Fernandes, Rita/0000-0003-4023-9326; Canhao, Helena/0000-0003-1894-4870; Pimentel-Santos, Fernando/0000-0002-2816-7705; Rodrigues, Ana Maria/0000-0003-2046-8017; Branco, Jaime/0000-0001-7024-4375	LISBOA 2020 - Regional Operational Program for Lisbon and Vale do Tejo; Portuguese Science & Technology Foundation [SAICT-POL/23439/2016, LISBOA-01-0145-FEDER-023439]	LISBOA 2020 - Regional Operational Program for Lisbon and Vale do Tejo; Portuguese Science & Technology Foundation	Funded study. Eduardo B. Cruz. The work presented in this paper is associated to a research project co-financed by the LISBOA 2020 - Regional Operational Program for Lisbon and Vale do Tejo and the Portuguese Science & Technology Foundation (Grant#SAICT-POL/23439/2016 vertical bar LISBOA-01-0145-FEDER-023439). This grant covers all the planned activities for this study including, the design of the study, data collection, data analysis and interpretation and the writing of this manuscript.The funder did not play any role in the study design, data collection and analysis, decision to publish, or preparation of this manuscript.	Airaksinen O, 2006, EUR SPINE J, V15, pS192, DOI 10.1007/s00586-006-1072-1; Artus M, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-68; Azevedo LF, 2012, J PAIN, V13, P773, DOI 10.1016/j.jpain.2012.05.012; Balague F, 2012, LANCET, V379, P482, DOI 10.1016/S0140-6736(11)60610-7; Bonferroni C. E., TEORIA STAT CLASS CA, P193; Branco JC, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen-2015-000166; Campbell P, 2013, J PAIN, V14, P873, DOI 10.1016/j.jpain.2013.03.013; Childs JD, 2005, SPINE, V30, P1331, DOI 10.1097/01.brs.0000164099.92112.29; Chou R, 2010, JAMA-J AM MED ASSOC, V303, P1295, DOI 10.1001/jama.2010.344; Costa LDM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3829; Dagenais S, 2008, SPINE J, V8, P8, DOI 10.1016/j.spinee.2007.10.005; Dionne CE, 2008, SPINE, V33, P95, DOI 10.1097/BRS.0b013e31815e7f94; Direc-Geral da Saude Institute for Health Metrics and Evaluation, 2018, PORT NAT HLTH 1990 2; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Ferreira LN, 2014, QUAL LIFE RES, V23, P413, DOI 10.1007/s11136-013-0448-z; Ferreira ML, 2010, EUR J PAIN, V14, DOI 10.1016/j.ejpain.2009.11.005; Ferreira PL, 2013, ACTA MEDICA PORT, V26, P664; Foster NE, 2008, PAIN, V136, P177, DOI 10.1016/j.pain.2007.12.007; Foster NE, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-108; Foster NE, 2010, PAIN, V148, P398, DOI 10.1016/j.pain.2009.11.002; FREEDMAN DA, 1983, AM STAT, V37, P152, DOI 10.2307/2685877; Freitas P, 2021, DISABIL REHABIL, V43, P1008, DOI 10.1080/09638288.2019.1648568; George SZ, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0509-2; Gouveia N, 2016, RHEUMATOL INT, V36, P183, DOI 10.1007/s00296-015-3398-7; Grotle M, 2003, J REHABIL MED, V35, P241, DOI 10.1080/16501970306094; Grotle M, 2010, PAIN, V151, P790, DOI 10.1016/j.pain.2010.09.014; Group Euroqol, 2000, EQ 5D MEAS HLTH REL; Hartvigsen J, 2018, LANCET, V391, P2356, DOI 10.1016/S0140-6736(18)30480-X; Henschke Nicholas, 2008, BMJ, V337, pa171, DOI 10.1136/bmj.a171; Hill JC, 2008, ARTHRIT RHEUM-ARTHR, V59, P632, DOI 10.1002/art.23563; Hill JC, 2011, LANCET, V378, P1560, DOI 10.1016/S0140-6736(11)60937-9; Hosmer D. W, 2000, APPL LOGISTIC REGRES, DOI [10.1002/0471722146, DOI 10.1002/0471722146]; Hoy D, 2010, BEST PRACT RES CL RH, V24, P155, DOI 10.1016/j.berh.2009.11.002; JENSEN MP, 1994, PAIN, V58, P387, DOI 10.1016/0304-3959(94)90133-3; Jordan KP, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-144; Kamper SJ, 2009, J MAN MANIP THER, V17, P163, DOI 10.1179/jmt.2009.17.3.163; Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31470-2; Maher C, 2017, LANCET, V389, P736, DOI 10.1016/S0140-6736(16)30970-9; Mehling WE, 2012, SPINE, V37, P678, DOI 10.1097/BRS.0b013e318230ab20; Costa LDM, 2012, CAN MED ASSOC J, V184, pE613, DOI 10.1503/cmaj.111271; Monteiro J, 2010, ACTA MEDICA PORT, V23, P761; Moons KGM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b375; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; Costa LOP, 2008, SPINE, V33, P2459, DOI 10.1097/BRS.0b013e3181849dbe; Ramond A, 2011, FAM PRACT, V28, P12, DOI 10.1093/fampra/cmq072; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Schiottz-Christensen B, 1999, FAM PRACT, V16, P223, DOI 10.1093/fampra/16.3.223; Thomas E, 1999, BRIT MED J, V318, P1662, DOI 10.1136/bmj.318.7199.1662; Vandenbroucke JP., 2007, EXPLAN ELAB, V4, P1628; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]	51	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2020	15	3							e0229265	10.1371/journal.pone.0229265	http://dx.doi.org/10.1371/journal.pone.0229265			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8GU	32218561	Green Published, gold			2023-01-03	WOS:000535935400003
J	Noblet, T; Marriott, J; Hensman-Crook, A; O'Shea, S; Friel, S; Rushton, A				Noblet, Tim; Marriott, John; Hensman-Crook, Amanda; O'Shea, Simon; Friel, Sarah; Rushton, Alison			Independent prescribing by advanced physiotherapists for patients with low back pain in primary care: A feasibility trial with an embedded qualitative component	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; FOLLOW-UP; OSTEOARTHRITIS PAIN; RANDOMIZED-TRIALS; DIRECT ACCESS; RATING-SCALE; START BACK; THERAPY; DESIGN; RECOMMENDATIONS	Background Low back pain (LBP) is the most prevalent musculoskeletal condition. Guidelines advocate a multimodal approach, including prescription of medications. Advanced Physiotherapy Practitioners (APPs) are well placed to manage LBP. To date no trial has evaluated the efficacy of physiotherapist-prescribing for LBP. Objectives To evaluate the feasibility, suitability and acceptability of assessing the effectiveness of physiotherapist-prescribing for LBP in primary care; informing the design of a future definitive stepped-wedged cluster trial (SWcRCT). Methods Mixed-methods, single-arm feasibility design with two components. 1) Trial component: participants with medium-risk LBP +/-leg pain were recruited across 3 sites. Outcome measures (primary outcome measures-Pain/RMDQ) were completed at baseline, 6 and 12 weeks Physical activity/sedentary behaviour were assessed over 7 days using accelerometery. A CONSORT diagram analysed recruitment/follow-up rates. Descriptive analysis evaluated procedure/floor-effects. 2) Embedded qualitative component: focus groups (n = 6) and semi-structured interviews (n = 3) evaluated the views/experiences of patients and APPs about feasibility/suitability/acceptability of the proposed trial. Thematic analysis synthesised the qualitative data. Findings were evaluated against a priori success criteria. Results n = 29 participants were recruited. 90% of success criteria were met. Loss to follow-up at 12 weeks (65.5%) did not satisfy success criteria. Primary and secondary outcome measures were suitable and acceptable with no floor effects. The addition of a sleep assessment tool was advised. Accelerometer use was acceptable with 100% adherence. APPs felt all patients presenting with non-specific LBP +/- leg pain and capture data representative of the full scope of physiotherapist independent prescribing should be included. Data collection methods were acceptable to APPs and patients. APPs advocated necessity for using research assistants owing to time limitations. Conclusions Methods evaluated are feasible, suitable and acceptable for a definitive SWcRCT, with modification of eligibility criteria, and use of research assistants to overcome limited clinician capacity. A definitive SWcRCT is feasible with minor modifications.	[Noblet, Tim; Rushton, Alison] Univ Birmingham, Ctr Precis Rehabil Spinal Pain, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England; [Noblet, Tim] St Georges Univ Hosp Fdn Trust, Physiotherapy Dept, London, England; [Marriott, John] Univ Birmingham, Coll Med & Dent Sci, Inst Clin Sci, Birmingham, W Midlands, England; [Hensman-Crook, Amanda] Windermere Hlth Ctr, Windermere, England; [O'Shea, Simon] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England; [Friel, Sarah] Guys & St ThomasNHS Fdn Trust, London, England	University of Birmingham; University of Birmingham; University of Sheffield	Noblet, T (corresponding author), Univ Birmingham, Ctr Precis Rehabil Spinal Pain, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England.; Noblet, T (corresponding author), St Georges Univ Hosp Fdn Trust, Physiotherapy Dept, London, England.	timnoblet@hotmail.com	Noblet, Tim/AAK-9611-2021; Rushton, Alison/V-1260-2017	Rushton, Alison/0000-0001-8114-7669; Noblet, Timothy/0000-0002-7032-9966; O'Shea, Simon/0000-0003-2636-8375	Health Education England (HEE)	Health Education England (HEE)	Health Education England (HEE) funding has allowed for the procurement of accelerometers and the associated IT programmes to ensure that innovative physical measures can be evaluated alongside patient reported outcome measures. The Private Physiotherapy Educational Fund has allowed for the procurement of x3 tablet computers for use in data collection and 7.5hrs per week of the principal Investigators time for 18 months. The funders have no direct role in study design, data collection and analysis decision to publish, or preparation of the manuscript. There were no conditions attached to funding. Identification of the trial funders provides transparency and accountability.	Abbott JH, 2002, NZ J PHYSIOTHER, V30, P8; Alsaadi SM, 2014, ARTHRITIS RHEUMATOL, V66, P1388, DOI 10.1002/art.38329; Alsaadi SM, 2011, EUR SPINE J, V20, P737, DOI 10.1007/s00586-010-1661-x; APA, 2015, PHYS PRESCR PATHW PR; Arain M, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-67; Arthritis Research UK, 2017, STAT MUSC HLTH 2017; Barker D, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0176-5; Beard E, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0839-2; Bernstein IA, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6748; Bloor M., 2001, FOCUS GROUPS SOCIAL, DOI DOI 10.4135/9781849209175; Bowen DJ, 2009, AM J PREV MED, V36, P452, DOI 10.1016/j.amepre.2009.02.002; Bowling A., 2001, RES METHODS HLTH INV; Bowling A., 2014, RES METHODS HLTH INV, Vfourth; Brett J, 2014, HEALTH EXPECT, V17, P637, DOI 10.1111/j.1369-7625.2012.00795.x; Burck C, 2005, J FAM THER, V27, P237, DOI 10.1111/j.1467-6427.2005.00314.x; Bury TJ, 2013, PHYS THER, V93, P449, DOI 10.2522/ptj.20120060; Butte NF, 2012, MED SCI SPORT EXER, V44, pS5, DOI 10.1249/MSS.0b013e3182399c0e; Campbell C., 2017, MEASURING PHYS BEHAV; Campbell J, 2013, BMJ, V347; Carey N., 2016, EVALUATION PHYSIOTHE; Charmaz K., 2012, SAGE HDB INTERVIEW R, V2, P347; Chartered Society of Physiotherapy, 2016, SCOP PRACT; Chastin SFM, 2010, GAIT POSTURE, V31, P82, DOI 10.1016/j.gaitpost.2009.09.002; Cherkin D, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1219-0; Chiarotto A, 2015, EUR SPINE J, V24, P1127, DOI 10.1007/s00586-015-3892-3; Childs JD, 2005, SPINE, V30, P1331, DOI 10.1097/01.brs.0000164099.92112.29; Corbin J.M., 2008, BASICS QUALITATIVE R, Vthird, DOI DOI 10.4135/9781452230153.N8; CSP, 2012, TREATM BACK PAIN; de Graaf I, 2006, SPINE, V31, P1168, DOI 10.1097/01.brs.0000216463.32136.7b; Denscombe M, 2009, INT J SOC RES METHOD, V12, P281, DOI 10.1080/13645570802054706; Edwardson CL, 2017, J SPORT HEALTH SCI, V6, P162, DOI 10.1016/j.jshs.2016.02.002; Eldridge S, 2013, TRIALS, V14; Eldridge Sandra M, 2016, BMJ, V355, pi5239, DOI 10.1136/bmj.i5239; Ewbank L, 2018, RISING COST MEDICINE; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; FERRAZ MB, 1990, J RHEUMATOL, V17, P1022; Fewtrell MS, 2008, ARCH DIS CHILD, V93, P458, DOI 10.1136/adc.2007.127316; Fraser S, 2009, ARCH PHYS MED REHAB, V90, P1964, DOI 10.1016/j.apmr.2009.03.021; Freedson P, 2012, MED SCI SPORT EXER, V44, pS1, DOI 10.1249/MSS.0b013e3182399b7e; Fritz JM, 2011, PHYS THER, V91, P722, DOI 10.2522/ptj.20100109; Galletta A., 2013, MASTERING SEMISTRUCT, DOI DOI 10.18574/NYU/9780814732939.001.0001; Gill P, 2008, BRIT DENT J, V204, P291, DOI 10.1038/bdj.2008.192; Griffin DW, 2012, PHYSIOTHERAPY, V98, P13, DOI 10.1016/j.physio.2011.04.350; Haack M, 2012, EUR J PAIN, V16, P522, DOI 10.1016/j.ejpain.2011.07.007; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Henschke N, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a171; Heyvaert M, 2013, QUAL QUANT, V47, P659, DOI 10.1007/s11135-011-9538-6; Hicks C. M., 2009, RES METHODS CLIN THE; Hill JC, 2011, LANCET, V378, P1560, DOI 10.1016/S0140-6736(11)60937-9; Hoy D, 2010, BEST PRACT RES CL RH, V24, P769, DOI 10.1016/j.berh.2010.10.002; Jamshed Shazia, 2014, J Basic Clin Pharm, V5, P87, DOI 10.4103/0976-0105.141942; Janssen MF, 2013, QUAL LIFE RES, V22, P1717, DOI 10.1007/s11136-012-0322-4; Jones M, 2011, GUIDING USE GROUNDED; Kaila-Kangas L, 2006, SPINE, V31, P51, DOI 10.1097/01.brs.0000193902.45315.e5; Kelley K, 2003, INT J QUAL HEALTH C, V15, P261, DOI 10.1093/intqhc/mzg031; Koes BW, 2010, EUR SPINE J, V19, P2075, DOI 10.1007/s00586-010-1502-y; Kozey-Keadle S, 2011, MED SCI SPORT EXER, V43, P1561, DOI 10.1249/MSS.0b013e31820ce174; Krebs EE, 2018, JAMA-J AM MED ASSOC, V319, P872, DOI 10.1001/jama.2018.0899; Kristunas CA, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017290; Lancaster GA, 2004, J EVAL CLIN PRACT, V10, P307, DOI 10.1111/j..2002.384.doc.x; Landry Glenn J, 2015, Front Aging Neurosci, V7, P166, DOI 10.3389/fnagi.2015.00166; Leeuw Maaike, 2007, Cognitive Behaviour Therapy, V36, P52, DOI 10.1080/16506070601070400; Lim CR, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007765; Lin CWC, 2011, PAIN, V152, P607, DOI 10.1016/j.pain.2010.11.034; Lonsdale C, 2006, J SPORT EXERCISE PSY, V28, P100, DOI 10.1123/jsep.28.1.100; Lutzner C, 2014, GAIT POSTURE, V39, P1126, DOI 10.1016/j.gaitpost.2014.01.022; Macfarlane GJ, 2012, PAIN, V153, P27, DOI 10.1016/j.pain.2011.08.005; Majeed A., 2017, BMJ, V358; McDonough SM, 2013, CLIN J PAIN, V29, P972, DOI 10.1097/AJP.0b013e31827f9d81; Mdege ND, 2011, J CLIN EPIDEMIOL, V64, P936, DOI 10.1016/j.jclinepi.2010.12.003; Meucci RD, 2015, REV SAUDE PUBL, V49, DOI 10.1590/S0034-8910.2015049005874; Montastruc F, 2018, JAMA-J AM MED ASSOC, V320, P2149, DOI 10.1001/jama.2018.12358; NHS Digital, 2019, PRACT LEV PRESCR ENG; NHS-Digital, 2017, GEN PERS MED SERV EN; NHS-England, 2015, INN ACT SUPP DEL NHS; NHS-England, 2015, GEN PRACT FORW VIEW; NHS-England, 2017, ALL HLTH PROF ACT US; NICE, 2018, DEV MAK MENT CAP; NICE, 2017, CLIN KNOWL SUMM BACK; NICE, 2016, LOW BACK PAIN SC 16S; Noblet T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193286; Noblet T, 2017, J PHYSIOTHER, V63, P221, DOI 10.1016/j.jphys.2017.09.001; Noblet TD, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027745; O'Cathain Alicia, 2015, Pilot Feasibility Stud, V1, P32; Ojha HA, 2014, PHYS THER, V94, P14, DOI 10.2522/ptj.20130096; Ostelo RWJG, 2005, BEST PRACT RES CL RH, V19, P593, DOI 10.1016/j.berh.2005.03.003; Page D., 2008, DEMENTIA, V7, P139; Parsons S., 2011, HEAVY BURDEN OCCURRE; Pengel LHM, 2003, BMJ-BRIT MED J, V327, P323, DOI 10.1136/bmj.327.7410.323; Prost A, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0837-4; Rabey M, 2009, CLIN GOV, V14, P15, DOI DOI 10.1108/14777270910933424; Ramdas J, 2018, PREVALENCE RISK FACT, V5, P4; Rhodes RE, 2012, AM J PREV MED, V42, pE3, DOI 10.1016/j.amepre.2011.10.020; Roelofs J, 2004, EUR J PAIN, V8, P495, DOI 10.1016/j.ejpain.2003.11.016; Roland M, 2000, SPINE, V25, P3115, DOI 10.1097/00007632-200012150-00006; Sandelowski Margarete, 2006, Res Sch, V13, P29; Saxon RL, 2014, J MULTIDISCIP HEALTH, V7, P479, DOI 10.2147/JMDH.S66746; Schneider GM, 2012, MANUAL THER, V17, P180, DOI 10.1016/j.math.2011.11.004; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c332, 10.1186/1741-7015-8-18]; Shanyinde M, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-117; Skender S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3172-0; Stanhope J, 2012, J MULTIDISCIP HEALTH, V5, P37, DOI 10.2147/JMDH.S28891; Staniszewska S, 2017, Res Involv Engagem, V3, P13, DOI 10.1186/s40900-017-0062-2; Staniszewska S, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3453; Stenner KL, 2011, INT J NURS STUD, V48, P37, DOI 10.1016/j.ijnurstu.2010.06.006; Stevens Matthew L, 2016, J Physiother, V62, P116, DOI 10.1016/j.jphys.2015.10.003; Stow R, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0952-2; Suckley J., 2012, CORE CLIN COMPETENCI; The Joanna Briggs Institute Joanna Briggs Institute Reviewers' Manual, 2014, J BRIGGS I REV MAN 2; Tickle-Degnen L, 2013, AM J OCCUP THER, V67, P171, DOI 10.5014/ajot.2013.006270; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Torrance N, 2018, BRIT J ANAESTH, V120, P1345, DOI 10.1016/j.bja.2018.02.022; Williams ACD, 2000, PAIN, V85, P457, DOI 10.1016/S0304-3959(99)00299-7; Woertman W, 2013, J CLIN EPIDEMIOL, V66, P752, DOI 10.1016/j.jclinepi.2013.01.009; Wright KB, 2005, J COMPUT-MEDIAT COMM, V10; Zelle BA, 2013, J ORTHOP TRAUMA, V27, P177, DOI 10.1097/BOT.0b013e31825cf367	116	5	5	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2020	15	3							e0229792	10.1371/journal.pone.0229792	http://dx.doi.org/10.1371/journal.pone.0229792			33	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ9DF	32182243	Green Accepted, Green Published, gold			2023-01-03	WOS:000535296400011
J	Han, M; Portnova, AA; Lester, M; Johnson, M				Han, Michelle; Portnova, Alexandra A.; Lester, Matthew; Johnson, Martha			A do-it-yourself 3D-printed thoracic spine model for anesthesia resident simulation	PLOS ONE			English	Article							LEARNING-CURVE; FIDELITY; NUMBER; SKILLS	Central line placement, cricothyroidotomy, and lumbar epidural placement are common procedures for which there are simulators to help trainees learn the procedures. However, a model or a simulator for thoracic epidurals is not commonly used by anesthesia training programs to help teach the procedure. This brief technical report aims to share the design and fabrication process of a low-cost and do-it-yourself (DIY) 3D-printed thoracic spine model. Ten expert anesthesiology attendings and fifteen novice anesthesiology residents practiced with the model and were subsequently surveyed to assess their attitudes towards its fidelity and usefulness as a teaching tool. Responses were recorded with a Likert scale and found to be positive for both groups. Design files and an assembly manual were developed and made public through an open-source website.	[Han, Michelle] Univ Washington, Dept Anesthesiol & Pain Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA; [Portnova, Alexandra A.] Northwestern Univ, Dept Mech Engn, Evanston, IL 60208 USA; [Lester, Matthew] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA; [Johnson, Martha] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Northwestern University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Han, M (corresponding author), Univ Washington, Dept Anesthesiol & Pain Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.	mhan2@uw.edu						3D GrabCAD Community, 2014, HUM SPIN MOD; Banks J, 2013, IEEE PULSE, V4, P22, DOI 10.1109/MPUL.2013.2279617; CAE Healthcare, 2018, LUMB PUNCT SPIN EP; Carmichael JC, 2017, DIS COLON RECTUM, V60, P761, DOI 10.1097/DCR.0000000000000883; Crafts TD, 2017, OTOLARYNG HEAD NECK, V156, P999, DOI 10.1177/0194599816678372; Dynamic Disc Designs, TROR EP PLAC SPIN MO; Epimed, 2016, THORAXIS NEUR SIM; Friedman Z, 2009, REGION ANESTH PAIN M, V34, P229, DOI 10.1097/AAP.0b013e3181a34345; Jeganathan J, 2017, REGION ANESTH PAIN M, V42, P469, DOI 10.1097/AAP.0000000000000580; Johnson MC, 2018, REGION ANESTH PAIN M, V43, P100, DOI 10.1097/AAP.0000000000000686; Klein GT, 2013, WORLD NEUROSURG, V80, P233, DOI 10.1016/j.wneu.2013.07.009; Kong XX, 2016, J SURG EDUC, V73, P264, DOI 10.1016/j.jsurg.2015.10.002; Konrad C, 1998, ANESTH ANALG, V86, P635; Kopacz DJ, 1996, REGION ANESTH, V21, P182; LEIGHTON BL, 1989, ANESTHESIOLOGY, V70, P368; Mashari A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191664; Matsumoto ED, 2002, J UROLOGY, V167, P1243, DOI 10.1016/S0022-5347(05)65274-3; Naik VN, 2003, CAN J ANAESTH, V50, P694, DOI 10.1007/BF03018712; Schmauss D, 2012, ANN THORAC SURG, V93, pE31, DOI 10.1016/j.athoracsur.2011.09.031; Tsui BCH, 2011, CAN J ANESTH, V58, P1051, DOI 10.1007/s12630-011-9571-x; Williams A, 2018, J PEDIATR SURG, V53, P937, DOI 10.1016/j.jpedsurg.2018.02.016; Woods AT, 2004, J PHYSIOL-PARIS, V98, P147, DOI 10.1016/j.jphysparis.2004.03.006	22	9	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2020	15	3							e0228665	10.1371/journal.pone.0228665	http://dx.doi.org/10.1371/journal.pone.0228665			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8YS	32160198	Green Published, gold			2023-01-03	WOS:000535284700010
J	Klotz, R; Seide, SE; Kriebel, P; Probst, P; Bruckner, T; Motsch, J; Hyhlik-Durr, A; Mockler, D; Larmann, J; Diener, MK; Weigand, MA; Buchler, MW; Mihaljevic, AL				Klotz, Rosa; Seide, Svenja E.; Kriebel, Phillip; Probst, Pascal; Bruckner, Thomas; Motsch, Johann; Hyhlik-Duerr, Alexander; Moeckler, Dittmar; Larmann, Jan; Diener, Markus K.; Weigand, Markus A.; Buechler, Markus W.; Mihaljevic, Andre L.			Continuous wound infiltration versus epidural analgesia for midline abdominal incisions - a randomized-controlled pilot trial (Painless-Pilot trial; DRKS Number: DRKS00008023)	PLOS ONE			English	Article							INTRAVENOUS OPIOID ANALGESIA; POSTOPERATIVE COMPLICATIONS; SURGERY; SUFENTANIL; ANESTHESIA; MORBIDITY; MORTALITY; IMPACT	Objectives To test the feasibility of a randomized controlled study design comparing epidural analgesia (EDA) with continuous wound infiltration (CWI) in respect to postoperative complications and mobility to design a future multicentre randomized controlled trial. Design, setting, participants CWI has been developed to address drawbacks of EDA. Previous studies have established the equivalent analgesic potential of CWI compared to EDA. This is a single centre, nonblinded pilot randomized controlled trial at a tertiary surgical centre. Patients undergoing elective non-colorectal surgery via a midline laparotomy were randomized to EDA or CWI. Endpoints included recruitment, feasibility of assessing postoperative mobility with a pedometer and morbidity. No primary endpoint was defined and all analyses were explorative. Interventions CWI with local anaesthetics (experimental group) vs. thoracic EDA (control). Results Of 846 patients screened within 14 months, 71 were randomized and 62 (31 per group) included in the intention-to-treat analysis. Mobility was assessed in 44 of 62 patients and revealed no differences within the first 3 postoperative days. Overall morbidity did not differ between the two groups (measured via the comprehensive complication index). Median pain scores at rest were comparable between the two groups, while EDA was superior in pain treatment during movement on the first, but not on the second and third postoperative day. Duration of preoperative induction of anaesthesia was shorter with CWI than with EDA. Of 17 serious adverse events, 3 were potentially related to EDA, while none was related to CWI. Conclusion This trial confirmed the feasibility of a randomized trial design to compare CWI and EDA regarding morbidity. Improvements in the education and training of team members are necessary to improve recruitment.	[Klotz, Rosa; Kriebel, Phillip; Probst, Pascal; Diener, Markus K.; Buechler, Markus W.; Mihaljevic, Andre L.] Univ Hosp Heidelberg, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany; [Seide, Svenja E.; Bruckner, Thomas] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany; [Motsch, Johann; Larmann, Jan; Weigand, Markus A.] Univ Hosp Heidelberg, Dept Anaesthesiol, Heidelberg, Germany; [Hyhlik-Duerr, Alexander; Moeckler, Dittmar] Univ Hosp Heidelberg, Dept Vasc & Endovasc Surg, Heidelberg, Germany; [Hyhlik-Duerr, Alexander] Klinikum Augsburg, Dept Vasc & Endovasc Surg, Augsburg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Klinikum Augsburg	Mihaljevic, AL (corresponding author), Univ Hosp Heidelberg, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany.	mihaljevic@uni-heidelberg.de	Larmann, Jan/B-4034-2011; Larmann, Jan/ABI-3699-2020; Probst, Pascal/GSD-6170-2022	Larmann, Jan/0000-0003-3365-4572; Larmann, Jan/0000-0003-3365-4572; Seide, Svenja/0000-0002-9113-7373	University Hospital Heidelberg "Heidelberger Stiftung Chirurgie"	University Hospital Heidelberg "Heidelberger Stiftung Chirurgie"	The study was funded by an intramural funding programme of the University Hospital Heidelberg "Heidelberger Stiftung Chirurgie" (www.stiftung-chirurgie.de/startseite.html).The authors did not receive individual grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aloia TA, 2017, ANN SURG, V266, P545, DOI 10.1097/SLA.0000000000002386; [Anonymous], ERAS SOC GUID; AWMF, 2009, S3 LEITL PROPH VEN T; Babazade R, 2019, J CLIN ANESTH, V53, P56, DOI 10.1016/j.jclinane.2018.10.003; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Bardia A, 2016, JAMA SURG, V151, P1116, DOI 10.1001/jamasurg.2016.2733; Bartley EJ, 2013, BRIT J ANAESTH, V111, P52, DOI 10.1093/bja/aet127; Bell R, 2019, ANN SURG, V269, P413, DOI 10.1097/SLA.0000000000002988; Cook TM, 2009, BRIT J ANAESTH, V102, P179, DOI 10.1093/bja/aen360; Craig Peter, 2008, BMJ, V337, pa1655, DOI 10.1136/bmj.a1655; Dexter F, 2013, ANESTH ANALG, V117, P537, DOI 10.1213/ANE.0b013e31829ed28f; Duncan F, 2011, J CLIN NURS, V20, P1870, DOI 10.1111/j.1365-2702.2011.03752.x; GELLER E, 1993, ANESTH ANALG, V76, P1243, DOI 10.1213/00000539-199376060-00011; IONESCU TI, 1991, BRIT J ANAESTH, V66, P458, DOI 10.1093/bja/66.4.458; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; Kooij FO, 2014, ANESTH ANALG, V119, P740, DOI 10.1213/ANE.0000000000000245; Laubenthal H, 2009, S3 LEITLINIE BEHANDL; Liu SS, 2007, ANESTH ANALG, V105, P789, DOI 10.1213/01.ane.0000278089.16848.1e; Liu SS, 2007, ANESTH ANALG, V104, P689, DOI 10.1213/01.ane.0000255040.71600.41; Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620; McCulloch P, 2009, LANCET, V374, P1105, DOI 10.1016/S0140-6736(09)61116-8; MIGUEL R, 1994, ANESTHESIOLOGY, V81, P346, DOI 10.1097/00000542-199408000-00012; Mouawad NJ, 2018, AM J SURG, V215, P570, DOI 10.1016/j.amjsurg.2017.06.031; Mungroop TH, 2019, ANN SURG, V269, P252, DOI 10.1097/SLA.0000000000002817; Panousis P, 2009, ANESTH ANALG, V108, P1971, DOI 10.1213/ane.0b013e3181a2a301; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Popping DM, 2014, ANN SURG, V259, P1056, DOI 10.1097/SLA.0000000000000237; Probst P, 2017, BRIT J SURG, V104, P1053, DOI 10.1002/bjs.10525; Probst P, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0226-4; Revie EJ, 2012, HPB, V14, P611, DOI 10.1111/j.1477-2574.2012.00490.x; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Salicath JH, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010434.pub2; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; Slankamenac K, 2017, INT J COLORECTAL DIS, V32, P805, DOI 10.1007/s00384-017-2811-y; Slankamenac K, 2014, ANN SURG, V260, P757, DOI 10.1097/SLA.0000000000000948; Slankamenac K, 2013, ANN SURG, V258, P1, DOI 10.1097/SLA.0b013e318296c732; TAVERNE RHT, 1992, CLIN PHARMACOKINET, V23, P231, DOI 10.2165/00003088-199223030-00005; Ventham NT, 2013, BRIT J SURG, V100, P1280, DOI 10.1002/bjs.9204; Weiss R, 2018, CURR OPIN ANESTHESIO, V31, P622, DOI 10.1097/ACO.0000000000000640; Werawatganon T, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004088.pub2	40	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2020	15	3							e0229898	10.1371/journal.pone.0229898	http://dx.doi.org/10.1371/journal.pone.0229898			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8TR	32142529	Green Published, gold			2023-01-03	WOS:000535271600023
J	Li, ZY; Philip, M; Ferrell, PB				Li, Zhuoyan; Philip, Mary; Ferrell, P. Brent			Alterations of T-cell-mediated immunity in acute myeloid leukemia	ONCOGENE			English	Review							ISOCITRATE DEHYDROGENASE MUTATIONS; INDOLEAMINE 2,3-DIOXYGENASE; CD200 EXPRESSION; SPONTANEOUS REMISSION; INCREASED FREQUENCY; PROGNOSTIC-FACTOR; PERIPHERAL-BLOOD; POOR-PROGNOSIS; PROLIFERATION; IMMUNOCOMPETENCE	Acute myeloid leukemia (AML) is a systemic, heterogeneous hematologic malignancy with poor overall survival. While some malignancies have seen improvements in clinical outcomes with immunotherapy, success of these agents in AML remains elusive. Despite limited progress, stem cell transplantation and donor lymphocyte infusions show that modulation of the immune system can improve overall survival of AML patients. Understanding the causes of immune evasion and disease progression will identify potential immune-mediated targets in AML. This review explores immunosuppressive mechanisms that alter T-cell-mediated immunity in AML.	[Li, Zhuoyan; Philip, Mary; Ferrell, P. Brent] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Nashville, TN 37232 USA	Vanderbilt University	Ferrell, PB (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Nashville, TN 37232 USA.	brent.ferrell@vumc.org		Li, Zhuoyan/0000-0003-2658-9071	 [K23HL138291];  [T32CA217834]	; 	The authors are supported by K23HL138291(PBF) and T32CA217834 (ZL).	Almosailleakh M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020453; Arandi N, 2018, BLOOD RES, V53, P294, DOI 10.5045/br.2018.53.4.294; Austin R, 2016, CRIT REV ONCOL HEMAT, V103, P62, DOI 10.1016/j.critrevonc.2016.04.020; Barosi G, 2014, CURR HEMATOL MALIG R, V9, P331, DOI 10.1007/s11899-014-0227-0; Boddu P, 2018, LEUKEMIA LYMPHOMA, V59, P790, DOI 10.1080/10428194.2017.1344905; Buggins AGS, 2001, J IMMUNOL, V167, P6021, DOI 10.4049/jimmunol.167.10.6021; Bunse L, 2018, NAT MED, V24, P1192, DOI 10.1038/s41591-018-0095-6; Cerrano M, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0764-8; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Chamuleau MED, 2008, HAEMATOL-HEMATOL J, V93, P1894, DOI 10.3324/haematol.13113; Christopher MJ, 2018, NEW ENGL J MED, V379, P2330, DOI 10.1056/NEJMoa1808777; Coles SJ, 2012, LEUKEMIA, V26, P2146, DOI 10.1038/leu.2012.75; Coles SJ, 2012, LEUKEMIA, V26, P2148, DOI 10.1038/leu.2012.77; Corm S, 2009, LEUKEMIA RES, V33, P490, DOI 10.1016/j.leukres.2008.06.014; Curti A, 2007, LEUKEMIA, V21, P353, DOI 10.1038/sj.leu.2404485; Curti A, 2007, BLOOD, V109, P2871, DOI 10.1182/blood-2006-07-036863; Dama P, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0611-3; Damiani D, 2015, ONCOTARGET, V6, P30212, DOI 10.18632/oncotarget.4901; Daver N, 2019, CANCER DISCOV, V9, P370, DOI 10.1158/2159-8290.CD-18-0774; Deng M, 2018, NATURE, V562, P605, DOI 10.1038/s41586-018-0615-z; DiNardo CD, 2013, BLOOD, V121, P4917, DOI 10.1182/blood-2013-03-493197; Dobrowolska H, 2013, CYTOM PART B-CLIN CY, V84B, P21, DOI 10.1002/cyto.b.21050; Ersvaer Elisabeth, 2010, BMC Immunol, V11, P38, DOI 10.1186/1471-2172-11-38; Fozza C, 2016, CRIT REV ONCOL HEMAT, V107, P90, DOI 10.1016/j.critrevonc.2016.08.016; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; Fukuno K, 2015, LEUKEMIA LYMPHOMA, V56, P1398, DOI 10.3109/10428194.2014.953150; Han YX, 2014, CANCER SCI, V105, P933, DOI 10.1111/cas.12459; Hasegawa K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144594; HERSH EM, 1974, J CLIN INVEST, V54, P401, DOI 10.1172/JCI107775; HERSH EM, 1971, NEW ENGL J MED, V285, P1211, DOI 10.1056/NEJM197111252852201; HOROWITZ MM, 1990, BLOOD, V75, P555; Howlader N, SEER CANC STAT REV 1; Jia B, 2019, CANC RES; Jia B, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0069-4; Kanakry CG, 2011, BLOOD, V117, P608, DOI 10.1182/blood-2010-04-277939; Kang XL, 2016, CELL CYCLE, V15, P25, DOI 10.1080/15384101.2015.1121324; Kawasaki BT, 2008, TRENDS IMMUNOL, V29, P464, DOI 10.1016/j.it.2008.07.005; Kelderman S, 2014, MOL ONCOL, V8, P1132, DOI 10.1016/j.molonc.2014.07.011; Kittang AO, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1062208; Klco JM, 2014, CANCER CELL, V25, P379, DOI 10.1016/j.ccr.2014.01.031; Knaus HA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120974; Kretz-Rommel A, 2007, J IMMUNOL, V178, P5595, DOI 10.4049/jimmunol.178.9.5595; LaBelle JL, 2002, BLOOD, V99, P2146, DOI 10.1182/blood.V99.6.2146; Lamble AJ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00213; Le Dieu R, 2009, BLOOD, V114, P3909, DOI 10.1182/blood-2009-02-206946; Lee JB, 2019, BLOOD REV, V35, P18, DOI 10.1016/j.blre.2019.02.001; Lichtenegger FS, 2014, LEUKEMIA RES, V38, P964, DOI 10.1016/j.leukres.2014.05.014; Liu YX, 2019, BLOOD REV, V34, P67, DOI 10.1016/j.blre.2018.12.001; Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677; Masarova L, 2018, ADV EXP MED BIOL, V995, P97, DOI 10.1007/978-3-030-02505-2_4; Medeiros BC, 2017, LEUKEMIA, V31, P272, DOI 10.1038/leu.2016.275; Menter T, 2018, BRIT J HAEMATOL, V182, P581, DOI 10.1111/bjh.14819; Moreaux J, 2008, BIOCHEM BIOPH RES CO, V366, P117, DOI 10.1016/j.bbrc.2007.11.103; Moreaux J, 2006, BLOOD, V108, P4194, DOI 10.1182/blood-2006-06-029355; Muller-Schmah C, 2012, ANN HEMATOL, V91, P27, DOI 10.1007/s00277-011-1332-y; Mussai F, 2019, INT J CANCER, V145, P2201, DOI 10.1002/ijc.32028; Mussai F, 2013, BLOOD, V122, P749, DOI 10.1182/blood-2013-01-480129; Musuraca G, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0590-1; Orleans-Lindsay JK, 2001, CLIN EXP IMMUNOL, V126, P403, DOI 10.1046/j.1365-2249.2001.01692.x; Paley MA, 2012, SCIENCE, V338, P1220, DOI 10.1126/science.1229620; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Philip M, 2017, NATURE, V545, P452, DOI 10.1038/nature22367; Pollyea DA, 2018, HEMATOL-AM SOC HEMAT, P45, DOI 10.1182/asheducation-2018.1.45; Radpour R, 2019, LEUKEMIA, V33, P2379, DOI 10.1038/s41375-019-0441-9; Rashidi A, 2015, LEUKEMIA LYMPHOMA, V56, P1727, DOI 10.3109/10428194.2014.970545; Schnorfeil FM, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0189-2; Sun YX, 2014, HUM IMMUNOL, V75, P113, DOI 10.1016/j.humimm.2013.11.014; Szczepanski MJ, 2009, CLIN CANCER RES, V15, P3325, DOI 10.1158/1078-0432.CCR-08-3010; Teague RM, 2013, J IMMUNOTHER CANCER, V1, DOI 10.1186/2051-1426-1-13; Tian T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131761; Tian T, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/915873; Tikhonova AN, 2019, NATURE, V569, P222, DOI 10.1038/s41586-019-1104-8; Tonks A, 2007, LEUKEMIA, V21, P566, DOI 10.1038/sj.leu.2404559; Ustun C, 2011, BLOOD, V118, P5084, DOI 10.1182/blood-2011-07-365817; van Galen P, 2019, CELL, V176, P1265, DOI 10.1016/j.cell.2019.01.031; Wang MJ, 2018, CLIN IMMUNOL, V190, P64, DOI 10.1016/j.clim.2017.08.021; Wang XB, 2005, EUR J HAEMATOL, V75, P468, DOI 10.1111/j.1600-0609.2005.00537.x; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Williams M, 2018, CANCERS, V10, DOI 10.3390/cancers10050129; Wouters BJ, 2016, BLOOD, V127, P42, DOI 10.1182/blood-2015-07-604512; Wu C, 2009, CLIN EXP IMMUNOL, V158, P199, DOI 10.1111/j.1365-2249.2009.04011.x; Xu T, 2017, NATURE, V548, P228, DOI 10.1038/nature23475; Zahran AM, 2018, CANCER BIOMARK, V22, P587, DOI 10.3233/CBM-181368; Zhang LJ, 2018, CLIN CANCER RES, V24, P5381, DOI 10.1158/1078-0432.CCR-17-3855; Zhang L, 2013, J CLIN INVEST, V123, P1999, DOI 10.1172/JCI63980; Zhang SH, 2011, INT J CANCER, V129, P1373, DOI 10.1002/ijc.25791; Zhou Q, 2011, BLOOD, V117, P4501, DOI 10.1182/blood-2010-10-310425; Zhou Q, 2009, BLOOD, V114, P3793, DOI 10.1182/blood-2009-03-208181; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	89	24	24	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3611	3619		10.1038/s41388-020-1239-y	http://dx.doi.org/10.1038/s41388-020-1239-y		MAR 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32127646	Green Accepted			2023-01-03	WOS:000517861800001
J	Hsieh, YC; Hsieh, WH; Li, CH; Liao, YC; Lin, JC; Weng, CJ; Lo, MT; Tuan, TC; Lin, SF; Yeh, HI; Huang, JL; Haugan, K; Larsen, BD; Lin, YJ; Lin, WW; Wu, TJ; Chen, SA				Hsieh, Yu-Cheng; Hsieh, Wan-Hsin; Li, Cheng-Hung; Liao, Ying-Chieh; Lin, Jiunn-Cherng; Weng, Chi-Jen; Lo, Men-Tzung; Tuan, Ta-Chuan; Lin, Shien-Fong; Yeh, Hung-, I; Huang, Jin-Long; Haugan, Ketil; Larsen, Bjarne D.; Lin, Yenn-Jiang; Lin, Wei-Wen; Wu, Tsu-Juey; Chen, Shih-Ann			Ventricular divergence correlates with epicardial wavebreaks and predicts ventricular arrhythmia in isolated rabbit hearts during therapeutic hypothermia	PLOS ONE			English	Article							T-WAVE ALTERNANS; INTRACELLULAR CALCIUM; DISCORDANT ALTERNANS; FIBRILLATION; INCREASES; TEMPERATURE; TACHYCARDIA; RESTITUTION; MECHANISM; ISCHEMIA	Introduction High beat-to-beat morphological variation (divergence) on the ventricular electrogram during programmed ventricular stimulation (PVS) is associated with increased risk of ventricular fibrillation (VF), with unclear mechanisms. We hypothesized that ventricular divergence is associated with epicardial wavebreaks during PVS, and that it predicts VF occurrence. Method and results Langendorff-perfused rabbit hearts (n = 10) underwent 30-min therapeutic hypothermia (TH, 30 degrees C), followed by a 20-min treatment with rotigaptide (300 nM), a gap junction modifier. VF inducibility was tested using burst ventricular pacing at the shortest pacing cycle length achieving 1:1 ventricular capture. Pseudo-ECG (p-ECG) and epicardial activation maps were simultaneously recorded for divergence and wavebreaks analysis, respectively. A total of 112 optical and p-ECG recordings (62 at TH, 50 at TH treated with rotigaptide) were analyzed. Adding rotigaptide reduced ventricular divergence, from 0.13 +/- 0.10 at TH to 0.09 +/- 0.07 (p = 0.018). Similarly, rotigaptide reduced the number of epicardial wavebreaks, from 0.59 +/- 0.73 at TH to 0.30 +/- 0.49 (p = 0.036). VF inducibility decreased, from 48 +/- 31% at TH to 22 +/- 32% after rotigaptide infusion (p = 0.032). Linear regression models showed that ventricular divergence correlated with epicardial wavebreaks during TH (p<0.001). Conclusion Ventricular divergence correlated with, and might be predictive of epicardial wavebreaks during PVS at TH. Rotigaptide decreased both the ventricular divergence and epicardial wavebreaks, and reduced the probability of pacing-induced VF during TH.	[Hsieh, Yu-Cheng; Li, Cheng-Hung; Liao, Ying-Chieh; Lin, Jiunn-Cherng; Weng, Chi-Jen; Huang, Jin-Long; Lin, Wei-Wen; Wu, Tsu-Juey] Taichung Vet Gen Hosp, Cardiovasc Ctr, Taichung, Taiwan; [Hsieh, Yu-Cheng; Li, Cheng-Hung; Liao, Ying-Chieh; Lin, Jiunn-Cherng; Weng, Chi-Jen; Huang, Jin-Long; Lin, Wei-Wen; Wu, Tsu-Juey] Chiayi Branch, Taichung, Taiwan; [Hsieh, Yu-Cheng; Li, Cheng-Hung; Liao, Ying-Chieh; Lin, Jiunn-Cherng; Weng, Chi-Jen; Huang, Jin-Long; Lin, Wei-Wen; Wu, Tsu-Juey] Taichung Vet Gen Hosp, Cardiovasc Ctr, Chiayi, Taiwan; [Hsieh, Yu-Cheng; Li, Cheng-Hung; Liao, Ying-Chieh; Lin, Jiunn-Cherng; Weng, Chi-Jen; Huang, Jin-Long; Lin, Wei-Wen; Wu, Tsu-Juey] Chiayi Branch, Chiayi, Taiwan; [Hsieh, Yu-Cheng; Li, Cheng-Hung; Liao, Ying-Chieh; Lin, Jiunn-Cherng; Weng, Chi-Jen; Tuan, Ta-Chuan; Huang, Jin-Long; Lin, Yenn-Jiang; Wu, Tsu-Juey; Chen, Shih-Ann] Natl Yang Ming Univ, Sch Med, Cardiovasc Res Ctr, Inst Clin Med,Fac Med,Dept Internal Med, Taipei, Taiwan; [Hsieh, Yu-Cheng; Li, Cheng-Hung; Liao, Ying-Chieh; Lin, Jiunn-Cherng; Weng, Chi-Jen] Providence Univ, Dept Data Sci & Big Data Analyt, Taichung, Taiwan; [Hsieh, Yu-Cheng; Li, Cheng-Hung; Liao, Ying-Chieh; Lin, Jiunn-Cherng; Weng, Chi-Jen] Providence Univ, Dept Financial Engn, Taichung, Taiwan; [Hsieh, Wan-Hsin] Ind Technol Res Inst, Biomed Technol & Device Res Labs, Hsinchu, Taiwan; [Lo, Men-Tzung] Natl Cent Univ, Res Ctr Adapt Data Anal, Jhongli, Taiwan; [Tuan, Ta-Chuan; Lin, Yenn-Jiang; Chen, Shih-Ann] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Taipei, Taiwan; [Lin, Shien-Fong] Indiana Univ Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; [Lin, Shien-Fong] Indiana Univ Sch Med, Div Cardiol, Dept Med, Indianapolis, IN 46202 USA; [Lin, Shien-Fong] Natl Chiao Tung Univ, Inst Biomed Engn, Hsinchu, Taiwan; [Yeh, Hung-, I] Mackay Mem Hosp, Mackay Med Coll, Dept Internal Med, New Taipei, Taiwan; [Yeh, Hung-, I] Mackay Mem Hosp, Mackay Med Coll, Dept Med Res, New Taipei, Taiwan; [Haugan, Ketil] Zealand Univ Hosp, Dept Cardiol, Roskilde, Denmark; [Larsen, Bjarne D.] Zealand Pharma AS, Glostrup, Denmark; [Lin, Wei-Wen] Tunghai Univ, Dept Life Sci, Taichung, Taiwan	Taichung Veterans General Hospital; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University; Providence University - Taiwan; Providence University - Taiwan; Industrial Technology Research Institute - Taiwan; National Central University; Taipei Veterans General Hospital; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; National Yang Ming Chiao Tung University; Mackay Medical College; Mackay Memorial Hospital; Mackay Medical College; Mackay Memorial Hospital; Zealand Pharma A/S; Tunghai University	Hsieh, YC (corresponding author), Taichung Vet Gen Hosp, Cardiovasc Ctr, Taichung, Taiwan.; Hsieh, YC (corresponding author), Chiayi Branch, Taichung, Taiwan.; Hsieh, YC (corresponding author), Taichung Vet Gen Hosp, Cardiovasc Ctr, Chiayi, Taiwan.; Hsieh, YC (corresponding author), Chiayi Branch, Chiayi, Taiwan.; Hsieh, YC (corresponding author), Natl Yang Ming Univ, Sch Med, Cardiovasc Res Ctr, Inst Clin Med,Fac Med,Dept Internal Med, Taipei, Taiwan.; Hsieh, YC (corresponding author), Providence Univ, Dept Data Sci & Big Data Analyt, Taichung, Taiwan.; Hsieh, YC (corresponding author), Providence Univ, Dept Financial Engn, Taichung, Taiwan.	ychsieh@vghtc.gov.tw		Lin, Shien-fong/0000-0003-1270-3961; Lin, Wei-Wen/0000-0002-9384-1970; Lin, Yenn-Jiang/0000-0001-8395-1052	National Science Council, Taipei, Taiwan [104-2314-B-367-001, 105-2314-B-075A-016 -MY3]; Taichung Veterans General Hospital, Taichung, Taiwan [TCVGH1033105C, TCVGH-1043109C, TCVGH-1053108C, VGHUST104-G5-2-2, VGHUST107-G5-1-3, TCVGH-VHCY1068606, TCVGH-VHCY1078603]	National Science Council, Taipei, Taiwan(Ministry of Science and Technology, Taiwan); Taichung Veterans General Hospital, Taichung, Taiwan	This study was supported by grants from the National Science Council (104-2314-B-367-001 and 105-2314-B-075A-016 -MY3), Taipei, Taiwan; and Taichung Veterans General Hospital (TCVGH1033105C, TCVGH-1043109C, TCVGH-1053108C, VGHUST104-G5-2-2, VGHUST107-G5-1-3, TCVGH-VHCY1068606, and TCVGH-VHCY1078603), Taichung, Taiwan. Zealand Pharma A/S provided support in the form of salaries for author [BDL] and rotigaptide, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Khatib Sana M, 2018, J Am Coll Cardiol, V72, pe91, DOI 10.1016/j.jacc.2017.10.054; Bardy GH, 2005, NEW ENGL J MED, V352, P2146; Camm AJ, 1996, EUR HEART J, V17, P354; Cao JM, 1999, CIRC RES, V84, P1318, DOI 10.1161/01.RES.84.11.1318; Choi BR, 2007, HEART RHYTHM, V4, P1057, DOI 10.1016/j.hrthm.2007.03.037; Chorro FJ, 2002, AM J PHYSIOL-HEART C, V283, pH2331, DOI 10.1152/ajpheart.00207.2002; Chou CC, 2005, CIRCULATION, V111, P2889, DOI 10.1161/CIRCULATIONAHA.104.498758; Donnino MW, 2015, CIRCULATION, V132, P2448, DOI 10.1161/CIR.0000000000000313; Erkapic D, 2015, EUROPACE, V17, P591, DOI 10.1093/europace/euu282; Gold MR, 2000, J AM COLL CARDIOL, V36, P2247, DOI 10.1016/S0735-1097(00)01017-2; Harada M, 2008, AM J PHYSIOL-HEART C, V294, pH1896, DOI 10.1152/ajpheart.00986.2007; Hayashi H, 2007, HEART RHYTHM, V4, P927, DOI 10.1016/j.hrthm.2007.02.028; Hsieh YC, 2016, HEART RHYTHM, V13, P251, DOI 10.1016/j.hrthm.2015.07.023; Hsieh YC, 2013, CIRC-ARRHYTHMIA ELEC, V6, P410, DOI 10.1161/CIRCEP.111.000152; Hsieh YC, 2011, CIRC J, V75, P1706, DOI 10.1253/circj.CJ-10-1001; Hsieh YC, 2009, CIRC J, V73, P2214, DOI 10.1253/circj.CJ-09-0432; Hwang GS, 2006, CIRCULATION, V114, P2595, DOI 10.1161/CIRCULATIONAHA.106.630509; Kjolbye AL, 2008, AM J PHYSIOL-HEART C, V294, pH41, DOI 10.1152/ajpheart.01089.2006; Liu YB, 2003, J CARDIOVASC ELECTR, V14, P1103, DOI 10.1046/j.1540-8167.2003.03218.x; Myerburg RJ, 2012, CIRCULATION, V125, P1043, DOI 10.1161/CIRCULATIONAHA.111.023846; Nearing BD, 2002, CIRC RES, V91, P727, DOI 10.1161/01.RES.0000038887.17976.33; Pastore JM, 1999, CIRCULATION, V99, P1385, DOI 10.1161/01.CIR.99.10.1385; Raatikainen MJP, 2005, PACE, V28, pS193, DOI 10.1111/j.1540-8159.2005.00110.x; Shiroshita-Takeshita A, 2007, CIRCULATION, V115, P310, DOI 10.1161/CIRCULATIONAHA.106.665547; Shusterman V, 2006, CIRCULATION, V113, P2880, DOI 10.1161/CIRCULATIONAHA.105.607895; SMITH JM, 1988, CIRCULATION, V77, P110, DOI 10.1161/01.CIR.77.1.110; Swerdlow C, 2011, CIRCULATION, V123, P1052, DOI 10.1161/CIRCULATIONAHA.110.986364; Tachibana H, 1998, AM J PHYSIOL-HEART C, V275, pH116, DOI 10.1152/ajpheart.1998.275.1.H116; Tuan TC, 2014, J CARDIOVASC ELECTR, V25, P411, DOI 10.1111/jce.12340; Ullah A, 1996, J STAT PLAN INFER, V49, P137, DOI 10.1016/0378-3758(95)00034-8; Weiss JN, 2000, CIRC RES, V87, P1103, DOI 10.1161/01.RES.87.12.1103; Xing DZ, 2003, J CARDIOVASC ELECTR, V14, P510, DOI 10.1046/j.1540-8167.2003.02329.x; Zaitsev AV, 2003, CIRC RES, V92, P546, DOI 10.1161/01.RES.0000061917.23107.F7	33	1	2	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2020	15	2							e0228818	10.1371/journal.pone.0228818	http://dx.doi.org/10.1371/journal.pone.0228818			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8DJ	32084145	Green Published, gold			2023-01-03	WOS:000535227900030
J	Fairfax, BP; Taylor, CA; Watson, RA; Nassiri, I; Danielli, S; Fang, H; Mahe, EA; Cooper, R; Woodcock, V; Traill, Z; Al-Mossawi, MH; Knight, JC; Klenerman, P; Payne, M; Middleton, MR				Fairfax, Benjamin P.; Taylor, Chelsea A.; Watson, Robert A.; Nassiri, Isar; Danielli, Sara; Fang, Hai; Mahe, Elise A.; Cooper, Rosalin; Woodcock, Victoria; Traill, Zoe; Al-Mossawi, M. Hussein; Knight, Julian C.; Klenerman, Paul; Payne, Miranda; Middleton, Mark R.			Peripheral CD8(+) T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma	NATURE MEDICINE			English	Article							THERAPY	Immune checkpoint blockade (ICB) of PD-1 and CTLA-4 to treat metastatic melanoma (MM) has variable therapeutic benefit. To explore this in peripheral samples, we characterized CD8(+) T cell gene expression across a cohort of patients with MM receiving anti-PD-1 alone (sICB) or in combination with anti-CTLA-4 (cICB). Whereas CD8(+) transcriptional responses to sICB and cICB involve a shared gene set, the magnitude of cICB response is over fourfold greater, with preferential induction of mitosis- and interferon-related genes. Early samples from patients with durable clinical benefit demonstrated overexpression of T cell receptor-encoding genes. By mapping T cell receptor clonality, we find that responding patients have more large clones (those occupying >0.5% of repertoire) post-treatment than non-responding patients or controls, and this correlates with effector memory T cell percentage. Single-cell RNA-sequencing of eight post-treatment samples demonstrates that large clones overexpress genes implicated in cytotoxicity and characteristic of effector memory T cells, including CCL4, GNLY and NKG7. The 6-month clinical response to ICB in patients with MM is associated with the large CD8(+) T cell clone count 21 d after treatment and agnostic to clonal specificity, suggesting that post-ICB peripheral CD8(+) clonality can provide information regarding long-term treatment response and, potentially, facilitate treatment stratification. Transcriptomic analysis of peripheral CD8(+) T cells in a cohort of patients with metastatic melanoma receiving checkpoint inhibitors shows that the number of large clones early post-treatment is strongly associated with six-month clinical outcome.	[Fairfax, Benjamin P.; Taylor, Chelsea A.; Watson, Robert A.; Nassiri, Isar; Mahe, Elise A.; Cooper, Rosalin] Univ Oxford, MRC Weatherall Inst Mol Med, Oxford, England; [Fairfax, Benjamin P.; Taylor, Chelsea A.; Watson, Robert A.; Nassiri, Isar; Danielli, Sara; Mahe, Elise A.; Cooper, Rosalin; Woodcock, Victoria; Payne, Miranda; Middleton, Mark R.] Univ Oxford, Dept Oncol, Oxford, England; [Fairfax, Benjamin P.; Taylor, Chelsea A.; Watson, Robert A.; Nassiri, Isar; Danielli, Sara; Mahe, Elise A.; Cooper, Rosalin; Woodcock, Victoria; Payne, Miranda; Middleton, Mark R.] Oxford Univ Hosp NHS Fdn Trust, Oxford Canc Ctr, Oxford, England; [Fairfax, Benjamin P.; Danielli, Sara; Knight, Julian C.; Klenerman, Paul; Middleton, Mark R.] Oxford Univ Hosp NHS Fdn Trust, NIHR Oxford Biomed Res Ctr, Oxford, England; [Fang, Hai; Knight, Julian C.] Univ Oxford, Wellcome Ctr Human Genet, Nuffield Dept Med, Oxford, England; [Traill, Zoe] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Dept Radiol, Oxford, England; [Al-Mossawi, M. Hussein] Univ Oxford, Botnar Res Ctr, NDORMS, Oxford, England; [Klenerman, Paul] John Radcliffe Hosp, Translat Gastroenterol Unit, Oxford, England	University of Oxford; University of Oxford; Oxford University Hospitals NHS Foundation Trust; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; University of Oxford	Fairfax, BP (corresponding author), Univ Oxford, MRC Weatherall Inst Mol Med, Oxford, England.; Fairfax, BP (corresponding author), Univ Oxford, Dept Oncol, Oxford, England.; Fairfax, BP (corresponding author), Oxford Univ Hosp NHS Fdn Trust, Oxford Canc Ctr, Oxford, England.; Fairfax, BP (corresponding author), Oxford Univ Hosp NHS Fdn Trust, NIHR Oxford Biomed Res Ctr, Oxford, England.	benjamin.fairfax@oncology.ox.ac.uk	Knight, Julian Charles/W-2399-2019	Knight, Julian Charles/0000-0002-0377-5536; Taylor, Chelsea/0000-0002-1635-4167; Cooper, Rosalin/0000-0002-8548-1178; klenerman, paul/0000-0003-4307-9161; Woodcock, Victoria/0000-0001-7656-728X; Danielli, Sara/0000-0003-4608-5751; Fairfax, Benjamin/0000-0001-7413-5002; Watson, Robert/0000-0002-8838-9406	Wellcome Intermediate Clinical Fellowship [201488/Z/16/Z]; CRUK predoctoral Fellowship [ANR00740]; CRUK Clinical Research Training Fellowship; Engineering & Physical Sciences Research Council; Balliol Jowett Society [D4T00070]; Wellcome Trust Investigator Award [204969/Z/16/Z]; NIHR Senior Fellowship; Wellcome Trust [WT109965MA]; CRUK CTAAC Clinical Trials Fellowship [C2195/A19716]; NIHR Oxford Biomedical Research Centre; EPSRC [1963686] Funding Source: UKRI	Wellcome Intermediate Clinical Fellowship(Wellcome Trust); CRUK predoctoral Fellowship; CRUK Clinical Research Training Fellowship; Engineering & Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Balliol Jowett Society; Wellcome Trust Investigator Award(Wellcome Trust); NIHR Senior Fellowship; Wellcome Trust(Wellcome Trust); CRUK CTAAC Clinical Trials Fellowship; NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	We are very grateful to all patients who generously contributed samples and participated in the study. We thank all the staff of the Day Treatment Unit, Oxford Cancer Centre, and N. Coupe and R. Matin for assistance in collecting patient samples. We thank R. Morgan for discussion and advice. This study was funded by a Wellcome Intermediate Clinical Fellowship to B.P.F. (no. 201488/Z/16/Z), additionally supporting E.A.M. and I.N. R.A.W. was a National Institute for Health Research (NIHR) Academic Clinical Fellow and was supported by a CRUK predoctoral Fellowship (no. ANR00740). R.C. is supported by a CRUK Clinical Research Training Fellowship. C.A.T. is funded by the Engineering & Physical Sciences Research Council and the Balliol Jowett Society (no. D4T00070). J.C.K. is funded by a Wellcome Trust Investigator Award (no. 204969/Z/16/Z). P.K. is supported by a NIHR Senior Fellowship and Wellcome Trust Award (no. WT109965MA). V.W. was supported by a CRUK CTAAC Clinical Trials Fellowship (no. C2195/A19716), and also by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Blank CU, 2016, SCIENCE, V352, P658, DOI 10.1126/science.aaf2834; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Brochez L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05047-1; Dahlin JS, 2018, BLOOD, V131, pE1, DOI 10.1182/blood-2017-12-821413; Das R, 2015, J IMMUNOL, V194, P950, DOI 10.4049/jimmunol.1401686; Daud AI, 2016, J CLIN ONCOL, V34, P4102, DOI 10.1200/JCO.2016.67.2477; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; Dixon P, 2003, J VEG SCI, V14, P927, DOI 10.1658/1100-9233(2003)014[0927:VAPORF]2.0.CO;2; Durovic B, 2013, J VIROL, V87, P6526, DOI 10.1128/JVI.00169-13; Fang H, 2019, NAT GENET, V51, P1082, DOI 10.1038/s41588-019-0456-1; Fang H, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0384-y; Gillespie GMA, 2000, J VIROL, V74, P8140, DOI 10.1128/JVI.74.17.8140-8150.2000; Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079; Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]; Jacquelot N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00608-2; Jun G, 2012, AM J HUM GENET, V91, P839, DOI 10.1016/j.ajhg.2012.09.004; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Krieg C, 2018, NAT MED, V24, P1773, DOI 10.1038/s41591-018-0094-7; Kugel CH, 2018, CLIN CANCER RES, V24, P5347, DOI 10.1158/1078-0432.CCR-18-1116; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Love M.I., 2014, GENOME BIOL, V15, P550, DOI [10.1186/s13059-014-0550-8, DOI 10.1186/S13059-014-0550-8]; Lun Aaron T L, 2016, F1000Res, V5, P2122; Lun ATL, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0947-7; McCarthy DJ, 2017, BIOINFORMATICS, V33, P1179, DOI 10.1093/bioinformatics/btw777; McQuade JL, 2018, LANCET ONCOL, V19, P310, DOI 10.1016/S1470-2045(18)30078-0; Miao D, 2018, NAT GENET, V50, P1271, DOI 10.1038/s41588-018-0200-2; Nicolet B. P, 2019, CD29 MARKS SUPERIOR, DOI [10.1101/562512, DOI 10.1101/562512]; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Patin E, 2018, NAT IMMUNOL, V19, P302, DOI 10.1038/s41590-018-0049-7; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Russo PST, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2053-1; Simoni Y, 2018, NATURE, V557, P575, DOI 10.1038/s41586-018-0130-2; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Suessmuth Y, 2015, BLOOD, V125, P3835, DOI 10.1182/blood-2015-03-631853; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Wang GC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003647; Wang WS, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-146; Weekes MP, 1999, J VIROL, V73, P2099, DOI 10.1128/JVI.73.3.2099-2108.1999; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035	42	120	122	3	34	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2020	26	2					193	+		10.1038/s41591-019-0734-6	http://dx.doi.org/10.1038/s41591-019-0734-6		FEB 2020	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	KK7DU	32042196	Green Accepted			2023-01-03	WOS:000512529400002
J	Stiell, IG; Sivilotti, MLA; Taljaard, M; Birnie, D; Vadeboncoeur, A; Hohl, CM; McRae, AD; Rowe, BH; Brison, RJ; Thiruganasambandamoorthy, V; Macle, L; Borgundvaag, B; Morris, J; Mercier, E; Clement, CM; Brinkhurst, J; Sheehan, C; Brown, E; Nemnom, MJ; Wells, GA; Perry, JJ				Stiell, Ian G.; Sivilotti, Marco L. A.; Taljaard, Monica; Birnie, David; Vadeboncoeur, Alain; Hohl, Corinne M.; McRae, Andrew D.; Rowe, Brian H.; Brison, Robert J.; Thiruganasambandamoorthy, Venkatesh; Macle, Laurent; Borgundvaag, Bjug; Morris, Judy; Mercier, Eric; Clement, Catherine M.; Brinkhurst, Jennifer; Sheehan, Connor; Brown, Erica; Nemnom, Marie-Joe; Wells, George A.; Perry, Jeffrey J.			Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial	LANCET			English	Article							CARDIOVASCULAR SOCIETY GUIDELINES; INTRAVENOUS PROCAINAMIDE; SINUS RHYTHM; ELECTRODE POSITION; FOCUSED UPDATE; MANAGEMENT; CONVERSION; EFFICACY; SAFETY; PROPAFENONE	Background Acute atrial fibrillation is the most common arrythmia treated in the emergency department. Our primary aim was to compare conversion to sinus rhythm between pharmacological cardioversion followed by electrical cardioversion (drug-shock), and electrical cardioversion alone (shock-only). Our secondary aim was to compare the effectiveness of two pad positions for electrical cardioversion. Methods We did a partial factorial trial of two protocols for patients with acute atrial fibrillation at 11 academic hospital emergency departments in Canada. We enrolled adult patients with acute atrial fibrillation. Protocol 1 was a randomised, blinded, placebo-controlled comparison of attempted pharmacological cardioversion with intravenous procainamide (15 mg/kg over 30 min) followed by electrical cardioversion if necessary (up to three shocks, each of >= 200 J), and placebo infusion followed by electrical cardioversion. For patients having electrical cardioversion, we used Protocol 2, a randomised, open-label, nested comparison of anteroposterior versus anterolateral pad positions. Patients were randomly assigned (1:1, stratified by study site) for Protocol 1 by on-site research personnel using an online electronic data capture system. Randomisation for Protocol 2 occurred 30 min after drug infusion for patients who had not converted and was stratified by site and Protocol 1 allocation. Patients and all research and emergency department staff were masked to treatment allocation for Protocol 1. The primary outcome was conversion to normal sinus rhythm for at least 30 min at any time after randomisation and up to a point immediately after three shocks. Protocol 1 was analysed by intention to treat and Protocol 2 excluded patients who did not receive electrical cardioversion. This study is registered at ClinicalTrials.gov, number NCT01891058. Findings Between July 18, 2013, and Oct 17, 2018, we enrolled 396 patients, and none were lost to follow-up. In the drug-shock group (n=204), conversion to sinus rhythm occurred in 196 (96%) patients and in the shock-only group (n=192), conversion occurred in 176 (92%) patients (absolute difference 4%; 95% CI 0-9; p=0.07). The proportion of patients discharged home was 97% (n=198) versus 95% (n=183; p=0.60). 106 (52%) patients in the drug-shock group converted after drug infusion only. No patients had serious adverse events in follow-up. The different pad positions in Protocol 2 (n=244), had similar conversions to sinus rhythm (119 [94%] of 127 in anterolateral group vs 108 [92%] of 117 in anteroposterior group; p=0.68). Interpretation Both the drug-shock and shock-only strategies were highly effective, rapid, and safe in restoring sinus rhythm for patients in the emergency department with acute atrial fibrillation, avoiding the need for return to hospital. The drug infusion worked for about half of patients and avoided the resource intensive procedural sedation required for electrical cardioversion. We also found no significant difference between the anterolateral and anteroposterior pad positions for electrical cardioversion. Immediate rhythm control for patients in the emergency department with acute atrial fibrillation leads to excellent outcomes. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Stiell, Ian G.; Thiruganasambandamoorthy, Venkatesh; Perry, Jeffrey J.] Univ Ottawa, Ottawa Hosp Res Inst, Dept Emergency Med, Ottawa, ON, Canada; [Taljaard, Monica; Clement, Catherine M.; Brinkhurst, Jennifer; Sheehan, Connor; Brown, Erica; Nemnom, Marie-Joe] Univ Ottawa, Ottawa Hosp Res Inst, Clin Epidemiol Program, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada; [Sivilotti, Marco L. A.; Brison, Robert J.] Queens Univ, Dept Emergency Med, Kingston, ON, Canada; [Birnie, David] Univ Ottawa, Div Cardiol, Ottawa, ON, Canada; [Wells, George A.] Univ Ottawa, Inst Heart, Ottawa, ON, Canada; [Vadeboncoeur, Alain; Macle, Laurent] Univ Montreal, Inst Cardiol Montreal, Montreal, PQ, Canada; [Morris, Judy] Univ Montreal, Dept Family Med & Emergency Med, Montreal, PQ, Canada; [Hohl, Corinne M.] Univ British Columbia, Dept Emergency Med, Ctr Clin Epidemiol & Evaluat, Vancouver Coastal Hlth Res Inst, Vancouver, BC, Canada; [McRae, Andrew D.] Univ Calgary, Dept Emergency Med, Calgary, AB, Canada; [McRae, Andrew D.] Univ Calgary, Community Hlth Sci, Calgary, AB, Canada; [Rowe, Brian H.] Univ Alberta, Dept Emergency Med, Edmonton, AB, Canada; [Rowe, Brian H.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; [Borgundvaag, Bjug] Univ Toronto, Div Emergency Med, Schwartz Reisman Emergency Med Inst, Mt Sinai Hosp, Toronto, ON, Canada; [Mercier, Eric] Univ Laval, Dept Family Med & Emergency Med, Ctr Rech, CHU Quebec, Quebec City, PQ, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Queens University - Canada; University of Ottawa; University of Ottawa; University of Ottawa Heart Institute; Universite de Montreal; Institut de Cardiologie de Montreal; Universite de Montreal; University of British Columbia; Vancouver Coastal Health Research Institute; University of Calgary; University of Calgary; University of Alberta; University of Alberta; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Laval University	Stiell, IG (corresponding author), Ottawa Hosp, Clin Epidemiol Unit, F657, Ottawa, ON K1Y 4E9, Canada.	istiell@ohri.ca	Macle, laurent/AAA-4675-2021; Sivilotti, Marco L.A./AAR-8892-2020; Hohl, Corinne M/AAY-3325-2021; Borgundvaag, Bjug/AAH-4446-2020; Borgundvaag, Bjug/AAE-8228-2020	Macle, laurent/0000-0002-3328-5239; Sivilotti, Marco L.A./0000-0001-6641-1118; Hohl, Corinne M/0000-0002-9210-7838; Taljaard, Monica/0000-0002-3978-8961; Nemnom, Marie-Joe/0000-0002-0102-1984	Heart and Stroke Foundation of Canada; Canadian Institutes of Health Research	Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Heart and Stroke Foundation of Canada and the Canadian Institutes of Health Research.	Airaksinen KEJ, 2013, J AM COLL CARDIOL, V62, P1187, DOI 10.1016/j.jacc.2013.04.089; Andrade JG, 2018, CAN J CARDIOL, V34, P1371, DOI 10.1016/j.cjca.2018.08.026; Brazdzionyte Julija, 2006, Medicina (Kaunas), V42, P994; Breslow N E, 1980, IARC Sci Publ, P5; Burton JH, 2004, ANN EMERG MED, V44, P20, DOI 10.1016/j.annemergmed.2004.02.016; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee, 2011, CAN J CARDIOL, V27, P1; Chan TB., 2001, EMERGENCY DEP SERVIC; Connors S, 1997, CAN J CARDIOL, V13, pA19; Decker WW, 2008, ANN EMERG MED, V52, P322, DOI 10.1016/j.annemergmed.2007.12.015; Domanovits H, 2000, RESUSCITATION, V45, P181, DOI 10.1016/S0300-9572(00)00180-5; Fay MP, 2001, BIOMETRICS, V57, P1198, DOI 10.1111/j.0006-341X.2001.01198.x; FENSTER PE, 1983, AM HEART J, V106, P501, DOI 10.1016/0002-8703(83)90692-0; FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.2307/2336755; FULHAM MJ, 1984, ANAESTH INTENS CARE, V12, P121, DOI 10.1177/0310057X8401200206; Geninatti M, 1990, J Emerg Med, V8, P209, DOI 10.1016/0736-4679(90)90236-O; HALPERN SW, 1980, BRIT HEART J, V44, P589; January CT, 2019, J AM COLL CARDIOL, V74, P104, DOI 10.1016/j.jacc.2019.01.011; Joseph AP, 2000, ANN EMERG MED, V36, P1, DOI 10.1067/mem.2000.107655; Kochiadakis GE, 1998, CARDIOVASC DRUG THER, V12, P75, DOI 10.1023/A:1007714203984; Kochiadakis GE, 2007, AM J CARDIOL, V99, P1721, DOI 10.1016/j.amjcard.2007.01.059; MADRID AH, 1993, EUR HEART J, V14, P1127, DOI 10.1093/eurheartj/14.8.1127; Mattioli AV, 1998, CLIN CARDIOL, V21, P763, DOI 10.1002/clc.4960211013; Michael JA, 1999, ANN EMERG MED, V33, P379, DOI 10.1016/S0196-0644(99)70300-8; Munoz-Martinez T, 2010, MED INTENSIVA, V34, P225, DOI 10.1016/j.medin.2009.10.004; Pitts Stephen R, 2008, Natl Health Stat Report, P1; Pluymaekers NAHA, 2019, NEW ENGL J MED, V380, P1499, DOI 10.1056/NEJMoa1900353; Rogenstein C, 2012, ACAD EMERG MED, V19, P1255, DOI 10.1111/acem.12016; Rozen G, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009024; Scheuermeyer FX, 2011, ANN EMERG MED, V57, P564, DOI 10.1016/j.annemergmed.2010.09.027; Scheuermeyer FX, 2010, ACAD EMERG MED, V17, P408, DOI 10.1111/j.1553-2712.2010.00697.x; Siaplaouras S, 2005, AM HEART J, V150, P150, DOI 10.1016/j.ahj.2004.08.009; Stanaitiene G, 2008, MEDICINA-LITHUANIA, V44, P665, DOI 10.3390/medicina44090085; Stiell IG, 2007, ACAD EMERG MED, V14, P1158, DOI 10.1197/j.aem.2007.07.016; Stiell IG, 2018, CAN J EMERG MED, V20, P334, DOI 10.1017/cem.2018.26; Stiell IG, 2017, ANN EMERG MED, V69, P562, DOI 10.1016/j.annemergmed.2016.10.013; Stiell IG, 2015, CAN J CARDIOL, V31, P239, DOI 10.1016/j.cjca.2014.11.027; Stiell IG, 2011, CAN J CARDIOL, V27, P38, DOI 10.1016/j.cjca.2010.11.014; Stiell IG, 2011, ANN EMERG MED, V57, P13, DOI 10.1016/j.annemergmed.2010.07.005; Stiell IG, 2010, CAN J EMERG MED, V12, P181; Taylor David McD, 2005, Emerg Med Australas, V17, P4, DOI 10.1111/j.1742-6723.2005.00687.x; Truchanwicz E, 2016, EUR HEART J, V37, P583; Verma A, 2014, CAN J CARDIOL, V30, P1114, DOI 10.1016/j.cjca.2014.08.001; Walsh SJ, 2005, EUR HEART J, V26, P1298, DOI 10.1093/eurheartj/ehi196; Xanthos T, 2007, Minerva Cardioangiol, V55, P433; Zhang BW, 2014, ARCH CARDIOVASC DIS, V107, P280, DOI 10.1016/j.acvd.2014.04.002	45	36	36	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 1	2020	395	10221					339	349						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH7WI	32007169				2023-01-03	WOS:000510860200034
J	Akilimali, PZ; Hernandez, J; Anglewicz, P; Kayembe, KP; Bertrand, J				Akilimali, P. Z.; Hernandez, J.; Anglewicz, P.; Kayembe, K. P.; Bertrand, J.			Incidence and determinants of Implanon discontinuation: Findings from a prospective cohort study in three health zones in Kinshasa, DRC	PLOS ONE			English	Article							VAGINAL BLEEDING PATTERNS; QUALITY-OF-CARE; CONTRACEPTIVE METHODS; RATES; WOMEN	Background Kinshasa is Africa's third largest city and one of the continent's most rapidly growing urban areas. PMA2020 data showed that Kinshasa has a modern contraceptive prevalence of 26.5% among married women in 2018. In Kinshasa's method mix, the contraceptive implant recently became the dominant method among contraceptive users married and in union. This study provides insight into patterns of implant use in a high-fertility setting by evaluating the 24-month continuation rate for Implanon NXT and identifying the characteristics associated with discontinuation. Methodology This community-based, prospective cohort study followed 531 Implanon users aged 18-49 years at 6, 12 and 24 months. The following information was collected: socio-demographic characteristics, Method Information Index (MII) and contraceptive history. The main outcome variable for this study was implant discontinuation. The incidence rate of discontinuation is presented as events per 1000 person/months (p-m), from the date of enrolment. The Cox proportional hazards modelling was used to measure predictors of discontinuation. Results A total of 9158.13 p-m were available for analysis, with an overall incidence rate of 9.06 (95% CI: 9.04-9.08) removals per 1000 p-m. Of nine possible co-variates tested, the likelihood of discontinuation was higher among women who lived in military camps, had less than three children, never used injectables or implants in the past, had experienced heavy/prolonged bleeding, and whose MII score was less than 3. Conclusion In addition to four client characteristics that predicted discontinuation, we identified one programmatic factor: quality of counseling as measured by the Method Information Index. Community providers in similar contexts should pay more attention to clients having less than three children, new adopters, and to clients living military camps as underserved population, where clients have less access to health facilities. More targeted counselling and follow-up is needed, especially on bleeding patterns.	[Akilimali, P. Z.; Kayembe, K. P.] Univ Kinshasa, Kinshasa Sch Publ Hlth, Kinshasa, DEM REP CONGO; [Hernandez, J.; Bertrand, J.] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA; [Anglewicz, P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA	Universite de Kinshasa; Tulane University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Akilimali, PZ (corresponding author), Univ Kinshasa, Kinshasa Sch Publ Hlth, Kinshasa, DEM REP CONGO.	pierretulanefp@gmail.com			NIH Fogarty International Center [D43TW009340]; Bill and Melinda Gates Foundation [OPP1128892]; UNFPA [COD04CSF]	NIH Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); UNFPA	APZ: received grant from NIH Fogarty International Center, (grant number #D43TW009340) for his PostDOC program JB received funding to implement the distribution of contraceptive methods at the community level from the Bill and Melinda Gates Foundation (OPP1128892), and UNFPA (Project ID COD04CSF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Affandi B, 1998, CONTRACEPTION, V58, p99S, DOI 10.1016/S0010-7824(98)00123-1; Akilimali P, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022295; [Anonymous], 2015, WORLD POP PROSP 2015; [Anonymous], 2014, ENQ DEM SANT REP DEM; Balogun OR, 2014, J MED BIOMED SCI, V3, P1, DOI 10.4314/jmbs.v3i1.1; Barden-O'Fallon J, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0529-9; BELSEY EM, 1988, CONTRACEPTION, V38, P207, DOI 10.1016/0010-7824(88)90039-X; BELSEY EM, 1986, CONTRACEPTION, V34, P253, DOI 10.1016/0010-7824(86)90006-5; Chakraborty NM, 2019, GLOB HEALTH-SCI PRAC, V7, P87, DOI 10.9745/GHSP-D-18-00407; Chang KT, 2019, STUD FAMILY PLANN, V50, P25, DOI 10.1111/sifp.12081; Chaudhuri SK., 2000, PRACTICE FERTILITY C; Choi Y, 2018, STUD FAMILY PLANN, V49, P23, DOI 10.1111/sifp.12044; Croxatto HB, 1999, HUM REPROD, V14, P976, DOI 10.1093/humrep/14.4.976; DATEY S, 1995, CONTRACEPTION, V51, P155, DOI 10.1016/0010-7824(95)00012-Y; Ezegwui HU, 2010, NIGER J MED, V20, P448; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Halpern V, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004317.pub2; Hardee K, 2014, STUD FAMILY PLANN, V45, P1, DOI 10.1111/j.1728-4465.2014.00373.x; Harvey C, 2009, CONTRACEPTION, V80, P527, DOI 10.1016/j.contraception.2009.05.132; Hubacher D, 1999, CONTRACEPTION, V60, P345, DOI 10.1016/S0010-7824(99)00104-3; Jain Anrudh K, 2013, Int Perspect Sex Reprod Health, V39, P133, DOI 10.1363/3913313; Jain AK, 2012, J BIOSOC SCI, V44, P27, DOI 10.1017/S0021932011000460; Kaplan B, 2005, EUR J OBSTET GYN R B, V123, P72, DOI 10.1016/j.ejogrb.2005.06.033; Kenya National Bureau of Statistics (KNBS) and ICF Macro, 2015, KEN DEM HLTH SURV KE; Koenig MA, 1997, STUD FAMILY PLANN, V28, P278, DOI 10.2307/2137859; Kulier R, 2007, COCHRANE DB SYST REV; Lei ZW, 1996, CONTRACEPTION, V53, P357, DOI 10.1016/0010-7824(96)00085-6; Maina SW, 2016, AFR J PHARM THER, V5, P28; Mansour D, 2008, EUR J CONTRACEP REPR, V13, P13, DOI 10.1080/13625180801959931; Melese S, 2015, IMPLANON DISCONTINUA; Ministere du Plan Macro International., 2008, ENQ DEM SANT REP DEM; PARIANI S, 1991, STUD FAMILY PLANN, V22, P384, DOI 10.2307/1966452; Performance Monitoring and Accountability 2020 (PMA2020), 2016, PERF MONT ACC 2020 P; RamaRao S, 2003, STUD FAMILY PLANN, V34, P227, DOI 10.1111/j.1728-4465.2003.00227.x; Smith A, 2002, J FAM PLAN REPROD H, V28, P193, DOI 10.1783/147118902101196540; Tolesa Bekele, 2015, Epidemiology: Open Access, V5, P179; Tolley E, 2005, INT FAM PLAN PERSPEC, V31, P15, DOI 10.1363/3101505; Uganda Bureau of Statistics, 2012, UG DEM HLTH SURV 201; United Nations Human Settlements Programme (UN -Habitat), 2003, CHALL SLUMS GLOB REP; World Health Organization, 1993, CONTR METH MIX GUID; Zambia Statistics Agency Ministry of Health Zambia ICF., 2019, ZAMB DEM HLTH SURV 2; Zimbabwe National Statistics Agency (ZIMSTAT) and ICF International, 2012, ZIMB DEM HLTH SURV 2	42	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2020	15	5							e0232582	10.1371/journal.pone.0232582	http://dx.doi.org/10.1371/journal.pone.0232582			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU0RD	32392216	gold, Green Published			2023-01-03	WOS:000537470300012
J	Fiedler, MO; Deutsch, BL; Simeliunas, E; Diktanaite, D; Harms, A; Brune, M; Uhle, F; Weigand, M; Brenner, T; Kalenka, A				Fiedler, Mascha O.; Deutsch, B. Luise; Simeliunas, Emilis; Diktanaite, Dovile; Harms, Alexander; Brune, Maik; Uhle, Florian; Weigand, Markus; Brenner, Thorsten; Kalenka, Armin			Effect of moderate elevated intra-abdominal pressure on lung mechanics and histological lung injury at different positive end-expiratory pressures	PLOS ONE			English	Article							ABDOMINAL COMPARTMENT SYNDROME; HYPERTENSION; DEFINITIONS; SOCIETY; OBESE	Introduction Intra-abdominal hypertension (IAH) is a well-known phenomenon in critically ill patients. Effects of a moderately elevated intra-abdominal pressure (IAP) on lung mechanics are still not fully analyzed. Moreover, the optimal positive end-expiratory pressure (PEEP) in elevated IAP is unclear. Methods We investigated changes in lung mechanics and transformation in histological lung patterns using three different PEEP levels in eighteen deeply anesthetized pigs with an IAP of 10 mmHg. After establishing the intra-abdominal pressure, we randomized the animals into 3 groups. Each of n = 6 (Group A = PEEP 5, B = PEEP 10 and C = PEEP 15 cmH(2)O). End-expiratory lung volume (EELV/kg body weight (bw)), pulmonary compliance (C-stat), driving pressure (Delta P) and transpulmonary pressure (Delta P-L) were measured for 6 hours. Additionally, the histological lung injury score was calculated. Results Comparing hours 0 and 6 in group A, there was a decrease of EELV/kg (27 +/- 2 vs. 16 +/- 1 ml/kg; p<0.05) and of C-stat (42 +/- 2 vs. 27 +/- 1 ml/cmH(2)O; p<0.05) and an increase of Delta P (11 +/- 0 vs. 17 +/- 1 cmH(2)O; p<0.05) and Delta P-L (6 +/- 0 vs. 10 +/- 1 cmH(2)O; p<0.05). In group B, there was no significant change in EELV/kg (27 +/- 3 vs. 24 +/- 3 ml/kg), but a decrease in Cstat (42 +/- 3 vs. 32 +/- 1 ml/cmH(2)O; p<0.05) and an increase in Delta P (11 +/- 1 vs. 15 +/- 1 cmH(2)O; p<0.05) and.PL (5 +/- 1 vs. 7 +/- 0 cmH(2)O; p< 0.05). In group C, there were no significant changes in EELV/kg (27 +/- 2 vs. 29 +/- 3 ml/kg), Delta P (10 +/- 1 vs. 12 +/- 1 cmH(2)O) and.PL (5 +/- 1 vs. 7 +/- 1 cmH(2)O), but a significant decrease of Cstat (43 +/- 1 vs. 37 +/- 1 ml/cmH(2)O; p<0.05). Histological lung injury score was lowest in group B. Conclusions A moderate elevated IAP of 10 mmHg leads to relevant changes in lung mechanics during mechanical ventilation. In our study, a PEEP of 10 cmH(2)O was associated with a lower lung injury score and was able to overcome the IAP induced alterations of EELV.	[Fiedler, Mascha O.; Simeliunas, Emilis; Diktanaite, Dovile; Uhle, Florian; Weigand, Markus; Brenner, Thorsten] Heidelberg Univ Hosp, Dept Anesthesiol, Heidelberg, Germany; [Deutsch, B. Luise] Justus Liebig Univ, Fac Med, Giessen, Germany; [Harms, Alexander] Heidelberg Univ Hosp, Inst Pathol, Heidelberg, Germany; [Brune, Maik] Heidelberg Univ Hosp, Dept Internal Med & Clin Chem 1, Heidelberg, Germany; [Kalenka, Armin] Dept Anesthesiol & Intens Care Med, Hosp Bergstr, Heppenheim, Germany; [Kalenka, Armin] Heidelberg Univ, Fac Med, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Kalenka, A (corresponding author), Dept Anesthesiol & Intens Care Med, Hosp Bergstr, Heppenheim, Germany.; Kalenka, A (corresponding author), Heidelberg Univ, Fac Med, Heidelberg, Germany.	armin.kalenka@med.uni-heidelberg.de						BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788; Blaser AR, 2019, CRIT CARE MED, V47, P535, DOI 10.1097/CCM.0000000000003623; Cortes-Puentes GA, 2013, CRIT CARE MED, V41, P1870, DOI 10.1097/CCM.0b013e31828a3bea; Fumagalli J, 2017, CRIT CARE MED, V45, P1374, DOI 10.1097/CCM.0000000000002460; Grieco DL, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.07.22; Hedenstierna G, 2012, CURR OPIN CRIT CARE, V18, P80, DOI 10.1097/MCC.0b013e32834e7c3a; Jakob SM, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-70; Kirkpatrick AW, 2013, INTENS CARE MED, V39, P1190, DOI 10.1007/s00134-013-2906-z; Krebs J, 2009, CRIT CARE, V13, DOI 10.1186/cc8118; Malbrain MLNG, 2014, MINERVA ANESTESIOL, V80, P293; Malbrain MLNG, 2007, INTENS CARE MED, V33, P1869, DOI 10.1007/s00134-007-0843-4; Malbrain MLNG, 2006, INTENS CARE MED, V32, P1722, DOI 10.1007/s00134-006-0349-5; Malbrain MLNG, 2006, CRIT CARE, V10, DOI 10.1186/cc4962; Malbrain MLNG, 2018, J CRIT CARE, V43, P387, DOI 10.1016/j.jcrc.2017.11.013; Malbrain MLNG, 2015, ANAESTH INTENSIVE TH, V47, P228, DOI 10.5603/AIT.a2015.0021; Malbrain MLNG, 2013, BEST PRACT RES-CLIN, V27, P249, DOI 10.1016/j.bpa.2013.06.009; Malbrain MLNG, 2005, CRIT CARE MED, V33, P315, DOI 10.1097/01.CCM.0000153408.09806.1B; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; MUTOH T, 1991, J APPL PHYSIOL, V70, P2611, DOI 10.1152/jappl.1991.70.6.2611; Olegard C, 2005, ANESTH ANALG, V101, P206, DOI 10.1213/01.ANE.0000165823.90368.55; Pelosi P, 2007, ACTA CLIN BELG, V62, P78, DOI 10.1179/acb.2007.62.s1.011; Pelosi P, 1997, J APPL PHYSIOL, V82, P811, DOI 10.1152/jappl.1997.82.3.811; Pelosi P, 1999, ANESTHESIOLOGY, V91, P1221, DOI 10.1097/00000542-199911000-00011; Regli A, 2018, J CRIT CARE, V43, P390, DOI 10.1016/j.jcrc.2017.10.012; Regli A, 2017, INTENS CARE MED EXP, V5, DOI 10.1186/s40635-017-0124-7; Regli A, 2012, CRIT CARE MED, V40, P1879, DOI 10.1097/CCM.0b013e31824e0e80; Regli A, 2010, CRIT CARE, V14, DOI 10.1186/cc9095; Rogers WK, 2018, CHEST, V153, P238, DOI 10.1016/j.chest.2017.07.023; Silva PL, 2015, BEST PRACT RES-CLIN, V29, P301, DOI 10.1016/j.bpa.2015.08.004; Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707; TSUNO K, 1991, AM REV RESPIR DIS, V143, P1115, DOI 10.1164/ajrccm/143.5_Pt_1.1115; Wauters J, 2007, ACTA CLIN BELG, V62, P200, DOI 10.1179/acb.2007.62.s1.026; Wauters J, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/763181	33	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2020	15	4							e0230830	10.1371/journal.pone.0230830	http://dx.doi.org/10.1371/journal.pone.0230830			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9GL	32294090	Green Published, gold, Green Submitted			2023-01-03	WOS:000536003500013
J	Tap, WD; Wagner, AJ; Schoffski, P; Martin-Broto, J; Krarup-Hansen, A; Ganjoo, KN; Yen, CC; Razak, AAR; Spira, A; Kawai, A; Le Cesne, A; Van Tine, BA; Naito, Y; Park, SH; Fedenko, A; Papai, Z; Soldatenkova, V; Shahir, A; Mo, G; Wright, J; Jones, RL				Tap, William D.; Wagner, Andrew J.; Schoffski, Patrick; Martin-Broto, Javier; Krarup-Hansen, Anders; Ganjoo, Kristen N.; Yen, Chueh-Chuan; Razak, Albiruni R.; Spira, Alexander; Kawai, Akira; Le Cesne, Axel; Van Tine, Brian A.; Naito, Yoichi; Park, Se Hoon; Fedenko, Alexander; Papai, Zsuzsanna; Soldatenkova, Victoria; Shahir, Ashwin; Mo, Gary; Wright, Jennifer; Jones, Robin L.		ANNOUNCE Investigators	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	55th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)	MAY 31-JUN 04, 2019	Chicago, IL	Amer Soc Clin Oncol			1ST-LINE TREATMENT; OPEN-LABEL	Question In patients with advanced soft tissue sarcoma (STS), does the addition of olaratumab to doxorubicin improve overall survival? Findings In this randomized clinical trial of 509 adults with advanced STS, there was no significant difference in overall survival between patients who received doxorubicin plus olaratumab and patients who received doxorubicin plus placebo in the total STS and leiomyosarcoma populations (total STS: hazard ratio, 1.05; median, 20.4 vs 19.7 months; leiomyosarcoma: hazard ratio, 0.95; median, 21.6 vs 21.9 months). Meaning There was no significant difference in overall survival with the addition of olaratumab to doxorubicin in patients with advanced STS. Importance Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxorubicin alone. Objective To determine the efficacy of doxorubicin plus olaratumab in patients with advanced/metastatic STS. Design, Setting, and Participants ANNOUNCE was a confirmatory, phase 3, double-blind, randomized trial conducted at 110 sites in 25 countries from September 2015 to December 2018; the final date of follow-up was December 5, 2018. Eligible patients were anthracycline-naive adults with unresectable locally advanced or metastatic STS, an Eastern Cooperative Oncology Group performance status of 0 to 1, and cardiac ejection fraction of 50% or greater. Interventions Patients were randomized 1:1 to receive doxorubicin, 75 mg/m(2) (day 1), combined with olaratumab (n = 258), 20 mg/kg in cycle 1 and 15 mg/kg in subsequent cycles, or placebo (n = 251) on days 1 and 8 for up to 8 21-day cycles, followed by olaratumab/placebo monotherapy. Main Outcomes and Measures Dual primary end points were overall survival with doxorubicin plus olaratumab vs doxorubicin plus placebo in total STS and leiomyosarcoma (LMS) populations. Results Among the 509 patients randomized (mean age, 56.9 years; 58.2% women; 46.0% with LMS), all were included in the primary analysis and had a median length of follow-up of 31 months. No statistically significant difference in overall survival was observed between the doxorubicin plus olaratumab group vs the doxorubicin plus placebo group in either population (total STS: hazard ratio, 1.05 [95% CI, 0.84-1.30], P = .69, median overall survival, 20.4 months vs 19.7 months; LMS: hazard ratio, 0.95 [95% CI, 0.69-1.31], P = .76, median overall survival, 21.6 months vs 21.9 months). Adverse events of grade 3 or greater reported in 15% or more of total patients with STS were neutropenia (46.3% vs 49.0%), leukopenia (23.3% vs 23.7%), and febrile neutropenia (17.5% vs 16.5%). Conclusions and Relevance In this phase 3 clinical trial of patients with advanced STS, treatment with doxorubicin plus olaratumab vs doxorubicin plus placebo resulted in no significant difference in overall survival. The findings did not confirm the overall survival benefit observed in the phase 2 trial. This randomized trial compares the effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on overall survival in patients with advanced/metastatic soft tissue sarcoma and leiomyosarcoma. (c) 2020 American Medical Association. All rights reserved.	[Tap, William D.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA; [Tap, William D.] Weill Cornell Med Coll, Dept Med, New York, NY USA; [Wagner, Andrew J.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Wagner, Andrew J.] Harvard Med Sch, Boston, MA 02115 USA; [Schoffski, Patrick] Univ Hosp Leuven, Leuven Canc Inst, Dept Gen Med Oncol, Leuven, Belgium; [Martin-Broto, Javier] Univ Seville, Univ Hosp Virgen Rocio, Med Oncol Dept, Seville, Spain; [Martin-Broto, Javier] Univ Seville, CSIC, HUVR, Inst Biomed Sevilla IBIS, Seville, Spain; [Krarup-Hansen, Anders] Univ Copenhagen, Copenhagen, Denmark; [Ganjoo, Kristen N.] Stanford Univ, Stanford, CA 94305 USA; [Yen, Chueh-Chuan] Taipei Vet Gen Hosp, Dept Oncol, Ctr Immunooncol, Div Med Oncol, Taipei, Taiwan; [Yen, Chueh-Chuan] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Razak, Albiruni R.] Princess Margaret Canc Ctr, Toronto, ON, Canada; [Spira, Alexander] Virginia Canc Specialists, Fairfax, VA USA; [Kawai, Akira] Natl Canc Ctr, Tokyo, Japan; [Le Cesne, Axel] Inst Gustave Roussy, Villejuif, France; [Van Tine, Brian A.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; [Naito, Yoichi] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan; [Park, Se Hoon] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea; [Fedenko, Alexander] Blokhin Canc Res Ctr, Moscow, Russia; [Papai, Zsuzsanna] Magyar Honvedseg Eu Kp, Budapest, Hungary; [Soldatenkova, Victoria; Mo, Gary; Wright, Jennifer] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Shahir, Ashwin] Eli Lilly & Co, Windlesham, Surrey, England; [Jones, Robin L.] Royal Marsden NHS Fdn Trust, Sarcoma Unit, London, England; [Jones, Robin L.] Inst Canc Res, London, England	Memorial Sloan Kettering Cancer Center; Cornell University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; KU Leuven; University Hospital Leuven; University of Sevilla; Virgen del Rocio University Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); University of Copenhagen; Stanford University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; National Cancer Center - Japan; UNICANCER; Gustave Roussy; Washington University (WUSTL); National Cancer Center - Japan; Sungkyunkwan University (SKKU); Samsung Medical Center; N.N. Blokhin Russian Cancer Research Center; Eli Lilly; Eli Lilly; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Tap, WD (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA.	tapw@mskcc.org	Park, Se Hoon/GMX-1199-2022; Abdul Razak, Albiruni Ryan/C-4608-2015; Jones, Robin L/AAO-3738-2020; Martín-Broto, Javier/AAI-2313-2019	Park, Se Hoon/0000-0001-5084-9326; Abdul Razak, Albiruni Ryan/0000-0001-7657-9950; Jones, Robin L/0000-0003-4173-3844; Martin-Broto, Javier/0000-0001-7350-6916	Eli Lilly and Company	Eli Lilly and Company(Eli Lilly)	All funding for the trial was provided by the sponsor, Eli Lilly and Company.	COX DR, 1972, J R STAT SOC B, V34, P187; Croswell JM, 2010, SEMIN ONCOL, V37, P202, DOI 10.1053/j.seminoncol.2010.05.006; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Holzer TR, 2016, J HISTOCHEM CYTOCHEM, V64, P785, DOI 10.1369/0022155416673979; Jones RL, 2019, ANN ONCOL, V30, DOI [10.1093/annonc/mdz283.004, DOI 10.1093/ANNONC/MDZ283.004]; Jones RL, 2019, CANCER CHEMOTH PHARM, V83, P191, DOI 10.1007/s00280-018-3723-4; Judson I, 2014, LANCET ONCOL, V15, P415, DOI 10.1016/S1470-2045(14)70063-4; Kramer BS, 2009, ANNU REV MED, V60, P125, DOI 10.1146/annurev.med.60.101107.134802; Lahat G, 2008, ANN SURG ONCOL, V15, P2739, DOI 10.1245/s10434-008-9970-6; Lartruvo, 2018, HIGHL PRESCR INF; Maurer W, 2013, STAT BIOPHARM RES, V5, P311, DOI 10.1080/19466315.2013.807748; Papadopoulos N, 2018, MOL ASPECTS MED, V62, P75, DOI 10.1016/j.mam.2017.11.007; Ryan CW, 2016, J CLIN ONCOL, V34, P3898, DOI 10.1200/JCO.2016.67.6684; Sbaraglia M, 2019, RADIOL MED, V124, P266, DOI 10.1007/s11547-018-0882-7; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Seddon B, 2017, LANCET ONCOL, V18, P1397, DOI 10.1016/S1470-2045(17)30622-8; Tap WD, 2016, LANCET, V388, P464, DOI 10.1016/S0140-6736(16)30587-6; Tap WD, 2017, LANCET ONCOL, V18, P1089, DOI 10.1016/S1470-2045(17)30381-9	18	129	129	7	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2020	323	13					1266	1276		10.1001/jama.2020.1707	http://dx.doi.org/10.1001/jama.2020.1707			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	LE3DZ	32259228	Green Published, Bronze			2023-01-03	WOS:000526602700016
J	Dhital, S; Vyavahare, NR				Dhital, Saphala; Vyavahare, Naren R.			Nanoparticle-based targeted delivery of pentagalloyl glucose reverses elastase-induced abdominal aortic aneurysm and restores aorta to the healthy state in mice	PLOS ONE			English	Article							TRANSFORMING-GROWTH-FACTOR; LOADED ALBUMIN NANOPARTICLES; MOUSE MODEL; PROGRESSION; THERAPY; CALCIFICATION; MACROPHAGES; INHIBITION; POLYPHENOL; PREVENTION	Aim Abdominal aortic aneurysms (AAA) is a life-threatening weakening and expansion of the abdominal aorta due to inflammatory cell infiltration and gradual degeneration of extracellular matrix (ECM). There are no pharmacological therapies to treat AAA. We tested the hypothesis that nanoparticle (NP) therapy that targets degraded elastin and delivers anti-inflammatory, anti-oxidative, and ECM stabilizing agent, pentagalloyl glucose (PGG) will reverse advance stage aneurysm in an elastase-induced mouse model of AAA. Method and results Porcine pancreatic elastase (PPE) was applied periadventitially to the infrarenal aorta in mice and AAA was allowed to develop for 14 days. Nanoparticles loaded with PGG (EL-PGG-NPs) were then delivered via IV route at 14-day and 21-day (10 mg/kg of body weight). A control group of mice received no therapy. The targeting of NPs to the AAA site was confirmed with fluorescent dye marked NPs and gold NPs. Animals were sacrificed at 28-d. We found that targeted PGG therapy reversed the AAA by decreasing matrix metalloproteinases MMP-9 and MMP-2, and the infiltration of macrophages in the medial layer. The increase in diameter of the aorta was reversed to healthy controls. Moreover, PGG treatment restored degraded elastic lamina and increased the circumferential strain of aneurysmal aorta to the healthy levels. Conclusion Our results support that site-specific delivery of PGG with targeted nanoparticles can be used to treat already developed AAA. Such therapy can reverse inflammatory markers and restore arterial homeostasis.	[Dhital, Saphala; Vyavahare, Naren R.] Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA	Clemson University	Vyavahare, NR (corresponding author), Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA.	narenv@clemson.edu		Vyavahare, Naren/0000-0002-4889-6542; Dhital, Saphala/0000-0001-5566-0733	National Institutes of Health (NIH) [R01HL133662, R01HL145064, P20GM103444, P30GM131959]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study is supported by the grants from the National Institutes of Health (NIH) (R01HL133662, R01HL145064, P20GM103444, P30GM131959 to NRV).	Ailawadi G, 2009, J THORAC CARDIOV SUR, V138, P1392, DOI 10.1016/j.jtcvs.2009.07.075; An FF, 2017, THERANOSTICS, V7, P3667, DOI 10.7150/thno.19365; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; Benjamin Mina M, 2012, Exp Suppl, V103, P209, DOI 10.1007/978-3-0348-0364-9_7; Bhamidipati CM, 2012, SURGERY, V152, P238, DOI 10.1016/j.surg.2012.02.010; Bigatel DA, 1999, J VASC SURG, V29, P130, DOI 10.1016/S0741-5214(99)70354-X; Chen Jeff Z, 2019, Circ Rep, V1, P199, DOI 10.1253/circrep.CR-18-0012; Cocciolone AJ, 2018, AM J PHYSIOL-HEART C, V315, pH189, DOI 10.1152/ajpheart.00087.2018; Cook JR, 2015, ARTERIOSCL THROM VAS, V35, P911, DOI 10.1161/ATVBAHA.114.305150; Dale MA, 2016, J IMMUNOL, V196, P4536, DOI 10.4049/jimmunol.1502454; Dale MA, 2015, ATHEROSCLEROSIS, V243, P621, DOI 10.1016/j.atherosclerosis.2015.10.006; Dhital S, 2017, CELL IMMUNOL, V312, P25, DOI 10.1016/j.cellimm.2016.11.006; Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287; Horiguchi M, 2012, J BIOCHEM, V152, P321, DOI 10.1093/jb/mvs089; Isenburg JC, 2007, CIRCULATION, V115, P1729, DOI 10.1161/CIRCULATIONAHA.106.672873; Karamched SR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39639-8; Kloesch B, 2013, INT IMMUNOPHARMACOL, V15, P400, DOI 10.1016/j.intimp.2013.01.003; Lareyre F, 2017, ARTERIOSCL THROM VAS, V37, P2171, DOI 10.1161/ATVBAHA.117.309999; Lei Y, 2014, J CONTROL RELEASE, V196, P79, DOI 10.1016/j.jconrel.2014.09.029; Liu ZZ, 2018, INT J MOL MED, V42, P3395, DOI 10.3892/ijmm.2018.3923; Longo GM, 2002, J CLIN INVEST, V110, P625, DOI 10.1172/JCI200215334; Merodio M, 2001, EUR J PHARM SCI, V12, P251, DOI 10.1016/S0928-0987(00)00169-X; Minami K, 2018, EXP THER MED, V15, P4465, DOI 10.3892/etm.2018.5959; Nordon IM, 2011, NAT REV CARDIOL, V8, P92, DOI 10.1038/nrcardio.2010.180; Nosoudi N, 2016, J CARDIOVASC TRANSL, V9, P445, DOI 10.1007/s12265-016-9709-x; Nosoudi N, 2016, THERANOSTICS, V6, P1975, DOI 10.7150/thno.16547; Nosoudi N, 2015, CIRC RES, V117, pE80, DOI 10.1161/CIRCRESAHA.115.307207; Parasaram V, 2018, BIOCHEM BIOPH RES CO, V499, P24, DOI 10.1016/j.bbrc.2018.03.100; Patnaik SS, 2019, BIOENGINEERING-BASEL, V6, DOI 10.3390/bioengineering6030058; Patnaik SS, 2019, ANN BIOMED ENG, V47, P39, DOI 10.1007/s10439-018-02145-5; Philips N, 2010, J COSMET SCI, V61, P125; Raffort J, 2017, NAT REV CARDIOL, V14, P457, DOI 10.1038/nrcardio.2017.52; SAGE H, 1979, COMP BIOCHEM PHYS B, V64, P313, DOI 10.1016/0305-0491(79)90277-3; Setozaki S, 2017, J VASC SURG, V65, P1803, DOI 10.1016/j.jvs.2016.06.003; Sinha A, 2014, BIOCHEM BIOPH RES CO, V444, P205, DOI 10.1016/j.bbrc.2014.01.027; Sivaraman B, 2012, DRUG DELIV TRANSL RE, V2, P323, DOI 10.1007/s13346-012-0070-6; Uemura Y, 1997, BIOCHEM MOL BIOL INT, V41, P1085; Wang C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09674-4; Wang XY, 2019, THERANOSTICS, V9, P4156, DOI 10.7150/thno.34441; Wynn TA, 2010, SEMIN LIVER DIS, V30, P245, DOI 10.1055/s-0030-1255354	40	16	16	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2020	15	3							e0227165	10.1371/journal.pone.0227165	http://dx.doi.org/10.1371/journal.pone.0227165			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8GU	32218565	Green Published, gold, Green Submitted			2023-01-03	WOS:000535935400001
J	Ouyang, DJ; Lief, L; Russell, D; Xu, JH; Berlin, DA; Gentzler, E; Su, A; Cooper, ZR; Senglaub, SS; Maciejewski, PK; Prigerson, HG				Ouyang, Daniel J.; Lief, Lindsay; Russell, David; Xu, Jiehui; Berlin, David A.; Gentzler, Eliza; Su, Amanda; Cooper, Zara R.; Senglaub, Steven S.; Maciejewski, Paul K.; Prigerson, Holly G.			Timing is everything: Early do-not-resuscitate orders in the intensive care unit and patient outcomes	PLOS ONE			English	Article							QUALITY-OF-LIFE; PALLIATIVE CARE; ADVANCED CANCER; END; DEATH; DISCUSSIONS; PREDICTORS; HEALTH; COMMUNICATION; ASSOCIATIONS	Background The use of Do-Not-Resuscitate (DNR) orders has increased but many are placed late in the dying process. This study is to determine the association between the timing of DNR order placement in the intensive care unit (ICU) and nurses' perceptions of patients' distress and quality of death. Methods 200 ICU patients and the nurses (n = 83) who took care of them during their last week of life were enrolled from the medical ICU and cardiac care unit of New York Presbyterian Hospital/Weill Cornell Medicine in Manhattan and the surgical ICU at the Brigham and Women's Hospital in Boston. Nurses were interviewed about their perceptions of the patients' quality of death using validated measures. Patients were divided into 3 groups-no DNR, early DNR, late DNR placement during the patient's final ICU stay. Logistic regression analyses modeled perceived patient quality of life as a function of timing of DNR order placement. Patient's comorbidities, length of ICU stay, and procedures were also included in the model. Results 59 patients (29.5%) had a DNR placed within 48 hours of ICU admission (early DNR), 110 (55%) placed after 48 hours of ICU admission (late DNR), and 31 (15.5%) had no DNR order placed. Compared to patients without DNR orders, those with an early but not late DNR order placement had significantly fewer non-beneficial procedures and lower odds of being rated by nurses as not being at peace (Adjusted Odds Ratio namely AOR = 0.30; [CI = 0.09-0.94]), and experiencing worst possible death (AOR = 0.31; [CI = 0.1-0.94]) before controlling for procedures; and consistent significance in severe suffering (AOR = 0.34; [CI = 0.12-0.96]), and experiencing a severe loss of dignity (AOR = 0.33; [CI = 0.12-0.94]), controlling for non-beneficial procedures. Conclusions Placement of DNR orders within the first 48 hours of the terminal ICU admission was associated with fewer non-beneficial procedures and less perceived suffering and loss of dignity, lower odds of being not at peace and of having the worst possible death.	[Ouyang, Daniel J.; Lief, Lindsay; Russell, David; Xu, Jiehui; Berlin, David A.; Gentzler, Eliza; Su, Amanda; Maciejewski, Paul K.; Prigerson, Holly G.] Weill Cornell Med, Ctr Res End Life Care, New York, NY 10065 USA; [Lief, Lindsay; Berlin, David A.; Maciejewski, Paul K.; Prigerson, Holly G.] Weill Cornell Med, Dept Med, New York, NY 10065 USA; [Russell, David] Appalachian State Univ, Dept Sociol, Boone, NC 28608 USA; [Cooper, Zara R.; Senglaub, Steven S.] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA; [Maciejewski, Paul K.] Weill Cornell Med, Dept Radiol, New York, NY USA	Cornell University; Cornell University; University of North Carolina; Appalachian State University; Harvard University; Brigham & Women's Hospital; Cornell University	Prigerson, HG (corresponding author), Weill Cornell Med, Ctr Res End Life Care, New York, NY 10065 USA.; Prigerson, HG (corresponding author), Weill Cornell Med, Dept Med, New York, NY 10065 USA.	hgp2001@med.cornell.edu	Russell, David/AAZ-6102-2020; Prigerson, Holly/GWV-3283-2022	Russell, David/0000-0001-8433-0821; Ouyang, Jie/0000-0001-5124-0504	NIH	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The corresponding author Holly Prigerson, PhD receives an R35 fund from NIH. She is the PI for the clinical trial described in the manuscript.	Adelman RD, 2014, JAMA-J AM MED ASSOC, V311, P1052, DOI 10.1001/jama.2014.304; Alsirafy SA, 2015, AM J HOSP PALLIAT ME, V32, P544, DOI 10.1177/1049909114529014; Araw AC, 2014, PALLIAT SUPPORT CARE, V12, P101, DOI 10.1017/S1478951512001010; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Bishop JP, 2010, AM J BIOETHICS, V10, P61, DOI 10.1080/15265160903469328; Burden E, 2020, POSTGRAD MED J, V96, P186, DOI 10.1136/postgradmedj-2019-136565; Chang DW, 2014, J GEN INTERN MED, V29, P1256, DOI 10.1007/s11606-014-2906-x; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Detsky ME, 2017, JAMA-J AM MED ASSOC, V317, P2187, DOI 10.1001/jama.2017.4078; Downey L, 2010, J PAIN SYMPTOM MANAG, V39, P9, DOI 10.1016/j.jpainsymman.2009.05.012; Faigle R, 2017, CRIT CARE MED, V45, P2046, DOI 10.1097/CCM.0000000000002762; Horton R, 2002, PALLIATIVE MED, V16, P488, DOI 10.1191/0269216302pm588oa; JAYES RL, 1993, JAMA-J AM MED ASSOC, V270, P2213, DOI 10.1001/jama.270.18.2213; JUDE JR, 1961, JAMA-J AM MED ASSOC, V178, P1063, DOI 10.1001/jama.1961.03040500005002; Krakauer EL, 2002, J AM GERIATR SOC, V50, P182, DOI 10.1046/j.1532-5415.2002.50027.x; Levin Tomer T, 2008, Palliat Support Care, V6, P341, DOI 10.1017/S1478951508000540; Loggers ET, 2013, J PALLIAT MED, V16, P1249, DOI 10.1089/jpm.2013.0164; Loggers ET, 2009, J CLIN ONCOL, V27, P5559, DOI 10.1200/JCO.2009.22.4733; Mack JW, 2008, CANCER-AM CANCER SOC, V112, P2509, DOI 10.1002/cncr.23476; Mack JW, 2010, J CLIN ONCOL, V28, P1203, DOI 10.1200/JCO.2009.25.4672; Maxfield M, 2007, PSYCHOL AGING, V22, P341, DOI 10.1037/0882-7974.22.2.341; Morrell ED, 2008, J MED ETHICS, V34, P642, DOI 10.1136/jme.2007.022517; Nekolaichuk CL, 1999, PALLIATIVE MED, V13, P311, DOI 10.1191/026921699675854885; Phillips RS, 2000, J AM GERIATR SOC, V48, pS1, DOI 10.1111/j.1532-5415.2000.tb03118.x; Prigerson HG, 2015, JAMA ONCOL, V1, P778, DOI 10.1001/jamaoncol.2015.2378; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; Richardson DK, 2013, RESUSCITATION, V84, P483, DOI 10.1016/j.resuscitation.2012.08.327; Scheunemann LP, 2011, CHEST, V139, P543, DOI 10.1378/chest.10-0595; Sharp T, 2013, BRIT J GEN PRACT, V63, pE657, DOI 10.3399/bjgp13X673667; Shepardson LB, 1999, J GEN INTERN MED, V14, P15, DOI 10.1046/j.1525-1497.1999.00275.x; Silvennoinen R, 2008, SPECULAR GLOSS, P53, DOI 10.1016/B978-008045314-9.50007-4; Sinuff T, 2004, CAN J ANAESTH, V51, P1034, DOI 10.1007/BF03018494; Sneeuw KCA, 2002, J CLIN EPIDEMIOL, V55, P1130, DOI 10.1016/S0895-4356(02)00479-1; Su A, 2018, J PAIN SYMPTOM MANAG, V55, P1591, DOI 10.1016/j.jpainsymman.2018.02.005; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; WENGER NS, 1995, ARCH INTERN MED, V155, P2056, DOI 10.1001/archinte.155.19.2056; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Wright AA, 2010, J CLIN ONCOL, V28, P4457, DOI 10.1200/JCO.2009.26.3863; Zhang BH, 2012, ARCH INTERN MED, V172, P1133, DOI 10.1001/archinternmed.2012.2364; Zingmond DS, 2005, ARCH INTERN MED, V165, P1705, DOI 10.1001/archinte.165.15.1705	42	12	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2020	15	2							e0227971	10.1371/journal.pone.0227971	http://dx.doi.org/10.1371/journal.pone.0227971			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ7XT	32069306	Green Published, gold			2023-01-03	WOS:000535212900037
J	Phipps, MS; Cronin, CA				Phipps, Michael S.; Cronin, Carolyn A.			Management of acute ischemic stroke	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TISSUE-PLASMINOGEN ACTIVATOR; HEALTH-CARE PROFESSIONALS; LARGE VESSEL OCCLUSION; STENT-RETRIEVER THROMBECTOMY; PLACEBO-CONTROLLED TRIAL; INDIVIDUAL PATIENT DATA; BLOOD-FLOW-VELOCITY; INTRAVENOUS T-PA; GENERAL-ANESTHESIA; ENDOVASCULAR THROMBECTOMY	Stroke is the leading cause of long term disability in developed countries and one of the top causes of mortality worldwide. The past decade has seen substantial advances in the diagnostic and treatment options available to minimize the impact of acute ischemic stroke. The key first step in stroke care is early identification of patients with stroke and triage to centers capable of delivering the appropriate treatment, as fast as possible. Here, we review the data supporting pre-hospital and emergency stroke care, including use of emergency medical services protocols for identification of patients with stroke, intravenous thrombolysis in acute ischemic stroke including updates to recommended patient eligibility criteria and treatment time windows, and advanced imaging techniques with automated interpretation to identify patients with large areas of brain at risk but without large completed infarcts who are likely to benefit from endovascular thrombectomy in extended time windows from symptom onset. We also review protocols for management of patient physiologic parameters to minimize infarct volumes and recent updates in secondary prevention recommendations including short term use of dual antiplatelet therapy to prevent recurrent stroke in the high risk period immediately after stroke. Finally, we discuss emerging therapies and questions for future research.	[Phipps, Michael S.; Cronin, Carolyn A.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; [Phipps, Michael S.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Phipps, MS (corresponding author), Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA.; Phipps, MS (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.	mphipps@som.umaryland.edu	Sharma, Vishal/B-9729-2011; Phipps, Michael S./P-3439-2019	Sharma, Vishal/0000-0003-2472-3409; Phipps, Michael S./0000-0001-8398-5404				Abou-Chebl A, 2010, STROKE, V41, P1175, DOI 10.1161/STROKEAHA.109.574129; ACR-ASNR-SIR-SNIS, 2018, ACR ASNR SIR SNIS PR; Adeoye O, 2019, STROKE, V50, pE187, DOI 10.1161/STR.0000000000000173; Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973; Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976; Alberts MJ, 2015, JAMA NEUROL, V72, P1101, DOI 10.1001/jamaneurol.2015.1743; Alexandrov AW, 2018, NEUROLOGY, V90, P885, DOI 10.1212/WNL.0000000000005481; Almekhlafi MA, 2019, STROKE, V50, P2118, DOI 10.1161/STROKEAHA.118.023102; Anderson CS, 2017, NEW ENGL J MED, V376, P2437, DOI 10.1056/NEJMoa1615715; Anderson CS, 2019, LANCET, V393, P877, DOI 10.1016/S0140-6736(19)30038-8; Ang TE, 2015, INT J STROKE, V10, P1014, DOI 10.1111/ijs.12605; Barber PA, 2000, LANCET, V355, P1670, DOI 10.1016/S0140-6736(00)02237-6; Bath PM, 2019, LANCET, V393, P1009, DOI 10.1016/S0140-6736(19)30194-1; Behrndtz A, 2020, INT J STROKE, V15, P103, DOI 10.1177/1747493019869830; Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659; Benoit JL, 2018, PREHOSP EMERG CARE, V22, P722, DOI 10.1080/10903127.2018.1465500; Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Boncoraglio GB, 2019, COCHRANE DB SYST REV, V5; Boulanger JM, 2018, INT J STROKE, V13, P949, DOI 10.1177/1747493018786616; Bracard S, 2016, LANCET NEUROL, V15, P1138, DOI 10.1016/S1474-4422(16)30177-6; Brehm A, 2019, AM J NEURORADIOL, V40, P1330, DOI 10.3174/ajnr.A6129; Brinjikji W, 2015, AM J NEURORADIOL, V36, P525, DOI 10.3174/ajnr.A4159; Broderick JP, 2013, NEW ENGL J MED, V368, P893, DOI 10.1056/NEJMoa1214300; Broussalis E, 2013, AM J NEURORADIOL, V34, P366, DOI 10.3174/ajnr.A3195; Burgos AM, 2019, STROKE, V50, P2156, DOI 10.1161/STROKEAHA.119.025080; Calderon VJ, 2018, INTERV NEUROL, V7, P347, DOI 10.1159/000487334; Campbell BCV, 2018, NEW ENGL J MED, V378, P1573, DOI 10.1056/NEJMoa1716405; Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792; Campbell BCV, 2019, LANCET, V394, P139, DOI 10.1016/S0140-6736(19)31053-0; Campbell BCV, 2019, LANCET NEUROL, V18, P46, DOI 10.1016/S1474-4422(18)30314-4; Campbell BCV, 2018, INT J STROKE, V13, P328, DOI 10.1177/1747493017733935; Campbell BCV, 2018, LANCET NEUROL, V17, P47, DOI 10.1016/S1474-4422(17)30407-6; Campbell BCV, 2016, STROKE, V47, P798, DOI 10.1161/STROKEAHA.115.012360; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; Ciccone A, 2013, NEW ENGL J MED, V368, P904, DOI 10.1056/NEJMoa1213701; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Clark WM, 2000, STROKE, V31, P811, DOI 10.1161/01.STR.31.4.811; del Zoppo GJ, 2009, STROKE, V40, P2945, DOI 10.1161/STROKEAHA.109.192535; Demaerschalk BM, 2016, STROKE, V47, P581, DOI 10.1161/STR.0000000000000086; Deng LH, 2019, WORLD NEUROSURG, V127, pE49, DOI 10.1016/j.wneu.2019.02.011; Ehrlich ME, 2016, STROKE, V47, P2045, DOI 10.1161/STROKEAHA.116.013973; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Fonarow GC, 2014, JAMA-J AM MED ASSOC, V311, P1632, DOI 10.1001/jama.2014.3203; Froehler MT, 2017, CIRCULATION, V136, P2311, DOI 10.1161/CIRCULATIONAHA.117.028920; Gory B, 2018, STROKE, V49, P461, DOI 10.1161/STROKEAHA.117.019598; Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Goyal N, 2017, NEUROLOGY, V89, P540, DOI 10.1212/WNL.0000000000004184; Griauzde J, 2019, J CLIN NEUROSCI, V69, P289, DOI 10.1016/j.jocn.2019.08.001; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 2004, LANCET, V363, P768; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Haley EC, 2010, STROKE, V41, P707, DOI 10.1161/STROKEAHA.109.572040; Hargroves D, 2008, AGE AGEING, V37, P581, DOI 10.1093/ageing/afn143; Helwig SA, 2019, JAMA NEUROL, V76, P1484, DOI 10.1001/jamaneurol.2019.2829; Henden PL, 2017, STROKE, V48, P1601, DOI 10.1161/STROKEAHA.117.016554; Hopyan JJ, 2008, AM J NEURORADIOL, V29, P1826, DOI 10.3174/ajnr.A1257; Huang XY, 2015, LANCET NEUROL, V14, P368, DOI 10.1016/S1474-4422(15)70017-7; Jadhav AP, 2018, STROKE, V49, P1015, DOI 10.1161/STROKEAHA.117.020273; Jindal G, 2017, J NEUROINTERV SURG, V9, P944, DOI 10.1136/neurintsurg-2016-012581; John N, 2013, NEURORADIOLOGY, V55, P93, DOI 10.1007/s00234-012-1084-y; Johnston KC, 2019, JAMA-J AM MED ASSOC, V322, P326, DOI 10.1001/jama.2019.9346; Johnston SC, 2018, NEW ENGL J MED, V379, P215, DOI 10.1056/NEJMoa1800410; Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780; Jumaa MA, 2010, STROKE, V41, P1180, DOI 10.1161/STROKEAHA.109.574194; Just C, 2016, CAN J NEUROL SCI, V43, P655, DOI 10.1017/cjn.2016.256; Katz BS, 2015, STROKE, V46, P1508, DOI 10.1161/STROKEAHA.115.008804; Kepplinger J, 2016, NEUROLOGY, V87, P1344, DOI 10.1212/WNL.0000000000003148; Kidwell CS, 2013, NEW ENGL J MED, V368, P914, DOI 10.1056/NEJMoa1212793; Kim JT, 2017, STROKE, V48, P298, DOI 10.1161/STROKEAHA.116.015247; Lapergue B, 2017, JAMA-J AM MED ASSOC, V318, P443, DOI 10.1001/jama.2017.9644; Lee M, 2015, STROKE, V46, P1883, DOI 10.1161/STROKEAHA.115.009552; Lima FO, 2010, AM J NEURORADIOL, V31, P817, DOI 10.3174/ajnr.A1927; Logallo N, 2017, LANCET NEUROL, V16, P781, DOI 10.1016/S1474-4422(17)30253-3; Ma H, 2019, NEW ENGL J MED, V380, P1795, DOI 10.1056/NEJMoa1813046; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; McMeekin P, 2017, EUR STROKE J, V2, P319, DOI 10.1177/2396987317733343; Mistry EA, 2018, J STROKE CEREBROVASC, V27, P2474, DOI 10.1016/j.jstrokecerebrovasdis.2018.05.003; Mocco J, 2016, STROKE, V47, P2331, DOI 10.1161/STROKEAHA.116.013372; Muir KW, 2017, J NEUROL NEUROSUR PS, V88, P38, DOI 10.1136/jnnp-2016-314117; Nagel S, 2018, STROKE, V49, P2391, DOI 10.1161/STROKEAHA.118.021106; Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442; Olavarria VV, 2018, INT J STROKE, V13, P600, DOI 10.1177/1747493017711943; Olavarria VV, 2014, CEREBROVASC DIS, V37, P401, DOI 10.1159/000362533; Parsons M, 2012, NEW ENGL J MED, V366, P1099, DOI 10.1056/NEJMoa1109842; Patel RAG, 2017, PROG CARDIOVASC DIS, V59, P542, DOI 10.1016/j.pcad.2017.04.005; de la Ossa NP, 2014, STROKE, V45, P87, DOI 10.1161/STROKEAHA.113.003071; Pierot L, 2018, J NEUROINTERV SURG, V10, P1121, DOI 10.1136/neurintsurg-2018-014287; Powers CJ, 2019, AM J NEURORADIOL, V40, P1001, DOI 10.3174/ajnr.A6059; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Prasad K, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k5130; Psychogios MN, 2017, STROKE, V48, P3152, DOI 10.1161/STROKEAHA.117.018077; Roffe C, 2017, JAMA-J AM MED ASSOC, V318, P1125, DOI 10.1001/jama.2017.11463; Roman LS, 2018, LANCET NEUROL, V17, P895, DOI 10.1016/S1474-4422(18)30242-4; Sandercock P, 1997, LANCET, V349, P1569; Sarraj A, 2018, STROKE, V49, P2398, DOI 10.1161/STROKEAHA.118.022114; Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647; Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061; Saver JL, 2012, LANCET, V380, P1241, DOI 10.1016/S0140-6736(12)61384-1; Scheitz JF, 2017, STROKE, V48, P290, DOI 10.1161/STROKEAHA.116.014431; Schonenberger S, 2019, JAMA-J AM MED ASSOC, V322, P1283, DOI 10.1001/jama.2019.11455; Schonenberger S, 2016, JAMA-J AM MED ASSOC, V316, P1986, DOI 10.1001/jama.2016.16623; Simonsen CZ, 2018, JAMA NEUROL, V75, P470, DOI 10.1001/jamaneurol.2017.4474; Teleb MS, 2017, J NEUROINTERV SURG, V9, P122, DOI 10.1136/neurintsurg-2015-012131; Thomalla G, 2018, NEW ENGL J MED, V379, P611, DOI 10.1056/NEJMoa1804355; Thomalla G, 2011, LANCET NEUROL, V10, P978, DOI 10.1016/S1474-4422(11)70192-2; Truijen J, 2018, EUR J NEUROL, V25, P1365, DOI 10.1111/ene.13737; Turk AS, 2015, J NEUROINTERV SURG, V7, P666, DOI 10.1136/neurintsurg-2014-011282; Turk AS, 2019, LANCET, V393, P998, DOI 10.1016/S0140-6736(19)30297-1; Vidale S, 2018, ACTA NEUROL SCAND, V138, P24, DOI 10.1111/ane.12908; Vidale S, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00130; Wan TF, 2019, BMC ANESTHESIOL, V19, DOI 10.1186/s12871-019-0741-7; Wang YJ, 2013, NEW ENGL J MED, V369, P11, DOI 10.1056/NEJMoa1215340; Wojner-Alexander AW, 2005, NEUROLOGY, V64, P1354, DOI 10.1212/01.WNL.0000158284.41705.A5; Yaghi S, 2017, STROKE, V48, pE343, DOI 10.1161/STR.0000000000000152; Zaidat OO, 2018, STROKE, V49, P1107, DOI 10.1161/STROKEAHA.117.020125; Zaidat OO, 2013, STROKE, V44, P2650, DOI 10.1161/STROKEAHA.113.001972; Zhang DL, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.118.005147	119	188	196	23	118	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 13	2020	368								l6983	10.1136/bmj.l6983	http://dx.doi.org/10.1136/bmj.l6983			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM4KZ	32054610				2023-01-03	WOS:000514099400001
J	Mendiguchia, J; Conceicao, F; Edouard, P; Fonseca, M; Pereira, R; Lopes, H; Morin, JB; Jimenez-Reyes, P				Mendiguchia, Jurdan; Conceicao, Filipe; Edouard, Pascal; Fonseca, Marco; Pereira, Rogerio; Lopes, Hernani; Morin, Jean-Benoit; Jimenez-Reyes, Pedro			Sprint versus isolated eccentric training: Comparative effects on hamstring architecture and performance in soccer players	PLOS ONE			English	Article							FEMORIS LONG HEAD; MUSCLE ARCHITECTURE; INJURY RISK; STRENGTH; EXERCISE; SPEED; QUANTIFICATION; ADAPTATION; ULTRASOUND; PREVENTION	Aims The purpose of this study was to compare the effects of hamstring eccentric (NHE) strength training versus sprint training programmed as complements to regular soccer practice, on sprint performance and its mechanical underpinnings, as well as biceps femoris long head (BFlh) architecture. Methods In this prospective interventional control study, sprint performance, sprint mechanics and BFlh architecture variables were compared before versus after six weeks of training during the first six preseason weeks, and between three different random match-pair groups of soccer players: "Soccer group" (n = 10), "Nordic group" (n = 12) and "Sprint group" (n = 10). Results For sprint performance and mechanics, small to large pre-post improvements were reported in "Sprint group" (except maximal running velocity), whereas only trivial to small negative changes were reported in "Soccer group" and "Nordic group". For BFlh architecture variables, "Sprint" group showed moderate increase in fascicle length compared to smaller augment for the "Nordic" group with trivial changes for "Soccer group". Only "Nordic" group presented small increases at pennation angle. Conclusions The results suggest that sprint training was superior to NHE in order to increase BFlh fascicle length although only the sprint training was able to both provide a preventive stimulus (increase fascicle length) and at the same time improve both sprint performance and mechanics. Further studies with advanced imaging techniques are needed to confirm the validity of the findings.	[Mendiguchia, Jurdan] ZENTRUM Rehab & Performance Ctr, Dept Phys Therapy, Baranain, Spain; [Conceicao, Filipe; Fonseca, Marco] Univ Porto, Fac Sports, Ctr Res Educ Innovat & Intervent Sport, Porto, Portugal; [Conceicao, Filipe; Fonseca, Marco] Univ Porto, LABIOMEP Porto Biomech Lab, Porto, Portugal; [Edouard, Pascal] Univ Jean Monnet, Univ Lyon, Interuniv Lab Human Movement Biol LIBM EA 7424, St Etienne, France; [Edouard, Pascal] Univ Hosp St Etienne, Fac Med, Dept Clin & Exercise Physiol, Sports Med Unity, St Etienne, France; [Edouard, Pascal] French Athlet Federat FFA, Med Commiss, Paris, France; [Fonseca, Marco] Portuguese Football Federat, Hlth & Performance Unit, Lisbon, Portugal; [Pereira, Rogerio] Espregueira Mendes Sports Ctr, FIFA Med Ctr Excellence, Clin Dragao, Porto, Portugal; [Lopes, Hernani] Polytech Porto, Sch Engn, DEM ISEP, Porto, Portugal; [Morin, Jean-Benoit] Univ Cote dAzur, LAMHESS, Nice, France; [Jimenez-Reyes, Pedro] Rey Juan Carlos Univ, Ctr Sport Studies, Madrid, Spain	Universidade do Porto; Universidade do Porto; CHU de St Etienne; Polytechnic Institute of Porto; UDICE-French Research Universities; Universite Cote d'Azur; Universidad Rey Juan Carlos	Jimenez-Reyes, P (corresponding author), Rey Juan Carlos Univ, Ctr Sport Studies, Madrid, Spain.	peterjr49@hotmail.com	Conceição, Filipe/AAK-7440-2020; Lopes, Hernani/AAM-7965-2020; Jimenez Reyes, Pedro/P-1075-2016	Lopes, Hernani/0000-0002-9344-8503; conceicao, filipe/0000-0002-1636-2685; Jimenez Reyes, Pedro/0000-0002-8156-243X				Alonso-Fernandez D, 2018, SCAND J MED SCI SPOR, V28, P88, DOI 10.1111/sms.12877; Arnason A, 2008, SCAND J MED SCI SPOR, V18, P40, DOI 10.1111/j.1600-0838.2006.00634.x; Azizi E, 2014, J EXP BIOL, V217, P376, DOI 10.1242/jeb.094383; Bahr R, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2015-094826; Batterham AM, 2006, INT J SPORT PHYSIOL, V1, P50, DOI 10.1123/ijspp.1.1.50; Blazevich AJ, 2003, MED SCI SPORT EXER, V35, P2013, DOI 10.1249/01.MSS.0000099092.83611.20; Bolsterlee B, 2015, J BIOMECH, V48, P1133, DOI 10.1016/j.jbiomech.2015.01.012; Butterfield TA, 2005, J APPL PHYSIOL, V99, P593, DOI 10.1152/japplphysiol.01128.2004; Chumanov ES, 2012, BRIT J SPORT MED, V46, P90, DOI 10.1136/bjsports-2011-090176; Cohen J., 2013, STAT POWER ANAL BEHA; di Prampero PE, 2005, J EXP BIOL, V208, P2809, DOI 10.1242/jeb.01700; Dick TJM, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.172371; Dorn TW, 2012, J EXP BIOL, V215, P1944, DOI 10.1242/jeb.064527; Douglas J, 2017, SPORTS MED, V47, P663, DOI 10.1007/s40279-016-0624-8; Ekstrand J, 2016, BRIT J SPORT MED, V50, P731, DOI 10.1136/bjsports-2015-095359; Faude O, 2012, J SPORT SCI, V30, P625, DOI 10.1080/02640414.2012.665940; Fiorentino NM, 2014, MED SCI SPORT EXER, V46, P776, DOI 10.1249/MSS.0000000000000172; Franchi MV, 2014, ACTA PHYSIOL, V210, P642, DOI 10.1111/apha.12225; Franchi MV, 2020, MED SCI SPORT EXER, V52, P233, DOI 10.1249/MSS.0000000000002123; Franchi MV, 2018, ULTRASOUND MED BIOL, V44, P2492, DOI 10.1016/j.ultrasmedbio.2018.07.010; Freeman BW, 2019, J SPORT MED PHYS FIT, V59, P1119, DOI 10.23736/S0022-4707.18.08703-0; Freitas SR, 2018, J ULTRAS MED, V37, P977, DOI 10.1002/jum.14436; Haugen TA, 2018, KINESIOLOGY, V50, P102; Hegyi A, 2019, MED SCI SPORT EXER, V51, P2274, DOI 10.1249/MSS.0000000000002060; Hopkins WG, 2004, INTRO PLANT PHYSL, P1; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Ishoi L, 2018, J SPORT SCI, V36, P1663, DOI 10.1080/02640414.2017.1409609; Jeong TS, 2011, J SPORT SCI, V29, P1161, DOI 10.1080/02640414.2011.583671; Klimstra M, 2007, J ELECTROMYOGR KINES, V17, P504, DOI 10.1016/j.jelekin.2006.04.011; Krommes K, 2017, BMC Res Notes, V10, P669, DOI 10.1186/s13104-017-2986-x; Lacome M, 2020, INT J SPORT PHYSIOL, V15, P81, DOI 10.1123/ijspp.2018-0947; Los Arcos A, 2015, J SPORT SCI MED, V14, P394; Lovell R, 2018, SCAND J MED SCI SPOR, V28, P658, DOI 10.1111/sms.12925; Malone S, 2018, J SCI MED SPORT, V21, P257, DOI 10.1016/j.jsams.2017.05.016; Malone S, 2017, J SCI MED SPORT, V20, P250, DOI 10.1016/j.jsams.2016.08.005; Mendiguchia J, 2016, J SPORT SCI, V34, P535, DOI 10.1080/02640414.2015.1122207; Mendiguchia J, 2015, SCAND J MED SCI SPOR, V25, pE621, DOI 10.1111/sms.12388; Mendiguchia J., 2019, SPORT PERFORM SCI RE, V1, P1, DOI [10.1136/bjsports-2015-095359, DOI 10.1136/BJSPORTS-2015-095359]; Morin JB, 2006, INT J SPORTS MED, V27, P158, DOI 10.1055/s-2005-837569; Morin JB, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00404; Morin JB, 2017, INT J SPORT PHYSIOL, V12, P840, DOI 10.1123/ijspp.2016-0444; Orchard JW, 2012, BRIT J SPORT MED, V46, P88, DOI 10.1136/bjsports-2011-090127; Petersen J, 2011, AM J SPORT MED, V39, P2296, DOI 10.1177/0363546511419277; Pimenta R, 2018, MED SCI SPORT EXER, V50, P2584, DOI 10.1249/MSS.0000000000001731; Potier TG, 2009, EUR J APPL PHYSIOL, V105, P939, DOI 10.1007/s00421-008-0980-7; Proske U, 2001, J PHYSIOL-LONDON, V537, P333, DOI 10.1111/j.1469-7793.2001.00333.x; Romero-Franco N, 2017, EUR J SPORT SCI, V17, P386, DOI 10.1080/17461391.2016.1249031; Samozino P, 2016, SCAND J MED SCI SPOR, V26, P648, DOI 10.1111/sms.12490; Stares J, 2018, J SCI MED SPORT, V21, P1019, DOI 10.1016/j.jsams.2018.03.012; Timmins RG, 2016, BRIT J SPORT MED, V50, P1524, DOI 10.1136/bjsports-2015-095362; Timmins RG, 2016, MED SCI SPORT EXER, V48, P499, DOI 10.1249/MSS.0000000000000795; Timmins RG, 2015, MED SCI SPORT EXER, V47, P905, DOI 10.1249/MSS.0000000000000507; van den Tillaar R, 2017, INT J SPORTS PHYS TH, V12, P718, DOI 10.16603/ijspt20170718	53	41	41	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2020	15	2							e0228283	10.1371/journal.pone.0228283	http://dx.doi.org/10.1371/journal.pone.0228283			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9KA	32045411	Green Published, gold			2023-01-03	WOS:000534633200009
J	Rosenbaum, L				Rosenbaum, Lisa			The Untold Toll - The Pandemic's Effects on Patients without Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								As the pandemic focuses medical attention on treating affected patients and protecting others from infection, how do we best care for people with non-Covid disease? Some physicians predict that "the toll on non-Covid patients will be much greater than Covid deaths."										Chakiba C, 2018, NEW ENGL J MED, V378, P2242, DOI 10.1056/NEJMc1803837; Garcia S, 2020, J AM COLL CARDIOL; Sheth K, 2020, WASH POST; Welt FGP, 2020, J AM COLL CARDIOL	4	407	414	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	2020	382	24					2368	2371		10.1056/NEJMms2009984	http://dx.doi.org/10.1056/NEJMms2009984			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LZ3TR	32302076	Bronze			2023-01-03	WOS:000541151500018
J	Markman, TM; Hamilton, RH; Marchlinski, FE; Nazarian, S				Markman, Timothy M.; Hamilton, Roy H.; Marchlinski, Francis E.; Nazarian, Saman			Case Series of Transcutaneous Magnetic Stimulation for Ventricular Tachycardia Storm	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter								This case series describes outcomes for 5 patients with VT storm refractory to drug therapy treated with left stellate ganglion transcutaneous magnetic stimulation (TCMS) to reduce cardiac sympathetic input.	[Markman, Timothy M.; Marchlinski, Francis E.; Nazarian, Saman] Hosp Univ Penn, Div Cardiol, 3400 Spruce St, Philadelphia, PA 19104 USA; [Hamilton, Roy H.] Hosp Univ Penn, Dept Neurol, 3400 Spruce St, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Markman, TM (corresponding author), Hosp Univ Penn, 3400 Civ Ctr Blvd, Philadelphia, PA 19146 USA.	timothy.markman@uphs.upenn.edu	Nazarian, Saman/ABC-8000-2020; Markman, Timothy/AAV-8786-2021	Nazarian, Saman/0000-0002-8369-0259				Al-Khatib SM, 2018, HEART RHYTHM, V15, pE190, DOI 10.1016/j.hrthm.2017.10.035; Gaynes BN, 2014, J CLIN PSYCHIAT, V75, P477, DOI 10.4088/JCP.13r08815; McClintock SM, 2018, J CLIN PSYCHIAT, V79, P35, DOI 10.4088/JCP.16cs10905; Tung R, 2015, J BIOMED RES, V29, P56, DOI 10.7555/JBR.29.20140161; Wang SY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30783; Yu LL, 2015, HEART RHYTHM, V12, P809, DOI 10.1016/j.hrthm.2014.12.022	6	6	6	4	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2020	323	21					2200	2202		10.1001/jama.2020.3833	http://dx.doi.org/10.1001/jama.2020.3833			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY8YS	32372071	Green Published, Bronze			2023-01-03	WOS:000540816000029
J	Stien, N; Pedersen, H; Ravnoy, AH; Andersen, V; Saeterbakken, AH				Stien, Nicolay; Pedersen, Helene; Ravnoy, Aril Hagen; Andersen, Vidar; Saeterbakken, Atle Hole			Training specificity performing single-joint vs. multi-joint resistance exercises among physically active females: A randomized controlled trial	PLOS ONE			English	Article							PROGRESSION MODELS; MUSCLE ACTIVATION; STRENGTH; HYPERTROPHY; ADAPTATIONS; TIME	Resistance-training of the lower limbs can be performed using exercises moving one (single -joint exercises) or several joints (multi-joint exercises). This study compared the effects of training one multi-joint exercise (leg press) or two single-joint exercises (leg extension and kickback) on dynamic and isometric strength and the transferability of dynamic strength between exercises. Fifty-three physically active women were randomized to a multi-joint (MJ) training group (age = 21.95 0.82 years, mass = 64.85 +/- 5.76 kg, height = 167.35 +/- 2.47 cm; n = 20), single-joint (SJ) training group (age = 22.56 +/- 1.66 years, mass = 64.85 5.76 kg, height = 165.94 +/- 2.84 cm; n = 18), or a control (CON) group (age = 21.27 +/- 0.68 years, mass = 68.43 +/- 4.86 kg, height = 168.63 +/- 2.84 cm; n = 15). The training groups participated in an 8 week supervised single- or multi-joint lower limb training consisting of 18 sessions. Pre- and post-training, six repetitions maximum (RM) and maximal voluntary isometric contraction in the three exercises were assessed, along with electromyography of the superficial quadriceps muscles. Improvements in all dynamic exercises were greatest after training the specific exercises (ES = 1.26-2.14, P<0.001-0.025) and all were greater in the training groups than in the CON group (ES = 1.43-3.31, P<0.001-0.021). The SJ group improved 6RM in leg extension and kickback more than leg press (ES = 1.51 and 2.04, respectively, P<0.001), whereas the MJ group improved leg press 6RM more than kickback (ES = 1.10, P= 0.002). However, leg press and leg extension strength improved similarly in the MJ group (ES = 0.54, P= 0.072). All strength and electromyographic measures remained unchanged in the CON group (ES = 0.00-0.44, P= 0.412-0.966). Improved dynamic strength in leg press, kickback and leg extension is best attained by training the specific exercises, but both training modalities can improve strength across all exercises.	[Stien, Nicolay; Pedersen, Helene; Ravnoy, Aril Hagen; Andersen, Vidar; Saeterbakken, Atle Hole] Western Norway Univ Appl Sci, Fac Educ Arts & Sports, Bergen, Norway	Western Norway University of Applied Sciences	Stien, N (corresponding author), Western Norway Univ Appl Sci, Fac Educ Arts & Sports, Bergen, Norway.	nicolay.stien@hvl.no		Stien, Nicolay/0000-0001-5161-9055				Aagaard P, 2002, J APPL PHYSIOL, V93, P1318, DOI 10.1152/japplphysiol.00283.2002; Appleby BB, 2019, J STRENGTH COND RES, V33, P318, DOI 10.1519/JSC.0000000000002923; Augustsson J, 1998, J ORTHOP SPORT PHYS, V27, P3, DOI 10.2519/jospt.1998.27.1.3; Barbalho M, 2020, INT J SPORTS MED; BEHM DG, 1993, SPORTS MED, V15, P374, DOI 10.2165/00007256-199315060-00003; Buckner SL, 2017, SPORTS MED, V47, P193, DOI 10.1007/s40279-016-0580-3; Chilibeck PD, 1998, EUR J APPL PHYSIOL O, V77, P170; Choi J, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4255-2; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Da Silva EM, 2008, J STRENGTH COND RES, V22, P1059, DOI 10.1519/JSC.0b013e3181739445; Dankel SJ, 2018, J STRENGTH COND RES; Del Vecchio A, 2019, J PHYSIOL-LONDON, V597, P1873, DOI 10.1113/JP277250; DELVECCHIO FB, 2015, ASIAN J SPORTS MED, V6, DOI DOI 10.3389/FPSYG.2015.01359; Duchateau J, 2006, J APPL PHYSIOL, V101, P1766, DOI 10.1152/japplphysiol.00543.2006; Ebben WP, 2009, INT J SPORTS MED, V30, P1, DOI 10.1055/s-2008-1038785; Ema R, 2016, EUR J APPL PHYSIOL, V116, P1031, DOI 10.1007/s00421-016-3363-5; Folland JP, 2007, SPORTS MED, V37, P145, DOI 10.2165/00007256-200737020-00004; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Gentil P, 2017, SPORTS MED, V47, P843, DOI 10.1007/s40279-016-0627-5; Gentil P, 2013, APPL PHYSIOL NUTR ME, V38, P341, DOI 10.1139/apnm-2012-0176; Gomez-Lopez M, 2010, J SPORT SCI MED, V9, P374; Goncalves A, 2019, EUR J TRANSL MYOL, V29, P14, DOI 10.4081/ejtm.2019.8052; HAKKINEN K, 1985, ACTA PHYSIOL SCAND, V125, P587, DOI 10.1111/j.1748-1716.1985.tb07760.x; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Kraemer WJ, 2004, MED SCI SPORT EXER, V36, P674, DOI 10.1249/01.MSS.0000121945.36635.61; Kraemer WJ, 2002, MED SCI SPORT EXER, V34, P364, DOI 10.1097/00005768-200202000-00027; MORITANI T, 1979, AM J PHYS MED REHAB, V58, P115; Paoli A, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01105; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; RUTHERFORD OM, 1986, EUR J APPL PHYSIOL O, V55, P100, DOI 10.1007/BF00422902; Saeterbakken AH, 2011, J SPORT SCI, V29, P533, DOI 10.1080/02640414.2010.543916; Saeterbakken AH, 2012, EUR J APPL PHYSIOL, V112, P1671, DOI 10.1007/s00421-011-2141-7; SALE D, 1981, Canadian Journal of Applied Sport Sciences, V6, P87; SALE DG, 1988, MED SCI SPORT EXER, V20, pS135, DOI 10.1249/00005768-198810001-00009; Schoenfeld BJ, 2019, SPORTS, V7, DOI 10.3390/sports7070177; THORSTENSSON A, 1976, ACTA PHYSIOL SCAND, V98, P232, DOI 10.1111/j.1748-1716.1976.tb00241.x; Wernbom M, 2007, SPORTS MED, V37, P225, DOI 10.2165/00007256-200737030-00004	37	4	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2020	15	5							e0233540	10.1371/journal.pone.0233540	http://dx.doi.org/10.1371/journal.pone.0233540			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1WS	32469946	Green Published, gold			2023-01-03	WOS:000537552800092
J	Jacob, MCM; de Medeiros, MFA; Albuquerque, UP				Medeiros Jacob, Michelle Cristine; Araujo de Medeiros, Maria Fernanda; Albuquerque, Ulysses Paulino			Biodiverse food plants in the semiarid region of Brazil have unknown potential: A systematic review	PLOS ONE			English	Review							DRY SEASONAL FORESTS; CAATINGA; NUTRITION; DIETETICS; KNOWLEDGE; SECURITY; POSITION; ACADEMY	Food biodiversity presents one of the most significant opportunities to enhance food and nutrition security today. The lack of data on many plants, however, limits our understanding of their potential and the possibility of building a research agenda focused on them. Our objective with this systematic review was to identify biodiverse food plants occurring in the Caatinga biome, Brazil, strategic for the promotion of food and nutrition security. We selected studies from the following databases: Web of Science, Medline/PubMed (via the National Library of Medicine), Scopus and Embrapa Agricultural Research Databases (BDPA). Eligible were original articles, published since 2008, studying food plants occurring in the Caatinga. We assessed the methodological quality of the studies we selected. We reviewed a total of fifteen studies in which 65 plants that met our inclusion criteria were mentioned. Of this amount, 17 species, including varieties, subspecies, and different parts of plants, had data on chemical composition, in addition to being mentioned as food consumed by rural communities in observational ethnobotanical studies. From the energy and protein data associated with these plants, we produced a ranking of strategic species. The plants with values higher than the average of the set were: Dioclea grandiflora Mart. ex Benth (mucuna), Hymenaea courbaril L. (jatoba), Syagrus cearensis Noblick (coco-catole), Libidibia ferrea (Mart. ex Tul.) L.P.Queiroz (juca), Sideroxylon obtusifolium (Roem. & Schult.) T. D.Penn. (quixabeira). We suggest that the scientific community concentrates research efforts on tree legumes, due to their resilience and physiological, nutritional, and culinary qualities.	[Medeiros Jacob, Michelle Cristine; Araujo de Medeiros, Maria Fernanda] Univ Fed Rio Grande do Norte, Lab Horta Comunitaria Nutrir, Nutr Dept, Natal, RN, Brazil; [Albuquerque, Ulysses Paulino] Univ Fed Pernambuco, Bot Dept, Lab Ecol & Evolucao Sistemas Socioecol, Recife, PE, Brazil	Universidade Federal do Rio Grande do Norte; Universidade Federal de Pernambuco	Jacob, MCM (corresponding author), Univ Fed Rio Grande do Norte, Lab Horta Comunitaria Nutrir, Nutr Dept, Natal, RN, Brazil.	michellejacob@ufrn.edu.br	Albuquerque, Ulysses P/I-5037-2012	Albuquerque, Ulysses P/0000-0002-8131-8429; Araujo de Medeiros, Maria Fernanda/0000-0001-7674-9307	Universidade Federal do Rio Grande do Norte [01/2018]; National Council for Scientific and Technological Development [150654/2019-7, 302380/2011-6]; Brazilian Coordenacao de Aperfeicoamento de Pessoal de Nivel [001]	Universidade Federal do Rio Grande do Norte; National Council for Scientific and Technological Development(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Brazilian Coordenacao de Aperfeicoamento de Pessoal de Nivel	This study was funded by the Universidade Federal do Rio Grande do Norte through a Scientific Initiation research scholarship to MFAM (UFRN call 01/2018), and by the National Council for Scientific and Technological Development through a postdoctoral scholarship to MCMJ (150654/2019-7) and research productivity scholarship granted to UPA (302380/2011-6). The Brazilian Coordenacao de Aperfeicoamento de Pessoal de Nivel financed the fee to publish this article (Finance Code 001). Funders had no role in the study design, data collection and analysis, decision to publish or prepare the manuscript.	Alencar NL, 2010, ECON BOT, V64, P68, DOI 10.1007/s12231-009-9104-5; Altman D, 2015, EPIDEMIOL SERV SAUDE, V24, P335, DOI 10.5123/S1679-49742015000200017; [Anonymous], 2014, PROMOTION UNDERUTILI; Arimond M, 2004, J NUTR, V134, P2579, DOI 10.1093/jn/134.10.2579; Berrazaga I, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081825; Almeida MLB, 2016, FOOD CHEM, V192, P1078, DOI 10.1016/j.foodchem.2015.07.129; Lima ADB, 2011, REV BRAS FRUTIC, V33, P877, DOI 10.1590/S0100-29452011000300023; Bramer WM, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0644-y; Burlingame B., 2012, SUSTAINABLE DIETS BI; Burlingame B, 2009, J FOOD COMPOS ANAL, V22, P361, DOI 10.1016/j.jfca.2009.05.003; Caceres MES, 2008, BIODIVERS CONSERV, V17, P1285, DOI 10.1007/s10531-008-9342-3; Cavalcanti MT, 2009, CIENC TECNOL ALIMENT; Cowan RS, 1980, TAXON, V29, P180; Cruz Garcia Gisella Susana, 2006, J Ethnobiol Ethnomed, V2, P39, DOI 10.1186/1746-4269-2-39; Cruz MP, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-45; Cruz MP, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-79; do Nascimento VT, 2013, ECOL FOOD NUTR, V52, P317, DOI 10.1080/03670244.2012.707434; do Nascimento VT, 2012, ECON BOT, V66, P22, DOI 10.1007/s12231-012-9187-2; do Nascimento VT, 2011, FOOD RES INT, V44, P2112, DOI 10.1016/j.foodres.2010.12.024; dos Santos LL, 2014, ECON BOT, V68, P283, DOI 10.1007/s12231-014-9281-8; dos Santos LL, 2009, ECON BOT, V63, P363, DOI 10.1007/s12231-009-9094-3; Dubeux JCB, 2017, REV BRAS ZOOTECN, V46, P689, DOI [10.1590/s1806-92902017000800010, 10.1590/S1806-92902017000800010]; Ferraz JSF, 2012, BOSQUE, V33, P183, DOI 10.4067/S0717-92002012000200008; Ferreira-Junior WashingtonSoares., 2018, ETNOBIOLOGIA BASES E, V2; FOLASHADE-BOLARINWA I., 2016, SOLONESKI, P179, DOI DOI 10.5772/64886; Food and Agriculture Organization, 2016, INT YEAR PULS; Food and Drug Administration, 2013, A FOOD LABELING GUID; Gilani GS, 2005, J AOAC INT, V88, P967; Global Facilitation Unit for Underutilized Species, 2017, GLOB FAC UN UND SPEC; Gomes Fábio P., 2007, Braz. J. Plant Physiol., V19, P377, DOI 10.1590/S1677-04202007000400008; GRANT G, 1986, QUAL PLANT, V36, P47, DOI 10.1007/BF01091753; Gubert MB, 2018, CIENC SAUDE COLETIVA, V23, P3433, DOI 10.1590/1413-812320182310.265120161; Guinand Y, 2001, POTENTIAL INDIGENOUS, P31; Huber L. S., 2008, Alimentos e Nutricao, V19, P97; Institute of Medicine, 2002, DIET REF INT VIT A A; Instituto Brasileiro de Geografia e Estatistica, 2004, MAP BIOM BRAS; Instituto de Pesquisas Jardim Botanico do Rio de Janeiro, 2020, REFL FLOR BRAZ 2020; International Panel of Experts on Sustainable Food Systems, 2015, UNIFORMITY DIVERSITY; International Panel of Experts on Sustainable Food Systems and Global Alliance for the Future of Food, 2017, UNR FOOD HLTH NEX AD; Jardim Botanico do Rio de Janeiro, 2018, FLOR BRAS 2020 CONST; Jones DA, 1998, PHYTOCHEMISTRY, V47, P155, DOI 10.1016/S0031-9422(97)00425-1; Juvik OJ, 2017, MOLECULES, V22, DOI 10.3390/molecules22091478; Lachat C, 2018, P NATL ACAD SCI USA, V115, P127, DOI 10.1073/pnas.1709194115; Levi-Strauss C., 2006, ORIGEM MODOS MESA; LIENER IE, 1994, CRIT REV FOOD SCI, V34, P31, DOI 10.1080/10408399409527649; Lignani JD, 2011, PUBLIC HEALTH NUTR, V14, P785, DOI 10.1017/S136898001000279X; Lynch H, 2018, NUTRIENTS, V10, DOI 10.3390/nu10121841; Medeiros MJ, 2015, TREES-STRUCT FUNCT, V29, P1219, DOI 10.1007/s00468-015-1202-7; Medeiros P, 2017, PLOS ONE, V12, P1; Melina V, 2016, J ACAD NUTR DIET, V116, P1970, DOI 10.1016/j.jand.2016.09.025; Novaes RLM, 2013, NATURE, V498, P170, DOI 10.1038/498170a; Nordic Committee on Food Analysis, 2011, AN QUAL CONTR GUID P, V2011; Nunes EN, 2018, J ETHNOBIOL ETHNOMED, V14, DOI 10.1186/s13002-018-0249-0; Rapoport E, 1998, REV DIVULG CIENTIFIC, V9, P49; Reyes-Garcia V., 2005, Ethnobotany Research and Applications, V3, P201; Rodrigues-Amaya DB, 2008, TABELA BRASILEIRA CO, V52; Roque AD, 2013, REV CAATINGA, V26, P88; Shackleton C, 2004, S AFR J SCI, V100, P658; Shelef O, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.02069; Shepon A, 2018, P NATL ACAD SCI USA, V115, P3804, DOI 10.1073/pnas.1713820115; SIDDIQUE KHM, 1993, AUST J EXP AGR, V33, P915, DOI 10.1071/EA9930915; Silva RB, 2015, AN ACAD BRAS CIENC, V87, P1701, DOI 10.1590/0001-3765201520140166; Stadlmayr B, 2012, GUIDELINES FOOD MATC; Swinburn BA, 2019, LANCET, V393, P791, DOI 10.1016/S0140-6736(18)32822-8; Termote C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030533; Thomas DT, 2016, J ACAD NUTR DIET, V116, P501, DOI 10.1016/j.jand.2015.12.006; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Medeiros MFT, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-50; UN General Assembly, 2015, TRANSF OUR WORLD 203; UNESCO, 2018, TEXT CONV SAF INT CU; United Nations, 2016, DEC ACT NUTR; Carvalho AFU, 2011, J FOOD COMPOS ANAL, V24, P487, DOI 10.1016/j.jfca.2011.01.013; von Elm E, 2014, INT J SURG; Weiler AM, 2015, HEALTH POLICY PLANN, V30, P1078, DOI 10.1093/heapol/czu109	74	19	19	5	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2020	15	5							e0230936	10.1371/journal.pone.0230936	http://dx.doi.org/10.1371/journal.pone.0230936			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT7ZX	32379775	Green Submitted, gold, Green Published			2023-01-03	WOS:000537285700012
J	Raveendran, RN; Tsang, K; Tiwana, D; Chow, A; Thompson, B				Raveendran, Rajkumar Nallour; Tsang, Katelyn; Tiwana, Dilraj; Chow, Amy; Thompson, Benjamin			Anodal transcranial direct current stimulation reduces collinear lateral inhibition in normal peripheral vision	PLOS ONE			English	Article							VISUAL-CORTEX; MOTOR CORTEX; TDCS; SUPPRESSION; AMBLYOPIA; FACILITATION; MODULATION; MECHANISMS; ATTENTION	Collinear flanking stimuli can reduce the detectability of a Gabor target presented in peripheral vision. This phenomenon is called collinear lateral inhibition and it may contribute to crowding in peripheral vision. Perceptual learning can reduce collinear lateral inhibition in peripheral vision, however intensive training is required. Our aim was to assess whether modulation of collinear lateral inhibition can be achieved within a short time-frame using a single 20-minute session of primary visual cortex anodal transcranial direct current stimulation (a-tDCS). Thirteen observers with normal vision performed a 2AFC contrast detection task with collinear flankers positioned at a distance of 2. from the target (lateral inhibition) or 6. (control condition). The stimuli were presented 6 degrees to the left of a central cross and fixation was monitored with an infra-red eye tracker. Participants each completed two randomly sequenced, single-masked stimulation sessions; real anodal tDCS and sham tDCS. For the 2. separation condition, a-tDCS induced a significant reduction in detection threshold (reduced lateral inhibition). Sham stimulation had no effect. No effects of a-tDCS were observed for the 6. separation condition. This result lays the foundation for future work investigating whether a-tDCS may be useful as a visual rehabilitation tool for individuals with central vision loss who are reliant on peripheral vision.	[Raveendran, Rajkumar Nallour] Envision Res Inst, Wichita, KS 67203 USA; [Raveendran, Rajkumar Nallour; Tsang, Katelyn; Tiwana, Dilraj; Chow, Amy; Thompson, Benjamin] Univ Waterloo, Sch Optometry & Vis Sci, Waterloo, ON, Canada	University of Waterloo	Raveendran, RN (corresponding author), Envision Res Inst, Wichita, KS 67203 USA.; Raveendran, RN (corresponding author), Univ Waterloo, Sch Optometry & Vis Sci, Waterloo, ON, Canada.	sachinrajopto@gmail.com		Tsang, Katelyn/0000-0001-9260-8483; Nallour Raveendran, Rajkumar/0000-0003-1536-6358	Envision Postdoctoral research fellowship by LC Industries; NSERC grants [RPIN-05394, RGPAS-477166]	Envision Postdoctoral research fellowship by LC Industries; NSERC grants	RNR - Envision Postdoctoral research fellowship by LC Industries. BT: NSERC grants RPIN-05394 and RGPAS-477166. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antonenko D, 2017, J NEUROSCI, V37, P4065, DOI 10.1523/JNEUROSCI.0079-17.2017; Behrens JR, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00238; Bonder T, 2018, FRONT PSYCHOL, V9, DOI [10.3389/fpsyg.2078.00159, 10.3389/fpsyg.2018.00159]; BOUMA H, 1970, NATURE, V226, P177, DOI 10.1038/226177a0; Chen J, 2014, J NEUROSCI, V34, P10465, DOI 10.1523/JNEUROSCI.1140-14.2014; Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071; Chung STL, 2007, J VISION, V7, DOI 10.1167/7.2.10; Chung STL, 2007, VISION RES, V47, P3150, DOI 10.1016/j.visres.2007.08.017; Contemori G, 2019, NEUROPSYCHOLOGIA, V125, P129, DOI 10.1016/j.neuropsychologia.2019.02.001; Ding ZF, 2016, SCI REP-UK, V6, DOI 10.1038/srep19280; Fahle M, 2005, CURR OPIN NEUROBIOL, V15, P154, DOI 10.1016/j.conb.2005.03.010; Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7; Freeman E, 2001, NAT NEUROSCI, V4, P1032, DOI 10.1038/nn728; Kim S, 2014, NEUROIMAGE, V99, P237, DOI 10.1016/j.neuroimage.2014.05.070; Kiorpes L, 2006, STRABISMUS, V14, P3, DOI 10.1080/09273970500536193; Lev M, 2015, J VISION, V15, DOI 10.1167/15.13.10; Lev M, 2011, VISION RES, V51, P2488, DOI 10.1016/j.visres.2011.10.008; Levi DM, 2006, STRABISMUS, V14, P11, DOI 10.1080/09273970500536243; Levi DM, 2008, VISION RES, V48, P635, DOI 10.1016/j.visres.2007.12.009; Levi DM, 2011, CURR BIOL, V21, pR678, DOI 10.1016/j.cub.2011.07.025; Levi DM, 2009, VISION RES, V49, P2535, DOI 10.1016/j.visres.2009.02.010; Lu ZL, 2009, PERCEPTION, V38, P11; Maniglia M, 2019, BRAIN STRUCT FUNCT, V224, P3399, DOI 10.1007/s00429-019-01964-z; Maniglia M, 2018, CURR OPIN BEHAV SCI, V20, P47, DOI 10.1016/j.cobeha.2017.10.004; Maniglia M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18261-6; Maniglia M, 2016, RESTOR NEUROL NEUROS, V34, P697, DOI 10.3233/RNN-150575; Maniglia M, 2015, SCI REP-UK, V5, DOI 10.1038/srep15530; Maniglia M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025568; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Peirce JW, 2007, J NEUROSCI METH, V162, P8, DOI 10.1016/j.jneumeth.2006.11.017; PEIRCE JW, 2009, FRONTIERS, V2, DOI DOI 10.3389/NEURO.11.010.2008; Pelli DG, 2008, CURR OPIN NEUROBIOL, V18, P445, DOI 10.1016/j.conb.2008.09.008; Pelli DG, 2004, J VISION, V4, P1136, DOI 10.1167/4.12.12; Pirulli C, 2013, BRAIN STIMUL, V6, P683, DOI 10.1016/j.brs.2012.12.005; Polat U, 1996, VISION RES, V36, P2099, DOI 10.1016/0042-6989(95)00281-2; Polat U, 2004, P NATL ACAD SCI USA, V101, P6692, DOI 10.1073/pnas.0401200101; Polat U, 1998, NATURE, V391, P580, DOI 10.1038/35372; Reinhart RMG, 2017, ATTEN PERCEPT PSYCHO, V79, P3, DOI 10.3758/s13414-016-1224-2; Reinhart RMG, 2016, CURR BIOL, V26, P1867, DOI 10.1016/j.cub.2016.05.019; Rushmore RJ, 2013, EUR J NEUROSCI, V38, P3799, DOI 10.1111/ejn.12373; Schwarzkopf DS, 2011, J NEUROSCI, V31, P3143, DOI 10.1523/JNEUROSCI.4863-10.2011; Shani R, 2005, VISION RES, V45, P2009, DOI 10.1016/j.visres.2005.01.024; Spiegel DP, 2013, NEUROTHERAPEUTICS, V10, P831, DOI 10.1007/s13311-013-0200-y; Spiegel DP, 2013, NEUROREHAB NEURAL RE, V27, P760, DOI 10.1177/1545968313491006; Spiegel DP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036220; Stagg CJ, 2009, J NEUROSCI, V29, P5202, DOI 10.1523/JNEUROSCI.4432-08.2009; Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177, DOI 10.1097/01.OPX.0000156311.49058.C8; Wallace JM, 2017, J VISION, V17, DOI 10.1167/17.1.33; Woods AJ, 2016, CLIN NEUROPHYSIOL, V127, P1031, DOI 10.1016/j.clinph.2015.11.012	50	7	7	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2020	15	5							e0232276	10.1371/journal.pone.0232276	http://dx.doi.org/10.1371/journal.pone.0232276			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT7ZB	32374787	Green Published, gold, Green Submitted			2023-01-03	WOS:000537283500029
J	Oh, SA; Yea, JW; Park, JW; Park, J				Oh, Se An; Yea, Ji Woon; Park, Jae Won; Park, Jaehyeon			Use of a head-tilting baseplate during volumetric-modulated arc therapy (VMAT) to better protect organs at risk in hippocampal sparing whole brain radiotherapy (HS-WBRT)	PLOS ONE			English	Article							RADIATION-THERAPY; INTRACRANIAL METASTASES; AVOIDANCE; PROGNOSIS; MEMORY	Purpose Coplanar arcs are used with limited arc range to prevent direct beam entrance through the lens, which is challenging for satisfactory planning of hippocampal sparing in whole brain radiotherapy (HS-WBRT) with VMAT. We evaluated the dosimetric impact of applying a head-tilting technique during VMAT, which allows unrestricted use of the arc range. Methods and materials Twenty patients with multiple brain metastases who had received two computed tomography (CT)-simulation sessions between January 2016 and December 2018 were included. One session was delivered in a traditional supine position; the other was delivered with a tilting acrylic supine baseplate (MedTec, USA) to elevate the patients' head by 40 degrees. For each patient, a VMAT without (sVMAT) and with head-tilting (htVMAT) plan was generated. Conformity index (CI), homogeneity index (HI), and organ at risk (OAR) dose were evaluated. The Wilcoxon-signed test was used to compare the effect between two plans. Results The mean CI was 0.860 +/- 0.007 and 0.864 +/- 0.008 (p<0.05), and mean HI was 0.179 +/- 0.020 and 0.167 +/- 0.021 (p<0.05) for sVMAT and htVMAT, respectively. The mean dose to the hippocampus (9.91 +/- 0.30 Gy) was significantly lower in htVMAT than in sVMAT (10.36 +/- 0.29 Gy, P<0.05). htVMAT was associated with significantly reduced mean dose to the parotid gland, and right and left lens (4.77 +/- 1.97 Gy vs. 5.92 +/- 1.68 Gy, p<0.05; 3.29 +/- 0.44 Gy vs. 7.22 +/- 1.26 Gy, p<0.05; 3.33 +/- 0.45 Gy vs. 6.73 +/- 1.01 Gy, p<0.05, respectively). Conclusion This is the first study to demonstrate that the head-tilting technique might be useful for HS-WBRT planning with VMAT. This method could remove the limitations associated with the arc range, resulting in improved dose distribution and conformity, while sparing healthy organs, including the hippocampus, lens, and parotid gland.	[Oh, Se An; Yea, Ji Woon; Park, Jae Won; Park, Jaehyeon] Yeungnam Univ, Med Ctr, Dept Radiat Oncol, Daegu, South Korea; [Yea, Ji Woon; Park, Jae Won; Park, Jaehyeon] Yeungnam Univ, Coll Med, Dept Radiat Oncol, Daegu, South Korea	Yeungnam University; Yeungnam University	Park, J (corresponding author), Yeungnam Univ, Med Ctr, Dept Radiat Oncol, Daegu, South Korea.; Park, J (corresponding author), Yeungnam Univ, Coll Med, Dept Radiat Oncol, Daegu, South Korea.	drjhyeon@gmail.com		Park, Jaewon/0000-0003-1100-5301; park, jaehyeon/0000-0003-2546-4808; Oh, SeAn/0000-0002-8835-2814	2019 Yeungnam University Research Grant [219A580063]	2019 Yeungnam University Research Grant	This study was supported by the 2019 Yeungnam University Research Grant (219A580063). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abayomi OK, 1996, ACTA ONCOL, V35, P659, DOI 10.3109/02841869609083995; Aoyama H, 2006, JAMA-J AM MED ASSOC, V295, P2483, DOI 10.1001/jama.295.21.2483; Buglione M, 2015, RADIOL MED, V120, P1146, DOI 10.1007/s11547-015-0542-0; Cagney DN, 2017, NEURO-ONCOLOGY, V19, P1511, DOI 10.1093/neuonc/nox077; Chang EL, 2009, LANCET ONCOL, V10, P1037, DOI 10.1016/S1470-2045(09)70263-3; Dobi A, 2020, PATHOL ONCOL RES, V26, P149, DOI 10.1007/s12253-018-0383-y; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Gondi V, 2014, J CLIN ONCOL, V32, P3810, DOI 10.1200/JCO.2014.57.2909; Gondi V, 2013, INT J RADIAT ONCOL, V85, P348, DOI 10.1016/j.ijrobp.2012.11.031; Gondi V, 2010, RADIOTHER ONCOL, V95, P327, DOI 10.1016/j.radonc.2010.02.030; Jiang AJ, 2019, RADIAT ONCOL, V14, DOI 10.1186/s13014-019-1255-7; Knisely JPS, 2011, INT J RADIAT ONCOL, V79, P957, DOI 10.1016/j.ijrobp.2010.11.001; Lee K, 2016, MED DOSIM, V41, P15, DOI 10.1016/j.meddos.2015.06.003; Neriishi K, 2012, RADIOLOGY, V265, P167, DOI 10.1148/radiol.12111947; Noh OK, 2011, RADIOTHER ONCOL, V98, P223, DOI 10.1016/j.radonc.2010.12.013; Park J, 2019, RADIAT ONCOL J, V37, P22, DOI 10.3857/roj.2019.00059; Rogers L, 2017, NEURO-ONCOLOGY, V19, P133; Rohan EA, 2018, CANCER CAUSE CONTROL, V29, P1277, DOI 10.1007/s10552-018-1107-z; Shen J, 2015, MED DOSIM, V40, P205, DOI 10.1016/j.meddos.2014.11.007; Sood S, 2017, MED DOSIM, V42, P375, DOI 10.1016/j.meddos.2017.07.005; Sun B, 2016, RADIOTHER ONCOL, V118, P181, DOI 10.1016/j.radonc.2015.11.010; Sundstrom JT, 1998, ANN MED, V30, P296, DOI 10.3109/07853899809005858; Wang K, 2019, JAMA ONCOL, V5, P221, DOI 10.1001/jamaoncol.2018.4951; Welzel G, 2008, INT J RADIAT ONCOL, V72, P1311, DOI 10.1016/j.ijrobp.2008.03.009; ZIMM S, 1981, CANCER, V48, P384, DOI 10.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8	25	3	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2020	15	4							e0232430	10.1371/journal.pone.0232430	http://dx.doi.org/10.1371/journal.pone.0232430			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LS8ZG	32348379	Green Published, gold			2023-01-03	WOS:000536668200067
J	Chukwusa, E; Yu, PH; Verne, J; Taylor, R; Higginson, IJ; Wei, G				Chukwusa, Emeka; Yu, Peihan; Verne, Julia; Taylor, Ros; Higginson, Irene J.; Wei, Gao			Regional variations in geographic access to inpatient hospices and Place of death: A Population-based study in England, UK	PLOS ONE			English	Article							PALLIATIVE CARE; END	Background There is much variation in hospice use with respect to geographic factors such as area-based deprivation, location of patient's residence and proximity to services location. However, little is known about how the association between geographic access to inpatient hospice and hospice deaths varies by patients' region of settlement. Study aim To examine regional differences in the association between geographic access to inpatient hospice and hospice deaths. Methods A regional population-based observational study in England, UK. Records of patients aged >= 25 years (n = 123088) who died from non-accidental causes in 2014, were extracted from the Office for National Statistics (ONS) death registry. Our cohort comprised of patients who died at home and in inpatient hospice. Decedents were allocated to each of the nine government office regions of England (London, East Midlands, West Midlands, East, Yorkshire and The Humber, South West, South East, North West and North East) through record linkage with their postcode of usual residence. We defined geographic access as a measure of drive times from patients' residential location to the nearest inpatient hospice. A modified Poisson regression estimated the association between geographic access to hospice, comparing hospice deaths (1) versus home deaths (0). We developed nine regional specific models and adjusted for regional differences in patient's clinical & socio-demographic characteristics. The strength of the association was estimated with adjusted Proportional Ratios (aPRs). Findings The percentage of deaths varied across regions (home: 86.7% in the North East to 73.0% in the South East; hospice: 13.3% in the North East to 27.0% in the South East). We found wide differences in geographic access to inpatient hospices across regions. Median drive times to hospice varied from 4.6 minutes in London to 25.9 minutes in the North East. We found a dose-response association in the East: (aPRs: 0.22-0.78); East Midlands: (aPRs: 0.33-0.63); North East (aPRs: 0.19-0.87); North West (aPRs: 0.69-0.88); South West (aPRs: 0.56-0.89) and West Midlands (aPRs: 0.28-0.92) indicating that decedents who lived further away from hospices locations (>= 10 minutes) were less likely to die in a hospice. Conclusion The clear dose-response associations in six regions underscore the importance of regional specific initiatives to improve and optimise access to hospices. Commissioners and policy-makers need to do more to ensure that home death is not due to limited geographic access to inpatient hospice care.	[Chukwusa, Emeka; Yu, Peihan; Higginson, Irene J.; Wei, Gao] Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London, England; [Verne, Julia] Publ Hlth England, Natl End Life Care Intelligence Network, Knowledge & Intelligence South West, Bristol, Avon, England; [Taylor, Ros] Royal Marsden NHS Hosp Trust, London, England; [Taylor, Ros] Hosp UK, London, England	University of London; King's College London; Public Health England; Royal Marsden NHS Foundation Trust	Chukwusa, E (corresponding author), Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London, England.	emeka.chukwusa@kcl.ac.uk	; Higginson, Irene Julie/C-7309-2012	Chukwusa, Emeka/0000-0003-2576-8633; /0000-0001-8298-3415; Higginson, Irene Julie/0000-0002-3687-1313; Yu, Peihan/0000-0003-1284-5193	National Institute for Health Research, Health Services and Delivery Research Program (NIHR HS DR) [14/19/22]; National Institute for Health Research (NIHR) Applied Research Collaborations (ARC) South London	National Institute for Health Research, Health Services and Delivery Research Program (NIHR HS DR); National Institute for Health Research (NIHR) Applied Research Collaborations (ARC) South London	WG, IJH, JV. Obtained funding from the National Institute for Health Research, Health Services and Delivery Research Program (NIHR HS & DR, 14/19/22). This project is partly supported by the National Institute for Health Research (NIHR) Applied Research Collaborations (ARC) South London. ARC South London is part of the National Institute for Health Research (NIHR) and is a partnership between King's Health Partners, St. George's, University London, and St George's Healthcare NHS Trust. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, STRENGTH PALL CAR CO; Barbara Gomes N.C., 2011, LOCAL PREFERENCES PL; Benchimol EI, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001885; Bone AE, 2018, PALLIATIVE MED, V32, P329, DOI 10.1177/0269216317734435; Brennan F, 2007, J PAIN SYMPTOM MANAG, V33, P494, DOI 10.1016/j.jpainsymman.2007.02.022; Brunsdon C., 2014, GISTOOLS SOME FURTHE; Buck J., 2018, BMJ SUPPORTIVE PALLI; Chukwusa E, 2019, INT J HEALTH GEOGR, V18, DOI 10.1186/s12942-019-0172-1; Clark D., 1998, MORTALITY, V3, P43, DOI [10.1080/713685885, DOI 10.1080/713685885]; Connor SR, 2007, J PAIN SYMPTOM MANAG, V34, P277, DOI 10.1016/j.jpainsymman.2007.03.007; Davies JM, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002782; Department of H., 2008, END LIFE CARE STRATE; Dixon D, 2015, EQUITY PROVISION PAL; England JA, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2599-6; Etkind S.N., 2017, BMC MED, P15; Gao W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001410; Gatrell AC, 2003, J PUBLIC HEALTH MED, V25, P53, DOI 10.1093/pubmed/fdg011; Gatrell AC, 2012, HEALTH PLACE, V18, P832, DOI 10.1016/j.healthplace.2012.03.009; Gwyther L, 2009, J PAIN SYMPTOM MANAG, V38, P767, DOI 10.1016/j.jpainsymman.2009.03.003; Lewin-Koh N, 2011, MAPTOOLS TOOLS READI, P74; Lewis JM, 2011, J PAIN SYMPTOM MANAG, V42, P105, DOI 10.1016/j.jpainsymman.2010.10.265; Martin D, 2013, J R STAT SOC A STAT, V176, P585, DOI 10.1111/j.1467-985X.2012.01054.x; Openshaw Stan, 1983, CONCEPTS TECHNIQUES; Osinowo A.V., 2011, JULIA EXTERNAL CAUSE; R Development Core Team, 2011, R LANG ENV STAT COMP, DOI DOI 10.1007/978-3-540-74686-7; Sleeman KE, 2019, LANCET GLOB HEALTH, V7, pE883, DOI 10.1016/S2214-109X(19)30172-X; Teno JM, 2016, JAMA INTERN MED, V176, P364, DOI 10.1001/jamainternmed.2015.7479; UK H.a., 2015, DIR UK HOSP COUNT; Wang SY, 2015, J PALLIAT MED, V18, P771, DOI 10.1089/jpm.2014.0425; World Health Organization, 2014, GLOBAL ATLAS PALLIAT, P111; World Health Organization (WHO), 2018, PALL CAR FACT SHEETS; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	32	6	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2020	15	4							e0231666	10.1371/journal.pone.0231666	http://dx.doi.org/10.1371/journal.pone.0231666			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9LH	32302344	gold, Green Published			2023-01-03	WOS:000536016100042
J	Kato, N; Negishi, K; Sakai, C; Tsubota, K				Kato, Naoko; Negishi, Kazuno; Sakai, Chikako; Tsubota, Kazuo			Baseline factors predicting the need for corneal crosslinking in patients with keratoconus	PLOS ONE			English	Article							PROGRESSIVE KERATOCONUS; CLINICAL-TRIAL	Introduction The primary purpose of crosslinking is to halt the progression of ectasia. We retrospectively assessed the condition of keratoconus patients who were followed-up at least twice after the initial examination to evaluate keratoconus progression, to identify definitive factors to predict a later need for corneal crosslinking (CXL). Methods The medical charts of 158 eyes of 158 keratoconus patients (112 males and 46 females; mean age, 27.8 +/- 11.7 years), who were followed up at the Department of Ophthalmology, Keio University School of Medicine at least twice after the initial examination to evaluate keratoconus progression were retrospectively reviewed. Best-spectacle corrected visual acuity, intraocular pressure, steepest corneal axis on the anterior float (Ks), thinnest corneal thickness according to Pentacam (R) HR, and corneal endothelial cell density were assessed. Gender, age, onset age of keratoconus, history of atopic dermatitis, and Pentacam (R) indices were also recorded. CXL was performed when the eye showed significant keratoconus progression, an increase in the steepest keratometric value, or an increase in the spherical equivalent or cylinder power of the manifest refraction by more than 1.0 D versus the respective values 2 years prior. Predictor variables and the requirement for CXL were analyzed using logistic regression. Results Fifty-eight eyes required CXL treatment. The best predictor of the requirement for CXL was patient age, followed by the Pentacam (R) Rmin (the minimum sagittal curvature evaluated by Pentacam (R)) value. The incidence of CXL was 86.4% in the < 20 years age group, with an Rmin of <= 5.73 mm, whereas 10.8% in the >= 27 years age group with an Rmin > 5.73 mm underwent treatment. Conclusions An age of < 20 years and an Rmin value of <= 5.73 mm predicted keratoconus progression and the requirement for CXL treatment in the near future.	[Kato, Naoko] Minamiaoyama Eye Clin, Tokyo, Japan; [Kato, Naoko; Negishi, Kazuno; Sakai, Chikako; Tsubota, Kazuo] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan; [Tsubota, Kazuo] Tsubota Lab Inc, Tokyo, Japan	Keio University	Kato, N (corresponding author), Minamiaoyama Eye Clin, Tokyo, Japan.; Kato, N (corresponding author), Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.	naokato@bc.iij4u.or.jp	Negishi, Kazuno/AAG-3260-2021; Tsubota, Kazuo/M-1915-2013	Negishi, Kazuno/0000-0002-2892-9810; Kato, Naoko/0000-0002-6670-2043; Tsubota, Kazuo/0000-0002-8874-7111	EyeLens Pte. Ltd.; Tsubota Laboratory, Inc.	EyeLens Pte. Ltd.; Tsubota Laboratory, Inc.	This work was partly supported by funding from EyeLens Pte. Ltd., a distributor of the products and/or procedures of corneal crosslinking. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Outside the submitted work, Kazuo Tsubota reports his position as CEO of Tsubota Laboratory, Inc., Tokyo, Japan, a company producing a keratoconus treatment-related device. Tsubota Laboratory, Inc. provided support in the form of salary for KT, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alhayek A, 2015, INT J OPHTHALMOL-CHI, V8, P407, DOI 10.3980/j.issn.2222-3959.2015.02.35; Asri D, 2011, J CATARACT REFR SURG, V37, P2137, DOI 10.1016/j.jcrs.2011.08.026; Blackburn BJ, 2019, FRONT BIOENG BIOTECH, V29, P7, DOI DOI 10.3389/FBI0E.2019.00066; Ferdi AC, 2019, OPHTHALMOLOGY, V126, P935, DOI 10.1016/j.ophtha.2019.02.029; Fujimoto H, 2016, INVEST OPHTH VIS SCI, V57, pOCT169, DOI 10.1167/iovs.15-18650; Gokul A, 2017, BRIT J OPHTHALMOL, V101, P839, DOI 10.1136/bjophthalmol-2016-308682; Henriquez MA, 2018, EUR J OPHTHALMOL, V28, P415, DOI 10.1177/1120672118760149; Hersh PS, 2017, OPHTHALMOLOGY, V124, P1259, DOI [10.1016/j.ophtha.2017.05.036, 10.1016/j.ophtha.2017.03.052]; Jedzierowska M, 2019, BIOMED ENG ONLINE, V18, DOI 10.1186/s12938-019-0636-3; Khattak A, 2015, SAUDI J OPHTHALMOL, V29, P249, DOI 10.1016/j.sjopt.2015.02.005; Mazzotta C, 2018, CORNEA, V37, P560, DOI 10.1097/ICO.0000000000001505; Moshirfar Majid, 2013, Oman J Ophthalmol, V6, P12, DOI 10.4103/0974-620X.111895; Mukhtar S, 2018, INT OPHTHALMOL, V38, P2257, DOI 10.1007/s10792-017-0699-8; Olivo-Payne A, 2019, CLIN OPHTHALMOL, V13, P1183, DOI 10.2147/OPTH.S183347; Perez-Straziota C, 2018, CORNEA, V37, P802, DOI 10.1097/ICO.0000000000001579; Romano V, 2018, J REFRACT SURG, V34, P177, DOI 10.3928/1081597X-20180104-01; Terai N, 2012, CURR EYE RES, V37, P553, DOI 10.3109/02713683.2012.669007; Tian L, 2014, J REFRACT SURG, V30, P785, DOI 10.3928/1081597X-20140930-01; Wagner H, 2007, Cont Lens Anterior Eye, V30, P223, DOI 10.1016/j.clae.2007.03.001; Wisse RPL, 2019, JAMA OPHTHALMOL, V137, P610, DOI 10.1001/jamaophthalmol.2019.0415; Wittig-Silva C, 2008, J REFRACT SURG, V24, pS720, DOI 10.3928/1081597X-20080901-15; Wollensak G, 2003, AM J OPHTHALMOL, V135, P620, DOI 10.1016/S0002-9394(02)02220-1	22	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2020	15	4							e0231439	10.1371/journal.pone.0231439	http://dx.doi.org/10.1371/journal.pone.0231439			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9JM	32298314	Green Published, gold, Green Submitted			2023-01-03	WOS:000536011400044
J	Deyle, GD; Allen, CS; Allison, SC; Gill, NW; Hando, BR; Petersen, EJ; Dusenberry, DI; Rhon, DI				Deyle, Gail D.; Allen, Chris S.; Allison, Stephen C.; Gill, Norman W.; Hando, Benjamin R.; Petersen, Evan J.; Dusenberry, Douglas I.; Rhon, Daniel I.			Physical Therapy versus Glucocorticoid Injection for Osteoarthritis of the Knee	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAARTICULAR HYALURONIC-ACID; CLINICAL-PRACTICE GUIDELINES; MANUAL THERAPY; CORTICOSTEROID INJECTIONS; EXERCISE THERAPY; AMERICAN-COLLEGE; BOOSTER SESSIONS; HIP; MANAGEMENT; EFFICACY	Background Both physical therapy and intraarticular injections of glucocorticoids have been shown to confer clinical benefit with respect to osteoarthritis of the knee. Whether the short-term and long-term effectiveness for relieving pain and improving physical function differ between these two therapies is uncertain. Methods We conducted a randomized trial to compare physical therapy with glucocorticoid injection in the primary care setting in the U.S. Military Health System. Patients with osteoarthritis in one or both knees were randomly assigned in a 1:1 ratio to receive a glucocorticoid injection or to undergo physical therapy. The primary outcome was the total score on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at 1 year (scores range from 0 to 240, with higher scores indicating worse pain, function, and stiffness). The secondary outcomes were the time needed to complete the Alternate Step Test, the time needed to complete the Timed Up and Go test, and the score on the Global Rating of Change scale, all assessed at 1 year. Results We enrolled 156 patients with a mean age of 56 years; 78 patients were assigned to each group. Baseline characteristics, including severity of pain and level of disability, were similar in the two groups. The mean (+/- SD) baseline WOMAC scores were 108.8 +/- 47.1 in the glucocorticoid injection group and 107.1 +/- 42.4 in the physical therapy group. At 1 year, the mean scores were 55.8 +/- 53.8 and 37.0 +/- 30.7, respectively (mean between-group difference, 18.8 points; 95% confidence interval, 5.0 to 32.6), a finding favoring physical therapy. Changes in secondary outcomes were in the same direction as those of the primary outcome. One patient fainted while receiving a glucocorticoid injection. Conclusions Patients with osteoarthritis of the knee who underwent physical therapy had less pain and functional disability at 1 year than patients who received an intraarticular glucocorticoid injection. (ClinicalTrials.gov number, .) A randomized trial that compared physical therapy with a glucocorticoid injection showed that at 1 year, scores on scales that assessed pain and functional ability and scores on timed performance tests were better among patients who underwent physical therapy than among patients who received glucocorticoids.	[Deyle, Gail D.; Allen, Chris S.; Allison, Stephen C.; Gill, Norman W.; Dusenberry, Douglas I.; Rhon, Daniel I.] Brooke Army Med Ctr, San Antonio, TX USA; [Allison, Stephen C.; Hando, Benjamin R.] US Air Force, Special Warfare Training Wing, San Antonio, TX USA; [Allison, Stephen C.; Petersen, Evan J.] Univ Incarnate Word, San Antonio, TX USA; [Allen, Chris S.; Allison, Stephen C.] Univ Cincinnati, Coll Allied Hlth Sci, Cincinnati, OH USA; [Allison, Stephen C.; Rhon, Daniel I.] Madigan Army Med Ctr, Tacoma, WA 98431 USA	San Antonio Military Medical Center; United States Department of Defense; United States Army; United States Department of Defense; United States Air Force; University System of Ohio; University of Cincinnati; Madigan Army Medical Center	Deyle, GD (corresponding author), Brooke Army Med Ctr, Dept Rehabil Med, Phys Therapy Doctoral Fellowship Program, 3100 Schofield Rd, Ft Sam Houston, TX 78234 USA.	gdeyle@gvtc.com	Rhon, Daniel/C-9542-2011	Rhon, Daniel/0000-0002-4320-990X; Hando, Ben/0000-0002-7054-8958; Petersen, Evan J./0000-0002-1106-2843				Abbott JH, 2013, OSTEOARTHR CARTILAGE, V21, P525, DOI 10.1016/j.joca.2012.12.014; Abbott JH, 2015, J ORTHOP SPORT PHYS, V45, P975, DOI 10.2519/jospt.2015.6015; Alghadir A, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0637-8; ALTMAN RD, 1991, J RHEUMATOL, V18, P10; ALTMAN RD, 1987, J RHEUMATOL, V14, P3; Angst F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0; [Anonymous], 2018, VOX 0919; [Anonymous], 2014, VA DOD CLIN PRACT GU; Bedard NA, 2018, J BONE JOINT SURG AM, V100, P827, DOI 10.2106/JBJS.17.01045; Berger A, 2011, ARTHRITIS RHEUM-US, V63, P2268, DOI 10.1002/art.30417; Bove AM, 2018, PHYS THER, V98, P16, DOI 10.1093/ptj/pzx104; Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis-2013-204763; Deyle GD, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010528; Deyle GD, 2000, ANN INTERN MED, V132, P173, DOI 10.7326/0003-4819-132-3-200002010-00002; Deyle GD, 2005, PHYS THER, V85, P1301, DOI 10.1093/ptj/85.12.1301; Dhawan A, 2014, ARTHROSCOPY, V30, P65, DOI 10.1016/j.arthro.2013.09.002; Graham JW, 2007, PREV SCI, V8, P206, DOI 10.1007/s11121-007-0070-9; Hatfield GL, 2016, PHYS THER, V96, P324, DOI 10.2522/ptj.20150025; He WW, 2017, INT J SURG, V39, P95, DOI 10.1016/j.ijsu.2017.01.087; Heinrich Heine University of Dusseldorf, G POW STAT POW AN WI; Henriksen M, 2015, JAMA INTERN MED, V175, P923, DOI 10.1001/jamainternmed.2015.0461; Hepper CT, 2009, J AM ACAD ORTHOP SUR, V17, P638, DOI 10.5435/00124635-200910000-00006; Hmamouchi Ihsane, 2012, BMC Res Notes, V5, P58, DOI 10.1186/1756-0500-5-58; Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Jamtvedt G, 2008, PHYS THER, V88, P123, DOI 10.2522/ptj.20070043; Juni P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005328.pub3; Katz JN, 2013, NEW ENGL J MED, V368, P1675, DOI 10.1056/NEJMoa1301408; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Khoja SS, 2020, ARTHRIT CARE RES, V72, P184, DOI 10.1002/acr.24064; Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI [10.1002/art.41142, 10.1002/acr.24131]; Kompel AJ, 2019, RADIOLOGY, V293, P656, DOI 10.1148/radiol.2019190341; Li H, 2018, INT J RHEUM DIS, V21, P982, DOI 10.1111/1756-185X.13314; Lo S, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01171; Matzkin EG, 2017, J AM ACAD ORTHOP SUR, V25, P703, DOI 10.5435/JAAOS-D-16-00541; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; McAlindon TE, 2017, JAMA-J AM MED ASSOC, V317, P1967, DOI 10.1001/jama.2017.5283; Rhon D, 2016, OSTEOARTHR CARTILAGE, V24, pS233, DOI 10.1016/j.joca.2016.01.452; Roos EM, 2016, NAT REV RHEUMATOL, V12, P92, DOI 10.1038/nrrheum.2015.135; Smith TO, 2019, J RHEUMATOL, V46, P976, DOI 10.3899/jrheum.181066; Taylor AL, 2014, J ORTHOP SPORT PHYS, V44, P273, DOI 10.2519/jospt.2014.4710; Wright AA, 2011, J ORTHOP SPORT PHYS, V41, P319, DOI 10.2519/jospt.2011.3515	42	95	96	14	60	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 9	2020	382	15					1420	1429		10.1056/NEJMoa1905877	http://dx.doi.org/10.1056/NEJMoa1905877			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE6DO	32268027				2023-01-03	WOS:000526813400009
J	Richards, R; Schwartz, HR; Honeywell, ME; Stewart, MS; Cruz-Gordillo, P; Joyce, AJ; Landry, BD; Lee, MJ				Richards, Ryan; Schwartz, Hannah R.; Honeywell, Megan E.; Stewart, Mariah S.; Cruz-Gordillo, Peter; Joyce, Anna J.; Landry, Benjamin D.; Lee, Michael J.			Drug antagonism and single-agent dominance result from differences in death kinetics	NATURE CHEMICAL BIOLOGY			English	Article							CELL-DEATH; CANCER; COMBINATION; SENSITIVITY; QUANTIFICATION; IDENTIFICATION; THERAPY; REVEALS	Cancer treatment generally involves drugs used in combinations. Most previous work has focused on identifying and understanding synergistic drug-drug interactions; however, understanding antagonistic interactions remains an important and understudied issue. To enrich for antagonism and reveal common features of these combinations, we screened all pairwise combinations of drugs characterized as activators of regulated cell death. This network is strongly enriched for antagonism, particularly a form of antagonism that we call 'single-agent dominance'. Single-agent dominance refers to antagonisms in which a two-drug combination phenocopies one of the two agents. Dominance results from differences in cell death onset time, with dominant drugs acting earlier than their suppressed counterparts. We explored mechanisms by which parthanatotic agents dominate apoptotic agents, finding that dominance in this scenario is caused by mutually exclusive and conflicting use of Poly(ADP-ribose) polymerase 1 (PARP1). Taken together, our study reveals death kinetics as a predictive feature of antagonism, due to inhibitory crosstalk between cell death pathways.	[Richards, Ryan; Schwartz, Hannah R.; Honeywell, Megan E.; Stewart, Mariah S.; Cruz-Gordillo, Peter; Joyce, Anna J.; Landry, Benjamin D.; Lee, Michael J.] Univ Massachusetts, Sch Med, PSB, Worcester, MA 01655 USA; [Lee, Michael J.] Univ Massachusetts, PMM, Med Sch, Worcester, MA 01655 USA; [Lee, Michael J.] Univ Massachusetts, Dept Mol Cell & Canc Biol MCCB, Med Sch, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Lee, MJ (corresponding author), Univ Massachusetts, Sch Med, PSB, Worcester, MA 01655 USA.; Lee, MJ (corresponding author), Univ Massachusetts, PMM, Med Sch, Worcester, MA 01655 USA.; Lee, MJ (corresponding author), Univ Massachusetts, Dept Mol Cell & Canc Biol MCCB, Med Sch, Worcester, MA 01655 USA.	michael.lee@umassmed.edu		Lee, Michael/0000-0003-3378-6196; Cruz-Gordillo, Peter/0000-0002-0264-7348; Honeywell, Megan/0000-0002-4894-8672; Schwartz, Hannah/0000-0003-3988-3798; Stewart, Mariah/0000-0003-2841-6932	National Institute of General Medical Sciences of the National Institutes of Health [R01GM127559]; American Cancer Society [RSG-17-011-01]; NIH/NCI training grant (Translational Cancer Biology Training Grant) [T32-CA130807]	National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); American Cancer Society(American Cancer Society); NIH/NCI training grant (Translational Cancer Biology Training Grant)	We thank current and past members of the Lee labotatory and all members of PSB for their helpful comments and critiques during the execution of this study. In addition, we thank M. Walhout, J. Dekker, A. Mitchell and J. Pritchard for their thoughtful comments during the preparation of this manuscript. The px330-puro-hSpCas9 plasmid was a kind gift from T. Fazzio (UMass Medical School). This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health (R01GM127559 to M.J.L.); the American Cancer Society (RSG-17-011-01 to M.J.L.); and an NIH/NCI training grant (Translational Cancer Biology Training Grant, T32-CA130807 to R.R., B.D.L. and P.C.G.).	Al-Lazikani B, 2012, NAT BIOTECHNOL, V30, P679, DOI 10.1038/nbt.2284; [Anonymous], CELL DEATH DIFFERENT; Axelrod M, 2013, ONCOTARGET, V4, P622, DOI 10.18632/oncotarget.938; Baeder DY, 2016, PHILOS T R SOC B, V371, DOI 10.1098/rstb.2015.0294; Chiu LY, 2011, BIOCHEM PHARMACOL, V81, P459, DOI 10.1016/j.bcp.2010.10.016; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cokol M, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.71; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Eling Nils, 2015, Oncoscience, V2, P517; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Forcina GC, 2017, CELL SYST, V4, P600, DOI 10.1016/j.cels.2017.05.002; Grootjans S, 2016, NAT PROTOC, V11, P1444, DOI 10.1038/nprot.2016.085; Hafner M, 2016, NAT METHODS, V13, P521, DOI [10.1038/nmeth.3853, 10.1038/NMETH.3853]; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Holbeck SL, 2017, CANCER RES, V77, P3564, DOI 10.1158/0008-5472.CAN-17-0489; Jaeger S, 2017, CANCER RES, V77, P459, DOI 10.1158/0008-5472.CAN-16-0097; Jouan-Lanhouet S, 2019, CELL DEATH DIFFER, V19, P1; Koplev S, 2017, CELL REP, V20, P2784, DOI 10.1016/j.celrep.2017.08.095; Kummar S, 2010, NAT REV DRUG DISCOV, V9, P843, DOI 10.1038/nrd3216; Landry BD, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20188322; LASTER SM, 1988, J IMMUNOL, V141, P2629; Lederer S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00031; Lee MJ, 2012, CELL, V149, P780, DOI 10.1016/j.cell.2012.03.031; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Louandre C, 2013, INT J CANCER, V133, P1732, DOI 10.1002/ijc.28159; Marusyk A, 2016, CANCER RES, V76, P6495, DOI 10.1158/0008-5472.CAN-16-1457; Menden MP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09799-2; Merino D, 2018, CANCER CELL, V34, P879, DOI 10.1016/j.ccell.2018.11.004; Michel JB, 2008, P NATL ACAD SCI USA, V105, P14918, DOI 10.1073/pnas.0800944105; Miller ML, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004014; Newton K, 2019, NATURE, V574, P428, DOI 10.1038/s41586-019-1548-x; O'Neil J, 2016, MOL CANCER THER, V15, P1155, DOI 10.1158/1535-7163.MCT-15-0843; Palmer AC, 2017, CELL, V171, P1678, DOI 10.1016/j.cell.2017.11.009; Pemovska T, 2018, CURR OPIN PHARMACOL, V42, P102, DOI 10.1016/j.coph.2018.07.008; Pritchard JR, 2013, P NATL ACAD SCI USA, V110, pE170, DOI 10.1073/pnas.1210419110; Rees MG, 2016, NAT CHEM BIOL, V12, P109, DOI [10.1038/NCHEMBIO.1986, 10.1038/nchembio.1986]; Roux J, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20145584; Russ D, 2018, NAT MICROBIOL, V3, P1339, DOI 10.1038/s41564-018-0252-1; Simpkins SW, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006532; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Tallarida RJ, 2002, PAIN, V98, P163, DOI 10.1016/S0304-3959(02)00041-6; Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737; Wang YF, 2016, SCIENCE, V354, DOI 10.1126/science.aad6872; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wlodkowic D, 2011, METHODS MOL BIOL, V731, P285, DOI 10.1007/978-1-61779-080-5_23; Yap Timothy A, 2019, Am Soc Clin Oncol Educ Book, V39, P185, DOI 10.1200/EDBK_238473; Yi N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093960; Zhao BY, 2014, CANCER DISCOV, V4, P166, DOI 10.1158/2159-8290.CD-13-0465; Zimmermann M, 2018, NATURE, V559, P285, DOI 10.1038/s41586-018-0291-z	50	10	10	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUL	2020	16	7					791	+		10.1038/s41589-020-0510-4	http://dx.doi.org/10.1038/s41589-020-0510-4		APR 2020	15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA4ME	32251407	Green Accepted			2023-01-03	WOS:000523953900005
J	Muyor, JM; Martin-Fuentes, I; Rodriguez-Ridao, D; Antequera-Vique, JA				Muyor, Jose M.; Martin-Fuentes, Isabel; Rodriguez-Ridao, David; Antequera-Vique, Jose A.			Electromyographic activity in the gluteus medius, gluteus maximus, biceps femoris, vastus lateralis, vastus medialis and rectus femoris during the Monopodal Squat, Forward Lunge and Lateral Step-Up exercises	PLOS ONE			English	Article							MUSCLE-ACTIVITY; THIGH MUSCLES; SURFACE ELECTROMYOGRAPHY; BACK SQUAT; HIP; STRENGTH; ACTIVATION; DEADLIFT; LOAD; PERFORMANCE	The Monopodal Squat, Forward Lunge and Lateral Step-Up exercises are commonly performed with one's own body weight for rehabilitation purposes. However, muscle activity evaluated using surface electromyography has never been analyzed among these three exercises. Therefore, the objectives of the present study were to evaluate the amplitude of the EMG activity of the gluteus medius, gluteus maximus, biceps femoris, vastus lateralis, vastus medialis and rectus femoris muscles in participants performing the Lateral Step-Up, Forward Lunge and Monopodal Squat exercises. A total of 20 physically active participants (10 men and 10 women) performed 5 repetitions at 60% (5 repetition maximum) in each of the evaluated exercises. The EMG amplitude was calculated in percentage of the maximum voluntary contraction. The Monopodal Squat exercise showed a higher EMG activity (p. 0.001) in relation to the Lateral Step-Up and Forward Lunge exercises in all of the evaluated muscles (d > 0.6) except for the rectus femoris. The three exercises showed significantly higher EMG activity in all of the muscles that were evaluated in the concentric phase in relation to the eccentric one. In the three evaluated exercises, vastus lateralis and vastus medialis showed the highest EMG activity, followed by gluteus medius and gluteus maximus. The Monopodal Squat, Forward Lunge and Lateral Step-Up exercises not only are recommended for their rehabilitation purposes but also should be recommended for performance objectives and strength improvement in the lower limbs.	[Muyor, Jose M.] Univ Almeria, Res Cent Serv, Lab Kinesiol Biomech & Ergon KIBIOMER Lab, Almeria, Spain; [Muyor, Jose M.; Martin-Fuentes, Isabel; Rodriguez-Ridao, David; Antequera-Vique, Jose A.] Univ Almeria, Hlth Res Ctr, Almeria, Spain; [Martin-Fuentes, Isabel] Univ Almeria, Fac Educ Sci, Edificio Cent, Almeria, Spain	Universidad de Almeria; Universidad de Almeria; Universidad de Almeria	Martin-Fuentes, I (corresponding author), Univ Almeria, Hlth Res Ctr, Almeria, Spain.; Martin-Fuentes, I (corresponding author), Univ Almeria, Fac Educ Sci, Edificio Cent, Almeria, Spain.	imf902@ual.es	Fuentes, Isabel Martín/AAC-8399-2019; Muyor, José M./M-7342-2015	Fuentes, Isabel Martín/0000-0003-4268-1935; Muyor, José M./0000-0003-2849-0323	Proyectos I+D +I Ministerio de Economia y Competitividad. Gobierno de Espana [DEP 2016-80296-R]	Proyectos I+D +I Ministerio de Economia y Competitividad. Gobierno de Espana	This work was supported by the Proyectos I+D +I Ministerio de Economia y Competitividad. Gobierno de Espana. Referencia: DEP 2016-80296-R (AEI/FEDER, UE).	Anders C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178957; Andersen LL, 2006, PHYS THER, V86, P683, DOI 10.1093/ptj/86.5.683; Andersen V, 2018, J STRENGTH COND RES, V32, P587, DOI 10.1519/JSC.0000000000001826; Andersen V, 2015, J STRENGTH COND RES, V29, P2932, DOI 10.1519/JSC.0000000000000950; Ankrum DR, 2000, P HUM FACTORS ERGON, V44, DOI [10.1177/00005768-200010000-00015, DOI 10.1177/00005768-200010000-00015]; Aspe RR, 2014, J STRENGTH COND RES, V28, P2827, DOI 10.1519/JSC.0000000000000462; Ayotte NW, 2007, J ORTHOP SPORT PHYS, V37, P48, DOI 10.2519/jospt.2007.2354; Bolgla LA, 2016, PHYSIOTHER THEOR PR, V32, P130, DOI 10.3109/09593985.2015.1092059; Bouillon LE, 2012, INT J SPORTS PHYS TH, V7, P595; Bourne MN, 2015, AM J SPORT MED, V43, P2663, DOI 10.1177/0363546515599633; Bussey MD, 2018, MUSCULOSKEL SCI PRAC, V34, P103, DOI 10.1016/j.msksp.2017.09.004; Camara KD, 2016, J STRENGTH COND RES, V30, P1183, DOI 10.1519/JSC.0000000000001352; DeFOREST Bradley A, 2014, Int J Exerc Sci, V7, P302; Earp JE, 2016, J STRENGTH COND RES, V30, P1585, DOI 10.1519/JSC.0000000000001405; Ebben WP, 2002, J STRENGTH COND RES, V16, P547, DOI 10.1519/00124278-200211000-00009; Ebenbichler GR, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00299; Eliassen W, 2018, INT J SPORTS PHYS TH, V13, P871, DOI 10.26603/ijspt20180871; Foley RCA, 2017, INT J SPORTS PHYS TH, V12, P550; Ford KR, 2015, OPEN ACCESS J SPORTS, V6, P291, DOI 10.2147/OAJSM.S72432; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Gianola S, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1660-8; Giorgio P, 2009, J STRENGTH COND RES, V23, P652, DOI 10.1519/JSC.0b013e31818f0950; Hatfield GL, 2017, J STRENGTH COND RES, V31, P3444, DOI 10.1519/JSC.0000000000001756; Hegyi A, 2018, SCAND J MED SCI SPOR, V28, P992, DOI 10.1111/sms.13016; Jonhagen S, 2009, SCAND J MED SCI SPOR, V19, P561, DOI 10.1111/j.1600-0838.2007.00692.x; Komi PV, 2000, MED SCI SPORT EXER, V32, P1757, DOI 10.1097/00005768-200010000-00015; Kraemer WJ, 1997, J STRENGTH COND RES, V11, P131; Krause DA, 2018, INT J SPORTS PHYS TH, V13, P137, DOI 10.26603/ijspt20180137; Krause DA, 2009, J STRENGTH COND RES, V23, P2689, DOI 10.1519/JSC.0b013e3181bbe861; Teixeira CVL, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00643; Lanza MB, 2018, J STRENGTH COND RES, V32, pE58, DOI 10.1519/JSC.0000000000002953; Lehecka BJ, 2017, INT J SPORTS PHYS TH, V12, P543; Levine TR, 2002, HUM COMMUN RES, V28, P612, DOI 10.1111/j.1468-2958.2002.tb00828.x; MacAskill MJ, 2014, INT J SPORTS PHYS TH, V9, P907; Maia MF, 2014, J STRENGTH COND RES, V28, P2529, DOI 10.1519/JSC.0000000000000451; Marcolin G, 2018, PEERJ, V6, DOI 10.7717/peerj.5165; Matheson JW, 2001, MED SCI SPORT EXER, V33, P1713, DOI 10.1097/00005768-200110000-00016; McCurdy K, 2018, J STRENGTH COND RES, V32, P594, DOI 10.1519/JSC.0000000000001893; McCurdy K, 2010, J SPORT REHABIL, V19, P57, DOI 10.1123/jsr.19.1.57; Nijem RM, 2014, STRENGTH COND J, V36, P113, DOI 10.1519/SSC.0000000000000085; O'Sullivan K, 2010, BMC SPORTS SCI MED R, V2, DOI 10.1186/1758-2555-2-17; Oshikawa Tomoki, 2018, J Phys Ther Sci, V30, P434, DOI 10.1589/jpts.30.434; Paoli A, 2009, J STRENGTH COND RES, V23, P246, DOI 10.1519/JSC.0b013e3181876811; Peterson MD, 2010, AGEING RES REV, V9, P226, DOI 10.1016/j.arr.2010.03.004; Pincivero DM, 2006, J BIOMECH, V39, P246, DOI 10.1016/j.jbiomech.2004.11.023; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; Reiman Michael P., 2012, Physiotherapy Theory and Practice, V28, P257, DOI 10.3109/09593985.2011.604981; Reiman MP, 2009, J SPORT REHABIL, V18, P33, DOI 10.1123/jsr.18.1.33; Renshaw Doug, 2010, Int J Exerc Sci, V3, P43; Schmitz RJ, 2002, J SPORT REHABIL, V11, P179, DOI 10.1123/jsr.11.3.179; Speirs DE, 2016, J STRENGTH COND RES, V30, P386, DOI 10.1519/JSC.0000000000001096; Stastny P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171632; Stastny P, 2015, ACTA GYMNICA, V45, P51, DOI 10.5507/ag.2015.011; Stastny P, 2015, J STRENGTH COND RES, V29, P3177, DOI 10.1519/JSC.0000000000000976; Stastny P, 2014, NEUROENDOCRINOL LETT, V35, P633; Vigotsky AD, 2018, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00985; Westcott WL, 2012, CURR SPORT MED REP, V11, P209, DOI 10.1249/JSR.0b013e31825dabb8; Yavuz HU, 2017, APPL BIONICS BIOMECH, V2017, DOI 10.1155/2017/9084725; Young WB, 1998, J STRENGTH COND RES, V12, P82, DOI 10.1519/1533-4287(1998)012<0082:AEOPPF>2.3.CO;2	59	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2020	15	4							e0230841	10.1371/journal.pone.0230841	http://dx.doi.org/10.1371/journal.pone.0230841			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8IA	32236133	Green Published, gold			2023-01-03	WOS:000535938700033
J	Weeks, MR; Lounsbury, DW; Li, JH; Hirsch, G; Berman, M; Green, HD; Rohena, L; Gonzalez, R; Montezuma-Rusca, JM; Jackson, S				Weeks, Margaret R.; Lounsbury, David W.; Li, Jianghong; Hirsch, Gary; Berman, Marcie; Green, Helena D.; Rohena, Lucy; Gonzalez, Rosely; Montezuma-Rusca, Jairo M.; Jackson, Seja			Simulating system dynamics of the HIV care continuum to achieve treatment as prevention	PLOS ONE			English	Article							PUBLIC-HEALTH; ANTIRETROVIRAL THERAPY; MODEL; ENGAGEMENT; IMPACT; VALIDATION; SCIENCE; POLICY; TRANSMISSION; PREVALENCE	The continuing HIV pandemic calls for broad, multi-sectoral responses that foster community control of local prevention and care services, with the goal of leveraging high quality treatment as a means of reducing HIV incidence. Service system improvements require stakeholder input from across the care continuum to identify gaps and to inform strategic plans that improve HIV service integration and delivery. System dynamics modeling offers a participatory research approach through which stakeholders learn about system complexity and about ways to achieve sustainable system-level improvements. Via an intensive group model building process with a task force of community stakeholders with diverse roles and responsibilities for HIV service implementation, delivery and surveillance, we designed and validated a multi-module system dynamics model of the HIV care continuum, in relation to local prevention and care service capacities. Multiple sources of data were used to calibrate the model for a three-county catchment area of central Connecticut. We feature a core module of the model for the purpose of illustrating its utility in understanding the dynamics of treatment as prevention at the community level. We also describe the methods used to validate the model and support its underlying assumptions to improve confidence in its use by stakeholders for systems understanding and decision making. The model's generalizability and implications of using it for future community-driven strategic planning and implementation efforts are discussed.	[Weeks, Margaret R.; Li, Jianghong; Berman, Marcie; Green, Helena D.; Rohena, Lucy; Gonzalez, Rosely] Inst Community Res, Hartford, CT 06106 USA; [Lounsbury, David W.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA; [Hirsch, Gary] Creator Learning Environm, Wayland, MA USA; [Montezuma-Rusca, Jairo M.] Univ Connecticut, Ctr Hlth, Dept Internal Med, Farmington, CT USA; [Jackson, Seja] Burgdorf Hlth Ctr, St Francis Hosp, Hartford, CT USA; [Jackson, Seja] Burgdorf Hlth Ctr, Med Ctr, Hartford, CT USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Connecticut; Saint Francis Hospital & Medical Center	Weeks, MR (corresponding author), Inst Community Res, Hartford, CT 06106 USA.	mweeks@icrweb.org		Montaque, Helena/0000-0003-2806-0921; Weeks, Margaret R./0000-0001-7493-0276	U.S. National Institute of Mental Health of the National Institutes of Health [R01MH103176, R21MH110335]	U.S. National Institute of Mental Health of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	(MRW) Research reported in this publication was supported by the U.S. National Institute of Mental Health of the National Institutes of Health (https://www.nimh.nih.gov/index.shtml) under Award Numbers R01MH103176 and R21MH110335. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arquitt S, 2004, SYST DYNAM REV, V20, P179, DOI 10.1002/sdr.292; Atkinson JAM, 2015, PUBLIC HEALTH RES PR, V25, DOI 10.17061/phrp2531531; Barlas Y, 1996, SYST DYNAM REV, V12, P183, DOI 10.1002/(SICI)1099-1727(199623)12:3<183::AID-SDR103>3.0.CO;2-4; BARLAS Y, 1989, EUR J OPER RES, V42, P59, DOI 10.1016/0377-2217(89)90059-3; Castel AD, 2012, AIDS, V26, P345, DOI 10.1097/QAD.0b013e32834de5fe; Centers for Disease Control and Prevention, 2012, US VIR LOAD DAT MON; Centers for Disease Control & Prevention, 2013, BACKGR BRIEF PREV BE; Chen YY, 2013, CURR HIV-AIDS REP, V10, P79, DOI 10.1007/s11904-012-0144-6; Cohen MS, 2012, HEALTH AFFAIR, V31, P1439, DOI 10.1377/hlthaff.2012.0250; Cohen MS, 2012, CLIN TRIALS, V9, P340, DOI 10.1177/1740774512443594; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; CT Department of Public Health, 2018, EST HIV PREV PERS AG; CT Department of Public Health, 2015, CONN HIV STAT 2014; CT Department of Public Health, 2018, EP PROF HIV CONN; Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068; Department of Public Health SF, 2000, MED CARE, V38, P58, DOI [10.1097/00005650-200001000-00007, DOI 10.1097/00005650-200001000-00007]; Eisinger RW, 2019, JAMA J AM MED ASS; Fauci AS, 2019, JAMA-J AM MED ASSOC, V321, P844, DOI 10.1001/jama.2019.1343; Forrester J. W., 1980, TIMS STUDIES MANAGEM, V14, P201; Foster-Fishman PG, 2007, AM J COMMUN PSYCHOL, V39, P197, DOI 10.1007/s10464-007-9109-0; Foster-Fishman PG, 2007, AM J COMMUN PSYCHOL, V39, P191, DOI 10.1007/s10464-007-9104-5; Foster-Fishman PG, 2001, AM J COMMUN PSYCHOL, V29, P241, DOI 10.1023/A:1010378613583; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Gillen EM, 2014, HEALTH EDUC BEHAV, V41, P63, DOI 10.1177/1090198113486804; Granich R, 2010, CURR OPIN HIV AIDS, V5, P298, DOI 10.1097/COH.0b013e32833a6c32; Hartford Department of Health and Human Services, 2016, RYAN WHIT PRIO UNPUB; Hirsch G, 2010, AM J PUBLIC HEALTH, V100, P616, DOI 10.2105/AJPH.2009.159434; Hirsch GB, 2007, AM J COMMUN PSYCHOL, V39, P239, DOI 10.1007/s10464-007-9114-3; Holtgrave DR, 2012, AIDS BEHAV, V16, P1085, DOI 10.1007/s10461-012-0186-1; Holtzman CW, 2015, DRUGS, V75, P445, DOI 10.1007/s40265-015-0373-2; Homer JB, 2006, AM J PUBLIC HEALTH, V96, P452, DOI 10.2105/AJPH.2005.062059; HOVMAND PETER S., 2014, COMMUNITY BASED SYST; Hull MW, 2012, CURR OPIN HIV AIDS, V7, P579, DOI 10.1097/COH.0b013e3283590617; Joint United Nations Programme on HIV/AIDS, 2010, GETT ZER 2011 2015 S; Kok S, 2015, HEALTH CARE MANAG SC, V18, P334, DOI 10.1007/s10729-014-9312-0; Leischow SJ, 2006, AM J PUBLIC HEALTH, V96, P403, DOI 10.2105/AJPH.2005.082842; Lounsbury DW, 2015, AIDS PATIENT CARE ST, V29, pS55, DOI 10.1089/apc.2014.0276; Lounsbury DW, 2014, QUAL LIFE RES, V23, P959, DOI 10.1007/s11136-013-0532-4; Luna-Reyes LF, 2006, SYST DYNAM REV, V22, P291, DOI 10.1002/sdr.349; Mabry PL, 2010, AM J PUBLIC HEALTH, V100, P1161, DOI 10.2105/AJPH.2010.198176; Macmillan A, 2016, ENVIRON HEALTH-GLOB, V15, DOI 10.1186/s12940-016-0098-z; Maglio PP, 2014, AM J PUBLIC HEALTH, V104, P1181, DOI 10.2105/AJPH.2014.301873; Marshall DA, 2015, VALUE HEALTH, V18, P5, DOI 10.1016/j.jval.2014.12.001; Martin EG, 2015, JAIDS-J ACQ IMM DEF, V68, pS59, DOI 10.1097/QAI.0000000000000395; Meadows DonellaH., 2015, THINKING SYSTEMS PRI; Montaner JSG, 2006, LANCET, V368, P531, DOI 10.1016/S0140-6736(06)69162-9; Northridge ME, 2016, HEALTH RES POLICY SY, V14, DOI 10.1186/s12961-016-0146-8; Oliva R, 2003, EUR J OPER RES, V151, P552, DOI 10.1016/S0377-2217(02)00622-7; Peterson S, 2019, SYST DYNAM REV, V35, P55, DOI 10.1002/sdr.1620; Qudrat-Ullah H, 2012, TELECOMMUN SYST, V51, P159, DOI 10.1007/s11235-011-9425-4; Qudrat-Ullah H, 2010, ENERG POLICY, V38, P2216, DOI 10.1016/j.enpol.2009.12.009; Richardson G. P., 1995, SYST DYNAM REV, V11, P1; Richardson G. P, 1999, FEEDBACK THOUGHT SOC; Richardson GP, 2011, SYST DYNAM REV, V27, P219, DOI 10.1002/sdr.462; Roussos ST, 2000, ANNU REV PUBL HEALTH, V21, P369, DOI 10.1146/annurev.publhealth.21.1.369; Schwarcz S, 2006, JAIDS-J ACQ IMM DEF, V43, P491, DOI 10.1097/01.qai.0000243114.37035.de; Scott RJ, 2013, SYST DYNAM REV, V29, P216, DOI 10.1002/sdr.1505; Song RG, 2017, JAIDS-J ACQ IMM DEF, V74, P3, DOI 10.1097/QAI.0000000000001151; Stave KA, 2002, SYST DYNAM REV, V18, P139, DOI 10.1002/sdr.237; Stave Krystyna, 2010, SUSTAINABILITY-BASEL, V2, DOI [10.3390/su2092762, DOI 10.3390/SU2092762]; Sterman, 1984, DYNAMICA, V10, P51; Sterman J., 2010, BUSINESS DYNAMICS, DOI DOI 10.4324/9781351152723-7; Sterman JD, 2006, AM J PUBLIC HEALTH, V96, P505, DOI 10.2105/AJPH.2005.066043; Sterman JD, 2002, SYST DYNAM REV, V18, P501, DOI 10.1002/sdr.261; STERMAN JD, 1994, SYST DYNAM REV, V10, P291, DOI 10.1002/sdr.4260100214; Terzian AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029679; Tozan Y, 2015, J URBAN HEALTH, V92, P490, DOI 10.1007/s11524-015-9963-2; UNAIDS, 2014, 90 90 90 AMBITIOUS T; Valdiserri R., HIV AIDS TREATMENT C; Van Olmen J, 2012, HLTH SYSTEM DYNAMICS; VANDENBELT M, 2004, MEDIATED MODELING SY; Vennix JAM, 1996, ENCY LIFE SUPPORT SY; Walensky RP, 2013, NEW ENGL J MED, V369, P1715, DOI 10.1056/NEJMsa1214720; Weeks MR, 2013, HEALTH EDUC RES, V28, P375, DOI 10.1093/her/cyt051; Weeks MR, 2017, AM J COMMUN PSYCHOL, V60, P584, DOI 10.1002/ajcp.12204; Zetola NM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-17; Zimmerman L, 2016, ADM POLICY MENT HLTH, V43, P834, DOI 10.1007/s10488-016-0754-1; Zolopa AR, 2010, ANTIVIR RES, V85, P241, DOI 10.1016/j.antiviral.2009.10.018	78	4	4	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2020	15	3							e0230568	10.1371/journal.pone.0230568	http://dx.doi.org/10.1371/journal.pone.0230568			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ9FM	32191771	gold, Green Published			2023-01-03	WOS:000535302300061
J	Chang, TS; Tsai, YH; Lin, YH; Chen, CH; Lu, CK; Huang, WS; Yang, YH; Chen, WM; Hsieh, YY; Wu, YC; Tung, SY; Huang, YH				Chang, Te-Sheng; Tsai, Ying-Huang; Lin, Yi-Heng; Chen, Chun-Hsien; Lu, Chung-Kuang; Huang, Wen-Shih; Yang, Yao-Hsu; Chen, Wei-Ming; Hsieh, Yung-Yu; Wu, Yu-Chih; Tung, Shui-Yi; Huang, Yen-Hua			Limited effects of antibiotic prophylaxis in patients with Child-Pugh class A/B cirrhosis and upper gastrointestinal bleeding	PLOS ONE			English	Article							ACUTE VARICEAL HEMORRHAGE; BACTERIAL-INFECTIONS; PORTAL-HYPERTENSION; RISK; CARE; THERAPY; ASCITES	Current guidelines recommend antibiotic prophylaxis for all patients with various degrees of cirrhosis and upper gastrointestinal (UGI) bleeding. This study assessed the need for antibiotic prophylaxis in patients with low Child-Pugh scores. We retrospectively screened all patients with cirrhosis who underwent upper endoscopies for UGI bleeding in a referral hospital in Taiwan between 2003 and 2014, from which 913 patients were enrolled after excluding patients with active bacterial infections, recent antibiotic use, early death, and Child-Pugh class C cirrhosis. Among them, 73 (8%) received prophylactic antibiotics, and 45 (4.9%) exhibited 14-day bacterial infection. Neither Child-Pugh score nor model for end stage liver disease score were optimal for predicting bacterial infection because their areas under the curves were 0.610 (95% confidence interval [CI]: 0.529-0.691) and 0.666 (95% CI: 0.591-0.742), respectively. Antibiotic prophylaxis did not reduce the risks of 14-day bacterial infection (relative risk [RR]: 0.932, 95% CI: 0.300-2.891, P = 0.902), 14-day rebleeding (RR: 0.791, 95% CI: 0.287-2.181, P = 0.650), or 42-day mortality (RR: 2.710, 95% CI: 0.769-9.524, P = 0.121). The results remained similar after propensity score adjustment. On-demand antibiotic treatment might suffice for patients with Child-Pugh class A/B cirrhosis and UGI bleeding.	[Chang, Te-Sheng; Chen, Chun-Hsien; Lu, Chung-Kuang; Chen, Wei-Ming; Hsieh, Yung-Yu; Tung, Shui-Yi] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Chiayi, Taiwan; [Chang, Te-Sheng; Tsai, Ying-Huang; Huang, Wen-Shih; Yang, Yao-Hsu; Chen, Wei-Ming; Hsieh, Yung-Yu; Tung, Shui-Yi] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Chang, Te-Sheng; Lin, Yi-Heng; Huang, Yen-Hua] Taipei Med Univ, Coll Med, Dept Biochem & Mol Cell Biol, Taipei, Taiwan; [Tsai, Ying-Huang] Chang Gung Mem Hosp, Dept Pulm & Crit Care Med, Chiayi, Taiwan; [Lin, Yi-Heng; Wu, Yu-Chih; Huang, Yen-Hua] Taipei Med Univ, Res Ctr Cell Therapy & Regenerat Med, Taipei, Taiwan; [Huang, Wen-Shih] Chang Gung Mem Hosp, Dept Surg, Div Colon & Rectal Surg, Chiayi, Taiwan; [Yang, Yao-Hsu] Chang Gung Mem Hosp, Dept Tradit Chinese Med, Chiayi, Taiwan; [Yang, Yao-Hsu] Chang Gung Mem Hosp, Hlth Informat & Epidemiol Lab, Chiayi, Taiwan; [Huang, Yen-Hua] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan; [Huang, Yen-Hua] Taipei Med Univ Hosp, Ctr Reprod Med, Taipei, Taiwan; [Huang, Yen-Hua] Taipei Med Univ, Comprehens Canc Ctr, Taipei, Taiwan; [Huang, Yen-Hua] Taipei Med Univ, Coll Med, Int PhD Program Cell Therapy & Regenerat Med, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Taipei Medical University; Chang Gung Memorial Hospital; Taipei Medical University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University	Tung, SY (corresponding author), Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Chiayi, Taiwan.; Tung, SY (corresponding author), Chang Gung Univ, Coll Med, Taoyuan, Taiwan.; Huang, YH (corresponding author), Taipei Med Univ, Coll Med, Dept Biochem & Mol Cell Biol, Taipei, Taiwan.; Huang, YH (corresponding author), Taipei Med Univ, Res Ctr Cell Therapy & Regenerat Med, Taipei, Taiwan.; Huang, YH (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan.; Huang, YH (corresponding author), Taipei Med Univ Hosp, Ctr Reprod Med, Taipei, Taiwan.; Huang, YH (corresponding author), Taipei Med Univ, Comprehens Canc Ctr, Taipei, Taiwan.; Huang, YH (corresponding author), Taipei Med Univ, Coll Med, Int PhD Program Cell Therapy & Regenerat Med, Taipei, Taiwan.	ma1898@cgmh.org.tw; rita1204@tmu.edu.tw	Yang, Yao-Hsu/A-3450-2019	Yang, Yao-Hsu/0000-0002-8080-0504; Hsieh, Yung-Yu/0000-0001-8465-5204; Chen, Wei-Ming/0000-0002-4949-393X	Chang Gung Memorial Hospital, Taiwan [CORPG6F0053]; Ministry of Science and Technology, Taiwan [MOST 1062314-B-182-065, MOST108-2314-B-038006, MOST108-2321-B-038-003]	Chang Gung Memorial Hospital, Taiwan(Chang Gung Memorial Hospital); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by research grants from Chang Gung Memorial Hospital, Taiwan (CORPG6F0053) to TSC, and the Ministry of Science and Technology, Taiwan (MOST 1062314-B-182-065 to TSC; MOST108-2314-B-038006 and MOST108-2321-B-038-003 to YHH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Razik A, 2020, EUR J GASTROEN HEPAT, V32, P718, DOI 10.1097/MEG.0000000000001578; Bonnel AR, 2011, CLIN GASTROENTEROL H, V9, P727, DOI 10.1016/j.cgh.2011.02.031; Boursier J, 2009, J CLIN GASTROENTEROL, V43, P580, DOI 10.1097/MCG.0b013e3181889468; Centers for Disease Control and Prevention, 2013, ANTIBIOTIC RESISTANC; Chavez-Tapia NC, 2011, ALIMENT PHARM THER, V34, P509, DOI 10.1111/j.1365-2036.2011.04746.x; Conejo I, 2016, LIVER INT, V36, P994, DOI 10.1111/liv.13038; de Franchis R, 2015, J HEPATOL, V63, P743, DOI 10.1016/j.jhep.2015.05.022; Deschenes M, 1999, AM J GASTROENTEROL, V94, P2193, DOI 10.1016/S0002-9270(99)00349-4; GARCIATSAO G, 1985, HEPATOLOGY, V5, P419, DOI 10.1002/hep.1840050313; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Hou MC, 2004, HEPATOLOGY, V39, P746, DOI 10.1002/hep.20126; Jalan R, 2014, J HEPATOL, V60, P1310, DOI 10.1016/j.jhep.2014.01.024; Kamath PS, 2015, J HEPATOL, V63, P543, DOI 10.1016/j.jhep.2015.07.001; Kanwal F, 2012, GASTROENTEROLOGY, V143, P70, DOI 10.1053/j.gastro.2012.03.038; Lin HC, 2016, E DA MED J, V3, P9; Moon AM, 2016, CLIN GASTROENTEROL H, V14, P1629, DOI 10.1016/j.cgh.2016.05.040; O'Leary JG, 2015, CLIN GASTROENTEROL H, V13, P753, DOI 10.1016/j.cgh.2014.07.060; Pauwels A, 1996, HEPATOLOGY, V24, P802; Runyon BA, 2009, HEPATOLOGY, V49, P2087, DOI 10.1002/hep.22853; Shehab N, 2008, CLIN INFECT DIS, V47, P735, DOI 10.1086/591126; Tandon P, 2015, CLIN GASTROENTEROL H, V13, P1189, DOI 10.1016/j.cgh.2014.11.019; Terg R, 2015, J HEPATOL, V62, P1056, DOI 10.1016/j.jhep.2014.11.036; Wu CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061666	23	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2020	15	2							e0229101	10.1371/journal.pone.0229101	http://dx.doi.org/10.1371/journal.pone.0229101			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8DJ	32084186	Green Published, gold			2023-01-03	WOS:000535227900052
J	[Anonymous]				[Anonymous]			Art of Therapy (Reprinted from JAMA, vol 211, pg 1002, 1970)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint																		[Anonymous], 1970, JAMA, V211, P1002	1	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2020	323	6					576	576		10.1001/jama.2019.13301	http://dx.doi.org/10.1001/jama.2019.13301			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KO5BC	32044934				2023-01-03	WOS:000515563800026
J	Pinkerton, JV				Pinkerton, JoAnn, V			Hormone Therapy for Postmenopausal Women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER RISK; VASOMOTOR SYMPTOMS; MENOPAUSAL SYMPTOMS; REPLACEMENT THERAPY; HEALTH; ESTROGEN; MANAGEMENT; SOCIETY; ENDOCRINOLOGY; ASSOCIATION	Hormone therapy is highly effective for the management of vasomotor symptoms in postmenopausal women; vaginal estrogen is used for genitourinary symptoms only. Hormone therapy is not recommended for primary or secondary prevention of coronary heart disease or dementia. Several nonhormonal therapies are also effective for vasomotor symptoms.	[Pinkerton, JoAnn, V] Univ Virginia Hlth Syst, Box 8041014, Charlottesville, VA 22908 USA	University of Virginia	Pinkerton, JV (corresponding author), Univ Virginia Hlth Syst, Box 8041014, Charlottesville, VA 22908 USA.	jvp9u@virginia.edu						Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; [Anonymous], 2016, OBSTET GYNECOL, V127, pE93; [Anonymous], 2014, Obstet Gynecol, V123, P202, DOI 10.1097/01.AOG.0000441353.20693.78; Avis NE, 2015, JAMA INTERN MED, V175, P531, DOI 10.1001/jamainternmed.2014.8063; Baber RJ, 2016, CLIMACTERIC, V19, P109, DOI 10.3109/13697137.2015.1129166; Bhupathiraju SN, 2019, MENOPAUSE, V26, P603, DOI 10.1097/GME.0000000000001284; Brinton LA, 2014, J STEROID BIOCHEM, V142, P83, DOI 10.1016/j.jsbmb.2013.05.001; Canonico M, 2016, MENOPAUSE, V23, P587, DOI 10.1097/GME.0000000000000665; Cobin RH, 2017, ENDOCR PRACT, V23, P869, DOI 10.4158/EP171828.PS; Cody JD, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001405.pub2; Collaborative Grp Hormonal Factors, 2019, LANCET, V394, P1159, DOI 10.1016/S0140-6736(19)31709-X; Crandall CJ, 2018, MENOPAUSE, V25, P11, DOI 10.1097/GME.0000000000000956; de Villiers TJ, 2016, CLIMACTERIC, V19, P313, DOI 10.1080/13697137.2016.1196047; Espeland MA, 2017, J GERONTOL A-BIOL, V72, P838, DOI 10.1093/gerona/glw156; Faubion SS, 2015, CLIMACTERIC, V18, P483, DOI 10.3109/13697137.2015.1020484; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Fournier A, 2008, BREAST CANCER RES TR, V107, P103, DOI 10.1007/s10549-007-9523-x; Franco OH, 2016, JAMA-J AM MED ASSOC, V315, P2554, DOI 10.1001/jama.2016.8012; Freedman RR, 2014, J STEROID BIOCHEM, V142, P115, DOI 10.1016/j.jsbmb.2013.08.010; Gibson CJ, 2019, JAMA INTERN MED, V179, P80, DOI 10.1001/jamainternmed.2018.5233; Grady Deborah, 2005, Am J Med, V118 Suppl 12B, P163, DOI 10.1016/j.amjmed.2005.09.051; Gramling R, 2009, EPIDEMIOLOGY, V20, P752, DOI 10.1097/EDE.0b013e3181a71279; Grossman DC, 2017, JAMA-J AM MED ASSOC, V318, P2224, DOI 10.1001/jama.2017.18261; Guthrie KA, 2015, OBSTET GYNECOL, V126, P413, DOI 10.1097/AOG.0000000000000927; Imtiaz B, 2017, NEUROLOGY, V88, P1062, DOI 10.1212/WNL.0000000000003696; Joffe H, 2014, JAMA INTERN MED, V174, P1058, DOI 10.1001/jamainternmed.2014.1891; Johnson A, 2019, J FUTURES STUD, V24, P5, DOI 10.6531/JFS.201912_24(2).0002; Kaunitz AM, 2014, MENOPAUSE, V21, P679, DOI [10.1097/gme.0000000000000175, 10.1097/GME.0000000000000175]; Lee AW, 2016, OBSTET GYNECOL, V127, P828, DOI 10.1097/AOG.0000000000001387; Lobo RA, 2017, NAT REV ENDOCRINOL, V13, P220, DOI 10.1038/nrendo.2016.164; Lumsden MA, 2016, JAMA INTERN MED, V176, P1205, DOI 10.1001/jamainternmed.2016.2761; Maclennan A H, 2004, Cochrane Database Syst Rev, pCD002978, DOI 10.1002/14651858.CD002978.pub2; Manson JE, 2017, JAMA-J AM MED ASSOC, V318, P927, DOI 10.1001/jama.2017.11217; Manson JE, 2016, NEW ENGL J MED, V374, P803, DOI 10.1056/NEJMp1514242; Manson JE, 2015, MENOPAUSE, V22, P247, DOI [10.1097/gme.0000000000000373, 10.1097/GME.0000000000000373]; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Marchetti C, 2018, CRIT REV ONCOL HEMAT, V132, P111, DOI 10.1016/j.critrevonc.2018.09.018; Pinkerton JV, 2019, CLIMACTERIC, V22, P544, DOI 10.1080/13697137.2019.1600501; Pinkerton JV, 2017, MENOPAUSE, V24, P728, DOI 10.1097/GME.0000000000000921; Pinkerton JV, 2014, J CLIN ENDOCR METAB, V99, pE189, DOI 10.1210/jc.2013-1707; Portman DJ, 2014, MENOPAUSE, V21, P1063, DOI [10.1097/gme.0000000000000329, 10.1097/GME.0000000000000329]; Reid R, 2014, J OBSTET GYNAECOL CA, V36, P830, DOI 10.1016/S1701-2163(15)30487-4; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Santen RJ, 2017, J CLIN ENDOCR METAB, V102, P3647, DOI 10.1210/jc.2017-01138; Santen RJ, 2019, MENOPAUSE; Santoro N, 2017, MENOPAUSE, V24, P238, DOI 10.1097/GME.0000000000000756; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Skorupskaite K, 2018, NEUROENDOCRINOLOGY, V106, P148, DOI 10.1159/000473893; Stuenkel CA, 2015, J CLIN ENDOCR METAB, V100, P3975, DOI 10.1210/jc.2015-2236; Taylor HS, 2017, JAMA INTERN MED, V177, P1471, DOI 10.1001/jamainternmed.2017.3877; Thurston RC, 2018, CLIMACTERIC, V21, P96, DOI 10.1080/13697137.2018.1430131; Vinogradova Y, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k4810; Zeleke BM, 2015, CLIMACTERIC, V18, P112, DOI 10.3109/13697137.2014.978754	53	65	68	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 30	2020	382	5					446	455		10.1056/NEJMcp1714787	http://dx.doi.org/10.1056/NEJMcp1714787			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH8WV	31995690	Green Submitted			2023-01-03	WOS:000510932000009
J	Schutte, C; Forsythe, S; Mdala, JF; Zieman, B; Linder, R; Vu, L				Schutte, Carl; Forsythe, Steven; Mdala, Johnface Fedes; Zieman, Brady; Linder, Rachael; Vu, Lung			The short-term effects of the implementation of the "Treat All" guidelines on ART service delivery costs in Namibia	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; HIV-1 TRANSMISSION; PREVENTION; INITIATION; INTERVENTIONS	The introduction of "Treat All" (TA) has been promoted to increase the effectiveness of HIV/AIDS treatment by having patients initiate antiretroviral therapy at an earlier stage of their illness. The impact of introducing TA on the unit cost of treatment has been less clear. The following study evaluated how costs changed after Namibia's introduction of TA in April 2017. A two-year analysis assessed the costs of antiretroviral therapy (ART) during the 12 months before TA (Phase I-April 1, 2016 to March 31, 2017) and the 12 months following (Phase II-April 1, 2017 to March 31, 2018). The analysis involved interviewing staff at ten facilities throughout Namibia, collecting data on resources utilized in the treatment of ART patients and analyzing how costs changed before and after the introduction of TA. An analysis of treatment costs indicated that the unit cost of treatment declined from USD360 per patient per year in Phase I to USD301 per patient per year in Phase II, a reduction of 16%. This decline in unit costs was driven by 3 factors: 1) shifts in antiretroviral (ARV) regimens that resulted in lower costs for drugs and consumables, 2) negotiated reductions in the cost of viral load tests and 3) declines in personnel costs. It is unlikely that the first two of these factors were significantly influenced by the introduction of TA. It is unclear if TA might have had an influence on personnel costs. The reduction in personnel costs may have either represented a positive development (fewer personnel costs associated with increased numbers of healthier patients and fewer visits required) or alternatively may reflect constraints in Namibia's staffing. Prior to this study, it was expected that the introduction of TA would lead to a significant increase in the number of ART patients. However, there was less than a 4% increase in the number of adult patients at the 10 studied facilities. From a financial point of view, TA did not significantly increase the resources required in the ten sampled facilities, either by raising unit costs or significantly increasing the number of ART patients.	[Schutte, Carl] Genesis Analyt, Johannesburg, South Africa; [Forsythe, Steven; Linder, Rachael] Avenir Hlth, Fountain Hills, AZ 85268 USA; [Mdala, Johnface Fedes] IntraHealth, Windhoek, Namibia; [Zieman, Brady; Vu, Lung] Populat Council, Washington, DC USA	Population Council	Forsythe, S (corresponding author), Avenir Hlth, Fountain Hills, AZ 85268 USA.	sforsythe@avenirhealth.org		Forsythe, Steven/0000-0002-4409-5991	USAID [AID-OAA-A-14-00060]	USAID(United States Agency for International Development (USAID))	All funding for this activity has been provided by USAID under a Cooperative Agreement called Project SOAR (AID-OAA-A-14-00060). Avenir Health, Genesis Analytics and IntraHealth are private contractors who receive funds from international donor organizations to conduct technical assistance and research. The funder (USAID) provided support in the form of salaries for authors (CS, SF, BZ, RL, LV), but did not have any additional role in the study design, data collection and analysis, or decision to publish. The fact that Avenir Health, IntraHealth and Genesis Analytics are private contractors does not alter our adherence to PLOS ONE policies on sharing data and materials.	Alistar SS, 2014, BMC MED, P12, DOI [10.1186/1741-7015-12-12, DOI 10.1186/1741-7015-12-12]; [Anonymous], 2017, PAY GRADING STRUCTUR; Atun R, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009656; Bango F, 2016, TROP MED INT HEALTH, V21, P1115, DOI 10.1111/tmi.12736; Bunnell R, 2006, AIDS, V20, P85, DOI 10.1097/01.aids.0000196566.40702.28; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Del Romero J, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2205; Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2; Eaton JW, 2014, LANCET GLOB HEALTH, V2, pE23, DOI 10.1016/S2214-109X(13)70172-4; Edwards S., 2018, INSIDE DEV; Emery S, 2008, J INFECT DIS, V197, P1133, DOI 10.1086/586713; Evans CJ, 2000, SCIENCEDIRECT COM VA, P3; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; Kato M, 2014, CURRENT HIV AIDS REP; Long LC, 2017, AIDS, V31, P1611, DOI 10.1097/QAD.0000000000001528; Ministerio da Saude, 2014, B EP HIV AIDS, DOI [DOI 14/56677/BOLETIM2014FINALPDF15565.PDF, 14/56677/boletim2014finalpdf15565.pdf]; Ministry of Health and Social Services Directorate of Special Programmes, 2017, NAT STRAT FRAM HIV A, P116; Namibia Ministry of Health and Social Services, 2017, NAM 2014 15 HLTH ACC; Namibia Ministry of Health and Social Services, 2016, NAT GUID ANT THER; Nsanzimana S., 2015, RAPID ASSESSMENT REP; PHIA Project, 2018, SUMMARY SHEET NAMIBI; Reynolds SJ, 2011, AIDS, V25, P473, DOI 10.1097/QAD.0b013e3283437c2b; Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370; Shade SB, 2017, TOPICS ANTIVIRAL MED, V32, P2179; Tagar E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108304; The Namibia Ministry of Minstry of Health and Social Services (MOHSS), 2013, DEM HLTH SURV; UN Joint Programme on HIV/AIDS (UNAIDS), 2018, UNAIDS DAT 2018, P2; UNAIDS, 2017, COUNTR FACTSH NAM; UNAIDS, 2019, UNAIDS DAT 2019; UNAIDS, 2014, 90 90 90 AMB TREATM; Vassall Anna, 2017, GHCC DRAFT REFERENCE; Walensky RP, 2013, NEW ENGL J MED, V369, P1715, DOI 10.1056/NEJMsa1214720; WHO, 2010, ANT THER HIV INF AD; World Health Organization, 2015, GUID START ANT THER; World Health Organization, 2004, SCAL ANT THER RES LT; World Health Organization, 2012, GUID OR PREEXP PROPH; Wu ZY, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001874; Zulliger R, 2014, AIDS BEHAV, V18, P697, DOI 10.1007/s10461-013-0641-7	38	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2020	15	1							e0228135	10.1371/journal.pone.0228135	http://dx.doi.org/10.1371/journal.pone.0228135			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP8YP	31986182	Green Published, gold			2023-01-03	WOS:000534603400038
J	Kischka, U				Kischka, Udo			Stroke: the doctor as patient	LANCET			English	Editorial Material									[Kischka, Udo] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England	University of Oxford	Kischka, U (corresponding author), Univ Oxford, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England.	kischka@btinternet.com							0	0	0	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 30	2019	394	10213					1984	1985		10.1016/S0140-6736(19)32642-X	http://dx.doi.org/10.1016/S0140-6736(19)32642-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JT4GR	32171417				2023-01-03	WOS:000500950200014
J	McCall, NM; Wojick, JA; Corder, G				McCall, Nora M.; Wojick, Jessica A.; Corder, Gregory			Anesthesia analgesia in the amygdala	NATURE NEUROSCIENCE			English	Editorial Material								General anesthetics during surgery are presumed to block pain by dampening brain activity and promoting loss-of-consciousness. A new study shows that anesthetics activate an endogenous analgesia neural ensemble in the central nucleus of the amygdala.	[McCall, Nora M.; Wojick, Jessica A.; Corder, Gregory] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA; [McCall, Nora M.; Wojick, Jessica A.; Corder, Gregory] Univ Penn, Dept Neurosci, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Corder, G (corresponding author), Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.; Corder, G (corresponding author), Univ Penn, Dept Neurosci, Perelman Sch Med, Philadelphia, PA 19104 USA.	gcorder@upenn.edu		McCall, Nora/0000-0001-5793-1701	NIDA NIH HHS [R00 DA043609] Funding Source: Medline; NIMH NIH HHS [T32 MH014654] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Brown EN, 2011, ANNU REV NEUROSCI, V34, P601, DOI 10.1146/annurev-neuro-060909-153200; Corder G, 2019, SCIENCE, V363, P276, DOI 10.1126/science.aap8586; Fadok JP, 2018, CURR OPIN NEUROBIOL, V49, P141, DOI 10.1016/j.conb.2018.02.009; Han S, 2015, CELL, V162, P363, DOI 10.1016/j.cell.2015.05.057; Hua T, 2020, NAT NEUROSCI, V23, P854, DOI 10.1038/s41593-020-0632-8; Jiang-Xie LF, 2019, NEURON, V102, P1053, DOI 10.1016/j.neuron.2019.03.033; John ER, 2005, ANESTHESIOLOGY, V102, P447, DOI 10.1097/00000542-200502000-00030; Kim J, 2017, NEURON, V93, P1464, DOI 10.1016/j.neuron.2017.02.034; Paretkar T, 2019, NEUROBIOL DIS, V124, P364, DOI 10.1016/j.nbd.2018.12.005; Sadler KE, 2017, PAIN, V158, P747, DOI 10.1097/j.pain.0000000000000830; Sakurai K, 2016, NEURON, V92, P739, DOI 10.1016/j.neuron.2016.10.015; Samuel N, 2018, BRIT J ANAESTH, V121, P219, DOI 10.1016/j.bja.2018.05.046; Schug SA, 2017, PAIN REP, V2, DOI 10.1097/PR9.0000000000000627; Vadivelu Nalini, 2016, J Anaesthesiol Clin Pharmacol, V32, P298, DOI 10.4103/0970-9185.168149; Wilson TD, 2019, CELL REP, V29, P332, DOI 10.1016/j.celrep.2019.09.011	15	1	1	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	JUL	2020	23	7					783	785		10.1038/s41593-020-0645-3	http://dx.doi.org/10.1038/s41593-020-0645-3		MAY 2020	3	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MD6MH	32424288	Green Accepted			2023-01-03	WOS:000533851500002
J	del Rio, C; Armstrong, WS				del Rio, Carlos; Armstrong, Wendy S.			How Much Are We Willing to Pay for Preexposure Prophylaxis in the United States?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[del Rio, Carlos] Emory Univ, Sch Med, Dept Med, 49 Jesse Hill Jr Dr,FOB Room 201, Atlanta, GA 30303 USA; [Armstrong, Wendy S.] Emory Univ, Sch Med, Dept Med, Grady Infect Dis Program, 341 Ponce Leon Ave, Atlanta, GA 30308 USA; [del Rio, Carlos; Armstrong, Wendy S.] Grady Hlth Syst, Atlanta, GA USA	Emory University; Emory University	del Rio, C (corresponding author), Emory Univ, Sch Med, Dept Med, 49 Jesse Hill Jr Dr,FOB Room 201, Atlanta, GA 30303 USA.	cdelrio@emory.edu	del Rio, Carlos/B-3763-2012	del Rio, Carlos/0000-0002-0153-3517				[Anonymous], 2019, PAN ANT GUID AD AD G; Grulich AE, 2018, LANCET HIV, V5, pE629, DOI 10.1016/S2352-3018(18)30215-7; Health Resources & Services Administration, 2020, END HIV EP PLAN AM; IQVIA Institute for Human Data Science, 2019, MED US SPEND US REV; Morne J, 2019, COMMUNICATION; Nwokolo N, 2017, LANCET HIV, V4, pE482, DOI 10.1016/S2352-3018(17)30181-9; Walensky RP, 2020, ANN INTERN MED, V172, P583, DOI [10.7326/M19-3478, 10.7326/L20-0693]	7	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 5	2020	172	9					623	+		10.7326/M20-0799	http://dx.doi.org/10.7326/M20-0799			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK7EH	32150617				2023-01-03	WOS:000531024900016
J	Buza , K; Peska, L; Koller, J				Buza, Krisztian; Peska, Ladislav; Koller, Julia			Modified linear regression predicts drug-target interactions accurately	PLOS ONE			English	Article							INFORMATION; MUTATIONS; IDENTIFICATION; HYPERTENSION; INTEGRATION; INHIBITOR; KERNELS	State-of-the-art approaches for the prediction of drug-target interactions (DTI) are based on various techniques, such as matrix factorisation, restricted Boltzmann machines, network-based inference and bipartite local models (BLM). In this paper, we propose the framework of Asymmetric Loss Models (ALM) which is more consistent with the underlying chemical reality compared with conventional regression techniques. Furthermore, we propose to use an asymmetric loss model with BLM to predict drug-target interactions accurately. We evaluate our approach on publicly available real-world drug-target interaction datasets. The results show that our approach outperforms state-of-the-art DTI techniques, including recent versions of BLM.	[Buza, Krisztian] Eotvos Lorand Univ, Fac Informat, Budapest, Hungary; [Buza, Krisztian] Babes Bolyai Univ, Ctr Study Complex, Cluj Napoca, Romania; [Peska, Ladislav] Charles Univ Prague, Fac Math & Phys, Dept Software Engn, Prague, Czech Republic; [Koller, Julia] Semmelweis Univ, Inst Genom Med & Rare Disorders, Budapest, Hungary	Eotvos Lorand University; Babes Bolyai University from Cluj; Charles University Prague; Semmelweis University	Buza , K (corresponding author), Eotvos Lorand Univ, Fac Informat, Budapest, Hungary.; Buza , K (corresponding author), Babes Bolyai Univ, Ctr Study Complex, Cluj Napoca, Romania.	buza@biointelligence.hu	Buza, Krisztian/H-6093-2012	Buza, Krisztian/0000-0002-7111-6452	National Research, Development and Innovation Fund of Hungary under the Thematic Excellence Programme funding scheme [ED_18-1-20190030]; BabesBolyai University, Cluj Napoca, Romania; Charles University [Progres Q48];  [ED_18-1-2019-0030]	National Research, Development and Innovation Fund of Hungary under the Thematic Excellence Programme funding scheme; BabesBolyai University, Cluj Napoca, Romania(Hungarian Academy of Sciences); Charles University; 	K. Buza was supported by the project ED_18-1-2019-0030. Project no. ED_18-1-20190030 (Application domain specific highly reliable IT solutions subprogramme) has been implemented with the support provided from the National Research, Development and Innovation Fund of Hungary, financed under the Thematic Excellence Programme funding scheme. K. Buza received the "Professor Ferencz Rado" Fellowship of the BabesBolyai University, Cluj Napoca, Romania. L. Peska was supported by Charles University grant Progres Q48. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banerjee I, 2018, DIABETIC MED; Bienengraeber M, 2004, NAT GENET, V36, P382, DOI 10.1038/ng1329; Bleakley K, 2009, BIOINFORMATICS, V25, P2397, DOI 10.1093/bioinformatics/btp433; Bolgar B., 2016, J MACH LEARN RES, P25; Buza K, 2017, LECT NOTES ARTIF INT, V10535, P322, DOI 10.1007/978-3-319-71246-8_20; Buza K, 2017, NEUROCOMPUTING, V260, P284, DOI 10.1016/j.neucom.2017.04.055; Cellier P, 2010, LECT NOTES COMPUT SC, V6008, P537, DOI 10.1007/978-3-642-12116-6_46; Chen X, 2012, MOL BIOSYST, V8, P1970, DOI 10.1039/c2mb00002d; Cheng AC, 2007, NAT BIOTECHNOL, V25, P71, DOI 10.1038/nbt1273; Cheng FX, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002503; Chutkow WA, 2002, J CLIN INVEST, V110, P203, DOI 10.1172/JCI200215672; Davis J, 2007, P INT C MACH LEARN, P217; Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990; Ding YJ, 2019, NEUROCOMPUTING, V325, P211, DOI 10.1016/j.neucom.2018.10.028; Fan X, 2018, LECT NOTES ARTIF INT, V10937, P348, DOI 10.1007/978-3-319-93034-3_28; Fayruzov T, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-374; Ferrer-Garcia JC, 2013, CLIN TRANSL ONCOL, V15, P725, DOI 10.1007/s12094-012-0996-7; Gonen M, 2012, BIOINFORMATICS, V28, P2304, DOI 10.1093/bioinformatics/bts360; Gunther S, 2008, NUCLEIC ACIDS RES, V36, pD919, DOI 10.1093/nar/gkm862; Hans M, 1999, J NEUROSCI, V19, P1610; Harakalova M, 2012, NAT GENET, V44, P793, DOI 10.1038/ng.2324; Hattori M, 2003, J AM CHEM SOC, V125, P11853, DOI 10.1021/ja036030u; Jamali AA, 2016, DRUG DISCOV TODAY, V21, P718, DOI 10.1016/j.drudis.2016.01.007; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Kang TS, 2016, J MED CHEM, V59, P4026, DOI 10.1021/acs.jmedchem.6b00112; Lan W, 2016, NEUROCOMPUTING, V206, P50, DOI 10.1016/j.neucom.2016.03.080; Liu LJ, 2016, ONCOTARGET, V7, P13965, DOI 10.18632/oncotarget.7369; Liu LJ, 2015, J MED CHEM, V58, P6697, DOI 10.1021/acs.jmedchem.5b00375; Lung RI, 2017, SOFT COMPUT, V21, P1253, DOI 10.1007/s00500-015-1858-3; Mei JP, 2013, BIOINFORMATICS, V29, P238, DOI 10.1093/bioinformatics/bts670; Morgan S, 2011, HEALTH POLICY, V100, P4, DOI 10.1016/j.healthpol.2010.12.002; Pahikkala T, 2015, BRIEF BIOINFORM, V16, P325, DOI 10.1093/bib/bbu010; Perot S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063730; Peska L, 2017, COMPUT METH PROG BIO, V152, P15, DOI 10.1016/j.cmpb.2017.09.003; Pilaszy I., 2009, P 3 ACM C REC SYST, P93, DOI DOI 10.1145/1639714.1639731; Schumacher T, 2017, MOLECULES, V22, DOI 10.3390/molecules22040589; Sonstrod C, 2008, SEVENTH INTERNATIONAL CONFERENCE ON MACHINE LEARNING AND APPLICATIONS, PROCEEDINGS, P559, DOI 10.1109/ICMLA.2008.130; Timlin MR, 2017, PEDIATR CARDIOL, V38, P1247, DOI 10.1007/s00246-017-1652-3; Ullrich K, 2016, LECT NOTES ARTIF INT, V9956, P474, DOI 10.1007/978-3-319-46307-0_30; van Laarhoven T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066952; van Laarhoven T, 2011, BIOINFORMATICS, V27, P3036, DOI 10.1093/bioinformatics/btr500; Wang YH, 2013, BIOINFORMATICS, V29, P126, DOI 10.1093/bioinformatics/btt234; Wei X, 2018, KIDNEY BLOOD PRESS R, V43, P439, DOI 10.1159/000488256; Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067; Xia Z, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-S2-S6; Yamanishi Y, 2008, BIOINFORMATICS, V24, pI232, DOI 10.1093/bioinformatics/btn162; Yang C, 2017, SCI REP-UK, V7, DOI 10.1038/srep42860; Zhang J, 2017, EXPERT SYST APPL, V84, P281, DOI 10.1016/j.eswa.2017.05.004; Zheng XD, 2013, 19TH ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING (KDD'13), P1025	49	7	7	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2020	15	4							e0230726	10.1371/journal.pone.0230726	http://dx.doi.org/10.1371/journal.pone.0230726			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8OD	32251481	Green Published, gold			2023-01-03	WOS:000535955000017
J	Alagoz, S; Dincer, MT; Eren, N; Bakir, A; Pekpak, M; Trabulus, S; Seyahi, N				Alagoz, Selma; Dincer, Mevlut Tamer; Eren, Necmi; Bakir, Alev; Pekpak, Meltem; Trabulus, Sinan; Seyahi, Nurhan			Prevalence of anemia in predialysis chronic kidney disease: Is the study center a significant factor?	PLOS ONE			English	Article							DIALYSIS PATIENTS; MANAGEMENT; IMPACT	Objectives Anemia is highly prevalent in chronic kidney disease patients; however, its identification and management have been reported to be suboptimal. In this study we aimed to describe the prevalence, severity, risk factors, and treatment of anemia in different nephrology centers, among chronic kidney disease patients who were not given renal replacement therapy. Materials and methods We performed a multicenter cross-sectional study in three different nephrology clinics. Adult (> 18 years of age) chronic kidney disease patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min, and who were not started dialysis were recruited. Demographic, clinical and laboratory data regarding anemia and its management were collected using a standard data form. Anemia was defined as a hemoglobin level below 12g/dL and severe anemia as a hemoglobin level below 10g/dl. Results A total of 1066 patients were enrolled in the study. Anemia and severe anemia were present in 55.9% and 14.9% of the patients, respectively. The mean hemoglobin level for the whole cohort was 11.8 +/- 1.8 g/dL. Univariate analyses revealed that the mean hemoglobin level was significantly different among the centers. Moreover, the frequency of the presence of anemia stratified by severity was also significantly different among the centers. According to binary logistic regression analysis, gender, levels of eGFR and iron, ferritin. 100 ng/mL, and the nephrology center were independent determinants of severe anemia. Conclusions We found a high prevalence of anemia among chronic kidney disease patients who were not on renal replacement therapy. Each center should determine the treatment strategy according to the patient's characteristics. According to our results, the center-specific management of anemia seems to be important.	[Alagoz, Selma] Univ Hlth Sci, Bagcilar Training & Res Hosp, Dept Nephrol, Istanbul, Turkey; [Dincer, Mevlut Tamer; Pekpak, Meltem; Trabulus, Sinan; Seyahi, Nurhan] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Nephrol, Istanbul, Turkey; [Eren, Necmi] Kocaeli Univ, Dept Nephrol, Med Fac, Kocaeli, Turkey; [Bakir, Alev] Halic Univ, Fac Med, Dept Biostat & Med Informat, Istanbul, Turkey	Istanbul Bagcilar Training & Research Hospital; University of Health Sciences Turkey; Istanbul University - Cerrahpasa; Kocaeli University; Halic University	Seyahi, N (corresponding author), Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Nephrol, Istanbul, Turkey.	nseyahi@yahoo.com	BAKIR, Alev/AAF-6907-2021; BAKIR, Alev/AAZ-8403-2021; Dincer, Mevlut Tamer/AAA-8435-2020; Pekpak, Meltem/AAC-2694-2021; Trabulus, Sinan/AAC-3572-2021	BAKIR, Alev/0000-0003-0664-5822; alagoz, selma/0000-0001-5416-2257; Seyahi, Nurhan/0000-0001-7427-618X				Balarajan Y, 2011, LANCET, V378, P2123, DOI 10.1016/S0140-6736(10)62304-5; Chan LN, 2014, JPEN-PARENTER ENTER, V38, P656, DOI 10.1177/0148607114533726; Dowling TC, 2007, AM J HLTH SYST PH S8, V1, P3; Gallieni M, 2016, J NEPHROL, V29, P71, DOI 10.1007/s40620-015-0202-4; Gaspar BL, 2015, HEMATOLOGY, V20, P18, DOI 10.1179/1607845414Y.0000000161; Ifudu O, 1997, NEPHRON, V77, P315, DOI 10.1159/000190294; Kausz AT, 2001, J AM SOC NEPHROL, V12, P1501, DOI 10.1681/ASN.V1271501; Kazmi WH, 2001, AM J KIDNEY DIS, V38, P803, DOI 10.1053/ajkd.2001.27699; Kinchen KS, 2002, ANN INTERN MED, V137, P479, DOI 10.7326/0003-4819-137-6-200209170-00007; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Levin A, 1999, AM J KIDNEY DIS, V34, P125, DOI 10.1016/S0272-6386(99)70118-6; LIM VS, 1989, ANN INTERN MED, V110, P108, DOI 10.7326/0003-4819-110-2-108; Liu HY, 2019, J INVEST MED, V67, P1002, DOI 10.1136/jim-2018-000915; Lorber Daniel L, 2006, Endocr Pract, V12, P506; McClellan W, 2004, CURR MED RES OPIN, V20, P1501, DOI 10.1185/030079904X2763; McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401; Mutter S, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101153; National Kidney Foundation, 2001, AM J KIDNEY DIS, V37, P182; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Pickett JL, 1999, AM J KIDNEY DIS, V33, P1122, DOI 10.1016/S0272-6386(99)70150-2; Shaheen FAM, 2011, SAUDI J KIDNEY DIS T, V22, P456; Siah KW, 2019, JCO CLIN CANCER INFO, V3, P1, DOI 10.1200/CCI.19.00046; Voormolen N, 2010, NEPHRON CLIN PRACT, V115, pC133, DOI 10.1159/000312876; Wetmore JB, 2018, PLOS ONE, V26, P1	24	3	6	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2020	15	4							e0230980	10.1371/journal.pone.0230980	http://dx.doi.org/10.1371/journal.pone.0230980			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8KJ	32240223	Green Published, gold			2023-01-03	WOS:000535945000070
J	Cash, MC; Cunnane, K; Fan, CY; Romero-Sandoval, EA				Cash, Mary Catherine; Cunnane, Katharine; Fan, Chuyin; Romero-Sandoval, E. Alfonso			Mapping cannabis potency in medical and recreational programs in the United States	PLOS ONE			English	Article							INHALED CANNABIS; MARIJUANA; PAIN; DISPENSARIES; SYMPTOMS; COLORADO; IMPACTS; PRICES; SAFETY; ONSET	Cannabis related online searches are associated with positive attitudes toward medical cannabis, particularly when information is obtained from dispensaries. Since pain is the main reason for medicinal cannabis use, information from dispensary websites has the potential to shape the attitude of pain patients towards cannabis. This is relevant because cannabis has demonstrated efficacy in neuropathic pain with low tetrahydrocannabinol (THC) concentrations (< 5-10%), in contrast to potent cannabis (> 15% THC), which is highly rewarded in the recreational realm. The role of CBD in pain is not clear, however it has gained popularity. Thus, we hypothesize that the potency of medical cannabis that is advertised online is similar to the cannabis advertised for recreational purposes, which would potentially create a misconception towards medical cannabis. The current lack of knowledge surrounding advertised potencies in the legal cannabis market limits the ability to generate clear policies regarding online advertising to protect patients that are willing to use cannabis for their condition. Thus, we evaluated the advertised THC and CBD content of cannabis products offered online in dispensaries in the United States to determine products' suitability to medicinal use and compare the strength of products offered in legal medical and recreational programs. We recorded THC and CBD concentrations for all herb cannabis products provided by dispensary websites and compared them between or within states. Four Western states (CA, CO, NM, WA) and five Northeastern states (ME, MA, NH, RI, VT) were included. A total of 8,505 cannabis products across 653 dispensaries were sampled. Despite the clear differences between medicinal and recreational uses of cannabis, the average THC concentration advertised online in medicinal programs was similar (19.2% +/- 6.2) to recreational programs (21.5% +/- 6.0) when compared between states with different programs, or between medicinal and recreational programs within the same states (CO or WA). Lower CBD concentrations accompanied higher THC products. The majority of products, regardless of medicinal or recreational programs, were advertised to have > 15% THC (70.3% - 91.4% of products). These stated concentrations seem unsuitable for medicinal purposes, particularly for patients with chronic neuropathic pain. Therefore, this information could induce the misconception that high potency cannabis is safe to treat pain. This data is consistent with reports in which THC and CBD in products from legal dispensaries or in nationwide products from the illegal market were actually measured, which indicates that patients consuming these products may be at risk of acute intoxication or long-term side effects. Our study offers grounds to develop policies that help prevent misconceptions toward cannabis and reduce risks in pain patients.	[Cash, Mary Catherine; Fan, Chuyin] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA; [Cunnane, Katharine; Romero-Sandoval, E. Alfonso] Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Winston Salem, NC 27109 USA	University of North Carolina; University of North Carolina Chapel Hill; Wake Forest University; Wake Forest Baptist Medical Center	Romero-Sandoval, EA (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Winston Salem, NC 27109 USA.	earomero.sandoval@gmail.com			Department of Anesthesiology at Wake Forest University School of Medicine	Department of Anesthesiology at Wake Forest University School of Medicine	Funding from Department of Anesthesiology at Wake Forest University School of Medicine (E.A.R.s.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to acknowledge the Department of Anesthesiology at Wake Forest University School of Medicine for funding.	Abrams DI, 2007, NEUROLOGY, V68, P515, DOI 10.1212/01.wnl.0000253187.66183.9c; Andreae MH, 2015, J PAIN, V16, P1221, DOI 10.1016/j.jpain.2015.07.009; [Anonymous], 2017, HLTH EFF CANN CANN C; Arterberry BJ, 2019, DRUG ALCOHOL DEPEN, V195, P186, DOI 10.1016/j.drugalcdep.2018.11.012; Bagot KS, 2015, SUBST ABUS, V36, P524, DOI 10.1080/08897077.2014.995332; Baron EP, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0862-2; Boehnke KF, 2019, J PAIN, V20, P830, DOI 10.1016/j.jpain.2019.01.010; Bonn-Miller MO, 2017, JAMA-J AM MED ASSOC, V318, P2142, DOI 10.1001/jama.2017.18218; Bradford AC, 2018, JAMA INTERN MED, V178, P667, DOI 10.1001/jamainternmed.2018.0266; Capler R, 2017, INT J DRUG POLICY, V47, P1, DOI 10.1016/j.drugpo.2017.05.046; CAPPELL H, 1973, PSYCHOPHARMACOLOGIA, V29, P177, DOI 10.1007/BF00414031; Caputi TL, 2018, AM J PREV MED, V54, P719, DOI 10.1016/j.amepre.2018.01.032; Cavazos-Rehg PA, 2019, PREV SCI, V20, P280, DOI 10.1007/s11121-018-0889-2; Chandra S, 2019, EUR ARCH PSY CLIN N, V269, P997, DOI 10.1007/s00406-019-01020-1; Chandra S, 2019, EUR ARCH PSY CLIN N, V269, P5, DOI 10.1007/s00406-019-00983-5; CLARK WC, 1981, J CLIN PHARMACOL, V21, pS299, DOI 10.1002/j.1552-4604.1981.tb02608.x; Corroon J, 2018, CANNABIS CANNABINOID, V3, P152, DOI 10.1089/can.2018.0006; Di Forti M, 2019, LANCET PSYCHIAT, V6, P427, DOI 10.1016/S2215-0366(19)30048-3; Donoghue K, 2014, PSYCHIAT RES, V215, P528, DOI 10.1016/j.psychres.2013.12.038; Ellis RJ, 2009, NEUROPSYCHOPHARMACOL, V34, P672, DOI 10.1038/npp.2008.120; ElSohly MA, 2000, J FORENSIC SCI, V45, P24; ElSohly MA, 2016, BIOL PSYCHIAT, V79, P613, DOI 10.1016/j.biopsych.2016.01.004; Englund A, 2013, J PSYCHOPHARMACOL, V27, P19, DOI 10.1177/0269881112460109; FDA AACatDSaRMAC, 2014, SUMM MIN JONT ARTH A; Freeman TP, 2015, PSYCHOL MED, V45, P3181, DOI 10.1017/S0033291715001178; Freeman TP, 2018, PSYCHOL MED, V48, P2346, DOI 10.1017/S0033291717003877; Hunt P, 2017, J PRIM PREV, V38, P221, DOI 10.1007/s10935-017-0471-x; Iffland K, 2017, CANNABIS CANNABINOID, V2, P139, DOI 10.1089/can.2016.0034; Jikomes N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22755-2; Klieger SB, 2017, ADDICTION, V112, P2206, DOI 10.1111/add.13910; Lewis N, 2019, INT J DRUG POLICY, V73, P219, DOI 10.1016/j.drugpo.2019.01.005; Li XX, 2019, COMPLEMENT THER MED, V46, P123, DOI 10.1016/j.ctim.2019.07.022; Liang D, 2018, ADDICTION, V113, P2060, DOI 10.1111/add.14382; Lin LA, 2016, ADDICT BEHAV, V61, P99, DOI 10.1016/j.addbeh.2016.05.015; Monte AA, 2019, ANN INTERN MED, V170, P531, DOI 10.7326/M18-2809; Morgan CJA, 2012, PSYCHOL MED, V42, P391, DOI 10.1017/S0033291711001322; Morgan CJA, 2010, BRIT J PSYCHIAT, V197, P285, DOI 10.1192/bjp.bp.110.077503; Obradovic I, 2021, INT J DRUG POLICY, V91, DOI 10.1016/j.drugpo.2019.11.002; Peiper NC, 2017, SUBST ABUS-RES TREAT, V11, DOI 10.1177/1178221817725515; Raji MA, 2019, PREV MED, V125, P62, DOI 10.1016/j.ypmed.2019.05.012; Romero-Sandoval EA, 2018, PHARMACOTHERAPY, V38, P651, DOI 10.1002/phar.2115; Schubart CD, 2011, SCHIZOPHR RES, V130, P216, DOI 10.1016/j.schres.2011.04.017; Shi YY, 2019, INT J DRUG POLICY, V74, P1, DOI 10.1016/j.drugpo.2019.07.037; Smart R, 2017, ADDICTION, V112, P2167, DOI 10.1111/add.13886; van der Pol P, 2014, ADDICTION, V109, P1101, DOI 10.1111/add.12508; Vergara D, 2017, SCI REP-UK, V7, DOI 10.1038/srep46528; Vigil JM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187795; Vindenes V, 2013, FORENSIC SCI INT, V226, P197, DOI 10.1016/j.forsciint.2013.01.017; Volkow ND, 2014, NEW ENGL J MED, V370, P2219, DOI 10.1056/NEJMra1402309; Wallace M, 2007, ANESTHESIOLOGY, V107, P785, DOI 10.1097/01.anes.0000286986.92475.b7; Wallace MS, 2015, J PAIN, V16, P616, DOI 10.1016/j.jpain.2015.03.008; Walsh J., 2015, URUGUAYS DRUG POLICY; Ware MA, 2010, CAN MED ASSOC J, V182, pE694, DOI 10.1503/cmaj.091414; WHO, 2016, HLTH SOCIAL EFFECTS; Wilsey B, 2008, J PAIN, V9, P506, DOI 10.1016/j.jpain.2007.12.010; Wilsey B, 2013, J PAIN, V14, P136, DOI 10.1016/j.jpain.2012.10.009	56	39	39	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2020	15	3							e0230167	10.1371/journal.pone.0230167	http://dx.doi.org/10.1371/journal.pone.0230167			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR8GI	32214334	gold, Green Published			2023-01-03	WOS:000535934200020
J	Ritter, SM; Gu, XJ; Crijns, M; Biekens, P				Ritter, Simone M.; Gu, Xiaojing; Crijns, Maurice; Biekens, Peter			Fostering students' creative thinking skills by means of a one-year creativity training program	PLOS ONE			English	Article							HIPPOCAMPAL REPLAY; INCUBATION; BRAIN; IDEAS	Creative thinking is among the most sought-after life and work skills in the 21st century. The demand for creativity, however, exceeds the degree to which it is available and developed. The current project aimed to test the effectiveness of a one-year creativity training program for higher education. The creativity of students following the training was measured before, halfway, and after the training. In addition to the within-subjects comparison across time, performance was compared to a matched control group. At each of the measurement points, different versions of seven well-validated creativity tasks (capturing divergent and convergent creative thinking skills) were employed. The creativity training increased students' ideation skills and, more importantly their cognitive flexibility. However, no difference in originality was observed. Finally, an increase in performance was observed for one of the convergent creativity tasks, the Remote Associate Test. Implications for educational settings and directions for future research are discussed.	[Ritter, Simone M.] Radboud Univ Nijmegen, Nijmegen Sch Management, Inst Management Res, Nijmegen, Netherlands; [Gu, Xiaojing] Radboud Univ Nijmegen, Behav Sci Inst, Nijmegen, Netherlands; [Crijns, Maurice] Brainnovat Fdn, Eindhoven, Netherlands; [Biekens, Peter] Fontys Univ Appl Sci, Venlo, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Gu, XJ (corresponding author), Radboud Univ Nijmegen, Behav Sci Inst, Nijmegen, Netherlands.	x.gu@bsi.ru.nl	Gu, Xiaojing/AAP-6581-2021	Gu, Xiaojing/0000-0001-5842-3821				Amabile T.M., 1996, CREATIVITY CONTEXT; AMABILE TM, 1983, J PERS SOC PSYCHOL, V45, P357, DOI 10.1037/0022-3514.45.2.357; [Anonymous], 2012, STATE CREATE STUDY; Australian Curriculum Assessment and Reporting Authority (ACARA), 2012, GEN CAP; Bateman K., 2013, COMPUTERWEEKLY  0418; Beaty RE, 2018, P NATL ACAD SCI USA, V115, P1087, DOI 10.1073/pnas.1713532115; Beaty RE, 2014, NEUROPSYCHOLOGIA, V64, P92, DOI 10.1016/j.neuropsychologia.2014.09.019; Beghetto RA, 2005, DOES ASSESSMENT KILL, P46268; Beghetto RA, 2007, THINK SKILLS CREAT, V2, P1, DOI 10.1016/j.tsc.2006.09.002; Bendor D, 2012, NAT NEUROSCI, V15, P1439, DOI 10.1038/nn.3203; Blair CS, 2007, J CREATIVE BEHAV, V41, P197, DOI 10.1002/j.2162-6057.2007.tb01288.x; Cai DJ, 2009, P NATL ACAD SCI USA, V106, P10130, DOI 10.1073/pnas.0900271106; Cohen J., 2013, STAT POWER ANAL BEHA; Colzato LS, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00116; Cotter KN, 2016, PSYCHOL AESTHET CREA, V10, P2, DOI 10.1037/a0039831; Cropley A. J., 1990, CREATIVITY RES J, V13, P167, DOI DOI 10.1080/10400419009534351; Curriculum Development Council (CDC), 2000, LEARN LEARN WAY FORW; Davidson TJ, 2009, NEURON, V63, P497, DOI 10.1016/j.neuron.2009.07.027; Davies D, 2013, THINK SKILLS CREAT, V8, P80, DOI 10.1016/j.tsc.2012.07.004; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Feist GJ, 1998, REV GEN PSYCHOL, V2, P3, DOI DOI 10.1037/1089-2680.2.1.3; Gabora L, 2010, CREATIVITY RES J, V22, P1, DOI 10.1080/10400410903579494; Gu XJ, 2019, THINK SKILLS CREAT, V32, P92, DOI 10.1016/j.tsc.2019.05.002; GUILFORD JP, 1967, J CREATIVE BEHAV, V1, P3, DOI 10.1002/j.2162-6057.1967.tb00002.x; Heinonen J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162234; Hirt ER, 2008, J PERS SOC PSYCHOL, V94, P214, DOI 10.1037/0022-3514.94.2.94.2.214; Kaufman JC, 2002, CREATIVITY RES J, V14, P27, DOI 10.1207/S15326934CRJ1401_3; Keynan JN, 2019, NAT HUM BEHAV, V3, P63, DOI 10.1038/s41562-018-0484-3; Kienitz E, 2014, THINK SKILLS CREAT, V13, P57, DOI 10.1016/j.tsc.2014.03.002; Kleibeuker SW, 2016, NEW DIR CHILD ADOLES, V151, P73, DOI 10.1002/cad.20148; Litchfield RC, 2013, IND MARKET MANAG, V42, P106, DOI 10.1016/j.indmarman.2012.11.010; MACKINNON DW, 1962, AM PSYCHOL, V17, P484, DOI 10.1037/h0046541; Mann S, 2014, CREATIVITY RES J, V26, P165, DOI 10.1080/10400419.2014.901073; MEDNICK SA, 1962, PSYCHOL REV, V69, P220, DOI 10.1037/h0048850; Mourgues C, 2014, OXFORD HDB HUMAN DEV, DOI [10.1093/oxfordhb/9780199948550.013.16, DOI 10.1093/OXFORDHB/9780199948550.013.16]; Mumford MD, 2003, CREATIVITY RES J, V15, P107, DOI 10.1207/S15326934CRJ152&3_01; National Advisory Committee on Creative and Cultural Education (NACCCE), 1999, ALL OUR FUT CREAT CU; Olafsdottir HF, 2015, ELIFE, V4, DOI 10.7554/eLife.06063; Oppezzo M, 2014, J EXP PSYCHOL LEARN, V40, P1142, DOI 10.1037/a0036577; Otani A., 2015, THESE ARE SKILLS YOU; Polman E, 2011, PERS SOC PSYCHOL B, V37, P492, DOI 10.1177/0146167211398362; Puccio GJ, 2017, J CREATIVE BEHAV, V51, P330, DOI 10.1002/jocb.203; Reiter-Palmon R, 1998, CREATIVITY RES J, V11, P187, DOI 10.1207/s15326934crj1103_1; Rietzschel EF, 2018, INDIVIDUAL CREATIVIT; Rietzschel EF, 2014, CREATIVITY RES J, V26, P185, DOI 10.1080/10400419.2014.901084; Rietzschel EF, 2010, BRIT J PSYCHOL, V101, P47, DOI 10.1348/000712609X414204; Ritter SM, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00215; Ritter SM, 2012, J EXP SOC PSYCHOL, V48, P961, DOI 10.1016/j.jesp.2012.02.009; Ritter SM, 2016, J COGN ENHANC, V1, P1; Robinson J., 2014, EMERGING JOHANNESBUR, P275; Runco M.A., 2004, CREATIVITY POTENTIAL, P21, DOI DOI 10.1037/10692-002; Scholte FA, 2008, SALUD PUBLICA MEXICO, V50, pS273, DOI 10.1590/S0036-36342008000800021; Scott G, 2004, CREATIVITY RES J, V16, P361, DOI 10.1207/s15326934crj1604_1; Simonton DK, 2000, DEV REV, V20, P283, DOI 10.1006/drev.1999.0504; Sio UN, 2009, PSYCHOL BULL, V135, P94, DOI 10.1037/a0014212; Sternberg R.J., 1998, HDB CREATIVITY; Sternberg RJ, 2009, TEACHING FOR WISDOM: CROSS-CULTURAL PERSPECTIVES ON FOSTERING WISDOM, P37, DOI 10.1007/978-1-4020-6532-3_3; US. Bureau of Labor Statistics, 2017, NUMB JOBS LAB MARK E; Wallas G, 1926, ART THOUGHT; Ward TB, 2004, J BUS VENTURING, V19, P173, DOI 10.1016/S0883-9026(03)00005-3; Ward TB, 1997, CREATIVE THOUGHT INV, DOI [10.1002/cad.20148, DOI 10.1002/CAD.20148]; Ward TB, 1995, CREATIVITY MIND; Wieth MB, 2011, THINK REASONING, V17, P387, DOI 10.1080/13546783.2011.625663; Wyse D, 2015, BRIT EDUC RES J, V41, P30, DOI 10.1002/berj.3135	64	12	13	6	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2020	15	3							e0229773	10.1371/journal.pone.0229773	http://dx.doi.org/10.1371/journal.pone.0229773			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ9FU	32196509	Green Published, gold			2023-01-03	WOS:000535303100013
J	Nogueira, OR; Botella-Rico, J; Gonzalez, MCM; Clavel, ML; Morera-Balaguer, J; Moreno-Poyato, AR				Rodriguez Nogueira, O.; Botella-Rico, J.; Martinez Gonzalez, M. C.; Leal Clavel, M.; Morera-Balaguer, J.; Moreno-Poyato, A. R.			Construction and content validation of a measurement tool to evaluate person-centered therapeutic relationships in physiotherapy services	PLOS ONE			English	Article							PATIENT-CENTEREDNESS; PHYSICAL-THERAPY; CARE; HEALTH; COMMUNICATION; FRAMEWORK; VALIDITY	Objectives This study sought to develop a tool for evaluating person-centered therapeutic relationships within physiotherapy services, and to examine the content validity of the same. Methods A mixed qualitative and quantitative study was performed in three distinct phases: 1) the items were generated based on a literature review and a content analysis of focus groups of patients and physiotherapists; 2) an e-Delphi survey process was performed based on three rounds to select and refine the proposed questionnaire; 3) two rounds of cognitive interviews were conducted to evaluate the comprehension of items, the clarity of language and the appropriateness and relevance of content. Results Thirty-one items were generated based on the seven domains identified after the analysis of four focus groups of physiotherapists and four patient focus groups. Nine experts participated in the e-Delphi survey. Fifty-five patients participated in the two rounds of the cognitive pre-tests. Participating patients were from public and private physical therapy services. Based on the participants' suggestions, four items were removed, and four were added, whereas 16 were reworded. Conclusions The final tool comprised 31 items divided into seven domains. The response format was based on a 5-point Likert frequency scale. The response options ranged from "strongly agree" to "strongly disagree".	[Rodriguez Nogueira, O.] Univ Leon, Hlth Sci Sch, Nursing & Phys Therapy Dept, Ponferrada Leon, Spain; [Botella-Rico, J.; Morera-Balaguer, J.] Univ Cardenal Herrera CEU, CEU Univ, Phys Therapy Dept, Plaza Reyes Catolicos, Alicante, Spain; [Martinez Gonzalez, M. C.] Univ Cardenal Herrera CEU, CEU Univ, Med Dept, Plaza Reyes Catolicos, Alicante, Spain; [Leal Clavel, M.] Univ Cardenal Herrera CEU, CEU Univ, Nursing Dept, Plaza Reyes Catolicos, Alicante, Spain; [Moreno-Poyato, A. R.] Univ Barcelona, Escola Infermeria, Dept Infermeria Salut Publ Salut Mental & Materno, Fac Med & Ciencies Salut, Campus Bellvitge Pavello Govern,C Feixa Llarga, Lhospitalet De Llobregat, Spain	Universidad de Leon; Universidad CEU Cardenal Herrera; Universidad CEU Cardenal Herrera; Universidad CEU Cardenal Herrera; University of Barcelona	Morera-Balaguer, J (corresponding author), Univ Cardenal Herrera CEU, CEU Univ, Phys Therapy Dept, Plaza Reyes Catolicos, Alicante, Spain.	jmorera.el@uchceu.es	Moreno-Poyato, Antonio R./O-3975-2019; Rodríguez, Oscar/AAF-8023-2021	Moreno-Poyato, Antonio R./0000-0002-5700-4315; Rodríguez, Oscar/0000-0002-4203-5784; Morera Balaguer, Jaume/0000-0001-8733-4406	CEU Cardenal Herrera University; San Pablo University-Santander Foundation (FUSP)	CEU Cardenal Herrera University; San Pablo University-Santander Foundation (FUSP)	Authors JMB, ORN, MMG, MLC, JBR are recipients of a grant from CEU Cardenal Herrera University (www.uchceu.es) and the San Pablo University-Santander Foundation (FUSP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1984, COGNITIVE ASPECTS SU, DOI [10.17226/930, DOI 10.17226/930]; Beatty PC, 2007, PUBLIC OPIN QUART, V71, P287, DOI 10.1093/poq/nfm006; Benhamou M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053886; Besley J., 2011, NZ J PHYSIOTHER, V39, P81; Castro EM, 2016, PATIENT EDUC COUNS, V99, P1923, DOI 10.1016/j.pec.2016.07.026; Cheng L, 2016, PHYS THER REV, V21, P109, DOI 10.1080/10833196.2016.1228558; Christalle E, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-025896; Conrad FG, 2009, PUBLIC OPIN QUART, V73, P32, DOI 10.1093/poq/nfp013; Constand MK, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-271; Corbin J.M., 2008, BASICS QUALITATIVE R, Vthird, DOI DOI 10.4135/9781452230153.N8; Sampaio FMC, 2017, ARCH PSYCHIAT NURS, V31, P147, DOI 10.1016/j.apnu.2016.09.007; DALKEY N, 1963, MANAGE SCI, V9, P458, DOI 10.1287/mnsc.9.3.458; Delaney KR, 2018, J CHILD ADOL PS NURS, V31, P100, DOI 10.1111/jcap.12221; Del Bano-Aledo ME, 2014, PHYSIOTHERAPY, V100, P73, DOI 10.1016/j.physio.2013.05.001; Elvins R, 2008, CLIN PSYCHOL REV, V28, P1167, DOI 10.1016/j.cpr.2008.04.002; Epstein RM, 2005, SOC SCI MED, V61, P1516, DOI 10.1016/j.socscimed.2005.02.001; Ericsson A, 1993, HERBERT PROTOCOL ANA; Escobar J., 2008, AVANCES MEDICION, V6, P27, DOI [10.32870/Ap.v9n2.993, DOI 10.1016/0032-3861(78)90049-6]; Falzarano Mary, 2013, J Allied Health, V42, P99; Finger ME, 2006, PHYS THER, V86, P1203, DOI 10.2522/ptj.20050134; Hall AM, 2010, PHYS THER, V90, P1099, DOI 10.2522/ptj.20090245; Hamilton CB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206588; Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x; Hobbs JL, 2009, NURS RES, V58, P52, DOI 10.1097/NNR.0b013e31818c3e79; Hsu CC, 2007, DELPHI TECHNIQUE MAK; Kamper SJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000963.pub3; Kim S C, 2001, Clin Nurs Res, V10, P314; Leal-Costa C, 2016, AN PSICOL-SPAIN, V32, P49, DOI 10.6018/analesps.31.3.184701; Leplege A, 2007, DISABIL REHABIL, V29, P1555, DOI 10.1080/09638280701618661; Linstone H., 1975, DELPHI METHOD; Little P, 2001, BMJ-BRIT MED J, V322, P468, DOI 10.1136/bmj.322.7284.468; McAndrew S, 2014, INT J MENT HEALTH NU, V23, P212, DOI 10.1111/inm.12044; McCormack B, 2006, J ADV NURS, V56, P472, DOI 10.1111/j.1365-2648.2006.04042.x; Mead N, 2000, SOC SCI MED, V51, P1087, DOI 10.1016/S0277-9536(00)00098-8; Medina-Mirapeix F, 2015, PHYS THER, V95, P767, DOI 10.2522/ptj.20140041; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; Morera-Balaguer J, 2018, BRAZILIAN J PHYS THE, V22, P328, DOI [10.1016/j.bjpt.2018.06.005, DOI 10.1016/J.BJPT.2018.06.005]; Morera-Balaguer J, 2021, PHYSIOTHER THEOR PR, V37, P17, DOI 10.1080/09593985.2019.1603258; Morgan S, 2012, J HOLIST NURS, V30, P6, DOI 10.1177/0898010111412189; Mudge S, 2014, DISABIL REHABIL, V36, P457, DOI 10.3109/09638288.2013.797515; Mukhopadhyay S, 2005, J LEUKOCYTE BIOL, P42; Murray A., 2018, DISABIL REHABIL, P1, DOI [10.1016/j.jclinepi.2010.02.006, DOI 10.1016/J.JCLINEPI.2010.02.006]; O'Keeffe M, 2016, PHYS THER, V96, P609, DOI 10.2522/ptj.20150240; Powell C, 2003, J ADV NURS, V41, P376, DOI 10.1046/j.1365-2648.2003.02537.x; Rathert C, 2015, HEALTH EXPECT, V18, P199, DOI 10.1111/hex.12020; Sanders T, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-65; Scholl I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107828; Sidani S, 2014, J INTERPROF CARE, V28, P134, DOI 10.3109/13561820.2013.862519; Stewart J, 1999, BMJ-BRIT MED J, V319, P224, DOI 10.1136/bmj.319.7204.224; Terwee CB, 2018, QUAL LIFE RES, V27, P1159, DOI 10.1007/s11136-018-1829-0; van der Zouwen J, 2004, METHODS TESTING EVAL, P109, DOI [10.1002/0471654728.ch6, DOI 10.1002/0471654728]; Wagner EH, 2005, J ALTERN COMPLEM MED, V11, pS7, DOI 10.1089/acm.2005.11.s-7; Wijma AJ, 2017, PHYSIOTHER THEOR PR, V33, P825, DOI 10.1080/09593985.2017.1357151; Zill JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141978; Zimmermann L, 2014, PATIENT EDUC COUNS, V96, P98, DOI 10.1016/j.pec.2014.04.015	55	8	8	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 2	2020	15	3							e0228916	10.1371/journal.pone.0228916	http://dx.doi.org/10.1371/journal.pone.0228916			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8JT	32119676	Green Published, gold			2023-01-03	WOS:000535245300010
J	Resneck, JS				Resneck, Jack S., Jr.			Refocusing Medication Prior Authorization on Its Intended Purpose	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMPACT; COSTS		[Resneck, Jack S., Jr.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, 1701 Divisadero St,POB 0316, San Francisco, CA 94143 USA; [Resneck, Jack S., Jr.] Univ Calif San Francisco, Sch Med, Dept Dermatol, 1701 Divisadero St,POB 0316, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Resneck, JS (corresponding author), Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, 1701 Divisadero St,POB 0316, San Francisco, CA 94143 USA.; Resneck, JS (corresponding author), Univ Calif San Francisco, Sch Med, Dept Dermatol, 1701 Divisadero St,POB 0316, San Francisco, CA 94143 USA.	resneckj@derm.ucsf.edu						American Medical Association, 2018 AMA PRIOR AUTH; American Medical Association, CONS STAT IMPR PRIOR; Bergeson JG, 2013, J MANAGE CARE PHARM, V19, P374, DOI 10.18553/jmcp.2013.19.5.374; CoverMyMeds, PREP SEAS INCR PRIOR; CoverMyMeds, 2019, 2019 EPA NAT AD SCOR; Medicare Payment Advisory Commission, HLTH CAR SPEND MED P; Milliman Inc, EV US RESTR COMM FOR; Murrin S, 2019, SOME MEDICARE D; Papanicolas I, 2018, JAMA-J AM MED ASSOC, V319, P1024, DOI 10.1001/jama.2018.1150; Seabury SA, 2014, AM J MANAG CARE, V20, pE52	10	20	20	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2020	323	8					703	704		10.1001/jama.2019.21428	http://dx.doi.org/10.1001/jama.2019.21428			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KS9GZ	32011641				2023-01-03	WOS:000518617500013
J	Laksono, AD; Rukmini, R; Wulandari, RD				Laksono, Agung Dwi; Rukmini, Rukmini; Wulandari, Ratna Dwi			Regional disparities in antenatal care utilization in Indonesia	PLOS ONE			English	Article							MATERNAL HEALTH-CARE; SERVICES; DETERMINANTS; PAKISTAN	Introduction The main strategy for decreasing maternal morbidity and mortality has been antenatal care (ANC). ANC aims to monitor and maintain the health and safety of the mother and the fetus, detect all complications of pregnancy and take the necessary actions, respond to complaints, prepare for birth, and promote a healthy lifestyle. This study aims to analyze interregional disparities in >= 4 ANC visits during pregnancy in Indonesia. Methods Data was acquired from the 2017 Indonesian Demographic and Health Survey (IDHS). The unit of analysis was women aged 15-49 years old, and a sample of 15,351 women was obtained. In addition to ANC as the dependent variable, the other variables analyzed in this study were a place of residence, age, husband/partner, education, parity, wealth status, and health insurance. For the final analysis, binary logistic regression was used to determine disparity. Results With the Papua region as a reference, all regions showed a gap except for the Maluku region, which was not significantly different in the use of ANC compared to the Papua region. Women in the Nusa Tenggara have 4.365 times the chance of making >= 4 ANC visits compared to those in the Papua region (95% CI 3.229-5.899). Women in Java-Bali have 3.607 times the chance of making >= 4 ANC visits compared to women in the Papua region (95% CI 2.741-4.746). Women in Sumatra have 1.370 times the chance of making >= 4 ANC visits compared to women in the Papua region (95% CI 1.066-1.761). Women in Kalimantan have 2.232 times the chance of making >= 4 ANC visits compared to women in the Papua region (1.664-2.994). Women in Sulawesi have 1.980 times more chance of making >= 4 ANC visits compared to women in the Papua region (1.523-2.574). In addition to the region category, other variables that contributed to the predictor were age, husband/partner, education, parity, wealth and insurance. Conclusion There were disparities in ANC utilization between the various regions of Indonesia. The structured policy is needed to reach regions that have low coverage of >= 4 ANC. Policymakers need to use the results of this study to take the necessary policies. Policies that focus on service equality to reduce disparities.	[Laksono, Agung Dwi; Rukmini, Rukmini] Minist Hlth, Natl Inst Hlth Res & Dev, Jakarta, Indonesia; [Wulandari, Ratna Dwi] Univ Airlangga, Fac Publ Hlth, Surabaya, Indonesia	Ministry of Health - Indonesia; National Institute of Health Research & Development - Indonesia; Airlangga University	Wulandari, RD (corresponding author), Univ Airlangga, Fac Publ Hlth, Surabaya, Indonesia.	ratna-d-w@fkm.unair.ac.id	Laksono, Agung Dwi/N-5161-2018; Wulandari, Ratna/AAN-9410-2020	Laksono, Agung Dwi/0000-0002-9056-0399; Wulandari, Ratna/0000-0003-4365-5747				Achadi EL, 2019, MATERNAL NEONATAL DE; Adewuyi EO, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197324; Agustina R, 2019, LANCET, V393, P75, DOI 10.1016/S0140-6736(18)31647-7; Ahmed S, 2019, EUR J HUM GENET, V27, P848, DOI 10.1038/s41431-019-0353-1; Ba DM, 2019, SEX REPROD HEALTHC, V21, P26, DOI 10.1016/j.srhc.2019.06.002; Baraki Z, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2338-z; Blanchard AK, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0554-8; Bobo FT, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0602-2; Caselli G., 2019, GENUS, V75, P11, DOI [10.1186/s41118-019-0055-0, DOI 10.1186/S41118-019-0055-0]; Chi PC, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0449-8; Chiang CL, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010802; Data and Information Center Ministry of Health, 2014, MOTH DAY MAT HLTH SI; Dey A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204810; Directorate General of Health Services, 2019, 2018 DIR GEN HLTH SE; El-Sayed AM, 2018, J GLOB HEALTH, V8, DOI 10.7189/jogh.08.020402; Hattar-Pollara M, 2019, J NURS SCHOLARSHIP, V51, P241, DOI 10.1111/jnu.12480; Hijazi HH, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0542-3; Jafaralilou H, 2019, J EGYPT PUBLIC HEAL, V94, DOI 10.1186/s42506-018-0001-6; Johar M, 2018, SOC SCI MED, V213, P134, DOI 10.1016/j.socscimed.2018.07.044; Jungari S, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2214-x; Laksono, 2019, HLTH SCI J INDONES, V10, P58, DOI [DOI 10.22435/HSJI.V10I1.1044, 10.22435/hsji.v10i1.1044]; Laksono A. D., 2019, MALAYSIAN J PUBLIC H, V19; Laksono AD., 2016, J REPROD HEAL, V07, P145, DOI [10.22435/kespro.v7i3.4349.145-155, DOI 10.22435/KESPRO.V7I3.4349.145-155]; Laksono AD, 2015, BUL PENELIT SIST KES, V18, P347; Luginaah IN, 2016, SOC SCI MED, V160, P75, DOI 10.1016/j.socscimed.2016.05.019; Megatsari H, 2018, BUL PENELIT SIST KES, V21, P247, DOI 10.22435/hsr.v2Ii4.231; Mekonnen T, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16050748; Ministry of National Development Planning / National Development Planning Agency, 2014, COLL SECT STUD EV SU; Miraldo M, 2018, SOC SCI MED, V217, P135, DOI 10.1016/j.socscimed.2018.09.028; Mubasyiroh R., 2016, ACCESSIBILITY HLTH S, P21; Mullerschon J, 2019, BMC INT HEALTH HUM R, V19, DOI 10.1186/s12914-019-0189-3; Mumtaz S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217827; National Institute of Health Research and Development of The Indonesia Ministry of Health, 2019, 2018 IND BAS HLTH SU; National Population and Family Planning Board Statistics Indonesia Ministry of Health The DHS Program, 2018, DHS PROGR; Nurrizka RH, 2018, INDONESIAN J PUB HLT, V14, P119; Olaitan T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176195; Olugbade Olukemi Titilope, 2019, Pan Afr Med J, V32, P13, DOI 10.11604/pamj.supp.2019.32.1.13345; Pafs J, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1051-4; Paul P, 2019, MIDWIFERY, V75, P66, DOI 10.1016/j.midw.2019.04.007; Pulok MH, 2018, HEALTH PLACE, V52, P205, DOI 10.1016/j.healthplace.2018.06.004; Sahito A, 2018, INT J HEALTH POLICY, V7, P699, DOI 10.15171/ijhpm.2017.148; Sakuma S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215635; Soewondo P., 2019, J ADM KESEHAT INDONE, V7, P89, DOI [10.20473/jaki.v7i1.2019.89-7, DOI 10.20473/JAKI.V7I1.2019.89-7, 10.20473/jaki.v7i1.2019.89-98, DOI 10.20473/JAKI.V7I1.2019.89-98]; Suharmiati, 2013, BUL PENELIT SIST KES, V16, P109; Sully EA, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001695; Sumankuuro J, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2414-4; Teye-Kwadjo E, 2019, INT J HEALTH PROMOT, V57, P256, DOI 10.1080/14635240.2019.1613163; Tikmani SS, 2019, SEMIN PERINATOL, V43, P297, DOI 10.1053/j.semperi.2019.03.020; Tirgil A, 2018, J GLOB HEALTH, V8, DOI 10.7189/jogh.08.020412; United Nations Group of Experts on Geographical Names, 2017, UN C STAND GEOGR NAM; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; Wilson M, 2019, MIDWIFERY, V78, P16, DOI 10.1016/j.midw.2019.07.005; Yesuf EA, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-131; You H, 2019, INQUIRY-J HEALTH CAR, V56, DOI 10.1177/0046958019865435; Zakar R, 2017, J OBSTET GYNAECOL, V37, P330, DOI 10.1080/01443615.2016.1250728	55	31	31	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2020	15	2							e0224006	10.1371/journal.pone.0224006	http://dx.doi.org/10.1371/journal.pone.0224006			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ7SH	32053621	Green Published, gold, Green Submitted			2023-01-03	WOS:000535198700007
J	Schunemann, HJ; Khabsa, J; Solo, K; Khamis, AM; Brignardello-Petersen, R; El-Harakeh, A; Darzi, A; Hajizadeh, A; Bognanni, A; Bak, A; Izcovich, A; Cuello-Garcia, CA; Chen, C; Borowiack, E; Chamseddine, F; Schunemann, F; Morgano, GP; Muti-Schunemann, GEU; Chen, G; Zhao, H; Neumann, I; Brozek, J; Schmidt, J; Hneiny, L; Harrison, L; Reinap, M; Junek, M; Santesso, N; El-Khoury, R; Thomas, R; Nieuwlaat, R; Stalteri, R; Yaacoub, S; Lotfi, T; Baldeh, T; Piggott, T; Zhang, Y; Saad, Z; Rochwerg, B; Perri, D; Fan, E; Stehling, F; Akl, IB; Loeb, M; Garner, P; Aston, S; Alhazzani, W; Szczeklik, W; Chu, DK; Akl, EA				Schunemann, Holger J.; Khabsa, Joanne; Solo, Karla; Khamis, Assem M.; Brignardello-Petersen, Romina; El-Harakeh, Amena; Darzi, Andrea; Hajizadeh, Anisa; Bognanni, Antonio; Bak, Anna; Izcovich, Ariel; Cuello-Garcia, Carlos A.; Chen, Chen; Borowiack, Ewa; Chamseddine, Fatimah; Schunemann, Finn; Morgano, Gian Paolo; Muti-Schunemann, Giovanna E. U.; Chen, Guang; Zhao, Hong; Neumann, Ignacio; Brozek, Jan; Schmidt, Joel; Hneiny, Layal; Harrison, Leila; Reinap, Marge; Junek, Mats; Santesso, Nancy; El-Khoury, Rayane; Thomas, Rebecca; Nieuwlaat, Robby; Stalteri, Rosa; Yaacoub, Sally; Lotfi, Tamara; Baldeh, Tejan; Piggott, Thomas; Zhang, Yuan; Saad, Zahra; Rochwerg, Bram; Perri, Dan; Fan, Eddy; Stehling, Florian; Akl, Imad Bou; Loeb, Mark; Garner, Paul; Aston, Stephen; Alhazzani, Waleed; Szczeklik, Wojciech; Chu, Derek K.; Akl, Elie A.			Ventilation Techniques and Risk for Transmission of Coronavirus Disease, Including COVID-19 A Living Systematic Review of Multiple Streams of Evidence	ANNALS OF INTERNAL MEDICINE			English	Review							FLOW NASAL CANNULA; CONVENTIONAL OXYGEN-THERAPY; ACUTE RESPIRATORY SYNDROME; HEALTH-CARE WORKERS; ENDOTRACHEAL INTUBATION; NONINVASIVE VENTILATION; MECHANICAL VENTILATION; FAILURE; GRADE; PRESSURE	Background: Mechanical ventilation is used to treat respiratory failure in coronavirus disease 2019 (COVID-19). Purpose: To review multiple streams of evidence regarding the benefits and harms of ventilation techniques for coronavirus infections, including that causing COVID-19. Data Sources: 21 standard, World Health Organization-specific and COVID-19-specific databases, without language restrictions, until 1 May 2020. Study Selection: Studies of any design and language comparing different oxygenation approaches in patients with coronavirus infections, including severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS), or with hypoxemic respiratory failure. Animal, mechanistic, laboratory, and preclinical evidence was gathered regarding aerosol dispersion of coronavirus. Studies evaluating risk for virus transmission to health care workers from aerosol-generating procedures (AGPs) were included. Data Extraction: Independent and duplicate screening, data abstraction, and risk-of-bias assessment (GRADE for certainty of evidence and AMSTAR 2 for included systematic reviews). Data Synthesis: 123 studies were eligible (45 on COVID-19, 70 on SARS, 8 on MERS), but only 5 studies (1 on COVID-19, 3 on SARS, 1 on MERS) adjusted for important confounders. A study in hospitalized patients with COVID-19 reported slightly higher mortality with noninvasive ventilation (NIV) than with invasive mechanical ventilation (IMV), but 2 opposing studies, 1 in patients with MERS and 1 in patients with SARS, suggest a reduction in mortality with NIV (very-low-certainty evidence). Two studies in patients with SARS report a reduction in mortality with NIV compared with no mechanical ventilation (low-certainty evidence). Two systematic reviews suggest a large reduction in mortality with NIV compared with conventional oxygen therapy. Other included studies suggest increased odds of transmission from AGPs. Limitation: Direct studies in COVID-19 are limited and poorly reported. Conclusion: Indirect and low-certainty evidence suggests that use of NIV, similar to IMV, probably reduces mortality but may increase the risk for transmission of COVID-19 to health care workers. Primary Funding Source: World Health Organization. (PROSPERO: CRD42020178187)	[Schunemann, Holger J.; Solo, Karla; Brignardello-Petersen, Romina; Darzi, Andrea; Hajizadeh, Anisa; Bognanni, Antonio; Cuello-Garcia, Carlos A.; Schunemann, Finn; Morgano, Gian Paolo; Brozek, Jan; Schmidt, Joel; Harrison, Leila; Junek, Mats; Santesso, Nancy; Nieuwlaat, Robby; Stalteri, Rosa; Lotfi, Tamara; Baldeh, Tejan; Piggott, Thomas; Zhang, Yuan; Rochwerg, Bram; Perri, Dan; Loeb, Mark; Alhazzani, Waleed; Chu, Derek K.] McMaster Univ, HSC-2C,1280 Main St West, Hamilton, ON L8N 3Z5, Canada; [Khabsa, Joanne; El-Harakeh, Amena; Chamseddine, Fatimah; Hneiny, Layal; El-Khoury, Rayane; Yaacoub, Sally; Saad, Zahra; Akl, Imad Bou; Akl, Elie A.] Amer Univ Beirut, Med Ctr, Beirut 11072020, Lebanon; [Khamis, Assem M.] Univ Hull, Cottingham Rd, Kingston Upon Hull HU6 7RX, East Riding Of, England; [Bak, Anna; Borowiack, Ewa] Evidence Prime, Torunska 5, PL-30056 Krakow, Poland; [Izcovich, Ariel] German Hosp Buenos Aires, Pueyrredon 1640,C1118 AAT, Buenos Aires, DF, Argentina; [Chen, Chen] Guangzhou Univ Chinese Med, Jichang Rd 12, Guangzhou, Guangdong, Peoples R China; [Muti-Schunemann, Giovanna E. U.] Univ Vita Salute San Raffaele, Via Olgettina Milano 58, I-20132 Milan, Italy; [Chen, Guang] Beijing Univ Chinese Med, 5 HaiYun Cang, Beijing, Peoples R China; [Zhao, Hong] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, 16 Nanxiaojie St, Beijing, Peoples R China; [Neumann, Ignacio] Pontificia Univ Catolica Chile, Alameda 340, Santiago, Chile; [Reinap, Marge] London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England; [Thomas, Rebecca; Garner, Paul] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England; [Fan, Eddy] Toronto Gen Hosp, 585 Univ Ave,PMB 11-123, Toronto, ON M5G 2N2, Canada; [Stehling, Florian] Univ Essen Gesamthsch, Abt Padiat Pneumol, Klin Kinderheilkunde 3, Hufelandstr 55, D-45147 Essen, Germany; [Aston, Stephen] Liverpool Univ Hosp NHS Trust, Trop & Infect Dis Unit, Prescot St, Liverpool L7 8XP, Merseyside, England; [Szczeklik, Wojciech] Jagiellonian Univ Med Coll, Dept Intens Care & Perioperat Med, Krakow, Poland	McMaster University; American University of Beirut; University of Hull; Hospital Aleman; University of Buenos Aires; Guangzhou University of Chinese Medicine; Vita-Salute San Raffaele University; Beijing University of Chinese Medicine; China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS; Pontificia Universidad Catolica de Chile; University of London; London School of Hygiene & Tropical Medicine; Liverpool School of Tropical Medicine; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Duisburg Essen; Jagiellonian University; Collegium Medicum Jagiellonian University	Schunemann, HJ (corresponding author), Michael G DeGroote Cochrane Canada, HSC-2C,1280 Main St West, Hamilton, ON L8N 3Z5, Canada.; Schunemann, HJ (corresponding author), McMaster Univ, McMaster GRADE Ctr, HSC-2C,1280 Main St West, Hamilton, ON L8N 3Z5, Canada.; Akl, EA (corresponding author), Amer Univ Beirut, Clin Res Inst, POB 11-0236 CRI E15, Beirut 11072020, Lebanon.; Akl, EA (corresponding author), Amer Univ Beirut, AUB GRADE Ctr, POB 11-0236 CRI E15, Beirut 11072020, Lebanon.	schuneh@mcmaster.ca; ea32@aub.edu.lb	Akl, Elie/K-5269-2019; Hneiny, Layal/AAU-7587-2020; Hnieny, Layal/AGQ-1697-2022; Garner, Paul/HII-5856-2022; Reinap, Marge/ABC-3984-2020; T, E/HII-8943-2022; Solo, Karla/I-4835-2018; Szczeklik, Wojciech/N-8096-2014; Stehling, Florian/AAX-9428-2020; Khamis, Assem/O-9365-2019; Neumann, Ignacio/ABB-5013-2020; Cuello-Garcia, Carlos/E-8620-2016	Hneiny, Layal/0000-0003-1073-4879; Szczeklik, Wojciech/0000-0002-1349-1123; Khamis, Assem/0000-0002-5567-7065; Cuello-Garcia, Carlos/0000-0002-1742-0242; Garner, Paul/0000-0002-0607-6941; Izcovich, Ariel/0000-0001-9053-4396; Baldeh, Tejan/0000-0001-9194-3319; Morgano, Gian Paolo/0000-0001-7577-7963; Lotfi, Tamara/0000-0001-6101-3946; Aston, Stephen/0000-0002-0701-8364; Chen, Guang/0000-0001-6644-9618; Schunemann, Holger/0000-0003-3211-8479; Bognanni, Antonio/0000-0003-0128-903X; El Harakeh, Amena/0000-0003-4554-5875; Khabsa, Joanne/0000-0002-4336-3501; Thomas, Rebecca/0000-0003-2607-000X; Piggott, Thomas/0000-0003-1643-5386; Chu, Derek/0000-0001-8269-4496; Junek, Mats/0000-0001-8416-3955; Yaacoub, Sally/0000-0003-0819-1561; Bou Akl, Imad/0000-0001-8984-6683; Hajizadeh, Anisa/0000-0003-1919-5189; Darzi, Andrea/0000-0002-2498-1697; Reinap, Marge/0000-0001-5836-7516	World Health Organization	World Health Organization(World Health Organization)	By the World Health Organization, which commissioned this review on 3 April 2020.	Adhikari U, 2019, RISK ANAL, V39, P2608, DOI 10.1111/risa.13389; Alanazi KH, 2019, INFECT CONT HOSP EP, V40, P79, DOI 10.1017/ice.2018.290; Alhazzani Waleed, 2020, Crit Care Med, V48, pe440, DOI [10.1007/s00134-020-06022-5, 10.1097/CCM.0000000000004363]; Alraddadi BM, 2019, INFLUENZA OTHER RESP, V13, P382, DOI 10.1111/irv.12635; Alraddadi BM, 2016, EMERG INFECT DIS, V22, P1915, DOI 10.3201/eid2211.160920; Anesi GL, 2020, UPTODATE; Angel L, 2020, ANN THORAC SURG, DOI [10.1016/j.athoracsur.2020.04.010, DOI 10.1016/J.ATH0RACSUR.2020.04.010]; [Anonymous], 2020, J NURSE TRAINING, DOI DOI 10.1080/07315724.2020.1751007; [Anonymous], 2020, NEW YORK TIMES STATE, DOI 10.1016/S2468-2667(20)30117-1; [Anonymous], 2020, ANN INTERN MED; Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Auld S, 2020, ICU VENTILATOR MORTA, DOI [10.1101/2020.04.23.20076737, DOI 10.1101/2020.04.23.20076737]; Australian and New Zealand Intensive Care Society (ANZICS), 2020, ANZICS COVID 19 GUID; Berbenetz N, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005351.pub4; Bharadwaj SK, 2020, ARCH DIS CHILD FETAL, DOI [10.1136/archdischild-2019-318165, DOI 10.1136/ARCHDISCHILD-2019-318165]; Bocchile RL, 2019, COCHRANE DATABASE SY, V1, DOI 10.1002/ 14651858.CD011231.pub2; Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Buchholz U, 2013, EURO SURVEILL, V18; Cai S J, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P332, DOI 10.3760/cma.j.cn112147-20200222-00153; Chen WQ, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-81; Chiang CH, 2004, MAYO CLIN PROC, V79, P1372, DOI 10.4065/79.11.1372; Chidini G, 2015, PEDIATRICS, V135, pE868, DOI 10.1542/peds.2014-1142; Choi WS, 2016, INFECT CHEMOTHER, V48, P118, DOI 10.3947/ic.2016.48.2.118; Duca A, PREPRINTS LANCET, DOI [10.2139/ssrn.3566170, DOI 10.2139/SSRN.3566170]; Fears A C, 2020, medRxiv, DOI 10.1101/2020.04.13.20063784; Fowler RA, 2004, AM J RESP CRIT CARE, V169, P1198, DOI 10.1164/rccm.200305-715OC; Garner P, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3507; Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z; Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE; Guo J, 2003, ZHONGGUO LINCHUANG Y, V31; Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885; Guyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P173, DOI 10.1016/j.jclinepi.2012.08.001; Hall AJ, 2014, EMERG INFECT DIS, V20, P2148, DOI 10.3201/eid2012.141211; He Y, 2020, PRACTICAL HOSP CLIN, V17, P59; Heinzerling A, 2020, MMWR-MORBID MORTAL W, V69, P472, DOI 10.15585/mmwr.mm6915e5; Higgins JP, 2019, COCHRANE HDB SYSTEMA; Hua DD, 2020, J PRACTICAL MED, P1; Hunter JC, 2016, EMERG INFECT DIS, V22, P647, DOI 10.3201/eid2204.151615; ICM Anaesthesia, 2020, CRIT CAR PREP MAN CO; Jat KR, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010473.pub3; Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6; Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797; Li H, 2003, J SHANXI MED U, V34; Li TS, 2007, J PHYSL 1, V580, P285, DOI [10.1113/jphysiol.2006.125336, DOI 10.1113/JPHYSI0L.2006.125336]; Liao X, 2020, CRITICAL CARE SEVERE, DOI [10.1101/2020.03.22.20041277, DOI 10.1101/2020.03.22.20041277]; Liu H, 2003, CRITICAL CARE MED CH, V15; Liu W, 2009, TROP MED INT HEALTH, V14, P52, DOI 10.1111/j.1365-3156.2009.02255.x; Liu X, 2020, WORKING PAPER; Loeb M, 2004, EMERG INFECT DIS, V10, P251, DOI 10.3201/eid1002.030838; Luo J, 2019, J PEDIATR-US, V215, P199, DOI 10.1016/j.jpeds.2019.07.059; Memish ZA, 2013, NEW ENGL J MED, V369, P884, DOI 10.1056/NEJMc1308698; Mo X, 2020, GUANGDONG MED, P1; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moskalewicz A, 2020, J CLIN EPIDEMIOL, V120, P94, DOI 10.1016/j.jclinepi.2019.12.013; Murad M.H., 2017, EVID BASED MED, V22, P85, DOI [10.1136/ebmed-2017-110668, DOI 10.1136/EBMED-2017-110668]; Nam HS, 2017, EPIDEMIOL HEALTH, V39, DOI 10.4178/epih.e2017052; National Health Service, 2020, AC US NONST ANT DRUG; Ng K, 2020, ANN INTERN MED, V172, P766, DOI 10.7326/L20-0175; Ni YN, 2018, AM J EMERG MED, V36, P226, DOI 10.1016/j.ajem.2017.07.083; Ni YN, 2017, CHEST, V151, P764, DOI 10.1016/j.chest.2017.01.004; Ou XF, 2017, CAN MED ASSOC J, V189, pE260, DOI 10.1503/cmaj.160570; Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338; Pei Li-ying, 2006, Beijing Da Xue Xue Bao Yi Xue Ban, V38, P271; Pyankov OV, 2018, J AEROSOL SCI, V115, P158, DOI 10.1016/j.jaerosci.2017.09.009; Qiangui L, 2004, CHINESE CRITICAL CAR, V16; Raboud J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010717; Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5; Santesso N, 2020, J CLIN EPIDEMIOL, V119, P126, DOI 10.1016/j.jclinepi.2019.10.014; Santesso N, 2016, J CLIN EPIDEMIOL, V74, P28, DOI 10.1016/j.jclinepi.2015.12.006; Scales DC, 2003, EMERG INFECT DIS, V9, P1205, DOI 10.3201/eid0910.030525; Schunemann HJ, 2015, SYST REV-LONDON, V4, DOI 10.1186/2046-4053-4-4; Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008; Suarez-Garcia I, 2020, J HOSP INFECT, V106, P357, DOI 10.1016/j.jhin.2020.07.020; Teleman MD, 2004, EPIDEMIOL INFECT, V132, P797, DOI [10.1017/S0950268804002766, 10.1017/s0950268804002766]; Thayer KA, 2016, ENVIRON INT, V92-93, P585, DOI 10.1016/j.envint.2016.03.027; Wan GH, 2004, INFECT CONT HOSP EP, V25, P1113, DOI 10.1086/502353; Wang K, 2004, J CLIN ANESTHESIOLOG, V20; Wang K, 2020, INTENS CARE MED, V46, P1472, DOI 10.1007/s00134-020-06047-w; Wang K, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00653-z; Wells G, 2009, NEWCASTLE OTTAWA SCA; World Health Organization, 2020, MERS SIT UPD; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Xu XP, 2017, CRIT CARE MED, V45, pE727, DOI 10.1097/CCM.0000000000002361; Xu Y, 2010, CHINESE J RESP CRITI, V9, P575; Yam LYC, 2005, CHINESE MED J-PEKING, V118, P1413; Yang L, 2004, CRITICAL CARE MED CH, V16; Yang Z, 2003, ARMED POLICE MED, P563; Yu L, 2003, ICML; Zhao HY, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1760-8; Zheng X, 2019, EUR REV MED PHARMACO, V23, P4382, DOI 10.26355/eurrev_201905_17945; Zheng Z, 2004, J GUANGZHOU MED COLL, P21; Zhong Q, 2020, BRIT J ANAESTH, V124, P670, DOI 10.1016/j.bja.2020.03.007	95	69	72	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 4	2020	173	3					204	+		10.7326/M20-2306	http://dx.doi.org/10.7326/M20-2306			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW7BG	32442035	Green Accepted, Green Published			2023-01-03	WOS:000557186700008
J	Jacobsen, JC; Tran, KM; Jackson, VA; Rubin, EB				Jacobsen, Juliet C.; Tran, Kathy M.; Jackson, Vicki A.; Rubin, Emily B.			Case 19-2020: A 74-Year-Old Man with Acute Respiratory Failure and Unclear Goals of Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; CODE STATUS DISCUSSIONS; SHARED DECISION-MAKING; END; RESUSCITATION; SURVIVAL; LIFE; RECOMMENDATIONS; COMMUNICATION; INFORMATION	A 74-year-old man with lymphoma was admitted to the hospital during the Covid-19 pandemic because of rapidly progressive respiratory failure. Several years earlier, when he had been critically ill, he had expressed a desire for "do not resuscitate" status. More recently, he had indicated that he would try all therapies that may be helpful. A consultation was requested.	[Jacobsen, Juliet C.; Tran, Kathy M.; Jackson, Vicki A.; Rubin, Emily B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Jacobsen, Juliet C.; Tran, Kathy M.; Jackson, Vicki A.; Rubin, Emily B.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Jacobsen, JC (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.							Alfandre David, 2016, J Clin Ethics, V27, P21; Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Back AL, 2008, CANCER-AM CANCER SOC, V113, P1897, DOI 10.1002/cncr.23653; Back AL, 2011, ONCOLOGIST, V16, P342, DOI 10.1634/theoncologist.2010-0274; Baker Mike, 2020, NEW YORK TIMES; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Berkey FJ, 2018, AM FAM PHYSICIAN, V98, P99; Blinderman CD, 2012, JAMA-J AM MED ASSOC, V307, P917, DOI 10.1001/jama.2012.236; Curtis JR, 2008, J PALLIAT MED, V11, P610, DOI 10.1089/jpm.2007.0209; Curtis JR, 2020, JAMA-J AM MED ASSOC, V323, P1771, DOI 10.1001/jama.2020.4894; Cwrtis JR, 2007, CHEST, V132, P748, DOI 10.1378/chest.07-0745; de Vreede-Swagemakers JJM, 1998, HEART, V79, P356, DOI 10.1136/hrt.79.4.356; Einstein DJ, 2016, JAMA ONCOL, V2, P429, DOI 10.1001/jamaoncol.2015.6349; Einstein DJ, 2015, J PALLIAT MED, V18, P535, DOI 10.1089/jpm.2014.0373; Elwyn G, 2012, J GEN INTERN MED, V27, P1361, DOI 10.1007/s11606-012-2077-6; Evans LR, 2009, AM J RESP CRIT CARE, V179, P48, DOI 10.1164/rccm.200806-969OC; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; GREENE HL, 1990, AM J CARDIOL, V65, pB4; Herlitz J, 2002, HEART, V88, P579, DOI 10.1136/heart.88.6.579; Hoffmann TC, 2014, JAMA-J AM MED ASSOC, V312, P1295, DOI 10.1001/jama.2014.10186; Isenschmid C, 2019, RESUSCITATION, V136, P21, DOI 10.1016/j.resuscitation.2018.10.022; Jackson VA, 2013, J PALLIAT MED, V16, P894, DOI 10.1089/jpm.2012.0547; Jacobsen J, 2018, J PAIN SYMPTOM MANAG, V55, P1229, DOI 10.1016/j.jpainsymman.2017.12.488; Jacobsen J, 2011, J PALLIAT MED, V14, P331, DOI 10.1089/jpm.2010.0383; Klitzman R, 2020, NEW YORK TIMES; Kutner JS, 1999, SOC SCI MED, V48, P1341, DOI 10.1016/S0277-9536(98)00453-5; Laffey JG, 2016, INTENS CARE MED, V42, P1865, DOI 10.1007/s00134-016-4571-5; Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1282; MARWICK TH, 1991, RESUSCITATION, V22, P129, DOI 10.1016/0300-9572(91)90003-H; Muscedere J, 2017, INTENS CARE MED, V43, P1105, DOI 10.1007/s00134-017-4867-0; Portanova J, 2015, RESUSCITATION, V96, P148, DOI 10.1016/j.resuscitation.2015.08.002; Prochaska MT, 2015, J PAIN SYMPTOM MANAG, V50, P693, DOI 10.1016/j.jpainsymman.2015.05.004; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; Rea TD, 2003, CIRCULATION, V107, P2780, DOI 10.1161/01.CIR.0000070950.17208.2A; Rea Thomas D, 2004, Curr Opin Crit Care, V10, P218, DOI 10.1097/01.ccx.0000125494.84614.fb; Schenker Y, 2013, J PALLIAT MED, V16, P243, DOI 10.1089/jpm.2012.0331; Sepucha KR, 2016, HEALTH AFFAIR, V35, P630, DOI 10.1377/hlthaff.2015.1376; Sharma RK, 2014, J GEN INTERN MED, V29, P750, DOI 10.1007/s11606-014-2791-3; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; Sudore RL, 2010, ANN INTERN MED, V153, P256, DOI 10.7326/0003-4819-153-4-201008170-00008; White DB, 2010, CRIT CARE MED, V38, P743, DOI 10.1097/CCM.0b013e3181c58842; Wong MKY, 2014, CIRCULATION, V130, P1883, DOI 10.1161/CIRCULATIONAHA.114.010633; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648	43	4	4	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 18	2020	382	25					2450	2457		10.1056/NEJMcpc2002419	http://dx.doi.org/10.1056/NEJMcpc2002419			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF9FX	32459917	Bronze			2023-01-03	WOS:000545644400011
J	Widyasari, V; Prabandari, YS; Utarini, A				Widyasari, Vita; Prabandari, Yayi Suryo; Utarini, Adi			Training intervention to improve hygiene practices in Islamic boarding school in Yogyakarta, Indonesia: A mixed-method study	PLOS ONE			English	Article							STUDENTS; PROGRAM	Background The primary objective of this study was to determine the effect of a training intervention in overall improvement in students' (santris) knowledge, behavior, and outcome. Methods A mixed-methods exploratory sequential design was applied. First, qualitative data were collected from three focus group discussions with 20 supervisors and one in-depth interview with school principal to explore current hygiene practices. The information was then used to develop training intervention using either video, poster, and leaflet. To measure the effect, a stepped wedge cluster design with pre-and post-test analyses was conducted. A total of 452 junior high school santris in one Islamic boarding school were non-randomly allocated to either three intervention groups. Outcome measures were knowledge, personal behavior, and room hygiene. Codes and categories were produced in the qualitative analysis, while paired t-tests and Wilcoxon rank tests test were used in the quantitative analysis. Results The qualitative study identified poor practices on personal and room hygiene among the santris and proposed a training intervention. Overall, there was a significant increase in knowledge and personal behavior after the intervention (7.22 +/- 1.34 pre-intervention to 7.70 +/- 0.74 post-intervention and 9.75 +/- 2.98 pre-intervention to 12.16 +/- 2.12 post-intervention, respectively, p < 0.001). Room hygiene was significantly improved among boys and those who received leaflets. Conclusion Having developed a specific training materials, school-based hygiene training intervention improved knowledge and personal behavior. Its effect on room hygiene particularly for female santris needs further strengthening of the intervention in this Islamic boarding school setting.	[Widyasari, Vita] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Publ Hlth Grad Program, Int Hlth, Yogyakarta, Indonesia; [Widyasari, Vita] Univ Islam Indonesia, Fac Med, Cluster Publ Hlth Sci, Yogyakarta, Indonesia; [Prabandari, Yayi Suryo] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Hlth Behav Environm & Social Med, Yogyakarta, Indonesia; [Utarini, Adi] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Hlth Policy & Management, Yogyakarta, Indonesia	Gadjah Mada University; Universitas Islam Indonesia; Gadjah Mada University; Gadjah Mada University	Widyasari, V (corresponding author), Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Publ Hlth Grad Program, Int Hlth, Yogyakarta, Indonesia.; Widyasari, V (corresponding author), Univ Islam Indonesia, Fac Med, Cluster Publ Hlth Sci, Yogyakarta, Indonesia.; Utarini, A (corresponding author), Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Hlth Policy & Management, Yogyakarta, Indonesia.	vita.widyasari@uii.ac.id; adiutarini@ugm.ac.id	Utarini, Adi/GQI-1980-2022	Widyasari, Vita/0000-0003-3277-7095				Azizah NN, 2013, HUBUNGAN ANTARA KEBE; Badan Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan RI, 2013, RISET KESEHATAN DASA; Beaujean DJMA, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3146-2; Benzian H, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.14870; Conrad A, 2010, AM J INFECT CONTROL, V38, P559, DOI 10.1016/j.ajic.2009.10.009; Cooper PJ, 2014, THORAX, V69, P232, DOI 10.1136/thoraxjnl-2013-203818; Creswell J. W., 2018, RES DESIGN QUALITATI; Delhi Tourism and Transportation Development Corporation, 2021, UNDP SUPP IMPL SUST; Hemming K, 2015, BMJ-BRIT MED J, V351, ph391; Ismihayati SN, 2013, HUBUNGAN PERILAKU PE; James K, 2001, J LEISURE RES, V33, P71, DOI 10.1080/00222216.2001.11949931; Januraga PP, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-832; Jussila AM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2007-8; Khasawneh S, 2015, INT J TRAIN DEV, V19, P53, DOI 10.1111/ijtd.12047; Kirkpatrick DL, 2006, EVALUATING TRAINING, V3rd; Kumar MS, 2015, IND J GERONTOL, V29, P100; Lathifa M, 2014, FAKTOR FAKTOR YANG B; Ma'rufi I, 2012, J IKESMA, V8, P119; Mairo QKN, 2014, JIKK, V5, P34; Martin AJ, 2014, AM EDUC RES J, V51, P1007, DOI 10.3102/0002831214532164; Miko E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071811; Mwidunda SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118541; Oyibo GP, 2012, CONT J TROP MED, V6, P5; Ozcelik CC, 2014, INT J PUBLIC HEALTH, V59, P799, DOI 10.1007/s00038-014-0595-1; Pavletic AC, 2016, J SCH NURS, V32, P304, DOI 10.1177/1059840516649234; Qomar M., 2002, PESANTREN DARI TRANS; Saffari M, 2013, ENV HLTH PREV MED, V19, P135; Sakamoto Y, 2014, J STROKE CEREBROVASC, V23, P1877, DOI 10.1016/j.jstrokecerebrovasdis.2014.02.015; Sibiya JE, 2013, INT J ENV RES PUB HE, V10, P2282, DOI 10.3390/ijerph10062282; Tan E, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-189; Widyasari V., 2016, PRELIMINARY ST UNPUB; Wilson KE, 2014, SLEEP, V37, P1117, DOI 10.5665/sleep.3774; Yue A, 2014, CHINA AGR ECON REV, V6, P523, DOI 10.1108/CAER-05-2012-0048	33	1	1	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2020	15	5							e0233267	10.1371/journal.pone.0233267	http://dx.doi.org/10.1371/journal.pone.0233267			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1WS	32469906	gold, Green Published			2023-01-03	WOS:000537552800051
J	Lorenz, S; Alex, B; Kammer, T				Lorenz, Sabrina; Alex, Birte; Kammer, Thomas			Ten minutes of transcranial static magnetic field stimulation does not reliably modulate motor cortex excitability	PLOS ONE			English	Article							INTERINDIVIDUAL VARIABILITY; CORTICOSPINAL EXCITABILITY; EVOKED POTENTIALS; BRAIN; ACTIVATION; PLASTICITY; INDUCTION; THRESHOLD; PULSES; SAFETY	Recently, modulatory effects of static magnetic field stimulation (tSMS) on excitability of the motor cortex have been reported. In our previous study we failed to replicate these results. It was suggested that the lack of modulatory effects was due to the use of an auditory oddball task in our study. Thus, we aimed to evaluate the role of an oddball task on the effects of tSMS on motor cortex excitability. In a within-subject-design we compared 10 minutes tSMS with and without oddball task. In one of the two sessions subjects had to solve an auditory oddball task during the exposure to the magnet, whereas there was no task during exposure in the other session. Motor cortex excitability was measured before and after tSMS. No modulation was observed in any condition. However, when data were pooled regarding the order of the sessions, a trend for an increase of excitability was observed in the first session compared to the second session. We now can rule out that the auditory oddball task destroys tSMS effects, as postulated. Our results rather suggest that fluctuations in the amplitudes of single pulse motor evoked potentials may possibly mask weak modulatory effects but may also lead to false positive results if the number of subjects in a study is too low. In addition, there might be a habituation effect to the whole procedure, resulting in less variability when subjects underwent the same experiment twice.	[Lorenz, Sabrina; Alex, Birte; Kammer, Thomas] Univ Ulm, Sect Neurostimulat, Dept Psychiat, Ulm, Germany	Ulm University	Lorenz, S (corresponding author), Univ Ulm, Sect Neurostimulat, Dept Psychiat, Ulm, Germany.	sabrina.lorenz@uni-ulm.de	Kammer, Thomas/K-2168-2012	Kammer, Thomas/0000-0002-2769-5645; Lorenz, Sabrina/0000-0001-5798-4838				Boggio PS, 2006, NEUROSCI LETT, V404, P232, DOI 10.1016/j.neulet.2006.05.051; Boroojerdi B, 2000, NEUROLOGY, V54, P1529, DOI 10.1212/WNL.54.7.1529; Bruckner S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167697; Chang WH, 2016, CLIN NEUROPHYSIOL, V127, P2892, DOI 10.1016/j.clinph.2016.04.001; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Cuypers K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086380; Dileone M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04254-y; Dileone M, 2018, BRAIN STIMUL, V11, P676, DOI 10.1016/j.brs.2018.02.005; Domahs F, 2010, COGNITION, V116, P251, DOI 10.1016/j.cognition.2010.05.007; Floel A, 2003, EUR J NEUROSCI, V18, P704, DOI 10.1046/j.1460-9568.2003.02774.x; Foffani G, 2017, BRAIN STIMUL, V10, P867, DOI 10.1016/j.brs.2017.04.121; Furubayashi T, 2008, EXP BRAIN RES, V185, P279, DOI 10.1007/s00221-007-1149-z; Gonzalez-Rosa JJ, 2015, J NEUROSCI, V35, P9182, DOI 10.1523/JNEUROSCI.4232-14.2015; Harpaz Y, 2009, CORTEX, V45, P1097, DOI 10.1016/j.cortex.2009.01.002; Julkunen P, 2012, BRAIN STIMUL, V5, P526, DOI 10.1016/j.brs.2011.07.006; Julkunen P, 2009, NEUROIMAGE, V44, P790, DOI 10.1016/j.neuroimage.2008.09.040; Jung NH, 2010, BRAIN STIMUL, V3, P87, DOI 10.1016/j.brs.2009.10.003; KIERS L, 1993, ELECTROEN CLIN NEURO, V89, P415, DOI 10.1016/0168-5597(93)90115-6; Kirimoto H, 2014, BRAIN STIMUL, V7, P836, DOI 10.1016/j.brs.2014.09.016; Kufner M, 2017, BRAIN STIMUL, V10, P868, DOI 10.1016/j.brs.2017.04.122; Kufner M, 2017, BRAIN STIMUL, V10, P703, DOI 10.1016/j.brs.2017.03.001; Lopez-Alonso V, 2014, BRAIN STIMUL, V7, P372, DOI 10.1016/j.brs.2014.02.004; Marquez J, 2015, RESTOR NEUROL NEUROS, V33, P509, DOI 10.3233/RNN-140490; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nojima I, 2015, CLIN NEUROPHYSIOL, V126, P2314, DOI 10.1016/j.clinph.2015.01.030; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Oliviero A, 2011, J PHYSIOL-LONDON, V589, P4949, DOI 10.1113/jphysiol.2011.211953; Pellicciari MC, 2016, CLIN NEUROPHYSIOL, V127, P621, DOI 10.1016/j.clinph.2015.03.002; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Ridding MC, 2006, EXP BRAIN RES, V171, P551, DOI 10.1007/s00221-005-0309-2; Rosler KM, 2008, EXP BRAIN RES, V187, P51, DOI 10.1007/s00221-008-1278-z; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Ruddy K, 2018, ELIFE, V7, DOI 10.7554/eLife.40843; Schilberg L, 2017, J COGNITIVE NEUROSCI, V29, P1022, DOI 10.1162/jocn_a_01100; Schmidt S, 2009, CLIN NEUROPHYSIOL, V120, P987, DOI 10.1016/j.clinph.2009.02.164; Silbert BI, 2013, BRAIN STIMUL, V6, P817, DOI 10.1016/j.brs.2013.03.007; Stagg CJ, 2009, EUR J NEUROSCI, V30, P1412, DOI 10.1111/j.1460-9568.2009.06937.x; Tschentscher N, 2012, NEUROIMAGE, V59, P3139, DOI 10.1016/j.neuroimage.2011.11.037; van de Ruit M, 2019, BRAIN STIMUL, V12, P314, DOI 10.1016/j.brs.2018.11.015; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Ziemann U, 2015, BRAIN STIMUL, V8, P662, DOI 10.1016/j.brs.2015.01.409	41	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2020	15	5							e0233614	10.1371/journal.pone.0233614	http://dx.doi.org/10.1371/journal.pone.0233614			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1NT	32453767	Green Published, gold			2023-01-03	WOS:000537529500036
J	O'Connor, E; Thomas, R; Senger, CA; Perdue, L; Robalino, S; Patnode, C				O'Connor, Elizabeth; Thomas, Rachel; Senger, Caitlyn A.; Perdue, Leslie; Robalino, Shannon; Patnode, Carrie			Interventions to Prevent Illicit and Nonmedical Drug Use in Children, Adolescents, and Young Adults Updated Evidence Report and Systematic Review for the US Preventive Services Task Force	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED-TRIAL; HOME-VISITING INTERVENTION; INDIAN TEEN MOTHERS; SUBSTANCE USE OUTCOMES; FAMILIES PROGRAM 10-14; PRIMARY-CARE; CANNABIS USE; HEALTHY SCHOOL; MARIJUANA USE; FOSTER-CARE	Importance Illicit and nonmedical (use in ways other than instructed) drug use is common in adolescents and young adults and increases the risk of harmful outcomes such as injuries, violence, and poorer academic performance. Objective To review the benefits and harms of interventions to prevent illicit and nonmedical drug use in children, adolescents, and young adults to inform the US Preventive Services Task Force. Data Sources MEDLINE, PubMED, PsycINFO, and the Cochrane Central Register of Controlled Trials (January 1, 2013, to January 31, 2019 [children and adolescents]; January 1, 1992, to January 31, 2019 [young adults <25 years]); surveillance through March 20, 2020. Study Selection Clinical trials of behavioral counseling interventions to prevent initiation of illicit and nonmedical drug use among young people. Data Extraction and Synthesis Critical appraisal was completed independently by 2 investigators. Data were extracted by 1 reviewer and checked by a second. Random-effects meta-analysis was used to estimate the effect sizes associated with the interventions. Main Outcomes and Measures Number of times illicit drugs were used; any illicit drug or any cannabis use. Results Twenty-nine trials (N = 18& x202f;353) met inclusion criteria. Health, social, or legal outcomes such as mental health symptoms, family functioning, consequences of drug use, and arrests were reported in 19 trials and most showed no group differences. The effects on illicit drug use in 26 trials among nonpregnant youth (n = 17& x202f;811) were highly variable; the pooled result did not show a clinically important or statistically significant association with illicit drug use (standardized mean difference, -0.08 [95% CI, -0.16 to 0.001]; 24 effects [from 23 studies]; n = 12& x202f;801; I-2 = 57.0%). The percentage of participants using illicit drugs ranged from 2.3% to 38.6% in the control groups and 2.4% to 33.7% in the intervention groups at 3 to 32 months' follow-up. The median absolute risk difference between groups was -2.8%, favoring the intervention group (range, -11.5% to 14.8%). The remaining 3 trials provided a perinatal home-visiting intervention to pregnant Native American youth. One trial (n=322) found a reduction in illicit drug use at 38 months (eg, cannabis use in the previous month, 10.7% in the intervention group and 15.6% in the control group) but not at earlier follow-up assessments. Across all 29 trials, only 1 trial reported on harms and found no statistically significant group differences. Conclusions and Relevance The evidence for behavioral counseling interventions to prevent initiation of illicit and nonmedical drug use among adolescents and young adults was inconsistent and imprecise, with some interventions associated with reduction in use and others associated with no benefit or increased use. Health, social, and legal outcomes were sparsely reported, and few showed improvements. This systematic review to support the 2020 US Preventive Services Task Force Recommendation Statement on interventions to prevent illicit and nonmedical drug use summarizes published evidence on the benefits and harms of primary care-based interventions to prevent illicit and nonmedical drug use in children, adolescents, and young adults.	[O'Connor, Elizabeth; Thomas, Rachel; Senger, Caitlyn A.; Perdue, Leslie; Patnode, Carrie] Kaiser Permanente, Evidence Based Practice Ctr, Ctr Hlth Res, Portland, OR USA; [Robalino, Shannon] Oregon Hlth & Sci Univ, Ctr Evidence Based Policy, Portland, OR 97201 USA	Kaiser Permanente; Oregon Health & Science University	O'Connor, E (corresponding author), Kaiser Permanente Northwest, Kaiser Permanente, Evidence Based Practice Ctr, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA.	Elizabeth.OConnor@kpchr.org	Robalino, Shannon/GRS-6021-2022; Robalino, Shannon/N-4113-2015	Robalino, Shannon/0000-0002-6359-1827	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services [HHSA-290-2015-000017-I-EPC5]	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services	This research was funded under contract HHSA-290-2015-000017-I-EPC5, Task Order 5, from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services, under a contract to support the USPSTF.	Agency for Healthcare Research and Quality, 2019, FIN RES PLAN DRUG US; [Anonymous], 2019, STRENGTH FAM PROGR; [Anonymous], 2019, NUMB NAT DRUG OV DEA; Baldus C, 2016, EUR J PUBLIC HEALTH, V26, P953, DOI 10.1093/eurpub/ckw082; Bannink R, 2014, J MED INTERNET RES, V16, P51, DOI 10.2196/jmir.3163; Barlow A, 2006, ARCH PEDIAT ADOL MED, V160, P1101, DOI 10.1001/archpedi.160.11.1101; Barlow A, 2015, AM J PSYCHIAT, V172, P154, DOI 10.1176/appi.ajp.2014.14030332; Barlow A, 2013, AM J PSYCHIAT, V170, P83, DOI 10.1176/appi.ajp.2012.12010121; Borenstein M., 2009, INTRO METAANALYSIS, DOI [10. 1002/9780470743386, DOI 10.1002/9780470743386]; Bourque J, 2018, JAMA PSYCHIAT, V75, P864, DOI 10.1001/jamapsychiatry.2018.1330; Broning S, 2017, PREV SCI, V18, P932, DOI 10.1007/s11121-017-0797-x; Broning S, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-83; CASA Columbia University, 2000, MISS OPP NAT SURV PR; Coatsworth JD, 2002, CLIN CHILD FAM PSYCH, V5, P113, DOI 10.1023/A:1015420503275; D'Amico EJ, 2018, J CONSULT CLIN PSYCH, V86, P775, DOI 10.1037/ccp0000332; Dembo R, 1999, AGGRESS VIOLENT BEH, V4, P41, DOI 10.1016/S1359-1789(97)00028-1; Dembo R, 2016, J CHILD ADOLES SUBST, V25, P18, DOI 10.1080/1067828X.2013.872068; Di Forti M, 2019, LANCET PSYCHIAT, V6, P427, DOI 10.1016/S2215-0366(19)30048-3; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elvik R, 2013, ACCIDENT ANAL PREV, V60, P254, DOI 10.1016/j.aap.2012.06.017; Estrada Y, 2019, PREV SCI, V20, P68, DOI 10.1007/s11121-018-0905-6; Estrada Y, 2017, AM J PUBLIC HEALTH, V107, P607, DOI 10.2105/AJPH.2017.303653; Estrada Y, 2015, J ADOLESCENT HEALTH, V57, P651, DOI 10.1016/j.jadohealth.2015.07.006; Fang L, 2013, PSYCHOL ADDICT BEHAV, V27, P788, DOI 10.1037/a0030925; Fang L, 2010, J ADOLESCENT HEALTH, V47, P529, DOI 10.1016/j.jadohealth.2010.03.011; Foxcroft DR, 2017, EUR J PUBLIC HEALTH, V27, P494, DOI 10.1093/eurpub/ckw195; Gmel G, 2013, J SUBST ABUSE TREAT, V44, P231, DOI 10.1016/j.jsat.2012.07.005; Goldman-Mellor S, 2019, GEN HOSP PSYCHIAT, V56, P28, DOI 10.1016/j.genhosppsych.2018.12.004; Grant I, 2003, J INT NEUROPSYCH SOC, V9, P679, DOI 10.1017/S1355617703950016; Green KM, 2017, AM J DRUG ALCOHOL AB, V43, P567, DOI 10.1080/00952990.2016.1258706; Harris SK, 2012, PEDIATRICS, V129, P1072, DOI 10.1542/peds.2011-1624; Heitzeg MM, 2015, DEV COGN NEUROS-NETH, V16, P71, DOI 10.1016/j.dcn.2015.09.003; Hodder RK, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004718; Hohl BC, 2017, JAMA INTERN MED, V177, P317, DOI 10.1001/jamainternmed.2016.8180; Jalling C, 2016, J CHILD FAM STUD, V25, P811, DOI 10.1007/s10826-015-0263-y; Kerr JC, 2013, AM J HEALTH EDUC, V44, P191, DOI 10.1080/19325037.2013.798218; Kim HK, 2013, J CHILD ADOLES SUBST, V22, P370, DOI 10.1080/1067828X.2013.788880; Kim HK, 2011, J CONSULT CLIN PSYCH, V79, P740, DOI 10.1037/a0025949; Knight JR, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.6258; Lee CM, 2010, PSYCHOL ADDICT BEHAV, V24, P265, DOI 10.1037/a0018859; Johnson S, 2015, AM J COMMUN PSYCHOL, V56, P36, DOI 10.1007/s10464-015-9734-y; Malmberg M, 2015, ADDICT BEHAV, V42, P194, DOI 10.1016/j.addbeh.2014.11.021; Malmberg M, 2014, ADDICTION, V109, P1031, DOI 10.1111/add.12526; Martin JL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187320; Mason M, 2015, J SUBST ABUSE TREAT, V58, P16, DOI 10.1016/j.jsat.2015.06.013; Miech R., 2018, NATL ADOLESCENT DRUG; Moyer VA, 2014, ANN INTERN MED, V160, P634, DOI 10.7326/M14-0334; Mullany B, 2012, PREV SCI, V13, P504, DOI 10.1007/s11121-012-0277-2; Patnode CD, 2014, ANN INTERN MED, V160, P612, DOI 10.7326/M13-2064; Rhee Hyekyun, 2008, J Pediatr Nurs, V23, P439, DOI 10.1016/j.pedn.2008.01.079; Sanci L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137581; Schinke SP, 2009, PREV MED, V49, P429, DOI 10.1016/j.ypmed.2009.08.001; Schinke SP, 2009, ADDICT BEHAV, V34, P1060, DOI 10.1016/j.addbeh.2009.06.007; Schreiner AM, 2012, EXP CLIN PSYCHOPHARM, V20, P420, DOI 10.1037/a0029117; Schwinn T, 2017, ADDICT BEHAV, V65, P207, DOI 10.1016/j.addbeh.2016.10.011; Schwinn TM, 2018, J YOUTH ADOLESCENCE, V47, P490, DOI 10.1007/s10964-017-0714-4; Schwinn TM, 2010, PREV SCI, V11, P24, DOI 10.1007/s11121-009-0146-9; Schwinn TM, 2015, J ADOLESCENT HEALTH, V56, P571, DOI 10.1016/j.jadohealth.2014.12.015; Spoth RL, 2012, J ADOLESCENT HEALTH, V50, P414, DOI 10.1016/j.jadohealth.2011.06.010; Spoth RL, 2001, J CONSULT CLIN PSYCH, V69, P627, DOI 10.1037//0022-006X.69.4.627; Substance Abuse and Mental Health Services Administration, 2017, KEY SUBST MENT HLTH; Townsend L, 2007, CLIN CHILD FAM PSYCH, V10, P295, DOI 10.1007/s10567-007-0023-7; United Nations Development Programme, 2016, HUMAN DEV REPORT; US Preventive Services Task Force, 2015, US PREV SERV TASK FO; Walkup JT, 2009, J AM ACAD CHILD PSY, V48, P591, DOI 10.1097/CHI.0b013e3181a0ab86; Walton MA, 2014, ADDICTION, V109, P786, DOI 10.1111/add.12469; Walton MA, 2013, DRUG ALCOHOL DEPEN, V132, P646, DOI 10.1016/j.drugalcdep.2013.04.020	67	14	14	4	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2020	323	20					2067	2079		10.1001/jama.2020.1432	http://dx.doi.org/10.1001/jama.2020.1432			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LU8UM	32453373	Bronze			2023-01-03	WOS:000538023900038
J							US Preventive Serv Task Force	Primary Care-Based Interventions to Prevent Illicit Drug Use in Children, Adolescents, and Young Adults US Preventive Services Task Force Recommendation Statement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED-TRIAL; HOME-VISITING INTERVENTION; SUBSTANCE USE; CANNABIS USE; MARIJUANA USE; PROGRAM; GIRLS; SCHOOL; RISK; EFFICACY	This 2020 Recommendation Statement from the US Preventive Services Task Force concludes that the current evidence is insufficient to assess the balance of benefits and harms of primary care-based behavioral counseling interventions to prevent illicit drug use, including nonmedical use of prescription drugs, in children, adolescents, and young adults (I statement). Importance In 2017, an estimated 7.9% of persons aged 12 to 17 years reported illicit drug use in the past month, and an estimated 50% of adolescents in the US had used an illicit drug by the time they graduated from high school. Young adults aged 18 to 25 years have a higher rate of current illicit drug use, with an estimated 23.2% currently using illicit drugs. Illicit drug use is associated with many negative health, social, and economic consequences and is a significant contributor to 3 of the leading causes of death among young persons (aged 10-24 years): unintentional injuries including motor vehicle crashes, suicide, and homicide. Objective To update its 2014 recommendation, the USPSTF commissioned a review of the evidence on the potential benefits and harms of interventions to prevent illicit drug use in children, adolescents, and young adults. Population This recommendation applies to children (11 years and younger), adolescents (aged 12-17 years), and young adults (aged 18-25 years), including pregnant persons. Evidence Assessment Because of limited and inadequate evidence, the USPSTF concludes that the benefits and harms of primary care-based interventions to prevent illicit drug use in children, adolescents, and young adults are uncertain and that the evidence is insufficient to assess the balance of benefits and harms. More research is needed. Recommendation The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of primary care-based behavioral counseling interventions to prevent illicit drug use, including nonmedical use of prescription drugs, in children, adolescents, and young adults. (I statement)					Epling, John W/J-1097-2019	Epling, John W/0000-0001-9445-8669; Wong, John/0000-0003-4203-9010	Agency for Healthcare Research and Quality (AHRQ)	Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.	[Anonymous], DRUG MIS PREV TARG I; [Anonymous], 2019, SCREEN ILL DRUG US I; [Anonymous], 2016, PEDIATRICS, V138; [Anonymous], 2019, PRIM CAR INT PREV CE; Baldus C, 2016, EUR J PUBLIC HEALTH, V26, P953, DOI 10.1093/eurpub/ckw082; Bannink R, 2014, J MED INTERNET RES, V16, P51, DOI 10.2196/jmir.3163; Barlow A, 2006, ARCH PEDIAT ADOL MED, V160, P1101, DOI 10.1001/archpedi.160.11.1101; Barlow A, 2013, AM J PSYCHIAT, V170, P83, DOI 10.1176/appi.ajp.2012.12010121; Crane E, 2015, EMERGENCY DEP VISITS; Curry SJ, 2018, JAMA-J AM MED ASSOC, V320, P1899, DOI 10.1001/jama.2018.16789; D'Amico EJ, 2018, J CONSULT CLIN PSYCH, V86, P775, DOI 10.1037/ccp0000332; Dembo R, 2014, J CHILD ADOLES SUBST, V23, P318, DOI 10.1080/1067828X.2014.928116; Drug Abuse Warning Network, 2013, 2011 NAT EST DRUG RE; Estrada Y, 2019, PREV SCI, V20, P68, DOI 10.1007/s11121-018-0905-6; Fang L, 2010, J ADOLESCENT HEALTH, V47, P529, DOI 10.1016/j.jadohealth.2010.03.011; Foxcroft DR, 2017, EUR J PUBLIC HEALTH, V27, P494, DOI 10.1093/eurpub/ckw195; Grant CN, 2017, PAED CHILD HEALT-CAN, V22, P98, DOI 10.1093/pch/pxx017; Grant I, 2003, J INT NEUROPSYCH SOC, V9, P679, DOI 10.1017/S1355617703950016; Green KM, 2017, AM J DRUG ALCOHOL AB, V43, P567, DOI 10.1080/00952990.2016.1258706; Hedegaard Holly, 2020, NCHS Data Brief, P1; Heron Melonie, 2018, Natl Vital Stat Rep, V67, P1; Jalling C, 2016, J CHILD FAM STUD, V25, P811, DOI 10.1007/s10826-015-0263-y; Johnston L, 2019, 2018 OVERVIEW KEY FI; Kann L, 2018, MMWR SURVEILL SUMM, V67, P1, DOI 10.15585/mmwr.ss6708a1; Kerr JC, 2013, AM J HEALTH EDUC, V44, P191, DOI 10.1080/19325037.2013.798218; Kim HK, 2011, J CONSULT CLIN PSYCH, V79, P740, DOI 10.1037/a0025949; Knight JR, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.6258; Lee CM, 2010, PSYCHOL ADDICT BEHAV, V24, P265, DOI 10.1037/a0018859; Lynskey MT, 2003, JAMA-J AM MED ASSOC, V289, P427, DOI 10.1001/jama.289.4.427; Malmberg M, 2014, ADDICTION, V109, P1031, DOI 10.1111/add.12526; Moyer VA, 2014, ANN INTERN MED, V160, P634, DOI 10.7326/M14-0334; Moyer VA, 2013, ANN INTERN MED, V159, P552, DOI 10.7326/0003-4819-159-8-201310150-00697; Nargiso JE, 2015, J STUD ALCOHOL DRUGS, V76, P5, DOI 10.15288/jsad.76.1.5; O'Connor E, 2019, AHRQ PUBLICATION; O'Connor E, 2020, JAMA-J AM MED ASSOC, V323, P2067, DOI 10.1001/jama.2020.1432; Rhee Hyekyun, 2008, J Pediatr Nurs, V23, P439, DOI 10.1016/j.pedn.2008.01.079; Sanci L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137581; Schinke SP, 2009, PREV MED, V49, P429, DOI 10.1016/j.ypmed.2009.08.001; Schinke SP, 2009, ADDICT BEHAV, V34, P1060, DOI 10.1016/j.addbeh.2009.06.007; Schreiner AM, 2012, EXP CLIN PSYCHOPHARM, V20, P420, DOI 10.1037/a0029117; Schwinn TM, 2018, J YOUTH ADOLESCENCE, V47, P490, DOI 10.1007/s10964-017-0714-4; Substance Abuse and Mental Health Services Administration, 2017, KEY SUBST US MENT HL; Substance Abuse and Mental Health Services Administration, 2017, SCREEN BRIEF INT REF; Townsend L, 2007, CLIN CHILD FAM PSYCH, V10, P295, DOI 10.1007/s10567-007-0023-7; U.S. Preventive Services Task Force, 2020, PROC MAN; Walkup JT, 2009, J AM ACAD CHILD PSY, V48, P591, DOI 10.1097/CHI.0b013e3181a0ab86; Walton MA, 2014, ADDICTION, V109, P786, DOI 10.1111/add.12469; Walton MA, 2013, DRUG ALCOHOL DEPEN, V132, P646, DOI 10.1016/j.drugalcdep.2013.04.020	48	12	12	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2020	323	20					2060	2066		10.1001/jama.2020.6774	http://dx.doi.org/10.1001/jama.2020.6774			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LU8UM	32453374	Bronze			2023-01-03	WOS:000538023900037
J	Cohen, IG; Crespo, AM; White, DB				Cohen, I. Glenn; Crespo, Andrew M.; White, Douglas B.			Potential Legal Liability for Withdrawing or Withholding Ventilators During COVID-19 Assessing the Risks and Identifying Needed Reforms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint discusses the legal risks to health care workers and hospital systems from withdrawing or withholding ventilation from COVID-19 patients and cites a Maryland statute that offers legal immunity to clinicians making good faith decisions under emergency conditions as an example for other states to follow.	[Cohen, I. Glenn; Crespo, Andrew M.] Harvard Univ, Harvard Law Sch, Cambridge, MA 02138 USA; [White, Douglas B.] Univ Pittsburgh, Dept Crit Care, Pittsburgh, PA USA	Harvard University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Cohen, IG (corresponding author), Harvard Law Sch, Griswold Hall,Room 503, Cambridge, MA 02138 USA.	igcohen@law.harvard.edu			NHLBI NIH HHS [K24 HL148314] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Hoffman Sharona, 2008, GEORGETOWN LAW J, V96, P1916; Koch JD, 2013, DEPAUL J HLTH CARE L, V14, P468, DOI 10.2139/ssrn.2174511; Opinions of the Maryland Attorney General, 2015, HLTH PUBL HLTH EN PR; TRUOG RD, 2020, N ENGL J MED; White DB, 2020, JAMA	5	60	61	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	2020	323	19					1901	1902		10.1001/jama.2020.5442	http://dx.doi.org/10.1001/jama.2020.5442			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT2XF	32236491	Bronze			2023-01-03	WOS:000536934300010
J	Tramer, L; Becker, C; Schumacher, C; Beck, K; Tschan, F; Semmer, NK; Hochstrasser, S; Marsch, S; Hunziker, S				Tramer, Lucas; Becker, Christoph; Schumacher, Cleo; Beck, Katharina; Tschan, Franziska; Semmer, Norbert K.; Hochstrasser, Seraina; Marsch, Stephan; Hunziker, Sabina			Association of self-esteem, personality, stress and gender with performance of a resuscitation team: A simulation-based study	PLOS ONE			English	Article							CARDIOPULMONARY-RESUSCITATION; HEART-RATE; TRAITS; LEADERSHIP; QUALITY	Background Gender composition, stress and leadership of a resuscitation team influence CPR performance. Whether psychological variables such as self-esteem, motivation and personality traits are associated with resuscitation performance, stress levels and gender of rescuers during a cardiac arrest scenario remains uncertain. Methods We included 108 medical students in this prospective, observational simulator study. We videotaped the resuscitation performance and assessed self-esteem, perceived stress-overload and personality traits using validated questionnaires. In addition, we analysed leadership utterances and ECG data of all participants during the simulation. The primary endpoint was cardiopulmonary resuscitation performance, defined as hands-on time within the first 180 sec. Secondary outcomes included first meaningful measure of resuscitation, leadership statements of group leaders and physiological stress parameters of rescuers. Results Adjusted for group size and leadership designation, mean self-esteem of students was significantly associated with hands-on time (adjusted regression coefficient 7.94 (95%CI 2.61 to 13.27), p< 0.01). The personality trait conscientiousness was positively associated with hands-on time (adjusted regression coefficient 38.4, [95%CI 7.41 to 69.38, p = 0.02]). However, after additional adjustment for self-esteem, this association was no longer significant. Further, agreeableness of team leaders was significantly associated with longer hands-on time (adjusted regression coefficient 20.87 [95%CI 3.81 to 37.94], p = 0.02). Openness to experience was negatively associated with heart rate reactivity (-5.92 (95%CI -10 to -1.85), p<0.01). Male students showed significantly higher (mean, [+/- SD]) self-esteem levels (24.6 [+/- 3.8] vs. 22.0 [+/- 4.4], p< 0.01), expressed significantly more leadership statements (7.9 [+/- 7.8] vs. 4.6 [+/- 3.8], p<0.01) and initiated first resuscitation measures more often (n, [%]) compared to female students (16, [23] vs. 7, [12], p = 0.01). Conclusion This simulator study found that self-esteem of resuscitation teams and agreeableness of team leaders of inexperienced students was associated with cardiopulmonary resuscitation performance. Whether enhancing these factors during resuscitation trainings serve for better performance remains to be studied.	[Tramer, Lucas; Schumacher, Cleo; Marsch, Stephan; Hunziker, Sabina] Univ Basel, Univ Hosp Basel, Med Intens Care Unit, Basel, Switzerland; [Tramer, Lucas; Becker, Christoph; Schumacher, Cleo; Beck, Katharina; Hochstrasser, Seraina; Hunziker, Sabina] Univ Basel, Univ Hosp Basel, Med Commun & Psychosomat Med, Basel, Switzerland; [Becker, Christoph] Univ Basel, Univ Hosp Basel, Dept Emergency Med, Basel, Switzerland; [Tschan, Franziska] Univ Neuchatel, Dept Psychol, Neuchatel, Switzerland; [Semmer, Norbert K.] Univ Bern, Dept Psychol, Bern, Switzerland	University of Basel; University of Basel; University of Basel; University of Neuchatel; University of Bern	Hunziker, S (corresponding author), Univ Basel, Univ Hosp Basel, Med Intens Care Unit, Basel, Switzerland.; Hunziker, S (corresponding author), Univ Basel, Univ Hosp Basel, Med Commun & Psychosomat Med, Basel, Switzerland.	Sabina.Hunziker@usb.ch		Beck, Katharina/0000-0002-6909-6210				Afrisham R, 2016, PSYCHIAT INVEST, V13, P637, DOI 10.4306/pi.2016.13.6.637; Afshar H, 2015, J RES MED SCI, V20, P353; Amacher SA, 2017, CRIT CARE MED, V45, P1184, DOI 10.1097/CCM.0000000000002375; Baumeister RF, 2003, PSYCHOL SCI, P1, DOI 10.1111/1529-1006.01431; Bibbey A, 2013, INT J PSYCHOPHYSIOL, V90, P28, DOI 10.1016/j.ijpsycho.2012.10.018; Bleidorn W, 2016, J PERS SOC PSYCHOL, V111, P396, DOI 10.1037/pspp0000078; Butler G., 1993, OCCAS PAP R COLL GEN, V61, P1; Camm AJ, 1996, CIRCULATION, V93, P1043; Cooper S, 1999, RESUSCITATION, V42, P27, DOI 10.1016/S0300-9572(99)00080-5; Costa PT, 2001, J PERS SOC PSYCHOL, V81, P322, DOI 10.1037//0022-3514.81.2.322; Crandal R, 1973, MEASURES SOCIAL PSYC, P80; De Maria S, 2010, MED EDUC, V44, P1006, DOI 10.1111/j.1365-2923.2010.03775.x; Ebstrup JF, 2011, ANXIETY STRESS COPIN, V24, P407, DOI 10.1080/10615806.2010.540012; FEINGOLD A, 1994, PSYCHOL BULL, V116, P429, DOI 10.1037/0033-2909.116.3.429; Ferring D, 1996, DIAGNOSTICA, V42, P284; Furedy JJ, 1996, INT J PSYCHOPHYSIOL, V22, P173, DOI 10.1016/0167-8760(96)00025-6; GOLDBERG LR, 1990, J PERS SOC PSYCHOL, V59, P1216, DOI 10.1037/0022-3514.59.6.1216; GrayLittle B, 1997, PERS SOC PSYCHOL B, V23, P443, DOI 10.1177/0146167297235001; Halpin AW, 1955, J APPL PSYCHOL, V39, P82, DOI 10.1037/h0047338; Hengartner MP, 2017, STRESS HEALTH, V33, P35, DOI 10.1002/smi.2671; Hockey GRJ, 1997, BIOL PSYCHOL, V45, P73; Hughes BM, 2007, ANXIETY STRESS COPIN, V20, P239, DOI 10.1080/10615800701330218; Hughes M.B., 2003, PSICOLOGICA, V24, P79; Hunziker S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-8; Hunziker S, 2012, RESUSCITATION, V83, P572, DOI 10.1016/j.resuscitation.2011.11.013; Hunziker S, 2011, INTENS CARE MED, V37, P1473, DOI 10.1007/s00134-011-2277-2; Hunziker S, 2010, CRIT CARE MED, V38, P1086, DOI 10.1097/CCM.0b013e3181cf7383; Hunziker S, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-3; Hyde JS, 2014, ANNU REV PSYCHOL, V65, P373, DOI 10.1146/annurev-psych-010213-115057; John O. P., 2008, HDB PERSONALITY THEO, P114158, DOI DOI 10.1016/S0191-8869(97)81000-8; John OP, 1991, BIG 5 INVENTORY VERS, DOI DOI 10.1037/T07550-000; Judge TA, 2002, J APPL PSYCHOL, V87, P765, DOI 10.1037/0021-9010.87.4.765; Kling KC, 1999, PSYCHOL BULL, V125, P470, DOI 10.1037/0033-2909.125.4.470; Lazarus R S, 1985, Issues Ment Health Nurs, V7, P399, DOI 10.3109/01612848509009463; Lee-Baggley D, 2005, J PERS, V73, P1141, DOI 10.1111/j.1467-6494.2005.00345.x; Li XS, 2015, INT J PSYCHOL, V50, P223, DOI 10.1002/ijop.12094; Marsch SCU, 2005, CRIT CARE MED, V33, P963, DOI 10.1097/01.CCM.0000157750.43459.07; Marsch SCU, 2004, RESUSCITATION, V60, P51, DOI 10.1016/j.resuscitation.2003.08.004; Martin-Albo J, 2009, SPAN J PSYCHOL, V12, P799, DOI 10.1017/S113874160000216X; Michael S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00301; Mount MK, 1998, PERS PSYCHOL, V51, P849, DOI 10.1111/j.1744-6570.1998.tb00743.x; Mount MK, 1998, HUM PERFORM, V11, P145, DOI 10.1207/s15327043hup1102&3_3; O'Donnell K, 2008, BRAIN BEHAV IMMUN, V22, P1241, DOI 10.1016/j.bbi.2008.06.012; PARKES KR, 1986, J PERS SOC PSYCHOL, V51, P1277, DOI 10.1037/0022-3514.51.6.1277; Rosenberg M., 1965, SOC ADOLESCENT SELF; Schallberger U, 1999, U ZURICH BERICHTE AB, P1; Streiff S, 2011, SIMUL HEALTHC, V6, P78, DOI 10.1097/SIH.0b013e318209382b; Taelman J, 2009, IFMBE PROC, V22, P1366; Tramer L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198661; Weisberg YJ, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00178	51	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2020	15	5							e0233155	10.1371/journal.pone.0233155	http://dx.doi.org/10.1371/journal.pone.0233155			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU0YZ	32407382	gold, Green Published			2023-01-03	WOS:000537490700076
J	Agnelli, G; Becattini, C; Meyer, G; Munoz, A; Huisman, MV; Connors, JM; Cohen, A; Bauersachs, R; Brenner, B; Torbicki, A; Sueiro, MR; Lambert, C; Gussoni, G; Campanini, M; Fontanella, A; Vescovo, G; Verso, M				Agnelli, Giancarlo; Becattini, Cecilia; Meyer, Guy; Munoz, Andres; Huisman, Menno, V; Connors, Jean M.; Cohen, Alexander; Bauersachs, Rupert; Brenner, Benjamin; Torbicki, Adam; Sueiro, Maria R.; Lambert, Catherine; Gussoni, Gualberto; Campanini, Mauro; Fontanella, Andrea; Vescovo, Giorgio; Verso, Melina		Caravaggio Investigators	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However, the benefit of these oral agents is limited by the increased risk of bleeding associated with their use. Methods This was a multinational, randomized, investigator-initiated, open-label, noninferiority trial with blinded central outcome adjudication. We randomly assigned consecutive patients with cancer who had symptomatic or incidental acute proximal deep-vein thrombosis or pulmonary embolism to receive oral apixaban (at a dose of 10 mg twice daily for the first 7 days, followed by 5 mg twice daily) or subcutaneous dalteparin (at a dose of 200 IU per kilogram of body weight once daily for the first month, followed by 150 IU per kilogram once daily). The treatments were administered for 6 months. The primary outcome was objectively confirmed recurrent venous thromboembolism during the trial period. The principal safety outcome was major bleeding. Results Recurrent venous thromboembolism occurred in 32 of 576 patients (5.6%) in the apixaban group and in 46 of 579 patients (7.9%) in the dalteparin group (hazard ratio, 0.63; 95% confidence interval [CI], 0.37 to 1.07; P<0.001 for noninferiority). Major bleeding occurred in 22 patients (3.8%) in the apixaban group and in 23 patients (4.0%) in the dalteparin group (hazard ratio, 0.82; 95% CI, 0.40 to 1.69; P=0.60). Conclusions Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding. (Funded by the Bristol-Myers Squibb-Pfizer Alliance; Caravaggio ClinicalTrials.gov number, NCT03045406.)	[Agnelli, Giancarlo; Becattini, Cecilia; Verso, Melina] Univ Perugia, Internal Vasc & Emergency Med Stroke Unit, Perugia 06124, Italy; [Gussoni, Gualberto] Federaz Assoc Dirigenti Osped Internisti FADOI Re, Milan, Italy; [Campanini, Mauro] Azienda Osped Univ Maggiore Carita, Dept Med, Novara, Italy; [Fontanella, Andrea] Buon Consiglio Fatebenefratelli Hosp, Dept Med, Naples, Italy; [Vescovo, Giorgio] Azienda Osped Univ, Internal Med, Padua, Italy; [Meyer, Guy] Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, Sorbonne Paris Cite, Paris, France; [Meyer, Guy] INNOVTE, St Etienne, France; [Munoz, Andres] Univ Complutense, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain; [Huisman, Menno, V] Leiden Univ, Dept Thrombosis & Hemostasis, Med Ctr, Leiden, Netherlands; [Connors, Jean M.] Brigham & Womens Hosp, Hematol Div, 75 Francis St, Boston, MA 02115 USA; [Connors, Jean M.] Harvard Med Sch, Boston, MA 02115 USA; [Cohen, Alexander] Kings Coll London, Guys & St Thomas NHS Fdn Trust Hosp, London, England; [Bauersachs, Rupert] Dept Vasc Med, Darmstadt, Germany; [Bauersachs, Rupert] Johannes Gutenberg Univ Mainz, Ctr Thrombosis & Hemostasis, Mainz, Germany; [Brenner, Benjamin] Technion Israel Inst Technol, Rambam Hlth Care Campus, Inst Hematol, Haifa, Israel; [Brenner, Benjamin] Technion Israel Inst Technol, Rambam Hlth Care Campus, Bone Marrow Transplantat Unit, Haifa, Israel; [Torbicki, Adam] Europejskie Ctr Zdrowia, Ctr Postgrad Med Educ, Dept Pulm Circulat, Otwock, Poland; [Torbicki, Adam] Europejskie Ctr Zdrowia, Ctr Postgrad Med Educ, Dept Thromboembol Dis, Otwock, Poland; [Torbicki, Adam] Europejskie Ctr Zdrowia, Ctr Postgrad Med Educ, Dept Cardiol, Otwock, Poland; [Sueiro, Maria R.] Inst Portugues Oncol Porto, Surg Oncol Dept, Porto, Portugal; [Lambert, Catherine] Clin Univ St Luc, Brussels, Belgium	University of Perugia; Azienda Ospedaliera Maggiore della Carita di Novara; University of Eastern Piedmont Amedeo Avogadro; University of Padua; Azienda Ospedaliera - Universita di Padova; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Complutense University of Madrid; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of London; King's College London; Johannes Gutenberg University of Mainz; Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Centre of Postgraduate Medical Education - Poland; Centre of Postgraduate Medical Education - Poland; Centre of Postgraduate Medical Education - Poland; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Agnelli, G (corresponding author), Univ Perugia, Internal Vasc & Emergency Med Stroke Unit, Perugia 06124, Italy.	giancarlo.agnelli@unipg.it	MONTAGNANI, ANDREA/AAF-8521-2020; Szmit, Sebastian/N-2487-2017; Benedetti, Raffaella/ABE-1226-2020; Jara-Palomares, Luis/A-4090-2017; Beyer-Westendorf, Jan/K-7569-2019; Biosca Gómez de Tejada, Mercedes/AAA-7676-2022; VERSO, Melina/L-7591-2016; Wilk, Michal/V-6527-2017	MONTAGNANI, ANDREA/0000-0001-7636-2700; Szmit, Sebastian/0000-0002-3075-1943; Benedetti, Raffaella/0000-0001-8127-8765; Jara-Palomares, Luis/0000-0002-4125-3376; Beyer-Westendorf, Jan/0000-0002-6983-9993; Biosca Gómez de Tejada, Mercedes/0000-0002-9204-1103; BECATTINI, Cecilia/0000-0002-8343-4888; VERSO, Melina/0000-0002-4185-979X; Carmona-Bayonas, Alberto/0000-0002-1930-9660; Hamulyak, Eva/0000-0002-9340-8771; Barcella, Luca/0000-0002-4576-0914; BERTOLETTI, Laurent/0000-0001-8214-3010; Couturaud, Francis/0000-0002-1855-8032; LE MOIGNE, Emmanuelle/0000-0001-5103-2406; Boon, Duliette/0000-0003-4532-436X; Wilk, Michal/0000-0002-0261-8133	Bristol-Myers Squibb-Pfizer Alliance	Bristol-Myers Squibb-Pfizer Alliance	Supported by the Bristol-Myers Squibb-Pfizer Alliance.	Agnelli G, 2018, THROMB HAEMOSTASIS, V118, P1668, DOI 10.1055/s-0038-1668523; Agnelli G, 2013, NEW ENGL J MED, V369, P799, DOI 10.1056/NEJMoa1302507; Agnelli G, 2013, NEW ENGL J MED, V368, P699, DOI 10.1056/NEJMoa1207541; Cohen AT, 2017, THROMB HAEMOSTASIS, V117, P57, DOI 10.1160/TH15-08-0686; Farge D, 2019, LANCET ONCOL, V20, pE566, DOI 10.1016/S1470-2045(19)30336-5; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Key NS, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01461; Khorana AA, 2018, J THROMB HAEMOST, V16, P1891, DOI 10.1111/jth.14219; Kirkilesis GI, 2019, EUR J VASC ENDOVASC, V57, P685, DOI 10.1016/j.ejvs.2018.11.004; Konstantinides SV, 2020, EUR HEART J, V41, P543, DOI 10.1093/eurheartj/ehz405; Lee AYY, 2015, JAMA-J AM MED ASSOC, V314, P677, DOI 10.1001/jama.2015.9243; Lee AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMoa025313; Mahe I, 2017, AM J MED, V130, P337, DOI 10.1016/j.amjmed.2016.10.017; Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108; Raskob GE, 2018, NEW ENGL J MED, V378, P615, DOI 10.1056/NEJMoa1711948; Streiff MB, 2018, J NATL COMPR CANC NE, V16, P1289, DOI 10.6004/jnccn.2018.0084; Young Annie M, 2018, J Clin Oncol, V36, P2017, DOI 10.1200/JCO.2018.78.8034	17	366	373	5	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 23	2020	382	17					1599	1607		10.1056/NEJMoa1915103	http://dx.doi.org/10.1056/NEJMoa1915103			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LI4YO	32223112	Bronze			2023-01-03	WOS:000529493200008
J	Watts, G				Watts, Geoff			Irene Higginson: progress towards a better ending	LANCET			English	Biographical-Item																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 11	2020	395	10231					1183	1183						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE6DW	32278376	Green Published			2023-01-03	WOS:000526814200016
J	Hu, C; Jurgutis, J; Edwards, D; O'Shea, T; Regenstreif, L; Bodkin, C; Amster, E; Kouyoumdjian, FG				Hu, Catherine; Jurgutis, Jessica; Edwards, Dan; O'Shea, Tim; Regenstreif, Lori; Bodkin, Claire; Amster, Ellen; Kouyoumdjian, Fiona G.			"When you first walk out the gates...where do [you] go?": Barriers and opportunities to achieving continuity of health care at the time of release from a provincial jail in Ontario	PLOS ONE			English	Article							POST-INCARCERATION; MASS INCARCERATION; CRIMINAL-JUSTICE; MENTAL-HEALTH; COMMUNITY; WOMEN; PRISON; INEQUALITY; ENGAGEMENT; OUTCOMES	We aimed to explore continuity of health care and health barriers, facilitators, and opportunities for people at the time of release from a provincial correctional facility in Ontario, Canada. We conducted focus groups in community-based organizations in a city in Ontario, Canada: a men's homeless shelter, a mental health service organization, and a social service agency with programs for people with substance use disorders. We included adults who spoke English well enough to participate in the discussion and who had been released from the provincial correctional facility in the previous year. We conducted three focus groups with 18 total participants. Participants had complex health needs on release, including ongoing physical and psychological impacts of time in custody. They identified lack of access to high quality health care; lack of housing, employment, social services, and social supports; and discrimination on the basis of incarceration history as barriers to health on release. Access to health care, housing, social services, and social supports all facilitated health on release. To address health needs on release, participants suggested providing health information in jail, improving discharge planning, and developing accessible clinics in the community. This pilot study identified opportunities to support health at the time of release from jail, including delivery of programs in jail, linkage with and development of programs in the community, and efforts to support structural changes to prevent and address discrimination. These data will inform ongoing work to support health and continuity of care on release from a provincial correctional facility.	[Hu, Catherine; Jurgutis, Jessica; Edwards, Dan; O'Shea, Tim; Regenstreif, Lori; Bodkin, Claire; Amster, Ellen; Kouyoumdjian, Fiona G.] McMaster Univ, Hamilton, ON, Canada; [Jurgutis, Jessica] Lakehead Univ, Thunder Bay, ON, Canada	McMaster University; Lakehead University	Kouyoumdjian, FG (corresponding author), McMaster Univ, Hamilton, ON, Canada.	kouyouf@mcmaster.ca		Regenstreif, Leonora Julie/0000-0001-7161-1712; Kouyoumdjian, Fiona/0000-0002-6869-7516; O'Shea, Tim/0000-0002-0793-6915; Bodkin, Claire/0000-0001-9560-1818	McMaster University Department of Family Medicine	McMaster University Department of Family Medicine	This study was funded with Pilot Funding from the McMaster University Department of Family Medicine to FGK, JJ, DE, TO, LR, and EA. The funder did not play any role in the study design, data collection and analysis, decision to publish, or manuscript preparation.	Abbott P, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0627-6; Abbott P, 2017, AUST HEALTH REV, V41, P268, DOI 10.1071/AH16007; [Anonymous], 2019, OP REL HARMS CAN OV; Baillargeon J, 2010, AM J COMMUN PSYCHOL, V46, P361, DOI 10.1007/s10464-010-9345-6; Begun AL, 2016, ADM POLICY MENT HLTH, V43, P207, DOI 10.1007/s10488-015-0632-2; Bergseth KJ, 2011, WOMEN CRIM JUSTICE, V21, P100, DOI 10.1080/08974454.2011.558799; Besney JD, 2018, J CORRECT HEALTH CAR, V24, P276, DOI 10.1177/1078345818780731; Binswanger IA, 2011, INT J LAW PSYCHIAT, V34, P249, DOI 10.1016/j.ijlp.2011.07.002; Binswanger IA, 2010, AM J PUBLIC HEALTH, V100, P476, DOI 10.2105/AJPH.2008.149591; Blankenship KM, 2018, SOC SCI MED, V215, P45, DOI 10.1016/j.socscimed.2018.08.042; Colbert AM, 2013, PUBLIC HEALTH NURS, V30, P409, DOI 10.1111/phn.12034; Doherty S, 2014, J OFFENDER REHABIL, V53, P562, DOI 10.1080/10509674.2014.944740; Flores JA, 2011, JOGNN-J OBST GYN NEO, V40, P486, DOI 10.1111/j.1552-6909.2011.01256.x; Fox AD, 2014, J HEALTH CARE POOR U, V25, P1139, DOI 10.1353/hpu.2014.0139; Frank JW, 2014, J GEN INTERN MED, V29, P1226, DOI 10.1007/s11606-014-2877-y; Freudenberg N, 2001, J URBAN HEALTH, V78, P214, DOI 10.1093/jurban/78.2.214; Gaetz Stephen., 2006, MISSING LINK DISCHAR; Green Samantha, 2016, BMC Res Notes, V9, P131, DOI 10.1186/s13104-016-1935-4; Hutchison B, 2013, HEALTH AFFAIR, V32, P695, DOI 10.1377/hlthaff.2012.1087; Janssen Patricia A, 2017, CMAJ Open, V5, pE717, DOI 10.9778/cmajo.20160165; Kendall Sacha, 2018, Health Justice, V6, P4, DOI 10.1186/s40352-018-0063-8; Khawcharoenporn T, 2019, AIDS CARE, V31, P777, DOI 10.1080/09540121.2018.1533236; Kinner SA, 2016, J EPIDEMIOL COMMUN H, V70, P683, DOI 10.1136/jech-2015-206565; Kinner SA, 2014, AM J PUBLIC HEALTH, V104, P1352, DOI 10.2105/AJPH.2014.301883; Kouyoumdjian F, 2019, CAN FAM PHYSICIAN, V65, pE433; Kouyoumdjian F, 2016, CAN FAM PHYSICIAN, V62, P215; Kouyoumdjian FG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201592; Kouyoumdjian Fiona G, 2016, CMAJ Open, V4, pE153, DOI 10.9778/cmajo.20150098; Kouyoumdjian FG, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010125; Madera JE, 2019, AM J PUBLIC HEALTH, V109, pe1; Mallik-Kane K, 2018, HLTH CARE INCARCERAT; Mallik-Kane K., 2008, HLTH PRISONER REENTR; Marlow Elizabeth, 2010, J Correct Health Care, V16, P17, DOI 10.1177/1078345809348201; Marmot M, 2018, LANCET, V391, P186, DOI 10.1016/S0140-6736(17)32848-9; Monchalin L., 2016, COLONIAL PROBLEM IND; Nelson L., 2018, GLOBE MAIL; Newton J., 2017, NEW FRAMINGS ANTIRAC, P45; Owusu-Bempah A, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-585; Paradies Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138511; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Reitano Julie, 2017, ADULT CORRECTIONAL S; Roberts JV, 1997, CRIME JUSTICE, V21, P469, DOI 10.1086/449256; Springer SA, 2010, J WOMENS HEALTH, V19, P13, DOI 10.1089/jwh.2009.1786; Stewart LA, 2017, CRIM BEHAV MENT HEAL, V27, P371, DOI 10.1002/cbm.2005; Timothy RobertaK., 2018, CONVERSATION; van Olphen J, 2009, SUBST ABUSE TREAT PR, V4, DOI 10.1186/1747-597X-4-10; Wang EA, 2013, JAMA INTERN MED, V173, P1621, DOI 10.1001/jamainternmed.2013.9008; Wang Emily A, 2012, Am J Public Health, V102, pe22, DOI 10.2105/AJPH.2012.300894; Wang EA, 2010, PUBLIC HEALTH REP, V125, P171, DOI 10.1177/003335491012500205; Wildeman C, 2017, LANCET, V389, P1464, DOI 10.1016/S0140-6736(17)30259-3; World Health Organization, 2019, CONST; World Health Organization. Commission on Social Determi-nants of Health, 2008, CLOS GAP GEN HLTH EQ; World Health Organization Regional Office for Europe, 2003, MOSC DECL PRIS HLTH; Zorzi R, 2006, HOUSING OPTIONS DISC	54	15	15	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2020	15	4							e0231211	10.1371/journal.pone.0231211	http://dx.doi.org/10.1371/journal.pone.0231211			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR8YT	32275680	gold, Green Submitted, Green Published			2023-01-03	WOS:000535983300036
J	Lim, C; Shimizu, J; Kawano, F; Kim, HJ; Kim, CK				Lim, Changhyun; Shimizu, Junya; Kawano, Fuminori; Kim, Hyo Jeong; Kim, Chang Keun			Adaptive responses of histone modifications to resistance exercise in human skeletal muscle	PLOS ONE			English	Article							PROTEIN-SYNTHESIS; EXPRESSION; HYPERTROPHY; ATROPHY; ACTIVATION; RESPONDERS; PATHWAY; BINDING; CELLS; MASS	Exercise training causes epigenetic changes in skeletal muscle, although it is unclear how resistance exercise (RE) affects histone modifications. The present study was carried out to investigate the effects of acute RE and RE training on gene expression profiles and histone modifications in human skeletal muscle. Healthy male adults were assigned to acute RE (n = 9, age = 20.5 +/- 4.3yr, BMI = 28.0 +/- 6.8kg/m(2)) or RE training (n = 21, age = 23.7 +/- 2.5yr, BMI = 24.2 +/- 2.7kg/m(2)) groups. Biopsy samples were obtained from the vastus lateralis muscle before and three hours after a single bout of acute RE, or 3-days after 10 weeks of RE training. RNA sequencing analysis revealed that 153 genes with GO terms including muscle development, stress response, metabolism, cell death, and transcription factor were significantly up-regulated (+291% vs. pre-acute RE) upon acute RE. Expressions of these genes were also greater (+9.6% vs. pre-RE training, p<0.05) in RE trained subjects. Significant upregulation of acetylated histone 3 (H3) (+235%) and H3 mono-methylated at lysine 4 (+290%) and tri-methylated at lysine 27 (+849%), whereas down-regulation of H3.3 variant (-39%) distributions relative to total H3 were observed at transcriptionally activated loci after acute RE compared to pre-acute RE levels. Interestingly, the distribution of acetylated H3 was found to be up-regulated as compared to the level of total H3 after RE training (+40%, p<0.05). These results indicate that a single bout of RE drastically alters both gene expressions and histone modifications in human skeletal muscle. It is also suggested that enhanced histone acetylation is closely related to up-regulation of gene expressions after RE training.	[Lim, Changhyun] McMaster Univ, Dept Kinesiol, Hamilton, ON, Canada; [Shimizu, Junya; Kawano, Fuminori] Matsumoto Univ, Dept Sports & Hlth Sci, Nagano, Japan; [Kawano, Fuminori] Matsumoto Univ, Grad Sch Hlth Sci, Nagano, Japan; [Kim, Hyo Jeong] Korea Natl Sport Univ, Dept Hlth Ageing, Seoul, South Korea; [Kim, Chang Keun] Zhejiang Normal Univ, Exercise & Metab Res Ctr, Jinhua, Zhejiang, Peoples R China; [Kim, Chang Keun] Korea Natl Sport Univ, Human Physiol, Seoul, South Korea	McMaster University; Korea National Sport University; Zhejiang Normal University; Korea National Sport University	Kawano, F (corresponding author), Matsumoto Univ, Dept Sports & Hlth Sci, Nagano, Japan.; Kawano, F (corresponding author), Matsumoto Univ, Grad Sch Hlth Sci, Nagano, Japan.	kawano@t.matsu.ac.jp	Lim, Changhyun/AAL-8368-2021	Kawano, Fuminori/0000-0002-3714-0360	Japan Society for the Promotion of Science KAKENHI [16H03263, 18H04987]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The present study was supported by Japan Society for the Promotion of Science KAKENHI Grant-in-Aid 16H03263 and 18H04987 to F. Kawano.	Apro W, 2013, AM J PHYSIOL-ENDOC M, V305, pE22, DOI 10.1152/ajpendo.00091.2013; Ato S, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00406; Baehr LM, 2017, J APPL PHYSIOL, V122, P1336, DOI 10.1152/japplphysiol.00703.2016; Bagley JR, 2020, J STRENGTH COND RES, V34, P1574, DOI 10.1519/JSC.0000000000003185; Bamman MM, 2007, J APPL PHYSIOL, V102, P2232, DOI 10.1152/japplphysiol.00024.2007; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Begue G, 2017, J APPL PHYSIOL, V122, P952, DOI 10.1152/japplphysiol.00867.2016; Blum R, 2012, GENE DEV, V26, P2763, DOI 10.1101/gad.200113.112; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Carow B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00058; Claeys KG, 2010, AM J PATHOL, V176, P2901, DOI 10.2353/ajpath.2010.090663; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; Davidsen PK, 2011, J APPL PHYSIOL, V110, P309, DOI 10.1152/japplphysiol.00901.2010; Dimauro I, 2018, CELL STRESS CHAPERON, V23, P491, DOI 10.1007/s12192-017-0866-x; Dohoney P., 2002, JEP ONLINE, V5, P54, DOI DOI 10.1519/R-15304.1; Glass DJ, 2005, INT J BIOCHEM CELL B, V37, P1974, DOI 10.1016/j.biocel.2005.04.018; Gordon BS, 2013, INT J BIOCHEM CELL B, V45, P2147, DOI 10.1016/j.biocel.2013.05.039; Joseph JS, 2017, BIOCHEM BIOPH RES CO, V486, P83, DOI 10.1016/j.bbrc.2017.03.002; Kawano F, 2007, AM J PHYSIOL-CELL PH, V293, pC35, DOI 10.1152/ajpcell.00297.2006; Kawano F, 2015, J APPL PHYSIOL, V119, P1042, DOI 10.1152/japplphysiol.00289.2015; Lim CH, 2017, EUR J APPL PHYSIOL, V117, P2355, DOI 10.1007/s00421-017-3722-x; Lim C, 2019, MED SCI SPORT EXER, V51, P2578, DOI 10.1249/MSS.0000000000002088; Mahoney DJ, 2005, FASEB J, V19, P1498, DOI 10.1096/fj.04-3149fje; Mao BJ, 2015, INT J ONCOL, V46, P459, DOI 10.3892/ijo.2014.2765; Masuzawa R, MUSCLE TYPE SPECIFIC, V125, P1238; Nakamura K, 2017, J APPL PHYSIOL, V123, P902, DOI 10.1152/japplphysiol.00289.2017; Ogasawara R, 2018, FASEB J, V32, P5824, DOI 10.1096/fj.201701422R; Ogasawara R, 2016, SCI REP-UK, V6, DOI 10.1038/srep31142; Ogasawara R, 2016, PHYSIOL GENOMICS, V48, P320, DOI 10.1152/physiolgenomics.00124.2015; Ogasawara R, 2013, J APPL PHYSIOL, V114, P934, DOI 10.1152/japplphysiol.01161.2012; Ohsawa I, 2018, J APPL PHYSIOL, V125, P1097, DOI 10.1152/japplphysiol.00074.2018; OSBALDESTON NJ, 1995, BIOCHEM J, V308, P465, DOI 10.1042/bj3080465; Porter C, 2015, MED SCI SPORT EXER, V47, P1922, DOI 10.1249/MSS.0000000000000605; Raffaello A, 2010, J CELL BIOL, V191, P101, DOI 10.1083/jcb.201001136; Romero MA, 2018, AM J PHYSIOL-CELL PH, V314, pC379, DOI 10.1152/ajpcell.00192.2017; Salanova M, 2008, J ANAT, V212, P306, DOI 10.1111/j.1469-7580.2008.00854.x; Seaborne RA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20287-3; Smith JAH, 2008, AM J PHYSIOL-ENDOC M, V295, pE698, DOI 10.1152/ajpendo.00747.2007; Stromberg A, 2017, J APPL PHYSIOL, V122, P1145, DOI 10.1152/japplphysiol.00956.2016; Turner DC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40787-0; Yasuhara K, 2011, J APPL PHYSIOL, V111, P1142, DOI 10.1152/japplphysiol.00471.2011	41	16	17	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2020	15	4							e0231321	10.1371/journal.pone.0231321	http://dx.doi.org/10.1371/journal.pone.0231321			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8WI	32271843	Green Published, gold			2023-01-03	WOS:000535977000072
J	Wolfel, R; Corman, VM; Guggemos, W; Seilmaier, M; Zange, S; Muller, MA; Niemeyer, D; Jones, TC; Vollmar, P; Rothe, C; Hoelscher, M; Bleicker, T; Brunink, S; Schneider, J; Ehmann, R; Zwirglmaier, K; Drosten, C; Wendtner, C				Woelfel, Roman; Corman, Victor M.; Guggemos, Wolfgang; Seilmaier, Michael; Zange, Sabine; Mueller, Marcel A.; Niemeyer, Daniela; Jones, Terry C.; Vollmar, Patrick; Rothe, Camilla; Hoelscher, Michael; Bleicker, Tobias; Bruenink, Sebastian; Schneider, Julia; Ehmann, Rosina; Zwirglmaier, Katrin; Drosten, Christian; Wendtner, Clemens			Virological assessment of hospitalized patients with COVID-2019	NATURE			English	Article							ACUTE RESPIRATORY SYNDROME; SARS CORONAVIRUS; VIRAL LOAD; ACE2	Detailed virological analysis of nine cases of coronavirus disease 2019 (COVID-19) provides proof of active replication of the SARS-CoV-2 virus in tissues of the upper respiratory tract. Coronavirus disease 2019 (COVID-19) is an acute infection of the respiratory tract that emerged in late 2019(1,2). Initial outbreaks in China involved 13.8% of cases with severe courses, and 6.1% of cases with critical courses(3). This severe presentation may result from the virus using a virus receptor that is expressed predominantly in the lung(2,4); the same receptor tropism is thought to have determined the pathogenicity-but also aided in the control-of severe acute respiratory syndrome (SARS) in 2003(5). However, there are reports of cases of COVID-19 in which the patient shows mild upper respiratory tract symptoms, which suggests the potential for pre- or oligosymptomatic transmission(6-8). There is an urgent need for information on virus replication, immunity and infectivity in specific sites of the body. Here we report a detailed virological analysis of nine cases of COVID-19 that provides proof of active virus replication in tissues of the upper respiratory tract. Pharyngeal virus shedding was very high during the first week of symptoms, with a peak at 7.11 x 10(8) RNA copies per throat swab on day 4. Infectious virus was readily isolated from samples derived from the throat or lung, but not from stool samples-in spite of high concentrations of virus RNA. Blood and urine samples never yielded virus. Active replication in the throat was confirmed by the presence of viral replicative RNA intermediates in the throat samples. We consistently detected sequence-distinct virus populations in throat and lung samples from one patient, proving independent replication. The shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 7 days in 50% of patients (and by day 14 in all patients), but was not followed by a rapid decline in viral load. COVID-19 can present as a mild illness of the upper respiratory tract. The confirmation of active virus replication in the upper respiratory tract has implications for the containment of COVID-19.	[Woelfel, Roman; Zange, Sabine; Vollmar, Patrick; Ehmann, Rosina; Zwirglmaier, Katrin] Bundeswehr Inst Microbiol, Munich, Germany; [Corman, Victor M.; Mueller, Marcel A.; Niemeyer, Daniela; Jones, Terry C.; Bleicker, Tobias; Bruenink, Sebastian; Schneider, Julia; Drosten, Christian] Charite Univ Med Berlin, Berlin, Germany; [Guggemos, Wolfgang; Seilmaier, Michael; Wendtner, Clemens] Klinikum Munchen Schwabing, Munich, Germany; [Jones, Terry C.] Univ Cambridge, Ctr Pathogen Evolut, Dept Zool, Cambridge, England; [Rothe, Camilla; Hoelscher, Michael] Univ Hosp LMU Munich, Munich, Germany	Bundeswehr Institute of Microbiology (IMB); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Munchen Klinik; University of Cambridge; University of Munich	Drosten, C (corresponding author), Charite Univ Med Berlin, Berlin, Germany.; Wendtner, C (corresponding author), Klinikum Munchen Schwabing, Munich, Germany.	christian.drosten@charite.de; clemens.wendtner@muenchen-klinik.de	Müller, Marcel A./O-2425-2019; Corman, Victor M/K-1319-2019; Wölfel, Roman/AAQ-3977-2021	Müller, Marcel A./0000-0003-2242-5117; Corman, Victor M/0000-0002-3605-0136; Wölfel, Roman/0000-0002-8756-7821; Ehmann, Rosina/0000-0002-4334-9427; Zange, Sabine/0000-0001-8721-9248	German Ministry of Research [01KI1723A]; European Union [602525]; German Bundeswehr Medical Service Biodefense Research Program	German Ministry of Research; European Union(European Commission); German Bundeswehr Medical Service Biodefense Research Program	This work was funded by grants from the German Ministry of Research (01KI1723A) and the European Union (602525) to C.D. as well as by the German Bundeswehr Medical Service Biodefense Research Program. The funders had no role in study design, data collection and analysis or decision to publish. We thank P. Mackeldanz, E. Moncke-Buchner, A. Richter, M. Schmidt and J. Beheim-Schwarzbach for technical assistance.	Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106; Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876; Bohmer MM, 2020, LANCET INFECT DIS, V20, P920, DOI 10.1016/S1473-3099(20)30314-5; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Corman VM, 2012, EUROSURVEILLANCE, V17, P3; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Corman VM, 2016, CLIN INFECT DIS, V62, P477, DOI 10.1093/cid/civ951; Drosten C, 2004, J CLIN MICROBIOL, V42, P2043, DOI 10.1128/JCM.42.5.2043-2047.2004; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Drosten C, 2014, NEW ENGL J MED, V371, P828, DOI 10.1056/NEJMoa1405858; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Hoehl S, 2020, NEW ENGL J MED, V382, P1278, DOI 10.1056/NEJMc2001899; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Leung GM, 2004, ANN INTERN MED, V141, P662, DOI 10.7326/0003-4819-141-9-200411020-00006; Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI [10.1016/j.gastro.2003.08.001, 10.1053/S0016-5085(03)01215-0]; Muller MA, 2015, LANCET INFECT DIS, V15, P559, DOI 10.1016/S1473-3099(15)70090-3; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Poon LLM, 2004, CLIN CHEM, V50, P67, DOI 10.1373/clinchem.2003.023663; Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468; WHO, 2020, REP WHO CHIN JOINT M; Xu H, 2020, INT J ORAL SCI, V12, DOI [10.1038/s41368-020-0074-x, 10.1038/s41368-020-0074-X]; Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204; Zhou J, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao4966; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737	28	1747	1777	9	35	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 28	2020	581	7809					465	+		10.1038/s41586-020-2196-x	http://dx.doi.org/10.1038/s41586-020-2196-x		APR 2020	9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX9ZL	32235945	Bronze			2023-01-03	WOS:000535223600001
J	Hernandez, I; Hershey, TB; Donohue, JM				Hernandez, Inmaculada; Hershey, Tina Batra; Donohue, Julie M.			Drug Shortages in the United States Are Some Prices Too Low?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint discusses underlying causes of generic drug shortages in the United States and proposes solutions to address those shortages, including financial incentives for manufacturers that provide a steady supply of high-quality products.	[Hernandez, Inmaculada] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA; [Hernandez, Inmaculada; Hershey, Tina Batra] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing CP3, Pittsburgh, PA USA; [Hershey, Tina Batra; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Donohue, JM (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St, Pittsburgh, PA 15261 USA.	jdonohue@pitt.edu	Hernandez, Inmaculada/AGZ-4219-2022	Hernandez, Inmaculada/0000-0002-0118-4986; Hershey, Tina/0000-0002-8600-6168	NHLBI NIH HHS [K01 HL142847] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 2011, COMMUNICATION   1207; Fox ER, 2014, MAYO CLIN PROC, V89, P361, DOI 10.1016/j.mayocp.2013.11.014; Hernandez I, 2019, ANN INTERN MED, V170, P74, DOI 10.7326/M18-1137; Rosenberg M, 2018, IDENTIFYING ROOT CAU; U.S. Food and Drug Administration, 2019, DRUG SHORT ROOT CAUS; Vail E, 2017, JAMA-J AM MED ASSOC, V317, P1433, DOI 10.1001/jama.2017.2841	6	6	6	2	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2020	323	9			SI		819	820		10.1001/jama.2019.20504	http://dx.doi.org/10.1001/jama.2019.20504			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU3SD	32125409	Green Accepted			2023-01-03	WOS:000519630600007
J	Singh, JA; Cleveland, JD				Singh, Jasvinder A.; Cleveland, John D.			National US time-trends in opioid use disorder hospitalizations and associated healthcare utilization and mortality	PLOS ONE			English	Article							UNITED-STATES; OVERDOSE DEATHS; CDC GUIDELINE; INCREASES; DRUG; PAIN	Background The opioid epidemic is a major public health crisis in the U.S. Contemporary data on opioid use disorder (OUD) related hospitalizations are needed. Our objective was to assess whether OUD hospitalizations and associated mortality are increasing over time and examine the factors associated healthcare utilization and mortality. Methods and findings We examined the rates of OUD hospitalizations and associated mortality using the U.S. National Inpatient Sample (NIS) data from 1998-2016. Multivariable-adjusted logistic regression assessed the association of demographic, clinical and hospital characteristics with inpatient mortality and healthcare utilization (total hospital charges, discharge to a rehabilitation facility, length of hospital stay) during the index hospitalization for opioid use disorder. We calculated the odds ratio (OR) and 95% confidence intervals (CI). We estimated 781,767 OUD hospitalizations. The rate of OUD hospitalization and associated mortality (/100,000 overall NIS hospitalizations) increased from 59.8 and 1.2 in 1998-2000 to 190.7 and 5.9 in 2015-16, respectively. In the multivariable-adjusted analysis, the following factors were associated with worse outcomes; compared to age < 34 years, older age was associated with higher risk of hospital charges above the median and length of stay > 3 days, slightly higher risk of discharge to a rehabilitation facility. Higher Deyo-Charlson score was associated with higher hospital charges, length of hospital stay, and inpatient mortality. Women had lower odds of inpatient mortality than men and blacks had lower odds of mortality than whites. Conclusions Rising OUD hospitalizations from 1998 to 2016 and increasing associated inpatient mortality are concerning. Certain groups are at higher risk of poor utilization outcomes and inpatient mortality. Resources and healthcare policies need to focus on the high-risk group to reduce mortality and associated utilization.	[Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Singh, Jasvinder A.; Cleveland, John D.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA; [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham	Singh, JA (corresponding author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.; Singh, JA (corresponding author), Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.; Singh, JA (corresponding author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA.	Jasvinder.md@gmail.com	Singh, Jasvinder/R-6172-2019	Singh, Jasvinder/0000-0003-3485-0006				Calcaterra S, 2013, DRUG ALCOHOL DEPEN, V131, P263, DOI 10.1016/j.drugalcdep.2012.11.018; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Dowell D, 2016, HEALTH AFFAIR, V35, P1876, DOI 10.1377/hlthaff.2016.0448; Dowell D, 2016, AM FAM PHYSICIAN, V93, P970; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Haight SC, 2018, MMWR-MORBID MORTAL W, V67, P845, DOI 10.15585/mmwr.mm6731a1; Hser YI, 2017, J ADDICT MED, V11, P315, DOI 10.1097/ADM.0000000000000312; Kattan JA, 2016, AM J PUBLIC HEALTH, V106, P1430, DOI 10.2105/AJPH.2016.303274; Larochelle MR, 2018, ANN INTERN MED, V169, P137, DOI 10.7326/M17-3107; MANCHIKANTI L, 2012, PAIN PHYS S, V15, pES; Menendez ME, 2015, CLIN ORTHOP RELAT R, V473, P2402, DOI 10.1007/s11999-015-4173-5; Murthy VH, 2016, NEW ENGL J MED, V375, P2413, DOI 10.1056/NEJMp1612578; Nelson LS, 2015, JAMA-J AM MED ASSOC, V314, P1453, DOI 10.1001/jama.2015.12397; Peterson C, 2018, J SUBST ABUSE TREAT, V92, P35, DOI 10.1016/j.jsat.2018.06.008; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Song ZR, 2017, HEALTH AFFAIR, V36, P2054, DOI 10.1377/hlthaff.2017.0689; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Unick GJ, 2017, INT J DRUG POLICY, V46, P112, DOI 10.1016/j.drugpo.2017.06.003; Veldhuizen S, 2014, ANN EPIDEMIOL, V24, P620, DOI 10.1016/j.annepidem.2014.06.001; Weiner SG, 2019, JT COMM J QUAL PATIE, V45, P3, DOI 10.1016/j.jcjq.2018.07.003; Yang YT, 2018, MAYO CLIN PROC, V93, P1177, DOI 10.1016/j.mayocp.2018.07.001	23	25	25	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2020	15	2							e0229174	10.1371/journal.pone.0229174	http://dx.doi.org/10.1371/journal.pone.0229174			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ7XT	32069314	Green Published, gold			2023-01-03	WOS:000535212900026
J	Paes, L; Lima, D; Matsuura, C; de Souza, MD; Cyrino, F; Barbosa, C; Ferrao, F; Bottino, D; Bouskela, E; Farinatti, P				Paes, Lorena; Lima, Daniel; Matsuura, Cristiane; de Souza, Maria das Gracas; Cyrino, Fatima; Barbosa, Carolina; Ferrao, Fernanda; Bottino, Daniel; Bouskela, Eliete; Farinatti, Paulo			Effects of moderate and high intensity isocaloric aerobic training upon microvascular reactivity and myocardial oxidative stress in rats	PLOS ONE			English	Article							ENDOTHELIAL FUNCTION; NITRIC-OXIDE; EXERCISE; INTERVAL; FLOW; MICROCIRCULATION; ADAPTATIONS; DYSFUNCTION; BIOMARKERS; DILATION	Systemic and central cardiovascular adaptations may vary in response to chronic exercise performed with different intensities and volumes. This study compared the effects of aerobic training with different intensities but equivalent volume upon microvascular reactivity in cremaster muscle and myocardial biomarkers of oxidative stress in Wistar rats. After peak oxygen uptake (VO2peak) assessment, rats (n = 24) were assigned into three groups: moderateintensity exercise training (MI); high-intensity exercise training (HI); sedentary control (SC). Treadmill training occurred during 4 weeks, with exercise bouts matched by the energy expenditure (3.0-3.5 Kcal). Microvascular reactivity was assessed in vivo by intravital microscopy in cremaster muscle arterioles, while biomarkers of oxidative stress and eNOS expression were quantified at left ventricle and at aorta, respectively. Similar increasing vs. sedentary control group (SC) occurred in moderate intensity training group (MI) and highintensity training group (HI) for endothelium-dependent vasodilation (10-4 M: MI: 168.7%, HI: 164.6% vs. SC: 146.6%, P = 0.0004). Superoxide dismutase (SOD) (HI: 0.13 U/mg vs. MI: 0.09 U/mg and SC: 0.06 U/mg; P = 0.02), glutathione peroxidase (GPX) (HI: 0.00038 U/mg vs. MI: 0.00034 U/mg and SC: 0.00024 U/mg; P = 0.04), and carbonyl protein content (HI: 0.04 U/mg vs. MI: 0.03 U/mg and SC: 0.01 U/mg; P = 0.003) increased only in HI. No difference across groups was detected for catalase (CAT) (P = 0.12), Thiobarbituric acid reactive substances (TBARS) (P = 0.38) or eNOS expression in aorta (P = 0.44). In conclusion, higher exercise intensity induced greater improvements in myocardium antioxidant defenses, while gains in microvascular reactivity appeared to rely more on exercise volume than intensity.	[Paes, Lorena; de Souza, Maria das Gracas; Cyrino, Fatima; Barbosa, Carolina; Ferrao, Fernanda; Bottino, Daniel; Bouskela, Eliete] Univ Estado Rio De Janeiro, Lab Clin & Expt Res Vasc Biol, Rio De Janeiro, RJ, Brazil; [Lima, Daniel; Matsuura, Cristiane] Univ Estado Rio De Janeiro, Dept Pharmacol & Psychobiol, Rio De Janeiro, RJ, Brazil; [Farinatti, Paulo] Univ Estado Rio De Janeiro, Lab Phys Act & Hlth Promot, Rio De Janeiro, RJ, Brazil; [Farinatti, Paulo] Univ Salgado de Oliveira, Grad Program Sci Phys Act, Niteroi, RJ, Brazil	Universidade do Estado do Rio de Janeiro; Universidade do Estado do Rio de Janeiro; Universidade do Estado do Rio de Janeiro; Universidade Salgado de Oliveira	Farinatti, P (corresponding author), Univ Estado Rio De Janeiro, Lab Phys Act & Hlth Promot, Rio De Janeiro, RJ, Brazil.; Farinatti, P (corresponding author), Univ Salgado de Oliveira, Grad Program Sci Phys Act, Niteroi, RJ, Brazil.	paulofarinatti@labsau.org	Lima, Daniel J M Medeiros/AAC-4741-2021; Farinatti, Paulo/AAG-7505-2019	Lima, Daniel J M Medeiros/0000-0003-4930-0533; Farinatti, Paulo/0000-0003-2463-1280; Matsuura, Cristiane/0000-0002-2317-5781				Abularrage CJ, 2005, J VASC SURG, V42, P574, DOI 10.1016/j.jvs.2005.05.019; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Bagher P, 2011, JOVE-J VIS EXP, DOI [10.3791/28742874, DOI 10.3791/28742874]; Barbosa VA, 2012, INT J CARDIOL, V157, P422, DOI 10.1016/j.ijcard.2012.03.153; Battault S, 2016, HYPERTENS RES, V39, P70, DOI 10.1038/hr.2015.114; Bloomer RJ, 2008, ADV CLIN CHEM, V46, P1, DOI 10.1016/S0065-2423(08)00401-0; de Souza MDC, 2016, CLIN HEMORHEOL MICRO, V64, P645, DOI 10.3233/CH-168018; Costa RRS, 2011, MICROVASC RES, V82, P416, DOI 10.1016/j.mvr.2011.08.007; Cunha FA, 2012, EUR J APPL PHYSIOL, V112, P3019, DOI 10.1007/s00421-011-2275-7; Dalle-Donne I, 2003, CLIN CHIM ACTA, V329, P23, DOI 10.1016/S0009-8981(03)00003-2; Dawson EA, 2013, J APPL PHYSIOL, V115, P1589, DOI 10.1152/japplphysiol.00450.2013; Di Francescomarino S, 2009, SPORTS MED, V39, P797, DOI 10.2165/11317750-000000000-00000; DRAPER HH, 1993, FREE RADICAL BIO MED, V15, P353, DOI 10.1016/0891-5849(93)90035-S; Durrant JR, 2009, J PHYSIOL-LONDON, V587, P3271, DOI 10.1113/jphysiol.2009.169771; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Gielen S, 2010, CIRCULATION, V122, P1221, DOI 10.1161/CIRCULATIONAHA.110.939959; Goto C, 2003, CIRCULATION, V108, P530, DOI 10.1161/01.CIR.0000080893.55729.28; Goutianos G, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12293; Hallmark R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085450; Haram PM, 2009, CARDIOVASC RES, V81, P723, DOI 10.1093/cvr/cvn332; Hudlicka O, 2011, MLTJ-MUSCLE LIGAMENT, V1, P3; Jasperse JL, 2006, MED SCI SPORT EXER, V38, P445, DOI 10.1249/01.mss.0000191187.24525.f2; Jasperse JL, 1999, J APPL PHYSIOL, V86, P441, DOI 10.1152/jappl.1999.86.2.441; Johnson BD, 2012, EUR J APPL PHYSIOL, V112, P33, DOI 10.1007/s00421-011-1946-8; Kemi OJ, 2005, CARDIOVASC RES, V67, P161, DOI 10.1016/j.cardiores.2005.03.010; LASH JM, 1992, J APPL PHYSIOL, V72, P2052, DOI 10.1152/jappl.1992.72.6.2052; LAUGHLIN MH, 1990, J APPL PHYSIOL, V68, P2337, DOI 10.1152/jappl.1990.68.6.2337; Leite RD, 2012, MICROVASC RES, V84, P94, DOI 10.1016/j.mvr.2012.03.009; Lennon SL, 2004, ACTA PHYSIOL SCAND, V182, P161, DOI 10.1111/j.1365-201X.2004.01346.x; Leong Xin-Fang, 2015, Biomed Res Int, V2015, P528757, DOI 10.1155/2015/528757; Li XC, 2012, J AGR FOOD CHEM, V60, P6418, DOI 10.1021/jf204970r; Liu JK, 2000, J APPL PHYSIOL, V89, P21; Lu K, 2015, MOL MED REP, V12, P2374, DOI 10.3892/mmr.2015.3669; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; McAllister RM, 2008, APPL PHYSIOL NUTR ME, V33, P173, DOI 10.1139/H07-146; McCullough DJ, 2011, J APPL PHYSIOL, V110, P695, DOI 10.1152/japplphysiol.01084.2010; Padilla J, 2011, PHYSIOLOGY, V26, P132, DOI 10.1152/physiol.00052.2010; Paes LS, 2016, BRAZ J MED BIOL RES, V49, DOI [10.1590/1414-431X20165200, 10.1590/1414-431x20165200]; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Powers SK, 2008, PHYSIOL REV, V88, P1243, DOI 10.1152/physrev.00031.2007; POWERS SK, 1993, AM J PHYSIOL, V265, pH2094, DOI 10.1152/ajpheart.1993.265.6.H2094; Radak Z, 2013, ANTIOXID REDOX SIGN, V18, P1208, DOI 10.1089/ars.2011.4498; Sarelius I, 2010, ACTA PHYSIOL, V199, P349, DOI 10.1111/j.1748-1716.2010.02129.x; Sawyer BJ, 2016, J APPL PHYSIOL, V121, P279, DOI 10.1152/japplphysiol.00024.2016; Sephro D, 2006, MICROVASCULAR RES BI; Trott DW, 2009, J APPL PHYSIOL, V106, P1925, DOI 10.1152/japplphysiol.91232.2008; Wehr Nancy B, 2013, Methods Mol Biol, V965, P265, DOI 10.1007/978-1-62703-239-1_18; Xiang LS, 2005, AM J PHYSIOL-REG I, V288, pR987, DOI 10.1152/ajpregu.00702.2004	48	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2020	15	2							e0218228	10.1371/journal.pone.0218228	http://dx.doi.org/10.1371/journal.pone.0218228			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9HH	32032358	Green Submitted, Green Published, gold			2023-01-03	WOS:000534626100001
J	Noh, GT; Han, J; Cho, MS; Hur, H; Lee, KY; Kim, NK; Min, BS				Noh, Gyoung Tae; Han, Jeonghee; Cho, Min Soo; Hur, Hyuk; Lee, Kang Young; Kim, Nam Kyu; Min, Byung Soh			The impact of early adjuvant chemotherapy in rectal cancer	PLOS ONE			English	Article							CLINICAL-PRACTICE GUIDELINES; SHORT-TERM OUTCOMES; COLORECTAL-CANCER; COLON-CANCER; NEOADJUVANT CHEMORADIOTHERAPY; LAPAROSCOPIC SURGERY; OPEN COLECTOMY; STAGE-II; SURVIVAL; FLUOROURACIL	Purposes Although adjuvant chemotherapy (AC) has been established as a standard of treatment for advanced rectal cancer, there is no guideline regarding the timing of AC initiation. In this study, we aimed to evaluate the oncologic outcome of early AC initiation and clarify the ideal time to AC among rectal cancer patients receiving preoperative chemo-radiotherapy (preCRT). Methods The medical records of 719 patients who underwent curative resection followed by AC for rectal cancer were analyzed retrospectively. Data distributions were compared according to the calculated cut-off for AC initiation, survival results, and chemotherapy-induced toxicity. Additionally, patients were divided into two groups according to preCRT status and compared with respect to differences in the optimal time to AC. Results Overall, a cut-off time point of 20 days after surgery for AC initiation was identified as the optimal interval; this yielded a significant difference in disease-free survival but no significant difference in AC toxicity. In the cut-off analysis of patients treated without preCRT, 19 days was identified as the optimal time to AC. However, for patients treated with preCRT, no significant value affected the survival outcome. Conclusions Earlier initiation of AC (within approximately 3 weeks) was associated with better oncological outcomes among patients with rectal cancer. Additionally, the optimal timing of AC was unclear among patients who received preCRT; this might be attributable to an undetermined role of AC after preCRT or the effects of complications such as anastomotic leakage.	[Noh, Gyoung Tae] Ewha Womans Univ, Dept Surg, Coll Med, Seoul, South Korea; [Han, Jeonghee] Hallym Univ, Dept Surg, Coll Med, Seoul, South Korea; [Cho, Min Soo; Hur, Hyuk; Lee, Kang Young; Kim, Nam Kyu; Min, Byung Soh] Yonsei Univ, Dept Surg, Coll Med, Seoul, South Korea	Ewha Womans University; Hallym University; Yonsei University; Yonsei University Health System	Min, BS (corresponding author), Yonsei Univ, Dept Surg, Coll Med, Seoul, South Korea.	bsmin@yuhs.ac		Hur, Hyuk/0000-0002-9864-7229; Kim, Nam-Kyu/0000-0003-0639-5632				Ahmed S, 2010, DIS COLON RECTUM, V53, P1432, DOI 10.1007/DCR.0b013e3181e78815; Aldo S, 2014, RADIOTHER ONCOL, V113, P223, DOI 10.1016/j.radonc.2014.10.006; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; [Anonymous], 1990, Consens Statement, V8, P1; Bayraktar UD, 2011, CANCER-AM CANCER SOC, V117, P2364, DOI 10.1002/cncr.25720; Biagi JJ, 2011, JAMA-J AM MED ASSOC, V305, P2335, DOI 10.1001/jama.2011.749; Bonjer HJ, 2005, LANCET ONCOL, V6, P477, DOI 10.1016/S1470-2045(05)70221-7; Bosset JF, 2014, LANCET ONCOL, V15, P184, DOI 10.1016/S1470-2045(13)70599-0; Breugom AJ, 2015, ANN ONCOL, V26, P696, DOI 10.1093/annonc/mdu560; Cheung WY, 2009, DIS COLON RECTUM, V52, P1054, DOI 10.1007/DCR.0b013e3181a51173; Day AR, 2014, COLORECTAL DIS, V16, P368, DOI 10.1111/codi.12570; Des Guetz G, 2010, EUR J CANCER, V46, P1049, DOI 10.1016/j.ejca.2010.01.020; Edge S.B., 2010, AJCC CANC STAGING MA, V649; EGGERMONT AMM, 1987, SURGERY, V102, P71; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Glimelius B, 2013, ANN ONCOL, V24, P81, DOI 10.1093/annonc/mdt240; Glynne-Jones R, 2014, ANN ONCOL, V25, P1356, DOI 10.1093/annonc/mdu147; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; Gray R, 2007, LANCET, V370, P2020, DOI 10.1016/s0140-6736(07)61866-2; Guillou PJ, 2005, LANCET, V365, P1718, DOI 10.1016/S0140-6736(05)66545-2; GUNDUZ N, 1979, CANCER RES, V39, P3861; Health UDo Services H. National Cancer Institute, 2013, COMMON TERMINOLOGY C; Hothorn T, 2002, R NEWS, V2, P3; Jeong WK, 2015, ANN SURG TREAT RES, V89, P124, DOI 10.4174/astr.2015.89.3.124; Kang J, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001202; Kang SB, 2010, LANCET ONCOL, V11, P637, DOI 10.1016/S1470-2045(10)70131-5; Kim HJ, 2014, AM J SURG, V207, P840, DOI 10.1016/j.amjsurg.2013.07.047; Kim IY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138720; Klein M, 2015, J SURG ONCOL, V112, P538, DOI 10.1002/jso.24017; Labianca R, 2013, ANN ONCOL, V24, P64, DOI 10.1093/annonc/mdt354; Lacy AM, 2002, LANCET, V359, P2224, DOI 10.1016/S0140-6736(02)09290-5; Lassen K, 2009, ARCH SURG-CHICAGO, V144, P961, DOI 10.1001/archsurg.2009.170; MCCULLOCH P, 1994, LANCET, V344, P402; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; Nachiappan S, 2015, EJSO-EUR J SURG ONC, V41, P1636, DOI 10.1016/j.ejso.2015.09.009; Nelson H, 2004, NEW ENGL J MED, V350, P2050; Network NCC, 2015, NCCN CLIN PRACT GUID; ONO I, 1994, SCAND J PLAST RECONS, V28, P269, DOI 10.3109/02844319409022010; Poulsen LO, 2015, ACTA ONCOL, V54, P437, DOI 10.3109/0284186X.2014.993768; Rayson D, 2012, J ONCOL PRACT, V8, P253, DOI 10.1200/JOP.2012.000578; Spanjersberg WR, 2015, SURG ENDOSC, V29, P3443, DOI 10.1007/s00464-015-4148-3; Spanjersberg WR, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007635.pub2; Glasgow SC, 2013, DIS COLON RECTUM, V56, P1339, DOI 10.1097/DCR.0b013e3182a857eb; Twelves C, 2005, NEW ENGL J MED, V352, P2696, DOI 10.1056/NEJMoa043116; van der Pas MHGM, 2013, LANCET ONCOL, V14, P210, DOI 10.1016/S1470-2045(13)70016-0; Yu S, 2013, CLIN COLORECTAL CANC, V12, P275, DOI 10.1016/j.clcc.2013.08.002	47	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2020	15	1							e0228060	10.1371/journal.pone.0228060	http://dx.doi.org/10.1371/journal.pone.0228060			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9CX	32004327	Green Published, gold			2023-01-03	WOS:000534614600013
J	Zante, B; Hautz, WE; Schefold, JC				Zante, Bjoern; Hautz, Wolf E.; Schefold, Joerg C.			Physiology education for intensive care medicine residents: A 15-minute interactive peer-led flipped classroom session	PLOS ONE			English	Article							STUDENTS; MOTIVATION; CONSTRUCTIVISM; DYSFUNCTION; PATIENT; TAUGHT; LEARN	Introduction In acute care medicine, knowledge of the underlying (patho)-physiology is of paramount importance. This may be especially relevant in intensive care medicine, where individual competence and proficiency greatly depend on knowledge and understanding of critical care physiology. In settings with time constraints such as intensive care units (ICUs), time allotted to education is often limited. We evaluated whether introduction of a short, interactive, peer-led flipped classroom session is feasible and can provide ICU residents with a better understanding of critical care physiology. Materials and methods Using the flipped classroom concept, we developed a 15-minute peer-led interactive "physiology education" session to introduce a total of 44 residents to critical care physiology. Using a nine-item electronic survey with open questions and a five-point Likert scale, we analysed the overall concept with regard to feasibility, motivation, and subjective learning of critical care physiology. Results The overall rate of response to the survey was 70.5% (31/44). The residents reported that these sessions sparked their interest (p = 0.005, Chi square 10.52), and that discussion and interaction during these sessions had promoted their knowledge and understanding. Both novice and experienced residents reported that new knowledge was imparted (both p< 0.0001, Chi-square 32.97 and 25.04, respectively). Conclusions In an environment with time constraints such as the ICU, a 15-minute, interactive, peer-led flipped classroom teaching session was considered feasible and generally appeared useful for teaching critical care physiology to ICU residents. Responses to questions on questionnaires indicated that teaching sessions sparked interest and increased motivation. This approach may theoretically induce a modification in professional behaviour and promote self-directed learning. We therefore support the use of peer-led flipped classroom training sessions in the ICU. Whether these sessions result in improved ICU care should be addressed in subsequent studies.	[Zante, Bjoern; Schefold, Joerg C.] Univ Bern, Bern Univ Hosp, Dept Intens Care Med, Inselspital, Bern, Switzerland; [Hautz, Wolf E.] Univ Bern, Bern Univ Hosp, Dept Emergency Med, Inselspital, Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Zante, B (corresponding author), Univ Bern, Bern Univ Hosp, Dept Intens Care Med, Inselspital, Bern, Switzerland.	bjoern.zante@insel.ch		Hautz, Wolf/0000-0002-2445-984X; Schefold, Joerg C./0000-0001-9162-5724				Allen RSF V, 1976, CHILDREN AS TEACHERS; Beard DA, 2011, AM J PHYSIOL-HEART C, V301, pH629, DOI 10.1152/ajpheart.00228.2011; Brandon AF, CONSTRUCTIVISM THEOR, P1536; BRUNER JS, 1961, HARVARD EDUC REV, V31, P21; Candela L, 2015, TEACHING NURSING GUI; Chen F, SYSTEMATIC REV EFFEC, P1365; Chen F, 2017, MED EDUC, V51, P585, DOI 10.1111/medu.13272; Colthorpe KL, 2018, ADV PHYSIOL EDUC, V42, P555, DOI 10.1152/advan.00102.2018; Cook DA, 2016, MED EDUC, V50, P997, DOI 10.1111/medu.13074; Croley WC, 2007, CRIT CARE MED, V35, pS117, DOI 10.1097/01.CCM.0000252917.25301.18; Curley G, 2010, CRIT CARE, V14, DOI 10.1186/cc8926; Custers EJFM, 2011, MED EDUC, V45, P422, DOI 10.1111/j.1365-2923.2010.03889.x; DeGrave WS, 1996, INSTR SCI, V24, P321, DOI 10.1007/BF00118111; Dennick R, 2016, INT J MED EDUC, V7, P200, DOI 10.5116/ijme.5763.de11; Dickinson BL, 2018, ADV PHYSIOL EDUC, V42, P118, DOI 10.1152/advan.00174.2017; Dybowski C, 2014, TEACH LEARN MED, V26, P393, DOI 10.1080/10401334.2014.910467; Ernst H, 2007, ADV PHYSIOL EDUC, V31, P41, DOI 10.1152/advan.00107.2006; Eva KW, 2009, MED EDUC, V43, P294, DOI 10.1111/j.1365-2923.2009.03342.x; Funk DJ, 2013, CRIT CARE MED, V41, P255, DOI 10.1097/CCM.0b013e3182772ab6; Joyce MF, 2017, WORLD J CRIT CARE ME, V6, P1, DOI DOI 10.5492/WJCCM.V6.I1.1; Kiani Q, 2014, CLIN TEACH, V11, P203, DOI 10.1111/tct.12109; Kimmoun A, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0896-7; Knowles EFH M.S, 2011, ADULT LEARNER DEFINI; Kruger J, 1999, J PERS SOC PSYCHOL, V77, P1121, DOI 10.1037/0022-3514.77.6.1121; Kusurkar RA, 2011, MED TEACH, V33, pE242, DOI 10.3109/0142159X.2011.558539; Legan SJ, 2001, ADV PHYSIOL EDUC, V25, P228, DOI 10.1152/advances.2001.25.4.228; Lockspeiser TM, 2008, ADV HEALTH SCI EDUC, V13, P361, DOI 10.1007/s10459-006-9049-8; Magder S, 2012, CRIT CARE, V16, DOI 10.1186/cc11395; Mahler D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207252; Michael JA, 1999, ADV PHYSIOL EDUC, V22, pS127, DOI 10.1152/advances.1999.277.6.S127; Michael J, 2007, ADV PHYSIOL EDUC, V31, P34, DOI 10.1152/advan.00057.2006; Miranda M, 2016, AM J PHYSIOL-HEART C, V311, pH24, DOI 10.1152/ajpheart.00034.2016; MOUST JHC, 1994, INSTR SCI, V22, P287; Orsini C, 2015, J EDUC EVAL HEALTH P, V12, DOI 10.3352/jeehp.2015.12.8; Pfortmueller CA, 2018, INTENS CARE MED EXP, V6, DOI 10.1186/s40635-018-0174-5; Piagnerelli M, 2003, INTENS CARE MED, V29, P1052, DOI 10.1007/s00134-003-1783-2; Prakash ES, 2010, ADV PHYSIOL EDUC, V34, P93, DOI 10.1152/advan.00025.2010; Qiao YQ, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-79; Robbins SB, 2004, PSYCHOL BULL, V130, P261, DOI 10.1037/0033-2909.130.2.261; Rovick AA, 1999, ADV PHYSIOL EDUC, V21, pS93, DOI 10.1152/advances.1999.276.6.S93; Sarbin TR, 1976, CHILDREN AS TEACHERS; Schefold JC, 2016, NAT REV NEPHROL, V12, P610, DOI 10.1038/nrneph.2016.113; Sefton AJ, 2005, ADV PHYSIOL EDUC, V29, P189, DOI 10.1152/advan.00001.2005; Smits PBA, 2004, MED EDUC, V38, P758, DOI 10.1111/j.1365-2929.2004.01846.x; Srivastava TK, 2015, J CLIN DIAGN RES, V9, pJC1, DOI 10.7860/JCDR/2015/15018.6323; Sunagawa K, 2017, J PHYSIOL SCI, V67, P447, DOI 10.1007/s12576-017-0533-0; Tainter CR, 2015, J CRIT CARE, V30, P550, DOI 10.1016/j.jcrc.2015.02.001; Takala J, 2003, INTENS CARE MED, V29, P890, DOI 10.1007/s00134-003-1749-4; Takala J, 2007, INTENS CARE MED, V33, P908, DOI 10.1007/s00134-007-0546-x; Ten Cate O, 2007, MED TEACH, V29, P591, DOI 10.1080/01421590701606799; Ten Cate O, 2007, MED TEACH, V29, P546, DOI 10.1080/01421590701583816; Topping K. J., 2005, ED PSYCHOL, V25, P631, DOI DOI 10.1080/01443410500345172; Vansteenkiste M, 2005, J EDUC PSYCHOL, V97, P468, DOI 10.1037/0022-0663.97.3.468; Vari RC, 2001, ADV PHYSIOL EDUC, V25, P241, DOI 10.1152/advances.2001.25.4.241; Vassilakopoulos T, 2008, INTENS CARE MED, V34, P1336, DOI 10.1007/s00134-008-1095-7; Vincent JL, 2018, CHEST, V154, P1267, DOI 10.1016/j.chest.2018.07.020; von Anrep G, 1912, J PHYSIOL-LONDON, V45, P307; Vygotsky L. S., 1978, MIND SOC DEV HIGHER; Walley KR, 2011, AM J RESP CRIT CARE, V184, P514, DOI 10.1164/rccm.201010-1584CI; Wlodkowski R., 2008, ENHANCING ADULT MOTI; Young JQ, 2014, MED TEACH, V36, P371, DOI 10.3109/0142159X.2014.889290	62	5	5	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2020	15	1							e0228257	10.1371/journal.pone.0228257	http://dx.doi.org/10.1371/journal.pone.0228257			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP8WY	31978206	Green Published, gold			2023-01-03	WOS:000534599100133
J	Vaduganathan, M; van Meijgaard, J; Mehra, MR; Joseph, J; O'Donnell, CJ; Warraich, HJ				Vaduganathan, Muthiah; van Meijgaard, Jeroen; Mehra, Mandeep R.; Joseph, Jacob; O'Donnell, Christopher J.; Warraich, Haider J.			Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Vaduganathan, Muthiah; Mehra, Mandeep R.] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA; [van Meijgaard, Jeroen] GoodRx, Santa Monica, CA USA; [Joseph, Jacob; O'Donnell, Christopher J.; Warraich, Haider J.] VA Boston Healthcare Syst, Dept Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Warraich, HJ (corresponding author), VA Boston Healthcare Syst, 1400 VFW Pkwy,4B-132, Boston, MA 02132 USA.	hwarraich@partners.org	Joseph, Jacob/GYR-1361-2022	Joseph, Jacob/0000-0002-7279-4896; van Meijgaard, Jeroen/0000-0002-3948-1556	NCATS NIH HHS [UL1 TR002541] Funding Source: Medline	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))		Food and Drug Administration, 2020, CURR RES DRUG SHORT; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Liu M, 2020, JAMA INTERN MED, V180, P1116, DOI 10.1001/jamainternmed.2020.1764; Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760; van Meijgaard J., 2020, GOODRX RES DATA DESC	5	74	74	2	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2020	323	24					2524	2526		10.1001/jama.2020.9184	http://dx.doi.org/10.1001/jama.2020.9184			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OS4QL	32463459	Green Published, Bronze			2023-01-03	WOS:000590149400028
J	Pisciotta, P; Costantino, A; Cammarata, FP; Torrisi, F; Calabrese, G; Marchese, V; Cirrone, GAP; Petringa, G; Forte, GI; Minafra, L; Bravata, V; Gulisano, M; Scopelliti, F; Tommasino, F; Scifoni, E; Cuttone, G; Ippolito, M; Parenti, R; Russo, G				Pisciotta, Pietro; Costantino, Angelita; Cammarata, Francesco Paolo; Torrisi, Filippo; Calabrese, Giovanna; Marchese, Valentina; Cirrone, Giuseppe Antonio Pablo; Petringa, Giada; Forte, Giusi Irma; Minafra, Luigi; Bravata, Valentina; Gulisano, Massimo; Scopelliti, Fabrizio; Tommasino, Francesco; Scifoni, Emanuele; Cuttone, Giacomo; Ippolito, Massimo; Parenti, Rosalba; Russo, Giorgio			Evaluation of proton beam radiation-induced skin injury in a murine model using a clinical SOBP	PLOS ONE			English	Article							BIOLOGICAL EFFECTIVENESS RBE; VALUES; MICE	The purpose of this paper is to characterize the skin deterministic damage due to the effect of proton beam irradiation in mice occurred during a long-term observational experiment. This study was initially defined to evaluate the insurgence of myelopathy irradiating spinal cords with the distal part of a Spread-out Bragg peak (SOBP). To the best of our knowledge, no study has been conducted highlighting high grades of skin injury at the dose used in this paper. Nevertheless these effects occurred. In this regard, the experimental evidence of significant insurgence of skin injury induced by protons using a SOBP configuration will be shown. Skin damages were classified into six scores (from 0 to 5) according to the severity of the injuries and correlated to ED50 (i.e. the radiation dose at which 50% of animals show a specific score) at 40 days post-irradiation (d.p.i.). The effects of radiation on the overall animal wellbeing have been also monitored and the severity of radiation-induced skin injuries was observed and quantified up to 40 d.p.i.	[Pisciotta, Pietro] Univ Catania, Phys & Astron Dept, Catania, Italy; [Pisciotta, Pietro; Cammarata, Francesco Paolo; Forte, Giusi Irma; Minafra, Luigi; Bravata, Valentina; Russo, Giorgio] Inst Mol Bioimaging & Physiol IBFM CNR, Cefalu, PA, Italy; [Pisciotta, Pietro; Cammarata, Francesco Paolo; Torrisi, Filippo; Cirrone, Giuseppe Antonio Pablo; Petringa, Giada; Cuttone, Giacomo; Russo, Giorgio] Natl Inst Nucl Phys LNS INFN, Natl Lab South, Catania, Italy; [Costantino, Angelita; Torrisi, Filippo; Calabrese, Giovanna; Marchese, Valentina; Parenti, Rosalba] Univ Catania, Biomed & Biotechnol Sci Dept, Lab Mol & Cellular Physiol, Catania, Italy; [Marchese, Valentina; Parenti, Rosalba] Univ Catania, Ctr Adv Preclin Vivo Res CAPiR, Catania, Italy; [Gulisano, Massimo] Univ Catania, Drug Sci Dept, Lab Synthet & Syst Biol, Catania, Italy; [Gulisano, Massimo; Parenti, Rosalba] Univ Catania, Mol Preclin & Translat Imaging Res Ctr IMPRonTe, Catania, Italy; [Scopelliti, Fabrizio] Cannizzaro Hosp, Nucl Med Dept, Radiopharm Lab, Catania, Italy; [Tommasino, Francesco] Univ Trento, Dept Phys, Povo, Italy; [Tommasino, Francesco; Scifoni, Emanuele] INFN, Natl Inst Nucl Phys, Trento Inst Fundamental Phys & Applicat TIFPA, Povo, Italy; [Ippolito, Massimo] Cannizzaro Hosp, Nucl Med Dept, Catania, Italy	University of Catania; Consiglio Nazionale delle Ricerche (CNR); Istituto di Bioimmagini e Fisiologia Molecolare (IBFM-CNR); University of Catania; University of Catania; University of Catania; University of Catania; University of Trento; Istituto Nazionale di Fisica Nucleare (INFN)	Cammarata, FP (corresponding author), Inst Mol Bioimaging & Physiol IBFM CNR, Cefalu, PA, Italy.; Cammarata, FP (corresponding author), Natl Inst Nucl Phys LNS INFN, Natl Lab South, Catania, Italy.; Parenti, R (corresponding author), Univ Catania, Biomed & Biotechnol Sci Dept, Lab Mol & Cellular Physiol, Catania, Italy.; Parenti, R (corresponding author), Univ Catania, Ctr Adv Preclin Vivo Res CAPiR, Catania, Italy.; Parenti, R (corresponding author), Univ Catania, Mol Preclin & Translat Imaging Res Ctr IMPRonTe, Catania, Italy.	francesco.cammarata@ibfm.cnr.it; parenti@unict.it	Russo, Giorgio/AAY-4770-2020; Parenti, Rosalba/AAS-5489-2020; Cammarata, Francesco Paolo/AAW-3132-2020; Parenti, Rosalba/ABC-5780-2020; Minafra, L/AFR-1042-2022; Gulisano, Massimo/F-6609-2012; Scifoni, Emanuele/B-5277-2013; Cammarata, Francesco Paolo/K-8653-2016; Cirrone, Giuseppe/AAF-7101-2021; Torrisi, Filippo/ABI-8101-2020	Russo, Giorgio/0000-0003-1493-1087; Cammarata, Francesco Paolo/0000-0002-0554-6649; Parenti, Rosalba/0000-0002-1614-4696; Minafra, L/0000-0003-3112-4519; Gulisano, Massimo/0000-0001-8654-1745; Scifoni, Emanuele/0000-0003-1851-5152; Cammarata, Francesco Paolo/0000-0002-0554-6649; Cirrone, Giuseppe/0000-0001-5733-9281; Torrisi, Filippo/0000-0002-5820-9160; Costantino, Angelita/0000-0002-2519-6279; Pisciotta, Pietro/0000-0002-5076-9796; Petringa, Giada/0000-0002-2854-8436; Calabrese, Giovanna/0000-0003-1937-5403	INFN CSN V - Call "MoVe-IT"; Italian Ministero dell'Istruzione, dell'Universita e della Ricerca, PRIN 2017 [2017XKWWK9_004]	INFN CSN V - Call "MoVe-IT"; Italian Ministero dell'Istruzione, dell'Universita e della Ricerca, PRIN 2017	The research was supported by the following grants: INFN CSN V - Call "MoVe-IT"; Italian Ministero dell'Istruzione, dell'Universita e della Ricerca, PRIN 2017, Grant no.: 2017XKWWK9_004 to R.P. and G.R. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2017, WELCOME GUIDE PHYS L; De Napoli M, NUCL REACTION MEASUR, DOI [10.1088/0031-9155/59/24/7643, DOI 10.1088/0031-9155/59/24/7643]; DeLaney TF, 2008, PROTON CHARGED PARTI; Gueulette J, 2000, INT J RADIAT ONCOL, V47, P1051, DOI 10.1016/S0360-3016(00)00535-6; Gueulette J, 2005, INT J RADIAT ONCOL, V62, P838, DOI 10.1016/j.ijrobp.2005.03.048; Gueulette J, 2001, RADIOTHER ONCOL, V61, P177, DOI 10.1016/S0167-8140(01)00446-7; Hall DC, 2016, PHYS MED BIOL, V61, pN1, DOI 10.1088/0031-9155/61/1/N1; IAEAICRU, 2008, IAEAICRU TECHN REP S, V461, P1; Jang WH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19216; Jourdan MM, 2011, RADIAT RES, V176, P636, DOI 10.1667/RR2422.1; LO YC, 1993, INT J RADIAT ONCOL, V27, P309, DOI 10.1016/0360-3016(93)90242-N; LO YC, 1992, INT J RADIAT ONCOL, V22, P57, DOI 10.1016/0360-3016(92)90982-N; Paganetti H, 2002, INT J RADIAT ONCOL, V53, P407, DOI 10.1016/S0360-3016(02)02754-2; Paganetti H, 2014, PHYS MED BIOL, V59, pR419, DOI 10.1088/0031-9155/59/22/R419; Pisciotta P, 2018, PHYS MEDICA, V54, P173, DOI 10.1016/j.ejmp.2018.07.003; Pisciotta P, 2016, PHYS MED, V32, P53, DOI [10.1016/j.ejmp.2016.01.184, DOI 10.1016/J.EJMP.2016.01.184]; Russo G, 2017, NUCL INSTRUM METH A, V846, P126, DOI 10.1016/j.nima.2016.10.021; Saager M, 2018, RADIOTHER ONCOL, V128, P115, DOI 10.1016/j.radonc.2018.03.002; Saager M, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-017-0950-5; Sorensen BS, 2017, ACTA ONCOL, V56, P1387, DOI 10.1080/0284186X.2017.1351621; Szabo ER, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206879; Willers H, 2018, RADIOTHER ONCOL, V128, P68, DOI 10.1016/j.radonc.2018.05.019	22	3	3	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2020	15	5							e0233258	10.1371/journal.pone.0233258	http://dx.doi.org/10.1371/journal.pone.0233258			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1MJ	32442228	gold, Green Published			2023-01-03	WOS:000537525900026
J	Driehuis, E; Oosterom, N; Heil, SG; Muller, IB; Lin, M; Kolders, S; Jansen, G; de Jonge, R; Pieters, R; Clevers, H; van den Heuvel-Eibrink, MM				Driehuis, E.; Oosterom, N.; Heil, S. G.; Muller, I. B.; Lin, M.; Kolders, S.; Jansen, G.; de Jonge, R.; Pieters, R.; Clevers, H.; van den Heuvel-Eibrink, M. M.			Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia	PLOS ONE			English	Article							HIGH-DOSE METHOTREXATE; STEM-CELLS; DIHYDROFOLATE-REDUCTASE; FOLYLPOLYGLUTAMATE SYNTHETASE; MEMBRANE-TRANSPORT; PROGENITOR CELLS; FOLINIC ACID; SINGLE LGR5; POLYGLUTAMYLATION; RESISTANCE	We have recently established a protocol to grow wildtype human oral mucosa organoids. These three-dimensional structures can be maintained in culture long-term, do not require immortalization, and recapitulate the multilayered composition of the epithelial lining of the oral mucosa. Here, we validate the use of this model to study the effect of Leucovorin (LV) on Methotrexate (MTX)-induced toxicity. MTX is a chemotherapeutic agent used in the treatment of pediatric acute lymphoblastic leukemia. Although effective, the use of MTX often results in severe side-effects, including oral mucositis, which is characterized by epithelial cell death. Here, we show that organoids are sensitive to MTX, and that the addition of LV reduces MTX toxicity, in both a concentration- and timing-dependent manner. Additionally, we show that a 24 hour 'pretreatment' with LV reduces MTX-induced cell death, suggesting that such a pretreatment could decrease mucositis in patients. Taken together, we provide the first in vitro model to study the effect of MTX on wildtype oral mucosa cells. Our findings underscore the relevance of the clinically applied LV regimen and highlight the potential of this model to further optimize modifications in dosing and timing of Leucovorin on oral mucosa cells.	[Driehuis, E.; Kolders, S.; Clevers, H.] Royal Netherlands Acad Arts & Sci KNAW, Hubrecht Inst, Oncode Inst, Utrecht, Netherlands; [Driehuis, E.; Kolders, S.; Clevers, H.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Oosterom, N.; Pieters, R.; Clevers, H.; van den Heuvel-Eibrink, M. M.] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands; [Heil, S. G.] Erasmus MC, Univ Med Ctr Rotterdam, Dept Clin Chem, Rotterdam, Netherlands; [Muller, I. B.; Lin, M.; de Jonge, R.] Amsterdam UMC, Dept Clin Chem, Amsterdam, Netherlands; [Jansen, G.] Amsterdam UMC, Amsterdam Rheumatol & Immunol Ctr, Dept Rheumatol, Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam	van den Heuvel-Eibrink, MM (corresponding author), Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands.	m.m.vandenheuvel-eibrink@prinsesmaximacentrum.nl		Jansen, Gerrit/0000-0001-8190-8368	Oncode Institute (Dutch Cancer Society); Netherlands Organization for Scientific Research (NWO); Stand Up to Cancer International Translational Cancer Research Grant, a program of the Entertainment Industry Foundation [SU2C-AACR-DT1213]; ZonMw grant [116.006.103]	Oncode Institute (Dutch Cancer Society); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Stand Up to Cancer International Translational Cancer Research Grant, a program of the Entertainment Industry Foundation; ZonMw grant	Funded by the Oncode Institute (partly financed by the Dutch Cancer Society), by the gravitation program CancerGenomiCs.nl from the Netherlands Organization for Scientific Research (NWO) and by a Stand Up to Cancer International Translational Cancer Research Grant, a program of the Entertainment Industry Foundation administered by the AACR (SU2C-AACR-DT1213) and a ZonMw grant (116.006.103).	ACKLAND SP, 1987, J CLIN ONCOL, V5, P2017, DOI 10.1200/JCO.1987.5.12.2017; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Berkers G, 2019, CELL REP, V26, P1701, DOI 10.1016/j.celrep.2019.01.068; BERRY CL, 1972, J EMBRYOL EXP MORPH, V28, P601; BERTINO JR, 1993, J CLIN ONCOL, V11, P5, DOI 10.1200/JCO.1993.11.1.5; Blutt SE, 2018, CELL MOL GASTROENTER, V5, P241, DOI 10.1016/j.jcmgh.2017.12.001; BORSI JD, 1991, EUR J CANCER, V27, P1006, DOI 10.1016/0277-5379(91)90269-J; Dekkers JF, 2013, NAT MED, V19, P939, DOI 10.1038/nm.3201; den Boer E, 2013, ANAL BIOANAL CHEM, V405, P1673, DOI 10.1007/s00216-012-6581-7; den Hoed MAH, 2015, PHARMACOGENOMICS J, V15, P248, DOI 10.1038/tpj.2014.63; DeWard AD, 2014, CELL REP, V9, P701, DOI 10.1016/j.celrep.2014.09.027; Driehuis E, 2019, P NATL ACAD SCI US; Driehuis E KS, 2019, CANC DISCOV; FABRE I, 1984, CANCER RES, V44, P3190; FRY DW, 1983, CANCER RES, V43, P1087; Galpin AJ, 1997, MOL PHARMACOL, V52, P155, DOI 10.1124/mol.52.1.155; GOLDIN A, 1953, CANCER RES, V13, P843; GOLDIN A, 1966, NATURE, V212, P1548, DOI 10.1038/2121548a0; GOLDMAN I D, 1987, NCI (National Cancer Institute) Monographs, P17; Gonen N, 2012, DRUG RESIST UPDATE, V15, P183, DOI 10.1016/j.drup.2012.07.002; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Howard SC, 2016, ONCOLOGIST, V21, P1471, DOI 10.1634/theoncologist.2015-0164; Huch M, 2015, CELL, V160, P299, DOI 10.1016/j.cell.2014.11.050; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Hunger SP, 2012, J CLIN ONCOL, V30, P1663, DOI 10.1200/JCO.2011.37.8018; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; Johnson JI, 2001, BRIT J CANCER, V84, P1424, DOI 10.1054/bjoc.2001.1796; Kamps WA, 2010, LEUKEMIA, V24, P309, DOI 10.1038/leu.2009.258; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Kessler M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9989; KOIZUMI S, 1985, J CLIN INVEST, V75, P1008, DOI 10.1172/JCI111761; Kopper O, 2019, NAT MED, V25, P838, DOI 10.1038/s41591-019-0422-6; Kretzschmar K, 2016, DEV CELL, V38, P590, DOI 10.1016/j.devcel.2016.08.014; Lee SH, 2018, CELL, V173, P515, DOI 10.1016/j.cell.2018.03.017; Linnemann JR, 2015, DEVELOPMENT, V142, P3239, DOI 10.1242/dev.123554; MATHERLY LH, 1986, CANCER RES, V46, P588; MATHERLY LH, 1987, J BIOL CHEM, V262, P710; Muller IB, 2019, THER DRUG MONIT; Nanduri LSY, 2014, STEM CELL REP, V3, P957, DOI 10.1016/j.stemcr.2014.09.015; Noel G, 2017, SCI REP-UK, V7, DOI 10.1038/srep45270; Ooft SN, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aay2574; Pauley JL, 2013, CANCER CHEMOTH PHARM, V72, P369, DOI 10.1007/s00280-013-2206-x; Pieters R, 2016, J CLIN ONCOL, V34, P2591, DOI 10.1200/JCO.2015.64.6364; POSER RG, 1981, CANCER RES, V41, P4441; Pui CH, 2011, J CLIN ONCOL, V29, P551, DOI 10.1200/JCO.2010.30.7405; Raz S, 2016, DRUG RESIST UPDATE, V28, P43, DOI 10.1016/j.drup.2016.06.004; Ren WW, 2014, P NATL ACAD SCI USA, V111, P16401, DOI 10.1073/pnas.1409064111; ROTHENBERG SP, 1982, J PHARMACOL EXP THER, V223, P631; Rots MG, 1999, BLOOD, V93, P1067, DOI 10.1182/blood.V93.3.1067.403k01_1067_1074; Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683; Sachs N, 2018, CELL, V172, P373, DOI 10.1016/j.cell.2017.11.010; SANDBERG JS, 1970, CANCER RES, V30, P1276; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schutgens F, 2019, NAT BIOTECHNOL, V37, P303, DOI 10.1038/s41587-019-0048-8; Skarby TVC, 2006, LEUKEMIA, V20, P1955, DOI 10.1038/sj.leu.2404404; Sonis ST, 2004, NAT REV CANCER, V4, P277, DOI 10.1038/nrc1318; Sonis Stephen T, 2010, Curr Opin Support Palliat Care, V4, P26, DOI 10.1097/SPC.0b013e328335fb76; Sterba J, 2006, CLIN CHEM, V52, P692, DOI 10.1373/clinchem.2005.061150; Tadokoro T, 2014, P NATL ACAD SCI USA, V111, pE3641, DOI 10.1073/pnas.1409781111; Tiriac H, 2018, CANCER DISCOV, V8, P1112, DOI 10.1158/2159-8290.CD-18-0349; Van der Beek JN, 2019, CRIT REV ONCOL HEMAT, V142, P1, DOI 10.1016/j.critrevonc.2019.07.003; VANDERLAAN BFAM, 1992, INT J CANCER, V51, P909, DOI 10.1002/ijc.2910510613; Villa A, 2015, CURR OPIN ONCOL, V27, P159, DOI 10.1097/CCO.0000000000000180; Vlachogiannis G, 2018, SCIENCE, V359, P920, DOI 10.1126/science.aao2774; Voskoglou-Nomikos T, 2003, CLIN CANCER RES, V9, P4227; WOLFROM C, 1990, EUR J CLIN PHARMACOL, V39, P377, DOI 10.1007/BF00315414; Yao Y, 2020, CELL STEM CELL, V26, P17, DOI 10.1016/j.stem.2019.10.010; Zhao RB, 2003, ONCOGENE, V22, P7431, DOI 10.1038/sj.onc.1206946; Zhao RB, 2011, ANNU REV NUTR, V31, P177, DOI 10.1146/annurev-nutr-072610-145133	70	11	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2020	15	5							e0231588	10.1371/journal.pone.0231588	http://dx.doi.org/10.1371/journal.pone.0231588			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1CK	32421698	Green Published, gold			2023-01-03	WOS:000537499600005
J	Zhu, XD; Hu, Z; Nie, Y; Zhu, TT; Kaminga, AC; Yu, YH; Xu, HL				Zhu, Xidi; Hu, Zhao; Nie, Yu; Zhu, Tingting; Kaminga, Atipatsa Chiwanda; Yu, Yunhan; Xu, Huilan			The prevalence of poor sleep quality and associated risk factors among Chinese elderly adults in nursing homes: A cross-sectional study	PLOS ONE			English	Article							DWELLING OLDER-ADULTS; SOCIAL SUPPORT; CARDIOVASCULAR-DISEASE; ANXIETY DISORDERS; PRIMARY-CARE; DEPRESSION; DISTURBANCES; PEOPLE; HEALTH; POPULATION	Background Sleep problems have become the most common complaints among the elderly. There are a few studies that explored the prevalence of poor sleep quality and its associated factors among the elderly in nursing homes. Therefore, this study aimed to examine the prevalence of poor sleep quality and its associated factors among the Chinese elderly in nursing homes. Methods A total of 817 elderly residents, from 24 nursing homes, were included in this cross-sectional study. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), and poor sleep quality was defined as PSQI >5. Multiple binary logistic regression was used to estimate the strength of the association between risk factors and poor sleep quality in terms of adjusted odds ratios (AORs) and their 95% confidence intervals (CIs), and interactions of risk factors for poor sleep quality were also examined. Results The prevalence of poor sleep quality was 67.3% (95% CI: 64.0, 70.5%) among the Chinese elderly in nursing homes. Multiple binary logistic regression results showed that participants with the following characteristics had an increased risk of poor sleep quality after adjustments for other confounders: being 70-79 years old (AOR: 1.78, 95% CI: 1.08, 2.92) or 80 years old and above (AOR: 2.67, 95% CI: 1.68, 4.24); having one to two kinds of chronic diseases (AOR: 2.05, 95% CI: 1.39, 3.01) or three or more kinds of chronic diseases (AOR: 2.35, 95% CI: 1.39, 4.00); depression symptoms (AOR: 1.08, 95% CI: 1.04, 1.11), anxiety symptoms (AOR: 1.11, 95% CI: 1.05, 1.18), and social support(AOR: 0.97, 95% CI: 0.95, 0.99). Additive interactions were detected between age and anxiety symptoms (AOR: 8.34, 95% CI: 4.43, 15.69); between chronic disease and anxiety symptoms (AOR: 8.61, 95% CI; 4.28, 17.31); and between social support and anxiety symptoms (AOR: 6.43, 95% CI: 3.22, 12.86). Conclusions The prevalence of poor sleep quality among the elderly in nursing homes is relatively high. Besides, anxiety symptoms has additive interactions with age, chronic disease and social support for poor sleep quality. These findings have significant implications for interventions that aim to improve sleep quality among elderly residents in nursing homes.	[Zhu, Xidi; Hu, Zhao; Nie, Yu; Yu, Yunhan; Xu, Huilan] Cent South Univ, Xiangya Sch Publ Hlth, Dept Social Med & Hlth Management, Changsha, Peoples R China; [Zhu, Tingting] Shanghai Hlth Dev Res Ctr, Dept Sci Res Management, Shanghai, Peoples R China; [Kaminga, Atipatsa Chiwanda] Mzuzu Univ, Dept Math & Stat, Mzuzu, Malawi; [Kaminga, Atipatsa Chiwanda] Cent South Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R China	Central South University; Central South University	Xu, HL (corresponding author), Cent South Univ, Xiangya Sch Publ Hlth, Dept Social Med & Hlth Management, Changsha, Peoples R China.	xhl6363@sina.com		xu, huilan/0000-0001-8948-3149; Hu, Zhao/0000-0002-6787-4074				Ahmed D, 2014, J EGYPT PUBLIC HEAL, V89, P127, DOI 10.1097/01.EPX.0000455729.66131.49; Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x; Aunjitsakul Warut, 2018, Journal of the Medical Association of Thailand, V101, P137; Bazargan M, 1996, INT J AGING HUM DEV, V42, P143, DOI 10.2190/GM89-NRTY-DERQ-LC7D; Beekman ATF, 2000, AM J PSYCHIAT, V157, P89, DOI 10.1176/ajp.157.1.89; Bo YC, 2019, J CLIN SLEEP MED, V15, P393, DOI 10.5664/jcsm.7660; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cacioppo JT, 2003, PERSPECT BIOL MED, V46, pS39, DOI 10.1353/pbm.2003.0049; Chang KJ, 2014, ARCH GERONTOL GERIAT, V59, P468, DOI 10.1016/j.archger.2014.04.007; Cho HJ, 2008, AM J PSYCHIAT, V165, P1543, DOI 10.1176/appi.ajp.2008.07121882; da Costa SV, 2011, REV LAT-AM ENFERM, V19, P920, DOI 10.1590/S0104-11692011000400010; da Silva RM, 2020, AGING MENT HEALTH, V24, P1452, DOI 10.1080/13607863.2019.1619168; de Pooter-Stijnman LMM, 2018, EUR GERIATR MED, V9, P829, DOI 10.1007/s41999-018-0115-6; Dong XL, 2018, SLEEP BREATH, V22, P1213, DOI 10.1007/s11325-018-1685-8; Ersser S, 1999, J CLIN NURS, V8, P360, DOI 10.1046/j.1365-2702.1999.00267.x; Eser I, 2007, J GERONTOL NURS, V33, P42, DOI 10.3928/00989134-20071001-07; Eshkoor SA, 2013, AM J ALZHEIMERS DIS, V28, P253, DOI 10.1177/1533317513481098; Fetveit A, 2002, INT J GERIATR PSYCH, V17, P604, DOI 10.1002/gps.639; Gelaye B, 2016, SLEEP BREATH, V20, P1319, DOI 10.1007/s11325-016-1418-9; Gentili A, 1997, AGING-CLIN EXP RES, V9, P207, DOI 10.1007/BF03340151; Gnadinger M, 2018, INT J PUBLIC HEALTH, V63, P1017, DOI 10.1007/s00038-018-1114-6; Gu DN, 2010, SLEEP, V33, P601, DOI 10.1093/sleep/33.5.601; Hayashino Y, 2010, SLEEP MED, V11, P366, DOI 10.1016/j.sleep.2009.05.021; Hoevenaar-Blom MP, 2011, SLEEP, V34, P1487, DOI 10.5665/sleep.1382; Kara B, 2017, J TRANSCULT NURS, V28, P296, DOI 10.1177/1043659615623330; Kirmizioglu Y, 2009, INT J GERIATR PSYCH, V24, P1026, DOI 10.1002/gps.2215; Kishimoto Y, 2016, ENVIRON HEALTH PREV, V21, P295, DOI 10.1007/s12199-016-0529-z; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; [刘杰 Liu Jie], 2013, [中国临床心理学杂志, Chinese Journal of Clinical Psychology], V21, P39; LIVINGSTON G, 1993, BRIT J GEN PRACT, V43, P445; Luo J, 2013, PLOS ONE, V8; Maggi S, 1998, J AM GERIATR SOC, V46, P161, DOI 10.1111/j.1532-5415.1998.tb02533.x; Matsuda R, 2017, INT J CARDIOL, V228, P977, DOI 10.1016/j.ijcard.2016.11.091; Mazzotti DR, 2012, SLEEP MED, V13, P697, DOI 10.1016/j.sleep.2012.02.009; National Bureau of Statistics of China, 2011, 6 NAT POP CENS DAT G; National committee on aging, 2007, NATL COMMITTEE AGING; Olivera J, 2008, INT J GERIATR PSYCH, V23, P915, DOI 10.1002/gps.2004; Orhan FO, 2012, SLEEP BREATH, V16, P1059, DOI 10.1007/s11325-011-0601-2; Park JH, 2013, INT J NURS PRACT, V19, P116, DOI 10.1111/ijn.12047; Paudel ML, 2008, J AM GERIATR SOC, V56, P1228, DOI 10.1111/j.1532-5415.2008.01753.x; Paukert AL, 2010, J CLIN PSYCHOL MED S, V17, P387, DOI 10.1007/s10880-010-9211-6; Pedraza Sandra, 2012, Aging Clin Exp Res, V24, P391, DOI 10.3275/8106; Potvin O, 2014, INT J GERIATR PSYCH, V29, P1262, DOI 10.1002/gps.4106; Press Y, 2018, AGING CLIN EXP RES, V30, P755, DOI 10.1007/s40520-017-0837-1; Qiu J, 2016, MODERN PREVENTIVE ME, V43, P1835; Quan SA, 2016, J KOREAN MED SCI, V31, P1689, DOI 10.3346/jkms.2016.31.11.1689; Razali R, 2016, NEUROL ASIA, V21, P265; Roberts RE, 2000, AM J PSYCHIAT, V157, P81, DOI 10.1176/ajp.157.1.81; Roepke SK, 2010, INDIAN J MED RES, V131, P302; Sagayadevan V, 2017, PSYCHOGERIATRICS, V17, P43, DOI 10.1111/psyg.12190; Smalbrugge M, 2008, AGING MENT HEALTH, V12, P244, DOI 10.1080/13607860801987238; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Stefan L, 2018, INT J ENV RES PUBLIC, V15; Stranges S, 2012, SLEEP, V35, P1173, DOI 10.5665/sleep.2012; Su TP, 2004, AUST NZ J PSYCHIAT, V38, P706, DOI 10.1111/j.1440-1614.2004.01444.x; Sukegawa T, 2003, PSYCHIAT CLIN NEUROS, V57, P265, DOI 10.1046/j.1440-1819.2003.01115.x; Teesson M, 2011, AUST NZ J PSYCHIAT, V45, P939, DOI 10.3109/00048674.2011.614590; Thichumpa W, 2018, EPIDEMIOL HEALTH, V40, DOI 10.4178/epih.e2018018; Troxel WM, 2010, J PSYCHOSOM RES, V69, P459, DOI 10.1016/j.jpsychores.2010.04.003; Tsai YF, 2008, J CLIN NURS, V17, P1219, DOI 10.1111/j.1365-2702.2007.02020.x; Uchmanowicz I, 2019, CLIN INTERV AGING, V14, P155, DOI 10.2147/CIA.S188499; Wang P, 2019, AGING CLIN EXPT RES; Wang Y, 2019, SLEEP MED, V54, P134, DOI 10.1016/j.sleep.2018.10.031; Wilfling D, 2019, J ALZHEIMERS DIS, V69, P227, DOI 10.3233/JAD-180784; Yang CY, 2012, J NURS RES, V20, P249, DOI 10.1097/jnr.0b013e3182736461; Yu JH, 2016, PSYCHOGERIATRICS, V16, P191, DOI 10.1111/psyg.12138; Zhang HQ, 2019, SLEEP MED, V58, P27, DOI 10.1016/j.sleep.2019.03.001	67	8	8	2	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2020	15	5							e0232834	10.1371/journal.pone.0232834	http://dx.doi.org/10.1371/journal.pone.0232834			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU1BA	32413064	Green Published, gold, Green Submitted			2023-01-03	WOS:000537496000023
J	Jacques, CN; Hulbert, AK; Westenskow, S; Neff, MM				Jacques, Caitlin N.; Hulbert, Anna K.; Westenskow, Shelby; Neff, Michael M.			Production location of the gelling agent Phytagel has a significant impact on Arabidopsis thaliana seedling phenotypic analysis	PLOS ONE			English	Article							BRASSINOSTEROID INACTIVATION; PHYTOCHROME	Background Recently, it was found that 1% Phytagel plates used to conduct Arabidopsis thaliana seedling phenotypic analysis no longer reproduced previously published results. This Phytagel, which is produced in China (Phytagel C), has replace American-made Phytagel (Phytagel), which is no longer commercially available. In this study, we present the impact of Phytagel produced in the United States vs. China on seedling phenotypic analysis. As a part of this study, an alternative gelling agent has been identified that is capable of reproducing previously published seedling morphometrics. Results Phytagel and Phytagel C were investigated based on their ability to reproduce the subtle phenotype of the sob3-4 esc-8 double mutant. Fluence-rate-response analysis of seedlings grown on 1% Phytagel C plates failed to replicate the sob3-4 esc-8 subtle phenotype seen on 1% Phytagel. Furthermore, root penetrance analysis showed a significant difference between sob3-4 esc-8 seedlings grown on 1% Phytagel and 1% Phytagel C. It was also found that 1% Phytagel C was significantly harder than 1% Phytagel. As a replacement for Phytagel C, Gellan was tested. 1% Gellan was able to reproduce the subtle phenotype of sob3-4 esc-8. Furthermore, there was no significant difference in root penetration of the wild type or sob3-4 esc-8 seedlings between 1% Phytagel and 1% Gellan. This may be due to the significant reduction in hardness in 1% Gellan plates compared to 1% Phytagel plates. Finally, we tested additional concentrations of Gellan and found that seedlings on 0.6% Gellan looked more uniform while also being able to reproduce previously published results. Conclusions Phytagel has been the standard gelling agent for several studies involving the characterization of subtle seedling phenotypes. After production was moved to China, Phytagel C was no longer capable of reproducing these previously published results. An alternative gelling agent, Gellan, was able to reproduce previously published seedling phenotypes at both 1% and 0.6% concentrations. The information provided in this manuscript is beneficial to the scientific community as whole, specifically phenomics labs, as it details key problematic differences between gelling agents that should be performing identically (Phytagel and Phytagel C).	[Jacques, Caitlin N.; Neff, Michael M.] Washington State Univ, Grad Program Mol Plant Sci, Pullman, WA 99164 USA; [Jacques, Caitlin N.; Hulbert, Anna K.; Westenskow, Shelby; Neff, Michael M.] Washington State Univ, Dept Crop & Soil Sci, Pullman, WA 99164 USA	Washington State University; Washington State University	Neff, MM (corresponding author), Washington State Univ, Grad Program Mol Plant Sci, Pullman, WA 99164 USA.; Neff, MM (corresponding author), Washington State Univ, Dept Crop & Soil Sci, Pullman, WA 99164 USA.	mmneff@wsu.edu			United States National Science Foundation [1656265]; USDA National Institute of Food and Agriculture, Hatch Umbrella Project [1015621]	United States National Science Foundation(National Science Foundation (NSF)); USDA National Institute of Food and Agriculture, Hatch Umbrella Project	This work was supported by the United States National Science Foundation Project #1656265 (to M.M.N.). This work was also supported by the USDA National Institute of Food and Agriculture, Hatch Umbrella Project #1015621 (to M.M.N.).	Favero DS, 2016, PLANT PHYSIOL, V171, P2701, DOI 10.1104/pp.16.00405; Millipore Sigma, 2019, GELL AG PLANT TISS C; Neff MM, 1998, PLANT PHYSIOL, V118, P27, DOI 10.1104/pp.118.1.27; Peng H, 2015, DEVELOPMENT, V142, P4129, DOI 10.1242/dev.124347; PhytoTechnology Laboratories, 2013, PROD INF SHEET; Street IH, 2008, PLANT J, V54, P1, DOI 10.1111/j.1365-313X.2007.03393.x; Turk EM, 2005, PLANT J, V42, P23, DOI 10.1111/j.1365-313X.2005.02358.x; Ward JM, 2006, PLANT CELL, V18, P29, DOI 10.1105/tpc.105.036707; Ward JM, 2005, PLANT CELL, V17, P475, DOI 10.1105/tpc.104.027722; Weigel D, 2000, PLANT PHYSIOL, V122, P1003, DOI 10.1104/pp.122.4.1003; Zhang J, 2006, PLANT J, V46, P834, DOI 10.1111/j.1365-313X.2006.02745.x; Zhao JF, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0266-7	12	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2020	15	5							e0228515	10.1371/journal.pone.0228515	http://dx.doi.org/10.1371/journal.pone.0228515			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU0YZ	32407318	Green Published, Green Submitted, gold			2023-01-03	WOS:000537490700005
J	Pillay, D; Stankevitz, K; Lanham, M; Ridgeway, K; Murire, M; Briedenhann, E; Jenkins, S; Subedar, H; Hoke, T; Mullick, S				Pillay, Diantha; Stankevitz, Kayla; Lanham, Michele; Ridgeway, Kathleen; Murire, Mercy; Briedenhann, Elmari; Jenkins, Sarah; Subedar, Hasina; Hoke, Theresa; Mullick, Saiqa			Factors influencing uptake, continuation, and discontinuation of oral PrEP among clients at sex worker and MSM facilities in South Africa	PLOS ONE			English	Article							PREEXPOSURE PROPHYLAXIS; HIV	Background South Africa became the first country in Africa to introduce oral PrEP in June 2016. The National Department of Health has used a phased approach to rollout, allowing for a dynamic learn-and-adapt process which will lead ultimately to scale-up. Phased rollout began with provision of oral PrEP at facilities providing services to sex workers in 2016 and was expanded in 2017, first to facilities providing services to MSM and then to students at selected university campus clinics, followed by provision at primary health care facilities. Programmatic data shows variability in initiation and continuation between these populations. This study examines factors related to PrEP initiation, continuation, and discontinuation at facilities providing services to sex workers and MSM during the national PrEP rollout. Methods A cross-sectional survey was administered September 2017-January 2018 among clients (ages 18-62 and providers at 9 facilities implementing oral PrEP in South Africa, followed by in-depth interviews. The client survey captured PrEP initiation, continuation and discontinuation. Analysis was performed in STATA 13 for survey data and thematic analysis was performed in NViVO 11 for in-depth interview data. Results 299 clients (203 from sex worker facilities, 96 from MSM facilities) participated in the survey and additionally, in-depth interviews were conducted with 29 clients. Participants self-identified as either current users (n = 94; 36.2%), past users (n = 80; 30.8%) and never users of PrEP (n = 86; 33.1%). Participants who had never used PrEP either cited not being offered PrEP by a provider (57%, n = 49) or declining PrEP (43%, n = 37) as reasons for lack of uptake. The primary reason for declining to use oral PrEP was fear of side effects (41.7%, n = 15). The primary reasons for initiating and continuing on oral PrEP were all related to perceived risk associated with sexual activity. The majority of participants (87.9%, n = 153) also noted that printed IEC materials influenced their decision to initiate PrEP. Qualitative data suggested that several clients initiated on PrEP because they wanted additional protection beyond using condoms due to challenges such as partners refusing to use condoms, having partners with unknown HIV status, having multiple partners, involvement in sex work, or having a partner living with HIV. The majority (73.8%, n = 59) of participants who discontinued oral PrEP cited side effects as the primary reason for discontinuation, followed by feeling stigmatized (18.8%, n = 15). Conclusion This study provides valuable insights on early rollout of PrEP of how clients perceive oral PrEP and where to target efforts to improve the uptake of this highly effective HIV prevention product. By identifying strengths and areas for improvement, the ACCESS study has generated evidence that can be used to guide high quality scale-up in South Africa and may be instructive for other countries' efforts to expand quality access to oral PrEP.	[Pillay, Diantha; Murire, Mercy; Briedenhann, Elmari; Mullick, Saiqa] Univ Witwatersrand, Fac Hlth Sci, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa; [Stankevitz, Kayla; Lanham, Michele; Ridgeway, Kathleen; Hoke, Theresa] FHI 360, Durham, NC USA; [Jenkins, Sarah] Clinton Hlth Access Initiat, Pretoria, South Africa; [Subedar, Hasina] Natl Dept Hlth, Pretoria, South Africa	University of Witwatersrand; FHI 360	Pillay, D (corresponding author), Univ Witwatersrand, Fac Hlth Sci, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa.	dpillay@wrhi.ac.za		Briedenhann, Elmari/0000-0001-8107-6223; Mullick, Saiqa/0000-0001-7039-1949; Lanham, Michele/0000-0003-3012-5683; Ridgeway, Kathleen/0000-0003-0839-2830	OPTIONS project - U.S. Agency for International Development; Prevention Market Manager project - Bill and Melinda Gates Foundation; PEPFAR [AID-OAA-A-15-00035]	OPTIONS project - U.S. Agency for International Development; Prevention Market Manager project - Bill and Melinda Gates Foundation; PEPFAR	his study was supported by the OPTIONS project, funded by the U.S. Agency for International Development (https://www.usaid.gov) in partnership with PEPFAR (Cooperative Agreement No. AID-OAA-A-15-00035); and by the Prevention Market Manager project, funded by the Bill and Melinda Gates Foundation (https://www.gatesfoundation.org).The contents do not necessarily reflect the views of the funders. The funders did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was supported by the OPTIONS project, funded by the U.S. Agency for International Development (USAID) in partnership with PEPFAR (Cooperative Agreement No. AIDOAA-A-15-00035), and by the Prevention Market Manager project, funded by the Bill and Melinda Gates Foundation. The contents do not necessarily reflect the views of the funders.	Albert B, 2016, KEOD: PROCEEDINGS OF THE 8TH INTERNATIONAL JOINT CONFERENCE ON KNOWLEDGE DISCOVERY, KNOWLEDGE ENGINEERING AND KNOWLEDGE MANAGEMENT - VOL. 2, P21, DOI 10.5220/0006048300210030; Baral S, 2012, LANCET INFECT DIS, V12, P538, DOI 10.1016/S1473-3099(12)70066-X; Council SANA, 2017, NAT STRAT PLAN HIV T; Delabre RM, HIV RES PREV C MADR; Elzette R-J, 2018, EARLY PERSISTENCE HI; Fonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145; Golub S., 2018, PREP MESSAGING TAKIN; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Holsti O.R., 1969, CONTENT ANAL SOCIAL; Matthew S, 2018, EXAMINING PREP INTER; NDoH, 2018, S AFR NAT DEP HLTH M; Newman AM, 2016, ADOLESCENT IDENTITY AND SCHOOLING: DIVERSE PERSPECTIVES, P21; Nicholas T, SO I DONT GET INFECT; Pillay Y, 2018, INT AIDS C AMST; PrEPWatch, 2018, OR PREP RISK ASS TOO; PSI, BREAK CYCL TRANSM 20; Scheibe A, 2011, GAP ANAL KEY POPULAT; Smith DK, 2012, AIDS EDUC PREV, V24, P408, DOI 10.1521/aeap.2012.24.5.408; Tolley E.E., 2016, QUALITATIVE METHODS, V2nd; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; UNAIDS, 2018, AIDS INF S AFR; World Health Organization, 2016, CONS GUID US ANT DRU	22	34	34	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2020	15	4							e0228620	10.1371/journal.pone.0228620	http://dx.doi.org/10.1371/journal.pone.0228620			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LS9BE	32352969	Green Published, gold			2023-01-03	WOS:000536673200008
J	Cao, HJ; Li, X; Li, XL; Ward, L; Xie, ZG; Hu, H; Zhang, YJ; Liu, JP				Cao, Hui-Juan; Li, Xun; Li, Xin-Lin; Ward, Lesley; Xie, Zhan-Guo; Hu, Hui; Zhang, Ya-Jing; Liu, Jian-Ping			Factors influencing participant compliance in acupuncture trials: An in-depth interview study	PLOS ONE			English	Article								Introduction Little is known of acupuncture patients' experiences and opinions of clinical trials, and what may influence their compliance when participating in an acupuncture trial. Objectives To explore the potential factors that influence patients' choice and determinants to participate in acupuncture clinical trials. Methods Ten qualitative, in-depth interviews were conducted with patients from acupuncture clinics in Beijing, who had previously participated in acupuncture clinical trials. Results Four main themes emerged from the interview data: effectiveness of the treatment, convenience of participating in a trial, doctor-participant communication, and participant acceptance of the treatment (or the trial). Effectiveness of acupuncture in treating the health condition was the most important factor for participant adherence. Pragmatics of treatment schedules, travel and attendance burden, together with confidence in the doctor's ability additionally influenced trial and treatment compliance. Conclusions In-depth interviews suggest that treatment effectiveness, the pragmatics of attending treatment sessions, and the expertise and attitudes of acupuncturists are determining factors of participation and compliance in acupuncture clinical trials. Participants' confidence in, and expectation of, acupuncture may facilitate compliance, while their fear of acupuncture and negative perceptions of the trial's purpose may reduce treatment compliance. Compliance may be facilitated by enhanced doctor-patient communication, personalized treatment programs, and feedback on treatment outcomes.	[Cao, Hui-Juan; Li, Xun; Liu, Jian-Ping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China; [Li, Xin-Lin] China Press Tradit Chinese Med, Beijing, Peoples R China; [Ward, Lesley] Northumbria Univ, Dept Sport Exercise & Rehabil, Newcastle Upon Tyne, Tyne & Wear, England; [Ward, Lesley] Univ Technol Sydney, Australian Res Ctr Complementary & Integrat Med, Ultimo, Australia; [Xie, Zhan-Guo] First Peoples Hosp Dongcheng Dist, Dept Acupuncture & Moxibust, Beijing, Peoples R China; [Hu, Hui] Beijing Univ Chinese Med, Dept Acupuncture & Metab Dis, Dongfang Hosp, Beijing, Peoples R China; [Zhang, Ya-Jing] Jiangxi Inst Tradit Chinese Med, Inst Informat & Literature, Nanchang, Jiangxi, Peoples R China	Beijing University of Chinese Medicine; Northumbria University; University of Technology Sydney; Beijing University of Chinese Medicine; Jiangxi University of Traditional Chinese Medicine	Cao, HJ; Liu, JP (corresponding author), Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China.	huijuancao327@hotmail.com; jianping_l@hotmail.com		Cao, Huijuan/0000-0003-3244-6288; Li, Xun/0000-0002-3513-5904; Ward, Lesley/0000-0001-7285-2032	National Natural Science Foundation of China [81804000]; Beijing Municipal Organization Department [2017000020124G292]; Key project of the National Natural Science Foundation of China [81830115]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Municipal Organization Department; Key project of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Hui-Juan Cao is supported by the National Natural Science Foundation of China (81804000) and the Beijing Municipal Organization Department (2017000020124G292). Jian-Ping Liu is supported by the Key project of the National Natural Science Foundation of China (No.81830115). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anneken C, 2001, EUR J MED RES, V6, P75; Cao HJ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/362831; Dziura James D., 2013, Yale Journal of Biology and Medicine, V86, P343; Gf L, 2012, J NURS TRAIN, V27, P926; Goh YL, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/871217; Hopton AK, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000456; Li XL, 2019, PATIENT PREFER ADHER, V13, P53, DOI 10.2147/PPA.S173202; [李欣霖 Li Xinlin], 2018, [中医杂志, Journal of Traditional Chinese Medicine], V59, P577; Liu Mai-Lan, 2012, Zhongguo Zhen Jiu, V32, P452; McDonald AM, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-9; Sully BGO, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-166; Sun Junjun, 2017, Zhongguo Zhen Jiu, V37, P1015, DOI 10.13703/j.0255-2930.2017.09.029; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Wang L, 2015, LIAONING J TRADITION, V42, P2399; Wang P, 2018, J TRADITIONAL CHINES, V59, P254; Wei J, 2014, BEIJING J TRADITIONA, V33, P97; Yin CS, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/635089	17	8	9	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2020	15	4							e0231780	10.1371/journal.pone.0231780	http://dx.doi.org/10.1371/journal.pone.0231780			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9JM	32298368	Green Accepted, Green Published, gold			2023-01-03	WOS:000536011400111
J	Moa, AM; Muscatello, DJ; Turner, RM; Macintyre, CR				Moa, Aye M.; Muscatello, David J.; Turner, Robin M.; Macintyre, C. Raina			Estimated hospitalisations attributable to seasonal and pandemic influenza in Australia: 2001-2013	PLOS ONE			English	Article							RESPIRATORY SYNCYTIAL VIRUS; VACCINE; DEATHS; METAANALYSIS; MORTALITY; COVERAGE; IMPACT	Background Influenza continues to cause seasonal epidemics and pandemics in humans. The burden of influenza is underestimated by traditional laboratory-based surveillance, and modelled estimates are required for influenza-attributable morbidity and mortality. We aimed to estimate the influenza-attributable hospitalisation in Australia, by influenza type. Methods A generalised-additive regression model was used to estimate type- and age-specific influenza-attributable hospitalisation rates per 100,000 population by principal diagnosis in Australia, from 2001 through 2013. Weekly counts of laboratory-confirmed influenza notifications and by type, influenza A and B were used as covariates in the model. Main principal diagnosis categories of interest were influenza and pneumonia and respiratory admissions. A smoothing spline was used to control for unmeasured time varying factors. Results for 2009, in which the pandemic influenza A(H1N1)pdm09 virus circulated, were not included in annual averages and are reported separately. Results During the study period, the estimated annual average, all-age, annual respiratory hospitalisation rates attributable to seasonal influenza type A, B and total influenza were 45.4 (95% CI: 34.9, 55.9), 32.6 (95% CI: 22.8, 42.4), and 76.9 (95% CI: 73.6, 80.2) per 100,000 population, respectively. During 2009, the estimated total pandemic influenza-attributable, all-age, respiratory hospitalisation rate was 56.1 (95% CI: 47.4, 64.9) per 100,000. Older adults (>= 85 years of age) experienced the highest influenza-attributable hospitalisation rates for both seasonal and 2009 pandemic influenza. Collinearity between influenza A and B time series in some years limited the ability of the model to resolve differences in influenza attribution between the two virus types. Conclusion Both seasonal and pandemic influenza caused considerable morbidity in Australia during the years studied, particularly among older adults. The pandemic hospitalisation rate in 2009 was lower than the average overall annual rate for seasonal influenza, but young to middle aged adults experience a hospitalisation rate similar to that of severe seasonal influenza.	[Moa, Aye M.; Macintyre, C. Raina] Univ New South Wales, Kirby Inst, Biosecur Program, Sydney, NSW, Australia; [Muscatello, David J.] Univ New South Wales, Fac Med, Sch Publ Hlth & Community Med, Sydney, NSW, Australia; [Turner, Robin M.] Univ Otago, Deans Off Dunedin Sch Med, Biostat Unit, Dunedin, New Zealand; [Macintyre, C. Raina] Arizona State Univ, Coll Publ Serv & Community Solut, Phoenix, AZ USA	University of New South Wales Sydney; Kirby Institute; University of New South Wales Sydney; University of Otago; Arizona State University; Arizona State University-Downtown Phoenix	Moa, AM (corresponding author), Univ New South Wales, Kirby Inst, Biosecur Program, Sydney, NSW, Australia.	a.moa@unsw.edu.au	Muscatello, David/HDO-2537-2022	MacIntyre, C Raina/0000-0002-3060-0555	Australian Government under the Research Training Program (RTP); NHMRC Principal Research Fellowship [1137582]	Australian Government under the Research Training Program (RTP); NHMRC Principal Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	Lab-confirmed influenza surveillance data were provided by the Department of Health, Australia. Time series hospitalisation data were retrieved from the Australian Institute of Health and Welfare (AIHW), National hospital morbidity database (NHMD), Australia. AMM received higher degree research scholarship support from the Australian Government under the Research Training Program (RTP) for her PhD. CRM is supported by a NHMRC Principal Research Fellowship, grant number 1137582.	ABS. Australian Bureau of Statistics, 2015, 3235 0 POP AG SEX RE; AIHW. Australian Institute of Health and Welfare, NAT HOSP MORB DAT NH; Australian Institute of Health and Welfare (AIHW), 2011, AD VACC SURV SUMM RE; Barnett AG, 2008, AUST NZ J PUBL HEAL, V32, P408, DOI 10.1111/j.1753-6405.2008.00270.x; Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8; Bishop JF, 2009, NEW ENGL J MED, V361, P2591, DOI 10.1056/NEJMp0910445; Caini S, 2015, INFLUENZA OTHER RESP, V9, P3, DOI 10.1111/irv.12319; Corvisy R, 2015, COMMUN DIS INTELL, V39, pE46; Davey HM, 2015, VACCINE, V33, P1726, DOI 10.1016/j.vaccine.2015.01.082; DoH, NAT NOT DIS SURV SYS; DoH, NAT NOT DIS SURV SYS; DoH. Australian Government Departemnt of Health, AUSTR IMM HDB; DoH. Australian Government Department of Health, 2016, NAT IMM PROGR SCHED; DoH. Australian Government Department of Health, AUSTR INFL SURV REP; Heikkinen T, 2014, CLIN INFECT DIS, V59, P1519, DOI 10.1093/cid/ciu664; Hull BP, 2017, COMMUN DIS INTELL, V41, pE68; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Khieu TQT, 2015, VACCINE, V33, P4087, DOI 10.1016/j.vaccine.2015.06.080; Matias G, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4177-z; Matias G, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3128-4; Moa AM, 2017, INFLUENZA OTHER RESP, V11, P102, DOI 10.1111/irv.12432; Moa AM, 2016, VACCINE, V34, P4092, DOI 10.1016/j.vaccine.2016.06.064; Muscatello DJ, 2019, J INFECTION, V78, P140, DOI 10.1016/j.jinf.2018.10.006; Muscatello DJ, 2017, WEST PAC SURVEILL RE, V8, DOI 10.5365/wpsar.2017.8.2.002; Muscatello DJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098446; Muscatello DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064734; NCIRS, HIST VACC AUSTR; Newall AT, 2008, VACCINE, V26, P6818, DOI 10.1016/j.vaccine.2008.09.086; Nicholson KG, 2003, LANCET, V362, P1733, DOI 10.1016/S0140-6736(03)14854-4; Owen R, 2008, COMMUN DIS INTELL, V32, P208; Rizzo C, 2007, EMERG INFECT DIS, V13, P694, DOI 10.3201/eid1305.061309; SASEG, SAS ENT GUID 6 1; Schanzer DL, 2013, INFLUENZA OTHER RESP, V7, P799, DOI 10.1111/irv.12011; Simonsen L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001558; Tempia S, 2015, EMERG INFECT DIS, V21, P600, DOI 10.3201/eid2104.141033; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; World Health Organization, INFL SEAS; Yohannes Keflemariam, 2004, Commun Dis Intell Q Rep, V28, P160; Zheng W, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-250; Zhou H, 2012, CLIN INFECT DIS, V54, P1427, DOI 10.1093/cid/cis211	41	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2020	15	4							e0230705	10.1371/journal.pone.0230705	http://dx.doi.org/10.1371/journal.pone.0230705			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9BE	32282849	Green Published, Green Submitted, gold			2023-01-03	WOS:000535989800006
J	Chavula, K; Guenther, T; Valsangkar, B; Lwesha, V; Banda, G; Wensaas, MB; Luhanga, R; Chimtembo, L; Kinney, MV; Dube, Q				Chavula, Kondwani; Guenther, Tanya; Valsangkar, Bina; Lwesha, Victoria; Banda, Gedesi; Wensaas, Marte Boe; Luhanga, Richard; Chimtembo, Lydia; Kinney, Mary, V; Dube, Queen			Improving Skin-to-Skin Practice for babies in Kangaroo Mother Care in Malawi through the use of a customized baby wrap: A randomized control trial	PLOS ONE			English	Article							BIRTH-WEIGHT INFANTS; BARRIERS	Background Complications of prematurity are a leading cause of newborn death in Malawi. Despite early adoption of Kangaroo mother care (KMC), coverage remains low and women have expressed challenges in using the traditional wrapper-chitenje. In 2016, a study was conducted to evaluate the acceptability and effectiveness of a customized KMC wrap in improving adherence to KMC practices among mothers. Methods Mother-baby dyads (301) were randomized to receive either a customized CarePlus Wrap developed by Laerdal Global Health or a traditional chitenje. Enrolled mother-baby dyads were assessed in the KMC ward at 2-3 days after of admission, and then again at 7-15 days post-discharge. Topics covered included skin-to-skin practices, breastfeeding, perceptions of the wrap, and family/community support. Chi square tests were used to assess associations between wrap type and KMC practices. The study received ethics approval. Results This study found that a customized KMC wrap is highly acceptable to women and improved skin-to-skin practices in facility-based KMC: 44% of mothers using a customized wrap reported 20 or more hours per day, compared to 33% of mothers using the traditional chitenje. Women using the customized wrap reported being comfortable in keeping the baby in skin-to-skin position more often than women using the chitenje (96% vs. 71%), and they were able to tie on the wrap themselves (86% vs. 10%). At the time of discharge from KMC, more women who used the customized wrap were satisfied with the wrap than those who used the traditional chitenje (94% vs. 56%). The customized wrap did not appear to impact other newborn practices, such as breastfeeding. Conclusions This study provides evidence that a customized KMC wrap is highly acceptable to mothers, and it can contribute to better skin-to-skin practices. Use of a customized wrap may be one mechanism to support mothers in practicing KMC and skin-to-skin contact in addition to other interventions.	[Chavula, Kondwani; Lwesha, Victoria; Banda, Gedesi; Luhanga, Richard; Chimtembo, Lydia] Save Children, Lilongwe, Malawi; [Guenther, Tanya; Valsangkar, Bina; Kinney, Mary, V] Save Children US, Dept Global Hlth, Washington, DC USA; [Wensaas, Marte Boe] Save Children, Oslo, Norway; [Dube, Queen] Univ Malawi, Coll Med, Blantyre, Malawi	Save the Children; Save the Children; Save the Children; University of Malawi	Chavula, K (corresponding author), Save Children, Lilongwe, Malawi.	Kondwani.Chavula@savethechildren.org	Valsangkar, Bina/CAF-1920-2022; Kinney, Mary/M-6952-2013	Kinney, Mary/0000-0002-2903-0161	Laerdal Global Health; Save the Children -Saving Newborn Lives	Laerdal Global Health; Save the Children -Saving Newborn Lives	Research was funded by Laerdal Global Health and implemented by Save the Children Norway, Malawi and US. The research, including the analysis and writing of the results, was also funded by Save the Children -Saving Newborn Lives. Any opinion, finding and conclusion, or recommendation expressed in this material is that of the authors. The funders did not influence the interpretation of the results.	Amaliya S, 2017, COMPR CHILD ADOLES N, V40, P52, DOI 10.1080/24694193.2017.1386971; Banda G, 2018, J DEV COMMUNICATION, V29; Blencowe H, 2009, J TROP PEDIATRICS, V55, P244, DOI 10.1093/tropej/fmn116; Chan G, 2017, HEALTH POLICY PLANN, V32, P1466, DOI 10.1093/heapol/czx098; Chavula K, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020802; Chisenga JZ, 2015, MIDWIFERY, V31, P305, DOI 10.1016/j.midw.2014.04.008; Conde-Agudelo A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002771.pub4; Dube Q, 2014, KMC ANAL MALAWI FIND; Dumbaugh M, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-269; Hasan R, 2017, FACILITY READINESS I; Joshi S, 2014, 10 INT C KANG MOTH C; Lawn JE, 2010, INT J EPIDEMIOL, pi1; Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8; Lydon M, 2018, J GLOB HEALTH, V8, DOI 10.7189/jogh.08.010703; Malawi Ministry of Health, 2015, MAL EV NEWB ACT PLAN; Malawi Ministry of Health, 2019, MAL NAT GUID KANG MO; Manjanja V, 2014, 10 INT C KANG MOTH C; Mazumder S, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5197-z; Nguah SB, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-99; Pratiwi IGAPE, 2009, PAEDIATR INDONES, V49, P253, DOI 10.14238/pi49.5.2009.253-8; Raajashri R, 2018, J MATERN-FETAL NEO M, V31, P666, DOI 10.1080/14767058.2017.1293035; Rai C., 2016, PROMOTING KANGAROO M; Save the Children, 2018, BRIEF EARL OUTC NEWB; Save the Children Malawi, 2018, BRIEF IMPR AV QUAL R; Seidman G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125643; Smith ER, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-016-0769-5; Suman RPN, 2008, INDIAN PEDIATR, V45, P17; Thapa K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207206; Van Rooyen E., 2007, GUIDELINES MOTHERS K; Watkins HC, 2018, ACTA PAEDIATR, V107, P1541, DOI 10.1111/apa.14344; World Health Organization, 2015, WHO RECOMMENDATIONS	31	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2020	15	3							e0229720	10.1371/journal.pone.0229720	http://dx.doi.org/10.1371/journal.pone.0229720			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ9FM	32191729	Green Published, gold			2023-01-03	WOS:000535302300015
J	Nteziyaremye, J; Iramiot, SJ; Nekaka, R; Musaba, MW; Wandabwa, J; Kisegerwa, E; Kiondo, P				Nteziyaremye, Julius; Iramiot, Stanley Jacob; Nekaka, Rebecca; Musaba, Milton W.; Wandabwa, Julius; Kisegerwa, Enoch; Kiondo, Paul			Asymptomatic bacteriuria among pregnant women attending antenatal care at Mbale Hospital, Eastern Uganda	PLOS ONE			English	Article							SUSCEPTIBILITY PATTERN; ESCHERICHIA-COLI; ENTEROBACTERIACEAE; PREVALENCE	Background Asymptomatic bacteriuria in pregnancy (ASBP) is associated with adverse pregnancy outcomes such as pyelonephritis, preterm or low birth weight delivery if untreated. The aim of this study was to determine the prevalence of asymptomatic bacteriuria, the isolated bacterial agents, and their antibiotic sensitivity patterns in pregnant women attending antenatal care at Mbale Hospital. Methods This was a cross sectional study in which 587 pregnant women with no symptoms and signs of urinary tract infection were recruited from January to March 2019. Mid-stream clean catch urine samples were collected from the women using sterile containers. The urine samples were cultured using standard laboratory methods. The bacterial colonies were identified and antibiotic sensitivity was done using disc diffusion method. Chi squared tests and logistic regression were done to identify factors associated with asymptomatic bacteriuria. A p value < 0.05 was considered statistically significant. Results Out of the 587 pregnant women, 22 (3.75%) tested positive for asymptomatic bacteriuria. Women aged 20-24 years were less likely to have ASBP when compared to women aged less than 20 years (AOR = 0.14, 95%CI 0.02-0.95, P = 0.004). The most common isolates in descending order were E. coli (n = 13, 46.4%) and S.aureus (n = 9, 32.1%). Among the gram negative isolates, the highest sensitivity was to gentamycin (82.4%) and imipenem (82.4%). The gram positive isolates were sensitive to gentamycin (90.9%) followed by imipenem (81.8%). All the isolates were resistant to sulphamethoxazole with trimethoprim (100%). Multidrug resistance was 82.4% among gram negative isolates and 72.4% among the gram positive isolates. Conclusion There was high resistance to the most commonly used antibiotics. There is need to do urine culture and sensitivity from women with ASBP so as to reduce the associated complications.	[Nteziyaremye, Julius; Kiondo, Paul] Makerere Univ, Coll Hlth Sci, Dept Obstet & Gynecol, Kampala, Uganda; [Nteziyaremye, Julius; Musaba, Milton W.; Wandabwa, Julius] Busitema Univ, Fac Hlth Sci, Dept Obstet & Gynecol, Mbale, Uganda; [Iramiot, Stanley Jacob] Busitema Univ, Fac Hlth Sci, Dept Microbiol & Immunol, Mbale, Uganda; [Nekaka, Rebecca] Busitema Univ, Fac Hlth Sci, Dept Community & Publ Hlth, Mbale, Uganda; [Kisegerwa, Enoch] Mulago Hosp, Dept Obstet & Gynecol, Kampala, Uganda	Makerere University; Mulago National Referral Hospital	Kiondo, P (corresponding author), Makerere Univ, Coll Hlth Sci, Dept Obstet & Gynecol, Kampala, Uganda.	kiondop@yahoo.com	Nekaka, Rebecca/GYQ-7546-2022; JacobStanley, Iramiot/AAN-4257-2020; Nteziyaremye, Julius/ABC-1324-2020	Nekaka, Rebecca/0000-0002-9199-7197; JacobStanley, Iramiot/0000-0002-9239-6641; Musaba, Milton/0000-0003-4145-4044				Adler A, 2016, INFECT DIS CLIN N AM, V30, P347, DOI 10.1016/j.idc.2016.02.003; Ali IE, 2018, TURK J UROL, V44, P251, DOI 10.5152/tud.2018.07741; Andabati G, 2010, AFR HEALTH SCI, V10, P349; Angelescu K, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1128-0; Ayoyi AO, 2017, PAN AFR MED J, V26, DOI 10.11604/pamj.2017.26.41.10975; (CLSI) CaLSI, 2015, M100S25 CLSI; Demilie T, 2012, ETHIOP J HEALTH SCI, V22, P121; Eksi F, 2011, J MICROBIOL IMMUNOL, V44, P57, DOI 10.1016/j.jmii.2011.01.011; Ekwealor Perpetua A, 2016, Int J Microbiol, V2016, P9740273, DOI 10.1155/2016/9740273; Emiru Tazebew, 2013, BMC Res Notes, V6, P292, DOI 10.1186/1756-0500-6-292; Farkash E, 2012, EUR J OBSTET GYN R B, V162, P24, DOI 10.1016/j.ejogrb.2012.01.024; Fredrick B., 2019, J ADV MED MED RES, V29, P1; Glaser AP, 2015, UROL CLIN N AM, V42, P547, DOI 10.1016/j.ucl.2015.05.004; Imade PE, 2010, N AM J MED SCI, V2, P263, DOI 10.4297/najms.2010.2263; Izuchukwu KE, 2017, PAN AFR MED J, V27, DOI 10.11604/pamj.2017.27.69.10492; Kazemier BM, 2015, LANCET INFECT DIS, V15, P1324, DOI 10.1016/S1473-3099(15)00070-5; Kibret M, 2011, AFR HEALTH SCI, V11, pS40; Masinde A, 2009, Tanzan J Health Res, V11, P154; Mohammed Ahmed, 2016, Afr Health Sci, V16, P69, DOI 10.4314/ahs.v16i1.9; Najjuka Christine F, 2016, BMC Res Notes, V9, P235, DOI 10.1186/s13104-016-2049-8; Oli AN, 2010, NIGER J CLIN PRACT, V13, P409; Owens DK, 2019, JAMA-J AM MED ASSOC, V322, P1188, DOI 10.1001/jama.2019.13069; Petersen I, 2010, J ANTIMICROB CHEMOTH, V65, P2238, DOI 10.1093/jac/dkq307; Prabhu Kavitha, 2011, J Lab Physicians, V3, P25, DOI 10.4103/0974-2727.78558; Renko M, 2011, DIABETES CARE, V34, P230, DOI 10.2337/dc10-0421; Ronald Mayanja PK, 2016, AM SCI RES J ENG TEC, V25, P131; SCHLESSELMAN JJ, 1974, AM J EPIDEMIOL, V99, P381, DOI 10.1093/oxfordjournals.aje.a121625; Smaill FM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000490.pub3; Stanley IJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200093; SUCAK A, 2011, ISRN OBSTET GYNECOLO, V2011, DOI DOI 10.5402/2011/721872; Sujatha R, 2014, J CLIN DIAGN RES, V8, pDC1, DOI 10.7860/JCDR/2014/6599.4205; Sultan A, 2015, UROL ANNALS, V7, P26, DOI 10.4103/0974-7796.148585; Tadesse Endale, 2014, BMC Res Notes, V7, P155, DOI 10.1186/1756-0500-7-155; Teklu DS, 2019, ANTIMICROB RESIST IN, V8, DOI 10.1186/s13756-019-0488-4; Wingert A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2017-021347; Yadav KK, 2015, ANTIMICROB RESIST IN, V4, DOI 10.1186/s13756-015-0085-0	36	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2020	15	3							e0230523	10.1371/journal.pone.0230523	http://dx.doi.org/10.1371/journal.pone.0230523			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ9FM	32191758	Green Published, gold			2023-01-03	WOS:000535302300055
J	Ma, S; Sun, SH; Geng, LL; Song, MS; Wang, W; Ye, YX; Ji, QZ; Zou, ZR; Wang, S; He, XJ; Li, W; Esteban, CR; Long, X; Guo, GJ; Chan, P; Zhou, Q; Belmonte, JCI; Zhang, WQ; Qu, J; Liu, GH				Ma, Shuai; Sun, Shuhui; Geng, Lingling; Song, Moshi; Wang, Wei; Ye, Yanxia; Ji, Qianzhao; Zou, Zhiran; Wang, Si; He, Xiaojuan; Li, Wei; Esteban, Concepcion Rodriguez; Long, Xiao; Guo, Guoji; Chan, Piu; Zhou, Qi; Belmonte, Juan Carlos Izpisua; Zhang, Weiqi; Qu, Jing; Liu, Guang-Hui			Caloric Restriction Reprograms the Single-Cell Transcriptional Landscape of Rattus Norvegicus Aging	CELL			English	Article							SPONTANEOUS TUMORIGENESIS; LIFE-SPAN; RNA-SEQ; MARROW; INFLAMMATION; VARIABILITY; NEUTROPHILS; DEFICIENCY; MECHANISMS; MEMORY	Aging causes a functional decline in tissues throughout the body that may be delayed by caloric restriction (CR). However, the cellular profiles and signatures of aging, as well as those ameliorated by CR, remain unclear. Here, we built comprehensive single-cell and single-nucleus transcriptomic atlases across various rat tissues undergoing aging and CR. CR attenuated aging-related changes in cell type composition, gene expression, and core transcriptional regulatory networks. Immune cells were increased during aging, and CR favorably reversed the aging-disturbed immune ecosystem. Computational prediction revealed that the abnormal cell-cell communication patterns observed during aging, including the excessive proinflammatory ligand-receptor interplay, were reversed by CR. Our work provides multi-tissue single-cell transcriptional landscapes associated with aging and CR in a mammal, enhances our understanding of the robustness of CR as a geroprotective intervention, and uncovers how metabolic intervention can act upon the immune system to modify the process of aging.	[Ma, Shuai; Song, Moshi; Wang, Wei; Ji, Qianzhao; Zou, Zhiran; Wang, Si; Liu, Guang-Hui] Chinese Acad Sci, Inst Zool, State Key Lab Membrane Biol, Beijing 100101, Peoples R China; [Ma, Shuai; Sun, Shuhui; Liu, Guang-Hui] Chinese Acad Sci, CAS Ctr Excellence Biomacromol, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; [Geng, Lingling; Ye, Yanxia; Zhou, Qi; Qu, Jing] Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China; [Geng, Lingling; Wang, Si; He, Xiaojuan; Li, Wei; Chan, Piu; Zhang, Weiqi; Liu, Guang-Hui] Capital Med Univ, Xuanwu Hosp, Adv Innovat Ctr Human Brain Protect, Beijing 100053, Peoples R China; [Geng, Lingling; Wang, Si; He, Xiaojuan; Li, Wei; Chan, Piu; Zhang, Weiqi; Liu, Guang-Hui] Capital Med Univ, Natl Clin Res Ctr Geriatr Disorders, Xuanwu Hosp, Beijing 100053, Peoples R China; [Song, Moshi; Ye, Yanxia; Wang, Si; Zhou, Qi; Zhang, Weiqi; Qu, Jing; Liu, Guang-Hui] Chinese Acad Sci, Inst Stem Cell & Regenerat, Beijing 100101, Peoples R China; [Song, Moshi; Wang, Wei; Ji, Qianzhao; Zou, Zhiran; Zhou, Qi; Zhang, Weiqi; Qu, Jing; Liu, Guang-Hui] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Esteban, Concepcion Rodriguez; Belmonte, Juan Carlos Izpisua] Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Long, Xiao] Peking Union Med Coll Hosp, Div Plast Surg, Beijing 100032, Peoples R China; [Guo, Guoji] Zhejiang Univ, Ctr Stem Cell & Regenerat Med, Sch Med, Hangzhou 310058, Peoples R China; [Zhang, Weiqi] Chinese Acad Sci, Beijing Inst Genom, Dis Genom & Individualized Med Lab, Beijing 100101, Peoples R China; [Zhang, Weiqi] China Natl Ctr Bioinformat, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Zoology, CAS; Capital Medical University; Capital Medical University; Chinese Academy of Sciences; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Salk Institute; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Zhejiang University; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS	Liu, GH (corresponding author), Chinese Acad Sci, Inst Zool, State Key Lab Membrane Biol, Beijing 100101, Peoples R China.; Liu, GH (corresponding author), Chinese Acad Sci, CAS Ctr Excellence Biomacromol, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.; Qu, J (corresponding author), Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China.; Zhang, WQ; Liu, GH (corresponding author), Capital Med Univ, Xuanwu Hosp, Adv Innovat Ctr Human Brain Protect, Beijing 100053, Peoples R China.; Zhang, WQ; Liu, GH (corresponding author), Capital Med Univ, Natl Clin Res Ctr Geriatr Disorders, Xuanwu Hosp, Beijing 100053, Peoples R China.; Zhang, WQ; Qu, J; Liu, GH (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Belmonte, JCI (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.; Zhang, WQ (corresponding author), Chinese Acad Sci, Beijing Inst Genom, Dis Genom & Individualized Med Lab, Beijing 100101, Peoples R China.; Zhang, WQ (corresponding author), China Natl Ctr Bioinformat, Beijing 100101, Peoples R China.	belmonte@salk.edu; zhangwq@big.ac.cr; qujing@ioz.ac.cn; ghliu@ioz.ac.cn	龙, 笑/GPW-6382-2022; Qu, Jing/ABB-9088-2020; Zou, Zhiran/GSI-9024-2022	Zhang, Weiqi/0000-0002-8885-5104; Guo, Guoji/0000-0002-1716-4621	National Key Research and Development Program of China [2018YFC2000100, 2018YFA0107203, 2017YFA0102802, 2017YFA0103304]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDA16010100]; National Natural Science Foundation of China [81921006, 81625009, 91749202, 81861168034, 31671429, 91949209, 81671377, 91749123, 81771515, 31601158, 81701388, 81601233, 31601109, 81822018, 81870228, 81801399, 31801010, 81801370, 81922027, 31900523, 81901432, 81901433, 31900524]; Program of Beijing Municipal Science and Technology Commission [Z191100001519005]; Beijing Natural Science Foundation [Z190019]; Beijing Municipal Commission of Health and Family Planning [PXM2018_026283_000002]; Advanced Innovation Center for HumanBrain Protection [3500-1192012]; K.C. Wong Education Foundation [GJTD-2019-06, GJTD-2019-08]; Key Research Program of the Chinese Academy of Sciences [KFZD-SW-221]; State Key Laboratory of StemCell and Reproductive Biology; State Key Laboratory of Membrane Biology; Moxie Foundation; Glenn Foundation	National Key Research and Development Program of China; Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program of Beijing Municipal Science and Technology Commission; Beijing Natural Science Foundation(Beijing Natural Science Foundation); Beijing Municipal Commission of Health and Family Planning; Advanced Innovation Center for HumanBrain Protection; K.C. Wong Education Foundation; Key Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); State Key Laboratory of StemCell and Reproductive Biology; State Key Laboratory of Membrane Biology; Moxie Foundation; Glenn Foundation	We thank Zhiheng He for his help in rat food intake. We thank Kai Du and Chunyu Chen from the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences for their help in animal breeding. We thank Jinghui Lei and Jingyi Jia for assisting with animal experiments. We thank Yifang He, Yaobin Jing, Zunpeng Liu, Zehua Wang, Jinghui Lei, Xuling Han, Yiyuan Zhang, Guoxing Liu, Xing Zhang, Yaxin Wang, Jingyi Jia, Liyun Zhao, and Zeming Wu for participating in the single-cell isolation from specific rat tissues. We thank Yandong Zheng and Jiaming Li for bioinformatic analysis. We are also grateful to Lei Bai, Ruijun Bai, Jing Lu, Qun Chu, Ying Yang, May Schwarz, and Shikun Ma for administrative assistance, to Junying Jia from Institute of Biophysics, Chinese Academy of Sciences for the fluorescence-activated cell sorting (FACS), and to Junfeng Hao from Institute of Biophysics, Chinese Academy of Sciences for image scanning and analysis of Hematoxylin and eosin (H&E) staining. We would like to thank Hezhen Shan for her assistance with frozen tissue sections. We thank Prof. Zhengwei Xie for his advice on manuscript writing. This work was supported by the National Key Research and Development Program of China (2018YFC2000100), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA16010100), the National Key Research and Development Program of China (2018YFA0107203, 2017YFA0102802, 2017YFA0103304), the National Natural Science Foundation of China (81921006, 81625009, 91749202, 81861168034, 31671429, 91949209, 81671377, 91749123, 81771515, 31601158, 81701388, 81601233, 31601109, 81822018, 81870228, 81801399, 31801010, 81801370, 81922027, 31900523, 81901432, 81901433, 31900524), Program of Beijing Municipal Science and Technology Commission (Z191100001519005), Beijing Natural Science Foundation (Z190019), Beijing Municipal Commission of Health and Family Planning (PXM2018_026283_000002), Advanced Innovation Center for HumanBrain Protection (3500-1192012), K.C. Wong Education Foundation (GJTD-2019-06, GJTD-2019-08), the Key Research Program of the Chinese Academy of Sciences (KFZD-SW-221), the State Key Laboratory of StemCell and Reproductive Biology, and the State Key Laboratory of Membrane Biology. J.C.I.B. was supported by the Moxie Foundation and the Glenn Foundation.	Ahmet I, 2011, J MOL CELL CARDIOL, V51, P263, DOI 10.1016/j.yjmcc.2011.04.015; Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/nmeth.4463, 10.1038/NMETH.4463]; Angelidis I, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08831-9; Anisimov VN, 2010, AGING-US, V2, P945, DOI 10.18632/aging.100245; Bi SR, 2018, MECH AGEING DEV, V175, P46, DOI 10.1016/j.mad.2018.07.005; Borregaard N, 2010, IMMUNITY, V33, P657, DOI 10.1016/j.immuni.2010.11.011; Buono R, 2019, CELL, V178, P1038, DOI 10.1016/j.cell.2019.07.052; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Campisi J, 2019, NATURE, V571, P183, DOI 10.1038/s41586-019-1365-2; Cheng F, 2019, PROTEIN CELL, V10, P846, DOI 10.1007/s13238-019-00659-9; Childs B, 2019, NATURE, V566, P46, DOI 10.1038/d41586-018-07553-0; Collins N, 2019, CELL, V178, P1088, DOI 10.1016/j.cell.2019.07.049; Contreras NA, 2018, GEROSCIENCE, V40, P279, DOI 10.1007/s11357-018-0022-2; Davie K, 2018, CELL, V174, P982, DOI 10.1016/j.cell.2018.05.057; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Di Giammartino DC, 2019, NAT CELL BIOL, V21, P1179, DOI 10.1038/s41556-019-0390-6; Dulken B, 2019, NATURE, V571, P205, DOI 10.1038/s41586-019-1362-5; Enge M, 2017, CELL, V171, P321, DOI 10.1016/j.cell.2017.09.004; Evrard M, 2018, IMMUNITY, V48, P364, DOI 10.1016/j.immuni.2018.02.002; Fontana L, 2015, CELL, V161, P106, DOI 10.1016/j.cell.2015.02.020; Forni MF, 2017, CELL REP, V20, P2678, DOI 10.1016/j.celrep.2017.08.052; Fujii N, 2019, EXP GERONTOL, V118, P55, DOI 10.1016/j.exger.2019.01.001; Geng LL, 2019, PROTEIN CELL, V10, P770, DOI 10.1007/s13238-019-0646-8; Glass CK, 2012, CELL METAB, V15, P635, DOI 10.1016/j.cmet.2012.04.001; Griffiths JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05083-x; Gu CF, 2013, CYTOKINE, V64, P477, DOI 10.1016/j.cyto.2013.07.022; Guo L, 2015, J BIOL CHEM, V290, P755, DOI 10.1074/jbc.R114.619957; Haase VH, 2015, KIDNEY INT, V88, P213, DOI 10.1038/ki.2015.89; Han XP, 2018, CELL, V172, P1091, DOI 10.1016/j.cell.2018.02.001; Huynh-Thu VA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012776; Jackaman C, 2017, AGEING RES REV, V36, P105, DOI 10.1016/j.arr.2017.03.008; Jordan S, 2019, CELL, V178, P1102, DOI 10.1016/j.cell.2019.07.050; Jung N, 2019, BIOCHEM PHARMACOL, V165, P170, DOI 10.1016/j.bcp.2019.03.010; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kretov DA, 2019, NUCLEIC ACIDS RES, V47, P3127, DOI 10.1093/nar/gky1303; Krishnaswami SR, 2016, NAT PROTOC, V11, P499, DOI 10.1038/nprot.2016.015; Lake BB, 2016, SCIENCE, V352, P1586, DOI 10.1126/science.aaf1204; Levay EA, 2007, PHYSIOL BEHAV, V92, P889, DOI 10.1016/j.physbeh.2007.06.018; LEVINE BL, 1995, INT IMMUNOL, V7, P891, DOI 10.1093/intimm/7.6.891; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liu YC, 2014, INT J BIOL SCI, V10, P520, DOI 10.7150/ijbs.8879; Lomako VV, 2019, ADV GERONTOL, V9, P298, DOI 10.1134/S2079057019030093; Lopez-Lluch G, 2016, J PHYSIOL-LONDON, V594, P2043, DOI 10.1113/JP270543; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ma Y., 2018, TRANSL RES, V191, P15; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Mahmoudi S, 2019, NATURE, V574, P553, DOI 10.1038/s41586-019-1658-5; Martinez-Jimenez CP, 2017, SCIENCE, V355, P1433, DOI 10.1126/science.aah4115; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; McGinnis CS, 2019, CELL SYST, V8, P329, DOI 10.1016/j.cels.2019.03.003; Menard C, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00081; Nagai M, 2019, CELL, V178, P1072, DOI 10.1016/j.cell.2019.07.047; Niederberger C, 2018, FERTIL STERIL, V110, P185, DOI 10.1016/j.fertnstert.2018.06.005; Oh HJ, 2016, NEUROPSYCHOPHARMACOL, V41, P3080, DOI 10.1038/npp.2016.126; Papalexi E, 2018, NAT REV IMMUNOL, V18, P35, DOI 10.1038/nri.2017.76; Pazhakh V, 2017, SCI REP-UK, V7, DOI 10.1038/srep44455; Pifferi F, 2019, PROG NEURO-PSYCHOPH, V95, DOI 10.1016/j.pnpbp.2019.109702; Pioli PD, 2019, IMMUNITY, V51, P351, DOI 10.1016/j.immuni.2019.06.006; Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/NMETH.4402, 10.1038/nmeth.4402]; Reckless J, 2001, IMMUNOLOGY, V103, P244, DOI 10.1046/j.1365-2567.2001.01228.x; Redman LM, 2018, CELL METAB, V27, P805, DOI 10.1016/j.cmet.2018.02.019; Rhoads TW, 2018, CELL METAB, V27, P677, DOI 10.1016/j.cmet.2018.01.014; Rojek A, 2013, AM J PHYSIOL-GASTR L, V304, pG501, DOI 10.1152/ajpgi.00208.2012; Roszer T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/816460; Sarkar D, 2006, CANCER LETT, V236, P13, DOI 10.1016/j.canlet.2005.04.009; Schaum N, 2018, NATURE, V562, P367, DOI 10.1038/s41586-018-0590-4; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Spindler SR, 2010, AGEING RES REV, V9, P324, DOI 10.1016/j.arr.2009.10.003; Talukdar S, 2012, NAT MED, V18, P1407, DOI 10.1038/nm.2885; Tang FC, 2009, NAT METHODS, V6, P377, DOI [10.1038/nmeth.1315, 10.1038/NMETH.1315]; Tangye SG, 2011, TRENDS IMMUNOL, V32, P595, DOI 10.1016/j.it.2011.09.001; Trim W, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00169; Vento-Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586-018-0698-6; Verfaillie A., 2015, CURR PROTOC BIOINFOR, V52, P1; Wang S, 2020, CELL, V180, P585, DOI 10.1016/j.cell.2020.01.009; Wang S, 2020, PROTEIN CELL, V11, P1, DOI 10.1007/s13238-019-0623-2; Wang Z, 2018, ONCOGENE, V37, P18, DOI 10.1038/onc.2017.310; Wasinski F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/395672; Wickham H., 2016, GGPLOT2 ELEGANT GRAP, DOI [10.1007/978-3-319-24277-4, DOI 10.1007/978-3-319-24277-4]; Wood SH, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0847-2; Zhang R, 2015, CELL SYST, V1, P180, DOI 10.1016/j.cels.2015.09.002; Zhang WQ, 2020, NAT REV MOL CELL BIO, V21, P137, DOI 10.1038/s41580-019-0204-5; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6; Zou K, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3483-2	86	101	107	19	118	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 5	2020	180	5					984	+		10.1016/j.cell.2020.02.008	http://dx.doi.org/10.1016/j.cell.2020.02.008			40	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KT7JN	32109414	Bronze			2023-01-03	WOS:000519189800016
J	Choi, J; Lee, D; Shim, JH; Kim, KM; Lim, YS; Lee, YS; Lee, HC				Choi, Jonggi; Lee, Danbi; Shim, Ju Hyun; Kim, Kang Mo; Lim, Young-Suk; Lee, Yung Sang; Lee, Han Chu			Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma	PLOS ONE			English	Article							CLINICAL-PRACTICE GUIDELINES; KINKI CRITERIA; MANAGEMENT; SORAFENIB; SUBCLASSIFICATION; VALIDATION; EFFICACY	Background & aim In clinical practice, transarterial chemoembolization (TACE) has been widely used for the treatment of hepatocellular carcinoma (HCC) beyond as well as within guideline recommendations. Here we aimed to verify whether two consecutive non-responses could be an optimal criterion for creating a rule to stop TACE being performed on these patients. Methods This study evaluated 200 patients with HCC beyond the Milan criteria, initially treated with TACE. TACE response was determined using the mRECIST criteria via dynamic CT or MRI. Median follow-up duration was 23.9 months. Results Within the 200 patients analyzed, 183 (91.5%) were male, with a total median age of 59.8 years. The mean size of the largest tumor was 6.8 cm, with 80 (40.0%) patients with >= 4 tumors. After the first TACE procedure, complete response, partial response, stable disease, or progressive disease were observed in 48 (24.0%), 87 (43.5%), 59 (29.5%) and 6 (3.0%) of patients, respectively. 45 (22.5%) patients showed no objective response (OR) following two consecutive TACE sessions. Of these, 28 received a subsequent TACE, with a 10.7% OR rate. Patients without OR showed poorer survival when compared to patients who achieved OR after repeated TACE. Multivariable analysis showed that size of the largest tumor > 5cm and high alpha-fetoprotein of > 200 ng/mL were significant factors associated with failure of OR to two consecutive TACE sessions. Conclusion Patients showing no OR to two consecutive TACE sessions will present a poor OR to subsequent TACE procedures. Early transition to systemic therapy may be advocated in such cases.	[Choi, Jonggi; Lee, Danbi; Shim, Ju Hyun; Kim, Kang Mo; Lim, Young-Suk; Lee, Yung Sang; Lee, Han Chu] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol,Liver Ctr, Seoul, South Korea	University of Ulsan; Asan Medical Center	Lee, HC (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol,Liver Ctr, Seoul, South Korea.	hch@amc.seoul.kr	Choi, Jonggi/L-1521-2019	Lim, Young-Suk/0000-0002-1544-577X; Lee, Han Chu/0000-0002-7631-4124	Bayer	Bayer(Bayer AG)	This study was supported by grants from Bayer. However, Bayer had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript. The final decision on content was exclusively retained by the authors.	Arizumi T, 2017, DIGEST DIS, V35, P589, DOI 10.1159/000480208; Arizumi T, 2015, LIVER CANCER, V4, P253, DOI 10.1159/000367743; Arizumi T, 2015, ONCOLOGY-BASEL, V89, P47, DOI 10.1159/000440631; Chung SR, 2015, J VASC INTERV RADIOL, V26, P1130, DOI 10.1016/j.jvir.2015.05.006; European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019; Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086; Ikeda M, 2014, J GASTROENTEROL, V49, P932, DOI 10.1007/s00535-013-0853-7; Kim JH, 2018, LIVER INT, V38, P1646, DOI 10.1111/liv.13719; Kim JH, 2017, LIVER INT, V37, P1861, DOI 10.1111/liv.13487; Kudo M, 2016, LIVER INT, V36, P1196, DOI 10.1111/liv.13096; Kudo M, 2015, DIGEST DIS, V33, P751, DOI 10.1159/000439290; Kudo M, 2014, LIVER CANCER, V3, P458, DOI 10.1159/000343875; Lencioni R, 2016, J HEPATOL, V64, P1090, DOI 10.1016/j.jhep.2016.01.012; Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156; MATSUI O, 1993, RADIOLOGY, V188, P79, DOI 10.1148/radiology.188.1.8390073; Miyayama S, 2016, J VASC INTERV RADIOL, V27, P1269, DOI 10.1016/j.jvir.2016.04.014; Ogasawara S, 2014, ONCOLOGY-BASEL, V87, P330, DOI 10.1159/000365993; Omata M, 2017, HEPATOL INT, V11, P317, DOI 10.1007/s12072-017-9799-9; Park JW, 2015, LIVER INT, V35, P2155, DOI 10.1111/liv.12818; Peck-Radosavljevic M, 2018, OUTCOMES PATIENTS PT; Shim JH, 2013, J VASC INTERV RADIOL, V24, P316, DOI 10.1016/j.jvir.2012.10.022; Shim JH, 2012, RADIOLOGY, V262, P708, DOI 10.1148/radiol.11110282	25	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2020	15	3							e0229696	10.1371/journal.pone.0229696	http://dx.doi.org/10.1371/journal.pone.0229696			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8QU	32130270	Green Published, gold			2023-01-03	WOS:000535264000044
J	Wall, A; Borg, J; Vreede, K; Palmcrantz, S				Wall, Anneli; Borg, Jorgen; Vreede, Katarina; Palmcrantz, Susanne			A randomized controlled study incorporating an electromechanical gait machine, the Hybrid Assistive Limb, in gait training of patients with severe limitations in walking in the subacute phase after stroke	PLOS ONE			English	Article							HEMIPARETIC PATIENTS; RECOVERY; ROBOT; REHABILITATION; RELIABILITY; IMPROVEMENT; VALIDATION; AMBULATION; ASSISTANCE; THERAPY	Early onset, intensive and repetitive, gait training may improve outcome after stroke but for patients with severe limitations in walking, rehabilitation is a challenge. The Hybrid Assistive Limb (HAL) is a gait machine that captures voluntary actions and support gait motions. Previous studies of HAL indicate beneficial effects on walking, but these results need to be confirmed in blinded, randomized controlled studies. This study aimed to explore effects of incorporating gait training with HAL as part of an inpatient rehabilitation program after stroke. Thirty-two subacute stroke patients with severe limitations in walking were randomized to incorporated HAL training (4 days/week for 4 weeks) or conventional gait training only. Blinded assessments were carried out at baseline, after the intervention, and at 6 months post stroke. The primary outcome was walking independence according to the Functional Ambulation Categories. Secondary outcomes were the Fugl-Meyer Assessment, 2-Minute Walk Test, Berg Balance Scale, and the Barthel Index. No significant between-group differences were found regarding any primary or secondary outcomes. At 6 months, two thirds of all patients were independent in walking. Prediction of independent walking at 6 months was not influenced by treatment group, but by age (OR 0.848, CI 0.719-0.998, p = 0.048). This study found no difference between groups for any outcomes despite the extra resources required for the HAL training, but highlights the substantial improvements in walking seen when evidence-based rehabilitation is provided to patients, with severe limitations in walking in the subacute stage after stroke. In future studies potential subgroups of patients who will benefit the most from electromechanically-assisted gait training should be explored.	[Wall, Anneli; Borg, Jorgen; Vreede, Katarina; Palmcrantz, Susanne] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Div Rehabil Med, Stockholm, Sweden	Danderyds Hospital; Karolinska Institutet	Wall, A (corresponding author), Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Div Rehabil Med, Stockholm, Sweden.	anneli.wall@sll.se			Promobilia Foundation [16096, 17097, 17066]; STROKE-Riksforbundet; NEURO Sweden; Norrbacka-Eugenia Foundation [865/16]; Karolinska Institutet [2-1582/2016]	Promobilia Foundation; STROKE-Riksforbundet; NEURO Sweden; Norrbacka-Eugenia Foundation; Karolinska Institutet(Karolinska Institutet)	This work was supported with grants from the Promobilia Foundation (16096, 17097, 17066) (AW), STROKE-Riksforbundet (na)(AW), NEURO Sweden (na) (AW), the Norrbacka-Eugenia Foundation (865/16) (AW), and a donation by Lars Hedlund (Karolinska Institutet Dnr 2-1582/2016) (JB). HAL suits were provided by Cyberdyne Inc., Japan. The study sponsors were not involved in the study design, data collection, analysis and interpretation of data, in writing the manuscript, or in the decision to submit the manuscript for publication. https://www.promobilia.se http://www.strokeforbundet.se https://neuro.se/http://www.norrbacka-eugenia.se/.	Alguren B, 2010, DISABIL REHABIL, V32, P551, DOI 10.3109/09638280903186335; BERG K, 1989, Physiotherapy Canada, V41, P304; BERG KO, 1992, ARCH PHYS MED REHAB, V73, P1073; Bowden MG, 2013, CURR OPIN NEUROL, V26, P37, DOI 10.1097/WCO.0b013e32835c5ba0; Chang WH, 2012, NEUROREHAB NEURAL RE, V26, P318, DOI 10.1177/1545968311408916; Diaz I, 2011, J ROBOT, V2011, DOI 10.1155/2011/759764; Dobkin BH, 2009, CURR OPIN NEUROL, V22, P563, DOI 10.1097/WCO.0b013e3283314b11; Fukuda H, 2015, NEUROL MED-CHIR, V55, P487, DOI 10.2176/nmc.oa.2014-0431; Govan L, 2009, STROKE, V40, P3396, DOI 10.1161/STROKEAHA.109.557645; Han EY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005078; Hesse S, 2012, J REHABIL RES DEV, V49, P613, DOI 10.1682/JRRD.2011.08.0142; Hidler Joseph, 2011, Top Spinal Cord Inj Rehabil, V17, P42; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; Hornby TG, 2016, CURR OPIN NEUROL, V29, P677, DOI 10.1097/WCO.0000000000000397; Hornby TG, 2016, NEUROREHAB NEURAL RE, V30, P440, DOI 10.1177/1545968315604396; Husemann B, 2007, STROKE, V38, P349, DOI 10.1161/01.STR.0000254607.48765.cb; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; Katz BS, 2015, STROKE, V46, P1508, DOI 10.1161/STROKEAHA.115.008804; Kawamoto H., 2002, Computers Helping People with Special Needs 8th International Conference, ICCHP 2002. Proceedings (Lecture Notes in Computer Science Vol.2398), P196; Kawamoto H, 2010, IEEE ENG MED BIO, P462, DOI 10.1109/IEMBS.2010.5626191; Kim SY, 2015, IEEE T NEUR SYS REH, V23, P1128, DOI 10.1109/TNSRE.2015.2497058; Kirtley C, 2006, CLIN GAIT ANAL THEOR; Kollen B, 2005, STROKE, V36, P2676, DOI 10.1161/01.STR.0000190839.29234.50; Kosak M, 2005, J REHABIL RES DEV, V42, P103, DOI 10.1682/JRRD.2003.11.0171; Krakauer JW, 2012, NEUROREHAB NEURAL RE, V26, P923, DOI 10.1177/1545968312440745; Kwah LK, 2013, J PHYSIOTHER, V59, P189, DOI 10.1016/S1836-9553(13)70183-8; Kwakkel G, 2004, RESTOR NEUROL NEUROS, V22, P281; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Levin MF, 2009, NEUROREHAB NEURAL RE, V23, P313, DOI 10.1177/1545968308328727; Lohse KR, 2014, STROKE, V45, P2053, DOI 10.1161/STROKEAHA.114.004695; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; MAHONEY F I, 1965, Md State Med J, V14, P61; Mayr A, 2018, EUR J PHYS REHAB MED, V54, P819, DOI 10.23736/S1973-9087.18.04832-3; Mehrholz J, 2007, ARCH PHYS MED REHAB, V88, P1314, DOI 10.1016/j.apmr.2007.06.764; Mehrholz J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub4; Morone G, 2018, RESTOR NEUROL NEUROS, V36, P293, DOI 10.3233/RNN-170799; Nilsson A, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-92; Ochi M, 2015, J NEUROL SCI, V353, P130, DOI 10.1016/j.jns.2015.04.033; Pennycott A, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-65; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Peurala SH, 2014, J REHABIL MED, V46, P387, DOI 10.2340/16501977-1805; Schneider EJ, 2016, J PHYSIOTHER, V62, P182, DOI 10.1016/j.jphys.2016.08.006; Schwartz I, 2009, PM&R, V1, P516, DOI 10.1016/j.pmrj.2009.03.009; Smith MC, 2017, NEUROREHAB NEURAL RE, V31, P955, DOI 10.1177/1545968317736820; Stinear CM, 2017, STROKE, V48, P1011, DOI 10.1161/STROKEAHA.116.015790; Suzuki K, 2007, ADV ROBOTICS, V21, P1441, DOI 10.1163/156855307781746061; Taveggia G, 2016, INT J REHABIL RES, V39, P29, DOI 10.1097/MRR.0000000000000137; van Nunen MPM, 2015, DISABIL REHABIL-ASSI, V10, P141, DOI 10.3109/17483107.2013.873489; Veerbeek JM, 2011, NEUROREHAB NEURAL RE, V25, P268, DOI 10.1177/1545968310384271; Veerbeek JM, 2011, STROKE, V42, P3311, DOI 10.1161/STROKEAHA.111.623819; Wall A, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00048; Watanabe H, 2017, NEUROREHABILITATION, V40, P363, DOI 10.3233/NRE-161424; Watanabe H, 2014, ARCH PHYS MED REHAB, V95, P2006, DOI 10.1016/j.apmr.2014.07.002; World Health Organisation, 2001, ICF INT CLASFUNCT; Yoshikawa K, 2017, NEUROREHABILITATION, V40, P87, DOI 10.3233/NRE-161393	57	10	11	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2020	15	2							e0229707	10.1371/journal.pone.0229707	http://dx.doi.org/10.1371/journal.pone.0229707			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8HR	32109255	Green Published, gold, Green Submitted			2023-01-03	WOS:000535239800023
J	Allen, TE; Morere, DA				Allen, Thomas E.; Morere, Donna A.			Early visual language skills affect the trajectory of literacy gains over a three-year period of time for preschool aged deaf children who experience signing in the home	PLOS ONE			English	Article							HARD-OF-HEARING; READING-COMPREHENSION; PHONOLOGICAL AWARENESS; ACADEMIC-ACHIEVEMENT; EMERGENT LITERACY; ASL; STUDENTS; WORD; KINDERGARTEN; PREDICTORS	Previous research has established a correlation between literacy skills and sign language skills among deaf children raised in signing families, but little research has examined the impact of early signing skills on the rate of growth of emergent literacy in early childhood. A subset of data was extracted from a larger dataset containing national longitudinal data from a three-year investigation of early literacy development of deaf children who were between the ages of three and six at the outset of the study. Selection criteria for inclusion in this limited sample included: 1) being rated as having little or no access to spoken language and 2) being raised in homes in which signs were regularly used as a means of communication (N = 56). Our purpose was twofold: 1) to examine and describe the trajectories of growth in letter and word identification skill for this sample in relation to the participants' initial ages; and 2) to assess the degree to which the presence or deaf parents in the home (DoD) and the receptive American Sign Language (ASL) skills of the participants impacted both the level of emerging print literacy and its rate of growth over the three year period. We hypothesized that both the presence of a deaf parent in the home and the acquisition of ASL skills, a strong native language, would contribute to both the overall letter and word identification skills and to the rates of growth of this skill over time. Results indicated that having a deaf parent did, indeed, impact emergent literacy attainment, but its effect was rendered nonsignificant when ASL skill was taken into consideration. Possession of stronger ASL skills, whether or not the children had deaf parents, contributed significantly to both the levels and rate of growth. The findings contribute to the body of work that emphasizes the importance early language skills (spoken or signed) to later academic success and dispels the myth that deaf children with deaf parents have exclusive access to the acquisition of these skills.	[Allen, Thomas E.; Morere, Donna A.] Gallaudet Univ, Sci Learning Ctr Visual Language & Visual Learnin, Washington, DC 20002 USA; [Allen, Thomas E.] Gallaudet Univ, PhD Educ Neurosci Program, Washington, DC 20002 USA; [Morere, Donna A.] Gallaudet Univ, Dept Psychol, Washington, DC 20002 USA		Allen, TE (corresponding author), Gallaudet Univ, Sci Learning Ctr Visual Language & Visual Learnin, Washington, DC 20002 USA.; Allen, TE (corresponding author), Gallaudet Univ, PhD Educ Neurosci Program, Washington, DC 20002 USA.	thomas.allen@gallaudet.edu		Allen, Thomas/0000-0002-1545-8853	National Science Foundation Science of Learning Center Program under Gallaudet University [SBE-0541953, SBE-1041725]	National Science Foundation Science of Learning Center Program under Gallaudet University	Support was provided by the National Science Foundation Science of Learning Center Program under Cooperative Agreements with Gallaudet University, SBE-0541953 (TEA, Principal Investigator) and SBE-1041725 (TEA and Laura Ann Petitto, Co-Principal Investigators). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adlof SM, 2010, J LEARN DISABIL-US, V43, P332, DOI 10.1177/0022219410369067; Allen T., 1986, DEAF CHILDREN AM, P161, DOI DOI 10.1177/15257401050270010201; Allen T., 2012, ASSESSING LITERACY D, P231; Allen T, 2014, VL2 EARLY ED LONGITU; Allen TE, 2013, SIGN LANG STUD, V14, P233; Allen TE, 2015, SIGN LANG STUD, V15, P233, DOI 10.1353/sls.2015.0006; Allen TE, 2014, AM ANN DEAF, V159, P346, DOI 10.1353/aad.2014.0030; Andrews J. F., 2016, PSYCHOLOGY, V7, P510, DOI [10.4236/psych.2016.74052, DOI 10.4236/PSYCH.2016.74052]; Chamberlain C, 2008, APPL PSYCHOLINGUIST, V29, P367, DOI 10.1017/S014271640808017X; Colin S, 2007, J CHILD PSYCHOL PSYC, V48, P139, DOI 10.1111/j.1469-7610.2006.01700.x; DeLana M, 2007, AM ANN DEAF, V152, P73, DOI 10.1353/aad.2007.0010; Dickinson DK, 2010, EDUC RESEARCHER, V39, P305, DOI 10.3102/0013189X10370204; Easterbrooks SR, 2008, VOLTA REV, V108, P91; Enns CJ, 2011, J DEAF STUD DEAF EDU, V16, P362, DOI 10.1093/deafed/enr004; Fernald A, 2013, DEVELOPMENTAL SCI, V16, P234, DOI 10.1111/desc.12019; Gallaudet Research Institute, 2011, REG NAT SUMM REP DAT; Goldin-Meadow S, 2014, AM PSYCHOL, V69, P588, DOI 10.1037/a0036886; Hall ML, 2019, DEAF CHILDREN NEED L; Harris M, 1998, J Deaf Stud Deaf Educ, V3, P205; Harris M, 2017, J DEAF STUD DEAF EDU, V22, P233, DOI 10.1093/deafed/enw101; Hoffmeister R, 1997, P DEAF STUD 5 C; Hoffmeister RJ, 2014, COGNITION, V132, P229, DOI 10.1016/j.cognition.2014.03.014; Holmer E, 2016, RES DEV DISABIL, V48, P145, DOI 10.1016/j.ridd.2015.10.008; Hrastinski I, 2016, J DEAF STUD DEAF EDU, V21, P156, DOI 10.1093/deafed/env072; Jaffe L. E., 2009, WOODCOCK JOHNSON 3 A, V11; Kyle FE, 2011, J DEAF STUD DEAF EDU, V16, P289, DOI 10.1093/deafed/enq069; Kyle FE, 2010, J EXP CHILD PSYCHOL, V107, P229, DOI 10.1016/j.jecp.2010.04.011; Lederberg AR, 2019, J DEAF STUD DEAF EDU, V24, P408, DOI 10.1093/deafed/enz011; Lederberg AR, 2013, DEV PSYCHOL, V49, P15, DOI 10.1037/a0029558; Mayberry RI, 2011, J DEAF STUD DEAF EDU, V16, P164, DOI 10.1093/deafed/enq049; MAYBERRY RI, 1991, J MEM LANG, V30, P486, DOI 10.1016/0749-596X(91)90018-F; Mayer C, 2007, J DEAF STUD DEAF EDU, V12, P411, DOI 10.1093/deafed/enm020; McGrew KS, 2014, TECHNICAL MANUAL; McQuarrie L, 2013, SIGN LANG STUD, V14, P80, DOI 10.1353/sls.2013.0028; Moats L., 2009, LANGUAGE ESSENTIALS; Moreno-Perez FJ, 2015, J DEAF STUD DEAF EDU, V20, P374, DOI 10.1093/deafed/env030; National Reading Panel (U.S.) & National Institute of Child Health and Human Development (U.S.) ., 2000, REP NAT READ PAN TEA; Novogrodsky R, 2014, SIGN LANG STUD, V14, P225, DOI 10.1353/sls.2014.0003; Novogrodsky R, 2014, LANG LEARN, V64, P749, DOI 10.1111/lang.12078; Petitto LA, 2016, WIRES COGN SCI, V7, P366, DOI 10.1002/wcs.1404; Petitto LA, 2000, SIGNS OF LANGUAGE REVISITED, P449; Prinz PM, 1998, TOP LANG DISORD, V18, P47; Qi S, 2012, J DEAF STUD DEAF EDU, V17, P1, DOI 10.1093/deafed/enr028; Raver CC, 1996, DEV PSYCHOL, V32, P850, DOI 10.1037/0012-1649.32.5.850; Schrank F. A., 2001, WOODCOCK JOHNSON 3 A, V2; Scott JA, 2017, J DEAF STUD DEAF EDU, V22, P59, DOI 10.1093/deafed/enw065; Singer J., 2003, APPL LONGITUDINAL DA; Singleton JL, 1998, TOP LANG DISORD, V18, P16; Stone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139610; Strong M, 2000, LANGUAGE ACQUISITION BY EYE, P131; Wauters LN, 2006, READ WRIT, V19, P49, DOI 10.1007/s11145-004-5894-0; Wilbur R B, 2000, J Deaf Stud Deaf Educ, V5, P81, DOI 10.1093/deafed/5.1.81; Woodcock R.W., 2001, WOODCOCK JOHNSON 3 N; Woodcock R.W., 2007, INT J NEUROSCI, DOI DOI 10.1080/00207450500535453; Worsfold S, 2018, RES DEV DISABIL, V77, P49, DOI 10.1016/j.ridd.2018.04.007	55	8	8	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2020	15	2							e0229591	10.1371/journal.pone.0229591	http://dx.doi.org/10.1371/journal.pone.0229591			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8GQ	32106252	Green Published, gold			2023-01-03	WOS:000535237000047
J	Rossler, B; Goschin, J; Maleczek, M; Piringer, F; Thell, R; Mittlbock, M; Schebesta, K				Roessler, Bernhard; Goschin, Julius; Maleczek, Mathias; Piringer, Felix; Thell, Rainer; Mittlboeck, Martina; Schebesta, Karl			Providing the best chest compression quality: Standard CPR versus chest compressions only in a bystander resuscitation model	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; BASIC LIFE-SUPPORT; EARLY DEFIBRILLATION; GUIDELINES; DEPTH	Aim of the study Bystander-initiated basic life support (BLS) for the treatment of prehospital cardiac arrest increases survival but is frequently not performed due to fear and a lack of knowledge. A simple flowchart can improve motivation and the quality of performance. Furthermore, guidelines do recommend a chest compression (CC)-only algorithm for dispatcher-assisted bystander resuscitation, which may lead to increased fatigue and a loss of compression depth. Consequently, we wanted to test the hypothesis that CCs are more correctly delivered in a flowchart-assisted standard resuscitation algorithm than in a CC-only algorithm. Methods With the use of a manikin model, 84 laypersons were randomized to perform either flowchart-assisted standard resuscitation or CC-only resuscitation for 5min. The primary outcome was the total number of CCs. Results The total number of correct CCs did not significantly differ between the CC-only group and the standard group (63 [+/- 81] vs. 79 [+/- 86]; p = 0.394; 95% CI of difference: 21-53). The total hand-off time was significantly lower in the CC-only group than in the standard BLS group. The relative number of correct CCs (the fraction of the total number of CCs achieving 5-6cm) and the level of exhaustion after BLS did not significantly differ between the groups. Conclusion Standard BLS did not lead to an increase in correctly delivered CCs compared to CC-only resuscitation and exhibited significantly more hand-off time. The low rate of CCs in both groups indicates the need for an increased focus on performance during BLS training.	[Roessler, Bernhard; Goschin, Julius; Maleczek, Mathias; Schebesta, Karl] Med Univ Vienna, Univ Dept Anaesthesia Intens Care Med & Pain Med, Med Simulat & Emergency Management Res Grp, Vienna, Austria; [Roessler, Bernhard; Schebesta, Karl] Med Univ Vienna, Acad Simulat Ctr Vienna, Vienna, Austria; [Roessler, Bernhard; Schebesta, Karl] Vienna Hosp Assoc, Vienna, Austria; [Maleczek, Mathias; Piringer, Felix; Thell, Rainer] St John Ambulance, Vienna, Austria; [Mittlboeck, Martina] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Schebesta, K (corresponding author), Med Univ Vienna, Univ Dept Anaesthesia Intens Care Med & Pain Med, Med Simulat & Emergency Management Res Grp, Vienna, Austria.; Schebesta, K (corresponding author), Med Univ Vienna, Acad Simulat Ctr Vienna, Vienna, Austria.; Schebesta, K (corresponding author), Vienna Hosp Assoc, Vienna, Austria.	karl.schebesta@meduniwien.ac.at	Schebesta, Karl/V-4626-2019	Mittlboeck, Martina/0000-0003-1097-4047; Maleczek, Mathias/0000-0002-1431-0742				Carifio J, 2008, MED EDUC, V42, P1150, DOI 10.1111/j.1365-2923.2008.03172.x; Hasselqvist-Ax I, 2015, N ENGL J MED; Heidenreich JW, 2006, ACAD EMERG MED; Heidenreich JW, 2012, J EMERG MED; Hellevuo H, 2013, RESUSCITATION; Hunziker S, 2011, INTENS CARE MED, V37, P1473, DOI 10.1007/s00134-011-2277-2; Hupfl M, 2010, LANCET; Iwami T, 2015, CIRCULATION; Koster RW, 2010, RESUSCITATION, V81, P1277, DOI 10.1016/j.resuscitation.2010.08.009; Larsen MP, 1993, ANN EMERG MED; McDonald CH, 2013, EMERG MED J; Min MK, 2013, RESUSCITATION; Muller D, 2006, CIRCULATION; Nolan JR, 2017, SEMIN NEUROL, V37, P5, DOI 10.1055/s-0036-1597832; Norman G, 2010, ADV HEALTH SCI EDUC, V15, P625, DOI 10.1007/s10459-010-9222-y; Perkins GD, 2015, RESUSCITATION; Rossler B, 2013, RESUSCITATION, V84, P982, DOI 10.1016/j.resuscitation.2013.01.001; Saner H, 2013, RESUSCITATION, V84, P1197, DOI 10.1016/j.resuscitation.2013.02.023; Sans S, 1997, EUR HEART J, V18, P1231; Savastano S, 2011, RESUSCITATION, V82, P568, DOI 10.1016/j.resuscitation.2010.12.010; Song Y, 2016, RESUSCITATION, V103, P20, DOI 10.1016/j.resuscitation.2016.03.014; Stiell IG, 2014, CIRCULATION, V130, P1962, DOI 10.1161/CIRCULATIONAHA.114.008671; Stiell IG, 2012, CRIT CARE MED, V40, P1192, DOI 10.1097/CCM.0b013e31823bc8bb; Swor R, 2006, ACAD EMERG MED, V13, P596, DOI 10.1197/j.aem.2005.12.021; van Alem AP, 2003, BMJ-BRIT MED J, V327, P1312, DOI 10.1136/bmj.327.7427.1312; Yamanaka S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189412; Zijlstra JA, 2014, RESUSCITATION, V85, P1444, DOI 10.1016/j.resuscitation.2014.07.020	28	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2020	15	2							e0228702	10.1371/journal.pone.0228702	http://dx.doi.org/10.1371/journal.pone.0228702			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ7SH	32053634	Green Published, gold			2023-01-03	WOS:000535198700047
J	Hsieh, HL; Hsu, SC; Cheng, HS; Chen, CY; Huang, WC; Sue, YM; Lin, FY; Shih, CM; Chen, JW; Lin, SJ; Huang, PH; Liu, CT				Hsieh, Hui-ling; Hsu, Shih-chang; Cheng, Ho-shun; Chen, Chun-you; Huang, Wen-cheng; Sue, Yuh-mou; Lin, Feng-yen; Shih, Chun-ming; Chen, Jaw-wen; Lin, Shing-jong; Huang, Po-hsun; Liu, Chung-te			The influence of atrial fibrillation on the mortality of incident ESRD patients undergoing maintenance hemodialysis	PLOS ONE			English	Article							STAGE RENAL-DISEASE; ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; CLINICAL-FEATURES; LIFETIME RISK; MANAGEMENT; ANTICOAGULATION; PREVALENCE; GUIDELINES; DIALYSIS	Background Atrial fibrillation (AF) is highly prevalent, occurring in 1%-2% of the adult population, increasing the risk of stroke, and resulting in considerable healthcare costs. While stroke is a major complication of AF, end-stage renal disease (ESRD) patients also have a high risk of stroke, suggesting that AF is a possible risk factor for mortality of ESRD patients. However, whether the existence of AF at the initiation of hemodialysis predicts higher mortality risk of incident ESRD patients remains to be defined. Methods This retrospective cohort study was performed at Wanfang Hospital from January 2004 to May 2018. The end points were mortality of patients or the end of the study. Incident ESRD patients who were on maintenance hemodialysis for more than 3 months were eligible for inclusion. Cox proportional regression and Kaplan-Meier survival curves were used to determine the association between predictors and mortality. The association between AF and echocardiographic parameters, causes of death were also investigated. Results Of the 393 incident ESRD patients at initiation of hemodialysis, 57 (14.5%) had AF and the median age was 71 years. Patients with AF were significantly older; showed significantly higher C-reactive protein levels, more heart failure, chronic obstructive pulmonary disease and mortality. Multivariate Cox regression showed that AF had a hazard ratio of 4.1 (95% confidence interval: 2.4-7.0) for mortality. Age-specific analysis showed that AF was significantly associated with mortality in all age groups. Echocardiography measurements including ejection fraction and left ventricular hypertrophy (LVH) were similar in AF and non-AF patients. Cause-specific analysis showed that AF significantly associated with overall cardiovascular death and death due to acute myocardial infarction/coronary artery disease and sepsis. Conclusions AF at the initiation of hemodialysis predicts higher mortality risk of incident ESRD patients regardless of age. The systolic function and degree of LVH were similar in AF and non-AF patients. The association between AF and sepsis-related death suggested the role of systemic inflammation on the pathogenesis of AF.	[Hsieh, Hui-ling; Sue, Yuh-mou; Liu, Chung-te] Taipei Med Univ, Wan Fang Hosp, Div Nephrol, Dept Internal Med, Taipei, Taiwan; [Hsieh, Hui-ling] Natl Def Med Ctr, Grad Inst Med Sci, Taipei, Taiwan; [Hsu, Shih-chang; Huang, Wen-cheng] Taipei Med Univ, Wan Fang Hosp, Dept Emergency & Crit Med, Emergency Dept, Taipei, Taiwan; [Hsu, Shih-chang; Huang, Wen-cheng] Taipei Med Univ, Sch Med, Dept Emergency Med, Coll Med, Taipei, Taiwan; [Cheng, Ho-shun] Taipei Med Univ, Wan Fang Hosp, Div Cardiol, Dept Internal Med, Taipei, Taiwan; [Chen, Chun-you] Taipei Med Univ, Wan Fang Hosp, Dept Radiat Oncol, Taipei, Taiwan; [Huang, Wen-cheng; Liu, Chung-te] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Lin, Feng-yen; Shih, Chun-ming; Liu, Chung-te] Taipei Med Univ, Sch Med, Dept Internal Med, Coll Med, Taipei, Taiwan; [Lin, Feng-yen; Shih, Chun-ming] Taipei Med Univ Hosp, Div Cardiol, Dept Internal Med, Taipei, Taiwan; [Lin, Feng-yen; Shih, Chun-ming] Taipei Med Univ Hosp, Cardiovasc Res Ctr, Dept Internal Med, Taipei, Taiwan; [Chen, Jaw-wen; Lin, Shing-jong; Huang, Po-hsun] Taipei Vet Gen Hosp, Div Cardiol, Dept Med, Taipei, Taiwan; [Chen, Jaw-wen; Lin, Shing-jong; Huang, Po-hsun] Natl Yang Ming Univ, Cardiovasc Res Ctr, Taipei, Taiwan; [Chen, Jaw-wen; Lin, Shing-jong] Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan; [Chen, Jaw-wen] Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan; [Lin, Shing-jong; Huang, Po-hsun] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan; [Lin, Shing-jong] Taipei Med Univ, Taipei, Taiwan	Taipei Medical University; Taipei Municipal WanFang Hospital; National Defense Medical Center; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Medical University	Liu, CT (corresponding author), Taipei Med Univ, Wan Fang Hosp, Div Nephrol, Dept Internal Med, Taipei, Taiwan.; Liu, CT (corresponding author), Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan.; Liu, CT (corresponding author), Taipei Med Univ, Sch Med, Dept Internal Med, Coll Med, Taipei, Taiwan.	96320@w.tmu.edu.tw	Hsieh, Hui-Ling/ABB-5601-2021; Huang, Wen-Cheng/AAM-2191-2021; Hsieh, Hui-Ling/GPW-9991-2022; Hsu, Shih-Chang/I-4277-2012	Hsieh, Hui-Ling/0000-0003-3024-3639; Hsu, Shih-Chang/0000-0003-1010-1182	Wan Fang Hospital, Taipei Medical University [108-wfswf-05]; Ministry of Science and Technology of Taiwan [MOST 106-2314-B-350001-MY3, MOST 104-2314-B-075047]; Taiwan Ministry of Science and Technology Academic Excellence Program [MOST 106-2633-B009-001]; Ministry of Health and Welfare [MOHW106-TDU-B-211-113001]; Taipei Veterans General Hospital [V105C-0207, V106C-045]	Wan Fang Hospital, Taipei Medical University; Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Taiwan Ministry of Science and Technology Academic Excellence Program; Ministry of Health and Welfare(Ministry of Health, Labour and Welfare, Japan); Taipei Veterans General Hospital(Taipei Veterans General Hospital)	This work was supported by the Wan Fang Hospital, Taipei Medical University, 108-wfswf-05 to C-tL; the Ministry of Science and Technology of Taiwan, MOST 104-2314-B-075047 to P-hH; the Ministry of Science and Technology of Taiwan, MOST 106-2314-B-350001-MY3 to P-hH; the Novel Bioengineering and Technological Approaches to Solve Two Major Health Problems in Taiwan program, sponsored by the Taiwan Ministry of Science and Technology Academic Excellence Program, MOST 106-2633-B009-001 to P-hH; the Ministry of Health and Welfare, MOHW106-TDU-B-211-113001 to P-hH and the Taipei Veterans General Hospital, V105C-0207, V106C-045 to P-hH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abuhasira R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21229-9; Bansal N, 2016, CLIN J AM SOC NEPHRO, V11, P1189, DOI 10.2215/CJN.10921015; Ceornodolea AD, 2017, STROKE RES TREAT, V2017, DOI 10.1155/2017/8593207; Chiang CE, 2016, J FORMOS MED ASSOC, V115, P893, DOI 10.1016/j.jfma.2016.10.005; Chugh SS, 2014, CIRCULATION, V129, P837, DOI 10.1161/CIRCULATIONAHA.113.005119; Esato M, 2017, CHEST, V152, P1266, DOI 10.1016/j.chest.2017.08.004; Gamst J, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006486; Genovesi S, 2017, BLOOD PURIFICAT, V44, P77, DOI 10.1159/000464347; Glotzer TV, 2013, CAN J CARDIOL, V29, pS14, DOI 10.1016/j.cjca.2013.03.023; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Goldstein BA, 2012, CIRCULATION, V126, P2293, DOI 10.1161/CIRCULATIONAHA.112.099606; Heeringa J, 2006, EUR HEART J, V27, P949, DOI 10.1093/eurheartj/ehi825; JANUARY CT, 2014, CIRCULATION, V30, P2014; Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210; Konigsbrugge O, 2017, THROMB RES, V158, P59, DOI 10.1016/j.thromres.2017.08.011; Kundu A, 2016, AM J CARDIOL, V117, P1213, DOI 10.1016/j.amjcard.2016.01.012; Lau YC, 2014, CHEST, V146, P1138, DOI 10.1378/chest.14-0986; Liao JN, 2015, KIDNEY INT, V87, P1209, DOI 10.1038/ki.2014.393; Lip GYH, 2012, CHEST, V142, P1489, DOI 10.1378/chest.11-2888; Lloyd-Jones DM, 2004, CIRCULATION, V110, P1042, DOI 10.1161/01.CIR.0000140263.20897.42; Marwick TH, 2015, J AM SOC ECHOCARDIOG, V28, P727, DOI 10.1016/j.echo.2015.05.002; Mori K, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1271-8; Odutayo A, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4482; Saran R, 2017, AM J KIDNEY DIS, V69, DOI 10.1053/j.ajkd.2016.12.004; Schmitt J, 2009, EUR HEART J, V30, P1038, DOI 10.1093/eurheartj/ehn579; Shah SR, 2018, J COMMUNITY HOSP INT, V8, P269, DOI 10.1080/20009666.2018.1514932; Shen CH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003933; Stewart S, 2002, AM J MED, V113, P359, DOI 10.1016/S0002-9343(02)01236-6; Sud M, 2014, CIRCULATION, V130, P458, DOI 10.1161/CIRCULATIONAHA.113.007106; Tsai Chieh, 2017, Can J Kidney Health Dis, V4, p2054358117735532, DOI 10.1177/2054358117735532; Vermond RA, 2015, J AM COLL CARDIOL, V66, P1000, DOI 10.1016/j.jacc.2015.06.1314; Violi F, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003347; Walkey AJ, 2016, JAMA CARDIOL, V1, P682, DOI 10.1001/jamacardio.2016.2181; Winkelmayer WC, 2011, J AM SOC NEPHROL, V22, P349, DOI 10.1681/ASN.2010050459; Wizemann V, 2010, KIDNEY INT, V77, P1098, DOI 10.1038/ki.2009.477; Wodchis WP, 2012, VALUE HEALTH, V15, P240, DOI 10.1016/j.jval.2011.09.009; Yamashita Y, 2016, HEART VESSELS, V31, P2025, DOI 10.1007/s00380-016-0818-x; Zhu JX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131782	38	3	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2020	15	1							e0228405	10.1371/journal.pone.0228405	http://dx.doi.org/10.1371/journal.pone.0228405			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9CB	31999778	Green Published, gold			2023-01-03	WOS:000534612400078
J	Yu, SR; Sha, HH; Qin, XB; Chen, Y; Li, XY; Shi, MQ; Feng, JF				Yu, Shaorong; Sha, Huanhuan; Qin, Xiaobing; Chen, Yan; Li, Xiaoyou; Shi, Meiqi; Feng, Jifeng			EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells	ONCOGENE			English	Article							TUMOR-DERIVED EXOSOMES; CHECKPOINT INHIBITORS; DOCETAXEL; CARCINOMA; BLOCKADE; PATHWAY; ALTERS	EGFR-mutant lung cancer (LC) patients display a poor response to PD-1/PD-L1 blockade. In the absence of independent genetic validation, whether EGFR mutation distorts host antitumor immunity is unknown. Here, we showed that in the clinic, LC with the E746-A750 deletion mutation (EGFR-19del) displayed a temporal association with the loss of intratumoral CD8+ T cells. In a xenograft model, EGFR-19del-expressing Lewis lung cancer (LLC) tumors had a low T cell density at the early stage of tumor development, along with dendritic cells (DCs) exhibiting variant phenotypes in the tumors and draining lymph nodes (LNs). Importantly, EGFR-19del DCs were observed in the LNs of tumor-bearing mice and LC patients. The proliferative activity of T cells within the LN was significantly dampened. In vitro experiments indicated that the function of DCs was repressed by EGFR-19del LLC cells through exosome uptake in which exosomes derived from the EGFR-19del LLC cells could efficiently transfer active EGFR-19del to the surface of the DCs. Injection of EGFR-19del tumor-derived exosomes promoted LLC tumor progression and induced immunosuppression. The combination of gefitinib and GM-CSF treatment recovered tumor T cell infiltration in EGFR-19del tumors by rescuing the function of DCs and increasing the efficacy of anti-PD-L1 treatment. Together, these results indicated that LC with the EGFR E746-A750 deletion mutation induced anergic DCs to repress antitumor immunity through exosomes.	[Yu, Shaorong; Sha, Huanhuan; Qin, Xiaobing; Li, Xiaoyou; Shi, Meiqi; Feng, Jifeng] Nanjing Med Univ, Affiliated Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China; [Yu, Shaorong; Sha, Huanhuan; Qin, Xiaobing; Chen, Yan; Li, Xiaoyou; Shi, Meiqi; Feng, Jifeng] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China; [Yu, Shaorong; Sha, Huanhuan; Qin, Xiaobing; Chen, Yan; Li, Xiaoyou; Shi, Meiqi; Feng, Jifeng] Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China; [Qin, Xiaobing] Xuzhou Med Univ, Affiliated Hosp, Dept Med Oncol, Xuzhou, Jiangsu, Peoples R China; [Chen, Yan] Nanjing Med Univ, Affiliated Canc Hosp, Dept Pathol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Xuzhou Medical University; Nanjing Medical University	Feng, JF (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China.; Feng, JF (corresponding author), Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China.; Feng, JF (corresponding author), Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China.	fjif@vip.sina.com			National Natural Science Foundation of China [81871873]; Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Youth Talent [QNRC2016646]; China Postdoctoral Science Foundation [2017M621680]; Six talent peaks project in Jiangsu Province [WSN-039]; talents program of Jiangsu Cancer Hospital [YC201807]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Youth Talent; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Six talent peaks project in Jiangsu Province; talents program of Jiangsu Cancer Hospital	This work was supported by grants from the National Natural Science Foundation of China (81871873); the Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Youth Talent (QNRC2016646); the China Postdoctoral Science Foundation (2017M621680); the Six talent peaks project in Jiangsu Province (WSN-039); and the talents program of Jiangsu Cancer Hospital (YC201807).	Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Anguille S, 2015, PHARMACOL REV, V67, P731, DOI 10.1124/pr.114.009456; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Choi D, 2018, MOL CELL PROTEOMICS, V17, P1948, DOI 10.1074/mcp.RA118.000644; Conejo-Garcia JR, 2016, PHARMACOL THERAPEUT, V164, P97, DOI 10.1016/j.pharmthera.2016.04.003; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Dong ZY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356145; Donnem T, 2015, CLIN CANCER RES, V21, P2635, DOI 10.1158/1078-0432.CCR-14-1905; Dresch C, 2012, TRENDS IMMUNOL, V33, P381, DOI 10.1016/j.it.2012.04.009; Eisenbarth SC, 2019, NAT REV IMMUNOL, V19, P89, DOI 10.1038/s41577-018-0088-1; Enamorado M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16073; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Gao L, 2018, NAT IMMUNOL, V19, P233, DOI 10.1038/s41590-017-0043-5; Jameson SC, 2018, IMMUNITY, V48, P214, DOI 10.1016/j.immuni.2018.02.010; Lee CK, 2018, JAMA ONCOL, V4, P210, DOI 10.1001/jamaoncol.2017.4427; Lee CK, 2017, J THORAC ONCOL, V12, P403, DOI 10.1016/j.jtho.2016.10.007; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Mascia F, 2016, INT J CANCER, V139, P2593, DOI 10.1002/ijc.30376; Mondanelli G, 2017, IMMUNITY, V46, P233, DOI 10.1016/j.immuni.2017.01.005; Park SL, 2018, NAT IMMUNOL, V19, P183, DOI 10.1038/s41590-017-0027-5; Qin XB, 2017, INT J NANOMED, V12, P3721, DOI 10.2147/IJN.S131516; Raulf N, 2018, EUR J CANCER, V102, P52, DOI 10.1016/j.ejca.2018.07.123; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Sanderson MP, 2008, J CELL BIOCHEM, V103, P1783, DOI 10.1002/jcb.21569; van de Laar L, 2012, BLOOD, V119, P3383, DOI 10.1182/blood-2011-11-370130; Wang SH, 2016, J BIOL CHEM, V291, P21085, DOI 10.1074/jbc.M116.717892; Zhang HY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15016; Zhang LL, 2019, THERANOSTICS, V9, P2541, DOI 10.7150/thno.32655; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020	33	22	22	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2643	2657		10.1038/s41388-020-1182-y	http://dx.doi.org/10.1038/s41388-020-1182-y		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32001818				2023-01-03	WOS:000510328400002
J	Wakam, GK; Montgomery, JR; Biesterveld, BE; Brown, CS				Wakam, Glenn K.; Montgomery, John R.; Biesterveld, Ben E.; Brown, Craig S.			Not Dying Alone - Modern Compassionate Care in the Covid-19 Pandemic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								When the wife of a severely ill patient with Covid-19 is told she can't visit him, her anger quickly gives way to pleading - "What if I only spent 5 minutes and left?" How can we harness creative solutions during this pandemic so that people don't have to die alone?	[Wakam, Glenn K.; Montgomery, John R.; Biesterveld, Ben E.; Brown, Craig S.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Wakam, GK (corresponding author), Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.		Biesterveld, Ben/AAM-1087-2021	Wakam, Glenn/0000-0002-0950-9554	AHRQ HHS [T32 HS000053] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539; VitalTalk, COVID READ COMM PLAB	2	131	131	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	2020	382	24								10.1056/NEJMp2007781	http://dx.doi.org/10.1056/NEJMp2007781			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LZ3TR	32289215	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000541151500001
J	Pauly, B; Wallace, B; Pagan, F; Phillips, J; Wilson, M; Hobbs, H; Connolly, J				Pauly, Bernadette; Wallace, Bruce; Pagan, Flora; Phillips, Jack; Wilson, Mark; Hobbs, Heather; Connolly, Joann			Impact of overdose prevention sites during a public health emergency in Victoria, Canada	PLOS ONE			English	Article							HARM-REDUCTION; PEOPLE; IMPLEMENTATION; PERSPECTIVES; FACILITIES; SERVICES; FENTANYL; PLEASURE; PROGRAM; HEROIN	The primary objective of this study was to examine the impacts associated with implementation of overdose preventions sites (OPSs) in Victoria, Canada during a declared provincial public health overdose emergency. A rapid case study design was employed with three OPSs constituting the cases. Data were collected through semi-structured interviews with 15 staff, including experiential staff, and 12 service users. Theoretically, we were informed by the Consolidated Framework for Implementation Research. This framework, combined with a case study design, is well suited for generating insight into the impacts of an intervention. Zero deaths were identified as a key impact and indicator of success. The implementation of OPSs increased opportunities for early intervention in the event of an overdose, reducing trauma for staff and service users, and facilitated organizational transitions from provision of safer supplies to safer spaces. Providing a safer space meant drug use no longer needed to be concealed, with the effect of mitigating drug related stigma and facilitating a shift from shame and blame to increasing trust and development of relationships with increased opportunities to provide connections to other services. These impacts were achieved with few new resources highlighting the commitment of agencies and harm reduction workers, particularly those with lived experience, in achieving beneficial impacts. Although mitigating harms of overdose, OPSs do not address the root problem of an unsafe drug supply. OPSs are important life-saving interventions, but more is needed to address the current contamination of the illicit drug supply including provision of a safer supply.	[Pauly, Bernadette; Wallace, Bruce; Pagan, Flora] Canadian Inst Subst Use Res, Victoria, BC, Canada; [Pauly, Bernadette] Univ Victoria, Sch Nursing, Victoria, BC, Canada; [Wallace, Bruce] Univ Victoria, Sch Social Work, Victoria, BC, Canada; [Phillips, Jack; Wilson, Mark] SOLID Outreach, Victoria, BC, Canada; [Hobbs, Heather] AIDS Vancouver Isl AVI, Victoria, BC, Canada; [Connolly, Joann] Victoria Cool Aid Soc, Victoria, BC, Canada	University of Victoria; University of Victoria	Pauly, B (corresponding author), Canadian Inst Subst Use Res, Victoria, BC, Canada.; Pauly, B (corresponding author), Univ Victoria, Sch Nursing, Victoria, BC, Canada.	bpauly@uvic.ca		Wallace, Bruce/0000-0003-0360-7302; Pagan, Flora/0000-0003-1499-044X	Bernadette Pauly's Island Health Scholar in Residence Award, Island Health	Bernadette Pauly's Island Health Scholar in Residence Award, Island Health	This research was supported by Bernadette Pauly's Island Health Scholar in Residence Award, Island Health. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2019, NATIONS HLTH PUBLICA, V49, P1; [Anonymous], 2016, SPEC ADV COMM EP OP; BC Centre for Disease Control, PUBL HLTH EM BC; Boucher LM, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0145-2; Boyd J, 2018, ADDICTION, V113, P2261, DOI 10.1111/add.14417; British Colubmia Centre for Substance Use, 2019, HER COMP CLUBS; British Columbia Center for Disease Control, 2019, OV RESP IND VANC; British Columbia Center for Disease Control, 2018, OV RESP IND; Canadian Association of People Who Use Drugs, 2019, SAFE SUPPL CONC DOC; Canadian Association of People Who Use Drugs (CAPUD), 2014, COLL VOIC EFF CHANG; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Duncan T, 2017, INT J DRUG POLICY, V49, P92, DOI 10.1016/j.drugpo.2017.07.005; Edland-Gryt M, 2013, INT J DRUG POLICY, V24, P257, DOI 10.1016/j.drugpo.2012.08.002; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Government of Canada, 2019, SUP CONS SIT STAT AP; Hyshka E, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0177-7; Hyshka E, 2013, ADDICTION, V108, P468, DOI 10.1111/add.12064; Irvine M, MODELLING COMBINED I; Israel BA, 1998, ANNU REV PUBL HEALTH, V19, P173, DOI 10.1146/annurev.publhealth.19.1.173; Kappel N, 2016, HARM REDUCT J, V13, DOI 10.1186/s12954-016-0109-y; Kennedy MC, 2017, CURR HIV-AIDS REP, V14, P161, DOI 10.1007/s11904-017-0363-y; Kennedy MC, PEER WORKER INVOLVEM; Kerr T, 2006, BRIT MED J, V332, P220, DOI 10.1136/bmj.332.7535.220; Kerr T, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0154-1; Kerr Thomas, 2004, Can HIV AIDS Policy Law Rev, V9, P13; Krusi A, 2009, AIDS CARE, V21, P638, DOI 10.1080/09540120802385645; Lee HS, 2010, SUBST USE MISUSE, V45, P2411, DOI 10.3109/10826081003712060; Macneil J, 2011, DRUG ALCOHOL REV, V30, P26, DOI 10.1111/j.1465-3362.2010.00188.x; MacNeil J, 2010, HARM REDUCT J, V7, DOI 10.1186/1477-7517-7-11; McNeil R, 2015, INT J DRUG POLICY, V26, P645, DOI 10.1016/j.drugpo.2015.01.015; McNeil R, 2014, AIDS BEHAV, V18, P473, DOI 10.1007/s10461-013-0540-y; Minkler M., 2005, J URBAN HEALTH, V82, P3, DOI DOI 10.1093/JURBAN/JTI034; Moore D, 2008, INT J DRUG POLICY, V19, P353, DOI 10.1016/j.drugpo.2007.07.004; National Institute on Drug Abuse, OV DEATH RAT; Office of the Provincial Health Officer, 2019, SPEC REP STOPP HARM; Pauly B., 2017, DRUGS ED PREVENTION, V25, P21; Pauly BM, 2017, DRUGS ED PREVENTION; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Rance J, 2011, CONTEMP DRUG PROBL, V38, P121, DOI [10.1177/009145091103800106, DOI 10.1177/009145091103800106]; Rance J, 2015, INT J DRUG POLICY, V26, P30, DOI 10.1016/j.drugpo.2014.05.002; Rudd RA, 2016, MMWR-MORBID MORTAL W, P64; Small W, 2011, SUBST USE MISUSE, V46, P561, DOI 10.3109/10826084.2010.517714; Stake R. E., 2006, MULTIPLE CASE STUDY; Treloar C, 2016, INT J DRUG POLICY, V27, P138, DOI 10.1016/j.drugpo.2015.08.018; Wallace B, 2016, EVERY WASHROOM DE FA; Wallace B, 2019, INT J DRUG POLICY, V66, P64, DOI 10.1016/j.drugpo.2019.01.017; Wallace B, 2018, INT J DRUG POLICY, V53, P83, DOI 10.1016/j.drugpo.2017.12.011; Wallace B, 2015, GATEWAYS, V8, P43, DOI 10.5130/ijcre.v8i1.3936; Wallerstein N., 2010, J INFORM, V100; Wild TC, 2017, INT J DRUG POLICY, V45, P9, DOI 10.1016/j.drugpo.2017.03.014; Wood E, 2003, J URBAN HEALTH, V80, P455, DOI 10.1093/jurban/jtg052; Wood E, 2008, INT J DRUG POLICY, V19, P220, DOI 10.1016/j.drugpo.2007.11.001; Yin RK., 2009, CASE STUDY RES DESIG, DOI [10.1016/j.ymeth.2008.10.015, DOI 10.1016/J.YMETH.2008.10.015]	54	25	25	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2020	15	5							e0229208	10.1371/journal.pone.0229208	http://dx.doi.org/10.1371/journal.pone.0229208			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU1JI	32438390	Green Published, gold			2023-01-03	WOS:000537517800008
J	Martin, RA; Couture, R; Tasker, N; Carter, C; Copeland, DM; Kibler, M; Whittle, JS				Martin, Rebecca A.; Couture, Rosanna; Tasker, Nicole; Carter, Christine; Copeland, David M.; Kibler, Mary; Whittle, Jessica S.			Emergency medical care of incarcerated patients: Opportunities for improvement and cost savings	PLOS ONE			English	Article							INJURY SURVEILLANCE; PUBLIC-HEALTH; ADDICTION; TRAUMA; SYSTEM; DRUG	In the United States (US), the lifetime incidence of incarceration is 6.6%, exceeding that of any other nation. Compared to the general US population, incarcerated individuals are disproportionally affected by chronic health conditions, mental illness, and substance use disorders. Barriers to accessing medical care are common in correctional facilities. We sought to characterize the local incarcerated patient population and explore barriers to medical care in these patients. We conducted a retrospective, observational cohort study by reviewing the medical records of incarcerated patients presenting to the adult emergency department (ED) of a single academic, tertiary care facility with medical or psychiatric (med/psych) and trauma-related emergencies between January 2012 and December 2014. Data on demographics, medical complexity, trauma intentionality, and barriers to medical care were analyzed using descriptive statistics, unpaired student's t-test or one-way analysis of variance for continuous variables, and chi-square analysis or Fisher's exact test as appropriate. Trauma patients were younger with fewer medical comorbidities and were less likely to be admitted to the hospital than med/psych patients. 47.8% of injuries resulted from violence or were self-inflicted. Most trauma-related complaints were managed by the emergency medicine physician in the ED. While barriers to medical care were not correlated with hospital admission, 5.4% of med/psych and 2.9% of trauma patients reported barriers as a contributing factor to the ED encounter. Med/psych patients commonly reported a lack of access to medications, while trauma patients reported a delay in medical care. Trauma-related presentations were less medically complex than med/psych-related complaints. Medical management of most injuries required no hospital resources outside of the ED, indicating a potential role for outpatient management of trauma-related complaints. Additional opportunities for health care improvement and cost savings include the implementation of programs that target violence, prevent injuries, and promote the continuity of medical care while incarcerated.	[Martin, Rebecca A.; Couture, Rosanna; Tasker, Nicole; Whittle, Jessica S.] Univ Tennessee, Hlth Sci Ctr, Coll Med Chattanooga, Dept Emergency Med, Chattanooga, TN 37403 USA; [Martin, Rebecca A.; Couture, Rosanna; Tasker, Nicole; Kibler, Mary; Whittle, Jessica S.] Erlanger Hlth Syst, Chattanooga, TN 37403 USA; [Carter, Christine; Copeland, David M.] Univ Tennessee, Coll Med, Memphis, TN USA; [Couture, Rosanna] Riverside Med Grp, Emergency Med, Newport News, VA USA; [Tasker, Nicole] Med Associates LLC, Emergency Med, Indianapolis, IN USA; [Carter, Christine] Univ Maryland, Med Ctr, Dept Emergency Med, Baltimore, MD 21201 USA; [Copeland, David M.] Univ Washington, Med Ctr, Dept Anesthesiol, Seattle, WA 98195 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University System of Maryland; University of Maryland Baltimore; University of Washington; University of Washington Seattle	Martin, RA (corresponding author), Univ Tennessee, Hlth Sci Ctr, Coll Med Chattanooga, Dept Emergency Med, Chattanooga, TN 37403 USA.; Martin, RA (corresponding author), Erlanger Hlth Syst, Chattanooga, TN 37403 USA.	Rebecca.martin@erlanger.org						ACEP Public Health Committee. Recognizing the Needs of Incarcerated Patients in the Emergency Department, 2006, REC NEEDS INC PAT EM; Ahalt C, 2015, ANN INTERN MED, V162, P345, DOI 10.7326/M14-2161; Ahalt C, 2012, J GEN INTERN MED, V27, P160, DOI 10.1007/s11606-011-1858-7; [Anonymous], 2016, INM AG STAT; [Anonymous], 2002, HLTH STAT SOON TO BE, V1; [Anonymous], 2017, NEWS; Bauer A, 2008, BURDEN TOBACCO TENNE; Binswanger IA, 2009, J EPIDEMIOL COMMUN H, V63, P912, DOI 10.1136/jech.2009.090662; Bonczar T., 2003, PREVALENCE IMPRISONM; Bronson J, 2017, INDICATORS MENTAL HL; CDC, 2012, NAT HOSP AMB MED CAR; Chandler RK, 2009, JAMA-J AM MED ASSOC, V301, P183, DOI 10.1001/jama.2008.976; Chattanooga-Hamilton County Health Department Office of Assessment and Planning, 2015, PICT OUR HLTH HAM CO; Dumont DM, 2012, ANNU REV PUBL HEALTH, V33, P325, DOI 10.1146/annurev-publhealth-031811-124614; Freudenberg N, 2001, J URBAN HEALTH, V78, P214, DOI 10.1093/jurban/78.2.214; Kinsella Chad, 2004, CORRECTIONS HLTH CAR; Ludwig A, 2012, AM J PUBLIC HEALTH, V102, P1108, DOI 10.2105/AJPH.2011.300306; Minton TD, 2015, CENSUS JAILS POPULAT, P1; Nacci P, 2002, IMPLEMENTING TELEMED; Nyamathi AM, 2017, NURS RES, V66, P432, DOI 10.1097/NNR.0000000000000249; Pfortmueller CA, 2013, SWISS MED WKLY, V143, DOI 10.4414/smw.2013.13753; Rui P, 2014, NATL HOSP AMBULATORY; Siegler A, 2017, J HEALTH CARE POOR U, V28, P1042, DOI 10.1353/hpu.2017.0095; Spaulding AC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191643; Sung Hung-En, 2010, J Correct Health Care, V16, P178, DOI 10.1177/1078345810366287; US Census Bureau, 2012, AM COMM SURV DEM HOU; Wagner P., 2018, MASS INCARCERATION W; Wagner Peter, 2016, STATES INCARCERATION; Wilper AP, 2009, AM J PUBLIC HEALTH, V99, P666, DOI 10.2105/AJPH.2008.144279; Wolff N, 2015, J ANXIETY DISORD, V30, P66, DOI 10.1016/j.janxdis.2014.10.009	30	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2020	15	4							e0232243	10.1371/journal.pone.0232243	http://dx.doi.org/10.1371/journal.pone.0232243			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LS8VC	32339213	gold, Green Published			2023-01-03	WOS:000536657400035
J	Hiensch, AE; Peeters, PHM; Jansen, M; van der Wall, E; Backx, FJG; Velthuis, MJ; May, AM				Hiensch, Anouk E.; Peeters, Petra H. M.; Jansen, Marijke; van der Wall, Elsken; Backx, Frank J. G.; Velthuis, Miranda J.; May, Anne M.			Socio-ecological correlates of physical activity in breast and colon cancer survivors 4 years after participation in a randomized controlled exercise trial (PACT study)	PLOS ONE			English	Article							FOLLOW-UP; BEHAVIOR; INSTRUMENT; PREDICTORS; FATIGUE; WOMEN	Background Having a physically active lifestyle after cancer diagnosis is beneficial for health, and this needs to be continued into survivorship to optimize long-term benefits. We found that patients, who participated in an 18-week exercise intervention, reported significant higher physical activity (PA) levels 4 years after participation in a randomized controlled trial of supervised exercise delivered during chemotherapy (PACT study). This study aimed to identify social-ecological correlates of PA levels in breast and colon cancer survivors 4 years after participation in the PACT study. Methods Self-reported PA levels and potential correlates (e.g. physical fitness, fatigue, exercise history, and built environment) were assessed in 127 breast and colon cancer survivors shortly after diagnosis (baseline), post-intervention and 4 years later. Multivariable linear regression analyses were performed to identify social-ecological correlates of PA 4 years post-baseline. Results The final model revealed that lower baseline physical fatigue (beta = -0.25, 95% CI -0.26; -0.24) and higher baseline total PA (0.06, 95% CI, 0.03; 0.10) were correlated with higher total PA levels 4 years post-baseline. Higher baseline leisure and sport PA (0.02, 95% CI 0.01; 0.03), more recreational facilities within a buffer of 1 km (4.05, 95% CI = 1.28; 6.83), lower physical fatigue at 4-year follow-up (-8.07, 95% CI -14.00; -2.13), and having a positive change in physical fatigue during the intervention period (0.04, 95% CI 0.001; 0.07) were correlates of sport and leisure PA levels 4 years post-baseline. Conclusions This study suggests that baseline and 4-year post-baseline physical fatigue, and past exercise behaviour, were significant correlates of PA 4 years after participation in an exercise trial. Additionally, this study suggests that the built environment should be taken into account when promoting PA. Understanding of socio-ecological correlates of PA can provide insights into how future exercise interventions should be designed to promote long-term exercise behaviour.	[Hiensch, Anouk E.; Peeters, Petra H. M.; May, Anne M.] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Jansen, Marijke] Univ Utrecht, Fac Geosci, Dept Human Geog & Spatial Planning, Utrecht, Netherlands; [Jansen, Marijke] Hogeschool Utrecht, Inst Nursing Studies, Utrecht, Netherlands; [van der Wall, Elsken] Univ Utrecht, Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands; [Backx, Frank J. G.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Rehabil Phys Therapy Sci & Sport, Utrecht, Netherlands; [Velthuis, Miranda J.] Netherlands Comprehens Canc Org IKNL, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	May, AM (corresponding author), Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.	A.M.May@umcutrecht.nl	Hiensch, Anouk/AAP-5372-2020	Hiensch, Anouk/0000-0002-6216-2609	Netherlands Organisation for Health Research and Development (ZonMw) [171002202]; Dutch Cancer Society (KWF Kankerbestrijding) [UU 2009-4473]; Dutch Pink Ribbon Foundation [WO02.C100]; VIOZ (Stichting Vrienden Integrale Oncologische Zorg)	Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development); Dutch Cancer Society (KWF Kankerbestrijding)(KWF Kankerbestrijding); Dutch Pink Ribbon Foundation; VIOZ (Stichting Vrienden Integrale Oncologische Zorg)	This work was supported by The Netherlands Organisation for Health Research and Development (ZonMw, project number: 171002202, https://www.zonmw.nl/nl/onderzoekresultaten/doelmatigheidsonderzoek/programmas/project-detail/doelmatigheidsonderzoek/physicalactivity-during-cancer-treatment-pact-studie-een-gerandomiseerde-studie-naar-de-effecten/, PHMP), the Dutch Cancer Society (KWF Kankerbestrijding. Project number: UU 2009-4473, PHMP), the Dutch Pink Ribbon Foundation (2011. WO02.C100, https://www.pinkribbon.nl/doelbestedingen/wetenschappelijk-onderzoek/2011/pact-studie.html, AMM) and VIOZ (Stichting Vrienden Integrale Oncologische Zorg (2015, MJV). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Bandura A, 1986, SOCIAL FDN THOUGHT A; Campbell KL, 2019, MED SCI SPORT EXER, V51, P2375, DOI 10.1249/MSS.0000000000002116; Courneya KS, 2009, BREAST CANCER RES TR, V114, P179, DOI 10.1007/s10549-008-9987-3; Eyl RE, 2018, J CANCER SURVIV, V12, P679, DOI 10.1007/s11764-018-0705-9; Gal R, 2019, ACTA ONCOL, V58, P673, DOI 10.1080/0284186X.2018.1563712; Grimmett C, 2019, INT J BEHAV NUTR PHY, V16, DOI 10.1186/s12966-019-0787-4; Grimmett C, 2011, QUAL LIFE RES, V20, P1237, DOI 10.1007/s11136-011-9855-1; Hawkes AL, 2015, J CANCER SURVIV, V9, P40, DOI 10.1007/s11764-014-0389-8; Hildebrandt VH, 2011, TRENDRAPPORT BEWEGEN; Holmes MD, 2005, JAMA-J AM MED ASSOC, V293, P2479, DOI 10.1001/jama.293.20.2479; Hong S, 2007, BREAST CANCER RES TR, V101, P225, DOI 10.1007/s10549-006-9284-y; James AP, 2017, CANC EPIDEMIOL BIOMA; Jones LW, 2011, ONCOLOGIST, V16, P112, DOI 10.1634/theoncologist.2010-0197; Kampshoff CS, 2016, SUPPORT CARE CANCER, V24, P3333, DOI 10.1007/s00520-016-3148-8; Kampshoff CS, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/1479-5868-11-80; Kemper HGC, 2000, TIJDSCHR SOC GEZONDH, V78, P180; Lee CE, 2016, ONCOL NURS FORUM, V43, P93, DOI 10.1188/16.ONF.43-01AP; Leitzmann M, 2015, CANCER EPIDEMIOL, V39, pS46, DOI 10.1016/j.canep.2015.03.009; Lynch BM, 2010, SUPPORT CARE CANCER, V18, P729, DOI 10.1007/s00520-009-0705-4; Mackenbach JD, 2016, OBES REV, V17, P68, DOI 10.1111/obr.12374; Mason C, 2013, CANCER EPIDEM BIOMAR, V22, P1153, DOI 10.1158/1055-9965.EPI-13-0141; Mishra SI, 2012, COCHRANE DATABASE SY; Mutrie N, 2012, J CANCER SURVIV, V6, P420, DOI 10.1007/s11764-012-0233-y; OSBORNE J. W., 2010, PRACTICAL ASSESSMENT, V15, P12, DOI [10.7275/qbpc-gk17, DOI 10.7275/QBPC-GK17]; Osborne RH, 2004, QUAL LIFE RES, V13, P191, DOI 10.1023/B:QURE.0000015292.56268.e7; Sallis J.F., 2008, HLTH BEHAV HLTH ED, V4th edition, P465; Schmid D, 2015, ANN ONCOL, V26, P272, DOI 10.1093/annonc/mdu250; Schmidt ME, 2017, ACTA ONCOL, V56, P618, DOI 10.1080/0284186X.2016.1275776; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Speed-Andrews AE, 2012, EUR J CANCER CARE, V21, P187, DOI 10.1111/j.1365-2354.2011.01290.x; Steyerberg E.W, 2019, CLIN PREDICTION MODE; Travier N, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0362-z; Trinh L, 2016, J CANCER SURVIV, V10, P164, DOI 10.1007/s11764-015-0462-y; van Buuren S, 2011, J STAT SOFTW, V45, P1; Van Vulpen JK, 2016, MED SCI SPORT EXER, V48, P767, DOI 10.1249/MSS.0000000000000855; van Vulpen JK, 2016, MATURITAS, V85, P104, DOI 10.1016/j.maturitas.2015.12.007; Velthuis MJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-272; Vergouwe Y, 2010, J CLIN EPIDEMIOL, V63, P205, DOI 10.1016/j.jclinepi.2009.03.017; Weggemans RM, 2018, INT J BEHAV NUTR PHY, V15, DOI 10.1186/s12966-018-0661-9; Wendel-Vos GCW, 2003, J CLIN EPIDEMIOL, V56, P1163, DOI 10.1016/S0895-4356(03)00220-8; Witlox L, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1075-x	42	2	2	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2020	15	4							e0231663	10.1371/journal.pone.0231663	http://dx.doi.org/10.1371/journal.pone.0231663			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR9JM	32298326	gold, Green Published			2023-01-03	WOS:000536011400084
J	Scimone, MT; Cramer, HC; Hopkins, P; Estrada, JB; Franck, C				Scimone, Mark T.; Cramer, Harry C. I. I. I. I. I. I.; Hopkins, Paul; Estrada, Jonathan B.; Franck, Christian			Application of mild hypothermia successfully mitigates neural injury in a 3D in-vitro model of traumatic brain injury	PLOS ONE			English	Article							PHARMACOLOGICALLY INDUCED HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; PROFESSIONAL FOOTBALL; MODERATE HYPOTHERMIA; GAME IMPACTS; II-SPECTRIN; CASPASE-3; CALPAIN; ACCUMULATION; PROTEOLYSIS	Therapeutic hypothermia (TH) is an attractive target for mild traumatic brain injury (mTBI) treatment, yet significant gaps in our mechanistic understanding of TH, especially at the cellular level, remain and need to be addressed for significant forward progress to be made. Using a recently-established 3D in-vitro neural hydrogel model for mTBI we investigated the efficacy of TH after compressive impact injury and established critical treatment parameters including target cooling temperature, and time windows for application and maintenance of TH. Across four temperatures evaluated (31.5, 33, 35, and 37 degrees C), 33 degrees C was found to be most neuroprotective after 24 and 48 hours post-injury. Assessment of TH administration onset time and duration showed that TH should be administered within 4 hours post-injury and be maintained for at least 6 hours for achieving maximum viability. Cellular imaging showed TH reduced the percentage of cells positive for caspases 3/7 and increased the expression of calpastatin, an endogenous neuroprotectant. These findings provide significant new insight into the biological parameter space that renders TH effective in mitigating the deleterious effects of cellular mTBI and provides a quantitative foundation for the future development of animal and preclinical treatment protocols.	[Scimone, Mark T.; Cramer, Harry C. I. I. I. I. I. I.; Hopkins, Paul] Brown Univ, Sch Engn, Providence, RI 02912 USA; [Scimone, Mark T.; Cramer, Harry C. I. I. I. I. I. I.; Hopkins, Paul] Brown Univ, Ctr Biomed Engn, Providence, RI 02912 USA; [Estrada, Jonathan B.] Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48109 USA; [Franck, Christian] Univ Wisconsin, Mech Engn, Madison, WI 53706 USA	Brown University; Brown University; University of Michigan System; University of Michigan; University of Wisconsin System; University of Wisconsin Madison	Franck, C (corresponding author), Univ Wisconsin, Mech Engn, Madison, WI 53706 USA.	cfranck@wisc.edu	Estrada, Jon B/ABC-3088-2020; Franck, Christian/C-6077-2012	Estrada, Jon B/0000-0003-1083-4597; Scimone, Mark/0000-0003-0123-3765; Cramer, Harry/0000-0002-3353-7723; Franck, Christian/0000-0002-2347-620X	United States Office of Naval Research (ONR) [N00014-13-1-0708, N00014-16-1-2869, N00014-17-1-2644]; Brown University	United States Office of Naval Research (ONR)(Office of Naval Research); Brown University	This research was supported by grants from the United States Office of Naval Research (ONR) - https://www.onr.navy.mil; grant numbers: N00014-13-1-0708, N00014-16-1-2869, and N00014-17-1-2644. Jonathan Estrada received a GAANN Fellowship from Brown University. No additional external funding was received for this study. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abele D, 2002, J EXP BIOL, V205, P1831; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Bar-Kochba E, 2016, SCI REP-UK, V6, DOI 10.1038/srep30550; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Carslaw H.S., 1959, CONDUCTION HEAT SOLI, V2nd; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; Darwazeh R, 2013, NEURAL REGEN RES, V8, P2677, DOI 10.3969/j.issn.1673-5374.2013.28.010; Davoli MA, 2002, NEUROSCIENCE, V115, P125, DOI 10.1016/S0306-4522(02)00376-7; Dingle YTL, 2015, TISSUE ENG PART C-ME, V21, P1274, DOI [10.1089/ten.tec.2015.0135, 10.1089/ten.TEC.2015.0135]; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Georgiou AP, 2013, BRIT J ANAESTH, V110, P357, DOI 10.1093/bja/aes500; Gu XH, 2015, EXP NEUROL, V267, P135, DOI 10.1016/j.expneurol.2015.02.029; Hopkins AM, 2015, PROG NEUROBIOL, V125, P1, DOI 10.1016/j.pneurobio.2014.11.003; Johnson VE, 2018, ACTA NEUROPATHOL, V135, P711, DOI 10.1007/s00401-018-1824-0; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kobeissy FH, 2015, MOL NEUROBIOL, V52, P696, DOI 10.1007/s12035-014-8898-z; Lamkanfi M, 2010, INT J BIOCHEM CELL B, V42, P21, DOI 10.1016/j.biocel.2009.09.013; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee JH, 2014, J NEUROTRAUM, V31, P1417, DOI 10.1089/neu.2013.3251; Lu J, 2014, WORLD J EMERG MED, V5, P298, DOI 10.5847/wjem.j.issn.1920-8642.2014.04.010; Maekawa T, 2015, J NEUROTRAUM, V32, P422, DOI 10.1089/neu.2013.3197; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Ming X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084557; Mrozek S, 2012, ANESTHESIOL RES PRAC, V2012, DOI 10.1155/2012/989487; Parikh S, 2007, INT ANESTHESIOL CLIN, V45, P119, DOI 10.1097/AIA.0b013e318078cfe7; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Saad Hesham, 2013, Glob Cardiol Sci Pract, V2013, P44, DOI 10.5339/gcsp.2013.7; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sadaka F, 2012, BRAIN INJURY, V26, P899, DOI 10.3109/02699052.2012.661120; Sadick JS, 2016, SCI REP-UK, V6, DOI 10.1038/srep33999; Sahuquillo J, 2007, CURR PHARM DESIGN, V13, P2310; Samanci MY, 2019, WORLD NEUROSURG, V121, pE481, DOI 10.1016/j.wneu.2018.09.142; Scimone MT, 2018, NAT PROTOC, V13, P3042, DOI 10.1038/s41596-018-0077-7; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361; van der Poel C, 2008, CLIN EXP PHARMACOL P, V35, P1482, DOI 10.1111/j.1440-1681.2008.05050.x; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Walsh JG, 2008, P NATL ACAD SCI USA, V105, P12815, DOI 10.1073/pnas.0707715105; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Yildiz-Unal A, 2015, NEUROPSYCH DIS TREAT, V11, P297, DOI 10.2147/NDT.S78226; Yokobori S, 2013, J NEUROSURG, V118, P370, DOI 10.3171/2012.10.JNS12725	51	1	2	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2020	15	4							e0229520	10.1371/journal.pone.0229520	http://dx.doi.org/10.1371/journal.pone.0229520			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8IA	32236105	Green Published, gold			2023-01-03	WOS:000535938700010
J	Devi, S				Devi, Sharmila			Building bridges in Yemen	LANCET			English	Editorial Material																			0	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	2020	395	10228					939	939						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KX2XG	32199481	Green Published, Bronze			2023-01-03	WOS:000521744600014
J	Dzudie, A; Njume, E; Abanda, M; Aminde, L; Hamadou, B; Dzekem, B; Azabji, M; Doualla, MS; Ngowe, M; Kengne, AP				Dzudie, Anastase; Njume, Epie; Abanda, Martin; Aminde, Leopold; Hamadou, Ba; Dzekem, Bonaventure; Azabji, Marcel; Doualla, Marie Solange; Ngowe, Marcelin; Kengne, Andre P.			Availability, cost and affordability of essential cardiovascular disease medicines in the south west region of Cameroon: Preliminary findings from the Cameroon science for disease study	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; NONCOMMUNICABLE DISEASES; MIDDLE-INCOME	Background More than 80% of premature deaths due to cardiovascular disease (CVD) occur in low-and middle-income countries. However, access to, and affordability of medications remain a challenge in these countries. Objective To assess the availability, cost and affordability of essential cardiovascular medicines in the South West region of Cameroon. Methods In an audit of 63 medicine outlets, twenty-six essential medicines were surveyed using the World Health Organisation (WHO) /Health Action International methodology. Availability, costs and the ratio of the median price to the international reference price were evaluated in public, confessional, private facility medicine outlets, and community pharmacies. Affordability was assessed by calculating the number of days' wages it will cost the lowest-paid unskilled government worker to purchase a month worth of chronic treatment. Findings Availability ranged from 25.3% (public facility outlets) to 49.2% (community pharmacies) for all medicines. This was higher in urban and semi-urban compared to rural outlets. Cost of medicines was highest in community pharmacies and lowest in public facility outlets. Aspirin, digoxin, furosemide, hydrochlorothiazide and nifedipine were affordable (cost a day's wage or less). Medicines for heart failure and dyslipidaemia (beta blockers, angiotensin converting enzyme inhibitors and statins) required 2-5 days and 6-13 days wages respectively for one month of chronic treatment. Conclusion Overall availability of CVD essential medicines was lower than WHO recommendations, and medicines were largely unaffordable. While primary prevention is pivotal, improving availability and affordability of medicines especially for public facilities would provide additional benefit in curbing the CVD burden.	[Dzudie, Anastase; Doualla, Marie Solange; Ngowe, Marcelin] Univ Buea, Fac Hlth Sci, Buea, Cameroon; [Dzudie, Anastase; Njume, Epie; Abanda, Martin; Aminde, Leopold; Dzekem, Bonaventure; Kengne, Andre P.] Clin Res Educ Networking & Consultancy CRENC, Douala, Cameroon; [Dzudie, Anastase; Hamadou, Ba; Azabji, Marcel; Doualla, Marie Solange] Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon; [Dzudie, Anastase] Univ Cape Town, Fac Hlth Sci, Dept Med, Cape Town, South Africa; [Njume, Epie] Cameroon Baptist Convent Hlth Serv, Nkwen Bamenda, Cameroon; [Aminde, Leopold] Univ Queensland, Fac Med, Sch Publ Hlth, Brisbane, Qld, Australia; [Kengne, Andre P.] MRC, Noncommunicable Dis Unit, Cape Town, South Africa	University of Yaounde I; University of Cape Town; University of Queensland	Njume, E (corresponding author), Clin Res Educ Networking & Consultancy CRENC, Douala, Cameroon.; Njume, E (corresponding author), Cameroon Baptist Convent Hlth Serv, Nkwen Bamenda, Cameroon.	enjume20181@outlook.com	Kengne, Andre Pascal/ABB-3696-2020	NJUME, EPIE/0000-0002-1788-6958; DZUDIE, Anastase/0000-0003-4038-4128; Kengne, Andre Pascal/0000-0002-5183-131X				Abegunde D., ESSENTIAL MED NONCOM; [Anonymous], 2010, I MED US COMM PREV G; Boutayeb A., 2005, DOUBLE BURDEN COMMUN, DOI DOI 10.1016; Bovet P, 2012, PUB HLTH REV, V33, P397, DOI DOI 10.1007/BF03391643; Cameroon Data Portal, 2015, CAM CENS DAT; Dabare PRL, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-817; Dalal S, 2011, INT J EPIDEMIOL, V40, P885, DOI 10.1093/ije/dyr050; Echouffo-Tcheugui JB, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-44; Huffman MD, 2014, J AM COLL CARDIOL, V63, P1368, DOI 10.1016/j.jacc.2013.08.1665; Huffman MD, APPL RECOMMEND FIXED; Islam SMS, 2014, GLOBALIZATION HEALTH, V10, DOI 10.1186/s12992-014-0081-9; Jingi AM, 2014, PLOS ONE; Kengne AP, 2013, PROG CARDIOVASC DIS, V56, P302, DOI 10.1016/j.pcad.2013.10.011; Laslett LJ, 2012, J AM COLL CARDIOL, V60, pS1, DOI 10.1016/j.jacc.2012.11.002; Mensah GA, 2015, CARDIOVASC J AFR, V26, pS6, DOI 10.5830/CVJA-2015-036; Muszbek N, 2008, INT J CLIN PRACT, V62, P338, DOI 10.1111/j.1742-1241.2007.01683.x; Pena MSB, 2015, GLOB HEART, V10, P71, DOI 10.1016/j.gheart.2014.12.006; Robertson J, 2015, GLOBALIZATION HEALTH, V11, DOI 10.1186/s12992-015-0105-0; Tchoumi JCT, 2013, CARDIOVASC DIAGN THE, V3, P236, DOI 10.3978/j.issn.2223-3652.2013.12.05; van Mourik MSM, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-25; *WHO, 2002, INT MAN CARD RISK RE; WHO, 2015, WHO MODEL LIST ESSEN; World Economic Forum and the Harvard School of Public Health, 2011, GLOB EC BURD NONC DI; World Health Organisation, 2008, INT DRUG PRIC IND GU; World Health Organization, 2014, INT DRUG PRIC IND GU; World Health Organization, GLOB STAT REP NONC D; World Health Organization, 2014, NONC DIS COUNTR PROF; Yusuf S, 2011, LANCET, V378, P1231, DOI 10.1016/S0140-6736(11)61215-4	28	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2020	15	3							e0229307	10.1371/journal.pone.0229307	http://dx.doi.org/10.1371/journal.pone.0229307			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8QU	32130252	Green Published, gold			2023-01-03	WOS:000535264000020
J	Hunter, BR; Kirschner, JM				Hunter, Benton R.; Kirschner, Jonathan M.			In coma after cardiac arrest with nonshockable rhythm, therapeutic hypothermia improved 90-d neurologic outcome	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TEMPERATURE MANAGEMENT		[Hunter, Benton R.; Kirschner, Jonathan M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Hunter, BR (corresponding author), Indiana Univ Sch Med, Indianapolis, IN 46202 USA.							Donnino MW, 2015, CIRCULATION, V132, P2448, DOI 10.1161/CIR.0000000000000313; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519	2	0	0	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 18	2020	172	4					JC17	JC17		10.7326/ACPJ202002180-017	http://dx.doi.org/10.7326/ACPJ202002180-017			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ2FN	32066150				2023-01-03	WOS:000516744600012
J	Lively, A; Minard, LV; Scott, S; Deal, H; Lambourne, T; Giffin, J				Lively, Allison; Minard, Laura, V; Scott, Samantha; Deal, Heidi; Lambourne, Tessa; Giffin, Jenn			Exploring the perspectives of healthcare professionals in delivering optimal oncology medication education	PLOS ONE			English	Article							RELATING INFORMATION-NEEDS; QUALITY-OF-LIFE; BREAST-CANCER; PATIENT; SATISFACTION; CHEMOTHERAPY; PHARMACISTS; EXPERIENCE	Background To optimize patient education, it is important to understand what healthcare professionals perceive to be ideal oncology medication education for patients to receive, and what they feel is their role and the role of others in its delivery. Education provided to patients is an important component of chemotherapy as it has been shown to benefit and positively impact patients who receive it. Educational interventions are often provided by multidisciplinary teams with the goal of improving patient care. However, few studies have explored the roles of healthcare professionals in delivering oncology medication education. Objective To explore the perspectives of healthcare professionals working in medical, gynaecological or hematological oncology to identify what they perceive to be optimal oncology medication education for patients. Methods Healthcare professionals (physicians, nurses and pharmacists) working in medical, gynaecological or hematological oncology at the Nova Scotia Health Authority, Central Zone were invited to participate in one-on-one, semi-structured interviews which were audio-recorded, transcribed and analyzed using thematic analysis. Findings Fifteen interviews, including five physicians, four nurses and six pharmacists were conducted from February to April 2018. Four major themes were identified: Delivery of oncology medication education, Facilitating the patient learning process, Multidisciplinary Approach and Understanding barriers to the healthcare professional in providing education. Conclusion The identified themes uncovered novel ideas about how healthcare professionals felt oncology medication education could ideally be delivered to patients, and supported findings in the literature. Although participants discussed barriers to their ability to deliver optimal education, they also identified ways in which they can facilitate patient learning, for example, through the reinforcement of education. Participants recognized the importance of increasing collaboration and communication with the multidisciplinary team. This research will inform the design of any new models for oncology medication education at the Nova Scotia Health Authority, Central Zone and potentially other sites.	[Lively, Allison; Minard, Laura, V; Scott, Samantha] QEII Hlth Sci Ctr, Dept Pharm, Nova Scotia Hlth Author Cent Zone, Halifax, NS, Canada; [Deal, Heidi] Dalhousie Univ, Coll Pharm, Halifax, NS, Canada; [Lambourne, Tessa] Aberdeen Reg Hosp, Dept Pharm, Nova Scotia Hlth Author Northern Zone, New Glasgow, NS, Canada; [Giffin, Jenn] QEII Hlth Sci Ctr, Nova Scotia Hlth Author Cent Zone, Halifax, NS, Canada	Queen Elizabeth II Health Sciences Centre; Dalhousie University; Queen Elizabeth II Health Sciences Centre	Lively, A (corresponding author), QEII Hlth Sci Ctr, Dept Pharm, Nova Scotia Hlth Author Cent Zone, Halifax, NS, Canada.	Allisona.lively@nshealth.ca						Ahmadidarrehsima Sudabeh, 2016, Asian Pac J Cancer Prev, V17, P4555; [Anonymous], 2017, CHEM WORKS; [Anonymous], 2009, STAND PRACT ONC PHAR; Arber A, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12413; Barbour SY, 2008, AM J HEALTH-SYST PH, V65, pS16, DOI 10.2146/ajhp080090; Basch E, 2016, J CLIN ONCOL, V34, P557, DOI 10.1200/JCO.2015.63.0830; Capirci C, 2005, PATIENT EDUC COUNS, V56, P174, DOI 10.1016/j.pec.2004.02.006; Chung C, 2011, AM J HEALTH-SYST PH, V68, P1740, DOI 10.2146/ajhp100626; Cohen MR, 1996, AM J HEALTH-SYST PH, V53, P737, DOI 10.1093/ajhp/53.7.737; DiCicco-Bloom B, 2006, MED EDUC, V40, P314, DOI 10.1111/j.1365-2929.2006.02418.x; Divakaruni A, 2018, J ONCOL PHARM PRACT, V24, P337, DOI 10.1177/1078155217703790; Dohler N, 2011, PATIENT EDUC COUNS, V83, P367, DOI 10.1016/j.pec.2011.03.002; Donald G, 2017, J ONCOL PHARM PRACT; Esper P, 2015, J AM ASSOC NURSE PRA, V27, P308, DOI 10.1002/2327-6924.12169; FREDETTE SL, 1990, CANCER NURS, V13, P207, DOI 10.1097/00002820-199008000-00001; Gourdji I, 2003, J NURS CARE QUAL, V18, P43, DOI 10.1097/00001786-200301000-00007; Harris KA, 1998, CANCER PRACT, V6, P39, DOI 10.1046/j.1523-5394.1998.1998006039.x; Heisig SR, 2015, PSYCHO-ONCOLOGY, V24, P130, DOI 10.1002/pon.3611; Holloway S, 2012, CL LYMPH MYELOM LEUK, V12, P88, DOI 10.1016/j.clml.2011.10.004; Husson O, 2011, ANN ONCOL, V22, P761, DOI 10.1093/annonc/mdq413; Husson O, 2013, PSYCHO-ONCOLOGY, V22, P490, DOI 10.1002/pon.3042; Arraras JI, 2010, EUR J CANCER, V46, P2726, DOI 10.1016/j.ejca.2010.06.118; Iskandarsyah A, 2013, SUPPORT CARE CANCER, V21, P2999, DOI 10.1007/s00520-013-1877-5; Kaupp K, 2019, J ONCOL PHARM PRACT; Lambourne T, 2018, J CANC ED; Liekweg A, 2005, PHARM WORLD SCI, V27, P96, DOI 10.1007/s11096-004-5337-7; Morse Janice., 1995, QUALITATIVE RES METH; Ortlipp M, 2008, QUAL REP, V13, P695; Piredda M, 2008, EUR J ONCOL NURS, V12, P120, DOI 10.1016/j.ejon.2007.10.004; Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8; Schrag D, 2007, J CLIN ONCOL, V25, P233, DOI 10.1200/JCO.2006.09.2437; Starks H, 2007, QUAL HEALTH RES, V17, P1372, DOI 10.1177/1049732307307031; Thoma J, 2016, INT J CLIN PHARM-NET, V38, P855, DOI 10.1007/s11096-016-0297-2; Timmers L, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3110-2; Van der Molen B, 2000, EUR J CANCER CARE, V9, P41; Van der Molen B, 2000, EUR J CANCER CARE, V9, P48; Viele CS, 2007, AM J HEALTH-SYST PH, V64, pS25, DOI 10.2146/ajhp070037; Willis J.W., 2007, FDN QUALITATIVE RES; Yildirim S, 2018, J CANC ED	39	4	6	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2020	15	2							e0228571	10.1371/journal.pone.0228571	http://dx.doi.org/10.1371/journal.pone.0228571			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ7PV	32049970	Green Published, gold			2023-01-03	WOS:000535192300016
J	Dufresne, S; Gueritat, J; Chiavassa, S; Noblet, C; Assi, M; Rioux-Leclercq, N; Rannou-Bekono, F; Lefeuvre-Orfila, L; Paris, F; Rebillard, A				Dufresne, Suzanne; Gueritat, Jordan; Chiavassa, Sophie; Noblet, Caroline; Assi, Mohamad; Rioux-Leclercq, Nathalie; Rannou-Bekono, Francoise; Lefeuvre-Orfila, Luz; Paris, Francois; Rebillard, Amelie			Exercise training improves radiotherapy efficiency in a murine model of prostate cancer	FASEB JOURNAL			English	Article						oncology; physical activity; radiation therapy; treatment	RUNNING WHEEL EXERCISE; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; AEROBIC EXERCISE; MAMMARY CARCINOGENESIS; CONTROLLED-TRIAL; NK CELLS; PROGRESSION; TUMORS; MECHANISMS	Engaging in exercise while undergoing radiotherapy (RT) has been reported to be safe and achievable. The impact of exercise training (ET) on RT efficiency is however largely unknown. Our study aims to investigate the interactions between ET and RT on prostate cancer growth. Athymic mice received a subcutaneous injection of PPC-1 cells and were randomly assigned to either cancer control, cancer ET, cancer RT, or cancer RT combined with ET (CaRT-ET). Mice were sacrificed 24 days post-injection. All three intervention groups had reduced tumor size, the most important decrease being observed in CaRT-ET mice. Apoptotic marker cleaved caspase-3 was not modified by ET, but enhanced with RT. Importantly, this increase was the highest when the two strategies were combined. Furthermore, NK1.1 staining and gene expression of natural killer (NK) cell receptors Klrk1 and Il2r beta were not affected by ET alone but were increased with RT, this effect being potentiated when combined with ET. Overall, our study shows that (a) ET enhances RT efficiency by potentiating NK cell infiltration, and (b) while ET alone and ET combined with RT both reduce tumor growth, the mechanisms mediating these effects are different.	[Dufresne, Suzanne; Gueritat, Jordan; Assi, Mohamad; Rannou-Bekono, Francoise; Lefeuvre-Orfila, Luz; Rebillard, Amelie] Univ Rennes 2, ENS Rennes, EA 1274, Movement Sport & Hlth Sci Lab, Bruz, France; [Chiavassa, Sophie; Noblet, Caroline; Paris, Francois] Univ Nantes, Univ Angers, INSERM, CRCINA, Nantes, France; [Chiavassa, Sophie; Noblet, Caroline; Paris, Francois] Ouest Ctr Rene Gauducheau, Inst Cancerol, St Herblain, France; [Rioux-Leclercq, Nathalie] Univ Rennes 1, Dept Pathol Anat & Cytol, Rennes, France	Ecole Normale Superieure de Rennes (ENS Rennes); Universite Rennes 2; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Universite de Rennes	Dufresne, S; Rebillard, A (corresponding author), Sport & Hlth Sci Lab, EA 1274, Campus Ker Lann,Ave Robert Schuman, F-35170 Bruz, France.	suzanne.dufresne@ens-rennes.fr; amelie.rebillard@univ-rennes2.fr	Paris, francois E/L-4915-2015	Paris, francois E/0000-0002-0176-7348	Ministere de l'Education Nationale, de l'Enseignement Superieur et de la Recherche (MENESR)	Ministere de l'Education Nationale, de l'Enseignement Superieur et de la Recherche (MENESR)	Ministere de l'Education Nationale, de l'Enseignement Superieur et de la Recherche (MENESR)	Acosta AM, 2018, HUM PATHOL, V75, P1, DOI 10.1016/j.humpath.2017.11.015; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aoi W, 2013, GUT, V62, P882, DOI 10.1136/gutjnl-2011-300776; Ashcraft KA, 2019, SEMIN RADIAT ONCOL, V29, P16, DOI 10.1016/j.semradonc.2018.10.001; Ashcraft KA, 2016, CANCER RES, V76, P4032, DOI 10.1158/0008-5472.CAN-16-0887; Baumfalk DR, 2019, J APPL PHYSIOL, V126, P668, DOI 10.1152/japplphysiol.00829.2018; Betof AS, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv040; Bonn SE, 2015, CANCER EPIDEM BIOMAR, V24, P57, DOI 10.1158/1055-9965.EPI-14-0707; Bray F, 2018, CA CANC J CLIN; Cantoni C, 2016, J IMMUNOL RES, V2016, P1; Chamie K, 2015, JAMA ONCOL, V1, P60, DOI 10.1001/jamaoncol.2014.192; Cooperberg MR, 2010, J CLIN ONCOL, V28, P1117, DOI 10.1200/JCO.2009.26.0133; DAVIES KJA, 1982, BIOCHEM BIOPH RES CO, V107, P1198, DOI 10.1016/S0006-291X(82)80124-1; Dayanc BE, 2008, INT J HYPERTHER, V24, P41, DOI 10.1080/02656730701858297; Domanska-Senderowska D, 2019, INT J SPORTS MED, V40, P227, DOI 10.1055/a-0824-4813; Dufresne S, 2018, CANCER EPIDEM BIOMAR, V27, P11, DOI 10.1158/1055-9965.EPI-16-0969; Eisemann N, 2015, BMC UROL, V15, DOI 10.1186/s12894-015-0025-6; Esser KA, 2009, PROSTATE, V69, P1372, DOI 10.1002/pros.20987; Feng X, 2015, ONCOTARGET, V6, P32353, DOI 10.18632/oncotarget.5898; Finne E, 2018, CANCER MANAG RES, V10, P5125, DOI 10.2147/CMAR.S170064; Meneses-Echavez JF, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2733-z; Galvao DA, 2018, MED SCI SPORT EXER, V50, P393, DOI 10.1249/MSS.0000000000001454; Gannon NP, 2015, INT J CANCER, V136, pE197, DOI 10.1002/ijc.29142; Garcia E, 2016, J APPL PHYSIOL, V121, P15, DOI 10.1152/japplphysiol.00266.2016; Gueritat J, 2014, FREE RADICAL BIO MED, V77, P95, DOI 10.1016/j.freeradbiomed.2014.09.009; Guo NN, 2018, ONCOL LETT, V16, P6045, DOI 10.3892/ol.2018.9399; Heywood R, 2017, SUPPORT CARE CANCER, V25, P3031, DOI 10.1007/s00520-017-3827-0; Hojman P, 2011, AM J PHYSIOL-ENDOC M, V301, pE504, DOI 10.1152/ajpendo.00520.2010; Idorn M, 2016, TRENDS MOL MED, V22, P565, DOI 10.1016/j.molmed.2016.05.007; IJsbrandy C, 2018, CRIT REV ONCOL HEMAT, V122, P157, DOI 10.1016/j.critrevonc.2017.09.005; Isanejad A, 2016, LIFE SCI, V151, P30, DOI 10.1016/j.lfs.2016.02.090; Jones LW, 2012, J APPL PHYSIOL, V113, P263, DOI 10.1152/japplphysiol.01575.2011; Jones LW, 2005, CLIN CANCER RES, V11, P6695, DOI 10.1158/1078-0432.CCR-05-0844; Karamanolis G, 2013, Mediators Inflamm, V2013, P515048, DOI 10.1155/2013/515048; Katz M, 2007, BBA-MOL CELL RES, V1773, P1161, DOI 10.1016/j.bbamcr.2007.01.002; Kaur P, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00191; Kenfield SA, 2011, J CLIN ONCOL, V29, P726, DOI 10.1200/JCO.2010.31.5226; Knols R, 2005, J CLIN ONCOL, V23, P3830, DOI 10.1200/JCO.2005.02.148; Koukourakis MI, 2001, ANTICANCER RES, V21, P4285; Larsen Stine K., 2014, Critical Reviews in Oncogenesis, V19, P91; Lin SC, 2012, J CLIN ENDOCR METAB, V97, pE1515, DOI 10.1210/jc.2012-1450; Liu FF, 2018, ACTA PHARM SIN B, V8, P552, DOI 10.1016/j.apsb.2018.01.008; Mah AY, 2016, CRIT REV IMMUNOL, V36, P131, DOI 10.1615/CritRevImmunol.2016017387; McCullough DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju036; McCullough DJ, 2013, J APPL PHYSIOL, V115, P1846, DOI 10.1152/japplphysiol.00949.2013; Mina DS, 2013, CUAJ-CAN UROL ASSOC, V7, pE692, DOI 10.5489/cuaj.235; Monga U, 2007, ARCH PHYS MED REHAB, V88, P1416, DOI 10.1016/j.apmr.2007.08.110; Park B, 2014, INT J MOL SCI, V15, P927, DOI 10.3390/ijms15010927; Pedersen L, 2016, CELL METAB, V23, P554, DOI 10.1016/j.cmet.2016.01.011; Pedersen L, 2015, CANCER J, V21, P111, DOI 10.1097/PPO.0000000000000096; Peeken JC, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00132; Phillips SM, 2015, J CANCER SURVIV, V9, P500, DOI 10.1007/s11764-015-0426-2; Quarmby S, 1999, ARTERIOSCL THROM VAS, V19, P588, DOI 10.1161/01.ATV.19.3.588; Reefman E, 2010, J IMMUNOL, V184, P4852, DOI 10.4049/jimmunol.0803954; Richman EL, 2011, CANCER RES, V71, P3889, DOI 10.1158/0008-5472.CAN-10-3932; Roth AJ, 2008, FUTURE ONCOL, V4, P561, DOI 10.2217/14796694.4.4.561; Sak K, 2018, ANTICANCER RES, V38, P6209, DOI 10.21873/anticanres.12975; Schadler KL, 2016, ONCOTARGET, V7, P65429, DOI 10.18632/oncotarget.11748; Schmitz KH, 2010, MED SCI SPORT EXER, V42, P1409, DOI 10.1249/MSS.0b013e3181e0c112; Segal RJ, 2009, J CLIN ONCOL, V27, P344, DOI 10.1200/JCO.2007.15.4963; SHEPHARD RJ, 1994, BRIT J SPORT MED, V28, P247, DOI 10.1136/bjsm.28.4.247; Shephard RJ, 2010, EXERC IMMUNOL REV, V16, P194; Smith DP, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4817; Smyth MJ, 2005, MOL IMMUNOL, V42, P501, DOI 10.1016/j.molimm.2004.07.034; Sturgeon K, 2014, AM J PHYSIOL-REG I, V307, pR685, DOI 10.1152/ajpregu.00082.2014; Truong PT, 2011, AM J CLIN ONCOL-CANC, V34, P350, DOI 10.1097/COC.0b013e3181e841ec; UHLENBRUCK G, 1991, INT J SPORTS MED, V12, pS63, DOI 10.1055/s-2007-1024753; Urgard E, 2017, NUCLEIC ACID THER, V27, P295, DOI 10.1089/nat.2017.0670; Vandersluis AD, 2013, PROSTATE, V73, P1223, DOI 10.1002/pros.22673; Walsh NP, 2011, EXERC IMMUNOL REV, V17, P64; Windsor PM, 2004, CANCER, V101, P550, DOI 10.1002/cncr.20378; Zhang Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0131-3; Zheng X, 2008, ONCOL REP, V19, P1583; Zheng X, 2012, NUTR CANCER, V64, P1029, DOI 10.1080/01635581.2012.716899; Zheng X, 2011, EXP THER MED, V2, P221, DOI 10.3892/etm.2011.203; Zhu ZJ, 2008, CANCER EPIDEM BIOMAR, V17, P1920, DOI 10.1158/1055-9965.EPI-08-0175; Zhu ZJ, 2012, CANCER PREV RES, V5, P414, DOI 10.1158/1940-6207.CAPR-11-0454	77	11	11	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2020	34	4					4984	4996		10.1096/fj.201901728R	http://dx.doi.org/10.1096/fj.201901728R		FEB 2020	13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LJ5ZA	32043634				2023-01-03	WOS:000512671900001
J	Fermont, JM; Bolton, CE; Fisk, M; Mohan, D; Macnee, W; Cockcroft, JR; McEniery, C; Fuld, J; Cheriyan, J; Tal-Singer, R; Wilkinson, IB; Wood, AM; Polkey, MI; Mullerova, H				Fermont, Jilles M.; Bolton, Charlotte E.; Fisk, Marie; Mohan, Divya; Macnee, William; Cockcroft, John R.; McEniery, Carmel; Fuld, Jonathan; Cheriyan, Joseph; Tal-Singer, Ruth; Wilkinson, Ian B.; Wood, Angela M.; Polkey, Michael I.; Mullerova, Hana			Risk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational study	PLOS ONE			English	Article							ACUTE EXACERBATIONS; DISEASE; MORTALITY; VALIDITY; STRENGTH	In chronic obstructive pulmonary disease (COPD), acute exacerbation of COPD requiring hospital admission is associated with mortality and healthcare costs. The ERICA study assessed multiple clinical measures in people with COPD, including the short physical performance battery (SPPB), a simple test of physical function with 3 components (gait speed, balance and sit-to-stand). We tested the hypothesis that SPPB score would relate to risk of hospital admissions and length of hospital stay. Data were analysed from 714 of the total 729 participants (434 men and 280 women) with COPD. Data from this prospective observational longitudinal study were obtained from 4 secondary and 1 tertiary centres from England, Scotland, and Wales. The main outcome measures were to estimate the risk of hospitalisation with acute exacerbation of COPD (AECOPD and length of hospital stay derived from hospital episode statistics (HES). In total, 291 of 714 individuals experienced 762 hospitalised AECOPD during five-year follow up. Poorer performance of SPPB was associated with both higher rate (IRR 1.08 per 1 point decrease, 95% CI 1.01 to 1.14) and increased length of stay (IRR 1.18 per 1 point decrease, 95% CI 1.10 to 1.27) for hospitalised AECOPD. For the individual sit-to-stand component of the SPPB, the association was even stronger (IRR 1.14, 95% CI 1.02 to 1.26 for rate and IRR 1.32, 95% CI 1.16 to 1.49 for length of stay for hospitalised AECOPD). The SPPB, and in particular the sit-to-stand component can both evaluate the risk of H-AECOPD and length of hospital stay in COPD. The SPPB can aid in clinical decision making and when prioritising healthcare resources.	[Fermont, Jilles M.; Fisk, Marie; McEniery, Carmel; Cheriyan, Joseph; Wilkinson, Ian B.] Univ Cambridge, Div Expt Med & Immunotherapeut, Dept Med, Cambridge, England; [Fermont, Jilles M.; Wood, Angela M.] Univ Cambridge, Dept Publ Hlth & Primary Care, British Heart Fdn, Cardiovasc Epidemiol Unit, Cambridge, England; [Bolton, Charlotte E.] Univ Nottingham, Sch Med, Div Resp Med, Nottingham, England; [Bolton, Charlotte E.] Univ Nottingham, Sch Med, NIHR Nottingham BRC Resp Theme, Nottingham, England; [Mohan, Divya; Tal-Singer, Ruth] Value Evidence & Outcomes GSK, Med Innovat, Collegeville, PA USA; [Macnee, William] Univ Edinburgh, Queens Med Res Inst, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland; [Cockcroft, John R.] Columbia Univ, Dept Cardiol, Med Ctr, New York, NY USA; [Fuld, Jonathan] Cambridge Univ Hosp NHS Fdn Trust, Dept Resp Med, Cambridge, England; [Wilkinson, Ian B.] Addenbrookes Hosp, Cambridge Univ Hosp NHS Fdn Trust, Cambridge Clin Trials Unit, Cambridge, England; [Wood, Angela M.] Univ Cambridge, British Heart Fdn, Ctr Res Excellence, Cambridge, England; [Wood, Angela M.] Univ Cambridge, Natl Inst Hlth Res Blood & Transplant Res Unit Do, Cambridge, England; [Wood, Angela M.] Univ Cambridge, Natl Inst Hlth Res, Cambridge Biomed Res Ctr, Cambridge, England; [Wood, Angela M.] Cambridge Univ Hosp, Cambridge, England; [Wood, Angela M.] Wellcome Genome Campus, Hlth Data Res UK Cambridge, Cambridge, England; [Wood, Angela M.] Univ Cambridge, Cambridge, England; [Polkey, Michael I.] Royal Brompton Hosp, Dept Resp Med, London, England; [Mullerova, Hana] Value Evidence & Outcomes GSK, Epidemiol, Uxbridge, Middx, England	University of Cambridge; University of Cambridge; University of Nottingham; University of Nottingham; University of Edinburgh; Columbia University; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Royal Brompton Hospital	Fermont, JM (corresponding author), Univ Cambridge, Div Expt Med & Immunotherapeut, Dept Med, Cambridge, England.; Fermont, JM (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, British Heart Fdn, Cardiovasc Epidemiol Unit, Cambridge, England.	jmf88@medschl.cam.ac.uk	Wood, Angela/GZA-5762-2022; Cheriyan, Joseph/B-2596-2009; Cockcroft, John/AAC-2545-2022; Tal-Singer, Ruth/AAQ-2925-2021; Bolton, Charlotte/S-9589-2017	Wood, Angela/0000-0002-7937-304X; Cheriyan, Joseph/0000-0001-6921-1592; Tal-Singer, Ruth/0000-0002-5275-8062; Fuld, Jonathan/0000-0003-1847-184X; Bolton, Charlotte/0000-0002-9578-2249; Fermont, Jilles/0000-0001-5042-5785; Fisk, Marie/0000-0002-1292-7642; wilkinson, ian/0000-0001-6598-9399	Innovate UK [9157-61188]; NIHR Cambridge Comprehensive Biomedical Research Centre; NIHR Nottingham BRC respiratory theme; UK Medical Research Council [MR/L003120/1]; British Heart Foundation [RG/13/13/30194, RG/18/13/33946]; National Institute for Health Research [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust]; Health Data Research UK - UK Medical Research Council; Engineering and Physical Sciences Research Council; Economic and Social Research Council; Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation; Wellcome; GSK; MRC [MR/K014811/1, G0701619, MR/L003120/1] Funding Source: UKRI	Innovate UK(UK Research & Innovation (UKRI)Innovate UK); NIHR Cambridge Comprehensive Biomedical Research Centre; NIHR Nottingham BRC respiratory theme; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); National Institute for Health Research [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust]; Health Data Research UK - UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation(British Heart Foundation); Wellcome; GSK(GlaxoSmithKline); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This was an investigator sponsored study. The study was funded by a grant (9157-61188) from Innovate UK (formerly known as Technology Strategy Board) with contributory funding in kind (e.g. scientific expertise and meeting rooms) from GSK, a consortium partner, who also funded the corresponding author's PhD. As a consortium partner, GSK was involved in the study design, data analysis, decision to publish, and preparation of the manuscript. The specific roles of all authors are articulated in the `author contributions' section. RTS was a co-investigator on the grant and as a consortium member was involved in the decision to publish, and preparation of the manuscript. IBW, JC and CMM acknowledge funding support from the NIHR Cambridge Comprehensive Biomedical Research Centre. CEB is supported by the NIHR Nottingham BRC respiratory theme. This work was supported by core funding from: the UK Medical Research Council (MR/L003120/1), the British Heart Foundation (RG/13/13/30194; RG/18/13/33946) and the National Institute for Health Research [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust] [.]. This work was also supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome.. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.	Barker R, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.congress-2018.PA3850; Bhatt SP, 2019, AM J RESP CRIT CARE, V200, P511, DOI 10.1164/rccm.201902-0314LE; Canavan JL, 2015, AM J RESP CRIT CARE, V192, P395, DOI 10.1164/rccm.201501-0082LE; Celli B, 2016, AM J RESP CRIT CARE, V194, P1483, DOI 10.1164/rccm.201508-1653OC; Cohen J., 2013, STAT POWER ANAL BEHA; Committee for Medicinal Products for Human Use, 2015, POINTS CONS FRAIL EV; Crook S, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0598-6; Ford ES, 2015, CHEST, V147, P31, DOI 10.1378/chest.14-0972; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2019, POCK GUID COPD DIAGN; Hopkinson NS, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4486; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Jinks RC, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0078-y; Jones SE, 2013, THORAX, V68, P1015, DOI 10.1136/thoraxjnl-2013-203576; Kon SSC, 2015, THORAX, V70, P1131, DOI 10.1136/thoraxjnl-2015-207046; McLean S, 2016, SCI REP-UK, V6, DOI 10.1038/srep31893; Mohan D, 2018, THORAX, V73, P1182, DOI 10.1136/thoraxjnl-2018-211556; Mohan D, 2014, COPD, V11, P552, DOI 10.3109/15412555.2014.898031; National Health Services Digital, HOSP ADM PAT CAR ACT; National Institute for Health and Care Excellence, 2018, CHRONIC OBSTRUCTIVE; NORRISH A, 1994, AM J EPIDEMIOL, V140, P938, DOI 10.1093/oxfordjournals.aje.a117182; Puhan MA, 2013, EUR RESPIR J, V42, P956, DOI 10.1183/09031936.00131612; Rothnie KJ, 2016, CLIN EPIDEMIOL, V8, P771, DOI 10.2147/CLEP.S117867; Sapey E, 2019, THORAX, V74, P898, DOI 10.1136/thoraxjnl-2018-213035; Seidl H, 2016, J EVAL CLIN PRACT, V22, P446, DOI 10.1111/jep.12506; Seymour JM, 2010, EUR RESPIR J, V36, P81, DOI 10.1183/09031936.00104909; Stone RA, 2017, WHO CARES IT MATTERS; Swallow EB, 2007, THORAX, V62, P115, DOI 10.1136/thx.2006.062026; Troosters T, 2000, AM J MED, V109, P207, DOI 10.1016/S0002-9343(00)00472-1; Troosters T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010106; Van Belle G., 2011, STAT RULES THUMB; Vestbo J, 2008, EUR RESPIR J, V31, P869, DOI 10.1183/09031936.00111707; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Walker PP, 2018, AM J RESP CRIT CARE, V198, P620, DOI 10.1164/rccm.201712-2404OC	33	9	9	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2020	15	2							e0228940	10.1371/journal.pone.0228940	http://dx.doi.org/10.1371/journal.pone.0228940			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9IO	32040531	gold, Green Published, Green Submitted			2023-01-03	WOS:000534629400056
J	Johr, J; Halimi, F; Pasquier, J; Pincherle, A; Schiff, N; Diserens, K				Joehr, Jane; Halimi, Floriana; Pasquier, Jerome; Pincherle, Alessandro; Schiff, Nicholas; Diserens, Karin			Recovery in cognitive motor dissociation after severe brain injury: A cohort study	PLOS ONE			English	Article							MINIMALLY CONSCIOUS STATE; INTERNATIONAL-CLASSIFICATION; BARTHEL INDEX; INPATIENT REHABILITATION; FOLLOW-UP; CORE SET; DISABILITY; SCALE; HEALTH; VALIDATION	Objective To investigate the functional and cognitive outcomes during early intensive neurorehabilitation and to compare the recovery patterns of patients presenting with cognitive motor dissociation (CMD), disorders of consciousness (DOC) and non-DOC. Methods We conducted a single center observational cohort study of 141 patients with severe acquired brain injury, consecutively admitted to an acute neurorehabilitation unit. We divided patients into three groups according to initial neurobehavioral diagnosis at admission using the Coma Recovery Scale-Revised (CRS-R) and the Motor Behavior Tool (MBT): potential clinical CMD, [N = 105]; DOC [N = 19]; non-DOC [N = 17]). Functional and cognitive outcomes were assessed at admission and discharge using the Glasgow Outcome Scale, the Early Rehabilitation Barthel Index, the Disability Rating Scale, the Rancho Los Amigos Levels of Cognitive Functioning, the Functional Ambulation Classification Scale and the modified Rankin Scale. Confirmed recovery of conscious awareness was based on CRS-R criteria. Results CMD patients were significantly associated with better functional outcomes and potential for improvement than DOC. Furthermore, outcomes of CMD patients did not differ significantly from those of non-DOC. Using the CRS-R scale only; approximatively 30% of CMD patients did not recover consciousness at discharge. Interpretation Our findings support the fact that patients presenting with CMD condition constitute a separate category, with different potential for improvement and functional outcomes than patients suffering from DOC. This reinforces the need for CMD to be urgently recognized, as it may directly affect patient care, influencing life-or-death decisions.	[Joehr, Jane; Halimi, Floriana; Pincherle, Alessandro; Diserens, Karin] Univ Hosp Lausanne, Dept Clin Neurosci, Neurol Serv, Acute Neu Rorehabil Unit, Lausanne, Switzerland; [Pasquier, Jerome] Univ Lausanne, Ctr Primary Care & Publ Hlth, Lausanne, Switzerland; [Schiff, Nicholas] Weill Cornell Med, Feil Family Brain & Mind Res Inst, New York, NY USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Cornell University	Johr, J (corresponding author), Univ Hosp Lausanne, Dept Clin Neurosci, Neurol Serv, Acute Neu Rorehabil Unit, Lausanne, Switzerland.	jane.johr@chuv.ch	Jöhr, Jane/AAL-3611-2021	Johr, Jane/0000-0003-4280-9310				Attwell C, 2019, NEUROREHABILITATION; Bagnato S, 2011, J PERIPHER NERV SYST, V16, P315, DOI 10.1111/j.1529-8027.2011.00363.x; Bates D, 2001, J NEUROL NEUROSUR PS, V71, P20; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Claassen J, 2019, NEW ENGL J MED, V380, P2497, DOI 10.1056/NEJMoa1812757; Curley WH, 2018, BRAIN, V141, P1404, DOI 10.1093/brain/awy070; Dahl TH, 2002, J REHABIL MED, V34, P201, DOI 10.1080/165019702760279170; Di HB, 2008, CLIN MED, V8, P502, DOI 10.7861/clinmedicine.8-5-502; Edlow BL, 2017, BRAIN, V140, P2399, DOI 10.1093/brain/awx176; Evans M, 2017, DISABIL REHABIL, V39, P2544, DOI 10.1080/09638288.2016.1239763; Faugeras F, 2018, BRAIN INJURY, V32, P72, DOI 10.1080/02699052.2017.1364421; Fernandez-Espejo D, 2015, JAMA NEUROL, V72, P1442, DOI 10.1001/jamaneurol.2015.2614; Forgacs PB, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00259; Forgacs PB, 2014, ANN NEUROL, V76, P869, DOI 10.1002/ana.24283; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gill-Thwaites H, 2006, BRAIN INJURY, V20, P1321, DOI 10.1080/02699050601081802; Grahn B, 2000, DISABIL REHABIL, V22, P639, DOI 10.1080/096382800445443; Hagen C, 1972, LEVELS COGNITIVE FUN, P6; Houlden H, 2006, CLIN REHABIL, V20, P153, DOI 10.1191/0269215506cr917oa; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Kondziella D, 2016, J NEUROL NEUROSUR PS, V87, P485, DOI 10.1136/jnnp-2015-310958; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Latronico N, 2011, LANCET NEUROL, V10, P931, DOI 10.1016/S1474-4422(11)70178-8; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; Lu J, 2008, J NEUROTRAUM, V25, P641, DOI 10.1089/neu.2007.0510; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Pignat JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156882; Pincherle A, 2019, ANN NEUROL, V85, P443, DOI 10.1002/ana.25417; Posner JB, 2007, PLUM POSNERS DIAGNOS; Quinn TJ, 2009, STROKE, V40, P3393, DOI [10.1161/STROKEAHA.109.557256, 10.1161/STROKEAHA.108.522516]; Quintas R, 2012, AM J PHYS MED REHAB, V91, pS14, DOI 10.1097/PHM.0b013e31823d4ba9; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rauch A, 2008, EUR J PHYS REHAB MED, V44, P329; Rollnik JD, 2011, REHABILITATION, V50, P408, DOI 10.1055/s-0031-1273728; Schiff ND, 2015, JAMA NEUROL, V72, P1413, DOI 10.1001/jamaneurol.2015.2899; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Siegert R, 2004, DISABIL REHABIL, V26, P1, DOI 10.1080/09638280410001644932; Silberstein Morry, 2002, Neurosurg Focus, V13, pecp2, DOI 10.3171/foc.2002.13.1.6; Spiegel DR, 2008, J NEUROPSYCH CLIN N, V20, P93, DOI 10.1176/jnp.2008.20.1.93; Stender J, 2014, LANCET, V384, P514, DOI 10.1016/S0140-6736(14)60042-8; Sulter G, 1999, STROKE, V30, P1538, DOI 10.1161/01.STR.30.8.1538; Viosca E, 2005, ARCH PHYS MED REHAB, V86, P1234, DOI 10.1016/j.apmr.2004.11.016; Wang FY, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0330-7; Willems M, 2015, INT J ENV RES PUB HE, V12, P3707, DOI 10.3390/ijerph120403707	50	18	19	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2020	15	2							e0228474	10.1371/journal.pone.0228474	http://dx.doi.org/10.1371/journal.pone.0228474			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP9FN	32023323	Green Published, gold			2023-01-03	WOS:000534621500056
J	Fujiyoshi, K; Minami, Y; Yamaoka-Tojo, M; Kutsuna, T; Obara, S; Aoyama, A; Ako, J				Fujiyoshi, Kazuhiro; Minami, Yoshiyasu; Yamaoka-Tojo, Minako; Kutsuna, Toshiki; Obara, Shinichi; Aoyama, Akihiro; Ako, Junya			Effect of cardiac rehabilitation on cognitive function in elderly patients with cardiovascular diseases	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; HEART-FAILURE; IMPAIRMENT; DEMENTIA; GAIT; GUIDELINES; PREDICTOR; STRENGTH	Background Cognitive function is an important factor for secondary prevention in elderly patients with cardiovascular diseases. The objective of this study was to evaluate the impact of cardiac rehabilitation (CR) on the improvement of cognitive function. Methods A total of 66 consecutive elderly patients (>70 years old) with cardiovascular diseases were prospectively enrolled. The change in cognitive function during 6 months was compared between the patients with monthly CR (at least once per month; n = 27) and those without monthly CR (n = 39). Cognitive function was evaluated using the Mini-mental State Examination (MMSE) and Frontal Assessment Battery (FAB). Results There was no significant difference in baseline characteristics between the 2 groups. The change in the MMSE score was significantly greater in patients with monthly CR than in those without monthly CR (2.3 +/- 0.4 vs. -0.1 0.3 points; p < 0.001). Among the MMSE items, the change in temporal orientation and attention and calculation was significantly greater in the monthly CR group than in the non-monthly CR group (0.8 +/- 0.7 vs. -0.1 +/- 0.8 points [p < 0.001] and 1.0 +/- 1.5 vs. -0.1 +/- 0.1 points [p < 0.001], respectively). The general linear model revealed that monthly CR (effect estimate, 1.455; 95% confidence interval, 0.747-2.163; p < 0.001) was independently associated with the change in the MMSE score. Conclusions Cognitive function may improve with regular CR. These results might partly explain the efficacy of CR for secondary prevention.	[Fujiyoshi, Kazuhiro; Minami, Yoshiyasu; Ako, Junya] Kitasato Univ Sch Med, Dept Cardiovasc Med, Sagamihara, Kanagawa, Japan; [Yamaoka-Tojo, Minako; Aoyama, Akihiro] Kitasato Univ, Sch Allied Hlth Sci, Dept Rehabil, Sagamihara, Kanagawa, Japan; [Kutsuna, Toshiki; Obara, Shinichi] Kitasato Univ, East Hosp, Dept Cardiac Rehabil, Sagamihara, Kanagawa, Japan	Kitasato University; Kitasato University; Kitasato University	Yamaoka-Tojo, M (corresponding author), Kitasato Univ, Sch Allied Hlth Sci, Dept Rehabil, Sagamihara, Kanagawa, Japan.	myamaoka@med.kitasato-u.ac.jp	prevention, Cardiovascular disease/AAQ-2486-2020; Minami, Yoshiyasu/GRY-2665-2022	prevention, Cardiovascular disease/0000-0003-3890-3777; Kutsuna, Toshiki/0000-0001-9252-4474	MEXT KAKENHI; (Ministry of Education, Culture, Sports, Science and Technology) [JP15K01389]	MEXT KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); (Ministry of Education, Culture, Sports, Science and Technology)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by MEXT KAKENHI (Grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology) grant number JP15K01389.	Abete P, 2014, AGEING RES REV, V18, P41, DOI 10.1016/j.arr.2014.07.003; Aguirre E, 2013, AGEING RES REV, V12, P253, DOI 10.1016/j.arr.2012.07.001; Alfini AJ, 2019, J ALZHEIMERS DIS, V67, P671, DOI 10.3233/JAD-180728; Blumenthal JA, 2016, CIRCULATION, V133, P1341, DOI 10.1161/CIRCULATIONAHA.115.018926; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Fletcher GF, 2018, J AM COLL CARDIOL, V72, P1622, DOI 10.1016/j.jacc.2018.08.2141; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fujiyoshi K, 2018, INT HEART J, V59, P1034, DOI 10.1536/ihj.17-610; Groot C, 2016, AGEING RES REV, V25, P13, DOI 10.1016/j.arr.2015.11.005; Jefferson AL, 2011, AM J CARDIOL, V108, P1346, DOI 10.1016/j.amjcard.2011.06.056; Kamiya K, 2018, EUR J PREV CARDIOL, V25, P212, DOI 10.1177/2047487317735715; Kamiya K, 2015, AM J MED, V128, P1212, DOI 10.1016/j.amjmed.2015.06.035; Kaufer DI, 2008, J AM MED DIR ASSOC, V9, P586, DOI 10.1016/j.jamda.2008.05.006; Kwak YS, 2008, INT J SPORT MED, V29, P2008; Leto L, 2014, J GERIATR CARDIOL, V11, P316, DOI 10.11909/j.issn.1671-5411.2014.04.007; Mavros Y, 2017, J AM GERIATR SOC, V65, P550, DOI 10.1111/jgs.14542; Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5; Nohara R, 2014, CIRC J, V78, P2022, DOI 10.1253/circj.CJ-66-0094; Rich MW, 2016, J AM COLL CARDIOL, V67, P2419, DOI 10.1016/j.jacc.2016.03.004; Salzwedel A, 2019, EUR J PREV CARDIOL, V26, P46, DOI 10.1177/2047487318791609; Sauve MJ, 2009, J CARD FAIL, V15, P1, DOI 10.1016/j.cardfail.2008.08.007; Shi J, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-2040-5; Sugie M, 2018, ESC HEART FAIL, V5, P877, DOI 10.1002/ehf2.12311; Thomas RJ, 2018, J AM COLL CARDIOL, V71, P1814, DOI 10.1016/j.jacc.2018.01.004; Tsoi KKF, 2015, JAMA INTERN MED, V175, P1450, DOI 10.1001/jamainternmed.2015.2152; Verghese J, 2002, NEW ENGL J MED, V347, P1761, DOI 10.1056/NEJMoa020441; Verghese J, 2008, J AM GERIATR SOC, V56, P1244, DOI 10.1111/j.1532-5415.2008.01758.x; Verma S, 2002, CIRCULATION, V106, P913, DOI 10.1161/01.CIR.0000029802.88087.5E	29	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2020	15	5							e0233688	10.1371/journal.pone.0233688	http://dx.doi.org/10.1371/journal.pone.0233688			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1WS	32470061	Green Published, gold			2023-01-03	WOS:000537552800135
J	Sandblom, V; Spetz, J; Shubbar, E; Montelius, M; Stahl, I; Swanpalmer, J; Nilsson, O; Forssell-Aronsson, E				Sandblom, Viktor; Spetz, Johan; Shubbar, Emman; Montelius, Mikael; Stahl, Ingun; Swanpalmer, John; Nilsson, Ola; Forssell-Aronsson, Eva			Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors	PLOS ONE			English	Article							RECEPTOR RADIONUCLIDE THERAPY; ENDOTHELIAL GROWTH-FACTOR; RET PROTOONCOGENE; CABOZANTINIB XL184; PHASE-III; CARCINOMA; LU-177-DOTATATE; SOMATOSTATIN; VANDETANIB; SURVIVAL	Since patients with medullary thyroid cancer (MTC) often have metastatic disease at the time of diagnosis, the development of efficient systemic treatment options for MTC is important. Vandetanib and cabozantinib are two tyrosine kinase inhibitors (TKIs) that were recently approved by FDA and EMA for systemic treatment of metastatic MTC. Additionally, since MTC is of a neuroendocrine tumour type, treatment with radiolabelled somatostatin analogues (e.g. Lu-177-octreotate) is a valid option for patients with MTC. The aim of this study was to investigate the potentially increased therapeutic effect of combining radiation therapy with these TKIs for treatment of MTC in a mouse model. Nude mice carrying patient-derived MTC tumours (GOT2) were treated with external beam radiotherapy (EBRT) and/or one of the two TKIs vandetanib or cabozantinib. The tumour volume was determined and compared with that of mock-treated controls. The treatment doses were chosen to give a moderate effect as monotherapy to be able to detect any increased therapeutic effect from the combination therapy. At the end of follow-up, tumours were processed for immunohistochemical (IHC) analyses. The animals in the combination therapy groups showed the largest reduction in tumour volume and the longest time to tumour progression. Two weeks after start of treatment, the tumour volume for these mice was reduced by about 70-75% compared with controls. Furthermore, also EBRT and TKI monotherapy resulted in a clear anti-tumour effect with a reduced tumour growth compared with controls. The results show that an increased therapeutic effect could be achieved when irradiation is combined with TKIs for treatment of MTC. Future studies should evaluate the potential of using Lu-177-octreotate therapy in combination with TKIs in patients.	[Sandblom, Viktor; Spetz, Johan; Shubbar, Emman; Montelius, Mikael; Stahl, Ingun; Swanpalmer, John; Forssell-Aronsson, Eva] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Sahlgrenska Canc Ctr,Dept Radiat Phys, Gothenburg, Sweden; [Stahl, Ingun; Swanpalmer, John; Forssell-Aronsson, Eva] Sahlgrens Univ Hosp, Dept Med Phys & Biomed Engn, Gothenburg, Sweden; [Nilsson, Ola] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Sahlgrenska Canc Ctr,Dept Pathol, Gothenburg, Sweden	University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg	Sandblom, V (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Sahlgrenska Canc Ctr,Dept Radiat Phys, Gothenburg, Sweden.	viktor.sandblom@vgregion.se	Spetz, Johan/P-1662-2017	Spetz, Johan/0000-0002-5216-9786; Forssell-Aronsson, Eva/0000-0002-7558-4368	Swedish Research Council [21073]; Swedish Cancer Society [3427]; BioCARE - a National Strategic Research Program at the University of Gothenburg; Swedish government [ALFGBG-725031]; King Gustav V Jubilee Clinic Cancer Research Foundation; Sahlgrenska University Hospital Research Funds; Assar Gabrielsson Cancer Research Foundation; Adlerbertska Research Foundation; Herbert & Karin Jacobsson Foundation; Royal Society of Arts and Sciences in Gothenburg (KVVS); Wilhelm and Martina Lundgren Research Foundation; Swedish county councils - the ALFagreement [ALFGBG-725031]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); BioCARE - a National Strategic Research Program at the University of Gothenburg; Swedish government; King Gustav V Jubilee Clinic Cancer Research Foundation; Sahlgrenska University Hospital Research Funds; Assar Gabrielsson Cancer Research Foundation; Adlerbertska Research Foundation; Herbert & Karin Jacobsson Foundation; Royal Society of Arts and Sciences in Gothenburg (KVVS); Wilhelm and Martina Lundgren Research Foundation; Swedish county councils - the ALFagreement	This study was supported by grants from the Swedish Research Council (grant no. 21073), the Swedish Cancer Society (grant no. 3427), BioCARE - a National Strategic Research Program at the University of Gothenburg, the Swedish state under the agreement between the Swedish government and the county councils - the ALFagreement (ALFGBG-725031), the King Gustav V Jubilee Clinic Cancer Research Foundation to EFA, as well as grants from the Sahlgrenska University Hospital Research Funds, the Assar Gabrielsson Cancer Research Foundation, the Adlerbertska Research Foundation, the Herbert & Karin Jacobsson Foundation, the Royal Society of Arts and Sciences in Gothenburg (KVVS), and the Wilhelm and Martina Lundgren Research Foundation to VS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bentzien F, 2013, THYROID, V23, P1569, DOI 10.1089/thy.2013.0137; Bergsma H, 2018, J NUCL MED, V59, P452, DOI 10.2967/jnumed.117.189712; Bergsma H, 2016, EUR J NUCL MED MOL I, V43, P1802, DOI 10.1007/s00259-016-3382-9; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; Bodei L, 2004, CANCER BIOTHER RADIO, V19, P65, DOI 10.1089/108497804773391694; Brabander T, 2017, CLIN CANCER RES, V23, P4617, DOI 10.1158/1078-0432.CCR-16-2743; Capp C, 2010, THYROID, V20, P863, DOI 10.1089/thy.2009.0417; Carlomagno F, 2002, CANCER RES, V62, P7284; Dalmo J, 2012, ONCOL REP, V27, P174, DOI 10.3892/or.2011.1494; Elisei R, 2013, J CLIN ONCOL, V31, P3639, DOI 10.1200/JCO.2012.48.4659; Forssell-Aronsson E, 2004, ACTA ONCOL, V43, P436, DOI 10.1080/02841860410030670; Forssell-Aronsson EB, 2000, J NUCL MED, V41, P636; Forssell-Aronsson E, 2013, NEUROENDOCRINOLOGY, V97, P86, DOI 10.1159/000336086; Greco WR, 1996, J NATL CANCER I, V88, P699, DOI 10.1093/jnci/88.11.699; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HOLM S, 1979, SCAND J STAT, V6, P65; Iten F, 2007, CLIN CANCER RES, V13, P6696, DOI 10.1158/1078-0432.CCR-07-0935; Johanson V, 2007, ENDOCR-RELAT CANCER, V14, P433, DOI 10.1677/ERC-06-0033; Kurzrock R, 2011, J CLIN ONCOL, V29, P2660, DOI 10.1200/JCO.2010.32.4145; Makis W, 2015, CLIN NUCL MED, V40, P408, DOI 10.1097/RLU.0000000000000706; Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P249, DOI 10.1046/j.1365-2265.1996.681503.x; Mato E, 1998, J CLIN ENDOCR METAB, V83, P2417, DOI 10.1210/jc.83.7.2417; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Palmer AC, 2017, CELL, V171, P1678, DOI 10.1016/j.cell.2017.11.009; Robinson BG, 2010, J CLIN ENDOCR METAB, V95, P2664, DOI 10.1210/jc.2009-2461; Roman S, 2006, CANCER, V107, P2134, DOI 10.1002/cncr.22244; Salavati A, 2016, SEMIN NUCL MED, V46, P215, DOI 10.1053/j.semnuclmed.2016.01.010; Sandblom V, 2014, CANCER CHEMOTH PHARM, V73, P219, DOI [10.1007/, DOI 10.1007/]; Smith M, 2016, J CLIN ONCOL, V34, P3005, DOI 10.1200/JCO.2015.65.5597; Strosberg J, 2017, NEW ENGL J MED, V376, P125, DOI 10.1056/NEJMoa1607427; Vaisman F, 2015, CLIN NUCL MED, V40, P123, DOI 10.1097/RLU.0000000000000628; Waldherr C, 2001, NUCL MED COMMUN, V22, P673, DOI 10.1097/00006231-200106000-00011; Wedge SR, 2002, CANCER RES, V62, P4645; Wells SA, 2015, THYROID, V25, P567, DOI 10.1089/thy.2014.0335; Wells SA, 2012, J CLIN ONCOL, V30, P134, DOI 10.1200/JCO.2011.35.5040; Wells SA, 2010, J CLIN ONCOL, V28, P767, DOI 10.1200/JCO.2009.23.6604; Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535-7163.MCT-11-0264; Yeh PJ, 2009, NAT REV MICROBIOL, V7, P460, DOI 10.1038/nrmicro2133	38	1	4	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2020	15	5							e0233720	10.1371/journal.pone.0233720	http://dx.doi.org/10.1371/journal.pone.0233720			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1ON	32459817	gold, Green Published			2023-01-03	WOS:000537531500024
J	Ghazi, IM; El Nekidy, WS; Asay, R; Fingmori, P; Knarr, A; Awad, M				Ghazi, Islam M.; El Nekidy, Wasim S.; Asay, Regan; Fingmori, Paul; Knarr, Anthony; Awad, Mina			Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach	PLOS ONE			English	Article							PHYSICAL COMPATIBILITY; DRUGS	Imipenem/cilastatin/relebactam is a beta-lactam/beta-lactamase inhibitor that has been recently FDA approved for complicated intra-abdominal and urinary tract infections under the brand name Recarbrio (R). It has activity against imipenem non-susceptible Pseudomonas species as well as KPC-producing Enterobacteriaceae. Optimization of PK/PD of antimicrobials particularly in critically-ill patients is essential, but unfortunately, is hindered by separate administration that requires significant resources. The objective of the study is to investigate the compatibility of Y-site administration of imipenem/cilastatin/relebactam with a wide range of antimicrobials. After admixture, physical characteristics, pH changes and turbidity were measured for each 2-drug combination at a time. With the exception of amphotericin B deoxycholate, and posaconazole, imipenem/cilastatin/relebactam was compatible with a variety of antimicrobial agents. The compatibility profile described, will facilitate incorporation into hospital protocols, contribute to therapy optimization and guide clinicians to avoid successive administration, consequently resulting in reduction of total infusion time, optimization of PK/PD, economizing nursing time and cost containment.	[Ghazi, Islam M.; Asay, Regan; Fingmori, Paul; Knarr, Anthony; Awad, Mina] Univ Sci, Philadelphia Coll Pharm, Philadelphia, PA USA; [El Nekidy, Wasim S.] Cleveland Clin Abu Dhabi, Abu Dhabi, U Arab Emirates; [El Nekidy, Wasim S.] Cleveland Clin, Lerner Coll Med, Abu Dhabi, U Arab Emirates	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Ghazi, IM (corresponding author), Univ Sci, Philadelphia Coll Pharm, Philadelphia, PA USA.	i.ghazi@usciences.edu	Ghazi, Islam/X-6108-2019; El Nekidy, Wasim S./I-6814-2019	Ghazi, Islam/0000-0003-1108-7706; El Nekidy, Wasim S./0000-0003-3109-0590	Merck Co USA	Merck Co USA(Merck & Company)	The corresponding author, IG received research grant from Merck & Co USA to support this study. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLEN LV, 1977, AM J HOSP PHARM, V34, P939, DOI 10.1093/ajhp/34.9.939; [Anonymous], 2019, CLIN INFECT DIS; Canver MC, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00672-19; Ghazi I, 2016, AM J HEALTH-SYST PH, V73, P1769, DOI 10.2146/ajhp150721; Kidd JM, 2018, CLIN THER, V40, P261, DOI 10.1016/j.clinthera.2017.12.007; Newton DW, 2009, AM J HEALTH-SYST PH, V66, P348, DOI 10.2146/ajhp080059; TRISSEL LA, 1992, AM J HOSP PHARM, V49, P1716, DOI 10.1093/ajhp/49.7.1716; Trissel LA, 2004, AM J HEALTH-SYST PH, V61, P2289, DOI 10.1093/ajhp/61.21.2289; Veiga RP, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2155-1; Young K, 2019, BMC MICROBIOL, V19, DOI 10.1186/s12866-019-1522-7	10	3	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2020	15	5							e0233335	10.1371/journal.pone.0233335	http://dx.doi.org/10.1371/journal.pone.0233335			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1CK	32421696	Green Published, gold			2023-01-03	WOS:000537499600043
J	Peterson, A; Largent, EA; Karlawish, J				Peterson, Andrew; Largent, Emily A.; Karlawish, Jason			Ethics of reallocating ventilators in the covid-19 pandemic	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CARE		[Peterson, Andrew] George Mason Univ, Inst Philosophy & Publ Policy, Dept Philosophy, Fairfax, VA 22030 USA; [Largent, Emily A.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA; [Largent, Emily A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Karlawish, Jason] Univ Penn, Dept Med, Med Ethics & Hlth Policy & Neurol, Penn Memory Ctr, Philadelphia, PA 19104 USA; [Karlawish, Jason] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	George Mason University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Peterson, A (corresponding author), George Mason Univ, Inst Philosophy & Publ Policy, Dept Philosophy, Fairfax, VA 22030 USA.	apeter31@gmu.edu		Largent, Emily/0000-0002-7536-5077	Greenwall Foundation faculty scholars programme; NIA [P30-AG01024]	Greenwall Foundation faculty scholars programme; NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	AP is supported by the Greenwall Foundation faculty scholars programme. EAL is supported by NIA grant K01-AG064123 and JK is supported by NIA grant P30-AG01024.	Alzheimer Europe, 2020, POS REG ALL SCARC ME; Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Biddison LD, 2014, CHEST, V146, pE145S, DOI 10.1378/chest.14-0742; British Medical Association, 2020, COV 19 ETH ISS GUID; Cook D, 2014, NEW ENGL J MED, V370, P2506, DOI 10.1056/NEJMra1208795; Corley MC, 2005, NURS ETHICS, V12, P381, DOI 10.1191/0969733005ne809oa; DYER O, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1483; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Greenberg N, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1211; HADORN DC, 1992, JAMA-J AM MED ASSOC, V268, P1454, DOI 10.1001/jama.268.11.1454; IACOBUCCI G, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1280; Jacoby L, 2010, AM J CRIT CARE, V19, pE52, DOI 10.4037/ajcc2010396; Litz BT, 2009, CLIN PSYCHOL REV, V29, P695, DOI 10.1016/j.cpr.2009.07.003; McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412; National Institute for Health and Care Excellence, 2020, COV 19 RAP GUID CRIT; New York State Task Force on Life and the Law New York State Department of Health, 2015, VENT ALL GUID 2015; NHS, 2020, CLIN GUID MAN PALL C; Peterson A, 2020, J MED ETHICS BL 0427; RADA AG, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1554; Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141; Richardson S, 2020, JAMA; Royal College of Physicians, 2020, ETH DIM COVID 19 FRO; US Department of Health and Human Services, OCR ANN COV 19 TRIAG; VitalTalk, COV 19 TALK POINTS; White DB, 2020, MODEL HOSP POLICY AL; White DB, 2020, JAMA-J AM MED ASSOC, V323, P1773, DOI 10.1001/jama.2020.5046; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5	28	28	30	3	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 12	2020	369								m1828	10.1136/bmj.m1828	http://dx.doi.org/10.1136/bmj.m1828			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV3IM	32398225				2023-01-03	WOS:000538333000002
J	Coffin, PO; Rowe, C; Oman, N; Sinchek, K; Santos, GM; Paul, M; Bagnulo, R; Mohamed, D; Vittinghoff, E				Coffin, Phillip O.; Rowe, Christopher; Oman, Natalie; Sinchek, Katie; Santos, Glenn-Milo; Paul, Mark; Bagnulo, Rita; Mohamed, Deeqa; Vittinghoff, Eric			Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain	PLOS ONE			English	Article							LIFETIME DRINKING HISTORY; OVERDOSE DEATHS; DRUG-USE; RELIABILITY; THERAPY; COHORT; FREQUENCY; PATTERNS; CLIENTS; FLORIDA	Background After decades of increased opioid pain reliever prescribing, providers are rapidly reducing prescribing. We hypothesized that reduced access to prescribed opioid pain relievers among patients previously reliant upon opioid pain relievers would result in increased illicit opioid use. Methods and findings We conducted a retrospective cohort study among 602 publicly insured primary care patients who had been prescribed opioids for chronic non-cancer pain for at least three consecutive months in San Francisco, recruited through convenience sampling. We conducted a historical reconstruction interview and medical chart abstraction focused on illicit substance use and opioid pain reliever prescriptions, respectively, from 2012 through the interview date in 2017-2018. We used a nested-cohort design, in which patients were classified, based on opioid pain reliever dose change, into a series of nested cohorts starting with each follow-up quarter. Using continuation-ratio models, we estimated associations between opioid prescription discontinuation or 30% increase or decrease in dose, relative to no change, and subsequent frequency of heroin and non-prescribed opioid pain reliever use, separately. Models controlled for demographics, clinical and behavioral characteristics, and past use of heroin or non-prescribed opioid pain relievers. A total of 56,372 and 56,484 participant-quarter observations were included from the 597 and 598 participants available for analyses of heroin and non-prescribed opioid pain reliever outcomes, respectively. Participants discontinued from prescribed opioids were more likely to use heroin (Adjusted Odds Ratio (AOR) = 1.57, 95% CI: 1.25-1.97) and non-prescribed opioid pain relievers (AOR = 1.75, 1.45-2.11) more frequently in subsequent quarters compared to participants with unchanged opioid prescriptions. Participants whose opioid pain reliever dose increased were more likely to use heroin more frequently (AOR = 1.67, 1.32-2.12). Results held throughout sensitivity analyses. The main limitations were the observational nature of results and limited generalizability beyond safety-net settings. Conclusions Discontinuation of prescribed opioid pain relievers was associated with more frequent non-prescribed opioid pain reliever and heroin use; increased dose was also associated with more frequent heroin use. Clinicians should be aware of these risks in determining pain management approaches.	[Coffin, Phillip O.; Rowe, Christopher; Oman, Natalie; Sinchek, Katie; Santos, Glenn-Milo; Bagnulo, Rita; Mohamed, Deeqa] San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA; [Coffin, Phillip O.; Santos, Glenn-Milo; Vittinghoff, Eric] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Rowe, Christopher] Univ Calif Berkeley, Berkeley, CA 94720 USA; [Paul, Mark] Ctr Dis Control & Prevent, Atlanta, GA USA	San Francisco Department of Public Health; University of California System; University of California San Francisco; University of California System; University of California Berkeley; Centers for Disease Control & Prevention - USA	Coffin, PO (corresponding author), San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA.; Coffin, PO (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	phillip.coffin@ucsf.edu	; Coffin, Phillip/G-3286-2012	Vittinghoff, Eric/0000-0001-8535-0920; Faul, Mark/0000-0002-7683-0348; Sinchek, Katherine/0000-0002-7049-8241; Coffin, Phillip/0000-0002-3891-6570	Centers for Disease Control and Prevention (CDC) [U01CE002793]	Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	PC received grant U01CE002793 from the Centers for Disease Control and Prevention (CDC; cdc.gov). The funder did not assist with the conduct of the study and collection, management, analysis, and interpretation of the data. The CDC reviewed the manuscript, but did not have a role in preparation or approval of the manuscript, or the decision to submit for publication. The CDC author had a role in preparation, review, and approval of the manuscript and the decision to submit the manuscript for publication.	[Anonymous], 2018, STATA J, V18, P924; Bohnert ASB, 2018, ANN INTERN MED, V169, P367, DOI 10.7326/M18-1243; Centers for Disease Control and Prevention, 2017, POCK GUID TAP OP CHR; CHAIKELSON JS, 1994, J STUD ALCOHOL, V55, P133, DOI 10.15288/jsa.1994.55.133; Chou R, 2014, NIH PATHWAYS PREVENT, P29; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Czermak C, 2005, ADDICT BEHAV, V30, P361, DOI 10.1016/j.addbeh.2004.05.005; Darke S, 2014, ADDICTION, V109, P1237, DOI 10.1111/add.12456; Dasgupta N, 2014, DRUG ALCOHOL DEPEN, V145, P238, DOI 10.1016/j.drugalcdep.2014.10.005; Dowell D, 2019, NEW ENGL J MED, V380, P2285, DOI 10.1056/NEJMp1904190; Dowell D, 2016, AM FAM PHYSICIAN, V93, P970; Frank JW, 2017, ANN INTERN MED, V167, P181, DOI 10.7326/M17-0598; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; GLADSJO JA, 1992, ADDICT BEHAV, V17, P347, DOI 10.1016/0306-4603(92)90040-3; Guarino H, 2018, ADDICT BEHAV, V86, P118, DOI 10.1016/j.addbeh.2018.04.017; Harocopos A, 2016, INT J DRUG POLICY, V28, P106, DOI 10.1016/j.drugpo.2015.12.021; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; Hernan MA, 2008, EPIDEMIOLOGY, V19, P766, DOI 10.1097/EDE.0b013e3181875e61; Huang XW, 2018, AM J PUBLIC HEALTH, V108, P131, DOI 10.2105/AJPH.2017.304142; Jacob T, 2006, PSYCHOL ADDICT BEHAV, V20, P333, DOI 10.1037/0893-164X.20.3.333; Johnson H, 2014, MMWR-MORBID MORTAL W, V63, P569; Kennedy-Hendricks A, 2016, AM J PUBLIC HEALTH, V106, P291, DOI 10.2105/AJPH.2015.302953; Koenig LB, 2009, J STUD ALCOHOL DRUGS, V70, P296, DOI 10.15288/jsad.2009.70.296; Lake S, 2015, AM J DRUG ALCOHOL AB, V41, P257, DOI 10.3109/00952990.2014.998366; Larance B, 2015, J SUBST ABUSE TREAT, V58, P51, DOI 10.1016/j.jsat.2015.06.001; Latimer J, 2016, INT J DRUG POLICY, V37, P111, DOI 10.1016/j.drugpo.2016.08.004; Liebling EJ, 2018, ADDICT BEHAV, V76, P20, DOI 10.1016/j.addbeh.2017.07.017; Mark TL, 2019, J SUBST ABUSE TREAT, V103, P58, DOI 10.1016/j.jsat.2019.05.001; Mars SG, 2015, SOC SCI MED, V140, P44, DOI 10.1016/j.socscimed.2015.06.032; Means B, 1989, NATL CTR HLTH STAT A; Paulozzi LJ, 2007, INJURY PREV, V13, P130, DOI 10.1136/ip.2006.014357; Pitt AL, 2018, AM J PUBLIC HEALTH, V108, P1394, DOI 10.2105/AJPH.2018.304590; Pouget ER, 2017, SUBST USE MISUSE, P1, DOI [10.1080/08897077.2017.1281646, DOI 10.1080/08897077.2017.1281646]; Robins JM, 1999, J AM STAT ASSOC, V94, P687, DOI 10.2307/2669978; Roxburg A, 2017, DRUG ALCOHOL DEPEN, V176, P126, DOI 10.1016/j.drugalcdep.2017.02.027; SAMUELS JF, 1992, BRIT J ADDICT, V87, P417; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; SOBELL LC, 1988, J STUD ALCOHOL, V49, P225, DOI 10.15288/jsa.1988.49.225; VLAHOV D, 1990, AM J EPIDEMIOL, V132, P847, DOI 10.1093/oxfordjournals.aje.a115727	42	21	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2020	15	5							e0232538	10.1371/journal.pone.0232538	http://dx.doi.org/10.1371/journal.pone.0232538			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LT3GS	32365132	gold, Green Published			2023-01-03	WOS:000536959700038
J	Ansari, M; Alanazi, A; Moin, A				Ansari, Mukhtar; Alanazi, Abdulrahman; Moin, Afrasim			Consumers' awareness, attitude and associated factors towards self-medication in Hail, Saudi Arabia	PLOS ONE			English	Article							UNIVERSITY-STUDENTS; PATTERNS; RISKS	Objectives To determine the factors motivating the consumers towards self-medication, the intended indications and the consumers' perceptions about complications that may arise due to its use. Design Cross-sectional community based prospective study Place and duration of study Community pharmacies located at various locations of Hail, Saudi Arabia from January 2019 to March 2019. Methods The subjects of this cross-sectional study were people visiting community pharmacies for self-medication. Data on 663 participants was collected through a validated questionnaire prepared on the basis of WHO guidelines for the regulatory assessment of medicinal products for use in self-medication. Two trained data collectors visited the randomly selected community pharmacies, approached and interviewed the consumers purchasing medicines without prescriptions. Data was entered in SPSS and analyzed using descriptive and inferential analyses (alpha level = 0.05). Results Out of 663 respondents, 68.6% were university graduates; and 33.9% were healthcare professionals. Consumers preferred self-medication mainly for headache (85.8%), cold and sore throat (80.8%), cough (75.7%) and fever (71.8%) with the justification that these illnesses were minor (90.2%), time saving (82.2%), convenient (74.7%), quicker relief (66.1%), and economical (61.2%). Occupation was significantly associated with the reasons for preferring self-medication (p<0.001). Similarly, age, gender and education were also significantly associated with most of the reasons for opting self-medication. People were quite aware about harmful consequences of self-medication. Multivariate logistic regression analysis showed that the respondents with lower education (AOR = 2.404 [95% CI: 1.579-3.661]), non-healthcare professionals (AOR = 1.712 [95% CI: 1.143-2.565]) and higher monthly income (AOR = 0.376 [95% CI: 0.236-0.599]) preferred self-medication (p < 0.001, p = 0.009, p <0.001) respectively. Conclusion Self-medication was prevalent among young university graduate males for minor ailments mainly due to convenience and time saving. Despite people beliefs about the harmful consequences of self-medication, its use was omnipresent particularly among the respondents with lower education, non-healthcare professionals and people with higher monthly income.	[Ansari, Mukhtar; Alanazi, Abdulrahman] Univ Hail, Dept Clin Pharm, Coll Pharm, Hail, Saudi Arabia; [Moin, Afrasim] Univ Hail, Dept Pharmaceut, Coll Pharm, Hail, Saudi Arabia	University Ha'il; University Ha'il	Ansari, M (corresponding author), Univ Hail, Dept Clin Pharm, Coll Pharm, Hail, Saudi Arabia.	mukhtaransari@hotmail.com	ansari, mukhtar/A-1506-2017; moin, afrasim/A-9254-2012	ansari, mukhtar/0000-0002-5247-6356; moin, afrasim/0000-0002-3902-1162	Research Deanship of University of Ha'il -Saudi Arabia [160873]	Research Deanship of University of Ha'il -Saudi Arabia	This research was funded by Research Deanship of University of Ha'il -Saudi Arabia through project grant number (160873). However, the funding agency had no role in study design, data collection, analyses, preparation of the manuscript and decision to publish.	Abahussain E, 2005, MED PRIN PRACT, V14, P161, DOI 10.1159/000084633; Al Flaiti M, 2014, J ACUTE DIS, V3, P249, DOI 10.1016/S2221-6189(14)60056-1; Albawani SM., 2016, INT J PHARM PHARM SC, V8, P119, DOI 10.22159/ijpps.2016v8i10.12748; Albusalih FA, 2017, PHARMACY, V5, DOI 10.3390/pharmacy5030051; Alghanim S. A., 2011, Eastern Mediterranean Health Journal, V17, P409; Aljadhey H, 2015, SAUDI MED J, V36, P328, DOI 10.15537/smj.2015.3.10523; Almalak H, 2014, SAUDI PHARM J, V22, P107, DOI 10.1016/j.jsps.2013.02.004; Alnemri AR, 2016, CURR PEDIAT RES, V20, P169; [Anonymous], 2016, RAOSOFT SAMPLE SIZE; Araia ZZ, 2019, J PHARM POLICY PRACT, V12, DOI 10.1186/s40545-019-0165-2; Awad AI, 2006, EUR J CLIN PHARMACOL, V62, P317, DOI 10.1007/s00228-006-0107-1; Bin Nafisah S, 2017, J INFECT PUBLIC HEAL, V10, P522, DOI 10.1016/j.jiph.2016.09.016; Clavijo H A, 1995, World Health Forum, V16, P403; Eldalo AS, 2013, ARCH PHARM PRACT, V4, P57, DOI 10.4103/2045-080X.112985; Ruiz ME, 2010, CURR DRUG SAF, V5, P315, DOI 10.2174/157488610792245966; Eticha T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097464; Albarran KF, 2008, PHARM WORLD SCI, V30, P863, DOI 10.1007/s11096-008-9241-4; Gelayee DA, 2017, J PHARMACEUTICS, V2017, DOI 10.1155/2017/8680714; Genral Authority for Statistics Kingdom of Saudi Arabia, 2015, POP HAIL REG GEND AG; George D, 2003, SPSS WINDOWS STEP ST; Hamel MJ, 2001, B WORLD HEALTH ORGAN, V79, P1014; Hughes CM, 2001, DRUG SAFETY, V24, P1027, DOI 10.2165/00002018-200124140-00002; James H, 2006, MED PRIN PRACT, V15, P270, DOI 10.1159/000092989; Jassim Abdul-Mohsin, 2010, Oman Med J, V25, P79, DOI 10.5001/omj.2010.25; Karimy M, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7302-3; Keshari SS, 2014, INDIAN J CLIN PRACT, V25, P636; Lei XS, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010068; Livemint, 2008, SELF MED POP MED STU; Loyola Filho Antônio I. de, 2004, Cad. Saúde Pública, V20, P1661, DOI 10.1590/S0102-311X2004000600025; Phalke VD, 2006, INDIAN J COMMUNITY M, V31, P34, DOI DOI 10.4103/0970-0218.54933; Saeed MS, 2014, ARCH PHARM PRACT, V5, P149, DOI 10.4103/2045-080X.142049; Saudi Business Directory, 2019, PHARM HAIL; Selvaraj Kalaiselvi, 2014, Perspect Clin Res, V5, P32, DOI 10.4103/2229-3485.124569; Shankar P R, 2002, BMC Fam Pract, V3, P17, DOI 10.1186/1471-2296-3-17; Sharif S., 2015, PHARM PHARMACOL-RUSS, V6, P428, DOI [10.4236/pp.2015.69044, DOI 10.4236/PP.2015.69044]; Sridhar Sathvik B, 2018, Int J Appl Basic Med Res, V8, P3, DOI 10.4103/ijabmr.IJABMR_46_17; Suleiman AK, 2013, ARCH PHARM PRACT, V4, P180, DOI 10.4103/2045-080X.123228; World Health Organization, 2000, REG GUID TEL PROD; World Health Organization, 2002, PROMOTING RATIONAL U; World Health Organization, 2000, GUID REG ASS MED PRO; Yousef AMM, 2008, PHARM WORLD SCI, V30, P24, DOI 10.1007/s11096-007-9135-x	41	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2020	15	4							e0232322	10.1371/journal.pone.0232322	http://dx.doi.org/10.1371/journal.pone.0232322			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LS8WP	32343748	Green Published, gold			2023-01-03	WOS:000536661300052
J	Efa, BW; Berhanie, E; Desta, KW; Hinkosa, L; Fetensa, G; Etafa, W; Tsegaye, R				Efa, Bizuneh Wakuma; Berhanie, Emebet; Desta, Kalkidan Wondwossen; Hinkosa, Leta; Fetensa, Getahun; Etafa, Werku; Tsegaye, Reta			Essential new-born care practices and associated factors among post natal mothers in Nekemte City, Western Ethiopia	PLOS ONE			English	Article								Background New-born survival is a prominent goal on the global health agenda and an important area of focus for programs seeking to ensure child survival. Geographically, neonatal deaths are most prevalent in Sub-Saharan Africa and southern Asia, accounting for 39% and 38% of all neonatal deaths respectively while Ethiopia in particular has 28% neonatal death. Promotion of essential new-born care practice is one of a cheap approach to improve health outcomes of new-born babies. Thus, this study was aimed to assess the magnitude of essential newborn care practices and associated factors among postnatal mothers in Nekemte city, Western Ethiopia. Methods An institution-based cross-sectional study was conducted from February to March, 2017, in Nekemte city, East Wollega Zone. Data was collected from 417 randomly selected mothers who have less than six months infants by face to face interview in three public health institutions of Nekemte City, Ethiopia. Women who were not biological mother to the new-born were excluded from the study. The collected data were coded, cleaned and entered using Epi-Data version 3.1 and analysed using Statistical Package for Social Science (SPSS) version 21.0. Both bivariable and multivariable logistic regression analysis were computed to identify associated factors. The strength of association was measured by odds ratios with 95% confidence interval (CI) at a p-value of < 0.05 and finally obtained results were presented by using simple frequency tables, graphs, and charts. Results The study revealed that the level of essential new-born care practice was 184(44.1%). The overall safe cord care practice of the respondents was 285 (68.3%) while the optimal thermal care practices and good neonatal feeding were 328 (78.7%) and 322 (77.2%) respectively. Having visit to Antenatal Care (ANC) [Adjusted Odds Ratio (AOR) = 4.38, 95% CI = (1.38, 13.94)], knowledge of essential new-born care [AOR = 4.58, 95% CI = (2.93, 7.16)], and counselled about essential new-born care [AOR = 2.32, 95% CI = (1.38, 3.91)] were factors significantly associated with good practices of essential new-born care. Conclusion This study indicated that the level of essential new-born care practice was unsatisfactory in the study area. Promotion of essential new-born care through the provision of community awareness and provision of counselling on essential new-born care and neonatal danger signs to all pregnant women should be given emphasis.	[Efa, Bizuneh Wakuma; Hinkosa, Leta; Fetensa, Getahun; Etafa, Werku; Tsegaye, Reta] Wollega Univ, Inst Hlth Sci, Sch Nursing & Midwifery, Nekemte, Ethiopia; [Berhanie, Emebet; Desta, Kalkidan Wondwossen] Addis Ababa Univ, Sch Allied Hlth Sci, Dept Nursing & Midwifery, Addis Ababa, Ethiopia	Addis Ababa University	Tsegaye, R (corresponding author), Wollega Univ, Inst Hlth Sci, Sch Nursing & Midwifery, Nekemte, Ethiopia.	retatg@gmail.com	Hirko, Getahun Fetensa/ABY-0109-2022; Ebi, Werku Etafa/Q-2742-2019	Ebi, Werku Etafa/0000-0001-9576-8888; Desta, Kalkidan Wondwossen/0000-0002-3508-1272; Tsegaye, Reta/0000-0003-4721-3647	Addis Ababa University	Addis Ababa University	BW received funding for this study from Addis Ababa University. The funder has no role in study design, data collection and analysis, decision to publish, or preparation of this manuscript.	Ababor S, 2019, ETHIOP J HEALTH SCI, V29, P343, DOI 10.4314/ejhs.v29i3.6; [Anonymous], 2004, WHAT WORKS CHILDREN; [Anonymous], 2014, MANAGEMENT PROTOCOL; [Anonymous], 2015, NATL NEWB CHILD SURV; Berhe M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175902; Berhea TA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202542; Callaghan-Koru JA, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-198; Carvajal-Aguirre L, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020508; Central statistical agency (CSA) [Ethiopia] and ICF, 2016, ETH DEM HLTH SURV 20; Chaudhary J., 2013, J CHITWAN MED COLL, V3, P42, DOI [DOI 10.3126/jcmc.v3i1.8465, 10.3126/jcmc.v3i1.8465, DOI 10.3126/JCMC.V3I1.8465]; Chichiabellu TY, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0609-1; Costello A, 2000, CURRENT STATE HLTH N; Federal Democratic Republic of Ethiopia Ministry of Health, 2010, MAN PROT SEL OBST TO; Gebretsadik A, 2018, DOVE PRESS J PEDIAT; Hug L, 2017, LEVELS TRENDS CHILD; Kokebie T., 2015, INT J ADV SCI RES, V1, P17, DOI [DOI 10.7439/ijasr.v1i1.1637, 10.7439/ijasr.v1i1.1637, DOI 10.7439/IJASR.V1I1.1637]; Mersha A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208984; Monebenimp F., 2013, HLTH SCI DIS, V14; Rahman M, 2011, JOGNN-J OBST GYN NEO, V40, P262, DOI 10.1111/j.1552-6909.2011.01240.x; Reshma, 2014, NITTE UNIV J HEALTH, V4, P21; Saaka M, 2014, INT J POPUL RES, V2014, P10, DOI DOI 10.1155/2014/404387; Semanew Y, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4133-3; Setegn T, 2011, BMC PUBLIC HEALTH, V11, P1; Shrestha T, 2013, J NEPAL MED ASS, V52; Sinha LN, 2014, WEST PAC SURVEILL RE, V5, P22, DOI [10.5365/WPSAR.2014.5.1.006, 10.5365/wpsar.2014.5.1.006]; Tafere TE, 2018, ITAL J PEDIATR, V44, DOI 10.1186/s13052-018-0544-3; Tinker A, 2010, GLOB PUBLIC HEALTH, V5, P28, DOI 10.1080/17441690903286572; Waiswa P, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-9; World Health Organization, 1996, REP TECHN WORK GROUP; You DZ, 2015, LANCET, V386, P2275, DOI 10.1016/S0140-6736(15)00120-8	30	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2020	15	4							e0231354	10.1371/journal.pone.0231354	http://dx.doi.org/10.1371/journal.pone.0231354			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9OP	32315342	Green Published, gold			2023-01-03	WOS:000536024800025
J	Barbe, A; Mellouk, N; Rame, C; Grandhaye, J; Staub, C; Venturi, E; Cirot, M; Petit, A; Anger, K; Chahnamian, M; Ganier, P; Callut, O; Cailleau-Audouin, E; Metayer-Coustard, S; Riva, A; Froment, P; Dupont, J				Barbe, Alix; Mellouk, Namya; Rame, Christelle; Grandhaye, Jeremy; Staub, Christophe; Venturi, Eric; Cirot, Marine; Petit, Angelique; Anger, Karine; Chahnamian, Marine; Ganier, Patrice; Callut, Olivier; Cailleau-Audouin, Estelle; Metayer-Coustard, Sonia; Riva, Antonella; Froment, Pascal; Dupont, Joelle			A grape seed extract maternal dietary supplementation in reproductive hens reduces oxidative stress associated to modulation of plasma and tissue adipokines expression and improves viability of offsprings	PLOS ONE			English	Article							HIGH-FAT DIET; ANTIOXIDANT CAPACITY; GROWTH-PERFORMANCE; SKELETAL-MUSCLE; PROCYANIDINS; PREGNANCY; INCREASES; POLYPHENOLS; METABOLISM; PROTECTS	In reproductive hens, a feed restriction is an usual practice to improve metabolic and reproductive disorders. However, it acts a stressor on the animal. In mammals, grape seed extracts (GSE) reduces oxidative stress. However, their effect on endocrine and tissue response need to be deepened in reproductive hens. Here, we evaluated the effects of time and level of GSE dietary supplementation on growth performance, viability, oxidative stress and metabolic parameters in plasma and metabolic tissues in reproductive hens and their offsprings. We designed an in vivo trial using 4 groups of feed restricted hens: A (control), B and C (supplemented with 0.5% and 1% of the total diet composition in GSE since week 4, respectively) and D (supplemented with 1% of GSE since the hatch). In hens from hatch to week 40, GSE supplementation did not affect food intake and fattening whatever the time and dose of supplementation. Body weight was significantly reduced in D group as compared to control. In all hen groups, GSE supplementation decreased plasma oxidative stress index associated to a decrease in the mRNA expression of the NOX4 and 5 oxidant genes in liver and muscle and an increase in SOD mRNA expression. This was also associated to decreased plasma chemerin and increased plasma adiponectin and visfatin levels. Interestingly, maternal GSE supplementation increased the live body weight and viability of chicks at hatching and 10 days of age. This was associated to a decrease in plasma and liver oxidative stress parameters. Taken together, GSE maternal dietary supplementation reduces plasma and tissue oxidative stress associated to modulation of adipokines without affecting fattening in reproductive hens. A 1% GSE maternal dietary supplementation increased offspring viability and reduced oxidative stress suggesting a beneficial transgenerational effect and a potential use to improve the quality of the progeny in reproductive hens.	[Barbe, Alix; Mellouk, Namya; Rame, Christelle; Grandhaye, Jeremy; Petit, Angelique; Froment, Pascal; Dupont, Joelle] INRAE UMR85 Physiol Reprod & Comportements, Nouzilly, France; [Barbe, Alix; Mellouk, Namya; Rame, Christelle; Grandhaye, Jeremy; Petit, Angelique; Froment, Pascal; Dupont, Joelle] CNRS UMR747 Physiol Reprod & Comportements, Nouzilly, France; [Barbe, Alix; Mellouk, Namya; Rame, Christelle; Grandhaye, Jeremy; Petit, Angelique; Froment, Pascal; Dupont, Joelle] Univ Francois Rabelais Tours, Tours, France; [Barbe, Alix; Mellouk, Namya; Rame, Christelle; Grandhaye, Jeremy; Petit, Angelique; Froment, Pascal; Dupont, Joelle] IFCE, Nouzilly, France; [Staub, Christophe; Venturi, Eric; Cirot, Marine] INRAE, Unite Expt Physiol Anim Orfrasiere UEPAO 1297, Nouzilly, France; [Anger, Karine; Chahnamian, Marine; Ganier, Patrice; Callut, Olivier] INRAE Unite Expt Pole Expt Avicole Tours UEPEAT, F-1295 Nouzilly, France; [Cailleau-Audouin, Estelle; Metayer-Coustard, Sonia] INRAE, UMR0083 Biol Oiseaux & Aviculture, Nouzilly, France; [Riva, Antonella] INDENA, Tours, France	INRAE; INRAE; INRAE; INRAE	Dupont, J (corresponding author), INRAE UMR85 Physiol Reprod & Comportements, Nouzilly, France.; Dupont, J (corresponding author), CNRS UMR747 Physiol Reprod & Comportements, Nouzilly, France.; Dupont, J (corresponding author), Univ Francois Rabelais Tours, Tours, France.; Dupont, J (corresponding author), IFCE, Nouzilly, France.	joelle.dupont@inrae.fr	Mellouk, Namya/AAL-7583-2021	Grandhaye, Jeremy/0000-0002-0909-837X	Reion Centre Val de Loire grant "PREVADI" [32000820]; Region Centre Val de Loire	Reion Centre Val de Loire grant "PREVADI"; Region Centre Val de Loire(Region Centre-Val de Loire)	This work has been supported by Reion Centre Val de Loire grant "PREVADI" N degrees 32000820 to JD. Alix Barbe is a PhD student supported by Region Centre Val de Loire. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abu Hafsa SH, 2018, J ANIM PHYSIOL AN N, V102, P268, DOI 10.1111/jpn.12688; Alexander BT, 2015, COMPR PHYSIOL, V5, P997, DOI 10.1002/cphy.c140036; Ariga T, 2004, BIOFACTORS, V21, P197, DOI 10.1002/biof.552210140; Asbaghi O, 2020, PHYTOTHER RES, V34, P239, DOI 10.1002/ptr.6518; Bagchi D, 1997, RES COMMUN MOL PATH, V95, P179; Baselga-Escudero L, 2015, NUTR RES, V35, P337, DOI 10.1016/j.nutres.2015.02.008; Bialek A, 2017, ACTA POL PHARM, V74, P624; Caimari A, 2013, INT J OBESITY, V37, P576, DOI 10.1038/ijo.2012.75; Caimari A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12597-9; Chen YP, 2013, BRIT POULTRY SCI, V54, P531, DOI 10.1080/00071668.2013.809402; Cho SY, 2007, AM J PHYSIOL-ENDOC M, V292, pE1166, DOI 10.1152/ajpendo.00436.2006; Crescenti A, 2015, J NUTR BIOCHEM, V26, P912, DOI 10.1016/j.jnutbio.2015.03.003; de Jong IC, 2002, BRIT POULTRY SCI, V43, P157, DOI 10.1080/00071660120121355; Decorde K, 2009, MOL NUTR FOOD RES, V53, P659, DOI 10.1002/mnfr.200800165; del Bas JM, 2015, INT J OBESITY, V39, P7, DOI 10.1038/ijo.2014.159; Del Bas JM, 2008, MOL NUTR FOOD RES, V52, P1172, DOI 10.1002/mnfr.200800054; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Emiliano AF, 2011, J CARDIOVASC PHARM, V58, P319, DOI 10.1097/FJC.0b013e3182244a51; Erel O, 2004, CLIN BIOCHEM, V37, P277, DOI 10.1016/j.clinbiochem.2003.11.015; Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008; Estienne A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184431; Farahat MH, 2017, ANIMAL, V11, P771, DOI 10.1017/S1751731116002251; Gerasopoulos K, 2015, FOOD CHEM TOXICOL, V82, P42, DOI 10.1016/j.fct.2015.04.021; Gonzalez-Abuin N, 2014, J AGR FOOD CHEM, V62, P1066, DOI 10.1021/jf405239p; Harma M, 2003, SWISS MED WKLY, V133, P563; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Helfer G, 2018, J ENDOCRINOL, V238, pR79, DOI 10.1530/JOE-18-0174; Kara K, 2016, J APPL ANIM RES, V44, P303, DOI 10.1080/09712119.2015.1031785; Krzysik-Walker SM, 2011, COMP BIOCHEM PHYS A, V159, P413, DOI 10.1016/j.cbpa.2011.04.007; Laudadio V, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0001-x; Liu XT, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9390810; Lykkesfeldt J, 2007, VET J, V173, P502, DOI 10.1016/j.tvjl.2006.06.005; Del Bas JM, 2009, MOL NUTR FOOD RES, V53, P805, DOI 10.1002/mnfr.200800364; Martinez-Micaelo N, 2012, BIOFACTORS, V38, P257, DOI 10.1002/biof.1019; Mellouk N, 2018, INT J ENDOCRINOL, V2018, DOI 10.1155/2018/4579734; Mellouk N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191121; Min B, 2008, J FOOD SCI, V73, pC439, DOI 10.1111/j.1750-3841.2008.00805.x; Morrissey KLH, 2014, POULTRY SCI, V93, P285, DOI 10.3382/ps.2013-03265; Ohashi K, 2007, ARTERIOSCL THROM VAS, V27, P1910, DOI 10.1161/ATVBAHA.107.147645; Oskoueian E, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-368; Pajuelo D, 2011, J AGR FOOD CHEM, V59, P4279, DOI 10.1021/jf200322x; Pan YE, 2014, ANIM REPROD SCI, V151, P229, DOI 10.1016/j.anireprosci.2014.10.003; Panickar KS, 2013, MOL NUTR FOOD RES, V57, P34, DOI 10.1002/mnfr.201200431; Papadopoulou A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8273160; Pinent M, 2006, CRIT REV FOOD SCI, V46, P543, DOI 10.1080/10408390500354537; Rajput SA, 2017, TOXINS, V9, DOI 10.3390/toxins9110371; Resende AC, 2013, J NUTR BIOCHEM, V24, P2119, DOI 10.1016/j.jnutbio.2013.08.003; Rhoads RP, 2013, ADV NUTR, V4, P267, DOI 10.3945/an.112.003376; Richards MP, 2007, POULTRY SCI, V86, P1478, DOI 10.1093/ps/86.7.1478; Rodriguez-Rodriguez P, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00602; Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096; Serrano J, 2016, FOOD FUNCT, V7, P483, DOI [10.1039/C5FO00892A, 10.1039/c5fo00892a]; Shi John, 2003, Journal of Medicinal Food, V6, P291, DOI 10.1089/109662003772519831; Sun PP, 2018, J APPL POULTRY RES, V27, P564, DOI 10.3382/japr/pfy035; Surai PF, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8070235; Surai PF, 2016, ANIM NUTR, V2, P1, DOI 10.1016/j.aninu.2016.01.001; Tallentire CW, 2016, AGRON SUSTAIN DEV, V36, DOI 10.1007/s13593-016-0398-2; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Zielinsky P, 2013, BIRTH DEFECTS RES C, V99, P256, DOI 10.1002/bdrc.21051	59	7	7	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2020	15	4							e0231131	10.1371/journal.pone.0231131	http://dx.doi.org/10.1371/journal.pone.0231131			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9BE	32282838	Green Published, gold			2023-01-03	WOS:000535989800021
J	Balskus, EP; Carlson, P; Honda, K; Backhed, F; Moissl-Eichinger, C				Balskus, Emily P.; Carlson, Paul, Jr.; Honda, Kenya; Backhed, Fredrik; Moissl-Eichinger, Christine			Translating Microbiome Research into Therapies: The Path Ahead	CELL			English	Editorial Material									[Balskus, Emily P.] Harvard Univ, Cambridge, MA 02138 USA; [Carlson, Paul, Jr.] US FDA, Rockville, MD 20857 USA; [Honda, Kenya] Keio Univ, Tokyo, Japan; [Backhed, Fredrik] Univ Gothenburg, Gothenburg, Sweden; [Moissl-Eichinger, Christine] Med Univ Graz, Graz, Austria	Harvard University; US Food & Drug Administration (FDA); Keio University; University of Gothenburg; Medical University of Graz	Balskus, EP (corresponding author), Harvard Univ, Cambridge, MA 02138 USA.		Backhed, Fredrik/ABE-6613-2020; Moissl-Eichinger, Christine/A-6682-2015	Backhed, Fredrik/0000-0002-4871-8818; Moissl-Eichinger, Christine/0000-0001-6755-6263					0	0	0	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2020	181	1					20	21		10.1016/j.cell.2020.03.009	http://dx.doi.org/10.1016/j.cell.2020.03.009			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KZ5RI	32243790	Bronze			2023-01-03	WOS:000523319000008
J	Bobbili, P; Ryan, K; DerSarkissian, M; Dua, A; Yee, C; Duh, MS; Gomez, JE				Bobbili, Priyanka; Ryan, Kellie; DerSarkissian, Maral; Dua, Akanksha; Yee, Christopher; Duh, Mei Sheng; Gomez, Jorge E.			Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer	PLOS ONE			English	Article							CONCURRENT; RADIOTHERAPY; MANAGEMENT	Introduction Concurrent chemoradiotherapy (cCRT) was the standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC) prior to the PACIFIC trial, however, patients also received single modality therapy. This study identified predictors of therapy and differences in overall survival (OS). Methods This retrospective study included stage III NSCLC patients aged >= 65 years, with >= 1 claim for systemic therapy (ST) or radiotherapy (RT) within 90 days of diagnosis, identified in SEER-Medicare data (2009-2014). Patients who had overlapping claims for chemotherapy and RT.90 days from start of therapy were classified as having received cCRT. Patients who received sequential CRT or surgical resection of tumor were excluded. Predictors of cCRT were analyzed using logistic regression. OS was compared between therapies using adjusted Cox proportional hazards models. Results Of 3,799 patients identified, 21.7% received ST; 26.3% received RT; and 52.0% received cCRT. cCRT patients tended to be younger (p < 0.001), White (p = 0.002), and have a good predicted performance status (p< 0.001). Patients who saw all three specialist types (medical oncologist, radiation oncologist, and surgeon) had increased odds of receiving cCRT (p< 0.001). ST and RT patients had higher mortality risk versus cCRT patients (hazard ratio [95% CI]: ST: 1.38 [1.26-1.51]; RT: 1.75 [1.61, 1.91]); p< 0.001). Conclusions Several factors contributed to treatment selection, including patient age and health status, and whether the patient received multidisciplinary care. Given the survival benefit of receiving cCRT over single-modality therapy, physicians should discuss treatment within a multidisciplinary team, and be encouraged to pursue cCRT for patients with unresectable stage III NSCLC.	[Bobbili, Priyanka; DerSarkissian, Maral; Dua, Akanksha; Yee, Christopher; Duh, Mei Sheng] Anal Grp Inc, Boston, MA 02199 USA; [Ryan, Kellie] AstraZeneca, Gaithersburg, MD USA; [Gomez, Jorge E.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA	Analysis Group Inc.; AstraZeneca; Icahn School of Medicine at Mount Sinai	Bobbili, P (corresponding author), Anal Grp Inc, Boston, MA 02199 USA.	Bobbili@analysisgroup.com		Dua, Akanksha/0000-0003-3594-0468; Bobbili, Priyanka/0000-0002-1343-8314; Gomez, Jorge/0000-0001-6859-363X	AstraZeneca, Gaithersburg, MD; AstraZeneca	AstraZeneca, Gaithersburg, MD(AstraZeneca); AstraZeneca(AstraZeneca)	This research was funded by AstraZeneca, Gaithersburg, MD. As detailed in the submission, Dr. Jorge Gomez is an employee of Mount Sinai Hospital and has received funding from AstraZeneca. Kellie Ryan received support in the form of salaries from AstraZeneca, and is a stockholder of AstraZeneca. Mei Sheng Duh, Akanksha Dua, Maral DerSarkissian, Christopher Yee, and I are employees of Analysis Group, Inc., a consultancy that has received research funding from AstraZeneca for this and other studies. All coauthors had a role in the conception and study design, administrative support, data analysis and interpretation, decision to publish, preparation and approval of the manuscript. AD, CY, PB, MSD, and MD had a role in the collection and assembly of data. The specific roles of these authors are articulated in the 'author contributions' section.	Ali A, 2013, CURR ONCOL, V20, pE300, DOI 10.3747/co.20.1481; American Cancer Society, 2017, NONSM CELL LUNG CANC, V2017; American Cancer Society, 2016, WHAT IS NONS CELL LU; American Cancer Society, 2018, LUNG CANC NONSM CELL; American Cancer Society, NONSM CELL LUNG CANC; American Cancer Society, 2016, NONSM CELL LUNG CANC; Amini A, 2016, CANCER-AM CANCER SOC, V122, P1533, DOI 10.1002/cncr.29956; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Auperin A, 2010, J CLIN ONCOL, V28, P2181, DOI 10.1200/JCO.2009.26.2543; Bobbili P, 2019, FUTURE ONCOL, V15, P3381, DOI 10.2217/fon-2019-0282; Boko D, 2019, FOREIGN POLICY; Bradley JD, 2015, LANCET ONCOL, V16, P187, DOI 10.1016/S1470-2045(14)71207-0; Curran WJ, 2011, J NATL CANCER I, V103, P1452, DOI 10.1093/jnci/djr325; Davidoff AJ, 2010, J CLIN ONCOL, V28, P2191, DOI 10.1200/JCO.2009.25.4052; Dovedi SJ, 2014, CANCER RES, V74, P5458, DOI 10.1158/0008-5472.CAN-14-1258; Eberhardt WEE, 2015, J CLIN ONCOL, V33, P532, DOI 10.1200/JCO.2014.58.9812; Freeman RK, 2015, ANN THORAC SURG, V100, P1834, DOI 10.1016/j.athoracsur.2015.05.056; Goulart BHL, 2013, J ONCOL PRACT, V9, P42, DOI 10.1200/JOP.2012.000640; GRUMBACH K, 1995, AM J PUBLIC HEALTH, V85, P1402, DOI 10.2105/AJPH.85.10.1402; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Hung MS, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016167; Kim E, 2016, PRACT RADIAT ONCOL, V6, pE163, DOI 10.1016/j.prro.2016.01.011; Kumar SS, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00197; National Comprehensive Cancer Network (NCCN), 2018, NCCN GUID PAT LUNG C; O'Rourke N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002140.pub3; Oh IJ, 2017, RADIAT ONCOL J, V35, P16, DOI 10.3857/roj.2017.00108; Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; Salloum RG, 2011, CANCER-AM CANCER SOC, V117, P1038, DOI 10.1002/cncr.25677; U.S. Food and Drug Administration, 2019, FDA APPR DURV CHEM U; Wauters E, 2014, J THORAC DIS, V6, P574, DOI 10.3978/j.issn.2072-1439.2014.05.16; Yoon SM, 2017, WORLD J CLIN ONCOL, V8, P1, DOI 10.5306/wjco.v8.i1.1	31	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2020	15	3							e0230444	10.1371/journal.pone.0230444	http://dx.doi.org/10.1371/journal.pone.0230444			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ9EP	32187231	gold, Green Published			2023-01-03	WOS:000535300000041
J	Martinengo, L; Spinazze, P; Car, J				Martinengo, Laura; Spinazze, Pier; Car, Josip			Mobile messaging with patients	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							TEXT; HEALTH; INTERVENTIONS; REMINDERS; TRIAL		[Martinengo, Laura; Spinazze, Pier; Car, Josip] Nanyang Technol Univ, Lee Kong Chian Sch Med, Ctr Populat Hlth Sci CePHaS, Singapore, Singapore; [Spinazze, Pier] Imperial Coll London, Sch Publ Hlth, Dept Primary Care & Publ Hlth, Global Digital Hlth Unit, London, England	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Imperial College London	Car, J (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Ctr Populat Hlth Sci CePHaS, Singapore, Singapore.	josip.car@ntu.edu.sg	Martinengo, Laura/AAY-8201-2020; Spinazze, Pier/AAP-6924-2020; Car, Josip/H-6755-2015	Martinengo, Laura/0000-0003-3539-7207; Spinazze, Pier/0000-0002-1416-0174; Car, Josip/0000-0001-8969-371X				Abroms LC, 2014, AM J PREV MED, V47, P242, DOI 10.1016/j.amepre.2014.04.010; Akdeniz Y., 1997, UK GOVT POLICY ENCRY, DOI [10.2139/ssrn.41701, DOI 10.2139/SSRN.41701]; Armanasco AA, 2017, AM J PREV MED, V52, P391, DOI 10.1016/j.amepre.2016.10.042; Cello Health Insight, 2015, DIG HLTH DEB REP DOC; De Grood C, 2016, J MULTIDISCIP HEALTH, V9, DOI 10.2147/JMDH.S103881; Dobson R, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1959; European Commission, 2018, DAT PROT; Free C, 2011, LANCET, V378, P49, DOI 10.1016/S0140-6736(11)60701-0; Gagnon MP, 2016, J AM MED INFORM ASSN, V23, P212, DOI 10.1093/jamia/ocv052; Giardina TD, 2015, PATIENT EDUC COUNS, V98, P788, DOI 10.1016/j.pec.2015.02.011; Ramon EXG, 2017, DILEMAS CONTEMP-EDUC, V5; Gurol-Urganci I, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007458.pub3; Hall AK, 2015, ANNU REV PUBL HEALTH, V36, P393, DOI 10.1146/annurev-publhealth-031914-122855; Haun Jolie N, 2015, J Med Internet Res, V17, pe282, DOI 10.2196/jmir.5152; IBM X-Force Research, 2016, REV YEAR SER DAT BRE; Information Governance Alliance, 2018, GEN DAT PROT REG GUI; International Telecommunications Union (ITU), 2018, ITU REL 2018 GLOB RE; Kang XY, 2016, CLIN GASTROENTEROL H, V14, P429, DOI 10.1016/j.cgh.2015.09.038; Kerrison RS, 2015, BRIT J CANCER, V112, P1005, DOI 10.1038/bjc.2015.36; Leahy D, 2017, BRIT J GEN PRACT, V67, pE744, DOI 10.3399/bjgp17X693065; Lester RT, 2010, LANCET, V376, P1838, DOI 10.1016/S0140-6736(10)61997-6; Lyles C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001852; Mbuagbaw L, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-014-0654-6; Moghaddasi Hamid, 2016, Open Med Inform J, V10, P4; Newport F., 2014, NEW ERA COMMUNICATIO; Patel Suha J, 2018, Mhealth, V4, P14, DOI 10.21037/mhealth.2018.04.05; Pew Research Center, 2018, DEM MOB DEV OWN AD U; Pillemer F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154743; Poorman E, 2015, MATERN CHILD HLTH J, V19, P969, DOI 10.1007/s10995-014-1595-8; Prater VS, 2014, BIOMEDICAL HLTH INFO; Quinlan D, 2018, Ir Med J, V111, P729; Ramachandran A, 2013, LANCET DIABETES ENDO, V1, P191, DOI 10.1016/S2213-8587(13)70067-6; Robotham D, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012116; Rohman L, 2015, J TELEMED TELECARE, V21, P408, DOI 10.1177/1357633X15583778; Sarkar U, 2010, J HEALTH COMMUN, V15, P183, DOI 10.1080/10810730.2010.499988; Stockwell MS, 2012, JAMA-J AM MED ASSOC, V307, P1702, DOI 10.1001/jama.2012.502; Thakkar J, 2016, JAMA INTERN MED, V176, P340, DOI 10.1001/jamainternmed.2015.7667; US Department of Health & Human Services, 2019, HLTH INF PRIV; West D., 2012, ISSUES TECHNOLOGY IN; Wilson E, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002479; Yasmin F, 2016, BMC MED INFORM DECIS, V16, DOI 10.1186/s12911-016-0286-3; Yusufovna Feruza Sattarova, 2011, [Asia-pacific Journal of Multimedia Services Convergent with Art, Humanities, and Sociology, 예술인문사회 융합 멀티미디어 논문지], V1, P91, DOI 10.14257/AJMAHS.2011.12.06; Zallman L, 2017, INFORM HEALTH SOC CA, V42, P32, DOI 10.3109/17538157.2015.1113177	43	11	11	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 16	2020	368								m884	10.1136/bmj.m884	http://dx.doi.org/10.1136/bmj.m884			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LA2CT	32179548				2023-01-03	WOS:000523761500002
J	Wataru, K; Sugiyama, A; Yoneyama, S; Matsubara, M; Fukuda, Y; Parikh, R; Sakurada, Y				Wataru, Kikushima; Sugiyama, Atsushi; Yoneyama, Seigo; Matsubara, Mio; Fukuda, Yoshiko; Parikh, Ravi; Sakurada, Yoichi			Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy	PLOS ONE			English	Article							VISUAL PROGNOSIS; LESION SIZE; EFFICACY; VERTEPORFIN; BEVACIZUMAB; THICKNESS; ASSOCIATION; GENOTYPE; SAFETY	We report 5-year visual and anatomical outcomes after combination therapy of photodynamic therapy (PDT) and intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy (PCV) and predictive factors for visual outcomes at 5-year and time to recurrence. Medical charts were retrospectively reviewed for 43 consecutive eyes with PCV treated with combination therapy of PDT and intravitreal injection of ranibizumab(n = 13) or aflibercept(n = 30) and completed 5-year follow-up. The variants of ARMS2 A69S and CFH I62V were genotyped using TaqMan assay. Best corrected visual acuity (BCVA) significantly improved at 5-year (P = 0.01) with 20% reduction of subfoveal choroidal thickness irrespective of presence or absence of recurrence. Visual improvement was associated with baseline shorter greatest linear dimension (GLD) (P = 1.0x10(-4)). Mean time to recurrence was 28.6 +/- 23.1 months (95% CI: 21.5-35.7, Median:18.0) and time to recurrence was associated with G allele (protective allele) of ARMS2 A69S and GLD (P = 4.0x10(-4) and 1.0x10(-2), respectively). Multiple regression analysis revealed that time to recurrence extended by 15.5 months when the G allele of ARMS2 A69S increased by one allele (TT: 15.7 +/- 17.0, TG: 30.8 +/- 23.5, GG: 41.1 +/- 22.6 months). The combination therapy resulted in a favorable visual outcome for PCV during 5-year follow-up.	[Wataru, Kikushima; Sugiyama, Atsushi; Yoneyama, Seigo; Matsubara, Mio; Fukuda, Yoshiko; Sakurada, Yoichi] Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan; [Parikh, Ravi] NYU, Sch Med, New York, NY USA; [Parikh, Ravi] Manhattan Retina & Eye Consultants, New York, NY USA	University of Yamanashi; New York University	Sakurada, Y (corresponding author), Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.	sakurada@yamanashi.ac.jp		Parikh, Ravi/0000-0003-3369-4224; Sakurada, Yoichi/0000-0002-2894-0454	JSPS (Japan Society for the promotion of Science) KAKENHI [18K16921]	JSPS (Japan Society for the promotion of Science) KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	JSPS (Japan Society for the promotion of Science) KAKENHI Grant Number 18K16921	Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056; Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6; Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283; Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008; Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308; Jain P, 2018, INDIAN J OPHTHALMOL, V66, P1119, DOI 10.4103/ijo.IJO_1222_17; Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1; Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020; Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y; Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030; Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051; Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041; Miyata M, 2019, BRIT J OPHTHALMOL, V103, P617, DOI 10.1136/bjophthalmol-2018-311963; Nakai S, 2019, JPN J OPHTHALMOL, V63, P389, DOI 10.1007/s10384-019-00683-6; Nakai S, 2019, JPN J OPHTHALMOL, V63, P100, DOI 10.1007/s10384-018-0636-z; Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/S0002-9394(03)01147-4; Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130; Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427; Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978; Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044; Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010; Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3; Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72; Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038; SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003; Sugiyama A, 2018, OPHTHALMOLOGICA, V239, P52, DOI 10.1159/000480439; Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002; Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0; Yang JY, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1245-4; YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001; Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964	31	10	11	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2020	15	2							e0229231	10.1371/journal.pone.0229231	http://dx.doi.org/10.1371/journal.pone.0229231			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8DW	32092094	Green Published, gold			2023-01-03	WOS:000535229300034
J	Teerawattananon, Y; Dabak, SV; Khoe, LC; Bayani, DBS; Isaranuwatchai, W				Teerawattananon, Yot; Dabak, Saudamini Vishwanath; Khoe, Levina Chandra; Bayani, Diana Beatriz S.; Isaranuwatchai, Wanrudee			To include or not include: renal dialysis policy in the era of universal health coverage	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							KIDNEY-DISEASE; ACCESS		[Teerawattananon, Yot; Dabak, Saudamini Vishwanath; Isaranuwatchai, Wanrudee] Minist Publ Hlth, HITAP, Nonthaburi, Thailand; [Teerawattananon, Yot; Bayani, Diana Beatriz S.] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Khoe, Levina Chandra] Univ Indonesia, Fac Med, Dept Community Med, Jakarta, Indonesia; [Bayani, Diana Beatriz S.] Dept Hlth, Hlth Technol Assessment Unit, Manila, Philippines; [Isaranuwatchai, Wanrudee] St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Excellence Econ Anal Res CLEAR, Toronto, ON, Canada	Ministry of Public Health - Thailand; National University of Singapore; University of Indonesia; Philippine Department Health; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Dabak, SV (corresponding author), Minist Publ Hlth, HITAP, Nonthaburi, Thailand.	saudamini.d@hitap.net		Teerawattananon, Yot/0000-0003-2217-2930; Bayani, Diana Beatriz/0000-0002-0042-8547; Khoe, Levina/0000-0002-2050-392X	Thailand Research Fund (TRF) [RTA5980011]; Bill and Melinda Gates Foundation [OPP1134345]; UK's Department for International Development; Rockefeller Foundation	Thailand Research Fund (TRF)(Thailand Research Fund (TRF)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); UK's Department for International Development; Rockefeller Foundation	The Health Intervention and Technology Assessment Program (HITAP) is funded by the Thailand Research Fund (TRF) under a grant for Senior Research Scholar (RTA5980011). HITAP's International Unit is supported by the International Decision Support Initiative (iDSI) to provide technical assistance on health intervention and technology assessment to governments in low and middle income countries. iDSI is funded by the Bill and Melinda Gates Foundation [OPP1134345], the UK's Department for International Development, and the Rockefeller Foundation. The findings, interpretations, and conclusions expressed in this article do not necessarily reflect the views of the funding agencies.	Andersen EL, 2018, EDITORS LETT REGION; Bayani DB, 2019, EC EVALUATION POLICY; Chuengsaman P, 2017, SEMIN NEPHROL, V37, P287, DOI 10.1016/j.semnephrol.2017.02.008; Essue BM, 2018, B WORLD HEALTH ORGAN, V96, P442, DOI 10.2471/BLT.18.208207; Glassman A, 2016, SETTING UNIVERSAL HL; Harris DCH, 2019, KIDNEY INT, V95, pS1, DOI 10.1016/j.kint.2018.12.005; Kesehtan BPJS, 2014, CLAIMS DATA; Korevaar JC, 2003, KIDNEY INT, V64, P2222, DOI 10.1046/j.1523-1755.2003.00321.x; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; Minister of Health, 2018, COMMUNICATION   1029; Mushi L, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1166-8; Niang A, 2018, CURR OPIN NEPHROL HY, V27, P463, DOI 10.1097/MNH.0000000000000455; Philippine Health Insurance Corporation (PhilHealth), 2017, CLAIMS DAT; Philippine Renal Disease Registry, 2016, ANN REP 2016; Prodjosudjadi Wiguno, 2009, Ethn Dis, V19, pS1; Tantivess S, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f462; Teerawattananon Y, 2007, VALUE HEALTH, V10, P61, DOI 10.1111/j.1524-4733.2006.00145.x; Teerawattananon Y, 2016, HEALTH RES POLICY SY, V14, DOI 10.1186/s12961-016-0090-7; Thailand National Health Security Office, 2017, ANN REPORT; World Bank, 2017, WORLD DEV INDICATORS	20	9	9	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 28	2020	368								m82	10.1136/bmj.m82	http://dx.doi.org/10.1136/bmj.m82			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH1EK	31992542	hybrid, Green Published			2023-01-03	WOS:000510389500020
J	Nagaya, N; Nagata, M; Lu, Y; Kanayama, M; Hou, Q; Hotta, ZU; China, T; Kitamura, K; Matsushita, K; Isotani, S; Muto, S; Sakamoto, Y; Horie, S				Nagaya, Naoya; Nagata, Masayoshi; Lu, Yan; Kanayama, Mayuko; Hou, Qi; Hotta, Zen-u; China, Toshiyuki; Kitamura, Kosuke; Matsushita, Kazuhito; Isotani, Shuji; Muto, Satoru; Sakamoto, Yoshiro; Horie, Shigeo			Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer	PLOS ONE			English	Article							ABIRATERONE; PSMA; ENZALUTAMIDE; THERAPY; MEN; EXPRESSION; AR-V7	The aim of this study is to elucidate the clinical significance of prostate-specific membrane antigen (PSMA) expression in circulating tumor cells (CTCs) from castration-resistant prostate cancer (CRPC) patients. We analyzed a total of 203 CTC samples from 79 CRPC patients to investigate the proportion of positive mRNA expressions at different treatment phases. Among them, we elected to focus on specimens from 56 CRPC patients who progressed on therapy and were subsequently provided a new treatment (treatment-switch cohort). In this cohort, we investigated the association between PSMA expression in CTCs and treatment response. CTCs were detected in 55/79 patients and median serum PSA in CTC-positive patients was 67.0 ng/ml. In the treatment-switch cohort of 56 patients, 20 patients were positive for PSMA in CTCs. PSMA expression was inversely associated with percentage of change in prostate-specific antigen (PSA). The median PSA progression-free survival and overall survival were significantly shorter in the PSMA-positive cohort. Furthermore, PSMA expression was predictive of poorer treatment response, shorter PSA progression-free survival and overall survival. PSMA expression in circulating tumor cells may be a novel poor prognostic marker for CRPC.	[Nagaya, Naoya; Nagata, Masayoshi; Lu, Yan; Kanayama, Mayuko; Hou, Qi; Hotta, Zen-u; China, Toshiyuki; Kitamura, Kosuke; Matsushita, Kazuhito; Isotani, Shuji; Muto, Satoru; Horie, Shigeo] Juntendo Univ, Dept Urol, Grad Sch Med, Tokyo, Japan; [Hotta, Zen-u] Univ Tokyo, Grad Sch Interdisciplinary Informat Studies, Interfac Initiat Informat Studies, Strateg Invest Comprehens Canc Network, Tokyo, Japan; [Muto, Satoru] Juntendo Univ, Grad Sch Med, Dept Adv Informat Genet Dis, Tokyo, Japan; [Sakamoto, Yoshiro] Juntendo Univ, Dept Urol, Nerima Hosp, Tokyo, Japan	Juntendo University; University of Tokyo; Juntendo University; Juntendo University	Horie, S (corresponding author), Juntendo Univ, Dept Urol, Grad Sch Med, Tokyo, Japan.	shorie@juntendo.ac.jp	kitamura, kosuke/AAZ-7999-2021	Nagata, Masayoshi/0000-0002-3077-191X				Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Antonarakis ES, 2017, J CLIN ONCOL, V35, P2149, DOI 10.1200/JCO.2016.70.1961; Antonarakis ES, 2015, JAMA ONCOL, V1, P582, DOI 10.1001/jamaoncol.2015.1341; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Bravaccini S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22594-1; Cattrini C, 2019, CANCERS, V11, DOI 10.3390/cancers11091365; Chi K, 2015, ANN ONCOL, V26, P2044, DOI 10.1093/annonc/mdv267; De Laere B, 2017, EUR UROL, V72, P192, DOI 10.1016/j.eururo.2017.01.011; Elgamal AAA, 2000, SEMIN SURG ONCOL, V18, P10, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<10::AID-SSU3>3.3.CO;2-M; Hodgkinson CL, 2014, NAT MED, V20, P897, DOI 10.1038/nm.3600; Kratochwil C, 2016, J NUCL MED, V57, P1941, DOI 10.2967/jnumed.116.178673; Kratochwil C, 2016, J NUCL MED, V57, P1170, DOI 10.2967/jnumed.115.171397; Lamb AD, 2018, EUR UROL, V73, P653, DOI 10.1016/j.eururo.2018.02.007; Loriot Y, 2015, EUR J CANCER, V51, P1946, DOI 10.1016/j.ejca.2015.06.128; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Marrugo-Ramirez J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102877; Maurer T, 2016, NAT REV UROL, V13, P226, DOI 10.1038/nrurol.2016.26; Meller B, 2015, EJNMMI RES, V5, DOI 10.1186/s13550-015-0145-8; Mezynski J, 2012, ANN ONCOL, V23, P2943, DOI 10.1093/annonc/mds119; Miyamoto DT, 2012, CANCER DISCOV, V2, P995, DOI 10.1158/2159-8290.CD-12-0222; Nakazawa M, 2015, ANN ONCOL, V26, P1859, DOI 10.1093/annonc/mdv282; Omlin A, 2014, THER ADV UROL, V6, P3, DOI 10.1177/1756287213509677; Onstenk W, 2015, EUR UROL, V68, P939, DOI 10.1016/j.eururo.2015.07.007; Parker C, 2015, ANN ONCOL, V26, pV69, DOI 10.1093/annonc/mdv222; Ross JS, 2003, CLIN CANCER RES, V9, P6357; Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Sweat SD, 1998, UROLOGY, V52, P637, DOI 10.1016/S0090-4295(98)00278-7; van Soest RJ, 2013, EUR J CANCER, V49, P3821, DOI 10.1016/j.ejca.2013.09.026; Wright GL, 1996, UROLOGY, V48, P326, DOI 10.1016/S0090-4295(96)00184-7; Zhang Q, 2018, EUR UROL, V73, P648, DOI 10.1016/j.eururo.2017.12.008	32	18	18	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2020	15	1							e0226219	10.1371/journal.pone.0226219	http://dx.doi.org/10.1371/journal.pone.0226219			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP8YP	31986176	Green Published, gold			2023-01-03	WOS:000534603400012
J	Bahta, M; Tesfamariam, S; Weldemariam, DG; Yemane, H; Tesfamariam, EH; Alem, T; Russom, M				Bahta, Merhawi; Tesfamariam, Sirak; Weldemariam, Dawit G.; Yemane, Hermella; Tesfamariam, Eyasu H.; Alem, Tesfamariam; Russom, Mulugeta			Dispensing of antibiotics without prescription and associated factors in drug retail outlets of Eritrea: A simulated client method	PLOS ONE			English	Article							COMMUNITY PHARMACIES; MEDICATION; RESISTANCE; SALE	Dispensing antibiotics without prescription is irrational and can hasten the emergence and spread of antibiotic resistance. This study aims at determining the extent of this practice and its determinants in all drug retail outlets of Eritrea. A cross-sectional simulated client method was used to conduct the study. Data was collected between July and August 2019, entered and analyzed using Statistical Package for Social Science version 22. Descriptive analysis was performed using mean (standard deviation), median (interquartile range), frequency, percentage, as appropriate, for independent variables. Logistic regression, at bivariate and multivariate levels, along with odds ratio (95% confidence interval) was used to determine the association between the dispensing of antibiotics without prescription and independent variables. P-values less than 0.05 were considered as statistically significant. The extent of dispensing antibiotics without prescription was found to be 87.6% with the most frequently dispensed antibiotics being ciprofloxacin (47.8%) and co-trimoxazole (37.5%). Furthermore, 12.4% of the drug retail outlet attendants did not dispense antibiotics because they preferred a referral to health facilities (52.6%), were following administrative restrictions not to sell antibiotics (42.1%), or did not have the necessary antibiotics (31.6%). Private community pharmacies (AOR = 7.68, 95% CI: 1.67, 35.37; p = 0.009) and private drug shops (AOR = 10.65, 95% CI: 1.96, 57.93; p = 0.006) were more likely to dispense antibiotics compared to the governmental community pharmacies. Dispensing antibiotics without prescription was more likely to occur in the Maekel (central) region (AOR = 3.76, 95% CI: 1.19, 11.92; p = 0.024) compared to the remaining regions combined. In conclusion, the sales of antibiotics without prescription in the drug retail outlets of Eritrea is alarming which requires immediate attention from policymakers.	[Bahta, Merhawi; Alem, Tesfamariam] Orotta Coll Med & Hlth Sci, Dept Med Sci, Pharm Unit, Asmera, Eritrea; [Tesfamariam, Sirak] Nakfa Hosp, Pharm, Nakfa, Eritrea; [Weldemariam, Dawit G.] Hazhaz Zonal Referral Hosp, Pharm, Asmera, Eritrea; [Yemane, Hermella] Southern Red Sea Zonal Med Store, Assab, Eritrea; [Tesfamariam, Eyasu H.] Eritrean Inst Technol, Dept Stat, Coll Sci, Biostat & Epidemiol Unit, Mai Nefhi, Eritrea; [Russom, Mulugeta] Natl Med & Food Adm, Eritrean Pharmacovigilance Ctr, Asmera, Eritrea		Weldemariam, DG (corresponding author), Hazhaz Zonal Referral Hosp, Pharm, Asmera, Eritrea.	dawitghiwet100@gmail.com	Russom, Mulugeta/ACM-0020-2022	Russom, Mulugeta/0000-0003-1939-5842; Weldemariam, Dawit/0000-0001-7179-4993; Tesfamariam, Sirak/0000-0003-4348-5952	NMFA; ERIPA's	NMFA; ERIPA's	The authors would like to thank the data collectors, NMFA as well as ERIPA's support in conducting the study. The authors' sincere gratitude also goes to Mr. Meswaiti Teklezghi, Mr. Tesfasilasie Ghedel, and Mr. Michael Ghirmay for their technical assistance in retrieving the detailed information of the dispensers.	Ateshim Y, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7020-x; Berger K, 2005, J CLIN PHARM THER, V30, P45, DOI 10.1111/j.1365-2710.2004.00611.x; Bisht R, 2009, ASIAN J PHARM CLIN R, P34; Bronzwaer SLAM, 2002, EMERG INFECT DIS, V8, P278, DOI 10.3201/eid0803.010192; Cars O., 2005, International Journal of Risk & Safety in Medicine, V17, P103; Chang J, 2017, J ANTIMICROB CHEMOTH, V72, P1235, DOI 10.1093/jac/dkw519; CHUA SS, 2006, INT J PHARM PRACT, V14, P171, DOI DOI 10.1211/ijpp.14.3.0003; Damisie G, 2019, J PHARMACEUTICS, V2019, DOI 10.1155/2019/3510659; Economist Intelligence Unit, 2014, FUT HEALTHC AFR; Economist Intelligence Unit, 2011, FUT HEALTHC AFR; Farah R, 2015, J INFECT PUBLIC HEAL, V8, P37, DOI 10.1016/j.jiph.2014.07.003; Gastelurrutia Miguel Angel, 2013, Pharm Pract (Granada), V11, P185; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Grigoryan L, 2007, PHARMACOEPIDEM DR S, V16, P1234, DOI 10.1002/pds.1479; Haddadin RN, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216115; Horumpende PG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207465; Hoxha I., 2005, LANCET, V365, P579, DOI DOI 10.1016/S0140-6736(05)17907-0; Kalungia AC, 2016, EXPERT REV ANTI-INFE, V14, P1215, DOI 10.1080/14787210.2016.1227702; Llor C, 2010, EUROSURVEILLANCE, V15; Madden JM, 1997, SOC SCI MED, V45, P1465, DOI 10.1016/S0277-9536(97)00076-2; Markovic-Pekovic V, 2017, J RES PHARM PRACT, V6, P120, DOI 10.4103/jrpp.JRPP_17_12; Roque F, 2013, INT J CLIN PHARM-NET, V35, P417, DOI 10.1007/s11096-013-9753-4; Schneider CR, 2009, ANN PHARMACOTHER, V43, P1512, DOI 10.1345/aph.1M086; Von Groll A, 2009, ANTIMICROB AGENTS CH, V53, P4498, DOI 10.1128/AAC.00287-09; WHO, 2017, GLOB ACT PLAN ABT RE; Who, 2015, GUID START ANT THER; World Health Organization, 2018, WHO REP SURV ANT CON; World Health Organization, 2019, MENT HOLIST HLTH SOM; Xu Tina, 2012, Int J Pharm Pract, V20, P307, DOI 10.1111/j.2042-7174.2012.00201.x; Zapata-Cachafeiro M, 2019, J ANTIMICROB CHEMOTH, V74, P511, DOI 10.1093/jac/dky440; Zawahir S, 2019, ANTIMICROB RESIST IN, V8, DOI 10.1186/s13756-019-0510-x	31	16	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2020	15	1							e0228013	10.1371/journal.pone.0228013	http://dx.doi.org/10.1371/journal.pone.0228013			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP8WY	31978180	Green Published, gold, Green Submitted			2023-01-03	WOS:000534599100095
J	Sternberg, CN; Fizazi, K; Saad, F; Shore, ND; De Giorgi, U; Penson, DF; Ferreira, U; Efstathiou, E; Madziarska, K; Kolinsky, MP; Cubero, DIG; Noerby, B; Zohren, F; Lin, X; Modelska, K; Sugg, J; Steinberg, J; Hussain, M				Sternberg, Cora N.; Fizazi, Karim; Saad, Fred; Shore, Neal D.; De Giorgi, Ugo; Penson, David F.; Ferreira, Ubirajara; Efstathiou, Eleni; Madziarska, Katarzyna; Kolinsky, Michael P.; Cubero, Daniel I. G.; Noerby, Bettina; Zohren, Fabian; Lin, Xun; Modelska, Katharina; Sugg, Jennifer; Steinberg, Joyce; Hussain, Maha		PROSPER Investigators	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; MEN; BICALUTAMIDE; APALUTAMIDE	BACKGROUND Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-deprivation therapy. Results from the final analysis of overall survival have not yet been reported. METHODS In this double-blind, phase 3 trial, men with nonmetastatic, castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of <= 10 months) who were continuing to receive androgen-deprivation therapy were randomly assigned (in a 2:1 ratio) to receive enzalutamide at a dose of 160 mg or placebo once daily. Overall survival was assessed with a group sequential testing procedure and an O'Brien-Fleming-type alpha-spending function. RESULTS As of October 15, 2019, a total of 288 of 933 patients (31%) in the enzalutamide group and 178 of 468 (38%) in the placebo group had died. Median overall survival was 67.0 months (95% confidence interval [CI], 64.0 to not reached) in the enzalutamide group and 56.3 months (95% CI, 54.4 to 63.0) in the placebo group (hazard ratio for death, 0.73; 95% CI, 0.61 to 0.89; P=0.001). The exposure-adjusted rate of adverse events of grade 3 or higher was 17 per 100 patient-years in the enzalutamide group and 20 per 100 patient-years in the placebo group. Adverse events in the enzalutamide group were consistent with those previously reported for enzalutamide; the most frequently reported events were fatigue and musculoskeletal events. CONCLUSIONS Enzalutamide plus androgen-deprivation therapy resulted in longer median overall survival than placebo plus androgen-deprivation therapy among men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level. The risk of death associated with enzalutamide was 27% lower than with placebo. Adverse events were consistent with the established safety profile of enzalutamide.	[Sternberg, Cora N.] Weill Cornell Med, Englander Inst Precis Med, New York, NY USA; [Fizazi, Karim] Univ Paris Saclay, Villejuif, France; [Saad, Fred] Univ Montreal Hosp Ctr, Montreal, PQ, Canada; [Kolinsky, Michael P.] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada; [Shore, Neal D.] Carolina Urol Res Ctr, Myrtle Beach, SC USA; [De Giorgi, Ugo] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy; [Penson, David F.] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA; [Ferreira, Ubirajara] State Univ Campinas Unicamp, Campinas, Brazil; [Cubero, Daniel I. G.] ABC Fdn Sch Med, Santo Andre, SP, Brazil; [Efstathiou, Eleni] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Madziarska, Katarzyna] Wroclaw Med Univ, Wroclaw, Poland; [Noerby, Bettina] Sygehus Lillebaelt, Vejle, Denmark; [Zohren, Fabian; Lin, Xun] Pfizer, La Jolla, CA USA; [Modelska, Katharina] Pfizer, San Francisco, CA USA; [Sugg, Jennifer; Steinberg, Joyce] Astellas Pharma, Northbrook, IL USA; [Hussain, Maha] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Cornell University; UDICE-French Research Universities; Universite Paris Saclay; Universite de Montreal; University of Alberta; Carolina Urologic Research Center; IRCCS Meldola (IRST); Vanderbilt University; Universidade Estadual de Campinas; University of Texas System; UTMD Anderson Cancer Center; Wroclaw Medical University; Pfizer; Pfizer; Astellas Pharmaceuticals; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Sternberg, CN (corresponding author), Weill Cornell Med, Belfer Res Bldg,413 E 69th St,Rm 1412, New York, NY 10021 USA.	cns9006@med.cornell.edu	Lin, Xun/AAM-9287-2021; Cubero, Daniel IG/N-8720-2013; Cubero, Daniel/ABD-1856-2020	Cubero, Daniel IG/0000-0002-1936-2605; Cubero, Daniel/0000-0002-1936-2605; ZAPATERO, ALMUDENA/0000-0003-2930-2312; OUDARD, Stephane/0000-0003-0893-285X; Lacombe, Louis/0000-0003-4811-0308; LADOIRE, Sylvain/0000-0002-0331-9194; Calabro', Fabio/0000-0002-7863-3540; de Jong, Igle J./0000-0002-3444-5548; Alcaraz Asensio, Antonio/0000-0003-2612-5250	Pfizer; Astellas Pharma	Pfizer(Pfizer); Astellas Pharma(Astellas Pharmaceuticals)	Funded by Pfizer and Astellas Pharma; PROSPER ClinicalTrials.gov number, NCT02003924.	Afshar M, 2015, UROL ONCOL, V33, P338, DOI DOI 10.1016/J.UR0L0NC.2015.05.003; [Anonymous], 2020, DAR PLUS ANDR DEPR T; [Anonymous], 2018, XTAND ENZ PRESCR INF; Appukkuttan S, 2020, PHARMACOECON-OPEN, V4, P439, DOI 10.1007/s41669-019-00185-8; Armstrong AJ, 2019, J CLIN ONCOL, V37, P2974, DOI 10.1200/JCO.19.00799; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Fendler WP, 2019, CLIN CANCER RES, V25, P7448, DOI 10.1158/1078-0432.CCR-19-1050; Fizazi K, 2019, NEW ENGL J MED, V380, P1235, DOI 10.1056/NEJMoa1815671; Gillessena S, 2020, EUR UROL, V77, P508, DOI 10.1016/j.eururo.2020.01.012; Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536; Jenkins V, 2019, CLIN ONCOL-UK, V31, P99, DOI 10.1016/j.clon.2018.11.001; Mateo J, 2019, EUR UROL, V75, P285, DOI 10.1016/j.eururo.2018.07.035; Penson DF, 2016, J CLIN ONCOL, V34, P2098, DOI 10.1200/JCO.2015.64.9285; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shore ND, 2016, LANCET ONCOL, V17, P153, DOI 10.1016/S1470-2045(15)00518-5; Small EJ, 2019, ANN ONCOL, V30, P1813, DOI 10.1093/annonc/mdz397; Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546; Smith MR, 2005, J CLIN ONCOL, V23, P2918, DOI 10.1200/JCO.2005.01.529; Tombal B, 2019, LANCET ONCOL, V20, P556, DOI 10.1016/S1470-2045(18)30898-2; WHO, 2020, 59 HLTH ASS; Xie WL, 2017, J CLIN ONCOL, V35, P3097, DOI 10.1200/JCO.2017.73.9987	21	153	157	3	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	2020	382	23					2197	2206		10.1056/NEJMoa2003892	http://dx.doi.org/10.1056/NEJMoa2003892			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV0NI	32469184	Bronze, Green Published			2023-01-03	WOS:000538140600013
J	Schneberk, T; Raffetto, B; Friedman, J; Wilson, A; Kim, D; Schriger, DL				Schneberk, Todd; Raffetto, Brian; Friedman, Joseph; Wilson, Andrew; Kim, David; Schriger, David L.			Opioid prescription patterns among patients who doctor shop; Implications for providers	PLOS ONE			English	Article							DRUG-MONITORING PROGRAMS; UNITED-STATES; CHRONIC PAIN; OVERDOSE; ABUSE; CARE	Introduction Patients who doctor shop for opioids are a vulnerable population that present a difficult dilemma for their health care providers regarding best methods of immediate treatment and how to manage their risk of harm from opioids. We aim to describe and compare opioid prescription patterns among high quantity prescription patients who doctor shopped, high quantity prescription patients who did not (doctor shopping eligible patients), and the remaining patients who received opioid prescriptions to guide population health policies for high risk opioid use patients. Methods We performed a cross-sectional descriptive analysis of opioid prescriptions during an 8-year period using California's de-identified Controlled Substance Utilization Review and Evaluation System (CURES) database from years 2008-2015. We identified the prevalence of patients who doctor shopped and depicted their opioid prescription patterns including prescriber characteristics, in comparison to the aforementioned groups. Doctor shopping was defined by patients who received greater than 6 or more prescriptions from at least 6 different prescribers within 6 months of time. Results Among the 3 million individuals who received an opioid prescription during the 8-year period, 1.3% met the doctor shopper definition. These patients received high levels of chronic opioids with 82% and 33% averaging greater than 20 and 100 morphine milligram equivalents (MME) daily, respectively, in comparison to 72% and 18% in the doctor shopping eligible group. Patients who doctor shopped received a significant proportion of their MME from 1 main prescriber (54%) and only received 2-5% of their total MME from episodic care providers, despite 88% receiving a prescription from these providers. Conclusions Patients who doctor shop are at high risk of opioid use disorder but represent a small fraction of those with dangerous opioid use. Furthermore, these individuals do not receive substantial opioids from episodic providers, which challenges the utility of prescription reduction programs in curbing use among this population. These results suggest we re-evaluate physician roles in the care of these patients and focus on referral to treatment and harm reduction strategies.	[Schneberk, Todd; Raffetto, Brian] Los Angeles Cty Univ Southern Calif, Dept Emergency Med, Los Angeles, CA 90007 USA; [Friedman, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Wilson, Andrew] Greater Los Angeles VA, Dept Neurol, Los Angeles, CA USA; [Wilson, Andrew] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Kim, David; Schriger, David L.] Univ Calif Los Angeles, Dept Emergency Med, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Schneberk, T (corresponding author), Los Angeles Cty Univ Southern Calif, Dept Emergency Med, Los Angeles, CA 90007 USA.	tschneberk@gmail.com	Wilson, Andrew/AAW-4889-2021; Friedman, Joseph/ABA-5864-2020	Wilson, Andrew/0000-0002-6367-0621; Friedman, Joseph/0000-0002-5225-3267				Baldacchino A, 2010, ADDICT BEHAV, V35, P270, DOI 10.1016/j.addbeh.2009.10.008; Bernstein E, 1997, ANN EMERG MED, V30, P181, DOI 10.1016/S0196-0644(97)70140-9; Buchmueller TC, 2018, AM ECON J-ECON POLIC, V10, P77, DOI 10.1257/pol.20160094; Carey CM, 2018, ANN INTERN MED, V168, P837, DOI 10.7326/M17-3065; CDC, 2016, WID RANG ONL DAT EP; Chen QS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7621; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Duber H.C., 2018, ANN EMERG MED; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Fink DS, 2018, ANN INTERN MED, V168, P783, DOI 10.7326/M17-3074; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Guarino H., 2018, ADDICT BEHAV; Gugelmann H, 2012, J MED TOXICOL, V8, P378, DOI 10.1007/s13181-012-0273-8; Haffajee RL, 2018, HEALTH AFFAIR, V37, P964, DOI 10.1377/hlthaff.2017.1321; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Ioannidis JPA, 2019, AM STAT, V73, P20, DOI 10.1080/00031305.2018.1447512; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Katz Nathaniel P, 2010, J Pain Palliat Care Pharmacother, V24, P141, DOI 10.3109/15360281003799098; Leppink J, 2017, PERSPECT MED EDUC, V6, P115, DOI 10.1007/s40037-017-0332-6; McDonald DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069241; Neven D, 2016, J EMERG MED, V51, P498, DOI 10.1016/j.jemermed.2016.06.057; Pharmacy B.o., 2018, LAWB PHARM; Samuels EA, 2019, ANN EMERG MED, V73, P237, DOI 10.1016/j.annemergmed.2018.08.439; Schneberk T, 2018, ANN EMERG MED, V71, P650, DOI [10.1016/j.annemergmed.2018.03.019, 10.1016/j.annemergmed.2017.10.016]; Schriger D L, 2002, Eur J Emerg Med, V9, P203, DOI 10.1097/00063110-200206000-00021; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Sun BC, 2018, ANN EMERG MED, V71, P679, DOI 10.1016/j.annemergmed.2017.10.007	28	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2020	15	5							e0232533	10.1371/journal.pone.0232533	http://dx.doi.org/10.1371/journal.pone.0232533			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU1NT	32453745	Green Published, gold			2023-01-03	WOS:000537529500005
J	Dai, Z; Liu, SR; Wu, JF; Li, MD; Liu, JL; Li, K				Dai, Zheng; Liu, Siru; Wu, Jinfa; Li, Mengdie; Liu, Jialin; Li, Ke			Analysis of adult disease characteristics and mortality on MIMIC-III	PLOS ONE			English	Article							ASSOCIATION	Purpose To deeply analyze the basic information and disease information of adult patients in the MIMIC-III (Medical Information Mart for Intensive Care III) database, and provide data reference for clinicians and researchers. Materials and methods Tableau2019.1.0 and Navicat12.0.29 were used for data analysis and extraction of disease distribution of adult patients in the MIMIC-III database. Result A total of 38,163 adult patients were included in the MIMIC-III database. Only 38,156 patients with the first diagnosis were selected. Among them, 21,598 were males accounting for 56.6% the median age was 66 years (Q1-Q3: 53-78), the median length of a hospital stay was 7 days (Q1-Q3: 4-12), and the median length of an ICU stay was 2.1 days (Q1-Q3: 1.2-4.1). Septicemia was the disease with the highest mortality rate among patients and the total mortality rate was 48.9%. The disease with the largest number of patients at the last time was other forms of chronic ischemic heart disease. Conclusion By analyzing the patients' basic information, the admission spectrum and the disease morbidity and mortality can help more researchers understand the MIMIC-III database and facilitate further research.	[Dai, Zheng; Wu, Jinfa; Li, Mengdie; Li, Ke] Univ Elect Sci & Technol China, Sch Life Sci & Technol, Chengdu, Sichuan, Peoples R China; [Liu, Siru] Univ Utah, Dept Biomed Informat, Salt Lake City, UT USA; [Liu, Jialin] Sichuan Univ, West China Med Sch, Dept Med Informat, Chengdu, Sichuan, Peoples R China; [Liu, Jialin] Sichuan Univ, West China Hosp, Informat Ctr, Chengdu, Sichuan, Peoples R China	University of Electronic Science & Technology of China; Utah System of Higher Education; University of Utah; Sichuan University; Sichuan University	Li, K (corresponding author), Univ Elect Sci & Technol China, Sch Life Sci & Technol, Chengdu, Sichuan, Peoples R China.; Liu, JL (corresponding author), Sichuan Univ, West China Med Sch, Dept Med Informat, Chengdu, Sichuan, Peoples R China.; Liu, JL (corresponding author), Sichuan Univ, West China Hosp, Informat Ctr, Chengdu, Sichuan, Peoples R China.	DLJL8@163.com; colinlike@163.com	Liu, Siru/AAM-8737-2021; Liu, Siru/GYA-2297-2022	Liu, Siru/0000-0002-5003-5354; Dai, zheng/0000-0003-1084-1762				Aboelsoud MM, 2017, J CRIT CARE, V41, P9, DOI 10.1016/j.jcrc.2017.04.040; [Anonymous], 2017, 9 REVISION INT CLASS; Beaulieu-Jones BK, 2018, PAC S BIOC PAC S BIO; Calvert J, 2016, ANN MED SURG, V11, P52, DOI 10.1016/j.amsu.2016.09.002; Desautels T, 2016, JMIR MED INF, V4, P67, DOI 10.2196/medinform.5909; Fan Yong, 2018, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V30, P531, DOI 10.3760/cma.j.issn.2095-4352.2018.06.006; Feng ML, 2018, INTENS CARE MED, V44, P884, DOI 10.1007/s00134-018-5208-7; Johnson AEW, 2018, J AM MED INFORM ASSN, V25, P32, DOI 10.1093/jamia/ocx084; Johnson AEW, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.35; Kurniati AP, 2018, J PHYS CONF SER, V971, DOI 10.1088/1742-6596/971/1/012008; Lacroix J, 2011, TRANSFUS MED REV, V25, P197, DOI 10.1016/j.tmrv.2011.03.001; Lee J, 2017, JMIR MED INF, V5, DOI 10.2196/medinform.6690; Marshall DC, 2017, J CRIT CARE, V40, P63, DOI 10.1016/j.jcrc.2017.02.012; Parreco JP, 2018, J CRIT CARE, V45, P156, DOI 10.1016/j.jcrc.2018.02.010; Purushotham S, 2018, J BIOMED INFORM, V83, P112, DOI 10.1016/j.jbi.2018.04.007; Raghupathi W, 2014, HEALTH INF SCI SYST, V2, DOI 10.1186/2047-2501-2-3; Rhee KJ, 2015, INT J MOL SCI, V16, P30015, DOI 10.3390/ijms161226215; Rood PJT, 2019, J CRIT CARE, V53, P120, DOI 10.1016/j.jcrc.2019.06.007; Sharukh Lokhandwala, 2018, PLOS ONE, V13; Shen YF, 2018, J CRIT CARE, V44, P273, DOI 10.1016/j.jcrc.2017.11.041; Hoang TN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162844; Zimmerman JE, 2013, CRIT CARE, V17, DOI 10.1186/cc12695	22	2	4	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2020	15	4							e0232176	10.1371/journal.pone.0232176	http://dx.doi.org/10.1371/journal.pone.0232176			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LS9BE	32353003	Green Published, gold			2023-01-03	WOS:000536673200048
J	Petrelli, A; Di Napoli, A; Demuru, E; Ventura, M; Gnavi, R; Di Minco, L; Tamburini, C; Mirisola, C; Sebastiani, G				Petrelli, Alessio; Di Napoli, Anteo; Demuru, Elena; Ventura, Martina; Gnavi, Roberto; Di Minco, Lidia; Tamburini, Cristina; Mirisola, Concetta; Sebastiani, Gabriella			Socioeconomic and citizenship inequalities in hospitalisation of the adult population in Italy	PLOS ONE			English	Article							HEALTH-CARE; SERVICES UTILIZATION; BRAIN-TUMOR; IMMIGRANTS; EDUCATION; EUROPE	Background Higher levels of hospital admissions among people with lower socioeconomic level, including immigrants, have been observed in developed countries. In Europe, immigrants present a more frequent use of emergency services compared to the native population. The aim of our study was to evaluate the socioeconomic and citizenship differences in the hospitalisation of the adult population in Italy. Methods The study was conducted using the database created by the record linkage between the National Health Interview Survey (2005) with the National Hospital Discharge Database (2005-2014). 79,341 individuals aged 18-64 years were included. The outcomes were acute hospital admissions, urgent admissions and length of stay (1-7 days, > = 8 days). Education level, occupational status, self-perceived economic resources and migratory status were considered as socioeconomic determinants. A multivariate proportional hazards model for recurrent events was used to estimate the risk of total hospital admissions. Logistic models were used to estimate the risk of urgent hospitalisation as well as of length of stay. Results Low education level, the lack of employment and negative self-perceived economic resources were conditions associated with the risk of hospitalisation, a longer hospital stay and greater recourse to urgent hospitalisation. Foreigners had a lower risk of hospitalisation (HR = 0.75; 95% CI:0.68-0.83) but a higher risk of urgent hospitalisation (OR = 1.36; 95% CI:1.18-1.55) and more frequent hospitalisations with a length of stay of at least eight days (OR = 1.19; 95% CI:1.02-1.40). Conclusions To improve equity in access, effective primary, secondary and tertiary prevention strategies must be strengthened, as should access to appropriate levels of care.	[Petrelli, Alessio; Di Napoli, Anteo; Demuru, Elena; Ventura, Martina; Mirisola, Concetta] Natl Inst Hlth Migrat & Poverty INMP, Rome, Italy; [Gnavi, Roberto] ASL TO3, Epidemiol Unit, Turin, Italy; [Di Minco, Lidia; Tamburini, Cristina] Minist Hlth, Rome, Italy; [Sebastiani, Gabriella] Italian Natl Inst Stat Istat, Rome, Italy		Petrelli, A (corresponding author), Natl Inst Hlth Migrat & Poverty INMP, Rome, Italy.	alessio.petrelli@inmp.it	Demuru, Elena/AAE-9183-2019; Di Napoli, Anteo/AAN-1659-2020; Gnavi, Roberto/J-9263-2016	Di Napoli, Anteo/0000-0003-3207-8761; Gnavi, Roberto/0000-0003-1919-2199; Demuru, Elena/0000-0003-2979-4169; Petrelli, Alessio/0000-0002-7533-7260				Afilalo J, 2009, AM J CARDIOL, V103, P1616, DOI 10.1016/j.amjcard.2009.01.375; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bonvicini L, 2011, EPIDEMIOL PREV, V35, P259; Brameld KJ, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-61; Dalla Zuanna T, 2017, EUR J PUBLIC HLTH, V27; de Waure C, 2015, BMC INT HEALTH HUM R, V15, DOI 10.1186/s12914-014-0032-9; Di Napoli A, 2017, EPIDEMIOL PREV, V41, P3, DOI [10.19191/EP17.1.P003.002, DOI 10.19191/EP17.1.P003.002]; Di Napoli A, 2017, EPIDEMIOL PREV, V41, P41, DOI 10.19191/EP17.3-4S1.P041.064; Fedeli U, 2015, PEERJ, V3, DOI 10.7717/peerj.975; Glazier RH, 2000, CAN J PUBLIC HEALTH, V91, P268, DOI 10.1007/BF03404286; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Hernandez-Quevedo C, 2009, SOC SCI MED, V69, P370, DOI 10.1016/j.socscimed.2009.05.005; Huang ME, 1998, ARCH PHYS MED REHAB, V79, P1386, DOI 10.1016/S0003-9993(98)90232-5; ISTAT, 2017, IND DEC CAUS MORT IN; ISTAT, 2008, COND SAL RIC SERV SA; ISTAT, 2016, DIS NELL SPER VIT LI; Luben R, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009461; Mackenbach JP, 2008, NEW ENGL J MED, V358, P2468, DOI 10.1056/NEJMsa0707519; Mccartney G., 2013, BMJ OPEN, V3; Ministero della Salute, 2017, RAPP ANN ATT RIC OSP; Norredam M, 2010, EUR J PUBLIC HEALTH, V20, P555, DOI 10.1093/eurpub/ckp195; Pace A, 2016, SUPPORT CARE CANCER, V24, P4801, DOI 10.1007/s00520-016-3333-9; Pappas G, 1997, AM J PUBLIC HEALTH, V87, P811, DOI 10.2105/AJPH.87.5.811; Peeters A, 2015, LANCET DIABETES ENDO, V3, P838, DOI 10.1016/S2213-8587(15)00373-3; Petrelli A, 2019, EPIDEMIOL PREV, V43, P1, DOI 10.19191/EP19.1.S1.002; Petrelli A, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021653; Petrelli A, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0596-9; Schifano P, 2009, INT J EQUITY HEALTH, V8, DOI 10.1186/1475-9276-8-33; Stevens A, 1998, BRIT MED J, V316, P1448, DOI 10.1136/bmj.316.7142.1448; Stirbu I, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-288; Takahashi PY, 2016, J EPIDEMIOL COMMUN H, V70, P286, DOI 10.1136/jech-2015-205925; Tamayo-Fonseca N, 2015, SELF RATED HLTH HOSP; Taylor CB, 2006, AM J PREV MED, V31, P127, DOI 10.1016/j.amepre.2006.03.025; Torssander J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152369; van Doorslaer E, 2000, J HEALTH ECON, V19, P553, DOI 10.1016/S0167-6296(00)00050-3; VanKampen IG, 2014, PLOS ONE, V9; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; Wiking E, 2004, J EPIDEMIOL COMMUN H, V58, P574, DOI 10.1136/jech.2003.011387	39	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2020	15	4							e0231564	10.1371/journal.pone.0231564	http://dx.doi.org/10.1371/journal.pone.0231564			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR9SA	32324771	Green Published, gold			2023-01-03	WOS:000536033700019
J	Ding, YQ; Ding, KJ; Qian, HD; Yu, XF; Zou, DH; Yang, HJ; Mo, WJ; He, XM; Zhang, FR; Qin, CD; Zheng, YR; Ding, XW				Ding, Yuqin; Ding, Kaijing; Qian, Hongdan; Yu, Xingfei; Zou, Dehong; Yang, Hongjian; Mo, Wenju; He, Xiangming; Zhang, Fanrong; Qin, Chengdong; Zheng, Yurong; Ding, Xiaowen			Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer	PLOS ONE			English	Article							INTERNATIONAL EXPERT CONSENSUS; GUIDELINE RECOMMENDATIONS; HORMONE-RECEPTORS; PROGNOSTIC VALUE; PRIMARY THERAPY; HIGHLIGHTS; EFFICACY; SUBTYPES; COLLEGE; SOCIETY	Purpose To investigate whether estrogen receptor (ER), progesterone receptor (PR) and Ki-67 expression discordance before and after neoadjuvant chemotherapy (NAC) correlates with prognosis and treatment of breast cancer patients. Methods The study cohort included 482 breast cancer patients at the Zhejiang Cancer Hospital from January 1, 2008, to December 31, 2018. Core needle biopsies and excised tissue biopsies pre- and post-NAC were obtained. Immunohistochemistry was used to determine ER, PR and Ki-67 status. The relationship between biomarker discordance before and after NAC and clinicopathological features was compared retrospectively. Results ER (n = 482), PR (n = 482) and Ki-67 (n = 448) expression was assessed in the same lesion pre- and post-NAC. Discordance in the three markers pre- and post-NAC was observed in 50 (10.4%), 82 (17.0%) and 373 (77.4%) cases, respectively. Positive-to-negative PR expression changes were the most common type of discordance observed. The risk of death in patients with a PR positive-to-negative conversion was 6.58 times greater than for patients with stable PR expression. The risk of death in patients with increased Ki-67 expression following NAC treatment was 2.05 times greater than for patients with stable Ki-67 expression. Conclusion Breast cancer patients showed changes in ER, PR and/or Ki-67 status throughout NAC, and these changes possibly influenced disease-free survival and overall survival. A switch to negative hormone receptor expression with increased Ki-67 expression following NAC could be indicators of a worse prognosis. Biomarker expression investigations following NAC may potentially improve patient management and survival.	[Ding, Yuqin; Yu, Xingfei; Zou, Dehong; Yang, Hongjian; Mo, Wenju; He, Xiangming; Zhang, Fanrong; Qin, Chengdong; Zheng, Yurong; Ding, Xiaowen] Univ Chinese Acad Sci, Chinese Acad Sci, Canc Hosp,Zhejiang Canc Hosp, Dept Breast Surg,Inst Canc Res & Basic Med Sci, Hangzhou, Zhejiang, Peoples R China; [Ding, Kaijing] Zhejiang Univ, Affiliated Mental Hlth Ctr, Hangzhou Peoples Hosp 7, Dept Child Psychol, Hangzhou, Zhejiang, Peoples R China; [Qian, Hongdan] Deqing Cty Hosp Tradit Chinese Med, Dept Gen Surg, Huzhou, Zhejiang, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Zhejiang Cancer Hospital; Zhejiang University	Ding, XW (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, Canc Hosp,Zhejiang Canc Hosp, Dept Breast Surg,Inst Canc Res & Basic Med Sci, Hangzhou, Zhejiang, Peoples R China.	dingxw@zjcc.org.cn		Zheng, Yurong/0000-0002-1224-4796; yuqin, ding/0000-0002-9562-7943	Hangzhou Health Commission [2015A32]	Hangzhou Health Commission	This study was funded by the general project supported by Hangzhou Health Commission (Grant number: 2015A32) to Kaijing Ding.	Arens N, 2005, VIRCHOWS ARCH, V446, P489, DOI 10.1007/s00428-005-1244-0; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Chen R, 2018, BREAST CANCER RES TR, V170, P35, DOI 10.1007/s10549-018-4730-1; Curigliano G, 2011, ANN ONCOL, V22, P2227, DOI 10.1093/annonc/mdq751; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Giuliano AE, 2018, ANN SURG ONCOL, V25, P1783, DOI 10.1245/s10434-018-6486-6; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Hirata T, 2009, BRIT J CANCER, V101, P1529, DOI 10.1038/sj.bjc.6605360; Huang JB, 2013, MED HYPOTHESES, V80, P441, DOI 10.1016/j.mehy.2012.12.037; Kasami M, 2008, BREAST, V17, P523, DOI 10.1016/j.breast.2008.04.002; Lindstrom LS, 2012, J CLIN ONCOL, V30, P2601, DOI 10.1200/JCO.2011.37.2482; Marcom PK, 2007, BREAST CANCER RES TR, V102, P43, DOI 10.1007/s10549-006-9307-8; Matsubara N, 2013, BREAST CANCER RES TR, V137, P203, DOI 10.1007/s10549-012-2344-6; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Singh K, 2017, HUM PATHOL, V65, P123, DOI 10.1016/j.humpath.2017.04.016; Singh K, 2016, BREAST CANCER RES TR, V157, P405, DOI 10.1007/s10549-016-3824-x; Spring LM, 2016, JAMA ONCOL, V2, P1477, DOI 10.1001/jamaoncol.2016.1897; Tacca O, 2007, ONCOLOGIST, V12, P636, DOI 10.1634/theoncologist.12-6-636; Tan QX, 2014, INT J CLIN EXP PATHO, V7, P6862; Thompson AM, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2771; van de Ven S, 2011, CANCER TREAT REV, V37, P422, DOI 10.1016/j.ctrv.2010.11.006; von Minckwitz G, 2013, CLIN CANCER RES, V19, P4521, DOI 10.1158/1078-0432.CCR-12-3628; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; Wu YT, 2018, J BIOMED RES, V32, P191, DOI 10.7555/JBR.32.20170059; Yamazaki N, 2015, EJSO-EUR J SURG ONC, V41, P617, DOI 10.1016/j.ejso.2015.01.036; Yoshioka T, 2015, BREAST CANCER-TOKYO, V22, P185, DOI 10.1007/s12282-013-0474-2	28	13	13	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2020	15	4							e0231895	10.1371/journal.pone.0231895	http://dx.doi.org/10.1371/journal.pone.0231895			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9JM	32298374	gold, Green Published			2023-01-03	WOS:000536011400121
J	Hopwood, CJ; Bleidorn, W; Schwaba, T; Chen, S				Hopwood, Christopher J.; Bleidorn, Wiebke; Schwaba, Ted; Chen, Sophia			Health, environmental, and animal rights motives for vegetarian eating	PLOS ONE			English	Article							LIFE-STYLE; MEAT CONSUMPTION; FOOD; ATTITUDES; PERSONALITY; IDENTITY; STUDENTS; VEGAN; YOUNG; PERCEPTIONS	Health, the environment, and animal rights represent the three main reasons people cite for vegetarian diet in Western societies. However, it has not been shown that these motives can be distinguished empirically, and little is known about what kind of people are likely to be compelled by these different motives. This study had three goals. First, we aimed to use construct validation to test whether develop health, environmental, and animal rights motives for a vegetarian diet could be distinguished. Second, we evaluated whether these motivations were associated with different demographic, behavioral, and personality profiles in three diverse samples. Third, we examined whether peoples' motivations were related to responses to vegetarian advocacy materials. We created the Vegetarian Eating Motives Inventory, a 15-item measure whose structure was invariant across three samples (N = 1006, 1004, 5478) and two languages (English and Dutch). Using this measure, we found that health was the most common motive for non-vegetarians to consider vegetarian diets and it had the broadest array of correlates, which primarily involved communal and agentic values. Correlates of environmental and animal rights motives were limited, but these motives were strong and specific predictors of advocacy materials in a fourth sample (N = 739). These results provide researchers with a useful tool for identifying vegetarian motives among both vegetarian and non-vegetarian respondents, offer useful insights into the nomological net of vegetarian motivations, and provide advocates with guidance about how to best target campaigns promoting a vegetarian diet.	[Hopwood, Christopher J.; Bleidorn, Wiebke; Schwaba, Ted; Chen, Sophia] Univ Calif Davis, Davis, CA 95616 USA	University of California System; University of California Davis	Hopwood, CJ (corresponding author), Univ Calif Davis, Davis, CA 95616 USA.	chopwoodmsu@gmail.com		Hopwood, Christopher/0000-0001-6645-8645	Animal Charity Evaluators	Animal Charity Evaluators	Funding was provided to Christopher J. Hopwood and Wiebke Bleidorn by Animal Charity Evaluators (https://animalcharityevaluators.org).The funding agency advised on study design issues prior to data collection; all decisions about study design were determined by the authors.	Allen MW, 2000, J SOC PSYCHOL, V140, P405, DOI 10.1080/00224540009600481; Arbit N, 2017, FOOD QUAL PREFER, V59, P35, DOI 10.1016/j.foodqual.2017.02.002; Aston LM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001072; Baines S, 2007, PUBLIC HEALTH NUTR, V10, P436, DOI 10.1017/S1368980007217938; Ball M., 2009, ANIMAL ACTIVISTS HDB; Barr SI, 2002, J AM DIET ASSOC, V102, P354, DOI 10.1016/S0002-8223(02)90083-0; Bastian B, 2012, PERS SOC PSYCHOL B, V38, P247, DOI 10.1177/0146167211424291; Beardsworth A., 1999, British Food Journal, V101, P289, DOI 10.1108/00070709910272169; Bilewicz M, 2011, EUR J SOC PSYCHOL, V41, P201, DOI 10.1002/ejsp.766; Bleidorn W, 2019, PERS SOC PSYCHOL REV, V23, P190, DOI 10.1177/1088868318772990; Bobic J, 2012, COLLEGIUM ANTROPOL, V36, P795; Byrd-Bredbenner C, 2010, NUTR DIET, V67, P143, DOI 10.1111/j.1747-0080.2010.01446.x; Caviola L, 2019, LIKING DEVALUING ANI, DOI 10.31234/osf.io/sx5uw; Caviola L, 2019, J PERS SOC PSYCHOL, V116, P1011, DOI 10.1037/pspp0000182; Chalmers RP, 2012, J STAT SOFTW, V48, P1; Chin MG, 2002, ANTHROZOOS, V15, P332, DOI 10.2752/089279302786992441; Cooney N, 2014, VEGANOMICS SURPRISIN, P194; de Boer J, 2011, ECOL ECON, V70, P1259, DOI 10.1016/j.ecolecon.2011.03.001; DIETZ T, 1995, RURAL SOCIOL, V60, P533, DOI 10.1111/j.1549-0831.1995.tb00589.x; Dyett PA, 2013, APPETITE, V67, P119, DOI 10.1016/j.appet.2013.03.015; Fox N, 2008, APPETITE, V50, P422, DOI 10.1016/j.appet.2007.09.007; Francione G.L., 2015, EAT YOU CARE EXAMINA; Furnham A, 2003, ANTHROZOOS, V16, P135, DOI 10.2752/089279303786992260; Gale CR, 2007, BMJ-BRIT MED J, V334, P245, DOI 10.1136/bmj.39030.675069.55; Godfray HCJ, 2018, SCIENCE, V361, DOI 10.1126/science.aam5324; Green R, 2015, CLIMATIC CHANGE, V129, P253, DOI 10.1007/s10584-015-1329-y; Haddad EH, 2003, AM J CLIN NUTR, V78, p626S, DOI 10.1093/ajcn/78.3.626S; Haverstock K, 2012, APPETITE, V58, P1030, DOI 10.1016/j.appet.2012.02.048; Hirschler CA, 2011, SOC ANIM, V19, P156, DOI 10.1163/156853011X562999; Hoek AC, 2004, APPETITE, V42, P265, DOI 10.1016/j.appet.2003.12.003; Hoffman SR, 2013, APPETITE, V65, P139, DOI 10.1016/j.appet.2013.02.009; Hopwood CJ, 2019, FOOD QUAL PREFER, V75, P10, DOI 10.1016/j.foodqual.2019.02.004; Izmirli S, 2011, BRIT FOOD J, V113, P436, DOI 10.1108/00070701111116482; Jabs J, 1998, J NUTR EDUC, V30, P196, DOI 10.1016/S0022-3182(98)70319-X; Jackson B, 2003, J RES PERS, V37, P297, DOI 10.1016/S0092-6566(02)00574-3; Joy M., 2008, STRATEGIC ACTION ANI; JOYCE A, 2014, ENERGY EMISS CONTROL, V2, P33, DOI DOI 10.2147/EECT.S58518; Kalof L, 1999, RURAL SOCIOL, V64, P500, DOI 10.1111/j.1549-0831.1999.tb00364.x; Kaluza J, 2012, STROKE, V43, P2556, DOI 10.1161/STROKEAHA.112.663286; Kerschke-Risch P., 2015, Ernahrungs Umschau, V62, P98; Lea E, 2001, APPETITE, V36, P127, DOI 10.1006/appe.2000.0386; Leenaert T., 2017, CREATE VEGAN WORLD P; Lindeman M, 2000, APPETITE, V34, P55, DOI 10.1006/appe.1999.0293; Lindeman M, 1999, APPETITE, V33, P141, DOI 10.1006/appe.1999.0241; Loughnan S, 2010, APPETITE, V55, P156, DOI 10.1016/j.appet.2010.05.043; Lund TB, 2016, ANTHROZOOS, V29, P89, DOI 10.1080/08927936.2015.1083192; Macdiarmid JI, 2016, APPETITE, V96, P487, DOI 10.1016/j.appet.2015.10.011; MacNair R. M., 1998, Vegetarian Nutrition, V2, P96; Mathews S, 1997, SOC ANIM, V5, P169, DOI 10.1163/156853097X00060; Mertens E, 2017, PUBLIC HEALTH NUTR, V20, P739, DOI 10.1017/S1368980016002664; Oppenlander R. A., 2013, FOOD CHOICE SUSTAINA; Phillips CJC, 2012, ANIM WELFARE, V21, P87, DOI 10.7120/096272812799129466; Piazza J, 2015, APPETITE, V91, P114, DOI 10.1016/j.appet.2015.04.011; Poore J, 2018, SCIENCE, V360, P987, DOI 10.1126/science.aaq0216; Preylo BD, 2008, ANTHROZOOS, V21, P387, DOI 10.2752/175303708X371654; Radnitz C, 2015, APPETITE, V90, P31, DOI 10.1016/j.appet.2015.02.026; Renner B, 2012, APPETITE, V59, P117, DOI 10.1016/j.appet.2012.04.004; Rimal A. P, 2002, FAMILY EC NUTR REV, V14, P36; Rimer BK, 2006, J COMMUN, V56, pS184, DOI 10.1111/j.1460-2466.2006.00289.x; Robinson-O'brien R, 2009, J AM DIET ASSOC, V109, P648, DOI 10.1016/j.jada.2008.12.014; Rosenfeld DL, 2019, MOTIV EMOTION, V43, P400, DOI 10.1007/s11031-018-9747-6; Rosenfeld DL, 2018, APPETITE, V127, P182, DOI 10.1016/j.appet.2018.05.003; Rosenfeld DL, 2017, APPETITE, V116, P456, DOI 10.1016/j.appet.2017.05.039; Rosenfeld DL, 2017, APPETITE, V112, P78, DOI 10.1016/j.appet.2017.01.017; Rothgerber H, 2014, APPETITE, V72, P98, DOI 10.1016/j.appet.2013.10.002; Rozin P, 1997, PSYCHOL SCI, V8, P67, DOI 10.1111/j.1467-9280.1997.tb00685.x; Ruby MB, 2012, APPETITE, V58, P141, DOI 10.1016/j.appet.2011.09.019; Ruby MB, 2011, APPETITE, V56, P447, DOI 10.1016/j.appet.2011.01.018; Sedova I, 2016, APPETITE, V107, P415, DOI 10.1016/j.appet.2016.08.102; Simikas S, 2018, IS PERCENTAGE VEGETA; Spencer EH, 2007, J AM DIET ASSOC, V107, P72, DOI 10.1016/j.jada.2006.10.034; STEPTOE A, 1995, APPETITE, V25, P267, DOI 10.1006/appe.1995.0061; Tiplady C. M., 2015, ANIMAL STUDIES J, V4, P116; Vainio A, 2016, APPETITE, V106, P92, DOI 10.1016/j.appet.2016.03.002; Vinnari M, 2010, BRIT FOOD J, V112, P836, DOI 10.1108/00070701011067451; White RF, 1999, J AM DIET ASSOC, V99, P595, DOI 10.1016/S0002-8223(99)00146-7; Worsley A, 1998, APPETITE, V30, P151, DOI 10.1006/appe.1997.0118	77	41	41	4	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2020	15	4							e0230609	10.1371/journal.pone.0230609	http://dx.doi.org/10.1371/journal.pone.0230609			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LI0PP	32240198	Green Accepted, Green Published, gold			2023-01-03	WOS:000529188400001
J	Hugues, A; Di Marco, J; Bonan, I; Rode, G; Cucherat, M; Gueyffier, F				Hugues, Aurelien; Di Marco, Julie; Bonan, Isabelle; Rode, Gilles; Cucherat, Michel; Gueyffier, Francois			Publication language and the estimate of treatment effects of physical therapy on balance and postural control after stroke in meta-analyses of randomised controlled trials	PLOS ONE			English	Article							COMMUNITY WALKING ACTIVITY; SYSTEMATIC REVIEWS; PREDICTING HOME; BIAS; AMBULATION; IMPACT; FALLS	Background Findings regarding the impact of language bias on treatment effect estimates (TEE) are conflicting, and very few studies have assessed these impacts in rehabilitation. The purpose was to compare TEE between studies published in non-English language (SPNEL) and those published in English language (SPEL) included in a previously published meta-analysis assessing the effects of physical therapy on balance and postural control after stroke. Methods Six databases were searched until January 2019. Two independent reviewers selected randomised trials, extracted data, and assessed risk of bias. We conducted subgroup metaanalyses according to the language of study publication, then compared TEE between SPEL and SPNEL subgroups by using a random-effects meta-regression model. Results From 13,123 records, 132 SPEL (n = 5219) and 13 SPNEL (n = 693) were included. SPNEL had a weight in the pooled estimate (8.2%) significantly lower than SPEL (91.8%; p< 0.001). Compared to SPEL, SPNEL had both significantly worse methodological quality (p = 0.002) and quality of reporting for blinding of outcome assessment (p< 0.001); and a significantly worse quality of reporting for incomplete outcome data (p< 0.001). SPNEL had a significantly worse precision (i.e. inverse of variance) of TEE than SPEL (p = 0.005). Overall, the TEE was not significantly different between SPNEL and SPEL (standardised mean difference -0.16, 95% confidence interval [-0.53; 0.22], heterogeneity I2 = 78%). However, when PT was compared to sham treatment or usual care, SPNEL significantly over-estimated treatment effects (SMD -0.68, 95%CI [-1.03; -0.33], I-2 = 39%) compared to SPEL. Restriction of the search to SPEL only did not change the direction of TEE for 8 out of 9 comparisons. Conclusions SPNEL had a worse methodological quality than SPEL and were likely to over-estimate treatment effect. If inclusion of SPNEL in a systematic review is considered to be relevant, the impact of such studies on TEE should be explored by sensitivity analyses to ensure the findings validity.	[Hugues, Aurelien; Rode, Gilles] Hosp Civils Lyon, Hop Henry Gabrielle, Serv Med Phys & Readaptat, St Genis Laval, France; [Hugues, Aurelien; Rode, Gilles] Hosp Civils Lyon, Hop Henry Gabrielle, Plate Forme Mouvement & Handicap, St Genis Laval, France; [Hugues, Aurelien; Rode, Gilles] Univ Lyon 1, Univ Lyon, Inserm UMR S 1028, CNRS,Ctr Rech Neurosci Lyon,Equipe ImpAct,UMR 529, Bron, France; [Di Marco, Julie] SSR Val Rosay, Serv Reeduc Neurol, St Didier Au Mt Dor, France; [Bonan, Isabelle] CHU Rennes, Serv Med Phys & Readaptat, Rennes, France; [Bonan, Isabelle] Univ Rennes 1, Inserm Unite U746, Equipe EMPEN, Rennes, France; [Cucherat, Michel; Gueyffier, Francois] Univ Lyon 1, Univ Lyon, CNRS Lyon, UMR 5558, Lyon, France; [Cucherat, Michel; Gueyffier, Francois] Hosp Civils Lyon, Grp Hosp Est, Serv Hosp Univ Pharmacotoxicol, Bron, France	CHU Lyon; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Rennes; Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup; Assistance Publique Hopitaux Paris (APHP); CHU Lyon	Hugues, A (corresponding author), Hosp Civils Lyon, Hop Henry Gabrielle, Serv Med Phys & Readaptat, St Genis Laval, France.; Hugues, A (corresponding author), Hosp Civils Lyon, Hop Henry Gabrielle, Plate Forme Mouvement & Handicap, St Genis Laval, France.; Hugues, A (corresponding author), Univ Lyon 1, Univ Lyon, Inserm UMR S 1028, CNRS,Ctr Rech Neurosci Lyon,Equipe ImpAct,UMR 529, Bron, France.	huguesaurelien@gmail.com		Hugues, Aurelien/0000-0001-9190-2867				Bardy AH, 1998, BRIT J CLIN PHARMACO, V46, P147, DOI 10.1046/j.1365-2125.1998.00759.x; Bonan IV, 2004, ARCH PHYS MED REHAB, V85, P268, DOI 10.1016/j.apmr.2003.06.017; Dechartres A, 2018, ANN INTERN MED, V169, P385, DOI 10.7326/M18-1517; Dechartres A, 2016, J CLIN EPIDEMIOL, V77, P24, DOI 10.1016/j.jclinepi.2016.04.005; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; Dickersin K, 1993, ONLINE J CURRENT CLI, V50, P4967; Durcan S, 2016, DISABIL REHABIL, V38, P245, DOI 10.3109/09638288.2015.1035460; Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; Egger M, 2003, HEALTH TECHNOL ASSES, V7, P82; Fulk GD, 2017, STROKE, V48, P406, DOI 10.1161/STROKEAHA.116.015309; Fulk GD, 2010, ARCH PHYS MED REHAB, V91, P1582, DOI 10.1016/j.apmr.2010.07.005; Genthon N, 2008, STROKE, V39, P1793, DOI 10.1161/STROKEAHA.107.497701; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Hopewell S, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000006.pub3; Hugues A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013348; Hugues A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221700; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; Jin ZC, 2015, STAT MED, V34, P343, DOI 10.1002/sim.6342; Juni P, 2002, INT J EPIDEMIOL, V31, P115, DOI 10.1093/ije/31.1.115; Moher D, 2003, Health Technol Assess, V7, P1; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Morrison A, 2012, INT J TECHNOL ASSESS, V28, P138, DOI 10.1017/S0266462312000086; Mueller KF, 2016, J CLIN EPIDEMIOL, V80, P25, DOI 10.1016/j.jclinepi.2016.04.015; MULROW CD, 1994, BRIT MED J, V309, P597, DOI 10.1136/bmj.309.6954.597; Perennou DA, 2008, BRAIN, V131, P2401, DOI 10.1093/brain/awn170; Pham B, 2005, J CLIN EPIDEMIOL, V58, P769, DOI 10.1016/j.jclinepi.2004.08.021; Pildal J, 2007, INT J EPIDEMIOL, V36, P847, DOI 10.1093/ije/dym087; Rode G, 1997, SCAND J REHABIL MED, V29, P11; Schmid AA, 2013, TOP STROKE REHABIL, V20, P340, DOI 10.1310/tsr2004-340; Schmid AA, 2012, ARCH PHYS MED REHAB, V93, P1101, DOI 10.1016/j.apmr.2012.01.020; Song F, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14080; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; Tyson SF, 2006, PHYS THER, V86, P30, DOI 10.1093/ptj/86.1.30; van de Port IG, 2008, J REHABIL MED, V40, P23, DOI 10.2340/16501977-0114; van der Kooi E, 2017, ARCH PHYS MED REHAB, V98, P2393, DOI 10.1016/j.apmr.2017.05.003; Xu TM, 2018, ARCH PHYS MED REHAB, V99, P563, DOI 10.1016/j.apmr.2017.06.032	37	2	2	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2020	15	3							e0229822	10.1371/journal.pone.0229822	http://dx.doi.org/10.1371/journal.pone.0229822			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8UT	32150596	Green Published, gold			2023-01-03	WOS:000535274400020
J	Khan, A; Valli, E; Lam, H; Scott, DA; Murray, J; Hanssen, KM; Eden, G; Gamble, LD; Pandher, R; Flemming, CL; Allan, S; Osterman, AL; Haber, M; Norris, MD; Fletcher, JI; Yu, DMT				Khan, Aaminah; Valli, Emanuele; Lam, Hayley; Scott, David A.; Murray, Jayne; Hanssen, Kimberley M.; Eden, Georgina; Gamble, Laura D.; Pandher, Rupinder; Flemming, Claudia L.; Allan, Sophie; Osterman, Andrei L.; Haber, Michelle; Norris, Murray D.; Fletcher, Jamie, I; Yu, Denise M. T.			Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition	ONCOGENE			English	Article							CANCER-CELLS; N-MYC; GLYCOLYSIS; HYPOXIA; GROWTH; ACTIVATION; PYRUVATE; GLUTAMINOLYSIS; COMBINATION; METASTASIS	Amplification of the MYCN oncogene occurs in similar to 25% of primary neuroblastomas and is the single most powerful biological marker of poor prognosis in this disease. MYCN transcriptionally regulates a range of biological processes important for cancer, including cell metabolism. The MYCN-regulated metabolic gene SLC16A1, encoding the lactate transporter monocarboxylate transporter 1 (MCT1), is a potential therapeutic target. Treatment of neuroblastoma cells with the MCT1 inhibitor SR13800 increased intracellular lactate levels, disrupted the nicotinamide adenine dinucleotide (NADH/NAD(+)) ratio, and decreased intracellular glutathione levels. Metabolite tracing with 13C-glucose and 13C-glutamine following MCT1 inhibitor treatment revealed increased quantities of tricarboxylic acid (TCA) cycle intermediates and increased oxygen consumption rate. MCT1 inhibition was highly synergistic with vincristine and LDHA inhibition under cell culture conditions, but this combination was ineffective against neuroblastoma xenografts. Posttreatment xenograft tumors had increased synthesis of the MCT1 homolog MCT4/SLC16A, a known resistance factor to MCT1 inhibition. We found that MCT4 was negatively regulated by MYCN in luciferase reporter assays and its synthesis in neuroblastoma cells was increased under hypoxic conditions and following hypoxia-inducible factor (HIF1) induction, suggesting that MCT4 may contribute to resistance to MCT1 inhibitor treatment in hypoxic neuroblastoma tumors. Co-treatment of neuroblastoma cells with inhibitors of MCT1 and LDHA, the enzyme responsible for lactate production, resulted in a large increase in intracellular pyruvate and was highly synergistic in decreasing neuroblastoma cell viability. These results highlight the potential of targeting MCT1 in neuroblastoma in conjunction with strategies that involve disruption of pyruvate homeostasis and indicate possible resistance mechanisms.	[Khan, Aaminah; Valli, Emanuele; Lam, Hayley; Murray, Jayne; Hanssen, Kimberley M.; Eden, Georgina; Gamble, Laura D.; Pandher, Rupinder; Flemming, Claudia L.; Allan, Sophie; Haber, Michelle; Norris, Murray D.; Fletcher, Jamie, I; Yu, Denise M. T.] UNSW Sydney, Childrens Canc Inst, Lowy Canc Res Ctr, Sydney, NSW 2052, Australia; [Khan, Aaminah; Lam, Hayley] UNSW Sydney, Sch Med Sci, Sydney, NSW 2052, Australia; [Valli, Emanuele; Hanssen, Kimberley M.; Fletcher, Jamie, I; Yu, Denise M. T.] UNSW Sydney, Sch Womens & Childrens Hlth, Sydney, NSW 2052, Australia; [Scott, David A.; Osterman, Andrei L.] Sanford Burnham Prebys Med Discovery Inst, Canc Metab Core, La Jolla, CA 92037 USA; [Norris, Murray D.] Univ New South Wales, Ctr Childhood Canc Res, Sydney, NSW, Australia	Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney; Sanford Burnham Prebys Medical Discovery Institute; University of New South Wales Sydney	Fletcher, JI; Yu, DMT (corresponding author), UNSW Sydney, Childrens Canc Inst, Lowy Canc Res Ctr, Sydney, NSW 2052, Australia.; Fletcher, JI; Yu, DMT (corresponding author), UNSW Sydney, Sch Womens & Childrens Hlth, Sydney, NSW 2052, Australia.	JFletcher@ccia.unsw.edu.au; DYu@ccia.unsw.edu.au	Valli, Emanuele/ABD-7213-2020; Murray, Jayne/AAM-8115-2021	Valli, Emanuele/0000-0002-0928-8624; Hanssen, Kimberley/0000-0002-2919-3104; Haber, Michelle/0000-0003-2036-8817; Scott, David/0000-0002-8668-2449; Fletcher, Jamie/0000-0003-2949-9469; Murray, Jayne/0000-0002-1861-6570; Gamble, Laura D./0000-0001-8496-9705	Balnaves Foundation Young Investigator Grant; National Health and Medical Research Council [APP1016699]; SBP NCI Cancer Center Support Grant [P30 CA030199]	Balnaves Foundation Young Investigator Grant; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); SBP NCI Cancer Center Support Grant	We thank Donna Lai and Sheng Hua from the Bosch Molecular Biology Facility, University of Sydney for support with Seahorse Analyses, and Alan Truong for technical support. This work was supported by a Balnaves Foundation Young Investigator Grant (DMTY), a National Health and Medical Research Council Program Grant APP1016699 (MH, MDN), and a SBP NCI Cancer Center Support Grant P30 CA030199 (DS, AO).	Benjamin D, 2018, CELL REP, V25, P3047, DOI 10.1016/j.celrep.2018.11.043; Birsoy K, 2013, NAT GENET, V45, P104, DOI 10.1038/ng.2471; Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Curtis NJ, 2017, ONCOTARGET, V8, P69219, DOI 10.18632/oncotarget.18215; Doherty JR, 2014, CANCER RES, V74, P908, DOI 10.1158/0008-5472.CAN-13-2034; Fang J, 2006, MOL PHARMACOL, V70, P2108, DOI 10.1124/mol.106.026245; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Gan L, 2016, ONCOGENE, V35, P3037, DOI 10.1038/onc.2015.360; Gherardi S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00042; Groninger E, 2002, INT J ONCOL, V21, P1339; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Henderson MJ, 2011, J NATL CANCER I, V103, P1236, DOI 10.1093/jnci/djr256; Hong CS, 2016, CELL REP, V14, P1590, DOI 10.1016/j.celrep.2016.01.057; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Jin L, 2016, ONCOGENE, V35, P3619, DOI 10.1038/onc.2015.447; Kocak H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.84; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Levy AG, 2012, INVEST NEW DRUG, V30, P191, DOI 10.1007/s10637-010-9551-y; Lin RY, 1998, J BIOL CHEM, V273, P28959, DOI 10.1074/jbc.273.44.28959; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Noble RA, 2017, HAEMATOLOGICA, V102, P1247, DOI 10.3324/haematol.2016.163030; Obre E, 2015, INT J BIOCHEM CELL B, V59, P167, DOI 10.1016/j.biocel.2014.12.008; Park JR, 2010, HEMATOL ONCOL CLIN N, V24, P65, DOI 10.1016/j.hoc.2009.11.011; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Pertega-Gomes N, 2015, ONCOTARGET, V6, P21675, DOI 10.18632/oncotarget.4328; Polanski R, 2014, CLIN CANCER RES, V20, P926, DOI 10.1158/1078-0432.CCR-13-2270; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Qing GL, 2010, CANCER RES, V70, P10351, DOI 10.1158/0008-5472.CAN-10-0740; Quanz M, 2018, MOL CANCER THER, V17, P2285, DOI 10.1158/1535-7163.MCT-17-1253; Ratnikov B, 2015, ONCOTARGET, V6, P7379, DOI 10.18632/oncotarget.3132; Ren P, 2015, J PATHOL, V235, P90, DOI 10.1002/path.4429; Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Sounni NE, 2014, CELL METAB, V20, P280, DOI 10.1016/j.cmet.2014.05.022; Sullivan LB, 2016, NAT REV CANCER, V16, P680, DOI 10.1038/nrc.2016.85; Thangaraju M, 2009, BIOCHEM J, V417, P379, DOI 10.1042/BJ20081132; Tu Y, 2013, INT J MOL MED, V31, P113, DOI 10.3892/ijmm.2012.1167; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; Valli E, 2012, BBA-GENE REGUL MECH, V1819, P1173, DOI 10.1016/j.bbagrm.2012.08.001; Wagner W, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0114-x; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xiao DB, 2015, ONCOTARGET, V6, P40655, DOI 10.18632/oncotarget.5821; Xu RH, 2005, CANCER RES, V65, P613; Zhang XL, 2011, MOL CELL BIOCHEM, V358, P287, DOI 10.1007/s11010-011-0979-y; Zhao L, 2004, CLIN CANCER RES, V10, P7994, DOI 10.1158/1078-0432.CCR-04-1087; Zhao YX, 2011, J CEREBR BLOOD F MET, V31, P1412, DOI 10.1038/jcbfm.2010.230	51	14	14	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3555	3570		10.1038/s41388-020-1235-2	http://dx.doi.org/10.1038/s41388-020-1235-2		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32123312	Green Accepted			2023-01-03	WOS:000517738400001
J	Porter, AS; Harman, S; Lakin, JR				Porter, Amy S.; Harman, Stephanie; Lakin, Joshua R.			Power and perils of prediction in palliative care	LANCET			English	Editorial Material									[Porter, Amy S.] Rainbow Babies & Childrens Hosp, Ctr Comprehens Care, 2101 Adelbert Rd, Cleveland, OH 44106 USA; [Harman, Stephanie] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; [Lakin, Joshua R.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Stanford University; Harvard University; Dana-Farber Cancer Institute	Porter, AS (corresponding author), Rainbow Babies & Childrens Hosp, Ctr Comprehens Care, 2101 Adelbert Rd, Cleveland, OH 44106 USA.	amy.porter@uhhospitals.org		Lakin, Joshua/0000-0002-7659-6512	Cambia Health Foundation through the Sojourns Scholar Leadership Program	Cambia Health Foundation through the Sojourns Scholar Leadership Program	SH and JRL have received funding from the Cambia Health Foundation through the Sojourns Scholar Leadership Program. SH and JRL both advise informatics teams at their local institutions about development of predictive algorithms but receive no financial support from that work. SH is a faculty teacher for VitalTalk.org, a not-for-profit that trains and supports clinicians who care for patients with serious illness. The authors would like to thank Arthur Kleinman and Nora Kenworthy for their guidance on applying social scientific analysis and social theory to clinical practice.		0	6	8	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 29	2020	395	10225					680	681						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ2JO	32113499				2023-01-03	WOS:000516755200017
J	Gough, N; Brkan, L; Subramaniam, P; Chiuccariello, L; De Petrillo, A; Mulsant, BH; Bowie, CR; Rajji, TK				Gough, Nicole; Brkan, Lea; Subramaniam, Ponnusamy; Chiuccariello, Lina; De Petrillo, Alessandra; Mulsant, Benoit H.; Bowie, Christopher R.; Rajji, Tarek K.			Feasibility of remotely supervised transcranial direct current stimulation and cognitive remediation: A systematic review	PLOS ONE			English	Review							ALZHEIMERS-DISEASE; VERBAL MEMORY; OLDER-ADULTS; HOME; IMPAIRMENT; REHABILITATION; INTERVENTION; THERAPY; PROGRAM; TDCS	With technological advancements and an aging population, there is growing interest in delivering interventions at home. Transcranial Direct Current Stimulation (tDCS) and Cognitive Remediation (CR) as well as Cognitive Training (CT) have been widely studied, but mainly in laboratories or hospitals. Thus, the objectives of this review are to examine feasibility and the interventions components to support the domiciliary administration of tDCS and CR. We performed a systematic search of electronic databases, websites and reference lists of included articles from the first date available until October 31, 2018. Articles included had to meet the following criteria: original work published in English using human subjects, majority of tDCS or CR intervention administered remotely. A total of 39 studies were identified (16 tDCS, 23 CR/CT, 5 using both tDCS & CT). Four studies were single case studies and two were multiple case studies. The remaining 33 studies had a range of 9-135 participants. Five tDCS and nine CR/CT studies were double blind randomized controlled trials. Most studies focused on schizophrenia (8/39) and multiple sclerosis (8/39). Literature examined suggests the feasibility of delivering tDCS or CR/CT remotely with the support of information and communication technologies.	[Gough, Nicole; Brkan, Lea; Subramaniam, Ponnusamy; Chiuccariello, Lina; De Petrillo, Alessandra; Mulsant, Benoit H.; Bowie, Christopher R.; Rajji, Tarek K.] Ctr Addict & Mental Hlth CAMH, Div Adult Neurodev & Geriatr Psychiat, Toronto, ON, Canada; [Subramaniam, Ponnusamy] Univ Kebangsaan Malaysia, Hlth Psychol Program, Kuala Lumpur, Malaysia; [Subramaniam, Ponnusamy] Univ Kebangsaan Malaysia, Ctr Healthy Ageing & Wellness, Fac Hlth Sci, Kuala Lumpur, Malaysia; [Mulsant, Benoit H.; Rajji, Tarek K.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Bowie, Christopher R.] Queens Univ, Dept Psychol, Kingston, ON, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia; University of Toronto; Queens University - Canada	Rajji, TK (corresponding author), Ctr Addict & Mental Hlth CAMH, Div Adult Neurodev & Geriatr Psychiat, Toronto, ON, Canada.; Rajji, TK (corresponding author), Univ Toronto, Dept Psychiat, Toronto, ON, Canada.	tarek.rajji@camh.ca	Subramaniam, Ponnusamy/AAX-3915-2020; Rajji, Tarek K/K-1543-2015	Subramaniam, Ponnusamy/0000-0002-2361-4780; De Petrillo, Alessandra/0000-0002-9727-7123	Centre for Addiction and Mental Health (CAMH) Foundation	Centre for Addiction and Mental Health (CAMH) Foundation	This research was partially funded by the Centre for Addiction and Mental Health (CAMH) Foundation.	Agarwal S, 2018, J CLIN NEUROSCI, V57, P51, DOI 10.1016/j.jocn.2018.08.037; Andrade C, 2013, J ECT, V29, P239, DOI 10.1097/YCT.0b013e3182843866; Andre S, 2016, J NEUROL SCI, V369, P185, DOI 10.1016/j.jns.2016.07.065; Anguera JA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172616; Boggio PS, 2009, J NEUROL NEUROSUR PS, V80, P444, DOI 10.1136/jnnp.2007.141853; Boggio PS, 2012, BRAIN STIMUL, V5, P223, DOI 10.1016/j.brs.2011.06.006; Boman IL, 2004, BRAIN INJURY, V18, P985, DOI 10.1080/02699050410001672396; Bowie C., COGNITIVE IMPAIRMENT, P306, DOI [10.1017/cbo9781139860567.022, DOI 10.1017/CBO9781139860567.022]; Bowie CR, 2013, J NERV MENT DIS, V201, P680, DOI 10.1097/NMD.0b013e31829c5030; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Bystad M, 2017, NEUROCASE, V23, P146, DOI 10.1080/13554794.2017.1325911; Caller TA, 2016, EPILEPSY BEHAV, V57, P111, DOI 10.1016/j.yebeh.2016.01.024; Carvalho F, 2018, JOVE-J VIS EXP, DOI 10.3791/57614; Cha YH, 2016, BRAIN STIMUL, V9, P539, DOI 10.1016/j.brs.2016.03.016; Charvet L E, 2015, Mult Scler J Exp Transl Clin, V1, p2055217315609629, DOI 10.1177/2055217315609629; Charvet L, 2018, NEUROMODULATION, V21, P383, DOI 10.1111/ner.12583; Charvet LE, 2018, MULT SCLER J, V24, P1760, DOI 10.1177/1352458517732842; Charvet LE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177177; Charvet LE, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00026; Cody SL, 2015, J NEUROSCI NURS, V47, P247, DOI 10.1097/JNN.0000000000000147; Deckersbach T, 2010, CNS NEUROSCI THER, V16, P298, DOI 10.1111/j.1755-5949.2009.00110.x; Elgamal S, 2007, PSYCHOL MED, V37, P1229, DOI 10.1017/S0033291707001110; Ferrucci R, 2008, NEUROLOGY, V71, P493, DOI 10.1212/01.wnl.0000317060.43722.a3; Fisher M, 2015, SCHIZOPHRENIA BULL, V41, P250, DOI 10.1093/schbul/sbt232; Fisher M, 2009, AM J PSYCHIAT, V166, P805, DOI 10.1176/appi.ajp.2009.08050757; Grill JD, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt58; Hagenacker T, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-78; Hyvarinen P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154286; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Johnstone SJ, 2017, INT J PSYCHOPHYSIOL, V116, P32, DOI 10.1016/j.ijpsycho.2017.02.015; Karssemeijer EGA, 2017, AGEING RES REV, V40, P75, DOI 10.1016/j.arr.2017.09.003; Kasschau M, 2016, NEUROMODULATION, V19, P824, DOI 10.1111/ner.12430; Kasschau M, 2015, JOVE-J VIS EXP, DOI 10.3791/53542; Kirk HE, 2016, J CHILD PSYCHOL PSYC, V57, P1380, DOI 10.1111/jcpp.12615; Kuo MF, 2014, NEUROIMAGE, V85, P948, DOI 10.1016/j.neuroimage.2013.05.117; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Loewy R, 2016, SCHIZOPHRENIA BULL, V42, pS118, DOI 10.1093/schbul/sbw009; Maffei L, 2017, SCI REP-UK, V7, DOI 10.1038/srep39471; Mariano MA, 2015, SCHIZOPHR RES, V166, P283, DOI 10.1016/j.schres.2015.05.030; Martens G, 2018, BRAIN STIMUL, V11, P982, DOI 10.1016/j.brs.2018.04.021; McBride RL, 2017, PSYCHIAT RES, V257, P400, DOI 10.1016/j.psychres.2017.08.035; Meusel LA, 2009, BIOL PSYCHIAT, V65, p234S; Milman U, 2014, J PARKINSON DIS, V4, P37, DOI 10.3233/JPD-130321; Mohanty M, 2013, ANN NEUROSCI, V20, P31, DOI 10.5214/ans.0972.7531.200111; Mortensen J, 2016, DISABIL REHABIL, V38, P637, DOI 10.3109/09638288.2015.1055379; Nahum Mor, 2014, Schizophr Res Cogn, V1, pe11; Naismith SL, 2010, J AFFECT DISORDERS, V121, P258, DOI 10.1016/j.jad.2009.06.028; Park SH, 2014, NEUROREPORT, V25, P122, DOI 10.1097/WNR.0000000000000080; Pyun SB, 2009, BRAIN INJURY, V23, P686, DOI 10.1080/02699050902997862; QUAYHAGEN MP, 1995, NURS RES, V44, P153; Quayhagen MP, 2001, NEUROPSYCHOL REHABIL, V11, P319, DOI 10.1080/09602010042000024; Rajeswaran J, 2017, INDIAN J PSYCHOL MED, V39, P797, DOI 10.4103/0253-7176.219648; Rajji TK, 2019, CLIN PHARMACOL THER, V106, P776, DOI 10.1002/cpt.1574; Rajji TK, 2019, EXPERT OPIN THER TAR, V23, P21, DOI 10.1080/14728222.2019.1550074; Regan B, 2017, AM J GERIAT PSYCHIAT, V25, P258, DOI 10.1016/j.jagp.2016.11.008; Riggs A, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00093; Rupp CI, 2012, J STUD ALCOHOL DRUGS, V73, P625, DOI 10.15288/jsad.2012.73.625; Shaw MT, 2017, JOVE-J VIS EXP, DOI 10.3791/56211; Sherman DS, 2017, NEUROPSYCHOL REV, V27, P440, DOI 10.1007/s11065-017-9363-3; Vazquez-Campo Miriam, 2016, Schizophr Res Cogn, V4, P10, DOI 10.1016/j.scog.2015.11.007; Ventura J, 2013, SCHIZOPHR RES, V143, P397, DOI 10.1016/j.schres.2012.11.033; WHO, 2018, TOP 10 CAUS DEATH; World Health Organization, 2017, DEMENTIA; Wykes T, 2011, AM J PSYCHIAT, V168, P472, DOI 10.1176/appi.ajp.2010.10060855	64	16	16	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2020	15	2							e0223029	10.1371/journal.pone.0223029	http://dx.doi.org/10.1371/journal.pone.0223029			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8DW	32092069	Green Submitted, Green Published, gold			2023-01-03	WOS:000535229300004
J	Figueroa-Vega, N; Marin-Aragon, CI; Lopez-Aguilar, I; Ibarra-Reynoso, L; Perez-Luque, E; Malacara, JM				Figueroa-Vega, Nicte; Marin-Aragon, Carolina I.; Lopez-Aguilar, Itzel; Ibarra-Reynoso, Lorena; Perez-Luque, Elva; Manuel Malacara, Juan			Analysis of the percentages of monocyte subsets and ILC2s, their relationships with metabolic variables and response to hypocaloric restriction in obesity	PLOS ONE			English	Article							INNATE LYMPHOID-CELLS; BLOOD MONONUCLEAR-CELLS; IMMUNE-SYSTEM; PERIPHERAL-BLOOD; WEIGHT-LOSS; EXPRESSION; ATHEROSCLEROSIS; INFLAMMATION; REGULATORS; RECEPTORS	Purpose Obesity results from excess energy intake over expenditure and is characterized by chronic low-grade inflammation involving circulating monocytes (Mo) and group 2 innate lymphoid cells (ILC2s) imbalance. We analyzed circulating Mo subsets and ILC2s percentages and beta 2-adrenergic receptor (beta 2AR) expression in lean and obese subjects, and the possible effect of hypocaloric restriction on these innate immune cells. Methods In 139 individuals aged 45 to 57 years, classified in 74 lean individuals (>18.9kg/m(2) BMI <24.9kg/m(2)) and 65 with obesity (n = 65), we collected fasting blood samples to detect Mo subsets, ILC2s number, and beta 2AR expression by flow cytometry. Lipids, insulin, leptin, and acylated-ghrelin concentrations were quantified. Resting energy expenditure (REE) was estimated by indirect calorimetry. These measurements were repeated in obese subjects after 7-weeks of hypocaloric restriction. Results Non-classical monocytes (NCM) and beta 2AR expression on intermediate Mo (IM) were increased in obese individuals (p<0.001, in both cases), whereas the percent of ILC2s was decreased (p<0.0001). Stepwise regression analysis showed significantly negative associations of ILC2s with caloric intake, beta 2AR expression on IM with REE, but a positive relationship between NCM and HOMA-IR. Caloric restriction allowed a significant diminution of NCM and the beta 2AR expression on IM, as well as, an increase in the percent of classical Mo (CM), and ILC2s. Delta REE was related to Delta CD16(+)/CD16(-) ratio. Conclusions These findings show that in obesity occur changes in NCM, ILC2s and beta 2AR expression, which contribute to the low-grade inflammation linked to obesity and might revert with caloric restriction.	[Figueroa-Vega, Nicte; Marin-Aragon, Carolina I.; Lopez-Aguilar, Itzel; Ibarra-Reynoso, Lorena; Perez-Luque, Elva; Manuel Malacara, Juan] Univ Guanajuato, Dept Med Sci, Leon Campus, Leon, Gto, Mexico	Universidad de Guanajuato	Figueroa-Vega, N; Malacara, JM (corresponding author), Univ Guanajuato, Dept Med Sci, Leon Campus, Leon, Gto, Mexico.	ng.figueroa@ugto.mx; jmmalacara@hotmail.com	del Rocio Ibarra-Reynoso, Lorena/AAR-9678-2021		Consejo Nacional de Ciencia y Tecnologia (CONACYT, Mexico) [CB2014-242065M]	Consejo Nacional de Ciencia y Tecnologia (CONACYT, Mexico)(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This work was supported by the grant CB2014-242065M from Consejo Nacional de Ciencia y Tecnologia (CONACYT, Mexico, to Juan M. Malacara). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abeles D, 2012, CYTOM PART A, V81A, P823, DOI 10.1002/cyto.a.22104; Aguilar-Ruiz SR, 2011, J LEUKOCYTE BIOL, V90, P1119, DOI 10.1189/jlb.0111022; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Berg KE, 2012, CIRC-CARDIOVASC GENE, V5, P122, DOI 10.1161/CIRCGENETICS.111.960385; Bolus WR, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13919; Bordon Y, 2012, NAT REV IMMUNOL, V12, P679, DOI 10.1038/nri3303; Brestoff JR, 2015, NATURE, V519, P242, DOI 10.1038/nature14115; Brodde O E, 1984, J Hypertens Suppl, V2, pS111; Canpolat U, 2016, CLIN APPL THROMB-HEM, V22, P476, DOI 10.1177/1076029615594002; Carneiro IP, 2016, ADV NUTR, V7, P476, DOI 10.3945/an.115.008755; Chalubinski M, 2016, IMMUNOL LETT, V179, P43, DOI 10.1016/j.imlet.2016.09.007; Pereira JAD, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/4527980; de Matos MA, 2016, CELL BIOCHEM FUNCT, V34, P209, DOI 10.1002/cbf.3178; De Rosa V, 2015, SEMIN IMMUNOL, V27, P300, DOI 10.1016/j.smim.2015.10.001; Devevre EF, 2015, J IMMUNOL, V194, P3917, DOI 10.4049/jimmunol.1402655; DiSpirito JR, 2015, SEMIN IMMUNOL, V27, P315, DOI 10.1016/j.smim.2015.10.005; Dixit VD, 2004, J CLIN INVEST, V114, P57, DOI 10.1172/JCI200421134; Fernandez-Riejos P, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/568343; Flach M, 2015, CELL METAB, V21, P152, DOI 10.1016/j.cmet.2015.01.015; Galvez I, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112630; Garcia T, 2017, CYTOKINE GROWTH F R, V16, pS1359; Halim TYF, 2016, INT IMMUNOL, V28, P13, DOI 10.1093/intimm/dxv050; Hong S, 2008, BRAIN BEHAV IMMUN, V22, P590, DOI 10.1016/j.bbi.2007.12.003; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Idzkowska E, 2015, SCAND J IMMUNOL, V82, P163, DOI 10.1111/sji.12314; Jin CC, 2013, CELL METAB, V17, P873, DOI 10.1016/j.cmet.2013.05.011; Kenney MJ, 2014, COMPR PHYSIOL, V4, P1177, DOI 10.1002/cphy.c130051; Kim JE, 2017, NUTR RES, V40, P75, DOI 10.1016/j.nutres.2017.02.007; Krinninger P, 2014, J CLIN ENDOCR METAB, V99, P2500, DOI 10.1210/jc.2013-2611; Krychtiuk KA, 2015, J CLIN LIPIDOL, V9, P533, DOI 10.1016/j.jacl.2015.04.005; Lee MW, 2015, CELL, V160, P74, DOI 10.1016/j.cell.2014.12.011; Leite F, 2017, INT J MED SCI, V14, P853, DOI 10.7150/ijms.19638; Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132; Manco M, 2007, J CLIN ENDOCR METAB, V92, P483, DOI 10.1210/jc.2006-0960; Martin SS, 2013, JAMA-J AM MED ASSOC, V310, P2061, DOI 10.1001/jama.2013.280532; Milling S, 2019, IMMUNOLOGY, V158, P1, DOI 10.1111/imm.13104; Mjosberg J, 2017, IMMUNITY, V46, P344, DOI 10.1016/j.immuni.2017.03.002; Monteiro L, 2019, J LEUKOCYTE BIOL, V106, P703, DOI 10.1002/JLB.MR1218-478R; Moriyama S, 2018, SCIENCE, V359, P1056, DOI 10.1126/science.aan4829; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Nieman DC, 1996, INT J OBESITY, V20, P353; Odegaard JI, 2013, IMMUNITY, V38, P644, DOI 10.1016/j.immuni.2013.04.001; Osborn O, 2012, NAT MED, V18, P363, DOI 10.1038/nm.2627; Pecht T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159350; Pivovarova O, 2015, PEPTIDES, V65, P12, DOI 10.1016/j.peptides.2014.11.009; Poitou C, 2011, ARTERIOSCL THROM VAS, V31, P2322, DOI 10.1161/ATVBAHA.111.230979; Saetang J, 2018, MOL MED REP, V17, P1403, DOI 10.3892/mmr.2017.8038; Sanchez-Margalet V, 2003, CLIN EXP IMMUNOL, V133, P11, DOI 10.1046/j.1365-2249.2003.02190.x; Scanzano A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00171; Shimobayashi M, 2018, J CLIN INVEST, V128, P1538, DOI 10.1172/JCI96139; Takatsu K, 2008, CURR OPIN IMMUNOL, V20, P288, DOI 10.1016/j.coi.2008.04.001; van der Laan AM, 2012, AM HEART J, V163, P57, DOI 10.1016/j.ahj.2011.09.002; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; Wang H, 2015, REV ENDOCR METAB DIS, V16, P47, DOI 10.1007/s11154-014-9306-8; Yona S, 2010, CURR OPIN HEMATOL, V17, P53, DOI 10.1097/MOH.0b013e3283324f80; Zawada AM, 2012, IMMUNOBIOLOGY, V217, P1273, DOI 10.1016/j.imbio.2012.07.001	56	2	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2020	15	2							e0228637	10.1371/journal.pone.0228637	http://dx.doi.org/10.1371/journal.pone.0228637			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8AS	32074122	Green Published, gold			2023-01-03	WOS:000535220600023
J	Pospisil, D; Novotny, T; Jarkovsky, J; Farkasova, B; Kozak, M; Krivan, L; Vlasinova, J; Kala, P; Sepsi, M				Pospisil, David; Novotny, Tomas; Jarkovsky, Jiri; Farkasova, Barbora; Kozak, Milan; Krivan, Lubomir; Vlasinova, Jitka; Kala, Petr; Sepsi, Milan			Differences in right-to-left vs left-to-right interventricular conduction times in patients indicated to cardiac resynchronization therapy	PLOS ONE			English	Article							ELECTRICAL DELAY; HEART-FAILURE	Introduction Differences in conduction times from right ventricle to left ventricle and from left ventricle to right ventricle respectively were observed during biventricular devices implantation when changing pacing vector direction. In this article the phenomenon of interventricular conduction time differences is described and assessed in relationship to various clinical and electrophysiological parameters. Methods In 62 consecutive patients (9 females) interventricular conduction times between right and left ventricle in both directions were measured during cardiac resynchronization therapy device implantation procedure. Complex pacing protocol was performed. Results Investigated individuals was divided into 3 subgroups according to type of interventricular conduction pattern and statistically tested with various clinical data. Substantial differences in right-to-left vs left-to-right conduction times (> 5 ms, range 7-72 ms) were observed in 24 (39%) of all patients. They were more common in patients with dilated cardiomyopathy (20 of 38, 53%) compared to 4 (17%) of 24 patients with coronary artery disease (p = 0.011). The phenomenon occurred more often in hypertensive patients (p = 0.012). Other tested factors were nonsignificant. Conclusions There are almost no data on this topic. The occurrence of conduction difference phenomenon is quite common in dilated cardiomyopathy while it is rare in coronary artery disease. We assume the diffuse nature of the disease and the way of remodeling of myocardium play the main role. Knowledge of this phenomenon could be useful in personalized cardiac resynchronization therapy optimization.	[Pospisil, David; Novotny, Tomas; Farkasova, Barbora; Kozak, Milan; Krivan, Lubomir; Vlasinova, Jitka; Kala, Petr; Sepsi, Milan] Univ Hosp Brno, Dept Internal Med & Cardiol, Brno, Czech Republic; [Pospisil, David; Novotny, Tomas; Farkasova, Barbora; Kozak, Milan; Krivan, Lubomir; Vlasinova, Jitka; Kala, Petr; Sepsi, Milan] Masaryk Univ, Fac Med, Brno, Czech Republic; [Jarkovsky, Jiri] Masaryk Univ, Inst Biostat & Anal, Fac Med, Brno, Czech Republic	University Hospital Brno; Masaryk University Brno; Institute of Biostatistics & Analyses; Masaryk University Brno	Sepsi, M (corresponding author), Univ Hosp Brno, Dept Internal Med & Cardiol, Brno, Czech Republic.; Sepsi, M (corresponding author), Masaryk Univ, Fac Med, Brno, Czech Republic.	sepsi.milan@fnbrno.cz	Novotny, Tomas/ABD-5968-2020; Pospisil, David/AAR-1141-2021	Pospisil, David/0000-0002-6173-5225	Ministry of Health, Czech Republic - conceptual development of research organization [65269705, MUNI/A/1446/2019]	Ministry of Health, Czech Republic - conceptual development of research organization	This work was supported by the Ministry of Health, Czech Republic - conceptual development of research organization (FNBr, 65269705) and MUNI/A/1446/2019. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Carita P, 2016, INT J CARDIOL, V225, P402, DOI 10.1016/j.ijcard.2016.09.037; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Coppola G, 2016, INT J CARDIOL, V221, P450, DOI 10.1016/j.ijcard.2016.06.203; de Leeuw N, 2001, TRANSPLANT INT, V14, P299, DOI 10.1007/s001470100339; Glukhov AV, 2012, CIRCULATION, V125, P1835, DOI 10.1161/CIRCULATIONAHA.111.047274; Gold MR, 2017, HEART RHYTHM, V14, P1748, DOI 10.1016/j.hrthm.2017.10.016; Gold Michael R, 2016, JACC Clin Electrophysiol, V2, P438, DOI 10.1016/j.jacep.2016.02.018; Gold MR, 2011, EUR HEART J, V32, P2516, DOI 10.1093/eurheartj/ehr329; HARE JM, 1992, J AM COLL CARDIOL, V20, P1318, DOI 10.1016/0735-1097(92)90243-G; McSwain RL, 2005, J CARDIOVASC ELECTR, V16, P1168, DOI 10.1111/j.1540-8167.2005.40719.x; Medtronic. Medtronic Online Manual Library, 2018, CLARIA MRI QUAD CRT, P440; Sassone B, 2010, EUROPACE, V12, P78, DOI 10.1093/europace/eup347; St Jude Medical, 2015, FRONT US MAN, P34; ter Horst IAH, 2017, PACE, V40, P873, DOI 10.1111/pace.13118	14	0	0	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 19	2020	15	2							e0228731	10.1371/journal.pone.0228731	http://dx.doi.org/10.1371/journal.pone.0228731			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8AS	32074118	Green Published, gold			2023-01-03	WOS:000535220600026
J	Magaziner, J; Craik, R				Magaziner, Jay; Craik, Rebecca			Home-Based Physical Therapy for Older Adults After Hip Fracture Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							REHABILITATION; RECOVERY; PROGRAM		[Magaziner, Jay] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, 660 W Redwood St,Ste 200, Baltimore, MD 21201 USA; [Craik, Rebecca] Arcadia Univ, Dept Phys Therapy, Coll Hlth Sci, Glenside, PA USA	University System of Maryland; University of Maryland Baltimore	Magaziner, J (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, 660 W Redwood St,Ste 200, Baltimore, MD 21201 USA.	jmagazin@som.umaryland.edu						Picorelli AMA, 2014, J PHYSIOTHER, V60, P151, DOI 10.1016/j.jphys.2014.06.012; Latham NK, 2014, JAMA-J AM MED ASSOC, V311, P700, DOI 10.1001/jama.2014.469; Magaziner J, 2019, JAMA-J AM MED ASSOC, V322, P946, DOI 10.1001/jama.2019.12964; Miller RR, 2009, AGE AGEING, V38, P570, DOI 10.1093/ageing/afp107; Resnick B, 2016, J AM MED DIR ASSOC, V17, P200, DOI 10.1016/j.jamda.2015.10.004; Sherrington C, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012424.pub2	6	0	1	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2020	323	4					379	379		10.1001/jama.2019.19272	http://dx.doi.org/10.1001/jama.2019.19272			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH6AF	31990308				2023-01-03	WOS:000510731600023
J	Werner, RM; Hoffman, AK; Coe, NB				Werner, Rachel M.; Hoffman, Allison K.; Coe, Norma B.			Long-Term Care Policy after Covid-19-Solving the Nursing Home Crisis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Covid-19 has exposed the cracks in the U.S. system of providing and funding long-term care, and there are no easy fixes. We need comprehensive policies that take the care of aging Americans seriously and fund it accordingly and in a wider range of settings.	[Werner, Rachel M.; Hoffman, Allison K.; Coe, Norma B.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Werner, Rachel M.; Coe, Norma B.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Hoffman, Allison K.] Univ Penn, Penn Law, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Werner, RM (corresponding author), Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.; Werner, RM (corresponding author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.			Coe, Norma/0000-0003-1228-0938; Werner, Rachel/0000-0003-3435-4221				Coe NB, 2018, J AM GERIATR SOC, V66, P2003, DOI 10.1111/jgs.15552; Goldstein M., 2020, NEW YORK TIMES; Weiner J, 2020, POLICY OPTIONS FINAN, V23; Werner RM, 2018, JAMA-J AM MED ASSOC, V319, P1616, DOI 10.1001/jama.2018.2408; Yourish K, 2020, NEW YORK TIMES	5	62	62	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	2020	383	10					903	905		10.1056/NEJMp2014811	http://dx.doi.org/10.1056/NEJMp2014811			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NO9YO	32459918	Bronze, Green Submitted			2023-01-03	WOS:000569841600009
J	Myers, LC; Parodi, SM; Escobar, GJ; Liu, VX				Myers, Laura C.; Parodi, Stephen M.; Escobar, Gabriel J.; Liu, Vincent X.			Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter								This case series characterizes the demographics, health services use, and vital status and discharge dispositions of patients with polymerase chain reaction-confirmed coronavirus disease 2019 (COVID-19) hospitalized in the Kaiser Permanente Northern California health system in March 2020.	[Myers, Laura C.; Parodi, Stephen M.; Escobar, Gabriel J.; Liu, Vincent X.] Kaiser Permanente Northern Calif, Permanente Med Grp, Oakland, CA USA	Kaiser Permanente; Permanente Medical Groups	Myers, LC (corresponding author), Kaiser Permanente Northern Calif, Div Res & Syst Res Initiat, 2000 Broadway, Oakland, CA 94612 USA.	laura.c.myers@kp.org		Myers, Laura/0000-0002-2872-3388	Permanente Medical Group Inc; Kaiser Foundation Hospitals Inc.	Permanente Medical Group Inc; Kaiser Foundation Hospitals Inc.	This work was supported by The Permanente Medical Group Inc and Kaiser Foundation Hospitals Inc.	Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Centers for Disease Control and Prevention, SEV OUTC PAT COR DIS; Escobar GJ, 2013, MED CARE, V51, P446, DOI 10.1097/MLR.0b013e3182881c8e; Grasselli G, 2020, JAMA; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032	5	254	256	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2020	323	21					2195	2198		10.1001/jama.2020.7202	http://dx.doi.org/10.1001/jama.2020.7202			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY8YS	32329797	Green Published, Bronze			2023-01-03	WOS:000540816000027
J	Gibore, NS; Bali, TAL				Gibore, Nyasiro S.; Bali, Theodora A. L.			Community perspectives: An exploration of potential barriers to men's involvement in maternity care in a central Tanzanian community	PLOS ONE			English	Article							HEALTH; PARTICIPATION; PERCEPTIONS; PREGNANCY; PARTNERS; SERVICES	Background Male involvement in maternal health has been linked to positive health outcomes for women and children, as they control household resources and make significant decisions, which influence maternal health. Despite of the important role they have in maternal health care, their actual involvement remains low. The objective of this study was to explore community perspectives on potential barriers to men's involvement in maternity care in central Tanzania. Methods Qualitative research methods were used in data collection. We conducted 32 focus group discussions (16 FGDs with men and 16 FGDs with women) and 34 in-depth interviews with community leaders, village health workers and health care providers. Interview guides were used to guide the focus group discussions and in-depth interviews. The interviews and discussions were audio recorded, transcribed and translated into English and imported into QSR NVivo 9 software for thematic analysis. Three themes emerged from the data; men's maternity care involvement indicators, benefits of men's involvement in maternity health care services and barriers to men's involvement in maternity health care services. Results Both men and women participants acknowledged the importance of men's involvement in maternity health care services, even though few men actually got involved. Identified benefits of men's involvement in maternity health care services include: Learning any risk factors directly from the health care providers and getting prepared in addressing them; and reinforcing adherence to instruction received from the health care provider as family protectors and guardians. Barriers to men's involvement in maternity health care services are systemic; starting from the family, health care and culture-specific gender norms for maternity related behaviour as well as healthcare facilities structural constrains inhibiting implementation of couple-friendly maternity health care services. Conclusions Men's involvement in maternity care is influenced by culture-specific maternity-related gender norms. This situation is compounded by the conditions of deprivation that deny women access to resources with which they could find alternative support during pregnancy. Moreover, structures meant for maternal health care services lack privacy, thus inhibiting male partners' presence in the delivery room. Intervention to increase men's involvement in maternity care should address individual and systemic barriers to men's involvement.	[Gibore, Nyasiro S.] Univ Dodoma, Coll Hlth Sci, Sch Med, Dept Publ Hlth, Dodoma, Tanzania; [Bali, Theodora A. L.] St Johns Univ Tanzania, Fac Humanities & Educ, Dept Educ, Dodoma, Tanzania		Gibore, NS (corresponding author), Univ Dodoma, Coll Hlth Sci, Sch Med, Dept Publ Hlth, Dodoma, Tanzania.	nyasiro@hotmail.com						Aarnio P, 2009, AIDS CARE, V21, P1537, DOI 10.1080/09540120902903719; Aborigo RA, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-017-1641-9; Alio AP, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-60; Aly HAA, 2015, WHO TECH REP SER, V994, P1; August F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125978; Becker S, 2010, AIDS BEHAV, V14, P558, DOI 10.1007/s10461-009-9607-1; Bhatta DN, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-14; Brusamento S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009468.pub2; Byamugisha R, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-43; Byamugisha R, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-12; Char A, 2011, MALE INVOLVEMENT FAM; Chibwae A, 2018, TANZAN J HLTH RES, V20, P2; Craymah JP, 2017, INT J REPROD MED, V2017; Daniele MAS, 2018, B WORLD HEALTH ORGAN, V96, P450, DOI [10.2471/BLT.17.206466, 10.2471/blt.17.206466]; Davis J, 2013, MEN MATERNAL NEWBORN, V28; Ditekemena J, 2011, INT J STD AIDS, V22, P165, DOI 10.1258/ijsa.2010.010379; Ditekemena J, REPROD HLTH; Ezeanolue EE, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2216-1; Falnes EF, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-21; Ganle JK, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0083-y; Gibore NS, 2019, J PREGNANCY, V2019, DOI 10.1155/2019/7637124; Greene ME, 2006, PRIVATE DECISIONS SE; Kabagenyi A, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-21; Kayombo EJ, 1997, ISSUES PERSPECTIVES, V8, P288; Kululanga LI, 2012, J RES NURS MIDWIFERY, V1, P1; Kululanga LI, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-36; Kwambai TK, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-134; Lincetto O., 2006, OPPORTUNITIES AFRICA, P51; Mahiti GR, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1361184; Maluka SO, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0512-9; Mbekenga CK, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-98; Mekonnen W, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-37; Ministry of Health Community Development Gender Elderly and Children (MoHCDGEC) [Tanzania Mainland] Ministry of Health (MoH) [Zanzibar] National Bureau of Statistics (NBS) Office of the Chief Government Statistician (OCGS) and ICF, 2016, TANZ DEM HLTH SURV M, P2015; Mkandawire E, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1669-5; MoHSW, 2003, GUID PREV MOTH CHILD; MOHSW, 2015, NAT ROAD MAP STRAT P; Msuya SE, 2008, AIDS CARE, V20, P700, DOI 10.1080/09540120701687059; Mullany BC, 2006, SOC SCI MED, V62, P2798, DOI 10.1016/j.socscimed.2005.11.013; Mullany BC, 2010, J BIOSOC SCI, V42, P689, DOI 10.1017/S0021932010000222; Mullick S, 2005, AGENDA SPECIAL FOCUS, V6, P124; Mushi D, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-14; Nasreen HE, 2012, REPROD HEALTH, V9, DOI 10.1186/1742-4755-9-18; Nkuoh GN, 2010, J MIDWIFERY WOM HEAL, V55, P363, DOI 10.1016/j.jmwh.2010.02.009; Onyango M. A., 2010, African Journal of Reproductive Health, V14, P33; Rammohan A, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-336; Redshaw M, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-70; Shattuck D, 2011, AM J PUBLIC HEALTH, V101, P1089, DOI 10.2105/AJPH.2010.300091; Steen M, 2012, MIDWIFERY, V28, P422, DOI 10.1016/j.midw.2011.06.009; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; Theuring S, 2010, AIDS CARE, V22, P1562, DOI 10.1080/09540121003758572; Theuring S, 2009, AIDS BEHAV, V13, pS92, DOI 10.1007/s10461-009-9543-0; Tweheyo R, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-53; United Nations Children's Fund (UNICEF), 2014, STATE WORLDS CHILDRE; United Nations Population Fund, 1996, PROGR ACT AD I9NT C; Venables E, 2012, CULT HEALTH SEX, V14, P181, DOI 10.1080/13691058.2011.630757; Vermeulen E, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0853-8; Wegner MN, 1998, INT FAM PLAN PERSPEC, V24, P38, DOI 10.2307/2991918; Yargawa J, 2015, J EPIDEMIOL COMMUN H, V69, P604, DOI 10.1136/jech-2014-204784	58	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2020	15	5							e0232939	10.1371/journal.pone.0232939	http://dx.doi.org/10.1371/journal.pone.0232939			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU1JI	32437360	Green Published, gold			2023-01-03	WOS:000537517800030
J	Finlayson, K; Crossland, N; Bonet, M; Downe, S				Finlayson, Kenneth; Crossland, Nicola; Bonet, Mercedes; Downe, Soo			What matters to women in the postnatal period: A meta-synthesis of qualitative studies	PLOS ONE			English	Article							POSTPARTUM PERIOD; 1ST-TIME MOTHERS; SOCIAL SUPPORT; CARE; NEEDS; BODY; EXPECTATIONS; EXPERIENCES; PUERPERIUM; PREGNANCY	Introduction The postnatal period is an underserved aspect of maternity care. Guidelines for postnatal care are not usually informed by what matters to the women who use it. This qualitative systematic review was undertaken to identify what matters to women in the postnatal period, to inform the scope of a new World Health Organization (WHO) postnatal guideline. Methods We searched MEDLINE, CINAHL, PsycINFO, POPLINE, Global Index Medicus, EMBASE, LILACS, AJOL, and reference lists of eligible studies published January 2000-July 2019, reporting qualitative data on women's beliefs, expectations, and values relating to the postnatal period. Data collection and analysis Author findings were extracted, coded and synthesised using techniques derived from thematic synthesis. Confidence in the quality, coherence, relevance and adequacy of data underpinning the resulting findings was assessed using GRADE-CERQual. Results We included 36 studies from 15 countries, representing the views of more than 800 women. Confidence in most results was moderate to high. What mattered to women was a positive postnatal experience where they were able to adapt to their new self-identity and develop a sense of confidence and competence as a mother; adjust to changes in their intimate and family relationships, including their relationship to their baby; navigate ordinary physical and emotional challenges; and experience the dynamic achievement of personal growth as they adjust to the 'new normal' of motherhood and parenting in their own cultural context. Conclusion This review provides evidence that what matters to women in the postnatal period is achieving positive motherhood (including maternal self-esteem, competence, and autonomy), as well as fulfilling adaptation to changed intimate and family relationships, and (re)gaining health and wellbeing for both their baby, and themselves. Where this process is optimal, it also results in joy, self-confidence, and an enhanced capacity to thrive in the new integrated identity of 'woman and mother'.	[Finlayson, Kenneth; Downe, Soo] Univ Cent Lancashire, Res Childbirth & Hlth ReaCH Grp, Preston, Lancs, England; [Crossland, Nicola] Univ Cent Lancashire, Fac Hlth & Wellbeing, Preston, Lancs, England; [Bonet, Mercedes] WHO, Dept Reprod Hlth & Res, World Bank Special Programme Res Dev & Res Traini, UNDP,UNFPA,UNICEF, Geneva, Switzerland	University of Central Lancashire; University of Central Lancashire; The World Bank; United Nations Population Fund; World Health Organization	Finlayson, K (corresponding author), Univ Cent Lancashire, Res Childbirth & Hlth ReaCH Grp, Preston, Lancs, England.	kwfinlayson1@uclan.ac.uk		Downe, Soo/0000-0003-2848-2550	World Health Organization (WHO)	World Health Organization (WHO)(World Health Organization)	The work was commissioned to the University of Central Lancashire by the UNDP/ UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), a cosponsored program executed by the World Health Organization (WHO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida MS, 2008, REV ESC ENFERM USP, V42, P347, DOI 10.1590/S0080-62342008000200019; [Anonymous], 2015, GLOBAL STRATEGY WOME; [Anonymous], 2017, TRACK PROGR UN COV R; Merighi MAB, 2006, REV BRAS ENFERM, V59, P775, DOI 10.1590/S0034-71672006000600010; Beake S, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-70; Benova L, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002943; Bolinlha ALL, 2010, ONLINE BRAZ J NURS, V63, P811; Chungu C, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00094; Clark A, 2009, J REPROD INFANT PSYC, V27, P330, DOI 10.1080/02646830903190904; Cronin C, 2003, J CLIN NURS, V12, P260, DOI 10.1046/j.1365-2702.2003.00684.x; Deave Toity, 2008, BMC Pregnancy Childbirth, V8, P30, DOI 10.1186/1471-2393-8-30; Demarchi RF, 2017, J NURSING UFPE LINE, V11; DeMaria AL, 2019, CULT HEALTH SEX, V21, P1162, DOI 10.1080/13691058.2018.1543802; Downe S, 2016, BJOG-INT J OBSTET GY, V123, P529, DOI 10.1111/1471-0528.13819; Downe S, 2007, J ADV NURS, V57, P127, DOI 10.1111/j.1365-2648.2006.04079.x; Downe Soo, 2018, PLoS One, V13, pe0194906, DOI 10.1371/journal.pone.0194906; Ellberg L, 2010, MIDWIFERY, V26, P463, DOI 10.1016/j.midw.2008.10.006; Forster Della A, 2008, BMC Pregnancy Childbirth, V8, P27, DOI 10.1186/1471-2393-8-27; Gaboury J, 2017, JOGNN-J OBST GYN NEO, V46, P40, DOI 10.1016/j.jogn.2016.08.008; Haga SM, 2012, SCAND J CARING SCI, V26, P458, DOI 10.1111/j.1471-6712.2011.00950.x; Javadifar Nahid, 2016, J Family Reprod Health, V10, P146; Kurth E, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1300-2; Kurth E, 2014, MIDWIFERY, V30, P742, DOI 10.1016/j.midw.2013.06.017; Kurth E, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-21; Laney EK, 2015, IDENTITY, V15, P126, DOI 10.1080/15283488.2015.1023440; Langlois EV, 2015, B WORLD HEALTH ORGAN, V93, P259, DOI 10.2471/BLT.14.140996; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Lewin S, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-017-0688-3; Maher J, 2006, HLTH SOCIOLOGY REV, V15, P104, DOI [10.5172/hesr.2006.15.1.104, DOI 10.5172/HESR.2006.15.1.104]; Malouf R, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022212; Martin A, 2014, MATERN CHILD HLTH J, V18, P707, DOI 10.1007/s10995-013-1297-7; Martinez-Martinez A, 2017, SEX RELATSH THER, V32, P181, DOI 10.1080/14681994.2016.1263389; Mbekenga CK, 2011, WOMEN BIRTH, V24, P24, DOI 10.1016/j.wombi.2010.06.004; Mbuthia F, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2531-0; National Institute for Health and Social Care Excellence, 2015, POSTN CAR 8 WEEKS AF; Negron R, 2013, MATERN CHILD HLTH J, V17, P616, DOI 10.1007/s10995-012-1037-4; Neiterman E, 2017, SOC SCI MED, V174, P142, DOI 10.1016/j.socscimed.2016.12.029; Pascual CP, 2016, ATEN PRIM, V48, P657, DOI 10.1016/j.aprim.2015.12.004; Price SL, 2018, QUAL HEALTH RES, V28, P1552, DOI 10.1177/1049732317748314; Raman S, 2014, MIDWIFERY, V30, P130, DOI 10.1016/j.midw.2013.03.003; Razurel C, 2011, MIDWIFERY, V27, P237, DOI 10.1016/j.midw.2009.06.005; Ribeiro JP, 2019, REV ENFERM UFPE LINE, V13, P61, DOI [10.5205/1981-8963-v13i01a235022p61-69-2019, DOI 10.5205/1981-8963-V13I01A235022P61-69-2019]; Rogan F, 1997, J ADV NURS, V25, P877, DOI 10.1046/j.1365-2648.1997.1997025877.x; Rotich E, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1576-1; Rubin R, 1984, MATERNAL IDENTITY MA; Runquist J, 2007, JOGNN-J OBST GYN NEO, V36, P28, DOI [10.1111/J.1552-6909.2006.00116.x, 10.1111/j.1552-6909.2006.00116.x]; Sacks E, 2016, LANCET GLOB HEALTH, V4, pE442, DOI 10.1016/S2214-109X(16)30092-4; Salim NR, 2010, REV ESC ENFERM USP, V44, P888, DOI 10.1590/S0080-62342010000400005; Salim NR, 2010, REV LAT-AM ENFERM, V18, P732, DOI 10.1590/S0104-11692010000400011; Salim NR, 2010, ONLINE BRAZILIAN J N, V9, P12; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Singh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037037; Slomian J, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1398-1; Stevens J, 2019, MIDWIFERY, V74, P140, DOI 10.1016/j.midw.2019.03.020; Thomas J, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-45; Toomey RB, 2013, HISPANIC J BEHAV SCI, V35, P194, DOI 10.1177/0739986312470636; Tsai SY, 2014, MIDWIFERY, V30, P750, DOI 10.1016/j.midw.2013.08.005; Walsh D, 2006, MIDWIFERY, V22, P108, DOI 10.1016/j.midw.2005.05.004; Way S, 2012, MIDWIFERY, V28, pE712, DOI 10.1016/j.midw.2011.08.011; WHO UNICEF World Bank Group., 2018, NURT CAR EARL CHILDH; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; Wilkins C, 2006, MIDWIFERY, V22, P169, DOI 10.1016/j.midw.2005.07.001; World Health Organization, 2014, EV NEWB ACT PLAN RED; World Health Organization, 2015, STRATEGIES ENDING PR; World Health Organization, 2014, WHO REC POSTN CAR MO; Yeh YC, 2017, CONTEMP NURSE, V53, P576, DOI 10.1080/10376178.2017.1389615; Young Eleanor, 2008, Community Pract, V81, P27; Zamawe CF, 2015, INT J WOMENS HEALTH, V7, P587, DOI 10.2147/IJWH.S83228	68	44	45	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2020	15	4							e0231415	10.1371/journal.pone.0231415	http://dx.doi.org/10.1371/journal.pone.0231415			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR9QD	32320424	Green Accepted, Green Published, gold			2023-01-03	WOS:000536028800019
J	Chen, HH; Lin, CH; Lai, KL; Hsieh, TY; Chen, YM; Tseng, CW; Gotcher, DF; Chang, YM; Chiou, CC; Liu, SC; Weng, SJ				Chen, Hsin-Hua; Lin, Ching-Heng; Lai, Kuo-Lung; Hsieh, Tsu-Yi; Chen, Yi-Ming; Tseng, Chih-Wei; Gotcher, Donald F.; Chang, Yu-Mei; Chiou, Chuang-Chun; Liu, Shih-Chia; Weng, Shao-Jen			Relative risk of end-stage renal disease requiring dialysis in treated ankylosing spondylitis patients compared with individuals without ankylosing spondylitis: A nationwide, population-based, matched-cohort study	PLOS ONE			English	Article							QUALITY-OF-LIFE; RHEUMATOID-ARTHRITIS; IGA NEPHROPATHY; TAIWAN; PREVALENCE; MELOXICAM	Objective To examine the relative risk of end-stage renal disease (ESRD) requiring dialysis among treated ankylosing spondylitis (AS) patients compared with non-AS individuals. Methods We used claims data from Taiwan's National Health Insurance Research Database obtained between 2003 and 2012, and enrolled 37,070 newly treated AS patients and randomly selected 370,700 non-AS individuals matched (1:10) for age, sex and year of index date. Those with a history of chronic renal failure or dialysis were excluded. After adjusting for age, sex, diabetes mellitus, hypertension, IgA nephropathy, frequency of serum creatinine examinations, use of methotrexate, sulfasalazine, ciclosporis, corticosteroid, aminoglycoside, amphotericin B, cisplatin, contrast agents and annual cumulative defined daily dose (cDDD) of traditional NSAIDs, selective cyclooxygenase-2 inhibitors (COX-2i) and preferential COX-2i, we calculated the adjusted hazard ratios (aHRs) with 95% confidence intervals using the Cox proportional hazard model to quantify the risk of ESRD in AS patients. We re-selected 6621 AS patients and 6621 non-AS subjects by further matching (1:1) for cDDDs of three groups of NSAIDs to re-estimate the aHRs for ESRD. Results Fifty-one (0.14%) of the 37,070 AS patients and 1417 (0.38%) of the non-AS individuals developed ESRD after a follow-up of 158,846 and 1,707,757 person-years, respectively. The aHR for ESRD was 0.59 (0.42-0.81) in AS patients compared with non-AS individuals. However, after further matching for cDDD of NSAIDs, the aHR of ESRD was 1.02 (0.412.53). Significant risk factors included hypertension, IgA nephropathy and use of COX-2i. Conclusions The risk of ESRD was not significantly different between treated AS patients and non-AS individuals matched for age, sex, year of index date and dose of NSAID.	[Chen, Hsin-Hua; Lin, Ching-Heng; Chen, Yi-Ming] Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan; [Chen, Hsin-Hua; Lai, Kuo-Lung; Hsieh, Tsu-Yi; Chen, Yi-Ming; Tseng, Chih-Wei] Taichung Vet Gen Hosp, Dept Internal Med, Div Allergy Immunol & Rheumatol, Taichung, Taiwan; [Chen, Hsin-Hua] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Chen, Hsin-Hua; Chen, Yi-Ming] Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan; [Chen, Hsin-Hua; Chen, Yi-Ming] Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung, Taiwan; [Chen, Hsin-Hua] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Chen, Hsin-Hua] Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan; [Chen, Hsin-Hua] Natl Yang Ming Univ, Community Med Res Ctr, Taipei, Taiwan; [Chen, Hsin-Hua; Chiou, Chuang-Chun; Liu, Shih-Chia; Weng, Shao-Jen] Tunghai Univ, Dept Ind Engn & Enterprise Informat, Taichung, Taiwan; [Lin, Ching-Heng] Natl Taipei Univ Nursing & Hlth Sci, Dept Healthcare Management, Taipei, Taiwan; [Hsieh, Tsu-Yi] Feng Chia Univ, Coll Business, Taichung, Taiwan; [Hsieh, Tsu-Yi] Taichung Vet Gen Hosp, Dept Med Educ, Taichung, Taiwan; [Gotcher, Donald F.] Tunghai Univ, Dept Int Business, Taichung, Taiwan; [Chang, Yu-Mei] Tunghai Univ, Dept Stat, Taichung, Taiwan	Taichung Veterans General Hospital; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University; National Chung Hsing University; National Chung Hsing University; Chung Shan Medical University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Tunghai University; National Taipei University of Nursing & Health Science (NTUNHS); Feng Chia University; Taichung Veterans General Hospital; Tunghai University; Tunghai University	Chen, HH (corresponding author), Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan.; Chen, HH (corresponding author), Taichung Vet Gen Hosp, Dept Internal Med, Div Allergy Immunol & Rheumatol, Taichung, Taiwan.; Chen, HH (corresponding author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.; Chen, HH (corresponding author), Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan.; Chen, HH (corresponding author), Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung, Taiwan.; Chen, HH (corresponding author), Chung Shan Med Univ, Sch Med, Taichung, Taiwan.; Chen, HH (corresponding author), Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan.; Chen, HH (corresponding author), Natl Yang Ming Univ, Community Med Res Ctr, Taipei, Taiwan.; Chen, HH; Weng, SJ (corresponding author), Tunghai Univ, Dept Ind Engn & Enterprise Informat, Taichung, Taiwan.	shc5555@hotmail.com; sjweng@thu.edu.tw	Chen, Yi-Ming/AAV-3806-2021	Chen, Yi-Ming/0000-0001-7593-3065; Chang, Yu-Mei/0000-0002-2332-6017; Hsieh, Tsu-Yi/0000-0001-9897-6957	Taichung Veterans General Hospital, Taiwan [TCVGH-1067313C]	Taichung Veterans General Hospital, Taiwan	This study was supported in part by grant TCVGH-1067313C from Taichung Veterans General Hospital, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	[Anonymous], 2007, US REN DAT SYST USRD; Ariza-Ariza R, 2003, ARTHRIT RHEUM-ARTHR, V49, P483, DOI 10.1002/art.11197; BEAUVAIS C, 1992, PRESSE MED, V21, P1655; Bevis PJR, 1996, BRIT J RHEUMATOL, V35, P56; Birck R, 2000, EXP NEPHROL, V8, P173; BoultonJones JM, 1997, BRIT J CLIN PHARMACO, V43, P35, DOI 10.1111/j.1365-2125.1997.tb00030.x; Boyer GS, 1997, ARCH INTERN MED, V157, P2111, DOI 10.1001/archinte.157.18.2111; CHANG YT, 2015, MEDICINE, V94, DOI DOI 10.1097/MD; Chen HH, 2017, CLIN RHEUMATOL, V36, P133, DOI 10.1007/s10067-016-3471-y; Chen HH, 2011, CLINICS, V66, P251, DOI 10.1590/S1807-59322011000200012; Cheng TM, 2003, HEALTH AFFAIR, V22, P61, DOI 10.1377/hlthaff.22.3.61; CHOU CT, 1994, J RHEUMATOL, V21, P302; Gordeev VS, 2010, ANN RHEUM DIS, V69, P108, DOI 10.1136/ard.2008.100164; Kang JH, 2010, ANN RHEUM DIS, V69, P1165, DOI 10.1136/ard.2009.116178; Kiltz U, 2009, CLIN EXP RHEUMATOL, V27, pS108; LAI KN, 1989, ANN RHEUM DIS, V48, P435, DOI 10.1136/ard.48.5.435; Liu Zhi-cun, 2004, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V29, P635; Perneger TV, 1997, J HYPERTENS, V15, P451, DOI 10.1097/00004872-199715040-00016; PERRY HM, 1995, HYPERTENSION, V25, P587, DOI 10.1161/01.HYP.25.4.587; Samia B, 2012, NEPHROL THER, V8, P220, DOI 10.1016/j.nephro.2011.10.005; Schena FP, 2000, KIDNEY INT, V57, pS39, DOI 10.1046/j.1523-1755.2000.07407.x; Stolwijk C, 2015, ANN RHEUM DIS, V74, P65, DOI 10.1136/annrheumdis-2013-203582; Tsai SY, 2009, J EPIDEMIOL, V19, P169, DOI 10.2188/jea.JE20080099; van der Heijde D, 2017, ANN RHEUM DIS, V76, P978, DOI 10.1136/annrheumdis-2016-210770; VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; WALL BA, 1984, RHEUMATOL INT, V4, P27, DOI 10.1007/BF00683881; Ward MM, 1999, ARTHRIT CARE RES, V12, P247, DOI 10.1002/1529-0131(199908)12:4<247::AID-ART3>3.0.CO;2-H; WHO Collaborating Center for Drugs Statistics Methodology. WHO Collaborating Center for Drugs Statistics, 2017, ATC IND DDDS 2017; Yang WC, 2008, NEPHROL DIAL TRANSPL, V23, P3977, DOI 10.1093/ndt/gfn406; Zhang LX, 2008, AM J KIDNEY DIS, V51, P373, DOI 10.1053/j.ajkd.2007.11.009	31	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2020	15	4							e0231458	10.1371/journal.pone.0231458	http://dx.doi.org/10.1371/journal.pone.0231458			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9MR	32310965	Green Published, gold			2023-01-03	WOS:000536019800016
J	Coetzee, R; Johnson, Y; van Niekerk, J; Namane, M				Coetzee, Renier; Johnson, Yasmina; van Niekerk, Johan; Namane, Mosedi			Amitriptyline prescribing in public sector healthcare facilities in the Western Cape, South Africa	PLOS ONE			English	Article								Background Inappropriate medication use is a major patient safety concern, especially for the elderly population. Amitriptyline is widely used in primary care in South Africa and a cross-sectional study found that amitriptyline was prescribed potentially inappropriately in 6.5% of elderly patients. An analysis of prescriptions from the Chronic Dispensing Unit in the Western Cape revealed that amitriptyline was one of the most common medicines prescribed without a suitable diagnosis listed on the prescription. Objective The main objective of the medicine use evaluation (MUE) was to determine whether amitriptyline was prescribed in accordance with recommendations from standard treatment guidelines (STG) and essential medicines lists (EML) endorsed by the National Department of Health, South Africa. Methods A retrospective, cross-sectional, multicentre review of patients' clinical notes was conducted. The study population was selected by systematic random sampling from adult outpatients who were prescribed amitriptyline for longer than three months. Criteria for evaluation included amitriptyline indication and total daily dose prescribed. Results Of the sample of 2237 patient medical records reviewed, 1732 (77.4%) included amitriptyline prescriptions that were according to the approved STG indications. For the approved STG indications, amitriptyline was prescribed mainly for osteoarthritis (25.8%), neuropathies (18.5%) and chronic non-cancer pain (17.9%). Major depressive disorders constituted only 8.6% of the patient records reviewed; however, doses were atypically low. The main inappropriate indication for amitriptyline was sleep disorders (16%). Conclusion This MUE has highlighted the need to improve the use of amitriptyline in specific patient populations, e.g. the elderly and patients with sleeping disorders.	[Coetzee, Renier] Univ Western Cape, Sch Pharm, Cape Town, South Africa; [Johnson, Yasmina] Western Cape Govt Hlth, Cape Town, South Africa; [van Niekerk, Johan] Western Cape Govt, Dept Hlth, Metro Hlth Serv, Khayelitsha Eastern Substruct, Cape Town, South Africa; [Namane, Mosedi] Univ Cape Town, Vanguard Community Hlth Ctr, Cape Town, South Africa; [Namane, Mosedi] Univ Cape Town, Sch Publ Hlth & Family Med, Cape Town, South Africa	University of the Western Cape; University of Cape Town; University of Cape Town	Coetzee, R (corresponding author), Univ Western Cape, Sch Pharm, Cape Town, South Africa.	recoetzee@uwc.ac.za		Coetzee, Renier/0000-0002-8779-3458	Western Cape's PTC	Western Cape's PTC	We wish to acknowledge and thank the Western Cape's PTC for their endorsement of the study. The authors would like to acknowledge the support of the MUE Committee, including J Louw, A Peters, P Steyn; and especially Zeenat Yusuf for her work with the pilot of the study and Renfred Joshua for designing the electronic data capture tool. We would also like to thank the pharmacists and doctors at healthcare facilities and the University of the Western Cape's School of Pharmacy students who assisted with the data collection.	Aina BA, 2008, J INFECT DEV COUNTR, V2, P68, DOI 10.3855/jidc.325; Aparasu RR, 1999, AM J HEALTH-SYST PH, V56, P433, DOI 10.1093/ajhp/56.5.433; Asnis GM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010050; Chaturvedi V P, 2012, Med J Armed Forces India, V68, P206, DOI 10.1016/j.mjafi.2012.04.002; Department of Health, 2015, STAND TREATM GUID ES; Department of Health, 2014, STAND TREATM GUID ES; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P316, DOI 10.1001/jama.272.4.316; Lyttle JR, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD012139, DOI 10.1002/14651858.CD012139]; Ramiro S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008886.pub2; Slabbert FN, 2015, SAMJ S AFR MED J, V105, P139, DOI [10.7196/SAMJ.8394, 10.7196/samj.8394]; Tomlinson M, 2009, SAMJ S AFR MED J, V99, P368; van den Driest JJ, 2017, FAM PRACT, V34, P138, DOI 10.1093/fampra/cmw134; van Heerden J A, 2016, SAMJ, S. Afr. med. j., V106, P1010, DOI [10.7196/samj.2016.v106i10.10627, 10.7196/SAMJ.2016.v106i10.10627]; Western Cape Government Health, 2013, RAT MED US AUD REP C; Western Cape Government Health, 2017, CAP MED DEP ISS DDV; WHO, RAT US MED; WHO, INVESTIGATE DRUG USE; WHO, ESS MED; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292; World Health Organization, WORLD MED STRAT 2008; World Health Organization, PROM RAT US MED COR; Zhang M, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a2752	22	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2020	15	4							e0231675	10.1371/journal.pone.0231675	http://dx.doi.org/10.1371/journal.pone.0231675			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9MR	32311002	Green Published, gold			2023-01-03	WOS:000536019800025
J	Gottlieb, DJ; Punjabi, NM				Gottlieb, Daniel J.; Punjabi, Naresh M.			Diagnosis and Management of Obstructive Sleep Apnea A Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							POSITIVE AIRWAY PRESSURE; CLINICAL-PRACTICE GUIDELINE; BLOOD-PRESSURE; WEIGHT-LOSS; AMERICAN ACADEMY; PORTABLE SLEEP; RESISTANT HYPERTENSION; SURGICAL MODIFICATIONS; CARDIOVASCULAR EVENTS; BERLIN QUESTIONNAIRE	Importance Obstructive sleep apnea (OSA) affects 17% of women and 34% of men in the US and has a similar prevalence in other countries. This review provides an update on the diagnosis and treatment of OSA. Observations The most common presenting symptom of OSA is excessive sleepiness, although this symptom is reported by as few as 15% to 50% of people with OSA in the general population. OSA is associated with a 2- to 3-fold increased risk of cardiovascular and metabolic disease. In many patients, OSA can be diagnosed with home sleep apnea testing, which has a sensitivity of approximately 80%. Effective treatments include weight loss and exercise, positive airway pressure, oral appliances that hold the jaw forward during sleep, and surgical modification of the pharyngeal soft tissues or facial skeleton to enlarge the upper airway. Hypoglossal nerve stimulation is effective in select patients with a body mass index less than 32. There are currently no effective pharmacological therapies. Treatment with positive airway pressure lowers blood pressure, especially in patients with resistant hypertension; however, randomized clinical trials of OSA treatment have not demonstrated significant benefit on rates of cardiovascular or cerebrovascular events. Conclusions and Relevance OSA is common and the prevalence is increasing with the increased prevalence of obesity. Daytime sleepiness is among the most common symptoms, but many patients with OSA are asymptomatic. Patients with OSA who are asymptomatic, or whose symptoms are minimally bothersome and pose no apparent risk to driving safety, can be treated with behavioral measures, such as weight loss and exercise. Interventions such as positive airway pressure are recommended for those with excessive sleepiness and resistant hypertension. Managing asymptomatic OSA to reduce cardiovascular and cerebrovascular events is not currently supported by high-quality evidence. This review provides an update on the epidemiology, pathophysiology, diagnosis, and management of obstructive sleep apnea, including the incorporation of questions regarding snoring, breathing pauses at night, and excessive fatigue or sleepiness during the day at routine clinician visits and the increased use of home sleep apnea testing rather than in-hospital testing for diagnostic purposes.	[Gottlieb, Daniel J.] VA Boston Healthcare Syst, Med Serv, Boston, MA USA; [Gottlieb, Daniel J.] Brigham & Womens Hosp, Dept Med, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA; [Gottlieb, Daniel J.] Brigham & Womens Hosp, Dept Neurol, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA; [Gottlieb, Daniel J.] Harvard Med Sch, Div Sleep Med, Boston, MA 02115 USA; [Punjabi, Naresh M.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Johns Hopkins University	Gottlieb, DJ (corresponding author), VA Boston Healthcare Syst, 1400 VFW Pkwy 111PI, West Roxbury, MA 02132 USA.	djgottlieb@partners.org	Punjabi, Naresh/EMH-1007-2022		National Institutes of Health [HL137234, DK120051, NR018335, HL11716, HL146709]; US Department of Veterans Affairs [CX000578, BX004821]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Veterans Affairs(US Department of Veterans Affairs)	Dr Gottlieb is supported by National Institutes of Health grants HL137234, DK120051, and NR018335 and by US Department of Veterans Affairs grants CX000578 and BX004821. Dr Punjabi is supported by National Institutes of Health grants HL11716, DK120051, and HL146709.	Abumuamar AM, 2018, CLIN CARDIOL, V41, P601, DOI 10.1002/clc.22933; Arnardottir ES, 2016, EUR RESPIR J, V47, P194, DOI 10.1183/13993003.01148-2015; Ashrafian H, 2015, OBES SURG, V25, P1239, DOI 10.1007/s11695-014-1533-2; Aurora RN, 2018, CHEST, V154, P91, DOI 10.1016/j.chest.2018.04.008; Aurora RN, 2010, SLEEP, V33, P1408, DOI 10.1093/sleep/33.10.1408; Bjornsdottir E, 2013, SLEEP, V36, P1901, DOI 10.5665/sleep.3226; Blackman A, 2016, INT J OBESITY, V40, P1310, DOI 10.1038/ijo.2016.52; Briancon-Marjollet A, 2015, DIABETOL METAB SYNDR, V7, DOI 10.1186/s13098-015-0018-3; Browaldh N, 2013, THORAX, V68, P846, DOI 10.1136/thoraxjnl-2012-202610; Budhiraja R, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00348-2017; Burks SV, 2016, SLEEP, V39, P967, DOI 10.5665/sleep.5734; Caples SM, 2010, SLEEP, V33, P1396, DOI 10.1093/sleep/33.10.1396; Carley DW, 2018, SLEEP, V41, DOI 10.1093/sleep/zsx184; Center for Medicare & Medicaid Services, PHYS FEE SCHED SEARC; Chang Y, 2019, J CLIN SLEEP MED, V15, P587, DOI 10.5664/jcsm.7720; Chen XL, 2015, SLEEP, V38, P877, DOI 10.5665/sleep.4732; Chervin RD, 2000, CHEST, V118, P372, DOI 10.1378/chest.118.2.372; Chiu HY, 2017, SLEEP MED REV, V36, P57, DOI 10.1016/j.smrv.2016.10.004; Chung F, 2008, ANESTHESIOLOGY, V108, P812, DOI 10.1097/ALN.0b013e31816d83e4; Cistulli P A, 1996, Respirology, V1, P167; Cistulli PA, 2019, SLEEP MED, V59, P114, DOI 10.1016/j.sleep.2019.01.004; Colvin LJ, 2016, J CLIN SLEEP MED, V12, P113, DOI 10.5664/jcsm.5408; DAVIES RJO, 1992, THORAX, V47, P101, DOI 10.1136/thx.47.2.101; Dempsey JA, 2010, PHYSIOL REV, V90, P47, DOI 10.1152/physrev.00043.2008; Dixon JB, 2012, JAMA-J AM MED ASSOC, V308, P1142, DOI 10.1001/2012.jama.11580; Eastwood PR, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01320-2019; Edwards BA, 2016, AM J RESP CRIT CARE, V194, P1413, DOI 10.1164/rccm.201601-0099OC; El Shayeb M, 2014, CAN MED ASSOC J, V186, pE25, DOI 10.1503/cmaj.130952; Feldstein CA, 2016, CLIN EXP HYPERTENS, V38, P337, DOI 10.3109/10641963.2016.1148156; Fietze I, 2019, J SLEEP RES, V28, DOI 10.1111/jsr.12770; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Foster GD, 2009, ARCH INTERN MED, V169, P1619, DOI 10.1001/archinternmed.2009.266; Foster GD, 2009, DIABETES CARE, V32, P1017, DOI 10.2337/dc08-1776; Gaisl T, 2019, SLEEP MED REV, V46, P74, DOI 10.1016/j.smrv.2019.04.009; Gao X M, 1999, Chin J Dent Res, V2, P27; Gasa M, 2013, J SLEEP RES, V22, P389, DOI 10.1111/jsr.12039; Gooneratne NS, 2011, SLEEP, V34, P435, DOI 10.1093/sleep/34.4.435; Gottlieb DJ, 2014, NEW ENGL J MED, V370, P2276, DOI 10.1056/NEJMoa1306766; Gross JB, 2014, ANESTHESIOLOGY, V120, P268, DOI 10.1097/ALN.0000000000000053; Guerrero A, 2014, SLEEP, V37, P1363, DOI 10.5665/sleep.3932; Guilleminault C, 2000, SLEEP MED, V1, P51, DOI 10.1016/S1389-9457(99)00011-8; He BT, 2019, J THORAC DIS, V11, P2153, DOI 10.21037/jtd.2019.05.04; Heinzer R, 2015, LANCET RESP MED, V3, P310, DOI 10.1016/S2213-2600(15)00043-0; Ho V, 2015, SLEEP, V38, P1887, DOI 10.5665/sleep.5234; Hudgel DW, 2018, AM J RESP CRIT CARE, V198, pE70, DOI [10.1164/rccm.201807-1326ST, 10.1164/rccm.201807-1326st]; Iftikhar IH, 2017, SLEEP MED, V30, P7, DOI 10.1016/j.sleep.2016.06.001; Jacobsen AR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189614; Javaheri S, 2017, J AM COLL CARDIOL, V69, P841, DOI 10.1016/j.jacc.2016.11.069; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johnson DA, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy154; Jonas DE, 2017, JAMA-J AM MED ASSOC, V317, P415, DOI 10.1001/jama.2016.19635; Jordan AS, 2008, RESP PHYSIOL NEUROBI, V160, P1, DOI 10.1016/j.resp.2007.07.009; Kapur VK, 2017, J CLIN SLEEP MED, V13, P479, DOI 10.5664/jcsm.6506; Kapur VK, 2005, SLEEP, V28, P472, DOI 10.1093/sleep/28.4.472; Karimi M, 2015, SLEEP, V38, P341, DOI 10.5665/sleep.4486; Kim AM, 2014, SLEEP, V37, P1639, DOI 10.5665/sleep.4072; Kline CE, 2011, SLEEP, V34, P1631, DOI 10.5665/sleep.1422; Kohler M, 2010, THORAX, V65, P829, DOI 10.1136/thx.2010.135848; Kuna ST, 2011, AM J RESP CRIT CARE, V183, P1238, DOI 10.1164/rccm.201011-1770OC; Lee RWW, 2010, SLEEP, V33, P1075, DOI 10.1093/sleep/33.8.1075; Lim KG, 2018, CHEST, V154, P963, DOI 10.1016/j.chest.2018.05.030; Linz D, 2018, JAMA CARDIOL, V3, P532, DOI 10.1001/jamacardio.2018.0095; Martin SA, 2016, UROLOGY, V97, P219, DOI 10.1016/j.urology.2016.06.022; Martinez-Garcia MA, 2013, JAMA-J AM MED ASSOC, V310, P2407, DOI 10.1001/jama.2013.281250; Mazzotti DR, 2019, AM J RESP CRIT CARE, V200, P493, DOI 10.1164/rccm.201808-1509OC; McEvoy RD, 2016, NEW ENGL J MED, V375, P919, DOI 10.1056/NEJMoa1606599; Mehta V, 2013, J CLIN SLEEP MED, V9, P271, DOI 10.5664/jcsm.2500; Mendelson M, 2016, EUR RESPIR J, V48, P142, DOI 10.1183/13993003.01897-2015; Muxfeldt ES, 2014, AM J HYPERTENS, V27, P1069, DOI 10.1093/ajh/hpu023; Myers KA, 2013, JAMA-J AM MED ASSOC, V310, P731, DOI 10.1001/jama.2013.276185; Naruse Y, 2013, HEART RHYTHM, V10, P331, DOI 10.1016/j.hrthm.2012.11.015; Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002; Opperer M, 2016, ANESTH ANALG, V122, P1321, DOI 10.1213/ANE.0000000000001178; Patil SP, 2019, J CLIN SLEEP MED, V15, P301, DOI 10.5664/jcsm.7638; Peppard PE, 2013, AM J EPIDEMIOL, V177, P1006, DOI 10.1093/aje/kws342; Peppard PE, 2004, SLEEP, V27, P480, DOI 10.1093/sleep/27.3.480; Pereira EJ, 2013, J CLIN SLEEP MED, V9, P1259, DOI 10.5664/jcsm.3264; Peromaa-Haavisto P, 2016, OBES SURG, V26, P1384, DOI 10.1007/s11695-015-1953-7; Punjabi Naresh M, 2008, Proc Am Thorac Soc, V5, P136, DOI 10.1513/pats.200709-155MG; Punjabi NM, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000132; Qaseem A, 2013, ANN INTERN MED, V159, P471, DOI 10.7326/00030003-4819-159-7-201310010-00704; Ramar K, 2015, J CLIN SLEEP MED, V11, P773, DOI 10.5664/jcsm.4858; Reutrakul S, 2017, CHEST, V152, P1070, DOI 10.1016/j.chest.2017.05.009; Rosen CL, 2012, SLEEP, V35, P757, DOI 10.5665/sleep.1870; Russell MB, 2014, CEPHALALGIA, V34, P752, DOI 10.1177/0333102414538551; Sanchez-de-la-Torre M, 2020, LANCET RESP MED, V8, P359, DOI 10.1016/S2213-2600(19)30271-1; Sands SA, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00674-2018; Sareli AE, 2011, OBES SURG, V21, P316, DOI 10.1007/s11695-009-9928-1; Schwab RJ, 2003, AM J RESP CRIT CARE, V168, P522, DOI 10.1164/rccm.200208-866OC; Seiler A, 2019, NEUROLOGY, V92, pe648, DOI 10.1212/WNL.0000000000006904; Somers VK, 2008, J AM COLL CARDIOL, V52, P686, DOI 10.1016/j.jacc.2008.05.002; Sommer JU, 2016, DTSCH ARZTEBL INT, V113, P1, DOI 10.3238/arztebl.2016.0001; Srijithesh PR, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010990.pub2; Strollo PJ, 2014, NEW ENGL J MED, V370, P139, DOI 10.1056/NEJMoa1308659; Taranto-Montemurro L, 2019, AM J RESP CRIT CARE, V199, P1267, DOI 10.1164/rccm.201808-1493OC; Tufik S, 2010, SLEEP MED, V11, P441, DOI 10.1016/j.sleep.2009.10.005; Tumbull CD, 2019, AM J RESP CRIT CARE, V199, P211, DOI 10.1164/rccm.201802-0240OC; Watson NF, 2015, SLEEP, V38, P843, DOI 10.5665/sleep.4716; Weaver TE, 2007, SLEEP, V30, P711, DOI 10.1093/sleep/30.6.711; Woodson BT, 2018, OTOLARYNG HEAD NECK, V159, P194, DOI 10.1177/0194599818762383; Wozniak DR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007736.pub2; Xie J, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007221; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 2002, ARCH INTERN MED, V162, P893, DOI 10.1001/archinte.162.8.893; Yu J, 2017, JAMA-J AM MED ASSOC, V318, P156, DOI 10.1001/jama.2017.7967; Zaghi S, 2016, JAMA OTOLARYNGOL, V142, P58, DOI 10.1001/jamaoto.2015.2678; Zeidler MR, 2015, J CLIN SLEEP MED, V11, P1313, DOI 10.5664/jcsm.5194	108	266	279	25	105	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	2020	323	14					1389	1400		10.1001/jama.2020.3514	http://dx.doi.org/10.1001/jama.2020.3514			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH1YB	32286648				2023-01-03	WOS:000528583600019
J	Lee, WY; Yang, DJ; Oh, JH				Lee, Wongyu; Yang, Dongjun; Oh, Je Hyeok			Differences in the performance of resuscitation according to the resuscitation guideline terminology during infant cardiopulmonary resuscitation: "Approximately 4 cm" versus "at least one-third the anterior-posterior diameter of the chest"	PLOS ONE			English	Article							BASIC LIFE-SUPPORT; HEART-ASSOCIATION GUIDELINES; 2010 INTERNATIONAL CONSENSUS; CARDIOVASCULAR CARE SCIENCE; COUNCIL GUIDELINES; KOREAN GUIDELINES; COMPRESSION DEPTH; QUALITY; 2-THUMB; FITNESS	Aim This study was conducted to investigate the effect of resuscitation guideline terminology on the performance of infant cardiopulmonary resuscitation (CPR). Methods A total of 40 intern or resident physicians conducted 2-min CPR with the two-finger technique (TFT) and two-thumb technique (TT) on a simulated infant cardiac arrest model with a 1-day interval. They were randomly assigned to Group A or B. The participants of Group A conducted CPR with the chest compression depth (CCD) target of "approximately 4 cm" and those of Group B conducted CPR with the CCD target of "at least one-third the anterior-posterior diameter of the chest". Single rescuer CPR was performed with a 15:2 compression to ventilation ratio on the floor. Results In both chest compression techniques, the average CCD of Group B was significantly deeper than that of Group A (TFT: 41.0 [range, 39.3-42.0] mm vs. 36.5 [34.0-37.9] mm, P = 0.002; TT: 42.0 [42.0-43.0] mm vs. 37.0 [35.3-38.0] mm, P < 0.001). Adequacy of CCD also showed similar results (Group B vs. A; TFT: 99% [82-100%] vs. 29% [12-58%], P = 0.001; TT: 100% [100-100%] vs. 28% [8-53%], P < 0.001). Conclusions Using the CCD target of "at least one-third the anterior-posterior diameter of the chest" resulted in deep and adequate chest compressions during simulated infant CPR in contrast to the CCD target of "approximately 4 cm". Therefore, changes in the terminology used in the guidelines should be considered to improve the quality of CPR.	[Lee, Wongyu; Yang, Dongjun; Oh, Je Hyeok] Chung Ang Univ, Dept Emergency Med, Coll Med, Seoul, South Korea	Chung Ang University; Chung Ang University Hospital	Oh, JH (corresponding author), Chung Ang Univ, Dept Emergency Med, Coll Med, Seoul, South Korea.	jehyeokoh@cau.ac.kr	Oh, Je Hyeok/D-4755-2015	Oh, Je Hyeok/0000-0002-5211-3838				Atkins DL, 2015, CIRCULATION, V132, pS519, DOI 10.1161/CIR.0000000000000265; Berg RA, 2010, CIRCULATION, V122, pS685, DOI 10.1161/CIRCULATIONAHA.110.970939; Biarent D, 2005, RESUSCITATION, V67, pS97, DOI 10.1016/j.resuscitation.2005.10.010; Biarent D, 2010, RESUSCITATION, V81, P1364, DOI 10.1016/j.resuscitation.2010.08.012; Christman C, 2011, ARCH DIS CHILD-FETAL, V96, pF99, DOI 10.1136/adc.2009.180406; Chung SP, 2016, RESUSCITATION, V105, P145, DOI 10.1016/j.resuscitation.2016.05.025; de Caen AR, 2010, RESUSCITATION, V81, pE213, DOI 10.1016/j.resuscitation.2010.08.028; Deakin CD, 2018, RESUSCITATION, V124, P58, DOI 10.1016/j.resuscitation.2018.01.010; Dorfsman ML, 2000, ACAD EMERG MED, V7, P1077, DOI 10.1111/j.1553-2712.2000.tb01255.x; ECC Committee S and A, 2005, CIRC S24, V112, pIV1; Handley AJ, 2005, RESUSCITATION, V67, pS7, DOI 10.1016/j.resuscitation.2005.10.007; Hansen D, 2012, EUR J EMERG MED, V19, P28, DOI 10.1097/MEJ.0b013e328347a2aa; Huynh TK, 2012, J PEDIATR-US, V161, P658, DOI 10.1016/j.jpeds.2012.03.019; Int Liaison Comm Resuscitation, 2005, RESUSCITATION, V67, P181, DOI 10.1016/j.resuscitation.2005.09.010; International Liaison Committee on Resuscitation, 2005, Resuscitation, V67, P271; Kim CW, 2019, EUR J PEDIATR, V178, P795, DOI 10.1007/s00431-019-03357-0; Kim YS, 2016, J KOREAN MED SCI, V31, P997, DOI 10.3346/jkms.2016.31.6.997; Kleinman ME, 2010, CIRCULATION, V122, pS876, DOI 10.1161/CIRCULATIONAHA.110.971101; Kleinman ME, 2010, CIRCULATION, V122, P8466, DOI [10.1161/CIRCULATIONAHA.110.971093, 10.1542/peds.2010-2972A]; Koster RW, 2010, RESUSCITATION, V81, pE48, DOI 10.1016/j.resuscitation.2010.08.005; Koster RW, 2010, RESUSCITATION, V81, P1277, DOI 10.1016/j.resuscitation.2010.08.009; Krikscionaitiene A, 2013, EMERG MED J, V30, P159, DOI 10.1136/emermed-2011-200634; Lee JS, 2016, CLIN EXP EMERG MED, V3, pS39, DOI 10.15441/ceem.16.131; Lee SY, 2018, EUR J EMERG MED, V25, P372, DOI 10.1097/MEJ.0000000000000461; Lopez-Gonzalez A, 2016, AM J EMERG MED, V34, P1845, DOI 10.1016/j.ajem.2016.06.058; Maconochie IK, 2015, RESUSCITATION, V95, pE147, DOI 10.1016/j.resuscitation.2015.07.044; Maconochie IK, 2015, RESUSCITATION, V95, P223, DOI 10.1016/j.resuscitation.2015.07.028; Oh JH, 2016, AM J EMERG MED, V34, P2411, DOI 10.1016/j.ajem.2016.09.006; Perkins GD, 2015, RESUSCITATION, V95, pE43, DOI 10.1016/j.resuscitation.2015.07.041; Song KJ, 2016, CLIN EXP EMERG MED, V3, pS10, DOI 10.15441/ceem.16.129; Stiell IG, 2014, CIRCULATION, V130, P1962, DOI 10.1161/CIRCULATIONAHA.114.008671; Sutton RM, 2014, RESUSCITATION, V85, P1179, DOI 10.1016/j.resuscitation.2014.05.007; Trethewey SP, 2019, RESUSCITATION, V142, P91, DOI 10.1016/j.resuscitation.2019.07.016; Udassi S, 2010, RESUSCITATION, V81, P712, DOI 10.1016/j.resuscitation.2009.12.029	36	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2020	15	3							e0230687	10.1371/journal.pone.0230687	http://dx.doi.org/10.1371/journal.pone.0230687			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ9GO	32208443	gold, Green Published			2023-01-03	WOS:000535305100039
J	Murry, CE; MacLellan, WR				Murry, Charles E.; MacLellan, W. Robb			Stem cells and the heart-the road ahead After 20 years of research, pluripotent stem cells move to the fore to treat heart disease	SCIENCE			English	Editorial Material									[Murry, Charles E.; MacLellan, W. Robb] Univ Washington, Ctr Cardiovasc Biol, Seattle, WA 98109 USA; [Murry, Charles E.; MacLellan, W. Robb] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA; [Murry, Charles E.] Sana Biotechnol, Seattle, WA 98102 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Murry, CE (corresponding author), Univ Washington, Ctr Cardiovasc Biol, Seattle, WA 98109 USA.; Murry, CE (corresponding author), Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA.; Murry, CE (corresponding author), Sana Biotechnol, Seattle, WA 98102 USA.	murry@uw.edu; wrmaclellan@cardiology.washington.edu						Aghajanian H, 2019, NATURE, V573, P430, DOI 10.1038/s41586-019-1546-z; Badin RA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12324-0; Bargehr J, 2019, NAT BIOTECHNOL, V37, P895, DOI 10.1038/s41587-019-0197-9; Boyiadzis MM, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0460-5; Chien KR, 2019, NAT BIOTECHNOL, V37, P232, DOI 10.1038/s41587-019-0042-1; Deuse T, 2019, NAT BIOTECHNOL, V37, P252, DOI 10.1038/s41587-019-0016-3; Kawamura T, 2016, STEM CELL REP, V6, P312, DOI 10.1016/j.stemcr.2016.01.012; Lanza R, 2019, NAT REV IMMUNOL, V19, P723, DOI 10.1038/s41577-019-0200-1; Liu YW, 2018, NAT BIOTECHNOL, V36, P597, DOI 10.1038/nbt.4162; Menasche P, 2018, NAT REV CARDIOL, V15, P659, DOI 10.1038/s41569-018-0013-0; Menasche P, 2015, EUR HEART J, V36, P2011, DOI 10.1093/eurheartj/ehv189; Nakamura K, 2019, CIRC J, V83, P2399, DOI 10.1253/circj.CJ-19-0567; Redd MA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08388-7; Romagnuolo R, 2019, STEM CELL REP, V12, P967, DOI 10.1016/j.stemcr.2019.04.005; Vagnozzi RJ, 2020, NATURE, V577, P405, DOI 10.1038/s41586-019-1802-2	15	25	26	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	2020	367	6480					854	855		10.1126/science.aaz3650	http://dx.doi.org/10.1126/science.aaz3650			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KO0KX	32079761				2023-01-03	WOS:000515235800024
J	Klompas, M; Osborn, TM; Rhee, C				Klompas, Michael; Osborn, Tiffany M.; Rhee, Chanu			Who Owns Sepsis?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							SEPTIC SHOCK; MORTALITY; ANTIBIOTICS; IMPACT		[Klompas, Michael; Rhee, Chanu] Harvard Med Sch, Harvard Pilgrim Hlth Care Inst, Boston, MA 02115 USA; [Klompas, Michael; Rhee, Chanu] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Osborn, Tiffany M.] Washington Univ, St Louis, MO 63110 USA; [Osborn, Tiffany M.] Washington Univ, Div Acute & Crit Care Surg, Dept Surg, 660 South Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Washington University (WUSTL); Washington University (WUSTL)	Klompas, M (corresponding author), Harvard Med Sch, Dept Populat Med, 401 Pk Dr,Suite 401 East, Boston, MA 02215 USA.; Klompas, M (corresponding author), Harvard Pilgrim Hlth Care Inst, 401 Pk Dr,Suite 401 East, Boston, MA 02215 USA.	mklompas@bwh.harvard.edu	Rhee, Chanu/AAO-8368-2020; Osborn, Tiffany/AAT-2281-2020		AHRQ HHS [K08 HS025008] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Ferrer R, 2014, CRIT CARE MED, V42, P1749, DOI 10.1097/CCM.0000000000000330; Klouwenberg PMCK, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1035-1; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Liu VX, 2017, AM J RESP CRIT CARE, V196, P856, DOI 10.1164/rccm.201609-1848OC; Lodise TP, 2007, ANTIMICROB AGENTS CH, V51, P3510, DOI 10.1128/AAC.00338-07; Rhee C, 2017, JAMA-J AM MED ASSOC, V318, P1241, DOI 10.1001/jama.2017.13836; Seymour CW, 2017, NEW ENGL J MED, V376, P2235, DOI 10.1056/NEJMoa1703058; Simpson SQ, 2016, CHEST, V149, P1117, DOI 10.1016/j.chest.2016.02.653; Sterling SA, 2015, CRIT CARE MED, V43, P1907, DOI 10.1097/CCM.0000000000001142; Wang HE, 2017, CRIT CARE MED, V45, P1443, DOI 10.1097/CCM.0000000000002538	10	9	9	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 4	2020	172	3					210	+		10.7326/M19-2966	http://dx.doi.org/10.7326/M19-2966			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ4HC	31986525				2023-01-03	WOS:000512018000007
J	Nash, Z; Thwaites, A; Davies, M				Nash, Zachary; Thwaites, Annette; Davies, Melanie			Tailored regimens for combined hormonal contraceptives	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PREGNANCY		[Nash, Zachary; Thwaites, Annette; Davies, Melanie] UCL, EGA Inst Womens Hlth, London, England; [Nash, Zachary; Davies, Melanie] Univ Coll London Hosp, London, England; [Thwaites, Annette] Kings Coll Hosp London, London, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; King's College Hospital NHS Foundation Trust; King's College Hospital	Nash, Z (corresponding author), UCL, EGA Inst Womens Hlth, London, England.; Nash, Z (corresponding author), Univ Coll London Hosp, London, England.	z.nash@ucl.ac.uk	Thwaites, Annette/AAR-3125-2020	Thwaites, Annette/0000-0002-5799-1955; Davies, Melanie/0000-0001-6907-5527				Akintomide H, 2018, BMJ SEX REPROD HEAL, V44, P36, DOI 10.1136/jfprhc-2017-101736; [Anonymous], 2015, MED EL CRIT CONTR US, V5th; Archer DF, 2009, CONTRACEPTION, V80, P245, DOI 10.1016/j.contraception.2009.03.006; Davis AR, 2008, FERTIL STERIL, V89, P1059, DOI 10.1016/j.fertnstert.2007.05.012; Dinger J, 2011, OBSTET GYNECOL, V117, P33, DOI 10.1097/AOG.0b013e31820095a2; Edelman AB, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004695.pub2; Faculty of Sexual and Reproductive Healthcare, 2018, INT FSRH GUID INC US; Faculty of Sexual and Reproductive Healthcare, 2019, COMB HORM CONTR; Freeman EW, 2012, CONTRACEPTION, V85, P437, DOI 10.1016/j.contraception.2011.09.010; Graham CA, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l335; Hannaford PC, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c927; Howard B, 2014, CONTRACEPTION, V89, P25, DOI 10.1016/j.contraception.2013.09.007; Iversen L, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2017.02.002; Legro RS, 2008, J CLIN ENDOCR METAB, V93, P420, DOI 10.1210/jc.2007-2287; Macgregor E Anne, 2009, Ther Adv Neurol Disord, V2, P327, DOI 10.1177/1756285609335537; Mendoza N, 2014, EUR J CONTRACEP REPR, V19, P321, DOI 10.3109/13625187.2014.927423; Morch LS, 2017, NEW ENGL J MED, V377, P2228, DOI 10.1056/NEJMoa1700732; Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021; World Health Organization, 2019, CONTR US METH; Zapata LB, 2013, CONTRACEPTION, V87, P685, DOI 10.1016/j.contraception.2012.08.035; Zorbas KA, 2015, ARCH GYNECOL OBSTET, V292, P37, DOI 10.1007/s00404-015-3641-1	21	0	0	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	2020	368								m200	10.1136/bmj.m200	http://dx.doi.org/10.1136/bmj.m200			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ9FO	32014854				2023-01-03	WOS:000512360400001
J	Niessl, J; Baxter, AE; Mendoza, P; Jankovic, M; Cohen, YZ; Butler, AL; Lu, CL; Dube, M; Shimeliovich, I; Gruell, H; Klein, F; Caskey, M; Nussenzweig, MC; Kaufmann, DE				Niessl, Julia; Baxter, Amy E.; Mendoza, Pilar; Jankovic, Mila; Cohen, Yehuda Z.; Butler, Allison L.; Lu, Ching-Lan; Dube, Mathieu; Shimeliovich, Irina; Gruell, Henning; Klein, Florian; Caskey, Marina; Nussenzweig, Michel C.; Kaufmann, Daniel E.			Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity	NATURE MEDICINE			English	Article							HIV-1; INFECTION; RESERVOIR; RESPONSES; VIREMIA	T cell responses specific for HIV-1 Gag peptides increased in HIV-positive recipients of two broadly neutralizing antibodies with prolonged suppression of blood viremia during antiretroviral treatment interruption. Combination antiretroviral therapy (ART) is highly effective in controlling human immunodeficiency virus (HIV)-1 but requires lifelong medication due to the existence of a latent viral reservoir(1,2). Potent broadly neutralizing antibodies (bNAbs) represent a potential alternative or adjuvant to ART. In addition to suppressing viremia, bNAbs may have T cell immunomodulatory effects as seen for other forms of immunotherapy(3). However, this has not been established in individuals who are infected with HIV-1. Here, we document increased HIV-1 Gag-specific CD8(+) T cell responses in the peripheral blood of all nine study participants who were infected with HIV-1 with suppressed blood viremia, while receiving bNAb therapy during ART interruption(4). Increased CD4(+) T cell responses were detected in eight individuals. The increased T cell responses were due both to newly detectable reactivity to HIV-1 Gag epitopes and the expansion of pre-existing measurable responses. These data demonstrate that bNAb therapy during ART interruption is associated with enhanced HIV-1-specific T cell responses. Whether these augmented T cell responses can contribute to bNAb-mediated viral control remains to be determined.	[Niessl, Julia; Baxter, Amy E.; Dube, Mathieu; Kaufmann, Daniel E.] Ctr Hosp Univ Montreal CRCHUM, Res Ctr, Montreal, PQ, Canada; [Niessl, Julia; Baxter, Amy E.; Kaufmann, Daniel E.] Univ Montreal, Montreal, PQ, Canada; [Niessl, Julia; Baxter, Amy E.; Kaufmann, Daniel E.] CHAVD, La Jolla, CA 92037 USA; [Mendoza, Pilar; Jankovic, Mila; Cohen, Yehuda Z.; Butler, Allison L.; Lu, Ching-Lan; Shimeliovich, Irina; Caskey, Marina; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA; [Gruell, Henning; Klein, Florian] Univ Cologne, Fac Med, Inst Virol, Lab Expt Immunol, Cologne, Germany; [Gruell, Henning; Klein, Florian] Univ Cologne, Univ Hosp Cologne, Cologne, Germany; [Gruell, Henning] Univ Cologne, Fac Med, Dept Internal Med 1, Cologne, Germany; [Gruell, Henning; Klein, Florian] German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany; [Klein, Florian] Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany; [Baxter, Amy E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lu, Ching-Lan] Columbia Univ, Med Ctr, Dept Internal Med, New York, NY USA	Universite de Montreal; Universite de Montreal; Rockefeller University; University of Cologne; University of Cologne; University of Cologne; German Center for Infection Research; University of Cologne; University of Cologne; University of Pennsylvania; Pennsylvania Medicine; Columbia University	Kaufmann, DE (corresponding author), Ctr Hosp Univ Montreal CRCHUM, Res Ctr, Montreal, PQ, Canada.; Kaufmann, DE (corresponding author), Univ Montreal, Montreal, PQ, Canada.; Kaufmann, DE (corresponding author), CHAVD, La Jolla, CA 92037 USA.; Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.	nussen@mail.rockefeller.edu; daniel.kaufmann@umontreal.ca	Dubé, Mathieu/AAN-7908-2020	Niessl, Julia/0000-0001-8852-1924; Grull, Henning/0000-0002-0725-7138; Dube, Mathieu/0000-0002-5522-9019	Canadian Institutes for Health Research [152977, 154049]; Canada Foundation for Innovation Program Leader grant [31756]; FRQS AIDS and Infectious Diseases Network; National Institutes of Health [UM1 AI-100663, AI-144462, R01AI-129795]; Einstein-Rockefeller-CUNY Center for AIDS Research [1P30AI124414-01A1]; BEAT-HIV Delaney grant [UM1 AI-126620]; Robertson Fund; Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery [OPP1092074, OPP1124068]; Quebec Health Research Fund (FRQS); Department of Microbiology, Immunology and Infectious Diseases, Universite de Montreal; CIHR Fellowship Award [152536]; Merit Award of the Quebec Health Research Fund (FRQS)	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canada Foundation for Innovation Program Leader grant(Canada Foundation for Innovation); FRQS AIDS and Infectious Diseases Network; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Einstein-Rockefeller-CUNY Center for AIDS Research; BEAT-HIV Delaney grant; Robertson Fund; Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery; Quebec Health Research Fund (FRQS); Department of Microbiology, Immunology and Infectious Diseases, Universite de Montreal; CIHR Fellowship Award(Canadian Institutes of Health Research (CIHR)); Merit Award of the Quebec Health Research Fund (FRQS)	We thank the clinical staff in the Laboratory of Molecular Immunology at the Rockefeller University and the Division of Infectious Diseases at the University Hospital Cologne, as well as all study participants for their invaluable role in this project; D. Gauchat, P. St-Onge and the CRCHUM Flow Cytometry Platform and O. Debbeche and the CRCHUM BSL3 platform for technical assistance. The following reagents were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Consensus B peptide pools for Gag (cat. no.12425), Pol (cat. no. 12438), Nef (cat. no. 12545), gp120 and gp41 (pools made using HIV-1 Consensus B Env Peptide Set, cat. no. 9480), Consensus B Gag Peptide Set (cat. no. 8117) and HIV-1BaL (cat. no. 510) from S. Gartner, M. Popovic and R. Gallo32. This study was supported by the Canadian Institutes for Health Research (grant nos. 152977 and 154049 to D.E.K), a Canada Foundation for Innovation Program Leader grant (no. 31756 to D.E.K); the FRQS AIDS and Infectious Diseases Network; the National Institutes of Health UM1 AI-100663 (CHAVI-ID) and AI-144462 (CHAVD); R01AI-129795 (M.C.N.); the Einstein-Rockefeller-CUNY Center for AIDS Research (1P30AI124414-01A1); BEAT-HIV Delaney grant UM1 AI-126620 (M.C.); and the Robertson Fund. We acknowledge grants from the Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery, nos. OPP1092074 and OPP1124068 (M.C.N.). J.N. is supported by scholarships from the Quebec Health Research Fund (FRQS) and the Department of Microbiology, Immunology and Infectious Diseases, Universite de Montreal. A.E.B. is the recipient of a CIHR Fellowship Award no. 152536. D.E.K is supported by a Merit Award of the Quebec Health Research Fund (FRQS). M.C.N. is an HHMI Investigator.	Achenbach CJ, 2015, LANCET HIV, V2, pE82, DOI 10.1016/S2352-3018(15)00026-0; Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Borducchi EN, 2018, NATURE, V563, P360, DOI 10.1038/s41586-018-0600-6; Bournazos S, 2015, IMMUNOL REV, V268, P88, DOI 10.1111/imr.12343; Caskey M, 2019, NAT MED, V25, P547, DOI 10.1038/s41591-019-0412-8; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Fagard C, 2003, ARCH INTERN MED, V163, P1220, DOI 10.1001/archinte.163.10.1220; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Freel SA, 2010, J VIROL, V84, P4998, DOI 10.1128/JVI.00138-10; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365; Gray CM, 1999, J IMMUNOL, V162, P1780; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lu CL, 2018, P NATL ACAD SCI USA, V115, pE11341, DOI 10.1073/pnas.1813512115; Lu CL, 2016, SCIENCE, V352, P1001, DOI 10.1126/science.aaf1279; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Morou A, 2019, NAT IMMUNOL, V20, P1059, DOI 10.1038/s41590-019-0418-x; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Oxenius A, 2002, P NATL ACAD SCI USA, V99, P13747, DOI 10.1073/pnas.202372199; PATARCA R, 1984, NATURE, V312, P496, DOI 10.1038/312496a0; Pelletier S, 2010, J HEPATOL, V53, P805, DOI 10.1016/j.jhep.2010.05.013; Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Prebensen C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176527; Reiss S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186998; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Saez-Cirion A, 2010, NAT PROTOC, V5, P1033, DOI 10.1038/nprot.2010.73; Salazar-Gonzalez JF, 2008, J VIROL, V82, P3952, DOI 10.1128/JVI.02660-07; Scheid JF, 2016, NATURE, V535, P556, DOI 10.1038/nature18929; Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033	32	64	64	0	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2020	26	2					222	+		10.1038/s41591-019-0747-1	http://dx.doi.org/10.1038/s41591-019-0747-1		FEB 2020	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	KK7DU	32015556	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000510822600004
J	Funk, M; Ash, C				Funk, Michael; Ash, Caroline			A CLEANER, GREENER FUTURE FOR CHEMICALS	SCIENCE			English	Editorial Material																			0	7	7	3	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 24	2020	367	6476			SI		378	379		10.1126/science.aba8242	http://dx.doi.org/10.1126/science.aba8242			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KG2ZB	31974241				2023-01-03	WOS:000509810200026
J	Herold, F; Hamacher, D; Torpel, A; Goldschmidt, L; Muller, NG; Schega, L				Herold, Fabian; Hamacher, Dennis; Toerpel, Alexander; Goldschmidt, Leonard; Mueller, Notger G.; Schega, Lutz			Does squatting need attention?-A dual-task study on cognitive resources in resistance exercise	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; MOTOR INTERFERENCE; OLDER; TRAIL; WALKING; PERFORMANCE; ADULTS; SPEED; PARTS; COST	Introduction Accumulating evidence shows that acute resistance exercises and long-term resistance training positively influence cognitive functions, but the underlying mechanisms have been rarely investigated. One explanatory approach assumes that the execution of resistance exercises requires higher cognitive processes which, in turn, lead to an `indirect' training of higher cognitive functions. However, current knowledge on the engagement of higher cognitive functions during the execution of resistance exercises is relatively sparse. Hence, the purpose of this study was to examine to what extent cognitive resources are needed to perform a resistance exercise in the form of barbell back squatting. Methods Twenty-four young adults performed a cognitive task (serial subtraction of 7's) during standing and during barbell back squatting on a Smith machine. The total number and the number of correct responses were analyzed and taken as indicators of the cognitive load imposed by the experimental condition (squatting) and the control condition (standing). Additionally, participants' perceived exertion, mean heart rate, and the number of squats they were able to perform were assessed. Results While accuracy scores were found not to be significantly different between conditions, the numbers of total and of correct responses were significantly lower during squatting than during standing. Additionally, during squatting a higher number of total answers was given in the fifth set compared to the first set. We attribute this phenomenon to a learning effect. Furthermore, there was no statistically significant correlation between cognitive measures and perceived exertion. Conclusion Results suggest that perceived exertion cannot explain the higher dual-task costs observed during squatting. They rather reflect that more cognitive resources are needed to perform low-load barbell back squats than during standing. However, further research is necessary to confirm and generalize these findings.	[Herold, Fabian; Mueller, Notger G.] German Ctr Neurodegenerat Dis DZNE, Res Grp Neuroprotect, Magdeburg, Germany; [Hamacher, Dennis; Toerpel, Alexander; Goldschmidt, Leonard; Schega, Lutz] Otto von Guericke Univ, Inst 3, Dept Sport Sci, Magdeburg, Germany; [Mueller, Notger G.] Ctr Behav Brain Sci CBBS, Magdeburg, Germany; [Mueller, Notger G.] Otto von Guericke Univ, Med Fac, Dept Neurol, Magdeburg, Germany	Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Otto von Guericke University; Otto von Guericke University	Hamacher, D (corresponding author), Otto von Guericke Univ, Inst 3, Dept Sport Sci, Magdeburg, Germany.	dennis.hamacher@ovgu.de	Herold, Fabian/J-6226-2019; Törpel, Alexander/AAN-4255-2020	Herold, Fabian/0000-0003-3453-090X; Törpel, Alexander/0000-0002-3142-6819; Mueller, Notger/0000-0002-5483-6423				Adams R, 1999, CAN FAM PHYSICIAN, V45, P992; Al-Yahya E, 2011, NEUROSCI BIOBEHAV R, V35, P715, DOI 10.1016/j.neubiorev.2010.08.008; [Anonymous], STAT DATA ANAL LC S; Atkinson G, 2002, PHYS THER SPORT, V3, P191, DOI 10.1054/ptsp.2002.0123; Baechle TR, 2008, ESSENTIALS STRENGTH, V3rd; Balady GJ, 1998, CIRCULATION, V97, P2283, DOI 10.1161/01.CIR.97.22.2283; Beck A.T., 1996, MANUAL BDI 2, DOI [10.1037/t00742-000, DOI 10.1037/T00742-000]; Bherer L, 2008, EXP AGING RES, V34, P188, DOI 10.1080/03610730802070068; Boisgontier MP, 2013, NEUROSCI BIOBEHAV R, V37, P1824, DOI 10.1016/j.neubiorev.2013.07.014; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Chang YK, 2012, J AGING PHYS ACTIV, V20, P497, DOI 10.1123/japa.20.4.497; Clark DJ, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00246; Coolican H., 2009, RES METHODS STAT PSY; CORRIGAN JD, 1987, J CLIN PSYCHOL, V43, P402, DOI 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E; Crowe SF, 1998, J CLIN PSYCHOL, V54, P585, DOI 10.1002/(SICI)1097-4679(199808)54:5<585::AID-JCLP4>3.0.CO;2-K; Finger JD, 2015, ARCH PUBLIC HEALTH, V73, DOI 10.1186/s13690-015-0109-5; Fissler P, 2013, PROG BRAIN RES, V207, P403, DOI 10.1016/B978-0-444-63327-9.00017-5; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fritz CO, 2012, J EXP PSYCHOL GEN, V141, P2, DOI 10.1037/a0024338; Fuchs R, 2015, Z GESUNDHEITSPSYCHOL, V23, P60, DOI 10.1026/0943-8149/a000137; Gail S, 2015, ISOKINET EXERC SCI, V23, P291, DOI 10.3233/IES-150590; Hamacher D, 2017, EXP BRAIN RES, V235, P2997, DOI 10.1007/s00221-017-5036-y; Herold F, 2019, EUR REV AGING PHYS A, V16, DOI 10.1186/s11556-019-0217-2; HOLM S, 1979, SCAND J STAT, V6, P65; Huang H J, 2001, Pediatr Phys Ther, V13, P133, DOI 10.1097/00001577-200110000-00005; Landrigan JF, 2020, PSYCHOL RES-PSYCH FO, V84, P1167, DOI 10.1007/s00426-019-01145-x; Li ZH, 2018, AGING CLIN EXP RES, V30, P1259, DOI 10.1007/s40520-018-0998-6; Ludbrook J, 1998, CLIN EXP PHARMACOL P, V25, P1032, DOI 10.1111/j.1440-1681.1998.tb02179.x; Mayer RE, 2003, WEB-BASED LEARNING: WHAT DO WE KNOW? WHERE DO WE GO?, P23; McLaughlin MJ, 2014, PM&R, V6, P544, DOI 10.1016/j.pmrj.2014.04.006; Patel P, 2014, NEUROSCIENCE, V260, P140, DOI 10.1016/j.neuroscience.2013.12.016; Pendleton DM, 2016, INT J PSYCHOPHYSIOL, V109, P124, DOI 10.1016/j.ijpsycho.2016.08.012; Regnaux JP, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-19; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Remy F, 2010, NEUROPSYCHOLOGIA, V48, P2517, DOI 10.1016/j.neuropsychologia.2010.04.026; Schaefer S, 2020, J MOTOR BEHAV, V52, P204, DOI 10.1080/00222895.2019.1602506; Schaefer S, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00316; Soga K, 2018, J COGN ENHANCE, V2, P200, DOI 10.1007/s41465-018-0079-y; Srygley JM, 2009, BRAIN RES, V1253, P92, DOI 10.1016/j.brainres.2008.11.067; Stillman CM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00626; Tarvainen MP, 2014, COMPUT METH PROG BIO, V113, P210, DOI 10.1016/j.cmpb.2013.07.024; Torpel A, 2018, J CLIN MED, V7, DOI 10.3390/jcm7100337; Tsukamoto H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184075; de Sousa TLW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210216; Whitley E, 2002, CRIT CARE, V6, P509, DOI 10.1186/cc1820; Wickens C. D., 1980, ATTENTION PERFORM, VVIII, P239; Wollesen B, 2016, NEUROSCIENCE, V318, P166, DOI 10.1016/j.neuroscience.2016.01.031; Woollacott M, 2002, GAIT POSTURE, V16, P1, DOI 10.1016/S0966-6362(01)00156-4; Zhu WM, 2012, J SPORT HEALTH SCI, V1, P9, DOI 10.1016/j.jshs.2012.02.002; Zourdos MC, 2016, J STRENGTH COND RES, V30, P267, DOI 10.1519/JSC.0000000000001049	51	5	5	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2020	15	1							e0226431	10.1371/journal.pone.0226431	http://dx.doi.org/10.1371/journal.pone.0226431			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP5QJ	31961904	gold, Green Published			2023-01-03	WOS:000534372000007
J	Kramer, DB; Lo, B; Dickert, NW				Kramer, Daniel B.; Lo, Bernard; Dickert, Neal W.			CPR in the Covid-19 Era - An Ethical Framework	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Unlike ventilator allocation, provision of CPR to patients cannot be practically adjudicated by a hospital-level triage team. How does the surge of patients with Covid-19 complicate standard CPR practices, and how can we best design crisis standards for inpatient CPR?	[Kramer, Daniel B.] Beth Israel Deaconess Med Ctr, Richard A & Susan F Smith Ctr Outcomes Res Cardio, Boston, MA 02215 USA; [Kramer, Daniel B.] Harvard Med Sch, Boston, MA 02115 USA; [Lo, Bernard] Greenwall Fdn, New York, NY USA; [Lo, Bernard] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Dickert, Neal W.] Emory Univ, Sch Med, Atlanta, GA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; Emory University	Kramer, DB (corresponding author), Beth Israel Deaconess Med Ctr, Richard A & Susan F Smith Ctr Outcomes Res Cardio, Boston, MA 02215 USA.; Kramer, DB (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.							Andersen LW, 2019, JAMA-J AM MED ASSOC, V321, P1200, DOI 10.1001/jama.2019.1696; [Anonymous], 2020, BMJ-BRIT MED J, V369, pm2170, DOI 10.1136/bmj.m2170; Edelson DP, 2020, CIRCULATION; Giroir AB, 2020, NATL ACAD SCI ENG ME; van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI [10.1101/2020.03.09.20033217, 10.1056/NEJMc2004973]	5	53	54	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	2020	383	2							e6	10.1056/NEJMp2010758	http://dx.doi.org/10.1056/NEJMp2010758			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NR9PO	32374958	Bronze			2023-01-03	WOS:000571894800002
J	Rubin, R				Rubin, Rita			Finding Ways to Reduce Coronavirus Exposure During Dialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item								This Medical News Feature examines what hemodialysis centers are doing to protect their high-risk patients from COVID-19.											0	4	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2020	323	20					1993	1993		10.1001/jama.2020.6158	http://dx.doi.org/10.1001/jama.2020.6158			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU8UM	32297904	Bronze			2023-01-03	WOS:000538023900002
J	Wolday, D; Kebede, Y; Legesse, D; Siraj, DS; McBride, JA; Kirsch, MJ; Striker, R				Wolday, Dawit; Kebede, Yazezew; Legesse, Dorsisa; Siraj, Dawd S.; McBride, Joseph A.; Kirsch, Mitchell J.; Striker, Robert			Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade	PLOS ONE			English	Article							RISK-FACTORS; POSITIVE PATIENTS; HAART; COHORT; TERM; INDIVIDUALS; ACTIVATION; INITIATION; RESPONSES; SUBSETS	Background The role of CD4/CD8 ratio on the incidence of tuberculosis (TB) in patients on antiretroviral therapy (ART) is unknown. Thus, we sought to determine whether the CD4/CD8 ratio was associated with development of TB in a cohort of HIV infected individuals on ART followed up for more than a decade in the setting of sub-Saharan Africa (SSA). Methods The cohort comprised adult patients who started ART between 2001 and 2007 and followed for up to 15 years. Clinical data were collected in retrospective manner. Patients with an AIDS defining illness or a CD4 count < 200 cell/mu L were started with a combination of ART. The participants have clinic visits every 6 months and/or as needed. Poisson regression models were used to identify factors associated with development of incident TB. KaplanMeier curves were used to estimate the probability of incident TB while on ART. Results A total of 347 patients with a median duration of follow-up on ART of 11.5 (IQR: 10.0-12.5) years were included. Incident TB developed in 47 patients during the 3259 person-years of follow-up, the majority (76.6%) occurred within five year of ART initiation. On univariate analysis, poor ART adherence (RR:2.57, 95% CI: 1.28-5.17), time-updated CD4 cell count of lower than 200 (RR: 4.86, 95%CI 2.33-10.15), or CD4 cell count between 200 and 500 (RR: 4.68, 95% CI: 2.17-10.09), time-updated CD8 cell count lower than 500 (RR: 2.83 95% CI 1.31-6.10), or CD8 cell count over 1000 (RR: 2.23, 95% CI: 1.12-4.45), timeupdated CD4/CD8 ratio of less than 0.30 (RR: 6.00, 95% CI: 2.96-12.14), lack of normalization of CD4 T-cell count (RR: 6.13, 95% CI: 2.20-17.07), and virological failure (RR: 2.35 (95% CI: 1.17-4.71) were all associated with increased risk of incident TB. In multivariate analysis, however, time-updated CD4/CD8 ratio of less than 0.30 (adjusted RR: 4.08, 95% CI: 1.31-12.68) was the only factor associated with increased risk of developing incident TB (p = 0.015). Similar results were obtained in a sensitivity analysis by including only those virally suppressed patients (n = 233, 69% of all patients). In this group, CD4/CD8 ratio of less than 0.30 was associated with development of incident TB (adjusted RR: 4.02, 95% CI: 1.14-14.19, p = 0.031). Overall, the incidence rate of TB in patients with an updated CD4/CD8 ratio of less than 0.30 was more than 5-fold higher when compared with those with a ratio more than 0.45. Conclusion Low CD4/CD8 ratio is independently associated with an increased risk of incident TB despite viral suppression. CD4/CD8 ratio may serve as a biomarker for identifying patients at risk of TB in patients on ART in the setting of SSA.	[Wolday, Dawit; Kebede, Yazezew] Mekelle Univ, Coll Hlth Sci, Mekelle, Ethiopia; [Legesse, Dorsisa] Hayat Gen Hosp, Addis Ababa, Ethiopia; [Siraj, Dawd S.; McBride, Joseph A.; Kirsch, Mitchell J.; Striker, Robert] Univ Wisconsin, Dept Med, Div Infect Dis, Madison, WI USA	Mekelle University; University of Wisconsin System; University of Wisconsin Madison	Wolday, D (corresponding author), Mekelle Univ, Coll Hlth Sci, Mekelle, Ethiopia.	dawwol@gmail.com		Striker, Rob/0000-0002-0454-895X	Division of Infectious Diseases, Department of Medicine, University of Wisconsin, Madison, USA	Division of Infectious Diseases, Department of Medicine, University of Wisconsin, Madison, USA	The study was supported by the Division of Infectious Diseases, Department of Medicine, University of Wisconsin, Madison, USA.	Ahmed A, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-016961; Andersen AB, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-66; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; Bock P, 2018, JAIDS-J ACQ IMM DEF, V77, P93, DOI 10.1097/QAI.0000000000001560; Buggert M, 2014, J IMMUNOL, V192, P2099, DOI 10.4049/jimmunol.1302596; Costagliola D, 2005, CLIN INFECT DIS, V41, P1772, DOI 10.1086/498315; Dean GL, 2002, AIDS, V16, P75, DOI 10.1097/00002030-200201040-00010; del Amo J, 2012, CLIN INFECT DIS, V54, P1364, DOI 10.1093/cid/cis203; Dembele M, 2010, INT J TUBERC LUNG D, V14, P318; Dravid A, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4361-0; Federal Ministry of Health, 2002, NAT TUB LEPR CONTR P; Federal Ministry of Health (MoH). HIV/AIDS Prevention and Control Office, 2001, NAT GUID US ANT DRUG; Fenner L, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21327; Geremew D, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4031-2; Gupta A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034156; Helleberg M, 2015, J INFECT DIS, V211, P1726, DOI 10.1093/infdis/jiu669; Hermans SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010527; Hsu DC, 2014, J INFECTION, V68, P344, DOI 10.1016/j.jinf.2013.11.016; Jerene Degu, 2006, AIDS Res Ther, V3, P10, DOI 10.1186/1742-6405-3-10; Karo B, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2627-y; Kassa D, 2013, AIDS RES THER, V10, DOI 10.1186/1742-6405-10-18; Kassu A, 2003, CLIN EXP IMMUNOL, V132, P113, DOI 10.1046/j.1365-2249.2003.02106.x; Kassu A, 2001, CLIN DIAGN LAB IMMUN, V8, P1171, DOI 10.1128/CDLI.8.6.1171-1176.2001; Khawcharoenporn T, 2012, INT J TUBERC LUNG D, V16, P336, DOI 10.5588/ijtld.11.0402; Kony SJ, 2000, J INFECTION, V41, P167, DOI 10.1053/jinf.2000.0721; Lawn SD, 2005, AIDS, V19, P2109, DOI 10.1097/01.aids.0000194808.20035.c1; Lawn SD, 2005, AIDS, V19, P1113, DOI 10.1097/01.aids.0000176211.08581.5a; Lawn SD, 2006, AIDS, V20, P1605, DOI 10.1097/01.aids.0000238406.93249.cd; Lawn SD, 2009, AIDS, V23, P1717, DOI 10.1097/QAD.0b013e32832d3b6d; Liu EJ, 2015, AIDS, V29, P1391, DOI 10.1097/QAD.0000000000000705; Lu W, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20052; Martin-Echevarria E, 2014, INT J TUBERC LUNG D, V18, P1080, DOI 10.5588/ijtld.13.0757; Moore D, 2007, AIDS, V21, P713, DOI 10.1097/QAD.0b013e328013f632; Mupfumi L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192030; Mussini C, 2015, LANCET HIV, V2, pE98, DOI 10.1016/S2352-3018(15)00006-5; Naidoo K, 2014, JAIDS-J ACQ IMM DEF, V65, P438, DOI 10.1097/QAI.0000000000000060; Nicholas S, 2011, JAIDS-J ACQ IMM DEF, V57, P311, DOI 10.1097/QAI.0b013e318218a713; Plana M, 2000, AIDS, V14, P1921, DOI 10.1097/00002030-200009080-00007; Sabasaba A, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3696-x; Semu M, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2109-7; Serrano-Villar S, 2013, J INFECTION, V66, P57, DOI 10.1016/j.jinf.2012.09.013; Seyler C, 2005, AM J RESP CRIT CARE, V172, P123, DOI 10.1164/rccm.200410-1342OC; Suthar AB, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001270; Tinago W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097011; Tsegaye A, 1999, CLIN DIAGN LAB IMMUN, V6, P410, DOI 10.1128/CDLI.6.3.410-414.1999; Van Rie A, 2011, JAIDS-J ACQ IMM DEF, V56, P349, DOI 10.1097/QAI.0b013e3181f9fb39; Wolday H, 2003, INT J TUBERC LUNG D, V7, P110; Wong NS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46570-5; World Health Organization, 2018, GLOBAL TUBERCULOSIS; Yirdaw KD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211688	50	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2020	15	5							e0233049	10.1371/journal.pone.0233049	http://dx.doi.org/10.1371/journal.pone.0233049			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1MJ	32442166	Green Published, gold			2023-01-03	WOS:000537525900017
J	Lai, HC; Lee, MS; Liu, YT; Lin, KT; Hung, KC; Chen, JY; Wu, ZF				Lai, Hou-Chuan; Lee, Meei-Shyuan; Liu, Yin-Tzu; Lin, Kuen-Tze; Hung, Kuo-Chuan; Chen, Jen-Yin; Wu, Zhi-Fu			Propofol-based intravenous anesthesia is associated with better survival than desflurane anesthesia in pancreatic cancer surgery	PLOS ONE			English	Article							TUMOR-METASTASIS; ISOFLURANE; MANAGEMENT; VOLATILE; INVASION; OVEREXPRESSION; ADENOCARCINOMA; RECURRENCE; HALOTHANE; PROGNOSIS	Background Previous researches have shown that anesthetic techniques can influence the patient outcomes of cancer surgery. Here, we studied the relationship between type of anesthetic and patient outcomes following elective, open pancreatic cancer surgery. Methods This was a retrospective cohort study of patients who received elective, open pancreatic cancer surgery between January 2005 and July 2018. Patients were grouped according to the anesthesia they received, namely desflurane or propofol. A Kaplan-Meier analysis was conducted, and survival curves were presented from the date of surgery to death. Univariable and multivariable Cox regression models were used to compare hazard ratios for death after propensity matching. Subgroup analyses were performed for all-cause mortality, cancer-specific mortality, and disease progression. Results A total of 68 patients (56 deaths, 82.0%) under desflurane anesthesia, and 72 patients (43 deaths, 60.0%) under propofol anesthesia were included. Fifty-eight patients remained in each group after propensity matching. The propofol anesthesia was associated with improved survival (hazard ratio, 0.65; 95% confidence interval, 0.42-0.99; P = 0.047) in the matched analysis. Subgroup analyses showed significantly better cancer-specific survival (hazard ratio, 0.63; 95% confidence interval, 0.40-0.97; P = 0.037) in the propofol group. Additionally, patients under propofol had less postoperative recurrence, but not fewer postoperative metastases formation, than those under desflurane (hazard ratio, 0.55; 95% confidence interval, 0.34-0.90; P = 0.028) in the matched analysis. Conclusions In a limited sample size, we observed that propofol anesthesia was associated with improved survival in open pancreatic cancer surgery compared with desflurane anesthesia. Further investigations are needed to inspect the influences of propofol anesthesia on patient outcomes of pancreatic cancer surgery.	[Lai, Hou-Chuan] Triserv Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Lai, Hou-Chuan; Lin, Kuen-Tze] Natl Def Med Ctr, Taipei, Taiwan; [Lee, Meei-Shyuan] Natl Def Med Ctr, Sch Publ Hlth, Taipei, Taiwan; [Liu, Yin-Tzu] Wanfang Hosp, Div Anesthesiol, Taipei, Taiwan; [Lin, Kuen-Tze] Triserv Gen Hosp, Dept Radiat Oncol, Taipei, Taiwan; [Hung, Kuo-Chuan; Chen, Jen-Yin; Wu, Zhi-Fu] Chi Mei Med Ctr, Dept Anesthesiol, Tainan, Taiwan; [Chen, Jen-Yin] Chia Nan Univ Pharm & Sci, Dept Senior Citizen Serv Management, Tainan, Taiwan	Tri-Service General Hospital; National Defense Medical Center; National Defense Medical Center; Taipei Municipal WanFang Hospital; Tri-Service General Hospital; Chi Mei Hospital; Chia Nan University of Pharmacy & Science	Wu, ZF (corresponding author), Chi Mei Med Ctr, Dept Anesthesiol, Tainan, Taiwan.	aneswu@gmail.com	Wu, Zhi-Fu/ABE-6379-2020; Hung, Kuo-Chuan/AAV-2625-2020	Wu, Zhi-Fu/0000-0001-6376-9085				Ahlers O, 2008, BRIT J ANAESTH, V101, P781, DOI 10.1093/bja/aen287; ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; Baba Y, 2010, AM J PATHOL, V176, P2292, DOI 10.2353/ajpath.2010.090972; Ballehaninna UK, 2012, J GASTROINTEST ONCOL, V3, P105, DOI 10.3978/j.issn.2078-6891.2011.021; Benzonana LL, 2013, ANESTHESIOLOGY, V119, P593, DOI 10.1097/ALN.0b013e31829e47fd; Call TR, 2015, ANESTHESIOLOGY, V122, P317, DOI 10.1097/ALN.0000000000000489; Chang MC, 2017, AM J CANCER RES, V7, P357; Chen XY, 2017, EUR J PHARMACOL, V795, P150, DOI 10.1016/j.ejphar.2016.12.017; Daamen LA, 2019, EJSO-EUR J SURG ONC, V45, P1770, DOI 10.1016/j.ejso.2019.05.031; De La Cruz MSD, 2014, AM FAM PHYSICIAN, V89, P626; Dias-Santos D, 2015, SURGERY, V157, P881, DOI 10.1016/j.surg.2014.12.006; Eagle KA, 2002, J AM COLL CARDIOL, V39, P542, DOI 10.1016/S0735-1097(01)01788-0; Enlund M, 2014, UPSALA J MED SCI, V119, P251, DOI 10.3109/03009734.2014.922649; Gilliland HE, 1997, ANESTH ANALG, V85, P1394, DOI 10.1097/00000539-199712000-00039; Groot VP, 2017, HPB, V19, P83, DOI 10.1016/j.hpb.2016.11.001; Huang H, 2014, BRIT J CANCER, V111, P1338, DOI 10.1038/bjc.2014.426; Huang YH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224728; Inada T, 2004, ANAESTHESIA, V59, P954, DOI 10.1111/j.1365-2044.2004.03837.x; Inada T, 2009, CAN J ANAESTH, V56, P222, DOI 10.1007/s12630-008-9035-0; Jun IJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14147-9; Kushida A, 2007, IMMUNOPHARM IMMUNOT, V29, P477, DOI 10.1080/08923970701675085; Lai HC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230290; Lai HC, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000018472; Lai HC, 2019, BRIT J ANAESTH, V123, P151, DOI 10.1016/j.bja.2019.04.057; Lee JH, 2016, KOREAN J ANESTHESIOL, V69, P126, DOI 10.4097/kjae.2016.69.2.126; Li M, 2019, J CONTROL RELEASE, V304, P204, DOI 10.1016/j.jconrel.2019.05.019; Liu ZM, 2016, AM J TRANSL RES, V8, P4120; Loop T, 2005, ANESTHESIOLOGY, V102, P1147, DOI 10.1097/00000542-200506000-00014; Mammoto T, 2002, CANCER LETT, V184, P165, DOI 10.1016/S0304-3835(02)00210-0; Marandola M, 2008, TRANSPL P, V40, P1195, DOI 10.1016/j.transproceed.2008.03.114; Melamed R, 2003, ANESTH ANALG, V97, P1331, DOI 10.1213/01.ANE.0000082995.44040.07; Moudgil GC, 1997, CAN J ANAESTH, V44, P90, DOI 10.1007/BF03014331; Sandini M, 2018, ANN SURG ONCOL, V25, P4020, DOI 10.1245/s10434-018-6827-5; SHAPIRO J, 1981, J CLIN INVEST, V68, P678, DOI 10.1172/JCI110303; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Soliz Jose M, 2017, Anesth Pain Med, V7, pe13879, DOI 10.5812/aapm.13879; Wang ZT, 2015, GENET MOL RES, V14, P7529, DOI 10.4238/2015.July.3.28; Wigmore TJ, 2016, ANESTHESIOLOGY, V124, P69, DOI 10.1097/ALN.0000000000000936; Wolf AM, 2014, SURGERY, V155, P39, DOI 10.1016/j.surg.2013.05.031; Wu ZF, 2018, ANESTHESIOLOGY, V129, P932, DOI 10.1097/ALN.0000000000002357; Yan T, 2017, Zhonghua Yi Xue Za Zhi, V97, P1719, DOI 10.3760/cma.j.issn.0376-2491.2017.22.009; Yu XD, 2019, BASIC CLIN PHARMACOL, V125, P271, DOI 10.1111/bcpt.13224; Zhong H, 1999, CANCER RES, V59, P5830; Zhou PT, 2017, ONCOTARGET, V8, P25242, DOI 10.18632/oncotarget.15692	44	17	17	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2020	15	5							e0233598	10.1371/journal.pone.0233598	http://dx.doi.org/10.1371/journal.pone.0233598			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1JI	32437450	gold, Green Published			2023-01-03	WOS:000537517800110
J	Duran-Frigola, M; Pauls, E; Guitart-Pla, O; Bertoni, M; Alcalde, V; Amat, D; Juan-Blanco, T; Aloy, P				Duran-Frigola, Miquel; Pauls, Eduardo; Guitart-Pla, Oriol; Bertoni, Martino; Alcalde, Victor; Amat, David; Juan-Blanco, Teresa; Aloy, Patrick			Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker	NATURE BIOTECHNOLOGY			English	Article							CONNECTIVITY MAP; NATURAL-PRODUCTS; DATABASE; GENERATION; INFORMATION; INHIBITION; EXPRESSION; PATHWAYS; NETWORK; DRUGS	Small molecules are usually compared by their chemical structure, but there is no unified analytic framework for representing and comparing their biological activity. We present the Chemical Checker (CC), which provides processed, harmonized and integrated bioactivity data on similar to 800,000 small molecules. The CC divides data into five levels of increasing complexity, from the chemical properties of compounds to their clinical outcomes. In between, it includes targets, off-targets, networks and cell-level information, such as omics data, growth inhibition and morphology. Bioactivity data are expressed in a vector format, extending the concept of chemical similarity to similarity between bioactivity signatures. We show how CC signatures can aid drug discovery tasks, including target identification and library characterization. We also demonstrate the discovery of compounds that reverse and mimic biological signatures of disease models and genetic perturbations in cases that could not be addressed using chemical information alone. Overall, the CC signatures facilitate the conversion of bioactivity data to a format that is readily amenable to machine learning methods. The biological activities of >800,000 small molecules are represented within a uniform framework.	[Duran-Frigola, Miquel; Pauls, Eduardo; Guitart-Pla, Oriol; Bertoni, Martino; Alcalde, Victor; Amat, David; Juan-Blanco, Teresa; Aloy, Patrick] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Joint IRB BSC CRG Program Computat Biol, Barcelona, Spain; [Aloy, Patrick] ICREA, Barcelona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA	Duran-Frigola, M; Aloy, P (corresponding author), Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Joint IRB BSC CRG Program Computat Biol, Barcelona, Spain.; Aloy, P (corresponding author), ICREA, Barcelona, Spain.	miquel.duran@irbbarcelona.org; patrick.aloy@irbbarcelona.org	Duran-Frigola, Miquel/AAO-3505-2021	Duran-Frigola, Miquel/0000-0002-9906-6936; Alcalde Adell, Victor/0000-0002-7868-2983; Bertoni, Martino/0000-0003-0720-1027; Aloy, Patrick/0000-0002-3557-0236; Pauls, Eduardo/0000-0002-2511-0711	Spanish Ministerio de Economia y Competitividad [BIO2016-77038-R]; European Research Council (SysPharmAD) [614944]; 'La Caixa' BioMedTec [CTEC_15]; INB/ELIXIR-ES [PT17/0009/0007]	Spanish Ministerio de Economia y Competitividad(Spanish Government); European Research Council (SysPharmAD); 'La Caixa' BioMedTec; INB/ELIXIR-ES	We thank the SB&NB laboratory members for their support and helpful discussions. We are grateful to the Broad Institute and National Center for Advancing Translational Sciences (NCATS-NIH) for providing compounds on request, and J. Duran-Frigola for the website design. We also thank the IRB Barcelona Biostatistics and Bioinformatics Unit and the IRB Functional Genomics Facility. P.A. acknowledges the support of the Spanish Ministerio de Economia y Competitividad (grant no. BIO2016-77038-R), the INB/ELIXIR-ES (grant no. PT17/0009/0007), the European Research Council (SysPharmAD, grant no. 614944) and 'La Caixa' BioMedTec (grant no. CTEC_15).	Anselmo AC, 2019, NAT REV DRUG DISCOV, V18, P19, DOI 10.1038/nrd.2018.183; Axen SD, 2017, J MED CHEM, V60, P7393, DOI 10.1021/acs.jmedchem.7b00696; Azur MJ, 2011, INT J METH PSYCH RES, V20, P40, DOI 10.1002/mpr.329; Badia R, 2017, ANTIVIR RES, V142, P123, DOI 10.1016/j.antiviral.2017.03.019; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Basu A, 2013, CELL, V154, P1151, DOI 10.1016/j.cell.2013.08.003; Bemis GW, 1996, J MED CHEM, V39, P2887, DOI 10.1021/jm9602928; Benson JM, 2011, NAT BIOTECHNOL, V29, P615, DOI 10.1038/nbt.1903; Bickerton GR, 2012, NAT CHEM, V4, P90, DOI [10.1038/NCHEM.1243, 10.1038/nchem.1243]; Bleicher KH, 2003, NAT REV DRUG DISCOV, V2, P369, DOI 10.1038/nrd1086; Brown AS, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.29; Campillos M, 2008, SCIENCE, V321, P263, DOI 10.1126/science.1158140; Carvalho-Silva D, 2019, NUCLEIC ACIDS RES, V47, pD1056, DOI 10.1093/nar/gky1133; Cerami EG, 2011, NUCLEIC ACIDS RES, V39, pD685, DOI 10.1093/nar/gkq1039; Chabner BA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv388; Chen B, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16022; Cheng H, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003926; Congreve M, 2003, DRUG DISCOV TODAY, V8, P876, DOI 10.1016/S1359-6446(03)02831-9; Corsello SM, 2017, NAT MED, V23, P405, DOI 10.1038/nm.4306; Nguyen DT, 2017, NUCLEIC ACIDS RES, V45, pD995, DOI 10.1093/nar/gkw1072; Davis AP, 2017, NUCLEIC ACIDS RES, V45, pD972, DOI 10.1093/nar/gkw838; DEPPER JM, 1983, J IMMUNOL, V131, P690; Duran-Frigola M., 2018, CURR OPIN SYST BIOL, V34, P95, DOI [10.1016/j. coisb.2017.04.010, 10.1093/, DOI 10.1016/J.COISB.2017.04.010]; Duran-Frigola M, 2019, WIRES COMPUT MOL SCI, V9, DOI 10.1002/wcms.1408; Duran-Frigola M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6676; Duran-Frigola M, 2013, CHEM BIOL, V20, P594, DOI 10.1016/j.chembiol.2013.03.017; Durant JL, 2002, J CHEM INF COMP SCI, V42, P1273, DOI 10.1021/ci010132r; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI [10.1093/nar/gkx1132, 10.1093/nar/gkz1031]; Fernandez-Torras A, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0626-x; Filzen TM, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005335; Gaulton A, 2017, NUCLEIC ACIDS RES, V45, pD945, DOI 10.1093/nar/gkw1074; Gilson MK, 2016, NUCLEIC ACIDS RES, V44, pD1045, DOI 10.1093/nar/gkv1072; Grover A, 2016, PREPRINT; Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440; Hastings J, 2016, NUCLEIC ACIDS RES, V44, pD1214, DOI 10.1093/nar/gkv1031; Holbeck SL, 2010, MOL CANCER THER, V9, P1451, DOI 10.1158/1535-7163.MCT-10-0106; Hu WJ, 2018, BIOMED PHARMACOTHER, V102, P681, DOI 10.1016/j.biopha.2018.03.111; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Iorio F, 2010, P NATL ACAD SCI USA, V107, P14621, DOI 10.1073/pnas.1000138107; Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+; Irwin JJ, 2018, J CHEM INF MODEL, V58, P148, DOI 10.1021/acs.jcim.7b00316; Jokinen E, 2015, THER ADV MED ONCOL, V7, P170, DOI 10.1177/1758834015571111; Kandasamy K, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-1-r3; Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070; Kelder T, 2012, NUCLEIC ACIDS RES, V40, pD1301, DOI 10.1093/nar/gkr1074; Kruger FA, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002333; Kuhn M, 2016, NUCLEIC ACIDS RES, V44, pD1075, DOI 10.1093/nar/gkv1075; Kuhn M, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.10; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lee YS, 2019, CELL SYST, V8, P152, DOI 10.1016/j.cels.2018.12.010; Leiserson MDM, 2015, NAT GENET, V47, P106, DOI 10.1038/ng.3168; Li TB, 2017, NAT METHODS, V14, P61, DOI 10.1038/nmeth.4083; Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007; Lo YC, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004153; Maaten L, 2013, PREPRINT; Masuelli L, 2011, FRONT BIOSCI-LANDMRK, V16, P1060, DOI 10.2741/3735; Matsui Y. O., 2017, PREPRINT; McInnes L., 2017, P 2017 IEEE INT C DA; Mendez-Lucio O, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13807-w; Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138; Mosca R, 2013, NAT METHODS, V10, P47, DOI [10.1038/NMETH.2289, 10.1038/nmeth.2289]; Nelson J, 2018, BIOINFORMATICS, V34, P1251, DOI 10.1093/bioinformatics/btx732; Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055; Papadatos G, 2015, J COMPUT AID MOL DES, V29, P885, DOI 10.1007/s10822-015-9860-5; Perszyk RE, 2016, MOL PHARMACOL, V90, P689, DOI 10.1124/mol.116.105130; Petrone FM, 2012, ACS CHEM BIOL, V7, P1399, DOI 10.1021/cb3001028; Pinero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943; Pryszcz LP, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq953; Reddy M, 2007, CELL IMMUNOL, V247, P1, DOI 10.1016/j.cellimm.2007.06.006; Rennie Jason D., 2003, P 20 INT C MACH LEAR, P616, DOI 10.5555/3041838.3041916; Reymond JL, 2015, ACCOUNTS CHEM RES, V48, P722, DOI 10.1021/ar500432k; Rodgers G, 2018, NAT REV DRUG DISCOV, V17, P301, DOI 10.1038/nrd.2017.252; Rodrigues T, 2016, NAT CHEM, V8, P531, DOI [10.1038/nchem.2479, 10.1038/NCHEM.2479]; Rouillard AD, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw100; Ryu JY, 2018, P NATL ACAD SCI USA, V115, pE4304, DOI 10.1073/pnas.1803294115; Sawai A, 2008, CANCER RES, V68, P589, DOI 10.1158/0008-5472.CAN-07-1570; Saxena V, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl766; Seashore-Ludlow B, 2015, CANCER DISCOV, V5, P1210, DOI 10.1158/2159-8290.CD-15-0235; Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Tanzi RE, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006296; Thiele I, 2013, NAT BIOTECHNOL, V31, P419, DOI 10.1038/nbt.2488; Wang B, 2014, NAT METHODS, V11, P333, DOI [10.1038/NMETH.2810, 10.1038/nmeth.2810]; Wang YL, 2017, NUCLEIC ACIDS RES, V45, pD955, DOI 10.1093/nar/gkw1118; Wawer MJ, 2014, P NATL ACAD SCI USA, V111, P10911, DOI 10.1073/pnas.1410933111; Webber W, 2010, ACM T INFORM SYST, V28, DOI 10.1145/1852102.1852106; Welsch ME, 2010, CURR OPIN CHEM BIOL, V14, P347, DOI 10.1016/j.cbpa.2010.02.018; Williams AJ, 2012, DRUG DISCOV TODAY, V17, P1188, DOI 10.1016/j.drudis.2012.05.016; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037; Wishart DS, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002805; Wu ZQ, 2018, CHEM SCI, V9, P513, DOI 10.1039/c7sc02664a; Xu MJ, 2017, CANCER METAST REV, V36, P463, DOI 10.1007/s10555-017-9687-8; Zwierzyna M, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005641	95	40	40	3	32	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2020	38	9					1087	+		10.1038/s41587-020-0502-7	http://dx.doi.org/10.1038/s41587-020-0502-7		MAY 2020	19	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	NJ2ZW	32440005				2023-01-03	WOS:000533829200001
J	Rowe, TA; Linder, JA				Rowe, Theresa A.; Linder, Jeffrey A.			Delayed Antibiotic Prescriptions in Ambulatory Care Reconsidering a Problematic Practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint discusses the unintended adverse consequences of delayed antibiotic prescribing-provision of an antibiotic prescription to be filled at a later date if a patient's condition has not improved-and calls on clinicians to avoid the practice in patients who have self-limited conditions with likely viral etiologies.	[Rowe, Theresa A.; Linder, Jeffrey A.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Linder, JA (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med & Geriatr, 750 N Lake Shore Dr, Chicago, IL 60611 USA.	jlinder@northwestern.edu	Linder, Jeffrey/AAF-3424-2021	Linder, Jeffrey/0000-0003-2217-184X	National Institute on Aging [R21AG057400, R21AG057396, R33AG057383]; National Institute on Drug Abuse [R33AG057395]; Agency for Healthcare Research and Quality [R01HS024930, R01HS026506, HHSP2332015000201]; US Centers for Disease Control and Prevention. [17PA1708457]; Peterson Center on Healthcare	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); US Centers for Disease Control and Prevention.(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Peterson Center on Healthcare	Dr Linder is supported by grants R21AG057400, R21AG057396, and R33AG057383 from the National Institute on Aging, grant R33AG057395 from the National Institute on Drug Abuse, grants R01HS024930 and R01HS026506 from the Agency for Healthcare Research and Quality, funding from the Peterson Center on Healthcare, and contract HHSP2332015000201 with the Agency for Healthcare Research and Quality. Dr Rowe is supported by grant R33AG057383 from the National Institute on Aging and grant 17PA1708457 from the US Centers for Disease Control and Prevention.	Dempsey PP, 2014, BMC FAM PRACT, V15, DOI 10.1186/s12875-014-0194-5; Keller SC, 2018, J AM BOARD FAM MED, V31, P417, DOI 10.3122/jabfm.2018.03.170225; LITTLE P, 2017, BMJ-BRIT MED J, V357, DOI DOI 10.1136/BMJ.J2148; Little P, 2019, ANN FAM MED, V17, P125, DOI 10.1370/afm.2356; National Institute for Health and Care Excellence, SELF LIM RESP TRACK; Sanchez GV, 2016, MMWR RECOMM REP, V65, DOI 10.15585/mmwr.rr6506a1; Schneider A, 2019, ANN FAM MED, V17, P239, DOI 10.1370/afm.2392; Spurling GKP, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004417.pub5; Szymczak JE, 2019, INFECT CONT HOSP EP, V40, P522, DOI 10.1017/ice.2019.47; US Centers for Disease Control and Prevention, ANT PRESCR US DOCT O	10	10	10	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2020	323	18					1779	1780		10.1001/jama.2020.2325	http://dx.doi.org/10.1001/jama.2020.2325			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LS2LS	32297898				2023-01-03	WOS:000536221500013
J	Nieuwenhuijs-Moeke, GJ; Sanders, JSF				Nieuwenhuijs-Moeke, Gertrude J.; Sanders, Jan Stephan F.			Timing of renal replacement therapy in acute kidney injury: case closed?	LANCET			English	Editorial Material							RISK; AKI		[Nieuwenhuijs-Moeke, Gertrude J.] Univ Groningen, Univ Med Ctr Groningen, Dept Anaesthesiol, NL-9713 GZ Groningen, Netherlands; [Sanders, Jan Stephan F.] Univ Groningen, Univ Med Ctr Groningen, Dept Nephrol, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen	Nieuwenhuijs-Moeke, GJ (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Anaesthesiol, NL-9713 GZ Groningen, Netherlands.	g.j.nieuwenhuijs-moeke@umcg.nl	Sanders, Jan-Stephan/ABC-6782-2021	Sanders, Jan-Stephan/0000-0002-0904-3969				Al-Jaghbeer M, 2018, J AM SOC NEPHROL, V29, P654, DOI 10.1681/ASN.2017070765; Bihorac A, 2009, ANN SURG, V249, P851, DOI 10.1097/SLA.0b013e3181a40a0b; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Gaudry S, 2020, LANCET, V395, P1506, DOI 10.1016/S0140-6736(20)30531-6; Hoste EAJ, 2018, NAT REV NEPHROL, V14, P607, DOI 10.1038/s41581-018-0052-0; Hoste E, 2015, INTENS CARE MED, V41, P1411, DOI 10.1007/s00134-015-3934-7; Fayad AII, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010612.pub2; Rachoin JS, 2019, CRIT CARE MED, V47, P715, DOI 10.1097/CCM.0000000000003701; Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2; See EJ, 2019, KIDNEY INT, V95, P160, DOI 10.1016/j.kint.2018.08.036; Selby NM, 2012, CLIN J AM SOC NEPHRO, V7, P533, DOI 10.2215/CJN.08970911; Srisawat N, 2020, NEPHROL DIAL TRANSPL, V35, P1729, DOI 10.1093/ndt/gfz087; STARRT-AKI Investigators, 2019, CAN J KIDNEY HEALTH, V6; Uchino S, 2010, NEPHROL DIAL TRANSPL, V25, P1833, DOI 10.1093/ndt/gfp624	14	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	2020	395	10235					1465	1467		10.1016/S0140-6736(20)30805-9	http://dx.doi.org/10.1016/S0140-6736(20)30805-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LO3QU	32334653	Green Published			2023-01-03	WOS:000533544900004
J	Coe, AB; Vincent, BM; Iwashyna, TJ				Coe, Antoinette B.; Vincent, Brenda M.; Iwashyna, Theodore J.			Statin discontinuation and new antipsychotic use after an acute hospital stay vary by hospital	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; AFTER-DISCHARGE; ICU SURVIVORS; MEDICATION; CONTINUATION; HEALTH; ADMISSION; THERAPY; PRESCRIPTIONS; MANAGEMENT	Introduction Patients are at risk for medication problems after hospital admissions, particularly those with critical illness. Medication problems include continuation of acute medications and discontinuation of chronic medications after discharge. Little is known across a national integrated health care system about the extent of these two medication problems. Objective To examine the extent of statin medication discontinuation and new antipsychotic medication use after hospital discharge. Design Retrospective cohort study. Setting Veterans Affairs healthcare system. Participants Veterans with an inpatient hospitalization from January 1, 2014-December 31, 2016, survived at least 180 days post-discharge, and received at least one medication through the VA outpatient pharmacy within one year around admission were included. Hospitalizations were grouped into: 1) direct admission to the intensive care unit (ICU) and a diagnosis of sepsis, 2) direct admission to the ICU without sepsis diagnosis, and 3) no ICU stay during the hospitalization. Main outcome measures Statin medication discontinuation and new antipsychotic use at six months post-hospital discharge. Results A total of 520,187 participants were included in the statin medication and 910,629 in the antipsychotic medication cohorts. Statin discontinuation ranged from 10-15% and new antipsychotic prescription fills from 2-4% across the three hospitalization groups, with highest rates in the ICU admission and sepsis diagnosis group. Statin discontinuation and new antipsychotic use after a hospitalization varied by hospital, with worse performing hospitals having 11% higher odds of discontinuing a statin (median odds ratio at hospital-level, adjusted for patient differences, aMOR: 1.11 (95% CI: 1.09, 1.13)) and 29% higher odds of new antipsychotic use (aMOR, 1.29 (95% CI: 1.24, 1.34)). Risk-adjusted hospital rates of these two medication changes were not correlated (p = 0.49). Conclusions Systemic variation in the rates of statin medication continuation and new antipsychotic use were found.	[Coe, Antoinette B.] Univ Michigan, Coll Pharm, Dept Clin Pharm, 428 Church St, Ann Arbor, MI 48109 USA; [Coe, Antoinette B.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA; [Vincent, Brenda M.; Iwashyna, Theodore J.] Vet Affairs Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA; [Iwashyna, Theodore J.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Iwashyna, Theodore J.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Coe, AB (corresponding author), Univ Michigan, Coll Pharm, Dept Clin Pharm, 428 Church St, Ann Arbor, MI 48109 USA.; Coe, AB (corresponding author), Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.	tonicoe@med.umich.edu	Coe, Antoinette/AAN-6533-2021; McGrath, Brenda/AAT-9185-2020	Coe, Antoinette/0000-0002-5723-0443; McGrath, Brenda/0000-0003-4208-1059	National Center for Advancing Translational Sciences of the National Institutes of Health [KL2TR002241]; U.S Department of Veterans Affairs, Health Services Research & Development Investigator Initiated Research [VA HSRD IIR 17-045]	National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); U.S Department of Veterans Affairs, Health Services Research & Development Investigator Initiated Research(US Department of Veterans Affairs)	Antoinette B. Coe is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health, award number KL2TR002241. Theodore J. Iwashyna is supported by the U.S Department of Veterans Affairs, Health Services Research & Development Investigator Initiated Research, award number VA HSR&D IIR 17-045. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the U.S. Department of Veterans Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bell CM, 2011, JAMA-J AM MED ASSOC, V306, P840, DOI 10.1001/jama.2011.1206; Bradley SM, 2017, AM HEART J, V193, P117, DOI 10.1016/j.ahj.2017.05.018; Cecconi M, 2018, LANCET, V392, P75, DOI 10.1016/S0140-6736(18)30696-2; Coe AB, 2019, HOSP PHARM, P1; Hert M, 2012, NAT REV ENDOCRINOL, V8, P114, DOI 10.1038/nrendo.2011.156; Dessap AM, 2011, CRIT CARE, V15, DOI 10.1186/cc10317; Eijsbroek H, 2013, J CRIT CARE, V28, P46, DOI 10.1016/j.jcrc.2012.06.002; Farrokh Salia, 2017, J Pharm Pract, V30, P342, DOI 10.1177/0897190016645026; Flurie RW, 2015, AM J HEALTH-SYST PH, V72, pS133, DOI 10.2146/ajhp150474; Gill SS, 2007, ANN INTERN MED, V146, P775, DOI 10.7326/0003-4819-146-11-200706050-00006; Jasiak Karalea D, 2013, J Pharm Pract, V26, P253, DOI 10.1177/0897190012465987; Kram BL, 2015, J CRIT CARE, V30, P814, DOI 10.1016/j.jcrc.2015.03.030; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Kutner JS, 2015, JAMA INTERN MED, V175, P691, DOI 10.1001/jamainternmed.2015.0289; Marshall J, 2016, J CRIT CARE, V33, P119, DOI 10.1016/j.jcrc.2015.12.017; McDonald EG, 2015, J HOSP MED, V10, P281, DOI 10.1002/jhm.2330; Morandi A, 2013, J AM GERIATR SOC, V61, P1128, DOI 10.1111/jgs.12329; Morandi A, 2011, ARCH INTERN MED, V171, P1032, DOI 10.1001/archinternmed.2011.233; Murphy CE, 2008, PHARMACOTHERAPY, V28, P968, DOI 10.1592/phco.28.8.968; Needham DM, 2012, CRIT CARE MED, V40, P502, DOI 10.1097/CCM.0b013e318232da75; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Pavlov A, 2014, RESP CARE, V59, P1524, DOI 10.4187/respcare.02913; Prescott HC, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2375; Prescott HC, 2014, AM J RESP CRIT CARE, V190, P62, DOI 10.1164/rccm.201403-0471OC; Radomski TR, 2016, J MANAG CARE SPEC PH, V22, P114, DOI 10.18553/jmcp.2016.14251; Render ML, 2008, CRIT CARE MED, V36, P1031, DOI 10.1097/CCM.0b013e318169f290; Rhee C, 2017, JAMA-J AM MED ASSOC, V318, P1241, DOI 10.1001/jama.2017.13836; Rowe AS, 2015, J CRIT CARE, V30, P1283, DOI 10.1016/j.jcrc.2015.08.009; Scales DC, 2016, J GEN INTERN MED, V31, P196, DOI 10.1007/s11606-015-3501-5; Sevin CM, 2018, J CRIT CARE, V46, P141, DOI 10.1016/j.jcrc.2018.02.011; Stollings JL, 2018, ANN PHARMACOTHER, V52, P713, DOI 10.1177/1060028018759343; Stollings JL, 2015, AM J HEALTH-SYST PH, V72, P1315, DOI 10.2146/ajhp140533; Tomichek JE, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1557-1; Trivedi RB, 2015, AM J PUBLIC HEALTH, V105, P2564, DOI 10.2105/AJPH.2015.302836; van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5; Wang XL, 2019, CELL DEATH DISCOV, V5	36	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2020	15	5							e0232707	10.1371/journal.pone.0232707	http://dx.doi.org/10.1371/journal.pone.0232707			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU0QJ	32384108	gold, Green Published			2023-01-03	WOS:000537468300025
J	Gomez-Garcia, FJ; Lopez, AL; Guerrero-Sanchez, Y; Siles, MS; Diaz, FM; Alonso, FC				Jose Gomez-Garcia, Francisco; Lopez Lopez, Antonia; Guerrero-Sanchez, Yolanda; Sanchez Siles, Mariano; Martinez Diaz, Francisco; Camacho Alonso, Fabio			Chemopreventive effect of pomegranate and cocoa extracts on ultraviolet radiation-induced photocarcinogenesis in SKH-1 mice	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASES; INDUCED DNA-DAMAGE; SKIN; UVA; PREVENTION; IMPACT; P53	Non-melanoma skin cancer (NMSC) has a high and increasing incidence all over the world. Solar radiation is the main aetiology for humans. Although most research into photocarcinogenesis uses UVB as a source of radiation, UVA is also carcinogenic in long term. Pomegranate (PGE) and cocoa (CE) extracts have been used for medicinal purposes for time immemorial. Recently, it has been claimed that some of their properties may be an effective preventative measure against photocarcinogenesis and photoaging, but to date in vivo models have not been tested using RUVA, the objective of the present work. A lower incidence of lesions was observed in SKH-1 mice treated with PGE (p<0.001), and lower incidence of invasive squamous carcinoma in both treatment groups (p<0.001 for PGE and p<0.05 for CE); the PGE group also showed a lower level of cell proliferation than the control group (p<0.001). Significantly greater p53 alteration was observed in the control group than the treatment groups (p<0.001 for PGE and p = 0.05 for CE). No significant differences were found in relation to TIMP-1 and MMP-9. Taken together, the results suggest that oral feeding of PGE and CE to SKH-1 mice affords substantial protection against the adverse effects of RUVA, especially PGE.	[Jose Gomez-Garcia, Francisco; Lopez Lopez, Antonia; Guerrero-Sanchez, Yolanda; Sanchez Siles, Mariano; Camacho Alonso, Fabio] Univ Murcia, Dept Dermatol Stomatol Radiol & Phys Med, Fac Med, Campus Excellence Mare Nostrum, Murcia, Spain; [Martinez Diaz, Francisco] Hosp Gen Univ Reina Sofia, Dept Pathol, Murcia, Spain	University of Murcia; Hospital Universitario Reina Sofia - Cordoba	Guerrero-Sanchez, Y (corresponding author), Univ Murcia, Dept Dermatol Stomatol Radiol & Phys Med, Fac Med, Campus Excellence Mare Nostrum, Murcia, Spain.	yolanda.guerreros@um.es	Gómez García, Francisco José/ABE-5240-2021	Gómez García, Francisco José/0000-0001-6795-1028; Camacho-Alonso, Fabio/0000-0002-3739-1792; Guerrero Sanchez, Yolanda/0000-0002-4228-2355	Ministerio de Ciencia, Innovacion y Universidades [PGC2018-097198-BI00]; Fundacion Seneca de la Region de Murcia [20783/PI/18]	Ministerio de Ciencia, Innovacion y Universidades; Fundacion Seneca de la Region de Murcia(Fundacion Seneca)	Yolanda Guerrero-Sanchez is partially supported by Ministerio de Ciencia, Innovacion y Universidades grant number PGC2018-097198-BI00 and Fundacion Seneca de la Region de Murcia grant number 20783/PI/18.	Afaq F, 2005, PHOTOCHEM PHOTOBIOL, V81, P38, DOI 10.1562/2004-08-06-RA-264.1; Afaq F, 2010, PHOTOCHEM PHOTOBIOL, V86, P1318, DOI 10.1111/j.1751-1097.2010.00815.x; Andisheh-Tadbir A, 2016, J CLIN EXP DENT, V8, P130; Bachelor MA, 2004, SEMIN CANCER BIOL, V14, P131, DOI 10.1016/j.semcancer.2003.09.017; Bassiri-Jahromi S, 2018, ONCOL REV, V12, P1, DOI 10.4081/oncol.2018.345; Benjamin CL, 2007, TOXICOL APPL PHARM, V224, P241, DOI 10.1016/j.taap.2006.12.006; Bosch R, 2015, ANTIOXIDANTS-BASEL, V4, P248, DOI 10.3390/antiox4020248; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; de Anda-Jauregui G, 2019, APPL MATH NONLIN SCI, V4, P223, DOI 10.2478/AMNS.2019.1.00020; de Gruijl FR, 2000, METHOD ENZYMOL, V319, P359; deLaat A, 1997, CARCINOGENESIS, V18, P1013, DOI 10.1093/carcin/18.5.1013; Duarte AF, 2018, CANCER EPIDEMIOL, V56, P154, DOI 10.1016/j.canep.2018.08.004; Eisemann N, 2014, J INVEST DERMATOL, V134, P43, DOI 10.1038/jid.2013.304; Fisher GJ, 2001, J INVEST DERMATOL, V117, P219, DOI 10.1046/j.0022-202x.2001.01432.x; FORBES PD, 1981, J INVEST DERMATOL, V77, P139, DOI 10.1111/1523-1747.ep12479351; Fu X.R., CMAJ, V34, P369; Gupta A, 2014, AGEING RES REV, V13, P65, DOI 10.1016/j.arr.2013.12.001; Ibrahim MAA, 2017, ANN ANAT, V211, P78, DOI 10.1016/j.aanat.2017.01.007; Justin J.H., 2004, J MED FOOD, V6, P157; Kim JE, 2016, J INVEST DERMATOL, V136, P1012, DOI 10.1016/j.jid.2015.11.032; Lopez AG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157689; Moller P, 2002, FASEB J, V16, P45, DOI 10.1096/fj.01-0386com; Park HM, 2010, INT J DERMATOL, V49, P276, DOI 10.1111/j.1365-4632.2009.04269.x; Poswar FO, 2013, PATHOL RES PRACT, V209, P705, DOI 10.1016/j.prp.2013.08.002; Preidl RHM, 2019, STRAHLENTHER ONKOL, V195, P52, DOI 10.1007/s00066-018-1382-3; Rigby CM, 2017, CARCINOGENESIS, V38, P40, DOI 10.1093/carcin/bgw106; Rojas C, 2018, APPL MATH NONLIN SCI, V3, P375, DOI DOI 10.21042/AMNS.2018.2.00029; Ruksha TG, 2007, B EXP BIOL MED+, V144, P77, DOI 10.1007/s10517-007-0259-8; Scapagnini G, 2014, NUTRIENTS, V6, P3202, DOI 10.3390/nu6083202; Seebode C, 2016, ANTICANCER RES, V36, P1371; Shaygannia E., 2015, J EVID BASED COMPLEM, V21, P221; Silva ES, 2019, PHOTOCHEM PHOTOBIOL, V95, P644, DOI 10.1111/php.13026; Singh RP, 2002, CARCINOGENESIS, V23, P499, DOI 10.1093/carcin/23.3.499; Smolarek AK, 2013, MOL CARCINOGEN, V52, P514, DOI 10.1002/mc.21886; Urpi-Sarda M, 2009, ANAL BIOANAL CHEM, V394, P1545, DOI 10.1007/s00216-009-2676-1; Vlachojannis C., SAFETY HERBAL MED PR; Waldman A, 2019, HEMATOL ONCOL CLIN N, V33, P1, DOI 10.1016/j.hoc.2018.08.001; Weinstock MA, 2008, AM J PREV MED, V34, P171, DOI 10.1016/j.amepre.2007.11.002	38	6	6	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2020	15	4							e0232009	10.1371/journal.pone.0232009	http://dx.doi.org/10.1371/journal.pone.0232009			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LS9BE	32353018	gold, Green Published			2023-01-03	WOS:000536673200033
J	Bretelle, F; Fabre, C; Golka, M; Pauly, V; Roth, B; Bechadergue, V; Blanc, J				Bretelle, Florence; Fabre, Chantal; Golka, Marine; Pauly, Vanessa; Roth, Brimbelle; Bechadergue, Valerie; Blanc, Julie			Capacitive-resistive radiofrequency therapy to treat postpartum perineal pain: A randomized study	PLOS ONE			English	Article							SEVERITY; DISEASE	Objective To evaluate the reduction of perineal pain after vaginal deliveries by capacitive resistive radiofrequency therapy (RF). Methods We conducted a double-blind randomized study in University Hospital Centre in France. We included women presenting either perineal tears or an episiotomy after vaginal delivery (instrumental assisted or not). The participants were randomly assigned to RF or not at day 1 and day 2 postpartum. The primary outcome was pain evaluated as visual analog scale (VAS) score > 4 at rest on day 2 after the treatment. Secondary outcomes included discomfort and pain while walking and seating two days after treatment, type of pain two days after treatment and analgesics intake two days after treatment, sexual intercourse retake and painful of intercourse were also assessed by phone call 30 days after delivery. We performed univariate analysis and multivariable regressions adjusting on the value of the outcome at baseline to improve precision of the estimated intervention effect. Results Between June 1, 2017 and October 8, 2017, the RF group included 29 women compared with 31 women in the group without RF. There was no significant difference on VAS > 4 between the two groups (13.8% vs. 9.7% p = 0.69; difference = 4.1%, 95%CI -12.2%20.4%); consumption of paracetamol was lower in the RF group (978.3 mg (sd = 804.5) vs 1703.7 mg (sd = 1381.6), p = 0.035; difference = -725.3 mg, 95%CI -1359.6 - -91.3). Multivariate analysis showed no association between RF and pain. Nevertheless, we found an association between RF and discomfort while walking (adjusted OR 0.24, 95% CI 0.07-0.90; p = 0.03). Conclusion VAS> 4 at day 2 was not different in the experimental and the control groups but RF was associated with less perineal discomfort while walking and lower consumption of paracetamol after delivery.	[Bretelle, Florence; Bechadergue, Valerie; Blanc, Julie] Assistance Publ Hop Marseille, Dept Gynecol & Obstet, Marseille, France; [Bretelle, Florence] INSERM 1095, IRD 198, CNRS 7278, Unite Rech Malad Infect Trop & Emergentes,UM63, Marseille, France; [Fabre, Chantal; Golka, Marine] Aix Marseille Univ, Midwife Sch, Fac Med & Paramed Sci, Marseille, France; [Pauly, Vanessa; Roth, Brimbelle] Aix Marseille Univ, Assistance Publ Hop Marseille, Med Evaluat, Dept Publ Hlth, Marseille, France; [Blanc, Julie] Aix Marseille Univ, Hlth Serv Res & Qual Life Ctr, CEReSS, EA 3279, Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite	Blanc, J (corresponding author), Assistance Publ Hop Marseille, Dept Gynecol & Obstet, Marseille, France.; Blanc, J (corresponding author), Aix Marseille Univ, Hlth Serv Res & Qual Life Ctr, CEReSS, EA 3279, Marseille, France.	julie.blanc@ap-hm.fr			Assistance Publique Hopitaux de Marseille (AP-HM) promotes the project [RCAPHM2016_0261]	Assistance Publique Hopitaux de Marseille (AP-HM) promotes the project	Assistance Publique Hopitaux de Marseille (AP-HM) promotes the project and a grant was dedicate to the study under the number No RCAPHM2016_0261. The company Winback provided the equipment for the duration of the study. The company Winback had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. FB received award.	[Anonymous], 2018, Obstet Gynecol, V132, P252, DOI 10.1097/AOG.0000000000002711; Chou D, 2013, COCHRANE DB SYST REV, V1; Clijsen R, 2020, J ALTERN COMPLEM MED, V26, P147, DOI 10.1089/acm.2019.0165; Costantino Cosimo, 2005, Acta Biomed, V76, P37; Cronkey Joseph, 2012, Foot Ankle Spec, V5, P293; Dunabeitia I, 2018, PHYS THER SPORT, V32, P227, DOI 10.1016/j.ptsp.2018.05.020; Fatton B, 2009, J GYNECOL OBST BIO R, V38, P662, DOI 10.1016/j.jgyn.2009.02.008; Gutton C, 2013, INT J GYNECOL OBSTET, V122, P33, DOI 10.1016/j.ijgo.2013.01.028; Kahan BC, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-139; Kaiser MG, 2014, J NEUROSURG-SPINE, V21, P133, DOI 10.3171/2014.4.SPINE14326; Kumaran B, 2015, INT J HYPERTHER, V31, P883, DOI 10.3109/02656736.2015.1092172; Leeman L, 2009, BIRTH-ISS PERINAT C, V36, P283, DOI 10.1111/j.1523-536X.2009.00355.x; Macarthur AJ, 2004, AM J OBSTET GYNECOL, V191, P1199, DOI 10.1016/j.ajog.2004.02.064; Molakatalla S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012129.pub2; Notarnicola A, 2017, J BIOL REG HOMEOS AG, V31, P509; Pavone C, 2017, UROL INT, V99, P77, DOI 10.1159/000467396; Pavone Carlo, 2013, Urologia, V80, P148; Persico G, 2013, Minerva Ginecol, V65, P669; Piazzolla A, 2015, J BIOL REG HOMEOS AG, V29, P637; Prabhu M, 2018, OBSTET GYNECOL, V132, P459, DOI 10.1097/AOG.0000000000002741; Schinkel N, 2010, INT J OBSTET ANESTH, V19, P293, DOI 10.1016/j.ijoa.2009.11.005; SKOVLUND E, 1991, EUR J CLIN PHARMACOL, V40, P343, DOI 10.1007/BF00265841; Turmo M, 2015, REV ESP ANEST REANIM, V62, P436, DOI 10.1016/j.redar.2014.10.008; Weber T, 2012, PM&R, V4, P176, DOI 10.1016/j.pmrj.2011.11.003; Yildizhan R, 2009, ARCH GYNECOL OBSTET, V280, P735, DOI 10.1007/s00404-009-1006-3; Zhou F, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010441.pub2	26	4	4	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2020	15	4							e0231869	10.1371/journal.pone.0231869	http://dx.doi.org/10.1371/journal.pone.0231869			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LS8VC	32339169	Green Published, gold			2023-01-03	WOS:000536657400016
J	Tassew, SG; Woldu, MA; Degu, WA; Shibeshi, W				Tassew, Segen Gebremeskel; Woldu, Minyahil Alebachew; Degu, Wondwossen Amogne; Shibeshi, Workineh			Management of hospital-acquired infections among patients hospitalized at Zewditu memorial hospital, Addis Ababa, Ethiopia: A prospective cross-sectional study	PLOS ONE			English	Article							CLINICAL-PRACTICE GUIDELINES; BLOOD-STREAM INFECTIONS; RISK-FACTORS; POINT PREVALENCE; DISEASES SOCIETY; NOSOCOMIAL INFECTIONS; SURVEILLANCE; AMERICA; PROPHYLAXIS; MORTALITY	Background Hospital-Acquired Infections (HAIs) are acquired when the patient is hospitalized for more than 48 hours. In Ethiopia data are scarce in management appropriateness of HAIs. Hence, this study was aimed to assess the prevalence and management of HAIs among patients admitted at Zewditu Memorial Hospital. Method A facility based prospective cross sectional study was conducted from March 1, 2017 to August 30, 2017. The sample was proportionally allocated among (medical, pediatrics, gynecology and obstetrics and surgical) wards, based on patient flow. Data were collected using data abstraction format and supplemented by key informant interview. Interview was made on eight physicians and four microbiologists who have been working in the wards during study period. Management appropriateness was assessed using Infectious Disease Society of America guideline and experts opinion (Infectious disease specialist). A multivariate logistic regression was used to identify factors associated with HAIs. Result The prevalence of HAIs was 19.8%. Surgical Site Infection (SSI) and pneumonia accounted for 20 (24.7%) of the infections. Culture and sensitivity was done for 24 (29.6%) patients. Of the 81 patients who developed HAIs, 54 (66.67%) of them were treated inappropriately. Physicians' response for this variation was information gap, forgetfulness, affordability and availability issue of first line medications. Younger age (AOR (Adjusted odds ratio) = 8.53, 95% CI: 2.67-27.30); male gender (AOR = 2.06, 95% CI: 1.01-4.22); longer hospital stay (AOR = 0.17, 95% CI: 0.06-0.51); and previous hospital admission (AOR = 3.22, 95% CI: 1.76-5.89); were independent predictors of HAIs. Conclusion Prevalence of HAIs and inappropriate management were substantially high in this study. Pneumonia and SSI were the common types of HAIs. Locally conformable guidelines could help to correct such problems.	[Tassew, Segen Gebremeskel] Mekelle Univ, Sch Pharm, Dept Clin Pharm, Coll Hlth Sci, Mekelle, Ethiopia; [Woldu, Minyahil Alebachew; Shibeshi, Workineh] Addis Ababa Univ, Sch Pharm, Dept Pharmacol & Clin Pharm, Coll Hlth Sci, Addis Ababa, Ethiopia; [Degu, Wondwossen Amogne] Addis Ababa Univ, Sch Med, Dept Internal Med, Coll Hlth Sci, Addis Ababa, Ethiopia	Mekelle University; Addis Ababa University; Addis Ababa University	Tassew, SG (corresponding author), Mekelle Univ, Sch Pharm, Dept Clin Pharm, Coll Hlth Sci, Mekelle, Ethiopia.	segengm@gmail.com	Degu, Wondwossen Amogne/GON-3590-2022; Woldu, Minyahil/ABD-9452-2020	Woldu, Minyahil/0000-0002-3163-0326; Gebremeskel, Segen/0000-0002-9308-6944				Abdulah R., 2012, PHARM REGUL AFF, V1, P2, DOI [10.4172/2167-7689.1000e106, DOI 10.4172/2167-7689.1000E106]; Ahoyo TA, 2014, ANTIMICROB RESIST IN, V3, DOI 10.1186/2047-2994-3-17; Amenu D, 2011, ETHIOP J HEALTH SCI, V21, P91; Amoran O, 2013, RATES RISK FACTORS A; [Anonymous], 2013, HLTH CAR ASS INF FAC; Asl HM, 2011, NATL NOSOCOMIAL INFE, P1; Assar S, 2012, SURVEY NOSOCOMIAL IN; Balkhy HH, 2006, INT J INFECT DIS, V10, P326, DOI 10.1016/j.ijid.2005.06.013; Cohen SH, 2010, INFECT CONT HOSP EP, V31, P431, DOI 10.1086/651706; Colpan A, 2005, AM J INFECT CONTROL, V33, P42, DOI 10.1016/j.ajic.2004.09.005; Dayanand M., 2004, MED J ARMED FORCES I, V60, P312, DOI [10.1016/S0377-1237(04)80079-0, DOI 10.1016/S0377-1237(04)80079-0]; Durando P, 2009, J HOSP INFECT, V71, P81, DOI 10.1016/j.jhin.2008.10.012; Elbur AI, 2012, INT J INFECT CONTROL, V8; Gailiene G, 2012, MED LITH, V48, P399; Garey KW, 2006, J ANTIMICROB CHEMOTH, V58, P645, DOI 10.1093/jac/dkl279; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Ginawi I, 2014, J CLIN DIAGN RES, V8, P81, DOI 10.7860/JCDR/2014/6673.4014; Gradel KO, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2233-z; Hajdu A, 2007, J HOSP INFECT, V66, P378, DOI 10.1016/j.jhin.2007.04.018; Kalil AC, 2016, CLIN INFECT DIS, V63, pE61, DOI 10.1093/cid/ciw353; Kallel H, 2005, J HOSP INFECT, V59, P343, DOI 10.1016/j.jhin.2004.09.015; Kang CI, 2005, ANTIMICROB AGENTS CH, V49, P760, DOI 10.1128/AAC.49.2.760-766.2005; King C, 2012, J HOSP INFECT, V82, P219, DOI 10.1016/j.jhin.2012.05.004; Laloto TL, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2167-x; Masterton R, 2003, J HOSP INFECT, V55, P1, DOI 10.1016/S0195-6701(03)00294-9; Mengesha Reiye Esayas, 2014, BMC Res Notes, V7, P575, DOI 10.1186/1756-0500-7-575; Messele G, 2009, ETHIOP J HLTH BIOMED, V2, P3; Miliani K, 2009, J ANTIMICROB CHEMOTH, V64, P1307, DOI 10.1093/jac/dkp367; Moyo S, 2010, SAMJ S AFR MED J, V100, P835, DOI 10.7196/SAMJ.4186; Mulu Andargachew, 2006, Ethiop Med J, V44, P125; Mulu W., 2013, CLIN MED RES, V2, P140, DOI DOI 10.11648/J.CMR.20130206.1514; Nair V, 2017, INDIAN J MED RES, V145, P824, DOI [10.4103/ijmr.IJMR_1167_15, 10.4103/ijmr.ijmr_1167_15]; Nejad Sepideh Bagheri, 2011, B WHO, V89; Nigatu Endalafer, 2011, Journal of Infection Prevention, V12, P38, DOI 10.1177/1757177410376680; Pourhoseingholi Mohamad Amin, 2013, Gastroenterol Hepatol Bed Bench, V6, P14; Raveh D, 2001, QJM-INT J MED, V94, P141, DOI 10.1093/qjmed/94.3.141; Razine Rachid, 2012, Int Arch Med, V5, P26, DOI 10.1186/1755-7682-5-26; Singh Shivinder, 2013, Med J Armed Forces India, V69, P124, DOI 10.1016/j.mjafi.2012.08.028; Tabatabaei S.M., 2015, INT J INFECT, V2; Tadesse ML, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1221; Tunkel AR, 2017, CLIN INFECT DIS, V64, pE34, DOI 10.1093/cid/ciw861; Wassef MA, 2012, AFR J MICROBIOL RES, V6, P3072, DOI 10.5897/AJMR12.377; Yallew WW, 2016, DRUG HEALTHC PATIENT, V8, P71, DOI 10.2147/DHPS.S107344; Zaman M, 2014, BANGLADESH J DENT RE, V4, P49; Zarb P, 2012, EUROSURVEILLANCE, V17, P4; Zilberberg M, 2012, SURG INFECT, V13, P377, DOI 10.1089/sur.2011.101	46	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2020	15	4							e0231949	10.1371/journal.pone.0231949	http://dx.doi.org/10.1371/journal.pone.0231949			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LS8RF	32330164	Green Published, gold			2023-01-03	WOS:000536647300033
J	Werner, AK; Koumans, EH; Chatham-Stephens, K; Salvatore, PP; Armatas, C; Byers, P; Clark, CR; Ghinai, I; Holzbauer, SM; Navarette, KA; Danielson, ML; Ellington, S; Moritz, ED; Petersen, EE; Kiernan, EA; Baldwin, GT; Briss, P; Jones, CM; King, BA; Krishnasamy, V; Rose, DA; Reagan-Steiner, S				Werner, A. K.; Koumans, E. H.; Chatham-Stephens, K.; Salvatore, P. P.; Armatas, C.; Byers, P.; Clark, C. R.; Ghinai, I; Holzbauer, S. M.; Navarette, K. A.; Danielson, M. L.; Ellington, S.; Moritz, E. D.; Petersen, E. E.; Kiernan, E. A.; Baldwin, G. T.; Briss, P.; Jones, C. M.; King, B. A.; Krishnasamy, V; Rose, D. A.; Reagan-Steiner, S.		Lung Injury Response Mortality Wor	Hospitalizations and Deaths Associated with EVALI	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UPDATE INTERIM GUIDANCE; SUSPECTED E-CIGARETTE; LUNG INJURY; UNITED-STATES; HEALTH; OUTBREAK; OBESITY; RISK	This study from the CDC compared the characteristics of 60 patients who died from EVALI with those of 2558 patients who were hospitalized for the condition but survived. The deaths were reported from 27 states and the District of Columbia, and most were associated with vaping THC-containing products before symptom onset. Background As of January 7, 2020, a total of 2558 hospitalized patients with nonfatal cases and 60 patients with fatal cases of e-cigarette, or vaping, product use-associated lung injury (EVALI) had been reported to the Centers for Disease Control and Prevention (CDC). Methods In a national study, we compared the characteristics of patients with fatal cases of EVALI with those of patients with nonfatal cases to improve the ability of clinicians to identify patients at increased risk for death from the condition. Health departments reported cases of EVALI to the CDC and included, when available, data from medical-record abstractions and patient interviews. Analyses included all the patients with fatal or nonfatal cases of EVALI that were reported to the CDC as of January 7, 2020. We also present three case reports of patients who died from EVALI to illustrate the clinical characteristics common among such patients. Results Most of the patients with fatal or nonfatal cases of EVALI were male (32 of 60 [53%] and 1666 of 2498 [67%], respectively). The proportion of patients with fatal or nonfatal cases was higher among those who were non-Hispanic white (39 of 49 [80%] and 1104 of 1818 [61%], respectively) than among those in other race or ethnic groups. The proportion of patients with fatal cases was higher among those 35 years of age or older (44 of 60 [73%]) than among those younger than 35 years, but the proportion with nonfatal cases was lower among those 35 years of age or older (551 of 2514 [22%]). Among the patients who had an available medical history, a higher proportion of those with fatal cases than those with nonfatal cases had a history of asthma (13 of 57 [23%] vs. 102 of 1297 [8%]), cardiac disease (26 of 55 [47%] vs. 115 of 1169 [10%]), or a mental health condition (32 of 49 [65%] vs. 575 of 1398 [41%]). A total of 26 of 50 patients (52%) with fatal cases had obesity. Half the patients with fatal cases (25 of 54 [46%]) were seen in an outpatient setting before hospitalization or death. Conclusions Chronic conditions, including cardiac and respiratory diseases and mental health conditions, were common among hospitalized patients with EVALI.	[Kiernan, E. A.] Ctr Dis Control & Prevent, 4770 Buford Hwy,MS 5106-6, Atlanta, GA 30341 USA; [Werner, A. K.; Moritz, E. D.] Natl Ctr Environm Hlth, Atlanta, GA USA; [Koumans, E. H.; Ellington, S.; Petersen, E. E.; Briss, P.; King, B. A.] Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA; [Chatham-Stephens, K.; Danielson, M. L.] Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA; [Salvatore, P. P.; Ghinai, I] Epidem Intelligence Serv Ctr Surveillance Epidemi, Atlanta, GA USA; [Salvatore, P. P.; Baldwin, G. T.; Jones, C. M.; Krishnasamy, V] Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Holzbauer, S. M.] Ctr Preparedness & Response, Atlanta, GA USA; [Kiernan, E. A.] Agcy Tox Subst & Dis Registry, Atlanta, GA USA; [Rose, D. A.; Reagan-Steiner, S.] Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA; [Kiernan, E. A.] Emory Univ, Sch Med, Atlanta, GA USA; [Armatas, C.] Calif Dept Publ Hlth, Sacramento, CA USA; [Byers, P.] Mississippi Dept Hlth, Jackson, MS USA; [Clark, C. R.] Indiana State Dept Hlth, Indianapolis, IN 46202 USA; [Ghinai, I] Illinois Dept Publ Hlth, Springfield, IL 62761 USA; [Holzbauer, S. M.] Minnesota Dept Hlth, St Paul, MN USA; [Navarette, K. A.] New York State Dept Hlth, Albany, NY USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University; California Department of Public Health; Minnesota Department of Health (MHD); State University of New York (SUNY) System	Werner, AK (corresponding author), Ctr Dis Control & Prevent, 4770 Buford Hwy,MS 5106-6, Atlanta, GA 30341 USA.	awerner@cdc.gov	Danielson, Melissa/AAW-9815-2020; Danielson, Melissa/AAW-9816-2020; Ghinai, Isaac/AAI-7985-2021; Rose, Dale/P-2721-2018	Danielson, Melissa/0000-0001-9461-0341; Kiernan, Emily/0000-0001-7006-4868; Rose, Dale/0000-0002-0943-6121; Ghinai, Isaac/0000-0003-1322-1331; Sherman, Adrienne/0000-0001-7210-2055; Salvatore, Phillip/0000-0001-8305-9056	Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		[Anonymous], 2018, VOX             0919; [Anonymous], 2019, 2019 LUNG INJ SURV C; Blagev DP, 2019, LANCET, V394, P2073, DOI 10.1016/S0140-6736(19)32679-0; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Centers for Disease Control and Prevention, 2019, 2019 LUNG INJ SURV P; Centers for Disease Control and Prevention, 2019, OUTBR LUNG INJ ASS E; Chatham-Stephens K, 2019, MMWR-MORBID MORTAL W, V68, P1076, DOI 10.15585/mmwr.mm6846e1; Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration, 2019, LANCET, V6, pe105; Davidson K, 2019, MMWR-MORBID MORTAL W, V68, P784, DOI 10.15585/mmwr.mm6836e1; Evans ME, 2020, MMWR-MORBID MORTAL W, V68, P1189, DOI 10.15585/mmwr.mm685152e2; Fernandez-Bustamante A, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0032-x; Franssen FME, 2014, CHEST, V146, P1426, DOI 10.1378/chest.14-1308; Ghinai I, 2019, MMWR-MORBID MORTAL W, V68, P865, DOI 10.15585/mmwr.mm6839e2; Giroud C, 2015, INT J ENV RES PUB HE, V12, P9988, DOI 10.3390/ijerph120809988; Grana R, 2014, CIRCULATION, V129, P1972, DOI 10.1161/CIRCULATIONAHA.114.007667; Howell MD, 2018, JAMA-J AM MED ASSOC, V319, P711, DOI 10.1001/jama.2018.0307; Jatlaoui TC, 2019, MMWR-MORBID MORTAL W, V68, P1081, DOI 10.15585/mmwr.mm6846e2; Kalininskiy A, 2019, LANCET RESP MED, V7, P1017, DOI 10.1016/S2213-2600(19)30415-1; Krishnasamy VP, 2020, MMWR-MORBID MORTAL W, V69, P90, DOI 10.15585/mmwr.mm6903e2; Layden JE, 2020, NEW ENGL J MED, V382, P903, DOI 10.1056/NEJMoa1911614; Lewis N, 2019, MMWR-MORBID MORTAL W, V68, P953, DOI 10.15585/mmwr.mm6842e1; Morean ME, 2017, SUBST USE MISUSE, V52, P974, DOI 10.1080/10826084.2016.1268162; Moritz ED, 2019, MMWR-MORBID MORTAL W, V68, P985, DOI 10.15585/mmwr.mm6843e1; Navon L, 2019, MMWR-MORBID MORTAL W, V68, P1034, DOI 10.15585/mmwr.mm6845e1; Office of Science Policy, 2019, OFF SCI POL PLANN CO; Office on Smoking and Health, 2016, E CIG US YOUTH YOUNG; Parraga G, 2020, CAN J RESP CRIT CARE, V4, P48, DOI 10.1080/24745332.2019.1684857; Perrine CG, 2019, MMWR-MORBID MORTAL W, V68, P860, DOI 10.15585/mmwr.mm6839e1; Peters EN, 2014, DRUG ALCOHOL DEPEN, V134, P228, DOI 10.1016/j.drugalcdep.2013.10.003; Peters U, 2018, CHEST, V153, P702, DOI 10.1016/j.chest.2017.07.010; Siegel DA, 2019, MMWR-MORBID MORTAL W, V68, P919, DOI 10.15585/mmwr.mm6841e3; Spears CA, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14010010; Suratt BT, 2017, ANN AM THORAC SOC, V14, P1050, DOI 10.1513/AnnalsATS.201703-263WS; Taylor J, 2019, MMWR-MORBID MORTAL W, V68, P1096, DOI 10.15585/mmwr.mm6847e1; Thanavala Y, 2019, LANCET RESP MED, V7, P1014, DOI [10.1016/S2213-2600(19)30350-9, 10.1016/s2213-2600(19)30350-9]; Zammit C, 2010, INT J GEN MED, V3, P335, DOI 10.2147/IJGM.S11926	36	84	86	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 23	2020	382	17					1589	1598		10.1056/NEJMoa1915314	http://dx.doi.org/10.1056/NEJMoa1915314			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LI4YO	32320569	Bronze, Green Accepted			2023-01-03	WOS:000529493200007
J	Wolfe, D; Kanji, S; Yazdi, F; Barbeau, P; Rice, D; Beck, A; Butler, C; Esmaeilisaraji, L; Skidmore, B; Moher, D; Hutton, B				Wolfe, Dianna; Kanji, Salmaan; Yazdi, Fatemeh; Barbeau, Pauline; Rice, Danielle; Beck, Andrew; Butler, Claire; Esmaeilisaraji, Leila; Skidmore, Becky; Moher, David; Hutton, Brian			Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations	PLOS ONE			English	Review							ACUTE NECROTIZING PANCREATITIS; RECURRENT ACUTE-PANCREATITIS; ACID-INDUCED PANCREATITIS; TAMOXIFEN-INDUCED HYPERTRIGLYCERIDEMIA; ACUTE HEMORRHAGIC-PANCREATITIS; FATAL ACUTE-PANCREATITIS; METRONIDAZOLE-INDUCED PANCREATITIS; AZATHIOPRINE-INDUCED PANCREATITIS; SODIUM STIBOGLUCONATE TREATMENT; THREATENING ACUTE-PANCREATITIS	Objective A current assessment of case reports of possible drug-induced pancreatitis is needed. We systematically reviewed the case report literature to identify drugs with potential associations with acute pancreatitis and the burden of evidence supporting these associations. Methods A protocol was developed a priori (PROSPERO CRD42017060473). We searched MEDLINE, Embase, the Cochrane Library, and additional sources to identify cases of drug-induced pancreatitis that met accepted diagnostic criteria of acute pancreatitis. Cases caused by multiple drugs or combination therapy were excluded. Established systematic review methods were used for screening and data extraction. A classification system for associated drugs was developed a priori based upon the number of cases, re-challenge, exclusion of non-drug causes of acute pancreatitis, and consistency of latency. Results Seven-hundred and thirteen cases of potential drug-induced pancreatitis were identified, implicating 213 unique drugs. The evidence base was poor: exclusion of non-drug causes of acute pancreatitis was incomplete or poorly reported in all cases, 47% had at least one underlying condition predisposing to acute pancreatitis, and causality assessment was not conducted in 81%. Forty-five drugs (21%) were classified as having the highest level of evidence regarding their association with acute pancreatitis; causality was deemed to be probable or definite for 19 of these drugs (42%). Fifty-seven drugs (27%) had the lowest level of evidence regarding an association with acute pancreatitis, being implicated in single case reports, without exclusion of other causes of acute pancreatitis. Discussion Much of the case report evidence upon which drug-induced pancreatitis associations are based is tenuous. A greater emphasis on exclusion of all non-drug causes of acute pancreatitis and on quality reporting would improve the evidence base. It should be recognized that reviews of case reports, are valuable scoping tools but have limited strength to establish drug-induced pancreatitis associations.	[Wolfe, Dianna; Kanji, Salmaan; Yazdi, Fatemeh; Barbeau, Pauline; Rice, Danielle; Beck, Andrew; Butler, Claire; Esmaeilisaraji, Leila; Skidmore, Becky; Moher, David; Hutton, Brian] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Kanji, Salmaan] Ottawa Hosp, Dept Pharm, Ottawa, ON, Canada; [Moher, David; Hutton, Brian] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Hutton, B (corresponding author), Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.; Hutton, B (corresponding author), Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada.	bhutton@ohri.ca	Wolfe, Dianna/ABA-4768-2020; Rice, Danielle B/AAS-3681-2020; Beck, Andrew/K-3382-2019	Wolfe, Dianna/0000-0003-1807-6647; Skidmore, Becky/0000-0001-8293-9238; Beck, Andrew/0000-0002-8308-2202; Esmaeilisaraji, Leila/0000-0002-6096-267X	Canadian Institutes of Health Research through the Drug Safety and Effectiveness Network	Canadian Institutes of Health Research through the Drug Safety and Effectiveness Network(Canadian Institutes of Health Research (CIHR))	This work was supported by a team grant (awarded to authors DM and BH) from the Canadian Institutes of Health Research through the Drug Safety and Effectiveness Network (https://cihr-irsc.gc.ca/e/39389.html).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABDULGHAFFAR NUAMA, 1995, J CLIN GASTROENTEROL, V21, P340, DOI 10.1097/00004836-199512000-00027; ABDULLAH AMA, 1993, J PEDIATR GASTR NUTR, V17, P441, DOI 10.1097/00005176-199311000-00019; Abou Chacra L, 2001, Hematol J, V2, P406, DOI 10.1038/sj.thj.6200132; Abraham Albin, 2012, Case Rep Gastroenterol, V6, P223, DOI 10.1159/000338652; Acharya Gyanendra Kumar, 2017, Ann Emerg Med, V69, P666, DOI 10.1016/j.annemergmed.2017.01.002; Justo LA, 2010, MED CLIN-BARCELONA, V134, P705, DOI 10.1016/j.medcli.2009.04.002; Adachi E, 1999, INT J PANCREATOL, V25, P217; Adam JP, 2016, J ONCOL PHARM PRACT; Agarwal M, 1997, NEW ZEAL MED J, V110, P426; Agito K, 2015, J INVEST MED HIGH IM, V3, DOI 10.1177/2324709615592229; Ahmad I, 2007, SOUTH MED J, V100, P409, DOI 10.1097/SMJ.0b013e3180374e4b; Aissaoui M, 1996, PRESSE MED, V25, P1650; Al-Zayani J., 1997, J BAHRAIN MED SOC, V9, P55; Alagozlu H, 2006, CLIN DRUG INVEST, V26, P297, DOI 10.2165/00044011-200626050-00007; ALBERTIFLOR JJ, 1995, J NATL CANCER I, V87, P689, DOI 10.1093/jnci/87.9.689-a; Alexander S, 2005, INTERN MED J, V35; Ali M F, 2013, Malays Fam Physician, V8, P28; Allaouchiche B, 1999, J ANTIMICROB CHEMOTH, V44, P137, DOI 10.1093/jac/44.1.137; Almeida DM, 2013, PANCREAS, V42, P177, DOI 10.1097/MPA.0b013e3182588c91; Alsubaie S, 2013, DERM-ENDOCRINOL, V5, P317, DOI 10.4161/derm.23792; ALTMAN AJ, 1982, CANCER, V49, P1384, DOI 10.1002/1097-0142(19820401)49:7<1384::AID-CNCR2820490714>3.0.CO;2-6; Amar S, 2007, MAYO CLIN PROC, V82, P521, DOI 10.4065/82.4.521; Amaravadi RK, 2002, AM J GASTROENTEROL, V97, P1077; Amery A, 1973, Tijdschr Gastroenterol, V16, P179; Anagnostopoulos George K, 2003, JOP, V4, P129; Anagnostopoulos GK, 2003, PANCREAS, V27, P278, DOI 10.1097/00006676-200310000-00017; Anand H, 2008, J POSTGRAD MED, V54, P153; ANDERSON J R, 1985, Digestive Surgery, V2, P24, DOI 10.1159/000171666; ANDERSON PE, 1991, AM J MED SCI, V302, P235, DOI 10.1097/00000441-199110000-00008; ANTONOW DR, 1986, ANN INTERN MED, V104, P363, DOI 10.7326/0003-4819-104-3-363; Arai Yoshinori, 2011, Case Rep Gastroenterol, V5, P610, DOI 10.1159/000333605; ARANDA EA, 1991, MED CLIN-BARCELONA, V96, P638; Arbel Yaron, 2008, Int J Surg, V6, P483, DOI 10.1016/j.ijsu.2006.06.024; Arellano L, 2014, ATEN PRIM, V46, P316, DOI 10.1016/j.aprim.2014.02.003; ARNOLD F, 1978, LANCET, V1, P382; Artero A, 2013, MED CLIN-BARCELONA, V141, P368, DOI 10.1016/j.medcli.2013.01.022; ATAM V, 2017, J MED SOC, V31, P48; AUBRY P, 1989, PRESSE MED, V18, P80; Avraam C, 2007, ANN GASTROENTEROL, V20, P35; Aygencel G, 2006, EUR J EMERG MED, V13, P372, DOI 10.1097/01.mej.0000224428.51623.b2; AYOOLA EA, 1994, ANN SAUDI MED, V14, P163, DOI 10.5144/0256-4947.1994.163; Ayoub WA, 2010, ENDOCR PRACT, V16, P80, DOI 10.4158/EP09104.CRR; Ayyildiz T, 2015, J EXP CLIN MED, V32, P133; Azar NJ, 2014, J CLIN NEUROSCI, V21, P1053, DOI 10.1016/j.jocn.2013.08.016; Baciewicz AM, 2000, ANN INTERN MED, V132, P680, DOI 10.7326/0003-4819-132-8-200004180-00027; Badalov N, 2007, CLIN GASTROENTEROL H, V5, P648, DOI 10.1016/j.cgh.2006.11.023; Baffoni L, 2004, ANN PHARMACOTHER, V38, P1088, DOI 10.1345/aph.1D582; Bahamonde Carrasco A, 1996, Gastroenterol Hepatol, V19, P253; BALASCH J, 1994, HUM REPROD, V9, P1163, DOI 10.1093/oxfordjournals.humrep.a138651; BANK L, 1984, DIGEST DIS SCI, V29, P357, DOI 10.1007/BF01318523; BANK S, 1970, POSTGRAD MED J, V46, P576, DOI 10.1136/pgmj.46.539.576; Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779; Bar Sarah, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2017-220328; BARTELS RHMA, 1992, SOUTHERN MED J, V85, P1006, DOI 10.1097/00007611-199210000-00018; BARTHET M, 1994, GASTROEN CLIN BIOL, V18, P90; Basturk A, 2017, GASTROENTEROL REV, V12, P235, DOI 10.5114/pg.2017.70479; BATALDEN PB, 1979, PEDIATRICS, V64, P520; Battaglia M, 2006, SCAND J UROL NEPHROL, V40, P423, DOI 10.1080/00365590500342190; Bauters T, 2013, INT J CLIN PHARM-NET, V35, P303, DOI 10.1007/s11096-010-9447-0; Bayard JMF, 2005, ACTA GASTRO-ENT BELG, V68, P92; Baysal B, 2015, TURK J GASTROENTEROL, V26, P289, DOI 10.5152/tjg.2015.0216; BEKASSY AN, 1992, LANCET, V340, P1552, DOI 10.1016/0140-6736(92)92809-T; Bekiari E, 2016, ENDOCRINE, V52, P458, DOI 10.1007/s12020-015-0841-1; Belaiche G, 2000, GASTROEN CLIN BIOL, V24, P471; Belli Hasan, 2005, Indian J Gastroenterol, V24, P273; Ben MH, 2002, VET HUM TOXICOL, V44, P47; Ben-Ami H, 1999, J RHEUMATOL, V26, P2049; Benavente Fernandez A, 2004, An Med Interna, V21, P199; Berent I, 1997, AM J PSYCHIAT, V154, P130; BERGER TM, 1992, PEDIATRICS, V90, P624; Albeniz AB, 2017, REV ESP ANEST REANIM, V64, P46, DOI 10.1016/j.redar.2016.05.009; Berrak SG, 2001, INT J PEDIAT HEM ONC, V7, P413; BERTOLONE SJ, 1982, CANCER, V50, P2964, DOI 10.1002/1097-0142(19821215)50:12<2964::AID-CNCR2820501244>3.0.CO;2-9; BESSEAU M, 1991, GASTROEN CLIN BIOL, V15, P174; Betrosian AP, 2001, ACTA ANAESTH SCAND, V45, P1052, DOI 10.1034/j.1399-6576.2001.450824.x; Bilar JM, 2014, BRAZ J INFECT DIS, V18, P454, DOI 10.1016/j.bjid.2014.03.008; BINEK J, 1991, J CLIN GASTROENTEROL, V13, P690, DOI 10.1097/00004836-199112000-00016; BIRCHFIELD GR, 1990, WESTERN J MED, V152, P714; Birck R, 1998, LANCET, V351, P1178, DOI 10.1016/S0140-6736(05)79122-4; Bird H, 2000, ANAESTHESIA, V55, P506; Blain H, 1999, EUR J INTERN MED, V10, P117; Blake WED, 2003, MENOPAUSE, V10, P99, DOI 10.1097/01.GME.0000026464.76786.51; BORIES JM, 1992, GASTROEN CLIN BIOL, V16, P817; Boruchowicz A, 2003, GASTROEN CLIN BIOL, V27, P560; BOSCH JA, 1985, ACTA GASTRO-ENT BELG, V48, P529; Bosch X, 1997, ANN INTERN MED, V127, P1043, DOI 10.7326/0003-4819-127-11-199712010-00031; Bosch X, 1997, LANCET, V350, P1300, DOI 10.1016/S0140-6736(05)62478-6; Bourezane H, 2012, THERAPIE, V67, P539, DOI 10.2515/therapie/2012076; BOUVET E, 1990, LANCET, V336, P1515, DOI 10.1016/0140-6736(90)93228-H; Bowers RD, 2019, J PHARM PRACT, V32, P586, DOI 10.1177/0897190018760645; Boyle MP, 2001, CHEST, V119, P1283, DOI 10.1378/chest.119.4.1283; BUNIN N, 1985, CANCER TREAT REP, V69, P236; Bustamante SE, 2006, PEDIATR ANESTH, V16, P680, DOI 10.1111/j.1460-9592.2005.01833.x; Buszek SM, 2016, ACG CASE REP J, V3, DOI 10.14309/crj.2016.77; BUZAN RD, 1995, J CLIN PSYCHIAT, V56, P529; CADRANEL JF, 1987, GASTROEN CLIN BIOL, V11, P99; CALDAROLA V, 1986, AM J GASTROENTEROL, V81, P579; CALL T, 1977, AM J DIG DIS, V22, P835, DOI 10.1007/BF01694517; CALMUS Y, 1985, GASTROEN CLIN BIOL, V9, P266; Can B, 2014, INTERNAL MED, V53, P703, DOI 10.2169/internalmedicine.53.0667; Canovas B, 2000, REV CLIN ESP, V200, P182, DOI 10.1016/S0014-2565(00)70601-1; CAPPELL MS, 1989, J CLIN GASTROENTEROL, V11, P679, DOI 10.1097/00004836-198912000-00017; Carnovale A, 2003, DIGEST LIVER DIS, V35, P55, DOI 10.1016/S1590-8658(02)00012-9; Carro PG, 2004, ANN PHARMACOTHER, V38, P508, DOI 10.1345/aph.1D288; CARRO PG, 1995, REV ESP ENFERM DIG, V87, P757; CASTIELLA A, 1995, J CLIN GASTROENTEROL, V21, P258, DOI 10.1097/00004836-199510000-00022; Castro JL, 2000, REV ESP ENFERM DIG, V92, P822; Castro MR, 1999, MAYO CLIN PROC, V74, P1125, DOI 10.4065/74.11.1125; CASTRO R, 1991, REV ESP ENFERM DIG, V79, P219; Cavanaugh Zachary, 2014, Conn Med, V78, P37; Cecchi Enrica, 2004, Emerg Med Australas, V16, P473, DOI 10.1111/j.1742-6723.2004.00653.x; CELIFARCO A, 1989, AM J GASTROENTEROL, V84, P958; Cerulli TR, 1999, HARVARD REV PSYCHIAT, V7, P61, DOI 10.1093/hrp/7.1.61; CHAMBON JP, 1993, J CHIR-PARIS, V130, P74; Chams S, 2018, BMC GASTROENTEROL, V18, DOI 10.1186/s12876-018-0851-6; Chan HY, 2012, HONG KONG MED J, V18, P526; CHAN KL, 1994, TUBERCLE LUNG DIS, V75, P383, DOI 10.1016/0962-8479(94)90086-8; Chang TG, 2014, J CLIN PSYCHOPHARM, V34, P382, DOI 10.1097/JCP.0000000000000047; Chao CT, 2013, CAN FAM PHYSICIAN, V59, P43; Charan V D, 1993, Indian Pediatr, V30, P809; Chen CL, 2004, J FORMOS MED ASSOC, V103, P380; Chen JL, 2003, PHARMACOTHERAPY, V23, P940, DOI 10.1592/phco.23.7.940.32725; Chen YY, 2007, WORLD J GASTROENTERO, V13, P975, DOI 10.3748/wjg.v13.i6.975; Chengappa KNR, 1995, J PSYCHOPHARMACOL, V9, P381, DOI 10.1177/026988119500900413; Chetaille E, 1998, GASTROEN CLIN BIOL, V22, P555; Cheung O, 2004, ANN INTERN MED, V140, P73, DOI 10.7326/0003-4819-140-1-200401060-00036; CHEUNG YF, 1994, MED PEDIATR ONCOL, V22, P421, DOI 10.1002/mpo.2950220614; Chhaparia Anuj, 2017, Del Med J, V89, P90; Chintanaboina J, 2012, CASE REP MED, V2012, DOI 10.1155/2012/973279; Chis Bogdan Augustin, 2018, Clujul Med, V91, P117, DOI 10.15386/cjmed-804; Chng CL, 2011, ENDOCR PRACT, V17, P960; Choi JW, 2016, CLIN MOL HEPATOL, V22, P168, DOI 10.3350/cmh.2016.22.1.168; Chow KM, 2004, NETH J MED, V62, P172; CHRISTOPHE JL, 1994, GUT, V35, P712, DOI 10.1136/gut.35.5.712; Chung LW, 2008, ANN HEMATOL, V87, P421, DOI 10.1007/s00277-007-0410-7; CINA SJ, 1994, AM J FOREN MED PATH, V15, P28, DOI 10.1097/00000433-199403000-00007; Collet T, 1995, GASTROEN CLIN BIOL, V19, P952; Colomina Aviles J, 1997, An Med Interna, V14, P487; Cooper MA, 2001, CAN J GASTROENTEROL, V15, P127, DOI 10.1155/2001/687087; Cordeiro Q, 2001, J CLIN PSYCHOPHARM, V21, P529, DOI 10.1097/00004714-200110000-00012; COREY WA, 1991, REV INFECT DIS, V13, P1213; CORTES E, 1995, MED CLIN-BARCELONA, V104, P578; Cortes J, 1999, FARM HOSP, V23, P325; COSCHIERI M, 1994, GASTROEN CLIN BIOL, V18, P1040; COUDERC M, 1991, GASTROEN CLIN BIOL, V15, P986; COWARD RA, 1977, BRIT MED J, V1, P1086, DOI 10.1136/bmj.1.6068.1086-a; CROIZET O, 1994, GASTROEN CLIN BIOL, V18, P910; Csomor J, 2017, J CLIN PHARM THER, V42, P495, DOI 10.1111/jcpt.12524; DABAGHI S, 1991, ANN INTERN MED, V115, P330, DOI 10.7326/0003-4819-115-4-330_3; Daniel F, 2004, INFLAMM BOWEL DIS, V10, P258, DOI 10.1097/00054725-200405000-00013; Das AK, 2014, INDIAN J PHARMACOL, V46, P455, DOI 10.4103/0253-7613.135967; Das S, 2013, J YOUNG PHARM, V5, P108, DOI [10.1016/j.jyp.2013.08.003, 10.1016/j.jyp.2013.06.002]; Das S, 2012, THER DRUG MONIT, V34, P242, DOI 10.1097/FTD.0b013e3182526e6a; Davido B, 2016, J ANTIMICROB CHEMOTH, V71, P2994, DOI 10.1093/jac/dkw255; de Beaufort C, 2006, EUR J PEDIATR, V165, P652, DOI 10.1007/s00431-006-0126-z; De Mesa C, 2013, J PHARM TECHNOL, V29, P3; DEBONGNIE JC, 1994, J CLIN GASTROENTEROL, V19, P348, DOI 10.1097/00004836-199412000-00024; Decocq G, 1999, THERAPIE, V54, P41; DEGENNES JL, 1978, ANN MED INTERNE, V129, P435; Antonana AD, 2014, J CLIN GASTROENTEROL, V48, P651, DOI 10.1097/MCG.0000000000000158; DELALLA F, 1993, CLIN INFECT DIS, V16, P730, DOI 10.1093/clind/16.5.730; Delcenserie R., 2001, GASTROENTEROL CLIN B, V25; Denker PS, 2006, DIABETES CARE, V29, P471, DOI 10.2337/diacare.29.02.06.dc05-2043; DEPREZ P, 1989, LANCET, V2, P445; Deshpande PR, 2011, J PHARMACOL PHARMACO, V2, P40, DOI 10.4103/0976-500X.77114; DEVARSDUMAYNE JF, 1980, NOUV PRESSE MED, V9, P3550; Di Martino V, 1999, AIDS, V13, P1421, DOI 10.1097/00002030-199907300-00028; Díaz F Javier, 2004, Rev. gastroenterol. Perú, V24, P353; DOMINGO JJS, 1994, J CLIN GASTROENTEROL, V18, P168, DOI 10.1097/00004836-199403000-00023; Domingo P, 1996, ARCH INTERN MED, V156, P1029, DOI 10.1001/archinte.156.9.1029; DONOVAN KL, 1990, J INFECTION, V21, P107, DOI 10.1016/0163-4453(90)90830-2; dos Santos BL, 2010, ARQ NEURO-PSIQUIAT, V68, P135, DOI 10.1590/S0004-282X2010000100029; Doucette DE, 2000, ANN PHARMACOTHER, V34, P1128; Drabo YJ, 2002, ANN FR ANESTH, V21, P68, DOI 10.1016/S0750-7658(01)00562-7; Drory VE, 1999, NEUROLOGY, V52, P892, DOI 10.1212/WNL.52.4.892; Duboeuf T, 2004, GASTROEN CLIN BIOL, V28, P409, DOI 10.1016/S0399-8320(04)94947-0; DUVILLE L, 1993, AM J GASTROENTEROL, V88, P464; Echarri A, 1996, REV ESP ENFERM DIG, V88, P645; ECHINARD E, 1986, THERAPIE, V41, P520; Eddoukani I, 2016, J AFR HEPAT GASTROEN, V10, P220, DOI 10.1007/s12157-016-0679-z; Einollahi Behzad, 2015, J Nephropharmacol, V4, P72; EISEMANN AD, 1989, ANN INTERN MED, V111, P860, DOI 10.7326/0003-4819-111-10-860_2; Eland IA, 2000, GASTROENTEROLOGY, V119, P230, DOI 10.1053/gast.2000.8528; Eland IA, 1999, AM J GASTROENTEROL, V94, P2417; Elisaf MS, 2000, ANN ONCOL, V11, P1067, DOI 10.1023/A:1008309613082; ELMORE MF, 1981, GASTROENTEROLOGY, V81, P1134; Engel T, 2013, ANN PHARMACOTHER, V47, pE3, DOI 10.1345/aph.1R334; ERDKAMP F, 1992, NETH J MED, V41, P71; Erenoglu C, 2007, ULUS TRAVMA ACIL CER, V13, P78; EVANS RJ, 1995, AM J FOREN MED PATH, V16, P62, DOI 10.1097/00000433-199503000-00014; FAINTUCH J, 1985, INT SURG, V70, P271; FALKO JM, 1975, ANN INTERN MED, V83, P832, DOI 10.7326/0003-4819-83-6-832; Famularo G, 2002, J CLIN GASTROENTEROL, V34, P283, DOI 10.1097/00004836-200203000-00021; Famularo G, 2005, PANCREAS, V31, P294, DOI 10.1097/01.mpa.0000178281.58158.64; Famularo G, 1999, Ann Ital Med Int, V14, P202; Famularo G, 2007, PANCREAS, V35, P187, DOI 10.1097/mpa.0b013e3180645d94; Famularo G, 2004, EUR J EMERG MED, V11, P305, DOI 10.1097/00063110-200410000-00015; Famularo G, 2012, J PANCREAS, V13, P540, DOI 10.6092/1590-8577/1107; Famularo G, 2005, J PANCREAS, V6, P605; Fang CC, 1996, J TOXICOL-CLIN TOXIC, V34, P93, DOI 10.3109/15563659609020240; Fathallah N, 2011, J PANCREAS, V12, P404; Fecik SE, 1999, J CLIN PSYCHOPHARM, V19, P483, DOI 10.1097/00004714-199910000-00021; Felig DM, 1996, ANN INTERN MED, V124, P1016, DOI 10.7326/0003-4819-124-11-199606010-00018; Feola DJ, 2002, PHARMACOTHERAPY, V22, P1508, DOI 10.1592/phco.22.16.1508.33691; Fernandez J, 1997, AM J GASTROENTEROL, V92, P2302; Fernandez Lison L C, 2010, Farm Hosp, V34, P310, DOI 10.1016/j.farma.2009.12.008; Ferreira M, 2009, IEEE INT VEH SYM, P99, DOI 10.1109/IVS.2009.5164260; FIORENTINI MT, 1990, DIGEST DIS SCI, V35, P1180, DOI 10.1007/BF01537594; Flaig T, 2016, J CLIN PHARM THER, V41, P718, DOI 10.1111/jcpt.12456; Flamenbaum M, 1998, GASTROEN CLIN BIOL, V22, P975; Floris-Moore MA, 2003, ANN PHARMACOTHER, V37, P1810, DOI 10.1345/aph.1D179; FLYNN WJ, 1987, ANN INTERN MED, V107, P63, DOI 10.7326/0003-4819-107-1-63; FOISY MM, 1994, ANN PHARMACOTHER, V28, P1025, DOI 10.1177/106002809402800905; FONTANEDA ED, 1991, REV ESP ENFERM DIG, V79, P439; Forte A, 1996, Riv Eur Sci Med Farmacol, V18, P187; Francobandiera G, 1999, HUM PSYCHOPHARM CLIN, V14, P211, DOI 10.1002/(SICI)1099-1077(199904)14:3<211::AID-HUP87>3.0.CO;2-3; Franga DL, 2000, GASTROINTEST ENDOSC, V52, P789, DOI 10.1067/mge.2000.109718; FREDENRICH A, 1991, LANCET, V338, P52, DOI 10.1016/0140-6736(91)90039-R; FUCHS JE, 1989, DICP ANN PHARMAC, V23, P711, DOI 10.1177/106002808902300918; Funayama Y, 2004, J GASTROENTEROL, V39, P592, DOI 10.1007/s00535-004-1350-9; Gabriel JG, 2018, AM J THER, V25, pE556, DOI 10.1097/MJT.0000000000000635; GALINDO C, 1995, REV ESP ENFERM DIG, V87, P597; Gallego-Gutierrez S, 2015, J CROHNS COLITIS, V9, P676, DOI 10.1093/ecco-jcc/jjv086; GallegoRojo FJ, 1997, DIGEST DIS SCI, V42, P1789, DOI 10.1023/A:1018838204781; Gang N, 1999, AM J GASTROENTEROL, V94, P3626, DOI 10.1016/S0002-9270(99)00680-2; GARAU P, 1994, J PEDIATR GASTR NUTR, V18, P481, DOI 10.1097/00005176-199405000-00015; Aguilera XG, 2008, MED CLIN-BARCELONA, V130, P557; Garg R, 2010, J PEDIATR SURG, V45, P2071, DOI 10.1016/j.jpedsurg.2010.07.028; Garrington T, 1998, MED PEDIATR ONCOL, V30, P106, DOI 10.1002/(SICI)1096-911X(199802)30:2<106::AID-MPO7>3.0.CO;2-M; GASSER RA, 1994, CLIN INFECT DIS, V18, P83, DOI 10.1093/clinids/18.1.83; Gatto EM, 1998, CLIN NEUROPHARMACOL, V21, P203; Gerson Raquel, 1997, Journal of Emergency Medicine, V15, P645, DOI 10.1016/S0736-4679(97)00143-1; Gill Christopher J., 2005, Journal of Pharmacy Technology, V21, P79; GILMORE IT, 1977, BRIT MED J, V1, P753, DOI 10.1136/bmj.1.6063.753; Gilson M, 2008, SCAND J INFECT DIS, V40, P681, DOI 10.1080/00365540801938949; Giorda CB, 2014, DIABETES OBES METAB, V16, P1041, DOI 10.1111/dom.12297; Girgis Christian M, 2011, Endocr Pract, V17, pe48, DOI 10.4158/EP10383.CR; Godino T, 1999, JCR-J CLIN RHEUMATOL, V5, P305; GOFFIN E, 1995, TRANSPLANTATION, V59, P1218; GOLDBERG BH, 1978, PEDIATRICS, V61, P317; Goldman KE, 2005, ORAL SURG ORAL MED O, V100, P285, DOI 10.1016/j.tripleo.2004.11.024; Gonzalez Ramallo V J, 1992, Eur J Med, V1, P123; Gottschling S, 2005, PEDIATR ANESTH, V15, P1006, DOI 10.1111/j.1460-9592.2004.01562.x; Goyal SB, 1998, ARCH INTERN MED, V158, P411, DOI 10.1001/archinte.158.4.411; GRADON JD, 1991, SOUTHERN MED J, V84, P1410, DOI 10.1097/00007611-199111000-00035; Granados L M, 1997, Rev Esp Anestesiol Reanim, V44, P87; Grauso-Eby NL, 2003, PEDIATR NEUROL, V28, P145, DOI 10.1016/S0887-8994(02)00517-9; Greenhalgh T, 1997, BMJ-BRIT MED J, V315, P243, DOI 10.1136/bmj.315.7102.243; GREENSTEIN R, 1979, CANCER, V43, P718, DOI 10.1002/1097-0142(197902)43:2<718::AID-CNCR2820430247>3.0.CO;2-R; GUERRA M, 1967, J AMER MED ASSOC, V200, P552, DOI 10.1001/jama.200.6.552; Guerrero Igea F J, 2001, An Med Interna, V18, P400; Guevara-Campos J, 2009, ARQ NEURO-PSIQUIAT, V67, P513, DOI 10.1590/S0004-282X2009000300028; GUILLAUME P, 1984, DIGEST DIS SCI, V29, P78, DOI 10.1007/BF01296866; GUMASTE VV, 1989, AM J MED, V86, P725, DOI 10.1016/0002-9343(89)90456-7; Gupta Ankur, 2014, Trop Gastroenterol, V35, P132; HAINAUT P, 1987, REV MED INTERNE, V8, P516, DOI 10.1016/S0248-8663(87)80204-7; HALIM MA, 1993, CLIN INFECT DIS, V16, P397, DOI 10.1093/clind/16.3.397; HAMED I, 1978, AM J MED SCI, V276, P211, DOI 10.1097/00000441-197809000-00009; Hanft A, 2004, J AM ACAD CHILD PSY, V43, P1458, DOI 10.1016/S0890-8567(09)61378-2; HANLINE MH, 1987, SOUTHERN MED J, V80, P1069, DOI 10.1097/00007611-198708000-00049; HARRIS AG, 1995, PANCREAS, V11, P318, DOI 10.1097/00006676-199510000-00019; HART CC, 1989, ANN INTERN MED, V111, P691, DOI 10.7326/0003-4819-111-8-691_1; Hastier P, 2000, AM J GASTROENTEROL, V95, P3295; HAWKSWORTH CRE, 1989, BRIT MED J, V298, P190, DOI 10.1136/bmj.298.6667.190-a; Hegazi MO, 2015, J CLIN PHARM THER, V40, P607, DOI 10.1111/jcpt.12307; Heluwaert F, 2006, GASTROEN CLIN BIOL, V30, P635, DOI 10.1016/S0399-8320(06)73248-1; HERER B, 1989, BRIT MED J, V298, P605, DOI 10.1136/bmj.298.6673.605-a; HERRMANN R, 1990, AUST NZ J MED, V20, P243, DOI 10.1111/j.1445-5994.1990.tb01028.x; HERSKOWITZ LJ, 1979, ARCH DERMATOL, V115, P179, DOI 10.1001/archderm.115.2.179; HOCHAIN P, 1991, GASTROEN CLIN BIOL, V15, P173; Holla S, 2016, RES J PHARM BIOL CHE, V7, P1099; Houben ML, 2005, EUR J PAEDIATR NEURO, V9, P77, DOI 10.1016/j.ejpn.2004.11.006; Hoyte FCL, 2012, J ALLERGY CLIN IMMUN, V129, P1684, DOI 10.1016/j.jaci.2011.12.003; Huang YJ, 2009, PROG NEURO-PSYCHOPH, V33, P1561, DOI 10.1016/j.pnpbp.2009.08.019; Hung Miao-Chiu, 2007, J Chin Med Assoc, V70, P176; Hung WY, 2009, INT J ANTIMICROB AG, V34, P486, DOI 10.1016/j.ijantimicag.2009.05.004; Hussain A, 2008, J PSYCHOPHARMACOL, V22, P336, DOI 10.1177/0269881107081517; Ianiro G, 2014, J CLIN GASTROENTEROL, V48, P563, DOI 10.1097/MCG.0000000000000063; Igarashi H, 2009, J PANCREAS, V10, P550; Ikeuchi K, 2016, LUNG CANCER, V99, P148, DOI 10.1016/j.lungcan.2016.07.001; Iliopoulou A, 2001, DIGEST DIS SCI, V46, P1882, DOI 10.1023/A:1010674812573; Im MS, 2013, EXP CLIN TRANSPLANT, V11, P72, DOI 10.6002/ect.2012.0106; Inayat F, 2016, N AM J MED SCI, V8, P117, DOI 10.4103/1947-2714.174348; Inoue H, 2005, DIGEST DIS SCI, V50, P1064, DOI 10.1007/s10620-005-2705-7; ISENBERG JN, 1978, J PEDIATR-US, V93, P1043, DOI 10.1016/S0022-3476(78)81256-6; IZRAELI S, 1994, CANCER, V74, P1627, DOI 10.1002/1097-0142(19940901)74:5<1627::AID-CNCR2820740522>3.0.CO;2-U; Izzedine H, 2001, AM J GASTROENTEROL, V96, P3206; Jain N, 2016, THER ADV DRUG SAF, V7, P236, DOI 10.1177/2042098616667352; Jamshidi Mohammad, 2002, J Okla State Med Assoc, V95, P79; Javaloyas M, 1998, MED CLIN-BARCELONA, V110, P437; Jawaid Q, 2002, DIGEST DIS SCI, V47, P614, DOI 10.1023/A:1017932522875; JEANDIDIER N, 1995, DIABETES CARE, V18, P410, DOI 10.2337/diacare.18.3.410; Jetha MM, 2012, PEDIATR DIABETES, V13, P444, DOI 10.1111/j.1399-5448.2011.00843.x; Jha SH, 2003, ANN PHARMACOTHER, V37, P1438, DOI 10.1345/aph.1C482; Jiang R, 2018, PANCREAS, V47, pE53, DOI 10.1097/MPA.0000000000001107; Johnson JL, 2006, PHARMACOTHERAPY, V26, P414, DOI 10.1592/phco.26.3.414; Jones MR, 2015, OCHSNER J, V15, P45; Juang P, 2006, ANN PHARMACOTHER, V40, P128, DOI 10.1345/aph.1G314; JUBERT P, 1994, ANN INTERN MED, V121, P722, DOI 10.7326/0003-4819-121-9-199411010-00021; Julve Pardo R, 1998, Neurologia, V13, P372; Jung JH, 2014, J KOREAN MED SCI, V29, P1170, DOI 10.3346/jkms.2014.29.8.1170; Jung M, 2019, J ALLER CL IMM-PRACT, V7, P336, DOI 10.1016/j.jaip.2018.06.009; KABANGU SKK, 1991, PEDIATRIE, V46, P839; Kanbay M, 2004, POSTGRAD MED J, V80, P617, DOI 10.1136/pgmj.2003.018119; Kanbay M, 2006, SOUTH MED J, V99, P1388, DOI 10.1097/01.smj.0000251413.20573.ad; Karangelis D., 2013, EUR J INTERN MED, V24, P77, DOI [10.1016/j.ejim.2013.08.189, DOI 10.1016/J.EJIM.2013.08.189, 10.1016/j.ejim.2013.01.007, DOI 10.1016/J.EJIM.2013.01.007]; Martinez LXK, 2018, EUR THYROID J, V7, P145, DOI 10.1159/000488316; Kawabe K, 2014, CLIN PSYCHOPHARM NEU, V12, P67, DOI 10.9758/cpn.2014.12.1.67; Kawakami H, 2018, PANCREAS, V47, pE34, DOI 10.1097/MPA.0000000000001061; KEEFE M, 1989, DERMATOLOGICA, V179, P73, DOI 10.1159/000248315; KHAN IH, 1993, POSTGRAD MED J, V69, P486, DOI 10.1136/pgmj.69.812.486; Khanna Sudeep, 2003, Journal of Gastroenterology and Hepatology, V18, P1110, DOI 10.1046/j.1440-1746.2003.03129.x; Khetpal N, 2018, CUREUS, V10, DOI 10.7759/cureus.3747; Kikuchi I, 2019, CLIN J GASTROENTEROL, V12, P239, DOI 10.1007/s12328-018-0926-5; Kim YA, 2014, CHINESE J CANCER RES, V26, P341, DOI 10.3978/j.issn.1000-9604.2014.05.01; Kitamura Yosuke, 2015, Keio Journal of Medicine, V64, P62, DOI 10.2302/kjm.2015-0001-CR; KLEIN SM, 1983, J RHEUMATOL, V10, P512; Knackstedt C, 2007, BRIT J DERMATOL, V156, P576, DOI 10.1111/j.1365-2133.2006.07658.x; Knezevich E, 2012, AM J HEALTH-SYST PH, V69, P386, DOI 10.2146/ajhp110221; Kobayashi Y, 2011, MED ONCOL, V28, P463, DOI 10.1007/s12032-010-9479-2; Kocak MZ, 2018, JCPSP-J COLL PHYSICI, V28, P334, DOI 10.29271/jcpsp.2018.04.334; KONIVER GA, 1978, DEL MED J, V50, P330; Kovacic S, 2017, COGENT MED, V4, DOI [10.1080/2331205X.2017.1312802, DOI 10.1080/2331205X.2017.1312802]; Kumar AN, 1999, CHEST, V115, P1198, DOI 10.1378/chest.115.4.1198; Kumar DM, 2003, CLIN ONCOL-UK, V15, P35, DOI 10.1053/clon.2002.0170; KUMAR S, 1989, AM J GASTROENTEROL, V84, P451; Kuyucu N, 2001, PEDIATR INFECT DIS J, V20, P455, DOI 10.1097/00006454-200104000-00021; Laczek JT, 2010, J CLIN GASTROENTEROL, V44, P153, DOI 10.1097/MCG.0b013e3181aae531; Lai SW, 2012, QJM-INT J MED, V105, P363, DOI 10.1093/qjmed/hcr041; LAMBRIANIDES AL, 1984, POSTGRAD MED J, V60, P491, DOI 10.1136/pgmj.60.705.491; Lankisch PG, 2003, PANCREAS, V26, P211, DOI 10.1097/00006676-200303000-00021; Laugel V, 2005, ARCH PEDIATRIE, V12, P34, DOI 10.1016/j.arcped.2004.07.020; LEBLANC A, 1983, PRESSE MED, V12, P1351; Ledder OD, 2013, J PEDIATR GASTR NUTR, V57, P583, DOI 10.1097/MPG.0b013e31829f16fc; Lee CF, 2014, INTERNAL MED, V53, P1351, DOI 10.2169/internalmedicine.53.1913; Lee HM, 2011, PANCREAS, V40, P780, DOI 10.1097/MPA.0b013e31821fa52f; Lee WC, 2006, CLIN NEPHROL, V65, P144; Lee YD, 2002, VET HUM TOXICOL, V44, P165; Leisure GS, 1996, ANESTHESIOLOGY, V84, P224, DOI 10.1097/00000542-199601000-00027; LERCHE A, 1987, HISTOPATHOLOGY, V11, P647, DOI 10.1111/j.1365-2559.1987.tb02675.x; Levin TL, 1997, PEDIATR RADIOL, V27, P189, DOI 10.1007/s002470050099; LEVINE RA, 1988, AM J GASTROENTEROL, V83, P1161; Li MQ, 2007, SOUTH MED J, V100, P909, DOI 10.1097/SMJ.0b013e31813c695d; LILLY EL, 1981, JAMA-J AM MED ASSOC, V246, P2680, DOI 10.1001/jama.246.23.2680; Lin JW, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3103-z; Lin YH, 2001, J CLIN GASTROENTEROL, V32, P276, DOI 10.1097/00004836-200103000-00027; Liou LS, 2014, YONSEI MED J, V55, P831, DOI 10.3349/ymj.2014.55.3.831; Lipshitz J, 2009, J CLIN GASTROENTEROL, V43, P93, DOI 10.1097/MCG.0b013e318164939c; Liu PH, 2008, CLIN TOXICOL, V46, P1103, DOI 10.1080/15563650802382183; Liviu L, 1996, ANN INTERN MED, V125, P701, DOI 10.7326/0003-4819-125-8-199610150-00031; LONS T, 1991, GASTROEN CLIN BIOL, V15, P93; da Silva JTSL, 2013, GASTROENT HEPAT-BARC, V36, P21, DOI 10.1016/j.gastrohep.2012.04.008; Lopes Mondejar P, 2007, ENDOCRINOL NUTR, V54, P340; Lopez Centeno B, 2013, ACUTE SECONDARY PANC, V15, P3; LOTT JA, 1990, CLIN CHEM, V36, P395; Loulergue P, 2008, AIDS, V22, P545, DOI 10.1097/QAD.0b013e328277ef16; Luo HX, 2015, J NEUROL, V262, P779, DOI 10.1007/s00415-015-7649-z; Madsen Jonna Skov, 1995, Blood Pressure, V4, P369, DOI 10.3109/08037059509077623; Magill P, 2006, J PANCREAS, V7, P311; Mahdi AS, 2018, IDCases, V12, P124, DOI 10.1016/j.idcr.2018.04.010; Mahto SK, 2018, INDIAN J PHARMACOL, V50, P212, DOI 10.4103/ijp.IJP_285_18; MALAMOOD M, 2017, J CLIN DIAGN RES JCD, V11, DOI DOI 10.2147/DDDT.S125743; MALIEKAL J, 1993, ANN PHARMACOTHER, V27, P1465, DOI 10.1177/106002809302701211; MALLORY A, 1980, GASTROENTEROLOGY, V78, P813, DOI 10.1016/0016-5085(80)90689-7; MALOZOWSKI S, 1995, NEW ENGL J MED, V332, P401, DOI 10.1056/NEJM199502093320618; Mann S, 2000, J CLIN GASTROENTEROL, V31, P336, DOI 10.1097/00004836-200012000-00014; Maranan MC, 1998, PEDIATR INFECT DIS J, V17, P662, DOI 10.1097/00006454-199807000-00022; Marazuela M, 2002, ENDOCR J, V49, P315, DOI 10.1507/endocrj.49.315; Mari B, 1999, Gastroenterol Hepatol, V22, P28; MARINELLA MA, 1995, WESTERN J MED, V163, P77; Maringhini A, 1997, AM J GASTROENTEROL, V92, P166; Markov M, 2007, DIGEST DIS SCI, V52, P3275, DOI 10.1007/s10620-005-9017-9; Marot JC, 2012, ACTA CLIN BELG, V67, P229, DOI 10.2143/ACB.67.3.2062663; Maroy B, 1998, THERAPIE, V53, P602; MARTIN A, 1992, AM J PSYCHIAT, V149, P714; MARTIN T, 1989, THERAPIE, V44, P449; Martinez-Granados F, 2008, PHARM WORLD SCI, V30, P278, DOI 10.1007/s11096-007-9178-z; MAXSON CJ, 1992, AM J GASTROENTEROL, V87, P708; McArthur KE, 1996, ALIMENT PHARM THERAP, V10, P23; McBride CE, 1996, CANCER, V77, P2588, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2588::AID-CNCR24>3.0.CO;2-N; MCBRIDE MO, 1995, CLIN INFECT DIS, V21, P710, DOI 10.1093/clinids/21.3.710; MCCARTER TL, 1992, AM J GASTROENTEROL, V87, P1855; MCCARTHY AE, 1993, CLIN INFECT DIS, V17, P952, DOI 10.1093/clinids/17.5.952; MCCORMICK PA, 1985, LANCET, V1, P752; McFadden M, 2016, AUST NZ J PSYCHIAT, V50, P701, DOI 10.1177/0004867416631830; McGowan J, 2016, J CLIN EPIDEMIOL, V75, P40, DOI 10.1016/j.jclinepi.2016.01.021; MCLEAN R, 1982, LANCET, V2, P1401; McMahon MA, 2006, IR MED J, V99; Meczker A, 2018, J GASTROINTEST LIVER, V27, P189, DOI 10.15403/jgld.2014.1121.272.asa; Medical Council of Canada, CLIN LAB TESTS NORM; Memis D, 2005, J PANCREAS, V6, P344; MEMON AN, 1982, ANN INTERN MED, V97, P139, DOI 10.7326/0003-4819-97-1-139_1; Mendoza J L, 1998, An Med Interna, V15, P588; Mennecier D, 2007, GASTROEN CLIN BIOL, V31, P668, DOI 10.1016/S0399-8320(07)91915-6; Midgard R, 2005, NEUROLOGY, V65, P170, DOI 10.1212/01.wnl.0000167191.02202.5e; Miller L G, 1999, J Am Board Fam Pract, V12, P150; Mirete G, 1998, EUR J CLIN MICROBIOL, V17, P810, DOI 10.1007/s100960050194; MOFENSON HC, 1991, J TOXICOL-CLIN TOXIC, V29, P223, DOI 10.3109/15563659109038615; Moher D, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-13; Infante JM, 2008, MED CLIN-BARCELONA, V131, P519, DOI 10.1157/13127282; Monami M, 2011, CURR MED RES OPIN, V27, P57, DOI 10.1185/03007995.2011.602964; Moreno Escobosa M C, 2005, Allergol Immunopathol (Madr), V33, P175; Mori S, 2008, MOD RHEUMATOL, V18, P634, DOI 10.1007/s10165-008-0106-4; Morse D, 2018, CONSULTANT, V58, P257; Moslim MA, 2016, AM J THER, V23, pE1918, DOI 10.1097/01.mjt.0000433943.93782.8a; Mouallem M, 2003, ISRAEL MED ASSOC J, V5, P754; Moy BT, 2016, AM J HEALTH-SYST PH, V73, P286, DOI 10.2146/ajhp150298; Muchnick JS, 1999, CLIN CARDIOL, V22, P50, DOI 10.1002/clc.4960220117; Muluneh B, 2013, PHARMACOTHERAPY, V33, pe43, DOI 10.1002/phar.1208; Muniraj T, 2012, J PANCREAS, V13, P451, DOI 10.6092/1590-8577/822; Murad MH, 2018, BMJ EVID-BASED MED, V23, P60, DOI 10.1136/bmjebm-2017-110853; MURAKAWA M, 1992, ANN HEMATOL, V64, P249, DOI 10.1007/BF01738305; MURPHEY SA, 1981, ARCH INTERN MED, V141, P56, DOI 10.1001/archinte.141.1.56; MURPHY MJ, 1981, LANCET, V1, P41; Murtaza Ghulam, 2017, World J Oncol, V8, P18, DOI 10.14740/wjon1006e; Muzaffar M, 2016, AM J THER, V23, pE572, DOI 10.1097/MJT.0000000000000179; Nadir A, 1995, J Okla State Med Assoc, V88, P295; Nakagawa Nozomu, 2018, Radiol Case Rep, V13, P43, DOI 10.1016/j.radcr.2017.10.022; Nakata H, 2012, INTERNAL MED, V51, P3045, DOI 10.2169/internalmedicine.51.7876; Nango D, 2018, J PHARM HEALTH CARE, V4, DOI 10.1186/s40780-018-0111-5; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Navarro-Mingorance A, 2014, INDIAN J PEDIATR, V81, P735, DOI 10.1007/s12098-013-1222-5; NELIS GF, 1983, GASTROENTEROLOGY, V84, P1032; NG JYK, 1982, MED J AUSTRALIA, V2, P362, DOI 10.5694/j.1326-5377.1982.tb132476.x; NICOLAU DP, 1991, AM J GASTROENTEROL, V86, P1669; Nieto Y, 2000, BONE MARROW TRANSPL, V26, P109, DOI 10.1038/sj.bmt.1702471; Nigwekar Sagar U, 2004, JOP, V5, P516; Nind G, 2002, INTERN MED J, V32, P624, DOI 10.1046/j.1445-5994.2002.00298.x; Nishawala MA, 1997, J CHILD ADOL PSYCHOP, V7, P211, DOI 10.1089/cap.1997.7.211; Nishioka Sergio de A., 2003, Journal of Pharmacy Technology, V19, P283; NOTT DM, 1989, BRIT J CLIN PRACT, V43, P264; Nwogbe B, 2009, J ROY SOC MED, V102, P118, DOI 10.1258/jrsm.2009.080314; Nykamp Diane, 2013, Consult Pharm, V28, P247, DOI 10.4140/TCP.n.2013.247; Oflazoglu U, 2016, J ONCOL SCI, V2, P63; Olson EL, 2002, AM J CLIN ONCOL-CANC, V25, P342, DOI 10.1097/00000421-200208000-00004; ONEIL MG, 1991, CLIN PHARMACY, V10, P56; OTSUBO S, 1995, BRAIN DEV-JPN, V17, P219, DOI 10.1016/0387-7604(95)00025-7; Ouakaa-Kchaou Asma, 2014, Tunis Med, V92, P423; Ozaydin E, 2008, EUR J PAEDIATR NEURO, V12, P141, DOI 10.1016/j.ejpn.2007.07.006; Ozdogan O, 2007, PANCREAS, V34, P485, DOI 10.1097/MPA.0b013e3180333afb; Pais J R, 1992, Eur J Med, V1, P251; PALOYAN D, 1977, AM J DIG DIS, V22, P839, DOI 10.1007/BF01694518; Pandey K, 2013, J POSTGRAD MED, V59, P306, DOI 10.4103/0022-3859.123161; Park TY, 2010, GUT LIVER, V4, P250, DOI 10.5009/gnl.2010.4.2.250; PARKER PH, 1981, GASTROENTEROLOGY, V80, P826; Passier JLM, 2010, NETH J MED, V68, P285; Patel KM, 2017, AM J THER, V24, pE496, DOI 10.1097/MJT.0000000000000561; Patrick KA, 2018, AM J THER, V25, pE584, DOI 10.1097/MJT.0000000000000684; Paul A C, 2000, Indian J Gastroenterol, V19, P195; PAUWELS A, 1990, J CLIN GASTROENTEROL, V12, P457, DOI 10.1097/00004836-199008000-00022; PECQUENARD L, 1990, THERAPIE, V45, P453; Pedregal M, 1992, GASTROENTEROL HEPATO, V15, P433; PEDROL E, 1989, REV CLIN ESP, V184, P392; Peery AF, 2012, GASTROENTEROLOGY, V143, P1179, DOI 10.1053/j.gastro.2012.08.002; Peron J, 2014, ANTI-CANCER DRUG, V25, P478, DOI 10.1097/CAD.0000000000000076; Pezzilli R, 2004, DIGEST LIVER DIS, V36, P639, DOI 10.1016/j.dld.2004.05.002; Philip A, 2012, J PEDIAT HEMATOL ONC, V34, P406, DOI 10.1097/MPH.0b013e318257dc7a; Picardo Sherman, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2017-222554; Plaza MM, 1999, CLIN NEPHROL, V51, P187; PLOTNICK BH, 1985, ANN INTERN MED, V103, P891, DOI 10.7326/0003-4819-103-6-891; POLDERMANS D, 1988, AM J GASTROENTEROL, V83, P578; Poropat G, 2018, UNITED EUR GASTROENT, V6, P1206, DOI 10.1177/2050640618781168; Prajapati S, 2010, INDIAN J PHARMACOL, V42, P324, DOI 10.4103/0253-7613.70400; PRIGOGINE T, 1978, ACTA CLIN BELG, V33, P272; Priya G, 2005, ACTA ANAESTH SCAND, V49, P1381, DOI 10.1111/j.1399-6576.2005.00751.x; Prot-Labarthe S, 2010, PEDIATR INFECT DIS J, V29, P890, DOI 10.1097/INF.0b013e3181e83a85; Quan W, 2018, CHINESE MED J-PEKING, V131, DOI 10.4103/0366-6999.237390; RABASSA AA, 1994, ANN INTERN MED, V121, P433, DOI 10.7326/0003-4819-121-6-199409150-00007; RADKE M, 1993, J PEDIATR GASTR NUTR, V16, P337, DOI 10.1097/00005176-199304000-00022; Raiss H, 2017, J GASTROINTEST ONCOL, V8, pE80, DOI 10.21037/jgo.2017.08.06; Raja M, 2011, OPEN NEUROPSYCHOPHAR, V4, P5; RAMDANI M, 1991, GASTROEN CLIN BIOL, V15, P986; Ratkovic M, 2016, THER APHER DIAL, V20, P208, DOI 10.1111/1744-9987.12371; RIEMENSCHNEIDER TA, 1968, PEDIATRICS, V41, P428; Rion R J, 1994, J Am Board Fam Pract, V7, P74; Rizos E, 2015, IN VIVO, V29, P529; ROBERGE RJ, 1994, J TOXICOL-CLIN TOXIC, V32, P425, DOI 10.3109/15563659409011044; ROBLIN X, 1990, ANN GASTROENT HEPATO, V26, P233; ROBLIN X, 1992, GASTROEN CLIN BIOL, V16, P96; Rodier JM, 1996, J CANCER RES CLIN, V122, P132, DOI 10.1007/BF01226272; Rodrigo L, 2001, AM J GASTROENTEROL, V96, P2268, DOI 10.1016/S0002-9270(01)02545-X; Roguedas AM, 2001, PRESSE MED, V30, P1105; Romero Ganuza F Javier, 2008, Gastroenterol Hepatol, V31, P264; ROSE E, 1991, PEDIATRIE, V46, P831; Rosenfeld GA, 2011, J MED CASE REPORTS, V5; Rossor AM, 2007, J CLIN PSYCHOPHARM, V27, P395, DOI 10.1097/01.jcp.0000264988.55603.bb; ROUSH MK, 1991, ANN INTERN MED, V114, P298, DOI 10.7326/0003-4819-114-4-298; RUBIN R, 1994, AM J GASTROENTEROL, V89, P789; Sabre A, 2015, BMJ CASE REP, V2015; SACHEDINA B, 1989, ANN INTERN MED, V110, P490, DOI 10.7326/0003-4819-110-6-490; Sadoff J, 1997, J PEDIATR SURG, V32, P860, DOI 10.1016/S0022-3468(97)90636-9; SADOUL JL, 1991, AM J MED, V90, P763; Saez-Royuela F, 1988, GASTROENTEROL HEPATO, V11, P434; SAFER L, 1995, SEM HOP PARIS, V71, P123; Sakhri J, 2010, J PANCREAS, V11, P382; SALAH A, 1994, PRESSE MED, V23, P49; Saleem AF, 2015, JCPSP-J COLL PHYSICI, V25, P299, DOI 04.2015/JCPSP.299300; SALMERON S, 1986, ANN INTERN MED, V105, P140, DOI 10.7326/0003-4819-105-1-140_2; Samanta S, 2014, INDIAN J ANAESTH, V58, P323, DOI 10.4103/0019-5049.135049; Briongos-Figuero LS, 2007, ENFERM INFEC MICR CL, V25, P217, DOI 10.1016/S0213-005X(07)74266-0; Monte Sanchez-Canete A, 1998, Aten Primaria, V22, P260; Nogueira Soriano JM, 1991, GASTROENTEROL HEPATO, V14, P44; Sanchez AJ, 2004, INFECT MED, V21, P622; SANFORD KA, 1988, ANN INTERN MED, V109, P756, DOI 10.7326/0003-4819-109-9-756; Santos J, 2000, An Med Interna, V17, P562; SASAKI M, 1980, LANCET, V1, P1196; Sato K, 2007, CLIN THER, V29, P1468, DOI 10.1016/j.clinthera.2007.07.012; Sato K, 2006, CLIN PHARMACOL THER, V80, P554, DOI 10.1016/j.clpt.2006.08.007; SAULEDA J, 1994, ANN PHARMACOTHER, V28, P52, DOI 10.1177/106002809402800111; Schouwenberg BJJW, 2003, NETH J MED, V61, P266; SCHULER D, 1976, Haematologia, V10, P205; Seo JH, 2013, INTERNAL MED, V52, P2245, DOI 10.2169/internalmedicine.52.0697; Sepulveda Vildosola AC, 1999, REV GASTROENTEROL ME, V64, P186; Sevastru S, 2012, BMJ CASE REP, V2012; Sevencan NO, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013284; Sevenet F, 1999, GASTROEN CLIN BIOL, V23, P1256; Sevin Adrienne, 2013, J Oncol Pharm Pract, V19, P257, DOI 10.1177/1078155212457968; Shafqet MA, 2015, AM J EMERG MED, V33, DOI 10.1016/j.ajem.2014.08.056; Shindano A, 2007, ACTA GASTRO-ENT BELG, V70, P32; Shirota T, 2015, CLIN J GASTROENTEROL, V8, P97, DOI 10.1007/s12328-015-0553-3; SIEFKIN AD, 1980, ANN INTERN MED, V93, P932, DOI 10.7326/0003-4819-93-6-932_2; SIEMERS RF, 1985, CANCER-AM CANCER SOC, V56, P1940, DOI 10.1002/1097-0142(19851015)56:8<1940::AID-CNCR2820560808>3.0.CO;2-N; Sinclair DB, 2004, J CHILD NEUROL, V19, P498, DOI 10.1177/08830738040190070401; SINGH G, 1995, GENITOURIN MED, V71, P130; Singh HK, 2016, J PHARMACOL PHARMACO, V7, P38, DOI 10.4103/0976-500X.179365; Siwach V, 1999, NEPHROL DIAL TRANSPL, V14, P2495, DOI 10.1093/ndt/14.10.2495; Slim R, 2010, J PANCREAS, V11, P85; SOTOMATSU M, 1995, AM J HEMATOL, V48, P211, DOI 10.1002/ajh.2830480321; SOUWEINE B, 1991, DICP ANN PHARMAC, V25, P1137, DOI 10.1177/106002809102501024; Soylu AR, 2004, J CLIN GASTROENTEROL, V38, P134, DOI 10.1097/00004836-200402000-00010; Srivali Narat, 2015, J Basic Clin Pharm, V6, P101, DOI 10.4103/0976-0105.160753; STANDRIDGE JB, 1994, SOUTHERN MED J, V87, P179, DOI 10.1097/00007611-199402000-00005; Steiner RE, 2018, ACTA HAEMATOL-BASEL, V139, P67, DOI 10.1159/000484655; STENVINKEL P, 1988, ACTA MED SCAND, V224, P89; Stephenson I, 2001, AM J GASTROENTEROL, V96, P2271, DOI 10.1016/S0002-9270(01)02547-3; Storer A, 2011, ADV EMERG NURS J, V33, P23, DOI 10.1097/TME.0b013e318209c57e; Straumann A, 1998, GASTROENTEROLOGY, V115, P452, DOI 10.1016/S0016-5085(98)70212-4; Subramaniam S, 2013, J NATL COMPR CANC NE, V11, P5, DOI 10.6004/jnccn.2013.0003; Sue M, 2013, CLIN MED INSIGHT-CAS, V6, P23, DOI 10.4137/CCRep.S10856; SUGERMAN HJ, 1989, AM SURGEON, V55, P536; Sura ME, 2000, ANN PHARMACOTHER, V34, P1152; SURINACH JM, 1993, REV CLIN ESP, V192, P458; Taguchi M, 1999, CLIN ENDOCRINOL, V51, P667, DOI 10.1046/j.1365-2265.1999.00888.x; Tahan V, 2007, J GASTROINTEST LIVER, V16, P224; Taira N, 2001, SURG TODAY, V31, P1027, DOI 10.1007/s005950170018; Talamo G, 2016, J ONCOL PHARM PRACT, V22, P332, DOI 10.1177/1078155214563813; TALWAR D, 1994, J CHILD NEUROL, V9, P36, DOI 10.1177/088307389400900107; Tan C L, 1974, Singapore Med J, V15, P278; TAN WW, 1995, ANN PHARMACOTHER, V29, P22, DOI 10.1177/106002809502900104; Tannir NM, 2000, LEUKEMIA LYMPHOMA, V39, P647, DOI 10.3109/10428190009113396; TARGARONA EM, 1990, MED CLIN-BARCELONA, V95, P116; TEILLET L, 1991, GASTROEN CLIN BIOL, V15, P265; Tenenbein MS, 2005, PEDIATR EMERG CARE, V21, P675, DOI 10.1097/01.pec.0000181419.49106.ec; Teng HW, 2005, JPN J CLIN ONCOL, V35, P94, DOI 10.1093/jjco/hyi027; Terzi C, 1999, LANCET, V354, P1789, DOI 10.1016/S0140-6736(99)03701-0; Thaker SJ, 2016, J PHARMACOL PHARMACO, V7, P31, DOI 10.4103/0976-500X.179361; Ting TW, 2012, ANAESTH INTENS CARE, V40, P561; TOBIAS JD, 1995, CLIN PEDIATR, V34, P446, DOI 10.1177/000992289503400810; Tobias PE, 2020, J PHARM PRACT, V33, P222, DOI 10.1177/0897190018782787; Top PC, 2005, PEDIATR BLOOD CANCER, V44, P95, DOI 10.1002/pbc.20187; TOROSIS J, 1987, J CLIN GASTROENTEROL, V9, P580, DOI 10.1097/00004836-198710000-00021; Torrus D, 1996, AM J GASTROENTEROL, V91, P820; Toubanakis C, 2003, EUR J GASTROEN HEPAT, V15, P933, DOI 10.1097/00042737-200308000-00019; Tragnone A, 1996, ITAL J GASTROENTEROL, V28, P102; TRAN K, 1991, J CLIN GASTROENTEROL, V13, P715, DOI 10.1097/00004836-199112000-00021; Tripathy N R, 2008, J Assoc Physicians India, V56, P987; Trivedi CD, 2005, J CLIN GASTROENTEROL, V39, P709, DOI 10.1097/01.mcg.0000173929.60115.b4; Tsesmeli NE, 2007, EUR J GASTROEN HEPAT, V19, P805, DOI 10.1097/MEG.0b013e328133f2fb; Tsigrelis C, 2006, WORLD J GASTROENTERO, V12, P7055, DOI 10.3748/wjg.v12.i43.7055; Tuon FF, 2008, BRAZ J INFECT DIS, V12, P263, DOI 10.1590/S1413-86702008000400001; Twohig P, 2019, J GASTROINTEST CANC, V50, P137, DOI 10.1007/s12029-017-9980-3; Tysk C, 2002, J CLIN GASTROENTEROL, V35, P406, DOI 10.1097/00004836-200211000-00010; UNDERWOOD TW, 1993, CLIN PHARMACY, V12, P440; Urru SAM, 2014, DRUGS R&D, V14, P9, DOI 10.1007/s40268-014-0036-x; Valencia M E, 2000, An Med Interna, V17, P54; Vallianou N, 2017, ARCH HELL MED, V34, P821; VANDERHEIDE H, 1981, BRIT MED J, V282, P1930, DOI 10.1136/bmj.282.6280.1930; VANWALRAVEN AA, 1982, CAN MED ASSOC J, V126, P894; VELASCO FP, 1991, MED CLIN-BARCELONA, V97, P473; Velicia M R, 1999, Gastroenterol Hepatol, V22, P186; Venkatesh PGK, 2011, J PANCREAS, V12, P250; Ventura C, 2013, DIGEST DIS SCI, V58, P887, DOI 10.1007/s10620-013-2576-2; Veri K, 2013, MED LITH, V49, P487; Verma Rajanshu, 2016, Prim Care Companion CNS Disord, V18, DOI 10.4088/PCC.16l01953; Versleijen MWJ, 2005, NETH J MED, V63, P275; VIDAL J, 1994, PANCREAS, V9, P395, DOI 10.1097/00006676-199405000-00021; Vignon RK, 2009, J GASTROINTEST LIVER, V18, P512; VILLAMIL A, 1991, SOUTH MED J, V84, P796, DOI 10.1097/00007611-199106000-00034; Waage Christian, 2004, JOP, V5, P388; Wang HH, 2014, LEUKEMIA LYMPHOMA, V55, P1404, DOI 10.3109/10428194.2013.831850; Weber A, 2008, GASTROEN CLIN BIOL, V32, P247, DOI 10.1016/j.gcb.2008.01.028; Wehmeier PM, 2003, J CLIN PSYCHOPHARM, V23, P102, DOI 10.1097/00004714-200302000-00017; WILKINSON ML, 1981, LANCET, V1, P610; WILLIAMS LHP, 1983, ARCH DIS CHILD, V58, P543, DOI 10.1136/adc.58.7.543; Wong PWK, 1998, SOUTHERN MED J, V91, P202, DOI 10.1097/00007611-199802000-00015; WOOD G, 1991, AUST NZ J MED, V21, P341, DOI 10.1111/j.1445-5994.1991.tb04702.x; Wu F, 2014, ONCOL LETT, V7, P1305, DOI 10.3892/ol.2014.1871; WU SM, 1978, ANN INTERN MED, V88, P128, DOI 10.7326/0003-4819-88-1-128_2; Wurm S, 2015, PANCREATOLOGY, V15, P570, DOI 10.1016/j.pan.2015.08.003; WYLLIE E, 1984, AM J DIS CHILD, V138, P912, DOI 10.1001/archpedi.1984.02140480014005; Yahiaoui N, 2017, EUR J CLIN PHARMACOL, V73, P645, DOI 10.1007/s00228-017-2207-5; Yamada T, 2016, INTERNAL MED, V55, P3495, DOI 10.2169/internalmedicine.55.7104; Yaman A, 2013, PEDIATR EMERG CARE, V29, P659, DOI 10.1097/PEC.0b013e31828ec2d5; Yang M, 2012, THYROID, V22, P94, DOI 10.1089/thy.2011.0210; Yang SH, 2002, AM J PSYCHIAT, V159, P1435, DOI 10.1176/appi.ajp.159.8.1435; Yazdani K, 2002, MEDICINE, V81, P305, DOI 10.1097/00005792-200207000-00006; Yen JM, 2017, EUR GERIATR MED, V8, P377, DOI 10.1016/j.eurger.2017.07.006; Yi PH, 2013, NETH J MED, V71, P104; Yoshizawa Y, 1999, DERMATOLOGY, V198, P304, DOI 10.1159/000018137; Youssef SS, 2005, INT J CLIN PHARM TH, V43, P558; Yu Chun-Hsien, 1994, Journal of the Formosan Medical Association, V93, P441; Yutsudo Y, 1997, ANN HEMATOL, V74, P295, DOI 10.1007/s002770050304; ZIMMERMANN AE, 1993, ANN PHARMACOTHER, V27, P36, DOI 10.1177/106002809302700108; ZINBERG J, 1991, AM J GASTROENTEROL, V86, P1251; ZUGER A, 1986, JAMA-J AM MED ASSOC, V256, P2383, DOI 10.1001/jama.256.17.2383; ZYGMUNT DJ, 1986, WESTERN J MED, V144, P461	616	35	36	8	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2020	15	4							e0231883	10.1371/journal.pone.0231883	http://dx.doi.org/10.1371/journal.pone.0231883			46	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR9LH	32302358	Green Published, gold			2023-01-03	WOS:000536016100060
J	Dossett, ML; Fricchione, GL; Benson, H				Dossett, Michelle L.; Fricchione, Gregory L.; Benson, Herbert			A New Era for Mind-Body Medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								The role of excessive or persistent stress as a major contributor to morbidity and mortality is well recognized. Meditation and other mind-body practices are increasingly popular for their perceived physical and mental health benefits and stress relief.	[Dossett, Michelle L.; Benson, Herbert] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Dossett, Michelle L.; Fricchione, Gregory L.; Benson, Herbert] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA; [Fricchione, Gregory L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Dossett, Michelle L.; Fricchione, Gregory L.; Benson, Herbert] Harvard Med Sch, Boston, MA 02115 USA; [Dossett, Michelle L.] Univ Calif Davis, Sacramento, CA 95817 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of California System; University of California Davis	Dossett, ML (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.; Dossett, ML (corresponding author), Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA.; Dossett, ML (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Dossett, ML (corresponding author), Univ Calif Davis, Sacramento, CA 95817 USA.				NCCIH NIH HHS [K23 AT009218] Funding Source: Medline	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Clarke TC, 2018, NCHS DATA BRIEF, V325, P1; Maynard B. R., 2017, CAMPBELL SYSTEMATIC; STOECKLE JD, 1964, J CHRON DIS, V17, P959, DOI 10.1016/0021-9681(64)90165-1; WALLACE RK, 1971, AM J PHYSIOL, V221, P795, DOI 10.1152/ajplegacy.1971.221.3.795; World Health Organization, 2017, DEPR OTH COMM MENT D	5	24	24	2	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 9	2020	382	15					1390	1391		10.1056/NEJMp1917461	http://dx.doi.org/10.1056/NEJMp1917461			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE6DO	32268025	Green Accepted			2023-01-03	WOS:000526813400005
J	Chalabi, M; Fanchi, LF; Dijkstra, KK; Van den Berg, JG; Aalbers, AG; Sikorska, K; Lopez-Yurda, M; Grootscholten, C; Beets, GL; Snaebjornsson, P; Maas, M; Mertz, M; Veninga, V; Bounova, G; Broeks, A; Beets-Tan, RG; de Wijkerslooth, TR; van Lent, AU; Marsman, HA; Nuijten, E; Kok, NF; Kuiper, M; Verbeek, WH; Kok, M; Van Leerdam, ME; Schumacher, TN; Voest, EE; Haanen, JB				Chalabi, Myriam; Fanchi, Lorenzo F.; Dijkstra, Krijn K.; Van den Berg, Jose G.; Aalbers, Arend G.; Sikorska, Karolina; Lopez-Yurda, Marta; Grootscholten, Cecile; Beets, Geerard L.; Snaebjornsson, Petur; Maas, Monique; Mertz, Marjolijn; Veninga, Vivien; Bounova, Gergana; Broeks, Annegien; Beets-Tan, Regina G.; de Wijkerslooth, Thomas R.; van Lent, Anja U.; Marsman, Hendrik A.; Nuijten, Elvira; Kok, Niels F.; Kuiper, Maria; Verbeek, Wieke H.; Kok, Marleen; Van Leerdam, Monique E.; Schumacher, Ton N.; Voest, Emile E.; Haanen, John B.			Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers	NATURE MEDICINE			English	Article							DNA MISMATCH REPAIR; NIVOLUMAB	PD-1 plus CTLA-4 blockade is highly effective in advanced-stage, mismatch repair (MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We postulated a higher efficacy of neoadjuvant immunotherapy in early-stage colon cancers. In the exploratory NICHE study (ClinicalTrials.gov: NCT03026140), patients with dMMR or pMMR tumors received a single dose of ipilimumab and two doses of nivolumab before surgery, the pMMR group with or without celecoxib. The primary objective was safety and feasibility; 40 patients with 21 dMMR and 20 pMMR tumors were treated, and 3 patients received nivolumab monotherapy in the safety run-in. Treatment was well tolerated and all patients underwent radical resections without delays, meeting the primary endpoint. Of the patients who received ipilimumab + nivolumab (20 dMMR and 15 pMMR tumors), 35 were evaluable for efficacy and translational endpoints. Pathological response was observed in 20/20 (100%; 95% exact confidence interval (CI): 86-100%) dMMR tumors, with 19 major pathological responses (MPRs, <= 10% residual viable tumor) and 12 pathological complete responses. In pMMR tumors, 4/15 (27%; 95% exact CI: 8-55%) showed pathological responses, with 3 MPRs and 1 partial response. CD8(+)PD-1(+) T cell infiltration was predictive of response in pMMR tumors. These data indicate that neoadjuvant immunotherapy may have the potential to become the standard of care for a defined group of colon cancer patients when validated in larger studies with at least 3 years of disease-free survival data.	[Chalabi, Myriam; Grootscholten, Cecile; de Wijkerslooth, Thomas R.; Kuiper, Maria; Verbeek, Wieke H.; Van Leerdam, Monique E.; Voest, Emile E.] Netherlands Canc Inst, Gastrointestinal Oncol, Amsterdam, Netherlands; [Chalabi, Myriam; Fanchi, Lorenzo F.; Dijkstra, Krijn K.; Veninga, Vivien; Schumacher, Ton N.; Voest, Emile E.; Haanen, John B.] Netherlands Canc Inst, Mol Oncol & Immunol, Amsterdam, Netherlands; [Chalabi, Myriam; Kok, Marleen; Haanen, John B.] Netherlands Canc Inst, Med Oncol, Amsterdam, Netherlands; [Fanchi, Lorenzo F.; Dijkstra, Krijn K.; Veninga, Vivien; Bounova, Gergana; Schumacher, Ton N.; Voest, Emile E.] Oncode Inst, Utrecht, Netherlands; [Van den Berg, Jose G.; Snaebjornsson, Petur] Netherlands Canc Inst, Pathol, Amsterdam, Netherlands; [Aalbers, Arend G.; Beets, Geerard L.; Kok, Niels F.] Netherlands Canc Inst, Surg Oncol, Amsterdam, Netherlands; [Sikorska, Karolina; Lopez-Yurda, Marta; Nuijten, Elvira] Netherlands Canc Inst, Biometr, Amsterdam, Netherlands; [Lopez-Yurda, Marta] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands; [Beets, Geerard L.; Beets-Tan, Regina G.] Maastricht Univ, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands; [Maas, Monique; Beets-Tan, Regina G.] Netherlands Canc Inst, Radiol, Amsterdam, Netherlands; [Mertz, Marjolijn] Netherlands Canc Inst, Bioimaging Facil, Amsterdam, Netherlands; [Bounova, Gergana] Netherlands Canc Inst, Mol Carcinogenesis, Amsterdam, Netherlands; [Broeks, Annegien] Netherlands Canc Inst, Core Facil Mol Pathol & Biobanking, Amsterdam, Netherlands; [van Lent, Anja U.] Onze Lieve Vrouw Hosp, Gastroenterol & Hepatol, Amsterdam, Netherlands; [Marsman, Hendrik A.] Onze Lieve Vrouw Hosp, Surg, Amsterdam, Netherlands; [Kok, Marleen] Netherlands Canc Inst, Tumor Biol & Immunol, Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Maastricht University; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Onze Lieve Vrouwe Gasthuis Hospital; Onze Lieve Vrouwe Gasthuis Hospital; Netherlands Cancer Institute	Chalabi, M; Voest, EE (corresponding author), Netherlands Canc Inst, Gastrointestinal Oncol, Amsterdam, Netherlands.; Chalabi, M; Voest, EE (corresponding author), Netherlands Canc Inst, Mol Oncol & Immunol, Amsterdam, Netherlands.; Chalabi, M (corresponding author), Netherlands Canc Inst, Med Oncol, Amsterdam, Netherlands.; Voest, EE (corresponding author), Oncode Inst, Utrecht, Netherlands.	m.chalabi@nki.nl; e.voest@nki.nl	van Leerdam, Monique/AAV-9185-2020; Beets, Geerard/G-2682-2013; Schumacher, Ton/Y-2432-2019; Haanen, John/AAD-8578-2022; Beets-Tan, Regina/AAZ-9119-2020; Haanen, John/AAD-8534-2022	van Leerdam, Monique/0000-0002-5719-3208; Beets, Geerard/0000-0002-1671-9912; Schumacher, Ton/0000-0003-0517-8804; Haanen, John/0000-0001-5884-7704; Lopez-Yurda, Marta/0000-0003-3678-3222; Snaebjornsson, Petur/0000-0002-1086-8108; Mertz, Marjolijn/0000-0002-9188-3579	BMS International Immuno-Oncology Network; NKI	BMS International Immuno-Oncology Network; NKI	We thank all patients and their families for participating in the present study. We thank: the Core Facility of Molecular Pathology and Biobanking, L. Braaf, S. Cornelissen and D. Peters for their support in processing of samples; C. Van Rooijen for setting up CD8/PD-1 co-stains; R. Kerkhoven and the Genomics Core Facility for their support with sequencing; the Flow Cytometry Core Facility for their support in flow cytometry; J. Lips from Adaptive Biotechnologies for his support; L. Al-van Wijck from the scientific administration department for data management; L. Hoes, F. Weeber, J. Westra, S. Visser and S. Kaing for facilitating sample acquisition and processing; A. Van der Leun for support in TIL isolation; T. Korse, M. Lucas and E. Platte for PBMC acquisition and processing; A. Atsma, P. Bottenberg, S. Oosterloo, M. van Wijngaarden, P. Den Hartog and S. Dokter for patient care; M. Mok, I. Honing, M. Van Nes and N. De Jong for patient care in the OLVG; P. Drillenburg for sample acquisition; Merus for provision of anti-PD-1 for in vitro experiments; M. Toebes, X. Kong and M. Ligtenberg for the lentiviral HLA-A2 vector and MART-1 peptide; S. Vanhoutvin for legal support; A. Evans, D. Tauriello, G. Sonke and H. Van Tinteren for scientific input. The present study was funded by the BMS International Immuno-Oncology Network and sponsored by the NKI. The funding source had no role in design and execution of the study, data analysis or writing of the manuscript.	Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Andre T, 2015, J CLIN ONCOL, V33, P4176, DOI 10.1200/JCO.2015.63.4238; [Anonymous], 2016, ANN ONCOL; [Anonymous], 2019, ANN ONCOL S5, DOI DOI 10.1093/ANNONC/MDZ246.001; [Anonymous], REV COMM TERM CRIT A; Asaoka Y, 2015, NEW ENGL J MED, V373, P1979, DOI 10.1056/NEJMc1510353; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Blank CU, 2016, SCIENCE, V352, P658, DOI 10.1126/science.aaf2834; Brierley J, 2017, TNM CLASSIFICATION M, VEighth, DOI DOI 10.1002/9780471420194.TNMC26.PUB3; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Cattaneo CM, 2020, NAT PROTOC, V15, P15, DOI 10.1038/s41596-019-0232-9; Cloughesy TF, 2019, NAT MED, V25, P477, DOI 10.1038/s41591-018-0337-7; Cottrell TR, 2018, ANN ONCOL, V29, P1853, DOI 10.1093/annonc/mdy218; Dijkstra KK, 2018, CELL, V174, P1586, DOI 10.1016/j.cell.2018.07.009; Dudley ME, 2003, J IMMUNOTHER, V26, P332, DOI 10.1097/00002371-200307000-00005; Fabrizio DA, 2018, J GASTROINTEST ONCOL, V9, P610, DOI 10.21037/jgo.2018.05.06; Germano G, 2017, NATURE, V552, P116, DOI 10.1038/nature24673; Gomez-Eerland R, 2014, HUM GENE THER METHOD, V25, P277, DOI 10.1089/hgtb.2014.004; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Huang AC, 2019, NAT MED, V25, P454, DOI 10.1038/s41591-019-0357-y; Jorritsma A, 2007, BLOOD, V110, P3564, DOI 10.1182/blood-2007-02-075010; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maby P, 2015, CANCER RES, V75, P3446, DOI 10.1158/0008-5472.CAN-14-3051; Mandal R, 2019, SCIENCE, V364, P485, DOI 10.1126/science.aau0447; MANDARD AM, 1994, CANCER, V73, P2680, DOI 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025; Mooi JK, 2018, ANN ONCOL, V29, P2240, DOI 10.1093/annonc/mdy410; Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901; Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9; Powles T, 2019, NAT MED, V25, P1706, DOI 10.1038/s41591-019-0628-7; Romero P, 2002, IMMUNOL REV, V188, P81, DOI 10.1034/j.1600-065X.2002.18808.x; Sinicrope FA, 2013, J CLIN ONCOL, V31, P3664, DOI 10.1200/JCO.2013.48.9591; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Tetzlaff MT, 2018, ANN ONCOL, V29, P1861, DOI 10.1093/annonc/mdy226; Thommen DS, 2018, NAT MED, V24, P994, DOI 10.1038/s41591-018-0057-z; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Yang X, 2018, NEW ENGL J MED, V379, DOI 10.1056/NEJMc1808251; Young L, 2010, NAT PROTOC, V5, P929, DOI 10.1038/nprot.2010.43; Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015	46	345	371	7	72	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2020	26	4					566	+		10.1038/s41591-020-0805-8	http://dx.doi.org/10.1038/s41591-020-0805-8		APR 2020	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH1UE	32251400	Green Published			2023-01-03	WOS:000524576000002
J	Imai, H; Hirai, T; Kumazawa, R; Nakagawa, S; Yonezawa, A; Matsubara, K; Nakao, H				Imai, Hirohisa; Hirai, Takuya; Kumazawa, Ryosuke; Nakagawa, Shunsaku; Yonezawa, Atsushi; Matsubara, Kazuo; Nakao, Hiroyuki			Prevalence of and risk factors for adverse events in Alzheimer's patients receiving anti-dementia drugs in at-home care	PLOS ONE			English	Article							CHOLINESTERASE-INHIBITORS; DEMENTIA; DISEASE; DONEPEZIL; MEMANTINE; SAFETY; COHORT; TRENDS	Objective The objective of this study was to clarify the types and prevalence of, and the risk factors for, the adverse events that occur in patients receiving anti-dementia drugs. Methods A questionnaire survey was conducted. The respondents were pharmacists who were dispensing anti-dementia drugs. The pharmacists responded to questions about patients who were receiving anti-dementia drugs delivered to them at home by the pharmacists. The survey questions included questions about whether or not the patients experienced adverse reactions to the drugs, about the patients' background characteristics, about the numbers of drugs the patients were taking when the pharmacists first visited the patients at home, and about the pharmacists' assessments of the appropriateness of the use of the anti-dementia drugs. Results Data were collected on 3712 patients from 1673 pharmacies in a nationwide survey. Antidementia drugs had been prescribed to 863 of these patients; and 801 (92.8%) of these 863 patients were 75 years of age or older, and. confirmed adverse events occurred in 170 (21%) of these 863 patients. The most common adverse event was excitation/anxiety, at 45.1%. A multivariate analysis found that polypharmacy (10 or more types of drugs per day) (P = 0.030), inappropriate use (P = 0.002), and irregular medication use (P = 0.034) were risk factors. Interpretation In order to avoid adverse events when using anti-dementia drugs, doctors and pharmacists should carefully examine the prescribing of multiple medications, assess the applicability of the use of anti-dementia drugs, and investigate how to best manage patients' drug use.	[Imai, Hirohisa] Univ Tokyo, Grad Sch Med, Dept Med & Pharmaceut Community Healthcare, Tokyo, Japan; [Hirai, Takuya] Univ Tokyo, Sch Publ Hlth, Grad Sch Med, Dept Biostat, Tokyo, Japan; [Kumazawa, Ryosuke] Univ Tokyo, Sch Publ Hlth, Dept Clin Epidemiol & Hlth Econ, Tokyo, Japan; [Nakagawa, Shunsaku; Yonezawa, Atsushi; Matsubara, Kazuo] Kyoto Univ Hosp, Dept Clin Pharmacol & Therapeut, Kyoto, Japan; [Nakao, Hiroyuki] Miyazaki Prefectural Nursing Univ, Fac Nursing, Basic Profess Educ Course, Human Nursing 3, Miyazaki, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Kyoto University	Imai, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Med & Pharmaceut Community Healthcare, Tokyo, Japan.	imai.hiro@m.u-tokyo.ac.jp		Imai, Hirohisa/0000-0003-3228-0417				Alva Gustavo, 2008, Psychiatry (Edgmont), V5, P27; [Anonymous], 2006, LANCET NEUROL, V5, P103, DOI 10.1016/S1474-4422(06)70328-3; [Anonymous], 2011, NICE SUBMISSION EVID; [Anonymous], POL GUID DEM; Awata Shuichi, 2016, Seishin Shinkeigaku Zasshi, V118, P77; Calvo-Perxas L, 2017, DRUG AGING, V34, P303, DOI 10.1007/s40266-017-0446-x; Credence Research, 2015, ALZH THER MARK DRUG; Donegan K, 2017, LANCET PUBLIC HEALTH, V2, pE149, DOI 10.1016/S2468-2667(17)30031-2; Gill SS, 2009, ARCH INTERN MED, V169, P867, DOI 10.1001/archinternmed.2009.43; Grossberg GT, 2003, CURR THER RES CLIN E, V64, P216, DOI 10.1016/S0011-393X(03)00059-6; Haeffner-Cavaillon N, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0144-z; Kanagaratnam L, 2014, DRUG AGING, V31, P769, DOI 10.1007/s40266-014-0206-0; Klinger T, 2005, CURR MED RES OPIN, V21, P723, DOI 10.1185/030079905X43668; Kmietowicz Z, 2006, BRIT MED J, V333, P165, DOI 10.1136/bmj.333.7560.165; Langa KM, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0118-1; Leroi I, 2018, NEURODEGENER DIS MAN, V8, P257, DOI 10.2217/nmt-2018-0007; Carrasco MM, 2011, ALZ DIS ASSOC DIS, V25, P333, DOI 10.1097/WAD.0b013e318212ab7a; Martin RM, 1998, BRIT MED J, V317, P119, DOI 10.1136/bmj.317.7151.119; Mayor S, 2006, BRIT MED J, V332, P195, DOI 10.1136/bmj.332.7535.195; Mehta N, 2017, J AM GERIATR SOC, V65, P2213, DOI 10.1111/jgs.15020; Miller MA, 2001, INT J TOXICOL, V20, P149, DOI 10.1080/109158101317097728; Mimica N, 2009, PSYCHIAT DANUB, V21, P108; Mount C, 2006, NAT MED, V12, P780, DOI 10.1038/nm0706-780; National Institute for Health and Care Excellence (NICE), 2006, DEMENTIA SUPPORTING; National Institute for Health and Care Excellence (UK), 2018, DEMENTIA ASSESSMENT; Nichols E, 2019, LANCET NEUROL, V18, P88, DOI 10.1016/S1474-4422(18)30403-4; Norgaard A, 2016, J ALZHEIMERS DIS, V49, P211, DOI 10.3233/JAD-150481; Okumura Y, 2018, INT J GERIATR PSYCH, V33, P1286, DOI 10.1002/gps.4892; Perrie Y, 2012, J CONTROL RELEASE, V161, P389, DOI 10.1016/j.jconrel.2012.01.020; Reisberg B., 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Riepe MW, 2007, CURR MED RES OPIN, V23, P1829, DOI 10.1185/030079907X210787; Stocks SJ, 2017, DRUG SAFETY, V40, P679, DOI 10.1007/s40264-017-0538-x; Tricco AC, 2018, J AM GERIATR SOC, V66, P170, DOI 10.1111/jgs.15069; Williams D, 1999, IRISH J MED SCI, V168, P257, DOI 10.1007/BF02944353; Winslow BT, 2011, AM FAM PHYSICIAN, V83, P1403; Wu YT, 2018, INT J EPIDEMIOL, V47, P709, DOI 10.1093/ije/dyy007	36	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2020	15	4							e0231226	10.1371/journal.pone.0231226	http://dx.doi.org/10.1371/journal.pone.0231226			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR8OD	32251456	gold, Green Published			2023-01-03	WOS:000535955000045
J	Girard, M; Hu, D; Pradervand, N; Neuenschwander, S; Bee, G				Girard, M.; Hu, D.; Pradervand, N.; Neuenschwander, S.; Bee, G.			Chestnut extract but not sodium salicylate decreases the severity of diarrhea and enterotoxigenic Escherichia coli F4 shedding in artificially infected piglets	PLOS ONE			English	Article							ANTIBACTERIAL ACTIVITIES; ANTIMICROBIAL ACTIVITY; ANTIBIOTIC-RESISTANCE; ETEC; PERFORMANCE; PIG; POLYPHENOLS; ADHESION; TANNINS; GROWTH	The development of alternatives to antibiotics is crucial to limiting the incidence of antimicrobial resistance, especially in prophylactic and metaphylactic use to control post-weaning diarrhea (PWD). Feed additives, including bioactive compounds, could be a promising alternative. This study aimed to test two bioactive compounds, sodium salicylate (SA) and a chestnut extract (CE) containing hydrolysable tannins, on the occurrence of PWD. At weaning, 72 piglets were assigned to four treatments that combined two factors: CE supplementation (with 2% of CE (CE+) or without (CE-)) and SA supplementation (with 35 mg/kg BW of SA (SA+) or without (SA-)). Then, 4 days after weaning, all piglets were infected with a suspension at 108 CFU/ml of enterotoxigenic Escherichia coli (ETEC F4ac). Each piglet had free access to an electrolyte solution containing, or not, SA. This SA supplementation was administered for 5 days (i.e., from the day of infection (day 0) to 4 days post-infection (day 4). During the 2 weeks post-infection, supplementation with SA had no effect (P > 0.05) on growth performances nor on fecal scores. A significant SA x time interaction (P < 0.01) for fecal scores and the percentage of diarrhea indicated that piglets with SA did not recover faster and did have a second episode of diarrhea. In contrast to SA treatment, inclusion of CE increased (P < 0.05) growth performances and feed intake. In the first week post-infection, CE decreased (P < 0.001) the overall fecal scores, the percentage of piglets with diarrhea, the days in diarrhea, and ETEC shedding in the feces. There was a SAxCE interaction (P < 0.05) for ETEC shedding, suggesting a negative effect of combining SA with CE. This study highlighted that, in contrast to SA, CE could represent a promising alternative to antibiotics immediately after weaning for improving growth performance and reducing PWD.	[Girard, M.; Pradervand, N.; Bee, G.] Agroscope, Fribourg, Switzerland; [Hu, D.; Neuenschwander, S.] Swiss Fed Inst Technol, Inst Agr Sci, Zurich, Switzerland	Swiss Federal Research Station Agroscope; Swiss Federal Institutes of Technology Domain; ETH Zurich	Bee, G (corresponding author), Agroscope, Fribourg, Switzerland.	giuseppe.bee@agroscope.admin.ch	Bee, Giuseppe/E-6139-2013	Bee, Giuseppe/0000-0002-6397-7543; Girard, Marion/0000-0003-1819-3800; Neuenschwander, Stefan/0000-0002-8348-261X				Agroscope, 2017, FUT NAHRW SCHWEIN; Al-Zoreky NS, 2009, INT J FOOD MICROBIOL, V134, P244, DOI 10.1016/j.ijfoodmicro.2009.07.002; Biagi G, 2010, ARCH ANIM NUTR, V64, P121, DOI 10.1080/17450390903461584; Boerlin P, 2005, APPL ENVIRON MICROB, V71, P6753, DOI 10.1128/AEM.71.11.6753-6761.2005; Brand P, 2017, SCHWEIZ ARCH TIERH, V159, P373, DOI 10.17236/sat00120; Brus M., 2013, Bulgarian Journal of Agricultural Science, V19, P841; Carstensen B., 2008, INT J BIOSTAT, V4, P16, DOI DOI 10.2202/1557-4679.1107; CEDERLUND H, 1993, J ANTIMICROB CHEMOTH, V32, P355, DOI 10.1093/jac/32.3.355; Coddens A, 2017, VET MICROBIOL, V202, P64, DOI 10.1016/j.vetmic.2017.01.019; COHEN SP, 1993, J BACTERIOL, V175, P7856, DOI 10.1128/JB.175.24.7856-7862.1993; Espin JC, 2007, J AGR FOOD CHEM, V55, P10476, DOI 10.1021/jf0723864; Fairbrother JM, 2012, DIS SWINE, P723; Fairbrother John M., 2005, Animal Health Research Reviews, V6, P17, DOI 10.1079/AHR2005105; Girard M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197878; Graziani R, 2006, EPC 2006, P328; Hu D, 2019, ANIM GENET, V50, P136, DOI 10.1111/age.12770; Kim JC, 2016, J ANIM SCI BIOTECHNO, V7, DOI 10.1186/s40104-016-0118-4; Lee CY, 2017, J ANIM PHYSIOL AN N, V101, P88, DOI 10.1111/jpn.12513; Lindsay BR, 2014, FEMS MICROBIOL LETT, V352, P25, DOI 10.1111/1574-6968.12362; Liu YT, 2006, BIOTECHNOL BIOENG, V93, P297, DOI 10.1002/bit.20675; MA D, 1995, MOL MICROBIOL, V16, P45, DOI 10.1111/j.1365-2958.1995.tb02390.x; Min BR, 2008, SCI RES ESSAYS, V3, P66; Min BR, 2007, J FOOD PROTECT, V70, P543, DOI 10.4315/0362-028X-70.3.543; Molist F, 2011, BRIT J NUTR, V105, P1592, DOI 10.1017/S0007114510004575; Morinaga N, 2005, J BIOL CHEM, V280, P23303, DOI 10.1074/JBC.M502093200; Myrie SB, 2008, J ANIM SCI, V86, P609, DOI 10.2527/jas.2006-793; Nagy B, 1999, VET RES, V30, P259; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; Nepomuceno RC, 2016, CIENC AGROTEC, V40, P205, DOI 10.1590/1413-70542016402043315; Price CTD, 2000, INT J BIOCHEM CELL B, V32, P1029, DOI 10.1016/S1357-2725(00)00042-X; RASKIN I, 1992, PLANT PHYSIOL, V99, P799, DOI 10.1104/pp.99.3.799; Rodea GE, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00187; Ropiak HM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170768; Schubnell F, 2016, PARASITOL INT, V65, P618, DOI 10.1016/j.parint.2016.09.005; Thomas Pious, 2015, Biotechnol Rep (Amst), V8, P45, DOI 10.1016/j.btre.2015.08.003; Valle Demetrio L. Jr., 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P532, DOI 10.1016/j.apjtb.2015.04.005; Van der Klis JD, 2012, 28 FFDNA C ADV AN NU; Verhelst R, 2014, LIVEST SCI, V160, P138, DOI 10.1016/j.livsci.2013.11.026; Verhelst R, 2010, LIVEST SCI, V133, P101, DOI 10.1016/j.livsci.2010.06.035; WISE CM, 1983, AM J VET RES, V44, P2221; XU ZR, 1990, J ANIM SCI, V68, P1639	41	11	11	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2020	15	2							e0214267	10.1371/journal.pone.0214267	http://dx.doi.org/10.1371/journal.pone.0214267			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8GQ	32106264	Green Published, gold			2023-01-03	WOS:000535237000001
J	Hashmat, D; Shoaib, MH; Ali, FR; Siddiqui, F				Hashmat, Durriya; Shoaib, Muhammad Harris; Ali, Fatima Ramzan; Siddiqui, Fahad			Lornoxicam controlled release transdermal gel patch: Design, characterization and optimization using co-solvents as penetration enhancers	PLOS ONE			English	Article							NANOSTRUCTURED LIPID CARRIERS; DRUG-DELIVERY SYSTEM; IN-VITRO EVALUATION; SKIN PERMEATION; FORMULATION DESIGN; PROPYLENE-GLYCOL; VIVO; HYDROCHLORIDE; NANOPARTICLES; TESTOSTERONE	The aim of the current study was to develop membrane-based transdermal patches of lornoxicam gel using oleic acid (OA)and propylene glycol (PG) as penetration enhancers to improve drug delivery across the skin and to evaluate in vivo analgesic and anti-inflammatory activity. For this purpose, nine formulations were developed in accordance with 32 factorial design using Design Expert (R) 11. The concentration of propylene glycol (X-1) and oleic acid (X-2) were selected as independent variable whereas Q(10) (Y-1), flux (Y-2) and lag time (Y-3) were considered as the response variables. The impact of drug loading, surface area, gel concentration, membrane variation and agitation speed on drug release and permeation was also studied. The skin sensitivity reaction, analgesic activity and anti-inflammatory action of the optimized patch were also determined in Albino Wistar rats. Stability studies were performed for three months at three different temperature conditions. The result suggests that a membrane-based system with controlled zero-order drug releaseof 95.8 +/- 1.121% for 10 h exhibiting flux of 126.51 +/- 1.19 mu g/cm(2)/h and lag time of 0.908 +/- 0.57h was optimized with the desired analgesic and anti-inflammatory effect can be obtained by using propylene glycol and oleic acid co-solvents as a penetration enhancer. The patch was also found stable at 4 degrees C for a period of 6.44 months. Formulation F9 comprising of 10% PG and 3% OA was selected as an optimized formulation. The study demonstrates that the fabricated transdermal system of lornoxicam can deliver the drug through the skin in a controlled manner with desired analgesic and anti-inflammatory activity and can be considered as a suitable alternative of the oral route.	[Hashmat, Durriya; Shoaib, Muhammad Harris; Ali, Fatima Ramzan; Siddiqui, Fahad] Univ Karachi, Fac Pharm & Pharmaceut Sci, Dept Pharmaceut, Karachi, Pakistan	University of Karachi	Shoaib, MH (corresponding author), Univ Karachi, Fac Pharm & Pharmaceut Sci, Dept Pharmaceut, Karachi, Pakistan.	harrisshoaib2000@yahoo.com	Hashmat, Durriya/ABD-7845-2021; 张, 张鑫月/AAP-1001-2020; Shoaib, Muhammad/AAR-8933-2020	Shoaib, Muhammad/0000-0002-3639-0026				Aboofazeli R, 2002, DRUG DELIV, V9, P239, DOI 10.1080/10717540260397855; Aggarwal G, 2013, PHARM DEV TECHNOL, V18, P916, DOI 10.3109/10837450.2011.609993; Ahad A, 2014, EXPERT OPIN DRUG DEL, V11, P1149, DOI 10.1517/17425247.2014.914027; Ahmed MO, 2011, PROF DRUG SUB EXCIP, V36, P205, DOI 10.1016/B978-0-12-387667-6.00006-3; Al-Achi A, 2013, INTEGRATED PHARMACEU; Al-Suwayeh SA, 2014, SCI WORLD J, DOI 10.1155/2014/127495; Allen L, 2013, ANSELS PHARM DOSAGE; Alves MP, 2007, INT J PHARMACEUT, V341, P215, DOI 10.1016/j.ijpharm.2007.03.031; [Anonymous], 2011, ASIAN J PHARM CLIN R; Arellano A, 1999, EUR J PHARM SCI, V7, P129, DOI 10.1016/S0928-0987(98)00010-4; Baker AK, 2002, PHARMACOL BIOCHEM BE, V74, P73, DOI 10.1016/S0091-3057(02)00961-9; Baker R., 1987, CONTROLLED RELEASE B; Baviskar D.T., 2013, J PHARM SCI TECHNOL, V67, P9, DOI DOI 10.5731/pdajpst.2013.00898; Beetge E, 2000, INT J PHARMACEUT, V193, P261, DOI 10.1016/S0378-5173(99)00340-3; Benecke AG, 1991, STORAGE STABLE TRANS; BENTLEY GA, 1983, BRIT J PHARMACOL, V79, P125, DOI 10.1111/j.1476-5381.1983.tb10504.x; Bowen JL, 2006, INT J PHARMACEUT, V307, P251, DOI 10.1016/j.ijpharm.2005.10.014; Chaisson D., 1995, DISSOLUTION TECHNOLO, V2, P7; Chaudhary H, 2013, INT J BIOL MACROMOL, V55, P246, DOI 10.1016/j.ijbiomac.2013.01.015; Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1; Costa P, 2003, DRUG DEV IND PHARM, V29, P89, DOI 10.1081/DDC-120016687; Dave BS, 2004, AAPS PHARMSCITECH, V5, DOI 10.1208/pt050234; Devi VK, 2003, DRUG DEV IND PHARM, V29, P495, DOI 10.1081/DDC-120018638; Draize JH, 1944, J PHARMACOL EXP THER, V82, P377; El Nabarawi MA, 2013, INT J PHARM PHARM SC, V5, P242; El Nabarawy NA, 2014, DEV EC TRANSDERMAL P; Gonullu U, 2015, ACTA PHARMACEUT, V65, P1, DOI 10.1515/acph-2015-0009; GREENBERGER JS, 2014, J PHARM, V4, P10925, DOI DOI 10.3389/FONC.2014.00024; Gwak HS, 2004, DRUG DEV IND PHARM, V30, P187, DOI 10.1081/DDC-120028714; Gwak HS, 2001, ARCH PHARM RES, V24, P578, DOI 10.1007/BF02975169; Hai NT, 2008, INT J PHARMACEUT, V357, P55, DOI 10.1016/j.ijpharm.2008.01.024; Hwang BY, 1997, J CONTROL RELEASE, V49, P177, DOI 10.1016/S0168-3659(97)00073-4; Kalia YN, 2001, ADV DRUG DELIVER REV, V48, P159, DOI 10.1016/S0169-409X(01)00113-2; Karande P, 2009, BBA-BIOMEMBRANES, V1788, P2362, DOI 10.1016/j.bbamem.2009.08.015; Kim MK, 2001, INT J PHARM, V219, P51, DOI 10.1016/S0378-5173(01)00631-7; Kumar R, 2007, TROP J PHARM RES, V6, P633; Mittal A, 2009, PHARM DEV TECHNOL, V14, P422, DOI 10.1080/10837450902748388; Morris Christopher J, 2003, Methods Mol Biol, V225, P115; Mundada MS, 2013, INDIAN J PHARM EDUC, V47, P168; Palei NN, 2017, J DRUG DELIV SCI TEC, V39, P490, DOI 10.1016/j.jddst.2017.05.001; Panigrahi L, 2005, AAPS PHARMSCITECH, V6; Park CW, 2012, INT J PHARMACEUT, V436, P32, DOI 10.1016/j.ijpharm.2012.06.057; Patel J., 2011, INT J DRUG DEV RES, V3, P156; Pichayakorn W, 2013, CHEM ENG RES DES, V91, P520, DOI 10.1016/j.cherd.2012.09.011; Prausnitz MR, 2004, NAT REV DRUG DISCOV, V3, P115, DOI 10.1038/nrd1304; Prodduturi S, 2009, PHARM RES-DORD, V26, P1344, DOI 10.1007/s11095-009-9843-0; Radhofer-Welte S, 2000, DRUG TODAY, V36, P55, DOI 10.1358/dot.2000.36.1.566627; Shahzad Y, 2013, INT J BIOL MACROMOL, V61, P26, DOI 10.1016/j.ijbiomac.2013.06.049; Sheikh NA, 2017, MATH PROBL ENG, V2017, DOI 10.1155/2017/9402964; Shin SC, 2002, EUR J PHARM BIOPHARM, V54, P201, DOI 10.1016/S0939-6411(02)00051-6; Singh B, 2006, INT J PHARM, V325, P15, DOI 10.1016/j.ijpharm.2006.06.007; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; THACHARODI D, 1995, BIOMATERIALS, V16, P145, DOI 10.1016/0142-9612(95)98278-M; Venkatraman S, 1998, BIOMATERIALS, V19, P1119, DOI 10.1016/S0142-9612(98)00020-9; Walters KA, 1993, PHARM SKIN PENETRATI; Wang MY, 2005, INT J PHARMACEUT, V290, P25, DOI 10.1016/j.ijpharm.2004.10.027; Welin-Berger K, 2001, EUR J PHARM SCI, V13, P309, DOI 10.1016/S0928-0987(01)00118-X; Williams AC, 2012, ADV DRUG DELIVER REV, V64, P128, DOI 10.1016/j.addr.2012.09.032; WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544; Wissing SA, 2002, J CONTROL RELEASE, V81, P225, DOI 10.1016/S0168-3659(02)00056-1; Yang Z, 2013, INT J PHARMACEUT, V447, P231, DOI 10.1016/j.ijpharm.2013.02.048; Yener G, 2010, CHEM PHARM BULL, V58, P1466, DOI 10.1248/cpb.58.1466; Zhan XP, 2015, BRAZ J PHARM SCI, V51, P373, DOI 10.1590/S1984-82502015000200015; Zhang Y, 2010, AAPS J, V12, P263, DOI 10.1208/s12248-010-9185-1; Zhang YX, 2014, ASIAN J PHARM SCI, V9, P251, DOI 10.1016/j.ajps.2014.07.007; Zhao H, 2002, DRUG DEV IND PHARM, V28, P1125, DOI 10.1081/DDC-120014579	66	10	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2020	15	2							e0228908	10.1371/journal.pone.0228908	http://dx.doi.org/10.1371/journal.pone.0228908			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8GQ	32107483	gold, Green Published			2023-01-03	WOS:000535237000015
J	Lawanprasert, A; Guinan, CA; Langford, EA; Hawkins, CE; Sloand, JN; Fescemyer, HW; Aronson, MR; Halle, JA; Marden, JH; Medina, SH				Lawanprasert, Atip; Guinan, Caitlin A.; Langford, Erica A.; Hawkins, Carly E.; Sloand, Janna N.; Fescemyer, Howard W.; Aronson, Matthew R.; Halle, Jacob A.; Marden, James H.; Medina, Scott H.			Discovery of antitumor lectins from rainforest tree root transcriptomes	PLOS ONE			English	Article							PLANT-LECTINS; PROTEIN GLYCOSYLATION; N-GLYCANS; MANNOSE; APOPTOSIS; RESISTANCE; PATHOGENS; BIOMARKER; PATHWAYS; MUCINS	Glycans are multi-branched sugars that are displayed from lipids and proteins. Through their diverse polysaccharide structures they can potentiate a myriad of cellular signaling pathways involved in development, growth, immuno-communication and survival. Not surprisingly, disruption of glycan synthesis is fundamental to various human diseases; including cancer, where aberrant glycosylation drives malignancy. Here, we report the discovery of a novel mannose-binding lectin, ML6, which selectively recognizes and binds to these irregular tumor-specific glycans to elicit potent and rapid cancer cell death. This lectin was engineered from gene models identified in a tropical rainforest tree root transcriptome and is unusual in its six canonical mannose binding domains (QxDxNxVxY), each with a unique amino acid sequence. Remarkably, ML6 displays antitumor activity that is > 10(5) times more potent than standard chemotherapeutics, while being almost completely inactive towards non-transformed, healthy cells. This activity, in combination with results from glycan binding studies, suggests ML6 differentiates healthy and malignant cells by exploiting divergent glycosylation pathways that yield naive and incomplete cell surface glycans in tumors. Thus, ML6 and other high-valence lectins may serve as novel biochemical tools to elucidate the glycomic signature of different human tumors and aid in the rational design of carbohydrate-directed therapies. Further, understanding how nature evolves proteins, like ML6, to combat the changing defenses of competing microorganisms may allow for fundamental advances in the way we approach combinatorial therapies to fight therapeutic resistance in cancer.	[Lawanprasert, Atip; Sloand, Janna N.; Aronson, Matthew R.; Halle, Jacob A.; Medina, Scott H.] Penn State Univ, Dept Biomed Engn, University Pk, PA 16802 USA; [Guinan, Caitlin A.; Langford, Erica A.; Hawkins, Carly E.; Fescemyer, Howard W.; Marden, James H.] Penn State Univ, Dept Biol, University Pk, PA 16802 USA; [Marden, James H.] Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Medina, SH (corresponding author), Penn State Univ, Dept Biomed Engn, University Pk, PA 16802 USA.; Marden, JH (corresponding author), Penn State Univ, Dept Biol, University Pk, PA 16802 USA.; Marden, JH (corresponding author), Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA.	jhm10@psu.edu; shm126@psu.edu		Aronson, Matthew/0000-0002-8871-8265; Hawkins, Carly/0000-0003-0133-6764	NSF [DEB1120476, DEB-1457571]; Charles E. Kaufman Foundation -New Initiative Award [KA201791785]	NSF(National Science Foundation (NSF)); Charles E. Kaufman Foundation -New Initiative Award	The ML6 sequence was obtained and characterized using support from NSF DEB1120476 and DEB-1457571, from material covered under export permits and a materials transfer agreement from Panama. This work was generously supported by a Charles E. Kaufman Foundation -New Initiative Award (KA201791785). There was no additional external funding received for this study.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnaud J, 2013, ACS CHEM BIOL, V8, P1918, DOI 10.1021/cb400254b; Azarkan M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29439-x; Bafna S, 2010, ONCOGENE, V29, P2893, DOI 10.1038/onc.2010.87; Barre A, 2001, BIOCHIMIE, V83, P645, DOI 10.1016/S0300-9084(01)01315-3; Barton C, 2014, ANTIMICROB AGENTS CH, V58, P120, DOI 10.1128/AAC.01407-13; Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662; Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421; [陈虹 Chen Hong], 2014, [低温工程, Cryogenics], P1; Chen ZH, 2017, GASTROENTEROLOGY, V153, P1120, DOI 10.1053/j.gastro.2016.12.036; Chugh S, 2015, BBA-REV CANCER, V1856, P211, DOI 10.1016/j.bbcan.2015.08.003; De Hoff PL, 2009, MOL GENET GENOMICS, V282, P1, DOI 10.1007/s00438-009-0460-8; De-la-Pena C, 2012, CURR PROTEOMICS, V9, P103, DOI 10.2174/157016412800786194; Drake PM, 2010, CLIN CHEM, V56, P223, DOI 10.1373/clinchem.2009.136333; Franz H, 2013, ADV LECTIN RES; Fu LL, 2011, INT J BIOCHEM CELL B, V43, P1442, DOI 10.1016/j.biocel.2011.07.004; Garcia-Guzman G, 2014, NEW PHYTOL, V201, P1106, DOI 10.1111/nph.12562; Guo J, 2014, MOLECULES, V19, P20073, DOI 10.3390/molecules191220073; Hossler P, 2009, GLYCOBIOLOGY, V19, P936, DOI 10.1093/glycob/cwp079; Ishikawa K, 2017, CELL CHEM BIOL, V24, P149, DOI 10.1016/j.chembiol.2016.12.009; Jiang QL, 2015, CELL PROLIFERAT, V48, P17, DOI 10.1111/cpr.12155; Karasaki Y, 2001, FOOD RES INT, V34, P7, DOI 10.1016/S0963-9969(00)00122-8; Kasanmoentalib ES, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0770-9; Krijger JJ, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-722; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Kurosu M, 2018, J MOL PHARM ORG PROC, V6, P141; Lannoo N, 2015, PLANT SCI, V239, P67, DOI 10.1016/j.plantsci.2015.06.023; Li YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep16556; Liu B, 2010, CANCER LETT, V287, P1, DOI 10.1016/j.canlet.2009.05.013; Liu B, 2009, ARCH BIOCHEM BIOPHYS, V482, P1, DOI 10.1016/j.abb.2008.12.003; Liu Z, 2012, APPL BIOCHEM BIOTECH, V168, P629, DOI 10.1007/s12010-012-9805-6; Liu ZY, 2010, APPL BIOCHEM BIOTECH, V162, P134, DOI 10.1007/s12010-009-8694-9; Marden JH, 2017, MOL ECOL, V26, P2498, DOI 10.1111/mec.13999; Mathesius U, 2009, J PROTEOMICS, V72, P353, DOI 10.1016/j.jprot.2008.12.006; Michelow IC, 2011, J INFECT DIS, V203, P175, DOI 10.1093/infdis/jiq025; Nilsson Carol L., 2007, P1; Nizet V, 2017, ESSENTIALS GLYCOBIOL, V3rd; Oliveira-Ferrer L, 2017, SEMIN CANCER BIOL, V44, P141, DOI 10.1016/j.semcancer.2017.03.002; Parret AHA, 2005, APPL ENVIRON MICROB, V71, P5197, DOI 10.1128/AEM.71.9.5197-5207.2005; Peng H, 2009, PEPTIDES, V30, P1805, DOI 10.1016/j.peptides.2009.06.027; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Remmert M, 2012, NAT METHODS, V9, P173, DOI [10.1038/NMETH.1818, 10.1038/nmeth.1818]; ROSEN S, 1992, J GEN MICROBIOL, V138, P2663, DOI 10.1099/00221287-138-12-2663; St Swierzko A, 2014, CANCER IMMUNOL IMMUN, V63, P1129, DOI 10.1007/s00262-014-1579-y; Stergiopoulos I, 2009, ANNU REV PHYTOPATHOL, V47, P233, DOI 10.1146/annurev.phyto.112408.132637; Taniguchi N, 2015, ADV CANCER RES, V126, P11, DOI 10.1016/bs.acr.2014.11.001; Tedersoo L, 2014, SCIENCE, V346, P1078, DOI 10.1126/science.1256688; VANDAMME EJM, 1987, FEBS LETT, V215, P140, DOI 10.1016/0014-5793(87)80129-1; Varki A., 2017, BIOL FUNCTIONS GLYCA; Varki A, 2012, ANN NY ACAD SCI, V1253, P16, DOI 10.1111/j.1749-6632.2012.06517.x; Wang Q, 2015, METHODS MOL BIOL, V1321, P287, DOI 10.1007/978-1-4939-2760-9_20; Wingfield PT, 2015, CURR PROTOC PROTEIN, V80; Xu XF, 2011, BIOTECHNOL ADV, V29, P667, DOI 10.1016/j.biotechadv.2011.05.003	52	2	2	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2020	15	2							e0229467	10.1371/journal.pone.0229467	http://dx.doi.org/10.1371/journal.pone.0229467			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8EV	32097449	gold, Green Published			2023-01-03	WOS:000535232000031
J	Lopez-Ejeda, N; Charle-Cuellar, P; Ale, FGB; Alvarez, JL; Vargas, A; Guerrero, S				Lopez-Ejeda, Noemi; Charle-Cuellar, Pilar; Ale, Franck G. B.; Alvarez, Jose Luis; Vargas, Antonio; Guerrero, Saul			Bringing severe acute malnutrition treatment close to households through community health workers can lead to early admissions and improved discharge outcomes	PLOS ONE			English	Article							CASE-MANAGEMENT; CARE; CHILDREN	Severe acute malnutrition (SAM) affects over 16.6 million children worldwide. The integrated Community Case Management (iCCM) strategy seeks to improve essential health by means of nonmedical community health workers (CHWs) who treat the deadliest infectious diseases in remote rural areas where there is no nearby health center. The objective of this study was to assess whether SAM treatment delivered by CHWs close to families' locations may improve the early identification of cases compared to outpatient treatment at health facilities (HFs), with a decreased number complicated cases referred to stabilization centers, increased anthropometric measurements at admission (closer to the admission threshold) and similarity in clinical outcomes (cure, death, and default). The study included 930 children aged 6 to 59 months suffering from SAM in the Kita district of the Kayes Region in Mali; 552 children were treated by trained CHWs. Anthropometric measurements, the presence of edema, and other medical signs were recorded at admission, and the length of stay and clinical outcomes were recorded at discharge. The results showed fewer children with edema at admission in the CHW group than in the HF group (0.4% vs. 3.7%; OR = 10.585 [2.222-50.416], p = 0.003). Anthropometric measurements at admission were higher in the CHW group, with fewer children falling into the lowest quartiles of both weight-for-height z-scores (20.2% vs. 31.5%; p = 0.002) and mid-upper arm circumference (18.0% vs. 32.4%; p<0.001), than in the HF group. There was no difference in the length of stay. More children in the CHW group were cured (95.9% vs. 88.7%; RR = 3.311 [1.772-6.185]; p<0.001), and there were fewer defaulters (3.7% vs. 9.8%; RR = 3.345 [1.702-6.577]; p<0.001) than in the HF group. Regression analyses demonstrated that less severe anthropometric measurements at admission resulted in an increased probability of cure at discharge. The study results also showed that CHWs provided more integrated care, as they diagnosed and treated significantly more cases of infectious diseases than HFs (diarrhea: 36.0% vs. 18.3%, p<0.001; malaria: 41.7% vs. 19.8%, p<0.001; acute respiratory infection: 34.8% vs. 25.2%, p = 0.007). The addition of SAM treatment in the curative tasks that the CHWs provided to the families resulted in earlier admission and more integrated care for children than those associated with HFs. CHW treatment also achieved better discharge outcomes than standard community treatment.	[Lopez-Ejeda, Noemi; Charle-Cuellar, Pilar; Vargas, Antonio] Act Hunger, Madrid, Spain; [Lopez-Ejeda, Noemi] Univ Complutense Madrid, EPINUT Res Grp Ref 920325, Madrid, Spain; [Ale, Franck G. B.] Act Hunger, Bamako, Mali; [Alvarez, Jose Luis] Act Hunger, London, England; [Guerrero, Saul] Act Hunger, New York, NY USA	Complutense University of Madrid	Lopez-Ejeda, N (corresponding author), Act Hunger, Madrid, Spain.; Lopez-Ejeda, N (corresponding author), Univ Complutense Madrid, EPINUT Res Grp Ref 920325, Madrid, Spain.	nlopez@accioncontraelhambre.org	Ejeda, Noemi Lopez/AAB-3384-2020	Ejeda, Noemi Lopez/0000-0003-1310-0134; vargas, Antonio/0000-0001-6507-1529	Innocent Foundation	Innocent Foundation	This research was made possible by the financial support of the Innocent Foundation. https://www.innocentfoundation.org/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, PANCREATOLOGY, V13, pe1; [Anonymous], 2018, J CANC RES THER, V14, pS622; Chisti MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107663; Chitete L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123021; Collins S, 2002, LANCET, V360, P1824, DOI 10.1016/S0140-6736(02)11770-3; Collins S, 2006, LANCET, V368, P1992, DOI 10.1016/S0140-6736(06)69443-9; Desalegn M., 2016, INT J NUTR METAB, V8, P12, DOI [10.5897/IJNAM2015.0193, DOI 10.5897/IJNAM2015.0193]; Gebremichael DY, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2593-5; Goossens S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049320; Goudet S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205688; John C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196971; Kabalo MY, 2017, J HEALTH POPUL NUTR, V36, DOI 10.1186/s41043-017-0083-3; Kerac M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096030; Lenters LM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-S3-S23; Linneman Z, 2007, MATERN CHILD NUTR, V3, P206, DOI 10.1111/j.1740-8709.2007.00095.x; Lopez-Ejeda N, 2019, MATERN CHILD NUTR, V15, DOI 10.1111/mcn.12719; Mengesha MM, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.30704; Ministere de la Sante et de L'Hygiene Publique et Direction National de la Sante Republique du Mali, 2015, GUID NAT MIS UVR; Moran JLA, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2987-z; Navarro-Colorado C, 2015, STANDARD INDICATORS; Olofin I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064636; Paintain LS, 2014, AM J TROP MED HYG, V91, P461, DOI 10.4269/ajtmh.14-0094; Pandey P, 2018, TROP DOCT, V48, P277, DOI 10.1177/0049475518786854; Puett C, 2013, HEALTH POLICY PLANN, V28, P386, DOI 10.1093/heapol/czs070; Puett C, 2012, FOOD NUTR BULL, V33, P273, DOI 10.1177/156482651203300408; Roberfroid D., 2013, MANAGEMENT OEDEMATOU; Rogers E, 2018, HUM RESOUR HEALTH, V16, DOI 10.1186/s12960-018-0273-0; Rogers E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128666; Sadler K., 2011, COMMUNITY CASE MANAG; Shanka NA., 2015, NUTR DISORDERS THERA, V5, P2; Stobaugh HC, 2019, MATERN CHILD NUTR, V15, DOI 10.1111/mcn.12702; The Lancet Global Health, 2018, LANCET GLOB HEALTH, V6, pE593; The Sphere Project,, 2018, HUM CHART MIN STAND; Theodoratou E, 2010, INT J EPIDEMIOL, V39, P155, DOI 10.1093/ije/dyq032; UNDP, 2018, HUMAN DEV INDICES IN; UNICEF, 2017, ENQ NAT NUTR ANTHR M; UNICEF WHO The World Bank Group, 2019, JOINT CHILD MALN EST; United Nations Children's Fund (UNICEF), 2015, SEV AC MALN; United Nations Office for the Coordination of Humanitarian Affairs (OCHA), 2018, MAL HUM RESP PLAN; United States Agency for International Development (USAID), 2018, TRAIN GUID COMM BAS; WHO Multicentre Growth Reference Study Group, 2007, WHO CHILD GROWTH STA, DOI 10.1093/tropej/fmn002; World Health Organization, 2013, GUID UPD MAN SEV AC; Young M, 2012, AM J TROP MED HYG, V87, P6, DOI 10.4269/ajtmh.2012.12-0221	43	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2020	15	2							e0227939	10.1371/journal.pone.0227939	http://dx.doi.org/10.1371/journal.pone.0227939			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KO3IG	32023265	Green Published, gold			2023-01-03	WOS:000515441500001
J	Douglas, NM; Kenangalemm, E; Hasanuddin, A; Anstey, NM; Sugiarto, P; Price, RN; Poespoprodjo, JR				Douglas, Nicholas M.; Kenangalemm, Enny; Hasanuddin, Afdhal; Anstey, Nicholas M.; Sugiarto, Paulus; Price, Ric N.; Poespoprodjo, Jeanne Rini			Malaria-related hospitalization during childhood in Papua, Indonesia: A retrospective cohort study	PLOS ONE			English	Article							PLASMODIUM-VIVAX; FALCIPARUM-MALARIA; CHILDREN; RISK; PERFORMANCE; INFECTIONS; MORTALITY	Background In endemic regions, the age distribution of malaria varies according to the infecting Plasmodium species. We aimed to delineate the pattern of malaria-related hospitalization from birth in Timika, Papua-an area co-endemic for P. falciparum and P. vivax Methods Between April 2004 and December 2013, infants born at Mitra Masyarakat Hospital, or presenting within the first 7 days of life, were enrolled retrospectively into a cohort study and followed passively using routinely-collected hospital surveillance data. Outcomes were stratified by the presence or absence of Plasmodium parasitemia and included re-presentation to hospital, requirement for hospital admission and death. Results Overall, 11,408 infants were enrolled into the cohort. Median follow-up was 4.3 (maximum 9.7) years. In total, 7,847 (68.9%) infants made 90,766 re-presentations to hospital, 18,105 (19.9%) of which were associated with Plasmodium parasitemia. The incidence of re-presentations with malaria during the first year of life was 213 per 1,000 person-years (py) for P. vivax and 79 per 1,000py for P. falciparum (Incidence Rate Ratio (IRR) = 2.69, 95% Confidence Interval (95%CI): 2.48-2.92). After the age of 5 years, the incidence of P. vivax had fallen to 77/1,000py and the incidence of P. falciparum had risen to 95/1,000py (IRR = 0.80, 95%CI: 0.73-0.88). Overall, 79.7% (14,431/18,105) of malaria re-presentations were recurrences rather than initial infections. Malaria accounted for 31.7% (2,126/3,120) of all hospital admissions. The infant mortality rate in this study was 52 deaths per 1,000 live births. Beyond the early neonatal period, 13.4% of deaths were associated with Plasmodium parasitemia. Conclusions In Papua, Indonesia, malaria is a major cause of hospital presentation and admission in early life. The initial predominance of P. vivax over P. falciparum inverts after five years of age. Malaria is directly associated with nearly one in seven deaths after the early neonatal period.	[Douglas, Nicholas M.; Anstey, Nicholas M.; Price, Ric N.] Charles Darwin Univ, Menzies Sch Hlth Res, Global & Trop Hlth Div, Darwin, NT, Australia; [Douglas, Nicholas M.; Anstey, Nicholas M.] Royal Darwin Hosp, Div Infect Dis, Darwin, NT, Australia; [Kenangalemm, Enny; Poespoprodjo, Jeanne Rini] Papuan Hlth & Community Dev Fdn, Timika Malaria Res Program, Timika, Papua, Indonesia; [Kenangalemm, Enny] Mimika Dist Hlth Author, Timika, Papua, Indonesia; [Hasanuddin, Afdhal; Sugiarto, Paulus] Rumah Sakit Mitra Masyarakat, Dept Paediat, Timika, Papua, Indonesia; [Price, Ric N.] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Clin Med, Oxford, England; [Price, Ric N.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand; [Poespoprodjo, Jeanne Rini] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Child Hlth, Yogyakarta, Indonesia; [Poespoprodjo, Jeanne Rini] Rumah Sakit Umum Daerah, Dept Paediat, Timika, Papua, Indonesia	Charles Darwin University; Menzies School of Health Research; University of Oxford; Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; Gadjah Mada University	Douglas, NM (corresponding author), Charles Darwin Univ, Menzies Sch Hlth Res, Global & Trop Hlth Div, Darwin, NT, Australia.; Douglas, NM (corresponding author), Royal Darwin Hosp, Div Infect Dis, Darwin, NT, Australia.	nicholas.douglas@gmail.com	Douglas, Nicholas/ABC-3052-2021	Douglas, Nicholas/0000-0002-7214-4244; Price, Richard/0000-0003-2000-2874	Wellcome Trust [200909, 099875]; Bill and Melinda Gates Foundation [OPP1054404]; Australian National Health and Medical Research Council [1132975, 1037304]; Australian National Health and Medical Research Council (Australian Centre of Research Excellence on Malaria Elimination, ACREME) [1134989]; Australian Department of Foreign Affairs and Trade (DFAT); Australian National Health and Medical Research Council (HOT NORTH initiative) [1131932, 1135820]	Wellcome Trust(Wellcome TrustEuropean Commission); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian National Health and Medical Research Council (Australian Centre of Research Excellence on Malaria Elimination, ACREME); Australian Department of Foreign Affairs and Trade (DFAT)(Australian Government); Australian National Health and Medical Research Council (HOT NORTH initiative)	The study was funded by the Wellcome Trust (Senior Fellowship in Clinical Science to RNP 200909 and Training Fellowship in Tropical Medicine to JRP 099875), the Bill and Melinda Gates Foundation (OPRA, OPP1054404), and the Australian National Health and Medical Research Council (Program grants #1132975 and #1037304; the HOT NORTH initiative #1131932 and a Fellowship to NMA #1135820; and the Australian Centre of Research Excellence on Malaria Elimination, ACREME #1134989). The Timika Research Facility and Papuan Community Health Foundation is supported by the Australian Department of Foreign Affairs and Trade (DFAT). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; Barcus MJ, 2007, AM J TROP MED HYG, V77, P984, DOI 10.4269/ajtmh.2007.77.984; Betuela I, 2012, J INFECT DIS, V206, P1771, DOI 10.1093/infdis/jis580; Chu CS, 2018, CLIN INFECT DIS, V67, P1543, DOI 10.1093/cid/ciy319; Commons RJ, 2018, LANCET INFECT DIS, V18, P1025, DOI 10.1016/S1473-3099(18)30348-7; Devine A, 2018, AM J TROP MED HYG, V98, P543, DOI 10.4269/ajtmh.17-0680; Douglas NM, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002379; Douglas NM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001575; Douglas NM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-135; Faiz MA, 2005, LANCET, V366, P717; Fernando D, 2003, T ROY SOC TROP MED H, V97, P161, DOI 10.1016/S0035-9203(03)90107-6; Fernando SD, 2003, AM J TROP MED HYG, V69, P582, DOI 10.4269/ajtmh.2003.69.582; Galappaththy GNL, 2008, COCHRANE DB SYST REV, DOI [10.1002/, DOI 10.1002/]; Genton B, 2008, PLOS MED, V5, P881, DOI 10.1371/journal.pmed.0050127; Karyana M, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-148; Karyana M, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1588-8; Kenangalem E, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002815; Lindblade KA, 2004, JAMA-J AM MED ASSOC, V291, P2571, DOI 10.1001/jama.291.21.2571; Mimika District Health Office, 2013, ANN STAT; Pava Z, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165340; Phimpraphi W, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-99; Poespoprodjo JR, 2011, J INFECT DIS, V204, P1613, DOI 10.1093/infdis/jir558; Poespoprodjo JR, 2009, CLIN INFECT DIS, V48, P1704, DOI 10.1086/599041; Poespoprodjo JR, 2008, CLIN INFECT DIS, V46, P1374, DOI 10.1086/586743; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Thriemer K, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1784-1; Tjitra E, 2008, PLOS MED, V5, P890, DOI 10.1371/journal.pmed.0050128; UNICEF World Health Organization Bank World United Nations Department of Economic and Social Affairs, 2018, LEV TRENDS CHILD MOR; White MT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05860-8; WHO, 2019, WORLD MALARIA REPORT	30	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2020	15	1							e0228018	10.1371/journal.pone.0228018	http://dx.doi.org/10.1371/journal.pone.0228018			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9AX	31995581	Green Published, gold			2023-01-03	WOS:000534609400037
J	Huhn, GD; Ramgopal, M; Jain, MK; Hinestrosa, F; Asmuth, DM; Slim, J; Goldstein, D; Applin, S; Ryu, JH; Jiang, SP; Cox, S; Das, M; Nguyen-Cleary, T; Piontkowsky, D; Guyer, B; Rossaro, L; Haubrich, RH				Huhn, Gregory D.; Ramgopal, Moti; Jain, Mamta K.; Hinestrosa, Federico; Asmuth, David M.; Slim, Jihad; Goldstein, Deborah; Applin, Shauna; Ryu, Julie H.; Jiang, Shuping; Cox, Stephanie; Das, Moupali; Nguyen-Cleary, Thai; Piontkowsky, David; Guyer, Bill; Rossaro, Lorenzo; Haubrich, Richard H.			HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens	PLOS ONE			English	Article							VIROLOGICALLY SUPPRESSED ADULTS; DIRECT-ACTING ANTIVIRALS; DISOPROXIL FUMARATE; HIV-1 INFECTION; DOUBLE-BLIND; HEPATITIS-C; COINFECTED PATIENTS; UNTREATED HCV; OPEN-LABEL; PHASE 3B	Introduction Guidelines advocate the treatment of HCV in all HIV/HCV co-infected individuals. The aim of this randomized, open-label study (ClinicalTrials.gov identifier: NCT02707601; https://clinicaltrials.gov/ct2/show/NCT02707601) was to evaluate the safety/efficacy of ledipasvir/sofosbuvir (LDV/SOF) co-administered with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or rilpivirine/F/TAF (R/F/TAF) in HIV-1/HCV co-infected participants. Methods Participants with HIV-1 RNA < 50 copies/mL and chronic HCV-genotype (GT) 1 (HCV treatment-naive +/- compensated cirrhosis or HCV treatment-experienced non-cirrhotic) were randomized 1:1 to switch to E/C/F/TAF or R/F/TAF. If HIV suppression was maintained at Week 8, participants received 12 weeks of LDV/SOF. The primary endpoint was sustained HCV virologic response 12 weeks after LDV/SOF completion (SVR12). Results Of 150 participants, 148 received.1 dose of HIV study drug and 144 received LDV/SOF (72 in each F/TAF group; 83% GT1a, 94% HCV treatment-naive, 12% cirrhotic). Overall, SVR12 was 97% (95% confidence interval: 93-99%). Black race did not affect SVR12. Of four participants not achieving SVR12, one had HCV relapse, one had HCV virologic non-response due to non-adherence, and two missed the post-HCV Week 12 visit. Of 148 participants, 96% receiving E/C/F/TAF and 95% receiving R/F/TAF maintained HIV suppression at Week 24; no HIV resistance was detected. No participant discontinued LDV/SOF or E/C/F/TAF due to adverse events; one participant discontinued R/F/TAF due to worsening of pre-existing hypercholesterolemia. Renal toxicity was not observed in either F/TAF regimen during LDV/SOF co-administration. In conclusion, high rates of HCV SVR12 and maintenance of HIV suppression were achieved with LDV/SOF and F/TAF-based regimens. Conclusion This study supports LDV/SOF co-administered with an F/TAF-based regimen in HIV-1/HCV-GT1 co-infected patients.	[Huhn, Gregory D.] Ruth M Rothstein CORE Ctr, Chicago, IL USA; [Ramgopal, Moti] Midway Res Ctr, Ft Pierce, FL USA; [Jain, Mamta K.] UT Southwestern Med Ctr, Dallas, TX USA; [Hinestrosa, Federico] Orlando Immunol Ctr, Orlando, FL USA; [Asmuth, David M.] Univ Calif Davis, Sacramento, CA 95817 USA; [Slim, Jihad] St Michaels Hosp, Newark, NJ USA; [Goldstein, Deborah] Whitman Walker Hlth, Washington, DC USA; [Applin, Shauna] Community Hlth Care, Tacoma, WA USA; [Ryu, Julie H.; Jiang, Shuping; Cox, Stephanie; Das, Moupali; Nguyen-Cleary, Thai; Piontkowsky, David; Guyer, Bill; Rossaro, Lorenzo; Haubrich, Richard H.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA; [Nguyen-Cleary, Thai] Arena Pharmaceut, San Diego, CA USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Orlando Immunology Center; University of California System; University of California Davis; Gilead Sciences	Haubrich, RH (corresponding author), Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA.	Richard.Haubrich@gilead.com		Asmuth, David/0000-0003-0916-7950; Jain, Mamta/0000-0003-2292-6544	Gilead Sciences, Inc., Foster City, CA, USA; Gilead Sciences, Inc.	Gilead Sciences, Inc., Foster City, CA, USA(Gilead Sciences); Gilead Sciences, Inc.(Gilead Sciences)	The study was funded by Gilead Sciences, Inc., Foster City, CA, USA. The study sponsor, Gilead Sciences, Inc., played a role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript.; We extend our thanks to the participants and their families, participating sites, site investigators, and study staff. Medical writing support, including outline and manuscript development in consultation with the authors, was provided by Ryan Woodrow from Aspire Scientific Ltd, Bollington, UK (funded by Gilead Sciences, Inc.).	Afdhal N, 2014, NEW ENGL J MED, V370, P1889, DOI 10.1056/NEJMoa1402454; Afdhal N, 2014, NEW ENGL J MED, V370, P1483, DOI 10.1056/NEJMoa1316366; [Anonymous], 2019, HCV GUID REC TEST MA; Bhagani S, 2015, 15 EUR AIDS C 21 24; Bhattacharya D, 2017, CLIN INFECT DIS, V64, P1711, DOI 10.1093/cid/cix111; Custodio JM, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.353; DeJesus E, 2017, LANCET HIV, V4, pE205, DOI 10.1016/S2352-3018(17)30032-2; Department of Health and Human Services, PAN ANT GUID AD AD G; EUROPEAN AIDS CLINICAL SOCIETY, 2017, EACS GUID VERS 9 0, P1; European Assoc Study Liver, 2018, J HEPATOL, V69, P461, DOI 10.1016/j.jhep.2018.03.026; Gallant JE, 2016, LANCET HIV, V3, pE158, DOI 10.1016/S2352-3018(16)00024-2; Garrison K, 2015, 16 INT WORKSH CLIN P; Gonzalez-Grande R, 2016, WORLD J GASTROENTERO, V22, P1421, DOI 10.3748/wjg.v22.i4.1421; GUNTHARD HF, 2016, JAMA-J AM MED ASSOC, V316, P191, DOI DOI 10.1001/JAMA.2016.8900; Hawkins C, 2016, J ANTIMICROB CHEMOTH, V71, P2642, DOI 10.1093/jac/dkw203; Jain MK, 2018, IDWEEK; Jayaweera D, 2018, GASTROENTEROLOGY, V154, pS1189; Keating GM, 2015, DRUGS, V75, P675, DOI 10.1007/s40265-015-0381-2; Kowdley KV, 2014, NEW ENGL J MED, V370, P1879, DOI 10.1056/NEJMoa1402355; Milazzo L, 2017, HIV MED, V18, P284, DOI 10.1111/hiv.12429; Mills A, 2016, LANCET INFECT DIS, V16, P43, DOI 10.1016/S1473-3099(15)00348-5; Naggie S, 2015, NEW ENGL J MED, V373, P705, DOI 10.1056/NEJMoa1501315; Orkin C, 2017, LANCET HIV, V4, pE195, DOI 10.1016/S2352-3018(17)30031-0; Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG AD AD; Patel M, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx062; Post FA, 2017, JAIDS-J ACQ IMM DEF, V74, P180, DOI 10.1097/QAI.0000000000001186; Raffi F, 2017, JAIDS-J ACQ IMM DEF, V75, P226, DOI [10.1097/QAI.0000000000001344, 10.1097/qai.0000000000001344]; Rice DP, 2016, J CLIN TRANSL HEPATO, V4, P234, DOI 10.14218/JCTH.2016.00026; Sax PE, 2015, LANCET, V385, P2606, DOI 10.1016/S0140-6736(15)60616-X; Townsend K, 2016, AIDS, V30, P261, DOI 10.1097/QAD.0000000000000903; Ward K, 2017, HEPATOLOGY, V66, p45A, DOI 10.1002/hep.29308; Younossi ZM, 2016, J VIRAL HEPATITIS, V23, P857, DOI 10.1111/jvh.12554	32	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2020	15	1							e0224875	10.1371/journal.pone.0224875	http://dx.doi.org/10.1371/journal.pone.0224875			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9AX	31995556	Green Published, gold			2023-01-03	WOS:000534609400007
J	Almagro, P; Ponce, A; Komal, S; Villaverde, MD; Castrillo, C; Grau, G; Simon, L; de la Sierra, A				Almagro, Pere; Ponce, Ana; Komal, Shakeel; de la Asuncion Villaverde, Maria; Castrillo, Cristina; Grau, Gemma; Simon, Lluis; de la Sierra, Alex			Multimorbidity gender patterns in hospitalized elderly patients	PLOS ONE			English	Article							PROGNOSTIC INDEX; CARE; COMORBIDITY; MORBIDITY; FRAILTY	Patients with multimorbidity and complex health care needs are usually vulnerable elders with several concomitant advanced chronic diseases. Our research aim was to evaluate differences in patterns of multimorbidity by gender in this population and their possible prognostic implications, measured as in-hospital mortality, 1-month readmissions, and 1-year mortality. We focused on a cohort of elderly patients with well-established multimorbidity criteria admitted to a specific unit for chronic complex-care patients. Multimorbidity criteria, the Charlson, PROFUND and Barthel indexes, and the Pfeiffer test were collected prospectively during their stays. A total of 843 patients (49.2% men) were included, with a median age of 84 [interquartile range (IQR) 79-89] years. The women were older, with greater functional dependence [Barthel index: 40 (IQR:10-65) vs. 60 (IQR: 25-90)], showed more cognitive deterioration [Pfeiffer test: 5 (IQR:1-9) vs. 1 (0-6)], and had worse scores on the PROFUND index [15 (IQR:9-18) vs. 11.5 (IQR: 6-15)], all p < 0.0001, while men had greater comorbidity measured with the Charlson index [5 (IQR: 3-7) vs. 4 (IQR: 3-6); p = 0.002]. In the multimorbidity criteria scale, heart failure, autoimmune diseases, dementia, and osteoarticular diseases were more frequent in women, while ischemic heart disease, chronic respiratory diseases, and neoplasms predominated in men. In the analysis of grouped patterns, neurological and osteoarticular diseases were more frequent in females, while respiratory and cancer predominated in males. We did not find gender differences for in-hospital mortality, 1-month readmissions, or 1-year mortality. In the multivariate analysis age, the Charlson, Barthel and PROFUND indexes, along with previous admissions, were independent predictors of 1-year mortality, while gender was non-significant. The Charlson and PROFUND indexes predicted mortality during follow-up more accurately in men than in women (AUC 0.70 vs. 0.57 and 0.74 vs. 0.62, respectively), with both p<0.001. In conclusion, our study shows differing patterns of multimorbidity by gender, with greater functional impairment in women and more comorbidity in men, although without differences in the prognosis. Moreover, some of these prognostic indicators had differing accuracy for the genders in predicting mortality.	[Almagro, Pere; Ponce, Ana; Komal, Shakeel; de la Asuncion Villaverde, Maria; Castrillo, Cristina; Grau, Gemma; Simon, Lluis; de la Sierra, Alex] Univ Barcelona, Univ Hosp Mutua Terrassa, Internal Med Serv, Multimorbid Unit, Terrassa, Spain; [Almagro, Pere; Ponce, Ana; Komal, Shakeel; de la Asuncion Villaverde, Maria; Castrillo, Cristina; Grau, Gemma; Simon, Lluis; de la Sierra, Alex] Univ Barcelona, Univ Hosp Mutua Terrassa, Internal Med Dept, Terrassa, Spain	Hospital Universitario Mutua Terrassa; University of Barcelona; Hospital Universitario Mutua Terrassa; University of Barcelona	Almagro, P (corresponding author), Univ Barcelona, Univ Hosp Mutua Terrassa, Internal Med Serv, Multimorbid Unit, Terrassa, Spain.; Almagro, P (corresponding author), Univ Barcelona, Univ Hosp Mutua Terrassa, Internal Med Dept, Terrassa, Spain.	19908pam@comb.cat		Malik Khanam, Komal/0000-0001-9761-8445; Almagro, Pere/0000-0002-8476-4942				Almagro P, 2010, RESP MED, V104, P253, DOI 10.1016/j.rmed.2009.09.019; Almagro P, 2012, CHEST, V142, P1126, DOI 10.1378/chest.11-2413; [Anonymous], 2018, PLAN ATENCION INTEGR; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bernabeu-Wittel M, 2014, J PAIN SYMPTOM MANAG, V47, P551, DOI 10.1016/j.jpainsymman.2013.04.011; Blinderman CD, 2015, NEW ENGL J MED, V373, P2549, DOI 10.1056/NEJMra1411746; Brown CJ, 2009, J AM GERIATR SOC, V57, P1660, DOI 10.1111/j.1532-5415.2009.02393.x; Buja A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208875; Buja A, 2020, J AGING HEALTH, V32, P259, DOI 10.1177/0898264318817091; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Clerencia-Sierra M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132909; Covinsky KE, 2003, J AM GERIATR SOC, V51, P451, DOI 10.1046/j.1532-5415.2003.51152.x; Diez-Manglano J, 2019, MED CLIN-BARCELONA, V153, P196, DOI 10.1016/j.medcli.2019.01.034; Diez-Manglano J, 2015, INTERN EMERG MED, V10, P915, DOI 10.1007/s11739-015-1252-2; Evans SJ, 2014, AGE AGEING, V43, P127, DOI 10.1093/ageing/aft156; Formiga F, 2013, EUR J INTERN MED, V24, P40, DOI 10.1016/j.ejim.2012.11.003; Goldwater Deena S, 2018, J Hosp Med, V13, DOI 10.12788/jhm.2986; Gomez-Aguirre N, 2019, AGING CLIN EXP RES, V31, P393, DOI 10.1007/s40520-018-0980-3; Gordon EH, 2017, EXP GERONTOL, V89, P30, DOI 10.1016/j.exger.2016.12.021; Gordon EH, 2018, MATURITAS, V107, P13, DOI 10.1016/j.maturitas.2017.09.011; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Jardine M, 2018, GERIATRICS-BASEL, V3, DOI 10.3390/geriatrics3040066; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Kyu HH, 2018, LANCET, V392, P1859, DOI [10.1016/S0140-6736(18)32335-3, 10.1016/s0140-6736(18)32335-3]; Le Reste JY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115796; Lobo A, 1999, MED CLIN-BARCELONA, V112, P767; MAHONEY F I, 1965, Md State Med J, V14, P61; Marengoni A, 2011, AGEING RES REV, V10, P430, DOI 10.1016/j.arr.2011.03.003; Martinez-Camblor P, 2016, J STAT COMPUT SIM, V86, P3582, DOI 10.1080/00949655.2016.1175442; Ministry of Health social services and equality, STAT INF HOSP STAT S; National Institute for Health and Care Excellence (NICE), MULT CLIN ASS MAN; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Rijken M, 2017, EUROPEAN OBSERVATORY; Rijken M, 2018, HEALTH POLICY, V122, P44, DOI 10.1016/j.healthpol.2017.10.002; Sociedad Espanola de Medicina Interna, INF RECALMIN; Stewart K, 2016, CLIN MED, V16, P530, DOI 10.7861/clinmedicine.16-6-530; Suarez-Dono J, 2016, EUR J INTERN MED, V36, P25, DOI 10.1016/j.ejim.2016.08.002; Taylor DR, 2014, THORAX, V69, P497, DOI 10.1136/thoraxjnl-2013-204943; Ungar A, 2011, AGE AGEING, V40, P696, DOI 10.1093/ageing/afr109; van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Yarnall AJ, 2017, AGE AGEING, V46, P882, DOI 10.1093/ageing/afx150	43	13	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2020	15	1							e0227252	10.1371/journal.pone.0227252	http://dx.doi.org/10.1371/journal.pone.0227252			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP8ZJ	31990911	Green Published, gold			2023-01-03	WOS:000534605400014
J	Stratilo, CW; Jager, S; Crichton, M; Blanchard, JD				Stratilo, Chad W.; Jager, Scott; Crichton, Melissa; Blanchard, James D.			Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax	PLOS ONE			English	Article							BACILLUS-ANTHRACIS; ENCAPSULATED CIPROFLOXACIN; INHALED ANTIBIOTICS; PROTECTIVE ANTIGEN; EFFICACY; DELIVERY; PHARMACOKINETICS; DISSEMINATION; MACROPHAGE; INFECTION	The in vivo efficacy of liposomal encapsulated ciprofloxacin in two formulations, lipoquin and apulmiq, were evaluated against the causative agent of anthrax, Bacillus anthracis. Liposomal encapsulated ciprofloxacin is attractive as a therapy since it allows for once daily dosing and achieves higher concentrations of the antibiotic at the site of initial mucosal entry but lower systemic drug concentrations. The in vivo efficacy of lipoquin and apulmiq delivered by intranasal instillation was studied at different doses and schedules in both a post exposure prophylaxis (PEP) therapy model and in a delayed treatment model of murine inhalational anthrax. In the mouse model of infection, the survival curves for all treatment cohorts differed significantly from the vehicle control. Ciprofloxacin, lipoquin and apulmiq provided a high level of protection (87-90%) after 7 days of therapy when administered within 24 hours of exposure. Reducing therapy to only three days still provided protection of 60-87%, if therapy was provided within 24 hours of exposure. If treatment was initiated 48 hours after exposure the survival rate was reduced to 46-65%. These studies suggest that lipoquin and apulmiq may be attractive therapies as PEP and as part of a treatment cocktail for B. anthracis.	[Stratilo, Chad W.; Jager, Scott; Crichton, Melissa] Def Res & Dev Canada, Suffield Res Ctr, Bio Threat Def Sect, Ralston, AB, Canada; [Blanchard, James D.] Aradigm Corp, Hayward, CA USA	Defence Research & Development Canada	Stratilo, CW (corresponding author), Def Res & Dev Canada, Suffield Res Ctr, Bio Threat Def Sect, Ralston, AB, Canada.	chad.stratilo@drdc-rddc.gc.ca						Baillie LW, 2010, VACCINE, V28, P6740, DOI 10.1016/j.vaccine.2010.07.075; Bilton D, 2009, AM J RESP CRIT CARE, V179; Blanchard JD, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.00440-18; Booth JL, 2016, MICROBES INFECT, V18, P615, DOI 10.1016/j.micinf.2016.06.004; Bruinenberg P, 2010, AM J RESP CRIT CARE, V181; Bruinenberg P, 2010, PEDIATR PULM, P354; Chono S, 2008, DRUG DEV IND PHARM, V34, P1090, DOI [10.1080/03639040801958421, 10.1080/03639040801958421 ]; Cipolla D, 2016, PHARMACEUTICS, V8, DOI 10.3390/pharmaceutics8010006; Cleret A, 2007, J IMMUNOL, V178, P7994, DOI 10.4049/jimmunol.178.12.7994; Conley J, 1997, ANTIMICROB AGENTS CH, V41, P1288, DOI 10.1128/AAC.41.6.1288; Corey A, 2013, TOXINS, V5, P120, DOI 10.3390/toxins5010120; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Dixon TC, 2000, CELL MICROBIOL, V2, P453, DOI 10.1046/j.1462-5822.2000.00067.x; Falagas ME, 2015, INT J ANTIMICROB AG, V45, P221, DOI 10.1016/j.ijantimicag.2014.10.008; Guidi-Rontani C, 2002, TRENDS MICROBIOL, V10, P405, DOI 10.1016/S0966-842X(02)02422-8; Hagerman Jennifer K, 2006, Expert Opin Drug Deliv, V3, P71, DOI 10.1517/17425247.3.1.71; Hamblin KA, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00091; Hamblin KA, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00079; Hamblin KA, 2014, ANTIMICROB AGENTS CH, V58, P3053, DOI 10.1128/AAC.02555-13; Haworth C, 2017, AM J RESP CRIT CARE, V195; Heine HS, 2007, ANTIMICROB AGENTS CH, V51, P1373, DOI 10.1128/AAC.01050-06; Heine HS, 2010, ANTIMICROB AGENTS CH, V54, P991, DOI 10.1128/AAC.00820-09; Hendricks Katherine A, 2014, Emerg Infect Dis, V20, DOI 10.3201/eid2002.130687; Holty JEC, 2006, ANN EMERG MED, V48, P200, DOI 10.1016/j.annemergmed.2005.11.035; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Jernigan JA, 2001, EMERG INFECT DIS, V7, P933, DOI 10.3201/eid0706.010604; KORANSKY JR, 1978, APPL ENVIRON MICROB, V35, P762, DOI 10.1128/AEM.35.4.762-765.1978; LEIGHTON TJ, 1971, J BIOL CHEM, V246, P3189; LETTIERI JT, 1992, ANTIMICROB AGENTS CH, V36, P993, DOI 10.1128/AAC.36.5.993; Loving CL, 2007, INFECT IMMUN, V75, P2689, DOI 10.1128/IAI.01875-06; Lyons CR, 2004, INFECT IMMUN, V72, P4801, DOI 10.1128/IAI.72.8.4801-4809.2004; MAGALLANES M, 1993, ANTIMICROB AGENTS CH, V37, P2293, DOI 10.1128/AAC.37.11.2293; Migone TS, 2009, NEW ENGL J MED, V361, P135, DOI 10.1056/NEJMoa0810603; Norville IH, 2014, ANTIMICROB AGENTS CH, V58, P5510, DOI 10.1128/AAC.03443-14; Peterson Johnny W, 2010, Open Microbiol J, V4, P34, DOI 10.2174/1874285801004010034; Riedel Stefan, 2005, Proc (Bayl Univ Med Cent), V18, P234; Serisier DJ, 2012, DRUG TODAY, V48, P339, DOI 10.1358/dot.2012.48.5.1789474; Serisier DJ, 2013, THORAX, V68, P812, DOI 10.1136/thoraxjnl-2013-203207; Velkov T, 2015, ADV DRUG DELIVER REV, V85, P65, DOI 10.1016/j.addr.2014.11.004; Vietri NJ, 2006, P NATL ACAD SCI USA, V103, P7813, DOI 10.1073/pnas.0602748103; Webb MS, 1998, ANTIMICROB AGENTS CH, V42, P45, DOI 10.1128/AAC.42.1.45; Weiner ZP, 2012, INFECT IMMUN, V80, P1626, DOI 10.1128/IAI.06061-11; Weiss S, 2015, ANTIMICROB AGENTS CH, V59, P7497, DOI 10.1128/AAC.01376-15; Weiss S, 2011, ANTIMICROB AGENTS CH, V55, P1533, DOI 10.1128/AAC.01689-10; Wong JP, 2003, J CONTROL RELEASE, V92, P265, DOI 10.1016/S0168-3659(03)00358-4; Wood GC, 2007, DRUGS, V67, P903, DOI 10.2165/00003495-200767060-00006	46	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2020	15	1							e0228162	10.1371/journal.pone.0228162	http://dx.doi.org/10.1371/journal.pone.0228162			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP8WY	31978152	gold, Green Submitted, Green Published			2023-01-03	WOS:000534599100119
J	Juraschek, SP; Kovell, LC; Appel, LJ; Miller, ER; Sacks, FM; Christenson, RH; Rebuck, H; Chang, AR; Mukamal, KJ				Juraschek, Stephen P.; Kovell, Lara C.; Appel, Lawrence J.; Miller, Edgar R., III; Sacks, Frank M.; Christenson, Robert H.; Rebuck, Heather; Chang, Alexander R.; Mukamal, Kenneth J.			Associations Between Dietary Patterns and Subclinical Cardiac Injury An Observational Analysis From the DASH Trial	ANNALS OF INTERNAL MEDICINE			English	Article							C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; HEART-FAILURE; NATRIURETIC PEPTIDE; NT-PROBNP; HYPERTENSION; SODIUM; RISK; GUIDELINES; MORTALITY	Background: The DASH diet has been found to lower blood pressure (BP) and low-density lipoprotein cholesterol levels. Objective: To compare diets rich in fruits and vegetables with a typical American diet in their effects on cardiovascular injury in middle-aged adults without known preexisting cardiovascular disease (CVD). Design: Observational study based on a 3-group, paralleldesign, randomized trial conducted in the United States from 1994 to 1996. (ClinicalTrials.gov: NCT00000544) Setting: 3 of the 4 original clinical trial centers. Participants: 326 of the original 459 trial participants with available stored specimens. Intervention: Participants were randomly assigned to 8 weeks of monitored feeding with a control diet typical of what many Americans eat; a diet rich in fruits and vegetables but otherwise similar to the control diet; or the DASH diet, which is rich in fruits, vegetables, low-fat dairy, and fiber and has low levels of saturated fat and cholesterol. Weight was kept constant throughout feeding. Measurements: Biomarkers collected at baseline and 8 weeks: high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity Creactive protein (hs-CRP). Results: The mean age of participants was 45.2 years, 48% were women, 49% were black, and mean baseline BP was 131/85 mm Hg. Compared with the control diet, the fruit-and-vegetable diet reduced hs-cTnI levels by 0.5 ng/L (95% CI, -0.9 to -0.2 ng/L) and NT-proBNP levels by 0.3 pg/mL (CI, -0.5 to -0.1 pg/mL). Compared with the control diet, the DASH diet reduced hs-cTnI levels by 0.5 ng/L (CI, -0.9 to -0.1 ng/L) and NT-proBNP levels by 0.3 pg/mL (CI, -0.5 to -0.04 pg/mL). Levels of hs-CRP did not differ among diets. None of the markers differed between the fruit-and-vegetable and DASH diets. Limitation: Short duration, missing specimens, and an inability to isolate the effects of specific foods or micronutrients. Conclusion: Diets rich in fruits and vegetables given over 8 weeks were associated with lower levels of markers for subclinical cardiac damage and strain in adults without preexisting CVD.	[Juraschek, Stephen P.; Mukamal, Kenneth J.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Kovell, Lara C.] Univ Massachusetts, Sch Med, Worcester, MA USA; [Appel, Lawrence J.; Miller, Edgar R., III] Johns Hopkins Univ, Sch Med, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Appel, Lawrence J.; Miller, Edgar R., III] Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; [Sacks, Frank M.] Harvard Med Sch, Brigham & Womens Hosp, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Christenson, Robert H.; Rebuck, Heather] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Chang, Alexander R.] Geisinger Hlth, Danville, PA USA; [Juraschek, Stephen P.; Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Div Gen Med, Sect Res, 330 Brookline Ave,CO-1309, Boston, MA USA; [Kovell, Lara C.] Univ Massachusetts, Med Ctr, 55 Lake Ave North, Worcester, MA 01650 USA; [Appel, Lawrence J.] Johns Hopkins Univ, Sch Med, 2024 East Monument St,Suite 2-500, Baltimore, MD 21205 USA; [Miller, Edgar R., III] 2024 East Monument St,Suite 1-500L, Baltimore, MD 21205 USA; [Sacks, Frank M.] Harvard TH Chan Sch Publ Hlth, Bldg 1,Room 203,665 Huntington Ave, Boston, MA 02115 USA; [Christenson, Robert H.; Rebuck, Heather] Univ Maryland, 685 West Baltimore St,Room MSTF 8-65, Baltimore, MD 21201 USA; [Chang, Alexander R.] Ctr Hlth Res, 100 North Acad Ave, Danville, PA 17822 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard T.H. Chan School of Public Health; University System of Maryland; University of Maryland Baltimore; Harvard University; Beth Israel Deaconess Medical Center; University of Massachusetts System; University of Massachusetts Worcester; Johns Hopkins University; Harvard University; Harvard T.H. Chan School of Public Health; University System of Maryland; University of Maryland Baltimore	Juraschek, SP (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med, Sect Res, 330 Brookline Ave,CO-1309, Boston, MA USA.	sjurasch@bidmc.harvard.edu	Mukamal, Kenneth/GVR-7978-2022; Appel, Larry/GLT-2608-2022	Kovell, Lara C/0000-0002-7919-2361	National Institutes of Health (NIH)/NHLBI [K23HL135273]; NIH/NHLBI [R21HL144876]; NHLBI [HL50981, HL50968, HL50972, HL50977, HL50982, HL02642, RR02635, RR00722]; Office of Research on Minority Health; National Center for Research Resources of the NIH; Mid-Atlantic Nutrition Obesity Research Center under NIH [P30DK072488]	National Institutes of Health (NIH)/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Office of Research on Minority Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); National Center for Research Resources of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Mid-Atlantic Nutrition Obesity Research Center under NIH	Dr. Juraschek is supported by National Institutes of Health (NIH)/NHLBI grant K23HL135273. The measurement of cardiac biomarkers was supported by NIH/NHLBI grant R21HL144876. The original DASH trial was supported by grants HL50981, HL50968, HL50972, HL50977, HL50982, HL02642, RR02635, and RR00722 from the NHLBI, the Office of Research on Minority Health, and the National Center for Research Resources of the NIH. Research reported in this publication was supported by the Mid-Atlantic Nutrition Obesity Research Center under NIH award number P30DK072488.	Alderman MH, 2012, AM J HYPERTENS, V25, P727, DOI 10.1038/ajh.2012.52; Anderson CAM, 2019, CIRCULATION, V139, pE1025, DOI 10.1161/CIR.0000000000000686; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Azadbakht L, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/971724; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; Bower JK, 2015, AM J HYPERTENS, V28, P1262, DOI 10.1093/ajh/hpv026; Brighenti F, 2005, BRIT J NUTR, V93, P619, DOI 10.1079/BJN20051400; Campos CL, 2019, AM J PREV MED, V56, P819, DOI 10.1016/j.amepre.2018.11.022; Doumatey AP, 2014, CLIN BIOCHEM, V47, P315, DOI 10.1016/j.clinbiochem.2013.12.014; Esposito K, 2003, JAMA-J AM MED ASSOC, V289, P1799, DOI 10.1001/jama.289.14.1799; Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/nejmoa1800389]; Everett BM, 2014, J AM COLL CARDIOL, V64, P1789, DOI 10.1016/j.jacc.2014.04.089; Ference BA, 2017, EUR HEART J, V38, P2459, DOI 10.1093/eurheartj/ehx144; Folsom AR, 2007, AM J HYPERTENS, V20, P225, DOI 10.1016/j.amjhyper.2006.09.003; Fung TT, 2008, ARCH INTERN MED, V168, P713, DOI 10.1001/archinte.168.7.713; Hummel SL, 2013, CIRC-HEART FAIL, V6, P1165, DOI 10.1161/CIRCHEARTFAILURE.113.000481; Jia XM, 2019, CIRCULATION, V139, P2642, DOI 10.1161/CIRCULATIONAHA.118.038772; King DE, 2007, ARCH INTERN MED, V167, P502, DOI 10.1001/archinte.167.5.502; Kleeberger C, 2018, EPIDEMIOLOGY, V29, P448, DOI 10.1097/EDE.0000000000000810; Kovell LC, 2020, INT J CARDIOL, V299, P282, DOI 10.1016/j.ijcard.2019.07.102; Lahoz C, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030379; Levitan EB, 2013, CIRC-HEART FAIL, V6, P1116, DOI 10.1161/CIRCHEARTFAILURE.113.000495; Levitan EB, 2009, ARCH INTERN MED, V169, P851, DOI 10.1001/archinternmed.2009.56; MacLeod SM, 2015, CAN MED ASSOC J, V187, P95, DOI 10.1503/cmaj.141011; Mckie PM, 2016, J AM COLL CARDIOL, V68, P2437, DOI 10.1016/j.jacc.2016.10.001; Mozaffarian D, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002661; Nguyen HT, 2012, J AM COLL NUTR, V31, P401, DOI 10.1080/07315724.2012.10720466; Nissen SE, 2016, ANN INTERN MED, V164, P558, DOI 10.7326/M16-0035; O'Donnell M, 2016, NEW ENGL J MED, V375, P2404, DOI 10.1056/NEJMc1612304; Obarzanek E, 2001, AM J CLIN NUTR, V74, P80; Parrinello CM, 2015, AM HEART J, V170, P380, DOI 10.1016/j.ahj.2015.04.017; Ramsden CE, 2017, LANCET, V390, P2018, DOI 10.1016/S0140-6736(17)32241-9; Rifai Luay, 2015, Proc (Bayl Univ Med Cent), V28, P151; Rubin J, 2012, J AM COLL CARDIOL, V59, P484, DOI 10.1016/j.jacc.2011.10.875; Sattar A, 2011, STAT MED, V30, P3167, DOI 10.1002/sim.4344; Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740; Sotos-Prieto M, 2017, NEW ENGL J MED, V377, P143, DOI [10.1056/NEJMoa1613502, 10.1056/nejmoa1613502]; Tahhan AS, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007914; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; Waldeyer C, 2018, ATHEROSCLEROSIS, V275, P256, DOI 10.1016/j.atherosclerosis.2018.06.877; Zile MR, 2016, J AM COLL CARDIOL, V68, P2425, DOI 10.1016/j.jacc.2016.09.931	41	8	8	2	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 16	2020	172	12					786	+		10.7326/M20-0336	http://dx.doi.org/10.7326/M20-0336			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MI6BB	32423348	Green Accepted			2023-01-03	WOS:000547489700013
J	de Abajo, FJ; Rodriguez-Martin, S; Lerma, V; Mejia-Abril, G; Aguilar, M; Garcia-Luque, A; Laredo, L; Laosa, O; Centeno-Soto, GA; Galvez, MA; Puerro, M; Gonzalez-Rojano, E; Pedraza, L; de Pablo, I; Abad-Santos, F; Rodriguez-Manas, L; Gil, M; Tobias, A; Rodriguez-Miguel, A; Rodriguez-Puyol, D				de Abajo, Francisco J.; Rodriguez-Martin, Sara; Lerma, Victoria; Mejia-Abril, Gina; Aguilar, Monica; Garcia-Luque, Amelia; Laredo, Leonor; Laosa, Olga; Centeno-Soto, Gustavo A.; Galvez, Maria Angeles; Puerro, Miguel; Gonzalez-Rojano, Esperanza; Pedraza, Laura; de Pablo, Itziar; Abad-Santos, Francisco; Rodriguez-Manas, Leocadio; Gil, Miguel; Tobias, Aurelio; Rodriguez-Miguel, Antonio; Rodriguez-Puyol, Diego		MED-ACE2-COVID19 Study Grp	Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study	LANCET			English	Article							CONVERTING ENZYME 2; ACE2; PROTECTS	Background Concerns have been raised about the possibility that inhibitors of the renin-angiotensin-aldosterone system (RAAS) could predispose individuals to severe COVID-19; however, epidemiological evidence is lacking. We report the results of a case-population study done in Madrid, Spain, since the outbreak of COVID-19. Methods In this case-population study, we consecutively selected patients aged 18 years or older with a PCR-confirmed diagnosis of COVID-19 requiring admission to hospital from seven hospitals in Madrid, who had been admitted between March 1 and March 24, 2020. As a reference group, we randomly sampled ten patients per case, individually matched for age, sex, region (ie, Madrid), and date of admission to hospital (month and day; index date), from Base de datos para la Investigacion Farmacoepidemiologica en Atencion Primaria (BIFAP), a Spanish primary health-care database, in its last available year (2018). We extracted information on comorbidities and prescriptions up to the month before index date (ie, current use) from electronic clinical records of both cases and controls. The outcome of interest was admission to hospital of patients with COVID-19. To minimise confounding by indication, the main analysis focused on assessing the association between COVID-19 requiring admission to hospital and use of RAAS inhibitors compared with use of other antihypertensive drugs. We calculated odds ratios (ORs) and 95% CIs, adjusted for age, sex, and cardiovascular comorbidities and risk factors, using conditional logistic regression. The protocol of the study was registered in the EU electronic Register of Post-Authorisation Studies, EUPAS34437. Findings We collected data for 1139 cases and 11 390 population controls. Among cases, 444 (39.0%) were female and the mean age was 69.1 years (SD 15.4), and despite being matched on sex and age, a significantly higher proportion of cases had pre-existing cardiovascular disease (OR 1.98, 95% CI 1.62-2.41) and risk factors (1.46, 1.23-1.73) than did controls. Compared with users of other antihypertensive drugs, users of RAAS inhibitors had an adjusted OR for COVID-19 requiring admission to hospital of 0.94 (95% CI 0.77-1.15). No increased risk was observed with either angiotensin-converting enzyme inhibitors (adjusted OR 0.80, 0.64-1.00) or angiotensin-receptor blockers (1.10, 0.88-1.37). Sex, age, and background cardiovascular risk did not modify the adjusted OR between use of RAAS inhibitors and COVID-19 requiring admission to hospital, whereas a decreased risk of COVID-19 requiring admission to hospital was found among patients with diabetes who were users of RAAS inhibitors (adjusted OR 0.53, 95% CI 0.34-0.80). The adjusted ORs were similar across severity degrees of COVID-19. Interpretation RAAS inhibitors do not increase the risk of COVID-19 requiring admission to hospital, including fatal cases and those admitted to intensive care units, and should not be discontinued to prevent a severe case of COVID-19.	[de Abajo, Francisco J.; Rodriguez-Martin, Sara; Lerma, Victoria; Rodriguez-Miguel, Antonio] Univ Hosp Principe Asturias, Clin Pharmacol Unit, Madrid, Spain; [Rodriguez-Puyol, Diego] Univ Hosp Principe Asturias, Dept Nephrol, Madrid, Spain; [de Abajo, Francisco J.; Rodriguez-Martin, Sara; Garcia-Luque, Amelia; Puerro, Miguel; Rodriguez-Miguel, Antonio] Univ Alcala IRYCIS, Dept Biomed Sci, Pharmacol Sect, Madrid, Spain; [Rodriguez-Puyol, Diego] Univ Alcala IRYCIS, Dept Med, Madrid, Spain; [Mejia-Abril, Gina; Abad-Santos, Francisco] Autonomous Univ Madrid, Inst Hlth La Princesa, Univ Hosp La Princesa, Dept Clin Pharmacol,Teofilo Hernando Inst, Madrid, Spain; [Aguilar, Monica; Galvez, Maria Angeles; de Pablo, Itziar] Univ Hosp Ramon y Cajal IRYCIS, Clin Pharmacol Unit, Madrid, Spain; [Garcia-Luque, Amelia; Puerro, Miguel] Def Cent Hosp, Dept Clin Pharmacol, Madrid, Spain; [Laredo, Leonor; Gonzalez-Rojano, Esperanza] Complutense Univ Madrid IdISSC, Clin Hosp San Carlos, Dept Clin Pharmacol, Dept Pharmacol andToxicol, Madrid, Spain; [Rodriguez-Manas, Leocadio] Univ Hosp Getafe, Dept Geriatr, Madrid, Spain; [Pedraza, Laura] Univ Hosp Getafe, Inst Biomed Res, Madrid, Spain; [Laosa, Olga; Rodriguez-Manas, Leocadio] Inst Hlth Carlos III, Ctr Network Biomed Res Frailty & Healthy Ageing C, Madrid, Spain; [Centeno-Soto, Gustavo A.] Univ Hosp Puerta Hierro, Dept Clin Pharmacol, Madrid, Spain; [Gil, Miguel] Spanish Agcy Med & Med Devices, Div Pharmacoepidemiol & Pharmacovigilance, Madrid, Spain; [Tobias, Aurelio] CSIC, Spanish Council Sci Res, Inst Environm Assessment & Water Res IDAEA, Barcelona, Spain	Prince of Asturias University Hospital; Prince of Asturias University Hospital; Universidad de Alcala; Universidad de Alcala; Autonomous University of Madrid; Hospital Clinico San Carlos; Hospital Universitario de Getafe; Hospital Universitario de Getafe; Hospital Puerta de Hierro-Majadahonda; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); CSIC - Instituto de Diagnostico Ambiental y Estudios del Agua (IDAEA)	de Abajo, FJ (corresponding author), Univ Alcala, Dept Biomed Sci, Madrid 28805, Spain.	francisco.abajo@uah.es	Laredo, Leonor/AAZ-8365-2021; de Abajo, Fancisco/Z-1711-2019; Zafra, Olga Laosa/AAA-7248-2021; Rodríguez-Martín, Sara/AAD-8563-2020; Tobias, Aurelio/ABE-5682-2020	Laredo, Leonor/0000-0001-8772-691X; de Abajo, Fancisco/0000-0001-9119-8646; Rodríguez-Martín, Sara/0000-0003-3539-1470; Tobias, Aurelio/0000-0001-6428-6755; Rodriguez Puyol, Diego/0000-0002-9125-9311; Navares Gomez, Marcos/0000-0003-2501-6845; Zubiaur, Pablo/0000-0002-6150-4320; Gonzalez-Rojano, Esperanza/0000-0002-8731-1025; Rodriguez-Miguel, Antonio/0000-0003-0799-1612; Lerma Hambleton, Victoria/0000-0002-3646-7281; Ascaso, Ana/0000-0002-9159-3520	Institute of Health Carlos III [COV20/00027]	Institute of Health Carlos III(Instituto de Salud Carlos III)	This study was funded by a research grant from the Institute of Health Carlos III (COV20/00027). We thank the health professionals, patients, and administrative staff from the hospitals that participated in this study, and the primary care practitioners and staff of BIFAP. We also thank Arturo Alvarez, for his diligence and skill in extracting the information from population controls, and Dolores Montero and Miguel A Macia. We also thank Maria Jose Bleda, Luis A Garcia Rodriguez, and Alberto Garcia-Lledo who provided helpful suggestions and comments during preparation of the protocol, statistical analysis plan, and manuscript. This Article is dedicated to all researchers' relatives and friends who have died due to COVID-19; they gave us moral strength to complete this research. The results, discussion, and conclusions in this Article are those of the authors and do not necessarily represent the position of their Institutions or the Spanish Agency for Medicines and Medical Devices.	Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; [Anonymous], 2015, PHILADELPHIA; [Anonymous], 2020, NEW YORK TIMES STATE, DOI 10.1016/S2468-2667(20)30117-1; Bean D, 2020, TREATMENT ACE INHIBI, DOI [10.1101/2020.04.07.20056788, DOI 10.1101/2020.04.07.20056788V1]; Cheng H, 2020, J MED VIROL, V92, P726, DOI 10.1002/jmv.25785; Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8; Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461; Guan WJ, 2020, NEW ENGL J MED, V382, P1861, DOI 10.1056/NEJMc2005203; Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219; Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319; Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; Keidar S, 2005, CIRC RES, V97, P946, DOI 10.1161/01.RES.0000187500.24964.7A; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624; Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005; Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8; Ocaranza MP, 2006, HYPERTENSION, V48, P572, DOI 10.1161/01.HYP.0000237862.94083.45; OMara G, 2020, BMJ, V368, pm406; Psaty BM, 1999, J AM GERIATR SOC, V47, P749, DOI 10.1111/j.1532-5415.1999.tb01603.x; Reddy R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213096; Roca-Ho H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030563; Rodriguez-Martin S, 2018, PHARMACOEPIDEM DR S, V27, P1042, DOI 10.1002/pds.4622; Soler MJ, 2009, AM J PHYSIOL-RENAL, V296, pF398, DOI 10.1152/ajprenal.90488.2008; Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509; Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20; Watkins J, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m810; Xie XD, 2006, LIFE SCI, V78, P2166, DOI 10.1016/j.lfs.2005.09.038; Yang PH, 2014, SCI REP-UK, V4, DOI 10.1038/srep07027; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594	34	265	270	4	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	2020	395	10238					1705	1714		10.1016/S0140-6736(20)31030-8	http://dx.doi.org/10.1016/S0140-6736(20)31030-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND0PJ	32416785	Bronze, Green Published			2023-01-03	WOS:000561610000024
J	Barbe, A; Mellouk, N; Rame, C; Grandhaye, J; Anger, K; Chahnamian, M; Ganier, P; Brionne, A; Riva, A; Froment, P; Dupont, J				Barbe, Alix; Mellouk, Namya; Rame, Christelle; Grandhaye, Jeremy; Anger, Karine; Chahnamian, Marine; Ganier, Patrice; Brionne, Aurelien; Riva, Antonella; Froment, Pascal; Dupont, Joelle			A grape seed extract maternal dietary supplementation improves egg quality and reduces ovarian steroidogenesis without affecting fertility parameters in reproductive hens	PLOS ONE			English	Article							BROILER BREEDER HENS; OXIDATIVE STRESS; PROANTHOCYANIDIN EXTRACT; FOOD RESTRICTION; LAYING HENS; BODY-WEIGHT; VITAMIN-E; ANTIOXIDANT; PERFORMANCE; HATCHABILITY	In broiler hens, the genetic selection increased susceptibility to metabolic disorders and reproductive dysfunctions. In human ovarian cells, grape seed extracts (GSE) improved steroid production. Here, we investigated the effects of a GSE dietary supplementation on egg production and quality, fertility parameters, Reactive Oxygen Species (ROS) and steroid content in yolk egg associated to plasma adipokines in broiler hens. For this, we designed two in vivo experiments, the first one included three groups of hens: A (control), B and C (supplemented with GSE at 0.5% and 1% of the total diet composition, respectively, since week 4), and the second one used two groups of hens: A (control) and D (supplemented with GSE at 1% of the total diet composition since hatching). We assessed the egg production from 23th to 40th weeks and quality at 33th week. After artificial inseminations, the fertility parameters were calculated. In egg yolk, Reactive Oxygen Species (ROS) level and steroid production were evaluated by Ros-Glo H202 and ELISA assay, respectively. Expression of steroidogenic enzymes and adipokines and their receptors was determined by RT-qPCR in ovarian cells and plasma adipokines (RARRES2, ADIPOQ and NAMPT) were evaluated by specific ELISA assays. The fertility parameters and egg production were unaffected by GSE supplementation whatever the experiment (exp.). However, the rate of double-yolk eggs decreased for all GSE supplemented groups (exp. 1 P < 0.01, exp.2, P< 0.02). In exp.1, C group eggs were bigger and larger (P< 0.0001) and the shell elasticity was higher for both B and C (P< 0.0003) as compared to control. In the egg yolk, GSE supplementation in both exp. reduced ROS content and steroidogenesis consistent with a decrease in P450 aromatase and StAR mRNA expression and basal in vitro progesterone secretion in granulosa cells (P< 0.001). Interestingly, in both exp. RARRES2 plasma levels were positively correlated while ADIPOQ and NAMPT plasma levels were negatively correlated, with steroids and ROS in yolk (P< 0.0001). Taken together, maternal dietary GSE supplementation did not affect egg production and fertility parameters whereas it reduced ROS content and steroidogenesis in yolk egg. Furthermore, it ameliorated egg quality by decreasing the number of double-yolk eggs and by improving the size of normal eggs and the elasticity of the shell. Taken together, our data suggest the possibility of using dietary maternal GSE to improve egg quality.	[Barbe, Alix; Mellouk, Namya; Rame, Christelle; Grandhaye, Jeremy; Froment, Pascal; Dupont, Joelle] INRAE, UMR85, Physiol Reprod & Comportements, Nouzilly, France; [Barbe, Alix; Mellouk, Namya; Rame, Christelle; Grandhaye, Jeremy; Froment, Pascal; Dupont, Joelle] CNRS, UMR7247, Physiol Reprod & Comportements, Nouzilly, France; [Barbe, Alix; Mellouk, Namya; Rame, Christelle; Grandhaye, Jeremy; Froment, Pascal; Dupont, Joelle] Univ Francois Rabelais Tours, Tours, France; [Barbe, Alix; Mellouk, Namya; Rame, Christelle; Grandhaye, Jeremy; Froment, Pascal; Dupont, Joelle] IFCE Nouzilly, Nouzilly, France; [Anger, Karine; Chahnamian, Marine; Ganier, Patrice] INRAE, UEPEAT, F-1295 Nouzilly, France; [Brionne, Aurelien] INRAE, Biol Oiseaux & Aviculture, UMR0083, Nouzilly, France; [Riva, Antonella] INDENA, Tours, France	INRAE; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; INRAE	Dupont, J (corresponding author), INRAE, UMR85, Physiol Reprod & Comportements, Nouzilly, France.; Dupont, J (corresponding author), CNRS, UMR7247, Physiol Reprod & Comportements, Nouzilly, France.; Dupont, J (corresponding author), Univ Francois Rabelais Tours, Tours, France.; Dupont, J (corresponding author), IFCE Nouzilly, Nouzilly, France.	joelle.dupont@inrae.fr	Mellouk, Namya/AAL-7583-2021	Grandhaye, Jeremy/0000-0002-0909-837X	Region Centre Val de Loire [32000820]	Region Centre Val de Loire(Region Centre-Val de Loire)	The funder is Region Centre Val de Loire (project number 32000820). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abarikwu SO, 2020, ANDROLOGIA, V52, DOI 10.1111/and.13509; Atanasov AG, 2015, BIOTECHNOL ADV, V33, P1582, DOI 10.1016/j.biotechadv.2015.08.001; Bagchi D, 2000, TOXICOLOGY, V148, P187, DOI 10.1016/S0300-483X(00)00210-9; Bagchi D, 2014, MUTAT RES-FUND MOL M, V768, P69, DOI 10.1016/j.mrfmmm.2014.04.004; Bailey RL, 2014, PEERJ, V2, DOI 10.7717/peerj.273; Barbe A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231131; Barbe A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174215; Barbe A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071526; Caimari A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12597-9; Canepa S., 2008, CAH TECHN INRA, V64, P19; Chen SE, 2006, POULTRY SCI, V85, P70, DOI 10.1093/ps/85.1.70; Choi SK, 2012, NUTR RES PRACT, V6, P3, DOI 10.4162/nrp.2012.6.1.3; Decorde K, 2009, J AGR FOOD CHEM, V57, P6461, DOI 10.1021/jf900504g; Decuypere E, 2010, BRIT POULTRY SCI, V51, P569, DOI 10.1080/00071668.2010.519121; Deeming DC, 2011, BRIT POULTRY SCI, V52, P40, DOI 10.1080/00071668.2010.538372; Downing LE, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600347; Dulundu E, 2007, J GASTROEN HEPATOL, V22, P885, DOI 10.1111/j.1440-1746.2007.04875.x; Dupont J, 2001, HORM RES, V55, P22, DOI 10.1159/000063469; Emamverdi M, 2019, THERIOGENOLOGY, V126, P279, DOI 10.1016/j.theriogenology.2018.12.001; ETCHES RJ, 1990, J EXP ZOOL, P112, DOI 10.1002/jez.1402560419; Fasenko GM, 2000, CAN J ANIM SCI, V80, P489, DOI 10.4141/A99-090; FECHHEIMER NS, 1966, J REPROD FERTIL, V12, P363, DOI 10.1530/jrf.0.0120363; Forni C, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8748253; Galli GM, 2018, RES VET SCI, V118, P101, DOI 10.1016/j.rvsc.2018.01.022; Gil D, 2008, HORM BEHAV, V54, P238, DOI 10.1016/j.yhbeh.2007.11.013; Gonzalez-Abuin N, 2014, FOOD FUNCT, V5, P2357, DOI [10.1039/C4FO00447G, 10.1039/c4fo00447g]; Groothuis TGG, 2005, NEUROSCI BIOBEHAV R, V29, P329, DOI 10.1016/j.neubiorev.2004.12.002; Hajati H., 2014, Research Opinions in Animal and Veterinary Sciences, V4, P633; Hocking PM, 1996, BRIT POULTRY SCI, V37, P263, DOI 10.1080/00071669608417858; Hou FY, 2016, ANAT REC, V299, P450, DOI 10.1002/ar.23320; JAAP RG, 1968, POULTRY SCI, V47, P417, DOI 10.3382/ps.0470417; Kara K, 2016, J APPL ANIM RES, V44, P303, DOI 10.1080/09712119.2015.1031785; LATSHAW JD, 1977, POULTRY SCI, V56, P1876, DOI 10.3382/ps.0561876; Leeson S, 2000, J APPL POULTRY RES, V9, P297, DOI 10.1093/japr/9.3.297; Li HX, 2015, MOL CELL ENDOCRINOL, V414, P216, DOI 10.1016/j.mce.2015.07.006; Lin Yu-Ting, 2019, Cell Physiol Biochem, V52, P1398, DOI 10.33594/000000098; Liu MJ, 2018, FERTIL STERIL, V109, P900, DOI 10.1016/j.fertnstert.2018.01.020; Liu XT, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9390810; Meeprom A, 2011, BRIT J NUTR, V106, P1173, DOI 10.1017/S0007114511001589; Mellouk N, 2018, REPRODUCTION, V155, P321, DOI 10.1530/REP-17-0678; Oita RC, 2010, PFLUG ARCH EUR J PHY, V459, P619, DOI 10.1007/s00424-009-0752-1; Olaku OO, 2015, NUTR CANCER, V67, P730, DOI 10.1080/01635581.2015.1029639; Pearson A. M., 1983, Food Technology, V37, P121; Rajput Shahid Ali, 2019, Toxins (Basel), V11, DOI 10.3390/toxins11010023; Reis JH, 2019, J THERM BIOL, V80, P141, DOI 10.1016/j.jtherbio.2019.01.003; Ribas-Latre A, 2015, SCI REP-UK, V5, DOI 10.1038/srep10954; Richards MP, 2007, POULTRY SCI, V86, P1478, DOI 10.1093/ps/86.7.1478; Sahin K, 2010, POULTRY SCI, V89, P1190, DOI 10.3382/ps.2010-00635; Salary Jalal, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, pS616; Sun YL, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101132; Surai PF, 2016, ANIM NUTR, V2, P1, DOI 10.1016/j.aninu.2016.01.001; Urso URA, 2015, POULTRY SCI, V94, P976, DOI 10.3382/ps/pev042; Wang F, 2018, INT J CLIN EXP PATHO, V11, P3338; WARREN D. C, 1935, POULTRY SCI, V14, P195, DOI 10.3382/ps.0140195; Xia EQ, 2010, INT J MOL SCI, V11, P622, DOI 10.3390/ijms11020622; Yao JN, 2019, BIOCHEM BIOPH RES CO, V510, P449, DOI 10.1016/j.bbrc.2019.01.125	56	9	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2020	15	5							e0233169	10.1371/journal.pone.0233169	http://dx.doi.org/10.1371/journal.pone.0233169			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU0YZ	32407420	Green Published, gold			2023-01-03	WOS:000537490700080
J	Hammond, A; Stuijfzand, B; Avison, MB; Hay, AD				Hammond, Ashley; Stuijfzand, Bobby; Avison, Matthew B.; Hay, Alastair D.			Antimicrobial resistance associations with national primary care antibiotic stewardship policy: Primary care-based, multilevel analytic study	PLOS ONE			English	Article							GENERAL-PRACTICE; COMMUNITY	Background Recent UK antibiotic stewardship policies have resulted in significant changes in primary care dispensing, but whether this has impacted antimicrobial resistance is unknown. Aim To evaluate associations between changes in primary care dispensing and antimicrobial resistance in community-acquired urinary Escherichia coli infections. Methods Multilevel logistic regression modelling investigating relationships between primary care practice level antibiotic dispensing for approximately 1.5 million patients in South West England and resistance in 152,704 community-acquired urinary E. coli between 2013 and 2016. Relationships presented for within and subsequent quarter drug-bug pairs, adjusted for patient age, deprivation, and rurality. Results In line with national trends, overall antibiotic dispensing per 1000 registered patients fell 11%. Amoxicillin fell 14%, cefalexin 20%, ciprofloxacin 24%, co-amoxiclav 49% and trimethoprim 8%. Nitrofurantoin increased 7%. Antibiotic reductions were associated with reduced within quarter same-antibiotic resistance to: amoxicillin, ciprofloxacin and trimethoprim. Subsequent quarter reduced resistance was observed for trimethoprim and amoxicillin. Antibiotic dispensing reductions were associated with increased within and subsequent quarter resistance to cefalexin and co-amoxiclav. Increased nitrofurantoin dispensing was associated with reduced within and subsequent quarter trimethoprim resistance without affecting nitrofurantoin resistance. Conclusions This evaluation of a national primary care stewardship policy on antimicrobial resistance in the community suggests both hoped-for benefits and unexpected harms. Some increase in resistance to cefalexin and co-amoxiclav could result from residual confounding. Randomised controlled trials are urgently required to investigate causality.	[Hammond, Ashley; Hay, Alastair D.] Univ Bristol, Bristol Med Sch, Ctr Acad Primary Care, Bristol, Avon, England; [Stuijfzand, Bobby] Univ Bristol, Jean Golding Inst, Royal Ft House, Bristol, Avon, England; [Avison, Matthew B.] Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England	University of Bristol; University of Bristol; University of Bristol	Hammond, A (corresponding author), Univ Bristol, Bristol Med Sch, Ctr Acad Primary Care, Bristol, Avon, England.	ashley.hammond@bristol.ac.uk		Hay, Alastair/0000-0003-3012-375X; Hammond, Ashley/0000-0002-6657-1514; Stuijfzand, Bobby/0000-0002-2782-3408; Avison, Matthew/0000-0003-1454-8440	 [NE/N01961X/1]; NERC [NE/N01961X/1] Funding Source: UKRI	; NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	Antimicrobial Resistance Cross Council Initiative supported by the seven research councils (www.mrc.ac.uk/amr).Grant reference is NE/N01961X/1.	Arcilla MS, 2017, LANCET INFECT DIS, V17, P78, DOI 10.1016/S1473-3099(16)30319-X; Balinskaite V, 2019, CLIN INFECT DIS, V69, P233, DOI 10.1093/cid/ciy904; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bell BG, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-13; Bevan ER, 2018, MBIO, V9, DOI 10.1128/mBio.02408-18; Bryce A, 2018, J ANTIMICROB CHEMOTH; Butler CC, 2007, BRIT J GEN PRACT, V57, P785; Costelloe Ceire, 2010, BMJ, V340, pc2096, DOI 10.1136/bmj.c2096; Curtice John, 2019, BRIT SOCIAL ATTITUDE; Department for Communities and Local Government, 2011, ENGLISH INDICES DEPR; Dolk FCK, 2018, J ANTIMICROB CHEMOTH, V73, P2, DOI 10.1093/jac/dkx504; Enne VI, 2010, J ANTIMICROB CHEMOTH, V65, P179, DOI 10.1093/jac/dkp443; Findlay J, 2019, BIORXIV; Gharbi M, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l525; Gottesman BS, 2009, CLIN INFECT DIS, V49, P869, DOI 10.1086/605530; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; Hay AD, 2016, BMJ BRIT MED J, V352, pI939, DOI DOI 10.1136/BMJ.I939; Heinemann JA, 2000, DRUG DISCOV TODAY, V5, P195, DOI 10.1016/S1359-6446(00)01483-5; Hox J., 2010, MULTILEVEL ANAL TECH; Ironmonger D, 2018, J ANTIMICROB CHEMOTH, V73, P787, DOI 10.1093/jac/dkx465; Jacoby GA, 2009, CLIN MICROBIOL REV, V22, P161, DOI 10.1128/CMR.00036-08; Kumar M, 2017, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.02023; Low M, 2019, LANCET INFECT DIS, V19, P419, DOI 10.1016/S1473-3099(18)30676-5; NHS Digital, 2019, PAT REG GP PRACT 201; NHS England, 2015, QUAL PREM 2015 16 GU; NICE, 2018, UR TRACT INF LOW ANT; Pouwels KB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218134; Pouwels KB, 2018, J ANTIMICROB CHEMOTH, V73, P1700, DOI 10.1093/jac/dky031; Priest P, 2001, BMJ-BRIT MED J, V323, P1037, DOI 10.1136/bmj.323.7320.1037; Public Health England, 2018, ENGL SURV PROGR ANT; R Core Team, 2021, R LANG ENV STAT COMP; Sommet A, 2004, J ANTIMICROB CHEMOTH, V54, P524, DOI 10.1093/jac/dkh342; Tonkin-Crine SKG, 2017, COCHRANE DB SYST REV, P9, DOI DOI 10.1038/S41598-021-87369-7; Wang H, 2013, BMJ OPEN, V3, DOI [10.1136/bmjopen-2013-003320, 10.1136/bmjopen-2012-001801]; Yamamoto S, 1997, J UROLOGY, V157, P1127, DOI 10.1016/S0022-5347(01)65154-1	35	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2020	15	5							e0232903	10.1371/journal.pone.0232903	http://dx.doi.org/10.1371/journal.pone.0232903			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU0YZ	32407346	Green Published, gold			2023-01-03	WOS:000537490700046
J	Harris, M; Bhatti, Y; Buckley, J; Sharma, D				Harris, Matthew; Bhatti, Yasser; Buckley, Jim; Sharma, Dhananjaya			Fast and frugal innovations in response to the COVID-19 pandemic	NATURE MEDICINE			English	Editorial Material							HEALTH-CARE		[Harris, Matthew] Imperial Coll London, London, England; [Bhatti, Yasser] Queen Mary Univ London, London, England; [Buckley, Jim] Royal Free Hosp, London, England; [Sharma, Dhananjaya] Govt NSCB Med Coll & Allied Hosp, Dept Surg, Jabalpur, India	Imperial College London; University of London; Queen Mary University London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Harris, M (corresponding author), Imperial Coll London, London, England.	m.harris@imperial.ac.uk		Bhatti, Yasser/0000-0001-5284-0261; Buckley, Jim/0000-0001-8110-5135; Harris, Matthew/0000-0002-0005-9710	NW London National Institute for Health Research (NIHR) Applied Research Collaboration; NW London NIHR Applied Research Collaboration; Imperial NIHR Biomedical Research Centre	NW London National Institute for Health Research (NIHR) Applied Research Collaboration; NW London NIHR Applied Research Collaboration; Imperial NIHR Biomedical Research Centre(National Institute for Health Research (NIHR))	No funding was received in direct relation to this article. M.H. is supported in part by the NW London National Institute for Health Research (NIHR) Applied Research Collaboration. Imperial College London is grateful for support from the NW London NIHR Applied Research Collaboration and the Imperial NIHR Biomedical Research Centre. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.	Ankel S, 2020, BUS INSIDER; [Anonymous], 2020, OXFORD NEWS EVENTS; [Anonymous], 2020, ECONOMIST 0326; [Anonymous], EXAMINER 0422; Basu R.R., 2013, J MANAG GLOB SUSTAIN, V1, P63, DOI [10.13185/JM2013.01204, DOI 10.13185/JM2013.01204]; Bhattacharyya O, 2017, GLOBALIZATION HEALTH, V13, DOI 10.1186/s12992-016-0225-1; Bhatti Y, 2018, FRUGAL INNOVATION: MODELS, MEANS, METHODS, P1, DOI 10.1017/9781316986783; Bhatti Y, 2017, HEALTH AFFAIR, V36, P1912, DOI 10.1377/hlthaff.2017.0480; Cash-Gibson L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191901; Department of Health and Social Care. UK Government, 2020, GUID RAP MAN VENT SY; Etherington D., 2020, TECHCRUNCH; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Govindarajan V., 2012, REVERSE INNOVATION C; Govindarajan V, 2013, HARVARD BUS REV, V91, P117; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Hadengue M, 2017, INT J EMERG MARK, V12, P142, DOI 10.1108/IJoEM-12-2015-0272; Haelle T., 2020, FORBES; Haines A, 2020, LANCET, V395, P1173, DOI 10.1016/S0140-6736(20)30735-2; Harris M, 2017, HEALTH AFFAIR, V36, P1997, DOI 10.1377/hlthaff.2017.0773; Harris M, 2017, GLOBALIZATION HEALTH, V13, DOI 10.1186/s12992-017-0304-y; Harris M, 2015, GLOBALIZATION HEALTH, V11, DOI 10.1186/s12992-015-0130-z; Henderson WR, 2014, CAN RESPIR J, V21, P213, DOI 10.1155/2014/472136; Hutt D, 2020, EURONEWS; India Today Web Desk, 2020, INDIA TODAY; Istratii Romina., 2020, CONVIVIAL THINKING; Lokugamage AU, 2020, J MED ETHICS, V46, P265, DOI 10.1136/medethics-2019-105866; Macinko James, 2015, N Engl J Med, V372, P2177, DOI 10.1056/NEJMp1501140; McGillivray B, 2018, RES INTEGR PEER REV, V3, DOI 10.1186/s41073-018-0049-z; Nandi T, 2020, LIVEMINT; Ohnsman A., 2020, FORBES; Prabhu J, 2017, PHILOS T R SOC A, V375, DOI 10.1098/rsta.2016.0372; Prahalad CK, 2009, FORTUNE BOTTOM PYRAM; Sackur S, 2020, BBC WORLD NEWS HARDT; Simpson P, 2020, SOCIOLOGY, V54, P856, DOI 10.1177/0038038519897907; Skopec M, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l6205; Wadge H., BRAZILS FAMILY HLTH; Wiah S., 2020, BMJ OPINION BLOG; 2020, UCL NEWS	38	58	58	4	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2020	26	6					814	817		10.1038/s41591-020-0889-1	http://dx.doi.org/10.1038/s41591-020-0889-1		MAY 2020	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	LZ3ZG	32393803	Green Submitted, Bronze			2023-01-03	WOS:000531781900002
J	Claus, J; Brietzke, A; Lehnert, C; Oschatz, S; Grabow, N; Kragl, U				Claus, Johanna; Brietzke, Andreas; Lehnert, Celina; Oschatz, Stefan; Grabow, Niels; Kragl, Udo			Swelling characteristics and biocompatibility of ionic liquid based hydrogels for biomedical applications	PLOS ONE			English	Article							NANOPARTICLES; DEGRADATION	Polymers are commonly used in medical device manufacturing, e.g. for drug delivery systems, bone substitutes and stent coatings. Especially hydrogels exhibit very promising properties in this field. Hence, the development of new hydrogel systems for customized application is of great interest, especially regarding the swelling behavior and mechanical properties as well as the biocompatibility. The aim of this work was the preparation and investigation of various polyelectrolyte and poly-ionic liquid based hydrogels accessible by radical polymerization. The obtained polymers were covalently crosslinked with N,N'-methylenebisacrylamide (MBAA) or different lengths of poly(ethyleneglycol)diacrylate (PEGDA). The effect of different crosslinker-to-monomer ratios has been examined. In addition to the compression curves and the maximum degree of swelling, the biocompatibility with L929 mouse fibroblasts of these materials was determined in direct cell seeding experiments and the outcome for the different hydrogels was compared.	[Claus, Johanna; Lehnert, Celina; Kragl, Udo] Univ Rostock, Dept Chem Ind & Appl Chem, Rostock, Germany; [Claus, Johanna; Lehnert, Celina; Grabow, Niels; Kragl, Udo] Univ Rostock, Dept Life Light & Matter, Rostock, Germany; [Brietzke, Andreas; Oschatz, Stefan; Grabow, Niels] Rostock Univ, Med Ctr, Inst Biomed Engn, Rostock, Germany	University of Rostock; University of Rostock; University of Rostock	Kragl, U (corresponding author), Univ Rostock, Dept Chem Ind & Appl Chem, Rostock, Germany.; Kragl, U (corresponding author), Univ Rostock, Dept Life Light & Matter, Rostock, Germany.	udo.kragl@uni-rostock.de	Kragl, Udo/A-3691-2015	Kragl, Udo/0000-0002-2507-7472; Meyer, Johanna/0000-0003-2557-4425; Oschatz, Stefan Thomas/0000-0003-2339-456X	Deutsche Forschungsgemeinschaft; University of Rostock; Federal Ministry of Education and Research within RESPONSE "Partnership for Innovation in Implant Technology" [FKZ 03ZZ0910B]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); University of Rostock; Federal Ministry of Education and Research within RESPONSE "Partnership for Innovation in Implant Technology"	We acknowledge financial support by Deutsche Forschungsgemeinschaft and University of Rostock within the funding programme Open Access Publishing. Funding by the Federal Ministry of Education and Research within RESPONSE "Partnership for Innovation in Implant Technology" (FKZ 03ZZ0910B) is gratefully acknowledged.	ALTANKOV G, 1994, J MATER SCI-MATER M, V5, P732, DOI 10.1007/BF00120366; Amer LD, 2019, ACTA BIOMATER, V100, P105, DOI 10.1016/j.actbio.2019.09.043; Bandomir J, 2014, MACROMOL CHEM PHYS, V215, P716, DOI 10.1002/macp.201400009; Behl G, 2016, PHARM RES-DORDR, V33, P1638, DOI 10.1007/s11095-016-1903-7; de Queiroz AAB, 2018, KNEE SURG SPORT TR A, V26, P2934, DOI 10.1007/s00167-018-4834-5; Bingol B, 2019, ACS APPL POLYM MATER, V1, P1724, DOI 10.1021/acsapm.9b00287; BONGRAND P, 1982, PROG SURF SCI, V12, P217, DOI 10.1016/0079-6816(82)90007-7; Brietzke A, 2017, CURR DIR BIOMED ENG, V3, P695, DOI [10.1515/cdbme-2017-0147, DOI 10.1515/CDBME-2017-0147]; Calvert P, 2009, ADV MATER, V21, P743, DOI 10.1002/adma.200800534; Chang S, 2000, J MED BIOL ENG, V20, P6; Chen YF, 2001, RADIAT PHYS CHEM, V61, P65; Claus J, 2018, SOLID STATE IONICS, V314, P119, DOI 10.1016/j.ssi.2017.11.012; Colter J, 2018, ANN BIOMED ENG, V46, P211, DOI 10.1007/s10439-017-1962-x; Cui ZW, 2011, J BIOMED MATER RES A, V98A, P159, DOI 10.1002/jbm.a.33093; Darwis D, 2002, RADIAT PHYS CHEM, V63, P539, DOI 10.1016/S0969-806X(01)00636-3; de Feng X, 1988, MAKROMOL CHEM, V189, P77; Deguchi Y, 2015, CHEM COMMUN, V51, P9287, DOI 10.1039/c5cc02189h; Fairbanks BD, 2014, BIOMACROMOLECULES, V15, P3259, DOI 10.1021/bm500654q; Highley CB, 2016, CURR OPIN BIOTECH, V40, P35, DOI 10.1016/j.copbio.2016.02.008; Hu XY, 2014, CARBOHYD POLYM, V105, P135, DOI 10.1016/j.carbpol.2014.01.051; Jamadi M, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201600479; Kamaly N, 2016, CHEM REV, V116, P2602, DOI 10.1021/acs.chemrev.5b00346; Kaufman JD, 2008, J MATER RES, V23, P1472, DOI 10.1557/JMR.2008.0185; Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003; Lu JM, 2009, PROG POLYM SCI, V34, P431, DOI 10.1016/j.progpolymsci.2008.12.001; Ma ZW, 2010, BIOMACROMOLECULES, V11, P1873, DOI 10.1021/bm1004299; Marcilla R, 2004, J POLYM SCI POL CHEM, V42, P208, DOI 10.1002/pola.11015; Mazzoli Robert A, 2004, Curr Opin Ophthalmol, V15, P426, DOI 10.1097/01.icu.0000138618.61059.4c; Moghadam MN, 2016, J BIOMED MATER RES B, V104, P1161, DOI 10.1002/jbm.b.33469; Motta A, 2004, J BIOMAT SCI-POLYM E, V15, P851, DOI 10.1163/1568562041271075; Mrksich M, 2000, CHEM SOC REV, V29, P267, DOI 10.1039/a705397e; Okafuji A, 2016, MACROMOL RAPID COMM, V37, P1130, DOI 10.1002/marc.201500752; Okay O, 2009, SPRINGER SER CHEM SE, V6, P1, DOI 10.1007/978-3-540-75645-3_1; Rayahin JE, 2017, RESULTS PROBL CELL D, V62, P317, DOI 10.1007/978-3-319-54090-0_13; Sigler M, 2005, Z KARDIOL, V94, P383, DOI 10.1007/s00392-005-0231-4; Smit TJ, 1991, ORBIT, V10, P63, DOI [10.3109/01676839109023086, DOI 10.3109/01676839109023086]; Strachota B, 2015, SOFT MATTER, V11, P9291, DOI 10.1039/c5sm01996f; Su E, 2019, MACROMOLECULES, V52, P3257, DOI 10.1021/acs.macromol.9b00032; Sun HF, 2015, J COLLOID INTERF SCI, V450, P353, DOI 10.1016/j.jcis.2015.03.037; Taksali Sudeep, 2004, Spine J, V4, p231S, DOI 10.1016/j.spinee.2004.07.012; TANAKA T, 1973, J CHEM PHYS, V59, P5151, DOI 10.1063/1.1680734; Tognetto D, 2005, EXPERT REV MED DEVIC, V2, P57, DOI 10.1586/17434440.2.1.57; Trindade R, 2016, CLIN IMPLANT DENT R, V18, P192, DOI 10.1111/cid.12274; Trindade R, 2015, ORAL MAXIL SURG CLIN, V27, P175, DOI 10.1016/j.coms.2015.01.004; Tummala GK, 2019, J FUNCT BIOMATER, V10, DOI 10.3390/jfb10030035; Verma AS, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-47	46	18	18	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2020	15	4							e0231421	10.1371/journal.pone.0231421	http://dx.doi.org/10.1371/journal.pone.0231421			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9MR	32310981	Green Published, gold			2023-01-03	WOS:000536019800015
J	Chinda, P; Poomthong, P; Toadithep, P; Thanakiattiwibun, C; Chaiwat, O				Chinda, Pornrat; Poomthong, Pulyamon; Toadithep, Puriwat; Thanakiattiwibun, Chayanan; Chaiwat, Onuma			The implementation of a nutrition protocol in a surgical intensive care unit; a randomized controlled trial at a tertiary care hospital	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; PARENTERAL-NUTRITION; GUIDELINES; PROVISION; MORTALITY; OUTCOMES; THERAPY; INJURY	Background Malnutrition in critically ill patients is linked with significant mortality and morbidity. However, it remains controversial whether nutrition therapy protocols are effective in improving clinical outcomes. The present study aimed to evaluate the effectiveness of a surgical ICU nutrition protocol, and to compare the hospital mortality, hospital LOS, and ICU LOS of protocol and non-protocol groups. Methods A randomized controlled trial was conducted at the Surgical ICU, Siriraj Hospital. The nutrition administration of the control group was at the discretion of the attending physicians, whereas that of the intervention group followed the "Siriraj Surgical ICU Nutrition Protocol". Details of the demographic data, nutritional data, and clinical outcomes were collected. Results In all, 170 patients underwent randomization, with 85 individuals each in the protocol and non-protocol groups. More than 90% of the patients in both groups were at risk of malnutrition, indicated by a score of. 3 on the Nutritional Risk Screening 2002 tool. The average daily calories of the 2 groups were very similar (protocol group, 775.4 +/- 342.2 kcal vs. control group, 773.0 +/- 391.9 kcal; p = 0.972). However, the median time to commence enteral nutrition was shorter for the protocol group (1.94 days) than the control group (2.25 days; p = 0.503). Enteral nutrition was provided within the first 48 hours to 53.7% of the protocol patients vs. 47.4% of the control patients (p = 0.589). In addition, a higher proportion of the protocol patients (36.5%) reached the 60% calorie-target on Day 4 after admission than that for the non-protocol group (25.9%; p = 0.136). All other clinical outcomes and nutrition-related complications were not significantly different. Conclusions The implementation of the nutrition protocol did not improve the feeding effectiveness or clinical outcomes as compared to usual nutrition management practices of the Surgical ICU.	[Chinda, Pornrat; Poomthong, Pulyamon] Mahidol Univ, Siriraj Hosp, Div Crit Care Med, Dept Med, Bangkok, Thailand; [Toadithep, Puriwat; Thanakiattiwibun, Chayanan; Chaiwat, Onuma] Mahidol Univ, Siriraj Hosp, Dept Anesthesiol, Fac Med, Bangkok, Thailand	Mahidol University; Mahidol University	Chaiwat, O (corresponding author), Mahidol Univ, Siriraj Hosp, Dept Anesthesiol, Fac Med, Bangkok, Thailand.	onuma.cha@mahidol.ac.th		CHAIWAT, ONUMA/0000-0001-5407-306X				Al-Dorzi HM, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1539-3; Auiwattanakul S, 2019, NUTRITION, V58, P94, DOI 10.1016/j.nut.2018.06.021; Barr J, 2004, CHEST, V125, P1446, DOI 10.1378/chest.125.4.1446; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Cahill NE, 2010, CRIT CARE MED, V38, P395, DOI 10.1097/CCM.0b013e3181c0263d; Casaer MP, 2014, NEW ENGL J MED, V370, P1227, DOI 10.1056/NEJMra1304623; Chittawatanarat K, 2006, THAI J SURG, V27, P5; Chittawatanarat Kaweesak, 2016, Journal of the Medical Association of Thailand, V99, pS163; Doig GS, 2008, JAMA-J AM MED ASSOC, V300, P2731, DOI 10.1001/jama.2008.826; Elia M, 2003, DEV USE MALNUTRITION; Elke G, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1298-1; Fan Ming-chao, 2016, Chinese Medical Sciences Journal, V31, P213; Gavri C, 2016, CLIN NUTR ESPEN, V12, pE14, DOI 10.1016/j.clnesp.2016.01.002; Heidegger CP, 2013, LANCET, V381, P385, DOI 10.1016/S0140-6736(12)61351-8; Heyland DK, 2011, CRIT CARE, V15, DOI 10.1186/cc10546; Heyland DK, 2010, CRIT CARE, V14, DOI 10.1186/cc8991; Kondrup J, 2003, CLIN NUTR, V22, P415, DOI 10.1016/S0261-5614(03)00098-0; Li Q, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182393; McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI [10.1177/0148607115621863, 10.1097/CCM.0000000000001525]; Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037; Wang D, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0094-0; Wischmeyer PE, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1736-8	23	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2020	15	4							e0231777	10.1371/journal.pone.0231777	http://dx.doi.org/10.1371/journal.pone.0231777			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9JM	32298381	Green Published, gold			2023-01-03	WOS:000536011400110
J	Nyarko, SH				Nyarko, Samuel H.			Spatial variations and socioeconomic determinants of modern contraceptive use in Ghana: A Bayesian multilevel analysis	PLOS ONE			English	Article								The literature on spatial patterns and contextual factors affecting modern contraceptive use is not well-documented in Ghana. This study describes the spatial variations and estimates the socioeconomic determinants of modern contraception among women in reproductive age in Ghana. Using data from the 2014 Ghana Demographic and Health Survey, both global and local Moran's I test were performed to show spatial autocorrelation and Bayesian multilevel models estimated to determine socioeconomic factors affecting modern contraceptive use. The results show evidence of low prevalence and spatial clustering of modern contraception use across the country. There were also notable regional disparities in contraceptive use that favour mostly the southern regions. Modern contraceptive use is significantly associated with socioeconomic factors such as educational attainment, work status, and marital status, as well as age, religious affiliation, and parity. Contextual factors such as the convenient location of health facility and family planning messages exposure also have a considerable positive effect on modern contraceptive use. Uneducated, unemployed and never-married women are considerably disadvantaged in the utilisation of modern contraception in Ghana. Socioeconomic and contextual factors play a key role in modern contraceptive use in Ghana.	[Nyarko, Samuel H.] Univ Hlth & Allied Sci, Dept Populat & Behav Sci, Hohoe, Ghana; [Nyarko, Samuel H.] Univ Texas San Antonio, Dept Demog, San Antonio, TX 78249 USA	University of Texas System; University of Texas at San Antonio (UTSA)	Nyarko, SH (corresponding author), Univ Hlth & Allied Sci, Dept Populat & Behav Sci, Hohoe, Ghana.; Nyarko, SH (corresponding author), Univ Texas San Antonio, Dept Demog, San Antonio, TX 78249 USA.	samharrenson@gmail.com		Nyarko, Samuel/0000-0002-6999-351X				Achana FS, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0017-8; [Anonymous], 2018, R LANG ENV STAT COMP; Babalola S, 2018, DEMOGR RES, V38, P287, DOI 10.4054/DemRes.2018.38.12; Cleland JG, 2011, B WORLD HEALTH ORGAN, V89, P137, DOI 10.2471/BLT.10.077925; Ettarh R. R., 2012, African Journal of Reproductive Health, V16, P47; Ghana Health Service (GHS) UNFPA, 2015, DAY DIAL FAM PLANN G; Ghana Statistical Service, 2014, GHANA DEMOGRAPHIC HL; Ghana Survey Department, 1996, COUNTR SHAP DAT; Government of Ghana, 2015, GHAN FAM PLANN COST; Government of Ghana, 1994, NAT POP POL; Guttmacher Institute, 2017, ADD IT INV CONTR MAT; Kandala NB, 2015, J BIOSOC SCI, V47, P345, DOI 10.1017/S0021932014000212; Lakew Y, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-52; Lamidi EO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135172; Nketiah-Amponsah E., 2012, African Journal of Reproductive Health, V16, P154; Nonvignon J., 2014, African Population Studies, V28, P956; Nyarko SH, 2019, J PREGNANCY, V2019, DOI 10.1155/2019/2920491; Nyarko SH., 2019, GENUS, V75, P22, DOI DOI 10.1186/S41118-019-0069-7; O'Hagan A, 2004, WAG UR FRON, V3, P31; Obwoya JG, 2018, INT J POPUL RES, P7; Okoli ML, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022221; Palamuleni Martin E, 2013, Afr J Reprod Health, V17, P91; Rue H, 2009, J R STAT SOC B, V71, P319, DOI 10.1111/j.1467-9868.2008.00700.x; Stephenson R, 2007, AM J PUBLIC HEALTH, V97, P1233, DOI 10.2105/AJPH.2005.071522; United Nations Department of Economic and Social Affairs Population Division, 2017, WORLD FAM PLANN 2017; Unumeri G, 2015, AFRICAN POPULATION S, V29, P1851, DOI DOI 10.11564/29-2-757; World Health Organization, 2014, CONTR FACT SHEET	27	11	11	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2020	15	3							e0230139	10.1371/journal.pone.0230139	http://dx.doi.org/10.1371/journal.pone.0230139			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8WI	32155217	Green Published, gold			2023-01-03	WOS:000535278500066
J	Evers, C; Ostheimer, C; Sieker, F; Vordermark, D; Medenwald, D				Evers, Christoph; Ostheimer, Christian; Sieker, Frank; Vordermark, Dirk; Medenwald, Daniel			Benefit from surgery with additional radiotherapy in N1 head and neck cancer at the time of IMRT: A population-based study on recent developments	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; MODULATED RADIATION-THERAPY; NODE-POSITIVE HEAD; HUMAN-PAPILLOMAVIRUS; POSTOPERATIVE RADIOTHERAPY; ADJUVANT RADIOTHERAPY; OROPHARYNGEAL CANCER; UNITED-STATES; ORAL-CAVITY; SURVIVAL	Background Currently, the role of adjuvant irradiation in head and neck cancer (HNC) patients with N1-lymph node status is not clarified. Objectives To assess the population-based effect of recent developments in radiotherapy such as intensity-modulated radiotherapy (IMRT) in relation to overall survival (OS) together with surgery in N1 HNC patients. Materials and methods We used 9,318 HNC cases with pT1/2 N0/1 disease from German cancer registries. Time of diagnosis ranged from January 2000 to December 2014, which we divided into three periods: (low [LIA] vs intermediate [IA] vs high [HIA] IMRT availability period) based on usage of IMRT in Germany. For each period, we examined a possible association between treatment (surgery vs. surgery and radiotherapy) in terms of OS. Statistical analyses included Kaplan-Meier and multivariate Cox regression (models adjusted for HPV-related cancer site). Results Temporal analysis revealed increasing usage of IMRT in Germany. In patients with N1 tumours, a comparison of patients treated with and without radiotherapy during the HIA period showed a superiority of the combined treatment as opposed to surgery alone (HR 0.54, 95%CI: 0.35-0.85, p = 0.003). The survival analyses related to treatments in terms of period underlined the superiority of surgery plus radiotherapy between periods IA and HIA (p = 0.03). Conclusion The advent of IMRT, additional radiotherapy may present a survival advantage in patients with N1 HNC when combined with surgery.	[Evers, Christoph] Martin Luther Univ Halle Wittenberg, Med Fac, Saale, Saxony Anhalt, Germany; [Evers, Christoph] Univ Hosp Leipzig, Dept Radiat Oncol, Leipzig, Saxony, Germany; [Ostheimer, Christian; Sieker, Frank; Vordermark, Dirk; Medenwald, Daniel] Martin Luther Univ Halle Wittenberg, Dept Radiat Oncol, Saale, Saxony Anhalt, Germany; [Medenwald, Daniel] Martin Luther Univ Halle Wittenberg, Inst Med Epidemiol, Saale, Saxony Anhalt, Germany	Martin Luther University Halle Wittenberg; Leipzig University; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Evers, C (corresponding author), Martin Luther Univ Halle Wittenberg, Med Fac, Saale, Saxony Anhalt, Germany.; Evers, C (corresponding author), Univ Hosp Leipzig, Dept Radiat Oncol, Leipzig, Saxony, Germany.	Christoph.evers@uk-halle.de		Evers, Christoph/0000-0002-7115-474X	Publishing Fund of Martin Luther University Halle-Wittenberg	Publishing Fund of Martin Luther University Halle-Wittenberg	The study was funded by the Publishing Fund of Martin Luther University Halle-Wittenberg The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Ang KK, 2001, INT J RADIAT ONCOL, V51, P571, DOI 10.1016/S0360-3016(01)01690-X; Barry CP, 2017, HEAD NECK-J SCI SPEC, V39, P1399, DOI 10.1002/hed.24780; Benard VB, 2008, CANCER-AM CANCER SOC, V113, P2910, DOI 10.1002/cncr.23742; Boero IJ, 2016, J CLIN ONCOL, V34, P684, DOI 10.1200/JCO.2015.63.9898; Chaturvedi AK, 2008, J CLIN ONCOL, V26, P612, DOI 10.1200/JCO.2007.14.1713; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chen MM, 2016, JAMA OTOLARYNGOL, V142, P1224, DOI 10.1001/jamaoto.2016.3519; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Fritz A., 2000, INT CLASSIFICATION D; Greene Frederick L, 2002, Bull Am Coll Surg, V87, P13; Gregoire V, 2007, ONCOLOGIST, V12, P555, DOI 10.1634/theoncologist.12-5-555; Hager B, 2015, RADIOTHER ONCOL, V115, P90, DOI 10.1016/j.radonc.2015.02.024; Ingarfield K, 2019, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00673; Jackel MC, 2008, HEAD NECK-J SCI SPEC, V30, P875, DOI 10.1002/hed.20794; Jansen L, 2018, ORAL ONCOL, V76, P8, DOI 10.1016/j.oraloncology.2017.11.015; Kao J, 2008, INT J RADIAT ONCOL, V71, P362, DOI 10.1016/j.ijrobp.2007.09.058; Lavaf A, 2008, CANCER-AM CANCER SOC, V112, P535, DOI 10.1002/cncr.23206; Liebig C, 2009, CANCER-AM CANCER SOC, V115, P3379, DOI 10.1002/cncr.24396; Marta GN, 2014, RADIOTHER ONCOL, V110, P9, DOI 10.1016/j.radonc.2013.11.010; Merlotti A, 2014, RADIAT ONCOL, V9, DOI 10.1186/s13014-014-0264-9; Moergel M, 2011, STRAHLENTHER ONKOL, V187, P337, DOI 10.1007/s00066-011-2206-x; Mohan R, 2000, INT J RADIAT ONCOL, V46, P619, DOI 10.1016/S0360-3016(99)00438-1; Nguyen NTA, 2018, CURR TREAT OPTION ON, V19, DOI 10.1007/s11864-018-0554-9; Nutting CM, 2011, LANCET ONCOL, V12, P127, DOI 10.1016/S1470-2045(10)70290-4; Ostheimer C, 2019, J CANCER RES CLIN, V145, P2813, DOI 10.1007/s00432-019-03013-y; Pagedar NA, 2017, CANCER CAUSE CONTROL, V28, P1085, DOI 10.1007/s10552-017-0938-3; Pfister DG SS, 2018, NCCN GUIDELINES HEAD; Pollom EL, 2017, INT J RADIAT ONCOL, V98, P177, DOI 10.1016/j.ijrobp.2017.01.006; Rathod S, 2013, ORAL ONCOL, V49, P634, DOI 10.1016/j.oraloncology.2013.02.013; Roman BR, 2017, J SURG ONCOL, V116, P351, DOI 10.1002/jso.24674; Schmitd LB, 2018, J DENT RES, V97, P742, DOI 10.1177/0022034518756297; Schmitz S, 2009, EUR ARCH OTO-RHINO-L, V266, P437, DOI 10.1007/s00405-008-0767-9; Shrime MG, 2010, ARCH OTOLARYNGOL, V136, P225, DOI 10.1001/archoto.2010.22; Stein AP, 2015, CANCER J, V21, P138, DOI 10.1097/PPO.0000000000000115; Studer G, 2006, RADIAT ONCOL, V1, DOI 10.1186/1748-717X-1-7; Tinhofer I, 2015, EUR J CANCER, V51, P514, DOI 10.1016/j.ejca.2014.12.018; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Ward MC, 2016, JAMA OTOLARYNGOL, V142, P1164, DOI 10.1001/jamaoto.2016.1876; Ward MC, 2017, ESSENTIALS CLIN RAD; World Health Organization, 2004, INT STAT CLASS DIS 1, V2nd; Yao M, 2005, INT J RADIAT ONCOL, V63, P410, DOI 10.1016/j.ijrobp.2005.02.025	42	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2020	15	2							e0229266	10.1371/journal.pone.0229266	http://dx.doi.org/10.1371/journal.pone.0229266			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8FM	32101560	gold, Green Published			2023-01-03	WOS:000535233700022
J	Valladales-Restrepo, LF; Duran-Lengua, M; Castro-Osorio, EE; Machado-Alba, JE				Fernando Valladales-Restrepo, Luis; Duran-Lengua, Marlene; Eduardo Castro-Osorio, Edgar; Enrique Machado-Alba, Jorge			Consistency between anticholinergic burden scales in the elderly with fractures	PLOS ONE			English	Article							POTENTIALLY INAPPROPRIATE MEDICATIONS; RISK SCALES; POLYPHARMACY; OUTCOMES; POPULATION; EXPOSURE	Objective Falls and bone fractures are important causes of morbidity and mortality in the elderly. The objective of this study was to identify the degree of consistency between the anticholinergic scales used for patients diagnosed with fractures. Methods This was an analytical agreement study conducted in patients diagnosed with vertebral and nonvertebral fractures in Colombia. The quadratic-weighted kappa coefficient was used to identify the consistency between the Anticholinergic Drug Scale-ADS, Anticholinergic Cognitive Burden Scale-ACB and Anticholinergic Risk Scale-ARS in assessing the prescriptions of fracture patients during the month prior to the fracture, during their stay as an inpatient and at discharge, according to Landis criteria. Results 220 patients with fractures were included, with a mean age of 75.3 +/- 10.3 years, and 68.2% were women. The ACB scale identified the highest anticholinergic burden (26.8%) in prescriptions made the month before the fracture, and the highest agreement was between ACB and ADS (0.717); during hospitalization and at discharge, the cholinergic antagonists were best identified with ADS (77.7% and 72.1%, respectively), with the best agreement between ACB and ARS (0.613 and 0.568, respectively). The prescription of tramadol was found in 64.1% of hospitalized patients and in 61.4% of patients at the time of discharge. Conclusions The scales evaluated show marked discrepancies between them, with highly variable frequencies of anticholinergic drugs identified at the different prescription times, and with low agreement among them, which is why the scales are not interchangeable in patients with bone fractures.	[Fernando Valladales-Restrepo, Luis; Enrique Machado-Alba, Jorge] Univ Tecnol Pereira Audifarma SA, Grp Invest Farmacoepidemiol & Farmacovigilancia, Pereira, Risaralda, Colombia; [Fernando Valladales-Restrepo, Luis] Fdn Univ Autonoma Amer, Grp Biomed, Pereira, Risaralda, Colombia; [Duran-Lengua, Marlene] Univ Cartagena, Cartagena, Bolivar, Colombia; [Eduardo Castro-Osorio, Edgar] Hosp Univ Caldas, Grp Invest Farmacoepidemiol & Farmacovigilancia, Geriatr, Internal Med, Manizales, Colombia	Universidad Tecnologica de Pereira; Universidad de Cartagena	Machado-Alba, JE (corresponding author), Univ Tecnol Pereira Audifarma SA, Grp Invest Farmacoepidemiol & Farmacovigilancia, Pereira, Risaralda, Colombia.	machado@utp.edu.co		Valladales Restrepo, Luis Fernando/0000-0002-4245-0101; Machado-Alba, Jorge Enrique/0000-0002-8455-0936				Alpert Patricia T, 2015, Home Healthc Now, V33, P524, DOI 10.1097/NHH.0000000000000299; Beuscart JB, 2014, ARCH GERONTOL GERIAT, V59, P630, DOI 10.1016/j.archger.2014.08.006; Boustani M., 2008, AGING HLTH, V4, P311, DOI [10.2217/1745509X.4.3.311, DOI 10.2217/1745509X.4.3.311, 10.2217/1745509XA3.311]; Carnahan RM, 2006, J CLIN PHARMACOL, V46, P1481, DOI 10.1177/0091270006292126; Collamati A, 2016, AGING CLIN EXP RES, V28, P25, DOI 10.1007/s40520-015-0359-7; Court-Brown CM, 2014, BONE JOINT J, V96B, P366, DOI 10.1302/0301-620X.96B3.33316; Court-Brown CM, 2016, J BONE JOINT SURG AM, V98, DOI 10.2106/JBJS.15.00793; Duran CE, 2013, EUR J CLIN PHARMACOL, V69, P1485, DOI 10.1007/s00228-013-1499-3; Machado-Alba JE, 2016, J AM MED DIR ASSOC, V17, DOI 10.1016/j.jamda.2015.12.003; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Hammond T, 2013, NURS MIDWIFERY STUD, V2, P171; Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), CONS REG SAN; Kim J, 2017, NURS CLIN N AM, V52, P457, DOI 10.1016/j.cnur.2017.04.007; Lertxundi U, 2013, PSYCHOGERIATRICS, V13, P17, DOI 10.1111/j.1479-8301.2012.00418.x; Lu WH, 2015, CAN MED ASSOC J, V187, pE130, DOI 10.1503/cmaj.141219; Machado-Duque ME, 2018, INT PSYCHOGERIATR, V30, P941, DOI 10.1017/S1041610217002745; Machado-Duque ME, 2018, J GERIATR PSYCH NEUR, V31, P63, DOI 10.1177/0891988718757370; Naples JG, 2015, J AM GERIATR SOC, V63, P2120, DOI 10.1111/jgs.13647; Nishtala PS, 2016, EXPERT OPIN DRUG SAF, V15, P753, DOI 10.1517/14740338.2016.1165664; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Pont LG, 2015, BRIT J CLIN PHARMACO, V80, P1169, DOI 10.1111/bcp.12670; Rudolph JL, 2008, ARCH INTERN MED, V168, P508, DOI 10.1001/archinternmed.2007.106; Salahudeen MS, 2016, DRUG AGING, V33, P305, DOI 10.1007/s40266-016-0362-5; Salahudeen MS, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0029-9; Turro-Garriga O, 2018, INT J GERIATR PSYCH, V33, P710, DOI 10.1002/gps.4844	25	5	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2020	15	2							e0228532	10.1371/journal.pone.0228532	http://dx.doi.org/10.1371/journal.pone.0228532			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8DW	32092055	Green Published, gold			2023-01-03	WOS:000535229300010
J	Doroudi, R; Sequeira, P; Marsella, S; Ergun, O; Azghandi, R; Kaeli, D; Sun, YF; Griffin, J				Doroudi, Rozhin; Sequeira, Pedro; Marsella, Stacy; Ergun, Ozlem; Azghandi, Rana; Kaeli, David; Sun, Yifan; Griffin, Jacqueline			Effects of trust-based decision making in disrupted supply chains	PLOS ONE			English	Article							ORDER ALLOCATION; MANAGEMENT; SYSTEMS; AGENTS	The United States has experienced prolonged severe shortages of vital medications over the past two decades. The causes underlying the severity and prolongation of these shortages are complex, in part due to the complexity of the underlying supply chain networks, which involve supplier-buyer interactions across multiple entities with competitive and cooperative goals. This leads to interesting challenges in maintaining consistent interactions and trust among the entities. Furthermore, disruptions in supply chains influence trust by inducing over-reactive behaviors across the network, thereby impacting the ability to consistently meet the resulting fluctuating demand. To explore these issues, we model a pharmaceutical supply chain with boundedly rational artificial decision makers capable of reasoning about the motivations and behaviors of others. We use multiagent simulations where each agent represents a key decision maker in a pharmaceutical supply chain. The agents possess a Theory-of-Mind capability to reason about the beliefs, and past and future behaviors of other agents, which allows them to assess other agents' trustworthiness. Further, each agent has beliefs about others' perceptions of its own trustworthiness that, in turn, impact its behavior. Our experiments reveal several counter-intuitive results showing how small, local disruptions can have cascading global consequences that persist over time. For example, a buyer, to protect itself from disruptions, may dynamically shift to ordering from suppliers with a higher perceived trustworthiness, while the supplier may prefer buyers with more stable ordering behavior. This asymmetry can put the trust-sensitive buyer at a disadvantage during shortages. Further, we demonstrate how the timing and scale of disruptions interact with a buyer's sensitivity to trustworthiness. This interaction can engender different behaviors and impact the overall supply chain performance, either prolonging and exacerbating even small local disruptions, or mitigating a disruption's effects. Additionally, we discuss the implications of these results for supply chain operations.	[Doroudi, Rozhin; Ergun, Ozlem; Azghandi, Rana; Griffin, Jacqueline] Northeastern Univ, Dept Mech & Ind Engn, Boston, MA 02115 USA; [Sequeira, Pedro] SRI Int, 333 Ravenswood Ave, Menlo Pk, CA 94025 USA; [Sequeira, Pedro; Marsella, Stacy] Northeastern Univ, Khoury Coll Comp Sci, Boston, MA 02115 USA; [Marsella, Stacy] Univ Glasgow, Inst Neurosci & Psychol, Glasgow, Lanark, Scotland; [Kaeli, David; Sun, Yifan] Northeastern Univ, Dept Elect & Comp Engn, Boston, MA 02115 USA	Northeastern University; SRI International; Northeastern University; University of Glasgow; Northeastern University	Doroudi, R (corresponding author), Northeastern Univ, Dept Mech & Ind Engn, Boston, MA 02115 USA.	doroudi.r@northeastern.edu	Doroudi, Rozhin/GPC-4555-2022	Doroudi, Rozhin/0000-0002-3152-2712; Kaeli, David/0000-0002-5692-0151; Sun, Yifan/0000-0003-3532-6521	National Science Foundation [CMMI 1638302]; SRI International	National Science Foundation(National Science Foundation (NSF)); SRI International	This work is supported by the National Science Foundation under grant CMMI 1638302 to JG. (https://www.nsf.gov/awardsearch/showAward?AWD_ID= 1638302&HistoricalAwards=false). SRI International provided support in the form of salaries for author P. Sequeira but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the 'author contributions' section.	[Anonymous], 2017, EXPL REL US MARK FOR; [Anonymous], 2019, THE ECONOMIST; Arbaeen AFS., 2019, PLATINUM ANTICANCER; Cachon GP, 1999, MANAGE SCI, V45, P1091, DOI 10.1287/mnsc.45.8.1091; Chen CM, 2018, PROD OPER MANAG, V27, P553, DOI 10.1111/poms.12814; Doroudi R, 2018, WINT SIMUL C PROC, P88, DOI 10.1109/WSC.2018.8632387; Drug Shortages, 2011, DRUG SHORT CLOS LOOK; Durango-Cohen EJ, 2017, INT J PROD ECON, V184, P256, DOI 10.1016/j.ijpe.2016.10.013; Emery-Montemerlo Rosemary, 2004, PROC 3 INT JOINT C A, P136; Fu JX, 2015, ENG APPL ARTIF INTEL, V44, P91, DOI 10.1016/j.engappai.2015.05.002; Ghadimi P, 2018, EUR J OPER RES, V269, P286, DOI 10.1016/j.ejor.2017.07.014; Giannakis M, 2011, J PURCH SUPPLY MANAG, V17, P23, DOI 10.1016/j.pursup.2010.05.001; Gomez J., 1991, NATURAL THEORIES MIN, P195; Hantel A, 2019, JAMA INTERN MED, V179, P710, DOI 10.1001/jamainternmed.2018.8251; Hawley KL, 2016, ACAD EMERG MED, V23, P63, DOI 10.1111/acem.12838; Jalbut A, 2018, INT WORKSH MULT AG S, P45; Kawtummachai R, 2005, INT J PROD ECON, V93-4, P231, DOI 10.1016/j.ijpe.2004.06.022; Kim WS, 2009, JASSS-J ARTIF SOC S, V12; Kimbrough SO, 2002, DECIS SUPPORT SYST, V33, P323, DOI 10.1016/S0167-9236(02)00019-2; Lee JH, 2008, INT J PROD RES, V46, P233, DOI 10.1080/00207540701441921; Moyaux T., 2006, MULTIAGENT BASED SUP, P1; National Academies of Sciences, MED PROD SHROT DIS O; Pauwels K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119322; Pynadath DV, 2005, 19TH INTERNATIONAL JOINT CONFERENCE ON ARTIFICIAL INTELLIGENCE (IJCAI-05), P1181; Rong Y, 2008, FLEX SERV MANUF J, V20, P95, DOI 10.1007/s10696-009-9054-3; SARGENT RG, 1991, 1991 WINTER SIMULATION CONFERENCE PROCEEDINGS, P37, DOI 10.1109/WSC.1991.185589; Sarkar S, 2015, INT J PROD ECON, V169, P169, DOI 10.1016/j.ijpe.2015.07.032; Sen S, 2015, PROCEEDINGS OF THE 2015 INTERNATIONAL CONFERENCE ON AUTONOMOUS AGENTS & MULTIAGENT SYSTEMS (AAMAS'15), P137; Shaban Hanan, 2018, Fed Pract, V35, P24; Sheridan Kate, 2017, NEWSWEEK; Simchi-Levi D., 2008, DESIGNING MANAGING S; Snyder LV, 2016, IIE TRANS, V48, P89, DOI 10.1080/0740817X.2015.1067735; Swaminathan JM, 1998, DECISION SCI, V29, P607, DOI 10.1111/j.1540-5915.1998.tb01356.x; Thomas Katie, 2017, NY TIMES; WOOLDRIDGE M, 1995, KNOWL ENG REV, V10, P115, DOI 10.1017/S0269888900008122	35	5	5	3	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2020	15	2							e0224761	10.1371/journal.pone.0224761	http://dx.doi.org/10.1371/journal.pone.0224761			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ7XT	32069295	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000535212900003
J	Bradley, PM; Journey, CA; Button, DT; Carlisle, DM; Huffman, BJ; Qi, SL; Romanok, KM; Van Metre, PC				Bradley, Paul M.; Journey, Celeste A.; Button, Daniel T.; Carlisle, Daren M.; Huffman, Bradley J.; Qi, Sharon L.; Romanok, Kristin M.; Van Metre, Peter C.			Multi-region assessment of pharmaceutical exposures and predicted effects in USA wadeable urban-gradient streams	PLOS ONE			English	Article							ANTIDIABETIC DRUG METFORMIN; COMBINED SEWER OVERFLOWS; PERSONAL CARE PRODUCTS; POTENTIOMETRIC ANALYTICAL MICROSYSTEM; THROUGHPUT SCREENING DATA; WASTE-WATER; ENDOCRINE DISRUPTION; GREAT-LAKES; AQUATIC ENVIRONMENT; ORGANIC-COMPOUNDS	Human-use pharmaceuticals in urban streams link aquatic-ecosystem health to human health. Pharmaceutical mixtures have been widely reported in larger streams due to historical emphasis on wastewater-treatment plant (WWTP) sources, with limited investigation of pharmaceutical exposures and potential effects in smaller headwater streams. In 2014-2017, the United States Geological Survey measured 111 pharmaceutical compounds in 308 headwater streams (261 urban-gradient sites sampled 3-5 times, 47 putative lowimpact sites sampled once) in 4 regions across the US. Simultaneous exposures to multiple pharmaceutical compounds (pharmaceutical mixtures) were observed in 91% of streams (248 urban-gradient, 32 low-impact), with 88 analytes detected across all sites and cumulative maximum concentrations up to 36,142 ng/L per site. Cumulative detections and concentrations correlated to urban land use and presence/absence of permitted WWTP discharges, but pharmaceutical mixtures also were common in the 75% of sampled streams without WWTP. Cumulative exposure-activity ratios (EAR) indicated widespread transient exposures with high probability of molecular effects to vertebrates. Considering the potential individual and interactive effects of the detected pharmaceuticals and the recognized analytical underestimation of the pharmaceutical-contaminant (unassessed parent compounds, metabolites, degradates) space, these results demonstrate a nation-wide environmental concern and the need for watershed-scale mitigation of in-stream pharmaceutical contamination.	[Bradley, Paul M.; Journey, Celeste A.; Huffman, Bradley J.] US Geol Survey, Columbia, SC 29201 USA; [Button, Daniel T.] US Geol Survey, Columbus, OH USA; [Carlisle, Daren M.] US Geol Survey, Lawrence, KS USA; [Qi, Sharon L.] US Geol Survey, Beaverton, OR USA; [Romanok, Kristin M.] US Geol Survey, Lawrenceville, NJ USA; [Van Metre, Peter C.] US Geol Survey, Austin, TX USA	United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey	Bradley, PM (corresponding author), US Geol Survey, Columbia, SC 29201 USA.	pbradley@usgs.gov	Bradley, Paul M./AAC-2451-2020	Bradley, Paul M./0000-0001-7522-8606; Van Metre, Peter/0000-0001-7564-9814; Journey, Celeste/0000-0002-2284-5851				Ahn MS, 2018, J COLLOID INTERF SCI, V516, P364, DOI 10.1016/j.jcis.2018.01.081; Altenburger R, 2013, ENVIRON TOXICOL CHEM, V32, P1685, DOI 10.1002/etc.2294; Altenburger R, 2012, ENVIRON SCI TECHNOL, V46, P2508, DOI 10.1021/es2038036; Anderson MJ, 2013, ECOL MONOGR, V83, P557, DOI 10.1890/12-2010.1; Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1046/j.1442-9993.2001.01070.x; [Anonymous], [No title captured]; [Anonymous], [No title captured]; [Anonymous], [No title captured]; Arnold KE, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0569; Artemyeva AA, 2016, ACTA ASTRONAUT, V126, P11, DOI 10.1016/j.actaastro.2016.04.016; ASTM International, 2018, D7729122018E1 ASTM A, DOI [10.1520/D7729-12R18E01, DOI 10.1520/D7729-12R18E01]; Bai Hua, 2013, Huanjing Kexue, V34, P2493; Barber LB, 2015, SCI TOTAL ENVIRON, V529, P264, DOI 10.1016/j.scitotenv.2015.04.112; Barber LB, 2012, ENVIRON SCI TECHNOL, V46, P2121, DOI 10.1021/es202880e; Batt AL, 2016, ENVIRON TOXICOL CHEM, V35, P874, DOI 10.1002/etc.3161; Becker RA, 2015, REGUL TOXICOL PHARM, V71, P398, DOI 10.1016/j.yrtph.2015.01.008; Ben Sahra I, 2010, MOL CANCER THER, V9, P1092, DOI 10.1158/1535-7163.MCT-09-1186; Bishop K, 2008, HYDROL PROCESS, V22, P1239, DOI 10.1002/hyp.7049; Black L, 2019, 2018 NATL HLTH INTER; Blackwell BR, 2017, ENVIRON SCI TECHNOL, V51, P8713, DOI 10.1021/acs.est.7b01613; Blair BD, 2013, CHEMOSPHERE, V93, P2116, DOI 10.1016/j.chemosphere.2013.07.057; Bostrom ML, 2015, WATER RES, V72, P154, DOI 10.1016/j.watres.2014.08.040; Boxall ABA, 2010, HANDB EXP PHARMACOL, V199, P291, DOI 10.1007/978-3-642-10324-7_12; Bradbury S P, 1994, SAR QSAR Environ Res, V2, P89, DOI 10.1080/10629369408028842; Bradley PM, 2019, SCI TOTAL ENVIRON, V655, P70, DOI 10.1016/j.scitotenv.2018.11.186; Bradley PM, 2017, ENVIRON SCI TECHNOL, V51, P4792, DOI 10.1021/acs.est.7b00012; Bradley PM, 2016, ENVIRON SCI TECH LET, V3, P243, DOI 10.1021/acs.estlett.6b00170; Bradley PM, 2016, SCI TOTAL ENVIRON, V568, P916, DOI 10.1016/j.scitotenv.2016.06.104; Bradley PM, 2016, REMEDIATION, V26, P9, DOI 10.1002/rem.21455; Brodin T, 2013, SCIENCE, V339, P814, DOI 10.1126/science.1226850; Brodin T, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0580; Bronmark C, 2012, CHEMICAL ECOLOGY IN AQUATIC SYSTEMS, P272; Brooks BW, 2014, AQUAT TOXICOL, V151, P61, DOI 10.1016/j.aquatox.2014.01.007; Brown AR, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0576; Calvo-Lopez A, 2017, ANAL CHIM ACTA, V995, P77, DOI 10.1016/j.aca.2017.08.043; Calvo-Lopez A, 2013, ANAL CHIM ACTA, V804, P190, DOI 10.1016/j.aca.2013.10.013; Capiotti KM, 2014, COMP BIOCHEM PHYS B, V171, P58, DOI 10.1016/j.cbpb.2014.03.005; Carrara C, 2008, ENVIRON SCI TECHNOL, V42, P2805, DOI 10.1021/es070344q; Carter LJ, 2015, ENVIRON SCI TECHNOL, V49, P12509, DOI 10.1021/acs.est.5b03468; Cedergreen N, 2008, ENVIRON TOXICOL CHEM, V27, P1621, DOI [10.1897/07-474.1, 10.1897/07-474]; Cedergreen N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096580; Clarke A, 2008, FRESHWATER BIOL, V53, P1707, DOI 10.1111/j.1365-2427.2008.02041.x; Clarke K.R., 2014, CHANGE MARINE COMMUN, V3; Coles J. F., 2019, OPEN FILE REPORT 201, DOI [10.3133/ofr20181183, DOI 10.3133/OFR20181183]; Conn KE, 2010, ENVIRON ENG SCI, V27, P347, DOI 10.1089/ees.2009.0364; Connor NP, 2014, APPL GEOCHEM, V47, P209, DOI 10.1016/j.apgeochem.2014.06.012; Corcoran J, 2010, CRIT REV TOXICOL, V40, P287, DOI 10.3109/10408440903373590; Corsi SR, 2019, SCI TOTAL ENVIRON, V686, P995, DOI 10.1016/j.scitotenv.2019.05.457; Corsi SR, 2015, SCI TOTAL ENVIRON, V508, P488, DOI 10.1016/j.scitotenv.2014.12.012; Corsi SR, 2010, ENVIRON SCI TECHNOL, V44, P7376, DOI 10.1021/es101333u; Crago J, 2018, CHEMOSPHERE, V193, P1226, DOI 10.1016/j.chemosphere.2017.11.043; Crago J, 2016, GEN COMP ENDOCR, V232, P185, DOI 10.1016/j.ygcen.2015.12.030; Cummings C, 2018, PAED CHILD HEALT-CAN, V23, pE18, DOI 10.1093/pch/pxx165; Daughton C, 2011, ENV CONTAMINANTS BIO, P288; Daughton CG, 1999, ENVIRON HEALTH PERSP, V107, P907, DOI 10.2307/3434573; Davies PJ, 2010, URBAN WATER J, V7, P233, DOI 10.1080/1573062X.2010.484502; DeCicco L.A., 2018, TOXEVAL EVALUATION M; Dobson CM, 2004, NATURE, V432, P824, DOI 10.1038/nature03192; Downing JA, 2012, INLAND WATERS, V2, P229, DOI 10.5268/IW-2.4.502; Elo B, 2007, J MOL ENDOCRINOL, V38, P433, DOI 10.1677/JME-06-0037; Eriksson E, 2003, WATER SA, V29, P135; Ermler S, 2011, TOXICOL APPL PHARM, V257, P189, DOI 10.1016/j.taap.2011.09.005; Falcone J.A., 2015, US GEOLOGICAL SURVEY, V948, DOI [10.3133/ds948, DOI 10.3133/DS948]; Fatta-Kassinos D, 2011, CHEMOSPHERE, V85, P693, DOI 10.1016/j.chemosphere.2011.06.082; Fatta-Kassinos D, 2011, SCI TOTAL ENVIRON, V409, P3555, DOI 10.1016/j.scitotenv.2010.03.036; Ferrell GM, 2014, USGS OPEN-FILE REP, DOI [10.3133/ofr20141215, DOI 10.3133/ofr20141215]; Fick J, 2010, ENVIRON SCI TECHNOL, V44, P2661, DOI 10.1021/es903440m; Fissore C, 2012, URBAN ECOSYST, V15, P1, DOI 10.1007/s11252-011-0189-0; Freeman MC, 2007, J AM WATER RESOUR AS, V43, P5, DOI 10.1111/j.1752-1688.2007.00002.x; Fuentes AV, 2018, PHARMACY, V6, DOI 10.3390/pharmacy6020043; Furlong E.T., 2014, US GEOLOGICAL SURVEY, V5, DOI [10.3133/tm5B10, DOI 10.3133/TM5B10]; Gallagher HC, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011091.pub2; Giacomini ACVV, 2016, BEHAV BRAIN RES, V296, P301, DOI 10.1016/j.bbr.2015.09.027; Gong L, 2012, PHARMACOGENET GENOM, V22, P820, DOI 10.1097/FPC.0b013e3283559b22; Gunnarsson L, 2008, ENVIRON SCI TECHNOL, V42, P5807, DOI 10.1021/es8005173; Hammer Oyvind, 2001, Palaeontologia Electronica, V4, pUnpaginated; Hossain SM, 2016, CLIN J PAIN, V32, P1005, DOI 10.1097/AJP.0000000000000343; Hughes SR, 2013, ENVIRON SCI TECHNOL, V47, P661, DOI 10.1021/es3030148; Humphrey C, 2015, WATER SCI TECHNOL, V72, P1851, DOI 10.2166/wst.2015.411; Jaywant SA, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19214781; Jiang JQ, 2006, CHEMOSPHERE, V63, P212, DOI 10.1016/j.chemosphere.2005.08.020; Jonsson H, 1997, WATER SCI TECHNOL, V35, P145, DOI 10.1016/S0273-1223(97)00192-3; Jonsson M, 2014, SCI TOTAL ENVIRON, V472, P108, DOI 10.1016/j.scitotenv.2013.10.104; Journey C.A., 2015, US GEOLOGICAL SURVEY, DOI [10.3133/ofr20151095, DOI 10.3133/OFR20151095]; Kaiser Family Foundation's State Health Facts INPAD, 2018, IQVIA 2018 RET SAL P; Kane S P, 2020, FLECAINIDE ACETATE C; Kaushal SS, 2018, P NATL ACAD SCI USA, V115, pE574, DOI 10.1073/pnas.1711234115; Kaushal SS, 2017, APPL GEOCHEM, V83, P121, DOI 10.1016/j.apgeochem.2017.02.006; Kaushal SS, 2014, BIOGEOCHEMISTRY, V121, P1, DOI 10.1007/s10533-014-0014-y; Kavlock R, 2012, CHEM RES TOXICOL, V25, P1287, DOI 10.1021/tx3000939; Kidd KA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0578; KONEMANN H, 1981, TOXICOLOGY, V19, P209, DOI 10.1016/0300-483X(81)90130-X; Kortenkamp A., 2009, STATE ART REPORT MIX; Kortenkamp A, 2007, ENVIRON HEALTH PERSP, V115, P98, DOI 10.1289/ehp.9357; LEOPOLD LB, 1962, AM SCI, V50, P511; Li SB, 2017, SCI TOTAL ENVIRON, V579, P825, DOI 10.1016/j.scitotenv.2016.11.021; Li WC, 2014, ENVIRON POLLUT, V187, P193, DOI 10.1016/j.envpol.2014.01.015; Lienert J, 2007, WATER SCI TECHNOL, V56, P87, DOI 10.2166/wst.2007.560; Truong L, 2014, TOXICOL SCI, V137, P212, DOI 10.1093/toxsci/kft235; Lowe WH, 2005, BIOSCIENCE, V55, P196, DOI 10.1641/0006-3568(2005)055[0196:MHSTTH]2.0.CO;2; Luo YL, 2014, SCI TOTAL ENVIRON, V473, P619, DOI 10.1016/j.scitotenv.2013.12.065; LYDEARD C, 1995, CONSERV BIOL, V9, P800, DOI 10.1046/j.1523-1739.1995.09040800.x; MacLaren RD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197259; Margalida A, 2014, SCIENCE, V346, P1296, DOI 10.1126/science.1260260; Masoner JR, 2019, ENVIRON SCI TECHNOL, V53, P10070, DOI 10.1021/acs.est.9b02867; McGrath P, 2008, DRUG DISCOV TODAY, V13, P394, DOI 10.1016/j.drudis.2008.03.002; McKinney ML, 2006, BIOL CONSERV, V127, P247, DOI 10.1016/j.biocon.2005.09.005; McRobb FM, 2014, ENVIRON SCI TECHNOL, V48, P1964, DOI 10.1021/es404568a; MEYBECK M, 1987, AM J SCI, V287, P401, DOI 10.2475/ajs.287.5.401; Meyer JL, 2007, J AM WATER RESOUR AS, V43, P86, DOI 10.1111/j.1752-1688.2007.00008.x; Michael I, 2013, WATER RES, V47, P957, DOI 10.1016/j.watres.2012.11.027; Monteiro SC, 2010, REV ENVIRON CONTAM T, V202, P53, DOI 10.1007/978-1-4419-1157-5_2; Moore RA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008242.pub3; Moretto A, 2017, CRIT REV TOXICOL, V47, P85, DOI 10.1080/10408444.2016.1211618; National Water Information System (NWIS), 2019, WEB INT; Niemuth NJ, 2018, AQUAT TOXICOL, V195, P33, DOI 10.1016/j.aquatox.2017.12.003; Niemuth NJ, 2015, ENVIRON TOXICOL CHEM, V34, P291, DOI 10.1002/etc.2793; Nodler K, 2011, APPL GEOCHEM, V26, P2172, DOI 10.1016/j.apgeochem.2011.08.001; NORTON SB, 1992, ENVIRON TOXICOL CHEM, V11, P1663, DOI 10.1897/1552-8618(1992)11[1663:AFFERA]2.0.CO;2; Oosterhuis M, 2013, SCI TOTAL ENVIRON, V442, P380, DOI 10.1016/j.scitotenv.2012.10.046; Oteng-Peprah M, 2018, WATER AIR SOIL POLL, V229, DOI 10.1007/s11270-018-3909-8; Padilla S, 2012, REPROD TOXICOL, V33, P174, DOI 10.1016/j.reprotox.2011.10.018; Painter MM, 2009, ENVIRON TOXICOL CHEM, V28, P2677, DOI 10.1897/08-556.1; Peacor S., 2015, REV ENVIRON CONTAM T, V235, P1, DOI DOI 10.1007/978-3-319-10861-2_1; Peters NE, 2009, HYDROL PROCESS, V23, P2860, DOI 10.1002/hyp.7373; Phillips P, 2009, J AM WATER RESOUR AS, V45, P45, DOI 10.1111/j.1752-1688.2008.00288.x; Phillips PJ, 2012, ENVIRON SCI TECHNOL, V46, P5336, DOI 10.1021/es3001294; Pol R, 2017, TRAC-TREND ANAL CHEM, V95, P62, DOI 10.1016/j.trac.2017.08.001; Pop-Busui R, 2017, DIABETES CARE, V40, P136, DOI 10.2337/dc16-2042; Quinlan EL, 2011, ENVIRON SCI TECHNOL, V45, P10684, DOI 10.1021/es202004k; R Core Team, 2019, R LANGUAGE ENV STAT; Raldua D, 2014, EXPERT OPIN DRUG MET, V10, P685, DOI 10.1517/17425255.2014.896339; Rand-Weaver M, 2013, ENVIRON SCI TECHNOL, V47, P11384, DOI 10.1021/es402065a; Richard AM, 2016, CHEM RES TOXICOL, V29, P1225, DOI 10.1021/acs.chemrestox.6b00135; Richmond EK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06822-w; Rodier D, EPA630R92001; Romanok KM, 2019, CONCENTRATIONS PHARM, DOI [10.5066/P97MW2T8, DOI 10.5066/P97MW2T8]; Rosi-Marshall EJ, 2013, ECOL APPL, V23, P583, DOI 10.1890/12-0491.1; Rosi-Marshall EJ, 2012, ECOSYSTEMS, V15, P867, DOI 10.1007/s10021-012-9553-z; Russom CL, 1997, ENVIRON TOXICOL CHEM, V16, P948, DOI 10.1002/etc.5620160514; Rutsch M, 2008, WATER RES, V42, P2385, DOI 10.1016/j.watres.2008.01.019; Sanchez W, 2011, ENVIRON INT, V37, P1342, DOI 10.1016/j.envint.2011.06.002; Scheurer M, 2012, WATER RES, V46, P4790, DOI 10.1016/j.watres.2012.06.019; Scheurer M, 2009, J ENVIRON MONITOR, V11, P1608, DOI 10.1039/b909311g; Schroeder AL, 2016, ENVIRON TOXICOL CHEM, V35, P513, DOI 10.1002/etc.3309; Schultz MM, 2011, AQUAT TOXICOL, V104, P38, DOI 10.1016/j.aquatox.2011.03.011; Scott MC, 2006, BIOL CONSERV, V127, P301, DOI 10.1016/j.biocon.2005.07.020; Tang T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003053.pub5; Temnerud J, 2010, HYDROL PROCESS, V24, P2269, DOI 10.1002/hyp.7615; Terando AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102261; Thrupp TJ, 2018, SCI TOTAL ENVIRON, V619, P1482, DOI 10.1016/j.scitotenv.2017.11.081; Trautwein C, 2014, ENVIRON INT, V70, P203, DOI 10.1016/j.envint.2014.05.008; Trautwein C, 2011, CHEMOSPHERE, V85, P765, DOI 10.1016/j.chemosphere.2011.06.057; U.S. Census Bureau, 2019, ANN EST RES POP; U.S. Environmental Protection Agency, 2013, NPDES PERM NAT; U.S. Geological Survey, 2014, NAT LAND COC DAT NLC; U.S. Geological Survey, 2020, USGS NEXT GEN WAT OB; U.S. Geological Survey, 2020, NEXT GEN WAT OBS SYS; United States Census Bureau, 2016, TIGER LIN SHAP; US Food and Drug Administration, 2018, OR BOOK APPR DRUG PR; Ussery E, 2019, ENVIRON TOXICOL CHEM, V38, P1023, DOI 10.1002/etc.4403; Ussery E, 2018, AQUAT TOXICOL, V205, P58, DOI 10.1016/j.aquatox.2018.10.003; van der Wouden J, 2018, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009321.pub2, DOI 10.1002/14651858.CD009321.PUB2]; Van Metre PC, 2014, SE STREAM QUALITY AS, DOI [10.3133/fs20143023, DOI 10.3133/FS20143023]; Van Metre PC, 20163021 US GEOL SUR, DOI [10.3133/fs20163021, DOI 10.3133/FS20163021]; Van Metre PC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222714; Vasquez MI, 2014, J HAZARD MATER, V279, P169, DOI 10.1016/j.jhazmat.2014.06.069; VEITH GD, 1983, CAN J FISH AQUAT SCI, V40, P743, DOI 10.1139/f83-096; Villarroel M, 2018, 2018 NATL HLTH INTER; Warner W, 2019, SCI TOTAL ENVIRON, V686, P75, DOI 10.1016/j.scitotenv.2019.05.385; Warren ML, 2000, FISHERIES, V25, P7, DOI 10.1577/1548-8446(2000)025<0007:DDACSO>2.0.CO;2; Weinberger J, 2014, AQUAT TOXICOL, V151, P77, DOI 10.1016/j.aquatox.2013.10.012; Weyrauch P, 2010, WATER RES, V44, P4451, DOI 10.1016/j.watres.2010.06.011; Wiffen PJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007938.pub4; Winker M, 2008, SCI TOTAL ENVIRON, V399, P96, DOI 10.1016/j.scitotenv.2008.03.027; Winker M, 2009, BIORESOURCE TECHNOL, V100, P4090, DOI 10.1016/j.biortech.2009.03.024; Wolf L, 2012, SCI TOTAL ENVIRON, V430, P8, DOI 10.1016/j.scitotenv.2012.04.059; World Health Organization, 2016, GLOB REP PSOR; Yu ZLT, 2013, WATER ENVIRON RES, V85, P650, DOI 10.2175/106143013X13698672321580; Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8	180	24	24	3	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2020	15	1							e0228214	10.1371/journal.pone.0228214	http://dx.doi.org/10.1371/journal.pone.0228214			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9CB	31999738	gold, Green Published			2023-01-03	WOS:000534612400056
J	Howard-Azzeh, M; Pearl, DL; O'Sullivan, TL; Berke, O				Howard-Azzeh, Mohammad; Pearl, David L.; O'Sullivan, Terri L.; Berke, Olaf			The identification of risk factors contributing to accidental opioid poisonings in companion dogs using data from a North American poison control center (2006-2014)	PLOS ONE			English	Article							UNITED-STATES; EXPOSURES; TRENDS; DRUG	In the last decade, there has been a marked increase in opioid-related human deaths in the U.S. However, the effects of the growth in opioid use on vulnerable populations, such as pet dogs, are largely unknown. The objective of this study was to investigate potential risk factors at the dog, county, and state-levels that contributed to accidental dog opioid poisonings. Dog demographic information was collected during calls to the Animal Poison Control Center (APCC), operated by the American Society for the Prevention of Cruelty to Animals, about pet dog exposures to poisons from 2006-2014. Data concerning state-level opioid-related human death rates and county-level human opioid prescription rates were collected from databases accessed from the Centers for Disease Control and Prevention. A multilevel logistic regression model with random intercepts for county and state was fitted to explore associations between the odds of a call to the APCC being related to dog opioid poisonings with the following independent variables: sex, weight, age, reproductive status, breed class, year, source of calls, county-level human opioid prescription rate, and state-level opioid human death rate. There was a significant non-linear positive association between accidental opioid dog poisoning calls and county-level human opioid prescription rates. Similarly, the odds of a call being related to an opioid poisoning significantly declined over the study period. Depending on the breed class, the odds of a call being related to an opioid poisoning event were generally lower for older and heavier dogs. The odds of a call being related to an opioid poisoning were significantly higher for intact compared to neutered dogs, and if the call was made by a veterinarian compared to a member of the public. Veterinarians responding to poisonings may benefit from knowledge of trends in the use and abuse of both legal and illegal drugs in human populations.	[Howard-Azzeh, Mohammad; Pearl, David L.; O'Sullivan, Terri L.; Berke, Olaf] Univ Guelph, Ontario Vet Coll, Dept Populat Med, Guelph, ON, Canada	University of Guelph	Howard-Azzeh, M (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Populat Med, Guelph, ON, Canada.	mhowardia@uoguelph.ca	Berke, Olaf/F-7798-2010	Berke, Olaf/0000-0003-3537-0629	Natural Sciences and Engineering Research Council (Discovery NSERC grant)	Natural Sciences and Engineering Research Council (Discovery NSERC grant)	The work was supported by a grant to DL Pearl from the Natural Sciences and Engineering Research Council (Discovery NSERC grant) -http://www.nserc-crsng.gc.ca/index_eng.asp.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bailey JE, 2009, ANN EMERG MED, V53, P419, DOI 10.1016/j.annemergmed.2008.07.015; Berny P, 2010, VET J, V183, P255, DOI 10.1016/j.tvjl.2009.03.034; Burghardt LC, 2013, PEDIATRICS, V132, P18, DOI 10.1542/peds.2012-2978; Center for Behavioral Health Statistics and Quality, 2017, NSDUH SER H, V51; Centers of Disease Control and Prevention, 2018, US OP PRECR RAT MAPS; Centers of Disease Control and Prevention, 2019, WID RANG DAT EP RES; Dohoo I. R., 2009, VET EPIDEMIOLOGIC RE, V2nd; Gaither JR, 2016, JAMA PEDIATR, V170, P1195, DOI 10.1001/jamapediatrics.2016.2154; Gfeller R.W., 2004, HDB SMALL ANIMAL TOX; Lovegrove MC, 2014, PEDIATRICS, V134, pE1009, DOI 10.1542/peds.2014-0840; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; Martin TC, 2011, CURR DRUG SAF, V6, P12, DOI 10.2174/157488611794480034; Meola SD, 2012, J VET EMERG CRIT CAR, V22, P690, DOI 10.1111/j.1476-4431.2012.00818.x; National Institute of Health, 2019, OV DEATH RAT; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Wang GS, 2013, JAMA PEDIATR, V167, P630, DOI 10.1001/jamapediatrics.2013.140; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Wasserstein RL, 2019, AM STAT, V73, P1, DOI 10.1080/00031305.2019.1583913	19	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2020	15	1							e0227701	10.1371/journal.pone.0227701	http://dx.doi.org/10.1371/journal.pone.0227701			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9AX	31995582	Green Published, gold			2023-01-03	WOS:000534609400026
J	Lee, C; McCrory, R; Tully, MP; Carrington, A; Donnelly, R; Dornan, T				Lee, Ciara; McCrory, Richard; Tully, Mary P.; Carrington, Angela; Donnelly, Rosie; Dornan, Tim			Readiness to prescribe: Using educational design to untie the Gordian Knot	PLOS ONE			English	Article							REGISTRATION HOUSE OFFICER; MEDICAL-STUDENTS; JUNIOR DOCTORS; ACUTE-CARE; PREPAREDNESS; PERCEPTIONS; VIEWS	Introduction Junior residents routinely prescribe medications for hospitalised patients with only arms-length supervision, which compromises patient safety. A cardinal example is insulin prescribing, which is commonplace, routinely delegated to very junior doctors, difficult, potentially very dangerous, and getting no better. Our aim was to operationalise the concept of 'readiness to prescribe' by validating an instrument to quality-improve residents' workplace prescribing education. Methods Guided by theories of behaviour change, implementation, and error, and by empirical evidence, we developed and refined a mixed-methods 24-item evaluation instrument, and analysed numerical responses from Foundation Trainees (junior residents) in Northern Ireland, UK using principal axis factoring, and conducted a framework analysis of participants' free-text responses. Results 255 trainees participated, 54% women and 46% men, 80% of whom were in the second foundation year. The analysis converged on a 4-factor solution explaining 57% of the variance. Participants rated their capability to prescribe higher (79%) than their capability to learn to prescribe (69%; p<0.001) and rated the support to their prescribing education lower still (43%; p<0.001). The findings were similar in men and women, first and second year trainees, and in different hospitals. Free text responses described an unreflective type of learning from experience in which participants tended to 'get by' when faced with complex problems. Discussion Operationalising readiness to prescribe as a duality, comprising residents' capability and the fitness of their educational environments, demonstrated room for improvement in both. We offer the instrument to help clinical educators improve the two in tandem.	[Lee, Ciara; McCrory, Richard; Dornan, Tim] Queens Univ Belfast, Ctr Med Educ, Belfast, Antrim, North Ireland; [Tully, Mary P.] Univ Manchester, Div Pharm & Optometry, Manchester, Lancs, England; [Carrington, Angela] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland; [Donnelly, Rosie] South Eastern Hlth & Social Care Trust, Belfast, Antrim, North Ireland; [Lee, Ciara] Univ Otago, Dept Gen Practice & Rural Hlth, Dunedin, New Zealand	Queens University Belfast; University of Manchester; University of Otago	Dornan, T (corresponding author), Queens Univ Belfast, Ctr Med Educ, Belfast, Antrim, North Ireland.	T.Dornan@qub.ac.uk	McCrory, Richard/AAY-8046-2021	McCrory, Richard/0000-0002-9451-1324; Lee, Ciara/0000-0002-2296-7867	Research and Development Division of the Public Health Agency of Health and Social Northern Ireland [RES/5199/15]	Research and Development Division of the Public Health Agency of Health and Social Northern Ireland	The Research and Development Division of the Public Health Agency of Health and Social Northern Ireland awarded TLD Grant no RES/5199/15 - URL: https://www.publichealth.hscni.net.The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berridge EJ, 2007, MED TEACH, V29, P119, DOI 10.1080/01421590701310897; Billett, 2014, MIMETIC LEARNING WOR; Billett S., 2006, MIND CULT ACT, V13, P53, DOI [10.1207/s15327884mca1301_5, DOI 10.1207/S15327884MCA1301_5]; Bleakley A, 2011, MED TEACH, V33, P459, DOI 10.3109/0142159X.2010.540267; Burford B, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-223; CLACK GB, 1994, MED EDUC, V28, P418, DOI 10.1111/j.1365-2923.1994.tb02553.x; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Dolmans DHJM, 2012, MED TEACH, V34, P1, DOI 10.3109/0142159X.2011.595437; Downing SM, 2003, MED EDUC, V37, P830, DOI 10.1046/j.1365-2923.2003.01594.x; Eppich WJ, 2019, ACAD MED, V94, P1033, DOI 10.1097/ACM.0000000000002713; Eraut M., 2004, STUD CONTIN EDUC, V26, P247, DOI [DOI 10.1080/158037042000225245, 10.1080/158037042000225245]; Han WH, 2006, SCOT MED J, V51, P27; Heaton A, 2008, BRIT J CLIN PHARMACO, V66, P128, DOI 10.1111/j.1365-2125.2008.03197.x; Illing J, 2008, PREPARED ARE MED GRA; Illing JC, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-34; Jones A, 2002, MED EDUC, V36, P16, DOI 10.1046/j.1365-2923.2002.01105.x; Jones A, 2001, MED EDUC, V35, P578, DOI 10.1046/j.1365-2923.2001.00955.x; Kellett J, 2015, MED TEACH, V37, P949, DOI 10.3109/0142159X.2014.970619; Lai SJ, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0336-1; Lave J., 1991, SITUATED LEARNING LE; Lewis PJ, 2014, BRIT J CLIN PHARMACO, V78, P310, DOI 10.1111/bcp.12332; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10; Monrouxe LV, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013656; NaDIA advisory group, 2018, NAT DIAB INP AUD ENG; Noble C, 2017, MED EDUC, V51, P442, DOI 10.1111/medu.13227; O'Donnell M., 1997, SCEPTICS MED DICT; Prince CJAH, 2006, PROBLEM BASED LEARNI; Prince KJAH, 2005, MED EDUC, V39, P704, DOI 10.1111/j.1365-2929.2005.02207.x; Reason J., 1990, HUMAN ERROR; T Dornan, 2009, DEPTH INVESTIGATION; Tabachnick B. G., 2007, USING MULTIVARIATE S, V5, P481; Tallentire VR, 2012, POSTGRAD MED J, V88, P365, DOI 10.1136/postgradmedj-2011-130232; Tallentire VR, 2011, MED EDUC, V45, P995, DOI 10.1111/j.1365-2923.2011.04024.x; Tobaiqy M, 2007, BRIT J CLIN PHARMACO, V64, P363, DOI 10.1111/j.1365-2125.2007.02925.x; Tully MP, 2009, DRUG SAFETY, V32, P819, DOI 10.2165/11316560-000000000-00000; Van Hamel C, 2015, MED TEACH, V37, P181, DOI 10.3109/0142159X.2014.947929	37	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2020	15	1							e0227865	10.1371/journal.pone.0227865	http://dx.doi.org/10.1371/journal.pone.0227865			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP8WY	31978199	Green Published, Green Submitted, gold			2023-01-03	WOS:000534599100069
J	Grande, SW; Adams, LV; Maseko, TSB; Talbot, EA; deGijsel, D; Mikal, J; Simelane, ZZ; Achili, A; Mkhontfo, M; Haumba, SM				Grande, S. W.; Adams, L. V.; Maseko, T. S. B.; Talbot, E. A.; deGijsel, D.; Mikal, J.; Simelane, Z. Z.; Achili, A.; Mkhontfo, M.; Haumba, S. M.			The social implications of participant choice on adherence to Isonaizid Preventive Therapy (IPT): A follow-up study to high completion rates in Eswatini	PLOS ONE			English	Article							HIV; IMPLEMENTATION; TB	Background Eswatini (formerly Swaziland) has one of the highest rates of TB and HIV co-disease in the world. Despite national efforts to improve service delivery and prevent TB and HIV transmission, rates remain high. A recent prospective, observational study of integrated, patient selected IPT delivery showed extraordinary improvements in IPT adherence, running counter to previous assumptions. This prompted the need to understand contextual and unseen study factors that contributed to high rates of adherence. Objective To investigate high rates of IPT adherence rates among people living with HIV who participated in an observational study comparing modes of IPT delivery. Methods Community-based participatory research guided the development of in-person administration of semi-structured questionnaires. Observational and field note data were analyzed. Qualitative data were analyzed using content analysis. Results We interviewed 150 participants and analyzed responses from the 136 who remembered being given a choice of their IPT delivery method. Fifty-seven percent were female and the median age was 42. Nearly 67% of participants chose to receive facility-based IPT. High rates of self-reported IPT treatment adherence were linked to four key concepts: 1) adherence was positively impacted by community education; 2) disclosure of status served to empower participant completion; 3) mode of delivery perceptions positively impacted adherence; and 4) choice of treatment delivery seen as helpful but not essential for treatment completion. Discussion Achieving higher rates of IPT adherence in Eswatini and similar rural areas requires community-engaged education and outreach in coordination with care delivery systems.	[Grande, S. W.; Adams, L. V.; Talbot, E. A.; deGijsel, D.] Geisel Sch Med Dartmouth, Hanover, NH 03755 USA; [Grande, S. W.; Mikal, J.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN 55455 USA; [Maseko, T. S. B.; Simelane, Z. Z.; Achili, A.; Mkhontfo, M.; Haumba, S. M.] Univ Res Co LLC URC, Mbabane, Eswatini	Dartmouth College; University of Minnesota System; University of Minnesota Twin Cities	Grande, SW (corresponding author), Geisel Sch Med Dartmouth, Hanover, NH 03755 USA.; Grande, SW (corresponding author), Univ Minnesota, Sch Publ Hlth, Minneapolis, MN 55455 USA.	stuart.s.w.grande@dartmouth.edu		Grande, Stuart/0000-0002-6796-7991; de Gijsel, David/0000-0002-7987-7168	TB CARE II project - United States Agency for International Development (USAID) [AID-OAA-A-10-00021]	TB CARE II project - United States Agency for International Development (USAID)(United States Agency for International Development (USAID))	Support for this work was provided by the TB CARE II project, which is funded by the United States Agency for International Development (USAID) under Cooperative Agreement Number AID-OAA-A-10-00021. The project's prime recipient is the University Research Co, LLC (URC), Chevy Chase, MD, USA, and the Geisel School of Medicine at the Dartmouth Section of Infectious Disease and International Health, Hanover, NH, USA, is a sub-recipient. The funding source for this work did not influence the study design, interpretation of data, writing of the manuscript, or the decision to submit the manuscript for publication. The funder provided support in the form of salaries for authors SWG, LVA, TSM, EAT, DG, ZZS, AA, MM, SMH, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the methods sections and can be clarified here. SWG, LVA, EAT, and SMH contributed to the design of the project methods. SWG, LVA, EAT, DG, ZZS, AA contributed to data collection, writing, and analysis. All authors contributed to completion of final manuscript.	Adams LV, 2017, INT J TUBERC LUNG D, V21, P1127, DOI 10.5588/ijtld.16.0946; Amo-Adjei J, 2013, INFECT DIS POVERTY, V2, DOI 10.1186/2049-9957-2-9; Berhe M., 2014, ISONIAZID PREVENTIVE, V2014, P1, DOI 10.1155/2014/230587; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Calnan M, 2017, SOUTH AFR J INFECT D, V32, P1, DOI 10.1080/23120053.2016.1181421; Cramm JM, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-72; Cronin Brendan J., 2015, ANN GLOB HEALTH, V1, P5; Fishbein M, 2008, MED DECIS MAKING, V28, P834, DOI 10.1177/0272989X08326092; Gebremariam MK, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-651; Haumba S, 2015, PUBLIC HEALTH ACTION, V5, P103, DOI 10.5588/pha.15.0008; Ishani Pathmanathan, 2018, PLOS ONE, V13; Kathy Charmaz, 2006, CONSTRUCTING GROUNDE; Lester R, 2010, AIDS, V24, pS45, DOI 10.1097/01.aids.0000391021.18284.12; Lia Cremers Anne, 2015, PLOS ONE, V10; Miria Nyangoma, 2020, PLOS ONE, V15; Montales MT, 2015, FRONT PUBLIC HEALTH, V3, DOI 10.3389/fpubh.2015.00281; Munro SA, 2007, PLOS MED, V4, P1230, DOI 10.1371/journal.pmed.0040238; ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203; Rowe KA, 2005, INT J TUBERC LUNG D, V9, P263; Shayo GA, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1085-7; Thindwa D, 2018, INT J TUBERC LUNG D, V22, P273, DOI 10.5588/ijtld.17.0370; Titilola Makanjuola, 2014, PLOS ONE, V9; van Griensven J, 2015, TROP MED INT HEALTH, V20, P1823, DOI 10.1111/tmi.12609	23	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2020	15	5							e0232841	10.1371/journal.pone.0232841	http://dx.doi.org/10.1371/journal.pone.0232841			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1WS	32469990	gold, Green Published			2023-01-03	WOS:000537552800034
J	Abadiga, M; Hasen, T; Mosisa, G; Abdisa, E				Abadiga, Muktar; Hasen, Tahir; Mosisa, Getu; Abdisa, Eba			Adherence to antiretroviral therapy and associated factors among Human immunodeficiency virus positive patients accessing treatment at Nekemte referral hospital, west Ethiopia, 2019	PLOS ONE			English	Article							OUTCOMES; ADOLESCENTS	Background Antiretroviral therapy has a remarkable clinical effect in reducing the progress of Acquired Immune Deficiency Syndrome. The clinical outcome of Anti-Retroviral therapy depends on strict adherence. Poor adherence reduces the effectiveness of antiretroviral therapy and increases viral replication. With changes in service delivery over time and differences in socio-demographic status from region to region, it is essential to measure adherence. Therefore, this study aimed to assess adherence to antiretroviral therapy and its associated factors among HIV/AIDS patients accessing treatment at Nekemte referral hospital, West Ethiopia. Methods Institutional based cross-sectional study was conducted on 311 HIV/AIDS patients from March 01 to March 30, 2019. The study participants were selected by a simple random sampling method and interviewed using structured questionnaires. Bivariable logistic regression was conducted to find an association between each independent variable and adherence to antiretroviral medication. Multivariable logistic regression was used to find the independent variables which best predict adherence. The statistical significance was measured using odds ratio at a 95% confidence interval with a p-value of less than 0.05. Results Out of a total of 311 patients sampled, 305 were participated in the study, making a response rate of 98.07%. From these 305 study participants,73.1% (95% CI = 68.2, 78.0) were adherent to their medication. Having knowledge about HIV and its treatment (AOR = 8.24, 95% CI: 3.10, 21.92), having strong family/social support (AOR = 6.21, 95% CI: 1.39, 27.62), absence of adverse drug reaction (AOR = 5.33, 95% CI: 1.95, 14.57), absence of comorbidity of other chronic diseases (AOR = 5.72, 95% CI: 1.91, 17.16) and disclosing HIV status to the family (AOR = 5.08, 95% CI: 2.09, 12.34) were significantly associated with an increased likelihood of adherence to antiretroviral medication. Conclusion The level of adherence to antiretroviral therapy was found low compared to WHO recommendation. The clinician should emphasize reducing adverse drug reaction, detecting and treating co-morbidities early, improving knowledge through health education, and encouraging the patients to disclose their HIV status to their families.	[Abadiga, Muktar; Hasen, Tahir; Mosisa, Getu; Abdisa, Eba] Wollega Univ, Inst Hlth Sci, Sch Nursing & Midwifery, Nekemte, Ethiopia		Abadiga, M (corresponding author), Wollega Univ, Inst Hlth Sci, Sch Nursing & Midwifery, Nekemte, Ethiopia.	muktarabadiga@gmail.com	Kebebew, Getu Mosisa/ABI-5268-2020	Abadiga, Muktar/0000-0002-3006-3155				Adeniyi OV, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3087-8; Ammon N, 2018, PUBLIC HEALTH, V157, P20, DOI 10.1016/j.puhe.2017.12.010; [Anonymous], 2007, ART FAILURE STRATEGI; Aye WL, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4309-5; De Geest S, 2003, EUR J CARDIOVASC NUR, V2, P323, DOI [DOI 10.1016/S1474-5151(03)00091-4, 10.1016/S1474-5151(03)00091-4]; Edward L, 2006, ADHERENCE HIV ANTIRE; Fonsah JY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170893; Silva JAG, 2015, CAD SAUDE PUBLICA, V31, P1188, DOI 10.1590/0102-311X00106914; Granich R., 2018, INT J VIROL AIDS, V5, DOI [10.23937/2469-567X/1510043, DOI 10.23937/2469-567X/1510043]; Hill A, 2015, AIDS, V29, P2523, DOI 10.1097/QAD.0000000000000864; Hogan D, 2005, B WHOM, V83, P2; Howard AA, 2002, AIDS, V16, P2175, DOI 10.1097/00002030-200211080-00010; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2020, SEIZ MOM TACKL ENTR; Kahema SE, 2018, INT ARCH MED MICROBI, V1, P002, DOI [10.23937/iamm-2017/1710002, DOI 10.23937/IAMM-2017/1710002]; Kocalevent Ruya-Daniela, 2018, BMC Psychol, V6, P31, DOI 10.1186/s40359-018-0249-9; Koyra HC, 2018, INT J VIROL AIDS, V5, P1, DOI [10.23937/2469-567X/1510038, DOI 10.23937/2469-567X/1510038]; Letta S, 2015, BMC INT HEALTH HUM R, V15, DOI 10.1186/s12914-015-0071-x; Li JZ, 2014, AIDS, V28, P181, DOI 10.1097/QAD.0000000000000123; Mannheimer S, 2002, CLIN INFECT DIS, V34, P1115, DOI 10.1086/339074; Molla AA, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3176-8; Nachega JB, 2007, ANN INTERN MED, V146, P564, DOI 10.7326/0003-4819-146-8-200704170-00007; Nachega JB, 2009, JAIDS-J ACQ IMM DEF, V51, P65, DOI 10.1097/QAI.0b013e318199072e; Neupane S, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7051-3; Obirikorang Christian, 2013, ISRN AIDS, V2013, P873939, DOI 10.1155/2013/873939; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Reinius M, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0691-z; Sahay S, 2011, INDIAN J MED RES, V134, P835, DOI 10.4103/0971-5916.92629; Semvua SK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189460; Suryana K., 2019, HIV AIDS RES PALLIAT, P11; Tefera G, 2011, J ASSOC NURSE AIDS C, V24, P530; U. Nation, 2016, UN POL DECL END AIDS; UNAIDS, 90 90 90 AMB TREATM; who, HIV AIDS; World Health Organization, 2008, HIV AIDS MENT HLTH; World Health Organization, 2013, ADH LONG TERM THER E, VXII, P92; Yaya I, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1308; Yu Y, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5731-z	37	9	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2020	15	5							e0232703	10.1371/journal.pone.0232703	http://dx.doi.org/10.1371/journal.pone.0232703			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU0RD	32392244	Green Published, gold			2023-01-03	WOS:000537470300019
J	Werner, A; Wu, CS; Zachariae, R; Nohr, EA; Uldbjerg, N; Hansen, AM				Werner, Anette; Wu, Chunsen; Zachariae, Robert; Nohr, Ellen A.; Uldbjerg, Niels; Hansen, Ase Marie			Effects of antenatal hypnosis on maternal salivary cortisol during childbirth and six weeks postpartum-A randomized controlled trial	PLOS ONE			English	Article							PROGRESSIVE MUSCLE-RELAXATION; CARDIFF PUERPERAL MOOD; PITUITARY-ADRENAL AXIS; AWAKENING RESPONSE; LATE PREGNANCY; SELF-HYPNOSIS; STRESS; IMPACT; LABOR; DEPRESSION	Background Cortisol has been used to capture psychophysiological stress during childbirth and postpartum wellbeing. We explored the effect of a brief antenatal training course in self-hypnosis on salivary cortisol during childbirth and 6 weeks postpartum. Methods In a randomized, controlled trial conducted at Aarhus University Hospital Skejby Denmark during the period January 2010 until October 2010, a total of 349 healthy nulliparous women were included. They were randomly allocated to a hypnosis group (n = 136) receiving three one-hour lessons in self-hypnosis with additional audio-recordings, a relaxation group (n = 134) receiving three one-hour lessons in various relaxation methods with audio-recordings for additional training, and a usual care group (n = 79) receiving ordinary antenatal care only. Salivary cortisol samples were collected during childbirth (at the beginning of the pushing state, 30 minutes, and 2 hours after childbirth), and 6 weeks postpartum (at wake up, 30 minutes after wake up, and evening). Cortisol concentrations were compared using a linear mixed-effects model. Correlations between cortisol concentrations and length of birth, experienced pain and calmness during birth were examined by a Spearman rank correlation test. Findings During childbirth, week correlations were found between cortisol concentrations 30 minutes after childbirth and length of birth. In the beginning of the pushing state and 2 hours after childbirth, we found a tendency towards higher cortisol concentrations in the hypnosis group compared to the other two groups (hypnosis versus relaxation p = 0.02 and 0.03, hypnosis versus usual care p = 0.08 and 0.05). No differences were observed in cortisol concentrations between the groups 30 minutes after childbirth (hypnosis versus relaxation p = 0.08, hypnosis versus usual care 0.10) or 6 weeks postpartum (hypnosis versus relaxation: p = 0.85, 0.51, and 0.68, hypnosis versus usual care: p = 0.85, 0.93, and 0.96). Conclusion Antenatal hypnosis training may increase the release of cortisol during childbirth with no long-term consequences. Further research is needed to help interpret these findings.	[Werner, Anette; Wu, Chunsen; Nohr, Ellen A.] Univ Southern Denmark, Inst Clin Res, Res Unit Gynecol & Obstet, Odense, Denmark; [Werner, Anette; Wu, Chunsen; Nohr, Ellen A.] Odense Univ Hosp, Dept Gynecol & Obstet, Odense, Denmark; [Zachariae, Robert] Aarhus Univ Hosp, Dept Oncol, Unit Psychooncol & Hlth Psychol, Aarhus, Denmark; [Zachariae, Robert] Aarhus Univ, Dept Psychol, Aarhus, Denmark; [Uldbjerg, Niels] Aarhus Univ Hosp Skejby, Dept Gynecol & Obstet, Aarhus, Denmark; [Hansen, Ase Marie] Univ Copenhagen, Dept Publ Hlth, Copenhagen, Denmark; [Hansen, Ase Marie] Natl Res Ctr Working Environm, Copenhagen, Denmark	University of Southern Denmark; University of Southern Denmark; Odense University Hospital; Aarhus University; Aarhus University; Aarhus University; University of Copenhagen; National Research Centre for the Working Environment	Werner, A (corresponding author), Univ Southern Denmark, Inst Clin Res, Res Unit Gynecol & Obstet, Odense, Denmark.; Werner, A (corresponding author), Odense Univ Hosp, Dept Gynecol & Obstet, Odense, Denmark.	awerner@health.sdu.dk	Uldbjerg, Niels/O-2038-2016	Uldbjerg, Niels/0000-0002-6449-6426; Werner, Anette/0000-0002-9977-609X; Hansen, Ase Marie/0000-0002-4075-3918	Aase og Ejnar Danielsen's foundation [10-000395, 10-000166]; VIFAB (Knowledge and Research Center for Alternative Medicine) [802-44-2009]; King Christian X's foundation [117/2009]; Danish Association of Midwives [56-089-MHJ]	Aase og Ejnar Danielsen's foundation; VIFAB (Knowledge and Research Center for Alternative Medicine); King Christian X's foundation; Danish Association of Midwives	Nordea Fonden: https://nordeafonden.dk/(Recieved 2008). Aase og Ejnar Danielsen's foundation: https://danielsensfond.dk/(Grant number:10-000395 and 10-000166). The Danish Society for Clinical Hypnosis: https://hypnoseselskabet.dk/(Recieved 2009). VIFAB (Knowledge and Research Center for Alternative Medicine): https://stps.dk/da/ansvar-ogretningslinjer/alternativ-behandling/(Grant number: 802-44-2009). King Christian X's foundation: http://kongehuset.dk/node/5556 (Grant number 117/2009). The Danish Association of Midwives: http://www.jordemoderforeningen.dk/fagforskning/forsknings-og-udviklings-beholdningen/(Grant number:56-089-MHJ) The following authors took part in all funding acquisitions: Anette Werner, Robert Zachariae, Ellen A Nohr, Niels Uldbjerg, Ase Marie Hansen The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The researchers acted independently from the study sponsors in all aspects of this study.	Alehagen S, 2005, J PSYCHOSOM OBST GYN, V26, P153, DOI 10.1080/0144361040023072; Alehagen S, 2001, ACTA OBSTET GYN SCAN, V80, P315, DOI 10.1034/j.1600-0412.2001.080004315.x; ALLOLIO B, 1990, CLIN ENDOCRINOL, V33, P279, DOI 10.1111/j.1365-2265.1990.tb00492.x; BACIGALUPO G, 1990, J PERINAT MED, V18, P289, DOI 10.1515/jpme.1990.18.4.289; Benfield RD, 2014, BIOL RES NURS, V16, P64, DOI 10.1177/1099800412471580; Creedy DK, 2000, BIRTH-ISS PERINAT C, V27, P104, DOI 10.1046/j.1523-536x.2000.00104.x; Cyna AM, 2006, ANAESTH INTENS CARE, V34, P464, DOI 10.1177/0310057X0603400402; de Weerth C, 2005, PSYCHONEUROENDOCRINO, V30, P902, DOI 10.1016/j.psyneuen.2005.05.003; DORR HG, 1989, J CLIN ENDOCR METAB, V68, P863; Garde AH, 2003, ACCREDIT QUAL ASSUR, V8, P16, DOI 10.1007/s00769-002-0548-x; Garthus-Niegel S, 2013, ARCH WOMEN MENT HLTH, V16, P1, DOI 10.1007/s00737-012-0301-3; GOLDKRAND JW, 1976, OBSTET GYNECOL, V47, P41; Groer MW, 2007, PSYCHONEUROENDOCRINO, V32, P133, DOI 10.1016/j.psyneuen.2006.11.007; Gurber S, 2012, J PSYCHOSOM OBST GYN, V33, P176, DOI 10.3109/0167482X.2012.730584; Hansen AM, 2003, SCAND J CLIN LAB INV, V63, P303, DOI 10.1080/00365510310001942; HARRIS B, 1994, BRIT MED J, V308, P949, DOI 10.1136/bmj.308.6934.949; Harris B, 1996, BRIT J PSYCHIAT, V168, P739, DOI 10.1192/bjp.168.6.739; HARRIS B, 1989, BRIT J PSYCHIAT, V154, P660, DOI 10.1192/bjp.154.5.660; Harville EW, 2007, BIOL PSYCHOL, V74, P85, DOI 10.1016/j.biopsycho.2006.07.005; Hellgren C, 2013, PSYCHONEUROENDOCRINO, V38, P3150, DOI 10.1016/j.psyneuen.2013.08.007; Henkel V, 2003, BRIT MED J, V326, P200, DOI 10.1136/bmj.326.7382.200; Iliadis SI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135471; Jolley SN, 2007, BIOL RES NURS, V8, P210, DOI 10.1177/1099800406294598; Jones Deborah, 2014, J Int Assoc Provid AIDS Care, V13, P318, DOI 10.1177/2325957413488186; Kammerer M, 2006, ARCH WOMEN MENT HLTH, V9, P187, DOI 10.1007/s00737-006-0131-2; Kivlighan KT, 2008, PSYCHONEUROENDOCRINO, V33, P1225, DOI 10.1016/j.psyneuen.2008.06.008; KONO H, 1987, TOHOKU J EXP MED, V152, P133, DOI 10.1620/tjem.152.133; Madden K, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009356.pub3; Mastorakos G, 2003, ANN NY ACAD SCI, V997, P136, DOI 10.1196/annals.1290.016; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; McLean M, 1999, TRENDS ENDOCRIN MET, V10, P174, DOI 10.1016/S1043-2760(98)00146-5; Mehl-Madrona LE, 2004, AM J CLIN HYPN, V46, P299, DOI 10.1080/00029157.2004.10403614; Nordsjaelland PC, 2012, WHO 5 WELL BEING IND; Obel C, 2005, PSYCHONEUROENDOCRINO, V30, P647, DOI 10.1016/j.psyneuen.2004.11.006; Ochedalski T, 2004, NEUROENDOCRINOL LETT, V25, P278; Pawlow LA, 2005, APPL PSYCHOPHYS BIOF, V30, P375, DOI 10.1007/s10484-005-8423-2; Pawlow LA, 2002, BIOL PSYCHOL, V60, P1, DOI 10.1016/S0301-0511(02)00010-8; Pluess M, 2012, PSYCHONEUROENDOCRINO, V37, P1336, DOI 10.1016/j.psyneuen.2012.01.006; Seth S, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0915-y; Stjernholm YV, 2016, ARCH GYNECOL OBSTET, V294, P267, DOI 10.1007/s00404-015-3981-x; Taylor A, 2009, PSYCHONEUROENDOCRINO, V34, P1184, DOI 10.1016/j.psyneuen.2009.03.004; Unger CA, 2017, J HEALTH PSYCHOL, V22, P29, DOI 10.1177/1359105315595118; Urizar GG, 2004, BIOL PSYCHOL, V67, P275, DOI 10.1016/j.biopsycho.2003.11.001; Vale RR G, 2012, CORTISOL PHYSL REGUL, P129; Vogl SE, 2006, BJOG-INT J OBSTET GY, V113, P441, DOI 10.1111/j.1471-0528.2006.00865.x; Wadhwa PD, 1996, PSYCHOSOM MED, V58, P432, DOI 10.1097/00006842-199609000-00006; Werner A, 2012, BJOG INT J OBSTET GY; Werner A, 2013, BIRTH-ISS PERINAT C, V40, P272, DOI 10.1111/birt.12071; Werner A, 2013, ACTA OBSTET GYN SCAN, V92, P816, DOI 10.1111/aogs.12141; WESTGARD JO, 1981, CLIN CHEM, V27, P493; Zaers S, 2008, J PSYCHOSOM OBST GYN, V29, P61, DOI 10.1080/01674820701804324	51	0	0	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2020	15	5							e0230704	10.1371/journal.pone.0230704	http://dx.doi.org/10.1371/journal.pone.0230704			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LT3FY	32357152	Green Published, gold			2023-01-03	WOS:000536957700004
J	Hoppe, MW; Barnics, V; Freiwald, J; Baumgart, C				Hoppe, Matthias W.; Barnics, Vadim; Freiwald, Juergen; Baumgart, Christian			Contrary to endurance, power associated capacities differ between different aged and starting-nonstarting elite junior soccer players	PLOS ONE			English	Article							MATCH RUNNING PERFORMANCE; SPRINT PERFORMANCE; 1ST TEAM; FOOTBALL; STRENGTH; RELIABILITY; PARAMETERS; SPEED; PHYSIOLOGY; MATURITY	This study aimed to investigate differences in anthropometric characteristics and physical capacities (1) between under (U) 17, 19, and 21 years old elite junior soccer players, and also (2) between starting and nonstarting players within each age group. Ninety-two male elite German junior field players were tested for height, mass, fat, and fat-free mass as well as aerobic endurance, squat (SJ) and counter movement jump (CMJ), linear sprint, core strength-endurance, and one repetition maximum (1RM) bench press performance. According to their age and competitive match playing times, the players were divided into the mentioned different groups. Magnitude-based inferences and effect sizes (ES) were computed for statistical analyses. The fat-free mass, SJ and CMJ, 1RM bench press, and linear sprinting performances increased likely to most likely from U17 to U21 players (ES: moderate to large), whereas the body fat, core strength-endurance, and aerobic endurance performances remain constant. The fat-free mass, 1RM bench press, and linear sprinting performances were likely to most likely higher in U21 starting compared to nonstarting players (ES: moderate to large). Our study shows that contrary to endurance, power associated capacities differ between different aged and starting-nonstarting elite junior soccer players. This outcome should be considered for training, testing, and talent selection procedures in elite junior soccer players.	[Hoppe, Matthias W.] Univ Leipzig, Inst Movement & Training Sci 1, Leipzig, Germany; [Barnics, Vadim; Freiwald, Juergen; Baumgart, Christian] Univ Wuppertal, Dept Movement & Training Sci, Wuppertal, Germany	Leipzig University; University of Wuppertal	Hoppe, MW (corresponding author), Univ Leipzig, Inst Movement & Training Sci 1, Leipzig, Germany.	matthias.hoppe@uni-leipzig.de	Hoppe, Matthias W./AAT-1168-2021		German Research Foundation (DFG); University of Leipzig	German Research Foundation (DFG)(German Research Foundation (DFG)); University of Leipzig	The publication fees were funded by the German Research Foundation (DFG) and University of Leipzig within the Program of Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson L, 2016, INT J SPORT PHYSIOL, V11, P1038, DOI 10.1123/ijspp.2015-0672; Bangsbo J, 2014, INDIVIDUAL TRAINING; Barnes C, 2014, INT J SPORTS MED, V35, P1095, DOI 10.1055/s-0034-1375695; Batterham AM, 2006, INT J SPORT PHYSIOL, V1, P50, DOI 10.1123/ijspp.1.1.50; Baumgart C, 2018, SPORTS, V6, DOI 10.3390/sports6040161; Bidaurrazaga-Letona I, 2019, J STRENGTH COND RES, V33, P2548, DOI 10.1519/JSC.0000000000001924; Bradley PS, 2018, INT J SPORT PHYSIOL, V13, P656, DOI 10.1123/ijspp.2017-0433; Buchheit M, 2010, INT J SPORTS MED, V31, P818, DOI 10.1055/s-0030-1262838; Buchheit M, 2010, INT J SPORTS MED, V31, P709, DOI 10.1055/s-0030-1261897; Buchheit M, 2017, ASPETAR SPORTS MED J, V6, P36; Buchheit M, 2014, J SPORT SCI, V32, P1271, DOI 10.1080/02640414.2014.884721; Rebelo ANC, 2016, J SPORT SCI, V34, P2246, DOI 10.1080/02640414.2016.1194527; Canhadas Ive Luz, 2010, Rev. bras. cineantropom. desempenho hum., V12, P239, DOI 10.5007/1980-0037.2010V12N4P239; Cardoso de Araujo M, 2018, J SPORT MED PHYS FIT, V58, P1204, DOI 10.23736/S0022-4707.17.07116-X; Castillo D, 2018, J SPORT MED PHYS FIT, V58, P392, DOI 10.23736/S0022-4707.16.06436-7; Deprez D, 2015, J SPORT SCI, V33, P243, DOI 10.1080/02640414.2014.934707; Da Silva CD, 2008, J SPORT SCI MED, V7, P309; Faude O, 2012, J SPORT SCI, V30, P625, DOI 10.1080/02640414.2012.665940; Gravina L, 2008, J STRENGTH COND RES, V22, P1308, DOI 10.1519/JSC.0b013e31816a5c8e; Haugen T, 2015, SPORT SCI, V19, P10; Haugen TA, 2014, INT J SPORT PHYSIOL, V9, P432, DOI [10.1123/ijspp.2013-0121, 10.1123/IJSPP.2013-0121]; Haugen TA, 2013, INT J SPORT PHYSIOL, V8, P148, DOI 10.1123/ijspp.8.2.148; Herrera E, 2015, REV INT MED CIENS AC, V15, P1; Hill-Haas SV, 2011, SPORTS MED, V41, P199, DOI 10.2165/11539740-000000000-00000; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Hoppe MW, 2015, SPORTVERLETZ SPORTSC, V29, P173, DOI 10.1055/s-0034-1399096; Hoppe MW, 2015, J SPORT MED PHYS FIT, V55, P150; Hoppe MW, 2013, J STRENGTH COND RES, V27, P31, DOI 10.1519/JSC.0b013e31824e1711; Hoppe MW, 2017, ASIAN J SPORTS MED, V8, P1; Kenney L., 2015, PHYSL SPORT EXERCISE; Linthorne NP, 2001, AM J PHYS, V69, P1198, DOI 10.1119/1.1397460; Mallo J., 2014, PERIODIZATION FITNES; Markovic G, 2004, J STRENGTH COND RES, V18, P551, DOI 10.1519/00124278-200408000-00028; Martinez-Santos R, 2016, J SPORT SCI, V34, P2279, DOI 10.1080/02640414.2016.1190460; Mendez-Villanueva A, 2011, J SPORT SCI, V29, P477, DOI 10.1080/02640414.2010.536248; Milsom J, 2015, J SPORT SCI, V33, P1799, DOI 10.1080/02640414.2015.1012101; Mirwald RL, 2002, MED SCI SPORT EXER, V34, P689, DOI 10.1097/00005768-200204000-00020; Morgans R, 2018, INT J SPORT PHYSIOL, V13, P665, DOI 10.1123/ijspp.2016-0412; Nesser TW, 2008, J STRENGTH COND RES, V22, P1750, DOI 10.1519/JSC.0b013e3181874564; Owen AL, 2012, J STRENGTH COND RES, V26, P2748, DOI 10.1519/JSC.0b013e318242d2d1; Vieira LHP, 2019, SPORTS MED, V49, P289, DOI 10.1007/s40279-018-01048-8; Reilly T, 2000, J SPORT SCI, V18, P695, DOI 10.1080/02640410050120050; Roth R, 2016, J APPL BIOMECH, V32, P241, DOI 10.1123/jab.2014-0303; Sannicandro I, 2015, MED SPORT, V68, P19; Schubert MM, 2019, CLIN PHYSIOL FUNCT I, V39, P150, DOI 10.1111/cpf.12550; Selmi MA, 2020, J STRENGTH COND RES, V34, P506, DOI 10.1519/JSC.0000000000002810; Seo DI, 2012, J SPORT SCI MED, V11, P221; Silva JR, 2015, SPORTS MED-OPEN, V1, DOI 10.1186/s40798-015-0006-z; Sporis G, 2011, J SPORT MED PHYS FIT, V51, P374; Stolen T, 2005, SPORTS MED, V35, P501; Thomann R, 2014, FUSSBALL FORSCHUNG L, P99; Tonnessen E, 2013, INT J SPORT PHYSIOL, V8, P323, DOI 10.1123/ijspp.8.3.323; Vaeyens R, 2005, J SPORT SCI, V23, P1003, DOI 10.1080/02640410400023266; [No title captured]	54	4	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2020	15	4							e0232118	10.1371/journal.pone.0232118	http://dx.doi.org/10.1371/journal.pone.0232118			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LS8WP	32343716	Green Published, gold			2023-01-03	WOS:000536661300035
J	Fringer, A; Stangle, S; Buche, D; Ott, SC; Schnepp, W				Fringer, Andre; Staengle, Sabrina; Bueche, Daniel; Ott, Stefan Ch.; Schnepp, Wilfried			The associations of palliative care experts regarding food refusal: A cross-sectional study with an open question evaluated by triangulation analysis	PLOS ONE			English	Article							NUTRITIONAL SUPPORT; EATING-DISORDERS; SCREENING TOOL; MALNUTRITION; APPETITE; PATIENT; CANCER; DEATH; END	Introduction Health professionals in oncologic and palliative care settings are often faced with the problem that patients stop eating and drinking. While the causes of food refusal are very different, the result is often malnutrition, which is linked to health comorbidities and a high mortality rate. However, the professionals lack the time and knowledge to clarify the cause for each patient. What associations do health professionals have when faced with food refusal? Objective To investigate the associations that health professionals in oncological and palliative settings have about denied eating behavior Methods A cross-sectional study, starting with an open question focusing professionals' associations regarding food refusal. The results were inductively analyzed, whereby generic categories were developed. Subsequently, the categories were transformed into quantitative data to calculate the relationships between the categories. Results A total of 350 out of 2000 participants completed the survey, resulting in a response rate of 17.5%. Food refusal is primarily associated with physical and ethical aspects and with end-of-life. Half of the participants frequently find that patients refuse to eat. The attitudes show that the autonomy of the patient is the highest good and is to be respected. Even in the case of patients with limited decision-making capacity, the refusal to eat is acceptable. Conclusion Clarifying the cause of food refusal requires a great deal of knowledge and is strongly influenced by the associations of health professionals. While the associations have very negative connotations, information and training is needed to make professionals aware of this and to change their associations. With this knowledge and in an interprofessional cooperation, mis-labelling of patient settings can be avoided and fears can be reduced.	[Fringer, Andre; Staengle, Sabrina] ZHAW Univ Appl Sci, Inst Nursing, Sch Hlth Profess, Winterthur, Switzerland; [Fringer, Andre; Staengle, Sabrina; Schnepp, Wilfried] Witten Herdecke Univ, Inst Hlth, Dept Nursing Sci, Witten, Germany; [Bueche, Daniel] Cantonal Hosp St Gallen, Palliat Ctr St Gallen, St Gallen, Switzerland; [Ott, Stefan Ch.] FHS St Gallen Univ Appl Sci St Gallen, Dept Econ, St Gallen, Switzerland	Kantonsspital St. Gallen	Fringer, A (corresponding author), ZHAW Univ Appl Sci, Inst Nursing, Sch Hlth Profess, Winterthur, Switzerland.; Fringer, A (corresponding author), Witten Herdecke Univ, Inst Hlth, Dept Nursing Sci, Witten, Germany.	andre.fringer@zhaw.ch	Andre, Fringer/S-4399-2016; Fringer, André/ABH-8388-2020	Andre, Fringer/0000-0003-4950-7788; Fringer, André/0000-0003-4950-7788; Stangle, Sabrina/0000-0003-1664-8824	vom Hans AltschuerFoundation, Switzerland	vom Hans AltschuerFoundation, Switzerland	A.F. reports grant vom Hans AltschuerFoundation, Switzerland. https://stiftungschweiz.ch/organisation/dr-hans-altschueler-stiftung The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, MAXQDA REFERENCE MAN, P221; Begley CM, 1996, J ADV NURS, V24, P122, DOI 10.1046/j.1365-2648.1996.15217.x; Berkman ND, 2007, INT J EAT DISORDER, V40, P293, DOI 10.1002/eat.20369; Berry EM, 2000, J ADULT DEV, V7, P87, DOI 10.1023/A:1009575706990; Bolt EE, 2015, ANN FAM MED, V13, P421, DOI 10.1370/afm.1814; Caracelli VJ, 2016, EDUC EVAL POLICY AN, V15, P195; Clark J, 2017, INT J PALLIAT NURS, V23, P74, DOI 10.12968/ijpn.2017.23.2.74; Conceicao EM, 2017, INT J EAT DISORD; Dillman D. A., 2014, TAILORED DESIGN METH; Donini LM, 2003, INT PSYCHOGERIATR, V15, P73, DOI 10.1017/S1041610203008779; Donini LM, 2013, J NUTR HEALTH AGING, P1; Duggal A, 2001, INT J EAT DISORDER, V30, P213, DOI 10.1002/eat.1075; Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x; Eychmuller Steffen, 2012, Ther Umsch, V69, P87, DOI 10.1024/0040-5930/a000256; Fehn S, 2017, SCHWEIZERISCHE ARZTE, V98, P1161; Flick U., 2000, QUALITATIVE RES TEXT, DOI [10.4135/9781849209731.n5, DOI 10.4135/9781849209731.N5]; Fogarty S, 2016, EAT BEHAV, V21, P66, DOI 10.1016/j.eatbeh.2015.12.004; Gizzi M., 2018, CODE RELATIONS BROWS; Groves RM., 2009, SURV METHODOL; Hopkinson JB, 2015, NUTRITION, V31, P598, DOI 10.1016/j.nut.2014.12.013; Keller HH, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0051-y; Kondrup J, 2003, CLIN NUTR, V22, P321, DOI 10.1016/S0261-5614(02)00214-5; Kruizenga HM, 2005, CLIN NUTR, V24, P75, DOI 10.1016/j.clnu.2004.07.015; Kuckartz U., 2014, MIXED METHODS METHOD, DOI 10.10007/978-3-531-93267-5; Lee JLC, 2016, SUPPORT CARE CANCER, V24, P469, DOI 10.1007/s00520-015-2958-4; Leistra E, 2014, CLIN NUTR, V33, P495, DOI 10.1016/j.clnu.2013.07.005; Miles M. B., 2014, QUALITATIVE DATA ANA; Miller I, 2017, BIOSOCIETIES, V12, P89, DOI 10.1057/s41292-016-0034-z; Norberg A, 1993, Pflege, V6, P43; Orrevall Y, 2015, NUTRITION, V31, P615, DOI 10.1016/j.nut.2014.12.004; palliative ch, 2019, PALL CH GEM KOMP BER; Parker BA, 2004, MECH AGEING DEV, V125, P859, DOI 10.1016/j.mad.2004.05.006; Poole K, 2002, PALLIATIVE MED, V16, P499, DOI 10.1191/0269216302pm593oa; Porst R., 2016, FRAGEBOGEN ARBEITSBU; Rabito EI, 2017, NUTR CLIN PRACT; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Sandelowski M, 2010, RES NURS HEALTH, V33, P77, DOI 10.1002/nur.20362; Schreier M, 2012, CONTENT ANAL QUALITA; Simmons SF, 2001, J GERONTOL A-BIOL, V56, pM790, DOI 10.1093/gerona/56.12.M790; Stangle S, 2019, PALLIATIVE CARE SOCI, V13, P1; Strasser F, 2003, SUPPORT CARE CANCER, V11, P11, DOI 10.1007/s00520-002-0391-y; Stratton RJ, 2004, BRIT J NUTR, V92, P799, DOI 10.1079/BJN20041258; Sullivan M., 2016, PATIENT AGENT HLTH H; van der Riet P, 2008, INT J PALLIATIVE NUR, V14; Vanderwee K, 2011, J ADV NURS, V67, P736, DOI 10.1111/j.1365-2648.2010.05531.x; Vellas B, 1999, NUTRITION, V15, P116, DOI 10.1016/S0899-9007(98)00171-3; Vogl S, 2017, KOLNER Z SOZIOL SOZ, V69, P287, DOI 10.1007/s11577-017-0461-2; Volkert D., 2002, CLIN NUTR S1, V21, P110, DOI DOI 10.1016/S0261-5614(02)80014-0; von Wartburg L, 2012, NATL STRATEGIE PALLI; Wittenberg-Lyles Elaine, 2014, Semin Oncol Nurs, V30, P280, DOI 10.1016/j.soncn.2014.08.010; Xia CF, 2006, J CLIN NURS, V15, P1221, DOI 10.1111/j.1365-2702.2006.01425.x	51	0	0	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2020	15	4							e0231312	10.1371/journal.pone.0231312	http://dx.doi.org/10.1371/journal.pone.0231312			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR8WI	32271841	gold, Green Published			2023-01-03	WOS:000535977000071
J	Martinez-Taboada, F; Redondo, JI				Martinez-Taboada, Fernando; Redondo, Jose Ignacio			The SIESTA (SEAAV Integrated evaluation sedation tool for anaesthesia) project: Initial development of a multifactorial sedation assessment tool for dogs	PLOS ONE			English	Article							MEDETOMIDINE; DEXMEDETOMIDINE; REVERSAL	Objective The aim of the study was to develop a multifactorial tool for assessment of sedation in dogs. Methods Following a modified Delphi method, thirty-eight veterinary anaesthetists were contacted to describe the following levels of awareness: no-sedation, light, moderate, profound sedation and excitation. The answers were summarized in descriptors for each level. A questionnaire was created with all the variables obtained from the descriptors. The questionnaire was returned to the panel of anaesthetists to be used before and after real sedations in conjunction with the previous 5-point categorical scale. Data obtained were analysed using the classification-tree and random-forest methods. Results Twenty-three anaesthetists (60%) replied with descriptions. The descriptors and study variables were grouped in categories: state-of-mind, posture, movements, stimuli-response, behaviour, response-to-restraint, muscle tone, physiological data, facial-expression, eye position, eyelids, pupils, vocalization and feasibility-to-perform-intended-procedure. The anaesthetists returned 205 completed questionnaires. The levels of awareness reported by the anaesthetists were: no sedation in 92, mild (26), moderate (37) and profound in 50 cases. The classification-tree detected 6 main classifying variables: change in posture, response-to-restraint, head-elevation, response-to-toe-pinching, response-to-name, and movements. The random-forest found that the following variables: change in posture, response-to-restraint, head-elevation, response-to-name, movements, posture, response-to-toe-pinching, demeanour, righting-reflex and response-to-handclap, were classified correctly in 100% awake, 62% mild, 70% moderate and 86% of profound sedation cases. Discussion and conclusion The questionnaire and methods developed here classified correctly the level of sedation in most cases. Further studies are needed to evaluate the validity of this tool in the clinical and research setting.	[Martinez-Taboada, Fernando] Univ Sydney, Fac Sci, Sch Vet Sci, Dept Vet Anaesthesia & Analgesia, Camperdown, NSW, Australia; [Redondo, Jose Ignacio] Univ CEU Cardenal Herrera, Fac Vet, Inst Ciencias Biomed, Dept Med & Cirugia Anim, Valencia, Spain	University of Sydney; Universidad CEU Cardenal Herrera	Martinez-Taboada, F (corresponding author), Univ Sydney, Fac Sci, Sch Vet Sci, Dept Vet Anaesthesia & Analgesia, Camperdown, NSW, Australia.	fer_m_taboada@hotmail.com		Redondo, Jose Ignacio/0000-0001-5377-9650; Martinez-Taboada, Fernando/0000-0002-0083-4764				Atkinson B, 2019, R PACKAGE VERSION 4; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Breiman L., 1984, CLASSIFICATION REGRE, DOI 10.1201/9781315139470; Garcia Perez A., 2014, CUADERNOS ESTADISTIC, P298; Gomez-Villamandos RJ, 2006, J VET MED A, V53, P471, DOI 10.1111/j.1439-0442.2006.00859.x; Granholm M, 2007, VET REC, V160, P891, DOI 10.1136/vr.160.26.891; Grint NJ, 2009, J SMALL ANIM PRACT, V50, P62, DOI 10.1111/j.1748-5827.2008.00670.x; Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x; Hofmeister EH, 2010, JAVMA-J AM VET MED A, V237, P1155, DOI 10.2460/javma.237.10.1155; Kuusela E, 2000, J VET PHARMACOL THER, V23, P15, DOI 10.1046/j.1365-2885.2000.00245.x; Liaw A, 2016, R PACKAGE VERSION 4; Martinez-Martin P, 2010, J NEUROL SCI, V289, P7, DOI 10.1016/j.jns.2009.08.013; Merola I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150040; Newton Tim, 2013, SAAD Dig, V29, P88; Ringer SK, 2012, VET ANAESTH ANALG, V39, P1, DOI 10.1111/j.1467-2995.2011.00653.x; Sessler CN, 2004, CHEST, V126, P1727, DOI 10.1378/chest.126.6.1727; Thangaratinam S, 2005, OBSTET GYNAECOL, V7, P120, DOI 10.1576/toag.7.2.120.27071; Tranquilli WJ, VET ANESTHESIA ANALG; Varela-Ruiz Margarita, 2012, Investigación educ. médica, V1, P90; Wagner MC, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1027-2; YOUNG LE, 1990, J SMALL ANIM PRACT, V31, P554, DOI 10.1111/j.1748-5827.1990.tb00685.x	21	6	6	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2020	15	4							e0230799	10.1371/journal.pone.0230799	http://dx.doi.org/10.1371/journal.pone.0230799			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8IA	32236148	gold, Green Published, Green Submitted			2023-01-03	WOS:000535938700031
J	Cappellini, MD; Viprakasit, V; Taher, AT; Georgiev, P; Kuo, KHM; Coates, T; Voskaridou, E; Liew, HK; Pazgal-Kobrowski, I; Forni, GL; Perrotta, S; Khelif, A; Lal, A; Kattamis, A; Vlachaki, E; Origa, R; Aydinok, Y; Bejaoui, M; Ho, PJ; Chew, LP; Bee, PC; Lim, SM; Lu, MY; Tantiworawit, A; Ganeva, P; Gercheva, L; Shah, F; Neufeld, EJ; Thompson, A; Laadem, A; Shetty, JK; Zou, J; Zhang, J; Miteva, D; Zinger, T; Linde, PG; Sherman, ML; Hermine, O; Porter, J; Piga, A				Cappellini, M. D.; Viprakasit, V.; Taher, A. T.; Georgiev, P.; Kuo, K. H. M.; Coates, T.; Voskaridou, E.; Liew, H. -K.; Pazgal-Kobrowski, I.; Forni, G. L.; Perrotta, S.; Khelif, A.; Lal, A.; Kattamis, A.; Vlachaki, E.; Origa, R.; Aydinok, Y.; Bejaoui, M.; Ho, P. J.; Chew, L. -P.; Bee, P. -C.; Lim, S. -M.; Lu, M. -Y.; Tantiworawit, A.; Ganeva, P.; Gercheva, L.; Shah, F.; Neufeld, E. J.; Thompson, A.; Laadem, A.; Shetty, J. K.; Zou, J.; Zhang, J.; Miteva, D.; Zinger, T.; Linde, P. G.; Sherman, M. L.; Hermine, O.; Porter, J.; Piga, A.		BELIEVE Investigators	A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent beta-Thalassemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; IRON; HEMOGLOBIN; THERAPY; COMPLICATIONS; SURVIVAL; ACE-536; DISEASE; ANEMIA	Background Patients with transfusion-dependent beta-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor beta superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units transfused) in such patients. Methods In this randomized, double-blind, phase 3 trial, we assigned, in a 2:1 ratio, adults with transfusion-dependent beta-thalassemia to receive best supportive care plus luspatercept (at a dose of 1.00 to 1.25 mg per kilogram of body weight) or placebo for at least 48 weeks. The primary end point was the percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval. Other efficacy end points included reductions in the transfusion burden during any 12-week interval and results of iron studies. Results A total of 224 patients were assigned to the luspatercept group and 112 to the placebo group. Luspatercept or placebo was administered for a median of approximately 64 weeks in both groups. The percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval was significantly greater in the luspatercept group than in the placebo group (21.4% vs. 4.5%, P < 0.001). During any 12-week interval, the percentage of patients who had a reduction in transfusion burden of at least 33% was greater in the luspatercept group than in the placebo group (70.5% vs. 29.5%), as was the percentage of those who had a reduction of at least 50% (40.2% vs. 6.3%). The least-squares mean difference between the groups in serum ferritin levels at week 48 was -348 mu g per liter (95% confidence interval, -517 to -179) in favor of luspatercept. Adverse events of transient bone pain, arthralgia, dizziness, hypertension, and hyperuricemia were more common with luspatercept than placebo. Conclusions The percentage of patients with transfusion-dependent beta-thalassemia who had a reduction in transfusion burden was significantly greater in the luspatercept group than in the placebo group, and few adverse events led to the discontinuation of treatment. (Funded by Celgene and Acceleron Pharma; BELIEVE ClinicalTrials.gov number, NCT02604433; EudraCT number, 2015-003224-31.)	[Cappellini, M. D.] Univ Milan, Dept Clin Sci & Community, IRCCS Ca Granda Fdn Maggiore Policlin Hosp, Via Francesco Sforza 35, I-20122 Milan, Italy; [Forni, G. L.] EO Osped Galliera, Ctr Microcitemia & Anemie Congenite & Dismetab Fe, Genoa, Italy; [Origa, R.] Azienda Osped G Brotzu, Osped Pediat Microcitem A Cao, Cagliari, Italy; [Perrotta, S.] Univ Campania L Vanvitelli, Ematol & Oncol Pediat, Caserta, Italy; [Piga, A.] Univ Turin, Dept Clin & Biol Sci, Turin, Italy; [Viprakasit, V.] Mahidol Univ, Siriraj Hosp, Bangkok, Thailand; [Tantiworawit, A.] Chiang Mai Univ, Dept Internal Med, Div Hematol, Chiang Mai, Thailand; [Taher, A. T.] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon; [Georgiev, P.] St George Univ Hosp Act Treatment, Plovdiv, Bulgaria; [Georgiev, P.] Med Univ Plovdiv, Plovdiv, Bulgaria; [Ganeva, P.] Univ Specialized Hosp Act Treatment Oncol, Sofia, Bulgaria; [Gercheva, L.] Univ Hosp St Marina, Varna, Bulgaria; [Kuo, K. H. M.] Univ Hlth Network, Div Med Oncol & Hematol, Dept Med, Toronto, ON, Canada; [Kuo, K. H. M.] Univ Toronto, Dept Med, Div Hematol, Toronto, ON, Canada; [Coates, T.] Childrens Hosp Los Angeles, Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90027 USA; [Coates, T.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA; [Lal, A.] Univ Calif San Francisco, Benioff Childrens Hosp, Oakland, CA USA; [Voskaridou, E.] Laikon Gen Hosp, Thalassemia & Sickle Cell Ctr, Athens, Greece; [Kattamis, A.] Natl & Kapodistrian Univ Athens, Dept Pediat 1, Athens, Greece; [Vlachaki, E.] Hippokrateion Hosp, Adult Thalassemia Unit, Thessaloniki, Greece; [Liew, H. -K.] Hosp Sultanah Bahiyah, Alor Setar, Malaysia; [Chew, L. -P.] Hosp Umum, Sarawak, Kuching, Malaysia; [Bee, P. -C.] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia; [Lim, S. -M.] Hosp Sultanah Aminah, Johor Baharu, Malaysia; [Pazgal-Kobrowski, I.] Beilinson Med Ctr, Rabin Med Ctr, Comprehens Ctr Thalassemia, Petah Tiqwa, Israel; [Khelif, A.] Farhat Hached Univ Hosp, Sousse, Tunisia; [Bejaoui, M.] Univ Tunis El Manar, Natl Bone Marrow Transplant Ctr, Tunis, Tunisia; [Bejaoui, M.] Univ Tunis El Manar, Fac Med, Tunis, Tunisia; [Aydinok, Y.] Ege Univ Hosp, Dept Pediat Hematol & Oncol, Izmir, Turkey; [Ho, P. J.] Royal Prince Alfred Hosp, Sydney, NSW, Australia; [Ho, P. J.] Univ Sydney, Sydney, NSW, Australia; [Lu, M. -Y.] Natl Taiwan Univ, Taipei, Taiwan; [Shah, F.] Whittington Hlth NHS Trust, Dept Haematol, London, England; [Porter, J.] UCL, Dept Haematol, London, England; [Porter, J.] Univ Coll London Hosp NHS Fdn Trust, London, England; [Neufeld, E. J.] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA; [Thompson, A.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Laadem, A.; Zou, J.; Zhang, J.] Celgene, Summit, NJ USA; [Shetty, J. K.; Miteva, D.; Zinger, T.] Celgene, Boudry, Switzerland; [Linde, P. G.; Sherman, M. L.] Acceleron Pharma, Cambridge, MA USA; [Hermine, O.] Hop Necker Enfants Malad, AP HP, Dept Hematol, Paris, France; [Hermine, O.] Univ Paris, INSERM, U1163, Imagine Inst, Paris, France	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Ente Ospedaliero Ospedali Galliera; Universita della Campania Vanvitelli; University of Turin; Mahidol University; Chiang Mai University; American University of Beirut; Medical University Plovdiv; Medical University Varna; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Children's Hospital Los Angeles; University of Southern California; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Laiko General Hospital; National & Kapodistrian University of Athens; Universiti Malaya; Rabin Medical Center; Universite de Sousse; Hopital Farhat Hached; Universite de Tunis-El-Manar; Centre Nationale de Greffe de la Moelle Osseuse; Universite de Tunis-El-Manar; Faculte de Medecine de Tunis (FMT); Ege University; University of Sydney; University of Sydney; National Taiwan University; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; St Jude Children's Research Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Bristol-Myers Squibb; Celgene Corporation; Acceleron Pharma; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Cappellini, MD (corresponding author), Univ Milan, Dept Clin Sci & Community, IRCCS Ca Granda Fdn Maggiore Policlin Hosp, Via Francesco Sforza 35, I-20122 Milan, Italy.	maria.cappellini@unimi.it	Ricchi, Paolo/J-5140-2019; Georgiev, Pencho/AAV-6464-2020; chew, lee ping/H-4355-2011; kuo, kevin/GXM-4399-2022; Neufeld, Ellis J./F-9331-2011; BEE, PING CHONG/B-5373-2010; Kuo, Kevin/AAV-5580-2021; Coates, Thomas/AAN-3556-2020	Ricchi, Paolo/0000-0001-7361-3308; Georgiev, Pencho/0000-0001-5677-6754; Neufeld, Ellis J./0000-0001-8092-6281; BEE, PING CHONG/0000-0003-4253-760X; Coates, Thomas/0000-0001-9878-6029; Durst, Ronen/0000-0003-3559-1050; Hill, Quentin/0000-0002-0627-4358; Pinto, Valeria Maria/0000-0002-8375-6289; Voi, Vincenzo/0000-0001-7249-2735	Celgene; Acceleron Pharma; EudraCT [2015--003224-31]; BELIEVE	Celgene(Bristol-Myers SquibbCelgene Corporation); Acceleron Pharma; EudraCT; BELIEVE	Funded by Celgene and Acceleron Pharma; BELIEVE ClinicalTrials.gov number, NCT02604433; EudraCT number, 2015--003224-31.	[Anonymous], 2019, ZYNT SUMM PROD CHAR; [Anonymous], 2012, KIDNEY INT, V2, ps1; Attie KM, 2014, AM J HEMATOL, V89, P766, DOI 10.1002/ajh.23732; Aydinok Y, 2015, EUR J HAEMATOL, V95, P244, DOI 10.1111/ejh.12487; Borgna-Pignatti C, 2004, HAEMATOLOGICA, V89, P1187; Brittenham GM, 2011, NEW ENGL J MED, V364, P146, DOI 10.1056/NEJMct1004810; Cappellini MD, 2018, BLOOD REV, V32, P300, DOI 10.1016/j.blre.2018.02.001; Cappellini MD, 2012, EXPERT REV HEMATOL, V5, P505, DOI [10.1586/ehm.12.42, 10.1586/EHM.12.42]; Cappellini MD, 2014, GUIDELINES MANAGEMEN; Coates TD, 2014, FREE RADICAL BIO MED, V72, P23, DOI 10.1016/j.freeradbiomed.2014.03.039; Gan GG, 2016, ANN ACAD MED SINGAP, V45, P520; Guerra A, 2019, BLOOD, V134, P568, DOI 10.1182/blood.2019001057; Locatelli F, 2013, BLOOD, V122, P1072, DOI 10.1182/blood-2013-03-489112; Modell B, 2000, LANCET, V355, P2051, DOI 10.1016/S0140-6736(00)02357-6; Modell B, 2008, B WORLD HEALTH ORGAN, V86, P480, DOI 10.2471/BLT.06.036673; Musallam KM, 2013, HAEMATOLOGICA, V98, P833, DOI 10.3324/haematol.2012.066845; Piga A, 2019, BLOOD, V133, P1279, DOI 10.1182/blood-2018-10-879247; Platzbecker U, 2017, LANCET ONCOL, V18, P1338, DOI 10.1016/S1470-2045(17)30615-0; Scalone L, 2008, CURR MED RES OPIN, V24, P1905, DOI 10.1185/03007990802160834 ; Suragani RNVS, 2014, BLOOD, V123, P3864, DOI 10.1182/blood-2013-06-511238; Suragani RNVS, 2014, NAT MED, V20, P408, DOI 10.1038/nm.3512; Taher AT, 2018, LANCET, V391, P155, DOI 10.1016/S0140-6736(17)31822-6; Taher AT, 2010, BLOOD, V115, P1886, DOI 10.1182/blood-2009-09-243154; Thompson AA, 2018, NEW ENGL J MED, V378, P1479, DOI 10.1056/NEJMoa1705342; Weatherall DJ, 2010, BLOOD, V115, P4331, DOI 10.1182/blood-2010-01-251348	25	99	102	5	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 26	2020	382	13					1219	1231		10.1056/NEJMoa1910182	http://dx.doi.org/10.1056/NEJMoa1910182			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY1UO	32212518	Green Published, Bronze			2023-01-03	WOS:000522357300009
J	Bivens, M				Bivens, Matt			The Dishonesty of Informed Consent Rituals	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Out of respect for patient autonomy, we ritually inform patients of self-evident risks, even as we mock the very idea of informed consent by routinely prescribing combined medications that we must know will cost 10 times as much as the separate components.	[Bivens, Matt] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; [Bivens, Matt] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Bivens, M (corresponding author), Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA.; Bivens, M (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.							Himmelstein DU, 2019, AM J PUBLIC HEALTH, V109, P431, DOI 10.2105/AJPH.2018.304901; Janitzky AA, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001852; Kliff S, 2018, VOX             1004; Rosenthal E, 2019, JAMA INTERN MED, V179, P114, DOI 10.1001/jamainternmed.2018.5007	4	1	1	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 19	2020	382	12					1089	1091		10.1056/NEJMp1916864	http://dx.doi.org/10.1056/NEJMp1916864			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KW7AJ	32187468				2023-01-03	WOS:000521333700008
J	Reynolds, KL; Sullivan, RJ; Fintelmann, FJ; Mansour, MK; England, J				Reynolds, Kerry L.; Sullivan, Ryan J.; Fintelmann, Florian J.; Mansour, Michael K.; England, Jonathan			Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								A 64-year-old man with a history of melanoma presented to the hospital after evaluation for clumsiness of the right arm had revealed a brain mass. Metastatic melanoma was diagnosed, and treatment included combination immune checkpoint inhibitor therapy. Fevers, dyspnea, and cough developed. Treatment decisions were made.	[Reynolds, Kerry L.; Sullivan, Ryan J.; Mansour, Michael K.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Fintelmann, Florian J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA; [England, Jonathan] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Reynolds, Kerry L.; Sullivan, Ryan J.; Mansour, Michael K.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Fintelmann, Florian J.] Harvard Med Sch, Dept Radiol, Boston, MA 02115 USA; [England, Jonathan] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Reynolds, KL (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.; Reynolds, KL (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.			England, Jonathan/0000-0002-6330-3688				[Anonymous], 2019, NEW ENGL J MED, V381, P1268; Baddley JW, 2009, J CLIN MICROBIOL, V47, P3271, DOI 10.1128/JCM.00854-09; Brahmer JR, 2018, J ONCOL PRACT, V14, P247, DOI 10.1200/JOP.18.00005; Champiat S, 2017, CLIN CANCER RES, V23, P1920, DOI 10.1158/1078-0432.CCR-16-1741; Chen JH, 2017, AM J SURG PATHOL, V41, P643, DOI 10.1097/PAS.0000000000000829; Haanen JBAG, 2017, ANN ONCOL, V28, P119, DOI 10.1093/annonc/mdx225; Kao JC, 2017, JAMA NEUROL, V74, P1216, DOI 10.1001/jamaneurol.2017.1912; Karamchandani DM, 2018, J CLIN PATHOL, V71, P665, DOI 10.1136/jclinpath-2018-205143; Molina DK, 2012, AM J FOREN MED PATH, V33, P368, DOI 10.1097/PAF.0b013e31823d29ad; Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005; National Comprehensive Cancer Network, 2019, NCCN IMM; Puzanov I, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0300-z; Risslegger B, 2017, CLIN MICROBIOL INFEC, V23, p776E1, DOI 10.1016/j.cmi.2017.04.012; Steinbach WJ, 2004, CLIN INFECT DIS, V39, P192, DOI 10.1086/421950; Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Zubiri L, 2020, ONCOLOGIST, V25, pE398, DOI 10.1634/theoncologist.2018-0883	17	4	4	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 19	2020	382	12					1150	1159		10.1056/NEJMcpc1909621	http://dx.doi.org/10.1056/NEJMcpc1909621			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW7AJ	32187473				2023-01-03	WOS:000521333700015
J	Clifton, J; Parent, J; Seehuus, M; Worrall, G; Forehand, R; Domar, A				Clifton, Jessica; Parent, Justin; Seehuus, Martin; Worrall, Garyn; Forehand, Rex; Domar, Alice			An internet-based mind/body intervention to mitigate distress in women experiencing infertility: A randomized pilot trial	PLOS ONE			English	Article							GROUP PSYCHOLOGICAL INTERVENTIONS; ASSISTED REPRODUCTIVE TECHNOLOGY; MENTAL-HEALTH; BEHAVIORAL TREATMENT; PREGNANCY RATES; DEPRESSION; INVENTORY; ANXIETY; STRESS; IMPACT	Objective To determine if an internet-based mind/body program would lead to participants experiencing infertility (1) being willing to be recruited and randomized and (2) accepting and being ready to engage in a fertility-specific intervention. Secondary exploratory goals were to examine reduced distress over the course of the intervention and increased likelihood to conceive. Methods This was a pilot randomized controlled feasibility trial with a between-groups, repeated measure design. Seventy-one women self-identified as nulliparous and meeting criteria for infertility. Participants were randomized to the internet-based version of the Mind/Body Program for Fertility or wait-list control group and asked to complete pre-, mid- and post-assessments. Primary outcomes include retention rates, number of modules completed, and satisfaction with intervention. Secondary exploratory outcomes sought to provide preliminary data on the impact of the program on distress (anxiety and depression) and self-reported pregnancy rates relative to a quasi-control group. Results The retention, adherence, and satisfaction rates were comparable to those reported in other internet-based RCTs. Although time between pre- and post-assessment differed between groups, using intent-to-treat analyses, women in the intervention group (relative to the waitlist group) had significant reduction in distress (anxiety, p =.003; depression, p =.007; stress, p =.041 fertility-social, p =.018; fertility-sexual, p =.006), estimated as medium-to-large effect sizes (ds = 0.45 to 0.86). The odds of becoming pregnant was 4.47 times higher for the intervention group participants as compared to the wait-list group, OR 95% CI [1.56, 12.85], p =.005 and occurred earlier. The findings suggest that the research design and program specific to this population are feasible and acceptable. Replication efforts with an active control group are needed to verify distress reduction and conception promotion findings.	[Clifton, Jessica; Seehuus, Martin; Forehand, Rex] Univ Vermont, Dept Psychol Sci, Burlington, VT 05405 USA; [Parent, Justin] Florida Int Univ, Dept Psychol, Miami, FL 33199 USA; [Seehuus, Martin] Middlebury Coll, Dept Psychol, Middlebury, VT 05753 USA; [Worrall, Garyn] Univ Vermont, Dept Med, Larner Coll Med, Burlington, VT USA; [Domar, Alice] Boston IVF, Waltham, MA USA; [Domar, Alice] Harvard Med Sch, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA	University of Vermont; State University System of Florida; Florida International University; University of Vermont; Harvard University; Harvard Medical School	Clifton, J (corresponding author), Univ Vermont, Dept Psychol Sci, Burlington, VT 05405 USA.	jclifton@uvm.edu	Seehuus, Martin/ABG-2394-2020	Seehuus, Martin/0000-0002-0068-1489; Parent, Justin/0000-0002-1659-8188	Department of Psychological Science, University of Vermont, Burlington, VT	Department of Psychological Science, University of Vermont, Burlington, VT	"JC This work was supported by the Department of Psychological Science, University of Vermont, Burlington, VT. AD is the Co-owner of FertiCalm LLC, FertiStrong LLC, and Aliz Health Apps LLC. FertiCalm LLC, FertiStrong LLC, and Aliz Health Apps LLC did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section."	Aarts JWM, 2012, HUM REPROD UPDATE, V18, P211, DOI 10.1093/humupd/dmr045; Andersson Gerhard, 2009, Cognitive Behaviour Therapy, V38, P55, DOI 10.1080/16506070902916400; [Anonymous], 2016, HOM SCREEN MIN NEUR; Beck A.T., 1993, BECK ANXIETY INVENTO; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1993, SUICIDE LIFE-THREAT, V23, P139; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Beijers R, 2010, PEDIATRICS, V126, pE401, DOI 10.1542/peds.2009-3226; BERG BJ, 1991, J BEHAV MED, V14, P11, DOI 10.1007/BF00844765; Boivin J, 1999, HUM REPROD, V14, P1384, DOI 10.1093/humrep/14.5.1384; Clarke DM, 2009, MED J AUSTRALIA, V190, pS54; Clifton J, 2015, RANDOMIZED PILOT TRI; Cohen J., 2013, STAT POWER ANAL BEHA; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Domar AD, 2000, HEALTH PSYCHOL, V19, P568, DOI 10.1037/0278-6133.19.6.568; Domar AD, 2000, FERTIL STERIL, V73, P805, DOI 10.1016/S0015-0282(99)00493-8; DOMAR AD, 1992, FERTIL STERIL, V58, P144; DOMAR AD, 1990, FERTIL STERIL, V53, P246; Domar AD, 2017, PSYCHOL STRESS INFER; Domar AD, 2011, FERTIL STERIL, V95, P2269, DOI 10.1016/j.fertnstert.2011.03.046; Enders CK, 2001, STRUCT EQU MODELING, V8, P128, DOI 10.1207/S15328007SEM0801_7; Gourounti K, 2016, WOMEN HEALTH, V56, P98, DOI 10.1080/03630242.2015.1074642; Gourounti K, 2010, CURR WOMENS HEALTH R, V6, P318, DOI 10.2174/157340410793362159; Greil AL, 2004, J REPROD INFANT PSYC, V22, P305, DOI 10.1080/02646830412331298332; Gurunath S, 2011, HUM REPROD UPDATE, V17, P575, DOI 10.1093/humupd/dmr015; Haahr M, RANDOM ORG RANDOM IN; Haemmerli K, 2010, J BEHAV MED, V33, P135, DOI 10.1007/s10865-009-9243-2; Hammerli K, 2009, HUM REPROD UPDATE, V15, P279, DOI 10.1093/humupd/dmp002; Hayes SC, 2017, WORLD PSYCHIATRY, V16, P245, DOI 10.1002/wps.20442; Herbert DL, 2010, FERTIL STERIL, V94, P1817, DOI 10.1016/j.fertnstert.2009.10.062; IBM Corp, IBM SPSS STAT WIND V; McArdle JJ, 2009, ANNU REV PSYCHOL, V60, P577, DOI 10.1146/annurev.psych.60.110707.163612; McMurtry SL, 2000, RES SOCIAL WORK PRAC, V10, P644, DOI 10.1177/104973150001000506; Muth?n B.O., 2012, MPLUS; Newton CR, 1999, FERTIL STERIL, V72, P54, DOI 10.1016/S0015-0282(99)00164-8; Pasch LA, 2016, FERTIL STERIL, V106, P209, DOI 10.1016/j.fertnstert.2016.03.006; Punamaki RL, 2006, INFANT BEHAV DEV, V29, P230, DOI 10.1016/j.infbeh.2005.12.001; Rounsaville BJ, 2001, CLIN PSYCHOL-SCI PR, V8, P133, DOI 10.1093/clipsy/8.2.133; Salim A, 2008, PSYCHIAT RES, V160, P335, DOI 10.1016/j.psychres.2007.08.005; Schmitz C, 2012, LIMESURVEY OPEN SOUR; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; van Dongen AJCM, 2016, HUM REPROD, V31, P1046, DOI 10.1093/humrep/dew040; Verberg MFG, 2008, HUM REPROD, V23, P2050, DOI 10.1093/humrep/den219; Wischmann T, 2005, UROLOGE A, V44, P185, DOI 10.1007/s00120-004-0779-7; Wischmann T, 2008, J PSYCHOSOM OBST GYN, V29, P83, DOI 10.1080/01674820701817870	45	7	7	3	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2020	15	3							e0229379	10.1371/journal.pone.0229379	http://dx.doi.org/10.1371/journal.pone.0229379			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ9EP	32187236	gold, Green Submitted, Green Published			2023-01-03	WOS:000535300000013
J	Shah, R; Ahluwalia, S				Shah, Rupal; Ahluwalia, Sanjiv			Different ways of knowing	LANCET			English	Editorial Material									[Shah, Rupal; Ahluwalia, Sanjiv] Hlth Educ England, London, England; [Shah, Rupal] Bridge Lane Grp Practice, London SW11 3AD, England; [Ahluwalia, Sanjiv] Wentworth Med Practice, London, England		Shah, R (corresponding author), Hlth Educ England, London, England.; Shah, R (corresponding author), Bridge Lane Grp Practice, London SW11 3AD, England.	rupal.shah@hee.nhs.uk		Ahluwalia, Sanjiv/0000-0002-5830-0853; Shah, Rupal/0000-0001-9079-0971					0	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 14	2020	395	10227					862	863						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC8NO	32171401				2023-01-03	WOS:000615088500001
J	McKinney, CA; Oliveira, BCM; Bedenice, D; Paradis, MR; Mazan, M; Sage, S; Sanchez, A; Widmer, G				McKinney, Caroline A.; Oliveira, Bruno C. M.; Bedenice, Daniela; Paradis, Mary-Rose; Mazan, Melissa; Sage, Sophie; Sanchez, Alfredo; Widmer, Giovanni			The fecal microbiota of healthy donor horses and geriatric recipients undergoing fecal microbial transplantation for the treatment of diarrhea	PLOS ONE			English	Article							PROBIOTIC USE; RISK-FACTORS; INTESTINE	Background and aims Fecal microbial transplantation (FMT), a treatment for certain gastrointestinal conditions associated with dysbiosis in people, is also empirically employed in horses with colitis. This study used microbiota high-throughput sequencing to compare the fecal microbial profile of healthy horses to that of geriatric microbial transplant recipients experiencing diarrhea and tested whether FMT restores microbiota diversity. Methods To evaluate the effect of environment and donor characteristics on the intestinal microbiota, fecal samples were collected per rectum from 15 healthy young-adult (2-12 years) and 15 geriatric (>= 20 years) horses. Additionally, FMT was performed for 3 consecutive days in 5 geriatric horses with diarrhea using feces from the same healthy donor. Fecal samples were collected from both donor and recipient prior to each FMT and from recipients 24 hours following the last FMT. The profile of the fecal bacterial microbiota was compared using 16S amplicon sequencing. Results and conclusions In contrast to diet and farm location, age did not significantly affect the healthy equine fecal microbiota, indicating that both healthy geriatric and young-adult horses may serve as FMT donors. The fecal microbiota of horses with diarrhea was significantly more variable in terms of beta-diversity than that of healthy horses. An inverse correlation between diarrhea score and relative abundance of Verrucomicrobia was identified in surviving FMT recipients. At study completion, the fecal microbiota of horses which responded to FMT had a higher alpha-diversity than prior to treatment and was phylogenetically more similar to that of the donor.	[McKinney, Caroline A.; Bedenice, Daniela; Paradis, Mary-Rose; Mazan, Melissa; Sage, Sophie; Sanchez, Alfredo] Tufts Univ, Dept Clin Sci, Cummings Sch Vet Med, North Grafton, MA 01536 USA; [Oliveira, Bruno C. M.; Widmer, Giovanni] Tufts Univ, Dept Infect Dis & Global Hlth, Cummings Sch Vet Med, North Grafton, MA USA; [Oliveira, Bruno C. M.] Univ Estadual Paulista Unesp, Fac Med Vet, Aracatuba, Brazil; [Sanchez, Alfredo] Auburn Univ, Equine Field Serv, Auburn, AL 36849 USA	Tufts University; Tufts University; Universidade Estadual Paulista; Auburn University System; Auburn University	Bedenice, D (corresponding author), Tufts Univ, Dept Clin Sci, Cummings Sch Vet Med, North Grafton, MA 01536 USA.	daniela.bedenice@tufts.edu		McKinney, Caroline/0000-0003-3167-2558; Sage, Sophie/0000-0002-6945-070X	Dorothy Russell Havemeyer Foundation [V320001 PV1215]; American College of Veterinary Internal Medicine Resident Research [102783-00001]; National Institute of Allergy and Infectious Disease (NIAID) [R21AI125891]	Dorothy Russell Havemeyer Foundation; American College of Veterinary Internal Medicine Resident Research; National Institute of Allergy and Infectious Disease (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding was provided by the Dorothy Russell Havemeyer Foundation grant V320001 PV1215 awarded to author MRP and DB (http://www.havemeyerfoundation.org/research.htm), the American College of Veterinary Internal Medicine Resident Research grant 102783-00001 (https://www.acvim.org/Awards-Grants/Fellowships_Grants) awarded to author CAM and DB, and the National Institute of Allergy and Infectious Disease (NIAID) award R21AI125891(https://www.niaid.nih.gov/research/research-funded-niaid) granted to GW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baker GC, 2003, J MICROBIOL METH, V55, P541, DOI 10.1016/j.mimet.2003.08.009; Bourlioux P, 2003, AM J CLIN NUTR, V78, P675, DOI 10.1093/ajcn/78.4.675; Cammarota G, 2017, GUT, V66, P569, DOI 10.1136/gutjnl-2016-313017; CLARKE KR, 1993, AUST J ECOL, V18, P117, DOI 10.1111/j.1442-9993.1993.tb00438.x; Cohen ND, 1999, J AM VET MED ASSOC, V214, P382; Costa MC, 2015, VET J, V205, P74, DOI 10.1016/j.tvjl.2015.03.018; Costa MC, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0335-7; Costa MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041484; Costa MC, 2018, VET CLIN N AM-EQUINE, V34, P1, DOI 10.1016/j.cveq.2017.11.005; Daly K, 2012, BRIT J NUTR, V107, P989, DOI 10.1017/S0007114511003825; Daotong L, 2016, BIOTECHNOLOGY ADV; Dougal K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087424; Feary DJ, 2006, VET CLIN N AM-EQUINE, V22, P437, DOI 10.1016/j.cveq.2006.03.008; Hamady M, 2008, NAT METHODS, V5, P235, DOI 10.1038/NMETH.1184; Julliand V, 2016, J ANIM SCI, V94, P2262, DOI 10.2527/jas.2015-0198; Kamada N, 2013, NAT IMMUNOL, V14, P685, DOI 10.1038/ni.2608; Khoruts A, 2010, J CLIN GASTROENTEROL, V44, P354, DOI 10.1097/MCG.0b013e3181c87e02; Kienzle E, 2016, J EQUINE VET SCI, V44, P32, DOI 10.1016/j.jevs.2016.04.098; Laustsen LEJ, 2018, P EUR WORKSH EQ NUTR; Lozupone C, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-371; Luo X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133427; MAIR TS, 1990, VET REC, V126, P479; McKinney C, PLOS ONE; Oliveira BCM, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007411; Morrison PK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03017; Mullen K, 2014, 4 6 MICROBIOTA TRANS, P600; Muller KR, 2014, P 11 INT COL RES S; Oliveira BCM, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.01408-18; Paradis MR, 2002, VET CLIN N AM-EQUINE, V18, P391, DOI 10.1016/S0749-0739(02)00021-4; Peakall R, 2012, BIOINFORMATICS, V28, P2537, DOI 10.1093/bioinformatics/bts460; Pereira GQ, 2018, J VET INTERN MED, V32, P707, DOI 10.1111/jvim.15072; Rea MC, 2012, J CLIN MICROBIOL, V50, P867, DOI 10.1128/JCM.05176-11; Rodriguez C, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0514-5; Sage S, 2019, J VET EMERGENCY CRIT; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Schoster A, 2014, J VET INTERN MED, V28, P1640, DOI 10.1111/jvim.12451; Schoster A, 2018, VET CLIN N AM-EQUINE, V34, P13, DOI 10.1016/j.cveq.2017.11.004; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Smilauer P., 2002, MICROCOMPUTER POWER; Suez J, 2018, CELL, V174, P1406, DOI 10.1016/j.cell.2018.08.047; Tlaskalova-Hogenova H, 2011, CELL MOL IMMUNOL, V8, P110, DOI 10.1038/cmi.2010.67; United States Department of Agriculture, 2016, 1 USDA AN PLANT HLTH; Westcott SL, 2017, MSPHERE, V2, DOI 10.1128/mSphereDirect.00073-17	43	21	22	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2020	15	3							e0230148	10.1371/journal.pone.0230148	http://dx.doi.org/10.1371/journal.pone.0230148			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8WI	32155205	Green Published, gold			2023-01-03	WOS:000535278500067
J	Yang, JC; Roman-Urrestarazu, A; Brayne, C				Yang, Justin C.; Roman-Urrestarazu, Andres; Brayne, Carol			Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16	PLOS ONE			English	Article							MEDICATION-ASSISTED TREATMENT; UNITED-STATES; USE DISORDERS; PRESCRIBE BUPRENORPHINE; CARE; BARRIERS; PROGRAMS; NEED	Objective To identify the geographic, organisational, and payment correlates of buprenorphine and methadone treatment among substance abuse treatment (SAT) providers. Methods Secondary analyses of the National Survey of Substance Abuse Treatment Services (NSSATS) from 2007-16 were conducted. We provide bivariate descriptive statistics regarding substance abuse treatment services which offered buprenorphine and methadone treatment from 2007-16. Using multiple logistic regression, we regressed geographic, organisational, and payment correlates on buprenorphine and methadone treatment. Results Buprenorphine is increasingly offered at SAT facilities though uptake remains comparatively low outside of the northeast. SAT facilities run by tribal governments or Indian Health Service which offer buprenorphine remain low compared to privately operated SAT facilities (AOR = 0.528). The odds of offering buprenorphine among facilities offering free or no charge treatment (AOR = 0.838) or a sliding fee scale (AOR = 0.464) was lower. SAT facilities accepting Medicaid payments showed higher odds of offering methadone treatment (AOR = 2.035). Conclusions Greater attention towards the disparities in provision of opioid agonist therapies is warranted, especially towards the reasons why uptake has been moderate among civilian providers. Additionally, the care needs of Native Americans facing opioid-related use disorders bears further scrutiny.	[Yang, Justin C.; Roman-Urrestarazu, Andres; Brayne, Carol] Univ Cambridge, Cambridge Inst Publ Hlth, Cambridge, England; [Yang, Justin C.] UCL, Fac Brain Sci, Div Psychiat, Dept Epidemiol & Appl Clin Res, London, England	University of Cambridge; University of London; University College London	Yang, JC (corresponding author), Univ Cambridge, Cambridge Inst Publ Hlth, Cambridge, England.; Yang, JC (corresponding author), UCL, Fac Brain Sci, Div Psychiat, Dept Epidemiol & Appl Clin Res, London, England.	justin.yang@ucl.ac.uk	Roman-Urrestarazu, Andres/U-9224-2018; Yang, Justin Christopher/H-1780-2018	Roman-Urrestarazu, Andres/0000-0002-2405-9432; Yang, Justin Christopher/0000-0003-2881-4906; Brayne, Carol/0000-0001-5307-663X				AJTJoP, 2005, TRENDS ABUSE OXYCONT, V6, P662; [Anonymous], 2013, STAT STAT SOFTW REL; Blum K, 2016, SUBST USE MISUSE, V51, P1674, DOI 10.1080/10826084.2016.1200097; Brady KT, 2016, AM J PSYCHIAT, V173, P18, DOI 10.1176/appi.ajp.2015.15020262; Cantor J, 2017, J SUBST ABUSE TREAT, V81, P59, DOI 10.1016/j.jsat.2017.07.005; Chen LY, 2013, J ADDICT MED, V7, P325, DOI 10.1097/ADM.0b013e31829b7afe; Choi NG, 2014, DRUG ALCOHOL DEPEN, V145, P113, DOI 10.1016/j.drugalcdep.2014.10.004; Clark RE, 2011, HEALTH AFFAIR, V30, P1425, DOI 10.1377/hlthaff.2010.0532; Duncan Laura G, 2015, J Addict Med Ther Sci, V1, P31; Fullerton CA, 2014, PSYCHIAT SERV, V65, P146, DOI 10.1176/appi.ps.201300235; Huhn AS, 2017, J SUBST ABUSE TREAT, V78, P1, DOI 10.1016/j.jsat.2017.04.005; Jones CM, 2015, AM J PUBLIC HEALTH, V105, pE55, DOI 10.2105/AJPH.2015.302664; Kampman K, 2015, J ADDICT MED, V9, P358, DOI 10.1097/ADM.0000000000000166; Knudsen HK, 2017, DRUG ALCOHOL DEPEN, V173, pS55, DOI 10.1016/j.drugalcdep.2016.08.642; Knudsen HK, 2015, DRUG ALCOHOL DEPEN, V157, P36, DOI 10.1016/j.drugalcdep.2015.09.032; Knudsen HK, 2015, J STUD ALCOHOL DRUGS, V76, P644, DOI 10.15288/jsad.2015.76.644; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Kresina T., 2009, J DRUG POLICY ANAL, V2, DOI [DOI 10.2202/1941-2851.1007, 10.2202/1941-2851.1007]; Lofwall MR, 2012, DRUG ALCOHOL DEPEN, V126, P379, DOI 10.1016/j.drugalcdep.2012.05.025; Meyer R, 2014, POPUL HEALTH MANAG, V17, P372, DOI 10.1089/pop.2013.0098; Momper SL, 2012, FAM SOC, V93, P312, DOI 10.1606/1044-3894.4242; Paulozzi LJ, 2006, AM J PREV MED, V31, P506, DOI 10.1016/j.amepre.2006.08.017; Pergolizzi JV, 2018, J PAIN RES, V11, P301, DOI 10.2147/JPR.S127602; Quinn PD, 2017, PAIN, V158, P140, DOI 10.1097/j.pain.0000000000000730; Rieckmann T, 2017, PSYCHIAT SERV, V68, P1136, DOI 10.1176/appi.ps.201600397; Rieckmann T, 2016, J SUBST ABUSE TREAT, V68, P46, DOI 10.1016/j.jsat.2016.05.007; Rieckmann TR, 2011, J SUBST ABUSE TREAT, V41, P374, DOI 10.1016/j.jsat.2011.05.005; Rosenblatt RA, 2015, ANN FAM MED, V13, P23, DOI 10.1370/afm.1735; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Short VL, 2018, J SUBST ABUSE TREAT, V89, P67, DOI 10.1016/j.jsat.2018.04.003; Stein BD, 2015, MILBANK Q, V93, P561, DOI 10.1111/1468-0009.12137; Substance Abuse and Mental Health Services Administration, 2016, LEARN 8 DIM WELLN; Substance Abuse and Mental Health Services Administration, 2011, NAT SURV SUBST AB TR; Thomas CP, 2014, PSYCHIAT SERV, V65, P158, DOI 10.1176/appi.ps.201300256; United States Department of Health and Human Services, 2015, NAT SURV SUBST AB TR; United States Department of Health and Human Services, 2014, NAT SURV SUBST AB TR; United States Department of Health and Human Services, 2013, NAT SURV SUBST AB TR; United States Department of Health and Human Services, 2010, NAT SURV SUBST AB TR; United States Department of Health and Human Services, 2012, NAT SURV SUBST AB TR; United States Department of Health and Human Services, 2008, NAT SURV SUBST AB TR; United States Department of Health and Human Services, 2007, NAT SURV SUBST AB TR; United States Department of Health and Human Services, 2009, NAT SURV SUBST AB TR; Vadivelu N, 2018, CURR PAIN HEADACHE R, V22, DOI 10.1007/s11916-018-0679-3; Vivolo-Kantor AM, 2018, MMWR-MORBID MORTAL W, V67, P279, DOI 10.15585/mmwr.mm6709e1	44	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2020	15	3							e0229787	10.1371/journal.pone.0229787	http://dx.doi.org/10.1371/journal.pone.0229787			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8MS	32126120	Green Published, gold			2023-01-03	WOS:000535253100052
J	Schmid, P; Cortes, J; Pusztai, L; McArthur, H; Kummel, S; Bergh, J; Denkert, C; Park, YH; Hui, R; Harbeck, N; Takahashi, M; Foukakis, T; Fasching, PA; Cardoso, F; Untch, M; Jia, LY; Karantza, V; Zhao, J; Aktan, G; Dent, R; O'Shaughnessy, J				Schmid, Peter; Cortes, Javier; Pusztai, Lajos; McArthur, Heather; Kuemmel, Sherko; Bergh, Jonas; Denkert, Carsten; Park, Yeon Hee; Hui, Rina; Harbeck, Nadia; Takahashi, Masato; Foukakis, Theodoros; Fasching, Peter A.; Cardoso, Fatima; Untch, Michael; Jia, Liyi; Karantza, Vassiliki; Zhao, Jing; Aktan, Gursel; Dent, Rebecca; O'Shaughnessy, Joyce		Keynote-522 Investigators	Pembrolizumab for Early Triple-Negative Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADVERSE EVENTS; CHEMOTHERAPY; CARBOPLATIN; IMPACT	Background Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear. Methods In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks for up to nine cycles. The primary end points were a pathological complete response at the time of definitive surgery and event-free survival in the intention-to-treat population. Results At the first interim analysis, among the first 602 patients who underwent randomization, the percentage of patients with a pathological complete response was 64.8% (95% confidence interval [CI], 59.9 to 69.5) in the pembrolizumab-chemotherapy group and 51.2% (95% CI, 44.1 to 58.3) in the placebo-chemotherapy group (estimated treatment difference, 13.6 percentage points; 95% CI, 5.4 to 21.8; P<0.001). After a median follow-up of 15.5 months (range, 2.7 to 25.0), 58 of 784 patients (7.4%) in the pembrolizumab-chemotherapy group and 46 of 390 patients (11.8%) in the placebo-chemotherapy group had disease progression that precluded definitive surgery, had local or distant recurrence or a second primary tumor, or died from any cause (hazard ratio, 0.63; 95% CI, 0.43 to 0.93). Across all treatment phases, the incidence of treatment-related adverse events of grade 3 or higher was 78.0% in the pembrolizumab-chemotherapy group and 73.0% in the placebo-chemotherapy group, including death in 0.4% (3 patients) and 0.3% (1 patient), respectively. Conclusions Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).) The addition of pembrolizumab to platinum-based neoadjuvant chemotherapy significantly increased the percentage of patients with a pathological complete response among patients with locally advanced triple-negative breast cancer. Side effects of the immunotherapy were added to the usual toxic effects of chemotherapy, but most patients completed planned treatment.	[Schmid, Peter] Queen Mary Univ London, Barts Canc Inst, London, England; [Cortes, Javier] Quiron Grp, Int Oncol Bur Inst Oncol, Madrid, Spain; [Cortes, Javier] Vall dHebron Inst Oncol, Barcelona, Spain; [Pusztai, Lajos] Yale Canc Ctr, Yale Sch Med, New Haven, CT USA; [McArthur, Heather] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; [Kuemmel, Sherko] Kliniken Essen Mitte, Essen, Germany; [Denkert, Carsten] Philipps Univ Marburg, Inst Pathol, Marburg, Germany; [Denkert, Carsten] Univ Marburg, Marburg, Germany; [Harbeck, Nadia] Univ Munich, Ludwig Maximilian Univ Munich, Breast Ctr, Dept Obstet & Gynecol, Munich, Germany; [Harbeck, Nadia] Univ Munich, Ludwig Maximilian Univ Munich, Ctr Comprehens Canc, Munich, Germany; [Fasching, Peter A.] Erlangen European Metropolitan Reg Nuremberg, Univ Hosp Erlangen, Dept Gynecol & Obstet, Ctr Comprehens Canc, Erlangen, Germany; [Untch, Michael] Helios Klinikum Berlin Buch, Breast Canc Ctr, Berlin, Germany; [Bergh, Jonas; Foukakis, Theodoros] Karolinska Inst, Dept Oncol Pathol, Solna, Sweden; [Bergh, Jonas; Foukakis, Theodoros] Karolinska Univ Hosp, Breast Canc Ctr, Theme Canc, Solna, Sweden; [Park, Yeon Hee] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea; [Hui, Rina] Westmead Hosp, Westmead Breast Canc Inst, Sydney, NSW, Australia; [Hui, Rina] Univ Sydney, Sydney, NSW, Australia; [Takahashi, Masato] Natl Hosp Org Hokkaido Canc Ctr, Dept Breast Surg, Sapporo, Hokkaido, Japan; [Cardoso, Fatima] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal; [Jia, Liyi; Karantza, Vassiliki; Zhao, Jing; Aktan, Gursel] Merck, Kenilworth, NJ USA; [Dent, Rebecca] Duke Natl Univ Singapore, Sch Med, Natl Canc Ctr Singapore, Singapore, Singapore; [O'Shaughnessy, Joyce] Baylor Univ, Med Ctr, Texas Oncol, Dallas, TX USA; [O'Shaughnessy, Joyce] US Oncol, Dallas, TX USA	University of London; Queen Mary University London; Vall d'Hebron Institut d'Oncologia (VHIO); Yale University; Cedars Sinai Medical Center; Kliniken Essen-Mitte; Philipps University Marburg; Philipps University Marburg; University of Munich; University of Munich; University of Erlangen Nuremberg; Helios Kliniken; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Sungkyunkwan University (SKKU); Samsung Medical Center; University of Sydney; University of Sydney; Fundacao Champalimaud; Merck & Company; National Cancer Centre Singapore (NCCS); National University of Singapore; Baylor University; Baylor University Medical Center; Texas Oncology; US Oncology Network	Schmid, P (corresponding author), Queen Mary Univ London, Ctr Expt Canc Med, Barts Canc Inst, Old Anat Bldg,Charterhouse Sq, London EC1M 6BQ, England.	p.schmid@qmul.ac.uk	Uslu, Ruchan/CAA-9946-2022; Watanabe, Junichiro/AAI-8481-2021; GIROTTO, GUSTAVO COLAGIOVANNI/AAF-4533-2021; Tarnawski, Rafal/N-7526-2016; Fasching, Peter A/ABH-9912-2020; Ganshina, Inna/AAJ-5754-2021; Kuemmel, Sherko/AFV-3420-2022; Takahashi, Masato/ABC-2223-2020; Denkert, Carsten/AHE-2675-2022; Uslu, Ruchan/C-6855-2008	Watanabe, Junichiro/0000-0001-9226-895X; GIROTTO, GUSTAVO COLAGIOVANNI/0000-0002-4098-1320; Tarnawski, Rafal/0000-0001-6802-5093; Fasching, Peter A/0000-0003-4885-8471; Ganshina, Inna/0000-0002-0105-9376; Kuemmel, Sherko/0000-0001-9355-494X; AKSOY, SERCAN/0000-0003-4984-1049; Diamond, Jennifer/0000-0002-0703-2772; Bergh, Jonas/0000-0001-5526-1847; Evron, Ella/0000-0002-1003-5042; Uslu, Ruchan/0000-0002-9584-6134	Merck Sharp AMP; Dohme, a subsidiary of Merck	Merck Sharp AMP; Dohme, a subsidiary of Merck	Supported by Merck Sharp & Dohme, a subsidiary of Merck.	Adams S, 2019, ANN ONCOL, V30, P405, DOI 10.1093/annonc/mdy518; Adams S, 2019, ANN ONCOL, V30, P397, DOI 10.1093/annonc/mdy517; Agency E.M., 2014, ROL PATH COMPL RESP; [Anonymous], 2017, PASCO S; Bretz F, 2009, STAT MED, V28, P586, DOI 10.1002/sim.3495; Briggs A, 2019, ISPOR NEW ORL MAY 18; Burstein HJ, 2019, ANN ONCOL, V30, P1541, DOI 10.1093/annonc/mdz235; Cardoso F, 2019, ANN ONCOL, V30, P1194, DOI 10.1093/annonc/mdz173; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Emens LA, 2018, SAN ANT BREAST CANC; Farkona S, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0623-5; FDA, 2014, GUID IND PATH COMPL; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.1200/JCO.2009.25.6529, 10.1043/1543-2165-134.6.907, 10.1200/JOP.777003]; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Hassett MJ, 2006, JNCI-J NATL CANCER I, V98, P1108, DOI 10.1093/jnci/djj305; Huang M, 2019, ESMO BREAST CANC BER; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Loibl S, 2018, LANCET ONCOL, V19, P497, DOI 10.1016/S1470-2045(18)30111-6; Masuda N, 2017, NEW ENGL J MED, V376, P2147, DOI 10.1056/NEJMoa1612645; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; Nanda R, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.506; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; National Cancer Institute (U.S.), 2009, COMMON TERMINOLOGY C; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Pusztai L, 2019, LANCET ONCOL, V20, pE390, DOI 10.1016/S1470-2045(19)30158-5; Qi C, 2019, NCCN ANN C ORL MARCH; Rashid N, 2015, J MANAG CARE SPEC PH, V21, P863, DOI 10.18553/jmcp.2015.21.10.863; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Sikov WM, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.591; Sikov WM, 2015, J CLIN ONCOL, V33, P13, DOI 10.1200/JCO.2014.57.0572; Spring LM, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-GS2-03; von Minckwitz G, 2014, LANCET ONCOL, V15, P747, DOI 10.1016/S1470-2045(14)70160-3; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Yoest JM, 2017, IMMUNOTARGETS THER, V6, P73, DOI 10.2147/ITT.S126227	35	796	815	17	121	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 27	2020	382	9					810	821		10.1056/NEJMoa1910549	http://dx.doi.org/10.1056/NEJMoa1910549			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KS8TT	32101663	Bronze			2023-01-03	WOS:000518581500007
J	Djebbari, F; Sharpley, FA; McLain-Smith, S; Vallance, G; Eyre, TA; Kothari, J; Moore, S; Ramasamy, K				Djebbari, Faouzi; Sharpley, Faye A.; McLain-Smith, Susan; Vallance, Grant; Eyre, Toby A.; Kothari, Jaimal; Moore, Sally; Ramasamy, Karthik			Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients	PLOS ONE			English	Article							QUALITY-OF-LIFE; MULTIPLE-MYELOMA; ELDERLY-PATIENTS; LENALIDOMIDE; DEXAMETHASONE; PREDNISONE; MELPHALAN; BORTEZOMIB	Treatment of transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM) requires a balance between disease control and maintaining quality of life (QoL). Patients value treatment-free remission periods in this incurable condition, as they are associated with better QoL. We set out to study clinical outcomes of consecutive TNE NDMM patients in routine care treated in Thames Valley Cancer Network between 2009 and 2017. The primary outcome was the evaluation of the treatment-free interval (TFI) after 1st and subsequent lines of therapy in the total cohort and in individual subgroups, according to age (<= 75 vs. >75 years), and co-morbidities using Charlson Co-morbidity Index (CCI): mild: 0-2 vs. moderate: 3-4 vs. severe: >= 5). Secondary outcomes include response rates, overall survival (OS) and progression-free survival (PFS) between subgroups: according to age and according to co-morbidities. In a total cohort of 292 patients, median TFI (IQR) was longest after first-line therapy 6.9 months (1.4-16.9), reducing after second line therapy to 1.8 months (.7-6.9), and after third line therapy to 0.6 months (0.2-1.5). Median TFI followed the same trend across the different subgroups, by age (<= 75, >75 years) and by CCI (0-2, 3-4, >= 5). Overall response rate (ORR) to first line therapy for total cohort was 67%, with responses categorised as complete response (CR): 21%, very good partial response: 16%, partial response: 30%, stable disease: 18%, and progressive disease: 8%. ORR in individual subgroups by age were (<= 75: 70% vs. > 75: 63%), and by CCI (0-2: 65% vs. 3-4: 71% vs. >= 5: 77%). Median OS and PFS for the total cohort were (30.2 months, 95% CI: 23.8-36.9), and (9 months, 95% CI: 7.9-9.8), respectively. Patients aged > 75 years showed a significant reduction in OS and PFS compared to those <= 75 years of age: OS (49.0 vs. 22.4 months, p<0.0001, HR: 2.08, 95% CI: 1.5-2.8), PFS (9.7 vs. 8.0 months, p<0.01, HR: 1.47, 95% CI: 1.1-1.9). Median OS was significantly reduced with worsening co-morbidities: (CCI 0-2: 52.4 months vs. CCI 3-4: 33.0 months vs. CCI >= 5: 24.0 months, p = 0.01, HR: 1.43, 95% CI: 1.1-1.9). Median PFS was significantly reduced in the severely co-morbid subgroup (CCI 0-2: 9.4 months vs. CCI 3-4: 9.6 months vs. CCI >= 5: 7.1 months, p = 0.025, HR: 1.3, 95% CI: 1.0-1.6). This study demonstrated that first line therapy in the TNE NDMM setting resulted in the longest TFI which was modest at a median of 6.9 months, and decreased significantly following subsequent lines of therapy and across the different subgroups by age and by co-morbidities. Therapy objective should be to maximise the benefit of first line treatment. We envisage that the recent shift towards a continuous therapeutic approach will benefit TNE patients in view of improved survival data demonstrated by a number phase 3 trials. When continuous therapy is not appropriate due to patient choice or toxicities, an efficacious (not limited to thalidomide and bortezomib) but tolerable first line FDT strategy, which can maximise TFI and maintain a good QoL, remains a reasonable alternative approach.	[Djebbari, Faouzi; Sharpley, Faye A.; Vallance, Grant; Eyre, Toby A.; Kothari, Jaimal; Moore, Sally; Ramasamy, Karthik] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford, England; [McLain-Smith, Susan] PH Associates, Marlow, Bucks, England	Oxford University Hospitals NHS Foundation Trust	Djebbari, F (corresponding author), Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford, England.	faouzi.djebbari@ouh.nhs.uk		Vallance, Grant/0000-0001-6539-4002; DJEBBARI, Faouzi/0000-0001-9578-7632; Ramasamy, Karthik/0000-0003-3385-3707				Acaster S, 2013, SUPPORT CARE CANCER, V21, P599, DOI 10.1007/s00520-012-1548-y; Benboubker L, 2014, NEW ENGL J MED, V371, P906, DOI 10.1056/NEJMoa1402551; Cancer Research UK, CANC STAT MYEL INC S; Delforge M, 2015, HAEMATOLOGICA, V100, P826, DOI 10.3324/haematol.2014.120121; Dimopoulos M.A, 2014, BLOOD; Facon T, 2019, NEW ENGL J MED, V380, P2104, DOI 10.1056/NEJMoa1817249; Mateos MV, 2018, NEW ENGL J MED, V378, P518, DOI 10.1056/NEJMoa1714678; Mateosi MV, 2017, HEMATOL-AM SOC HEMAT, P498, DOI 10.1182/asheducation-2017.1.498; Matsue K, 2016, LEUKEMIA LYMPHOMA, V57, P110, DOI 10.3109/10428194.2015.1041386; Muhlbacher A.C, 2018, PSYCHOSOCIAL MED, V5, P1; National Institute for Health and Care Excellence, LEN PLUS DEX PREV UN; Palumbo A, 2012, NEW ENGL J MED, V366, P1759, DOI 10.1056/NEJMoa1112704; Richardson P, 2017, EXPERT REV HEMATOL, V10, P933, DOI 10.1080/17474086.2017.1369399; San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479; Yong K, 2016, BRIT J HAEMATOL, V175, P252, DOI 10.1111/bjh.14213; Zweegman S, 2017, CURR OPIN ONCOL, V29, P315, DOI 10.1097/CCO.0000000000000395	16	4	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2020	15	2							e0229469	10.1371/journal.pone.0229469	http://dx.doi.org/10.1371/journal.pone.0229469			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8DJ	32084254	Green Published, gold			2023-01-03	WOS:000535227900110
J	Xia, Y; Li, JD; Zhang, ZJ; Luo, S; Liu, SX; Ma, CH; Li, W				Xia, Yu; Li, Jingdu; Zhang, Zhijun; Luo, Sha; Liu, Shouxin; Ma, Chunhui; Li, Wei			Decoding biomass recalcitrance: Dispersion of ionic liquid in aqueous solution and efficient extraction of lignans with microwave magnetic field	PLOS ONE			English	Article							BIPHENYL CYCLOOCTENE LIGNANS; SCHISANDRA-CHINENSIS; ASSISTED EXTRACTION; MACROPOROUS RESIN; EXCHANGE-RESIN; PRETREATMENT; WATER; ORGANIZATION; PYROLYSIS; LIGNIN	Alkaline ionic liquid aqueous solutions were used to extract biphenyl cyclooctene lignans derivatives, and hydrolyze to the free-state biphenyl cyclooctene lignans simultaneously from Schisandra chinensis by microwave-assisted heating. The hydrogen bonds formatted between ionic liquid and water molecular attacks the amorphous region of cellulose. Selective heating by microwave produce the more polar regions, which results in swelling and fragmentation of raw materials near the hot spots. Therefore, ionic liquid-microwave-assisted extraction method of free-state biphenyl cyclooctene lignans was set up. The solid residue after treatment was characterized by infrared spectroscopy and scanning electron microscopy, which showed that cellulose, hemicellulose, and lignin were removed partially. The water content of ionic liquid solution affected its viscosity and diffusivity, and in turns the extraction efficiency of lignans. The IL solutions with different mole fractions of IL were detected by FTIR and Raman spectroscopy, the result shows that IL solutions with higher water contents (> 0.6) won't form clusters. The optimum hydrolysis conditions were 0.2 g of ionic liquid catalyst per 5.0 g of S. chinensis fruits, a microwave irradiation power of 600 W, and heating time of 12 min, which gave a yield of free-state biphenyl cyclooctene lignans of 4.12 +/- 0.37 mg g(-1). Besides, a hydrolysis mechanism of ester-bond biphenyl cyclooctene lignans and decreasing "biomass recalcitrance effect" by ionic liquid microwave-assisted method was proposed.	[Xia, Yu; Li, Jingdu; Zhang, Zhijun; Luo, Sha; Liu, Shouxin; Ma, Chunhui; Li, Wei] Northeast Forestry Univ, Coll Mat Sci & Engn, Harbin, Peoples R China; [Xia, Yu; Li, Jingdu; Zhang, Zhijun; Luo, Sha; Liu, Shouxin; Ma, Chunhui; Li, Wei] Northeast Forestry Univ, Key Lab Biobased Mat Sci & Technol, Minist Educ, Harbin, Peoples R China; [Xia, Yu] Chinese Acad Agr Sci, Inst Urban Agr, Chengdu, Peoples R China	Northeast Forestry University - China; Northeast Forestry University - China; Chinese Academy of Agricultural Sciences; Institute of Urban Agriculture, CAAS	Ma, CH; Li, W (corresponding author), Northeast Forestry Univ, Coll Mat Sci & Engn, Harbin, Peoples R China.; Ma, CH; Li, W (corresponding author), Northeast Forestry Univ, Key Lab Biobased Mat Sci & Technol, Minist Educ, Harbin, Peoples R China.	mchmchmchmch@163.com; liwei19820927@126.com			National Natural Science Foundation of China [31890773]; Fundamental Research Funds for the Central Universities [2572019BB02]; postdoctoral scientific research developmental fund of Heilongjiang Province [LBH-Q16001]; Research Start-up Funding of Introduce Talents in Northeast Forestry University [YQ2015-02]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); postdoctoral scientific research developmental fund of Heilongjiang Province; Research Start-up Funding of Introduce Talents in Northeast Forestry University	The authors thank the National Natural Science Foundation of China (31890773), the Fundamental Research Funds for the Central Universities (2572019BB02), the postdoctoral scientific research developmental fund of Heilongjiang Province in 2016 (LBH-Q16001), and the Research Start-up Funding of Introduce Talents in Northeast Forestry University (YQ2015-02). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALVAREZ GA, 2014, J CHEM PHYS, V140, DOI DOI 10.1063/1.4879660; Blesic M, 2007, GREEN CHEM, V9, P481, DOI 10.1039/b615406a; Boonmanumsin P, 2012, BIORESOURCE TECHNOL, V103, P425, DOI 10.1016/j.biortech.2011.09.136; Cammarata L, 2001, PHYS CHEM CHEM PHYS, V3, P5192, DOI 10.1039/b106900d; Chang GT, 2005, J ETHNOPHARMACOL, V102, P430, DOI 10.1016/j.jep.2005.07.003; Chen SM, 2014, PHYS CHEM CHEM PHYS, V16, P5893, DOI 10.1039/c3cp53116c; Choi YW, 2006, J NAT PROD, V69, P356, DOI 10.1021/np0503707; Desai RK, 2012, GREEN CHEM, V18, P1; Dong K, 2017, CHEM REV, V117, P6636, DOI 10.1021/acs.chemrev.6b00776; El Seoud OA, 2007, J COLLOID INTERF SCI, V313, P296, DOI 10.1016/j.jcis.2007.04.028; Fazio B, 2008, J RAMAN SPECTROSC, V39, P233, DOI 10.1002/jrs.1825; Ferraz R, 2011, CHEMMEDCHEM, V6, P975, DOI 10.1002/cmdc.201100082; Gomez LD, 2008, NEW PHYTOL, V178, P473, DOI 10.1111/j.1469-8137.2008.02422.x; Hallett JP, 2011, CHEM REV, V111, P3508, DOI 10.1021/cr1003248; Harris D, 2010, PLANT BIOTECHNOL J, V8, P244, DOI 10.1111/j.1467-7652.2009.00481.x; Hassan HMA, 2017, J MOL LIQ, V236, P385, DOI 10.1016/j.molliq.2017.04.034; Hayouni S, 2017, MOL CATAL, V437, P121, DOI 10.1016/j.mcat.2017.05.007; Jiang N, 2010, CHEMSUSCHEM, V3, P1285, DOI 10.1002/cssc.201000120; Jiang X, 2016, J CO2 UTIL, V16, P264, DOI 10.1016/j.jcou.2016.08.003; Kaparaju P, 2010, BIORESOURCE TECHNOL, V101, P3175, DOI 10.1016/j.biortech.2009.12.008; Katayanagi H, 2004, J PHYS CHEM B, V108, P19451, DOI 10.1021/jp0477607; Kostas ET, 2017, RENEW SUST ENERG REV, V77, P12, DOI 10.1016/j.rser.2017.03.135; Lee HJ, 2010, FOOD CHEM, V120, P1224, DOI 10.1016/j.foodchem.2009.11.068; Li CL, 2011, BIORESOURCE TECHNOL, V102, P6928, DOI 10.1016/j.biortech.2011.04.005; Li CL, 2010, BIORESOURCE TECHNOL, V101, P4900, DOI 10.1016/j.biortech.2009.10.066; Lu Y, 2009, J CHROMATOGR A, V1216, P1980, DOI 10.1016/j.chroma.2008.09.070; Ma CH, 2015, J CHROMATOGR B, V976, P1, DOI 10.1016/j.jchromb.2014.11.003; Ma CH, 2011, J CHROMATOGR A, V1218, P8573, DOI 10.1016/j.chroma.2011.09.075; Ma CH, 2011, J CHROMATOGR B, V879, P3444, DOI 10.1016/j.jchromb.2011.09.022; Ma CH, 2011, ANAL CHIM ACTA, V689, P110, DOI 10.1016/j.aca.2011.01.012; MacFarlane DR, 2006, CHEM COMMUN, P1905, DOI 10.1039/b516961p; Macquarrie DJ, 2012, BIOFUEL BIOPROD BIOR, V6, P549, DOI 10.1002/bbb.1344; Matharu AS, 2018, CHEMSUSCHEM, V11, P1344, DOI 10.1002/cssc.201702456; Mele A, 2003, ANGEW CHEM INT EDIT, V42, P4364, DOI 10.1002/anie.200351783; Miki K, 2005, J PHYS CHEM B, V109, P9014, DOI 10.1021/jp046309c; Sahraoui N, 2008, J CHROMATOGR A, V1210, P229, DOI 10.1016/j.chroma.2008.09.078; Scheller HV, 2010, ANNU REV PLANT BIOL, V61, P263, DOI 10.1146/annurev-arplant-042809-112315; Vinatoru M, 2017, TRAC-TREND ANAL CHEM, V97, P159, DOI 10.1016/j.trac.2017.09.002; Watanabe M, 2017, CHEM REV, V117, P7190, DOI 10.1021/acs.chemrev.6b00504; Yang QW, 2018, CHEM SOC REV, V47, P2020, DOI 10.1039/c7cs00464h; Zhang LH, 2017, CHEM ENG J, V328, P445, DOI 10.1016/j.cej.2017.07.060; Zheng AQ, 2015, GREEN CHEM, V17, P1167, DOI 10.1039/c4gc01724b	42	1	1	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2020	15	2							e0226901	10.1371/journal.pone.0226901	http://dx.doi.org/10.1371/journal.pone.0226901			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8DJ	32084140	Green Published, gold			2023-01-03	WOS:000535227900008
J	Safar, HA; Mustafa, A; Amoudy, HA; El-Hashim, A				Safar, Hussain A.; Mustafa, Abu Salim; Amoudy, Hanady A.; El-Hashim, Ahmed			The effect of adjuvants and delivery systems on Th1, Th2, Th17 and Treg cytokine responses in mice immunized with Mycobacterium tuberculosis-specific proteins	PLOS ONE			English	Article							DNA VACCINE CONSTRUCTS; GENOMIC REGIONS; BOVIS BCG; IN-VITRO; SMEGMATIS; DIFFERENCE; EFFICIENT; ANTIGENS; GENES; IMMUNOGENICITY	Tuberculosis (TB) is a major health problem of global concern. The control of this disease requires appropriate preventive measures, including vaccines. In TB, T helper (Th)1 cytokines provide protection whereas Th2 and T regulatory (Treg) cytokines contribute to the pathogenesis and Th17 cytokines play a role in both protection and pathogenesis. Previous studies with Mycobacterium tuberculosis-specific proteins have identified seven low molecular weight proteins, PE35, ESXA, ESXB, Rv2346c, Rv2347c, Rv3619c, and Rv3620c, as immunodominant antigens inducing Th1-cell responses in humans following natural infection with M. tuberculosis. The aim of this study was to characterize the cytokine responses induced in mice immunized with these proteins, using various adjuvants and delivery systems, i.e. chemical adjuvants (Alum and IFA), non-pathogenic mycobacteria (M. smegmatis and M. vaccae) and a DNA vaccine plasmid (pUMVC6). The immune responses were monitored by quantifying the marker cytokines secreted by Th1 (IFN-gamma), Th2 (IL-5), Treg (IL-10), and Th17 (IL-17A) cells. DNA corresponding to pe35, esxa, esxb, rv2346c, rv2347c, rv3619c, and rv3620c genes were cloned into the expression vectors pGES-TH-1, pDE22 and pUMVC6 for expression in Escherichia coli, mycobacteria and eukaryotic cells, respectively. Mice were immunized with the recombinants using different adjuvants and delivery systems, and spleen cells were stimulated in vitro with peptides of immunizing proteins to investigate antigen-specific secretion of Th1 (IFN-gamma), Th2 (IL-5), Treg (IL-10), and Th17 (IL-17A) cytokines. The results showed that spleen cells, from mice immunized with all antigens, secreted the protective Th1 cytokine IFN-gamma, except ESXB, with one or more adjuvants and delivery systems. However, only Rv3619c consistently induced Th1-biased responses, without the secretion of significant concentrations of Th2, Th17 and Treg cytokines, with all adjuvants and delivery systems. Rv3619c also induced antigen-specific IgG antibodies in immunized mice.	[Safar, Hussain A.; Mustafa, Abu Salim; Amoudy, Hanady A.] Kuwait Univ, Fac Med, Dept Microbiol, Kuwait, Kuwait; [El-Hashim, Ahmed] Fac Pharm, Dept Pharmacol & Therapeut, Kuwait, Kuwait	Kuwait University	Mustafa, A (corresponding author), Kuwait Univ, Fac Med, Dept Microbiol, Kuwait, Kuwait.	abusalim@hsc.edu.kw		Mustafa, AbuSalim/0000-0002-6074-1041	College of Graduate Studies, Kuwait University; Kuwait University [YM06/15, SRU02/13]; Kuwait Foundation for the Advancement of Sciences [CB17-63MM-03]	College of Graduate Studies, Kuwait University; Kuwait University; Kuwait Foundation for the Advancement of Sciences(Kuwait Foundation for the Advancement of Sciences (KFAS))	ASM HAA AE HAS: A graduate research grant from the College of Graduate Studies, Kuwait University (kuniv.edu/COGS/index.htm) ASM HAA AE HAS: grant numbers YM06/15 and SRU02/13 from the Research Sector, Kuwait University (www.ovpr.kuniv.edu/) ASM HAS: grant number CB17-63MM-03 from Kuwait Foundation for the Advancement of Sciences (kfas.org.kw/) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aagaard C, 2009, IMMUNOL CELL BIOL, V87, P279, DOI 10.1038/icb.2009.14; Abu-Raddad LJ, 2009, P NATL ACAD SCI USA, V106, P13980, DOI 10.1073/pnas.0901720106; Achkar JM, 2015, IMMUNOL REV, V264, P167, DOI 10.1111/imr.12276; Agger EM, 2008, IMMUNOLOGY, V124, P175, DOI 10.1111/j.1365-2567.2007.02751.x; Ahmad S, 2005, SCAND J IMMUNOL, V62, P16, DOI 10.1111/j.1365-3083.2005.01639.x; Ahmad S, 2003, PROTEIN EXPRES PURIF, V29, P167, DOI 10.1016/S1046-5928(03)00052-4; Al-Attiyah R, 2008, INFECT IMMUN, V76, P4190, DOI 10.1128/IAI.00199-08; Al-Attiyah R, 2010, FEMS IMMUNOL MED MIC, V59, P177, DOI 10.1111/j.1574-695X.2010.00677.x; Alving CR, 2014, VACCINE, V32, P5382, DOI 10.1016/j.vaccine.2014.07.085; Amoudy HA, 2014, SAUDI MED J, V35, P350; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Chen Qunfei, 2011, J Evid Based Med, V4, P122, DOI 10.1111/j.1756-5391.2011.01121.x; Ciabattini A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00427; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Correia-Neves M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01968; Counoupas C, 2019, EXPERT REV VACCINES, V18, P353, DOI 10.1080/14760584.2019.1585246; Da Silva DA, 2014, J VET MED SCI, V76, P979, DOI 10.1292/jvms.13-0338; de Cerio ALD, 1999, INT IMMUNOL, V11, P2025, DOI 10.1093/intimm/11.12.2025; Garcia MD, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273129; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x; Ha SJ, 2003, GENE THER, V10, P1592, DOI 10.1038/sj.gt.3302057; Hanif SNM, 2011, SCAND J IMMUNOL, V74, P554, DOI 10.1111/j.1365-3083.2011.02604.x; Hanif SNM, 2010, SCAND J IMMUNOL, V72, P408, DOI 10.1111/j.1365-3083.2010.02452.x; Hanif SNM, 2010, SCAND J IMMUNOL, V71, P353, DOI 10.1111/j.1365-3083.2010.02388.x; Hanif SNM, 2017, INT J MYCOBACT, V6, P281, DOI 10.4103/ijmy.ijmy_98_17; Houben RMGJ, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002152, 10.1371/journal.pmed.1002119]; Huang CY, 2017, HUM VACC IMMUNOTHER, V13, P1960, DOI 10.1080/21645515.2017.1335374; Jacobs AJ, 2016, TUBERCULOSIS, V101, P102, DOI 10.1016/j.tube.2016.08.001; Junqueira-Kipnis AP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078639; Kadir NA, 2016, INT J MYCOBACT, V5, P7, DOI 10.1016/j.ijmyco.2015.09.006; Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558; Kaufmann SHE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01203; Kaufmann SHE, 2017, INT J INFECT DIS, V56, P263, DOI 10.1016/j.ijid.2016.10.018; Kwon BE, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e17; LoBue PA, 2010, INT J TUBERC LUNG D, V14, P1226; Luo ZC, 2012, MOL MED REP, V6, P1309, DOI 10.3892/mmr.2012.1079; Lyadova IV, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/854507; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Mahmood A, 2011, FEBS J, V278, P341, DOI 10.1111/j.1742-4658.2010.07958.x; Mani R, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00537-18; Mustafa A., 2013, J MYCOBAC DIS, V03; Mustafa AS, 2012, MED PRIN PRACT, V21, P195, DOI 10.1159/000337919; Mustafa AS, 2011, MICROBIOL IMMUNOL, V55, P267, DOI 10.1111/j.1348-0421.2011.00307.x; Mustafa AS, 2009, EXPERT REV VACCINES, V8, P1309, DOI [10.1586/erv.09.93, 10.1586/ERV.09.93]; O'Hagan DT, 2009, DRUG DISCOV TODAY, V14, P541, DOI 10.1016/j.drudis.2009.02.009; Orr MT, 2013, J CONTROL RELEASE, V172, P190, DOI 10.1016/j.jconrel.2013.07.030; Perrie Y, 2008, INT J PHARMACEUT, V364, P272, DOI 10.1016/j.ijpharm.2008.04.036; Rodriguez L, 2011, VACCINE, V29, P6236, DOI 10.1016/j.vaccine.2011.06.077; Shaban K, 2013, CLIN VACCINE IMMUNOL, V20, P1230, DOI 10.1128/CVI.00090-12; Sun SQ, 1998, J EXP MED, V187, P1145, DOI 10.1084/jem.187.7.1145; Tirado Y, 2016, TUBERCULOSIS, V101, P44, DOI 10.1016/j.tube.2016.07.017; World Health Organization, 2018, GLOBAL TUBERCULOSIS; Xiang ZH, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00226; Yin YL, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00407; Young SL, 2004, INT J CANCER, V112, P653, DOI 10.1002/ijc.20442; Yu DH, 2008, GENE THER, V15, P652, DOI 10.1038/gt.2008.13; Zhang H, 2010, SCAND J IMMUNOL, V72, P349, DOI 10.1111/j.1365-3083.2010.02448.x	61	19	22	4	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2020	15	2							e0228381	10.1371/journal.pone.0228381	http://dx.doi.org/10.1371/journal.pone.0228381			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9GK	32027660	Green Published, gold			2023-01-03	WOS:000534623800026
J	Zhang, T; Liu, Y; Yan, JK; Cai, W				Zhang, Tian; Liu, Yang; Yan, Jun-Kai; Cai, Wei			Early downregulation of P-glycoprotein facilitates bacterial attachment to intestinal epithelial cells and thereby triggers barrier dysfunction in a rodent model of total parenteral nutrition	FASEB JOURNAL			English	Article						Escherichia coli; intestinal barrier function; Occludin; P-glycoprotein; total parenteral nutrition	ENTEROPATHOGENIC ESCHERICHIA-COLI; MOUSE MODEL; LIVER-DISEASE; CACO-2 CELLS; I INTERFERON; INFLAMMATION; PERMEABILITY; ACTIVATION; MICROBIOTA; EXPRESSION	Intestinal barrier dysfunction is a major complication of total parenteral nutrition (TPN). Our preliminary study revealed that intestinal P-glycoprotein (P-gp) was significantly downregulated under TPN treatment followed by disruption of barrier function, and thus the significance of early downregulation of P-gp needs to be addressed. Herein, we report a pivotal role of P-gp in the development of intestinal barrier dysfunction under TPN. Functional suppression of P-gp may facilitate bacterial attachment to intestinal epithelial cells (IECs) and thereby induce degradation of tight junctions to trigger barrier dysfunction. By using a rat model of TPN, we found early downregulation of P-gp function in ileum after 3-day TPN, followed by disruption of barrier function after 7-day TPN. By using Escherichia coli (E. coli) k88 and DH5 alpha as type strains, we found significantly increased bacterial attachment to IECs in TPN group compared to sham. By using Caco-2 cells as an IEC model in vitro, we found that functional suppression of P-gp remarkably facilitated bacterial attachment to Caco-2 cells, leading to subsequent disruption of intestinal barrier function. Of note, Occludin was significantly downregulated by bacterial attachment when P-gp was functionally suppressed. Mechanistically, changes on Occludin were attributed to enhanced protein degradation instead of suppressed protein translation. Despite the half-life of Occludin protein being unchanged by DH5 alpha treatment alone, it was decreased by about 40% when P-gp was simultaneously suppressed. Taken together, our findings revealed that early downregulation of intestinal P-gp under TPN may be a potential therapeutic target to prevent the development of barrier dysfunction.	[Zhang, Tian; Liu, Yang; Yan, Jun-Kai; Cai, Wei] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Shanghai, Peoples R China; [Yan, Jun-Kai; Cai, Wei] Shanghai Inst Pediat Res, Shanghai Key Lab Pediat Gastroenterol & Nutr, Shanghai 200092, Peoples R China	Shanghai Jiao Tong University	Yan, JK; Cai, W (corresponding author), Shanghai Inst Pediat Res, Shanghai Key Lab Pediat Gastroenterol & Nutr, Shanghai 200092, Peoples R China.	yanjunkai@xinhuamed.com.cn; caiw204@sjtu.edu.cn			Foundation of Shanghai Municipal Commission of Health and Family Planning (Shanghai Municipal Commission of Health and Family Planning Foundation) [20184Y0337]; National Natural Science Foundation of China (NSFC) [81630039, 81700787]; Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition [17DZ2272000]	Foundation of Shanghai Municipal Commission of Health and Family Planning (Shanghai Municipal Commission of Health and Family Planning Foundation); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition	Foundation of Shanghai Municipal Commission of Health and Family Planning (Shanghai Municipal Commission of Health and Family Planning Foundation), Grant/Award Number: 20184Y0337; National Natural Science Foundation of China (NSFC), Grant/Award Number: 81630039 and 81700787; Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Grant/Award Number: 17DZ2272000	Aluko K, 2017, ANIM NUTR, V3, P353, DOI 10.1016/j.aninu.2017.06.006; [Anonymous], 2017, NUTRIENTS, DOI [DOI 10.3390/nu9090987, DOI 10.3390/NU9090987]; Bielawska B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050466; Bleier BS, 2016, INT FORUM ALLERGY RH, V6, P169, DOI 10.1002/alr.21566; Braga M, 2009, CLIN NUTR, V28, P378, DOI 10.1016/j.clnu.2009.04.002; Buyse M, 2005, BIOCHEM PHARMACOL, V69, P1745, DOI 10.1016/j.bcp.2005.03.025; Crowe A, 2012, EUR J PHARMACOL, V689, P204, DOI 10.1016/j.ejphar.2012.05.047; Crowe A, 2011, J CROHNS COLITIS, V5, P531, DOI 10.1016/j.crohns.2011.05.002; Demehri FR, 2015, NUTR CLIN PRACT, V30, P798, DOI 10.1177/0884533615609904; Didziapetris R, 2003, J DRUG TARGET, V11, P391, DOI 10.1080/10611860310001648248; Feng YJ, 2016, AM J PHYSIOL-GASTR L, V310, pG273, DOI 10.1152/ajpgi.00335.2015; Feng YJ, 2013, J PHYSIOL-LONDON, V591, P3709, DOI 10.1113/jphysiol.2013.253518; Freeman JJ, 2015, FASEB J, V29, P2943, DOI 10.1096/fj.14-269480; Glotfelty LG, 2014, CELL MICROBIOL, V16, P1767, DOI 10.1111/cmi.12323; Groschwitz KR, 2013, AM J PHYSIOL-GASTR L, V304, pG479, DOI 10.1152/ajpgi.00186.2012; Heneghan AF, 2013, ANN SURG, V258, P1065, DOI 10.1097/SLA.0b013e318277ea9e; Ho GT, 2003, GUT, V52, P759, DOI 10.1136/gut.52.5.759; Hodin CM, 2012, J NUTR, V142, P2141, DOI 10.3945/jn.112.162388; Huang YH, 2017, J GASTROEN HEPATOL, V32, P1949, DOI 10.1111/jgh.13806; Jirsova Z, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7084734; Kim J, 2012, GRAEF ARCH CLIN EXP, V250, P691, DOI 10.1007/s00417-011-1912-5; Lavallee CM, 2017, JPEN-PARENTER ENTER, V41, P1301, DOI 10.1177/0148607116662972; Lei QC, 2018, NUTR RES, V49, P56, DOI 10.1016/j.nutres.2017.10.007; Li QR, 2008, FEBS J, V275, P6022, DOI 10.1111/j.1742-4658.2008.06731.x; Lilja HE, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0084-7; Liu J, 2012, J NEUROSCI, V32, P3044, DOI 10.1523/JNEUROSCI.6409-11.2012; Long TM, 2014, INFECT IMMUN, V82, P2802, DOI 10.1128/IAI.00105-14; Lu A, 2013, NEUROSCIENCE, V253, P361, DOI 10.1016/j.neuroscience.2013.08.068; Mitra A, 2017, CLIN LIVER DIS, V21, P687, DOI 10.1016/j.cld.2017.06.008; Miyasaka EA, 2013, J IMMUNOL, V190, P6607, DOI 10.4049/jimmunol.1201746; Neudeck BL, 2004, INFECT IMMUN, V72, P3849, DOI 10.1128/IAI.72.7.3849-3854.2004; Parm U, 2015, NUTR RES, V35, P496, DOI 10.1016/j.nutres.2015.04.006; Parveen Z, 2011, MOL PHARMACOL, V79, P443, DOI 10.1124/mol.110.067611; Peralta-Ramirez J, 2008, INFECT IMMUN, V76, P3854, DOI 10.1128/IAI.00072-08; Ralls MW, 2014, JPEN-PARENTER ENTER, V38, P392, DOI 10.1177/0148607113486482; Roselli M, 2006, BRIT J NUTR, V95, P1177, DOI 10.1079/BJN20051681; Sigal N, 2015, INFECT IMMUN, V83, P2358, DOI 10.1128/IAI.00380-15; Szabady RL, 2018, J CLIN INVEST, V128, P4044, DOI 10.1172/JCI96817; Takizawa Y, 2013, INT J PHARMACEUT, V450, P31, DOI 10.1016/j.ijpharm.2013.04.026; Xiao WD, 2014, FASEB J, V28, P2073, DOI 10.1096/fj.13-238311; Yamada H, 2013, BIOCHEM PHARMACOL, V85, P1770, DOI 10.1016/j.bcp.2013.04.006; Yan JK, 2019, FASEB J, V33, P3378, DOI [10.1096/fj.201801695r, 10.1096/fj.201801695R]; Yan JK, 2018, J CELL MOL MED, V22, P1562, DOI 10.1111/jcmm.13430; Yan JK, 2017, CELL PHYSIOL BIOCHEM, V41, P711, DOI 10.1159/000458430; Yan JK, 2016, CELL PHYSIOL BIOCHEM, V39, P1581, DOI 10.1159/000447860	45	1	1	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2020	34	3					4670	4683		10.1096/fj.201902513R	http://dx.doi.org/10.1096/fj.201902513R		FEB 2020	14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KT7UL	32027421				2023-01-03	WOS:000520982300001
J	Mittmann, N; Liu, N; MacKinnon, M; Seung, SJ; Hong, NJL; Earle, CC; Gradin, S; Sati, S; Buchman, S; Jakda, A; Wright, FC				Mittmann, Nicole; Liu, Ning; MacKinnon, Marnie; Seung, Soo Jin; Hong, Nicole J. Look; Earle, Craig C.; Gradin, Sharon; Sati, Saurabh; Buchman, Sandy; Jakda, Ahmed; Wright, Frances C.			Does early palliative identification improve the use of palliative care services?	PLOS ONE			English	Article							ADVANCED CANCER; OUTCOMES; PATIENT; LUNG; TOOL	Purpose To evaluate whether the early identification of patients who may benefit from palliative care impacts on the use of palliative, community and acute-based care services. Methods Between 2014 and 2017, physicians from eight sites were encouraged to systematically identify patients who were likely to die within one year and would were thought to benefit from early palliative care. Patients in the INTEGRATE Intervention Group were 1:1 matched to controls selected from provincial healthcare administrative data using propensity score-matching. The use of palliative care, community-based care services (home care, physician home visit, and outpatient opioid use) and acute care (emergency department, hospitalization) was each evaluated within one year after the date of identification. The hazard ratio (HR) in the Intervention Group was calculated for each outcome. Results Of the 1,185 patients in the Intervention Group, 951 (80.3%) used palliative care services during follow-up, compared to 739 (62.4%) among 1,185 patients in the Control Group [HR of 1.69 (95% CI 1.56 to 1.82)]. The Intervention Group also had higher proportions of patients who used home care [81.4% vs. 55.2%; HR 2.07 (95% CI 1.89 to 2.27)], had physician home visits [35.5% vs. 23.7%; HR 1.63 (95% CI 1.46 to 1.92)] or had increased outpatient opioid use [64.3% vs. 52.1%); HR 1.43 (95% CI 1.30 to 1.57]. The Intervention Group was also more likely to have a hospitalization that was not primarily focused on palliative care (1.42 (95% CI 1.28 to 1.58)) and an unplanned emergency department visit for non-palliative care purpose (1.47 (95% CI 1.32 to 1.64)). Conclusion Physicians actively identifying patients who would benefit from palliative care resulted in increased use of palliative and community-based care services, but also increased use of acute care services.	[Mittmann, Nicole; MacKinnon, Marnie; Gradin, Sharon; Sati, Saurabh] Canc Care Ontario, Toronto, ON, Canada; [Mittmann, Nicole; Seung, Soo Jin] Sunnybrook Res Inst, Toronto, ON, Canada; [Liu, Ning; Hong, Nicole J. Look; Earle, Craig C.] ICES, Toronto, ON, Canada; [Seung, Soo Jin] Hlth Outcomes & PharmacoEcon HOPE Res Ctr, Toronto, ON, Canada; [Hong, Nicole J. Look; Earle, Craig C.; Wright, Frances C.] Odette Canc Ctr, Toronto, ON, Canada; [Earle, Craig C.] Canadian Partnership Canc, Toronto, ON, Canada; [Buchman, Sandy] Sinai Hlth Syst, Temmy Latner Ctr Palliat Care, Toronto, ON, Canada; [Jakda, Ahmed] McMaster Univ, Hamilton, ON, Canada; [Jakda, Ahmed] Ontario Palliat Care Network, Toronto, ON, Canada; [Jakda, Ahmed] Grand River Reg Canc Ctr, Kitchener, ON, Canada	Cancer Care Ontario; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; McMaster University	Mittmann, N (corresponding author), Canc Care Ontario, Toronto, ON, Canada.; Mittmann, N (corresponding author), Sunnybrook Res Inst, Toronto, ON, Canada.	nicole.mittmann@sunnybook.ca		Liu, Ning/0000-0001-9215-475X	Cancer Care Ontario through the Ontario Ministry of Health and Long-Term Care; Canadian Partnership Against Cancer	Cancer Care Ontario through the Ontario Ministry of Health and Long-Term Care; Canadian Partnership Against Cancer	This study was conducted with the support of Cancer Care Ontario through funding provided by the Ontario Ministry of Health and Long-Term Care. This is a secondary analysis of a study that was funded by the Canadian Partnership Against Cancer.	Ambroggi M, 2018, SUPPORT CARE CANCER, V26, P2945, DOI 10.1007/s00520-018-4184-3; Austin PC, 2016, CIRCULATION, V133, P601, DOI 10.1161/CIRCULATIONAHA.115.017719; Austin PC, 2013, STAT MED, V32, P2837, DOI 10.1002/sim.5705; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Badger F, 2012, INT J NURS STUD, V49, P586, DOI 10.1016/j.ijnurstu.2011.10.021; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Bakitas MA, 2015, J CLIN ONCOL, V33, P1438, DOI 10.1200/JCO.2014.58.6362; Buchman S, 2018, PSYCHO-ONCOLOGY, V27, P2673, DOI 10.1002/pon.4858; Canadian Institute for Health Information, 2018, ACC PALL CAR CAN; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Gold Standards Framework, 2013, GSF IMPR OUTC ALL SE; Gomes B, 2015, J CLIN ONCOL, V33, P1420, DOI 10.1200/JCO.2014.60.5386; Gomez-Batiste X, 2013, BMJ SUPPORT PALLIAT, V3, P300, DOI 10.1136/bmjspcare-2012-000211; Health Improvement Scotland, 2018, PALL CAR ID TOOLS CO; Health Quality Ontario, 2018, PALL CAR CAR AD PROG; Highet G, 2014, BMJ SUPPORT PALLIAT, V4, P285, DOI 10.1136/bmjspcare-2013-000488; ICES, 2017, DAT REP; Jones A, 2018, CAN MED ASSOC J, V190, pE525, DOI 10.1503/cmaj.170892; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Lutz ST, 2014, J CLIN ONCOL, V32, P2913, DOI 10.1200/JCO.2014.55.1143; Merchant SJ, 2018, ANN SURG ONCOL, V25, P1478, DOI 10.1245/s10434-018-6430-9; Mittmann N, 2014, CURR ONCOL, V21, P281, DOI 10.3747/co.21.2143; Pallium Canada, 2016, LEARN ESS APPR PALL; Seow H, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3496; Tanuseputro P, 2017, PALLIATIVE MED, V31, P247, DOI 10.1177/0269216316653524; Temel JS, 2017, J CLIN ONCOL, V35, P834, DOI 10.1200/JCO.2016.70.5046; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; The Johns Hoplins University, 2017, ACG SYST VERS 10 0 T; World Health Organization, 2007, CANC CONTR KNOWL ACT; Wright F, 2017, J CLIN ONCOL S8, V35; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2	32	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2020	15	1							e0226597	10.1371/journal.pone.0226597	http://dx.doi.org/10.1371/journal.pone.0226597			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9CX	32005036	Green Published, gold			2023-01-03	WOS:000534614600004
J	Devkota, B; Maskey, J; Pandey, AR; Karki, D; Godwin, P; Gartoulla, P; Mehata, S; Aryal, KK				Devkota, Bikash; Maskey, Jasmine; Pandey, Achyut Raj; Karki, Deepak; Godwin, Peter; Gartoulla, Pragya; Mehata, Suresh; Aryal, Krishna Kumar			Determinants of home delivery in Nepal - A disaggregated analysis of marginalised and non-marginalised women from the 2016 Nepal Demographic and Health Survey	PLOS ONE			English	Article							PLANNED HOME; BIRTHS; PREGNANCY; BARRIERS; OUTCOMES; PLACE; RISK	Introduction In Nepal, a substantial proportion of women still deliver their child at home. Disparities have been observed in utilisation of institutional delivery and skilled birth attendant services. We performed a disaggregated analysis among marginalised and non-marginalised women to identify if different factors are associated with home delivery among these groups. Materials and methods This study used data from the 2016 Nepal Demographic and Health Survey. It involves the analysis of 3,837 women who had experienced at least one live birth in the five years preceding the survey. Women were categorised as marginalised and non-marginalised based on ethnic group. Bivariate and multivariable logistic regression analysis were performed to identify factors associated with home delivery. Results A higher proportion of marginalised women delivered at home (47%) than non-marginalised women (26%). Compared to non-marginalised women (35%), a larger proportion of marginalised women (64%) felt that it was not necessary to give birth at health facility. The multivariable analysis indicated an independent association of having no or basic education, belonging to middle, poorer and the poorest wealth quintile, residing in Province 2 and not having completed of four antenatal care visits per protocol with home delivery among both marginalised and non-marginalised women. Whereas residing in a rural area, residing in Province 7, and at a distance of >30 minutes to a health facility were factors independently associated with home delivery only among marginalised women. Conclusion We conclude that poor education, poor economic status, non-completion of four ANC visits and belonging to Province 2 particularly determined either group of women to deliver at home, whereas residing in rural areas, living far from health facility, and belonging to Province 7 determined marginalised women to deliver at home. Preventing mothers from delivering at home would thus require focusing on specific geographical areas besides considering wider socio-economic determinants.	[Devkota, Bikash; Mehata, Suresh] Minist Hlth & Populat, Policy Planning & Monitoring Div, Kathmandu, Nepal; [Maskey, Jasmine; Pandey, Achyut Raj; Godwin, Peter; Gartoulla, Pragya; Aryal, Krishna Kumar] Abt Associates Inc, DFID Nepal Hlth Sect Programme Monitoring Evaluat, Kathmandu, Nepal; [Karki, Deepak] UK Dept Int Dev Nepal, Kathmandu, Nepal; [Gartoulla, Pragya] Monash Univ, Melbourne, Vic, Australia	Monash University	Maskey, J (corresponding author), Abt Associates Inc, DFID Nepal Hlth Sect Programme Monitoring Evaluat, Kathmandu, Nepal.	jasmine.maskey@abtassoc.com.au			United Kingdom Department of International development (DFID) Nepal Health Sector Programme 3 (NHSP3)	United Kingdom Department of International development (DFID) Nepal Health Sector Programme 3 (NHSP3)	We acknowledge the Demographic and Health Surveys (DHS) programme for availing the Nepal DHS for public use. We appreciate the support of Ms. Fiona Mactaggart for reviewing and copyediting the manuscript. This manuscript is produced as a part of the evidence generation activities within Monitoring, Evaluation and Operational Research (MEOR) project supported by the United Kingdom Department of International development (DFID) Nepal Health Sector Programme 3 (NHSP3). The content is solely the responsibility of authors and does not necessarily represent the official views of DFID Nepal or the UK Government.	Acharya P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185667; Adamson PC, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-30; Adinew YM, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3249786; Agadjanian V, 2016, INT PERSPECT SEX R H, V42, P21, DOI 10.1363/42e0116; [Anonymous], 2015, CONST NEP; Bennett L., 2008, CASTE ETHNIC REGIONA; Boateng D, 2017, CIRCULATION CARDIOVA, V10; Brocklehurst P, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d7400; Davies-Tuck ML, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1996-6; de Jonge E, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0834-9; Department of Economic and Social Affairs United Nations, SUST DEV GOALS GOAL; Department of Health Services Ministry of Health and Population, 2016, ANN REPORT, V2073; Dhakal S, 2011, J HEALTH POPUL NUTR, V29, P371, DOI 10.3329/jhpn.v29i4.8453; Exavery A, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/1475-9276-13-48; Ganle JK, 2015, SOCIOCULTURAL BARRIE; Geidam AD, 2011, J OBSTET GYNAECOL, V31, P404, DOI 10.3109/01443615.2011.561383; Government of Nepal, 2018, MULT POV IND AN ACT; Government of Nepal Ministry of Health, 2015, NAT STRAT REACH UNR; Gunnarsson B, 2014, ACTA OBSTET GYN SCAN, V93, P1003, DOI 10.1111/aogs.12450; Gupta N, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6282-z; Gurung Mongal Singh, 2018, WHO South East Asia J Public Health, V7, P36, DOI 10.4103/2224-3151.228426; Huang Y, 2018, LANCET GLOB HEALTH, V6, pE39, DOI [10.1016/S2214-109X(17)30445-X, 10.1016/s2214-109x(17)30445-x]; Javed SA, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-137; Karkee R, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-193; Kitui J, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-40; Li Y, 2015, BJOG-INT J OBSTET GY, V122, P741, DOI 10.1111/1471-0528.13283; Ministry of Health and Population Government of Nepal., 2015, NEP HLTH SECT STRAT; Ministry of Health and Population New ERA ICF International Inc, 2012, NEP DEM HLTH SURV 20; Ministry of Health-MOH/Nepal New ERA/Nepal ICF., 2017, NEP DEM HLTH SURV 20; Morrison J, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-89; Pandey J.P., 2013, MATERNAL CHILD HLTH; Pokharel T., 2015, HUMAN DEV, V11; Pradhan A, 2010, NEPAL MATERNAL MORTA; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Rossi AC, 2018, EUR J OBSTET GYN R B, V222, P102, DOI 10.1016/j.ejogrb.2018.01.016; Sahoo J, 2015, J EPIDEMIOL GLOB HEA, V5, pS27, DOI 10.1016/j.jegh.2015.05.002; Scott NA, 2018, INT J WOMENS HEALTH, V10, P589, DOI 10.2147/IJWH.S169067; Seward N, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001180; Shah R, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0454-y; Shahabuddin ASM, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012446; Simkhada B, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-34; Sprague DA, 2016, EMERG THEMES EPIDEMI, V13, DOI 10.1186/s12982-016-0049-8; Stuart E., 2016, GENDER DEV, V24, P69, DOI [10.1080/13552074.2016.1142206, DOI 10.1080/13552074.2016.1142206]; Sumankuuro J, 2018, PUBLIC HEALTH, V157, P77, DOI 10.1016/j.puhe.2018.01.014; UN Department of Economic and Social Affairs Statistic Division, SDG IND MET REP 2018; UNICEF, 2018, DEL CAR UNICEF WHO J; WHO, 2017, GLOB STRAT ACT PLAN; World Health Organization, 2015, TRACK UN HLTH COV 1; World Health Organization, 2018, FACT SHEETS MAT MORT; World Health Organization, 2018, WORLD HLTH STAT MON; World Health Organization (WHO), 2004, MAK PREGN SAF CRIT R; Yaya S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196896; Yebyo H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124718	53	17	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2020	15	1							e0228440	10.1371/journal.pone.0228440	http://dx.doi.org/10.1371/journal.pone.0228440			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9CB	31999784	Green Published, gold			2023-01-03	WOS:000534612400083
J	Alexander, GC; Qato, DM				Alexander, G. Caleb; Qato, Dima M.			Ensuring Access to Medications in the US During the COVID-19 Pandemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD USA; [Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St,W6035, Baltimore, MD 21205 USA; [Qato, Dima M.] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Alexander, GC (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St,W6035, Baltimore, MD 21205 USA.	galexan9@jhmi.edu		Qato, Dima/0000-0001-5411-6998				[Anonymous], 2020, MCKESSONS RESPONSE C; Erman M, 2020, REUTERS         0319; IQVIA Institute for Human Data Science, 2019, MED US SPEND US REV; Marchione M, 2020, NY TIMES; Neil M., 2020, IMPERIAL COLL LONDON; Oehler RL, 2020, JAMA-J AM MED ASSOC, V324, P143, DOI 10.1001/jama.2020.1634; The U.S. Food and Medication Administration, 2020, COR COVID 19 SUPPL C; World Health Organization, 2019, MENT HOLIST HLTH SOM	8	40	41	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2020	324	1					31	32		10.1001/jama.2020.6016	http://dx.doi.org/10.1001/jama.2020.6016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM5FX	32271871	Bronze			2023-01-03	WOS:000568123600013
J	Netea, MG; Giamarellos-Bourboulis, EJ; Dominguez-Andres, J; Curtis, N; van Crevel, R; van de Veerdonk, FL; Bonten, M				Netea, Mihai G.; Giamarellos-Bourboulis, Evangelos J.; Dominguez-Andres, Jorge; Curtis, Nigel; van Crevel, Reinout; van de Veerdonk, Frank L.; Bonten, Marc			Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection	CELL			English	Review							NONSPECIFIC PROTECTION; VIRUS-INFECTION; CYTOKINE STORM; MICE; RESISTANCE; INTERFERON	SARS-CoV-2 infection is mild in the majority of individuals but progresses into severe pneumonia in a small proportion of patients. The increased susceptibility to severe disease in the elderly and individuals with co-morbidities argues for an initial defect in anti-viral host defense mechanisms. Long-term boosting of innate immune responses, also termed "trained immunity,'' by certain live vaccines (BCG, oral polio vaccine, measles) induces heterologous protection against infections through epigenetic, transcriptional, and functional reprogramming of innate immune cells. We propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2.	[Netea, Mihai G.; Dominguez-Andres, Jorge; van Crevel, Reinout; van de Veerdonk, Frank L.] Radboud Univ Nijmegen, Dept Internal Med, NL-6500 Nijmegen, Netherlands; [Netea, Mihai G.; Dominguez-Andres, Jorge; van Crevel, Reinout; van de Veerdonk, Frank L.] Radboud Univ Nijmegen, Ctr Infect Dis, NL-6500 Nijmegen, Netherlands; [Netea, Mihai G.] Univ Bonn, Immunol & Metab Life & Med Sci Inst, D-53115 Bonn, Germany; [Giamarellos-Bourboulis, Evangelos J.] Natl & Kapodistrian Univ Athens, Dept Internal Med 4, Athens 12462, Greece; [Curtis, Nigel] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Curtis, Nigel] Royal Childrens Hosp Melbourne, Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Bonten, Marc] Univ Utrecht, Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; University of Bonn; National & Kapodistrian University of Athens; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Utrecht University; Utrecht University Medical Center	Netea, MG (corresponding author), Radboud Univ Nijmegen, Dept Internal Med, NL-6500 Nijmegen, Netherlands.; Netea, MG (corresponding author), Radboud Univ Nijmegen, Ctr Infect Dis, NL-6500 Nijmegen, Netherlands.; Netea, MG (corresponding author), Univ Bonn, Immunol & Metab Life & Med Sci Inst, D-53115 Bonn, Germany.	mihai.netea@radboudumc.nl	van de Veerdonk, Frank L/C-7256-2008; Dominguez-Andres, Jorge/S-6211-2017; van Crevel, reinout/A-6636-2010	van de Veerdonk, Frank L/0000-0002-1121-4894; Dominguez-Andres, Jorge/0000-0002-9091-1961; van Crevel, reinout/0000-0002-6233-6410	ERC [833247]; Spinoza grant of the Netherlands Association for Scientific Research; National Institutes of Health [R01AI145781]; European Union [RIA2018CO-2514-PROTID]	ERC(European Research Council (ERC)European Commission); Spinoza grant of the Netherlands Association for Scientific Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Union(European Commission)	M.G.N. was supported by an ERC advanced grant (833247) and a Spinoza grant of the Netherlands Association for Scientific Research. R.v.C. is supported by the National Institutes of Health (R01AI145781) and European Union (RIA2018CO-2514-PROTID).	Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010; Benn CS, 2013, TRENDS IMMUNOL, V34, P431, DOI 10.1016/j.it.2013.04.004; Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x; Dayal D., 2020, CONNECTING BCG VACCI, DOI [10.1101/2020.04.07.20053272, DOI 10.1101/2020.04.07.20053272]; FLOCH F, 1976, ANN INST PASTEUR IMM, VC127, P173; Freyne B, 2015, T ROY SOC TROP MED H, V109, P52, DOI 10.1093/trstmh/tru197; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10; Goodridge HS, 2016, NAT REV IMMUNOL, V16, P392, DOI 10.1038/nri.2016.43; Green CM, 2020, MEDRXIV, V2020, DOI [10.1101/2020.04.10.20060905, DOI 10.1101/2020.04.10.20060905]; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hatherill M, 2014, VACCINE, V32, P3982, DOI 10.1016/j.vaccine.2014.04.084; Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170; Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255; ISHIHARA C, 1987, VACCINE, V5, P295, DOI 10.1016/0264-410X(87)90155-1; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Kumaki Y, 2017, ANTIVIR RES, V139, P1, DOI 10.1016/j.antiviral.2016.12.007; Machiels B, 2017, NAT IMMUNOL, V18, P1310, DOI 10.1038/ni.3857; Miller A., 2020, MEDRXIV, DOI 10.1101/2020.03.24.20042937; Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034; Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020; Mukherjee S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180143; Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Nieuwenhuizen NE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01147; Ohrui Takashi, 2005, Nihon Ronen Igakkai Zasshi, V42, P34; Ong EZY, 2020, CELL HOST MICROBE, V27, P879, DOI 10.1016/j.chom.2020.03.021; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Sheahan T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000240; Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7; Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10; SPENCER JC, 1977, J INFECT DIS, V136, P171, DOI 10.1093/infdis/136.2.171; STARR SE, 1976, P SOC EXP BIOL MED, V152, P57; SUENAGA T, 1978, INFECT IMMUN, V20, P312, DOI 10.1128/IAI.20.1.312-314.1978; ter Horst R, 2016, CELL, V167, P1111, DOI 10.1016/j.cell.2016.10.018; Thevarajan I, 2020, NAT MED, V26, P453, DOI 10.1038/s41591-020-0819-2; Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15; Wardhana, 2011, Acta Med Indones, V43, P185; Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x; Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yao YS, 2018, CELL, V175, P1634, DOI 10.1016/j.cell.2018.09.042; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	44	246	248	8	41	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	2020	181	5					969	977		10.1016/j.cell.2020.04.042	http://dx.doi.org/10.1016/j.cell.2020.04.042			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT9QF	32437659	Green Published, Bronze			2023-01-03	WOS:000537399500005
J	Gerry, S; Bonnici, T; Birks, J; Kirtley, S; Virdee, PS; Watkinson, PJ; Collins, GS				Gerry, Stephen; Bonnici, Timothy; Birks, Jacqueline; Kirtley, Shona; Virdee, Pradeep S.; Watkinson, Peter J.; Collins, Gary S.			Early warning scores for detecting deterioration in adult hospital patients: systematic review and critical appraisal of methodology	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTENSIVE-CARE-UNIT; MULTIVARIABLE PREDICTION MODEL; INFLAMMATORY RESPONSE SYNDROME; LOGISTIC-REGRESSION MODELS; ELECTRONIC HEALTH RECORDS; ORGAN FAILURE ASSESSMENT; CARDIAC-ARREST; CLINICAL DETERIORATION; MEDICAL ADMISSIONS; VITAL SIGNS	OBJECTIVE To provide an overview and critical appraisal of early warning scores for adult hospital patients. DESIGN Systematic review. DATA SOURCES Medline, CINAHL, PsycInfo, and Embase until June 2019. ELIGIBILITY CRITERIA FOR STUDY SELECTION Studies describing the development or external validation of an early warning score for adult hospital inpatients. RESULTS 13 171 references were screened and 95 articles were included in the review. 11 studies were development only, 23 were development and external validation, and 61 were external validation only. Most early warning scores were developed for use in the United States (n=13/34, 38%) and the United Kingdom (n=10/34, 29%). Death was the most frequent prediction outcome for development studies (n=10/23, 44%) and validation studies (n=66/84, 79%), with different time horizons (the most frequent was 24 hours). The most common predictors were respiratory rate (n=30/34, 88%), heart rate (n=28/34, 83%), oxygen saturation, temperature, and systolic blood pressure (all n=24/34, 71%). Age (n=13/34, 38%) and sex (n=3/34, 9%) were less frequently included. Key details of the analysis populations were often not reported in development studies (n=12/29, 41%) or validation studies (n=33/84, 39%). Small sample sizes and insufficient numbers of event patients were common in model development and external validation studies. Missing data were often discarded, with just one study using multiple imputation. Only nine of the early warning scores that were developed were presented in sufficient detail to allow individualised risk prediction. Internal validation was carried out in 19 studies, but recommended approaches such as bootstrapping or cross validation were rarely used (n=4/19, 22%). Model performance was frequently assessed using discrimination (development n=18/22, 82%; validation n=69/84, 82%), while calibration was seldom assessed (validation n=13/84, 15%). All included studies were rated at high risk of bias. CONCLUSIONS Early warning scores are widely used prediction models that are often mandated in daily clinical practice to identify early clinical deterioration in hospital patients. However, many early warning scores in clinical use were found to have methodological weaknesses. Early warning scores might not perform as well as expected and therefore they could have a detrimental effect on patient care. Future work should focus on following recommended approaches for developing and evaluating early warning scores, and investigating the impact and safety of using these scores in clinical practice.	[Gerry, Stephen; Birks, Jacqueline; Kirtley, Shona; Virdee, Pradeep S.; Collins, Gary S.] Univ Oxford, Ctr Stat Med, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 7LD, England; [Bonnici, Timothy] Univ Coll London Hosp NHS Trust, Crit Care Div, London, England; [Birks, Jacqueline; Collins, Gary S.] Oxford Univ Hosp NHS Fdn Trust, Oxford, England; [Watkinson, Peter J.] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England	University of Oxford; University College London Hospitals NHS Foundation Trust; University of London; University College London; Oxford University Hospitals NHS Foundation Trust; University of Oxford	Collins, GS (corresponding author), Univ Oxford, Ctr Stat Med, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 7LD, England.; Collins, GS (corresponding author), Oxford Univ Hosp NHS Fdn Trust, Oxford, England.	stephen.gerry@csm.ox.ac.uk	Collins, Gary Stephen/A-2258-2014; Virdee, Pradeep/AAI-1261-2019	Collins, Gary Stephen/0000-0002-2772-2316; Virdee, Pradeep/0000-0002-3006-8730; Kirtley, Shona/0000-0002-7801-5777; Gerry, Stephen/0000-0003-4654-7311; Watkinson, Peter/0000-0003-1023-3927	National Institute for Health Research (NIHR) Doctoral Research Fellowship [DRF-2016-09-173]; NIHR Oxford Biomedical Research Centre; Cancer Research UK [C49297/A27294]; NIHR Doctoral Research Fellowship [DRF2018-11-ST2-057]	National Institute for Health Research (NIHR) Doctoral Research Fellowship(National Institute for Health Research (NIHR)); NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK); NIHR Doctoral Research Fellowship	SG is funded by a National Institute for Health Research (NIHR) Doctoral Research Fellowship (DRF-2016-09-173). JB, PJW, and GSC are funded by the NIHR Oxford Biomedical Research Centre. SK and GSC are funded by Cancer Research UK (grant No C49297/A27294). PV is funded by an NIHR Doctoral Research Fellowship (DRF2018-11-ST2-057). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, or Cancer Research UK.	Abbott TEF, 2016, EUR J INTERN MED, V35, P78, DOI 10.1016/j.ejim.2016.06.014; Abbott TEF, 2015, RESUSCITATION, V92, P89, DOI 10.1016/j.resuscitation.2015.04.020; Alam N, 2014, RESUSCITATION, V85, P587, DOI 10.1016/j.resuscitation.2014.01.013; Albert BL, 2011, DIMENS CRIT CARE NUR, V30, P283, DOI 10.1097/DCC.0b013e318227761d; Alvarez CA, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-28; Ambler G, 2007, STAT METHODS MED RES, V16, P277, DOI 10.1177/0962280206074466; Atmaca O, 2018, TURK J MED SCI, V48, P1087, DOI 10.3906/sag-1706-67; Austin PC, 2016, STAT MED, V35, P4056, DOI 10.1002/sim.6994; Austin PC, 2016, CIRCULATION, V133, P601, DOI 10.1161/CIRCULATIONAHA.115.017719; Austin PC, 2014, STAT MED, V33, P517, DOI 10.1002/sim.5941; Badriyah T, 2014, RESUSCITATION, V85, P418, DOI 10.1016/j.resuscitation.2013.12.011; Bartkowiak B, 2019, ANN SURG, V269, P1059, DOI 10.1097/SLA.0000000000002665; Beane A, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019387; Blanche P, 2013, STAT MED, V32, P5381, DOI 10.1002/sim.5958; Bleyer AJ, 2011, RESUSCITATION, V82, P1387, DOI 10.1016/j.resuscitation.2011.06.033; Bouwmeester W, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001221; Brabrand M, 2018, LUNG, V196, P359, DOI 10.1007/s00408-018-0105-y; Brabrand M, 2017, EUR J INTERN MED, V45, P32, DOI 10.1016/j.ejim.2017.09.042; Brangan E, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022528; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Cei M, 2009, INT J CLIN PRACT, V63, P591, DOI 10.1111/j.1742-1241.2008.01986.x; Christodoulou E, 2019, J CLIN EPIDEMIOL, V110, P12, DOI 10.1016/j.jclinepi.2019.02.004; Churpek MM, 2017, CRIT CARE MED, V45, P1805, DOI 10.1097/CCM.0000000000002648; Churpek MM, 2017, AM J RESP CRIT CARE, V195, P906, DOI 10.1164/rccm.201604-0854OC; Churpek MM, 2016, RESUSCITATION, V102, P1, DOI 10.1016/j.resuscitation.2016.02.005; Churpek MM, 2014, AM J RESP CRIT CARE, V190, P649, DOI 10.1164/rccm.201406-1022OC; Churpek MM, 2014, CRIT CARE MED, V42, P841, DOI 10.1097/CCM.0000000000000038; Churpek MM, 2013, CHEST, V143, P1758, DOI 10.1378/chest.12-1605; Churpek MM, 2013, RESUSCITATION, V84, P564, DOI 10.1016/j.resuscitation.2012.09.024; Churpek MM, 2012, CRIT CARE MED, V40, P2102, DOI 10.1097/CCM.0b013e318250aa5a; Churpek MM, 2012, CHEST, V141, P1170, DOI 10.1378/chest.11-1301; Collins GS, 2016, STAT MED, V35, P214, DOI 10.1002/sim.6787; Collins GS, 2015, ANN INTERN MED, V162, P55, DOI [10.7326/M14-0697, 10.1161/CIRCULATIONAHA.114.014508, 10.1038/bjc.2014.639, 10.1136/bmj.g7594, 10.1016/j.eururo.2014.11.025, 10.1016/j.jclinepi.2014.11.010, 10.7326/M14-0698, 10.1002/bjs.9736, 10.1186/s12916-014-0241-z]; Collins GS, 2013, J CLIN EPIDEMIOL, V66, P268, DOI 10.1016/j.jclinepi.2012.06.020; Collins GS, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-103; Cooksley T, 2012, QJM-INT J MED, V105, P1083, DOI 10.1093/qjmed/hcs138; Corfield AR, 2014, EMERG MED J, V31, P482, DOI 10.1136/emermed-2012-202186; Cuthbertson BH, 2010, J ROY COLL PHYS EDIN, V40, P19, DOI 10.4997/JRCPE.2010.105; Damen JAAG, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2416; De Meester K, 2013, RESUSCITATION, V84, P184, DOI 10.1016/j.resuscitation.2012.06.017; DeVoe B, 2016, HEART LUNG, V45, P497, DOI 10.1016/j.hrtlng.2016.08.010; Douw G, 2017, J CLIN NURS, V26, P2605, DOI 10.1111/jocn.13648; Douw G, 2016, INT J NURS STUD, V59, P134, DOI 10.1016/j.ijnurstu.2016.04.006; Duckitt RW, 2007, BRIT J ANAESTH, V98, P769, DOI 10.1093/bja/aem097; Dziadzko MA, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2194-7; Eccles SR, 2014, RESUSCITATION, V85, P109, DOI 10.1016/j.resuscitation.2013.08.277; Escobar GJ, 2012, J HOSP MED, V7, P388, DOI 10.1002/jhm.1929; Fairclough E, 2009, CLIN MED, V9, P30, DOI 10.7861/clinmedicine.9-1-30; Faisal M, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022939; Finlay GD, 2014, J HOSP MED, V9, P116, DOI 10.1002/jhm.2132; Forster S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020269; Gao HY, 2007, INTENS CARE MED, V33, P667, DOI 10.1007/s00134-007-0532-3; Garcea G, 2006, J GASTROINTEST SURG, V10, P1008, DOI 10.1016/j.gassur.2006.03.008; Gardner-Thorpe J, 2006, ANN ROY COLL SURG, V88, P571, DOI 10.1308/003588406X130615; Gerds TA, 2014, STAT MED, V33, P3191, DOI 10.1002/sim.6152; Gerds TA, 2012, STAT MED, V31, P3921, DOI 10.1002/sim.5459; Gerry S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-019268; Ghanem-Zoubi NO, 2011, CRIT CARE, V15, DOI 10.1186/cc10102; Ghosh E, 2018, RESUSCITATION, V122, P99, DOI 10.1016/j.resuscitation.2017.10.026; Goldhill DR, 2004, BRIT J ANAESTH, V92, P882, DOI 10.1093/bja/aeh113; Goldstein BA, 2017, STAT MED, V36, P2750, DOI 10.1002/sim.7308; Goldstein BA, 2017, J AM MED INFORM ASSN, V24, P198, DOI 10.1093/jamia/ocw042; Green M, 2018, RESUSCITATION, V123, P86, DOI 10.1016/j.resuscitation.2017.10.028; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Harrison GA, 2006, RESUSCITATION, V71, P327, DOI 10.1016/j.resuscitation.2006.05.008; Hillman KM, 2002, INTENS CARE MED, V28, P1629, DOI 10.1007/s00134-002-1496-y; Hodgson LE, 2017, THORAX, V72, P23, DOI 10.1136/thoraxjnl-2016-208436; Hydes TJ, 2018, CLIN GASTROENTEROL H, V16, P1657, DOI 10.1016/j.cgh.2017.12.035; Inada-Kim M, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k1260; Janssen KJM, 2010, J CLIN EPIDEMIOL, V63, P721, DOI 10.1016/j.jclinepi.2009.12.008; Jo S, 2016, AM J EMERG MED, V34, P536, DOI 10.1016/j.ajem.2015.12.067; Jones M, 2012, CLIN MED, V12, P501, DOI 10.7861/clinmedicine.12-6-501; Kellett J, 2006, QJM-INT J MED, V99, P771, DOI 10.1093/qjmed/hcl112; Kellett J, 2008, RESUSCITATION, V78, P52, DOI 10.1016/j.resuscitation.2008.02.011; Kellett J, 2016, RESUSCITATION, V102, P94, DOI 10.1016/j.resuscitation.2016.02.020; Kellett J, 2012, RESUSCITATION, V83, P297, DOI 10.1016/j.resuscitation.2011.08.022; Kim D, 2018, CLIN EXP EMERG MED, V5, P219, DOI 10.15441/ceem.17.268; Kim WY, 2017, J CRIT CARE, V40, P213, DOI 10.1016/j.jcrc.2017.04.024; Kipnis P, 2016, J BIOMED INFORM, V64, P10, DOI 10.1016/j.jbi.2016.09.013; Kirkland LL, 2013, AM J MED QUAL, V28, P135, DOI 10.1177/1062860612450459; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, P17, DOI [10.17226/9728, DOI 10.17226/9728, https://doi.org/10.17226/9728]; Kovacs C, 2016, BRIT J SURG, V103, P1385, DOI 10.1002/bjs.10267; Kruisselbrink R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151408; Kwon JM, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008678; Kyriacos U, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0087073, 10.1371/journal.pone.0087320]; Le Lagadec MD, 2020, AUST CRIT CARE, V33, P47, DOI 10.1016/j.aucc.2019.03.001; Lee YS, 2018, J CRIT CARE, V47, P222, DOI 10.1016/j.jcrc.2018.07.011; Liljehult J, 2016, ACTA NEUROL SCAND, V133, P261, DOI 10.1111/ane.12452; Linnen DT, 2019, J HOSP MED, V14, P161, DOI 10.12788/jhm.3151; Little R.J.A., 2002, STAT ANAL MISSING DA, V2nd Edn, DOI [10.1002/9781119013563, DOI 10.1002/9781119013563]; LITTLE RJA, 1992, J AM STAT ASSOC, V87, P1227, DOI 10.2307/2290664; Luis L, 2018, AUST CRIT CARE, V31, P376, DOI 10.1016/j.aucc.2017.11.004; McGaughey J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005529; Meads C, 2012, BREAST CANCER RES TR, V132, P365, DOI 10.1007/s10549-011-1818-2; Moher David, 2009, Open Med, V3, pe123; Moore CC, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2017-000344; Morgan R.L, 1997, EARLY WARNING SCORIN; Mulligan Alison, 2010, Intensive Crit Care Nurs, V26, P196, DOI 10.1016/j.iccn.2010.03.002; National Institute for Health and Care Excellence, AC ILL AD HOSP REC R; Nickel CH, 2016, RESUSCITATION, V106, P49, DOI 10.1016/j.resuscitation.2016.06.012; Ohman MC, 2018, QJM-INT J MED, V111, P385, DOI 10.1093/qjmed/hcy053; Opio M O, 2013, Acute Med, V12, P135; Opio MO, 2013, RESUSCITATION, V84, P743, DOI 10.1016/j.resuscitation.2013.02.007; Pedersen NE, 2018, ACTA ANAESTH SCAND, V62, P242, DOI 10.1111/aas.13020; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Perera Yashasvi Sanja, 2011, Acute Med, V10, P126; Pimentel MAF, 2019, RESUSCITATION, V134, P147, DOI 10.1016/j.resuscitation.2018.09.026; Plate Joost Dj, 2018, World J Crit Care Med, V7, P39, DOI 10.5492/wjccm.v7.i3.39; Prince Charles Hospital, MOD EARL WARN SCOR M; Prytherch DR, 2010, RESUSCITATION, V81, P932, DOI 10.1016/j.resuscitation.2010.04.014; Redfern OC, 2018, RESUSCITATION, V133, P75, DOI 10.1016/j.resuscitation.2018.09.021; Redfern OC, 2018, CRIT CARE MED, V46, P1923, DOI 10.1097/CCM.0000000000003359; Riley RD, 2019, STAT MED, V38, P5672, DOI 10.1002/sim.8409; Roberts D, 2017, AM J EMERG MED, V35, P1601, DOI 10.1016/j.ajem.2017.04.072; Romero-Brufau S, 2017, J HOSP MED, V12, P217, DOI 10.12788/jhm.2712; Romero-Brufau S, 2014, RESUSCITATION, V85, P549, DOI 10.1016/j.resuscitation.2013.12.017; Royal College of Physicians, 2017, ROYAL COLL PHYS NAT; Rylance J, 2009, T ROY SOC TROP MED H, V103, P790, DOI 10.1016/j.trstmh.2009.05.004; Silcock DJ, 2015, RESUSCITATION, V89, P31, DOI 10.1016/j.resuscitation.2014.12.029; Silke B, 2010, QJM-INT J MED, V103, P23, DOI 10.1093/qjmed/hcp149; Smith GB, 2008, RESUSCITATION, V77, P170, DOI 10.1016/j.resuscitation.2007.12.004; Smith GB, 2016, CRIT CARE MED, V44, P2171, DOI 10.1097/CCM.0000000000002000; Smith GB, 2013, RESUSCITATION, V84, P465, DOI 10.1016/j.resuscitation.2012.12.016; Smith HJ, 2016, GYNECOL ONCOL, V143, P105, DOI 10.1016/j.ygyno.2016.08.153; Smith M E Beth, 2014, Ann Am Thorac Soc, V11, P1454, DOI 10.1513/AnnalsATS.201403-102OC; Spagnolli W, 2017, INT J CLIN PRACT, V71, DOI 10.1111/ijcp.12934; Stark AP, 2015, AM SURGEON, V81, P916; Steyerberg EW, 2004, STAT MED, V23, P2567, DOI 10.1002/sim.1844; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Straede M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105695; Subbe CP, 2001, QJM-MON J ASSOC PHYS, V94, P521, DOI 10.1093/qjmed/94.10.521; Suppiahl A, 2014, J PANCREAS, V15, P569, DOI 10.6092/1590-8577/2829; Tarassenko L, 2011, RESUSCITATION, V82, P1013, DOI 10.1016/j.resuscitation.2011.03.006; Tirkkonen J, 2014, ACTA ANAESTH SCAND, V58, P411, DOI 10.1111/aas.12277; Tirotta D, 2017, QJM-INT J MED, V110, P369, DOI 10.1093/qjmed/hcw229; Van Calster B, 2018, EUR UROL, V74, P796, DOI 10.1016/j.eururo.2018.08.038; Van Calster B, 2016, J CLIN EPIDEMIOL, V74, P167, DOI 10.1016/j.jclinepi.2015.12.005; van Smeden M, 2019, STAT METHODS MED RES, V28, P2455, DOI 10.1177/0962280218784726; Vaughn JL, 2018, LEUKEMIA LYMPHOMA, V59, P1498, DOI 10.1080/10428194.2017.1376744; Vergouwe Y, 2010, J CLIN EPIDEMIOL, V63, P205, DOI 10.1016/j.jclinepi.2009.03.017; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; von Lilienfeld-Toal M, 2007, BIOL BLOOD MARROW TR, V13, P568, DOI 10.1016/j.bbmt.2006.12.455; Watkinson PJ, 2018, RESUSCITATION, V129, P55, DOI 10.1016/j.resuscitation.2018.06.003; Wheeler I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059830; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Wolbers M, 2014, EUR HEART J, V35, P2936, DOI 10.1093/eurheartj/ehu131; Wolbers M, 2009, EPIDEMIOLOGY, V20, P555, DOI 10.1097/EDE.0b013e3181a39056; Wolff RF, 2019, ANN INTERN MED, V170, P51, DOI 10.7326/M18-1376; Wong D, 2015, BMC MED INFORM DECIS, V15, DOI [10.1186/s12911-016-0257-8, 10.1186/s12911-015-0186-y]; Wynants L, 2019, Diagn Progn Res, V3, P6, DOI 10.1186/s41512-019-0046-9	152	89	90	2	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2020	369								m1501	10.1136/bmj.m1501	http://dx.doi.org/10.1136/bmj.m1501			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LV3JK	32434791	Green Published, hybrid			2023-01-03	WOS:000538335800002
J	Fink, HA; Linskens, EJ; MacDonald, R; Silverman, PC; McCarten, JR; Talley, KMC; Forte, ML; Desai, PJ; Nelson, VA; Miller, MA; Hemmy, LS; Brasure, M; Taylor, BC; Ng, WW; Ouellette, JM; Sheets, KM; Wilt, TJ; Butler, M				Fink, Howard A.; Linskens, Eric J.; MacDonald, Roderick; Silverman, Pombie C.; McCarten, J. Riley; Talley, Kristine M. C.; Forte, Mary L.; Desai, Priyanka J.; Nelson, Victoria A.; Miller, Margaret A.; Hemmy, Laura S.; Brasure, Michelle; Taylor, Brent C.; Ng, Weiwen; Ouellette, Jeannine M.; Sheets, Kerry M.; Wilt, Timothy J.; Butler, Mary			Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia A Systematic Review and Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; NEUROPSYCHIATRIC SYMPTOMS; MEMANTINE TREATMENT; RIVASTIGMINE PATCH; CHOLINESTERASE INHIBITOR; DISEASE PSYCHOSIS; COGNITIVE DECLINE; JAPANESE PATIENTS; LIFE EXPECTANCY	Background: Effects of drug treatment of clinical Alzheimer-type dementia (CATD) are uncertain. Purpose: To summarize evidence on the effects of prescription drugs and supplements for CATD treatment. Data Sources: Electronic bibliographic databases (inception to November 2019), ClinicalTrials.gov (to November 2019), and systematic review bibliographies. Study Selection: English-language trials of prescription drug and supplement treatment in older adults with CATD that report cognition, function, global measures, behavioral and psychological symptoms of dementia (BPSD), or harms. Minimum treatment was 24 weeks (>= 2 weeks for selected BPSD). Data Extraction: Studies with low or medium risk of bias (ROB) were analyzed. Two reviewers rated ROB. One reviewer extracted data; another verified extraction accuracy. Data Synthesis: Fifty-five studies reporting non-BPSD outcomes (most <= 26 weeks) and 12 reporting BPSD (most <= 12 weeks) were analyzed. Across CATD severity, mostly low-strength evidence suggested that, compared with placebo, cholinesterase inhibitors produced small average improvements in cognition (median standardized mean difference [SMD], 0.30 [range, 0.24 to 0.52]), no difference to small improvement in function (median SMD, 0.19 [range, -0.10 to 0.22]), no difference in the likelihood of at least moderate improvement in global clinical impression (median absolute risk difference, 4% [range, 2% to 4%]), and increased withdrawals due to adverse events. In adults with moderate to severe CATD receiving cholinesterase inhibitors, low- to insufficient-strength evidence suggested that, compared with placebo, add-on memantine inconsistently improved cognition and improved global clinical impression but not function. Evidence was mostly insufficient about prescription drugs for BPSD and about supplements for all outcomes. Limitation: Most drugs had few trials without high ROB, especially for supplements, active drug comparisons, BPSD, and longer trials. Conclusion: Cholinesterase inhibitors and memantine slightly reduced short-term cognitive decline, and cholinesterase inhibitors slightly reduced reported functional decline, but differences versus placebo were of uncertain clinical importance. Evidence was mostly insufficient on drug treatment of BPSD and on supplements for all outcomes.	[Fink, Howard A.; Linskens, Eric J.; McCarten, J. Riley; Miller, Margaret A.; Hemmy, Laura S.; Wilt, Timothy J.] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA; [Taylor, Brent C.] Minneapolis VA Hlth Care Syst, Ctr Care Delivery & Outcomes Res, 152,One Vet Dr, Minneapolis, MN 55417 USA; [Fink, Howard A.; McCarten, J. Riley; Hemmy, Laura S.; Taylor, Brent C.; Wilt, Timothy J.] Univ Minnesota, Minneapolis, MN USA; [MacDonald, Roderick; Sheets, Kerry M.; Wilt, Timothy J.] Minneapolis VA Hlth Care Syst, Ctr Care Delivery & Outcomes Res, 111-0,One Vet Dr, Minneapolis, MN 55417 USA; [Silverman, Pombie C.] Univ Iowa, Carver Coll Med, 375 Newton Rd, Iowa City, IA 52246 USA; [Talley, Kristine M. C.] Univ Minnesota, Sch Nursing, 5-140 Weaver Densford Hall,308 Harvard St SE, Minneapolis, MN 55455 USA; [Forte, Mary L.] Univ Minnesota, Div Hlth Policy & Management, Sch Publ Hlth, MMC 729 8729A,D330-4 Mayo Mem Bldg, Minneapolis, MN 55455 USA; [Desai, Priyanka J.; Nelson, Victoria A.; Brasure, Michelle; Ng, Weiwen; Ouellette, Jeannine M.] Univ Minnesota, Div Hlth Policy & Management, Sch Publ Hlth, MMC 197,D330-6 Mayo Mem Bldg,420 Delaware St SE, Minneapolis, MN 55455 USA; [Butler, Mary] Univ Minnesota, Div Hlth Policy & Management, Sch Publ Hlth, MMC 729,D381 Mayo Mem Bldg,420 Delaware St SE, Minneapolis, MN 55455 USA; [Sheets, Kerry M.] Hennepin Healthcare, Minneapolis, MN USA; [Fink, Howard A.; Linskens, Eric J.; McCarten, J. Riley; Miller, Margaret A.; Hemmy, Laura S.] Minneapolis VA Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 11-G,One Vet Dr, Minneapolis, MN 55417 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Iowa; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Fink, HA (corresponding author), Minneapolis VA Hlth Care Syst 11G, Geriatr Res Educ & Clin Ctr, One Vet Dr, Minneapolis, MN 55417 USA.	Howard.fink@va.gov	Taylor, Brent C/A-8069-2009	Taylor, Brent C/0000-0002-2140-8377; Talley, Kristine/0000-0002-3402-3222; Forte, Mary/0000-0003-4566-2529	Agency for Healthcare Research and Quality [PROSPERO: CRD42018117897]; Minnesota Evidence-based Practice Center [HHSA 290-2015-00008-I]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Minnesota Evidence-based Practice Center	Agency for Healthcare Research and Quality. (PROSPERO: CRD42018117897); This article is based on research conducted by the Minnesota Evidence-based Practice Center under contract HHSA 290-2015-00008-I to the AHRQ.	Aisen PS, 2008, JAMA-J AM MED ASSOC, V300, P1774, DOI 10.1001/jama.300.15.1774; Alzheimer's Research & Prevention Foundation, PILL 1 DIET SUPPL; [Anonymous], 2019, QUALIFYING CONDITION; Ballard C, 2019, JPAD-J PREV ALZHEIM, V6, P27, DOI 10.14283/jpad.2018.30; Ballard C, 2005, BMJ-BRIT MED J, V330, P874, DOI 10.1136/bmj.38369.459988.8F; Ballard C, 2018, LANCET NEUROL, V17, P213, DOI 10.1016/S1474-4422(18)30039-5; Ballard C, 2015, J AM MED DIR ASSOC, V16, P316, DOI 10.1016/j.jamda.2014.11.002; Banerjee S, 2011, LANCET, V378, P403, DOI 10.1016/S0140-6736(11)60830-1; Black SE, 2007, NEUROLOGY, V69, P459, DOI 10.1212/01.wnl.0000266627.96040.5a; Burns A, 1999, DEMENT GERIATR COGN, V10, P237, DOI 10.1159/000017126; Burns A, 2009, LANCET NEUROL, V8, P39, DOI 10.1016/S1474-4422(08)70261-8; Cohen J., 2013, STAT POWER ANAL BEHA; Cornelli U, 2010, NEURODEGENER DIS, V7, P193, DOI 10.1159/000295663; Cummings J, 2012, DEMENT GERIATR COGN, V33, P341, DOI 10.1159/000340056; De Deyn P, 2005, J CLIN PSYCHOPHARM, V25, P463, DOI 10.1097/01.jcp.0000178415.22309.8f; Devanand DP, 1998, AM J PSYCHIAT, V155, P1512, DOI 10.1176/ajp.155.11.1512; dos Santos Moraes WA, 2006, SLEEP, V29, P199, DOI 10.1093/sleep/29.2.199; Eriksdotter M, 2015, J ALZHEIMERS DIS, V48, P805, DOI 10.3233/JAD-150102; Farlow MR, 2010, AM J ALZHEIMERS DIS, V25, P347, DOI 10.1177/1533317510365344; Farokhnia M, 2014, HUM PSYCHOPHARM CLIN, V29, P351, DOI 10.1002/hup.2412; Feldman H, 2001, NEUROLOGY, V57, P613, DOI 10.1212/WNL.57.4.613; Feldman HH, 2007, J NEUROL NEUROSUR PS, V78, P1056, DOI 10.1136/jnnp.2006.099424; Finkel SI, 2004, INT J GERIATR PSYCH, V19, P9, DOI 10.1002/gps.998; Freund-Levi Y, 2006, ARCH NEUROL-CHICAGO, V63, P1402, DOI 10.1001/archneur.63.10.1402; Furukawa K, 2017, GERIATR GERONTOL INT, V17, P211, DOI 10.1111/ggi.12696; Gleason CE, 2015, J ALZHEIMERS DIS, V47, P1009, DOI 10.3233/JAD-142958; Grossberg GT, 2013, CNS DRUGS, V27, P469, DOI 10.1007/s40263-013-0077-7; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Homma A, 2000, DEMENT GERIATR COGN, V11, P299, DOI 10.1159/000017259; Homma A, 2008, DEMENT GERIATR COGN, V25, P399, DOI 10.1159/000122961; Homma A, 2016, J ALZHEIMERS DIS, V52, P345, DOI 10.3233/JAD-151149; Howard R, 2012, NEW ENGL J MED, V366, P893, DOI 10.1056/NEJMoa1106668; Howard RJ, 2007, NEW ENGL J MED, V357, P1382, DOI 10.1056/NEJMoa066583; Hurd MD, 2013, NEW ENGL J MED, V368, P1326, DOI 10.1056/NEJMsa1204629; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Jia JP, 2017, J ALZHEIMERS DIS, V56, P1495, DOI 10.3233/JAD-161117; Jia JY, 2019, J NEUROL NEUROSUR PS, V90, P1347, DOI 10.1136/jnnp-2018-320199; Kales HC, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h369; Kano O, 2013, NEUROPSYCH DIS TREAT, V9, P259, DOI 10.2147/NDT.S40682; Kessler H, 2008, J NEURAL TRANSM, V115, P1181, DOI 10.1007/s00702-008-0080-1; Krishnan KRR, 2003, AM J PSYCHIAT, V160, P2003, DOI 10.1176/appi.ajp.160.11.2003; Langa KM, 2017, JAMA INTERN MED, V177, P51, DOI 10.1001/jamainternmed.2016.6807; Leonpacher AK, 2016, AM J PSYCHIAT, V173, P473, DOI 10.1176/appi.ajp.2016.15020248; Lorenzi M, 2011, DRUG AGING, V28, P205, DOI 10.2165/11586440-000000000-00000; Maher-Edwards Gareth, 2015, Alzheimers Dement (N Y), V1, P23, DOI 10.1016/j.trci.2015.04.001; Maher-Edwards G, 2011, INT J GERIATR PSYCH, V26, P536, DOI 10.1002/gps.2562; Malpas CB, 2016, J ALZHEIMERS DIS, V54, P223, DOI 10.3233/JAD-160544; Mazza M, 2006, EUR J NEUROL, V13, P981, DOI 10.1111/j.1468-1331.2006.01409.x; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Modrego PJ, 2010, EUR J NEUROL, V17, P405, DOI 10.1111/j.1468-1331.2009.02816.x; Mohs RC, 2001, NEUROLOGY, V57, P481, DOI 10.1212/WNL.57.3.481; Molnar FJ, 2009, J AM GERIATR SOC, V57, P536, DOI 10.1111/j.1532-5415.2008.02122.x; Moreno MD, 2003, CLIN THER, V25, P178; Nakamura Y, 2011, DEMENT GER COGN D EX, V1, P163, DOI 10.1159/000328929; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Peskind ER, 2006, AM J GERIAT PSYCHIAT, V14, P704, DOI 10.1097/01.JGP.0000224350.82719.83; Plassman BL, 2007, NEUROEPIDEMIOLOGY, V29, P125, DOI 10.1159/000109998; Porsteinsson AP, 2008, CURR ALZHEIMER RES, V5, P83, DOI 10.2174/156720508783884576; Porsteinsson AP, 2014, JAMA-J AM MED ASSOC, V311, P682, DOI 10.1001/jama.2014.93; Qaseem A, 2008, ANN INTERN MED, V148, P370, DOI 10.7326/0003-4819-148-5-200803040-00008; Raina P, 2008, ANN INTERN MED, V148, P379, DOI 10.7326/0003-4819-148-5-200803040-00009; Rikkert MGMO, 2015, J ALZHEIMERS DIS, V44, P471, DOI 10.3233/JAD-141305; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rosler M, 1999, BMJ-BRIT MED J, V318, P633, DOI 10.1136/bmj.318.7184.633; Scheltens P, 2012, J ALZHEIMERS DIS, V31, P225, DOI 10.3233/JAD-2012-121189; Schwarzer G, 2007, META R PACKAGE METAA, V7, P3; Seltzer B, 2004, ARCH NEUROL-CHICAGO, V61, P1852, DOI 10.1001/archneur.61.12.1852; Shah RC, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt224; Shinto L, 2014, J ALZHEIMERS DIS, V38, P111, DOI 10.3233/JAD-130722; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; Tariot PN, 2001, J AM GERIATR SOC, V49, P1590, DOI 10.1046/j.1532-5415.2001.t01-1-49266.x; Tariot PN, 2005, AM J GERIAT PSYCHIAT, V13, P942, DOI 10.1176/appi.ajgp.13.11.942; The Alzheimer's Organization, VIT ALZH DEM; Thomas A, 2001, CLIN NEUROPHARMACOL, V24, P31, DOI 10.1097/00002826-200101000-00007; Tom SE, 2015, AM J PUBLIC HEALTH, V105, P408, DOI 10.2105/AJPH.2014.301935; Tune L, 2003, AM J GERIAT PSYCHIAT, V11, P169, DOI 10.1176/appi.ajgp.11.2.169; U.S. Food and Drug Administration, 2005, PUBLIC HLTH ADVISORY; U.S. Food and Drug Administration, ADV LETT PROD ILL MA; U.S. Food and Drug Administration, 1989, PER CENTR NERV SYST, P227; U.S. Food and Drug Administration, 2012, FDA DRUG SAF COMM RE; US Food and Drug Administration, INF HEALTHC PROF CON; Veroniki AA, 2019, RES SYNTH METHODS, V10, P23, DOI 10.1002/jrsm.1319; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Viswanathan M, 2008, ASSESSING RISK BIAS; Wade AG, 2014, CLIN INTERV AGING, V9, P947, DOI 10.2147/CIA.S65625; Wilcock G, 2003, DRUG AGING, V20, P777, DOI 10.2165/00002512-200320100-00006; Wilcock GK, 2000, BRIT MED J, V321, P1445, DOI 10.1136/bmj.321.7274.1445; Winblad B, 2001, NEUROLOGY, V57, P489, DOI 10.1212/WNL.57.3.489; Winblad B, 2006, LANCET, V367, P1057, DOI 10.1016/S0140-6736(06)68350-5; Winblad B, 2007, INT J GERIATR PSYCH, V22, P456, DOI 10.1002/gps.1788; Yang Y, 2019, CHIN J INTEGR MED, V25, P574, DOI 10.1007/s11655-018-3054-7; Zanetti O, 2009, ARCH GERONTOL GERIAT, V49, P237, DOI 10.1016/j.archger.2009.09.035; Zhao QF, 2016, J AFFECT DISORDERS, V190, P264, DOI 10.1016/j.jad.2015.09.069; Zhou TT, 2019, EXP THER MED, V17, P1625, DOI 10.3892/etm.2018.7124	94	28	29	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 19	2020	172	10					656	+		10.7326/M19-3887	http://dx.doi.org/10.7326/M19-3887			24	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LP8XQ	32340037				2023-01-03	WOS:000534600900014
J	Akhtar, S; Nasir, JA; Usman, M; Sarwar, A; Majeed, R; Billah, B				Akhtar, Sohail; Nasir, Jamal Abdul; Usman, Muhammad; Sarwar, Aqsa; Majeed, Rizwana; Billah, Baki			The prevalence of hepatitis C virus in hemodialysis patients in Pakistan: A systematic review and meta-analysis	PLOS ONE			English	Review							STATISTICAL-METHODS; INFECTION; PROFILE	Background Hepatitis C virus (HCV) infection is one of the most common bloodborne viral infections reported in Pakistan. Frequent dialysis treatment of hemodialysis patients exposes them to a high risk of HCV infection. The main purpose of this paper is to quantify the prevalence of HCV in hemodialysis patients through a systematic review and meta-analysis. Methods We systematically searched PubMed, Medline, EMBASE, Pakistani Journals Online and Web of Science to identify studies published between 1 January 1995 and 30 October 2019, reporting on the prevalence of HCV infection in hemodialysis patients. Meta-analysis was performed using a random-effects model to obtain pooled estimates. A funnel plot was used in conjunction with Egger's regression test for asymmetry and to assess publication bias. Meta-regression and subgroup analyses were used to identify potential sources of heterogeneity among the included studies. This review was registered on PROSPERO (registration number CRD42019159345). Results Out of 248 potential studies, 19 studies involving 3446 hemodialysis patients were included in the meta-analysis. The pooled prevalence of HCV in hemodialysis patients in Pakistan was 32.33% (95% CI: 25.73-39.30; I-2 = 94.3%, p < 0.01). The subgroup analysis showed that the prevalence of HCV among hemodialysis patients in Punjab was significantly higher (37.52%; 95% CI: 26.66-49.03; I-2 = 94.5, p < 0.01) than 34.42% (95% CI: 14.95-57.05; I-2 = 91.3%, p < 0.01) in Baluchistan, 27.11% (95% CI: 15.81-40.12; I-2 = 94.5, p < 0.01) in Sindh and 22.61% (95% CI: 17.45-28.2; I-2 = 78.6, p < 0.0117) in Khyber Pukhtoonkhuwa. Conclusions In this study, we found a high prevalence (32.33%) of HCV infection in hemodialysis patients in Pakistan. Clinically, hemodialysis patients require more attention and resources than the general population. Preventive interventions are urgently needed to decrease the high risk of HCV infection in hemodialysis patients in Pakistan.	[Akhtar, Sohail; Nasir, Jamal Abdul; Sarwar, Aqsa; Majeed, Rizwana] Govt Coll Univ Lahore, Dept Stat, Lahore, Pakistan; [Usman, Muhammad] Univ Peshawar, Dept Stat, Peshawar, Pakistan; [Usman, Muhammad] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England; [Billah, Baki] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia	Government College University Lahore; University of Peshawar; University of Leicester; Monash University	Akhtar, S (corresponding author), Govt Coll Univ Lahore, Dept Stat, Lahore, Pakistan.	s.akhtar@gcu.edu.pk		Akhtar, Sohail/0000-0003-4870-152X; Majeed, Rizwana/0000-0001-7889-6175				Al Kanaani Z, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.180257; Alavian SM, 2010, HEMODIAL INT, V14, P253, DOI 10.1111/j.1542-4758.2010.00437.x; Alavian SM, 2009, WORLD J GASTROENTERO, V15, P641, DOI 10.3748/wjg.15.641; Ali I, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-296; Ali N, 2019, EUR J GASTROEN HEPAT, V31, P29, DOI 10.1097/MEG.0000000000001220; Alp E, 2011, ANN CLIN MICROB ANTI, V10, DOI 10.1186/1476-0711-10-36; Anjum MU, 2015, PROFESSIONAL MED J, V22; [Anonymous], 2008, SYST REV INT, V5, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Anwar K, 2016, J HUMAN VIROLOGY RET, V3; Barendregt JJ, 2013, J EPIDEMIOL COMMUN H, V67, P974, DOI 10.1136/jech-2013-203104; Brockwell SE, 2001, STAT MED, V20, P825, DOI 10.1002/sim.650; Butt N, 2019, CUREUS, V11, DOI 10.7759/cureus.5702; Chang JM, 2014, INT J MED SCI, V11, P436, DOI 10.7150/ijms.8265; Chen H, 2012, BIOMETRICS, V68, P1278, DOI 10.1111/j.1541-0420.2012.01761.x; Chishti SMI, 2015, MED FORUM MON, V26, P6; Denniston MM, 2012, HEPATOLOGY, V55, P1652, DOI 10.1002/hep.25556; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fabrizi F, 2019, SEMIN DIALYSIS, V32, P93, DOI 10.1111/sdi.12757; Fissell RB, 2004, KIDNEY INT, V65, P2335, DOI 10.1111/j.1523-1755.2004.00649.x; Ghorbani NR, 2017, J RES MED SCI, V22, DOI 10.4103/jrms.JRMS_223_17; Gul Ambreen, 2003, J Coll Physicians Surg Pak, V13, P15; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hofmeister MG, 2019, HEPATOLOGY, V69, P1020, DOI 10.1002/hep.30297; Hussain Y, 2019, PAK J MED SCI, V35, P66, DOI 10.12669/pjms.35.1.366; Ismail T, 2016, J RAWAL MED COLL S S, V20, P34; Karkar A, 2018, KIDNEY RES CLIN PRAC, V37, P1, DOI 10.23876/j.krcp.2018.37.1.1; Khan AA, 2010, J PAK MED ASSOC, V60, P300; Khan S, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-438; Khokhar Nasir, 2005, J Coll Physicians Surg Pak, V15, P326; Kiani Ismaa Ghazanfar, 2018, J Ayub Med Coll Abbottabad, V30, P397; Kontopantelis E, 2012, STAT METHODS MED RES, V21, P657, DOI 10.1177/0962280211413451; Lodhi A, 2019, DRUG DISCOV THER, V13, P274, DOI 10.5582/ddt.2019.01044; Mahmud HM, 2014, PAK J MED SCI, V30, P1327, DOI 10.12669/pjms.306.5364; Moher D., 2009, BMJ-BRIT MED J, V6, DOI [DOI 10.1023/B:MEDI.0000005484.26741.79, 10.1371/journal.pmed1000097.]; Mumtaz Asim, 2009, J Ayub Med Coll Abbottabad, V21, P4; Munn Z, 2015, INT J EVID-BASED HEA, V13, P147, DOI 10.1097/XEB.0000000000000054; R Core Team, 2021, R LANG ENV STAT COMP; Roy Partha, 2019, Med J Armed Forces India, V75, P74, DOI 10.1016/j.mjafi.2018.08.001; Saifan C, 2013, INT J NEPHROL RENOV, V6, P121, DOI 10.2147/IJNRD.S44656; Shafi ST, 2017, PAK J MED SCI, V33, P18, DOI 10.12669/pjms.331.11553; Shafiq F, 2002, PAK J GASTROENTEROL, V16, P17; Shafiq ST, 2003, P SHAIKH ZAYED POSTG, V17, P19; Sun JH, 2009, RENAL FAILURE, V31, P610, DOI 10.1080/08860220903003446; United Nations Development Programme, 2018, HUMAN DEV REPORT; Zarkoon AK, 2008, GOMAL J MED SCI, V6	46	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2020	15	5							e0232931	10.1371/journal.pone.0232931	http://dx.doi.org/10.1371/journal.pone.0232931			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU0YZ	32407423	Green Published, gold			2023-01-03	WOS:000537490700048
J	Gaudry, S; Hajage, D; Benichou, N; Chaibi, K; Barbar, S; Zarbock, A; Lumlertgul, N; Wald, R; Bagshaw, SM; Srisawat, N; Combes, A; Geri, G; Jamale, T; Dechartres, A; Quenot, JP; Dreyfuss, D				Gaudry, Stephane; Hajage, David; Benichou, Nicolas; Chaibi, Khalil; Barbar, Saber; Zarbock, Alexander; Lumlertgul, Nuttha; Wald, Ron; Bagshaw, Sean M.; Srisawat, Nattachai; Combes, Alain; Geri, Guillaume; Jamale, Tukaram; Dechartres, Agnes; Quenot, Jean-Pierre; Dreyfuss, Didier			Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta -analysis of randomised clinical trials	LANCET			English	Review							ORGAN FAILURE; CARE; HEMOFILTRATION; DIALYSIS; STANDARD; SEPSIS; AKI	Background The timing of renal replacement therapy (RRT) for severe acute kidney injury is highly debated when no life-threatening complications are present. We assessed whether a strategy of delayed versus early RRT initiation affects 28-day survival in critically ill adults with severe acute kidney injury. Methods In this systematic review and individual patient data meta-analysis, we searched MEDLINE (via PubMed), Embase, and the Cochrane Central Register of Controlled Trials for randomised trials published from April 1, 2008, to Dec 20, 2019, that compared delayed and early RRT initiation strategies in patients with severe acute kidney injury. Trials were eligible for inclusion if they included critically ill patients aged 18 years or older with acute kidney injury (defined as a Kidney Disease: Improving Global Outcomes [KDIGO] acute kidney injury stage 2 or 3, or, where KDIGO was unavailable, a renal Sequential Organ Failure Assessment score of 3 or higher). We contacted the principal investigator of each eligible trial to request individual patient data. From the included trials, any patients without acute kidney injury or who were not randomly allocated were not included in the individual patient data meta-analysis. The primary outcome was all-cause mortality at day 28 after randomisation. This study is registered with PROSPERO (CRD42019125025). Findings Among the 1031 studies identified, one study that met the eligibility criteria was excluded because the recruitment period was not recent enough, and ten (including 2143 patients) were included in the analysis. Individual patient data were available for nine studies (2083 patients), from which 1879 patients had severe acute kidney injury and were randomly allocated: 946 (50%) to the delayed RRT group and 933 (50%) to the early RRT group. 390 (42%) of 929 patients allocated to the delayed RRT group and who had available data did not receive RRT. The proportion of patients who died by day 28 did not significantly differ between the delayed RRT group (366 [44%] of 837) and the early RRT group (355 [43%] of 827; risk ratio 1 center dot 01 [95% CI 0 center dot 91 to 1 center dot 13], p=0 center dot 80), corresponding to an overall risk difference of 0 center dot 01 (95% CI -0 center dot 04 to 0 center dot 06). There was no heterogeneity across studies (I-2=0%; t(2)=0), and most studies had a low risk of bias. Interpretation The timing of RRT initiation does not affect survival in critically ill patients with severe acute kidney injury in the absence of urgent indications for RRT. Delaying RRT initiation, with close patient monitoring, might lead to a reduced use of RRT, thereby saving health resources. Copyright (c) 2020 Elsevier Ltd. All rights reserved.	[Gaudry, Stephane] Hop Avicenne, AP HP, Dept Reanimat Med Chirurg, Bobigny, France; [Gaudry, Stephane] Univ Sorbonne Paris Nord, UFR SMBH, Hlth Care Simulat Ctr, Bobigny, France; [Gaudry, Stephane; Benichou, Nicolas; Chaibi, Khalil; Dreyfuss, Didier] Sorbonne Univ, INSERM, UMR S 1155, Common & Rare Kidney Dis, Paris, France; [Gaudry, Stephane] Invest Network Initiat Cardiovasc & Renal Clin Tr, Bobigny, France; [Hajage, David; Dechartres, Agnes] Sorbonne Univ, Ctr Pharmacoepidemiol Cephepi, Inst Pierre Louis Epidemiol & Sante Publ, INSERM,AP HP,Dept Sante Publ, Paris, France; [Combes, Alain] Sorbonne Univ, Serv Med Intens Reanimat, Inst Cardiometab & Nutr,Hop Pitie Salpetriere, INSERM,UMR S 1166,ICAN,Inst Cardiol,AP HP, Paris, France; [Zarbock, Alexander] Univ Hosp Munster, Dept Anaesthesiol Intens Care Med & Pain Med, Munster, Germany; [Lumlertgul, Nuttha; Srisawat, Nattachai] Chulalongkorn Univ, Dept Med, Fac Med, Div Nephrol, Bangkok, Thailand; [Lumlertgul, Nuttha; Srisawat, Nattachai] Chulalongkorn Univ, Fac Med, Crit Care Nephrol Res Unit, Bangkok, Thailand; [Srisawat, Nattachai] Chulalongkorn Univ, Trop Med Cluster, Bangkok, Thailand; [Lumlertgul, Nuttha; Srisawat, Nattachai] King Chulalongkorn Mem Hosp, Excellence Ctr Crit Care Nephrol, Bangkok, Thailand; [Srisawat, Nattachai] King Chulalongkorn Mem Hosp, Excellence Ctr Crit Care Med, Bangkok, Thailand; [Wald, Ron] St Michaels Hosp, Div Nephrol, Toronto, ON, Canada; [Wald, Ron] Univ Toronto, Toronto, ON, Canada; [Bagshaw, Sean M.] Univ Alberta, Fac Med & Dent, Dept Crit Care Med, Edmonton, AB, Canada; [Geri, Guillaume] Univ Paris Saclay, Serv Med Intens Reanimat, Hop Ambroise Pare, AP HP,INSERM,UMR 1018, Paris, France; [Jamale, Tukaram] King Edward Mem Hosp, Seth GS Med Coll, Dept Nephrol, Bombay, Maharashtra, India; [Srisawat, Nattachai] Royal Soc Thailand, Acad Sci, Bangkok, Thailand; [Quenot, Jean-Pierre] Mitterrand Univ Hosp, Dept Intens Care, Dijon, France; [Quenot, Jean-Pierre] Univ Burgundy, Dept Lipness Team, INSERM, Res Ctr,LNC,UMR 1231, Dijon, France; [Quenot, Jean-Pierre] Univ Burgundy, LabExLipSTIC, Dijon, France; [Quenot, Jean-Pierre] Univ Burgundy, INSERM, CIC 1432, Dept Clin Epidemiol, Dijon, France; [Barbar, Saber] Hop Caremeau, Dept Reanimat Med, Nimes, France; [Dreyfuss, Didier] Univ Paris, Hop Louis Mourier, AP HP, Med Intensive Reanimat, F-92700 Colombes, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Munster; Chulalongkorn University; Chulalongkorn University; Chulalongkorn University; Chulalongkorn University; Chulalongkorn University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Alberta; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Montpellier; CHU de Nimes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite	Dreyfuss, D (corresponding author), Univ Paris, Hop Louis Mourier, AP HP, Med Intensive Reanimat, F-92700 Colombes, France.	didier.dreyfuss@aphp.fr	Hajage, David/D-5226-2014	Hajage, David/0000-0002-8475-4090; Barbar, Saber Davide/0000-0002-5089-8088; QUENOT, Jean-Pierre/0000-0003-2351-682X; Jamale, Tukaram/0000-0003-4334-1860	French Ministry of Health; Else-Kroner Fresenius Stiftung; Canadian Institutes of Health Research; University of Alberta Hospital Foundation; National Kidney Foundation of Thailand; Ratchadapiseksomphot endowment fund	French Ministry of Health; Else-Kroner Fresenius Stiftung; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); University of Alberta Hospital Foundation(University of Alberta); National Kidney Foundation of Thailand; Ratchadapiseksomphot endowment fund	We thank all researchers, patients, and surrogates involved in the individual trials. We thank Hala Alfaisal for assistance in data management. The AKIKI, IDEAL-ICU, HEROICS, and HYPERDIA trials were funded by the French Ministry of Health. The ELAIN trial was funded by the Else-Kroner Fresenius Stiftung. The STARRT-AKI pilot trial was funded with support from the Canadian Institutes of Health Research and the University of Alberta Hospital Foundation. The FST trial was funded by the National Kidney Foundation of Thailand. The trial by Srisawat and colleagues was funded by the Ratchadapiseksomphot endowment fund.	Barbar SD, 2018, NEW ENGL J MED, V379, P1431, DOI 10.1056/NEJMoa1803213; Bonventre JV, 2008, NEW ENGL J MED, V359, P82, DOI 10.1056/NEJMe0803765; Bonventre JV, 2013, CLIN J AM SOC NEPHRO, V8, P1606, DOI 10.2215/CJN.06040613; Combes A, 2015, AM J RESP CRIT CARE, V192, P1179, DOI 10.1164/rccm.201503-0516OC; Feng YM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174158; Gaudry S, 2018, INTENS CARE MED, V44, P1360, DOI 10.1007/s00134-018-5210-0; Gaudry S, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3774-9; Gaudry S, 2016, NEW ENGL J MED, V375, P122, DOI 10.1056/NEJMoa1603017; Gaudry S, 2014, J CRIT CARE, V29, P1022, DOI 10.1016/j.jcrc.2014.07.014; Geri G, 2019, RESUSCITATION, V140, P170, DOI 10.1016/j.resuscitation.2019.03.045; Hoste E, 2015, INTENS CARE MED, V41, P1411, DOI 10.1007/s00134-015-3934-7; Fayad AII, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010612.pub2; Jamale TE, 2013, AM J KIDNEY DIS, V62, P1116, DOI 10.1053/j.ajkd.2013.06.012; Karvellas CJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10061; KDIGO, 2012, 2012 KIDN DIS IMPR G; Lai TS, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0265-6; Lumlertgul N, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2021-1; Mehta RL, 2015, LANCET, V385, P2616, DOI 10.1016/S0140-6736(15)60126-X; Palevsky PM, 2008, CRIT CARE MED, V36, pS224, DOI 10.1097/CCM.0b013e318168e3fb; Payen D, 2009, CRIT CARE MED, V37, P803, DOI 10.1097/CCM.0b013e3181962316; Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2; Schneider AG, 2012, NEPHROL DIAL TRANSPL, V27, P947, DOI 10.1093/ndt/gfr501; Seabra VF, 2008, AM J KIDNEY DIS, V52, P272, DOI 10.1053/j.ajkd.2008.02.371; Shingarev R, 2011, SEMIN DIALYSIS, V24, P164, DOI 10.1111/j.1525-139X.2011.00828.x; Srisawat N, 2018, J CRIT CARE, V43, P36, DOI 10.1016/j.jcrc.2017.08.029; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Stewart LA, 2015, JAMA-J AM MED ASSOC, V313, P1657, DOI 10.1001/jama.2015.3656; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wald R, 2019, CAN J KIDNEY HEALTH, V6, DOI 10.1177/2054358119852937; Wald R, 2015, KIDNEY INT, V88, P897, DOI 10.1038/ki.2015.184; Wald R, 2014, CRIT CARE MED, V42, P1933, DOI 10.1097/CCM.0000000000000432; [夏艳梅 Xia Yanmei], 2019, [解放军医学杂志, Medical Journal of Chinese People's Liberation Army], V44, P605; Xiao L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223493; Yang XM, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0667-6; Yehya N, 2019, AM J RESP CRIT CARE, V200, P828, DOI 10.1164/rccm.201810-2050CP; Zarbock A, 2016, JAMA-J AM MED ASSOC, V315, P2190, DOI 10.1001/jama.2016.5828; Zhang ZH, 2019, CRIT CARE MED, V47, P315, DOI 10.1097/CCM.0000000000003499; Zimmerman JE, 2013, CRIT CARE, V17, DOI 10.1186/cc12695	38	84	90	5	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	2020	395	10235					1506	1515		10.1016/S0140-6736(20)30531-6	http://dx.doi.org/10.1016/S0140-6736(20)30531-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LO3QU	32334654				2023-01-03	WOS:000533544900015
J	Chakraborty, A; Jacob, J				Chakraborty, Arup; Jacob, John			Ptosis that resolves with application of an ice pack	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Chakraborty, Arup; Jacob, John] Milton Keynes Univ Hosp, Milton Keynes, Bucks, England; [Jacob, John] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England	University of Oxford	Chakraborty, A (corresponding author), Milton Keynes Univ Hosp, Milton Keynes, Bucks, England.	arup24@doctors.org.uk						Chatzistefanou KI, 2009, OPHTHALMOLOGY, V116, P2236, DOI 10.1016/j.ophtha.2009.04.039; ERTAS M, 1994, ACTA NEUROL SCAND, V89, P227; Hilton-Jones D., 2002, PRACT NEUROL, V3, P173, DOI 10.1046/j.1474-7766.2002.05056.x; Kearsey Christopher, 2010, JRSM Short Rep, V1, P14, DOI 10.1258/shorts.2009.090037; Larner AJ, 2000, POSTGRAD MED J, V76, P162, DOI 10.1136/pmj.76.893.162; Natarajan B, 2016, NEUROL INDIA, V64, P1169, DOI 10.4103/0028-3886.193780; Ramirez-Antunez AG, 2013, REV NEUROLOGIA, V57, P385, DOI 10.33588/rn.5709.2013193; Tabassi A, 2005, ACTA MED IRAN, V43, P2	8	0	0	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	2020	369								m1147	10.1136/bmj.m1147	http://dx.doi.org/10.1136/bmj.m1147			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF9CM	32299807	Green Published			2023-01-03	WOS:000527710800002
J	Chowdhury, UR; Kudgus, RA; Rinkoski, TA; Holman, BH; Bahler, CK; Hann, CR; Reid, JM; Dosa, PI; Fautsch, MP				Chowdhury, Uttio Roy; Kudgus, Rachel A.; Rinkoski, Tommy A.; Holman, Bradley H.; Bahler, Cindy K.; Hann, Cheryl R.; Reid, Joel M.; Dosa, Peter I.; Fautsch, Michael P.			Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits	PLOS ONE			English	Article							INTRAOCULAR-PRESSURE; CHANNEL OPENERS; CROMAKALIM; GLAUCOMA	Elevated intraocular pressure is the only treatable risk factor for glaucoma, an eye disease that is the leading cause of irreversible blindness worldwide. We have identified cromakalim prodrug 1 (CKLP1), a novel water-soluble ATP-sensitive potassium channel opener, as a new ocular hypotensive agent. To evaluate the pharmacokinetic and safety profile of CKLP1 and its parent compound levcromakalim, Dutch-belted pigmented rabbits were treated intravenously (0.25 mg/kg) or topically (10 mM; 4.1 mg/ml) with CKLP1. Body fluids (blood, aqueous and vitreous humor) were collected at multiple time points and evaluated for the presence of CKLP1 and levcromakalim using a liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) based assay. Histology of tissues isolated from Dutch-belted pigmented rabbits treated once daily for 90 days was evaluated in a masked manner by a certified veterinary pathologist. The estimated plasma parameters following intravenous administration of 0.25 mg/kg of CKLP1 showed CKLP1 had a terminal half-life of 61.8 +/- 55.2 min, T-max of 19.8 +/- 23.0 min and C-max of 1968.5 +/- 831.0 ng/ml. Levcromakalim had a plasma terminal half-life of 85.0 +/- 37.0 min, T-max of 61.0 +/- 32.0 min and C-max of 10.6 +/- 1.2 ng/ml. Topical CKLP1 treatment in the eye showed low levels (< 0.3 ng/mL) of levcromakalim in aqueous and vitreous humor, and trace amounts of CKLP1 and levcromakalim in the plasma. No observable histological changes were noted in selected tissues that were examined following topical application of CKLP1 for 90 consecutive days. These results suggest that CKPL1 is converted to levcromakalim in the eye and likely to some extent in the systemic circulation.	[Chowdhury, Uttio Roy; Rinkoski, Tommy A.; Holman, Bradley H.; Bahler, Cindy K.; Hann, Cheryl R.; Fautsch, Michael P.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA; [Kudgus, Rachel A.; Reid, Joel M.] Mayo Clin, Dept Oncol Res, Rochester, MN USA; [Dosa, Peter I.] Univ Minnesota, Dept Med Chem, Inst Therapeut Discovery & Dev, Minneapolis, MN 55455 USA	Mayo Clinic; Mayo Clinic; University of Minnesota System; University of Minnesota Twin Cities	Fautsch, MP (corresponding author), Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.	Fautsch@mayo.edu		Fautsch, Michael/0000-0002-9115-2485	NIH [EY21727, EY26490]; Minnesota Partnership for Biotechnology and Medical Genomics [12.06]; Minnesota Partnership for Biotechnology and Medical Genomics TPDF [15.01]; National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000114]; Mayo Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Minnesota Partnership for Biotechnology and Medical Genomics; Minnesota Partnership for Biotechnology and Medical Genomics TPDF; National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Mayo Foundation	NIH grants EY21727 (MPF), EY26490 (MPF); Minnesota Partnership for Biotechnology and Medical Genomics #12.06 (MPF, PID); Minnesota Partnership for Biotechnology and Medical Genomics TPDF #15.01 (MPF, PID); National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 (PID); Mayo Foundation (MPF).	Boland MV, 2013, ANN INTERN MED, V158, P271, DOI 10.7326/0003-4819-158-4-201302190-00008; Boland MV, TREATMENT GLAUCOMA C; Chowdhury UR, 2017, INVEST OPHTH VIS SCI, V58, P5723, DOI 10.1167/iovs.17-22538; Chowdhury UR, 2017, EXP EYE RES, V158, P85, DOI 10.1016/j.exer.2016.04.020; Chowdhury UR, 2016, J MED CHEM, V59, P6221, DOI 10.1021/acs.jmedchem.6b00406; Chowdhury UR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141783; Chowdhury UR, 2015, INVEST OPHTH VIS SCI, V56, P2993, DOI 10.1167/iovs.15-16744; Chowdhury UR, 2013, INVEST OPHTH VIS SCI, V54, P4892, DOI 10.1167/iovs.13-11872; Chowdhury UR, 2011, INVEST OPHTH VIS SCI, V52, P6435, DOI 10.1167/iovs.11-7523; Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268; Roy Chowdhury U, 2018, GLAUCOMA RES CLIN AD, P201; Scherer WJ, 2002, J OCUL PHARMACOL TH, V18, P287, DOI 10.1089/108076802760116205; Schmidl D, 2015, J OCUL PHARMACOL TH, V31, P63, DOI 10.1089/jop.2014.0067; Shen J, 2014, INVEST OPHTH VIS SCI, V55, P1056, DOI 10.1167/iovs.13-13650; Sjoquist B, 1998, DRUG METAB DISPOS, V26, P745; SUGRUE MF, 1989, PHARMACOL THERAPEUT, V43, P91, DOI 10.1016/0163-7258(89)90049-1	16	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2020	15	4							e0231841	10.1371/journal.pone.0231841	http://dx.doi.org/10.1371/journal.pone.0231841			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9JM	32298376	Green Published, gold			2023-01-03	WOS:000536011400118
J	DeLeon, TT; Almquist, DR; Kipp, BR; Langlais, BT; Mangold, A; Winters, JL; Kosiorek, HE; Joseph, RW; Dronca, RS; Block, MS; McWilliams, RR; Kottschade, LA; Rumilla, KM; Voss, JS; Seetharam, M; Sekulic, A; Markovic, SN; Bryce, AH				DeLeon, Thomas T.; Almquist, Daniel R.; Kipp, Benjamin R.; Langlais, Blake T.; Mangold, Aaron; Winters, Jennifer L.; Kosiorek, Heidi E.; Joseph, Richard W.; Dronca, Roxana S.; Block, Matthew S.; McWilliams, Robert R.; Kottschade, Lisa A.; Rumilla, Kandelaria M.; Voss, Jesse S.; Seetharam, Mahesh; Sekulic, Aleksandar; Markovic, Svetomir N.; Bryce, Alan H.			Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations	PLOS ONE			English	Article							CUTANEOUS MELANOMA; BRAF; EXPRESSION; LANDSCAPE	Background CDKN2A and TP53 mutations are recurrent events in melanoma, occurring in 13.3% and 15.1% of cases respectively and are associated with poorer outcomes. It is unclear what effect CDKN2A and TP53 mutations have on the clinical outcomes of patients treated with checkpoint inhibitors. Methods All patients with cutaneous melanoma or melanoma of unknown primary who received checkpoint inhibitor therapy and underwent genomic profiling with the 50-gene Mayo Clinic solid tumor targeted cancer gene panel were included. Patients were stratified according to the presence or absence of mutations in BRAF, NRAS, CDKN2A, and TP53. Patients without mutations in any of these genes were termed quadruple wild type (Quad(WT)). Clinical outcomes including median time to progression (TTP), median overall survival (OS), 6-month and 12-month OS, 6-month and 12-month without progression, ORR and disease control rate (DCR) were analyzed according to the mutational status of CDKN2A, TP53 and Quad(WT). Results A total of 102 patients were included in this study of which 14 had mutations of CDKN2A (CDKN2A(mut)), 21 had TP53 mutations (TP53(mut)), and 12 were Quad(WT). TP53(mut), CDKN2A-(mut) and Quad(WT) mutational status did not impact clinical outcomes including median TTP, median OS, 6-month and 12-month OS, 6-month and 12-month without progression, ORR and DCR. There was a trend towards improved median TTP and DCR in CDKN2A(mut) cohort and a trend towards worsened median TTP in the Quad(WT) cohort. Conclusion Cell cycle regulators such as TP53 and CDKN2A do not appear to significantly alter clinical outcomes when immune checkpoint inhibitors are used.	[DeLeon, Thomas T.; Almquist, Daniel R.; Seetharam, Mahesh; Bryce, Alan H.] Mayo Clin Arizona, Dept Hematol & Oncol, Scottsdale, AZ 85259 USA; [Kipp, Benjamin R.; Winters, Jennifer L.; Rumilla, Kandelaria M.; Voss, Jesse S.] Mayo Clin Rochester, Dept Lab Med & Pathol, Rochester, MN USA; [Langlais, Blake T.; Kosiorek, Heidi E.] Mayo Clin Arizona, Dept Biostat, Scottsdale, AZ USA; [Mangold, Aaron; Sekulic, Aleksandar] Mayo Clin Arizona, Dept Dermatol, Scottsdale, AZ USA; [Joseph, Richard W.; Dronca, Roxana S.; Block, Matthew S.; McWilliams, Robert R.; Kottschade, Lisa A.; Markovic, Svetomir N.] Mayo Clin Rochester, Dept Hematol & Oncol, Rochester, MN USA; [Sekulic, Aleksandar] Mayo Clin Canc Ctr, Phoenix, AZ USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix	Bryce, AH (corresponding author), Mayo Clin Arizona, Dept Hematol & Oncol, Scottsdale, AZ 85259 USA.	Bryce.Alan@Mayo.edu	Bryce, Alan/W-1765-2019	Bryce, Alan/0000-0002-0206-3895; Mangold, Aaron/0000-0001-6873-1705				Bennett DC, 2016, PIGM CELL MELANOMA R, V29, P122, DOI 10.1111/pcmr.12422; Busch C, 2010, J INVEST DERMATOL, V130, P2514, DOI 10.1038/jid.2010.138; Carlino MS, 2014, BRIT J CANCER, V111, P292, DOI 10.1038/bjc.2014.287; Cullen SP, 2008, CELL DEATH DIFFER, V15, P251, DOI 10.1038/sj.cdd.4402244; Dixon H, 2002, CELL CYCLE, V1, P362, DOI 10.4161/cc.1.6.257; Dovey M, 2009, ZEBRAFISH, V6, P397, DOI 10.1089/zeb.2009.0606; Gallagher SJ, 2008, NEOPLASIA, V10, P1231, DOI 10.1593/neo.08702; Goel VK, 2009, ONCOGENE, V28, P2289, DOI 10.1038/onc.2009.95; Grafstrom E, 2005, CLIN CANCER RES, V11, P2991, DOI 10.1158/1078-0432.CCR-04-1731; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Iwadate Y, 2000, INT J ONCOL, V17, P501; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Johnson DB, 2015, CANCER IMMUNOL RES, V3, P288, DOI 10.1158/2326-6066.CIR-14-0207; Kato S, 2016, JNCI-J NATL CANCER I, V108, P5780, DOI [10.1200/JCO.2009.22.8239, DOI 10.1200/JCO.2009.22.8239]; Kim DW, 2017, CANCER-AM CANCER SOC, V123, P1372, DOI 10.1002/cncr.30463; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rothberg BEG, 2009, J CLIN ONCOL, V27, P5772, DOI 10.1200/JCO.2009.22.8239; Rudolf K, 2010, NEOPLASMA, V57, P316, DOI 10.4149/neo_2010_04_316; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Viros A, 2014, NATURE, V511, P478, DOI 10.1038/nature13298; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu H, 2009, AM J PATHOL, V174, P2367, DOI 10.2353/ajpath.2009.081057; Zhang J, 2017, CELL CYCLE, V16, P1193, DOI 10.1080/15384101.2017.1320005; Zhang TW, 2016, PIGM CELL MELANOMA R, V29, P266, DOI 10.1111/pcmr.12459	25	9	9	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2020	15	3							e0230306	10.1371/journal.pone.0230306	http://dx.doi.org/10.1371/journal.pone.0230306			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ9FU	32196516	gold, Green Published			2023-01-03	WOS:000535303100026
J	Park, SM; Hwang, CY; Choi, J; Joung, CY; Cho, KH				Park, Sang-Min; Hwang, Chae Young; Choi, Jihye; Joung, Chang Young; Cho, Kwang-Hyun			Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy	ONCOGENE			English	Article							MEK INHIBITION; SYSTEMS BIOLOGY; NETWORKS; DYNAMICS; BRAF; PATHWAY; SRC; KINOME; ENCYCLOPEDIA; ACTIVATION	Targeted drugs aim to treat cancer by directly inhibiting oncogene activity or oncogenic pathways, but drug resistance frequently emerges. Due to the intricate dynamics of cancer signaling networks, which contain complex feedback regulations, cancer cells can rewire these networks to adapt to and counter the cytotoxic effects of a drug, thereby limiting the efficacy of targeted therapies. To identify a combinatorial drug target that can overcome such a limitation, we developed a Boolean network simulation and analysis framework and applied this approach to a large-scale signaling network of colorectal cancer with integrated genomic information. We discovered Src as a critical combination drug target that can overcome the adaptive resistance to the targeted inhibition of mitogen-activated protein kinase pathway by blocking the essential feedback regulation responsible for resistance. The proposed framework is generic and can be widely used to identify drug targets that can overcome adaptive resistance to targeted therapies.	[Park, Sang-Min; Hwang, Chae Young; Choi, Jihye; Joung, Chang Young; Cho, Kwang-Hyun] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Lab Syst Biol & Bioinspired Engn, Daejeon 34141, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Cho, KH (corresponding author), Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Lab Syst Biol & Bioinspired Engn, Daejeon 34141, South Korea.	ckh@kaist.ac.kr	Cho, Kwang-Hyun/C-1684-2011	Park, Sang-Min/0000-0003-2915-0742	National Research Foundation of Korea (NRF) - Korea Government; Ministry of Science and ICT [2017R1A2A1A17069642, 2015M3A9A7067220]	National Research Foundation of Korea (NRF) - Korea Government(National Research Foundation of Korea); Ministry of Science and ICT(Ministry of Science, ICT & Future Planning, Republic of Korea)	We thank Dr Ki-Sun Kwon (Korea Research Institute of Bioscience and Biotechnology) for the rabbit polyclonal anti-GAPDH antibody, Nancy R. Gough (BioSerendipity, LLC) for editorial assistance, and Sea Choi for her editorial assistance during revision. This work was supported by the National Research Foundation of Korea (NRF) grants funded by the Korea Government, the Ministry of Science and ICT (2017R1A2A1A17069642 and 2015M3A9A7067220).	Abdi A, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.2000008; Aldridge BB, 2006, NAT CELL BIOL, V8, P1195, DOI 10.1038/ncb1497; Anderson GR, 2017, CELL REP, V20, P999, DOI 10.1016/j.celrep.2017.07.006; Assmus HE, 2006, EXPERT REV MOL DIAGN, V6, P891, DOI 10.1586/14737159.6.6.891; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Chen SH, 2016, CURR OPIN STRUC BIOL, V41, P145, DOI 10.1016/j.sbi.2016.07.020; Cho SH, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-016-0341-9; Choi M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02160-5; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Creixell P, 2015, CELL, V163, P202, DOI 10.1016/j.cell.2015.08.056; Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Dunn EF, 2011, ONCOGENE, V30, P561, DOI 10.1038/onc.2010.430; Eshaghi M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011620; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Gargalionis AN, 2014, INT J CANCER, V134, P2019, DOI 10.1002/ijc.28299; Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474; Helikar T, 2008, P NATL ACAD SCI USA, V105, P1913, DOI 10.1073/pnas.0705088105; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Imperial R, 2019, SEMIN CANCER BIOL, V54, P14, DOI 10.1016/j.semcancer.2017.11.016; Jeong WJ, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0049-y; Johnson GL, 2014, CLIN CANCER RES, V20, P2516, DOI 10.1158/1078-0432.CCR-13-1081; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kim JR, 2006, COMPUT BIOL CHEM, V30, P438, DOI 10.1016/j.compbiolchem.2006.09.004; Kim JR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001390; Kim J, 2013, SCI REP-UK, V3, DOI 10.1038/srep02223; Kim S, 2007, COMPUT BIOL CHEM, V31, P239, DOI 10.1016/j.compbiolchem.2007.03.013; Kirouac DC, 2017, NPJ SYST BIOL APPL, V3, DOI 10.1038/s41540-017-0016-1; Klinger B, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.29; Kolch W, 2015, NAT REV CANCER, V15, P515, DOI 10.1038/nrc3983; Konieczkowski DJ, 2018, CANCER CELL, V33, P801, DOI 10.1016/j.ccell.2018.03.025; Kopetz S, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3534; Kwon YK, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-430; Kwon YK, 2007, BIOPHYS J, V92, P2975, DOI 10.1529/biophysj.106.097097; Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033; Lee HS, 2015, SCI REP-UK, V5, DOI 10.1038/srep10305; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Murray PJ, 2010, BIOPHYS J, V99, P716, DOI 10.1016/j.bpj.2010.05.016; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Ornes S, 2016, P NATL ACAD SCI USA, V113, P7007, DOI 10.1073/pnas.1608277113; Park D, 2018, J MOL CELL BIOL, V10, P180, DOI 10.1093/jmcb/mjy019; Park SM, 2019, FEBS J, V286, P1305, DOI 10.1111/febs.14773; Park SG, 2006, FEBS LETT, V580, P822, DOI 10.1016/j.febslet.2006.01.004; Parseghian CM, 2017, CLIN CANCER RES, V23, P4146, DOI 10.1158/1078-0432.CCR-16-3138; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Saez-Rodriguez J, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.87; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Scaltriti J, 2017, CANC CONVERG, V1, P5, DOI DOI 10.1186/s41236-017-0007-6; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Schmidt H, 2005, FEBS J, V272, P2141, DOI 10.1111/j.1742-4658.2005.04605.x; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Shin D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01171-6; Shmulevich I, 2002, BIOINFORMATICS, V18, P261, DOI 10.1093/bioinformatics/18.2.261; Sontag ED, 2008, ESSAYS BIOCHEM, V45, P161, DOI 10.1042/BSE0450161; Sreenath SN, 2008, ESSAYS BIOCHEM, V45, P1, DOI 10.1042/BSE0450001; Sturm OE, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001212; Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010; Thieffry D, 1999, BIOSYSTEMS, V50, P49, DOI 10.1016/S0303-2647(98)00087-2; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	68	8	8	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3803	3820		10.1038/s41388-020-1255-y	http://dx.doi.org/10.1038/s41388-020-1255-y		MAR 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32157217				2023-01-03	WOS:000518886000008
J	Hyde, R				Hyde, Rob			Germany overturns ban on assisted suicide	LANCET			English	Editorial Material																			0	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	2020	395	10226					774	774						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KU2KH	32145781				2023-01-03	WOS:000519536900017
J	DeBerardinis, RJ				DeBerardinis, Ralph J.			Tumor Microenvironment, Metabolism, and Immunotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GLUTAMINE	The newly diversified experimental strategies to treat cancer include those that involve tweaks to host immunity. A recently described strategy, conducted in mouse models of cancer, targets tumor cells while simultaneously boosting T-cell function.	[DeBerardinis, Ralph J.] Univ Texas Southwestern Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; [DeBerardinis, Ralph J.] Univ Texas Southwestern Med Ctr Dallas, Childrens Med Res Inst, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	DeBerardinis, RJ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA.; DeBerardinis, RJ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Childrens Med Res Inst, Dallas, TX 75390 USA.							BRAND K, 1985, BIOCHEM J, V228, P353, DOI 10.1042/bj2280353; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Leone RD, 2019, SCIENCE, V366, P1013, DOI 10.1126/science.aav2588; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Venneti S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1009	5	98	101	4	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 27	2020	382	9					869	871		10.1056/NEJMcibr1914890	http://dx.doi.org/10.1056/NEJMcibr1914890			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KS8TT	32101671				2023-01-03	WOS:000518581500015
J	Amari, Y; Morimoto, S; Iida, T; Takimoto, H; Okuda, H; Yurugi, T; Oyama, Y; Aoyama, N; Nakajima, F; Ichihara, A				Amari, Yoshifumi; Morimoto, Satoshi; Iida, Takeshi; Takimoto, Hiroki; Okuda, Hidenobu; Yurugi, Takatomi; Oyama, Yasuo; Aoyama, Naoki; Nakajima, Fumitaka; Ichihara, Atsuhiro			Association between serum soluble (pro)renin receptor level and worsening of cardiac function in hemodialysis patients: A prospective observational study	PLOS ONE			English	Article							NATRIURETIC-PEPTIDE; DIALYSIS PATIENTS; RENIN RECEPTOR; PRORENIN; FAILURE	The (pro)renin receptor ((P)RR) is cleaved to generate soluble (P)RR (s(P)RR), which reflects the status of the tissue renin-angiotensin system. Hemodialysis (HD) patients have a poor prognosis due to the increased prevalence of cardiovascular diseases. The present study aimed to investigate whether serum s(P)RR level is associated with the worsening of cardiac function in HD patients. A total of 258 maintenance HD patients were recruited and serum s(P)RR concentration was measured. Background factors in patients who survived (S group) and patients who died (D group) during the 12-month follow-up period and relationships between serum s(P)RR level and changes in cardiac function during the follow-up period in the S group were investigated. The median serum s(P)RR value at baseline was 29.8 ng/ml. Twenty-four patients died during the follow-up period. Cardiothoracic ratio, human atrial natriuretic peptide (hANP), brain natriuretic peptide (BNP), and E over e-prime were significantly higher in the D group. In the S group, changes in hANP or BNP were significantly greater in the higher serum s(P)RR group than in the lower serum s(P)RR group. High serum s(P)RR level was significantly correlated with changes in BNP, independent of other factors. High serum s(P)RR level was associated with increases in BNP, independent of other risk factors, suggesting that an increased expression of (P)RR may be associated with a progression of heart failure in HD patients and that serum s(P)RR concentration could be used as a biomarker for selecting patients requiring intensive care.	[Amari, Yoshifumi; Iida, Takeshi; Takimoto, Hiroki; Okuda, Hidenobu; Yurugi, Takatomi] Moriguchi Keijinkai Hosp, Dept Nephrol, Osaka, Japan; [Amari, Yoshifumi; Morimoto, Satoshi; Iida, Takeshi; Ichihara, Atsuhiro] Tokyo Womens Med Univ, Dept Endocrinol & Hypertens, Tokyo, Japan; [Oyama, Yasuo] Neyagawa Keijinkai Clin, Dept Nephrol & Dialysis, Osaka, Japan; [Aoyama, Naoki] Moriguchi Keijinkai Clin, Dept Nephrol & Dialysis, Osaka, Japan; [Nakajima, Fumitaka] Kadoma Keijinkai Clin, Dept Nephrol & Dialysis, Osaka, Japan	Tokyo Women's Medical University	Morimoto, S (corresponding author), Tokyo Womens Med Univ, Dept Endocrinol & Hypertens, Tokyo, Japan.	morimoto.satoshi@twmu.ac.jp						Achard V, 2007, AM J PHYSIOL-REG I, V292, pR274, DOI 10.1152/ajpregu.00439.2005; Amari Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158068; Atisha D, 2004, AM HEART J, V148, P518, DOI 10.1016/j.ahj.2004.03.014; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; Fukushima A, 2013, INT J CARDIOL, V168, P4313, DOI 10.1016/j.ijcard.2013.04.176; Hamada K, 2013, CLIN EXP NEPHROL, V17, P848, DOI 10.1007/s10157-013-0803-y; HARNETT JD, 1995, KIDNEY INT, V47, P884, DOI 10.1038/ki.1995.132; Ichihara A, 2006, HYPERTENSION, V47, P894, DOI 10.1161/01.HYP.0000215838.48170.0b; Ichihara A, 2019, NAT REV NEPHROL, V15, P693, DOI 10.1038/s41581-019-0160-5; Iseki K, 2011, CLIN EXP NEPHROL, V15, P450, DOI 10.1007/s10157-011-0439-8; Ishida A, 2018, HYPERTENS RES, V41, P539, DOI 10.1038/s41440-018-0047-z; Kopple JD, 1999, J NUTR, V129, p247S, DOI 10.1093/jn/129.1.247S; Kuwahara M, 1992, Hinyokika Kiyo, V38, P5; Levey AS, 1998, AM J KIDNEY DIS, V32, P853, DOI 10.1016/S0272-6386(98)70145-3; Maruyama Nobuhiro, 2013, Front Biosci (Elite Ed), V5, P583; Metry G, 2001, ACTA PHYSIOL SCAND, V171, P117, DOI 10.1046/j.1365-201x.2001.00792.x; Mizuguchi Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195464; Morimoto S, 2014, HYPERTENS RES, V37, P642, DOI 10.1038/hr.2014.46; Nguyen G, 2002, J CLIN INVEST, V109, P1417, DOI 10.1172/JCI200214276; Ommen SR, 2003, HEART, V89, P18; Parfrey PS, 1996, NEPHROL DIAL TRANSPL, V11, P1277; Plum J, 2001, NEPHROL DIAL TRANSPL, V16, P2378, DOI 10.1093/ndt/16.12.2378; Suzuki F, 2003, J BIOL CHEM, V278, P22217, DOI 10.1074/jbc.M302579200; Watanabe N, 2013, J CLIN ENDOCR METAB, V98, P2528, DOI 10.1210/jc.2012-4139; Watanabe N, 2012, HYPERTENSION, V60, P1250, DOI 10.1161/HYPERTENSIONAHA.112.197418; Yamashina A, 2002, HYPERTENS RES, V25, P359, DOI 10.1291/hypres.25.359; Yokoyama Hisayo, 2003, J Atheroscler Thromb, V10, P253; Zoccali C, 2001, J AM SOC NEPHROL, V12, P2768, DOI 10.1681/ASN.V12122768	28	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2020	15	5							e0233312	10.1371/journal.pone.0233312	http://dx.doi.org/10.1371/journal.pone.0233312			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1WS	32469890	gold, Green Published			2023-01-03	WOS:000537552800062
J	Wakeman, SE				Wakeman, Sarah E.			Diagnosis and Treatment of Opioid Use Disorder in 2020	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MULTICENTER		[Wakeman, Sarah E.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Wakeman, Sarah E.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Wakeman, SE (corresponding author), 55 Fruit St,Founders 860, Boston, MA 02114 USA.	swakeman@partners.org			Massachusetts General Hospital from the National Institutes of Health [1R01DA044526-01A1]; National Institute on Drug Abuse [3UG1DA015831-17S2]; Substance Abuse and Mental Health Services Administration [1H79TI081442-01]; Laura and John Arnold Foundation; OptumLabs	Massachusetts General Hospital from the National Institutes of Health; National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Substance Abuse and Mental Health Services Administration(United States Department of Health & Human Services); Laura and John Arnold Foundation; OptumLabs	Dr Wakeman reported receiving research support through Massachusetts General Hospital from the National Institutes of Health (1R01DA044526-01A1), the National Institute on Drug Abuse (3UG1DA015831-17S2), the Substance Abuse and Mental Health Services Administration (1H79TI081442-01), and the Laura and John Arnold Foundation and salary support from OptumLabs as a co-investigator on a research project.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Compton WM, 2013, DRUG ALCOHOL DEPEN, V132, P387, DOI 10.1016/j.drugalcdep.2013.02.036; Fiscella K, 2019, JAMA PSYCHIAT, V76, P229, DOI 10.1001/jamapsychiatry.2018.3685; Haight BR, 2019, LANCET, V393, P778, DOI 10.1016/S0140-6736(18)32259-1; Lee JD, 2018, LANCET, V391, P309, DOI 10.1016/S0140-6736(17)32812-X; Leshner AI, 2019, JAMA-J AM MED ASSOC, V321, P2071, DOI 10.1001/jama.2019.5523; McNeely J, 2015, J GEN INTERN MED, V30, P1757, DOI 10.1007/s11606-015-3391-6; Olfson M, 2019, JAMA-J AM MED ASSOC, V322, P2340, DOI 10.1001/jama.2019.16566; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Wakeman SE, 2019, TREATING OPIOID ADDI, P169, DOI DOI 10.1007/978-3-030-16257-3_8	10	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2020	323	20					2082	2083		10.1001/jama.2020.4104	http://dx.doi.org/10.1001/jama.2020.4104			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU8UM	32329798				2023-01-03	WOS:000538023900040
J	Leonardsen, ACL; Svendsen, EJ; Heitmann, GB; Dhayyat, A; Morris, A; Sjoborg, KD; Olsen, RM; Hardeland, C				Leonardsen, Ann-Chatrin L.; Svendsen, Edel J.; Heitmann, Grethe B.; Dhayyat, Adam; Morris, Ann; Sjoborg, Katrine D.; Olsen, Richard M.; Hardeland, Camilla			Development and validation of a questionnaire to assess healthcare personnel competence in cardiac arrest and resuscitation in pregnancy	PLOS ONE			English	Article							PERIMORTEM CESAREAN DELIVERY; OLDER-PEOPLE; NURSES; STATEMENT; KNOWLEDGE; LABOR	Background Cardiac arrest is rare in pregnancy, and up-to date competence can be difficult to assess and maintain. The objective of this study was to develop and validate a questionnaire to assess healthcare personnel experiences, self-assessed competence and perception of role and resposibility related to cardiac arrest and cardio-pulmonary resuscitation (CPR) in pregnancy Methods The study had a cross-sectional design, developing and validating a questionnaire: the Competence in cardiac arrest and CPR in pregnancy (ComCA-P). Development and validation of the ComCA-P was conducted in three stages: 1) Literature review and expert group panel inputs, 2) a pilot study and 3) a cross-sectional questionnaire study. In stage one, the ComCA-P was developed over several iterations between the researchers, including inputs from an expert group panel consisting of highly competent professionals (n = 11). In stage two, the questionnaire was piloted in a group of healthcare personnel with relevant competence (n = 16). The ComCA-P was then used in a baseline study including healthcare personnel potentially involved in CPR in pregnancy (n = 527) in six hospital wards. Based on these data, internal consistency, intra-class correlations, and confirmatory factor analysis were utilized to validate the questionnaire. Results The expert group and pilot study participants evaluated the appropriateness, relevance and accuracy to be high. Formulation of the items was considered appropriate, with no difficulties identified related to content- or face validity. Cronbach's alpha was 0.8 on the thematic area self-assessment, and 0.73 on the theoretical knowledge area of the ComCA-P. On both the self-assessed competence items and the teoretical knowledge items, Kaiser-Meyer-Olkin was 0.8. Moreover, the Bertletts' test of sphericity was greater than the critical value for chi-square, and significant (p < .0001). Conclusions Findings indicate that the ComCA-P is a valid questionnaire that can be used to assess healthcare personnel competence in cardiac arrest and resuscitation in pregnancy.	[Leonardsen, Ann-Chatrin L.; Hardeland, Camilla] Ostfold Univ Coll, Dept Hlth & Welf, Halden, Norway; [Leonardsen, Ann-Chatrin L.; Heitmann, Grethe B.] Ostfold Hosp Trust, Dept Anesthesiol, Gralum, Norway; [Svendsen, Edel J.] Univ Oslo, Dept Hlth & Soc, Oslo, Norway; [Dhayyat, Adam] Ostfold Hosp Trust, Dept Med, Gralum, Norway; [Morris, Ann; Sjoborg, Katrine D.] Ostfold Hosp Trust, Dept Obstet & Gynecol, Gralum, Norway; [Olsen, Richard M.] Ostfold Hosp Trust, Dept Competence Dev, Gralum, Norway	Ostfold University College; University of Oslo	Leonardsen, ACL (corresponding author), Ostfold Univ Coll, Dept Hlth & Welf, Halden, Norway.; Leonardsen, ACL (corresponding author), Ostfold Hosp Trust, Dept Anesthesiol, Gralum, Norway.	ann.c.leonardsen@hiof.no	Leonardsen, A./AAV-1809-2021	Leonardsen, A./0000-0001-5608-9401; Olsen, Richard Monroe/0000-0001-8178-3972				Baghirzada L, 2013, CAN J ANESTH, V60, P1077, DOI 10.1007/s12630-013-0021-9; Banks A, 2008, INT J OBSTET ANESTH, V17, P289, DOI 10.1016/j.ijoa.2008.07.008; Beckett VA, 2017, BJOG-INT J OBSTET GY, V124, P1374, DOI 10.1111/1471-0528.14521; Bing-Jonsson PC, 2015, INT J OLDER PEOPLE N, V10, P59, DOI 10.1111/opn.12057; CERNY BA, 1977, MULTIVAR BEHAV RES, V12, P43, DOI 10.1207/s15327906mbr1201_3; Cohen SE, 2008, INT J OBSTET ANESTH, V17, P20, DOI 10.1016/j.ijoa.2007.10.002; Cowan DT, 2008, INT J NURS STUD, V45, P902, DOI 10.1016/j.ijnurstu.2007.03.004; Cowan DT, 2005, NURS EDUC TODAY, V25, P355, DOI 10.1016/j.nedt.2005.03.002; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Dijkman A, 2010, BJOG-INT J OBSTET GY, V117, P282, DOI 10.1111/j.1471-0528.2009.02461.x; Einav S, 2012, RESUSCITATION, V83, P1191, DOI 10.1016/j.resuscitation.2012.05.005; Elnava S, 2008, INT J OBSTET ANESTH, V17, P238, DOI 10.1016/j.ijoa.2008.01.015; Finnbakk E, 2015, BMC NURS, V14, DOI 10.1186/s12912-015-0109-3; Hunziker S, 2011, J AM COLL CARDIOL, V57, P2381, DOI 10.1016/j.jacc.2011.03.017; Isidore J, 2018, MIDWIFERY, V62, P214, DOI 10.1016/j.midw.2018.04.017; Jeejeebhoy FM, 2015, CIRCULATION, V132, P1747, DOI 10.1161/CIR.0000000000000300; Jirwe M, 2009, J CLIN NURS, V18, P2622, DOI 10.1111/j.1365-2702.2008.02734.x; KAISER HF, 1974, PSYCHOMETRIKA, V39, P31, DOI 10.1007/BF02291575; Karlstedt M, 2015, SCAND J CARING SCI, V29, P307, DOI 10.1111/scs.12164; Katz V, 2005, AM J OBSTET GYNECOL, V192, P1916, DOI 10.1016/j.ajog.2005.02.038; KATZ VL, 1986, OBSTET GYNECOL, V68, P571; Keeney S, 2011, DELPHI TECHNIQUE NUR; Kikuchi J, 2018, SEMIN PERINATOL, V42, P33, DOI 10.1053/j.semperi.2017.11.007; Kirwan M, 2013, INT J NURS STUD, V50, P253, DOI 10.1016/j.ijnurstu.2012.08.020; Kitson AL, 2008, IMPLEMENT SCI, V3, DOI 10.1186/1748-5908-3-1; Krywko D, AORTACAVAL COMPRESSI; Lai NM, 2011, BMC MED EDUC, V11, DOI 10.1186/1472-6920-11-25; Lavonas E, 2015, SPECIAL CIRCUMSTANCE, DOI [10.1161/CIR, DOI 10.1161/CIR]; Lewis G., 2007, 7 CONFIDENTIAL ENQUI; Lipman S, 2014, ANESTH ANALG, V118, P1003, DOI 10.1213/ANE.0000000000000171; Mhyre JM, 2014, ANESTHESIOLOGY, V120, P810, DOI 10.1097/ALN.0000000000000159; Morris S, 2003, BRIT MED J, V327, P1277, DOI 10.1136/bmj.327.7426.1277; Naylor M, 2013, MED CARE, V51, P6, DOI [10.1097/MLR, DOI 10.1097/MLR]; Needleman J, 2009, HEALTH AFFAIR, V28, pW625, DOI 10.1377/hlthaff.28.4.w625; Paterson-Brown S, 2014, MOET COURSE MANUAL M; Sears K., 2014, JBI DATABASE SYSTEMA, V12, P221, DOI [10.11124/jbisrir-2014-1605, DOI 10.11124/jbisrir-2014-1605, DOI 10.11124/JBISRIR-2014-1605]; Streiner D, 2008, HLTH MEASUREMENT SCA; Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; World Medical Association, 2015, DECL HELS ETH PRINC, V310, P2191, DOI [10.5116/IJME.4DFB.8DFD, DOI 10.5116/IJME.4DFB.8DFD]; Zelop CM, 2018, AM J OBSTET GYNECOL, V219, P52, DOI 10.1016/j.ajog.2017.12.232	41	3	3	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2020	15	5							e0232984	10.1371/journal.pone.0232984	http://dx.doi.org/10.1371/journal.pone.0232984			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU0SY	32396569	Green Published, gold			2023-01-03	WOS:000537475000033
J	Narayan, M; Fey, AM				Narayan, Meenakshi; Fey, Ann Majewicz			Developing a novel force forecasting technique for early prediction of critical events in robotics	PLOS ONE			English	Article							NEEDLE INSERTION; TISSUE; MODEL	Safety critical events in robotic applications can often be characterized by forces between the robot end-effector and the environment. One application in which safe interaction between the robot and environment is critical is in the area of medical robots. In this paper, we propose a novel Compact Form Dynamic Linearization Model-Free Prediction (CFDLMFP) technique to predict future values of any time-series sensor data, such as interaction forces. Existing time series forecasting methods have high computational times which motivates the development of a novel technique. Using Autoregressive Integrated Moving Average (ARIMA) forecasting as benchmark, the performance of the proposed model was evaluated in terms of accuracy, computation efficiency, and stability on various force profiles. The proposed algorithm was 11% more accurate than ARIMA and maximum computation time of CFDL-MFP was 4ms, compared to ARIMA (7390ms). Furthermore, we evaluate the model in the special case of predicting needle buckling events, before they occur, by using only axial force and needle-tip position data. The model was evaluated experimentally for robustness with steerable needle insertions into different tissues including gelatin and biological tissue. For a needle insertion velocity of 2.5mm/s, the proposed algorithm was able to predict needle buckling 2.03s sooner than human detections. In biological tissue, no false positive or false negative buckling detections occurred and the rates were low in artificial tissue. The proposed forecasting model can be used to ensure safe robot interactions with delicate environments by predicting adverse force-based events before they occur.	[Narayan, Meenakshi; Fey, Ann Majewicz] Univ Texas Dallas, Dept Mech Engn, Richardson, TX 75083 USA; [Fey, Ann Majewicz] UT Southwestern Med Ctr, Dept Surg, Dallas, TX USA	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Narayan, M (corresponding author), Univ Texas Dallas, Dept Mech Engn, Richardson, TX 75083 USA.	Meenakshi.Narayan@utdallas.edu		Majewicz Fey, Ann/0000-0002-1802-6730	National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR001105]	National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award Number UL1TR001105. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Abdulali A, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18010237; Abolhassani N, 2007, MED ENG PHYS, V29, P413, DOI 10.1016/j.medengphy.2006.07.003; Adebar TK, 2014, IEEE T BIO-MED ENG, V61, P2899, DOI 10.1109/TBME.2014.2334309; Ahmed NK, 2010, ECONOMET REV, V29, P594, DOI 10.1080/07474938.2010.481556; Alemzadeh H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151470; Assimakopoulos V, 2000, INT J FORECASTING, V16, P521, DOI 10.1016/S0169-2070(00)00066-2; Ben Taieb S, 2014, P 31 INT C MACH LEAR, P109; Billis A., 2014, NETMED ECAI, P31; Bui C, 2018, 6 INT C DEV BIOMED E, P809, DOI [10.1007/978-981-10-4361-1_138, DOI 10.1007/978-981-10-4361-1_138]; Buzurovic I, 2010, J ROBOT, V2010, DOI 10.1155/2010/581840; Carroll AL, 2010, USDA FOR SERV N RES, V75, P1; Chevillon G, 2005, INT J FORECASTING, V21, P201, DOI 10.1016/j.ijforecast.2004.08.004; de Jong TL, 2017, DATA BRIEF, V11, P308, DOI 10.1016/j.dib.2017.01.018; Demiris Yiannis, 2007, Cogn Process, V8, P151, DOI 10.1007/s10339-007-0168-9; Elgezua I, 2014, IEEE INT C INT ROBOT, P4315, DOI 10.1109/IROS.2014.6943172; Elgezua I, 2013, PROC CIRP, V5, P94, DOI 10.1016/j.procir.2013.01.019; Engh JA, 2010, NEUROSURGERY, V67, P1117, DOI 10.1227/NEU.0b013e3181ec1551; Fioruci J.A., 2015, ARXIV150303529; Fukushima Y, 2013, PROC CIRP, V5, P265, DOI 10.1016/j.procir.2013.01.052; Gessert N, 2019, INT J COMPUTER ASSIS, P1; Ghezzi TL, 2016, WORLD J SURG, V40, P2550, DOI 10.1007/s00268-016-3543-9; Grespan L, 2019, MEASURING SAFETY ROB, P37; Gruijthuijsen Caspar, 2018, J Med Robot Res, V3, DOI 10.1142/S2424905X18410015; Hameed HH, 2015, SMOOTHING TECHNIQUES; Hardy J, 2015, INT J ROBOT RES, V34, P1211, DOI 10.1177/0278364915584007; Hastie T., 2005, ELEMENTS STAT LEARNI, V27, P83, DOI [10.1007/BF02985802, 10.1007/978-0-387-84858-7]; Hernandez-Hernandez C, 2017, ENERGIES, V10, DOI 10.3390/en10070884; Hou ZS, 2011, IEEE T NEURAL NETWOR, V22, P2173, DOI 10.1109/TNN.2011.2176141; Hyndman RJ, 2019, OTEXTS, V3rd; Kronreif G, 2003, ADV ROBOTICS, V17, P541, DOI 10.1163/15685530360675532; Lehmann T, 2013, J SENSORS, V2013, DOI 10.1155/2013/263153; Li MH, 2018, IEEE-ASME T MECH, V23, P286, DOI 10.1109/TMECH.2017.2775663; Lokare N, 2017, INVENTIONS-BASEL, V2, DOI 10.3390/inventions2040032; Mahvash Mohsen, 2009, 2009 IEEE International Conference on Robotics and Automation (ICRA), P3097, DOI 10.1109/ROBOT.2009.5152617; Majewicz A, 2014, IEEE INT CONF ROBOT, P5883, DOI 10.1109/ICRA.2014.6907725; Majewicz A, 2013, 2013 WORLD HAPTICS CONFERENCE (WHC), P395, DOI 10.1109/WHC.2013.6548441; Makridakis S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194889; Martens P, 2018, ACTA CARDIOL, V73, P115, DOI 10.1080/00015385.2017.1351239; Minhas DS, 2007, P ANN INT IEEE EMBS, P2756, DOI 10.1109/IEMBS.2007.4352899; Misra S, 2010, INT J ROBOT RES, V29, P1640, DOI 10.1177/0278364910369714; Najmaei N, 2010, IEEE INT CONF ROBOT, P3434, DOI 10.1109/ROBOT.2010.5509179; Narayan M, 2018, 2018 INTERNATIONAL SYMPOSIUM ON MEDICAL ROBOTICS (ISMR); Narazani M., 2018, P 2018 INT ELECT ENG, P1, DOI DOI 10.1109/IEECON.2018.8712218; Oldewurtel F, 2012, ENERG BUILDINGS, V45, P15, DOI 10.1016/j.enbuild.2011.09.022; Paxton C, 2019, IEEE INT CONF ROBOT, P6942, DOI 10.1109/ICRA.2019.8794441; Piccin O, 2009, INT J ROBOT RES, V28, P1154, DOI 10.1177/0278364909101408; Reed KB, 2011, IEEE ROBOT AUTOM MAG, V18, P35, DOI 10.1109/MRA.2011.942997; Rossa C, 2017, MED BIOL ENG COMPUT, V55, P1401, DOI 10.1007/s11517-016-1599-1; Rossa C, 2017, CONTROL ENG PRACT, V62, P55, DOI 10.1016/j.conengprac.2017.03.004; Russell S., 2002, ARTIF INTELL; Sakes A, 2016, BIOINSPIR BIOMIM, V11, DOI 10.1088/1748-3190/11/2/021001; Sangvinatsos A, 2017, QUANT FINANC, V17, P327, DOI 10.1080/14697688.2016.1256598; Sato RC, 2013, EINSTEIN-SAO PAULO, V11, P128, DOI 10.1590/S1679-45082013000100024; Scali M, 2017, P I MECH ENG H, V231, P250, DOI 10.1177/0954411916672149; Shahriari N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0210052; Siciliano B., 2016, SPRINGER HDB ROBOTIC, DOI DOI 10.1007/978-3-540-30301-5; Simone C, 2002, MODELING NEEDLE INSE; Sprang T, 2016, LECT NOTES COMPUT SC, V9793, P307, DOI 10.1007/978-3-319-42417-0_28; Storms J, 2017, INT J ROBOT RES, V36, P820, DOI 10.1177/0278364917693690; Taieb SB, 2012, RECURSIVE DIRECT MUL, V19; Tang LB, 2007, 2007 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND BIOMIMETICS, VOLS 1-5, P612, DOI 10.1109/ROBIO.2007.4522232; van de Berg NJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40477; van de Berg NJ, 2015, IEEE-ASME T MECH, V20, P2172, DOI 10.1109/TMECH.2014.2365999; van Gerwen DJ, 2014, ANN BIOMED ENG, V42, P685, DOI 10.1007/s10439-013-0924-1; van Gerwen DJ, 2012, MED ENG PHYS, V34, P665, DOI 10.1016/j.medengphy.2012.04.007; Wang YL, 2014, LECT NOTES COMPUT SC, V8866, P69, DOI 10.1007/978-3-319-12436-0_9; Webster RJ, 2006, INT J ROBOT RES, V25, P509, DOI 10.1177/0278364906065388; Yan K, 2009, MED PHYS, V36, P3356, DOI 10.1118/1.3148834; Yang CJ, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18020561; Young P. C., 1989, ADV THEORY APPL, V30, P119; Zhang YX, 2019, J NAVIGATION, V72, P375, DOI 10.1017/S0373463318000760; Zhou T, 2019, INT J ROBOT RES, DOI 10.1177/0278364919872252	73	0	0	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2020	15	5							e0230009	10.1371/journal.pone.0230009	http://dx.doi.org/10.1371/journal.pone.0230009			34	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT7ZX	32379827	Green Published, gold			2023-01-03	WOS:000537285700009
J	[Anonymous]				[Anonymous]			Covid-19 and pregnancy	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material								Guideline: Coronavirus (COVID-19) Infection in pregnancy Published by the Royal College of Obstetricians and Gynaecologists (RCOG), with input from the Royal College of Midwives, the Royal College of Paediatrics and Child Health (RCPH), the Royal College of Anaesthetists, and the Obstetric Anaesthetists' Association. This summary is based on version 8 of the guideline, published on 17 April 2020 (https://www.rcog.org.uk/globalassets/documents/guidelines/2020-04-17-coronavirus-covid-19-infection-in-pregnancy.pdf)										Public Health England, 2020, GUID SOC DIST EV UK; UK Health Security Agency, 2020, GUID SHIELD PROT PEO	2	21	21	1	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 4	2020	369								m1672	10.1136/bmj.m1672	http://dx.doi.org/10.1136/bmj.m1672			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL2FG	32366505				2023-01-03	WOS:000531369700003
J	Hsiang, MS; Ntuku, H; Roberts, KW; Dufour, MSK; Whittemore, B; Tambo, M; McCreesh, P; Medzihradsky, OF; Prach, LM; Siloka, G; Siame, N; Gueye, CS; Schrubbe, L; Wu, L; Scott, V; Tessema, S; Greenhouse, B; Erlank, E; Koekemoer, LL; Sturrock, HJW; Mwilima, A; Katokele, S; Uusiku, P; Bennett, A; Smith, JL; Kleinschmidt, I; Mumbengegwi, D; Gosling, R				Hsiang, Michelle S.; Ntuku, Henry; Roberts, Kathryn W.; Dufour, Mi-Suk Kang; Whittemore, Brooke; Tambo, Munyaradzi; McCreesh, Patrick; Medzihradsky, Oliver F.; Prach, Lisa M.; Siloka, Griffith; Siame, Noel; Gueye, Cara Smith; Schrubbe, Leah; Wu, Lindsey; Scott, Valerie; Tessema, Sofonias; Greenhouse, Bryan; Erlank, Erica; Koekemoer, Lizette L.; Sturrock, Hugh J. W.; Mwilima, Agnes; Katokele, Stark; Uusiku, Petrina; Bennett, Adam; Smith, Jennifer L.; Kleinschmidt, Immo; Mumbengegwi, Davis; Gosling, Roly			Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial	LANCET			English	Article							PLASMODIUM-FALCIPARUM; ELIMINATION; STRATEGIES; AFRICA	Background In low malaria-endemic settings, screening and treatment of individuals in close proximity to index cases, also known as reactive case detection (RACD), is practised for surveillance and response. However, other approaches could be more effective for reducing transmission. We aimed to evaluate the effectiveness of reactive focal mass drug administration (rfMDA) and reactive focal vector control (RAVC) in the low malaria-endemic setting of Zambezi (Namibia). Methods We did a cluster-randomised controlled, open-label trial using a two-by-two factorial design of 56 enumeration area clusters in the low malaria-endemic setting of Zambezi (Namibia). We randomly assigned these clusters using restricted randomisation to four groups: RACD only, rfMDA only, RAVC plus RACD, or rfMDA plus RAVC. RACD involved rapid diagnostic testing and treatment with artemether-lumefantrine and single-dose primaquine, rfMDA involved presumptive treatment with artemether-lumefantrine, and RAVC involved indoor residual spraying with pirimiphos-methyl. Interventions were administered within 500 m of index cases. To evaluate the effectiveness of interventions targeting the parasite reservoir in humans (rfMDA vs RACD), in mosquitoes (RAVC vs no RAVC), and in both humans and mosquitoes (rfMDA plus RAVC vs RACD only), an intention-to-treat analysis was done. For each of the three comparisons, the primary outcome was the cumulative incidence of locally acquired malaria cases. This trial is registered with ClinicalTrials.gov, number NCT02610400. Findings Between Jan 1, 2017, and Dec 31, 2017, 55 enumeration area clusters had 1118 eligible index cases that led to 342 interventions covering 8948 individuals. The cumulative incidence of locally acquired malaria was 30.8 per 1000 person-years (95% CI 12.8-48.7) in the clusters that received rfMDA versus 38.3 per 1000 person-years (23.0-53.6) in the clusters that received RACD; 30.2 per 1000 person-years (15.0-45.5) in the clusters that received RAVC versus 38.9 per 1000 person-years (20.7-57.1) in the clusters that did not receive RAVC; and 25.0 per 1000 person-years (5.2-44.7) in the clusters that received rfMDA plus RAVC versus 41.4 per 1000 person-years (21.5-61.2) in the clusters that received RACD only. After adjusting for imbalances in baseline and implementation factors, the incidence of malaria was lower in clusters receiving rfMDA than in those receiving RACD (adjusted incidence rate ratio 0.52 [95% CI 0.16-0.88], p=0.009), lower in clusters receiving RAVC than in those that did not (0.48 [0.16-0.80], p=0.002), and lower in clusters that received rfMDA plus RAVC than in those receiving RACD only (0.26 [0.10-0.68], p=0.006). No serious adverse events were reported. Interpretation In a low malaria-endemic setting, rfMDA and RAVC, implemented alone and in combination, reduced malaria transmission and should be considered as alternatives to RACD for elimination of malaria.	[Hsiang, Michelle S.; Whittemore, Brooke; McCreesh, Patrick] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Hsiang, Michelle S.; Ntuku, Henry; Roberts, Kathryn W.; McCreesh, Patrick; Medzihradsky, Oliver F.; Prach, Lisa M.; Gueye, Cara Smith; Schrubbe, Leah; Scott, Valerie; Sturrock, Hugh J. W.; Bennett, Adam; Smith, Jennifer L.; Gosling, Roly] Univ Calif San Francisco, Malaria Eliminat Initiat, Global Hlth Grp, San Francisco, CA 94143 USA; [Hsiang, Michelle S.; Medzihradsky, Oliver F.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Hsiang, Michelle S.; Medzihradsky, Oliver F.; Tessema, Sofonias; Greenhouse, Bryan] Univ Calif San Francisco, Div Expt Med, Dept Med, San Francisco, CA 94143 USA; [Tambo, Munyaradzi; Mumbengegwi, Davis; Gosling, Roly] Univ Namibia, Multidisciplinary Res Ctr, Windhoek, Namibia; [Siloka, Griffith; Siame, Noel; Mwilima, Agnes] Zambezi Minist Hlth & Social Serv, Katima, Namibia; [Wu, Lindsey] London Sch Hyg & Trop Med, Dept Immunol & Infect, Fac Infect & Trop Dis, London, England; [Kleinschmidt, Immo] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England; [Erlank, Erica; Koekemoer, Lizette L.; Kleinschmidt, Immo] Univ Witwatersrand, Fac Hlth Sci, Ctr Multidisciplinary Res Malaria, Sch Pathol,Wits Res Inst Malaria,South African Me, Johannesburg, South Africa; [Katokele, Stark; Uusiku, Petrina] Namibia Minist Hlth & Social Serv, Natl Vector Borne Dis Control Programme, Windhoek, Namibia; [Kleinschmidt, Immo] Malaria Eliminat Eight Secretariat, Southern African Dev Commun, Windhoek, Namibia; [Dufour, Mi-Suk Kang] Univ Calif San Francisco, Div Prevent Sci, San Francisco, CA USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Namibia; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Witwatersrand; University of California System; University of California San Francisco	Hsiang, MS (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.	michelle.hsiang@utsouthwestern.edu		Schrubbe, Leah/0000-0002-3039-7155; Koekemoer, Lizette/0000-0003-4236-6345; Roberts, Kathryn W./0000-0002-3558-7644	Novartis Foundation; Bill AMP; Melinda Gates Foundation; Horchow Family Fund	Novartis Foundation(Novartis); Bill AMP; Melinda Gates Foundation(CGIAR); Horchow Family Fund	Novartis Foundation, Bill & Melinda Gates Foundation, and Horchow Family Fund.	Baltzell KA, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2877-9; Bhatt S, 2015, NATURE, V526, P207, DOI 10.1038/nature15535; Bousema T, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001993; Chaccour CJ, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000610; Chanda E, 2018, T ROY SOC TROP MED H, V112, P546, DOI 10.1093/trstmh/try097; Cotter C, 2013, LANCET, V382, P900, DOI 10.1016/S0140-6736(13)60310-4; Eisele TP, 2016, J INFECT DIS, V214, P1831, DOI 10.1093/infdis/jiw416; Feachem RGA, 2019, LANCET, V394, P1056, DOI 10.1016/S0140-6736(19)31139-0; Foy BD, 2019, LANCET, V393, P1517, DOI 10.1016/S0140-6736(18)32321-3; Gueye CS, 2016, MALARIA J, V15, DOI 10.1186/s12936-015-1054-z; Gueye CS, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1190; Hayes RJ, 2009, INTERD STAT, P3; Hemingway J, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0431; Herdiana H, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1523-z; Hofmann N, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001788; Hsiang MS, 2020, CLIN INFECT DIS, V70, P1316, DOI 10.1093/cid/ciz403; Kelly GC, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-108; Kesteman Thomas, 2017, F1000Res, V6, P1932, DOI 10.12688/f1000research.12952.1; Killeen GF, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000211; McCreesh P, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2626-5; Medzihradsky Oliver F, 2018, BMJ Open, V8, pe019294, DOI 10.1136/bmjopen-2017-019294; Mwesigwa J, 2019, CLIN INFECT DIS, V69, P278, DOI 10.1093/cid/ciy870; Newby G., 2018, SCREEN TREAT STRATEG; Newby G, 2015, AM J TROP MED HYG, V93, P125, DOI 10.4269/ajtmh.14-0254; Oxborough RM, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1201-1; Oxborough RM, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-37; Pluess B, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006657.pub2; Rowland M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069516; Shekalaghe SA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-247; Slater HC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09441-1; Smith JL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180845; Sturrock HJW, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001467; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; Tripura R, 2018, CLIN INFECT DIS, V67, P817, DOI 10.1093/cid/ciy196; von Seidlein L, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002745; WHO, 2015, WHO EV REV GROUP MAS; WHO, 2017, FRAM MAL EL; Wu L, 2015, NATURE, V528, pS86, DOI 10.1038/nature16039	38	27	27	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 25	2020	395	10233					1361	1373						13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP7SQ	32334702	Green Published, hybrid			2023-01-03	WOS:000552401700028
J	Schneider, PP; Pouwels, XGLV; Passos, VL; Ramaekers, BLT; Geurts, SME; Ibragimova, KIE; de Boer, M; Erdkamp, F; Vriens, BEPJ; van de Wouw, AJ; den Boer, MO; Pepels, MJ; Tjan-Heijnen, VCG; Joore, MA				Schneider, Paul P.; Pouwels, Xavier G. L. V.; Passos, Valeria Lima; Ramaekers, Bram L. T.; Geurts, Sandra M. E.; Ibragimova, Khava I. E.; de Boer, Maaike; Erdkamp, Frans; Vriens, Birgit E. P. J.; van de Wouw, Agnes J.; den Boer, Marien O.; Pepels, Manon J.; Tjan-Heijnen, Vivianne C. G.; Joore, Manuela A.			Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands	PLOS ONE			English	Article							ECONOMIC BURDEN	Objective In breast cancer patients, treatment at the end of life accounts for a major share of medical spending. However, little is known about the variability of cost trajectories between patients. This study aims to identify underlying latent groups of advanced breast cancer patients with similar cost trajectories over the last year before death. Methods Data from deceased advanced breast cancer patients, diagnosed between 2010 and 2017, were retrieved from the Southeast Netherlands Advanced Breast Cancer (SONABRE) Registry. Costs of hospital care over the last twelve months before death were analyzed, and the variability of longitudinal patterns between patients were explored using group-based trajectory modeling. Descriptive statistics and multinomial logistic regression were applied to investigate differences between the identified latent groups. Results We included 558 patients. Over the last twelve months before death, mean hospital costs were (sic)2,255 (SD = (sic)492) per month. Costs increased over the last five months and reached a maximum of (sic)3,614 in the last month of life, driven by hospital admissions, while spending for medication declined over the last three months of life. Based on patients' individual cost trajectories, we identified six latent groups with distinct longitudinal patterns, of which only two showed a marked increase in costs over the last twelve months before death. Latent groups were constituted of heterogeneous patients, and clinical characteristics explained membership only to a limited extent. Conclusions The average costs of advanced breast cancer patients increased towards the end of life. However, we uncovered several latent groups of patients with divergent cost trajectories, which did not reflect the overall increasing trend. The mechanisms underlying the variability in cost trajectories warrants further research.	[Schneider, Paul P.; Pouwels, Xavier G. L. V.; Ramaekers, Bram L. T.; Joore, Manuela A.] Maastricht Univ Med Ctr, Dept Clin Epidemiol & Med Technol Assessment KEMT, Maastricht, Netherlands; [Schneider, Paul P.] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England; [Passos, Valeria Lima] Maastricht Univ, Dept Methodol & Stat, CAPHRI Care & Publ Hlth Res Inst, Maastricht, Netherlands; [Geurts, Sandra M. E.; Ibragimova, Khava I. E.; de Boer, Maaike; Tjan-Heijnen, Vivianne C. G.] Maastricht Univ Med Ctr, GROW Sch Oncol & Dev Biol, Dept Med Oncol, Maastricht, Netherlands; [Erdkamp, Frans] Zuyderland Med Ctr, Sittard Geleen, Netherlands; [Vriens, Birgit E. P. J.] Catharina Hosp, Eindhoven, Netherlands; [van de Wouw, Agnes J.] VieCuri Med Ctr, Venlo, Netherlands; [den Boer, Marien O.] Laurentius Hosp Roermond, Roermond, Netherlands; [Pepels, Manon J.] Elkerliek Hosp, Helmond, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); University of Sheffield; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Catharina Hospital; VieCuri Medical Center	Schneider, PP (corresponding author), Maastricht Univ Med Ctr, Dept Clin Epidemiol & Med Technol Assessment KEMT, Maastricht, Netherlands.; Schneider, PP (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England.	p.schneider@sheffield.ac.uk	Pouwels, Xavier/AAQ-2092-2021; Lima Passos, Valeria/AFT-1000-2022	Pouwels, Xavier/0000-0003-3563-0013; Schneider, Paul/0000-0003-3552-1087; Joore, Manuela/0000-0002-5649-6768; Lima Passos, Valeria/0000-0003-0580-6639; Ramaekers, Bram/0000-0001-5785-9228	Netherlands Organization for Health Research and Development (ZonMw); Novartis; Pfizer; Roche Nederland B.V.; Eisai B.V.; Eli Lilly NL; Wellcome [108903/B/15/Z]; University of Sheffield	Netherlands Organization for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development); Novartis(Novartis); Pfizer(Pfizer); Roche Nederland B.V.; Eisai B.V.; Eli Lilly NL(Eli Lilly); Wellcome; University of Sheffield	The data collection of the Southeast Netherlands Advanced Breast Cancer Registry was funded by the Netherlands Organization for Health Research and Development (ZonMw), Novartis, Pfizer, Roche Nederland B.V., Eisai B.V., and Eli Lilly NL. This work was supported by funding from Wellcome [108903/B/15/Z] and the University of Sheffield. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Aldridge MD, 2015, AM J PUBLIC HEALTH, V105, P2411, DOI 10.2105/AJPH.2015.302889; Andridge RR, 2010, INT STAT REV, V78, P40, DOI 10.1111/j.1751-5823.2010.00103.x; Bramley T, 2016, J MED ECON, V19, P1075, DOI 10.1080/13696998.2016.1197130; Centraal Bureau voor de Statisitek, 2017, CONS PRIC IND 2017; Chastek B, 2012, J ONCOL PRACT, V8, p75S, DOI 10.1200/JOP.2011.000469; Clark SL., 2009, RELATING LATENT CLAS; Foster TS, 2011, CANCER TREAT REV, V37, P405, DOI 10.1016/j.ctrv.2010.12.008; Jiang JF, 2016, CLIN TRANSL GASTROEN, V7, DOI 10.1038/ctg.2016.39; Lauffenburger JC, 2017, MED CARE, V55, P64, DOI 10.1097/MLR.0000000000000623; Lobbezoo DJA, 2013, BREAST CANCER RES TR, V141, P507, DOI 10.1007/s10549-013-2711-y; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; Nielsen JD, 2014, COMMUN STAT-THEOR M, V43, P4337, DOI 10.1080/03610926.2012.719986; Pearce N, 2000, J EPIDEMIOL COMMUN H, V54, P326, DOI 10.1136/jech.54.5.326; Reed E, 2015, BMJ SUPPORT PALLIAT, V5, P358, DOI 10.1136/bmjspcare-2012-000415; Riley GF, 2010, HEALTH SERV RES, V45, P565, DOI 10.1111/j.1475-6773.2010.01082.x; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Venables W.N., 2002, MODERN APPL STAT S; von Wyl V, 2018, BMJ SUPPORT PALLIAT, V8, P325, DOI 10.1136/bmjspcare-2014-000784; Vondeling GT, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4158-3	20	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2020	15	4							e0230909	10.1371/journal.pone.0230909	http://dx.doi.org/10.1371/journal.pone.0230909			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR8WI	32271794	Green Published, Green Accepted, gold			2023-01-03	WOS:000535977000038
J	Mangine, GT; Stratton, MT; Almeda, CG; Roberts, MD; Esmat, TA; VanDusseldorp, TA; Feito, Y				Mangine, Gerald T.; Stratton, Matthew T.; Almeda, Christian G.; Roberts, Michael D.; Esmat, Tiffany A.; VanDusseldorp, Trisha A.; Feito, Yuri			Physiological differences between advanced CrossFit athletes, recreational CrossFit participants, and physically-active adults	PLOS ONE			English	Article							RESTING METABOLIC-RATE; ALL-OUT TEST; CRITICAL POWER; ANAEROBIC THRESHOLD; BODY-COMPOSITION; ECHO INTENSITY; OXYGEN-UPTAKE; GAS-EXCHANGE; PERFORMANCE; MUSCLE	This investigation examined anthropometric, hormonal, and physiological differences between advanced (ADV; n = 8, 27.8 +/- 4.2 years, 170 +/- 11 cm, 79.8 +/- 13.3 kg) and recreational (REC; n = 8, 33.5 +/- 8.1 years, 172 +/- 14 cm, 76.3 +/- 19.5 kg) CrossFit (CF) trained participants in comparison to physically-active controls (CON; n = 7, 27.5 +/- 6.7 years, 171 +/- 14 cm, 74.5 +/- 14.3 kg). ADV and REC were distinguished by their past competitive success. REC and CON were resistance-trained (>2 years) and exercised on 3-5 days.wk(-1) for the past year, but CON utilized traditional resistance and cardiovascular exercise. All participants provided a fasted, resting blood sample and completed assessments of resting metabolic rate, body composition, muscle morphology, isometric mid-thigh pull strength, peak aerobic capacity, and a 3-minute maximal cycle ergometer sprint across two separate occasions (separated by 3-7 days). Blood samples were analyzed for testosterone, cortisol, and insulin-like growth factor-1. Compared to both REC and CON, one-way analysis of variance revealed ADV to possess lower body fat percentage (6.7-8.3%, p = 0.007), greater bone and non-bone lean mass (12.5-26.8%, p <= 0.028), muscle morphology characteristics (14.2-59.9%, p < 0.05), isometric strength characteristics (15.4-41.8%, p < 0.05), peak aerobic capacity (18.8-19.1%, p = 0.002), and 3-minute cycling performance (15.4-51.1%, p <= 0.023). No differences were seen between REC and CON, or between all groups for resting metabolic rate or hormone concentrations. These data suggest ADV possess several physiological advantages over REC and CON, whereas similar physiological characteristics were present in individuals who have been regularly participating in either CF or resistance and cardiovascular training for the past year.	[Mangine, Gerald T.; Stratton, Matthew T.; Almeda, Christian G.; Esmat, Tiffany A.; VanDusseldorp, Trisha A.; Feito, Yuri] Kennesaw State Univ, Exercise Sci & Sport Management, Kennesaw, GA 30144 USA; [Roberts, Michael D.] Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA	University System of Georgia; Kennesaw State University; Auburn University System; Auburn University	Mangine, GT (corresponding author), Kennesaw State Univ, Exercise Sci & Sport Management, Kennesaw, GA 30144 USA.	gmangine@kennesaw.edu	; Feito, Yuri/D-8255-2013	Mangine, Gerald/0000-0003-2718-2564; Feito, Yuri/0000-0001-6790-6294				Arroyo E, 2018, CLIN PHYSIOL FUNCT I, V38, P155, DOI 10.1111/cpf.12403; Astorino T.A., 2000, J EXERC PHYSL ONLINE, V3, P1; BAHR R, 1991, ACTA PHYSIOL SCAND, V141, P555, DOI 10.1111/j.1748-1716.1991.tb09117.x; BARBIERI R, 2017, J HIGH ENERGY PHYS, DOI DOI 10.4081/EJTM.2019.8331; Barfield J., 2014, J SPORT HUMAN PERFOR, V2, P23; Barfield JP, 2012, PHYS EDUC-US, V69, P325; BEAVER WL, 1986, J APPL PHYSIOL, V60, P2020, DOI 10.1152/jappl.1986.60.6.2020; Beckham G, 2013, J SPORT MED PHYS FIT, V53, P573; Bellar D, 2015, BIOL SPORT, V32, P315, DOI 10.5604/20831862.1174771; Bemben MG, 2002, J STRENGTH COND RES, V16, P103, DOI 10.1519/00124278-200202000-00016; Bergstrom HC, 2014, J STRENGTH COND RES, V28, P592, DOI 10.1519/JSC.0b013e31829b576d; Bergstrom HC, 2013, RES Q EXERCISE SPORT, V84, P232, DOI 10.1080/02701367.2013.784723; Buckley S, 2015, APPL PHYSIOL NUTR ME, V40, P1157, DOI 10.1139/apnm-2015-0238; Burnley M, 2006, MED SCI SPORT EXER, V38, P1995, DOI 10.1249/01.mss.0000232024.06114.a6; Butcher SJ, 2015, OPEN ACCESS J SPORTS, V6, P241, DOI 10.2147/OAJSM.S88265; Cadore EL, 2012, EXP GERONTOL, V47, P473, DOI 10.1016/j.exger.2012.04.002; Carnes AJ, 2019, INT J SPORT PHYSIOL, V14, P105, DOI 10.1123/ijspp.2018-0040; Casto KV, 2016, HORM BEHAV, V82, P21, DOI 10.1016/j.yhbeh.2016.04.004; Chapman DW, 2008, EUR J APPL PHYSIOL, V104, P531, DOI 10.1007/s00421-008-0806-7; Chicharro JL, 2000, BRIT J SPORT MED, V34, P450, DOI 10.1136/bjsm.34.6.450; Compher C, 2006, J AM DIET ASSOC, V106, P881, DOI 10.1016/j.jada.2006.02.009; CrossFit, 2019, CROSSFIT GAM; CrossFit, 2019, OP WORK CROSSFIT GAM; CrossFit, 2019, FIND FITT EARTH; de Sousa AF, 2016, J EXERCISE PHYSL ONL, V19; Feito Y, 2019, HUMAN MOVEMENT, V20, P1, DOI [10.5114/hm.2019.81020, DOI 10.5114/HM.2019.81020]; Feito Y, 2019, SPORTS, V7, DOI 10.3390/sports7020051; Feito Y, 2019, APPL PHYSIOL NUTR ME, V44, P727, DOI 10.1139/apnm-2018-0509; Feito Y, 2018, SPORTS, V6, DOI 10.3390/sports6030076; Glassman G, 2011, CROSSFIT J; Haff GG, 2015, J STRENGTH COND RES, V29, P386, DOI 10.1519/JSC.0000000000000705; Haff GG., 2015, NSCAS ESSENTIALS TAC, V1st ed, pp. 181; Heinrich KM, 2012, MIL MED, V177, P1125, DOI 10.7205/MILMED-D-12-00143; Hoffman JR, 2009, J STRENGTH COND RES, V23, P2173, DOI 10.1519/JSC.0b013e3181bcd5fe; Ichinose Y, 1998, EUR J APPL PHYSIOL O, V78, P109, DOI 10.1007/s004210050394; Kivlighan KT, 2006, PSYCHONEUROENDOCRINO, V31, P703, DOI 10.1016/j.psyneuen.2006.01.007; Kraemer WJ, 2005, SPORTS MED, V35, P339, DOI 10.2165/00007256-200535040-00004; Kumagai K, 2000, J APPL PHYSIOL, V88, P811, DOI 10.1152/jappl.2000.88.3.811; Lee EC, 2017, J STRENGTH COND RES, V31, P2920, DOI 10.1519/JSC.0000000000002122; Lieber RL, 2000, MUSCLE NERVE, V23, P1647, DOI 10.1002/1097-4598(200011)23:11<1647::AID-MUS1>3.3.CO;2-D; Mangine GT, 2019, SPORTS, V7, DOI 10.3390/sports7090199; Mangine GT, 2018, SPORTS MED-OPEN, V4, DOI 10.1186/s40798-018-0156-x; Mangine GT, 2014, J STRENGTH COND RES, V28, P2406, DOI 10.1519/JSC.0000000000000550; Mangine GT, 2013, INT J SPORT PHYSIOL, V8, P510, DOI 10.1123/ijspp.8.5.510; Marsh AP, 1997, MED SCI SPORT EXER, V29, P1225, DOI 10.1097/00005768-199709000-00016; Martinez-Gomez R, 2019, INT J SPORTS MED, V40, P592, DOI 10.1055/a-0960-9717; McCrory MA, 1998, J APPL PHYSIOL, V84, P1475, DOI 10.1152/jappl.1998.84.4.1475; McGee KJ, 2003, J STRENGTH COND RES, V17, P6; McGuigan MR, 2008, J SPORT SCI MED, V7, P101; MEDBO JI, 1989, J APPL PHYSIOL, V67, P1881, DOI 10.1152/jappl.1989.67.5.1881; Miller T, 2012, NSCAS GUIDE TESTS AS; O'Connor H., 2011, Sport and exercise nutrition, P210; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; Rouder JN, 2012, J MATH PSYCHOL, V56, P356, DOI 10.1016/j.jmp.2012.08.001; Scanlon TC, 2013, MUSCLE NERVE, DOI [10.1152/jappl.2000.88.3.811, DOI 10.1152/JAPPL.2000.88.3.811]; Schipilow JD, 2013, BONE, V56, P281, DOI 10.1016/j.bone.2013.06.014; Serafini PR, 2018, J STRENGTH COND RES, V32, P3474, DOI 10.1519/JSC.0000000000001843; Sheppard JM., 2015, ESSENTIALS STRENGTH, V4th ed, pp. 439; Snell PG, 2007, MED SCI SPORT EXER, V39, P103, DOI 10.1249/01.mss.0000241641.75101.64; Stock MS, 2017, MUSCLE NERVE, V55, P685, DOI 10.1002/mus.25395; Stone MH, 2003, J STRENGTH COND RES, V17, P739, DOI 10.1519/00124278-200311000-00019; Thompson WR, 2017, ACSMS HEALTH FIT J, V21, P10; Vanhatalo A, 2007, MED SCI SPORT EXER, V39, P548, DOI 10.1249/mss.0b013e31802dd3e6; Wagenmakers EJ, 2018, PSYCHON B REV, V25, P58, DOI [10.3758/s13423-017-1323-7, 10.3758/s13423-017-1343-3]; Wang ZM, 1998, INT J OBESITY, V22, P329, DOI 10.1038/sj.ijo.0800590; WASSERMAN K, 1964, AM J CARDIOL, V14, P844, DOI 10.1016/0002-9149(64)90012-8; WASSERMAN K, 1973, J APPL PHYSIOL, V35, P236, DOI 10.1152/jappl.1973.35.2.236; Young HJ, 2015, MUSCLE NERVE, V52, P963, DOI 10.1002/mus.24656	69	18	18	7	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2020	15	4							e0223548	10.1371/journal.pone.0223548	http://dx.doi.org/10.1371/journal.pone.0223548			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8PU	32255792	gold, Green Submitted, Green Published			2023-01-03	WOS:000535959400002
J	Sands, M; Aunger, R				Sands, Madeline; Aunger, Robert			Determinants of hand hygiene compliance among nurses in US hospitals: A formative research study	PLOS ONE			English	Article							PROFESSIONAL IDENTITY; PATIENT SAFETY; CARE; BEHAVIOR; HABIT; WORK; IMPACT; PREVENTION; PSYCHOLOGY; INFECTION	Hand hygiene is the simplest and most effective measure for preventing healthcare-associated infections. Despite the simplicity of this procedure and advances made in infection control, hospital health care workers' compliance to hand hygiene recommendations is generally low. Nurses have the most frequent patient care interactions, and thus more opportunities to practice hand hygiene. As such, it is important to identify and understand determinants of nurses' reported compliance. Formative research was undertaken to assess the potential impact of several unexamined factors that could influence HH among nurses: professional role and status, social affiliation, social norms, and physical modifications to the work environment (as well as institutional factors like safety climate). A survey questionnaire was developed primarily to inform the creation of a behaviour change intervention. The survey looked at how these factors influence HH among nurses and sought to identify barriers and levers to reported hand hygiene. It was administered to a survey panel of acute care nurses, working in US hospitals, with a year or more of experience. Multivariate regression modelling suggested that reported hand hygiene compliance was most likely to be a function of a hospital management's communication openness, perceived performance by peers, increased interactions with patients and other staff members, and the reduction in stress, busyness, and cognitive load associated with role performance. A powerful, effective intervention on HH among nurses therefore could be directed at improving communication openness, consider the impact of perceived performance by peers, increase interactions with patients and staff, and determine how to reduce the stress and cognitive load associated with role performance.	[Sands, Madeline; Aunger, Robert] London Sch Hyg & Trop Med, Dept Infect Dis, London, England; [Sands, Madeline] Univ Arizona, Coll Med, Tucson, AZ USA	University of London; London School of Hygiene & Tropical Medicine; University of Arizona	Sands, M (corresponding author), London Sch Hyg & Trop Med, Dept Infect Dis, London, England.; Sands, M (corresponding author), Univ Arizona, Coll Med, Tucson, AZ USA.	mhsands@email.arizona.edu			London School of Hygiene and Tropical Medicine	London School of Hygiene and Tropical Medicine	MHS and RA received financial compensation as affiliates of the London School of Hygiene and Tropical Medicine, which served as a paid consultant to GOJO Industries, Inc. for the creation and evaluation of the intervention. The funders had no role in study design, data analysis, decision to publish, or preparation of the manuscript.	Alzyood M, 2018, J CLIN NURS, V27, P1329, DOI 10.1111/jocn.14305; [Anonymous], 2013, B MUSEI CIVICI VENEZ, V8, P49; Ashforth B.E., 2000, ROLE TRANSITIONS ORG; Aunger R., 2015, GAINING CONTROL HUMA; Aunger R, 2016, HEALTH PSYCHOL REV, V10, P425, DOI 10.1080/17437199.2016.1219673; Azoulay E, 2009, AM J RESP CRIT CARE, V180, P853, DOI 10.1164/rccm.200810-1614OC; Barker RG, 1968, ECOLOGICAL PSYCHOL C, Vvi; Baumeister R.F., 1998, HDB, V1, P680; Berger Z, 2014, BMJ QUAL SAF, V23, P548, DOI 10.1136/bmjqs-2012-001769; Bicchieri C, 2000, THEOR DEC A, V28, P153; Bicchieri C, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01418; Bicchieri C, 2010, POLIT PHILOS ECON, V9, P297, DOI 10.1177/1470594X10369276; Cantrell D, 2009, AM J INFECT CONTROL, V37, P301, DOI 10.1016/j.ajic.2008.05.001; Casida J, 2008, NURS ECON, V26, P106; Chreim S, 2007, ACAD MANAGE J, V50, P1515; Cimiotti JP, 2012, AM J INFECT CONTROL, V40, P486, DOI 10.1016/j.ajic.2012.02.029; Dai HC, 2015, J APPL PSYCHOL, V100, P846, DOI 10.1037/a0038067; Danner UN, 2008, BRIT J SOC PSYCHOL, V47, P245, DOI 10.1348/014466607X230876; DEJOY DM, 2004, PROF SAF, V49, P50; Erasmus V, 2010, INFECT CONT HOSP EP, V31, P283, DOI 10.1086/650451; Fagermoen MS, 1997, J ADV NURS, V25, P434, DOI 10.1046/j.1365-2648.1997.1997025434.x; Franken R., 2001, HUMAN MOTIVATION; Fuller C, 2011, INFECT CONT HOSP EP, V32, P1194, DOI 10.1086/662619; Gardner B, 2014, BRIT J HEALTH PSYCH, V19, P258, DOI 10.1111/bjhp.12060; Gardner B, 2012, BRIT J GEN PRACT, V62, P664, DOI 10.3399/bjgp12X659466; Goodrick E, 2010, J MANAGE STUD, V47, P55, DOI 10.1111/j.1467-6486.2009.00860.x; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Graybiel AM, 2008, ANNU REV NEUROSCI, V31, P359, DOI 10.1146/annurev.neuro.29.051605.112851; Gurses AP, 2009, HEALTH SERV RES, V44, P422, DOI 10.1111/j.1475-6773.2008.00934.x; Hessels AJ, 2016, J HOSP INFECT, V92, P349, DOI 10.1016/j.jhin.2015.08.023; Hughes R, 2002, J ADV NURS, V37, P382, DOI 10.1046/j.1365-2648.2002.02100.x; Huis A, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-92; Jackson C, 2014, INT J NURS STUD, V51, P400, DOI 10.1016/j.ijnurstu.2013.07.002; Jang JH, 2010, INFECT CONT HOSP EP, V31, P144, DOI 10.1086/649792; Jenner EA, 2006, J HOSP INFECT, V63, P418, DOI 10.1016/j.jhin.2006.03.012; Kiekkas P, 2008, J NURS SCHOLARSHIP, V40, P385, DOI 10.1111/j.1547-5069.2008.00254.x; Lankford MG, 2003, EMERG INFECT DIS, V9, P217; Leary MR., 2011, HDB SELF IDENTITY; Longtin Yves, 2011, N Engl J Med, V364, pe24, DOI 10.1056/NEJMvcm0903599; Monsalve MN, 2014, INFECT CONT HOSP EP, V35, P1277, DOI 10.1086/678068; Muhlenkamp AF, 1972, J VOCAT BEHAV, V2, P261; Organization WH, 2009, WHO GUID HAND HYG HL; Oyserman D., 2007, HDB SOCIAL PSYCHOL, P432; Pratt MG, 2006, ACAD MANAGE J, V49, P235, DOI 10.5465/AMJ.2006.20786060; Presti P. Lo, 2016, ADAPT BEHAV, V24, P3; Raboud J, 2004, INFECT CONT HOSP EP, V25, P198, DOI 10.1086/502377; Randle J, 2003, J ADV NURS, V43, P395, DOI 10.1046/j.1365-2648.2003.02728.x; RUIZ MCJ, 1981, NURS RES, V30, P177; Scheithauer S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-367; Sorra J, 2021, AHRQ PUBLICATION, V19, P76; Sorra JS, 2004, AHRQ PUBLICATION, V04-0041; Srigley JA, 2015, J HOSP INFECT, V91, P202, DOI 10.1016/j.jhin.2015.06.019; Stock S, 2016, NURS EDUC TODAY, V36, P407, DOI 10.1016/j.nedt.2015.10.012; Sutton R.S., 1998, INTRO REINFORCEMENT, V135; Takase M, 2006, J ADV NURS, V53, P333, DOI 10.1111/j.1365-2648.2006.03729.x; ten Hoeve Y, 2014, J ADV NURS, V70, P295, DOI 10.1111/jan.12177; US Agency for Healthcare Research and Quality, 2010, NAT HEALTHC QUAL REP, P2635; Vaismoradi M, 2015, J CLIN NURS, V24, P627, DOI 10.1111/jocn.12664; van den Berg TIJ, 2006, INT J NURS STUD, V43, P491, DOI 10.1016/j.ijnurstu.2005.06.007; Verplanken B, 1997, EUR J SOC PSYCHOL, V27, P539, DOI 10.1002/(SICI)1099-0992(199709/10)27:5<539::AID-EJSP831>3.3.CO;2-1; VERPLANKEN B, 1994, J APPL SOC PSYCHOL, V24, P285, DOI 10.1111/j.1559-1816.1994.tb00583.x; Verplanken B, 2003, J APPL SOC PSYCHOL, V33, P1313, DOI 10.1111/j.1559-1816.2003.tb01951.x; White KM, 2015, HEALTH PROMOT J AUST, V26, P74, DOI 10.1071/HE14059; Wood W, 2016, ANNU REV PSYCHOL, V67, P289, DOI 10.1146/annurev-psych-122414-033417; Young DR, 2006, HEALTH EDUC BEHAV, V33, P97, DOI 10.1177/1090198105282444; Zingg W, 2015, LANCET INFECT DIS, V15, P212, DOI 10.1016/S1473-3099(14)70854-0	66	13	13	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 7	2020	15	4							e0230573	10.1371/journal.pone.0230573	http://dx.doi.org/10.1371/journal.pone.0230573			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LI0PB	32255783	gold, Green Published			2023-01-03	WOS:000529186800001
J	Zhao, J; Sun, Y; Lin, H; Chou, FJ; Xiao, Y; Jin, RA; Cai, XJ; Chang, CS				Zhao, Jie; Sun, Yin; Lin, Hui; Chou, Fuju; Xiao, Yao; Jin, Ren'an; Cai, Xiujun; Chang, Chawnshang			Olaparib and enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a-5p/BRCA1 signaling	FASEB JOURNAL			English	Article						androgen receptor; enzalutamide; hepatocellular carcinoma; olaparib; synergistic effect	UNRESECTABLE HEPATOCELLULAR-CARCINOMA; PROSTATE-CANCER; ANTIANDROGEN THERAPY; DNA-DAMAGE; REPAIR; SORAFENIB; MIR-146A; GENES; PATHOGENESIS; INHIBITION	Hepatocellular carcinoma (HCC) is one of most common cancers worldwide, however, the treatment for advanced HCC remains unsatisfactory. We focused on the function of the androgen receptor (AR) in HCC and tried to find new treatment strategy based on antiandrogen enzalutamide (Enz). Here, we found that olaparib, a FDA-approved PARP inhibitor, could enhance the cytotoxicity in HCC cells with a lower BRCA1 expression, and suppressing the AR with either Enz or AR-shRNA could further increase the olaparib sensitivity to better suppress the HCC cell growth via a synergistic mechanism that may involve suppressing the expression of BRCA1 and other DNA damage response (DDR) genes. Mechanism studies revealed that Enz/AR signaling might transcriptionally regulate the miR-146a-5p expression via binding to the Androgen Response Elements on its 5 ' promoter region, which could then lead to suppress the homologous recombination-related BRCA1 expression via direct binding to the mRNA 3 ' UTR. Preclinical studies using an in vivo mouse model also demonstrated that combining Enz plus olaparib led to better suppression of the HCC progression. Together, these in vitro/in vivo data suggest that combining Enz and olaparib may help in the development of a novel therapy to better suppress the HCC progression.	[Zhao, Jie; Lin, Hui; Jin, Ren'an; Cai, Xiujun] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gen Surg,Innovat Ctr Minimally Invas Tech &, Hangzhou 310016, Peoples R China; [Zhao, Jie; Lin, Hui; Jin, Ren'an; Cai, Xiujun] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Urol,Innovat Ctr Minimally Invas Tech & Devi, Hangzhou, Peoples R China; [Zhao, Jie; Sun, Yin; Chou, Fuju; Xiao, Yao; Jin, Ren'an; Chang, Chawnshang] Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Zhao, Jie; Sun, Yin; Chou, Fuju; Xiao, Yao; Jin, Ren'an; Chang, Chawnshang] Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Zhao, Jie; Sun, Yin; Chou, Fuju; Xiao, Yao; Jin, Ren'an; Chang, Chawnshang] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA; [Chang, Chawnshang] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung, Taiwan	Zhejiang University; Zhejiang University; University of Rochester; University of Rochester; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan	Cai, XJ (corresponding author), Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gen Surg,Innovat Ctr Minimally Invas Tech &, Hangzhou 310016, Peoples R China.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA.	srrsh_cxj@zju.edu.cn; chang@urmc.rochester.edu	Xiao, Yao/AEX-1775-2022	Xiao, Yao/0000-0002-4638-4148; Chang, Chawnshang/0000-0001-8510-3516	NCI NIH HHS [R01 CA156700] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asim M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00393-y; Bandiera S, 2016, J VIROL, V90, P6387, DOI 10.1128/JVI.00619-16; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Brechot C, 2004, GASTROENTEROLOGY, V127, pS56, DOI 10.1053/j.gastro.2004.09.016; Chen CF, 2010, HEPATOLOGY, V52, P1690, DOI 10.1002/hep.23847; CHOU TC, 1994, JNCI-J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517; Cui YJ, 2016, ONCOL RES, V23, P275, DOI 10.3727/096504016X14562725373798; Di Maio M, 2006, ANN NY ACAD SCI, V1089, P252, DOI 10.1196/annals.1386.007; El-Amm J, 2013, CLIN MED INSIGHTS-ON, V7, P235, DOI 10.4137/CMO.S11670; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Fautrel A, 2005, J HEPATOL, V43, P288, DOI 10.1016/j.jhep.2005.02.020; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Garcia AI, 2011, EMBO MOL MED, V3, P279, DOI 10.1002/emmm.201100136; Grimaldi C, 1998, J CLIN ONCOL, V16, P411, DOI 10.1200/JCO.1998.16.2.411; GUPTA S, 1988, J CLIN GASTROENTEROL, V10, P651, DOI 10.1097/00004836-198812000-00016; Hu QM, 2018, ONCOL REP, V39, P3015, DOI 10.3892/or.2018.6391; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Lacona JR, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1533; Li Y., 2010, CANCER RES, V70, P5703, DOI [10.1158/1538-7445.AM10-5703, DOI 10.1158/1538-7445.AM10-5703]; Li YL, 2016, ONCOTARGET, V7, P59287, DOI 10.18632/oncotarget.11040; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]; Ma CL, 2008, GASTROENTEROLOGY, V135, P947, DOI 10.1053/j.gastro.2008.05.046; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159-8290.CD-13-0172; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Sasaki H, 2016, CLIN GENITOURIN CANC, V14, pE493, DOI 10.1016/j.clgc.2016.04.002; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sun Q, 2014, PROSTATE, V74, P1613, DOI 10.1002/pros.22878; Tangkijvanich P, 2004, WORLD J GASTROENTERO, V10, P1547, DOI 10.3748/wjg.v10.i11.1547; Wang C, 2016, BRIT J CANCER, V115, P1548, DOI 10.1038/bjc.2016.367; Warde P, 2011, LANCET, V378, P2104, DOI 10.1016/S0140-6736(11)61095-7; Wu MH, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001143; Xu JJ, 2016, EBIOMEDICINE, V12, P55, DOI 10.1016/j.ebiom.2016.07.013; Yang SF, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/153867	42	6	7	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2020	34	4					5877	5891		10.1096/fj.201903045RR	http://dx.doi.org/10.1096/fj.201903045RR			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LJ5ZA	32134529	Green Accepted, Green Submitted, Bronze			2023-01-03	WOS:000530242100071
J	Vallabhajosyula, S; Ingram, C				Vallabhajosyula, Saraschandra; Ingram, Cory			In high-risk ICU patients, early palliative care consultation increased transition to DNR/DNI status	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Vallabhajosyula, Saraschandra; Ingram, Cory] Mayo Clin, Rochester, MN 55902 USA	Mayo Clinic	Vallabhajosyula, S (corresponding author), Mayo Clin, Rochester, MN 55902 USA.		Vallabhajosyula, Saraschandra/I-9707-2019	Vallabhajosyula, Saraschandra/0000-0002-1631-8238				Aslakson RA, 2014, CRIT CARE MED, V42, P2418, DOI 10.1097/CCM.0000000000000573; Kamal AH, 2017, AM J MED, V130, P113, DOI 10.1016/j.amjmed.2016.08.046; Vallabhajosyula S, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.011954	3	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 17	2020	172	6					JC30	JC30		10.7326/ACPJ202003170-030	http://dx.doi.org/10.7326/ACPJ202003170-030			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV1FY	32176896				2023-01-03	WOS:000520170800013
J	Ackerman, LS; Chopik, WJ				Ackerman, Lindsay S.; Chopik, William J.			Individual differences in personality predict the use and perceived effectiveness of essential oils	PLOS ONE			English	Article							HEALTH-RELATED BEHAVIORS; RELIGIOSITY; CONSCIENTIOUSNESS; AROMATHERAPY; INHALATION; MOOD; SPIRITUALITY; COMPONENTS; BULLSHIT; STRESS	Essential oil (EO) use is growing in popularity and ostensibly used for treating or preventing various ailments or conditions. Despite the increase in use, there is a paucity of research on psychosocial predictors of EO use and their perceived effectiveness. However, several psychosocial characteristics are associated with health-promoting behavior and a tendency to believe in homeopathic cures. In the current study, we examined a variety of individual differences in the use and perceived effectiveness of essential oils in a sample of 1,202 participants (M-age = 31.33, SD = 13.77; 61.7% women, 75.6% Caucasian). We found that receptivity to pseudo-profound fabricated statements and religiosity were the most consistent predictors of greater use of, perceived effectiveness of, and a willingness to spend more money on EOs.	[Ackerman, Lindsay S.; Chopik, William J.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA	Michigan State University	Chopik, WJ (corresponding author), Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA.	chopikwi@msu.edu		Chopik, William/0000-0003-1748-8738				Aguiar JJS, 2015, EUR J INTEGR MED, V7, P151, DOI 10.1016/j.eujim.2014.10.005; Ahuja K, 2018, ESSENTIAL OILS MARKE; Al-Lahham S, 2020, EUR J INTEGR MED, V33, DOI 10.1016/j.eujim.2019.101039; Ali Babar, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P601, DOI 10.1016/j.apjtb.2015.05.007; [Anonymous], 2019, ESSENTIAL OIL MERRIA; Barros FJ, 2016, EUR J INTEGR MED, V8, P505, DOI 10.1016/j.eujim.2016.02.011; Batish DR, 2008, FOREST ECOL MANAG, V256, P2166, DOI 10.1016/j.foreco.2008.08.008; Boersma H, 2016, ANOINTING SICK; Bogg T, 2004, PSYCHOL BULL, V130, P887, DOI 10.1037/0033-2909.130.6.887; Bogg T, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00370; Britt RK, 2013, SAGE OPEN, V3, DOI 10.1177/2158244013508957; Budhwar S, 2020, AM J REPROD IMMUNOL, V83, DOI 10.1111/aji.13201; Burits M, 2000, PHYTOTHER RES, V14, P323, DOI 10.1002/1099-1573(200008)14:5&lt;323::AID-PTR621&gt;3.0.CO;2-Q; CACIOPPO JT, 1982, J PERS SOC PSYCHOL, V42, P116, DOI 10.1037/0022-3514.42.1.116; CARSON CF, 1995, J APPL BACTERIOL, V78, P264, DOI 10.1111/j.1365-2672.1995.tb05025.x; Charles CH, 2004, J CLIN PERIODONTOL, V31, P878, DOI 10.1111/j.1600-051X.2004.00578.x; Chopik WJ, 2016, PERS INDIV DIFFER, V96, P202, DOI 10.1016/j.paid.2016.02.076; Clements AD, 2012, PSYCHOL RELIG SPIRIT, V4, P93, DOI 10.1037/a0025109; Cobanoglu A, 2020, EUR J INTEGR MED, V34, DOI 10.1016/j.eujim.2019.100995; Dalton C, 2016, JUDGM DECIS MAK, V11, P121; DeYoung CG, 2012, J RES PERS, V46, P63, DOI 10.1016/j.jrp.2011.12.003; Diego MA, 1998, INT J NEUROSCI, V96, P217, DOI 10.3109/00207459808986469; Ferraro KF, 2014, SOC SCI MED, V120, P92, DOI 10.1016/j.socscimed.2014.08.030; Frankfurt HG, 2005, ON BULLSHIT, P1; Gale CR, 2015, J EPIDEMIOL COMMUN H, V69, P530, DOI 10.1136/jech-2014-204888; Henningsgaard JM, 2008, PERS INDIV DIFFER, V45, P703, DOI 10.1016/j.paid.2008.07.004; Hildreth KD, 2007, SOCIOL INQ, V77, P76, DOI 10.1111/j.1475-682X.2007.00178.x; Hill PL, 2011, HEALTH PSYCHOL, V30, P536, DOI 10.1037/a0023859; Hills P, 2005, PERS INDIV DIFFER, V38, P1389, DOI 10.1016/j.paid.2004.09.006; Hoverd W.J., 2013, INT J WELLBEING, V3; Hur MH, 2019, EUR J INTEGR MED, V31, DOI 10.1016/j.eujim.2019.100978; John O. P., 1999, HDB PERSONALITY THEO, V2; Kim ES, 2019, AM J EPIDEMIOL, V188, P96, DOI 10.1093/aje/kwy211; KIM JM, 1995, J AGR FOOD CHEM, V43, P2839, DOI 10.1021/jf00059a013; Knobloch K., 1989, Journal of Essential Oil Research, V1, P119; Lakhan SE, 2016, PAIN RES TREAT, V2016, DOI 10.1155/2016/8158693; Lasikiewicz N., 2016, IMAGINATION COGNITIO, V35, P306; Lee MK, 2017, EUR J INTEGR MED, V12, P79, DOI 10.1016/j.eujim.2017.04.009; Lee YT, 2016, EUR J INTEGR MED, V8, P781, DOI 10.1016/j.eujim.2016.05.008; Leibowitz KA, 2019, HEALTH PSYCHOL, V38, P613, DOI 10.1037/hea0000751; Lillehei AS, 2014, J ALTERN COMPLEM MED, V20, P441, DOI 10.1089/acm.2013.0311; Lindeman M, 2016, APPL COGNITIVE PSYCH, V30, P736, DOI 10.1002/acp.3248; Moss M, 2003, INT J NEUROSCI, V113, P15, DOI 10.1080/00207450390161903; OLECKNO WA, 1991, PSYCHOL REP, V68, P819, DOI 10.2466/PR0.68.3.819-826; Pecina M, 2013, NEUROPSYCHOPHARMACOL, V38, P639, DOI 10.1038/npp.2012.227; Pennycook G, 2015, JUDGMENT DECISION MA; Pennycook G, 2016, JUDGM DECIS MAK, V11, P123; Polonini H, 2019, EUROPEAN J INTEGRATI; POTGIETER JR, 1995, PERCEPT MOTOR SKILL, V81, P520, DOI 10.2466/pms.1995.81.2.520; Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941; Puchalski CM, 2001, BAYLOR U MED CTR P; Reutter KK, 2014, J SCI STUD RELIG, V53, P56, DOI 10.1111/jssr.12081; Reyna VF, 2004, CURR DIR PSYCHOL SCI, V13, P60, DOI 10.1111/j.0963-7214.2004.00275.x; Roberts BW, 2005, REV GEN PSYCHOL, V9, P156, DOI 10.1037/1089-2680.9.2.156; Rohrer JM, 2018, ADV METH PRACT PSYCH, V1, P27, DOI 10.1177/2515245917745629; Schweinhardt P, 2009, J NEUROSCI, V29, P4882, DOI 10.1523/JNEUROSCI.5634-08.2009; Seo EY, 2017, EUR J INTEGR MED, V10, P82, DOI 10.1016/j.eujim.2017.03.001; Seong K, 2013, EUR J INTEGR MED, V5, P254, DOI 10.1016/j.eujim.2012.12.003; Smith J, 2015, Structures Congress 2015, P63; Soto CJ, 2017, J PERS SOC PSYCHOL, V113, P117, DOI 10.1037/pspp0000096; Sowndhararajan K, 2016, EUR J INTEGR MED, V8, P453, DOI 10.1016/j.eujim.2016.01.005; Tildesley NTJ, 2005, PHYSIOL BEHAV, V83, P699, DOI 10.1016/j.physbeh.2004.09.010; Weston SJ, SOCIAL PSYCHOL PERSO; Wheatley D, 2005, J PSYCHOPHARMACOL, V19, P414, DOI 10.1177/0269881105053309	64	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2020	15	3							e0229779	10.1371/journal.pone.0229779	http://dx.doi.org/10.1371/journal.pone.0229779			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ9AF	32163451	Green Published, gold			2023-01-03	WOS:000535288600022
J	Levy, Y; Lelievre, JD; Assoumou, L; Aznar, E; Pulido, F; Tambussi, G; Crespo, M; Meybeck, A; Molina, JM; Delaugerre, C; Izopet, J; Peytavin, G; Cardon, F; Diallo, A; Lancar, R; Beniguel, L; Costagliola, D				Levy, Yves; Lelievre, Jean-Daniel; Assoumou, Lambert; Aznar, Esther; Pulido, Federico; Tambussi, Giuseppe; Crespo, Manuel; Meybeck, Agnes; Molina, Jean-Michel; Delaugerre, Constance; Izopet, Jacques; Peytavin, Gilles; Cardon, Fanny; Diallo, Alpha; Lancar, Remi; Beniguel, Lydie; Costagliola, Dominique			Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MOTIVATE 1; OPEN-LABEL; REGIMENS; 3-DRUG; INTENSIFICATION; CCR5	Background: Patients diagnosed with advanced HIV infection have a poor prognosis despite initiation of combined antiretroviral therapy (c-ART). Objective: To assess the benefit of adding maraviroc, an antiretroviral drug with immunologic effects, to standard c-ART for patients with advanced disease at HIV diagnosis. Design: Randomized controlled trial. (ClinicalTrials.gov: NCT01348308) Setting: Clinical sites in France (n = 25), Italy (n = 5), and Spain (n = 20). Participants: 416 HIV-positive, antiretroviral-naive adults with CD4 counts less than 0.200 x 10(9) cells/L and/or a previous AIDS-defining event (ADE). Intervention: C-ART plus placebo or maraviroc (300 mg twice daily with dose modification) for 72 weeks. Measurements: The primary end point was first occurrence of severe morbidity (new ADE, selected serious infections, serious non-ADE, immune reconstitution inflammatory syndrome, or death). Prespecified secondary outcomes included primary outcome components, biological and pharmacokinetic measures, and adverse events graded 2 or higher. Results: 409 randomly assigned participants (207 in the placebo group and 202 in the maraviroc group) who received more than 1 dose were included in the analysis. During 72 weeks of follow-up, incidence of severe morbidity was 11.1 per 100 person-years in the maraviroc group and 11.2 per 100 person-years in the placebo group (hazard ratio, 0.97 [95% CI, 0.57 to 1.67]). Incidence of adverse events graded 2 or higher was 36.1 versus 41.5 per 100 person-years (incidence rate ratio, 0.87 [CI, 0.65 to 1.15]). Limitations: Sixty-four participants discontinued therapy during follow-up. The study was not designed to evaluate time-dependent outcomes or effect modification. Conclusion: Addition of maraviroc to standard c-ART does not improve clinical outcomes of patients initiating therapy for advanced HIV infection.	[Levy, Yves; Lelievre, Jean-Daniel] INSERM, Vaccine Res Inst, Creteil, France; [Levy, Yves; Lelievre, Jean-Daniel] Hop H Mondor, AP HP, Creteil, France; [Assoumou, Lambert; Lancar, Remi; Beniguel, Lydie; Costagliola, Dominique] Sorbonne Univ, IPLESP, INSERM, 56 Bd Vincent Auriol, F-75013 Paris, France; [Aznar, Esther] Grp Estudio SIDA, Soc Espanola Enfermedades Infecciosas Microbiol C, Madrid, Spain; [Pulido, Federico] UCM, Hosp Univ 12 Octubre, imas12, Madrid, Spain; [Tambussi, Giuseppe] Osped San Raffaele, Ist Ricovero & Cura Carattere Sci, IRCCS, Via Stamira Ancona 20, I-20127 Milan, Italy; [Crespo, Manuel] Hosp Univ Vall dHebron, Barcelona, Spain; [Meybeck, Agnes] Ctr Hosp Tourcoing, Serv Univ Malad Infect & Voyageur, 135 Ave President Coty,59, Tourcoing, France; [Molina, Jean-Michel; Delaugerre, Constance] Univ Paris, Hop St Louis, AP HP, INSERM,U944, 1 Ave Claude Vellefaux, F-75010 Paris, France; [Izopet, Jacques] Univ Toulouse III Paul Sabatier, INSERM, U1043, Fac Med Toulouse Purpan, 330 Ave Grande Bretagne,TSA 4003, F-31059 Toulouse, France; [Peytavin, Gilles] Univ Paris Diderot, Sorbonne Paris Cite, Hop Bichat Claude Bernard, AP HP,Lab Pharmacol Toxicol, 46 Rue Henri Huchard, F-75018 Paris, France; [Cardon, Fanny; Diallo, Alpha] France Rech Nord & Sud Sida Hiv Hepatites, ANRS, Agence Autonome, INSERM, 101 Rue Tolbiac, F-75013 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Complutense University of Madrid; Hospital Universitario 12 de Octubre; IRCCS Ca Granda Ospedale Maggiore Policlinico; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Hospital Universitari Vall d'Hebron; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Levy, Y; Lelievre, JD (corresponding author), Henri Mondor Hosp, Clin Immunol & Infect Dis Dept, 51 Ave Marechal Lattre Tassigny, F-94010 Creteil, France.	yves.levy@aphp.fr; jean-daniel.lelievre@aphp.fr	Pulido, Federico/B-8417-2009; DIALLO, Alpha/L-7897-2018; Di Biagio, Antonio/J-4901-2019; Costagliola, Dominique/H-5849-2011; Montero, Marta/H-7555-2017; Gutierrez, Felix/Q-7880-2018	Pulido, Federico/0000-0002-7414-8812; DIALLO, Alpha/0000-0001-9642-0584; Di Biagio, Antonio/0000-0003-1436-5089; Costagliola, Dominique/0000-0003-0765-0869; Tambussi, Giuseppe/0000-0002-0604-2960; Montero, Marta/0000-0002-3432-5394; Gutierrez, Felix/0000-0002-9485-6867	INSERM-ANRS (French National Agency for Research on AIDS); ViiV Healthcare	INSERM-ANRS (French National Agency for Research on AIDS); ViiV Healthcare	By INSERM-ANRS (French National Agency for Research on AIDS) and ViiV Healthcare.	Anderegg N, 2018, CLIN INFECT DIS, V66, P893, DOI 10.1093/cid/cix915; Asmuth DM, 2010, JAIDS-J ACQ IMM DEF, V54, P394, DOI 10.1097/QAI.0b013e3181c5c83b; Belaunzaran-Zamudio Pablo F, 2017, Pathog Immun, V2, P151, DOI 10.20411/pai.v2i2.181; Cheret A, 2015, LANCET INFECT DIS, V15, P387, DOI 10.1016/S1473-3099(15)70021-6; Cooper DA, 2010, J INFECT DIS, V201, P803, DOI 10.1086/650697; Critchley JA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011370; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Fischl MA, 2003, J INFECT DIS, V188, P625, DOI 10.1086/377311; Gulick RM, 2008, NEW ENGL J MED, V359, P1429, DOI 10.1056/NEJMoa0803152; Gulick RM, 2006, JAMA-J AM MED ASSOC, V296, P769, DOI 10.1001/jama.296.7.769; Hakim J, 2017, NEW ENGL J MED, V377, P233, DOI 10.1056/NEJMoa1615822; Hardy WD, 2010, JAIDS-J ACQ IMM DEF, V55, P558, DOI 10.1097/QAI.0b013e3181ee3d82; Hunt PW, 2013, BLOOD, V121, P4635, DOI 10.1182/blood-2012-06-436345; Joly V, 2013, ANTIMICROB AGENTS CH, V57, P758, DOI 10.1128/AAC.01662-12; Jung BH, 2007, BIOMED CHROMATOGR, V21, P1095, DOI 10.1002/bmc.865; Kaufmann SHE, 2018, NAT REV DRUG DISCOV, V17, P35, DOI 10.1038/nrd.2017.162; Kim CJ, 2017, AIDS, V31, P1529, DOI [10.1097/QAD.0000000000001515, 10.1097/qad.0000000000001515]; Kityo C, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002706; Lederman MM, 2006, JAMA-J AM MED ASSOC, V296, P815, DOI 10.1001/jama.296.7.815; May MT, 2014, INT J EPIDEMIOL, V43, P691, DOI 10.1093/ije/dyt010; Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16; Raymond S, 2010, J CLIN VIROL, V47, P126, DOI 10.1016/j.jcv.2009.11.018; Shafer RW, 2003, NEW ENGL J MED, V349, P2304, DOI 10.1056/NEJMoa030265; Sierra-Madero JG, 2014, LANCET HIV, V1, pE60, DOI 10.1016/S2352-3018(14)70027-X; Weber R, 2006, ARCH INTERN MED, V166, P1632, DOI 10.1001/archinte.166.15.1632; Wilkin TJ, 2010, HIV CLIN TRIALS, V11, P351, DOI 10.1310/hct1106-351; Yeni P, 2006, LANCET, V368, P287, DOI 10.1016/S0140-6736(06)69074-0	27	5	5	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 3	2020	172	5					297	+		10.7326/M19-2133	http://dx.doi.org/10.7326/M19-2133			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV1BP	32040959				2023-01-03	WOS:000520159500002
J	Ennishi, D; Healy, S; Bashashati, A; Saberi, S; Hother, C; Mottok, A; Chan, FC; Chong, L; Abraham, L; Kridel, R; Boyle, M; Meissner, B; Aoki, T; Takata, K; Woolcock, BW; Vigano, E; Gold, M; Molday, LL; Molday, RS; Telenius, A; Li, MY; Wretham, N; Dos Santos, N; Wong, M; Viller, NN; Uger, RA; Duns, G; Baticados, A; Madero, A; Bristow, BN; Farinha, P; Slack, GW; Ben-Neriah, S; Lai, D; Zhang, AW; Salehi, S; Shulha, HP; Chiu, DS; Mostafavi, S; Gerrie, AS; Huang, DW; Rushton, C; Villa, D; Sehn, LH; Savage, KJ; Mungall, AJ; Weng, AP; Bally, MB; Morin, RD; Freue, GVC; Staudt, LM; Connors, JM; Marra, MA; Shah, SP; Gascoyne, RD; Scott, DW; Steidl, C				Ennishi, Daisuke; Healy, Shannon; Bashashati, Ali; Saberi, Saeed; Hother, Christoffer; Mottok, Anja; Chan, Fong Chun; Chong, Lauren; Abraham, Libin; Kridel, Robert; Boyle, Merrill; Meissner, Barbara; Aoki, Tomohiro; Takata, Katsuyoshi; Woolcock, Bruce W.; Vigano, Elena; Gold, Michael; Molday, Laurie L.; Molday, Robert S.; Telenius, Adele; Li, Michael Y.; Wretham, Nicole; Dos Santos, Nancy; Wong, Mark; Viller, Natasja N.; Uger, Robert A.; Duns, Gerben; Baticados, Abigail; Madero, Angel; Bristow, Brianna N.; Farinha, Pedro; Slack, Graham W.; Ben-Neriah, Susana; Lai, Daniel; Zhang, Allen W.; Salehi, Sohrab; Shulha, Hennady P.; Chiu, Derek S.; Mostafavi, Sara; Gerrie, Alina S.; Huang, Da Wei; Rushton, Christopher; Villa, Diego; Sehn, Laurie H.; Savage, Kerry J.; Mungall, Andrew J.; Weng, Andrew P.; Bally, Marcel B.; Morin, Ryan D.; Cohen Freue, Gabriela V.; Staudt, Louis M.; Connors, Joseph M.; Marra, Marco A.; Shah, Sohrab P.; Gascoyne, Randy D.; Scott, David W.; Steidl, Christian			TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma	NATURE MEDICINE			English	Article							PHOSPHATIDYLSERINE EXPOSURE; PHOSPHOLIPID FLIPPASES; SIRP-ALPHA; EXPRESSION; RITUXIMAB; RECEPTOR; SIGNAL; CHEMOTHERAPY; P4-ATPASES; MECHANISM	Integrative analysis in patients with diffuse large B-cell lymphoma uncovers that biallelic mutations on TMEM30A are associated with a favorable outcome and enhanced sensitivity to CD47 blockade. Transmembrane protein 30A (TMEM30A) maintains the asymmetric distribution of phosphatidylserine, an integral component of the cell membrane and 'eat-me' signal recognized by macrophages. Integrative genomic and transcriptomic analysis of diffuse large B-cell lymphoma (DLBCL) from the British Columbia population-based registry uncovered recurrent biallelic TMEM30A loss-of-function mutations, which were associated with a favorable outcome and uniquely observed in DLBCL. Using TMEM30A-knockout systems, increased accumulation of chemotherapy drugs was observed in TMEM30A-knockout cell lines and TMEM30A-mutated primary cells, explaining the improved treatment outcome. Furthermore, we found increased tumor-associated macrophages and an enhanced effect of anti-CD47 blockade limiting tumor growth in TMEM30A-knockout models. By contrast, we show that TMEM30A loss-of-function increases B-cell signaling following antigen stimulation-a mechanism conferring selective advantage during B-cell lymphoma development. Our data highlight a multifaceted role for TMEM30A in B-cell lymphomagenesis, and characterize intrinsic and extrinsic vulnerabilities of cancer cells that can be therapeutically exploited.	[Ennishi, Daisuke; Healy, Shannon; Hother, Christoffer; Mottok, Anja; Chan, Fong Chun; Chong, Lauren; Kridel, Robert; Boyle, Merrill; Meissner, Barbara; Aoki, Tomohiro; Takata, Katsuyoshi; Woolcock, Bruce W.; Vigano, Elena; Telenius, Adele; Li, Michael Y.; Duns, Gerben; Baticados, Abigail; Madero, Angel; Bristow, Brianna N.; Farinha, Pedro; Slack, Graham W.; Ben-Neriah, Susana; Shulha, Hennady P.; Gerrie, Alina S.; Villa, Diego; Sehn, Laurie H.; Savage, Kerry J.; Connors, Joseph M.; Gascoyne, Randy D.; Scott, David W.; Steidl, Christian] British Columbia Canc, Ctr Lymphoid Canc, Vancouver, BC, Canada; [Ennishi, Daisuke] Okayama Univ Hosp, Dept Hematol & Oncol, Okayama, Japan; [Bashashati, Ali; Saberi, Saeed; Lai, Daniel; Zhang, Allen W.; Salehi, Sohrab; Shah, Sohrab P.] British Columbia Canc, Mol Oncol, Vancouver, BC, Canada; [Mottok, Anja] Ulm Univ, Inst Human Genet, Ulm, Germany; [Mottok, Anja] Ulm Univ, Med Ctr, Ulm, Germany; [Chan, Fong Chun] Univ British Columbia, Bioinformat Grad Program, Vancouver, BC, Canada; [Abraham, Libin; Gold, Michael] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC, Canada; [Molday, Laurie L.; Molday, Robert S.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada; [Wretham, Nicole; Dos Santos, Nancy; Bally, Marcel B.] British Columbia Canc, Dept Expt Therapeut, Vancouver, BC, Canada; [Wong, Mark; Viller, Natasja N.; Uger, Robert A.] Trillium Therapeut Inc, Mississauga, ON, Canada; [Chiu, Derek S.; Mostafavi, Sara; Cohen Freue, Gabriela V.] Univ British Columbia, Dept Stat, Vancouver, BC, Canada; [Mostafavi, Sara; Marra, Marco A.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada; [Huang, Da Wei; Staudt, Louis M.] NCI, Lymphoid Malignancies Branch, NIH, Bethesda, MD 20892 USA; [Rushton, Christopher; Morin, Ryan D.] Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC, Canada; [Mungall, Andrew J.; Morin, Ryan D.; Marra, Marco A.; Shah, Sohrab P.] British Columbia Canc, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC, Canada; [Weng, Andrew P.] British Columbia Canc, Terry Fox Lab, Vancouver, BC, Canada; [Shah, Sohrab P.; Gascoyne, Randy D.; Steidl, Christian] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada	Okayama University; Ulm University; Ulm University; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Simon Fraser University; University of British Columbia	Scott, DW; Steidl, C (corresponding author), British Columbia Canc, Ctr Lymphoid Canc, Vancouver, BC, Canada.; Steidl, C (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada.	dscott8@bccancer.bc.ca; CSteidl@bccancer.bc.ca	Gascoyne, Randy D/A-6009-2013; Mungall, Andrew J./U-7067-2018; Morin, Ryan/AAE-7824-2019; Villa, Diego/CAF-2455-2022; Savage, Kerry/HCH-5539-2022; Mottok, Anja/AAO-1801-2021; Marra, Marco A/B-5987-2008	Gascoyne, Randy D/0000-0002-2610-5690; Mungall, Andrew J./0000-0002-0905-2742; Morin, Ryan/0000-0003-2932-7800; Villa, Diego/0000-0002-4625-3009; Marra, Marco A/0000-0001-7146-7175; Madero Rincon, Angel/0000-0002-6238-4658; Dos Santos, Nancy/0000-0003-3619-8306; Gerrie, Alina/0000-0003-4727-1425; Mottok, Anja/0000-0003-3125-0494; Kridel, Robert/0000-0003-0287-7124; Rushton, Christopher/0000-0001-6306-9361; Hother, Christoffer Egeberg/0000-0001-8778-9662; Bristow, Brianna/0000-0002-0411-916X; Farinha, Pedro/0000-0001-9364-9391	Terry Fox Research Institute; Large Scale Applied Research Project (LSARP) from Genome Canada [13124]; Genome British Columbia [271LYM]; Canadian Institutes of Health Research (CIHR); British Columbia Cancer Foundation (BCCF); Michael Smith Foundation for Health Research (MSFHR); Japanese Society for The Promotion of Science; British Columbia Cancer Agency Centre for Lymphoid Cancer; Genome Canada; Genome British Columbia, CIHR; Alfred Benzon foundation; Mildred-Scheel-Cancer-Foundation (German Cancer Aid); MSFHR and Lymphoma Canada; Michael Smith Foundation for Health Research; NSERC Discovery grant - CIHR New Investigator Award; CIHR [PJT-148649]; Canada Research Chair in Computational Cancer Genomics; CIHR Foundation; BCCF; Uehara Memorial Foundation; Kanae Foundation for the Promotion of Medical Science; CIHR grant [PJT-152946]; Canada Research Chair in Vision and Macular Degeneration	Terry Fox Research Institute; Large Scale Applied Research Project (LSARP) from Genome Canada; Genome British Columbia; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); British Columbia Cancer Foundation (BCCF); Michael Smith Foundation for Health Research (MSFHR)(Michael Smith Foundation for Health Research); Japanese Society for The Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); British Columbia Cancer Agency Centre for Lymphoid Cancer; Genome Canada(Genome Canada); Genome British Columbia, CIHR; Alfred Benzon foundation; Mildred-Scheel-Cancer-Foundation (German Cancer Aid); MSFHR and Lymphoma Canada; Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); NSERC Discovery grant - CIHR New Investigator Award; CIHR(Canadian Institutes of Health Research (CIHR)); Canada Research Chair in Computational Cancer Genomics; CIHR Foundation(Canadian Institutes of Health Research (CIHR)); BCCF; Uehara Memorial Foundation(Uehara Memorial Foundation); Kanae Foundation for the Promotion of Medical Science; CIHR grant(Canadian Institutes of Health Research (CIHR)); Canada Research Chair in Vision and Macular Degeneration	This study was supported by a Program Project Grant from the Terry Fox Research Institute (R.D.G, grant no. 1023; C.S., grant no. 1061), a Large Scale Applied Research Project (LSARP) from Genome Canada (C.S., grant no. 13124), Genome British Columbia (C.S., 271LYM), Canadian Institutes of Health Research (CIHR) (C.S., GP1-155873) and the British Columbia Cancer Foundation (BCCF). D.E. was supported by fellowships from the Michael Smith Foundation for Health Research (MSFHR), Canadian Institutes of Health Research (CIHR) and Japanese Society for The Promotion of Science. D.W.S. is supported by the British Columbia Cancer Foundation (BCCF) and the Michael Smith Foundation for Health Research (MSFHR). J.M.C. was the Clinical Director of the British Columbia Cancer Agency Centre for Lymphoid Cancer and received research funding support from the Terry Fox Research Institute, Genome Canada, Genome British Columbia, CIHR and the BCCF. C.H. was supported by the Alfred Benzon foundation. A.M. is supported by fellowships from the Mildred-Scheel-Cancer-Foundation (German Cancer Aid), the MSFHR and Lymphoma Canada. E.V. is supported by a fellowship from the Michael Smith Foundation for Health Research. G.V.C.F is supported by an NSERC Discovery grant. R.D.M. is funded by a CIHR New Investigator Award. M.A.M. is UBC Canada Research Chair in Genome Science and is pleased to acknowledge support from CIHR (FDN-143288) and the Terry Fox Research Institute. S.P.S. holds the Canada Research Chair in Computational Cancer Genomics, is a MSFHR scholar, holds a CIHR Foundation grant and acknowledges support from the BCCF. T.A. was supported by the Japanese Society for the Promotion of Science and the Uehara Memorial Foundation. T.A. received research funding support from The Kanae Foundation for the Promotion of Medical Science. L.A., as well as the experiments carried out by L.A., were supported by CIHR grant PJT-152946 (to M.R.G.). R.S.M holds a Canada Research Chair in Vision and Macular Degeneration and acknowledges support from CIHR (PJT-148649). K.T. was supported by fellowships from the Uehara Memorial Foundation. We thank E. Toombs for assistance in performing research, analyzing and interpreting data.	Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Andersen JP, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00275; Barclay AN, 2014, ANNU REV IMMUNOL, V32, P25, DOI 10.1146/annurev-immunol-032713-120142; Birge RB, 2016, CELL DEATH DIFFER, V23, P962, DOI 10.1038/cdd.2016.11; Chapuy B, 2018, NAT MED, V24, P679, DOI 10.1038/s41591-018-0016-8; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Coleman JA, 2011, J BIOL CHEM, V286, P17205, DOI 10.1074/jbc.M111.229419; Das R, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000556; Ding JR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9554; Elliott JI, 2006, BLOOD, V108, P1611, DOI 10.1182/blood-2005-11-012328; Elliott JI, 2005, NAT CELL BIOL, V7, P808, DOI 10.1038/ncb1279; Ennishi D, 2019, J CLIN ONCOL, V37, P190, DOI 10.1200/JCO.18.01583; Ennishi D, 2017, BLOOD, V129, P2760, DOI 10.1182/blood-2016-11-747022; Freeman SA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7168; Gagnon E, 2012, J EXP MED, V209, P2423, DOI 10.1084/jem.20120790; Hankins HM, 2015, TRAFFIC, V16, P35, DOI 10.1111/tra.12233; Kridel R, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002197; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Lopez-Marques RL, 2014, PFLUG ARCH EUR J PHY, V466, P1227, DOI 10.1007/s00424-013-1363-4; Mattila PK, 2016, J CELL BIOL, V212, P267, DOI 10.1083/jcb.201504137; Mattila PK, 2013, IMMUNITY, V38, P461, DOI 10.1016/j.immuni.2012.11.019; Moreno-Smith M, 2013, J CLIN INVEST, V123, P2119, DOI 10.1172/JCI65425; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Nagata S, 2016, CELL DEATH DIFFER, V23, P952, DOI 10.1038/cdd.2016.7; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Petrova PS, 2017, CLIN CANCER RES, V23, P1068, DOI 10.1158/1078-0432.CCR-16-1700; Phelan JD, 2018, NATURE, V560, P387, DOI 10.1038/s41586-018-0290-0; Puts CF, 2009, BBA-MOL CELL BIOL L, V1791, P603, DOI 10.1016/j.bbalip.2009.02.005; Raghupathy R, 2015, CELL, V161, P581, DOI 10.1016/j.cell.2015.03.048; Reddy A, 2017, CELL, V171, P481, DOI 10.1016/j.cell.2017.09.027; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Schmitz R, 2018, NEW ENGL J MED, V378, P1396, DOI 10.1056/NEJMoa1801445; Segawa K, 2018, J BIOL CHEM, V293, P2172, DOI 10.1074/jbc.RA117.000289; Segawa K, 2015, TRENDS CELL BIOL, V25, P639, DOI 10.1016/j.tcb.2015.08.003; Segawa K, 2014, SCIENCE, V344, P1164, DOI 10.1126/science.1252809; Sehn LH, 2005, J CLIN ONCOL, V23, P5027, DOI 10.1200/JCO.2005.09.137; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Suzuki J, 2016, P NATL ACAD SCI USA, V113, P9509, DOI 10.1073/pnas.1610403113; Suzuki J, 2014, J BIOL CHEM, V289, P30257, DOI 10.1074/jbc.M114.583419; Suzuki J, 2013, SCIENCE, V341, P403, DOI 10.1126/science.1236758; Suzuki J, 2010, NATURE, V468, P834, DOI 10.1038/nature09583; Swerdlow S. H, 2008, WHO CLASSIFICATION T, V2; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Treanor B, 2012, IMMUNOLOGY, V136, P21, DOI 10.1111/j.1365-2567.2012.03564.x; Treanor B, 2010, IMMUNITY, V32, P187, DOI 10.1016/j.immuni.2009.12.005; van Blitterswijk WJ, 2013, BBA-MOL CELL BIOL L, V1831, P663, DOI 10.1016/j.bbalip.2012.10.008; van der Mark VA, 2013, INT J MOL SCI, V14, P7897, DOI 10.3390/ijms14047897; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110	49	26	27	4	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2020	26	4					577	+		10.1038/s41591-020-0757-z	http://dx.doi.org/10.1038/s41591-020-0757-z		FEB 2020	29	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH1UE	32094924	Green Accepted			2023-01-03	WOS:000515477500001
J	Faury, S; Foucaud, J				Faury, Stephane; Foucaud, Jerome			Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials	PLOS ONE			English	Review							CELL LUNG-CANCER; MELANOMA EORTC 18071; OPEN-LABEL; CLINICAL-TRIALS; STAGE-III; INVESTIGATORS CHOICE; ADJUVANT IPILIMUMAB; COMPLETE RESECTION; COLORECTAL-CANCER; RESPONSE SHIFT	Objective Immune checkpoint inhibitors (ICIs) have recently shown tremendous promise in the treatment of diverse cancers. The available data suggests that ICIs are well tolerated in terms of health-related quality of life (HRQOL) compared to other anticancer therapies. However, it appears that instruments currently used to evaluate HRQOL in this context may fail to capture important symptomatology unique to ICIs. This systematic review was designed to assess the adequacy of methods used to report HRQOL in cancer patients treated with ICIs and to identify the quality of life scales used. Method A systematic review was performed (systematic registration number: PROSPERO: CRD42019121427). A search of the PubMed, PsycINFO, PsycARTICLES, Psychology and Behavioral Sciences collection, and SocINDEX databases was carried out for publications in English and in French. Relevant databases were searched from the earliest records through to March 2019. Publications were selected if they reported on HRQOL in patients with cancer treated by ICIs. Risk of bias was scored using the Cochrane Collaboration bias assessment tool. Results Our search identified 144 publications between 2012 and 2019, of which 15 RCTs met the inclusion criteria. The results suggest that even though the overall reporting of HRQOL was deemed to be of good quality, the data available was marred by methodological aspects such as the lack of HRQOL research hypotheses and the lack of questionnaires validated for cancer patients treated with immunotherapy. Conclusion This study provides a comprehensive analysis of the current state of the art and identifies gaps in knowledge on HRQOL analysis with respect to ICIs. It also suggests avenues for further research.	[Faury, Stephane] Univ Bordeaux, Lab Handicap, Act, Cognit,Hlth,EA, Bordeaux, France; [Foucaud, Jerome] Inst Natl Canc, INCa, Boulogne Billancourt, France	UDICE-French Research Universities; Universite de Bordeaux; Institut National du Cancer (INCA) France	Foucaud, J (corresponding author), Inst Natl Canc, INCa, Boulogne Billancourt, France.	jfoucaud@institutcancer.fr		jerome, Foucaud/0000-0001-9246-7721	INCa	INCa(Institut National du Cancer (INCA) France)	Financial support for this research was provided by INCa (SF) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Rahman O, 2018, EXPERT REV ANTICANC, V18, P1231, DOI 10.1080/14737140.2018.1528146; Aburub AS, 2016, SUPPORT CARE CANCER, V24, P437, DOI 10.1007/s00520-015-2821-7; Administration U.S.F.a.D, 2018, DRUGS FDA FDA APPR D; Andrykowski M.A., 1993, PSYCHO-ONCOLOGY, V2, P261, DOI DOI 10.1002/PON.2960020406; Au HJ, 2010, EXPERT REV PHARM OUT, V10, P119, DOI 10.1586/ERP.10.15; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bordoni R, 2018, CLIN LUNG CANCER, V19, P441, DOI 10.1016/j.cllc.2018.05.011; Bottomley A, 2005, EUR J CANCER, V41, P1697, DOI 10.1016/j.ejca.2005.05.007; Bottomley A, 2002, LANCET ONCOL, V3, P620, DOI 10.1016/S1470-2045(02)00876-8; Brahmer JR, 2018, J CLIN ONCOL, V36, P1714, DOI 10.1200/JCO.2017.77.6385; Brahmer JR, 2017, LANCET ONCOL, V18, P1600, DOI 10.1016/S1470-2045(17)30690-3; BREETVELT IS, 1991, SOC SCI MED, V32, P981, DOI 10.1016/0277-9536(91)90156-7; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Campbell A., 1976, QUALITY AM LIFE; Cella D, 2019, LANCET ONCOL, V20, P297, DOI 10.1016/S1470-2045(18)30778-2; Cella D, 2016, LANCET ONCOL, V17, P994, DOI 10.1016/S1470-2045(16)30125-5; Chassany O, 2002, DRUG INF J, V36, P209, DOI 10.1177/009286150203600127; Coens C, 2017, LANCET ONCOL, V18, P393, DOI 10.1016/S1470-2045(17)30015-3; Day SJ, 2000, BRIT MED J, V321, P504, DOI 10.1136/bmj.321.7259.504; de Haes J, 2000, EUR J CANCER, V36, P821, DOI 10.1016/S0959-8049(00)00007-1; Dine J, 2017, ASIA-PAC J ONCOL NUR, V4, P127, DOI 10.4103/apjon.apjon_4_17; Downing A, 2015, J CLIN ONCOL, V33, P616, DOI 10.1200/JCO.2014.56.6539; Efficace F, 2003, J CLIN ONCOL, V21, P3502, DOI 10.1200/JCO.2003.12.121; Efficace F, 2015, CANCER-AM CANCER SOC, V121, P3335, DOI 10.1002/cncr.29489; Eggermont AMM, 2015, LANCET ONCOL, V16, P522, DOI 10.1016/S1470-2045(15)70122-1; Emens LA, 2017, EUR J CANCER, V81, P116, DOI 10.1016/j.ejca.2017.01.035; European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP), REFL PAP REG GUID US; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Fielding S, 2016, QUAL LIFE RES, V25, P2977, DOI 10.1007/s11136-016-1411-6; Galffy Gabriella, 2017, Magy Onkol, V61, P107; Ghislain I, 2016, LANCET ONCOL, V17, pE294, DOI 10.1016/S1470-2045(16)30099-7; Hall ET, 2019, J PAIN SYMPTOM MANAG, V58, P137, DOI 10.1016/j.jpainsymman.2019.03.015; Hamel JF, 2017, EUR J CANCER, V83, P166, DOI 10.1016/j.ejca.2017.06.025; Harrington KJ, 2017, LANCET ONCOL, V18, P1104, DOI 10.1016/S1470-2045(17)30421-7; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hosseini Bayan, 2017, Med J Islam Repub Iran, V31, P120, DOI 10.14196/mjiri.31.120; Jacobsen PB, 2002, ONCOLOGY-NY, V16, P133; KAGAWASINGER M, 1993, SOC SCI MED, V37, P295, DOI 10.1016/0277-9536(93)90261-2; Kopp I, 2004, INFLAMM RES, V53, pS130, DOI 10.1007/s00011-004-0361-6; Larkin J, 2018, J CLIN ONCOL, V36, P383, DOI 10.1200/JCO.2016.71.8023; Lee CW, 2000, J CLIN EPIDEMIOL, V53, P451, DOI 10.1016/S0895-4356(99)00221-8; Leventhal H., 1980, CONTRIBUTIONS MED PS, VVol. II, P7, DOI DOI 10.1093/GERONJ/46.4.P181; Long GV, 2016, ANN ONCOL, V27, P1940, DOI 10.1093/annonc/mdw265; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Maringwa JT, 2011, SUPPORT CARE CANCER, V19, P1753, DOI 10.1007/s00520-010-1016-5; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Morrissey KM, 2016, CTS-CLIN TRANSL SCI, V9, P89, DOI 10.1111/cts.12391; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Patel KK, 2003, VALUE HEALTH, V6, P595, DOI 10.1046/j.1524-4733.2003.65236.x; Petrella TM, 2017, EUR J CANCER, V86, P115, DOI 10.1016/j.ejca.2017.08.032; Puzanov I, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0300-z; Ramsey SD, 2000, CANCER-AM CANCER SOC, V88, P1294, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1294::AID-CNCR4>3.3.CO;2-D; Reck M, 2018, J THORAC ONCOL, V13, P194, DOI 10.1016/j.jtho.2017.10.029; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Revicki DA, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-66; Ribas A, 2015, LANCET ONCOL, V16, P908, DOI 10.1016/S1470-2045(15)00083-2; Richardson EM, 2017, PSYCHO-ONCOLOGY, V26, P724, DOI 10.1002/pon.4213; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Sanders C, 1998, BRIT MED J, V317, P1191, DOI 10.1136/bmj.317.7167.1191; Schadendorf D, 2014, ANN ONCOL, V25, P700, DOI 10.1093/annonc/mdt580; Schadendorf D, 2017, EUR J CANCER, V82, P80, DOI 10.1016/j.ejca.2017.05.031; Schadendorf D, 2016, EUR J CANCER, V67, P46, DOI 10.1016/j.ejca.2016.07.018; Singer S, 2017, LANCET ONCOL, V18, P993, DOI 10.1016/S1470-2045(17)30463-1; Sparano F, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e18218; Sprangers MAG, 2002, MAYO CLIN PROC, V77, P561, DOI 10.4065/77.6.561; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Sprangers MAG, 1999, ANN ONCOL, V10, P747, DOI 10.1023/A:1008305523548; Staquet M, 1996, QUAL LIFE RES, V5, P496, DOI 10.1007/BF00540022; Tang JA, 2014, ONCOL REV, V8, P7, DOI 10.4081/oncol.2014.245; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Vaughn DJ, 2018, J CLIN ONCOL, V36, P1579, DOI 10.1200/JCO.2017.76.9562; Voudouri D, 2017, CURR PROB CANCER, V41, P407, DOI 10.1016/j.currproblcancer.2017.10.003; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Zikos E, 2014, LANCET ONCOL, V15, pE78, DOI 10.1016/S1470-2045(13)70493-5	83	21	21	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2020	15	1							e0227344	10.1371/journal.pone.0227344	http://dx.doi.org/10.1371/journal.pone.0227344			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP8WY	31978145	Green Published, gold			2023-01-03	WOS:000534599100033
J	Murphy, EM; Centner, CS; Bates, PJ; Malik, MT; Kopechek, JA				Murphy, Emily M.; Centner, Connor S.; Bates, Paula J.; Malik, Mohammad T.; Kopechek, Jonathan A.			Delivery of thymoquinone to cancer cells with as1411-conjugated nanodroplets	PLOS ONE			English	Article							PHASE-SHIFT; POLYMERIC MICELLES; DRUG-DELIVERY; APTAMER; AS1411; NANOPARTICLES; NANOEMULSIONS; VAPORIZATION; EMULSIONS; TOXICITY	Systemic delivery of conventional chemotherapies can cause negative systemic toxicity, including reduced immunity and damage to organs such as the heart and kidneys-limiting the maximum dose that can be administered. Targeted therapies appear to address this problem by having a specific target while mitigating off-target effects. Biocompatible perfluorocarbon-based nanodroplet emulsions encapsulated by a phospholipid shell are in development for delivery of molecular compounds and hold promise as vehicles for targeted delivery of chemotherapeutics to tumors. When ultrasound is applied, perfluorocarbon will undergo a phase change-ultimately inducing transient perforation of the cell membrane when in close proximity, which is more commonly known as "sonoporation." Sonoporation allows enhanced intracellular delivery of molecular compounds and will reseal to encapsulate the molecular compound intracellularly. In this study, we investigated delivery of thymoquinone (TQ), a natural hydrophobic phytochemical compound with bioactivity in cancer cells. In addition, we conjugated a G-quadruplex aptamer, 'AS1411', to TQ-loaded nanodroplets and explored their effects on multiple human cancer cell lines. AS1411 binds nucleolin, which is over-expressed on the surface of cancer cells, and in addition to its tumor-targeting properties AS1411 has also been shown to induce anti-cancer effects. Thymoquinone was loaded onto AS1411-conjugated nanodroplet emulsion to assess activity against cancer cells. Confocal microscopy indicated uptake of AS1411-conjugated nanodroplets by cancer cells. Furthermore, AS1411-conjugated nanoemulsions loaded with TQ significantly enhanced cytotoxicity in cancer cells compared to free compound. These results demonstrate that AS1411 can be conjugated onto nanodroplet emulsions for targeted delivery to human cancer cells. This novel formulation offers significant potential for targeted delivery of hydrophobic chemotherapeutics to tumors for cancer treatment.	[Murphy, Emily M.; Centner, Connor S.; Kopechek, Jonathan A.] Univ Louisville, Dept Bioengn, Louisville, KY 40292 USA; [Murphy, Emily M.; Bates, Paula J.; Malik, Mohammad T.] Univ Louisville, Dept Med, Louisville, KY 40292 USA; [Bates, Paula J.; Malik, Mohammad T.] Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Program, Louisville, KY 40292 USA; [Malik, Mohammad T.] Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40292 USA	University of Louisville; University of Louisville; University of Louisville; University of Louisville	Kopechek, JA (corresponding author), Univ Louisville, Dept Bioengn, Louisville, KY 40292 USA.	jonathan.kopechek@louisville.edu		Bates, Paula/0000-0002-4622-4152; Malik, Mohammad/0000-0001-9972-5850; Centner, Connor/0000-0002-9775-5455	Robert W. Rounsavall Family Foundation Inc.; Speed School of Engineering at the University of Louisville	Robert W. Rounsavall Family Foundation Inc.; Speed School of Engineering at the University of Louisville	This study was supported by an award from the Robert W. Rounsavall Family Foundation Inc. (MTM) and by funding from the Speed School of Engineering at the University of Louisville (JAK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aravind A, 2012, BIOTECHNOL BIOENG, V109, P2920, DOI 10.1002/bit.24558; Bates PJ, 2017, BBA-GEN SUBJECTS, V1861, P1414, DOI 10.1016/j.bbagen.2016.12.015; Chen ZJ, 2016, EUR J PHARM BIOPHARM, V107, P130, DOI 10.1016/j.ejpb.2016.07.007; Duncanson WJ, 2014, LANGMUIR, V30, P13765, DOI 10.1021/la502473w; Fabiilli ML, 2010, ULTRASOUND MED BIOL, V36, P1364, DOI 10.1016/j.ultrasmedbio.2010.04.019; Fernandes DA, 2016, LANGMUIR; Goodarzi F, 2019, CAN J CHEM ENG, V97, P281, DOI 10.1002/cjce.23336; Gupta R, 2015, J CONTROL RELEASE, V212, P70, DOI 10.1016/j.jconrel.2015.06.019; Khader M, 2014, IRAN J BASIC MED SCI, V17, P950; Kopechek JA, 2014, PHYS MED BIOL, V59, P3465, DOI 10.1088/0031-9155/59/13/3465; Kopechek JA, 2013, J HEALTHC ENG, V4, P109, DOI 10.1260/2040-2295.4.1.109; Kopechek JA, 2012, JOVE-J VIS EXP, DOI 10.3791/4308; Kripfgans OD, 2000, ULTRASOUND MED BIOL, V26, P1177, DOI 10.1016/S0301-5629(00)00262-3; Kutova OM, 2019, CANCERS, V11, DOI 10.3390/cancers11010068; Kwan JJ, 2015, SMALL, V11, P5305, DOI 10.1002/smll.201501322; Latorre A, 2014, NANOSCALE, V6, P7436, DOI 10.1039/c4nr00019f; Li LY, 2014, BIOMATERIALS, V35, P3840, DOI 10.1016/j.biomaterials.2014.01.019; Liao ZX, 2015, J CONTROL RELEASE, V208, P42, DOI 10.1016/j.jconrel.2015.01.032; Malik MT, 2015, ONCOTARGET, V6, P22270, DOI 10.18632/oncotarget.4207; Mannaris C, 2019, ULTRASOUND MED BIOL, V45, P954, DOI 10.1016/j.ultrasmedbio.2018.10.033; Marshalek JP, 2016, J CONTROL RELEASE, V243, P69, DOI 10.1016/j.jconrel.2016.09.010; Rapoport N, 2015, J CONTROL RELEASE, V206, P153, DOI 10.1016/j.jconrel.2015.03.010; Rapoport N, 2012, WIRES NANOMED NANOBI, V4, P492, DOI 10.1002/wnan.1176; Reyes-Reyes EM, 2010, CANCER RES, V70, P8617, DOI 10.1158/0008-5472.CAN-10-0920; Riess JG, 1998, UPDATE PERFLUOROCARB; Rosenberg JE, 2014, INVEST NEW DRUG, V32, P178, DOI 10.1007/s10637-013-0045-6; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Shiao YS, 2014, ACS APPL MATER INTER, V6, P21832, DOI 10.1021/am5026243; Strohm E, 2011, BIOMED OPT EXPRESS, V2, P1432, DOI 10.1364/BOE.2.001432; Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042-7158.2012.01567.x; Taylor P, 2003, ADV COLLOID INTERFAC, V106, P261, DOI 10.1016/S0001-8686(03)00113-1; Wang CH, 2012, BIOMATERIALS, V33, P1939, DOI 10.1016/j.biomaterials.2011.11.036; Wilson K, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1627; Woo CC, 2012, BIOCHEM PHARMACOL, V83, P443, DOI 10.1016/j.bcp.2011.09.029; Wu JH, 2013, MOL PHARMACEUT, V10, P3555, DOI 10.1021/mp300686g; Zhang JM, 2015, J CONTROL RELEASE, V213, pE137, DOI 10.1016/j.jconrel.2015.05.232	36	9	9	2	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2020	15	5							e0233466	10.1371/journal.pone.0233466	http://dx.doi.org/10.1371/journal.pone.0233466			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1JI	32437399	Green Published, gold			2023-01-03	WOS:000537517800091
J	Wittwer, A; Hascoet, JM				Wittwer, Apolline; Hascoet, Jean-Michel			Impact of introducing a standardized nutrition protocol on very premature infants' growth and morbidity	PLOS ONE			English	Article							POSTNATAL-GROWTH; PRETERM INFANT; VLBW INFANTS; BIRTH; OUTCOMES; RECOMMENDATIONS; MALNUTRITION	Background Inappropriate nutritional intake in premature infants may be responsible for postnatal growth restriction (PGR) and adverse long-term outcomes. Objective We evaluated the impact of an updated nutrition protocol on very premature infants' longitudinal growth and morbidity, and secondly the compliance to this new protocol. Design All infants born between 26-32 weeks gestation (GA) were studied retrospectively during two 6-month periods before (group 1) and after (group 2) the introduction of an optimized nutrition protocol, in a longitudinal comparative analysis. Results 158 infants were included; 72 before and 86 after the introduction of the protocol (Group 1: (mean +/- SD) birthweight (BW) 1154 +/- 276 g, GA 29.0 +/- 1.4 weeks; Group 2: BW 1215 +/- 332 g, GA 28.9 +/- 1.7 weeks). We observed growth improvement in Group 2 more pronounced in males (weight z-score) at D42 (-1.688 +/- 0.758 vs. -1.370 +/- 0.762, p = 0.045), D49 (- 1.696 +/- 0.776 vs. -1.370 +/- 0.718, p = 0.051), D56 (-1.748 +/- 0.855 vs. -1.392 +/- 0.737, p = 0.072), D63 (-1.885 +/- 0.832 vs. -1.336 +/- 0.779 p = 0.016), and D70 (-2.001 +/- 0.747 vs. -1.228 +/- 0.765 p = 0.004). There was no difference in females or in morbidities between the groups. We observed low compliance to the protocol in both groups: similar energy intake but higher lipid intake in Group 1 and higher protein intake in Group 2. Conclusion The quality of nutritional care with a strictly-defined protocol may significantly improve weight gain for very preterm infants. As compliance remained low, an educational reinforcement is needed to prevent PGR.	[Wittwer, Apolline; Hascoet, Jean-Michel] DevAH Univ Lorraine, CHRU Nancy, Dept Neonatol, Maternite Reg, Nancy, France	CHU de Nancy	Wittwer, A (corresponding author), DevAH Univ Lorraine, CHRU Nancy, Dept Neonatol, Maternite Reg, Nancy, France.	a.wittwer@chru-nancy.fr						Agostoni C, 2010, J PEDIATR GASTR NUTR, V50, P85, DOI 10.1097/MPG.0b013e3181adaee0; Andrews ET, 2019, ARCH DIS CHILD-FETAL, V104, pF235, DOI 10.1136/archdischild-2018-315082; [Anonymous], 1987, Acta Paediatr Scand Suppl, V336, P1; Barker DJP, 1997, ACTA PAEDIATR, V86, P178; BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; Billard H, 2016, J HUM LACT, V32, pNP19, DOI 10.1177/0890334415588513; Christmann V, 2017, ACTA PAEDIATR, V106, P242, DOI 10.1111/apa.13669; Dusick AM, 2003, SEMIN PERINATOL, V27, P302, DOI 10.1016/S0146-0005(03)00044-2; Ehrenkranz RA, 2006, PEDIATRICS, V117, P1253, DOI 10.1542/peds.2005-1368; Embleton NE, 2001, PEDIATRICS, V107, P270, DOI 10.1542/peds.107.2.270; Grover A, 2008, JPEN-PARENTER ENTER, V32, P140, DOI 10.1177/0148607108314373; Hack M, 2014, PEDIATR RES, V75, P358, DOI 10.1038/pr.2013.209; Hascoet JM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020366; Iacobelli S, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0426-4; Klein CJ, 2002, J NUTR, V132, p1395S, DOI 10.1093/jn/132.6.1395S; Lapillonne A, 2011, ARCH PEDIATRIE, V18, P313, DOI 10.1016/j.arcped.2010.12.006; Lee PA, 2003, PEDIATRICS, V111, P1253, DOI 10.1542/peds.111.6.1253; Maas C, 2015, ARCH DIS CHILD-FETAL, V100, pF76, DOI 10.1136/archdischild-2014-306195; Monset-Couchard M, 2002, BIOL NEONATE, V81, P244, DOI 10.1159/000056755; Olsen IE, 2010, PEDIATRICS, V125, pE214, DOI 10.1542/peds.2009-0913; Rochow N, 2012, CLIN NUTR, V31, P124, DOI 10.1016/j.clnu.2011.07.004; Roggero P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051166; Senterre T, 2013, ARCH PEDIATRIE, V20, P986, DOI 10.1016/j.arcped.2013.05.021; Senterre T, 2012, ACTA PAEDIATR, V101, pE64, DOI 10.1111/j.1651-2227.2011.02443.x; Senterre T, 2011, J PEDIATR GASTR NUTR, V53, P536, DOI 10.1097/MPG.0b013e31822a009d; SMART JL, 1973, J NUTR, V103, P1327, DOI 10.1093/jn/103.9.1327; Stefanescu BM, 2016, EARLY HUM DEV, V94, P25, DOI 10.1016/j.earlhumdev.2016.01.011; Sudo N, 1997, J IMMUNOL, V159, P1739; Thomas EL, 2011, PEDIATR RES, V70, P507, DOI 10.1203/PDR.0b013e31822d7860; Tremblay Genevieve, 2017, Neonatology, V111, P214, DOI 10.1159/000450882; Zozaya C, 2018, NEONATOLOGY, V114, P177, DOI 10.1159/000489388	31	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2020	15	5							e0232659	10.1371/journal.pone.0232659	http://dx.doi.org/10.1371/journal.pone.0232659			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1JI	32437423	Green Published, gold			2023-01-03	WOS:000537517800021
J	Fabrick, JA; Yool, AJ; Spurgeon, DW				Fabrick, Jeffrey A.; Yool, Andrea J.; Spurgeon, Dale W.			Insecticidal activity of marigold Tagetes patula plants and foliar extracts against the hemipteran pests, Lygus hesperus and Bemisia tabaci	PLOS ONE			English	Article							ASTERACEAE ESSENTIAL OIL; HELICOVERPA-ARMIGERA; LARVICIDAL ACTIVITY; L. ASTERACEAE; FRUIT BORER; RESISTANCE; MOSQUITO; DIPTERA; COLEOPTERA; MANAGEMENT	The western tarnished plant bug, Lygus hesperus Knight (Hemiptera: Miridae) and the whitefly, Bemisia tabaci Gennadius (Hemiptera: Aleyrodidae) are key hemipteran pests of numerous crop plants throughout the western United States and Mexico. Management in the U.S. currently relies on only a few insecticides and is threatened by the evolution of resistance. New chemistries or alternative management strategies are needed to reduce selection pressure on current insecticides and enhance control. Here, we investigated the bio-insecticidal toxicity of the French marigold, Tagetes patula Linnaeus (Asterales: Asteraceae), against both L. hesperus and B. tabaci. Assays indicated significantly reduced survival of both pest species on T. patula plants, and in diet incorporation assays containing aqueous and methanolic marigold foliar extracts. Mortality was concentration-dependent, indicating the presence of one or more extractable toxicants. These data suggest that T. patula plants have insecticidal constituents that might be identified and developed as novel alternatives to conventional chemical treatments.	[Fabrick, Jeffrey A.; Spurgeon, Dale W.] Agr Res Serv ARS, US Dept Agr USDA, US Arid Land Agr Res Ctr, Maricopa, AZ 85138 USA; [Yool, Andrea J.] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia	University of Adelaide	Fabrick, JA (corresponding author), Agr Res Serv ARS, US Dept Agr USDA, US Arid Land Agr Res Ctr, Maricopa, AZ 85138 USA.	jeff.fabrick@usba.gov		Fabrick, Jeffrey/0000-0002-3893-9545	U.S. Department of Agriculture, Agricultural Research Service, National Program 304 -Crop Protection Quarantine [2020-22620-022-00D]; Bayer CropScience AG Grants4Targets Grant [2016-01-51]; National Cotton Council [2020-22620-021-16J]	U.S. Department of Agriculture, Agricultural Research Service, National Program 304 -Crop Protection Quarantine; Bayer CropScience AG Grants4Targets Grant(Bayer AG); National Cotton Council	This research was supported by the U.S. Department of Agriculture, Agricultural Research Service, National Program 304 -Crop Protection & Quarantine (#2020-22620-022-00D to JF and DS), Bayer CropScience AG Grants4Targets Grant (#2016-01-51 to JF), and the National Cotton Council (#2020-22620-021-16J to JF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aldana-Llanos L, 2012, SOUTHWEST ENTOMOL, V37, P31, DOI 10.3958/059.037.0104; Andreotti R, 2013, VET PARASITOL, V197, P341, DOI 10.1016/j.vetpar.2013.04.045; [Anonymous], 2005, J PHARM SCI-US; ARNASON T, 1981, BIOCHEM SYST ECOL, V9, P63, DOI 10.1016/0305-1978(81)90061-2; Barbosa P, 2009, ANNU REV ECOL EVOL S, V40, P1, DOI 10.1146/annurev.ecolsys.110308.120242; Barkat Hussain, 2007, International Journal of Agricultural Research, V2, P185; Barman AK, 2010, INSECT SCI, V17, P542, DOI 10.1111/j.1744-7917.2010.01334.x; Ben-Issa R, 2017, PEST MANAG SCI, V8, P112, DOI DOI 10.3390/INSECTS8040112); Biondi A, 2018, ANNU REV ENTOMOL, V63, P239, DOI 10.1146/annurev-ento-031616-034933; Boeke SJ, 2004, J STORED PROD RES, V40, P423, DOI 10.1016/S0022-474X(03)00046-8; Campolo O, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13413-0; Campolo O, 2016, J ECON ENTOMOL, V109, P360, DOI 10.1093/jee/tov270; Campolo O, 2014, PHYTOPARASITICA, V42, P223, DOI 10.1007/s12600-013-0355-4; Campos E. V. R., 2019, Ecological Indicators, V105, P483, DOI 10.1016/j.ecolind.2018.04.038; Cestari IM, 2004, NEOTROP ENTOMOL, V33, P805, DOI 10.1590/S1519-566X2004000600021; Conboy NJA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213071; Conti B, 2011, J PEST SCI, V84, P219, DOI 10.1007/s10340-010-0343-0; Dayan FE, 2009, BIOORGAN MED CHEM, V17, P4022, DOI 10.1016/j.bmc.2009.01.046; DEBOLT JW, 1982, ANN ENTOMOL SOC AM, V75, P119, DOI 10.1093/aesa/75.2.119; Dennehy TJ, 2010, J ECON ENTOMOL, V103, P2174, DOI 10.1603/EC10239; Desneux N, 2007, ANNU REV ENTOMOL, V52, P81, DOI 10.1146/annurev.ento.52.110405.091440; Dinesh DS, 2014, J VECTOR DIS, V51, P1; Du WX, 2016, SCI REP-UK, V6, DOI 10.1038/srep22140; Elango G, 2012, IND CROP PROD, V36, P524, DOI 10.1016/j.indcrop.2011.10.032; Ellsworth PC, 1999, AZ1123 U AR COLL AGR; EMILIE D., 2015, J ECON ENTOMOL, V108, P1890, DOI DOI 10.1093/jee/tov118; Flores G, 2008, REV BIOL TROP, V56, P2115; Gil A, 2002, BIOCHEM SYST ECOL, V30, P1, DOI 10.1016/S0305-1978(01)00058-8; Godfrey LD, 2019, ANR PUBLICATION, V3444; GREEN MM, 1991, J AM MOSQUITO CONTR, V7, P282; Greene J. K, 2006, CLEMSON U COOP EXT S, V158; Gupta P, 2012, HARDARD MEDICUS, V55, P45; Hammad EAF, 2014, J INSECT SCI, V14, DOI 10.1673/031.014.105; HOKKANEN H M T, 1989, Acta Entomologica Fennica, V53, P25; Hooks CRR, 2010, APPL SOIL ECOL, V46, P307, DOI 10.1016/j.apsoil.2010.09.005; Institute SAS, 2012, SAS REL; Isman MB, 2006, ANNU REV ENTOMOL, V51, P45, DOI 10.1146/annurev.ento.51.110104.151146; Isman MB, 2015, PEST MANAG SCI, V71, P1587, DOI 10.1002/ps.4088; Jankowska Beata, 2009, Folia Horticulturae, V21, P95; Jiao XG, 2012, J PEST SCI, V85, P423, DOI 10.1007/s10340-012-0441-2; Keita SM, 2000, J STORED PROD RES, V36, P355, DOI 10.1016/S0022-474X(99)00055-7; Koch KG, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.01363; Krcmar S, 2016, ENTOMOL GEN, V36, P97, DOI 10.1127/entomologia/2016/0121; Kumar Vijay, 2017, Journal of Entomology and Zoology Studies, V5, P803; Legaspi JC, 2010, J ENTOMOL SCI, V45, P262, DOI 10.18474/0749-8004-45.3.262; Leger C, 2009, J SUSTAIN AGR, V33, P128, DOI 10.1080/10440040802394992; Ma W, 2010, J ECON ENTOMOL, V103, P158, DOI 10.1603/EC09122; MARADUFU A, 1978, LLOYDIA, V41, P181; Marahatta SP, 2012, J NEMATOL, V44, P26; Mitchell C, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.01132; Morallo-Rejesus B., 1978, Philippine Entomologist, V4, P87; Naranjo SE, 2009, PEST MANAG SCI, V65, P1267, DOI 10.1002/ps.1861; Painter RH, 1951, INSECT RESISTANCE CR; Palacios-Landin Josefina, 2015, Turkiye Parazitoloji Dergisi, V39, P260, DOI 10.5152/tpd.2015.4523; Palumbo JC, 2001, CROP PROT, V20, P739, DOI 10.1016/S0261-2194(01)00117-X; Parys KA, 2018, J INSECT SCI, V18, DOI 10.1093/jisesa/iey015; Pavela R, 2016, TRENDS PLANT SCI, V21, P1000, DOI 10.1016/j.tplants.2016.10.005; PERICH MJ, 1995, J AM MOSQUITO CONTR, V11, P307; PERICH MJ, 1994, J MED ENTOMOL, V31, P833, DOI 10.1093/jmedent/31.6.833; Ravikumar P., 2010, Asian Journal of Bio Science, V5, P29; Regnault-Roger C, 2012, ANNU REV ENTOMOL, V57, P405, DOI 10.1146/annurev-ento-120710-100554; Rodriguez E, 1977, BIOL CHEM COMPOSITAE, V2, P785; Politi FAS, 2017, PARASITOL RES, V116, P415, DOI 10.1007/s00436-016-5305-x; Politi FAS, 2013, PARASITOL RES, V112, P2261, DOI 10.1007/s00436-013-3386-3; Scott D.R., 1977, Bulletin Ent Soc Amer, V23, P19; SEVACHERIAN V, 1975, ENVIRON ENTOMOL, V4, P163, DOI 10.1093/ee/4.1.163; Sharma Manik, 1994, Indian Journal of Malariology, V31, P21; Snodgrass GL, 2009, J ECON ENTOMOL, V102, P699, DOI 10.1603/029.102.0231; Spurgeon DW, 2012, ENVIRON ENTOMOL, V41, P415, DOI [10.1093/ee/41.2.415, 10.1603/EN11248]; SRINIVASAN K, 1994, INT J PEST MANAGE, V40, P56, DOI 10.1080/09670879409371854; Stenberg JA, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.00663; STERN V. M., 1964, CALIF AGR, V18, P4; STERN VM, 1969, CALIF AGR, V23, P8; Van Ekert E, 2016, INSECT BIOCHEM MOLEC, V77, P39, DOI 10.1016/j.ibmb.2016.07.010; Vasudevan P, 1997, BIORESOURCE TECHNOL, V62, P29, DOI 10.1016/S0960-8524(97)00101-6; Weaver DK, 1997, J ECON ENTOMOL, V90, P1678, DOI 10.1093/jee/90.6.1678; WEAVER DK, 1994, J ECON ENTOMOL, V87, P1718, DOI 10.1093/jee/87.6.1718; Wheeler A.G., 2001, BIOL PLANT BUGS	78	11	12	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2020	15	5							e0233511	10.1371/journal.pone.0233511	http://dx.doi.org/10.1371/journal.pone.0233511			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1DW	32428032	gold, Green Published			2023-01-03	WOS:000537503400049
J	Raikkonen, K; Gissler, M; Kajantie, E				Raikkonen, Katri; Gissler, Mika; Kajantie, Eero			Associations Between Maternal Antenatal Corticosteroid Treatment and Mental and Behavioral Disorders in Children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EUROPEAN CONSENSUS GUIDELINES; RESPIRATORY-DISTRESS; PSYCHIATRIC-DISORDERS; PRETERM BIRTH; CHILDHOOD; OUTCOMES; BETAMETHASONE; MANAGEMENT; RISK	This population cohort study uses national Finnish birth registry data to assess associations between antenatal corticosteroid treatment to accelerate fetal maturation and mental and behavioral disorders in term and preterm children. Question Is maternal antenatal corticosteroid treatment associated with mental and behavioral disorders in children? Findings In this population-based retrospective cohort study that included 670 & x202f;097 children, exposure to maternal antenatal corticosteroid treatment, compared with nonexposure, was significantly associated with mental and behavioral disorders in children (hazard ratio, 1.33). Meaning These findings may help inform decisions about maternal antenatal corticosteroid treatment. Importance Maternal antenatal corticosteroid treatment is standard care to accelerate fetal maturation when birth before 34 weeks is imminent. Recently, expansion of the indications beyond 34 gestational weeks has been debated. However, data about long-term outcomes remain limited, especially among infants who after treatment exposure are born at term. Objective To study if antenatal corticosteroid treatment is associated with mental and behavioral disorders in children born at term (>= 37 weeks 0 days' gestation) and preterm (<37 weeks 0 days' gestation) and if unmeasured familial confounding explains these associations. Design, Setting, and Participants Population-based retrospective cohort study using nationwide registries of all singleton live births in Finland surviving until 1 year and a within-sibpair comparison among term siblings. Children were born between January 1, 2006, and December 31, 2017, and followed up until December 31, 2017. Exposures Maternal antenatal corticosteroid treatment. Main Outcomes and Measures Primary outcome was any childhood mental and behavioral disorder diagnosed in public specialized medical care settings. Results Of the 674 & x202f;877 singleton children born in Finland during the study period, 670 & x202f;097 were eligible for analysis. The median length of follow-up was 5.8 (interquartile-range, 3.1-8.7) years. Of the 14 & x202f;868 (2.22%; 46.1% female) corticosteroid treatment-exposed children, 6730 (45.27%) were born at term and 8138 (54.74%) were born preterm; of the 655 & x202f;229 (97.78%; 48.9% female) nonexposed children, 634 & x202f;757 (96.88%) were born at term and 20 & x202f;472 (3.12%) were born preterm. Among the 241 & x202f;621 eligible term-born maternal sibpairs nested within this population, 4128 (1.71%) pairs were discordant for treatment exposure. Treatment exposure, compared with nonexposure, was significantly associated with higher risk of any mental and behavioral disorder in the entire cohort of children (12.01% vs 6.45%; absolute difference, 5.56% [95% CI, 5.04%-6.19%]; adjusted hazard ratio [HR], 1.33 [95% CI, 1.26-1.41]), in term-born children (8.89% vs 6.31%; absolute difference, 2.58% [95% CI, 1.92%-3.29%]; HR, 1.47 [95% CI, 1.36-1.69]), and when sibpairs discordant for treatment exposure were compared with sibpairs concordant for nonexposure (6.56% vs 4.17% for within-sibpair differences; absolute difference, 2.40% [95% CI, 1.67%-3.21%]; HR, 1.38 [95% CI, 1.21-1.58]). In preterm-born children, the cumulative incidence rate of any mental and behavioral disorder was also significantly higher for the treatment-exposed compared with the nonexposed children, but the HR was not significant (14.59% vs 10.71%; absolute difference, 3.38% [95% CI, 2.95%-4.87%]; HR, 1.00 [95% CI, 0.92-1.09]). Conclusions and Relevance In this population-based cohort study, exposure to maternal antenatal corticosteroid treatment was significantly associated with mental and behavioral disorders in children. These findings may help inform decisions about maternal antenatal corticosteroid treatment.	[Raikkonen, Katri] Univ Helsinki, Dept Psychol & Logoped, Fac Med, POB 21 Haartmaninkatu 3, Helsinki 00014, Finland; [Gissler, Mika] THL Finnish Inst Hlth & Welf, Informat Serv Dept, Helsinki, Finland; [Gissler, Mika] Univ Turku, Res Ctr Child Psychiat, Turku, Finland; [Gissler, Mika] Karolinska Inst, Dept Neurobiol, Stockholm, Sweden; [Kajantie, Eero] THL Finnish Inst Hlth & Welf, Dept Publ Hlth Solut, Helsinki, Finland; [Kajantie, Eero] THL Finnish Inst Hlth & Welf, Dept Publ Hlth Solut, Oulu, Finland; [Kajantie, Eero] Univ Oulu, Oulu Univ Hosp, PEDEGO Res Unit, MRC Oulu, Oulu, Finland; [Kajantie, Eero] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway; [Kajantie, Eero] Univ Helsinki, Helsinki Univ Hosp, Childrens Hosp, Helsinki, Finland	University of Helsinki; University of Turku; Karolinska Institutet; University of Oulu; Norwegian University of Science & Technology (NTNU); University of Helsinki; Helsinki University Central Hospital	Raikkonen, K (corresponding author), Univ Helsinki, Dept Psychol & Logoped, Fac Med, POB 21 Haartmaninkatu 3, Helsinki 00014, Finland.	katri.raikkonen@helsinki.fi		Raikkonen, Katri/0000-0003-3124-3470	Academy of Finland; European Commission (Horizon 2020) [SC1-2016-RTD-733280 RECAP]; European Commission Dynamics of Inequality Across the Life-course: structures and processes (DIAL) [724363]; Foundation for Pediatric Research; Signe and Ane Gyllenberg Foundation; Novo Nordisk Foundation; Sigrid Juselius Foundation; Juho Vainio Foundation	Academy of Finland(Academy of Finland); European Commission (Horizon 2020)(European Commission); European Commission Dynamics of Inequality Across the Life-course: structures and processes (DIAL); Foundation for Pediatric Research; Signe and Ane Gyllenberg Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Juho Vainio Foundation	This study was funded by the Academy of Finland, European Commission (Horizon 2020 Award SC1-2016-RTD-733280 RECAP), European Commission Dynamics of Inequality Across the Life-course: structures and processes (DIAL) No. 724363 for PremLife, Foundation for Pediatric Research, the Signe and Ane Gyllenberg Foundation, the Novo Nordisk Foundation, the Sigrid Juselius Foundation, and the Juho Vainio Foundation.	Asztalos E, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-272; Copel J, 2017, OBSTET GYNECOL, V130, pE210, DOI [10.1097/AOG.0000000000002237, 10.1097/AOG.0000000000002355]; Copeland WE, 2015, JAMA PSYCHIAT, V72, P892, DOI 10.1001/jamapsychiatry.2015.0730; Copeland WE, 2009, ARCH GEN PSYCHIAT, V66, P764, DOI 10.1001/archgenpsychiatry.2009.85; Costello EJ, 2003, ARCH GEN PSYCHIAT, V60, P837, DOI 10.1001/archpsyc.60.8.837; Crowther CA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0947; Crowther CA, 2016, NEW ENGL J MED, V374, P1376, DOI 10.1056/NEJMe1601867; Gissler M., 2010, FINN YEARB POPUL RES, V45, P171, DOI [10.23979/fypr.45059, DOI 10.23979/FYPR.45059]; Gyamfi-Bannerman C, 2016, NEW ENGL J MED, V374, P1311, DOI 10.1056/NEJMoa1516783; Heinonen K, 2016, PSYCHOL MED, V46, P2227, DOI 10.1017/S0033291716000830; Kamath-Rayne BD, 2016, AM J OBSTET GYNECOL, V215, P423, DOI 10.1016/j.ajog.2016.06.023; Kerstjens JM, 2012, PEDIATRICS, V130, pE265, DOI 10.1542/peds.2012-0079; Kong LH, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-0776; Lahti M, 2015, PSYCHOL MED, V45, P985, DOI 10.1017/S0033291714001998; Lampi KM, 2010, ACTA PAEDIATR, V99, P1425, DOI 10.1111/j.1651-2227.2010.01835.x; Martin Joyce A, 2018, Natl Vital Stat Rep, V67, P1; Pyhala R, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2690; Reynolds RM, 2012, J CLIN ENDOCR METAB, V97, P3457, DOI 10.1210/jc.2012-3201; Roberts D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub3; Rodriguez A, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002746; Saccone G, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5044; Seckl JR, 2004, ANN NY ACAD SCI, V1032, P63, DOI 10.1196/annals.1314.006; Sotiriadis A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006614.pub2; Stutchfield P, 2005, BMJ-BRIT MED J, V331, P662, DOI 10.1136/bmj.38547.416493.06; Sudan M, 2014, J EXPO SCI ENV EPID, V24, P482, DOI 10.1038/jes.2013.56; Sund R, 2012, SCAND J PUBLIC HEALT, V40, P505, DOI 10.1177/1403494812456637; Sweet DG, 2019, NEONATOLOGY, V115, P432, DOI 10.1159/000499361; Sweet DG, 2017, NEONATOLOGY, V111, P107, DOI 10.1159/000448985; Wolford E, 2020, PSYCHOL MED, V50, P247, DOI 10.1017/S0033291718004129; World Health Organization, 2015, WHO RECOMMENDATIONS	30	95	101	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	2020	323	19					1924	1933		10.1001/jama.2020.3937	http://dx.doi.org/10.1001/jama.2020.3937			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LT2XF	32427304	Bronze, Green Published			2023-01-03	WOS:000536934300019
J	Yang, CL; Yong, L; Liang, C; Li, Y; Ma, YL; Wei, F; Jiang, L; Zhou, H; He, GP; Pan, XY; Hai, B; Wu, J; Xu, YL; Liu, ZJ; Liu, XG				Yang, Chenlong; Yong, Lei; Liang, Chen; Li, Yan; Ma, Yunlong; Wei, Feng; Jiang, Liang; Zhou, Hua; He, Guanping; Pan, Xiaoyu; Hai, Bao; Wu, Jian; Xu, Yulun; Liu, Zhongjun; Liu, Xiaoguang			Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target	ONCOGENE			English	Article							PATHWAY; GROWTH; CANCER; EXPRESSION; CARCINOMA; MUTATIONS; BIOLOGY; BCL-2; PTCH; GLI1	Chordoma, a rare neoplasm derived from intraosseous notochordal remnants, is unresponsive to conventional chemotherapy and radiotherapy. Sonic Hedgehog (Shh) is a crucial fetal notochord-secreted morphogen that directs notochordal development. The aim of this study was to determine the functional roles and therapeutic potential of Shh-Gli1 signaling in chordomas. Tissue samples and clinical profiles were collected from 42 patients with chordoma. The chordoma cell lines U-CH1 and MUG-Chor1 were used for functional experiments. Shh-Gli1 signaling pathway genetic alterations were screened, and the functions of the identified novel variants were analyzed using in silico analyses, real-time quantitative PCR, and minigene assays. Ligand-dependent Shh-Gli1 signaling activation was assessed using single- and dual-label immunostaining, western blot analysis, and a Shh-responsive Gli-luciferase reporter assay. The small-molecule inhibitor vismodegib was used to target Shh-Gli1 signaling in vitro and in vivo. Overall, 44 genetic alterations were identified, including four novel variants (c.67_69dupCTG in SMO, c.-6_-4dupGGC and c.3306 + 83_3306 + 84insG in PTCH1, and c.183-67_183-66delinsA in SUFU). Shh, PTCH1, SMO, SUFU, and Gli1 were extensively expressed in chordomas, and higher Gli1 expression correlated with poorer prognosis. A luciferase reporter assay and dual-label immunostaining indicated the occurrence of juxtacrine ligand-dependent Shh-Gli1 signaling activation. Vismodegib significantly inhibited cell proliferation and induced apoptosis and G1/S cell cycle arrest. In vivo investigation demonstrated that vismodegib effectively inhibited chordoma xenograft growth. This current preclinical evidence elucidates the therapeutic potential of Shh-Gli1 signaling pathway targeting for chordoma treatment. Vismodegib may be a promising targeted agent, and further clinical trials are warranted.	[Yang, Chenlong; Yong, Lei; Liang, Chen; Ma, Yunlong; Wei, Feng; Jiang, Liang; Zhou, Hua; He, Guanping; Pan, Xiaoyu; Hai, Bao; Liu, Zhongjun; Liu, Xiaoguang] Peking Univ, Hosp 3, Dept Orthoped, Beijing, Peoples R China; [Li, Yan] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Pathol, Beijing, Peoples R China; [Wu, Jian] Capital Med Univ, Sch Clin Med, Beijing, Peoples R China; [Xu, Yulun] Capital Med Univ, Beijing Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Dept Neurosurg, Beijing, Peoples R China	Peking University; Peking University; Capital Medical University; Capital Medical University	Liu, XG (corresponding author), Peking Univ, Hosp 3, Dept Orthoped, Beijing, Peoples R China.	liuxg.puth@hotmail.com	Zhou, Hua/HGC-9504-2022; Pan, Xiaoyu/ABE-1764-2021	Pan, Xiaoyu/0000-0002-5184-222X; Wu, Jian/0000-0003-3199-0492; Zhou, hua/0000-0002-2718-4108; Yang, Chenlong/0000-0001-8102-8811; Yang, Jun/0000-0002-7460-2800	National Natural Science Foundation of China [81641103, 81901202]; Postdoctoral Science Foundation of China [2018M630047]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (81641103 to XL; 81901202 to CY) and the Postdoctoral Science Foundation of China (2018M630047 to CY).	Ahmed AT, 2018, SPINE, V43, pE1157, DOI 10.1097/BRS.0000000000002638; Akhavan-Sigari R, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020248; Amini P, 2017, BMC MOL BIOL, V18, DOI 10.1186/s12867-017-0099-7; Armas-Lopez L, 2017, ONCOTARGET, V8, P60684, DOI 10.18632/oncotarget.19527; Bari R, 2015, SCI REP-UK, V5, DOI 10.1038/srep11098; Begnini A, 2010, BRIT J DERMATOL, V163, P364, DOI 10.1111/j.1365-2133.2010.09776.x; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Cates JMM, 2010, HISTOPATHOLOGY, V56, P978, DOI 10.1111/j.1365-2559.2010.03572.x; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Chen H, 2017, CLIN CANCER RES, V23, P5176, DOI 10.1158/1078-0432.CCR-17-0177; Choi KS, 2008, DEV DYNAM, V237, P3953, DOI 10.1002/dvdy.21805; Cortes JE, 2019, CANCER TREAT REV, V76, P41, DOI 10.1016/j.ctrv.2019.04.005; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; GOTZ W, 1995, CELL TISSUE RES, V280, P455; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Incardona JP, 2000, CELL MOL LIFE SCI, V57, P1709, DOI 10.1007/PL00000653; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kitamura Y, 2017, BRAIN TUMOR PATHOL, V34, P78, DOI 10.1007/s10014-017-0283-y; Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416; Lee IJ, 2017, WORLD NEUROSURG, V104, P346, DOI 10.1016/j.wneu.2017.04.118; Magic M, 2019, CLIN ORAL INVEST, V23, P2675, DOI 10.1007/s00784-018-2686-5; Otani R, 2018, J NEUROSURG, V128, P1428, DOI 10.3171/2016.12.JNS161444; Raffel C, 1997, CANCER RES, V57, P842; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Sari IN, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110208; Scheil-Bertram S, 2014, INT J ONCOL, V44, P1041, DOI 10.3892/ijo.2014.2268; Sebaugh JL, 2011, PHARM STAT, V10, P128, DOI 10.1002/pst.426; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; SINICROPE FA, 1995, CANCER RES, V55, P237; Skoda AM, 2018, BOSNIAN J BASIC MED, V18, P8, DOI 10.17305/bjbms.2018.2756; Sun X, 2015, CURR REV MUSCULOSKE, V8, P344, DOI 10.1007/s12178-015-9311-x; Szkandera J, 2014, CLIN CANCER RES, V20, P1687, DOI 10.1158/1078-0432.CCR-13-1517; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Theunissen JW, 2009, CANCER RES, V69, P6007, DOI 10.1158/0008-5472.CAN-09-0756; Tian H, 2009, P NATL ACAD SCI USA, V106, P4254, DOI 10.1073/pnas.0813203106; Vinall RL, 2007, CLIN CANCER RES, V13, P6204, DOI 10.1158/1078-0432.CCR-07-0600; Wang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075407; Williams S, 2019, CURR TOP DEV BIOL, V133, P49, DOI 10.1016/bs.ctdb.2018.11.018; Wu FJ, 2017, CELL CHEM BIOL, V24, P252, DOI 10.1016/j.chembiol.2017.02.010; Yakldoui Y, 2014, BBA-REV CANCER, V1846, P655, DOI 10.1016/j.bbcan.2014.07.012; Zhu JJ, 2016, P NATL ACAD SCI USA, V113, P3820, DOI 10.1073/pnas.1601252113	44	6	6	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4711	4727		10.1038/s41388-020-1324-2	http://dx.doi.org/10.1038/s41388-020-1324-2		MAY 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32404987				2023-01-03	WOS:000532807900002
J	Nikinmaa, S; Alapulli, H; Auvinen, P; Vaara, M; Rantala, J; Kankuri, E; Sorsa, T; Meurman, J; Patila, T				Nikinmaa, Sakari; Alapulli, Heikki; Auvinen, Petri; Vaara, Martti; Rantala, Juha; Kankuri, Esko; Sorsa, Timo; Meurman, Jukka; Patila, Tommi			Dual-light photodynamic therapy administered daily provides a sustained antibacterial effect on biofilm and prevents Streptococcus mutans adaptation	PLOS ONE			English	Article							INDOCYANINE GREEN; RESISTANCE; CARIES	Antibacterial photodynamic therapy (aPDT) and antibacterial blue light (aBL) are emerging treatment methods auxiliary to mechanical debridement for periodontitis. APDT provided with near-infrared (NIR) light in conjunction with an indocyanine green (ICG) photosensitizer has shown efficacy in several dental in-office-treatment protocols. In this study, we tested Streptococcus mutans biofilm sensitivity to either aPDT, aBL or their combination dual-light aPDT (simultaneous aPDT and aBL) exposure. Biofilm was cultured by pipetting diluted Streptococcus mutans suspension with growth medium on the bottom of well plates. Either aPDT (810 nm) or aBL (405 nm) or a dual-light aPDT (simultaneous 810 nm aPDT and 405 nm aBL) was applied with an ICG photosensitizer in cases of aPDT or dual-light, while keeping the total given radiant exposure constant at 100 J/cm(2). Single-dose light exposures were given after one-day or four-day biofilm incubations. Also, a model of daily treatment was provided by repeating the same light dose daily on four-day and fourteen-day biofilm incubations. Finally, the antibacterial action of the dual-light aPDT with different energy ratios of 810 nm and 405 nm of light were examined on the single-day and four-day biofilm protocols. At the end of each experiment the bacterial viability was assessed by colony-forming unit method. Separate samples were prepared for confocal 3D biofilm imaging. On a one-day biofilm, the dual-light aPDT was significantly more efficient than aBL or aPDT, although all modalities were bactericidal. On a four-day biofilm, a single exposure of aPDT or dual-light aPDT was more efficient than aBL, resulting in a four logarithmic scale reduction in bacterial counts. Surprisingly, when the same amount of aPDT was repeated daily on a four-day or a fourteen-day biofilm, bacterial viability improved significantly. A similar improvement in bacterial viability was observed after repetitive aBL application. This viability improvement was eliminated when dual-light aPDT was applied. By changing the 405 nm to 810 nm radiant exposure ratio in dual-light aPDT, the increase in aBL improved the antibacterial action when the biofilm was older. In conclusion, when aPDT is administered repeatedly to S. mutans biofilm, a single wavelength-based aBL or aPDT leads to a significant biofilm adaptation and increased S. mutans viability. The combined use of aBL light in synchrony with aPDT arrests the adaptation and provides significantly improved and sustained antibacterial efficacy.	[Nikinmaa, Sakari; Meurman, Jukka; Patila, Tommi] Aalto Univ, Dept Neurosci & Biomed Engn, Espoo, Finland; [Nikinmaa, Sakari; Rantala, Juha; Patila, Tommi] Koite Hlth Oy, Espoo, Finland; [Alapulli, Heikki; Sorsa, Timo; Meurman, Jukka] Univ Helsinki, Dept Oral & Maxillofacial Dis, Helsinki, Finland; [Auvinen, Petri] Univ Helsinki, Inst Biotechnol, Helsinki, Finland; [Vaara, Martti] Northern Antibiot, Espoo, Finland; [Vaara, Martti] Univ Helsinki, Med Sch, Dept Bacteriol & Immunol, Helsinki, Finland; [Kankuri, Esko] Univ Helsinki, Dept Pharmacol, Helsinki, Finland; [Sorsa, Timo] Karolinska Inst, Dept Oral Dis, Huddinge, Sweden; [Patila, Tommi] Univ Helsinki, New Childrens Hosp, Dept Congenital Heart Surg & Organ Transplantat, Helsinki, Finland	Aalto University; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Karolinska Institutet; University of Helsinki	Patila, T (corresponding author), Aalto Univ, Dept Neurosci & Biomed Engn, Espoo, Finland.; Patila, T (corresponding author), Koite Hlth Oy, Espoo, Finland.; Patila, T (corresponding author), Univ Helsinki, New Childrens Hosp, Dept Congenital Heart Surg & Organ Transplantat, Helsinki, Finland.	tommi.patila@hus.fi	Auvinen, Petri/AAP-8117-2021; Auvinen, Petri/D-5044-2009	Auvinen, Petri/0000-0002-3947-4778; Kankuri, Esko/0000-0002-2193-8773				Chenicheri S, 2017, OPEN DENT J, V11, P312, DOI 10.2174/1874210601711010312; Cieplik F, 2018, CRIT REV MICROBIOL, V44, P571, DOI 10.1080/1040841X.2018.1467876; Claydon NC, CURRENT CONCEPTS TOO; Costa EM, 2013, ANAEROBE, V20, P27, DOI 10.1016/j.anaerobe.2013.02.002; CRUZ CD, 2018, BMC MICROBIOL, V18, P4806, DOI DOI 10.1186/S12866-017-1144-X; de Sousa DL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131941; Engel E, 2008, INVEST OPHTH VIS SCI, V49, P1777, DOI 10.1167/iovs.07-0911; Esberg A, 2017, EBIOMEDICINE, V24, P205, DOI 10.1016/j.ebiom.2017.09.027; Fekrazad R, 2013, PHOTODIAGN PHOTODYN, V10, P626, DOI 10.1016/j.pdpdt.2013.07.002; Guffey JS, 2013, PHOTOMED LASER SURG, V31, P179, DOI 10.1089/pho.2012.3450; HOLLINS B, 1987, CLIN CHEM, V33, P765; Konopka K, 2007, J DENT RES, V86, P694, DOI 10.1177/154405910708600803; Larsen T, 2017, APMIS, V125, P376, DOI 10.1111/apm.12688; Lee YH, 2012, INT J ORAL SCI, V4, P196, DOI 10.1038/ijos.2012.63; Liu CC, 2015, SCI REP-UK, V5, DOI 10.1038/srep12929; Rineh A, 2018, BIOORG MED CHEM LETT, V28, P2736, DOI 10.1016/j.bmcl.2018.02.041; Robinson JM, 2009, HISTOCHEM CELL BIOL, V131, P465, DOI 10.1007/s00418-009-0565-5; Shafirstein G, 2012, INT J CANCER, V130, P1208, DOI 10.1002/ijc.26126; Socransky SS, 2002, PERIODONTOL 2000, V28, P12, DOI 10.1034/j.1600-0757.2002.280102.x; Song T, 2013, PROCEEDINGS OF THE 2013 SUZHOU-SILICON VALLEY-BEIJING INTERNATIONAL INNOVATION CONFERENCE (SIIC): TECHNOLOGY INNOVATION AND DIASPORAS IN A GLOBAL ERA, P72, DOI 10.1109/SIIC.2013.6624169; Soukos NS, 2005, ANTIMICROB AGENTS CH, V49, P1391, DOI 10.1128/AAC.49.4.1391-1396.2005; Steinberg D, 2008, ANTIMICROB AGENTS CH, V52, P2626, DOI 10.1128/AAC.01666-07; Tam K, 2007, CARIES RES, V41, P474, DOI 10.1159/000108321; Tavares A, 2010, MAR DRUGS, V8, P91, DOI 10.3390/md8010091; Tegos GP, 2006, ANTIMICROB AGENTS CH, V50, P196, DOI 10.1128/AAC.50.1.196-203.2006; Wang YC, 2017, DRUG RESIST UPDATE, V33-35, P1, DOI 10.1016/j.drup.2017.10.002; Yuan BH, 2004, J BIOMED OPT, V9, P497, DOI 10.1117/1.1695411	27	17	17	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2020	15	5							e0232775	10.1371/journal.pone.0232775	http://dx.doi.org/10.1371/journal.pone.0232775			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT7ZB	32374766	Green Published, Green Submitted, gold			2023-01-03	WOS:000537283500060
J	Dirisu, O; Eluwa, G; Adams, E; Torpey, K; Shittu, O; Adebajo, S				Dirisu, Osasuyi; Eluwa, George; Adams, Eseoghene; Torpey, Kwasi; Shittu, Oladapo; Adebajo, Sylvia			"I think this is the only challenge ... the stigma" Stakeholder perceptions about barriers to Antenatal care (ANC) and Prevention of mother-to-child transmission (PMTCT) uptake in Kano state, Nigeria	PLOS ONE			English	Article							FOLLOW-UP; HIV; IMPLEMENTATION; PROGRAM; CASCADE	Background Despite the progress made so far in reducing mother-to-child transmission (MTCT), Nigeria still contributes significantly to the global burden of new pediatric HIV infections. The elimination target for MTCT has not been reached and the decline in new infections among all Global Plan countries from 2009 to 2015 was lowest in Nigeria. This qualitative study explores the barriers to uptake of prevention of mother-to-child transmission (PMTCT) intervention in Kano, the second most populous state in Nigeria. Methods Key informant interviews (KIIs) were conducted among twelve stakeholders who were purposively selected based on their knowledge and involvement in PMTCT program activities in the state. The KII guide explored the status and challenges of PMTCT uptake in Kano state. Qualitative data analysis was managed using NVIVO 11 software and themes were analyzed using thematic analysis. Results We found that the key barriers to uptake of PMTCT identified by stakeholders cut across the domains of the socio-ecological model. These include-fear of stigma associated with being seen accessing HIV related services, low male partner involvement, socio-cultural beliefs about the dangers of hospital-based delivery, poor attitude of health workers, distance/cost to facilities, issues with availability of HIV test kits and poor organization of health services. Conclusion The implementation of effective PMTCT programs would require innovative strategies that leverage improvement of Antenatal care (ANC) uptake as an entry point for PMTCT. In addition, sustaining engagement in care requires creating a supportive stigma-free environment in the community as well as spousal support to ensure women can navigate the socio-cultural barriers that limit access to health services.	[Dirisu, Osasuyi; Eluwa, George; Adebajo, Sylvia] Populat Council, HIV & AIDS Program, Abuja, Nigeria; [Adams, Eseoghene] LEEDx Africa, Abuja, Nigeria; [Torpey, Kwasi] Univ Ghana, Coll Hlth Sci, Accra, Ghana; [Shittu, Oladapo] Ahmadu Bello Univ, Teaching Hosp, Dept Obstet & Gynaecol, Zaria, Kaduna, Nigeria	University of Ghana; Ahmadu Bello University	Dirisu, O (corresponding author), Populat Council, HIV & AIDS Program, Abuja, Nigeria.	osasuyidirisu@gmail.com			United States Presidential Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID) [AID-620-A-00002]	United States Presidential Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID)(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This study was carried out as part of Strengthening Integrated Delivery of HIV/AIDS Services (SIDSHAS) project, funded by the United States Presidential Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID) under the Cooperative Agreement AID-620-A-00002, managed by an FHI 360-led consortium. The funders played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.	Aizire J, 2013, CURR HIV RES, V11, P144, DOI 10.2174/1570162X11311020007; Al-Mujtaba M, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3645415; Avert, 2019, HIV AIDS NIG; Bwirire LD, 2008, T ROY SOC TROP MED H, V102, P1195, DOI 10.1016/j.trstmh.2008.04.002; Ezeanolue EE, 2016, JAIDS-J ACQ IMM DEF, V72, pS161, DOI 10.1097/QAI.0000000000001066; Fagbamigbe AF, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0527-y; Ginsburg AS, 2007, AIDS, V21, P2529, DOI 10.1097/QAD.0b013e3282f155f4; Gourlay A, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18588; Gulaid LA, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.4.17390; Hampanda K., 2013, ISRN INFECT DIS, V2012; Haroz D, 2017, JAIDS-J ACQ IMM DEF, V75, pS2, DOI 10.1097/QAI.0000000000001318; HIarlaithe MO, 2014, AIDS BEHAV, V18, pS516, DOI 10.1007/s10461-014-0756-5; Igwegbe A., 2010, J MED MED SCI, V1, P296; Iwelunmor J, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-771; Kalembo FW, 2012, ISRN AIDS, V2012; Liu JX, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2172-3; Lumbantoruan C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198329; National Population Commission (NPC), 2012, KAN STAT POP PROJ 20; National Population Commission (NPC) [Nigeria] ICF, 2019, NIG DEM HLTH SURV 20; Nyasulu J. Y., 2011, Journal of Rural and Tropical Public Health, V10, P48; Okoli JC, 2014, PAN AFR MED J, V19, DOI 10.11604/pamj.2014.19.154.4225; Olugbenga-Bello AI, 2013, INT J WOMENS HEALTH, V5, P399, DOI 10.2147/IJWH.S45815; Onono M., 2015, J AIDS CLIN RES, V6; Rawizza HE, 2015, CURR HIV RES, V13, P201, DOI 10.2174/1570162X1303150506183256; Rollins N, 2014, JAIDS-J ACQ IMM DEF, P67; Sam-Agudu NA, 2014, JAIDS-J ACQ IMM DEF, P67; Sam-Agudu NA, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1417-2; Sloan NL, 2018, MATERN CHILD HLTH J, P1; Theuring S, 2009, AIDS BEHAV, V13, pS92, DOI 10.1007/s10461-009-9543-0; Turan JM, 2015, JAIDS-J ACQ IMM DEF, V69, pe172, DOI 10.1097/QAI.0000000000000678; UNAIDS, 2016, PREV GAP REP; UNAIDS, 2019, EXP DAT COLL AN PROV; UNAIDS, 2021, GLOB HIV AIDS STAT F; UNAIDS, 2011, COUNTD ZER GLOB PLAN; WHO, MOTH TO CHILD TRANSM; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; World Bank, 2019, TRENDS MAT MORT 2000; World Health Organization, 2010, PMTCT STRAT VIS 2010; Youngleson MS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013891	39	4	4	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2020	15	4							e0232028	10.1371/journal.pone.0232028	http://dx.doi.org/10.1371/journal.pone.0232028			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LS8VC	32339180	Green Published, gold			2023-01-03	WOS:000536657400022
J	Yeh, YT; Lu, TJ; Lian, GT; Lung, MC; Lee, YL; Chiang, AN; Hsieh, SC				Yeh, Yu-Te; Lu, Ting-Jang; Lian, Guan-Ting; Lung, Meng-Chuan; Lee, Yu-Lin; Chiang, An-Na; Hsieh, Shu-Chen			Chinese olive (Canarium album L.) fruit regulates glucose utilization by activating AMP-activated protein kinase	FASEB JOURNAL			English	Article						AMPK; Chinese olive (Canarium album L; ); high-fat diet; glucose uptake; mitochondrial	INSULIN-RESISTANCE; SKELETAL-MUSCLE; GLYCOGEN-SYNTHASE; MOLECULAR-MECHANISMS; GLUT4 TRANSLOCATION; IN-VIVO; INHIBITION; METFORMIN; POLYPHENOLS; EXERCISE	A growing body of evidence demonstrates obesity-induced insulin resistance is associated with the development of metabolic diseases. This study was designed to investigate ethyl acetate fraction of Chinese olive fruit extract (CO-EtOAc)-mediated attenuation of obesity and hyperglycemia in a mouse model. About 60% HFD-fed mice were treated intragastrically with CO-EtOAc for last 6 weeks, and body weight, blood biochemical parameters as well as hepatic inflammation response were investigated. Our results showed that CO-EtOAc treatment significantly reduced the formation of hepatic lipid droplets, body weight gain, blood glucose, and improved serum biochemical parameters in HFD-induced obese and insulin resistant mice. We further explored the molecular mechanism underlying the blood glucose modulating effect of CO-EtOAc using L6 myotubes model. We conclude that CO-EtOAc effectively increases the glycogen content and glucose uptake by stimulating the membrane translocation of glucose transporter 4. In addition, CO-EtOAc depolarizes the mitochondrial membrane and decreases the mitochondrial oxygen consumption, which may result in AMPK activation and the consequent mitochondrial fission. This study shows that CO-EtOAc prevents the development of obesity in mice fed with HFD and is also capable of stimulating glucose uptake. The possible mechanism might be due to the effects of CO-EtOAc on activation of AMPK and promotion of mitochondrial fission.	[Yeh, Yu-Te; Lu, Ting-Jang; Lian, Guan-Ting; Lung, Meng-Chuan; Hsieh, Shu-Chen] Natl Taiwan Univ, Inst Food Sci & Technol, Taipei 106, Taiwan; [Yeh, Yu-Te] Johns Hopkins Univ, Johns Hopkins All Childrens Hosp, Inst Fundamental Biomed Res, Dept Med,Div Endocrinol Diabet & Metab,Sch Med, St Petersburg, FL USA; [Lee, Yu-Lin; Chiang, An-Na] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan	National Taiwan University; Johns Hopkins University; Johns Hopkins Medicine; National Yang Ming Chiao Tung University	Hsieh, SC (corresponding author), Natl Taiwan Univ, Inst Food Sci & Technol, Taipei 106, Taiwan.	schsieh@ntu.edu.tw		LU, TING-JANG/0000-0002-3956-8272	Ministry of Science and Technology, Taiwan (MOST) [104&-3011&-B&-010-001-1-4-2, 104&-2320-B-002-039]	Ministry of Science and Technology, Taiwan (MOST)(Ministry of Science and Technology, Taiwan)	Ministry of Science and Technology, Taiwan (MOST), Grant/Award Number: 104&-3011&-B&-010&-001&-1&-4&-2 and 104&-2320&-B&-002&-039	Atanasov AG, 2015, BIOTECHNOL ADV, V33, P1582, DOI 10.1016/j.biotechadv.2015.08.001; Bahadoran Z, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251-6581-12-43; Boden G, 1999, P ASSOC AM PHYSICIAN, V111, P241, DOI 10.1046/j.1525-1381.1999.99220.x; Calmettes G, 2015, J MOL CELL CARDIOL, V78, P107, DOI 10.1016/j.yjmcc.2014.09.020; Cao J, 2014, J BIOL CHEM, V289, P20435, DOI 10.1074/jbc.M114.567271; Chen XP, 2009, CELL BIOCHEM FUNCT, V27, P407, DOI 10.1002/cbf.1596; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dali-Youcef N, 2013, ANN MED, V45, P242, DOI 10.3109/07853890.2012.705015; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; Doan KV, 2015, ENDOCRINOLOGY, V156, P157, DOI 10.1210/en.2014-1354; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Gaemers IC, 2011, BBA-MOL BASIS DIS, V1812, P447, DOI 10.1016/j.bbadis.2011.01.003; Gledhill JR, 2007, P NATL ACAD SCI USA, V104, P13632, DOI 10.1073/pnas.0706290104; Graham TE, 2007, HORM METAB RES, V39, P717, DOI 10.1055/s-2007-985879; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Grover JK, 2002, J ETHNOPHARMACOL, V81, P81, DOI 10.1016/S0378-8741(02)00059-4; Gupta RN, 2009, INT J DIABETES DEV C, V29, P170, DOI 10.4103/0973-3930.57349; Hardie DG, 2014, CELL METAB, V20, P939, DOI 10.1016/j.cmet.2014.09.013; Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001; Hsieh SC, 2016, FOOD FUNCT, V7, P4797, DOI [10.1039/c6fo01202g, 10.1039/C6FO01202G]; Hu RK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00925-y; Hur KY, 2015, J DIABETES INVEST, V6, P600, DOI 10.1111/jdi.12328; Jeon M, 2016, BIOCHEM BIOPH RES CO, V479, P22, DOI 10.1016/j.bbrc.2016.08.178; Kanamaru Yusuke, 2012, J Signal Transduct, V2012, P931215, DOI 10.1155/2012/931215; Lazar MA, 2005, SCIENCE, V307, P373, DOI 10.1126/science.1104342; Lee EY, 2017, YONSEI MED J, V58, P312, DOI 10.3349/ymj.2017.58.2.312; Liew YF, 2005, J NUTR, V135, P2151, DOI 10.1093/jn/135.9.2151; LILLIOJA S, 1986, J CLIN ENDOCR METAB, V62, P922, DOI 10.1210/jcem-62-5-922; Liu HY, 2008, FOOD RES INT, V41, P363, DOI 10.1016/j.foodres.2007.12.012; Lizcano JM, 2002, CURR BIOL, V12, pR236, DOI 10.1016/S0960-9822(02)00777-7; Manchester J, 1996, P NATL ACAD SCI USA, V93, P10707, DOI 10.1073/pnas.93.20.10707; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Musi N, 2006, CURR MED CHEM, V13, P583, DOI 10.2174/092986706776055724; Nagano T, 2015, FOOD SCI TECHNOL RES, V21, P489, DOI 10.3136/fstr.21.489; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Polce SA, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050531; Poulose N, 2011, J DIABETES METAB, V2, DOI 10.4172/2155-6156.1000149; Prasad CNV, 2010, FEBS LETT, V584, P531, DOI 10.1016/j.febslet.2009.11.092; Rizza RA, 2010, DIABETES, V59, P2697, DOI 10.2337/db10-1032; Sajan MP, 2010, AM J PHYSIOL-ENDOC M, V298, pE179, DOI 10.1152/ajpendo.00392.2009; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; Solini A, 2001, HYPERTENSION, V37, P1492, DOI 10.1161/01.HYP.37.6.1492; Sriwijitkamol A, 2007, DIABETES, V56, P836, DOI 10.2337/db06-1119; Stanford KI, 2014, ADV PHYSIOL EDUC, V38, P308, DOI 10.1152/advan.00080.2014; Tantama M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3550; Taylor R, 1996, J CLIN INVEST, V97, P126, DOI 10.1172/JCI118379; Thornton C, 2017, NEURONAL SIGNALING, V1, P1; Toyama EQ, 2016, SCIENCE, V351, P275, DOI 10.1126/science.aab4138; Unger RH, 2003, ENDOCRINOLOGY, V144, P5159, DOI 10.1210/en.2003-0870; Xiao JB, 2015, CURR MED CHEM, V22, P23; Yamada E, 2010, FUTURE MED CHEM, V2, P1785, DOI 10.4155/FMC.10.264; Yang JZ, 2014, PROG MOL BIOL TRANSL, V121, P133, DOI 10.1016/B978-0-12-800101-1.00005-3; Yeh YT, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19553-1; Yeh YT, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101123; Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012; Zhang CS, 2016, CELL METAB, V23, P399, DOI 10.1016/j.cmet.2016.02.017; Zhang JD, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4353510	57	4	6	1	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2020	34	6					7866	7884		10.1096/fj.201902494RR	http://dx.doi.org/10.1096/fj.201902494RR		APR 2020	19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MR4QG	32333610				2023-01-03	WOS:000529447300001
J	Katz, P				Katz, Paul			Stemming the Escalating Costs of Prescription Drugs	ANNALS OF INTERNAL MEDICINE			English	Letter									[Katz, Paul] George Washington Univ, Sch Publ Hlth, Milken Inst, Washington, DC 20052 USA	George Washington University	Katz, P (corresponding author), George Washington Univ, Sch Publ Hlth, Milken Inst, Washington, DC 20052 USA.							[Anonymous], HHS SUGG GETT RID D; CongressionalBudgetOffice, 2019, INC EFF PROP RUL SAF; Daniel H, 2019, ANN INTERN MED, V171, P823, DOI 10.7326/M19-0035	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 21	2020	172	8					573	574		10.7326/L20-0110	http://dx.doi.org/10.7326/L20-0110			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF9LH	32311709				2023-01-03	WOS:000527733800025
J	Tan, CQ; Wu, C; Huang, YL; Wu, CJ; Chen, H				Tan, Chaoqun; Wu, Chong; Huang, Yongliang; Wu, Chunjie; Chen, Hu			Identification of different species of Zanthoxyli Pericarpium based on convolution neural network	PLOS ONE			English	Article							BUNGEANUM MAXIM.	Zanthoxyli Pericarpium (ZP) are the dried ripe peel of Zanthoxylum schinifolium Sieb. et Zucc (ZC) or Zanthoxylum bungeanum Maxim (ZB). It has wide range of uses both medicine and food, and favorable market value. The diverse specifications of components of ZP is exceptional, and the common aims of adulteration for economic profit is conducted. In this work, a novel method for the identification different species of ZP is proposed using convolutional neural networks (CNNs). The data used for the experiment is 5 classes obtained from camera and mobile phones. Firstly, the data considering 2 categories are trained to detect the labels by YOLO. Then, the multiple deep learning including VGG, ResNet, Inception v4, and DenseNet are introduced to identify the different species of ZP (HZB, DZB, OZB, ZA and JZC). In order to assess the performance of CNNs, compared with two traditional identification models including Support Vector Machines (SVM) and Back Propagation (BP). The experimental results demonstrate that the CNN model have a better performance to identify different species of ZP and the highest identification accuracy is 99.35%. The present study is proved to be a useful strategy for the discrimination of different traditional Chinese medicines (TCMs).	[Tan, Chaoqun; Wu, Chong; Chen, Hu] Sichuan Univ, Natl Key Lab Fundamental Sci Synthet Vis, Coll Comp Sci, Chengdu, Peoples R China; [Tan, Chaoqun; Wu, Chunjie] Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu, Peoples R China; [Huang, Yongliang] Chengdu Univ Tradit Chinese Med, Affiliated Hosp, Chengdu, Peoples R China	Sichuan University; Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine	Chen, H (corresponding author), Sichuan Univ, Natl Key Lab Fundamental Sci Synthet Vis, Coll Comp Sci, Chengdu, Peoples R China.	huchen@scu.edu.cn			Key Project of Sichuan Province Ministry of Science and Technology [2018JY0435]; Project of State Administration of Traditional Chinese Medicine of China [2018QN003]; Information Research Project of Chengdu University of Traditional Chinese Medicine [MIEC1803]	Key Project of Sichuan Province Ministry of Science and Technology; Project of State Administration of Traditional Chinese Medicine of China; Information Research Project of Chengdu University of Traditional Chinese Medicine	This study is supported by the Key Project of Sichuan Province Ministry of Science and Technology (No.2018JY0435), Project of State Administration of Traditional Chinese Medicine of China (No.2018QN003) and Information Research Project of Chengdu University of Traditional Chinese Medicine (No.MIEC1803).	Altuntas Y, 2019, COMPUT ELECTRON AGR, V163, DOI 10.1016/j.compag.2019.104874; Artzai P, 2019, COMPUTERS ELECT AGR, V167; Batchuluun G, 2018, EXPERT SYST APPL, V101, P56, DOI 10.1016/j.eswa.2018.02.016; [陈光静 Chen Guangjing], 2015, [中国粮油学报, Journal of the Chinese Cereals and Oils Association], V30, P81; China Pharmaceutical Technology Press, 2015, PHARM PEOPL REP CH 1; Diao YF, 2020, NEUROCOMPUTING, V381, P105, DOI 10.1016/j.neucom.2019.09.042; Fricker GA, 2019, REMOTE SENS-BASEL, V11, DOI 10.3390/rs11192326; Geetharamani G, 2019, COMPUT ELECTR ENG, V76, P323, DOI 10.1016/j.compeleceng.2019.04.011; Hansen ME, 2018, COMPUT IND, V98, P145, DOI 10.1016/j.compind.2018.02.016; Huang S, 2012, CHINESE CHEM LETT, V23, P1247, DOI 10.1016/j.cclet.2012.09.022; Hussein B R, 2019, LECT NOTES ELECT ENG, V2020, P85; Kattenborn T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53797-9; Ke J, 2016, IND CROP PROD, V119, P267; Kuang HL, 2018, NEUROCOMPUTING, V283, P241, DOI 10.1016/j.neucom.2017.12.057; Lan Y., 2016, J TRADI CHINESE MED, V3, P157; Lan Y, 2014, J ZHEJIANG UNIV-SC B, V15, P153, DOI 10.1631/jzus.B1300230; Le THN, 2018, PATTERN RECOGN, V80, P32, DOI 10.1016/j.patcog.2018.01.005; Li H, 2016, J ALLERGY CLIN IMMUN, V137, pAB143, DOI 10.1016/j.jaci.2015.12.600; Li YZ, 2018, NEUROCOMPUTING, V314, P336, DOI 10.1016/j.neucom.2018.06.068; Park YJ, 2017, KNOWL-BASED SYST, V138, P15, DOI 10.1016/j.knosys.2017.09.028; Saleem MH, 2019, PLANTS-BASEL, V8, DOI 10.3390/plants8110468; Sun XD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150513; Tan CQ, 2018, ANAL CHEM, V90, P3460, DOI 10.1021/acs.analchem.7b05189; Tang WZ, 2014, J ETHNOPHARMACOL, V152, P444, DOI 10.1016/j.jep.2014.01.013; Tao O, 2014, WORLD SCI TECHNOLOGY, V16, P2558; Tao O, 2014, WORLD SCI TECHNOLOGY, V16, P2550; Tao O, 2014, WORLD SCI TECHNOLOGY, V16, P2531; Tao XB, 2017, INT J FOOD PROP, V20, P3056, DOI 10.1080/10942912.2016.1271808; Tezuka Y, 2001, J ETHNOPHARMACOL, V77, P209, DOI 10.1016/S0378-8741(01)00300-2; Traore BB, 2018, ECOL INFORM, V48, P257, DOI 10.1016/j.ecoinf.2018.10.002; [吴莉莉 Wu Lili], 2016, [传感技术学报, Chinese Journal of Sensors and Actuators], V29, P136; [吴莉莉 Wu Lili], 2013, [传感技术学报, Chinese Journal of Sensors and Actuators], V26, P1473; Wu XY, 2018, SPECTROSC SPECT ANAL, V38, P2369, DOI 10.3964/j.issn.1000-0593(2018)08-2369-05; Wu XJ, 2020, FOOD CHEM, V311, DOI 10.1016/j.foodchem.2019.125882; Xue W, 2019, BIORESOURCE TECHNOL, V290, DOI 10.1016/j.biortech.2019.121761; Yan ZM, 2021, INT J CONTROL, V94, P111, DOI 10.1080/00207179.2019.1585955; Yang Zheng, 2014, Journal of Chinese Institute of Food Science and Technology, V14, P226; Zhang MM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102172; Zhang SW, 2019, COMPUT ELECTRON AGR, V162, P422, DOI 10.1016/j.compag.2019.03.012; Zhao LC, 2019, REMOTE SENS-BASEL, V11, DOI 10.3390/rs11222641; Zhu H, 2016, QUATERN INT, V392, P224, DOI 10.1016/j.quaint.2015.05.020	41	6	8	4	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2020	15	4							e0230287	10.1371/journal.pone.0230287	http://dx.doi.org/10.1371/journal.pone.0230287			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR9BE	32282810	gold, Green Published			2023-01-03	WOS:000535989800005
J	Dominguez-Rodriguez, S; Prieto, L; McPhee, CF; Illaan-Ramos, M; Beceiro, J; Escosa, L; Munoz, E; Olabarrieta, I; Regidor, FJ; Roa, MA; Beneitez, MDV; Guillen, S; Navarro-Gomez, ML; Amador, JTR				Dominguez-Rodriguez, Sara; Prieto, Luis; Fernandez McPhee, Carolina; Illan-Ramos, Marta; Beceiro, Jose; Escosa, Luis; Munoz, Eloy; Olabarrieta, Iciar; Javier Regidor, Francisco; Angel Roa, Miguel; Vinuela Beneitez, Maria del Carmen; Guillen, Sara; Luisa Navarro-Gomez, Maria; Ramos Amador, Jose Tomas		Madrid Cohort HIV	Perinatal HCV Transmission Rate in HIV/HCV Coinfected women with access to ART in Madrid, Spain	PLOS ONE			English	Article							HEPATITIS-C VIRUS; TO-CHILD TRANSMISSION; VERTICAL TRANSMISSION; RISK-FACTORS; INFECTION; PREGNANCY; IMPACT; HIV; ERA	Background Maternal HIV coinfection is a key factor for mother-to-child transmission (MTCT) of HCV. However, data about HCV MTCT in HIV/HCV-coinfected pregnant women on combined antiretroviral treatment (ART) are scarce. This study assessed the HCV MTCT rate in the Madrid Cohort of HIV-infected women. Methods Retrospective study within the Madrid Cohort of HIV-infected pregnant women (2000-2012). Epidemiological, clinical and treatment related variables were analysed for the mother and infant pairs. HCV MTCT rate was determined. Results Three hundred thirty-nine HIV/HCV-coinfected women and their exposed infants were recorded. A total of 227 (67%) paired mother-children had available data of HCV follow-up and were included for the analysis. Sixteen children (rate 7.0%, 95%CI 3.7-10.4%) were HCV infected by 18 months of age, none of them coinfected with HIV. HIV/HCV-coinfected pregnant women were mostly of Spanish origin with a background of previous injection drug use. HCV-genotype 1 was predominant. The characteristics of mothers that transmitted HCV were similar to those that did not transmit HCV with respect to sociodemographic and clinical features. A high rate (50%) of preterm deliveries was observed. Infants infected with HCV were similar at birth in weight, length and head circumference than those uninfected. Conclusion MTCT rates of HCV among HIV/HCV-coinfected women on ART within the Madrid cohort were lower than previously described. However, rates are still significant and strategies to eliminate any HCV transmission from mother to child are needed.	[Dominguez-Rodriguez, Sara; Prieto, Luis; Munoz, Eloy] Hosp Univ 12 Octubre, Madrid, Spain; [Dominguez-Rodriguez, Sara] Fdn SEIMC GESIDA, Madrid, Spain; [Fernandez McPhee, Carolina; Vinuela Beneitez, Maria del Carmen; Luisa Navarro-Gomez, Maria] Spain Univ Complutense, Inst Invest Sanitaria Gregorio Maranon IISGM, Hosp Gen Univ Gregorio Maranon, CoRISpe, Madrid, Spain; [Illan-Ramos, Marta; Ramos Amador, Jose Tomas] Hosp Clin San Carlos, Madrid, Spain; [Beceiro, Jose; Olabarrieta, Iciar] Hosp Principe Asturias, Alcala De Henares, Spain; [Escosa, Luis; Javier Regidor, Francisco] Hosp Univ La Paz, Serv Pediatria Hosp Enfermedades Infecciosas & Tr, Inst Invest IdiPAZ, Madrid, Spain; [Luisa Navarro-Gomez, Maria; Ramos Amador, Jose Tomas] Red Invest Translac Infectol Pediat RITIP, Madrid, Spain; [Angel Roa, Miguel] Hosp Gen Mostoles, Mostoles, Spain; [Guillen, Sara] Hosp Getafe, Getafe, Spain	Hospital Universitario 12 de Octubre; General University Gregorio Maranon Hospital; Hospital Clinico San Carlos; Prince of Asturias University Hospital; Hospital Universitario La Paz; Hospital Universitario de Getafe	Dominguez-Rodriguez, S (corresponding author), Hosp Univ 12 Octubre, Madrid, Spain.; Dominguez-Rodriguez, S (corresponding author), Fdn SEIMC GESIDA, Madrid, Spain.; Navarro-Gomez, ML (corresponding author), Spain Univ Complutense, Inst Invest Sanitaria Gregorio Maranon IISGM, Hosp Gen Univ Gregorio Maranon, CoRISpe, Madrid, Spain.; Navarro-Gomez, ML (corresponding author), Red Invest Translac Infectol Pediat RITIP, Madrid, Spain.	sara.dominguez.r@gmail.com; marisa.navarro.gomez@gmail.com	Prieto, Luis Enrique/HFZ-7903-2022; Domínguez Rodríguez, Sara/AFO-1443-2022; Escosa-Garcia, Luis/AFZ-2323-2022	Domínguez Rodríguez, Sara/0000-0003-3747-9265; Illan Ramos, Marta/0000-0003-2491-1549	Instituto de Salud Carlos III-Spanish Ministry of Science and Innovation under The Spanish National Cohort of HIV-infected Children (CoRISpe) [EC11-130]; Spanish National AIDS Research Network (RIS) [RD16/0025/0019]; "Fundacion para la Investigacion y Prevencion del SIDA en Espana (FIPSE)" [3049, 362991, 36531/05, 36737/08]	Instituto de Salud Carlos III-Spanish Ministry of Science and Innovation under The Spanish National Cohort of HIV-infected Children (CoRISpe); Spanish National AIDS Research Network (RIS); "Fundacion para la Investigacion y Prevencion del SIDA en Espana (FIPSE)"	This study was supported by the Instituto de Salud Carlos III-Spanish Ministry of Science and Innovation (EC11-130) under The Spanish National Cohort of HIV-infected Children (CoRISpe), included in the Spanish National AIDS Research Network (RIS) [Grant no RD16/0025/0019 cofounded by "Fondo Europeo de Desarrollo Regional (FEDER)"], and by the "Fundacion para la Investigacion y Prevencion del SIDA en Espana (FIPSE)" covered by 3049; 362991; 36531/05 and 36737/08 projects. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aebi-Popp K, 2016, J VIRUS ERAD, V2, P52; Munoz-Gamez JA, 2016, MED CLIN-BARCELONA, V147, P499, DOI 10.1016/j.medcli.2016.04.003; Arshad M, 2011, J VIRAL HEPATITIS, V18, P229, DOI 10.1111/j.1365-2893.2010.01413.x; Benhammou V, 2018, JAIDS-J ACQ IMM DEF, V77, P439, DOI 10.1097/QAI.0000000000001618; Benova L, 2014, CLIN INFECT DIS, V59, P765, DOI 10.1093/cid/ciu447; Bortolotti F, 2007, J HEPATOL, V46, P783, DOI 10.1016/j.jhep.2006.12.014; Chappell CA, PHASE 1 PHARMACOKINE; Cabot CAC, 2013, J PEDIAT INF DIS SOC, V2, P126, DOI 10.1093/jpids/pis091; Claret-Teruel G, 2011, PEDIATR INFECT DIS J, V30, P801, DOI 10.1097/INF.0b013e3182196ab4; Delgado-Borrego A, 2012, J PEDIATR-US, V161, P915, DOI 10.1016/j.jpeds.2012.05.002; Garcia-Tejedor A, 2015, EUR J OBSTET GYN R B, V194, P173, DOI 10.1016/j.ejogrb.2015.09.009; Gibb DM, 2000, LANCET, V356, P904, DOI 10.1016/S0140-6736(00)02681-7; Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027; Hughes BL, 2017, AM J OBSTET GYNECOL, V217, pB2, DOI 10.1016/j.ajog.2017.07.039; Indolfi G, 2019, LANCET GASTROENTEROL, V4, P477, DOI 10.1016/S2468-1253(19)30046-9; Indolfi G, 2009, J MED VIROL, V81, P836, DOI 10.1002/jmv.21437; Kanninen TT, 2015, HEPATOLOGY, V62, P1656, DOI 10.1002/hep.28032; Kuncio DE, 2016, CLIN INFECT DIS, V62, P980, DOI 10.1093/cid/ciw026; Prieto LM, 2012, PEDIATR INFECT DIS J, V31, P1053, DOI 10.1097/INF.0b013e31826fe968; Marine-Barjoana E, 2007, AIDS, V21, P1811, DOI 10.1097/QAD.0b013e3282703810; Papaevangelou V, 1998, J INFECT DIS, V178, P1047, DOI 10.1086/515668; Polis CB, 2007, CLIN INFECT DIS, V44, P1123, DOI 10.1086/512815; Rumbo C, 2006, J PEDIATR GASTR NUTR, V43, P209, DOI 10.1097/01.mpg.0000228117.52229.32; Team R.C., 2021, R FOUN DATION STAT C; Tovo PA, 2005, J INFECT DIS, V192, P1872, DOI 10.1086/497695; Wirth S, 2012, WORLD J GASTROENTERO, V18, P99, DOI 10.3748/wjg.v18.i2.99; ZUCCOTTI GV, 1995, J PEDIATR-US, V127, P278, DOI 10.1016/S0022-3476(95)70309-8	27	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2020	15	4							e0230109	10.1371/journal.pone.0230109	http://dx.doi.org/10.1371/journal.pone.0230109			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR8WI	32271775	gold, Green Published			2023-01-03	WOS:000535977000013
J	Barden-O'Fallon, J; Mason, J; Tluway, E; Kwesigabo, G; Kamanyi, E				Barden-O'Fallon, Janine; Mason, Jennifer; Tluway, Emmanuel; Kwesigabo, Gideon; Kamanyi, Egidius			Counseling on injectable contraception and HIV risk: Evaluation of a pilot intervention in Tanzania	PLOS ONE			English	Article							TIME-SERIES ANALYSIS	In a context of high rates of HIV prevalence, concerns over hormonal contraceptive use and the potential for increased risk of HIV acquisition have led to increased attention to counseling messages, particularly for users of the injectable. However, the consequence of adding additional HIV risk messages to family planning counseling sessions was not well understood. This evaluation assessed the effect of providing revised injectable and HIV risk counseling messages on contraceptive knowledge and behavior during a three month pilot intervention. The pilot intervention was conducted September-November 2018 with all eligible family planning clients in ten healthcare facilities located in the Iringa and Njombe regions of Tanzania. Data collection for the evaluation occurred November-December 2018 and included 471 client exit interviews, 26 healthcare provider interviews, and the extraction of service statistics for 12 months prior to the intervention and three months of the intervention. Univariate and bivariate analyses were used to assess quantitative interview data. Thematic qualitative assessment was used to assess qualitative interview data from healthcare providers. Interrupted time series analysis was used to assess changes in the trend of contraceptive uptake. Results indicate that the counseling messages did not cause a decrease in the uptake of injectables (Depo-Provera): 97 percent of interviewed clients received Depo-Provera at their visit; sixty percent reported an intention to use condoms for dual protection. The analysis of service statistics showed no statistical difference in the trend of Depo-Provera uptake between the pre-intervention and intervention periods (p = 0.116). Overall knowledge of counseling messages by clients was good; however only 64.8% of women correctly responded that women at risk of getting HIV can use any method of family planning. Providers' knowledge of the messages was high, though it appears that not all messages were consistently provided during the counseling sessions. The findings from this evaluation provide evidence that complex HIV counseling messages can be implemented in family planning programs in Tanzania, and potentially in other countries that are considering how to better integrate HIV risk messages into family planning counseling.	[Barden-O'Fallon, Janine] Univ N Carolina, Carolina Populat Ctr, MEASURE Evaluat, Chapel Hill, NC 27515 USA; [Barden-O'Fallon, Janine] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27515 USA; [Mason, Jennifer] US Agcy Int Dev, Washington, DC 20523 USA; [Tluway, Emmanuel] US Agcy Int Dev, Dar Es Salaam, Tanzania; [Kwesigabo, Gideon] Muhimbili Univ Hlth & Allied Sci, Dept Epidemiol & Biostat, Dar Es Salaam, Tanzania; [Kamanyi, Egidius] Univ Dar Es Salaam, Dept Sociol, Dar Es Salaam, Tanzania	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; United States Agency for International Development (USAID); United States Agency for International Development (USAID); Muhimbili University of Health & Allied Sciences; University of Dar es Salaam	Barden-O'Fallon, J (corresponding author), Univ N Carolina, Carolina Populat Ctr, MEASURE Evaluat, Chapel Hill, NC 27515 USA.; Barden-O'Fallon, J (corresponding author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27515 USA.	bardenof@email.unc.edu		KWESIGABO, GIDEON/0000-0003-3302-6736	U.S. Agency for International Development (USAID) [AID-OAA-L-14-00004]; Carolina Population Center and its NIH Center grant [P2C HD050924]	U.S. Agency for International Development (USAID)(United States Agency for International Development (USAID)); Carolina Population Center and its NIH Center grant	Financial support for this work is provided by the U.S. Agency for International Development (USAID) under terms of cooperative agreement AID-OAA-L-14-00004. General support is provided by the Carolina Population Center and its NIH Center grant (P2C HD050924). JM and ET contributed to the review of data collection tools, interpretation of results, and the development of the manuscript. Additional logistical support from USAID/Tanzania is noted in the acknowledgements section. The contents in this article are those of the authors and do not necessarily reflect the views of USAID or the U.S. Government.	Baeten JM, 2019, LANCET, V394, P303, DOI 10.1016/S0140-6736(19)31288-7; Chibwesha Carla J, 2011, Infect Dis Obstet Gynecol, V2011, P261453, DOI 10.1155/2011/261453; Dehlendorf C, 2014, CLIN OBSTET GYNECOL, V57, P659, DOI 10.1097/GRF.0000000000000059; Gebrehiwot SW, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0390-6; Health Communication Capacity Collaborative, 2017, STRAT COMM FRAM HORM; Johns Hopkins Center for Communication Programs, RES 4 INF CHOIC KEY; Linden A, 2015, STATA J, V15, P480, DOI 10.1177/1536867X1501500208; MacPhail C, 2007, CONTRACEPTION, V75, P383, DOI 10.1016/j.contraception.2006.12.020; Maughan-Brown B, 2017, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-017-4593-0; MEASURE Evaluation, 2019, COUNS HORM CONTR HIV; Ministry of Health Community Development Gender Elderly and Children (MoHCDGEC), 2017, 2016 2017 INT BIOL D; Ministry of Health Community Development Gender Elderly and Children (MoHCDGEC) [Tanzania Mainland] Ministry of Health (MoH) [Zanzibar] National Bureau of Statistics (NBS) Office of the Chief Government Statistician (OCGS) and ICF International, 2016, TANZ DEM HLTH SURV M; Penfold RB, 2013, ACAD PEDIATR, V13, pS38, DOI 10.1016/j.acap.2013.08.002; Polis CB, 2016, AIDS, V30, P2665, DOI 10.1097/QAD.0000000000001228; Schaefer R, 2019, AIDS BEHAV, V23, P2199, DOI 10.1007/s10461-018-2374-0; Tsui AO, 2017, POPUL DEV REV, V43, P166, DOI 10.1111/padr.12051; UNAIDS, 2019, COUNTR FACTSH; World Health Organization, 2019, CONTR EL WOM HIGH RI; World Health Organization, 2017, HLTH STAT INF SYST E, P2; World Health Organization, 2018, INT SOC BEH CHANG CO	20	1	1	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2020	15	4							e0231070	10.1371/journal.pone.0231070	http://dx.doi.org/10.1371/journal.pone.0231070			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC8OO	32243478	Green Published, Green Submitted, gold			2023-01-03	WOS:000525592400001
J	Weber, EW; Maus, MV; Mackall, CL				Weber, Evan W.; Maus, Marcela V.; Mackall, Crystal L.			The Emerging Landscape of Immune Cell Therapies	CELL			English	Review							CHIMERIC-ANTIGEN-RECEPTOR; CAR-T-CELLS; EPSTEIN-BARR-VIRUS; TUMOR-INFILTRATING LYMPHOCYTES; CHRONIC MYELOGENOUS LEUKEMIA; ENHANCED ANTITUMOR-ACTIVITY; DONOR LEUKOCYTE INFUSIONS; B-CELL; ADOPTIVE IMMUNOTHERAPY; METASTATIC MELANOMA	Cell therapies present an entirely new paradigm in drug development. Within this class, immune cell therapies are among the most advanced, having already demonstrated definitive evidence of clinical benefits in cancer and infectious disease. Numerous features distinguish these "living therapies'' from traditional medicines, including their ability to expand and contract in proportion to need and to mediate therapeutic benefits for months or years following a single application. Continued advances in fundamental immunology, genetic engineering, gene editing, and synthetic biology exponentially expand opportunities to enhance the sophistication of immune cell therapies, increasing potency and safety and broadening their potential for treatment of disease. This perspective will summarize the current status of immune cell therapies for cancer, infectious disease, and autoimmunity, and discuss advances in cellular engineering to overcome barriers to progress.	[Weber, Evan W.; Mackall, Crystal L.] Stanford Univ, Sch Med, Ctr Canc Cell Therapy, Stanford Canc Inst, Stanford, CA 94305 USA; [Maus, Marcela V.] Massachusetts Gen Hosp, Canc Ctr, Cellular Immunotherapy Program, Boston, MA 02114 USA; [Maus, Marcela V.] Harvard Med Sch, Boston, MA 02115 USA; [Mackall, Crystal L.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; [Mackall, Crystal L.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA	Stanford Cancer Institute; Stanford University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Stanford University; Stanford University	Mackall, CL (corresponding author), Stanford Univ, Sch Med, Ctr Canc Cell Therapy, Stanford Canc Inst, Stanford, CA 94305 USA.; Mackall, CL (corresponding author), Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA.; Mackall, CL (corresponding author), Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA.	cmackall@stanford.edu			St Baldrick's/Stand Up 2 Cancer Pediatric Dream Team Translational Cancer Research Grant; SU2C innovator award; Virginia and D.K. Ludwig Fund for Cancer Research; NIH [2P01CA049605-29A1, P01CA217959-01, 5P30CA124435, U54 CA232568-01]	St Baldrick's/Stand Up 2 Cancer Pediatric Dream Team Translational Cancer Research Grant; SU2C innovator award; Virginia and D.K. Ludwig Fund for Cancer Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a St Baldrick's/Stand Up 2 Cancer Pediatric Dream Team Translational Cancer Research Grant (to C.L.M.) and an SU2C innovator award (to M.V.M.). Stand Up 2 Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. C.L.M. is a member of the Parker Institute for Cancer Immunotherapy, which supports the Stanford University Cancer Immunotherapy Program. The work was also supported by the Virginia and D.K. Ludwig Fund for Cancer Research (to C.L.M.) and NIH grants 2P01CA049605-29A1, P01CA217959-01, and 5P30CA124435 (to C.L.M.) and U54 CA232568-01 (to E.W.W. and C.L.M.).	Abramson JS, 2017, BLOOD, V130; Adusumilli PS, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010162; Aghajanian H, 2019, NATURE, V573, P430, DOI 10.1038/s41586-019-1546-z; Ahmed N, 2017, JAMA ONCOL, V3, P1094, DOI 10.1001/jamaoncol.2017.0184; Ahmed N, 2015, J CLIN ONCOL, V33, P1688, DOI 10.1200/JCO.2014.58.0225; Ali SA, 2016, BLOOD, V128, P1688, DOI 10.1182/blood-2016-04-711903; Avanzi MP, 2018, CELL REP, V23, P2130, DOI 10.1016/j.celrep.2018.04.051; Ayala VI, 2017, J VIROL, V91, DOI 10.1128/JVI.02507-16; Beatty GL, 2014, CANCER IMMUNOL RES, V2, P112, DOI 10.1158/2326-6066.CIR-13-0170; Bejestani EP, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1342909; Bengsch B, 2018, IMMUNITY, V48, P1029, DOI 10.1016/j.immuni.2018.04.026; Bertoletti A, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008354; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Blank CU, 2019, NAT REV IMMUNOL, V19, P665, DOI 10.1038/s41577-019-0221-9; Bluestone JA, 2015, SCI TRANSL MED, V7; Bollard CM, 2018, J CLIN ONCOL, V36, P1128, DOI 10.1200/JCO.2017.74.3179; Bollard CM, 2014, J CLIN ONCOL, V32, P798, DOI 10.1200/JCO.2013.51.5304; Bonifant CL, 2016, MOL THER, V24, P1615, DOI 10.1038/mt.2016.116; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; Boroughs AC, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126194; Bosse KR, 2017, CANCER CELL, V32, P295, DOI 10.1016/j.ccell.2017.08.003; Bowerman NA, 2009, MOL IMMUNOL, V46, P3000, DOI 10.1016/j.molimm.2009.06.012; Brentjens RJ, 2007, CLIN CANCER RES, V13, P5426, DOI 10.1158/1078-0432.CCR-07-0674; Brentjens RJ, 2011, BLOOD, V118, P4817, DOI 10.1182/blood-2011-04-348540; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Brudno JN, 2018, J CLIN ONCOL, V36, P2267, DOI 10.1200/JCO.2018.77.8084; Brunstein CG, 2011, BLOOD, V117, P1061, DOI 10.1182/blood-2010-07-293795; Busch DH, 2016, SEMIN IMMUNOL, V28, P28, DOI 10.1016/j.smim.2016.02.001; Cameron BJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006034; Capsomidis A, 2018, MOL THER, V26, P354, DOI 10.1016/j.ymthe.2017.12.001; Chapuis AG, 2019, NAT MED, V25, P1064, DOI 10.1038/s41591-019-0472-9; Chapuis AG, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004916; Chen J, 2019, NATURE, V567, P530, DOI 10.1038/s41586-019-0985-x; Chervin AS, 2009, J IMMUNOL, V183, P1166, DOI 10.4049/jimmunol.0900054; Chheda ZS, 2018, J EXP MED, V215, P141, DOI 10.1084/jem.20171046; Cho JH, 2018, CELL, V173, P1426, DOI 10.1016/j.cell.2018.03.038; Choi BD, 2019, NAT BIOTECHNOL, V37, P1049, DOI 10.1038/s41587-019-0192-1; Chong EA, 2017, BLOOD, V129, P1039, DOI 10.1182/blood-2016-09-738245; Cohen AD, 2019, J CLIN INVEST, V129, P2210, DOI 10.1172/JCI126397; Cohen CJ, 2007, CANCER RES, V67, P3898, DOI 10.1158/0008-5472.CAN-06-3986; Cohen CJ, 2006, CANCER RES, V66, P8878, DOI 10.1158/0008-5472.CAN-06-1450; Cohen CJ, 2015, J CLIN INVEST, V125, P3981, DOI 10.1172/JCI82416; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; CULLIS JO, 1992, BLOOD, V79, P1379; Curran KJ, 2015, MOL THER, V23, P769, DOI 10.1038/mt.2015.4; D'Angelo SP, 2018, CANCER DISCOV, V8, P944, DOI 10.1158/2159-8290.CD-17-1417; Deeks SG, 2002, MOL THER, V5, P788, DOI 10.1006/mthe.2002.0611; Deniger DC, 2018, CLIN CANCER RES, V24, P5562, DOI 10.1158/1078-0432.CCR-18-0573; Deniger DC, 2016, MOL THER, V24, P1078, DOI 10.1038/mt.2016.51; Deuse T, 2019, NAT BIOTECHNOL, V37, P252, DOI 10.1038/s41587-019-0016-3; Di Stasi A, 2011, NEW ENGL J MED, V365, P1673, DOI 10.1056/NEJMoa1106152; Diaconu I, 2017, MOL THER, V25, P580, DOI 10.1016/j.ymthe.2017.01.011; Drent E, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.2170.2170; DROBYSKI WR, 1992, BONE MARROW TRANSPL, V10, P301; Dudley ME, 2008, J CLIN ONCOL, V26, P5233, DOI 10.1200/JCO.2008.16.5449; Elinav E, 2009, GASTROENTEROLOGY, V136, P1721, DOI 10.1053/j.gastro.2009.01.049; Ellebrecht CT, 2016, SCIENCE, V353, P179, DOI 10.1126/science.aaf6756; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Fedorov VD, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006597; Finney OC, 2019, J CLIN INVEST, V129, P2123, DOI 10.1172/JCI125423; Foster AE, 2008, J IMMUNOTHER, V31, P500, DOI 10.1097/CJI.0b013e318177092b; Fraietta JA, 2018, NATURE, V558, P307, DOI 10.1038/s41586-018-0178-z; Fraietta JA, 2016, BLOOD, V127, P1117, DOI 10.1182/blood-2015-11-679134; Fransson M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-112; Frigault MJ, 2015, CANCER IMMUNOL RES, V3, P356, DOI 10.1158/2326-6066.CIR-14-0186; Fry TJ, 2018, NAT MED, V24, P20, DOI 10.1038/nm.4441; Fry TJ, 2001, BLOOD, V97, P2983, DOI 10.1182/blood.V97.10.2983; Fry TJ, 2001, TRENDS IMMUNOL, V22, P564, DOI 10.1016/S1471-4906(01)02028-2; Gardner RA, 2017, BLOOD, V129, P3322, DOI 10.1182/blood-2017-02-769208; Gattinoni L, 2005, J EXP MED, V202, P907, DOI 10.1084/jem.20050732; Gee MH, 2018, CELL, V172, P549, DOI 10.1016/j.cell.2017.11.043; Giavridis T, 2018, NAT MED, V24, P731, DOI 10.1038/s41591-018-0041-7; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; GROSS G, 1989, TRANSPLANT P, V21, P127; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Gust J, 2017, CANCER DISCOV, V7, P1404, DOI 10.1158/2159-8290.CD-17-0698; Hale M, 2017, MOL THER, V25, P570, DOI 10.1016/j.ymthe.2016.12.023; Harrer DC, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3539-3; Harris DT, 2018, J IMMUNOL, V200, P1088, DOI 10.4049/jimmunol.1700236; Hart DP, 2008, GENE THER, V15, P625, DOI 10.1038/sj.gt.3303078; Heczey A, 2014, BLOOD, V124, P2824, DOI 10.1182/blood-2013-11-541235; Hegde M, 2016, J CLIN INVEST, V126, P3036, DOI 10.1172/JCI83416; Heitzeneder S, 2019, JNCI-J NATL CANCER I, V111, P970, DOI 10.1093/jnci/djy209; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; Heslop HE, 2010, BLOOD, V115, P925, DOI 10.1182/blood-2009-08-239186; Imai C, 2004, LEUKEMIA, V18, P676, DOI 10.1038/sj.leu.2403302; Iwahori K, 2015, MOL THER, V23, P171, DOI 10.1038/mt.2014.156; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Jones S, 2009, HUM GENE THER, V20, P630, DOI 10.1089/hum.2008.048; Juillerat A, 2017, SCI REP-UK, V7, DOI 10.1038/srep39833; Kakarla S, 2013, MOL THER, V21, P1611, DOI 10.1038/mt.2013.110; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; Kershaw MH, 2006, CLIN CANCER RES, V12, P6106, DOI 10.1158/1078-0432.CCR-06-1183; Klebanoff CA, 2018, J EXP MED, V215, P5, DOI 10.1084/jem.20172188; Kloss CC, 2018, MOL THER, V26, P1855, DOI 10.1016/j.ymthe.2018.05.003; Kloss CC, 2013, NAT BIOTECHNOL, V31, P71, DOI 10.1038/nbt.2459; Kochenderfer JN, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2016.71.3024; Kochenderfer JN, 2012, BLOOD, V119, P2709, DOI 10.1182/blood-2011-10-384388; Kochenderfer JN, 2010, BLOOD, V116, P4099, DOI 10.1182/blood-2010-04-281931; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; Koneru M, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.994446; Kuball J, 2007, BLOOD, V109, P2331, DOI 10.1182/blood-2006-05-023069; Kudo K, 2014, CANCER RES, V74, P93, DOI 10.1158/0008-5472.CAN-13-1365; Lamers C., 2006, J CLIN ONCOL, V24, P20, DOI DOI 10.1200/JCO.2006.05.9964; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Leung WH, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124430; Li Y, 2018, CELL STEM CELL, V23, P181, DOI 10.1016/j.stem.2018.06.002; Linette GP, 2013, BLOOD, V122, P863, DOI 10.1182/blood-2013-03-490565; Liu E, 2018, LEUKEMIA, V32, P520, DOI 10.1038/leu.2017.226; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; Liu XJ, 2016, CANCER RES, V76, P1578, DOI 10.1158/0008-5472.CAN-15-2524; Liu XJ, 2015, CANCER RES, V75, P3596, DOI 10.1158/0008-5472.CAN-15-0159; Lo W, 2019, CANCER IMMUNOL RES, V7, P534, DOI 10.1158/2326-6066.CIR-18-0686; Locke FL, 2019, LANCET ONCOL, V20, P31, DOI 10.1016/S1470-2045(18)30864-7; Long AH, 2016, CANCER IMMUNOL RES, V4, P869, DOI 10.1158/2326-6066.CIR-15-0230; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Long MX, 2017, J CLIN INVEST, V127, P3052, DOI 10.1172/JCI89756; Louis CU, 2011, BLOOD, V118, P6050, DOI 10.1182/blood-2011-05-354449; Lynn RC, 2019, NATURE, V576, P293, DOI 10.1038/s41586-019-1805-z; MacDonald KG, 2016, J CLIN INVEST, V126, P1413, DOI 10.1172/JCI82771; Majzner R.G., 2020, CANCER DISCOV, DOI [10.1158/2159-8290, DOI 10.1158/2159-8290]; Majzner RG, 2019, NAT MED, V25, P1341, DOI 10.1038/s41591-019-0564-6; Majzner RG, 2019, CLIN CANCER RES, V25, P2560, DOI 10.1158/1078-0432.CCR-18-0432; Majzner RG, 2018, CANCER DISCOV, V8, P1219, DOI 10.1158/2159-8290.CD-18-0442; Maldini CR, 2018, NAT REV IMMUNOL, V18, P605, DOI 10.1038/s41577-018-0042-2; Marcucci KT, 2018, MOL THER, V26, P269, DOI 10.1016/j.ymthe.2017.10.012; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2015, BLOOD, V125, P4017, DOI 10.1182/blood-2014-12-580068; McLaughlin LP, 2018, BLOOD, V132, P2351, DOI 10.1182/blood-2018-07-863654; Melenhorst JJ, 2010, BLOOD, V116, P4700, DOI 10.1182/blood-2010-06-289991; Mestermann K, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau5907; Morgan RA, 2013, J IMMUNOTHER, V36, P133, DOI 10.1097/CJI.0b013e3182829903; Mount CW, 2018, NAT MED, V24, P572, DOI 10.1038/s41591-018-0006-x; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4; O'Reilly RJ, 2016, BONE MARROW TRANSPL, V51, P1163, DOI 10.1038/bmt.2016.17; Ormhoj M, 2019, CLIN CANCER RES, V25, P7046, DOI 10.1158/1078-0432.CCR-19-1337; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; Park JR, 2007, MOL THER, V15, P825, DOI 10.1038/sj.mt.6300104; Pauken KE, 2016, SCIENCE, V354, P1160, DOI 10.1126/science.aaf2807; Pegram HJ, 2012, BLOOD, V119, P4133, DOI 10.1182/blood-2011-12-400044; Perdigoto AL, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00654; Perez EE, 2008, NAT BIOTECHNOL, V26, P808, DOI 10.1038/nbt1410; Pont MJ, 2019, BLOOD, V134, P1585, DOI 10.1182/blood.2019000050; Posey AD, 2016, IMMUNITY, V44, P1444, DOI 10.1016/j.immuni.2016.05.014; Priceman SJ, 2018, CLIN CANCER RES, V24, P95, DOI 10.1158/1078-0432.CCR-17-2041; Pule MA, 2008, NAT MED, V14, P1264, DOI 10.1038/nm.1882; Qasim W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj2013; Qin HY, 2018, MOL THER-ONCOLYTICS, V11, P127, DOI 10.1016/j.omto.2018.10.006; Quigley M, 2010, NAT MED, V16, P1147, DOI 10.1038/nm.2232; Rafiq S, 2018, NAT BIOTECHNOL, V36, P847, DOI 10.1038/nbt.4195; Raje N, 2019, NEW ENGL J MED, V380, P1726, DOI 10.1056/NEJMoa1817226; Ramakrishna S, 2019, CLIN CANCER RES, V25, P5329, DOI 10.1158/1078-0432.CCR-18-3784; Rapoport AP, 2015, NAT MED, V21, P914, DOI 10.1038/nm.3910; Ren JT, 2017, CLIN CANCER RES, V23, P2255, DOI 10.1158/1078-0432.CCR-16-1300; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; Robbins PF, 2008, J IMMUNOL, V180, P6116, DOI 10.4049/jimmunol.180.9.6116; Robbins PF, 2015, CLIN CANCER RES, V21, P1019, DOI 10.1158/1078-0432.CCR-14-2708; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Rodgers DT, 2016, P NATL ACAD SCI USA, V113, pE459, DOI 10.1073/pnas.1524155113; ROSENBERG SA, 1994, J NATL CANCER I, V86, P1159, DOI 10.1093/jnci/86.15.1159; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; Roybal KT, 2016, CELL, V167, P419, DOI 10.1016/j.cell.2016.09.011; Roybal KT, 2016, CELL, V164, P770, DOI 10.1016/j.cell.2016.01.011; Ruella M, 2016, J CLIN INVEST, V126, P3814, DOI 10.1172/JCI87366; Sabatino M, 2016, BLOOD, V128, P519, DOI 10.1182/blood-2015-11-683847; Sagiv-Barfi I, 2015, P NATL ACAD SCI USA, V112, pE966, DOI 10.1073/pnas.1500712112; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sarukhan A, 1998, IMMUNITY, V8, P563, DOI 10.1016/S1074-7613(00)80561-0; Scarfo I, 2018, BLOOD, V132, P1495, DOI 10.1182/blood-2018-04-842708; Schmidts A, 2019, BLOOD ADV, V3, P3248, DOI 10.1182/bloodadvances.2019000703; Schmitt TM, 2013, BLOOD, V122, P348, DOI 10.1182/blood-2013-01-478164; Schneider D, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0246-1; Scholler J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003761; Schultz LM, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-117445; Schuster SJ, 2017, NEW ENGL J MED, V377, P2545, DOI 10.1056/NEJMoa1708566; Seaman S, 2017, CANCER CELL, V31, P501, DOI 10.1016/j.ccell.2017.03.005; Sen DR, 2016, SCIENCE, V354, P1165, DOI 10.1126/science.aae0491; Shah NN, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2510; Sharma P, 2019, CANCER IMMUNOL RES, V7, P2025, DOI 10.1158/2326-6066.CIR-19-0035; Slaney CY, 2017, CLIN CANCER RES, V23, P2478, DOI 10.1158/1078-0432.CCR-16-1860; Sommermeyer D, 2016, LEUKEMIA, V30, P492, DOI 10.1038/leu.2015.247; Sotillo E, 2015, CANCER DISCOV, V5, P1282, DOI 10.1158/2159-8290.CD-15-1020; Spiotto MT, 2004, NAT MED, V10, P294, DOI 10.1038/nm999; Srivastava S, 2019, CANCER CELL, V35, P489, DOI 10.1016/j.ccell.2019.02.003; Stadtmauer E.A., 2020, SCIENCE, V367; Stone JD, 2009, IMMUNOLOGY, V126, P165, DOI 10.1111/j.1365-2567.2008.03015.x; Tamada K, 2012, CLIN CANCER RES, V18, P6436, DOI 10.1158/1078-0432.CCR-12-1449; Tebas P, 2014, NEW ENGL J MED, V370, P901, DOI 10.1056/NEJMoa1300662; Themeli M, 2013, NAT BIOTECHNOL, V31, P928, DOI 10.1038/nbt.2678; Thomas S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12441-w; Till BG, 2008, BLOOD, V112, P2261, DOI 10.1182/blood-2007-12-128843; Torikai H, 2012, BLOOD, V119, P5697, DOI 10.1182/blood-2012-01-405365; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Turtle CJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8621; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; Tzannou I, 2017, J CLIN ONCOL, V35, P3547, DOI [10.1200/jco.2017.73.0655, 10.1200/JCO.2017.73.0655]; Urbanska K, 2012, CANCER RES, V72, P1844, DOI 10.1158/0008-5472.CAN-11-3890; Velasquez MP, 2016, SCI REP-UK, V6, DOI 10.1038/srep27130; Voss RH, 2006, IMMUNOL RES, V34, P67, DOI 10.1385/IR:34:1:67; Walker AJ, 2017, MOL THER, V25, P2189, DOI 10.1016/j.ymthe.2017.06.008; Wang LCS, 2014, CANCER IMMUNOL RES, V2, P154, DOI 10.1158/2326-6066.CIR-13-0027; Wang XL, 2016, BLOOD, V127, P2980, DOI 10.1182/blood-2015-12-686725; Wang ZX, 2017, INT J DISTRIB SENS N, V13, DOI 10.1177/1550147717726309; Weber EW, 2019, BLOOD ADV, V3, P711, DOI 10.1182/bloodadvances.2018028720; Weber EW., 2020, BIORXIV, DOI [10.1101/2020.01.26.920496, DOI 10.1101/2020.01.26.920496]; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Wu CY, 2015, SCIENCE, V350, DOI 10.1126/science.aab4077; Xiao L, 2018, CYTOTHERAPY, V20, P420, DOI 10.1016/j.jcyt.2017.12.014; Xu X, 2019, CLIN CANCER RES, V25, P7126, DOI 10.1158/1078-0432.CCR-19-0421; Xue SA, 2005, BLOOD, V106, P3062, DOI 10.1182/blood-2005-01-0146; Yamamoto TN, 2019, J CLIN INVEST, V129, P1551, DOI 10.1172/JCI121491; Yan ZL, 2019, LANCET HAEMATOL, V6, pE521, DOI 10.1016/S2352-3026(19)30115-2; Yee C, 2000, J EXP MED, V192, P1637, DOI 10.1084/jem.192.11.1637; Yossef R, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122467; Zacharakis N, 2018, NAT MED, V24, P724, DOI 10.1038/s41591-018-0040-8; Zah E, 2016, CANCER IMMUNOL RES, V4, P498, DOI 10.1158/2326-6066.CIR-15-0231; Zamora AE, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat8549; Zhao Y, 2007, J IMMUNOL, V179, P5845, DOI 10.4049/jimmunol.179.9.5845; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774	226	122	129	10	96	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2020	181	1					46	62		10.1016/j.cell.2020.03.001	http://dx.doi.org/10.1016/j.cell.2020.03.001			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KZ5RI	32243795	Green Accepted, Bronze			2023-01-03	WOS:000523319000012
J	Gaines, ME; Auleta, AD; Berwick, DM				Gaines, Martha E.; Auleta, Austin D.; Berwick, Donald M.			Changing the Game of Prior Authorization The Patient Perspective	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Gaines, Martha E.] Univ Wisconsin, Ctr Patient Partnerships, 975 Bascom Mall, Madison, WI 53706 USA; [Auleta, Austin D.] Univ Wisconsin, Sch Law, Madison, WI 53706 USA; [Berwick, Donald M.] Inst Healthcare Improvement, Editorial Affairs, Boston, MA USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Institute for Healthcare Improvement	Gaines, ME (corresponding author), Univ Wisconsin, Ctr Patient Partnerships, 975 Bascom Mall, Madison, WI 53706 USA.	meg.gaines@wisc.edu						American Bar Association, ASS BEN PROT PROV RI; American Medical Association, CONS STAT IMP PRIOR; American Medical Association, PRIOR AUTH UT MAN RE; American Medical Association, ENS TRANSP PRIO AUTH; Brook RH, 2009, JAMA-J AM MED ASSOC, V302, P997, DOI 10.1001/jama.2009.1279; Himmelstein DU, 2019, AM J PUBLIC HEALTH, V109, P431, DOI 10.2105/AJPH.2018.304901; Patient Advocate Foundation, WHAT DOES APPR PREAU	7	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2020	323	8					705	706		10.1001/jama.2020.0070	http://dx.doi.org/10.1001/jama.2020.0070			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KS9GZ	32011646				2023-01-03	WOS:000518617500014
J	Huang, YT; Wang, YW; Chi, CW; Hu, WY; Lin, R; Shiao, CC; Tang, OR				Huang, Ya-Ting; Wang, Ying-Wei; Chi, Chou-Wen; Hu, Wen-Yu; Lin, Rung, Jr.; Shiao, Chih-Chung; Tang, Woung-Ru			Differences in medical costs for end-of-life patients receiving traditional care and those receiving hospice care: A retrospective study	PLOS ONE			English	Article							ILL CANCER-PATIENTS; PALLIATIVE CARE; FAMILY CAREGIVERS; CONSULTATION; IMPACT; LENGTH; DEATH; EXPENDITURES; ASSOCIATION; PREFERENCES	Background Hospice care has a positive effect on medical costs. The correlation between survival time after receiving hospice care and medical costs has not been previously investigated in the literature on Taiwan. This study aimed to compare the differences in medical costs between traditional care and hospice care among end-of-life patients with cancer. Methods Data from Taiwan's National Health Insurance program on all patients who had passed away between 2010 and 2013 were used. Those whose year of death was between 2010 and 2013 were defined as end-of-life patients. The patients were divided into two groups: traditional care and hospice care. We then analyzed the differences in end-of-life medical cost between the two groups. Results From 2010 to 2013, the proportion of patients receiving hospice care significantly increased from 22.2% to 41.30%. In the hospice group, compared with the traditional group, the proportions of hospital stays over 14 days and deaths in a hospital were significantly higher, but the proportions of outpatient clinic visits; emergency room admissions; intensive care unit admissions; use of ventilator; use of cardiopulmonary resuscitation; and use of hemodialysis, surgery, and chemotherapy were significantly lower. Total medical costs were significantly lower. A greater number of days of survival for end-of-life patients when receiving hospice care results in higher saved medical costs. Conclusion Hospice care can effectively save a large amount of end-of-life medical costs, and more medical costs are saved when patients are referred to hospice care earlier.	[Huang, Ya-Ting] Camillian St Marys Hosp Luodong, Dept Nursing, Yilan, Taiwan; [Huang, Ya-Ting; Shiao, Chih-Chung] St Marys Jr Coll Med Nursing & Management, Sanxing Township, Taiwan; [Wang, Ying-Wei] Minist Hlth & Welf, Hlth Promot Adm, Taipei, Taiwan; [Chi, Chou-Wen] Chang Gung Mem Hosp Linkou, Div Hematol Oncol, Taoyuan, Taiwan; [Chi, Chou-Wen] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Hu, Wen-Yu] Natl Taiwan Univ, Coll Med, Dept Nursing, Taipei, Taiwan; [Lin, Rung, Jr.] Chang Gung Mem Hosp Linkou, Dept Anesthesiol, Taoyuan, Taiwan; [Lin, Rung, Jr.] Chang Gung Univ, Clin Informat & Med Stat Res Ctr, Taoyuan, Taiwan; [Lin, Rung, Jr.] Chang Gung Univ, Grad Inst Clin Med, Taoyuan, Taiwan; [Shiao, Chih-Chung] Camillian St Marys Hosp Luodong, Dept Internal Med, Div Nephrol, Yilan, Taiwan; [Tang, Woung-Ru] Chang Gung Univ, Sch Nursing, Taoyuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; National Taiwan University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung University	Huang, YT (corresponding author), Camillian St Marys Hosp Luodong, Dept Nursing, Yilan, Taiwan.; Huang, YT (corresponding author), St Marys Jr Coll Med Nursing & Management, Sanxing Township, Taiwan.; Tang, OR (corresponding author), Chang Gung Univ, Sch Nursing, Taoyuan, Taiwan.	frankie7451@gmail.com; wtang@mail.cgu.edu.tw	Shiao, Chih-Chung/AAM-2716-2020	Shiao, Chih-Chung/0000-0003-2220-7574; HU, WEN-YU/0000-0001-5244-2458	Camillian Saint Mary's Hospital Research Fund [SMHRF-104004]; Bureau of National Health Insurance, Department of Health	Camillian Saint Mary's Hospital Research Fund; Bureau of National Health Insurance, Department of Health	The research was supported by a grant from Camillian Saint Mary's Hospital Research Fund (SMHRF-104004) to C.C. Shiao. The study was based in part on data from the National Health Insurance Research Database (NHIRD) supported by the Bureau of National Health Insurance, Department of Health, and managed by the National Health Research Institutes (NHIRD-104-157). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank Ms. Siew Tzuh Tang for her expert advice. The study was based in part on data from the National Health Insurance Research Database (NHIRD) supported by the Bureau of National Health Insurance, Department of Health, and managed by the National Health Research Institutes (NHIRD-104-157). Editorial support was provided to the authors by Editage.	Anderson G, 2004, PUBLIC HEALTH REP, V119, P263, DOI 10.1016/j.phr.2004.04.005; [Anonymous], 2010, DATABASE NHIR 2010 L; Bell CL, 2011, J PAIN SYMPTOM MANAG, V42, P557, DOI 10.1016/j.jpainsymman.2011.01.010; Bogasky S, 2014, MED MED RES REV, V4, DOI [10.5600/mmrr.004, DOI 10.5600/MMRR.004]; Bradley EH, 2004, AM J PSYCHIAT, V161, P2257, DOI 10.1176/appi.ajp.161.12.2257; Brinkman-Stoppelenburg A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201191; Canadian Hospice Palliative Care Association, 2014, FACT SHEET HOSP PALL; Carlson MDA, 2010, J CLIN ONCOL, V28, P4371, DOI 10.1200/JCO.2009.26.1818; Chang HT, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005216; Chen LF, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001613; Cheng SY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001573; Chiang JK, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007825; Chiang JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138773; Chiang JK, 2015, SUPPORT CARE CANCER, V23, P1049, DOI 10.1007/s00520-014-2447-1; Ciemins EL, 2007, J PALLIAT MED, V10, P1347, DOI 10.1089/jpm.2007.0065; Friedrichsen M, 2017, SUPPORT CARE CANCER, V25, P371, DOI 10.1007/s00520-016-3406-9; Gade G, 2008, J PALLIAT MED, V11, P180, DOI 10.1089/jpm.2007.0055; Gelfman LP, 2008, J PAIN SYMPTOM MANAG, V36, P22, DOI 10.1016/j.jpainsymman.2007.09.008; Glass AP, 2010, J CROSS-CULT GERONTO, V25, P1, DOI 10.1007/s10823-009-9108-8; Gomez-Batiste X, 2012, CURR OPIN SUPPORT PA, V6, P371, DOI 10.1097/SPC.0b013e328356aaed; HopiceUK, 2017, HOSP CAR UK 2016 201; Hu WH, 2014, J PAIN SYMPTOM MANAG, V47, P231, DOI 10.1016/j.jpainsymman.2013.03.021; Huang, 2007, TAIWAN J HOSP PALLIA, V12, P312, DOI [10.6537/TJHPC.2007.12(3).5, DOI 10.6537/TJHPC.2007.12(3).5]; Hung YN, 2018, J PAIN SYMPTOM MANAG, V55, P755, DOI 10.1016/j.jpainsymman.2017.10.010; Hwang SJ, 2013, J PALLIAT MED, V16, P780, DOI 10.1089/jpm.2012.0482; Jordan RE, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-707; Kao YH, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0036-9; Keam B, 2008, JPN J CLIN ONCOL, V38, P381, DOI 10.1093/jjco/hyn031; Kelley AS, 2013, HEALTH AFFAIR, V32, P552, DOI 10.1377/hlthaff.2012.0851; Kim SN, 2017, CANCER RES TREAT, V49, P559, DOI 10.4143/crt.2016.276; Kim SJ, 2015, PALLIATIVE MED, V29, P808, DOI 10.1177/0269216315582123; Ko LC., 2007, J PUBLIC HEALTH-UK, V26, P491; Kris AE, 2006, AM J GERIAT PSYCHIAT, V14, P264, DOI 10.1097/01.JGP.0000194642.86116.ce; Lee HL., 2013, TAIWAN J PUBLIC HLTH, V32, P231; Lee MY, 2012, METABOLISM, V61, P242, DOI 10.1016/j.metabol.2011.06.020; Lim T, 2013, AM J HOSP PALLIAT ME, V30, P50, DOI 10.1177/1049909112442586; Lin WY, 2014, RESPIROL CASE REP, V2, P27, DOI 10.1002/rcr2.38; Lin WY, 2009, J FORMOS MED ASSOC, V108, P794, DOI 10.1016/S0929-6646(09)60407-1; Liu C. N., 2007, TAIWAN J PUBL HLTH, V26, P118; Lo CM, 2007, CHIN J PUBLIC HLTH, V26, P270; Lo JC, 2002, SOC SCI MED, V54, P981, DOI 10.1016/S0277-9536(01)00071-5; Lojan Radoslav., 2015, ART BEING FULLY PRES; Ministry of Health and Welfare, 2018, TAIW NAT HLTH INS AD; Miyashita M, 2015, J PAIN SYMPTOM MANAG, V50, P38, DOI 10.1016/j.jpainsymman.2015.01.007; Mori Masanori, 2016, [The Korean Journal of Hospice and Palliative Care, 한국호스피스완화의료학회지], V19, P283, DOI 10.14475/kjhpc.2016.19.4.283; Morita T, 2015, J PAIN SYMPTOM MANAG, V50, P190, DOI 10.1016/j.jpainsymman.2015.02.020; Morrison RS, 2008, ARCH INTERN MED, V168, P1783, DOI 10.1001/archinte.168.16.1783; Murtagh FEM, 2004, CLIN MED, V4, P39, DOI 10.7861/clinmedicine.4-1-39; National Health Insurance, 2012, PALL CAR TERM CRIT P, P96; National Health Insurance Administration, 2014, HLTH INS FEE CAN EFF; National Health Insurance Research Database N, 2013, 2010 LONG HLTH INS D; Nevadunsky NS, 2014, GYNECOL ONCOL, V132, P3, DOI 10.1016/j.ygyno.2013.10.025; O'Connor NR, 2018, AM J HOSP PALLIAT ME, V35, P966, DOI 10.1177/1049909117743475; Obermeyer Z, 2014, JAMA-J AM MED ASSOC, V312, P1888, DOI 10.1001/jama.2014.14950; Payne S, 2005, J PALLIAT CARE, V21, P111, DOI 10.1177/082585970502100207; Penrod JD, 2010, J PALLIAT MED, V13, P973, DOI 10.1089/jpm.2010.0038; Pyenson B, 2004, J PAIN SYMPTOM MANAG, V28, P200, DOI 10.1016/j.jpainsymman.2004.05.003; Rhee YongJoo, 2015, Health, V7, P689, DOI 10.4236/health.2015.76082; Shao YY, 2017, ONCOLOGIST, V22, P843, DOI 10.1634/theoncologist.2016-0367; Shih C.Y., 2013, TAIWAN J HOSP PALLIA, V18, P320, DOI [10.6537/tjhpc.2013.18(3).6, DOI 10.6537/TJHPC.2013.18(3).6]; Smith S, 2014, PALLIATIVE MED, V28, P130, DOI 10.1177/0269216313493466; Tang ST, 2014, PALLIATIVE MED, V28, P1222, DOI 10.1177/0269216314540974; Tang ST, 2010, PSYCHO-ONCOLOGY, V19, P1213, DOI 10.1002/pon.1690; Tang ST, 2005, J PAIN SYMPTOM MANAG, V30, P510, DOI 10.1016/j.jpainsymman.2005.05.019; Tang ST, 2005, SOC SCI MED, V61, P1560, DOI 10.1016/j.socscimed.2005.02.006; Tangeman JC, 2014, J PALLIAT MED, V17, P1005, DOI 10.1089/jpm.2013.0612; Taylor DH, 2007, SOC SCI MED, V65, P1466, DOI 10.1016/j.socscimed.2007.05.028; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Tsuneto S., 2012, JAPANESE J CLIN ONCO, V43, P17, DOI [10.1093/jjco/hys188JournalofClinicalOncology, DOI 10.1093/JJCO/HYS188JOURNALOFCLINICALONCOLOGY]; Walbert T, 2015, NEURO-ONCOL PRACT, V2, P62, DOI 10.1093/nop/npu037; Yamaguchi T, 2017, BMJ SUPPORT PALLIAT, V7, P23, DOI 10.1136/bmjspcare-2013-000588; Yang MH, 2010, TAIWAN J HOSP PALLIA, V15, P145	73	7	7	7	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2020	15	2							e0229176	10.1371/journal.pone.0229176	http://dx.doi.org/10.1371/journal.pone.0229176			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LQ8CF	32078660	Green Published, gold			2023-01-03	WOS:000535224600021
J	Holloway, KA; Ivanovska, V; Manikandan, S; Jayanthi, M; Mohan, A; Forte, G; Henry, D				Holloway, Kathleen Anne; Ivanovska, Verica; Manikandan, Solaiappan; Jayanthi, Mathaiyan; Mohan, Anbarasan; Forte, Gilles; Henry, David			Identifying the most effective essential medicines policies for quality use of medicines: A replicability study using three World Health Organisation data-sets	PLOS ONE			English	Article							ADVERSE DRUG-REACTIONS; PERFORMANCE; RESISTANCE; WORKERS	Background Poor quality use of medicines (QUM) has adverse outcomes. Governments' implementation of essential medicines (EM) policies is often suboptimal and there is limited information on which policies are most effective. Methods We analysed data on policy implementation from World Health Organisation (WHO) surveys in 2007 and 2011, and QUM data from surveys during 2006-2012 in developing and transitional countries. We compared QUM scores in countries that did or did not implement specific policies and regressed QUM composite scores on the numbers of policies implemented. We compared the ranking of policies in this and two previous studies, one from the same WHO databases (2003-2007) the other from data obtained during country visits in South-East Asia (2010-2015). The rankings of a common set of 17 policies were correlated and we identified those that were consistently highly ranked. Findings Fifty-three countries had data on both QUM and policy implementation. Forty policies were associated with effect sizes ranging from +13% to -5%. There was positive correlation between the composite QUM indicator and the number of policies reported implemented: (r) = 0.437 (95% CI 0.188 to 0.632). Comparison of policy rankings between the present and previous studies showed positive correlation with the WHO 2003-7 study: Spearman's rank correlation coefficient 0.498 (95% CI 0.022 to 0.789). Across the three studies, five policies were in the top five ranked positions 11 out of a possible 15 times: drugs available free at the point of care; a government QUM unit; undergraduate training of prescribers in standard treatment guidelines, antibiotics not available without prescription and generic substitution in the public sector. Interpretation Certain EM policies are associated with better QUM and impact increases with co-implementation. Analysis across three datasets provides a policy short-list as a minimum investment by countries trying to improve QUM and reduce antimicrobial drug misuse.	[Holloway, Kathleen Anne] Univ Sussex, Inst Dev Studies, Hlth & Nutr, Brighton, E Sussex, England; [Ivanovska, Verica; Forte, Gilles] WHO, Essential Med & Hlth Prod, Geneva, Switzerland; [Manikandan, Solaiappan; Jayanthi, Mathaiyan] Jawarhalal Nehru Inst Med Educ & Res, Dept Pharmacol, Pondicherry, India; [Mohan, Anbarasan] Govt Theni Med Coll, Dept Pharmacol, Theni, Tamil Nadu, India; [Henry, David] Bond Univ, Inst Evidence Based Healthcare, Gold Coast, Qld, Australia; [Henry, David] Univ Melbourne, Melbourne, Vic, Australia	University of Sussex; World Health Organization; Bond University; University of Melbourne	Holloway, KA (corresponding author), Univ Sussex, Inst Dev Studies, Hlth & Nutr, Brighton, E Sussex, England.	kaholloway54@gmail.com	Henry, David/AAU-4650-2020; Henry, David/AAJ-4332-2020	Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242	World Health Organization [001] Funding Source: Medline	World Health Organization(World Health Organization)		Bavestrello L, 2002, REV MED CHILE, V130, P1265; Francke AL, 2008, BMC MED INFORM DECIS, V8, DOI 10.1186/1472-6947-8-38; Goossens H, 2009, CLIN MICROBIOL INFEC, V15, P12, DOI 10.1111/j.1469-0691.2009.02725.x; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7; Harbarth S, 2005, EMERG INFECT DIS, V11, P794, DOI 10.3201/eid1106.050167; Hitchen L, 2006, BRIT MED J, V332, P1109, DOI 10.1136/bmj.332.7550.1109; Holloway K, 2011, WHOEMPMIE201122; Holloway KA, 2013, TROP MED INT HEALTH, V18, P656, DOI 10.1111/tmi.12123; Holloway KA, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3333-1; Holloway KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152020; Holloway KA, 2015, PAEDIATR INT CHILD H, V35, P5, DOI 10.1179/2046905514Y.0000000115; Holloway KA, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001724; Howard RL, 2007, BRIT J CLIN PHARMACO, V63, P136, DOI 10.1111/j.1365-2125.2006.02698.x; Huttner B, 2010, LANCET INFECT DIS, V10, P17, DOI 10.1016/S1473-3099(09)70305-6; Jaffer B., 2007, WHO NGO TECHN BRIEF; Laing RO, 2001, HEALTH POLICY PLANN, V16, P13, DOI 10.1093/heapol/16.1.13; Livermore DM, 2003, CLIN INFECT DIS, V36, pS11, DOI 10.1086/344654; Park S, 2005, HEALTH POLICY PLANN, V20, P302, DOI 10.1093/heapol/czi033; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Rowe AK, 2005, LANCET, V366, P1026, DOI 10.1016/S0140-6736(05)67028-6; Sabuncu E, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000084; Sketris IS, 2009, J POPUL THER CLIN PH, V16, pE103; Trap B, 2002, HEALTH POLICY PLANN, V17, P288, DOI 10.1093/heapol/17.3.288; Trap B, 2002, J CLIN PHARM THER, V27, P289, DOI 10.1046/j.1365-2710.2002.00425.x; Vang C, 2006, EUR J CLIN PHARMACOL, V62, P57, DOI 10.1007/s00228-005-0069-8; Wirtz VJ, 2017, LANCET, V389, P403, DOI 10.1016/S0140-6736(16)31599-9; World Health Organisation, 2002, WHO POL PERSP MED, V5; World Health Organisation, 2004, EDM RES SER, V32; World Health Organisation, 2011, COUNTR PHARM PROF; World Health Organization, 2007, WHOTCM20072; World Health Organization, 1993, INVESTIGATE DRUG USE; World Health Organization, 2009, MED US PRIM CAR DEV; World Health Organization, 2010, WHOEMPMPC20101	33	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2020	15	2							e0228201	10.1371/journal.pone.0228201	http://dx.doi.org/10.1371/journal.pone.0228201			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP9GK	32027679	gold, Green Published			2023-01-03	WOS:000534623800016
J	Atuhaire, P; Brummel, SS; Mmbaga, BT; Angelidou, K; Fairlie, L; Violari, A; Theron, G; Mukuzunga, C; Mawlana, S; Mubiana-Mbewe, M; Naidoo, M; Makanani, B; Mandima, P; Nematadzira, T; Suryavanshi, N; Mbengeranwa, T; Loftis, A; Basar, M; McCarthy, K; Currier, JS; Fowler, MG				Atuhaire, Patience; Brummel, Sean S.; Mmbaga, Blandina Theophil; Angelidou, Konstantia; Fairlie, Lee; Violari, Avy; Theron, Gerhard; Mukuzunga, Cornelius; Mawlana, Sajeeda; Mubiana-Mbewe, Mwangelwa; Naidoo, Megeshinee; Makanani, Bonus; Mandima, Patricia; Nematadzira, Teacler; Suryavanshi, Nishi; Mbengeranwa, Tapiwa; Loftis, Amy; Basar, Michael; McCarthy, Katie; Currier, Judith S.; Fowler, Mary Glenn		1077BF-1077FF PROMISE Team	The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trial	PLOS ONE			English	Article							WOMEN; PREGNANCY	Background Given well documented challenges faced by pregnant women living with HIV taking lifetime ART, it is critical to understand the impact of short-term ART exposure followed by treatment interruption on maternal health outcomes. Methods HIV+ breastfeeding (BF) and Formula Feeding (FF) women with CD4 counts > 350 cells/mm3, enrolled in the 1077BF/1077FF PROMISE trial were followed to assess the effect of ART during pregnancy and breastfeeding respectively. The first analysis compared ART use limited to the antepartum period (AP-only) relative to women randomized to Zidovudine. The second analysis included women with no pregnancy combination ART exposure; and compared women randomized to either ART or no ART during postpartum (PP-only). Both analyses included follow-up time beyond breastfeeding period. The primary outcome was progression to AIDS and/or death. Secondary outcomes included adverse events and HIV-related events. Results 3490 and 1137 HIV+ women were enrolled from 14 sites in Africa and India from April 2011 through September 2014 in cohort AP-only and PP-only, respectively. Most were Black African (96%); median age was 27 years; 97% were WHO Clinical Stage I; and most had a screening CD4 count >= 500 cells/mm3 (78%). The rate of progression to AIDS and/or death was similar and low across all comparison arms (AP comparison, HR = 1.14, 95%CI (0.44, 2.96), p-value = 0.79). In the PP-only cohort, the rate of WHO stage 2-3 events was lower for women randomized to ART(HR = 0.65, 95% CI 0.42, 1.01, p-value = 0.05). Conclusion The incidence of AIDS and/or death was low in pregnant/postpartum HIV+ women with highCD4 cell counts for all comparison arms. This provides some reassurance that there were limited consequences for short term ART interruption in this group of asymptomatic HIV+ women during up to 4 years of follow up; and underscores that even short term ART exposure postpartum may reduce the risk of WHO grade 2-3 disease progression.	[Atuhaire, Patience] Makerere Univ John Hopkins Univ Res Collaborat MU, Kampala, Uganda; [Brummel, Sean S.; Angelidou, Konstantia] Harvard Sch Publ Hlth, Boston, MA USA; [Mmbaga, Blandina Theophil] Kilimanjaro Christian Med Ctr KCMC, Moshi, Tanzania; [Fairlie, Lee] Wits RHI Shandukani Res Ctr CRS, Johannesburg, South Africa; [Violari, Avy] Soweto IMPAACT CRS, Johannesburg, South Africa; [Theron, Gerhard] FAM CRU CRS, Cape Town, South Africa; [Mukuzunga, Cornelius] Malawi CRS, Lilongwe, Malawi; [Mawlana, Sajeeda] Durban Paediat HIV CRS, Durban, South Africa; [Mubiana-Mbewe, Mwangelwa] George CRS, Lusaka, Zambia; [Naidoo, Megeshinee] Umlazi CRS, Durban, South Africa; [Makanani, Bonus] Blantyre CRS, Blantyre, Malawi; [Mandima, Patricia] St Marys CRS, Harare, Zimbabwe; [Nematadzira, Teacler] Seke North CRS, Harare, Zimbabwe; [Suryavanshi, Nishi] Byramjee Jeejeebhoy Med Coll BJMC CRS, Pune, Maharashtra, India; [Mbengeranwa, Tapiwa] Harare Family Care CRS, Harare, Zimbabwe; [Loftis, Amy] UNC, Chapel Hill, NC USA; [Basar, Michael] Frontier Sci, Amherst, MA USA; [McCarthy, Katie] FHI 360, Durham, NC USA; [Currier, Judith S.] Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, Los Angeles, CA USA; [Fowler, Mary Glenn] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA; [Fowler, Mary Glenn] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA	Harvard University; Harvard T.H. Chan School of Public Health; Kilimanjaro Christian Medical Centre; B.J. Govt. Medical College & Sassoon General Hospitals, Pune; University of North Carolina; University of North Carolina Chapel Hill; FHI 360; University of California System; University of California Los Angeles; Johns Hopkins University; Johns Hopkins University	Atuhaire, P (corresponding author), Makerere Univ John Hopkins Univ Res Collaborat MU, Kampala, Uganda.	patuhaire@mujhu.org	Nematadzira, Teacler/GNW-2713-2022; Mmbaga, Blandina Theophil/AAR-8707-2021	Mmbaga, Blandina Theophil/0000-0002-5550-1916; Nematadzira, Teacler/0000-0003-4786-1396; Atuhaire, Patience/0000-0002-2662-0756; Mubiana-Mbewe, Mwangelwa/0000-0002-7122-842X	National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) [UM1AI068632, UM1AI068616, UM1AI106716]; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH)	National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Funding for this study was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH). Study drugs were provided by AbbVie, BoehringerIngelheim, Gilead Sciences, and ViiV/GlaxoSmithKline.	[Anonymous], 2018, WOM GIRLS HIV; Bernardino JI, 2015, LANCET HIV, V2, pE464, DOI 10.1016/S2352-3018(15)00181-2; Currier JS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176009; DAIDS, 2009, DIV AIDS TABL GRAD S; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Flynn PM, 2018, JAIDS-J ACQ IMM DEF, V77, P383, DOI 10.1097/QAI.0000000000001612; Fowler MG, 2016, NEW ENGL J MED, V375, P1726, DOI 10.1056/NEJMoa1511691; Hoffman RM, 2018, HIV CLIN TRIALS, V19, P209, DOI 10.1080/15284336.2018.1537327; Hoffmann CJ, 2016, JAIDS-J ACQ IMM DEF, V71, P31, DOI 10.1097/QAI.0000000000000811; Kourtis AP, 2017, JAIDS-J ACQ IMM DEF, V74, P38, DOI 10.1097/QAI.0000000000001199; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Nachega JB, 2012, AIDS, V26, P2039, DOI 10.1097/QAD.0b013e328359590f; Taha E., 2018, C RETR OPP INF MARCH	13	3	3	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2020	15	1							e0228003	10.1371/journal.pone.0228003	http://dx.doi.org/10.1371/journal.pone.0228003			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9CB	31999753	gold, Green Published			2023-01-03	WOS:000534612400038
J	Sungpud, C; Panpipat, W; Chaijan, M; Yoon, AS				Sungpud, Chatchai; Panpipat, Worawan; Chaijan, Manat; Yoon, Attawadee Sae			Techno-biofunctionality of mangostin extract-loaded virgin coconut oil nanoemulsion and nanoemulgel	PLOS ONE			English	Article							DRUG-DELIVERY SYSTEM; HYDROPHILIC-LIPOPHILIC BALANCE; PHYSICOCHEMICAL PROPERTIES; ANTIMICROBIAL PROPERTIES; ANTIOXIDANT PROPERTIES; OXIDATIVE STABILITY; LIPID OXIDATION; IN-VITRO; FORMULATION; EMULSION	Techno-biofunctional characteristics of nanoemulsion and (nano)emulgel loaded with mangostin extracts were elucidated. Crude mangostins from mangosteen peels recovered by virgin coconut oil (VCO), mixed VCO and propylene glycol (PG), and pure PG were used. The extracts were loaded in the dispersed phase in the presence of mixed surfactants (Tween20/Span20) with a varying hydrophilic-lipophilic balance (HLB) from 10.2 to 15.1. Results showed that globular and uniformly distributed droplets of the nanoemulsion were observed. The small particle sizes (typically 18-62 nm) with the zeta potential of -39 to -54.5 mV were obtained when mixed emulsifiers with HLB values of 12.6 and 15.1 were employed. With HLB values of 12.6 and 15.1, nanoemulsions loaded with mangostin extracts prepared with mixed VCO-PG and pure PG-based extracts showed approximately a 2 to 3-fold lower droplet size diameter when compared with the VCO-based extract. For the stability test, all nanoemulsions were stable over three freeze-thaw cycles with some changes in pH, zeta potential, and droplet size. The DPPH. scavenging activity, H2O2 scavenging activity, reducing power and antibacterial activities (E. coli and S. aureus) of the nanoemulsions were greater than their corresponding bulk extracts. Nanoemulgels produced by embedding the nanoemulsions in a hydrogel matrix was homogeneous and creamy yellow-white in appearance. The nanoemulgels had a higher mangostin release (87-92%) than their normal emulgels (74-78%). Therefore, this study presented the feasibility of nanoemulsions and nanoemulgels loaded with mangostin extracts as a promising delivery system for bioactive polyphenol in food supplements, pharmaceuticals and cosmetics.	[Sungpud, Chatchai; Panpipat, Worawan; Chaijan, Manat] Walailak Univ, Food Technol & Innovat Res Ctr Excellence, Sch Agr Technol, Dept Agroind, Nakhon Si Thammarat, Thailand; [Yoon, Attawadee Sae] Walailak Univ, Drug & Cosmet Excellence Ctr, Sch Pharm, Nakhon Si Thammarat, Thailand	Walailak University; Walailak University	Panpipat, W (corresponding author), Walailak Univ, Food Technol & Innovat Res Ctr Excellence, Sch Agr Technol, Dept Agroind, Nakhon Si Thammarat, Thailand.	pworawan@wu.ac.th			Walailak University [22/2562]; Nakhon Si Thammarat Rajabhat University; New Strategic Research (P2P) project, Walailak University, Thailand	Walailak University; Nakhon Si Thammarat Rajabhat University; New Strategic Research (P2P) project, Walailak University, Thailand	The authors gratefully acknowledge the financial supports from Walailak University (Grant No. 22/2562) and Nakhon Si Thammarat Rajabhat University to CS. This research was partially supported by the New Strategic Research (P2P) project, Walailak University, Thailand to WP.	Aboalnaja KO, 2016, EXPERT OPIN DRUG DEL, V13, P1327, DOI 10.1517/17425247.2016.1162154; Ali SM, 2013, ACTA DERM-VENEREOL, V93, P261, DOI 10.2340/00015555-1531; Ambala R., 2015, J APPL PHARM SCI, V5, P112, DOI DOI 10.7324/JAPS.2015.50717; [Anonymous], [No title captured]; Ariyaprakai S, 2015, J FOOD ENG, V152, P57, DOI 10.1016/j.jfoodeng.2014.11.023; AUNGST BJ, 1993, J PHARM SCI-US, V82, P979, DOI 10.1002/jps.2600821002; Beikert FC, 2013, DERMATOLOGY, V226, P47, DOI 10.1159/000346641; Berton-Carabin CC, 2014, COMPR REV FOOD SCI F, V13, P945, DOI 10.1111/1541-4337.12097; Biruss B, 2007, INT J PHARMACEUT, V328, P142, DOI 10.1016/j.ijpharm.2006.08.003; Brunstein John, 2015, MLO Med Lab Obs, V47, P44; Canabady-Rochelle LLS, 2015, FOOD CHEM, V183, P129, DOI 10.1016/j.foodchem.2015.02.147; Carson J, 1999, COSMET SCI TECHNOL S, V21, P111; Chang WC, 2020, LWT-FOOD SCI TECHNOL, V117, DOI 10.1016/j.lwt.2019.108619; Chen GQ, 2018, EXPERT OPIN THER PAT, V28, P415, DOI 10.1080/13543776.2018.1455829; Donsi F, 2014, INNOV FOOD SCI EMERG, V22, P212, DOI 10.1016/j.ifset.2014.01.008; Donsi F, 2012, J BIOTECHNOL, V159, P342, DOI 10.1016/j.jbiotec.2011.07.001; Ereifej Evon S, 2017, Vet Med Int, V2017, P1757059, DOI 10.1155/2017/1757059; Fofaria NM, 2016, INT J PHARMACEUT, V498, P12, DOI 10.1016/j.ijpharm.2015.11.045; Gershanik T, 2000, INT J PHARM, V211, P29, DOI 10.1016/S0378-5173(00)00591-3; Gibis Monika, 2013, Pharmaceutics, V5, P421, DOI 10.3390/pharmaceutics5030421; Gomes C, 2011, J FOOD SCI, V76, pS16, DOI 10.1111/j.1750-3841.2010.01985.x; Gupta A, 2016, SOFT MATTER, V12, P2826, DOI 10.1039/c5sm02958a; Gupta P., 2015, WORLD J PHARM PHARM, V4, P1871; Nguyen HH, 2013, J FOOD PROCESS PRES, V37, P139, DOI 10.1111/j.1745-4549.2011.00633.x; Ibrahim N., 2015, MALAYS J ANAL SCI, V19, P261; Jadhav C, 2015, J NANOSTRUCTURE CHEM, V5, P107, DOI 10.1007/s40097-014-0141-y; Kamarza M., 2018, MATEC WEB C EDP SCI, V156, P1; Kaur L.P., 2013, ASIAN J BIOMED PHARM, V3, P1, DOI DOI 10.15272/AJBPS.V3I17.183; Khanum R, 2017, ASIAN J PHARM SCI, V12, P401, DOI 10.1016/j.ajps.2017.05.003; Khor YP, 2014, MOLECULES, V19, P9187, DOI 10.3390/molecules19079187; Kong M, 2011, CARBOHYD POLYM, V83, P462, DOI 10.1016/j.carbpol.2010.08.001; Kotyla T, 2008, INT J PHARMACEUT, V347, P144, DOI 10.1016/j.ijpharm.2007.06.045; Krongrawa W, 2018, ASIAN J PHARM SCI, V13, P415, DOI 10.1016/j.ajps.2018.01.005; Lethuaut L, 2002, J AM OIL CHEM SOC, V79, P425, DOI 10.1007/s11746-002-0500-z; Liang R, 2012, J AGR FOOD CHEM, V60, P7548, DOI 10.1021/jf301129k; Lim Terri Y, 2014, J Pediatr Pharmacol Ther, V19, P277, DOI 10.5863/1551-6776-19.4.277; Loung F. S., 2014, International Journal of PharmTech Research, V6, P628; McClements DJ, 2011, CRIT REV FOOD SCI, V51, P285, DOI 10.1080/10408398.2011.559558; Mirhosseini H, 2008, COLLOID SURFACE A, V315, P47, DOI 10.1016/j.colsurfa.2007.07.007; Mohamed MI, 2004, AAPS J, V6; Mohammed A., 2016, INT J SCI BASIC APPL, V25, P256; Mukhopadhyay D., 2016, FREE RADIC ANTIOX, V6, P123; Nejadmansouri M, 2016, COLLOID SURFACE A, V506, P821, DOI 10.1016/j.colsurfa.2016.07.075; Nikumbh KV, 2015, DRUG DELIV, V22, P509, DOI 10.3109/10717544.2013.859186; Patel J, 2011, J ADV PHARM TECHNOL, V2, P9, DOI 10.4103/2231-4040.79799; Pengon S, 2018, ASIAN J PHARM SCI, V13, P409, DOI 10.1016/j.ajps.2018.02.005; Peshkovsky AS, 2013, CHEM ENG PROCESS, V69, P77, DOI 10.1016/j.cep.2013.02.010; Reeves Anna, 2015, Mol Cell Pharmacol, V7, P25; Safdar MN, 2017, J FOOD DRUG ANAL, V25, P488, DOI 10.1016/j.jfda.2016.07.010; Sarkar R, 2017, INT J DERMATOL, V56, P1080, DOI 10.1111/ijd.13623; SHIMADA K, 1992, J AGR FOOD CHEM, V40, P945, DOI 10.1021/jf00018a005; Sivakumar M, 2014, ULTRASON SONOCHEM, V21, P2069, DOI 10.1016/j.ultsonch.2014.03.025; Suksamrarn S, 2003, CHEM PHARM BULL, V51, P857, DOI 10.1248/cpb.51.857; Sungpud C, 2019, PROCESS BIOCHEM, V87, P179, DOI 10.1016/j.procbio.2019.08.023; Suttirak W, 2014, J FOOD SCI TECH MYS, V51, P3546, DOI 10.1007/s13197-012-0887-5; Tadros T, 2004, ADV COLLOID INTERFAC, V108, P303, DOI 10.1016/j.cis.2003.10.023; Ha TVA, 2015, FOOD CHEM, V178, P115, DOI 10.1016/j.foodchem.2015.01.048; Topuz OK, 2016, FOOD CHEM, V203, P117, DOI 10.1016/j.foodchem.2016.02.051; Tubtimsri S, 2018, ASIAN J PHARM SCI, V13, P425, DOI 10.1016/j.ajps.2018.02.003; Uslinawaty Z., 2015, INT J PHARM PHARM SC, V7, P419; VAUGHAN CD, 1990, J DISPER SCI TECHNOL, V11, P83, DOI 10.1080/01932699008943238; Wang LJ, 2009, J COLLOID INTERF SCI, V330, P443, DOI 10.1016/j.jcis.2008.10.077; Wani R.R., 2015, INT J PHARM RES, V4, P398; WARSHAW TG, 1952, J INVEST DERMATOL, V19, P423, DOI 10.1038/jid.1952.118; Weerapol Y, 2014, AAPS PHARMSCITECH, V15, P456, DOI 10.1208/s12249-014-0078-y; Weiss J., 2009, GLOBAL ISSUES FOOD S, V1, P425, DOI DOI 10.1016/B978-0-12-374124-0.00024-7; Yadav S.K., 2016, INT J CURR PHARM RES, V9, P15, DOI 10.22159/ijcpr.2017v9i1.16628; Zarena A. S., 2009, Journal of Natural Products (India), V2, P23; Zarena AS, 2009, ACTA SCI POLON-TECHN, V8, P23	69	16	16	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2020	15	1							e0227979	10.1371/journal.pone.0227979	http://dx.doi.org/10.1371/journal.pone.0227979			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP9AX	31995599	Green Published, gold			2023-01-03	WOS:000534609400035
J	Hunter, MM; Huang, AJ; Wallhagen, MI				Hunter, Mary M.; Huang, Alison J.; Wallhagen, Margaret I.			"I'm going to stay young": Belief in anti-aging efficacy of menopausal hormone therapy drives prolonged use despite medical risks	PLOS ONE			English	Article							REPLACEMENT THERAPY; DECISION-MAKING; BREAST-CANCER; ESTROGEN; TRENDS; WOMEN	Background Over a third of menopausal hormone therapy (HT) prescriptions in the US are written for women over age 60. Use of HT more than 5 years is associated with increased risk for cardiovascular disease; breast, ovarian, and endometrial cancers; thromboembolic stroke; gallbladder disease; dementia; and incontinence. Objectives To explore older women's perceptions of the benefits and risks of long-term HT and examine factors influencing their decisions to use HT > 5 years despite medical risks. Methods A qualitative approach was selected to broadly explore thought processes and social phenomena underlying long-term users' decisions not to discontinue HT. Interviews were conducted with 30 women over age 60 reporting use of systemic HT more than 5 years recruited from an urban area in California and a small city in the Rocky Mountain region. Transcripts of interviews were analyzed using conventional grounded theory methods. Results Women reported using HT to preserve youthful physical and mental function and prevent disease. Gynecologists had reassured participants regarding risk, about which all 30 expressed little concern. Participants, rather than providers, were the principal drivers of long-term use. Conclusions Participants perceived estrogen to have anti-aging efficacy, and using HT imparted a sense of control over various aspects of aging. Maintaining this sense of control was prioritized over potential risk from prolonged use. Our findings provide an additional perspective on previous work suggesting the pharmaceutical industry has leveraged older women's selfesteem, vanity, and fear of aging to sell hormones through marketing practices designed to shape the beliefs of both clinicians and patients. Efforts are needed to: 1) address misconceptions among patients and providers about medically supported uses and risks of prolonged HT, and 2) examine commercial influences, such as medical ghostwriting, that may lead to distorted views of HT efficacy and risk.	[Hunter, Mary M.; Wallhagen, Margaret I.] Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA; [Huang, Alison J.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hunter, MM (corresponding author), Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA.	mary.hunter@ucsf.edu		Hunter, Mary/0000-0002-2445-2648	NIH/NINR [1F31NR01517001A1]	NIH/NINR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	MMH received a National Research Service Award from NIH/NINR 1F31NR01517001A1. The funder played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arenas A, 2008, IEEE INTERNET COMPUT, V12, P13, DOI 10.1109/MIC.2008.28; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Beral V, 2011, JNCI-J NATL CANCER I, V103, P296, DOI 10.1093/jnci/djq527; Collaborative Grp Hormonal Factors, 2019, LANCET, V394, P1159, DOI 10.1016/S0140-6736(19)31709-X; Coney S, 1994, MENOPAUSE IND MED ES; French Linda M, 2006, BMC Fam Pract, V7, P61, DOI 10.1186/1471-2296-7-61; Fugh-Berman A, 2006, PERSPECT BIOL MED, V49, P115, DOI 10.1353/pbm.2006.0006; Fugh-Berman A, 2011, AM FAM PHYSICIAN, V84, P489; Fugh-Berman A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000425; Fugh-Berman AJ, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000335; Gass MLS, 2015, MENOPAUSE, V22, P1276, DOI 10.1097/GME.0000000000000553; HEMMINKI E, 1993, OBSTET GYNECOL, V82, P1021; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Holm E, 2014, MATURITAS, V78, P293, DOI 10.1016/j.maturitas.2014.05.006; Hunter M, HORMONE THERAPY DECI; Hunter MS, 1997, SOC SCI MED, V45, P1541, DOI 10.1016/S0277-9536(97)00091-9; Krishna S, 2002, INT CONGR SER, V1229, P207, DOI 10.1016/S0531-5131(01)00490-3; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Martin K, TREATMENT MENOPAUSAL; Rolnick SJ, 2005, MENOPAUSE, V12, P399, DOI 10.1097/01.GME.0000148644.55486.36; Savolainen-Peltonen H, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l665; Theroux R, 2010, J AM ACAD NURSE PRAC, V22, P612, DOI 10.1111/j.1745-7599.2010.00553.x; Weissfeld JL, 2018, MENOPAUSE, V25, P611, DOI 10.1097/GME.0000000000001054	23	4	5	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2020	15	5							e0233703	10.1371/journal.pone.0233703	http://dx.doi.org/10.1371/journal.pone.0233703			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU1WS	32469976	gold, Green Published			2023-01-03	WOS:000537552800143
J	Swanton, C				Swanton, Charles			Take lessons from cancer evolution to the clinic	NATURE			English	Editorial Material									[Swanton, Charles] Canc Res UK TRACERx Clin Study, London, England; [Swanton, Charles] Francis Crick Inst, Canc Evolut & Genome Instabil Lab, London, England; [Swanton, Charles] UCL Canc Inst, London, England	Francis Crick Institute; University of London; University College London	Swanton, C (corresponding author), Canc Res UK TRACERx Clin Study, London, England.; Swanton, C (corresponding author), Francis Crick Inst, Canc Evolut & Genome Instabil Lab, London, England.; Swanton, C (corresponding author), UCL Canc Inst, London, England.	charles.swanton@crick.ac.uk						Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; AbdulJabbar K., NATURE MED; Chemi F, 2019, NAT MED, V25, P1534, DOI 10.1038/s41591-019-0593-1; de Koning HJ, 2020, NEW ENGL J MED, V382, P503, DOI 10.1056/NEJMoa1911793; Ghorani E., NATURE CANC; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Joshi K, 2019, NAT MED, V25, P1549, DOI 10.1038/s41591-019-0592-2; Lopez S, 2020, NAT GENET, V52, P283, DOI 10.1038/s41588-020-0584-7; McFadden DG, 2016, P NATL ACAD SCI USA, V113, pE6409, DOI 10.1073/pnas.1613601113; McGranahan N, 2017, CELL, V170, P825, DOI 10.1016/j.cell.2017.08.012; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Rosenthal R, 2019, NATURE, V567, P479, DOI 10.1038/s41586-019-1032-7; Rozenblatt-Rosen O, 2017, NATURE, V550, P451, DOI 10.1038/550451a	13	9	10	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 28	2020	581	7809					382	383		10.1038/d41586-020-01347-z	http://dx.doi.org/10.1038/d41586-020-01347-z			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NX9ZI	32461644	Bronze			2023-01-03	WOS:000576059900001
J	Obembe, T; Fonn, S				Obembe, Taiwo; Fonn, Sharon			Affording unavoidable emergency surgical care - The lived experiences and payment coping strategies of households in Ibadan metropolis, Southwestern Nigeria	PLOS ONE			English	Article							CATASTROPHIC HEALTH EXPENDITURE; INSURANCE SCHEME; GENERAL-SURGERY; OBSTETRIC CARE; OYO STATE; SERVICES; COST; CONSTRAINTS; DISEASE; SEEKING	Background Pre-payment and risk pooling schemes, central to the idea of universal health coverage, should protect households from catastrophic health expenditure and impoverishment; particularly when emergency care is required. Inadequate financial protection consequent on surgical emergencies occurs despite the existence of risk-pooling schemes. This study documented the experiences and coping strategies of slum and non-slum dwellers in a southwestern metropolis of Nigeria who had undergone emergency surgery. Methods In-depth interviews were conducted with 31 participants (13 slums dwellers, 18 non-slum dwellers) who had recently paid for emergency surgical care in Ibadan. Patients who had experienced catastrophic health expenditure from the use of emergency surgical care were identified and people who paid for the care were purposively selected for the interviews. Using an in-depth interview guide, information on the experiences and overall coping strategies during and after the hospitalization was collected. Data were analyzed inductively using the thematic approach. Results The mean age of the 31 participants (consisting of 7 men and 24 women) was 31 +/- 5.6years. Apathy to savings limited the preparation for unplanned healthcare needs. Choice of hospital was determined by word of mouth, perceptions of good quality or prompt care and availability of staff. Social networks were relied on widely as a coping mechanism before and during the admission. Patients that were unable to pay experienced poor and humiliating treatment (in severe cases, incarceration). Inability to afford care was exacerbated by double billing and extraneous charges. It was opined that health care should be more affordable for all and that the current National Health Insurance Scheme, that was operating suboptimally, should be strengthened appropriately for all to benefit. Conclusion The study highlights households' poor attitude to health-related savings and pre-payment into a social solidarity fund to cover the costs of emergency surgical care. It also highlights the factors influencing costs of emergency surgical care and the role of social networks in mitigating the high costs of care. Improving financial protection from emergency surgical care would entail promoting a positive attitude to health-related savings, social solidarity and extending the benefits of social health insurance.	[Obembe, Taiwo; Fonn, Sharon] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa; [Obembe, Taiwo] Univ Ibadan, Dept Hlth Policy & Management, Ibadan, Nigeria	University of Witwatersrand; University of Ibadan	Obembe, T (corresponding author), Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa.; Obembe, T (corresponding author), Univ Ibadan, Dept Hlth Policy & Management, Ibadan, Nigeria.	tobembe@cartafrica.org	Obembe, Taiwo/GMW-8754-2022	Obembe, Taiwo/0000-0001-9610-1137	CARTA; Carnegie Corporation of New York [B 8606.R02]; Sida Grant [54100113]; DELTAS Africa Initiative [107768/Z/15/Z]; Deutscher Akademischer Austauschdienst (DAAD); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust (UK); UK government; University of Southern California; Oppenheimer Memorial Trust; Anderson Capelli fellowship; Premier Medicaid International HMO	CARTA; Carnegie Corporation of New York; Sida Grant; DELTAS Africa Initiative; Deutscher Akademischer Austauschdienst (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust (UK)(Wellcome Trust); UK government; University of Southern California; Oppenheimer Memorial Trust; Anderson Capelli fellowship; Premier Medicaid International HMO	T.O is a fellow of the Consortium for Advanced Research Training in Africa (CARTA) and this research is supported by CARTA. CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No-B 8606.R02), Sida Grant No:54100113), the DELTAS Africa Initiative (Grant No: 107768/Z/15/Z) and Deutscher Akademischer Austauschdienst (DAAD). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (UK) and the UK government. The research was also partly funded by Premier Medicaid International HMO. At the time of writing, S.F was supported by a Fulbright Senior Fellow Award at the University of Southern California, an award from the Oppenheimer Memorial Trust, and an Anderson Capelli fellowship. The funders had no role in the study design, data collection and analysis, decision to publish or manuscript preparation.	Abiiro GA, 2015, BMC INT HEALTH HUM R, V15, DOI 10.1186/s12914-015-0056-9; Adamu A, 2010, AFR HEALTH SCI, V10, P46; Adetunji M.O., 2013, J SCI RES REPORTS, V2, P35, DOI [10.9734/JSRR/2013/2196, DOI 10.9734/JSRR/2013/2196]; Akkad A, 2004, BJOG-INT J OBSTET GY, V111, P1133, DOI 10.1111/j.1471-0528.2004.00240.x; Alatise O. I., 2007, East and Central African Journal of Surgery, V12, P28; Ali S, 2015, INT J QUAL STUD HEAL, V10, P1; Aregbeshola BS, 2018, INT J HEALTH POLICY, V7, P1015, DOI 10.15171/ijhpm.2018.68; Aregbeshola BS, 2018, INT J HEALTH POLICY, V7, P798, DOI 10.15171/ijhpm.2018.19; Aregbeshola BS, 2018, EUR J HEALTH ECON, V19, P521, DOI 10.1007/s10198-017-0899-1; Arhin-Tenkorang D., 2001, COMMISSION MACROECON, P1; Arsenault C, 2013, B WORLD HEALTH ORGAN, V91, P207, DOI 10.2471/BLT.12.108969; Atlas.Ti, 2010, ATL TI VERS 7 5 21 G; Ayantayo JK, 2008, CODESRIA 12 GEN ASSE, P1; Balogun O. L., 2011, Journal of Agriculture and Social Sciences, V7, P41; Bamgboye EA, 2016, AFR J REPROD HEALTH, V20, P88, DOI 10.29063/ajrh2016/v20i1.9; Barros PP, 2008, J HEALTH ECON, V27, P1006, DOI 10.1016/j.jhealeco.2008.02.007; Birt L, 2016, QUAL HEALTH RES, V26, P1802, DOI 10.1177/1049732316654870; Biya O, 2010, FACTORS ASS DELAYED, P1; Borghi J, 2008, REDUCING FINANCIAL B, P23; Bruijns SR, 2011, AFR J EMERG MED, V1, P1, DOI 10.1016/j.afjem.2011.05.007; Chu K, 2015, WORLD J SURG, V39, P350, DOI 10.1007/s00268-014-2840-4; Daivadanam M, 2012, INDIAN J MED RES, V136, P585; Desserud KF, 2016, BRIT J SURG, V103, pE52, DOI 10.1002/bjs.10044; Dienye PO, 2011, RURAL REMOTE HEALTH, V11, P1; Edgren G, 2016, LAKARTIDNINGEN, V113; Edoh T., 2019, MED INTERNET THINGS, P1; Ekpemo SC, 2018, CHALLENGES OUTCOME N, V6, P69; Fourchard L., 2003, UNDERSTANDING SLUMS, P1; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Ghiasvand H, 2015, IRAN RED CRESCENT ME, V17, DOI 10.5812/ircmj.30974; Gosling CM, 2013, CLIN J SPORT MED, V23, P70, DOI 10.1097/JSM.0b013e318271c5e1; Goudge J, 2012, HEALTH POLICY PLANN, V27, pi55, DOI 10.1093/heapol/czs008; Grimes CE, 2014, WORLD J SURG, V38, P252, DOI 10.1007/s00268-013-2243-y; Gyedu A, 2019, J SURG RES, V9, P1; Hoque ME, 2015, TROP MED INT HEALTH, V20, P1368, DOI 10.1111/tmi.12546; Ibiwoye A, 2008, GENEVA PAP R I-ISS P, V33, P219, DOI 10.1057/gpp.2008.6; Iganiga B. O., 2008, J SOCIAL SCI, V17, P89, DOI DOI 10.1080/09718923.2008.11892638; Ilesanmi OS, 2014, INT J HEALTH POLICY, V2, P175, DOI 10.15171/ijhpm.2014.39; Kruk ME, 2009, HEALTH AFFAIR, V28, P1056, DOI 10.1377/hlthaff.28.4.1056; Meremikwu MM, 2005, TROP MED INT HEALTH, V10, P92, DOI 10.1111/j.1365-3156.2004.01348.x; Mock CN, 2003, ACCIDENT ANAL PREV, V35, P81, DOI 10.1016/S0001-4575(01)00092-6; Morakinyo K.O., 2012, DEV COUNTRY STUDIES, V2, P1; Moran AC, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-54; Moses JF, 2015, AFR J EMERG MED, V5, P60, DOI 10.1016/j.afjem.2014.11.002; Mpimbaza A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217262; National Population Commission (NPC) [Nigeria] and ICF International, 2014, NIG DEM HLTH SURV 20; NHIS, 2018, EAS ACC HEALTHC ALL; Nnabugwu II, 2019, ANN AFRICAN SURG, V16, P69; Obermann K, 2006, SOC SCI MED, V62, P3177, DOI 10.1016/j.socscimed.2005.11.047; Odeyemi IAO, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/1475-9276-13-20; Ogbuabor DC, 2018, GLOBAL HEALTH ACTION, V11, DOI 10.1080/16549716.2017.1421002; Ogbuabor DC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220292; Ogbuabor DC, 2019, HEALTH ECON REV, V9, DOI 10.1186/s13561-019-0235-9; Ogola GO, 2016, J TRAUMA ACUTE CARE, V80, P265, DOI 10.1097/TA.0000000000000911; Oha O., 2005, INTERVENTIONS, V7, P21; Oke JTO, 2007, J HUM BEHAV SOC ENVI, V16, P37, DOI 10.1300/10911350802081592; Olatunya OS, 2015, CLINICOECONOMIC OUTC, V7, P545, DOI 10.2147/CEOR.S86599; Omonona B, 2016, AUST J BUS MANAG RES, V02, P33; Onoka CA, 2013, HEALTH RES POLICY SY, V11, DOI 10.1186/1478-4505-11-20; Onwujekwe O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040811; Onwujekwe O, 2009, HEALTH POLICY, V92, P96, DOI 10.1016/j.healthpol.2009.02.007; Osubor KM, 2006, MATERN CHILD HLTH J, V10, P159, DOI 10.1007/s10995-005-0037-z; Oyediran AO, J SCI TECHNOL MATH E, V127; Oyibo PG, 2011, AFR HEALTH SCI, V11, P481; Oyo, 2014, PAC STAT; Perun P., 2006, SENSIBLE SYSTEM SAVI, P1; Quintussi M, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0833-0; Renedo A, 2019, BMC HEAL SERV REEARC, V19, P1; Rutebemberwa E, 2009, TROP MED INT HEALTH, V14, P472, DOI 10.1111/j.1365-3156.2009.02237.x; Saito E, 2014, B WORLD HEALTH ORGAN, V92, P760, DOI 10.2471/BLT.13.126615; Shorenstein WH, 2010, CATASTROPHIC PAYMENT; Smith KV, 2008, SOC SCI MED, V66, P2460, DOI 10.1016/j.socscimed.2008.01.044; Stewart B, 2014, BRIT J SURG, V101, pE9, DOI 10.1002/bjs.9329; Sumalinog R, 2015, PRESERVING MEDICARE, P1; Thomas DR, 2006, AM J EVAL, V27, P237, DOI 10.1177/1098214005283748; Ucha C., 2010, GLOB MAJORITY E J, V1, P46; Uchendu O C, 2013, Ann Ib Postgrad Med, V11, P87; United Nations, 2017, UN SUSTAINABLE DEV G, P1, DOI [10.1016/j.precon.2005.06.007, DOI 10.1016/J.PRECON.2005.06.007]; Wanders JOP, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-870; World Bank Group, 2018, POP LIV SLUMS URB PO; World Health Organization, 2018, WORLD HLTH STAT MON; Yates R., 2018, MEDICAL BRIEF AFRICA, P1; Yates R., 2017, CHATHAM HOUSE R I IN, P1	83	4	4	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2020	15	5							e0232882	10.1371/journal.pone.0232882	http://dx.doi.org/10.1371/journal.pone.0232882			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LU1GK	32433652	Green Published, gold			2023-01-03	WOS:000537510100023
J	Finn, RS; Qin, SK; Ikeda, M; Galle, PR; Ducreux, M; Kim, TY; Kudo, M; Breder, V; Merle, P; Kaseb, AO; Li, DN; Verret, W; Xu, DZ; Hernandez, S; Liu, J; Huang, C; Mulla, S; Wang, YL; Lim, HY; Zhu, AX; Cheng, AL				Finn, Richard S.; Qin, Shukui; Ikeda, Masafumi; Galle, Peter R.; Ducreux, Michel; Kim, Tae-You; Kudo, Masatoshi; Breder, Valeriy; Merle, Philippe; Kaseb, Ahmed O.; Li, Daneng; Verret, Wendy; Xu, Derek-Zhen; Hernandez, Sairy; Liu, Juan; Huang, Chen; Mulla, Sohail; Wang, Yulei; Lim, Ho Yeong; Zhu, Andrew X.; Cheng, Ann-Lii			Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MONOCLONAL-ANTIBODY; PATIENTS PTS; PHASE-III; ANGIOGENESIS; SORAFENIB; VEGF; EXPRESSION; EFFICACY; THERAPY	BackgroundThe combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. MethodsIn a global, open-label, phase 3 trial, patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib until unacceptable toxic effects occurred or there was a loss of clinical benefit. The coprimary end points were overall survival and progression-free survival in the intention-to-treat population, as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). ResultsThe intention-to-treat population included 336 patients in the atezolizumab-bevacizumab group and 165 patients in the sorafenib group. At the time of the primary analysis (August 29, 2019), the hazard ratio for death with atezolizumab-bevacizumab as compared with sorafenib was 0.58 (95% confidence interval [CI], 0.42 to 0.79; P<0.001). Overall survival at 12 months was 67.2% (95% CI, 61.3 to 73.1) with atezolizumab-bevacizumab and 54.6% (95% CI, 45.2 to 64.0) with sorafenib. Median progression-free survival was 6.8 months (95% CI, 5.7 to 8.3) and 4.3 months (95% CI, 4.0 to 5.6) in the respective groups (hazard ratio for disease progression or death, 0.59; 95% CI, 0.47 to 0.76; P<0.001). Grade 3 or 4 adverse events occurred in 56.5% of 329 patients who received at least one dose of atezolizumab-bevacizumab and in 55.1% of 156 patients who received at least one dose of sorafenib. Grade 3 or 4 hypertension occurred in 15.2% of patients in the atezolizumab-bevacizumab group; however, other high-grade toxic effects were infrequent. ConclusionsIn patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT03434379.) In patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab was associated with better progression-free and overall survival outcomes, response rate, and preservation of quality of life than sorafenib. Serious toxic effects were noted in 38% of patients, similar to that seen in previous studies of these agents.	[Finn, Richard S.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Geffen Sch Med, Los Angeles, CA 90024 USA; [Li, Daneng] City Hope Comprehens Canc Ctr, Duarte, CA USA; [Li, Daneng] Beckman Res Inst, Duarte, CA USA; [Verret, Wendy; Hernandez, Sairy; Wang, Yulei] Genentech Inc, San Francisco, CA 94080 USA; [Qin, Shukui] Jinling Hosp, Peoples Liberat Army Canc Ctr, Nanjing, Peoples R China; [Xu, Derek-Zhen; Liu, Juan; Huang, Chen] Jiahui Hlth, Roche Prod Dev, Shanghai, Peoples R China; [Zhu, Andrew X.] Jiahui Hlth, Jiahui Int Canc Ctr, Shanghai, Peoples R China; [Ikeda, Masafumi] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan; [Kudo, Masatoshi] Kindai Univ, Fac Med, Osaka, Japan; [Galle, Peter R.] Univ Med Ctr Mainz, Mainz, Germany; [Ducreux, Michel] Paris Saclay Univ, Gustave Roussy Canc Ctr, Villejuif, France; [Merle, Philippe] Univ Hosp La Croix Rousse, Lyon, France; [Kim, Tae-You] Seoul Natl Univ, Coll Med, Seoul, South Korea; [Lim, Ho Yeong] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea; [Breder, Valeriy] NN Blokhin Russian Canc Res Ctr, Moscow, Russia; [Kaseb, Ahmed O.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Mulla, Sohail] Hoffmann La Roche, Mississauga, ON, Canada; [Zhu, Andrew X.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA; [Cheng, Ann-Lii] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan; [Cheng, Ann-Lii] Natl Taiwan Univ Hosp, Taipei, Taiwan	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; City of Hope; City of Hope; Beckman Research Institute of City of Hope; Roche Holding; Genentech; National Cancer Center - Japan; Kindai University (Kinki University); Johannes Gutenberg University of Mainz; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; CHU Lyon; Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center; N.N. Blokhin Russian Cancer Research Center; University of Texas System; UTMD Anderson Cancer Center; Roche Holding; Harvard University; Harvard Medical School; Massachusetts General Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital	Cheng, AL (corresponding author), Natl Taiwan Univ, Ctr Canc, 7 Chung Shan South Rd, Taipei 10002, Taiwan.; Cheng, AL (corresponding author), Natl Taiwan Univ Hosp, 7 Chung Shan South Rd, Taipei 10002, Taiwan.; Finn, RS (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Geffen Sch Med, 2825 Santa Monica Blvd,Suite 200, Santa Monica, CA 90404 USA.	alcheng@ntu.edu.tw; alcheng@ntu.edu.tw	Galle, Peter R/T-5292-2018; Galle, Peter/ABE-2872-2021; Touchefeu, Yann/M-2969-2015; zagonel, vittorina/F-4226-2014	Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992; Touchefeu, Yann/0000-0001-8421-3182; ZEKRY, AMANY/0000-0002-5675-1810; zagonel, vittorina/0000-0002-0829-2525; Breder, Valeriy/0000-0002-6244-4294; Wang, Yulei/0000-0002-9057-9786; Anty, Rodolphe/0000-0001-8194-9805	F. Hoffmann-La Roche/Genentech	F. Hoffmann-La Roche/Genentech(Hoffmann-La RocheRoche HoldingGenentech)	Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT03434379.	Boige V, 2012, ONCOLOGIST, V17, P1063, DOI 10.1634/theoncologist.2011-0465; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bretz F, 2009, STAT MED, V28, P586, DOI 10.1002/sim.3495; Calderaro J, 2016, HEPATOLOGY, V64, P2038, DOI 10.1002/hep.28710; Chen DS, 2018, CANCER J, V24, P193, DOI 10.1097/PPO.0000000000000327; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132; Finn RS, 2020, J CLIN ONCOL, V38, P193, DOI 10.1200/JCO.19.01307; Finn RS, 2009, EXPERT REV ANTICANC, V9, P503, DOI 10.1586/ERA.09.6; Finn RS, 2009, LIVER INT, V29, P284, DOI 10.1111/j.1478-3231.2008.01762.x; Hegde PS, 2018, SEMIN CANCER BIOL, V52, P117, DOI 10.1016/j.semcancer.2017.12.002; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Lau WY, 2001, ANN SURG, V233, P236, DOI 10.1097/00000658-200102000-00013; Lee M, 2019, ANN ONCOL, V30, P875; Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Marrero JA, 2018, HEPATOLOGY, V68, P723, DOI 10.1002/hep.29913; Morse MA, 2019, CLIN CANCER RES, V25, P912, DOI 10.1158/1078-0432.CCR-18-1254; Motz GT, 2014, NAT MED, V20, P607, DOI 10.1038/nm.3541; Rini BI, 2019, LANCET, V393, P2404, DOI 10.1016/S0140-6736(19)30723-8; Roland CL, 2009, MOL CANCER THER, V8, P1761, DOI 10.1158/1535-7163.MCT-09-0280; Siegel AB, 2008, J CLIN ONCOL, V26, P2992, DOI 10.1200/JCO.2007.15.9947; Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559; Wallin JJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12624; Yau T, 2019, ANN ONCOL, V30, P874; Zhu AX, 2018, LANCET ONCOL, V19, P940, DOI 10.1016/S1470-2045(18)30351-6; Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30	28	2041	2137	54	201	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 14	2020	382	20					1894	1905		10.1056/NEJMoa1915745	http://dx.doi.org/10.1056/NEJMoa1915745			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR8KG	32402160	Bronze			2023-01-03	WOS:000535944700018
J	Umek, N; Hodzovic, I; Damjanovska, M; Cvetko, E; Zel, J; Seliskar, A; Pintaric, TS				Umek, Nejc; Hodzovic, Iljaz; Damjanovska, Marija; Cvetko, Erika; Zel, Jurij; Seliskar, Alenka; Pintaric, Tatjana Stopar			Rescue oxygenation success by cannula or scalpel-bougie emergency front-of-neck access in an anaesthetised porcine model	PLOS ONE			English	Article							DIFFICULT INTUBATION; AIRWAY MANAGEMENT; SURGICAL CRICOTHYROIDOTOMY; CANNOT VENTILATE; JET VENTILATION; GUIDELINES	In the obese, the evidence for the choice of the optimal emergency front-of-neck access technique is very limited and conflicting. We compared cannula and scalpel-bougie emergency front-of-neck access techniques in an anaesthetised porcine model with thick pretracheal tissue. Cannula and scalpel-bougie cricothyroidotomy techniques were performed in 11 and 12 anaesthetised pigs, respectively. Following successful tracheal access, oxygenation was commenced and continued for 5 min using Rapid-O2 device for cannula and circle breathing system for scalpel-bougie study groups. The primary outcome was a successful rescue oxygenation determined by maintenance of arterial oxygen saturation > 90% 5 min after the beginning of oxygenation. Secondary outcomes included success rate of airway device placement, time to successful airway device placement, and trauma to the neck and airway. The success rate of rescue oxygenation was 18% after cannula, and 83% after scalpel-bougie technique (P = 0.003). The success rate of airway device placement was 73% with cannula and 92% with scalpel-bougie technique (P = 0.317). Median (inter-quartilerange) times to successful airway device placement were 108 (30-256) and 90 (63-188) seconds (P = 0.762) for cannula and scalpel-bougie emergency front-of-neck access, respectively. Proportion of animals with iatrogenic trauma additional to the procedure itself was 27% for cannula and 75% for scalpel-bougie technique (P = 0.039). Thus, in the porcine model of obesity, the scalpel-bougie technique was more successful in establishing and maintaining rescue oxygenation than cannula-based technique; however, it was associated with a higher risk of severe trauma.	[Umek, Nejc; Cvetko, Erika; Pintaric, Tatjana Stopar] Univ Ljubljana, Fac Med, Inst Anat, Ljubljana, Slovenia; [Hodzovic, Iljaz] Cardiff Univ, Univ Hosp Wales, Dept Anaesthet Intens Care & Pain Med, Cardiff, Wales; [Damjanovska, Marija; Pintaric, Tatjana Stopar] Univ Med Ctr Ljubljana, Dept Anaesthesiol & Surg Intens Therapy, Ljubljana, Slovenia; [Zel, Jurij; Seliskar, Alenka] Univ Ljubljana, Vet Fac, Small Anim Clin, Ljubljana, Slovenia	University of Ljubljana; Cardiff University; University Medical Centre Ljubljana; University of Ljubljana	Umek, N (corresponding author), Univ Ljubljana, Fac Med, Inst Anat, Ljubljana, Slovenia.	nejc.umek@mf.uni-lj.si	Umek, Nejc/AAX-8299-2020	Umek, Nejc/0000-0001-5831-2216	Slovenian Research Agency [P30043, P4-0053]	Slovenian Research Agency(Slovenian Research Agency - Slovenia)	NU, EC, and TSP received grant No. P30043 from Slovenian Research Agency, and JZ and AS received grant No. P4-0053 from Slovenian Research Agency. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baker PA, 2016, BRIT J ANAESTH, V117, P17, DOI 10.1093/bja/aew219; Berry M, 2014, BRIT J ANAESTH, V113, P1039, DOI 10.1093/bja/aeu188; Cho J, 2008, EMERG MED J, V25, P732, DOI 10.1136/emj.2008.059014; Cook TM, 2011, BRIT J ANAESTH, V106, P617, DOI 10.1093/bja/aer058; DeVore EK, 2019, LARYNGOSCOPE INVEST, V4, P602, DOI 10.1002/lio2.314; Ezri T, 2003, CAN J ANAESTH, V50, P179, DOI 10.1007/BF03017853; Frerk C, 2015, BRIT J ANAESTH, V115, P827, DOI 10.1093/bja/aev371; Frova G, 2009, MINERVA ANESTESIOL, V75, P201; Habib CA, 2013, J MAGN RESON IMAGING, V38, P641, DOI 10.1002/jmri.24003; Heard A, 2016, BRIT J ANAESTH, V117, P533, DOI 10.1093/bja/aew286; Heard A, 2013, 02 SCALPEL BOUGI; Heard A., 2013, PERCUTANEOUS EMERGEN; Heard A, 2013, 01 CANNULA INSERTION; Heard AMB, 2009, ANAESTHESIA, V64, P601, DOI 10.1111/j.1365-2044.2009.05888.x; Hill C, 2010, ACAD EMERG MED, V17, P666, DOI 10.1111/j.1553-2712.2010.00753.x; Howes TE, 2015, BRIT J ANAESTH, V114, P136, DOI 10.1093/bja/aeu336; Kristensen MS, 2015, BRIT J ANAESTH, V114, P357, DOI 10.1093/bja/aev029; Kristensenh MS, 2016, BRIT J ANAESTH, V117, P39, DOI 10.1093/bja/aew176; Kumar SP, 2014, INDIAN J OTOLARYNGOL, V66, pS261, DOI 10.1007/s12070-012-0477-x; Langvad S, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-43; Manoach S, 2004, RESUSCITATION, V62, P79, DOI 10.1016/j.resuscitation.2004.02.005; Onrubia X, 2018, TRENDS ANAESTH CRIT, V22, P45, DOI 10.1016/j.tacc.2018.06.001; Pairaudeau CF, 2018, ANAESTHESIA, V73, P579, DOI 10.1111/anae.14218; Patel RG, 1999, CHEST, V116, P1689, DOI 10.1378/chest.116.6.1689; Pintaric TS, 2013, ZDR VESTN, V82, P791; Rees KA, 2019, ANAESTHESIA, V74, P1153, DOI 10.1111/anae.14706; ROMITA MC, 1977, SURG FORUM, V28, P174; Schaumann N, 2005, ANESTHESIOLOGY, V102, P7, DOI 10.1097/00000542-200501000-00005; Sorbello M, 2018, EUR J ANAESTH, V35, P811, DOI 10.1097/EJA.0000000000000893; Szeto C, 2010, OTOLARYNG HEAD NECK, V143, P223, DOI 10.1016/j.otohns.2010.03.007; Timmermann A, 2016, BRIT J ANAESTH, V117, P5, DOI 10.1093/bja/aew107; Watterson L, 2014, TRANSITION SUPRAGLOT; Weightman WM, 2018, BRIT J ANAESTH, V121, P1166, DOI 10.1016/j.bja.2018.07.013; Wong DT, 2014, CAN J ANESTH, V61, P717, DOI 10.1007/s12630-014-0183-0; Wong DT, 2005, ANESTH ANALG, V100, P1439, DOI 10.1213/01.ANE.0000148695.37190.34; Yeow C, 2018, ANAESTHESIA, V73, P1235, DOI 10.1111/anae.14321; Zel J, 2019, BRIT J ANAESTH, V122, P379, DOI 10.1016/j.bja.2018.10.025; ZRUNEK M, 1988, ACTA OTO-LARYNGOL, V105, P155, DOI 10.3109/00016488809119460	38	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2020	15	5							e0232510	10.1371/journal.pone.0232510	http://dx.doi.org/10.1371/journal.pone.0232510			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT3GS	32365136	Green Published, gold			2023-01-03	WOS:000536959700035
J	Bill, AS; Dubois, J; Pasquier, J; Burnand, B; Rodondi, PY				Bill, Anne-Sylvie; Dubois, Julie; Pasquier, Jerome; Burnand, Bernard; Rodondi, Pierre-Yves			Osteopathy in the French-speaking part of Switzerland: Practitioners' profile and scope of back pain management	PLOS ONE			English	Article							SPINAL MANIPULATIVE THERAPY; PERCEPTIONS; LENGTH	Background Osteopathy is commonly used for spinal pain, but knowledge about back pain management by osteopaths is scarce. Objective The aim of this study was to survey osteopaths across the French-speaking part of Switzerland about the scope of their practice and their management of patients with back pain. Design This cross-sectional observational study was based on an online survey conducted from March to June 2017. Setting and participants: All registered osteopaths of the French-speaking part of Switzerland were asked to complete the survey. Outcome measures: In addition to descriptive statistics (practice characteristics, patients' profiles, scope of treatment modalities, health promotion, research, and osteopathic practice), we explored variables associated with osteopaths' practice, such as age and gender. Results A total of 241 osteopaths completed the questionnaire (response rate: 28.8%). Almost two thirds of osteopaths were female. Ages ranged from 25 to 72 years with an overall mean of 42.0 (SD 10.7) years. Male osteopaths reported more weekly working hours than female osteopaths did (38.2 [SD 11.0] vs 31.6 [SD 8.9], respectively, p< 0.001). Almost a third (27.8%,) of osteopaths could arrange an appointment for acute conditions on the same day and 62.0% within a week. Acute or subacute spinal conditions, mainly low back and neck pain, were the most frequent conditions seen by our respondents. For 94.4% of osteopaths, one to three consultations were required for the management of such conditions. Conclusion Osteopaths play a role in the management of spinal conditions, especially for acute problems. These findings, combined with short waiting times for consultations for acute conditions, as well as prompt management capabilities for acute low back and acute neck pain, support the view that the osteopathic profession constitutes an added value to primary care.	[Bill, Anne-Sylvie; Dubois, Julie; Pasquier, Jerome; Burnand, Bernard; Rodondi, Pierre-Yves] Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante, Lausanne, Switzerland; [Bill, Anne-Sylvie; Dubois, Julie; Rodondi, Pierre-Yves] Univ Fribourg, Inst Family Med, Fribourg, Switzerland	University of Lausanne; University of Fribourg	Bill, AS (corresponding author), Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante, Lausanne, Switzerland.; Bill, AS (corresponding author), Univ Fribourg, Inst Family Med, Fribourg, Switzerland.	anne-syhrie.bill@unisante.ch	Rodondi, Pierre-Yves/AAU-3708-2020	Dubois, Julie/0000-0001-9241-0231; Rodondi, Pierre-Yves/0000-0003-2007-2995				Adams J, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3158-y; Adams J, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-016-1542-x; Airaksinen O, 2006, EUR SPINE J, V15, pS192, DOI 10.1007/s00586-006-1072-1; Bustins GA, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2190-0; [Anonymous], 2019, MASTER OSTEOPATHY; Bardelli P, 2013, SWISS MED WKLY, V143, DOI 10.4414/smw.2013.13760; Burke SR, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-227; Cassidy JD, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3680; Cerritelli F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211353; Crow WT, 2009, J AM OSTEOPATH ASSOC, V109, P229; Diserens L, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14123; Dubois J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224098; Dunn KM, 2013, BEST PRACT RES CL RH, V27, P591, DOI 10.1016/j.berh.2013.09.007; Edwards J, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1511-7; Fawkes CA, 2014, MANUAL THER, V19, P125, DOI 10.1016/j.math.2013.09.001; Franke H, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-286; Friedman BW, 2010, SPINE, V35, pE1406, DOI 10.1097/BRS.0b013e3181d952a5; Gamber R, 2005, J AM OSTEOPATH ASSOC, V105, P357; Giusti R., 2017, GLOSSARY OSTEOPATHIC, V3rd Edn; Hedden Lindsay, 2014, Hum Resour Health, V12, P32, DOI 10.1186/1478-4491-12-32; Humphreys BK, 2010, J MANIP PHYSIOL THER, V33, P519, DOI 10.1016/j.jmpt.2010.08.003; Huntley A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004746; Jefferson L, 2015, J ROY SOC MED, V108, P136, DOI 10.1177/0141076814558522; Johnson SM, 2002, SOC SCI MED, V55, P2141, DOI 10.1016/S0277-9536(01)00357-4; Klein SD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144676; Klein SD, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13666; KPMG, 2011, KPMG DAT SURV OST PR; Lanaro D, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006408; Licciardone JC, 2013, MANUAL THER, V18, P533, DOI 10.1016/j.math.2013.05.006; Licciardone John C., 2001, Journal of the American Osteopathic Association, V101, P374; Michaleff ZA, 2012, J ELECTROMYOGR KINES, V22, P655, DOI 10.1016/j.jelekin.2012.02.011; Morin C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106259; OFS) FSO, 2017, TRAV TEMPS PART SUIS; Ong CK, 2004, HEALTH SOC CARE COMM, V12, P265, DOI 10.1111/j.1365-2524.2004.00497.x; Orrock P, 2009, INT J OSTEOPATH MED, V12, P14, DOI 10.1016/j.ijosm.2008.04.002; Orton PK, 2016, FAM PRACT, V33, P529, DOI 10.1093/fampra/cmw056; Paige NM, 2017, JAMA-J AM MED ASSOC, V317, P1451, DOI 10.1001/jama.2017.3086; Qaseem Amir, 2017, Ann Intern Med, V166, P514, DOI 10.7326/M16-2367; Rubinstein SM, 2013, SPINE, V38, pE158, DOI 10.1097/BRS.0b013e31827dd89d; Rubinstein SM, 2011, SPINE, V36, pE825, DOI 10.1097/BRS.0b013e3182197fe1; Savigny P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1805; Schwarz Ilke, 2007, Chiropr Osteopat, V15, P6, DOI 10.1186/1746-1340-15-6; Stevens S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018261; Tamcan O, 2010, PAIN, V150, P451, DOI 10.1016/j.pain.2010.05.019; Tsugawa Y, 2017, JAMA INTERN MED, V177, P206, DOI 10.1001/jamainternmed.2016.7875; van Dun PLS, 2016, INT J OSTEOPATH MED, V20, P3, DOI 10.1016/j.ijosm.2016.01.003; van Tulder M, 2006, EUR SPINE J, V15, pS169, DOI 10.1007/s00586-006-1071-2; Vaucher P, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023770; Wallis CJD, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4366; Wand BM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3679; Xue CCL, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-105	51	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2020	15	5							e0232607	10.1371/journal.pone.0232607	http://dx.doi.org/10.1371/journal.pone.0232607			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT3FY	32357175	Green Published, gold, Green Submitted			2023-01-03	WOS:000536957700042
J	Furst, P; Lundstrom, S; Strang, P				Furst, Per; Lundstrom, Staffan; Strang, Peter			Methadone in Swedish specialized palliative care-Is it the magic bullet in complex cancer-related pain?	PLOS ONE			English	Article							QUALITATIVE CONTENT-ANALYSIS; ASPARTATE NMDA RECEPTOR; UK ASSOCIATION; ROYAL-COLLEGE; PERSPECTIVE; MANAGEMENT; MEDICINE; MORPHINE	Context Despite being associated with dependence and social stigma, methadone is a potential end-of-life option in complex cancer pain. Objectives To explore attitudes and opinions about methadone and its potential role and current use in complex end-of-life pain. Methods Semi-structured interviews (n = 30) with physicians in specialized palliative care, transcribed and analyzed with conventional qualitative content analysis. Results According to the physicians, patients and relatives expressed unexpectedly few negative attitudes, not affecting methadone's use as an analgesic. Complex pain in bone-metastatic cancer of the prostate, breast and kidney, as well as pancreatic cancer and sarcomas were recurrent suggestions of appropriate indications. Most of the informants stated that they applied a mechanism-based treatment and mainly prescribed low-dose methadone as an add-on to an existing opioid therapy to benefit from methadone's proposed NMDA-receptor inhibiting properties, e.g. in cases with reduced opioid sensitivity. Despite its complex pharmacokinetics with a long half-life, most informants expressed defined strategies to avoid side-effects such as respiratory depression, especially when initiating treatment in the home-care setting. While many palliative care physicians expressed an overly enthusiastic attitude, others stressed the risks of overconfidence, low precision in use, and overlooked treatment options. Besides the obvious physical pain-relieving effects, they stated that effective pain relief could result in a reduced workload and emotional empowerment, both for physicians and staff. Conclusion Methadone, especially in the form of low-dose add-on to other opioids is widely advocated in Swedish specialized palliative care as a practical and safe method with rapid onset in complex pain situations at the end of life.	[Furst, Per; Lundstrom, Staffan; Strang, Peter] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Furst, Per; Lundstrom, Staffan; Strang, Peter] Stockholms Sjukhem Fdn, Palliat Med, Stockholm, Sweden	Karolinska Institutet	Furst, P (corresponding author), Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.; Furst, P (corresponding author), Stockholms Sjukhem Fdn, Palliat Med, Stockholm, Sweden.	per.furst@ki.se		Furst, Per/0000-0001-5363-833X; Strang, Peter/0000-0001-8514-5433	Stockholm Sjukhem Foundation	Stockholm Sjukhem Foundation	This study was financially supported by the Stockholm Sjukhem Foundation to PS. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; [Anonymous], 2011, OPENCODE 4 0; ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; Borgbjerg FM, 1996, PAIN, V64, P123, DOI 10.1016/0304-3959(95)00088-7; Courtemanche F, 2016, J PALLIAT MED, V19, P972, DOI 10.1089/jpm.2015.0525; Davis MP, 2001, SUPPORT CARE CANCER, V9, P73, DOI 10.1007/s005200000180; Dickman A, 2011, SYRINGE DRIVER, P103; EBERT B, 1995, NEUROSCI LETT, V187, P165, DOI 10.1016/0304-3940(95)11364-3; Falk S, 2014, BRIT J PAIN, V8, P154, DOI 10.1177/2049463714545136; Finnerup Nanna B, 2015, Lancet Neurol, V14, P162, DOI 10.1016/S1474-4422(14)70251-0; Fitzgibbon DR, 2010, CANC PAIN ASSESSMENT; Furst P, 2020, J PALLIAT MED, V23, P226, DOI 10.1089/jpm.2019.0253; Furst P, 2018, J PALLIAT MED, V21, P177, DOI 10.1089/jpm.2017.0157; Gorman AL, 1997, NEUROSCI LETT, V223, P5; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Graneheim UH, 2017, NURS EDUC TODAY, V56, P29, DOI 10.1016/j.nedt.2017.06.002; GROCHOW L, 1989, PAIN, V38, P151, DOI 10.1016/0304-3959(89)90233-9; HANKS GW, 1984, LANCET, V1, P1477; Hernansanz S, 2006, J PAIN SYMPTOM MANAG, V31, P2, DOI 10.1016/j.jpainsymman.2005.12.005; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Kvale S., 1989, ISSUES VALIDITY QUAL; Lee M, 2011, PAIN PHYSICIAN, V14, P145; Mantyh PW, 2019, BRIT J CLIN PHARMACO, V85, P1103, DOI 10.1111/bcp.13801; McKenna M, 2011, J PAIN SYMPTOM MANAG, V42, pE4, DOI 10.1016/j.jpainsymman.2011.06.005; McNicol ED, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012499.pub2; Morse J.M., 1994, HDB QUALITATIVE INQU, P220, DOI DOI 10.1109/HICSS.2013.531; Patton M. Q., 1990, QUALITATIVE RES EVAL; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; Raphael J, 2010, PAIN MED, V11, P872, DOI 10.1111/j.1526-4637.2010.00841.x; Raphael J, 2010, PAIN MED, V11, P742, DOI 10.1111/j.1526-4637.2010.00840.x; Rayment C, 2013, PALLIATIVE MED, V27, P714, DOI 10.1177/0269216312464408; SAWE J, 1981, BRIT MED J, V282, P771, DOI 10.1136/bmj.282.6266.771; Shah S, 2010, PAIN PHYSICIAN, V13, P289; Sotgiu ML, 2009, PHARMACOL RES, V60, P284, DOI 10.1016/j.phrs.2009.04.002; Strang P, 2004, J PAIN SYMPTOM MANAG, V27, P241, DOI 10.1016/j.jpainsymman.2003.07.003; Terpening Chris M, 2007, W V Med J, V103, P14; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Wallace E, 2013, J PALLIAT MED, V16, P305, DOI 10.1089/jpm.2012.0335; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030	39	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2020	15	4							e0230845	10.1371/journal.pone.0230845	http://dx.doi.org/10.1371/journal.pone.0230845			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR8YT	32275723	gold, Green Published			2023-01-03	WOS:000535983300024
J	Sarma, H; Jabeen, I; Luies, SK; Uddin, MF; Ahmed, T; Bossert, TJ; Banwell, C				Sarma, Haribondhu; Jabeen, Ishrat; Luies, Sharmin Khan; Uddin, Md Fakhar; Ahmed, Tahmeed; Bossert, Thomas J.; Banwell, Cathy			Performance of volunteer community health workers in implementing home-fortification interventions in Bangladesh: A qualitative investigation	PLOS ONE			English	Article								Introduction BRAC, an international development organisation based in Bangladesh, uses female volunteer community health workers called Shasthya Shebika (SS), who receive small incentives to implement its home-fortification interventions at the community level. This paper examines the individual, community and BRAC work environment factors that exert an influence on the performance of SS. Methods This qualitative study was conducted between the period of June 2014 to December 2016 as part of a larger evaluation of BRAC's home-fortification programme. Data were collected through in-depth interviews, focus group discussions, and key informant interviews and analysed thematically. The participants were SS and their supervisors working for BRAC, caregivers of children aged 6-59 months, husbands of SS, village doctors, and Upazila Health and Family Planning Officers. Results Younger, better educated and more experienced SS with positive self-efficacy were perceived to have performed better than their peers. Social and community factors, such as community recognition of the SS's services, social and religious norms, family support, and household distance, also affected the performance of the SS. There were several challenges at the programme and organisational level that needed to be addressed, including appropriate recruitment, timely basic training and income-generation guidance for the SS. Conclusion BRAC's volunteer SS model faces challenges at individual, community, programme and organisational level. Importantly, BRAC's SS require a living wage to earn essential income for their family. Considering the current socio-cultural and economic context of Bangladesh, BRAC may need to revise the existing volunteer SS model to ensure that SS receive an adequate income so that they can devote themselves to implementing its home-fortification intervention.	[Sarma, Haribondhu; Banwell, Cathy] Australian Natl Univ, Coll Hlth & Med, Res Sch Populat Hlth, Acton, ACT, Australia; [Sarma, Haribondhu; Jabeen, Ishrat; Luies, Sharmin Khan; Uddin, Md Fakhar; Ahmed, Tahmeed] Icddr B, Nutr & Clin Serv Div, Dhaka, Bangladesh; [Bossert, Thomas J.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA	Australian National University; International Centre for Diarrhoeal Disease Research (ICDDR); Harvard University; Harvard T.H. Chan School of Public Health	Sarma, H (corresponding author), Australian Natl Univ, Coll Hlth & Med, Res Sch Populat Hlth, Acton, ACT, Australia.; Sarma, H (corresponding author), Icddr B, Nutr & Clin Serv Div, Dhaka, Bangladesh.	haribondhu.sarma@anu.edu.au	Jabeen, Ishrat/AAD-1389-2022	Sarma, Haribondhu/0000-0003-1553-8498	Children's Investment Fund Foundation (CIFF) of UK	Children's Investment Fund Foundation (CIFF) of UK	Research for this article was founded by the Children's Investment Fund Foundation (CIFF) of UK. The views, opinions, assumptions, or any other information set out in this article are solely those of the authors and should not be attributed to CIFF or any person connected with CIFF.	Afsana K, 2012, MATERNAL AND PERINATAL HEALTH IN DEVELOPING COUNTRIES, P170, DOI 10.1079/9781845937454.0170; Ahmed M, 2016, AGR MECHANIZATION NO; Ahmed S., 2008, BRAC U J, VV, P39; Alam K, 2012, SOC SCI MED, V75, P511, DOI 10.1016/j.socscimed.2012.03.039; [Anonymous], GLOB HLTH WORKF ALL; Anyangwe Stella C E, 2007, Int J Environ Res Public Health, V4, P93, DOI 10.3390/ijerph2007040002; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BRAC International, RAIS AW HEALTH LIF; Chen L, 2004, LANCET, V364, P1984, DOI 10.1016/S0140-6736(04)17482-5; Cherrington A, 2008, DIABETES EDUCATOR, V34, P824, DOI 10.1177/0145721708323643; Cherrington A, 2010, ETHNIC DIS, V20, P189; Cometto G, 2018, LANCET GLOB HEALTH, V6, P1397, DOI 10.1016/S2214-109X(18)30482-0; Dieleman M., 2006, IMPROVING HLTH WORKE; Fereday J, 2006, INT J QUAL METH, P5, DOI [DOI 10.1177/160940690600500107, 10.1177/160940690600500107]; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Gerein N, 2006, REPROD HEALTH MATTER, V14, P40, DOI 10.1016/S0968-8080(06)27225-2; Gilroy K, 2006, MANAGEMENT SICK CHIL; Golden SD, 2012, HEALTH EDUC BEHAV, V39, P364, DOI 10.1177/1090198111418634; Gopalan SS, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001557; Haggblade S, 2010, WORLD DEV, V38, P1429, DOI 10.1016/j.worlddev.2009.06.008; Hashima-E-Nasreen, 2011, GLOBAL HEALTH ACTION, V4, DOI 10.3402/gha.v4i0.7017; Kambarami RA, 2016, GLOB HEALTH-SCI PRAC, V4, P238, DOI 10.9745/GHSP-D-16-00003; Kawakatsu Y, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1117-4; Khan S H, 1998, Health Care Superv, V17, P37; Kok MC, 2015, HEALTH RES POLICY SY, V13, DOI 10.1186/s12961-015-0001-3; Kok MC, 2014, HLTH POLICY PLAN, V30, P1, DOI [10.1093/heapol/czs111, DOI 10.1093/HEAPOL/CZS111]; Miyaguchi M, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-383; Mukanga D, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-121; Ndima SD, 2015, HUM RESOUR HEALTH, V13, DOI 10.1186/s12960-015-0063-x; Perez LM, 2008, AM J PUBLIC HEALTH, V98, P11, DOI 10.2105/AJPH.2006.100842; Prata N, 2012, SOC SCI MED, V74, P1288, DOI 10.1016/j.socscimed.2011.11.035; Rashid SF, 2001, TROP MED INT HEALTH, V6, P249, DOI 10.1046/j.1365-3156.2001.00702.x; Razee H, 2012, SOC SCI MED, V75, P828, DOI 10.1016/j.socscimed.2012.04.013; Ritchie J, 2013, QUALITATIVE RES PRAC, P295, DOI [10.7748/nr2011.01.18.2.52.c8284, DOI 10.7748/NR2011.01.18.2.52.C8284]; Rowe AK, 2005, LANCET, V366, P1026, DOI 10.1016/S0140-6736(05)67028-6; Sarma H, 2021, PUBLIC HEALTH NUTR, V24, pS23, DOI 10.1017/S1368980019003768; Sarma H, 2016, FOOD NUTR BULL, V37, P340, DOI 10.1177/0379572116645916; Scott K, 2010, AIDS CARE, V22, P1606, DOI 10.1080/09540121.2010.507751; Sikder M. J. U., 2017, MIGRATION DEV, V6, P253, DOI [10.1080/21632324.2016.1142752, DOI 10.1080/21632324.2016.1142752]; Smith Joanna, 2011, Nurse Res, V18, P52; Standing H, 2008, SOC SCI MED, V66, P2096, DOI 10.1016/j.socscimed.2008.01.046; Swider SM, 2002, PUBLIC HEALTH NURS, V19, P11, DOI 10.1046/j.1525-1446.2002.19003.x; Viswanathan K, 2012, J EPIDEMIOL COMMUN H, V66, P894, DOI 10.1136/jech-2011-200275; WHO, 2006, WORK TOG HLTH WORLD; Wiggins N, 1998, FINAL FULL REPORT NA, P11; World Health Organization, WORLD HLTH STAT 2016	46	8	8	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2020	15	4							e0230709	10.1371/journal.pone.0230709	http://dx.doi.org/10.1371/journal.pone.0230709			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LR8IA	32236114	Green Published, gold, Green Submitted			2023-01-03	WOS:000535938700023
J	Bedard, PL; Hyman, DM; Davids, MS; Siu, LLL				Bedard, Philippe L.; Hyman, David M.; Davids, Matthew S.; Siu, Lillian L.			Small molecules, big impact: 20 years of targeted therapy in oncology	LANCET			English	Review							CELL LUNG-CANCER; TYROSINE KINASE INHIBITOR; OPEN-LABEL; ANTITUMOR-ACTIVITY; PHASE-III; 1ST-LINE TREATMENT; SOLID TUMORS; DOUBLE-BLIND; I TRIALS; SAFETY	The identification of molecular targets and the growing knowledge of their cellular functions have led to the development of small molecule inhibitors as a major therapeutic class for cancer treatment. Both multitargeted and highly selective kinase inhibitors are used for the treatment of advanced treatment-resistant cancers, and many have also achieved regulatory approval for early clinical settings as adjuvant therapies or as first-line options for recurrent or metastatic disease. Lessons learned from the development of these agents can accelerate the development of next-generation inhibitors to optimise the therapeutic index, overcome drug resistance, and establish combination therapies. The future of small molecule inhibitors is promising as there is the potential to investigate novel difficult-to-drug targets, to apply predictive non-clinical models to select promising drug candidates for human evaluation, and to use dynamic clinical trial interventions with liquid biopsies to deliver precision medicine.	[Bedard, Philippe L.; Siu, Lillian L.] Univ Toronto, Dept Med, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON M5G 1Z5, Canada; [Hyman, David M.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Hyman, David M.] Weill Cornell Med Coll, New York, NY USA; [Davids, Matthew S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Memorial Sloan Kettering Cancer Center; Cornell University; Harvard University; Dana-Farber Cancer Institute	Siu, LLL (corresponding author), Univ Toronto, Dept Med, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON M5G 1Z5, Canada.	lillian.siu@uhn.ca		Bedard, Philippe/0000-0002-6771-2999				AHN ER, 2019, J CLIN ONCOL S, V37; AlBaghdadi T, 2019, JCO PRECIS ONCOL, V3, P1; Allan JA, 2019, HEMASPHERE, V3, P520; ALVA AS, 2019, J CLIN ONCOL S, V37; Alvarez RH, 2019, AM ASS CANC RES ANN; [Anonymous], 2019, NAT BIOTECHNOL, V37, P701, DOI 10.1038/s41587-019-0189-9; Azad N, 2017, 32 ANN M SOC IMM CAN; Baselga J, 2016, AM ASS CANC RES 107; Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627; Bedard PL, 2019, AM ASS CANC RES ANN; BENDELL JC, 2014, J CLIN ONCOL S, V32; Berry DA, 2012, NAT REV CLIN ONCOL, V9, P199, DOI 10.1038/nrclinonc.2011.165; Brana I, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS3151; Camidge DR, 2018, NEW ENGL J MED, V379, P2027, DOI 10.1056/NEJMoa1810171; Camidge DR, 2012, LANCET ONCOL, V13, P1011, DOI 10.1016/S1470-2045(12)70344-3; Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1; Chang GC, 2017, LUNG CANCER, V104, P58, DOI 10.1016/j.lungcan.2016.12.002; Clark AS, 2019, AM ASS CANC RES ANN; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36; Davids MS, 2019, LANCET HAEMATOL, V6, pE38, DOI 10.1016/S2352-3026(18)30196-0; Davids MS, 2017, J CLIN ONCOL, V35, P826, DOI 10.1200/JCO.2016.70.4320; Davids MS, 2018, 23 EUR HEM ASS C STO; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Deng J, 2017, LEUKEMIA, V31, P2075, DOI 10.1038/leu.2017.32; Diamond EL, 2018, JAMA ONCOL, V4, P384, DOI 10.1001/jamaoncol.2017.5029; DiNardo CD, 2018, NEW ENGL J MED, V378, P2386, DOI 10.1056/NEJMoa1716984; DiNardo CD, 2019, BLOOD, V133, P7, DOI 10.1182/blood-2018-08-868752; Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448; Drilon A, 2018, CANCER DISCOV, V8, P1227, DOI 10.1158/2159-8290.CD-18-0484; Drilon A, 2017, CANCER DISCOV, V7, P400, DOI 10.1158/2159-8290.CD-16-1237; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Elisei R, 2013, J CLIN ONCOL, V31, P3639, DOI 10.1200/JCO.2012.48.4659; Faivre S, 2006, J CLIN ONCOL, V24, P25, DOI 10.1200/JCO.2005.02.2194; Fischer K, 2019, NEW ENGL J MED, V380, P2225, DOI 10.1056/NEJMoa1815281; Fisher J, 2019, AM ASS CANC RES ANN; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Flinn IW, 2018, BLOOD, V132, P2446, DOI 10.1182/blood-2018-05-850461; Ghoreschi K, 2009, NAT IMMUNOL, V10, P356, DOI 10.1038/ni.1701; Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387; Gong XQ, 2019, CANCER DISCOV, V9, P248, DOI 10.1158/2159-8290.CD-18-0469; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Guarducci C, 2018, SAN ANT BREAST CANC; Hainsworth JD, 2018, J CLIN ONCOL, V36, P536, DOI 10.1200/JCO.2017.75.3780; Hall CR, 2019, AM ASS CANC RES ANN; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hillmen P, 2019, J CLIN ONCOL, V37, P2722, DOI 10.1200/JCO.19.00894; Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236; Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475; Hyman DM, 2017, J CLIN ONCOL, V35, P2251, DOI 10.1200/JCO.2017.73.0143; Jaglowski SM, 2018, BLOOD ADV, V2, P2012, DOI 10.1182/bloodadvances.2018013060; Jain N, 2019, NEW ENGL J MED, V380, P2095, DOI 10.1056/NEJMoa1900574; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Janku F, 2018, ANN ONCOL, V29, P137; Jhaveri KL, 2019, ANN ONCOL, V30, P1821, DOI 10.1093/annonc/mdz291; Jia Y, 2016, NATURE, V534, P129, DOI 10.1038/nature17960; Kaley T, 2018, J CLIN ONCOL, V36, P3477, DOI 10.1200/JCO.2018.78.9990; Kalinsky K, 2018, 30 EUR ORG RES TREAT; Kim DW, 2017, J CLIN ONCOL, V35, P2490, DOI 10.1200/JCO.2016.71.5904; Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Kluk MJ, 2016, J MOL DIAGN, V18, P507, DOI 10.1016/j.jmoldx.2016.02.003; Ko AH, 2016, CLIN CANCER RES, V22, P61, DOI 10.1158/1078-0432.CCR-15-0979; Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075; Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497; Krop IE, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.101; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Kummar S, 2019, AM ASS CANC RES ANN; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6; Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535; Lin A, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw8412; Litton JK, 2018, NEW ENGL J MED, V379, P753, DOI 10.1056/NEJMoa1802905; Lok SW, 2019, CANCER DISCOV, V9, P354, DOI 10.1158/2159-8290.CD-18-1151; Moreau P, 2017, BLOOD, V130, P2392, DOI 10.1182/blood-2017-06-788323; Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989; Ng M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2584; NikitorowiczBuniak J, 2018, AM ASS CANC RES ANN; Oser MG, 2019, CANCER DISCOV, V9, P230, DOI 10.1158/2159-8290.CD-18-0389; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Papadopoulos KP, 2019, J CLIN ONCOL, V37, P37; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Salama AKS, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3002; Schick M, 2017, BRIT J HAEMATOL, V179, P724, DOI 10.1111/bjh.14917; Schlumberger M, 2016, CLIN CANCER RES, V22, P44, DOI 10.1158/1078-0432.CCR-15-1127; Schlumberger M, 2015, NEW ENGL J MED, V372, P621, DOI 10.1056/NEJMoa1406470; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; Sharman JP, 2019, J CLIN ONCOL, V37, P1391, DOI 10.1200/JCO.18.01460; Shaw AT, 2016, LANCET ONCOL, V17, P234, DOI 10.1016/S1470-2045(15)00488-X; Shaw AT, 2014, NEW ENGL J MED, V370, P2537, DOI 10.1056/NEJMc1404894; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Skamene T, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.TPS12127; Solomon BJ, 2018, LANCET ONCOL, V19, P1654, DOI 10.1016/S1470-2045(18)30649-1; Sondka Z, 2018, NAT REV CANCER, V18, P696, DOI 10.1038/s41568-018-0060-1; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Spring LM, 2020, LANCET, V395, P817, DOI 10.1016/S0140-6736(20)30165-3; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Stone RM, 2017, NEW ENGL J MED, V377, P454, DOI 10.1056/NEJMoa1614359; Strumberg D, 2007, ONCOLOGIST, V12, P426, DOI 10.1634/theoncologist.12-4-426; Subbiah V, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00266; Tannock IF, 2016, NEW ENGL J MED, V375, P1289, DOI 10.1056/NEJMsb1607705; Tolcher AW, 2018, MOL CANCER THER, V17, P3, DOI 10.1158/1535-7163.MCT-17-0349; Valpione S, 2018, EUR J CANCER, V91, P116, DOI 10.1016/j.ejca.2017.12.007; Van Cutsem E, 2019, CLIN CANCER RES, V25, P2414, DOI 10.1158/1078-0432.CCR-18-1337; van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5; Van der Velden DL, 2019, NATURE, V574, P127, DOI 10.1038/s41586-019-1600-x; Verstovsek S, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0527-7; Voest EE, 2016, CANCER DISCOV, V6, P130, DOI 10.1158/2159-8290.CD-15-1321; WAINBERG ZA, 2019, J CLIN ONCOL S, V37; Wells SA, 2012, J CLIN ONCOL, V30, P134, DOI 10.1200/JCO.2011.35.5040; Wise-Draper TM, 2017, TARGET ONCOL, V12, P323, DOI 10.1007/s11523-017-0482-9; Wylie AA, 2017, NATURE, V543, P733, DOI 10.1038/nature21702; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	117	148	158	18	119	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	2020	395	10229					1078	1088						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY5YW	32222192				2023-01-03	WOS:000522650100035
J	Brant, EJ; Rietman, EA; Klement, GL; Cavaglia, M; Tuszynski, JA				Brant, Elizabeth J.; Rietman, Edward A.; Klement, Giannoula Lakka; Cavaglia, Marco; Tuszynski, Jack A.			Personalized therapy design for systemic lupus erythematosus based on the analysis of protein-protein interaction networks	PLOS ONE			English	Article							RIBOSOMAL-PROTEINS; EXPRESSION; CANCER; CELLS; AUTOANTIBODIES; ASSOCIATION; MECHANISMS; BIOMARKERS; PATHOGENESIS; DYSFUNCTION	We analyzed protein expression data for Lupus patients, which have been obtained from publicly available databases. A combination of systems biology and statistical thermodynamics approaches was used to extract topological properties of the associated protein-protein interaction networks for each of the 291 patients whose samples were used to provide the molecular data. We have concluded that among the many proteins that appear to play critical roles in this pathology, most of them are either ribosomal proteins, ubiquitination pathway proteins or heat shock proteins. We propose some of the proteins identified in this study to be considered for drug targeting.	[Brant, Elizabeth J.] Dartmouth Hitchcock Med Ctr, Nephrol, Lebanon, NH 03766 USA; [Rietman, Edward A.] Univ Massachusetts, Coll Informat & Comp Sci, BINDS Lab, Amherst, MA 01003 USA; [Rietman, Edward A.] Univ Mass, Dept Mech & Ind Engn, Amherst, MA USA; [Klement, Giannoula Lakka] CSTS, Toronto, ON, Canada; [Cavaglia, Marco] ACTISMED Srl, Turin, Italy; [Tuszynski, Jack A.] Politecn Torino, DIMEAS, Turin, Italy; [Tuszynski, Jack A.] Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada	Dartmouth College; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; Polytechnic University of Turin; University of Alberta	Tuszynski, JA (corresponding author), Politecn Torino, DIMEAS, Turin, Italy.; Tuszynski, JA (corresponding author), Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada.	jackt@ualberta.ca	Tuszynski, Jack/AAA-2073-2020; Cavaglià, Marco/AAW-6540-2021	Tuszynski, Jack/0000-0001-9976-0429; Cavaglia, Marco/0000-0003-1313-9696	CSTS-Healthcare, Toronto, Canada; NSERC (Canada)	CSTS-Healthcare, Toronto, Canada; NSERC (Canada)(Natural Sciences and Engineering Research Council of Canada (NSERC))	EAR and GLK acknowledge partial funding from CSTS-Healthcare, Toronto, Canada. JAT acknowledges funding support from NSERC (Canada).	Abbas W, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00075; Benzekry S, 2015, BIOL DIRECT, V10, DOI 10.1186/s13062-015-0058-5; Berthier CC, 2012, J IMMUNOL, V189, P988, DOI 10.4049/jimmunol.1103031; Bienkowska J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112545; Breitkreutz D, 2012, P NATL ACAD SCI USA, V109, P9209, DOI 10.1073/pnas.1201416109; Budarf ML, 2011, GENES IMMUN, V12, P51, DOI 10.1038/gene.2010.47; Cardenas-Gonzalez M, 2017, CLIN CHEM, V63, P1515, DOI 10.1373/clinchem.2017.274175; Carels N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115054; Chaussabel D, 2008, IMMUNITY, V29, P150, DOI 10.1016/j.immuni.2008.05.012; Choubey D, 2008, IMMUNOL LETT, V119, P32, DOI 10.1016/j.imlet.2008.06.001; Dai Y, 2010, CLIN EXP RHEUMATOL, V28, P158; Donauer J, 1999, INT IMMUNOL, V11, P125, DOI 10.1093/intimm/11.2.125; Feng X, 2017, LUPUS, V26, P62, DOI 10.1177/0961203316651738; Fierabracci A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17121975; Fu LY, 2016, HUM IMMUNOL, V77, P1, DOI 10.1016/j.humimm.2014.09.002; Geo Y, 2013, PLOS ONE, V8, DOI [10.1371/, DOI 10.1371/]; Grammatikos AP, 2012, TRENDS MOL MED, V18, P101, DOI 10.1016/j.molmed.2011.10.005; Guerra SG, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3844; Harley JB, 2018, NAT GENET, V50, P699, DOI 10.1038/s41588-018-0102-3; Hinow P, 2015, MATH BIOSCI ENG, V12, P1289, DOI 10.3934/mbe.2015.12.1289; Hsieh SC, 2016, OPEN ACCESS RHEUMATO, V8, P81, DOI 10.2147/OARRR.S112829; Huang S, 2011, SEMIN CANCER BIOL, V21, P183, DOI 10.1016/j.semcancer.2011.05.003; Hui-Yuen JS, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1169-9; Kim MS, 2014, NATURE, V509, P575, DOI 10.1038/nature13302; Lai NS, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1465-z; Lai ZW, 2012, ARTHRITIS RHEUM-US, V64, P2937, DOI 10.1002/art.34502; Li LJ, 2017, CELL IMMUNOL, V319, P17, DOI 10.1016/j.cellimm.2017.06.004; Lisnevskaia L, 2014, LANCET, V384, P1878, DOI 10.1016/S0140-6736(14)60128-8; Lu MC, 2015, RHEUMATOLOGY, V54, P343, DOI 10.1093/rheumatology/keu322; Manson JJ, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-6; Mikdashi J, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0702-6; Moris N, 2016, NAT REV GENET, V17, P693, DOI 10.1038/nrg.2016.98; Mukhyapranaprabhu M, SYSTEMIC LUPUS RECEN; Nobee A., 2015, AM J CLIN MED RES, V3, P60; Perl A, 2004, TRENDS IMMUNOL, V25, P360, DOI 10.1016/j.it.2004.05.001; Perl A, 2010, AUTOIMMUNITY, V43, P32, DOI 10.3109/08916930903374774; Perl A, 2010, AUTOIMMUNITY, V43, P1, DOI 10.3109/08916930903374741; Petri M, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-018-0468-1; Rai G, 2016, IMMUNOL RES, V64, P14, DOI 10.1007/s12026-015-8672-y; Raiser DM, 2014, LEUKEMIA LYMPHOMA, V55, P491, DOI 10.3109/10428194.2013.812786; Reichlin M, 1998, J AUTOIMMUN, V11, P557, DOI 10.1006/jaut.1998.0219; Ren JQ, 2010, J BIOL CHEM, V285, P12695, DOI 10.1074/jbc.M110.103911; Rietman EA, 2017, ONCOTARGET, V8, P18735, DOI 10.18632/oncotarget.12932; Rietman EA, 2016, J BIOL PHYS, V42, P339, DOI 10.1007/s10867-016-9410-y; Rietman EA, 2011, THEOR BIOL MED MODEL, V8, DOI 10.1186/1742-4682-8-21; Salmond RJ, 2015, J IMMUNOL, V195, P4615, DOI 10.4049/jimmunol.1501473; Scaggiante B, 2012, BRIT J CANCER, V106, P166, DOI 10.1038/bjc.2011.500; Shukla HD, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/728605; Streicher K, 2014, ARTHRITIS RHEUMATOL, V66, P173, DOI 10.1002/art.38194; Stypinska B, 2015, INT J MOL SCI, V16, P24194, DOI 10.3390/ijms161024194; Sun KH, 2005, J AUTOIMMUN, V24, P135, DOI 10.1016/j.jaut.2005.01.002; Tsai C-Y., 2018, J LAB PRECIS MED, V3, P1, DOI [10.21037/jlpm.2018.05.02, DOI 10.21037/JLPM.2018.05.02]; Tsai C-Y, 2017, J LAB PRECIS MED, V2; Wang W, 2015, MED RES REV, V35, P225, DOI 10.1002/med.21327; Wilhelm M, 2014, NATURE, V509, P582, DOI 10.1038/nature13319; Wu TF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037210; Xiao G, 2016, BIOMED REP, V4, P135, DOI 10.3892/br.2015.556; Yaniv G, 2015, AUTOIMMUN REV, V14, P75, DOI 10.1016/j.autrev.2014.10.003; Yuan Y, 2018, Z RHEUMATOL, V77, P256, DOI 10.1007/s00393-017-0274-8; Zandman-Goddard G, 2007, SEMIN ARTHRITIS RHEU, V36, P297, DOI 10.1016/j.semarthrit.2006.11.003; Zhang Z, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0179-4; Zhou X, 2015, J MOL CELL BIOL, V7, P92, DOI 10.1093/jmcb/mjv014	62	2	2	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2020	15	3							e0226883	10.1371/journal.pone.0226883	http://dx.doi.org/10.1371/journal.pone.0226883			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ9FM	32191711	Green Submitted, Green Published, gold			2023-01-03	WOS:000535302300007
J	Dang, XF; Xu, MJ; Liu, DR; Zhou, DJ; Yang, WH				Dang, Xiaofei; Xu, Mingjie; Liu, Duanrui; Zhou, Dajie; Yang, Weihua			Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis	PLOS ONE			English	Review							INFLAMMATORY-BOWEL-DISEASE; 5-AMINOSALICYLIC ACID; INTESTINAL MICROBIOTA; IN-VITRO; REMISSION; BACTERIA; QUALITY; RISK; VIVO	Background Fecal microbiota transplantation is an effective treatment for many gastrointestinal diseases, such as Clostridium difficile infection and inflammatory bowel disease, especially ulcerative colitis. Changes in colonic microflora may play an important role in the pathogenesis of ulcerative colitis, and improvements in the intestinal microflora may relieve the disease. Fecal bacterial transplants and oral probiotics are becoming important ways to relieve active ulcerative colitis. Purpose This systematic review with meta-analysis compared the efficacy and safety of basic treatment combined with fecal microbiota transplantation or mixed probiotics therapy in relieving mild to moderate ulcerative colitis. Methods The PubMed, Embase, and Cochrane libraries (updated September 2019) were searched to identify randomized, placebo-controlled, or head-to-head trials assessing fecal microbiota transplantation or probiotic VSL#3 as induction therapy in active ulcerative colitis. We analyze data using the R program to obtain evidence of direct comparison and to generate intermediate variables for indirect treatment comparisons. Results Seven randomized, double-blind, placebo-controlled trials were used as the sources of the induction data. All treatments were superior to placebo. In terms of clinical remission and clinical response to active ulcerative colitis, direct comparisons showed fecal microbiota transplantation (OR = 3.47, 95% CI = 1.93-6.25) (OR = 2.48, 95% CI = 1.18-5.21) and mixed probiotics VSL#3 (OR = 2.40, 95% CI = 1.49-3.88) (OR = 3.09, 95% CI = 1.53-6.25) to have better effects than the placebo. Indirect comparison showed fecal microbiota transplantation and probiotic VSL#3 did not reach statistical significance either in clinical remission (RR = 1.20, 95% CI = 0.70-2.06) or clinical response (RR = 0.95, 95% CI = 0.62-1.45). In terms of safety, fecal microbiota transplantation (OR = 1.15, 95% CI = 0.51-2.61) and VSL #3 (OR = 0.90, 95% CI = 0.33-2.49) showed no statistically significant increase in adverse events compared with the control group. In terms of serious adverse events, there was no statistical difference between the fecal microbiota transplantation group and the control group (OR = 1.29, 95% CI = 0.46-3.57). The probiotics VSL#3 seems more safer than fecal microbiota transplantation, because serious adverse events were not reported in the VSL#3 articles. Conclusions Fecal microbiota transplantation or mixed probiotics VSL#3 achieved good results in clinical remission and clinical response in active ulcerative colitis, and there was no increased risk of adverse reactions. There was no statistical difference between the therapeutic effect of fecal microbiota transplantation and that of mixed probiotics VSL#3. However, the use of fecal microbiota transplantation and probiotics still has many unresolved problems in clinical applications, and more randomized controlled trials are required to confirm its efficacy.	[Dang, Xiaofei; Xu, Mingjie; Yang, Weihua] Shandong Univ, Dept Clin Microbiol, Med Res & Lab Diagnost Ctr, Jinan Cent Hosp, Jinan, Shandong, Peoples R China; [Liu, Duanrui; Zhou, Dajie] Shandong Univ, Cent Lab, Jinan Cent Hosp, Jinan, Shandong, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University	Yang, WH (corresponding author), Shandong Univ, Dept Clin Microbiol, Med Res & Lab Diagnost Ctr, Jinan Cent Hosp, Jinan, Shandong, Peoples R China.	whyxp@163.com		Dang, Xiaofei/0000-0002-7117-5508; Yang, Weihua/0000-0001-5468-758X	Jinan Science and Technology Innovation Project [201805027]	Jinan Science and Technology Innovation Project	This work was funded by the Jinan Science and Technology Innovation Project (201805027) to WY. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed J, 2013, INT J SURG, V11, P1131, DOI 10.1016/j.ijsu.2013.08.019; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Berg D, 2015, EXPERT REV GASTROENT, V9, P781, DOI 10.1586/17474124.2015.1013031; Bibiloni R, 2005, AM J GASTROENTEROL, V100, P1539, DOI 10.1111/j.1572-0241.2005.41794.x; Bonovas S, 2015, EUR J EPIDEMIOL, V30, P249, DOI 10.1007/s10654-015-0015-8; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Campieri M, 1999, GASTROENTEROLOGY, V116, P1246, DOI 10.1016/S0016-5085(99)70029-6; Cordina C, 2010, COLORECTAL DIS, V12, P44; Costello SP, 2019, JAMA-J AM MED ASSOC, V321, P156, DOI 10.1001/jama.2018.20046; Costello SP, 2017, GASTROENTEROLOGY, V152, pS198, DOI 10.1016/S0016-5085(17)30969-1; Dai C, 2012, INT J MOL MED, V29, P202, DOI 10.3892/ijmm.2011.839; Danese S, 2011, NEW ENGL J MED, V365, P1713, DOI 10.1056/NEJMra1102942; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Feuerstein JD, 2014, MAYO CLIN PROC, V89, P1553, DOI 10.1016/j.mayocp.2014.07.002; Fuentes S, 2017, ISME J, V11, P1877, DOI 10.1038/ismej.2017.44; Ganji-Arjenaki M, 2018, J CELL PHYSIOL, V233, P2091, DOI 10.1002/jcp.25911; Goyal A., 2016, J PEDIAT GASTROENTER, V63, pS212; Graff LA, 2009, AM J GASTROENTEROL, V104, P2959, DOI 10.1038/ajg.2009.529; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Higgins PDR, 2005, GUT, V54, P782, DOI 10.1136/gut.2004.056358; Imhann F, 2018, GUT, V67, P108, DOI 10.1136/gutjnl-2016-312135; Jitsumura M, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021987; Khan N, 2013, GASTROENTEROLOGY, V145, P1007, DOI 10.1053/j.gastro.2013.07.035; Khoruts A, 2010, J CLIN GASTROENTEROL, V44, P354, DOI 10.1097/MCG.0b013e3181c87e02; Kimoto-Nira H, 2008, J MICROBIOL BIOTECHN, V18, P1286; Kostic AD, 2014, GASTROENTEROLOGY, V146, P1489, DOI 10.1053/j.gastro.2014.02.009; Kump P, 2018, ALIMENT PHARM THER, V47, P67, DOI 10.1111/apt.14387; Lee CH, 2016, JAMA-J AM MED ASSOC, V315, P142, DOI 10.1001/jama.2015.18098; LENNARDJONES JE, 1960, GUT, V1, P217, DOI 10.1136/gut.1.3.217; MANTEL N, 1959, J NATL CANCER I, V22, P719; Matsuoka K, 2015, SEMIN IMMUNOPATHOL, V37, P47, DOI 10.1007/s00281-014-0454-4; Miele E, 2009, AM J GASTROENTEROL, V104, P437, DOI 10.1038/ajg.2008.118; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Moayyedi P, 2014, CAN J GASTROENTEROL, V28, P66, DOI 10.1155/2014/346590; Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]; Narula N, 2017, INFLAMM BOWEL DIS, V23, P1702, DOI 10.1097/MIB.0000000000001228; Ng SC, 2010, INFLAMM BOWEL DIS, V16, P1286, DOI 10.1002/ibd.21222; Nusbaum DJ, 2018, FEMS MICROBIOL ECOL, V94, DOI 10.1093/femsec/fiy133; Oremus M, 2001, DEMENT GERIATR COGN, V12, P232, DOI 10.1159/000051263; Pai N, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016698; Paramsothy S, 2016, J GASTROEN HEPATOL, V31, P143; Paramsothy S, 2016, HELICOBACTER, V21, P72; Paramsothy S, 2015, INFLAMM BOWEL DIS, V21, P1600, DOI 10.1097/MIB.0000000000000405; Pigneur B, 2016, MUCOSAL IMMUNOL, V9, P1360, DOI 10.1038/mi.2016.67; Reinisch W, 2017, DIGEST DIS, V35, P123, DOI 10.1159/000449092; Reinshagen M, 2017, Z GASTROENTEROL, V55, P779, DOI [10.1055/s-0043-109349, 10.1055/s-0043-103830]; Rossen N, 2015, J CROHNS COLITIS, V9, pS2; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; Segal JP, 2018, CLIN EXP GASTROENTER, V11, P179, DOI 10.2147/CEG.S159609; Shen ZH, 2018, WORLD J GASTROENTERO, V24, P5, DOI 10.3748/wjg.v24.i1.5; Soo I, 2008, CAN J GASTROENTEROL, V22, P237, DOI 10.1155/2008/520383; Sood A, 2009, CLIN GASTROENTEROL H, V7, P1202, DOI 10.1016/j.cgh.2009.07.016; Sullivan S, 2017, CRIT PHILOS RACE, V5, P1; SUTHERLAND LR, 1987, GASTROENTEROLOGY, V92, P1894, DOI 10.1016/0016-5085(87)90621-4; Turcotte Jean-Francois, 2011, Evid Based Med, V16, P108, DOI 10.1136/ebm1189; Tursi A, 2004, MED SCI MONITOR, V10, pPI126; Tursi A, 2010, AM J GASTROENTEROL, V105, P2218, DOI 10.1038/ajg.2010.218; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Walmsley RS, 1998, GUT, V43, P29, DOI 10.1136/gut.43.1.29; Wang HG, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010675; Zhou M, 2017, ROSETTA STONE PATHOG, V2017, DOI [10.1155/2017/8201672, DOI 10.1155/2017/8201672]	64	24	26	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2020	15	3							e0228846	10.1371/journal.pone.0228846	http://dx.doi.org/10.1371/journal.pone.0228846			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ9DF	32182248	Green Published, gold			2023-01-03	WOS:000535296400003
J	Martin-Fuentes, I; Oliva-Lozano, JM; Muyor, JM				Martin-Fuentes, Isabel; Oliva-Lozano, Jose M.; Muyor, Jose M.			Electromyographic activity in deadlift exercise and its variants. A systematic review	PLOS ONE			English	Review							MUSCLE ACTIVATION PATTERNS; HAMSTRING ACTIVATION; PHYSICAL-ACTIVITY; TRAINING STATUS; HIP THRUST; STRENGTH; FORCE; LOAD	The main purpose of this review was to systematically analyze the literature concerning studies which have investigated muscle activation when performing the Deadlift exercise and its variants. This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement (PRISMA). Original studies from inception until March 2019 were sourced from four electronic databases including PubMed, OVID, Scopus and Web of Science. Inclusion criteria were as follows: (a) a cross-sectional or longitudinal study design; (b) evaluation of neuromuscular activation during Deadlift exercise or variants; (c) inclusion of healthy and trained participants, with no injury issues at least for six months before measurements; and (d) analyzed "sEMG amplitude", "muscle activation" or "muscular activity" with surface electromyography (sEMG) devices. Major findings indicate that the biceps femoris is the most studied muscle, followed by gluteus maximus, vastus lateralis and erector spinae. Erector spinae and quadriceps muscles reported greater activation than gluteus maximus and biceps femoris muscles during Deadlift exercise and its variants. However, the Romanian Deadlift is associated with lower activation for erector spinae than for biceps femoris and semitendinosus. Deadlift also showed greater activation of the quadriceps muscles than the gluteus maximus and hamstring muscles. In general, semitendinosus muscle activation predominates over that of biceps femoris within hamstring muscles complex. In conclusion 1) Biceps femoris is the most evaluated muscle, followed by gluteus maximus, vastus lateralis and erector spinae during Deadlift exercises; 2) Erector spinae and quadriceps muscles are more activated than gluteus maximus and biceps femoris muscles within Deadlift exercises; 3) Within the hamstring muscles complex, semitendinosus elicits slightly greater muscle activation than biceps femoris during Deadlift exercises; and 4) A unified criterion upon methodology is necessary in order to report reliable outcomes when using surface electromyography recordings.	[Martin-Fuentes, Isabel; Oliva-Lozano, Jose M.; Muyor, Jose M.] Univ Almeria, Hlth Res Ctr, Almeria, Spain; [Muyor, Jose M.] Univ Almeria, Res Cent Serv, Lab Kinesiol Biomech & Ergon KIBIOMER Lab, Almeria, Spain	Universidad de Almeria; Universidad de Almeria	Muyor, JM (corresponding author), Univ Almeria, Hlth Res Ctr, Almeria, Spain.; Muyor, JM (corresponding author), Univ Almeria, Res Cent Serv, Lab Kinesiol Biomech & Ergon KIBIOMER Lab, Almeria, Spain.	josemuyor@ual.es	Fuentes, Isabel Martín/AAC-8399-2019; Muyor, José M./M-7342-2015; Lozano, José María Oliva/AAR-2315-2020	Fuentes, Isabel Martín/0000-0003-4268-1935; Muyor, José M./0000-0003-2849-0323; Lozano, José María Oliva/0000-0002-7257-3620	Proyectos I+D +I Ministerio de Economia y Competitividad. Gobierno de Espana [DEP 2016-80296-R]; Spanish Ministry of Science, Innovation and Universities [FPU17/03787, FPU18/04434]	Proyectos I+D +I Ministerio de Economia y Competitividad. Gobierno de Espana; Spanish Ministry of Science, Innovation and Universities(Spanish Government)	This work was supported by the Proyectos I+D +I Ministerio de Economia y Competitividad. Gobierno de Espana. Referencia: DEP 2016-80296-R (AEI/FEDER, UE). Isabel Martin-Fuentes was supported by a scholarship funded by the Spanish Ministry of Science, Innovation and Universities (FPU17/03787) Jose M. Oliva-Lozano was supported by a scholarship funded by the Spanish Ministry of Science, Innovation and Universities (FPU18/04434).	Aamot IL, 2016, PHYSIOTHER RES INT, V21, P54, DOI 10.1002/pri.1619; Andersen V, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211021; Andersen V, 2018, J STRENGTH COND RES, V32, P587, DOI 10.1519/JSC.0000000000001826; Bezerra ES, 2013, ELECTROMYOGRAPHIC AC, V13, P30; Bourne MN, 2017, BRIT J SPORT MED, V51, P1021, DOI 10.1136/bjsports-2015-095739; Brearley S, 2019, STRENGTH COND J, V41, P97, DOI 10.1519/SSC.0000000000000450; Caine D, 2016, EXCEPTIONALITY YOUNG; Camara KD, 2016, J STRENGTH COND RES, V30, P1183, DOI 10.1519/JSC.0000000000001352; Choe KH, 2021, J STRENGTH COND RES, V35, P1364, DOI 10.1519/JSC.0000000000002908; Chulvi-Medrano I, 2010, J STRENGTH COND RES, V24, P2723, DOI 10.1519/JSC.0b013e3181f0a8b9; Cussler EC, 2003, MED SCI SPORT EXER, V35, P10, DOI 10.1097/00005768-200301000-00003; Dicus Jeremy R, 2018, Int J Exerc Sci, V11, P708; Ebben WP, 2009, INT J SPORT PHYSIOL, V4, P84, DOI 10.1123/ijspp.4.1.84; Edington C, 2018, SPORTS, V6, DOI 10.3390/sports6030090; El-Ashker S, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00782; Escamilla RF, 2002, MED SCI SPORT EXER, V34, P682, DOI 10.1097/00005768-200204000-00019; Faigenbaum AD, 2010, BRIT J SPORT MED, V44, P56, DOI 10.1136/bjsm.2009.068098; Ferland PM, 2019, J STRENGTH COND RES, V33, pS194, DOI 10.1519/JSC.0000000000003099; Gentil P, 2017, PHYSIOL BEHAV, V179, P148, DOI 10.1016/j.physbeh.2017.06.004; Hamlyn N, 2007, J STRENGTH COND RES, V21, P1108; Hug F, 2011, J ELECTROMYOGR KINES, V21, P1, DOI 10.1016/j.jelekin.2010.08.009; Hunter GR, 2000, J APPL PHYSIOL, V89, P977, DOI 10.1152/jappl.2000.89.3.977; Iversen VM, 2017, EUR J SPORT SCI, V17, P973, DOI 10.1080/17461391.2017.1337229; Komi PV, 2000, MED SCI SPORT EXER, V32, P1757, DOI 10.1097/00005768-200010000-00015; Korak JA, 2018, J STRENGTH COND RES, V32, P2770, DOI 10.1519/JSC.0000000000002513; Krajewski KT, 2019, J STRENGTH COND RES, V33, pS70, DOI 10.1519/JSC.0000000000002545; Krings B, 2021, J STRENGTH COND RES, V35, pS152, DOI 10.1519/JSC.0000000000002954; Lee S, 2018, J EXERC SCI FIT, V16, P87, DOI 10.1016/j.jesf.2018.08.001; Matheson JW, 2001, MED SCI SPORT EXER, V33, P1713, DOI 10.1097/00005768-200110000-00016; McAllister MJ, 2014, J STRENGTH COND RES, V28, P1573, DOI 10.1519/JSC.0000000000000302; McCurdy K, 2018, J STRENGTH COND RES, V32, P594, DOI 10.1519/JSC.0000000000001893; Merlo A., 2010, OPEN REHABIL J, V3, P98, DOI [10.2174/1874943701003010098, DOI 10.2174/1874943701003010098]; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Myers AM, 2017, TRANSL PEDIATR, V6, P137, DOI 10.21037/tp.2017.04.01; Neto WK, 2019, J SPORT SCI MED, V18, P198; Nijem RM, 2016, J STRENGTH COND RES, V30, P1177, DOI 10.1519/JSC.0000000000001351; O'Connor PJ, 2010, AM J LIFESTYLE MED, V4, P377, DOI 10.1177/1559827610368771; Ono T, 2010, RES SPORTS MED, V18, P188, DOI 10.1080/15438627.2010.490185; Papagiannis Georgios I., 2019, Journal of Medical Engineering & Technology, V43, P59, DOI 10.1080/03091902.2019.1609610; Sanderson A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029850; Schoenfeld BJ, 2015, J STRENGTH COND RES, V29, P159, DOI 10.1519/JSC.0000000000000598; Schott N, 2019, EXP GERONTOL, V122, P15, DOI 10.1016/j.exger.2019.03.012; Slater LV, 2017, J STRENGTH COND RES, V31, P667, DOI 10.1519/JSC.0000000000001323; Snyder BJ, 2017, J STRENGTH COND RES, V31, P2859, DOI 10.1519/JSC.0000000000001723; Stastny P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171632; Stock MS, 2014, J MUSCULOSKEL NEURON, V14, P387; Strasser B, 2011, J OBES, V2011, DOI 10.1155/2011/482564; Trevino MA, 2015, ACTA BIOENG BIOMECH, V17, P107, DOI 10.5277/ABB-00221-2014-03; Urrutia G, 2010, MED CLIN-BARCELONA, V135, P507, DOI 10.1016/j.medcli.2010.01.015; Wakeling JM, 2006, J R SOC INTERFACE, V3, P533, DOI 10.1098/rsif.2006.0113; Westcott WL, 2012, CURR SPORT MED REP, V11, P209, DOI 10.1249/JSR.0b013e31825dabb8; Westcott WL, 2009, PHYSICIAN SPORTSMED, V37, P51, DOI 10.3810/psm.2009.06.1709; Wu H, 2020, J NONLINEAR SCI, V30, P23, DOI 10.1007/s00332-019-09567-y; Yavuz HU, 2017, APPL BIONICS BIOMECH, V2017, DOI 10.1155/2017/9084725; Young W, 2019, STRENGTH COND J, V41, P47, DOI 10.1519/SSC.0000000000000443	55	10	10	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2020	15	2							e0229507	10.1371/journal.pone.0229507	http://dx.doi.org/10.1371/journal.pone.0229507			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ8GQ	32107499	gold, Green Published			2023-01-03	WOS:000535237000037
J	Tripple, JW; Ameredes, BT; Calhoun, WJ				Tripple, Julia W.; Ameredes, Bill T.; Calhoun, William J.			Outpatient Management of Chronic Asthma in 2020	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BUDESONIDE-FORMOTEROL	This JAMA Insights Clinical Update reviews recent evidence favoring use of inhaled corticosteroids (ICS)in all patients with asthma, regardless of frequency, and summarizes the SMART (single maintenance and reliever therapy) treatment approach, which uses an inhaler combining ICS and formoterol for control and relief of symptoms, and differences between SMART and symptom-driven therapy.	[Tripple, Julia W.; Calhoun, William J.] Univ Texas Med Branch, Div Allergy & Immunol, Galveston, TX 77555 USA; [Ameredes, Bill T.; Calhoun, William J.] Univ Texas Med Branch, Div Pulm Crit Care & Sleep Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Calhoun, WJ (corresponding author), Univ Texas Med Branch, Dept Internal Med, 301 Univ Blvd, Galveston, TX 77555 USA.	wjcalhou@utmb.edu		Calhoun, William/0000-0001-7075-712X				Bateman ED, 2018, NEW ENGL J MED, V378, P1877, DOI 10.1056/NEJMoa1715275; Busse WW, 2018, NEW ENGL J MED, V378, P2497, DOI 10.1056/NEJMoa1716868; Global Initiative for Asthma, GUID REP; Mann M, 2003, CHEST, V124, P70, DOI 10.1378/chest.124.1.70; National Asthma Education and Prevention Program National Heart Lung and Blood Institute, 2017, 3 NAT ASTHM ED PREV; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; O'Byrne PM, 2018, NEW ENGL J MED, V378, P1865, DOI 10.1056/NEJMoa1715274; Reddel HK, 2017, LANCET, V389, P157, DOI 10.1016/S0140-6736(16)31399-X; Sobieraj DM, 2018, JAMA-J AM MED ASSOC, V319, P1485, DOI 10.1001/jama.2018.2769; Sobieraj DM, 2018, JAMA-J AM MED ASSOC, V319, P1473, DOI 10.1001/jama.2018.2757	10	9	9	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2020	323	6					561	562		10.1001/jama.2019.19986	http://dx.doi.org/10.1001/jama.2019.19986			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KO5BC	32044930				2023-01-03	WOS:000515563800021
J	Mack, MR; Kim, BS				Mack, Madison R.; Kim, Brian S.			A precision medicine-based strategy for a severe adverse drug reaction	NATURE MEDICINE			English	Editorial Material							SYSTEMIC SYMPTOMS; EOSINOPHILIA; DRESS	Detailed single-cell RNA-sequencing analysis of skin and blood from a patient with DRESS, a severe adverse drug reaction, leads to a personalized, hypothesis-driven treatment.	[Mack, Madison R.; Kim, Brian S.] Washington Univ, Sch Med, Ctr Study Itch & Sensory Disorders, St Louis, MO 63110 USA; [Mack, Madison R.; Kim, Brian S.] Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; [Kim, Brian S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Kim, BS (corresponding author), Washington Univ, Sch Med, Ctr Study Itch & Sensory Disorders, St Louis, MO 63110 USA.; Kim, BS (corresponding author), Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA.; Kim, BS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.	briankim@wustl.edu	Kim, Brian/GZK-6649-2022	Kim, Brian/0000-0002-8100-7161; Mack, Madison/0000-0003-2812-0349				[Anonymous], 2015, PHARM PRACT; Chen CB, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6431694; Cho YT, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/1503709; Cho YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061243; Damsky William E, 2019, JAAD Case Rep, V5, P1018, DOI 10.1016/j.jdcr.2019.07.004; Kardaun SH, 2007, BRIT J DERMATOL, V156, P609, DOI 10.1111/j.1365-2133.2006.07704.x; Kim D, 2020, NAT MED, V26, P236, DOI 10.1038/s41591-019-0733-7; Miyagawa F, 2016, J DERMATOL SCI, V83, P151, DOI 10.1016/j.jdermsci.2016.05.001; Mockenhaupt M, 2017, Allergol Select, V1, P96, DOI 10.5414/ALX01508E; Sultana J, 2013, J PHARMACOL PHARMACO, V4, pS73, DOI 10.4103/0976-500X.120957	10	4	4	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2020	26	2					167	168		10.1038/s41591-020-0756-0	http://dx.doi.org/10.1038/s41591-020-0756-0		FEB 2020	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	KK7DU	32015558				2023-01-03	WOS:000510822600001
J	Ahsan, T; Urmi, NJ; Sajib, A				Ahsan, Tamim; Urmi, Nusrat Jahan; Sajib, Abu Ashfaqur			Heterogeneity in the distribution of 159 drug-response related SNPs in world populations and their genetic relatedness	PLOS ONE			English	Article							LINKAGE DISEQUILIBRIUM PATTERNS; NICOTINE REPLACEMENT THERAPY; AFRICAN-AMERICAN MEN; ALLELE FREQUENCY; ROSUVASTATIN PHARMACOKINETICS; NEANDERTHAL ANCESTRY; SMOKING-CESSATION; ASIAN POPULATIONS; NATURAL-SELECTION; PROSTATE-CANCER	Interethnic variability in drug response arises from genetic differences associated with drug metabolism, action and transport. These genetic variations can affect drug efficacy as well as cause adverse drug reactions (ADRs). We retrieved drug-response related single nucleotide polymorphism (SNP) associated data from databases and analyzed to elucidate population specific distribution of 159 drug-response related SNPs in twenty six populations belonging to five super-populations (African, Admixed Americans, East Asian, European and South Asian). Significant interpopulation differences exist in the minor (variant) allele frequencies (MAFs), linkage disequilibrium (LD) and haplotype distributions among these populations. 65 of the drug-response related alleles, which are considered as minor (variant) in global population, are present as the major alleles (frequency >= 0.5) in at least one or more populations. Populations that belong to the same super-population have similar distribution pattern for majority of the variant alleles. These drug response related variant allele frequencies and their pairwise LD measure (r(2)) can clearly distinguish the populations in a way that correspond to the known evolutionary history of human and current geographic distributions, while D' cannot. The data presented here may aid in identifying drugs that are more appropriate and/or require pharmacogenetic testing in these populations. Our findings emphasize on the importance of distinct, ethnicity-specific clinical guidelines, especially for the African populations, to avoid ADRs and ensure effective drug treatment.	[Ahsan, Tamim] Bangabandhu Sheikh Mujibur Rahman Maritime Univ, Dept Genet Engn & Biotechnol, Dhaka, Bangladesh; [Urmi, Nusrat Jahan] BIRDEM Gen Hosp, Dept Med, Dhaka, Bangladesh; [Sajib, Abu Ashfaqur] Univ Dhaka, Dept Genet Engn & Biotechnol, Dhaka, Bangladesh	University of Dhaka	Sajib, A (corresponding author), Univ Dhaka, Dept Genet Engn & Biotechnol, Dhaka, Bangladesh.	abu.sajib@du.ac.bd			Ministry of Science and Technology, Bangladesh	Ministry of Science and Technology, Bangladesh	This work was supported by the Ministry of Science and Technology, Bangladesh. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adeloye D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153496; Ahsan T, 2019, META GENE, V21, DOI 10.1016/j.mgene.2019.100585; Aka I, 2017, J PERS MED, V7, DOI 10.3390/jpm7040014; Alhusain L, 2018, HUM GENOMICS, V12, DOI 10.1186/s40246-018-0156-4; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Ampadu HH, 2016, DRUG SAFETY, V39, P335, DOI 10.1007/s40264-015-0387-4; Anderson KO, 2009, J PAIN, V10, P1187, DOI 10.1016/j.jpain.2009.10.002; Antunez de Mayolo G, 2002, ELECTROPHORESIS, V23, P3346, DOI 10.1002/1522-2683(200210)23:19<3346::AID-ELPS3346>3.0.CO;2-J; Ardlie KG, 2002, NAT REV GENET, V3, P299, DOI 10.1038/nrg777; Asamoah FA, 2018, J GLOB ONCOL, V4, DOI 10.1200/JGO.17.00234; Bachtiar M., 2013, CURR GENET MED REP, V1, P162, DOI DOI 10.1007/S40142-013-0017-3; Bahar MA, 2017, PHARMACOGENOMICS, V18, P701, DOI 10.2217/pgs-2017-0194; Brown AMK, 2014, PHARMACOGENOMICS, V15, P1185, DOI [10.2217/PGS.14.81, 10.2217/pgs.14.81]; Browning SR, 2018, CELL, V173, P53, DOI 10.1016/j.cell.2018.02.031; Campbell MC, 2008, ANNU REV GENOM HUM G, V9, P403, DOI 10.1146/annurev.genom.9.081307.164258; Campbell MC, 2014, CURR OPIN GENET DEV, V29, P120, DOI 10.1016/j.gde.2014.09.003; Cepeda-Benito A, 2004, J CONSULT CLIN PSYCH, V72, P712, DOI 10.1037/0022-006X.72.4.712; CHAKRABORTY R, 1986, YEARB PHYS ANTHROPOL, V29, P1; Claudio-Campos Karla, 2015, Drug Metabolism and Personalized Therapy, V30, P87, DOI 10.1515/dmdi-2014-0023; Cokugras A.N., 2003, TURK J BIOCHEM, V28, P54, DOI DOI 10.1016/J.CBI.2005.10.013; David SM, 2013, CHEM-BIOL INTERACT, V203, P30, DOI 10.1016/j.cbi.2012.10.010; Nagar SD, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00241; Dou YL, 2018, DRUG METAB PHARMACOK, V33, P228, DOI 10.1016/j.dmpk.2018.08.001; Duncan G, 1996, GENETICA, V98, P277, DOI 10.1007/BF00057592; Etter JF, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015487; Evans DM, 2005, AM J HUM GENET, V76, P681, DOI 10.1086/429274; EXCOFFIER L, 1994, GENETICS, V136, P343; Fan SH, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1679-2; Fischer J, 2012, HEPATOLOGY, V55, P1700, DOI 10.1002/hep.25582; Gammal RS, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3479; Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024; Gonzalez-Neira Anna, 2004, Human Genomics, V1, P399; Goulding R, 2015, BRIT J CLIN PHARMACO, V80, P868, DOI 10.1111/bcp.12475; Gross Tonya, 2018, Ment Health Clin, V8, P235, DOI 10.9740/mhc.2018.09.235; Grosse SD, 2011, AM J PREV MED, V41, pS398, DOI 10.1016/j.amepre.2011.09.013; Grossman I, 2009, EXPERT OPIN DRUG MET, V5, P449, DOI [10.1517/17425250902902322 , 10.1517/17425250902902322]; Hariprakash JM, 2018, PHARMACOGENOMICS, V19, P227, DOI 10.2217/pgs-2017-0101; Hayes VM, 2017, J GLOB ONCOL, V4, DOI 10.1200/JGO.2016.008862; He P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12104-0; Hellwege Jacklyn N, 2017, Curr Protoc Hum Genet, V95, DOI 10.1002/cphg.48; Hofer T, 2009, ANN HUM GENET, V73, P95, DOI 10.1111/j.1469-1809.2008.00489.x; Homburger JR, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005602; Impicciatore P, 2001, BRIT J CLIN PHARMACO, V52, P77, DOI 10.1046/j.0306-5251.2001.01407.x; Ingelman-Sundberg M, 2004, TRENDS PHARMACOL SCI, V25, P193, DOI 10.1016/j.tips.2004.02.007; Ivanov M, 2012, CLIN PHARMACOL THER, V92, P727, DOI 10.1038/clpt.2012.152; Katoh T, 2002, AM J HUM GENET, V71, P395, DOI 10.1086/341608; Kawaguchi DM, 2014, PHARMACOGENOMICS, V15, P1451, DOI [10.2217/pgs.14.96, 10.2217/PGS.14.96]; Khan A, 2016, SCI REP-UK, V6, DOI 10.1038/srep18755; Kim BY, 2015, AM J HUM GENET, V96, P454, DOI 10.1016/j.ajhg.2014.12.029; Kim IW, 2012, PHARMACOGENET GENOM, V22, P829, DOI 10.1097/FPC.0b013e328358dd70; Kirchheiner J, 2007, PHARMACOGENOMICS J, V7, P257, DOI 10.1038/sj.tpj.6500406; Knisely MR, 2017, APPL NURS RES, V38, P107, DOI 10.1016/j.apnr.2017.10.001; Lam MPS, 2012, BRIT J CLIN PHARMACO, V73, P340, DOI 10.1111/j.1365-2125.2011.04097.x; Lambert CA, 2009, COLD SH Q B, V74, P395, DOI 10.1101/sqb.2009.74.053; Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113; Laval G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010284; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lee E, 2005, CLIN PHARMACOL THER, V78, P330, DOI 10.1016/j.clpt.2005.06.013; Lee YF, 2017, PHARMACOGENOMIC ERA, V8; Li J, 2011, HUM MOL GENET, V20, P528, DOI 10.1093/hmg/ddq498; Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717; Losi L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061559; Luikart G, 1998, J HERED, V89, P238, DOI 10.1093/jhered/89.3.238; MACHIELA MJ, 2015, BIOINFORMATICS, V31, P3555, DOI DOI 10.1093/BI0INF0RMATICS/BTV402; Maekawa K, 2012, DRUG METAB PHARMACOK, V27, P447, DOI 10.2133/dmpk.DMPK-11-NT-120; Mahasirimongkol S, 2006, J HUM GENET, V51, P896, DOI 10.1007/s10038-006-0041-1; Manoharan I, 2006, PHARMACOGENET GENOM, V16, P461; Marigorta UM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003566; McGraw J, 2012, EXPERT OPIN DRUG MET, V8, P371, DOI 10.1517/17425255.2012.657626; Meisner J, 2018, GENETICS, V210, P719, DOI 10.1534/genetics.118.301336; Moaddeb J, 2013, THER ADV DRUG SAF, V4, P155, DOI 10.1177/2042098613485595; Montinaro F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7596; Mouton JP, 2015, BRIT J CLIN PHARMACO, V80, P818, DOI 10.1111/bcp.12567; Mueller JC, 2005, AM J HUM GENET, V76, P387, DOI 10.1086/427925; Mukerjee G, 2018, NPJ GENOM MED, V3, DOI 10.1038/s41525-018-0065-4; Mustafina O E, 2015, Genetika, V51, P109; Nebert D. W., 2001, Pharmacogenomics Journal, V1, P19; Norris ET, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-5195-7; Odedina Folakemi T, 2009, Infect Agent Cancer, V4 Suppl 1, pS2, DOI 10.1186/1750-9378-4-S1-S2; Oetting WS, 2016, AM J TRANSPLANT, V16, P574, DOI 10.1111/ajt.13495; Ortega VE, 2014, J ALLERGY CLIN IMMUN, V133, P16, DOI 10.1016/j.jaci.2013.10.040; Paschou P, 2007, PLOS GENET, V3, P1672, DOI 10.1371/journal.pgen.0030160; Patillon B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053049; Pickrell JK, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002967; Pittman AM, 2005, J MED GENET, V42, P837, DOI 10.1136/jmg.2005.031377; Qin PF, 2015, SCI REP-UK, V5, DOI 10.1038/srep09500; Rahal AJ, 2016, SAUDI MED J, V37, P1051, DOI 10.15537/smj.2016.10.16078; Rahman Siddiqur, 2018, Current Pharmacogenomics & Personalized Medicine, V16, P199, DOI 10.2174/1875692117666181207121639; Rajman I, 2017, EBIOMEDICINE, V17, P67, DOI 10.1016/j.ebiom.2017.02.017; Ray B, 2019, PHARMACOGENET GENOM, V29, P39, DOI 10.1097/FPC.0000000000000363; Reich D, 2009, NATURE, V461, P489, DOI 10.1038/nature08365; Ross KA, 2010, J HUM GENET, V55, P582, DOI 10.1038/jhg.2010.73; Rotimi CN, 2017, HUM MOL GENET, V26, pR225, DOI 10.1093/hmg/ddx253; Rotimi CN, 2016, CURR OPIN GENET DEV, V41, P77, DOI 10.1016/j.gde.2016.08.005; Ruiz-Linares A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004572; Salzano FM, 2014, GENET MOL BIOL, V37, P151, DOI 10.1590/S1415-47572014000200003; Sanghavi K, 2017, PHARMACOGENOMICS J, V17, P61, DOI 10.1038/tpj.2015.87; Sanghera DK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33981-z; Sattar NA, 2014, ATHEROSCLEROSIS SUPP, V15, P1, DOI 10.1016/j.atherosclerosissup.2014.04.001; Shenoy D, 2016, BMC UROL, V16, DOI 10.1186/s12894-016-0137-7; Shifman S, 2003, HUM MOL GENET, V12, P771, DOI 10.1093/hmg/ddg088; Solovieff N, 2011, BLOOD CELL MOL DIS, V47, P41, DOI 10.1016/j.bcmd.2011.04.002; Spratt DE, 2018, INT J RADIAT ONCOL, V102, pS3, DOI 10.1016/j.ijrobp.2018.06.104; Srivastava MR, 2017, ENDOCRINOL METAB INT, V5, P241; Sticchi L, 2013, J Prev Med Hyg, V54, P83; Suarez-Kurtz G, 2018, ADV PHARMACOL, V83, P133, DOI 10.1016/bs.apha.2018.02.001; Szpiech ZA, 2011, THEOR POPUL BIOL, V80, P100, DOI 10.1016/j.tpb.2011.03.006; Taranto F, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3297-7; Teo YY, 2009, GENOME RES, V19, P1849, DOI 10.1101/gr.092189.109; Teo YY, 2010, GENET EPIDEMIOL, V34, P653, DOI 10.1002/gepi.20522; Thummel KE, 2014, METHODS MOL BIOL, V1113, P363, DOI 10.1007/978-1-62703-758-7_17; Tishkoff SA, 2009, SCIENCE, V324, P1035, DOI 10.1126/science.1172257; VanLiere JM, 2008, THEOR POPUL BIOL, V74, P130, DOI 10.1016/j.tpb.2008.05.006; Vernot B, 2012, GENOME RES, V22, P1689, DOI 10.1101/gr.134890.111; Villanea FA, 2019, NAT ECOL EVOL, V3, P39, DOI 10.1038/s41559-018-0735-8; Visscher H, 2009, PHARMACOGENOMICS J, V9, P362, DOI 10.1038/tpj.2009.36; Visscher PM, 2017, AM J HUM GENET, V101, P5, DOI 10.1016/j.ajhg.2017.06.005; Wall JD, 2013, GENETICS, V194, P199, DOI 10.1534/genetics.112.148213; Whirl-Carrillo M, 2012, CLIN PHARMACOL THER, V92, P414, DOI 10.1038/clpt.2012.96; Williams DR, 2007, ARCH GEN PSYCHIAT, V64, P305, DOI 10.1001/archpsyc.64.3.305; Wray NR, 2005, TWIN RES HUM GENET, V8, P87; Wu HF, 2017, J PHARM SCI-US, V106, P2751, DOI 10.1016/j.xphs.2017.03.027; Xia JG, 2009, NUCLEIC ACIDS RES, V37, pW652, DOI 10.1093/nar/gkp356; Xu Shuhua, 2012, Genomics & Informatics, V10, P133, DOI 10.5808/GI.2012.10.3.133; Yang Yao, 2014, Drug Metabolism and Drug Interactions, V29, P221, DOI 10.1515/dmdi-2013-0069; Zagars GK, 1998, INT J RADIAT ONCOL, V42, P517, DOI 10.1016/S0360-3016(98)00260-0; Zencirci Beyazit, 2009, Cases J, V2, P9148, DOI 10.1186/1757-1626-2-9148	128	14	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2020	15	1							e0228000	10.1371/journal.pone.0228000	http://dx.doi.org/10.1371/journal.pone.0228000			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP5RH	31971968	Green Published, gold			2023-01-03	WOS:000534374400031
J	Davies, R				Davies, Rachael			Liz Grant: prioritising palliative care and planetary health	LANCET			English	Biographical-Item																			0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 30	2019	394	10213					1983	1983						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT4GR	32171416				2023-01-03	WOS:000500950200013
J	Walensky, RP; Horn, T; McCann, NC; Freedberg, KA; Paltiel, AD				Walensky, Rochelle P.; Horn, Tim; McCann, Nicole C.; Freedberg, Kenneth A.; Paltiel, A. David			Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis	ANNALS OF INTERNAL MEDICINE			English	Article							COST-EFFECTIVENESS; UNITED-STATES	Background: Tenofovir alafenamide- emtricitabine (F/TAF) was recently approved as a noninferior and potentially safer option than tenofovir disoproxil fumarate- emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) in the United States. Objective: To estimate the greatest possible clinical benefits and economic savings attributable to the improved safety profile of F/TAF and the maximum price payers should be willing to pay for F/TAF over generic F/TDF. Design: Cost-effectiveness analysis. Data Sources: Published literature on F/TDF safety (in persons with and those without HIV) and the cost and quality-of-life effects of fractures and end-stage renal disease (ESRD). Target Population: Age-stratified U.S. men who have sex with men (MSM) using PrEP. Time Horizon: Five years. Perspective: Health care sector. Intervention: Preexposure prophylaxis with F/TAF versus F/TDF. Outcome Measures: Fractures averted, cases of ESRD averted, quality-adjusted life-years (QALYs) saved, costs, incremental cost-effectiveness ratios (ICERs), and maximum justifiable price for F/TAF compared with generic F/TDF. Results of Base-Case Analysis: Over a 5-year horizon, compared with F/TDF, F/TAF averted 2101 fractures and 25 cases of ESRD for the 123 610 MSM receiving PrEP, with an ICER of more than $7 million per QALY. At a 50% discount for generic F/TDF ($8300 per year) and a societal willingness to pay up to $100 000 per QALY, the maximum fair price for F/TAF was $8670 per year. Results of Sensitivity Analysis: Among persons older than 55 years, the ICER for F/TAF remained more than $3 million per QALY and the maximum permissible fair price for F/TAF was $8970 per year. Results were robust to alternative time horizons and PrEP-using population sizes. Limitation: Intermittent use and on- demand PrEP were not considered. Conclusion: In the presence of a generic F/TDF alternative, the improved safety of F/TAF is worth no more than an additional $370 per person per year.	[Walensky, Rochelle P.] Harvard Univ, Massachusetts Gen Hosp, Harvard Med Sch, Ctr AIDS Res,Med Practice Evaluat Ctr, Boston, MA 02115 USA; [Horn, Tim] Natl Alliance State & Terr AIDS Directors, 444 North Capitol St NW,Suite 339, Washington, DC 20001 USA; [McCann, Nicole C.; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Freedberg, Kenneth A.] Harvard Univ, Harvard Med Sch, Ctr AIDS Res, Boston, MA 02115 USA; [Paltiel, A. David] Yale Sch Publ Hlth, 60 Coll St, New Haven, CT 06510 USA; [Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,GJ504, Boston, MA 02114 USA; [McCann, Nicole C.; Freedberg, Kenneth A.] Med Practice Evaluat Ctr, 100 Cambridge St, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Yale University; Harvard University; Massachusetts General Hospital	Walensky, RP (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,Bul 130, Boston, MA 02114 USA.; Walensky, RP (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,GJ504, Boston, MA 02114 USA.	rwalensky@mgh.harvard.edu		McCann, Nicole/0000-0002-4916-4319	National Institute of Allergy and Infectious Diseases [R01 AI042006]; National Institute on Drug Abuse [R37 DA015612]; National Institute of Mental Health [R01 MH105203]; Massachusetts General Hospital Executive Committee on Research	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Massachusetts General Hospital Executive Committee on Research	By the National Institute of Allergy and Infectious Diseases (R01 AI042006), National Institute on Drug Abuse (R37 DA015612), and National Institute of Mental Health (R01 MH105203), and the Massachusetts General Hospital Executive Committee on Research (Steve and Deborah Gorlin Research Scholars Award to Dr. Walensky).	AIDSVu, 2020, LOC DAT US; [Anonymous], 2019, HEALIO INFECT DIS NE; Cambiano V, 2016, CURR OPIN HIV AIDS, V11, P56, DOI 10.1097/COH.0000000000000217; Centers for Disease Control and Prevention, 2019, INDICATOR DETAILS IN; Cutler DM, 2006, NEW ENGL J MED, V355, P920, DOI 10.1056/NEJMsa054744; Eckman MH, 2018, ANN INTERN MED, V169, P214, DOI 10.7326/M17-3088; FDA, 2019, FDA APPR 2 DRUG PREV; Gilead Sciences, 2020, CEO DAN ODAY PRESENT; Gilead Sciences Inc. (GILD), 2019, CEO DAN ODAY Q2 2019; Gopalappa C, 2012, JAIDS-J ACQ IMM DEF, V61, P99, DOI 10.1097/QAI.0b013e31825bd862; Gu Q, 2014, CLIN ORTHOP RELAT R, V472, P3536, DOI 10.1007/s11999-014-3820-6; Hare C, 2019, C RETR OPP INF SEATT; Henry J., 2019, US FEDERAL FUNDING H; Hill A, 2018, J VIRUS ERAD, V4, P72; HIV.gov, 2019, WHAT IS END HIV EP P; IMS Institute for Health Informatics, 2016, PRICE DECLINES BRAND; Institute of Medicine Committee on the Consequences of Uninsurance, 2003, HIDDEN COSTS VALUE L; Komatsu A, 2018, DRUG SAFETY, V41, P843, DOI 10.1007/s40264-018-0665-z; Krakower DS, 2020, ANN INTERN MED, V172, P281, DOI 10.7326/M19-3337; Nkhoma ET, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166982; Paltiel AD, 2009, CLIN INFECT DIS, V48, P806, DOI 10.1086/597095; Parthan A, 2013, APPL HEALTH ECON HEA, V11, P485, DOI 10.1007/s40258-013-0047-8; Sax PE, 2020, CLIN INFECT DIS, V71, P1379, DOI 10.1093/cid/ciz999; Schafer JJ, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz414; Smith DK, 2015, MMWR-MORBID MORTAL W, V64, P1291, DOI 10.15585/mmwr.mm6446a4; Surial B, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4454-9; Svedbom A, 2018, OSTEOPOROSIS INT, V29, P557, DOI 10.1007/s00198-017-4317-4; U.S. Department of Veterans Affairs, NATL ACQUISITION CTR; U.S. Food and Drug Administration, 2019, FDA BRIEF DOC M ANT; U.S. Renal Data System, 2018, 2018 ADR REFERENCE T; US Preventive Services Task Force, 2019, FINAL RECOMMENDATION; Yacoub R, 2016, JAIDS-J ACQ IMM DEF, V71, pe115, DOI 10.1097/QAI.0000000000000906	32	22	22	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 5	2020	172	9					583	+		10.7326/M19-3478	http://dx.doi.org/10.7326/M19-3478			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK7EH	32926822	Green Accepted			2023-01-03	WOS:000531024900008
J	Petrilli, CM; Jones, SA; Yang, J; Rajagopalan, H; O'Donnell, L; Chernyak, Y; Tobin, KA; Cerfolio, RJ; Francois, F; Horwitz, LI				Petrilli, Christopher M.; Jones, Simon A.; Yang, Jie; Rajagopalan, Harish; O'Donnell, Luke; Chernyak, Yelena; Tobin, Katie A.; Cerfolio, Robert J.; Francois, Fritz; Horwitz, Leora I.			Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; INFLUENZA	OBJECTIVE To describe outcomes of people admitted to hospital with coronavirus disease 2019 (covid-19) in the United States, and the clinical and laboratory characteristics associated with severity of illness. DESIGN Prospective cohort study. SETTING Single academic medical center in New York City and Long Island. PARTICIPANTS 5279 patients with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection between 1 March 2020 and 8 April 2020. The final date of follow up was 5 May 2020. MAIN OUTCOME MEASURES Outcomes were admission to hospital, critical illness (intensive care, mechanical ventilation, discharge to hospice care, or death), and discharge to hospice care or death. Predictors included patient characteristics, medical history, vital signs, and laboratory results. Multivariable logistic regression was conducted to identify risk factors for adverse outcomes, and competing risk survival analysis for mortality. RESULTS Of 11544 people tested for SARS-Cov-2, 5566 (48.2%) were positive. After exclusions, 5279 were included. 2741 of these 5279 (51.9%) were admitted to hospital, of whom 1904 (69.5%) were discharged alive without hospice care and 665 (24.3%) were discharged to hospice care or died. Of 647 (23.6%) patients requiring mechanical ventilation, 391 (60.4%) died and 170 (26.2%) were extubated or discharged. The strongest risk for hospital admission was associated with age, with an odds ratio of >2 for all age groups older than 44 years and 37.9 (95% confidence interval 26.1 to 56.0) for ages 75 years and older. Other risks were heart failure (4.4, 2.6 to 8.0), male sex (2.8, 2.4 to 3.2), chronic kidney disease (2.6, 1.9 to 3.6), and any increase in body mass index (BMI) (eg, for BMI >40: 2.5, 1.8 to 3.4). The strongest risks for critical illness besides age were associated with heart failure (1.9,1.4 to 2.5), BMI >40 (1.5, 1.0 to 2.2), and male sex (1.5, 1.3 to 1.8). Admission oxygen saturation of <88% (3.7, 2.8 to 4.8), troponin level >1 (4.8, 2.1 to 10.9), C reactive protein level >200 (5.1, 2.8 to 9.2), and D-dimer level >2500 (3.9, 2.6 to 6.0) were, however, more strongly associated with critical illness than age or comorbidities. Risk of critical illness decreased significantly over the study period. Similar associations were found for mortality alone. CONCLUSIONS Age and comorbidities were found to be strong predictors of hospital admission and to a lesser extent of critical illness and mortality in people with covid-19; however, impairment of oxygen on admission and markers of inflammation were most strongly associated with critical illness and mortality. Outcomes seem to be improving over time, potentially suggesting improvements in care.	[Petrilli, Christopher M.; O'Donnell, Luke; Horwitz, Leora I.] NYU, Dept Med, Grossman Sch Med, Div Gen Internal Med & Clin Innovat, 550 1St Ave, New York, NY 10016 USA; [Petrilli, Christopher M.; Rajagopalan, Harish; Chernyak, Yelena; Tobin, Katie A.; Cerfolio, Robert J.; Francois, Fritz] NYU, Langone Hlth, New York, NY USA; [Jones, Simon A.; Horwitz, Leora I.] NYU, Grossman Sch Med, Dept Populat Hlth, Div Healthcare Delivery Sci, 227 East 30th St 633, New York, NY 10016 USA; [Jones, Simon A.; Yang, Jie; Horwitz, Leora I.] NYU, Langone Hlth, Ctr Healthcare Innovat & Delivery Sci, New York, NY 10016 USA; [Cerfolio, Robert J.] NYU, Grossman Sch Med, Dept Cardiothorac Surg, New York, NY USA; [Francois, Fritz] NYU, Dept Med, Grossman Sch Med, Div Gastroenterol, 550 1St Ave, New York, NY 10016 USA	New York University; New York University; New York University; New York University; New York University; New York University	Horwitz, LI (corresponding author), NYU, Dept Med, Grossman Sch Med, Div Gen Internal Med & Clin Innovat, 550 1St Ave, New York, NY 10016 USA.; Horwitz, LI (corresponding author), NYU, Grossman Sch Med, Dept Populat Hlth, Div Healthcare Delivery Sci, 227 East 30th St 633, New York, NY 10016 USA.; Horwitz, LI (corresponding author), NYU, Langone Hlth, Ctr Healthcare Innovat & Delivery Sci, New York, NY 10016 USA.	leora.horwitz@nyulangone.org	Horwitz, Leora/ABD-1292-2020	BEZERRA HOLANDA, JORGE LUIS/0000-0001-9334-6411; Francois, Fritz/0000-0003-4491-2637; Santos Leite Pessoa, Mariana/0000-0003-3495-0779; Cerfolio, Robert/0000-0002-5598-599X; Jones, Simon/0000-0002-8267-5647	Kenneth C Griffin Charitable Fund	Kenneth C Griffin Charitable Fund	This work was funded in part by the Kenneth C Griffin Charitable Fund, which had no role in the study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the article for publication.	Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Caer C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02660-w; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6915e4; Cecconi M, 2018, LANCET, V392, P75, DOI 10.1016/S0140-6736(18)30696-2; Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2; Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; FOX J, 1992, J AM STAT ASSOC, V87, P178, DOI 10.2307/2290467; Geovanini GR, 2018, CLIN SCI, V132, P1243, DOI 10.1042/CS20180306; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Grey RJ, 2019, ANN STAT, V16, P1141; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017; Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e132; Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344; Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007; Melby C, 2020, MAPPING NEW YORK CIT; NYC Health, 2020, CAS HOSP DEATHS; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Popescu I, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.8577; Richardson S, 2020, JAMA, DOI [10.1001/jama.2020.6775, DOI 10.1001/JAMA.2020.6775]; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Schmidt FM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121971; Sfumato P, 2020, GOODNESS FIT TIME EV; Simonsen L, 2000, J INFECT DIS, V181, P831, DOI 10.1086/315320; Venables W.N., 2002, MODERN APPL STAT S 4, VFourth, DOI [DOI 10.1007/978-0-387-21706-2, 10.1007/978-0-387-21706-2]; VENZON DJ, 1988, J R STAT SOC C-APPL, V37, P87, DOI 10.2307/2347496; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]; Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272; World Health Organization, 2020, HOSP BEDS PER 10 000; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou H, 2012, CLIN INFECT DIS, V54, P1427, DOI 10.1093/cid/cis211	38	1367	1386	16	65	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	2020	369								m1966	10.1136/bmj.m1966	http://dx.doi.org/10.1136/bmj.m1966			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV3JU	32444366	Green Submitted, Green Published, hybrid			2023-01-03	WOS:000538336800002
